
Varicella	B-protein
-	I-protein
zoster	I-protein
virus	I-protein
(	I-protein
VZV	I-protein
)	I-protein
glycoprotein	I-protein
gI	I-protein
is	O
a	O
type	B-protein
1	I-protein
transmembrane	I-protein
glycoprotein	I-protein
which	O
is	O
one	O
component	O
of	O
the	O
heterodimeric	O
gE	B-protein
:	O
gI	B-protein
Fc	I-protein
receptor	I-protein
complex	O
.	O

A	O
segment	O
of	O
mRNA	O
encoding	O
the	O
leader	O
peptide	O
of	O
the	O
CPA1	B-protein
gene	I-protein
confers	O
repression	O
by	O
arginine	O
on	O
a	O
heterologous	O
yeast	O
gene	O
transcript	O
.	O

In	O
addition	O
,	O
lexical	O
priming	O
was	O
examined	O
by	O
presenting	O
an	O
identity	O
prime	O
earlier	O
in	O
the	O
text	O
.	O

Lower	O
extremity	O
weight	O
bearing	O
under	O
various	O
standing	O
conditions	O
in	O
independently	O
ambulatory	O
patients	O
with	O
hemiparesis	O
.	O

This	O
approach	O
enables	O
the	O
sources	O
of	O
error	O
in	O
the	O
calculation	O
of	O
nutrient	O
utilization	O
to	O
be	O
readily	O
identified	O
,	O
and	O
their	O
effect	O
on	O
precision	O
to	O
be	O
assessed	O
in	O
different	O
nutritional	O
and	O
metabolic	O
states	O
.	O

We	O
identify	O
the	O
`	O
`	O
M	O
region	O
'	O
'	O
of	O
the	O
muscle	B-protein
-	I-protein
specific	I-protein
Xenopus	I-protein
cardiac	I-protein
actin	I-protein
gene	I-protein
promoter	I-protein
from	O
-	O
282	O
to	O
-	O
348	O
as	O
necessary	O
for	O
the	O
embryonic	O
expression	O
of	O
a	O
cardiac	B-protein
actin	I-protein
-	I-protein
beta	I-protein
-	I-protein
globin	I-protein
reporter	I-protein
gene	I-protein
injected	O
into	O
fertilized	O
eggs	O
.	O

We	O
found	O
that	O
120	O
bp	O
of	O
the	O
enhancer	O
'	O
s	O
transcriptional	O
core	O
becomes	O
DNase	B-protein
I	I-protein
hypersensitive	O
early	O
in	O
B	O
-	O
cell	O
development	O
.	O

Biochemical	O
experiments	O
have	O
shown	O
that	O
CopG	B-protein
co	O
-	O
operatively	O
associates	O
to	O
its	O
target	O
DNA	O
at	O
low	O
protein	O
:	O
DNA	O
ratios	O
,	O
completely	O
protecting	O
four	O
helical	O
turns	O
on	O
the	O
same	O
face	O
of	O
the	O
double	O
helix	O
in	O
both	O
directions	O
from	O
the	O
inverted	O
repeat	O
that	O
constitutes	O
the	O
CopG	B-protein
primary	O
target	O
.	O

Competition	O
needs	O
to	O
be	O
better	O
studied	O
,	O
since	O
in	O
Central	O
America	O
and	O
Caribean	O
islands	O
this	O
kind	O
of	O
study	O
has	O
favored	O
the	O
biological	O
control	O
of	O
planorbid	O
species	O
.	O

Echocardiography	O
revealed	O
right	O
ventricular	O
diastolic	O
collapse	O
(	O
RVDC	O
)	O
without	O
physical	O
signs	O
of	O
cardiac	O
tamponade	O
.	O

Structure	O
and	O
expression	O
of	O
a	O
gene	O
from	O
Arabidopsis	O
thaliana	O
encoding	O
a	O
protein	O
related	O
to	O
SNF1	B-protein
protein	I-protein
kinase	I-protein
.	O

Our	O
results	O
indicate	O
that	O
the	O
retroplasmid	O
reverse	B-protein
transcriptase	I-protein
is	O
uniquely	O
adapted	O
to	O
initiate	O
cDNA	O
synthesis	O
by	O
recognizing	O
a	O
3	O
'	O
CCA	O
sequence	O
.	O

The	O
LMW	B-protein
FGF	I-protein
-	I-protein
2	I-protein
up	O
-	O
regulated	O
the	O
PKC	B-protein
epsilon	I-protein
levels	O
by	O
1	O
.	O
6	O
-	O
fold	O
;	O
by	O
contrast	O
the	O
HMW	B-protein
isoform	I-protein
down	O
-	O
regulated	O
the	O
level	O
of	O
this	O
PKC	B-protein
isotype	I-protein
by	O
about	O
3	O
-	O
fold	O
and	O
increased	O
the	O
amount	O
of	O
PKC	B-protein
delta	I-protein
by	O
1	O
.	O
7	O
-	O
fold	O
.	O

Urine	O
samples	O
collected	O
after	O
the	O
administration	O
of	O
these	O
supplements	O
can	O
test	O
positive	O
.	O

In	O
the	O
ultramarathon	O
runner	O
the	O
testosterone	O
levels	O
sharply	O
rose	O
at	O
the	O
beginning	O
of	O
the	O
training	O
session	O
(	O
from	O
the	O
7	O
,	O
20	O
ng	O
/	O
ml	O
to	O
11	O
,	O
50	O
ng	O
/	O
ml	O
after	O
20	O
'	O
training	O
)	O
,	O
and	O
subsequently	O
decrease	O
after	O
3	O
hours	O
(	O
9	O
,	O
20	O
ng	O
/	O
ml	O
)	O
and	O
at	O
the	O
end	O
of	O
the	O
6	O
hours	O
training	O
(	O
4	O
,	O
60	O
ng	O
/	O
ml	O
)	O
.	O

A	O
significant	O
direct	O
relationship	O
was	O
observed	O
between	O
the	O
percent	O
area	O
density	O
of	O
smooth	O
muscle	O
and	O
the	O
percent	O
change	O
in	O
peak	O
urinary	O
flow	O
rate	O
.	O

In	O
a	O
previous	O
study	O
(	O
Brandl	O
,	O
C	O
.	O

Thrombolysis	O
was	O
followed	O
by	O
a	O
similar	O
increase	O
of	O
platelet	O
activity	O
with	O
maximal	O
values	O
reached	O
at	O
the	O
3rd	O
hour	O
in	O
both	O
groups	O
(	O
196	O
+	O
/	O
-	O
43	O
IU	O
/	O
ml	O
in	O
Group	O
1	O
and	O
192	O
+	O
/	O
-	O
39	O
in	O
Group	O
2	O
:	O
p	O
<	O
001versus	O
baseline	O
and	O
p	O
NS	O
between	O
the	O
groups	O
)	O
.	O

The	O
latter	O
was	O
determined	O
as	O
follows	O
:	O
Type	O
I	O
-	O
solid	O
tumor	O
tissue	O
without	O
significant	O
peripheral	O
isolated	O
tumor	O
cells	O
;	O
Type	O
II	O
-	O
solid	O
tumor	O
tissue	O
associated	O
with	O
peripheral	O
isolated	O
tumor	O
cells	O
;	O
Type	O
III	O
-	O
isolated	O
tumor	O
cells	O
only	O
.	O

Comparison	O
of	O
the	O
nucleotide	O
sequences	O
between	O
the	O
human	O
and	O
bovine	O
DNA	O
showed	O
that	O
the	O
sequence	O
similarity	O
extended	O
2400	O
bp	O
downstream	O
from	O
the	O
coding	O
region	O
.	O

Antivitamin	O
K	O
agents	O
.	O

Simultaneously	O
a	O
greater	O
NA	O
was	O
found	O
with	O
no	O
change	O
in	O
plasma	O
epinephrine	O
response	O
.	O

The	O
behavior	O
of	O
different	O
types	O
of	O
polytetrafluoroethylene	O
(	O
PTFE	O
)	O
prostheses	O
in	O
the	O
reparative	O
scarring	O
process	O
of	O
abdominal	O
wall	O
defects	O
.	O

IX	O
.	O

Among	O
the	O
mixed	O
race	O
persons	O
one	O
Chukcha	O
-	O
Eskimo	O
had	O
AS	O
,	O
one	O
Eskimo	O
-	O
Russian	O
had	O
psoriatic	O
arthritis	O
(	O
PsA	O
)	O
.	O

To	O
examine	O
the	O
basis	O
for	O
the	O
apparent	O
differences	O
in	O
postsegregational	O
killing	O
between	O
the	O
two	O
E	O
.	O
coli	O
strains	O
,	O
transformation	O
assays	O
were	O
carried	O
out	O
to	O
determine	O
the	O
relative	O
sensitivities	O
of	O
the	O
strains	O
to	O
the	O
ParE	B-protein
toxin	I-protein
protein	I-protein
.	O

The	O
mHIF	B-protein
-	I-protein
1	I-protein
alpha	I-protein
structural	I-protein
gene	I-protein
is	O
composed	O
of	O
15	O
exons	O
.	O

Variability	O
within	O
Down	O
'	O
s	O
syndrome	O
(	O
trisomy	O
-	O
21	O
)	O
:	O
empirically	O
observed	O
sex	O
differences	O
in	O
IQs	O
.	O

Very	O
small	O
deletions	O
within	O
the	O
conserved	O
region	O
completely	O
abolished	O
transforming	O
activity	O
of	O
dbl	B-protein
,	O
while	O
extensive	O
deletion	O
outside	O
of	O
this	O
region	O
had	O
no	O
effect	O
.	O

Studies	O
on	O
the	O
organic	O
matrix	O
of	O
human	O
ear	O
ossicles	O
.	O

These	O
differences	O
are	O
smaller	O
than	O
those	O
described	O
in	O
standard	O
textbooks	O
.	O

The	O
algorithm	O
also	O
limited	O
TG	O
to	O
20	O
and	O
64	O
%	O
,	O
apoB	B-protein
to	O
6	O
and	O
20	O
%	O
,	O
and	O
Lp	B-protein
(	I-protein
a	I-protein
)	I-protein
to	O
15	O
and	O
56	O
%	O
,	O
of	O
low	O
-	O
and	O
high	O
-	O
risk	O
groups	O
,	O
respectively	O
.	O

Following	O
the	O
patients	O
during	O
a	O
course	O
of	O
therapy	O
with	O
a	O
selective	O
vasodilator	O
calcium	O
antagonist	O
,	O
the	O
beta	O
-	O
adrenergic	O
reflex	O
vasodilation	O
became	O
substantially	O
attenuated	O
but	O
was	O
preserved	O
during	O
a	O
placebo	O
course	O
of	O
therapy	O
.	O

Two	O
members	O
of	O
the	O
Cbl	B-protein
family	I-protein
have	O
since	O
been	O
defined	O
in	O
mammals	O
(	O
c	B-protein
-	I-protein
Cbl	I-protein
and	O
Cbl	B-protein
-	I-protein
b	I-protein
)	O
,	O
one	O
in	O
C	O
.	O
elegans	O
(	O
Sli	B-protein
-	I-protein
1	I-protein
)	O
and	O
one	O
in	O
Drosophila	O
(	O
D	B-protein
-	I-protein
Cbl	I-protein
)	O
.	O

Fourteen	O
healthy	O
male	O
volunteers	O
completed	O
the	O
study	O
.	O

Comparisons	O
of	O
the	O
four	O
operon	O
control	O
regions	O
studied	O
indicate	O
that	O
the	O
NarL	B-protein
heptamers	I-protein
are	O
arranged	O
with	O
diverse	O
orientations	O
and	O
spacing	O
.	O

Sci	O
.	O

The	O
secondary	O
,	O
but	O
not	O
the	O
primary	O
,	O
antibody	O
responses	O
of	O
male	O
C57Bl	O
/	O
6	O
mice	O
were	O
higher	O
among	O
mice	O
housed	O
alone	O
compared	O
to	O
mice	O
housed	O
in	O
groups	O
;	O
differences	O
were	O
observed	O
for	O
both	O
IgM	B-protein
and	O
IgG	B-protein
anti	I-protein
-	I-protein
KLH	I-protein
antibodies	I-protein
.	O

TaV	O
particles	O
have	O
a	O
buoyant	O
density	O
of	O
1	O
.	O
296	O
g	O
/	O
cm3	O
in	O
CsCl	O
and	O
consist	O
of	O
two	O
capsid	O
proteins	O
of	O
56	O
and	O
6	O
kDa	O
.	O

Demonstration	O
of	O
tissue	O
lesions	O
after	O
intramuscular	O
injection	O
by	O
determination	O
of	O
creatine	B-protein
kinase	I-protein
in	O
blood	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
control	O
hypertension	O
and	O
keep	O
appropriate	O
renal	O
blood	O
flow	O
during	O
living	O
renal	O
transplantation	O
surgery	O
.	O

Neither	O
mutant	O
exhibited	O
derepression	O
of	O
the	O
silent	B-protein
mating	I-protein
type	I-protein
loci	I-protein
.	O

Transcriptional	O
activation	O
of	O
the	O
chicken	B-protein
lysozyme	I-protein
gene	I-protein
by	O
NF	B-protein
-	I-protein
kappa	I-protein
Bp65	I-protein
(	O
RelA	B-protein
)	O
and	O
c	B-protein
-	I-protein
Rel	I-protein
,	O
but	O
not	O
by	O
NF	B-protein
-	I-protein
kappa	I-protein
Bp50	I-protein
.	O

Current	O
diagnostic	O
uses	O
of	O
computerized	O
tomography	O
in	O
clinical	O
medicine	O
.	O

Re	O
-	O
examining	O
methylbenzene	O
(	O
toluene	O
)	O
as	O
a	O
treatment	O
for	O
Ancylostomum	O
caninum	O
.	O

Mean	O
fluorosis	O
scores	O
,	O
however	O
,	O
were	O
similar	O
.	O

The	O
subgroup	O
innervating	O
the	O
medial	O
rectus	O
lies	O
exclusively	O
along	O
the	O
medial	O
face	O
of	O
the	O
oculomotor	O
nucleus	O
,	O
with	O
no	O
aberrant	O
neurons	O
in	O
the	O
medial	O
longitudinal	O
fasciculus	O
,	O
as	O
have	O
been	O
found	O
in	O
other	O
mammals	O
.	O

Responsiveness	O
to	O
beta	O
-	O
2	O
agonist	O
therapy	O
was	O
retained	O
with	O
both	O
agents	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
TCF	B-protein
-	I-protein
1	I-protein
alpha	I-protein
binding	I-protein
site	I-protein
was	O
also	O
required	O
for	O
TCR	B-protein
alpha	I-protein
enhancer	I-protein
activity	O
in	O
transcriptionally	O
active	O
extracts	O
from	O
Jurkat	O
but	O
not	O
HeLa	O
cells	O
,	O
confirming	O
that	O
TCF	B-protein
-	I-protein
1	I-protein
alpha	I-protein
is	O
a	O
T	B-protein
-	I-protein
cell	I-protein
-	I-protein
specific	I-protein
transcription	I-protein
factor	I-protein
.	O

The	O
interleukin	B-protein
2	I-protein
receptor	I-protein
alpha	I-protein
-	I-protein
chain	I-protein
(	O
IL	B-protein
-	I-protein
2R	I-protein
alpha	I-protein
)	O
gene	O
is	O
rapidly	O
and	O
potently	O
induced	O
in	O
T	O
cells	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O

Prediction	O
of	O
the	O
times	O
of	O
sandfly	O
development	O
.	O

A	O
mixture	O
of	O
human	B-protein
albumin	I-protein
5	O
%	O
and	O
hydroxy	O
-	O
ethyl	O
-	O
starch	O
was	O
used	O
as	O
a	O
solution	O
for	O
dilution	O
.	O

Several	O
7SL	B-protein
RNA	I-protein
-	I-protein
encoding	I-protein
sequences	I-protein
and	O
various	O
intergenic	O
spacers	O
were	O
amplified	O
from	O
the	O
individual	O
HindIII	B-protein
fragments	I-protein
of	O
about	O
1	O
.	O
3	O
and	O
2	O
.	O
8	O
kb	O
.	O

Tctex	B-protein
-	I-protein
1	I-protein
binding	O
required	O
the	O
first	O
19	O
amino	O
acids	O
of	O
Fyn	B-protein
and	O
integrity	O
of	O
two	O
lysine	O
residues	O
within	O
this	O
sequence	O
that	O
were	O
previously	O
shown	O
to	O
be	O
important	O
for	O
Fyn	B-protein
interactions	O
with	O
the	O
immunoreceptor	B-protein
tyrosine	I-protein
-	I-protein
based	I-protein
activation	I-protein
motifs	I-protein
(	O
ITAMs	B-protein
)	O
of	O
lymphocyte	B-protein
Ag	I-protein
receptors	I-protein
.	O

Hydroxypropyl	O
methacrylate	O
,	O
a	O
new	O
water	O
-	O
miscible	O
embedding	O
medium	O
for	O
electron	O
microscopy	O
.	O

Significant	O
correlations	O
between	O
mental	O
status	O
as	O
measured	O
by	O
the	O
Mini	O
-	O
Mental	O
State	O
Examination	O
and	O
NA	O
/	O
mI	O
,	O
mI	O
/	O
Cr	O
and	O
NA	O
were	O
found	O
.	O

Like	O
humans	O
,	O
the	O
PITSLRE	B-protein
PK	I-protein
genes	I-protein
in	I-protein
chickens	I-protein
must	O
be	O
closely	O
linked	O
,	O
based	O
on	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
localization	O
of	O
these	O
genes	O
to	O
a	O
single	O
chicken	O
microchromosome	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
kinetics	O
of	O
erythropoietin	B-protein
(	O
EPO	B-protein
)	O
production	O
and	O
address	O
the	O
pathogenesis	O
of	O
anemia	O
of	O
prematurity	O
,	O
we	O
measured	O
EPO	B-protein
levels	O
in	O
infants	O
during	O
the	O
first	O
year	O
of	O
life	O
.	O

Protein	B-protein
kinases	I-protein
play	O
pivotal	O
roles	O
in	O
the	O
control	O
of	O
many	O
cellular	O
processes	O
.	O

In	O
the	O
former	O
cells	O
,	O
ets	B-protein
-	I-protein
2	I-protein
was	O
a	O
CSF	B-protein
-	I-protein
1	I-protein
immediate	I-protein
-	I-protein
early	I-protein
response	I-protein
gene	I-protein
,	O
and	O
phosphorylated	O
ets	B-protein
-	I-protein
2	I-protein
was	O
detected	O
after	O
2	O
to	O
4	O
h	O
,	O
coincident	O
with	O
expression	O
of	O
ets	B-protein
-	I-protein
2	I-protein
protein	I-protein
.	O

Mutation	O
analysis	O
implicated	O
multiple	O
segments	O
of	O
the	O
5	O
'	O
untranslated	O
region	O
as	O
contributing	O
to	O
the	O
inhibitory	O
effect	O
.	O

Pathology	O
of	O
neuritis	O
caudae	O
equinae	O
in	O
the	O
horse	O
.	O

Two	O
new	O
glucosidase	B-protein
inhibitors	O
(	O
BAY	O
m	O
1099	O
and	O
BAY	O
o	O
1248	O
)	O
were	O
studied	O
in	O
volunteers	O
and	O
type	O
II	O
diabetics	O
under	O
various	O
conditions	O
.	O

The	O
characteristics	O
of	O
the	O
VirD1	O
/	O
VirD2	O
-	O
mediated	O
cleavage	O
reaction	O
strongly	O
resemble	O
those	O
observed	O
with	O
relaxosomes	O
of	O
IncP	O
plasmids	O
involved	O
in	O
initiation	O
of	O
transfer	O
DNA	O
replication	O
during	O
bacterial	O
conjugation	O
.	O

These	O
results	O
suggest	O
that	O
UBP41	B-protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
recycling	O
of	O
ubiquitin	B-protein
by	O
hydrolysis	O
of	O
branched	B-protein
poly	I-protein
-	I-protein
ubiquitin	I-protein
chains	I-protein
generated	O
by	O
the	O
action	O
of	O
26	B-protein
S	I-protein
proteasome	I-protein
on	O
poly	O
-	O
ubiquitinated	O
protein	O
substrates	O
,	O
as	O
well	O
as	O
in	O
the	O
production	O
of	O
free	O
ubiquitin	B-protein
from	O
linear	B-protein
poly	I-protein
-	I-protein
ubiquitin	I-protein
chains	I-protein
and	O
of	O
certain	O
ribosomal	O
proteins	O
from	O
ubiquitin	B-protein
fusion	I-protein
proteins	I-protein
.	O

Results	O
of	O
the	O
ECAT	O
Angina	O
Pectoris	O
Study	O
Group	O
.	O

Conversely	O
,	O
activation	O
of	O
Oct	B-protein
-	I-protein
3	I-protein
/	I-protein
4	I-protein
promoter	I-protein
by	O
RAR	B-protein
:	O
RXR	B-protein
heterodimers	I-protein
was	O
completely	O
abolished	O
by	O
EAR	B-protein
-	I-protein
3	I-protein
/	I-protein
COUP	I-protein
-	I-protein
TFI	I-protein
and	O
by	O
ARP	B-protein
-	I-protein
1	I-protein
/	I-protein
COUP	I-protein
-	I-protein
TFII	I-protein
.	O

At	O
both	O
water	O
temperatures	O
,	O
VO2	O
increased	O
linearly	O
with	O
increasing	O
swimming	O
velocity	O
.	O

In	O
adult	O
tissues	O
,	O
it	O
was	O
less	O
restricted	O
,	O
indicating	O
that	O
RAFTK	B-protein
expression	O
is	O
developmentally	O
up	O
-	O
regulated	O
.	O

A	O
cytosolic	O
variant	O
of	O
the	O
protein	O
underwent	O
efficient	O
transphosphorylation	O
,	O
yet	O
failed	O
to	O
activate	O
appreciably	O
either	O
p70	B-protein
(	I-protein
S6k	I-protein
)	I-protein
or	O
MAP	B-protein
kinase	I-protein
following	O
treatment	O
with	O
FK1012	O
.	O

Recent	O
studies	O
have	O
shown	O
the	O
rat	O
larynx	O
to	O
be	O
an	O
important	O
organ	O
in	O
the	O
evaluation	O
of	O
irritancy	O
of	O
inhaled	O
materials	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
Rat7p	B-protein
/	I-protein
Nup159p	I-protein
is	O
anchored	O
within	O
the	O
NPC	B-protein
through	O
its	O
coiled	O
-	O
coil	O
region	O
and	O
adjacent	O
sequences	O
.	O

There	O
is	O
now	O
a	O
significative	O
difference	O
between	O
age	O
group	O
1	O
-	O
5	O
and	O
the	O
others	O
(	O
p	O
Less	O
Than	O
0	O
,	O
02	O
)	O
.	O

Role	O
of	O
histoclinical	O
studies	O
in	O
the	O
prophylaxis	O
of	O
spontaneous	O
abortions	O
.	O

Our	O
results	O
indicate	O
that	O
RA	O
-	O
mediated	O
repression	O
of	O
the	O
hMGP	B-protein
gene	I-protein
is	O
due	O
to	O
binding	O
of	O
liganded	O
RAR	B-protein
/	I-protein
RXR	I-protein
to	O
a	O
novel	O
negative	O
RA	B-protein
response	I-protein
element	I-protein
.	O

The	O
mean	O
waiting	O
time	O
to	O
receive	O
the	O
pancreas	O
transplant	O
was	O
244	O
days	O
for	O
SPK	O
and	O
167	O
days	O
for	O
PAK	O
recipients	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

The	O
prevalence	O
of	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
is	O
relatively	O
low	O
in	O
childhood	O
,	O
with	O
anti	O
-	O
HCV	O
prevalence	O
rates	O
of	O
0	O
.	O
1	O
-	O
0	O
.	O
4	O
%	O
in	O
the	O
Western	O
world	O
.	O

Hybridization	O
of	O
a	O
probe	O
from	O
this	O
region	O
to	O
electrophoretic	O
blots	O
of	O
RNAs	O
from	O
different	O
human	O
tissues	O
showed	O
a	O
predominant	O
2	O
.	O
8	O
-	O
kilobase	O
(	O
kb	O
)	O
message	O
accompanied	O
by	O
weaker	O
bands	O
4	O
.	O
1	O
and	O
2	O
.	O
1	O
kb	O
in	O
size	O
.	O

Both	O
strains	O
grew	O
very	O
poorly	O
,	O
or	O
not	O
at	O
all	O
,	O
on	O
nonfermentable	O
carbon	O
sources	O
and	O
exhibited	O
,	O
at	O
most	O
,	O
only	O
5	O
%	O
of	O
wild	B-protein
-	I-protein
type	I-protein
ubiquinol	I-protein
-	I-protein
cytochrome	I-protein
c	I-protein
oxidoreductase	I-protein
activity	O
.	O

Consciousness	O
is	O
connected	O
with	O
attention	O
,	O
working	O
memory	O
and	O
perception	O
.	O

Certain	O
transcript	O
patterns	O
in	O
Epifagus	O
plastids	O
are	O
highly	O
complex	O
and	O
similar	O
to	O
those	O
of	O
tobacco	O
operons	O
.	O

The	O
putative	O
immunity	O
protein	O
was	O
detected	O
among	O
the	O
[	O
35S	O
]	O
methionine	O
-	O
labelled	O
proteins	O
produced	O
by	O
minicells	O
carrying	O
cni	B-protein
cloned	O
under	O
lac	B-protein
promoter	I-protein
control	O
,	O
and	O
when	O
the	O
gene	O
was	O
subcloned	O
into	O
expression	O
vectors	O
under	O
the	O
control	O
of	O
a	O
bacteriophage	O
T7	O
promoter	O
.	O

This	O
region	O
includes	O
verA	B-protein
,	O
a	O
structural	O
gene	O
previously	O
shown	O
to	O
be	O
required	O
for	O
ST	B-protein
biosynthesis	O
,	O
and	O
24	O
additional	O
closely	O
spaced	O
transcripts	O
ranging	O
in	O
size	O
from	O
0	O
.	O
6	O
to	O
7	O
.	O
2	O
kb	O
that	O
are	O
coordinately	O
induced	O
only	O
under	O
ST	O
-	O
producing	O
conditions	O
.	O

In	O
transformed	O
E	O
.	O
coli	O
,	O
constitutive	B-protein
CAT	I-protein
expression	O
is	O
maintained	O
when	O
as	O
little	O
as	O
0	O
.	O
3	O
kilobase	O
of	O
DNA	O
from	O
the	O
3	O
'	O
end	O
of	O
the	O
1	O
.	O
6	O
-	O
kilobase	O
segment	O
is	O
inserted	O
in	O
the	O
correct	O
orientation	O
in	O
front	O
of	O
the	O
CAT	B-protein
gene	I-protein
.	O

The	O
determination	O
of	O
physical	O
performance	O
capacity	O
was	O
based	O
on	O
W170	O
,	O
W85	O
%	O
and	O
on	O
predicted	O
VO2	O
max	O
measured	O
with	O
continuously	O
increasing	O
work	O
load	O
on	O
a	O
bicycle	O
ergometer	O
.	O

The	O
effects	O
of	O
a	O
1	O
-	O
or	O
24	O
-	O
hour	O
pretreatment	O
regimen	O
with	O
monophosphoryl	O
lipid	O
A	O
(	O
MLA	O
,	O
35	O
micrograms	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
on	O
myocardial	O
stunning	O
produced	O
by	O
repetitive	O
coronary	O
occlusions	O
were	O
studied	O
in	O
barbital	O
-	O
anesthetized	O
dogs	O
.	O

The	O
spermicide	O
nonoxynol	O
-	O
9	O
is	O
a	O
member	O
of	O
a	O
homologous	O
series	O
of	O
alkylphenol	O
-	O
ethoxylates	O
(	O
polyethoxyethanols	O
)	O
of	O
general	O
formula	O
C9H19	O
-	O
C6H6	O
-	O
O	O
-	O
(	O
CH2CH2O	O
)	O
n	O
-	O
1	O
CH2CH2OH	O
.	O

According	O
to	O
their	O
functional	O
properties	O
the	O
latter	O
neurons	O
were	O
subdivided	O
into	O
:	O
(	O
a	O
)	O
neurons	O
responding	O
to	O
stimuli	O
near	O
the	O
eyes	O
;	O
(	O
b	O
)	O
neurons	O
triggered	O
by	O
complex	O
visual	O
stimuli	O
;	O
(	O
c	O
)	O
neurons	O
inhibited	O
by	O
visual	O
stimuli	O
.	O

Observers	O
with	O
brain	O
injury	O
and	O
control	O
participants	O
performed	O
a	O
vigilance	O
task	O
during	O
which	O
they	O
received	O
periodic	O
whiffs	O
of	O
unscented	O
air	O
or	O
air	O
scented	O
with	O
peppermint	O
.	O

To	O
explore	O
the	O
functional	O
relationship	O
between	O
c	B-protein
-	I-protein
fos	I-protein
and	O
Rb	B-protein
,	O
a	O
eukaryotic	O
expression	O
plasmid	O
was	O
constructed	O
containing	O
the	O
c	B-protein
-	I-protein
fos	I-protein
gene	I-protein
under	O
control	O
of	O
the	O
SV40	O
promoter	O
complex	O
.	O

The	O
neuroleptic	O
-	O
induced	O
increase	O
in	O
central	O
DA	O
turnover	O
(	O
an	O
indicator	O
for	O
the	O
degree	O
of	O
DA	B-protein
receptor	I-protein
blocking	O
)	O
was	O
found	O
to	O
be	O
positively	O
correlated	O
with	O
the	O
therapeutic	O
effect	O
of	O
neuroleptics	O
and	O
the	O
development	O
of	O
hypokinetic	O
-	O
rigid	O
symptoms	O
.	O

Effects	O
of	O
Trypanosoma	O
vivax	O
on	O
pregnancy	O
of	O
Yankasa	O
sheep	O
and	O
the	O
results	O
of	O
homidum	O
chloride	O
chemotherapy	O
.	O

155	O
aa	O
,	O
shares	O
78	O
%	O
identity	O
with	O
the	O
analogous	O
region	O
of	O
Xenopus	O
laevis	O
FGF3	B-protein
and	O
72	O
%	O
identity	O
with	O
the	O
product	O
of	O
the	O
more	O
distantly	O
related	O
human	O
gene	O
.	O

J	O
.	O

Removal	O
of	O
all	O
core	B-protein
histone	I-protein
tail	O
domains	O
by	O
limited	O
trypsin	B-protein
proteolysis	O
or	O
acetylation	O
of	O
the	O
core	B-protein
histone	I-protein
tails	O
significantly	O
relieves	O
this	O
inhibition	O
and	O
allows	O
TFIIIA	B-protein
to	O
exhibit	O
high	O
-	O
affinity	O
binding	O
to	O
nucleosomal	O
DNA	O
.	O

Agonist	B-protein
-	I-protein
induced	I-protein
receptor	I-protein
internalization	O
,	O
determined	O
as	O
the	O
percent	O
of	O
total	O
[	O
125I	O
]	O
Tyr0	B-protein
-	I-protein
oCRF	I-protein
bound	O
located	O
in	O
the	O
acid	O
-	O
resistant	O
fraction	O
of	O
transfected	O
Cos	O
7	O
cells	O
,	O
increased	O
with	O
time	O
(	O
0	O
-	O
60	O
min	O
at	O
37	O
degrees	O
C	O
)	O
for	O
both	O
wild	O
-	O
type	O
and	O
variant	O
oCRF1	B-protein
.	O

Surprisingly	O
,	O
Northern	O
(	O
RNA	O
)	O
blot	O
analysis	O
and	O
reverse	O
transcriptase	O
-	O
PCRs	O
performed	O
after	O
transfection	O
of	O
COS	O
-	O
7	O
or	O
HeLa	O
cells	O
with	O
these	O
viral	O
RNAs	O
revealed	O
that	O
Y88S	B-protein
and	O
Y88L	B-protein
RNAs	I-protein
replicated	O
at	O
only	O
very	O
low	O
levels	O
.	O

Comparison	O
of	O
the	O
genomic	O
DNA	O
sequence	O
with	O
that	O
of	O
the	O
four	O
different	O
mRNAs	O
indicates	O
that	O
these	O
transcripts	O
are	O
produced	O
by	O
alternative	O
splicing	O
of	O
the	O
murine	O
pre	O
-	O
mRNA	O
according	O
to	O
a	O
cassette	O
model	O
.	O

The	O
STAT	B-protein
protein	I-protein
accumulation	O
resulting	O
from	O
C	B-protein
/	I-protein
EBP	I-protein
expression	O
was	O
tightly	O
coupled	O
to	O
the	O
morphological	O
conversion	O
of	O
fibroblasts	O
to	O
adipocytes	O
and	O
represents	O
an	O
expression	O
profile	O
identical	O
to	O
that	O
reported	O
for	O
mature	O
adipocytes	O
in	O
vivo	O
.	O

To	O
illustrate	O
its	O
performance	O
,	O
measurements	O
of	O
photoluminescence	O
in	O
GaAs	O
/	O
AlGaAs	O
heterostructures	O
are	O
presented	O
.	O

Further	O
,	O
the	O
ability	O
of	O
recombinant	B-protein
beta	I-protein
and	I-protein
/	I-protein
or	I-protein
gamma	I-protein
chains	I-protein
to	O
function	O
in	O
defined	O
biochemical	O
assays	O
of	O
beta	B-protein
gamma	I-protein
activity	O
was	O
assessed	O
for	O
membrane	O
extracts	O
and	O
supernatant	O
fractions	O
from	O
infected	O
Sf9	O
cells	O
.	O

TRAF2	B-protein
is	O
known	O
to	O
associate	O
with	O
TRADD	B-protein
,	O
and	O
expression	O
of	O
a	O
dominant	O
-	O
negative	O
N	O
-	O
terminal	O
deletion	O
TRAF2	B-protein
mutant	I-protein
was	O
found	O
to	O
partially	O
inhibit	O
LMP1	O
-	O
induced	O
JNK	B-protein
activation	O
in	O
293	O
cells	O
.	O

A	O
portion	O
of	O
Region	O
II	O
also	O
resembles	O
part	O
of	O
the	O
human	O
c	B-protein
-	I-protein
jun	I-protein
oncoprotein	O
'	O
s	O
leucine	O
zipper	O
,	O
which	O
in	O
turn	O
,	O
has	O
been	O
demonstrated	O
to	O
be	O
the	O
heterodimerization	O
site	O
between	O
the	O
jun	B-protein
and	O
fos	B-protein
oncoproteins	I-protein
.	O

Buflomedil	O
(	O
i	O
.	O
v	O
.	O
)	O
induced	O
a	O
dose	O
-	O
dependent	O
increase	O
of	O
cardiac	O
output	O
at	O
0	O
.	O
16	O
-	O
0	O
.	O
64	O
mg	O
/	O
kg	O
,	O
biphasic	O
changes	O
at	O
1	O
.	O
28	O
and	O
2	O
.	O
56	O
mg	O
/	O
kg	O
and	O
a	O
marked	O
decrease	O
and	O
subsequent	O
slight	O
increase	O
at	O
a	O
large	O
dose	O
of	O
5	O
.	O
12	O
mg	O
/	O
kg	O
.	O

The	O
rates	O
of	O
total	O
energy	O
use	O
(	O
mean	O
+	O
/	O
-	O
SD	O
=	O
39	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
2	O
vs	O
35	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
3	O
kJ	O
X	O
min	O
-	O
1	O
;	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
were	O
significantly	O
higher	O
at	O
-	O
10	O
degrees	O
C	O
than	O
at	O
22	O
degrees	O
C	O
.	O

In	O
addition	O
to	O
the	O
protein	B-protein
-	I-protein
tyrosine	I-protein
kinase	I-protein
domain	I-protein
,	O
p56lck	B-protein
possesses	O
Src	B-protein
homology	I-protein
2	I-protein
and	I-protein
3	I-protein
(	O
SH2	B-protein
and	O
SH3	B-protein
)	O
domains	O
as	O
well	O
as	O
a	O
unique	O
N	O
-	O
terminal	O
region	O
.	O

Each	O
binding	O
site	O
,	O
however	O
,	O
was	O
different	O
in	O
its	O
preference	O
for	O
binding	O
partners	O
.	O

An	O
ASIC	O
-	O
chip	O
for	O
stereoscopic	O
depth	O
analysis	O
in	O
video	O
-	O
real	O
-	O
time	O
based	O
on	O
visual	O
cortical	O
cell	O
behavior	O
.	O

We	O
have	O
isolated	O
a	O
cDNA	O
encoding	O
human	B-protein
MEKK3	I-protein
.	O

Human	B-protein
acid	I-protein
ceramidase	I-protein
(	I-protein
(	I-protein
AC	I-protein
)	I-protein
N	I-protein
-	I-protein
acylsphingosine	I-protein
amidohydrolase	I-protein
,	O
EC	B-protein
3	I-protein
.	I-protein
5	I-protein
.	O

Mutagenesis	O
of	O
SNT1	B-protein
(	I-protein
IRS	I-protein
)	I-protein
CX	I-protein
identified	O
three	O
classes	O
of	O
effector	O
motifs	O
within	O
SNT	B-protein
critical	O
for	O
both	O
sustained	O
ERK	B-protein
activation	O
and	O
neuronal	O
differentiation	O
:	O
1	O
)	O
four	O
phosphotyrosine	O
motifs	O
that	O
mediate	O
recruitment	O
of	O
Grb2	B-protein
,	O
2	O
)	O
two	O
phosphotyrosine	O
motifs	O
that	O
mediate	O
recruitment	O
of	O
Shp2	B-protein
,	O
and	O
3	O
)	O
a	O
C	O
-	O
terminal	O
motif	O
that	O
functions	O
by	O
helping	O
to	O
recruit	O
Sos	B-protein
.	O

Indium	O
-	O
111	O
leukocyte	O
imaging	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
.	O

The	O
only	O
isolate	O
of	O
Aeromonas	O
hydrophila	O
produced	O
cytotoxic	O
enterotoxin	B-protein
and	O
was	O
invasive	O
.	O

On	O
Days	O
1	O
and	O
14	O
,	O
most	O
young	O
and	O
elderly	O
subjects	O
exhibited	O
monoexponential	O
decline	O
in	O
bevantolol	O
plasma	O
concentrations	O
after	O
absorption	O
phase	O
.	O

Although	O
the	O
mechanism	O
of	O
action	O
of	O
ICRF	O
-	O
159	O
and	O
187	O
has	O
not	O
been	O
clearly	O
defined	O
,	O
it	O
is	O
evident	O
from	O
both	O
preclinical	O
and	O
early	O
clinical	O
studies	O
that	O
these	O
compounds	O
are	O
of	O
interest	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
KRAB	B-protein
domain	I-protein
present	O
in	O
the	O
non	O
-	O
finger	O
region	O
of	O
many	O
ZFP	B-protein
genes	I-protein
quenches	O
transcription	O
possibly	O
due	O
to	O
specific	O
protein	O
-	O
protein	O
interactions	O
between	O
the	O
KRAB	B-protein
-	I-protein
A	I-protein
domain	I-protein
and	O
components	O
of	O
the	O
proximal	O
transcriptional	O
apparatus	O
.	O

We	O
investigated	O
the	O
incidence	O
of	O
congenital	O
color	O
deficiency	O
among	O
Koreans	O
by	O
the	O
use	O
of	O
H	O
-	O
R	O
-	O
R	O
pseudoisochromatic	O
plates	O
.	O

We	O
suggest	O
that	O
sensitivity	O
to	O
photoperiod	O
in	O
pallid	O
bats	O
,	O
as	O
in	O
several	O
other	O
mammals	O
,	O
is	O
mediated	O
by	O
the	O
pineal	O
gland	O
.	O

The	O
debate	O
over	O
electives	O
-	O
-	O
1899	O
.	O

This	O
report	O
presents	O
an	O
analysis	O
of	O
the	O
vocal	O
repertoire	O
of	O
howler	O
monkeys	O
(	O
Alouatta	O
palliata	O
)	O
observed	O
during	O
a	O
field	O
study	O
in	O
southwestern	O
Panama	O
.	O

The	O
sequence	O
analysis	O
of	O
both	O
products	O
of	O
individual	O
phi	O
80	O
site	O
-	O
specific	O
recombination	O
events	O
in	O
vivo	O
shows	O
that	O
recombination	O
with	O
a	O
secondary	O
attachment	O
(	O
att	O
)	O
site	O
generates	O
several	O
different	O
novel	O
joints	O
at	O
the	O
mismatched	O
position	O
:	O
one	O
recombination	O
event	O
resulted	O
in	O
a	O
single	O
base	O
-	O
pair	O
deletion	O
and	O
two	O
other	O
recombination	O
events	O
resulted	O
in	O
two	O
different	O
single	O
base	O
-	O
pair	O
substitutions	O
.	O

Epidermal	B-protein
growth	I-protein
factor	I-protein
receptor	I-protein
transcriptionally	O
up	O
-	O
regulates	O
vascular	B-protein
endothelial	I-protein
growth	I-protein
factor	I-protein
expression	O
in	O
human	O
glioblastoma	O
cells	O
via	O
a	O
pathway	O
involving	O
phosphatidylinositol	B-protein
3	I-protein
'	I-protein
-	I-protein
kinase	I-protein
and	O
distinct	O
from	O
that	O
induced	O
by	O
hypoxia	O
.	O

A	O
candidate	O
gene	O
for	O
Bcg	B-protein
,	O
designated	O
natural	B-protein
resistance	I-protein
-	I-protein
associated	I-protein
macrophage	I-protein
protein	I-protein
(	O
Nramp	B-protein
)	O
,	O
has	O
been	O
isolated	O
and	O
shown	O
to	O
encode	O
a	O
novel	O
macrophage	O
-	O
specific	O
membrane	O
protein	O
,	O
which	O
is	O
altered	O
in	O
susceptible	O
animals	O
.	O

The	O
triple	O
combination	O
of	O
nizatidine	O
,	O
clarithromycin	O
,	O
and	O
bismuth	O
subcitrate	O
resulted	O
in	O
an	O
ulcer	O
healing	O
rate	O
of	O
98	O
%	O
and	O
an	O
H	O
.	O
pylori	O
eradication	O
rate	O
of	O
90	O
%	O
.	O

Continued	O
absorption	O
of	O
amino	O
acids	O
by	O
the	O
NBB	O
carrier	O
(	O
for	O
neutral	O
amino	O
acids	O
)	O
,	O
the	O
Y	O
+	O
system	O
(	O
for	O
dibasic	O
amino	O
acids	O
)	O
,	O
and	O
the	O
PHE	O
carrier	O
were	O
operative	O
even	O
during	O
the	O
actively	O
purging	O
stage	O
of	O
watery	O
diarrhoea	O
due	O
to	O
cholera	O
.	O

Weaned	O
rats	O
were	O
fed	O
a	O
normal	O
diet	O
or	O
a	O
low	O
-	O
protein	O
,	O
low	O
-	O
energy	O
diet	O
,	O
and	O
injected	O
with	O
saline	O
or	O
thyroxine	O
(	O
5	O
micrograms	O
/	O
100	O
g	O
BW	O
)	O
for	O
22	O
days	O
.	O

They	O
also	O
occur	O
in	O
similar	O
locations	O
in	O
the	O
promoters	O
of	O
several	O
other	O
ribosomal	B-protein
protein	I-protein
genes	I-protein
.	O

In	O
the	O
present	O
work	O
,	O
the	O
complete	O
genome	O
sequences	O
of	O
Pyrococcus	O
horikoshii	O
and	O
Pyrococcus	O
abyssi	O
,	O
two	O
species	O
in	O
a	O
genus	O
of	O
hyperthermophilic	O
archaeon	O
(	O
archaebacterium	O
)	O
,	O
were	O
compared	O
to	O
detect	O
large	O
genome	O
polymorphisms	O
linked	O
with	O
restriction	B-protein
-	I-protein
modification	I-protein
gene	I-protein
homologs	I-protein
.	O

A	O
similar	O
chimera	O
was	O
assembled	O
from	O
the	O
two	O
halves	O
of	O
the	O
molecule	O
expressed	O
separately	O
in	O
different	O
bacteria	O
and	O
refolded	O
together	O
.	O

The	O
lemdr1	B-protein
gene	I-protein
was	O
cloned	O
in	O
the	O
expression	O
vector	O
pALTNEO	O
and	O
transfected	O
into	O
wild	O
-	O
type	O
L	O
.	O
enriettii	O
and	O
the	O
resulting	O
transfected	O
cells	O
were	O
resistant	O
to	O
vinblastine	O
but	O
at	O
lower	O
levels	O
than	O
in	O
the	O
selected	O
mutant	O
cells	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
is	O
78	O
.	O
0	O
%	O
identical	O
to	O
the	O
cytoplasmic	B-protein
dynein	I-protein
heavy	I-protein
chain	I-protein
of	I-protein
Neurospora	I-protein
crassa	I-protein
,	O
70	O
.	O
2	O
%	O
identical	O
to	O
that	O
of	O
Aspergillus	O
nidulans	O
and	O
24	O
.	O
8	O
%	O
identical	O
to	O
that	O
of	O
Saccharomyces	O
cerevisiae	O
.	O

Dose	O
standardisation	O
of	O
botulinum	B-protein
toxin	I-protein
.	O

In	O
contrast	O
,	O
an	O
amino	O
-	O
terminal	O
fragment	O
containing	O
the	O
C	B-protein
/	I-protein
H1	I-protein
domain	I-protein
was	O
sufficient	O
for	O
coactivation	O
of	O
Zta	B-protein
transcription	O
and	O
viral	O
reactivation	O
function	O
.	O

The	O
pathogenesis	O
of	O
Dupuytren	O
'	O
s	O
contracture	O
.	O

The	O
uptake	O
of	O
fluorine	O
-	O
18	O
fluorodeoxyglucose	O
(	O
F	O
-	O
18	O
FDG	O
)	O
by	O
a	O
malignant	O
tumor	O
depends	O
on	O
the	O
blood	O
glucose	O
level	O
.	O

The	O
inhibition	O
of	O
StAR	B-protein
gene	I-protein
transcription	O
by	O
DAX	B-protein
-	I-protein
1	I-protein
was	O
dose	O
-	O
dependent	O
reducing	O
transcription	O
to	O
6	O
%	O
of	O
control	O
levels	O
.	O

These	O
results	O
suggest	O
that	O
5	O
KE	O
X	O
3	O
/	O
W	O
may	O
be	O
the	O
optimal	O
regimen	O
to	O
augment	O
the	O
antitumor	O
immunity	O
of	O
RNL	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
silymarin	O
may	O
exert	O
a	O
strong	O
anticarcinogenic	O
effect	O
against	O
PCA	O
and	O
that	O
this	O
effect	O
is	O
likely	O
to	O
involve	O
impairment	O
of	O
erbB1	O
-	O
SHC	O
-	O
mediated	O
signaling	O
pathway	O
,	O
induction	O
of	O
CDKIs	B-protein
,	O
and	O
a	O
resultant	O
G1	O
arrest	O
.	O

Articles	O
addressing	O
valvular	O
heart	O
disease	O
or	O
heart	O
failure	O
secondary	O
to	O
acute	O
myocardial	O
infarction	O
or	O
Chagas	O
'	O
disease	O
were	O
excluded	O
.	O

We	O
further	O
show	O
that	O
proteolytic	O
targeting	O
by	O
calpain	B-protein
II	I-protein
and	O
the	O
proteasome	O
involves	O
different	O
structural	O
elements	O
of	O
YY1	B-protein
.	O

Like	O
their	O
yeast	O
counterpart	O
,	O
the	O
mouse	O
GCN2	B-protein
isoforms	O
contain	O
HisRS	B-protein
-	I-protein
related	I-protein
sequences	I-protein
juxtaposed	O
to	O
the	O
kinase	O
catalytic	O
domain	O
.	O

Vitamin	O
D3	O
plus	O
nicotine	O
treatment	O
produced	O
parallel	O
increases	O
in	O
cardiac	O
mass	O
and	O
elastic	O
modulus	O
,	O
with	O
a	O
significant	O
correlation	O
between	O
the	O
two	O
.	O

Microvessels	O
were	O
counted	O
in	O
a	O
x200	O
field	O
(	O
0	O
.	O
754	O
mm2	O
)	O
in	O
the	O
area	O
of	O
maximal	O
angiogenesis	O
.	O

In	O
endemic	O
BL	O
,	O
the	O
RB2	B-protein
/	I-protein
p130	I-protein
gene	I-protein
is	O
mutated	O
in	O
most	O
of	O
the	O
cases	O
,	O
and	O
the	O
protein	O
is	O
restricted	O
to	O
the	O
cytoplasm	O
.	O

The	O
avian	O
cellular	O
homolog	O
of	O
the	O
oncogene	B-protein
jun	I-protein
.	O

The	O
availability	O
of	O
cryoprecipitate	O
and	O
DDAVP	O
offers	O
an	O
alternative	O
and	O
effective	O
treatment	O
for	O
the	O
temporary	O
reversal	O
of	O
uremic	O
bleeding	O
in	O
patients	O
who	O
require	O
urgent	O
invasive	O
procedures	O
.	O

The	O
intranodal	O
mesothelial	O
cells	O
occupied	O
the	O
sinusoids	O
of	O
the	O
lymph	O
nodes	O
and	O
were	O
initially	O
suspected	O
of	O
being	O
metastatic	O
from	O
the	O
ovarian	O
tumor	O
in	O
each	O
case	O
.	O

A	O
total	O
of	O
7	O
(	O
4	O
males	O
and	O
3	O
females	O
)	O
patients	O
were	O
included	O
in	O
this	O
retrospective	O
study	O
to	O
determine	O
the	O
sensitivity	O
of	O
radioimmunoscintigraphy	O
with	O
I	O
-	O
131	O
labeled	O
anti	O
CEA	B-protein
/	I-protein
CA	I-protein
19	O
-	O
9	O
monoclonal	O
antibodies	O
.	O

We	O
find	O
that	O
the	O
measured	O
Nusselt	O
number	O
decreased	O
about	O
20	O
%	O
over	O
the	O
range	O
of	O
Pr	O
spanned	O
in	O
the	O
experiment	O
.	O

Sodium	O
dodecyl	O
sulphate	O
-	O
induced	O
cleavage	O
by	O
eukaryotic	B-protein
topoisomerase	I-protein
I	I-protein
is	O
known	O
to	O
yield	O
enzyme	O
covalently	O
attached	O
to	O
the	O
3	O
'	O
cut	O
end	O
of	O
the	O
DNA	O
.	O

To	O
identify	O
some	O
of	O
the	O
genes	O
expressed	O
in	O
LPS	O
-	O
activated	O
coelomocytes	O
,	O
we	O
sequenced	O
randomly	O
chosen	O
clones	O
from	O
a	O
directionally	O
constructed	O
cDNA	O
library	O
to	O
produce	O
a	O
set	O
of	O
expressed	O
sequence	O
tags	O
(	O
ESTs	O
)	O
.	O

Adding	O
10	O
mmol	O
SDS	O
/	O
l	O
led	O
to	O
transient	O
inhibition	O
of	O
acidification	O
,	O
metal	O
solubilization	O
and	O
sulfur	O
oxidation	O
.	O

It	O
contained	O
seven	O
extra	O
amino	O
acids	O
of	O
FVVLNLQ	B-protein
;	O
this	O
short	O
stretch	O
of	O
extra	O
sequence	O
was	O
found	O
between	O
Gln	O
(	O
421	O
)	O
and	O
Phe	O
(	O
422	O
)	O
within	O
the	O
SET	B-protein
(	O
Suvar3	B-protein
-	I-protein
9	I-protein
,	I-protein
Enhancer	I-protein
-	I-protein
of	I-protein
-	I-protein
zeste	I-protein
,	I-protein
Trithorax	I-protein
)	O
interacting	O
domain	O
(	O
SID	B-protein
)	O
of	O
rMTM	B-protein
.	O

Therapeutic	O
use	O
of	O
continuous	O
subcutaneous	O
infusion	O
of	O
recombinant	B-protein
human	I-protein
erythropoietin	I-protein
in	O
malnourished	O
predialysis	O
anemic	O
patients	O
with	O
diabetic	O
nephropathy	O
.	O

Circulating	O
platelets	O
may	O
be	O
activated	O
by	O
exposed	O
triple	O
-	O
helical	O
collagen	B-protein
in	O
atherosclerotic	O
lesions	O
in	O
Mg	O
-	O
deficient	O
ruminants	O
.	O

Elevated	O
maternal	B-protein
alpha	I-protein
fetoproteins	I-protein
and	O
oligoamnios	O
:	O
fetal	O
prognosis	O
.	O

Overexpression	O
of	O
the	O
bZip	O
interaction	O
domain	O
of	O
CBP	B-protein
specifically	O
abolishes	O
the	O
positive	O
cross	O
talk	O
between	O
TR	B-protein
and	O
p45	B-protein
/	I-protein
NF	I-protein
-	I-protein
E2	I-protein
.	O

Of	O
these	O
179	O
samples	O
,	O
Mobiluncus	O
SP	O
was	O
observed	O
in	O
35	O
(	O
19	O
.	O
6	O
%	O
)	O
using	O
Gram	O
staining	O
and	O
in	O
18	O
(	O
10	O
.	O
1	O
%	O
)	O
this	O
microorganism	O
was	O
isolated	O
in	O
agar	O
RLK	O
and	O
anaerobic	O
atmosphere	O
.	O

The	O
phi	B-protein
AP3	I-protein
factor	I-protein
is	O
a	O
nuclear	O
phosphoprotein	O
;	O
the	O
extent	O
of	O
its	O
phosphorylation	O
is	O
regulated	O
during	O
the	O
cell	O
cycle	O
.	O

As	O
the	O
half	O
-	O
life	O
of	O
the	O
compound	O
did	O
never	O
exceed	O
8	O
-	O
9	O
h	O
,	O
the	O
data	O
do	O
not	O
support	O
any	O
change	O
of	O
pidotimod	O
administration	O
schedule	O
(	O
every	O
24	O
-	O
12	O
h	O
)	O
.	O

One	O
member	O
of	O
this	O
multigene	O
family	O
,	O
GATA	B-protein
-	I-protein
3	I-protein
,	O
is	O
most	O
abundantly	O
expressed	O
in	O
T	O
lymphocytes	O
,	O
a	O
cellular	O
target	O
for	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
and	O
replication	O
.	O

There	O
were	O
minimal	O
negative	O
effects	O
on	O
hematological	O
parameters	O
,	O
acid	O
-	O
base	O
status	O
,	O
and	O
blood	O
gases	O
.	O

A	O
crucial	O
transcription	O
factor	O
in	O
this	O
process	O
is	O
STAT6	B-protein
,	O
which	O
binds	O
to	O
a	O
specific	O
DNA	O
element	O
upon	O
cytokine	O
activation	O
.	O

Using	O
Ki	O
-	O
ras	O
-	O
transformed	O
3T3	O
cells	O
as	O
a	O
model	O
system	O
,	O
we	O
show	O
that	O
both	O
RA	O
and	O
the	O
'	O
dissociating	O
'	O
retinoids	O
inhibit	O
anchorage	O
-	O
independent	O
cell	O
proliferation	O
,	O
suggesting	O
that	O
retinoid	O
-	O
induced	O
growth	O
inhibition	O
may	O
be	O
related	O
to	O
AP1	B-protein
transrepression	O
.	O

Altogether	O
,	O
our	O
results	O
indicate	O
that	O
the	O
transcriptional	O
activity	O
of	O
Cut	B-protein
proteins	I-protein
is	O
modulated	O
by	O
PKC	B-protein
.	O

References	O
for	O
occupational	O
fitness	O
of	O
adolescents	O
with	O
diseases	O
of	O
the	O
respiratory	O
tract	O
and	O
lungs	O
.	O

Lysosomal	O
enzymes	O
that	O
degrade	O
cartilage	O
are	O
released	O
.	O

We	O
have	O
previously	O
mapped	O
the	O
defect	O
in	O
RIIIS	O
/	O
J	O
to	O
distal	O
mouse	O
Chr	O
11	O
,	O
distinct	O
from	O
the	O
Vwf	B-protein
locus	I-protein
on	O
Chr	O
6	O
.	O

In	O
addition	O
a	O
significant	O
Treatment	O
X	O
Strain	O
interaction	O
was	O
due	O
to	O
the	O
larger	O
defecation	O
numbers	O
displayed	O
by	O
the	O
taurine	O
-	O
injected	O
MR	O
rats	O
relative	O
to	O
the	O
saline	O
-	O
injected	O
MR	O
rats	O
.	O

Retroviral	O
transduction	O
of	O
T	B-protein
/	I-protein
T	I-protein
(	I-protein
L	I-protein
)	I-protein
causes	O
a	O
rapidly	O
fatal	O
myeloproliferative	O
disease	O
in	O
a	O
murine	O
bone	O
marrow	O
transplant	O
(	O
BMT	O
)	O
model	O
,	O
whereas	O
T	B-protein
/	I-protein
T	I-protein
(	I-protein
F	I-protein
)	I-protein
causes	O
a	O
long	O
-	O
latency	O
,	O
pre	O
-	O
B	O
-	O
cell	O
lymphoblastic	O
lymphoma	O
.	O

Typical	O
configurations	O
of	O
psychosocial	O
stress	O
factors	O
of	O
psychiatrically	O
conspicuous	O
children	O
and	O
adolescents	O
.	O

The	O
mutant	O
allele	O
of	O
the	O
alpha	B-protein
1	I-protein
-	I-protein
tubulin	I-protein
gene	I-protein
was	O
designated	O
tua1	B-protein
-	I-protein
1	I-protein
.	O

Similarly	O
approximately	O
300	O
bp	O
of	O
sequence	O
downstream	O
of	O
the	O
translation	O
terminator	O
TGA	O
of	O
the	O
beta	B-protein
-	I-protein
tubulin	I-protein
2	I-protein
(	O
BTU2	B-protein
)	O
gene	O
could	O
substitute	O
for	O
the	O
3	O
'	O
region	O
of	O
the	O
H4	B-protein
-	I-protein
I	I-protein
gene	I-protein
.	O

The	O
gene	O
was	O
uniquely	O
mapped	O
with	O
odds	O
>	O
1	O
,	O
000	O
:	O
1	O
on	O
chromosome	O
3p	O
in	O
Centre	O
d	O
'	O
Etude	O
du	O
Polymorphisme	O
Humain	O
pedigrees	O
.	O

Furthermore	O
,	O
the	O
soluble	O
forms	O
of	O
ATF6	B-protein
and	O
the	O
G13	B-protein
gene	I-protein
product	I-protein
are	O
unable	O
to	O
bind	O
to	O
several	O
point	O
mutants	O
of	O
the	O
cis	O
-	O
acting	O
ER	B-protein
stress	I-protein
response	I-protein
element	I-protein
in	O
vitro	O
that	O
hardly	O
respond	O
to	O
ER	O
stress	O
in	O
vivo	O
.	O

A	O
retrospective	O
study	O
of	O
banked	O
sera	O
from	O
19	O
cats	O
with	O
the	O
eosinophilic	O
granuloma	O
complex	O
revealed	O
that	O
68	O
%	O
of	O
affected	O
cats	O
had	O
circulating	O
antibodies	O
to	O
components	O
of	O
normal	O
cat	O
epithelium	O
.	O

The	O
first	O
one	O
is	O
a	O
TPA	B-protein
-	I-protein
responsive	I-protein
element	I-protein
that	O
controls	O
the	O
base	O
-	O
line	O
ST3	B-protein
promoter	I-protein
activity	O
but	O
is	O
not	O
required	O
for	O
its	O
activation	O
.	O

Cyclic	B-protein
AMP	I-protein
-	I-protein
dependent	I-protein
protein	I-protein
kinase	I-protein
binding	O
to	O
A	B-protein
-	I-protein
kinase	I-protein
anchoring	O
proteins	O
in	O
living	O
cells	O
by	O
fluorescence	O
resonance	O
energy	O
transfer	O
of	O
green	O
fluorescent	O
protein	O
fusion	O
proteins	O
.	O

RESULTS	O
:	O
In	O
the	O
pregnant	O
group	O
,	O
serum	O
PP14	B-protein
concentrations	O
were	O
markedly	O
increased	O
after	O
ET	O
,	O
and	O
a	O
significant	O
difference	O
between	O
the	O
pregnant	O
group	O
and	O
the	O
nonpregnant	O
group	O
was	O
observed	O
8	O
days	O
following	O
ET	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Paf1p	B-protein
may	O
therefore	O
be	O
required	O
for	O
both	O
positive	O
and	O
negative	O
regulation	O
of	O
subsets	O
of	O
yeast	O
genes	O
.	O

We	O
have	O
initiated	O
studies	O
to	O
identify	O
candidate	O
signal	O
transducers	O
that	O
associate	O
with	O
the	O
cytosolic	O
domain	O
(	O
cd	O
)	O
of	O
the	O
IL	B-protein
-	I-protein
1R	I-protein
.	O

To	O
test	O
whether	O
or	O
not	O
SOCS	B-protein
-	I-protein
3	I-protein
also	O
binds	O
to	O
the	O
IGFIR	B-protein
,	O
we	O
cloned	O
human	B-protein
SOCS	I-protein
-	I-protein
3	I-protein
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
from	O
human	O
skeletal	O
muscle	O
mRNA	O
.	O

The	O
CD4	B-protein
count	O
at	O
which	O
remission	O
occurs	O
may	O
reflect	O
severe	O
immunodeficiency	O
such	O
that	O
risk	O
for	O
AIDS	O
-	O
related	O
infection	O
is	O
high	O
.	O

Platelet	O
counts	O
and	O
function	O
as	O
well	O
as	O
fibrinogen	B-protein
and	O
von	B-protein
Willebrand	I-protein
factor	I-protein
(	O
vWF	B-protein
)	O
levels	O
were	O
determined	O
in	O
each	O
sample	O
.	O

The	O
absence	O
of	O
other	O
regions	O
of	O
hybridization	O
suggests	O
that	O
there	O
are	O
no	O
closely	O
related	O
sequences	O
(	O
e	O
.	O
g	O
.	O
,	O
reverse	O
transcribed	O
pseudogenes	O
)	O
scattered	O
throughout	O
the	O
genome	O
and	O
that	O
if	O
there	O
are	O
closely	O
related	O
genes	O
,	O
they	O
must	O
be	O
clustered	O
near	O
GSTT2	B-protein
.	O

Recent	O
advances	O
have	O
shown	O
that	O
volatile	O
sulfur	O
is	O
a	O
result	O
of	O
ecological	O
interactions	O
and	O
transformation	O
processes	O
through	O
planktonic	O
food	O
webs	O
.	O

Cdk2	B-protein
and	O
MAPK	B-protein
precipitates	O
from	O
untreated	O
tumor	O
lysates	O
phosphorylated	O
recombinant	B-protein
wild	I-protein
-	I-protein
type	I-protein
p27	I-protein
but	O
not	O
the	O
T187A	O
mutant	O
in	O
vitro	O
.	O

Ribonuclease	B-protein
protection	O
assays	O
revealed	O
that	O
hmg1	B-protein
and	O
hmg2	B-protein
are	O
differentially	O
expressed	O
in	O
a	O
developmentally	O
-	O
and	O
spatially	O
-	O
modulated	O
manner	O
during	O
morphogenesis	O
of	O
specialized	O
terpenoid	O
-	O
containing	O
pigment	O
glands	O
in	O
embryos	O
.	O

From	O
these	O
results	O
,	O
it	O
is	O
concluded	O
that	O
EDLF	O
has	O
clear	O
vasoconstrictor	O
properties	O
which	O
are	O
not	O
due	O
to	O
adrenergic	O
or	O
calcium	O
entry	O
mechanisms	O
and	O
that	O
there	O
are	O
differences	O
in	O
the	O
vasoconstrictor	O
effects	O
of	O
EDLFs	O
with	O
respect	O
to	O
different	O
vascular	O
beds	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
Dbf8p	B-protein
plays	O
an	O
essential	O
role	O
in	O
chromosome	O
segregation	O
.	O

The	O
HOI	O
induced	O
a	O
nearly	O
fourfold	O
increase	O
in	O
ANF	B-protein
in	O
the	O
elderly	O
,	O
whereas	O
that	O
for	O
the	O
young	O
was	O
threefold	O
.	O

The	O
sequence	O
data	O
now	O
permit	O
a	O
detailed	O
interpretation	O
of	O
the	O
X	O
-	O
ray	O
crystallographic	O
structure	O
of	O
the	O
enzyme	O
and	O
the	O
cloning	O
and	O
expression	O
of	O
the	O
clostridial	O
gene	O
will	O
facilitate	O
site	O
-	O
directed	O
mutagenesis	O
.	O

The	O
steepness	O
of	O
the	O
standard	O
O2	O
dissociation	O
curve	O
becomes	O
greater	O
during	O
the	O
training	O
period	O
(	O
increase	O
in	O
Hill	O
'	O
s	O
n	O
from	O
2	O
.	O
68	O
+	O
/	O
-	O
0	O
.	O
10	O
to	O
2	O
.	O
96	O
+	O
/	O
-	O
0	O
.	O
15	O
)	O
.	O

Subcutaneous	O
administration	O
of	O
the	O
somatostatin	B-protein
analogue	O
,	O
octreotide	O
,	O
100	O
micrograms	O
thrice	O
daily	O
,	O
resulted	O
in	O
a	O
sustained	O
improvement	O
in	O
diarrhoea	O
and	O
disappearance	O
of	O
faecal	O
incontinence	O
without	O
reducing	O
calcitonin	B-protein
levels	O
.	O

The	O
fracture	O
groups	O
were	O
significantly	O
older	O
and	O
had	O
more	O
years	O
since	O
menopause	O
than	O
the	O
control	O
groups	O
.	O

Total	O
serum	O
calcium	O
was	O
7	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
8	O
mg	O
/	O
dl	O
,	O
whereas	O
ionized	O
calcium	O
was	O
5	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
7	O
mg	O
/	O
dl	O
,	O
phosphorus	O
3	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
2	O
mg	O
/	O
dl	O
,	O
and	O
alkaline	B-protein
phosphatase	I-protein
149	O
+	O
/	O
-	O
48	O
.	O
6	O
U	O
/	O
liter	O
.	O

Cell	O
viability	O
and	O
lysosomal	O
enzymes	O
.	O

Automatic	O
view	O
box	O
.	O

Reporter	O
constructs	O
function	O
in	O
a	O
parallel	O
manner	O
,	O
demonstrating	O
the	O
key	O
role	O
of	O
the	O
AhR	B-protein
in	O
constitutive	O
as	O
well	O
as	O
TCDD	O
-	O
induced	O
expression	O
of	O
Cyp1B1	B-protein
in	O
mouse	O
embryo	O
fibroblasts	O
.	O

At	O
baseline	O
,	O
serum	O
levels	O
of	O
lycopene	O
and	O
FLOP	O
were	O
abnormally	O
high	O
and	O
serum	O
FLOP	O
was	O
correlated	O
significantly	O
with	O
plasma	O
cyclosporine	O
levels	O
(	O
r	O
=	O
0	O
.	O
646	O
,	O
p	O
=	O
0	O
.	O
016	O
)	O
.	O

Pmt2	B-protein
is	O
a	O
member	O
of	O
a	O
six	O
-	O
protein	O
family	O
in	O
yeast	O
that	O
catalyzes	O
the	O
first	O
step	O
in	O
O	O
mannosylation	O
of	O
target	O
proteins	O
.	O

Promoter	O
activity	O
was	O
high	O
in	O
cell	O
lines	O
that	O
expressed	O
high	O
levels	O
of	O
endogenous	O
D3	B-protein
mRNA	I-protein
,	O
as	O
indicated	O
by	O
Northern	O
blot	O
analyses	O
,	O
and	O
was	O
significantly	O
reduced	O
when	O
the	O
promoter	O
was	O
truncated	O
to	O
-	O
122	O
bp	O
.	O

Sequencing	O
analysis	O
has	O
shown	O
that	O
each	O
rap1t	B-protein
allele	I-protein
contains	O
a	O
nonsense	O
mutation	O
within	O
a	O
discrete	O
region	O
between	O
amino	O
acids	O
663	O
and	O
684	O
.	O

This	O
protein	O
is	O
present	O
in	O
both	O
HeLa	O
nuclear	O
extracts	O
and	O
S100	O
extracts	O
but	O
absent	O
from	O
SR	B-protein
protein	I-protein
preparations	O
,	O
suggesting	O
that	O
it	O
is	O
not	O
a	O
classical	O
SR	B-protein
protein	I-protein
.	O

Alternating	O
proline	O
/	O
alanine	O
sequence	O
of	O
beta	B-protein
B1	I-protein
subunit	I-protein
originates	O
from	O
a	O
repetitive	O
DNA	O
sequence	O
.	O

The	O
distribution	O
and	O
organization	O
of	O
projections	O
from	O
the	O
spinal	O
cervical	O
enlargement	O
to	O
subnucleus	O
reticularis	O
dorsalis	O
(	O
SRD	O
)	O
and	O
the	O
neighbouring	O
Cuneate	O
nucleus	O
(	O
Cu	O
)	O
area	O
was	O
studied	O
in	O
the	O
rat	O
by	O
using	O
microinjections	O
of	O
Phaseolus	B-protein
vulgaris	I-protein
leucoagglutinin	I-protein
(	O
PHA	B-protein
-	I-protein
L	I-protein
)	O
into	O
different	O
laminae	O
around	O
the	O
C7	O
level	O
.	O

Retreatment	O
of	O
these	O
2	O
dogs	O
resulted	O
in	O
a	O
similar	O
,	O
but	O
blunted	O
,	O
response	O
to	O
human	B-protein
immunoglobulin	I-protein
.	O

Cloning	O
and	O
sequence	O
analyses	O
revealed	O
a	O
second	O
cDNA	O
with	O
a	O
95	O
-	O
nt	O
deletion	O
in	O
the	O
region	O
coding	O
for	O
the	O
putative	O
second	O
intracellular	O
loop	O
and	O
the	O
fourth	O
transmembrane	O
domain	O
of	O
the	O
5	B-protein
-	I-protein
HT2C	I-protein
-	I-protein
R	I-protein
.	O

In	O
the	O
region	O
Walgau	O
with	O
mixed	O
industrial	O
-	O
rural	O
population	O
an	O
iodine	O
deficiency	O
I	O
was	O
found	O
in	O
81	O
%	O
and	O
an	O
iodine	O
deficiency	O
II	O
in	O
45	O
%	O
.	O

We	O
propose	O
that	O
plasmids	O
of	O
the	O
pLS1	O
family	O
(	O
pE194	O
,	O
pADB201	O
,	O
and	O
pLB4	O
)	O
share	O
functional	O
and	O
structural	O
characteristics	O
for	O
the	O
regulation	O
of	O
their	O
copy	O
numbers	O
.	O

Reye	O
'	O
s	O
syndrome	O
:	O
reports	O
of	O
7	O
cases	O
in	O
the	O
period	O
1982	O
-	O
1987	O
.	O

The	O
new	O
FIGO	O
definition	O
of	O
cervical	O
cancer	O
stage	O
IA	O
:	O
a	O
critique	O
.	O

Among	O
six	O
different	O
library	O
isolates	O
containing	O
6	B-protein
.	I-protein
5	I-protein
-	I-protein
to	I-protein
7	I-protein
-	I-protein
kb	I-protein
IAP	I-protein
units	I-protein
,	O
some	O
restriction	O
sites	O
were	O
highly	O
conserved	O
whereas	O
others	O
varied	O
in	O
both	O
occurrence	O
and	O
position	O
.	O

Immunochemotherapy	O
with	O
schizophyllan	O
(	O
SPG	O
)	O
combined	O
with	O
chemotherapeutic	O
agents	O
was	O
evaluated	O
in	O
two	O
syngeneic	O
tumor	O
-	O
C3H	O
/	O
He	O
mouse	O
systems	O
.	O

Mutation	O
of	O
the	O
octamer	O
element	O
also	O
significantly	O
reduced	O
the	O
ability	O
of	O
HDAC1	B-protein
to	O
confer	O
repression	O
of	O
inducible	O
HLA	B-protein
-	I-protein
DRA	I-protein
promoter	I-protein
activation	O
.	O

Outflow	O
obstruction	O
of	O
pancreatic	O
juice	O
,	O
i	O
.	O
e	O
.	O
,	O
`	O
`	O
relative	O
stenosis	O
of	O
the	O
minor	O
papilla	O
,	O
`	O
`	O
was	O
considered	O
to	O
be	O
present	O
in	O
the	O
patients	O
with	O
type	O
II	O
papilla	O
,	O
and	O
,	O
therefore	O
,	O
the	O
patients	O
with	O
type	O
II	O
papilla	O
might	O
suffer	O
from	O
acute	O
pancreatitis	O
resulting	O
from	O
poor	O
drainage	O
of	O
pancreatic	O
juice	O
and	O
excessive	O
pressure	O
in	O
the	O
dorsal	O
duct	O
.	O

Pharmacological	O
and	O
pharmacokinetic	O
characteristics	O
of	O
the	O
non	O
-	O
ionic	O
monomeric	O
X	O
-	O
ray	O
contrast	O
agent	O
iopromide	O
(	O
Ultravist	O
,	O
CAS	O
73334	O
-	O
07	O
-	O
3	O
)	O
were	O
evaluated	O
in	O
preclinical	O
studies	O
.	O

The	O
membrane	O
-	O
distal	O
cytoplasmic	O
region	O
of	O
human	B-protein
granulocyte	I-protein
colony	I-protein
-	I-protein
stimulating	I-protein
factor	I-protein
receptor	I-protein
is	O
required	O
for	O
STAT3	B-protein
but	O
not	O
STAT1	B-protein
homodimer	I-protein
formation	O
.	O

The	O
mean	O
value	O
of	O
the	O
CD79b	B-protein
to	O
the	O
CD79b	B-protein
internally	O
deleted	O
ratio	O
was	O
0	O
.	O
64	O
+	O
/	O
-	O
0	O
.	O
20	O
SD	O
in	O
normal	O
donors	O
and	O
0	O
.	O
44	O
+	O
/	O
-	O
0	O
.	O
27	O
SD	O
in	O
B	O
-	O
CLL	O
(	O
P	O
=	O
.	O
01	O
)	O
.	O

Amino	O
acid	O
sequence	O
of	O
one	O
human	O
liver	O
clone	O
(	O
HL	O
-	O
14	O
)	O
was	O
identical	O
to	O
the	O
rabbit	B-protein
skeletal	I-protein
muscle	I-protein
phosphatase	I-protein
2A	I-protein
cDNA	I-protein
(	O
with	O
97	O
%	O
nucleotide	O
identity	O
)	O
.	O

The	O
effect	O
of	O
ibopamine	O
and	O
furosemide	O
in	O
130	O
patients	O
with	O
NYHA	O
Class	O
I	O
and	O
II	O
heart	O
failure	O
were	O
studied	O
in	O
a	O
parallel	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
placebo	O
-	O
controlled	O
multi	O
-	O
centre	O
trial	O
.	O

The	O
assembly	O
of	O
sequence	O
ready	O
,	O
high	O
-	O
resolution	O
physical	O
maps	O
and	O
construction	O
of	O
minimally	O
overlapping	O
contigs	O
for	O
the	O
human	O
as	O
well	O
as	O
model	O
genomes	O
requires	O
accurate	O
determination	O
of	O
the	O
extent	O
of	O
overlap	O
between	O
adjacent	O
clones	O
as	O
well	O
as	O
their	O
relative	O
orientation	O
.	O

The	O
SSB	O
-	O
poly	O
(	O
dT	O
)	O
affinity	O
is	O
too	O
high	O
to	O
measure	O
in	O
buffers	O
containing	O
even	O
5	O
M	O
NaCl	O
;	O
however	O
,	O
in	O
1	O
.	O
8	O
-	O
2	O
.	O
5	O
M	O
NaBr	O
,	O
we	O
measure	O
alpha	O
log	O
Kobsd	O
/	O
alpha	O
log	O
[	O
NaBr	O
]	O
=	O
-	O
5	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
7	O
,	O
with	O
a	O
lower	O
value	O
of	O
omega	O
T	O
/	O
O	O
=	O
130	O
+	O
/	O
-	O
70	O
.	O

Selenium	O
is	O
an	O
essential	O
element	O
for	O
humans	O
,	O
animals	O
and	O
some	O
species	O
of	O
microorganisms	O
.	O

Acute	O
type	O
A	O
hepatitis	O
in	O
three	O
patients	O
with	O
chronic	O
HBV	O
infection	O
.	O

A	O
potential	O
TATA	O
box	O
is	O
located	O
29	O
base	O
pairs	O
upstream	O
of	O
the	O
first	O
transcription	O
initiation	O
site	O
.	O

Use	O
of	O
radioactive	O
isotopes	O
in	O
the	O
chemistry	O
of	O
proteins	O
.	O

Mutations	O
at	O
two	O
neighboring	O
sites	O
,	O
serine	O
242	O
and	O
threonine	O
255	O
,	O
exacerbated	O
the	O
effect	O
.	O

Light	O
microscopical	O
and	O
routine	O
immunohistochemical	O
studies	O
of	O
a	O
cervical	O
neoplasm	O
in	O
a	O
32	O
year	O
old	O
woman	O
initially	O
suggested	O
a	O
histiocytic	O
lymphoma	O
,	O
but	O
histochemical	O
staining	O
for	O
chloroacetate	B-protein
esterase	I-protein
established	O
the	O
correct	O
diagnosis	O
.	O

All	O
of	O
the	O
newly	O
acquired	O
proviruses	O
identified	O
in	O
mosaic	O
founder	O
SWR	B-protein
/	I-protein
J	I-protein
-	I-protein
RF	I-protein
/	I-protein
J	I-protein
mice	O
that	O
could	O
be	O
transmitted	O
through	O
the	O
germ	O
line	O
were	O
also	O
present	O
in	O
somatic	O
tissues	O
,	O
demonstrating	O
that	O
viral	O
integration	O
occurred	O
before	O
the	O
germ	O
line	O
was	O
set	O
aside	O
from	O
the	O
somatic	O
lineages	O
.	O

Autoionization	O
rates	O
and	O
energy	O
levels	O
of	O
triplet	O
nf	O
,	O
v	O
=	O
1	O
Rydberg	O
states	O
of	O
H2	O
.	O

At	O
20	O
days	O
(	O
D	O
)	O
and	O
at	O
3	O
months	O
post	O
-	O
TBI	O
,	O
irradiated	O
rats	O
had	O
a	O
significantly	O
lower	O
percentage	O
of	O
avoidance	O
than	O
controls	O
but	O
no	O
statistical	O
difference	O
was	O
found	O
at	O
5	O
months	O
post	O
-	O
TBI	O
.	O
b	O
/	O
Two	O
-	O
way	O
avoidance	O
test	O
:	O
this	O
test	O
was	O
performed	O
only	O
after	O
TBI	O
.	O

Thin	O
-	O
layer	O
chromatographic	O
methods	O
were	O
up	O
-	O
dated	O
for	O
pharmacokinetic	O
studies	O
of	O
imipramine	O
in	O
plasma	O
and	O
urine	O
.	O

This	O
study	O
was	O
designed	O
to	O
compare	O
the	O
efficacy	O
of	O
efegatran	O
plus	O
streptokinase	B-protein
versus	O
heparin	O
plus	O
accelerated	O
tissue	B-protein
plasminogen	I-protein
activator	I-protein
(	O
TPA	B-protein
)	O
in	O
coronary	O
reperfusion	O
in	O
acute	O
MI	O
.	O

Based	O
on	O
the	O
current	O
literature	O
,	O
the	O
mechanisms	O
involved	O
in	O
the	O
toxicity	O
of	O
OA	O
indicate	O
three	O
major	O
effects	O
:	O
(	O
1	O
)	O
inhibition	O
of	O
mitochondrial	O
respiration	O
correlated	O
with	O
a	O
depletion	O
of	O
ATP	O
;	O
(	O
2	O
)	O
inhibition	O
of	O
tRNA	B-protein
-	I-protein
synthetase	I-protein
accompanied	O
by	O
a	O
reduced	O
protein	O
synthesis	O
;	O
and	O
(	O
3	O
)	O
enhanced	O
lipid	O
peroxidation	O
.	O

And	O
,	O
most	O
importantly	O
,	O
reconstitution	O
of	O
a	O
consensus	B-protein
CRE	I-protein
,	O
within	O
the	O
21	O
-	O
bp	O
enhancers	O
increases	O
binding	O
of	O
CREB	B-protein
/	I-protein
ATF	I-protein
proteins	I-protein
but	O
abrogates	O
basal	O
repression	O
of	O
LTR	O
-	O
directed	O
transcription	O
in	O
vitro	O
.	O

In	O
doses	O
of	O
0	O
.	O
03	O
-	O
0	O
.	O
3	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
,	O
SG	O
-	O
75	O
did	O
not	O
significantly	O
affect	O
pulse	O
pressure	O
,	O
heart	O
rate	O
,	O
aortic	O
blood	O
flow	O
,	O
left	O
ventricular	O
pressure	O
(	O
LVP	O
)	O
and	O
LVdP	O
/	O
dt	O
max	O
.	O

The	O
RNA	O
aptamer	O
contains	O
three	O
stems	O
separated	O
by	O
a	O
pair	O
of	O
two	O
-	O
base	O
bulges	O
,	O
and	O
adopts	O
an	O
unanticipated	O
fold	O
in	O
which	O
both	O
junctional	O
sites	O
are	O
anchored	O
through	O
base	O
triple	O
formation	O
.	O

Phase	O
II	O
study	O
of	O
VP	O
-	O
16	O
(	O
capsule	O
)	O
in	O
solid	O
tumors	O
.	O

These	O
results	O
suggest	O
that	O
leader	O
-	O
mRNA	O
fusion	O
in	O
coronavirus	O
transcription	O
does	O
not	O
require	O
direct	O
RNA	O
-	O
RNA	O
interaction	O
between	O
complementary	O
sequences	O
.	O

A	O
cAMP	B-protein
-	I-protein
responsive	I-protein
element	I-protein
-	I-protein
like	I-protein
(	O
CRE	B-protein
-	I-protein
like	I-protein
,	O
TGACGTGA	B-protein
)	O
promoter	O
sequence	O
and	O
a	O
protein	B-protein
kinase	I-protein
A	I-protein
signaling	O
pathway	O
are	O
involved	O
in	O
this	O
induction	O
,	O
and	O
activation	O
of	O
both	O
CRE	B-protein
binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
and	O
activating	B-protein
transcription	I-protein
factor	I-protein
-	I-protein
2	I-protein
(	O
ATF	B-protein
-	I-protein
2	I-protein
)	O
is	O
required	O
in	O
the	O
above	O
process	O
.	O

These	O
data	O
suggest	O
that	O
a	O
major	O
part	O
of	O
the	O
reduction	O
in	O
food	O
intake	O
in	O
hyperphagic	O
rats	O
eating	O
a	O
quinine	O
-	O
adulterated	O
diet	O
is	O
due	O
to	O
postingestional	O
events	O
.	O

Similarly	O
,	O
we	O
examined	O
whether	O
the	O
ELK1	B-protein
,	O
SAP1a	B-protein
,	O
FLI1	B-protein
,	O
EWS	B-protein
-	I-protein
FLI1	I-protein
,	O
ETS1	B-protein
,	O
ETS2	B-protein
,	O
PEA3	B-protein
and	O
PU	B-protein
.	I-protein
1	I-protein
proteins	I-protein
can	O
form	O
ternary	O
complexes	O
with	O
SRF	B-protein
on	O
the	O
Egr1	B-protein
SREI	I-protein
and	I-protein
II	I-protein
.	O

In	O
Arabidopsis	O
,	O
the	O
induction	O
of	O
a	O
dehydration	B-protein
-	I-protein
responsive	I-protein
gene	I-protein
,	O
rd22	B-protein
,	O
is	O
mediated	O
by	O
abscisic	O
acid	O
(	O
ABA	O
)	O
and	O
requires	O
protein	O
biosynthesis	O
for	O
ABA	B-protein
-	I-protein
dependent	I-protein
gene	I-protein
expression	O
.	O

During	O
skeletal	O
muscle	O
development	O
,	O
different	O
types	O
of	O
muscle	O
fibers	O
are	O
generated	O
,	O
which	O
express	O
different	O
combinations	O
of	O
muscle	O
-	O
specific	O
gene	O
products	O
.	O

This	O
resulted	O
in	O
a	O
complete	O
inhibition	O
of	O
Site	O
-	O
1	O
cleavage	O
that	O
was	O
restored	O
by	O
concomitant	O
overexpression	O
of	O
full	O
-	O
length	O
SCAP	B-protein
.	O

Elimination	O
of	O
Haemophilus	O
influenzae	O
type	O
b	O
meningitis	O
after	O
introduction	O
of	O
vaccination	O
.	O

MK	O
-	O
801	O
administration	O
resulted	O
in	O
a	O
biphasic	O
response	O
in	O
seizure	O
latency	O
.	O

Using	O
anchored	O
PCR	O
,	O
a	O
VL	B-protein
element	I-protein
rearranged	O
to	O
CL2	B-protein
was	O
isolated	O
.	O

The	O
Schistosoma	B-protein
mansoni	I-protein
homologue	I-protein
(	O
SmSmad2	B-protein
)	O
was	O
overexpressed	O
in	O
bacteria	O
as	O
a	O
Sj26	B-protein
-	I-protein
GST	I-protein
fusion	I-protein
protein	I-protein
and	O
used	O
to	O
raise	O
specific	O
antibodies	O
.	O

In	O
addition	O
,	O
5	O
'	O
deletions	O
removing	O
all	O
but	O
34	O
bp	O
upstream	O
of	O
the	O
transcription	O
start	O
point	O
retained	O
greater	O
than	O
90	O
%	O
promoter	O
activity	O
,	O
suggesting	O
that	O
the	O
-	O
35	O
hexamer	O
was	O
not	O
essential	O
for	O
promoter	O
activity	O
.	O

This	O
loss	O
was	O
independent	O
of	O
drug	O
concentration	O
and	O
a	O
correction	O
factor	O
was	O
employed	O
to	O
calculate	O
the	O
true	O
free	O
diazepam	O
concentration	O
.	O

Indeed	O
,	O
it	O
is	O
shown	O
that	O
it	O
mediates	O
the	O
formation	O
of	O
disulfide	O
-	O
linked	O
homodimers	O
and	O
that	O
the	O
formation	O
of	O
homo	O
-	O
and	O
heterodimers	O
are	O
mutually	O
excluded	O
.	O

We	O
enrolled	O
253	O
HIV	B-protein
-	I-protein
antibody	I-protein
positive	O
heroin	O
addicts	O
without	O
HIV	O
-	O
related	O
disease	O
(	O
n	O
=	O
81	O
)	O
or	O
with	O
persistent	O
generalized	O
lymphadenopathy	O
(	O
n	O
=	O
172	O
)	O
in	O
a	O
prospective	O
study	O
to	O
evaluate	O
clinical	O
progression	O
to	O
AIDS	O
related	O
complex	O
(	O
ARC	O
)	O
or	O
AIDS	O
and	O
to	O
identify	O
factors	O
of	O
possible	O
prognostic	O
relevance	O
.	O

Functional	O
tests	O
using	O
a	O
reporter	O
gene	O
,	O
containing	O
Stat5	B-protein
-	I-protein
binding	I-protein
elements	I-protein
,	O
confirmed	O
that	O
while	O
the	O
variant	O
form	O
was	O
inactive	O
by	O
itself	O
,	O
it	O
could	O
inhibit	O
the	O
function	O
of	O
the	O
full	O
-	O
length	O
receptor	O
.	O

The	O
monkey	B-protein
LHR	I-protein
cDNA	I-protein
displayed	O
83	O
-	O
94	O
%	O
overall	O
sequence	O
homology	O
with	O
the	O
other	O
mammalian	B-protein
LHR	I-protein
cDNAs	I-protein
.	O

Removal	O
of	O
beta	B-protein
2	I-protein
-	I-protein
microglobulin	I-protein
by	O
hemodialysis	O
and	O
hemofiltration	O
:	O
a	O
four	O
year	O
follow	O
up	O
.	O

Most	O
of	O
the	O
patients	O
presented	O
with	O
Transient	O
Ischemic	O
Attacks	O
(	O
64	O
%	O
)	O
or	O
Reversible	O
Ischemic	O
Neurologic	O
Deficits	O
(	O
19	O
%	O
)	O
.	O

Another	O
segment	O
of	O
CRL3	B-protein
(	O
-	O
296	O
to	O
-	O
184	O
)	O
,	O
also	O
displaying	O
enhancer	O
function	O
,	O
contained	O
tandem	O
repeated	O
sequences	O
(	O
DR	B-protein
-	I-protein
A1	I-protein
and	O
DR	B-protein
-	I-protein
A2	I-protein
)	O
.	O

In	O
Klinefelter	O
'	O
s	O
syndrome	O
(	O
47XXY	O
)	O
,	O
serum	O
testosterone	O
levels	O
are	O
at	O
the	O
lower	O
end	O
of	O
the	O
normal	O
range	O
and	O
dihydrotestosterone	O
levels	O
are	O
low	O
.	O

Homology	O
with	O
the	O
human	O
protein	O
is	O
only	O
34	O
%	O
in	O
the	O
tandem	O
repeat	O
domain	O
,	O
mainly	O
showing	O
conservation	O
of	O
serines	O
and	O
threonines	O
,	O
presumed	O
sites	O
of	O
O	O
-	O
linked	O
carbohydrate	O
attachment	O
.	O

Efficacy	O
of	O
a	O
three	O
-	O
versus	O
a	O
five	O
-	O
week	O
alcohol	O
treatment	O
program	O
.	O

An	O
overexpression	O
of	O
the	O
betaAPP	B-protein
gene	I-protein
in	O
certain	O
areas	O
of	O
the	O
AD	O
brain	O
has	O
been	O
suggested	O
to	O
be	O
an	O
important	O
factor	O
in	O
the	O
neuropathology	O
of	O
AD	O
.	O

Widening	O
of	O
the	O
abdominal	O
aortic	O
wall	O
on	O
an	O
ultrasound	O
examination	O
was	O
the	O
key	O
to	O
the	O
incidental	O
diagnosis	O
of	O
a	O
clinically	O
unsuspected	O
type	O
B	O
dissection	O
.	O

These	O
techniques	O
have	O
been	O
used	O
by	O
many	O
people	O
for	O
many	O
years	O
and	O
no	O
claim	O
is	O
being	O
made	O
for	O
any	O
innovation	O
in	O
this	O
regard	O
.	O

In	O
conclusion	O
,	O
primary	O
chemotherapy	O
based	O
on	O
high	O
dose	O
MTX	O
and	O
ara	O
-	O
C	O
is	O
highly	O
efficient	O
in	O
PCNSL	O
.	O

His	O
HC	B-protein
II	I-protein
activity	O
and	O
antigen	O
levels	O
were	O
49	O
%	O
and	O
50	O
%	O
,	O
respectively	O
,	O
and	O
his	O
daughter	O
also	O
showed	O
similar	O
low	O
levels	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
four	O
distinct	O
E2F	B-protein
complexes	I-protein
present	O
in	O
aged	O
and	O
senescent	O
normal	O
,	O
human	O
diploid	O
fibroblasts	O
.	O

Selected	O
topics	O
in	O
pediatric	O
ultrasonography	O
-	O
-	O
1992	O
.	O

We	O
report	O
here	O
on	O
the	O
molecular	O
nature	O
of	O
an	O
EMS	O
-	O
induced	O
mutant	O
,	O
mn1	B-protein
-	I-protein
89	I-protein
,	O
a	O
leaky	O
semidominant	O
allele	O
of	O
the	O
Miniature1	B-protein
(	O
Mn1	B-protein
)	O
seed	O
locus	O
that	O
encodes	O
a	O
seed	B-protein
-	I-protein
specific	I-protein
cell	I-protein
wall	I-protein
invertase	I-protein
,	O
INCW2	B-protein
.	O

These	O
data	O
indicate	O
that	O
although	O
218leu	O
retains	O
normal	O
transactivation	O
activity	O
on	O
a	O
p53	B-protein
promoter	I-protein
in	O
yeast	O
at	O
physiological	O
temperatures	O
,	O
it	O
is	O
not	O
capable	O
of	O
normal	O
p53	B-protein
function	O
in	O
the	O
presence	O
of	O
a	O
248trp	B-protein
allele	I-protein
in	O
SNU	O
-	O
C5	O
cells	O
.	O

Increase	O
in	O
urinary	O
calcium	O
and	O
oxalate	O
after	O
fructose	O
infusion	O
.	O

METHODS	O
:	O
This	O
retrospective	O
review	O
comprised	O
2711	O
eyes	O
that	O
had	O
LASIK	O
between	O
September	O
1996	O
and	O
September	O
1999	O
.	O

The	O
Saccharomyces	O
cerevisiae	O
spindle	O
pole	O
body	O
duplication	O
gene	B-protein
MPS1	I-protein
is	O
part	O
of	O
a	O
mitotic	O
checkpoint	O
.	O

These	O
features	O
were	O
considered	O
consistent	O
with	O
a	O
diagnosis	O
of	O
Rothmund	O
-	O
Thomson	O
syndrome	O
.	O

Transfection	O
analyses	O
indicated	O
that	O
the	O
expression	O
of	O
Tbxas1	B-protein
is	O
controlled	O
by	O
a	O
short	O
(	O
70	O
-	O
bp	O
)	O
positive	O
regulatory	O
sequence	O
and	O
several	O
upstream	O
repressive	O
elements	O
.	O

Effect	O
of	O
variations	O
in	O
time	O
interval	O
between	O
treatment	O
with	O
BCG	O
and	O
quartz	O
dust	O
on	O
translocation	O
of	O
quartz	O
dust	O
from	O
the	O
lungs	O
to	O
their	O
regional	O
lymph	O
nodes	O
.	O

To	O
the	O
problem	O
of	O
the	O
stimulation	O
of	O
the	O
growth	O
of	O
transplantable	O
tumors	O
of	O
animals	O
previously	O
treated	O
with	O
antineoplastic	O
antibiotics	O
.	O

Despite	O
the	O
absence	O
of	O
exercise	O
-	O
induced	O
asthma	O
(	O
EIA	O
)	O
while	O
breathing	O
WH	O
air	O
,	O
asthmatic	O
patients	O
still	O
had	O
significantly	O
higher	O
mean	O
GH	O
increments	O
than	O
normal	O
subjects	O
(	O
9	O
.	O
2	O
vs	O
2	O
.	O
3	O
ng	O
/	O
ml	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
cut	O
-	O
off	O
percentage	O
positivity	O
value	O
was	O
established	O
using	O
500	O
brucellosis	O
-	O
positive	O
and	O
500	O
brucellosis	O
-	O
negative	O
serum	O
samples	O
,	O
confirmed	O
with	O
reference	O
to	O
the	O
sample	O
data	O
using	O
the	O
indirect	O
ELISA	O
kit	O
.	O

Airflow	O
was	O
measured	O
with	O
a	O
custom	O
-	O
designed	O
turbine	O
and	O
a	O
45	O
-	O
ft	O
.	O
-	O
long	O
cable	O
to	O
reach	O
the	O
volume	O
-	O
measuring	O
module	O
.	O

Viral	O
RNA	O
,	O
molecularly	O
cloned	O
proviral	O
DNA	O
,	O
and	O
virus	O
-	O
specific	O
protein	O
of	O
avian	O
retrovirus	O
MH2	O
were	O
analyzed	O
.	O

To	O
study	O
the	O
mechanisms	O
as	O
well	O
as	O
magnitude	O
of	O
the	O
transmembrane	O
transfer	O
of	O
bacterial	O
products	O
from	O
the	O
dialysate	O
,	O
we	O
developed	O
a	O
computerized	O
in	O
vitro	O
dialysis	O
model	O
which	O
provides	O
continuous	O
pressure	O
recording	O
from	O
the	O
arterial	O
,	O
venous	O
,	O
dialysate	O
inflow	O
and	O
outflow	O
ports	O
.	O

Mutations	O
in	O
the	O
RP2	B-protein
locus	I-protein
at	I-protein
Xp11	I-protein
.	I-protein
3	I-protein
were	O
found	O
in	O
a	O
further	O
10	O
-	O
20	O
%	O
of	O
XLRP	O
patients	O
,	O
as	O
predicted	O
from	O
linkage	O
studies	O
.	O

METHODS	O
:	O
We	O
studied	O
20	O
symptomatic	O
patients	O
with	O
HOCM	O
(	O
12	O
men	O
)	O
,	O
mean	O
age	O
52	O
+	O
/	O
-	O
17	O
years	O
,	O
before	O
and	O
after	O
septal	O
reduction	O
using	O
echocardiography	O
and	O
electrocardiogram	O
(	O
ECG	O
)	O
.	O

The	O
intensity	O
of	O
the	O
SSTEs	O
is	O
an	O
order	O
of	O
magnitude	O
larger	O
than	O
that	O
of	O
the	O
MSEs	O
and	O
determines	O
the	O
signal	O
contrast	O
if	O
both	O
effects	O
are	O
selected	O
simultaneously	O
.	O

The	O
limit	O
between	O
the	O
cecum	O
and	O
the	O
ascending	O
colon	O
was	O
externally	O
marked	O
by	O
the	O
sulcus	O
cecocolicus	O
dorsalis	O
and	O
ventralis	O
.	O

Special	O
issues	O
devoted	O
to	O
the	O
biosynthesis	O
of	O
woody	O
plant	O
biopolymers	O
and	O
related	O
substances	O
.	O

Consequently	O
,	O
it	O
is	O
not	O
known	O
how	O
knee	O
loading	O
changes	O
following	O
ACL	O
transection	O
,	O
and	O
how	O
it	O
contributes	O
to	O
cartilage	O
degeneration	O
.	O

Increased	O
PTHRP	B-protein
production	O
by	O
a	O
tyrosine	B-protein
kinase	I-protein
oncogene	I-protein
,	O
Tpr	B-protein
-	I-protein
Met	I-protein
:	O
role	O
of	O
the	O
Ras	B-protein
signaling	O
pathway	O
.	O

The	O
95	O
%	O
confidence	O
values	O
(	O
2SD	O
)	O
for	O
the	O
change	O
in	O
Ros	O
required	O
to	O
exclude	O
natural	O
variability	O
were	O
0	O
.	O
39	O
,	O
0	O
.	O
50	O
and	O
0	O
.	O
53	O
cmH2O	O
l	O
-	O
1	O
s	O
,	O
respectively	O
.	O

Expression	O
of	O
the	O
proapoptotic	B-protein
protein	I-protein
Bax	I-protein
under	O
the	O
control	O
of	O
a	O
GAL10	B-protein
promoter	I-protein
in	O
Saccharomyces	O
cerevisiae	O
resulted	O
in	O
galactose	O
-	O
inducible	O
cell	O
death	O
.	O

I	O
.	O

We	O
analyzed	O
the	O
modular	O
organization	O
of	O
DNA	B-protein
polymerase	I-protein
beta	I-protein
and	O
found	O
that	O
residues	O
making	O
contact	O
with	O
DNA	O
phosphates	O
were	O
localized	O
to	O
five	O
modules	O
.	O

The	O
effects	O
initiated	O
from	O
the	O
nucleus	O
accumbens	O
septi	O
were	O
most	O
marked	O
.	O

Using	O
various	O
techniques	O
,	O
we	O
have	O
undertaken	O
a	O
systematic	O
analysis	O
of	O
the	O
natural	O
TATA	O
-	O
less	O
human	B-protein
DNA	I-protein
polymerase	I-protein
beta	I-protein
(	O
beta	B-protein
-	I-protein
pol	I-protein
)	O
gene	O
promoter	O
.	O

Molecular	O
neurochemistry	O
of	O
addictive	O
drugs	O
.	O

Radiolabelled	O
palmitate	O
was	O
not	O
incorporated	O
into	O
the	O
mutated	O
protein	O
,	O
showing	O
that	O
lipid	O
modification	O
occurs	O
at	O
the	O
Cys	O
-	O
22	O
residue	O
.	O

METHODS	O
:	O
Fibrotic	O
changes	O
involving	O
bone	O
marrow	O
were	O
evaluated	O
histologically	O
semiquantitatively	O
using	O
reticulin	O
fiber	O
impregnation	O
(	O
method	O
of	O
Gomori	O
)	O
.	O

LPO	O
and	O
SOD	B-protein
levels	O
were	O
measured	O
at	O
five	O
points	O
before	O
and	O
during	O
the	O
operation	O
.	O

In	O
contrast	O
,	O
2	O
,	O
397	O
(	O
74	O
%	O
)	O
had	O
one	O
or	O
more	O
risk	O
factors	O
(	O
not	O
low	O
risk	O
)	O
;	O
of	O
these	O
,	O
5	O
.	O
3	O
%	O
died	O
in	O
6	O
weeks	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Activation	O
of	O
alpha	B-protein
4	I-protein
beta	I-protein
1	I-protein
with	O
TS2	B-protein
/	I-protein
16	I-protein
inhibited	O
the	O
cytoplasmic	O
protrusions	O
and	O
cell	O
migration	O
but	O
did	O
not	O
affect	O
the	O
pattern	O
of	O
phosphorylation	O
.	O

Mitomycin	O
-	O
C	O
can	O
cause	O
severe	O
necrosis	O
and	O
ulceration	O
when	O
extravasated	O
inadvertently	O
into	O
skin	O
and	O
soft	O
tissues	O
following	O
IV	O
drug	O
administration	O
.	O

The	O
transposon	O
-	O
inactivated	O
gene	O
,	O
designated	O
pilP	B-protein
,	O
is	O
525	O
bp	O
long	O
,	O
potentially	O
encoding	O
a	O
19	O
.	O
1	O
-	O
kDa	O
protein	O
precursor	O
that	O
contains	O
a	O
typical	O
membrane	O
lipoprotein	O
leader	O
sequence	O
.	O

The	O
seco	O
-	O
steroid	O
hormone	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
is	O
known	O
to	O
induce	O
the	O
expression	O
of	O
a	O
calcium	O
binding	O
protein	O
termed	O
calbindin	B-protein
-	I-protein
D28K	I-protein
in	O
a	O
variety	O
of	O
target	O
tissues	O
.	O

In	O
all	O
cases	O
the	O
antigenemia	O
was	O
transient	O
and	O
cleared	O
by	O
28th	O
day	O
post	O
-	O
vaccination	O
.	O

The	O
interferon	B-protein
(	O
IFN	B-protein
)	O
-	O
induced	O
double	B-protein
-	I-protein
stranded	I-protein
RNA	I-protein
(	I-protein
dsRNA	I-protein
)	I-protein
-	I-protein
activated	I-protein
Ser	I-protein
/	I-protein
Thr	I-protein
protein	I-protein
kinase	I-protein
(	O
PKR	B-protein
)	O
plays	O
a	O
role	O
in	O
the	O
antiviral	O
and	O
antiproliferative	O
effects	O
of	O
IFN	B-protein
.	O

Differential	O
association	O
of	O
products	O
of	O
alternative	O
transcripts	O
of	O
the	O
candidate	O
tumor	B-protein
suppressor	I-protein
ING1	I-protein
with	O
the	O
mSin3	B-protein
/	I-protein
HDAC1	I-protein
transcriptional	I-protein
corepressor	I-protein
complex	I-protein
.	O

DNA	O
-	O
binding	O
activity	O
was	O
not	O
increased	O
by	O
the	O
addition	O
of	O
forskolin	O
to	O
thecal	O
or	O
luteal	O
cells	O
.	O

Badcock	O
and	O
Westheimer	O
(	O
Spatial	O
Vision	O
1	O
(	O
1	O
)	O
,	O
3	O
-	O
11	O
,	O
1985	O
)	O
showed	O
that	O
a	O
thin	O
vertical	O
line	O
induces	O
nearby	O
zones	O
of	O
attraction	O
and	O
repulsion	O
;	O
this	O
study	O
extends	O
those	O
results	O
by	O
more	O
closely	O
examining	O
the	O
horizontal	O
and	O
vertical	O
extents	O
of	O
the	O
repulsion	O
zone	O
and	O
by	O
using	O
an	O
illusory	O
contour	O
to	O
induce	O
repulsion	O
.	O

Forty	O
-	O
one	O
ASA	O
physical	O
status	O
I	O
or	O
II	O
adult	O
patients	O
undergoing	O
a	O
variety	O
of	O
1	O
-	O
1	O
.	O
5	O
h	O
surgical	O
procedures	O
were	O
randomly	O
allocated	O
to	O
receive	O
CCA	O
with	O
desflurane	O
or	O
isoflurane	O
with	O
ventilation	O
being	O
either	O
spontaneous	O
or	O
controlled	O
.	O

The	O
codon	O
usage	O
is	O
particularly	O
marked	O
for	O
the	O
gag	B-protein
,	O
pol	B-protein
,	O
and	O
env	B-protein
genes	I-protein
.	O

Position	O
-	O
independent	O
expression	O
of	O
a	O
human	B-protein
nerve	I-protein
growth	I-protein
factor	I-protein
-	I-protein
luciferase	I-protein
reporter	I-protein
gene	I-protein
cloned	O
on	O
a	O
yeast	O
artificial	O
chromosome	O
vector	O
.	O

Judicious	O
use	O
of	O
laboratory	O
testing	O
,	O
including	O
monitoring	O
of	O
CD4	B-protein
cell	O
counts	O
,	O
is	O
recommended	O
.	O

Plasma	O
Al	O
was	O
obtained	O
during	O
each	O
baseline	O
and	O
drug	O
course	O
.	O

The	O
exploratory	O
behaviour	O
in	O
normal	O
and	O
aggressive	O
mice	O
.	O

The	O
relatively	O
scanty	O
number	O
of	O
examples	O
,	O
which	O
could	O
be	O
justified	O
by	O
the	O
variety	O
and	O
complexity	O
of	O
combined	O
exposure	O
,	O
allows	O
to	O
conclude	O
that	O
life	O
-	O
style	O
factors	O
have	O
considerable	O
influence	O
on	O
interindividual	O
differences	O
in	O
susceptibility	O
to	O
xenobiotics	O
toxicity	O
.	O

However	O
,	O
the	O
action	O
of	O
each	O
cognate	O
ligand	O
and	O
the	O
accessory	O
cellular	O
factors	O
that	O
can	O
differentially	O
regulate	O
the	O
transcriptional	O
responses	O
of	O
a	O
heterodimer	O
-	O
DNA	O
complex	O
are	O
not	O
well	O
understood	O
.	O

REM	O
dream	O
content	O
was	O
scored	O
for	O
categories	O
suggesting	O
the	O
predominant	O
influence	O
of	O
the	O
left	O
hemisphere	O
,	O
e	O
.	O
g	O
.	O
,	O
good	O
ego	O
functioning	O
,	O
verbalization	O
,	O
or	O
the	O
right	O
hemisphere	O
,	O
e	O
.	O
g	O
.	O
,	O
music	O
,	O
spatial	O
salience	O
,	O
bizarreness	O
.	O

We	O
suggest	O
that	O
FlgN	B-protein
and	O
FliT	B-protein
are	O
substrate	O
-	O
specific	O
flagellar	O
chaperones	O
that	O
prevent	O
oligomerization	O
of	O
the	O
HAPs	B-protein
by	O
binding	O
to	O
their	O
helical	O
domains	O
before	O
export	O
.	O

Forty	O
-	O
five	O
cases	O
were	O
surgically	O
by	O
direct	O
approach	O
to	O
the	O
tumour	O
,	O
while	O
two	O
cases	O
were	O
treated	O
only	O
with	O
a	O
shunt	O
.	O

In	O
line	O
with	O
the	O
small	O
values	O
for	O
QS	O
/	O
QC	O
,	O
our	O
results	O
further	O
indicate	O
that	O
even	O
large	O
,	O
well	O
-	O
perfused	O
,	O
occluded	O
air	O
spaces	O
in	O
the	O
lung	O
will	O
hardly	O
affect	O
the	O
recovered	O
ventilation	O
/	O
perfusion	O
distribution	O
obtained	O
from	O
inert	O
gas	O
data	O
when	O
CDCSF6	O
exceeds	O
0	O
.	O
1	O
ml	O
.	O
min	O
-	O
1	O
.	O
mmHg	O
-	O
1	O
.	O

All	O
13	O
patients	O
showed	O
endoscopic	O
evidence	O
of	O
oesophagitis	O
,	O
moderate	O
in	O
4	O
and	O
severe	O
in	O
9	O
.	O

A	O
transformation	O
-	O
competent	O
mutant	O
,	O
like	O
the	O
wild	B-protein
-	I-protein
type	I-protein
E5	I-protein
protein	I-protein
,	O
bound	O
the	O
receptor	O
and	O
induced	O
receptor	O
tyrosine	O
phosphorylation	O
and	O
down	O
-	O
regulation	O
.	O

The	O
initial	O
inpatient	O
experience	O
for	O
individuals	O
with	O
HIV	O
-	O
related	O
TB	O
may	O
be	O
pivotal	O
to	O
the	O
acceptance	O
of	O
and	O
participation	O
in	O
ongoing	O
TB	O
care	O
.	O

T	O
.	O
,	O
Patel	O
,	O
S	O
.	O

DNA	O
sequence	O
analysis	O
showed	O
that	O
the	O
gene	O
was	O
525	O
bp	O
long	O
and	O
encoded	O
a	O
175	O
-	O
amino	O
-	O
acid	O
protein	O
with	O
a	O
molecular	O
weight	O
of	O
19	O
,	O
094	O
containing	O
a	O
21	O
-	O
residue	O
typical	O
lipoprotein	O
signal	O
peptide	O
and	O
consensus	O
prolipoprotein	O
processing	O
site	O
.	O

Zn	B-protein
(	I-protein
II	I-protein
)	I-protein
coordination	I-protein
domain	I-protein
mutants	I-protein
of	I-protein
T4	I-protein
gene	I-protein
32	I-protein
protein	I-protein
.	O

Xylose	O
-	O
and	O
arabinose	O
-	O
containing	O
polymers	O
were	O
better	O
digested	O
than	O
was	O
cellulose	B-protein
for	O
both	O
breads	O
.	O

Saturable	O
spermidine	O
transport	O
in	O
stk2	B-protein
:	O
:	O
lacZ	B-protein
mutants	I-protein
had	O
an	O
approximately	O
fivefold	O
-	O
lower	O
affinity	O
and	O
twofold	O
-	O
lower	O
Vmax	O
than	O
in	O
the	O
parental	O
strain	O
.	O

Unlike	O
other	O
progenitor	O
cells	O
of	O
the	O
brain	O
,	O
SVZa	O
progenitor	O
cells	O
have	O
the	O
capacity	O
to	O
divide	O
even	O
though	O
they	O
express	O
a	O
neuronal	O
phenotype	O
.	O

The	O
decrease	O
of	O
TNF	B-protein
receptors	I-protein
by	O
IL	B-protein
-	I-protein
4	I-protein
was	O
accompanied	O
by	O
down	O
-	O
regulation	O
of	O
TNF	O
-	O
induced	O
activities	O
,	O
including	O
cytotoxicity	O
,	O
caspase	B-protein
-	I-protein
3	I-protein
activation	O
,	O
NF	B-protein
-	I-protein
kappaB	I-protein
and	O
AP	B-protein
-	I-protein
1	I-protein
activation	O
,	O
and	O
c	B-protein
-	I-protein
Jun	I-protein
N	I-protein
-	I-protein
terminal	I-protein
kinase	I-protein
induction	O
.	O

Rac	B-protein
causes	O
uncapping	O
of	O
actin	B-protein
filaments	I-protein
(	O
F	B-protein
-	I-protein
actin	I-protein
)	O
at	O
the	O
plus	O
-	O
ends	O
,	O
through	O
phosphatidylinositol	O
4	O
,	O
5	O
bisphosphate	O
(	O
PIP2	O
)	O
,	O
and	O
eventually	O
induces	O
membrane	O
ruffling	O
.	O

Assays	O
of	O
total	O
cholesterol	O
as	O
well	O
as	O
the	O
HDL	B-protein
,	O
HDL2	B-protein
,	O
LDL	B-protein
,	O
triglycerides	O
,	O
endothelin	B-protein
-	I-protein
1	I-protein
,	O
lipoprotein	B-protein
(	I-protein
a	I-protein
)	I-protein
,	O
estradiol	O
and	O
FSH	B-protein
were	O
also	O
obtained	O
at	O
baseline	O
before	O
receiving	O
ERT	O
and	O
after	O
3	O
months	O
of	O
ERT	O
.	O

These	O
transcripts	O
have	O
a	O
unique	O
5	O
'	O
untranslated	O
region	O
and	O
NH2	O
-	O
terminal	O
sequence	O
and	O
encode	O
a	O
predicted	O
protein	O
of	O
121	O
kD	O
.	O

Trinipatch	O
is	O
a	O
small	O
,	O
transparent	O
,	O
matricial	O
,	O
monolayer	O
patch	O
with	O
an	O
absorption	O
promoter	O
,	O
marketed	O
in	O
two	O
dose	O
-	O
strengths	O
(	O
5	O
mg	O
/	O
24	O
h	O
and	O
10	O
mg	O
/	O
24	O
h	O
)	O
by	O
Laboratoires	O
Synthelabo	O
.	O

The	O
activity	O
of	O
6	O
-	O
fluoroquinolones	O
and	O
their	O
nonfluorinated	O
derivatives	O
is	O
compared	O
in	O
general	O
.	O

Lars	O
has	O
AIDS	O
-	O
-	O
a	O
more	O
dignified	O
life	O
with	O
care	O
at	O
home	O
.	O

Transcriptional	O
regulators	O
utilizing	O
the	O
POU	B-protein
domain	I-protein
DNA	O
-	O
binding	O
motif	O
have	O
been	O
shown	O
to	O
form	O
multi	O
-	O
protein	O
complexes	O
dependent	O
on	O
the	O
POU	B-protein
domain	I-protein
itself	O
and	O
its	O
flexible	O
recognition	O
of	O
various	O
octamer	O
sequence	O
elements	O
.	O

These	O
elements	O
comprise	O
a	O
binding	O
site	O
for	O
Krox	B-protein
proteins	I-protein
,	O
one	O
for	O
nuclear	B-protein
factor	I-protein
1	I-protein
,	O
an	O
octamer	O
motif	O
that	O
binds	O
POU	B-protein
-	I-protein
homeodomain	I-protein
proteins	I-protein
,	O
and	O
a	O
novel	O
TN	B-protein
control	I-protein
element	I-protein
.	O

It	O
has	O
been	O
calculated	O
that	O
600	O
,	O
000	O
new	O
cases	O
of	O
lung	O
cancer	O
occur	O
worldwide	O
every	O
year	O
,	O
most	O
of	O
them	O
due	O
to	O
smoking	O
.	O

In	O
this	O
manuscript	O
we	O
demonstrate	O
that	O
two	O
tandem	B-protein
Ets	I-protein
sites	I-protein
in	O
the	O
mouse	B-protein
GL	I-protein
alpha	I-protein
promoter	I-protein
bind	O
the	O
transcription	B-protein
factors	I-protein
Elf	I-protein
-	I-protein
1	I-protein
and	O
PU	B-protein
.	I-protein
1	I-protein
,	O
and	O
that	O
the	O
3	O
'	O
site	O
is	O
essential	O
for	O
expression	O
of	O
a	O
luciferase	B-protein
reporter	I-protein
gene	I-protein
driven	O
by	O
the	O
GL	B-protein
alpha	I-protein
promoter	I-protein
.	O

The	O
mean	O
total	O
white	O
cell	O
count	O
increased	O
from	O
a	O
baseline	O
of	O
11	O
.	O
3	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
(	O
SD	O
2	O
.	O
3	O
)	O
to	O
16	O
.	O
2	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
(	O
SD	O
4	O
.	O
6	O
)	O
on	O
day	O
1	O
,	O
normalising	O
thereafter	O
.	O

The	O
level	O
of	O
serum	B-protein
creatine	I-protein
kinase	I-protein
was	O
significantly	O
high	O
2	O
days	O
after	O
ESWIB	O
,	O
but	O
it	O
recovered	O
in	O
a	O
week	O
.	O

FLP	B-protein
and	O
Cre	B-protein
recombinase	I-protein
function	O
in	O
Xenopus	O
embryos	O
.	O

We	O
detected	O
no	O
effect	O
of	O
deleting	O
YCL024W	B-protein
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
deletion	O
of	O
GIN4	B-protein
.	O

Recombinant	B-protein
AROM	I-protein
-	I-protein
p64	I-protein
displayed	O
high	O
binding	O
to	O
single	O
-	O
stranded	O
DNA	O
and	O
poly	O
(	O
A	O
)	O
homopolymers	O
suggesting	O
that	O
this	O
protein	O
could	O
play	O
a	O
role	O
in	O
mRNA	O
maturation	O
/	O
metabolism	O
.	O

In	O
our	O
studies	O
,	O
we	O
utilized	O
HIV	O
-	O
1	O
HXB2	B-protein
and	O
HIV	O
-	O
1	O
Z2Z6	B-protein
core	I-protein
enhancers	I-protein
because	O
the	O
Z2Z6	O
strain	O
has	O
a	O
single	O
point	O
mutation	O
flanking	O
the	O
right	O
ETS	B-protein
-	I-protein
binding	I-protein
site	I-protein
.	O

ZEBRA	B-protein
and	O
cellular	O
AP	B-protein
-	I-protein
1	I-protein
bZip	I-protein
activators	I-protein
,	O
such	O
as	O
c	B-protein
-	I-protein
Fos	I-protein
,	O
have	O
homologous	O
DNA	O
-	O
binding	O
domains	O
,	O
and	O
their	O
DNA	O
-	O
binding	O
specificities	O
overlap	O
.	O

Drug	O
effect	O
,	O
measured	O
as	O
postural	O
sway	O
,	O
was	O
also	O
similar	O
in	O
the	O
patients	O
with	O
cirrhosis	O
and	O
control	O
subjects	O
;	O
therefore	O
the	O
ratio	O
of	O
effect	O
area	O
under	O
the	O
curve	O
to	O
concentration	O
area	O
under	O
the	O
curve	O
,	O
a	O
measure	O
of	O
sensitivity	O
,	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
patients	O
with	O
cirrhosis	O
and	O
the	O
control	O
subjects	O
.	O

Damage	O
to	O
the	O
BBB	O
was	O
judged	O
by	O
extravasation	O
of	O
Evans	O
Blue	O
(	O
EB	O
)	O
dye	O
,	O
which	O
was	O
administered	O
either	O
2	O
,	O
3	O
,	O
24	O
or	O
48	O
h	O
after	O
onset	O
of	O
MCAo	O
.	O

At	O
the	O
carboxyl	O
terminus	O
,	O
deletion	O
as	O
far	O
as	O
residue	O
388	O
did	O
not	O
affect	O
in	O
vitro	O
TRF	B-protein
.	I-protein
C	I-protein
assembly	O
,	O
although	O
trans	O
-	O
activating	O
activity	O
was	O
abolished	O
.	O

Histological	O
signs	O
of	O
the	O
flare	O
-	O
up	O
reaction	O
were	O
already	O
present	O
at	O
6	O
hr	O
after	O
i	O
.	O
v	O
.	O
challenge	O
and	O
lasted	O
for	O
at	O
least	O
4	O
days	O
.	O

Moxidectin	O
(	O
at	O
3	O
times	O
the	O
therapeutic	O
dose	O
)	O
did	O
not	O
have	O
deleterious	O
effects	O
on	O
cow	O
reproductive	O
performance	O
as	O
examined	O
(	O
eg	O
,	O
at	O
folliculogenesis	O
,	O
ovulation	O
,	O
and	O
the	O
early	O
embryonic	O
phase	O
of	O
development	O
)	O
.	O

To	O
this	O
end	O
,	O
an	O
expression	O
cassette	O
consisting	O
of	O
the	O
gene	O
for	O
a	O
green	B-protein
fluorescent	I-protein
protein	I-protein
(	O
GFP	B-protein
)	O
flanked	O
at	O
its	O
3	O
'	O
end	O
by	O
EAV	O
-	O
specific	O
transcription	O
-	O
regulating	O
sequences	O
was	O
constructed	O
.	O

Promoter	O
recognition	O
algorithms	O
identified	O
divergent	O
promoter	O
elements	O
within	O
the	O
CpG	O
island	O
,	O
which	O
lies	O
between	O
the	O
ATM	B-protein
and	O
E14	B-protein
/	I-protein
NPAT	I-protein
genes	I-protein
,	O
and	O
provide	O
evidence	O
for	O
a	O
putative	O
second	O
ATM	B-protein
promoter	I-protein
located	O
within	O
intron	O
3	O
,	O
immediately	O
upstream	O
of	O
the	O
first	O
coding	O
exon	O
.	O

Thus	O
,	O
SAG	B-protein
appears	O
to	O
control	O
cell	O
cycle	O
progression	O
in	O
yeast	O
by	O
promoting	O
ubiquitination	O
and	O
degradation	O
of	O
cell	O
cycle	O
regulatory	O
proteins	O
.	O

The	O
main	O
issues	O
are	O
the	O
need	O
to	O
explain	O
a	O
number	O
of	O
still	O
unknown	O
mechanisms	O
,	O
to	O
determine	O
which	O
`	O
`	O
natural	O
diet	O
'	O
'	O
carries	O
the	O
minimum	O
coronary	O
risk	O
and	O
whether	O
`	O
`	O
new	O
'	O
'	O
foods	O
produced	O
by	O
modern	O
technology	O
are	O
really	O
needed	O
to	O
contrast	O
this	O
epidemic	O
.	O

BACKGROUND	O
:	O
Diazepam	O
,	O
one	O
of	O
the	O
benzodiazepine	O
group	O
of	O
tranquilizers	O
,	O
is	O
used	O
as	O
an	O
adjunctive	O
drug	O
for	O
sedation	O
and	O
for	O
relief	O
of	O
anxiety	O
in	O
the	O
treatment	O
of	O
epilepsy	O
.	O

Hippocampal	O
stimulation	O
overlapping	O
conditioned	O
stimulus	O
preexposure	O
produced	O
attenuation	O
of	O
latent	O
inhibition	O
,	O
as	O
did	O
stimulation	O
presented	O
during	O
conditioning	O
after	O
preexposure	O
.	O

However	O
,	O
five	O
new	O
mutation	O
sites	O
(	O
S61	B-protein
,	O
SL1	B-protein
,	O
S29	B-protein
,	O
SL11	B-protein
,	O
SL196	B-protein
and	O
SL126	B-protein
)	O
are	O
unique	O
to	O
the	O
nrdB	B-protein
intron	O
and	O
disrupt	O
self	O
-	O
splicing	O
.	O

The	O
murine	O
chromosomal	O
locations	O
of	O
the	O
five	O
NMDA	B-protein
receptor	I-protein
channel	I-protein
subunits	I-protein
,	O
the	O
epsilon	B-protein
1	I-protein
(	O
Grin2a	B-protein
)	O
,	O
epsilon	B-protein
2	I-protein
(	O
Grin2b	B-protein
)	O
,	O
epsilon	B-protein
3	I-protein
(	O
Grin2c	B-protein
)	O
,	O
epsilon	B-protein
4	I-protein
(	O
Grin2d	B-protein
)	O
and	O
zeta	B-protein
1	I-protein
(	O
Grinl	B-protein
)	O
subunits	O
,	O
were	O
determined	O
using	O
an	O
interspecific	O
backcross	O
mapping	O
panel	O
derived	O
from	O
crosses	O
of	O
[	O
(	O
C57BL	O
/	O
6JxM	O
.	O
spretus	O
)	O
F1xC57BL	O
/	O
6J	O
]	O
mice	O
.	O

Surprisingly	O
,	O
however	O
,	O
TCR	O
-	O
mediated	O
tyrosine	O
phosphorylation	O
of	O
phospholipase	B-protein
C	I-protein
gamma	I-protein
1	I-protein
remains	O
intact	O
in	O
the	O
Jurkat	O
cells	O
expressing	O
the	O
A2	B-protein
/	I-protein
HCP	I-protein
chimera	O
.	O

Serum	B-protein
creatine	I-protein
kinase	I-protein
(	O
SCK	B-protein
)	O
was	O
measured	O
in	O
ten	O
subjects	O
in	O
the	O
laboratory	O
before	O
and	O
after	O
the	O
performance	O
of	O
bicycle	O
ergometry	O
and	O
a	O
lifting	O
task	O
.	O

This	O
indicates	O
that	O
under	O
certain	O
experimental	O
conditions	O
cdc2	B-protein
/	I-protein
p58	I-protein
and	O
cdc2	B-protein
/	I-protein
p62	I-protein
may	O
express	O
some	O
differences	O
in	O
their	O
catalytic	O
activity	O
.	O

Plasma	B-protein
histaminase	I-protein
in	O
patients	O
of	O
bronchial	O
asthma	O
and	O
the	O
effect	O
of	O
prednisolone	O
administration	O
on	O
it	O
.	O

40	O
.	O
3	O
+	O
/	O
-	O
10	O
.	O
1	O
mg	O
/	O
l	O
(	O
SD	O
)	O
vs	O
31	O
.	O
2	O
+	O
/	O
-	O
8	O
.	O
0	O
,	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
beta	O
2m	O
was	O
not	O
significantly	O
higher	O
in	O
patients	O
with	O
bone	O
cysts	O
(	O
37	O
.	O
7	O
+	O
/	O
-	O
11	O
.	O
4	O
mg	O
/	O
l	O
vs	O
37	O
.	O
0	O
+	O
/	O
-	O
10	O
.	O
0	O
)	O
,	O
but	O
median	O
duration	O
of	O
dialysis	O
was	O
significantly	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
longer	O
in	O
patients	O
with	O
bone	O
cysts	O
(	O
90	O
vs	O
57	O
months	O
)	O
.	O
beta	B-protein
2m	I-protein
was	O
lower	O
in	O
patients	O
maintained	O
on	O
dialysis	O
for	O
less	O
than	O
1	O
year	O
and	O
whose	O
residual	O
urine	O
volume	O
was	O
greater	O
than	O
0	O
.	O
1	O
litre	O
per	O
day	O
.	O

The	O
susceptibility	O
of	O
Aspergillus	O
fumigatus	O
to	O
mulundocandin	O
,	O
an	O
echinocandin	O
-	O
like	O
compound	O
,	O
and	O
other	O
antifungal	O
agents	O
was	O
assessed	O
by	O
the	O
National	O
Committee	O
for	O
Clinical	O
Laboratory	O
Standards	O
(	O
NCCLS	O
)	O
M38	O
-	O
P	O
method	O
,	O
a	O
2	O
,	O
3	O
-	O
bis	O
(	O
2	O
-	O
methoxy	O
-	O
4	O
-	O
nitro	O
-	O
5	O
-	O
sulfophenyl	O
)	O
-	O
5	O
-	O
[	O
(	O
phenyl	O
-	O
amino	O
)	O
carbonyl	O
]	O
-	O
2H	O
-	O
tetrazolium	O
hydroxide	O
(	O
XTT	O
)	O
-	O
based	O
colorimetric	O
assay	O
,	O
and	O
determination	O
of	O
morphologic	O
alterations	O
by	O
microscopy	O
.	O

Number	O
of	O
patients	O
infected	O
with	O
nontuberculous	O
mycobacteria	O
(	O
NTM	O
)	O
is	O
increasing	O
world	O
-	O
wide	O
in	O
recent	O
years	O
.	O

An	O
F222W	B-protein
:	I-protein
W21F	I-protein
rGST	I-protein
A1	I-protein
-	I-protein
1	I-protein
double	I-protein
mutant	I-protein
provides	O
a	O
direct	O
fluorescence	O
probe	O
of	O
changes	O
in	O
the	O
environment	O
of	O
the	O
C	O
-	O
terminal	O
residue	O
.	O

Comparison	O
of	O
the	O
plant	B-protein
nuclear	I-protein
tRNA	I-protein
3	I-protein
'	I-protein
processing	I-protein
enzyme	I-protein
with	O
the	O
plant	O
mitochondrial	O
one	O
suggests	O
that	O
both	O
activities	O
are	O
different	O
enzymes	O
.	O

DtxR	B-protein
is	O
an	O
iron	O
-	O
dependent	O
sequence	O
-	O
specific	O
DNA	O
-	O
binding	O
protein	O
that	O
binds	O
to	O
the	O
tox	B-protein
operator	I-protein
,	O
an	O
inverted	O
-	O
repeat	O
nucleotide	O
sequence	O
located	O
upstream	O
from	O
the	O
diphtheria	B-protein
toxin	I-protein
gene	I-protein
.	O

Laboratory	O
studies	O
using	O
Ca45	O
labeled	O
teeth	O
and	O
biologically	O
stained	O
teeth	O
confirmed	O
that	O
the	O
dentifrice	O
did	O
not	O
decalcify	O
enamel	O
or	O
bleach	O
teeth	O
.	O

Autonomic	O
dysfunctions	O
were	O
restricted	O
to	O
tonic	O
pupils	O
.	O

Results	O
from	O
the	O
mechanism	O
study	O
have	O
revealed	O
that	O
YY1	B-protein
is	O
able	O
to	O
inhibit	O
transactivation	O
mediated	O
by	O
either	O
AP1	B-protein
or	O
the	O
Sp1	B-protein
-	I-protein
related	I-protein
protein	I-protein
,	O
and	O
YY1	B-protein
suppressive	O
activity	O
is	O
DNA	O
binding	O
dependent	O
.	O

The	O
men	O
self	O
-	O
selected	O
a	O
prescribed	O
diet	O
at	O
home	O
emphasizing	O
saturated	O
fat	O
as	O
the	O
visible	O
fat	O
for	O
1	O
week	O
.	O

One	O
patients	O
had	O
plasma	B-protein
C	I-protein
-	I-protein
peptide	I-protein
greater	O
than	O
3	O
pM	O
and	O
was	O
therefore	O
excluded	O
from	O
analysis	O
.	O

NF	B-protein
-	I-protein
kappa	I-protein
B	I-protein
p65	I-protein
,	O
p50	B-protein
,	O
and	O
Rel	B-protein
functionally	O
synergize	O
with	O
C	B-protein
/	I-protein
EBP	I-protein
alpha	I-protein
,	O
C	B-protein
/	I-protein
EBP	I-protein
beta	I-protein
,	O
and	O
C	B-protein
/	I-protein
EBP	I-protein
delta	I-protein
.	O

Cryoglobulinemia	O
in	O
Raynaud	O
'	O
s	O
syndrome	O
.	O

Freezing	O
of	O
plasma	O
to	O
obtain	O
better	O
yield	O
of	O
factor	B-protein
VIII	I-protein
:	O
C	O
.	O

In	O
the	O
VA	O
-	O
SMV	O
mode	O
,	O
the	O
connection	O
was	O
made	O
with	O
valved	O
conduits	O
from	O
the	O
LV	O
apex	O
(	O
inflow	O
)	O
to	O
the	O
ascending	O
aorta	O
(	O
outflow	O
)	O
(	O
n	O
=	O
11	O
)	O
or	O
to	O
the	O
DAo	O
(	O
n	O
=	O
12	O
)	O
.	O

To	O
circumvent	O
this	O
problem	O
,	O
a	O
simple	O
two	O
-	O
step	O
strategy	O
was	O
devised	O
by	O
which	O
essential	O
cis	O
-	O
acting	O
sites	O
like	O
the	O
a	O
sequence	O
can	O
be	O
readily	O
deleted	O
from	O
their	O
natural	O
loci	O
in	O
large	O
viral	O
DNA	O
genomes	O
.	O

The	O
reduction	O
in	O
saturated	O
fatty	O
acids	O
intake	O
led	O
to	O
modest	O
(	O
but	O
in	O
group	O
1	O
significant	O
)	O
0	O
.	O
15	O
mmol	O
/	O
l	O
(	O
2	O
.	O
5	O
%	O
)	O
reduction	O
in	O
total	O
serum	O
cholesterol	O
level	O
.	O

We	O
cloned	O
a	O
DNA	O
fragment	O
encoding	O
the	O
N	O
-	O
terminal	O
part	O
of	O
a	O
protein	O
with	O
significant	O
similarity	O
to	O
members	O
of	O
the	O
LysR	B-protein
family	I-protein
of	I-protein
transcriptional	I-protein
regulators	I-protein
(	O
LTTRs	B-protein
)	O
.	O

The	O
records	O
from	O
1948	O
through	O
1967	O
of	O
344	O
previously	O
untreated	O
patients	O
with	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
oral	O
cavity	O
,	O
oropharynx	O
,	O
supraglottic	O
larynx	O
and	O
hypopharynx	O
who	O
had	O
clinically	O
positive	O
cervical	O
lymph	O
node	O
metastases	O
staged	O
N1	O
,	O
N2A	O
,	O
or	O
N2B	O
,	O
and	O
whose	O
initial	O
neck	O
treatment	O
consisted	O
of	O
external	O
radiation	O
therapy	O
alone	O
were	O
reviewed	O
.	O

A	O
comparative	O
analysis	O
of	O
the	O
reported	O
MOCT	O
-	O
associated	O
malignant	O
melanomas	O
emphasizes	O
the	O
singularity	O
of	O
our	O
case	O
in	O
the	O
amelanotic	O
character	O
of	O
the	O
melanoma	O
,	O
its	O
lymphotropism	O
and	O
the	O
coexistence	O
of	O
invasive	O
squamous	O
cell	O
carcinoma	O
.	O

The	O
remaining	O
RAD	B-protein
+	I-protein
cells	O
progressed	O
to	O
form	O
microcolonies	O
(	O
<	O
30	O
cells	O
)	O
containing	O
aberrantly	O
shaped	O
inviable	O
cells	O
.	O

Increasing	O
the	O
phosphorus	O
content	O
of	O
the	O
diet	O
improved	O
the	O
reabsorption	O
of	O
calcium	O
and	O
magnesium	O
.	O

Drug	O
inhibition	O
of	O
whole	O
blood	O
aspirin	B-protein
esterase	I-protein
.	O

The	O
actuarial	O
local	O
control	O
rates	O
at	O
10	O
years	O
for	O
the	O
three	O
treatment	O
groups	O
were	O
as	O
follows	O
:	O
subtotal	O
excision	O
alone	O
,	O
18	O
%	O
;	O
subtotal	O
excision	O
plus	O
postoperative	O
radiation	O
therapy	O
,	O
82	O
%	O
;	O
and	O
total	O
excision	O
alone	O
,	O
77	O
%	O
.	O

It	O
is	O
related	O
to	O
a	O
variety	O
of	O
mammalian	O
Golgi	O
-	O
associated	O
proteins	O
and	O
to	O
the	O
yeast	O
Uso1p	B-protein
,	O
an	O
essential	O
protein	O
involved	O
in	O
docking	O
of	O
endoplasmic	O
reticulum	O
-	O
derived	O
vesicles	O
to	O
the	O
cis	O
-	O
Golgi	O
.	O

We	O
found	O
three	O
out	O
of	O
four	O
original	O
(	O
Volkan	O
'	O
s	O
)	O
groups	O
of	O
linking	O
objects	O
,	O
but	O
also	O
an	O
additional	O
one	O
,	O
hitherto	O
undescribed	O
,	O
comprising	O
objects	O
used	O
for	O
designing	O
a	O
memorial	O
shrine	O
to	O
the	O
deceased	O
.	O

The	O
upstream	O
delta	O
-	O
alpha	O
breakpoint	O
is	O
flanked	O
by	O
the	O
direct	O
repeats	O
of	O
the	O
acceptor	O
splice	O
site	O
,	O
whereas	O
the	O
down	O
-	O
stream	O
alpha	O
-	O
delta	O
breakpoint	O
is	O
located	O
in	O
the	O
adjacent	O
intron	O
.	O

Like	O
Epo	B-protein
,	O
HNF	B-protein
-	I-protein
4	I-protein
is	O
expressed	O
in	O
kidney	O
,	O
liver	O
,	O
and	O
Hep3B	O
cells	O
but	O
not	O
in	O
HeLa	O
cells	O
.	O

The	O
centromeric	O
YAC	O
contig	O
,	O
which	O
consists	O
of	O
23	O
overlapping	O
YACs	O
and	O
orders	O
19	O
sequence	O
-	O
tagged	O
sites	O
(	O
STSs	O
)	O
,	O
covers	O
a	O
minimum	O
of	O
2	O
.	O
2	O
Mb	O
and	O
spans	O
the	O
Ewing	O
sarcoma	O
breakpoint	O
.	O
c	B-protein
-	I-protein
ets	I-protein
1	I-protein
and	O
Fli	B-protein
-	I-protein
1	I-protein
,	O
two	O
members	O
of	O
the	O
ets	B-protein
family	I-protein
,	O
have	O
been	O
linked	O
within	O
400	O
kb	O
of	O
intervening	O
DNA	O
within	O
this	O
contig	O
,	O
which	O
also	O
comprises	O
a	O
polymorphic	O
microsatellite	O
,	O
D11S912	B-protein
(	I-protein
CA	I-protein
)	I-protein
n	I-protein
,	O
which	O
we	O
have	O
localized	O
within	O
the	O
Fli	B-protein
-	I-protein
1	I-protein
gene	I-protein
.	O

Null	O
alleles	O
of	O
SAS4	B-protein
and	O
SAS5	B-protein
bypassed	O
the	O
role	O
of	O
the	O
Abf1p	B-protein
binding	I-protein
site	I-protein
of	O
the	O
HMR	B-protein
-	I-protein
E	I-protein
silencer	I-protein
but	O
not	O
the	O
role	O
of	O
the	O
ACS	B-protein
or	O
Rap1p	B-protein
binding	I-protein
site	I-protein
.	O

The	O
initial	O
patients	O
treated	O
with	O
AZQ	O
and	O
mitroxantrone	O
experienced	O
prolonged	O
bone	O
marrow	O
suppression	O
and	O
,	O
therefore	O
,	O
subsequent	O
cohorts	O
were	O
treated	O
with	O
G	B-protein
-	I-protein
CSF	I-protein
,	O
5	O
micrograms	O
/	O
kg	O
,	O
beginning	O
the	O
day	O
after	O
completion	O
of	O
the	O
third	O
cycle	O
of	O
chemotherapy	O
.	O

The	O
basal	O
promoter	O
strength	O
of	O
constructs	O
that	O
contained	O
deletions	O
in	O
the	O
U5	B-protein
region	I-protein
of	O
the	O
LTR	B-protein
was	O
analyzed	O
by	O
chloramphenicol	B-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
assays	O
following	O
transfection	O
of	O
HeLa	O
cells	O
or	O
Jurkat	O
T	O
-	O
cells	O
in	O
the	O
presence	O
or	O
absence	O
of	O
viral	O
transactivator	O
tax	B-protein
protein	O
.	O

In	O
Schizosaccharomyces	O
pombe	O
,	O
the	O
activity	O
of	O
the	O
M	O
-	O
phase	O
-	O
inducing	O
Cdc2	B-protein
/	I-protein
Cdc13	I-protein
cyclin	I-protein
-	I-protein
dependent	I-protein
kinase	I-protein
is	O
inhibited	O
by	O
Wee1	B-protein
and	O
Mik1	B-protein
tyrosine	I-protein
kinases	I-protein
,	O
and	O
activated	O
by	O
Cdc25	B-protein
and	O
Pyp3	B-protein
tyrosine	I-protein
phosphatases	I-protein
.	O

Measurement	O
of	O
the	O
time	O
constant	O
of	O
VO2	O
and	O
oxygen	O
pulse	O
during	O
constant	O
work	O
rate	O
exercise	O
are	O
useful	O
for	O
the	O
objective	O
evaluation	O
of	O
the	O
training	O
effect	O
of	O
patients	O
with	O
COPD	O
.	O

The	O
direct	O
effects	O
of	O
transmitter	O
release	O
were	O
(	O
a	O
)	O
an	O
early	O
fall	O
in	O
MAP	O
followed	O
by	O
a	O
late	O
pressor	O
effect	O
;	O
and	O
(	O
b	O
)	O
an	O
early	O
bradycardia	O
followed	O
by	O
a	O
late	O
tachycardia	O
.	O

66	O
:	O
469	O
-	O
479	O
,	O
1992	O
)	O
.	O

A	O
724	O
-	O
bp	O
segment	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
consisting	O
of	O
the	O
proximal	O
E	O
-	O
box	O
flanked	O
upstream	O
by	O
a	O
mammalian	O
-	O
specific	O
352	O
-	O
bp	O
region	O
was	O
sufficient	O
for	O
maximal	O
transcriptional	O
activation	O
in	O
postconfluent	O
BC3H1	O
myoblasts	O
.	O

Arachnoid	O
cyst	O
.	O

It	O
encodes	O
a	O
protein	O
with	O
three	O
zinc	O
fingers	O
similar	O
to	O
those	O
of	O
the	O
transcription	B-protein
factor	I-protein
Sp1	I-protein
.	O

Liver	O
regional	O
blood	O
volume	O
(	O
LRBV	O
)	O
is	O
altered	O
by	O
several	O
disease	O
states	O
and	O
various	O
drugs	O
.	O

The	O
ESEM	O
differs	O
from	O
conventional	O
SEM	O
in	O
that	O
no	O
sample	O
preparation	O
is	O
needed	O
,	O
eliminating	O
artifactual	O
changes	O
.	O

Enhancers	O
containing	O
disrupted	O
Ets	B-protein
-	I-protein
1	I-protein
binding	I-protein
sites	I-protein
were	O
tested	O
in	O
transient	O
expression	O
assays	O
in	O
the	O
murine	O
T	O
-	O
cell	O
line	O
EL4	O
.	O
E1	O
;	O
alterations	O
in	O
the	O
LVb	B-protein
element	I-protein
affected	O
constitutive	O
enhancer	O
activity	O
,	O
while	O
mutation	O
of	O
either	O
the	O
LVb	B-protein
or	O
LVc	B-protein
element	I-protein
disrupted	O
phorbol	O
ester	O
-	O
induced	O
enhancer	O
activity	O
.	O

The	O
results	O
confirm	O
and	O
extend	O
previous	O
work	O
by	O
other	O
researchers	O
.	O

In	O
the	O
final	O
model	O
,	O
grade	O
(	O
p	O
=	O
0	O
.	O
0002	O
)	O
,	O
peritoneal	O
cytologic	O
results	O
(	O
p	O
=	O
0	O
.	O
0002	O
)	O
,	O
progesterone	B-protein
receptor	I-protein
status	O
(	O
p	O
=	O
0	O
.	O
004	O
)	O
,	O
and	O
age	O
as	O
a	O
continuous	O
variable	O
(	O
p	O
=	O
0	O
.	O
008	O
)	O
were	O
most	O
closely	O
associated	O
with	O
disease	O
-	O
free	O
survival	O
.	O

The	O
lack	O
of	O
change	O
in	O
the	O
ratio	O
of	O
the	O
two	O
spliced	O
products	O
expressed	O
from	O
either	O
the	O
normal	O
or	O
the	O
5	B-protein
'	I-protein
-	I-protein
rearranged	I-protein
myb	I-protein
further	O
indicates	O
that	O
the	O
insertion	O
of	O
the	O
unique	O
121	O
amino	O
acids	O
in	O
the	O
larger	O
myb	B-protein
transcripts	I-protein
is	O
not	O
a	O
consequence	O
of	O
tumor	O
-	O
specific	O
activation	O
of	O
the	O
mouse	B-protein
myb	I-protein
oncogene	I-protein
.	O

Removal	O
of	O
beta	B-protein
2	I-protein
-	I-protein
microglobulin	I-protein
by	O
hemodialysis	O
and	O
hemofiltration	O
:	O
a	O
four	O
year	O
follow	O
up	O
.	O

The	O
statistical	O
analysis	O
consist	O
of	O
the	O
F	O
test	O
followed	O
by	O
Snedecor	O
'	O
s	O
contrast	O
test	O
.	O

In	O
conclusion	O
,	O
USPIO	O
-	O
enhanced	O
MRI	O
data	O
were	O
capable	O
to	O
characterize	O
tumor	O
microvessel	O
properties	O
in	O
this	O
breast	O
cancer	O
model	O
:	O
microvascular	O
permeability	O
(	O
determined	O
using	O
USPIO	O
)	O
correlated	O
significantly	O
with	O
tumor	O
grade	O
.	O

Furthermore	O
,	O
the	O
PH	B-protein
and	O
PTB	O
domains	O
are	O
highly	O
homologous	O
(	O
at	O
least	O
40	O
%	O
identical	O
)	O
to	O
those	O
found	O
in	O
insulin	B-protein
receptor	I-protein
substrates	I-protein
1	I-protein
,	I-protein
2	I-protein
,	I-protein
and	I-protein
3	I-protein
(	O
IRS	B-protein
-	I-protein
1	I-protein
,	O
IRS	B-protein
-	I-protein
2	I-protein
,	O
and	O
IRS	B-protein
-	I-protein
3	I-protein
)	O
.	O

The	O
authors	O
describe	O
the	O
technique	O
of	O
transverse	O
axial	O
tomography	O
of	O
the	O
spine	O
and	O
give	O
a	O
detailed	O
description	O
of	O
the	O
axial	O
anatomy	O
of	O
the	O
normal	O
lumbar	O
spine	O
from	O
L	O
-	O
4	O
to	O
the	O
sacrum	O
.	O

Foxp1	B-protein
and	O
Foxp2	B-protein
are	O
expressed	O
at	O
high	O
levels	O
in	O
the	O
lung	O
as	O
early	O
as	O
E12	O
.	O
5	O
of	O
mouse	O
development	O
with	O
Foxp2	B-protein
expression	O
restricted	O
to	O
the	O
airway	O
epithelium	O
.	O

In	O
the	O
unclipped	O
group	O
arterial	O
pressure	O
decreased	O
50	O
mmHg	O
to	O
normal	O
by	O
24	O
h	O
and	O
was	O
associated	O
with	O
increased	O
diuresis	O
and	O
a	O
small	O
decrease	O
in	O
blood	O
volume	O
(	O
9	O
.	O
8	O
%	O
)	O
.	O

The	O
mean	O
times	O
to	O
detection	O
of	O
all	O
mycobacteria	O
with	O
BACTEC	O
9000	O
MB	O
and	O
BACTEC	O
460	O
TB	O
were	O
similar	O
(	O
10	O
.	O
3	O
and	O
10	O
.	O
0	O
days	O
,	O
respectively	O
)	O
.	O

The	O
alpha	B-protein
inhibin	I-protein
promoter	I-protein
containing	O
a	O
mutated	O
CRE	B-protein
was	O
not	O
regulated	O
by	O
forskolin	O
in	O
granulosa	O
cells	O
and	O
did	O
not	O
bind	O
the	O
CREB	B-protein
protein	I-protein
.	O

We	O
also	O
compared	O
the	O
sequence	O
with	O
the	O
partly	O
homologous	O
products	O
of	O
the	O
S	O
.	O
cerevisiae	O
genes	O
TPS2	B-protein
and	O
TSL1	B-protein
which	O
code	O
for	O
the	O
larger	O
subunits	O
of	O
the	O
trehalose	B-protein
synthase	I-protein
complex	I-protein
and	O
with	O
a	O
TSL1	B-protein
homologue	I-protein
,	O
TPS3	B-protein
,	O
of	O
unknown	O
function	O
.	O

Seventy	O
-	O
two	O
hours	O
after	O
administration	O
of	O
vitamin	O
K1	O
,	O
plasma	O
concentrations	O
of	O
the	O
vitamin	O
were	O
not	O
different	O
from	O
normal	O
.	O

Methanesulfonyl	O
fluoride	O
(	O
MSF	O
)	O
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
of	O
safety	O
and	O
efficacy	O
in	O
the	O
treatment	O
of	O
senile	O
dementia	O
of	O
the	O
Alzheimer	O
type	O
.	O

FDA	O
regulations	O
for	O
growth	B-protein
factors	I-protein
and	O
related	O
products	O
.	O

The	O
histidine	O
-	O
tagged	O
gene	O
,	O
rpoCHIS	B-protein
,	O
was	O
used	O
to	O
replace	O
the	O
wild	O
-	O
type	O
allele	O
in	O
the	O
chromosome	O
of	O
S	O
.	O
coelicolor	O
and	O
S	O
.	O
lividans	O
.	O

Identification	O
of	O
a	O
spliced	O
gene	O
from	O
Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
encoding	O
a	O
protein	O
with	O
similarities	O
to	O
latent	B-protein
membrane	I-protein
proteins	I-protein
1	I-protein
and	I-protein
2A	I-protein
of	I-protein
Epstein	I-protein
-	I-protein
Barr	I-protein
virus	I-protein
.	O

To	O
identify	O
these	O
sites	O
,	O
the	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
3T3	O
-	O
L1	O
adipocyte	B-protein
insulin	I-protein
receptor	I-protein
of	O
the	O
mouse	O
was	O
determined	O
.	O

Wild	B-protein
type	I-protein
HA	I-protein
-	I-protein
p190	I-protein
induced	O
a	O
phenotype	O
of	O
rounded	O
cells	O
with	O
long	O
,	O
beaded	O
extensions	O
similar	O
to	O
that	O
seen	O
when	O
Rho	B-protein
function	O
is	O
disrupted	O
by	O
ADP	O
-	O
ribosylation	O
.	O

In	O
summary	O
,	O
the	O
data	O
establish	O
that	O
the	O
previously	O
reported	O
human	B-protein
MAdCAM	I-protein
-	I-protein
1	I-protein
cDNA	I-protein
does	O
indeed	O
encode	O
the	O
human	O
homologue	O
of	O
mouse	B-protein
MAdCAM	I-protein
-	I-protein
1	I-protein
,	O
despite	O
gross	O
dissimilarities	O
in	O
the	O
MAdCAM	B-protein
-	I-protein
1	I-protein
C	O
-	O
terminal	O
structures	O
.	O

Upstream	O
of	O
the	O
dra	B-protein
gene	I-protein
an	O
open	O
reading	O
frame	O
of	O
313	O
amino	O
acids	O
was	O
identified	O
.	O

Chemical	O
uptake	O
into	O
human	O
stratum	O
corneum	O
in	O
vivo	O
from	O
volatile	O
and	O
non	O
-	O
volatile	O
solvents	O
.	O

Diet	O
therapy	O
with	O
soy	O
proteins	O
for	O
chronic	O
stomach	O
ulcers	O
.	O

In	O
patients	O
who	O
had	O
received	O
no	O
previous	O
drug	O
treatment	O
,	O
log	O
baseline	O
plasma	B-protein
renin	I-protein
activity	O
and	O
change	O
in	O
mean	O
blood	O
pressure	O
after	O
SQ	O
20881	O
correlated	O
significantly	O
(	O
r	O
=	O
0	O
.	O
651	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

We	O
conclude	O
that	O
sequences	O
outside	O
of	O
the	O
hLEF	B-protein
HMG	I-protein
box	I-protein
mediate	O
cell	O
-	O
and	O
context	O
-	O
specific	O
activation	O
of	O
the	O
TCR	B-protein
alpha	I-protein
enhancer	I-protein
and	O
may	O
facilitate	O
interactions	O
between	O
hLEF	B-protein
and	O
other	O
T	O
-	O
cell	O
-	O
specific	O
factors	O
recruited	O
to	O
the	O
enhancer	O
.	O

More	O
mRNA	O
corresponding	O
to	O
nagB	B-protein
and	O
nagA	B-protein
is	O
detected	O
than	O
that	O
corresponding	O
to	O
the	O
distal	O
genes	O
,	O
nagC	B-protein
and	O
nagD	B-protein
.	O

However	O
,	O
its	O
participation	O
in	O
collagen	B-protein
binding	O
has	O
not	O
been	O
shown	O
.	O

The	O
sequenced	O
genomic	O
region	O
thus	O
accounts	O
for	O
essentially	O
all	O
of	O
the	O
longest	O
known	O
transcript	O
(	O
4	O
.	O
5	O
kb	O
)	O
,	O
although	O
the	O
precise	O
ends	O
of	O
this	O
transcript	O
have	O
not	O
been	O
defined	O
.	O

Neonatal	O
Chagas	O
disease	O
:	O
laboratory	O
diagnosis	O
during	O
the	O
first	O
year	O
of	O
life	O
.	O

This	O
study	O
evaluates	O
the	O
feasibility	O
of	O
indirect	O
mesenteric	O
lymphangiography	O
as	O
a	O
colonoscopic	O
technique	O
in	O
a	O
canine	O
model	O
.	O

The	O
gonadotrope	O
-	O
specific	O
and	O
regulated	O
expression	O
of	O
the	O
GnRH	B-protein
receptor	I-protein
(	O
GnRH	B-protein
-	I-protein
R	I-protein
)	O
gene	O
is	O
dependent	O
on	O
multiple	O
transcription	O
factors	O
that	O
interact	O
with	O
the	O
noncanonical	B-protein
GnRH	I-protein
-	I-protein
R	I-protein
activating	I-protein
sequence	I-protein
(	O
GRAS	B-protein
)	O
,	O
the	O
activator	B-protein
protein	I-protein
-	I-protein
1	I-protein
(	O
AP	B-protein
-	I-protein
1	I-protein
)	O
element	O
,	O
and	O
the	O
steroidogenic	B-protein
factor	I-protein
-	I-protein
1	I-protein
(	O
SF	B-protein
-	I-protein
1	I-protein
)	O
binding	O
site	O
.	O

Comparison	O
of	O
the	O
deduced	O
amino	O
acid	O
sequences	O
with	O
protein	O
sequences	O
of	O
T	O
.	O
pyriformis	O
H2As	B-protein
showed	O
only	O
two	O
and	O
three	O
differences	O
respectively	O
,	O
in	O
a	O
total	O
of	O
137	O
amino	O
acids	O
for	O
H2A1	B-protein
,	O
and	O
132	O
amino	O
acids	O
for	O
H2A2	B-protein
,	O
indicating	O
the	O
two	O
genes	O
arose	O
before	O
the	O
divergence	O
of	O
these	O
two	O
species	O
.	O

Anecdotal	O
observations	O
scattered	O
throughout	O
the	O
literature	O
have	O
often	O
provided	O
clues	O
to	O
underlying	O
variations	O
in	O
humans	O
'	O
ability	O
to	O
handle	O
dietary	O
chemicals	O
.	O

Fewer	O
recombination	O
events	O
are	O
detected	O
in	O
four	O
different	O
B	O
and	O
T	O
cell	O
lines	O
that	O
do	O
not	O
undergo	O
switch	O
recombination	O
of	O
their	O
endogenous	O
genes	O
.	O

These	O
observations	O
establish	O
that	O
RsmC	B-protein
negatively	O
regulates	O
rsmB	B-protein
transcription	O
but	O
positively	O
affects	O
RsmA	B-protein
production	O
.	O

This	O
was	O
most	O
pronounced	O
during	O
the	O
initial	O
phase	O
of	O
Erk	B-protein
activation	O
.	O

Institution	O
of	O
both	O
intravenous	O
and	O
intracisternal	O
administration	O
of	O
amphotericin	O
B	O
and	O
possibly	O
concomitant	O
intravenous	O
administration	O
of	O
dexamethasone	O
may	O
be	O
warranted	O
in	O
situations	O
in	O
which	O
the	O
association	O
of	O
C	O
.	O
immitis	O
with	O
CNS	O
vasculitis	O
or	O
encephalitis	O
appears	O
likely	O
before	O
serologic	O
or	O
cultural	O
confirmation	O
of	O
C	O
.	O
immitis	O
infection	O
involving	O
the	O
CNS	O
is	O
available	O
.	O

Increasing	O
mean	O
arterial	O
pressure	O
by	O
phenylephrine	O
infusion	O
to	O
levels	O
much	O
greater	O
than	O
produced	O
by	O
NMA	O
and	O
NNA	O
caused	O
only	O
small	O
reductions	O
in	O
cardiac	O
output	O
.	O

The	O
nucleotide	O
sequence	O
of	O
22	O
,	O
846	O
bp	O
of	O
the	O
left	O
arm	O
of	O
chromosome	O
IV	O
is	O
described	O
.	O

From	O
all	O
clinically	O
important	O
yeasts	O
species	O
,	O
a	O
total	O
of	O
96	O
%	O
were	O
identified	O
by	O
ATB	O
method	O
according	O
to	O
conventional	O
methods	O
.	O

To	O
account	O
for	O
this	O
observation	O
,	O
other	O
possible	O
causes	O
include	O
increased	O
CSF	O
pulsation	O
in	O
children	O
creating	O
motion	O
artifact	O
,	O
changes	O
in	O
arterial	O
oxygen	O
concentration	O
intrinsic	O
to	O
propofol	O
or	O
related	O
to	O
the	O
supplemental	O
oxygen	O
normally	O
administered	O
,	O
or	O
changes	O
in	O
CSF	O
protein	O
levels	O
related	O
to	O
propofol	O
binding	O
to	O
proteins	O
for	O
uptake	O
into	O
CSF	O
.	O

A	O
gas	O
-	O
liquid	O
chromatographic	O
method	O
for	O
the	O
determination	O
of	O
p	O
-	O
chlorophenoxyisobutyric	O
(	O
CPIB	O
)	O
acid	O
in	O
blood	O
plasma	O
is	O
described	O
.	O

The	O
fatigue	O
exercise	O
showed	O
relatively	O
high	O
blood	O
lactate	O
concentration	O
[	O
12	O
.	O
5	O
(	O
SD	O
2	O
.	O
6	O
)	O
mmol	O
x	O
l	O
(	O
-	O
1	O
)	O
]	O
and	O
an	O
increase	O
of	O
serum	B-protein
creatine	I-protein
kinase	I-protein
(	O
CK	B-protein
)	O
activity	O
delayed	O
by	O
2	O
days	O
[	O
540	O
(	O
SD	O
407	O
)	O
U	O
x	O
l	O
(	O
-	O
1	O
)	O
]	O
.	O

We	O
have	O
investigated	O
the	O
role	O
of	O
NGF	B-protein
in	O
regulating	O
gene	O
transcription	O
in	O
PC12	O
and	O
INS	O
-	O
1	O
cells	O
,	O
in	O
order	O
to	O
define	O
if	O
there	O
are	O
NGF	O
-	O
regulated	O
genes	O
per	O
se	O
.	O

Chloroplast	B-protein
mutator	I-protein
(	O
chm	B-protein
)	O
of	O
Arabidopsis	O
is	O
a	O
recessive	O
nuclear	O
mutation	O
that	O
causes	O
green	O
and	O
white	O
variegation	O
in	O
leaves	O
and	O
is	O
inherited	O
in	O
a	O
non	O
-	O
Mendelian	O
fashion	O
.	O

In	O
three	O
of	O
the	O
seven	O
,	O
inhalation	O
of	O
2	O
ml	O
normal	O
saline	O
produced	O
FEV1	O
falls	O
of	O
25	O
%	O
to	O
30	O
%	O
,	O
but	O
these	O
falls	O
were	O
not	O
as	O
great	O
as	O
each	O
subject	O
'	O
s	O
reactions	O
to	O
the	O
test	O
solutions	O
.	O

As	O
demonstrated	O
by	O
gel	O
mobility	O
shift	O
analysis	O
and	O
supershift	O
experiments	O
,	O
FIRE1	B-protein
,	O
located	O
between	O
-	O
516	O
and	O
-	O
498	O
,	O
is	O
responsible	O
for	O
binding	O
NF	B-protein
-	I-protein
Y	I-protein
.	O

Electrophile	B-protein
Response	I-protein
Elements	I-protein
(	O
EpREs	B-protein
)	O
,	O
located	O
in	O
5	O
'	O
-	O
flanking	O
sequences	O
of	O
both	O
the	O
GCSh	B-protein
and	O
GCSl	B-protein
subunit	I-protein
genes	I-protein
,	O
are	O
hypothesized	O
to	O
at	O
least	O
partially	O
mediate	O
gene	O
induction	O
following	O
xenobiotic	O
exposure	O
.	O

Extreme	O
potency	O
of	O
botulinum	B-protein
toxin	I-protein
.	O

It	O
appears	O
that	O
the	O
pulmonary	O
gas	O
exchange	O
parenchyma	O
of	O
these	O
smallest	O
mammals	O
is	O
well	O
suited	O
to	O
supply	O
the	O
organism	O
with	O
the	O
comparatively	O
high	O
levels	O
of	O
O2	O
required	O
by	O
the	O
high	O
metabolic	O
rates	O
,	O
exhibiting	O
a	O
structural	O
adaptation	O
of	O
the	O
lung	O
to	O
higher	O
VO2	O
.	O

The	O
development	O
and	O
histostructural	O
organization	O
of	O
intrahepatic	O
biliary	O
ducts	O
were	O
studied	O
on	O
a	O
human	O
embryofetal	O
material	O
6	O
to	O
32	O
weeks	O
old	O
.	O

Age	O
at	O
POI	O
and	O
asymptote	O
were	O
achieved	O
later	O
for	O
Line	O
RBC2	O
than	O
for	O
Line	O
F	O
.	O

Disorders	O
of	O
platelet	O
function	O
in	O
chronic	O
myeloid	O
leukemias	O
.	O

Hepatitis	B-protein
B	I-protein
surface	I-protein
antigen	I-protein
was	O
detected	O
in	O
2	O
patients	O
,	O
with	O
negative	O
hepatitis	B-protein
C	I-protein
virus	I-protein
antibody	I-protein
.	O

Clinical	O
and	O
angiographic	O
examinations	O
in	O
occlusion	O
disease	O
of	O
the	O
great	O
intestinal	O
arteries	O
.	O

CONCLUSIONS	O
:	O
Two	O
consecutive	O
sets	O
of	O
transrectal	O
ultrasound	O
guided	O
sextant	O
biopsies	O
of	O
the	O
prostate	O
performed	O
in	O
a	O
single	O
office	O
visit	O
represent	O
a	O
cost	O
-	O
effective	O
biopsy	O
strategy	O
for	O
men	O
presenting	O
with	O
an	O
abnormal	O
digital	O
rectal	O
examination	O
and	O
/	O
or	O
elevated	O
serum	B-protein
PSA	I-protein
.	O

We	O
compare	O
the	O
results	O
of	O
this	O
algorithm	O
with	O
the	O
results	O
obtained	O
with	O
two	O
other	O
algorithms	O
,	O
the	O
optimal	O
algorithm	O
for	O
monochannel	O
nonoverlapping	O
noise	O
and	O
the	O
optimal	O
algorithm	O
for	O
multichannel	O
additive	O
noise	O
,	O
and	O
we	O
show	O
that	O
in	O
both	O
cases	O
improvement	O
can	O
be	O
obtained	O
.	O

A	O
safe	O
and	O
simple	O
system	O
for	O
the	O
detection	O
of	O
sudden	O
infant	O
death	O
syndrome	O
(	O
SIDS	O
)	O
is	O
proposed	O
.	O

Transactivation	O
of	O
naturally	O
occurring	O
HIV	O
-	O
1	O
long	O
terminal	O
repeats	O
by	O
the	O
JNK	B-protein
signaling	O
pathway	O
.	O

Those	O
dosages	O
that	O
inhibited	O
mean	O
NTE	B-protein
activity	O
in	O
spinal	O
cord	O
greater	O
than	O
or	O
equal	O
to	O
72	O
%	O
and	O
brain	O
greater	O
than	O
or	O
equal	O
to	O
66	O
%	O
of	O
control	O
values	O
within	O
44	O
hr	O
postexposure	O
produced	O
marked	O
spinal	O
cord	O
pathology	O
14	O
days	O
postexposure	O
in	O
greater	O
than	O
or	O
equal	O
to	O
90	O
%	O
of	O
similarly	O
dosed	O
animals	O
.	O

RESULTS	O
:	O
An	O
herpetic	O
seroconversion	O
is	O
observed	O
with	O
presence	O
of	O
type	O
I	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
I	O
)	O
nucleic	O
acids	O
in	O
the	O
recipient	O
'	O
s	O
aqueous	O
humor	O
.	O

Plasma	O
NE	O
was	O
also	O
low	O
in	O
the	O
anephric	O
group	O
(	O
289	O
mg	O
/	O
liter	O
+	O
/	O
-	O
126	O
(	O
1	O
SD	O
)	O
vs	O
612	O
+	O
/	O
-	O
189	O
,	O
P	O
=	O
0	O
.	O
033	O
,	O
resting	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

A	O
gene	O
homologous	O
to	O
the	O
Escherichia	B-protein
coli	I-protein
dnaA	I-protein
gene	I-protein
was	O
isolated	O
from	O
Pseudomonas	O
putida	O
and	O
its	O
transcription	O
was	O
investigated	O
in	O
E	O
.	O
coli	O
as	O
well	O
as	O
in	O
P	O
.	O
putida	O
.	O

Concussion	O
of	O
the	O
spinal	O
cord	O
.	O

Relatively	O
large	O
DNA	O
rearrangements	O
spanning	O
the	O
region	O
with	O
tandem	O
direct	O
repeats	O
encoding	O
the	O
carboxy	B-protein
-	I-protein
terminal	I-protein
histone	I-protein
H1	I-protein
-	I-protein
like	I-protein
structure	I-protein
of	O
AlgP	B-protein
were	O
detected	O
in	O
several	O
strains	O
upon	O
conversion	O
from	O
the	O
mucoid	O
to	O
the	O
nonmucoid	O
phenotype	O
.	O

This	O
approach	O
places	O
gHoxb	B-protein
-	I-protein
1	I-protein
into	O
the	O
normal	O
embryonic	O
spatiotemporal	O
context	O
in	O
which	O
lab	O
acts	O
.	O

IVOX	O
was	O
named	O
as	O
an	O
acronym	O
for	O
intravascular	O
oxygenator	O
.	O

However	O
,	O
serial	O
passages	O
of	O
fetal	O
lamb	O
kidney	O
(	O
FLK	O
)	O
cells	O
,	O
which	O
are	O
sensitive	O
to	O
infection	O
with	O
BLV	O
,	O
after	O
transient	O
transfection	O
revealed	O
that	O
mutation	O
of	O
a	O
second	O
tyrosine	O
residue	O
in	O
the	O
N	O
-	O
terminal	O
motif	O
completely	O
prevented	O
the	O
propagation	O
of	O
the	O
virus	O
.	O

Serum	O
levels	O
of	O
IgG	B-protein
and	O
IgM	B-protein
were	O
also	O
raised	O
,	O
but	O
contrary	O
to	O
the	O
findings	O
of	O
other	O
observers	O
IgA	B-protein
levels	O
were	O
normal	O
.	O

The	O
performance	O
of	O
three	O
commonly	O
used	O
chemical	O
cartridge	O
respirators	O
for	O
SO2	O
was	O
measured	O
under	O
working	O
conditions	O
in	O
a	O
copper	O
smelter	O
.	O

The	O
promoter	O
region	O
(	O
P1	O
)	O
corresponding	O
to	O
the	O
main	O
group	O
of	O
transcription	O
initiation	O
sites	O
is	O
devoid	O
of	O
TATA	O
and	O
CAAT	O
boxes	O
but	O
has	O
putative	O
binding	O
sites	O
for	O
the	O
transcription	B-protein
factor	I-protein
SP1	I-protein
and	O
is	O
embedded	O
in	O
a	O
large	O
G	O
+	O
C	O
-	O
rich	O
domain	O
of	O
a	O
CpG	O
island	O
,	O
features	O
shared	O
by	O
the	O
promoters	O
of	O
constitutively	O
expressed	O
housekeeping	O
genes	O
.	O

THE	O
SCALING	O
OF	O
SONG	O
FREQUENCY	O
IN	O
CICADAS	O
.	O

HIV	O
infectiousness	O
and	O
the	O
AIDS	O
epidemic	O
.	O

Endocytosis	O
and	O
lysosomal	O
targeting	O
of	O
epidermal	B-protein
growth	I-protein
factor	I-protein
receptors	I-protein
are	O
mediated	O
by	O
distinct	O
sequences	O
independent	O
of	O
the	O
tyrosine	B-protein
kinase	I-protein
domain	I-protein
.	O

Expansins	B-protein
are	O
a	O
family	O
of	O
proteins	O
that	O
catalyse	O
long	O
-	O
term	O
extension	O
of	O
isolated	O
plant	O
cell	O
walls	O
due	O
to	O
an	O
as	O
yet	O
unknown	O
biochemical	O
mechanism	O
.	O

Problems	O
common	O
to	O
pediatrics	O
and	O
anesthesiology	O
.	O

Shc	B-protein
stimulates	O
Ras	B-protein
/	I-protein
mitogen	I-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
through	O
forming	O
a	O
complex	O
with	O
Grb2	B-protein
at	O
the	O
phosphorylated	O
tyrosine	O
(	O
Y	O
)	O
residue	O
317	O
.	O

Cholangiography	O
was	O
performed	O
in	O
all	O
cases	O
and	O
classified	O
by	O
a	O
scoring	O
system	O
specifically	O
developed	O
for	O
pediatric	O
patients	O
.	O

Frog	O
type	O
I	O
(	O
Ft	O
I	O
)	O
and	O
frog	O
type	O
II	O
(	O
Ft	O
II	O
)	O
slowly	O
adapting	O
(	O
SA	O
)	O
units	O
produced	O
spikes	O
only	O
at	O
the	O
indentation	O
phase	O
,	O
and	O
the	O
threshold	O
response	O
phase	O
(	O
TRP	O
)	O
,	O
i	O
.	O
e	O
.	O
.	O
the	O
phase	O
of	O
the	O
first	O
spike	O
was	O
for	O
ca	O
.	O

Chem	O
.	O

A	O
single	O
N	O
-	O
glycosylation	O
site	O
present	O
in	O
chicken	B-protein
gp42	I-protein
is	O
conserved	O
among	O
all	O
five	O
of	O
these	O
proteins	O
:	O
carbohydrate	O
analysis	O
of	O
gp42	B-protein
revealed	O
the	O
presence	O
of	O
a	O
complex	O
type	O
glycan	O
chain	O
at	O
this	O
site	O
.	O

Different	O
doses	O
of	O
15	O
-	O
methyl	O
-	O
PGF2	O
alpha	O
(	O
0	O
.	O
125	O
-	O
10	O
mg	O
)	O
were	O
used	O
to	O
induce	O
luteolysis	O
and	O
oestrus	O
in	O
7	O
heifers	O
with	O
28	O
treatments	O
on	O
day	O
8	O
-	O
12	O
of	O
the	O
oestrous	O
cycle	O
.	O

BSE	O
and	O
farmworkers	O
.	O

A	O
pre	O
-	O
boutonniere	O
deformity	O
was	O
simulated	O
by	O
dividing	O
the	O
central	O
slip	O
.	O

First	O
,	O
human	O
erythroid	O
K562	O
cells	O
stably	O
integrated	O
with	O
various	O
HS	B-protein
-	I-protein
40	I-protein
mutants	I-protein
cis	O
linked	O
to	O
a	O
human	B-protein
alpha	I-protein
-	I-protein
globin	I-protein
promoter	I-protein
-	I-protein
growth	I-protein
hormone	I-protein
hybrid	I-protein
gene	I-protein
were	O
analyzed	O
by	O
genomic	O
footprinting	O
and	O
expression	O
analysis	O
.	O

Electron	O
microscopic	O
picture	O
of	O
the	O
cerebral	O
cortex	O
in	O
rats	O
cooled	O
to	O
22	O
degrees	O
C	O
.	O

Enterococcus	O
faecium	O
strains	O
with	O
vanA	O
-	O
mediated	O
glycopeptide	O
resistance	O
were	O
isolated	O
by	O
enrichment	O
culture	O
from	O
the	O
intestines	O
and	O
feces	O
of	O
several	O
animal	O
species	O
,	O
mainly	O
horses	O
and	O
dogs	O
(	O
8	O
%	O
positive	O
)	O
,	O
chickens	O
(	O
7	O
%	O
positive	O
)	O
,	O
and	O
pigs	O
(	O
6	O
%	O
positive	O
)	O
.	O

Studies	O
on	O
powdered	O
preparations	O
.	O

Ultraviolet	O
light	O
-	O
induced	O
kinin	B-protein
formation	O
in	O
human	O
skin	O
.	O

Effect	O
of	O
bromazepam	O
on	O
growth	B-protein
hormone	I-protein
and	O
prolactin	B-protein
secretion	O
in	O
normal	O
subjects	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
cloned	O
a	O
region	O
that	O
complements	O
the	O
exoenzyme	O
S	O
-	O
deficient	O
phenotype	O
of	O
strain	O
388	O
exs1	B-protein
:	O
:	O
Tn1	B-protein
,	O
a	O
chromosomal	B-protein
Tn1	I-protein
insertional	I-protein
mutation	I-protein
.	O

The	O
BAL	O
concentrations	O
of	O
the	O
nine	O
cytokines	O
evaluated	O
for	O
the	O
more	O
and	O
less	O
affected	O
lungs	O
were	O
compared	O
:	O
interleukin	B-protein
-	I-protein
6	I-protein
(	O
IL	B-protein
-	I-protein
6	I-protein
)	O
,	O
IL	B-protein
-	I-protein
8	I-protein
,	O
IL	B-protein
-	I-protein
12	I-protein
,	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
-	I-protein
alpha	I-protein
(	O
TNF	B-protein
-	I-protein
alpha	I-protein
)	O
,	O
and	O
interferon	B-protein
gamma	I-protein
(	O
IFN	B-protein
-	I-protein
gamma	I-protein
)	O
showed	O
significant	O
differences	O
(	O
p	O
ranged	O
between	O
0	O
.	O

Comparison	O
of	O
the	O
cDNA	O
-	O
predicted	O
avian	B-protein
TnIcardiac	I-protein
amino	I-protein
acid	I-protein
sequences	I-protein
with	O
known	O
TnI	B-protein
sequences	I-protein
indicated	O
1	O
)	O
that	O
the	O
presence	O
of	O
an	O
N	O
-	O
terminal	O
extension	O
sequence	O
carrying	O
a	O
dual	O
protein	B-protein
kinase	I-protein
A	I-protein
phosphorylation	O
target	O
site	O
and	O
an	O
adjacent	O
proline	O
-	O
rich	O
segment	O
is	O
an	O
ancient	O
cardiac	O
-	O
specific	O
feature	O
of	O
TnI	B-protein
which	O
has	O
been	O
conserved	O
since	O
the	O
bird	O
/	O
mammal	O
divergence	O
,	O
2	O
)	O
that	O
features	O
of	O
the	O
near	O
-	O
N	O
-	O
terminal	O
troponin	B-protein
C	I-protein
(	O
TnC	B-protein
)	O
-	O
binding	O
site	O
sequence	O
suggest	O
isoform	O
-	O
specific	O
adaptation	O
of	O
TnI	B-protein
and	O
TnC	B-protein
,	O
and	O
3	O
)	O
that	O
the	O
avian	O
TnIcardiac	B-protein
internal	O
actin	B-protein
/	I-protein
TnC	I-protein
-	I-protein
binding	I-protein
,	I-protein
actomyosin	I-protein
-	I-protein
inhibitory	I-protein
,	I-protein
domain	I-protein
shows	O
significant	O
sequence	O
divergence	O
from	O
mammalian	B-protein
TnIcardiac	I-protein
sequences	I-protein
,	O
including	O
the	O
absence	O
of	O
a	O
protein	B-protein
kinase	I-protein
C	I-protein
target	O
site	O
which	O
is	O
a	O
cardiac	O
-	O
specific	O
feature	O
of	O
TnI	B-protein
in	O
mammals	O
.	O

Certain	O
spt10	B-protein
spontaneous	O
alleles	O
are	O
good	O
suppressors	O
but	O
have	O
a	O
normal	O
growth	O
rate	O
,	O
suggesting	O
that	O
the	O
SPT10	B-protein
protein	I-protein
may	O
have	O
two	O
distinct	O
functions	O
.	O

Genomic	O
libraries	O
were	O
stored	O
as	O
frozen	O
cultures	O
in	O
a	O
96	O
-	O
well	O
format	O
,	O
each	O
well	O
containing	O
approximately	O
300	O
-	O
600	O
colonies	O
(	O
12	O
plates	O
for	O
small	O
library	O
,	O
four	O
for	O
medium	O
-	O
size	O
library	O
and	O
four	O
for	O
large	O
library	O
)	O
.	O

Immobilized	O
dimers	O
of	O
N	B-protein
-	I-protein
cadherin	I-protein
-	I-protein
Fc	I-protein
chimera	I-protein
mimic	O
cadherin	O
-	O
mediated	O
cell	O
contact	O
formation	O
:	O
contribution	O
of	O
both	O
outside	O
-	O
in	O
and	O
inside	O
-	O
out	O
signals	O
.	O

In	O
contrast	O
,	O
gel	O
mobility	O
shift	O
experiments	O
have	O
failed	O
to	O
reveal	O
that	O
HAP2	B-protein
or	O
HAP3	B-protein
binds	O
to	O
domain	O
1	O
or	O
that	O
hap3	B-protein
mutations	O
affect	O
the	O
complexes	O
bound	O
to	O
it	O
.	O

The	O
PDH	B-protein
complex	I-protein
-	I-protein
encoding	I-protein
genes	I-protein
were	O
identified	O
by	O
hybridization	O
experiments	O
and	O
sequence	O
analysis	O
in	O
two	O
separate	O
gene	O
regions	O
in	O
the	O
genome	O
of	O
Z	O
.	O
mobilis	O
.	O

None	O
of	O
the	O
patients	O
was	O
obese	O
.	O

Mucosal	O
application	O
of	O
NCX	O
-	O
4016	O
,	O
however	O
,	O
did	O
not	O
cause	O
PD	O
reduction	O
and	O
luminal	O
H	O
+	O
loss	O
,	O
but	O
produced	O
a	O
marked	O
hyperemia	O
,	O
resulting	O
in	O
no	O
damage	O
in	O
the	O
stomach	O
of	O
both	O
normal	O
and	O
STZ	O
-	O
diabetic	O
rats	O
.	O

A	O
role	O
for	O
glycogen	B-protein
synthase	I-protein
kinase	I-protein
-	I-protein
3	I-protein
in	O
the	O
control	O
of	O
gene	O
expression	O
.	O

CONCLUSION	O
:	O
Our	O
study	O
shows	O
that	O
(	O
1	O
)	O
total	O
body	O
BMD	O
and	O
femoral	O
neck	O
BMD	O
were	O
significantly	O
higher	O
in	O
the	O
study	O
group	O
that	O
performed	O
weight	O
-	O
bearing	O
exercises	O
than	O
in	O
control	O
subjects	O
,	O
(	O
2	O
)	O
swimming	O
exercise	O
had	O
no	O
effect	O
on	O
BMD	O
,	O
and	O
(	O
3	O
)	O
although	O
swimming	O
is	O
not	O
a	O
bone	O
-	O
building	O
exercise	O
,	O
it	O
can	O
significantly	O
improve	O
shoulder	O
,	O
back	O
,	O
and	O
grip	O
muscle	O
strength	O
.	O

Adjuvant	O
therapy	O
for	O
colon	O
cancer	O
Surgery	O
alone	O
may	O
fail	O
to	O
cure	O
a	O
considerable	O
number	O
of	O
locally	O
advanced	O
colon	O
cancers	O
.	O

Identification	O
of	O
an	O
AfsA	B-protein
homologue	I-protein
(	O
BarX	B-protein
)	O
from	O
Streptomyces	O
virginiae	O
as	O
a	O
pleiotropic	O
regulator	O
controlling	O
autoregulator	O
biosynthesis	O
,	O
virginiamycin	O
biosynthesis	O
and	O
virginiamycin	O
M1	O
resistance	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
was	O
highly	O
conserved	O
across	O
the	O
wide	O
range	O
of	O
eukaryotes	O
(	O
vertebrates	O
,	O
invertebrates	O
,	O
fungi	O
,	O
plants	O
and	O
protozoa	O
)	O
in	O
which	O
this	O
gene	O
has	O
now	O
been	O
identified	O
.	O

We	O
observed	O
NP	B-protein
/	I-protein
NMP4	I-protein
/	I-protein
CIZ	I-protein
expression	O
in	O
osteocytes	O
,	O
osteoblasts	O
,	O
and	O
chondrocytes	O
in	O
rat	O
bone	O
.	O

Southwestern	O
blot	O
analysis	O
demonstrated	O
that	O
this	O
phosphoprotein	O
can	O
bind	O
the	O
kappa	B-protein
B	I-protein
element	I-protein
directly	O
and	O
specifically	O
.	O

Results	O
of	O
this	O
study	O
indicate	O
that	O
GLC	O
of	O
short	O
chain	O
fatty	O
acids	O
produced	O
on	O
agar	O
medium	O
by	O
anaerobes	O
,	O
combined	O
with	O
simple	O
tests	O
such	O
as	O
Gram	O
'	O
s	O
stain	O
and	O
colonial	O
morphology	O
,	O
may	O
allow	O
fir	O
direct	O
presumptive	O
genus	O
identification	O
from	O
an	O
initial	O
pure	O
agar	O
culture	O
.	O

Moreover	O
,	O
the	O
mass	O
estimated	O
with	O
the	O
QCM	O
response	O
through	O
the	O
Sauerbrey	O
equation	O
and	O
the	O
mass	O
which	O
can	O
be	O
measured	O
thanks	O
to	O
other	O
analytical	O
techniques	O
,	O
in	O
our	O
case	O
an	O
enzymatic	O
assay	O
,	O
are	O
different	O
:	O
the	O
deposited	O
mass	O
is	O
generally	O
overestimated	O
by	O
the	O
QCM	O
.	O

The	O
Wnt	B-protein
signaling	O
pathway	O
functions	O
reiteratively	O
during	O
animal	O
development	O
to	O
control	O
cell	O
fate	O
decisions	O
.	O

The	O
relationship	O
of	O
human	O
umbilical	O
arterial	O
and	O
venous	O
plasma	O
levels	O
of	O
corticosteroids	O
to	O
gestational	O
age	O
.	O

BACKGROUND	O
:	O
Defensins	B-protein
,	O
also	O
known	O
as	O
human	B-protein
neutrophil	I-protein
peptides	I-protein
,	O
are	O
antimicrobial	O
peptides	O
present	O
in	O
the	O
azurophil	O
granules	O
of	O
neutrophils	O
.	O

We	O
also	O
show	O
by	O
immunogold	O
electron	O
microscopy	O
immunocytochemistry	O
that	O
amphiphysin	B-protein
I	I-protein
is	O
localized	O
in	O
the	O
nerve	O
terminal	O
cytomatrix	O
and	O
is	O
partially	O
associated	O
with	O
endocytic	O
intermediates	O
.	O

The	O
human	B-protein
gp39	I-protein
promoter	I-protein
.	O

The	O
metabolic	O
clearance	O
rate	O
of	O
progesterone	O
was	O
295	O
+	O
/	O
-	O
49	O
(	O
S	O
.	O
E	O
.	O
)	O
1	O
/	O
day	O
.	O

Disulfiram	O
and	O
the	O
drug	O
-	O
induced	O
effects	O
on	O
motility	O
.	O

Resistance	O
training	O
shifts	O
the	O
power	O
curve	O
in	O
a	O
positive	O
direction	O
when	O
the	O
measurements	O
are	O
determined	O
with	O
absolute	O
loads	O
,	O
but	O
the	O
increased	O
power	O
may	O
not	O
be	O
transferred	O
to	O
an	O
absolute	O
performance	O
task	O
like	O
the	O
SSP	O
.	O

The	O
authors	O
concluded	O
that	O
ultrasonic	O
Doppler	O
-	O
cardiography	O
can	O
be	O
used	O
for	O
measuring	O
the	O
relative	O
changes	O
in	O
the	O
stroke	O
volume	O
.	O

The	O
c	B-protein
-	I-protein
Ets	I-protein
-	I-protein
1	I-protein
oncoprotein	I-protein
is	O
a	O
transcription	O
activator	O
that	O
specifically	O
binds	O
to	O
DNA	O
.	O

Percent	O
identities	O
of	O
the	O
mouse	B-protein
PP2	I-protein
to	O
mouse	B-protein
Y1	I-protein
,	O
mouse	B-protein
Y4	I-protein
/	I-protein
PP1	I-protein
and	O
human	B-protein
Y2	I-protein
receptors	I-protein
are	O
53	O
,	O
42	O
,	O
and	O
31	O
,	O
respectively	O
.	O

ZK7	B-protein
and	O
HZF16	B-protein
genes	I-protein
appear	O
to	O
be	O
the	O
splice	O
variants	O
transcribed	O
from	O
the	O
same	O
gene	O
.	O

Evidence	O
for	O
two	O
distinctive	O
clinical	O
,	O
epidemiological	O
,	O
and	O
immunological	O
types	O
of	O
infection	O
.	O

Positional	O
cloning	O
has	O
already	O
produced	O
the	O
sequences	O
of	O
more	O
than	O
70	O
human	O
genes	O
associated	O
with	O
specific	O
diseases	O
.	O

Serum	O
lipid	O
changes	O
during	O
pregnancy	O
due	O
to	O
oral	O
calcium	O
administration	O
.	O

The	O
protein	O
is	O
composed	O
of	O
two	O
major	O
domains	O
separated	O
by	O
a	O
hydrophobic	O
linker	O
region	O
of	O
20	O
amino	O
acid	O
residues	O
.	O

MEK	B-protein
itself	O
is	O
activated	O
via	O
serine	O
phosphorylation	O
by	O
upstream	B-protein
activator	I-protein
kinases	I-protein
,	O
including	O
c	B-protein
-	I-protein
raf	I-protein
,	O
mos	B-protein
and	O
MEK	B-protein
kinase	I-protein
.	O

A	O
protein	O
lacking	O
the	O
SH2	B-protein
and	O
RING	O
finger	O
domains	O
has	O
no	O
activity	O
,	O
but	O
a	O
chimeric	O
protein	O
with	O
the	O
SH2	B-protein
and	O
RING	O
finger	O
domains	O
of	O
SLI	B-protein
-	I-protein
1	I-protein
replaced	O
by	O
the	O
equivalent	O
domains	O
of	O
c	B-protein
-	I-protein
Cbl	I-protein
has	O
activity	O
.	O

The	O
central	O
globular	O
domain	O
is	O
highly	O
similar	O
to	O
those	O
regions	O
from	O
other	O
H1	B-protein
molecules	I-protein
,	O
and	O
the	O
carboxyl	O
-	O
terminal	O
domain	O
contains	O
a	O
repeating	O
hexapeptide	O
motif	O
,	O
variants	O
of	O
which	O
are	O
conserved	O
among	O
H1	B-protein
molecules	I-protein
.	O

Neither	O
side	O
effect	O
nor	O
abnormal	O
laboratory	O
findings	O
due	O
to	O
this	O
drug	O
were	O
observed	O
.	O

One	O
group	O
(	O
n	O
=	O
9	O
)	O
was	O
premedicated	O
with	O
midazolam	O
,	O
0	O
.	O
1	O
mg	O
kg	O
-	O
1	O
,	O
and	O
atropine	O
0	O
.	O
2	O
-	O
0	O
.	O
4	O
mg	O
i	O
.	O
m	O
.	O

No	O
evidence	O
for	O
the	O
presence	O
of	O
introns	O
within	O
the	O
acvA	B-protein
gene	I-protein
has	O
been	O
found	O
.	O

Weak	O
promoter	O
activity	O
was	O
observed	O
for	O
the	O
promoter	O
of	O
the	O
C1	B-protein
and	I-protein
C2	I-protein
ORFs	I-protein
(	O
C1	B-protein
-	I-protein
C2	I-protein
gene	I-protein
)	O
and	O
for	O
the	O
promoter	O
of	O
the	O
V1	B-protein
ORF	I-protein
.	O

These	O
results	O
strongly	O
suggested	O
that	O
similar	O
,	O
if	O
not	O
identical	O
,	O
the	O
CArG	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
interact	O
with	O
the	O
functionally	O
different	O
promoter	O
element	O
in	O
the	O
VLC1	B-protein
,	O
cardiac	B-protein
alpha	I-protein
-	I-protein
actin	I-protein
,	O
and	O
c	B-protein
-	I-protein
fos	I-protein
genes	I-protein
.	O

The	O
ORFII	B-protein
gene	I-protein
product	I-protein
is	O
targeted	O
to	O
the	O
chloroplast	O
,	O
which	O
is	O
consistent	O
with	O
previous	O
data	O
indicating	O
the	O
presence	O
of	O
PMSR	B-protein
activity	O
in	O
the	O
chloroplast	O
.	O

BACKGROUND	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
response	O
rates	O
and	O
toxicity	O
of	O
two	O
regimens	O
containing	O
granulocyte	B-protein
-	I-protein
macrophage	I-protein
-	I-protein
colony	I-protein
stimulating	I-protein
factor	I-protein
(	O
GM	B-protein
-	I-protein
CSF	I-protein
)	O
in	O
combination	O
with	O
interleukin	B-protein
-	I-protein
2	I-protein
(	O
IL	B-protein
-	I-protein
2	I-protein
)	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
metastatic	O
renal	O
cell	O
carcinoma	O
.	O

For	O
this	O
purpose	O
,	O
a	O
simple	O
respiration	O
-	O
control	O
device	O
has	O
been	O
developed	O
that	O
enables	O
the	O
patient	O
to	O
monitor	O
breath	O
-	O
holding	O
during	O
successive	O
scans	O
.	O

Additional	O
education	O
and	O
research	O
is	O
needed	O
to	O
provide	O
further	O
direction	O
for	O
intervention	O
and	O
incorporation	O
into	O
practice	O
.	O

The	O
438	B-protein
bp	I-protein
EcoRI	I-protein
fragment	I-protein
,	O
which	O
was	O
detected	O
by	O
Southern	O
hybridization	O
,	O
reveals	O
an	O
open	O
reading	O
frame	O
which	O
encodes	O
a	O
protein	O
of	O
103	O
amino	O
acids	O
.	O

In	O
the	O
meantime	O
,	O
one	O
has	O
succeeded	O
to	O
establish	O
the	O
deammonification	O
processes	O
in	O
a	O
continuous	O
flow	O
moving	O
-	O
bed	O
pilot	O
plant	O
.	O

While	O
this	O
Saccharomyces	O
cerevisiae	O
SIN4	B-protein
gene	I-protein
product	I-protein
is	O
a	O
component	O
of	O
a	O
mediator	O
complex	O
associated	O
with	O
RNA	B-protein
polymerase	I-protein
II	I-protein
,	O
various	O
studies	O
suggest	O
the	O
involvement	O
of	O
Sin4	B-protein
in	O
the	O
alteration	O
of	O
higher	O
-	O
order	O
chromatin	O
structure	O
.	O

A	O
high	O
-	O
resolution	O
restriction	O
map	O
of	O
over	O
200	O
kb	O
of	O
contiguous	O
DNA	O
containing	O
N	B-protein
-	I-protein
myc	I-protein
has	O
been	O
generated	O
by	O
subcloning	O
YACs	O
into	O
cosmids	O
.	O

While	O
the	O
latter	O
corresponded	O
to	O
a	O
protein	O
of	O
824	O
amino	O
acids	O
,	O
an	O
upstream	O
open	O
reading	O
frame	O
(	O
uORF	O
)	O
within	O
the	O
5	O
'	O
leader	O
could	O
potentially	O
encode	O
a	O
54	O
amino	O
acid	O
peptide	O
.	O

In	O
summary	O
,	O
the	O
no	O
-	O
adverse	O
-	O
effect	O
-	O
level	O
for	O
this	O
study	O
was	O
determined	O
to	O
be	O
1000	O
ppm	O
,	O
based	O
on	O
decreased	O
weight	O
gain	O
in	O
female	O
rats	O
,	O
and	O
on	O
slight	O
organ	O
weight	O
changes	O
in	O
both	O
sexes	O
at	O
3000	O
ppm	O
.	O

The	O
FMN	O
moiety	O
but	O
not	O
the	O
[	O
3Fe	O
-	O
4S	O
]	O
cluster	O
of	O
the	O
subunit	O
appears	O
to	O
participate	O
in	O
this	O
reaction	O
.	O

It	O
thus	O
appears	O
that	O
MAPK	B-protein
functions	O
in	O
meiotic	O
maturation	O
by	O
preventing	O
unfertilized	O
eggs	O
from	O
proceeding	O
into	O
parthenogenetic	O
development	O
.	O

Tolterodine	O
users	O
were	O
7	O
.	O
5	O
times	O
more	O
likely	O
to	O
have	O
received	O
another	O
spasmolytic	O
drug	O
(	O
RR	O
7	O
.	O
5	O
,	O
95	O
%	O
CI	O
4	O
.	O
8	O
to	O
11	O
.	O
9	O
)	O
.	O

Effect	O
of	O
immune	O
lymphocytes	O
and	O
of	O
rabbit	B-protein
-	I-protein
anti	I-protein
-	I-protein
lymphocyte	I-protein
globulin	I-protein
(	O
RAMLG	B-protein
)	O
on	O
infected	O
macrophages	O
exposed	O
to	O
increased	O
incubation	O
temperature	O
in	O
vitro	O
.	O

CONCLUSION	O
:	O
Patients	O
wit	O
clinically	O
palpable	O
neck	O
disease	O
(	O
N1	O
-	O
3	O
)	O
,	O
histological	O
evidence	O
of	O
metastatic	O
nodal	O
disease	O
,	O
extracapsular	O
spread	O
,	O
and	O
three	O
or	O
more	O
positive	O
lymph	O
nodes	O
are	O
at	O
greater	O
risk	O
of	O
developing	O
failure	O
at	O
distant	O
sites	O
.	O

Cardiac	O
disease	O
was	O
not	O
detected	O
with	O
M	O
-	O
mode	O
,	O
2	O
-	O
dimensional	O
real	O
-	O
time	O
or	O
pulsed	O
-	O
wave	O
Doppler	O
echocardiography	O
.	O

Bupropion	O
to	O
aid	O
smoking	O
cessation	O
.	O

One	O
extract	O
with	O
the	O
lowest	O
PCA	O
content	O
was	O
non	O
-	O
carcinogenic	O
.	O

Interestingly	O
,	O
the	O
interaction	O
of	O
ZAP	B-protein
-	I-protein
70	I-protein
with	O
the	O
motif	O
was	O
dependent	O
on	O
the	O
presence	O
of	O
both	O
ZAP	B-protein
-	I-protein
70	I-protein
SH2	I-protein
domains	I-protein
and	O
both	O
of	O
the	O
tyrosine	O
residues	O
in	O
the	O
motif	O
,	O
suggesting	O
that	O
ZAP	B-protein
-	I-protein
70	I-protein
interacts	O
with	O
two	O
phosphotyrosine	O
residues	O
and	O
that	O
the	O
binding	O
of	O
the	O
two	O
SH2	B-protein
domains	I-protein
is	O
cooperative	O
.	O

The	O
baroreflex	O
latency	O
(	O
from	O
the	O
ECG	O
R	O
-	O
wave	O
to	O
the	O
integrated	O
MSNA	O
burst	O
peak	O
)	O
was	O
constant	O
at	O
approximately	O
1	O
.	O
20	O
s	O
during	O
sleep	O
,	O
suggesting	O
that	O
pulse	O
-	O
synchronicity	O
was	O
maintained	O
.	O

One	O
CKD	O
patient	O
'	O
s	O
journey	O
.	O

The	O
mode	O
of	O
resistance	O
to	O
quinupristin	O
/	O
dalfopristin	O
was	O
not	O
evident	O
(	O
sat	O
A	O
-	O
negative	O
by	O
PCR	O
)	O
;	O
and	O
these	O
cases	O
illustrate	O
the	O
existence	O
of	O
streptogramin	O
-	O
resistant	O
isolates	O
before	O
the	O
introduction	O
of	O
this	O
antimicrobial	O
class	O
into	O
human	O
clinical	O
practice	O
.	O

In	O
the	O
past	O
decade	O
,	O
there	O
have	O
been	O
enormous	O
advances	O
in	O
the	O
use	O
of	O
Bayesian	O
methodology	O
for	O
analysis	O
of	O
epidemiologic	O
data	O
,	O
and	O
there	O
are	O
now	O
many	O
practical	O
advantages	O
to	O
the	O
Bayesian	O
approach	O
.	O

Binding	O
affinities	O
of	O
different	O
nucleotide	O
mono	O
-	O
,	O
di	O
-	O
and	O
triphosphates	O
and	O
non	O
-	O
hydrolyzable	O
analogs	O
indicate	O
that	O
the	O
beta	O
-	O
phosphate	O
moiety	O
is	O
required	O
for	O
substrate	O
binding	O
.	O

The	O
LTR	O
-	O
binding	O
activities	O
of	O
VBP	B-protein
,	O
a1	B-protein
/	I-protein
EBP	I-protein
,	O
and	O
B	O
-	O
cell	O
nuclear	O
extract	O
protein	O
were	O
compared	O
and	O
mapped	O
by	O
gel	O
shift	O
,	O
DNase	B-protein
I	I-protein
footprinting	O
,	O
and	O
methylation	O
interference	O
assays	O
.	O

The	O
importance	O
of	O
temporal	O
factors	O
on	O
the	O
presence	O
and	O
severity	O
of	O
ethanol	O
withdrawal	O
signs	O
in	O
the	O
rat	O
was	O
quantified	O
using	O
rating	O
scale	O
,	O
tremor	O
,	O
and	O
acoustic	O
startle	O
paradigms	O
.	O

BACKGROUND	O
AND	O
DESIGN	O
:	O
Fifty	O
-	O
nine	O
melanocytic	O
nevi	O
with	O
eccentric	O
foci	O
of	O
hyperpigmentation	O
(	O
`	O
`	O
small	O
dark	O
dots	O
'	O
'	O
)	O
that	O
measured	O
primarily	O
1	O
to	O
2	O
mm	O
in	O
diameter	O
were	O
prospectively	O
examined	O
to	O
determine	O
the	O
histologic	O
correlates	O
of	O
the	O
dark	O
dots	O
.	O

Phosphocreatine	O
hydrolysis	O
during	O
submaximal	O
exercise	O
:	O
the	O
effect	O
of	O
FIO2	O
.	O

Present	O
results	O
reveal	O
a	O
frequency	O
-	O
dependent	O
inhibition	O
of	O
ganglionic	O
transmission	O
by	O
diltiazem	O
,	O
and	O
suggest	O
that	O
diltiazem	O
may	O
depress	O
excessive	O
sympathetic	O
activity	O
without	O
affecting	O
normal	O
ganglionic	O
transmission	O
.	O

Thus	O
,	O
quantitative	O
analysis	O
of	O
thallium	O
-	O
201	O
uptake	O
and	O
washout	O
provided	O
objective	O
evidence	O
for	O
improved	O
myocardial	O
perfusion	O
after	O
coronary	O
angioplasty	O
.	O

However	O
,	O
overexpression	O
of	O
both	O
the	O
STE4	B-protein
and	O
STE18	B-protein
proteins	I-protein
did	O
not	O
generate	O
a	O
stronger	O
pheromone	O
response	O
than	O
overexpression	O
of	O
STE4	B-protein
in	O
the	O
presence	O
of	O
wild	O
-	O
type	O
levels	O
of	O
STE18	B-protein
.	O

In	O
a	O
gel	O
retardation	O
assay	O
using	O
HepG2	O
nuclear	O
extracts	O
,	O
the	O
5	O
'	O
flanking	O
sequence	O
from	O
-	O
74	O
to	O
-	O
46	O
showed	O
a	O
shifted	O
band	O
.	O

In	O
an	O
attempt	O
to	O
reduce	O
the	O
incidence	O
of	O
NSAID	O
-	O
induced	O
gastrointestinal	O
lesions	O
,	O
the	O
following	O
approaches	O
have	O
been	O
proposed	O
:	O
(	O
i	O
)	O
use	O
of	O
the	O
prostaglandin	O
analogue	O
misoprostol	O
,	O
which	O
is	O
an	O
antiulcer	O
drug	O
which	O
has	O
been	O
proven	O
to	O
be	O
as	O
effective	O
in	O
the	O
prevention	O
of	O
NSAID	O
-	O
induced	O
gastric	O
and	O
duodenal	O
ulcers	O
as	O
in	O
the	O
reduction	O
of	O
serious	O
upper	O
gastrointestinal	O
complications	O
;	O
(	O
ii	O
)	O
histamine	B-protein
H2	I-protein
receptor	I-protein
antagonists	O
(	O
H2	O
antagonists	O
)	O
,	O
e	O
.	O
g	O
.	O
ranitidine	O
,	O
cimetidine	O
and	O
famotidine	O
,	O
which	O
are	O
useful	O
in	O
the	O
prevention	O
of	O
NSAID	O
-	O
induced	O
duodenal	O
ulcers	O
during	O
long	O
term	O
treatment	O
,	O
but	O
not	O
in	O
the	O
prevention	O
of	O
NSAID	O
-	O
induced	O
gastric	O
ulcers	O
;	O
(	O
iii	O
)	O
proton	O
pump	O
inhibitors	O
,	O
e	O
.	O
g	O
omeprazole	O
,	O
and	O
pantoprazole	O
,	O
whose	O
efficacy	O
in	O
preventing	O
NSAID	O
-	O
associated	O
ulcers	O
has	O
been	O
recently	O
demonstrated	O
;	O
and	O
(	O
iv	O
)	O
barrier	O
agents	O
,	O
e	O
.	O
g	O
.	O
sucralfate	O
,	O
which	O
can	O
not	O
be	O
recommended	O
as	O
prophylactic	O
agents	O
to	O
prevent	O
NSAID	O
-	O
induced	O
gastropathy	O
.	O

SRC	B-protein
-	I-protein
1	I-protein
can	O
relieve	O
the	O
NF	O
-	O
kappaB	O
-	O
mediated	O
repression	O
of	O
GR	B-protein
activity	O
.	O

Biol	O
.	O

Thin	O
melanomas	O
can	O
metastasize	O
and	O
be	O
lethal	O
.	O

The	O
chromosomal	O
localization	O
on	O
distal	O
chromosome	O
7	O
places	O
it	O
in	O
a	O
cluster	O
of	O
imprinted	O
genes	O
,	O
flanked	O
by	O
the	O
previously	O
described	O
Tapa1	B-protein
and	O
Kcnq1	B-protein
genes	I-protein
.	O

Consistent	O
with	O
this	O
interpretation	O
,	O
a	O
mutant	O
form	O
of	O
XRN1	B-protein
,	O
which	O
encodes	O
a	O
5	O
'	O
-	O
3	O
'	O
exonuclease	O
,	O
was	O
identified	O
as	O
an	O
extragenic	O
suppressor	O
that	O
increases	O
the	O
half	O
-	O
life	O
of	O
rhis4	B-protein
mRNA	I-protein
,	O
leading	O
to	O
a	O
10	O
-	O
fold	O
increase	O
in	O
steady	O
-	O
state	O
mRNA	O
levels	O
compared	O
to	O
the	O
wild	B-protein
-	I-protein
type	I-protein
HIS4	I-protein
mRNA	I-protein
level	O
.	O

Topological	O
and	O
Mutational	O
Analysis	O
of	O
Saccharomyces	B-protein
cerevisiae	I-protein
Ste14p	I-protein
,	O
Founding	O
Member	O
of	O
the	O
Isoprenylcysteine	B-protein
Carboxyl	I-protein
Methyltransferase	I-protein
Family	I-protein
.	O

The	O
pexB	B-protein
upstream	I-protein
region	I-protein
contained	O
245	O
nucleotides	O
within	O
which	O
sequences	O
approximating	O
the	O
consensus	O
for	O
cyclic	B-protein
AMP	I-protein
receptor	I-protein
protein	I-protein
and	O
integration	B-protein
host	I-protein
factor	I-protein
binding	I-protein
sites	I-protein
were	O
discernible	O
.	O

Transient	O
transfections	O
of	O
a	O
construct	O
expressing	O
the	O
RNA	O
transcript	O
defined	O
by	O
clone	O
B1	O
.	O
1	O
into	O
D17	O
cells	O
led	O
to	O
the	O
expression	O
of	O
an	O
Env	B-protein
/	I-protein
Mlvi	I-protein
-	I-protein
4	I-protein
fusion	I-protein
protein	I-protein
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
33	O
kDa	O
.	O

This	O
study	O
suggests	O
that	O
PSP	O
is	O
more	O
common	O
than	O
previously	O
considered	O
,	O
is	O
commonly	O
misdiagnosed	O
and	O
that	O
the	O
majority	O
of	O
cases	O
are	O
not	O
initially	O
referred	O
to	O
neurologists	O
.	O

The	O
application	O
of	O
the	O
biotechnology	O
at	O
the	O
plants	O
for	O
treatment	O
of	O
the	O
surface	O
storm	O
waters	O
from	O
the	O
industrial	O
zone	O
Telychka	O
of	O
the	O
city	O
of	O
Kyiv	O
has	O
allowed	O
the	O
content	O
of	O
petroleum	O
in	O
water	O
dropped	O
to	O
the	O
Dnieper	O
to	O
be	O
constantly	O
reduced	O
50	O
-	O
100	O
times	O
.	O

Structural	O
organization	O
and	O
expression	O
of	O
the	O
mouse	B-protein
estrogen	I-protein
receptor	I-protein
.	O

These	O
data	O
suggest	O
that	O
dopaminergic	O
regulation	O
of	O
adrenal	O
zona	O
glomerulosa	O
corticosteroid	O
and	O
renal	B-protein
renin	I-protein
secretion	O
is	O
absent	O
in	O
patients	O
with	O
high	O
spinal	O
cord	O
transections	O
,	O
suggesting	O
that	O
intact	O
neural	O
pathways	O
from	O
the	O
central	O
nervous	O
system	O
are	O
necessary	O
for	O
metoclopramide	O
stimulation	O
of	O
aldosterone	O
and	O
renin	B-protein
secretion	O
in	O
men	O
.	O

Thus	O
,	O
VF	O
resistant	O
to	O
defibrillation	O
is	O
not	O
necessarily	O
associated	O
with	O
both	O
toxic	O
plasma	O
drug	O
level	O
and	O
remarkably	O
decreased	O
conduction	O
.	O

Comparison	O
of	O
elastase	B-protein
-	I-protein
1	I-protein
with	O
amylase	B-protein
,	O
lipase	B-protein
,	O
and	O
trypsin	O
-	O
like	O
immunoreactivity	O
in	O
the	O
diagnosis	O
of	O
acute	O
pancreatitis	O
.	O

The	O
Sox	B-protein
gene	I-protein
family	I-protein
(	O
Sry	B-protein
like	O
HMG	B-protein
box	I-protein
gene	I-protein
)	O
is	O
characterised	O
by	O
a	O
conserved	O
DNA	O
sequence	O
encoding	O
a	O
domain	O
of	O
approximately	O
80	O
amino	O
acids	O
which	O
is	O
responsible	O
for	O
sequence	O
specific	O
DNA	O
binding	O
.	O

The	O
dose	O
was	O
50	O
Gy	O
/	O
20	O
fractions	O
/	O
5	O
weeks	O
.	O

Vasoactive	B-protein
intestinal	I-protein
peptide	I-protein
and	O
pituitary	B-protein
adenylate	I-protein
cyclase	I-protein
-	I-protein
activating	I-protein
polypeptide	I-protein
inhibit	O
nuclear	B-protein
factor	I-protein
-	I-protein
kappa	I-protein
B	I-protein
-	I-protein
dependent	I-protein
gene	I-protein
activation	O
at	O
multiple	O
levels	O
in	O
the	O
human	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
.	O

A	O
subsequent	O
screen	O
for	O
the	O
loss	O
of	O
the	O
positively	O
selectable	O
target	O
locus	O
marker	O
detects	O
the	O
desired	O
replacement	O
at	O
modest	O
frequency	O
(	O
>	O
2	O
%	O
)	O
.	O

Here	O
we	O
report	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
forkhead	B-protein
homologue	I-protein
in	I-protein
rhabdomyosarcoma	I-protein
(	O
FKHR	B-protein
)	O
,	O
a	O
recently	O
described	O
member	O
of	O
the	O
hepatocyte	B-protein
nuclear	I-protein
factor	I-protein
3	I-protein
/	I-protein
forkhead	I-protein
homeotic	I-protein
gene	I-protein
family	O
,	O
as	O
a	O
nuclear	B-protein
hormone	I-protein
receptor	I-protein
(	O
NR	B-protein
)	O
intermediary	O
protein	O
.	O

Ultrastructural	O
and	O
morphometric	O
study	O
of	O
the	O
myeloid	O
parenchyma	O
cells	O
of	O
mice	O
prior	O
and	O
after	O
X	O
-	O
ray	O
exposure	O
.	O

Cloning	O
of	O
higher	B-protein
plant	I-protein
omega	I-protein
-	I-protein
3	I-protein
fatty	I-protein
acid	I-protein
desaturases	I-protein
.	O

Synchronous	O
extracts	O
showed	O
no	O
significant	O
migration	O
inhibition	O
in	O
allogeneic	O
assays	O
.	O

In	O
order	O
to	O
decipher	O
the	O
pathway	O
that	O
leads	O
to	O
Hox	B-protein
gene	I-protein
induction	O
,	O
we	O
have	O
investigated	O
whether	O
a	O
Hox	B-protein
gene	I-protein
regulator	O
,	O
the	O
leucine	O
zipper	O
transcription	O
factor	O
MafB	B-protein
/	I-protein
Kr	I-protein
,	O
is	O
itself	O
transcriptionally	O
regulated	O
by	O
the	O
environmental	O
signals	O
.	O

Eight	O
cats	O
infected	O
with	O
H	O
.	O
pylori	O
were	O
used	O
in	O
the	O
study	O
.	O

However	O
,	O
subcutaneously	O
administered	O
pneumococci	O
gave	O
a	O
lower	O
mortality	O
than	O
pneumococci	O
given	O
intravenously	O
or	O
intraperitoneally	O
.	O

The	O
ligand	O
for	O
RXR	B-protein
,	O
9	O
-	O
cis	O
retinoic	O
acid	O
,	O
has	O
the	O
opposite	O
effect	O
of	O
destabilizing	O
the	O
heterodimeric	O
-	O
DNA	O
complex	O
.	O

The	O
majority	O
of	O
PI	B-protein
kinase	I-protein
activity	O
appeared	O
to	O
be	O
cbl	O
-	O
associated	O
after	O
PRL	B-protein
stimulation	O
.	O

Current	O
world	O
literature	O
.	O

Defects	O
of	O
fibrillin	B-protein
(	O
FBN1	B-protein
)	O
,	O
a	O
glycoprotein	O
component	O
of	O
the	O
extracellular	O
microfibril	O
,	O
cause	O
Marfan	O
syndrome	O
.	O

DNA	O
binding	O
and	O
glutathione	B-protein
S	I-protein
-	I-protein
transferase	I-protein
pull	O
-	O
down	O
assays	O
demonstrate	O
that	O
binding	O
requires	O
Elk	B-protein
-	I-protein
1	I-protein
(	I-protein
1	I-protein
-	I-protein
212	I-protein
)	I-protein
but	O
not	O
the	O
C	O
-	O
terminal	O
transactivation	O
domain	O
.	O

(	O
1994	O
,	O
Hum	O
.	O

The	O
synergistic	O
effect	O
due	O
to	O
the	O
5	O
'	O
-	O
3	O
'	O
cooperation	O
was	O
at	O
least	O
fourfold	O
greater	O
than	O
the	O
sum	O
of	O
the	O
contributions	O
of	O
the	O
individual	O
UTRs	O
.	O

At	O
Cabras	O
(	O
Oristano	O
)	O
,	O
a	O
town	O
characterized	O
by	O
a	O
high	O
incidence	O
of	O
thalassaemia	O
and	O
G6PD	B-protein
deficiency	O
less	O
than	O
half	O
the	O
people	O
between	O
18	O
and	O
35	O
have	O
a	O
fair	O
knowledge	O
of	O
genetic	O
diseases	O
and	O
of	O
their	O
prevention	O
.	O

16	O
subjects	O
were	O
repatch	O
tested	O
to	O
ethylmercury	O
chloride	O
(	O
EtHgCl	O
)	O
and	O
to	O
solutions	O
containing	O
EtHgCl	O
mixed	O
with	O
L	O
-	O
cysteine	O
and	O
glutathione	O
,	O
respectively	O
.	O

Adhesion	O
,	O
phagocytosis	O
,	O
chemotactic	O
and	O
random	O
migration	O
,	O
nitroblue	O
tetrazolium	O
dye	O
reduction	O
of	O
peritoneal	O
exudate	O
neutrophils	O
and	O
macrophages	O
,	O
fibrinogen	B-protein
level	O
,	O
gelation	O
of	O
soluble	O
fibrin	B-protein
and	O
serial	O
dilution	O
protamine	O
sulfate	O
test	O
were	O
investigated	O
in	O
115	O
New	O
Zealand	O
white	O
rabbits	O
with	O
experimentally	O
induced	O
Shwartzman	O
phenomenon	O
in	O
the	O
colon	O
,	O
and	O
in	O
control	O
animals	O
.	O

Corticosteroid	O
therapy	O
is	O
known	O
to	O
be	O
hazardous	O
in	O
patients	O
with	O
occult	O
infection	O
but	O
the	O
mechanism	O
by	O
which	O
the	O
host	O
parasite	O
relationship	O
is	O
altered	O
by	O
steroids	O
is	O
not	O
known	O
.	O
We	O
have	O
used	O
an	O
intestinal	O
protozoal	O
parasite	O
,	O
Giardia	O
muris	O
,	O
to	O
examine	O
the	O
effects	O
of	O
corticosteroids	O
on	O
the	O
number	O
of	O
parasites	O
in	O
the	O
intestine	O
in	O
the	O
course	O
of	O
a	O
primary	O
infection	O
.	O

Each	O
recombinant	O
product	O
was	O
a	O
fusion	O
protein	O
with	O
a	O
B	B-protein
domain	I-protein
of	O
Staphylococcal	B-protein
protein	I-protein
A	I-protein
(	O
SPA	B-protein
)	O
.	O

METHODS	O
:	O
Four	O
hundred	O
fifty	O
patients	O
with	O
the	O
diagnosis	O
of	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
oral	O
cavity	O
received	O
their	O
primary	O
treatment	O
at	O
Roswell	O
Park	O
Cancer	O
Center	O
(	O
RPCI	O
)	O
from	O
1971	O
to	O
1991	O
.	O

Eighty	O
patients	O
presenting	O
to	O
HGGM	O
with	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphomas	O
between	O
1962	O
and	O
1986	O
,	O
were	O
reviewed	O
.	O

In	O
contrast	O
,	O
dig1	B-protein
dig2	I-protein
cells	O
constitutively	O
invade	O
agar	O
medium	O
,	O
whereas	O
a	O
dig1	B-protein
dig2	I-protein
ste12	I-protein
triple	O
mutant	O
does	O
not	O
,	O
indicating	O
that	O
Dig1	B-protein
and	O
Dig2	B-protein
share	O
a	O
role	O
in	O
negatively	O
regulating	O
the	O
invasive	O
growth	O
pathway	O
.	O

During	O
presentation	O
of	O
happy	O
facial	O
expressions	O
,	O
we	O
detected	O
a	O
signal	O
increase	O
predominantly	O
in	O
the	O
left	O
anterior	O
cingulate	O
gyrus	O
,	O
bilateral	O
posterior	O
cingulate	O
gyri	O
,	O
medial	O
frontal	O
cortex	O
and	O
right	O
supramarginal	O
gyrus	O
,	O
brain	O
regions	O
previously	O
implicated	O
in	O
visuospatial	O
and	O
emotion	O
processing	O
tasks	O
.	O

Considerably	O
high	O
levels	O
of	O
IgE	B-protein
antibodies	I-protein
was	O
also	O
established	O
while	O
other	O
pollens	O
did	O
not	O
show	O
such	O
correspondence	O
.	O

Coexpression	O
of	O
mouse	O
PKR	B-protein
(	I-protein
1	I-protein
-	I-protein
515	I-protein
)	I-protein
WT	I-protein
as	O
a	O
Gal4	B-protein
DNA	O
-	O
binding	O
domain	O
fusion	O
with	O
either	O
the	O
catalytic	O
-	O
deficient	O
human	O
PKR	B-protein
(	I-protein
1	I-protein
-	I-protein
551	I-protein
)	I-protein
K296R	O
mutant	O
,	O
the	O
RNA	O
-	O
binding	O
-	O
deficient	O
human	O
PKR	B-protein
(	I-protein
1	I-protein
-	I-protein
551	I-protein
)	I-protein
K64E	I-protein
/	I-protein
K296R	I-protein
double	O
mutant	O
,	O
or	O
wild	O
-	O
type	O
mouse	O
PKR	B-protein
(	I-protein
1	I-protein
-	I-protein
515	I-protein
)	I-protein
WT	I-protein
as	O
full	O
-	O
length	O
PKR	B-protein
-	I-protein
Gal4	I-protein
activation	O
domain	O
fusions	O
resulted	O
in	O
activation	O
of	O
the	O
HIS3	B-protein
and	O
lacZ	B-protein
reporters	O
.	O

Overexpression	O
of	O
either	O
DAP	B-protein
-	I-protein
1	I-protein
or	O
sentrin	B-protein
causes	O
apoptosis	O
of	O
TNF	O
-	O
sensitive	O
L929	O
fibroblast	O
cell	O
line	O
,	O
as	O
well	O
as	O
TNF	O
-	O
resistant	O
osteosarcoma	O
cell	O
line	O
,	O
U2OS	O
.	O

An	O
association	O
between	O
hSIE	B-protein
and	O
Stat	B-protein
-	I-protein
3	I-protein
after	O
MHC	B-protein
-	I-protein
I	I-protein
ligation	O
was	O
directly	O
demonstrated	O
by	O
precipitating	O
Stat	B-protein
-	I-protein
3	I-protein
from	O
nuclear	O
extracts	O
with	O
biotinylated	O
hSIE	B-protein
probe	O
and	O
avidin	O
-	O
coupled	O
agarose	O
.	O

We	O
have	O
isolated	O
cDNA	O
clones	O
from	O
rat	O
brain	O
and	O
human	O
liver	O
encoding	O
a	O
putative	O
isoform	O
of	O
the	O
Na	B-protein
,	I-protein
K	I-protein
-	I-protein
ATPase	I-protein
beta	I-protein
subunit	I-protein
.	O

I	O
.	O

Src	B-protein
activation	O
induced	O
by	O
FGF1	B-protein
was	O
blocked	O
by	O
the	O
SH2	B-protein
domain	I-protein
of	O
Src	B-protein
and	O
PP2	B-protein
,	O
a	O
specific	O
inhibitor	O
of	O
Src	B-protein
.	O

In	O
a	O
third	O
experiment	O
,	O
crossover	O
AM	O
between	O
dissimilar	O
textures	O
was	O
investigated	O
,	O
and	O
it	O
was	O
found	O
that	O
the	O
more	O
salient	O
textures	O
carried	O
the	O
AM	O
.	O

Chemical	O
constituents	O
of	O
the	O
gentianaceae	O
V	O
:	O
tetraoxygenated	O
xanthones	O
of	O
Swertia	O
chirata	O
Buch	O
.	O
-	O
Ham	O
.	O

However	O
,	O
although	O
deletion	O
of	O
Fp1	B-protein
in	O
the	O
hCRBP1	B-protein
gene	I-protein
yielded	O
increased	O
CAT	B-protein
activity	O
,	O
pointing	O
toward	O
a	O
negative	O
regulatory	O
function	O
exerted	O
by	O
this	O
element	O
,	O
its	O
insertion	O
upstream	O
of	O
the	O
p12	B-protein
basal	I-protein
promoter	I-protein
results	O
in	O
an	O
impressive	O
positive	O
stimulation	O
of	O
CAT	B-protein
gene	I-protein
expression	O
.	O

Mutational	O
analyses	O
have	O
demonstrated	O
the	O
importance	O
of	O
sequences	O
within	O
the	O
327	O
bp	O
segment	O
that	O
contain	O
a	O
putative	O
cyclic	B-protein
AMP	I-protein
responsive	I-protein
element	I-protein
binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
binding	O
site	O
for	O
TGF	B-protein
-	I-protein
beta	I-protein
1	I-protein
and	O
PMA	O
responsiveness	O
and	O
putative	O
PU	B-protein
-	I-protein
1	I-protein
and	O
Sp1	B-protein
binding	I-protein
sites	I-protein
for	O
basal	O
promoter	O
activity	O
.	O

Response	O
durations	O
were	O
short	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
exhibited	O
70	O
%	O
identity	O
to	O
that	O
of	O
Bacillus	B-protein
stearothermophilus	I-protein
TyrTS	I-protein
and	O
55	O
%	O
identity	O
to	O
that	O
of	O
E	B-protein
.	I-protein
coli	I-protein
TyrTS	I-protein
,	O
while	O
identity	O
to	O
a	O
second	O
cryptic	O
B	B-protein
.	I-protein
subtilis	I-protein
TyrTS	I-protein
gene	I-protein
,	O
designated	O
tyrZ	B-protein
,	O
was	O
only	O
27	O
%	O
.	O

Behaviorally	O
,	O
a	O
pain	O
-	O
tolerant	O
group	O
(	O
PT	O
=	O
29	O
Ss	O
)	O
tolerated	O
the	O
entire	O
3	O
-	O
min	O
test	O
(	O
means	O
=	O
180	O
+	O
/	O
-	O
0	O
sec	O
)	O
,	O
while	O
a	O
pain	O
-	O
sensitive	O
group	O
(	O
PS	O
=	O
13	O
Ss	O
)	O
averaged	O
only	O
50	O
.	O
31	O
+	O
/	O
-	O
20	O
.	O
81	O
sec	O
of	O
the	O
cold	O
-	O
pressor	O
test	O
(	O
t	O
=	O
16	O
.	O
75	O
,	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
,	O
replicating	O
our	O
earlier	O
studies	O
.	O

Sequence	O
conservation	O
is	O
greatest	O
for	O
residues	O
located	O
near	O
the	O
active	O
centers	O
of	O
the	O
exo	B-protein
and	O
pol	B-protein
domains	I-protein
of	O
the	O
E	B-protein
.	I-protein
coli	I-protein
DNA	I-protein
polymerase	I-protein
I	I-protein
structure	O
.	O

This	O
study	O
compared	O
the	O
gross	O
and	O
fine	O
motor	O
performance	O
of	O
14	O
traumatically	O
brain	O
-	O
injured	O
children	O
(	O
five	O
to	O
15	O
years	O
old	O
,	O
with	O
loss	O
of	O
consciousness	O
for	O
at	O
least	O
24	O
hours	O
)	O
to	O
14	O
normal	O
children	O
group	O
matched	O
for	O
age	O
and	O
sex	O
.	O

One	O
was	O
allowed	O
fresh	O
drinking	O
water	O
ad	O
libitum	O
whilst	O
the	O
other	O
received	O
Aludrox	O
in	O
their	O
drinking	O
water	O
.	O

Although	O
the	O
gene	O
is	O
substantially	O
smaller	O
than	O
the	O
human	O
genes	O
for	O
other	O
mitochondrial	O
enzymes	O
,	O
its	O
intron	O
/	O
exon	O
organization	O
is	O
very	O
similar	O
,	O
especially	O
to	O
that	O
of	O
P450scc	B-protein
.	O

This	O
and	O
previous	O
results	O
suggest	O
that	O
the	O
CRE	B-protein
and	O
Sp1	B-protein
site	I-protein
may	O
synergistically	O
activate	O
TH	B-protein
transcription	O
in	O
a	O
promoter	O
context	O
-	O
dependent	O
manner	O
.	O

The	O
same	O
rhythmic	O
structure	O
enables	O
a	O
prediction	O
to	O
be	O
made	O
concerning	O
when	O
vowels	O
of	O
stressed	O
syllables	O
will	O
be	O
auditorily	O
perceived	O
.	O

We	O
have	O
previously	O
shown	O
that	O
LBP	B-protein
-	I-protein
1	I-protein
represses	O
HIV	O
-	O
1	O
transcription	O
by	O
inhibiting	O
the	O
binding	O
of	O
TFIID	B-protein
to	O
the	O
TATA	O
box	O
.	O

Leptinaemia	O
does	O
not	O
correlate	O
with	O
the	O
actual	O
or	O
mean	O
blood	O
pressure	O
reading	O
nor	O
with	O
stage	O
of	O
hypertension	O
according	O
to	O
the	O
WHO	O
classification	O
.	O

Hex	B-protein
is	O
expressed	O
in	O
the	O
developing	O
liver	O
coincident	O
with	O
the	O
forkhead	B-protein
/	I-protein
winged	I-protein
helix	I-protein
transcription	I-protein
factor	I-protein
,	O
Hepatocyte	B-protein
Nuclear	I-protein
Factor	I-protein
3beta	I-protein
(	O
HNF3beta	B-protein
)	O
.	O

The	O
SEN1	B-protein
gene	I-protein
corresponds	O
to	O
a	O
6	O
,	O
336	O
-	O
bp	O
open	O
reading	O
frame	O
coding	O
for	O
a	O
2	O
,	O
112	O
-	O
amino	O
-	O
acid	O
protein	O
(	O
molecular	O
mass	O
,	O
239	O
kDa	O
)	O
.	O

A	O
synthetic	O
oligonucleotide	O
containing	O
the	O
SRE	B-protein
sequence	I-protein
from	O
the	O
mouse	B-protein
c	I-protein
-	I-protein
fos	I-protein
gene	I-protein
promoter	I-protein
(	O
-	O
299	O
to	O
-	O
322	O
)	O
was	O
radioactively	O
labeled	O
,	O
used	O
as	O
a	O
probe	O
for	O
the	O
mobility	O
shift	O
assay	O
and	O
Southwestern	O
(	O
DNA	O
-	O
protein	O
)	O
blotting	O
,	O
and	O
also	O
used	O
for	O
sequence	O
-	O
specific	O
affinity	O
chromatography	O
.	O

As	O
extensively	O
examined	O
with	O
the	O
myogenin	B-protein
promoter	I-protein
,	O
presence	O
of	O
one	O
or	O
multiple	O
copies	O
of	O
Me	B-protein
in	O
the	O
vectors	O
elevated	O
the	O
expression	O
activity	O
in	O
myotubes	O
by	O
4	O
.	O
5	O
-	O
to	O
19	O
-	O
fold	O
over	O
those	O
without	O
Me	B-protein
,	O
but	O
not	O
significantly	O
in	O
myoblasts	O
.	O

The	O
proteins	O
differ	O
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
21	O
-	O
amino	O
-	O
acid	O
sequence	O
located	O
24	O
amino	O
acids	O
C	O
terminal	O
of	O
the	O
translational	O
initiation	O
codon	O
.	O

Subunit	O
composition	O
and	O
domain	O
structure	O
of	O
the	O
Spo0A	B-protein
sporulation	I-protein
transcription	I-protein
factor	I-protein
of	I-protein
Bacillus	I-protein
subtilis	I-protein
.	O

Previous	O
experience	O
and	O
contextual	O
cues	O
are	O
essential	O
elements	O
in	O
the	O
generation	O
of	O
a	O
subjective	O
prediction	O
.	O

Increases	O
in	O
the	O
perfusate	O
PCO2	O
but	O
not	O
in	O
the	O
perfusate	O
H	O
+	O
were	O
highly	O
correlated	O
with	O
decreases	O
in	O
both	O
myocardial	O
contractility	O
and	O
oxygen	O
consumption	O
(	O
r2	O
=	O
.	O
88	O
)	O
.	O

Although	O
previous	O
data	O
have	O
suggested	O
that	O
Rev	B-protein
uses	O
the	O
same	O
export	O
pathway	O
as	O
uracil	B-protein
-	I-protein
rich	I-protein
small	I-protein
nuclear	I-protein
RNAs	I-protein
and	O
5S	B-protein
ribosomal	I-protein
RNA	I-protein
,	O
the	O
CTE	B-protein
seems	O
to	O
interact	O
with	O
evolutionarily	O
conserved	O
factors	O
that	O
are	O
essential	O
for	O
cellular	O
mRNA	O
export	O
.	O

These	O
exons	O
were	O
identified	O
by	O
cloning	O
and	O
sequencing	O
cDNAs	O
obtained	O
by	O
polymerase	B-protein
chain	O
reaction	O
amplification	O
of	O
a	O
fibroblast	O
cDNA	O
library	O
.	O

Consanguinity	O
and	O
migration	O
in	O
the	O
marriages	O
of	O
the	O
region	O
of	O
Nunoa	O
,	O
Santiago	O
,	O
1850	O
-	O
1960	O
.	O

Approximately	O
50	O
%	O
of	O
the	O
residues	O
are	O
conserved	O
among	O
all	O
three	O
sequences	O
,	O
yet	O
all	O
three	O
viruses	O
have	O
retained	O
response	O
elements	O
for	O
glucocorticoids	O
,	O
two	O
positionally	O
conserved	O
CCAAT	O
boxes	O
,	O
and	O
positionally	O
conserved	O
TATA	O
boxes	O
.	O

TMBr	B-protein
-	I-protein
1	I-protein
is	O
identical	O
to	O
striated	B-protein
muscle	I-protein
alpha	I-protein
-	I-protein
tropomyosin	I-protein
from	O
amino	O
acids	O
1	O
through	O
258	O
but	O
contains	O
a	O
novel	O
COOH	O
-	O
terminal	O
region	O
from	O
amino	O
acids	O
259	O
through	O
281	O
.	O

Most	O
of	O
the	O
prepeptide	O
portion	O
of	O
the	O
precursor	O
polypeptide	O
is	O
encoded	O
by	O
the	O
next	O
three	O
exons	O
,	O
and	O
the	O
mature	O
form	O
of	O
IL	B-protein
-	I-protein
1	I-protein
alpha	I-protein
is	O
encoded	O
by	O
the	O
remaining	O
three	O
exons	O
.	O

Its	O
expression	O
pattern	O
is	O
representative	O
of	O
many	O
B	O
cell	O
-	O
specific	O
proteins	O
,	O
which	O
are	O
essential	O
for	O
B	O
cell	O
development	O
and	O
activation	O
but	O
are	O
down	O
-	O
regulated	O
after	O
B	O
cells	O
become	O
terminally	O
differentiated	O
plasma	O
cells	O
.	O

The	O
implications	O
for	O
estimates	O
of	O
cortical	O
magnification	O
and	O
possible	O
differences	O
in	O
the	O
specializations	O
of	O
foveal	O
and	O
peripheral	O
vision	O
are	O
discussed	O
.	O

Pargyline	O
,	O
a	O
monoamine	B-protein
oxidase	I-protein
inhibitor	O
,	O
reduces	O
peak	O
3	O
transiently	O
(	O
max	O
.	O

The	O
stoichiometry	O
of	O
the	O
complexes	O
formed	O
with	O
the	O
dodeca	B-protein
-	I-protein
satellite	I-protein
C	I-protein
strand	I-protein
suggests	O
that	O
,	O
in	O
DDP1	B-protein
,	O
the	O
15	O
consecutive	O
KH	B-protein
domains	I-protein
are	O
organized	O
such	O
that	O
they	O
define	O
two	O
nucleic	O
acid	O
binding	O
surfaces	O
.	O

Overexpression	O
of	O
BAG	B-protein
-	I-protein
1	I-protein
also	O
protected	O
certain	O
cell	O
lines	O
from	O
heat	O
shock	O
-	O
induced	O
cell	O
death	O
.	O

Thus	O
,	O
VDR	B-protein
acts	O
selectively	O
on	O
the	O
two	O
components	O
required	O
for	O
activation	O
of	O
this	O
promoter	O
/	O
enhancer	O
:	O
it	O
competes	O
with	O
NFAT1	B-protein
for	O
binding	O
to	O
the	O
composite	O
site	O
,	O
positioning	O
itself	O
adjacent	O
to	O
Jun	B-protein
-	I-protein
Fos	I-protein
on	O
the	O
DNA	O
.	O

The	O
nucleosomal	O
response	O
associated	O
with	O
immediate	B-protein
-	I-protein
early	I-protein
gene	I-protein
induction	O
is	O
mediated	O
via	O
alternative	O
MAP	B-protein
kinase	I-protein
cascades	I-protein
:	O
MSK1	B-protein
as	O
a	O
potential	O
histone	B-protein
H3	I-protein
/	I-protein
HMG	I-protein
-	I-protein
14	I-protein
kinase	I-protein
.	O

More	O
importantly	O
,	O
this	O
fusion	O
converted	O
a	O
less	O
effective	O
vaccine	O
into	O
one	O
with	O
significant	O
potency	O
against	O
established	O
E7	O
-	O
expressing	O
metastatic	O
tumors	O
.	O

Elimination	O
of	O
ETH1	B-protein
in	O
apn1	B-protein
strains	O
also	O
increased	O
spontaneous	O
mutation	O
rates	O
9	O
-	O
or	O
31	O
-	O
fold	O
compared	O
to	O
the	O
wild	O
type	O
as	O
determined	O
by	O
reversion	O
to	O
adenine	O
or	O
lysine	O
prototrophy	O
,	O
respectively	O
.	O

The	O
MCAD	B-protein
nuclear	I-protein
receptor	I-protein
response	I-protein
element	I-protein
1	I-protein
(	O
NRRE	B-protein
-	I-protein
1	I-protein
)	O
interacts	O
in	O
vitro	O
with	O
ERR	B-protein
alpha	I-protein
expressed	O
in	O
COS	O
-	O
7	O
cells	O
.	O

Fulminant	O
hepatitis	O
A	O
in	O
chronic	O
HBV	O
carrier	O
.	O

Srb10	B-protein
is	O
a	O
physiological	O
regulator	O
of	O
Gcn4	B-protein
stability	O
because	O
both	O
phosphorylation	O
and	O
turnover	O
of	O
Gcn4	B-protein
are	O
diminished	O
in	O
srb10	B-protein
mutants	I-protein
.	O

These	O
sites	O
are	O
also	O
potential	O
keratan	O
sulfate	O
attachment	O
sites	O
.	O

The	O
concept	O
of	O
`	O
`	O
structural	O
identifiability	O
'	O
'	O
is	O
employed	O
in	O
this	O
analysis	O
to	O
determine	O
which	O
model	O
parameters	O
can	O
be	O
and	O
which	O
can	O
not	O
be	O
determined	O
`	O
`	O
uniquely	O
'	O
'	O
from	O
given	O
input	O
-	O
output	O
data	O
;	O
a	O
step	O
-	O
by	O
-	O
step	O
procedure	O
based	O
on	O
an	O
extension	O
of	O
this	O
concept	O
is	O
presented	O
for	O
adapting	O
the	O
overall	O
approach	O
to	O
the	O
experimental	O
design	O
problem	O
.	O

DNA	O
sequence	O
analysis	O
revealed	O
that	O
these	O
clones	O
encode	O
two	O
distinct	O
forms	O
of	O
translocase	B-protein
.	O

Protamine	B-protein
and	O
heparin	O
doses	O
,	O
their	O
sum	O
(	O
Sigma	O
-	O
dose	O
)	O
and	O
differential	O
(	O
Delta	O
-	O
dose	O
)	O
doses	O
,	O
and	O
activated	O
clotting	O
times	O
were	O
tabulated	O
.	O

This	O
structure	O
of	O
cucumisin	B-protein
suggests	O
that	O
it	O
is	O
probably	O
synthesized	O
as	O
an	O
inactive	O
precursor	O
.	O

Identification	O
and	O
estimation	O
of	O
monosaccharides	O
and	O
disaccharides	O
in	O
urine	O
by	O
gas	O
-	O
liquid	O
chromatography	O
.	O

In	O
the	O
current	O
model	O
,	O
Wingless	B-protein
/	I-protein
Wnt	I-protein
signal	O
stabilizes	O
Armadillo	B-protein
/	I-protein
beta	I-protein
-	I-protein
catenin	I-protein
,	O
which	O
then	O
accumulates	O
in	O
nuclei	O
and	O
binds	O
TCF	B-protein
/	I-protein
LEF	I-protein
family	I-protein
proteins	I-protein
,	O
forming	O
bipartite	O
transcription	O
factors	O
which	O
activate	O
transcription	O
of	O
Wingless	B-protein
/	I-protein
Wnt	I-protein
responsive	I-protein
genes	I-protein
.	O

In	O
DNA	O
strand	O
exchange	O
reactions	O
using	O
oligonucleotides	O
,	O
we	O
found	O
that	O
Rec2	B-protein
exhibited	O
a	O
pairing	O
bias	O
that	O
is	O
opposite	O
that	O
of	O
RecA	B-protein
.	O

Endorphins	B-protein
and	O
legal	O
issues	O
.	O

Human	O
brain	O
cDNA	O
library	O
screening	O
and	O
5	O
'	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
yielded	O
full	B-protein
-	I-protein
length	I-protein
DENTT	I-protein
cDNA	I-protein
containing	O
an	O
1899	O
-	O
bp	O
open	O
reading	O
frame	O
encoding	O
a	O
predicted	O
633	O
-	O
amino	O
-	O
acid	O
protein	O
with	O
four	O
potential	O
nuclear	O
localization	O
signals	O
(	O
NLSs	O
)	O
and	O
two	O
coiled	O
-	O
coil	O
regions	O
.	O

The	O
orientations	O
of	O
the	O
contact	O
surfaces	O
and	O
their	O
locations	O
relative	O
to	O
the	O
object	O
'	O
s	O
center	O
of	O
mass	O
were	O
varied	O
.	O

The	O
carboxyl	O
-	O
terminal	O
portion	O
of	O
UKLF	B-protein
contains	O
three	O
zinc	O
fingers	O
of	O
the	O
Cys2	O
-	O
His2	O
type	O
and	O
binds	O
in	O
vitro	O
to	O
the	O
CACCC	B-protein
motif	I-protein
of	O
the	O
beta	B-protein
-	I-protein
globin	I-protein
promoter	I-protein
and	O
to	O
the	O
Sp1	B-protein
recognition	I-protein
sequence	I-protein
.	O

Cloning	O
and	O
characterization	O
of	O
the	O
murine	B-protein
beta	I-protein
(	I-protein
3	I-protein
)	I-protein
integrin	I-protein
gene	I-protein
promoter	O
:	O
identification	O
of	O
an	O
interleukin	B-protein
-	I-protein
4	I-protein
responsive	I-protein
element	I-protein
and	O
regulation	O
by	O
STAT	B-protein
-	I-protein
6	I-protein
.	O

Polarised	O
expression	O
of	O
human	O
intestinal	O
N	B-protein
-	I-protein
benzoyl	I-protein
-	I-protein
L	I-protein
-	I-protein
tyrosyl	I-protein
-	I-protein
p	I-protein
-	I-protein
aminobenzoic	I-protein
acid	I-protein
hydrolase	I-protein
(	O
human	B-protein
meprin	I-protein
)	O
alpha	O
and	O
beta	O
subunits	O
in	O
Madin	O
-	O
Darby	O
canine	O
kidney	O
cells	O
.	O

ME1a1	B-protein
,	O
a	O
16	O
-	O
base	O
-	O
pair	O
nuclear	O
factor	O
binding	O
site	O
residing	O
between	O
the	O
c	B-protein
-	I-protein
MYC	I-protein
P1	I-protein
and	I-protein
P2	I-protein
transcription	I-protein
initiation	I-protein
sites	I-protein
,	O
is	O
required	O
for	O
P2	B-protein
activity	O
.	O

Protein	B-protein
tyrosine	I-protein
kinases	I-protein
(	O
PTKs	B-protein
)	O
are	O
implicated	O
in	O
the	O
control	O
of	O
cell	O
growth	O
by	O
virtue	O
of	O
their	O
frequent	O
appearance	O
as	O
products	O
of	O
retroviral	O
oncogenes	O
,	O
as	O
intracellular	O
signal	O
transducers	O
,	O
and	O
as	O
growth	B-protein
factor	I-protein
receptors	I-protein
or	O
components	O
thereof	O
.	O

Abnormal	O
technetium	O
Tc	O
99m	O
medronate	O
scans	O
in	O
patients	O
with	O
previously	O
undiagnosed	O
polyarthralgias	O
suggested	O
inflammatory	O
arthropathy	O
and	O
influenced	O
management	O
decisions	O
with	O
favorable	O
therapeutic	O
outcomes	O
.	O

However	O
,	O
regional	O
MVO2	O
increased	O
to	O
about	O
the	O
same	O
extent	O
in	O
the	O
CFX	O
(	O
from	O
6	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
7	O
to	O
12	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
9	O
ml	O
O2	O
.	O
min	O
-	O
1	O
times	O
100	O
g	O
-	O
1	O
)	O
and	O
the	O
LAD	O
region	O
(	O
from	O
7	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
6	O
to	O
14	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
3	O
ml	O
O2	O
.	O
min	O
-	O
1	O
times	O
100	O
g	O
-	O
1	O
)	O
.	O

Among	O
the	O
patients	O
grades	O
1	O
-	O
2	O
-	O
3	O
,	O
81	O
%	O
had	O
a	O
good	O
out	O
come	O
without	O
any	O
neurological	O
abnormality	O
,	O
among	O
the	O
patients	O
graded	O
4	O
-	O
5	O
,	O
only	O
27	O
%	O
had	O
a	O
fair	O
out	O
come	O
.	O

1st	O
data	O
on	O
the	O
immunosuppressive	O
therapy	O
of	O
scleroderma	O
.	O

These	O
components	O
both	O
had	O
a	O
median	O
R2	O
of	O
0	O
.	O
84	O
,	O
compared	O
to	O
median	O
R2s	O
ranging	O
from	O
0	O
.	O
37	O
to	O
0	O
.	O
83	O
for	O
five	O
commonly	O
used	O
ad	O
hoc	O
EEG	O
components	O
.	O

By	O
DNase	B-protein
I	I-protein
footprint	O
analysis	O
of	O
the	O
PNR	B-protein
element	I-protein
,	O
a	O
palindrome	O
of	O
two	O
high	O
-	O
affinity	O
Ets	B-protein
-	I-protein
binding	I-protein
sites	I-protein
(	O
CTTCCCTGGAAG	B-protein
)	O
was	O
identified	O
.	O

Toxicity	O
during	O
the	O
therapeutic	O
period	O
was	O
not	O
significant	O
in	O
the	O
study	O
group	O
compared	O
with	O
the	O
historical	O
control	O
,	O
treated	O
with	O
the	O
same	O
regimen	O
without	O
G	B-protein
-	I-protein
CSF	I-protein
.	O

Transcripts	O
from	O
a	O
second	O
POU	B-protein
-	I-protein
domain	I-protein
gene	I-protein
,	O
Oct	B-protein
-	I-protein
25	I-protein
,	O
were	O
present	O
at	O
low	O
levels	O
in	O
oocytes	O
and	O
early	O
embryos	O
and	O
were	O
dramatically	O
upregulated	O
during	O
early	O
gastrulation	O
.	O

Discrimination	O
between	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
showed	O
evidence	O
for	O
the	O
presence	O
of	O
HIV	O
-	O
1	O
only	O
.	O

The	O
functional	O
mature	O
domain	O
of	O
pediocin	B-protein
AcH	I-protein
(	I-protein
Lys	I-protein
+	I-protein
1	I-protein
to	I-protein
Cys	I-protein
+	I-protein
44	I-protein
)	I-protein
is	O
targeted	O
into	O
the	O
E	O
.	O
coli	O
sec	O
machinery	O
and	O
secreted	O
to	O
the	O
periplasm	O
in	O
active	O
form	O
when	O
fused	O
in	O
frame	O
to	O
the	O
COOH	O
terminus	O
of	O
the	O
secretory	B-protein
protein	I-protein
maltose	I-protein
-	I-protein
binding	I-protein
protein	I-protein
(	O
MBP	B-protein
)	O
.	O

In	O
yeast	O
,	O
the	O
products	O
of	O
the	O
UPF1	B-protein
and	O
UPF3	B-protein
genes	I-protein
are	O
required	O
for	O
this	O
decay	O
pathway	O
,	O
and	O
in	O
this	O
report	O
we	O
focus	O
on	O
the	O
identification	O
and	O
characterization	O
of	O
additional	O
factors	O
required	O
for	O
rapid	O
decay	O
of	O
nonsense	O
-	O
containing	O
mRNAs	O
.	O

Unified	O
theory	O
of	O
segregated	O
-	O
stack	O
organic	O
charge	O
-	O
transfer	O
solids	O
:	O
Magnetic	O
properties	O
.	O

In	O
gel	O
retardation	O
assays	O
,	O
an	O
RCS	O
cell	O
-	O
specific	O
protein	O
and	O
another	O
closely	O
related	O
protein	O
expressed	O
only	O
in	O
RCS	O
cells	O
and	O
primary	O
chondrocytes	O
bound	O
to	O
a	O
10	O
-	O
bp	O
sequence	O
within	O
the	O
18	O
-	O
mer	O
.	O

Copyright	O
2001	O
Academic	O
Press	O
.	O

It	O
is	O
surprising	O
that	O
dnaE173	O
,	O
a	O
potent	O
mutator	O
mutation	O
specific	O
for	O
sequence	O
substitution	O
as	O
well	O
as	O
single	O
-	O
base	O
frameshift	O
,	O
did	O
not	O
enhance	O
the	O
frequency	O
of	O
the	O
hot	O
-	O
spot	O
frameshift	O
mutation	O
.	O

However	O
,	O
the	O
relative	O
positions	O
of	O
the	O
VV	O
genes	O
(	O
genus	O
Orthopoxvirus	O
)	O
are	O
different	O
than	O
those	O
of	O
the	O
corresponding	O
ORFs	O
in	O
SFV	O
(	O
genus	O
Leporipoxvirus	O
)	O
,	O
indicating	O
complex	O
rearrangements	O
of	O
DNA	O
in	O
the	O
genome	O
of	O
one	O
or	O
both	O
of	O
these	O
viruses	O
subsequent	O
to	O
their	O
divergence	O
from	O
a	O
common	O
ancestor	O
.	O

Ki	B-protein
-	I-protein
ras	I-protein
and	O
p53	B-protein
mutations	I-protein
in	O
pancreatic	O
ductal	O
adenocarcinoma	O
.	O

Eleven	O
healthy	O
,	O
normotensive	O
males	O
undergoing	O
routine	O
restorative	O
dental	O
care	O
were	O
evaluated	O
during	O
treatment	O
for	O
possible	O
hemodynamic	O
alterations	O
in	O
response	O
to	O
potential	O
sympathetic	O
nervous	O
system	O
stimulation	O
.	O

CSR	O
is	O
directed	O
to	O
specific	O
heavy	O
chain	O
isotypes	O
by	O
cytokines	O
and	O
B	O
cell	O
activators	O
that	O
induce	O
transcription	O
from	O
the	O
unrearranged	O
,	O
or	O
germline	O
(	O
GL	O
)	O
,	O
C	O
(	O
H	O
)	O
region	O
genes	O
.	O

As	O
predicted	O
by	O
the	O
Wing	O
and	O
Kristofferson	O
model	O
,	O
the	O
durations	O
of	O
successive	O
ISIs	O
tended	O
to	O
be	O
negatively	O
correlated	O
.	O

Symptomatic	O
hyperventilators	O
had	O
a	O
larger	O
number	O
of	O
sighs	O
and	O
abnormally	O
wide	O
fluctuations	O
in	O
baseline	O
for	O
inspiratory	O
time	O
,	O
expiratory	O
time	O
,	O
and	O
PETCO2	O
.	O

As	O
the	O
high	O
-	O
affinity	O
Mg2	O
+	O
binding	O
sites	O
are	O
filled	O
,	O
the	O
primer	O
terminus	O
migrates	O
from	O
the	O
exonuclease	B-protein
site	I-protein
to	O
a	O
highly	O
based	O
stacked	O
polymerase	B-protein
active	I-protein
site	I-protein
.	O

A	O
population	O
pharmacokinetic	O
study	O
of	O
cyclosporin	O
in	O
organ	O
transplant	O
patients	O
,	O
including	O
elderly	O
allograft	O
recipients	O
up	O
to	O
75	O
years	O
of	O
age	O
,	O
did	O
not	O
identify	O
age	O
as	O
a	O
covariable	O
influencing	O
cyclosporin	O
pharmacokinetics	O
.	O

The	O
same	O
response	O
occurs	O
whether	O
acrylamide	O
is	O
given	O
immediately	O
after	O
nerve	O
ligation	O
or	O
1	O
week	O
later	O
.	O

Early	O
heparin	O
therapy	O
in	O
60	O
children	O
with	O
acute	O
meningococcemia	O
.	O

The	O
highest	O
decrease	O
in	O
mutagenic	O
activity	O
was	O
observed	O
when	O
enzymatic	O
bleaching	O
was	O
used	O
together	O
with	O
chlorine	O
.	O

Regarding	O
gestational	O
risk	O
,	O
3	O
,	O
243	O
drugs	O
used	O
(	O
34	O
%	O
)	O
belonged	O
to	O
category	O
A	O
risk	O
,	O
1	O
,	O
923	O
(	O
22	O
.	O
6	O
%	O
)	O
to	O
category	O
B	O
,	O
3	O
,	O
798	O
(	O
39	O
.	O
7	O
%	O
)	O
to	O
category	O
C	O
,	O
289	O
(	O
3	O
.	O
0	O
%	O
)	O
to	O
category	O
D	O
,	O
and	O
55	O
(	O
0	O
.	O
6	O
%	O
)	O
to	O
category	O
X	O
.	O

These	O
same	O
regions	O
showed	O
remarkable	O
homology	O
to	O
two	O
invertebrate	O
proteins	O
,	O
CNC	B-protein
and	O
skin	B-protein
-	I-protein
1	I-protein
,	O
postulated	O
to	O
regulate	O
embryonic	O
development	O
in	O
Drosophila	O
melanogaster	O
and	O
Caenorhabditis	O
elegans	O
,	O
respectively	O
.	O

The	O
other	O
element	O
bound	O
RBP	B-protein
-	I-protein
J	I-protein
kappa	I-protein
with	O
low	O
affinity	O
.	O

Copyright	O
2001	O
S	O
.	O

In	O
addition	O
,	O
on	O
the	O
Cohler	O
'	O
s	O
maternal	O
scale	O
,	O
Korean	O
mothers	O
were	O
found	O
to	O
view	O
their	O
infants	O
as	O
more	O
passive	O
and	O
dependent	O
than	O
American	O
mothers	O
did	O
(	O
P	O
less	O
than	O
0	O
.	O
00	O
)	O
.	O

A	O
2	O
years	O
and	O
9	O
months	O
old	O
female	O
patient	O
,	O
with	O
the	O
diagnosis	O
of	O
Weaver	O
syndrome	O
is	O
reported	O
.	O

Ex	O
vivo	O
MAO	B-protein
inhibition	O
data	O
indicated	O
DPGPEA	O
to	O
be	O
an	O
inhibitor	O
of	O
MAO	B-protein
-	I-protein
B	I-protein
,	O
although	O
the	O
effect	O
was	O
much	O
weaker	O
than	O
seen	O
with	O
tranylcypromine	O
or	O
pargyline	O
.	O

For	O
this	O
purpose	O
,	O
the	O
writhing	O
test	O
,	O
capsaicin	O
and	O
formalin	O
induced	O
-	O
pain	O
in	O
mice	O
were	O
used	O
.	O

Brain	O
pH	O
following	O
3	O
h	O
of	O
cerebral	O
focal	O
ischemia	O
changed	O
from	O
a	O
normal	O
value	O
of	O
7	O
.	O
0	O
to	O
6	O
.	O
5	O
and	O
6	O
.	O
2	O
in	O
animals	O
studied	O
under	O
barbiturate	O
and	O
halothane	O
anesthesia	O
,	O
respectively	O
.	O

The	O
CHARGE	O
association	O
is	O
a	O
collection	O
of	O
multisystem	O
congenital	O
anomalies	O
including	O
choanal	O
atresia	O
.	O

Because	O
of	O
this	O
latter	O
phenomenon	O
,	O
we	O
were	O
able	O
to	O
identify	O
a	O
particular	O
cysteine	O
motif	O
that	O
was	O
repeated	O
multiple	O
times	O
in	O
Dfurin2	B-protein
but	O
present	O
only	O
twice	O
in	O
mammalian	B-protein
furin	I-protein
.	O

We	O
have	O
synthesized	O
[	O
7	O
,	O
7	O
-	O
2H2	O
]	O
-	O
19	O
-	O
OHA	O
with	O
high	O
deuterium	O
content	O
and	O
,	O
together	O
with	O
[	O
7	O
,	O
7	O
-	O
2H2	O
]	O
A	O
and	O
[	O
9	O
,	O
11	O
-	O
2H2	O
]	O
estrone	O
(	O
E1	O
)	O
,	O
have	O
developed	O
a	O
quantitative	O
assay	O
of	O
serum	O
level	O
19	O
-	O
OHA	O
,	O
A	O
,	O
and	O
E1	O
using	O
the	O
gas	O
chromatography	O
/	O
mass	O
spectrometry	O
-	O
mass	O
fragmentography	O
method	O
to	O
monitor	O
individual	O
subjects	O
throughout	O
pregnancy	O
.	O

The	O
human	B-protein
purH	I-protein
cDNA	I-protein
is	O
1776	O
base	O
pairs	O
in	O
length	O
encoding	O
for	O
a	O
591	O
-	O
amino	O
acid	O
polypeptic	O
(	O
Mr	O
=	O
64	O
,	O
425	O
)	O
.	O

Incorporation	O
of	O
0	O
.	O
1	O
or	O
0	O
.	O
2	O
M	O
sodium	O
dihydrogen	O
phosphate	O
in	O
the	O
sugar	O
solutions	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
shelf	O
-	O
life	O
of	O
diltiazem	O
.	O

Spleen	O
weight	O
in	O
rats	O
during	O
tumour	O
growth	O
and	O
in	O
homograft	O
rejection	O
.	O

We	O
have	O
found	O
out	O
that	O
one	O
-	O
year	O
-	O
old	O
carps	O
are	O
extremely	O
sensitive	O
to	O
ichthiomycin	O
in	O
concentrations	O
between	O
25	O
-	O
125	O
micrograms	O
/	O
dm3	O
.	O

Remarkably	O
,	O
U21	B-protein
contains	O
a	O
long	O
stretch	O
(	O
13	O
nt	O
.	O
)	O
of	O
complementarity	O
to	O
a	O
highly	O
conserved	O
sequence	O
in	O
28S	B-protein
rRNA	I-protein
.	O

The	O
humanized	B-protein
LL2	I-protein
(	O
hLL2	B-protein
)	O
,	O
lacking	O
light	B-protein
chain	I-protein
variable	I-protein
region	I-protein
glycosylation	O
,	O
exhibited	O
immunoreactivities	O
that	O
were	O
comparable	O
to	O
that	O
of	O
chimeric	B-protein
LL2	I-protein
(	O
cLL2	B-protein
)	O
,	O
which	O
was	O
shown	O
previously	O
to	O
have	O
antigen	O
-	O
binding	O
properties	O
similar	O
to	O
its	O
murine	O
counterpart	O
,	O
suggesting	O
that	O
the	O
VK	O
-	O
appended	O
oligosaccharides	O
found	O
in	O
mLL2	B-protein
are	O
not	O
necessary	O
for	O
antigen	O
binding	O
.	O

Whereas	O
creatine	B-protein
kinase	I-protein
activity	O
declined	O
exponentially	O
from	O
a	O
single	O
peak	O
,	O
myoglobin	B-protein
appeared	O
in	O
multiple	O
episodes	O
inadequately	O
represented	O
by	O
a	O
single	O
peak	O
value	O
and	O
having	O
no	O
clear	O
clinical	O
correlation	O
.	O

Twelve	O
genomic	O
fragments	O
containing	O
novel	O
response	O
elements	O
are	O
described	O
,	O
and	O
the	O
transcription	O
unit	O
associated	O
with	O
one	O
of	O
them	O
,	O
NN	B-protein
-	I-protein
84AG	I-protein
,	O
was	O
characterized	O
in	O
detail	O
.	O

Analysis	O
of	O
the	O
consensus	O
binding	O
sequence	O
and	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
ZF5	B-protein
.	O

Sequencing	O
of	O
the	O
TP53	B-protein
transcripts	I-protein
from	O
exons	O
2	O
to	O
10	O
,	O
however	O
,	O
did	O
not	O
reveal	O
mutations	O
of	O
the	O
remaining	O
allele	O
in	O
any	O
of	O
these	O
tumors	O
.	O

The	O
iterative	O
method	O
proposed	O
by	O
Bengtsson	O
[	O
Appl	O
.	O

CONCLUSION	O
:	O
The	O
alpha2	O
-	O
adrenergic	O
antagonist	O
idazoxan	O
increases	O
glucose	O
-	O
induced	O
sympathetic	O
activity	O
but	O
not	O
energy	O
expenditure	O
in	O
obese	O
subjects	O
.	O

These	O
losses	O
account	O
for	O
the	O
resistance	O
of	O
EDS	O
-	O
IV	O
collagen	B-protein
to	O
cyanogen	O
bromide	O
and	O
mammalian	B-protein
collagenase	I-protein
digestion	O
.	O

Relations	O
between	O
cellular	O
electrical	O
activity	O
and	O
cardiac	O
mechanical	O
activity	O
in	O
man	O
,	O
the	O
dog	O
and	O
the	O
rabbit	O
.	O

Skeletal	B-protein
muscle	I-protein
metaboreceptor	I-protein
responses	O
are	O
impaired	O
in	O
heart	O
failure	O
.	O

The	O
purified	O
recombinant	O
protein	O
was	O
assayed	O
for	O
its	O
enzyme	O
activity	O
by	O
monitoring	O
transfer	O
of	O
[	O
3H	O
]	O
methyl	O
groups	O
from	O
the	O
substrate	O
DNA	O
to	O
the	O
MGMT	B-protein
protein	I-protein
;	O
the	O
activity	O
was	O
found	O
to	O
be	O
stable	O
at	O
90	O
degrees	O
C	O
for	O
at	O
least	O
30	O
min	O
.	O

This	O
interaction	O
involved	O
the	O
SH3	B-protein
region	I-protein
of	O
p50	B-protein
(	I-protein
csk	I-protein
)	I-protein
and	O
a	O
proline	O
-	O
rich	O
region	O
(	O
PPPLPERTPESFVLADM	B-protein
)	O
outside	O
the	O
catalytic	O
region	O
of	O
PTP	B-protein
-	I-protein
PEST	I-protein
.	O

SETTING	O
-	O
-	O
Delhi	O
,	O
urban	O
India	O
,	O
1985	O
-	O
6	O
.	O

Data	O
from	O
in	O
vitro	O
splicing	O
assays	O
,	O
UV	O
crosslinking	O
and	O
RNA	O
-	O
binding	O
competition	O
experiments	O
indicates	O
a	O
strong	O
correlation	O
between	O
the	O
binding	O
affinities	O
of	O
PSI	B-protein
for	O
the	O
SELEX	O
sequences	O
and	O
their	O
ability	O
to	O
modulate	O
splicing	O
of	O
P	B-protein
element	I-protein
IVS3	I-protein
in	O
vitro	O
.	O

Use	O
of	O
subcutaneous	O
deferoxamine	O
in	O
a	O
child	O
with	O
hemochromatosis	O
associated	O
with	O
congenital	O
dyserythropoietic	O
anemia	O
,	O
type	O
I	O
.	O

The	O
primary	O
CT	O
findings	O
were	O
misinterpreted	O
as	O
a	O
brain	O
infarct	O
or	O
possibly	O
a	O
tumour	O
.	O

If	O
hnRNP	B-protein
K	I-protein
is	O
a	O
transcription	O
factor	O
,	O
then	O
interactions	O
with	O
the	O
RNA	B-protein
polymerase	I-protein
II	I-protein
transcription	O
apparatus	O
are	O
predicted	O
.	O

We	O
report	O
here	O
that	O
constitutively	O
active	O
Mek1	B-protein
could	O
activate	O
p96h2bk	B-protein
in	O
the	O
absence	O
of	O
oncogenic	B-protein
Ras	I-protein
.	O

Botulinum	B-protein
toxin	I-protein
A	I-protein
in	O
the	O
treatment	O
of	O
hemiplegic	O
spastic	O
foot	O
drop	O
-	O
-	O
clinical	O
and	O
functional	O
outcomes	O
.	O

Mutational	O
analysis	O
of	O
the	O
P2	B-protein
-	I-protein
proximal	I-protein
CTCF	I-protein
binding	I-protein
site	I-protein
and	O
transient	O
-	O
cotransfection	O
experiments	O
demonstrate	O
that	O
CTCF	B-protein
is	O
a	O
transcriptional	O
repressor	O
of	O
the	O
human	B-protein
c	I-protein
-	I-protein
myc	I-protein
gene	I-protein
.	O

To	O
determine	O
whether	O
the	O
excess	O
prevalence	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
in	O
US	O
black	O
and	O
Hispanic	O
homosexual	O
men	O
relative	O
to	O
white	O
men	O
can	O
be	O
explained	O
by	O
differences	O
in	O
sociodemographic	O
factors	O
,	O
history	O
of	O
sexually	O
transmitted	O
diseases	O
,	O
or	O
sexual	O
and	O
drug	O
-	O
use	O
behaviors	O
,	O
the	O
authors	O
conducted	O
a	O
cross	O
-	O
sectional	O
analysis	O
of	O
baseline	O
HIV	O
-	O
1	O
seroprevalence	O
and	O
HIV	O
-	O
1	O
risk	O
factors	O
among	O
4	O
,	O
475	O
non	O
-	O
Hispanic	O
white	O
,	O
234	O
Hispanic	O
white	O
,	O
and	O
194	O
black	O
homosexual	O
men	O
from	O
four	O
centers	O
in	O
the	O
United	O
States	O
(	O
Baltimore	O
/	O
Washington	O
,	O
DC	O
,	O
Pittsburgh	O
,	O
Chicago	O
,	O
and	O
Los	O
Angeles	O
)	O
.	O

Potscoital	O
test	O
.	O

Fibular	O
dimelia	O
with	O
deficiency	O
of	O
the	O
tibia	O
.	O

Thus	O
,	O
although	O
p28	B-protein
may	O
play	O
only	O
a	O
limited	O
role	O
during	O
the	O
early	O
embryonic	O
cleavages	O
,	O
it	O
may	O
function	O
later	O
in	O
development	O
to	O
establish	O
a	O
somatic	O
type	O
of	O
cell	O
cycle	O
.	O

In	O
Denmark	O
only	O
1	O
-	O
3	O
cases	O
of	O
transfusion	O
-	O
associated	O
hepatitis	O
NANB	O
(	O
TAH	O
-	O
NANB	O
)	O
are	O
registered	O
annually	O
or	O
about	O
1	O
case	O
per	O
100	O
,	O
000	O
units	O
transfused	O
.	O

Interestingly	O
,	O
this	O
mutant	O
cell	O
line	O
lacks	O
expression	O
of	O
the	O
IKK	B-protein
regulatory	I-protein
protein	I-protein
,	O
IKKgamma	B-protein
.	O

Membrane	O
-	O
bound	O
Steel	B-protein
factor	I-protein
induces	O
more	O
persistent	O
tyrosine	B-protein
kinase	I-protein
activation	O
and	O
longer	O
life	O
span	O
of	O
c	B-protein
-	I-protein
kit	I-protein
gene	O
-	O
encoded	O
protein	O
than	O
its	O
soluble	O
form	O
.	O

Replacement	B-protein
variant	I-protein
histone	I-protein
genes	I-protein
contain	O
intervening	O
sequences	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
GluR2	B-protein
gene	I-protein
:	O
neural	O
-	O
specific	O
expression	O
,	O
multiple	O
promoters	O
,	O
and	O
regulatory	O
elements	O
.	O

The	O
central	O
(	O
R	O
)	O
domain	O
is	O
responsible	O
for	O
receptor	O
-	O
binding	O
activity	O
whereas	O
the	O
N	O
-	O
terminal	O
(	O
T	O
)	O
domain	O
mediates	O
translocation	O
,	O
the	O
process	O
by	O
which	O
the	O
C	O
-	O
terminal	O
cytotoxic	O
domain	O
is	O
transported	O
from	O
the	O
receptor	O
to	O
the	O
site	O
of	O
its	O
cytotoxicity	O
.	O

To	O
determine	O
whether	O
interaction	O
of	O
arsenite	O
with	O
the	O
hormone	O
-	O
binding	O
domain	O
results	O
in	O
receptor	O
activation	O
,	O
COS	O
-	O
1	O
cells	O
were	O
transiently	O
cotransfected	O
with	O
the	O
chimeric	B-protein
receptors	I-protein
GAL	I-protein
-	I-protein
ER	I-protein
,	O
which	O
contains	O
the	O
hormone	O
-	O
binding	O
domain	O
of	O
ERalpha	B-protein
and	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
transcription	O
factor	O
GAL4	B-protein
,	O
and	O
a	O
GAL4	O
-	O
responsive	O
CAT	B-protein
reporter	I-protein
gene	I-protein
.	O

The	O
JHRLSS	O
has	O
been	O
used	O
in	O
prior	O
studies	O
to	O
assess	O
RLS	O
severity	O
,	O
but	O
has	O
not	O
previously	O
been	O
validated	O
in	O
relation	O
to	O
direct	O
measures	O
of	O
the	O
morbidity	O
associated	O
with	O
RLS	O
.	O

VP	O
-	O
16	O
,	O
ifosfamide	O
and	O
cisplatin	O
(	O
VIP	O
)	O
for	O
extensive	O
small	O
cell	O
lung	O
cancer	O
.	O

The	O
experimentally	O
mapped	O
regions	O
of	O
RPB5	B-protein
involved	O
in	O
these	O
interactions	O
correspond	O
to	O
distinct	O
and	O
surface	O
-	O
exposed	O
alpha	O
-	O
helical	O
structures	O
.	O

The	O
role	O
of	O
daunorubicin	O
in	O
induction	O
therapy	O
for	O
adult	O
acute	O
myeloid	O
leukemia	O
.	O

These	O
data	O
suggest	O
that	O
hypocitraturia	O
in	O
type	O
I	O
renal	O
tubular	O
acidosis	O
may	O
be	O
due	O
to	O
a	O
defect	O
in	O
proximal	O
tubule	O
function	O
.	O

Each	O
expressed	O
domain	O
,	O
as	O
well	O
as	O
FKBP	B-protein
-	I-protein
33	I-protein
itself	O
,	O
possesses	O
peptidyl	B-protein
-	I-protein
prolyl	I-protein
cis	I-protein
-	I-protein
trans	I-protein
isomerase	I-protein
activity	O
,	O
though	O
with	O
much	O
lower	O
specific	O
activities	O
than	O
FKBP	B-protein
-	I-protein
12	I-protein
.	O

The	O
induction	O
of	O
RNKP	B-protein
-	I-protein
1	I-protein
expression	O
in	O
the	O
Con	O
A	O
-	O
cultured	O
spleen	O
cells	O
is	O
accompanied	O
by	O
increases	O
in	O
both	O
NK	O
and	O
lymphokine	O
-	O
activated	O
killer	O
lymphocyte	O
activities	O
.	O

Cephradine	O
250	O
mg	O
at	O
night	O
for	O
12	O
months	O
was	O
given	O
as	O
a	O
prophylactic	O
measure	O
to	O
33	O
female	O
patients	O
of	O
mean	O
age	O
41	O
.	O
6	O
years	O
,	O
who	O
had	O
a	O
history	O
in	O
the	O
preceding	O
12	O
months	O
of	O
between	O
three	O
and	O
24	O
(	O
median	O
=	O
7	O
)	O
episodes	O
of	O
frequency	O
and	O
/	O
or	O
dysuria	O
.	O

Sterile	O
mutants	O
of	O
Saccharomyces	O
cerevisiae	O
were	O
isolated	O
from	O
alpha	O
*	O
cells	O
having	O
the	O
a	B-protein
/	I-protein
alpha	I-protein
aar1	I-protein
-	I-protein
6	I-protein
genotype	O
(	O
exhibiting	O
alpha	O
mating	O
ability	O
and	O
weak	O
a	O
mating	O
ability	O
as	O
a	O
result	O
of	O
a	O
defect	O
in	O
a1	B-protein
-	I-protein
alpha	I-protein
2	I-protein
repression	O
)	O
.	O

Four	O
cases	O
of	O
synovial	O
chondromatosis	O
are	O
presented	O
.	O

Twenty	O
-	O
nine	O
days	O
after	O
injection	O
of	O
5	O
.	O
8	O
mCi	O
of	O
Tc	O
-	O
99m	O
,	O
which	O
gives	O
28	O
rads	O
to	O
the	O
testis	O
,	O
the	O
number	O
of	O
sperm	O
hads	O
decreased	O
to	O
70	O
%	O
of	O
control	O
.	O

Fluorometric	O
methods	O
can	O
also	O
provide	O
information	O
about	O
porphyrin	O
binding	O
sites	O
that	O
is	O
useful	O
in	O
understanding	O
porphyrin	O
transport	O
and	O
clearance	O
.	O

Homozygous	O
individuals	O
usually	O
develop	O
purpura	O
fulminans	O
as	O
newborns	O
;	O
heterozygous	O
protein	O
C	O
-	O
deficient	O
individuals	O
are	O
at	O
increased	O
risk	O
for	O
venous	O
thrombosis	O
and	O
pulmonary	O
embolism	O
.	O

DAF16	B-protein
is	O
known	O
to	O
be	O
a	O
component	O
of	O
a	O
signaling	O
pathway	O
that	O
has	O
been	O
partially	O
dissected	O
genetically	O
and	O
includes	O
homologues	O
of	O
the	O
insulin	B-protein
/	I-protein
IGF	I-protein
-	I-protein
1	I-protein
receptor	I-protein
,	O
PtdIns	B-protein
3	I-protein
-	I-protein
kinase	I-protein
and	O
PKB	B-protein
.	O

The	O
identification	O
of	O
viable	O
myocardium	O
with	O
both	O
99mTc	O
-	O
tetrofosmin	O
and	O
201Tl	O
can	O
be	O
greatly	O
enhanced	O
to	O
a	O
similar	O
degree	O
if	O
the	O
severity	O
of	O
reduction	O
in	O
activity	O
within	O
nonreversible	O
defects	O
is	O
considered	O
.	O

Molecular	O
analysis	O
of	O
a	O
novel	O
schizosaccharomyces	O
pombe	O
gene	O
containing	O
two	O
RNP	B-protein
consensus	I-protein
-	I-protein
sequence	I-protein
RNA	I-protein
-	I-protein
binding	I-protein
domains	I-protein
.	O

Interestingly	O
,	O
a	O
decreased	O
transcription	O
from	O
the	O
endogenous	O
c	B-protein
-	I-protein
Myb	I-protein
promoter	I-protein
was	O
observed	O
in	O
several	O
HTLV	O
-	O
I	O
transformed	O
T	O
-	O
cell	O
lines	O
.	O

The	O
role	O
of	O
pharmacological	O
profiling	O
in	O
safety	O
assessment	O
.	O

Catch	O
-	O
up	O
growth	O
and	O
craniofacial	O
dimensions	O
following	O
administration	O
of	O
the	O
antineoplastic	O
agent	O
vincristine	O
to	O
young	O
rats	O
.	O

Previous	O
experimental	O
evidence	O
had	O
indicated	O
that	O
Reg1	B-protein
might	O
target	O
Glc7	B-protein
to	O
nuclear	O
substrates	O
such	O
as	O
the	O
Snf1	B-protein
kinase	I-protein
complex	I-protein
.	O

The	O
main	O
causes	O
of	O
liver	O
disease	O
in	O
the	O
patients	O
with	O
HCC	O
were	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
(	O
77	O
%	O
)	O
,	O
alcohol	O
abuse	O
(	O
73	O
%	O
)	O
,	O
and	O
the	O
combination	O
of	O
HCV	O
and	O
alcohol	O
abuse	O
(	O
50	O
%	O
)	O
.	O

Recommendations	O
to	O
deal	O
with	O
these	O
and	O
related	O
issues	O
are	O
presented	O
.	O

Specific	O
class	B-protein
I	I-protein
and	I-protein
II	I-protein
histone	I-protein
deacetylases	I-protein
(	O
HDACs	B-protein
)	O
interact	O
in	O
vivo	O
with	O
BCoR	B-protein
,	O
suggesting	O
that	O
BCoR	B-protein
may	O
functionally	O
link	O
these	O
two	O
classes	O
of	O
HDACs	B-protein
.	O

Preliminary	O
report	O
.	O

Using	O
varying	O
conditions	O
,	O
three	O
distinct	O
complexes	O
were	O
shown	O
to	O
interact	O
specifically	O
with	O
the	O
NIP	B-protein
region	I-protein
,	O
although	O
only	O
one	O
correlates	O
with	O
repressor	O
activity	O
.	O

Localization	O
of	O
the	O
brachial	O
plexus	O
with	O
the	O
nerve	O
stimulator	O
is	O
equally	O
effective	O
at	O
the	O
interscalene	O
,	O
supraclavicular	O
,	O
and	O
axillary	O
sites	O
.	O

We	O
critically	O
assess	O
current	O
systematic	O
uncertainties	O
and	O
determine	O
the	O
primordial	O
Li	O
abundance	O
within	O
new	O
,	O
much	O
tighter	O
limits	O
:	O
@	O
parl0	O
;	O
Li	O
@	O
solm0	O
;	O
H	O
@	O
parr0	O
;	O
p	O
=	O
1	O
.	O
23	O
+	O
0	O
.	O
68	O
-	O
0	O
.	O
32x10	O
-	O
10	O
.	O

In	O
64	O
%	O
a	O
small	O
cardiac	O
vein	O
does	O
not	O
exist	O
,	O
but	O
its	O
origin	O
,	O
the	O
right	O
marginal	O
vein	O
,	O
joins	O
the	O
system	O
of	O
anterior	O
cardiac	O
veins	O
.	O

These	O
results	O
indicate	O
that	O
the	O
cis	O
-	O
regulatory	O
elements	O
required	O
for	O
developmental	O
control	O
of	O
the	O
HaG3	B-protein
-	I-protein
A	I-protein
helianthinin	I-protein
gene	I-protein
are	O
located	O
in	O
a	O
2	O
.	O
4	O
kb	O
upstream	O
region	O
of	O
this	O
gene	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
yeast	B-protein
PHO8	I-protein
promoter	I-protein
in	O
comparison	O
to	O
the	O
coregulated	O
PHO5	B-protein
promoter	I-protein
.	O

Substrates	O
include	O
the	O
p21	B-protein
(	I-protein
ras	I-protein
)	I-protein
proteins	I-protein
,	O
nuclear	B-protein
lamins	I-protein
,	O
and	O
a	O
series	O
of	O
retinal	O
proteins	O
.	O

Transcription	O
of	O
the	O
metH	B-protein
gene	I-protein
in	I-protein
Salmonella	I-protein
typhimurium	I-protein
and	I-protein
Escherichia	I-protein
coli	I-protein
is	O
positively	O
regulated	O
by	O
the	O
metR	B-protein
gene	I-protein
product	I-protein
,	O
a	O
DNA	O
binding	O
protein	O
.	O

Morphine	O
-	O
dependent	O
and	O
control	O
rats	O
in	O
an	O
oral	O
free	O
-	O
choice	O
protocol	O
were	O
treated	O
with	O
gamma	O
-	O
vinyl	O
GABA	O
(	O
GVG	O
)	O
,	O
60	O
,	O
120	O
and	O
240	O
mg	O
/	O
kg	O
IP	O
,	O
for	O
3	O
days	O
over	O
three	O
successive	O
periods	O
.	O

Approximately	O
20	O
%	O
of	O
ALCLs	O
that	O
express	O
ALK	B-protein
do	O
not	O
contain	O
the	O
t	O
(	O
2	O
;	O
5	O
)	O
,	O
suggesting	O
that	O
other	O
genetic	O
abnormalities	O
can	O
result	O
in	O
aberrant	O
ALK	B-protein
expression	O
.	O

Cytogenetic	O
and	O
molecular	O
characterization	O
of	O
random	O
chromosomal	O
rearrangements	O
activating	O
the	O
drug	O
resistance	O
gene	O
,	O
MDR1	B-protein
/	I-protein
P	I-protein
-	I-protein
glycoprotein	I-protein
,	O
in	O
drug	O
-	O
selected	O
cell	O
lines	O
and	O
patients	O
with	O
drug	O
refractory	O
ALL	O
.	O

The	O
husband	O
in	O
one	O
of	O
the	O
married	O
couples	O
was	O
treated	O
for	O
hepatitis	O
of	O
unidentified	O
etiology	O
in	O
an	O
Infectology	O
Department	O
four	O
years	O
ago	O
.	O

These	O
genetic	O
alterations	O
do	O
not	O
affect	O
synthesis	O
of	O
the	O
major	O
c	B-protein
-	I-protein
myc	I-protein
protein	I-protein
,	O
p64	B-protein
,	O
which	O
is	O
initiated	O
from	O
the	O
first	O
AUG	O
codon	O
in	O
exon	O
2	O
.	O

Its	O
application	O
in	O
Madagascar	O
:	O
advantages	O
and	O
disadvantages	O
.	O

What	O
'	O
s	O
new	O
in	O
gynecologic	O
and	O
obstetrical	O
surgery	O
.	O

Treatment	O
with	O
heparin	O
,	O
plasminogen	B-protein
activators	O
and	O
fibrinogenolytic	O
agents	O
was	O
disappointing	O
although	O
renal	O
function	O
has	O
stabilized	O
in	O
one	O
patient	O
on	O
long	O
term	O
oral	O
anticoagulant	O
therapy	O
.	O

M	O
.	O

There	O
was	O
a	O
weak	O
significant	O
correlation	O
between	O
TGF	B-protein
beta	I-protein
1	I-protein
levels	O
and	O
normal	O
cell	O
radiosensitivity	O
(	O
lymphocyte	O
SF2	O
)	O
.	O

We	O
describe	O
a	O
genetic	O
system	O
for	O
further	O
characterizing	O
the	O
role	O
of	O
the	O
extreme	O
C	O
-	O
terminus	O
of	O
the	O
beta	O
subunit	O
of	O
E	B-protein
.	I-protein
coli	I-protein
RNA	I-protein
polymerase	I-protein
.	O

The	O
single	O
site	O
of	O
glycosylation	O
is	O
located	O
near	O
the	O
C	O
-	O
terminus	O
in	O
the	O
N	B-protein
-	I-protein
glycosylation	I-protein
sequon	I-protein
-	I-protein
Asn	I-protein
-	I-protein
Cys	I-protein
-	I-protein
Ser	I-protein
-	I-protein
in	O
which	O
Cys	O
forms	O
part	O
of	O
a	O
disulphide	O
bridge	O
.	O

P	O
.	O

Mental	O
rotation	O
of	O
paired	O
figures	O
engendered	O
activation	O
in	O
the	O
left	O
superior	O
parietal	O
lobule	O
and	O
the	O
right	O
frontal	O
medial	O
gyrus	O
.	O

The	O
csbA	B-protein
fusion	I-protein
was	O
maximally	O
expressed	O
during	O
early	O
stationary	O
phase	O
in	O
cells	O
grown	O
in	O
Luria	O
broth	O
containing	O
5	O
%	O
glucose	O
and	O
0	O
.	O
2	O
%	O
glutamine	O
.	O

9	O
.	O
7	O
(	O
95	O
%	O
CI	O
:	O
9	O
.	O
6	O
-	O
9	O
.	O
7	O
)	O
micromol	O
/	O
L	O
among	O
women	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
.	O

A	O
single	O
protease	O
-	O
resistant	O
structure	O
formed	O
by	O
the	O
entirety	O
of	O
both	O
PDZ	B-protein
repeats	I-protein
1	I-protein
and	I-protein
2	I-protein
(	O
PDZ1	B-protein
-	I-protein
2	I-protein
)	O
contains	O
the	O
protein	B-protein
4	I-protein
.	I-protein
1	I-protein
-	I-protein
binding	I-protein
site	I-protein
.	O

All	O
other	O
changes	O
at	O
the	O
3	O
-	O
,	O
5	O
-	O
,	O
and	O
6	O
-	O
positions	O
,	O
as	O
well	O
as	O
the	O
replacement	O
of	O
the	O
phenyl	O
group	O
at	O
position	O
2	O
,	O
caused	O
a	O
marked	O
decrease	O
of	O
activity	O
.	O

The	O
cleavage	O
dipeptides	O
of	O
C1YVV	B-protein
NIa	I-protein
protease	I-protein
are	O
Q	B-protein
(	I-protein
E	I-protein
)	I-protein
/	I-protein
S	I-protein
(	I-protein
A	I-protein
,	I-protein
G	I-protein
)	I-protein
.	O

Using	O
mouse	O
-	O
human	O
somatic	O
hybrids	O
and	O
FISH	O
analysis	O
,	O
the	O
PE	B-protein
-	I-protein
2	I-protein
gene	I-protein
is	O
localized	O
to	O
human	O
chromosome	O
19q13	O
.	O
2	O
,	O
a	O
region	O
involved	O
in	O
translocations	O
and	O
deletions	O
in	O
leukemias	O
and	O
several	O
solid	O
tumors	O
,	O
suggesting	O
that	O
this	O
novel	O
ETS	B-protein
factor	I-protein
may	O
play	O
a	O
role	O
in	O
carcinogenesis	O
.	O

Maximum	O
number	O
of	O
strains	O
(	O
39	O
.	O
1	O
%	O
)	O
were	O
resistant	O
in	O
S	O
.	O
bareilly	O
serotype	O
,	O
followed	O
by	O
S	O
.	O
typhimurium	O
(	O
21	O
.	O
7	O
%	O
)	O
and	O
least	O
in	O
S	O
.	O
typhi	O
(	O
17	O
.	O
4	O
%	O
)	O
.	O

Use	O
of	O
prostaglandin	O
F2	O
alpha	O
(	O
PGF2	O
alpha	O
)	O
in	O
cattle	O
breeding	O
.	O

Mutations	O
within	O
the	O
C	O
terminus	O
of	O
c	B-protein
-	I-protein
fos	I-protein
at	O
serine	O
residues	O
that	O
are	O
phosphorylation	O
targets	O
for	O
growth	B-protein
factors	I-protein
and	O
MAP	B-protein
kinase	I-protein
completely	O
abrogate	O
transactivation	O
and	O
block	O
potentiation	O
by	O
MAP	B-protein
kinase	I-protein
.	O

Efficacy	O
and	O
field	O
evaluation	O
of	O
Bacillus	O
thuringiensis	O
(	O
H	O
-	O
14	O
)	O
and	O
B	O
.	O
sphaericus	O
against	O
floodwater	O
mosquitoes	O
in	O
California	O
.	O

The	O
range	O
of	O
200	O
000	O
-	O
300	O
000	O
spermatozoa	O
/	O
microl	O
appeared	O
to	O
be	O
a	O
reasonable	O
compromise	O
for	O
both	O
criteria	O
.	O

The	O
characterized	O
Aplysia	B-protein
Afurin2	I-protein
is	O
a	O
candidate	O
PC	B-protein
that	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
processing	O
of	O
egg	B-protein
-	I-protein
laying	I-protein
hormone	I-protein
(	O
ELH	B-protein
)	O
-	O
related	O
precursors	O
in	O
the	O
secretory	O
cells	O
of	O
the	O
atrial	O
gland	O
.	O

Analyses	O
of	O
hGMR	B-protein
beta	I-protein
subunit	I-protein
mutants	I-protein
revealed	O
two	O
cytoplasmic	O
regions	O
involved	O
in	O
activation	O
of	O
the	O
c	B-protein
-	I-protein
myc	I-protein
promoter	I-protein
,	O
one	O
is	O
essential	O
and	O
the	O
other	O
is	O
dispensable	O
but	O
enhances	O
the	O
activity	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
scanthrough	O
translation	O
,	O
where	O
the	O
initiating	O
AUG	O
of	O
a	O
primary	O
open	O
reading	O
frame	O
is	O
bypassed	O
,	O
is	O
most	O
likely	O
to	O
account	O
for	O
the	O
presentation	O
of	O
cryptic	O
epitopes	O
from	O
alternative	O
reading	O
frames	O
within	O
the	O
influenza	B-protein
A	I-protein
PR	I-protein
/	I-protein
8	I-protein
/	I-protein
34	I-protein
nucleoprotein	I-protein
gene	I-protein
.	O

Lowering	O
of	O
the	O
renal	O
blood	O
flow	O
alters	O
the	O
glomerular	O
and	O
tubular	O
excretion	O
processes	O
.	O

We	O
find	O
that	O
BCL	B-protein
-	I-protein
6	I-protein
POZ	I-protein
domain	I-protein
mutations	O
that	O
disrupt	O
the	O
interaction	O
with	O
N	B-protein
-	I-protein
CoR	I-protein
and	O
SMRT	B-protein
no	O
longer	O
repress	O
transcription	O
.	O

Children	O
who	O
developed	O
lower	O
respiratory	O
tract	O
infections	O
or	O
PCP	O
had	O
increased	O
rates	O
of	O
decline	O
of	O
CD4	B-protein
cell	O
counts	O
during	O
the	O
first	O
6	O
months	O
of	O
life	O
.	O

Selective	O
stimulation	O
of	O
central	O
alpha	B-protein
-	I-protein
autoreceptors	I-protein
following	O
treatment	O
with	O
alpha	O
-	O
methyldopa	O
and	O
FLA	O
136	O
.	O

OBJECTIVE	O
:	O
Our	O
goal	O
was	O
to	O
determine	O
whether	O
chlamydia	O
-	O
infected	O
women	O
have	O
a	O
higher	O
rate	O
of	O
febrile	O
complications	O
after	O
postpartum	O
tubal	O
ligation	O
.	O

The	O
pre	O
-	O
mRNA	O
splicing	O
factor	O
U2AF	B-protein
(	O
U2	B-protein
small	I-protein
nuclear	I-protein
ribonucleoprotein	I-protein
particle	I-protein
[	I-protein
snRNP	I-protein
]	I-protein
auxiliary	I-protein
factor	I-protein
)	O
plays	O
a	O
critical	O
role	O
in	O
3	O
'	O
splice	O
site	O
selection	O
.	O

The	O
linear	O
plasmid	O
pCLU1	O
from	O
the	O
yeast	O
Kluyveromyces	O
lactis	O
normally	O
replicates	O
in	O
the	O
cytoplasm	O
,	O
with	O
the	O
aid	O
of	O
the	O
helper	O
linear	O
plasmid	O
pGKL2	O
,	O
using	O
terminal	B-protein
protein	I-protein
(	O
TP	B-protein
)	O
as	O
a	O
primer	O
.	O

A	O
high	O
-	O
efficiency	O
cross	O
-	O
flow	O
micronebulizer	O
interface	O
for	O
capillary	O
electrophoresis	O
and	O
inductively	O
coupled	O
plasma	O
mass	O
spectrometry	O
.	O

This	O
hypothesis	O
is	O
consistent	O
with	O
the	O
occurrence	O
of	O
PEA3	B-protein
binding	I-protein
sites	I-protein
in	O
the	O
PEA3	B-protein
promoter	I-protein
and	O
with	O
the	O
ability	O
of	O
PEA3	B-protein
to	O
transactivate	O
this	O
promoter	O
.	O

DMCM	O
also	O
permits	O
extension	O
of	O
the	O
possibilities	O
of	O
obtaining	O
and	O
transplanting	O
donor	O
organs	O
.	O

When	O
10	O
fields	O
were	O
analysed	O
,	O
a	O
strong	O
relationship	O
was	O
found	O
between	O
the	O
presence	O
of	O
bacteria	O
on	O
Gram	O
staining	O
and	O
the	O
final	O
diagnosis	O
of	O
VAP	O
(	O
for	O
PSB	O
and	O
PTC	O
respectively	O
:	O
sensitivity	O
74	O
and	O
81	O
%	O
,	O
specificity	O
94	O
and	O
100	O
%	O
,	O
positive	O
predictive	O
value	O
91	O
and	O
100	O
%	O
,	O
negative	O
predictive	O
value	O
82	O
and	O
88	O
%	O
)	O
.	O

They	O
correspond	O
to	O
nucleotides	O
equivalent	O
to	O
base	O
-	O
pair	O
C1	O
-	O
G72	O
and	O
discriminator	O
base	O
A73	O
in	O
the	O
amino	O
acid	O
-	O
acceptor	O
branch	O
of	O
the	O
molecule	O
.	O

As	O
a	O
reflection	O
of	O
uncertainties	O
in	O
the	O
estimates	O
for	O
individual	O
sources	O
,	O
the	O
90th	O
percentiles	O
of	O
PCDD	O
/	O
F	O
releases	O
for	O
1999	O
ranged	O
up	O
to	O
4	O
.	O
1	O
g	O
I	O
-	O
TEQ	O
/	O
y	O
.	O

The	O
evaluation	O
was	O
performed	O
using	O
a	O
retrospective	O
study	O
design	O
with	O
newborn	O
blood	O
samples	O
from	O
three	O
screening	O
centres	O
.	O

The	O
MRS	O
II	O
meets	O
a	O
high	O
methodological	O
standard	O
as	O
an	O
instrument	O
standardized	O
in	O
the	O
population	O
.	O

Duration	O
of	O
remission	O
in	O
advanced	O
gastric	O
cancer	O
patients	O
responding	O
to	O
sequential	O
dose	O
of	O
MTX	O
and	O
5	O
-	O
FU	O
.	O

Northern	O
analysis	O
indicated	O
differential	O
expression	O
by	O
tissue	O
with	O
highest	O
expression	O
in	O
the	O
heart	O
.	O

These	O
data	O
show	O
that	O
the	O
spv	B-protein
virulence	I-protein
genes	I-protein
belong	O
simultaneously	O
to	O
several	O
regulons	O
in	O
the	O
cell	O
,	O
raising	O
the	O
possibility	O
that	O
spv	B-protein
expression	O
can	O
be	O
fine	O
-	O
tuned	O
in	O
response	O
to	O
multiple	O
environmental	O
inputs	O
.	O

Cbf3	B-protein
contains	O
three	O
proteins	O
,	O
Cbf3a	B-protein
,	O
Cbf3b	B-protein
and	O
Cbf3c	B-protein
.	O

The	O
results	O
of	O
induced	O
coexpression	O
were	O
also	O
supported	O
by	O
rapid	O
generation	O
of	O
FeLV	O
recombinants	O
when	O
FeLV	O
-	O
C	O
was	O
used	O
to	O
infect	O
the	O
feline	O
3201B	O
cell	O
line	O
that	O
constitutively	O
expresses	O
high	O
levels	O
of	O
endogenous	O
FeLV	O
-	O
specific	O
mRNAs	O
.	O

COGLAB	O
includes	O
measures	O
of	O
preattentional	O
,	O
attentional	O
,	O
conceptual	O
,	O
and	O
psychomotor	O
performance	O
.	O

We	O
discuss	O
these	O
results	O
in	O
terms	O
of	O
the	O
influence	O
that	O
time	O
and	O
nutritional	O
constraints	O
have	O
on	O
odonate	O
development	O
patterns	O
and	O
fitness	O
.	O

N	O
.	O
van	O
Hoek	O
,	O
and	O
M	O
.	O

Use	O
of	O
serum	O
thyroglobulin	B-protein
determination	O
in	O
the	O
follow	O
-	O
up	O
of	O
differentiated	O
carcinomas	O
of	O
the	O
thyroid	O
.	O

Large	O
and	O
small	O
medullary	O
lesions	O
inhibited	O
the	O
occurrence	O
of	O
target	O
fibres	O
in	O
the	O
tenotomized	O
muscles	O
,	O
the	O
smallest	O
one	O
being	O
neurolysis	O
of	O
the	O
dorsal	O
roots	O
.	O

No	O
such	O
benefits	O
were	O
seen	O
for	O
children	O
with	O
CD4	B-protein
+	I-protein
counts	O
below	O
0	O
.	O
2	O
x	O
10	O
(	O
9	O
)	O
per	O
liter	O
at	O
entry	O
.	O

Supplementing	O
a	O
soybean	O
protein	O
and	O
sucrose	O
-	O
based	O
diet	O
with	O
levels	O
of	O
2	O
.	O
2	O
,	O
11	O
,	O
and	O
55	O
ppm	O
of	O
the	O
antibiotic	O
,	O
from	O
the	O
two	O
sources	O
each	O
with	O
two	O
different	O
purities	O
,	O
improved	O
weight	O
gain	O
of	O
chicks	O
an	O
average	O
of	O
23	O
%	O
and	O
improved	O
feed	O
efficiency	O
an	O
average	O
of	O
13	O
%	O
at	O
the	O
higher	O
levels	O
(	O
all	O
P	O
less	O
than	O
.	O
01	O
)	O
.	O

Mutagenesis	O
of	O
IM1	B-protein
enhances	O
the	O
ability	O
of	O
c	B-protein
-	I-protein
Fos	I-protein
to	O
activate	O
an	O
AP1	B-protein
bearing	I-protein
promoter	I-protein
.	O

Hypothermia	O
After	O
Cardiac	O
Arrest	O
(	O
HACA	O
)	O
Study	O
Group	O
.	O

Intrathecal	O
acetyl	B-protein
cholinesterase	I-protein
inhibitors	O
produce	O
analgesia	O
that	O
is	O
synergistic	O
with	O
morphine	O
and	O
clonidine	O
in	O
rats	O
.	O

Combining	O
multiple	O
laboratory	O
studies	O
may	O
be	O
of	O
value	O
in	O
predetermining	O
the	O
eventual	O
outcome	O
in	O
near	O
-	O
drowning	O
.	O

STUDY	O
DESIGN	O
.	O

A	O
tobacco	O
homologue	O
(	O
trolC	B-protein
)	O
of	O
the	O
rolC	B-protein
gene	I-protein
of	I-protein
the	I-protein
Agrobacterium	I-protein
rhizogenes	I-protein
Ri	I-protein
-	I-protein
plasmid	I-protein
was	O
cloned	O
and	O
sequenced	O
from	O
Nicotiana	O
tabacum	O
L	O
.	O
cv	O
.	O

Sternocleidomastoid	O
,	O
neck	O
or	O
facial	O
muscles	O
wasting	O
were	O
also	O
found	O
in	O
three	O
cases	O
.	O

The	O
prescription	O
for	O
apoplexy	O
includes	O
C1	O
-	O
7	O
,	O
T1	O
-	O
9	O
and	O
L2	O
-	O
4	O
.	O

The	O
expression	O
of	O
the	O
putative	O
operon	O
bglPH	B-protein
of	O
Bacillus	O
subtilis	O
was	O
studied	O
by	O
using	O
bglP	B-protein
'	I-protein
-	I-protein
lacZ	I-protein
transcriptional	I-protein
fusions	I-protein
.	O

The	O
correlation	O
between	O
PaCO2	O
and	O
PtcO2	O
in	O
RDS	O
was	O
insufficient	O
to	O
make	O
clinical	O
judgement	O
.	O

A	O
series	O
of	O
amino	O
terminal	O
deletion	O
mutants	O
(	O
d10	O
,	O
d20	O
,	O
d27	O
,	O
d31	O
,	O
d40	O
,	O
d44	O
,	O
and	O
d73	O
)	O
were	O
compared	O
for	O
processing	O
,	O
cell	O
surface	O
expression	O
,	O
and	O
maintenance	O
of	O
their	O
biological	O
attributes	O
by	O
recombinant	O
expression	O
of	O
mutant	O
genes	O
using	O
a	O
plasmid	O
vector	O
(	O
pcDL	O
-	O
SR	O
alpha	O
-	O
296	O
)	O
in	O
CV	O
-	O
1	O
and	O
HeLa	O
cells	O
.	O

As	O
a	O
result	O
,	O
beta	O
-	O
apo	O
-	O
8	O
'	O
-	O
carotenoic	O
acid	O
ethyl	O
ester	O
(	O
apo	O
-	O
EE	O
)	O
was	O
used	O
as	O
a	O
reference	O
standard	O
in	O
Experiments	O
4	O
to	O
6	O
.	O

Nevertheless	O
,	O
in	O
view	O
of	O
the	O
potential	O
transmission	O
rates	O
of	O
HGV	O
and	O
the	O
lack	O
of	O
effective	O
immunization	O
,	O
HGV	O
should	O
be	O
regarded	O
as	O
a	O
potential	O
occupational	O
hazard	O
for	O
medical	O
and	O
dental	O
staff	O
.	O

Disruption	O
of	O
any	O
one	O
of	O
the	O
four	O
genes	O
encoding	O
the	O
newly	O
identified	O
SRP	B-protein
proteins	I-protein
results	O
in	O
slow	O
cell	O
growth	O
and	O
inefficient	O
protein	O
translocation	O
across	O
the	O
ER	O
membrane	O
.	O

We	O
derive	O
joint	O
probability	O
density	O
distributions	O
for	O
three	O
key	O
uncertain	O
properties	O
of	O
the	O
climate	O
system	O
,	O
using	O
an	O
optimal	O
fingerprinting	O
approach	O
to	O
compare	O
simulations	O
of	O
an	O
intermediate	O
complexity	O
climate	O
model	O
with	O
three	O
distinct	O
diagnostics	O
of	O
recent	O
climate	O
observations	O
.	O

Among	O
a	O
population	O
of	O
18	O
,	O
175	O
children	O
below	O
7	O
years	O
of	O
age	O
in	O
medium	O
sized	O
towns	O
and	O
rural	O
areas	O
in	O
south	O
-	O
western	O
Germany	O
552	O
(	O
3	O
.	O
03	O
%	O
)	O
cases	O
of	O
croup	O
were	O
registered	O
during	O
a	O
12	O
months	O
period	O
in	O
1984	O
-	O
85	O
by	O
their	O
physicians	O
.	O

The	O
7	O
-	O
day	O
treatment	O
resulted	O
in	O
a	O
decrease	O
in	O
mitochondrial	O
uptake	O
of	O
Rh123	O
and	O
an	O
increase	O
in	O
NAO	O
uptake	O
.	O

Primer	O
extension	O
and	O
mung	B-protein
bean	I-protein
and	I-protein
S1	I-protein
nuclease	I-protein
mapping	O
indicated	O
multiple	O
transcription	O
initiation	O
sites	O
and	O
were	O
consistent	O
with	O
Northern	O
analyses	O
.	O

GCN4	B-protein
encodes	O
a	O
transcriptional	O
activator	O
of	O
amino	O
acid	O
biosynthetic	O
genes	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
cysteine	O
-	O
rich	O
region	O
of	O
raf	B-protein
-	I-protein
1	I-protein
kinase	I-protein
contains	O
zinc	O
,	O
translocates	O
to	O
liposomes	O
,	O
and	O
is	O
adjacent	O
to	O
a	O
segment	O
that	O
binds	O
GTP	B-protein
-	I-protein
ras	I-protein
.	O

The	O
CBF1	B-protein
site	I-protein
within	O
HS2	B-protein
resides	O
near	O
sites	O
for	O
hematopoietic	O
regulators	O
such	O
as	O
GATA	B-protein
-	I-protein
1	I-protein
,	O
NF	B-protein
-	I-protein
E2	I-protein
,	O
and	O
TAL1	B-protein
.	O

Here	O
we	O
provide	O
the	O
first	O
evidence	O
for	O
the	O
involvement	O
of	O
GCN1	B-protein
-	I-protein
GCN2	I-protein
interaction	O
in	O
activation	O
of	O
GCN2	B-protein
per	O
se	O
.	O

The	O
results	O
of	O
these	O
experiments	O
indicate	O
that	O
at	O
least	O
two	O
upstream	O
activator	O
sequences	O
(	O
UAS	O
)	O
mediate	O
maximum	O
induction	O
by	O
galactose	O
.	O

Significant	O
correlations	O
existed	O
between	O
FEV1	O
and	O
the	O
corresponding	O
values	O
of	O
Raw	O
,	O
MEF50	O
and	O
MEF25	O
,	O
although	O
there	O
were	O
considerable	O
individual	O
differences	O
between	O
test	O
results	O
.	O

The	O
liver	O
in	O
the	O
severely	O
ill	O
.	O

20	O
%	O
of	O
total	O
HSL	B-protein
transcripts	I-protein
in	O
human	O
subcutaneous	O
adipocytes	O
.	O

Western	O
analyses	O
with	O
antisera	O
raised	O
against	O
Lu	B-protein
-	I-protein
ECAM	I-protein
-	I-protein
1	I-protein
peptides	I-protein
show	O
that	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
predicted	O
open	O
reading	O
frame	O
is	O
present	O
only	O
in	O
the	O
larger	O
size	O
proteins	O
(	O
i	O
.	O
e	O
.	O

In	O
contrast	O
,	O
the	O
action	O
of	O
GLP	B-protein
-	I-protein
1	I-protein
at	O
the	O
CRE	B-protein
was	O
not	O
blocked	O
by	O
cotransfection	O
with	O
M1	B-protein
-	I-protein
CREB	I-protein
,	O
an	O
isoform	O
that	O
lacks	O
a	O
consensus	O
serine	O
residue	O
serving	O
as	O
substrate	O
for	O
PKA	O
-	O
mediated	O
phosphorylation	O
.	O

Post	O
-	O
operative	O
functional	O
outcome	O
is	O
related	O
to	O
pre	O
-	O
operative	O
functional	O
status	O
.	O

The	O
cleavage	O
of	O
Fak	B-protein
by	O
caspases	B-protein
may	O
thus	O
play	O
an	O
important	O
role	O
in	O
the	O
execution	O
of	O
the	O
suicide	O
program	O
by	O
disabling	O
the	O
anti	O
-	O
apoptotic	O
function	O
of	O
Fak	B-protein
.	O

As	O
authorized	O
by	O
the	O
World	O
Health	O
Organization	O
29th	O
Expert	O
Committee	O
on	O
Biological	O
Standardization	O
,	O
the	O
preparation	O
of	O
human	B-protein
prolactin	I-protein
in	O
ampoules	O
coded	O
75	O
/	O
504	O
has	O
been	O
established	O
as	O
the	O
International	O
Reference	O
Preparation	O
(	O
IRP	O
)	O
of	O
human	B-protein
prolactin	I-protein
for	O
immunoassay	O
.	O

The	O
SH2	B-protein
and	O
SH3	B-protein
domains	I-protein
of	O
pp60src	B-protein
direct	O
stable	O
association	O
with	O
tyrosine	O
phosphorylated	O
proteins	O
p130	B-protein
and	O
p110	B-protein
.	O

The	O
use	O
of	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
has	O
resulted	O
in	O
significant	O
improvements	O
in	O
the	O
treatment	O
of	O
HIV	O
infection	O
,	O
including	O
a	O
decrease	O
in	O
the	O
incidence	O
and	O
severity	O
of	O
several	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
-	O
related	O
malignancies	O
.	O

A	O
particularly	O
striking	O
HpaII	B-protein
tiny	O
fragment	O
island	O
,	O
extending	O
over	O
nearly	O
2	O
,	O
000	O
base	O
pairs	O
,	O
surrounds	O
the	O
USF2	B-protein
translation	I-protein
initiation	I-protein
site	I-protein
.	O

Our	O
results	O
implicate	O
TGF	B-protein
-	I-protein
beta	I-protein
RII	I-protein
as	O
a	O
direct	O
target	O
of	O
EWS	B-protein
-	I-protein
FLI1	I-protein
.	O

Requirements	O
for	O
the	O
nuclear	O
-	O
cytoplasmic	O
translocation	O
of	O
infected	B-protein
-	I-protein
cell	I-protein
protein	I-protein
0	I-protein
of	O
herpes	O
simplex	O
virus	O
1	O
.	O

Localization	O
of	O
67	O
exons	O
on	O
a	O
YAC	O
contig	O
spanning	O
1	O
.	O
5	O
Mb	O
around	O
the	O
multidrug	B-protein
resistance	I-protein
gene	I-protein
region	I-protein
of	O
human	O
chromosome	O
7q21	O
.	O
1	O
.	O

The	O
role	O
of	O
'	O
scientific	O
psychiatry	O
'	O
in	O
understanding	O
patients	O
with	O
chronic	O
schizophrenia	O
or	O
severe	O
personality	O
disorder	O
.	O

The	O
genes	O
encoding	O
(	B-protein
2Fe	I-protein
-	I-protein
2S	I-protein
)	I-protein
plant	I-protein
-	I-protein
like	I-protein
ferredoxins	I-protein
were	O
studied	O
in	O
the	O
widely	O
used	O
cyanobacterium	O
Synechocystis	O
PCC6803	O
.	O

Transfer	B-protein
RNA	I-protein
genes	I-protein
from	I-protein
Dictyostelium	I-protein
discoideum	I-protein
are	O
frequently	O
associated	O
with	O
repetitive	O
elements	O
and	O
contain	O
consensus	O
boxes	O
in	O
their	O
5	O
'	O
and	O
3	O
'	O
-	O
flanking	O
regions	O
.	O

Ultrastructural	O
studies	O
of	O
retinopathy	O
of	O
premature	O
infants	O
.	O

The	O
present	O
studies	O
compare	O
the	O
biochemical	O
characteristics	O
,	O
Kanagawa	O
hemolysin	O
reactions	O
,	O
and	O
plasmid	O
profiles	O
of	O
13	O
patient	O
and	O
221	O
environmental	O
isolates	O
of	O
the	O
organism	O
.	O

A	O
preliminary	O
study	O
of	O
vincristine	O
,	O
methotrexate	O
,	O
and	O
prednisolone	O
(	O
VM	O
*	O
P	O
)	O
combination	O
chemotherapy	O
for	O
advanced	O
adult	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
.	O

In	O
addition	O
,	O
C	B-protein
/	I-protein
EBP	I-protein
beta	I-protein
and	O
C	B-protein
/	I-protein
EBP	I-protein
gamma	I-protein
readily	O
heterodimerize	O
with	O
each	O
other	O
as	O
well	O
as	O
with	O
C	B-protein
/	I-protein
EBP	I-protein
alpha	I-protein
.	O

Intraoperative	O
measurement	O
of	O
activated	O
partial	O
thromboplastin	B-protein
time	O
and	O
prothrombin	B-protein
time	O
with	O
a	O
new	O
compact	O
monitor	O
.	O

The	O
pattern	O
of	O
RNase	B-protein
E	I-protein
digestion	O
of	O
finP305	B-protein
RNA	I-protein
differed	O
from	O
FinP	B-protein
,	O
and	O
GST	B-protein
-	I-protein
FinO	I-protein
did	O
not	O
protect	O
finP305	B-protein
RNA	I-protein
from	O
cleavage	O
in	O
vitro	O
.	O

During	O
exercise	O
K	O
+	O
is	O
released	O
from	O
contracting	O
muscle	O
and	O
plasma	O
K	O
+	O
concentration	O
rises	O
.	O

In	O
vitro	O
affinity	O
analyses	O
demonstrated	O
that	O
recombinant	O
130	O
-	O
kD	O
protein	O
directly	O
interacts	O
with	O
ZO	B-protein
-	I-protein
1	I-protein
and	O
the	O
cytoplasmic	O
domain	O
of	O
occludin	B-protein
,	O
but	O
not	O
with	O
ZO	B-protein
-	I-protein
2	I-protein
.	O

Clinical	O
differentiation	O
of	O
patients	O
with	O
mild	O
diplegic	O
cerebral	O
palsy	O
(	O
CP	O
)	O
and	O
idiopathic	O
toe	O
walking	O
(	O
ITW	O
)	O
can	O
be	O
difficult	O
.	O

Next	O
,	O
we	O
stably	O
overexpressed	O
wild	B-protein
-	I-protein
type	I-protein
Shc	I-protein
or	O
Y317F	B-protein
mutant	I-protein
Shc	I-protein
into	O
HIRc	O
cells	O
.	O

CONCLUSIONS	O
:	O
A	O
comparison	O
of	O
the	O
LysU	B-protein
crystal	O
structure	O
with	O
the	O
structures	O
of	O
seryl	B-protein
-	I-protein
and	I-protein
aspartyl	I-protein
-	I-protein
tRNA	I-protein
synthetases	I-protein
enables	O
a	O
conserved	O
core	O
to	O
be	O
identified	O
.	O

Thirty	O
-	O
two	O
rats	O
were	O
divided	O
into	O
four	O
groups	O
.	O

Mice	O
homozygous	O
for	O
the	O
dlg	B-protein
mutation	O
exhibit	O
growth	O
retardation	O
in	O
utero	O
,	O
have	O
hypoplasia	O
of	O
the	O
premaxilla	O
and	O
mandible	O
,	O
have	O
a	O
cleft	O
secondary	O
palate	O
,	O
and	O
die	O
perinatally	O
.	O

Here	O
we	O
focused	O
on	O
the	O
role	O
of	O
the	O
5	O
'	O
proximal	O
regulatory	O
cassette	O
(	O
-	O
190	O
;	O
+	O
53	O
bp	O
)	O
of	O
the	O
rat	B-protein
enkephalin	I-protein
(	O
rENK	B-protein
)	O
gene	O
in	O
the	O
developmental	O
regulation	O
of	O
the	O
enkephalin	B-protein
phenotype	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
gene	O
predicts	O
a	O
polypeptide	O
of	O
215	O
amino	O
acids	O
(	O
25	O
.	O
2	O
kDa	O
)	O
with	O
two	O
putative	O
membrane	O
-	O
spanning	O
domains	O
.	O

Depletion	O
of	O
dopamine	O
in	O
the	O
nucleus	O
accumbens	O
led	O
to	O
a	O
dramatic	O
shift	O
in	O
behavior	O
in	O
which	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
lever	O
pressing	O
but	O
a	O
significant	O
increase	O
in	O
consumption	O
of	O
lab	O
chow	O
.	O

The	O
two	O
genes	O
code	O
for	O
polypeptides	B-protein
of	I-protein
420	I-protein
amino	I-protein
acids	I-protein
(	I-protein
M	I-protein
.	I-protein
HgiCI	I-protein
)	I-protein
and	O
345	B-protein
amino	I-protein
acids	I-protein
(	I-protein
R	I-protein
.	I-protein
HgiCI	I-protein
)	I-protein
.	O

Glucose	B-protein
-	I-protein
6	I-protein
-	I-protein
phosphate	I-protein
dehydrogenase	I-protein
(	O
G	B-protein
-	I-protein
6	I-protein
-	I-protein
PD	I-protein
)	O
deficiency	O
in	O
the	O
newborn	O
.	O

Angiography	O
of	O
aneurysmal	O
bone	O
cyst	O
.	O

These	O
results	O
are	O
the	O
first	O
to	O
demonstrate	O
the	O
structural	O
organization	O
of	O
a	O
vertebrate	O
gene	O
encoding	O
an	O
integral	O
membrane	O
protein	O
of	O
the	O
nuclear	O
envelope	O
that	O
may	O
be	O
a	O
member	O
of	O
a	O
family	O
of	O
polypeptides	O
conserved	O
in	O
evolution	O
.	O

Previous	O
work	O
has	O
shown	O
that	O
spleen	O
necrosis	O
virus	O
(	O
SNV	O
)	O
long	O
terminal	O
repeats	O
(	O
LTRs	O
)	O
are	O
associated	O
with	O
Rex	O
/	O
Rex	O
-	O
responsive	O
element	O
-	O
independent	O
expression	O
of	O
bovine	O
leukemia	O
virus	O
RNA	O
and	O
supports	O
the	O
hypothesis	O
that	O
SNV	O
RNA	O
contains	O
a	O
cis	O
-	O
acting	O
element	O
that	O
interacts	O
with	O
cellular	B-protein
Rex	I-protein
-	I-protein
like	I-protein
proteins	I-protein
.	O

After	O
successful	O
subtotal	O
parathyroidectomy	O
,	O
evident	O
by	O
the	O
decrease	O
of	O
serum	O
iPTH	B-protein
levels	O
,	O
both	O
the	O
CL	O
of	O
group	O
2	O
PMNs	O
and	O
the	O
ability	O
of	O
group	O
2	O
sera	O
to	O
induce	O
augmented	O
CL	O
in	O
normal	O
PMNs	O
decreased	O
(	O
p	O
<	O
0	O
.	O
025	O
)	O
.	O

Current	O
status	O
of	O
chemotherapy	O
for	O
Hodgkin	O
'	O
s	O
disease	O
.	O

Lethal	O
Tachmalcor	O
(	O
4	O
-	O
(	O
3	O
'	O
-	O
diethylamino	O
-	O
2	O
'	O
-	O
hydroxypropyl	O
)	O
-	O
ajmaline	O
)	O
poisoning	O
in	O
childhood	O
.	O

IgG	B-protein
levels	O
of	O
1	O
/	O
100	O
were	O
present	O
in	O
only	O
four	O
out	O
of	O
ten	O
samples	O
obtained	O
150	O
days	O
after	O
the	O
clinical	O
onset	O
.	O

RNase	B-protein
protection	O
and	O
primer	O
extension	O
assays	O
confirmed	O
that	O
the	O
5	O
'	O
non	O
-	O
coding	O
exon	O
is	O
included	O
in	O
the	O
DDT1	O
aFGF	B-protein
mRNA	I-protein
and	O
that	O
a	O
major	O
transcription	O
start	O
site	O
is	O
approximately	O
136	O
bp	O
upstream	O
of	O
the	O
5	O
'	O
non	O
-	O
coding	O
splice	O
junction	O
of	O
this	O
exon	O
.	O

Cytoskeletal	O
polarization	O
of	O
T	O
cells	O
is	O
regulated	O
by	O
an	O
immunoreceptor	O
tyrosine	O
-	O
based	O
activation	O
motif	O
-	O
dependent	O
mechanism	O
.	O

(	O
1988	O
)	O
J	O
.	O

The	O
effect	O
of	O
acetazolamide	O
(	O
ACZ	O
)	O
on	O
HCO3	O
-	O
and	O
Cl	O
-	O
activities	O
in	O
inner	O
ear	O
fluid	O
was	O
investigated	O
by	O
ion	O
-	O
selective	O
microelectrode	O
methods	O
.	O

Eukaryotic	B-protein
initiation	I-protein
factor	I-protein
3	I-protein
(	O
eIF3	B-protein
)	O
is	O
a	O
large	O
multisubunit	O
complex	O
that	O
stabilizes	O
the	O
ternary	O
complex	O
,	O
eIF2	B-protein
x	O
GTP	B-protein
x	O
tRNA	B-protein
(	I-protein
Met	I-protein
)	I-protein
i	I-protein
and	O
promotes	O
mRNA	O
binding	O
to	O
the	O
40	B-protein
S	I-protein
ribosomal	I-protein
subunit	I-protein
.	O
eIF3	B-protein
also	O
functions	O
as	O
a	O
ribosome	O
subunit	O
anti	O
-	O
association	O
factor	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
isotretinoin	O
on	O
HDL	B-protein
,	O
we	O
measured	O
HDL	B-protein
-	I-protein
C	I-protein
,	O
HDL	B-protein
phospholipids	O
(	O
HDL	B-protein
-	I-protein
PL	I-protein
)	O
,	O
apoprotein	B-protein
A1	I-protein
(	O
apo	B-protein
A	I-protein
-	I-protein
1	I-protein
)	O
,	O
and	O
HDL	B-protein
-	I-protein
C	I-protein
subfractions	O
(	O
HDL2	B-protein
-	I-protein
C	I-protein
and	O
HDL3	B-protein
-	I-protein
C	I-protein
)	O
in	O
24	O
healthy	O
,	O
male	O
patients	O
receiving	O
a	O
16	O
-	O
week	O
course	O
of	O
isotretinoin	O
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
/	O
day	O
)	O
for	O
treatment	O
of	O
severe	O
acne	O
vulgaris	O
.	O

These	O
results	O
indicate	O
that	O
patients	O
who	O
undergo	O
postoperative	O
irradiation	O
for	O
low	O
grade	O
spinal	O
astrocytomas	O
and	O
localized	O
spinal	O
ependymomas	O
achieve	O
excellent	O
survival	O
.	O

A	O
one	O
-	O
week	O
ulcer	O
therapy	O
with	O
atropine	O
and	O
Vikalin	O
(	O
Roter	O
)	O
led	O
to	O
a	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
reduction	O
of	O
the	O
nocturnal	O
proteolytic	O
activity	O
.	O

This	O
GAP	B-protein
activity	O
was	O
observed	O
in	O
3T3	O
-	O
L1	O
adipocyte	O
lysates	O
,	O
and	O
was	O
able	O
to	O
accelerate	O
the	O
hydrolysis	O
of	O
the	O
[	O
alpha	O
-	O
32P	O
]	O
GTP	O
bound	O
to	O
GST	B-protein
-	I-protein
Rab4	I-protein
into	O
[	O
alpha	O
-	O
32P	O
]	O
GDP	O
.	O

NF	B-protein
-	I-protein
kappa	I-protein
B	I-protein
/	I-protein
Rel	I-protein
transcription	I-protein
factors	I-protein
participate	O
in	O
the	O
activation	O
of	O
numerous	O
genes	O
involved	O
in	O
immune	O
regulation	O
/	O
inflammation	O
including	O
cytokines	O
,	O
cell	O
surface	O
receptors	O
,	O
adhesion	O
molecules	O
,	O
and	O
acute	O
phase	O
proteins	O
.	O

The	O
predicted	O
protein	O
,	O
Seb1p	B-protein
,	O
consists	O
of	O
82	O
amino	O
acids	O
and	O
contains	O
one	O
potential	O
membrane	O
-	O
spanning	O
region	O
at	O
the	O
C	O
-	O
terminus	O
but	O
no	O
N	O
-	O
terminal	O
signal	O
sequence	O
.	O

Droperidol	O
-	O
induced	O
extrapyramidal	O
symptoms	O
in	O
an	O
adolescent	O
following	O
strabismus	O
surgery	O
.	O

Northern	O
blot	O
analysis	O
revealed	O
the	O
expression	O
of	O
LIMK	B-protein
-	I-protein
1	I-protein
mRNA	I-protein
predominantly	O
in	O
the	O
brain	O
and	O
the	O
expression	O
of	O
LIMK	B-protein
-	I-protein
2	I-protein
mRNA	I-protein
in	O
various	O
tissues	O
in	O
the	O
rat	O
.	O

Cyclin	B-protein
-	I-protein
dependent	I-protein
kinase	I-protein
-	I-protein
2	I-protein
(	O
Cdk2	B-protein
)	O
forms	O
an	O
inactive	O
complex	O
with	O
cyclin	B-protein
D1	I-protein
since	O
Cdk2	B-protein
associated	O
with	O
cyclin	B-protein
D1	I-protein
is	O
not	O
phosphorylated	O
by	O
Cdk7	B-protein
-	I-protein
cyclin	I-protein
-	I-protein
H	I-protein
.	O

I	O
propose	O
that	O
their	O
gene	O
products	O
bind	O
to	O
the	O
chromatin	O
to	O
establish	O
or	O
maintain	O
a	O
proper	O
higher	O
order	O
structure	O
as	O
a	O
prerequisite	O
for	O
a	O
regulated	O
gene	O
expression	O
.	O

The	O
invasive	O
pattern	O
of	O
squamous	O
cell	O
carcinoma	O
in	O
the	O
mandibular	O
gingiva	O
.	O

Paraneoplastic	O
rheumatic	O
syndromes	O
.	O

The	O
distribution	O
of	O
the	O
various	O
repeats	O
suggests	O
its	O
organization	O
is	O
similar	O
to	O
the	O
beta	O
-	O
heterochromatic	O
regions	O
near	O
the	O
base	O
of	O
the	O
major	O
chromosome	O
arms	O
.	O

The	O
p34	B-protein
.	I-protein
8	I-protein
gene	I-protein
has	O
a	O
strong	O
codon	O
usage	O
bias	O
which	O
is	O
strikingly	O
different	O
from	O
that	O
of	O
the	O
polyhedrin	B-protein
gene	I-protein
.	O

There	O
was	O
an	O
increase	O
in	O
protein	O
binding	O
onto	O
this	O
element	O
only	O
after	O
peptide	O
treatment	O
.	O

The	O
purposes	O
of	O
this	O
study	O
were	O
1	O
)	O
to	O
examine	O
the	O
effect	O
of	O
high	O
intensity	O
,	O
low	O
frequency	O
transcutaneous	O
electrical	O
nerve	O
stimulation	O
at	O
auricular	O
acupuncture	O
points	O
on	O
experimental	O
pain	O
threshold	O
measured	O
at	O
the	O
wrist	O
and	O
2	O
)	O
to	O
determine	O
the	O
changes	O
in	O
effect	O
over	O
time	O
.	O

The	O
chloramphenicol	B-protein
-	I-protein
resistance	I-protein
transposon	I-protein
Tn4451	I-protein
undergoes	O
precise	O
conjugative	O
deletion	O
from	O
its	O
parent	O
plasmid	O
plP401	O
in	O
Clostridium	O
perfringens	O
and	O
precise	O
spontaneous	O
excision	O
from	O
multicopy	O
plasmids	O
in	O
Escherichia	O
coli	O
.	O

These	O
data	O
are	O
consistent	O
with	O
a	O
model	O
in	O
which	O
GATA	B-protein
-	I-protein
5	I-protein
performs	O
a	O
unique	O
temporally	O
and	O
spatially	O
restricted	O
function	O
in	O
the	O
embryonic	O
heart	O
and	O
lung	O
.	O

Mesial	O
temporal	O
sclerosis	O
.	O

The	O
Cili	B-protein
-	I-protein
2	I-protein
sequences	I-protein
possess	O
similarity	O
to	O
the	O
RNaseH	B-protein
domain	I-protein
of	O
Lian	B-protein
-	I-protein
Aa1	I-protein
,	O
a	O
mosquito	O
non	O
-	O
LTR	O
retrotransposon	O
.	O

Whole	O
bowel	O
irrigation	O
is	O
a	O
recently	O
described	O
technique	O
to	O
enhance	O
the	O
passage	O
of	O
drugs	O
already	O
beyond	O
the	O
pylorus	O
.	O

Heterogeneous	B-protein
nuclear	I-protein
ribonucleoprotein	I-protein
(	I-protein
hnRNP	I-protein
)	I-protein
core	I-protein
protein	I-protein
A1	I-protein
is	O
a	O
major	O
component	O
of	O
mammalian	B-protein
hnRNP	I-protein
40	I-protein
S	I-protein
particles	I-protein
.	O

Monkeys	O
were	O
evaluated	O
before	O
and	O
after	O
unilateral	O
and	O
serial	O
bilateral	O
removal	O
of	O
superior	O
temporal	O
cortex	O
.	O

Yeast	B-protein
U1	I-protein
snRNP	I-protein
is	O
considerably	O
more	O
complex	O
than	O
its	O
metazoan	O
counterpart	O
,	O
which	O
suggests	O
possible	O
differences	O
between	O
yeast	O
and	O
metazoa	O
in	O
early	O
splicing	O
events	O
.	O

Plasma	O
CCK	B-protein
levels	O
were	O
determined	O
at	O
regular	O
intervals	O
.	O

12	O
healthy	O
women	O
(	O
age	O
18	O
-	O
38	O
years	O
)	O
were	O
examined	O
using	O
the	O
2	O
-	O
hour	O
'	O
s	O
method	O
of	O
passive	O
leg	O
rising	O
(	O
PLR	O
)	O
in	O
follicular	O
(	O
FP	O
)	O
and	O
luteal	O
(	O
LP	O
)	O
phases	O
of	O
normal	O
ovulatory	O
cycle	O
.	O

E1A	B-protein
represses	O
apolipoprotein	B-protein
AI	I-protein
enhancer	I-protein
activity	O
in	O
liver	O
cells	O
through	O
a	O
pRb	O
-	O
and	O
CBP	O
-	O
independent	O
pathway	O
.	O

RESULTS	O
:	O
Circulating	O
leptin	B-protein
concentrations	O
in	O
AN	O
were	O
3	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
5	O
versus	O
7	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
2	O
ng	O
/	O
ml	O
in	O
control	O
subjects	O
.	O

In	O
addition	O
,	O
two	O
internal	O
promoters	O
,	O
PmiaA	B-protein
and	O
P1hfq	B-protein
were	O
identified	O
and	O
mapped	O
to	O
201	O
and	O
837	O
nucleotides	O
upstream	O
from	O
the	O
respective	O
translation	O
start	O
sites	O
.	O

Effects	O
of	O
alcoholism	O
on	O
the	O
family	O
.	O

These	O
results	O
were	O
superior	O
to	O
those	O
in	O
24	O
patients	O
with	O
conventional	O
end	O
-	O
to	O
-	O
end	O
sutures	O
on	O
clinical	O
testing	O
.	O

These	O
results	O
indicate	O
that	O
virulence	O
-	O
associated	O
genes	O
and	O
their	O
overall	O
chromosomal	O
arrangement	O
are	O
relatively	O
well	O
conserved	O
between	O
B	O
.	O
henselae	O
and	O
other	O
gram	O
-	O
negative	O
bacteria	O
such	O
as	O
A	O
.	O
tumefaciens	O
.	O

Effect	O
of	O
triftazin	O
and	O
aminazin	O
on	O
hippocampal	O
bioelectric	O
activity	O
.	O

Comparison	O
of	O
remnant	O
-	O
like	O
lipoprotein	O
particles	O
in	O
postmenopausal	O
women	O
with	O
and	O
without	O
coronary	O
artery	O
disease	O
and	O
in	O
men	O
with	O
coronary	O
artery	O
disease	O
.	O

One	O
phage	O
clone	O
contains	O
a	O
junction	O
between	O
alpha	O
satellite	O
DNA	O
and	O
a	O
novel	O
low	O
-	O
copy	O
repeated	O
sequence	O
.	O

The	O
yeast	B-protein
MMS2	I-protein
gene	I-protein
was	O
cloned	O
by	O
its	O
ability	O
to	O
complement	O
the	O
methyl	O
methanesulfonate	O
sensitivity	O
of	O
the	O
mms2	B-protein
-	I-protein
1	I-protein
mutant	I-protein
and	O
was	O
later	O
shown	O
to	O
be	O
involved	O
in	O
DNA	O
post	O
-	O
replication	O
repair	O
.	O

Biopsies	O
of	O
the	O
jejunal	O
mucosa	O
have	O
shown	O
abnormal	O
enzyme	O
activity	O
or	O
deficiencies	O
in	O
transport	O
mechanisms	O
.	O

Genes	O
belonging	O
to	O
the	O
ras	B-protein
superfamily	I-protein
encode	O
low	B-protein
-	I-protein
molecular	I-protein
-	I-protein
weight	I-protein
GTP	I-protein
/	I-protein
GDP	I-protein
-	I-protein
binding	I-protein
proteins	I-protein
that	O
are	O
highly	O
conserved	O
in	O
wide	O
variety	O
of	O
organisms	O
.	O

Four	O
forms	O
of	O
salmonellosis	O
were	O
recognised	O
in	O
feedlots	O
and	O
during	O
transport	O
by	O
sea	O
:	O
septicaemic	O
,	O
and	O
acute	O
,	O
subacute	O
and	O
chronic	O
enteric	O
.	O

A	O
cDNA	O
encoding	O
a	O
MYC	B-protein
-	I-protein
related	I-protein
DNA	I-protein
binding	I-protein
protein	I-protein
was	O
isolated	O
by	O
DNA	O
-	O
ligand	O
binding	O
screening	O
,	O
using	O
the	O
67	O
-	O
bp	O
region	O
as	O
a	O
probe	O
,	O
and	O
designated	O
rd22BP1	B-protein
.	O

Two	O
phosphopeptides	O
,	O
identified	O
as	O
RS	B-protein
-	I-protein
[	I-protein
32P	I-protein
]	I-protein
SGASGLLTSEHHSR	I-protein
and	O
S	B-protein
-	I-protein
[	I-protein
32P	I-protein
]	I-protein
SGASGLLTSEHHSR	I-protein
,	O
were	O
obtained	O
after	O
stoichiometric	O
phosphorylation	O
and	O
trypsinization	O
of	O
the	O
peptide	O
.	O

We	O
present	O
the	O
preliminary	O
results	O
obtained	O
on	O
36	O
patients	O
which	O
were	O
followed	O
for	O
a	O
mean	O
period	O
of	O
12	O
months	O
.	O

Moreover	O
,	O
expression	O
of	O
CBF1	B-protein
in	O
yeast	O
was	O
found	O
to	O
activate	O
transcription	O
of	O
reporter	O
genes	O
containing	O
the	O
C	B-protein
-	I-protein
repeat	I-protein
/	I-protein
DRE	I-protein
as	O
an	O
upstream	O
activator	O
sequence	O
but	O
not	O
mutant	O
versions	O
of	O
the	O
DNA	O
element	O
.	O

The	O
computer	O
-	O
programmed	O
cytocentrifuge	O
is	O
currently	O
most	O
popular	O
.	O

Levels	O
of	O
TSG	B-protein
-	I-protein
14	I-protein
protein	I-protein
(	O
also	O
termed	O
PTX	B-protein
-	I-protein
3	I-protein
)	O
become	O
elevated	O
in	O
the	O
serum	O
of	O
mice	O
and	O
humans	O
after	O
injection	O
with	O
bacterial	O
lipopolysaccharide	O
,	O
but	O
in	O
contrast	O
to	O
conventional	O
acute	O
phase	O
proteins	O
,	O
the	O
bulk	O
of	O
TSG	B-protein
-	I-protein
14	I-protein
synthesis	O
in	O
the	O
intact	O
organism	O
occurs	O
outside	O
the	O
liver	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
F	O
-	O
wave	O
may	O
be	O
elicited	O
in	O
motoneuron	O
of	O
different	O
depolarization	O
threshold	O
but	O
primarily	O
in	O
larger	O
and	O
faster	O
nerve	O
fibers	O
,	O
with	O
a	O
lower	O
threshold	O
of	O
depolarization	O
.	O

Microcirculatory	O
oxygenation	O
and	O
shunting	O
in	O
sepsis	O
and	O
shock	O
.	O

Thus	O
,	O
the	O
characterization	O
of	O
the	O
promoter	O
region	O
should	O
help	O
to	O
define	O
regulatory	O
elements	O
that	O
control	O
neuron	O
-	O
specific	O
and	O
developmental	O
expression	O
of	O
the	O
MAP1B	B-protein
gene	I-protein
.	O

The	O
induced	O
respiratory	O
burst	O
was	O
investigated	O
by	O
the	O
intracellular	O
oxidative	O
transformation	O
of	O
dihydrorhodamine	O
123	O
to	O
the	O
fluorescent	O
dye	O
rhodamine	O
123	O
via	O
flow	O
cytometry	O
.	O

The	O
results	O
suggest	O
that	O
the	O
bulbospinal	O
micturition	O
reflex	O
evoked	O
by	O
bladder	O
filling	O
and	O
L	O
-	O
dopa	O
involves	O
a	O
descending	O
pathway	O
where	O
transmission	O
is	O
partly	O
mediated	O
by	O
spinal	B-protein
alpha	I-protein
1	I-protein
-	I-protein
adrenoceptors	I-protein
.	O

Although	O
isl	B-protein
-	I-protein
1	I-protein
binds	O
to	O
both	O
the	O
insulin	B-protein
and	O
amylin	B-protein
gene	I-protein
promoter	I-protein
elements	I-protein
in	O
vitro	O
,	O
these	O
sequences	O
display	O
marked	O
differences	O
in	O
their	O
relative	O
transcriptional	O
properties	O
when	O
ligated	O
adjacent	O
to	O
a	O
heterologous	O
promoter	O
and	O
transfected	O
into	O
InR1	O
-	O
G9	O
islet	O
cells	O
.	O

RESULTS	O
:	O
The	O
subjects	O
in	O
the	O
augmented	O
feedback	O
group	O
significantly	O
reduced	O
their	O
peak	O
vertical	O
ground	O
reaction	O
force	O
in	O
both	O
post	O
-	O
test	O
conditions	O
(	O
2	O
-	O
minute	O
post	O
-	O
test	O
reduction	O
,	O
0	O
.	O
85	O
+	O
/	O
-	O
0	O
.	O
62	O
;	O
1	O
-	O
week	O
post	O
-	O
test	O
reduction	O
,	O
0	O
.	O
74	O
+	O
/	O
-	O
0	O
.	O
58	O
)	O
as	O
compared	O
to	O
the	O
sensory	O
,	O
control	O
I	O
,	O
and	O
control	O
II	O
feedback	O
groups	O
.	O

Study	O
of	O
antinuclear	B-protein
autoantibodies	I-protein
by	O
immunofluorescence	O
technic	O
in	O
collagen	B-protein
diseases	O
.	O

Effects	O
of	O
negative	O
pleural	O
pressure	O
on	O
left	O
ventricular	O
hemodynamics	O
.	O

These	O
data	O
indicate	O
that	O
RNK	B-protein
-	I-protein
Met	I-protein
-	I-protein
1	I-protein
is	O
a	O
serine	B-protein
protease	I-protein
with	O
unique	O
activity	O
that	O
is	O
expressed	O
in	O
the	O
granules	O
of	O
large	O
granular	O
lymphocytes	O
.	O

No	O
effect	O
of	O
the	O
intervention	O
on	O
depression	O
scores	O
was	O
found	O
.	O

Ruddell	O
,	O
M	O
.	O

Together	O
,	O
these	O
results	O
identify	O
HPK1	B-protein
as	O
a	O
new	O
component	O
of	O
TCR	B-protein
signaling	O
.	O

Nine	O
cases	O
of	O
GBS	O
and	O
five	O
of	O
TM	O
reported	O
to	O
the	O
active	O
AFP	O
surveillance	O
were	O
not	O
found	O
in	O
the	O
hospital	O
searches	O
.	O

The	O
B	O
-	O
oligomer	O
of	O
pertussis	B-protein
toxin	I-protein
deactivates	O
CC	B-protein
chemokine	I-protein
receptor	I-protein
5	I-protein
and	O
blocks	O
entry	O
of	O
M	O
-	O
tropic	O
HIV	O
-	O
1	O
strains	O
.	O

The	O
mass	O
-	O
specific	O
resting	O
minute	O
ventilation	O
(	O
E	O
)	O
and	O
the	O
ventilatory	O
equivalent	O
(	O
E	O
/	O
(	O
O	O
(	O
2	O
)	O
)	O
)	O
were	O
approximately	O
the	O
same	O
at	O
the	O
two	O
ages	O
,	O
with	O
a	O
breathing	O
pattern	O
significantly	O
deeper	O
and	O
slower	O
at	O
day	O
1	O
.	O

The	O
different	O
holoenzyme	B-protein
RNA	I-protein
polymerases	I-protein
generated	O
upon	O
reconstituting	O
these	O
mutants	O
independently	O
with	O
core	B-protein
RNA	I-protein
polymerase	I-protein
(	O
alpha2beta	B-protein
beta	I-protein
'	I-protein
)	O
have	O
shown	O
reduced	O
transcriptional	O
activity	O
in	O
comparison	O
to	O
the	O
enzyme	O
containing	O
wild	B-protein
-	I-protein
type	I-protein
sigma	I-protein
factor	I-protein
.	O

Thyrotropin	O
-	O
releasing	O
hormone	O
-	O
induced	O
contraction	O
of	O
urethral	O
and	O
vaginal	O
muscle	O
.	O

Contacts	O
between	O
Bacillus	O
subtilis	O
catabolite	O
regulatory	O
protein	O
CcpA	B-protein
and	O
amyO	B-protein
target	O
site	O
.	O

Thus	O
,	O
the	O
tri	B-protein
-	I-protein
snRNP	I-protein
-	I-protein
specific	I-protein
27K	I-protein
protein	I-protein
could	O
potentially	O
be	O
involved	O
in	O
SR	B-protein
protein	O
-	O
mediated	O
protein	O
/	O
protein	O
interactions	O
and	O
,	O
additionally	O
,	O
its	O
phosphorylation	O
state	O
could	O
modulate	O
pre	O
-	O
mRNA	O
splicing	O
.	O

A	O
comparison	O
of	O
the	O
Flavobacterium	O
glycosylasparaginase	B-protein
with	O
a	O
mammalian	O
glycosylasparaginase	B-protein
revealed	O
30	O
%	O
structural	O
identity	O
and	O
60	O
%	O
overall	O
similarity	O
between	O
the	O
prokaryotic	O
and	O
eukaryotic	O
forms	O
of	O
the	O
enzyme	O
.	O

This	O
region	O
,	O
however	O
,	O
contains	O
a	O
CCAATC	O
box	O
in	O
the	O
reverse	O
complement	O
and	O
several	O
GC	O
boxes	O
that	O
are	O
recognition	O
sites	O
for	O
SP1	B-protein
.	O

Furthermore	O
,	O
the	O
amount	O
of	O
tRNA	B-protein
(	I-protein
3Lys	I-protein
)	I-protein
that	O
was	O
placed	O
onto	O
viral	O
RNA	O
in	O
mutated	O
viruses	O
was	O
significantly	O
less	O
than	O
that	O
placed	O
in	O
the	O
wild	O
-	O
type	O
virus	O
.	O

All	O
62	O
isolates	O
were	O
resistant	O
to	O
lincomycin	O
,	O
colistin	O
,	O
nystatin	O
,	O
amphotericin	O
B	O
,	O
trimethoprim	O
lactate	O
,	O
polymyxin	O
B	O
,	O
and	O
anisomycin	O
.	O

These	O
results	O
indicate	O
that	O
significant	O
pulmonary	O
metabolism	O
of	O
5	O
-	O
HT	O
followed	O
by	O
efflux	O
of	O
5	O
-	O
HIAA	O
into	O
venous	O
output	O
occurs	O
during	O
single	O
-	O
pass	O
circulation	O
.	O

Thirty	O
seven	O
patients	O
(	O
amitriptyline	O
n	O
=	O
16	O
,	O
moclobemide	O
n	O
=	O
21	O
)	O
completed	O
the	O
six	O
week	O
protocol	O
,	O
which	O
was	O
conducted	O
under	O
double	O
blind	O
conditions	O
.	O

Evidence	O
for	O
the	O
promoting	O
role	O
of	O
the	O
intra	B-protein
-	I-protein
uterine	I-protein
kinin	I-protein
release	O
in	O
the	O
development	O
of	O
late	O
hypertonic	O
saline	O
-	O
induced	O
abortion	O
.	O

Cross	O
-	O
linking	O
FcalphaR	B-protein
on	O
wt	B-protein
-	I-protein
ITAM	I-protein
or	O
IIA	B-protein
-	I-protein
ITAM	I-protein
cells	O
triggered	O
equivalent	O
PI	O
3	O
-	O
kinase	O
-	O
dependent	O
activation	O
of	O
PKBalpha	B-protein
.	O

We	O
conclude	O
that	O
cephalothin	O
clearance	O
of	O
S	O
.	O
aureus	O
from	O
a	O
site	O
accessible	O
to	O
phagocytes	O
was	O
delayed	O
when	O
compared	O
to	O
a	O
phagocyte	O
-	O
inaccessible	O
site	O
.	O

Recently	O
,	O
we	O
discovered	O
that	O
alanine	O
substitutions	O
of	O
the	O
active	O
center	O
cleft	O
residues	O
significantly	O
impair	O
the	O
depurinating	O
and	O
ribosome	O
inhibitory	O
activity	O
of	O
PAP	B-protein
.	O

The	O
decrements	O
in	O
cerebrovascular	O
resistance	O
induced	O
by	O
hexamethonium	O
,	O
in	O
mm	O
Hg	O
ml	O
(	O
-	O
1	O
)	O
.	O
min	O
(	O
-	O
1	O
)	O
,	O
were	O
:	O
under	O
control	O
.	O

The	O
resulting	O
integrated	O
physical	O
,	O
genetic	O
,	O
and	O
cytogenetic	O
map	O
constitutes	O
a	O
resource	O
for	O
the	O
characterization	O
of	O
genes	O
that	O
may	O
be	O
involved	O
in	O
the	O
WAGR	O
syndrome	O
.	O

In	O
Experiment	O
2	O
,	O
we	O
again	O
used	O
classification	O
,	O
but	O
the	O
fixed	O
standard	O
75	O
was	O
not	O
at	O
the	O
center	O
of	O
the	O
range	O
of	O
target	O
numbers	O
(	O
20	O
,	O
21	O
,	O
.	O
.	O
.	O

Leukemia	O
in	O
twins	O
:	O
world	O
-	O
wide	O
review	O
of	O
clinical	O
cases	O
.	O

The	O
TUP1	B-protein
gene	I-protein
was	O
isolated	O
in	O
a	O
screen	O
for	O
genes	O
that	O
regulate	O
mating	O
type	O
(	O
V	O
.	O
L	O
.	O

The	O
Caenorhabditis	B-protein
elegans	I-protein
death	I-protein
susceptibility	I-protein
gene	I-protein
,	O
ced	B-protein
-	I-protein
3	I-protein
,	O
has	O
a	O
number	O
of	O
homologs	O
in	O
vertebrate	O
species	O
,	O
including	O
interleukin	B-protein
-	I-protein
1	I-protein
beta	I-protein
(	I-protein
IL	I-protein
-	I-protein
1	I-protein
beta	I-protein
)	I-protein
-	I-protein
converting	I-protein
enzyme	I-protein
(	O
ICE	B-protein
)	O
,	O
Ich	B-protein
-	I-protein
1long	I-protein
,	O
and	O
CPP32	B-protein
.	O

Transcription	O
factors	O
of	O
the	O
Stat	B-protein
family	I-protein
are	O
controlled	O
by	O
protein	B-protein
kinases	I-protein
.	O

A	O
novel	O
,	O
testis	B-protein
-	I-protein
specific	I-protein
mRNA	I-protein
transcript	I-protein
encoding	O
an	O
NH2	B-protein
-	I-protein
terminal	I-protein
truncated	I-protein
nitric	I-protein
-	I-protein
oxide	I-protein
synthase	I-protein
.	O
mRNA	O
diversity	O
represents	O
a	O
major	O
theme	O
of	O
neuronal	B-protein
nitric	I-protein
-	I-protein
oxide	I-protein
synthase	I-protein
(	O
nNOS	B-protein
)	O
gene	O
expression	O
in	O
somatic	O
cells	O
/	O
tissues	O
.	O

The	O
isoform	O
,	O
designated	O
HDAC9a	B-protein
,	O
is	O
132	O
aa	O
shorter	O
at	O
the	O
C	O
terminus	O
than	O
HDAC9	B-protein
.	O

The	O
ESEG	O
'	O
s	O
are	O
a	O
direct	O
result	O
of	O
the	O
NEXT	O
study	O
.	O

After	O
6	O
months	O
,	O
definite	O
improvement	O
in	O
strength	O
occurred	O
in	O
4	O
of	O
7	O
carnitine	O
-	O
treated	O
patients	O
and	O
in	O
none	O
of	O
7	O
controls	O
.	O

Fifty	O
-	O
seven	O
patients	O
aged	O
<	O
55	O
years	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
in	O
second	O
or	O
third	O
bone	O
marrow	O
(	O
BM	O
)	O
relapse	O
or	O
refractory	O
to	O
first	O
-	O
line	O
therapy	O
were	O
enrolled	O
in	O
an	O
Italian	O
cooperative	O
study	O
.	O

After	O
gamma	O
-	O
irradiation	O
,	O
the	O
majority	O
of	O
F9	O
cells	O
undergo	O
apoptosis	O
implying	O
that	O
wt	B-protein
-	I-protein
p53	I-protein
likely	O
triggers	O
pro	O
-	O
apoptotic	O
gene	O
expression	O
in	O
DNA	O
damaged	O
cells	O
.	O

While	O
fusion	O
to	O
the	O
N	O
-	O
terminus	O
required	O
a	O
linker	O
to	O
become	O
surface	O
accessible	O
,	O
both	O
fusion	O
to	O
the	O
N	O
-	O
terminus	O
and	O
to	O
the	O
C	O
-	O
terminus	O
was	O
compatible	O
with	O
particle	O
assembly	O
and	O
preserved	O
the	O
native	O
antigenicity	O
and	O
immunogenicity	O
of	O
HBcAg	B-protein
.	O

Grade	O
3	O
mucositis	O
was	O
reported	O
in	O
1	O
patient	O
.	O

Multiparous	O
women	O
presented	O
higher	O
BMI	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
PBF	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
compared	O
with	O
primi	O
-	O
and	O
nulliparous	O
groups	O
.	O

Isolation	O
by	O
PCR	O
of	O
a	O
cDNA	O
clone	O
from	O
pea	O
petals	O
with	O
similarity	O
to	O
petunia	O
and	O
wheat	B-protein
zinc	I-protein
finger	I-protein
proteins	I-protein
.	O

Gastritis	O
score	O
was	O
significantly	O
lower	O
in	O
nodminus	O
sign	O
/	O
CagAminus	O
signchildren	O
than	O
in	O
nod	O
+	O
/	O
CagAminus	O
sign	O
(	O
p	O
=	O
.	O
004	O
)	O
,	O
nodminus	O
sign	O
/	O
CagA	O
+	O
(	O
p	O
=	O
.	O
002	O
)	O
and	O
nod	O
+	O
/	O
CagA	O
+	O
(	O
p	O
<	O
.	O
001	O
)	O
,	O
both	O
in	O
the	O
antrum	O
and	O
corpus	O
.	O

The	O
227	O
-	O
to	O
-	O
239	O
region	O
blocked	O
ADR1	B-protein
activity	O
independently	O
of	O
the	O
TAD	B-protein
present	O
on	O
ADR1	B-protein
,	O
ADR1	B-protein
DNA	O
binding	O
,	O
and	O
specific	O
ADH2	B-protein
promoter	I-protein
sequences	I-protein
.	O

A	O
polypeptide	O
chain	O
of	O
34	O
residues	O
of	O
the	O
deduced	O
yeast	O
amino	O
acid	O
sequence	O
closely	O
resembles	O
a	O
peptide	O
sequence	O
at	O
the	O
ADP	O
binding	O
site	O
of	O
bovine	B-protein
muscle	I-protein
pyruvate	I-protein
kinase	I-protein
.	O

The	O
enzymic	O
hydrolysis	O
of	O
urea	O
produces	O
ammonia	O
which	O
causes	O
a	O
vivid	O
yellow	O
to	O
purple	O
colour	O
change	O
in	O
the	O
pH	O
indicator	O
.	O

ZIOS	O
was	O
significantly	O
more	O
sensitive	O
than	O
all	O
subsequent	O
methods	O
,	O
and	O
Ptc	O
,	O
O2	O
was	O
significantly	O
more	O
sensitive	O
than	O
FEV1	O
.	O

Nuclear	B-protein
hormone	I-protein
receptors	I-protein
(	O
NRs	B-protein
)	O
are	O
ligand	O
-	O
inducible	O
transcription	O
factors	O
that	O
mediate	O
critical	O
functions	O
in	O
many	O
species	O
.	O

OBJECTIVES	O
:	O
The	O
objective	O
of	O
this	O
review	O
was	O
to	O
assess	O
the	O
effects	O
of	O
prophylactic	O
prostaglandin	O
use	O
in	O
the	O
third	O
stage	O
of	O
labour	O
.	O

Ethylene	O
is	O
involved	O
in	O
endosperm	O
rupture	O
and	O
high	O
-	O
level	O
betaGLU	B-protein
I	I-protein
expression	O
;	O
but	O
,	O
it	O
does	O
not	O
affect	O
the	O
spatial	O
and	O
temporal	O
pattern	O
of	O
betaGLU	B-protein
I	I-protein
expression	O
.	O

The	O
presence	O
of	O
visna	O
-	O
maedi	O
in	O
Italy	O
is	O
reported	O
for	O
the	O
first	O
time	O
.	O

The	O
normal	O
cell	O
cycle	O
is	O
regulated	O
by	O
several	O
molecules	O
,	O
such	O
as	O
the	O
tumor	B-protein
-	I-protein
suppressor	I-protein
protein	I-protein
pRb	I-protein
,	O
the	O
G1	B-protein
cyclins	I-protein
,	O
the	O
cyclin	B-protein
-	I-protein
dependent	I-protein
kinases	I-protein
,	O
and	O
their	O
inhibitors	O
.	O

Fast	O
continuous	O
expansion	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
binding	O
of	O
the	O
GA	B-protein
-	I-protein
binding	I-protein
protein	I-protein
(	O
GABP	B-protein
)	O
to	O
ets	B-protein
sequence	I-protein
motifs	I-protein
within	O
each	O
repeated	O
unit	O
is	O
required	O
for	O
transcriptional	O
activation	O
of	O
the	O
COXIV	B-protein
promoter	I-protein
.	O

(	O
1997	O
)	O
Science	O
275	O
,	O
1927	O
-	O
1930	O
)	O
.	O

Overall	O
,	O
these	O
findings	O
demonstrate	O
that	O
mutations	O
E768D	O
and	O
V804L	O
are	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
that	O
confer	O
to	O
the	O
long	B-protein
RET	I-protein
isoform	I-protein
the	O
capacity	O
to	O
exert	O
a	O
biological	O
effect	O
,	O
although	O
these	O
mutations	O
are	O
more	O
weakly	O
activating	O
than	O
the	O
MEN2A	B-protein
and	O
MEN2B	B-protein
mutations	O
.	O

Several	O
of	O
the	O
exon	O
boundaries	O
correspond	O
to	O
the	O
boundaries	O
of	O
functional	O
domains	O
in	O
the	O
p55	B-protein
protein	I-protein
.	O

HS	O
inducibility	O
required	O
the	O
HSE	B-protein
which	O
was	O
bound	O
by	O
HS	B-protein
transcription	I-protein
factor	I-protein
-	I-protein
1	I-protein
(	I-protein
HSF	I-protein
-	I-protein
1	I-protein
)	I-protein
present	O
in	O
extracts	O
prepared	O
from	O
cells	O
exposed	O
to	O
HS	O
.	O

Comprehensive	O
care	O
of	O
the	O
patient	O
exposed	O
to	O
a	O
human	O
teratogen	O
may	O
also	O
include	O
discussion	O
of	O
prenatal	O
diagnostic	O
procedures	O
and	O
other	O
pregnancy	O
management	O
options	O
.	O

Therefore	O
,	O
both	O
the	O
Chilean	O
and	O
the	O
Japanese	O
samples	O
collected	O
in	O
high	O
-	O
risk	O
areas	O
showed	O
higher	O
mutagenic	O
rates	O
than	O
the	O
Japanese	O
ones	O
in	O
a	O
low	O
-	O
risk	O
area	O
,	O
with	O
a	O
statistical	O
significance	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
chi	O
-	O
square	O
test	O
)	O
.	O

Counter	O
-	O
current	O
heat	O
exchange	O
in	O
the	O
respiratory	O
passages	O
:	O
effect	O
on	O
water	O
and	O
heat	O
balance	O
.	O

Both	O
mutant	O
receptors	O
were	O
expressed	O
on	O
the	O
cell	O
surface	O
and	O
bound	O
insulin	B-protein
normally	O
,	O
but	O
showed	O
markedly	O
impaired	O
autophosphorylation	O
in	O
response	O
to	O
insulin	B-protein
.	O

Marked	O
sedative	O
activity	O
was	O
observed	O
with	O
9	O
-	O
methoxy	O
-	O
5	O
-	O
phenylpyrrolo	O
[	O
2	O
,	O
1	O
-	O
d	O
]	O
[	O
1	O
,	O
5	O
]	O
benzothiazepin	O
-	O
6	O
,	O
6	O
-	O
dioxide	O
(	O
NF19	O
)	O
and	O
9	O
-	O
chloro	O
-	O
5	O
-	O
p	O
-	O
nitrophenylpyrrolo	O
[	O
2	O
,	O
1	O
-	O
d	O
]	O
[	O
1	O
,	O
5	O
]	O
benzothiazepin	O
-	O
6	O
,	O
6	O
-	O
dioxide	O
(	O
NF20	O
)	O
.	O

The	O
mouse	O
extracellular	B-protein
signal	I-protein
-	I-protein
regulated	I-protein
kinase	I-protein
2	I-protein
gene	I-protein
.	O

Interaction	O
of	O
H	B-protein
-	I-protein
2Eb	I-protein
with	O
an	O
IAP	B-protein
retrotransposon	I-protein
in	O
the	O
A20	O
/	O
2J	O
B	O
cell	O
lymphoma	O
.	O

The	O
Lp	B-protein
mouse	I-protein
mutant	I-protein
provides	O
a	O
model	O
for	O
the	O
severe	O
human	O
neural	O
tube	O
defect	O
(	O
NTD	O
)	O
,	O
cranio	O
-	O
rachischisis	O
.	O

These	O
effects	O
were	O
not	O
seen	O
with	O
SHIP2	B-protein
possessing	O
a	O
mutation	O
in	O
the	O
SH2	B-protein
domain	I-protein
(	O
R47G	B-protein
)	O
.	O

Plasma	O
concentrations	O
of	O
atracurium	O
and	O
laudanosine	O
were	O
0	O
.	O
73	O
-	O
3	O
.	O
11	O
micrograms	O
ml	O
-	O
1	O
and	O
0	O
.	O
48	O
-	O
8	O
.	O
65	O
micrograms	O
ml	O
-	O
1	O
,	O
respectively	O
;	O
CSF	O
concentration	O
of	O
laudanosine	O
was	O
70	O
-	O
440	O
ng	O
ml	O
-	O
1	O
.	O

These	O
findings	O
suggest	O
that	O
intraarterial	O
neoadjuvant	O
chemotherapy	O
should	O
be	O
effective	O
on	O
advanced	O
cervical	O
cancer	O
.	O

Distinguishing	O
roles	O
of	O
the	O
membrane	O
-	O
cytoskeleton	O
and	O
cadherin	B-protein
mediated	O
cell	O
-	O
cell	O
adhesion	O
in	O
generating	O
different	O
Na	B-protein
+	I-protein
,	I-protein
K	I-protein
(	I-protein
+	I-protein
)	I-protein
-	I-protein
ATPase	I-protein
distributions	O
in	O
polarized	O
epithelia	O
.	O

These	O
results	O
suggest	O
that	O
gluconeogenic	O
genes	O
are	O
derepressed	O
upon	O
binding	O
of	O
Cat8p	B-protein
,	O
whose	O
synthesis	O
depends	O
on	O
the	O
release	O
of	O
Cat4p	B-protein
(	O
Mig1p	B-protein
)	O
from	O
the	O
CAT8	B-protein
promoter	I-protein
.	O

The	O
interaction	O
of	O
AF	B-protein
-	I-protein
1	I-protein
with	O
proteins	O
that	O
regulate	O
distinct	O
steps	O
of	O
transcription	O
may	O
provide	O
a	O
mechanism	O
for	O
synergistic	O
activation	O
of	O
gene	O
expression	O
by	O
AF	B-protein
-	I-protein
1	I-protein
.	O

The	O
N	O
-	O
terminal	O
portion	O
of	O
Notch	B-protein
(	I-protein
IC	I-protein
)	I-protein
inhibited	O
p50	B-protein
DNA	O
binding	O
and	O
interacted	O
specifically	O
with	O
p50	B-protein
subunit	I-protein
,	O
not	O
p65	B-protein
of	O
NF	B-protein
-	I-protein
kappaB	I-protein
.	O

2	O
cases	O
of	O
type	O
II	O
tyrosinosis	O
(	O
Richner	O
-	O
Hanhart	O
syndrome	O
)	O
.	O

Expression	O
of	O
the	O
human	O
T	B-protein
cell	I-protein
receptor	I-protein
(	I-protein
TCR	I-protein
)	I-protein
alpha	I-protein
gene	I-protein
is	O
regulated	O
by	O
a	O
T	O
cell	O
-	O
specific	O
transcriptional	O
enhancer	O
that	O
is	O
located	O
4	O
.	O
5	O
kilobases	O
(	O
kb	O
)	O
3	O
'	O
to	O
the	O
C	B-protein
alpha	I-protein
gene	I-protein
segment	I-protein
.	O

Infectious	O
mutant	O
virus	O
progeny	O
was	O
obtained	O
only	O
on	O
complementing	O
gK	O
-	O
expressing	O
cells	O
,	O
suggesting	O
that	O
gK	B-protein
has	O
an	O
important	O
function	O
in	O
the	O
replication	O
cycle	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
the	O
protein	O
in	O
the	O
region	O
of	O
the	O
specificity	O
pocket	O
is	O
similar	O
to	O
that	O
of	O
S	B-protein
.	I-protein
griseus	I-protein
proteases	I-protein
A	I-protein
,	I-protein
B	I-protein
,	I-protein
and	I-protein
C	O
.	O

The	O
prevalence	O
and	O
incidence	O
of	O
human	O
immunodeficiency	O
virus	O
types	O
1	O
and	O
2	O
(	O
HIV	O
-	O
1	O
,	O
HIV	O
-	O
2	O
)	O
,	O
human	O
T	O
-	O
lymphotropic	O
virus	O
types	O
I	O
and	O
II	O
(	O
HTLV	O
-	O
I	O
/	O
II	O
)	O
,	O
and	O
syphilitic	O
infections	O
and	O
the	O
association	O
between	O
these	O
infections	O
were	O
determined	O
in	O
a	O
cohort	O
of	O
police	O
officers	O
in	O
Guinea	O
-	O
Bissau	O
.	O

As	O
expected	O
,	O
the	O
heparin	O
did	O
produce	O
increased	O
recalcification	O
times	O
and	O
the	O
development	O
of	O
occasional	O
subcutaneous	O
hematomas	O
.	O

Expression	O
of	O
thiamin	B-protein
biosynthetic	I-protein
genes	I-protein
(	O
thiCOGE	B-protein
)	O
and	O
production	O
of	O
symbiotic	B-protein
terminal	I-protein
oxidase	I-protein
cbb3	I-protein
in	O
Rhizobium	O
etli	O
.	O

In	O
this	O
regard	O
,	O
we	O
have	O
recently	O
observed	O
that	O
a	O
constitutively	O
active	O
G	B-protein
protein	I-protein
-	I-protein
coupled	I-protein
receptor	I-protein
(	O
GPCR	B-protein
)	O
encoded	O
by	O
the	O
Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpes	O
virus	O
(	O
KSHV	O
)	O
/	O
human	O
herpes	O
virus	O
8	O
is	O
oncogenic	O
and	O
stimulates	O
angiogenesis	O
by	O
increasing	O
the	O
secretion	O
of	O
vascular	B-protein
endothelial	I-protein
growth	I-protein
factor	I-protein
(	O
VEGF	B-protein
)	O
,	O
which	O
is	O
a	O
key	O
angiogenic	O
stimulator	O
and	O
a	O
critical	O
mitogen	O
for	O
the	O
development	O
of	O
Kaposi	O
'	O
s	O
sarcoma	O
.	O

Selected	O
topics	O
in	O
laboratory	O
animal	O
medicine	O
.	O

II	O
.	O

These	O
regions	O
may	O
be	O
differentially	O
involved	O
in	O
tissue	O
-	O
specificity	O
,	O
and	O
/	O
or	O
circadian	O
regulation	O
,	O
of	O
the	O
human	B-protein
hPer1	I-protein
gene	I-protein
transcription	O
.	O

Polyclonal	O
antiserum	O
generated	O
to	O
the	O
fusion	O
protein	O
was	O
capable	O
of	O
detecting	O
42	O
-	O
and	O
46	O
-	O
kilodalton	O
polypeptides	O
from	O
virus	O
particles	O
;	O
both	O
polypeptides	O
were	O
also	O
shown	O
to	O
contain	O
HBsAg	B-protein
determinants	I-protein
.	O

The	O
LA	O
50s	O
derived	O
from	O
this	O
combined	O
data	O
when	O
compared	O
with	O
our	O
earlier	O
series	O
from	O
1965	O
to	O
1970	O
also	O
did	O
not	O
show	O
a	O
significant	O
change	O
in	O
mortality	O
.	O

The	O
amount	O
of	O
drained	O
effusion	O
was	O
measured	O
,	O
and	O
fluid	O
was	O
sent	O
for	O
diagnostic	O
assessment	O
.	O

Asymptomatic	O
bacteriospermia	O
and	O
fertility	O
.	O

There	O
was	O
no	O
difference	O
in	O
plasma	O
concentrations	O
of	O
PGI2	O
(	O
figure	O
4	O
)	O
and	O
TxA2	O
in	O
patients	O
with	O
normal	O
blood	O
pressure	O
,	O
mild	O
preeclampsia	O
and	O
hypotension	O
,	O
whereas	O
in	O
severe	O
preeclampsia	O
,	O
the	O
plasma	O
concentration	O
of	O
PGI2	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
of	O
TxA2	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Labial	O
bar	O
.	O

Reperfusion	O
with	O
normal	O
blood	O
in	O
the	O
beating	O
,	O
working	O
hearts	O
caused	O
extensive	O
structural	O
damage	O
,	O
reduced	O
reflow	O
,	O
and	O
failed	O
to	O
restore	O
contractility	O
in	O
any	O
instance	O
(	O
-	O
27	O
%	O
systolic	O
shortening	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

GCD10	B-protein
was	O
first	O
identified	O
genetically	O
as	O
a	O
translational	O
repressor	O
of	O
GCN4	B-protein
.	O

Analysis	O
of	O
a	O
Mac1p	B-protein
mutant	I-protein
,	O
refractile	O
for	O
copper	O
-	O
dependent	O
repression	O
of	O
the	O
Cu	B-protein
(	I-protein
I	I-protein
)	I-protein
transport	I-protein
genes	I-protein
,	O
showed	O
an	O
aberrant	O
pattern	O
of	O
CUP1	B-protein
expression	O
and	O
copper	O
sensitivity	O
.	O

French	O
,	O
M	O
.	O

Stromelysin	B-protein
-	I-protein
1	I-protein
,	O
matrix	B-protein
metalloproteinase	I-protein
-	I-protein
3	I-protein
(	O
MMP	B-protein
-	I-protein
3	I-protein
)	O
,	O
is	O
an	O
important	O
endopeptidase	B-protein
selectively	O
expressed	O
by	O
somatic	O
cells	O
in	O
organ	O
tissues	O
.	O

A	O
soap	O
and	O
water	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
solution	O
effectively	O
decontaminated	O
powdered	O
stratum	O
corneum	O
.	O

Each	O
repeat	O
consists	O
of	O
12	O
nt	O
,	O
coding	O
for	O
the	O
reiterated	O
sequence	O
,	O
K	B-protein
/	I-protein
NPAG	I-protein
.	O

Purification	O
of	O
MvaT	B-protein
enriched	O
for	O
two	O
polypeptides	O
of	O
approximate	O
molecular	O
mass	O
15	O
kDa	O
and	O
16	O
kDa	O
,	O
designated	O
P15	B-protein
and	O
P16	B-protein
.	O

The	O
Asian	O
mouse	O
Mus	O
castaneus	O
is	O
resistant	O
to	O
infection	O
by	O
the	O
polytropic	O
mink	O
cell	O
focus	O
-	O
inducing	O
(	O
MCF	O
)	O
subgroup	O
of	O
murine	O
leukemia	O
viruses	O
(	O
MuLVs	O
)	O
.	O

The	O
10	O
kDa	O
polypeptide	O
was	O
phosphorylated	O
in	O
vitro	O
by	O
incubating	O
wheat	O
etioplast	O
membranes	O
with	O
[	O
gamma	O
32P	O
]	O
ATP	O
.	O

The	O
RMRI	O
was	O
tested	O
for	O
interrater	O
reliability	O
using	O
three	O
simulated	O
and	O
10	O
actual	O
patients	O
.	O

The	O
rat	O
incisor	O
is	O
an	O
excellent	O
model	O
system	O
in	O
which	O
to	O
study	O
amelgenesis	O
.	O

Haploid	O
cells	O
of	O
mating	O
type	O
A	O
of	O
the	O
basidiomycetous	O
yeast	O
Rhodosporidium	O
toruloides	O
secrete	O
a	O
mating	O
pheromone	O
,	O
rhodotorucine	B-protein
A	I-protein
,	O
which	O
is	O
an	O
undecapeptide	O
containing	O
S	O
-	O
farnesyl	O
cysteine	O
at	O
its	O
carboxy	O
terminus	O
.	O

Magnetic	O
trapping	O
of	O
spin	O
-	O
polarized	O
atomic	O
hydrogen	O
.	O

The	O
transcription	O
and	O
alternative	O
splicing	O
of	O
human	B-protein
ORL1	I-protein
and	O
GAIP	B-protein
are	O
cell	O
-	O
type	O
specific	O
.	O

In	O
the	O
single	O
case	O
the	O
restoration	O
of	O
a	O
structured	O
daily	O
routine	O
represents	O
the	O
presupposition	O
for	O
a	O
cognitive	O
therapy	O
.	O

Exercise	O
training	O
has	O
become	O
increasingly	O
important	O
in	O
the	O
treatment	O
of	O
heart	O
failure	O
patients	O
.	O

The	O
similar	O
phenotypes	O
of	O
bur6	B-protein
and	O
bur3	B-protein
(	O
mot1	B-protein
)	O
mutations	O
suggest	O
that	O
Bur6p	B-protein
and	O
Mot1p	B-protein
have	O
related	O
,	O
but	O
not	O
identical	O
,	O
functions	O
in	O
modulating	O
the	O
activity	O
of	O
the	O
general	O
transcription	O
machinery	O
in	O
vivo	O
.	O

Escherichia	O
coli	O
BL21	O
(	O
DE3	O
)	O
plysS	O
,	O
harbouring	O
a	O
recombinant	O
plasmid	O
containing	O
the	O
catalase	B-protein
-	I-protein
peroxidase	I-protein
gene	I-protein
,	O
produced	O
a	O
large	O
amount	O
of	O
proteins	O
that	O
co	O
-	O
migrated	O
on	O
SDS	O
/	O
PAGE	O
with	O
the	O
native	O
enzyme	O
.	O

Uracil	B-protein
DNA	I-protein
glycosylase	I-protein
catalyzes	O
the	O
initial	O
step	O
in	O
the	O
repair	O
pathway	O
that	O
removes	O
potentially	O
mutagenic	O
uracil	O
from	O
duplex	O
DNA	O
.	O

Disruption	O
of	O
re	O
-	O
replication	O
control	O
by	O
overexpression	O
of	O
human	B-protein
ORC1	I-protein
in	O
fission	O
yeast	O
.	O

DATA	O
SOURCES	O
:	O
Epidemiologic	O
studies	O
,	O
research	O
studies	O
,	O
review	O
articles	O
,	O
and	O
government	O
reports	O
pertaining	O
to	O
epidemiology	O
of	O
lung	O
cancer	O
.	O

Both	O
alleles	O
are	O
functionally	O
expressed	O
and	O
are	O
distributed	O
within	O
CD4	B-protein
+	I-protein
/	I-protein
CD8	I-protein
+	I-protein
T	O
cell	O
subsets	O
.	O

The	O
Italian	O
Lung	O
Cancer	O
Task	O
Force	O
(	O
FONICAP	O
)	O
.	O

These	O
show	O
that	O
the	O
collagen	B-protein
in	O
this	O
tissue	O
is	O
modified	O
compared	O
with	O
that	O
in	O
tendon	O
.	O

The	O
spontaneous	O
mutation	O
blocking	O
pca	B-protein
gene	I-protein
expression	O
was	O
located	O
in	O
the	O
promoter	O
for	O
the	O
pca	B-protein
operon	I-protein
.	O

The	O
binding	O
specificity	O
of	O
this	O
protein	O
was	O
compared	O
to	O
that	O
of	O
human	B-protein
E2F	I-protein
using	O
a	O
number	O
of	O
mutant	B-protein
E2F	I-protein
sites	I-protein
as	O
competitors	O
.	O

These	O
case	O
reports	O
provide	O
further	O
evidence	O
that	O
LiCO3	O
can	O
be	O
a	O
useful	O
medication	O
in	O
the	O
treatment	O
of	O
aggressive	O
behavior	O
and	O
affective	O
instability	O
after	O
brain	O
injury	O
,	O
but	O
that	O
it	O
has	O
significant	O
potential	O
for	O
neurotoxicity	O
in	O
this	O
population	O
,	O
particularly	O
when	O
used	O
in	O
conjunction	O
with	O
neuroleptic	O
agents	O
.	O

We	O
also	O
isolated	O
two	O
alternatively	O
spliced	O
forms	O
of	O
human	B-protein
CD6	I-protein
cDNA	I-protein
lacking	O
sequences	O
encoding	O
membrane	O
-	O
proximal	O
regions	O
of	O
the	O
cytoplasmic	O
domain	O
which	O
maintain	O
the	O
same	O
reading	O
frame	O
as	O
CD6	B-protein
-	I-protein
PB1	I-protein
.	O

Judge	O
OKs	O
docs	O
'	O
bid	O
for	O
Chicago	O
hospital	O
.	O

The	O
characterization	O
of	O
the	O
promoter	O
region	O
indicated	O
that	O
three	O
distinct	O
regulatory	O
elements	O
corresponding	O
to	O
an	O
AP	B-protein
-	I-protein
1	I-protein
binding	I-protein
site	I-protein
(	O
or	O
TRE	B-protein
)	O
,	O
a	O
PRDII	B-protein
/	I-protein
kappaB	I-protein
domain	I-protein
,	O
and	O
a	O
CAAT	O
box	O
are	O
involved	O
in	O
the	O
activation	O
by	O
pp60	B-protein
(	I-protein
v	I-protein
-	I-protein
)	I-protein
src	I-protein
.	O

The	O
-	O
64	O
/	O
-	O
37	O
region	O
interacted	O
with	O
purified	O
Sp1	B-protein
and	O
an	O
unidentified	O
protein	O
(	O
s	O
)	O
,	O
proximal	B-protein
regulatory	I-protein
factor	I-protein
(	I-protein
s	I-protein
)	I-protein
I	I-protein
(	O
PRF	B-protein
-	I-protein
I	I-protein
)	O
.	O

Although	O
most	O
SH2	B-protein
-	I-protein
pTyr	I-protein
interactions	O
occur	O
between	O
two	O
different	O
types	O
of	O
molecules	O
,	O
some	O
appear	O
to	O
involve	O
only	O
a	O
single	O
molecular	O
type	O
.	O

Similarly	O
,	O
in	O
mammalian	O
cells	O
PBP74	B-protein
is	O
synthesized	O
as	O
a	O
pre	O
-	O
protein	O
that	O
requires	O
membrane	O
potential	O
-	O
dependent	O
import	O
into	O
mitochondria	O
for	O
its	O
maturation	O
.	O

The	O
M	B-protein
reading	I-protein
frame	I-protein
differed	O
from	O
the	O
reported	O
sequence	O
by	O
a	O
single	O
nucleotide	O
corresponding	O
to	O
a	O
conservative	O
lysine	O
to	O
arginine	O
amino	O
acid	O
substitution	O
near	O
the	O
carboxy	O
-	O
terminus	O
conserved	O
among	O
the	O
M	B-protein
proteins	I-protein
of	O
paramyxoviruses	O
.	O

Occupational	O
exposure	O
to	O
hepatitis	O
B	O
virus	O
and	O
human	O
immunodeficiency	O
virus	O
:	O
a	O
comparative	O
risk	O
analysis	O
.	O

Although	O
it	O
is	O
well	O
known	O
that	O
calcium	O
channel	O
blockers	O
can	O
influence	O
contraction	O
of	O
vascular	O
smooth	O
muscle	O
,	O
there	O
is	O
less	O
knowledge	O
on	O
its	O
effect	O
on	O
excitation	O
contraction	O
coupling	O
in	O
the	O
endocrine	O
glands	O
and	O
more	O
specifically	O
on	O
insulin	B-protein
and	O
glucagon	O
release	O
.	O

Clinical	O
applications	O
of	O
inhibition	O
of	O
beta	B-protein
-	I-protein
adrenergic	I-protein
receptors	I-protein
with	O
propranolol	O
.	O

Improved	O
methods	O
have	O
been	O
developed	O
for	O
maintaining	O
and	O
breeding	O
the	O
neotropical	O
short	O
-	O
tailed	O
fruit	O
bat	O
,	O
Carollia	O
perspicillata	O
,	O
in	O
an	O
easily	O
-	O
reproduced	O
,	O
laboratory	O
setting	O
.	O

The	O
intensity	O
of	O
myocardial	O
uptake	O
of	O
Tc	O
-	O
99m	O
-	O
PYP	O
in	O
patients	O
with	O
echocardiographic	O
left	O
ventricular	O
hypertrophy	O
and	O
/	O
or	O
highly	O
refractile	O
myocardial	O
echoes	O
,	O
so	O
-	O
called	O
granular	O
sparkling	O
appearance	O
(	O
GS	O
)	O
was	O
slightly	O
greater	O
than	O
that	O
in	O
patients	O
with	O
neither	O
myocardial	O
hypertrophy	O
nor	O
GS	O
.	O

The	O
only	O
predictor	O
of	O
response	O
to	O
tacrolimus	O
was	O
a	O
previous	O
response	O
to	O
cyclosporin	O
and	O
prednisone	O
,	O
either	O
as	O
a	O
complete	O
or	O
partial	O
remission	O
(	O
remission	O
rate	O
75	O
%	O
vs	O
15	O
.	O
3	O
;	O
P	O
=	O
0	O
.	O
036	O
)	O
.	O

CAL	O
gain	O
amounted	O
to	O
4	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
3	O
mm	O
,	O
60	O
%	O
of	O
the	O
defects	O
showing	O
CAL	O
gain	O
>	O
or	O
=	O
4	O
mm	O
.	O

After	O
clofelin	O
administration	O
the	O
autoregulation	O
borders	O
shifted	O
to	O
the	O
right	O
i	O
.	O
e	O
.	O
towards	O
higher	O
AP	O
levels	O
.	O

Persistent	O
acantholytic	O
dermatosis	O
with	O
increased	O
light	O
sensitivity	O
.	O

In	O
fact	O
,	O
SPT	B-protein
activity	O
in	O
the	O
fly	O
expressing	O
epitope	O
-	O
tagged	O
Lace	B-protein
was	O
absorbed	O
by	O
epitope	O
-	O
specific	O
antibody	O
.	O

C	O
.	O

DESIGN	O
:	O
Prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
controlled	O
trial	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
signal	O
transduction	O
pathways	O
that	O
are	O
involved	O
in	O
OM	O
-	O
induced	O
LDLR	B-protein
transcription	O
.	O

The	O
hexanucleotide	B-protein
5	I-protein
'	I-protein
-	I-protein
TGTCCT	I-protein
-	I-protein
3	I-protein
'	I-protein
,	O
thought	O
to	O
be	O
important	O
for	O
GRE	B-protein
activity	O
,	O
not	O
only	O
was	O
found	O
in	O
this	O
sequence	O
and	O
in	O
the	O
5	O
'	O
-	O
flanking	O
region	O
,	O
but	O
also	O
was	O
present	O
twice	O
in	O
the	O
3	O
'	O
end	O
of	O
the	O
gene	O
that	O
did	O
not	O
show	O
specific	O
receptor	O
binding	O
.	O

Mutations	O
at	O
the	O
extreme	O
C	O
-	O
terminus	O
of	O
EIAV	B-protein
Tat	I-protein
impaired	O
both	O
RNA	O
binding	O
and	O
activation	O
domain	O
functions	O
,	O
suggesting	O
effects	O
on	O
secondary	O
or	O
tertiary	O
structure	O
.	O

Repeated	O
efforts	O
to	O
isolate	O
recombinant	O
baculoviruses	O
containing	O
a	O
wild	B-protein
-	I-protein
type	I-protein
kinase	I-protein
failed	O
,	O
whereas	O
recombinants	O
expressing	O
a	O
nonfunctional	O
kinase	B-protein
with	O
a	O
catalytic	O
domain	B-protein
II	I-protein
mutation	O
were	O
readily	O
isolated	O
.	O

Elementary	O
visual	O
hallucinations	O
in	O
migraine	O
and	O
epilepsy	O
.	O

RT	O
-	O
PCR	O
was	O
performed	O
using	O
previously	O
reported	O
degenerate	O
oligonucleotide	O
primers	O
to	O
the	O
ligand	O
binding	O
domain	O
(	O
LBD	O
)	O
of	O
known	O
beta	B-protein
integrin	I-protein
subunits	I-protein
and	O
Bge	B-protein
cDNA	I-protein
.	O

Efficient	O
phosphorylation	O
of	O
BRDG1	B-protein
by	O
Tec	B-protein
required	O
the	O
PH	B-protein
and	O
SH2	B-protein
domains	I-protein
as	O
well	O
as	O
the	O
kinase	O
domain	O
of	O
the	O
latter	O
.	O

Evidence	O
-	O
based	O
care	O
:	O
a	O
new	O
formula	O
for	O
an	O
old	O
problem	O
?	O

With	O
this	O
GH	B-protein
and	O
estrogen	O
treatment	O
regimen	O
,	O
most	O
girls	O
with	O
TS	O
can	O
grow	O
and	O
develop	O
much	O
more	O
in	O
conformity	O
with	O
their	O
healthy	O
peers	O
.	O

After	O
acclimation	O
,	O
resting	O
supine	O
and	O
sitting	O
DPB	O
decreased	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
by	O
6	O
and	O
9	O
mmHg	O
,	O
respectively	O
.	O

With	O
regard	O
to	O
nonhematologic	O
toxicities	O
,	O
diarrhea	O
,	O
infection	O
and	O
elevated	O
serum	B-protein
alkaline	I-protein
phosphatase	I-protein
of	O
grade	O
3	O
or	O
over	O
were	O
observed	O
in	O
2	O
%	O
of	O
cycles	O
,	O
but	O
were	O
tolerable	O
and	O
reversible	O
.	O

Tests	O
showed	O
that	O
an	O
overall	O
impression	O
of	O
the	O
force	O
applied	O
could	O
be	O
obtained	O
from	O
a	O
laboratory	O
simulation	O
,	O
but	O
that	O
clearing	O
cement	O
and	O
testing	O
cement	O
were	O
not	O
modelled	O
by	O
this	O
method	O
.	O

These	O
lesions	O
were	O
asymptomatic	O
,	O
but	O
both	O
were	O
characterized	O
clinically	O
by	O
central	O
ulceration	O
.	O

In	O
addition	O
,	O
double	O
mutants	O
with	O
either	O
dim1	B-protein
-	I-protein
delta	I-protein
or	O
dim2	B-protein
-	I-protein
1	I-protein
and	O
the	O
endocytosis	O
mutants	B-protein
end4	I-protein
-	I-protein
1	I-protein
or	O
act1	B-protein
-	I-protein
1	I-protein
displayed	O
synthetic	O
growth	O
defects	O
,	O
indicating	O
that	O
the	O
DIM	B-protein
gene	I-protein
products	I-protein
function	O
in	O
a	O
common	O
or	O
parallel	O
endocytic	O
pathway	O
.	O

Moreover	O
,	O
it	O
is	O
the	O
assumptions	O
behind	O
steady	O
-	O
state	O
O2	O
uptake	O
that	O
do	O
not	O
permit	O
proper	O
interpretation	O
of	O
energy	O
expenditure	O
during	O
EPOC	O
;	O
1	O
l	O
O2	O
not	O
=	O
20	O
.	O
9	O
kJ	O
.	O

An	O
examination	O
of	O
the	O
properties	O
of	O
sequences	O
surrounding	O
ARS1	B-protein
left	O
open	O
the	O
possibility	O
that	O
ABFI	B-protein
enhances	O
the	O
initiation	O
of	O
DNA	O
replication	O
at	O
ARS1	B-protein
by	O
transcriptional	O
activation	O
.	O

The	O
intron	O
is	O
capable	O
of	O
splicing	O
despite	O
the	O
fact	O
that	O
both	O
the	O
EBS1	B-protein
/	I-protein
IBS1	I-protein
and	O
the	O
EBS2	B-protein
/	I-protein
IBS2	I-protein
sequence	I-protein
motifs	I-protein
,	O
thought	O
to	O
be	O
necessary	O
for	O
correct	O
splicing	O
,	O
extend	O
over	O
5	O
instead	O
of	O
6	O
bp	O
.	O

From	O
day	O
10	O
,	O
a	O
significant	O
increase	O
in	O
platelet	O
count	O
was	O
observed	O
in	O
eight	O
of	O
the	O
ten	O
patients	O
treated	O
with	O
heparin	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
with	O
return	O
to	O
the	O
initial	O
value	O
after	O
heparin	O
cessation	O
in	O
six	O
of	O
the	O
responders	O
.	O

In	O
rats	O
anaesthetized	O
with	O
+	O
-	O
chloralose	O
the	O
changes	O
in	O
extracellular	O
pH	O
and	O
K	O
+	O
in	O
spinal	O
cord	O
dorsal	O
horn	O
were	O
studied	O
using	O
pH	O
and	O
K	O
+	O
ion	O
-	O
selective	O
electrodes	O
.	O

Rather	O
,	O
usp	B-protein
is	O
required	O
in	O
late	O
third	O
instar	O
larvae	O
for	O
appropriate	O
developmental	O
and	O
transcriptional	O
responses	O
to	O
the	O
ecdysone	O
pulse	O
that	O
triggers	O
puparium	O
formation	O
.	O

The	O
majority	O
of	O
MRF	O
units	O
were	O
behaviorally	O
incongruent	O
;	O
in	O
the	O
most	O
frequently	O
observed	O
case	O
,	O
their	O
activity	O
failed	O
to	O
change	O
reliably	O
when	O
behavior	O
habituated	O
.	O

There	O
were	O
no	O
significant	O
changes	O
in	O
either	O
the	O
fatty	O
acid	O
composition	O
of	O
biliary	O
lecithin	O
or	O
in	O
the	O
bile	O
acid	O
composition	O
of	O
bile	O
.	O

Survey	O
on	O
antibody	O
against	O
egg	O
drop	O
syndrome	O
-	O
1976	O
virus	O
among	O
chicken	O
flocks	O
in	O
Japan	O
.	O

We	O
present	O
evidence	O
that	O
the	O
upstream	O
open	O
reading	O
frame	O
(	O
uORF	O
)	O
represses	O
the	O
translation	O
of	O
the	O
downstream	O
major	O
open	O
reading	O
frame	O
(	O
mORF	O
)	O
.	O

In	O
EEG	O
only	O
single	O
slow	O
waves	O
above	O
left	O
temporal	O
region	O
were	O
revealed	O
.	O

No	O
increased	O
tumor	O
-	O
related	O
mortality	O
was	O
observed	O
after	O
a	O
mean	O
follow	O
-	O
up	O
of	O
44	O
months	O
.	O

Carbonic	B-protein
anhydrase	I-protein
V	I-protein
(	O
CA	B-protein
V	I-protein
)	O
is	O
expressed	O
in	O
mitochondrial	O
matrix	O
in	O
liver	O
and	O
several	O
other	O
tissues	O
.	O

Metabolism	O
of	O
calcium	O
and	O
vitamin	O
D3	O
in	O
patients	O
with	O
acute	O
tubulointerstitial	O
nephritis	O
:	O
a	O
study	O
of	O
41	O
patients	O
with	O
nephropathia	O
epidemica	O
.	O

OBJECTIVES	O
:	O
The	O
objective	O
of	O
this	O
review	O
was	O
to	O
compare	O
the	O
effectiveness	O
,	O
safety	O
and	O
acceptability	O
of	O
the	O
diaphragm	O
with	O
and	O
without	O
spermicide	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
A	O
64	O
-	O
year	O
-	O
old	O
woman	O
with	O
confirmed	O
AV	O
nodal	O
reentrant	O
tachycardia	O
underwent	O
a	O
successful	O
`	O
`	O
slow	O
pathway	O
'	O
'	O
AV	O
modification	O
with	O
a	O
single	O
radiofrequency	O
application	O
.	O

We	O
show	O
that	O
stimulation	O
of	O
resting	O
splenic	O
B	O
cells	O
with	O
CD40L	O
-	O
expressing	O
Sf9	O
cells	O
induces	O
germ	O
-	O
line	O
gamma	B-protein
1	I-protein
and	O
epsilon	B-protein
transcripts	I-protein
independently	O
of	O
cytokines	O
.	O

Routine	O
blood	O
examination	O
showed	O
leukocytosis	O
,	O
thrombocytopenia	O
,	O
positive	O
CRP	B-protein
,	O
and	O
elevated	O
myocardial	O
enzymes	O
.	O

We	O
propose	O
that	O
refeeding	O
may	O
be	O
an	O
important	O
mechanism	O
for	O
activation	O
of	O
certain	O
viral	O
infections	O
previously	O
suppressed	O
by	O
famine	O
.	O

Survival	O
after	O
development	O
of	O
symptomatic	O
infection	O
(	O
P	O
-	O
2	O
)	O
did	O
not	O
differ	O
by	O
transmission	O
mode	O
.	O

Constipation	O
is	O
not	O
a	O
risk	O
factor	O
for	O
hemorrhoids	O
:	O
a	O
case	O
-	O
control	O
study	O
of	O
potential	O
etiological	O
agents	O
.	O

Mutational	O
analysis	O
of	O
chromosomal	O
segment	O
64AB	O
,	O
a	O
region	O
containing	O
the	O
glutamic	B-protein
acid	I-protein
decarboxylase	I-protein
gene	I-protein
.	O

Substitution	O
of	O
the	O
DR1	B-protein
beta	I-protein
chain	I-protein
with	O
H	B-protein
-	I-protein
2E	I-protein
beta	I-protein
k	I-protein
led	O
to	O
a	O
dramatic	O
loss	O
of	O
recognition	O
;	O
alpha	O
chain	O
substitution	O
had	O
a	O
less	O
marked	O
effect	O
.	O

In	O
contrast	O
to	O
the	O
selective	O
expression	O
of	O
the	O
receptor	O
,	O
FL	B-protein
expression	O
was	O
detected	O
in	O
90	O
-	O
100	O
%	O
of	O
the	O
various	O
cell	O
types	O
of	O
leukemia	O
cell	O
lines	O
from	O
all	O
hematopoietic	O
cell	O
lineages	O
.	O

The	O
combination	O
of	O
Pitx2	B-protein
and	O
another	O
homeodomain	B-protein
protein	I-protein
,	O
Pit	B-protein
-	I-protein
1	I-protein
,	O
yielded	O
a	O
synergistic	O
55	O
-	O
fold	O
activation	O
of	O
the	O
prolactin	B-protein
promoter	I-protein
in	O
transfection	O
assays	O
.	O

Consistent	O
with	O
the	O
specificity	O
observed	O
for	O
the	O
interaction	O
of	O
DmCKIIalpha	B-protein
with	O
these	O
bHLH	B-protein
proteins	I-protein
,	O
sequence	O
alignment	O
suggests	O
that	O
only	O
m5	B-protein
,	O
m7	B-protein
,	O
and	O
m8	B-protein
contain	O
a	O
consensus	O
site	O
for	O
phosphorylation	O
by	O
CKII	B-protein
within	O
a	O
subdomain	O
unique	O
to	O
these	O
three	O
proteins	O
.	O

The	O
transcription	O
start	O
point	O
of	O
the	O
proximal	O
promoter	O
aligns	O
to	O
that	O
of	O
mouse	B-protein
promoter	I-protein
P3	I-protein
and	O
lies	O
within	O
a	O
conserved	O
region	O
of	O
sequence	O
.	O

METHODS	O
:	O
One	O
hundred	O
fourteen	O
consecutive	O
patients	O
(	O
mean	O
age	O
61	O
years	O
)	O
with	O
focal	O
pancreatic	O
masses	O
,	O
detected	O
on	O
CT	O
,	O
underwent	O
EUS	O
-	O
FNA	O
by	O
using	O
a	O
linear	O
-	O
array	O
echoendoscope	O
and	O
22	O
-	O
gauge	O
needles	O
.	O

Here	O
is	O
presented	O
the	O
monitoring	O
of	O
the	O
accidental	O
spill	O
on	O
vertical	O
distribution	O
of	O
heavy	O
metals	O
in	O
the	O
estuarine	O
sediments	O
.	O

A	O
mutant	O
in	O
the	O
AAV	O
terminal	O
resolution	O
site	O
(	O
trs	O
)	O
was	O
defective	O
for	O
DNA	O
replication	O
in	O
the	O
in	O
vitro	O
assay	O
.	O

Analysis	O
of	O
homologous	O
DNA	O
sequences	O
within	O
the	O
first	O
intron	O
of	O
the	O
mouse	B-protein
and	I-protein
human	I-protein
mts1	I-protein
genes	I-protein
:	O
kB	B-protein
-	I-protein
like	I-protein
site	I-protein
and	O
microsatellite	O
DNA	O
.	O

The	O
medium	O
chains	O
of	O
these	O
complexes	O
,	O
mu1	B-protein
and	O
mu2	B-protein
,	O
have	O
been	O
implicated	O
in	O
two	O
types	O
of	O
interaction	O
:	O
assembly	O
with	O
the	O
beta1	B-protein
and	I-protein
beta2	I-protein
chains	I-protein
of	O
the	O
corresponding	O
complexes	O
and	O
recognition	O
of	O
tyrosine	O
-	O
based	O
sorting	O
signals	O
.	O

The	O
rats	O
were	O
used	O
for	O
the	O
study	O
of	O
the	O
effects	O
of	O
sepsis	O
on	O
the	O
utilization	O
of	O
exogenous	O
fat	O
emulsion	O
.	O

Its	O
interaction	O
with	O
RFX5	B-protein
and	O
RFXAP	B-protein
is	O
essential	O
for	O
binding	O
of	O
the	O
RFX	B-protein
complex	I-protein
to	O
MHC	B-protein
-	I-protein
II	I-protein
promoters	I-protein
.	O

In	O
CV	O
-	O
1	O
cells	O
,	O
cotransfection	O
of	O
the	O
retinoid	B-protein
and	I-protein
estrogen	I-protein
receptors	I-protein
led	O
to	O
mutual	O
inhibition	O
of	O
the	O
other	O
'	O
s	O
activity	O
,	O
while	O
an	O
RA	O
-	O
dependent	O
inhibition	O
of	O
ER	B-protein
activity	O
was	O
observed	O
in	O
breast	O
cancer	O
cells	O
.	O

Thirty	O
minutes	O
of	O
supine	O
restraint	O
decreased	O
DOPAC	O
concentrations	O
in	O
the	O
median	O
eminence	O
of	O
female	O
rats	O
that	O
were	O
not	O
exposed	O
to	O
ether	O
,	O
and	O
brief	O
exposure	O
to	O
ether	O
enhanced	O
this	O
effect	O
.	O

The	O
first	O
follow	O
-	O
up	O
was	O
at	O
a	O
nearly	O
constant	O
interval	O
of	O
5	O
.	O
1	O
years	O
in	O
Caerphilly	O
and	O
3	O
.	O
2	O
years	O
in	O
Speedwell	O
;	O
251	O
major	O
IHD	O
events	O
had	O
occurred	O
.	O

A	O
transgenic	O
complementation	O
assay	O
was	O
used	O
to	O
test	O
whether	O
NIa	B-protein
supplied	O
in	O
trans	O
could	O
rescue	O
amplification	O
-	O
defective	O
viral	O
genomes	O
encoding	O
altered	O
NIa	B-protein
proteins	I-protein
.	O

Chirality	O
-	O
glass	O
and	O
spin	O
-	O
glass	O
correlations	O
in	O
the	O
two	O
-	O
dimensional	O
random	O
-	O
bond	O
XY	O
model	O
.	O

Initial	O
results	O
indicate	O
that	O
this	O
23S	B-protein
pre	I-protein
-	I-protein
rRNA	I-protein
is	O
the	O
same	O
as	O
the	O
species	O
detected	O
on	O
depletion	O
of	O
the	O
small	B-protein
nucleolar	I-protein
RNA	I-protein
-	I-protein
associated	I-protein
proteins	I-protein
NOP1	I-protein
and	O
GAR1	B-protein
and	O
in	O
an	O
snr10	B-protein
mutant	I-protein
strain	O
.	O

To	O
understand	O
further	O
the	O
expression	O
and	O
regulation	O
of	O
the	O
V1aR	B-protein
,	O
we	O
now	O
describe	O
the	O
genomic	O
characteristics	O
,	O
tissue	O
expression	O
,	O
chromosomal	O
localization	O
,	O
and	O
regional	O
mapping	O
of	O
the	O
human	B-protein
V1aR	I-protein
gene	I-protein
,	O
AVPR1A	B-protein
.	O

Vaccinia	O
virus	O
-	O
expressed	O
,	O
purified	O
full	B-protein
-	I-protein
length	I-protein
HPV	I-protein
-	I-protein
16	I-protein
and	I-protein
BPV	I-protein
-	I-protein
1	I-protein
E2	I-protein
proteins	I-protein
bound	O
a	O
consensus	O
E2	B-protein
site	I-protein
with	O
high	O
specific	O
affinities	O
(	O
Kd	O
=	O
approximately	O
10	O
(	O
-	O
9	O
)	O
M	O
)	O
and	O
stimulated	O
in	O
vitro	O
transcription	O
up	O
to	O
six	O
-	O
to	O
eightfold	O
.	O

Genes	O
for	O
ocs	B-protein
element	I-protein
binding	I-protein
factors	I-protein
(	O
OBFs	B-protein
)	O
,	O
belonging	O
to	O
a	O
specific	O
class	O
of	O
basic	B-protein
-	I-protein
region	I-protein
leucine	I-protein
zipper	I-protein
(	I-protein
bZIP	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
,	O
have	O
been	O
isolated	O
in	O
a	O
number	O
of	O
plants	O
.	O

Interestingly	O
,	O
highly	O
charged	O
residues	O
were	O
abundantly	O
possessed	O
in	O
the	O
carboxy	O
-	O
terminal	O
part	O
of	O
the	O
MDV2	B-protein
UL10	I-protein
protein	I-protein
.	O

We	O
show	O
here	O
that	O
RA	O
and	O
E1A	B-protein
induce	O
phosphorylation	O
of	O
the	O
E1A	B-protein
-	I-protein
associated	I-protein
300	I-protein
kDa	I-protein
protein	I-protein
(	O
p300	B-protein
)	O
during	O
the	O
differentiation	O
of	O
F9	O
cells	O
.	O

Pathophysiology	O
of	O
bone	O
loss	O
in	O
castrated	O
animals	O
.	O

A	O
strong	O
correlation	O
exists	O
between	O
the	O
numbers	O
of	O
CFU	O
-	O
GM	O
transfused	O
and	O
the	O
rate	O
of	O
granulocytes	O
and	O
platelets	O
recovery	O
.	O

Because	O
of	O
serious	O
infections	O
(	O
fever	O
larger	O
than	O
or	O
equal	O
to	O
101	O
degrees	O
F	O
.	O
granulocytes	O
less	O
than	O
1	O
,	O
000	O
/	O
mm	O
,	O
3	O
and	O
hospitalization	O
)	O
and	O
1	O
drug	O
death	O
in	O
the	O
first	O
4	O
patients	O
,	O
oral	O
calcium	O
leucovorin	O
,	O
20	O
to	O
30	O
mg	O
/	O
m2	O
orally	O
,	O
was	O
given	O
2	O
days	O
after	O
methotrexate	O
in	O
subsequent	O
treatment	O
cycles	O
.	O

Successful	O
interaction	O
of	O
ARF	B-protein
and	O
PKC	B-protein
-	I-protein
alpha	I-protein
with	O
PLD1	B-protein
was	O
not	O
achieved	O
,	O
but	O
a	O
C	O
-	O
terminal	O
fragment	O
of	O
human	B-protein
PLD1	I-protein
(	O
denoted	O
`	O
`	O
D4	O
'	O
'	O
)	O
interacted	O
with	O
the	O
active	O
mutant	O
of	O
RhoA	B-protein
,	O
RhoAVal	B-protein
-	I-protein
14	I-protein
.	O

Repetitive	O
sequences	O
are	O
present	O
in	O
at	O
least	O
three	O
introns	O
of	O
the	O
cytochrome	B-protein
P	I-protein
-	I-protein
450PBc2	I-protein
gene	I-protein
,	O
but	O
not	O
in	O
exons	O
or	O
the	O
5	O
'	O
-	O
flanking	O
region	O
.	O

(	O
GUT	O
)	O
Sera	O
of	O
30	O
montoux	O
negative	O
healthy	O
adults	O
(	O
age	O
/	O
sex	O
matched	O
)	O
were	O
taken	O
as	O
control	O
by	O
detecting	O
IgG	B-protein
anti	I-protein
bodies	I-protein
to	O
A60	B-protein
antigen	I-protein
.	O

Using	O
immunolocalization	O
,	O
we	O
observe	O
that	O
ACE3	B-protein
,	O
a	O
440	O
-	O
bp	O
chorion	O
element	O
that	O
contains	O
information	O
sufficient	O
to	O
drive	O
amplification	O
,	O
directs	O
DmORC	O
localization	O
in	O
follicle	O
cells	O
.	O

The	O
rate	O
-	O
decreasing	O
effects	O
of	O
morphine	O
and	O
U50488	O
were	O
reversed	O
completely	O
by	O
a	O
0	O
.	O
01	O
and	O
1	O
.	O
0	O
mg	O
/	O
kg	O
dose	O
of	O
naloxone	O
,	O
respectively	O
.	O

Demonstration	O
of	O
fine	O
structure	O
of	O
the	O
guinea	O
pig	O
organ	O
of	O
Corti	O
after	O
electron	O
microscopic	O
silver	O
staining	O
.	O

A	O
cDNA	O
encoding	O
the	O
NF	B-protein
-	I-protein
4FB	I-protein
enhancer	I-protein
binding	I-protein
protein	I-protein
has	O
been	O
cloned	O
by	O
screening	O
a	O
lambda	O
gt11	O
cDNA	O
library	O
with	O
a	O
rabiolabelled	O
oligonucleotide	O
corresponding	O
to	O
the	O
NF	B-protein
-	I-protein
4FB	I-protein
recognition	I-protein
sequence	I-protein
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
correlate	O
the	O
responsiveness	O
to	O
bronchoprovocation	O
with	O
methacholine	O
in	O
subjects	O
a	O
with	O
allergic	O
rhinitis	O
during	O
and	O
out	O
of	O
the	O
pollen	O
season	O
with	O
total	O
serum	O
IgE	B-protein
and	O
blood	O
eosinophils	O
.	O

The	O
interaction	O
between	O
piroxicam	O
and	O
poloxamer	O
was	O
studied	O
by	O
x	O
-	O
ray	O
diffractometry	O
(	O
XRD	O
)	O
,	O
infrared	O
(	O
IR	O
)	O
spectroscopy	O
and	O
differential	O
thermal	O
analysis	O
(	O
DTA	O
)	O
with	O
a	O
solid	O
dispersion	O
,	O
coprecipitate	O
,	O
or	O
physical	O
mixture	O
.	O

Immunelectrophoretic	O
pattern	O
of	O
Wassermann	O
reagin	O
and	O
comparison	O
of	O
the	O
appearance	O
time	O
between	O
RPCF	B-protein
and	O
FTA	B-protein
antibodies	I-protein
.	O

Reactive	O
lymphoid	O
hyperplasia	O
was	O
found	O
in	O
15	O
cases	O
,	O
2	O
cases	O
had	O
angiofollicular	O
lymphoid	O
hyperplasia	O
or	O
Castleman	O
'	O
s	O
disease	O
,	O
atypical	O
lymphoid	O
hyperplasia	O
suggestive	O
of	O
malignant	O
lymphoma	O
was	O
observed	O
in	O
3	O
cases	O
,	O
and	O
malignant	O
lymphoma	O
was	O
diagnosed	O
in	O
the	O
remaining	O
4	O
cases	O
.	O

In	O
this	O
report	O
,	O
we	O
investigate	O
the	O
mechanism	O
underlying	O
Ras	B-protein
activation	O
upon	O
stimulation	O
of	O
these	O
two	O
types	O
of	O
receptors	O
in	O
hematopoietic	O
cells	O
.	O

OKA	O
and	O
calyculin	O
A	O
do	O
not	O
decrease	O
OCFRE	B-protein
DNA	O
-	O
protein	O
interactions	O
,	O
suggesting	O
that	O
important	O
protein	O
-	O
protein	O
interactions	O
are	O
phosphatase	O
regulated	O
.	O

In	O
addition	O
,	O
media	O
containing	O
F	B-protein
beta	I-protein
alpha	I-protein
/	I-protein
CG	I-protein
beta	I-protein
displayed	O
high	O
-	O
affinity	O
binding	O
to	O
both	O
CG	B-protein
and	O
FSH	B-protein
receptors	I-protein
.	O

Antisense	O
transcription	O
of	O
a	O
murine	B-protein
FGFR	I-protein
-	I-protein
3	I-protein
psuedogene	I-protein
during	O
fetal	O
developement	O
.	O

Within	O
the	O
Strep	O
.	O
mutans	O
group	O
there	O
was	O
a	O
highly	O
-	O
significant	O
difference	O
between	O
Strep	O
.	O
mutans	O
/	O
Strep	O
.	O
cricetus	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
with	O
respect	O
to	O
mean	O
clump	O
size	O
.	O

Both	O
BG	O
and	O
IRI	B-protein
concentrations	O
during	O
the	O
OGTT	O
were	O
the	O
lowest	O
in	O
body	O
builders	O
,	O
medium	O
in	O
controls	O
,	O
and	O
the	O
highest	O
in	O
obese	O
men	O
.	O

Hypersplenism	O
.	O

We	O
report	O
the	O
construction	O
of	O
an	O
approximately	O
1	O
.	O
7	O
-	O
Mb	O
sequence	O
-	O
ready	O
YAC	O
/	O
BAC	O
clone	O
contig	O
of	O
8p22	O
-	O
p23	O
.	O

In	O
the	O
ePTFE	O
specimens	O
,	O
tissue	O
coverage	O
had	O
increased	O
.	O

In	O
this	O
study	O
,	O
we	O
elucidate	O
signaling	O
pathways	O
induced	O
by	O
photodynamic	O
therapy	O
(	O
PDT	O
)	O
with	O
hypericin	O
.	O

In	O
situ	O
copper	O
-	O
phenanthroline	O
footprinting	O
of	O
individual	O
gel	O
shift	O
assembly	O
intermediates	O
shows	O
that	O
on	O
the	O
302	O
-	O
nucleotide	O
G4oric	O
,	O
the	O
first	O
two	O
SSB	B-protein
tetramers	I-protein
assemble	O
at	O
random	O
,	O
but	O
the	O
addition	O
of	O
more	O
SSB	B-protein
tetramers	I-protein
results	O
in	O
formation	O
of	O
a	O
unique	O
structure	O
.	O

The	O
distribution	O
of	O
patients	O
was	O
as	O
follows	O
:	O
group	O
1	O
-	O
-	O
complex	O
gamma	O
-	O
therapy	O
(	O
55	O
cases	O
)	O
,	O
group	O
2	O
-	O
-	O
complex	O
gamma	O
-	O
therapy	O
plus	O
iliac	O
lymphadenectomy	O
(	O
50	O
cases	O
)	O
and	O
group	O
3	O
-	O
-	O
complex	O
radiation	O
treatment	O
with	O
megavolt	O
bremsstrahlung	O
beam	O
from	O
the	O
luc	O
type	O
installation	O
and	O
iliac	O
lymphadenectomy	O
(	O
50	O
cases	O
)	O
.	O

Cellular	B-protein
Csk	I-protein
was	O
associated	O
with	O
several	O
phosphoproteins	O
,	O
some	O
of	O
which	O
were	O
interacting	O
with	O
the	O
Csk	B-protein
SH2	I-protein
domain	I-protein
.	O

Enhancer	O
activity	O
requires	O
both	O
the	O
AP	B-protein
-	I-protein
1	I-protein
site	I-protein
and	O
these	O
adjacent	O
sequences	O
.	O

A	O
significant	O
association	O
between	O
a	O
family	O
history	O
and	O
a	O
higher	O
urinary	O
pH	O
was	O
observed	O
among	O
the	O
female	O
calcium	O
stone	O
patients	O
.	O

Successful	O
treatment	O
of	O
candidiasis	O
with	O
transfer	O
factor	O
.	O

Disturbances	O
of	O
placental	O
maturation	O
,	O
2	O
.	O

Workload	O
,	O
UAPs	O
,	O
and	O
you	O
.	O

This	O
unique	O
location	O
of	O
cavernous	O
malformation	O
is	O
associated	O
with	O
a	O
risk	O
of	O
permanent	O
loss	O
of	O
the	O
vision	O
.	O

Results	O
for	O
men	O
who	O
drank	O
up	O
to	O
two	O
drinks	O
per	O
day	O
suggest	O
that	O
if	O
the	O
dependence	O
criteria	O
were	O
invalid	O
,	O
reductions	O
in	O
the	O
prevalence	O
of	O
specific	O
indicators	O
of	O
alcohol	O
dependence	O
would	O
range	O
from	O
0	O
.	O
3	O
%	O
to	O
5	O
.	O
2	O
%	O
.	O

The	O
complete	O
response	O
(	O
CR	O
)	O
rate	O
was	O
34	O
%	O
in	O
the	O
CODE	O
with	O
rhG	B-protein
-	I-protein
CSF	I-protein
group	O
and	O
23	O
%	O
in	O
the	O
CODE	O
alone	O
group	O
;	O
the	O
median	O
survival	O
was	O
59	O
and	O
32	O
weeks	O
,	O
respectively	O
,	O
in	O
these	O
groups	O
(	O
P	O
=	O
0	O
.	O
004	O
)	O
.	O

Chromatin	O
repression	O
of	O
these	O
replacement	O
genes	O
would	O
be	O
avoided	O
,	O
consistent	O
with	O
the	O
high	O
,	O
constitutive	O
expression	O
of	O
replacement	O
H3	B-protein
histone	I-protein
genes	I-protein
in	O
plants	O
.	O

The	O
mutants	O
were	O
obtained	O
by	O
substitution	O
into	O
a	O
molecular	O
clone	O
of	O
M	O
-	O
MuLV	O
DNA	O
by	O
DNA	O
from	O
two	O
acutely	O
transforming	O
viruses	O
,	O
Ableson	O
MuLV	O
(	O
Ab	O
-	O
MuLV	O
)	O
and	O
Moloney	O
murine	O
sarcoma	O
virus	O
(	O
M	O
-	O
MSV	O
)	O
.	O

Plasmids	O
pAMS12	O
,	O
pAMS13	O
and	O
pAMS14	O
were	O
transformed	O
into	O
a	O
laboratory	O
strain	O
of	O
Saccharomyces	O
cerevisiae	O
,	O
whereas	O
pAMS15	O
was	O
stably	O
introduced	O
into	O
two	O
commercial	O
wine	O
yeast	O
strains	O
.	O

Within	O
Stage	O
IA	O
,	O
141	O
patients	O
had	O
well	O
differentiated	O
tumor	O
(	O
G1	O
)	O
,	O
20	O
had	O
moderately	O
well	O
differentiated	O
tumor	O
(	O
G2	O
)	O
,	O
and	O
12	O
patients	O
had	O
poorly	O
differentiated	O
(	O
G3	O
)	O
.	O

USF	B-protein
synthesized	O
in	O
an	O
in	O
vitro	O
transcription	O
and	O
translation	O
system	O
also	O
binds	O
to	O
the	O
ADH	B-protein
promoter	I-protein
as	O
well	O
as	O
to	O
the	O
MLP	O
.	O

In	O
lean	O
mice	O
,	O
the	O
fat	O
/	O
water	O
intensity	O
ratio	O
was	O
about	O
1	O
:	O
4	O
,	O
about	O
half	O
that	O
in	O
normal	O
mice	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
The	O
authors	O
analyzed	O
41	O
persons	O
formerly	O
submitted	O
to	O
surgery	O
(	O
after	O
8	O
years	O
and	O
4	O
months	O
,	O
as	O
a	O
mean	O
)	O
,	O
31	O
to	O
highly	O
selective	O
vagotomy	O
,	O
and	O
10	O
to	O
truncal	O
or	O
selective	O
vagotomy	O
plus	O
gastroduodenal	O
drainage	O
.	O

Ultimate	O
strengthes	O
seem	O
to	O
be	O
reached	O
for	O
cast	O
cobalt	O
alloys	O
,	O
whereas	O
titanium	O
alloys	O
,	O
such	O
as	O
Ta	O
6	O
V	O
,	O
present	O
very	O
high	O
fatigue	O
limit	O
under	O
corrosion	O
.	O

NOT4	B-protein
interacts	O
with	O
NOT1	B-protein
and	O
NOT3	B-protein
in	O
the	O
two	O
-	O
hybrid	O
assay	O
,	O
and	O
overexpression	O
of	O
NOT3	B-protein
or	O
NOT4	B-protein
suppresses	O
not1	B-protein
and	O
not2	B-protein
mutations	O
.	O

Six	O
patients	O
with	O
human	O
T	O
-	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
-	O
associated	O
myelopathy	O
(	O
HAM	O
)	O
were	O
studied	O
by	O
electrophysiologic	O
methods	O
.	O

The	O
naltrexone	O
/	O
lofexidine	O
combination	O
was	O
associated	O
with	O
a	O
more	O
rapid	O
resolution	O
of	O
the	O
opiate	O
withdrawal	O
syndrome	O
than	O
a	O
7	O
-	O
day	O
lofexidine	O
-	O
only	O
treatment	O
schedule	O
,	O
without	O
substantial	O
increases	O
in	O
withdrawal	O
symptoms	O
or	O
hypotensive	O
side	O
-	O
effects	O
.	O

PBSX	O
is	O
induced	O
by	O
agents	O
which	O
elicit	O
the	O
SOS	O
response	O
.	O

Five	O
control	O
subjects	O
with	O
COPD	O
,	O
who	O
performed	O
the	O
same	O
sequence	O
of	O
tests	O
without	O
breathing	O
30	O
%	O
O2	O
,	O
showed	O
no	O
change	O
in	O
flow	O
rates	O
or	O
density	O
dependence	O
.	O

The	O
protein	O
was	O
associated	O
with	O
purified	O
vaccinia	O
virus	O
particles	O
and	O
with	O
membranes	O
of	O
immature	O
and	O
mature	O
virions	O
that	O
were	O
visualized	O
by	O
electron	O
microscopy	O
of	O
infected	O
cells	O
.	O

Both	O
factors	O
demonstrated	O
significant	O
correlations	O
with	O
rCBF	O
in	O
the	O
medial	O
prefrontal	O
cortex	O
and	O
frontal	O
polar	O
cortex	O
while	O
for	O
each	O
factor	O
there	O
were	O
also	O
unique	O
patterns	O
of	O
correlations	O
with	O
posterior	O
brain	O
regions	O
.	O

Sudomoina	O
,	O
A	O
.	O

The	O
results	O
revealed	O
increased	O
blood	O
lead	O
level	O
associated	O
with	O
decreased	O
blood	B-protein
haemoglobin	I-protein
and	O
increased	O
urinary	O
excretion	O
of	O
delta	O
amino	O
levulinic	O
acid	O
.	O

An	O
in	O
vivo	O
ZAP	B-protein
-	I-protein
70	I-protein
substrate	O
,	O
SLP	B-protein
-	I-protein
76	I-protein
,	O
implicated	O
in	O
Erk	B-protein
activation	O
,	O
also	O
became	O
rapidly	O
tyrosine	O
-	O
phosphorylated	O
in	O
Jurkat	O
cells	O
,	O
but	O
not	O
in	O
P116	O
cells	O
,	O
upon	O
treatment	O
with	O
H2O2	O
.	O

Promoter	O
activity	O
was	O
dose	O
-	O
dependently	O
inhibited	O
by	O
cotransfection	O
with	O
either	O
ras	B-protein
or	O
mos	B-protein
oncogenes	I-protein
,	O
but	O
oncogene	O
inhibition	O
was	O
reversed	O
and	O
the	O
overall	O
activity	O
increased	O
when	O
cells	O
were	O
treated	O
with	O
the	O
MAP	B-protein
kinase	I-protein
kinase	I-protein
(	O
MKK	B-protein
)	O
inhibitor	O
PD98059	O
.	O

Bone	O
and	O
bones	O
.	O

Furthermore	O
,	O
we	O
have	O
identified	O
a	O
soluble	O
form	O
of	O
ERp57	B-protein
/	I-protein
GRP58	I-protein
by	O
Western	O
blotting	O
and	O
biosynthetic	O
labeling	O
.	O

The	O
models	O
accurately	O
localized	O
the	O
common	O
boundaries	O
between	O
the	O
PBB	O
and	O
CN	O
.	O

This	O
experiment	O
was	O
conducted	O
to	O
determine	O
if	O
the	O
sex	O
or	O
actual	O
egg	O
production	O
was	O
the	O
important	O
factor	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Respiratory	O
adaptation	O
to	O
chronic	O
hypoxia	O
in	O
newborn	O
rats	O
.	O

Today	O
there	O
is	O
no	O
doubt	O
that	O
elevated	O
plasma	O
cholesterol	O
levels	O
should	O
be	O
lowered	O
first	O
by	O
dietary	O
modification	O
even	O
in	O
early	O
childhood	O
,	O
beginning	O
at	O
the	O
age	O
of	O
two	O
years	O
.	O

HEED	B-protein
was	O
found	O
to	O
bind	O
to	O
MA	B-protein
protein	I-protein
in	O
vitro	O
,	O
as	O
efficiently	O
as	O
in	O
vivo	O
in	O
yeast	O
cells	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
treatment	O
with	O
the	O
ACE	B-protein
inhibitor	O
perindopril	O
(	O
and	O
the	O
diuretic	O
indapamide	O
for	O
those	O
with	O
no	O
definite	O
indication	O
for	O
or	O
contraindication	O
to	O
treatment	O
with	O
a	O
diuretic	O
)	O
or	O
matching	O
placebo	O
(	O
s	O
)	O
.	O

I	O
.	O

RVR	B-protein
'	O
loss	O
of	O
function	O
'	O
studies	O
by	O
constitutive	O
over	O
-	O
expression	O
of	O
a	O
dominant	O
negative	O
RVR	B-protein
delta	I-protein
E	I-protein
resulted	O
in	O
increased	O
levels	O
of	O
p21Cip1	B-protein
/	I-protein
Waf1	I-protein
and	O
myogenin	B-protein
mRNAs	I-protein
after	O
serum	O
withdrawal	O
.	O

Consistent	O
with	O
this	O
,	O
purified	O
Dlk	B-protein
phosphorylated	O
core	O
histones	B-protein
H3	I-protein
,	O
H2A	B-protein
and	O
H4	B-protein
as	O
exogenous	O
substrates	O
and	O
endogenous	O
histone	B-protein
H3	I-protein
in	O
kinase	O
assays	O
with	O
nuclear	O
extracts	O
.	O

The	O
effects	O
of	O
taloximine	O
and	O
aminophylline	O
on	O
isolated	O
human	O
smooth	O
muscle	O
.	O

In	O
a	O
highly	O
select	O
group	O
of	O
stable	O
hypertensive	O
patients	O
,	O
we	O
have	O
assessed	O
the	O
strength	O
of	O
association	O
between	O
various	O
blood	O
pressure	O
measurements	O
(	O
24	O
h	O
average	O
automated	O
ambulatory	O
blood	O
pressure	O
,	O
4	O
h	O
automated	O
ambulatory	O
morning	O
average	O
blood	O
pressure	O
,	O
multiple	O
office	O
visit	O
average	O
blood	O
pressure	O
,	O
and	O
a	O
single	O
office	O
visit	O
average	O
blood	O
pressure	O
)	O
and	O
various	O
echocardiographic	O
indices	O
of	O
hypertensive	O
cardiac	O
target	O
organ	O
damage	O
(	O
left	O
atrial	O
diameter	O
,	O
left	O
ventricular	O
end	O
diastolic	O
diameter	O
,	O
posterior	O
wall	O
thickness	O
,	O
combined	O
wall	O
thickness	O
,	O
relative	O
wall	O
thickness	O
,	O
left	O
ventricular	O
mass	O
and	O
mass	O
index	O
,	O
and	O
combined	O
wall	O
thickness	O
/	O
left	O
ventricular	O
diastolic	O
diameter	O
ratio	O
)	O
.	O

Overexpression	O
of	O
H411	B-protein
cDNA	I-protein
in	O
the	O
RAW	O
264	O
.	O
7	O
macrophage	O
cell	O
line	O
promoted	O
an	O
increased	O
growth	O
rate	O
,	O
suggesting	O
that	O
expression	O
of	O
H411	B-protein
is	O
part	O
of	O
the	O
proliferative	O
cell	O
response	O
to	O
LPS	O
.	O

Number	O
and	O
size	O
of	O
the	O
myelin	O
structures	O
in	O
the	O
pneumocytes	O
typ	O
II	O
increased	O
simultaneously	O
.	O

cDNA	O
and	O
structural	O
organization	O
of	O
the	O
gene	B-protein
Pole1	I-protein
for	O
the	O
mouse	B-protein
DNA	I-protein
polymerase	I-protein
epsilon	I-protein
catalytic	I-protein
subunit	I-protein
.	O

A	O
transcription	O
factor	O
exclusion	O
assay	O
was	O
used	O
to	O
show	O
that	O
the	O
PCF1	B-protein
mutation	I-protein
affects	O
two	O
distinct	O
stages	O
in	O
transcription	O
:	O
one	O
prior	O
to	O
and	O
one	O
after	O
stable	O
complex	O
formation	O
;	O
and	O
that	O
these	O
effects	O
are	O
mediated	O
by	O
a	O
component	O
of	O
the	O
stable	O
complex	O
.	O

The	O
1489	O
-	O
base	O
pair	O
EFIA	B-protein
cDNA	O
encodes	O
a	O
322	O
-	O
amino	O
acid	O
protein	O
which	O
is	O
nearly	O
identical	O
to	O
two	O
previously	O
described	O
human	O
DNA	O
binding	O
proteins	O
.	O

PRL	B-protein
receptor	I-protein
also	O
activates	O
SHP	B-protein
-	I-protein
2	I-protein
,	O
a	O
cytosolic	B-protein
tyrosine	I-protein
phosphatase	I-protein
.	O

Thirty	O
-	O
one	O
age	O
-	O
matched	O
,	O
conscious	O
,	O
virgin	O
,	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
and	O
spontaneously	O
hypertensive	O
rats	O
(	O
SHRs	O
)	O
were	O
individually	O
injected	O
with	O
a	O
single	O
subcutaneous	O
dose	O
of	O
85	O
mg	O
/	O
kg	O
dl	O
-	O
isoproterenol	O
to	O
determine	O
the	O
degree	O
and	O
time	O
course	O
of	O
drug	O
-	O
induced	O
cardiac	O
failure	O
and	O
functional	O
recovery	O
.	O

Termination	O
of	O
induced	O
VT	O
on	O
the	O
first	O
attempt	O
was	O
comparable	O
with	O
BV	O
pacing	O
(	O
87	O
.	O
4	O
%	O
)	O
versus	O
RV	O
pacing	O
(	O
89	O
.	O
6	O
%	O
)	O
.	O

60	O
patients	O
were	O
entered	O
into	O
a	O
randomised	O
study	O
comparing	O
vindesine	O
(	O
3	O
mg	O
/	O
m2	O
/	O
week	O
)	O
plus	O
interferon	B-protein
-	I-protein
alpha	I-protein
2b	I-protein
(	O
6	O
U	O
/	O
m2	O
3	O
times	O
per	O
week	O
)	O
to	O
vindesine	O
alone	O
or	O
to	O
interferon	B-protein
alone	O
for	O
the	O
treatment	O
of	O
metastatic	O
malignant	O
melanoma	O
.	O

However	O
,	O
mutations	O
in	O
the	O
HNF	B-protein
-	I-protein
4	I-protein
binding	I-protein
site	I-protein
on	O
element	B-protein
CIIB	I-protein
and	O
inhibition	O
of	O
HNF	B-protein
-	I-protein
4	I-protein
synthesis	O
in	O
HepG2	O
cells	O
by	O
antisense	O
HNF	B-protein
-	I-protein
4	I-protein
constructs	I-protein
decreased	O
the	O
apoCII	B-protein
promoter	I-protein
activity	O
to	O
25	O
-	O
40	O
%	O
of	O
the	O
control	O
,	O
indicating	O
that	O
HNF	B-protein
-	I-protein
4	I-protein
is	O
a	O
positive	O
regulator	O
of	O
the	O
apoCII	B-protein
gene	I-protein
.	O

Our	O
results	O
indicate	O
that	O
D	B-protein
(	I-protein
4	I-protein
)	I-protein
and	O
D	B-protein
(	I-protein
2L	I-protein
)	I-protein
receptors	I-protein
activate	O
the	O
ERK	B-protein
kinase	I-protein
cascade	O
by	O
first	O
mobilizing	O
signaling	O
by	O
the	O
PDGF	B-protein
receptor	I-protein
,	O
followed	O
by	O
the	O
subsequent	O
activation	O
of	O
ERK1	B-protein
/	I-protein
2	I-protein
by	O
pathways	O
associated	O
with	O
this	O
receptor	B-protein
tyrosine	I-protein
kinase	I-protein
.	O

The	O
effects	O
of	O
anabolic	O
implants	O
on	O
rate	O
,	O
composition	O
and	O
energetic	O
efficiency	O
of	O
growth	O
were	O
determined	O
in	O
steers	O
fed	O
diets	O
varying	O
in	O
forage	O
and	O
grain	O
content	O
.	O

The	O
FAS	B-protein
promoter	I-protein
was	O
up	O
-	O
regulated	O
by	O
insulin	B-protein
through	O
the	O
proximal	O
insulin	B-protein
response	I-protein
sequence	I-protein
containing	O
an	O
E	O
-	O
box	O
motif	O
at	O
the	O
-	O
65	O
-	O
base	O
pair	O
position	O
.	O

In	O
cell	O
lines	O
transformed	O
by	O
BCR	B-protein
/	I-protein
ABL	I-protein
,	O
CRKL	B-protein
was	O
tyrosine	O
phosphorylated	O
,	O
while	O
CRK	B-protein
was	O
not	O
.	O

The	O
two	O
-	O
hybrid	O
assay	O
was	O
then	O
performed	O
using	O
full	O
-	O
length	O
genes	O
of	O
CI	B-protein
,	O
HC	B-protein
-	I-protein
Pro	I-protein
,	O
P1	B-protein
,	O
P3	B-protein
,	O
and	O
CP	B-protein
,	O
but	O
no	O
heterologous	O
interactions	O
were	O
detected	O
.	O

The	O
nucleolin	B-protein
gene	I-protein
extends	O
over	O
9000	O
base	O
-	O
pairs	O
and	O
is	O
split	O
into	O
14	O
exons	O
that	O
encode	O
the	O
706	O
amino	O
acid	O
residues	O
of	O
the	O
protein	O
.	O

With	O
the	O
exception	O
of	O
mutants	O
that	O
remove	O
the	O
membrane	O
anchor	O
domain	O
,	O
all	O
of	O
the	O
mutant	O
glycoproteins	O
retained	O
the	O
ability	O
to	O
cause	O
fusion	O
of	O
CD4	O
-	O
bearing	O
cells	O
.	O

We	O
also	O
present	O
evidence	O
that	O
human	B-protein
HYAL1	I-protein
is	O
identical	O
to	O
an	O
uncharacterized	O
gene	O
positionally	O
cloned	O
by	O
others	O
from	O
chromosome	O
3p21	O
.	O
3	O
that	O
is	O
homozygously	O
deleted	O
in	O
several	O
small	O
-	O
cell	O
lung	O
carcinoma	O
cell	O
lines	O
.	O

Furthermore	O
,	O
strains	O
with	O
mutant	B-protein
RPM1	I-protein
genes	I-protein
also	O
accumulate	O
precursor	B-protein
Rpm1r	I-protein
,	O
suggesting	O
that	O
mutations	O
in	O
either	O
gene	O
can	O
lead	O
to	O
similar	O
biogenesis	O
defects	O
.	O

Isolated	O
Systolic	O
Hypertension	O
:	O
An	O
Update	O
.	O

Also	O
,	O
the	O
BALB	B-protein
/	I-protein
c	I-protein
gene	I-protein
contains	O
a	O
single	O
substitution	O
in	O
a	O
conserved	O
octamer	O
sequence	O
approximately	O
equal	O
to	O
100	O
nucleotides	O
upstream	O
of	O
the	O
coding	O
region	O
,	O
which	O
could	O
affect	O
its	O
expression	O
.	O

Immunological	O
testing	O
was	O
performed	O
on	O
all	O
brewery	O
workers	O
and	O
some	O
control	O
volunteers	O
using	O
skin	O
prick	O
testing	O
with	O
hops	O
,	O
barley	O
,	O
and	O
yeast	O
antigens	O
as	O
well	O
as	O
other	O
nonoccupational	O
allergens	O
,	O
and	O
by	O
determining	O
total	O
serum	B-protein
IgE	I-protein
levels	O
.	O

Purified	O
CarP	B-protein
binds	O
in	O
vitro	O
to	O
the	O
carAB	B-protein
control	I-protein
region	I-protein
and	O
protects	O
against	O
DNase	B-protein
I	I-protein
two	O
approximately	O
25	O
bp	O
long	O
stretches	O
,	O
one	O
of	O
which	O
is	O
located	O
just	O
downstream	O
of	O
the	O
GATC	B-protein
sequence	I-protein
.	O

An	O
intact	O
neurovascular	O
supply	O
is	O
essential	O
for	O
the	O
viability	O
of	O
a	O
muscle	O
flap	O
.	O

The	O
pCMBS	O
-	O
reactive	O
sulfhydryl	O
groups	O
were	O
located	O
exclusively	O
in	O
the	O
exofacial	O
half	O
of	O
the	O
plasma	O
membrane	O
and	O
,	O
when	O
presented	O
in	O
a	O
helical	O
model	O
,	O
lie	O
along	O
one	O
side	O
of	O
the	O
helices	O
.	O

These	O
mutations	O
alter	O
two	O
regions	O
of	O
GAL4	B-protein
protein	I-protein
:	O
the	O
DNA	O
binding	O
domain	O
,	O
and	O
the	O
transcription	O
activation	O
domain	O
.	O

However	O
,	O
deletions	O
of	O
the	O
C	O
terminal	O
11	O
or	O
14	O
amino	O
acids	O
had	O
more	O
substantial	O
effects	O
.	O

In	O
the	O
local	O
geomagnetic	O
field	O
,	O
the	O
animals	O
preferred	O
the	O
SE	O
-	O
sector	O
.	O

Audiological	O
findings	O
in	O
pregnancy	O
.	O

Hemodynamic	O
assessment	O
was	O
obtained	O
before	O
and	O
following	O
administration	O
of	O
digoxin	O
10	O
micrograms	O
/	O
kg	O
IV	O
or	O
dopamine	O
,	O
5	O
to	O
12	O
micrograms	O
/	O
kg	O
/	O
min	O
IV	O
.	O

Both	O
groups	O
were	O
subjected	O
to	O
tests	O
of	O
delayed	O
hypersensitivity	O
with	O
Candidin	O
,	O
Trycophytin	O
and	O
Tuberculin	O
.	O

Notably	O
,	O
these	O
residues	O
are	O
located	O
in	O
different	O
domains	O
.	O

The	O
diagnostic	O
accuracy	O
of	O
serum	O
PE	B-protein
-	I-protein
1	I-protein
was	O
0	O
.	O
80	O
,	O
and	O
that	O
of	O
amylase	B-protein
0	O
.	O
97	O
.	O

Six	O
healthy	O
male	O
subjects	O
received	O
single	O
oral	O
doses	O
of	O
regular	O
release	O
(	O
RR	O
)	O
quinidine	O
sulfate	O
,	O
sustained	O
release	O
(	O
SR	O
)	O
quinidine	O
bisulfate	O
and	O
the	O
same	O
dose	O
of	O
the	O
SR	O
product	O
with	O
food	O
(	O
SR	O
-	O
F	O
)	O
.	O

We	O
discuss	O
the	O
results	O
in	O
relation	O
to	O
previous	O
systems	O
for	O
parcellating	O
the	O
posterior	O
ectosylvian	O
gyrus	O
of	O
the	O
cat	O
and	O
consider	O
the	O
possibility	O
that	O
divisions	O
of	O
the	O
feline	O
posterior	O
ectosylvian	O
gyrus	O
correspond	O
directly	O
to	O
areas	O
making	O
up	O
the	O
superior	O
temporal	O
gyrus	O
in	O
primates	O
.	O

The	O
results	O
indicate	O
that	O
anthraquinone	O
sennoside	O
B	O
and	O
rhein	O
are	O
weakly	O
genotoxic	O
.	O

The	O
motility	O
of	O
sperm	O
,	O
except	O
for	O
those	O
adjacent	O
to	O
both	O
electrodes	O
,	O
did	O
not	O
change	O
after	O
stimulation	O
for	O
60s	O
,	O
despite	O
a	O
high	O
electrical	O
energy	O
.	O

11	O
-	O
Aminoundecanoyl	O
-	O
SK	O
-	O
NH2	O
and	O
11	O
-	O
aminoundecanoyl	O
-	O
SH	O
-	O
NH2	O
establish	O
that	O
a	O
simple	O
alkyl	O
backbone	O
can	O
maintain	O
an	O
appropriate	O
distance	O
between	O
three	O
elements	O
critical	O
for	O
recognition	O
by	O
the	O
fungal	O
enzyme	O
'	O
s	O
peptide	O
-	O
binding	O
site	O
:	O
a	O
simple	O
omega	O
-	O
terminal	O
amino	O
group	O
,	O
a	O
beta	O
-	O
hydroxyl	O
,	O
and	O
an	O
epsilon	O
-	O
amino	O
group	O
or	O
an	O
imidazole	O
.	O

Homo	O
-	O
oligomerisation	O
and	O
nuclear	O
localisation	O
of	O
mouse	B-protein
histone	I-protein
deacetylase	I-protein
1	I-protein
.	O

Phorbol	O
esters	O
stimulated	O
phosphorylation	O
of	O
CSK	B-protein
35H	I-protein
proteins	I-protein
,	O
thus	O
emphasizing	O
that	O
sequences	O
isolated	O
according	O
to	O
PKC	B-protein
binding	O
activity	O
in	O
vitro	O
are	O
also	O
PKC	B-protein
substrates	O
in	O
vivo	O
.	O

TBP	B-protein
can	O
be	O
phosphorylated	O
in	O
vitro	O
by	O
extracts	O
of	O
U937	O
cells	O
or	O
by	O
bacterially	O
expressed	O
activated	O
ERK2	B-protein
;	O
the	O
phosphorylation	O
sites	O
were	O
mapped	O
to	O
ERK	B-protein
kinase	I-protein
consensus	I-protein
sites	I-protein
in	O
the	O
TBP	B-protein
amino	I-protein
-	I-protein
terminal	I-protein
domain	I-protein
.	O

Sodium	O
-	O
taurocholate	O
-	O
induced	O
acute	O
necrotizing	O
pancreatitis	O
does	O
not	O
affect	O
jejunal	O
oxygenation	O
in	O
pigs	O
.	O

Laser	O
ablation	O
has	O
been	O
employed	O
as	O
a	O
therapeutic	O
measure	O
for	O
chronic	O
pulmonary	O
emphysema	O
.	O

This	O
differential	O
sensitivity	O
to	O
DB	O
,	O
as	O
measured	O
by	O
a	O
lower	O
concentration	O
of	O
DB	O
which	O
caused	O
loss	O
of	O
righting	O
in	O
LS	O
,	O
was	O
accompanied	O
by	O
an	O
equal	O
rate	O
of	O
water	O
-	O
soluble	O
barbiturate	O
brain	O
distribution	O
and	O
elimination	O
in	O
the	O
two	O
lines	O
.	O

Smoking	O
was	O
regarded	O
as	O
the	O
major	O
contribution	O
to	O
pulmonary	O
dysfunction	O
.	O

Deletion	O
analysis	O
showed	O
that	O
the	O
-	O
321	O
/	O
+	O
41	O
sequence	O
was	O
sufficient	O
for	O
both	O
the	O
constitutive	O
promoter	O
activity	O
and	O
auto	O
-	O
activation	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
identified	O
the	O
interaction	O
of	O
C	B-protein
/	I-protein
EBPs	I-protein
and	O
Sp1	B-protein
to	O
this	O
region	O
.	O

A	O
reduction	O
of	O
the	O
aspartate	B-protein
aminotransferase	I-protein
activity	O
was	O
observed	O
from	O
800	O
mg	O
/	O
kg	O
b	O
.	O
w	O
.	O
/	O
d	O
onwards	O
.	O

Through	O
two	O
novel	O
mechanisms	O
,	O
Arf	B-protein
inhibits	O
the	O
oncoprotein	B-protein
Hdm2	I-protein
,	O
a	O
negative	O
regulator	O
of	O
p53	B-protein
.	O

On	O
the	O
basis	O
of	O
its	O
bZIP	B-protein
structural	O
homology	O
,	O
meq	B-protein
is	O
perhaps	O
the	O
only	O
member	O
of	O
the	O
jun	B-protein
-	I-protein
fos	I-protein
gene	I-protein
family	I-protein
completely	O
viral	O
in	O
origin	O
.	O

Although	O
further	O
studies	O
are	O
required	O
to	O
determine	O
the	O
precise	O
role	O
of	O
PEBP2	B-protein
in	O
the	O
GM	B-protein
-	I-protein
CSF	I-protein
promoter	I-protein
activity	O
,	O
the	O
present	O
findings	O
suggested	O
the	O
importance	O
of	O
the	O
relative	O
ratio	O
of	O
different	O
PEBP2	B-protein
isoforms	I-protein
in	O
regulating	O
the	O
levels	O
of	O
the	O
promoter	O
activity	O
.	O

FAK	B-protein
localizes	O
to	O
sites	O
of	O
transmembrane	B-protein
integrin	I-protein
receptor	I-protein
clustering	O
and	O
facilitates	O
intracellular	O
signaling	O
events	O
.	O

In	O
concert	O
with	O
the	O
coactivator	O
CREB	B-protein
binding	I-protein
protein	I-protein
/	I-protein
p300	I-protein
,	O
which	O
interacts	O
with	O
GABPalpha	B-protein
,	O
the	O
binding	O
of	O
GABPalpha	B-protein
and	I-protein
-	I-protein
beta	I-protein
to	O
the	O
dyad	O
symmetry	O
element	O
controls	O
the	O
induction	O
of	O
IL	B-protein
-	I-protein
16	I-protein
promoter	I-protein
in	O
T	O
cells	O
.	O

You	O
make	O
the	O
diagnosis	O
.	O

In	O
hemodialyzed	O
patients	O
(	O
Epo	B-protein
and	O
Non	O
-	O
Epo	O
group	O
)	O
leptin	B-protein
levels	O
were	O
significantly	O
higher	O
when	O
compared	O
to	O
CAPD	O
patients	O
(	O
Epo	B-protein
and	O
Non	O
-	O
Epo	O
group	O
,	O
respectively	O
)	O
.	O

Osteogenesis	O
imperfecta	O
.	O

This	O
region	O
of	O
60	O
amino	O
acids	O
may	O
be	O
involved	O
in	O
coiled	O
-	O
coil	O
interactions	O
similar	O
to	O
those	O
that	O
facilitate	O
the	O
filament	O
formation	O
in	O
the	O
rod	O
region	O
.	O

DNase	B-protein
I	I-protein
footprinting	O
and	O
electrophoretic	O
mobility	O
shift	O
analyses	O
revealed	O
two	O
hepatocyte	B-protein
nuclear	I-protein
factor	I-protein
-	I-protein
1	I-protein
(	O
HNF1	B-protein
)	O
,	O
three	O
CCAAT	B-protein
/	I-protein
enhancer	I-protein
-	I-protein
binding	I-protein
protein	I-protein
(	O
C	B-protein
/	I-protein
EBP	I-protein
)	O
,	O
and	O
one	O
consensus	O
palindromic	O
thyroid	B-protein
hormone	I-protein
response	I-protein
elements	I-protein
within	O
the	O
first	O
215	O
base	O
pairs	O
(	O
bp	O
)	O
of	O
the	O
promoter	O
sequence	O
of	O
rat	B-protein
Std	I-protein
.	O

GR63178A	O
is	O
a	O
water	O
-	O
soluble	O
analogue	O
of	O
mitoquidone	O
,	O
a	O
pentacyclic	O
pyrroloquinone	O
.	O

Identification	O
of	O
a	O
proline	O
-	O
rich	O
sequence	O
in	O
the	O
CD2	B-protein
cytoplasmic	I-protein
domain	I-protein
critical	O
for	O
regulation	O
of	O
integrin	O
-	O
mediated	O
adhesion	O
and	O
activation	O
of	O
phosphoinositide	B-protein
3	I-protein
-	I-protein
kinase	I-protein
.	O

16	O
women	O
were	O
treated	O
with	O
methadone	O
to	O
prevent	O
withdrawal	O
symptoms	O
.	O

Fundus	O
changes	O
in	O
(	O
type	O
II	O
)	O
mesangiocapillary	O
glomerulonephritis	O
simulating	O
drusen	O
:	O
a	O
histopathological	O
report	O
.	O

The	O
malate	B-protein
synthase	I-protein
gene	I-protein
,	O
MLS1	B-protein
,	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
is	O
transcriptionally	O
regulated	O
by	O
the	O
carbon	O
source	O
in	O
the	O
growth	O
medium	O
.	O

OBJECTIVE	O
:	O
To	O
follow	O
-	O
up	O
prospectively	O
patients	O
with	O
arthritis	O
after	O
infection	O
with	O
beta	O
-	O
haemolytic	O
streptococci	O
of	O
Lancefield	O
group	O
A	O
(	O
beta	O
HSA	O
)	O
,	O
with	O
emphasis	O
on	O
clinical	O
characteristics	O
and	O
serological	O
features	O
.	O

Gemfibrozil	O
in	O
hyperlipidaemic	O
patients	O
with	O
peripheral	O
arterial	O
disease	O
:	O
some	O
undiscovered	O
actions	O
.	O

The	O
results	O
support	O
earlier	O
reports	O
that	O
collagenase	B-protein
inhibitors	O
are	O
useful	O
in	O
controlling	O
blister	O
formation	O
in	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
.	O

Framingham	O
Type	O
A	O
behavior	O
was	O
positively	O
associated	O
with	O
diastolic	O
blood	O
pressure	O
(	O
r	O
=	O
0	O
.	O
17	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
among	O
the	O
women	O
.	O

The	O
neglect	O
of	O
Richards	O
'	O
s	O
theory	O
demonstrates	O
the	O
range	O
of	O
factors	O
,	O
other	O
than	O
the	O
strictly	O
scientific	O
,	O
which	O
can	O
be	O
important	O
in	O
determining	O
the	O
influence	O
or	O
otherwise	O
of	O
a	O
psychological	O
theory	O
.	O

C	B-protein
/	I-protein
EBP	I-protein
beta	I-protein
V	I-protein
>	O
A	O
selectively	O
binds	O
only	O
the	O
subset	O
of	O
C	B-protein
/	I-protein
EBP	I-protein
sites	I-protein
that	O
are	O
also	O
DBP	B-protein
sites	I-protein
,	O
both	O
as	O
oligonucleotides	O
and	O
within	O
the	O
natural	O
contexts	O
of	O
the	O
albumin	B-protein
and	O
cholesterol	B-protein
hydroxylase	I-protein
promoters	I-protein
.	O

The	O
first	O
algorithm	O
,	O
FOREPROJ	O
,	O
is	O
a	O
fast	O
-	O
forward	O
projection	O
algorithm	O
that	O
allows	O
calculation	O
of	O
the	O
3	O
-	O
D	O
attenuation	O
correction	O
factors	O
(	O
ACF	O
'	O
s	O
)	O
directly	O
from	O
a	O
two	O
-	O
dimensional	O
(	O
2	O
-	O
D	O
)	O
transmission	O
scan	O
,	O
without	O
first	O
reconstructing	O
the	O
attenuation	O
map	O
and	O
then	O
performing	O
a	O
3	O
-	O
D	O
forward	O
projection	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
reproducibility	O
of	O
a	O
number	O
of	O
simplified	O
clearance	O
methods	O
using	O
chromium	O
-	O
51	O
ethylenediamine	O
tetraacetic	O
acid	O
(	O
51Cr	O
-	O
EDTA	O
)	O
and	O
to	O
compare	O
these	O
with	O
the	O
multiple	O
blood	O
sample	O
technique	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
CAR	B-protein
revealed	O
that	O
CAR	B-protein
residues	I-protein
Leu73	I-protein
and	I-protein
Lys121	I-protein
and	I-protein
/	I-protein
or	I-protein
Lys123	I-protein
are	O
critical	O
contact	O
residues	O
,	O
with	O
Tyr80	O
and	O
Tyr83	O
being	O
peripherally	O
involved	O
in	O
the	O
binding	O
interaction	O
with	O
the	O
Ad5	O
,	O
Ad9	O
,	O
Ad12	O
,	O
and	O
Ad41L	O
fiber	O
knobs	O
.	O

The	O
Prolactin	B-protein
levels	O
were	O
within	O
the	O
physiological	O
norms	O
;	O
the	O
responses	O
to	O
TRH	B-protein
were	O
normal	O
,	O
and	O
elevated	O
only	O
in	O
a	O
few	O
cases	O
.	O

Interleukin	B-protein
-	I-protein
1	I-protein
levels	O
remained	O
low	O
throughout	O
the	O
course	O
.	O

This	O
dominant	O
-	O
negative	O
effect	O
of	O
FRNK	B-protein
was	O
reversed	O
by	O
a	O
point	O
mutation	O
(	O
Leu	O
-	O
1034	O
to	O
Ser	O
)	O
which	O
prevented	O
FRNK	B-protein
localization	O
to	O
focal	O
contact	O
sites	O
.	O

In	O
ten	O
other	O
experiments	O
(	O
5	O
experimental	O
and	O
5	O
control	O
rats	O
)	O
99mTc	O
-	O
sulfur	O
colloid	O
was	O
injected	O
intravenously	O
.	O

Additionally	O
,	O
the	O
mouse	O
promoter	O
contains	O
22	O
copies	O
of	O
a	O
CT	B-protein
dinucleotide	I-protein
repeat	I-protein
sequence	I-protein
located	O
approximately	O
155	O
bp	O
5	O
'	O
to	O
exon	O
1	O
.	O

In	O
contrast	O
,	O
over	O
-	O
expression	O
of	O
RAR	B-protein
beta	I-protein
only	O
poorly	O
restored	O
differentiation	O
,	O
although	O
it	O
could	O
replace	O
RAR	B-protein
gamma	I-protein
for	O
the	O
activation	O
of	O
target	O
genes	O
.	O

CONCLUSION	O
:	O
Human	O
preterm	O
birth	O
is	O
associated	O
with	O
significantly	O
lower	O
progesterone	O
/	O
17	O
beta	O
-	O
estradiol	O
ratios	O
than	O
those	O
of	O
women	O
with	O
preterm	O
labor	O
delivered	O
at	O
term	O
.	O

Thus	O
,	O
two	O
very	O
different	O
regulatory	O
elements	O
are	O
used	O
to	O
mediate	O
estrogen	O
induction	O
of	O
related	O
genes	O
in	O
chickens	O
and	O
amphibians	O
.	O

Specifically	O
,	O
by	O
oligonucleotide	O
-	O
directed	O
site	O
-	O
specific	O
mutagenesis	O
,	O
we	O
demonstrate	O
that	O
of	O
10	O
cysteine	O
residues	O
in	O
the	O
ORF4	O
polypeptide	O
,	O
only	O
C	O
-	O
421	O
and	O
C	O
-	O
426	O
are	O
essential	O
for	O
transactivator	O
function	O
and	O
suggest	O
that	O
these	O
cysteine	O
residues	O
may	O
participate	O
in	O
critical	O
protein	O
-	O
protein	O
interactions	O
rather	O
than	O
protein	O
-	O
nucleic	O
acid	O
interactions	O
to	O
mediate	O
ORF4	O
inducibility	O
.	O

The	O
effect	O
of	O
these	O
cell	O
cycle	O
regulators	O
is	O
not	O
specific	O
to	O
the	O
rap1s	B-protein
or	O
hmr	B-protein
delta	I-protein
A	I-protein
mutation	I-protein
,	O
since	O
swi6	B-protein
,	O
swi4	B-protein
,	O
and	O
clb5	B-protein
mutations	I-protein
also	O
suppress	O
mutations	O
in	O
SIR1	B-protein
,	O
another	O
gene	O
implicated	O
in	O
the	O
establishment	O
of	O
silencing	O
.	O

Some	O
of	O
the	O
peptide	B-protein
:	I-protein
MBP	I-protein
fusions	I-protein
were	O
also	O
analyzed	O
using	O
surface	O
plasmon	O
resonance	O
.	O

3	O
.	O

METHODS	O
:	O
We	O
studied	O
the	O
clinical	O
benefit	O
of	O
depth	O
-	O
dependent	O
RR	O
,	O
nonuniform	O
AC	O
using	O
a	O
scanning	O
line	O
source	O
,	O
and	O
scatter	O
correction	O
(	O
photon	O
energy	O
recovery	O
[	O
PER	O
]	O
)	O
compared	O
with	O
filtered	O
backprojection	O
alone	O
.	O

In	O
contrast	O
,	O
a	O
Maf	B-protein
-	I-protein
related	I-protein
protein	I-protein
,	O
Nrl	B-protein
,	O
completely	O
mimicked	O
c	B-protein
-	I-protein
Maf	I-protein
actions	O
.	O

TRAF2	B-protein
is	O
a	O
potent	O
activator	O
of	O
a	O
95	B-protein
-	I-protein
kDa	I-protein
serine	I-protein
/	I-protein
threonine	I-protein
kinase	I-protein
termed	O
germinal	B-protein
center	I-protein
kinase	I-protein
related	I-protein
(	O
GCKR	B-protein
,	O
also	O
referred	O
to	O
as	O
KHS1	B-protein
)	O
,	O
which	O
signals	O
activation	O
of	O
the	O
SAPK	B-protein
pathway	O
.	O

Clinical	O
and	O
epidemiological	O
characteristics	O
of	O
oral	O
squamous	O
cell	O
carcinoma	O
in	O
women	O
BACKGROUND	O
:	O
Squamous	O
cell	O
carcinoma	O
(	O
SCC	O
)	O
of	O
the	O
oral	O
cavity	O
occurs	O
mainly	O
in	O
the	O
male	O
population	O
.	O

The	O
TraD	B-protein
protein	I-protein
(	I-protein
83	I-protein
,	I-protein
899	I-protein
Da	I-protein
)	I-protein
contains	O
three	O
hydrophobic	O
regions	O
,	O
of	O
which	O
two	O
are	O
located	O
near	O
the	O
amino	O
-	O
terminal	O
region	O
.	O

Human	O
ZFM1	B-protein
protein	I-protein
is	O
a	O
transcriptional	O
repressor	O
that	O
interacts	O
with	O
the	O
transcription	B-protein
activation	I-protein
domain	I-protein
of	I-protein
stage	I-protein
-	I-protein
specific	I-protein
activator	I-protein
protein	I-protein
.	O

Reaction	O
times	O
to	O
tachistoscopically	O
presented	O
stimuli	O
in	O
diabetics	O
.	O

Following	O
the	O
satisfactory	O
results	O
and	O
taking	O
into	O
account	O
that	O
the	O
complications	O
had	O
reduced	O
to	O
a	O
very	O
low	O
rate	O
(	O
in	O
2	O
cases	O
lead	O
tip	O
displacement	O
and	O
pouch	O
haematoma	O
occurred	O
respectively	O
)	O
,	O
the	O
Authors	O
consider	O
the	O
adopted	O
method	O
an	O
useful	O
approach	O
for	O
PMK	O
implantation	O
particularly	O
when	O
the	O
use	O
of	O
the	O
vena	O
cephalica	O
is	O
deemed	O
impossible	O
.	O

In	O
patients	O
with	O
type	O
IA	O
maple	O
syrup	O
urine	O
disease	O
,	O
the	O
E1alpha	B-protein
subunit	I-protein
is	O
affected	O
,	O
resulting	O
in	O
the	O
loss	O
of	O
E1	B-protein
and	O
branched	B-protein
-	I-protein
chain	I-protein
ketoacid	I-protein
dehydrogenase	I-protein
catalytic	O
activities	O
.	O

These	O
data	O
indicate	O
that	O
the	O
largest	O
subunit	O
of	O
RNA	B-protein
polymerase	I-protein
II	I-protein
and	O
TFIIB	B-protein
are	O
important	O
determinants	O
of	O
transcription	O
start	O
site	O
selection	O
in	O
S	O
.	O
cerevisiae	O
and	O
suggest	O
that	O
this	O
function	O
might	O
be	O
conferred	O
by	O
interaction	O
between	O
these	O
two	O
proteins	O
.	O

Two	O
patients	O
with	O
recurrent	O
tumors	O
had	O
high	O
S	O
-	O
phase	O
fractions	O
both	O
on	O
the	O
first	O
resected	O
specimens	O
and	O
at	O
the	O
time	O
of	O
the	O
second	O
operation	O
.	O

SIN	O
-	O
1	O
had	O
no	O
influence	O
on	O
either	O
the	O
ischemic	O
parameters	O
in	O
the	O
surface	O
electrocardiogram	O
(	O
ECG	O
)	O
or	O
the	O
intracoronary	O
ECG	O
.	O

Human	O
isoforms	O
,	O
designated	O
1	O
to	O
4	O
,	O
differ	O
from	O
each	O
other	O
by	O
the	O
start	O
codon	O
used	O
.	O

The	O
orf61	B-protein
gene	I-protein
product	I-protein
,	O
when	O
expressed	O
from	O
an	O
exogenous	O
promoter	O
,	O
inhibited	O
int	O
-	O
mediated	O
integration	O
at	O
the	O
chromosomal	B-protein
attB	I-protein
site	I-protein
.	O

Surgical	O
treatment	O
of	O
pathologic	O
scars	O
of	O
myocardial	O
infarct	O
.	O

Hybrid	O
female	O
mice	O
(	O
C57BL	O
x	O
CBA	O
)	O
were	O
paired	O
with	O
breeder	O
males	O
(	O
CD	O
-	O
1	O
)	O
and	O
LNG	O
pellets	O
were	O
implanted	O
on	O
day	O
0	O
,	O
the	O
day	O
on	O
which	O
copulation	O
plugs	O
were	O
found	O
,	O
or	O
on	O
day	O
2	O
or	O
day	O
3	O
in	O
the	O
postcoital	O
period	O
.	O

Temafloxacin	O
400	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
administered	O
orally	O
for	O
28	O
days	O
represents	O
a	O
safe	O
and	O
effective	O
treatment	O
for	O
chronic	O
bacterial	O
prostatitis	O
.	O

Low	O
MAO	B-protein
subjects	O
showed	O
a	O
pattern	O
of	O
higher	O
scores	O
in	O
KSP	O
Impulsiveness	O
,	O
EPQ	O
Neuroticism	O
,	O
and	O
KSP	O
Somatic	O
Anxiety	O
and	O
Irritability	O
and	O
lower	O
scores	O
in	O
KSP	O
Socialization	O
,	O
in	O
line	O
with	O
personality	O
profiles	O
found	O
in	O
alcoholics	O
,	O
psychopaths	O
,	O
and	O
suicide	O
attempters	O
who	O
also	O
tend	O
to	O
have	O
low	O
platelet	O
MAO	B-protein
activity	O
.	O

It	O
brings	O
about	O
fatigue	O
,	O
negative	O
moods	O
,	O
and	O
impaired	O
health	O
,	O
sleep	O
,	O
safety	O
,	O
and	O
working	O
capacity	O
.	O

Next	O
,	O
we	O
show	O
that	O
two	O
EMS	O
-	O
induced	O
mutations	O
,	O
previously	O
shown	O
to	O
interact	O
genetically	O
with	O
zipper	B-protein
(	I-protein
Ebr	I-protein
)	I-protein
,	O
disrupt	O
the	O
RhoA	B-protein
locus	I-protein
.	O

HSF	B-protein
binds	O
DNA	O
as	O
a	O
trimer	O
,	O
and	O
additional	O
trimers	O
can	O
bind	O
DNA	O
co	O
-	O
operatively	O
.	O

Mouse	B-protein
Impact	I-protein
is	O
a	O
paternally	O
expressed	O
gene	O
encoding	O
an	O
evolutionarily	O
conserved	O
protein	O
of	O
unknown	O
function	O
.	O

BACKGROUND	O
:	O
Mitosis	O
is	O
regulated	O
by	O
MPF	B-protein
(	O
maturation	B-protein
promoting	I-protein
factor	I-protein
)	O
,	O
the	O
active	O
form	O
of	O
Cdc2	B-protein
/	I-protein
28	I-protein
-	I-protein
cyclin	I-protein
B	I-protein
complexes	I-protein
.	O

We	O
report	O
an	O
example	O
of	O
an	O
MDV	O
-	O
transformed	O
T	O
-	O
lymphoblastoid	O
cell	O
line	O
(	O
T9	O
)	O
expressing	O
high	O
levels	O
of	O
a	O
truncated	B-protein
C	I-protein
-	I-protein
MYB	I-protein
protein	I-protein
as	O
a	O
result	O
of	O
RAV	O
integration	O
within	O
one	O
c	B-protein
-	I-protein
myb	I-protein
allele	I-protein
.	O

The	O
interaction	O
of	O
caffeine	O
,	O
theophylline	O
and	O
theobromine	O
with	O
monoamine	B-protein
oxidase	I-protein
inhibitors	O
.	O

To	O
gain	O
an	O
understanding	O
of	O
the	O
mGSTM2	B-protein
regulation	O
,	O
we	O
have	O
also	O
cloned	O
and	O
analyzed	O
its	O
promoter	O
region	O
.	O

Mutations	O
in	O
three	O
loci	O
(	O
SIC1	B-protein
,	O
SWI5	B-protein
,	O
and	O
RIC3	B-protein
)	O
were	O
identified	O
.	O

Therefore	O
,	O
mechanisms	O
that	O
control	O
activation	O
of	O
the	O
MAP	B-protein
kinase	I-protein
cascade	I-protein
temporally	O
and	O
spatially	O
may	O
be	O
important	O
for	O
specification	O
of	O
cellular	O
responses	O
.	O

None	O
had	O
a	O
past	O
history	O
of	O
opportunistic	O
infections	O
;	O
neither	O
did	O
any	O
have	O
lymphopenia	O
.	O

In	O
H4IIE	O
rat	O
hepatoma	O
cells	O
,	O
glucocorticoids	O
,	O
retinoic	O
acid	O
and	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
increase	O
PEPCK	B-protein
gene	I-protein
transcription	O
whereas	O
insulin	B-protein
and	O
phorbol	O
esters	O
have	O
the	O
opposite	O
effect	O
.	O

Until	O
such	O
investigations	O
are	O
performed	O
,	O
we	O
conclude	O
that	O
the	O
role	O
for	O
adjuvant	O
treatment	O
is	O
questionable	O
and	O
that	O
TME	O
surgery	O
is	O
preferred	O
as	O
the	O
treatment	O
option	O
for	O
Stage	O
T1	O
-	O
T3	O
rectal	O
cancers	O
.	O

It	O
was	O
established	O
that	O
intrathecal	O
or	O
intraperitoneal	O
PTFL	O
,	O
elevated	O
the	O
nociceptive	O
threshold	O
for	O
mechanical	O
stimuli	O
in	O
the	O
formalin	O
test	O
in	O
rats	O
.	O

The	O
E1	B-protein
nuclear	I-protein
transport	I-protein
motif	I-protein
is	O
highly	O
conserved	O
in	O
the	O
animal	O
and	O
human	O
papillomaviruses	O
and	O
is	O
encoded	O
in	O
a	O
similar	O
region	O
in	O
the	O
related	O
E1	B-protein
genes	I-protein
.	O

The	O
gene	O
is	O
contained	O
within	O
a	O
1	B-protein
.	I-protein
8	I-protein
-	I-protein
kilobase	I-protein
AccI	I-protein
-	I-protein
EcoRI	I-protein
restriction	I-protein
fragment	I-protein
mapping	O
at	O
map	O
coordinates	O
0	O
.	O
136	O
to	O
0	O
.	O
148	O
in	O
the	O
UL	B-protein
region	I-protein
of	O
the	O
EHV	O
-	O
1	O
genome	O
and	O
is	O
transcribed	O
from	O
right	O
to	O
left	O
.	O

Alternatively	O
processed	O
isoforms	O
of	O
cellular	B-protein
nucleic	I-protein
acid	I-protein
-	I-protein
binding	I-protein
protein	I-protein
interact	O
with	O
a	O
suppressor	O
region	O
of	O
the	O
human	B-protein
beta	I-protein
-	I-protein
myosin	I-protein
heavy	I-protein
chain	I-protein
gene	I-protein
.	O

Improvement	O
of	O
the	O
polypyrimidine	O
tract	O
also	O
increased	O
the	O
splicing	O
efficiency	O
,	O
but	O
to	O
a	O
degree	O
slightly	O
less	O
than	O
that	O
obtained	O
with	O
the	O
branchpoint	O
mutation	O
.	O

Thus	O
,	O
the	O
predicted	O
CD30v	B-protein
protein	I-protein
retains	O
most	O
of	O
the	O
cytoplasmic	O
region	O
,	O
but	O
lacks	O
the	O
extracellular	O
and	O
transmembrane	O
domains	O
.	O

Validity	O
of	O
immunohistology	O
and	O
in	O
situ	O
hybridization	O
in	O
the	O
differential	O
diagnosis	O
of	O
cytomegalovirus	O
pneumonia	O
and	O
idiopathic	O
interstitial	O
pneumonia	O
after	O
allogenic	O
bone	O
marrow	O
transplantation	O
.	O

This	O
work	O
,	O
therefore	O
,	O
also	O
emphasizes	O
the	O
importance	O
of	O
careful	O
choice	O
of	O
oligonucleotide	O
and	O
cDNA	O
probes	O
to	O
study	O
PKC	B-protein
zeta	I-protein
mRNA	I-protein
.	O

A	O
prospective	O
observational	O
study	O
was	O
conducted	O
to	O
identify	O
early	O
indicators	O
of	O
acute	O
dengue	O
virus	O
infection	O
.	O

The	O
homeobox	B-protein
gene	I-protein
ATK1	I-protein
of	O
Arabidopsis	O
thaliana	O
is	O
expressed	O
in	O
the	O
shoot	O
apex	O
of	O
the	O
seedling	O
and	O
in	O
flowers	O
and	O
inflorescence	O
stems	O
of	O
mature	O
plants	O
.	O

Since	O
glutathione	B-protein
peroxidase	I-protein
(	O
GPX	B-protein
)	O
and	O
superoxide	B-protein
dismutase	I-protein
(	O
SOD	B-protein
)	O
play	O
a	O
significant	O
role	O
in	O
erythrocyte	O
antioxidative	O
defence	O
,	O
it	O
is	O
very	O
important	O
to	O
determine	O
their	O
activity	O
in	O
occupationally	O
exposed	O
workers	O
.	O

Oligosynaptic	O
EPSP	O
components	O
were	O
consistently	O
modulated	O
only	O
in	O
the	O
superficial	O
peroneal	O
responses	O
in	O
flexor	O
motoneurons	O
,	O
which	O
exhibited	O
enhanced	O
amplitude	O
during	O
the	O
flexion	O
phase	O
.	O

Like	O
the	O
consensus	B-protein
mammalian	I-protein
LHbeta	I-protein
gene	I-protein
,	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
gpLH	B-protein
/	I-protein
CGbeta	I-protein
gene	I-protein
contains	O
a	O
single	O
TATA	O
sequence	O
37	O
bp	O
upstream	O
of	O
the	O
translation	O
start	O
codon	O
.	O

Marrow	O
cell	O
necrosis	O
in	O
anorexia	O
nervosa	O
and	O
involuntary	O
starvation	O
.	O

Because	O
the	O
hcf109	B-protein
locus	I-protein
was	O
mapped	O
at	O
a	O
distance	O
<	O
0	O
.	O
1	O
centimorgans	O
from	O
the	O
phytochrome	B-protein
C	I-protein
gene	I-protein
,	O
its	O
molecular	O
characterization	O
by	O
positional	O
cloning	O
is	O
possible	O
.	O

Despite	O
this	O
there	O
was	O
no	O
difference	O
in	O
the	O
intubating	O
conditions	O
at	O
one	O
minute	O
with	O
25	O
excellent	O
/	O
5	O
good	O
in	O
the	O
suxamethonium	O
group	O
and	O
27	O
excellent	O
/	O
3	O
good	O
in	O
the	O
rocuronium	O
group	O
.	O

However	O
,	O
by	O
an	O
NS35	B-protein
-	I-protein
specific	I-protein
RNA	I-protein
capture	O
assay	O
,	O
the	O
multimers	O
were	O
shown	O
to	O
possess	O
the	O
RNA	O
-	O
binding	O
activity	O
previously	O
demonstrated	O
for	O
NS35	B-protein
.	O

This	O
molecule	O
,	O
wH22xeGFP	B-protein
,	O
consists	O
of	O
the	O
entire	B-protein
humanized	I-protein
anti	I-protein
-	I-protein
FcgammaRI	I-protein
mAb	I-protein
H22	I-protein
with	O
eGFP	B-protein
genetically	O
fused	O
to	O
the	O
C	O
-	O
terminal	O
end	O
of	O
each	O
CH3	B-protein
domain	I-protein
.	O
wH22xeGFP	B-protein
binds	O
within	O
the	O
ligand	O
-	O
binding	O
region	O
by	O
its	O
Fc	B-protein
end	O
,	O
as	O
well	O
as	O
outside	O
the	O
ligand	O
-	O
binding	O
region	O
by	O
its	O
Fab	B-protein
ends	O
,	O
thereby	O
cross	O
-	O
linking	O
FcgammaRI	B-protein
.	O

For	O
example	O
,	O
introduction	O
of	O
immunogenic	O
and	O
purification	O
tag	O
sequences	O
into	O
the	O
C	O
-	O
terminal	O
coding	O
region	O
significantly	O
decreased	O
bop	B-protein
gene	I-protein
mRNA	I-protein
and	O
protein	O
accumulation	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
carboxyl	O
terminus	O
of	O
CFTR	B-protein
contains	O
a	O
tyrosine	O
-	O
based	O
internalization	O
signal	O
that	O
interacts	O
with	O
the	O
endocytic	O
adaptor	O
complex	O
AP	B-protein
-	I-protein
2	I-protein
to	O
facilitate	O
efficient	O
entry	O
of	O
CFTR	B-protein
into	O
clathrin	O
-	O
coated	O
vesicles	O
.	O

After	O
treatment	O
with	O
tunicamycin	O
,	O
the	O
transfectants	O
secreted	O
unglycosylated	O
18	O
-	O
kDa	O
polypeptides	O
which	O
could	O
also	O
bind	O
IgE	B-protein
.	O

Fisher	O
'	O
s	O
exact	O
test	O
or	O
Pearson	O
'	O
s	O
chi2	O
test	O
were	O
used	O
for	O
statistical	O
analysis	O
.	O

RESULTS	O
:	O
Basal	O
plasma	B-protein
IGF	I-protein
-	I-protein
I	I-protein
levels	O
as	O
well	O
as	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
were	O
lower	O
in	O
amenorrheic	O
patients	O
than	O
in	O
healthy	O
controls	O
.	O

Studies	O
on	O
Coxsackie	O
B	O
Type	O
5	O
virus	O
infections	O
.	O

Polymerase	O
chain	O
reaction	O
analysis	O
of	O
ETS1	B-protein
cDNA	I-protein
identified	O
several	O
amplified	O
products	O
,	O
indicating	O
alternative	O
splicing	O
.	O

Platelet	O
-	O
derived	O
growth	O
factor	O
-	O
dependent	O
activation	O
of	O
phosphatidylinositol	B-protein
3	I-protein
-	I-protein
kinase	I-protein
is	O
regulated	O
by	O
receptor	O
binding	O
of	O
SH2	B-protein
-	I-protein
domain	I-protein
-	I-protein
containing	I-protein
proteins	I-protein
which	O
influence	O
Ras	B-protein
activity	O
.	O

The	O
activity	O
of	O
the	O
coat	B-protein
protein	I-protein
promoter	I-protein
of	O
chloris	O
striate	O
mosaic	O
virus	O
is	O
enhanced	O
by	O
its	O
own	O
and	O
C1	B-protein
-	I-protein
C2	I-protein
gene	I-protein
products	I-protein
.	O

The	O
ether	O
phospholipid	O
1	O
-	O
O	O
-	O
octadecyl	O
-	O
2	O
-	O
O	O
-	O
methyl	O
-	O
rac	O
-	O
glycero	O
-	O
3	O
-	O
phosphocholine	O
(	O
ET	O
-	O
18	O
-	O
OCH3	O
;	O
edelfosine	O
)	O
is	O
a	O
potent	O
inducer	O
of	O
apoptosis	O
in	O
human	O
tumor	O
cells	O
.	O

The	O
factor	O
structure	O
of	O
`	O
`	O
schizotypal	O
'	O
traits	O
:	O
a	O
large	O
replication	O
study	O
.	O

Resistance	O
to	O
the	O
simulated	O
physiologic	O
environment	O
was	O
tested	O
by	O
measured	O
retention	O
of	O
mechanical	O
properties	O
after	O
immersion	O
times	O
in	O
pseudo	O
-	O
extracellular	O
fluid	O
(	O
PECF	O
)	O
at	O
37	O
degrees	O
C	O
for	O
as	O
long	O
as	O
three	O
years	O
.	O

We	O
found	O
that	O
lung	O
cancer	O
tissues	O
of	O
positive	O
67Ga	O
scan	O
expressed	O
TFR	B-protein
,	O
but	O
those	O
of	O
a	O
negative	O
scan	O
did	O
not	O
.	O

The	O
results	O
of	O
replicase	B-protein
assays	O
performed	O
with	O
mutant	B-protein
VP2	I-protein
containing	O
a	O
deletion	O
in	O
its	O
RNA	O
-	O
binding	O
domain	O
suggests	O
that	O
the	O
essential	O
role	O
for	O
VP2	B-protein
in	O
replication	O
is	O
linked	O
to	O
the	O
protein	O
'	O
s	O
ability	O
to	O
bind	O
the	O
mRNA	O
template	O
for	O
minus	O
-	O
strand	O
synthesis	O
.	O

No	O
significant	O
differences	O
were	O
found	O
between	O
the	O
TS	O
and	O
the	O
PTS	O
.	O

Recurrent	O
arterial	O
thrombotic	O
disease	O
on	O
young	O
onset	O
and	O
protein	B-protein
S	I-protein
deficiency	O
.	O

Hemolytic	O
jaundice	O
due	O
to	O
G6PD	B-protein
deficiency	O
causing	O
kernicterus	O
in	O
a	O
female	O
newborn	O
.	O

The	O
presence	O
of	O
locus	O
-	O
specific	O
residues	O
throughout	O
the	O
entire	O
promoter	O
region	O
strongly	O
suggests	O
that	O
the	O
various	O
HLA	B-protein
class	I-protein
I	I-protein
loci	I-protein
are	O
differentially	O
regulated	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Computer	O
assisted	O
mapping	O
in	O
quantitative	O
analysis	O
of	O
cerebral	O
positron	O
emission	O
tomograms	O
.	O

Maternal	O
lactation	O
.	O

In	O
mouse	O
,	O
Mmip1	B-protein
(	O
Mad	B-protein
member	I-protein
interacting	I-protein
protein	I-protein
1	I-protein
)	O
and	O
Smc3	B-protein
share	O
99	O
%	O
sequence	O
identity	O
and	O
are	O
products	O
of	O
the	O
same	O
gene	O
.	O

Intracellular	O
pH	O
,	O
H	O
ion	O
flux	O
and	O
H	O
ion	O
permeability	O
coefficient	O
in	O
bullfrog	O
toe	O
muscle	O
.	O

The	O
variability	O
is	O
most	O
likely	O
a	O
result	O
of	O
alternative	O
splicing	O
of	O
exons	O
from	O
the	O
primary	O
elastin	B-protein
transcripts	I-protein
.	O

Analysis	O
of	O
the	O
promoter	O
sequence	O
revealed	O
the	O
presence	O
of	O
a	O
major	O
transcriptional	O
start	O
site	O
,	O
a	O
canonical	O
TATA	O
box	O
and	O
putative	O
cis	O
regulatory	O
elements	O
for	O
pituitary	O
specific	O
expression	O
as	O
well	O
as	O
an	O
E	B-protein
-	I-protein
responsive	I-protein
element	I-protein
.	O

We	O
previously	O
showed	O
that	O
the	O
upstream	B-protein
promoter	I-protein
element	I-protein
of	O
the	O
yeast	B-protein
RP39A	I-protein
gene	I-protein
consists	O
of	O
these	O
identical	O
sequence	O
motifs	O
.	O

The	O
roles	O
of	O
phorbol	O
esters	O
and	O
cyclic	O
AMP	O
in	O
mediating	O
the	O
GnRH	B-protein
response	O
were	O
also	O
investigated	O
.	O

Clinical	O
and	O
haematological	O
signs	O
are	O
not	O
specific	O
in	O
this	O
setting	O
,	O
and	O
the	O
diagnosis	O
relies	O
on	O
histological	O
features	O
,	O
mainly	O
bone	O
marrow	O
examination	O
.	O

The	O
prevalence	O
of	O
tobacco	O
dependence	O
diagnosed	O
according	O
to	O
the	O
ICD	O
-	O
10	O
criteria	O
was	O
higher	O
in	O
alcohol	O
-	O
dependent	O
individuals	O
(	O
58	O
.	O
1	O
%	O
)	O
than	O
in	O
nondrinkers	O
or	O
social	O
drinkers	O
(	O
12	O
.	O
8	O
%	O
)	O
.	O

The	O
carboxyl	O
-	O
terminal	O
transactivation	O
domain	O
of	O
heat	B-protein
shock	I-protein
factor	I-protein
1	I-protein
is	O
negatively	O
regulated	O
and	O
stress	O
responsive	O
.	O

Three	O
new	O
aromatase	B-protein
inhibitors	O
have	O
recently	O
completed	O
phase	O
III	O
evaluation	O
as	O
treatment	O
of	O
metastatic	O
breast	O
cancer	O
in	O
post	O
-	O
menopausal	O
women	O
whose	O
disease	O
has	O
progressed	O
despite	O
tamoxifen	O
therapy	O
:	O
anastrozole	O
(	O
ARIMIDEX	O
,	O
Zeneca	O
)	O
,	O
letrozole	O
(	O
FEMARA	O
,	O
Novartis	O
)	O
and	O
vorozole	O
(	O
RIVIZOR	O
,	O
Janssen	O
)	O
.	O

The	O
recognition	O
specificity	O
of	O
the	O
p55	B-protein
PDZ	I-protein
domain	I-protein
appears	O
to	O
be	O
unique	O
,	O
since	O
the	O
three	O
PDZ	B-protein
domains	I-protein
of	O
hDlg	B-protein
(	O
human	O
lymphocyte	O
homologue	O
of	O
the	O
Drosophila	B-protein
discs	I-protein
large	I-protein
tumor	I-protein
suppressor	I-protein
)	O
do	O
not	O
bind	O
the	O
cytoplasmic	O
domain	O
of	O
glycophorin	B-protein
C	I-protein
.	O

The	O
Fas	B-protein
receptor	I-protein
mediates	O
a	O
signalling	O
cascade	O
resulting	O
in	O
programmed	O
cell	O
death	O
(	O
apoptosis	O
)	O
within	O
hours	O
of	O
receptor	O
cross	O
-	O
linking	O
.	O

Moreover	O
,	O
it	O
also	O
discusses	O
the	O
effects	O
of	O
antihypertensive	O
drugs	O
currently	O
regarded	O
as	O
first	O
-	O
choice	O
agents	O
,	O
i	O
.	O
e	O
.	O
calcium	O
antagonists	O
and	O
the	O
angiotensin	B-protein
converting	I-protein
enzyme	I-protein
inhibitors	O
,	O
on	O
intrarenal	O
hemodynamics	O
.	O

Regulation	O
of	O
laminin	B-protein
beta2	I-protein
chain	I-protein
gene	I-protein
expression	O
in	O
human	O
cancer	O
cell	O
lines	O
.	O

Lesion	O
diameters	O
of	O
greater	O
than	O
20	O
mm	O
and	O
the	O
large	O
sessile	O
-	O
type	O
configurations	O
were	O
factors	O
that	O
were	O
associated	O
with	O
incomplete	O
removal	O
.	O

Thus	O
,	O
diamide	O
treatment	O
of	O
nuclear	O
extracts	O
strongly	O
reduces	O
the	O
binding	O
of	O
NFI	B-protein
proteins	I-protein
,	O
and	O
the	O
addition	O
of	O
higher	O
concentrations	O
of	O
dithiothreitol	O
to	O
nuclear	O
extracts	O
from	O
TG	O
-	O
treated	O
cells	O
restores	O
NFI	B-protein
-	I-protein
DNA	I-protein
binding	O
to	O
levels	O
in	O
extracts	O
from	O
untreated	O
cells	O
.	O

Subjects	O
were	O
16	O
male	O
chronic	O
schizophrenics	O
consisting	O
of	O
8	O
DST	O
suppressors	O
and	O
8	O
nonsuppressors	O
.	O

In	O
these	O
cells	O
,	O
E2	B-protein
proteins	I-protein
had	O
little	O
or	O
no	O
stimulatory	O
effect	O
on	O
the	O
transcriptional	O
activity	O
of	O
the	O
HPV	B-protein
-	I-protein
11	I-protein
enhancer	I-protein
-	I-protein
SV40	I-protein
promoter	I-protein
.	O

Constructs	O
designed	O
and	O
expressed	O
were	O
E2L1	B-protein
(	I-protein
1	I-protein
-	I-protein
98	I-protein
)	I-protein
,	O
E2L1	B-protein
.	I-protein
H1	I-protein
(	I-protein
1	I-protein
-	I-protein
128	I-protein
)	I-protein
,	O
E2L2	B-protein
(	I-protein
120	I-protein
-	I-protein
233	I-protein
)	I-protein
,	O
E2H1	B-protein
.	I-protein
L2	I-protein
(	I-protein
98	I-protein
-	I-protein
233	I-protein
)	I-protein
,	O
and	O
E2L1	B-protein
.	I-protein
H1	I-protein
.	I-protein
L2	I-protein
(	I-protein
1	I-protein
-	I-protein
233	I-protein
)	I-protein
,	O
where	O
numbers	O
in	O
parentheses	O
give	O
the	O
amino	O
acid	O
sequence	O
for	O
the	O
portions	O
of	O
the	O
E2	B-protein
component	O
incorporated	O
into	O
a	O
construct	O
.	O

Deglycosylation	O
with	O
endoglycosidase	B-protein
H	I-protein
showed	O
that	O
the	O
mutant	O
receptors	O
had	O
mainly	O
high	O
-	O
mannose	O
oligosaccharide	O
chains	O
.	O

Pulmonary	O
arterial	O
pressure	O
and	O
structure	O
in	O
the	O
patas	O
monkey	O
after	O
prolonged	O
administration	O
of	O
aminorex	O
fumarate	O
.	O

This	O
multiple	O
-	O
electrode	O
array	O
for	O
round	O
window	O
cochlear	O
implantation	O
is	O
a	O
robust	O
,	O
reliable	O
system	O
for	O
inserting	O
20	O
mm	O
along	O
the	O
scala	O
tympani	O
with	O
a	O
minimum	O
of	O
trauma	O
and	O
can	O
provide	O
for	O
bipolar	O
stimulation	O
.	O

Although	O
there	O
is	O
little	O
evidence	O
that	O
diet	O
composition	O
plays	O
a	O
clinically	O
important	O
role	O
in	O
the	O
absorption	O
or	O
expenditure	O
of	O
energy	O
,	O
it	O
does	O
appear	O
to	O
play	O
a	O
role	O
in	O
food	O
intake	O
.	O

Interference	O
with	O
rheumatoid	B-protein
factor	I-protein
was	O
only	O
observed	O
in	O
the	O
ELISA	O
enzygnost	O
if	O
sera	O
were	O
not	O
pretreated	O
with	O
latex	O
adsorbents	O
.	O

A	O
comparison	O
of	O
the	O
promoters	O
for	O
muMIP	B-protein
-	I-protein
1	I-protein
beta	I-protein
and	O
muMIP	B-protein
-	I-protein
1	I-protein
alpha	I-protein
reveals	O
a	O
conserved	O
CK	B-protein
-	I-protein
1	I-protein
element	I-protein
,	O
but	O
transient	O
expression	O
studies	O
in	O
RAW	O
264	O
.	O
7	O
macrophages	O
with	O
proximal	O
fragments	O
of	O
either	O
the	O
muMIP	B-protein
-	I-protein
1	I-protein
beta	I-protein
or	O
the	O
muMIP	B-protein
-	I-protein
1	I-protein
alpha	I-protein
5	I-protein
'	I-protein
promoter	I-protein
fused	O
to	O
a	O
human	B-protein
growth	I-protein
hormone	I-protein
reporter	I-protein
gene	I-protein
link	O
LPS	O
-	O
inducibility	O
in	O
both	O
to	O
promoter	O
segments	O
near	O
to	O
,	O
but	O
not	O
identical	O
with	O
,	O
the	O
consensus	B-protein
CK	I-protein
-	I-protein
1	I-protein
sequence	I-protein
.	O

Cardiac	O
markers	O
troponin	B-protein
T	I-protein
,	O
CK	B-protein
-	I-protein
MB	I-protein
mass	O
and	O
myoglobin	B-protein
were	O
helpful	O
in	O
the	O
differential	O
diagnosis	O
of	O
chest	O
pain	O
,	O
even	O
when	O
the	O
ECG	O
was	O
unremarkable	O
or	O
nonspecific	O
.	O

We	O
have	O
determined	O
that	O
the	O
mutants	O
define	O
two	O
complementation	O
groups	O
,	O
designated	O
cgs1	B-protein
+	I-protein
and	O
cgs2	B-protein
+	I-protein
(	O
continues	O
to	O
grow	O
in	O
stationary	O
)	O
.	O

The	O
accumulation	O
of	O
both	O
LHA4	B-protein
and	O
LHA2	B-protein
mRNAs	I-protein
is	O
induced	O
by	O
the	O
addition	O
of	O
exogenous	O
sugars	O
and	O
this	O
induction	O
appears	O
to	O
be	O
dependent	O
on	O
sugar	O
uptake	O
and	O
metabolism	O
,	O
because	O
mannitol	O
and	O
3	O
-	O
O	O
-	O
methylglucose	O
do	O
not	O
stimulate	O
mRNA	O
accumulation	O
.	O

A	O
further	O
study	O
on	O
plasminogen	B-protein
activator	I-protein
release	O
by	O
vasoactive	O
agents	O
in	O
the	O
isolated	O
perfused	O
dog	O
leg	O
.	O

Distal	O
lower	O
motor	O
neuron	O
syndrome	O
with	O
high	O
-	O
titer	O
serum	B-protein
IgM	I-protein
anti	I-protein
-	I-protein
GM1	I-protein
antibodies	I-protein
:	O
improvement	O
following	O
immunotherapy	O
with	O
monthly	O
plasma	O
exchange	O
and	O
intravenous	O
cyclophosphamide	O
.	O

Spfkh1	B-protein
is	O
transcribed	O
in	O
one	O
open	O
reading	O
frame	O
that	O
contains	O
the	O
DNA	O
binding	O
domain	O
,	O
nuclear	O
localization	O
signal	O
and	O
transactivation	O
domain	O
.	O

The	O
presence	O
of	O
such	O
a	O
putative	O
RNA	O
-	O
binding	O
domain	O
suggests	O
a	O
mechanism	O
for	O
the	O
observed	O
autoregulation	O
of	O
bacteriophage	O
T4	B-protein
DNA	I-protein
polymerase	I-protein
synthesis	O
by	O
binding	O
to	O
its	O
own	O
mRNA	O
.	O

Glutathione	B-protein
S	I-protein
-	I-protein
transferase	I-protein
(	O
GST	B-protein
)	O
-	B-protein
E2F	I-protein
and	O
GST	B-protein
-	I-protein
DP	I-protein
fusion	I-protein
proteins	I-protein
were	O
found	O
to	O
cooperate	O
in	O
binding	O
to	O
the	O
three	O
E2F	B-protein
sites	I-protein
in	O
the	O
DNA	B-protein
polymerase	I-protein
alpha	I-protein
gene	I-protein
promoter	I-protein
in	O
vitro	O
.	O

Influence	O
of	O
metoprolol	O
treatment	O
on	O
sympatho	O
-	O
adrenal	O
activation	O
of	O
fibrinolysis	O
.	O

Secondary	O
cleavage	O
of	O
RT	B-protein
at	O
Trp	B-protein
-	I-protein
595	I-protein
-	I-protein
Tyr	I-protein
-	I-protein
596	I-protein
of	I-protein
Pol	I-protein
yields	O
a	O
truncated	O
form	O
lacking	O
the	O
C	B-protein
-	I-protein
terminal	I-protein
RNase	I-protein
H	I-protein
domain	I-protein
.	O

The	O
second	O
method	O
,	O
the	O
`	O
`	O
macro	O
'	O
'	O
assay	O
,	O
has	O
a	O
sensitivity	O
range	O
of	O
0	O
.	O
03	O
-	O
5	O
.	O
0	O
micrograms	O
phosphorus	O
with	O
100	O
-	O
500	O
microliters	O
HClO4	O
.	O

In	O
contrast	O
,	O
c	B-protein
-	I-protein
Src	I-protein
-	I-protein
derived	I-protein
construct	I-protein
(	O
a	B-protein
-	I-protein
Src	I-protein
)	O
,	O
that	O
was	O
excluded	O
from	O
detergent	O
-	O
resistant	O
membranes	O
,	O
could	O
not	O
restore	O
the	O
series	O
of	O
phagocytosis	O
signaling	O
.	O

Ime1	B-protein
plays	O
a	O
pivotal	O
role	O
in	O
the	O
initiation	O
of	O
meiosis	O
in	O
a	O
/	O
alpha	O
diploid	O
cells	O
of	O
Saccharomyces	O
cerevisiae	O
.	O

Concentrations	O
of	O
N	O
(	O
O3	O
-	O
)	O
-	O
N	O
and	O
N	O
(	O
H3	O
-	O
)	O
-	O
N	O
at	O
Deoprayag	O
varied	O
from	O
0	O
.	O
30	O
to	O
0	O
.	O
50	O
and	O
0	O
.	O
02	O
to	O
0	O
.	O
12	O
mg	O
/	O
L	O
,	O
respectively	O
,	O
depending	O
on	O
season	O
.	O

Innervation	O
of	O
the	O
ventral	O
diaphragm	O
of	O
the	O
locust	O
(	O
Locusta	O
migratoria	O
)	O
.	O

In	O
the	O
37	O
patients	O
without	O
lung	O
disease	O
respiratory	O
muscle	O
weakness	O
was	O
accompanied	O
by	O
significant	O
decreases	O
in	O
vital	O
capacity	O
,	O
total	O
lung	O
capacity	O
,	O
and	O
maximum	O
voluntary	O
ventilation	O
;	O
by	O
significant	O
increases	O
in	O
residual	O
volume	O
and	O
arterial	O
carbon	O
dioxide	O
tension	O
(	O
PaCO2	O
)	O
;	O
and	O
greater	O
likelihood	O
of	O
dependence	O
on	O
ventilators	O
,	O
atelectasis	O
,	O
and	O
pneumonia	O
.	O

Of	O
600	O
mediastinoscopies	O
carried	O
out	O
from	O
1966	O
to	O
1973	O
,	O
479	O
were	O
performed	O
to	O
assess	O
the	O
operability	O
of	O
a	O
pulmonary	O
carcinoma	O
.	O

These	O
data	O
provide	O
the	O
molecular	O
tools	O
for	O
the	O
final	O
identification	O
of	O
the	O
MKS	B-protein
and	O
the	O
MUL	B-protein
genes	I-protein
.	O

Implications	O
in	O
biomonitoring	O
of	O
the	O
observed	O
accumulation	O
patterns	O
,	O
especially	O
in	O
the	O
different	O
tissues	O
of	O
Posidonia	O
oceanica	O
,	O
are	O
discussed	O
.	O

T	B-protein
-	I-protein
cell	I-protein
receptor	I-protein
beta	I-protein
(	O
TCR	B-protein
beta	I-protein
)	O
gene	O
rearrangements	O
occur	O
in	O
a	O
third	O
of	O
early	O
B	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemias	O
(	O
ALLs	O
)	O
.	O

This	O
study	O
assesses	O
the	O
feasibility	O
and	O
toxicity	O
of	O
adoptive	O
immunotherapy	O
with	O
tumor	O
infiltrating	O
lymphocytes	O
and	O
recombinant	B-protein
interleukin	I-protein
-	I-protein
2	I-protein
in	O
29	O
patients	O
who	O
underwent	O
resection	O
for	O
stage	O
III	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
.	O

The	O
MXR	B-protein
gene	I-protein
encodes	O
a	O
half	O
-	O
transporter	O
and	O
the	O
absence	O
of	O
cytogenetic	O
evidence	O
of	O
coamplification	O
of	O
other	O
regions	O
suggests	O
that	O
a	O
partner	O
may	O
not	O
be	O
overexpressed	O
,	O
and	O
instead	O
the	O
MXR	B-protein
half	I-protein
-	I-protein
transporter	I-protein
homodimerizes	O
to	O
mediate	O
drug	O
transport	O
.	O

176	O
:	O
787	O
-	O
792	O
,	O
1992	O
;	O
M	O
.	O

An	O
immunologically	O
related	O
protein	O
was	O
detected	O
in	O
ribosome	O
and	O
membrane	O
fractions	O
of	O
mitochondria	O
from	O
Saccharomyces	O
cerevisiae	O
.	O

As	O
the	O
components	O
of	O
these	O
complexes	O
,	O
at	O
least	O
five	O
TRBPs	B-protein
(	O
p30	B-protein
,	O
p37	B-protein
,	O
p46	B-protein
,	O
p50	B-protein
,	O
and	O
p56	B-protein
)	O
showing	O
specific	O
binding	O
to	O
the	O
TAR	B-protein
RNA	I-protein
were	O
detected	O
in	O
the	O
uv	O
cross	O
-	O
linking	O
assay	O
.	O

Acute	O
stress	O
in	O
7	O
rats	O
also	O
increased	O
the	O
mean	O
amount	O
of	O
IL	B-protein
-	I-protein
6	I-protein
released	O
in	O
the	O
urine	O
by	O
31	O
.	O
5	O
%	O
from	O
775	O
.	O
9	O
+	O
/	O
-	O
69	O
.	O
2	O
to	O
1	O
,	O
021	O
.	O
1	O
+	O
/	O
-	O
93	O
.	O
3	O
pg	O
.	O
/	O
ml	O
.	O

We	O
used	O
stored	O
plasma	O
samples	O
from	O
409	O
patients	O
in	O
the	O
National	O
Institute	O
of	O
Neurological	O
Diseases	O
and	O
Stroke	O
(	O
NINDS	O
)	O
tissue	B-protein
plasminogen	I-protein
activator	I-protein
(	O
t	B-protein
-	I-protein
PA	I-protein
)	O
Stroke	O
Trial	O
to	O
examine	O
the	O
relationship	O
between	O
an	O
apolipoprotein	B-protein
(	I-protein
Apo	I-protein
)	I-protein
E2	I-protein
or	O
an	O
Apo	B-protein
E4	I-protein
phenotype	O
and	O
a	O
favorable	O
outcome	O
3	O
months	O
after	O
stroke	O
,	O
the	O
risk	O
of	O
intracerebral	O
hemorrhage	O
,	O
and	O
the	O
response	O
to	O
intravenous	O
t	B-protein
-	I-protein
PA	I-protein
therapy	O
.	O

The	O
introns	O
are	O
1	O
.	O
6	O
-	O
1	O
.	O
9	O
kbp	O
long	O
.	O

Relations	O
between	O
adrenergic	O
mechanisms	O
and	O
analgesic	O
effects	O
.	O

Here	O
we	O
demonstrate	O
that	O
native	B-protein
MRCK	I-protein
exists	O
in	O
high	O
-	O
molecular	O
-	O
weight	O
complexes	O
.	O

The	O
antihypertensive	O
effect	O
of	O
Estulic	O
has	O
been	O
examined	O
over	O
a	O
12	O
-	O
month	O
period	O
in	O
101	O
hypertensive	O
patients	O
.	O

The	O
thrombolytic	O
effects	O
of	O
native	O
tissue	B-protein
-	I-protein
type	I-protein
plasminogen	I-protein
activator	I-protein
(	O
AK	B-protein
-	I-protein
124	I-protein
)	O
on	O
experimental	O
canine	O
coronary	O
thrombosis	O
.	O

Both	O
immunophilins	B-protein
may	O
have	O
important	O
roles	O
in	O
receptor	O
assembly	O
and	O
may	O
represent	O
a	O
new	O
category	O
of	O
ligand	O
-	O
and	O
calcium	O
-	O
dependent	O
modulators	O
of	O
protein	O
function	O
.	O

Substitutions	O
of	O
region	O
I	O
with	O
synthetic	O
sequences	O
showed	O
that	O
no	O
specific	O
sequence	O
but	O
rather	O
repeats	O
of	O
three	O
or	O
more	O
consecutive	O
adenines	O
or	O
thymines	O
,	O
without	O
interruption	O
by	O
guanine	O
or	O
cytosine	O
,	O
are	O
required	O
for	O
the	O
ARS	B-protein
activity	O
.	O

Both	O
neural	O
and	O
hormonal	O
pathways	O
and	O
both	O
opiate	O
and	O
nonopiate	O
substances	O
play	O
roles	O
in	O
the	O
complex	O
modulation	O
of	O
pain	O
transmission	O
.	O

Sequence	O
analysis	O
suggests	O
that	O
TtrA	B-protein
contains	O
a	O
molybdopterin	O
guanine	O
dinucleotide	O
cofactor	O
and	O
a	O
[	O
4Fe	O
-	O
4S	O
]	O
cluster	O
,	O
that	O
TtrB	B-protein
binds	O
four	O
[	O
4Fe	O
-	O
4S	O
]	O
clusters	O
,	O
and	O
that	O
TtrC	B-protein
is	O
an	O
integral	O
membrane	O
protein	O
containing	O
a	O
quinol	O
oxidation	O
site	O
.	O

A	O
tyrosine	O
-	O
based	O
sorting	O
signal	O
in	O
the	O
beta2	B-protein
integrin	I-protein
cytoplasmic	I-protein
domain	I-protein
mediates	O
its	O
recycling	O
to	O
the	O
plasma	O
membrane	O
and	O
is	O
required	O
for	O
ligand	O
-	O
supported	O
migration	O
.	O

The	O
IE0	B-protein
gene	I-protein
product	O
also	O
transactivated	O
the	O
IE1	B-protein
promoter	I-protein
but	O
did	O
not	O
affect	O
expression	O
from	O
its	O
own	O
promoter	O
.	O

The	O
probability	O
of	O
treatment	O
with	O
lamotrigine	O
being	O
maintained	O
for	O
six	O
months	O
was	O
86	O
%	O
,	O
for	O
twelve	O
months	O
61	O
%	O
and	O
for	O
three	O
years	O
31	O
%	O
.	O

The	O
ventilation	O
did	O
not	O
increase	O
when	O
PACO2	O
was	O
increased	O
.	O

The	O
Arabidopsis	B-protein
FAD7	I-protein
gene	I-protein
encodes	O
a	O
chloroplast	B-protein
omega	I-protein
-	I-protein
3	I-protein
fatty	I-protein
acid	I-protein
desaturase	I-protein
that	O
catalyzes	O
the	O
desaturation	O
of	O
lipid	O
-	O
linked	O
dienoic	O
fatty	O
acids	O
(	O
18	O
:	O
2	O
and	O
16	O
:	O
2	O
)	O
.	O

Transient	O
overexpression	O
of	O
c	B-protein
-	I-protein
Jun	I-protein
induced	O
tenascin	B-protein
-	I-protein
C	I-protein
expression	O
in	O
primary	O
REF	O
and	O
in	O
FR3T3	O
,	O
an	O
established	O
fibroblast	O
cell	O
line	O
.	O

Arterial	O
radioactivity	O
content	O
after	O
the	O
intravenous	O
administration	O
of	O
HMPAO	O
in	O
seven	O
human	O
subjects	O
was	O
analyzed	O
.	O

The	O
alterations	O
of	O
5	O
-	O
HT	O
and	O
5	O
-	O
HIAA	O
levels	O
in	O
several	O
regions	O
of	O
the	O
brain	O
under	O
the	O
conditions	O
examined	O
may	O
indicate	O
that	O
IDPN	O
'	O
s	O
neurotoxicity	O
primarily	O
affects	O
5	O
-	O
HT	O
-	O
containing	O
neurones	O
.	O

The	O
recruitment	O
of	O
constitutively	O
phosphorylated	O
p185	B-protein
(	I-protein
neu	I-protein
)	I-protein
and	O
the	O
activated	O
mitogenic	O
pathway	O
proteins	O
to	O
this	O
membrane	O
-	O
microfilament	O
interaction	O
site	O
provides	O
a	O
physical	O
model	O
for	O
integrating	O
the	O
assembly	O
of	O
the	O
mitogenic	O
pathway	O
with	O
the	O
transmission	O
of	O
growth	B-protein
factor	I-protein
signal	O
to	O
the	O
cytoskeleton	O
.	O

The	O
outcome	O
of	O
the	O
optimization	O
of	O
the	O
seven	O
-	O
field	O
plan	O
prompted	O
an	O
investigation	O
into	O
the	O
best	O
results	O
that	O
could	O
be	O
achieved	O
by	O
an	O
`	O
`	O
ideal	O
'	O
'	O
conformal	O
radiotherapy	O
technique	O
.	O

METHODS	O
:	O
P	B-protein
-	I-protein
selectin	I-protein
expression	O
of	O
nonstimulated	O
and	O
ADP	O
-	O
stimulated	O
platelets	O
was	O
flow	O
cytometrically	O
measured	O
before	O
the	O
clopidogrel	O
loading	O
dose	O
and	O
on	O
3	O
consecutive	O
days	O
in	O
52	O
patients	O
with	O
coronary	O
artery	O
disease	O
:	O
21	O
patients	O
in	O
group	O
1	O
received	O
300	O
mg	O
of	O
clopidogrel	O
after	O
stent	O
implantation	O
and	O
11	O
patients	O
in	O
group	O
2	O
received	O
the	O
higher	O
450	O
-	O
mg	O
clopidogrel	O
loading	O
dose	O
followed	O
by	O
a	O
daily	O
dose	O
of	O
75	O
mg	O
of	O
clopidogrel	O
for	O
both	O
groups	O
.	O

The	O
mouse	B-protein
beta	I-protein
2	I-protein
-	I-protein
syntrophin	I-protein
gene	I-protein
(	O
>	O
33	O
kilobases	O
)	O
contains	O
seven	O
exons	O
,	O
all	O
of	O
which	O
have	O
homologues	O
at	O
the	O
corresponding	O
position	O
in	O
the	O
alpha	B-protein
1	I-protein
-	I-protein
syntrophin	I-protein
gene	I-protein
.	O

Interestingly	O
,	O
the	O
avirulent	O
strain	O
H37Ra	O
showed	O
weak	O
hybridization	O
with	O
these	O
two	O
probes	O
,	O
suggesting	O
that	O
these	O
genes	O
might	O
have	O
been	O
deleted	O
in	O
the	O
avirulent	O
strain	O
or	O
are	O
present	O
in	O
limited	O
copy	O
numbers	O
as	O
opposed	O
to	O
those	O
in	O
the	O
virulent	O
strain	O
H37Rv	O
.	O

In	O
contrast	O
to	O
MPc3	B-protein
,	O
data	O
indicate	O
that	O
the	O
Pc	B-protein
protein	I-protein
M33	I-protein
does	O
not	O
interact	O
with	O
AF9	B-protein
.	O

Nucleotide	O
sequence	O
analysis	O
of	O
the	O
Pseudomonas	B-protein
putida	I-protein
PpG7	I-protein
salicylate	I-protein
hydroxylase	I-protein
gene	I-protein
(	O
nahG	B-protein
)	O
and	O
its	O
3	O
'	O
-	O
flanking	O
region	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
PecS	B-protein
attenuates	O
pelD	B-protein
and	O
pelE	B-protein
expression	O
rather	O
than	O
acting	O
as	O
a	O
true	O
repressor	O
like	O
KdgR	B-protein
.	O

In	O
several	O
cell	O
lines	O
,	O
mTOR	B-protein
or	O
its	O
downstream	O
targets	O
can	O
be	O
regulated	O
by	O
phosphatidylinositol	B-protein
(	I-protein
PI	I-protein
)	I-protein
3	I-protein
-	I-protein
kinase	I-protein
;	O
protein	B-protein
kinases	I-protein
A	I-protein
,	I-protein
B	I-protein
,	I-protein
and	I-protein
C	I-protein
;	O
heterotrimeric	B-protein
G	I-protein
-	I-protein
proteins	I-protein
;	O
a	O
PD98059	O
-	O
sensitive	O
kinase	B-protein
or	O
calcium	O
;	O
as	O
well	O
as	O
by	O
amino	O
acids	O
.	O

Sequences	O
downstream	O
of	O
the	O
two	O
human	B-protein
CA	I-protein
genes	I-protein
,	O
possibly	O
containing	O
homologous	O
enhancer	O
elements	O
,	O
have	O
not	O
yet	O
been	O
reported	O
.	O

However	O
,	O
plasmids	O
carrying	O
the	O
yeast	B-protein
TyrRS	I-protein
gene	I-protein
could	O
not	O
be	O
stably	O
maintained	O
in	O
E	O
.	O
coli	O
.	O

16	O
percent	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
sustained	O
normalization	O
of	O
serum	B-protein
alanine	I-protein
aminotransferase	I-protein
levels	O
(	O
41	O
percent	O
vs	O
.	O

The	O
sequence	O
was	O
determined	O
of	O
6493	O
nucleotides	O
encompassing	O
the	O
bet	B-protein
genes	I-protein
of	I-protein
Escherichia	I-protein
coli	I-protein
which	O
encode	O
the	O
osmoregulatory	O
choline	B-protein
-	I-protein
glycine	I-protein
betaine	I-protein
pathway	I-protein
.	O

135	O
students	O
had	O
a	O
count	O
of	O
less	O
than	O
50	O
eggs	O
/	O
10	O
ml	O
.	O
urine	O
and	O
56	O
had	O
more	O
than	O
50	O
eggs	O
/	O
10	O
ml	O
.	O

Evidence	O
for	O
a	O
novel	O
MAPKKK	O
-	O
independent	O
pathway	O
controlling	O
the	O
stress	O
activated	O
Sty1	B-protein
/	I-protein
Spc1	I-protein
MAP	I-protein
kinase	I-protein
in	O
fission	O
yeast	O
.	O

A	O
recombinant	O
derivative	O
harboring	O
the	O
pMJ101	O
replication	O
region	O
proved	O
to	O
be	O
compatible	O
with	O
pJM1	O
,	O
a	O
plasmid	O
containing	O
the	O
iron	O
acquisition	O
system	O
required	O
for	O
the	O
virulence	O
of	O
V	O
.	O
anguillarum	O
775	O
,	O
another	O
important	O
pathogen	O
that	O
causes	O
vibriosis	O
.	O

Five	O
of	O
these	O
have	O
ocular	O
or	O
oculocutaneous	O
albinism	O
.	O

NH3	O
and	O
NO	O
interaction	O
with	O
Si	O
(	O
100	O
)	O
-	O
(	O
2	O
x	O
1	O
)	O
surfaces	O
.	O

Lipoprotein	B-protein
lipase	I-protein
(	O
LPL	B-protein
)	O
,	O
a	O
key	O
enzyme	O
in	O
normal	O
lipoprotein	O
metabolism	O
,	O
has	O
a	O
complex	O
pattern	O
of	O
regulation	O
and	O
tissue	O
-	O
specific	O
expression	O
.	O

Protein	O
electrophoresis	O
showed	O
decreased	O
albumin	B-protein
levels	O
in	O
both	O
groups	O
,	O
with	O
lower	O
values	O
in	O
G2	O
.	O

A	O
xylE	B-protein
transcriptional	I-protein
fusion	I-protein
to	O
the	O
putative	O
mxbD	B-protein
promoter	I-protein
showed	O
low	O
-	O
level	O
expression	O
in	O
wild	O
-	O
type	O
cells	O
grown	O
on	O
one	O
-	O
carbon	O
(	O
C1	O
)	O
compounds	O
and	O
no	O
detectable	O
expression	O
in	O
cells	O
grown	O
on	O
succinate	O
.	O

The	O
variable	O
phenotype	O
of	O
the	O
allotetraploids	O
could	O
not	O
be	O
explained	O
by	O
cytological	O
abnormalities	O
.	O

Studies	O
on	O
the	O
method	O
of	O
size	O
reduction	O
of	O
medicinal	O
compounds	O
.	O

A	O
human	B-protein
Raf	I-protein
-	I-protein
responsive	I-protein
zinc	I-protein
-	I-protein
finger	I-protein
protein	I-protein
that	O
binds	O
to	O
divergent	O
sequences	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

One	O
of	O
these	O
small	B-protein
inteins	I-protein
might	O
be	O
inactive	O
or	O
a	O
`	B-protein
`	I-protein
pseudo	I-protein
intein	I-protein
.	I-protein
`	I-protein
`	I-protein
The	O
results	O
suggest	O
a	O
modular	O
architecture	O
for	O
inteins	B-protein
,	O
clarify	O
their	O
origin	O
and	O
relationship	O
to	O
other	O
protein	O
families	O
,	O
and	O
extend	O
recent	O
experimental	O
findings	O
on	O
the	O
functional	O
roles	O
of	O
intein	B-protein
N	I-protein
,	I-protein
C	I-protein
,	I-protein
and	I-protein
EN	I-protein
motifs	I-protein
.	O

As	O
in	O
S	O
.	O
cerevisiae	O
,	O
the	O
sequence	O
of	O
rhp51	B-protein
+	I-protein
showed	O
two	O
MluI	B-protein
cell	I-protein
-	I-protein
cycle	I-protein
boxes	I-protein
and	O
a	O
putative	O
DNA	O
damage	O
-	O
responsive	O
element	O
in	O
its	O
upstream	O
region	O
.	O

There	O
was	O
no	O
competition	O
between	O
activin	B-protein
A	I-protein
and	O
OP	B-protein
-	I-protein
1	I-protein
for	O
availability	O
of	O
Smad4	B-protein
,	O
indicating	O
that	O
the	O
concentration	O
of	O
this	O
common	O
signal	O
transducer	O
is	O
not	O
limiting	O
for	O
generating	O
the	O
observed	O
biological	O
responses	O
.	O

Intra	O
-	O
articular	O
dislocation	O
of	O
the	O
patella	O
.	O

Pneumothorax	O
during	O
laparoscopic	O
dissection	O
of	O
the	O
diaphragmatic	O
hiatus	O
.	O

Molecular	O
cloning	O
and	O
functional	O
characterization	O
of	O
murine	B-protein
sphingosine	I-protein
kinase	I-protein
.	O

Processing	O
of	O
the	O
polycistronic	O
precursor	O
requires	O
nucleases	B-protein
also	O
involved	O
in	O
rRNA	B-protein
processing	O
,	O
i	O
.	O
e	O
.	O
,	O
Rnt1p	B-protein
and	O
Rat1p	B-protein
.	O

Hyperactivation	O
of	O
Cdc2	B-protein
in	O
fission	O
yeast	O
causes	O
cells	O
to	O
undergo	O
a	O
lethal	O
premature	O
mitosis	O
called	O
mitotic	O
catastrophe	O
.	O

Tissue	O
-	O
specific	O
expression	O
of	O
the	O
diazepam	B-protein
-	I-protein
binding	I-protein
inhibitor	I-protein
in	O
Drosophila	O
melanogaster	O
:	O
cloning	O
,	O
structure	O
,	O
and	O
localization	O
of	O
the	O
gene	O
.	O

Nevertheless	O
,	O
we	O
demonstrate	O
that	O
the	O
entire	O
three	O
-	O
component	O
yeast	O
capping	O
apparatus	O
,	O
consisting	O
of	O
RNA	B-protein
5	I-protein
'	I-protein
-	I-protein
triphosphatase	I-protein
(	O
Cet1p	B-protein
)	O
,	O
RNA	B-protein
guanylyltransferase	I-protein
(	O
Ceg1p	B-protein
)	O
,	O
and	O
Abd1p	B-protein
could	O
be	O
replaced	O
in	O
vivo	O
by	O
the	O
two	O
-	O
component	O
mammalian	O
apparatus	O
consisting	O
of	O
a	O
bifunctional	O
triphosphatase	B-protein
-	I-protein
guanylyltransferase	I-protein
Mce1p	I-protein
and	O
the	O
methyltransferase	B-protein
Hcm1	I-protein
(	I-protein
121	I-protein
-	I-protein
476	I-protein
)	I-protein
p	I-protein
.	O

We	O
purified	O
a	O
Ca2	B-protein
+	I-protein
/	I-protein
calmodulin	I-protein
(	I-protein
CaM	I-protein
)	I-protein
-	I-protein
dependent	I-protein
protein	I-protein
kinase	I-protein
(	I-protein
CaM	I-protein
kinase	I-protein
)	I-protein
from	I-protein
the	I-protein
yeast	I-protein
Saccharomyces	I-protein
cerevisiae	I-protein
with	O
properties	O
similar	O
to	O
mammalian	B-protein
type	I-protein
II	I-protein
CaM	I-protein
kinases	I-protein
.	O

The	O
247	O
-	O
kDa	O
complex	O
appears	O
to	O
contain	O
two	O
distinct	O
protein	O
-	O
DNA	O
complexes	O
of	O
approximately	O
232	O
and	O
256	O
kDa	O
and	O
represents	O
two	O
proteins	O
covalently	O
cross	O
-	O
linked	O
to	O
a	O
single	O
DRE	B-protein
oligonucleotide	O
,	O
while	O
the	O
97	O
,	O
105	O
,	O
and	O
115	O
-	O
kDa	O
complexes	O
represent	O
single	O
protein	B-protein
-	I-protein
DRE	I-protein
cross	O
-	O
links	O
.	O

Identification	O
of	O
a	O
promoter	O
-	O
specific	O
transactivation	O
domain	O
in	O
the	O
herpes	B-protein
simplex	I-protein
virus	I-protein
regulatory	I-protein
protein	I-protein
ICP4	I-protein
.	O

Eliminating	O
any	O
subset	O
of	O
ASCUS	O
reduces	O
the	O
ASCUS	O
/	O
SIL	O
ratio	O
but	O
also	O
significantly	O
diminishes	O
the	O
sensitivity	O
of	O
the	O
Papanicolaou	O
test	O
.	O

The	O
enteric	O
route	O
is	O
the	O
principal	O
mode	O
of	O
transmission	O
for	O
hepatitis	O
A	O
,	O
but	O
maximal	O
levels	O
of	O
hepatitis	O
A	O
virus	O
excretion	O
occur	O
before	O
the	O
onset	O
of	O
jaundice	O
.	O

Km	O
values	O
for	O
ammonium	O
,	O
2	O
-	O
oxoglutarate	O
,	O
NADH	O
,	O
glutamate	O
and	O
NAD	O
+	O
were	O
6	O
.	O
5	O
,	O
3	O
.	O
5	O
,	O
0	O
.	O
06	O
,	O
37	O
.	O
1	O
and	O
0	O
.	O
046	O
mM	O
,	O
respectively	O
.	O

ROS	B-protein
x	O
SRC	B-protein
(	O
R	B-protein
)	O
contains	O
a	O
16	O
-	O
amino	O
-	O
acid	O
deletion	O
that	O
includes	O
the	O
3	O
'	O
half	O
of	O
the	O
transmembrane	O
domain	O
of	O
ros	B-protein
.	O

We	O
present	O
this	O
case	O
because	O
of	O
the	O
rarity	O
of	O
left	O
ventricular	O
involvement	O
associated	O
with	O
ARVD	O
.	O

We	O
describe	O
a	O
novel	O
zinc	B-protein
finger	I-protein
protein	I-protein
,	O
dsRBP	B-protein
-	I-protein
ZFa	I-protein
,	O
isolated	O
by	O
screening	O
an	O
expression	O
library	O
with	O
dsRNA	O
.	O

With	O
respect	O
to	O
effective	O
diffusivity	O
of	O
platelets	O
(	O
De	O
)	O
and	O
the	O
surface	O
reactivity	O
constant	O
(	O
K	O
)	O
,	O
less	O
significant	O
differences	O
were	O
found	O
among	O
artificial	O
materials	O
.	O

Catch	O
-	O
up	O
growth	O
was	O
observed	O
only	O
for	O
a	O
12	O
-	O
month	O
period	O
in	O
4	O
children	O
with	O
a	O
bone	O
age	O
of	O
7	O
to	O
8	O
years	O
.	O

The	O
frequency	O
of	O
PPNG	O
strains	O
increased	O
from	O
1	O
.	O
7	O
%	O
in	O
1981	O
to	O
6	O
.	O
7	O
%	O
in	O
1985	O
.	O

These	O
results	O
suggested	O
that	O
NfxB	B-protein
negatively	O
autoregulates	O
the	O
expression	O
of	O
nfxB	B-protein
itself	O
.	O

An	O
egg	O
protein	O
,	O
lysozyme	B-protein
,	O
is	O
a	O
still	O
unlabeled	O
additive	O
currently	O
used	O
in	O
cheese	O
preparation	O
.	O

Component	O
P100	O
was	O
associated	O
with	O
a	O
frontal	O
negativity	O
of	O
similar	O
latency	O
favoring	O
the	O
hypothesis	O
of	O
a	O
dipolar	O
occipital	O
generator	O
.	O

No	O
direct	O
repeats	O
flank	O
the	O
pseudogene	O
in	O
the	O
U2	B-protein
/	I-protein
4	I-protein
locus	I-protein
.	O

Crossover	O
in	O
the	O
specific	O
heat	O
of	O
dilute	O
magnets	O
induced	O
by	O
critical	O
spin	O
-	O
wave	O
dynamics	O
.	O

The	O
effects	O
on	O
reflex	O
latencies	O
but	O
not	O
on	O
paCO2	O
or	O
pHa	O
were	O
blocked	O
by	O
naloxone	O
(	O
2	O
mg	O
/	O
kg	O
)	O
,	O
and	O
were	O
not	O
present	O
in	O
morphine	O
-	O
tolerant	O
animals	O
.	O

Pharmacologic	O
doses	O
of	O
vitamin	O
B6	O
administered	O
to	O
lactating	O
women	O
have	O
been	O
reported	O
to	O
suppress	O
plasma	B-protein
prolactin	I-protein
.	O

In	O
a	O
previous	O
interim	O
report	O
we	O
noted	O
more	O
prompt	O
resolution	O
of	O
dermatomal	O
signs	O
and	O
symptoms	O
with	O
acyclovir	O
treatment	O
.	O

In	O
cellular	O
supernatant	O
fraction	O
,	O
SHRSP	O
showed	O
a	O
decrease	O
of	O
magnesium	O
in	O
many	O
tissues	O
and	O
an	O
elevation	O
of	O
the	O
calcium	O
to	O
magnesium	O
ratio	O
when	O
compared	O
to	O
age	O
-	O
matched	O
WKY	O
and	O
SHRSR	O
.	O

Cloning	O
of	O
a	O
human	B-protein
phosphoinositide	I-protein
3	I-protein
-	I-protein
kinase	I-protein
with	O
a	O
C2	B-protein
domain	I-protein
that	O
displays	O
reduced	O
sensitivity	O
to	O
the	O
inhibitor	O
wortmannin	O
.	O

Selective	O
bronchial	O
intubation	O
in	O
the	O
management	O
of	O
unilateral	O
pulmonary	O
interstitial	O
emphysema	O
.	O

However	O
,	O
inhibition	O
of	O
both	O
the	O
ERK	B-protein
/	I-protein
RSK	I-protein
and	O
the	O
p38	B-protein
/	I-protein
MAPKAP	I-protein
kinase	I-protein
2	I-protein
pathways	O
completely	O
abolished	O
NGF	O
-	O
induced	O
CREB	B-protein
Ser	O
-	O
133	O
phosphorylation	O
.	O

Malaria	O
,	O
anaemia	O
,	O
and	O
HIV	O
-	O
1	O
transmission	O
in	O
central	O
Africa	O
.	O

Association	O
with	O
HL	B-protein
-	I-protein
A	I-protein
W	I-protein
-	I-protein
27	I-protein
.	O

Endonuclease	B-protein
III	I-protein
(	O
Nth	B-protein
)	O
of	O
Escherichia	O
coli	O
is	O
a	O
DNA	B-protein
glycosylase	I-protein
essential	O
for	O
the	O
removal	O
of	O
oxidised	O
pyrimidine	O
base	O
residues	O
from	O
DNA	O
.	O

Hierarchy	O
of	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
in	O
interleukin	B-protein
-	I-protein
2	I-protein
(	O
IL	B-protein
-	I-protein
2	I-protein
)	O
signaling	O
:	O
activation	O
of	O
syk	B-protein
depends	O
on	O
Jak3	B-protein
;	O
however	O
,	O
neither	O
Syk	B-protein
nor	O
Lck	B-protein
is	O
required	O
for	O
IL	O
-	O
2	O
-	O
mediated	O
STAT	B-protein
activation	O
.	O

Multifunctional	B-protein
protein	I-protein
kinase	I-protein
(	O
MFPK	B-protein
)	O
phosphorylates	O
ATP	B-protein
-	I-protein
citrate	I-protein
lyase	I-protein
on	O
peptide	B-protein
B	I-protein
on	O
two	O
sites	O
,	O
BT	O
and	O
BS	O
,	O
on	O
threonine	O
and	O
serine	O
,	O
respectively	O
,	O
inhibitor	B-protein
2	I-protein
on	O
a	O
threonyl	O
residue	O
,	O
and	O
glycogen	B-protein
synthase	I-protein
at	O
sites	O
2	O
and	O
3	O
.	O

Prrp	B-protein
can	O
also	O
associate	O
with	O
the	O
EVH1	B-protein
domain	I-protein
of	O
Mena	B-protein
,	O
another	O
microfilament	O
-	O
associated	O
protein	O
.	O

The	O
full	O
length	O
cDNA	O
sequence	O
of	O
a	O
Type	B-protein
I	I-protein
transforming	I-protein
growth	I-protein
factor	I-protein
-	I-protein
beta	I-protein
(	I-protein
TGF	I-protein
-	I-protein
beta	I-protein
)	I-protein
receptor	I-protein
has	O
been	O
isolated	O
from	O
the	O
filarial	O
parasitic	O
nematode	O
Brugia	O
pahangi	O
.	O

Angiography	O
was	O
performed	O
following	O
the	O
rCBF	O
study	O
and	O
the	O
degree	O
of	O
vasospasm	O
was	O
measured	O
on	O
the	O
angiograms	O
.	O

Furthermore	O
,	O
no	O
transcripts	O
of	O
the	O
same	O
size	O
and	O
having	O
the	O
same	O
developmental	O
profile	O
as	O
those	O
generated	O
by	O
the	O
wild	B-protein
-	I-protein
type	I-protein
E10	I-protein
fragment	I-protein
were	O
identified	O
by	O
probes	O
covering	O
the	O
remainder	O
of	O
the	O
cloned	O
region	O
.	O

We	O
discuss	O
the	O
need	O
to	O
use	O
animals	O
older	O
than	O
3	O
months	O
for	O
the	O
study	O
of	O
'	O
adult	O
'	O
regeneration	O
phenomena	O
since	O
3	O
-	O
month	O
-	O
old	O
rats	O
may	O
be	O
somewhat	O
immature	O
.	O

Sequence	O
analysis	O
of	O
reverse	O
transcribed	O
,	O
amplified	O
cDNA	O
generated	O
from	O
total	O
RNA	O
isolated	O
from	O
transfected	O
cells	O
demonstrated	O
the	O
presence	O
of	O
abnormally	O
spliced	O
products	O
containing	O
13	O
and	O
78	O
additional	O
bases	O
as	O
well	O
as	O
the	O
accumulation	O
of	O
unspliced	O
mRNA	O
.	O

Diet	O
and	O
atopic	O
eczema	O
.	O

High	O
values	O
of	O
both	O
retinol	O
and	O
beta	O
-	O
carotene	O
were	O
found	O
in	O
full	O
fat	O
cheeses	O
and	O
whipping	O
cream	O
:	O
from	O
179	O
.	O
0	O
(	O
cheese	O
,	O
Edam	O
-	O
type	O
)	O
to	O
318	O
.	O
7	O
micrograms	O
/	O
100	O
g	O
(	O
whipping	O
cream	O
)	O
and	O
from	O
86	O
.	O
7	O
(	O
cheese	O
,	O
Edam	O
-	O
type	O
)	O
to	O
186	O
.	O
5	O
micrograms	O
/	O
100	O
g	O
(	O
whipping	O
cream	O
)	O
for	O
all	O
-	O
trans	O
retinol	O
and	O
total	O
beta	O
-	O
carotene	O
,	O
respectively	O
.	O

Troubled	O
CareNetwork	O
gets	O
pact	O
from	O
largest	O
teacher	O
union	O
in	O
Wis	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
relationship	O
between	O
blood	O
flow	O
in	O
the	O
tumor	O
assessed	O
by	O
color	O
Doppler	O
ultrasound	O
,	O
microvessel	O
density	O
,	O
and	O
vascular	B-protein
endothelial	I-protein
growth	I-protein
factor	I-protein
levels	O
in	O
endometrial	O
carcinoma	O
.	O

Elevated	O
IOP	O
developed	O
in	O
35	O
patients	O
(	O
44	O
eyes	O
)	O
during	O
the	O
study	O
.	O

To	O
determine	O
the	O
function	O
of	O
VZV	B-protein
gK	I-protein
in	O
virus	O
growth	O
,	O
a	O
series	O
of	O
gK	B-protein
deletion	I-protein
mutants	I-protein
were	O
constructed	O
with	O
VZV	O
cosmid	O
DNA	O
derived	O
from	O
the	O
Oka	O
strain	O
.	O

The	O
effect	O
of	O
independent	O
predictors	O
on	O
survival	O
was	O
examined	O
in	O
a	O
Cox	O
regression	O
model	O
with	O
adjustment	O
for	O
existing	O
illnesses	O
.	O

Ectopic	O
ACTH	B-protein
syndrome	O
and	O
medullary	O
thyroid	O
carcinoma	O
.	O

Furthermore	O
,	O
phosphatidylinositol	O
(	O
3	O
,	O
4	O
,	O
5	O
)	O
trisphosphate	O
specifically	O
stimulates	O
the	O
activity	O
of	O
ILK	B-protein
in	O
vitro	O
,	O
and	O
in	O
addition	O
,	O
membrane	O
targetted	O
constitutively	O
active	O
Pi	B-protein
(	I-protein
3	I-protein
)	I-protein
K	I-protein
activates	O
ILK	B-protein
in	O
vivo	O
.	O

49	O
,	O
XXXXY	O
chromosome	O
anomaly	O
:	O
an	O
unusual	O
variant	O
of	O
Klinefelter	O
'	O
s	O
syndrome	O
.	O

Propafenone	O
is	O
well	O
tolerated	O
in	O
the	O
majority	O
of	O
young	O
patients	O
.	O

Furthermore	O
,	O
our	O
novel	O
observation	O
that	O
expression	O
of	O
a	O
highly	O
activated	O
FGFR3	B-protein
kinase	I-protein
domain	I-protein
is	O
able	O
to	O
morphologically	O
transform	O
fibroblasts	O
suggests	O
that	O
dysregulation	O
of	O
FGFR3	B-protein
has	O
the	O
potential	O
to	O
play	O
a	O
role	O
in	O
human	O
neoplasia	O
.	O

C	B-protein
/	I-protein
EBP	I-protein
alpha	I-protein
also	O
activates	O
the	O
promoter	O
of	O
the	O
rat	B-protein
class	I-protein
-	I-protein
I	I-protein
ADH	I-protein
gene	I-protein
in	O
a	O
sequence	O
-	O
specific	O
manner	O
[	O
Potter	O
et	O
al	O
.	O
,	O
Arch	O
.	O

An	O
experimental	O
long	O
-	O
term	O
study	O
.	O

XYL1	B-protein
was	O
isolated	O
as	O
a	O
highly	O
expressed	O
fusion	O
clone	O
from	O
a	O
'	B-protein
lacZ	I-protein
translational	O
fusion	O
library	O
.	O

Only	O
transcripts	O
specific	O
for	O
TSGF	B-protein
-	I-protein
2	I-protein
are	O
detected	O
in	O
ovary	O
and	O
testes	O
tissues	O
of	O
adults	O
as	O
well	O
as	O
in	O
puparia	O
,	O
while	O
neither	O
gene	O
is	O
expressed	O
during	O
the	O
larval	O
developmental	O
stages	O
.	O

Currently	O
,	O
the	O
clinical	O
use	O
of	O
5	O
-	O
aminolaevulinic	O
acid	O
(	O
ALA	O
)	O
induced	O
protoporphyrin	B-protein
IX	I-protein
(	O
PPIX	B-protein
)	O
for	O
photodynamic	O
therapy	O
(	O
PDT	O
)	O
is	O
limited	O
by	O
the	O
maximum	O
tolerated	O
oral	O
ALA	O
dose	O
(	O
60	O
mg	O
/	O
kg	O
)	O
.	O

The	O
presence	O
of	O
an	O
unusual	O
transcript	O
possessing	O
IVS2C	B-protein
beta	I-protein
1	I-protein
at	O
the	O
5	O
'	O
terminus	O
suggests	O
that	O
cleavage	O
of	O
its	O
splice	O
acceptor	O
is	O
inefficient	O
or	O
negatively	O
regulated	O
.	O

We	O
found	O
sequences	O
related	O
to	O
this	O
insertion	O
in	O
wild	O
-	O
type	O
strains	O
of	O
N	O
.	O
crassa	O
and	O
other	O
Neurospora	O
species	O
.	O

The	O
altered	O
amino	O
acid	O
residues	O
of	O
the	O
seven	O
mutant	B-protein
9ORF1	I-protein
polypeptides	I-protein
clustered	O
within	O
three	O
separate	O
regions	O
referred	O
to	O
as	O
region	O
I	O
(	O
residues	O
34	O
to	O
41	O
)	O
,	O
region	O
II	O
(	O
residues	O
89	O
to	O
91	O
)	O
,	O
and	O
C	O
-	O
terminal	O
region	O
III	O
(	O
residues	O
122	O
to	O
125	O
)	O
.	O

The	O
recombinant	O
purified	O
protein	O
expressed	O
in	O
the	O
baculovirus	O
system	O
had	O
an	O
approximate	O
molecular	O
size	O
20	O
kDa	O
with	O
amino	B-protein
-	I-protein
terminal	I-protein
sequence	I-protein
of	I-protein
AVQGP	I-protein
.	O

During	O
the	O
2h	O
resuscitation	O
period	O
,	O
extracellular	O
aspartate	O
and	O
glutamate	O
concentrations	O
in	O
the	O
cerebral	O
striatum	O
were	O
higher	O
during	O
hypoxaemic	O
resuscitation	O
(	O
p	O
=	O
0	O
.	O
044	O
and	O
p	O
=	O
0	O
.	O
055	O
,	O
respectively	O
)	O
than	O
during	O
resuscitation	O
with	O
21	O
%	O
O2	O
or	O
100	O
%	O
O2	O
,	O
suggesting	O
an	O
unfavourable	O
accumulation	O
of	O
potent	O
excitotoxins	O
during	O
hypoxaemic	O
resuscitation	O
.	O

When	O
overexpressed	O
in	O
an	O
appropriate	O
cell	O
line	O
,	O
TAN	B-protein
-	I-protein
1C	I-protein
prevented	O
kappa	O
B	O
-	O
dependent	O
transactivation	O
in	O
transient	O
reporter	O
gene	O
assays	O
in	O
a	O
fashion	O
similar	O
to	O
the	O
structurally	O
related	O
protein	O
,	O
Bcl	B-protein
-	I-protein
3	I-protein
.	O

Ras	B-protein
-	I-protein
GRF1	I-protein
transiently	O
expressed	O
with	O
v	B-protein
-	I-protein
Src	I-protein
was	O
tyrosine	O
-	O
phosphorylated	O
and	O
showed	O
significant	O
GEF	B-protein
activity	O
toward	O
Rac	B-protein
,	O
but	O
not	O
Rho	B-protein
and	O
Cdc42	B-protein
,	O
which	O
was	O
comparable	O
with	O
that	O
induced	O
by	O
Gbetagamma	B-protein
.	O

The	O
5	O
'	O
flanking	O
region	O
of	O
the	O
CD1	B-protein
gene	I-protein
contained	O
the	O
binding	O
motifs	O
for	O
two	O
cytokine	O
-	O
inducible	O
transcription	O
factors	O
,	O
NF	B-protein
-	I-protein
IL2	I-protein
-	I-protein
A	I-protein
and	O
NF	B-protein
-	I-protein
IL6	I-protein
.	O

This	O
,	O
together	O
with	O
the	O
data	O
obtained	O
with	O
haloperidol	O
,	O
suggests	O
that	O
a	O
minimal	O
increase	O
in	O
the	O
firing	O
rate	O
of	O
LC	O
cells	O
(	O
+	O
140	O
%	O
)	O
is	O
required	O
before	O
it	O
could	O
influence	O
the	O
turnover	O
of	O
NA	O
,	O
as	O
measured	O
by	O
DOPAC	O
changes	O
.	O

A	O
.	O

Replacement	O
of	O
the	O
CRE	B-protein
with	O
a	O
second	O
copy	O
of	O
the	O
AP	B-protein
-	I-protein
1	I-protein
site	I-protein
results	O
in	O
a	O
level	O
of	O
transcriptional	O
activity	O
comparable	O
with	O
that	O
of	O
the	O
wild	O
-	O
type	O
sequence	O
,	O
but	O
replacement	O
of	O
the	O
AP	B-protein
-	I-protein
1	I-protein
site	I-protein
with	O
a	O
CRE	B-protein
abolishes	O
activity	O
.	O

In	O
mammals	O
,	O
the	O
transcriptional	O
repressors	O
in	O
the	O
Wnt	B-protein
pathway	I-protein
are	O
not	O
well	O
defined	O
.	O

They	O
were	O
found	O
to	O
be	O
seropositive	O
for	O
antibodies	O
to	O
hepatitis	O
C	O
virus	O
by	O
second	O
-	O
generation	O
testing	O
(	O
RIBA	O
2	O
,	O
Ortho	O
Diagnostic	O
Systems	O
Inc	O
,	O
Westwood	O
,	O
MA	O
)	O
.	O

Replacing	O
the	O
aspartic	O
acid	O
with	O
a	O
lysine	O
but	O
not	O
with	O
an	O
alanine	O
or	O
valine	O
residue	O
allowed	O
formation	O
of	O
disulfide	O
-	O
linked	O
dimers	O
.	O

Acute	O
effects	O
of	O
LI	O
160	O
(	O
extract	O
of	O
Hypericum	O
perforatum	O
,	O
St	O
John	O
'	O
s	O
wort	O
)	O
and	O
two	O
of	O
its	O
constituents	O
on	O
neuroendocrine	O
responses	O
in	O
the	O
rat	O
.	O

Within	O
this	O
sequence	O
the	O
MSAS	B-protein
gene	I-protein
was	O
identified	O
as	O
a	O
5322	O
-	O
bp	O
-	O
long	O
open	O
reading	O
frame	O
coding	O
for	O
a	O
protein	O
of	O
1774	O
amino	O
acids	O
and	O
190	O
,	O
731	O
Da	O
molecular	O
mass	O
.	O

These	O
introns	O
belong	O
to	O
the	O
class	O
of	O
nuclear	O
pre	O
-	O
mRNA	O
introns	O
and	O
contain	O
typical	O
5	O
'	O
-	O
and	O
3	O
'	O
-	O
consensus	O
sequences	O
,	O
as	O
well	O
as	O
unique	O
features	O
.	O

Due	O
to	O
its	O
relatively	O
soluble	O
chemical	O
form	O
,	O
90Sr	O
was	O
rapidly	O
translocated	O
from	O
lung	O
to	O
bone	O
where	O
a	O
substantial	O
portion	O
was	O
retained	O
for	O
a	O
long	O
period	O
of	O
time	O
.	O

Patients	O
and	O
their	O
relatives	O
must	O
be	O
informed	O
about	O
the	O
available	O
effective	O
treatment	O
possibilities	O
and	O
about	O
the	O
right	O
moment	O
for	O
their	O
application	O
in	O
an	O
individual	O
patient	O
.	O

Regional	O
cerebral	O
blood	O
flow	O
(	O
rCBF	O
)	O
measurements	O
and	O
psychiatric	O
ratings	O
were	O
performed	O
on	O
seven	O
schizophrenic	O
patients	O
(	O
mean	O
age	O
=	O
41	O
.	O
4	O
years	O
)	O
who	O
had	O
been	O
examined	O
18	O
years	O
previously	O
in	O
a	O
study	O
that	O
used	O
similar	O
psychiatric	O
ratings	O
and	O
a	O
comparable	O
rCBF	O
technique	O
.	O

The	O
Dox	B-protein
-	I-protein
A2	I-protein
ORF	I-protein
driven	O
by	O
the	O
TDH3	B-protein
promoter	I-protein
complemented	O
the	O
phenotype	O
of	O
a	O
strain	O
deleted	O
for	O
sun2	B-protein
.	O

Examples	O
are	O
using	O
more	O
subjects	O
or	O
an	O
improved	O
research	O
design	O
,	O
developing	O
consensus	O
statements	O
or	O
using	O
meta	O
-	O
analysis	O
.	O

Eight	O
highly	O
trained	O
male	O
kayakers	O
were	O
studied	O
to	O
determine	O
the	O
relationship	O
between	O
critical	O
power	O
(	O
CP	O
)	O
and	O
the	O
onset	O
of	O
blood	O
lactate	O
accumulation	O
(	O
OBLA	O
)	O
.	O

We	O
have	O
isolated	O
and	O
functionally	O
characterized	O
the	O
mouse	O
gene	O
for	O
the	O
C2	B-protein
subunit	I-protein
of	O
the	O
20S	B-protein
proteasome	I-protein
.	O

A	O
fluoroimmunoassay	O
for	O
the	O
determination	O
of	O
serum	O
of	O
plasma	O
levels	O
of	O
propranolol	O
was	O
developed	O
using	O
antibodies	O
to	O
propranolol	O
coupled	O
to	O
magnetizable	O
solid	O
-	O
phase	O
particles	O
and	O
fluorescein	O
-	O
labeled	O
propranolol	O
as	O
tracer	O
.	O

A	O
beta2	B-protein
RARE	I-protein
reporter	I-protein
construct	I-protein
in	O
which	O
the	O
methylation	O
-	O
susceptible	O
cytosines	O
in	O
the	O
sense	O
strand	O
were	O
replaced	O
by	O
thymine	O
displayed	O
marked	O
loss	O
of	O
activity	O
in	O
a	O
replicated	O
chromatin	O
-	O
dependent	O
manner	O
.	O

I	O
.	O

The	O
subjects	O
received	O
a	O
single	O
500	O
mg	O
dose	O
of	O
acetaminophen	O
i	O
.	O
v	O
.	O
and	O
concentrations	O
in	O
plasma	O
were	O
measured	O
for	O
360	O
minutes	O
and	O
in	O
urine	O
for	O
24	O
h	O
in	O
order	O
to	O
estimate	O
the	O
production	O
of	O
metabolites	O
.	O

The	O
H	O
-	O
reflex	O
recovery	O
curve	O
was	O
obtained	O
after	O
stimulation	O
of	O
the	O
median	O
nerve	O
at	O
the	O
elbow	O
and	O
recording	O
from	O
the	O
flexor	O
carpi	O
radialis	O
.	O

The	O
experimental	O
results	O
showed	O
that	O
the	O
coagulation	O
-	O
electrooxidation	O
process	O
could	O
efficiently	O
remove	O
the	O
color	O
and	O
the	O
COD	O
from	O
the	O
simulated	O
dye	O
wastewater	O
.	O

The	O
predicted	O
L	B-protein
mRNA	I-protein
was	O
6398	O
nucleotides	O
long	O
and	O
contained	O
a	O
single	O
open	O
reading	O
frame	O
corresponding	O
to	O
an	O
L	B-protein
protein	I-protein
encompassing	I-protein
2109	I-protein
amino	I-protein
acids	I-protein
with	O
a	O
MW	O
of	O
241	O
,	O
546	O
.	O

Thyrotropin	O
-	O
induced	O
expression	O
of	O
a	O
gene	O
for	O
a	O
ribosomal	O
protein	O
related	O
to	O
the	O
trk	B-protein
oncogene	I-protein
.	O

Gap	B-protein
b3	I-protein
consists	O
of	O
two	O
polypeptide	O
chains	O
(	O
Mr	O
=	O
110	O
,	O
000	O
and	O
30	O
,	O
000	O
)	O
,	O
which	O
seem	O
to	O
be	O
proteolytic	O
cleavage	O
products	O
connected	O
by	O
disulfide	O
bonds	O
from	O
a	O
precursor	O
protein	O
.	O

The	O
observed	O
sequence	O
variation	O
disrupts	O
the	O
first	O
ORF	O
in	O
many	O
Y	B-protein
'	I-protein
s	I-protein
while	O
most	O
of	O
the	O
second	O
ORF	O
including	O
the	O
putative	O
helicase	B-protein
region	I-protein
is	O
unaffected	O
.	O

Serum	O
IgG	B-protein
was	O
initially	O
elevated	O
in	O
6	O
patients	O
.	O

Twenty	O
-	O
one	O
percent	O
of	O
these	O
patients	O
had	O
neurologic	O
disease	O
that	O
appeared	O
to	O
be	O
responsible	O
for	O
the	O
tinnitus	O
.	O

The	O
indoor	O
radon	O
concentration	O
in	O
the	O
summer	O
(	O
1990	O
)	O
period	O
ranged	O
between	O
8	O
and	O
81	O
Bq	O
m	O
-	O
3	O
,	O
while	O
in	O
the	O
winter	O
(	O
1989	O
-	O
1990	O
)	O
it	O
ranged	O
between	O
20	O
and	O
143	O
Bq	O
m	O
-	O
3	O
for	O
the	O
first	O
year	O
of	O
measurements	O
or	O
between	O
8	O
and	O
92	O
Bq	O
m	O
-	O
3	O
in	O
the	O
summer	O
(	O
1991	O
)	O
period	O
and	O
between	O
12	O
and	O
119	O
Bq	O
m	O
-	O
3	O
in	O
the	O
winter	O
(	O
1990	O
-	O
1991	O
)	O
for	O
the	O
second	O
year	O
of	O
measurements	O
.	O

The	O
model	O
is	O
able	O
to	O
anticipate	O
why	O
the	O
effect	O
of	O
water	O
fluoridation	O
on	O
caries	O
prevalence	O
is	O
most	O
pronounced	O
when	O
caries	O
is	O
diagnosed	O
at	O
cavity	O
level	O
.	O

Coronary	O
arteries	O
-	O
-	O
old	O
and	O
new	O
.	O

These	O
changes	O
were	O
the	O
result	O
of	O
a	O
decrease	O
in	O
afterload	O
:	O
mean	O
aortic	O
pressure	O
fell	O
from	O
85	O
+	O
/	O
-	O
11	O
.	O
8	O
to	O
68	O
+	O
/	O
-	O
19	O
.	O
6	O
mmHg	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
systemic	O
arterial	O
resistance	O
fell	O
from	O
2	O
886	O
+	O
/	O
-	O
745	O
to	O
2	O
010	O
+	O
/	O
-	O
610	O
dynes	O
/	O
cm	O
-	O
5	O
/	O
sec	O
/	O
m	O
-	O
2	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
ERSF	B-protein
including	O
NF	B-protein
-	I-protein
Y	I-protein
and	O
ATF6alpha	B-protein
and	I-protein
/	I-protein
or	I-protein
beta	I-protein
and	O
capable	O
of	O
binding	O
to	O
ERSE	B-protein
is	O
indeed	O
formed	O
when	O
the	O
cellular	O
UPR	B-protein
is	O
activated	O
.	O

Demographic	O
and	O
clinical	O
data	O
were	O
compared	O
with	O
a	O
control	O
group	O
of	O
339	O
healthy	O
age	O
-	O
matched	O
women	O
and	O
with	O
a	O
sample	O
of	O
224	O
women	O
with	O
wrist	O
fracture	O
.	O

The	O
gene	O
sequence	O
also	O
identified	O
a	O
340	O
-	O
nucleotide	O
RNA	O
in	O
total	O
yeast	O
RNA	O
and	O
in	O
purified	O
RNase	B-protein
MRP	I-protein
enzyme	I-protein
preparations	O
.	O

The	O
murine	B-protein
MHC	I-protein
class	I-protein
I	I-protein
genes	I-protein
,	O
H	B-protein
-	I-protein
2Dq	I-protein
and	O
H	B-protein
-	I-protein
2Lq	I-protein
,	O
are	O
strikingly	O
homologous	O
to	O
each	O
other	O
,	O
H	B-protein
-	I-protein
2Ld	I-protein
,	O
and	O
two	O
genes	O
reported	O
to	O
encode	O
tumor	B-protein
-	I-protein
specific	I-protein
antigens	I-protein
.	O

The	O
introduction	O
of	O
an	O
acidic	O
residue	O
at	O
the	O
second	O
site	O
was	O
essential	O
for	O
suppression	O
of	O
the	O
Asn	O
-	O
285	O
mutation	O
because	O
Lys	O
-	O
220	O
and	O
Gln	O
-	O
220	O
second	O
-	O
site	O
mutants	O
of	O
the	O
Asn	O
-	O
285	O
mutant	O
showed	O
very	O
low	O
tetracycline	O
resistance	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
effects	O
of	O
antithrombotic	O
drugs	O
in	O
patients	O
with	O
left	O
ventricular	O
thrombi	O
:	O
assessment	O
with	O
indium	O
-	O
111	O
platelet	O
imaging	O
and	O
two	O
-	O
dimensional	O
echocardiography	O
.	O

To	O
identify	O
additional	O
non	B-protein
-	I-protein
Sir	I-protein
factors	I-protein
that	O
affect	O
rDNA	O
silencing	O
,	O
we	O
performed	O
a	O
genetic	O
screen	O
designed	O
to	O
isolate	O
mutations	O
which	O
alter	O
the	O
expression	O
of	O
reporter	O
genes	O
integrated	O
within	O
the	O
rDNA	O
.	O

The	O
first	O
85	O
nt	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
of	O
the	O
mouse	B-protein
desmin	I-protein
gene	I-protein
,	O
which	O
contain	O
an	O
E	O
box	O
(	O
E1	B-protein
)	O
,	O
the	O
binding	O
site	O
of	O
the	O
helix	O
-	O
loop	O
-	O
helix	O
myogenic	O
regulators	O
,	O
are	O
sufficient	O
to	O
confer	O
low	O
level	O
muscle	O
-	O
specific	O
expression	O
.	O

The	O
first	O
involved	O
complementation	O
of	O
a	O
nonphotosynthetic	O
mutant	O
of	O
Chlamydomonas	O
,	O
CC	O
-	O
2341	O
(	O
ac	O
-	O
u	O
-	O
g	O
-	O
2	O
.	O
3	O
)	O
,	O
which	O
has	O
a	O
frameshift	O
mutation	O
in	O
the	O
psaB	B-protein
gene	I-protein
,	O
and	O
selection	O
of	O
photosynthetic	O
transformants	O
on	O
minimal	O
medium	O
.	O

Moreover	O
,	O
the	O
second	O
RCC1	B-protein
-	I-protein
like	I-protein
motif	I-protein
located	O
at	O
the	O
amino	O
-	O
terminus	O
of	O
p619	B-protein
stimulates	O
guanine	O
nucleotide	O
exchange	O
on	O
ARF1	B-protein
and	O
on	O
members	O
of	O
the	O
related	O
Rab	B-protein
proteins	I-protein
,	O
but	O
not	O
on	O
other	O
small	B-protein
GTP	I-protein
binding	I-protein
proteins	I-protein
such	O
as	O
Ran	B-protein
or	O
R	B-protein
-	I-protein
Ras2	I-protein
/	I-protein
TC21	I-protein
.	O

Subcloning	O
of	O
DNA	O
fragments	O
from	O
the	O
8	O
.	O
5	O
-	O
kilobase	O
(	O
kb	O
)	O
insert	O
of	O
pAVO4	O
defined	O
a	O
4	O
-	O
kb	O
DNA	O
fragment	O
which	O
contained	O
the	O
functional	B-protein
FBP	I-protein
+	I-protein
gene	I-protein
and	O
its	O
regulatory	O
region	O
.	O

Bandshift	O
experiments	O
demonstrate	O
that	O
BmHR3A	B-protein
binds	O
specifically	O
to	O
RORE	B-protein
(	O
Retinoic	B-protein
acid	I-protein
-	I-protein
related	I-protein
Orphan	I-protein
receptor	I-protein
Response	I-protein
Element	I-protein
)	O
-	O
like	O
sequences	O
in	O
the	O
promoters	O
of	O
both	O
genes	O
,	O
thus	O
suggesting	O
a	O
direct	O
role	O
for	O
BmHR3A	B-protein
in	O
regulating	O
the	O
expression	O
of	O
BmGATAbeta	B-protein
and	O
ESP	B-protein
genes	I-protein
during	O
vitellogenesis	O
.	O

Drugs	O
that	O
are	O
transformed	O
via	O
phase	O
II	O
reactions	O
usually	O
do	O
not	O
require	O
dosage	O
adjustment	O
.	O

100	O
years	O
of	O
dentistry	O
at	O
the	O
Friedrich	O
Schiller	O
University	O
in	O
Jena	O
.	O

Gamma	B-protein
glutamyl	I-protein
transpeptidase	I-protein
(	O
GGTP	B-protein
)	O
activity	O
in	O
the	O
seminal	O
fluid	O
.	O

The	O
morphological	O
effects	O
of	O
two	O
snake	O
venoms	O
,	O
N	O
.	O
naja	O
and	O
A	O
.	O
piscivorus	O
,	O
and	O
of	O
the	O
Direct	B-protein
Lytic	I-protein
Factor	I-protein
and	O
Phospholipase	B-protein
-	I-protein
A	I-protein
,	O
compounds	O
purified	O
from	O
N	O
.	O
naja	O
crude	O
venom	O
,	O
were	O
investigated	O
on	O
lung	O
and	O
cremaster	O
vessels	O
of	O
rats	O
.	O

The	O
regional	O
blockade	O
of	O
H1R	B-protein
was	O
observed	O
mainly	O
in	O
the	O
frontal	O
,	O
temporal	O
and	O
anterior	O
cingulate	O
cortices	O
,	O
and	O
the	O
intravenous	O
administration	O
of	O
d	O
-	O
chlorpheniramine	O
as	O
a	O
therapeutic	O
dose	O
(	O
2	O
mg	O
)	O
blocked	O
over	O
60	O
%	O
of	O
H1R	B-protein
in	O
the	O
frontal	O
cortices	O
.	O

The	O
frequency	O
of	O
positive	O
anti	B-protein
-	I-protein
GM1	I-protein
antibody	I-protein
titers	O
in	O
the	O
Guillain	O
-	O
Barre	O
syndrome	O
patients	O
with	O
PEN	O
19	O
isolates	O
was	O
higher	O
than	O
that	O
in	O
the	O
Guillain	O
-	O
Barre	O
syndrome	O
and	O
Fisher	O
'	O
s	O
syndrome	O
patients	O
without	O
PEN	O
19	O
isolates	O
.	O

TG	O
-	O
day	O
and	O
TG	O
-	O
night	O
were	O
19	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
1	O
%	O
,	O
26	O
.	O
6	O
+	O
/	O
-	O
5	O
.	O
3	O
%	O
,	O
(	O
750	O
mm3	O
<	O
T	O
.	O

However	O
,	O
there	O
were	O
some	O
properties	O
of	O
Rak	B-protein
that	O
are	O
distinct	O
from	O
Src	B-protein
-	I-protein
like	I-protein
kinases	I-protein
:	O
(	O
a	O
)	O
expression	O
of	O
Rak	B-protein
was	O
predominantly	O
in	O
epithelial	O
-	O
derived	O
cell	O
lines	O
and	O
tissues	O
,	O
especially	O
normal	O
liver	O
and	O
kidney	O
,	O
and	O
cell	O
lines	O
of	O
breast	O
and	O
colon	O
origin	O
;	O
(	O
b	O
)	O
Rak	B-protein
does	O
not	O
harbor	O
the	O
NH2	O
-	O
terminal	O
glycine	O
essential	O
for	O
myristylation	O
and	O
membrane	O
localization	O
;	O
and	O
(	O
c	O
)	O
Rak	B-protein
possesses	O
a	O
putative	O
bipartite	O
nuclear	O
localization	O
signal	O
in	O
the	O
SH2	B-protein
domain	I-protein
,	O
and	O
subcellular	O
fractionation	O
studies	O
revealed	O
that	O
p54rak	B-protein
resides	O
predominantly	O
in	O
the	O
nucleus	O
.	O

The	O
role	O
of	O
DNA	O
rearrangement	O
and	O
alternative	O
RNA	O
processing	O
in	O
the	O
expression	O
of	O
immunoglobulin	B-protein
delta	I-protein
genes	I-protein
.	O

Genomic	O
and	O
functional	O
characterization	O
of	O
the	O
oas	B-protein
gene	I-protein
family	I-protein
encoding	O
O	B-protein
-	I-protein
acetylserine	I-protein
(	I-protein
thiol	I-protein
)	I-protein
lyases	I-protein
,	O
enzymes	O
catalyzing	O
the	O
final	O
step	O
in	O
cysteine	O
biosynthesis	O
in	O
Arabidopsis	O
thaliana	O
.	O

The	O
results	O
indicate	O
that	O
the	O
open	O
-	O
section	O
effect	O
decreases	O
the	O
torsional	O
stiffness	O
and	O
stress	O
concentration	O
effects	O
decrease	O
the	O
torsional	O
strength	O
of	O
a	O
long	O
bone	O
with	O
a	O
longitudinal	O
defect	O
.	O

Evaluating	O
dietary	O
department	O
management	O
.	O

A	O
review	O
of	O
studies	O
published	O
between	O
1983	O
and	O
1995	O
shows	O
that	O
there	O
are	O
some	O
common	O
factors	O
as	O
regards	O
the	O
psychological	O
distress	O
and	O
social	O
and	O
functional	O
limitations	O
this	O
group	O
of	O
patients	O
has	O
to	O
deal	O
with	O
.	O

Plasma	O
and	O
bladder	O
platinum	O
concentration	O
were	O
measured	O
following	O
intravesical	O
DDP	O
,	O
and	O
also	O
histopathological	O
examination	O
,	O
urinalysis	O
,	O
complete	O
blood	O
count	O
and	O
blood	O
chemistry	O
were	O
performed	O
in	O
order	O
to	O
know	O
the	O
toxicity	O
of	O
intravesical	O
DDP	O
.	O

The	O
cDNA	O
sequence	O
has	O
an	O
813	O
-	O
bp	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
whose	O
predicted	O
amino	O
acid	O
sequence	O
is	O
97	O
.	O
6	O
%	O
identical	O
to	O
the	O
272	O
carboxy	O
-	O
terminal	O
amino	O
acids	O
of	O
the	O
human	B-protein
ets	I-protein
-	I-protein
1	I-protein
protein	I-protein
.	O

These	O
results	O
support	O
the	O
view	O
that	O
clonidine	O
and	O
6	O
-	O
OHDA	O
,	O
but	O
not	O
alpha	O
-	O
MD	O
,	O
have	O
central	O
pressor	O
actions	O
in	O
the	O
rat	O
that	O
oppose	O
their	O
antihypertensive	O
action	O
.	O

Lauciello	O
describes	O
a	O
technique	O
for	O
the	O
placement	O
of	O
functionally	O
generated	O
amalgam	O
stops	O
as	O
restorations	O
within	O
mandibular	O
acrylic	O
teeth	O
.	O

Here	O
we	O
present	O
evidence	O
that	O
major	B-protein
IE	I-protein
proteins	I-protein
IE86	I-protein
,	O
IE72	B-protein
,	O
and	O
IE55	B-protein
are	O
capable	O
of	O
trans	O
-	O
activating	O
the	O
HIV	O
LTR	O
in	O
a	O
T	O
-	O
cell	O
line	O
,	O
HUT	O
-	O
78	O
.	O

A	O
phylogenetic	O
analysis	O
with	O
the	O
TK	B-protein
domains	I-protein
from	O
these	O
sequences	O
and	O
a	O
fourth	O
,	O
from	O
a	O
novel	O
scavenger	B-protein
RTK	I-protein
(	O
all	O
domains	O
comprise	O
the	O
signature	O
for	O
the	O
TK	B-protein
class	I-protein
II	I-protein
receptors	I-protein
)	O
,	O
showed	O
that	O
they	O
are	O
distantly	O
related	O
to	O
the	O
insulin	B-protein
and	O
insulin	B-protein
-	I-protein
like	I-protein
receptors	I-protein
.	O

We	O
show	O
that	O
IL	B-protein
-	I-protein
6	I-protein
activates	O
JRE	B-protein
-	I-protein
IL6	I-protein
through	O
an	O
H7	O
-	O
sensitive	O
pathway	O
that	O
does	O
not	O
involve	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
cyclic	B-protein
AMP	I-protein
-	I-protein
dependent	I-protein
kinase	I-protein
,	O
Ca	B-protein
(	I-protein
2	I-protein
+	I-protein
)	I-protein
-	I-protein
or	I-protein
calmodulin	I-protein
-	I-protein
dependent	I-protein
kinases	I-protein
,	O
Ras	B-protein
,	O
Raf	B-protein
-	I-protein
1	I-protein
,	O
or	O
NF	B-protein
-	I-protein
IL6	I-protein
(	O
C	B-protein
/	I-protein
EBP	I-protein
beta	I-protein
)	O
.	O

Histological	O
analysis	O
showed	O
that	O
the	O
neuronal	O
loss	O
in	O
the	O
DHED	O
-	O
treated	O
group	O
was	O
notably	O
reduced	O
in	O
the	O
hippocampal	O
area	O
(	O
CA1	O
)	O
of	O
ischemic	O
rats	O
and	O
in	O
the	O
dentate	O
gyrus	O
and	O
hippocampal	O
area	O
(	O
CA1	O
and	O
CA3	O
)	O
of	O
EC	O
-	O
lesioned	O
rats	O
compared	O
with	O
the	O
nontreated	O
group	O
.	O

Expression	O
of	O
the	O
human	B-protein
papillomavirus	I-protein
type	I-protein
11	I-protein
E5A	I-protein
protein	I-protein
from	O
the	O
E1E4	B-protein
,	I-protein
E5	I-protein
transcript	I-protein
.	O

The	O
next	O
twenty	O
years	O
of	O
prevention	O
in	O
Indian	O
country	O
:	O
visionary	O
,	O
complex	O
,	O
and	O
practical	O
.	O

We	O
have	O
utilized	O
the	O
human	B-protein
4F2	I-protein
heavy	I-protein
chain	I-protein
(	O
4F2HC	B-protein
)	O
gene	O
as	O
a	O
model	O
system	O
in	O
studies	O
designed	O
to	O
elucidate	O
the	O
molecular	O
events	O
involved	O
in	O
regulating	O
inducible	O
gene	O
expression	O
during	O
normal	O
human	O
T	O
-	O
cell	O
activation	O
.	O

We	O
cloned	O
the	O
third	O
human	O
gene	O
for	O
the	O
LD78	B-protein
,	O
termed	O
LD78	B-protein
gamma	I-protein
and	O
the	O
sequence	O
analysis	O
showed	O
that	O
it	O
is	O
a	O
5	O
'	O
-	O
truncated	O
pseudogene	O
.	O

Moreover	O
,	O
the	O
reconstitution	O
of	O
eUSF	B-protein
and	O
TFIID	O
-	O
depleted	O
transcription	O
complexes	O
with	O
purified	O
protein	O
fractions	O
demonstrate	O
that	O
not	O
only	O
TFIID	B-protein
but	O
also	O
eUSF	B-protein
essentially	O
participates	O
in	O
complex	O
formation	O
even	O
on	O
H5	B-protein
promoter	I-protein
mutations	O
lacking	O
the	O
TATA	O
-	O
box	O
.	O

Histamine	O
reactivity	O
had	O
returned	O
to	O
normal	O
in	O
half	O
the	O
workers	O
who	O
had	O
left	O
their	O
original	O
factories	O
,	O
but	O
in	O
only	O
one	O
worker	O
who	O
had	O
moved	O
within	O
her	O
original	O
factory	O
.	O

Together	O
these	O
data	O
imply	O
that	O
the	O
HFV	B-protein
R	I-protein
region	I-protein
acts	O
in	O
the	O
nucleus	O
to	O
modify	O
the	O
cytoplasmic	O
fate	O
of	O
target	B-protein
HFV	I-protein
mRNA	I-protein
.	O

Transcription	O
factor	O
recognition	O
surface	O
on	O
the	O
RNA	B-protein
polymerase	I-protein
alpha	I-protein
subunit	I-protein
is	O
involved	O
in	O
contact	O
with	O
the	O
DNA	O
enhancer	O
element	O
.	O

Rind	O
et	O
al	O
.	O
'	O
s	O
study	O
'	O
s	O
main	O
conclusions	O
were	O
not	O
supported	O
by	O
the	O
original	O
data	O
.	O

Thus	O
,	O
transcriptional	O
regulation	O
,	O
splicing	O
,	O
kinase	O
interaction	O
sites	O
,	O
and	O
tyrosine	O
phosphorylation	O
of	O
the	O
LMP2A	B-protein
homologs	I-protein
have	O
been	O
conserved	O
despite	O
significant	O
sequences	O
heterogeneity	O
in	O
the	O
preterminal	O
repeat	O
regions	O
of	O
these	O
human	O
and	O
nonhuman	O
primate	O
EBVs	O
.	O

The	O
Saccharomyces	B-protein
cerevisiae	I-protein
RAD30	I-protein
gene	I-protein
,	O
a	O
homologue	B-protein
of	I-protein
Escherichia	I-protein
coli	I-protein
dinB	I-protein
and	O
umuC	B-protein
,	O
is	O
DNA	O
damage	O
inducible	O
and	O
functions	O
in	O
a	O
novel	O
error	O
-	O
free	O
postreplication	O
repair	O
mechanism	O
.	O

Right	O
LHR	O
(	O
R	O
-	O
LHR	O
)	O
provided	O
the	O
best	O
interobserver	O
and	O
intraobserver	O
reproducibility	O
.	O

Two	O
-	O
Channel	O
Kondo	O
Lattice	O
:	O
An	O
Incoherent	O
Metal	O
.	O

A	O
limiting	O
factor	O
were	O
disturbances	O
in	O
the	O
system	O
of	O
energy	O
transport	O
(	O
creatine	O
phosphate	O
,	O
creatine	B-protein
phosphokinase	I-protein
)	O
and	O
of	O
the	O
calcium	O
pump	O
(	O
Ca	B-protein
+	I-protein
+	I-protein
-	I-protein
ATPase	I-protein
of	O
the	O
sarcoplasmic	O
reticulum	O
,	O
SPR	O
)	O
,	O
which	O
evidently	O
led	O
to	O
a	O
decrease	O
of	O
the	O
inotropic	O
properties	O
of	O
the	O
myocardium	O
at	O
70	O
%	O
restriction	O
of	O
coronary	O
blood	O
flow	O
.	O

It	O
is	O
shown	O
that	O
the	O
(	O
G	O
+	O
C	O
)	O
-	O
rich	O
element	O
of	O
the	O
aldolase	B-protein
C	I-protein
promoter	I-protein
directs	O
transcription	O
in	O
neuronal	O
as	O
well	O
as	O
in	O
nonneuronal	O
cells	O
.	O

During	O
most	O
of	O
the	O
cell	O
cycle	O
,	O
separase	B-protein
is	O
kept	O
inactive	O
by	O
binding	O
to	O
an	O
inhibitory	O
protein	O
called	O
securin	B-protein
.	O

A	O
comparison	O
of	O
the	O
nucleotide	O
sequence	O
of	O
the	O
p54	B-protein
gene	I-protein
carried	O
by	O
two	O
virulent	O
ASFV	O
strains	O
(	O
E70	O
and	O
E75	O
)	O
with	O
that	O
obtained	O
from	O
virus	O
Ba71V	O
showed	O
100	O
%	O
similarity	O
.	O

The	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
-	I-protein
1	I-protein
(	I-protein
HIV	I-protein
-	I-protein
1	I-protein
)	I-protein
Tat	I-protein
protein	I-protein
regulates	O
transcription	O
by	O
stimulating	O
RNA	B-protein
polymerase	I-protein
processivity	O
.	O

TB	O
bone	O
area	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
height	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
years	O
in	O
present	O
colony	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
,	O
and	O
menses	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
predicted	O
TB	O
BMC	O
.	O

Cotransfection	O
of	O
the	O
coactivator	O
CREB	B-protein
-	I-protein
binding	I-protein
protein	I-protein
relieved	O
the	O
transcriptional	O
repression	O
of	O
PPARalphawt	B-protein
by	O
PPARalphatr	B-protein
,	O
suggesting	O
that	O
the	O
dominant	O
negative	O
effect	O
of	O
PPARalphatr	B-protein
might	O
occur	O
through	O
competition	O
for	O
essential	O
coactivators	O
.	O

Looming	O
detectors	O
in	O
the	O
human	O
visual	O
pathway	O
.	O

In	O
contrast	O
,	O
exogenous	B-protein
PTHrP1	I-protein
-	I-protein
34	I-protein
and	I-protein
1	I-protein
-	I-protein
86	I-protein
peptides	I-protein
did	O
not	O
significantly	O
affect	O
IL	B-protein
-	I-protein
8	I-protein
production	O
;	O
moreover	O
,	O
PTHrP	B-protein
-	I-protein
neutralizing	I-protein
antibodies	I-protein
did	O
not	O
inhibit	O
the	O
production	O
of	O
IL	B-protein
-	I-protein
8	I-protein
by	O
transfected	O
PTHrP	B-protein
.	O

Results	O
:	O
Transpulmonary	O
passage	O
of	O
contrast	O
occurred	O
in	O
sufficient	O
amounts	O
to	O
enhance	O
the	O
intensity	O
of	O
the	O
Doppler	O
signal	O
significantly	O
,	O
but	O
the	O
duration	O
of	O
this	O
effect	O
was	O
short	O
.	O

Rams	O
were	O
weighed	O
and	O
testis	O
size	O
was	O
estimated	O
by	O
orchimetry	O
at	O
each	O
time	O
period	O
.	O

Although	O
the	O
terminase	B-protein
apparently	O
interacts	O
with	O
this	O
gp20	B-protein
portal	I-protein
peptide	I-protein
,	O
polyclonal	O
antibody	O
against	O
the	O
portal	O
peptide	O
appears	O
unable	O
to	O
access	O
it	O
in	O
the	O
native	O
structure	O
,	O
suggesting	O
intimate	O
association	O
of	O
gp20	B-protein
and	O
gp17	B-protein
possibly	O
internalizes	O
terminase	B-protein
regions	I-protein
within	O
the	O
portal	O
in	O
the	O
packasome	O
complex	O
.	O

Simulating	O
the	O
impact	O
during	O
human	O
jumping	O
by	O
means	O
of	O
a	O
4	O
-	O
degrees	O
-	O
of	O
-	O
freedom	O
model	O
.	O

The	O
m7GpppN	O
cap	O
structure	O
of	O
eukaryotic	O
mRNA	O
is	O
formed	O
cotranscriptionally	O
by	O
the	O
sequential	O
action	O
of	O
three	O
enzymes	O
:	O
RNA	B-protein
triphosphatase	I-protein
,	O
RNA	B-protein
guanylyltransferase	I-protein
,	O
and	O
RNA	B-protein
(	I-protein
guanine	I-protein
-	I-protein
7	I-protein
)	I-protein
-	I-protein
methyltransferase	I-protein
.	O

R	O
.	O
,	O
Fleischmann	O
,	O
R	O
.	O
,	O
Venter	O
,	O
J	O
.	O

In	O
addition	O
,	O
two	O
-	O
dimensional	O
nuclear	O
magnetic	O
resonance	O
studies	O
with	O
F17A	O
,	O
K13Q	O
,	O
F15Y	O
and	O
F27Y	O
revealed	O
that	O
the	O
mutants	O
have	O
the	O
same	O
overall	O
structure	O
as	O
the	O
wild	B-protein
-	I-protein
type	I-protein
CspB	I-protein
protein	I-protein
.	O

The	O
extraction	O
recovery	O
of	O
Amphotericin	O
B	O
from	O
the	O
cerebrospinal	O
fluid	O
is	O
higher	O
than	O
90	O
%	O
over	O
the	O
entire	O
linear	O
range	O
.	O

In	O
addition	O
,	O
we	O
find	O
that	O
E2F	B-protein
-	I-protein
1	I-protein
can	O
cause	O
apoptosis	O
in	O
p53	B-protein
-	I-protein
/	I-protein
-	I-protein
tumour	O
cells	O
and	O
further	O
p300	B-protein
,	O
which	O
also	O
functions	O
as	O
a	O
co	O
-	O
activator	O
for	O
the	O
E2F	B-protein
/	I-protein
DP	I-protein
heterodimer	I-protein
,	O
enhances	O
the	O
apoptotic	O
activity	O
of	O
E2F	B-protein
-	I-protein
1	I-protein
.	O

Following	O
retransfusion	O
,	O
the	O
affected	O
epithelial	O
lining	O
appeared	O
greatly	O
distended	O
over	O
the	O
oedematous	O
lamina	O
propria	O
,	O
with	O
almost	O
complete	O
loss	O
of	O
structural	O
detail	O
.	O

Here	O
we	O
report	O
that	O
the	O
proline	O
-	O
rich	O
region	O
of	O
CAP	B-protein
is	O
recognized	O
by	O
the	O
SH3	B-protein
domains	I-protein
of	O
several	O
proteins	O
,	O
including	O
the	O
yeast	B-protein
actin	I-protein
-	I-protein
associated	I-protein
protein	I-protein
Abp1p	I-protein
.	O

Molecular	O
cloning	O
of	O
a	O
P	B-protein
-	I-protein
type	I-protein
ATPase	I-protein
gene	I-protein
from	O
the	O
cyanobacterium	O
Synechocystis	O
sp	O
.	O

In	O
the	O
work	O
reported	O
here	O
,	O
we	O
used	O
peptide	O
mapping	O
,	O
mass	O
spectrometry	O
,	O
and	O
site	O
-	O
directed	O
mutagenesis	O
to	O
identify	O
two	O
sets	O
of	O
pAP	B-protein
phosphorylation	O
sites	O
.	O

The	O
RAT3	B-protein
gene	I-protein
encodes	O
an	O
1157	O
-	O
amino	O
acid	O
protein	O
without	O
similarity	O
to	O
other	O
known	O
proteins	O
.	O

The	O
high	O
conservation	O
of	O
the	O
3	O
'	O
terminus	O
suggests	O
that	O
this	O
region	O
directs	O
the	O
assembly	O
of	O
proteins	O
required	O
for	O
the	O
initiation	O
of	O
RNA	O
replication	O
.	O

Sixteen	O
patients	O
were	O
studied	O
within	O
24	O
hours	O
of	O
resuscitation	O
and	O
all	O
showed	O
depressed	O
right	O
ventricular	O
ejection	O
(	O
RVEF	O
)	O
and	O
/	O
or	O
an	O
increased	O
end	O
-	O
diastolic	O
volume	O
(	O
RVEDVI	O
)	O
.	O

In	O
10	O
control	O
sheep	O
mean	O
plasma	O
TXB2	O
concentration	O
increased	O
from	O
0	O
.	O
39	O
ng	O
/	O
ml	O
prebypass	O
to	O
about	O
1	O
.	O
1	O
ng	O
/	O
ml	O
at	O
8	O
and	O
16	O
min	O
of	O
bypass	O
.	O

J	O
.	O

The	O
distributed	O
current	O
density	O
J	O
is	O
calculated	O
within	O
the	O
volume	O
defined	O
by	O
the	O
motor	O
unit	O
.	O

The	O
PI3K	B-protein
_	I-protein
68D	I-protein
cDNA	I-protein
encodes	O
a	O
protein	O
of	O
210	O
kDa	O
,	O
which	O
lacks	O
sequences	O
implicated	O
in	O
linking	O
p110	O
PI	B-protein
3	I-protein
-	I-protein
kinases	I-protein
to	O
p85	B-protein
adaptor	I-protein
proteins	I-protein
,	O
but	O
contains	O
an	O
amino	O
-	O
terminal	O
proline	O
-	O
rich	O
sequence	O
,	O
which	O
could	O
bind	O
to	O
SH3	B-protein
domains	I-protein
,	O
and	O
a	O
carboxy	O
-	O
terminal	O
C2	O
domain	O
.	O

Nursing	O
of	O
patients	O
with	O
gynecological	O
diseases	O
.	O

Prominent	O
findings	O
were	O
chronic	O
pancreatitis	O
with	O
acinar	O
and	O
ductal	O
plugs	O
,	O
granulomatous	O
and	O
necrotizing	O
peripancreatic	O
steatitis	O
,	O
degenerative	O
myopathy	O
,	O
testicular	O
atrophy	O
,	O
candidiasis	O
and	O
bacterial	O
necrotizing	O
glossitis	O
.	O

Nipponbare	O
as	O
well	O
as	O
O	O
.	O
australiensis	O
.	O

We	O
show	O
that	O
the	O
Sm	B-protein
-	I-protein
binding	I-protein
site	I-protein
and	O
stem	O
-	O
loop	O
III	O
structures	O
are	O
necessary	O
for	O
correct	O
3	O
'	O
-	O
end	O
formation	O
.	O

Viral	O
cell	O
-	O
to	O
-	O
cell	O
movement	O
of	O
PVX	B-protein
CP	I-protein
mutant	I-protein
was	O
complemented	O
in	O
Nicotiana	O
tabacum	O
cv	O
.	O

The	O
percentage	O
RFR	O
reduction	O
at	O
the	O
end	O
of	O
CPB	O
showed	O
significant	O
correlation	O
with	O
1	O
)	O
CPB	O
duration	O
(	O
r	O
=	O
0	O
.	O
49	O
)	O
,	O
2	O
)	O
oxygen	O
flow	O
rate	O
index	O
(	O
OFRI	O
)	O
,	O
i	O
.	O
e	O
.	O
flow	O
/	O
min	O
in	O
the	O
bubble	O
oxygenator	O
/	O
m2	O
bsa	O
(	O
r	O
=	O
0	O
.	O
38	O
)	O
,	O
and	O
3	O
)	O
blood	O
flow	O
rate	O
index	O
(	O
BFRI	O
)	O
,	O
i	O
.	O
e	O
.	O
average	O
volume	O
of	O
blood	O
pumped	O
through	O
the	O
heart	O
-	O
lung	O
machine	O
/	O
min	O
CPB	O
time	O
/	O
m2	O
bsa	O
(	O
r	O
=	O
0	O
.	O
51	O
)	O
.	O

Risk	O
of	O
HTLV	O
infection	O
in	O
patients	O
on	O
haemodialysis	O
.	O

Unfolding	O
can	O
be	O
described	O
by	O
a	O
two	O
-	O
state	O
process	O
since	O
a	O
ratio	O
of	O
delta	O
Hcalorimetric	O
to	O
delta	O
Hva	O
n	O
'	O
t	O
Hoff	O
equals	O
0	O
.	O
96	O
.	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
sodium	O
channel	O
blocking	O
drugs	O
selectively	O
prolong	O
the	O
late	O
potential	O
,	O
or	O
terminal	O
low	O
amplitude	O
signal	O
,	O
portion	O
of	O
the	O
signal	O
-	O
averaged	O
QRS	O
complex	O
and	O
that	O
prolongation	O
of	O
the	O
late	O
potential	O
would	O
correlate	O
with	O
slowing	O
of	O
ventricular	O
tachycardia	O
.	O

The	O
in	O
vitro	O
activity	O
of	O
mecillinam	O
and	O
amoxicillin	O
/	O
clavulanic	O
acid	O
against	O
Escherichia	O
coli	O
strains	O
producing	O
beta	B-protein
-	I-protein
lactamases	I-protein
of	O
the	O
TEM	B-protein
-	I-protein
1	I-protein
,	O
Oxa	B-protein
-	I-protein
1	I-protein
and	O
chromosomal	O
type	O
were	O
studied	O
using	O
the	O
broth	O
and	O
agar	O
dilution	O
technique	O
.	O

The	O
cop	B-protein
region	I-protein
also	O
harbors	O
a	O
region	O
of	O
plasmid	O
incompatibility	O
,	O
inc	B-protein
,	O
encompassing	O
a	O
stem	O
-	O
loop	O
structure	O
,	O
the	O
repA	B-protein
promoter	I-protein
,	O
Prep	B-protein
,	O
as	O
well	O
as	O
two	O
distinct	O
RepA	B-protein
binding	I-protein
sites	I-protein
,	O
BD	B-protein
-	I-protein
1	I-protein
and	O
BD	B-protein
-	I-protein
2	I-protein
.	O

IL	B-protein
-	I-protein
12	I-protein
production	O
was	O
correlated	O
with	O
C3a	O
concentration	O
measured	O
at	O
the	O
outlet	O
of	O
hemodialyzer	O
after	O
15	O
min	O
of	O
dialysis	O
(	O
r	O
=	O
0	O
.	O
69	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

DNA	O
sequence	O
analysis	O
reveals	O
that	O
the	O
gene	O
encodes	O
a	O
protein	O
highly	O
homologous	O
to	O
rat	B-protein
CRP1	I-protein
.	O

When	O
cysteine	O
is	O
scanned	O
through	O
the	O
helices	O
,	O
characteristic	O
repeating	O
patterns	O
of	O
solvent	O
exposure	O
and	O
burial	O
are	O
observed	O
.	O

Recombinant	O
expression	O
of	O
a	O
chimeric	O
EGFR	B-protein
/	I-protein
ErbB	I-protein
-	I-protein
3	I-protein
receptor	I-protein
in	O
NIH	O
3T3	O
fibroblasts	O
allowed	O
us	O
to	O
investigate	O
cytoplasmic	O
events	O
associated	O
with	O
ErbB	B-protein
-	I-protein
3	I-protein
signal	O
transduction	O
upon	O
ligand	O
activation	O
.	O

Replicating	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
chromosomes	O
were	O
found	O
to	O
be	O
similar	O
to	O
other	O
eukaryotic	O
chromosomes	O
in	O
that	O
the	O
rate	O
and	O
extent	O
of	O
micrococcal	B-protein
nuclease	I-protein
(	O
MNase	B-protein
)	O
digestion	O
were	O
greater	O
with	O
replicating	O
than	O
with	O
nonreplicating	O
mature	O
SV40	O
chromatin	O
.	O

Recurrence	O
of	O
oxalate	O
deposition	O
in	O
a	O
renal	O
transplant	O
during	O
ciclosporin	O
A	O
therapy	O
.	O

As	O
retinoic	O
acid	O
and	O
thyroid	O
hormone	O
are	O
frequently	O
involved	O
in	O
developmental	O
regulatory	O
processes	O
,	O
it	O
is	O
possible	O
that	O
this	O
element	O
may	O
be	O
important	O
in	O
the	O
process	O
of	O
islet	O
cell	O
differentiation	O
.	O

We	O
have	O
shown	O
that	O
the	O
epidural	O
(	O
EPI	O
)	O
delivery	O
of	O
morphine	O
encapsulated	O
in	O
multivesicular	O
liposomes	O
(	O
DepoFoam	O
drug	O
delivery	O
system	O
)	O
produces	O
a	O
sustained	O
clearance	O
of	O
morphine	O
and	O
a	O
prolonged	O
analgesia	O
.	O

The	O
results	O
of	O
these	O
studies	O
support	O
a	O
model	O
in	O
which	O
VirB4	B-protein
dimers	I-protein
or	O
homomultimers	O
contribute	O
structural	O
information	O
for	O
the	O
assembly	O
of	O
a	O
transenvelope	O
channel	O
competent	O
for	O
bidirectional	O
DNA	O
transfer	O
,	O
whereas	O
an	O
ATP	O
-	O
dependent	O
activity	O
is	O
required	O
for	O
configuring	O
this	O
channel	O
as	O
a	O
dedicated	O
export	O
machine	O
.	O

It	O
is	O
concluded	O
that	O
haloperidol	O
selectively	O
reduced	O
the	O
animal	O
'	O
s	O
capacity	O
to	O
'	O
programme	O
non	O
-	O
stimulus	O
directed	O
motor	O
behaviour	O
'	O
.	O

Sleep	O
was	O
determined	O
again	O
for	O
an	O
additional	O
3	O
days	O
and	O
6	O
hours	O
.	O

Histochemical	O
localization	O
of	O
GUS	B-protein
revealed	O
promoter	O
function	O
in	O
leaf	O
epidermis	O
,	O
mesophyll	O
and	O
vascular	O
bundles	O
,	O
in	O
the	O
cortex	O
and	O
vascular	O
cylinder	O
of	O
the	O
root	O
.	O

We	O
show	O
here	O
that	O
the	O
in	O
vitro	O
transcription	O
extract	O
contains	O
a	O
binding	O
activity	O
that	O
is	O
specific	O
for	O
the	O
initiator	O
element	O
and	O
thus	O
may	O
participate	O
in	O
recruiting	O
RNA	B-protein
polymerase	I-protein
II	I-protein
to	O
the	O
SL	B-protein
RNA	I-protein
gene	I-protein
promoter	I-protein
.	O

Localization	O
of	O
the	O
insertion	O
locus	O
in	O
the	O
yeast	O
genome	O
and	O
complementation	O
studies	O
with	O
the	O
temperature	O
-	O
sensitive	O
mutant	O
indicate	O
that	O
the	O
two	O
mutations	O
are	O
allelic	O
.	O

The	O
conditions	O
for	O
obtaining	O
titanium	O
dioxide	O
from	O
the	O
substrates	O
titanium	O
tetrachloride	O
and	O
oxygen	O
and	O
applying	O
this	O
to	O
a	O
surgical	O
stainless	O
steel	O
of	O
the	O
type	O
316L	O
by	O
the	O
plasma	O
assisted	O
chemical	O
vapour	O
deposition	O
method	O
have	O
been	O
determined	O
.	O

The	O
growth	O
defect	O
of	O
a	O
reg1	B-protein
reg2	I-protein
double	I-protein
mutant	I-protein
is	O
alleviated	O
by	O
a	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
in	O
the	O
SNF1	B-protein
-	I-protein
encoded	I-protein
protein	I-protein
kinase	I-protein
.	O

When	O
combined	O
with	O
serum	O
ferritin	B-protein
and	O
hemoglobin	B-protein
determinations	O
,	O
the	O
serum	O
transferrin	B-protein
receptor	I-protein
assay	O
is	O
a	O
valuable	O
addition	O
in	O
epidemiologic	O
surveys	O
because	O
it	O
provides	O
a	O
quantitative	O
measure	O
of	O
functional	O
iron	O
deficiency	O
and	O
it	O
distinguishes	O
true	O
IDA	O
from	O
the	O
anemia	O
of	O
chronic	O
disease	O
.	O

In	O
this	O
study	O
,	O
to	O
characterize	O
the	O
gene	O
for	O
protein	B-protein
Z	I-protein
,	O
its	O
organization	O
and	O
structure	O
were	O
determined	O
by	O
a	O
combination	O
of	O
PCR	O
amplification	O
of	O
leukocyte	O
DNA	O
and	O
isolation	O
of	O
phage	O
clones	O
from	O
a	O
human	O
genomic	O
library	O
.	O

A	O
genomic	O
DNA	O
clone	O
encoding	O
oryzacystatin	B-protein
(	O
Oc	B-protein
)	O
,	O
a	O
cysteine	B-protein
proteinase	I-protein
inhibitor	I-protein
(	O
cystatin	B-protein
)	O
of	O
rice	O
,	O
was	O
isolated	O
from	O
a	O
lambda	O
EMBL3	O
phage	O
library	O
constructed	O
with	O
Sau3AI	B-protein
partial	O
digests	O
of	O
rice	O
chromosomal	O
DNA	O
,	O
by	O
screening	O
with	O
an	O
oc	B-protein
cDNA	I-protein
as	O
a	O
probe	O
.	O

Surprisingly	O
,	O
the	O
RXR	O
-	O
specific	O
ligand	O
9	O
-	O
cis	O
-	O
retinoic	O
acid	O
induced	O
binding	O
of	O
SRC	B-protein
-	I-protein
1	I-protein
to	O
the	O
RXR	B-protein
component	I-protein
of	O
the	O
TRE	O
-	O
bound	O
heterodimer	O
.	O

The	O
average	O
coefficients	O
of	O
correlation	O
were	O
0	O
.	O
9998	O
and	O
0	O
.	O
9993	O
for	O
the	O
QMF	O
and	O
the	O
QIT	O
system	O
,	O
respectively	O
.	O

When	O
RNA	O
encoding	O
the	O
tail	O
domain	O
of	O
desmoglein	B-protein
was	O
coinjected	O
with	O
plakoglobin	B-protein
RNA	I-protein
,	O
both	O
the	O
dorsalizing	O
effect	O
and	O
nuclear	O
accumulation	O
of	O
plakoglobin	B-protein
were	O
suppressed	O
.	O

Two	O
related	O
cDNAs	O
were	O
isolated	O
that	O
encode	O
proteins	O
that	O
recognize	O
the	O
XMyoDa	B-protein
TATA	I-protein
motif	I-protein
.	O

Fluorimetric	O
determination	O
of	O
methylmercury	O
as	O
an	O
ion	O
-	O
association	O
complex	O
with	O
rhodamine	O
B	O
in	O
the	O
presence	O
of	O
iodide	O
.	O

Expression	O
from	O
this	O
element	O
is	O
regulated	O
by	O
a	O
heteromeric	O
protein	O
complex	O
containing	O
ubiquitous	O
(	O
i	O
.	O
e	O
.	O
the	O
E2A	B-protein
-	I-protein
and	O
HEB	B-protein
-	I-protein
encoded	I-protein
proteins	I-protein
)	O
and	O
islet	O
-	O
enriched	O
members	O
of	O
the	O
bHLH	B-protein
family	I-protein
.	O

The	O
amplification	O
was	O
achieved	O
using	O
two	O
primers	O
which	O
correspond	O
to	O
TRH	B-protein
progenitor	I-protein
sequence	I-protein
(	O
Lys	B-protein
/	I-protein
Arg	I-protein
-	I-protein
Arg	I-protein
-	I-protein
Gln	I-protein
-	I-protein
His	I-protein
-	I-protein
Pro	I-protein
-	I-protein
Gly	I-protein
-	I-protein
Lys	I-protein
/	I-protein
Arg	I-protein
-	I-protein
Arg	I-protein
)	O
.	O

Pilot	O
study	O
of	O
blood	O
coagulation	O
in	O
gout	O
patients	O
.	O

The	O
well	O
-	O
known	O
Rel	B-protein
/	I-protein
NF	I-protein
-	I-protein
kappaB	I-protein
family	I-protein
of	O
vertebrate	O
transcription	O
factors	O
comprises	O
a	O
number	O
of	O
structurally	O
related	O
,	O
interacting	O
proteins	O
that	O
bind	O
DNA	O
as	O
dimers	O
and	O
whose	O
activity	O
is	O
regulated	O
by	O
subcellular	O
location	O
.	O

Contractile	O
responses	O
to	O
norepinephrine	O
,	O
serotonin	O
and	O
potassium	O
(	O
K	O
+	O
)	O
and	O
relaxant	O
responses	O
to	O
isoproterenol	O
and	O
papaverine	O
were	O
studied	O
in	O
vitro	O
with	O
spirally	O
cut	O
thoracic	O
aortic	O
strips	O
from	O
aortic	O
coarcted	O
hypertensive	O
rats	O
(	O
AHR	O
)	O
2	O
,	O
6	O
,	O
14	O
and	O
28	O
days	O
postoperatively	O
and	O
compared	O
to	O
time	O
-	O
matched	O
,	O
sham	O
-	O
operated	O
normotensive	O
controls	O
.	O

These	O
intron	O
chimeras	O
show	O
that	O
peripheral	O
sequences	O
and	O
the	O
elements	O
that	O
define	O
the	O
splice	O
sites	O
are	O
adequate	O
for	O
self	O
-	O
splicing	O
activity	O
but	O
that	O
the	O
central	O
portions	O
containing	O
the	O
catalytic	O
cores	O
of	O
ai4	B-protein
and	O
bi4	B-protein
are	O
deficient	O
;	O
these	O
cores	O
are	O
the	O
likely	O
targets	O
of	O
the	O
splicing	O
proteins	O
.	O

Km	O
and	O
Vmax	O
for	O
two	O
substrates	O
,	O
src	B-protein
-	I-protein
related	I-protein
peptide	I-protein
and	O
poly	O
(	O
Glu	O
,	O
Tyr	O
)	O
(	O
4	O
:	O
1	O
)	O
,	O
were	O
2	O
.	O
4	O
mM	O
and	O
2	O
.	O
5	O
mumol	O
min	O
-	O
1	O
mg	O
-	O
1	O
and	O
0	O
.	O
26	O
mM	O
and	O
1	O
.	O
2	O
mumol	O
min	O
-	O
1	O
mg	O
-	O
1	O
,	O
respectively	O
.	O

Human	B-protein
ULK1	I-protein
,	O
a	O
novel	O
serine	B-protein
/	I-protein
threonine	I-protein
kinase	I-protein
related	O
to	O
UNC	B-protein
-	I-protein
51	I-protein
kinase	I-protein
of	O
Caenorhabditis	O
elegans	O
:	O
cDNA	O
cloning	O
,	O
expression	O
,	O
and	O
chromosomal	O
assignment	O
.	O

Sulfhydryl	O
titration	O
with	O
iodoacetamide	O
,	O
monitored	O
by	O
quantitating	O
the	O
residual	O
thiols	O
after	O
reaction	O
with	O
a	O
maleimide	O
derivative	O
of	O
biotin	O
,	O
revealed	O
a	O
striking	O
difference	O
in	O
the	O
apparent	O
pK	O
(	O
a	O
)	O
values	O
of	O
the	O
cysteines	O
at	O
the	O
two	O
splice	O
junctions	O
.	O

In	O
such	O
a	O
manner	O
,	O
activated	O
PKR	B-protein
inhibits	O
cell	O
growth	O
and	O
induces	O
apoptosis	O
,	O
whereas	O
disruption	O
of	O
normal	O
PKR	B-protein
signaling	O
results	O
in	O
unregulated	O
cell	O
growth	O
.	O

When	O
a	O
tumour	O
is	O
present	O
nipple	O
discharge	O
is	O
of	O
little	O
importance	O
for	O
the	O
diagnosis	O
and	O
treatment	O
.	O

When	O
the	O
CO2	O
content	O
reached	O
9	O
Vol	O
%	O
the	O
animals	O
became	O
apathic	O
and	O
lost	O
body	O
weight	O
.	O

The	O
results	O
demonstrate	O
that	O
(	O
i	O
)	O
no	O
intact	O
capsids	O
were	O
assembled	O
when	O
the	O
full	O
-	O
length	O
or	O
a	O
truncated	O
(	O
missing	O
the	O
C	O
-	O
terminal	O
65	O
amino	O
acids	O
)	O
UL80	B-protein
.	I-protein
5	I-protein
protein	I-protein
was	O
tested	O
;	O
(	O
ii	O
)	O
when	O
the	O
C	O
-	O
terminal	O
65	O
amino	O
acids	O
of	O
the	O
UL80	B-protein
.	I-protein
5	I-protein
protein	I-protein
were	O
replaced	O
with	O
the	O
C	O
-	O
terminal	O
25	O
amino	O
acids	O
of	O
the	O
UL26	B-protein
.	I-protein
5	I-protein
protein	I-protein
,	O
intact	O
capsids	O
were	O
made	O
and	O
direct	O
interaction	O
of	O
the	O
UL80	B-protein
.	I-protein
5	I-protein
protein	I-protein
with	O
VP5	B-protein
was	O
detected	O
;	O
(	O
iii	O
)	O
assembly	O
of	O
intact	O
capsids	O
was	O
demonstrated	O
when	O
the	O
sequence	O
of	O
the	O
last	O
12	O
amino	O
acids	O
of	O
the	O
UL80	B-protein
.	I-protein
5	I-protein
protein	I-protein
was	O
changed	O
from	O
RRIFVA	B-protein
ALNKLE	I-protein
to	O
RRIFVAAMMKLE	B-protein
;	O
(	O
iv	O
)	O
self	O
-	O
interaction	O
of	O
the	O
scaffold	O
proteins	O
is	O
mediated	O
by	O
sequences	O
N	O
terminal	O
to	O
the	O
maturation	O
cleavage	O
site	O
;	O
and	O
(	O
v	O
)	O
the	O
UL26	B-protein
.	I-protein
5	I-protein
and	O
UL80	B-protein
.	I-protein
5	I-protein
proteins	I-protein
will	O
not	O
coassemble	O
into	O
scaffold	O
structures	O
.	O

Sixty	O
days	O
after	O
the	O
intervention	O
,	O
twitch	O
and	O
tetanic	O
tensions	O
remained	O
dependent	O
upon	O
the	O
extracellular	O
Ca2	O
+	O
concentration	O
(	O
[	O
Ca	O
]	O
o	O
)	O
both	O
in	O
groups	O
A	O
and	O
B	O
.	O

Methoxyflurane	O
and	O
renal	O
function	O
.	O

In	O
the	O
present	O
experiments	O
,	O
we	O
investigate	O
the	O
role	O
played	O
by	O
the	O
temporal	O
pattern	O
of	O
neural	O
activity	O
during	O
the	O
ontogeny	O
of	O
frequency	O
tuning	O
in	O
the	O
mouse	O
central	O
auditory	O
system	O
.	O

Because	O
the	O
mutant	O
defective	O
in	O
DNA	O
binding	O
also	O
fails	O
to	O
stimulate	O
Abf1	B-protein
ARS1	I-protein
DNA	O
-	O
binding	O
activity	O
,	O
our	O
results	O
suggest	O
that	O
Cdc6	B-protein
DNA	O
-	O
binding	O
activity	O
may	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
initiation	O
of	O
DNA	O
replication	O
.	O

Potential	O
treatments	O
include	O
dobutamine	O
,	O
KATP	O
channel	O
activators	O
,	O
and	O
21	O
-	O
aminosteroids	O
.	O

According	O
to	O
Sugiura	O
'	O
s	O
classification	O
,	O
they	O
consisted	O
of	O
Type	O
Ia	O
in	O
63	O
%	O
,	O
Type	O
Ib	O
in	O
11	O
%	O
,	O
Type	O
II	O
in	O
11	O
%	O
,	O
and	O
Type	O
III	O
in	O
16	O
%	O
.	O

METHODS	O
:	O
In	O
the	O
current	O
study	O
the	O
authors	O
reported	O
on	O
PPB	O
cases	O
from	O
a	O
national	O
retrospective	O
search	O
performed	O
in	O
18	O
Italian	O
Associations	O
for	O
Pediatric	O
Hematology	O
and	O
Oncology	O
centers	O
.	O

D	O
.	O

Consistent	O
with	O
its	O
role	O
in	O
p53	B-protein
ubiquitination	O
,	O
mE6	B-protein
-	I-protein
AP	I-protein
was	O
found	O
both	O
in	O
the	O
nucleus	O
and	O
cytosol	O
,	O
while	O
Nedd	B-protein
-	I-protein
4	I-protein
was	O
found	O
only	O
in	O
the	O
cytosol	O
.	O

Tests	O
of	O
the	O
method	O
indicate	O
(	O
1	O
)	O
the	O
Mossbauer	O
source	O
can	O
be	O
placed	O
on	O
the	O
basilar	O
membrane	O
without	O
altering	O
the	O
signal	O
-	O
transmission	O
properties	O
of	O
the	O
cochlea	O
,	O
and	O
(	O
2	O
)	O
the	O
source	O
adheres	O
to	O
the	O
basilar	O
membrane	O
.	O

When	O
expressed	O
alone	O
in	O
test	O
cells	O
,	O
Atr	B-protein
-	I-protein
I	I-protein
is	O
unable	O
to	O
bind	O
TGF	B-protein
-	I-protein
beta	I-protein
,	O
activin	B-protein
,	O
or	O
bone	B-protein
morphogenetic	I-protein
protein	I-protein
2	I-protein
.	O

One	O
of	O
these	O
elements	O
,	O
the	O
homeodomain	B-protein
-	I-protein
binding	I-protein
element	I-protein
,	O
was	O
identified	O
to	O
mediate	O
negative	O
regulation	O
.	O

Increasing	O
the	O
extracellular	O
calcium	O
concentration	O
enhanced	O
detrusor	O
contractility	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
in	O
both	O
control	O
and	O
obstructed	O
bladders	O
.	O

These	O
six	O
districts	O
have	O
an	O
area	O
of	O
34	O
,	O
000	O
km2	O
and	O
hold	O
a	O
population	O
of	O
30	O
million	O
.	O

Anti	B-protein
-	I-protein
hepatitis	I-protein
A	I-protein
virus	O
(	O
HAV	O
)	O
titer	O
after	O
vaccination	O
was	O
measured	O
in	O
83	O
HIV	O
-	O
positive	O
and	O
39	O
HIV	O
-	O
negative	O
men	O
.	O

An	O
endometrial	O
luteal	O
phase	O
deficiency	O
was	O
detected	O
in	O
15	O
(	O
30	O
%	O
)	O
of	O
aborting	O
patients	O
.	O

RNase	B-protein
protection	O
analysis	O
of	O
two	O
rRNA	B-protein
fragments	I-protein
whose	O
genes	O
are	O
adjacent	O
provided	O
evidence	O
for	O
a	O
polycistronic	O
transcript	O
containing	O
sequences	O
from	O
both	O
,	O
as	O
well	O
as	O
separate	O
small	O
RNAs	O
.	O

A	O
38	O
-	O
year	O
-	O
old	O
woman	O
with	O
ulcerative	O
colitis	O
subsequently	O
developed	O
sarcoidosis	O
.	O

Patients	O
receiving	O
VPA	O
showed	O
differences	O
in	O
attention	O
,	O
visuomotor	O
performance	O
,	O
verbal	O
span	O
and	O
sensory	O
discrimination	O
tasks	O
at	O
T1	O
,	O
in	O
visuomotor	O
performance	O
at	O
T2	O
and	O
in	O
spatial	O
span	O
at	O
T3	O
,	O
whereas	O
no	O
differences	O
were	O
detected	O
at	O
T4	O
.	O

Recently	O
,	O
an	O
electrical	O
-	O
mechanical	O
analog	O
model	O
of	O
heat	O
flow	O
within	O
the	O
brain	O
has	O
been	O
developed	O
from	O
which	O
an	O
expression	O
for	O
CBF	O
has	O
been	O
derived	O
:	O
CBF	O
=	O
Cb	O
/	O
(	O
tau	O
rho	O
c	O
)	O
where	O
tau	O
is	O
the	O
thermal	O
decay	O
constant	O
,	O
rho	O
is	O
the	O
density	O
of	O
blood	O
,	O
and	O
c	O
is	O
its	O
specific	O
heat	O
.	O

`	O
`	O
Complex	O
partial	O
'	O
'	O
seizures	O
.	O

Acute	O
feasibility	O
and	O
safety	O
of	O
a	O
smoking	O
reduction	O
strategy	O
for	O
smokers	O
with	O
schizophrenia	O
.	O

RESULTS	O
:	O
A	O
novel	O
gene	O
was	O
cloned	O
.	O

To	O
compare	O
the	O
PAX3	B-protein
and	O
putative	O
PAX3	B-protein
-	I-protein
FKHR	I-protein
transactivation	I-protein
domains	I-protein
,	O
we	O
fused	O
C	O
-	O
terminal	O
test	O
fragments	O
to	O
the	O
heterologous	O
GAL4	B-protein
DNA	I-protein
-	I-protein
binding	I-protein
domain	I-protein
and	O
tested	O
activation	O
of	O
a	O
reporter	O
gene	O
co	O
-	O
transfected	O
into	O
four	O
cell	O
types	O
.	O

Removal	O
of	O
PDMP	O
from	O
the	O
cell	O
medium	O
resulted	O
in	O
reversal	O
of	O
the	O
cell	O
cycle	O
changes	O
,	O
with	O
cells	O
re	O
-	O
entering	O
the	O
S	O
phase	O
.	O

The	O
phosphotransferase	B-protein
system	O
(	O
PTS	O
)	O
of	O
Streptomyces	O
coelicolor	O
identification	O
and	O
biochemical	O
analysis	O
of	O
a	O
histidine	B-protein
phosphocarrier	I-protein
protein	I-protein
HPr	I-protein
encoded	O
by	O
the	O
gene	O
ptsH	B-protein
.	O

One	O
member	O
of	O
this	O
family	O
,	O
RFX1	B-protein
,	O
is	O
a	O
transcription	O
factor	O
for	O
a	O
variety	O
of	O
viral	O
and	O
cellular	O
genes	O
.	O

Evaluation	O
of	O
desmopressin	O
for	O
dental	O
extractions	O
in	O
patients	O
with	O
hemostatic	O
disorders	O
.	O

RESULTS	O
:	O
The	O
standardised	O
mortality	O
ratio	O
(	O
SMR	O
)	O
for	O
all	O
malignant	O
neoplasms	O
was	O
94	O
(	O
95	O
%	O
CI	O
74	O
to	O
118	O
)	O
.	O

Erythrocyte	O
AA	O
in	O
FO	O
+	O
EPO	O
-	O
supplemented	O
infants	O
remained	O
low	O
and	O
below	O
breast	O
-	O
and	O
placebo	O
formula	O
-	O
fed	O
levels	O
.	O

A	O
semiautomatic	O
digital	O
system	O
(	O
Videoplan	O
2	O
)	O
was	O
used	O
.	O

On	O
histologic	O
examination	O
the	O
cuboidal	O
epithelium	O
of	O
the	O
mucous	O
membrane	O
was	O
found	O
to	O
be	O
changed	O
into	O
columnar	O
epithelium	O
,	O
with	O
uneven	O
distribution	O
of	O
enlarged	O
nuclei	O
in	O
the	O
vacuolized	O
cytoplasm	O
.	O

The	O
rat	B-protein
aldolase	I-protein
C	I-protein
gene	I-protein
encodes	O
a	O
glycolytic	O
enzyme	O
strongly	O
expressed	O
in	O
adult	O
brain	O
.	O

The	O
human	O
cDNA	O
clone	O
NFBD1	O
(	O
previously	O
designated	O
KIAA0170	O
)	O
encodes	O
a	O
novel	O
protein	O
(	O
2089	O
amino	O
acids	O
in	O
length	O
;	O
calculated	O
molecular	O
mass	O
226	O
,	O
440	O
D	O
)	O
with	O
possible	O
BRCT	B-protein
domains	I-protein
at	O
its	O
carboxy	O
terminus	O
(	O
amino	O
acid	O
residues	O
1894	O
-	O
2089	O
)	O
.	O

The	O
effects	O
of	O
systemic	O
glucose	O
concentration	O
on	O
brain	O
metabolism	O
following	O
repeated	O
brain	O
ischemia	O
.	O

Mechanism	O
of	O
interferon	B-protein
action	O
:	O
identification	O
of	O
essential	O
positions	O
within	O
the	O
novel	O
15	B-protein
-	I-protein
base	I-protein
-	I-protein
pair	I-protein
KCS	I-protein
element	I-protein
required	O
for	O
transcriptional	O
activation	O
of	O
the	O
RNA	B-protein
-	I-protein
dependent	I-protein
protein	I-protein
kinase	I-protein
pkr	I-protein
gene	I-protein
.	O

A	O
single	O
five	O
minute	O
period	O
of	O
rapid	O
atrial	O
pacing	O
fails	O
to	O
limit	O
infarct	O
size	O
in	O
the	O
in	O
situ	O
rabbit	O
heart	O
.	O

Finally	O
,	O
three	O
new	O
missense	O
mutations	O
,	O
E138V	B-protein
,	O
R254G	B-protein
,	O
and	O
P362R	B-protein
,	O
were	O
identified	O
in	O
the	O
human	B-protein
AC	I-protein
gene	I-protein
from	O
FD	O
patients	O
.	O

Although	O
the	O
spatial	O
and	O
temporal	O
variability	O
of	O
LDF	O
signals	O
evoked	O
by	O
cerebrocortical	O
microflow	O
is	O
in	O
the	O
same	O
range	O
as	O
with	O
other	O
methods	O
and	O
in	O
other	O
organs	O
,	O
LDF	O
cerebrocortical	O
mapping	O
is	O
restricted	O
by	O
the	O
large	O
temporal	O
and	O
spatial	O
heterogeneity	O
of	O
the	O
cerebrocortical	O
vasculature	O
.	O

Taken	O
together	O
,	O
the	O
results	O
suggest	O
that	O
chlorphentermine	O
may	O
be	O
capable	O
of	O
producing	O
dual	O
stimulus	O
effects	O
in	O
animals	O
.	O

Nuclease	B-protein
probing	O
and	O
structure	O
-	O
directed	O
mutagenesis	O
revealed	O
that	O
the	O
105	B-protein
-	I-protein
nt	I-protein
TE	I-protein
(	O
TE105	B-protein
)	O
forms	O
a	O
cruciform	O
secondary	O
structure	O
containing	O
four	O
helices	O
connected	O
by	O
single	O
-	O
stranded	O
regions	O
.	O

These	O
results	O
suggested	O
that	O
the	O
GG	O
motifs	O
contributed	O
to	O
the	O
cell	O
-	O
specific	O
transcription	O
of	O
the	O
human	B-protein
insulin	I-protein
gene	I-protein
in	O
association	O
with	O
the	O
binding	O
of	O
the	O
sequence	O
-	O
specific	O
nuclear	O
factor	O
.	O

To	O
investigate	O
the	O
potential	O
role	O
of	O
SP1	B-protein
,	O
we	O
examined	O
nuclear	O
extracts	O
from	O
HCMV	O
-	O
infected	O
cells	O
.	O

In	O
contrast	O
,	O
the	O
differentiation	O
of	O
neoplastically	O
transformed	O
cells	O
does	O
not	O
repress	O
mitogenic	O
responsiveness	O
or	O
junB	B-protein
or	O
c	B-protein
-	I-protein
fos	I-protein
inducibility	O
.	O

Here	O
,	O
we	O
report	O
that	O
swa5	B-protein
-	I-protein
1	I-protein
is	O
a	O
new	O
temperature	O
-	O
sensitive	O
allele	O
of	O
the	O
clathrin	B-protein
heavy	I-protein
chain	I-protein
gene	I-protein
(	O
chc1	B-protein
-	I-protein
5	I-protein
)	O
,	O
which	O
carries	O
a	O
frameshift	O
mutation	O
near	O
the	O
3	O
'	O
end	O
of	O
the	O
CHC1	B-protein
open	O
reading	O
frame	O
.	O

Artificial	O
ventilation	O
was	O
conducted	O
using	O
a	O
tidal	O
volume	O
of	O
10	O
ml	O
X	O
kg	O
-	O
1	O
and	O
a	O
rate	O
of	O
10	O
to	O
12	O
c	O
X	O
min	O
-	O
1	O
.	O

Active	O
complexes	O
eluted	O
at	O
a	O
higher	O
molecular	O
weight	O
than	O
inactive	O
complexes	O
,	O
were	O
relatively	O
deficient	O
in	O
both	O
p21	B-protein
and	O
p27	B-protein
,	O
and	O
contained	O
Cdk2	B-protein
with	O
increased	O
threonine	O
160	O
phosphorylation	O
,	O
consistent	O
with	O
a	O
mechanism	O
of	O
activation	O
of	O
cyclin	B-protein
E	I-protein
-	I-protein
Cdk2	I-protein
involving	O
both	O
reduced	O
CDK	B-protein
inhibitor	O
association	O
and	O
CDK	O
-	O
activating	O
kinase	O
-	O
mediated	O
phosphorylation	O
of	O
Cdk2	B-protein
.	O

Pancreaticoduodenal	O
lymph	O
node	O
enlargement	O
,	O
regardless	O
of	O
cause	O
,	O
has	O
been	O
a	O
source	O
of	O
imaging	O
confusion	O
because	O
of	O
its	O
propensity	O
to	O
mimic	O
pancreatic	O
malignancy	O
yet	O
not	O
cause	O
biliary	O
obstruction	O
.	O

Mutation	O
of	O
KRKR	B-protein
to	O
NGER	B-protein
retains	O
MO15	B-protein
in	O
the	O
cytoplasmic	O
compartment	O
,	O
whilst	O
the	O
wild	O
-	O
type	O
protein	O
is	O
detected	O
exclusively	O
in	O
the	O
nucleus	O
.	O

However	O
,	O
when	O
combined	O
with	O
mitomycin	O
C	O
given	O
with	O
1	O
to	O
5	O
-	O
days	O
interval	O
,	O
the	O
concurrent	O
administration	O
of	O
SPG	O
prolonged	O
significantly	O
the	O
life	O
-	O
span	O
of	O
the	O
tumor	O
-	O
bearing	O
mice	O
.	O

The	O
equilibrium	O
phosphorus	O
content	O
(	O
EPC0	O
)	O
of	O
surface	O
soil	O
was	O
generally	O
higher	O
than	O
the	O
SRP	O
content	O
of	O
drainage	O
water	O
,	O
at	O
one	O
farm	O
by	O
1	O
order	O
of	O
magnitude	O
.	O

When	O
blood	O
samples	O
of	O
patients	O
with	O
hyperbilirubinemia	O
were	O
analyzed	O
,	O
direct	O
measurement	O
of	O
ZPP	O
by	O
this	O
fluorimeter	O
yielded	O
significantly	O
higher	O
levels	O
than	O
did	O
an	O
alternate	O
extraction	O
method	O
.	O

The	O
monoexponential	O
rate	O
of	O
clearance	O
of	O
tracer	O
-	O
-	O
obtained	O
from	O
the	O
portion	O
of	O
the	O
residue	O
-	O
detection	O
curve	O
reflecting	O
metabolism	O
of	O
fatty	O
acid	O
incorporated	O
into	O
neutral	O
lipids	O
-	O
-	O
correlated	O
directly	O
with	O
induced	O
changes	O
in	O
tension	O
-	O
time	O
index	O
after	O
injections	O
into	O
the	O
left	O
atrium	O
(	O
r	O
=	O
0	O
.	O
96	O
,	O
n	O
=	O
12	O
)	O
,	O
right	O
atrium	O
(	O
r	O
=	O
0	O
.	O
86	O
,	O
n	O
=	O
14	O
)	O
,	O
and	O
ear	O
vein	O
(	O
r	O
=	O
0	O
.	O
93	O
,	O
n	O
=	O
14	O
)	O
.	O

Using	O
a	O
previously	O
published	O
two	O
-	O
frequency	O
(	O
AC	O
excitation	O
)	O
three	O
-	O
electrode	O
method	O
,	O
the	O
admittance	O
locus	O
plot	O
(	O
ALP	O
)	O
in	O
the	O
low	O
-	O
frequency	O
region	O
(	O
<	O
1000	O
Hz	O
)	O
has	O
been	O
shown	O
to	O
be	O
very	O
well	O
approximated	O
by	O
a	O
straight	O
line	O
and	O
can	O
be	O
described	O
with	O
frequency	O
-	O
independent	O
parameters	O
;	O
phase	O
angle	O
alpha	O
pi	O
/	O
2	O
,	O
conductance	O
at	O
extrapolated	O
zero	O
frequency	O
G0	O
=	O
1	O
/	O
R0	O
,	O
and	O
ion	O
relaxation	O
time	O
tau	O
.	O

A	O
rather	O
similar	O
pattern	O
of	O
results	O
was	O
obtained	O
with	O
respect	O
to	O
LMP2B	B-protein
mRNA	I-protein
expression	O
,	O
such	O
transcripts	O
being	O
detectable	O
only	O
in	O
a	O
subset	O
of	O
tumors	O
,	O
and	O
then	O
at	O
apparently	O
low	O
levels	O
.	O

Temporal	O
relationships	O
and	O
the	O
development	O
phase	O
affected	O
.	O

The	O
influence	O
of	O
p53	B-protein
on	O
cytokine	O
-	O
triggered	O
Janus	B-protein
kinase	I-protein
-	I-protein
STAT	I-protein
signaling	O
was	O
investigated	O
in	O
human	O
hepatoma	O
Hep3B	O
cell	O
lines	O
engineered	O
to	O
constitutively	O
express	O
the	O
temperature	O
-	O
sensitive	O
Val135	B-protein
mutant	I-protein
of	I-protein
p53	I-protein
.	O

Anatomy	O
of	O
the	O
uterine	O
artery	O
.	O

Neurofibromatosis	O
of	O
the	O
breast	O
in	O
a	O
patient	O
with	O
Morbus	O
von	O
Recklinghausen	O
.	O

Endovascular	O
aneurysm	O
repair	O
with	O
the	O
AneuRx	O
stent	O
-	O
graft	O
is	O
safe	O
,	O
but	O
is	O
it	O
effective	O
?	O

This	O
caused	O
severe	O
cortical	O
damage	O
and	O
neuronal	O
loss	O
in	O
hippocampus	O
subfields	O
CA1	O
,	O
CA3	O
,	O
and	O
hilus	O
.	O

Only	O
the	O
3	O
.	O
0	O
-	O
kb	O
transcript	O
was	O
detected	O
in	O
adult	O
tissues	O
,	O
where	O
its	O
expression	O
was	O
restricted	O
almost	O
exclusively	O
to	O
the	O
central	O
nervous	O
system	O
.	O

A	O
third	O
prominent	O
component	O
of	O
apparent	O
molecular	O
mass	O
16	O
kDa	O
displayed	O
several	O
properties	O
,	O
including	O
ability	O
to	O
bind	O
45Ca2	O
+	O
,	O
that	O
are	O
characteristic	O
of	O
the	O
regulatory	O
(	O
B	O
)	O
subunit	O
of	O
mammalian	B-protein
calcineurin	I-protein
and	O
was	O
recognized	O
by	O
an	O
antiserum	O
raised	O
against	O
bovine	B-protein
calcineurin	I-protein
.	O

Escalation	O
to	O
180	O
mg	O
/	O
m2	O
was	O
to	O
be	O
carried	O
out	O
if	O
white	O
blood	O
cell	O
nadir	O
count	O
was	O
>	O
2	O
.	O
0	O
x	O
10	O
(	O
9	O
)	O
/	O
l	O
and	O
platelet	O
nadir	O
count	O
was	O
>	O
75	O
x	O
10	O
(	O
9	O
)	O
/	O
l	O
.	O

Preflight	O
,	O
inflight	O
,	O
and	O
postflight	O
exercise	O
response	O
tests	O
were	O
conducted	O
on	O
the	O
astronauts	O
of	O
the	O
second	O
Skylab	O
mission	O
(	O
Skylab	O
3	O
)	O
as	O
part	O
of	O
an	O
evaluation	O
of	O
physiological	O
adaptation	O
to	O
long	O
-	O
term	O
weightlessness	O
.	O

When	O
data	O
were	O
expressed	O
in	O
a	O
cumulative	O
manner	O
,	O
the	O
response	O
to	O
intravenous	O
adenosine	O
3	O
mg	O
,	O
6	O
mg	O
,	O
9	O
mg	O
and	O
12	O
mg	O
in	O
the	O
24	O
episodes	O
of	O
PSVT	O
were	O
5	O
episodes	O
(	O
21	O
%	O
)	O
,	O
16	O
episodes	O
(	O
67	O
%	O
)	O
,	O
20	O
episodes	O
(	O
83	O
%	O
)	O
and	O
20	O
episodes	O
(	O
83	O
%	O
)	O
respectively	O
.	O

Letter	O
:	O
Aryl	B-protein
hydrocarbon	I-protein
hydroxylase	I-protein
and	O
smoking	O
.	O

Measurements	O
of	O
activity	O
with	O
the	O
radioprotective	O
chamber	O
VA	O
-	O
K	O
-	O
254	O
of	O
the	O
osimeter	O
VA	O
-	O
J18	O
.	O

On	O
the	O
other	O
hand	O
,	O
forced	O
overexpression	O
of	O
the	O
wild	O
type	O
,	O
but	O
not	O
the	O
kinase	O
-	O
inactivated	O
mutant	O
of	O
nm23H1	B-protein
,	O
converted	O
the	O
GDP	O
-	O
bound	O
forms	O
of	O
Rac1	B-protein
,	O
Cdc42	B-protein
,	O
and	O
RhoA	B-protein
to	O
their	O
GTP	O
-	O
bound	O
forms	O
in	O
vitro	O
by	O
its	O
nucleoside	B-protein
diphosphate	I-protein
kinase	I-protein
activity	O
,	O
but	O
nm23H1	B-protein
alone	O
apparently	O
did	O
not	O
produce	O
the	O
GTP	O
-	O
bound	O
form	O
of	O
these	O
GTPases	B-protein
in	O
vivo	O
.	O

Mobility	O
and	O
supershift	O
assays	O
demonstrated	O
that	O
upstream	B-protein
stimulatory	I-protein
factor	I-protein
(	O
USF	B-protein
)	O
and	O
Sp1	B-protein
bind	O
to	O
the	O
former	O
elements	O
and	O
competition	O
experiments	O
confirmed	O
that	O
CREB	B-protein
/	I-protein
ATF	I-protein
and	O
AP	B-protein
-	I-protein
1	I-protein
bind	O
to	O
the	O
CRE	B-protein
/	I-protein
TRE	I-protein
element	I-protein
.	O

The	O
results	O
showed	O
that	O
MIP	O
,	O
MMIF	O
,	O
FIC	O
,	O
Wimax	O
,	O
P0	O
.	O
1	O
and	O
minute	O
ventilation	O
(	O
Vr	O
)	O
were	O
significantly	O
increased	O
after	O
administration	O
of	O
methylphenidatum	O
and	O
aminophylline	O
.	O

During	O
BH	O
the	O
ventilator	O
was	O
disconnected	O
and	O
a	O
bias	O
flow	O
of	O
50	O
%	O
O2	O
at	O
4	O
-	O
5	O
l	O
/	O
min	O
was	O
delivered	O
through	O
the	O
side	O
ports	O
of	O
a	O
small	O
catheter	O
whose	O
tip	O
was	O
positioned	O
1	O
cm	O
cephalad	O
of	O
the	O
carina	O
.	O

In	O
this	O
report	O
this	O
technique	O
was	O
applied	O
to	O
human	O
breast	O
carcinoma	O
MDA	O
-	O
MB231	O
cells	O
overexpressing	O
human	B-protein
MPG	I-protein
in	O
order	O
to	O
assess	O
whether	O
up	O
-	O
regulation	O
of	O
the	O
initial	O
step	O
in	O
BER	O
alters	O
the	O
activity	O
of	O
selected	O
other	O
BER	O
(	O
hOGG1	B-protein
and	O
APE	B-protein
/	I-protein
ref	I-protein
-	I-protein
1	I-protein
)	O
or	O
direct	O
reversal	O
(	O
MGMT	B-protein
)	O
repair	O
activities	O
.	O

When	O
BFDS	O
was	O
taken	O
as	O
the	O
reference	O
,	O
W	O
/	O
A	O
Z	O
scores	O
showed	O
consistent	O
positive	O
increments	O
,	O
from	O
birth	O
in	O
girls	O
and	O
1	O
mo	O
in	O
boys	O
.	O

Plasmids	O
for	O
the	O
cloning	O
and	O
expression	O
of	O
full	O
-	O
length	O
double	O
-	O
stranded	O
cDNAs	O
under	O
control	O
of	O
the	O
SV40	B-protein
early	I-protein
or	I-protein
late	I-protein
gene	I-protein
promoter	I-protein
.	O

Regarding	O
`	O
`	O
the	O
relation	O
between	O
sexual	O
orientation	O
and	O
penile	O
size	O
,	O
`	O
`	O
by	O
A	O
.	O

A	O
substantial	O
fraction	O
of	O
Cbl	B-protein
was	O
constitutively	O
associated	O
with	O
Grb2	B-protein
and	O
this	O
interaction	O
was	O
mediated	O
by	O
Grb2	B-protein
SH3	I-protein
domains	I-protein
.	O

The	O
AGM	B-protein
and	I-protein
NIH	I-protein
/	I-protein
Swiss	I-protein
mouse	I-protein
CCR5	I-protein
proteins	I-protein
are	O
97	O
.	O
7	O
to	O
98	O
.	O
3	O
%	O
and	O
79	O
.	O
8	O
%	O
identical	O
to	O
the	O
human	O
protein	O
,	O
respectively	O
.	O

Mutagenesis	O
of	O
the	O
CDE	B-protein
/	I-protein
CHR	I-protein
elements	I-protein
and	O
Sp1	B-protein
sites	I-protein
in	O
this	O
region	O
,	O
alone	O
or	O
in	O
combination	O
,	O
reduced	O
transcriptional	O
activity	O
by	O
40	O
-	O
60	O
%	O
in	O
asynchronously	O
growing	O
cells	O
and	O
abolished	O
cell	O
cycle	O
periodicity	O
in	O
G2	O
-	O
M	O
-	O
synchronized	O
cells	O
.	O

All	O
our	O
patients	O
had	O
polyps	O
,	O
23	O
(	O
54	O
%	O
)	O
had	O
asthma	O
,	O
12	O
(	O
27	O
%	O
)	O
had	O
aspirin	O
sensitivity	O
,	O
20	O
(	O
65	O
%	O
)	O
had	O
eosinophilia	O
,	O
and	O
9	O
(	O
69	O
%	O
)	O
had	O
increased	O
total	O
IgE	B-protein
levels	O
.	O

By	O
contrast	O
,	O
PvirE	B-protein
or	O
Plac	B-protein
promoter	I-protein
constructs	I-protein
yielded	O
functional	O
VirE2	B-protein
only	O
if	O
virE1	B-protein
was	O
coexpressed	O
with	O
virE2	B-protein
.	O

PURPOSE	O
:	O
To	O
introduce	O
an	O
image	O
analysis	O
of	O
the	O
cornea	O
in	O
photorefractive	O
keratectomy	O
(	O
PRK	O
)	O
for	O
preoperative	O
and	O
early	O
postoperative	O
determination	O
of	O
changes	O
in	O
the	O
condition	O
of	O
the	O
cornea	O
.	O

Normal	O
alpha1	B-protein
(	I-protein
I	I-protein
)	I-protein
collagen	I-protein
mRNA	I-protein
showed	O
no	O
significant	O
reduction	O
when	O
AR	O
or	O
IR	O
was	O
expressed	O
from	O
the	O
pHbetaAPr	O
-	O
1	O
-	O
neo	O
vector	O
and	O
a	O
small	O
(	O
10	O
-	O
20	O
%	O
)	O
but	O
significant	O
reduction	O
when	O
either	O
ribozyme	B-protein
was	O
expressed	O
from	O
the	O
pCI	O
.	O
neo	O
vector	O
.	O

Patients	O
with	O
apparently	O
minor	O
CT	O
abnormalities	O
may	O
have	O
significant	O
epidural	O
disease	O
.	O

Transformed	O
cell	O
lines	O
expressing	O
solely	O
E1a	B-protein
or	O
E1a	B-protein
and	O
E1b	B-protein
gene	I-protein
products	I-protein
derived	O
from	O
these	O
viruses	O
display	O
enhanced	O
anchorage	O
-	O
independent	O
growth	O
at	O
37	O
degrees	O
C	O
versus	O
32	O
degrees	O
C	O
and	O
display	O
a	O
cytoskeletal	O
architecture	O
resembling	O
untransformed	O
fibroblastic	O
CREF	O
cells	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
the	O
S	O
.	O
aureus	O
peptide	O
carrying	O
the	O
phosphoryl	O
group	O
was	O
found	O
to	O
be	O
Gln	B-protein
-	I-protein
Val	I-protein
-	I-protein
Val	I-protein
-	I-protein
Ser	I-protein
-	I-protein
Thr	I-protein
-	I-protein
Phe	I-protein
-	I-protein
Met	I-protein
-	I-protein
Gly	I-protein
-	I-protein
Asn	I-protein
-	I-protein
Gly	I-protein
-	I-protein
Leu	I-protein
-	I-protein
Ala	I-protein
-	I-protein
Ile	I-protein
-	I-protein
Pro	I-protein
-	I-protein
His	I-protein
-	I-protein
Gly	I-protein
-	I-protein
Thr	I-protein
-	I-protein
Asp	I-protein
-	I-protein
Asp	I-protein
.	O

PKC	B-protein
-	I-protein
gamma	I-protein
,	O
which	O
is	O
not	O
present	O
in	O
keratinocytes	O
,	O
also	O
induces	O
involucrin	B-protein
gene	I-protein
expression	O
in	O
a	O
TPA	O
-	O
independent	O
manner	O
,	O
when	O
introduced	O
into	O
SVHK	O
cells	O
.	O

The	O
exogenous	O
fos	B-protein
gene	I-protein
was	O
rapidly	O
induced	O
to	O
maximal	O
levels	O
within	O
1	O
-	O
2	O
hr	O
of	O
estrogen	O
addition	O
.	O

Examination	O
of	O
ANCA	O
is	O
not	O
only	O
a	O
significant	O
contribution	O
towards	O
a	O
more	O
accurate	O
diagnosis	O
of	O
renal	O
vasculitis	O
,	O
but	O
also	O
an	O
indicator	O
of	O
the	O
activity	O
of	O
the	O
disease	O
and	O
thus	O
of	O
the	O
effectiveness	O
of	O
immunosuppressive	O
treatment	O
.	O

NaeI	B-protein
,	O
a	O
novel	O
DNA	B-protein
endonuclease	I-protein
,	O
shows	O
topoisomerase	B-protein
and	O
recombinase	B-protein
activities	O
when	O
a	O
Lys	O
residue	O
is	O
substituted	O
for	O
Leu	O
43	O
.	O

Expression	O
of	O
class	B-protein
IV	I-protein
ADH	I-protein
mRNA	I-protein
was	O
detected	O
in	O
human	O
stomach	O
but	O
not	O
liver	O
.	O

Within	O
the	O
3	O
'	O
terminal	O
50	O
nucleotides	O
,	O
the	O
mouse	B-protein
mt	I-protein
12S	I-protein
rRNA	I-protein
contains	O
a	O
potential	O
10	O
bp	O
hairpin	O
structure	O
and	O
a	O
sequence	O
of	O
15	O
consecutive	O
nucleotides	O
common	O
to	O
the	O
RNA	O
of	O
the	O
small	O
ribosomal	O
subunit	O
in	O
all	O
systems	O
,	O
but	O
does	O
not	O
contain	O
the	O
mRNA	O
binding	O
site	O
(	O
ACCUCC	B-protein
)	O
found	O
in	O
E	O
.	O
coli	O
and	O
corn	O
chloroplast	O
rRNAs	O
.	O

In	O
addition	O
to	O
its	O
effect	O
in	O
augmenting	O
the	O
neutrophil	O
response	O
to	O
eccentric	O
exercise	O
,	O
vitamin	O
E	O
causes	O
a	O
greater	O
increase	O
in	O
circulating	O
creatine	B-protein
kinase	I-protein
activity	O
,	O
perhaps	O
indicating	O
increased	O
skeletal	O
muscle	O
repair	O
.	O

The	O
NR2	O
hybrid	O
is	O
a	O
powerful	O
tool	O
for	O
the	O
mapping	O
of	O
new	O
probes	O
of	O
this	O
region	O
,	O
as	O
well	O
as	O
for	O
obtaining	O
new	O
informative	O
probes	O
specific	O
for	O
the	O
deletion	O
by	O
subtractive	O
cloning	O
of	O
the	O
region	O
.	O

The	O
sequence	O
similarity	O
has	O
suggested	O
that	O
SCG10	B-protein
and	O
stathmin	B-protein
have	O
been	O
derived	O
from	O
structurally	O
and	O
evolutionarily	O
related	O
genes	O
.	O

PSI	B-protein
-	I-protein
G	I-protein
and	O
PSI	B-protein
-	I-protein
K	I-protein
probably	O
have	O
evolved	O
from	O
a	O
gene	O
duplication	O
of	O
an	O
ancestral	O
gene	O
.	O

Chimaeric	B-protein
VP16	I-protein
-	I-protein
E2	I-protein
molecules	I-protein
suggest	O
that	O
the	O
epithelial	O
specific	O
transcriptional	O
activation	O
of	O
the	O
BPV	O
-	O
4	O
LCR	O
promoter	O
is	O
mediated	O
by	O
the	O
E2	B-protein
transactivation	I-protein
domain	I-protein
.	O

The	O
pigment	O
intensity	O
of	O
both	O
melanized	O
colonies	O
and	O
appressoria	O
of	O
CAL	O
transformants	O
was	O
weaker	O
than	O
that	O
of	O
the	O
wild	O
type	O
.	O

Mutations	O
in	O
the	O
alpha	B-protein
and	I-protein
sigma	I-protein
-	I-protein
70	I-protein
subunits	I-protein
of	I-protein
RNA	I-protein
polymerase	I-protein
affect	O
expression	O
of	O
the	O
mer	B-protein
operon	I-protein
.	O

Heterogeneity	O
of	O
human	B-protein
serum	I-protein
albumin	I-protein
.	O

This	O
300	O
bp	O
5	O
'	O
-	O
upstream	O
sequence	O
of	O
K3	B-protein
keratin	I-protein
gene	I-protein
,	O
which	O
can	O
function	O
in	O
vitro	O
as	O
a	O
keratinocyte	O
-	O
specific	O
promoter	O
,	O
contains	O
two	O
clusters	O
of	O
partially	O
overlapping	O
motifs	O
,	O
one	O
with	O
an	O
NFkB	B-protein
consensus	O
sequence	O
and	O
another	O
with	O
a	O
GC	O
box	O
.	O

The	O
effect	O
of	O
feeding	O
patterns	O
on	O
fat	O
deposition	O
in	O
mice	O
.	O

A	O
mutant	O
form	O
of	O
Vps1p	B-protein
lacking	O
the	O
entire	O
GTP	O
-	O
binding	O
domain	O
interfered	O
with	O
vacuolar	O
protein	O
sorting	O
in	O
wild	O
-	O
type	O
cells	O
.	O

Both	O
proprioceptive	O
and	O
electroreceptive	O
units	O
showed	O
a	O
progression	O
of	O
receptive	O
fields	O
from	O
anterior	O
to	O
posterior	O
body	O
in	O
the	O
rostral	O
to	O
caudal	O
direction	O
along	O
the	O
length	O
of	O
DGR	O
.	O

Of	O
these	O
patients	O
,	O
46	O
,	O
164	O
were	O
placed	O
on	O
a	O
waiting	O
list	O
for	O
transplantation	O
,	O
23	O
,	O
275	O
of	O
whom	O
received	O
a	O
first	O
cadaveric	O
transplant	O
between	O
1991	O
and	O
1997	O
.	O

Radiotherapy	O
and	O
early	O
orchiectomy	O
in	O
stage	O
D1	O
prostatic	O
carcinoma	O
.	O

Interestingly	O
,	O
the	O
RNA	O
sequences	O
selected	O
by	O
the	O
mutated	O
zinc	B-protein
knuckle	I-protein
9G8	I-protein
variant	I-protein
are	O
efficiently	O
recognized	O
by	O
SRp20	B-protein
,	O
in	O
agreement	O
with	O
the	O
fact	O
that	O
the	O
RBD	O
of	O
9G8	B-protein
and	O
SRp20	B-protein
are	O
similar	O
.	O

Krox	B-protein
-	I-protein
20	I-protein
,	O
a	O
zinc	O
finger	O
gene	O
,	O
has	O
a	O
highly	O
conserved	O
pattern	O
of	O
expression	O
in	O
r3	B-protein
and	O
r5	B-protein
and	O
is	O
functionally	O
required	O
for	O
their	O
maintenance	O
in	O
mouse	O
embryos	O
.	O

The	O
cytosolic	O
glutathione	B-protein
S	I-protein
-	I-protein
transferases	I-protein
(	O
GSTs	B-protein
,	O
EC	O
2	O
.	O
5	O
.	O
1	O
.	O
18	O
)	O
are	O
a	O
superfamily	O
of	O
dimeric	O
isoenzymes	O
which	O
catalyze	O
the	O
conjugation	O
of	O
electrophilic	O
substrates	O
with	O
glutathione	O
.	O

The	O
patient	O
had	O
developed	O
left	O
-	O
sided	O
low	O
-	O
frequency	O
tremor	O
and	O
hemidystonia	O
after	O
a	O
severe	O
head	O
trauma	O
sustained	O
at	O
15	O
years	O
of	O
age	O
.	O

Full	O
thyroid	O
function	O
testing	O
was	O
performed	O
on	O
600	O
randomly	O
selected	O
samples	O
with	O
normal	O
TSH	B-protein
values	O
and	O
also	O
on	O
subjects	O
with	O
abnormal	O
TSH	B-protein
levels	O
.	O

17	O
.	O
5	O
%	O
of	O
cycles	O
)	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
two	O
genes	B-protein
encoding	I-protein
gp138	I-protein
,	O
a	O
cell	O
surface	O
glycoprotein	O
involved	O
in	O
the	O
sexual	O
cell	O
fusion	O
of	O
Dictyostelium	O
discoideum	O
.	O

Routinely	O
collected	O
,	O
processed	O
and	O
stored	O
breast	O
cancer	O
tissue	O
blocks	O
recovered	O
from	O
the	O
archives	O
of	O
the	O
Pathology	O
laboratory	O
in	O
Dar	O
es	O
Salaam	O
after	O
storage	O
of	O
up	O
to	O
3	O
years	O
were	O
analysed	O
by	O
a	O
flow	O
cytometry	O
for	O
DNA	O
ploidy	O
and	O
S	O
-	O
phase	O
fraction	O
.	O

The	O
daily	O
administration	O
of	O
betamethasone	O
for	O
three	O
weeks	O
markedly	O
reduced	O
the	O
absorption	O
of	O
calcium	O
and	O
phosphate	O
as	O
well	O
as	O
the	O
growth	O
rate	O
.	O

Overall	O
prevalences	O
of	O
antibody	O
were	O
70	O
per	O
cent	O
in	O
cattle	O
,	O
67	O
per	O
cent	O
in	O
sheep	O
and	O
76	O
per	O
cent	O
in	O
goats	O
as	O
assessed	O
by	O
an	O
immunodiffusion	O
test	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
of	O
metaphase	O
spreads	O
of	O
chromosome	O
8	O
,	O
containing	O
hybrid	O
cell	O
line	O
706	O
-	O
B6	O
clone	O
17	O
(	O
CL	O
-	O
17	O
)	O
with	O
cosmid	O
c101F1	O
,	O
placed	O
the	O
9804	B-protein
gene	I-protein
close	O
to	O
the	O
telomere	O
at	O
8q24	O
.	O
3	O
.	O

Typical	O
and	O
atypical	O
clinical	O
features	O
of	O
this	O
lacrimal	O
sac	O
cyst	O
are	O
emphasized	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
the	O
activated	O
GH	B-protein
receptor	I-protein
can	O
stimulate	O
Stat1	B-protein
,	O
a	O
cytoplasmic	O
transcription	O
factor	O
that	O
becomes	O
tyrosine	O
phosphorylated	O
and	O
translocates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
can	O
interact	O
with	O
specific	O
DNA	O
sequences	O
to	O
modulate	O
gene	O
expression	O
.	O

Different	O
sequence	O
elements	O
of	O
both	O
the	O
retroviral	O
vectors	O
and	O
the	O
c	B-protein
-	I-protein
myc	I-protein
gene	I-protein
recombined	O
during	O
genesis	O
of	O
highly	O
oncogenic	O
retroviruses	O
CMII	O
,	O
MC29	O
,	O
or	O
MH2	O
.	O

Effect	O
of	O
2	O
-	O
(	O
p	O
-	O
chlorophenyl	O
)	O
cyclopropylamine	O
on	O
5	O
-	O
hydroxyindole	O
concentration	O
and	O
monoamine	B-protein
oxidase	I-protein
activity	O
in	O
rat	O
brain	O
.	O

Mutations	O
affecting	O
only	O
CD4	B-protein
regulation	O
mapped	O
to	O
residues	O
previously	O
shown	O
to	O
mediate	O
the	O
binding	O
of	O
Nef	B-protein
to	O
this	O
receptor	O
,	O
such	O
as	O
W57	O
and	O
L58	O
,	O
as	O
well	O
as	O
to	O
an	O
AP	B-protein
-	I-protein
recruiting	I-protein
dileucine	I-protein
motif	I-protein
and	O
to	O
an	O
acidic	O
dipeptide	O
in	O
the	O
C	O
-	O
terminal	O
region	O
of	O
the	O
protein	O
.	O

Furthermore	O
,	O
we	O
notice	O
two	O
potential	O
consensus	O
motifs	O
which	O
are	O
also	O
found	O
in	O
corresponding	O
positions	O
in	O
the	O
genes	O
for	O
the	O
nerve	B-protein
growth	I-protein
factor	I-protein
receptor	I-protein
and	O
the	O
68	B-protein
-	I-protein
kDa	I-protein
neurofilament	I-protein
protein	I-protein
.	O

Pathogens	O
(	O
Staphylococcus	O
aureus	O
or	O
Gram	O
-	O
negative	O
bacilli	O
)	O
were	O
isolated	O
from	O
only	O
one	O
member	O
of	O
staff	O
in	O
small	O
numbers	O
and	O
irregularly	O
and	O
rarely	O
in	O
large	O
numbers	O
from	O
patients	O
.	O

The	O
nature	O
of	O
the	O
process	O
formed	O
by	O
the	O
successive	O
occurrences	O
of	O
this	O
arrhythmia	O
was	O
studied	O
in	O
8	O
patients	O
with	O
a	O
history	O
of	O
symptomatic	O
paroxysmal	O
AF	O
.	O

Interferon	O
-	O
alpha	O
-	O
induced	O
gene	O
expression	O
:	O
evidence	O
for	O
a	O
selective	O
effect	O
of	O
ouabain	O
on	O
activation	O
of	O
the	O
ISGF3	B-protein
transcription	I-protein
complex	I-protein
.	O

Molecular	O
and	O
genetic	O
analysis	O
of	O
the	O
yeast	B-protein
early	I-protein
meiotic	I-protein
recombination	I-protein
genes	I-protein
REC102	I-protein
and	O
REC107	B-protein
/	I-protein
MER2	I-protein
.	O

Antibodies	O
made	O
against	O
fusion	O
protein	O
produced	O
by	O
the	O
DP1A	B-protein
clone	O
reacted	O
specifically	O
with	O
DP	B-protein
-	I-protein
I	I-protein
and	I-protein
-	I-protein
II	I-protein
on	O
immunoblots	O
.	O

Binding	O
of	O
U2	B-protein
small	I-protein
nuclear	I-protein
ribonucleoprotein	I-protein
was	O
partially	O
inhibited	O
.	O

Hematology	O
problem	O
of	O
the	O
month	O
:	O
band	O
or	O
seg	O
?	O

Heme	B-protein
oxygenase	I-protein
1	I-protein
is	O
an	O
essential	O
enzyme	O
in	O
heme	O
catabolism	O
that	O
cleaves	O
heme	O
to	O
form	O
biliverdin	O
,	O
iron	O
,	O
and	O
carbon	O
monoxide	O
.	O

The	O
characteristic	O
feature	O
of	O
liver	O
and	O
spleen	O
MP	O
function	O
in	O
patients	O
with	O
VHA	O
associated	O
with	O
HBsAg	B-protein
carriership	O
consisted	O
in	O
the	O
lack	O
of	O
the	O
compensatory	O
reaction	O
on	O
the	O
part	O
of	O
spleen	O
MP	O
,	O
which	O
was	O
likely	O
to	O
be	O
connected	O
with	O
overstrain	O
of	O
long	O
standing	O
and	O
depletion	O
of	O
the	O
MP	O
system	O
due	O
to	O
permanent	O
antigenic	O
stimulation	O
of	O
HBsAg	B-protein
.	O

The	O
hepatitis	B-protein
A	I-protein
virus	I-protein
antibody	I-protein
(	O
anti	B-protein
-	I-protein
HAV	I-protein
)	O
in	O
chronic	O
diffuse	O
liver	O
diseases	O
.	O

Nature	O
398	O
,	O
828	O
-	O
830	O
)	O
that	O
the	O
amino	O
acid	O
sequences	O
of	O
peptide	O
fragments	O
obtained	O
from	O
a	O
polypeptide	O
found	O
in	O
a	O
complex	O
of	O
proteins	O
that	O
alters	O
chromatin	O
structure	O
(	O
ARC	B-protein
)	O
are	O
identical	O
to	O
portions	O
of	O
the	O
deduced	O
open	O
reading	O
frame	O
of	O
TIG	B-protein
-	I-protein
1	I-protein
mRNA	I-protein
.	O

Diazepam	O
(	O
3	O
mg	O
/	O
kg	O
)	O
generalized	O
to	O
Ro	O
11	O
-	O
6896	O
whereas	O
the	O
structurally	O
related	O
Ro	O
5	O
-	O
4864	O
(	O
3	O
mg	O
/	O
kg	O
and	O
30	O
mg	O
/	O
kg	O
)	O
did	O
not	O
.	O

Additional	O
factors	O
such	O
as	O
advanced	O
age	O
,	O
concomitant	O
use	O
of	O
corticosteroids	O
or	O
anticoagulants	O
,	O
prior	O
ulcer	O
complications	O
and	O
co	O
-	O
morbid	O
diseases	O
may	O
further	O
increase	O
the	O
risk	O
of	O
bleeding	O
.	O

In	O
the	O
eight	O
patients	O
with	O
persistent	O
generalized	O
lymph	O
-	O
adenopathy	O
(	O
PGL	O
)	O
and	O
nontender	O
,	O
nonenlarging	O
nodes	O
,	O
pathologic	O
analysis	O
revealed	O
lymphoid	O
hyperplasia	O
.	O

We	O
conclude	O
that	O
(	O
a	O
)	O
the	O
likelihood	O
of	O
detecting	O
carcinoma	O
or	O
atypical	O
hyperplasia	O
exclusively	O
in	O
the	O
adipose	O
tissue	O
component	O
of	O
grossly	O
benign	O
breast	O
biopsies	O
is	O
extremely	O
low	O
,	O
and	O
(	O
b	O
)	O
a	O
possible	O
cost	O
-	O
effective	O
method	O
of	O
sampling	O
grossly	O
benign	O
breast	O
biopsies	O
consists	O
of	O
initially	O
submitting	O
a	O
maximum	O
of	O
10	O
blocks	O
of	O
fibrous	O
parenchyma	O
for	O
each	O
case	O
,	O
then	O
examining	O
the	O
remaining	O
tissue	O
histologically	O
only	O
if	O
carcinoma	O
or	O
atypical	O
hyperplasia	O
is	O
found	O
among	O
these	O
blocks	O
.	O

Simian	O
parainfluenza	O
virus	O
5	O
(	O
SV5	O
)	O
is	O
a	O
prototype	O
of	O
the	O
Paramyxoviridae	O
family	O
of	O
nonsegmented	O
negative	O
-	O
sense	O
RNA	O
viruses	O
.	O

Nephrotoxicity	O
after	O
orthotopic	O
liver	O
transplantation	O
in	O
cyclosporin	O
A	O
and	O
FK	O
506	O
-	O
treated	O
patients	O
.	O

The	O
standard	O
principles	O
of	O
surgical	O
management	O
must	O
be	O
adhered	O
to	O
when	O
using	O
Sandostatin	O
to	O
treat	O
patients	O
with	O
these	O
disorders	O
.	O

Polycythemia	O
-	O
1973	O
.	O

From	O
two	O
inhibitor	O
scaffolds	O
,	O
we	O
have	O
identified	O
potent	O
and	O
selective	O
inhibitors	O
for	O
sensitized	O
kinases	B-protein
from	O
five	O
distinct	O
subfamilies	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
study	O
the	O
morphological	O
characteristics	O
of	O
the	O
fibrous	O
tissue	O
capsule	O
resulting	O
from	O
the	O
implantation	O
of	O
aluminum	O
calcium	O
phosphate	O
(	O
ALCAP	O
)	O
and	O
hydroxyapetite	O
(	O
HA	O
)	O
bioceramics	O
.	O

A	O
distinct	O
staining	O
pattern	O
for	O
the	O
N	B-protein
-	I-protein
utrophin	I-protein
was	O
not	O
detectable	O
,	O
although	O
it	O
was	O
expected	O
to	O
localise	O
at	O
the	O
actin	B-protein
stress	O
fibers	O
.	O

The	O
sequence	O
of	O
the	O
repressor	O
locus	O
,	O
c	O
,	O
of	O
the	O
Streptomyces	O
temperate	O
phage	O
,	O
phi	O
C31	O
,	O
was	O
shown	O
previously	O
to	O
contain	O
an	O
open	O
reading	O
frame	O
encoding	O
a	O
74	O
kDa	O
protein	O
.	O

Introductory	O
remarks	O
.	O

Accumulated	O
evidence	O
indicates	O
that	O
,	O
upon	O
stimulation	O
with	O
interferon	B-protein
-	I-protein
gamma	I-protein
(	O
IFN	B-protein
-	I-protein
gamma	I-protein
)	O
,	O
three	O
beta	O
-	O
type	O
subunits	O
,	O
designated	O
LMP2	B-protein
,	O
LMP7	B-protein
,	O
and	O
PSMB10	B-protein
,	O
are	O
incorporated	O
into	O
the	O
20S	B-protein
proteasome	I-protein
by	O
displacing	O
the	O
housekeeping	O
beta	O
-	O
type	O
subunits	O
designated	O
PSMB6	B-protein
,	O
PSMB5	B-protein
,	O
and	O
PSMB7	B-protein
,	O
respectively	O
.	O

The	O
Dax	B-protein
-	I-protein
1	I-protein
gene	I-protein
encodes	O
a	O
protein	O
that	O
is	O
structurally	O
related	O
to	O
members	O
of	O
the	O
orphan	B-protein
nuclear	I-protein
receptor	I-protein
superfamily	I-protein
.	O

Human	B-protein
AP	I-protein
-	I-protein
2rep	I-protein
repressed	O
both	O
reporter	O
expression	O
from	O
a	O
transiently	O
transfected	O
AP	B-protein
-	I-protein
2alpha	I-protein
promoter	I-protein
and	O
the	O
endogenous	O
AP	B-protein
-	I-protein
2alpha	I-protein
gene	I-protein
and	O
inversely	O
was	O
negatively	O
regulated	O
by	O
AP	B-protein
-	I-protein
2alpha	I-protein
.	O

The	O
radial	O
forearm	O
flap	O
is	O
used	O
most	O
commonly	O
,	O
however	O
the	O
lateral	O
arm	O
flap	O
may	O
be	O
the	O
flap	O
of	O
choice	O
in	O
certain	O
situations	O
.	O

Similarly	O
,	O
the	O
N	O
-	O
terminal	O
cytoplasmic	O
domain	O
of	O
the	O
latent	B-protein
membrane	I-protein
protein	I-protein
2A	I-protein
(	O
LMP2A	B-protein
)	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
contains	O
a	O
single	O
copy	O
of	O
the	O
Tyr	B-protein
-	I-protein
X	I-protein
-	I-protein
X	I-protein
-	I-protein
Leu	I-protein
/	I-protein
Ile	I-protein
-	I-protein
containing	I-protein
motif	I-protein
which	O
could	O
play	O
a	O
critical	O
role	O
in	O
B	O
cell	O
transformation	O
.	O

VEGF	B-protein
promoter	I-protein
activity	O
in	O
transient	O
transfections	O
was	O
decreased	O
by	O
either	O
pharmacological	O
or	O
genetic	O
inhibition	O
of	O
EGFR	B-protein
,	O
Ras	B-protein
,	O
or	O
phosphatidylinositol	B-protein
3	I-protein
'	I-protein
-	I-protein
kinase	I-protein
[	I-protein
PI	I-protein
(	I-protein
3	I-protein
)	I-protein
kinase	I-protein
]	I-protein
.	O

A	O
murine	O
expressed	O
sequence	O
tag	O
(	O
EST	O
)	O
showing	O
homology	O
with	O
erythropoietin	B-protein
receptor	I-protein
(	O
EPOR	B-protein
)	O
was	O
identified	O
in	O
the	O
EST	O
database	O
.	O

The	O
Schizosaccharomyces	B-protein
pombe	I-protein
rad1	I-protein
+	I-protein
cell	I-protein
cycle	I-protein
checkpoint	I-protein
control	I-protein
gene	I-protein
is	O
required	O
for	O
S	O
-	O
phase	O
and	O
G2	O
/	O
M	O
arrest	O
in	O
response	O
to	O
both	O
DNA	O
damage	O
and	O
incomplete	O
DNA	O
replication	O
.	O

The	O
mobility	O
of	O
the	O
upper	O
and	O
lower	O
premolars	O
under	O
load	O
was	O
investigated	O
in	O
relation	O
to	O
the	O
interproximal	O
contact	O
and	O
occlusal	O
facets	O
.	O

Exons	O
A1a	O
and	O
A1b	O
are	O
separated	O
from	O
each	O
other	O
by	O
a	O
124	O
-	O
nucleotide	O
intron	O
.	O

Immunostaining	O
of	O
cells	O
transfected	O
with	O
these	O
constructs	O
revealed	O
that	O
both	O
the	O
myristoylated	O
and	O
nonmyristoylated	O
mutants	O
were	O
localized	O
in	O
nuclei	O
,	O
whereas	O
wild	B-protein
-	I-protein
type	I-protein
PKC	I-protein
alpha	I-protein
was	O
primarily	O
cytoplasmic	O
and	O
perinuclear	O
.	O

Plasma	B-protein
lecithin	I-protein
/	I-protein
cholesterol	I-protein
acyltransferase	I-protein
(	O
LCAT	B-protein
)	O
activity	O
in	O
multiple	O
-	O
organ	O
donors	O
:	O
a	O
predictor	O
of	O
allograft	O
viability	O
in	O
clinical	O
liver	O
transplantation	O
.	O

Western	O
blot	O
analysis	O
of	O
various	O
bovine	O
tissues	O
with	O
human	O
NMT	B-protein
peptide	I-protein
antibody	I-protein
indicated	O
a	O
common	O
prominent	O
immunoreactive	O
band	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
48	O
.	O
5	O
-	O
50	O
kDa	O
in	O
all	O
tissues	O
.	O

Transient	O
transfection	O
assays	O
showed	O
that	O
site	O
A	O
is	O
necessary	O
and	O
sufficient	O
for	O
RXR	B-protein
alpha	O
-	O
mediated	O
transactivation	O
of	O
the	O
apoAI	B-protein
gene	I-protein
basal	I-protein
promoter	I-protein
in	O
human	O
hepatoma	O
HepG2	O
cells	O
in	O
the	O
presence	O
of	O
RA	O
and	O
that	O
this	O
transactivation	O
is	O
abolished	O
by	O
increasing	O
amounts	O
of	O
cotransfected	O
ARP	B-protein
-	I-protein
1	I-protein
.	O

This	O
structure	O
interconnects	O
specific	O
triplets	O
of	O
the	O
basal	O
bodies	O
with	O
the	O
microtubular	O
bundles	O
that	O
emerge	O
from	O
the	O
basal	O
apparatus	O
.	O

When	O
this	O
DNA	O
fragment	O
was	O
placed	O
upstream	O
of	O
the	O
chloramphenicol	B-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
reporter	O
gene	O
and	O
transfected	O
into	O
a	O
carp	O
CF	O
cell	O
line	O
,	O
it	O
could	O
drive	O
the	O
synthesis	O
of	O
CAT	B-protein
enzyme	I-protein
16	O
times	O
more	O
efficiently	O
than	O
the	O
promoterless	O
pCAT	B-protein
-	I-protein
Basic	I-protein
.	O

A	O
single	O
i	O
.	O
p	O
.	O
injection	O
of	O
d	O
,	O
l	O
-	O
baclofen	O
10	O
mg	O
/	O
kg	O
both	O
reduced	O
noradrenaline	O
(	O
NA	O
)	O
biosynthesis	O
in	O
vivo	O
(	O
31	O
%	O
)	O
and	O
the	O
endogenous	O
concentration	O
of	O
normetanephrine	O
(	O
NMN	O
)	O
(	O
32	O
%	O
)	O
and	O
increased	O
NA	O
levels	O
(	O
28	O
%	O
)	O
.	O

The	O
active	O
site	O
includes	O
the	O
acidic	O
triad	O
Asp53	O
(	O
the	O
site	O
of	O
phosphorylation	O
)	O
,	O
Asp10	O
and	O
Glu9	O
.	O

Furthermore	O
the	O
median	O
increase	O
in	O
cyclosporine	O
DR	O
/	O
C	O
(	O
SS	O
trough	O
)	O
was	O
18	O
l	O
h	O
-	O
1	O
(	O
-	O
3	O
.	O
1	O
to	O
42	O
.	O
1	O
l	O
h	O
-	O
1	O
,	O
interquartile	O
range	O
)	O
.	O

These	O
results	O
show	O
that	O
the	O
CAAT	O
-	O
region	O
is	O
involved	O
in	O
upregulating	O
the	O
MDR1	B-protein
promoter	I-protein
in	O
HL60	O
/	O
VCR	O
cells	O
.	O

The	O
virus	O
-	O
associated	O
VAI	O
RNA	O
of	O
adenovirus	O
is	O
a	O
small	O
highly	O
structured	O
RNA	O
that	O
is	O
required	O
for	O
the	O
efficient	O
translation	O
of	O
cellular	O
and	O
viral	O
mRNAs	O
at	O
late	O
times	O
after	O
infection	O
.	O

While	O
interactions	O
of	O
WT	B-protein
and	O
variant	O
TGF	B-protein
-	I-protein
alpha	I-protein
with	O
the	O
ErbBs	B-protein
all	O
result	O
in	O
ErbB2	B-protein
activation	O
,	O
they	O
produce	O
different	O
biological	O
consequences	O
,	O
suggesting	O
that	O
the	O
various	O
TGF	B-protein
-	I-protein
alpha	I-protein
precursors	I-protein
differentially	O
modulate	O
ErbB	B-protein
signaling	O
.	O

By	O
contrast	O
,	O
secretory	B-protein
HI	I-protein
antibodies	I-protein
were	O
not	O
demonstrated	O
at	O
the	O
onset	O
of	O
illness	O
in	O
any	O
of	O
the	O
patients	O
,	O
but	O
their	O
formation	O
started	O
early	O
and	O
the	O
antibodies	O
reached	O
maximal	O
levels	O
about	O
10	O
days	O
after	O
onset	O
of	O
illness	O
.	O

Mammalian	B-protein
ABPs	I-protein
and	O
SHBGs	B-protein
bind	O
sex	O
steroids	O
with	O
high	O
affinity	O
,	O
but	O
some	O
binding	O
properties	O
differ	O
among	O
species	O
.	O

PRDII	B-protein
-	I-protein
BF1	I-protein
-	I-protein
derived	I-protein
cDNAs	I-protein
did	O
not	O
result	O
in	O
stimulation	O
of	O
either	O
basal	O
or	O
tat	O
-	O
induced	O
activated	O
gene	O
expression	O
.	O

We	O
isolated	O
several	O
overlapping	O
A	O
-	O
phage	O
and	O
cosmid	O
clones	O
that	O
cover	O
more	O
than	O
100	O
kb	O
of	O
human	O
DNA	O
and	O
contained	O
the	O
entire	O
VDR	B-protein
gene	I-protein
.	O

The	O
treatment	O
group	O
also	O
showed	O
in	O
vivo	O
T	O
-	O
cell	O
activation	O
with	O
an	O
initial	O
lymphopenia	O
followed	O
by	O
a	O
rebound	O
lymphocytosis	O
and	O
upregulation	O
of	O
the	O
subset	O
markers	O
CD25	B-protein
(	O
interleukin	B-protein
2	I-protein
receptor	I-protein
)	O
and	O
CD45RO	B-protein
(	O
T	O
-	O
memory	O
cells	O
)	O
.	O

Selected	O
parameters	O
:	O
heart	O
rate	O
(	O
HR	O
)	O
,	O
arterial	O
blood	O
pressure	O
(	O
ABP	O
)	O
and	O
arterial	O
O2	O
saturation	O
(	O
SaO2	O
)	O
monitored	O
by	O
pulsoximetry	O
were	O
measured	O
during	O
the	O
procedure	O
.	O

Persistent	O
activation	O
of	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinases	I-protein
p42	I-protein
and	O
p44	B-protein
and	O
ets	B-protein
-	I-protein
2	I-protein
phosphorylation	O
in	O
response	O
to	O
colony	B-protein
-	I-protein
stimulating	I-protein
factor	I-protein
1	I-protein
/	I-protein
c	I-protein
-	I-protein
fms	I-protein
signaling	O
.	O

It	O
is	O
transparent	O
,	O
cheap	O
to	O
be	O
made	O
,	O
and	O
easy	O
to	O
empty	O
and	O
was	O
tested	O
in	O
118	O
animals	O
for	O
two	O
and	O
four	O
weeks	O
.	O

Coenzyme	B-protein
Q10	I-protein
:	O
blood	O
levels	O
and	O
metabolic	O
demand	O
.	O

A	O
drug	O
with	O
ISA	O
`	O
`	O
down	O
regulates	O
'	O
'	O
beta	B-protein
receptors	I-protein
;	O
thus	O
,	O
when	O
the	O
drug	O
is	O
withdrawn	O
there	O
is	O
no	O
post	O
-	O
beta	O
-	O
blocking	O
drug	O
hypersensitivity	O
in	O
contrast	O
to	O
agents	O
without	O
ISA	O
.	O

The	O
workup	O
included	O
skin	O
tests	O
(	O
up	O
to	O
1	O
microgram	O
/	O
ml	O
,	O
Pharmacia	O
)	O
,	O
measurement	O
of	O
specific	O
serum	O
IgE	B-protein
with	O
RAST	O
-	O
CAP	O
(	O
Pharmacia	O
)	O
,	O
and	O
CAST	O
with	O
three	O
concentrations	O
of	O
bee	O
(	O
Apis	O
mellifera	O
)	O
and	O
wasp	O
(	O
Vespula	O
spec	O
.	O
)	O
venom	O
(	O
Aquagen	O
ALK	O
)	O
.	O

Mutations	O
in	O
genes	O
encoding	O
PR65	B-protein
/	I-protein
A	I-protein
subunits	I-protein
have	O
been	O
identified	O
in	O
several	O
different	O
human	O
cancers	O
and	O
the	O
PP2A	B-protein
inhibitor	O
,	O
termed	O
fostriecin	O
,	O
is	O
being	O
tested	O
as	O
an	O
anticancer	O
drug	O
.	O

In	O
contrast	O
to	O
the	O
wild	O
-	O
type	O
protein	O
,	O
expression	O
of	O
p45	B-protein
NF	I-protein
-	I-protein
E2	I-protein
lacking	O
this	O
activation	O
domain	O
in	O
an	O
NF	B-protein
-	I-protein
E2	I-protein
null	O
cell	O
line	O
fails	O
to	O
support	O
enhancer	O
-	O
dependent	O
transcription	O
in	O
transient	O
assays	O
.	O

Similar	O
clinical	O
evaluation	O
of	O
an	O
obligate	O
carrier	O
revealed	O
no	O
ocular	O
abnormalities	O
.	O

The	O
present	O
study	O
reports	O
visual	O
evoked	O
potential	O
responses	O
to	O
pattern	O
reversal	O
(	O
VEP	O
-	O
P	O
)	O
in	O
ten	O
third	O
trimester	O
pregnant	O
women	O
and	O
changes	O
in	O
latency	O
of	O
NPN	O
complex	O
when	O
compared	O
with	O
these	O
responses	O
in	O
the	O
non	O
pregnant	O
state	O
.	O

55	O
+	O
/	O
-	O
11	O
%	O
)	O
,	O
all	O
other	O
parameters	O
showed	O
a	O
significant	O
increase	O
:	O
RS	O
index	O
5	O
.	O
4	O
+	O
/	O
-	O
1	O
.	O
4	O
mVolt	O
to	O
6	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
7	O
mVolt	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
;	O
EDD	O
6	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
7	O
to	O
6	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
9	O
cm	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
;	O
HV	O
1017	O
+	O
/	O
-	O
151	O
ml	O
to	O
1099	O
+	O
/	O
-	O
261	O
ml	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
;	O
EDV	O
371	O
+	O
/	O
-	O
131	O
ml	O
to	O
441	O
+	O
/	O
-	O
175	O
ml	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
;	O
RBV	O
117	O
+	O
/	O
-	O
57	O
ml	O
to	O
151	O
+	O
/	O
-	O
77	O
ml	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Significant	O
immunoglobulinuria	O
developed	O
prior	O
to	O
the	O
development	O
of	O
azotemia	O
,	O
significantly	O
decreased	O
creatinine	O
clearance	O
,	O
significant	O
proteinuria	O
(	O
greater	O
than	O
or	O
equal	O
to	O
3	O
+	O
dipstick	O
or	O
greater	O
than	O
or	O
equal	O
to	O
5	O
gm	O
per	O
24	O
-	O
hour	O
urine	O
collection	O
)	O
,	O
or	O
oliguria	O
.	O

ECM	O
disruption	O
in	O
Lytechinus	O
embryos	O
caused	O
a	O
relative	O
drop	O
in	O
USF	B-protein
RNA	I-protein
accumulation	O
levels	O
to	O
approximately	O
60	O
%	O
of	O
control	O
embryos	O
,	O
while	O
LpS1	B-protein
RNA	I-protein
accumulation	O
levels	O
dropped	O
to	O
less	O
than	O
5	O
%	O
.	O

Deep	O
tans	O
were	O
induced	O
over	O
the	O
backs	O
of	O
volunteers	O
with	O
repeated	O
exposure	O
to	O
longwave	O
ultraviolet	O
radiation	O
(	O
UV	O
-	O
A	O
)	O
.	O

It	O
is	O
shown	O
that	O
the	O
displacement	O
distribution	O
measured	O
by	O
q	O
-	O
space	O
MRI	O
in	O
both	O
the	O
large	O
displacement	O
(	O
i	O
.	O
e	O
.	O
,	O
large	O
r	O
)	O
and	O
the	O
long	O
-	O
wavelength	O
(	O
i	O
.	O
e	O
.	O
,	O
small	O
q	O
)	O
limits	O
is	O
the	O
same	O
3D	O
Gaussian	O
displacement	O
distribution	O
assumed	O
in	O
DT	O
-	O
MRI	O
.	O

Electrophoretic	O
mobility	O
shift	O
analysis	O
indicates	O
that	O
NF	B-protein
-	I-protein
IL	I-protein
-	I-protein
6	I-protein
,	O
as	O
well	O
as	O
other	O
related	O
members	O
of	O
this	O
family	O
,	O
bind	O
specifically	O
to	O
the	O
NF	B-protein
-	I-protein
IL	I-protein
-	I-protein
6	I-protein
site	O
in	O
the	O
IL	B-protein
-	I-protein
8	I-protein
promoter	I-protein
.	O

The	O
ICBF	O
in	O
the	O
ischaemic	O
cortex	O
revealed	O
a	O
graded	O
reduction	O
from	O
the	O
ischaemic	O
centre	O
to	O
the	O
surrounding	O
tissues	O
.	O

These	O
changes	O
at	O
the	O
site	O
of	O
injection	O
consist	O
of	O
a	O
focal	O
abnormality	O
characterized	O
by	O
a	O
slight	O
increase	O
in	O
signal	O
intensity	O
on	O
T1	O
weighted	O
images	O
and	O
markedly	O
increased	O
signal	O
intensity	O
on	O
T2	O
weighted	O
images	O
.	O

3	O
-	O
(	O
N	O
-	O
Alkyl	O
-	O
N	O
-	O
2	O
-	O
chloroethylaminomethyl	O
)	O
-	O
5	O
-	O
or	O
7	O
-	O
halogenobenzo	O
[	O
b	O
]	O
thiophen	O
hydrochlorides	O
.	O

Transcervical	O
amnioinfusion	O
.	O

A	O
computer	O
program	O
,	O
ACCESS	O
-	O
IAQ	O
,	O
is	O
developed	O
to	O
simulate	O
the	O
airflow	O
pattern	O
,	O
the	O
time	O
history	O
of	O
the	O
contaminant	O
concentrations	O
in	O
the	O
occupied	O
zone	O
,	O
and	O
the	O
inhalation	O
exposures	O
.	O

As	O
with	O
VP16	B-protein
,	O
the	O
transactivation	O
function	O
of	O
Luman	B-protein
is	O
also	O
regulated	O
by	O
HCF	B-protein
.	O

Hypomagnesemia	O
was	O
due	O
to	O
magnesium	O
wasting	O
by	O
the	O
kidney	O
.	O

Interestingly	O
,	O
although	O
E	B-protein
domains	I-protein
of	O
these	O
two	O
receptors	O
are	O
much	O
less	O
conserved	O
,	O
replacement	O
of	O
this	O
domain	O
in	O
rtER	B-protein
by	O
its	O
human	O
counterpart	O
resulted	O
in	O
higher	O
estradiol	O
sensitivity	O
but	O
no	O
increase	O
in	O
the	O
magnitude	O
of	O
transactivation	O
.	O

Propranolol	O
also	O
effectively	O
controlled	O
her	O
familial	O
tremor	O
.	O

From	O
sequence	O
alignments	O
with	O
phylogenetically	O
related	O
viruses	O
,	O
including	O
tymoviruses	O
,	O
we	O
predicted	O
that	O
p223	B-protein
contained	O
a	O
papain	B-protein
-	I-protein
like	I-protein
proteinase	I-protein
domain	I-protein
with	O
a	O
putative	O
catalytic	O
cysteine994	O
and	O
histidine1075	O
.	O

The	O
aim	O
of	O
this	O
retrospective	O
study	O
was	O
to	O
demonstrate	O
that	O
in	O
certain	O
cases	O
of	O
expulsive	O
choroidal	O
hemorrhage	O
(	O
ECH	O
)	O
anatomical	O
success	O
and	O
useful	O
vision	O
can	O
be	O
obtained	O
with	O
repeated	O
vitreoretinal	O
surgery	O
.	O

17	O
volunteer	O
deaf	O
Ss	O
were	O
compared	O
with	O
18	O
volunteer	O
hearing	O
Ss	O
on	O
the	O
Stanford	O
Hypnotic	O
Clinical	O
Scale	O
(	O
SHCS	O
)	O
of	O
Morgan	O
and	O
J	O
.	O

1	O
The	O
effects	O
in	O
normal	O
subjects	O
of	O
a	O
single	O
oral	O
dose	O
of	O
Motival	O
(	O
one	O
tablet	O
,	O
containing	O
fluphenazine	O
0	O
.	O
5	O
mg	O
and	O
nortriptyline	O
10	O
mg	O
)	O
on	O
the	O
contingent	O
negative	O
variation	O
(	O
CNV	O
)	O
,	O
reaction	O
time	O
,	O
heart	O
rate	O
,	O
blood	O
pressure	O
and	O
self	O
-	O
rating	O
scales	O
for	O
alertness	O
,	O
anxiety	O
,	O
tension	O
,	O
detachment	O
and	O
depression	O
were	O
compared	O
with	O
those	O
of	O
diazepam	O
(	O
5	O
mg	O
and	O
7	O
.	O
5	O
mg	O
)	O
and	O
placebo	O
or	O
propranolol	O
(	O
60	O
mg	O
)	O
.	O

Summers	O
,	O
Virology	O
89	O
:	O
517	O
-	O
527	O
,	O
1978	O
)	O
.	O

This	O
DNA	O
motif	O
represents	O
a	O
novel	O
protein	O
-	O
binding	O
sequence	O
.	O

The	O
virus	O
encodes	O
a	O
40	O
-	O
kDa	O
protein	O
,	O
tax	B-protein
,	O
that	O
is	O
important	O
for	O
the	O
immortalization	O
of	O
T	O
cells	O
.	O

[	B-protein
Ala85	I-protein
]	I-protein
Dk	I-protein
(	I-protein
69	I-protein
-	I-protein
85	I-protein
)	I-protein
retains	O
full	O
biological	O
activity	O
.	O

Platelet	O
serotonin	O
(	O
5	O
-	O
HT	O
)	O
and	O
5	B-protein
-	I-protein
HT	I-protein
releasing	I-protein
factor	I-protein
in	O
plasma	O
of	O
migrainous	O
patients	O
.	O

Strontium	O
-	O
90	O
was	O
inject	O
i	O
.	O
v	O
.	O
into	O
pregnant	O
rats	O
on	O
day	O
18	O
post	O
conception	O
(	O
p	O
.	O
c	O
.	O
)	O
.	O

Iodine	O
metabolism	O
in	O
chronic	O
thyroiditis	O
.	O

However	O
,	O
with	O
the	O
alpha1	O
antagonist	O
prazosin	O
(	O
5	O
x	O
10	O
(	O
-	O
8	O
)	O
-	O
5	O
x	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
,	O
no	O
relaxation	O
occurred	O
.	O

RESULTS	O
:	O
At	O
latest	O
examination	O
,	O
mean	O
UPDRS	O
II	O
and	O
III	O
scores	O
had	O
improved	O
by	O
30	O
%	O
(	O
on	O
stimulation	O
,	O
off	O
therapy	O
)	O
with	O
mean	O
50	O
%	O
reduction	O
in	O
daily	O
off	O
time	O
.	O

Instead	O
,	O
it	O
contained	O
two	O
tandem	O
kappaB	B-protein
elements	I-protein
and	O
a	O
variant	O
activating	B-protein
transcription	I-protein
factor	I-protein
/	I-protein
cAMP	I-protein
response	I-protein
element	I-protein
site	O
,	O
which	O
closely	O
resembled	O
sites	O
in	O
the	O
E	B-protein
-	I-protein
selectin	I-protein
gene	I-protein
that	O
are	O
required	O
for	O
TNF	O
-	O
alpha	O
-	O
or	O
LPS	O
-	O
inducible	O
expression	O
.	O

Copyright	O
2000	O
Academic	O
Press	O
.	O

This	O
paper	O
describes	O
the	O
genomic	O
organization	O
of	O
mouse	O
gC1qBP	B-protein
and	O
the	O
characterization	O
of	O
its	O
5	O
'	O
flanking	O
region	O
.	O

PRL	B-protein
-	I-protein
1	I-protein
is	O
able	O
to	O
dephosphorylate	O
phosphotyrosine	O
substrates	O
,	O
and	O
mutation	O
of	O
the	O
active	O
-	O
site	O
cysteine	O
residue	O
abolishes	O
this	O
activity	O
.	O

Infarct	O
regional	O
ejection	O
fraction	O
improved	O
by	O
10	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
1	O
%	O
between	O
early	O
and	O
late	O
studies	O
when	O
the	O
infarct	O
-	O
related	O
artery	O
was	O
patent	O
and	O
by	O
4	O
.	O
8	O
+	O
/	O
-	O
1	O
.	O
4	O
%	O
if	O
it	O
was	O
occluded	O
(	O
p	O
=	O
0	O
.	O
048	O
)	O
;	O
changes	O
in	O
global	O
and	O
noninfarct	O
regional	O
ejection	O
fraction	O
were	O
similar	O
irrespective	O
of	O
perfusion	O
status	O
.	O

The	O
activated	O
glucocorticoid	B-protein
receptor	I-protein
forms	O
a	O
complex	O
with	O
Stat5	B-protein
and	O
enhances	O
Stat5	O
-	O
mediated	O
transcriptional	O
induction	O
.	O

This	O
partial	O
transection	O
could	O
permit	O
vasopressin	B-protein
to	O
be	O
secreted	O
in	O
response	O
to	O
a	O
larger	O
rise	O
in	O
plasma	O
sodium	O
concentration	O
.	O

This	O
repressor	O
is	O
however	O
unlikely	O
to	O
mediate	O
spi	B-protein
2	I-protein
.	I-protein
3	I-protein
3	I-protein
'	I-protein
UTR	I-protein
silencer	I-protein
action	O
since	O
it	O
was	O
not	O
detected	O
in	O
rat	O
hepatocytes	O
.	O

The	O
severity	O
of	O
pathologic	O
changes	O
increased	O
with	O
the	O
magnitude	O
of	O
percussion	O
.	O

ANIMALS	O
:	O
Fifty	O
dogs	O
with	O
naturally	O
developing	O
DM	O
.	O

Acute	O
pancreatitis	O
:	O
a	O
multisystem	O
disease	O
.	O

Interestingly	O
,	O
the	O
RXRalphaF318A	B-protein
constitutive	O
activity	O
generated	O
within	O
heterodimers	O
in	O
the	O
presence	O
of	O
BMS614	O
requires	O
the	O
integrity	O
of	O
both	O
RXR	B-protein
and	O
RAR	B-protein
AF	I-protein
-	I-protein
2	I-protein
domains	I-protein
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
determine	O
and	O
rank	O
the	O
frequency	O
of	O
self	O
reported	O
visual	O
disability	O
in	O
daily	O
tasks	O
performed	O
by	O
glaucoma	O
patients	O
;	O
to	O
examine	O
the	O
interrelation	O
between	O
disabilities	O
using	O
factor	O
analysis	O
;	O
to	O
study	O
the	O
relation	O
between	O
perceived	O
visual	O
difficulty	O
and	O
a	O
measure	O
of	O
the	O
severity	O
of	O
visual	O
field	O
loss	O
;	O
to	O
develop	O
a	O
glaucoma	O
specific	O
subgroup	O
of	O
questions	O
;	O
and	O
examine	O
the	O
validity	O
and	O
reliability	O
of	O
this	O
subgroup	O
of	O
questions	O
.	O

The	O
amino	O
-	O
terminal	O
third	O
of	O
the	O
protein	O
contains	O
a	O
high	B-protein
-	I-protein
mobility	I-protein
-	I-protein
group	I-protein
motif	I-protein
characteristic	O
of	O
DNA	O
-	O
binding	O
proteins	O
.	O

In	O
rlf2	B-protein
mutants	I-protein
,	O
telomeric	O
chromatin	O
is	O
perturbed	O
:	O
Telomeric	O
silencing	O
is	O
reduced	O
and	O
Rap1p	B-protein
localization	O
is	O
altered	O
.	O

Solution	O
structure	O
and	O
mechanism	O
of	O
the	O
MutT	B-protein
pyrophosphohydrolase	I-protein
.	O

Against	O
gram	O
-	O
positive	O
organisms	O
,	O
E	O
-	O
4767	O
and	O
E	O
-	O
5065	O
were	O
,	O
in	O
general	O
,	O
eight	O
-	O
and	O
fourfold	O
more	O
active	O
than	O
tosufloxacin	O
,	O
which	O
is	O
the	O
most	O
potent	O
of	O
the	O
reference	O
compounds	O
.	O

A	O
significant	O
degree	O
of	O
homology	O
was	O
also	O
found	O
among	O
these	O
genes	O
and	O
the	O
Mtase	B-protein
gene	I-protein
of	O
related	O
phage	O
SPR	O
,	O
which	O
codes	O
for	O
an	O
enzyme	O
with	O
different	O
modification	O
specificity	O
.	O

These	O
results	O
suggest	O
that	O
NZ	O
-	O
107	O
may	O
be	O
a	O
useful	O
drug	O
for	O
the	O
treatment	O
of	O
bronchial	O
asthma	O
by	O
reducing	O
late	O
-	O
phase	O
airway	O
responses	O
and	O
airway	O
hyperreactivity	O
.	O

RESULTS	O
:	O
Of	O
the	O
patients	O
with	O
IS	O
,	O
67	O
%	O
had	O
significantly	O
greater	O
values	O
of	O
directional	O
preponderance	O
on	O
the	O
OVAR	O
test	O
(	O
a	O
measure	O
of	O
otolith	O
system	O
imbalance	O
)	O
compared	O
with	O
control	O
subjects	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
has	O
the	O
greatest	O
homology	O
(	O
61	O
%	O
)	O
to	O
the	O
green	B-protein
alga	I-protein
Scenedemus	I-protein
obliquus	I-protein
plastocyanin	I-protein
.	O

The	O
viral	O
LTR	O
was	O
used	O
as	O
the	O
promoter	O
.	O

We	O
also	O
examined	O
the	O
relationship	O
between	O
the	O
side	O
of	O
sinusitis	O
and	O
the	O
cleft	O
side	O
in	O
patients	O
with	O
unilateral	O
cleft	O
palate	O
.	O

When	O
nifA	B-protein
mRNA	I-protein
5	O
'	O
start	O
points	O
were	O
mapped	O
by	O
primer	O
extension	O
,	O
both	O
a	O
minor	O
upstream	O
transcript	O
(	O
s	O
)	O
starting	O
45	O
bp	O
distal	O
to	O
the	O
anaerobox	O
and	O
a	O
major	O
downstream	O
transcript	O
starting	O
10	O
bp	O
distal	O
to	O
the	O
sigma	B-protein
54	I-protein
box	O
were	O
observed	O
.	O

It	O
is	O
the	O
oxidation	O
peak	O
of	O
this	O
product	O
,	O
arising	O
in	O
acidic	O
media	O
at	O
0	O
.	O
42	O
V	O
,	O
which	O
was	O
analysed	O
using	O
DPV	O
,	O
again	O
following	O
the	O
accumulation	O
of	O
clenbuterol	O
at	O
the	O
Nafion	O
-	O
modified	O
CPE	O
.	O

Its	O
potential	O
as	O
a	O
diagnostic	O
tool	O
for	O
epidemiological	O
surveillance	O
was	O
assessed	O
in	O
comparison	O
with	O
three	O
other	O
diagnostic	O
tests	O
:	O
stool	O
examination	O
,	O
ELISA	O
with	O
soluble	B-protein
egg	I-protein
antigen	I-protein
(	O
SEA	B-protein
)	O
and	O
the	O
circumoval	O
precipitin	O
test	O
(	O
COPT	O
)	O
.	O

Albumin	B-protein
expression	O
is	O
maintained	O
in	O
the	O
liver	O
by	O
a	O
combination	O
of	O
liver	O
-	O
enriched	O
transcription	O
factors	O
such	O
as	O
CAAT	B-protein
enhancer	I-protein
-	I-protein
binding	I-protein
protein	I-protein
(	I-protein
C	I-protein
/	I-protein
EBP	I-protein
)	I-protein
alpha	I-protein
and	O
C	B-protein
/	I-protein
EBPbeta	I-protein
.	O

T2	O
cancers	O
should	O
not	O
be	O
excluded	O
from	O
the	O
benefit	O
of	O
preoperative	O
irradiation	O
.	O

A	O
gapped	O
search	O
with	O
the	O
C	O
-	O
terminal	O
region	O
of	O
CDED	B-protein
/	I-protein
LIOR	I-protein
revealed	O
a	O
36	O
-	O
41	O
%	O
similarity	O
to	O
several	O
proteins	O
related	O
to	O
signal	O
transduction	O
and	O
cell	O
replication	O
,	O
such	O
as	O
ORC1	B-protein
and	O
KSR	B-protein
.	O

Circulating	O
oxytocin	B-protein
in	O
male	O
guinea	O
pigs	O
affected	O
by	O
the	O
female	O
cohabitation	O
and	O
reproductive	O
condition	O
.	O

Prophylactic	O
lymph	O
node	O
dissection	O
or	O
radiation	O
therapy	O
to	O
the	O
nodal	O
chain	O
may	O
decrease	O
local	O
recurrence	O
but	O
does	O
not	O
consistently	O
affect	O
overall	O
survival	O
.	O

The	O
COL7A1	B-protein
gene	I-protein
,	O
which	O
encodes	O
type	B-protein
VII	I-protein
collagen	I-protein
,	O
has	O
been	O
implicated	O
as	O
a	O
candidate	O
gene	O
for	O
dominantly	O
and	O
recessively	O
inherited	O
forms	O
of	O
dystrophic	O
epidermolysis	O
bullosa	O
.	O

AIMS	O
:	O
To	O
establish	O
a	O
baseline	O
and	O
intraindividual	O
fluctuations	O
of	O
the	O
tumour	O
markers	O
CEA	B-protein
,	O
CA	B-protein
50	I-protein
and	O
CA	B-protein
242	I-protein
in	O
patients	O
cured	O
from	O
colorectal	O
cancer	O
,	O
and	O
to	O
test	O
the	O
hypothesis	O
that	O
serum	O
concentrations	O
and	O
intraindividual	O
fluctuations	O
do	O
not	O
differ	O
from	O
the	O
concentrations	O
in	O
cancer	O
-	O
free	O
individuals	O
.	O

Effects	O
of	O
thromboxane	B-protein
synthetase	I-protein
inhibition	O
on	O
postburn	O
mesenteric	O
vascular	O
resistance	O
and	O
the	O
rate	O
of	O
bacterial	O
translocation	O
in	O
a	O
chronic	O
porcine	O
model	O
.	O

Formation	O
of	O
hyphae	O
and	O
chlamydospores	O
by	O
Cryptococcus	O
laurentii	O
.	O

The	O
transforming	O
protein	O
of	O
Rous	O
sarcoma	O
virus	O
,	O
pp60v	B-protein
-	I-protein
src	I-protein
,	O
and	O
its	O
normal	O
cellular	O
homolog	O
,	O
pp60c	B-protein
-	I-protein
src	I-protein
,	O
differ	O
not	O
only	O
in	O
oncogenic	O
potential	O
but	O
also	O
in	O
their	O
subcellular	O
localization	O
and	O
cytoskeletal	O
binding	O
ability	O
.	O
pp60v	B-protein
-	I-protein
src	I-protein
has	O
been	O
shown	O
to	O
stably	O
associate	O
with	O
a	O
detergent	O
-	O
insoluble	O
cytoskeletal	O
matrix	O
,	O
whereas	O
pp60c	B-protein
-	I-protein
src	I-protein
does	O
not	O
.	O

The	O
importin	B-protein
alpha	I-protein
.	I-protein
beta	I-protein
heterodimer	I-protein
mediates	O
nuclear	O
import	O
of	O
proteins	O
containing	O
classical	O
nuclear	O
localization	O
signals	O
.	O

Nineteen	O
patients	O
with	O
non	O
-	O
visualized	O
gallbladder	O
with	O
OCG	O
subsequently	O
had	O
Tc	O
-	O
99m	O
-	O
PyG	O
cholescintigraphy	O
performed	O
.	O

The	O
EC	O
(	O
50	O
)	O
for	O
suppression	O
of	O
long	O
-	O
term	O
memory	O
(	O
the	O
concentration	O
decreasing	O
memory	O
by	O
50	O
%	O
)	O
of	O
fear	O
conditioning	O
to	O
context	O
was	O
2	O
.	O
00	O
%	O
plus	O
/	O
minus	O
0	O
.	O
01	O
%	O
(	O
mean	O
plus	O
/	O
minus	O
SEM	O
)	O
,	O
and	O
for	O
fear	O
conditioning	O
to	O
tone	O
was	O
3	O
.	O
45	O
%	O
plus	O
/	O
minus	O
0	O
.	O
26	O
%	O
,	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

OBJECTIVE	O
:	O
Although	O
the	O
preponderance	O
of	O
findings	O
offer	O
support	O
for	O
transient	O
(	O
where	O
is	O
it	O
?	O
)	O
as	O
opposed	O
to	O
sustained	O
(	O
what	O
is	O
it	O
?	O
)	O
deficit	O
,	O
a	O
need	O
remains	O
for	O
specific	O
depiction	O
of	O
the	O
deficit	O
.	O

Dietary	O
supplement	O
with	O
fish	O
oil	O
and	O
related	O
n	O
-	O
3	O
EFAs	O
has	O
been	O
used	O
to	O
study	O
their	O
antihypertensive	O
property	O
in	O
animals	O
and	O
humans	O
with	O
borderline	O
and	O
essential	O
hypertension	O
.	O

HCV	O
infection	O
acquired	O
during	O
or	O
after	O
BMT	O
caused	O
only	O
mild	O
acute	O
hepatitis	O
C	O
,	O
which	O
progressed	O
to	O
chronic	O
hepatitis	O
C	O
in	O
one	O
patient	O
surviving	O
10	O
years	O
after	O
BMT	O
.	O

Gel	O
-	O
shift	O
assays	O
with	O
nuclear	O
extracts	O
and	O
oligonucleotide	O
sequences	O
spanning	O
the	O
0	O
.	O
125	O
-	O
kb	O
promoter	O
region	O
detected	O
an	O
ETS	O
-	O
immunoreactive	O
complex	O
,	O
present	O
most	O
abundantly	O
in	O
cells	O
overexpressing	O
HER2	B-protein
,	O
whose	O
high	O
-	O
affinity	O
binding	O
depended	O
on	O
the	O
GAGGAA	B-protein
response	I-protein
element	I-protein
.	O

Northern	O
analyses	O
of	O
RNAs	O
from	O
mouse	O
tissues	O
and	O
cell	O
lines	O
indicated	O
that	O
p11	B-protein
mRNA	I-protein
levels	O
vary	O
widely	O
.	O

If	O
delay	O
has	O
occurred	O
between	O
centrifugation	O
and	O
the	O
measurement	O
,	O
causing	O
substantial	O
loss	O
of	O
CO2	O
,	O
equilibration	O
of	O
the	O
sample	O
with	O
a	O
gas	O
mixture	O
corresponding	O
to	O
PCO2	O
=	O
5	O
.	O
3	O
kPa	O
prior	O
to	O
the	O
measurement	O
is	O
recommended	O
.	O

Magnetic	O
resonance	O
imaging	O
in	O
coccidioidal	O
arthritis	O
.	O

For	O
steers	O
the	O
urinary	O
N	O
values	O
were	O
403	O
and	O
295	O
mg	O
/	O
kg	O
W0	O
.	O
75	O
at	O
200	O
and	O
350	O
kg	O
live	O
weight	O
respectively	O
and	O
total	O
N	O
excretion	O
including	O
faecal	O
N	O
was	O
408	O
and	O
320	O
mg	O
/	O
kg	O
W0	O
.	O
75	O
.	O

Data	O
from	O
the	O
V	O
-	O
HeFT	O
II	O
show	O
that	O
at	O
2	O
-	O
year	O
follow	O
-	O
up	O
,	O
a	O
progressive	O
rise	O
of	O
plasma	O
norepinephrine	O
was	O
observed	O
in	O
both	O
treatment	O
arms	O
,	O
suggesting	O
that	O
disease	O
progresses	O
despite	O
treatment	O
with	O
either	O
an	O
angiotensin	B-protein
-	I-protein
converting	I-protein
enzyme	I-protein
inhibitor	O
,	O
enalapril	O
,	O
or	O
vasodilator	O
therapy	O
with	O
hydralazine	O
/	O
isosorbide	O
dinitrate	O
.	O

Phosphorylation	O
of	O
tyrosine	O
residues	O
in	O
the	O
kinase	B-protein
domain	I-protein
and	O
juxtamembrane	O
region	O
regulates	O
the	O
biological	O
and	O
catalytic	O
activities	O
of	O
Eph	B-protein
receptors	I-protein
.	O

The	O
indications	O
for	O
its	O
use	O
include	O
every	O
primary	O
and	O
secondary	O
rhinoplasty	O
candidate	O
unless	O
tip	O
grafts	O
are	O
going	O
to	O
be	O
under	O
tension	O
or	O
if	O
the	O
deformity	O
is	O
minor	O
.	O

The	O
effect	O
of	O
pure	O
natural	O
porcine	B-protein
secretin	I-protein
on	O
endocrine	O
and	O
exocrine	O
pancreatic	O
secretion	O
was	O
studied	O
in	O
the	O
totally	O
isolated	O
perfused	O
porcine	O
pancreas	O
.	O

Exogenous	O
LHRH	B-protein
is	O
also	O
known	O
to	O
facilitate	O
mating	O
behavior	O
in	O
several	O
species	O
.	O

The	O
in	O
vivo	O
profile	O
of	O
ZFH	B-protein
-	I-protein
2	I-protein
in	O
the	O
larval	O
CNS	O
shows	O
intriguing	O
overlap	O
with	O
DDC	B-protein
in	O
specific	O
serotonin	O
and	O
dopamine	O
neurons	O
.	O

Using	O
this	O
reporter	O
gene	O
system	O
,	O
we	O
previously	O
showed	O
that	O
EPO	O
-	O
induced	O
activation	O
of	O
the	O
c	B-protein
-	I-protein
fos	I-protein
promoter	I-protein
can	O
be	O
detected	O
rapidly	O
and	O
sensitively	O
as	O
an	O
elevation	O
of	O
cellular	B-protein
luciferase	I-protein
activity	O
.	O

Demonstration	O
of	O
the	O
agent	O
was	O
performed	O
from	O
the	O
6th	O
to	O
the	O
11th	O
day	O
p	O
.	O
i	O
.	O
by	O
direct	O
microscopic	O
methods	O
(	O
Stamp	O
and	O
auramine	O
staining	O
,	O
fluorescent	O
antibody	O
technique	O
)	O
;	O
the	O
Coxiella	O
content	O
was	O
determined	O
by	O
titration	O
in	O
embryonated	O
hen	O
'	O
s	O
eggs	O
.	O

These	O
characteristic	O
structural	O
features	O
were	O
used	O
to	O
create	O
the	O
abbreviation	O
AZF1	B-protein
(	O
Asparagine	B-protein
-	I-protein
rich	I-protein
Zinc	I-protein
Finger	I-protein
protein	I-protein
)	O
.	O

Cost	O
-	O
effectiveness	O
of	O
interferon	B-protein
beta	I-protein
-	I-protein
1b	I-protein
in	O
slowing	O
multiple	O
sclerosis	O
disability	O
progression	O
.	O

Pseudosubstrate	O
(	O
19	O
-	O
36	O
)	O
,	O
derived	O
from	O
the	O
C	O
-	O
terminus	O
of	O
Ca	B-protein
-	I-protein
dependent	I-protein
PKC	I-protein
isotypes	I-protein
,	O
inhibited	O
beta	B-protein
-	I-protein
PKC	I-protein
but	O
not	O
nPKC	B-protein
activity	O
using	O
either	O
Histone	B-protein
IIIS	I-protein
or	O
peptide	O
(	O
19	O
-	O
31	O
)	O
as	O
substrate	O
.	O

Sensing	O
with	O
chemically	O
and	O
biologically	O
modified	O
carbon	O
electrodes	O
.	O

Structure	O
,	O
promoter	O
analysis	O
and	O
chromosomal	O
assignment	O
of	O
the	O
human	B-protein
APEX	I-protein
gene	I-protein
.	O

Homologous	O
recombination	O
between	O
the	O
Autographa	O
californica	O
nuclear	O
polyhedrosis	O
virus	O
(	O
AcNPV	O
)	O
genome	O
and	O
a	O
0	O
.	O
6	O
-	O
kbp	O
-	O
long	O
DNA	O
fragment	O
derived	O
from	O
the	O
putative	O
DNA	B-protein
helicase	I-protein
gene	I-protein
of	I-protein
Bombyx	I-protein
mori	I-protein
nuclear	I-protein
polyhedrosis	I-protein
virus	I-protein
generates	O
eh2	O
-	O
AcNPV	O
,	O
an	O
expanded	O
-	O
host	O
-	O
range	O
AcNPV	O
mutant	O
(	O
S	O
.	O

The	O
transcriptional	O
activities	O
of	O
the	O
full	O
-	O
length	O
promoter	O
(	O
-	O
295	O
to	O
+	O
85	O
)	O
and	O
of	O
three	O
deletion	O
constructs	O
(	O
-	O
197	O
,	O
-	O
154	O
and	O
-	O
74	O
to	O
+	O
85	O
)	O
were	O
significantly	O
down	O
-	O
regulated	O
in	O
resistant	O
cells	O
.	O

Both	O
variants	O
display	O
the	O
seven	O
-	O
transmembrane	O
topology	O
that	O
is	O
typical	O
for	O
G	B-protein
protein	I-protein
-	I-protein
coupled	I-protein
receptors	I-protein
.	O

This	O
region	O
does	O
not	O
contain	O
an	O
identifiable	O
TATA	O
element	O
,	O
indicating	O
that	O
transcription	O
of	O
the	O
glutaminase	B-protein
gene	I-protein
is	O
driven	O
by	O
a	O
TATA	O
-	O
less	O
promoter	O
.	O

XXI	O
.	O

They	O
generated	O
ca	O
.	O

Northern	O
blot	O
analyses	O
demonstrate	O
that	O
3	O
.	O
9	O
-	O
and	O
5	O
-	O
kilobase	O
mRNAs	O
corresponding	O
to	O
the	O
cDNA	O
were	O
present	O
in	O
all	O
tissues	O
examined	O
,	O
suggesting	O
that	O
the	O
protein	O
it	O
encodes	O
performs	O
a	O
housekeeping	O
function	O
.	O

Furthermore	O
,	O
the	O
DNA	B-protein
polymerase	I-protein
II	I-protein
complex	I-protein
was	O
difficult	O
to	O
obtain	O
from	O
dpb2	B-protein
-	I-protein
1	I-protein
mutant	O
cells	O
,	O
suggesting	O
that	O
a	O
stable	O
DNA	B-protein
polymerase	I-protein
II	I-protein
complex	I-protein
requires	O
DPB2	B-protein
and	O
is	O
essential	O
for	O
chromosomal	O
replication	O
.	O

Levels	O
of	O
the	O
MEK	B-protein
inhibitor	O
PD98059	O
that	O
block	O
EGF	O
-	O
induced	O
mitogenesis	O
and	O
MAP	B-protein
kinase	I-protein
phosphorylation	O
also	O
abrogate	O
EGF	O
-	O
induced	O
focal	O
adhesion	O
disassembly	O
and	O
cell	O
motility	O
.	O

IFI16	B-protein
consists	O
of	O
ten	O
exons	O
and	O
nine	O
intervening	O
introns	O
spanning	O
at	O
least	O
28	O
kilobases	O
(	O
kb	O
)	O
of	O
DNA	O
.	O

Smoking	O
history	O
and	O
awake	O
oxygen	O
saturation	O
(	O
SaO2	O
)	O
was	O
recorded	O
in	O
all	O
of	O
them	O
.	O

In	O
a	O
heterologous	O
transcriptional	O
system	O
in	O
which	O
the	O
upstream	O
regions	O
of	O
oIFNtau	B-protein
were	O
inserted	O
in	O
front	O
of	O
simian	B-protein
virus	I-protein
40	I-protein
(	I-protein
SV40	I-protein
)	I-protein
promoter	I-protein
,	O
the	O
regions	O
between	O
bases	O
-	O
654	O
and	O
-	O
555	O
were	O
determined	O
as	O
being	O
the	O
enhancer	O
region	O
required	O
for	O
oIFNtau	B-protein
-	I-protein
SV40	I-protein
-	I-protein
CAT	I-protein
transactivation	O
.	O

However	O
,	O
the	O
elderly	O
group	O
showed	O
significantly	O
longer	O
mean	O
residence	O
times	O
(	O
MRTs	O
)	O
and	O
lower	O
plasma	O
clearance	O
of	O
lidocaine	O
during	O
the	O
period	O
compared	O
with	O
the	O
adult	O
group	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

Two	O
major	O
and	O
one	O
minor	O
transcription	O
initiation	O
sites	O
were	O
assigned	O
to	O
positions	O
+	O
1	O
and	O
+	O
24	O
and	O
position	O
+	O
14	O
,	O
respectively	O
,	O
by	O
a	O
combination	O
of	O
ribonuclease	B-protein
protection	O
,	O
primer	O
extension	O
,	O
and	O
5	O
'	O
RACE	O
analyses	O
.	O

Taking	O
into	O
consideration	O
weight	O
and	O
seasonal	O
changes	O
in	O
bone	O
mass	O
,	O
total	O
(	O
TBBMC	O
)	O
and	O
regional	O
body	O
bone	O
mineral	O
content	O
were	O
measured	O
in	O
38	O
women	O
treated	O
with	O
GnRH	B-protein
agonists	O
for	O
6	O
months	O
for	O
endometriosis	O
or	O
leiomyomata	O
.	O

Time	O
to	O
progression	O
was	O
6	O
months	O
(	O
5	O
-	O
7	O
months	O
)	O
with	O
a	O
median	O
survival	O
from	O
registration	O
of	O
9	O
.	O
6	O
months	O
(	O
95	O
%	O
CI	O
8	O
-	O
12	O
months	O
)	O
.	O

In	O
addition	O
to	O
the	O
previously	O
identified	O
and	O
characterized	O
attenuator	B-protein
1	I-protein
situated	O
93	O
nucleotides	O
downstream	O
from	O
the	O
major	O
late	O
transcription	O
start	O
site	O
,	O
a	O
second	O
attenuator	O
,	O
attenuator	B-protein
2	I-protein
,	O
situated	O
55	O
nucleotides	O
downstream	O
from	O
it	O
,	O
has	O
been	O
identified	O
.	O

A	O
long	O
follow	O
-	O
up	O
study	O
revealed	O
that	O
convalescent	O
stage	O
children	O
still	O
have	O
the	O
potency	O
to	O
have	O
an	O
immediate	O
type	O
hypersensitivity	O
reaction	O
on	O
exposure	O
to	O
mite	O
antigen	O
,	O
with	O
a	O
high	O
titer	O
of	O
mite	B-protein
specific	I-protein
IgE	I-protein
in	O
their	O
sera	O
,	O
but	O
they	O
are	O
free	O
from	O
asthmatic	O
attacks	O
because	O
of	O
the	O
reduction	O
in	O
the	O
amount	O
of	O
mite	O
antigen	O
in	O
the	O
body	O
,	O
as	O
shown	O
by	O
the	O
reduction	O
in	O
the	O
amount	O
of	O
mite	B-protein
specific	I-protein
IgG	I-protein
.	O

These	O
changes	O
were	O
n	O
'	O
t	O
so	O
significant	O
in	O
the	O
group	O
of	O
obese	O
children	O
who	O
did	O
n	O
'	O
t	O
lose	O
weight	O
.	O

USA	O
80	O
,	O
3618	O
-	O
3622	O
)	O
The	O
two	O
proteins	O
show	O
36	O
%	O
identities	O
in	O
their	O
amino	O
acid	O
sequence	O
,	O
in	O
an	O
alignment	O
requiring	O
six	O
gaps	O
.	O

POU	O
-	O
specific	O
and	O
POU	B-protein
-	I-protein
homeo	I-protein
domains	I-protein
of	O
Oct3	B-protein
were	O
produced	O
in	O
Echerichia	O
coli	O
for	O
characterization	O
of	O
DNA	O
binding	O
to	O
the	O
octamer	O
sequence	O
.	O

Bullous	O
angiolymphoid	O
hyperplasia	O
with	O
eosinophilia	O
.	O

No	O
title	O
available	O
.	O

Regulation	O
of	O
urokinase	B-protein
plasminogen	I-protein
activator	I-protein
gene	I-protein
transcription	O
in	O
the	O
RAW264	O
murine	O
macrophage	O
cell	O
line	O
by	O
macrophage	B-protein
colony	I-protein
-	I-protein
stimulating	I-protein
factor	I-protein
(	O
CSF	B-protein
-	I-protein
1	I-protein
)	O
is	O
dependent	O
upon	O
the	O
level	O
of	O
cell	O
-	O
surface	O
receptor	O
.	O

It	O
is	O
thus	O
one	O
of	O
the	O
key	O
enzymes	O
involved	O
in	O
the	O
triiodothyronine	O
-	O
mediated	O
control	O
of	O
growth	O
,	O
differentiation	O
and	O
basal	O
metabolism	O
in	O
vertebrates	O
.	O

Similarly	O
,	O
comparison	O
of	O
percentage	O
reductions	O
of	O
heart	O
rate	O
at	O
supine	O
,	O
sitting	O
and	O
exercise	O
by	O
repeated	O
measure	O
analysis	O
showed	O
the	O
Malays	O
to	O
have	O
significantly	O
higher	O
change	O
compared	O
to	O
the	O
Chinese	O
(	O
p	O
=	O
0	O
.	O
040	O
)	O
.	O

To	O
analyze	O
the	O
mechanism	O
of	O
fos	B-protein
/	I-protein
jun	I-protein
activation	O
by	O
TCDD	O
we	O
have	O
used	O
electrophoretic	O
mobility	O
shift	O
and	O
transient	O
expression	O
assays	O
of	O
reporter	O
gene	O
constructs	O
containing	O
response	O
elements	O
for	O
12	O
-	O
O	O
-	O
tetradecanoyl	O
-	O
phorbol	O
-	O
13	O
-	O
acetate	O
(	O
TRE	B-protein
)	O
,	O
serum	O
(	O
SRE	B-protein
)	O
,	O
cAMP	O
(	O
CRE	B-protein
)	O
,	O
and	O
aromatic	O
hydrocarbons	O
(	O
AhRE	O
)	O
from	O
the	O
fos	B-protein
and	O
jun	B-protein
genes	I-protein
fused	O
to	O
the	O
firefly	B-protein
luciferase	I-protein
gene	I-protein
under	O
the	O
control	O
of	O
the	O
SV40	B-protein
minimal	I-protein
promoter	I-protein
.	O

The	O
mysteries	O
of	O
geographic	O
variability	O
in	O
nonmelanoma	O
skin	O
cancer	O
incidence	O
.	O

Changes	O
in	O
tissue	O
PCO2	O
were	O
less	O
dramatic	O
and	O
did	O
not	O
vary	O
significantly	O
from	O
those	O
recorded	O
in	O
venous	O
blood	O
.	O

To	O
improve	O
test	O
efficiency	O
,	O
we	O
modified	O
our	O
previously	O
introduced	O
contrast	O
/	O
color	O
card	O
test	O
by	O
including	O
a	O
patterned	O
test	O
stimulus	O
and	O
reducing	O
the	O
number	O
of	O
stimuli	O
in	O
both	O
experimental	O
phases	O
.	O

Sequence	O
comparisons	O
of	O
prokaryotic	B-protein
RCR	I-protein
initiators	I-protein
has	O
revealed	O
a	O
set	O
of	O
three	O
common	O
motifs	O
,	O
two	O
of	O
which	O
,	O
a	O
putative	O
metal	O
coordination	O
site	O
and	O
a	O
downstream	O
active	O
-	O
site	O
tyrosine	O
motif	O
,	O
could	O
be	O
tentatively	O
identified	O
in	O
parvoviral	B-protein
replicator	I-protein
proteins	I-protein
.	O

An	O
even	O
greater	O
inflammatory	O
response	O
was	O
observed	O
after	O
intratracheal	O
instillation	O
of	O
ufCB	O
,	O
but	O
not	O
after	O
CB	O
instillation	O
.	O

Ten	O
males	O
performed	O
both	O
test	O
conditions	O
and	O
oxygen	O
uptake	O
VO2	O
,	O
heart	O
rate	O
,	O
minute	O
ventilation	O
VE	O
,	O
perceived	O
exertion	O
and	O
spinal	O
shrinkage	O
were	O
recorded	O
.	O

A	O
major	O
mechanism	O
whereby	O
steroid	B-protein
hydroxylase	I-protein
gene	I-protein
transcription	O
is	O
regulated	O
in	O
the	O
adrenal	O
cortex	O
requires	O
the	O
pituitary	O
peptide	O
hormone	O
,	O
ACTH	B-protein
,	O
which	O
acts	O
via	O
cAMP	O
.	O

AF	B-protein
showed	O
a	O
mixed	O
nuclear	O
/	O
cytoplasmic	O
pattern	O
of	O
expression	O
in	O
the	O
epithelial	O
,	O
endothelial	O
,	O
and	O
stromal	O
component	O
of	O
the	O
normal	O
breast	O
and	O
benign	O
lesions	O
,	O
whereas	O
an	O
impressive	O
loss	O
of	O
AF	B-protein
expression	O
was	O
noted	O
in	O
in	O
situ	O
and	O
invasive	O
breast	O
cancer	O
and	O
tumoral	O
stroma	O
.	O

Based	O
on	O
213	O
determinations	O
,	O
the	O
control	O
mean	O
serum	B-protein
CPK	I-protein
activity	O
was	O
262	O
+	O
/	O
-	O
113	O
I	O
.	O
U	O
.	O
/	O
liter	O
.	O

At	O
all	O
time	O
-	O
points	O
,	O
most	O
patients	O
(	O
>	O
/	O
=	O
87	O
%	O
)	O
were	O
receiving	O
irbesartan	O
/	O
HCTZ	O
alone	O
.	O

A	O
leucine	O
zipper	O
domain	O
of	O
the	O
suppressor	B-protein
of	I-protein
Hairy	I-protein
-	I-protein
wing	I-protein
protein	I-protein
mediates	O
its	O
repressive	O
effect	O
on	O
enhancer	O
function	O
.	O

Analysis	O
of	O
the	O
inferred	O
1	B-protein
,	I-protein
859	I-protein
-	I-protein
residue	I-protein
ama	I-protein
-	I-protein
1	I-protein
product	I-protein
showed	O
considerable	O
identity	O
with	O
the	O
largest	O
subunit	O
of	O
RNAP	B-protein
II	I-protein
from	O
other	O
organisms	O
,	O
including	O
the	O
presence	O
of	O
a	O
zinc	O
finger	O
motif	O
near	O
the	O
amino	O
terminus	O
,	O
and	O
a	O
carboxyl	O
-	O
terminal	O
domain	O
of	O
42	O
tandemly	O
reiterated	O
heptamers	O
with	O
the	O
consensus	O
Tyr	O
Ser	O
Pro	O
Thr	O
Ser	O
Pro	O
Ser	O
.	O

The	O
two	O
contiguous	O
IGF2	B-protein
(	O
human	B-protein
insulin	I-protein
-	I-protein
like	I-protein
growth	I-protein
factor	I-protein
II	I-protein
)	O
and	O
H19	B-protein
genes	I-protein
are	O
reciprocally	O
imprinted	O
in	O
both	O
human	O
and	O
mouse	O
.	O

In	O
serum	O
-	O
stimulated	O
cells	O
,	O
the	O
binding	O
of	O
NF	B-protein
-	I-protein
Y	I-protein
/	I-protein
CBF	I-protein
to	O
TKC1	B-protein
increased	O
gradually	O
,	O
reaching	O
a	O
plateau	O
at	O
the	O
S	O
phase	O
.	O

Data	O
are	O
presented	O
hinting	O
that	O
the	O
15	O
beta	O
-	O
hydroxy	O
-	O
,	O
metabolite	O
of	O
CPA	O
may	O
actually	O
be	O
the	O
biologically	O
active	O
agent	O
.	O

A	O
sharp	O
outbreak	O
of	O
influenza	O
A	O
occurred	O
on	O
the	O
base	O
during	O
February	O
that	O
was	O
due	O
to	O
an	O
A	O
/	O
Texas	O
/	O
1	O
/	O
77	O
-	O
like	O
virus	O
,	O
a	O
variant	O
of	O
the	O
A	O
/	O
Victoria	O
/	O
3	O
/	O
75	O
prototpye	O
.	O

One	O
missense	O
allele	O
(	O
P236S	B-protein
)	O
with	O
complete	O
loss	O
of	O
function	O
at	O
30	O
degreesC	O
and	O
four	O
missense	O
alleles	O
(	O
L173F	B-protein
,	O
E225K	B-protein
,	O
S269L	B-protein
and	O
E274K	B-protein
)	O
that	O
conferred	O
a	O
temperature	O
sensitive	O
phenotype	O
were	O
identified	O
.	O

Pentane	O
and	O
ethane	O
,	O
which	O
arise	O
during	O
lipid	O
peroxidation	O
in	O
vivo	O
,	O
were	O
measured	O
by	O
gas	O
chromatography	O
in	O
breath	O
samples	O
of	O
rats	O
fed	O
for	O
8	O
weeks	O
a	O
vitamin	O
E	O
-	O
deficient	O
diet	O
to	O
which	O
had	O
been	O
added	O
0	O
,	O
11	O
,	O
or	O
40	O
IU	O
vitamin	O
E	O
acetate	O
per	O
kg	O
.	O

Here	O
we	O
have	O
determined	O
the	O
nucleotide	O
sequence	O
of	O
3	O
.	O
5	O
kb	O
from	O
the	O
3	O
'	O
end	O
of	O
delta	B-protein
gag	I-protein
to	O
the	O
3	O
'	O
end	O
of	O
molecularly	O
cloned	O
proviral	O
MH2	O
DNA	O
,	O
in	O
order	O
to	O
elucidate	O
the	O
genetic	O
structure	O
of	O
the	O
virus	O
and	O
to	O
compare	O
it	O
with	O
other	O
mht	B-protein
-	O
and	O
myc	O
-	O
containing	O
oncogenic	O
viruses	O
as	O
well	O
as	O
with	O
the	O
chicken	B-protein
proto	I-protein
-	I-protein
myc	I-protein
gene	I-protein
.	O

Concurrent	O
with	O
ligand	O
-	O
dependent	O
uptake	O
,	O
we	O
now	O
show	O
that	O
the	O
receptor	O
undergoes	O
ligand	O
-	O
induced	O
ubiquitination	O
,	O
suggesting	O
that	O
receptor	O
ubiquitination	O
may	O
function	O
in	O
the	O
ligand	O
-	O
dependent	O
endocytosis	O
of	O
the	O
a	B-protein
-	I-protein
factor	I-protein
receptor	I-protein
as	O
well	O
as	O
in	O
its	O
constitutive	O
endocytosis	O
.	O

Cleavage	O
and	O
DNA	O
joining	O
reactions	O
,	O
carried	O
out	O
by	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV	I-protein
-	I-protein
1	I-protein
)	I-protein
integrase	I-protein
,	O
are	O
necessary	O
to	O
effect	O
the	O
covalent	O
insertion	O
of	O
HIV	O
-	O
1	O
DNA	O
into	O
the	O
host	O
genome	O
.	O

The	O
requirement	O
for	O
proteolytic	O
activity	O
of	O
both	O
FVIIa	B-protein
and	O
FXa	B-protein
suggests	O
that	O
protease	O
-	O
activated	O
receptors	O
may	O
be	O
involved	O
.	O

The	O
weight	O
-	O
bearing	O
surface	O
of	O
the	O
PE	O
head	O
became	O
smoother	O
with	O
time	O
after	O
THA	O
,	O
and	O
the	O
friction	O
coefficient	O
did	O
not	O
differ	O
significantly	O
from	O
that	O
of	O
an	O
unused	O
PE	O
head	O
.	O

Collaborative	O
study	O
of	O
Japanese	O
Pharmacopoeia	O
Heparin	O
Sodium	O
Reference	O
Standard	O
.	O

The	O
cDNA	O
corresponding	O
to	O
the	O
FPS1	B-protein
gene	I-protein
was	O
isolated	O
by	O
functional	O
complementation	O
of	O
a	O
mutant	O
yeast	O
strain	O
defective	O
in	O
FPS	B-protein
activity	O
(	O
Delourme	O
,	O
D	O
.	O
,	O
Lacroute	O
,	O
F	O
.	O
,	O
and	O
Karst	O
,	O
F	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
expression	O
of	O
TD	B-protein
-	I-protein
IkappaBalpha	I-protein
blocked	O
phorbol	O
myristate	O
acetate	B-protein
-	I-protein
phytohemagglutinin	I-protein
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	O
-	O
induced	O
IkappaBalpha	B-protein
gene	I-protein
transcription	O
and	O
abolished	O
NF	B-protein
-	I-protein
kappaB	I-protein
DNA	O
binding	O
activity	O
,	O
due	O
to	O
the	O
continued	O
cytoplasmic	O
sequestration	O
of	O
RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
by	O
TD	B-protein
-	I-protein
IkappaBalpha	I-protein
.	O

A	O
second	O
promoter	O
activity	O
was	O
identified	O
in	O
the	O
region	O
between	O
the	O
two	O
major	O
transcriptional	O
start	O
sites	O
.	O

Unique	O
to	O
this	O
system	O
,	O
the	O
activity	O
of	O
TraR	B-protein
is	O
negatively	O
modulated	O
by	O
an	O
antiactivator	O
called	O
TraM	B-protein
.	O

Direct	O
and	O
inverted	O
repeat	O
elements	O
of	O
10	O
,	O
11	O
,	O
16	O
,	O
19	O
,	O
and	O
22	O
nucleotides	O
(	O
nt	O
)	O
flank	O
the	O
promoter	O
site	O
.	O

Interestingly	O
,	O
the	O
positions	O
of	O
these	O
introns	O
have	O
been	O
conserved	O
in	O
comparison	O
with	O
the	O
genes	O
of	O
two	O
other	O
transglutaminase	O
-	O
like	O
activities	O
described	O
in	O
the	O
literature	O
,	O
but	O
the	O
TGM1	B-protein
gene	I-protein
is	O
by	O
far	O
the	O
smallest	O
characterized	O
to	O
date	O
because	O
its	O
introns	O
are	O
relatively	O
smaller	O
.	O

Studies	O
on	O
swine	O
enteroviruses	O
.	O

In	O
addition	O
,	O
anti	B-protein
-	I-protein
phosphotyrosine	I-protein
antibodies	I-protein
immunoprecipitated	O
80K	B-protein
-	I-protein
H	I-protein
from	O
cell	O
lysates	O
of	O
FGF	O
-	O
stimulated	O
but	O
not	O
from	O
control	O
fibroblasts	O
.	O

Splice	O
variations	O
in	O
genes	O
coding	O
for	O
the	O
transmembrane	B-protein
FGF	I-protein
receptor	I-protein
(	O
FGFR	B-protein
)	O
result	O
in	O
isoforms	O
that	O
vary	O
in	O
the	O
ectodomain	O
,	O
intracellular	O
juxtamembrane	O
domain	O
,	O
and	O
the	O
intracellular	B-protein
kinase	I-protein
domain	I-protein
.	O

During	O
the	O
period	O
from	O
May	O
to	O
August	O
,	O
1978	O
,	O
an	O
epidemic	O
of	O
hand	O
,	O
foot	O
and	O
mouth	O
disease	O
(	O
HFMD	O
)	O
occurred	O
in	O
Gifu	O
prefecture	O
.	O

The	O
design	O
principle	O
based	O
on	O
a	O
uniform	O
vibration	O
mode	O
is	O
presented	O
.	O

The	O
enzymatic	O
response	O
of	O
neutrophils	O
and	O
monocytes	O
was	O
similar	O
although	O
the	O
magnitude	O
of	O
the	O
NADPH	B-protein
oxidase	I-protein
activity	O
was	O
significantly	O
higher	O
in	O
neutrophils	O
than	O
in	O
monocytes	O
.	O

These	O
results	O
suggest	O
that	O
beta	B-protein
-	I-protein
1	I-protein
may	O
act	O
as	O
a	O
tissue	O
-	O
specific	O
,	O
trans	O
-	O
acting	O
regulator	O
of	O
the	O
expression	O
of	O
the	O
beta	B-protein
-	I-protein
zein	I-protein
gene	I-protein
in	O
developing	O
maize	O
endosperm	O
.	O

Mothers	O
with	O
severe	O
anatomical	O
abnormalities	O
,	O
who	O
are	O
HIV	O
positive	O
,	O
have	O
active	O
TB	O
or	O
whose	O
children	O
have	O
inherited	O
mono	O
-	O
or	O
disaccharide	O
intolerances	O
should	O
not	O
breastfeed	O
.	O

Metal	O
coordination	O
compounds	O
of	O
thiabendazole	O
.	O

The	O
responsiveness	O
of	O
visual	O
cortex	O
(	O
VC	O
)	O
and	O
superior	O
colliculus	O
(	O
SC	O
)	O
was	O
simultaneously	O
compared	O
following	O
conditioning	O
`	O
`	O
ON	O
'	O
'	O
or	O
`	O
`	O
OFF	O
'	O
'	O
stimulation	O
,	O
in	O
the	O
rabbit	O
.	O

Existence	O
and	O
uniqueness	O
of	O
solutions	O
of	O
the	O
appropriate	O
boundary	O
value	O
problems	O
are	O
established	O
,	O
in	O
the	O
case	O
of	O
small	O
permeability	O
coefficients	O
and	O
transport	O
rates	O
,	O
or	O
large	O
diffusion	O
coefficients	O
and	O
small	O
resistance	O
to	O
flow	O
constants	O
.	O

MK	O
-	O
927	O
:	O
a	O
topically	O
active	O
ocular	O
hypotensive	O
carbonic	B-protein
anhydrase	I-protein
inhibitor	O
.	O

Because	O
of	O
differences	O
in	O
patient	O
characteristics	O
,	O
control	O
measurements	O
were	O
obtained	O
from	O
normal	O
muscle	O
in	O
all	O
patients	O
.	O

We	O
have	O
cloned	O
the	O
single	O
-	O
copy	O
gene	O
for	O
the	O
trans	B-protein
-	I-protein
spliceosomal	I-protein
U5	I-protein
snRNA	I-protein
from	O
the	O
trypanosomatid	O
species	O
Leptomonas	O
seymouri	O
,	O
using	O
U5	B-protein
RNA	I-protein
affinity	O
selection	O
and	O
cDNA	O
cloning	O
.	O

In	O
these	O
experiments	O
we	O
begin	O
to	O
study	O
the	O
potential	O
functions	O
of	O
the	O
alpha	B-protein
7	I-protein
cytoplasmic	I-protein
domain	I-protein
by	O
analyzing	O
homologies	O
between	O
the	O
rat	O
and	O
human	O
sequences	O
,	O
by	O
immunologic	O
studies	O
using	O
an	O
anti	O
-	O
cytoplasmic	O
domain	O
antiserum	O
,	O
and	O
by	O
identifying	O
two	O
alternate	O
forms	O
.	O

RESULTS	O
:	O
The	O
target	O
dose	O
was	O
comparable	O
in	O
the	O
3D	O
-	O
CRT	O
and	O
IMRT	O
plans	O
,	O
although	O
improvements	O
were	O
seen	O
when	O
seven	O
and	O
nine	O
IMRT	O
fields	O
were	O
used	O
.	O

[	O
Pulmonary	O
vascular	O
resistance	O
(	O
PVR	O
)	O
during	O
10	O
%	O
O2	O
-	O
PVR	O
during	O
21	O
%	O
O2	O
/	O
PVR	O
during	O
21	O
%	O
O2	O
]	O
x	O
100	O
was	O
termed	O
as	O
hypoxic	O
pulmonary	O
vasoconstriction	O
(	O
HPV	O
)	O
.	O

This	O
analysis	O
revealed	O
an	O
intact	O
gene	O
(	O
arg4	B-protein
)	O
showing	O
a	O
high	O
degree	O
of	O
homology	O
with	O
the	O
Saccharomyces	B-protein
cerevisiae	I-protein
CPA2	I-protein
gene	I-protein
encoding	O
the	O
large	O
subunit	O
of	O
carbamoyl	B-protein
-	I-protein
phosphate	I-protein
synthetase	I-protein
(	O
CPS	B-protein
-	I-protein
A	I-protein
)	O
.	O

Diminished	O
forearm	O
arteriolar	O
dilator	O
capacity	O
produced	O
by	O
mineralocorticoid	O
-	O
induced	O
salt	O
retention	O
in	O
man	O
.	O

During	O
flexion	O
whiplash	O
,	O
the	O
torque	O
at	O
the	O
occipital	O
condyle	O
reverses	O
its	O
direction	O
at	O
about	O
25	O
ms	O
after	O
impact	O
.	O

Mutations	O
of	O
the	O
RET	B-protein
gene	I-protein
,	O
encoding	O
a	O
receptor	B-protein
tyrosine	I-protein
kinase	I-protein
,	O
have	O
been	O
associated	O
with	O
the	O
inherited	O
cancer	O
syndromes	O
MEN	O
2A	O
and	O
MEN	O
2B	O
.	O

Analyses	O
revealed	O
that	O
scale	O
matters	O
above	O
and	O
beyond	O
the	O
effect	O
of	O
quadrat	O
area	O
.	O

The	O
topology	O
and	O
chain	O
folding	O
of	O
the	O
beta	O
subunits	O
in	O
the	O
artifactual	O
beta	O
60	O
capsid	O
are	O
similar	O
to	O
the	O
native	B-protein
alpha	I-protein
3	I-protein
beta	I-protein
60	I-protein
enzyme	I-protein
.	O

Together	O
,	O
these	O
data	O
identify	O
ERK2	B-protein
as	O
a	O
specific	O
and	O
direct	O
target	O
of	O
HePTP	B-protein
and	O
are	O
consistent	O
with	O
a	O
model	O
in	O
which	O
HePTP	B-protein
negatively	O
regulates	O
ERK2	B-protein
activity	O
as	O
part	O
of	O
a	O
feedback	O
mechanism	O
.	O

UV	O
cross	O
-	O
linking	O
experiments	O
demonstrated	O
that	O
HSV	O
infection	O
caused	O
enhanced	O
binding	O
of	O
protein	O
factors	O
,	O
including	O
the	O
64	B-protein
-	I-protein
kDa	I-protein
component	I-protein
of	I-protein
cleavage	I-protein
stimulation	I-protein
factor	I-protein
(	O
CstF	B-protein
)	O
,	O
to	O
poly	O
(	O
A	O
)	O
site	O
RNAs	O
from	O
virus	O
genes	O
of	O
all	O
temporal	O
classes	O
and	O
that	O
this	O
enhanced	O
binding	O
required	O
expression	O
of	O
IE63	B-protein
.	O

However	O
,	O
little	O
was	O
understood	O
about	O
the	O
normal	O
function	O
of	O
CREB	B-protein
-	I-protein
2	I-protein
in	O
mammalian	O
development	O
or	O
organ	O
physiology	O
.	O

Follow	O
-	O
up	O
study	O
showed	O
85	O
%	O
of	O
these	O
patients	O
with	O
effectiveness	O
.	O

However	O
,	O
when	O
directed	O
to	O
the	O
nucleosome	O
by	O
fusion	O
to	O
core	B-protein
histone	I-protein
H2A	I-protein
or	O
H2B	B-protein
,	O
the	O
non	O
-	O
histone	O
tail	O
forms	O
an	O
MCB	O
that	O
appears	O
identical	O
to	O
that	O
of	O
the	O
endogenous	O
protein	O
.	O

A	O
novel	O
growth	O
-	O
related	O
nuclear	O
protein	O
binds	O
and	O
inhibits	O
rat	O
aldolase	B-protein
B	I-protein
gene	I-protein
promoter	O
.	O

The	O
investigation	O
was	O
apt	O
at	O
studying	O
the	O
relationship	O
between	O
urinary	O
metabolites	O
of	O
serotonin	O
and	O
catecholamine	O
(	O
5	O
-	O
HIAA	O
and	O
VMA	O
)	O
,	O
T	O
-	O
cells	O
(	O
OKT3	B-protein
+	I-protein
)	O
,	O
T	O
-	O
helper	O
(	O
OKT4	B-protein
+	I-protein
)	O
,	O
T	O
-	O
suppressor	O
(	O
OKT8	B-protein
+	I-protein
)	O
and	O
B	O
-	O
cells	O
(	O
EAC	O
-	O
rosette	O
forming	O
cells	O
)	O
in	O
normal	O
(	O
10	O
subjects	O
,	O
1	O
female	O
,	O
9	O
male	O
,	O
age	O
21	O
+	O
/	O
-	O
5	O
years	O
)	O
and	O
stress	O
administered	O
subjects	O
(	O
20	O
subjects	O
,	O
3	O
female	O
,	O
17	O
male	O
,	O
age	O
20	O
+	O
/	O
-	O
4	O
years	O
)	O
.	O

During	O
the	O
following	O
pregnancy	O
ultrasonographic	O
studies	O
of	O
the	O
male	O
fetus	O
in	O
the	O
16th	O
week	O
of	O
gestation	O
revealed	O
severe	O
micrognathia	O
,	O
short	O
and	O
wide	O
thumbs	O
,	O
and	O
big	O
toes	O
,	O
and	O
bowed	O
tibiae	O
.	O

A	O
cDNA	O
clone	O
was	O
isolated	O
from	O
a	O
chicken	O
embryo	O
cDNA	O
library	O
employing	O
a	O
PCR	O
-	O
generated	O
radiolabeled	O
probe	O
specific	O
for	O
the	O
U3	B-protein
region	I-protein
of	O
the	O
Rous	O
sarcoma	O
virus	O
LTR	O
.	O

Finally	O
,	O
there	O
are	O
a	O
growing	O
number	O
of	O
arguments	O
favouring	O
the	O
use	O
of	O
ACE	B-protein
inhibitors	O
very	O
early	O
in	O
patients	O
with	O
diabetes	O
mellitus	O
.	O

5	O
micrograms	O
/	O
l	O
was	O
detected	O
in	O
urine	O
from	O
some	O
non	O
-	O
occupationally	O
exposed	O
persons	O
.	O

Lipiodol	O
was	O
covalently	O
conjugated	O
with	O
EDTB	O
.	O

Comparison	O
of	O
cDNA	O
and	O
genomic	O
sequences	O
shows	O
that	O
the	O
ZNF189	B-protein
gene	I-protein
spans	O
approximately	O
11	O
kb	O
and	O
is	O
organized	O
into	O
at	O
least	O
four	O
exons	O
,	O
the	O
large	O
3	O
'	O
-	O
end	O
exon	O
coding	O
for	O
the	O
complete	O
zinc	O
finger	O
domain	O
and	O
the	O
3	O
'	O
untranslated	O
region	O
.	O

86	O
:	O
3199	O
-	O
3203	O
)	O
or	O
G1	O
to	O
S	O
phase	O
(	O
Reilly	O
,	O
C	O
.	O

Mutations	O
truncating	O
as	O
many	O
as	O
143	O
C	O
-	O
terminal	O
residues	O
from	O
the	O
transcriptional	O
activator	O
encoded	O
by	O
the	O
areA	B-protein
gene	I-protein
,	O
mediating	O
nitrogen	O
metabolite	O
repression	O
in	O
Aspergillus	O
nidulans	O
,	O
do	O
not	O
significantly	O
reduce	O
the	O
ability	O
of	O
the	O
areA	B-protein
product	I-protein
to	O
activate	O
expression	O
of	O
most	O
genes	O
under	O
areA	B-protein
control	O
.	O

However	O
,	O
we	O
identified	O
a	O
gene	O
between	O
the	O
MDV2	B-protein
UL54	I-protein
and	O
UL55	B-protein
genes	I-protein
with	O
homology	O
to	O
the	O
first	O
ORF	O
(	O
ORF	B-protein
-	I-protein
1	I-protein
)	O
of	O
equine	O
herpesvirus	O
type	O
1	O
and	O
corresponding	O
gene	O
identified	O
in	O
pseudorabies	O
virus	O
.	O

The	O
first	O
case	O
of	O
HCV	O
seroconversion	O
in	O
Portugal	O
after	O
the	O
introduction	O
of	O
HCV	O
NAT	O
screening	O
.	O

Analysis	O
of	O
hematopoietic	B-protein
growth	I-protein
factor	I-protein
prescriptions	O
in	O
19	O
french	O
cancer	O
centers	O
.	O

The	O
mechanism	O
underlying	O
such	O
analgesia	O
has	O
been	O
suggested	O
to	O
involve	O
the	O
interaction	O
between	O
the	O
two	O
separate	O
but	O
interconnected	O
motivational	O
systems	O
`	O
`	O
defense	O
'	O
'	O
and	O
`	O
`	O
pain	O
.	O
`	O
`	O
To	O
determine	O
the	O
developmental	O
course	O
of	O
defense	O
and	O
nociception	O
,	O
these	O
processes	O
were	O
analyzed	O
during	O
early	O
ontogeny	O
in	O
rats	O
.	O

By	O
in	O
vitro	O
immunoprecipitations	O
and	O
gel	O
shift	O
assays	O
,	O
we	O
identified	O
two	O
classes	O
of	O
high	O
affinity	O
Engrailed	B-protein
-	I-protein
binding	I-protein
sites	I-protein
upstream	O
of	O
each	O
of	O
the	O
two	O
polyhomeotic	O
transcription	O
units	O
.	O

METHODS	O
:	O
Experiments	O
testing	O
the	O
new	O
catheter	O
and	O
comparing	O
it	O
to	O
the	O
existing	O
catheter	O
included	O
:	O
(	O
1	O
)	O
measurement	O
of	O
the	O
laser	O
output	O
beam	O
sizes	O
and	O
divergences	O
;	O
(	O
2	O
)	O
evaluation	O
of	O
particulate	O
matter	O
generation	O
during	O
ablation	O
of	O
atherosclerotic	O
tissue	O
;	O
(	O
3	O
)	O
measurement	O
of	O
ablation	O
hole	O
sizes	O
and	O
tissue	O
penetration	O
rates	O
;	O
(	O
4	O
)	O
histopathologic	O
examination	O
of	O
laser	O
-	O
induced	O
in	O
vivo	O
vessel	O
wall	O
injury	O
.	O

Treatment	O
of	O
suppurative	O
peritonitis	O
.	O

In	O
Experiment	O
2	O
scopolamine	O
hydrobromide	O
,	O
0	O
.	O
5	O
and	O
1	O
.	O
0	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
was	O
administered	O
1	O
h	O
before	O
each	O
electrical	O
stimulation	O
until	O
each	O
rat	O
showed	O
the	O
stage	O
-	O
3	O
seizure	O
.	O

In	O
the	O
clinical	O
study	O
,	O
the	O
defect	O
size	O
shown	O
by	O
BMIPP	O
imaging	O
was	O
greater	O
in	O
anterior	O
than	O
in	O
inferior	O
infarcts	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
correlated	O
well	O
with	O
the	O
risk	O
area	O
revealed	O
by	O
contrast	O
ventriculography	O
(	O
r	O
=	O
0	O
.	O
80	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
CONCLUSION	O
:	O
The	O
above	O
preliminary	O
data	O
,	O
admittedly	O
from	O
a	O
small	O
group	O
of	O
patients	O
,	O
suggest	O
that	O
tomographic	O
BMIPP	O
imaging	O
provides	O
an	O
accurate	O
quantification	O
of	O
defect	O
size	O
by	O
means	O
of	O
a	O
simple	O
threshold	O
technique	O
and	O
,	O
in	O
the	O
subacute	O
phase	O
,	O
permits	O
determination	O
of	O
the	O
amount	O
of	O
myocardium	O
at	O
risk	O
after	O
acute	O
myocardial	O
infarction	O
.	O

Characterization	O
of	O
FIII	B-protein
/	I-protein
YY1	I-protein
,	O
a	O
Xenopus	O
laevis	O
conserved	O
zinc	O
-	O
finger	O
protein	O
binding	O
to	O
the	O
first	O
exon	O
of	O
L1	B-protein
and	O
L14	B-protein
ribosomal	I-protein
protein	I-protein
genes	I-protein
.	O

This	O
binary	O
repeat	O
contains	O
repetitive	O
DNA	O
elements	O
that	O
include	O
LINES	O
,	O
SINES	O
,	O
medium	O
reiteration	O
frequency	O
repeats	O
,	O
and	O
a	O
transposon	O
-	O
like	O
element	O
.	O

Corticosteroid	O
-	O
mediated	O
transcriptional	O
inhibition	O
was	O
greater	O
for	O
MR	B-protein
/	I-protein
GR	I-protein
in	O
combination	O
than	O
for	O
MR	B-protein
or	O
GR	B-protein
alone	O
.	O

The	O
other	O
model	O
was	O
a	O
continuous	O
exponential	O
plus	O
constant	O
of	O
the	O
form	O
La	O
-	O
=	O
a	O
+	O
b	O
[	O
exp	O
(	O
cVO2	O
)	O
]	O
.	O

Interestingly	O
,	O
dTFIIA	B-protein
-	I-protein
L	I-protein
/	I-protein
S	I-protein
is	O
also	O
able	O
to	O
significantly	O
enhance	O
transcriptional	O
activation	O
by	O
upstream	O
transcription	O
factors	O
including	O
Sp1	B-protein
,	O
VP16	B-protein
,	O
and	O
NTF	B-protein
-	I-protein
1	I-protein
.	O

A	O
`	O
`	O
Level	O
A	O
'	O
'	O
in	O
vitro	O
/	O
in	O
vivo	O
correlation	O
was	O
established	O
for	O
a	O
sustained	O
release	O
theophylline	O
(	O
CAS	O
58	O
-	O
55	O
-	O
9	O
)	O
preparation	O
(	O
Bronchoretard	O
)	O
under	O
investigation	O
.	O

The	O
most	O
frequent	O
risk	O
factor	O
for	O
ischaemic	O
was	O
hypertension	O
.	O

Prostate	B-protein
-	I-protein
specific	I-protein
antigen	I-protein
(	O
PSA	B-protein
)	O
promoter	O
-	O
driven	O
androgen	O
-	O
inducible	O
expression	O
of	O
sodium	B-protein
iodide	I-protein
symporter	I-protein
in	O
prostate	O
cancer	O
cell	O
lines	O
.	O

Prostaglandin	O
synthesis	O
inhibitors	O
have	O
been	O
shown	O
to	O
delay	O
healing	O
of	O
bone	O
and	O
this	O
has	O
led	O
to	O
limitations	O
on	O
their	O
use	O
clinically	O
in	O
some	O
situations	O
.	O

Here	O
we	O
show	O
that	O
independent	O
of	O
uncertainties	O
in	O
the	O
models	O
,	O
terrestrial	O
planets	O
with	O
dense	O
atmosphere	O
like	O
Venus	O
can	O
evolve	O
into	O
one	O
of	O
only	O
four	O
possible	O
rotation	O
states	O
.	O

Elimination	O
of	O
ETH1	B-protein
in	O
apn1	B-protein
strains	O
also	O
increased	O
spontaneous	O
mutation	O
rates	O
9	O
-	O
or	O
31	O
-	O
fold	O
compared	O
to	O
the	O
wild	O
type	O
as	O
determined	O
by	O
reversion	O
to	O
adenine	O
or	O
lysine	O
prototrophy	O
,	O
respectively	O
.	O

In	O
flies	O
,	O
the	O
dShc	B-protein
protein	I-protein
physically	O
associates	O
with	O
the	O
activated	O
Drosophila	B-protein
epidermal	I-protein
growth	I-protein
factor	I-protein
receptor	I-protein
homolog	I-protein
(	O
DER	B-protein
)	O
and	O
is	O
inducibly	O
phosphorylated	O
on	O
tyrosine	O
by	O
DER	B-protein
.	O

Helicobacter	O
pylori	O
and	O
stomach	O
diseases	O
:	O
from	O
clinical	O
point	O
of	O
view	O

Its	O
cognate	O
binding	O
protein	O
,	O
REST	B-protein
/	I-protein
NRSF	I-protein
,	O
is	O
an	O
essential	O
transcription	O
factor	O
;	O
its	O
null	O
mutations	O
result	O
in	O
embryonic	O
lethality	O
,	O
and	O
its	O
dominant	O
negative	O
mutants	O
produce	O
aberrant	O
expression	O
of	O
neuron	O
-	O
specific	O
genes	O
.	O

These	O
two	O
repeat	O
motifs	O
are	O
organized	O
in	O
an	O
extremely	O
well	O
-	O
ordered	O
pattern	O
in	O
each	O
domain	O
,	O
which	O
suggests	O
that	O
SbHRGP3	B-protein
belongs	O
to	O
a	O
new	O
group	O
of	O
proteins	O
having	O
the	O
repeat	O
motifs	O
of	O
two	O
distinct	O
groups	O
of	O
dicot	B-protein
extensins	I-protein
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
zinc	B-protein
finger	I-protein
protein	I-protein
Gis1	I-protein
acts	O
as	O
a	O
dosage	O
-	O
dependent	O
suppressor	O
of	O
the	O
rim15Delta	B-protein
defect	O
in	O
nutrient	O
limitation	O
-	O
induced	O
transcriptional	O
derepression	O
of	O
SSA3	B-protein
.	O

Angina	O
haemorrhagica	O
bullosa	O
causing	O
respiratory	O
obstruction	O
postoperatively	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
cloned	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
human	B-protein
nidogen	I-protein
gene	I-protein
.	O

Phagocytosis	O
of	O
tubercle	O
bacilli	O
by	O
macrophages	O
.	O

Acad	O
.	O

A	O
statistically	O
significant	O
improvement	O
due	O
to	O
the	O
administration	O
of	O
Bromergon	O
was	O
observed	O
in	O
symptoms	O
associated	O
with	O
overreactiveness	O
to	O
normal	O
prolactin	B-protein
levels	O
,	O
i	O
.	O
e	O
.	O
abdominal	O
tension	O
,	O
edema	O
,	O
weight	O
gain	O
and	O
breast	O
tenderness	O
.	O

Structural	O
organization	O
and	O
developmental	O
expression	O
pattern	O
of	O
the	O
mouse	B-protein
WD	I-protein
-	I-protein
repeat	I-protein
gene	I-protein
DMR	I-protein
-	I-protein
N9	I-protein
immediately	O
upstream	O
of	O
the	O
myotonic	B-protein
dystrophy	I-protein
locus	I-protein
.	O

Visual	O
averaged	O
evoked	O
responses	O
and	O
platelet	B-protein
monoamine	I-protein
oxidase	I-protein
in	O
patients	O
suffering	O
from	O
alcoholism	O
.	O

Notice	O
of	O
retraction	O
.	O

In	O
this	O
study	O
,	O
evidence	O
is	O
presented	O
that	O
temporally	O
and	O
spatially	O
specific	O
mef2	B-protein
expression	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
cis	O
-	O
acting	O
regulatory	O
modules	O
that	O
are	O
responsive	O
to	O
different	O
genetic	O
signals	O
.	O

BACKGROUND	O
:	O
We	O
hypothesized	O
that	O
the	O
postoperative	O
serum	O
level	O
of	O
TA90	B-protein
-	I-protein
IC	I-protein
,	O
an	O
immune	O
complex	O
of	O
a	O
90	O
-	O
kDa	O
tumor	O
-	O
associated	O
antigen	O
and	O
its	O
antibody	O
,	O
might	O
have	O
a	O
significant	O
correlation	O
with	O
recurrence	O
and	O
survival	O
in	O
patients	O
with	O
thick	O
primary	O
melanomas	O
.	O

Tolerance	O
test	O
of	O
HB	O
419	O
in	O
animal	O
experiments	O
.	O

The	O
present	O
data	O
also	O
demonstrate	O
that	O
ectopic	O
expression	O
of	O
blr1	B-protein
increased	O
JNK	B-protein
/	I-protein
SAPK	I-protein
activity	O
,	O
but	O
JNK	B-protein
/	I-protein
SAPK	I-protein
activation	O
was	O
not	O
needed	O
for	O
accelerated	O
RA	O
-	O
induced	O
differentiation	O
and	O
growth	O
arrest	O
.	O

To	O
identify	O
nuclear	O
regulatory	O
factors	O
,	O
we	O
have	O
located	O
and	O
functionally	O
characterized	O
the	O
CCR5	B-protein
gene	I-protein
promoter	I-protein
.	O

Effects	O
of	O
estradiol	O
on	O
worm	O
burden	O
and	O
peripheral	O
leukocytes	O
in	O
Parastrongylus	O
malaysiensis	O
-	O
infected	O
rats	O
.	O

The	O
protein	O
expressed	O
by	O
F2771	B-protein
cDNA	I-protein
in	O
transfected	O
COS	O
cells	O
is	O
localized	O
in	O
the	O
cytoplasm	O
.	O

No	O
mutations	O
were	O
found	O
in	O
follicular	O
adenomas	O
.	O

The	O
present	O
study	O
sought	O
to	O
develop	O
an	O
equation	O
to	O
estimate	O
VO2peak	O
in	O
peripheral	O
arterial	O
occlusive	O
disease	O
(	O
PAOD	O
)	O
patients	O
with	O
intermittent	O
claudication	O
and	O
to	O
determine	O
independent	O
predictors	O
of	O
VO2peak	O
in	O
this	O
population	O
.	O

The	O
predominant	O
sensitizing	O
allergens	O
in	O
Swedish	O
asthmatic	O
children	O
are	O
furred	O
pet	O
animals	O
.	O

There	O
were	O
45	O
to	O
56	O
nt	O
differences	O
between	O
the	O
virulent	O
and	O
avirulent	O
groups	O
while	O
there	O
were	O
6	O
to	O
14	O
nt	O
differences	O
among	O
four	O
avirulent	O
strains	O
.	O

These	O
data	O
demonstrate	O
that	O
DMVA	O
does	O
not	O
cause	O
more	O
myocardial	O
trauma	O
than	O
CPB	O
when	O
used	O
to	O
provide	O
resuscitative	O
circulatory	O
support	O
.	O

Magnetically	O
induced	O
optical	O
self	O
-	O
pulsing	O
in	O
a	O
nonlinear	O
resonator	O
.	O

Furthermore	O
,	O
transfection	O
of	O
cells	O
with	O
the	O
spacer	O
-	O
RING	O
domain	O
alone	O
suppressed	O
the	O
antiapoptotic	O
function	O
of	O
the	O
N	O
-	O
terminal	O
BIR	O
domain	O
of	O
c	B-protein
-	I-protein
IAP1	I-protein
and	O
induced	O
apoptosis	O
.	O

Factors	O
associated	O
with	O
intrafamilial	O
transmission	O
of	O
hepatitis	O
B	O
virus	O
infection	O
in	O
Korea	O
.	O

N	O
-	O
terminal	O
sequence	O
analysis	O
and	O
NMR	O
measurements	O
revealed	O
that	O
this	O
fragment	O
originates	O
from	O
the	O
C	O
-	O
terminal	O
80	O
residues	O
of	O
MBF1	B-protein
and	O
form	O
a	O
well	O
structured	O
C	O
-	O
terminal	O
domain	O
of	O
MBF1	B-protein
,	O
MBF1CTD	B-protein
.	O

Eight	O
rabbits	O
were	O
exposed	O
to	O
0	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
4	O
mg	O
/	O
m3	O
Co2	O
+	O
as	O
CoCl2	O
and	O
1	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
7	O
mg	O
/	O
m3	O
Cr3	O
+	O
as	O
Cr	O
(	O
NO3	O
)	O
3	O
(	O
group	O
Co	O
+	O
Cr	O
)	O
,	O
eight	O
to	O
0	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
/	O
m3	O
Co2	O
+	O
(	O
group	O
Co	O
)	O
,	O
and	O
eight	O
to	O
filtered	O
air	O
(	O
control	O
group	O
)	O
,	O
for	O
4	O
months	O
,	O
5	O
days	O
/	O
week	O
,	O
and	O
6	O
hr	O
/	O
day	O
.	O

From	O
life	O
-	O
table	O
analyses	O
of	O
these	O
patients	O
,	O
we	O
estimated	O
that	O
the	O
incidence	O
of	O
secondary	O
chondrosarcoma	O
in	O
patients	O
who	O
have	O
Ollier	O
disease	O
is	O
about	O
25	O
per	O
cent	O
at	O
the	O
age	O
of	O
forty	O
years	O
,	O
and	O
that	O
malignant	O
degeneration	O
is	O
almost	O
a	O
certainty	O
in	O
patients	O
who	O
have	O
Maffucci	O
syndrome	O
.	O

Reagent	O
strips	O
are	O
frequently	O
used	O
in	O
the	O
practice	O
of	O
laboratory	O
medicine	O
as	O
well	O
as	O
outside	O
the	O
professional	O
laboratories	O
.	O

Having	O
an	O
LRR	B-protein
domain	I-protein
and	O
an	O
SH3	B-protein
-	I-protein
binding	I-protein
domain	I-protein
,	O
Acan125	B-protein
and	O
the	O
C	O
.	O
elegans	O
homologue	O
define	O
a	O
novel	O
family	O
of	O
bifunctional	O
binding	O
proteins	O
.	O

Valuing	O
families	O
:	O
social	O
work	O
practice	O
with	O
families	O
from	O
a	O
strengths	O
perspective	O
.	O

The	O
Psc2	B-protein
cDNA	I-protein
contained	O
an	O
open	O
reading	O
frame	O
homologous	O
to	O
CP2	B-protein
family	I-protein
proteins	I-protein
.	O

These	O
data	O
show	O
that	O
PTH	B-protein
and	O
cAMP	O
can	O
repress	O
collagen	B-protein
promoter	I-protein
activity	O
in	O
calvariae	O
from	O
transgenic	O
mice	O
,	O
suggesting	O
that	O
the	O
alpha	B-protein
1	I-protein
(	I-protein
I	I-protein
)	I-protein
collagen	I-protein
promoter	I-protein
may	O
contain	O
cis	O
elements	O
down	O
-	O
stream	O
of	O
-	O
2	O
.	O
3	O
kilobases	O
that	O
mediate	O
PTH	B-protein
and	O
cAMP	O
repression	O
of	O
collagen	B-protein
gene	I-protein
expression	O
in	O
bone	O
.	O

Mean	O
corpuscular	B-protein
hemoglobin	I-protein
concentrations	O
remained	O
normal	O
for	O
48	O
h	O
and	O
then	O
decreased	O
in	O
both	O
groups	O
,	O
the	O
CO2	O
group	O
showing	O
the	O
larger	O
decrease	O
.	O

Effects	O
of	O
methiothepin	O
and	O
lysergic	O
acid	O
diethylamide	O
on	O
serotonin	O
release	O
in	O
vitro	O
and	O
serotonin	O
synthesis	O
in	O
vivo	O
:	O
possible	O
relation	O
to	O
serotonin	B-protein
autoreceptor	I-protein
function	O
.	O

Rabbit	O
eyes	O
were	O
removed	O
and	O
held	O
in	O
temperature	O
-	O
regulated	O
chambers	O
and	O
irrigated	O
with	O
saline	O
.	O

In	O
contrast	O
to	O
the	O
myoD	B-protein
promoter	I-protein
,	O
the	O
myoD	B-protein
enhancer	I-protein
shows	O
striking	O
conservation	O
between	O
humans	O
and	O
mice	O
both	O
in	O
its	O
sequence	O
and	O
its	O
distal	O
position	O
.	O

Serum	B-protein
beta	I-protein
2	I-protein
-	I-protein
microglobulin	I-protein
levels	O
(	O
beta	B-protein
-	I-protein
2	I-protein
-	I-protein
M	I-protein
)	O
were	O
studied	O
in	O
150	O
drug	O
addicts	O
,	O
50	O
of	O
them	O
asymptomatic	O
carriers	O
of	O
anti	B-protein
HIV	I-protein
-	I-protein
1	I-protein
antibodies	I-protein
,	O
50	O
symptomatic	O
carriers	O
with	O
persistent	O
generalized	O
lymphadenopathy	O
(	O
P	O
.	O
G	O
.	O
L	O
.	O
)	O
and	O
50	O
serum	O
negative	O
patients	O
who	O
had	O
been	O
living	O
in	O
a	O
closed	O
community	O
for	O
at	O
least	O
2	O
years	O
.	O

The	O
Bacillus	B-protein
subtilis	I-protein
phage	I-protein
phi	I-protein
105	I-protein
repressor	I-protein
,	O
a	O
lambda	B-protein
repressor	O
-	O
like	O
transcriptional	O
regulatory	O
protein	B-protein
,	O
was	O
overproduced	O
in	O
Escherichia	O
coli	O
and	O
purified	O
to	O
near	O
homogeneity	O
in	O
order	O
to	O
examine	O
its	O
in	O
vitro	O
DNA	O
-	O
binding	O
properties	O
.	O

The	O
present	O
study	O
examined	O
the	O
dependence	O
of	O
difference	O
tone	O
level	O
[	O
L	O
(	O
f2	O
-	O
f1	O
)	O
]	O
on	O
the	O
following	O
parameters	O
of	O
the	O
two	O
-	O
tone	O
input	O
:	O
f1	O
,	O
f2	O
/	O
f1	O
(	O
f2	O
greater	O
than	O
f1	O
)	O
,	O
L1	O
,	O
L2	O
,	O
and	O
L1	O
=	O
L2	O
.	O

We	O
now	O
show	O
that	O
regulation	O
of	O
flaN	B-protein
transcription	O
in	O
vivo	O
depends	O
on	O
a	O
sigma	B-protein
54	I-protein
promoter	I-protein
and	O
two	O
ftr	B-protein
elements	I-protein
located	O
downstream	O
of	O
the	O
transcription	O
start	O
site	O
at	O
+	O
86	O
(	O
ftr2	B-protein
)	O
and	O
+	O
120	O
(	O
ftr3	B-protein
)	O
.	O

Subsequently	O
,	O
we	O
show	O
that	O
the	O
reexpression	O
of	O
the	O
r	B-protein
-	I-protein
PTPeta	I-protein
gene	I-protein
in	O
highly	O
malignant	O
rat	O
thyroid	O
cells	O
transformed	O
by	O
retroviruses	O
carrying	O
the	O
v	B-protein
-	I-protein
mos	I-protein
and	O
v	B-protein
-	I-protein
ras	I-protein
-	I-protein
Ki	I-protein
oncogenes	I-protein
suppresses	O
their	O
malignant	O
phenotype	O
.	O

In	O
vitro	O
binding	O
studies	O
using	O
GST	B-protein
fusion	O
proteins	O
and	O
yeast	O
extracts	O
defined	O
distinct	O
binding	O
sites	O
on	O
yAP180A	B-protein
for	O
Pan1p	B-protein
and	O
clathrin	B-protein
.	O
yAP180	B-protein
proteins	I-protein
and	O
Pan1p	B-protein
,	O
like	O
actin	B-protein
,	O
localize	O
to	O
peripheral	O
patches	O
along	O
the	O
plasma	O
membrane	O
.	O

The	O
availability	O
of	O
potent	O
regulatory	O
DNA	O
cassettes	O
harboring	O
the	O
murine	B-protein
D1A	I-protein
gene	I-protein
promoter	I-protein
could	O
aid	O
testing	O
the	O
neuronal	O
-	O
specific	O
expression	O
of	O
transgenes	O
in	O
vivo	O
.	O

Autoradiographic	O
localisation	O
of	O
its	O
cellular	O
distribution	O
in	O
the	O
kidney	O
.	O

Syndromes	O
of	O
abnormal	O
fat	O
redistribution	O
and	O
metabolic	O
complications	O
in	O
HIV	O
-	O
infected	O
patients	O
.	O

Effects	O
of	O
estrogen	O
and	O
glucocorticoids	O
on	O
the	O
adrenal	O
development	O
of	O
the	O
fetus	O
.	O

A	O
concentration	O
of	O
12	O
.	O
5	O
ppm	O
SO2	O
induced	O
a	O
decrease	O
from	O
baseline	O
values	O
of	O
approximately	O
80	O
%	O
in	O
mean	O
MCA	O
and	O
of	O
roughly	O
70	O
%	O
in	O
mean	O
CBF	O
.	O

CM	O
reduced	O
the	O
nuclear	O
binding	O
activity	O
of	O
transcription	B-protein
factor	I-protein
AP	I-protein
-	I-protein
1	I-protein
.	O

The	O
SUP44	B-protein
suppressor	I-protein
mutation	I-protein
occurs	O
near	O
a	O
region	O
of	O
the	O
protein	O
that	O
corresponds	O
to	O
the	O
known	O
positions	O
of	O
alterations	O
in	O
E	B-protein
.	I-protein
coli	I-protein
S5	I-protein
ram	I-protein
mutations	I-protein
.	O

The	O
expression	O
pattern	O
of	O
GL2	B-protein
,	O
as	O
demonstrated	O
by	O
in	O
situ	O
hybridization	O
,	O
indicated	O
that	O
the	O
gene	O
is	O
expressed	O
in	O
trichome	O
progenitor	O
cells	O
and	O
at	O
stages	O
associated	O
with	O
trichome	O
development	O
.	O

The	O
amount	O
of	O
these	O
factors	O
was	O
reduced	O
in	O
GEO	O
cells	O
in	O
which	O
the	O
u	B-protein
-	I-protein
PAR	I-protein
gene	I-protein
is	O
only	O
weakly	O
transcriptionally	O
activated	O
.	O

Homozygous	O
mutant	O
mice	O
,	O
designated	O
Cux	B-protein
/	I-protein
CDPDeltaCR1	I-protein
,	O
display	O
a	O
phenotype	O
characterized	O
by	O
curly	O
vibrissae	O
and	O
wavy	O
hair	O
.	O

In	O
the	O
3	O
'	O
flanking	O
region	O
of	O
the	O
27	B-protein
kDa	I-protein
zein	I-protein
gene	I-protein
,	O
several	O
AATAAA	O
-	O
like	O
sequences	O
and	O
a	O
sequence	O
resembling	O
the	O
mammalian	O
GT	O
-	O
rich	O
sequence	O
are	O
present	O
around	O
the	O
polyadenylation	O
sites	O
.	O

CONCLUSION	O
:	O
SPT	O
is	O
more	O
useful	O
than	O
WST	O
in	O
differentiating	O
patients	O
predisposed	O
to	O
aspiration	O
.	O

The	O
qualitative	O
concentrations	O
of	O
HCG	B-protein
had	O
a	O
sensitivity	O
of	O
37	O
.	O
5	O
%	O
and	O
a	O
specificity	O
of	O
100	O
%	O
.	O

Mapping	O
of	O
RNA	O
-	O
temperature	B-protein
-	I-protein
sensitive	I-protein
mutants	I-protein
of	I-protein
Sindbis	I-protein
virus	I-protein
:	I-protein
complementation	I-protein
group	I-protein
F	I-protein
mutants	I-protein
have	O
lesions	O
in	O
nsP4	B-protein
.	O

In	O
addition	O
to	O
a	O
previously	O
characterized	O
promoter	O
(	O
P1	B-protein
)	O
,	O
we	O
now	O
show	O
the	O
existence	O
of	O
a	O
second	O
promoter	O
for	O
the	O
human	B-protein
IL	I-protein
-	I-protein
5Ralpha	I-protein
gene	I-protein
.	O

This	O
approach	O
was	O
examined	O
utilizing	O
the	O
fetal	O
protein	O
,	O
HGB	B-protein
F	I-protein
.	O

Data	O
were	O
processed	O
with	O
a	O
semi	O
-	O
automatic	O
computer	O
program	O
which	O
develops	O
an	O
averaged	O
-	O
volume	O
curve	O
from	O
an	O
assigned	O
LV	O
region	O
-	O
of	O
-	O
interest	O
.	O

The	O
mouse	B-protein
M	I-protein
-	I-protein
lysozyme	I-protein
downstream	I-protein
enhancer	I-protein
has	O
been	O
previously	O
characterized	O
on	O
several	O
levels	O
of	O
gene	O
regulation	O
.	O

This	O
complex	O
interacts	O
at	O
the	O
GTPase	B-protein
domain	I-protein
in	O
the	O
large	B-protein
subunit	I-protein
rRNA	I-protein
,	O
overlapping	O
the	O
binding	O
site	O
of	O
the	O
protein	B-protein
L11	I-protein
-	I-protein
like	I-protein
eukaryotic	I-protein
counterpart	I-protein
(	O
Saccharomyces	B-protein
cerevisiae	I-protein
protein	I-protein
L15	I-protein
and	O
mammalian	B-protein
protein	I-protein
L12	I-protein
)	O
.	O

Using	O
one	O
of	O
the	O
six	O
fragments	O
(	O
CPK3	B-protein
-	I-protein
8	I-protein
)	O
,	O
we	O
isolated	O
a	O
2022	B-protein
bp	I-protein
cDNA	I-protein
(	I-protein
VrCDPK	I-protein
-	I-protein
1	I-protein
)	I-protein
from	O
a	O
Vigna	O
radiata	O
lambda	O
gt11	O
library	O
.	O

TIEG	B-protein
expression	O
in	O
hFOB	O
cells	O
was	O
highly	O
induced	O
by	O
TGF	B-protein
-	I-protein
beta	I-protein
and	O
bone	B-protein
morphogenetic	I-protein
protein	I-protein
-	I-protein
2	I-protein
(	O
BMP	B-protein
-	I-protein
2	I-protein
)	O
,	O
with	O
a	O
moderate	O
induction	O
by	O
epidermal	B-protein
growth	I-protein
factor	I-protein
(	O
EGF	B-protein
)	O
,	O
but	O
no	O
induction	O
by	O
other	O
growth	O
factors	O
/	O
cytokines	O
was	O
observed	O
.	O

Introduction	O
of	O
v	B-protein
-	I-protein
fms	I-protein
into	O
a	O
CSF	B-protein
-	I-protein
1	I-protein
dependent	O
murine	O
macrophage	O
cell	O
line	O
induced	O
factor	O
independence	O
and	O
tumorigenicity	O
by	O
a	O
nonautocrine	O
mechanism	O
.	O

Eighteen	O
patients	O
were	O
untreated	O
,	O
and	O
8	O
had	O
been	O
given	O
previous	O
treatment	O
with	O
depot	O
testosterone	O
100	O
mg	O
intramuscularly	O
every	O
2	O
-	O
3	O
weeks	O
for	O
an	O
average	O
duration	O
of	O
4	O
.	O
7	O
years	O
.	O

Isolation	O
of	O
T	O
.	O
gambiense	O
strains	O
in	O
Zaire	O
and	O
their	O
adaptation	O
to	O
laboratory	O
animals	O
.	O

The	O
mRNA	O
identified	O
in	O
both	O
human	O
and	O
rat	O
cells	O
with	O
the	O
human	B-protein
clathrin	I-protein
clone	O
revealed	O
transcripts	O
of	O
approximately	O
6	O
.	O
5	O
kb	O
,	O
which	O
is	O
consistent	O
with	O
the	O
predicted	O
180	O
kDa	O
molecular	O
weight	O
of	O
the	O
clathrin	B-protein
heavy	I-protein
chain	I-protein
.	O

Survival	O
of	O
111	O
Indium	O
-	O
labelled	O
autologous	O
platelets	O
was	O
studied	O
in	O
2	O
patients	O
after	O
correction	O
of	O
platelet	O
count	O
and	O
was	O
still	O
found	O
shortened	O
.	O

Analysis	O
of	O
mCTR	B-protein
mRNAs	I-protein
has	O
revealed	O
that	O
the	O
three	O
alternative	O
promoters	O
give	O
rise	O
to	O
at	O
least	O
seven	O
mCTR	B-protein
isoforms	I-protein
in	O
the	O
5	O
'	O
region	O
of	O
the	O
gene	O
and	O
generate	O
5	O
'	O
-	O
untranslated	O
regions	O
of	O
very	O
different	O
lengths	O
.	O

A	O
method	O
for	O
the	O
simultaneous	O
determination	O
of	O
de	O
(	O
N	O
-	O
methyl	O
)	O
-	O
N	O
-	O
ethyl	O
-	O
8	O
,	O
9	O
-	O
anhydroerythromycin	O
A	O
6	O
,	O
9	O
-	O
hemiacetal	O
(	O
EM523	O
,	O
I	O
)	O
and	O
its	O
three	O
metabolites	O
in	O
human	O
plasma	O
and	O
urine	O
has	O
been	O
developed	O
using	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
with	O
chemiluminescence	O
(	O
CL	O
)	O
detection	O
.	O

Expression	O
of	O
the	O
CYP11A1	B-protein
gene	I-protein
is	O
increased	O
by	O
hormones	O
,	O
such	O
as	O
adrenocorticotropin	B-protein
and	O
luteinizing	B-protein
hormone	I-protein
,	O
as	O
well	O
as	O
by	O
a	O
number	O
of	O
growth	B-protein
factors	I-protein
,	O
suggesting	O
that	O
its	O
promoter	O
may	O
contain	O
regulatory	O
elements	O
that	O
respond	O
to	O
multiple	O
signal	O
transduction	O
pathways	O
.	O

Deletion	O
analysis	O
of	O
the	O
ICL1	B-protein
promoter	I-protein
led	O
to	O
the	O
identification	O
of	O
an	O
upstream	O
activating	O
sequence	O
element	O
,	O
UASICL1	B-protein
(	O
5	B-protein
'	I-protein
CATTCATCCG	I-protein
3	I-protein
'	I-protein
)	O
,	O
necessary	O
and	O
sufficient	O
for	O
conferring	O
carbon	O
source	O
-	O
dependent	O
regulation	O
on	O
a	O
heterologous	O
reporter	O
gene	O
.	O

Cotransfections	O
with	O
ATF	B-protein
-	I-protein
2	I-protein
and	O
HNF	B-protein
-	I-protein
4	I-protein
expression	O
plasmids	O
resulted	O
in	O
additive	O
transactivation	O
of	O
the	O
apoCIII	B-protein
promoter	I-protein
.	O

Once	O
NGF	B-protein
administration	O
is	O
proven	O
effective	O
it	O
will	O
be	O
possible	O
to	O
develop	O
alternative	O
ways	O
of	O
NGF	B-protein
administration	O
.	O

Environmental	O
factors	O
were	O
more	O
important	O
in	O
the	O
older	O
cohorts	O
(	O
perhaps	O
because	O
of	O
less	O
reliable	O
recall	O
)	O
.	O

Two	O
-	O
dimensional	O
gel	O
electrophoresis	O
of	O
anti	B-protein
-	I-protein
p59fyn	I-protein
immunoprecipitates	O
obtained	O
from	O
non	O
-	O
transformed	O
resting	O
human	O
T	O
lymphocytes	O
resulted	O
in	O
the	O
identification	O
of	O
an	O
oligomeric	O
protein	O
complex	O
which	O
is	O
constitutively	O
formed	O
between	O
Fyn	B-protein
and	O
several	O
additional	O
phosphoproteins	O
(	O
pp43	B-protein
,	O
pp72	B-protein
,	O
pp85	B-protein
,	O
the	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
Pyk2	I-protein
,	O
as	O
well	O
as	O
the	O
two	O
recently	O
cloned	O
adaptor	O
proteins	O
,	O
SKAP55	B-protein
and	O
SLAP	B-protein
-	I-protein
130	I-protein
)	O
.	O

Sequence	O
analysis	O
of	O
the	O
zebrafish	B-protein
egr1	I-protein
coding	I-protein
region	I-protein
revealed	O
a	O
high	O
level	O
of	O
homology	O
to	O
the	O
mouse	O
,	O
rat	O
,	O
and	O
human	B-protein
Egr1	I-protein
genes	I-protein
with	O
the	O
notable	O
exception	O
of	O
a	O
polymorphic	O
,	O
triplet	O
nucleotide	O
repeat	O
sequence	O
in	O
the	O
region	O
coding	O
for	O
the	O
amino	O
terminus	O
of	O
the	O
Egr1	B-protein
protein	I-protein
.	O

However	O
,	O
no	O
studies	O
have	O
been	O
conducted	O
to	O
further	O
investigate	O
this	O
potentially	O
hazardous	O
effect	O
of	O
lidocaine	O
.	O

On	O
the	O
basis	O
of	O
these	O
unique	O
properties	O
,	O
the	O
newly	O
characterized	O
hemagglutinin	B-protein
has	O
been	O
termed	O
Limulus	B-protein
18K	I-protein
agglutination	I-protein
-	I-protein
aggregation	I-protein
factor	I-protein
(	O
18K	B-protein
-	I-protein
LAF	I-protein
)	O
.	O

Products	O
of	O
immune	O
cells	O
such	O
as	O
transfer	B-protein
factor	I-protein
and	O
lymphokines	O
form	O
the	O
third	O
and	O
possibly	O
most	O
important	O
group	O
of	O
immune	O
-	O
stimulating	O
agents	O
.	O

Its	O
clearance	O
has	O
been	O
found	O
to	O
be	O
decreased	O
(	O
typically	O
by	O
around	O
25	O
%	O
,	O
but	O
often	O
by	O
far	O
more	O
)	O
by	O
erythromycin	O
,	O
troleandomycin	O
(	O
triacetyloleandomycin	O
)	O
,	O
roxithromycin	O
,	O
enoxacin	O
,	O
ciprofloxacin	O
,	O
pefloxacin	O
,	O
norfloxacin	O
,	O
ofloxacin	O
,	O
fluoroquinolone	O
T	O
-	O
3262	O
,	O
pipemidic	O
acid	O
,	O
cimetidine	O
,	O
etintidine	O
,	O
propranolol	O
,	O
verapamil	O
,	O
diltiazem	O
,	O
nifedipine	O
,	O
furosemide	O
(	O
frusemide	O
)	O
,	O
at	O
least	O
some	O
anovulent	O
agents	O
,	O
viloxazine	O
,	O
allopurinol	O
,	O
ticlopidine	O
,	O
idrocilamide	O
,	O
thiabendazole	O
,	O
disulfiram	O
,	O
influenza	O
-	O
and	O
BCG	O
-	O
vaccination	O
,	O
interferon	B-protein
,	O
and	O
caffeine	O
(	O
half	O
-	O
life	O
increase	O
)	O
.	O

Grippers	O
with	O
integrated	O
piezoresistive	O
force	O
sensors	O
and	O
with	O
attached	O
strain	O
gauges	O
have	O
been	O
reported	O
.	O

Advanced	O
adenoma	O
was	O
defined	O
as	O
an	O
adenoma	O
larger	O
than	O
10	O
mm	O
or	O
an	O
adenoma	O
of	O
any	O
size	O
with	O
villous	O
component	O
,	O
high	O
-	O
grade	O
dysplasia	O
or	O
invasive	O
carcinoma	O
.	O

Here	O
,	O
we	O
identified	O
three	O
cis	O
-	O
elements	O
required	O
for	O
replication	O
within	O
the	O
200	O
bp	O
promoter	O
,	O
using	O
autonomously	O
replicating	O
plasmids	O
carrying	O
various	O
mutations	O
and	O
deletions	O
.	O

Oligonucleotides	O
,	O
designed	O
on	O
the	O
basis	O
of	O
conserved	O
flanking	O
amino	O
acid	O
sequence	O
segments	O
within	O
the	O
catalytic	O
domain	O
of	O
eukaryotic	B-protein
protein	I-protein
kinase	I-protein
C	I-protein
(	I-protein
PKC	I-protein
)	I-protein
proteins	I-protein
,	O
were	O
used	O
as	O
primers	O
for	O
polymerase	O
chain	O
reactions	O
to	O
amplify	O
a	O
427	O
-	O
bp	O
chromosomal	O
DNA	O
fragment	O
from	O
the	O
filamentous	O
fungus	O
Trichoderma	O
reesei	O
.	O

Two	O
patients	O
were	O
treated	O
successfully	O
with	O
a	O
combination	O
of	O
metronidazole	O
(	O
a	O
tissue	O
amoebicide	O
)	O
and	O
diloxanide	O
(	O
a	O
lumenal	O
amoebicide	O
)	O
.	O

The	O
interindividual	O
variability	O
of	O
the	O
parameters	O
is	O
taken	O
into	O
consideration	O
by	O
interactively	O
determining	O
the	O
threshold	O
levels	O
.	O

Merlie	O
,	O
Cold	O
Spring	O
Harbor	O
Symp	O
.	O

Late	O
complications	O
of	O
catheterisation	O
for	O
intravenous	O
nutrition	O
[	O
letter	O
]	O
.	O

To	O
investigate	O
the	O
mechanisms	O
involved	O
in	O
the	O
transcriptional	O
control	O
of	O
retinoid	B-protein
X	I-protein
receptor	I-protein
(	O
RXR	B-protein
)	O
gene	O
expression	O
,	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
human	B-protein
RXRgamma2	I-protein
isoform	I-protein
was	O
characterized	O
.	O

The	O
E1	B-protein
gene	I-protein
is	O
located	O
within	O
the	O
first	O
intron	O
of	O
the	O
gene	O
for	O
RCC1	B-protein
,	O
a	O
protein	O
that	O
regulates	O
onset	O
of	O
mitosis	O
.	O

Young	O
CD	O
-	O
1	O
mice	O
,	O
4	O
days	O
old	O
,	O
exposed	O
to	O
0	O
.	O
1	O
%	O
nicotine	O
sulfate	O
on	O
gestational	O
days	O
6	O
-	O
20	O
were	O
compared	O
with	O
untreated	O
pups	O
of	O
the	O
same	O
age	O
to	O
determine	O
its	O
effect	O
on	O
the	O
development	O
of	O
mandibular	O
first	O
molars	O
.	O

Here	O
we	O
demonstrate	O
that	O
AML1a	B-protein
,	O
which	O
solely	O
has	O
no	O
effects	O
as	O
a	O
transcriptional	O
regulator	O
,	O
dominantly	O
suppresses	O
transcriptional	O
activation	O
by	O
AML1b	B-protein
,	O
and	O
that	O
AML1a	B-protein
exhibits	O
the	O
higher	O
affinity	O
for	O
DNA	O
-	O
binding	O
than	O
AML1b	B-protein
.	O

Four	O
patients	O
(	O
group	O
1	O
)	O
had	O
type	O
I	O
basement	O
membrane	O
nephropathy	O
,	O
characterized	O
by	O
marked	O
thickening	O
and	O
lamellation	O
of	O
the	O
basement	O
membrane	O
in	O
a	O
pattern	O
resembling	O
that	O
of	O
Alport	O
'	O
s	O
syndrome	O
.	O

A	O
genetic	O
screen	O
in	O
yeast	O
has	O
allowed	O
us	O
to	O
identify	O
a	O
novel	O
transcriptional	O
factor	O
binding	O
to	O
the	O
GlRE	B-protein
,	O
i	O
.	O
e	O
.	O
the	O
chicken	B-protein
ovalbumin	I-protein
upstream	I-protein
promoter	I-protein
-	I-protein
transcription	I-protein
factor	I-protein
II	I-protein
(	O
COUP	B-protein
-	I-protein
TFII	I-protein
)	O
.	O

SAPK	B-protein
/	I-protein
JNK	I-protein
activation	O
was	O
completely	O
abolished	O
in	O
the	O
absence	O
of	O
MKK7	B-protein
,	O
even	O
though	O
expression	O
of	O
MKK4	B-protein
was	O
strongly	O
upregulated	O
in	O
mkk7	B-protein
(	I-protein
-	I-protein
/	I-protein
-	I-protein
)	I-protein
mast	O
cell	O
lines	O
,	O
and	O
phosphorylation	O
of	O
MKK4	B-protein
occurred	O
normally	O
in	O
response	O
to	O
multiple	O
stress	O
stimuli	O
.	O

In	O
a	O
PC12	O
cell	O
mutant	O
that	O
is	O
deficient	O
in	O
protein	B-protein
kinase	I-protein
A	I-protein
activity	O
(	O
AB	O
.	O
11	O
)	O
,	O
all	O
three	O
differentiating	O
agents	O
were	O
unable	O
to	O
down	O
-	O
regulate	O
nrg	B-protein
-	I-protein
1	I-protein
mRNA	I-protein
.	O

99mTc	O
-	O
HMPAO	O
was	O
distributed	O
in	O
the	O
territories	O
of	O
the	O
ACA	O
and	O
MCA	O
in	O
the	O
two	O
patients	O
who	O
were	O
treated	O
with	O
intraarterial	O
infusion	O
of	O
papaverine	O
from	O
the	O
C4	O
segment	O
,	O
but	O
was	O
distributed	O
only	O
to	O
the	O
territory	O
of	O
the	O
ACA	O
in	O
four	O
patients	O
who	O
were	O
treated	O
with	O
intraarterial	O
infusion	O
of	O
papaverine	O
from	O
the	O
C1	O
segment	O
at	O
1	O
ml	O
/	O
min	O
.	O

The	O
diabetic	O
state	O
was	O
characterized	O
by	O
mild	O
insulin	B-protein
deficiency	O
,	O
plasma	O
levels	O
being	O
73	O
%	O
of	O
controls	O
,	O
and	O
mild	O
hyperglycemia	O
,	O
with	O
nonfasting	O
plasma	O
glucose	O
levels	O
of	O
1	O
.	O
5	O
times	O
normal	O
.	O

Acquired	O
antithrombin	B-protein
deficiency	O
in	O
sepsis	O
.	O

Thrombolytic	O
therapy	O
in	O
spontaneous	O
coronary	O
artery	O
dissection	O
.	O

The	O
bearing	O
of	O
season	O
and	O
sequence	O
of	O
calving	O
on	O
frequency	O
of	O
male	O
,	O
female	O
and	O
total	O
calvings	O
in	O
Hariana	O
cows	O
.	O

Histological	O
evaluation	O
revealed	O
a	O
more	O
than	O
twofold	O
increase	O
in	O
the	O
number	O
of	O
interepithelial	O
mononuclear	O
cells	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
,	O
while	O
the	O
number	O
of	O
epithelial	O
cells	O
/	O
100	O
microns	O
of	O
villous	O
mucosa	O
and	O
the	O
mean	O
height	O
of	O
the	O
epithelial	O
cells	O
were	O
comparable	O
in	O
both	O
groups	O
.	O

8	O
%	O
(	O
95	O
%	O
CI	O
,	O
21	O
.	O
3	O
-	O
44	O
.	O
3	O
%	O
)	O
.	O

The	O
responsive	O
region	O
of	O
the	O
alpha	B-protein
2	I-protein
(	I-protein
V	I-protein
)	I-protein
collagen	I-protein
gene	I-protein
was	O
localized	O
to	O
a	O
fragment	O
including	O
100	O
bp	O
of	O
basal	O
promoter	O
and	O
150	O
bp	O
of	O
exon	O
1	O
sequences	O
,	O
which	O
contained	O
two	O
CRE	B-protein
-	I-protein
like	I-protein
elements	I-protein
.	O

A	O
model	O
with	O
age	O
and	O
weight	O
described	O
the	O
best	O
fit	O
for	O
TBBMD	O
,	O
whereas	O
age	O
,	O
weight	O
,	O
and	O
height	O
described	O
the	O
best	O
fit	O
for	O
total	O
body	O
TBBMC	O
.	O

In	O
view	O
of	O
the	O
short	O
t1	O
/	O
2	O
,	O
we	O
used	O
three	O
doses	O
/	O
day	O
.	O

These	O
findings	O
suggest	O
a	O
novel	O
ankyrin	O
-	O
independent	O
role	O
for	O
LAD	B-protein
-	I-protein
1	I-protein
related	O
to	O
FGFR	B-protein
signaling	O
.	O

To	O
facilitate	O
the	O
investigation	O
of	O
parameters	O
that	O
govern	O
selective	O
export	O
in	O
adenovirus	O
-	O
infected	O
cells	O
,	O
we	O
constructed	O
a	O
marked	O
human	O
beta	B-protein
-	I-protein
actin	I-protein
minigene	I-protein
under	O
the	O
control	O
of	O
the	O
glucocorticoid	B-protein
-	I-protein
inducible	I-protein
enhancer	I-protein
-	I-protein
promoter	I-protein
of	O
mouse	O
mammary	O
tumor	O
virus	O
and	O
introduced	O
it	O
into	O
the	O
left	O
end	O
of	O
the	O
adenovirus	O
type	O
5	O
(	O
Ad5	O
)	O
genome	O
.	O

A	O
human	B-protein
SPT3	I-protein
-	I-protein
TAFII31	I-protein
-	I-protein
GCN5	I-protein
-	I-protein
L	I-protein
acetylase	I-protein
complex	I-protein
distinct	O
from	O
transcription	B-protein
factor	I-protein
IID	I-protein
.	O

It	O
is	O
possible	O
that	O
cyclic	O
variations	O
in	O
heme	O
turnover	O
are	O
related	O
to	O
changes	O
in	O
erythrocyte	O
characteristics	O
during	O
the	O
progesterone	O
phase	O
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
a	O
cDNA	O
that	O
encodes	O
a	O
new	O
member	O
of	O
the	O
GTPase	B-protein
-	I-protein
activating	I-protein
protein	I-protein
(	O
GAP	B-protein
)	O
family	O
of	O
GTPase	B-protein
regulators	O
.	O

In	O
addition	O
,	O
CaMig1	B-protein
formed	O
specific	O
complexes	O
with	O
the	O
URS1	B-protein
region	I-protein
of	O
the	O
S	B-protein
.	I-protein
cerevisiae	I-protein
FBP1	I-protein
gene	I-protein
.	O

The	O
nucleotide	O
sequence	O
alignment	O
between	O
mouse	O
and	O
human	B-protein
CA	I-protein
IV	I-protein
shows	O
69	O
%	O
identity	O
in	O
the	O
coding	O
region	O
and	O
all	O
of	O
the	O
exon	O
-	O
intron	O
boundaries	O
are	O
conserved	O
,	O
as	O
are	O
the	O
sizes	O
of	O
the	O
introns	O
.	O

The	O
transcription	O
factor	O
Sp1	B-protein
bound	O
to	O
eight	O
sites	O
,	O
as	O
demonstrated	O
by	O
footprinting	O
assays	O
and	O
gel	O
shift	O
analysis	O
with	O
purified	O
Sp1	B-protein
.	O

Thus	O
,	O
a	O
negative	O
test	O
is	O
compatible	O
with	O
low	O
disease	O
activity	O
and	O
/	O
or	O
efficacy	O
of	O
calcium	O
antagonist	O
treatment	O
.	O

Structural	O
changes	O
in	O
the	O
C	O
-	O
terminus	O
of	O
Ca2	O
+	O
-	O
bound	O
rat	B-protein
S100B	I-protein
(	O
beta	B-protein
beta	I-protein
)	O
upon	O
binding	O
to	O
a	O
peptide	O
derived	O
from	O
the	O
C	O
-	O
terminal	O
regulatory	O
domain	O
of	O
p53	B-protein
.	O

These	O
disorders	O
include	O
low	O
-	O
back	O
pain	O
,	O
saddle	O
anesthesia	O
,	O
bilateral	O
sciatica	O
,	O
then	O
motor	O
weakness	O
of	O
the	O
lower	O
extremities	O
or	O
chronic	O
paraplegia	O
and	O
,	O
bladder	O
dysfunction	O
.	O

Weight	O
loss	O
reduces	O
arterial	O
pressure	O
by	O
a	O
decrease	O
in	O
intravascular	O
volume	O
and	O
cardiac	O
output	O
associated	O
with	O
a	O
fall	O
in	O
sympathetic	O
activity	O
.	O

A	O
promising	O
new	O
cement	O
,	O
4	O
-	O
META	O
/	O
MMA	O
-	O
TBB	O
opaque	O
resin	O
,	O
has	O
shown	O
remarkable	O
adhesive	O
properties	O
as	O
a	O
bone	O
cement	O
in	O
vivo	O
.	O

The	O
first	O
symptoms	O
of	O
enzootic	O
calcinosis	O
were	O
noted	O
in	O
March	O
1998	O
,	O
when	O
some	O
of	O
the	O
cows	O
developed	O
locomotor	O
abnormalities	O
.	O

These	O
results	O
indicate	O
that	O
TGF	B-protein
-	I-protein
betaf	I-protein
potentiates	O
the	O
c	B-protein
-	I-protein
fos	I-protein
SRE	I-protein
activated	O
by	O
PKC	B-protein
through	O
the	O
SRF	B-protein
binding	I-protein
site	I-protein
.	O

By	O
using	O
a	O
DNA	O
sequence	O
selected	O
for	O
its	O
ability	O
to	O
bind	O
recombinant	B-protein
BCL	I-protein
-	I-protein
6	I-protein
in	O
vitro	O
,	O
we	O
show	O
here	O
that	O
BCL	B-protein
-	I-protein
6	I-protein
is	O
present	O
in	O
DNA	O
-	O
binding	O
complexes	O
in	O
nuclear	O
extracts	O
from	O
various	O
B	O
-	O
cell	O
lines	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
protein	O
product	O
of	O
the	O
ref	B-protein
-	I-protein
1	I-protein
gene	I-protein
stimulates	O
the	O
DNA	O
binding	O
activity	O
of	O
Fos	B-protein
-	I-protein
Jun	I-protein
heterodimers	I-protein
,	O
Jun	B-protein
-	I-protein
Jun	I-protein
homodimers	I-protein
and	O
Hela	O
cell	O
AP	B-protein
-	I-protein
1	I-protein
proteins	I-protein
as	O
well	O
as	O
that	O
of	O
several	O
other	O
transcription	O
factors	O
including	O
NF	B-protein
-	I-protein
kappa	I-protein
B	I-protein
,	O
Myb	B-protein
and	O
members	O
of	O
the	O
ATF	B-protein
/	I-protein
CREB	I-protein
family	I-protein
.	O

The	O
data	O
obtained	O
up	O
to	O
now	O
only	O
suggest	O
the	O
future	O
potentiality	O
of	O
Bestatin	O
treatment	O
for	O
these	O
types	O
of	O
malignancy	O
.	O

Ki	B-protein
-	I-protein
ras4BVal	I-protein
-	I-protein
12	I-protein
transfectant	O
cells	O
expressed	O
2	O
-	O
fold	O
elevated	O
protein	O
levels	O
of	O
the	O
lysosomal	B-protein
cysteine	I-protein
protease	I-protein
cathepsin	I-protein
B	I-protein
but	O
did	O
not	O
up	O
-	O
regulate	O
cathepsin	B-protein
B	I-protein
mRNA	I-protein
expression	O
.	O

Fgd3	B-protein
and	O
FGD1	B-protein
share	O
a	O
high	O
degree	O
of	O
sequence	O
identity	O
that	O
spans	O
>	O
560	O
contiguous	O
amino	O
acid	O
residues	O
.	O

Conformational	O
studies	O
combining	O
secondary	O
structure	O
predictions	O
,	O
CD	O
and	O
NMR	O
spectroscopy	O
together	O
with	O
ELISA	O
assays	O
,	O
showed	O
that	O
the	O
greater	O
is	O
the	O
propensity	O
of	O
the	O
epitope	O
for	O
helix	O
formation	O
the	O
higher	O
is	O
the	O
recognition	O
by	O
anti	B-protein
-	I-protein
K159	I-protein
.	O

Spores	O
from	O
Rhizopus	O
stolonifer	O
were	O
suspended	O
in	O
distilled	O
water	O
(	O
1	O
x	O
10	O
(	O
6	O
)	O
spores	O
/	O
mL	O
)	O
and	O
used	O
as	O
starter	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
The	O
sexually	O
transmitted	O
diseases	O
(	O
STD	O
)	O
control	O
program	O
for	O
female	O
sex	O
workers	O
(	O
FSW	O
)	O
in	O
Lima	O
,	O
Peru	O
,	O
provided	O
periodic	O
serological	O
tests	O
for	O
syphilis	O
and	O
cervical	O
smears	O
for	O
gonococci	O
,	O
but	O
not	O
medication	O
for	O
STD	O
or	O
condoms	O
.	O

Ciprofloxacin	O
:	O
an	O
overview	O
of	O
adverse	O
experiences	O
.	O

Persistence	O
of	O
toxaphene	O
in	O
treated	O
lakes	O
.	O

Nevertheless	O
cryopreservation	O
of	O
spermatozoa	O
in	O
a	O
medium	O
containing	O
neither	O
SP	O
nor	O
biological	O
substances	O
could	O
offer	O
an	O
acceptable	O
cryoprotection	O
of	O
spermatozoa	O
to	O
be	O
used	O
in	O
assisted	O
fertilization	O
procedures	O
,	O
especially	O
for	O
intracytoplasmic	O
sperm	O
injection	O
.	O

Fenoldopam	O
,	O
a	O
dopamine	B-protein
receptor	I-protein
agonist	O
,	O
has	O
been	O
shown	O
,	O
in	O
animal	O
experiments	O
,	O
to	O
improve	O
renal	O
perfusion	O
.	O

Escherichia	O
coli	O
JRG582	O
is	O
an	O
ampD	B-protein
ampE	I-protein
deletion	O
derivative	O
of	O
strain	O
HfrH	O
and	O
accordingly	O
it	O
is	O
derepressed	O
for	O
expression	O
of	O
the	O
cloned	O
inducible	O
beta	B-protein
-	I-protein
lactamase	I-protein
gene	I-protein
of	O
Citrobacter	O
freundii	O
,	O
carried	O
on	O
plasmid	O
pNU305	O
.	O

Guinea	O
pigs	O
weighing	O
300	O
approximately	O
350	O
g	O
were	O
used	O
.	O

Alginate	B-protein
biosynthesis	O
is	O
controlled	O
by	O
a	O
complex	O
regulatory	O
mechanism	O
.	O

Molecules	O
of	O
NH3	O
are	O
capable	O
of	O
emitting	O
stimulated	O
radiation	O
(	O
MASER	O
)	O
.	O

A	O
simplified	O
thin	O
-	O
layer	O
chromatographic	O
determination	O
of	O
hippuric	O
acid	O
and	O
methylhippuric	O
acids	O
.	O

Mutations	O
in	O
the	O
nuclear	B-protein
gene	I-protein
CBP1	I-protein
of	I-protein
Saccharomyces	I-protein
cerevisiae	I-protein
result	O
in	O
degradation	O
of	O
mitochondrially	B-protein
encoded	I-protein
cytochrome	I-protein
b	I-protein
(	O
cob	B-protein
)	O
RNA	O
;	O
thus	O
,	O
the	O
cells	O
are	O
unable	O
to	O
respire	O
.	O

Radiative	O
corrections	O
to	O
beta	O
decay	O
and	O
the	O
possibility	O
of	O
a	O
fourth	O
generation	O
.	O

TFEC	B-protein
,	O
a	O
basic	B-protein
helix	I-protein
-	I-protein
loop	I-protein
-	I-protein
helix	I-protein
protein	I-protein
,	O
forms	O
heterodimers	O
with	O
TFE3	B-protein
and	O
inhibits	O
TFE3	O
-	O
dependent	O
transcription	O
activation	O
.	O

Ly	B-protein
-	I-protein
49	I-protein
is	O
a	O
family	B-protein
type	I-protein
II	I-protein
transmembrane	I-protein
proteins	I-protein
encoded	O
by	O
a	O
gene	O
cluster	O
on	O
murine	O
chromosome	O
6	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
crucial	O
role	O
of	O
the	O
mutations	O
activating	O
v	B-protein
-	I-protein
erbA	I-protein
as	O
an	O
oncogene	O
is	O
to	O
'	O
freeze	O
'	O
c	B-protein
-	I-protein
ErbA	I-protein
/	I-protein
TRalpha	I-protein
in	O
its	O
non	O
-	O
liganded	O
,	O
repressive	O
conformation	O
and	O
to	O
facilitate	O
its	O
overexpression	O
.	O

All	O
were	O
experienced	O
hearing	O
aid	O
users	O
who	O
wore	O
linear	O
Class	O
D	O
instruments	O
with	O
input	O
compression	O
limiting	O
at	O
the	O
time	O
of	O
their	O
enrollment	O
in	O
this	O
study	O
.	O

In	O
whole	O
sardine	O
,	O
domoic	O
acid	O
was	O
detected	O
in	O
levels	O
exceeding	O
sometimes	O
the	O
regulatory	O
limit	O
.	O

Comparison	O
of	O
beta	B-protein
2	I-protein
-	I-protein
microglobulin	I-protein
removal	O
using	O
the	O
same	O
polysulphone	O
membrane	O
for	O
haemodialysis	O
and	O
haemofiltration	O
shows	O
that	O
beta	B-protein
2	I-protein
-	I-protein
microglobulin	I-protein
is	O
more	O
effectively	O
removed	O
by	O
convection	O
than	O
by	O
diffusion	O
when	O
both	O
treatment	O
modes	O
are	O
matched	O
for	O
blood	O
flow	O
and	O
urea	O
clearance	O
.	O

The	O
mice	O
are	O
phenotypically	O
normal	O
and	O
do	O
not	O
develop	O
spontaneous	O
tumors	O
at	O
an	O
early	O
age	O
,	O
in	O
contrast	O
to	O
knock	O
-	O
out	O
(	O
p53	B-protein
(	I-protein
-	I-protein
/	I-protein
-	I-protein
)	I-protein
)	O
strains	O
with	O
a	O
defective	O
p53	B-protein
gene	I-protein
.	O

At	O
this	O
timepoint	O
,	O
many	O
leucocytes	O
in	O
the	O
ME	O
and	O
ET	O
mucosa	O
had	O
incorporated	O
BrdU	O
(	O
between	O
15	O
and	O
25	O
%	O
within	O
the	O
subsets	O
)	O
.	O

Effect	O
of	O
succimer	O
on	O
the	O
intensity	O
of	O
tricarboxylic	B-protein
acid	I-protein
dehydrogenase	I-protein
reactions	O
in	O
the	O
brain	O
of	O
rats	O
poisoned	O
with	O
mercuric	O
chloride	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
C	O
-	O
terminal	O
region	O
of	O
Crk	B-protein
contains	O
negative	O
regulatory	O
elements	O
important	O
for	O
both	O
Abl	B-protein
and	O
FAK	B-protein
dependent	O
signal	O
pathways	O
,	O
and	O
offers	O
a	O
paradigm	O
for	O
an	O
autoinhibitory	O
region	O
in	O
the	O
SH3	B-protein
linker	I-protein
/	I-protein
C	I-protein
-	I-protein
terminal	I-protein
SH3	I-protein
domain	I-protein
.	O

Adriamycin	O
:	O
comparison	O
of	O
a	O
5	O
-	O
week	O
schedule	O
with	O
a	O
3	O
-	O
week	O
schedule	O
in	O
the	O
treatment	O
of	O
breast	O
cancer	O
.	O

In	O
contrast	O
,	O
mutations	O
affecting	O
the	O
other	O
two	O
Nim1p	B-protein
-	I-protein
related	I-protein
kinases	I-protein
in	O
S	O
.	O
cerevisiae	O
,	O
Hsl1p	B-protein
and	O
Kcc4p	B-protein
,	O
produce	O
no	O
detectable	O
effect	O
on	O
septin	B-protein
organization	O
.	O

Group	O
psychometric	O
functions	O
for	O
listeners	O
with	O
hearing	O
loss	O
do	O
not	O
show	O
a	O
decrease	O
in	O
performance	O
at	O
the	O
largest	O
values	O
of	O
delta	O
f	O
included	O
in	O
this	O
study	O
.	O

Thus	O
,	O
blocks	O
in	O
the	O
RARalpha	O
-	O
specific	O
pathway	O
of	O
retinoid	O
-	O
induced	O
differentiation	O
may	O
be	O
bypassed	O
during	O
retinoid	O
induction	O
of	O
FR	B-protein
-	I-protein
beta	I-protein
expression	O
.	O

Once	O
the	O
proliferation	O
of	O
fibroblasts	O
and	O
collagen	B-protein
synthesis	O
had	O
led	O
to	O
an	O
increase	O
of	O
mechanical	O
strength	O
,	O
no	O
negative	O
effect	O
on	O
wound	O
healing	O
could	O
be	O
detected	O
applying	O
the	O
same	O
chemotherapeutic	O
agents	O
.	O

In	O
10	O
pentobarbitalized	O
dogs	O
,	O
plasma	O
viscosity	O
(	O
Ep	O
)	O
was	O
raised	O
fourfold	O
while	O
apparent	O
blood	O
viscosity	O
(	O
Ea	O
)	O
increased	O
about	O
twofold	O
by	O
two	O
steps	O
of	O
exchange	O
transfusion	O
of	O
200	O
ml	O
of	O
plasma	O
with	O
plasma	O
containing	O
high	O
molecular	O
weight	O
dextran	O
(	O
mol	O
wt	O
500	O
,	O
000	O
,	O
20	O
%	O
wt	O
/	O
vol	O
)	O
.	O

After	O
overtraining	O
on	O
the	O
original	O
discrimination	O
,	O
the	O
controls	O
showed	O
the	O
normal	O
difficulty	O
in	O
learning	O
the	O
first	O
reversal	O
.	O

Interestingly	O
,	O
the	O
activity	O
of	O
IkappaB	B-protein
kinase	I-protein
(	O
IKK	B-protein
-	I-protein
beta	I-protein
)	O
,	O
which	O
plays	O
an	O
essential	O
role	O
in	O
NF	B-protein
-	I-protein
kappaB	I-protein
activation	O
through	O
IkappaB	B-protein
phosphorylation	O
,	O
was	O
largely	O
enhanced	O
in	O
paclitaxel	O
-	O
treated	O
cells	O
,	O
detected	O
as	O
IkappaBalpha	B-protein
phosphorylation	O
.	O

We	O
evaluated	O
regional	O
right	O
ventricular	O
wall	O
motion	O
during	O
systole	O
in	O
patients	O
with	O
surgically	O
repaired	O
tetralogy	O
of	O
Fallot	O
(	O
TOF	O
)	O
using	O
color	O
kinesis	O
imaging	O
.	O

The	O
effect	O
of	O
Rho	B-protein
on	O
AP	B-protein
-	I-protein
1	I-protein
is	O
independent	O
of	O
the	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
pathway	I-protein
,	O
as	O
a	O
dominant	B-protein
-	I-protein
negative	I-protein
MEK	I-protein
and	O
a	O
MEK	B-protein
inhibitor	O
(	O
PD98059	O
)	O
did	O
not	O
affect	O
Rho	B-protein
-	I-protein
induced	I-protein
AP	I-protein
-	I-protein
1	I-protein
activity	O
.	O

Influence	O
of	O
oil	O
emulsions	O
and	O
diphenyl	O
on	O
post	O
-	O
harvest	O
physiconutritional	O
changes	O
in	O
Kagzi	O
limes	O
(	O
Citrus	O
aurantifolia	O
)	O
was	O
studied	O
.	O

IFN	B-protein
-	I-protein
stimulated	I-protein
gene	I-protein
factor	I-protein
-	I-protein
3	I-protein
and	O
STAT1	B-protein
homodimers	I-protein
formed	O
and	O
bound	O
an	O
IFN	B-protein
-	I-protein
stimulated	I-protein
response	I-protein
element	I-protein
(	O
ISRE	B-protein
)	O
and	O
gamma	B-protein
-	I-protein
activated	I-protein
sequence	I-protein
(	O
GAS	B-protein
)	O
element	O
,	O
respectively	O
.	O

Re	O
:	O
A	O
modified	O
method	O
for	O
the	O
in	O
vivo	O
labeling	O
of	O
red	O
blood	O
cells	O
with	O
Tc	O
-	O
99m	O
.	O

ORF	B-protein
M1	I-protein
has	O
striking	O
homology	O
to	O
poxvirus	O
serpins	B-protein
,	O
while	O
ORF	B-protein
M11	I-protein
encodes	O
a	O
potential	O
homolog	O
of	O
Bcl	B-protein
-	I-protein
2	I-protein
-	I-protein
like	I-protein
molecules	I-protein
encoded	O
by	O
other	O
gammaherpesviruses	O
(	O
gene	B-protein
16	I-protein
of	O
HVS	O
and	O
KSHV	O
and	O
the	O
BHRF1	B-protein
gene	I-protein
of	O
EBV	O
)	O
.	O

Two	O
hundred	O
sixty	O
-	O
four	O
patients	O
scheduled	O
for	O
DCBM	O
were	O
randomized	O
to	O
receive	O
intravenously	O
geG	O
0	O
.	O
25	O
mg	O
(	O
geG	O
-	O
25	O
)	O
,	O
or	O
geG	O
0	O
.	O
5	O
mg	O
(	O
geG	O
-	O
50	O
)	O
,	O
or	O
HBB	O
20	O
mg	O
as	O
hypotonic	O
agent	O
.	O

Estrogen	O
replacement	O
,	O
either	O
as	O
17	O
beta	O
-	O
estradiol	O
or	O
beta	O
-	O
estradiol	O
-	O
3	O
-	O
benzoate	O
via	O
subcutaneous	O
Silastic	O
capsules	O
,	O
was	O
associated	O
with	O
elevated	O
rates	O
of	O
heat	O
production	O
and	O
dry	O
heat	O
loss	O
relative	O
to	O
untreated	O
ovariectomized	O
controls	O
.	O

Sodium	O
restriction	O
in	O
cardiac	O
failure	O
.	O

Rapamycin	O
(	O
FRAP	B-protein
/	I-protein
mTOR	I-protein
inhibitor	O
)	O
blocked	O
4E	B-protein
-	I-protein
BP1	I-protein
phosphorylation	O
causing	O
a	O
predominance	O
of	O
the	O
alpha	O
(	O
hypophosphorylated	O
)	O
band	O
.	O

A	O
unique	O
leucine	B-protein
-	I-protein
proline	I-protein
repeat	I-protein
element	I-protein
found	O
N	O
-	O
terminal	O
to	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
EmBP	B-protein
-	I-protein
1	I-protein
does	O
not	O
appear	O
to	O
play	O
a	O
role	O
in	O
DNA	O
-	O
binding	O
or	O
dimerization	O
.	O

Endosonography	O
accurately	O
assessed	O
tumor	O
extension	O
in	O
two	O
T2	O
tumors	O
,	O
14	O
T3	O
tumors	O
,	O
and	O
seven	O
T4	O
tumors	O
.	O

The	O
PDE4A	B-protein
-	I-protein
subfamily	I-protein
-	I-protein
specific	I-protein
linker	I-protein
region	I-protein
LR1	I-protein
,	O
which	O
joins	O
UCR1	B-protein
and	O
UCR2	B-protein
,	O
is	O
encoded	O
by	O
two	O
exons	O
,	O
whereas	O
LR2	B-protein
,	O
which	O
joins	O
UCR2	B-protein
to	O
the	O
catalytic	O
unit	O
,	O
is	O
encoded	O
by	O
a	O
single	O
exon	O
.	O

Range	O
behavior	O
of	O
Hereford	O
,	O
Hereford	O
x	O
Holstein	O
and	O
Holstein	O
non	O
-	O
lactating	O
heifers	O
.	O

Oxidative	O
degradation	O
of	O
adrenaline	O
solutions	O
:	O
study	O
of	O
the	O
intermediate	O
stages	O
and	O
their	O
analytic	O
value	O
for	O
the	O
control	O
of	O
this	O
solute	O
.	O

Forskolin	O
treatment	O
(	O
10	O
microM	O
)	O
of	O
the	O
transfected	O
cells	O
for	O
3	O
-	O
-	O
6	O
h	O
maximally	O
induced	O
luciferase	B-protein
threefold	O
.	O

We	O
have	O
used	O
these	O
modified	O
assay	O
conditions	O
to	O
extend	O
studies	O
on	O
the	O
transposition	O
pathway	O
.	O

Thirty	O
Class	O
I	O
and	O
Class	O
II	O
recessions	O
in	O
30	O
patients	O
were	O
treated	O
with	O
a	O
modified	O
subepithelial	O
connective	O
tissue	O
graft	O
procedure	O
.	O

The	O
results	O
also	O
imply	O
that	O
the	O
absence	O
of	O
perforin	B-protein
expression	O
in	O
non	O
-	O
cytotoxic	O
cells	O
may	O
be	O
due	O
to	O
the	O
suppression	O
of	O
the	O
induction	O
of	O
the	O
killer	O
-	O
cell	O
-	O
specific	O
trans	O
-	O
acting	O
factor	O
NF	B-protein
-	I-protein
P2	I-protein
.	O

Vibrio	O
cholerae	O
O139	O
in	O
Calcutta	O
.	O

A	O
brief	O
account	O
of	O
the	O
1988	O
seminar	O
in	O
Shanghai	O
on	O
viral	O
hepatitis	O
A	O
.	O

To	O
characterize	O
the	O
expression	O
of	O
this	O
DNA	B-protein
repair	I-protein
enzyme	I-protein
,	O
we	O
have	O
isolated	O
the	O
corresponding	O
genomic	O
clone	O
.	O

Snail	O
mortality	O
did	O
not	O
differ	O
among	O
the	O
various	O
treatment	O
conditions	O
.	O

The	O
effect	O
of	O
a	O
constant	O
magnetic	O
field	O
on	O
the	O
phagocytic	O
activity	O
of	O
Paramecia	O
.	O

However	O
,	O
one	O
CAK	O
-	O
phosphorylated	O
phosphopeptide	O
comigrates	O
with	O
a	O
Cdc2	O
-	O
phosphorylated	O
phosphopeptide	O
previously	O
shown	O
to	O
be	O
mitosis	O
-	O
specific	O
,	O
suggesting	O
that	O
,	O
in	O
vitro	O
,	O
CAK	B-protein
is	O
able	O
to	O
phosphorylate	O
at	O
least	O
one	O
site	O
that	O
is	O
also	O
phosphorylated	O
in	O
vivo	O
.	O

The	O
5	O
-	O
year	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
rates	O
were	O
58	O
.	O
9	O
%	O
and	O
55	O
.	O
4	O
%	O
for	O
arm	O
A	O
and	O
44	O
.	O
5	O
%	O
and	O
41	O
.	O
3	O
%	O
for	O
arm	O
B	O
(	O
P	O
=	O
.	O
007	O
and	O
P	O
=	O
.	O
02	O
)	O
,	O
respectively	O
.	O

Overall	O
least	O
-	O
squares	O
means	O
for	O
uncooked	O
and	O
cooked	O
longissimus	O
muscle	O
and	O
subcutaneous	O
fat	O
were	O
63	O
.	O
32	O
,	O
80	O
.	O
27	O
and	O
98	O
.	O
90	O
mg	O
of	O
cholesterol	O
/	O
100	O
g	O
of	O
tissue	O
,	O
respectively	O
.	O

Sequence	O
analysis	O
of	O
the	O
isolated	O
genomic	O
clone	O
revealed	O
that	O
the	O
DNA	O
binding	O
domain	O
of	O
this	O
orphan	B-protein
receptor	I-protein
is	O
most	O
homologous	O
to	O
the	O
human	B-protein
TR2	I-protein
receptor	I-protein
.	O

Interestingly	O
,	O
this	O
amino	O
-	O
terminal	O
determinant	O
appears	O
not	O
to	O
reside	O
in	O
the	O
HSV	O
-	O
alpha	O
TIF	B-protein
,	O
which	O
displays	O
no	O
independent	O
amino	O
-	O
terminal	O
activity	O
.	O

UVA	O
-	O
induced	O
melanocytic	O
lesions	O
.	O

The	O
hybrid	O
viruses	O
were	O
found	O
to	O
accumulate	O
to	O
high	O
levels	O
in	O
infected	O
plants	O
,	O
to	O
form	O
stable	O
virions	O
,	O
and	O
to	O
be	O
mechanically	O
transmissible	O
.	O

The	O
ORs	O
of	O
GC	O
,	O
adjusted	O
for	O
age	O
and	O
sex	O
,	O
varied	O
from	O
17	O
.	O
1	O
,	O
for	O
those	O
with	O
baseline	O
diagnoses	O
of	O
superficial	O
intestinal	O
metaplasia	O
(	O
IM	O
)	O
,	O
to	O
29	O
.	O
3	O
,	O
for	O
those	O
with	O
deep	O
IM	O
or	O
mild	O
dysplasia	O
(	O
DYS	O
)	O
or	O
IM	O
with	O
glandular	O
atrophy	O
and	O
neck	O
hyperplasia	O
,	O
to	O
104	O
.	O
2	O
,	O
for	O
those	O
with	O
moderate	O
or	O
severe	O
DYS	O
,	O
as	O
compared	O
with	O
subjects	O
with	O
superficial	O
gastritis	O
(	O
SG	O
)	O
or	O
chronic	O
atrophic	O
gastritis	O
(	O
CAG	O
)	O
at	O
baseline	O
.	O

Lesions	O
were	O
made	O
by	O
pressure	O
injection	O
of	O
kainic	O
acid	O
into	O
the	O
SOC	O
through	O
a	O
stereotaxically	O
positioned	O
glass	O
micropipette	O
.	O

Analysis	O
of	O
the	O
intact	O
hGH	B-protein
gene	I-protein
or	O
hGH	B-protein
5	I-protein
'	I-protein
-	I-protein
flanking	I-protein
DNA	I-protein
(	I-protein
5	I-protein
'	I-protein
-	I-protein
FR	I-protein
)	I-protein
coupled	O
to	O
the	O
hGh	B-protein
cDNA	I-protein
or	O
chloramphenicol	B-protein
acetyltransferase	I-protein
or	O
luciferase	B-protein
genes	I-protein
,	O
indicated	O
that	O
cAMP	O
primarily	O
stimulated	O
hGH	B-protein
promoter	I-protein
activity	O
.	O

Clone	O
39	O
was	O
a	O
homolog	O
of	O
CONSTANS	B-protein
,	O
which	O
is	O
a	O
gene	O
involved	O
in	O
controlling	O
the	O
flowering	O
time	O
in	O
Arabidopsis	O
.	O

Here	O
we	O
describe	O
the	O
identification	O
and	O
characterization	O
of	O
several	O
Sp100	B-protein
splice	I-protein
variant	I-protein
proteins	I-protein
and	O
support	O
their	O
existence	O
by	O
elucidation	O
of	O
the	O
3	O
'	O
-	O
end	O
of	O
the	O
Sp100	B-protein
gene	I-protein
.	O

Although	O
linker	O
regions	O
in	O
transcription	O
factors	O
are	O
known	O
to	O
modulate	O
DNA	O
binding	O
specificity	O
,	O
our	O
studies	O
suggest	O
that	O
the	O
human	B-protein
HSF1	I-protein
linker	O
plays	O
no	O
role	O
in	O
determining	O
HSF1	B-protein
binding	O
preferences	O
in	O
vivo	O
but	O
is	O
a	O
critical	O
determinant	O
in	O
regulating	O
the	O
HSF1	B-protein
monomer	I-protein
-	I-protein
trimer	I-protein
equilibrium	O
.	O

They	O
also	O
negatively	O
modulate	O
the	O
PI	B-protein
3	I-protein
-	I-protein
kinase	I-protein
catalytic	O
activity	O
but	O
to	O
different	O
extents	O
,	O
dependent	O
on	O
the	O
unique	O
N	O
-	O
terminal	O
structure	O
of	O
each	O
isoform	O
.	O

In	O
contrast	O
,	O
the	O
PPSF	O
+	O
DBP	O
side	O
showed	O
large	O
amounts	O
of	O
bone	O
formation	O
,	O
and	O
bone	O
almost	O
covered	O
the	O
implant	O
.	O

Clinicopathologic	O
studies	O
in	O
feminizing	O
tumors	O
of	O
the	O
ovary	O
.	O

A	O
case	O
of	O
a	O
dense	O
epidermoid	O
cyst	O
of	O
the	O
suprasellar	O
cistern	O
is	O
presented	O
.	O

The	O
divergence	O
in	O
primary	O
structure	O
between	O
the	O
sheep	O
CRF1	B-protein
and	O
the	O
other	O
mammalian	B-protein
CRF1s	I-protein
is	O
primarily	O
localized	O
to	O
the	O
extracellular	O
amino	O
terminal	O
domain	O
of	O
the	O
receptor	O
(	O
18	O
of	O
22	O
divergent	O
residues	O
,	O
ovine	O
vs	O
human	B-protein
CRF1	I-protein
)	O
.	O

Comparison	O
of	O
human	B-protein
and	I-protein
murine	I-protein
blk	I-protein
sequences	I-protein
indicated	O
that	O
they	O
share	O
86	O
%	O
amino	O
acid	O
identity	O
,	O
the	O
most	O
conserved	O
region	O
being	O
the	O
catalytic	O
domain	O
(	O
93	O
%	O
identity	O
)	O
.	O

An	O
experiment	O
on	O
the	O
return	O
-	O
of	O
-	O
fear	O
(	O
ROF	O
)	O
was	O
carried	O
out	O
on	O
40	O
snake	O
-	O
or	O
spider	O
-	O
phobic	O
subjects	O
in	O
order	O
to	O
determine	O
whether	O
an	O
arousing	O
event	O
that	O
occurs	O
shortly	O
before	O
retest	O
influences	O
the	O
magnitude	O
of	O
the	O
ROF	O
.	O

Members	O
of	O
the	O
Ras	B-protein
subfamily	I-protein
of	O
small	B-protein
GTP	I-protein
-	I-protein
binding	I-protein
proteins	I-protein
have	O
been	O
shown	O
to	O
be	O
promiscuous	O
towards	O
a	O
variety	O
of	O
putative	O
effector	O
molecules	O
such	O
as	O
the	O
protein	B-protein
kinase	I-protein
c	I-protein
-	I-protein
Raf	I-protein
and	O
the	O
Ral	B-protein
-	I-protein
specific	I-protein
guanine	I-protein
nucleotide	I-protein
exchange	I-protein
factor	I-protein
(	O
Ral	B-protein
-	I-protein
GEF	I-protein
)	O
.	O

Targeted	O
disruption	O
of	O
the	O
OGG1	B-protein
gene	I-protein
in	O
yeast	O
revealed	O
a	O
second	O
OG	B-protein
glycosylase	I-protein
/	I-protein
lyase	I-protein
protein	I-protein
,	O
tentatively	O
named	O
Ogg2	B-protein
,	O
which	O
differs	O
from	O
Ogg1	B-protein
in	O
that	O
it	O
preferentially	O
acts	O
on	O
OG	O
:	O
G	O
.	O

Ectopic	O
expression	O
of	O
Apo	B-protein
-	I-protein
3	I-protein
in	O
HEK293	O
or	O
HeLa	O
cells	O
induced	O
marked	O
apoptosis	O
.	O

Here	O
we	O
report	O
the	O
complete	O
6	O
-	O
kilobase	O
cDNA	O
sequence	O
coding	O
for	O
a	O
chain	O
of	O
1775	O
amino	O
acids	O
,	O
as	O
well	O
as	O
the	O
genomic	O
structure	O
.	O

Regulation	O
of	O
RhoA	B-protein
is	O
required	O
to	O
maintain	O
adhesion	O
in	O
stationary	O
cells	O
,	O
but	O
is	O
also	O
critical	O
for	O
cell	O
spreading	O
and	O
migration	O
[	O
3	O
]	O
.	O

Prolonged	O
heavy	O
work	O
effected	O
an	O
increase	O
of	O
10	O
.	O
3	O
plus	O
or	O
minus	O
0	O
.	O
9	O
mmHg	O
in	O
in	O
vivo	O
P50	O
(	O
7	O
.	O
30	O
PH	O
-	O
v	O
,	O
41	O
degrees	O
C	O
-	O
v	O
,	O
and	O
45	O
Pv	O
-	O
CO2	O
)	O
;	O
due	O
entirely	O
to	O
the	O
additive	O
effects	O
of	O
increased	O
venous	O
temperature	O
and	O
[	O
H	O
+	O
]	O
.	O

Atmospheric	O
benzene	O
,	O
urinary	O
muconic	O
acid	O
(	O
tt	O
-	O
MA	O
)	O
and	O
leukocyte	B-protein
alkaline	I-protein
phosphatase	I-protein
activity	O
(	O
LAPA	O
)	O
were	O
evaluated	O
among	O
66	O
car	O
mechanics	O
,	O
34	O
road	O
tanker	O
drivers	O
,	O
and	O
28	O
nonexposed	O
workers	O
.	O

These	O
results	O
indicate	O
that	O
residue	O
266	O
serves	O
as	O
a	O
`	O
`	O
protein	O
sensor	O
'	O
'	O
of	O
altered	O
minor	O
groove	O
interactions	O
and	O
identifies	O
which	O
base	O
pair	O
interactions	O
are	O
altered	O
by	O
these	O
lesions	O
.	O

Supraventricular	O
arrhythmias	O
-	O
-	O
digoxin	O
and	O
quinidine	O
revisited	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
functional	O
role	O
of	O
the	O
other	O
MAP	B-protein
kinases	I-protein
in	O
PDGF	O
-	O
mediated	O
cellular	O
responses	O
.	O

Biological	O
action	O
and	O
kinetics	O
of	O
the	O
elimination	O
of	O
tritium	O
oxide	O
in	O
dogs	O
.	O

Chordoma	O
of	O
the	O
spinal	O
cord	O
in	O
a	O
F344	O
rat	O
.	O

Does	O
afferent	O
loop	O
syndrome	O
exist	O
?	O
It	O
is	O
the	O
author	O
'	O
s	O
opinion	O
that	O
diagnosis	O
of	O
the	O
`	O
`	O
adducent	O
loop	O
syndrome	O
'	O
'	O
is	O
unlikely	O
to	O
be	O
correct	O
in	O
patients	O
subjected	O
to	O
Billroth	O
-	O
II	O
gastrectomy	O
.	O

The	O
active	O
derivatives	O
of	O
the	O
present	O
series	O
were	O
also	O
tested	O
for	O
their	O
analgesic	O
activity	O
against	O
aconitine	O
-	O
induced	O
writhing	O
in	O
albino	O
mice	O
and	O
ulcerogenic	O
activity	O
in	O
albino	O
rats	O
.	O

Human	B-protein
Duo	I-protein
contains	O
a	O
guanine	B-protein
nucleotide	I-protein
exchange	I-protein
factor	I-protein
(	O
GEF	B-protein
)	O
domain	O
that	O
is	O
likely	O
to	O
be	O
rac1	O
-	O
specific	O
,	O
a	O
pleckstrin	B-protein
homology	I-protein
(	O
PH	B-protein
)	O
domain	O
and	O
spectrin	B-protein
-	I-protein
like	I-protein
repeat	I-protein
units	I-protein
.	O

The	O
relations	O
between	O
type	O
A	O
behavior	O
,	O
clinically	O
relevant	O
behavior	O
,	O
academic	O
achievement	O
,	O
and	O
IQ	O
in	O
children	O
.	O

The	O
results	O
suggest	O
that	O
the	O
greater	O
estrogenic	O
influence	O
associated	O
with	O
the	O
ethinyl	O
estradiol	O
-	O
containing	O
OC	O
resulted	O
in	O
inhibition	O
of	O
coronary	O
artery	O
atherosclerosis	O
despite	O
a	O
pronounced	O
progestin	O
-	O
induced	O
lowering	O
of	O
plasma	O
HDL	O
cholesterol	O
concentration	O
and	O
,	O
further	O
,	O
that	O
hormonal	O
balance	O
may	O
have	O
a	O
marked	O
influence	O
on	O
the	O
relationship	O
between	O
plasma	O
lipids	O
and	O
atherogenesis	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
a	O
mammalian	O
cell	O
-	O
free	O
transcription	O
system	O
reconstituted	O
with	O
only	O
recombinant	O
proteins	O
and	O
epitope	O
-	O
tagged	O
multiprotein	O
complexes	O
.	O

Physical	O
analysis	O
maps	O
SAL6	B-protein
to	O
chromosome	O
XVI	O
between	O
TPK2	B-protein
and	O
spt14	B-protein
.	O

Calcium	O
and	O
phosphorus	O
metabolism	O
in	O
chronic	O
uremia	O
.	O

Role	O
of	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
baculovirus	B-protein
p10	I-protein
mRNA	I-protein
in	O
high	O
-	O
level	O
expression	O
of	O
foreign	O
genes	O
.	O

The	O
three	O
isoforms	O
purified	O
with	O
anti	B-protein
-	I-protein
FLAG	I-protein
antibody	I-protein
affinity	O
column	O
transferred	O
sulfate	O
to	O
heparan	O
sulfate	O
and	O
heparin	O
but	O
not	O
to	O
other	O
glycosaminoglycans	O
.	O

Higher	O
fasting	O
serum	O
gastrin	B-protein
concentration	O
(	O
102	O
.	O
0	O
+	O
/	O
-	O
21	O
.	O
1	O
vs	O
63	O
.	O
3	O
+	O
/	O
-	O
8	O
.	O
3	O
ng	O
.	O
l	O
-	O
1	O
)	O
,	O
and	O
greater	O
postprandial	O
gastrin	B-protein
release	O
(	O
AUC0	O
-	O
120	O
:	O
16690	O
+	O
/	O
-	O
2648	O
vs	O
10654	O
+	O
/	O
-	O
1283	O
ng	O
.	O
l	O
-	O
1	O
min	O
)	O
were	O
observed	O
after	O
VTP	O
-	O
HM	O
than	O
after	O
VTP	O
-	O
Cas	O
.	O

Second	O
,	O
the	O
transcription	B-protein
factor	I-protein
Gal	I-protein
-	I-protein
ER	I-protein
was	O
rendered	O
more	O
potent	O
and	O
less	O
susceptible	O
to	O
cell	O
type	O
-	O
specific	O
variation	O
by	O
fusing	O
the	O
strong	O
activating	O
domain	O
of	O
the	O
herpesvirus	B-protein
protein	I-protein
VP16	I-protein
onto	O
its	O
C	O
terminus	O
.	O

A	O
progressive	O
growth	O
of	O
blood	O
erythrocyte	O
membrane	O
injury	O
has	O
been	O
demonstrated	O
after	O
rats	O
were	O
exposed	O
to	O
gamma	O
-	O
irradiaton	O
at	O
a	O
dose	O
of	O
100	O
to	O
500	O
Gy	O
.	O

VDR	B-protein
/	I-protein
RXR	I-protein
bound	O
well	O
to	O
the	O
VDREs	B-protein
and	O
to	O
DR4	B-protein
and	O
DR5	B-protein
using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Acad	O
.	O

The	O
amplitudes	O
of	O
DPOAE	O
also	O
recovered	O
to	O
a	O
greater	O
extent	O
and	O
outer	O
hair	O
cell	O
losses	O
were	O
less	O
severe	O
in	O
the	O
R	O
-	O
PIA	O
-	O
treated	O
ears	O
.	O

Furthermore	O
,	O
beta	B-protein
2	I-protein
-	I-protein
adrenoceptor	I-protein
sensitivity	O
appears	O
to	O
be	O
unaltered	O
in	O
BHT	O
.	O

Fifty	O
-	O
eight	O
RMI	O
'	O
s	O
occurred	O
in	O
the	O
placebo	O
group	O
as	O
compared	O
to	O
only	O
twenty	O
in	O
the	O
AC	O
group	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

HYPOTHESIS	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
oxidative	O
susceptibility	O
of	O
apolipoprotein	B-protein
B	I-protein
-	I-protein
containing	I-protein
lipoproteins	I-protein
and	O
antioxidant	O
status	O
in	O
patients	O
with	O
acute	O
coronary	O
syndromes	O
and	O
chronic	O
stable	O
angina	O
pectoris	O
.	O

Cost	O
-	O
effectiveness	O
analysis	O
provides	O
a	O
rational	O
means	O
of	O
allocating	O
limited	O
health	O
care	O
resources	O
by	O
allowing	O
the	O
comparison	O
of	O
the	O
costs	O
of	O
lipid	O
-	O
lowering	O
therapy	O
,	O
in	O
particular	O
,	O
therapy	O
with	O
beta	B-protein
-	I-protein
hydroxy	I-protein
-	I-protein
beta	I-protein
-	I-protein
methylglutaryl	I-protein
-	I-protein
CoA	I-protein
(	I-protein
coenzyme	I-protein
A	I-protein
)	I-protein
reductase	I-protein
inhibitors	O
(	O
statins	O
)	O
,	O
with	O
the	O
costs	O
of	O
atherosclerosis	O
that	O
could	O
be	O
prevented	O
by	O
lowering	O
cholesterol	O
.	O

Further	O
,	O
Ser	O
/	O
Thr	O
phosphorylation	O
of	O
downstream	O
molecules	O
Akt	B-protein
and	O
p70	B-protein
S6	I-protein
kinase	I-protein
was	O
inhibited	O
.	O

The	O
cloning	O
of	O
PTR2	B-protein
represents	O
the	O
first	O
example	O
of	O
the	O
molecular	O
genetic	O
characterization	O
of	O
a	O
eucaryotic	O
peptide	O
transport	O
gene	O
.	O

Sixty	O
-	O
nine	O
(	O
44	O
%	O
)	O
patients	O
were	O
administered	O
250	O
MBq	O
(	O
7	O
mCi	O
)	O
99Tcm	O
-	O
tetrofosmin	O
at	O
rest	O
followed	O
4	O
h	O
later	O
by	O
750	O
MBq	O
(	O
21	O
mCi	O
)	O
during	O
stress	O
(	O
the	O
1	O
day	O
protocol	O
)	O
,	O
whereas	O
88	O
(	O
56	O
%	O
)	O
patients	O
had	O
rest	O
and	O
stress	O
imaging	O
studies	O
on	O
two	O
separate	O
days	O
,	O
receiving	O
a	O
500	O
MBq	O
(	O
14	O
mCi	O
)	O
dose	O
of	O
99Tcm	O
-	O
tetrofosmin	O
on	O
each	O
occasion	O
(	O
the	O
2	O
day	O
protocol	O
)	O
.	O

Liver	O
microsomes	O
of	O
the	O
shag	O
showed	O
smaller	O
than	O
8	O
%	O
of	O
the	O
epoxide	B-protein
hydrase	I-protein
activity	O
and	O
smaller	O
than	O
14	O
%	O
of	O
the	O
hydroxylating	O
capacity	O
of	O
liver	O
microsomes	O
from	O
the	O
rat	O
.	O

Deletion	O
analysis	O
of	O
rOC	B-protein
promoter	I-protein
-	I-protein
chloramphenicol	I-protein
acetyltransferase	I-protein
constructs	I-protein
demonstrates	O
that	O
an	O
AML	B-protein
-	I-protein
1	I-protein
-	I-protein
binding	I-protein
sequence	I-protein
within	O
the	O
proximal	O
promoter	O
(	O
-	O
138	O
to	O
-	O
130	O
nt	O
)	O
contributes	O
to	O
75	O
%	O
of	O
the	O
level	O
of	O
osteocalcin	B-protein
gene	I-protein
expression	O
.	O

Recently	O
,	O
it	O
was	O
shown	O
that	O
purified	O
RAG1	B-protein
/	I-protein
2	I-protein
proteins	I-protein
can	O
cleave	O
DNA	O
hairpins	O
in	O
vitro	O
,	O
but	O
the	O
same	O
activity	O
was	O
also	O
described	O
for	O
a	O
protein	O
complex	O
of	O
the	O
DNA	B-protein
repair	I-protein
proteins	I-protein
Nbs1	I-protein
/	I-protein
Mre11	I-protein
/	I-protein
Rad50	I-protein
.	O

Our	O
studies	O
extend	O
these	O
findings	O
and	O
show	O
that	O
the	O
E2	B-protein
transactivation	I-protein
gene	I-protein
is	O
expressed	O
from	O
multiple	O
promoters	O
.	O

Expression	O
of	O
a	O
hybrid	O
protein	O
containing	O
the	O
cytoplasmic	O
C	O
-	O
terminal	O
half	O
of	O
UhpB	B-protein
fused	O
to	O
glutathione	B-protein
S	I-protein
-	I-protein
transferase	I-protein
(	O
GST	B-protein
)	O
also	O
interfered	O
with	O
Uhp	B-protein
signaling	O
.	O

Morphological	O
and	O
functional	O
alterations	O
noted	O
after	O
baboon	O
renal	O
allotransplantation	O
.	O

The	O
sequence	O
of	O
the	O
HIR1	B-protein
gene	I-protein
predicts	O
an	O
88	O
-	O
kDa	O
protein	O
with	O
three	O
repeats	O
of	O
a	O
motif	O
found	O
in	O
the	O
G	B-protein
beta	I-protein
subunit	I-protein
of	O
retinal	B-protein
transducin	I-protein
and	O
in	O
a	O
yeast	O
transcriptional	O
repressor	O
,	O
Tup1	B-protein
.	O

The	O
murine	B-protein
mutation	I-protein
dominant	I-protein
white	I-protein
spotting	I-protein
(	O
W	B-protein
)	O
is	O
in	O
the	O
proto	O
-	O
oncogene	O
,	O
c	B-protein
-	I-protein
kit	I-protein
.	O

Protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
,	O
a	O
widely	O
-	O
distributed	O
enzyme	O
implicated	O
in	O
the	O
regulation	O
of	O
many	O
physiological	O
processes	O
,	O
consists	O
of	O
a	O
family	O
of	O
at	O
least	O
twelve	O
isoenzymes	O
which	O
differ	O
in	O
tissue	O
distribution	O
,	O
subcellular	O
localization	O
,	O
regulatory	O
properties	O
,	O
etc	O
.	O

Therefore	O
,	O
the	O
rbcL	B-protein
-	I-protein
rbcS	I-protein
locus	I-protein
seems	O
to	O
be	O
barely	O
expressed	O
under	O
a	O
standard	O
condition	O
for	O
photoautotrophic	O
growth	O
.	O

In	O
particular	O
,	O
the	O
S1	B-protein
'	I-protein
specificity	I-protein
site	I-protein
is	O
a	O
deep	O
and	O
highly	O
hydrophobic	O
cavity	O
.	O

In	O
broken	O
L	O
-	O
cell	O
membranes	O
expressing	O
wild	B-protein
type	I-protein
or	I-protein
mutant	I-protein
M6P	I-protein
/	I-protein
IGF	I-protein
II	I-protein
receptors	I-protein
,	O
30	O
nM	O
IGF	B-protein
II	I-protein
also	O
failed	O
to	O
affect	O
the	O
pertussis	B-protein
toxin	I-protein
substrate	O
activity	O
.	O

NF	B-protein
-	I-protein
HB	I-protein
(	O
BSAP	B-protein
)	O
is	O
a	O
repressor	O
of	O
the	O
murine	B-protein
immunoglobulin	I-protein
heavy	I-protein
-	I-protein
chain	I-protein
3	I-protein
'	I-protein
alpha	I-protein
enhancer	I-protein
at	O
early	O
stages	O
of	O
B	O
-	O
cell	O
differentiation	O
.	O

We	O
found	O
that	O
RhoA	B-protein
can	O
initiate	O
a	O
linear	O
kinase	O
cascade	O
leading	O
to	O
the	O
activation	O
of	O
ERK6	B-protein
(	O
p38	B-protein
gamma	I-protein
)	O
,	O
a	O
recently	O
identified	O
member	O
of	O
the	O
p38	B-protein
family	I-protein
of	O
MAPKs	B-protein
.	O

Granulocyte	B-protein
colony	I-protein
-	I-protein
stimulating	I-protein
factor	I-protein
(	O
G	B-protein
-	I-protein
CSF	I-protein
)	O
administration	O
in	O
vivo	O
has	O
been	O
shown	O
to	O
improve	O
the	O
defence	O
mechanisms	O
against	O
infection	O
by	O
different	O
microbes	O
.	O

100	O
and	O
14	O
p	O
.	O

GN101	O
,	O
YC819	O
-	O
9	O
,	O
and	O
SB3	O
.	O

Another	O
common	O
mutation	O
involved	O
amino	O
acids	O
that	O
are	O
thought	O
to	O
make	O
specific	O
contacts	O
with	O
DNA	O
.	O

Patients	O
were	O
assessed	O
for	O
cardiac	O
MIBG	O
uptake	O
,	O
circulating	O
norepinephrine	O
concentration	O
,	O
LVEF	O
,	O
peak	O
Vo2	O
,	O
x	O
-	O
ray	O
cardiothoracic	O
ratio	O
,	O
M	O
-	O
mode	O
echographic	O
end	O
-	O
diastolic	O
diameter	O
and	O
right	O
-	O
sided	O
heart	O
catheterization	O
parameters	O
.	O

This	O
revealed	O
a	O
minimum	O
of	O
six	O
novel	O
OSBP	B-protein
-	I-protein
related	I-protein
proteins	I-protein
,	O
designated	O
ORP	B-protein
-	I-protein
1	I-protein
to	O
ORP	B-protein
-	I-protein
6	I-protein
.	O

Hp	O
positive	O
relatives	O
of	O
gastric	O
cancer	O
had	O
a	O
markedly	O
higher	O
prevalence	O
of	O
atrophy	O
than	O
those	O
with	O
Hp	O
negativity	O
without	O
cancer	O
relatives	O
(	O
29	O
vs	O
.	O

A	O
.	O
,	O
Swift	O
,	O
A	O
.	O

We	O
have	O
been	O
studying	O
the	O
interaction	O
of	O
the	O
oncogenic	O
human	O
polyomavirus	O
BK	O
(	O
BKV	O
)	O
with	O
the	O
tumor	B-protein
-	I-protein
suppressor	I-protein
protein	I-protein
p53	I-protein
to	O
understand	O
the	O
biology	O
of	O
this	O
virus	O
as	O
well	O
as	O
to	O
understand	O
the	O
basic	O
mechanisms	O
of	O
p53	B-protein
transactivation	O
.	O

This	O
report	O
substantiates	O
that	O
at	O
least	O
two	O
of	O
the	O
18	O
kDa	O
hsps	B-protein
in	O
maize	O
are	O
products	O
of	O
different	O
but	O
related	O
genes	O
.	O

The	O
novel	O
hematopoietic	B-protein
growth	I-protein
factor	I-protein
FLT3	I-protein
ligand	I-protein
(	O
FL	B-protein
)	O
is	O
the	O
cognate	O
ligand	O
for	O
the	O
FLT3	B-protein
,	O
tyrosine	B-protein
kinase	I-protein
receptor	I-protein
(	O
R	B-protein
)	O
,	O
also	O
referred	O
to	O
as	O
FLK	B-protein
-	I-protein
2	I-protein
and	O
STK	B-protein
-	I-protein
1	I-protein
.	O

The	O
mucosal	O
defence	O
capacity	O
against	O
proteolytic	O
leukocyte	O
enzymes	O
.	O

The	O
Mif1	B-protein
5	I-protein
'	I-protein
flanking	I-protein
region	I-protein
contains	O
a	O
functional	O
ER	B-protein
stress	I-protein
-	I-protein
responsive	I-protein
element	I-protein
which	O
is	O
sufficient	O
for	O
induction	O
by	O
tunicamycin	O
.	O

This	O
prospective	O
study	O
compared	O
the	O
measured	O
energy	O
expenditures	O
of	O
30	O
patients	O
using	O
indirect	O
calorimetry	O
with	O
their	O
predicted	O
basal	O
energy	O
expenditure	O
according	O
to	O
the	O
Harris	O
-	O
Benedict	O
equation	O
,	O
or	O
their	O
calculated	O
energy	O
expenditure	O
derived	O
from	O
basal	O
energy	O
expenditure	O
times	O
,	O
an	O
activity	O
factor	O
,	O
and	O
a	O
stress	O
factor	O
.	O

To	O
determine	O
what	O
role	O
eIF4E	B-protein
might	O
play	O
in	O
c	B-protein
-	I-protein
myc	I-protein
expression	O
,	O
the	O
c	B-protein
-	I-protein
myc	I-protein
5	I-protein
'	I-protein
untranslated	I-protein
region	I-protein
(	I-protein
UTR	I-protein
)	I-protein
was	O
fused	O
in	O
-	O
frame	O
to	O
CAT	B-protein
reporters	I-protein
,	O
and	O
several	O
more	O
derivative	O
constructs	O
were	O
made	O
.	O

Such	O
a	O
change	O
may	O
involve	O
increased	O
mammary	O
utilization	O
of	O
pre	O
-	O
formed	O
long	O
-	O
chain	O
fatty	O
acid	O
and	O
increased	O
metabolism	O
of	O
glucose	O
via	O
glycolysis	O
.	O

Unaided	O
attempts	O
to	O
quit	O
smoking	O
are	O
generally	O
unsuccessful	O
.	O

The	O
experiments	O
show	O
that	O
it	O
is	O
the	O
micromilieu	O
of	O
the	O
alveoli	O
and	O
the	O
condition	O
of	O
the	O
AM	O
(	O
certain	O
physiological	O
activation	O
states	O
,	O
such	O
as	O
phagocytic	O
activity	O
)	O
that	O
essentially	O
determine	O
the	O
degree	O
of	O
recovery	O
.	O

Comparative	O
studies	O
of	O
the	O
antithrombin	B-protein
III	I-protein
level	O
and	O
plasminogen	B-protein
activator	I-protein
activity	O
in	O
patients	O
with	O
thrombophlebitis	O
.	O

Thus	O
,	O
YMIP	B-protein
is	O
a	O
functional	O
homolog	O
of	O
RMIP	B-protein
and	O
represents	O
a	O
new	O
component	O
of	O
the	O
yeast	O
mitochondrial	O
import	O
machinery	O
.	O

METHODS	O
:	O
Forty	O
-	O
nine	O
cases	O
with	O
intrahepatic	O
multiple	O
nodules	O
of	O
HCC	O
,	O
by	O
gross	O
examination	O
,	O
among	O
184	O
consecutive	O
resected	O
HCCs	O
were	O
examined	O
clinicopathologically	O
.	O

During	O
the	O
program	O
'	O
s	O
use	O
at	O
the	O
RSNA	O
meeting	O
,	O
the	O
program	O
selected	O
the	O
correct	O
diagnosis	O
in	O
the	O
top	O
five	O
22	O
%	O
of	O
the	O
time	O
.	O

Mutation	O
of	O
Enh4	B-protein
,	O
an	O
essential	O
GT	B-protein
-	I-protein
IIC	I-protein
-	I-protein
like	I-protein
enhanson	I-protein
in	O
the	O
context	O
of	O
the	O
intact	O
enhancer	O
,	O
abolishes	O
silencer	O
activity	O
,	O
and	O
multimerized	O
GT	B-protein
-	I-protein
IIC	I-protein
enhansons	I-protein
mimic	O
the	O
intact	O
CSEn	B-protein
enhancer	I-protein
/	I-protein
silencer	I-protein
activities	O
in	O
BeWo	O
and	O
GC	O
cells	O
,	O
respectively	O
.	O

The	O
complete	O
gene	O
organization	O
was	O
obtained	O
by	O
combining	O
the	O
results	O
of	O
the	O
sequence	O
of	O
these	O
clones	O
and	O
those	O
of	O
the	O
characterization	O
of	O
polymerase	B-protein
chain	O
reaction	O
-	O
amplified	O
genomic	O
segments	O
.	O

The	O
dopamine	B-protein
D4	I-protein
receptor	I-protein
as	O
well	O
as	O
many	O
other	O
catecholaminergic	B-protein
receptors	I-protein
contain	O
several	O
putative	O
SH3	B-protein
binding	I-protein
domains	I-protein
.	O

EXAFS	O
measurements	O
around	O
the	O
Ge	O
-	O
K	O
edge	O
have	O
been	O
carried	O
out	O
for	O
liquid	O
Ge	O
-	O
Si	O
alloys	O
for	O
the	O
first	O
time	O
to	O
investigate	O
the	O
local	O
structure	O
around	O
a	O
Ge	O
atom	O
.	O

We	O
used	O
the	O
Toshiba	O
IIDR	O
system	O
,	O
which	O
is	O
composed	O
of	O
an	O
X	O
-	O
ray	O
TV	O
system	O
and	O
a	O
digital	O
image	O
managing	O
circuit	O
.	O

Dissociable	O
effects	O
of	O
lidocaine	O
inactivation	O
of	O
the	O
rostral	O
and	O
caudal	O
basolateral	O
amygdala	O
on	O
the	O
maintenance	O
and	O
reinstatement	O
of	O
cocaine	O
-	O
seeking	O
behavior	O
in	O
rats	O
.	O

Spontaneous	O
degradation	O
of	O
atracurium	O
in	O
plasma	O
is	O
the	O
major	O
route	O
of	O
elimination	O
in	O
man	O
and	O
contributes	O
to	O
a	O
short	O
elimination	O
half	O
-	O
life	O
(	O
approximatively	O
20	O
min	O
)	O
.	O

Almost	O
complete	O
sequence	O
identity	O
was	O
found	O
between	O
the	O
3	O
'	O
end	O
of	O
the	O
DXS6673E	B-protein
gene	I-protein
and	O
two	O
expressed	O
sequence	O
tags	O
(	O
ESTs	O
)	O
and	O
between	O
the	O
5	O
'	O
end	O
of	O
the	O
DXS6673E	B-protein
gene	I-protein
and	O
a	O
third	O
EST	O
.	O

1	O
.	O

The	O
rate	O
-	O
limiting	O
step	O
for	O
telomerase	B-protein
activity	O
seems	O
to	O
be	O
the	O
expression	O
of	O
the	O
catalytic	O
subunit	O
of	O
the	O
enzyme	O
,	O
encoded	O
by	O
the	O
human	B-protein
telomerase	I-protein
reverse	I-protein
transcriptase	I-protein
(	O
hTERT	B-protein
)	O
gene	O
.	O

Characterization	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
human	B-protein
multidrug	I-protein
resistance	I-protein
protein	I-protein
2	I-protein
(	O
MRP2	B-protein
)	O
gene	O
and	O
its	O
regulation	O
in	O
comparison	O
withthe	O
multidrug	B-protein
resistance	I-protein
protein	I-protein
3	I-protein
(	O
MRP3	B-protein
)	O
gene	O
.	O

Regulation	O
of	O
parathyroid	B-protein
hormone	I-protein
-	I-protein
related	I-protein
protein	I-protein
(	O
PTHrP	B-protein
)	O
gene	O
expression	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
the	O
antagonistic	O
effects	O
of	O
CRP	B-protein
and	O
KdgR	B-protein
on	O
the	O
expression	O
of	O
the	O
pectinolysis	B-protein
genes	I-protein
occur	O
by	O
different	O
mechanisms	O
,	O
including	O
direct	O
competition	O
between	O
the	O
two	O
regulators	O
or	O
between	O
the	O
repressor	O
and	O
RNA	B-protein
polymerase	I-protein
for	O
the	O
occupation	O
of	O
a	O
common	O
DNA	O
region	O
on	O
the	O
target	O
genes	O
.	O

In	O
a	O
gntR	B-protein
deletion	I-protein
mutant	I-protein
,	O
the	O
expression	O
of	O
a	O
chromosomal	B-protein
gntT	I-protein
:	I-protein
:	I-protein
lacZ	I-protein
fusion	I-protein
is	O
both	O
high	O
and	O
constitutive	O
,	O
confirming	O
that	O
GntR	B-protein
is	O
the	O
negative	O
regulator	O
of	O
gntT	B-protein
.	O

Consistent	O
with	O
the	O
protein	O
expression	O
data	O
,	O
V	B-protein
beta	I-protein
8	I-protein
.	I-protein
3	I-protein
gene	I-protein
transcripts	I-protein
were	O
found	O
only	O
in	O
the	O
transgenic	O
lines	O
with	O
the	O
wild	O
-	O
type	O
promoter	O
.	O

Their	O
afterglows	O
are	O
brighter	O
than	O
supernovae	O
and	O
therefore	O
are	O
called	O
hypernovae	O
.	O

AMDA	O
white	O
paper	O
identifies	O
ways	O
to	O
improve	O
pharmaceutical	O
care	O
in	O
SNFs	O
.	O

Compensatory	O
renal	O
hypertrophy	O
in	O
parabiotic	O
rats	O
.	O

Story	O
of	O
a	O
hospital	O
that	O
filmed	O
its	O
employee	O
orientation	O
program	O
.	O

TNF	O
Treatment	O
of	O
cell	O
activated	O
the	O
p38	B-protein
MAP	I-protein
kinase	I-protein
pathway	O
,	O
as	O
revealed	O
by	O
increased	O
phosphorylation	O
of	O
p38	B-protein
MAP	I-protein
kinase	I-protein
itself	O
,	O
activation	O
of	O
the	O
substrate	O
protein	O
MAPKAP	B-protein
kinase	I-protein
-	I-protein
2	I-protein
,	O
and	O
culminating	O
in	O
the	O
phosphorylation	O
of	O
the	O
heat	B-protein
shock	I-protein
protein	I-protein
27	I-protein
(	O
hsp27	B-protein
)	O
.	O

Nernst	O
-	O
-	O
Planck	O
analog	O
equations	O
and	O
stationary	O
state	O
membrane	O
electric	O
potentials	O
.	O

Two	O
of	O
the	O
three	O
groups	O
were	O
administered	O
dauricine	O
,	O
as	O
a	O
new	O
calcium	O
channel	O
blocker	O
,	O
and	O
verapamil	O
,	O
as	O
a	O
generally	O
recognized	O
calcium	O
channel	O
blocker	O
,	O
respectively	O
,	O
from	O
15	O
minutes	O
pre	O
-	O
bypass	O
to	O
the	O
end	O
of	O
the	O
bypass	O
procedure	O
(	O
a	O
period	O
of	O
95	O
minutes	O
)	O
.	O

Contrary	O
to	O
1	O
,	O
8	O
-	O
dihydroxy	O
-	O
9	O
-	O
anthrone	O
,	O
1	O
,	O
8	O
,	O
9	O
-	O
triacetoxyanthracene	O
and	O
1	O
,	O
8	O
-	O
diacetoxy	O
-	O
9	O
-	O
anthrone	O
are	O
effective	O
against	O
psoriatic	O
lesions	O
without	O
accompanying	O
inflammations	O
of	O
the	O
skin	O
.	O

Underlying	O
the	O
clustering	O
of	O
these	O
risk	O
variables	O
were	O
three	O
factors	O
.	O

We	O
found	O
that	O
the	O
gene	O
segment	O
containing	O
the	O
mu	B-protein
m	I-protein
poly	I-protein
(	I-protein
A	I-protein
)	I-protein
signals	I-protein
,	O
along	O
with	O
536	O
bp	O
of	O
downstream	O
flanking	O
sequence	O
,	O
acted	O
as	O
a	O
transcription	O
terminator	O
in	O
both	O
myeloma	O
cells	O
and	O
L	O
cell	O
fibroblasts	O
.	O

These	O
results	O
continue	O
to	O
support	O
the	O
hypothesis	O
that	O
HS2	B-protein
,	O
HS3	B-protein
,	O
and	O
HS4	B-protein
act	O
as	O
a	O
single	O
,	O
integral	O
unit	O
to	O
regulate	O
human	B-protein
globin	I-protein
gene	I-protein
transcription	O
as	O
a	O
holocomplex	O
,	O
but	O
they	O
can	O
also	O
be	O
interpreted	O
to	O
say	O
that	O
formation	O
of	O
a	O
DNase	B-protein
I	I-protein
hypersensitive	O
holocomplex	O
alone	O
is	O
not	O
sufficient	O
for	O
mediating	O
high	O
-	O
level	O
globin	B-protein
gene	I-protein
transcription	O
.	O

Ischemia	O
and	O
reperfusion	O
markedly	O
increased	O
the	O
release	O
of	O
6	B-protein
-	I-protein
keto	I-protein
-	I-protein
PGF1	I-protein
alpha	I-protein
and	O
TXB2	B-protein
.	O

Calibration	O
and	O
a	O
correction	O
of	O
blood	O
O2	O
content	O
measured	O
by	O
Po2	O
and	O
CO	O
saturation	O
.	O

In	O
addition	O
,	O
we	O
observe	O
that	O
the	O
hUBF	B-protein
-	I-protein
promoter	I-protein
interaction	O
is	O
highly	O
sensitive	O
to	O
the	O
antagonistic	O
effects	O
of	O
cisplatin	O
-	O
DNA	O
adducts	O
.	O

Using	O
the	O
two	O
-	O
hybrid	O
system	O
,	O
we	O
show	O
that	O
nonprenylated	O
Rac1	B-protein
interacts	O
very	O
weakly	O
with	O
Rho	B-protein
-	I-protein
GDI	I-protein
,	O
pointing	O
to	O
the	O
predominant	O
role	O
of	O
protein	O
-	O
isoprene	O
interaction	O
in	O
complex	O
formation	O
.	O

Tele	O
-	O
Talk	O
has	O
the	O
extra	O
capability	O
of	O
operating	O
in	O
live	O
conference	O
situations	O
using	O
microphone	O
input	O
.	O

Neither	O
ethanol	O
regimen	O
impaired	O
spontaneous	O
alternation	O
,	O
but	O
the	O
4	O
g	O
ethanol	O
.	O
kg	O
-	O
1	O
x	O
day	O
-	O
1	O
regimen	O
increased	O
the	O
percent	O
completed	O
trials	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
traI	B-protein
structural	I-protein
gene	I-protein
and	O
application	O
of	O
purified	O
mutant	O
TraI	B-protein
proteins	I-protein
for	O
in	O
vitro	O
assays	O
served	O
to	O
evaluate	O
the	O
functional	O
importance	O
of	O
conserved	O
amino	O
acid	O
residues	O
.	O

This	O
indicates	O
that	O
the	O
mechanism	O
by	O
which	O
CX	O
blocks	O
rapid	O
degradation	O
of	O
tubulin	B-protein
mRNA	I-protein
in	O
vivo	O
is	O
not	O
simply	O
by	O
preventing	O
its	O
translation	O
and	O
suggests	O
the	O
involvement	O
of	O
an	O
altered	O
trans	O
-	O
factor	O
.	O

By	O
using	O
space	O
-	O
discrete	O
/	O
continuous	O
metapopulation	O
dynamic	O
models	O
and	O
computer	O
simulations	O
,	O
we	O
show	O
that	O
there	O
can	O
be	O
two	O
principally	O
different	O
regimes	O
of	O
metapopulation	O
dynamics	O
.	O

The	O
protein	O
product	O
of	O
orfD	B-protein
,	O
which	O
is	O
probably	O
a	O
new	O
tra	B-protein
gene	I-protein
(	O
named	O
traX	B-protein
)	O
,	O
contains	O
65	O
%	O
hydrophobic	O
amino	O
acids	O
,	O
especially	O
rich	O
in	O
alanine	O
and	O
leucine	O
.	O

Members	O
of	O
the	O
titin	B-protein
/	I-protein
myosin	I-protein
light	I-protein
chain	I-protein
kinase	I-protein
family	I-protein
play	O
an	O
essential	O
role	O
in	O
the	O
organization	O
of	O
the	O
actin	O
/	O
myosin	O
cytoskeleton	O
,	O
especially	O
in	O
sarcomere	O
assembly	O
and	O
function	O
.	O

Purified	O
Hsk1	B-protein
phosphorylates	O
the	O
Cdc19	B-protein
(	O
Mcm2	B-protein
)	O
subunit	O
of	O
the	O
six	B-protein
-	I-protein
member	I-protein
minichromosome	I-protein
maintenance	I-protein
protein	I-protein
complex	I-protein
purified	O
from	O
fission	O
yeast	O
.	O

In	O
these	O
vectors	O
the	O
chimeric	O
long	O
terminal	O
repeat	O
(	O
chLTR	O
)	O
drives	O
the	O
expression	O
of	O
the	O
chloramphenicol	B-protein
acetyl	I-protein
transferase	I-protein
(	O
CAT	B-protein
)	O
reporter	O
gene	O
that	O
is	O
followed	O
by	O
an	O
internal	O
SV40	O
virus	O
early	O
region	O
promoter	O
linked	O
to	O
the	O
neomycin	B-protein
phosphotransferase	I-protein
II	I-protein
(	O
NEO	B-protein
)	O
gene	O
.	O

Some	O
reflexions	O
apropos	O
of	O
a	O
personal	O
statistical	O
study	O
of	O
513	O
arterial	O
embolisms	O
.	O

Mutational	O
analysis	O
of	O
mRNA	B-protein
capping	I-protein
enzyme	I-protein
identifies	O
amino	O
acids	O
involved	O
in	O
GTP	O
binding	O
,	O
enzyme	O
-	O
guanylate	O
formation	O
,	O
and	O
GMP	O
transfer	O
to	O
RNA	O
.	O

Preferential	O
heterodimeric	O
parallel	O
coiled	O
-	O
coil	O
formation	O
by	O
synthetic	B-protein
Max	I-protein
and	O
c	B-protein
-	I-protein
Myc	I-protein
leucine	I-protein
zippers	I-protein
:	O
a	O
description	O
of	O
putative	O
electrostatic	O
interactions	O
responsible	O
for	O
the	O
specificity	O
of	O
heterodimerization	O
.	O

For	O
oral	O
administration	O
,	O
AUC0	O
-	O
infinity	O
was	O
58	O
.	O
47	O
+	O
/	O
-	O
16	O
.	O
37	O
microg	O
x	O
h	O
/	O
ml	O
,	O
t1	O
/	O
2beta	O
was	O
18	O
.	O
39	O
+	O
/	O
-	O
0	O
.	O
06	O
hours	O
,	O
maximum	O
concentration	O
(	O
Cmax	O
)	O
was	O
2	O
.	O
12	O
+	O
/	O
-	O
00	O
.	O
51	O
microg	O
/	O
ml	O
,	O
time	O
to	O
Cmax	O
was	O
2	O
.	O
20	O
+	O
/	O
-	O
2	O
.	O
17	O
hours	O
,	O
mean	O
absorption	O
time	O
was	O
2	O
.	O
09	O
+	O
/	O
-	O
0	O
.	O
51	O
hours	O
,	O
and	O
bioavailability	O
was	O
42	O
+	O
/	O
-	O
0	O
.	O
42	O
%	O
.	O

In	O
addition	O
,	O
depletion	O
of	O
Oct	B-protein
-	I-protein
1	I-protein
from	O
the	O
nuclear	O
extract	O
by	O
using	O
Oct	O
-	O
1	O
-	O
specific	O
antiserum	O
or	O
a	O
sequence	O
-	O
specific	O
DNA	O
affinity	O
resin	O
decreased	O
in	O
vitro	O
transcription	O
from	O
the	O
wild	O
-	O
type	O
MMTV	O
promoter	O
to	O
a	O
level	O
identical	O
to	O
that	O
obtained	O
from	O
a	O
promoter	O
in	O
which	O
all	O
three	O
octamer	O
-	O
related	O
sequences	O
were	O
mutated	O
.	O

Bacterially	O
expressed	O
protein	O
,	O
as	O
well	O
as	O
the	O
in	O
vitro	O
reticulocyte	O
lysate	O
translation	O
product	O
,	O
comigrated	O
with	O
the	O
purified	O
37	O
-	O
kDa	O
protein	O
on	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gels	O
.	O

Although	O
diagnostic	O
laparoscopy	O
is	O
still	O
considered	O
the	O
standard	O
reference	O
in	O
the	O
diagnosis	O
of	O
ectopic	O
pregnancy	O
(	O
EP	O
)	O
,	O
use	O
of	O
high	O
-	O
resolution	O
endovaginal	O
sonography	O
,	O
in	O
conjunction	O
with	O
qualitative	O
serum	O
assays	O
of	O
the	O
beta	O
subunit	O
of	O
human	B-protein
chorionic	I-protein
gonadotropin	I-protein
(	O
beta	B-protein
-	I-protein
hCG	I-protein
)	O
,	O
allows	O
detection	O
of	O
earlier	O
and	O
smaller	O
EPs	O
.	O

Proprotein	O
processing	O
occurs	O
intracellularly	O
.	O

Patients	O
with	O
low	O
probability	O
of	O
having	O
aluminum	O
overload	O
(	O
serum	O
iron	O
levels	O
<	O
40	O
micrograms	O
/	O
L	O
and	O
DAI	O
<	O
150	O
micrograms	O
/	O
L	O
)	O
had	O
significantly	O
higher	O
values	O
of	O
serum	O
iron	O
,	O
iron	O
transferrin	B-protein
saturation	O
,	O
and	O
serum	B-protein
ferritin	I-protein
levels	O
compared	O
with	O
those	O
patients	O
with	O
a	O
high	O
probability	O
of	O
having	O
aluminum	O
overload	O
(	O
serum	O
aluminum	O
levels	O
>	O
40	O
micrograms	O
/	O
L	O
and	O
DAI	O
>	O
150	O
micrograms	O
/	O
L	O
)	O
.	O

It	O
has	O
a	O
grave	O
prognosis	O
with	O
>	O
70	O
%	O
mortality	O
in	O
3	O
months	O
,	O
despite	O
mechanical	O
ventilation	O
.	O

In	O
calves	O
receiving	O
milk	O
-	O
substitute	O
diets	O
containing	O
80	O
-	O
260	O
g	O
DM	O
/	O
kg	O
,	O
milk	O
intakes	O
were	O
reduced	O
by	O
up	O
to	O
30	O
%	O
on	O
the	O
1st	O
day	O
that	O
calves	O
were	O
fed	O
once	O
daily	O
instead	O
of	O
twice	O
daily	O
.	O

Our	O
results	O
suggest	O
that	O
Lrp	B-protein
binds	O
a	O
central	O
palindromic	O
site	O
,	O
interacting	O
predominantly	O
with	O
the	O
major	O
groove	O
of	O
its	O
DNA	O
target	O
,	O
and	O
that	O
additional	O
dimers	O
bind	O
to	O
flanking	O
sites	O
to	O
form	O
a	O
nucleoprotein	O
activation	O
complex	O
.	O

It	O
could	O
also	O
inhibit	O
C1q	O
-	O
dependent	O
haemolysis	O
of	O
both	O
IgG	O
-	O
and	O
IgM	O
-	O
sensitized	O
erythrocytes	O
.	O

After	O
resection	O
of	O
the	O
proximal	O
fragment	O
,	O
all	O
scaphoid	O
contact	O
area	O
and	O
pressure	O
was	O
born	O
by	O
the	O
distal	O
scaphoid	O
fragment	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
association	O
between	O
complete	O
congenital	O
heart	O
block	O
(	O
CCHB	O
)	O
in	O
the	O
fetus	O
and	O
adult	O
disease	O
.	O

Polypyrimidine	O
and	O
ssDNA	O
binding	O
by	O
the	O
isolated	O
VH	B-protein
domain	I-protein
of	O
immunization	O
-	O
induced	O
anti	B-protein
-	I-protein
Z	I-protein
-	I-protein
DNA	I-protein
Ab	I-protein
resembles	O
the	O
activity	O
of	O
natural	O
autoantibodies	O
and	O
suggests	O
that	O
VH	O
-	O
dependent	O
binding	O
to	O
a	O
ligand	O
mimicked	O
by	O
polypyrimidines	O
may	O
play	O
a	O
role	O
in	O
B	O
cell	O
selection	O
before	O
immunization	O
with	O
Z	O
-	O
DNA	O
.	O

In	O
this	O
report	O
we	O
studied	O
the	O
role	O
of	O
protein	B-protein
-	I-protein
tyrosine	I-protein
phosphatase	I-protein
SHP	I-protein
-	I-protein
2	I-protein
in	O
ErbB	O
-	O
mediated	O
activation	O
of	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
by	O
overexpressing	O
SHP	B-protein
-	I-protein
2	I-protein
mutants	I-protein
in	O
COS	O
-	O
7	O
cells	O
.	O

I	O
hypothesize	O
that	O
white	B-protein
gene	I-protein
expression	O
from	O
P	O
[	O
en	O
]	O
is	O
repressed	O
by	O
the	O
formation	O
of	O
a	O
protein	O
complex	O
which	O
is	O
initiated	O
at	O
the	O
engrailed	B-protein
PS	I-protein
sites	I-protein
and	O
also	O
requires	O
interactions	O
with	O
flanking	O
genomic	O
DNA	O
.	O

Ninety	O
-	O
four	O
percent	O
of	O
the	O
EPs	O
were	O
tubal	O
,	O
and	O
90	O
%	O
of	O
the	O
tubes	O
exhibited	O
some	O
pathologic	O
changes	O
,	O
including	O
chronic	O
salpingitis	O
(	O
49	O
.	O
5	O
%	O
)	O
and	O
follicular	O
salpingitis	O
(	O
10	O
%	O
)	O
,	O
among	O
others	O
.	O

A	O
comparison	O
of	O
the	O
clinical	O
profile	O
of	O
cavernous	O
malformations	O
with	O
and	O
without	O
associated	O
venous	O
malformations	O
.	O

The	O
Caenorhabditis	B-protein
elegans	I-protein
vitellogenin	I-protein
genes	I-protein
are	O
subject	O
to	O
sex	O
-	O
,	O
stage	O
-	O
,	O
and	O
tissue	O
-	O
specific	O
regulation	O
:	O
they	O
are	O
expressed	O
solely	O
in	O
the	O
adult	O
hermaphrodite	O
intestine	O
.	O

For	O
colostral	O
milk	O
there	O
was	O
a	O
significant	O
correlation	O
of	O
vitamin	O
K1	O
to	O
cholesterol	O
(	O
r	O
=	O
0	O
.	O
62	O
)	O
but	O
not	O
to	O
total	O
lipid	O
or	O
phospholipid	O
suggesting	O
a	O
role	O
for	O
cholesterol	O
in	O
the	O
secretion	O
of	O
vitamin	O
K1	O
into	O
colostral	O
milk	O
.	O

Hypercalcemia	O
associated	O
with	O
elevated	O
serum	B-protein
PTH	I-protein
concentration	O
indicating	O
primary	O
hyperparathyroidism	O
was	O
found	O
in	O
7	O
BC	O
patients	O
(	O
7	O
%	O
)	O
and	O
in	O
none	O
of	O
healthy	O
women	O
or	O
patients	O
with	O
thyroid	O
cancer	O
.	O

Effect	O
of	O
heat	O
treatments	O
on	O
the	O
meltability	O
of	O
cheeses	O
.	O

In	O
8	O
healthy	O
volunteers	O
there	O
were	O
no	O
significant	O
differences	O
in	O
AUC	O
,	O
peak	O
plasma	O
concentrations	O
or	O
time	O
to	O
peak	O
concentration	O
when	O
OXC	O
was	O
administered	O
either	O
with	O
or	O
without	O
ERY	O
.	O

Salient	O
applications	O
of	O
PB	O
-	O
PK	O
modeling	O
to	O
toxicological	O
problems	O
are	O
illustrated	O
with	O
examples	O
.	O

Determination	O
of	O
20	O
alpha	O
-	O
hydroxy	O
-	O
9	O
beta	O
,	O
10	O
alpha	O
-	O
pregna	O
-	O
4	O
,	O
6	O
-	O
dien	O
-	O
3	O
-	O
one	O
in	O
plasma	O
by	O
selected	O
ion	O
monitoring	O
.	O

Metabolic	O
labeling	O
studies	O
in	O
S	O
.	O
cerevisiae	O
and	O
co	O
-	O
expression	O
of	O
nmt72p	B-protein
with	O
several	O
protein	O
substrates	O
of	O
Nmt1p	B-protein
in	O
Escherichia	O
coli	O
indicate	O
that	O
the	O
Leu99	O
-	O
-	O
>	O
Pro	O
substitution	O
causes	O
a	O
reduction	O
in	O
the	O
acylation	O
of	O
some	O
but	O
not	O
all	O
protein	O
substrates	O
.	O

Schooling	O
is	O
found	O
to	O
be	O
related	O
to	O
good	O
health	O
even	O
after	O
controlling	O
for	O
differences	O
in	O
observable	O
health	O
inputs	O
.	O

The	O
reason	O
that	O
nitrous	O
oxide	O
does	O
not	O
produce	O
hydroxyl	O
radicals	O
readily	O
might	O
be	O
that	O
the	O
one	O
-	O
electron	O
reduction	O
proceeds	O
through	O
an	O
N2O	O
-	O
intermediate	O
which	O
is	O
energetically	O
very	O
unfavourable	O
:	O
EO	O
(	O
N2O	O
/	O
N2O	O
-	O
)	O
=	O
-	O
1	O
.	O
1	O
V	O
.	O

Parkinsonian	O
patients	O
had	O
a	O
significantly	O
lower	O
prevalence	O
of	O
alcohol	O
use	O
.	O

There	O
was	O
evidence	O
of	O
attenuated	O
regression	O
slopes	O
relating	O
recalled	O
to	O
observed	O
portion	O
sizes	O
for	O
4	O
of	O
the	O
10	O
food	O
groups	O
;	O
adjusted	O
r2	O
values	O
for	O
the	O
recalled	O
portion	O
sizes	O
ranged	O
from	O
0	O
.	O
02	O
to	O
0	O
.	O
94	O
.	O

Binding	O
of	O
serum	B-protein
response	I-protein
factor	I-protein
to	O
CArG	B-protein
box	I-protein
sequences	I-protein
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
restrict	O
gene	O
expression	O
to	O
arterial	O
smooth	O
muscle	O
cells	O
.	O

Acquired	O
bile	O
duct	O
blockage	O
:	O
entry	O
of	O
hepatobiliary	O
agent	O
into	O
an	O
intrahepatic	O
abscess	O
.	O

The	O
patients	O
were	O
divided	O
into	O
3	O
subgroups	O
:	O
1	O
)	O
13	O
N	O
+	O
patients	O
with	O
multiple	O
hot	O
spots	O
(	O
greater	O
than	O
2	O
)	O
(	O
N	O
+	O
IM	O
)	O
;	O
2	O
)	O
24	O
N	O
+	O
patients	O
with	O
single	O
hot	O
spots	O
(	O
less	O
than	O
or	O
equal	O
to	O
2	O
)	O
(	O
N	O
+	O
IS	O
)	O
;	O
3	O
)	O
12	O
N	O
-	O
patients	O
with	O
single	O
hot	O
spots	O
(	O
less	O
than	O
or	O
equal	O
to	O
2	O
)	O
(	O
N	O
-	O
IS	O
)	O
.	O

Carbon	O
catabolite	O
repression	O
of	O
the	O
gnt	B-protein
operon	I-protein
of	I-protein
Bacillus	I-protein
subtilis	I-protein
is	O
mediated	O
by	O
the	O
catabolite	O
control	O
protein	O
CcpA	B-protein
and	O
by	O
HPr	B-protein
,	O
a	O
phosphocarrier	O
protein	O
of	O
the	O
phosphotransferase	B-protein
system	I-protein
.	O

Interferon	B-protein
-	I-protein
alpha	I-protein
treatment	O
of	O
posttransplant	O
lymphoproliferative	O
disorder	O
in	O
recipients	O
of	O
solid	O
organ	O
transplants	O
.	O

ATP	O
-	O
dependent	O
assembly	O
of	O
a	O
ternary	O
complex	O
consisting	O
of	O
a	O
DNA	O
mismatch	O
and	O
the	O
yeast	B-protein
MSH2	I-protein
-	I-protein
MSH6	I-protein
and	O
MLH1	B-protein
-	I-protein
PMS1	I-protein
protein	I-protein
complexes	I-protein
.	O

Since	O
1967	O
at	O
the	O
times	O
of	O
their	O
biennial	O
ABCC	O
/	O
RERF	O
radiological	O
examinations	O
,	O
all	O
Adult	O
Health	O
Study	O
(	O
AHS	O
)	O
subjects	O
have	O
been	O
interviewed	O
to	O
determine	O
the	O
exposures	O
to	O
medical	O
x	O
-	O
rays	O
they	O
experienced	O
in	O
institutions	O
other	O
than	O
RERF	O
in	O
order	O
to	O
estimate	O
the	O
numbers	O
of	O
examinations	O
and	O
corresponding	O
doses	O
which	O
they	O
received	O
.	O

We	O
have	O
determined	O
that	O
these	O
nicks	O
occur	O
in	O
both	O
the	O
wild	O
-	O
type	O
and	O
the	O
mutant	O
sites	O
.	O

Treatment	O
of	O
PCC4	O
.	O
aza1R	O
cells	O
with	O
an	O
RAR	O
-	O
selective	O
agonist	O
also	O
repressed	O
the	O
expression	O
of	O
EC	B-protein
-	I-protein
1	I-protein
mRNA	I-protein
while	O
treatment	O
with	O
an	O
RXR	O
-	O
selective	O
agonist	O
reduced	O
EC	B-protein
-	I-protein
1	I-protein
expression	O
slightly	O
.	O

By	O
comparing	O
the	O
abundances	O
of	O
many	O
yeast	O
transcripts	O
in	O
isogenic	O
wild	O
-	O
type	O
and	O
paf1	B-protein
mutant	I-protein
strains	O
,	O
we	O
have	O
identified	O
genes	O
whose	O
expression	O
is	O
affected	O
by	O
PAF1	B-protein
.	O

The	O
physical	O
characteristics	O
of	O
these	O
calls	O
vary	O
among	O
species	O
of	O
bat	O
,	O
and	O
variations	O
also	O
exist	O
in	O
the	O
timing	O
and	O
patterns	O
of	O
respiratory	O
muscle	O
recruitment	O
during	O
echolocation	O
.	O

Most	O
important	O
,	O
infection	O
of	O
the	O
cells	O
with	O
an	O
adenoviral	O
construct	O
expressing	O
this	O
mutant	O
inhibited	O
the	O
induction	O
of	O
VEGF	B-protein
mRNA	I-protein
under	O
conditions	O
that	O
mimic	O
hypoxia	O
.	O

The	O
end	O
-	O
stage	O
or	O
involutional	O
phase	O
of	O
proliferative	O
diabetic	O
retinopathy	O
may	O
result	O
in	O
stabilization	O
of	O
vision	O
for	O
long	O
periods	O
of	O
time	O
.	O

We	O
have	O
previously	O
reported	O
that	O
expression	O
of	O
a	O
tumour	O
derived	O
brk	B-protein
cDNA	I-protein
in	O
mouse	O
embryonic	O
fibroblasts	O
and	O
human	O
mammary	O
epithelial	O
cells	O
supports	O
anchorage	O
independent	O
growth	O
,	O
and	O
in	O
the	O
latter	O
potentiates	O
the	O
mitogenic	O
response	O
to	O
epidermal	B-protein
growth	I-protein
factor	I-protein
.	O

A	O
total	O
of	O
26	O
BCG	O
strains	O
,	O
out	O
of	O
them	O
10	O
Czechoslovak	O
strains	O
(	O
2	O
lyophilized	O
cultures	O
of	O
BCG	O
of	O
different	O
batch	O
,	O
6	O
strains	O
isolated	O
from	O
abscesses	O
of	O
children	O
after	O
BCG	O
-	O
vaccination	O
and	O
2	O
strains	O
from	O
fatal	O
cases	O
after	O
BCG	O
-	O
vaccination	O
)	O
and	O
16	O
strains	O
obtained	O
from	O
foreign	O
laboratories	O
,	O
were	O
used	O
.	O

The	O
myeloproliferative	O
sarcoma	O
virus	O
(	O
MPSV	O
)	O
was	O
derived	O
by	O
passage	O
of	O
Moloney	O
sarcoma	O
virus	O
(	O
Mo	O
-	O
MuSV	O
)	O
in	O
adult	O
mice	O
.	O

Standard	O
curve	O
correlation	O
coefficients	O
of	O
0	O
.	O
995	O
or	O
greater	O
were	O
obtained	O
during	O
validation	O
experiments	O
and	O
analysis	O
of	O
study	O
samples	O
.	O

Echosismography	O
enables	O
to	O
improve	O
the	O
diagnosis	O
when	O
compared	O
with	O
classical	O
sonography	O
in	O
about	O
20	O
%	O
of	O
cases	O
.	O

The	O
serine	B-protein
/	I-protein
threonine	I-protein
kinase	I-protein
Raf	I-protein
-	I-protein
1	I-protein
functions	O
downstream	O
of	O
Rats	B-protein
in	O
a	O
signal	O
transduction	O
cascade	O
which	O
transmits	O
mitogenic	O
stimuli	O
from	O
the	O
plasma	O
membrane	O
to	O
the	O
nucleus	O
.	O

Furthermore	O
,	O
the	O
over	O
-	O
replication	O
phenotype	O
produced	O
by	O
this	O
mutant	B-protein
p65cdc18	I-protein
is	O
resistant	O
to	O
increased	O
mitotic	O
cyclin	B-protein
/	I-protein
CDK	I-protein
activity	O
,	O
a	O
known	O
inhibitor	O
of	O
over	O
-	O
replication	O
.	O

For	O
various	O
dog	O
vessels	O
in	O
vivo	O
,	O
Q	O
/	O
Dk	O
ranged	O
from	O
0	O
.	O
15	O
to	O
47	O
X	O
10	O
(	O
5	O
)	O
Torr	O
/	O
cm2	O
.	O

Plate	O
luting	O
,	O
a	O
technique	O
that	O
uses	O
polymethylmethacrylate	O
(	O
PMMA	O
)	O
interposed	O
between	O
the	O
plate	O
and	O
the	O
bone	O
,	O
as	O
well	O
as	O
between	O
the	O
screw	O
heads	O
and	O
the	O
plate	O
,	O
to	O
improve	O
the	O
stability	O
of	O
internal	O
fixation	O
was	O
tested	O
in	O
vitro	O
using	O
20	O
paired	O
equine	O
third	O
metacarpal	O
bones	O
with	O
mid	O
-	O
diaphyseal	O
osteotomies	O
plated	O
with	O
six	O
-	O
hole	O
broad	O
ASIF	O
compression	O
plates	O
.	O

Our	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effect	O
of	O
MMF	O
on	O
in	O
vivo	O
bone	O
mineral	O
metabolism	O
.	O

These	O
data	O
suggest	O
that	O
these	O
sequences	O
located	O
immediately	O
3	O
'	O
to	O
the	O
breakpoint	O
of	O
the	O
HPFH	B-protein
-	I-protein
3	I-protein
deletion	I-protein
,	O
exhibit	O
both	O
the	O
structure	O
and	O
the	O
function	O
of	O
an	O
enhancer	O
,	O
and	O
can	O
modify	O
the	O
developmental	O
specificity	O
of	O
the	O
fetal	B-protein
gamma	I-protein
-	I-protein
globin	I-protein
genes	I-protein
,	O
resulting	O
in	O
their	O
continued	O
expression	O
during	O
adult	O
life	O
.	O

Sensory	O
kindling	O
:	O
implications	O
for	O
development	O
of	O
sensory	O
prostheses	O
.	O

A	O
rapid	O
fluorimetric	O
procedure	O
for	O
the	O
determination	O
of	O
the	O
fungicide	O
5	O
-	O
fluorocytosine	O
in	O
serum	O
is	O
described	O
.	O

In	O
this	O
study	O
,	O
we	O
examine	O
the	O
effects	O
of	O
Msx2	B-protein
expression	O
on	O
OC	B-protein
promoter	I-protein
activation	O
(	O
luciferase	B-protein
reporter	I-protein
)	O
by	O
FGF2	B-protein
/	I-protein
FSK	I-protein
and	O
calcitriol	O
in	O
MC3T3	O
-	O
E1	O
osteoblasts	O
.	O

Human	B-protein
neuronal	I-protein
Elav	I-protein
-	I-protein
like	I-protein
proteins	I-protein
contain	O
three	O
RNP	B-protein
-	I-protein
type	I-protein
RNA	I-protein
recognition	I-protein
motifs	I-protein
(	O
RRMs	B-protein
)	O
.	O

Interestingly	O
,	O
internal	O
and	O
5	O
'	O
deletions	O
revealed	O
tha	O
the	O
distal	O
promoter	O
was	O
not	O
required	O
for	O
full	O
transcriptional	O
activity	O
and	O
that	O
the	O
first	O
631	O
base	O
pairs	O
of	O
WNT	B-protein
-	I-protein
5A	I-protein
harbored	O
the	O
strongest	O
promoter	O
activity	O
.	O

Truncated	O
forms	O
of	O
a	O
novel	O
yeast	O
protein	O
suppress	O
the	O
lethality	O
of	O
a	O
G	B-protein
protein	I-protein
alpha	I-protein
subunit	I-protein
deficiency	O
by	O
interacting	O
with	O
the	O
beta	O
subunit	O
.	O

Thus	O
,	O
BALB	O
/	O
c	O
mice	O
appear	O
to	O
be	O
the	O
most	O
appropriate	O
strain	O
of	O
mice	O
to	O
perform	O
studies	O
on	O
the	O
possible	O
connection	O
between	O
infection	O
with	O
T	O
.	O
canis	O
and	O
allergic	O
asthma	O
.	O

These	O
studies	O
demonstrate	O
that	O
site	O
-	O
specific	O
recognition	O
of	O
the	O
bxd	B-protein
PRE	I-protein
by	O
d	O
(	O
GA	O
)	O
(	O
n	O
)	O
repeat	O
binding	O
activities	O
mediates	O
PcG	O
-	O
dependent	O
silencing	O
.	O

Binding	O
affinities	O
of	O
these	O
recombinant	O
phages	O
as	O
determined	O
by	O
the	O
retention	O
of	O
these	O
phages	O
by	O
a	O
His	O
-	O
tag	O
immobilized	O
gp17	B-protein
column	O
,	O
and	O
by	O
co	O
-	O
immunoprecipitation	O
with	O
purified	O
terminase	B-protein
supported	O
the	O
specific	O
nature	O
of	O
the	O
portal	B-protein
protein	I-protein
and	O
terminase	B-protein
interaction	I-protein
sites	I-protein
.	O

During	O
the	O
following	O
9	O
1	O
/	O
2	O
years	O
three	O
sequential	O
liver	O
biopsies	O
were	O
performed	O
.	O

Toward	O
absolute	O
methods	O
in	O
clinical	O
chemistry	O
:	O
application	O
of	O
mass	O
fragmentography	O
to	O
high	O
-	O
accuracy	O
analyses	O
.	O

Psychiatric	O
disorders	O
in	O
children	O
and	O
adolescents	O
carry	O
considerable	O
morbidity	O
,	O
impede	O
development	O
,	O
and	O
carry	O
a	O
significant	O
mortality	O
by	O
suicide	O
.	O

Here	O
,	O
we	O
describe	O
the	O
isolation	O
of	O
MdPin1	B-protein
,	O
a	O
Pin1	B-protein
homologue	O
from	O
the	O
plant	O
species	O
apple	O
(	O
Malus	O
domestica	O
)	O
and	O
show	O
that	O
it	O
has	O
the	O
same	O
phosphorylation	O
-	O
specific	O
substrate	O
specificity	O
and	O
can	O
be	O
inhibited	O
by	O
juglone	O
in	O
vitro	O
,	O
as	O
is	O
the	O
case	O
for	O
Pin1	B-protein
.	O

Commun	O
.	O

Teratological	O
study	O
of	O
etoperidone	O
in	O
the	O
rat	O
and	O
rabbit	O
.	O

(	O
3	O
)	O
This	O
effect	O
occurs	O
without	O
removing	O
TRs	B-protein
from	O
the	O
TRE	B-protein
.	O

Nine	O
animals	O
served	O
as	O
control	O
animals	O
,	O
whereas	O
20	O
animals	O
received	O
a	O
focal	O
arachnoid	O
scar	O
at	O
C1	O
-	O
C2	O
,	O
which	O
was	O
produced	O
by	O
placement	O
of	O
a	O
kaolin	O
-	O
soaked	O
fibrin	B-protein
sponge	O
on	O
the	O
posterior	O
surface	O
of	O
the	O
spinal	O
cord	O
.	O

High	O
ATP	O
/	O
GTP	O
ratios	O
promoted	O
initiation	O
of	O
RNA	O
primer	O
synthesis	O
at	O
3	B-protein
'	I-protein
-	I-protein
dCTTT	I-protein
sites	I-protein
,	O
whereas	O
low	O
ATP	O
/	O
GTP	O
ratios	O
promoted	O
initiation	O
at	O
3	B-protein
'	I-protein
-	I-protein
dCCC	I-protein
sites	I-protein
.	O

Two	O
predominant	O
effects	O
were	O
noted	O
:	O
(	O
i	O
)	O
the	O
Xaa	O
residue	O
in	O
the	O
dual	B-protein
phosphorylation	I-protein
motif	I-protein
Thr	I-protein
-	I-protein
Xaa	I-protein
-	I-protein
Tyr	I-protein
as	O
well	O
as	O
the	O
length	O
of	O
L12	O
influence	O
p38	B-protein
substrate	O
specificity	O
,	O
and	O
(	O
ii	O
)	O
the	O
length	O
of	O
L12	O
plays	O
a	O
major	O
role	O
in	O
controlling	O
autophosphorylation	O
.	O

This	O
L	B-protein
-	I-protein
myc	I-protein
sequence	I-protein
is	O
amplified	O
10	O
-	O
20	O
-	O
fold	O
in	O
four	O
SCLC	O
cell	O
line	O
DNAs	O
and	O
in	O
one	O
SCLC	O
tumour	O
specimen	O
taken	O
directly	O
from	O
a	O
patient	O
.	O

Significant	O
increases	O
in	O
mean	O
serum	O
E2	O
concentration	O
(	O
100	O
to	O
150	O
pg	O
/	O
ml	O
)	O
were	O
noted	O
at	O
6	O
and	O
8	O
hours	O
after	O
administration	O
on	O
day	O
1	O
and	O
at	O
8	O
hours	O
on	O
day	O
4	O
.	O

Paleoceanographic	O
data	O
from	O
the	O
Laurentian	O
Fan	O
,	O
used	O
as	O
a	O
proxy	O
for	O
sea	O
surface	O
temperature	O
,	O
reveal	O
that	O
surface	O
slope	O
waters	O
north	O
of	O
the	O
Gulf	O
Stream	O
experienced	O
warming	O
during	O
the	O
Little	O
Ice	O
Age	O
of	O
the	O
16th	O
to	O
19th	O
centuries	O
and	O
support	O
the	O
notion	O
of	O
an	O
NAO	O
-	O
driven	O
coupled	O
system	O
.	O

Six	O
putative	O
MDV	O
genome	O
products	O
,	O
including	O
one	O
Rep	B-protein
and	O
five	O
non	O
-	O
Rep	O
proteins	O
,	O
show	O
high	O
(	O
70	O
.	O
4	O
-	O
90	O
.	O
9	O
%	O
)	O
amino	O
acid	O
identity	O
to	O
the	O
corresponding	O
six	O
FBNYV	B-protein
proteins	I-protein
,	O
whereas	O
two	O
other	O
Rep	B-protein
proteins	I-protein
encoded	O
by	O
MDV	B-protein
-	I-protein
C2	I-protein
and	O
C3	B-protein
are	O
82	O
.	O
3	O
%	O
and	O
73	O
.	O
0	O
%	O
identical	O
to	O
those	O
encoded	O
by	O
SCSV	B-protein
-	I-protein
C2	I-protein
and	O
C6	B-protein
,	O
respectively	O
.	O

We	O
investigated	O
the	O
smoking	O
habits	O
of	O
relapsers	O
1	O
year	O
after	O
quitting	O
in	O
a	O
smoking	O
cessation	O
trial	O
using	O
nicotine	O
or	O
placebo	O
patches	O
.	O

Transcriptional	O
regulation	O
of	O
SUP35	B-protein
and	O
SUP45	B-protein
in	I-protein
Saccharomyces	I-protein
cerevisiae	I-protein
.	O

The	O
clinical	O
relevance	O
of	O
these	O
findings	O
is	O
strengthened	O
by	O
the	O
observation	O
that	O
similar	O
results	O
were	O
obtained	O
when	O
P	O
.	O
HCl	O
was	O
given	O
by	O
the	O
intravenous	O
route	O
.	O

RESULTS	O
:	O
Looking	O
at	O
the	O
question	O
of	O
its	O
benefits	O
,	O
we	O
were	O
unable	O
to	O
find	O
any	O
methodologically	O
sound	O
studies	O
that	O
have	O
shown	O
efficacy	O
for	O
EMDR	O
in	O
eating	O
disorders	O
,	O
or	O
,	O
indeed	O
,	O
any	O
psychiatric	O
disorder	O
.	O

The	O
2	O
kb	O
of	O
5	O
'	O
-	O
flanking	O
region	O
and	O
the	O
1	O
.	O
1	O
kb	O
of	O
the	O
entire	O
sGTH	B-protein
alpha	I-protein
subunit	I-protein
coding	O
region	O
were	O
sequenced	O
from	O
the	O
genomic	O
clone	O
,	O
sGTH	B-protein
alpha	I-protein
-	I-protein
G1	I-protein
.	O

These	O
data	O
demonstrate	O
that	O
paxillin	B-protein
localizes	O
to	O
focal	O
adhesions	O
independent	O
of	O
interactions	O
with	O
vinculin	B-protein
and	O
/	O
or	O
FAK	B-protein
,	O
and	O
represents	O
the	O
first	O
definitive	O
demonstration	O
of	O
LIM	B-protein
domains	I-protein
functioning	O
as	O
a	O
primary	O
determinant	O
of	O
protein	O
subcellular	O
localization	O
to	O
focal	O
adhesions	O
.	O

Systematic	O
functional	O
analysis	O
of	O
V1a	B-protein
/	I-protein
V2	I-protein
hybrid	I-protein
receptors	I-protein
showed	O
that	O
the	O
second	O
intracellular	O
loop	O
of	O
the	O
V1a	B-protein
receptor	I-protein
is	O
required	O
and	O
sufficient	O
for	O
efficient	O
coupling	O
to	O
Gq	B-protein
/	I-protein
11	I-protein
,	O
whereas	O
the	O
third	O
intracellular	O
loop	O
of	O
the	O
V2	B-protein
receptor	I-protein
is	O
required	O
and	O
sufficient	O
for	O
coupling	O
to	O
Gs	B-protein
.	O

Both	O
NUP98	B-protein
-	I-protein
HOXA9	I-protein
chimeras	I-protein
transformed	O
NIH	O
3T3	O
fibroblasts	O
,	O
and	O
this	O
transformation	O
required	O
the	O
HOXA9	B-protein
domains	I-protein
for	O
DNA	O
binding	O
and	O
PBX	B-protein
interaction	O
.	O

KFC	B-protein
,	O
a	O
Ste20	B-protein
-	I-protein
like	I-protein
kinase	I-protein
with	O
mitogenic	O
potential	O
and	O
capability	O
to	O
activate	O
the	O
SAPK	B-protein
/	I-protein
JNK	I-protein
pathway	I-protein
.	O

Cytogenetic	O
analysis	O
of	O
LOH	O
mutants	O
by	O
chromosome	O
painting	O
indicated	O
a	O
mosaic	O
of	O
chromosomal	O
aberrations	O
involving	O
chromosome	O
17	O
,	O
in	O
which	O
partial	O
chromosome	O
deletions	O
,	O
amplifications	O
,	O
and	O
multiple	O
translocations	O
appeared	O
heterogeneously	O
in	O
a	O
single	O
mutant	O
.	O

In	O
addition	O
,	O
a	O
potent	O
splicing	O
enhancer	O
sequence	O
isolated	O
in	O
the	O
selection	O
specifically	O
binds	O
a	O
20	B-protein
-	I-protein
kDa	I-protein
SR	I-protein
protein	I-protein
.	O

A	O
dose	O
-	O
dependent	O
fall	O
in	O
GABA	O
content	O
was	O
observed	O
;	O
GABA	O
decrease	O
was	O
evident	O
15	O
min	O
after	O
the	O
administration	O
,	O
reached	O
its	O
nadir	O
at	O
60	O
min	O
and	O
disappeared	O
at	O
120	O
minutes	O
.	O

Within	O
their	O
polypeptide	O
chain	O
,	O
they	O
all	O
contain	O
those	O
conserved	O
features	O
that	O
define	O
a	O
plant	O
CDPK	B-protein
;	O
kinase	B-protein
catalytic	I-protein
sequences	I-protein
are	O
linked	O
to	O
a	O
calmodulin	B-protein
-	I-protein
like	I-protein
regulatory	I-protein
domain	I-protein
through	O
a	O
junction	O
region	O
.	O

Involvement	O
of	O
AP	B-protein
-	I-protein
2	I-protein
in	O
regulation	O
of	O
the	O
R	B-protein
-	I-protein
FABP	I-protein
gene	I-protein
in	O
the	O
developing	O
chick	O
retina	O
.	O

Two	O
studies	O
assessed	O
two	O
types	O
of	O
reliability	O
of	O
the	O
student	O
Jenkins	O
Activity	O
Survey	O
(	O
JAS	O
;	O
a	O
questionnaire	O
measure	O
of	O
Type	O
A	O
behavior	O
)	O
.	O

Two	O
-	O
way	O
analysis	O
of	O
variance	O
was	O
used	O
to	O
determine	O
whether	O
composite	O
knowledge	O
score	O
differed	O
among	O
patient	O
groups	O
.	O

We	O
have	O
shown	O
previously	O
that	O
in	O
contrast	O
to	O
other	O
extracellular	O
matrix	O
molecules	O
pepsin	O
-	O
solubilized	O
collagen	B-protein
VI	I-protein
(	O
CVI	B-protein
)	O
can	O
stimulate	O
DNA	O
synthesis	O
of	O
various	O
mesenchymal	O
cell	O
types	O
,	O
apparently	O
independent	O
of	O
integrin	O
-	O
mediated	O
signal	O
transduction	O
.	O

In	O
the	O
studies	O
reported	O
here	O
,	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
human	B-protein
gp130	I-protein
gene	I-protein
was	O
isolated	O
and	O
the	O
transcription	O
initiation	O
sites	O
were	O
mapped	O
.	O

Preimmune	B-protein
IgG	I-protein
,	O
anti	B-protein
-	I-protein
GalT	I-protein
Fab	I-protein
fragments	I-protein
,	O
irrelevant	O
polymers	O
and	O
monomeric	O
N	O
-	O
acetylglucosamine	O
had	O
no	O
effect	O
.	O

Cloning	O
and	O
characterization	O
of	O
a	O
cDNA	O
encoding	O
a	O
bacteriophage	B-protein
-	I-protein
type	I-protein
RNA	I-protein
polymerase	I-protein
from	O
the	O
higher	O
plant	O
Chenopodium	O
album	O
.	O

Female	O
but	O
not	O
male	O
mortalities	O
were	O
significantly	O
higher	O
for	O
cake	O
-	O
fed	O
rats	O
than	O
for	O
those	O
fed	O
diet	O
41B	O
.	O

Its	O
transcription	O
in	O
vitro	O
by	O
pol	B-protein
III	I-protein
requires	O
the	O
same	O
factors	O
as	O
the	O
U6	B-protein
gene	I-protein
with	O
the	O
major	O
exception	O
that	O
the	O
modified	O
TATA	O
-	O
box	O
of	O
this	O
construct	O
only	O
interacts	O
with	O
a	O
TATA	B-protein
-	I-protein
binding	I-protein
protein	I-protein
(	O
TBP	B-protein
)	O
mutant	O
(	O
TBP	B-protein
-	I-protein
DR2	I-protein
)	O
but	O
not	O
with	O
TBP	B-protein
wild	I-protein
-	I-protein
type	I-protein
(	O
TBPwt	B-protein
)	O
.	O

How	O
do	O
graduates	O
of	O
different	O
types	O
of	O
programs	O
perform	O
on	O
state	O
boards	O
?	O

Interdomain	O
signaling	O
in	O
a	O
two	O
-	O
domain	O
fragment	O
of	O
the	O
human	B-protein
glucocorticoid	I-protein
receptor	I-protein
.	O

Teratological	O
studies	O
on	O
SF	O
-	O
837	O
.	O

She	O
has	O
since	O
developed	O
a	O
positive	O
anti	B-protein
-	I-protein
cardiolipin	I-protein
antibody	I-protein
but	O
does	O
not	O
meet	O
diagnostic	O
criteria	O
for	O
systemic	O
lupus	O
erythematosis	O
.	O
Conclusion	O
:	O
The	O
presence	O
of	O
known	O
autoimmune	O
disease	O
in	O
a	O
woman	O
with	O
POF	O
should	O
not	O
dissuade	O
the	O
clinician	O
from	O
evaluating	O
for	O
a	O
potential	O
genetic	O
cause	O
.	O

Forced	O
expression	O
of	O
BZAP45	B-protein
strongly	O
stimulates	O
H4	B-protein
promoter	I-protein
(	O
nt	O
-	O
215	O
to	O
-	O
1	O
)	O
/	B-protein
CAT	I-protein
reporter	I-protein
gene	I-protein
activity	O
.	O

This	O
up	O
-	O
grading	O
of	O
the	O
final	O
score	O
by	O
the	O
CA	O
component	O
is	O
greater	O
(	O
3	O
-	O
8	O
%	O
)	O
in	O
the	O
less	O
able	O
students	O
with	O
scores	O
below	O
the	O
mean	O
level	O
.	O

The	O
ORF	O
was	O
analyzed	O
for	O
secondary	O
structural	O
features	O
,	O
and	O
the	O
sequence	O
data	O
bases	O
were	O
searched	O
for	O
homologies	O
.	O

The	O
transcripts	O
were	O
equally	O
active	O
with	O
or	O
without	O
a	O
5	O
'	O
methylated	O
capstructure	O
as	O
expected	O
,	O
since	O
EMCV	O
-	O
RNA	O
is	O
one	O
of	O
the	O
mRNAs	O
capable	O
of	O
internal	O
initiation	O
.	O

Patients	O
were	O
divided	O
into	O
two	O
group	O
;	O
Control	O
group	O
A	O
in	O
which	O
a	O
hot	O
-	O
water	O
circulating	O
system	O
was	O
used	O
and	O
group	O
B	O
in	O
which	O
a	O
transtracheal	O
heating	O
and	O
humidification	O
system	O
by	O
ANAMED	O
HUMITUBE	O
was	O
used	O
,	O
during	O
gastric	O
cancer	O
operation	O
.	O

The	O
equilibrium	O
dissociation	O
binding	O
constant	O
for	O
the	O
interaction	O
of	O
TnrA	B-protein
with	O
the	O
nrgAB	B-protein
promoter	I-protein
fragment	I-protein
was	O
7	O
.	O
7	O
nM	O
under	O
the	O
conditions	O
used	O
here	O
.	O

Tissue	O
-	O
specific	O
expression	O
of	O
the	O
tmy	B-protein
-	I-protein
1	I-protein
gene	I-protein
was	O
determined	O
by	O
microinjection	O
of	O
a	O
promoter	B-protein
/	I-protein
lacZ	I-protein
fusion	I-protein
gene	I-protein
and	O
with	O
immunohistochemistry	O
by	O
using	O
affinity	O
-	O
purified	O
tissue	B-protein
-	I-protein
specific	I-protein
anti	I-protein
-	I-protein
tropomyosins	I-protein
.	O

Intravenous	O
versus	O
oral	O
administration	O
of	O
amitriptyline	O
in	O
patients	O
with	O
major	O
depression	O
.	O

One	O
enigmatic	O
aspect	O
of	O
GATA	B-protein
factor	I-protein
expression	O
is	O
that	O
several	O
GATA	B-protein
proteins	I-protein
,	O
which	O
ostensibly	O
share	O
the	O
same	O
DNA	O
-	O
binding	O
site	O
specificity	O
,	O
are	O
coexpressed	O
in	O
erythroid	O
cells	O
.	O

Calcitriol	O
therapy	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
serum	O
iPTH	B-protein
levels	O
(	O
701	O
+	O
/	O
-	O
103	O
.	O
9	O
vs	O
.	O

In	O
most	O
subjects	O
,	O
markers	O
of	O
bone	O
formation	O
and	O
resorption	O
were	O
normal	O
.	O

Moreover	O
,	O
this	O
enhancement	O
of	O
transcriptional	O
activation	O
by	O
COUP	B-protein
-	I-protein
TFI	I-protein
requires	O
specifically	O
the	O
AF	B-protein
-	I-protein
1	I-protein
transactivation	O
function	O
of	O
ER	B-protein
and	O
can	O
be	O
observed	O
in	O
the	O
presence	O
of	O
E2	O
or	O
4	O
-	O
hydroxytamoxifen	O
but	O
not	O
ICI	O
164384	O
.	O

A	O
pharmacokinetic	O
study	O
of	O
apalcillin	O
was	O
performed	O
in	O
12	O
patients	O
in	O
an	O
intensive	O
-	O
care	O
unit	O
.	O

Autoimmune	O
manipulation	O
aids	O
juvenile	O
diabetes	O
management	O
.	O

Effect	O
of	O
indoramin	O
in	O
small	O
doses	O
on	O
the	O
central	O
vasomotor	O
loci	O
has	O
been	O
studied	O
in	O
chloralose	O
anesthetized	O
cats	O
by	O
localizing	O
it	O
to	O
the	O
central	O
sites	O
.	O

Baseline	O
electrocorticography	O
over	O
the	O
surface	O
of	O
the	O
temporal	O
lobe	O
and	O
depth	O
electrode	O
recordings	O
in	O
the	O
amygdala	O
and	O
hippocampus	O
were	O
obtained	O
,	O
followed	O
by	O
10	O
min	O
of	O
recording	O
before	O
and	O
after	O
the	O
i	O
.	O
v	O
.	O
administration	O
of	O
both	O
alfentanil	O
50	O
microg	O
/	O
kg	O
and	O
fentanyl	O
10	O
microg	O
/	O
kg	O
.	O

Although	O
elevated	O
serum	O
levels	O
of	O
antibodies	O
to	O
the	O
nicotinic	B-protein
acetylcholine	I-protein
receptor	I-protein
(	O
nAChR	B-protein
)	O
have	O
been	O
reported	O
in	O
neuroleptic	O
treated	O
patients	O
with	O
tardive	O
dyskinesia	O
,	O
such	O
antibodies	O
have	O
not	O
been	O
determined	O
in	O
comparable	O
nondyskinetic	O
patients	O
.	O

VII	O
.	O

Recently	O
,	O
a	O
mutation	O
in	O
the	O
amino	O
-	O
terminus	O
of	O
IB1	B-protein
was	O
associated	O
with	O
diabetes	O
.	O

We	O
show	O
that	O
p73	B-protein
can	O
transcriptionally	O
inhibit	O
a	O
number	O
of	O
cellular	O
and	O
viral	O
promoters	O
.	O

Induced	O
expression	O
of	O
Rnd3	B-protein
is	O
associated	O
with	O
transformation	O
of	O
polarized	O
epithelial	O
cells	O
by	O
the	O
Raf	B-protein
-	I-protein
MEK	I-protein
-	I-protein
extracellular	I-protein
signal	I-protein
-	I-protein
regulated	I-protein
kinase	I-protein
pathway	I-protein
.	O

How	O
does	O
a	O
nurse	O
go	O
about	O
maintaining	O
her	O
level	O
of	O
competence	O
when	O
she	O
is	O
one	O
of	O
the	O
few	O
local	O
practitioners	O
in	O
her	O
field	O
?	O
Vancouver	O
sex	O
therapist	O
Bianca	O
Rucker	O
is	O
doing	O
it	O
by	O
cultivating	O
a	O
network	O
of	O
colleagues	O
and	O
mentors	O
in	O
related	O
fields	O
both	O
at	O
home	O
and	O
across	O
the	O
continent	O
.	O

In	O
addition	O
,	O
benzocaine	O
and	O
2	O
-	O
phenoxyethanol	O
depressed	O
complement	O
activity	O
and	O
phagocytosis	O
,	O
while	O
MS222	O
and	O
quinaldine	O
sulphate	O
did	O
not	O
.	O

Expression	O
of	O
neuronal	O
traits	O
in	O
pancreatic	O
beta	O
cells	O
.	O

All	O
four	O
domains	O
were	O
linked	O
via	O
proline	O
-	O
threonine	O
-	O
rich	O
peptides	O
.	O

Both	O
genes	O
comprise	O
three	O
exons	O
,	O
two	O
introns	O
and	O
an	O
unusually	O
long	O
3	O
'	O
-	O
untranslated	O
region	O
(	O
3	O
.	O
2	O
kilobase	O
pairs	O
)	O
,	O
specificying	O
a	O
mRNA	O
of	O
approximately	O
4	O
.	O
1	O
kilobases	O
.	O

Convulsive	O
seizure	O
during	O
a	O
treatment	O
with	O
interferon	B-protein
alpha	I-protein
for	O
chronic	O
viral	O
hepatitis	O
C	O
.	O

Pathogenetic	O
relationships	O
between	O
renal	O
tubular	O
acidosis	O
and	O
sodium	O
metabolism	O
alterations	O
in	O
liver	O
cirrhosis	O
.	O

At	O
the	O
end	O
of	O
the	O
experiment	O
the	O
urinary	O
porphyrin	B-protein
excretion	O
and	O
the	O
porphyrin	B-protein
content	O
in	O
lijver	O
and	O
skin	O
were	O
diminished	O
in	O
HCB	O
-	O
CQ	O
-	O
treated	O
animals	O
by	O
about	O
50	O
%	O
compared	O
to	O
the	O
HCB	O
controls	O
.	O

YAC	O
and	O
cosmid	O
contigs	O
spanning	O
the	O
Batten	B-protein
disease	I-protein
(	I-protein
CLN3	I-protein
)	I-protein
region	I-protein
at	O
16p12	O
.	O
1	O
-	O
p11	O
.	O
2	O
.	O

Hu	B-protein
-	I-protein
Met	I-protein
-	I-protein
1	I-protein
mRNA	I-protein
expression	O
in	O
a	O
small	O
number	O
of	O
human	O
T	O
cell	O
tumor	O
lines	O
did	O
not	O
correlate	O
with	O
any	O
particular	O
phenotype	O
or	O
stage	O
of	O
development	O
.	O

The	O
granules	O
grew	O
as	O
the	O
melted	O
material	O
immersed	O
into	O
the	O
void	O
space	O
among	O
the	O
adhered	O
particles	O
.	O

We	O
conclude	O
that	O
administration	O
of	O
the	O
calcium	O
antagonist	O
Verapamil	O
is	O
of	O
no	O
additional	O
value	O
in	O
tocolytic	O
treatment	O
with	O
beta	O
-	O
mimetics	O
.	O

The	O
method	O
was	O
adapted	O
for	O
the	O
determination	O
of	O
nadolol	O
racemate	O
A	O
by	O
a	O
change	O
in	O
mobile	O
phase	O
composition	O
.	O

Examples	O
of	O
its	O
use	O
in	O
the	O
intensive	O
therapy	O
unit	O
are	O
described	O
.	O

However	O
,	O
the	O
increase	O
in	O
biliary	O
excretion	O
did	O
not	O
compensate	O
for	O
the	O
reduced	O
elimination	O
of	O
bretylium	O
and	O
hexylsalicylic	O
acid	O
via	O
the	O
kidney	O
.	O

Therefore	O
,	O
the	O
positive	O
cAMP	O
control	O
of	O
the	O
hypoxic	O
SRP1	B-protein
and	O
HEM13	B-protein
genes	I-protein
was	O
uncoupled	O
from	O
the	O
HOG	O
pathway	O
.	O

Auditory	O
threshold	O
shifts	O
,	O
as	O
measured	O
by	O
the	O
auditory	O
evoked	O
brainstem	O
response	O
,	O
were	O
measured	O
at	O
2	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
16	O
,	O
20	O
and	O
24	O
kHz	O
.	O

The	O
hybridizing	O
clone	O
of	O
V	O
.	O
vulnificus	O
chromosomal	O
DNA	O
complemented	O
a	O
V	B-protein
.	I-protein
cholerae	I-protein
fur	I-protein
mutant	I-protein
.	O

TPTA	O
produced	O
brain	O
congestion	O
,	O
and	O
hepatic	O
and	O
pulmonary	O
petechial	O
and	O
generalized	O
hemorrhages	O
.	O

A	O
patient	O
with	O
an	O
infected	O
wound	O
or	O
one	O
on	O
a	O
primary	O
area	O
(	O
hands	O
,	O
feet	O
,	O
face	O
,	O
or	O
perineum	O
)	O
may	O
have	O
to	O
be	O
hospitalized	O
to	O
ensure	O
proper	O
care	O
.	O

STUDY	O
DESIGN	O
:	O
Fine	O
needle	O
aspiration	O
cytologic	O
smears	O
from	O
21	O
cases	O
of	O
invasive	O
lobular	O
carcinoma	O
(	O
ILC	O
)	O
of	O
breast	O
were	O
subjected	O
to	O
detailed	O
cytomorphologic	O
analysis	O
.	O

Detection	O
of	O
exercise	O
-	O
induced	O
asynergy	O
by	O
M	O
-	O
mode	O
echocardiography	O
.	O

We	O
have	O
reviewed	O
the	O
experience	O
of	O
a	O
major	O
MMT	O
general	O
practice	O
with	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
from	O
1991	O
to	O
1995	O
.	O

An	O
intralobar	O
change	O
in	O
temperature	O
above	O
or	O
below	O
36	O
degrees	O
C	O
decreases	O
only	O
the	O
lobar	O
bronchial	O
blood	O
flow	O
and	O
does	O
not	O
influence	O
blood	O
flow	O
to	O
other	O
nearby	O
tissues	O
including	O
those	O
vascularized	O
by	O
the	O
bronchial	O
circulation	O
.	O

The	O
cloned	O
HindIII	B-protein
fragment	I-protein
,	O
which	O
was	O
shown	O
by	O
DNA	O
sequence	O
analysis	O
to	O
encode	O
the	O
N	O
-	O
terminal	O
half	O
of	O
the	O
B	B-protein
.	I-protein
subtilis	I-protein
IF2	I-protein
protein	I-protein
and	O
0	O
.	O
2	O
kb	O
of	O
upstream	O
flanking	O
sequence	O
,	O
was	O
utilized	O
as	O
a	O
homologous	O
probe	O
to	O
clone	O
an	O
overlapping	O
2	B-protein
.	I-protein
76	I-protein
-	I-protein
kb	I-protein
ClaI	I-protein
chromosomal	I-protein
fragment	I-protein
containing	O
the	O
entire	B-protein
IF2	I-protein
structural	I-protein
gene	I-protein
.	O

The	O
5	O
'	O
flanking	O
region	O
is	O
highly	O
GC	O
rich	O
,	O
with	O
multiple	O
CpG	O
doublets	O
,	O
and	O
contains	O
multiple	O
binding	O
sites	O
for	O
Sp1	B-protein
.	O

The	O
gene	O
product	O
of	O
cotS	B-protein
was	O
confirmed	O
to	O
be	O
identical	O
to	O
Cot40	B-protein
-	I-protein
2	I-protein
by	O
SDS	O
-	O
PAGE	O
and	O
immunoblotting	O
from	O
Escherichia	O
coli	O
transformed	O
with	O
a	O
plasmid	O
containing	O
the	O
cotS	B-protein
region	I-protein
.	O

All	O
four	O
of	O
the	O
genes	O
have	O
a	O
similar	O
structure	O
,	O
with	O
the	O
receptor	O
protein	O
encoded	O
in	O
a	O
single	O
exon	O
.	O

During	O
surgery	O
bone	O
cysts	O
were	O
excised	O
and	O
filled	O
by	O
bone	O
grafts	O
.	O

Presentation	O
of	O
a	O
horse	B-protein
cytochrome	I-protein
c	I-protein
peptide	I-protein
by	O
multiple	O
H	B-protein
-	I-protein
2b	I-protein
class	I-protein
I	I-protein
major	I-protein
histocompatibility	I-protein
complex	I-protein
(	O
MHC	B-protein
)	O
molecules	O
to	O
C57BL	O
/	O
6	O
-	O
and	O
bm1	O
-	O
derived	O
cytotoxic	O
T	O
lymphocytes	O
:	O
presence	O
of	O
a	O
single	O
MHC	B-protein
anchor	I-protein
residue	I-protein
may	O
confer	O
efficient	O
peptide	O
-	O
specific	O
CTL	O
recognition	O
.	O

The	O
differences	O
in	O
the	O
CPIgG	B-protein
,	O
CRP	B-protein
,	O
and	O
fibrinogen	B-protein
levels	O
in	O
patients	O
who	O
were	O
diagnosed	O
with	O
ACS	O
versus	O
those	O
who	O
were	O
not	O
(	O
non	O
-	O
ACS	O
)	O
were	O
evaluated	O
.	O

FTF	B-protein
is	O
also	O
abundantly	O
expressed	O
in	O
the	O
pancreas	O
and	O
may	O
exert	O
differentiation	O
functions	O
in	O
endodermal	O
sublineages	O
,	O
similar	O
to	O
SF	B-protein
-	I-protein
1	I-protein
in	O
steroidogenic	O
tissues	O
.	O

The	O
2	O
cDNAs	O
differed	O
in	O
the	O
length	O
of	O
their	O
respective	O
3	O
'	O
untranslated	O
regions	O
,	O
of	O
577	O
bp	O
in	O
Cp	B-protein
.	I-protein
F6	I-protein
and	O
72	O
bp	O
in	O
Cp	B-protein
.	I-protein
F10	I-protein
,	O
in	O
both	O
of	O
which	O
a	O
putative	O
polyadenylation	O
signal	O
was	O
identified	O
.	O

Iron	O
and	O
folate	O
deficiency	O
in	O
pregnancy	O
.	O

However	O
,	O
excretion	O
of	O
6	O
-	O
keto	O
-	O
prostaglandin	O
F1	O
alpha	O
was	O
further	O
reduced	O
in	O
the	O
smokers	O
who	O
used	O
oral	O
contraceptives	O
(	O
133	O
+	O
/	O
-	O
20	O
to	O
86	O
+	O
/	O
-	O
9	O
ng	O
/	O
gm	O
of	O
creatinine	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

R	O
-	O
wave	O
voltage	O
in	O
the	O
right	O
precordial	O
leads	O
in	O
anthracycline	O
cardiomyopathy	O
:	O
a	O
clinical	O
study	O
.	O

A	O
single	O
NMSC	O
was	O
present	O
in	O
69	O
.	O
4	O
%	O
,	O
two	O
in	O
16	O
%	O
,	O
three	O
in	O
6	O
.	O
4	O
%	O
,	O
four	O
in	O
3	O
.	O
5	O
%	O
,	O
five	O
to	O
nine	O
in	O
4	O
.	O
2	O
%	O
,	O
and	O
0	O
.	O
5	O
%	O
had	O
ten	O
or	O
more	O
.	O

To	O
overcome	O
this	O
problem	O
,	O
we	O
have	O
overexpressed	O
Kex2p	B-protein
using	O
the	O
baculovirus	O
/	O
insect	O
cell	O
expression	O
system	O
.	O

In	O
contrast	O
,	O
no	O
change	O
was	O
detected	O
in	O
the	O
phenotype	O
of	O
'	O
unstressed	O
'	O
clones	O
,	O
with	O
respect	O
to	O
any	O
of	O
the	O
following	O
parameters	O
:	O
proliferation	O
rate	O
in	O
monolayer	O
,	O
serum	O
-	O
dependence	O
for	O
proliferation	O
or	O
survival	O
,	O
tumorigenicity	O
,	O
cellular	O
morphology	O
,	O
or	O
tissue	O
-	O
specific	O
differentiation	O
markers	O
.	O

In	O
vitro	O
penetration	O
tests	O
of	O
human	O
sperm	O
into	O
cervical	O
mucus	O
were	O
introduced	O
in	O
order	O
to	O
study	O
the	O
interaction	O
between	O
sperm	O
and	O
cervical	O
mucus	O
.	O

The	O
concentration	O
of	O
PGI2	O
on	O
the	O
newly	O
-	O
formed	O
luminal	O
surface	O
remained	O
low	O
.	O

The	O
most	O
important	O
risk	O
factors	O
are	O
:	O
1	O
)	O
genetic	O
;	O
2	O
)	O
Epstein	O
-	O
Barr	O
virus	O
(	O
infectious	O
mononucleosis	O
)	O
;	O
3	O
)	O
congenital	O
and	O
acquired	O
immunodeficiency	O
;	O
4	O
)	O
occupational	O
exposure	O
(	O
the	O
wood	O
industry	O
)	O
.	O

Statistically	O
significant	O
effects	O
were	O
noted	O
at	O
doses	O
which	O
did	O
not	O
appear	O
to	O
be	O
maternally	O
toxic	O
.	O

Recently	O
,	O
a	O
human	B-protein
transcription	I-protein
elongation	I-protein
factor	I-protein
P	I-protein
-	I-protein
TEFb	I-protein
,	O
consisting	O
of	O
CDK9	B-protein
kinase	I-protein
,	O
cyclin	B-protein
T	I-protein
and	O
other	O
associated	O
factors	O
,	O
has	O
been	O
shown	O
to	O
interact	O
with	O
Tat	B-protein
to	O
restore	O
Tat	B-protein
activation	O
in	O
HeLa	O
nuclear	O
extract	O
depleted	O
of	O
P	B-protein
-	I-protein
TEFb	I-protein
.	O

Following	O
the	O
injection	O
of	O
PGF2	B-protein
alpha	I-protein
,	O
heifers	O
were	O
observed	O
visually	O
for	O
signs	O
of	O
estrus	O
at	O
0730	O
and	O
1630	O
(	O
45	O
min	O
each	O
)	O
.	O

ECP	B-protein
and	O
tryptase	B-protein
levels	O
in	O
serum	O
were	O
measured	O
before	O
and	O
after	O
the	O
last	O
oral	O
challenge	O
.	O

Other	O
therapies	O
are	O
also	O
available	O
,	O
including	O
hypertonic	O
saline	O
solution	O
,	O
THAM	O
(	O
Tris	O
-	O
hydroxy	O
-	O
methyl	O
-	O
aminomethane	O
)	O
buffer	O
,	O
and	O
high	O
-	O
dose	O
barbiturates	O
.	O

Mean	O
+	O
/	O
-	O
SD	O
serum	B-protein
VEGF	I-protein
concentrations	O
were	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
women	O
with	O
PCO	O
and	O
PCOS	O
(	O
3	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
7	O
and	O
3	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
66	O
ng	O
/	O
ml	O
respectively	O
)	O
compared	O
with	O
women	O
with	O
normal	O
ovaries	O
(	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
5	O
ng	O
/	O
ml	O
)	O
.	O

During	O
V	O
-	O
A	O
bypass	O
,	O
hemodynamics	O
were	O
stable	O
.	O

However	O
,	O
a	O
zinc	O
-	O
depleted	O
enzyme	O
was	O
obtained	O
after	O
prolonged	O
dialysis	O
against	O
the	O
specific	O
chelating	O
agent	O
1	O
,	O
10	O
-	O
phenanthroline	O
.	O

Major	O
clinical	O
symptoms	O
of	O
the	O
disease	O
were	O
defined	O
in	O
this	O
group	O
of	O
patients	O
.	O

The	O
effect	O
of	O
dietary	O
zinc	O
deficiency	O
on	O
the	O
mossy	O
fiber	O
zinc	O
content	O
of	O
the	O
rat	O
hippocampus	O
.	O

To	O
investigate	O
the	O
functions	O
of	O
GE	O
,	O
IG	O
,	O
and	O
GS	O
sequences	O
in	O
transcription	O
,	O
we	O
constructed	O
plasmids	O
containing	O
cDNAs	O
of	O
the	O
full	O
-	O
length	O
SV5	O
genome	O
in	O
which	O
the	O
gene	O
junction	O
sequences	O
(	O
GE	O
,	O
IG	O
,	O
and	O
GS	O
sequences	O
)	O
located	O
between	O
the	O
hemagglutinin	B-protein
-	I-protein
neuraminidase	I-protein
(	O
HN	B-protein
)	O
and	O
the	O
polymerase	B-protein
(	I-protein
L	I-protein
)	I-protein
genes	I-protein
were	O
replaced	O
with	O
the	O
counterpart	O
sequences	O
from	O
other	O
gene	O
junctions	O
.	O

Effect	O
of	O
tracheal	O
insufflation	O
of	O
deferoxamine	O
on	O
acute	O
ozone	O
toxicity	O
in	O
rats	O
.	O

The	O
addition	O
of	O
an	O
equimolar	O
complex	O
of	O
the	O
fourth	O
and	O
seventh	O
largest	O
subunits	O
,	O
purified	O
from	O
pol	B-protein
II	I-protein
holoenzyme	I-protein
by	O
ion	O
-	O
exchange	O
chromatography	O
in	O
the	O
presence	O
of	O
urea	O
,	O
restored	O
promoter	O
-	O
directed	O
initiation	O
activity	O
to	O
pol	B-protein
II	I-protein
delta	I-protein
4	I-protein
/	I-protein
7	I-protein
.	O

We	O
propose	O
that	O
TFOs	O
represent	O
a	O
therapeutic	O
potential	O
to	O
specifically	O
diminish	O
the	O
expression	O
of	O
c	B-protein
-	I-protein
sis	I-protein
/	I-protein
PDGF	I-protein
-	I-protein
B	I-protein
proto	I-protein
-	I-protein
oncogene	I-protein
in	O
various	O
pathologic	O
settings	O
where	O
constitutive	O
expression	O
of	O
this	O
gene	O
has	O
been	O
observed	O
.	O

We	O
found	O
that	O
the	O
3	O
'	O
-	O
end	O
-	O
adjacent	O
sequence	O
CA	O
(	O
N	O
)	O
3	O
-	O
10AGTNNAA	O
,	O
conserved	O
in	O
plant	O
Pol	B-protein
II	I-protein
-	I-protein
specific	I-protein
U	I-protein
snRNA	I-protein
genes	I-protein
,	O
is	O
essential	O
for	O
the	O
3	O
'	O
-	O
end	O
formation	O
of	O
U2	B-protein
transcripts	I-protein
and	O
,	O
similar	O
to	O
the	O
vertebrate	O
3	O
'	O
box	O
,	O
is	O
highly	O
tolerant	O
to	O
mutation	O
.	O

The	O
effectiveness	O
of	O
the	O
haemodialysate	O
Solcoseryl	O
for	O
second	O
-	O
intention	O
wound	O
healing	O
in	O
horses	O
and	O
ponies	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
characterization	O
of	O
two	O
early	O
class	B-protein
II	I-protein
flagellar	I-protein
genes	I-protein
contained	O
in	O
the	O
orfX	B-protein
-	I-protein
fliP	I-protein
locus	I-protein
.	O

The	O
effect	O
of	O
the	O
fatty	B-protein
acid	I-protein
cyclo	I-protein
-	I-protein
oxygenase	I-protein
inhibitor	O
indomethacin	O
on	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
and	O
the	O
metabolic	O
rate	O
for	O
oxygen	O
(	O
CMRO2	O
)	O
was	O
studied	O
in	O
paralyzed	O
and	O
artificially	O
ventilated	O
rats	O
.	O

From	O
February	O
1991	O
to	O
August	O
1997	O
,	O
124	O
patients	O
with	O
endometrial	O
carcinoma	O
were	O
treated	O
postoperatively	O
with	O
high	O
-	O
dose	O
-	O
rate	O
vaginal	O
vault	O
brachytherapy	O
as	O
the	O
only	O
adjuvant	O
treatment	O
.	O

Contingency	O
contracting	O
between	O
clients	O
and	O
their	O
parents	O
/	O
caregivers	O
was	O
used	O
to	O
specify	O
consequences	O
for	O
daily	O
self	O
-	O
monitoring	O
,	O
reduced	O
caloric	O
intake	O
,	O
weight	O
loss	O
,	O
and	O
exercise	O
.	O

The	O
expressed	O
G1	B-protein
-	I-protein
G2	I-protein
bound	O
to	O
both	O
hyaluronan	O
and	O
link	B-protein
protein	I-protein
indicating	O
that	O
the	O
immunoglobulin	B-protein
-	I-protein
fold	I-protein
motif	I-protein
and	O
proteoglycan	O
tandem	O
repeat	O
loops	O
of	O
the	O
G1	B-protein
domain	I-protein
were	O
correctly	O
folded	O
.	O

Among	O
genes	O
induced	O
by	O
added	O
pMesogenin1	B-protein
is	O
Xwnt	B-protein
-	I-protein
8	I-protein
,	O
a	O
signaling	O
factor	O
that	O
induces	O
a	O
similar	O
repertoire	O
of	O
marker	O
genes	O
and	O
a	O
similar	O
cellular	O
phenotype	O
.	O

A	O
phylogenetic	O
tree	O
of	O
members	O
of	O
the	O
T2	B-protein
/	I-protein
S	I-protein
-	I-protein
RNase	I-protein
superfamily	I-protein
in	O
plants	O
was	O
obtained	O
.	O

Characterization	O
of	O
the	O
promoter	O
for	O
the	O
human	B-protein
85	I-protein
kDa	I-protein
cytosolic	I-protein
phospholipase	I-protein
A2	I-protein
gene	I-protein
.	O

Two	O
separate	O
NF1	B-protein
-	I-protein
binding	I-protein
loci	I-protein
were	O
also	O
found	O
in	O
the	O
equivalent	O
IE68	B-protein
gene	I-protein
of	O
HCMV	O
(	O
Towne	O
)	O
DNA	O
,	O
but	O
in	O
this	O
case	O
the	O
DNA	O
sequence	O
and	O
competition	O
filter	O
binding	O
experiments	O
indicated	O
a	O
maximum	O
of	O
only	O
four	O
to	O
five	O
consensus	O
binding	O
sites	O
encompassing	O
the	O
promoter	O
-	O
enhancer	O
region	O
.	O

The	O
second	O
patient	O
had	O
received	O
pituitary	B-protein
-	I-protein
derived	I-protein
growth	I-protein
hormone	I-protein
for	O
treatment	O
of	O
growth	B-protein
hormone	I-protein
deficiency	O
,	O
secondary	O
to	O
a	O
third	O
ventricle	O
teratoma	O
,	O
exised	O
13	O
yr	O
earlier	O
.	O

The	O
shift	O
in	O
the	O
earliest	O
activation	O
site	O
after	O
administration	O
of	O
esmolol	O
was	O
compared	O
with	O
the	O
shift	O
after	O
RFA	O
.	O
The	O
heart	O
rate	O
at	O
rest	O
and	O
in	O
drug	O
-	O
free	O
state	O
ranged	O
between	O
95	O
and	O
125	O
beats	O
/	O
min	O
(	O
mean	O
99	O
+	O
/	O
-	O
14	O
beats	O
/	O
min	O
)	O
.	O

The	O
hypertension	O
with	O
elevated	O
PRA	O
,	O
however	O
,	O
was	O
resistant	O
to	O
the	O
angiotensin	B-protein
II	I-protein
(	O
AII	B-protein
)	O
analog	O
[	O
Sar1	O
,	O
Ile8	O
]	O
ALL	O
.	O

The	O
Escherichia	B-protein
coli	I-protein
tet	I-protein
-	I-protein
repressor	I-protein
(	O
TetR	B-protein
)	O
operator	O
system	O
was	O
used	O
to	O
develop	O
a	O
variation	O
of	O
the	O
yeast	O
two	O
-	O
hybrid	O
assay	O
in	O
which	O
disruptions	O
of	O
protein	O
-	O
protein	O
interactions	O
can	O
be	O
identified	O
by	O
a	O
positive	O
selection	O
.	O

Western	O
blotting	O
(	O
immunoblotting	O
)	O
with	O
an	O
antiserum	O
to	O
a	O
partial	O
SOD	B-protein
expressed	O
in	O
Escherichia	O
coli	O
revealed	O
two	O
proteins	O
with	O
estimated	O
molecular	O
masses	O
of	O
19	O
and	O
29	O
kDa	O
.	O

D	O
.	O

Determination	O
of	O
an	O
RNA	O
structure	O
involved	O
in	O
splicing	O
inhibition	O
of	O
a	O
muscle	O
-	O
specific	O
exon	O
.	O

A	O
total	O
of	O
112	O
patients	O
received	O
anistreplase	O
and	O
119	O
received	O
heparin	O
within	O
a	O
mean	O
period	O
of	O
188	O
+	O
/	O
-	O
62	O
min	O
following	O
the	O
onset	O
of	O
symptoms	O
.	O

Unlike	O
wild	B-protein
-	I-protein
type	I-protein
p53	I-protein
,	O
the	O
delta	B-protein
proAE	I-protein
mutant	I-protein
cDNA	I-protein
can	O
be	O
stably	O
expressed	O
in	O
tumor	O
derived	O
cell	O
lines	O
with	O
few	O
immediate	O
detrimental	O
effects	O
.	O

The	O
complete	O
exon	O
-	O
intron	O
structure	O
of	O
the	O
156	B-protein
-	I-protein
kb	I-protein
human	I-protein
gene	I-protein
NFKB1	I-protein
,	O
which	O
encodes	O
the	O
p105	B-protein
and	O
p50	B-protein
proteins	I-protein
of	O
transcription	O
factors	O
NF	B-protein
-	I-protein
kappa	I-protein
B	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
-	I-protein
gamma	I-protein
:	O
implications	O
for	O
NF	O
-	O
kappa	O
B	O
-	O
mediated	O
signal	O
transduction	O
.	O

The	O
platelet	O
adhesion	O
rate	O
on	O
these	O
layers	O
were	O
tested	O
concerning	O
the	O
valuation	O
of	O
the	O
haemocompatibility	O
of	O
the	O
basic	O
-	O
polymers	O
polyurethane	O
(	O
PUR	O
)	O
,	O
polyvinylchloride	O
(	O
PVC	O
)	O
,	O
and	O
polystyrene	O
(	O
PS	O
)	O
in	O
two	O
different	O
worked	O
test	O
chambers	O
.	O

To	O
test	O
promotor	O
function	O
,	O
chimeric	O
genes	O
were	O
constructed	O
linking	O
fragments	O
of	O
chicken	O
IGF	B-protein
-	I-protein
I	I-protein
5	O
'	O
-	O
flanking	O
DNA	O
to	O
a	O
promoterless	O
reporter	O
plasmid	O
.	O

Here	O
,	O
we	O
identify	O
Rsc3	B-protein
and	O
Rsc30	B-protein
as	O
novel	O
components	O
of	O
the	O
essential	O
yeast	B-protein
remodeler	I-protein
RSC	I-protein
complex	I-protein
.	O

Urinary	O
LTE4	O
increased	O
after	O
both	O
challenges	O
the	O
rise	O
being	O
higher	O
following	O
oral	O
as	O
compared	O
to	O
inhalation	O
provocation	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
.	O

The	O
subepicardial	O
lymphatic	O
capillaries	O
were	O
ramified	O
and	O
anastomosed	O
with	O
each	O
other	O
to	O
form	O
a	O
relatively	O
dense	O
network	O
which	O
extended	O
over	O
the	O
entire	O
surface	O
of	O
both	O
ventricles	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
locally	O
-	O
applied	O
TTC	O
in	O
combination	O
with	O
FDBA	O
enhances	O
new	O
bone	O
formation	O
in	O
experimental	O
alveolar	O
bone	O
defects	O
.	O

To	O
confirm	O
the	O
GapIII	B-protein
protein	I-protein
activity	O
,	O
constructs	O
containing	O
different	O
GapIII	B-protein
-	I-protein
GRD	I-protein
domains	I-protein
were	O
transformed	O
into	O
iral	O
mutant	O
yeast	O
to	O
determine	O
their	O
relative	O
ability	O
to	O
replace	O
IRA1	B-protein
functionally	O
.	O

The	O
clinical	O
tolerance	O
and	O
pharmacokinetics	O
of	O
FCE	O
22101	O
(	O
sodium	O
(	O
5R	O
,	O
6S	O
)	O
-	O
6	O
-	O
[	O
(	O
1R	O
)	O
-	O
hydroxyethyl	O
]	O
-	O
2	O
-	O
carbamoyloxymethyl	O
-	O
2	O
-	O
penem	O
-	O
3	O
-	O
carboxylate	O
)	O
,	O
a	O
new	O
penem	O
antibiotic	O
,	O
have	O
been	O
studied	O
after	O
giving	O
a	O
single	O
i	O
.	O
v	O
.	O
dose	O
of	O
4	O
mg	O
.	O
kg	O
-	O
1	O
to	O
ten	O
healthy	O
male	O
volunteers	O
.	O

RESULTS	O
:	O
Acetabular	O
index	O
returned	O
to	O
normal	O
gradually	O
as	O
the	O
time	O
went	O
by	O
and	O
significantly	O
within	O
one	O
year	O
after	O
the	O
reduction	O
of	O
developmental	O
dislocation	O
of	O
the	O
hip	O
.	O

Inhibition	O
of	O
erythromycin	O
synthesis	O
by	O
disruption	O
of	O
malonyl	B-protein
-	I-protein
coenzyme	I-protein
A	I-protein
decarboxylase	I-protein
gene	I-protein
eryM	I-protein
in	O
Saccharopolyspora	O
erythraea	O
.	O

This	O
experimental	O
design	O
was	O
used	O
to	O
determine	O
the	O
effect	O
of	O
displacement	O
of	O
the	O
alpha	B-protein
4	I-protein
-	I-protein
2	I-protein
binding	I-protein
site	I-protein
on	O
the	O
repression	O
of	O
alpha	B-protein
4	I-protein
gene	I-protein
transcription	O
by	O
ICP4	B-protein
.	O

We	O
analyzed	O
data	O
from	O
56	O
patients	O
with	O
Systemic	O
Lupus	O
Erythematosus	O
(	O
SLE	O
)	O
in	O
whom	O
renal	O
biopsies	O
were	O
done	O
systematically	O
.	O

We	O
have	O
screened	O
the	O
elastin	B-protein
gene	I-protein
for	O
mutations	O
responsible	O
for	O
supravalvular	O
aortic	O
stenosis	O
(	O
SVAS	O
)	O
in	O
two	O
large	O
,	O
independently	O
collected	O
families	O
with	O
isolated	O
(	O
nonsyndromic	O
)	O
SVAS	O
.	O

Southern	O
blotting	O
and	O
single	O
strand	O
conformation	O
polymorphism	O
analyses	O
did	O
not	O
show	O
tumor	O
-	O
specific	O
alterations	O
of	O
this	O
gene	O
in	O
gliomas	O
and	O
RT	O
-	O
PCR	O
studies	O
showed	O
expression	O
in	O
glioma	O
cell	O
lines	O
,	O
suggesting	O
that	O
ANOVA	B-protein
is	O
not	O
the	O
chromosome	O
19q	O
glioma	O
tumor	O
suppressor	O
gene	O
.	O

The	O
backbone	O
dynamics	O
of	O
residues	O
located	O
in	O
the	O
folded	O
part	O
of	O
CRP2	B-protein
(	I-protein
LIM2	I-protein
)	I-protein
R122A	I-protein
have	O
been	O
characterized	O
by	O
proton	O
-	O
detected	O
(	O
15	O
)	O
N	O
NMR	O
spectroscopy	O
.	O

In	O
protocol	O
2	O
,	O
eight	O
different	O
subjects	O
performed	O
Con	O
and	O
Ecc	O
arm	O
curls	O
to	O
fatigue	O
,	O
followed	O
by	O
postexercise	O
muscle	O
ischemia	O
,	O
by	O
using	O
the	O
same	O
resistance	O
as	O
in	O
protocol	O
1	O
.	O

This	O
study	O
examined	O
the	O
role	O
of	O
cholesteryl	O
ester	O
transfer	O
(	O
CET	O
)	O
,	O
cholesteryl	B-protein
ester	I-protein
transfer	I-protein
protein	I-protein
(	O
CETP	B-protein
)	O
activity	O
,	O
and	O
phospholipid	B-protein
transfer	I-protein
protein	I-protein
(	O
PLTP	B-protein
)	O
activity	O
in	O
the	O
increased	O
prevalence	O
of	O
coronary	O
artery	O
calcification	O
(	O
CAC	O
)	O
in	O
diabetic	O
subjects	O
compared	O
with	O
nondiabetic	O
subjects	O
and	O
in	O
the	O
loss	O
of	O
the	O
sex	O
difference	O
in	O
CAC	O
in	O
diabetes	O
.	O

The	O
corresponding	O
gene	O
was	O
identified	O
in	O
the	O
GenBankTM	O
data	O
base	O
by	O
sequence	O
alignment	O
and	O
termed	O
RPS30A	B-protein
.	O

Southern	O
blot	O
analysis	O
of	O
endonuclease	O
-	O
digested	O
genomic	O
DNA	O
from	O
primary	O
chick	O
embryo	O
fibroblasts	O
(	O
CEF	O
)	O
suggested	O
that	O
MEK2	B-protein
is	O
a	O
single	O
-	O
copy	O
gene	O
in	O
this	O
vertebrate	O
species	O
.	O

The	O
members	O
of	O
the	O
Myb	B-protein
family	I-protein
of	I-protein
transcription	I-protein
factors	I-protein
are	O
defined	O
by	O
homology	O
in	O
the	O
DNA	O
-	O
binding	O
domain	O
;	O
all	O
bind	O
the	O
Myb	B-protein
-	I-protein
binding	I-protein
site	I-protein
(	O
MBS	B-protein
)	O
sequence	O
(	O
YG	B-protein
(	I-protein
A	I-protein
/	I-protein
G	I-protein
)	I-protein
C	I-protein
(	I-protein
A	I-protein
/	I-protein
C	I-protein
/	I-protein
G	I-protein
)	I-protein
GTT	I-protein
(	I-protein
G	I-protein
/	I-protein
A	I-protein
)	I-protein
)	I-protein
.	O

The	O
predominant	O
binding	O
activity	O
was	O
not	O
Ets	B-protein
-	I-protein
1	I-protein
but	O
rather	O
two	O
independent	O
DNA	O
-	O
protein	O
complexes	O
that	O
comigrated	O
in	O
mobility	O
shift	O
assays	O
.	O

Chronic	O
E	O
-	O
B	O
virus	O
infection	O
terminated	O
in	O
malignant	O
lymphoma	O
:	O
a	O
case	O
report	O
.	O

High	O
plasma	B-protein
AVP	I-protein
levels	O
observed	O
in	O
the	O
two	O
cases	O
suggest	O
that	O
SSRIs	O
stimulate	O
AVP	B-protein
secretion	O
,	O
thereby	O
causing	O
SIADH	O
.	O

These	O
data	O
indicate	O
a	O
functional	O
role	O
for	O
U1	B-protein
in	O
NRS	O
-	O
mediated	O
splicing	O
inhibition	O
.	O

Based	O
on	O
subcellular	O
fractionation	O
,	O
the	O
47	B-protein
-	I-protein
kDa	I-protein
P	I-protein
-	I-protein
CIP2	I-protein
protein	I-protein
is	O
mostly	O
cytosolic	O
.	O

Binding	O
of	O
cell	O
type	O
-	O
specific	O
nuclear	O
proteins	O
to	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
maize	B-protein
C4	I-protein
phosphoenolpyruvate	I-protein
carboxylase	I-protein
gene	I-protein
confers	O
its	O
differential	O
transcription	O
in	O
mesophyll	O
cells	O
.	O

With	O
histology	O
and	O
Evans	O
blue	O
injections	O
,	O
blood	O
-	O
brain	O
barrier	O
alterations	O
were	O
seen	O
as	O
early	O
as	O
4	O
days	O
after	O
a	O
dose	O
of	O
50	O
Gy	O
.	O

The	O
identity	O
between	O
hnRNPs	B-protein
H	I-protein
and	O
H	B-protein
'	I-protein
is	O
96	O
%	O
,	O
between	O
H	B-protein
and	O
F	B-protein
78	O
%	O
,	O
and	O
between	O
H	B-protein
'	I-protein
and	O
F	B-protein
75	O
%	O
,	O
respectively	O
.	O

Jkappa	B-protein
DNA	I-protein
-	I-protein
binding	I-protein
sites	I-protein
were	O
not	O
required	O
for	O
this	O
activation	O
,	O
and	O
a	O
mutant	B-protein
EBNA	I-protein
-	I-protein
3C	I-protein
protein	I-protein
unable	O
to	O
bind	O
Jkappa	B-protein
activated	O
transcription	O
as	O
efficiently	O
as	O
wild	B-protein
-	I-protein
type	I-protein
EBNA	I-protein
-	I-protein
3C	I-protein
,	O
indicating	O
that	O
EBNA	B-protein
-	I-protein
3C	I-protein
can	O
regulate	O
transcription	O
through	O
a	O
mechanism	O
that	O
is	O
independent	O
of	O
Jkappa	B-protein
.	O

Upon	O
UV	O
damage	O
,	O
Crb2	B-protein
is	O
transiently	O
modified	O
,	O
probably	O
phosphorylated	O
,	O
with	O
a	O
similar	O
timing	O
of	O
phosphorylation	O
in	O
Chk1	B-protein
kinase	I-protein
,	O
which	O
is	O
reported	O
to	O
restrain	O
Cdc2	B-protein
activation	O
.	O

CONCLUSION	O
:	O
This	O
retrospective	O
analysis	O
does	O
not	O
confirm	O
the	O
efficacy	O
of	O
one	O
course	O
of	O
simultaneous	O
Mitomycin	O
-	O
C	O
and	O
5	O
-	O
fluorouracil	O
,	O
at	O
least	O
in	O
association	O
with	O
full	O
-	O
dose	O
radiotherapy	O
incorporating	O
Iridium	O
-	O
192	O
boost	O
.	O

Furthermore	O
,	O
ICER	B-protein
negatively	O
autoregulates	O
the	O
alternative	O
promoter	O
,	O
thus	O
generating	O
a	O
feedback	O
loop	O
.	O

Consistent	O
with	O
this	O
similarity	O
,	O
the	O
cdc28	B-protein
-	I-protein
P8	I-protein
mutant	I-protein
accumulates	O
unspliced	O
precursors	O
at	O
the	O
restrictive	O
temperature	O
.	O

A	O
reduction	O
in	O
blood	O
pressure	O
was	O
only	O
observed	O
at	O
the	O
end	O
of	O
the	O
study	O
,	O
from	O
142	O
+	O
/	O
-	O
17	O
/	O
86	O
.	O
6	O
+	O
/	O
-	O
9	O
.	O
1	O
to	O
139	O
+	O
/	O
-	O
13	O
/	O
82	O
.	O
9	O
+	O
/	O
-	O
8	O
.	O
9	O
mmHg	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
for	O
DBP	O
)	O
.	O

With	O
chemical	O
shift	O
imaging	O
,	O
the	O
signal	O
intensity	O
decreased	O
on	O
the	O
out	O
-	O
of	O
-	O
phase	O
images	O
in	O
six	O
of	O
seven	O
(	O
86	O
%	O
)	O
patients	O
with	O
APA	O
and	O
in	O
eight	O
of	O
nine	O
(	O
89	O
%	O
)	O
patients	O
with	O
BAH	O
.	O

Creatine	B-protein
kinase	I-protein
release	O
after	O
hepatic	O
artery	O
embolization	O
in	O
patients	O
with	O
carcinoid	O
tumors	O
.	O

BACKGROUND	O
:	O
Ischemic	O
heart	O
disease	O
is	O
the	O
primary	O
cause	O
of	O
morbidity	O
and	O
mortality	O
among	O
diabetics	O
,	O
especially	O
those	O
who	O
became	O
ill	O
at	O
a	O
young	O
age	O
.	O

Significantly	O
,	O
two	O
proximal	O
GATA	B-protein
-	I-protein
1	I-protein
-	I-protein
binding	I-protein
sites	I-protein
(	O
-	O
118	O
/	O
-	O
113	O
and	O
-	O
98	O
/	O
-	O
93	O
)	O
and	O
a	O
region	O
located	O
within	O
-	O
518	O
to	O
-	O
315bp	O
of	O
the	O
mouse	B-protein
ALAS2	I-protein
promoter	I-protein
were	O
essential	O
for	O
transcriptional	O
activation	O
during	O
chemically	O
induced	O
differentiation	O
of	O
MEL	O
cells	O
,	O
implying	O
their	O
importance	O
in	O
conferring	O
erythroid	O
specificity	O
to	O
the	O
ALAS2	B-protein
transcriptional	O
activation	O
.	O

The	O
p73pct1	B-protein
/	I-protein
p85cdc10	I-protein
complex	I-protein
binds	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
to	O
MCB	B-protein
but	O
not	O
SCB	B-protein
or	O
E2F	B-protein
sites	I-protein
.	O

Transient	O
expression	O
of	O
VSF	B-protein
-	I-protein
1	I-protein
in	O
protoplasts	O
stimulated	O
vs	B-protein
-	I-protein
1	I-protein
dependent	O
activation	O
of	O
the	O
-	B-protein
76	I-protein
/	I-protein
grp1	I-protein
.	I-protein
8	I-protein
minimal	I-protein
promoter	I-protein
.	O

To	O
analyze	O
the	O
VH	B-protein
regions	I-protein
of	O
polyreactive	O
antibodies	O
,	O
with	O
particular	O
attention	O
at	O
their	O
somatically	O
mutated	O
status	O
,	O
we	O
generated	O
five	O
IgG	B-protein
(	O
three	O
IgG1	B-protein
and	O
two	O
IgG3	B-protein
)	O
mAb	O
(	O
using	O
B	O
cells	O
from	O
a	O
healthy	O
subject	O
,	O
a	O
patient	O
with	O
insulin	O
-	O
dependent	O
diabetes	O
mellitus	O
and	O
a	O
patient	O
with	O
SLE	O
)	O
,	O
which	O
bound	O
with	O
various	O
efficiencies	O
a	O
number	O
of	O
different	O
self	O
and	O
foreign	O
Ag	O
.	O

The	O
c	B-protein
-	I-protein
myc	I-protein
/	I-protein
TGF	I-protein
-	I-protein
alpha	I-protein
HCCs	O
were	O
also	O
characterized	O
by	O
a	O
particularly	O
strong	O
expression	O
of	O
TGF	B-protein
-	I-protein
alpha	I-protein
and	O
very	O
low	O
apoptotic	O
index	O
in	O
contrast	O
to	O
high	O
levels	O
of	O
apoptosis	O
in	O
peritumorous	O
tissues	O
and	O
c	B-protein
-	I-protein
myc	I-protein
HCCs	O
.	O

The	O
primary	O
structure	O
of	O
each	O
of	O
the	O
three	O
proteins	O
has	O
about	O
70	O
%	O
homology	O
with	O
that	O
of	O
mouse	B-protein
contrapsin	I-protein
,	O
in	O
contrast	O
to	O
43	O
-	O
46	O
%	O
homology	O
with	O
that	O
of	O
rat	B-protein
alpha	I-protein
1	I-protein
-	I-protein
protease	I-protein
inhibitor	O
.	O

Linear	O
extrapolation	O
is	O
used	O
below	O
the	O
experimental	O
data	O
range	O
to	O
establish	O
an	O
upper	O
bound	O
on	O
carcinogenic	O
risk	O
at	O
low	O
doses	O
.	O

This	O
study	O
was	O
performed	O
to	O
assess	O
the	O
role	O
of	O
additional	O
diagnostic	O
laparoscopy	O
in	O
the	O
preoperative	O
staging	O
of	O
patients	O
with	O
adenocarcinoma	O
of	O
the	O
esophagus	O
,	O
gastric	O
cancer	O
and	O
pancreatic	O
cancer	O
prior	O
to	O
intended	O
curative	O
surgery	O
.	O

Of	O
these	O
carriers	O
149	O
were	O
diagnosed	O
to	O
be	O
asymptomatic	O
clinically	O
,	O
biochemically	O
and	O
echographically	O
.	O

Animals	O
were	O
put	O
to	O
death	O
8	O
weeks	O
later	O
and	O
the	O
grafts	O
were	O
sterilely	O
explanted	O
and	O
analyzed	O
via	O
microbiologic	O
culture	O
and	O
standard	O
histologic	O
procedures	O
for	O
evidence	O
of	O
infection	O
.	O

A	O
13	O
base	O
-	O
pair	O
oligonucleotide	O
spanning	O
nucleotides	O
+	O
80	O
to	O
+	O
92	O
of	O
the	O
5	B-protein
S	I-protein
RNA	I-protein
gene	I-protein
retained	O
specific	O
and	O
high	O
-	O
affinity	O
binding	O
,	O
although	O
the	O
latter	O
was	O
reduced	O
sixfold	O
relative	O
to	O
longer	O
DNA	O
fragments	O
.	O

(	O
1986	O
)	O
method	O
of	O
separation	O
of	O
Cryptosporidium	O
spp	O
.	O
oocysts	O
from	O
feces	O
by	O
using	O
a	O
percoll	O
discontinuous	O
density	O
gradient	O
appeared	O
a	O
method	O
of	O
choice	O
for	O
obtaining	O
large	O
numbers	O
of	O
oocysts	O
of	O
C	O
.	O
parvum	O
free	O
of	O
fecal	O
contamination	O
.	O

The	O
relationships	O
between	O
the	O
partial	O
pressures	O
of	O
O2	O
and	O
CO2	O
as	O
well	O
as	O
between	O
their	O
gradients	O
,	O
become	O
stronger	O
with	O
the	O
increase	O
of	O
the	O
ventilation	O
-	O
perfusion	O
ratio	O
.	O

Two	O
promoters	O
were	O
identified	O
by	O
S1	B-protein
nuclease	I-protein
mapping	O
:	O
P1	O
,	O
which	O
lies	O
about	O
72	O
bp	O
upstream	O
from	O
the	O
structural	O
gene	O
;	O
and	O
P2	O
,	O
which	O
lies	O
about	O
35	O
bp	O
upstream	O
.	O

Multiple	O
regression	O
analyses	O
revealed	O
that	O
WAIS	O
-	O
R	O
factor	O
scores	O
Verbal	O
Comprehension	O
and	O
Freedom	O
from	O
Distractibility	O
accounted	O
for	O
up	O
to	O
42	O
%	O
of	O
the	O
variance	O
in	O
WMS	O
-	O
R	O
and	O
CVLT	O
indices	O
.	O

The	O
second	O
transcriptional	O
unit	O
,	O
designated	O
UL26	B-protein
.	I-protein
5	I-protein
,	O
predicted	O
to	O
specify	O
a	O
protein	O
of	O
329	O
amino	O
acids	O
,	O
encodes	O
the	O
family	B-protein
35	I-protein
proteins	I-protein
;	O
it	O
is	O
transcribed	O
by	O
an	O
mRNA	O
which	O
initiates	O
at	O
approximately	O
nucleotide	O
+	O
1000	O
of	O
the	O
UL26	B-protein
transcription	O
initiation	O
site	O
and	O
is	O
translated	O
from	O
the	O
methionine	O
initiation	O
codon	O
located	O
at	O
position	O
+	O
1099	O
of	O
the	O
UL26	B-protein
transcriptional	I-protein
unit	I-protein
.	O

(	O
1997	O
)	O
Nature	O
387	O
,	O
370	O
-	O
376	O
)	O
]	O
,	O
we	O
suggest	O
that	O
the	O
metal	O
fluoride	O
ions	O
replaced	O
phosphate	O
at	O
the	O
two	O
ATP	O
-	O
binding	O
sites	O
of	O
the	O
iron	O
protein	O
,	O
Kp2	B-protein
.	O

Only	O
one	O
gene	O
,	O
fibronectin	B-protein
(	O
FN	B-protein
)	O
,	O
was	O
highly	O
overexpressed	O
(	O
>	O
60	O
-	O
fold	O
)	O
in	O
LNCaP	O
-	O
r	O
cells	O
,	O
consistent	O
with	O
previously	O
reported	O
overexpression	O
of	O
FN	B-protein
in	O
prostate	O
cancer	O
.	O

The	O
former	O
procedure	O
is	O
economical	O
but	O
complicated	O
,	O
whereas	O
the	O
latter	O
is	O
simple	O
and	O
labour	O
-	O
saving	O
,	O
but	O
a	O
special	O
ultrafiltration	O
tube	O
is	O
required	O
.	O

Rat	B-protein
kidney	I-protein
carboxylesterase	I-protein
.	O

The	O
human	B-protein
insulin	I-protein
-	I-protein
like	I-protein
growth	I-protein
factor	I-protein
II	I-protein
(	O
IGF	B-protein
-	I-protein
II	I-protein
)	O
gene	O
contains	O
four	O
promoters	O
(	O
P1	O
,	O
P2	O
,	O
P3	O
and	O
P4	O
)	O
.	O

The	O
symptoms	O
and	O
objective	O
findings	O
were	O
caused	O
by	O
a	O
malignant	O
lymphoma	O
,	O
and	O
the	O
diagnosis	O
was	O
established	O
from	O
a	O
drill	O
biopsy	O
.	O

The	O
cis	O
-	O
acting	O
element	O
,	O
identified	O
as	O
CACGTGACCCG	B-protein
,	O
is	O
located	O
34	O
bp	O
upstream	O
from	O
the	O
transcription	O
initiation	O
site	O
,	O
and	O
contains	O
the	O
core	O
sequence	O
of	O
the	O
upstream	O
promoter	O
sequence	O
of	O
Ad2MLP	O
.	O

Two	O
techniques	O
based	O
on	O
assay	O
coefficients	O
of	O
variation	O
were	O
employed	O
to	O
characterize	O
a	O
normal	O
circadian	O
pattern	O
of	O
cortisol	O
.	O

The	O
differences	O
among	O
subgenera	O
of	O
the	O
genus	O
Dermacentor	O
are	O
more	O
significant	O
.	O

Luteinizing	B-protein
hormone	I-protein
-	I-protein
releasing	I-protein
hormone	I-protein
analog	O
therapy	O
of	O
uterine	O
fibroid	O
:	O
analysis	O
of	O
results	O
obtained	O
with	O
buserelin	O
administered	O
intranasally	O
and	O
goserelin	O
administered	O
subcutaneously	O
as	O
a	O
monthly	O
depot	O
.	O

Proteins	O
known	O
to	O
bind	O
the	O
PEPCK	B-protein
CRE	I-protein
include	O
the	O
CRE	B-protein
-	I-protein
binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
and	O
members	O
of	O
the	O
CCAAT	B-protein
/	I-protein
enhancer	I-protein
-	I-protein
binding	I-protein
protein	I-protein
(	O
C	B-protein
/	I-protein
EBP	I-protein
)	O
family	O
.	O

RESULTS	O
:	O
Statistically	O
significant	O
differences	O
were	O
obtained	O
between	O
group	O
I	O
and	O
II	O
concerning	O
the	O
number	O
of	O
patients	O
in	O
whom	O
induced	O
atrial	O
fibrillation	O
with	O
conduction	O
by	O
the	O
accessory	O
pathway	O
and	O
RR	O
<	O
or	O
=	O
250	O
msec	O
was	O
found	O
(	O
0	O
vs	O
6	O
,	O
p	O
=	O
0	O
.	O
0045	O
)	O
.	O

The	O
human	O
gene	O
fragment	O
ligated	O
to	O
the	O
minimal	O
rat	O
liver	O
glucokinase	B-protein
promoter	O
was	O
shown	O
to	O
work	O
as	O
an	O
enhancer	O
in	O
the	O
hepatocyte	O
transfection	O
system	O
.	O

Esophageal	O
brush	O
cytological	O
screening	O
was	O
undertaken	O
and	O
blood	O
concentrations	O
of	O
micronutrients	O
(	O
vitamin	O
A	O
,	O
E	O
,	O
B12	O
,	O
folic	O
acid	O
and	O
methionine	O
)	O
determined	O
from	O
adults	O
at	O
risk	O
for	O
esophageal	O
carcinoma	O
(	O
EC	O
)	O
in	O
Transkei	O
and	O
Ciskei	O
,	O
Southern	O
Africa	O
.	O

The	O
large	O
fluxes	O
of	O
239	O
+	O
240Pu	O
might	O
be	O
attributed	O
to	O
episodic	O
lateral	O
transport	O
of	O
particles	O
that	O
flow	O
down	O
the	O
continental	O
slope	O
with	O
the	O
nepheloid	O
layer	O
which	O
was	O
considered	O
to	O
be	O
significant	O
for	O
239	O
+	O
240Pu	O
transport	O
on	O
the	O
continental	O
slope	O
in	O
the	O
East	O
China	O
Sea	O
.	O

In	O
only	O
two	O
patients	O
were	O
we	O
able	O
to	O
demonstrate	O
changes	O
suggestive	O
of	O
pulmonary	O
metastases	O
any	O
earlier	O
with	O
a	O
99mTc	O
-	O
EHDP	O
scan	O
than	O
with	O
chest	O
radiographs	O
and	O
one	O
of	O
these	O
resolved	O
spontaneously	O
.	O

An	O
examination	O
of	O
the	O
role	O
of	O
the	O
carboxyl	O
terminus	O
in	O
regulating	O
NGFI	B-protein
-	I-protein
B	I-protein
transcriptional	O
activity	O
revealed	O
that	O
,	O
in	O
accordance	O
with	O
other	O
nuclear	O
receptors	O
,	O
mutants	O
lacking	O
portions	O
of	O
the	O
carboxyl	O
terminus	O
had	O
greatly	O
decreased	O
activity	O
.	O

They	O
were	O
then	O
subjected	O
to	O
whole	O
-	O
body	O
heat	O
stress	O
(	O
water	O
-	O
perfused	O
suits	O
)	O
,	O
and	O
the	O
3	O
minutes	O
of	O
LBNP	O
was	O
repeated	O
.	O

Preservatives	O
are	O
an	O
important	O
component	O
of	O
ophthalmic	O
preparations	O
,	O
providing	O
antimicrobial	O
activity	O
in	O
the	O
bottle	O
and	O
preventing	O
decomposition	O
of	O
active	O
drug	O
.	O

Vaccinia	O
virus	O
(	O
VV	O
)	O
is	O
a	O
potent	O
immunogen	O
,	O
but	O
the	O
nature	O
of	O
VV	O
proteins	O
involved	O
in	O
the	O
activation	O
of	O
the	O
immune	O
response	O
of	O
the	O
host	O
is	O
not	O
yet	O
known	O
.	O

In	O
addition	O
,	O
an	O
mck1	B-protein
mds1	I-protein
mrk1	I-protein
triple	O
disruptant	O
was	O
viable	O
.	O

Evaluation	O
of	O
antiepileptic	O
drug	O
effect	O
on	O
membrane	O
fluidity	O
.	O

One	O
defective	O
RNA	O
with	O
a	O
large	O
deletion	O
in	O
the	O
p70	B-protein
coding	I-protein
region	I-protein
was	O
able	O
to	O
replicate	O
efficiently	O
,	O
both	O
when	O
inoculated	O
with	O
the	O
helper	O
genome	O
and	O
when	O
inoculated	O
with	O
a	O
second	O
complementing	O
defective	O
RNA	O
that	O
supplied	O
a	O
wild	B-protein
-	I-protein
type	I-protein
p70	I-protein
.	O

In	O
contrast	O
,	O
H	B-protein
-	I-protein
NS	I-protein
negative	O
regulation	O
operated	O
only	O
in	O
the	O
absence	O
of	O
Fur	B-protein
.	O

The	O
sequence	O
up	O
to	O
-	O
267	O
bp	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
was	O
sufficient	O
to	O
enhance	O
reporter	O
gene	O
expression	O
depending	O
on	O
the	O
mesodermal	O
differentiation	O
of	O
P19	O
cells	O
.	O

In	O
this	O
article	O
,	O
the	O
clinical	O
actions	O
of	O
the	O
principal	O
dopamine	B-protein
receptor	I-protein
stimulating	O
agents	O
(	O
apomorphine	O
and	O
its	O
derivatives	O
;	O
piribedil	O
,	O
rye	O
-	O
ergot	O
derivatives	O
)	O
are	O
discussed	O
on	O
the	O
basis	O
of	O
their	O
biochemical	O
and	O
pharmacological	O
properties	O
.	O

To	O
address	O
these	O
questions	O
,	O
a	O
recombinant	B-protein
FRAP	I-protein
/	I-protein
mTOR	I-protein
protein	I-protein
and	O
a	O
FRAP	B-protein
/	I-protein
mTOR	I-protein
immunoprecipitate	O
were	O
utilized	O
in	O
in	O
vitro	O
kinase	B-protein
assays	O
to	O
phosphorylate	O
4E	B-protein
-	I-protein
BP1	I-protein
.	O

Here	O
we	O
report	O
the	O
cloning	O
,	O
expression	O
,	O
and	O
biochemical	O
characterization	O
of	O
the	O
32	O
-	O
kDa	O
subunit	O
of	O
human	O
(	O
h	O
)	O
TFIID	B-protein
,	O
termed	O
hTAFII32	B-protein
.	O

Clb	B-protein
/	I-protein
Cdc28	I-protein
kinases	I-protein
promote	O
nuclear	O
export	O
of	O
the	O
replication	B-protein
initiator	I-protein
proteins	I-protein
Mcm2	I-protein
-	I-protein
7	I-protein
.	O

This	O
repression	O
was	O
reversed	O
agonists	O
of	O
either	O
receptor	O
demonstrating	O
a	O
functional	O
interaction	O
between	O
NCoR	B-protein
and	O
PPARalpha	B-protein
.	I-protein
RXRalpha	I-protein
heterodimeric	I-protein
complexes	I-protein
in	O
mammalian	O
cells	O
.	O

When	O
the	O
degree	O
of	O
exercise	O
was	O
maximal	O
,	O
mPAP	O
was	O
maintained	O
,	O
SVI	O
decreased	O
,	O
HR	O
was	O
unchanged	O
,	O
and	O
CO	O
and	O
VO2	O
decreased	O
.	O

Thus	O
,	O
the	O
association	O
of	O
PS1	B-protein
fragments	I-protein
may	O
be	O
maintained	O
during	O
cycles	O
of	O
phosphorylation	O
/	O
dephosphorylation	O
of	O
the	O
PS1	B-protein
CTF	I-protein
.	O

Four	O
casein	B-protein
kinase	I-protein
I	I-protein
isoforms	I-protein
are	O
differentially	O
partitioned	O
between	O
nucleus	O
and	O
cytoplasm	O
.	O

Furthermore	O
,	O
the	O
validity	O
of	O
this	O
new	O
subset	O
of	O
questions	O
was	O
shown	O
to	O
be	O
significant	O
(	O
r	O
=	O
0	O
.	O
037	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
for	O
the	O
correlation	O
between	O
a	O
measure	O
of	O
the	O
severity	O
of	O
binocular	O
visual	O
field	O
loss	O
and	O
the	O
mean	O
score	O
of	O
the	O
variables	O
used	O
in	O
the	O
glaucoma	O
specific	O
subgroup	O
of	O
questions	O
.	O

FASEB	O
Federal	O
Funding	O
Consensus	O
Conference	O
FY	O
2000	O
.	O

Azithromycin	O
is	O
a	O
new	O
generation	O
macrolide	O
antibiotic	O
with	O
unusual	O
and	O
favorable	O
pharmacokinetics	O
,	O
and	O
seems	O
to	O
be	O
a	O
very	O
promising	O
agent	O
for	O
innovative	O
anti	O
-	O
H	O
.	O
pylori	O
regimens	O
.	O

Peroxisome	B-protein
proliferator	I-protein
-	I-protein
activated	I-protein
receptors	I-protein
(	O
PPARs	B-protein
)	O
and	O
retinoid	B-protein
X	I-protein
receptors	I-protein
(	O
RXRs	B-protein
)	O
are	O
nuclear	O
hormone	O
receptors	O
that	O
are	O
activated	O
by	O
fatty	O
acids	O
and	O
9	O
-	O
cis	O
-	O
retinoic	O
acid	O
,	O
respectively	O
.	O

Chenodeoxycholic	O
acid	O
(	O
cheno	O
)	O
and	O
ursodeoxycholic	O
acid	O
(	O
urso	O
)	O
dissolve	O
cholesterol	O
gallstones	O
in	O
man	O
.	O

The	O
second	O
part	O
of	O
this	O
paper	O
shows	O
some	O
medical	O
applications	O
of	O
these	O
two	O
aspects	O
of	O
NMR	O
,	O
with	O
help	O
of	O
some	O
examples	O
,	O
taken	O
from	O
the	O
literature	O
,	O
according	O
to	O
what	O
is	O
concerned	O
with	O
endocrinology	O
.	O

However	O
,	O
D8	B-protein
binding	O
was	O
observed	O
by	O
nuclease	B-protein
protection	O
with	O
lactotroph	O
-	O
as	O
well	O
as	O
somatotroph	B-protein
-	I-protein
like	I-protein
cell	I-protein
nuclear	I-protein
protein	I-protein
.	O

The	O
significance	O
of	O
the	O
phenolphthalein	B-protein
sulphatase	I-protein
test	O
for	O
the	O
differentiation	O
and	O
identification	O
of	O
Nocardia	O
species	O
.	O

These	O
results	O
indicate	O
that	O
T	O
.	O
C	O
.	O
,	O
LDL	B-protein
-	I-protein
C	I-protein
.	O
,	O
HDL	B-protein
-	I-protein
C	I-protein
.	O
,	O
HDL2	B-protein
-	I-protein
C	I-protein
.	O
,	O
apo	B-protein
B	I-protein
,	O
apo	B-protein
A	I-protein
-	I-protein
I	I-protein
/	I-protein
B	I-protein
ratio	O
and	O
apo	B-protein
A	I-protein
-	I-protein
II	I-protein
/	I-protein
B	I-protein
ratio	O
are	O
predictive	O
risk	O
factors	O
of	O
the	O
coronary	O
heart	O
disease	O
.	O

This	O
last	O
includes	O
tissue	O
O2	O
transfer	O
(	O
Ft	O
'	O
)	O
and	O
mitochondrial	O
O2	O
utilization	O
(	O
Fm	O
'	O
)	O
.	O

To	O
identify	O
cis	O
-	O
acting	O
elements	O
that	O
target	O
c	B-protein
-	I-protein
myc	I-protein
mRNA	I-protein
for	O
downregulation	O
during	O
myogenesis	O
,	O
we	O
stably	O
transfected	O
C2C12	O
cells	O
with	O
mutant	B-protein
myc	I-protein
genes	I-protein
or	O
chimeric	O
genes	O
in	O
which	O
various	O
myc	B-protein
sequences	I-protein
were	O
fused	O
to	O
the	O
human	B-protein
beta	I-protein
-	I-protein
globin	I-protein
gene	I-protein
or	O
to	O
the	O
bacterial	B-protein
chloramphenicol	I-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
gene	O
.	O

These	O
findings	O
and	O
the	O
differential	O
tissue	O
distribution	O
of	O
p54	B-protein
suggest	O
that	O
this	O
novel	O
SR	B-protein
protein	I-protein
may	O
participate	O
in	O
regulation	O
of	O
alternative	O
splicing	O
in	O
a	O
tissue	O
-	O
and	O
substrate	O
-	O
dependent	O
manner	O
.	O

Nine	O
cats	O
received	O
PMEA	O
at	O
a	O
dosage	O
of	O
10	O
mg	O
/	O
kg	O
body	O
weight	O
,	O
nine	O
cats	O
received	O
FPMPA	O
at	O
a	O
dosage	O
of	O
25	O
mg	O
/	O
kg	O
body	O
weight	O
.	O

Mutational	O
studies	O
revealed	O
that	O
it	O
was	O
the	O
homeodomain	B-protein
binding	I-protein
site	I-protein
II	I-protein
sequence	I-protein
that	O
was	O
required	O
for	O
this	O
regulation	O
.	O

BACKGROUND	O
:	O
Left	O
ventricular	O
hypertrophy	O
is	O
a	O
heterogeneous	O
disorder	O
with	O
distinct	O
morphologies	O
.	O

Additionally	O
,	O
MIP	B-protein
-	I-protein
2A	I-protein
antagonizes	O
cell	O
growth	O
regulatory	O
role	O
of	O
MBP	B-protein
-	I-protein
1	I-protein
.	O

We	O
also	O
reported	O
the	O
identification	O
of	O
three	O
corresponding	O
alternative	O
first	O
exons	O
and	O
an	O
intronic	O
promoter	O
in	O
the	O
human	B-protein
PDE5A	I-protein
gene	I-protein
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Studies	O
were	O
undertaken	O
in	O
9	O
isolated	O
guinea	O
pig	O
hearts	O
,	O
which	O
demonstrated	O
reverse	O
use	O
-	O
dependent	O
prolongation	O
of	O
cardiac	O
repolarization	O
by	O
100	O
nmol	O
/	O
L	O
domperidone	O
.	O

In	O
the	O
point	O
mutant	O
we	O
observed	O
normal	O
repair	O
of	O
endonuclease	B-protein
III	I-protein
site	I-protein
(	O
i	O
.	O
e	O
.	O
as	O
wild	O
type	O
)	O
,	O
but	O
no	O
removal	O
of	O
CPDs	O
at	O
the	O
MAT	B-protein
alpha	I-protein
and	O
HML	B-protein
alpha	I-protein
loci	I-protein
.	O

Two	O
putative	O
Rev	B-protein
proteins	I-protein
with	O
apparent	O
molecular	O
masses	O
of	O
18	O
and	O
16	O
kDa	O
were	O
expressed	O
by	O
p2	O
/	O
2	O
and	O
p176	O
,	O
while	O
p20	O
expressed	O
only	O
a	O
16	O
-	O
kDa	O
species	O
.	O

These	O
analyses	O
re	O
-	O
open	O
the	O
question	O
whether	O
all	O
the	O
CesA	B-protein
genes	I-protein
encode	O
cellulose	B-protein
synthases	I-protein
or	O
whether	O
some	O
of	O
the	O
sub	O
-	O
class	O
members	O
may	O
encode	O
other	O
non	B-protein
-	I-protein
cellulosic	I-protein
(	I-protein
1	I-protein
-	I-protein
-	I-protein
>	I-protein
4	I-protein
)	I-protein
beta	I-protein
-	I-protein
glycan	I-protein
synthases	I-protein
in	O
plants	O
.	O

E	O
50	O
,	O
843	O
(	O
1994	O
)	O
]	O
.	O

In	O
this	O
situation	O
the	O
convlusion	O
threshold	O
for	O
the	O
8	O
substances	O
is	O
as	O
follows	O
:	O
pethidine	O
20	O
mg	O
.	O
kg	O
-	O
1	O
I	O
.	O
V	O
.	O
,	O
piritramide	O
30	O
,	O
morphine	O
180	O
,	O
phenoperidine	O
4	O
,	O
R	O
39	O
209	O
5	O
,	O
fentanyl	O
4	O
,	O
sufentanil	O
4	O
and	O
R	O
34	O
995	O
10	O
mg	O
.	O
kg	O
-	O
1	O
I	O
.	O
V	O
.	O

To	O
assess	O
the	O
ability	O
of	O
the	O
atria	O
to	O
maintain	O
elevated	O
plasma	O
concentrations	O
of	O
atrial	B-protein
natriuretic	I-protein
peptide	I-protein
(	O
ANP	B-protein
)	O
,	O
the	O
temporal	O
changes	O
in	O
plasma	B-protein
ANP	I-protein
concentrations	O
were	O
studied	O
in	O
seven	O
chloralose	O
-	O
anaesthetized	O
dogs	O
during	O
4	O
h	O
of	O
sustained	O
rapid	O
cardiac	O
pacing	O
.	O

Our	O
results	O
show	O
that	O
the	O
temperature	B-protein
-	I-protein
sensitive	I-protein
rad54	I-protein
-	I-protein
3	I-protein
allele	I-protein
blocks	O
mitotic	O
recombination	O
between	O
tandemly	O
repeated	O
DYZ3	B-protein
satellite	I-protein
sequences	I-protein
and	O
significantly	O
stabilizes	O
a	O
human	B-protein
DYZ5	I-protein
satellite	O
-	O
containing	O
YAC	O
clone	O
.	O

Again	O
residue	O
Glu	O
-	O
381	O
of	O
beta	O
was	O
notably	O
reduced	O
and	O
no	O
missing	O
residue	O
from	O
the	O
epsilon	B-protein
peptide	I-protein
could	O
be	O
identified	O
,	O
but	O
the	O
peptide	O
sequence	O
limited	O
the	O
possible	O
choices	O
to	O
Ser	O
-	O
106	O
,	O
Ser	O
-	O
107	O
,	O
or	O
Ser	O
-	O
108	O
.	O

Differential	O
expression	O
and	O
regulation	O
by	O
20	O
-	O
hydroxyecdysone	O
of	O
mosquito	O
ultraspiracle	O
isoforms	O
.	O

As	O
a	O
part	O
of	O
a	O
large	O
examination	O
,	O
total	O
and	O
free	O
serum	O
cholesterol	O
,	O
total	O
lipid	O
and	O
triglyceride	O
levels	O
were	O
determined	O
.	O

Only	O
two	O
patients	O
(	O
0	O
.	O
3	O
%	O
)	O
had	O
a	O
CA	O
125	O
response	O
at	O
the	O
time	O
of	O
clinical	O
progression	O
.	O

The	O
alterations	O
in	O
differentiation	O
of	O
osteoprogenitor	O
cells	O
,	O
together	O
with	O
the	O
failure	O
of	O
mineralization	O
,	O
resulted	O
in	O
significantly	O
lower	O
rates	O
of	O
bone	O
formation	O
(	O
as	O
measured	O
by	O
fluorochrome	O
labeling	O
)	O
in	O
the	O
magnesium	O
-	O
deficient	O
rats	O
.	O

Radionuclide	O
study	O
and	O
endomyocardial	O
biopsy	O
revealed	O
remarkable	O
degeneration	O
of	O
myocardium	O
.	O

In	O
contrast	O
,	O
similar	O
rates	O
of	O
B	O
.	O
sphaericus	O
products	O
,	O
ABG	O
-	O
6184	O
technical	O
powder	O
and	O
BSP	O
-	O
2	O
flowable	O
concentrate	O
,	O
produced	O
no	O
significant	O
reduction	O
.	O

The	O
aspirate	O
from	O
a	O
parathyroid	O
cyst	O
was	O
watery	O
clear	O
and	O
contained	O
high	O
amount	O
of	O
parathyroid	B-protein
hormone	I-protein
.	O

The	O
number	O
of	O
fecal	O
pellets	O
ingested	O
peaked	O
at	O
5	O
to	O
6	O
weeks	O
old	O
(	O
13	O
pellets	O
/	O
day	O
)	O
and	O
gradually	O
decreased	O
,	O
thereafter	O
(	O
2	O
.	O
1	O
pellets	O
at	O
78	O
weeks	O
old	O
,	O
1	O
.	O
5	O
pellets	O
at	O
104	O
weeks	O
old	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
Shh	B-protein
can	O
drive	O
continued	O
cycling	O
in	O
immature	O
,	O
proliferating	O
CGNPs	O
.	O

Urease	B-protein
activity	O
,	O
judged	O
as	O
the	O
amount	O
of	O
ammonia	O
production	O
from	O
urea	O
,	O
could	O
be	O
measured	O
at	O
25	O
ng	O
per	O
tube	O
(	O
S	O
/	O
N	O
=	O
1	O
.	O
5	O
)	O
with	O
Jack	B-protein
bean	I-protein
meal	I-protein
urease	I-protein
.	O

These	O
data	O
confirm	O
the	O
existence	O
of	O
hyperlipemic	O
abdominal	O
crisis	O
as	O
a	O
distinct	O
entity	O
and	O
testify	O
to	O
the	O
importance	O
of	O
recognizing	O
this	O
syndrome	O
in	O
order	O
to	O
avoid	O
the	O
occurrence	O
of	O
acute	O
pancreatitis	O
and	O
the	O
performance	O
of	O
unnecessary	O
and	O
potentially	O
harmful	O
surgery	O
.	O

Using	O
reference	O
probes	O
as	O
internal	O
standards	O
,	O
we	O
show	O
that	O
the	O
ost	B-protein
transcription	I-protein
unit	I-protein
is	O
located	O
within	O
the	O
cytogenetic	O
band	O
interval	O
89A1	O
,	O
2	O
on	O
the	O
right	O
arm	O
of	O
the	O
third	O
chromosome	O
,	O
and	O
that	O
it	O
exerts	O
diagnostic	O
segmentation	O
gene	O
expression	O
patterns	O
in	O
the	O
embryo	O
.	O

The	O
proteasome	O
is	O
a	O
large	O
complex	O
consisting	O
of	O
two	O
multisubunit	O
structures	O
,	O
the	O
20S	B-protein
and	O
19S	B-protein
(	I-protein
PA700	I-protein
)	I-protein
or	O
P28	B-protein
complexes	I-protein
,	O
that	O
combine	O
to	O
form	O
the	O
26S	B-protein
particles	I-protein
.	O

The	O
UBA	B-protein
domains	I-protein
of	O
RAD23	B-protein
and	O
DDI1	B-protein
are	O
required	O
for	O
these	O
interactions	O
.	O

Intracellular	O
recordings	O
were	O
performed	O
on	O
the	O
optic	O
tectum	O
of	O
the	O
carp	O
in	O
vitro	O
.	O

RESULTS	O
:	O
Nodular	O
opacities	O
,	O
mainly	O
centrilobular	O
in	O
distribution	O
,	O
were	O
the	O
most	O
common	O
finding	O
,	O
seen	O
in	O
21	O
(	O
72	O
%	O
)	O
and	O
15	O
(	O
65	O
%	O
)	O
of	O
patients	O
with	O
MTB	O
and	O
NTMB	O
,	O
respectively	O
.	O

The	O
results	O
strengthen	O
the	O
conclusion	O
that	O
predominantly	O
dynamic	O
activity	O
increases	O
the	O
G4	B-protein
content	O
of	O
mature	O
innervated	O
fast	O
muscles	O
.	O

Serum	O
ferritin	B-protein
concentration	O
and	O
bone	O
marrow	O
iron	O
stores	O
.	O

The	O
mechanism	O
of	O
ligand	O
-	O
activated	O
estrogen	B-protein
receptor	I-protein
alpha	I-protein
(	O
ERalpha	B-protein
)	O
-	O
dependent	O
activation	O
of	O
gene	O
expression	O
through	O
the	O
SRE	B-protein
was	O
determined	O
by	O
mutational	O
analysis	O
of	O
the	O
promoter	O
,	O
analysis	O
of	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
pathway	O
activation	O
by	O
E2	B-protein
,	O
and	O
transforming	B-protein
growth	I-protein
factor	I-protein
alpha	I-protein
(	O
TGF	B-protein
-	I-protein
alpha	I-protein
)	O
as	O
a	O
positive	O
control	O
.	O

Risk	O
of	O
infection	O
in	O
the	O
treatment	O
of	O
fractures	O
.	O

The	O
large	O
subfamily	O
of	O
receptor	B-protein
tyrosine	I-protein
kinases	I-protein
(	O
RTKs	B-protein
)	O
for	O
which	O
EPH	B-protein
is	O
the	O
prototype	O
have	O
likely	O
roles	O
in	O
intercellular	O
communication	O
during	O
normal	O
mammalian	O
development	O
,	O
but	O
the	O
biochemical	O
signalling	O
pathways	O
utilised	O
by	O
this	O
family	O
are	O
poorly	O
characterised	O
.	O

At	O
both	O
companies	O
sites	O
Salmonella	O
enteritidis	O
and	O
Salmonella	O
typhimurium	O
Tr104	O
were	O
also	O
isolated	O
occasionally	O
from	O
various	O
locations	O
.	O

Comparison	O
of	O
the	O
proportion	O
of	O
nonsynonymous	O
(	O
pN	O
)	O
and	O
synonymous	O
(	O
pS	O
)	O
substitutions	O
occurring	O
per	O
site	O
within	O
tamarin	B-protein
variable	I-protein
region	I-protein
genes	I-protein
demonstrated	O
a	O
reduction	O
in	O
pN	O
in	O
the	O
framework	O
regions	O
compared	O
with	O
pN	O
in	O
the	O
presumed	O
MHC	B-protein
contact	I-protein
regions	I-protein
(	O
CDR1	B-protein
and	O
CDR2	B-protein
)	O
.	O

Tracheal	O
transsection	O
combined	O
with	O
hilar	O
ligation	O
(	O
TL	O
@	O
PL	O
)	O
effected	O
a	O
reduction	O
of	O
19	O
.	O
9	O
%	O
(	O
n	O
.	O
s	O
.	O
)	O
.	O

Papers	O
of	O
the	O
Society	O
for	O
Clinical	O
Vascular	O
Surgery	O
.	O

Dual	O
radionuclide	O
subtraction	O
imaging	O
of	O
the	O
spleen	O
using	O
67Ga	O
citrate	O
and	O
99mTc	O
is	O
useful	O
in	O
further	O
delineating	O
lesions	O
that	O
are	O
identified	O
on	O
either	O
a	O
routine	O
radiogallium	O
survey	O
or	O
on	O
a	O
conventional	O
sulfur	O
colloid	O
liver	O
-	O
spleen	O
image	O
.	O

Gene	O
constructs	O
consisting	O
of	O
human	B-protein
growth	I-protein
hormone	I-protein
(	O
hGH	B-protein
)	O
gene	O
driven	O
by	O
promoter	O
/	O
regulatory	O
sequence	O
of	O
mouse	B-protein
metallothionein	I-protein
(	O
mMT	B-protein
)	O
,	O
viral	B-protein
thymidine	I-protein
kinase	I-protein
(	O
vTK	B-protein
)	O
,	O
rat	B-protein
cholecystokinin	I-protein
(	O
rCCK	B-protein
)	O
,	O
or	O
chicken	B-protein
beta	I-protein
-	I-protein
actin	I-protein
(	O
cBA	B-protein
)	O
gene	O
were	O
injected	O
into	O
the	O
cytoplasm	O
of	O
fertilized	O
medaka	O
eggs	O
via	O
the	O
micropyle	O
.	O

DNase	B-protein
I	I-protein
footprinting	O
analysis	O
indicated	O
that	O
DREF	B-protein
binds	O
to	O
the	O
24	O
-	O
bp	O
DRE	B-protein
region	O
of	O
the	O
DNA	B-protein
polymerase	I-protein
alpha	I-protein
gene	I-protein
in	O
which	O
8	O
-	O
bp	O
palindromic	O
sequences	O
are	O
centered	O
.	O

This	O
study	O
was	O
carried	O
out	O
to	O
analyze	O
PRL	B-protein
secretion	O
in	O
metastatic	O
prostate	O
cancer	O
patients	O
both	O
at	O
basal	O
conditions	O
and	O
in	O
response	O
to	O
L	O
-	O
Dopa	O
and	O
metoclopramide	O
,	O
which	O
represents	O
the	O
most	O
classical	O
inhibitory	O
and	O
stimulatory	O
tests	O
for	O
PRL	B-protein
secretion	O
,	O
respectively	O
.	O

A	O
3	O
-	O
yr	O
retrospective	O
review	O
is	O
effective	O
and	O
detects	O
94	O
%	O
of	O
the	O
undercalls	O
.	O

The	O
partial	O
farm	O
budget	O
highlighted	O
the	O
importance	O
of	O
reducing	O
sub	O
-	O
clinical	O
lesions	O
in	O
a	O
feedlot	O
.	O

Additional	O
exonuclease	B-protein
III	I-protein
protection	O
was	O
observed	O
beyond	O
the	O
core	O
region	O
on	O
both	O
the	O
5	O
'	O
and	O
3	O
'	O
sides	O
,	O
suggesting	O
that	O
E1	B-protein
interacted	O
with	O
more	O
distal	O
sequences	O
as	O
well	O
.	O

Serum	O
antibodies	O
were	O
detected	O
in	O
at	O
least	O
95	O
%	O
of	O
the	O
infected	O
guinea	O
pigs	O
between	O
4	O
-	O
30	O
WPI	O
and	O
rats	O
between	O
3	O
-	O
16	O
WPI	O
.	O

Two	O
experiments	O
were	O
conducted	O
to	O
study	O
the	O
vacuous	O
jaw	O
movements	O
induced	O
in	O
rats	O
by	O
acute	O
administration	O
of	O
the	O
monoamine	O
-	O
depleting	O
agent	O
reserpine	O
.	O

Impaction	O
of	O
gastrostomy	O
tube	O
in	O
the	O
abdominal	O
wall	O
.	O

However	O
,	O
during	O
our	O
work	O
with	O
a	O
replication	O
-	O
deficient	O
virus	O
expressing	O
the	O
ASF	B-protein
/	I-protein
SF2	I-protein
splicing	I-protein
factor	O
from	O
a	O
progesterone	O
antagonist	O
-	O
inducible	O
gene	O
cassette	O
,	O
we	O
discovered	O
that	O
ASF	B-protein
/	I-protein
SF2	I-protein
was	O
expressed	O
at	O
a	O
significant	O
level	O
in	O
the	O
293	O
producer	O
cell	O
line	O
,	O
even	O
in	O
the	O
absence	O
of	O
inducer	O
.	O

Molecular	O
cloning	O
of	O
mouse	B-protein
glycolate	I-protein
oxidase	I-protein
.	O

The	O
MVV	O
-	O
value	O
is	O
under	O
the	O
predicted	O
level	O
in	O
the	O
case	O
of	O
67	O
-	O
76	O
percent	O
.	O

Using	O
the	O
rap1t	B-protein
alleles	I-protein
to	O
generate	O
wild	O
-	O
type	O
cells	O
differing	O
only	O
in	O
telomere	O
tract	O
lengths	O
,	O
we	O
also	O
show	O
that	O
telomere	O
position	O
effects	O
are	O
highly	O
sensitive	O
to	O
changes	O
in	O
the	O
size	O
(	O
or	O
structure	O
)	O
of	O
the	O
telomeric	O
tract	O
.	O

Two	O
protease	O
-	O
resistant	O
fragments	O
spanning	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
halves	O
of	O
the	O
nuclease	B-protein
were	O
identified	O
using	O
different	O
proteases	B-protein
which	O
cleave	O
the	O
protein	O
in	O
the	O
same	O
region	O
.	O

Dorsal	O
root	O
ganglia	O
neuron	O
-	O
specific	O
promoter	O
activity	O
of	O
the	O
rabbit	B-protein
beta	I-protein
-	I-protein
galactoside	I-protein
alpha1	I-protein
,	I-protein
2	I-protein
-	I-protein
fucosyltransferase	I-protein
gene	I-protein
.	O

A	O
prospectively	O
gated	O
2D	O
axial	O
sequence	O
with	O
velocity	O
encoding	O
in	O
the	O
craniocaudal	O
direction	O
in	O
the	O
cervical	O
region	O
was	O
set	O
at	O
a	O
velocity	O
of	O
+	O
/	O
-	O
10	O
cm	O
/	O
s	O
.	O

Alterations	O
of	O
the	O
5q23	O
-	O
q31	O
interval	O
are	O
frequently	O
observed	O
in	O
myelodysplasia	O
and	O
myeloid	O
leukemia	O
.	O

Mechanistically	O
,	O
the	O
presence	O
of	O
the	O
GRR	O
appears	O
to	O
stop	O
further	O
degradation	O
of	O
p50	B-protein
and	O
to	O
stabilize	O
the	O
molecule	O
.	O

Suppressive	O
therapy	O
for	O
thyroid	O
nodules	O
.	O

A	O
high	O
-	O
frequency	O
restriction	O
fragment	O
length	O
polymorphism	O
was	O
evident	O
in	O
the	O
DNA	O
from	O
29	O
unrelated	O
individuals	O
using	O
the	O
enzyme	O
BglII	B-protein
.	O

RPA190	B-protein
encodes	O
a	O
polypeptide	O
chain	O
of	O
186	O
,	O
270	O
daltons	O
in	O
a	O
large	O
uninterrupted	O
reading	O
frame	O
.	O

The	O
arginyl	O
peptide	O
bonds	O
that	O
are	O
cleaved	O
in	O
the	O
conversion	O
of	O
human	B-protein
factor	I-protein
IX	I-protein
to	O
factor	B-protein
IXa	I-protein
by	O
factor	B-protein
XIa	I-protein
were	O
identified	O
as	O
Arg145	O
-	O
Ala146	O
and	O
Arg180	O
-	O
Val181	O
.	O

Synthetic	O
oligonucleotides	O
representing	O
the	O
19	O
bp	O
repeat	O
unit	O
strongly	O
reduced	O
the	O
activity	O
of	O
the	O
IE1	B-protein
/	I-protein
2	I-protein
enhancer	I-protein
/	I-protein
promoter	I-protein
in	O
cotransfection	O
assays	O
after	O
transient	O
expression	O
.	O

Despite	O
the	O
existence	O
of	O
30	O
cysteine	O
residues	O
,	O
carboxymethylation	O
prevented	O
the	O
formation	O
of	O
most	O
if	O
not	O
all	O
disulfide	O
bonds	O
that	O
otherwise	O
occurred	O
when	O
the	O
cells	O
were	O
sonicated	O
.	O

A	O
control	O
group	O
of	O
nine	O
women	O
(	O
age	O
23	O
-	O
40	O
years	O
)	O
on	O
oral	O
contraceptives	O
(	O
Nordette	O
-	O
28	O
)	O
was	O
also	O
studied	O
four	O
times	O
during	O
a	O
pill	O
cycle	O
.	O

This	O
motif	O
has	O
been	O
shown	O
to	O
mediate	O
protein	O
interactions	O
in	O
the	O
case	O
of	O
ankyrin	B-protein
as	O
well	O
as	O
several	O
other	O
repeat	O
-	O
bearing	O
proteins	O
.	O

The	O
coating	O
materials	O
were	O
poloxamine	O
904	O
,	O
poloxamine	O
908	O
,	O
poloxamine	O
1508	O
,	O
poloxamer	O
338	O
,	O
and	O
Brij	O
35	O
.	O

Mycobacterium	O
avium	O
-	O
intracellulare	O
complex	O
infections	O
in	O
the	O
acquired	O
immunodeficiency	O
syndrome	O
.	O

Recent	O
application	O
of	O
recombinant	O
canarypox	O
ALVAC	O
/	O
HIV	O
-	O
1	O
vectors	O
as	O
vaccine	O
immunogens	O
in	O
HIV	O
-	O
1	O
,	O
-	O
noninfected	O
volunteers	O
has	O
produced	O
CTL	O
responses	O
in	O
a	O
significant	O
number	O
of	O
vaccinees	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
simplified	O
methods	O
for	O
estimation	O
of	O
Technetium	O
Tc	O
99m	O
(	O
99mTc	O
)	O
-	O
pentetate	O
and	O
orthoiodohippurate	O
I	O
131	O
(	O
131I	O
-	O
OIH	O
)	O
plasma	O
clearance	O
in	O
dogs	O
and	O
cats	O
with	O
1	O
and	O
2	O
blood	O
samples	O
.	O

Hovenitin	O
I	O
and	O
(	O
+	O
)	O
-	O
ampelopsin	O
,	O
both	O
of	O
which	O
were	O
principal	O
ingredients	O
of	O
the	O
active	O
fractions	O
from	O
this	O
natural	O
medicine	O
,	O
were	O
found	O
to	O
show	O
an	O
inhibitory	O
activity	O
on	O
the	O
ethanol	O
-	O
induced	O
muscle	O
relaxation	O
in	O
rats	O
.	O

This	O
observation	O
suggests	O
that	O
the	O
methyl	O
-	O
directed	O
repair	O
system	O
utilizes	O
the	O
proximal	O
d	O
(	O
GATC	O
)	O
sequence	O
to	O
direct	O
correction	O
.	O

Elements	O
that	O
are	O
fundamental	O
to	O
the	O
safety	O
evaluation	O
of	O
flavor	O
ingredients	O
include	O
exposure	O
,	O
structural	O
analogy	O
,	O
metabolism	O
,	O
pharmacokinetics	O
and	O
toxicology	O
.	O

This	O
repression	O
does	O
not	O
require	O
the	O
PU	B-protein
.	I-protein
1	I-protein
transactivation	O
or	O
PEST	B-protein
domains	I-protein
and	O
can	O
not	O
be	O
reversed	O
by	O
p300	B-protein
expression	O
.	O

Possible	O
roles	O
of	O
RAD5	B-protein
putative	O
ATPase	B-protein
/	I-protein
DNA	I-protein
helicase	I-protein
activity	O
in	O
DNA	O
repair	O
and	O
in	O
the	O
maintenance	O
of	O
wild	O
-	O
type	O
rates	O
of	O
instability	O
of	O
simple	O
repetitive	O
sequences	O
are	O
discussed	O
.	O

CDC31	B-protein
is	O
required	O
for	O
SPB	O
duplication	O
and	O
encodes	O
a	O
calmodulin	B-protein
-	I-protein
like	I-protein
protein	I-protein
that	O
is	O
most	O
closely	O
related	O
to	O
caltractin	O
/	O
centrin	O
,	O
a	O
protein	O
associated	O
with	O
the	O
Chlamydomonas	O
basal	O
body	O
.	O

The	O
occurrence	O
of	O
multiple	O
malignancy	O
was	O
studied	O
in	O
674	O
patients	O
with	O
hematologic	O
malignancies	O
who	O
were	O
admitted	O
to	O
this	O
department	O
during	O
the	O
past	O
10	O
years	O
.	O

RESULTS	O
:	O
Of	O
the	O
24	O
patients	O
,	O
6	O
had	O
Grade	O
1	O
pneumonitis	O
,	O
and	O
13	O
had	O
Grade	O
2	O
pneumonitis	O
.	O

The	O
effect	O
of	O
ethanol	O
on	O
human	O
sensorimotor	O
reactivity	O
was	O
assessed	O
by	O
examining	O
the	O
acoustic	O
startle	O
response	O
.	O

A	O
bovine	O
abomasum	O
lambda	O
gt11	O
cDNA	O
library	O
was	O
screened	O
with	O
a	O
monoclonal	O
antibody	O
raised	O
against	O
the	O
rabbit	B-protein
H	I-protein
,	I-protein
K	I-protein
-	I-protein
ATPase	I-protein
beta	I-protein
subunit	I-protein
.	O

All	O
pigs	O
had	O
significant	O
regional	O
LV	O
dysfunction	O
and	O
reduced	O
LV	O
ejection	O
fraction	O
(	O
41	O
+	O
/	O
-	O
11	O
%	O
)	O
.	O

After	O
MOPP	O
therapy	O
,	O
complete	O
remission	O
of	O
Hodgkin	O
'	O
s	O
disease	O
was	O
accompanied	O
by	O
normalization	O
of	O
the	O
glucocerebrosidase	B-protein
level	O
and	O
disappearance	O
of	O
Gaucher	O
'	O
s	O
cells	O
.	O

67	O
393	O
bp	O
of	O
contiguous	O
DNA	O
located	O
between	O
markers	O
cdc18	B-protein
and	O
cdc14	B-protein
on	O
the	O
right	O
arm	O
of	O
fission	O
yeast	O
chromosome	O
II	O
has	O
been	O
sequenced	O
as	O
part	O
of	O
the	O
European	O
Union	O
Schizosaccharomyces	O
pombe	O
genome	O
sequencing	O
project	O
.	O

Neither	O
gene	O
possesses	O
a	O
distinct	O
transcriptional	O
start	O
site	O
as	O
shown	O
by	O
nuclease	B-protein
S1	I-protein
analysis	O
.	O

Treatment	O
was	O
well	O
-	O
tolerated	O
.	O

Deletion	O
analyses	O
of	O
the	O
construct	O
revealed	O
that	O
the	O
transcription	O
of	O
BOXF1	B-protein
gene	I-protein
is	O
regulated	O
by	O
BOX	B-protein
DNA	I-protein
,	O
preferentially	O
in	O
undifferentiated	O
EC	O
cells	O
versus	O
differentiated	O
cells	O
.	O

Fluid	O
(	O
AVLF	O
)	O
31	O
.	O

Ig	B-protein
-	I-protein
alpha	I-protein
and	O
Ig	B-protein
-	I-protein
beta	I-protein
contain	O
extended	O
cytoplasmic	O
structure	O
(	O
61	O
and	O
48	O
amino	O
acids	O
,	O
respectively	O
)	O
and	O
associate	O
with	O
cytoplasmic	O
effectors	O
indicating	O
that	O
they	O
are	O
directly	O
involved	O
in	O
signal	O
transduction	O
.	O

Topics	O
reviewed	O
here	O
include	O
:	O
data	O
supporting	O
the	O
association	O
of	O
myositis	O
with	O
cancer	O
and	O
the	O
appropriate	O
evaluations	O
for	O
malignancy	O
in	O
a	O
myositis	O
patient	O
;	O
an	O
approach	O
to	O
the	O
assessment	O
of	O
patients	O
with	O
dermatomyositis	O
sine	O
myositis	O
;	O
the	O
usefulness	O
of	O
the	O
clinicopathological	O
and	O
serological	O
classifications	O
;	O
a	O
discussion	O
of	O
whether	O
childhood	O
and	O
adult	O
myositis	O
are	O
the	O
same	O
or	O
different	O
entities	O
;	O
a	O
review	O
of	O
those	O
prognostic	O
factors	O
to	O
consider	O
in	O
the	O
clinical	O
management	O
of	O
myositis	O
patients	O
;	O
current	O
approaches	O
and	O
their	O
limitations	O
for	O
assessing	O
disease	O
activity	O
and	O
damage	O
.	O

Examination	O
of	O
the	O
sequence	O
of	O
the	O
Punta	B-protein
Toro	I-protein
M	I-protein
gene	I-protein
product	I-protein
reveals	O
the	O
presence	O
of	O
multiple	O
hydrophobic	O
sequences	O
including	O
a	O
19	B-protein
-	I-protein
amino	I-protein
acid	I-protein
,	I-protein
carboxy	I-protein
-	I-protein
proximal	I-protein
,	I-protein
hydrophobic	I-protein
region	I-protein
(	I-protein
G2	I-protein
)	I-protein
.	O

In	O
angiodysplasia	O
,	O
ectatic	O
vessels	O
in	O
the	O
mucosa	O
appeared	O
to	O
contain	O
less	O
collagen	B-protein
type	I-protein
IV	I-protein
than	O
similarly	O
sized	O
vessels	O
in	O
the	O
submucosa	O
,	O
and	O
perforating	O
vessels	O
appeared	O
in	O
many	O
cases	O
to	O
lose	O
staining	O
at	O
the	O
level	O
of	O
the	O
muscularis	O
mucosae	O
.	O

In	O
ischemic	O
and	O
hypoxic	O
hypoxia	O
,	O
a	O
strong	O
correlation	O
was	O
found	O
between	O
cyt	O
a	O
,	O
a3	O
oxidation	O
level	O
and	O
VO2	O
in	O
both	O
ischemic	O
and	O
hypoxic	O
hypoxia	O
(	O
r2	O
=	O
.	O
90	O
and	O
.	O
87	O
,	O
respectively	O
)	O
.	O

The	O
sequence	O
of	O
the	O
putative	O
RBP1	B-protein
protein	I-protein
contains	O
two	O
copies	O
of	O
an	O
RNA	O
recognition	O
motif	O
,	O
two	O
glutamine	O
stretches	O
,	O
an	O
asparagine	O
-	O
rich	O
region	O
,	O
a	O
methionine	O
-	O
rich	O
region	O
,	O
and	O
two	O
long	O
potential	O
alpha	O
-	O
helixes	O
.	O

In	O
a	O
group	O
of	O
13	O
patients	O
with	O
obliterative	O
arteriopathies	O
of	O
the	O
lower	O
limbs	O
the	O
plasma	O
levels	O
of	O
thrombomodulin	B-protein
(	O
TM	B-protein
)	O
,	O
betathromboglobulin	B-protein
(	O
beta	B-protein
-	I-protein
TG	I-protein
)	O
,	O
D	B-protein
-	I-protein
dimer	I-protein
(	O
DD	B-protein
)	O
and	O
plasminogen	B-protein
activator	I-protein
-	I-protein
inhibitor	I-protein
(	O
pAI	B-protein
-	I-protein
1	I-protein
)	O
were	O
measured	O
,	O
and	O
compared	O
to	O
the	O
values	O
obtained	O
from	O
10	O
healthy	O
volunteers	O
.	O

Research	O
was	O
carried	O
out	O
on	O
the	O
rheumatoid	B-protein
factors	I-protein
in	O
the	O
serum	O
of	O
917	O
patients	O
by	O
means	O
of	O
two	O
tests	O
(	O
one	O
using	O
polystyrene	O
and	O
one	O
with	O
erythrocytes	O
)	O
and	O
the	O
results	O
obtained	O
were	O
compared	O
using	O
a	O
method	O
of	O
reference	O
.	O

However	O
,	O
alterations	O
in	O
electrostatic	O
and	O
hydrophobic	O
interactions	O
created	O
by	O
the	O
three	O
amino	O
acid	O
substitutions	O
prevent	O
the	O
conformational	O
change	O
in	O
the	O
enzyme	O
usually	O
produced	O
by	O
calmodulin	B-protein
binding	O
.	O

The	O
products	O
of	O
the	O
Saccharomyces	B-protein
cerevisiae	I-protein
CIN1	I-protein
,	O
CIN2	B-protein
and	O
CIN4	B-protein
genes	I-protein
participate	O
in	O
a	O
nonessential	O
pathway	O
required	O
for	O
normal	O
microtubule	O
function	O
.	O

This	O
study	O
indicates	O
that	O
this	O
dose	O
-	O
intense	O
regimen	O
can	O
be	O
safely	O
administered	O
,	O
even	O
with	O
the	O
use	O
of	O
purged	O
marrow	O
,	O
with	O
an	O
acceptable	O
toxicity	O
profile	O
.	O

Transcription	O
initiation	O
sites	O
of	O
the	O
rat	B-protein
II	I-protein
beta	I-protein
-	I-protein
,	I-protein
III	I-protein
beta	I-protein
,	I-protein
and	I-protein
O	I-protein
beta	I-protein
-	I-protein
globin	I-protein
genes	I-protein
were	O
determined	O
to	O
be	O
52	O
base	O
pairs	O
(	O
bp	O
)	O
5	O
'	O
-	O
upstream	O
of	O
the	O
translation	O
initiation	O
codon	O
(	O
ATG	O
)	O
,	O
in	O
each	O
gene	O
by	O
primer	O
extension	O
analysis	O
.	O

RESULTS	O
:	O
The	O
main	O
effect	O
of	O
muscle	O
pain	O
,	O
compared	O
to	O
non	O
-	O
painful	O
stimulation	O
,	O
was	O
a	O
significant	O
and	O
long	O
-	O
lasting	O
increase	O
of	O
delta	O
(	O
1	O
-	O
3	O
Hz	O
)	O
power	O
and	O
an	O
alpha	O
-	O
1	O
(	O
9	O
-	O
11	O
Hz	O
)	O
power	O
increase	O
over	O
the	O
contralateral	O
parietal	O
locus	O
.	O

Here	O
we	O
present	O
evidence	O
that	O
the	O
distal	O
half	O
(	O
Stem	O
2	O
)	O
of	O
the	O
conserved	O
base	O
-	O
paired	O
stem	O
structure	O
found	O
in	O
all	O
hY	B-protein
RNAs	I-protein
also	O
plays	O
a	O
critical	O
role	O
in	O
the	O
export	O
process	O
.	O

While	O
the	O
examiner	O
observed	O
the	O
interior	O
of	O
the	O
eye	O
with	O
indirect	O
ophthalmoscopy	O
,	O
the	O
point	O
source	O
of	O
light	O
from	O
the	O
fiberoptic	O
light	O
pipe	O
was	O
moved	O
along	O
the	O
margins	O
of	O
the	O
episcleral	O
plaque	O
.	O

In	O
contrast	O
to	O
some	O
results	O
previously	O
published	O
for	O
a	O
very	O
close	O
sequence	O
variant	O
(	O
see	O
ref	O
.	O

The	O
nifJ	B-protein
and	O
nifH	B-protein
promoters	I-protein
of	I-protein
Klebsiella	I-protein
pneumoniae	I-protein
are	O
divergently	O
transcribed	O
sigma	B-protein
54	I-protein
-	I-protein
dependent	I-protein
promoters	I-protein
that	O
are	O
positively	O
activated	O
by	O
the	O
NifA	B-protein
protein	I-protein
.	O

Both	O
toxins	O
in	O
a	O
dose	O
10	O
-	O
fold	O
surpassimg	O
the	O
maximum	O
permissible	O
concentration	O
increased	O
activity	O
of	O
glutathione	B-protein
peroxidase	I-protein
in	O
brain	O
tissue	O
;	O
moreover	O
,	O
toluene	O
increased	O
chemiluminescence	O
intensity	O
,	O
which	O
attested	O
to	O
activation	O
of	O
free	O
radical	O
processes	O
.	O

To	O
this	O
end	O
,	O
we	O
analyzed	O
the	O
phosphorylation	O
status	O
of	O
a	O
universal	O
tyrosine	B-protein
kinase	I-protein
substrate	O
,	O
the	O
transforming	O
Shc	B-protein
adapter	I-protein
protein	I-protein
,	O
in	O
fibroblasts	O
expressing	O
the	O
viral	O
oncogene	O
.	O

Partial	O
characterization	O
of	O
the	O
active	O
site	O
human	B-protein
platelet	I-protein
cAMP	I-protein
phosphodiesterase	I-protein
,	O
PDE3A	B-protein
,	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

Biochemical	O
characterization	O
of	O
valosin	B-protein
-	I-protein
containing	I-protein
protein	I-protein
,	O
a	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
substrate	O
in	O
hematopoietic	O
cells	O
.	O

The	O
latency	O
time	O
for	O
the	O
lactate	O
concentration	O
to	O
reach	O
the	O
top	O
values	O
was	O
reduced	O
by	O
aerobic	O
training	O
(	O
T2	O
)	O
.	O

We	O
also	O
provide	O
evidence	O
that	O
gar2	B-protein
is	O
phosphorylated	O
in	O
vitro	O
by	O
a	O
p13	B-protein
(	O
suc1	B-protein
)	O
-	O
Sepharose	O
-	O
bound	O
kinase	B-protein
from	O
Schizosaccharomyces	O
pombe	O
extracts	O
that	O
displays	O
cell	O
cycle	O
-	O
regulated	O
activity	O
similar	O
to	O
that	O
of	O
the	O
p34	B-protein
(	I-protein
cdc2	I-protein
(	I-protein
kinase	I-protein
.	O

Our	O
results	O
support	O
a	O
model	O
where	O
both	O
E2F	O
-	O
and	O
CDE	O
-	O
mediated	O
repression	O
,	O
acting	O
at	O
different	O
stages	O
in	O
the	O
cell	O
cycle	O
,	O
are	O
dependent	O
on	O
promoter	O
-	O
specific	O
CHR	B-protein
elements	I-protein
.	O

CONCLUSIONS	O
.	O

Preceptorship	O
of	O
CNS	O
students	O
:	O
an	O
exploratory	O
study	O
.	O

The	O
difference	O
of	O
hardness	O
over	O
time	O
of	O
composite	O
specimens	O
was	O
measured	O
using	O
Knoop	O
hardness	O
measurements	O
taken	O
at	O
the	O
top	O
and	O
bottom	O
surfaces	O
of	O
resin	O
specimens	O
made	O
in	O
a	O
Teflon	O
mold	O
the	O
same	O
dimensions	O
as	O
the	O
cavity	O
prepared	O
in	O
dentin	B-protein
.	O

An	O
alternatively	O
spliced	O
MAdCAM	B-protein
-	I-protein
1	I-protein
variant	O
was	O
identified	O
that	O
lacks	O
exon	O
4	O
encoding	O
the	O
mucin	B-protein
domain	O
,	O
and	O
may	O
mediate	O
leukocyte	O
adhesion	O
to	O
LPAM	B-protein
-	I-protein
1	I-protein
without	O
adhesion	O
to	O
the	O
alternate	O
receptor	O
,	O
L	B-protein
-	I-protein
selectin	I-protein
.	O

EM	O
analysis	O
demonstrated	O
that	O
only	O
one	O
Rep	B-protein
-	I-protein
DNA	I-protein
complex	I-protein
was	O
formed	O
on	O
ch	O
-	O
19	O
target	O
DNA	O
.	O

Epithelial	O
nerve	O
fiber	O
defects	O
included	O
absence	O
or	O
distorted	O
architecture	O
of	O
the	O
basal	O
epithelial	O
plexus	O
and	O
intra	O
-	O
epithelial	O
terminals	O
.	O

In	O
an	O
effort	O
to	O
contribute	O
to	O
the	O
transcript	O
map	O
of	O
human	O
chromosome	O
21	O
and	O
the	O
understanding	O
of	O
the	O
pathophysiology	O
of	O
trisomy	O
21	O
,	O
we	O
have	O
used	O
exon	O
trapping	O
to	O
identify	O
fragments	O
of	O
chromosome	O
21	O
genes	O
.	O

We	O
previously	O
demonstrated	O
that	O
acute	O
expression	O
of	O
the	O
bovine	O
papillomavirus	O
type	O
1	O
(	O
BPV1	O
)	O
E2	B-protein
protein	I-protein
in	O
HeLa	O
and	O
HT	O
-	O
3	O
cervical	O
carcinoma	O
cell	O
lines	O
greatly	O
reduced	O
cellular	O
proliferation	O
by	O
imposing	O
a	O
specific	O
G1	O
/	O
S	O
phase	O
growth	O
arrest	O
.	O

In	O
insulin	O
-	O
responsive	O
cells	O
,	O
Akt	B-protein
phosphorylates	O
and	O
inactivates	O
the	O
serine	B-protein
/	I-protein
threonine	I-protein
kinase	I-protein
glycogen	I-protein
synthase	I-protein
kinase	I-protein
-	I-protein
3	I-protein
(	O
GSK	B-protein
-	I-protein
3	I-protein
)	O
.	O

Cyclin	B-protein
D1	I-protein
-	I-protein
associated	I-protein
kinase	I-protein
activity	O
and	O
protein	O
levels	O
were	O
increased	O
in	O
mammary	O
tumors	O
from	O
murine	B-protein
mammary	I-protein
tumor	I-protein
virus	I-protein
-	I-protein
pp60	I-protein
(	I-protein
c	I-protein
-	I-protein
src527F	I-protein
)	I-protein
transgenic	O
mice	O
.	O

We	O
conducted	O
a	O
prospective	O
,	O
randomized	O
controlled	O
trial	O
of	O
metoprolol	O
,	O
a	O
selective	O
beta	O
-	O
blocker	O
for	O
prevention	O
of	O
gastrointestinal	O
bleeding	O
from	O
portal	O
hypertension	O
in	O
29	O
non	O
-	O
selected	O
patients	O
with	O
liver	O
disease	O
and	O
previous	O
gastrointestinal	O
bleeding	O
.	O

[	O
Treatment	O
of	O
early	O
T1	O
small	O
T2N	O
breast	O
cancers	O
.	O

Cdc2	B-protein
co	O
-	O
precipitates	O
with	O
Pch1	B-protein
in	O
S	O
.	O
pombe	O
cell	O
lysates	O
,	O
although	O
Cdc2	B-protein
may	O
not	O
be	O
the	O
major	O
catalytic	O
partner	O
of	O
a	O
Pch1	B-protein
kinase	I-protein
in	O
vivo	O
.	O

This	O
paper	O
presents	O
the	O
reasons	O
why	O
countries	O
to	O
which	O
Chagas	O
disease	O
is	O
endemic	O
should	O
carry	O
out	O
the	O
relevant	O
research	O
themselves	O
.	O

Copyright	O
2000	O
Academic	O
Press	O
.	O

Despite	O
significant	O
lethality	O
and	O
cardiovascular	O
dysfunction	O
,	O
in	O
the	O
septic	O
group	O
on	O
Days	O
1	O
and	O
2	O
,	O
septic	O
versus	O
control	O
animals	O
had	O
no	O
significant	O
differences	O
in	O
mean	O
metabolic	O
cart	O
measured	O
(	O
Vo2DIR	O
,	O
ml	O
/	O
kg	O
/	O
min	O
;	O
Day	O
1	O
:	O
11	O
.	O
9	O
versus	O
12	O
.	O
4	O
,	O
p	O
=	O
0	O
.	O
81	O
;	O
Day	O
2	O
:	O
14	O
.	O
2	O
versus	O
13	O
.	O
5	O
,	O
p	O
=	O
0	O
.	O
72	O
,	O
respectively	O
)	O
and	O
intravascular	O
catheter	O
calculated	O
(	O
Vo2INDIR	O
,	O
ml	O
/	O
kg	O
/	O
min	O
;	O
Day	O
1	O
:	O
11	O
.	O
2	O
versus	O
11	O
.	O
2	O
,	O
p	O
=	O
0	O
.	O
99	O
;	O
Day	O
2	O
:	O
12	O
.	O
8	O
versus	O
15	O
.	O
4	O
,	O
p	O
=	O
0	O
.	O
49	O
,	O
respectively	O
)	O
.	O

T1	O
-	O
weighted	O
MRI	O
on	O
the	O
49th	O
postoperative	O
day	O
demonstrated	O
bilateral	O
and	O
symmetrical	O
hyperintense	O
lesions	O
in	O
the	O
globus	O
pallidus	O
.	O

The	O
side	O
-	O
to	O
-	O
side	O
difference	O
was	O
statistically	O
significant	O
at	O
EXT	O
30	O
degrees	O
/	O
s	O
and	O
60	O
degrees	O
/	O
s	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Formalin	O
activated	O
both	O
SNO	O
NS	O
and	O
NnS	O
neurones	O
,	O
but	O
,	O
when	O
they	O
responded	O
,	O
NS	O
neurones	O
(	O
n	O
=	O
5	O
)	O
showed	O
only	O
the	O
first	O
phase	O
of	O
activity	O
while	O
NnS	O
neurones	O
showed	O
either	O
one	O
(	O
n	O
=	O
13	O
)	O
or	O
two	O
phases	O
(	O
n	O
=	O
6	O
)	O
.	O

The	O
IgG	B-protein
subclass	O
profile	O
of	O
untreated	O
coeliac	O
disease	O
was	O
found	O
to	O
be	O
the	O
same	O
as	O
in	O
healthy	O
controls	O
(	O
IgG1	B-protein
approximately	O
IgG2	B-protein
>	O
IgG3	B-protein
>	O
IgG4	B-protein
)	O
,	O
with	O
only	O
the	O
magnitude	O
of	O
the	O
individual	O
subclass	O
responses	O
being	O
increased	O
in	O
coeliac	O
patients	O
.	O

An	O
8	O
-	O
h	O
exposure	O
to	O
10	O
mg	O
DMEA	O
/	O
m3	O
corresponds	O
to	O
a	O
postexposure	O
plasma	O
concentration	O
and	O
2	O
-	O
h	O
postexposure	O
urinary	O
excretion	O
of	O
4	O
.	O
9	O
mumol	O
/	O
l	O
and	O
75	O
mmol	O
/	O
mol	O
creatinine	O
,	O
respectively	O
.	O

Sequence	O
analysis	O
of	O
this	O
region	O
revealed	O
three	O
eight	O
-	O
bp	O
repetitive	O
elements	O
,	O
the	O
deletion	O
of	O
which	O
restored	O
wild	O
-	O
type	O
levels	O
of	O
luciferase	B-protein
activity	O
to	O
the	O
-	O
916	O
-	O
bp	O
reporter	O
plasmid	O
.	O

The	O
radiation	O
burden	O
associated	O
with	O
the	O
majority	O
of	O
examinations	O
in	O
nuclear	O
medicine	O
expressed	O
as	O
the	O
effective	O
dose	O
is	O
comparable	O
with	O
the	O
radiation	O
burden	O
of	O
radiodiagnostic	O
examinations	O
,	O
only	O
after	O
administration	O
of	O
preparations	O
with	O
131I	O
,	O
201Tl	O
,	O
67Ga	O
and	O
111In	O
it	O
is	O
markedly	O
higher	O
.	O

Here	O
,	O
we	O
describe	O
directional	O
chromosome	O
walking	O
studies	O
starting	O
from	O
D8S260	B-protein
as	O
well	O
as	O
D8S285	B-protein
.	O

Reduction	O
in	O
dosage	O
restored	O
normal	O
taste	O
sense	O
in	O
all	O
three	O
,	O
but	O
in	O
two	O
the	O
drug	O
had	O
to	O
be	O
discontinued	O
because	O
of	O
persisting	O
high	O
transaminase	B-protein
levels	O
.	O

Thus	O
analysis	O
indicated	O
no	O
reliable	O
evidence	O
that	O
conscious	O
presleep	O
suggestions	O
become	O
incorporated	O
into	O
dream	O
content	O
.	O

Thus	O
,	O
our	O
studies	O
suggest	O
that	O
pV	O
-	O
mediated	O
activation	O
of	O
HIV	B-protein
-	I-protein
1	I-protein
LTR	I-protein
activity	O
is	O
controlled	O
by	O
the	O
nuclear	O
translocation	O
of	O
the	O
NF	B-protein
-	I-protein
kappaB	I-protein
transcription	I-protein
factor	I-protein
,	O
which	O
is	O
mediated	O
by	O
IkappaBalpha	B-protein
serine	O
phosphorylation	O
and	O
degradation	O
,	O
but	O
also	O
by	O
a	O
still	O
undefined	O
NF	O
-	O
kappaB	O
-	O
independent	O
pathway	O
.	O

Acute	O
appearance	O
of	O
hemiparesis	O
or	O
hemiplegia	O
with	O
initial	O
marked	O
spasticity	O
was	O
observed	O
in	O
8	O
stroke	O
patients	O
.	O

Analysis	O
of	O
one	O
cDNA	O
revealed	O
an	O
unusual	O
splicing	O
event	O
involving	O
EZH1	B-protein
and	O
a	O
tandemly	O
linked	O
gene	O
GPR2	B-protein
and	O
suggests	O
a	O
potential	O
mechanism	O
for	O
modifying	O
the	O
EZH1	B-protein
protein	I-protein
in	O
the	O
conserved	O
C	O
-	O
terminal	O
domain	O
.	O

We	O
analysed	O
two	O
regions	O
involved	O
in	O
preS2	B-protein
/	I-protein
S	I-protein
gene	I-protein
transcription	O
of	O
the	O
HBV	O
adw	O
subtype	O
:	O
the	O
diverged	O
TATA	O
box	O
and	O
a	O
putative	O
initiator	O
element	O
.	O

Effect	O
of	O
chronic	O
undernutrition	O
on	O
susceptibility	O
to	O
cold	O
stress	O
in	O
young	O
adult	O
and	O
aged	O
rats	O
.	O

During	O
this	O
time	O
,	O
the	O
patients	O
all	O
had	O
the	O
characteristic	O
plasma	O
thyroid	O
hormone	O
changes	O
associated	O
with	O
amiodarone	O
therapy	O
,	O
i	O
.	O
e	O
.	O
increased	O
T4	O
,	O
free	O
T4	O
,	O
and	O
rT3	O
and	O
decreased	O
T3	O
,	O
while	O
remaining	O
clinically	O
euthyroid	O
.	O

The	O
C18	O
:	O
1	O
:	O
C10	O
value	O
is	O
a	O
convenient	O
measure	O
of	O
these	O
changes	O
and	O
can	O
be	O
determined	O
more	O
rapidly	O
than	O
determining	O
all	O
the	O
lower	O
fatty	O
acids	O
.	O

The	O
cytoprotective	O
and	O
antiulcer	O
activities	O
of	O
the	O
antacid	O
magaldrate	O
(	O
ES	O
Riopan	O
)	O
as	O
well	O
as	O
its	O
effects	O
on	O
gastric	O
mucosal	O
blood	O
flow	O
and	O
mucus	O
secretions	O
,	O
were	O
determined	O
in	O
the	O
rat	O
.	O

Retinal	O
changes	O
in	O
pigmentary	O
retinopathy	O
in	O
children	O
.	O

The	O
overall	O
prevalence	O
of	O
psoriasis	O
was	O
4	O
.	O
79	O
%	O
in	O
men	O
and	O
4	O
.	O
85	O
%	O
in	O
women	O
.	O

Previous	O
studies	O
showed	O
that	O
mutations	O
in	O
the	O
6K	O
protein	O
led	O
to	O
the	O
slow	O
release	O
of	O
aberrant	O
,	O
multi	O
-	O
cored	O
infectious	O
virions	O
.	O

Performance	O
on	O
two	O
verbal	O
measures	O
-	O
the	O
National	O
Adult	O
Reading	O
Test	O
-	O
Revised	O
(	O
NART	O
-	O
R	O
)	O
and	O
the	O
Vocabulary	O
subtest	O
from	O
the	O
Wechsler	O
Adult	O
Intelligence	O
Scale	O
-	O
Revised	O
(	O
WAIS	O
-	O
R	O
)	O
-	O
showed	O
strong	O
correlations	O
with	O
level	O
of	O
education	O
.	O

The	O
influence	O
of	O
Epstein	O
-	O
Barr	O
virus	O
seropositivity	O
on	O
the	O
efficacy	O
of	O
intravenous	O
immune	B-protein
globulin	I-protein
in	O
children	O
with	O
immune	O
thrombocytopenic	O
purpura	O
.	O

Malaria	O
had	O
diminished	O
significantly	O
by	O
the	O
early	O
1940s	O
,	O
and	O
this	O
paper	O
queries	O
whether	O
that	O
reduction	O
was	O
due	O
to	O
the	O
control	O
projects	O
of	O
the	O
thirties	O
,	O
and	O
,	O
if	O
so	O
,	O
whether	O
such	O
projects	O
should	O
be	O
a	O
model	O
for	O
the	O
current	O
developing	O
world	O
,	O
where	O
malaria	O
is	O
a	O
growing	O
problem	O
today	O
.	O

On	O
the	O
role	O
of	O
transferrin	B-protein
in	O
the	O
uptake	O
of	O
gallium	O
by	O
tumor	O
cells	O
.	O

Spatial	O
accuracy	O
of	O
primary	O
and	O
secondary	O
memory	O
-	O
guided	O
saccades	O
in	O
schizophrenic	O
patients	O
.	O

A	O
16	O
-	O
year	O
follow	O
-	O
up	O
study	O
of	O
69	O
paraplegics	O
with	O
complete	O
lesions	O
from	O
T1	O
-	O
L3	O
is	O
presented	O
.	O

Combination	O
of	O
a	O
Shwachman	O
syndrome	O
and	O
a	O
complex	O
granulocyte	O
function	O
disorder	O
in	O
a	O
girl	O
.	O

Interestingly	O
,	O
the	O
IR5	B-protein
ORF	I-protein
of	O
EHV	O
-	O
1	O
possesses	O
a	O
sequence	O
of	O
13	O
amino	O
acids	O
(	O
CAYWCCLGHAFAC	B-protein
)	O
that	O
is	O
a	O
perfect	O
match	O
to	O
the	O
consensus	O
zinc	O
finger	O
motif	O
(	O
C	B-protein
-	I-protein
X2	I-protein
-	I-protein
4	I-protein
-	I-protein
C	I-protein
-	I-protein
X2	I-protein
-	I-protein
15	I-protein
-	I-protein
C	I-protein
/	I-protein
H	I-protein
-	I-protein
X2	I-protein
-	I-protein
4	I-protein
-	I-protein
C	I-protein
/	I-protein
H	I-protein
)	O
.	O

Mutating	O
a	O
potential	O
cleavage	O
site	O
located	O
N	O
-	O
terminal	O
to	O
the	O
protease	B-protein
domain	I-protein
,	I-protein
Gln2526	I-protein
-	I-protein
Asp2527	I-protein
,	O
diminished	O
processing	O
.	O

The	O
German	O
Society	O
of	O
Pediatric	O
Oncology	O
in	O
1981	O
initiated	O
the	O
Cooperative	O
Ewing	O
'	O
s	O
Sarcoma	O
Study	O
(	O
CESS	O
81	O
)	O
using	O
a	O
four	O
-	O
drug	O
combination	O
of	O
chemotherapy	O
prior	O
to	O
definitive	O
local	O
control	O
with	O
surgery	O
and	O
/	O
or	O
radiation	O
.	O

An	O
RME1	O
-	O
independent	O
pathway	O
for	O
sporulation	O
control	O
in	O
Saccharomyces	O
cerevisiae	O
acts	O
through	O
IME1	B-protein
transcript	I-protein
accumulation	O
.	O

The	O
effect	O
of	O
osmotic	O
flow	O
on	O
the	O
distribution	O
of	O
horseradish	B-protein
peroxidase	I-protein
within	O
the	O
intercellular	O
spaces	O
of	O
toad	O
bladder	O
epithelium	O
.	O

There	O
was	O
no	O
evident	O
inciting	O
agent	O
of	O
the	O
disease	O
.	O

A	O
three	O
-	O
phased	O
analysis	O
of	O
treatment	O
plans	O
for	O
45	O
patients	O
was	O
undertaken	O
.	O

M	O
.	O
,	O
and	O
D	O
.	O

The	O
kappa	O
coefficient	O
of	O
agreement	O
between	O
the	O
Patho	O
Dx	O
Kit	O
and	O
the	O
standard	O
method	O
was	O
0	O
.	O
958	O
.	O

Transient	O
transfection	O
assays	O
using	O
reporter	O
gene	O
constructs	O
containing	O
various	O
lengths	O
of	O
the	O
5	B-protein
'	I-protein
mdr1b	I-protein
sequences	I-protein
revealed	O
that	O
the	O
sequence	O
located	O
between	O
-	O
247	O
to	O
-	O
126	O
bp	O
was	O
important	O
for	O
the	O
expression	O
of	O
the	O
reporter	O
gene	O
in	O
many	O
different	O
cell	O
lines	O
.	O

It	O
is	O
concluded	O
that	O
opiate	B-protein
receptors	I-protein
bordering	O
the	O
fourth	O
cerebral	O
ventricle	O
mediate	O
the	O
cardiovascular	O
and	O
hypnotic	O
action	O
of	O
fentanyl	O
.	O

A	O
number	O
of	O
serological	O
tests	O
measuring	O
the	O
presence	O
of	O
Helicobacter	O
pylori	O
-	O
specific	O
serum	O
immunoglobulin	B-protein
G	I-protein
(	O
IgG	B-protein
)	O
are	O
now	O
commercially	O
available	O
.	O

Twenty	O
-	O
three	O
sequence	O
-	O
tagged	O
sites	O
(	O
STSs	O
)	O
were	O
mapped	O
within	O
the	O
contig	O
,	O
a	O
density	O
of	O
approximately	O
1	O
per	O
200	O
kb	O
.	O

RT	O
-	O
PCR	O
and	O
in	O
situ	O
hybridization	O
analyses	O
of	O
a	O
time	O
course	O
of	O
juvenile	O
testis	O
development	O
indicate	O
that	O
Spo11	B-protein
expression	O
begins	O
in	O
early	O
meiotic	O
Prophase	O
I	O
,	O
prior	O
to	O
the	O
pachytene	O
stage	O
,	O
with	O
increasing	O
accumulation	O
of	O
mRNA	O
through	O
the	O
pachytene	O
stage	O
.	O

However	O
,	O
the	O
beta5L	B-protein
splice	I-protein
variant	I-protein
was	O
found	O
only	O
in	O
the	O
retina	O
.	O

The	O
P	B-protein
-	I-protein
wr	I-protein
and	O
P	B-protein
-	I-protein
rr	I-protein
cDNA	I-protein
sequences	I-protein
are	O
very	O
similar	O
in	O
their	O
5	O
'	O
regions	O
.	O

Electronic	O
structure	O
of	O
a	O
buried	O
NiSi2	O
or	O
CoSi2	O
layer	O
in	O
bulk	O
Si	O
.	O

Six	O
tandem	O
repeats	O
of	O
the	O
P	B-protein
element	I-protein
linked	O
to	O
the	O
SV40	B-protein
promoter	I-protein
responded	O
to	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
,	O
while	O
that	O
of	O
other	O
elements	O
did	O
not	O
.	O

The	O
pWP	B-protein
-	I-protein
19	I-protein
also	O
encodes	O
the	O
AAV	O
inverted	O
terminal	O
repeats	O
for	O
integration	O
and	O
replication	O
and	O
the	O
herpes	O
virus	O
thymidine	B-protein
kinase	I-protein
promoter	O
-	O
driven	O
gene	O
for	O
neomycin	O
resistance	O
(	O
neoR	B-protein
)	O
.	O

Binding	O
site	O
selection	O
using	O
in	O
vitro	O
-	O
synthesized	O
proteins	O
reveals	O
that	O
the	O
ROR	B-protein
alpha	I-protein
1	I-protein
and	O
ROR	B-protein
alpha	I-protein
2	I-protein
isoforms	I-protein
bind	O
DNA	O
as	O
monomers	O
to	O
hormone	B-protein
response	I-protein
elements	I-protein
composed	O
of	O
a	O
6	O
-	O
bp	O
AT	O
-	O
rich	O
sequence	O
preceding	O
a	O
half	O
-	O
site	O
core	B-protein
motif	I-protein
PuGGTCA	I-protein
(	O
RORE	B-protein
)	O
.	O

Our	O
findings	O
also	O
provide	O
the	O
basis	O
for	O
the	O
development	O
of	O
assays	O
to	O
screen	O
for	O
the	O
ligands	O
to	O
testis	B-protein
receptor	I-protein
2	I-protein
and	O
hERR1	B-protein
.	O

The	O
response	O
chain	O
in	O
each	O
component	O
was	O
maintained	O
by	O
food	O
presentation	O
under	O
a	O
fixed	O
-	O
ratio	O
schedule	O
.	O

Signaling	O
from	O
the	O
small	B-protein
GTP	I-protein
-	I-protein
binding	I-protein
proteins	I-protein
Rac1	I-protein
and	O
Cdc42	B-protein
to	O
the	O
c	B-protein
-	I-protein
Jun	I-protein
N	I-protein
-	I-protein
terminal	I-protein
kinase	I-protein
/	I-protein
stress	I-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
pathway	O
.	O

METHODS	O
:	O
We	O
retrospectively	O
reviewed	O
242	O
adult	O
cadaveric	O
renal	O
transplant	O
recipients	O
treated	O
between	O
11	O
/	O
91	O
and	O
5	O
/	O
97	O
.	O

Elevated	O
expression	O
of	O
a	O
previously	O
uncharacterized	O
gene	O
,	O
SPP381	B-protein
,	O
efficiently	O
suppresses	O
the	O
growth	O
and	O
splicing	O
defects	O
of	O
a	O
temperature	O
-	O
sensitive	O
(	O
Ts	O
)	O
mutant	B-protein
prp38	I-protein
-	I-protein
1	I-protein
.	O

Based	O
on	O
a	O
type	O
I	O
error	O
of	O
0	O
.	O
05	O
,	O
our	O
study	O
had	O
a	O
power	O
greater	O
than	O
or	O
equal	O
to	O
75	O
%	O
to	O
detect	O
group	O
differences	O
in	O
treatment	O
effect	O
of	O
greater	O
than	O
or	O
equal	O
to	O
15	O
%	O
to	O
20	O
%	O
.	O

Expression	O
of	O
activated	O
Cdc42	B-protein
results	O
in	O
the	O
translocation	O
of	O
PKClambda	B-protein
from	O
the	O
nucleus	O
into	O
the	O
cytosol	O
,	O
and	O
Cdc42	B-protein
and	O
PKClambda	B-protein
colocalize	O
at	O
the	O
plasma	O
membrane	O
and	O
in	O
the	O
cytoplasm	O
.	O

NPT	B-protein
II	I-protein
synthesis	O
,	O
measured	O
by	O
agar	O
plate	O
assays	O
of	O
kanamycin	O
resistance	O
and	O
by	O
immunoprecipitation	O
of	O
the	O
NPT	B-protein
II	I-protein
protein	I-protein
,	O
was	O
repressed	O
in	O
the	O
presence	O
of	O
cysteine	O
and	O
derepressed	O
in	O
its	O
absence	O
.	O

The	O
5	O
'	O
region	O
of	O
ADH5	B-protein
contains	O
consensus	O
binding	O
sites	O
for	O
the	O
transcriptional	O
regulatory	O
proteins	O
,	O
Sp1	B-protein
,	O
AP2	B-protein
,	O
LF	B-protein
-	I-protein
A1	I-protein
,	O
NF	B-protein
-	I-protein
1	I-protein
,	O
NF	B-protein
-	I-protein
A2	I-protein
,	O
and	O
NF	B-protein
-	I-protein
E1	I-protein
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
signaling	O
to	O
stress	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
(	O
SAPK	B-protein
)	O
/	B-protein
Jun	I-protein
NH2	I-protein
-	I-protein
terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
and	O
p38	B-protein
.	O

The	O
class	B-protein
II	I-protein
Escherichia	I-protein
coli	I-protein
alanine	I-protein
tRNA	I-protein
synthetase	I-protein
aminoacylates	I-protein
RNA	I-protein
miniduplexes	I-protein
,	O
which	O
reconstruct	O
the	O
acceptor	O
end	O
of	O
alanine	B-protein
tRNA	I-protein
with	O
the	O
critical	O
G3	O
:	O
U70	O
base	O
pair	O
.	O

Breast	O
-	O
fed	O
newborn	O
infants	O
synthesize	O
n	O
-	O
6	O
long	O
-	O
chain	O
polyunsaturated	O
fatty	O
acids	O
already	O
during	O
the	O
first	O
week	O
of	O
life	O
,	O
but	O
the	O
contribution	O
of	O
endogenous	O
synthesis	O
to	O
the	O
total	O
plasma	O
long	O
-	O
chain	O
polyunsaturated	O
pool	O
is	O
small	O
.	O

Ten	O
days	O
of	O
cefadroxil	O
therapy	O
was	O
used	O
to	O
treat	O
44	O
children	O
with	O
urinary	O
tract	O
infection	O
and	O
CRP	B-protein
values	O
greater	O
than	O
or	O
equal	O
to	O
28	O
microgram	O
/	O
ml	O
(	O
CRP	O
-	O
positive	O
group	O
)	O
.	O

Studies	O
on	O
the	O
life	O
cycle	O
of	O
Haplorchis	O
pumilio	O
(	O
Looss	O
,	O
1896	O
)	O
Looss	O
,	O
1899	O
with	O
morphological	O
redescription	O
of	O
larval	O
and	O
adult	O
stages	O
.	O

R	O
.	O

The	O
amino	O
acid	O
sequence	O
alignment	O
of	O
TC	B-protein
II	I-protein
with	O
that	O
of	O
other	O
Cbl	B-protein
binding	I-protein
proteins	I-protein
(	O
rat	B-protein
intrinsic	I-protein
factor	I-protein
,	O
human	B-protein
transcobalamin	I-protein
I	I-protein
and	O
porcine	B-protein
haptocorrin	I-protein
)	O
revealed	O
only	O
33	O
%	O
overall	O
homology	O
.	O

A	O
reassessment	O
of	O
the	O
prevalence	O
data	O
was	O
carried	O
out	O
in	O
the	O
southern	O
province	O
of	O
Uusimaa	O
and	O
in	O
the	O
western	O
province	O
of	O
Vaasa	O
,	O
the	O
prevalence	O
day	O
being	O
January	O
1	O
,	O
1979	O
.	O

New	O
technologies	O
in	O
diagnosis	O
and	O
classification	O
of	O
malignancy	O
.	O

Me	O
(	O
2	O
)	O
SO	O
-	O
induced	O
neuronal	O
differentiation	O
of	O
N1E	O
-	O
115	O
neuroblastoma	O
cells	O
increased	O
both	O
the	O
expression	O
of	O
the	O
endogenous	B-protein
Ntr	I-protein
-	I-protein
1	I-protein
gene	I-protein
and	O
reporter	O
genes	O
driven	O
by	O
NTR	B-protein
-	I-protein
1	I-protein
promoter	I-protein
sequences	I-protein
by	O
3	O
-	O
4	O
-	O
fold	O
.	O

This	O
phenomenon	O
may	O
be	O
regarded	O
as	O
a	O
variant	O
of	O
selective	O
individual	O
cell	O
death	O
,	O
currently	O
referred	O
to	O
as	O
apoptosis	O
,	O
which	O
has	O
not	O
been	O
previously	O
reported	O
in	O
a	O
case	O
of	O
embryonal	O
rhabdomyosarcoma	O
.	O

The	O
effect	O
of	O
calcitonin	B-protein
,	O
a	O
large	O
amount	O
of	O
calcium	O
given	O
orally	O
,	O
pentagastrin	O
and	O
glucagon	O
on	O
plasma	O
47Ca	O
radioactivity	O
curves	O
in	O
subjects	O
pretreated	O
with	O
47Ca	O
was	O
examined	O
.	O

CO2	O
assimilation	O
by	O
chloroplasts	O
illuminated	O
on	O
filter	O
paper	O
.	O

Comparative	O
analysis	O
of	O
various	O
techniques	O
of	O
prostatic	O
drainage	O
in	O
patients	O
with	O
chronic	O
obstructive	O
prostatitis	O
The	O
efficacy	O
of	O
prostatic	O
drainage	O
using	O
transurethral	O
vacuum	O
aspiration	O
(	O
Introl	O
-	O
4	O
unit	O
)	O
and	O
transrectal	O
pneumovibromassage	O
(	O
PVM	O
-	O
R	O
-	O
01	O
)	O
was	O
compared	O
in	O
1511	O
patients	O
with	O
chronic	O
obstructive	O
prostatitis	O
.	O

As	O
the	O
rate	O
of	O
protein	O
synthesis	O
decreases	O
during	O
late	O
embryogenesis	O
,	O
levels	O
of	O
SEC	B-protein
-	I-protein
1	I-protein
and	O
its	O
cognate	O
mRNA	O
decline	O
precipitously	O
.	O

No	O
TATA	O
or	O
Inr	B-protein
sequence	I-protein
was	O
found	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
roles	O
of	O
two	O
putative	O
cis	O
-	O
acting	O
elements	O
within	O
the	O
-	O
73	O
to	O
+	O
44	O
region	O
in	O
basal	O
exon	O
2	O
promoter	O
activity	O
were	O
evaluated	O
using	O
mutagenesis	O
and	O
nuclear	O
protein	O
-	O
DNA	O
binding	O
assays	O
.	O

Radionuclide	O
angiography	O
and	O
static	O
whole	O
body	O
imaging	O
performed	O
with	O
technetium	O
-	O
99m	O
-	O
labeled	O
particulates	O
can	O
clearly	O
demonstrate	O
differential	O
shunting	O
in	O
patients	O
with	O
patent	O
ductus	O
arteriosus	O
(	O
PDA	O
)	O
with	O
Eisenmenger	O
physiology	O
.	O

The	O
evolution	O
of	O
the	O
CCR5	B-protein
cis	I-protein
-	I-protein
regulatory	I-protein
region	I-protein
versus	O
the	O
open	O
reading	O
frame	O
as	O
well	O
as	O
among	O
different	O
domains	O
of	O
the	O
open	O
reading	O
frame	O
differed	O
from	O
one	O
another	O
.	O

Gene	O
and	O
pseudogene	O
of	O
the	O
mouse	O
cation	O
-	O
dependent	O
mannose	B-protein
6	I-protein
-	I-protein
phosphate	I-protein
receptor	I-protein
.	O

L	O
-	O
735	O
,	O
524	O
free	O
base	O
or	O
sulfate	O
salt	O
was	O
administered	O
orally	O
as	O
suspension	O
,	O
solution	O
or	O
in	O
solid	O
dosage	O
forms	O
to	O
fasted	O
or	O
fed	O
Beagle	O
dogs	O
.	O

The	O
results	O
strongly	O
support	O
the	O
notion	O
that	O
the	O
OBF1	B-protein
-	I-protein
binding	I-protein
sites	I-protein
and	O
the	O
OBF1	B-protein
protein	I-protein
are	O
important	O
for	O
normal	O
ARS	B-protein
function	O
as	O
an	O
origin	O
of	O
replication	O
.	O

Moreover	O
,	O
in	O
one	O
patient	O
with	O
a	O
sarcoma	O
who	O
underwent	O
a	O
leg	O
-	O
sparing	O
procedure	O
,	O
no	O
sciatic	O
nerve	O
enlargement	O
was	O
seen	O
postoperatively	O
.	O

D	O
.	O

After	O
tilting	O
,	O
systolic	O
blood	O
pressure	O
fell	O
an	O
average	O
of	O
17	O
%	O
in	O
patients	O
who	O
cramped	O
infrequently	O
(	O
p	O
=	O
0	O
.	O
0031	O
)	O
but	O
only	O
10	O
%	O
in	O
frequently	O
cramping	O
patients	O
.	O

The	O
tissue	O
specificity	O
of	O
gene	O
expression	O
was	O
identical	O
to	O
that	O
described	O
previously	O
for	O
the	O
CaMV	B-protein
35S	I-protein
domain	I-protein
B	I-protein
enhancer	I-protein
element	I-protein
.	O

Substitution	O
of	O
the	O
Ser	O
-	O
Thr	O
sites	O
with	O
the	O
phosphomimetic	O
Asp	O
generated	O
a	O
constitutively	O
active	O
form	O
of	O
IRF	B-protein
-	I-protein
3	I-protein
that	O
functioned	O
as	O
a	O
very	O
strong	O
activator	O
of	O
promoters	O
containing	O
PRDI	B-protein
-	I-protein
PRDIII	I-protein
or	O
ISRE	B-protein
regulatory	I-protein
elements	I-protein
.	O

Precipitation	O
using	O
GST	B-protein
fusion	I-protein
proteins	I-protein
containing	O
Fyn	B-protein
SH2	I-protein
,	O
SH3	B-protein
,	O
and	O
SH2	B-protein
/	I-protein
SH3	I-protein
domains	I-protein
revealed	O
that	O
PI	B-protein
3	I-protein
-	I-protein
kinase	I-protein
bound	O
principally	O
to	O
the	O
SH3	B-protein
domain	I-protein
of	O
Fyn	B-protein
.	O

Five	O
of	O
the	O
Aeromonas	O
strains	O
and	O
one	O
of	O
V	O
cholerae	O
non	O
-	O
O1	O
were	O
positive	O
for	O
enterotoxin	B-protein
activity	O
.	O

Northern	O
blot	O
analysis	O
of	O
total	O
cellular	O
RNA	O
indicated	O
that	O
xylP	B-protein
encodes	O
a	O
1	O
.	O
3	O
-	O
kb	O
transcript	O
which	O
is	O
induced	O
by	O
xylan	O
.	O

Effects	O
of	O
spatial	O
and	O
temporal	O
smoothing	O
on	O
stimulated	O
brillouin	O
scattering	O
in	O
the	O
independent	O
-	O
hot	O
-	O
spot	O
model	O
limit	O
The	O
influence	O
of	O
laser	O
beam	O
smoothing	O
on	O
stimulated	O
Brillouin	O
backscattering	O
(	O
SBBS	O
)	O
is	O
studied	O
analytically	O
in	O
the	O
limit	O
of	O
the	O
independent	O
hot	O
spot	O
model	O
.	O

Mean	O
(	O
+	O
/	O
-	O
SE	O
)	O
measurements	O
of	O
clearance	O
(	O
24	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
06	O
v	O
26	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
05	O
mL	O
/	O
min	O
/	O
m2	O
)	O
,	O
half	O
-	O
life	O
(	O
5	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
5	O
v	O
6	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
5	O
hours	O
)	O
,	O
and	O
volume	O
of	O
distribution	O
(	O
12	O
.	O
4	O
+	O
/	O
-	O
1	O
.	O
1	O
v	O
13	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
6	O
L	O
/	O
m2	O
)	O
were	O
not	O
significantly	O
different	O
in	O
patients	O
with	O
jaundice	O
when	O
compared	O
with	O
controls	O
.	O

Immunity	O
acquired	O
by	O
mice	O
during	O
I	O
.	O
scapularis	O
nymphal	O
activity	O
in	O
early	O
summer	O
may	O
exclude	O
a	O
large	O
proportion	O
of	O
the	O
mouse	O
population	O
from	O
maintaining	O
E	O
.	O
phagocytophila	O
during	O
the	O
period	O
of	O
larval	O
activity	O
later	O
in	O
the	O
season	O
.	O

To	O
evaluate	O
the	O
gas	O
chromatographic	O
electron	O
capture	O
detection	O
method	O
described	O
earlier	O
,	O
23	O
plasma	O
samples	O
have	O
been	O
analysed	O
by	O
both	O
techniques	O
.	O

Despite	O
abundant	O
expression	O
of	O
NtmybAS	B-protein
transcripts	I-protein
in	O
mature	O
pollen	O
,	O
gPAL1	B-protein
transcripts	I-protein
were	O
not	O
detectable	O
in	O
pollen	O
.	O

The	O
muscles	O
from	O
the	O
ischemic	O
group	O
had	O
significantly	O
lower	O
(	O
P	O
less	O
than	O
.	O
05	O
)	O
values	O
for	O
capillary	O
density	O
and	O
capillary	O
to	O
fiber	O
ratio	O
and	O
significantly	O
higher	O
intercapillary	O
distance	O
than	O
those	O
from	O
the	O
normal	O
group	O
.	O

For	O
this	O
purpose	O
,	O
we	O
used	O
a	O
series	O
of	O
plasmid	O
constructs	O
encoding	O
different	O
forms	O
of	O
the	O
envelope	B-protein
glycoprotein	I-protein
E	I-protein
of	I-protein
the	I-protein
flavivirus	I-protein
tick	I-protein
-	I-protein
borne	I-protein
encephalitis	I-protein
virus	I-protein
.	O

We	O
constructed	O
a	O
yeast	O
reporter	O
strain	O
containing	O
the	O
lacZ	B-protein
gene	I-protein
under	O
the	O
control	O
of	O
the	O
CYC1	B-protein
promoter	I-protein
associated	O
with	O
three	O
copies	O
of	O
TRE	B-protein
-	I-protein
1	I-protein
.	O

Differences	O
in	O
profiles	O
of	O
viscosity	O
variables	O
between	O
subgroups	O
of	O
EAD	O
in	O
RA	O
patients	O
were	O
observed	O
.	O

Fifteen	O
light	O
for	O
dates	O
infants	O
and	O
their	O
placentae	O
were	O
compared	O
to	O
15	O
well	O
-	O
grown	O
infants	O
and	O
their	O
placentae	O
.	O

Although	O
it	O
has	O
two	O
potential	O
binding	O
sites	O
,	O
the	O
purified	O
MerR	B-protein
homodimer	I-protein
binds	O
only	O
one	O
Hg	O
(	O
II	O
)	O
ion	O
,	O
employing	O
Cys82	O
from	O
one	O
monomer	O
and	O
Cys117	O
and	O
Cys126	O
from	O
the	O
other	O
.	O

The	O
envelope	B-protein
glycoproteins	I-protein
of	I-protein
Rous	I-protein
sarcoma	I-protein
virus	I-protein
(	I-protein
RSV	I-protein
)	I-protein
,	O
gp85	B-protein
and	O
gp37	B-protein
,	O
are	O
anchored	O
in	O
the	O
membrane	O
by	O
a	O
27	O
-	O
amino	O
acid	O
,	O
hydrophobic	O
domain	O
that	O
lies	O
adjacent	O
to	O
a	O
22	O
-	O
amino	O
acid	O
,	O
cytoplasmic	O
domain	O
at	O
the	O
carboxy	O
terminus	O
of	O
gp37	B-protein
.	O

HupI	B-protein
showed	O
strong	O
identity	O
to	O
rubredoxin	B-protein
and	O
rubredoxin	B-protein
-	I-protein
like	I-protein
proteins	I-protein
from	O
many	O
other	O
bacteria	O
.	O

Osteocalcin	B-protein
(	O
serum	B-protein
bone	I-protein
-	I-protein
Gla	I-protein
protein	I-protein
,	O
sBGP	B-protein
)	O
,	O
serum	B-protein
alkaline	I-protein
phosphatase	I-protein
(	O
sAP	B-protein
)	O
and	O
urinary	O
hydroxyproline	O
/	O
creatinine	O
ratio	O
(	O
uOH	O
-	O
Prol	O
/	O
creatinine	O
)	O
have	O
been	O
measured	O
in	O
21	O
patients	O
with	O
primary	O
hyperparathyroidism	O
(	O
PHPT	O
)	O
and	O
in	O
nine	O
patients	O
with	O
hypercalcaemia	O
of	O
malignancy	O
(	O
HM	O
)	O
.	O

During	O
the	O
conditioning	O
procedure	O
,	O
the	O
C	O
-	O
fiber	O
reflex	O
was	O
facilitated	O
(	O
wind	O
-	O
up	O
)	O
in	O
a	O
stimulus	O
-	O
dependent	O
fashion	O
in	O
intact	O
,	O
anesthetized	O
animals	O
during	O
the	O
application	O
of	O
the	O
first	O
seven	O
conditioning	O
stimuli	O
;	O
thereafter	O
,	O
the	O
magnitude	O
of	O
the	O
responses	O
reached	O
a	O
plateau	O
and	O
then	O
decreased	O
.	O

In	O
35	O
of	O
those	O
patients	O
DD	O
was	O
measured	O
also	O
with	O
microlatex	O
tests	O
-	O
-	O
Tinaquant	O
and	O
BC	O
d	O
-	O
dimer	O
.	O

The	O
purpose	O
of	O
this	O
article	O
is	O
to	O
discuss	O
the	O
factors	O
involved	O
in	O
the	O
selection	O
of	O
antibodies	O
,	O
radionuclides	O
and	O
labeling	O
methods	O
in	O
the	O
development	O
of	O
radioimmunotherapy	O
(	O
RIT	O
)	O
for	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
(	O
NHL	O
)	O
from	O
a	O
single	O
clinical	O
study	O
site	O
through	O
multicenter	O
trials	O
and	O
commercialization	O
.	O

In	O
contrast	O
,	O
the	O
Anabaena	O
strain	O
7120	O
leuA	B-protein
gene	O
did	O
not	O
complement	O
the	O
nifV	B-protein
mutation	I-protein
of	O
R229I	O
efficiently	O
.	O

Y15170	B-protein
(	O
Surf	B-protein
-	I-protein
2	I-protein
,	O
Surf	B-protein
-	I-protein
4	I-protein
)	O
,	O
Y15171	B-protein
(	O
Surf	B-protein
-	I-protein
3	I-protein
,	O
Surf	B-protein
-	I-protein
1	I-protein
,	O
Surf	B-protein
-	I-protein
6	I-protein
)	O
,	O
and	O
Y15172	B-protein
(	O
Surf	B-protein
-	I-protein
5	I-protein
.	O
)	O
]	O

Yusuf	O
Dawood	O
Docrat	O
L	O
.	O
R	O
.	O
C	O
.	O
P	O
.	O

A	O
total	O
of	O
576	O
1	O
-	O
day	O
-	O
old	O
Ross	O
broiler	O
chicks	O
were	O
housed	O
in	O
six	O
treatment	O
groups	O
[	O
six	O
replicates	O
of	O
16	O
each	O
;	O
control	O
,	O
CLI	O
(	O
15	O
g	O
kg	O
(	O
-	O
1	O
)	O
diet	O
)	O
,	O
50	O
parts	O
per	O
billion	O
(	O
ppb	O
)	O
AF	O
,	O
50	O
ppb	O
AF	O
plus	O
CLI	O
,	O
100	O
ppb	O
AF	O
,	O
100	O
ppb	O
AF	O
plus	O
CLI	O
]	O
for	O
42	O
days	O
.	O

The	O
RNA	O
-	O
binding	O
and	O
RNA	B-protein
-	I-protein
DNA	I-protein
helicase	I-protein
activities	O
of	O
the	O
Escherichia	B-protein
coli	I-protein
transcription	I-protein
termination	I-protein
factor	I-protein
rho	I-protein
have	O
been	O
investigated	O
using	O
natural	O
RNA	O
molecules	O
that	O
are	O
255	O
and	O
391	O
nucleotide	O
residues	O
in	O
length	O
and	O
that	O
contain	O
the	O
trp	B-protein
t	I-protein
'	I-protein
rho	I-protein
-	I-protein
dependent	I-protein
termination	I-protein
sequence	I-protein
of	O
E	O
.	O
coli	O
.	O

Effects	O
of	O
chronic	O
descending	O
tractotomy	O
on	O
the	O
response	O
patterns	O
of	O
neurons	O
in	O
the	O
trigeminal	O
nuclei	O
principalis	O
and	O
oralis	O
.	O

Short	O
therapy	O
with	O
omeprazole	O
20	O
mg	O
/	O
b	O
.	O
i	O
.	O
d	O
.	O
,	O
clarithromycin	O
500	O
mg	O
/	O
b	O
.	O
i	O
.	O
d	O
.	O
,	O
and	O
CBS	O
120	O
mg	O
/	O
q	O
.	O
i	O
.	O
d	O
.	O
is	O
a	O
safe	O
,	O
well	O
tolerated	O
combination	O
that	O
achieves	O
a	O
80	O
.	O
6	O
%	O
eradication	O
rate	O
of	O
H	O
.	O
pylori	O
and	O
duodenal	O
ulcer	O
healing	O
rates	O
as	O
good	O
as	O
those	O
achieved	O
by	O
omeprazole	O
20	O
mg	O
/	O
d	O
when	O
given	O
for	O
4	O
wk	O
.	O

Using	O
adenoviral	O
transfer	O
of	O
IkappaBalpha	B-protein
(	O
IkappaBalpha	B-protein
overexpression	O
)	O
,	O
the	O
production	O
of	O
TNF	B-protein
-	I-protein
alpha	I-protein
induced	O
by	O
whole	O
GBS	O
was	O
inhibited	O
by	O
only	O
20	O
%	O
.	O

Documentation	O
of	O
a	O
successful	O
intrauterine	O
fertilization	O
with	O
delivery	O
of	O
a	O
term	O
baby	O
supports	O
the	O
theoretical	O
feasibility	O
of	O
the	O
EP	O
;	O
however	O
,	O
anovulation	O
incurred	O
by	O
our	O
procedure	O
appears	O
to	O
be	O
the	O
major	O
drawback	O
.	O

4	O
.	O
26	O
+	O
/	O
-	O
1	O
.	O
54	O
mmol	O
/	O
l	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
systolic	O
BP	O
responses	O
to	O
intravenous	O
norepinephrine	O
and	O
angiotensin	B-protein
II	I-protein
were	O
significantly	O
higher	O
on	O
glibenclamide	O
than	O
on	O
metformin	O
(	O
P	O
<	O
0	O
.	O
02	O
and	O
P	O
<	O
0	O
.	O
05	O
,	O
respectively	O
)	O
.	O

Experimental	O
chlorpromazine	O
cataracts	O
.	O

Interactions	O
between	O
adrenergics	O
,	O
adrenolytics	O
and	O
monoamine	B-protein
oxidase	I-protein
inhibitors	O
.	O

Using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
to	O
screen	O
for	O
proteins	O
which	O
interact	O
with	O
Tax1	B-protein
,	O
we	O
isolated	O
the	O
B	O
subunit	O
of	O
the	O
CCAAT	B-protein
binding	I-protein
protein	I-protein
NF	I-protein
-	I-protein
Y	I-protein
from	O
a	O
HeLa	O
cDNA	O
library	O
.	O

Amisulpride	O
400	O
mg	O
had	O
several	O
adverse	O
effects	O
on	O
psychomotor	O
and	O
,	O
although	O
less	O
severe	O
,	O
on	O
cognitive	O
performance	O
on	O
the	O
fifth	O
day	O
only	O
.	O

The	O
pharmacokinetic	O
profiles	O
of	O
digoxin	O
and	O
warfarin	O
were	O
not	O
altered	O
by	O
the	O
simultaneous	O
and	O
continued	O
administration	O
of	O
sevelamer	O
.	O

Band	O
-	O
shift	O
assays	O
and	O
DNase	B-protein
I	I-protein
footprinting	O
experiments	O
using	O
purified	O
42	O
kDa	O
repressor	O
isoform	O
confirmed	O
that	O
CIRs	B-protein
5	I-protein
and	I-protein
6	I-protein
were	O
indeed	O
the	O
targets	O
for	O
binding	O
of	O
this	O
protein	O
.	O

The	O
average	O
backscatter	O
coefficient	O
was	O
six	O
time	O
larger	O
in	O
regions	O
of	O
infarct	O
studied	O
8	O
-	O
-	O
10	O
weeks	O
after	O
occlusion	O
than	O
that	O
in	O
regions	O
of	O
infarct	O
studied	O
5	O
-	O
-	O
6	O
weeks	O
after	O
occlusion	O
.	O

INTERVENTIONS	O
:	O
Study	O
patients	O
were	O
randomly	O
divided	O
into	O
four	O
parallel	O
groups	O
to	O
receive	O
either	O
terbinafine	O
250	O
mg	O
a	O
day	O
for	O
12	O
or	O
16	O
weeks	O
(	O
groups	O
T12	O
and	O
T16	O
)	O
or	O
itraconazole	O
400	O
mg	O
a	O
day	O
for	O
1	O
week	O
in	O
every	O
4	O
weeks	O
for	O
12	O
or	O
16	O
weeks	O
(	O
groups	O
I3	O
and	O
I4	O
)	O
.	O

However	O
,	O
limited	O
comparisons	O
reveal	O
domains	O
in	O
the	O
NH2	O
and	O
COOH	O
termini	O
that	O
have	O
a	O
high	O
degree	O
of	O
similarity	O
suggesting	O
functional	O
conservation	O
.	O

Interaction	O
of	O
HRI	B-protein
with	O
Hsc70	B-protein
was	O
required	O
for	O
the	O
transformation	O
of	O
HRI	B-protein
,	O
as	O
the	O
Hsc70	B-protein
antagonist	O
clofibric	O
acid	O
inhibited	O
the	O
folding	O
of	O
HRI	B-protein
into	O
a	O
mature	O
-	O
competent	O
conformation	O
.	O

Long	O
-	O
term	O
results	O
with	O
MACOP	O
-	O
B	O
and	O
radiation	O
therapy	O
for	O
aggressive	O
lymphomas	O
BACKGROUND	O
:	O
Long	O
-	O
term	O
results	O
are	O
needed	O
to	O
evaluate	O
chemotherapy	O
regimens	O
and	O
prognostic	O
factors	O
in	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphomas	O
(	O
NHL	O
)	O
.	O

In	O
analyses	O
with	O
control	O
for	O
multiple	O
variables	O
,	O
relative	O
risk	O
for	O
microalbuminuria	O
(	O
urinary	O
albumin	B-protein
excretion	O
,	O
20	O
-	O
199	O
microg	O
/	O
min	O
)	O
in	O
men	O
and	O
women	O
was	O
2	O
.	O
51	O
and	O
1	O
.	O
62	O
,	O
respectively	O
,	O
with	O
18	O
mm	O
Hg	O
higher	O
(	O
1	O
SD	O
)	O
systolic	O
blood	O
pressure	O
;	O
2	O
.	O
25	O
and	O
2	O
.	O
10	O
,	O
respectively	O
,	O
with	O
1	O
.	O
0	O
-	O
mmol	O
/	O
L	O
(	O
40	O
mg	O
/	O
dL	O
)	O
higher	O
plasma	O
cholesterol	O
level	O
;	O
1	O
.	O
99	O
and	O
1	O
.	O
91	O
,	O
respectively	O
,	O
for	O
smokers	O
vs	O
nonsmokers	O
;	O
and	O
1	O
.	O
83	O
and	O
1	O
.	O
33	O
,	O
respectively	O
,	O
with	O
4	O
kg	O
/	O
m2	O
higher	O
body	O
mass	O
index	O
.	O

Solving	O
an	O
age	O
old	O
problem	O
.	O

DNA	O
sequencing	O
of	O
a	O
17	O
-	O
kb	O
segment	O
encompassing	O
a	O
gammaherpesvirus	O
divergent	O
locus	O
(	O
DL	O
-	O
B	O
)	O
between	O
ORF11	O
and	O
ORF17	O
revealed	O
the	O
presence	O
of	O
nine	O
viral	O
ORFs	O
with	O
predicted	O
gene	O
products	O
related	O
to	O
cellular	O
proteins	O
.	O

The	O
RFLP	O
patterns	O
of	O
the	O
isolates	O
from	O
six	O
of	O
these	O
patients	O
remained	O
essentially	O
unchanged	O
(	O
two	O
strains	O
showed	O
one	O
additional	O
band	O
)	O
despite	O
the	O
development	O
of	O
drug	O
resistance	O
.	O

Max	B-protein
:	O
functional	O
domains	O
and	O
interaction	O
with	O
c	B-protein
-	I-protein
Myc	I-protein
.	O

Conversely	O
,	O
treatment	O
of	O
human	B-protein
protein	I-protein
-	I-protein
tyrosine	I-protein
phosphatase	I-protein
alpha	O
-	O
overexpressing	O
cells	O
with	O
phenylarsine	O
oxide	O
led	O
to	O
a	O
loss	O
of	O
the	O
constitutive	O
NF	B-protein
-	I-protein
kappa	I-protein
B	I-protein
activity	O
.	O

2	O
cases	O
of	O
toxic	O
lymphomononucleosis	O
.	O

1	O
,	O
among	O
which	O
nine	O
have	O
been	O
cloned	O
and	O
two	O
(	O
potentially	O
functional	O
)	O
sequenced	O
.	O

Using	O
immunogold	O
electron	O
microscopy	O
,	O
we	O
found	O
that	O
p58	B-protein
/	I-protein
p45	I-protein
and	O
p54	B-protein
are	O
localized	O
on	O
both	O
sides	O
of	O
the	O
nuclear	O
pore	O
complex	O
,	O
like	O
p62	B-protein
.	O

HEF1	B-protein
,	O
p130	B-protein
(	I-protein
Cas	I-protein
)	I-protein
,	O
and	O
Efs	B-protein
/	I-protein
Sin	I-protein
constitute	O
a	O
family	O
of	O
multidomain	O
docking	O
proteins	O
that	O
have	O
been	O
implicated	O
in	O
coordinating	O
the	O
regulation	O
of	O
cell	O
adhesion	O
.	O

Role	O
of	O
biocenosis	O
in	O
the	O
manifestation	O
of	O
Shigella	O
virulence	O
.	O

In	O
all	O
cells	O
,	O
the	O
accumulation	O
of	O
high	O
Dsg	B-protein
protein	I-protein
levels	O
required	O
calcium	O
and	O
was	O
not	O
observed	O
in	O
low	O
calcium	O
(	O
0	O
.	O
05	O
-	O
0	O
.	O
07	O
mM	O
)	O
media	O
.	O

Point	O
mutations	O
that	O
suppressed	O
the	O
in	O
vitro	O
binding	O
of	O
NF	B-protein
-	I-protein
Y	I-protein
to	O
the	O
internal	O
palindromic	O
arm	O
reduced	O
the	O
activity	O
of	O
the	O
resident	O
P4	B-protein
promoter	I-protein
,	O
while	O
those	O
preventing	O
complex	O
formation	O
with	O
USF	B-protein
did	O
not	O
,	O
as	O
determined	O
by	O
transient	O
expression	O
assays	O
using	O
the	O
luciferase	B-protein
reporter	O
gene	O
.	O

Two	O
specific	O
DNA	O
-	O
protein	O
complexes	O
were	O
identified	O
in	O
gel	O
retardation	O
assays	O
using	O
HeLa	O
cell	O
nuclear	O
extracts	O
and	O
an	O
oligonucleotide	O
probe	O
spanning	O
the	O
footprinted	O
region	O
.	O

We	O
present	O
a	O
case	O
of	O
type	O
II	O
hyperbetalipoproteinemia	O
in	O
a	O
patient	O
whose	O
diagnosis	O
had	O
been	O
previously	O
unrecognized	O
,	O
and	O
who	O
had	O
previously	O
been	O
misdiagnosed	O
with	O
rheumatoid	O
arthritis	O
and	O
later	O
gout	O
.	O

TPA	O
and	O
TGF	B-protein
-	I-protein
beta	I-protein
1	I-protein
did	O
not	O
markedly	O
affect	O
the	O
activities	O
of	O
the	O
72	O
-	O
kDa	O
enzyme	O
.	O

The	O
remaining	O
six	O
patients	O
had	O
slightly	O
decreased	O
(	O
n	O
=	O
3	O
)	O
or	O
normal	O
(	O
n	O
=	O
3	O
)	O
seminal	O
parameters	O
.	O

AMY	B-protein
-	I-protein
1	I-protein
was	O
localized	O
in	O
the	O
cytoplasm	O
in	O
cells	O
expressing	O
c	B-protein
-	I-protein
myc	I-protein
at	O
low	O
levels	O
,	O
but	O
in	O
the	O
nucleus	O
in	O
the	O
cells	O
of	O
a	O
high	O
c	B-protein
-	I-protein
myc	I-protein
expression	O
in	O
transiently	O
transfected	O
cells	O
.	O

Methysergide	O
is	O
a	O
serotonin	O
antagonist	O
and	O
has	O
been	O
demonstrated	O
to	O
reduce	O
wound	O
blood	O
flow	O
and	O
edema	O
formation	O
.	O

Because	O
the	O
adrenergic	O
nervous	O
system	O
influences	O
cardiac	O
arrhythmias	O
and	O
myocardial	O
infarction	O
can	O
directly	O
affect	O
sympathetic	O
innervation	O
in	O
the	O
heart	O
,	O
we	O
investigated	O
the	O
role	O
of	O
the	O
sympathetic	O
nervous	O
system	O
on	O
reentry	O
in	O
the	O
canine	O
heart	O
4	O
days	O
after	O
infarction	O
.	O

Though	O
the	O
BACTEC	O
9000	O
MB	O
system	O
is	O
recommended	O
for	O
respiratory	O
specimens	O
,	O
we	O
demonstrated	O
that	O
it	O
can	O
be	O
successfully	O
used	O
also	O
for	O
recovery	O
of	O
mycobacteria	O
from	O
clinical	O
specimens	O
from	O
various	O
extrapulmonary	O
sites	O
.	O

HL	O
02	O
type	O
oculomotor	O
stimulator	O
.	O

OBJECTIVE	O
:	O
This	O
meta	O
-	O
analysis	O
of	O
67	O
controlled	O
trials	O
was	O
performed	O
to	O
quantify	O
the	O
cholesterol	O
-	O
lowering	O
effect	O
of	O
major	O
dietary	O
fibers	O
.	O

These	O
studies	O
suggest	O
an	O
additional	O
component	O
or	O
cellular	O
environment	O
is	O
required	O
for	O
SPRK	B-protein
activation	O
by	O
Cdc42	B-protein
.	O

The	O
response	O
of	O
serum	B-protein
GH	I-protein
to	O
arginine	O
infusion	O
was	O
normal	O
,	O
while	O
that	O
to	O
insulin	O
-	O
induced	O
hypoglycemia	O
was	O
poor	O
.	O

Convulsive	O
status	O
epilepticus	O
after	O
infusion	O
of	O
cisplatin	O
.	O

NDRF	B-protein
/	I-protein
NeuroD2	I-protein
was	O
co	O
-	O
precipitated	O
with	O
PKN	B-protein
from	O
the	O
lysate	O
of	O
COS	O
-	O
7	O
cells	O
transfected	O
with	O
both	O
expression	O
constructs	O
for	O
NDRF	B-protein
/	I-protein
NeuroD2	I-protein
and	O
PKN	B-protein
.	O

While	O
blood	O
pressure	O
and	O
noradrenergic	O
activity	O
,	O
assessed	O
as	O
changes	O
in	O
the	O
plasma	O
levels	O
and	O
urinary	O
excretion	O
of	O
norepinephrine	O
,	O
remained	O
unaffected	O
in	O
the	O
Pl	O
group	O
,	O
a	O
significant	O
drop	O
in	O
the	O
supine	O
systolic	O
and	O
diastolic	O
blood	O
pressures	O
,	O
as	O
well	O
as	O
in	O
the	O
resting	O
venous	O
norepinephrine	O
level	O
and	O
in	O
urinary	O
norepinephrine	O
excretion	O
was	O
found	O
after	O
the	O
first	O
month	O
of	O
dF	O
administration	O
.	O

In	O
vitro	O
protein	O
retention	O
experiments	O
in	O
which	O
Hsp90	B-protein
heterocomplexes	I-protein
were	O
precipitated	O
resulted	O
in	O
coprecipitation	O
of	O
Cns1	B-protein
.	O

We	O
have	O
identified	O
two	O
functional	O
elements	O
,	O
both	O
located	O
downstream	O
from	O
the	O
TATA	O
motif	O
,	O
that	O
control	O
Id4	B-protein
promoter	I-protein
activity	O
.	O

Four	O
of	O
these	O
five	O
subjects	O
also	O
performed	O
mixed	O
sequences	O
under	O
conditional	O
control	O
of	O
the	O
words	O
(	O
e	O
.	O
g	O
.	O
,	O
A1	O
-	O
-	O
-	O
-	O
B2	O
-	O
-	O
-	O
-	O
A3	O
-	O
-	O
-	O
-	O
B4	O
-	O
-	O
-	O
-	O
A5	O
and	O
its	O
reversal	O
)	O
,	O
verifying	O
that	O
the	O
stimuli	O
which	O
occupied	O
the	O
same	O
position	O
in	O
each	O
sequence	O
were	O
members	O
of	O
the	O
same	O
class	O
.	O

Zhu	O
,	O
V	O
.	O

The	O
xylose	B-protein
isomerase	I-protein
-	I-protein
encoding	I-protein
gene	I-protein
(	O
xylA	B-protein
)	O
of	O
Clostridium	O
thermosaccharolyticum	O
:	O
cloning	O
,	O
sequencing	O
and	O
phylogeny	O
of	O
XylA	B-protein
enzymes	I-protein
.	O

Two	O
disulphide	O
bridges	O
,	O
which	O
are	O
conserved	O
in	O
all	O
spermadhesin	O
molecules	O
and	O
many	O
CUB	B-protein
domains	I-protein
,	O
crosslink	O
loop	O
LA	O
and	O
strand	O
beta	O
4	O
and	O
loops	O
LE	O
and	O
LG	O
,	O
respectively	O
,	O
at	O
opposite	O
edges	O
of	O
the	O
same	O
face	O
of	O
the	O
domain	O
.	O

A	O
.	O

Detection	O
of	O
anti	O
-	O
lymphocyte	O
antibodies	O
using	O
the	O
immunoperoxidase	B-protein
antiglobulin	I-protein
technic	O
.	O

Remarkably	O
,	O
both	O
TTD	O
-	O
A	O
and	O
XP	O
-	O
D	O
defects	O
are	O
associated	O
with	O
subunits	O
of	O
TFIIH	B-protein
,	O
a	O
basal	O
transcription	O
factor	O
with	O
a	O
second	O
function	O
in	O
DNA	O
repair	O
.	O

Monotherapy	O
with	O
ceftazidime	O
was	O
clinically	O
and	O
bacteriologically	O
as	O
effective	O
as	O
a	O
combination	O
therapy	O
with	O
cefazolin	O
and	O
tobramycin	O
.	O

The	O
skp1	B-protein
+	I-protein
gene	I-protein
is	O
not	O
essential	O
.	O

To	O
evaluate	O
the	O
effects	O
of	O
propranolol	O
on	O
myocardial	O
metabolism	O
after	O
coronary	O
reperfusion	O
,	O
serial	O
measurements	O
of	O
myocardial	B-protein
creatine	I-protein
kinase	I-protein
(	O
CK	B-protein
)	O
and	O
calcium	O
(	O
Ca	O
)	O
contents	O
and	O
CK	B-protein
and	O
lactic	O
acid	O
(	O
LA	O
)	O
concentrations	O
in	O
coronary	O
sinus	O
blood	O
were	O
carried	O
out	O
in	O
33	O
open	O
-	O
chest	O
dogs	O
.	O

Titration	O
of	O
the	O
human	O
and	O
porcine	O
proteins	O
with	O
2	O
-	O
nitro	O
-	O
5	O
-	O
thiosulfabenzoate	O
indicates	O
that	O
membrane	B-protein
dipeptidase	I-protein
additionally	O
possesses	O
two	O
intrachain	O
disulfide	O
bonds	O
.	O

The	O
first	O
identification	O
of	O
the	O
active	B-protein
37LRP	I-protein
/	I-protein
p40	I-protein
gene	I-protein
presented	O
in	O
this	O
study	O
is	O
a	O
critical	O
step	O
toward	O
the	O
isolation	O
of	O
the	O
corresponding	O
human	O
gene	O
and	O
the	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
up	O
-	O
regulation	O
of	O
its	O
expression	O
during	O
tumor	O
invasion	O
and	O
metastasis	O
.	O

Analyses	O
of	O
additional	O
tumors	O
induced	O
in	O
mice	O
from	O
two	O
reciprocal	O
crosses	O
,	O
A	O
/	O
J	O
x	O
C3H	O
/	O
HeJ	O
F1	O
(	O
hereafter	O
called	O
AC3F1	O
)	O
and	O
C3H	O
/	O
HeJ	O
x	O
A	O
/	O
J	O
F1	O
(	O
hereafter	O
called	O
C3AF1	O
)	O
,	O
provided	O
evidence	O
for	O
the	O
inactivation	O
of	O
one	O
allele	O
of	O
the	O
putative	O
chromosome	O
4	O
tumor	O
suppressor	O
gene	O
by	O
parental	O
imprinting	O
.	O

Venkatesan	O
,	O
and	O
D	O
.	O

The	O
lack	O
of	O
the	O
C2	B-protein
domain	I-protein
of	O
the	O
Ca	B-protein
(	I-protein
2	I-protein
+	I-protein
)	I-protein
-	I-protein
dependent	I-protein
PKCs	I-protein
and	O
the	O
presence	O
of	O
a	O
unique	O
NH2	O
-	O
terminal	O
sequence	O
with	O
a	O
potential	O
signal	O
peptide	O
and	O
a	O
transmembrane	O
domain	O
suggest	O
that	O
PKC	B-protein
mu	I-protein
is	O
a	O
novel	O
member	O
of	O
the	O
subgroup	O
of	O
atypical	O
PKCs	B-protein
.	O

However	O
,	O
whether	O
or	O
not	O
nonsense	O
codon	O
recognition	O
within	O
TPI	B-protein
transcripts	I-protein
takes	O
place	O
prior	O
to	O
or	O
after	O
splicing	O
remained	O
unresolved	O
.	O

18F	O
and	O
85Sr	O
scintimetry	O
in	O
the	O
study	O
of	O
primary	O
arthropathies	O
.	O

Molecular	O
analysis	O
of	O
the	O
pRA2	O
partitioning	O
region	O
:	O
ParB	B-protein
autoregulates	O
parAB	B-protein
transcription	O
and	O
forms	O
a	O
nucleoprotein	O
complex	O
with	O
the	O
plasmid	O
partition	O
site	O
,	O
parS	B-protein
.	O

The	O
5	O
'	O
untranslated	O
and	O
coding	O
regions	O
are	O
contained	O
within	O
12	O
exons	O
,	O
with	O
the	O
translation	O
start	O
site	O
located	O
within	O
the	O
first	O
exon	O
.	O

A	O
mutation	O
in	O
the	O
C	O
domain	O
of	O
Rb	B-protein
,	O
L901Q	O
,	O
has	O
been	O
identified	O
that	O
completely	O
abolishes	O
cdk4	B-protein
/	I-protein
D1	I-protein
phosphorylation	O
of	O
the	O
isolated	O
C	O
domain	O
.	O

Specific	O
clotting	O
factor	O
assays	O
showed	O
an	O
isolated	O
deficiency	O
of	O
factor	B-protein
X	I-protein
ranging	O
from	O
7	O
to	O
12	O
per	O
cent	O
on	O
three	O
determinations	O
.	O

These	O
data	O
should	O
be	O
useful	O
in	O
developing	O
reagents	O
for	O
heterozygote	O
detection	O
and	O
prenatal	O
diagnosis	O
of	O
11	B-protein
beta	I-protein
-	I-protein
hydroxylase	I-protein
deficiency	O
,	O
the	O
second	O
most	O
frequent	O
cause	O
of	O
congenital	O
adrenal	O
hyperplasia	O
.	O

These	O
exons	O
,	O
further	O
identified	O
as	O
exons	O
9	O
,	O
10	O
,	O
and	O
11	O
,	O
together	O
encode	O
the	O
37	O
amino	O
acid	O
residues	O
present	O
in	O
alpha	B-protein
s1	I-protein
-	I-protein
casein	I-protein
variant	I-protein
A	I-protein
but	O
missing	O
in	O
variant	O
F	O
.	O

Since	O
1970	O
the	O
frequency	O
of	O
potassium	O
-	O
induced	O
ulceration	O
has	O
been	O
low	O
-	O
-	O
3	O
cases	O
per	O
100	O
000	O
patient	O
-	O
years	O
of	O
slow	O
-	O
release	O
tablet	O
use	O
.	O

Examination	O
of	O
neurohumoral	O
factors	O
revealed	O
a	O
hyperactive	O
sympathetic	O
nervous	O
system	O
and	O
an	O
increase	O
in	O
plasma	O
renin	B-protein
activity	O
.	O

This	O
investigation	O
was	O
undertaken	O
to	O
determine	O
whether	O
consuming	O
several	O
small	O
feedings	O
of	O
preexercise	O
carbohydrate	O
(	O
CHO	O
)	O
,	O
rather	O
than	O
a	O
single	O
bolus	O
,	O
would	O
affect	O
blood	O
glucose	O
and	O
insulin	B-protein
responses	O
during	O
rest	O
and	O
exercise	O
.	O

A	O
triple	O
Ser	O
-	O
-	O
>	O
Ala	O
mutant	O
form	O
of	O
yeast	O
eIF	B-protein
-	I-protein
2	I-protein
alpha	I-protein
was	O
found	O
to	O
be	O
no	O
longer	O
phosphorylated	O
by	O
either	O
of	O
the	O
yeast	O
(	O
or	O
mammalian	O
)	O
casein	B-protein
kinase	I-protein
activities	O
in	O
vitro	O
.	O

HexA71	B-protein
negatively	O
affects	O
RpoS	B-protein
,	O
as	O
the	O
levels	O
of	O
this	O
alternative	O
sigma	B-protein
factor	I-protein
are	O
higher	O
in	O
the	O
HexA	B-protein
-	I-protein
mutant	I-protein
than	O
in	O
the	O
HexA	B-protein
+	I-protein
strain	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
binding	O
sites	O
for	O
the	O
repressor	B-protein
proteins	I-protein
BP1	I-protein
and	O
BP2	B-protein
in	O
the	O
upstream	O
portion	O
of	O
the	O
beta	B-protein
globin	I-protein
gene	I-protein
flanking	I-protein
region	I-protein
led	O
to	O
a	O
4	O
-	O
6	O
fold	O
increase	O
in	O
promoter	O
activity	O
.	O

The	O
results	O
suggested	O
that	O
,	O
depending	O
upon	O
the	O
cell	O
type	O
,	O
gene	O
cotransfer	O
using	O
aminoglycoside	O
resistance	O
as	O
a	O
selectable	O
marker	O
may	O
seriously	O
perturb	O
important	O
cellular	O
control	O
mechanisms	O
such	O
as	O
the	O
PKC	B-protein
pathway	O
leading	O
to	O
activation	O
of	O
gene	O
expression	O
.	O

Pulmonary	O
embolectomy	O
and	O
lung	O
transplantation	O
are	O
the	O
main	O
indications	O
for	O
the	O
use	O
of	O
heart	O
-	O
lung	O
-	O
machine	O
.	O

With	O
the	O
increasing	O
use	O
of	O
ACE	B-protein
inhibitors	O
,	O
the	O
incidence	O
of	O
rare	O
adverse	O
effects	O
such	O
as	O
potentially	O
lethal	O
pancreatitis	O
is	O
likely	O
to	O
increase	O
.	O

Staphylococcus	O
aureus	O
and	O
CNS	O
showed	O
high	O
or	O
moderate	O
resistance	O
rates	O
to	O
methicillin	O
(	O
DMPPC	O
)	O
.	O

The	O
genome	O
of	O
Thogoto	O
virus	O
comprises	O
six	O
segments	O
of	O
single	O
-	O
stranded	O
,	O
negative	O
sense	O
RNA	O
.	O

Overexpression	O
of	O
EFG1	B-protein
in	O
C	O
.	O
albicans	O
leads	O
to	O
enhanced	O
filamentous	O
growth	O
in	O
the	O
form	O
of	O
extended	O
pseudohyphae	O
in	O
liquid	O
and	O
on	O
solid	O
media	O
.	O

The	O
26S	B-protein
rRNA	I-protein
binding	I-protein
ribosomal	I-protein
protein	I-protein
equivalent	O
to	O
bacterial	B-protein
protein	I-protein
L11	I-protein
is	O
encoded	O
by	O
unspliced	O
duplicated	O
genes	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

An	O
unexpected	O
finding	O
was	O
the	O
presence	O
at	O
position	O
-	O
403	O
to	O
-	O
385	O
of	O
a	O
putative	O
dioxin	B-protein
responsive	I-protein
element	I-protein
,	O
a	O
sequence	O
found	O
to	O
be	O
responsible	O
for	O
the	O
induction	O
of	O
transcription	O
of	O
the	O
cytochrome	B-protein
P450IA1	I-protein
gene	I-protein
(	O
CYPIA1	B-protein
)	O
and	O
other	O
genes	O
involved	O
in	O
detoxification	O
/	O
activation	O
of	O
polycyclic	O
aromatic	O
hydrocarbons	O
.	O

APOE	B-protein
-	I-protein
epsilon4	I-protein
count	O
predicts	O
age	O
when	O
prevalence	O
of	O
AD	O
increases	O
,	O
then	O
declines	O
:	O
the	O
Cache	O
County	O
Study	O
.	O

In	O
contrast	O
,	O
resensitization	O
of	O
a	O
sequestration	O
-	O
impaired	O
beta2AR	B-protein
mutant	I-protein
(	I-protein
Y326A	I-protein
)	I-protein
was	O
reestablished	O
following	O
the	O
overexpression	O
of	O
either	O
GRK2	B-protein
or	O
beta	B-protein
-	I-protein
arrestin	I-protein
1	I-protein
.	O

In	O
contrast	O
to	O
hemodynamic	O
and	O
histopathological	O
predictors	O
of	O
survival	O
,	O
vWF	O
:	O
Ag	O
does	O
not	O
require	O
invasive	O
techniques	O
to	O
be	O
determined	O
.	O

Despite	O
supraphysiologic	O
E2	O
concentrations	O
,	O
however	O
,	O
cervical	O
mucus	O
scores	O
were	O
significantly	O
reduced	O
in	O
the	O
CC	O
-	O
treated	O
group	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Patients	O
with	O
a	O
secondary	O
cardiac	O
event	O
had	O
more	O
common	O
Type	O
A	O
behavior	O
patterns	O
and	O
higher	O
Bortner	O
scores	O
than	O
patients	O
without	O
a	O
secondary	O
cardiac	O
event	O
.	O

McCann	O
III	O
,	O
F	O
.	O

A	O
deproteinization	O
procedure	O
was	O
coupled	O
with	O
a	O
reversed	O
-	O
phase	O
HPLC	O
separation	O
using	O
a	O
250x4	O
.	O
6	O
mm	O
I	O
.	O
D	O
.	O

Recently	O
,	O
a	O
distantly	O
related	O
UmuC	B-protein
-	I-protein
homolog	I-protein
,	O
DinB	B-protein
,	O
has	O
also	O
been	O
identified	O
in	O
E	O
.	O
coli	O
.	O

On	O
the	O
constituents	O
of	O
Dryopteris	O
polylepis	O
.	O

The	O
basal	O
promoter	O
elements	O
of	O
murine	B-protein
cytochrome	I-protein
c	I-protein
oxidase	I-protein
subunit	I-protein
IV	I-protein
gene	I-protein
consist	O
of	O
tandemly	O
duplicated	O
ets	B-protein
motifs	I-protein
that	O
bind	O
to	O
GABP	B-protein
-	I-protein
related	I-protein
transcription	I-protein
factors	I-protein
.	O

The	O
alcoholic	O
patient	O
,	O
his	O
work	O
and	O
the	O
subjectivity	O
of	O
the	O
period	O
.	O

Expression	O
of	O
SREBP	B-protein
-	I-protein
1a	I-protein
stimulated	O
StAR	B-protein
promoter	I-protein
activity	O
in	O
the	O
context	O
of	O
COS	O
-	O
1	O
cells	O
and	O
human	O
granulosa	O
-	O
lutein	O
cells	O
.	O

In	O
10	O
patients	O
with	O
subacute	O
cardiac	O
tamponade	O
,	O
pulmonary	O
wedge	O
pressure	O
(	O
PWP	O
)	O
,	O
RAP	O
,	O
and	O
IPP	O
were	O
measured	O
along	O
with	O
indexes	O
of	O
systolic	O
function	O
.	O

The	O
Drosophila	O
clathrin	B-protein
heavy	I-protein
chain	I-protein
gene	O
:	O
clathrin	B-protein
function	O
is	O
essential	O
in	O
a	O
multicellular	O
organism	O
.	O

Experimental	O
studies	O
on	O
virus	O
excretion	O
and	O
non	O
-	O
arthropod	O
transmission	O
.	O

Fregnac	O
,	O
M	O
.	O

After	O
28	O
days	O
of	O
haloperidol	O
treatment	O
,	O
similar	O
changes	O
were	O
observed	O
for	O
delta	O
,	O
together	O
with	O
an	O
increase	O
of	O
alpha	O
1	O
,	O
and	O
a	O
decrease	O
of	O
fast	O
beta	O
.	O

Incidences	O
of	O
nonfatal	O
stroke	O
,	O
myocardial	O
infarction	O
,	O
angina	O
pectoris	O
und	O
left	O
ventricular	O
hypertrophy	O
could	O
also	O
be	O
lowered	O
.	O

Kidney	O
length	O
did	O
not	O
significantly	O
differ	O
between	O
right	O
and	O
left	O
,	O
however	O
,	O
kidney	O
width	O
,	O
cortical	O
thickness	O
and	O
size	O
did	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
late	O
MYO	O
/	O
M	O
is	O
more	O
useful	O
than	O
washout	O
rate	O
to	O
assess	O
the	O
effect	O
of	O
treatment	O
on	O
heart	O
failure	O
due	O
to	O
DCM	O
.	O

Cells	O
differentiate	O
in	O
response	O
to	O
various	O
extracellular	O
stimuli	O
.	O

The	O
pathogenesis	O
of	O
Limited	O
Joint	O
Mobility	O
(	O
LJM	O
)	O
in	O
diabetes	O
is	O
unknown	O
,	O
but	O
the	O
abnormality	O
is	O
said	O
to	O
be	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
microangiopathy	O
.	O

Radiolabeled	O
biantennary	O
N	O
-	O
glycans	O
synthesized	O
by	O
Pro	B-protein
(	I-protein
-	I-protein
)	I-protein
5Lec20	I-protein
were	O
proportionately	O
less	O
ricin	O
-	O
bound	O
than	O
similar	O
species	O
from	O
parental	O
CHO	O
cells	O
,	O
and	O
Lec20	O
cell	O
extracts	O
had	O
a	O
markedly	O
reduced	O
ability	O
to	O
transfer	O
Gal	O
to	O
GlcNAc	O
-	O
terminating	O
acceptors	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
the	O
cAMP	B-protein
-	I-protein
dependent	I-protein
kinases	I-protein
(	O
PKAs	B-protein
)	O
promote	O
cytoplasmic	O
growth	O
and	O
modulate	O
the	O
growth	O
-	O
regulated	O
mechanism	O
triggering	O
the	O
begin	O
of	O
DNA	O
synthesis	O
.	O

Kinetic	O
experiments	O
revealed	O
that	O
within	O
10	O
min	O
this	O
radiolabeled	O
precursor	O
protein	O
was	O
converted	O
in	O
HL	O
-	O
60	O
cells	O
into	O
an	O
Mr	O
approximately	O
150	O
,	O
000	O
chondroitin	O
sulfate	O
proteoglycan	O
intermediate	O
.	O

Heparin	O
had	O
no	O
effect	O
on	O
rAC	B-protein
-	I-protein
st	I-protein
myosin	I-protein
light	I-protein
chain	I-protein
phosphatase	I-protein
activity	O
,	O
while	O
the	O
B	O
subunit	O
-	O
containing	O
forms	O
were	O
stimulated	O
2	O
-	O
3	O
-	O
fold	O
.	O

Randomly	O
selected	O
300	O
children	O
aged	O
3	O
months	O
-	O
3	O
yr	O
were	O
analysed	O
over	O
a	O
period	O
of	O
one	O
year	O
for	O
estimating	O
prevalence	O
of	O
nutritional	O
anaemia	O
.	O

Studies	O
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
also	O
did	O
not	O
provide	O
evidence	O
for	O
the	O
formation	O
of	O
a	O
VDR	B-protein
-	I-protein
TR	I-protein
protein	O
-	O
protein	O
interaction	O
.	O

(	O
iii	O
)	O
In	O
these	O
cells	O
,	O
PKCbeta	B-protein
plays	O
a	O
unique	O
Ras	O
-	O
independent	O
role	O
in	O
mediating	O
insulin	B-protein
but	O
not	O
EGF	B-protein
or	O
other	O
growth	B-protein
factor	I-protein
mitogenic	O
signals	O
.	O

Chem	O
.	O

Adenylosuccinate	B-protein
synthetase	I-protein
(	O
IMP	O
:	O
L	B-protein
-	I-protein
aspartate	I-protein
ligase	I-protein
(	O
GDP	O
)	O
,	O
EC	O
6	O
.	O
3	O
.	O
4	O
.	O
4	O
)	O
plays	O
an	O
important	O
role	O
in	O
purine	O
biosynthesis	O
catalyzing	O
the	O
GTP	O
-	O
dependent	O
conversion	O
of	O
IMP	O
to	O
AMP	O
.	O

Glucocorticoid	O
induced	O
hypertension	O
has	O
been	O
regarded	O
as	O
independent	O
of	O
sodium	O
(	O
Na	O
)	O
,	O
in	O
contrast	O
to	O
mineralocorticoid	O
induced	O
hypertension	O
,	O
which	O
is	O
Na	O
+	O
-	O
dependent	O
.	O

Northern	O
blot	O
analysis	O
demonstrated	O
that	O
the	O
STORP	B-protein
gene	I-protein
has	O
a	O
ubiquitous	O
pattern	O
of	O
expression	O
similar	O
to	O
that	O
of	O
the	O
PML	B-protein
gene	I-protein
.	O

These	O
data	O
provide	O
strong	O
evidence	O
that	O
E2F	B-protein
or	O
an	O
E2F	B-protein
-	I-protein
related	I-protein
transcription	I-protein
factor	I-protein
is	O
involved	O
in	O
the	O
regulation	O
of	O
nonmuscle	B-protein
myosin	I-protein
expression	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
entry	O
into	O
mitosis	O
requires	O
activation	O
of	O
the	O
cyclin	B-protein
-	I-protein
dependent	I-protein
kinase	I-protein
Cdc28	I-protein
in	O
its	O
cyclin	B-protein
B	I-protein
(	O
Clb	B-protein
)	O
-	O
associated	O
form	O
.	O

Similar	O
data	O
were	O
also	O
obtained	O
when	O
either	O
dominant	B-protein
negative	I-protein
EGFR	I-protein
-	I-protein
CD533	I-protein
or	O
dominant	B-protein
negative	I-protein
Ras	I-protein
N17	I-protein
were	O
used	O
to	O
block	O
MAPK	B-protein
activation	O
.	O

By	O
far	O
-	O
Western	O
analysis	O
and	O
coimmunoprecipitation	O
studies	O
,	O
we	O
demonstrate	O
that	O
ZNF74	B-protein
interacts	O
,	O
via	O
its	O
zinc	O
finger	O
domain	O
,	O
with	O
the	O
hyperphosphorylated	O
largest	O
subunit	O
of	O
RNA	B-protein
polymerase	I-protein
II	I-protein
(	O
pol	B-protein
IIo	I-protein
)	O
but	O
not	O
with	O
the	O
hypophosphorylated	O
form	O
.	O

The	O
examination	O
must	O
include	O
T1	O
and	O
T2	O
sequences	O
and	O
scans	O
in	O
three	O
planes	O
.	O

Genetic	O
and	O
biochemical	O
evidence	O
suggests	O
that	O
v	B-protein
-	I-protein
Crk	I-protein
can	O
induce	O
transformation	O
of	O
chicken	O
embryo	O
fibroblasts	O
by	O
influencing	O
the	O
activity	O
of	O
cellular	O
proteins	O
involved	O
in	O
growth	O
regulation	O
.	O

Heating	O
cells	O
to	O
43	O
degrees	O
C	O
decreased	O
the	O
amount	O
of	O
newly	O
synthesized	O
rRNA	B-protein
to	O
less	O
than	O
5	O
%	O
of	O
the	O
control	O
level	O
and	O
led	O
to	O
greater	O
than	O
95	O
%	O
inhibition	O
of	O
transcription	O
termination	O
at	O
a	O
region	O
355	O
to	O
362	O
nucleotides	O
downstream	O
of	O
the	O
3	O
'	O
end	O
of	O
28S	B-protein
rRNA	I-protein
,	O
with	O
readthrough	O
continuing	O
into	O
the	O
next	O
transcription	O
unit	O
.	O

Antibodies	O
affinity	O
-	O
purified	O
using	O
the	O
bacterially	O
expressed	O
recombinant	O
protein	O
recognized	O
the	O
56K	B-protein
autoantigen	I-protein
in	O
a	O
HeLa	O
cell	O
extract	O
.	O
cDNA	O
sequencing	O
revealed	O
that	O
the	O
56K	B-protein
cDNA	I-protein
shares	O
a	O
high	O
degree	O
of	O
homology	O
in	O
both	O
nucleotide	O
(	O
87	O
%	O
)	O
and	O
amino	O
acid	O
sequence	O
(	O
92	O
.	O
5	O
%	O
)	O
with	O
bovine	B-protein
annexin	I-protein
XI	I-protein
,	O
indicating	O
that	O
the	O
56K	B-protein
cDNA	I-protein
encodes	O
the	O
human	B-protein
homologue	I-protein
of	I-protein
annexin	I-protein
XI	I-protein
,	O
a	O
member	O
of	O
the	O
Ca	B-protein
(	I-protein
2	I-protein
+	I-protein
)	I-protein
-	I-protein
dependent	I-protein
phospholipid	I-protein
binding	I-protein
protein	I-protein
family	I-protein
.	O

Protein	B-protein
cHMGI	I-protein
binds	O
preferentially	O
to	O
AT	O
-	O
rich	O
DNA	O
with	O
a	O
half	O
-	O
saturation	O
value	O
of	O
1	O
.	O
1	O
nM	O
.	O

Total	O
VO2	O
was	O
decreased	O
in	O
both	O
groups	O
during	O
severe	O
hypoxia	O
but	O
limb	O
VO2	O
was	O
maintained	O
in	O
the	O
beta	O
-	O
block	O
group	O
.	O
beta	O
-	O
Block	O
prevented	O
the	O
fall	O
in	O
total	O
and	O
limb	O
peripheral	O
resistance	O
seen	O
in	O
severe	O
hypoxia	O
but	O
did	O
not	O
alter	O
the	O
consistently	O
more	O
efficient	O
utilization	O
of	O
total	O
O2	O
delivery	O
shown	O
by	O
the	O
limb	O
in	O
comparison	O
to	O
the	O
whole	O
body	O
by	O
higher	O
O2	O
extraction	O
ratios	O
and	O
lower	O
venous	O
O2	O
pressure	O
.	O
beta	B-protein
-	I-protein
Vasodilator	I-protein
receptors	I-protein
evidently	O
played	O
an	O
active	O
part	O
in	O
the	O
vasodilatation	O
seen	O
during	O
severe	O
hypoxia	O
.	O

SPECT	O
examination	O
of	O
the	O
TMJ	O
using	O
99m	O
Tc	O
-	O
MDP	O
was	O
performed	O
in	O
43	O
patients	O
with	O
arthrographically	O
proven	O
anterior	O
dislocation	O
of	O
the	O
disc	O
and	O
in	O
30	O
normals	O
.	O

The	O
size	O
of	O
the	O
group	O
allocated	O
to	O
the	O
good	O
compliance	O
category	O
by	O
the	O
use	O
of	O
the	O
digoxin	O
marker	O
was	O
equivalent	O
in	O
size	O
to	O
a	O
group	O
of	O
patients	O
who	O
had	O
returned	O
less	O
than	O
15	O
%	O
of	O
their	O
prescribed	O
dose	O
or	O
reported	O
a	O
deviation	O
of	O
less	O
than	O
6	O
%	O
from	O
their	O
prescription	O
.	O

In	O
the	O
mouse	O
,	O
CtBP1	B-protein
is	O
expressed	O
from	O
embryo	O
to	O
adult	O
,	O
but	O
CtBP2	B-protein
is	O
mainly	O
expressed	O
during	O
embryogenesis	O
.	O

Intracranial	O
arachnoid	O
cyst	O
of	O
the	O
middle	O
fossa	O
demonstrated	O
by	O
positive	O
99mTc	O
brainscintigraphy	O
.	O

Rat	B-protein
liver	I-protein
catalase	I-protein
is	O
sorted	O
to	O
peroxisomes	O
by	O
its	O
C	O
-	O
terminal	O
tripeptide	O
Ala	B-protein
-	I-protein
Asn	I-protein
-	I-protein
Leu	I-protein
,	O
not	O
by	O
the	O
internal	B-protein
Ser	I-protein
-	I-protein
Lys	I-protein
-	I-protein
Leu	I-protein
motif	I-protein
.	O

The	O
encoded	O
amino	O
acid	O
sequences	O
in	O
the	O
full	O
-	O
length	O
bovine	O
and	O
porcine	O
cDNAs	O
were	O
identical	O
,	O
consisting	O
of	O
209	O
amino	O
acid	O
residues	O
,	O
and	O
were	O
nearly	O
the	O
same	O
as	O
the	O
published	O
sequence	O
determined	O
by	O
Edman	O
degradation	O
.	O

The	O
4	O
days	O
dexamethasone	O
suppression	O
test	O
showed	O
more	O
than	O
80	O
%	O
suppression	O
of	O
dehydroepiandrosterone	O
-	O
sulphate	O
and	O
a	O
variable	O
(	O
40	O
-	O
60	O
%	O
)	O
reduction	O
of	O
testosterone	O
and	O
androstenedione	O
levels	O
.	O

Dd	B-protein
PK1	I-protein
RNA	I-protein
decreases	O
after	O
6	O
h	O
of	O
starvation	O
to	O
re	O
-	O
accumulate	O
once	O
the	O
cells	O
have	O
aggregated	O
.	O

She	O
also	O
had	O
slight	O
weakness	O
of	O
the	O
upper	O
extremities	O
.	O

In	O
some	O
cases	O
,	O
the	O
aberrant	O
methylation	O
of	O
CpGs	O
within	O
5	O
'	O
regulatory	O
regions	O
has	O
led	O
to	O
suppression	O
of	O
gene	O
activity	O
.	O

The	O
second	O
transcript	O
,	O
rhis4l	B-protein
,	O
is	O
bicistronic	O
.	O

Current	O
status	O
and	O
future	O
perspectives	O
.	O

In	O
support	O
of	O
this	O
interpretation	O
we	O
demonstrate	O
that	O
MQ9b	B-protein
binds	O
strongly	O
5	O
of	O
17	O
motif	O
-	O
positive	O
,	O
pathogen	O
-	O
derived	O
synthetic	O
peptides	O
.	O

Irradiation	O
of	O
human	O
blood	O
platelets	O
with	O
UV	O
-	O
A	O
in	O
vitro	O
impairs	O
their	O
ability	O
to	O
aggregate	O
after	O
challenge	O
with	O
collagen	B-protein
.	O

Exploration	O
on	O
the	O
effects	O
of	O
activating	O
blood	O
circulation	O
to	O
remove	O
blood	O
stasis	O
on	O
barrier	O
action	O
of	O
gastric	O
wall	O
in	O
chronic	O
atrophic	O
gastritis	O

Diagnosis	O
of	O
FHCS	O
has	O
been	O
weighed	O
upon	O
laparoscopic	O
findings	O
.	O

Because	O
all	O
PDGFbetaR	B-protein
fusions	I-protein
described	O
thus	O
far	O
result	O
in	O
splicing	O
to	O
a	O
common	O
exon	O
of	O
this	O
gene	O
,	O
we	O
performed	O
5	O
'	O
-	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
PCR	O
on	O
patient	O
RNA	O
.	O

To	O
determine	O
whether	O
mononuclear	O
cell	O
secretory	O
products	O
contribute	O
to	O
the	O
changes	O
in	O
bone	O
turnover	O
that	O
characterize	O
the	O
development	O
of	O
postmenopausal	O
osteoporosis	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
oophorectomy	O
and	O
subsequent	O
estrogen	O
replacement	O
on	O
the	O
spontaneous	O
secretion	O
of	O
interleukin	B-protein
1	I-protein
(	O
IL	B-protein
-	I-protein
1	I-protein
)	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
-	I-protein
alpha	I-protein
)	O
and	O
on	O
the	O
phytohemagglutinin	O
A	O
-	O
induced	O
secretion	O
of	O
granulocyte	B-protein
-	I-protein
macrophage	I-protein
colony	I-protein
-	I-protein
stimulating	I-protein
factor	I-protein
(	O
GM	B-protein
-	I-protein
CSF	I-protein
)	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

METHODS	O
:	O
A	O
structured	O
interview	O
was	O
undertaken	O
at	O
the	O
time	O
of	O
initial	O
consultation	O
and	O
at	O
subsequent	O
1	O
-	O
year	O
intervals	O
regarding	O
type	O
of	O
BHS	O
,	O
frequency	O
of	O
spells	O
,	O
associated	O
phenomenon	O
,	O
sequelae	O
,	O
family	O
history	O
,	O
and	O
age	O
at	O
termination	O
of	O
spells	O
.	O

Selective	O
macrophage	O
inhibition	O
abolishes	O
warfarin	O
-	O
induced	O
reduction	O
of	O
metastasis	O
.	O

The	O
human	O
cDNA	O
was	O
used	O
to	O
demonstrate	O
that	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
-	I-protein
alpha	I-protein
could	O
rapidly	O
stimulate	O
MARCKS	B-protein
gene	I-protein
transcription	O
in	O
the	O
human	O
promyelocytic	O
leukemia	O
cell	O
line	O
HL60	O
.	O

The	O
predicted	O
receptor	O
structure	O
includes	O
a	O
cysteine	O
-	O
rich	O
extracellular	O
domain	O
,	O
a	O
single	O
hydrophobic	O
transmembrane	O
domain	O
,	O
and	O
a	O
predicted	O
cytoplasmic	B-protein
serine	I-protein
/	I-protein
threonine	I-protein
kinase	I-protein
domain	I-protein
.	O

DESIGN	O
:	O
A	O
retrospective	O
chart	O
review	O
of	O
9	O
,	O
322	O
patients	O
undergoing	O
surgical	O
procedures	O
in	O
the	O
period	O
January	O
1993	O
to	O
December	O
1998	O
.	O

Genetic	O
and	O
molecular	O
complexity	O
of	O
the	O
position	O
effect	O
variegation	O
modifier	O
mod	B-protein
(	I-protein
mdg4	I-protein
)	I-protein
in	O
Drosophila	O
.	O
mod	B-protein
(	I-protein
mdg4	I-protein
)	I-protein
,	O
also	O
known	O
as	O
E	B-protein
(	I-protein
var	I-protein
)	I-protein
3	I-protein
-	I-protein
93D	I-protein
,	O
is	O
involved	O
in	O
a	O
variety	O
of	O
processes	O
,	O
such	O
as	O
gene	O
silencing	O
in	O
position	O
effect	O
variegation	O
(	O
PEV	O
)	O
,	O
the	O
control	O
of	O
gypsy	B-protein
insulator	I-protein
sequences	I-protein
,	O
regulation	O
of	O
homeotic	B-protein
gene	I-protein
expression	O
,	O
and	O
programmed	O
cell	O
death	O
.	O

Studies	O
of	O
lipoproteins	O
should	O
,	O
however	O
,	O
be	O
made	O
in	O
children	O
from	O
families	O
known	O
to	O
have	O
FH	O
or	O
early	O
coronary	O
heart	O
disease	O
.	O

Eight	O
of	O
the	O
non	O
-	O
acceptable	O
inlays	O
/	O
onlays	O
and	O
five	O
of	O
the	O
direct	O
restorations	O
were	O
replaced	O
,	O
while	O
the	O
other	O
ones	O
were	O
repaired	O
with	O
resin	O
composite	O
.	O

Before	O
this	O
date	O
,	O
the	O
drug	O
directly	O
inhibits	O
fetal	O
weight	O
gain	O
,	O
whereas	O
the	O
sensitivity	O
of	O
the	O
placenta	O
is	O
only	O
transient	O
at	O
day	O
16	O
resulting	O
in	O
maximum	O
weight	O
decrease	O
of	O
this	O
organ	O
24	O
h	O
later	O
.	O

When	O
cotransfected	O
in	O
fibroblasts	O
with	O
a	O
C	B-protein
/	I-protein
EBP	I-protein
alpha	I-protein
expression	O
vector	O
,	O
reporter	O
gene	O
expression	O
increased	O
3	O
-	O
fold	O
only	O
in	O
the	O
wild	O
-	O
type	O
constructs	O
.	O

This	O
utilization	O
of	O
an	O
intronic	O
polyadenylation	O
site	O
without	O
alternative	O
exon	O
usage	O
is	O
comparable	O
to	O
the	O
mechanism	O
whereby	O
both	O
secreted	O
and	O
membrane	O
-	O
bound	O
forms	O
of	O
the	O
immunoglobulin	B-protein
mu	I-protein
heavy	I-protein
chain	I-protein
are	O
made	O
from	O
a	O
single	O
genetic	O
locus	O
.	O

Also	O
discussed	O
is	O
the	O
possibility	O
of	O
a	O
combined	O
genetic	O
and	O
environmental	O
etiology	O
.	O

In	O
these	O
constructs	O
,	O
GUS	B-protein
expression	O
was	O
driven	O
by	O
promoter	O
regions	O
derived	O
from	O
the	O
Arabidopsis	B-protein
alcohol	I-protein
dehydrogenase	I-protein
(	O
Adh1	B-protein
)	O
,	O
maize	B-protein
ubiquitin	I-protein
(	O
Ubi1	B-protein
)	O
,	O
rice	B-protein
actin	I-protein
(	O
Act1	B-protein
)	O
and	O
CaMV	B-protein
35S	I-protein
genes	I-protein
.	O

The	O
films	O
were	O
analyzed	O
using	O
a	O
scanning	O
helium	O
-	O
neon	O
laser	O
densitometer	O
with	O
a	O
small	O
aperture	O
of	O
5	O
-	O
10	O
microns	O
.	O

While	O
no	O
obvious	O
transmembrane	O
regions	O
were	O
identified	O
,	O
several	O
short	O
hydrophobic	O
amino	O
acid	O
stretches	O
were	O
found	O
to	O
be	O
localized	O
in	O
and	O
around	O
the	O
Pro	B-protein
II	I-protein
region	I-protein
,	O
and	O
these	O
may	O
be	O
responsible	O
for	O
attachment	O
of	O
precursors	O
to	O
membranes	O
.	O

U73	B-protein
contains	O
C	O
,	O
D	O
and	O
D	O
'	O
boxes	O
and	O
a	O
12	O
-	O
nucleotide	O
antisense	O
complementarity	O
to	O
the	O
28S	B-protein
ribosomal	I-protein
RNA	I-protein
.	O

This	O
paper	O
gives	O
an	O
overview	O
of	O
the	O
global	O
pattern	O
of	O
casualties	O
in	O
earthquakes	O
which	O
occurred	O
during	O
the	O
30	O
-	O
month	O
period	O
from	O
1	O
September	O
1993	O
to	O
29	O
February	O
1996	O
.	O

By	O
contrast	O
,	O
deletion	O
of	O
this	O
Ras	B-protein
-	I-protein
binding	I-protein
site	I-protein
did	O
not	O
diminish	O
activation	O
of	O
Raf	B-protein
-	I-protein
1	I-protein
kinase	I-protein
by	O
Src	B-protein
,	O
implying	O
that	O
Src	B-protein
and	O
Ras	B-protein
can	O
activate	O
Raf	B-protein
-	I-protein
1	I-protein
through	O
independent	O
mechanisms	O
.	O

The	O
clinical	O
picture	O
and	O
laboratory	O
parameters	O
were	O
consistent	O
with	O
a	O
serum	O
sickness	O
reaction	O
.	O

Expression	O
of	O
the	O
wt1	B-protein
gene	I-protein
via	O
transient	O
transfection	O
in	O
COS	O
-	O
1	O
cells	O
revealed	O
a	O
52	O
kDa	O
protein	O
which	O
was	O
immunoprecipitated	O
by	O
both	O
the	O
N	O
-	O
terminal	O
-	O
and	O
C	O
-	O
terminal	O
-	O
specific	O
antisera	O
.	O

Cotransfection	O
of	O
either	O
construct	O
with	O
plasmids	O
encoding	O
PKI	B-protein
(	I-protein
1	I-protein
-	I-protein
31	I-protein
)	I-protein
inhibits	O
cAMP	O
-	O
stimulated	O
but	O
not	O
basal	O
-	O
or	O
phorbol	O
ester	O
-	O
stimulated	O
expression	O
.	O

Sequence	O
analysis	O
showed	O
that	O
the	O
5	O
'	O
-	O
flanking	O
region	O
upstream	O
to	O
the	O
ATG	O
codon	O
did	O
not	O
contain	O
a	O
conventional	O
TATA	O
box	O
.	O

Tensile	O
bond	O
strengths	O
between	O
resin	O
composite	O
and	O
bovine	B-protein
dentin	I-protein
using	O
dentin	B-protein
adhesive	O
systems	O
(	O
Clearfil	O
Liner	O
Bond	O
II	O
:	O
LB	O
II	O
;	O
Scotchbond	O
Multi	O
-	O
Purpose	O
:	O
MP	O
)	O
bonding	O
systems	O
showed	O
a	O
large	O
scatter	O
among	O
students	O
and	O
dentists	O
.	O

At	O
the	O
end	O
of	O
each	O
day	O
of	O
migration	O
the	O
pulmonary	O
hemolymph	O
PO2	O
decreased	O
by	O
1	O
-	O
2	O
.	O
5	O
kPa	O
,	O
but	O
the	O
hemocyanin	O
remained	O
saturated	O
with	O
O2	O
and	O
the	O
venous	O
reserve	O
was	O
largely	O
unchanged	O
(	O
O2	O
>	O
0	O
.	O
4	O
mmol	O
x	O
l	O
(	O
-	O
1	O
)	O
)	O
.	O

Prominent	O
protein	B-protein
kinase	I-protein
cascades	I-protein
are	O
those	O
that	O
activate	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinases	I-protein
.	O

A	O
constitutive	O
mutant	O
form	O
with	O
a	O
single	O
substitution	O
(	O
V88A	O
)	O
in	O
the	O
amino	O
-	O
terminal	O
(	O
response	O
regulator	O
)	O
region	O
was	O
used	O
.	O

Substitution	O
of	O
a	O
threonine	O
residue	O
by	O
an	O
alanine	O
residue	O
at	O
position	O
-	O
2	O
(	O
P2	O
)	O
of	O
this	O
cleavage	O
site	O
abolished	O
cleavage	O
,	O
whereas	O
substitution	O
of	O
a	O
tyrosine	O
residue	O
by	O
a	O
phenylalanine	O
residue	O
at	O
amino	O
acid	O
position	O
-	O
1	O
(	O
P1	O
)	O
of	O
the	O
cleavage	O
site	O
did	O
not	O
influence	O
processing	O
.	O

In	O
the	O
SPP2	O
screening	O
test	O
,	O
a	O
few	O
plates	O
were	O
not	O
seen	O
in	O
both	O
groups	O
.	O

Hydrocortisone	O
caused	O
lymphopenia	O
and	O
inhibited	O
the	O
blastogenic	O
response	O
of	O
peripheral	O
blood	O
lymphocytes	O
to	O
phytohemagglutinin	B-protein
and	O
concanavalin	B-protein
A	I-protein
mitogens	O
.	O

A	O
deletion	O
series	O
of	O
the	O
5	O
'	O
flanking	O
region	O
was	O
created	O
from	O
position	O
-	O
1329	O
to	O
-	O
74	O
relative	O
to	O
the	O
transcriptional	O
initiation	O
site	O
and	O
similarly	O
examined	O
in	O
transgenic	O
tobacco	O
.	O

A	O
subset	O
of	O
these	O
DMP1	B-protein
recognition	I-protein
sequences	I-protein
containing	O
a	O
GGA	O
trinucleotide	O
core	O
can	O
also	O
function	O
as	O
Ets	B-protein
-	I-protein
responsive	I-protein
elements	I-protein
.	O

The	O
promoter	O
activity	O
of	O
the	O
gene	B-protein
encoding	I-protein
Alzheimer	I-protein
beta	I-protein
-	I-protein
amyloid	I-protein
precursor	I-protein
protein	I-protein
(	O
APP	B-protein
)	O
is	O
regulated	O
by	O
two	O
blocks	O
of	O
upstream	O
sequences	O
.	O

High	O
-	O
affinity	O
site	O
-	O
specific	O
DNA	O
binding	O
by	O
POU	B-protein
domain	I-protein
transcription	O
factors	O
requires	O
both	O
the	O
POU	O
-	O
specific	O
and	O
the	O
POU	B-protein
-	I-protein
homeodomain	I-protein
.	O

These	O
utilisation	O
data	O
imply	O
annual	O
drug	O
costs	O
in	O
the	O
range	O
of	O
$	O
US	O
480	O
,	O
000	O
to	O
$	O
US	O
3	O
,	O
600	O
,	O
000	O
for	O
TNF	B-protein
antagonists	O
for	O
RA	O
per	O
1	O
million	O
population	O
.	O

Prognosis	O
in	O
Bowen	O
'	O
s	O
disease	O
localized	O
to	O
the	O
ano	O
-	O
genital	O
region	O
.	O

Hepatitis	O
B	O
vaccination	O
strategy	O
for	O
health	O
-	O
care	O
workers	O
in	O
a	O
country	O
of	O
intermediate	O
hepatitis	O
B	O
endemicity	O
.	O

So	O
far	O
no	O
problems	O
with	O
multiply	O
resistant	O
strains	O
have	O
developed	O
.	O

These	O
observed	O
drug	O
interactions	O
,	O
plus	O
the	O
known	O
effect	O
of	O
probenecid	O
to	O
block	O
secretion	O
of	O
PZA	O
,	O
have	O
to	O
be	O
considered	O
in	O
evaluating	O
the	O
effect	O
of	O
the	O
two	O
drugs	O
given	O
together	O
,	O
compared	O
to	O
the	O
effect	O
of	O
each	O
drug	O
given	O
separately	O
.	O

A	O
385	B-protein
bp	I-protein
Glucocorticoid	I-protein
Response	I-protein
Unit	I-protein
(	O
GRU	B-protein
)	O
was	O
identified	O
whose	O
glucocorticoid	O
induction	O
was	O
enhanced	O
by	O
dibutyryl	O
-	O
cAMP	O
and	O
reduced	O
by	O
phorbol	O
esters	O
.	O

In	O
the	O
absence	O
of	O
Mg2	O
+	O
,	O
a	O
hydrophobic	O
exonuclease	B-protein
site	I-protein
dominates	O
over	O
the	O
polymerase	B-protein
site	I-protein
for	O
possession	O
of	O
the	O
primer	O
terminus	O
.	O

Both	O
carbachol	O
(	O
100	O
microM	O
)	O
and	O
EGF	B-protein
(	O
10	O
nM	O
)	O
induced	O
Ras	B-protein
activation	O
.	O

Statistics	O
for	O
nurse	O
managers	O
-	O
-	O
3	O
.	O

These	O
results	O
suggest	O
that	O
low	O
concentrations	O
of	O
IL	B-protein
-	I-protein
1	I-protein
beta	I-protein
may	O
be	O
useful	O
for	O
nonsurgical	O
treatment	O
of	O
human	O
vitreous	O
hemorrhage	O
.	O

T	O
cell	O
leukemia	O
-	O
associated	O
human	O
Notch	O
/	O
translocation	O
-	O
associated	O
Notch	B-protein
homologue	I-protein
has	O
I	O
kappa	O
B	O
-	O
like	O
activity	O
and	O
physically	O
interacts	O
with	O
nuclear	B-protein
factor	I-protein
-	I-protein
kappa	I-protein
B	I-protein
proteins	I-protein
in	O
T	O
cells	O
.	O

A	O
stratified	O
random	O
sample	O
of	O
20	O
active	O
employees	O
from	O
a	O
cohort	O
of	O
phenoxy	O
herbicide	O
workers	O
was	O
selected	O
in	O
1995	O
for	O
determining	O
PCDD	O
and	O
PCDF	O
congeners	O
in	O
blood	O
lipids	O
to	O
assess	O
the	O
extent	O
of	O
past	O
PCDD	O
and	O
PCDF	O
exposure	O
in	O
this	O
cohort	O
and	O
whether	O
that	O
exposure	O
might	O
explain	O
site	O
-	O
specific	O
cancer	O
findings	O
in	O
the	O
total	O
cohort	O
.	O

A	O
point	O
mutation	O
in	O
Galphao	B-protein
and	O
Galphai1	B-protein
blocks	O
interaction	O
with	O
regulator	O
of	O
G	B-protein
protein	I-protein
signaling	O
proteins	O
.	O

Linear	O
regression	O
analysis	O
was	O
performed	O
and	O
the	O
following	O
result	O
was	O
obtained	O
:	O
clearance	O
(	O
HMPAO	O
)	O
=	O
0	O
.	O
07	O
+	O
0	O
.	O
43	O
.	O
rCBF	O
with	O
a	O
high	O
significance	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Conformational	O
changes	O
of	O
the	O
ferric	O
uptake	O
regulation	O
protein	O
upon	O
metal	O
activation	O
and	O
DNA	O
binding	O
;	O
first	O
evidence	O
of	O
structural	O
homologies	O
with	O
the	O
diphtheria	B-protein
toxin	I-protein
repressor	I-protein
.	O

The	O
genome	O
organization	O
of	O
the	O
mite	O
-	O
transmitted	O
wheat	O
streak	O
mosaic	O
virus	O
(	O
WSMV	O
)	O
appears	O
to	O
parallel	O
that	O
of	O
members	O
of	O
the	O
Potyviridae	O
with	O
monopartite	O
genomes	O
,	O
but	O
there	O
are	O
substantial	O
amino	O
acid	O
dissimilarities	O
with	O
other	O
potyviral	O
polyproteins	O
.	O

Acupuncture	O
effect	O
on	O
deep	O
receptors	O
was	O
not	O
limited	O
to	O
one	O
point	O
but	O
within	O
a	O
certain	O
area	O
,	O
namely	O
distant	O
effect	O
existed	O
.	O

Cbl	B-protein
constitutively	O
interacts	O
with	O
the	O
SH3	B-protein
domains	I-protein
of	O
Grb2	B-protein
,	O
with	O
a	O
preference	O
for	O
the	O
amino	O
-	O
terminal	O
domain	O
,	O
and	O
is	O
in	O
this	O
way	O
recruited	O
to	O
Shc	B-protein
upon	O
BCR	B-protein
stimulation	O
.	O

The	O
frequency	O
of	O
previous	O
transfusion	O
in	O
chronic	O
hepatitis	O
,	O
cirrhosis	O
and	O
hepatocellular	O
carcinoma	O
of	O
type	O
NANB	O
was	O
42	O
.	O
8	O
,	O
37	O
.	O
1	O
and	O
15	O
.	O
1	O
%	O
,	O
respectively	O
,	O
whereas	O
the	O
incidence	O
of	O
early	O
posttransfusion	O
hepatitis	O
was	O
8	O
.	O
5	O
,	O
8	O
.	O
6	O
and	O
7	O
.	O
5	O
%	O
,	O
respectively	O
.	O
in	O
chronic	O
liver	O
diseases	O
with	O
a	O
history	O
of	O
jaundice	O
and	O
/	O
or	O
hepatitis	O
,	O
previous	O
transfusions	O
are	O
more	O
frequently	O
associated	O
with	O
type	O
NANB	O
than	O
with	O
type	O
B	O
disease	O
.	O

Distribution	O
and	O
changing	O
morphological	O
course	O
.	O

Bacteriol	O
.	O

By	O
creating	O
Pax	B-protein
-	I-protein
6	I-protein
-	I-protein
BSAP	I-protein
fusion	I-protein
proteins	I-protein
,	O
we	O
were	O
able	O
to	O
identify	O
a	O
short	O
amino	O
acid	O
stretch	O
in	O
the	O
N	O
-	O
terminal	O
part	O
of	O
the	O
paired	O
domain	O
which	O
is	O
responsible	O
for	O
these	O
differences	O
in	O
DNA	O
-	O
binding	O
specificity	O
.	O

Significance	O
of	O
delta	O
-	O
aminolevulinic	O
acid	O
analysis	O
in	O
clinical	O
tests	O
.	O

Following	O
iv	O
injection	O
of	O
0	O
.	O
5	O
g	O
galactose	O
per	O
kg	O
body	O
weight	O
,	O
together	O
with	O
2	O
mu	O
Ci	O
generally	O
14C	O
-	O
labelled	O
galactose	O
,	O
14CO2	O
is	O
collected	O
in	O
regular	O
intervals	O
during	O
one	O
hour	O
.	O

A	O
clinically	O
useful	O
diagnostic	O
method	O
has	O
been	O
developed	O
for	O
detecting	O
and	O
quantitating	O
periods	O
of	O
apnea	O
in	O
pediatric	O
patients	O
.	O

A	O
value	O
of	O
1	O
.	O
1	O
l	O
/	O
kg	O
was	O
used	O
for	O
V	O
in	O
calculating	O
all	O
single	O
sample	O
estimates	O
of	O
clearance	O
(	O
CL	O
)	O
,	O
and	O
a	O
value	O
of	O
4	O
.	O
3	O
l	O
/	O
kg	O
was	O
used	O
to	O
calculate	O
single	O
sample	O
estimates	O
of	O
clearance	O
of	O
plasma	O
unbound	O
drug	O
(	O
CLunb	O
)	O
.	O

The	O
rhaB	B-protein
transcription	I-protein
start	I-protein
site	I-protein
was	O
mapped	O
to	O
-	O
24	O
relative	O
to	O
the	O
start	O
of	O
translation	O
.	O

Despite	O
the	O
activation	O
of	O
these	O
intracellular	O
signaling	O
molecules	O
,	O
PDGF	B-protein
beta	I-protein
receptor	I-protein
activation	O
elicited	O
no	O
detectable	O
effect	O
on	O
cell	O
proliferation	O
or	O
differentiation	O
.	O

A	O
fusion	O
protein	O
composed	O
of	O
beta	B-protein
-	I-protein
galactosidase	I-protein
and	O
full	B-protein
-	I-protein
length	I-protein
Ahr	I-protein
translocates	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
.	O

In	O
strains	O
lacking	O
tup11	B-protein
and	O
tup12	B-protein
,	O
the	O
atf1	B-protein
-	I-protein
pcr1	I-protein
transcriptional	I-protein
activator	I-protein
continues	O
to	O
play	O
a	O
central	O
role	O
in	O
fbp1	B-protein
-	I-protein
lacZ	I-protein
expression	O
;	O
however	O
,	O
spc1	B-protein
MAPK	I-protein
phosphorylation	O
of	O
atf1	B-protein
is	O
no	O
longer	O
essential	O
for	O
its	O
activation	O
.	O

A	O
5	B-protein
.	I-protein
8S	I-protein
-	I-protein
like	I-protein
structure	I-protein
is	O
present	O
within	O
the	O
5	O
'	O
-	O
terminal	O
region	O
of	O
all	O
three	O
fungal	B-protein
mitochondrial	I-protein
LSU	I-protein
rRNAs	I-protein
;	O
in	O
contrast	O
,	O
no	O
4	B-protein
.	I-protein
5S	I-protein
-	I-protein
like	I-protein
structure	I-protein
is	O
evident	O
at	O
the	O
3	O
'	O
end	O
of	O
these	O
molecules	O
.	O

Phenotypic	O
changes	O
induced	O
by	O
wild	B-protein
type	I-protein
and	I-protein
variant	I-protein
c	I-protein
-	I-protein
src	I-protein
genes	I-protein
carrying	O
C	O
-	O
terminal	O
sequence	O
alterations	O
.	O

These	O
results	O
suggest	O
that	O
members	O
of	O
the	O
ATF	B-protein
family	I-protein
are	O
involved	O
in	O
mediating	O
the	O
transcriptional	O
regulation	O
of	O
the	O
KGF	B-protein
gene	I-protein
in	O
response	O
to	O
extracellular	O
stimuli	O
via	O
a	O
novel	O
CRE	B-protein
regulatory	I-protein
element	I-protein
.	O

Unusual	O
two	B-protein
-	I-protein
domain	I-protein
arginine	I-protein
kinases	I-protein
(	O
AKs	B-protein
)	O
arose	O
independently	O
at	O
least	O
two	O
times	O
during	O
molecular	O
evolution	O
of	O
phosphagen	B-protein
kinases	I-protein
:	O
AKs	B-protein
from	O
the	O
primitive	O
sea	O
anemone	O
Anthopleurura	O
japonicus	O
and	O
from	O
the	O
clam	O
Pseudocardium	O
sachalinensis	O
.	O

Ca2	O
+	O
decreased	O
Zn2	O
+	O
binding	O
in	O
S100	B-protein
beta	I-protein
but	O
it	O
did	O
not	O
influence	O
binding	O
to	O
MRP14	B-protein
,	O
suggesting	O
that	O
the	O
Zn2	O
+	O
binding	O
site	O
was	O
distinct	O
from	O
and	O
independent	O
of	O
the	O
two	O
Ca2	O
+	O
binding	O
domains	O
.	O

However	O
,	O
rapamycin	O
inhibited	O
proliferation	O
of	O
Ba	O
/	O
F3	O
-	O
EpoRgp55	O
but	O
not	O
of	O
MEL	O
cells	O
despite	O
inhibition	O
of	O
p70	B-protein
S6	I-protein
kinase	I-protein
activity	O
in	O
both	O
cells	O
.	O

Further	O
,	O
the	O
PIP2	O
content	O
of	O
the	O
85	O
-	O
90	O
kDa	O
protein	O
appeared	O
to	O
decrease	O
with	O
CSF	B-protein
-	I-protein
1	I-protein
treatment	O
.	O

Experimental	O
ischemic	O
heart	O
disease	O
induced	O
by	O
thromboxane	B-protein
A2	I-protein
in	O
rabbits	O
.	O

The	O
discordant	O
behaviour	O
in	O
weakly	O
infected	O
mice	O
was	O
due	O
to	O
the	O
occurrence	O
in	O
some	O
animals	O
of	O
a	O
second	O
phase	O
of	O
more	O
rapid	O
increase	O
of	O
the	O
parasitemia	O
.	O

Behcet	O
'	O
s	O
syndrome	O
.	O

Serum	O
lipids	O
and	O
lipoproteins	O
of	O
29	O
insulin	B-protein
dependent	O
diabetic	O
children	O
have	O
been	O
determined	O
and	O
related	O
to	O
the	O
metabolic	O
status	O
of	O
the	O
patients	O
.	O

Since	O
general	B-protein
regulatory	I-protein
factor	I-protein
I	I-protein
(	O
GRFI	B-protein
)	O
/	B-protein
repressor	I-protein
/	I-protein
activator	I-protein
site	I-protein
binding	I-protein
protein	I-protein
1	I-protein
(	O
RAP1	B-protein
)	O
/	B-protein
translation	I-protein
upstream	I-protein
factor	I-protein
(	O
TUF	B-protein
)	O
is	O
believed	O
to	O
be	O
an	O
activator	O
of	O
MAT	B-protein
alpha	I-protein
expression	O
,	O
we	O
examined	O
whether	O
PYK1	B-protein
,	O
which	O
is	O
known	O
to	O
be	O
regulated	O
by	O
GRFI	B-protein
/	I-protein
RAP1	I-protein
/	I-protein
TUF	I-protein
,	O
is	O
also	O
affected	O
by	O
the	O
gal11	B-protein
mutation	I-protein
.	O

LHbeta	B-protein
is	O
expressed	O
in	O
pituitary	O
gonadotrope	O
cells	O
and	O
CGbeta	B-protein
is	O
expressed	O
in	O
placental	O
trophoblast	O
cells	O
.	O

Williams	O
,	O
2	O
August	O
1977	O
.	O

These	O
results	O
suggest	O
that	O
,	O
in	O
this	O
experimental	O
model	O
,	O
ACE	B-protein
inhibitors	O
limit	O
the	O
arrhythmias	O
following	O
ischemia	O
-	O
reperfusion	O
and	O
free	O
radical	O
scavenging	O
action	O
of	O
these	O
drugs	O
does	O
not	O
have	O
a	O
major	O
contributory	O
role	O
in	O
their	O
protective	O
effect	O
.	O

Skin	O
cancers	O
,	O
followed	O
by	O
gastrointestinal	O
tract	O
and	O
male	O
genital	O
system	O
affected	O
mostly	O
older	O
age	O
patients	O
.	O

CONCLUSIONS	O
:	O
EBCT	O
technology	O
allows	O
minimally	O
invasive	O
evaluation	O
of	O
intramyocardial	O
microcirculatory	O
function	O
and	O
permits	O
assessment	O
of	O
microvascular	O
BV	O
distribution	O
in	O
different	O
functional	O
components	O
.	O

(	O
2	O
)	O
The	O
inappropriateness	O
of	O
adaptive	O
segmentation	O
for	O
the	O
isolation	O
of	O
spikes	O
and	O
sharp	O
waves	O
,	O
which	O
had	O
been	O
anticipated	O
in	O
view	O
of	O
the	O
short	O
duration	O
of	O
such	O
transients	O
in	O
relation	O
to	O
the	O
length	O
of	O
the	O
window	O
(	O
1	O
.	O
2	O
sec	O
)	O
used	O
for	O
the	O
autocorrelation	O
functions	O
employed	O
in	O
the	O
segmentation	O
algorithm	O
,	O
was	O
confirmed	O
.	O

The	O
acids	O
were	O
obtained	O
by	O
hydrolysis	O
of	O
the	O
corresponding	O
esters	O
,	O
and	O
their	O
anti	O
-	O
inflammatory	O
activity	O
was	O
tested	O
.	O

All	O
six	O
genes	O
were	O
cloned	O
and	O
characterised	O
.	O

The	O
mean	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
was	O
31	O
.	O
8	O
+	O
/	O
-	O
6	O
.	O
3	O
kg	O
/	O
m2	O
and	O
28	O
.	O
5	O
+	O
/	O
-	O
6	O
.	O
3	O
kg	O
/	O
m2	O
in	O
women	O
and	O
men	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
In	O
women	O
who	O
want	O
or	O
require	O
conservative	O
management	O
of	O
grade	O
4	O
prolapse	O
and	O
are	O
unable	O
to	O
retain	O
a	O
single	O
pessary	O
,	O
the	O
placement	O
of	O
two	O
pessaries	O
often	O
will	O
be	O
successful	O
.	O

JCAHO	O
asks	O
for	O
hospitals	O
'	O
patience	O
.	O

This	O
interaction	O
is	O
reciprocal	O
,	O
since	O
C	B-protein
/	I-protein
EBP	I-protein
dimer	I-protein
binding	O
to	O
a	O
strong	O
C	B-protein
/	I-protein
EBP	I-protein
site	I-protein
leads	O
to	O
enhanced	O
CREB	B-protein
-	I-protein
1	I-protein
recruitment	O
to	O
ATF	B-protein
/	I-protein
CREB	I-protein
sites	I-protein
that	O
are	O
weakly	O
bound	O
by	O
CREB	B-protein
.	O

Mutations	O
in	O
the	O
alpha	B-protein
-	I-protein
amanitin	I-protein
conserved	O
domain	O
of	O
the	O
largest	O
subunit	O
of	O
yeast	B-protein
RNA	I-protein
polymerase	I-protein
III	I-protein
affect	O
pausing	O
,	O
RNA	O
cleavage	O
and	O
transcriptional	O
transitions	O
.	O

Since	O
very	O
recent	O
scanning	O
-	O
deletion	O
analysis	O
indicates	O
that	O
there	O
is	O
a	O
critical	O
region	O
for	O
activity	O
near	O
Cys	O
-	O
118	O
and	O
that	O
Cys	O
-	O
118	O
is	O
necessary	O
for	O
maximal	O
activity	O
,	O
we	O
conclude	O
that	O
the	O
Cys	O
-	O
118	O
residue	O
is	O
necessary	O
for	O
proper	O
glycosylation	O
and	O
maximal	O
biologic	O
activity	O
of	O
GM	B-protein
-	I-protein
CSF	I-protein
.	O

1972	O
.	O

The	O
findings	O
suggest	O
that	O
,	O
although	O
iodine	O
deficiency	O
is	O
the	O
most	O
probable	O
cause	O
of	O
goiter	O
among	O
immigrants	O
of	O
the	O
1928	O
cohort	O
,	O
where	O
the	O
native	O
population	O
is	O
concerned	O
(	O
both	O
men	O
and	O
women	O
)	O
,	O
some	O
other	O
goitrogenic	O
factor	O
(	O
s	O
)	O
must	O
be	O
involved	O
.	O

Fragments	O
and	O
analogs	O
of	O
the	O
hormone	O
ACTH	B-protein
were	O
previously	O
shown	O
to	O
have	O
beneficial	O
effect	O
on	O
the	O
outcome	O
of	O
head	O
injury	O
,	O
while	O
elevated	O
levels	O
of	O
corticosterone	O
(	O
CS	O
)	O
exacerbate	O
it	O
.	O

Cardiac	O
taurine	O
levels	O
and	O
sarcolemmal	O
calcium	O
binding	O
activity	O
in	O
furazolidone	O
-	O
induced	O
cardiomyopathy	O
.	O

This	O
is	O
concluded	O
from	O
the	O
isolation	O
of	O
cDNAs	O
from	O
spinach	O
(	O
Spinacia	O
oleracea	O
)	O
and	O
barley	O
(	O
Hordeum	O
vulgare	O
cv	O
.	O

Over	O
-	O
expression	O
of	O
Azf1p	B-protein
in	O
the	O
yeast	O
cell	O
does	O
not	O
influence	O
the	O
expression	O
level	O
of	O
the	O
mitochondrial	B-protein
transcription	I-protein
factor	I-protein
Mtf1p	I-protein
,	O
indicating	O
that	O
the	O
influence	O
of	O
Azf1p	B-protein
on	O
the	O
suppression	O
of	O
the	O
special	O
mitochondrial	B-protein
RNA	I-protein
polymerase	I-protein
mutant	I-protein
is	O
an	O
indirect	O
one	O
.	O

We	O
have	O
also	O
found	O
that	O
the	O
in	O
vitro	O
interaction	O
between	O
the	O
SV40	O
octamer	O
motif	O
and	O
the	O
lymphoid	B-protein
cell	I-protein
-	I-protein
specific	I-protein
protein	I-protein
oct	I-protein
-	I-protein
B2	I-protein
was	O
negatively	O
modulated	O
by	O
a	O
component	O
present	O
in	O
the	O
nuclear	O
extracts	O
from	O
several	O
lymphoid	O
cell	O
lines	O
.	O

The	O
appearance	O
of	O
dyskinetic	O
movement	O
disorders	O
in	O
humans	O
following	O
the	O
chronic	O
use	O
of	O
levodopa	O
or	O
amphetamine	O
may	O
be	O
a	O
manifestation	O
of	O
similarly	O
increased	O
dopamine	B-protein
receptor	I-protein
site	I-protein
sensitivity	O
within	O
the	O
striatum	O
.	O

The	O
obtained	O
results	O
were	O
compared	O
with	O
control	O
group	O
(	O
10	O
female	O
volunteers	O
)	O
.	O

DNA	B-protein
-	I-protein
STAT	I-protein
complexes	I-protein
were	O
detected	O
in	O
all	O
Bcr	O
/	O
Abl	O
-	O
transformed	O
cell	O
lines	O
and	O
they	O
were	O
supershifted	O
by	O
antibodies	O
against	O
STAT1	B-protein
and	O
STAT5	B-protein
.	O

Four	O
CsA	O
-	O
treated	O
patients	O
developed	O
persistently	O
elevated	O
UAER	O
>	O
30	O
mg	O
/	O
24	O
h	O
(	O
n	O
=	O
3	O
with	O
microalbuminuria	O
)	O
,	O
whereas	O
all	O
the	O
17	O
placebo	O
-	O
treated	O
patients	O
had	O
normal	O
UAER	O
(	O
<	O
30	O
mg	O
/	O
24	O
h	O
)	O
after	O
7	O
years	O
of	O
follow	O
-	O
up	O
.	O

This	O
brief	O
review	O
analyses	O
these	O
interactions	O
and	O
defines	O
clinical	O
settings	O
where	O
antibiotic	O
-	O
induced	O
endotoxin	B-protein
release	O
may	O
prove	O
to	O
be	O
clinically	O
relevant	O
.	O

These	O
studies	O
serve	O
as	O
the	O
basis	O
for	O
the	O
further	O
characterization	O
of	O
the	O
regulatory	O
mechanism	O
of	O
aromatase	B-protein
expression	O
in	O
human	O
breast	O
cancer	O
and	O
ASCs	O
.	O

However	O
,	O
a	O
similar	O
mutation	O
of	O
a	O
leucine	O
residue	O
to	O
arginine	O
at	O
position	O
422	O
showed	O
no	O
alteration	O
of	O
heterodimerization	O
,	O
DNA	O
binding	O
,	O
or	O
transcriptional	O
activation	O
.	O

Steal	O
is	O
a	O
pathophysiological	O
process	O
in	O
which	O
increased	O
blood	O
flow	O
through	O
a	O
low	O
-	O
resistance	O
vascular	O
bed	O
is	O
sufficient	O
to	O
divert	O
flow	O
away	O
from	O
a	O
region	O
of	O
the	O
central	O
nervous	O
system	O
.	O

Cross	O
-	O
reaction	O
between	O
a	O
monoclonal	O
antibody	O
and	O
two	O
alpha	B-protein
beta	I-protein
T	I-protein
cell	I-protein
receptors	I-protein
.	O

The	O
coordinate	O
increase	O
in	O
cyclin	B-protein
D1	I-protein
and	O
p21	B-protein
had	O
the	O
effect	O
of	O
decreasing	O
the	O
specific	O
but	O
not	O
absolute	O
activity	O
of	O
cyclin	B-protein
D1	I-protein
/	I-protein
cdk4	I-protein
.	O
p53	B-protein
was	O
not	O
involved	O
since	O
CSF	B-protein
-	I-protein
1	I-protein
induction	O
of	O
p21	B-protein
was	O
unaffected	O
by	O
dominant	B-protein
-	I-protein
negative	I-protein
p53	I-protein
expression	O
.	O

We	O
show	O
that	O
stabilization	O
of	O
the	O
hairpin	O
reduced	O
the	O
amount	O
of	O
tRNA	O
primer	O
that	O
is	O
annealed	O
to	O
the	O
PBS	O
.	O

Myocardial	O
antioxidant	O
enzymes	O
,	O
catalase	B-protein
,	O
glutathione	B-protein
peroxidase	I-protein
and	O
superoxide	B-protein
dismutase	I-protein
,	O
in	O
the	O
MCT	O
-	O
treated	O
rats	O
were	O
not	O
different	O
compared	O
to	O
control	O
rats	O
.	O

Dietetics	O
of	O
childhood	O
-	O
and	O
juvenile	O
diabetes	O
.	O

AP	O
was	O
induced	O
by	O
intraductal	O
infusion	O
of	O
two	O
different	O
concentrations	O
of	O
glycodeoxycholic	O
acid	O
(	O
GDOC	O
17	O
mmol	O
and	O
34	O
mmol	O
)	O
.	O

Penicillinase	B-protein
production	O
in	O
Staphylococcus	O
aureus	O
strains	O
of	O
clinical	O
importance	O
.	O

Our	O
data	O
show	O
also	O
that	O
phagocytic	O
killing	O
of	O
meningococci	O
is	O
probably	O
a	O
more	O
consistent	O
assay	O
than	O
antibody	O
titer	O
levels	O
for	O
antimeningococcal	O
immunity	O
,	O
especially	O
in	O
LCC	O
-	O
deficient	O
patients	O
.	O

Human	O
synovial	O
fluid	O
:	O
detection	O
of	O
a	O
new	O
component	O
.	O

Desmethylferrochloroquine	O
1a	O
and	O
didesmethylferrochloroquine	O
2	O
would	O
be	O
more	O
potent	O
against	O
schizontocides	O
than	O
CQ	O
in	O
vitro	O
against	O
two	O
strains	O
(	O
HB3	O
and	O
Dd2	O
)	O
of	O
Plasmodium	O
falciparum	O
.	O

Furthermore	O
,	O
this	O
study	O
looks	O
at	O
the	O
impact	O
of	O
synthesis	O
conditions	O
on	O
block	O
length	O
and	O
crystallinity	O
,	O
and	O
the	O
impact	O
of	O
the	O
blocking	O
on	O
both	O
,	O
crystallinity	O
and	O
solubility	O
of	O
the	O
polymers	O
.	O

10	O
long	O
-	O
term	O
hemodialysis	O
patients	O
had	O
immediate	O
and	O
redistribution	O
thallium	O
-	O
201	O
myocardial	O
imaging	O
performed	O
after	O
a	O
course	O
of	O
hemodialysis	O
.	O

However	O
,	O
L	B-protein
-	I-protein
plastin	I-protein
has	O
been	O
found	O
in	O
many	O
types	O
of	O
malignant	O
human	O
cells	O
of	O
non	O
-	O
hemopoietic	O
origin	O
suggesting	O
that	O
its	O
expression	O
is	O
induced	O
accompanying	O
tumorigenesis	O
in	O
solid	O
tissues	O
.	O

Neither	O
is	O
it	O
a	O
major	O
cause	O
of	O
rehydration	O
-	O
induced	O
renal	O
Na	O
retention	O
.	O

Gel	O
mobility	O
shift	O
and	O
super	O
-	O
shift	O
assays	O
using	O
liver	O
nuclear	O
extracts	O
from	O
either	O
rat	O
liver	O
or	O
DDT1MF	O
-	O
2	O
cells	O
demonstrated	O
that	O
the	O
CRE	B-protein
in	O
the	O
alpha	B-protein
1B	I-protein
-	I-protein
AR	I-protein
gene	I-protein
bound	O
CRE	B-protein
binding	I-protein
protein	I-protein
.	O

A	O
larger	O
region	O
upstream	O
of	O
human	B-protein
CMV	I-protein
dbp	I-protein
also	O
mediated	O
replication	O
in	O
transient	O
assays	O
.	O

There	O
is	O
no	O
TATA	O
box	O
appropriately	O
spaced	O
upstream	O
from	O
the	O
transcription	O
initiation	O
site	O
.	O

Using	O
this	O
method	O
,	O
we	O
were	O
able	O
to	O
select	O
strong	O
enhancer	O
-	O
type	O
activation	O
domains	O
from	O
the	O
immediate	B-protein
early	I-protein
regions	I-protein
of	O
two	O
herpesviruses	O
,	O
namely	O
pseudorabies	O
virus	O
and	O
bovine	O
herpesvirus	O
1	O
.	O

An	O
association	O
was	O
demonstrated	O
between	O
the	O
expression	O
of	O
aberrantly	O
and	O
/	O
or	O
alternatively	O
spliced	O
mdm2	B-protein
mRNAs	I-protein
and	O
a	O
lack	O
of	O
progesterone	B-protein
receptor	I-protein
.	O

Data	O
supported	O
the	O
brevity	O
of	O
the	O
WISC	O
-	O
III	O
short	O
form	O
and	O
the	O
criterion	O
-	O
related	O
validity	O
of	O
both	O
the	O
K	O
-	O
FAST	O
and	O
and	O
Kaufman	O
Short	O
Neuropsychological	O
Assessment	O
Procedure	O
(	O
K	O
-	O
SNAP	O
)	O
.	O

In	O
contrast	O
,	O
rats	O
receiving	O
U74500A	O
(	O
2	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
infusion	O
commencing	O
30	O
min	O
prior	O
to	O
revascularisation	O
)	O
exhibited	O
enhanced	O
GMBF	O
throughout	O
reperfusion	O
[	O
PI	O
10	O
min	O
:	O
3	O
.	O
26	O
(	O
2	O
.	O
56	O
-	O
3	O
.	O
63	O
)	O
;	O
120	O
min	O
:	O
2	O
.	O
03	O
(	O
1	O
.	O
73	O
-	O
2	O
.	O
25	O
)	O
;	O
240	O
min	O
:	O
2	O
.	O
13	O
(	O
1	O
.	O
75	O
-	O
2	O
.	O
44	O
)	O
,	O
p	O
<	O
0	O
.	O
01	O
vs	O
.	O
controls	O
and	O
normals	O
]	O
with	O
complete	O
muscle	O
salvage	O
[	O
GMV	O
100	O
%	O
in	O
all	O
reperfused	O
muscles	O
,	O
p	O
<	O
0	O
.	O
01	O
vs	O
.	O
controls	O
,	O
not	O
significant	O
(	O
NS	O
)	O
vs	O
.	O
normals	O
and	O
6	O
h	O
ischaemia	O
]	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Phosphotyrosyl	B-protein
peptides	I-protein
block	O
Stat3	O
-	O
mediated	O
DNA	O
-	O
binding	O
activity	O
,	O
gene	O
regulation	O
and	O
cell	O
transformation	O
.	O

The	O
therapy	O
time	O
to	O
deliver	O
the	O
NCS	O
therapeutic	O
dose	O
of	O
10000	O
RBE	O
-	O
cGy	O
,	O
is	O
27	O
times	O
longer	O
when	O
157Gd	O
is	O
used	O
instead	O
of	O
10B	O
.	O

A	O
significant	O
relationship	O
existed	O
during	O
the	O
evolution	O
of	O
the	O
disease	O
between	O
CRS	O
/	O
BW	O
and	O
gas	O
exchange	O
parameters	O
(	O
FIO2	O
and	O
a	O
/	O
AO2	O
ratio	O
)	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
but	O
gas	O
exchange	O
improved	O
earlier	O
than	O
lung	O
mechanics	O
.	O

Specific	O
IgE	B-protein
levels	O
decreased	O
slightly	O
,	O
but	O
always	O
remained	O
within	O
the	O
pathological	O
range	O
.	O

Mutating	O
the	O
E	O
-	O
box	O
in	O
the	O
context	O
of	O
the	O
3	O
'	O
-	O
flanking	O
region	O
confirmed	O
that	O
it	O
contributes	O
to	O
the	O
enhancement	O
of	O
transcriptional	O
activity	O
of	O
the	O
alpha1	B-protein
(	I-protein
I	I-protein
)	I-protein
collagen	I-protein
gene	I-protein
promoter	I-protein
.	O

The	O
study	O
was	O
repeated	O
after	O
administration	O
of	O
oral	O
amiodarone	O
,	O
50	O
mg	O
/	O
kg	O
/	O
day	O
for	O
2	O
days	O
in	O
8	O
divided	O
doses	O
(	O
mean	O
dose	O
6	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
4	O
g	O
)	O
.	O

Ischemic	O
heart	O
disease	O
,	O
age	O
of	O
more	O
than	O
75	O
years	O
,	O
and	O
the	O
fact	O
that	O
the	O
patient	O
was	O
a	O
woman	O
were	O
independent	O
predictors	O
of	O
poor	O
cardiac	O
function	O
.	O

To	O
determine	O
if	O
the	O
NF	B-protein
(	I-protein
H	I-protein
)	I-protein
promoter	I-protein
can	O
be	O
activated	O
in	O
a	O
tissue	O
specific	O
manner	O
during	O
development	O
transgenic	O
mice	O
containing	O
the	O
promoter	O
region	O
linked	O
to	O
a	O
beta	B-protein
-	I-protein
galactosidase	I-protein
reporter	I-protein
gene	I-protein
were	O
generated	O
.	O

Serum	B-protein
IgE	I-protein
levels	O
in	O
Tauranga	O
children	O
.	O

Renal	O
excretion	O
of	O
sulphadimidine	O
in	O
normal	O
and	O
uraemic	O
subjects	O
.	O

Changes	O
of	O
thirtynine	O
serum	O
protein	O
components	O
following	O
surgical	O
stress	O
.	O

The	O
TAF	O
factor	O
appears	O
to	O
be	O
particularly	O
significant	O
in	O
OCD	O
.	O

A	O
developmentally	O
regulated	O
4	O
.	O
6	O
kb	O
mRNA	O
is	O
recognized	O
on	O
Northern	O
blots	O
of	O
oocyte	O
RNA	O
using	O
the	O
X	O
.	O
laevis	O
cDNA	O
.	O

Cell	O
.	O

Secondary	O
pancreatic	O
involvement	O
of	O
mycosis	O
fungoides	O
detected	O
by	O
a	O
clinically	O
palpable	O
mass	O
.	O

The	O
relationship	O
between	O
primary	O
malignant	O
lymphoma	O
of	O
the	O
thyroid	O
and	O
chronic	O
thyroiditis	O
is	O
discussed	O
.	O

Finally	O
,	O
antibody	O
binding	O
to	O
site	O
IIIa	O
on	O
the	O
hCG	B-protein
-	I-protein
ectodomain	I-protein
complex	I-protein
was	O
also	O
hindered	O
by	O
an	O
anti	B-protein
-	I-protein
peptide	I-protein
mAb	I-protein
directed	O
against	O
a	O
peptide	O
encoded	O
by	O
the	O
eighth	O
exon	O
(	O
pE	O
x	O
8	O
)	O
of	O
the	O
LHR	B-protein
.	O

Identical	O
c	B-protein
-	I-protein
erbB3	I-protein
transcripts	I-protein
are	O
expressed	O
in	O
normal	O
human	O
placental	O
tissues	O
.	O

These	O
data	O
demonstrate	O
the	O
presence	O
of	O
a	O
single	O
binding	O
site	O
for	O
vinculin	B-protein
,	O
and	O
at	O
least	O
two	O
binding	O
sites	O
for	O
FAK	B-protein
that	O
are	O
separated	O
by	O
an	O
intervening	O
stretch	O
of	O
100	O
amino	O
acids	O
.	O

As	O
stands	O
shifted	O
in	O
dominance	O
from	O
pine	O
to	O
fir	O
with	O
age	O
,	O
subalpine	O
fir	O
appeared	O
to	O
maintain	O
gradually	O
increasing	O
rates	O
of	O
whole	O
-	O
forest	O
productivity	O
until	O
stands	O
were	O
approximately	O
400	O
years	O
old	O
.	O

We	O
have	O
identified	O
and	O
characterized	O
the	O
structure	O
of	O
the	O
Spec1	B-protein
gene	I-protein
in	O
the	O
sea	O
urchin	O
Strongylocentrotus	O
purpuratus	O
.	O

The	O
cDNA	O
contained	O
an	O
open	O
reading	O
frame	O
of	O
1392	O
bp	O
that	O
predicted	O
a	O
protein	O
of	O
464	O
amino	O
acids	O
and	O
a	O
molecular	O
mass	O
of	O
52	O
kDa	O
;	O
this	O
protein	O
has	O
97	O
%	O
identity	O
to	O
rat	B-protein
liver	I-protein
glucokinase	I-protein
.	O

This	O
study	O
was	O
designed	O
to	O
assess	O
and	O
compare	O
the	O
ability	O
of	O
three	O
different	O
forms	O
of	O
DSG	O
to	O
block	O
EIB	O
.	O

In	O
the	O
whole	O
group	O
of	O
infected	O
children	O
,	O
an	O
age	O
-	O
specific	O
z	O
score	O
<	O
-	O
2	O
for	O
weight	O
and	O
for	O
FFM	O
was	O
significantly	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	O
[	O
relative	O
risk	O
(	O
95	O
%	O
CI	O
)	O
=	O
11	O
.	O
4	O
(	O
3	O
.	O
1	O
,	O
41	O
.	O
0	O
)	O
and	O
5	O
.	O
1	O
(	O
1	O
.	O
5	O
,	O
18	O
.	O
2	O
)	O
,	O
respectively	O
]	O
;	O
when	O
only	O
children	O
with	O
more	O
severe	O
disease	O
were	O
considered	O
,	O
only	O
z	O
score	O
for	O
weight	O
was	O
significantly	O
associated	O
with	O
an	O
increased	O
risk	O
[	O
4	O
.	O
6	O
(	O
1	O
.	O
4	O
,	O
14	O
.	O
9	O
)	O
]	O
.	O

His	O
carnitine	B-protein
palmitoyltransferase	I-protein
(	I-protein
CPT	I-protein
)	I-protein
I	I-protein
and	I-protein
II	I-protein
activities	O
were	O
0	O
.	O
06	O
and	O
0	O
.	O
12	O
nmol	O
/	O
min	O
/	O
mg	O
protein	O
,	O
as	O
compared	O
with	O
a	O
mean	O
value	O
of	O
0	O
.	O
22	O
+	O
/	O
-	O
0	O
.	O
14	O
and	O
0	O
.	O
27	O
+	O
/	O
-	O
0	O
.	O
07	O
nmol	O
/	O
min	O
/	O
mg	O
protein	O
,	O
respectively	O
,	O
in	O
control	O
subjects	O
.	O

However	O
,	O
neu	B-protein
differentiation	O
factor	O
-	O
induced	O
heterodimers	O
of	O
ErbB2	B-protein
and	O
ErbB4	B-protein
activated	O
Stat5	B-protein
.	O

In	O
a	O
control	O
group	O
both	O
common	O
carotid	O
arteries	O
(	O
CCA	O
)	O
were	O
ligated	O
.	O

Thus	O
,	O
it	O
was	O
confirmed	O
that	O
the	O
sodium	O
lauryl	O
sulfate	O
method	O
of	O
estimating	O
hemoglobin	B-protein
concentration	O
is	O
an	O
appropriate	O
alternative	O
to	O
the	O
cyanmethemoglobin	O
method	O
and	O
avoids	O
the	O
generation	O
of	O
toxic	O
wastes	O
.	O

CTF1alpha	B-protein
,	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
showed	O
specific	O
binding	O
to	O
the	O
palindrome	O
2	O
DNA	O
fragment	O
but	O
not	O
to	O
palindrome	O
1	O
or	O
mutant	O
palindrome	O
2	O
DNA	O
fragments	O
,	O
suggesting	O
specific	O
binding	O
of	O
CTF1alpha	B-protein
to	O
palindrome	O
2	O
.	O

BACKGROUND	O
:	O
The	O
effectiveness	O
of	O
monoamine	B-protein
oxidase	I-protein
inhibitors	O
(	O
MAOIs	O
)	O
in	O
tricyclic	O
resistant	O
depression	O
has	O
received	O
surprisingly	O
little	O
systematic	O
study	O
.	O

However	O
,	O
at	O
18	O
months	O
of	O
age	O
,	O
significantly	O
higher	O
levels	O
of	O
IgG1	B-protein
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
of	O
IgG4	B-protein
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
were	O
found	O
in	O
infants	O
with	O
an	O
elevated	O
IgE	B-protein
(	O
greater	O
than	O
or	O
equal	O
to	O
8	O
.	O
0	O
kU	O
/	O
l	O
)	O
than	O
in	O
those	O
with	O
a	O
lower	O
level	O
.	O

RNA	O
gel	O
retardation	O
and	O
competition	O
analyses	O
indicate	O
that	O
TRP	B-protein
-	I-protein
185	I-protein
binding	O
is	O
strongly	O
dependent	O
on	O
the	O
TAR	B-protein
RNA	I-protein
loop	I-protein
sequences	I-protein
.	O

Transcript	O
analysis	O
reveals	O
that	O
lethal	O
B	B-protein
block	I-protein
substitutions	O
reduce	O
U6	B-protein
RNA	I-protein
synthesis	O
at	O
least	O
10	O
-	O
fold	O
in	O
vivo	O
and	O
20	O
-	O
fold	O
in	O
vitro	O
.	O

KEY	O
WORDS	O
:	O
Melaleuca	O
;	O
Lake	O
Okeechobee	O
;	O
Littoral	O
zone	O
;	O
Water	O
level	O
;	O
Regulation	O
schedule	O

Therefore	O
,	O
the	O
results	O
indicate	O
that	O
repeated	O
exposure	O
to	O
amphetamine	O
or	O
apomorphine	O
overcomes	O
the	O
context	O
-	O
dependent	O
component	O
of	O
sensitization	O
of	O
amphetamine	O
-	O
or	O
apomorphine	O
-	O
induced	O
stereotyped	O
behavior	O
.	O

An	O
end	O
-	O
to	O
-	O
end	O
pancreaticojejunostomy	O
using	O
a	O
mechanical	O
purse	O
-	O
string	O
device	O
.	O

Because	O
the	O
CAP	O
measures	O
variables	O
predictive	O
of	O
abusive	O
behavior	O
,	O
a	O
substantial	O
relationship	O
was	O
expected	O
between	O
the	O
CAP	O
and	O
the	O
MHI	O
Loss	O
of	O
Behavioral	O
/	O
Emotional	O
Control	O
scale	O
.	O

Soft	O
-	O
x	O
-	O
ray	O
lasing	O
at	O
32	O
.	O
6	O
nm	O
in	O
Ne	O
-	O
like	O
Ti	O
ions	O
driven	O
by	O
40	O
J	O
of	O
energy	O
from	O
two	O
650	O
-	O
ps	O
laser	O
pulses	O
.	O

Isoelectric	O
focusing	O
of	O
tryptic	O
peptides	O
generated	O
from	O
MHC	B-protein
-	I-protein
B	I-protein
phosphorylated	O
with	O
cdc2	B-protein
kinase	I-protein
revealed	O
one	O
major	O
phosphopeptide	O
that	O
was	O
purified	O
by	O
reverse	O
-	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
and	O
sequenced	O
.	O

Such	O
an	O
interaction	O
could	O
be	O
detected	O
using	O
a	O
GST	B-protein
-	I-protein
POU	I-protein
fusion	I-protein
protein	I-protein
bound	O
to	O
glutathione	O
-	O
agarose	O
beads	O
.	O

Molecular	O
cloning	O
of	O
mouse	B-protein
thioredoxin	I-protein
reductases	I-protein
.	O

Factors	O
that	O
showed	O
significant	O
correlation	O
to	O
elevated	O
CIC	O
'	O
s	O
in	O
the	O
highly	O
elevated	O
portion	O
of	O
our	O
CIC	O
population	O
were	O
poor	O
NIH	O
score	O
,	O
increased	O
patient	O
age	O
,	O
low	O
peak	O
expiratory	O
flow	O
rate	O
,	O
and	O
elevated	O
total	O
serum	B-protein
IgG	I-protein
.	O

A	O
chaotropic	O
detergent	O
,	O
0	O
.	O
1	O
%	O
Nonidet	O
P	O
-	O
40	O
,	O
also	O
abolished	O
the	O
interaction	O
,	O
further	O
supporting	O
the	O
hydrophobic	O
nature	O
of	O
the	O
interaction	O
.	O

Thus	O
,	O
the	O
inhibition	O
of	O
pepsin	B-protein
in	O
human	O
gastric	O
juice	O
does	O
not	O
appear	O
to	O
have	O
a	O
major	O
influence	O
on	O
the	O
healing	O
of	O
duodenal	O
ulcer	O
.	O

Restarting	O
time	O
was	O
not	O
affected	O
by	O
magnesium	O
cardioplegia	O
.	O

These	O
cell	O
lines	O
displayed	O
methylation	O
of	O
the	O
CpG	O
island	O
surrounding	O
the	O
first	O
exon	O
of	O
p16INK4A	B-protein
and	O
expressed	O
abundant	O
levels	O
of	O
a	O
nontranslated	O
mRNA	O
containing	O
an	O
alternative	O
first	O
exon	O
(	O
E1	B-protein
beta	I-protein
)	O
,	O
as	O
did	O
all	O
other	O
cell	O
lines	O
in	O
which	O
the	O
p16INK4A	B-protein
locus	I-protein
was	O
not	O
deleted	O
.	O

These	O
mutants	O
were	O
tested	O
for	O
ability	O
to	O
bind	O
each	O
of	O
the	O
Site	B-protein
II	I-protein
cognate	I-protein
proteins	I-protein
,	O
and	O
subsequently	O
evaluated	O
for	O
ability	O
to	O
confer	O
H4	B-protein
transcriptional	O
activity	O
using	O
chimeric	O
H4	B-protein
promoter	O
/	O
CAT	B-protein
fusion	O
constructs	O
in	O
different	O
cell	O
types	O
.	O

The	O
determination	O
of	O
the	O
double	O
bounds	O
in	O
blood	O
serum	O
lipids	O
by	O
titration	O
with	O
ozone	O
:	O
the	O
pathophysiology	O
and	O
diagnostic	O
significance	O
In	O
this	O
article	O
the	O
method	O
of	O
definition	O
of	O
double	O
binders	O
in	O
lipids	O
of	O
blood	O
serum	O
in	O
patients	O
with	O
different	O
diseases	O
basically	O
atherosclerosis	O
and	O
ischemic	O
heart	O
disease	O
,	O
with	O
use	O
titration	O
by	O
ozone	O
is	O
given	O
.	O

On	O
the	O
other	O
hand	O
,	O
neither	O
phosphate	O
buffered	O
saline	O
injection	O
into	O
the	O
ES	O
nor	O
primary	O
KLH	B-protein
challenges	O
of	O
the	O
ES	O
were	O
capable	O
of	O
elevating	O
the	O
threshold	O
level	O
and	O
changing	O
the	O
latency	O
.	O

Viral	O
and	O
atypical	O
pathogens	O
as	O
causes	O
of	O
type	O
1	O
acute	O
exacerbations	O
of	O
chronic	O
bronchitis	O
.	O

The	O
5	O
'	O
end	O
of	O
the	O
genomic	O
RNA	O
of	O
rubella	O
virus	O
(	O
RUB	O
)	O
contains	O
a	O
14	O
-	O
nucleotide	O
(	O
nt	O
)	O
single	O
-	O
stranded	O
leader	O
(	O
ss	O
-	O
leader	O
)	O
followed	O
by	O
a	O
stem	O
-	O
and	O
-	O
loop	O
structure	O
[	O
5	O
'	O
(	O
+	O
)	O
SL	O
]	O
(	O
nt	O
15	O
to	O
65	O
)	O
,	O
the	O
complement	O
of	O
which	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
minus	O
-	O
strand	O
RNA	O
[	O
3	O
'	O
(	O
-	O
)	O
SL	O
]	O
has	O
been	O
proposed	O
to	O
function	O
as	O
a	O
promoter	O
for	O
synthesis	O
of	O
genomic	O
plus	O
strands	O
.	O

We	O
examined	O
behavioral	O
alterations	O
in	O
the	O
brown	O
cockroach	O
,	O
Periplaneta	O
brunnea	O
,	O
infected	O
with	O
the	O
acanthocephalan	O
,	O
Moniliformis	O
moniliformis	O
.	O

The	O
prominent	O
lesions	O
were	O
confined	O
to	O
the	O
cerebral	O
surface	O
layer	O
and	O
leptomeningeal	O
tissue	O
including	O
the	O
arachnoid	O
vessels	O
,	O
which	O
were	O
all	O
bathed	O
in	O
the	O
cerebrospinal	O
fluid	O
,	O
suggesting	O
that	O
some	O
necrotizing	O
toxins	O
had	O
been	O
secreted	O
into	O
the	O
fluid	O
by	O
the	O
B	O
.	O
cereus	O
.	O

A	O
decrease	O
in	O
insulin	O
-	O
induced	O
receptor	B-protein
kinase	I-protein
activity	O
was	O
observed	O
for	O
solubilized	O
chimeric	O
receptors	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
results	O
indicate	O
that	O
p53	B-protein
plays	O
a	O
defensive	O
role	O
against	O
HBV	O
by	O
transcriptionally	O
repressing	O
the	O
HBV	B-protein
core	I-protein
promoter	I-protein
through	O
liver	B-protein
-	I-protein
specific	I-protein
enhancer	I-protein
II	I-protein
and	O
HBx	B-protein
is	O
required	O
to	O
counteract	O
this	O
inhibitory	O
function	O
of	O
p53	B-protein
.	O

The	O
vaccine	O
used	O
was	O
known	O
to	O
be	O
immunogenic	O
for	O
older	O
children	O
and	O
adults	O
.	O

The	O
first	O
group	O
of	O
sequential	O
BMB	O
showed	O
a	O
significant	O
progress	O
to	O
myelofibrosis	O
in	O
so	O
-	O
called	O
`	O
`	O
Chronic	O
Megakaryocytic	O
-	O
Granulocytic	O
Myelosis	O
'	O
'	O
-	O
-	O
CMGM	O
-	O
,	O
which	O
corresponds	O
to	O
Agnogenic	O
Myeloid	O
Metaplasia	O
-	O
AMM	O
-	O
in	O
72	O
.	O
4	O
%	O
(	O
21	O
/	O
29	O
patients	O
)	O
,	O
as	O
well	O
as	O
in	O
CML	O
with	O
megakaryocytic	O
increase	O
-	O
CML	O
.	O
MI	O
-	O
in	O
39	O
.	O
2	O
%	O
(	O
20	O
/	O
51	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
V3	B-protein
peptides	O
from	O
all	O
major	O
clades	O
of	O
HIV	O
-	O
1	O
carried	O
by	O
HIV	B-protein
-	I-protein
2	I-protein
gag	I-protein
can	O
be	O
used	O
as	O
a	O
potential	O
HIV	O
/	O
AIDS	O
vaccine	O
.	O

Thrombophlebitis	O
and	O
pulmonary	O
embolism	O
in	O
congenital	O
factor	B-protein
XII	I-protein
deficiency	O
.	O

Guidelines	O
for	O
performing	O
a	O
routine	O
spiral	O
assay	O
are	O
presented	O
,	O
and	O
alternative	O
test	O
methods	O
intended	O
to	O
overcome	O
a	O
variety	O
of	O
technical	O
difficulties	O
(	O
such	O
as	O
restricted	O
sample	O
availability	O
,	O
sample	O
viscosity	O
or	O
volatility	O
,	O
etc	O
.	O
)	O
are	O
recommended	O
.	O

A	O
further	O
subdivision	O
of	O
Category	O
pN1	O
into	O
pN1a	O
(	O
metastasis	O
in	O
single	O
node	O
)	O
and	O
pN1b	O
(	O
two	O
or	O
more	O
nodes	O
)	O
is	O
recommended	O
.	O

In	O
contrast	O
,	O
the	O
CRE	B-protein
of	O
the	O
human	B-protein
c	I-protein
-	I-protein
fos	I-protein
promoter	I-protein
located	O
at	O
-	O
60	O
was	O
weakly	O
induced	O
by	O
cAMP	O
and	O
E1a	B-protein
in	O
both	O
HeLa	O
and	O
PC12	O
cells	O
.	O

Deletion	O
of	O
a	O
53	O
-	O
bp	O
early	O
promoter	O
region	O
containing	O
the	O
transcription	O
start	O
site	O
and	O
a	O
putative	O
TATA	O
box	O
completely	O
abolishes	O
the	O
ability	O
of	O
upstream	O
elements	O
to	O
drive	O
transcription	O
of	O
the	O
luciferase	B-protein
cDNA	I-protein
.	O

However	O
,	O
the	O
few	O
studies	O
that	O
address	O
antimicrobial	O
prophylaxis	O
in	O
bone	O
marrow	O
transplantation	O
have	O
not	O
always	O
shown	O
a	O
survival	O
benefit	O
.	O

Transcriptional	O
control	O
of	O
a	O
nuclear	O
gene	O
encoding	O
a	O
mitochondrial	O
fatty	O
acid	O
oxidation	O
enzyme	O
in	O
transgenic	O
mice	O
:	O
role	O
for	O
nuclear	O
receptors	O
in	O
cardiac	O
and	O
brown	O
adipose	O
expression	O
.	O

Insulin	B-protein
stimulation	O
promoted	O
the	O
association	O
of	O
mIRS3	B-protein
with	O
p85	B-protein
,	O
SHP2	B-protein
,	O
Nck	B-protein
,	O
and	O
Shc	B-protein
.	O

In	O
particular	O
,	O
71	O
and	O
69	O
%	O
amino	O
acid	O
sequence	O
similarities	O
were	O
identified	O
with	O
hsp70	B-protein
of	I-protein
Escherichia	I-protein
coli	I-protein
and	I-protein
Bacillus	I-protein
megaterium	I-protein
,	O
respectively	O
.	O

Thirty	O
cadaver	O
brains	O
were	O
examined	O
under	O
X	O
6	O
to	O
16	O
magnification	O
in	O
order	O
to	O
define	O
the	O
microsurgical	O
anatomy	O
of	O
the	O
pineal	O
region	O
,	O
particularly	O
the	O
relationship	O
of	O
the	O
pineal	O
body	O
,	O
posterior	O
cerebral	O
artery	O
,	O
superior	O
cerebellar	O
artery	O
,	O
vein	O
of	O
Galen	O
,	O
basal	O
vein	O
of	O
Rosenthal	O
,	O
internal	O
cerebral	O
vein	O
,	O
straight	O
sinus	O
,	O
bridging	O
vein	O
,	O
the	O
size	O
of	O
the	O
tentorial	O
notch	O
,	O
and	O
the	O
third	O
and	O
the	O
fourth	O
cranial	O
nerves	O
.	O

Increased	O
erythropoietin	B-protein
synthesis	O
in	O
patients	O
with	O
COLD	O
or	O
left	O
heart	O
failure	O
is	O
related	O
to	O
alterations	O
in	O
renal	O
haemodynamics	O
.	O

Unlike	O
ARF	B-protein
,	O
the	O
ARP	B-protein
immunoreactivity	O
was	O
detected	O
in	O
plasma	O
membranes	O
but	O
not	O
in	O
cytosol	O
of	O
fractionated	O
3T3	O
-	O
L1	O
cells	O
.	O

Effects	O
of	O
chronic	O
metaraminol	O
treatment	O
on	O
the	O
sympathetic	O
activity	O
of	O
intact	O
and	O
adrenal	O
demedullated	O
rats	O
kept	O
in	O
warm	O
or	O
cold	O
environments	O
.	O

Bepridil	O
,	O
a	O
calcium	O
antagonist	O
with	O
a	O
half	O
-	O
life	O
of	O
approximately	O
42	O
hours	O
,	O
was	O
compared	O
with	O
placebo	O
in	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
crossover	O
trial	O
.	O

Involvement	O
of	O
AP1	B-protein
and	O
PEA3	B-protein
binding	I-protein
sites	I-protein
in	O
the	O
regulation	O
of	O
murine	B-protein
tissue	I-protein
inhibitor	I-protein
of	I-protein
metalloproteinases	I-protein
-	I-protein
1	I-protein
(	O
TIMP	B-protein
-	I-protein
1	I-protein
)	O
transcription	O
.	O

Alternative	O
processing	O
of	O
the	O
tryptophanyl	B-protein
-	I-protein
tRNA	I-protein
synthetase	I-protein
mRNA	I-protein
from	O
interferon	O
-	O
treated	O
human	O
cells	O
.	O

The	O
East	O
African	O
dik	O
-	O
dik	O
antelope	O
represents	O
a	O
miniature	O
model	O
ruminant	O
for	O
comparative	O
studies	O
.	O

Three	O
patients	O
had	O
well	O
-	O
,	O
6	O
patients	O
had	O
moderately	O
-	O
,	O
and	O
5	O
patients	O
had	O
poorly	O
-	O
differentiated	O
adenocarcinoma	O
of	O
the	O
prostate	O
.	O

The	O
`	O
`	O
28	O
percent	O
'	O
'	O
Venturi	O
mask	O
in	O
obstructive	O
airway	O
disease	O
.	O

Human	B-protein
LAF	I-protein
-	I-protein
4	I-protein
readily	O
hybridized	O
with	O
genes	O
in	O
mouse	O
and	O
chicken	O
,	O
thus	O
showing	O
that	O
this	O
gene	O
family	O
has	O
been	O
highly	O
conserved	O
during	O
vertebrate	O
evolution	O
.	O

RESULTS	O
:	O
In	O
an	O
18	O
moth	O
period	O
and	O
out	O
of	O
a	O
total	O
of	O
284	O
positive	O
blood	O
cultures	O
(	O
154	O
significant	O
isolations	O
)	O
14	O
episodes	O
of	O
bacteremia	O
by	O
M	O
.	O
tuberculosis	O
were	O
studied	O
in	O
12	O
prison	O
patients	O
coinfected	O
by	O
the	O
human	O
immunodeficiency	O
virus	O
with	O
associated	O
severe	O
immunosuppression	O
(	O
mean	O
of	O
CD4	B-protein
=	O
0	O
.	O
068	O
x	O
10	O
(	O
9	O
)	O
/	O
l	O
)	O
.	O

Morphologic	O
variables	O
included	O
cancer	O
volume	O
,	O
histologic	O
grade	O
,	O
capsular	O
penetration	O
,	O
seminal	O
vesicle	O
invasion	O
,	O
and	O
lymph	O
node	O
metastasis	O
.	O

The	O
genes	O
encoding	O
the	O
transcription	B-protein
factor	I-protein
yTAFII60	I-protein
,	O
the	O
G4p1	B-protein
protein	I-protein
and	O
a	O
putative	O
glucose	B-protein
transporter	I-protein
are	O
contained	O
in	O
a	O
12	O
.	O
3	O
kb	O
DNA	O
fragment	O
on	O
the	O
left	O
arm	O
of	O
Saccharomyces	O
cerevisiae	O
chromosome	O
VII	O
.	O

Evaluation	O
of	O
the	O
new	O
Gravigard	O
IUCD	O
inserter	O
.	O

Not	O
Available	O

Functional	O
and	O
regulatory	O
analysis	O
of	O
the	O
two	O
copies	O
of	O
the	O
fixNOQP	B-protein
operon	I-protein
of	O
Rhizobium	O
leguminosarum	O
strain	O
VF39	O
.	O

The	O
9	O
;	O
22	O
chromosomal	O
translocation	O
characteristic	O
of	O
CML	O
results	O
in	O
a	O
fused	B-protein
bcr	I-protein
/	I-protein
abl	I-protein
gene	I-protein
and	O
an	O
abnormal	O
fusion	O
protein	O
,	O
p210bcr	B-protein
/	I-protein
abl	I-protein
.	O

We	O
have	O
measured	O
the	O
MBF	O
on	O
incisors	O
and	O
its	O
direction	O
in	O
three	O
dimensions	O
for	O
different	O
jaw	O
openings	O
in	O
ten	O
subjects	O
.	O

Subcellular	O
localizations	O
of	O
the	O
wild	B-protein
-	I-protein
type	I-protein
CBFbeta	I-protein
and	O
the	O
CBFbeta	B-protein
-	I-protein
SMMHC	I-protein
fusion	I-protein
protein	I-protein
were	O
determined	O
by	O
immunofluorescence	O
of	O
NIH	O
3T3	O
cells	O
that	O
overexpress	O
wild	O
-	O
type	O
or	O
fusion	O
protein	O
.	O

In	O
conclusion	O
,	O
IgM	B-protein
class	O
CIC	O
is	O
the	O
predominant	O
CIC	O
in	O
acute	O
hepatitis	O
A	O
and	O
correlated	O
with	O
disease	O
activity	O
.	O

Echinostomiasis	O
is	O
aggravated	O
by	O
socioeconomic	O
factors	O
such	O
as	O
poverty	O
,	O
malnutrition	O
,	O
an	O
explosively	O
growing	O
free	O
-	O
food	O
market	O
,	O
a	O
lack	O
of	O
supervised	O
food	O
inspection	O
,	O
poor	O
or	O
insufficient	O
sanitation	O
,	O
other	O
helminthiases	O
,	O
and	O
declining	O
economic	O
conditions	O
.	O

We	O
further	O
demonstrate	O
that	O
the	O
Stress	B-protein
-	I-protein
Activated	I-protein
-	I-protein
Protein	I-protein
-	I-protein
Kinase	I-protein
(	O
SAPK	B-protein
)	O
target	O
sites	O
of	O
ATF2	B-protein
,	O
Thr69	O
and	O
Thr71	O
are	O
not	O
required	O
for	O
the	O
formation	O
of	O
the	O
p300	B-protein
/	I-protein
CBP	I-protein
-	I-protein
ATF2	I-protein
multiprotein	O
complex	O
.	O

Mae	O
West	O
and	O
the	O
doctor	O
shortage	O
.	O

Oncogenic	O
capacity	O
of	O
the	O
E2F1	B-protein
gene	I-protein
.	O

Thus	O
,	O
Sir	B-protein
proteins	I-protein
from	O
K	O
.	O
lactis	O
have	O
roles	O
in	O
both	O
silencing	O
and	O
telomere	O
length	O
maintenance	O
,	O
reflecting	O
conserved	O
functional	O
themes	O
.	O

The	O
p55	B-protein
mRNA	I-protein
is	O
undetectable	O
in	O
non	O
-	O
EBV	O
-	O
infected	O
B	O
-	O
and	O
T	O
-	O
cell	O
lines	O
or	O
in	O
a	O
myelomonocytic	O
cell	O
line	O
(	O
U937	O
)	O
.	O

In	O
Experiments	O
1	O
and	O
2	O
,	O
infants	O
,	O
like	O
adults	O
,	O
initially	O
categorized	O
novel	O
objects	O
on	O
the	O
basis	O
of	O
physical	O
appearance	O
,	O
but	O
only	O
if	O
trained	O
with	O
multiple	O
exemplars	O
,	O
after	O
delays	O
of	O
1	O
and	O
7	O
days	O
.	O

Successful	O
use	O
of	O
transureteroureterostomy	O
to	O
salvage	O
ureterosigmoidostomy	O
after	O
anastomotic	O
failure	O
.	O

SRF	O
-	O
deficient	O
embryos	O
(	O
Srf	B-protein
-	O
/	O
-	O
)	O
have	O
a	O
severe	O
gastrulation	O
defect	O
and	O
do	O
not	O
develop	O
to	O
term	O
.	O

Four	O
full	O
-	O
thickness	O
skin	O
incisions	O
were	O
made	O
in	O
the	O
back	O
of	O
10	O
female	O
pigs	O
that	O
treated	O
twice	O
a	O
day	O
for	O
14	O
days	O
with	O
2	O
ml	O
of	O
epidermal	B-protein
growth	I-protein
factor	I-protein
(	O
300	O
ng	O
/	O
ml	O
)	O
or	O
2	O
ml	O
of	O
Ringer	O
'	O
s	O
lactate	O
solution	O
in	O
a	O
single	O
-	O
blind	O
,	O
randomized	O
fashion	O
.	O

In	O
mammalian	O
tissue	O
culture	O
cells	O
,	O
overexpression	O
of	O
any	O
of	O
the	O
four	O
mouse	O
deltex	O
homologs	O
suppressed	O
the	O
transcriptional	O
activity	O
of	O
E47	B-protein
,	O
a	O
basic	B-protein
helix	I-protein
-	I-protein
loop	I-protein
-	I-protein
helix	I-protein
(	I-protein
bHLH	I-protein
)	I-protein
protein	I-protein
,	O
in	O
a	O
manner	O
similar	O
to	O
suppression	O
by	O
an	O
activated	O
form	O
of	O
human	B-protein
Notch1	I-protein
or	O
human	B-protein
DTX1	I-protein
.	O

However	O
,	O
kidneys	O
perfused	O
for	O
72	O
hr	O
demonstrated	O
more	O
similar	O
renal	O
functions	O
when	O
tested	O
by	O
either	O
IMPK	O
or	O
IBPK	O
.	O

Patients	O
with	O
antibody	O
peaks	O
,	O
defined	O
as	O
fivefold	O
or	O
higher	O
increase	O
in	O
antibody	O
titer	O
compared	O
to	O
the	O
lowest	O
antibody	O
titer	O
over	O
the	O
course	O
of	O
GBS	O
,	O
had	O
higher	O
disability	O
scores	O
during	O
the	O
first	O
two	O
weeks	O
of	O
GBS	O
and	O
a	O
worse	O
clinical	O
outcome	O
(	O
anti	B-protein
-	I-protein
GM1	I-protein
IgG	I-protein
and	O
anti	B-protein
-	I-protein
GD1a	I-protein
IgM	I-protein
antibody	I-protein
peaks	O
)	O
and	O
axonal	O
damage	O
(	O
anti	B-protein
-	I-protein
GD1a	I-protein
IgM	I-protein
antibody	I-protein
peaks	O
)	O
,	O
compared	O
to	O
patients	O
without	O
peak	O
antibody	O
titers	O
.	O

This	O
core	O
sequence	O
,	O
along	O
with	O
additional	O
nonspecific	O
downstream	O
nucleotides	O
,	O
is	O
sufficient	O
for	O
partial	O
suppression	O
of	O
spliceosome	O
assembly	O
and	O
splicing	O
of	O
BPV	O
-	O
1	O
pre	O
-	O
mRNAs	O
.	O

Inhibition	O
of	O
the	O
Raf	B-protein
-	I-protein
1	I-protein
target	I-protein
ERK	I-protein
kinase	I-protein
(	O
MEK	B-protein
)	O
either	O
attenuated	O
or	O
abolished	O
Rp	O
-	O
cAMPS	O
-	O
and	O
PKI	O
-	O
induced	O
ERK	B-protein
activation	O
,	O
caldesmon	B-protein
phosphorylation	O
,	O
and	O
stress	O
fiber	O
formation	O
.	O

METHODS	O
:	O
T2	O
*	O
-	O
weighted	O
,	O
three	O
-	O
dimensional	O
gradient	O
-	O
echo	O
images	O
were	O
acquired	O
by	O
exploiting	O
the	O
magnetic	O
susceptibility	O
difference	O
between	O
oxygenated	O
and	O
deoxygenated	O
hemoglobin	B-protein
in	O
the	O
vasculature	O
and	O
microvasculature	O
.	O

In	O
a	O
second	O
experiment	O
involving	O
an	O
18	O
-	O
h	O
lung	O
clearance	O
assay	O
,	O
we	O
used	O
the	O
mAb	O
3	O
.	O
2	O
.	O
3	O
to	O
deplete	O
rats	O
of	O
LGL	O
/	O
NK	O
cells	O
with	O
the	O
following	O
rationale	O
:	O
if	O
LGL	O
/	O
NK	O
cells	O
are	O
necessary	O
to	O
mediate	O
an	O
event	O
,	O
then	O
in	O
their	O
absence	O
,	O
that	O
event	O
should	O
not	O
occur	O
.	O

The	O
rci	B-protein
gene	I-protein
was	O
fused	O
with	O
lacZ	B-protein
and	O
its	O
gene	O
product	O
was	O
identified	O
by	O
Western	O
blot	O
analysis	O
.	O

Variety	O
of	O
cows	O
and	O
sires	O
according	O
to	O
types	O
of	O
dermatoglyphics	O
(	O
patterns	O
)	O
of	O
the	O
nose	O
-	O
labial	O
mirror	O
of	O
cattle	O
.	O

Many	O
cells	O
were	O
negative	O
for	O
endothelial	O
-	O
cell	O
markers	O
,	O
and	O
they	O
reacted	O
with	O
a	O
monoclonal	O
antibody	O
against	O
muscle	O
actin	B-protein
.	O

We	O
studied	O
the	O
role	O
of	O
prostaglandins	O
in	O
acid	O
-	O
induced	O
esophagitis	O
and	O
the	O
associated	O
LES	O
hypotension	O
by	O
simultaneous	O
treatment	O
of	O
some	O
animals	O
with	O
indomethacin	O
(	O
150	O
micrograms	O
/	O
kg	O
intravenous	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
prostaglandin	O
synthesis	O
,	O
either	O
during	O
production	O
of	O
esophagitis	O
or	O
during	O
recovery	O
.	O

Of	O
these	O
sites	O
,	O
PEA3	B-protein
and	O
STAT	B-protein
contributed	O
specifically	O
to	O
induction	O
by	O
v	B-protein
-	I-protein
src	I-protein
,	O
whereas	O
the	O
remaining	O
elements	O
were	O
also	O
involved	O
in	O
induction	O
by	O
the	O
phorbol	O
ester	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O

An	O
ASSEMBLER	O
routine	O
for	O
on	O
-	O
line	O
graphic	O
display	O
and	O
averaging	O
of	O
data	O
acquired	O
on	O
a	O
personal	O
microcomputer	O
.	O

The	O
exodomain	O
alone	O
has	O
the	O
high	O
affinity	O
hormone	O
binding	O
site	O
but	O
is	O
not	O
capable	O
of	O
generating	O
hormonal	O
signal	O
.	O

We	O
therefore	O
applied	O
a	O
radiolabelled	O
serumalbumin	O
method	O
to	O
determine	O
blood	O
volume	O
after	O
haemodilution	O
with	O
crosslinked	O
or	O
conjugated	O
haemoglobin	B-protein
,	O
in	O
comparison	O
with	O
a	O
reference	O
solution	O
of	O
hydroxyethyl	O
starch	O
(	O
HES	O
)	O
.	O

The	O
average	O
birth	O
mass	O
of	O
these	O
newborns	O
was	O
3491	O
.	O
9	O
+	O
/	O
-	O
2	O
SD	O
780	O
.	O
5	O
g	O
and	O
that	O
in	O
the	O
control	O
group	O
3	O
,	O
767	O
.	O
5	O
+	O
/	O
-	O
2	O
SD	O
824	O
.	O
2	O
g	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

This	O
exon	O
,	O
here	O
named	O
exon	O
0	O
,	O
contained	O
the	O
entire	O
5	O
'	O
untranslated	O
region	O
and	O
the	O
N	O
-	O
terminal	O
signal	O
sequence	O
of	O
the	O
polypeptide	O
.	O

Expression	O
of	O
herpes	B-protein
simplex	I-protein
virus	I-protein
beta	I-protein
and	I-protein
gamma	I-protein
genes	I-protein
integrated	O
in	O
mammalian	O
cells	O
and	O
their	O
induction	O
by	O
an	O
alpha	B-protein
gene	I-protein
product	I-protein
.	O

A	O
.	O
,	O
Slatkin	O
,	O
D	O
.	O

Analysis	O
of	O
the	O
rate	O
constants	O
indicated	O
that	O
the	O
isomerization	O
rate	O
k12	O
was	O
approximately	O
equal	O
to	O
the	O
apparent	O
degradation	O
rate	O
of	O
the	O
delta	O
3	O
ester	O
kdeg	O
,	O
and	O
slower	O
than	O
the	O
hydrolysis	O
rate	O
of	O
the	O
delta	O
2	O
ester	O
k24	O
.	O

Yap1p	B-protein
is	O
constitutively	O
nuclear	O
in	O
a	O
crm1	B-protein
mutant	I-protein
,	O
and	O
Crm1p	B-protein
binds	O
to	O
a	O
nuclear	O
export	O
sequence	O
(	O
NES	O
)	O
-	O
like	O
sequence	O
in	O
Yap1p	B-protein
in	O
the	O
presence	O
of	O
RanGTP	B-protein
.	O

Clinical	O
chemistry	O
.	O

Hematopoietic	O
system	O
in	O
streptococcal	O
allergy	O
.	O

However	O
,	O
using	O
ATL	O
-	O
16T	O
nuclear	O
extract	O
,	O
we	O
demonstrated	O
that	O
GATA	B-protein
-	I-protein
4	I-protein
is	O
the	O
only	O
GATA	B-protein
-	I-protein
binding	I-protein
protein	I-protein
that	O
forms	O
specific	O
DNA	O
-	O
protein	O
complex	O
with	O
the	O
-	B-protein
70	I-protein
GATA	I-protein
site	I-protein
.	O

Toluene	O
is	O
the	O
chemical	O
most	O
frequently	O
present	O
in	O
cases	O
involving	O
volatile	O
solvents	O
.	O

Thus	O
,	O
we	O
have	O
produced	O
lipoyl	O
domain	O
constructs	O
that	O
can	O
be	O
employed	O
in	O
sorting	O
the	O
specific	O
roles	O
of	O
E2L1	B-protein
and	O
E2L2	B-protein
in	O
facilitating	O
catalytic	O
and	O
regulatory	O
processes	O
.	O

Transfecting	O
the	O
cloned	B-protein
bovine	I-protein
PBR	I-protein
/	I-protein
IBP	I-protein
cDNA	I-protein
into	O
COS	O
-	O
7	O
cells	O
resulted	O
in	O
an	O
11	O
-	O
fold	O
increase	O
in	O
the	O
density	O
of	O
high	O
affinity	O
[	O
3H	O
]	O
PK	O
11195	O
binding	O
sites	O
which	O
had	O
only	O
low	O
affinity	O
for	O
Ro5	O
-	O
4864	O
.	O

Digestion	O
of	O
NF	B-protein
-	I-protein
IL6	I-protein
with	O
endoprotease	B-protein
Asp	I-protein
-	I-protein
N	I-protein
produced	O
a	O
domain	O
smaller	O
than	O
the	O
TCD	B-protein
(	O
NF	B-protein
-	I-protein
IL6	I-protein
bZIP	I-protein
domains	I-protein
(	O
NFBD	B-protein
)	O
(	O
272	O
-	O
345	O
)	O
)	O
,	O
a	O
domain	O
identified	O
either	O
in	O
the	O
absence	O
or	O
the	O
presence	O
of	O
DNA	O
.	O

Hypothalamic	O
control	O
of	O
coronary	O
circulation	O
in	O
the	O
dog	O
.	O

Intensification	O
of	O
human	O
myocardial	O
contractile	O
activity	O
as	O
affected	O
by	O
blood	O
serum	O
.	O

These	O
results	O
demonstrate	O
that	O
although	O
PI2	O
and	O
PI3	O
viruses	O
belong	O
to	O
the	O
same	O
parainfluenza	O
virus	O
genus	O
,	O
these	O
viruses	O
show	O
marked	O
differences	O
with	O
respect	O
to	O
functional	O
requirements	O
for	O
the	O
cytoplasmic	O
tail	O
of	O
the	O
F	B-protein
glycoprotein	I-protein
.	O

The	O
human	B-protein
cytomegalovirus	I-protein
(	I-protein
HCMV	I-protein
)	I-protein
major	I-protein
immediate	I-protein
-	I-protein
early	I-protein
protein	I-protein
IE2	I-protein
is	O
a	O
nuclear	B-protein
phosphoprotein	I-protein
that	O
is	O
believed	O
to	O
be	O
a	O
key	O
regulator	O
in	O
both	O
lytic	O
and	O
latent	O
infections	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
Lung	O
elastance	O
(	O
EL	O
)	O
and	O
resistance	O
(	O
RL	O
)	O
were	O
calculated	O
from	O
measurements	O
of	O
airway	O
pressure	O
,	O
esophageal	O
pressure	O
,	O
and	O
airway	O
flow	O
in	O
five	O
anesthetized	O
,	O
paralyzed	O
dogs	O
during	O
sinusoidal	O
forcing	O
at	O
a	O
constant	O
mean	O
airway	O
pressure	O
of	O
10	O
cmH2O	O
in	O
a	O
wide	O
range	O
of	O
breathing	O
frequencies	O
(	O
0	O
.	O
2	O
to	O
1	O
.	O
0	O
Hz	O
in	O
intervals	O
of	O
0	O
.	O
2	O
)	O
and	O
tidal	O
volumes	O
(	O
50	O
,	O
100	O
,	O
200	O
,	O
and	O
to	O
300	O
mL	O
)	O
.	O

The	O
mean	O
power	O
(	O
in	O
mu	O
W	O
)	O
required	O
to	O
produce	O
the	O
observed	O
flow	O
rate	O
was	O
estimated	O
at	O
each	O
outflow	O
pressure	O
as	O
the	O
product	O
of	O
the	O
flow	O
rate	O
and	O
the	O
pressure	O
across	O
the	O
lymphatic	O
vessel	O
.	O

A	O
mutational	O
analysis	O
has	O
resolved	O
a	O
region	O
of	O
seven	O
amino	O
acids	O
(	O
amino	O
acids	O
26	O
-	O
32	O
)	O
in	O
the	O
N	O
-	O
terminus	O
of	O
Bob1	B-protein
that	O
are	O
important	O
for	O
contacting	O
the	O
DNA	O
binding	O
POU	B-protein
domain	I-protein
of	O
Oct	B-protein
-	I-protein
1	I-protein
or	O
Oct	B-protein
-	I-protein
2	I-protein
.	O

Ethylene	O
glycol	O
and	O
diethylene	O
glycol	O
were	O
each	O
administered	O
once	O
weekly	O
subcutaneously	O
to	O
groups	O
of	O
100	O
female	O
NMRI	O
mice	O
at	O
3	O
dosages	O
(	O
30	O
;	O
10	O
und	O
3	O
mg	O
single	O
dose	O
per	O
mouse	O
)	O
.	O

METHODS	O
:	O
Sixteen	O
pigs	O
were	O
assigned	O
randomly	O
to	O
control	O
and	O
shock	O
groups	O
.	O

Because	O
endogenous	O
HSF	B-protein
DNA	O
-	O
binding	O
activity	O
is	O
low	O
and	O
anti	B-protein
-	I-protein
hHSF1	I-protein
antibody	I-protein
does	O
not	O
recognize	O
Xenopus	B-protein
HSF	I-protein
,	O
we	O
employed	O
this	O
system	O
for	O
mapping	O
regions	O
in	O
hHSF1	B-protein
that	O
are	O
required	O
for	O
the	O
maintenance	O
of	O
the	O
monomeric	O
state	O
.	O

On	O
the	O
comparison	O
of	O
correlated	O
proportions	O
for	O
clustered	O
data	O
.	O

No	O
significant	O
correlations	O
of	O
peak	O
VO2	O
were	O
observed	O
between	O
the	O
3	O
tests	O
.	O

We	O
were	O
interested	O
in	O
studying	O
the	O
relationship	O
between	O
the	O
circadian	O
rhythm	O
in	O
body	O
temperature	O
and	O
24	O
-	O
h	O
variations	O
in	O
plasma	O
concentrations	O
of	O
iron	O
,	O
zinc	O
,	O
circulating	O
leukocyte	O
counts	O
,	O
and	O
plasma	O
interleukin	B-protein
1	I-protein
(	O
IL	B-protein
-	I-protein
1	I-protein
)	O
activity	O
.	O

Activation	O
was	O
biphasic	O
;	O
peaking	O
at	O
5	O
-	O
10	O
min	O
and	O
24	O
h	O
after	O
treatment	O
.	O

Three	O
cysteine	O
and	O
four	O
tryptophan	O
residues	O
,	O
previously	O
identified	O
as	O
conserved	O
amongst	O
nitrous	B-protein
-	I-protein
oxide	I-protein
reductases	I-protein
,	O
are	O
found	O
in	O
the	O
Paracoccus	O
enzyme	O
.	O

Animal	O
age	O
and	O
sex	O
had	O
no	O
significant	O
effects	O
on	O
CSF	O
composition	O
,	O
but	O
serum	O
IgG	B-protein
concentration	O
increased	O
with	O
age	O
.	O

This	O
gene	O
encodes	O
a	O
putative	O
transcription	O
factor	O
with	O
regions	O
of	O
homology	O
to	O
several	O
other	O
proteins	O
including	O
the	O
zinc	O
fingers	O
and	O
other	O
domains	O
of	O
the	O
Drosophila	B-protein
trithorax	I-protein
gene	I-protein
product	I-protein
,	O
and	O
the	O
`	B-protein
`	I-protein
AT	I-protein
-	I-protein
hook	I-protein
'	I-protein
'	I-protein
DNA	I-protein
-	I-protein
binding	I-protein
motif	I-protein
of	O
high	B-protein
mobility	I-protein
group	I-protein
proteins	I-protein
.	O

High	O
trough	O
serum	O
TOB	O
concentrations	O
were	O
associated	O
with	O
death	O
and	O
very	O
low	O
levels	O
with	O
recovery	O
.	O

Baseline	O
MBF	O
in	O
females	O
was	O
significantly	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
higher	O
than	O
in	O
males	O
.	O

Delayed	O
or	O
paradoxically	O
emptying	O
regions	O
of	O
the	O
left	O
ventricle	O
were	O
detected	O
by	O
a	O
relatively	O
new	O
nuclear	O
technique	O
-	O
-	O
phase	O
imaging	O
.	O

The	O
11	O
;	O
22	O
chromosomal	O
translocation	O
specifically	O
linked	O
to	O
Ewing	O
sarcoma	O
and	O
primitive	O
neuroectodermal	O
tumor	O
results	O
in	O
a	O
chimeric	O
molecule	O
fusing	O
the	O
amino	O
-	O
terminal	O
-	O
encoding	O
portion	O
of	O
the	O
EWS	B-protein
gene	I-protein
to	O
the	O
carboxyl	O
-	O
terminal	O
DNA	O
-	O
binding	O
domain	O
encoded	O
by	O
the	O
FLI1	B-protein
gene	I-protein
.	O

Immediately	O
after	O
surgery	O
,	O
dialysate	O
PGE2	O
and	O
adenosine	O
concentrations	O
were	O
3	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
7	O
and	O
296	O
+	O
/	O
-	O
127	O
nM	O
,	O
respectively	O
.	O

We	O
randomly	O
assigned	O
1	O
,	O
219	O
subjects	O
to	O
receive	O
either	O
the	O
standard	O
three	O
-	O
times	O
-	O
weekly	O
(	O
TIW	O
)	O
interferon	B-protein
alfa	I-protein
-	I-protein
2b	I-protein
dose	O
(	O
3	O
MIU	O
)	O
or	O
the	O
once	O
-	O
weekly	O
(	O
QW	O
)	O
peginterferon	O
alfa	O
-	O
2b	O
(	O
0	O
.	O
5	O
,	O
1	O
.	O
0	O
,	O
or	O
1	O
.	O
5	O
microg	O
/	O
kg	O
)	O
.	O

We	O
show	O
that	O
CBF	B-protein
-	I-protein
A	I-protein
and	O
CBF	B-protein
-	I-protein
C	I-protein
interact	O
with	O
each	O
other	O
to	O
form	O
a	O
CBF	B-protein
-	I-protein
A	I-protein
-	I-protein
CBF	I-protein
-	I-protein
C	I-protein
complex	I-protein
and	O
that	O
CBF	B-protein
-	I-protein
B	I-protein
does	O
not	O
interact	O
with	O
CBF	B-protein
-	I-protein
A	I-protein
or	O
CBF	B-protein
-	I-protein
C	I-protein
individually	O
but	O
that	O
it	O
associates	O
with	O
the	O
CBF	B-protein
-	I-protein
A	I-protein
-	I-protein
CBF	I-protein
-	I-protein
C	I-protein
complex	I-protein
.	O

Low	O
-	O
grade	O
glioma	O
.	O

While	O
Pt	B-protein
;	I-protein
cycH	I-protein
;	I-protein
1	I-protein
and	O
Os	B-protein
;	I-protein
cycH	I-protein
;	I-protein
1	I-protein
were	O
expressed	O
in	O
all	O
tissues	O
examined	O
,	O
the	O
transcripts	O
accumulated	O
abundantly	O
in	O
dividing	O
cells	O
.	O

In	O
patients	O
in	O
group	O
A	O
(	O
`	O
`	O
normal	O
'	O
'	O
CI	O
)	O
,	O
the	O
CI	O
,	O
heart	O
rate	O
and	O
the	O
mean	O
circumferential	O
fiber	O
shortening	O
velocity	O
(	O
mVCF	O
)	O
were	O
normal	O
,	O
but	O
the	O
TPR	O
was	O
increased	O
significantly	O
.	O

The	O
other	O
patients	O
continued	O
the	O
trial	O
with	O
single	O
daily	O
doses	O
of	O
monotherapy	O
.	O

Potency	O
of	O
enflurane	O
in	O
dogs	O
:	O
comparison	O
with	O
halothane	O
and	O
isoflurane	O
.	O

Oxfendazole	O
,	O
which	O
was	O
active	O
for	O
the	O
shortest	O
time	O
(	O
about	O
65	O
days	O
)	O
from	O
the	O
start	O
of	O
grazing	O
(	O
May	O
1	O
)	O
,	O
produced	O
a	O
78	O
.	O
1	O
per	O
cent	O
reduction	O
in	O
Ostertagia	O
species	O
and	O
an	O
84	O
.	O
4	O
per	O
cent	O
reduction	O
in	O
D	O
viviparus	O
.	O

METHODS	O
:	O
93	O
female	O
and	O
43	O
male	O
patients	O
undergoing	O
thyroid	O
surgery	O
were	O
stratified	O
according	O
to	O
gender	O
and	O
then	O
randomised	O
to	O
receive	O
double	O
-	O
blind	O
one	O
of	O
four	O
antiemetic	O
regimes	O
:	O
50	O
mg	O
dolasetron	O
given	O
orally	O
45	O
minutes	O
prior	O
to	O
induction	O
of	O
anaesthesia	O
(	O
group	O
I	O
)	O
,	O
12	O
.	O
5	O
mg	O
dolasetron	O
given	O
intravenously	O
during	O
induction	O
of	O
anaesthesia	O
(	O
group	O
II	O
)	O
,	O
1	O
.	O
25	O
mg	O
DHB	B-protein
given	O
intravenously	O
during	O
induction	O
of	O
anaesthesia	O
(	O
group	O
III	O
)	O
or	O
placebo	O
(	O
group	O
IV	O
)	O
.	O

The	O
specific	O
interaction	O
between	O
a	O
defined	O
structural	O
element	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
mRNA	O
(	O
RRE	B-protein
,	O
the	O
Rev	B-protein
response	I-protein
element	I-protein
)	O
and	O
the	O
virus	B-protein
-	I-protein
encoded	I-protein
protein	I-protein
Rev	I-protein
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
the	O
export	O
of	O
unspliced	O
or	O
singly	O
spliced	O
mRNA	O
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O

The	O
4	O
degrees	O
stimuli	O
were	O
found	O
to	O
elicit	O
scalp	O
distributions	O
for	O
the	O
pattern	O
reversal	O
P100	O
and	O
the	O
pattern	O
onset	O
C1	O
consistent	O
with	O
striate	O
and	O
extrastriate	O
visual	O
cortical	O
origins	O
respectively	O
.	O

In	O
conclusion	O
,	O
these	O
observations	O
demonstrated	O
that	O
stratification	O
of	O
acute	O
MI	O
patients	O
by	O
plasma	O
ANF	B-protein
level	O
is	O
a	O
useful	O
non	O
-	O
invasive	O
method	O
for	O
predicting	O
prognosis	O
and	O
for	O
identifying	O
individuals	O
at	O
high	O
risk	O
of	O
cardiac	O
death	O
.	O

Heat	O
-	O
inducible	O
CAT	B-protein
activity	O
was	O
detectable	O
when	O
additional	O
sequences	O
from	O
the	O
native	O
promoter	O
containing	O
three	O
CCAAT	O
boxes	O
and	O
a	O
single	O
HSE	B-protein
were	O
present	O
in	O
the	O
constructions	O
.	O

Characterization	O
of	O
a	O
Xenopus	B-protein
laevis	I-protein
CXC	I-protein
chemokine	I-protein
receptor	I-protein
4	I-protein
:	O
implications	O
for	O
hematopoietic	O
cell	O
development	O
in	O
the	O
vertebrate	O
embryo	O
.	O

Moreover	O
,	O
the	O
hypoxia	O
-	O
induced	O
expression	O
of	O
the	O
endogenous	O
Epo	B-protein
gene	I-protein
was	O
significantly	O
inhibited	O
in	O
Hep3B	O
cells	O
stably	O
transfected	O
with	O
HNF	B-protein
-	I-protein
4	I-protein
delta	I-protein
C	I-protein
.	O

The	O
subjects	O
were	O
shown	O
to	O
be	O
capable	O
of	O
assessing	O
integrally	O
the	O
value	O
of	O
accelerations	O
and	O
estimating	O
it	O
with	O
an	O
error	O
of	O
0	O
.	O
1	O
-	O
0	O
.	O
12	O
g	O
.	O

Two	O
XPG	B-protein
regions	I-protein
with	O
putative	O
NLS	O
[	O
amino	O
acid	O
(	O
AA	O
)	O
coordinates	O
:	O
NLS	O
-	O
B	O
(	O
AA	O
1057	O
-	O
1074	O
)	O
and	O
NLS	O
-	O
C	O
(	O
AA	O
1171	O
-	O
1185	O
)	O
]	O
were	O
each	O
shown	O
to	O
independently	O
localize	O
the	O
beta	B-protein
-	I-protein
gal	I-protein
extensively	O
(	O
>	O
80	O
%	O
)	O
to	O
the	O
nucleus	O
of	O
HeLa	O
cells	O
.	O

Although	O
metabolized	O
by	O
the	O
cytochrome	B-protein
P	I-protein
-	I-protein
450	I-protein
(	O
CYP	B-protein
)	O
system	O
,	O
venlafaxine	O
inhibits	O
CYP	B-protein
2D6	I-protein
and	I-protein
3A4	I-protein
to	O
a	O
far	O
lesser	O
extent	O
than	O
do	O
the	O
SSRIs	O
.	O

In	O
addition	O
,	O
and	O
in	O
support	O
of	O
a	O
mediating	O
role	O
of	O
STATs	B-protein
in	O
the	O
activation	O
of	O
the	O
p21	B-protein
promoter	I-protein
,	O
overexpression	O
of	O
Stat3	B-protein
potentiated	O
the	O
cytokine	O
effect	O
on	O
the	O
p21	B-protein
promoter	I-protein
;	O
whereas	O
a	O
dominant	B-protein
negative	I-protein
Stat3	I-protein
,	O
or	O
a	O
mutation	O
of	O
the	O
STAT	B-protein
response	I-protein
element	I-protein
on	O
the	O
promoter	O
,	O
significantly	O
reduced	O
the	O
cytokine	O
effect	O
.	O

Extramedullary	O
relapse	O
in	O
childhood	O
leukemia	O
.	O

Testing	O
for	O
serum	B-protein
IgM	I-protein
binding	O
to	O
GM1	O
ganglioside	O
in	O
clinical	O
practice	O
.	O

Using	O
GST	B-protein
-	I-protein
PKR	I-protein
fusion	I-protein
chromatography	O
,	O
direct	O
physical	O
interaction	O
between	O
the	O
mouse	O
and	O
human	B-protein
PKR	I-protein
homologs	I-protein
was	O
established	O
.	O

Sp1	O
'	O
s	O
role	O
in	O
transactivation	O
of	O
the	O
pgp2	B-protein
/	I-protein
mdr1b	I-protein
promoter	I-protein
was	O
tested	O
in	O
Drosophila	O
Schneider	O
cells	O
.	O

Prostaglandins	O
and	O
gallstones	O
.	O

Studies	O
were	O
performed	O
on	O
several	O
superficial	O
veins	O
from	O
the	O
rabbit	O
face	O
to	O
examine	O
the	O
relationship	O
between	O
beta	B-protein
adrenoceptor	I-protein
subtype	I-protein
distribution	O
,	O
intrinsic	O
myogenic	O
tone	O
and	O
sympathetic	O
nerve	O
innervation	O
.	O

Several	O
lines	O
of	O
evidence	O
demonstrate	O
that	O
this	O
growth	O
inhibition	O
requires	O
active	O
PKA	B-protein
subunits	I-protein
and	O
cAMP	O
:	O
(	O
i	O
)	O
this	O
phenotype	O
is	O
dependent	O
on	O
cAMP	O
since	O
it	O
is	O
not	O
seen	O
in	O
a	O
strain	O
lacking	O
adenylyl	B-protein
cyclase	I-protein
activity	O
,	O
but	O
the	O
growth	O
rate	O
of	O
these	O
transformants	O
is	O
slower	O
when	O
exogenous	O
cAMP	O
is	O
added	O
;	O
(	O
ii	O
)	O
normal	O
growth	O
occurs	O
when	O
wild	O
-	O
type	O
RI	B-protein
cDNA	O
is	O
replaced	O
by	O
a	O
mutant	B-protein
RI	I-protein
cDNA	I-protein
encoding	O
a	O
RI	B-protein
protein	I-protein
with	O
reduced	O
cAMP	O
binding	O
;	O
and	O
(	O
iii	O
)	O
the	O
growth	O
-	O
inhibited	O
phenotype	O
of	O
the	O
transformed	O
BL21	O
(	O
DE3	O
)	O
cells	O
requires	O
soluble	O
,	O
active	O
C	B-protein
alpha	I-protein
protein	I-protein
.	O

The	O
author	O
analyzes	O
extensive	O
own	O
data	O
based	O
on	O
study	O
into	O
particular	O
features	O
of	O
cardiovascular	O
disorders	O
in	O
chronic	O
renal	O
impairement	O
with	O
making	O
use	O
of	O
modern	O
diagnostic	O
tools	O
.	O

Nuclear	B-protein
protein	I-protein
phosphatase	I-protein
2A	I-protein
dephosphorylates	O
protein	B-protein
kinase	I-protein
A	O
-	O
phosphorylated	O
CREB	B-protein
and	O
regulates	O
CREB	B-protein
transcriptional	O
stimulation	O
.	O

Antileukoproteinase	B-protein
(	O
ALP	B-protein
)	O
is	O
a	O
low	O
mol	O
wt	O
mucosal	O
secretory	O
protein	O
which	O
,	O
in	O
human	O
tissues	O
,	O
inhibits	O
the	O
activities	O
of	O
the	O
neutral	O
serine	B-protein
lysosomal	I-protein
proteinases	I-protein
elastase	I-protein
and	O
cathepsin	B-protein
-	I-protein
G	I-protein
.	O

No	O
dominant	O
clinical	O
factor	O
of	O
risk	O
was	O
found	O
,	O
but	O
multiple	O
regression	O
analysis	O
identified	O
age	O
,	O
body	O
surface	O
area	O
,	O
valve	O
size	O
,	O
shop	O
order	O
fracture	O
rate	O
,	O
and	O
manufacturing	O
period	O
as	O
risk	O
factors	O
for	O
OSF	O
.	O

There	O
was	O
however	O
,	O
no	O
significant	O
difference	O
in	O
the	O
prevalence	O
of	O
chronic	O
respiratory	O
symptoms	O
between	O
animal	O
food	O
workers	O
with	O
positive	O
and	O
negative	O
skin	O
tests	O
to	O
house	O
dust	O
or	O
to	O
fish	O
flour	O
or	O
among	O
those	O
with	O
increased	O
or	O
normal	O
IgE	B-protein
(	O
except	O
for	O
dyspnea	O
)	O
.	O

This	O
protein	O
with	O
a	O
hydrophobic	O
amino	O
terminus	O
appears	O
to	O
be	O
a	O
secreted	O
protein	O
.	O

Initial	O
estimates	O
indicate	O
that	O
27	O
,	O
193	O
people	O
are	O
either	O
in	O
receipt	O
of	O
or	O
in	O
need	O
of	O
mental	O
handicap	O
services	O
.	O

Significance	O
of	O
the	O
biopsy	O
site	O
of	O
the	O
latissimus	O
dorsi	O
muscle	O
for	O
fiber	O
typing	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
was	O
designed	O
to	O
analyze	O
the	O
common	O
cause	O
of	O
asthenopia	O
,	O
mixed	O
astigmatism	O
.	O

The	O
5	O
-	O
year	O
OS	O
for	O
stage	O
IIIB	O
was	O
30	O
.	O
9	O
%	O
,	O
compared	O
to	O
7	O
.	O
8	O
%	O
for	O
stage	O
IV	O
.	O

The	O
simultaneous	O
recording	O
of	O
electrical	O
activity	O
from	O
the	O
surface	O
electrocardiogram	O
,	O
right	O
ventricular	O
apex	O
,	O
His	O
bundle	O
,	O
high	O
right	O
atrium	O
,	O
coronary	O
sinus	O
,	O
with	O
or	O
without	O
a	O
roving	O
mapping	O
catheter	O
,	O
enables	O
us	O
to	O
precisely	O
map	O
the	O
electrical	O
activation	O
sequence	O
in	O
the	O
heart	O
.	O

As	O
with	O
the	O
murine	B-protein
and	I-protein
human	I-protein
mb	I-protein
-	I-protein
1	I-protein
genes	I-protein
,	O
the	O
5	O
'	O
region	O
of	O
the	O
bovine	B-protein
mb	I-protein
-	I-protein
1	I-protein
gene	I-protein
lacked	O
a	O
TATA	O
box	O
.	O

Furthermore	O
,	O
analysis	O
of	O
the	O
E2	B-protein
proteins	I-protein
present	O
in	O
various	O
cell	O
lines	O
harboring	O
specific	O
BPV	O
-	O
1	O
mutants	O
,	O
including	O
the	O
2558	B-protein
acceptor	I-protein
mutant	I-protein
,	O
proves	O
that	O
alternate	O
modes	O
of	O
E2	B-protein
expression	O
exist	O
.	O

When	O
statistically	O
analyzed	O
in	O
various	O
subgroupings	O
,	O
the	O
obtained	O
average	O
sedimentation	O
coefficients	O
and	O
polydispersity	O
profiles	O
supported	O
the	O
following	O
conclusions	O
:	O
(	O
a	O
)	O
loss	O
of	O
proteoglycan	O
aggregation	O
and	O
sedimentability	O
is	O
confirmed	O
to	O
be	O
a	O
primary	O
sign	O
of	O
cartilage	O
matrix	O
degradation	O
;	O
(	O
b	O
)	O
higher	O
S	O
values	O
for	O
proteoglycans	O
of	O
the	O
high	O
weight	O
(	O
HW	O
)	O
-	O
bearing	O
areas	O
and	O
lower	O
values	O
for	O
those	O
of	O
the	O
low	O
weight	O
(	O
LW	O
)	O
-	O
bearing	O
areas	O
were	O
a	O
typical	O
finding	O
in	O
normal	O
cartilage	O
samples	O
;	O
(	O
c	O
)	O
inversion	O
of	O
this	O
pattern	O
was	O
indicative	O
of	O
matrix	O
degradation	O
,	O
suggesting	O
that	O
the	O
HW	O
regions	O
are	O
more	O
affected	O
than	O
the	O
LW	O
-	O
bearing	O
areas	O
;	O
(	O
d	O
)	O
the	O
average	O
S	O
value	O
distribution	O
across	O
cartilage	O
thickness	O
tended	O
to	O
resemble	O
the	O
corresponding	O
proteoglycan	O
content	O
versus	O
distance	O
from	O
articular	O
surface	O
;	O
and	O
(	O
e	O
)	O
the	O
deepest	O
cartilage	O
layer	O
had	O
,	O
in	O
most	O
cases	O
,	O
the	O
smallest	O
amount	O
of	O
aggregates	O
while	O
the	O
highest	O
average	O
sedimentability	O
was	O
observed	O
at	O
the	O
middle	O
zone	O
of	O
the	O
normal	O
samples	O
.	O

Cyclins	B-protein
are	O
one	O
of	O
the	O
pivotal	O
determinants	O
regulating	O
cell	O
cycle	O
progression	O
.	O

A	O
centromere	O
in	O
S	O
.	O
cerevisiae	O
consists	O
of	O
a	O
region	O
of	O
DNA	O
,	O
approximately	O
150	O
bp	O
in	O
length	O
,	O
containing	O
three	O
important	O
sequence	O
elements	O
,	O
which	O
are	O
folded	O
with	O
proteins	O
into	O
a	O
specific	O
conformation	O
in	O
the	O
chromatin	O
(	O
the	O
yeast	O
kinetochore	O
)	O
.	O

Two	O
scintigraphic	O
methods	O
,	O
resting	O
dipyridamole	O
and	O
exercise	O
thallium	O
-	O
201	O
myocardial	O
perfusion	O
imaging	O
,	O
to	O
detect	O
and	O
localize	O
coronary	O
artery	O
stenosis	O
were	O
compared	O
in	O
32	O
patients	O
suffering	O
from	O
coronary	O
artery	O
disease	O
.	O

In	O
all	O
sessions	O
under	O
IFN	B-protein
,	O
the	O
latency	O
of	O
the	O
P100	O
component	O
of	O
the	O
VEP	O
was	O
shortened	O
as	O
compared	O
to	O
baseline	O
conditions	O
.	O

CONCLUSIONS	O
:	O
Our	O
meta	O
-	O
analysis	O
of	O
randomized	O
controlled	O
trials	O
of	O
HRT	O
noted	O
a	O
statistically	O
significant	O
reduction	O
in	O
nonvertebral	O
fractures	O
.	O

Prevention	O
of	O
transfusion	O
reactions	O
by	O
the	O
use	O
of	O
saline	O
washed	O
red	O
blood	O
cells	O
.	O

The	O
delta	B-protein
srb10	I-protein
mutation	I-protein
also	O
influenced	O
on	O
the	O
transcript	O
levels	O
of	O
meiosis	O
-	O
inducing	O
genes	O
called	O
IME1	B-protein
and	O
IME2	B-protein
:	O
the	O
mutation	O
elevated	O
the	O
transcript	O
level	O
of	O
IME1	B-protein
but	O
reduced	O
that	O
of	O
IME2	B-protein
,	O
resulting	O
in	O
partial	O
defects	O
in	O
premeiotic	O
DNA	O
synthesis	O
and	O
meiosis	O
.	O

After	O
screening	O
the	O
Berkeley	O
Drosophila	O
Genome	O
Project	O
database	O
with	O
sequences	O
from	O
a	O
recently	O
characterized	O
Leu	B-protein
-	I-protein
rich	I-protein
repeats	I-protein
-	I-protein
containing	I-protein
G	I-protein
protein	I-protein
-	I-protein
coupled	I-protein
receptor	I-protein
(	O
LGR	B-protein
)	O
from	O
Drosophila	O
(	O
DLGR	B-protein
-	I-protein
1	I-protein
)	O
,	O
we	O
identified	O
a	O
second	O
gene	O
for	O
a	O
different	O
LGR	B-protein
(	O
DLGR	B-protein
-	I-protein
2	I-protein
)	O
and	O
cloned	O
its	O
cDNA	O
.	O

Takahashi	O
,	O
H	O
.	O

The	O
telomerase	B-protein
RNA	I-protein
-	I-protein
protein	I-protein
complex	I-protein
responsible	O
for	O
maintenance	O
of	O
telomeric	O
DNA	O
at	O
chromosome	O
ends	O
,	O
is	O
usually	O
inactive	O
in	O
most	O
primary	O
somatic	O
human	O
cells	O
,	O
but	O
is	O
specifically	O
activated	O
with	O
in	O
vitro	O
immortalization	O
and	O
during	O
tumorigenesis	O
.	O

Interferon	B-protein
type	I-protein
I	I-protein
in	O
protective	O
body	O
reactions	O
in	O
an	O
experimental	O
Klebsiella	O
infection	O
.	O

In	O
addition	O
,	O
the	O
consensus	O
amino	O
acid	O
motif	O
for	O
serine	B-protein
threonine	I-protein
receptor	I-protein
kinases	I-protein
was	O
also	O
present	O
.	O

However	O
,	O
despite	O
its	O
relationship	O
to	O
the	O
TR	B-protein
,	O
Rev	B-protein
-	I-protein
Erb	I-protein
bound	O
poorly	O
to	O
TR	B-protein
binding	I-protein
sites	I-protein
.	O

These	O
data	O
suggest	O
that	O
the	O
G	B-protein
-	I-protein
protein	I-protein
gene	I-protein
family	I-protein
may	O
be	O
distributed	O
over	O
at	O
least	O
two	O
human	O
chromosomes	O
.	O

Two	O
potential	O
regulatory	O
sequences	O
for	O
DNA	O
binding	O
proteins	O
were	O
found	O
in	O
the	O
non	O
-	O
coding	O
5	O
'	O
region	O
:	O
a	O
HAP2	B-protein
/	I-protein
HAP3	I-protein
consensus	I-protein
recognition	I-protein
sequence	I-protein
at	O
nucleotide	O
-	O
154	O
and	O
a	O
BAF1	B-protein
consensus	I-protein
recognition	I-protein
sequence	I-protein
at	O
nucleotide	O
-	O
136	O
.	O

Transfection	O
experiments	O
using	O
preformed	O
triplexes	O
with	O
a	O
reporter	O
plasmid	O
containing	O
the	O
collagen	B-protein
promoter	I-protein
sequence	I-protein
showed	O
significant	O
inhibition	O
of	O
transcription	O
when	O
compared	O
with	O
a	O
control	O
phosphorothioate	O
ODN	O
.	O

The	O
nucleotide	O
sequences	O
at	O
the	O
5	O
'	O
and	O
3	O
'	O
ends	O
of	O
these	O
introns	O
are	O
characteristic	O
of	O
spliced	O
transcripts	O
from	O
eukaryotic	O
protein	O
-	O
encoding	O
genes	O
,	O
with	O
one	O
significant	O
difference	O
;	O
i	O
.	O
e	O
.	O
,	O
the	O
5	O
'	O
end	O
of	O
the	O
LAT	B-protein
intron	I-protein
is	O
GC	O
instead	O
of	O
the	O
consensus	O
sequence	O
GT	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
Tax	B-protein
activation	O
of	O
NF	B-protein
-	I-protein
kappa	I-protein
B	I-protein
/	I-protein
Rel	I-protein
involves	O
phosphorylation	O
and	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
RelA	B-protein
(	O
p65	B-protein
)	O
-	O
mediated	O
induction	O
of	O
the	O
c	B-protein
-	I-protein
rel	I-protein
gene	I-protein
.	O

Habituation	O
of	O
completely	O
isolated	O
neurons	O
of	O
the	O
edible	O
snail	O
to	O
electrical	O
stimulation	O
.	O

A	O
synergistic	O
effect	O
on	O
HCK	B-protein
promoter	I-protein
activity	O
was	O
observed	O
at	O
high	O
concentrations	O
of	O
Sp1	B-protein
.	O

Further	O
characterization	O
of	O
these	O
putative	O
Hoxa	B-protein
-	I-protein
1	I-protein
target	I-protein
genes	I-protein
will	O
aid	O
in	O
delineating	O
the	O
functions	O
of	O
the	O
Hoxa	B-protein
-	I-protein
1	I-protein
protein	I-protein
in	O
the	O
differentiation	O
processes	O
which	O
occur	O
during	O
embryogenesis	O
.	O

The	O
ANB1	B-protein
locus	I-protein
of	O
Saccharomyces	O
cerevisiae	O
encodes	O
the	O
protein	B-protein
synthesis	I-protein
initiation	I-protein
factor	I-protein
eIF	I-protein
-	I-protein
4D	I-protein
.	O

Although	O
the	O
risk	O
of	O
malformation	O
in	O
children	O
born	O
after	O
ICSI	O
is	O
not	O
increased	O
there	O
is	O
an	O
increased	O
risk	O
to	O
transmit	O
genetic	O
abnormalities	O
in	O
case	O
of	O
NOA	O
(	O
such	O
as	O
the	O
rate	O
of	O
sex	O
chromosome	O
,	O
or	O
microdeletions	O
of	O
the	O
Y	O
chromosome	O
)	O
and	O
in	O
case	O
of	O
congenital	O
OA	O
(	O
mutations	O
of	O
the	O
cystic	B-protein
fibrosis	I-protein
gene	I-protein
)	O
.	O

Mg2	O
+	O
and	O
Mn2	O
+	O
compete	O
for	O
binding	O
sites	O
,	O
with	O
the	O
former	O
having	O
lower	O
affinity	O
.	O

Promoter	O
activities	O
were	O
estimated	O
using	O
beta	B-protein
-	I-protein
glucuronidase	I-protein
and	O
neomycin	B-protein
phosphotransferase	I-protein
II	I-protein
reporter	I-protein
gene	I-protein
systems	I-protein
.	O

Timing	O
of	O
symptoms	O
and	O
oocyst	O
excretion	O
in	O
human	O
cryptosporidiosis	O
.	O

The	O
first	O
gene	O
codes	O
for	O
a	O
protein	O
containing	O
11	O
cystein	O
residues	O
in	O
an	O
arrangement	O
typical	O
for	O
Fe	B-protein
/	I-protein
S	I-protein
proteins	I-protein
.	O

In	O
7	O
of	O
9	O
cases	O
,	O
the	O
enhancer	O
is	O
fused	O
to	O
the	O
c	B-protein
-	I-protein
myc	I-protein
bearing	I-protein
sequences	I-protein
of	O
chromosome	O
8	O
.	O

The	O
critical	O
mutations	O
were	O
likely	O
to	O
have	O
been	O
multiple	O
and	O
dispersed	O
,	O
including	O
elongation	O
of	O
the	O
TM	B-protein
and	O
Nef	B-protein
coding	I-protein
sequences	I-protein
;	O
changes	O
in	O
RNA	O
splice	O
donor	O
and	O
acceptor	O
sites	O
,	O
TATA	O
box	O
sites	O
,	O
and	O
Sp1	B-protein
sites	I-protein
;	O
multiple	O
changes	O
in	O
the	O
V2	B-protein
region	I-protein
of	O
SU	B-protein
,	O
including	O
a	O
consensus	O
neutralization	O
epitope	O
;	O
and	O
five	O
new	O
N	O
-	O
linked	O
glycosylation	O
sites	O
in	O
SU	B-protein
.	O

These	O
patients	O
failed	O
to	O
respond	O
to	O
intravenous	O
cyclophosphamide	O
and	O
steroids	O
and	O
were	O
then	O
changed	O
to	O
receive	O
oral	O
cyclosporine	O
A	O
,	O
at	O
a	O
dose	O
of	O
5	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Each	O
immunoprecipitate	O
contained	O
a	O
complex	O
of	O
N1	B-protein
(	I-protein
deltaEC	I-protein
)	I-protein
and	O
CBF1	B-protein
.	O

In	O
vitro	O
evaluation	O
of	O
the	O
mucolytic	O
action	O
of	O
urea	O
.	O

The	O
hBRAG	B-protein
gene	I-protein
was	O
localized	O
to	O
the	O
long	O
arm	O
of	O
chromosome	O
10	O
(	O
10q26	O
)	O
.	O

Dopamine	B-protein
receptor	I-protein
blockade	O
and	O
the	O
neuroleptics	O
,	O
a	O
crystallographic	O
study	O
.	O

Pharmacologic	O
aspects	O
of	O
neonatal	O
hyperbilirubinemia	O
.	O

Of	O
the	O
21	O
quadrants	O
positive	O
in	O
the	O
controls	O
,	O
17	O
were	O
correlated	O
with	O
previously	O
detected	O
jaw	O
pathoses	O
.	O

In	O
15	O
ventilator	O
-	O
dependent	O
,	O
SB	O
,	O
and	O
actively	O
expiring	O
patients	O
,	O
we	O
found	O
that	O
the	O
difference	O
PEEP	O
(	O
i	O
)	O
,	O
dyn	O
-	O
Pga	O
,	O
total	O
decay	O
(	O
mean	O
+	O
/	O
-	O
SD	O
,	O
5	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
9	O
cm	O
H	O
(	O
2	O
)	O
O	O
)	O
was	O
quite	O
similar	O
to	O
PEEP	O
(	O
i	O
)	O
,	O
dyn	O
ref	O
(	O
5	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
cm	O
H	O
(	O
2	O
)	O
O	O
)	O
.	O

Perfusion	O
technique	O
for	O
perfusion	O
-	O
assisted	O
direct	O
coronary	O
artery	O
bypass	O
(	O
PADCAB	O
)	O
.	O

This	O
phosphorylation	O
can	O
be	O
catalyzed	O
by	O
a	O
break	O
-	O
ended	O
double	O
-	O
stranded	O
DNA	O
-	O
activated	O
protein	B-protein
kinase	I-protein
activity	O
from	O
the	O
sea	O
urchin	O
nucleus	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
we	O
also	O
show	O
that	O
cdk7	B-protein
may	O
phosphorylate	O
the	O
carboxy	O
-	O
terminal	O
domain	O
(	O
CTD	O
)	O
of	O
RNA	B-protein
pol	I-protein
II	I-protein
in	O
the	O
absence	O
of	O
promoter	O
opening	O
.	O

Delayed	O
gallbladder	O
visualization	O
and	O
reduction	O
in	O
ejection	O
fraction	O
were	O
sensitive	O
but	O
nonspecific	O
indicators	O
of	O
biliary	O
disease	O
.	O

Managing	O
vertigo	O
and	O
vertigo	O
syndromes	O
in	O
the	O
elderly	O

Mean	O
intake	O
of	O
vitamin	O
A	O
amounted	O
to	O
1	O
.	O
1	O
and	O
0	O
.	O
9	O
mg	O
RE	O
/	O
day	O
for	O
men	O
and	O
women	O
,	O
respectively	O
;	O
the	O
contributions	O
of	O
meat	O
,	O
fats	O
and	O
oils	O
,	O
vegetables	O
and	O
dairy	O
products	O
to	O
total	O
intake	O
were	O
35	O
%	O
,	O
24	O
%	O
,	O
16	O
%	O
,	O
and	O
16	O
%	O
,	O
respectively	O
.	O

The	O
risk	O
for	O
these	O
complications	O
is	O
increased	O
by	O
the	O
following	O
factors	O
:	O
multiple	O
gestation	O
,	O
the	O
combination	O
of	O
magnesium	O
sulfate	O
and	O
beta	O
-	O
adrenergic	O
agonist	O
,	O
and	O
the	O
use	O
of	O
adrenocortico	O
-	O
steroids	O
to	O
hasten	O
fetal	O
pulmonary	O
maturity	O
.	O

Human	B-protein
rIL	I-protein
-	I-protein
3	I-protein
expressed	O
in	O
COS7	O
cells	O
has	O
multipotential	O
CSF	B-protein
activity	O
in	O
semisolid	O
cultures	O
of	O
bone	O
marrow	O
cells	O
,	O
and	O
selectively	O
induced	O
the	O
proliferation	O
of	O
My	O
-	O
10	O
+	O
marrow	O
or	O
cord	O
blood	O
cells	O
in	O
liquid	O
cultures	O
.	O

EBER1	B-protein
mRNA	I-protein
,	O
a	O
consistent	O
marker	O
of	O
viral	O
latency	O
,	O
was	O
positive	O
in	O
all	O
PEL	O
cases	O
,	O
although	O
at	O
lower	O
levels	O
than	O
in	O
the	O
non	O
-	O
PEL	O
controls	O
due	O
to	O
EBER1	B-protein
expression	O
by	O
only	O
a	O
variable	O
subset	O
of	O
lymphoma	O
cells	O
.	O

Interestingly	O
,	O
one	O
IRF	B-protein
binding	I-protein
site	I-protein
was	O
found	O
within	O
the	O
IRF	B-protein
-	I-protein
2	I-protein
promoter	I-protein
,	O
and	O
expression	O
of	O
the	O
IRF	B-protein
-	I-protein
2	I-protein
gene	I-protein
was	O
affected	O
by	O
both	O
transient	O
and	O
stable	O
IRF	B-protein
-	I-protein
1	I-protein
expression	O
.	O

The	O
domains	O
involved	O
in	O
superactivation	O
appear	O
to	O
be	O
a	O
subset	O
of	O
those	O
necessary	O
to	O
achieve	O
synergistic	O
activation	O
.	O

Effects	O
of	O
posteroventral	O
pallidotomy	O
on	O
Parkinson	O
'	O
s	O
disease	O
.	O

We	O
also	O
demonstrate	O
that	O
preformed	O
triplexes	O
are	O
quite	O
stable	O
when	O
precipitated	O
with	O
ethanol	O
and	O
resuspended	O
in	O
water	O
.	O

2	O
.	O

All	O
patients	O
were	O
evaluable	O
for	O
toxicity	O
and	O
9	O
for	O
response	O
.	O

It	O
was	O
found	O
that	O
increase	O
in	O
the	O
RH	O
level	O
boosts	O
the	O
current	O
values	O
by	O
2	O
-	O
3	O
orders	O
of	O
magnitude	O
;	O
contrariwise	O
,	O
the	O
voltage	O
values	O
rise	O
by	O
about	O
three	O
times	O
with	O
drop	O
in	O
the	O
RH	O
.	O

Both	O
verapamil	O
and	O
propranolol	O
can	O
exhibit	O
additive	O
effects	O
with	O
adenosine	O
in	O
prolonging	O
AV	O
nodal	O
conduction	O
time	O
;	O
however	O
,	O
only	O
verapamil	O
can	O
reduce	O
the	O
dose	O
of	O
adenosine	O
required	O
to	O
produce	O
AV	O
nodal	O
block	O
.	O

DNA	O
blot	O
hybridization	O
suggests	O
that	O
the	O
rat	O
genome	O
may	O
contain	O
more	O
than	O
one	O
gene	O
encoding	O
PtdIns	B-protein
transfer	I-protein
protein	I-protein
.	O

The	O
deduced	O
protein	O
sequence	O
was	O
88	O
%	O
homologous	O
to	O
that	O
of	O
hNUC	B-protein
I	I-protein
,	O
isolated	O
from	O
human	O
osteosarcoma	O
cells	O
.	O

The	O
experimental	O
end	O
points	O
were	O
the	O
time	O
required	O
for	O
treated	O
tumors	O
to	O
reach	O
3	O
times	O
their	O
treatment	O
size	O
,	O
the	O
survival	O
of	O
stem	O
cells	O
in	O
the	O
duodenal	O
crypts	O
,	O
and	O
the	O
breathing	O
rate	O
measured	O
early	O
(	O
19	O
-	O
23	O
weeks	O
)	O
and	O
late	O
(	O
41	O
-	O
46	O
weeks	O
)	O
after	O
treatment	O
.	O

Recruitment	O
of	O
an	O
RNA	B-protein
polymerase	I-protein
II	I-protein
complex	I-protein
is	O
mediated	O
by	O
the	O
constitutive	O
activation	O
domain	O
in	O
CREB	B-protein
,	O
independently	O
of	O
CREB	B-protein
phosphorylation	O
.	O

The	O
procedure	O
is	O
less	O
aggressive	O
and	O
painful	O
than	O
sternotomy	O
.	O

Treatment	O
of	O
keratinocytes	O
expressing	O
a	O
normal	O
epidermal	B-protein
growth	I-protein
factor	I-protein
receptor	I-protein
(	O
EGFR	B-protein
)	O
with	O
TGFalpha	B-protein
or	O
epidermal	B-protein
growth	I-protein
factor	I-protein
for	O
5	O
min	O
induced	O
PKCdelta	B-protein
tyrosine	O
phosphorylation	O
.	O

SV	O
increased	O
less	O
in	O
SHR	O
,	O
mainly	O
reflecting	O
the	O
reduced	O
diastolic	O
compliance	O
of	O
the	O
hypertrophied	O
SHR	O
left	O
ventricle	O
and	O
the	O
consequent	O
rightward	O
shift	O
of	O
its	O
Frank	O
-	O
Starling	O
curve	O
.	O

The	O
first	O
transfusion	O
resulted	O
in	O
a	O
platelet	O
increment	O
to	O
32	O
Gpt	O
/	O
l	O
(	O
CCI	O
11	O
)	O
.	O

265	O
,	O
1102	O
-	O
1110	O
)	O
.	O

As	O
an	O
oral	O
,	O
nontoxic	O
compound	O
with	O
a	O
mechanism	O
of	O
action	O
distinct	O
from	O
that	O
of	O
ABL	B-protein
tyrosine	I-protein
kinase	I-protein
inhibition	O
,	O
FTI	O
SCH66336	O
shows	O
promise	O
for	O
the	O
treatment	O
of	O
BCR	O
/	O
ABL	O
-	O
induced	O
leukemia	O
.	O

REM	O
sleep	O
deprivation	O
was	O
performed	O
using	O
the	O
platform	O
technique	O
.	O

Genomic	O
locus	O
of	O
chCTCF	B-protein
contains	O
a	O
GC	O
-	O
rich	O
untranslated	O
exon	O
separated	O
from	O
seven	O
coding	O
exons	O
by	O
a	O
long	O
intron	O
.	O

Heparin	O
(	O
100	O
Ucenter	O
dotkg	O
(	O
minus	O
sign1	O
)	O
center	O
dotday	O
(	O
minus	O
sign1	O
)	O
)	O
was	O
injected	O
subcutaneously	O
to	O
the	O
rats	O
in	O
H	O
group	O
while	O
normal	O
saline	O
to	O
those	O
in	O
N	O
group	O
once	O
a	O
day	O
.	O

Deletion	O
and	O
site	O
-	O
directed	O
mutagenesis	O
localized	O
a	O
novel	O
SF	B-protein
-	I-protein
1	I-protein
regulatory	I-protein
element	I-protein
(	O
TCA	B-protein
GGGCCA	I-protein
;	O
-	O
137	O
to	O
-	O
129	O
)	O
adjacent	O
to	O
a	O
variant	O
cAMP	B-protein
-	I-protein
response	I-protein
element	I-protein
(	O
CRE	B-protein
;	O
-	O
120	O
to	O
-	O
114	O
)	O
.	O

If	O
we	O
apply	O
the	O
finding	O
of	O
non	O
-	O
visualization	O
of	O
the	O
GB	O
at	O
4	O
h	O
post	O
injection	O
as	O
the	O
criterion	O
for	O
the	O
diagnosis	O
of	O
AC	O
,	O
the	O
diagnostic	O
accuracy	O
was	O
only	O
40	O
.	O
7	O
%	O
(	O
11	O
/	O
27	O
)	O
.	O

Regional	O
insertional	O
mutagenesis	O
of	O
specific	O
genes	O
on	O
the	O
CIC5F11	B-protein
/	I-protein
CIC2B9	I-protein
locus	I-protein
of	O
Arabidopsis	O
thaliana	O
chromosome	O
5	O
using	O
the	O
Ac	B-protein
/	I-protein
Ds	I-protein
transposon	I-protein
in	O
combination	O
with	O
the	O
cDNA	O
scanning	O
method	O
.	O

Three	O
of	O
the	O
short	O
ORFs	O
in	O
the	O
central	O
region	O
of	O
BIV	O
have	O
been	O
identified	O
by	O
location	O
and	O
structural	O
similarity	O
to	O
the	O
nonstructural	O
/	O
regulatory	O
genes	O
(	O
vif	B-protein
,	O
tat	B-protein
,	O
and	O
rev	B-protein
)	O
of	O
other	O
lentiviruses	O
;	O
we	O
also	O
discovered	O
two	O
unique	O
ORFs	O
,	O
termed	O
W	B-protein
and	O
Y	B-protein
,	O
which	O
may	O
serve	O
as	O
exons	O
for	O
novel	O
genes	O
.	O

This	O
dependence	O
,	O
however	O
,	O
can	O
be	O
overcome	O
to	O
a	O
large	O
extent	O
by	O
dividing	O
min	O
LVdP	O
/	O
dt	O
by	O
mean	O
aortic	O
pressure	O
.	O

A	O
randomized	O
clinical	O
trial	O
in	O
sixty	O
-	O
two	O
adult	O
patients	O
suffering	O
from	O
typhoid	O
fever	O
,	O
proved	O
by	O
blood	O
and	O
marrow	O
culture	O
,	O
showed	O
that	O
amoxycillin	O
in	O
a	O
dosage	O
schedule	O
of	O
1	O
g	O
8	O
-	O
hourly	O
orally	O
for	O
fourteen	O
days	O
was	O
better	O
than	O
chloramphenicol	O
with	O
regard	O
to	O
clinical	O
and	O
temperature	O
response	O
and	O
in	O
respect	O
of	O
carriers	O
and	O
relapse	O
rates	O
.	O

The	O
systolic	O
pressure	O
gradient	O
(	O
SPG	O
)	O
between	O
the	O
left	O
ventricle	O
(	O
LV	O
)	O
and	O
left	O
atrium	O
(	O
LA	O
)	O
was	O
obtained	O
from	O
high	O
-	O
fidelity	O
pressure	O
transducers	O
.	O

When	O
multiple	O
copies	O
of	O
the	O
IL	B-protein
-	I-protein
1	I-protein
beta	I-protein
NF	I-protein
-	I-protein
kappa	I-protein
B	I-protein
site	I-protein
were	O
linked	O
to	O
an	O
enhancerless	O
simian	O
virus	O
40	O
promoter	O
,	O
this	O
element	O
was	O
able	O
to	O
mediate	O
phorbol	O
ester	O
-	O
or	O
lipopolysaccharide	O
-	O
inducible	O
gene	O
expression	O
.	O

The	O
ability	O
of	O
BCL	B-protein
-	I-protein
6	I-protein
to	O
function	O
as	O
a	O
transcriptional	O
repressor	O
may	O
contribute	O
to	O
its	O
ability	O
to	O
transform	O
B	O
lymphocytes	O
in	O
diffuse	O
large	O
cell	O
lymphoma	O
.	O

Recipients	O
with	O
acute	O
leukaemia	O
in	O
first	O
remission	O
or	O
chronic	O
myeloid	O
leukaemia	O
in	O
first	O
chronic	O
phase	O
were	O
analysed	O
as	O
good	O
risk	O
,	O
and	O
those	O
beyond	O
these	O
stages	O
,	O
as	O
poor	O
risk	O
patients	O
.	O

It	O
can	O
also	O
be	O
used	O
to	O
examine	O
various	O
laryngeal	O
parameters	O
obtained	O
from	O
videotaped	O
endoscopic	O
and	O
stroboscopic	O
examinations	O
.	O

Diagnostic	O
value	O
of	O
serum	B-protein
myoglobin	I-protein
in	O
cases	O
of	O
neuromuscular	O
disease	O
.	O

We	O
found	O
the	O
following	O
:	O
Specific	O
mutations	O
affected	O
the	O
precise	O
carbohydrate	O
structure	O
and	O
folding	O
of	O
the	O
HA	B-protein
trimer	I-protein
.	O

The	O
patients	O
undergoing	O
VTLB	O
had	O
significantly	O
shorter	O
operative	O
times	O
(	O
VTLB	O
,	O
100	O
.	O
2	O
+	O
/	O
-	O
27	O
.	O
2	O
min	O
.	O
vs	O
OLB	O
,	O
119	O
.	O
8	O
+	O
/	O
-	O
42	O
.	O
6	O
min	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
less	O
blood	O
loss	O
(	O
VTLB	O
,	O
4	O
.	O
7	O
+	O
/	O
-	O
14	O
.	O
6	O
ml	O
vs	O
OLB	O
,	O
65	O
.	O
7	O
+	O
/	O
-	O
77	O
.	O
0	O
ml	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
'	O
Newcastle	O
'	O
model	O
,	O
which	O
is	O
based	O
on	O
Hotelling	O
'	O
s	O
T2	O
statistic	O
,	O
proved	O
to	O
be	O
more	O
sensitive	O
and	O
diagnosed	O
a	O
systematic	O
displacement	O
for	O
three	O
prostate	O
patients	O
.	O

Radioligand	O
binding	O
was	O
indistinguishable	O
for	O
both	O
transiently	O
expressed	O
constructs	O
.	O

A	O
22K	O
polypeptide	O
was	O
detected	O
as	O
a	O
translation	O
product	O
of	O
late	O
RNA	O
that	O
hybridized	O
to	O
this	O
DNA	O
fragment	O
.	O

Gastrointestinal	O
manifestations	O
of	O
systemic	O
sclerosis	O
.	O

Transient	O
transfection	O
experiments	O
revealed	O
that	O
Pax	B-protein
-	I-protein
8	I-protein
isoforms	I-protein
a	I-protein
and	I-protein
b	I-protein
,	O
but	O
not	O
c	O
and	O
d	O
,	O
strongly	O
stimulate	O
transcription	O
from	O
a	O
promoter	O
containing	O
six	O
copies	O
of	O
a	O
paired	B-protein
-	I-protein
domain	I-protein
recognition	I-protein
sequence	I-protein
.	O

In	O
DNase	B-protein
I	I-protein
footprinting	O
protection	O
analysis	O
,	O
both	O
SFRE	B-protein
and	O
ERE	B-protein
regions	I-protein
were	O
protected	O
by	O
glutathione	B-protein
S	I-protein
-	I-protein
transferase	I-protein
-	I-protein
ERRalpha1	I-protein
fusion	I-protein
protein	I-protein
.	O

In	O
the	O
BF	O
ECT	O
group	O
the	O
-	O
age	O
based	O
dose	O
would	O
have	O
been	O
similarly	O
dependent	O
on	O
the	O
initial	O
seizure	O
threshold	O
level	O
.	O

CONCLUSIONS	O
:	O
The	O
mechanism	O
of	O
MIRI	O
is	O
Qi	O
deficiency	O
and	O
blood	O
stasis	O
in	O
TCM	O
,	O
its	O
treating	O
principles	O
should	O
be	O
promoting	O
Qi	O
and	O
removing	O
the	O
blood	O
stasis	O
.	O

Instead	O
,	O
mRNA	O
of	O
2	O
.	O
0	O
and	O
2	O
.	O
8	O
kb	O
are	O
detected	O
in	O
varying	O
abundance	O
.	O

Three	O
women	O
have	O
had	O
abnormal	O
endocervical	O
follow	O
up	O
cytology	O
suggestive	O
of	O
residual	O
disease	O
.	O

Clone	O
pSRc200	O
hybrid	O
selected	O
an	O
mRNA	O
that	O
on	O
cell	O
-	O
free	O
translation	O
produced	O
a	O
38	O
-	O
kDa	O
polypeptide	O
.	O

More	O
generally	O
,	O
Ets1	B-protein
and	O
Ets2	B-protein
could	O
regulate	O
transcription	O
of	O
cellular	O
genes	O
.	O

The	O
cdr1	B-protein
sequence	I-protein
includes	O
an	O
additional	O
237	O
amino	O
acids	O
of	O
the	O
contiguous	O
fragment	O
and	O
encodes	O
a	O
product	O
of	O
predicted	O
Mr	O
67	O
,	O
000	O
.	O

In	O
one	O
,	O
exploratory	O
behavior	O
(	O
assessed	O
by	O
hole	O
pokes	O
)	O
and	O
locomotion	O
were	O
assessed	O
during	O
a	O
10	O
-	O
min	O
test	O
session	O
.	O

Sequence	O
analysis	O
of	O
these	O
regions	O
showed	O
a	O
CAAT	O
box	O
upstream	O
of	O
exon	O
1a	O
and	O
high	O
G	O
-	O
C	O
content	O
regions	O
within	O
both	O
P1	B-protein
and	O
P2	B-protein
.	O

Both	O
reduced	O
spontaneous	O
locomotor	O
activity	O
in	O
mice	O
,	O
protected	O
them	O
from	O
death	O
from	O
amphetamine	O
induced	O
toxicity	O
,	O
prolonged	O
hexobarbitone	O
sleeping	O
time	O
and	O
caused	O
a	O
depletion	O
of	O
catecholamines	O
from	O
various	O
organs	O
of	O
the	O
rat	O
.	O

This	O
construct	O
,	O
termed	O
pDeltaCREC	B-protein
/	I-protein
EBP	I-protein
,	O
binds	O
C	B-protein
/	I-protein
EBPalpha	I-protein
and	I-protein
beta	I-protein
but	O
not	O
CREB	B-protein
,	O
yet	O
it	O
confers	O
a	O
nearly	O
complete	O
glucocorticoid	O
response	O
when	O
transiently	O
transfected	O
into	O
H4IIE	O
rat	O
hepatoma	O
cells	O
.	O

Echinococcus	O
granulosus	O
was	O
diagnosed	O
by	O
fine	O
-	O
needle	O
aspiration	O
cytology	O
of	O
a	O
lung	O
cyst	O
in	O
a	O
6	O
-	O
yr	O
-	O
old	O
white	O
female	O
in	O
central	O
Missouri	O
.	O

Herein	O
,	O
we	O
show	O
that	O
Smad3	B-protein
physically	O
interacts	O
with	O
the	O
HMG	B-protein
box	I-protein
domain	I-protein
of	O
LEF1	B-protein
and	O
that	O
TGFbeta	B-protein
and	O
Wnt	B-protein
pathways	I-protein
synergize	O
to	O
activate	O
transcription	O
of	O
the	O
Xenopus	B-protein
homeobox	I-protein
gene	I-protein
twin	I-protein
(	O
Xtwn	B-protein
)	O
.	O

The	O
association	O
of	O
clopamide	O
and	O
hydergine	O
(	O
Brinedine	O
)	O
in	O
the	O
treatment	O
of	O
the	O
vasculo	O
-	O
renal	O
syndromes	O
of	O
pregnancy	O
.	O

Thromboelastography	O
is	O
a	O
test	O
that	O
could	O
potentially	O
correlate	O
with	O
the	O
degree	O
of	O
anticoagulation	O
produced	O
by	O
low	O
molecular	O
weight	O
heparin	O
.	O

Within	O
12	O
hours	O
after	O
MR	O
tomography	O
the	O
patients	O
were	O
surgically	O
explored	O
,	O
biopsied	O
and	O
if	O
necessary	O
orchiectomised	O
.	O

The	O
human	O
protein	O
sequence	O
exhibits	O
a	O
putative	O
DNA	O
-	O
binding	O
domain	O
similar	O
to	O
that	O
seen	O
in	O
rat	B-protein
HBP1	I-protein
and	O
shows	O
homology	O
with	O
the	O
activation	O
and	O
repressor	O
domains	O
previously	O
demonstrated	O
in	O
the	O
rat	O
protein	O
.	O

These	O
results	O
demonstrate	O
that	O
EKLF	B-protein
provides	O
a	O
crucial	O
transactivation	O
function	O
for	O
globin	B-protein
expression	O
and	O
further	O
reinforce	O
the	O
idea	O
that	O
EKLF	B-protein
is	O
an	O
important	O
regulator	O
of	O
CACCC	O
element	O
-	O
directed	O
transcription	O
in	O
erythroid	O
cells	O
.	O

Although	O
the	O
DSK2	B-protein
-	I-protein
1	I-protein
mutation	I-protein
alters	O
a	O
conserved	O
residue	O
in	O
the	O
Dsk2p	B-protein
ubiquitin	I-protein
-	I-protein
like	I-protein
domain	I-protein
,	O
we	O
detect	O
no	O
differences	O
in	O
Dsk2p	B-protein
or	O
Cdc31p	B-protein
stability	O
.	O

The	O
complete	O
cDNA	O
sequence	O
of	O
human	B-protein
betaV	I-protein
spectrin	I-protein
is	O
available	O
from	O
GenBank	O
(	O
TM	O
)	O
as	O
accession	O
number	O
.	O

Although	O
the	O
effects	O
of	O
the	O
calcium	O
supplement	O
or	O
calcium	O
antagonist	O
alone	O
were	O
significant	O
,	O
such	O
hypotensive	O
responses	O
were	O
not	O
optimal	O
or	O
predictable	O
or	O
clearly	O
dose	O
-	O
dependent	O
.	O

At	O
a	O
PaCO2	O
of	O
40	O
mmHg	O
,	O
baseline	O
brain	O
pHi	O
measured	O
7	O
.	O
03	O
+	O
/	O
-	O
0	O
.	O
04	O
,	O
while	O
regional	O
cortical	O
blood	O
flow	O
was	O
47	O
.	O
0	O
+	O
/	O
-	O
4	O
.	O
3	O
ml	O
.	O
100	O
g	O
-	O
1	O
.	O
min	O
-	O
1	O
.	O

In	O
contrast	O
,	O
the	O
neu	B-protein
proto	I-protein
-	I-protein
oncogene	I-protein
did	O
not	O
show	O
kinase	O
activity	O
or	O
transforming	O
properties	O
when	O
expressed	O
at	O
similar	O
levels	O
in	O
NIH	O
3T3	O
cells	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Furthermore	O
,	O
interactions	O
were	O
identified	O
between	O
endogenous	B-protein
E	I-protein
-	I-protein
cadherin	I-protein
and	O
the	O
chimera	O
containing	O
the	O
E	B-protein
-	I-protein
cadherin	I-protein
extracellular	I-protein
domain	I-protein
and	O
the	O
desmoglein	B-protein
1	I-protein
intracellular	I-protein
domain	I-protein
providing	O
in	O
vivo	O
evidence	O
for	O
previously	O
predicted	O
lateral	O
interactions	O
of	O
E	B-protein
-	I-protein
cadherin	I-protein
extracellular	I-protein
domains	I-protein
.	O

No	O
UOxase	B-protein
mRNA	I-protein
was	O
detected	O
in	O
11	O
nonhepatic	O
tissues	O
of	O
rat	O
,	O
suggesting	O
tissue	O
specificity	O
of	O
expression	O
of	O
this	O
UOxase	B-protein
gene	I-protein
.	O

CONCLUSION	O
:	O
We	O
were	O
unable	O
to	O
identify	O
features	O
of	O
disease	O
likely	O
to	O
be	O
associated	O
with	O
a	O
clinically	O
useful	O
response	O
to	O
inhaled	O
NO	O
therapy	O
using	O
the	O
parameters	O
studied	O
.	O

High	O
levels	O
of	O
IC	O
coincided	O
with	O
relative	O
hypocomplementemia	O
.	O

Besides	O
the	O
characterization	O
and	O
discussion	O
of	O
the	O
experimental	O
setup	O
used	O
,	O
the	O
rate	O
constants	O
obtained	O
are	O
discussed	O
and	O
compared	O
with	O
estimated	O
values	O
.	O

We	O
consider	O
that	O
DIL	O
-	O
CP	O
is	O
a	O
safe	O
and	O
excellent	O
CP	O
in	O
CABG	O
surgery	O
and	O
we	O
are	O
now	O
utilizing	O
this	O
CP	O
in	O
all	O
patients	O
requiring	O
CABG	O
surgery	O
.	O

Isolation	O
of	O
a	O
temperature	O
-	O
sensitive	O
mutant	O
with	O
an	O
altered	O
tRNA	B-protein
nucleotidyltransferase	I-protein
and	O
cloning	O
of	O
the	O
gene	B-protein
encoding	I-protein
tRNA	I-protein
nucleotidyltransferase	I-protein
in	I-protein
the	I-protein
yeast	I-protein
Saccharomyces	I-protein
cerevisiae	I-protein
.	O

Measurement	O
of	O
open	O
-	O
loop	O
responses	O
to	O
electrical	O
stimulation	O
in	O
olfactory	O
bulb	O
of	O
cat	O
.	O

The	O
UV	O
absorption	O
spectrum	O
revealed	O
a	O
shoulder	O
at	O
250	O
nm	O
,	O
characteristic	O
of	O
CysS	O
-	O
Cd	O
(	O
II	O
)	O
ligand	O
-	O
to	O
-	O
metal	O
charge	O
-	O
transfer	O
transitions	O
,	O
and	O
the	O
difference	O
absorption	O
coefficient	O
after	O
acidification	O
(	O
delta	O
epsilon	O
248	O
,	O
24	O
mM	O
-	O
1	O
cm	O
-	O
1	O
)	O
indicated	O
the	O
presence	O
of	O
a	O
Cd	O
(	O
Cys	O
-	O
S	O
)	O
4	O
center	O
.	O

Growth	B-protein
hormone	I-protein
and	O
insulin	B-protein
-	I-protein
like	I-protein
growth	I-protein
factor	I-protein
I	I-protein
receptors	I-protein
in	O
the	O
temporomandibular	O
joint	O
of	O
the	O
rat	O
.	O

Adverse	O
foetal	O
outcome	O
in	O
specific	O
IgM	B-protein
positive	O
Chlamydia	O
trachomatis	O
infection	O
in	O
pregnancy	O
.	O

On	O
the	O
basis	O
of	O
size	O
,	O
the	O
CRS	B-protein
sequence	I-protein
to	O
which	O
it	O
binds	O
,	O
and	O
its	O
tentative	O
identification	O
as	O
a	O
zinc	B-protein
finger	I-protein
protein	I-protein
,	O
Adx	B-protein
factor	I-protein
has	O
been	O
identified	O
as	O
a	O
Kruppel	B-protein
-	I-protein
like	I-protein
zinc	I-protein
finger	I-protein
protein	I-protein
(	O
a	O
mouse	B-protein
ZBP	I-protein
-	I-protein
89	I-protein
homologue	I-protein
)	O
.	O

The	O
downstream	O
,	O
TATA	O
-	O
less	O
promoter	O
has	O
high	O
G	O
+	O
C	O
content	O
,	O
and	O
exon	O
1b	O
predominates	O
among	O
abundantly	O
expressed	O
mRNA	O
species	O
.	O

Both	O
P5CDh	B-protein
cDNA	I-protein
clones	O
detect	O
a	O
single	O
3	O
.	O
2	O
-	O
kb	O
transcript	O
on	O
Northern	O
blots	O
of	O
multiple	O
human	O
tissues	O
,	O
indicating	O
the	O
long	O
cDNA	O
containing	O
the	O
3	O
'	O
-	O
untranslated	O
intron	O
represents	O
the	O
predominant	O
transcript	O
.	O

Although	O
there	O
are	O
no	O
octamer	O
elements	O
in	O
the	O
adenovirus	O
genome	O
that	O
are	O
known	O
to	O
be	O
important	O
for	O
transcription	O
,	O
there	O
are	O
octamer	O
elements	O
in	O
the	O
viral	O
terminal	O
repeat	O
sequences	O
.	O

Carcinoembryonic	B-protein
antigen	I-protein
(	O
CEA	B-protein
)	O
procedures	O
and	O
clinical	O
evaluation	O
.	O
pp	O
.	O

Acylation	O
with	O
the	O
palmitate	O
analog	O
was	O
prevented	O
when	O
Gly	O
-	O
2	O
was	O
mutated	O
to	O
alanine	O
,	O
implying	O
that	O
N	O
-	O
myristylation	O
is	O
required	O
for	O
palmitylation	O
,	O
and	O
when	O
either	O
Cys	O
-	O
3	O
or	O
Cys	O
-	O
6	O
was	O
mutated	O
to	O
serine	O
.	O

Follow	O
-	O
up	O
controls	O
of	O
luteinizing	B-protein
hormone	I-protein
(	O
LH	B-protein
)	O
,	O
follicle	B-protein
stimulating	I-protein
hormone	I-protein
(	O
FSH	B-protein
)	O
,	O
prolactin	B-protein
(	O
HPRL	B-protein
)	O
,	O
oestradiol	O
(	O
E2	O
)	O
,	O
progesterone	O
(	O
P	O
)	O
and	O
testosterone	O
(	O
T	O
)	O
in	O
the	O
catabolic	O
and	O
healing	O
phase	O
of	O
burn	O
disease	O
.	O

Confirming	O
measures	O
made	O
by	O
nurses	O
and	O
additionally	O
,	O
ABPM	O
for	O
women	O
,	O
seem	O
to	O
lessen	O
this	O
effect	O
.	O

The	O
gene	B-protein
cat	I-protein
-	I-protein
86	I-protein
,	O
specifying	O
chloramphenicol	B-protein
-	I-protein
inducible	I-protein
chloramphenicol	I-protein
acetyltransferase	I-protein
,	O
is	O
located	O
on	O
the	O
1	O
.	O
1	O
-	O
kilobase	O
cloned	O
DNA	O
.	O

UDP	B-protein
-	I-protein
GlcNAc	I-protein
:	O
alpha	B-protein
-	I-protein
6	I-protein
-	I-protein
D	I-protein
-	I-protein
mannoside	I-protein
beta	I-protein
-	I-protein
1	I-protein
,	I-protein
2	I-protein
-	I-protein
N	I-protein
-	I-protein
acetylglucosaminyltransferase	I-protein
II	I-protein
(	O
GnT	B-protein
II	I-protein
;	O
EC	B-protein
2	I-protein
.	I-protein
4	I-protein
.	I-protein
1	I-protein
.	I-protein
143	I-protein
)	O
is	O
essential	O
for	O
the	O
normal	O
assembly	O
of	O
complex	O
Asn	O
-	O
linked	O
glycans	O
.	O

The	O
MET4	B-protein
gene	O
was	O
cloned	O
,	O
and	O
its	O
sequence	O
reveals	O
that	O
it	O
encodes	O
a	O
protein	O
related	O
to	O
the	O
family	O
of	O
the	O
bZIP	B-protein
transcriptional	I-protein
activators	I-protein
.	O

This	O
region	O
of	O
hsp90	B-protein
mediates	O
ATP	O
-	O
independent	O
chaperone	B-protein
activity	O
,	O
overlaps	O
the	O
hsp90	B-protein
dimerization	I-protein
domain	I-protein
,	O
and	O
includes	O
structural	O
elements	O
important	O
for	O
steroid	B-protein
receptor	I-protein
interaction	O
.	O

The	O
novel	O
Notch	B-protein
homologue	I-protein
mouse	I-protein
Notch	I-protein
3	I-protein
lacks	O
specific	O
epidermal	B-protein
growth	I-protein
factor	I-protein
-	I-protein
repeats	I-protein
and	O
is	O
expressed	O
in	O
proliferating	O
neuroepithelium	O
.	O

Structure	O
and	O
expression	O
of	O
the	O
alternative	O
sigma	O
factor	O
,	O
RpoN	B-protein
,	O
in	O
Rhodobacter	O
capsulatus	O
;	O
physiological	O
relevance	O
of	O
an	O
autoactivated	O
nifU2	B-protein
-	I-protein
rpoN	I-protein
superoperon	O
.	O

Pneumonia	O
in	O
children	O
.	O

Statement	O
on	O
the	O
development	O
of	O
guidelines	O
for	O
the	O
prevention	O
of	O
AIDS	O
transmission	O
in	O
the	O
workplace	O
.	O

M	B-protein
-	I-protein
Ras	I-protein
interacted	O
poorly	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
assay	O
with	O
multiple	O
Ras	B-protein
effectors	O
,	O
including	O
c	B-protein
-	I-protein
Raf	I-protein
-	I-protein
1	I-protein
,	O
A	B-protein
-	I-protein
Raf	I-protein
,	O
B	B-protein
-	I-protein
Raf	I-protein
,	O
phosphoinositol	B-protein
-	I-protein
3	I-protein
kinase	I-protein
delta	I-protein
,	O
RalGDS	B-protein
,	O
and	O
Rin1	B-protein
.	O

The	O
3	O
.	O
3	O
-	O
fold	O
higher	O
expression	O
in	O
the	O
fetal	O
heart	O
than	O
in	O
the	O
adult	O
heart	O
suggests	O
that	O
HFHZ	B-protein
mRNA	I-protein
is	O
downregulated	O
in	O
the	O
process	O
of	O
development	O
.	O

On	O
an	O
antithrombin	O
unit	O
basis	O
,	O
CY	O
216	O
and	O
CY	O
222	O
were	O
equivalent	O
and	O
more	O
potent	O
than	O
UH	O
.	O

Marked	O
racial	O
variation	O
in	O
birthweight	O
percentiles	O
by	O
gestational	O
age	O
was	O
evident	O
.	O

2	O
-	O
Chemical	O
occlusion	O
of	O
vas	O
is	O
quite	O
effective	O
in	O
producing	O
a	O
block	O
in	O
the	O
vas	O
deferens	O
of	O
dogs	O
.	O

The	O
observation	O
of	O
late	O
effects	O
after	O
irradiations	O
or	O
after	O
space	O
flights	O
show	O
the	O
difficulties	O
encountered	O
in	O
assessing	O
radiative	O
risks	O
during	O
long	O
duration	O
space	O
flights	O
.	O

TEMTU	O
and	O
DPTU	O
were	O
the	O
most	O
potent	O
teratogens	O
.	O

An	O
intravenous	O
drip	O
infusion	O
of	O
AMK	O
in	O
adequate	O
dosage	O
would	O
be	O
beneficial	O
to	O
use	O
against	O
some	O
infectious	O
diseases	O
of	O
otorhinolaryngologic	O
field	O
.	O

Antithrombin	B-protein
III	I-protein
deficiency	O
:	O
when	O
substitute	O
,	O
when	O
heparin	O
?	O
Thrombosis	O
ABC	O
,	O
3	O
:	O
The	O
role	O
of	O
antithrombin	B-protein
III	I-protein
.	O

40	O
patients	O
with	O
chronic	O
osteomyelitis	O
were	O
treated	O
per	O
os	O
with	O
the	O
bactericidal	O
beta	O
-	O
lactam	O
-	O
antibiotic	O
cephalexin	O
during	O
3	O
to	O
60	O
weeks	O
.	O

It	O
was	O
concluded	O
that	O
both	O
of	O
these	O
surgical	O
procedures	O
were	O
as	O
effective	O
as	O
pinealectomy	O
in	O
reversing	O
the	O
pineal	O
-	O
induced	O
alterations	O
in	O
the	O
reproductive	O
physiology	O
of	O
the	O
blind	O
-	O
anosmic	O
female	O
rat	O
.	O

Is	O
nisoldipine	O
capable	O
of	O
reducing	O
left	O
ventricular	O
preload	O
?	O
In	O
ten	O
anesthetized	O
pigs	O
,	O
nisoldipine	O
(	O
2	O
-	O
4	O
micrograms	O
X	O
kg	O
-	O
1	O
X	O
min	O
-	O
1	O
)	O
,	O
a	O
calcium	O
channel	O
blocker	O
structurally	O
related	O
to	O
nifedipine	O
,	O
reduced	O
left	O
ventricular	O
systolic	O
pressure	O
(	O
40	O
%	O
)	O
and	O
systemic	O
vascular	O
resistance	O
(	O
35	O
%	O
)	O
,	O
whereas	O
maxLVdP	O
/	O
dt	O
decreased	O
by	O
20	O
%	O
and	O
cardiac	O
output	O
was	O
unchanged	O
.	O

In	O
a	O
reconstituted	O
human	O
DNA	O
repair	O
system	O
containing	O
DNA	B-protein
polymerase	I-protein
beta	I-protein
and	O
DNA	B-protein
ligase	I-protein
III	I-protein
-	I-protein
XRCC1	I-protein
,	O
accurate	O
rejoining	O
of	O
a	O
3	O
'	O
mismatched	O
base	O
residue	O
at	O
a	O
single	O
-	O
strand	O
break	O
is	O
dependent	O
on	O
addition	O
of	O
the	O
exonuclease	B-protein
.	O

Furthermore	O
,	O
co	O
-	O
expression	O
of	O
both	O
p46	B-protein
and	O
p54	B-protein
subunits	I-protein
markedly	O
altered	O
the	O
subcellular	O
distribution	O
of	O
p46	B-protein
;	O
co	O
-	O
expressed	O
p46	B-protein
was	O
transported	O
into	O
the	O
nucleus	O
as	O
efficiently	O
as	O
p54	B-protein
.	O

Evaluation	O
of	O
myocardial	O
perfusion	O
by	O
99mTc	O
-	O
tetrofosmin	O
SPECT	O
before	O
and	O
after	O
emergent	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
for	O
acute	O
myocardial	O
infarction	O
.	O

These	O
results	O
support	O
a	O
model	O
in	O
which	O
p53	B-protein
protein	I-protein
contributes	O
to	O
the	O
maintenance	O
of	O
genomic	O
integrity	O
through	O
recombinational	O
repair	O
.	O

Posttranslational	O
regulation	O
of	O
Ty1	B-protein
retrotransposition	O
by	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
Fus3	I-protein
.	O

The	O
5	O
'	O
flanking	O
region	O
contains	O
potential	O
binding	O
sites	O
for	O
TATA	B-protein
-	I-protein
binding	I-protein
protein	I-protein
,	O
Sp1	B-protein
,	O
nuclear	B-protein
factor	I-protein
1	I-protein
(	O
NF1	B-protein
)	O
,	O
CAAT	B-protein
-	I-protein
box	I-protein
binding	I-protein
protein	I-protein
(	O
C	B-protein
/	I-protein
EBP	I-protein
)	O
,	O
hepatocyte	B-protein
nuclear	I-protein
factors	I-protein
1	I-protein
and	I-protein
5	I-protein
(	O
HNF1	B-protein
,	O
HNF5	B-protein
)	O
and	O
activator	B-protein
proteins	I-protein
1	I-protein
and	I-protein
2	I-protein
(	O
AP1	B-protein
,	O
AP2	B-protein
)	O
.	O

The	O
most	O
likely	O
explanation	O
for	O
this	O
is	O
that	O
gold	O
principally	O
accumulates	O
in	O
the	O
Kupffer	O
cells	O
and	O
renal	O
cortex	O
and	O
these	O
cells	O
do	O
not	O
express	O
Type	B-protein
I	I-protein
deiodinase	I-protein
.	O

The	O
importance	O
of	O
this	O
new	O
epidemiological	O
profile	O
of	O
schistosomiasis	O
in	O
the	O
State	O
of	O
Pernambuco	O
relies	O
on	O
the	O
fact	O
that	O
it	O
can	O
be	O
related	O
with	O
the	O
drastic	O
human	O
interference	O
on	O
the	O
environment	O
.	O

All	O
nuclear	O
receptors	O
have	O
several	O
well	O
-	O
characterized	O
structural	O
domains	O
,	O
including	O
a	O
conserved	O
DNA	O
-	O
binding	O
domain	O
,	O
and	O
a	O
ligand	O
binding	O
domain	O
at	O
the	O
carboxyl	O
terminus	O
of	O
the	O
receptor	O
.	O

In	O
order	O
to	O
investigate	O
to	O
what	O
extent	O
this	O
interaction	O
might	O
contribute	O
to	O
tumor	O
induction	O
by	O
the	O
virus	O
,	O
we	O
have	O
introduced	O
two	O
different	O
point	O
mutations	O
within	O
the	O
putative	O
pRb	B-protein
-	I-protein
binding	I-protein
sequence	I-protein
of	O
large	B-protein
T	I-protein
antigen	I-protein
,	O
and	O
as	O
a	O
preliminary	O
to	O
in	O
vivo	O
experiments	O
we	O
have	O
studied	O
their	O
effects	O
in	O
vitro	O
on	O
some	O
biological	O
activities	O
relevant	O
to	O
tumor	O
induction	O
.	O

However	O
,	O
calphostin	O
C	O
,	O
a	O
specific	O
inhibitor	O
of	O
PKC	B-protein
,	O
abolished	O
the	O
TPA	O
-	O
induced	O
increase	O
in	O
CFI	B-protein
mRNA	I-protein
levels	O
.	O

An	O
intravenous	O
preparation	O
of	O
doxycycline	O
(	O
DOTC	O
,	O
Vibramycin	O
'	O
Pfizer	O
'	O
)	O
,	O
a	O
long	O
-	O
lasting	O
tetracycline	O
,	O
was	O
administered	O
mainly	O
by	O
drip	O
infusion	O
for	O
a	O
series	O
of	O
study	O
in	O
the	O
pediatrics	O
field	O
,	O
and	O
the	O
results	O
were	O
as	O
follows	O
:	O
1	O
)	O
DOTC	O
(	O
100	O
mg	O
)	O
was	O
dissolved	O
in	O
a	O
100	O
ml	O
of	O
glucose	O
solution	O
and	O
2	O
-	O
-	O
3	O
mg	O
/	O
kg	O
was	O
administered	O
intravenously	O
.	O

Cytomegalovirus	O
,	O
Chlamydia	O
pneumoniae	O
,	O
and	O
Helicobacter	O
pylori	O
IgG	B-protein
antibodies	I-protein
and	O
restenosis	O
after	O
stent	O
implantation	O
:	O
an	O
angiographic	O
and	O
intravascular	O
ultrasound	O
study	O
.	O

Upon	O
serum	O
withdrawal	O
at	O
the	O
permissive	O
temperature	O
,	O
p53	O
-	O
mediated	O
apoptosis	O
was	O
induced	O
in	O
50	O
to	O
60	O
%	O
of	O
the	O
cells	O
.	O

A	O
needs	O
assessment	O
of	O
these	O
families	O
was	O
also	O
done	O
.	O

Recording	O
of	O
the	O
digital	O
sphygmic	O
activity	O
in	O
the	O
lower	O
extremities	O
with	O
the	O
photoplethysmographic	O
and	O
strain	O
-	O
gauge	O
methods	O
.	O

No	O
positive	O
family	O
history	O
was	O
obtained	O
.	O

Consistent	O
with	O
ErbB	B-protein
-	I-protein
2	I-protein
being	O
a	O
shared	O
receptor	O
subunit	O
,	O
its	O
tyrosine	O
phosphorylation	O
was	O
increased	O
by	O
both	O
heterologous	O
ligands	O
and	O
it	O
mediated	O
a	O
trans	O
-	O
inhibitory	O
effect	O
of	O
NDF	B-protein
on	O
EGF	B-protein
binding	O
.	O

This	O
conformer	O
features	O
a	O
Type	O
I	O
beta	O
-	O
turn	O
and	O
has	O
extensive	O
hydrophobic	O
contacts	O
with	O
the	O
FKBP12	B-protein
binding	O
surface	O
.	O

Endocytosis	O
and	O
vacuolar	O
degradation	O
of	O
the	O
plasma	O
membrane	O
-	O
localized	O
Pdr5	B-protein
ATP	I-protein
-	I-protein
binding	I-protein
cassette	I-protein
multidrug	I-protein
transporter	I-protein
in	O
Saccharomyces	O
cerevisiae	O
.	O

Of	O
7	O
patients	O
treated	O
with	O
cyclophosphamide	O
,	O
hexamethylmelamine	O
,	O
adriamycin	O
and	O
cisplatin	O
(	O
CHAP	O
-	O
5	O
)	O
,	O
6	O
had	O
measurable	O
disease	O
,	O
of	O
whom	O
5	O
yielded	O
a	O
response	O
(	O
2	O
complete	O
responses	O
for	O
19	O
+	O
and	O
40	O
months	O
and	O
3	O
partial	O
responses	O
for	O
4	O
,	O
7	O
and	O
8	O
months	O
)	O
.	O

The	O
degree	O
of	O
lung	O
destruction	O
,	O
reflected	O
by	O
interstitial	O
hemorrhage	O
was	O
assessed	O
by	O
measuring	O
hemoglobin	B-protein
content	O
in	O
the	O
fluid	O
of	O
the	O
lavaged	O
lungs	O
.	O

To	O
elucidate	O
the	O
functional	O
significance	O
of	O
Fyn	B-protein
in	O
the	O
expression	O
of	O
viral	O
promoters	O
,	O
we	O
transfected	O
a	O
Fyn	O
-	O
expression	O
vector	O
together	O
with	O
a	O
reporter	O
plasmid	O
containing	O
the	O
chloramphenicol	B-protein
acetyltransferase	I-protein
gene	I-protein
driven	O
by	O
HIV	B-protein
LTR	I-protein
into	O
a	O
human	O
T	O
cell	O
line	O
,	O
Jurkat	O
.	O

They	O
consist	O
of	O
at	O
least	O
two	O
separable	O
components	O
,	O
one	O
heat	O
stable	O
and	O
the	O
other	O
heat	O
labile	O
.	O

Polymyxin	O
B	O
was	O
given	O
intravenously	O
for	O
1	O
week	O
postburn	O
in	O
doses	O
designed	O
to	O
neutralize	O
circulating	O
endotoxemia	O
.	O

We	O
studied	O
GSH	B-protein
-	I-protein
Px	I-protein
enzyme	I-protein
activity	O
in	O
serum	O
after	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
and	O
unstable	O
angina	O
pectoris	O
(	O
UAP	O
)	O
.	O

The	O
N	O
-	O
terminal	O
115	O
amino	O
acids	O
correspond	O
to	O
a	O
putative	O
DNA	O
-	O
binding	O
domain	O
and	O
show	O
significant	O
sequence	O
similarity	O
with	O
other	O
cloned	O
IFN	B-protein
response	I-protein
factors	I-protein
(	O
IRF	B-protein
-	I-protein
1	I-protein
and	O
IRF	B-protein
-	I-protein
2	I-protein
)	O
.	O

OBJECTIVE	O
:	O
The	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
frequency	O
of	O
alterations	O
in	O
serum	O
creatinine	O
in	O
patients	O
with	O
psoriasis	O
receiving	O
5	O
mg	O
/	O
kg	O
/	O
day	O
of	O
cyclosporine	O
.	O

Thirty	O
isolates	O
of	O
Haemophilus	O
influenzae	O
type	O
b	O
were	O
obtained	O
during	O
an	O
outbreak	O
of	O
invasive	O
H	O
.	O
influenzae	O
type	O
b	O
disease	O
and	O
were	O
classified	O
by	O
the	O
electrophoretic	O
profile	O
of	O
their	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

NE	B-protein
and	O
PR3	B-protein
assist	O
in	O
the	O
destruction	O
of	O
phagocytosed	O
microorganisms	O
,	O
cleave	O
the	O
important	O
connective	B-protein
-	I-protein
tissue	I-protein
protein	I-protein
elastin	I-protein
,	O
and	O
generate	O
chemotactic	O
activities	O
by	O
forming	O
alpha	B-protein
1	I-protein
-	I-protein
proteinase	I-protein
inhibitor	I-protein
complexes	I-protein
and	O
elastin	B-protein
peptides	I-protein
.	O

They	O
suggest	O
that	O
decreased	O
steady	O
-	O
state	O
levels	O
of	O
IME1	B-protein
and	O
IME2	B-protein
mRNA	I-protein
were	O
not	O
merely	O
the	O
result	O
of	O
non	O
-	O
specific	O
adverse	O
affects	O
on	O
nucleic	O
acid	O
metabolism	O
caused	O
by	O
the	O
yvh1	B-protein
disruption	O
.	O

Blood	O
levels	O
of	O
melatonin	O
,	O
serotonin	O
,	O
cortisol	O
,	O
and	O
prolactin	B-protein
in	O
relation	O
to	O
the	O
circadian	O
rhythm	O
of	O
platelet	O
serotonin	O
uptake	O
.	O

Induction	O
of	O
correctly	O
spliced	O
germline	O
transcripts	O
is	O
necessary	O
to	O
target	O
a	O
switch	O
region	O
for	O
recombination	O
and	O
switching	O
.	O

Tranilast	O
in	O
the	O
Therapy	O
of	O
Coronary	O
Artery	O
Disease	O
.	O

Analysis	O
of	O
this	O
sequence	O
combined	O
with	O
that	O
previously	O
reported	O
for	O
the	O
5	O
'	O
-	O
flanking	O
region	O
directly	O
proximal	O
to	O
the	O
start	O
of	O
transcription	O
revealed	O
several	O
putative	O
regulatory	O
sequences	O
.	O

Polyadenylation	O
of	O
B4	B-protein
RNA	I-protein
,	O
which	O
occurs	O
very	O
early	O
during	O
maturation	O
,	O
is	O
limited	O
to	O
150	O
residues	O
,	O
and	O
it	O
is	O
this	O
number	O
that	O
is	O
required	O
for	O
polysomal	O
recruitment	O
.	O

In	O
comparison	O
of	O
cDNA	O
and	O
genomic	O
sequences	O
four	O
RNA	O
editing	O
events	O
were	O
found	O
in	O
both	O
atp9	B-protein
genes	I-protein
.	O

Overlapping	O
cDNA	O
clones	O
were	O
isolated	O
and	O
sequenced	O
.	O

Of	O
270	O
patients	O
with	O
well	O
-	O
defined	O
drug	O
reactions	O
,	O
190	O
(	O
70	O
per	O
cent	O
)	O
gave	O
a	O
positive	O
response	O
to	O
the	O
mast	O
cell	O
test	O
.	O

(	O
2	O
)	O
Diffusion	O
limitation	O
in	O
the	O
heterogeneous	O
model	O
sets	O
in	O
at	O
a	O
lower	O
O2	O
requirement	O
value	O
,	O
and	O
increases	O
more	O
gradually	O
with	O
increasing	O
O2	O
requirement	O
,	O
than	O
in	O
the	O
corresponding	O
homogeneous	O
models	O
with	O
the	O
same	O
average	O
cylinder	O
diameter	O
.	O

BACKGROUND	O
:	O
There	O
is	O
increasing	O
interest	O
on	O
the	O
part	O
of	O
investigators	O
and	O
the	O
public	O
at	O
large	O
in	O
finding	O
ways	O
to	O
study	O
and	O
improve	O
treatments	O
for	O
the	O
seriously	O
mentally	O
ill	O
without	O
exposing	O
such	O
individuals	O
to	O
unnecessary	O
risks	O
.	O

The	O
data	O
imply	O
that	O
JAK	B-protein
/	I-protein
STAT	I-protein
signaling	O
has	O
a	O
role	O
in	O
EBV	O
-	O
associated	O
malignancies	O
.	O

Against	O
200	O
strains	O
of	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
isolated	O
from	O
1990	O
to	O
1991	O
,	O
minimum	O
inhibitory	O
concentrations	O
(	O
MICs	O
)	O
of	O
a	O
total	O
of	O
15	O
antibacterial	O
agents	O
including	O
arbekacin	O
(	O
ABK	O
)	O
were	O
determined	O
.	O

The	O
perioperative	O
mortality	O
of	O
all	O
patients	O
was	O
1	O
.	O
9	O
%	O
,	O
the	O
mortality	O
of	O
patients	O
older	O
than	O
70	O
years	O
was	O
4	O
.	O
3	O
%	O
.	O

We	O
determined	O
whether	O
a	O
single	O
injection	O
of	O
slow	O
-	O
release	O
estradiol	O
-	O
17beta	O
(	O
SRE2	O
)	O
would	O
induce	O
pseudopregnancy	O
in	O
gilts	O
and	O
whether	O
PGF2alpha	O
would	O
regress	O
the	O
corpora	O
lutea	O
(	O
CL	O
)	O
of	O
pseudopregnancy	O
.	O

Analysis	O
for	O
DNA	O
-	O
protein	O
interactions	O
by	O
in	O
vitro	O
DNase	B-protein
-	I-protein
I	I-protein
footprinting	O
identified	O
a	O
broad	O
region	O
of	O
protection	O
extending	O
from	O
nt	O
-	O
12	O
to	O
+	O
38	O
.	O

Using	O
himA	B-protein
mutants	I-protein
,	O
we	O
confirmed	O
that	O
IHF	B-protein
plays	O
a	O
role	O
in	O
the	O
molybdate	O
-	O
dependent	O
regulation	O
of	O
dmsA	B-protein
-	I-protein
lacZ	I-protein
expression	O
in	O
vivo	O
.	O

A	O
heterologous	O
promoter	O
construct	O
containing	O
three	O
repeats	O
of	O
a	O
consensus	O
Sp1	B-protein
site	I-protein
,	O
cloned	O
upstream	O
of	O
a	O
single	O
copy	O
of	O
the	O
ZII	B-protein
(	O
CREB	B-protein
/	I-protein
AP1	I-protein
)	O
element	O
from	O
the	O
BZLF1	B-protein
promoter	I-protein
linked	O
to	O
the	O
beta	B-protein
-	I-protein
globin	I-protein
TATA	O
box	O
,	O
exhibited	O
phorbol	O
ester	O
inducibility	O
.	O

Early	O
-	O
onset	O
scleral	O
necrosis	O
after	O
iodine	O
I	O
125	O
plaque	O
radiotherapy	O
for	O
ciliochoroidal	O
melanoma	O
.	O

Identification	O
and	O
structure	O
of	O
the	O
Marek	B-protein
'	I-protein
s	I-protein
disease	I-protein
virus	I-protein
serotype	I-protein
2	I-protein
glycoprotein	I-protein
M	I-protein
gene	I-protein
:	O
comparison	O
with	O
glycoprotein	B-protein
M	I-protein
genes	I-protein
of	O
Herpesviridae	O
family	O
.	O

Dimerization	O
of	O
Myf	B-protein
-	I-protein
5	I-protein
with	O
the	O
ubiquitously	O
expressed	O
bHLH	B-protein
protein	I-protein
E12	I-protein
not	O
only	O
increases	O
the	O
affinity	O
for	O
DNA	O
but	O
also	O
stimulates	O
transactivation	O
independently	O
of	O
DNA	O
binding	O
.	O

Myocardial	O
perfusion	O
was	O
evaluated	O
using	O
the	O
enhanced	O
gray	O
level	O
after	O
contrast	O
injection	O
,	O
and	O
the	O
level	O
was	O
compared	O
with	O
the	O
morphology	O
and	O
degree	O
of	O
collateral	O
development	O
.	O

Changes	O
in	O
body	O
weight	O
and	O
agonistic	O
behavior	O
were	O
also	O
recorded	O
.	O

A	O
segmental	O
analysis	O
of	O
the	O
key	O
regions	O
of	O
HLA	B-protein
-	I-protein
DR1	I-protein
that	O
control	O
T	O
cell	O
allorecognition	O
was	O
performed	O
by	O
using	O
a	O
series	O
of	O
transfected	O
cell	O
lines	O
expressing	O
the	O
products	O
of	O
recombinant	B-protein
DRB	I-protein
/	I-protein
H	I-protein
-	I-protein
2Eb	I-protein
genes	I-protein
,	O
paired	O
with	O
either	O
DR	B-protein
alpha	I-protein
or	O
H	B-protein
-	I-protein
2E	I-protein
alpha	I-protein
.	O

Effects	O
of	O
methylene	O
chloride	O
,	O
trichloroethane	O
,	O
trichloroethylene	O
,	O
tetrachloroethylene	O
and	O
toluene	O
on	O
the	O
development	O
of	O
chick	O
embryos	O
.	O

To	O
assess	O
more	O
specific	O
PKA	O
-	O
dependent	O
mediation	O
of	O
LH	B-protein
'	I-protein
s	I-protein
contribution	O
to	O
combined	O
hormonal	O
drive	O
,	O
the	O
LDL	B-protein
receptor	I-protein
(	I-protein
-	I-protein
1076	I-protein
to	I-protein
+	I-protein
11	I-protein
bp	I-protein
)	I-protein
reporter	I-protein
plasmid	O
was	O
cotransfected	O
with	O
a	O
full	B-protein
-	I-protein
sequence	I-protein
rabbit	I-protein
muscle	I-protein
protein	I-protein
kinase	I-protein
inhibitor	I-protein
(	O
PKI	B-protein
)	O
minigene	O
driven	O
constitutively	O
by	O
a	O
Rous	O
sarcoma	O
virus	O
promoter	O
.	O

A	O
full	B-protein
-	I-protein
length	I-protein
human	I-protein
pim	I-protein
-	I-protein
1	I-protein
cDNA	I-protein
was	O
subcloned	O
into	O
the	O
bacterial	O
vector	O
pGEX	O
-	O
2T	O
and	O
the	O
Pim	B-protein
-	I-protein
1	I-protein
protein	I-protein
expressed	O
as	O
a	O
fusion	O
product	O
with	O
bacterial	B-protein
glutathione	I-protein
S	I-protein
-	I-protein
transferase	I-protein
(	O
GST	B-protein
)	O
.	O

Circulating	O
thrombomodulin	B-protein
:	O
current	O
knowledge	O
and	O
future	O
prospects	O
.	O

Six	O
hours	O
after	O
the	O
last	O
administration	O
,	O
uterus	O
of	O
Gf	O
and	O
Cv	O
mice	O
were	O
weight	O
337	O
.	O
6	O
mg	O
%	O
and	O
423	O
.	O
5	O
mg	O
%	O
respectively	O
,	O
the	O
difference	O
was	O
statistically	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

In	O
contrast	O
to	O
the	O
situation	O
in	O
mammalian	O
cells	O
,	O
prolonged	O
exposure	O
of	O
the	O
agonist	O
(	O
24	O
h	O
)	O
does	O
not	O
result	O
in	O
down	O
regulation	O
of	O
the	O
remaining	O
70	O
%	O
of	O
the	O
receptors	O
.	O

The	O
mitochondrial	B-protein
regulatory	I-protein
region	I-protein
(	O
mrr	B-protein
)	O
located	O
between	O
the	O
tRNAPhe	B-protein
and	O
tRNAPro	B-protein
genes	I-protein
of	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
is	O
essential	O
for	O
regulation	O
of	O
replication	O
and	O
transcription	O
of	O
the	O
mitochondrial	O
genome	O
.	O

The	O
gene	O
structure	O
of	O
Elk1	B-protein
spans	O
15	O
.	O
2	O
kb	O
and	O
consists	O
of	O
seven	O
exons	O
and	O
six	O
introns	O
.	O

The	O
structure	O
of	O
digiprogenin	O
.	O

We	O
have	O
isolated	O
and	O
characterised	O
a	O
differentially	O
-	O
regulated	O
gene	O
family	O
in	O
the	O
protozoan	O
parasite	O
Leishmania	O
major	O
.	O

The	O
quantitative	O
determination	O
of	O
HBSAG	O
-	O
-	O
a	O
valuable	O
aid	O
in	O
evaluating	O
the	O
infectiousness	O
of	O
hepatitis	O
B	O
virus	O
carriers	O
.	O

Saccharomyces	O
cerevisiae	O
activates	O
a	O
regulatory	O
network	O
called	O
`	O
`	O
general	O
control	O
'	O
'	O
that	O
provides	O
the	O
cell	O
with	O
sufficient	O
amounts	O
of	O
protein	O
precursors	O
during	O
amino	O
acid	O
starvation	O
.	O

The	O
cardiac	B-protein
myosin	I-protein
light	I-protein
chain	I-protein
-	I-protein
2	I-protein
(	O
MLC	B-protein
-	I-protein
2	I-protein
)	O
gene	O
promoter	O
contains	O
several	O
positive	O
and	O
negative	O
cis	O
-	O
acting	O
sequences	O
that	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
its	O
expression	O
.	O

No	O
apparent	O
clinical	O
signs	O
indicative	O
of	O
systemic	O
toxicity	O
were	O
observed	O
in	O
the	O
F0	O
and	O
F1	O
animals	O
of	O
either	O
sex	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
endometriosis	O
increases	O
soluble	O
CD23	B-protein
levels	O
,	O
which	O
can	O
be	O
suppressed	O
with	O
either	O
danazol	O
or	O
leuprolide	O
acetate	O
injection	O
.	O

Insulin	O
-	O
regulated	O
events	O
,	O
however	O
,	O
occur	O
in	O
all	O
cells	O
.	O

The	O
major	O
urinary	O
metabolites	O
were	O
3	O
-	O
(	O
3	O
-	O
carboxyphenyl	O
)	O
-	O
5	O
-	O
hydroxymethyl	O
-	O
2	O
-	O
oxazolidinone	O
and	O
a	O
glucuronide	O
of	O
toloxatone	O
.	O

This	O
suggested	O
that	O
baboon	B-protein
liver	I-protein
class	I-protein
I	I-protein
ADH	I-protein
is	O
of	O
the	O
same	O
ancestral	O
lineage	O
as	O
the	O
human	B-protein
ADH	I-protein
-	I-protein
beta	I-protein
.	O

Nine	O
DNA	O
fragments	O
that	O
were	O
specifically	O
recognized	O
and	O
bound	O
by	O
histidine	O
-	O
tagged	O
AdpA	B-protein
were	O
isolated	O
by	O
cycles	O
of	O
a	O
gel	O
mobility	O
shift	O
-	O
PCR	O
method	O
.	O

The	O
zta	B-protein
transactivator	I-protein
involved	O
in	O
induction	O
of	O
lytic	O
cycle	O
gene	O
expression	O
in	O
Epstein	O
-	O
Barr	O
virus	O
-	O
infected	O
lymphocytes	O
binds	O
to	O
both	O
AP	B-protein
-	I-protein
1	I-protein
and	O
ZRE	B-protein
sites	I-protein
in	O
target	O
promoter	O
and	O
enhancer	O
regions	O
.	O

The	O
pen	O
can	O
heal	O
.	O

The	O
nuclear	O
proteins	O
encoded	O
by	O
the	O
c	B-protein
-	I-protein
fos	I-protein
and	O
c	B-protein
-	I-protein
jun	I-protein
protooncogenes	I-protein
are	O
expressed	O
during	O
the	O
proliferation	O
period	O
of	O
osteoblast	O
phenotype	O
development	O
.	O

The	O
effect	O
of	O
the	O
thromboxane	B-protein
A2	I-protein
(	I-protein
TXA2	I-protein
)	I-protein
/	I-protein
prostaglandin	I-protein
endoperoxide	I-protein
receptor	I-protein
antagonist	O
,	O
SQ	O
29	O
,	O
548	O
on	O
pacing	O
-	O
induced	O
ischemia	O
was	O
determined	O
in	O
anesthetized	O
open	O
-	O
chest	O
dogs	O
.	O

Two	O
differentially	O
expressed	O
LNX	B-protein
messages	I-protein
encode	O
overlapping	O
proteins	O
with	O
predicted	O
molecular	O
masses	O
of	O
80	B-protein
kDa	I-protein
(	I-protein
LNX	I-protein
)	I-protein
and	O
70	B-protein
kDa	I-protein
(	I-protein
LNX	I-protein
-	I-protein
b	I-protein
)	I-protein
.	O

Recessive	O
lethal	O
mutations	O
were	O
isolated	O
based	O
upon	O
failure	O
to	O
complement	O
the	O
recessive	O
lethality	O
of	O
Df	O
(	O
3L	O
)	O
RR2	O
,	O
a	O
deletion	O
of	O
the	O
DRE	B-protein
region	I-protein
that	O
removes	O
16	O
-	O
18	O
polytene	O
chromosome	O
bands	O
.	O

Therefore	O
,	O
the	O
molecular	O
mechanisms	O
of	O
the	O
estrogen	O
action	O
that	O
govern	O
the	O
lactoferrin	B-protein
gene	I-protein
expression	O
differ	O
between	O
mouse	O
and	O
human	O
.	O

The	O
program	O
has	O
been	O
written	O
in	O
a	O
generic	O
BASIC	O
in	O
order	O
to	O
make	O
the	O
procedure	O
user	O
-	O
friendly	O
.	O

Small	B-protein
Maf	I-protein
proteins	I-protein
heterodimerize	O
with	O
Fos	B-protein
and	O
may	O
act	O
as	O
competitive	O
repressors	O
of	O
the	O
NF	B-protein
-	I-protein
E2	I-protein
transcription	I-protein
factor	I-protein
.	O

These	O
and	O
other	O
data	O
presented	O
suggest	O
that	O
TAg	B-protein
'	O
re	O
-	O
models	O
'	O
host	O
cell	O
transcription	O
factors	O
that	O
are	O
used	O
early	O
in	O
viral	O
infection	O
,	O
and	O
thereby	O
mimics	O
an	O
event	O
that	O
naturally	O
occurs	O
during	O
transformation	O
.	O

One	O
P1	O
genomic	O
clone	O
and	O
six	O
subsequent	O
plasmid	O
subclones	O
were	O
isolated	O
and	O
analyzed	O
for	O
the	O
exon	O
-	O
intron	O
organization	O
of	O
the	O
Ctpct	B-protein
gene	I-protein
.	O

A	O
second	O
study	O
group	O
,	O
with	O
intact	O
cardiac	O
innervation	O
,	O
consisted	O
of	O
19	O
patients	O
with	O
stable	O
angina	O
pectoris	O
class	O
I	O
to	O
III	O
.	O

No	O
significant	O
differences	O
could	O
be	O
seen	O
in	O
response	O
rates	O
according	O
to	O
the	O
concentration	O
of	O
estrogen	B-protein
receptors	I-protein
or	O
presence	O
of	O
progesteron	B-protein
receptors	I-protein
in	O
this	O
group	O
of	O
patients	O
.	O

Surface	O
-	O
coil	O
experiments	O
on	O
phantoms	O
and	O
on	O
human	O
calf	O
muscles	O
in	O
vivo	O
are	O
presented	O
.	O

Six	O
patients	O
with	O
glomerulonephritis	O
in	O
association	O
with	O
a	O
ventriculovascular	O
shunt	O
were	O
treated	O
with	O
three	O
basic	O
modes	O
of	O
therapy	O
.	O

The	O
results	O
obtained	O
tend	O
to	O
prove	O
that	O
the	O
reticuloendothelial	O
system	O
mainly	O
participated	O
in	O
beryllium	O
retention	O
.	O

One	O
hundred	O
twenty	O
units	O
of	O
deglycerolized	O
red	O
blood	O
cells	O
,	O
some	O
with	O
glycerol	O
added	O
so	O
as	O
to	O
exceed	O
an	O
acceptable	O
1	O
%	O
glycerol	O
content	O
,	O
had	O
measurements	O
made	O
of	O
the	O
post	O
-	O
wash	O
supernatant	O
fluid	O
by	O
refractive	O
index	O
and	O
osmometry	O
.	O

The	O
E	O
-	O
box	O
sequence	O
in	O
the	O
SE2	B-protein
fragment	I-protein
of	O
the	O
transferrin	B-protein
promoter	I-protein
was	O
CATCTG	O
and	O
was	O
similar	O
in	O
gel	O
shifts	O
to	O
the	O
consensus	O
E	O
-	O
box	O
elements	O
(	O
CANNTG	O
)	O
previously	O
characterized	O
.	O

Although	O
human	O
infections	O
with	O
bacteraemia	O
due	O
to	O
Pasteurella	O
multocida	O
are	O
not	O
uncommon	O
,	O
endocarditis	O
associated	O
with	O
P	O
.	O
haemolytica	O
is	O
rare	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
association	O
of	O
depressive	O
symptoms	O
with	O
HIV	O
-	O
related	O
mortality	O
and	O
decline	O
in	O
CD4	B-protein
lymphocyte	O
counts	O
among	O
women	O
with	O
HIV	O
.	O

Positive	O
CRP	B-protein
test	O
were	O
seen	O
.	O

RA	O
-	O
treatment	O
of	O
these	O
transfectants	O
induced	O
morphologic	O
and	O
immunophenotypic	O
maturation	O
,	O
changes	O
in	O
RA	O
-	O
regulated	O
genes	O
,	O
and	O
a	O
G1	O
cell	O
cycle	O
arrest	O
in	O
a	O
manner	O
similar	O
to	O
parental	O
NT2	O
/	O
D1	O
cells	O
.	O

Surprisingly	O
,	O
TFIIIC	B-protein
alpha	I-protein
has	O
no	O
homology	O
to	O
any	O
of	O
the	O
yeast	B-protein
TFIIIC	I-protein
subunits	I-protein
already	O
cloned	O
,	O
suggesting	O
a	O
significant	O
degree	O
of	O
evolutionary	O
divergence	O
for	O
RNA	B-protein
polymerase	I-protein
III	I-protein
factors	I-protein
.	O

When	O
used	O
subcutaneously	O
or	O
intravenously	O
in	O
maximum	O
tolerated	O
doses	O
the	O
antibiotic	O
inhibited	O
the	O
development	O
of	O
lymphadenosis	O
NK	O
/	O
Li	O
by	O
90	O
and	O
70	O
per	O
cent	O
respectively	O
.	O

Only	O
after	O
a	O
pretreatment	O
aimed	O
at	O
increasing	O
its	O
oxide	O
surface	O
layer	O
was	O
titanium	O
powder	O
found	O
to	O
accelerate	O
the	O
precipitation	O
from	O
solutions	O
containing	O
2	O
mmol	O
/	O
L	O
CaCl2	O
,	O
2	O
mmol	O
/	O
L	O
KH2PO4	O
,	O
50	O
mmol	O
/	O
L	O
Hepes	O
,	O
pH	O
7	O
.	O
2	O
,	O
and	O
to	O
induce	O
precipitation	O
from	O
metastable	O
solutions	O
containing	O
1	O
.	O
2	O
mmol	O
/	O
L	O
CaCl2	O
,	O
1	O
.	O
2	O
mmol	O
/	O
L	O
KH2PO4	O
,	O
50	O
mmol	O
/	O
L	O
Hepes	O
,	O
pH	O
7	O
.	O
2	O
,	O
at	O
37	O
degrees	O
C	O
.	O

The	O
approach	O
derives	O
from	O
a	O
recently	O
described	O
strategy	O
for	O
making	O
recombinants	O
from	O
five	O
overlapping	O
EBV	O
cosmid	O
-	O
cloned	O
DNAs	O
(	O
B	O
.	O

Using	O
homology	O
cloning	O
techniques	O
,	O
we	O
identified	O
a	O
mouse	O
homologue	O
of	O
E	B-protein
(	I-protein
Pc	I-protein
)	I-protein
,	O
termed	O
Epc1	B-protein
,	O
a	O
yeast	O
protein	O
that	O
we	O
name	O
EPL1	B-protein
,	O
and	O
as	O
well	O
as	O
additional	O
ESTs	O
from	O
Caenorhabditis	O
elegans	O
,	O
mice	O
and	O
humans	O
.	O

The	O
promoter	O
of	O
the	O
rat	B-protein
pgp2	I-protein
/	I-protein
mdr1b	I-protein
gene	I-protein
has	O
a	O
GC	O
-	O
rich	O
region	O
(	O
pgp2GC	B-protein
)	O
that	O
is	O
highly	O
conserved	O
in	O
mdr	B-protein
genes	I-protein
and	O
contains	O
an	O
consensus	O
Sp1	B-protein
site	I-protein
.	O

Detection	O
of	O
congenital	O
hypothyroidism	O
in	O
26	O
,	O
282	O
newborn	O
infants	O
.	O

A	O
polymorphic	O
bipartite	O
motif	O
signals	O
nuclear	O
targeting	O
of	O
early	O
auxin	O
-	O
inducible	O
proteins	O
related	O
to	O
PS	B-protein
-	I-protein
IAA4	I-protein
from	I-protein
pea	I-protein
(	I-protein
Pisum	I-protein
sativum	I-protein
)	I-protein
.	O

A	O
two	O
phase	O
slug	O
flow	O
tubular	O
heat	O
exchanger	O
was	O
used	O
for	O
the	O
thermal	O
inactivation	O
of	O
Listeria	O
monocytogenes	O
in	O
natural	O
infected	O
milk	O
from	O
seven	O
cows	O
.	O

Granisetron	O
,	O
but	O
not	O
saline	O
,	O
abolished	O
vomiting	O
and	O
nausea	O
when	O
given	O
as	O
intervention	O
after	O
this	O
combined	O
emetic	O
regimen	O
.	O

Upstream	O
of	O
-	O
37	O
,	O
the	O
5	O
'	O
untranslated	O
sequences	O
of	O
the	O
isolates	O
differ	O
in	O
both	O
length	O
and	O
sequence	O
.	O

Lysine	B-protein
-	I-protein
ketoglutarate	I-protein
reductase	I-protein
and	O
saccharopine	B-protein
dehydrogenase	I-protein
from	O
Arabidopsis	O
thaliana	O
:	O
nucleotide	O
sequence	O
and	O
characterization	O
.	O

To	O
test	O
the	O
feasibility	O
of	O
using	O
liposomes	O
to	O
deliver	O
therapeutic	O
agents	O
to	O
the	O
lungs	O
,	O
the	O
effect	O
of	O
liposome	O
-	O
encapsulated	O
superoxide	B-protein
dismutase	I-protein
(	O
SOD	B-protein
)	O
or	O
catalase	B-protein
on	O
pulmonary	O
oxygen	O
toxicity	O
was	O
studied	O
in	O
rats	O
.	O

3	O
activities	O
of	O
the	O
factor	B-protein
II	I-protein
molecule	O
in	O
the	O
newborn	O
infant	O
at	O
term	O
.	O

Patients	O
with	O
lesions	O
affecting	O
the	O
PRC	O
but	O
sparing	O
the	O
PHC	O
,	O
and	O
patients	O
with	O
lesions	O
affecting	O
both	O
PRC	O
and	O
PHC	O
,	O
performed	O
an	O
oculomotor	O
delayed	O
response	O
task	O
with	O
unpredictably	O
varied	O
memory	O
delays	O
of	O
up	O
to	O
30	O
s	O
.	O

Relaxation	O
of	O
catch	O
in	O
a	O
molluscan	O
smooth	O
muscle	O
.	O

Chinese	O
Spring	O
(	O
CS	O
)	O
carrying	O
the	O
Q	B-protein
gene	I-protein
to	O
those	O
of	O
a	O
chromosome	O
deletion	O
line	O
of	O
CS	O
,	O
namely	O
,	O
q5	O
,	O
which	O
lacks	O
15	O
%	O
of	O
5AL	O
including	O
the	O
Q	B-protein
gene	I-protein
.	O

The	O
resulting	O
R	B-protein
protein	I-protein
terminates	O
five	O
codons	O
downstream	O
of	O
the	O
frameshift	O
site	O
at	O
the	O
V	B-protein
protein	I-protein
stop	O
codon	O
.	O

Perilunar	O
luxation	O
-	O
-	O
an	O
unusual	O
injury	O
demanding	O
immediate	O
and	O
correct	O
treatment	O
.	O

Insulin	B-protein
-	I-protein
like	I-protein
growth	I-protein
factor	I-protein
-	I-protein
binding	I-protein
protein	I-protein
-	I-protein
2	I-protein
(	O
IGF	B-protein
-	I-protein
BP	I-protein
-	I-protein
2	I-protein
)	O
transcription	O
in	O
rat	O
liver	O
varies	O
with	O
developmental	O
age	O
and	O
fasting	O
.	O

In	O
recent	O
years	O
,	O
successful	O
physiological	O
models	O
have	O
been	O
developed	O
for	O
a	O
variety	O
of	O
volatile	O
and	O
nonvolatile	O
chemicals	O
,	O
and	O
their	O
ability	O
to	O
perform	O
the	O
extrapolations	O
needed	O
in	O
risk	O
assessment	O
has	O
been	O
demonstrated	O
.	O

These	O
data	O
indicate	O
that	O
the	O
third	O
intracellular	O
loop	O
of	O
the	O
rat	B-protein
GnRH	I-protein
-	I-protein
R	I-protein
is	O
involved	O
in	O
receptor	B-protein
G	I-protein
(	I-protein
q	I-protein
/	I-protein
11	I-protein
)	I-protein
protein	I-protein
coupling	O
and	O
/	O
or	O
selectivity	O
,	O
and	O
in	O
the	O
GGH	O
(	O
3	O
)	O
1	O
'	O
cell	O
line	O
,	O
this	O
loop	O
is	O
also	O
involved	O
in	O
signal	O
transduction	O
mediated	O
through	O
the	O
Gs	B-protein
protein	I-protein
pathway	I-protein
.	O

Evidence	O
from	O
the	O
structure	O
of	O
a	O
number	O
of	O
cDNA	O
clones	O
,	O
as	O
well	O
as	O
S1	B-protein
nuclease	I-protein
and	O
primer	O
extension	O
studies	O
supports	O
the	O
hypothesis	O
that	O
the	O
PTHrP	B-protein
gene	I-protein
contains	O
at	O
least	O
two	O
mRNA	O
transcription	O
start	O
points	O
that	O
define	O
two	O
putative	O
regulatory	O
domains	O
.	O

Since	O
proteins	O
containing	O
TPR	B-protein
elements	I-protein
are	O
typically	O
involved	O
in	O
multiple	O
protein	O
-	O
protein	O
interactions	O
,	O
we	O
suggest	O
that	O
the	O
102kD	O
protein	O
interacts	O
within	O
the	O
tri	B-protein
-	I-protein
snRNP	I-protein
with	O
both	O
the	O
U5	B-protein
and	I-protein
U4	I-protein
/	I-protein
U6	I-protein
snRNPs	I-protein
,	O
thus	O
bridging	O
the	O
two	O
particles	O
.	O

The	O
comparison	O
of	O
the	O
expression	O
patterns	O
of	O
the	O
known	O
Kv4	B-protein
family	I-protein
members	I-protein
shows	O
subtype	O
specificity	O
with	O
significant	O
overlaps	O
.	O

Some	O
strains	O
of	O
A	O
.	O
parasiticus	O
produced	O
all	O
four	O
aflatoxins	B-protein
B1	I-protein
B2	I-protein
G1	I-protein
G2	I-protein
,	O
while	O
the	O
other	O
ones	O
produced	O
AF	B-protein
B1	I-protein
+	O
G1	B-protein
only	O
,	O
with	O
concentrations	O
of	O
aflatoxins	B-protein
from	O
0	O
.	O
1	O
to	O
450	O
mg	O
/	O
kg	O
.	O

4	O
.	O

We	O
have	O
examined	O
the	O
ability	O
of	O
various	O
NF	B-protein
-	I-protein
kappa	I-protein
B	I-protein
subunits	I-protein
to	O
bind	O
to	O
,	O
and	O
activate	O
transcription	O
from	O
,	O
the	O
IL	B-protein
-	I-protein
8	I-protein
promoter	I-protein
.	O

In	O
another	O
study	O
,	O
intravenous	O
administration	O
of	O
devazepide	O
,	O
a	O
specific	O
cholecystokinin	B-protein
-	I-protein
A	I-protein
receptor	I-protein
antagonist	O
,	O
at	O
a	O
dose	O
of	O
0	O
.	O
1	O
mg	O
/	O
kg	O
/	O
hr	O
was	O
begun	O
15	O
min	O
before	O
postprandial	O
saline	O
intake	O
and	O
continued	O
for	O
1	O
hr	O
.	O

In	O
the	O
icosahaedral	O
MVMi	O
capsid	O
,	O
this	O
sequence	O
forms	O
the	O
carboxy	O
end	O
of	O
the	O
amphipathic	O
beta	B-protein
-	I-protein
strand	I-protein
I	I-protein
(	O
betaI	B-protein
)	O
,	O
and	O
all	O
its	O
basic	O
residues	O
are	O
contiguously	O
positioned	O
at	O
the	O
face	O
that	O
in	O
the	O
unassembled	O
subunit	O
would	O
be	O
exposed	O
to	O
solvent	O
.	O

Both	O
receptors	O
utilize	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
(	O
PTKs	B-protein
)	O
for	O
the	O
phosphorylation	O
of	O
various	O
signaling	O
molecules	O
,	O
a	O
process	O
that	O
is	O
critical	O
for	O
the	O
function	O
of	O
both	O
receptors	O
.	O

Because	O
the	O
Pit	B-protein
-	I-protein
1	I-protein
sites	I-protein
in	O
the	O
hGH	B-protein
-	I-protein
N	I-protein
gene	I-protein
promoter	I-protein
are	O
insufficient	O
for	O
such	O
gene	O
activation	O
in	O
vivo	O
,	O
these	O
data	O
suggested	O
a	O
unique	O
chromatin	O
-	O
mediated	O
developmental	O
role	O
for	O
Pit	B-protein
-	I-protein
1	I-protein
in	O
the	O
hGH	B-protein
LCR	I-protein
.	O

Optical	O
-	O
absorption	O
spectra	O
,	O
crystal	O
-	O
field	O
energy	O
levels	O
,	O
and	O
transition	O
line	O
strengths	O
of	O
holmium	O
in	O
trigonal	O
Na3	O
[	O
Ho	O
(	O
C4H4O5	O
)	O
3	O
]	O
[	O
sdot	O
]	O
2NaClO4	O
[	O
sdot	O
]	O
6H2O	O
.	O

During	O
organogenesis	O
,	O
HFH	B-protein
-	I-protein
8	I-protein
expression	O
is	O
found	O
in	O
the	O
splanchnic	O
mesoderm	O
in	O
close	O
apposition	O
of	O
the	O
gut	O
endoderm	O
,	O
suggesting	O
a	O
role	O
in	O
mesenchymal	O
-	O
epithelial	O
induction	O
of	O
lung	O
and	O
gut	O
morphogenesis	O
.	O

The	O
IgA	B-protein
deficiency	O
is	O
combined	O
with	O
the	O
IgE	B-protein
one	O
.	O

Our	O
results	O
suggest	O
that	O
Anu2p	B-protein
is	O
the	O
yeast	B-protein
homologue	I-protein
of	I-protein
mammalian	I-protein
epsilon	I-protein
-	I-protein
COP	I-protein
and	O
the	O
abrupt	O
accumulation	O
of	O
the	O
ER	O
membrane	O
caused	O
by	O
a	O
blockage	O
of	O
the	O
early	O
protein	O
transport	O
pathway	O
leads	O
to	O
alteration	O
of	O
nuclear	O
morphology	O
of	O
the	O
budding	O
yeast	O
cells	O
.	O

The	O
penicillin	B-protein
binding	I-protein
proteins	I-protein
(	O
PBPs	B-protein
)	O
synthesize	O
and	O
remodel	O
peptidoglycan	O
,	O
the	O
structural	O
component	O
of	O
the	O
bacterial	O
cell	O
wall	O
.	O

Effect	O
of	O
hyperglycemia	O
on	O
pain	O
threshold	O
in	O
alloxan	O
-	O
diabetic	O
rats	O
.	O

Using	O
an	O
ELISA	O
,	O
we	O
found	O
that	O
surfactant	B-protein
protein	I-protein
A	I-protein
(	O
SP	B-protein
-	I-protein
A	I-protein
)	O
was	O
markedly	O
elevated	O
in	O
the	O
pneumonia	O
patients	O
.	O

Resistance	O
ratios	O
for	O
the	O
other	O
field	O
strains	O
obtained	O
by	O
comparison	O
with	O
the	O
R5	O
strain	O
ranged	O
from	O
24	O
.	O
5	O
to	O
239	O
for	O
topical	O
application	O
and	O
from	O
1	O
.	O
2	O
to	O
9	O
.	O
8	O
for	O
the	O
glass	O
jar	O
method	O
.	O

Among	O
the	O
v	B-protein
-	I-protein
myc	I-protein
codons	O
,	O
the	O
first	O
5	O
are	O
derived	O
from	O
the	O
noncoding	O
5	O
'	O
terminus	O
of	O
the	O
second	O
c	B-protein
-	I-protein
myc	I-protein
exon	O
,	O
and	O
412	O
codons	O
correspond	O
to	O
the	O
c	B-protein
-	I-protein
myc	I-protein
coding	O
region	O
.	O

A	O
cDNA	O
for	O
a	O
newly	O
discovered	O
pseudogene	O
,	O
closely	O
related	O
to	O
the	O
mouse	B-protein
mast	I-protein
cell	I-protein
chymases	I-protein
was	O
isolated	O
by	O
polymerase	B-protein
chain	O
reaction	O
amplification	O
from	O
a	O
mouse	O
connective	O
tissue	O
-	O
like	O
mast	O
cell	O
line	O
.	O

Expression	O
of	O
the	O
mouse	B-protein
TSH	I-protein
beta	I-protein
gene	I-protein
,	O
therefore	O
,	O
gives	O
rise	O
to	O
multiple	O
mRNAs	O
,	O
each	O
with	O
a	O
unique	O
5	O
'	O
-	O
untranslated	O
region	O
.	O

The	O
nucleotide	O
sequences	O
of	O
these	O
genes	O
differ	O
at	O
only	O
nine	O
positions	O
,	O
resulting	O
in	O
three	O
amino	O
acid	O
differences	O
.	O

Thromboplastic	O
and	O
fibrynolytic	O
activity	O
of	O
the	O
blood	O
after	O
administration	O
of	O
intralipid	O
in	O
men	O
with	O
history	O
of	O
myocardial	O
infarction	O
up	O
to	O
45	O
year	O
of	O
life	O
.	O

Many	O
factors	O
do	O
influence	O
the	O
educational	O
outcome	O
in	O
students	O
and	O
large	O
statistical	O
power	O
(	O
such	O
as	O
meta	O
analysis	O
)	O
should	O
be	O
helpful	O
to	O
eliminate	O
many	O
souces	O
of	O
error	O
.	O

We	O
show	O
that	O
a	O
protein	O
,	O
UBC9	B-protein
,	O
interacts	O
specifically	O
with	O
TEL	B-protein
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Thus	O
,	O
this	O
reading	O
frame	O
was	O
concluded	O
to	O
encode	O
the	O
precursor	O
of	O
mitochondrial	B-protein
fumarase	I-protein
.	O

By	O
contrast	O
,	O
all	O
proteins	O
initiated	O
with	O
a	O
methionine	O
placed	O
one	O
residue	O
upstream	O
of	O
the	O
natural	O
N	O
terminus	O
of	O
PR	B-protein
failed	O
to	O
show	O
specific	O
proteolysis	O
.	O

In	O
this	O
paper	O
,	O
characterization	O
is	O
given	O
of	O
clinical	O
and	O
biochemical	O
features	O
of	O
VH	O
B	O
course	O
against	O
the	O
background	O
of	O
narcomania	O
.	O

Current	O
evidence	O
for	O
this	O
type	O
of	O
DNA	O
supercoiling	O
-	O
dependent	O
transcriptional	O
coupling	O
,	O
based	O
largely	O
on	O
the	O
in	O
vivo	O
activities	O
of	O
promoters	O
contained	O
in	O
engineered	O
DNA	O
constructs	O
,	O
suggests	O
that	O
the	O
transcription	O
complex	O
must	O
be	O
physically	O
hindered	O
to	O
generate	O
DNA	O
supercoils	O
and	O
to	O
prevent	O
their	O
diffusion	O
throughout	O
the	O
DNA	O
duplex	O
.	O

With	O
the	O
help	O
of	O
a	O
nomogram	O
one	O
can	O
read	O
off	O
the	O
refraction	O
,	O
when	O
axis	O
length	O
and	O
corneal	O
curvature	O
are	O
known	O
.	O

A	O
subset	O
of	O
patients	O
(	O
n	O
=	O
30	O
)	O
underwent	O
multichannel	O
pressure	O
flow	O
studies	O
,	O
which	O
demonstrated	O
that	O
transrectal	O
HIFU	O
reduces	O
bladder	O
outflow	O
obstruction	O
.	O

Two	O
of	O
seven	O
initiation	O
sites	O
were	O
flanked	O
by	O
a	O
sequence	O
homologous	O
to	O
the	O
consensus	O
promoter	O
motif	O
that	O
includes	O
the	O
CRTA	O
motif	O
(	O
where	O
R	O
is	O
A	O
or	O
G	O
)	O
of	O
the	O
rice	O
mitochondrion	O
.	O

The	O
major	O
type	O
involves	O
activator	O
proteins	O
that	O
bind	O
to	O
DNA	O
adjacent	O
to	O
where	O
the	O
RNA	B-protein
polymerase	I-protein
(	O
RNAP	B-protein
)	O
holoenzyme	O
binds	O
,	O
usually	O
assisting	O
in	O
recruitment	O
of	O
the	O
RNAP	B-protein
to	O
the	O
promoter	O
.	O

The	O
sub	O
-	O
acute	O
inhalation	O
toxicity	O
of	O
furfural	O
was	O
studied	O
in	O
Syrian	O
golden	O
hamsters	O
.	O

Gel	O
retardation	O
assays	O
combined	O
with	O
DNase	B-protein
I	I-protein
footprinting	O
and	O
diethyl	O
pyrocarbonate	O
interference	O
showed	O
that	O
a	O
nuclear	O
factor	O
from	O
differentiated	O
C2	O
myotubes	O
and	O
BC3H1	O
myocytes	O
recognized	O
a	O
conserved	O
A	O
+	O
T	O
-	O
rich	O
sequence	O
within	O
the	O
peripheral	O
activating	O
region	O
.	O

The	O
application	O
of	O
these	O
instruments	O
allows	O
occlusion	O
of	O
the	O
ascending	O
aorta	O
traversed	O
by	O
the	O
perfusion	O
cannula	O
inserted	O
directly	O
or	O
through	O
the	O
apex	O
of	O
the	O
heart	O
as	O
well	O
as	O
simultaneous	O
left	O
ventricular	O
venting	O
.	O

In	O
the	O
formalin	O
test	O
,	O
however	O
,	O
naloxone	O
attenuated	O
morphine	O
analgesia	O
at	O
the	O
lower	O
doses	O
(	O
0	O
.	O
1	O
and	O
0	O
.	O
3	O
mg	O
/	O
kg	O
)	O
and	O
potentiated	O
morphine	O
analgesia	O
at	O
the	O
highest	O
dose	O
(	O
10	O
mg	O
/	O
kg	O
)	O
.	O

5	O
(	O
Sunset	O
Yellow	O
FCF	O
)	O
were	O
determined	O
using	O
liquid	O
chromatography	O
/	O
mass	O
spectrometry	O
(	O
LC	O
/	O
MS	O
)	O
with	O
electrospray	O
ionization	O
.	O

The	O
present	O
results	O
demonstrate	O
that	O
rats	O
with	O
relatively	O
small	O
remnants	O
of	O
one	O
olfactory	O
bulb	O
can	O
perform	O
a	O
variety	O
of	O
odor	O
detection	O
and	O
discrimination	O
tasks	O
as	O
well	O
or	O
nearly	O
as	O
well	O
as	O
controls	O
.	O

Most	O
patients	O
preferred	O
tablets	O
to	O
injection	O
both	O
on	O
day	O
1	O
(	O
313	O
v	O
200	O
)	O
and	O
at	O
follow	O
up	O
(	O
373	O
v	O
104	O
)	O
.	O

IV	O
.	O

Competitive	O
mobility	O
shift	O
assays	O
using	O
either	O
alphaT3	O
-	O
1	O
nuclear	O
extract	O
or	O
recombinant	B-protein
SF	I-protein
-	I-protein
1	I-protein
protein	I-protein
clearly	O
indicated	O
that	O
SF	B-protein
-	I-protein
1	I-protein
is	O
able	O
to	O
interact	O
specifically	O
with	O
this	O
GSE	B-protein
element	I-protein
positioned	O
at	O
-	O
134	O
.	O

A	O
liquid	O
chromatographic	O
method	O
is	O
described	O
for	O
analysis	O
of	O
beta	O
-	O
carotene	O
in	O
medical	O
food	O
.	O

Animals	O
that	O
received	O
DSP	O
-	O
4	O
were	O
significantly	O
retarded	O
in	O
motor	O
recovery	O
compared	O
with	O
the	O
saline	O
group	O
.	O

We	O
determined	O
whether	O
the	O
human	B-protein
StAR	I-protein
promoter	I-protein
is	O
responsive	O
to	O
sterol	B-protein
regulatory	I-protein
element	I-protein
-	I-protein
binding	I-protein
proteins	I-protein
(	O
SREBPs	B-protein
)	O
.	O

We	O
show	O
that	O
other	O
cdc33	B-protein
mutants	I-protein
also	O
arrest	O
in	O
G1	O
.	O

The	O
network	O
evolution	O
was	O
interpreted	O
by	O
an	O
approach	O
based	O
on	O
the	O
Flory	O
model	O
.	O

In	O
addition	O
,	O
the	O
ketamine	O
-	O
treated	O
rats	O
had	O
more	O
neurons	O
and	O
glial	O
cells	O
surrounding	O
the	O
ventricles	O
.	O

The	O
results	O
presented	O
suggest	O
that	O
TIQ	O
reduces	O
the	O
turnover	O
rate	O
of	O
the	O
nigrostriatal	O
dopamine	O
neurons	O
after	O
repeated	O
administration	O
for	O
a	O
long	O
period	O
in	O
mice	O
.	O

And	O
the	O
natural	O
barriers	O
?	O

In	O
experiments	O
with	O
the	O
D1	B-protein
antagonist	O
SCH	O
23390	O
,	O
buprenorphine	O
-	O
induced	O
depression	O
was	O
consistently	O
blocked	O
,	O
but	O
facilitation	O
was	O
unaffected	O
.	O

Each	O
individual	O
shot	O
25	O
bullets	O
in	O
about	O
5	O
minutes	O
,	O
at	O
an	O
intensity	O
level	O
calculated	O
at	O
163	O
dB	O
.	O

Morphine	O
injected	O
into	O
the	O
lateral	O
ventricle	O
of	O
the	O
rat	O
produced	O
unilateral	O
analgesia	O
in	O
the	O
formalin	O
test	O
,	O
which	O
involves	O
continuous	O
,	O
moderate	O
pain	O
.	O

The	O
subjects	O
from	O
the	O
two	O
regions	O
with	O
a	O
higher	O
pollution	O
level	O
had	O
lower	O
FVC	O
and	O
FEV1	O
values	O
than	O
those	O
from	O
the	O
Viskovo	O
region	O
.	O

Specific	O
hyperimmune	B-protein
globulins	I-protein
to	O
pathogens	O
such	O
as	O
Haemophilus	O
influenzae	O
and	O
Streptococcus	O
pneumoniae	O
have	O
also	O
been	O
studied	O
.	O

From	O
day	O
30	O
after	O
turnout	O
,	O
the	O
PFB	O
-	O
group	O
had	O
significantly	O
lower	O
serum	B-protein
pepsinogen	I-protein
levels	O
,	O
which	O
reflects	O
the	O
low	O
degree	O
of	O
abomasal	O
damage	O
in	O
these	O
animals	O
.	O

At	O
the	O
C	O
-	O
terminus	O
of	O
the	O
protein	O
is	O
a	O
domain	O
that	O
contains	O
sequences	O
very	O
similar	O
to	O
those	O
found	O
in	O
the	O
breakpoint	O
cluster	O
region	O
gene	O
product	O
,	O
n	B-protein
-	I-protein
chimerin	I-protein
,	O
and	O
rho	B-protein
GAP	I-protein
,	O
all	O
of	O
which	O
have	O
been	O
shown	O
to	O
possess	O
intrinsic	O
GAP	B-protein
activity	O
on	O
small	B-protein
GTPases	I-protein
.	O

Skin	O
and	O
bowel	O
TPO2	O
varied	O
with	O
DO2	O
and	O
each	O
other	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
order	O
to	O
identify	O
and	O
classify	O
the	O
basic	O
CT	O
appearances	O
of	O
interstitial	O
pneumonia	O
,	O
radiologic	O
-	O
pathologic	O
correlative	O
study	O
was	O
performed	O
using	O
inflated	O
and	O
fixed	O
lungs	O
from	O
autopsy	O
and	O
surgery	O
.	O

Thrombotic	O
thrombocytopenic	O
purpura	O
in	O
systemic	O
lupus	O
erythematosus	O
.	O

Local	O
graft	O
irradiation	O
as	O
an	O
adjunct	O
to	O
pharmacologic	O
immunosuppression	O
.	O

The	O
US	O
National	O
Institute	O
on	O
Alcohol	O
Abuse	O
and	O
Alcoholism	O
(	O
NIAAA	O
)	O
recognizes	O
two	O
forms	O
of	O
problematic	O
drinking	O
:	O
'	O
willful	O
alcohol	O
abuse	O
'	O
,	O
a	O
behavioural	O
problem	O
,	O
and	O
'	O
alcohol	O
dependence	O
'	O
,	O
a	O
true	O
medical	O
disorder	O
,	O
which	O
includes	O
a	O
genetic	O
component	O
,	O
that	O
can	O
be	O
scientifically	O
understood	O
and	O
medically	O
treated	O
.	O

Oleate	O
induced	O
steady	O
-	O
state	O
levels	O
of	O
M	B-protein
-	I-protein
CPT	I-protein
I	I-protein
mRNA	I-protein
4	O
.	O
5	O
-	O
fold	O
.	O

A	O
MEK	O
-	O
specific	O
inhibitor	O
(	O
PD098059	O
)	O
(	O
Dudley	O
,	O
D	O
.	O

Of	O
major	O
concern	O
to	O
food	O
processors	O
is	O
the	O
inadvertent	O
cross	O
-	O
contact	O
of	O
food	O
products	O
with	O
allergenic	O
residues	O
,	O
which	O
could	O
result	O
in	O
potentially	O
life	O
-	O
threatening	O
reactions	O
in	O
those	O
with	O
a	O
food	O
allergy	O
.	O

No	O
homologs	O
of	O
other	O
members	O
of	O
the	O
Surfeit	B-protein
gene	I-protein
cluster	I-protein
were	O
detected	O
in	O
close	O
proximity	O
to	O
the	O
D	B-protein
.	I-protein
melanogaster	I-protein
Surf	I-protein
-	I-protein
3	I-protein
/	I-protein
rpL7a	I-protein
gene	I-protein
.	I-protein
(	I-protein
ABSTRACT	I-protein
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Dopamine	O
caused	O
a	O
prominent	O
potassium	O
efflux	O
measured	O
as	O
86Rb	O
+	O
efflux	O
from	O
control	O
glands	O
,	O
but	O
was	O
without	O
effect	O
in	O
denervated	O
glands	O
.	O

DATA	O
SYNTHESIS	O
:	O
Intracoronary	O
ultrasound	O
has	O
been	O
shown	O
to	O
improve	O
upon	O
demonstrated	O
weaknesses	O
of	O
coronary	O
angiography	O
.	O

Serial	O
levels	O
of	O
troponin	B-protein
T	I-protein
and	O
the	O
activity	O
of	O
CK	B-protein
-	I-protein
MB	I-protein
were	O
measured	O
6	O
,	O
12	O
,	O
24	O
and	O
48	O
h	O
after	O
aortic	O
unclamping	O
.	O

We	O
also	O
show	O
that	O
activation	O
of	O
protein	B-protein
kinase	I-protein
A	I-protein
(	O
PKA	B-protein
)	O
signaling	O
is	O
sufficient	O
to	O
down	O
-	O
regulate	O
caveolin	B-protein
-	I-protein
1	I-protein
protein	I-protein
expression	O
and	O
promoter	O
activity	O
.	O

As	O
expected	O
,	O
glycosylation	O
of	O
Env	B-protein
produced	O
from	O
mutants	O
was	O
affected	O
but	O
,	O
irrespective	O
of	O
the	O
glycosylation	O
phenotype	O
,	O
(	O
i	O
)	O
similar	O
quantities	O
of	O
Env	B-protein
were	O
synthesized	O
,	O
(	O
ii	O
)	O
the	O
immunoreactivity	O
of	O
V3	O
was	O
similar	O
,	O
(	O
iii	O
)	O
gp160	B-protein
was	O
efficiently	O
cleaved	O
into	O
gp120	B-protein
and	O
gp41	B-protein
,	O
(	O
vi	O
)	O
Env	B-protein
was	O
exposed	O
at	O
the	O
cell	O
membrane	O
,	O
(	O
v	O
)	O
secreted	O
gp120	B-protein
bound	O
CD4	B-protein
,	O
and	O
(	O
vi	O
)	O
membrane	O
gp41	B-protein
was	O
able	O
to	O
induce	O
membrane	O
fusion	O
with	O
CD4	B-protein
+	I-protein
cells	O
.	O

Significantly	O
,	O
the	O
polymerase	O
chain	O
reaction	O
results	O
demonstrated	O
that	O
gene	B-protein
IV	I-protein
transcripts	I-protein
were	O
associated	O
with	O
hepatic	O
polysome	O
fractions	O
,	O
indicating	O
their	O
active	O
utilization	O
in	O
this	O
tissue	O
.	O

On	O
transition	O
from	O
high	O
to	O
low	O
voltage	O
there	O
was	O
a	O
significant	O
fall	O
in	O
arterial	O
pressure	O
(	O
7	O
%	O
)	O
and	O
an	O
increase	O
in	O
flow	O
(	O
19	O
-	O
38	O
%	O
)	O
to	O
areas	O
of	O
the	O
brain	O
corresponding	O
to	O
the	O
arborization	O
of	O
the	O
reticular	O
formation	O
,	O
i	O
.	O
e	O
.	O
excluding	O
the	O
cerebrum	O
and	O
cerebellum	O
.	O

The	O
results	O
indicate	O
that	O
the	O
pooling	O
requirements	O
are	O
task	O
dependent	O
.	O

Also	O
,	O
the	O
anti	O
-	O
inflammatory	O
activities	O
of	O
an	O
aqueous	O
extract	O
of	O
Buddleia	O
cordata	O
and	O
its	O
principal	O
glycoside	O
linarin	O
were	O
evaluated	O
.	O

The	O
possible	O
mechanisms	O
underlying	O
differences	O
in	O
post	O
-	O
tetanic	O
effects	O
from	O
muscle	O
and	O
cutaneous	O
afferents	O
in	O
adults	O
and	O
neonates	O
are	O
discussed	O
.	O

This	O
report	O
provides	O
further	O
evidence	O
for	O
the	O
riMLF	O
in	O
the	O
control	O
of	O
downgaze	O
,	O
and	O
a	O
synkinesis	O
is	O
postulated	O
for	O
the	O
development	O
of	O
the	O
convergence	O
retraction	O
nystagmus	O
.	O

Abnormal	O
calcium	O
metabolism	O
in	O
normocalcaemic	O
sarcoidosis	O
[	O
letter	O
]	O
.	O

All	O
patients	O
diagnosed	O
of	O
H	O
.	O
influenza	O
type	O
b	O
meningitis	O
were	O
less	O
than	O
3	O
years	O
old	O
.	O

This	O
lack	O
of	O
correlation	O
may	O
be	O
due	O
to	O
variations	O
in	O
the	O
metabolic	O
activity	O
of	O
the	O
endometriotic	O
implants	O
present	O
at	O
different	O
stages	O
of	O
the	O
disease	O
.	O

A	O
probe	O
evoked	O
potentials	O
procedure	O
was	O
used	O
to	O
assess	O
the	O
relative	O
engagement	O
of	O
both	O
cerebral	O
hemispheres	O
during	O
a	O
language	O
task	O
in	O
the	O
following	O
four	O
groups	O
of	O
dextral	O
adults	O
:	O
left	O
hemisphere	O
(	O
LH	O
)	O
-	O
damaged	O
aphasics	O
recovering	O
from	O
stroke	O
,	O
dysarthrics	O
,	O
right	O
hemisphere	O
(	O
RH	O
)	O
-	O
damaged	O
nonaphasic	O
patients	O
,	O
and	O
normal	O
control	O
subjects	O
.	O

On	O
Day	O
8	O
,	O
the	O
CIDR	O
-	O
B	O
was	O
removed	O
and	O
500	O
micrograms	O
cloprostenol	O
injected	O
,	O
IM	O
.	O

Plasma	O
glucose	O
,	O
immunoreactive	B-protein
insulin	I-protein
(	O
IRI	B-protein
)	O
,	O
C	B-protein
-	I-protein
peptide	I-protein
,	O
glucagon	B-protein
,	O
and	O
GLP	B-protein
-	I-protein
1	I-protein
levels	O
at	O
each	O
time	O
point	O
during	O
OGTT	O
were	O
measured	O
.	O

The	O
Drosophila	B-protein
insulin	I-protein
receptor	I-protein
homolog	I-protein
:	O
a	O
gene	O
essential	O
for	O
embryonic	O
development	O
encodes	O
two	O
receptor	O
isoforms	O
with	O
different	O
signaling	O
potential	O
.	O

Vitrectomy	O
was	O
still	O
a	O
significant	O
risk	O
factor	O
when	O
macular	O
holes	O
were	O
excluded	O
.	O

The	O
absolute	O
concentrations	O
of	O
alpha	B-protein
2	I-protein
-	I-protein
plasmin	I-protein
inhibitor	O
,	O
alpha	B-protein
2	I-protein
-	I-protein
macroglobulin	I-protein
,	O
and	O
antithrombin	B-protein
III	I-protein
increased	O
with	O
exercise	O
(	O
all	O
P	O
less	O
than	O
0	O
.	O
005	O
)	O
,	O
but	O
when	O
concentrations	O
were	O
corrected	O
for	O
acute	O
shifts	O
of	O
plasma	O
water	O
during	O
exercise	O
,	O
the	O
quantity	O
of	O
these	O
inhibitors	O
actually	O
decreased	O
(	O
all	O
P	O
less	O
than	O
0	O
.	O
005	O
)	O
.	O

In	O
Rat	O
1a	O
cells	O
,	O
m1R	B-protein
stimulation	O
of	O
phospholipase	B-protein
C	I-protein
beta	I-protein
and	O
the	O
marked	O
rise	O
in	O
intracellular	O
calcium	O
stimulated	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
synthesis	O
,	O
resulting	O
in	O
the	O
activation	O
of	O
protein	B-protein
kinase	I-protein
A	O
.	O

Electron	O
microscopic	O
and	O
enzymatic	O
analyses	O
revealed	O
that	O
the	O
A118	O
genome	O
is	O
a	O
linear	O
,	O
circularly	O
permuted	O
,	O
terminally	O
redundant	O
collection	O
of	O
double	O
-	O
stranded	O
DNA	O
molecules	O
.	O

Immunophenotyping	O
in	O
four	O
cases	O
,	O
demonstrated	O
non	O
-	O
B	O
,	O
non	O
-	O
T	O
cell	O
origin	O
in	O
three	O
and	O
pre	O
-	O
B	O
cell	O
origin	O
in	O
one	O
.	O

Of	O
254	O
children	O
with	O
neuroblastoma	O
treated	O
at	O
St	O
.	O

SAMPLE	O
POPULATION	O
:	O
MCB	O
from	O
7	O
racing	O
Greyhounds	O
euthanatized	O
for	O
reasons	O
unrelated	O
to	O
MCB	O
abnormalities	O
.	O

Wild	O
-	O
type	O
protein	O
bound	O
azido	O
-	O
ATP	O
well	O
,	O
but	O
mutants	O
with	O
substitutions	O
in	O
the	O
consensus	O
amino	O
acids	O
were	O
unable	O
to	O
bind	O
azido	O
-	O
ATP	O
.	O

At	O
temperatures	O
permissive	O
for	O
transformation	O
,	O
6m2	O
cells	O
contain	O
P58gag	B-protein
produced	O
from	O
the	O
4	O
.	O
0	O
-	O
kilobase	O
(	O
kb	O
)	O
viral	O
RNA	O
genome	O
and	O
P85gag	B-protein
-	I-protein
mos	I-protein
translated	O
from	O
a	O
3	O
.	O
5	O
-	O
kb	O
spliced	O
mRNA	O
.	O

The	O
reconstituted	O
RNA	B-protein
polymerases	I-protein
containing	O
the	O
mutant	O
alpha	O
subunits	O
were	O
examined	O
for	O
their	O
response	O
to	O
transcription	O
activation	O
by	O
cAMP	B-protein
-	I-protein
CRP	I-protein
and	O
the	O
rrnBP1	B-protein
UP	I-protein
element	I-protein
.	O

2001	O
.	O

In	O
short	O
-	O
term	O
cotransfections	O
,	O
a	O
pFRTK	B-protein
-	I-protein
CAT	I-protein
target	O
containing	O
EBNA	B-protein
-	I-protein
1	I-protein
-	I-protein
binding	I-protein
sites	I-protein
from	O
the	O
EBV	O
origin	O
of	O
plasmid	O
replication	O
,	O
ori	B-protein
-	I-protein
P	I-protein
,	O
was	O
transactivated	O
by	O
a	O
carboxy	B-protein
-	I-protein
terminal	I-protein
EBNA	I-protein
-	I-protein
1	I-protein
construction	I-protein
(	O
amino	O
acids	O
450	O
to	O
641	O
)	O
that	O
also	O
carried	O
a	O
c	B-protein
-	I-protein
myc	I-protein
nuclear	I-protein
localization	I-protein
signal	I-protein
.	O

REV	O
I	O
:	O
All	O
vessels	O
up	O
to	O
50	O
%	O
stenosed	O
have	O
a	O
patent	O
graft	O
.	O

One	O
is	O
to	O
act	O
within	O
the	O
visceral	O
endoderm	O
to	O
promote	O
proper	O
streak	O
morphogenesis	O
.	O

Interestingly	O
,	O
the	O
activated	O
PDGF	B-protein
beta	I-protein
-	I-protein
receptor	I-protein
was	O
found	O
not	O
to	O
bind	O
Crk	B-protein
proteins	I-protein
.	O

The	O
transverse	O
magnetization	O
decays	O
mentioned	O
above	O
exhibited	O
two	O
components	O
,	O
a	O
T2	O
fast	O
(	O
T2f	O
)	O
and	O
a	O
T2	O
slow	O
(	O
T2s	O
)	O
component	O
.	O

Furthermore	O
,	O
SB203580	O
inhibited	O
LPS	O
-	O
induced	O
activation	O
of	O
Sp1	B-protein
,	O
as	O
well	O
as	O
the	O
promoter	O
activity	O
in	O
cells	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
Sp1	B-protein
consensus	O
sequence	O
.	O

It	O
is	O
now	O
recognized	O
that	O
essentially	O
all	O
eukaryotic	O
and	O
prokaryotic	O
genes	O
whose	O
5	O
'	O
-	O
flanking	O
regions	O
are	O
known	O
and	O
that	O
encode	O
barbiturate	O
-	O
inducible	O
proteins	O
contain	O
the	O
Barbie	B-protein
box	I-protein
element	I-protein
.	O

The	O
effects	O
of	O
mean	O
luminance	O
were	O
also	O
measured	O
and	O
a	O
general	O
expression	O
that	O
would	O
take	O
them	O
into	O
account	O
was	O
derived	O
.	O

The	O
structural	O
study	O
of	O
peptides	O
belonging	O
to	O
the	O
terminal	O
domains	O
of	O
histone	B-protein
H1	I-protein
can	O
be	O
considered	O
as	O
a	O
step	O
toward	O
the	O
understanding	O
of	O
the	O
function	O
of	O
H1	B-protein
in	O
chromatin	O
.	O

Clear	O
and	O
evidenced	O
-	O
based	O
information	O
should	O
be	O
provided	O
to	O
patients	O
as	O
to	O
the	O
means	O
of	O
prevention	O
with	O
special	O
attention	O
to	O
individual	O
risk	O
groups	O
such	O
as	O
IV	O
drug	O
abusers	O
.	O

The	O
eating	O
and	O
drinking	O
patterns	O
of	O
pygmy	O
goats	O
fed	O
ad	O
lib	O
and	O
kept	O
on	O
a	O
12	O
h	O
light	O
/	O
12	O
h	O
dark	O
cycle	O
were	O
recorded	O
and	O
analyzed	O
.	O

Chaotic	O
electron	O
dynamics	O
around	O
a	O
single	O
elliptically	O
shaped	O
antidot	O
.	O

In	O
the	O
present	O
study	O
we	O
demonstrated	O
a	O
unique	O
mechanism	O
of	O
action	O
of	O
8	O
-	O
Cl	O
-	O
cAMP	O
in	O
the	O
regulation	O
of	O
these	O
kinase	B-protein
isozymes	I-protein
in	O
HL	O
-	O
60	O
human	O
promyelocytic	O
leukemia	O
cells	O
.	O

Efficacy	O
and	O
safety	O
of	O
aspirin	O
in	O
the	O
long	O
-	O
term	O
management	O
of	O
atherothrombosis	O
.	O

Northern	O
(	O
RNA	O
)	O
blot	O
analyses	O
indicated	O
that	O
the	O
cdh	B-protein
genes	I-protein
encoding	O
the	O
five	O
subunits	O
and	O
an	O
open	O
reading	O
frame	O
(	O
ORF1	O
)	O
with	O
unknown	O
function	O
are	O
cotranscribed	O
during	O
growth	O
on	O
acetate	O
.	O

Prospects	O
for	O
controlled	O
-	O
delivery	O
systems	O
.	O

Mycoplasma	O
hominis	O
infections	O
are	O
easily	O
missed	O
because	O
conventional	O
methods	O
for	O
bacterial	O
detection	O
may	O
fail	O
.	O

The	O
1	O
.	O
7	O
kb	O
cloned	O
fragment	O
was	O
sequenced	O
and	O
shown	O
to	O
contain	O
the	O
entire	O
fliA	B-protein
gene	I-protein
.	O

The	O
results	O
indicate	O
that	O
the	O
carbon	O
-	O
perfused	O
areas	O
and	O
MBF	O
in	O
the	O
liver	O
,	O
renal	O
cortex	O
,	O
spleen	O
,	O
and	O
small	O
intestinal	O
serosa	O
(	O
only	O
MBF	O
)	O
increased	O
significantly	O
5	O
h	O
after	O
CLP	O
.	O

Since	O
RCC1p	B-protein
acts	O
as	O
GNRP	B-protein
for	O
Ran	B-protein
,	O
a	O
small	B-protein
nuclear	I-protein
GTPase	I-protein
of	O
the	O
ras	B-protein
superfamily	I-protein
,	O
we	O
have	O
identified	O
two	O
homologs	O
of	O
Ran	B-protein
in	O
S	O
.	O
cerevisiae	O
(	O
CNR1	B-protein
and	O
CNR2	B-protein
)	O
.	O

These	O
mutant	O
proteins	O
retained	O
the	O
ability	O
to	O
competitively	O
inhibit	O
kappa	O
B	O
-	O
mediated	O
transcriptional	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
but	O
failed	O
to	O
efficiently	O
transform	O
chicken	O
lymphoid	O
cells	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Mapping	O
of	O
the	O
human	B-protein
Voltage	I-protein
-	I-protein
Dependent	I-protein
Anion	I-protein
Channel	I-protein
isoforms	I-protein
1	I-protein
and	I-protein
2	I-protein
reconsidered	O
.	O

The	O
Functional	O
Independence	O
Measure	O
:	O
a	O
comparative	O
study	O
of	O
clinician	O
and	O
self	O
ratings	O
.	O

The	O
combination	O
of	O
MISO	O
and	O
WR	O
-	O
2721	O
gave	O
an	O
intermediate	O
response	O
compared	O
with	O
either	O
drug	O
used	O
alone	O
,	O
resulting	O
in	O
some	O
sensitization	O
with	O
single	O
doses	O
and	O
an	O
overall	O
protection	O
with	O
repeated	O
small	O
doses	O
.	O

To	O
determine	O
whether	O
P35	B-protein
could	O
activate	O
the	O
39k	O
promoter	O
in	O
the	O
absence	O
of	O
IE1	B-protein
,	O
the	O
p35	B-protein
open	O
reading	O
frame	O
was	O
cloned	O
under	O
the	O
control	O
of	O
the	O
ie1	B-protein
promoter	I-protein
.	O

In	O
summary	O
,	O
the	O
segments	O
of	O
C3	B-protein
represented	O
by	O
amino	O
acid	O
residues	O
1082	O
-	O
1118	O
,	O
1117	O
-	O
1155	O
,	O
1234	O
-	O
1294	O
and	O
1312	O
-	O
1404	O
accommodate	O
C3	B-protein
(	I-protein
D	I-protein
)	I-protein
epitopes	I-protein
that	O
are	O
expressed	O
by	O
erythrocyte	O
-	O
bound	O
C3	B-protein
fragments	I-protein
,	O
but	O
not	O
by	O
the	O
corresponding	O
fluid	O
-	O
phase	O
fragment	O
,	O
whereas	O
the	O
segments	O
spanning	O
residues	O
973	O
-	O
1026	O
and	O
1477	O
-	O
1510	O
contain	O
C3	B-protein
(	I-protein
D	I-protein
)	I-protein
epitopes	I-protein
that	O
are	O
exposed	O
exclusively	O
in	O
denatured	O
C3	B-protein
and	O
therefore	O
hidden	O
in	O
physiological	O
fragments	O
of	O
the	O
protein	O
.	O

Thus	O
,	O
TRAF2	B-protein
initiates	O
SAPK	B-protein
and	O
p38	B-protein
activation	O
by	O
binding	O
two	O
proximal	O
protein	B-protein
kinases	I-protein
:	O
GCK	B-protein
and	O
RIP	B-protein
.	O

Of	O
the	O
43	O
infants	O
with	O
a	O
(	O
probable	O
)	O
loss	O
18	O
were	O
examined	O
again	O
at	O
3	O
months	O
corrected	O
age	O
.	O

3	O
cases	O
.	O

Intensive	O
synthesis	O
of	O
PNA	B-protein
in	O
the	O
cells	O
of	O
microvascular	O
wall	O
evidenced	O
of	O
their	O
high	O
functional	O
activity	O
,	O
and	O
the	O
synthesis	O
of	O
DNA	O
in	O
them	O
showed	O
their	O
ability	O
for	O
proliferation	O
,	O
i	O
.	O
g	O
.	O
-	O
-	O
for	O
growth	O
.	O

In	O
a	O
randomized	O
study	O
on	O
150	O
patients	O
(	O
ASA	O
1	O
)	O
undergoing	O
induction	O
of	O
anaesthesia	O
,	O
the	O
effects	O
of	O
Fentanyl	O
(	O
0	O
.	O
1	O
mg	O
)	O
,	O
the	O
combination	O
of	O
Fentanyl	O
(	O
0	O
.	O
1	O
mg	O
)	O
and	O
Droperidol	O
(	O
5	O
mg	O
)	O
(	O
Innovar	O
,	O
Thalamonal	O
)	O
and	O
Atropine	O
(	O
0	O
.	O
01	O
mg	O
/	O
kg	O
b	O
.	O
w	O
.	O
)	O
alone	O
on	O
cardiocirculatory	O
parameters	O
were	O
studied	O
.	O

Since	O
the	O
ETS	B-protein
domain	I-protein
,	O
which	O
is	O
localized	O
in	O
the	O
carboxy	O
terminal	O
region	O
of	O
the	O
encoded	O
protein	O
,	O
is	O
95	O
%	O
and	O
96	O
%	O
identical	O
to	O
that	O
of	O
PEA3	B-protein
and	O
ER81	B-protein
,	O
respectively	O
,	O
we	O
named	O
this	O
new	O
member	O
'	B-protein
Ets	I-protein
Related	I-protein
Molecule	I-protein
PEA3	I-protein
-	I-protein
like	I-protein
'	I-protein
(	O
ERM	B-protein
)	O
.	O

Relative	O
to	O
coherent	O
control	O
words	O
(	O
e	O
.	O
g	O
.	O
,	O
quick	O
)	O
,	O
these	O
discourse	O
-	O
dependent	O
semantic	O
anomalies	O
elicited	O
a	O
large	O
N400	O
effect	O
that	O
began	O
at	O
about	O
200	O
to	O
250	O
msec	O
after	O
word	O
onset	O
.	O

The	O
fast	O
real	O
-	O
time	O
digital	O
processing	O
of	O
the	O
N2	O
and	O
flow	O
signals	O
incorporated	O
filtering	O
,	O
delay	O
compensation	O
,	O
and	O
corrections	O
for	O
the	O
effects	O
of	O
changes	O
in	O
gas	O
composition	O
and	O
temperature	O
.	O

In	O
patients	O
with	O
myalgia	O
,	O
Raynaud	O
'	O
s	O
syndrome	O
,	O
skin	O
vasculitis	O
and	O
vascular	O
diseases	O
WFAg	B-protein
concentrations	O
were	O
higher	O
than	O
in	O
patients	O
without	O
them	O
.	O

The	O
Y	O
.	O
lipolytica	O
genomic	O
POT1	B-protein
gene	O
was	O
disrupted	O
by	O
replacing	O
120	O
bp	O
of	O
its	O
coding	O
sequence	O
with	O
2	O
.	O
7	O
kbp	O
of	O
DNA	O
including	O
the	O
Y	O
.	O
lipolytica	O
LEU2	B-protein
gene	I-protein
.	O

Activated	O
PKR	B-protein
may	O
exist	O
as	O
a	O
dimer	O
and	O
phosphorylates	O
the	O
eukaryotic	B-protein
translation	I-protein
initiation	I-protein
factor	I-protein
2	I-protein
alpha	I-protein
subunit	I-protein
(	O
cIF	B-protein
-	I-protein
2	I-protein
alpha	I-protein
)	O
to	O
inhibit	O
polypeptide	O
chain	O
initiation	O
.	O

SGPT	B-protein
,	O
SGOT	B-protein
,	O
and	O
alkaline	B-protein
phosphatase	I-protein
concentrations	O
were	O
essentially	O
normal	O
in	O
all	O
subjects	O
.	O

Weak	O
allergenicity	O
of	O
recombinant	B-protein
hirudin	I-protein
CGP	I-protein
39393	I-protein
(	O
REVASC	O
)	O
in	O
immunocompetent	O
volunteers	O
.	O

The	O
DNA	O
sequencing	O
of	O
the	O
recombinant	O
clones	O
revealed	O
the	O
expression	O
of	O
RXR	B-protein
alpha	I-protein
and	O
RXR	B-protein
beta	I-protein
.	O

TBARS	O
levels	O
,	O
oxygen	O
-	O
radical	O
absorbing	O
capacity	O
assay	O
and	O
AFR	O
release	O
assessed	O
by	O
electron	O
paramagnetic	O
resonance	O
(	O
EPR	O
)	O
were	O
used	O
to	O
explore	O
the	O
existence	O
of	O
oxidative	O
stress	O
in	O
diabetes	O
.	O

A	O
73	B-protein
bp	I-protein
fragment	I-protein
(	I-protein
X1	I-protein
region	I-protein
)	I-protein
of	O
the	O
PRB	B-protein
-	I-protein
1b	I-protein
promoter	I-protein
,	O
located	O
between	O
positions	O
-	O
213	O
and	O
-	O
141	O
,	O
was	O
sufficient	O
to	O
confer	O
ethylene	O
responsiveness	O
to	O
the	O
reporter	O
gene	O
.	O

More	O
recently	O
,	O
however	O
,	O
a	O
number	O
of	O
developments	O
such	O
as	O
the	O
successful	O
use	O
of	O
the	O
inhaled	O
steroid	O
budesonide	O
and	O
oral	O
dexamethasone	O
have	O
reinforced	O
the	O
argument	O
for	O
using	O
steroids	O
.	O

Comparison	O
with	O
a	O
recently	O
described	O
c	B-protein
-	I-protein
sis	I-protein
cDNA	I-protein
clone	I-protein
(	O
Collins	O
et	O
al	O
.	O
,	O
Nature	O
316	O
,	O
748	O
-	O
750	O
(	O
1985	O
)	O
)	O
revealed	O
that	O
the	O
1	O
.	O
9	O
kbp	O
DNA	O
region	O
contained	O
a	O
large	O
5	B-protein
'	I-protein
c	I-protein
-	I-protein
sis	I-protein
exon	I-protein
of	O
at	O
least	O
1050	O
bp	O
.	O

This	O
cluster	O
consisted	O
of	O
four	O
apparently	O
unrelated	O
ESTs	O
and	O
two	O
genes	O
,	O
pregnancy	B-protein
-	I-protein
associated	I-protein
plasma	I-protein
protein	I-protein
-	I-protein
A	I-protein
(	O
PAPP	B-protein
-	I-protein
A	I-protein
)	O
and	O
a	O
novel	O
gene	O
(	O
tentatively	O
named	O
EST	B-protein
-	I-protein
YD1	I-protein
)	O
.	O

Higher	O
CYP3A23	B-protein
basal	O
activity	O
appears	O
to	O
be	O
due	O
to	O
an	O
E	O
-	O
box	O
in	O
3A23SiteA	B-protein
that	O
interacts	O
with	O
USF1	B-protein
,	O
a	O
ubiquitous	O
bHLH	B-protein
/	I-protein
leucine	I-protein
zipper	I-protein
transcription	I-protein
factor	I-protein
.	O

Transcription	O
factor	O
binding	O
sites	O
downstream	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
start	O
site	O
are	O
important	O
for	O
virus	O
infectivity	O
.	O

Results	O
from	O
our	O
and	O
other	O
laboratories	O
have	O
suggested	O
that	O
UCN	O
-	O
01	O
induces	O
preferential	O
G1	O
-	O
phase	O
accumulation	O
in	O
several	O
human	O
tumor	O
cell	O
lines	O
tested	O
.	O

To	O
understand	O
the	O
basis	O
for	O
the	O
increased	O
cell	O
surface	O
stability	O
compared	O
with	O
wild	O
-	O
type	O
peptide	O
and	O
to	O
understand	O
the	O
differences	O
in	O
T	O
cell	O
recognition	O
between	O
I1Y	B-protein
and	O
I1F	B-protein
,	O
we	O
determined	O
the	O
x	O
-	O
ray	O
crystal	O
structures	O
of	O
the	O
two	O
class	B-protein
I	I-protein
MHC	I-protein
-	I-protein
peptide	I-protein
complexes	I-protein
.	O

Stress	O
effects	O
on	O
affiliation	O
preferences	O
among	O
subjects	O
possessing	O
the	O
type	O
A	O
coronary	O
-	O
prone	O
behavior	O
pattern	O
.	O

The	O
performance	O
of	O
pH	O
-	O
sensitive	O
particles	O
is	O
attributed	O
to	O
their	O
ability	O
to	O
release	O
the	O
drug	O
selectively	O
in	O
the	O
upper	O
part	O
of	O
the	O
intestine	O
in	O
a	O
molecular	O
or	O
amorphous	O
form	O
.	O

Chlamydia	O
and	O
cervical	O
cancer	O
:	O
a	O
real	O
association	O
?	O

From	O
250	O
g	O
of	O
cells	O
,	O
we	O
isolated	O
1	O
mg	O
of	O
PDH	B-protein
complex	I-protein
with	O
a	O
specific	O
activity	O
of	O
12	O
.	O
6	O
U	O
/	O
mg	O
of	O
protein	O
.	O

The	O
histopathology	O
and	O
neovascularization	O
did	O
not	O
appreciably	O
differ	O
between	O
xenograft	O
tumors	O
derived	O
from	O
FGF4	B-protein
over	O
-	O
expressing	O
versus	O
control	O
transfectants	O
.	O

ORF	O
2	O
potentially	O
encoded	O
a	O
hydrophobic	O
protein	O
of	O
29	O
,	O
705	O
Da	O
with	O
six	O
potential	O
membrane	O
-	O
spanning	O
regions	O
.	O

Genomic	O
structure	O
and	O
chromosomal	O
location	O
of	O
the	O
mouse	B-protein
pre	I-protein
-	I-protein
T	I-protein
-	I-protein
cell	I-protein
receptor	I-protein
alpha	I-protein
gene	I-protein
.	O

When	O
the	O
entire	O
diet	O
consisted	O
of	O
SBF	O
,	O
voluntary	O
feed	O
intake	O
was	O
reduced	O
,	O
indicating	O
that	O
SBF	O
should	O
not	O
be	O
fed	O
to	O
ponies	O
as	O
the	O
sole	O
dietary	O
ingredient	O
.	O

Therefore	O
,	O
it	O
is	O
hoped	O
that	O
by	O
defining	O
the	O
transcriptional	O
control	O
of	O
the	O
L7	B-protein
gene	I-protein
insights	O
into	O
the	O
mechanisms	O
that	O
control	O
functional	O
fate	O
and	O
organization	O
in	O
the	O
nervous	O
system	O
can	O
be	O
gained	O
.	O

We	O
showed	O
previously	O
that	O
a	O
fusion	O
protein	O
(	O
GAL4	B-protein
-	I-protein
p40	I-protein
)	O
containing	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
GAL4	B-protein
and	O
sequences	O
of	O
chicken	B-protein
l	I-protein
kappa	I-protein
B	I-protein
-	I-protein
alpha	I-protein
(	O
p40	B-protein
)	O
inhibits	O
growth	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

Activation	O
of	O
the	O
SH2	B-protein
-	I-protein
containing	I-protein
protein	I-protein
tyrosine	I-protein
phosphatase	I-protein
,	O
SH	B-protein
-	I-protein
PTP2	I-protein
,	O
by	O
phosphotyrosine	O
-	O
containing	O
peptides	O
derived	O
from	O
insulin	B-protein
receptor	I-protein
substrate	I-protein
-	I-protein
1	I-protein
.	O

We	O
thus	O
conclude	O
that	O
the	O
NFAT	B-protein
RIR	I-protein
plays	O
an	O
essential	O
dual	O
role	O
in	O
DNA	O
recognition	O
and	O
cooperative	O
binding	O
to	O
AP	B-protein
-	I-protein
1	I-protein
family	I-protein
transcription	I-protein
factors	I-protein
.	O

After	O
that	O
report	O
,	O
carboxypeptidase	B-protein
D	I-protein
(	O
CPD	B-protein
)	O
was	O
subsequently	O
purified	O
from	O
bovine	O
pituitary	O
and	O
characterized	O
as	O
a	O
novel	O
carboxypeptidase	B-protein
E	I-protein
(	O
CPE	B-protein
)	O
-	O
like	O
enzyme	O
,	O
with	O
many	O
characteristics	O
in	O
common	O
with	O
duck	O
gp180	B-protein
(	O
Song	O
,	O
L	O
.	O
,	O
Fricker	O
,	O
L	O
.	O
D	O
.	O
,	O
1995	O
.	O

Proteinuria	O
-	O
-	O
selected	O
physiopathological	O
and	O
clinical	O
problems	O
.	O

Although	O
popular	O
this	O
hypothesis	O
is	O
far	O
from	O
explaining	O
all	O
the	O
clinical	O
facts	O
,	O
namely	O
that	O
rigidity	O
is	O
equal	O
in	O
extensor	O
and	O
flexor	O
,	O
proximal	O
and	O
distal	O
muscles	O
.	O

In	O
patients	O
with	O
osteomyelitis	O
and	O
joint	O
empyema	O
(	O
n	O
=	O
48	O
)	O
PMN	B-protein
elastase	I-protein
had	O
a	O
sensitivity	O
of	O
77	O
%	O
,	O
which	O
was	O
only	O
exceeded	O
by	O
that	O
of	O
the	O
unspecific	O
erythrocyte	O
sedimentation	O
rate	O
(	O
sensitivity	O
89	O
%	O
)	O
.	O

The	O
authors	O
undertook	O
a	O
retrospective	O
analysis	O
of	O
pathology	O
with	O
quantification	O
of	O
the	O
percentage	O
of	O
papillary	O
serous	O
component	O
(	O
%	O
PSC	O
)	O
and	O
p53	B-protein
expression	O
.	O

The	O
maximum	O
induction	O
of	O
ACC	B-protein
-	I-protein
oxidase	I-protein
transcripts	I-protein
occurred	O
at	O
about	O
6	O
h	O
after	O
excision	O
,	O
while	O
the	O
maximum	O
enzyme	O
activity	O
was	O
observed	O
at	O
24	O
h	O
.	O

TPO	B-protein
by	O
itself	O
did	O
not	O
activate	O
ERK1	B-protein
,	O
ERK2	B-protein
and	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
,	O
whereas	O
TPO	B-protein
directly	O
enhanced	O
the	O
PKC	O
-	O
dependent	O
activation	O
of	O
ERKs	B-protein
induced	O
by	O
other	O
agonists	O
including	O
thrombin	B-protein
and	O
phorbol	O
esters	O
,	O
without	O
affecting	O
the	O
PKC	B-protein
activation	O
by	O
those	O
agonists	O
.	O

Except	O
for	O
nonperfusion	O
of	O
neurosensory	O
retinal	O
vessels	O
at	O
a	O
light	O
dose	O
of	O
150	O
J	O
/	O
cm2	O
,	O
no	O
other	O
adverse	O
events	O
were	O
of	O
concern	O
.	O

With	O
constructs	O
containing	O
the	O
binding	O
site	O
of	O
one	O
gene	O
fused	O
to	O
the	O
promoter	O
of	O
the	O
other	O
,	O
we	O
demonstrated	O
that	O
the	O
positional	O
requirements	O
are	O
a	O
function	O
of	O
the	O
specific	O
binding	O
site	O
,	O
not	O
the	O
promoter	O
.	O

These	O
results	O
indicate	O
that	O
CSFHU	B-protein
can	O
increase	O
neutrophil	O
counts	O
by	O
increasing	O
the	O
number	O
and	O
maturity	O
of	O
the	O
marrow	O
neutrophil	O
precursors	O
in	O
some	O
types	O
of	O
childhood	O
chronic	O
neutropenia	O
.	O

Initial	O
experience	O
with	O
a	O
serotonin	O
agonist	O
.	O

(	O
1998	O
)	O
FASEB	O
J	O
.	O

Nucleotide	O
sequence	O
analysis	O
of	O
R	B-protein
has	O
revealed	O
similarities	O
to	O
the	O
R1	O
plasmid	O
found	O
in	O
some	O
South	O
American	O
maize	O
races	O
with	O
RU	O
cytoplasm	O
,	O
to	O
the	O
M1	O
plasmid	O
found	O
in	O
one	O
source	O
of	O
Zea	O
luxurians	O
teosinte	O
,	O
to	O
the	O
atp9	B-protein
mitochondrial	I-protein
gene	I-protein
and	O
its	O
3	O
'	O
flanking	O
sequence	O
,	O
and	O
also	O
to	O
a	O
region	O
3	O
'	O
to	O
the	O
orf221	B-protein
gene	I-protein
.	O

The	O
P13	O
and	O
N22	O
of	O
ppSEPs	O
had	O
phase	O
reversal	O
relationship	O
with	O
the	O
P2	O
and	O
N2	O
recorded	O
from	O
the	O
PES	O
,	O
respectively	O
.	O

Three	O
classes	O
of	O
test	O
objects	O
were	O
considered	O
:	O
(	O
1	O
)	O
a	O
multicompartment	O
test	O
object	O
for	O
31P	O
MRS	O
measurements	O
performed	O
with	O
slice	O
-	O
selective	O
sequences	O
;	O
(	O
2	O
)	O
a	O
two	O
-	O
compartment	O
test	O
object	O
for	O
volume	O
-	O
selection	O
1H	O
MRS	O
;	O
and	O
(	O
3	O
)	O
two	O
-	O
compartment	O
test	O
objects	O
for	O
assessing	O
the	O
performance	O
of	O
experimental	O
systems	O
using	O
ISIS	O
as	O
volume	O
localization	O
sequence	O
in	O
31P	O
MRS	O
.	O

Purified	O
spleen	O
GAP	B-protein
accelerated	O
hydrolysis	O
of	O
GTP	O
bound	O
to	O
recombinant	B-protein
ARF1	I-protein
,	O
ARF3	B-protein
,	O
ARF5	B-protein
,	O
and	O
ARF6	B-protein
;	O
no	O
effect	O
of	O
NH2	O
-	O
terminal	O
myristoylation	O
was	O
observed	O
.	O

Twenty	O
patients	O
aged	O
45	O
or	O
older	O
with	O
the	O
diagnosis	O
of	O
endogenous	O
depression	O
were	O
evaluated	O
in	O
terms	O
of	O
safety	O
and	O
efficacy	O
in	O
their	O
response	O
to	O
multiple	O
monitored	O
electroconvulsive	O
therapy	O
(	O
MMECT	O
)	O
versus	O
single	O
electroconvulsive	O
therapy	O
(	O
SECT	O
)	O
.	O

Despite	O
the	O
reported	O
detrimental	O
effects	O
on	O
CNS	O
development	O
,	O
a	O
number	O
of	O
animal	O
studies	O
have	O
shown	O
that	O
pretreatment	O
with	O
corticosteroids	O
nevertheless	O
protect	O
the	O
brain	O
from	O
hypoxia	O
-	O
ischemic	O
injury	O
;	O
however	O
,	O
clinically	O
such	O
treatment	O
is	O
no	O
longer	O
favored	O
.	O

V	O
.	O

No	O
previous	O
studies	O
have	O
determined	O
the	O
pharmaco	O
-	O
dynamics	O
of	O
intravenous	O
procainamide	O
when	O
administered	O
in	O
a	O
dose	O
of	O
15	O
mg	O
/	O
kg	O
and	O
at	O
a	O
rate	O
of	O
50	O
mg	O
/	O
min	O
,	O
as	O
is	O
common	O
practice	O
during	O
electropharmacologic	O
testing	O
.	O

Separate	O
experiments	O
measured	O
AIB	O
and	O
86RbCl	O
uptake	O
in	O
36B	O
-	O
10	O
cells	O
in	O
vitro	O
1	O
and	O
2	O
days	O
following	O
20	O
Gy	O
irradiation	O
to	O
assess	O
whether	O
this	O
radiation	O
dose	O
reduced	O
the	O
capacity	O
of	O
tumor	O
cells	O
to	O
trap	O
AIB	O
or	O
Rb	O
+	O
.	O

Hydropathy	O
analysis	O
of	O
KCC1	B-protein
indicates	O
structural	O
homology	O
to	O
NKCC	B-protein
,	O
including	O
12	O
transmembrane	O
domains	O
,	O
a	O
large	O
extracellular	O
loop	O
with	O
potential	O
N	O
-	O
linked	O
glycosylation	O
sites	O
,	O
and	O
cytoplasmic	O
N	O
-	O
and	O
C	O
-	O
terminal	O
regions	O
.	O

Liver	O
injuries	O
.	O

Furthermore	O
,	O
experiments	O
with	O
32D	O
temperature	O
-	O
sensitive	O
p53	B-protein
cells	O
indicate	O
that	O
aberrant	O
tal	B-protein
-	I-protein
1	I-protein
expression	O
at	O
the	O
permissive	O
temperature	O
does	O
not	O
exert	O
a	O
proliferative	O
effect	O
but	O
causes	O
p53	O
-	O
mediated	O
apoptosis	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
tal	B-protein
-	I-protein
1	I-protein
proliferative	O
effect	O
depends	O
on	O
the	O
integrity	O
of	O
the	O
cell	O
cycle	O
checkpoints	O
of	O
the	O
host	O
cell	O
,	O
as	O
observed	O
for	O
c	B-protein
-	I-protein
myc	I-protein
and	O
other	O
oncogenes	O
.	O
tal	B-protein
-	I-protein
1	I-protein
mutant	I-protein
experiments	O
indicate	O
that	O
ectopic	O
tal	B-protein
-	I-protein
1	I-protein
effects	O
are	O
mediated	O
by	O
both	O
the	O
DNA	O
-	O
binding	O
and	O
the	O
heterodimerization	O
domains	O
,	O
while	O
the	O
N	B-protein
-	I-protein
terminally	I-protein
truncated	I-protein
tal	I-protein
-	I-protein
1	I-protein
variant	I-protein
(	O
M3	B-protein
)	O
expressed	O
in	O
T	O
-	O
ALL	O
malignant	O
cells	O
mimics	O
the	O
effects	O
of	O
the	O
wild	O
-	O
type	O
protein	O
.	O

Computer	O
software	O
assisted	O
ordering	O
(	O
CSAO	O
)	O
was	O
developed	O
to	O
integrate	O
PN	O
Ca	O
:	O
P	O
solubility	O
with	O
clinical	O
data	O
to	O
improve	O
parenteral	O
Ca	O
and	O
P	O
administration	O
.	O

In	O
adulthood	O
these	O
rats	O
were	O
hyperactive	O
and	O
learned	O
the	O
active	O
avoidance	O
response	O
later	O
than	O
the	O
controls	O
.	O

Activation	O
of	O
PKA	B-protein
by	O
8	O
-	O
bromo	O
-	O
cyclic	O
AMP	O
or	O
forskolin	O
,	O
and	O
inhibition	O
of	O
PKC	B-protein
by	O
calphostin	O
C	O
,	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
3TP	B-protein
activity	O
as	O
well	O
as	O
in	O
vitro	O
ERK	B-protein
kinase	I-protein
activity	O
in	O
CRAC	O
.	O

When	O
tested	O
with	O
wild	O
-	O
type	O
(	O
DBA	O
/	O
2	O
)	O
p16	B-protein
,	O
both	O
A134C	O
and	O
G232A	O
BALB	O
/	O
c	O
-	O
specific	O
variants	O
of	O
p16	B-protein
were	O
inefficient	O
in	O
their	O
ability	O
to	O
inhibit	O
the	O
activity	O
of	O
cyclin	B-protein
D2	I-protein
/	I-protein
CDK4	I-protein
in	O
kinase	O
assays	O
with	O
retinoblastoma	B-protein
protein	I-protein
,	O
suggesting	O
this	O
defective	O
,	O
inherited	O
allele	O
plays	O
an	O
important	O
role	O
in	O
the	O
genetic	O
susceptibility	O
of	O
BALB	O
/	O
c	O
mice	O
for	O
plasmacytoma	O
induction	O
and	O
that	O
p16	B-protein
(	I-protein
INK4a	I-protein
)	I-protein
is	O
a	O
strong	O
candidate	O
for	O
the	O
Pctr1	B-protein
locus	I-protein
.	O

DESIGN	O
:	O
A	O
cross	O
-	O
sectional	O
study	O
.	O

Therefore	O
,	O
in	O
a	O
large	O
animal	O
model	O
of	O
permanent	O
focal	O
ischemia	O
in	O
which	O
transfusion	O
starts	O
30	O
min	O
after	O
ischemia	O
,	O
tetrameric	O
cross	O
-	O
linked	O
hemoglobin	B-protein
transfusion	O
can	O
augment	O
oxygen	O
transport	O
to	O
the	O
ischemic	O
cortex	O
,	O
but	O
the	O
increase	O
can	O
be	O
delayed	O
and	O
not	O
necessarily	O
provide	O
protection	O
.	O

One	O
such	O
element	O
,	O
1P	B-protein
,	O
was	O
employed	O
to	O
clone	O
from	O
a	O
rat	O
pituitary	O
cDNA	O
expression	O
library	O
a	O
novel	O
417	B-protein
-	I-protein
amino	I-protein
acid	I-protein
WD	I-protein
protein	I-protein
,	O
designated	O
PREB	B-protein
(	I-protein
PRL	I-protein
regulatory	I-protein
element	I-protein
binding	I-protein
)	I-protein
protein	I-protein
.	O

Thus	O
,	O
a	O
critical	O
question	O
is	O
how	O
HOX	B-protein
proteins	I-protein
select	O
the	O
correct	O
sets	O
of	O
target	O
genes	O
in	O
vivo	O
.	O

Thus	O
,	O
the	O
human	B-protein
D1A	I-protein
gene	I-protein
belongs	O
to	O
the	O
category	O
of	O
tissue	O
-	O
specific	O
,	O
regulated	O
genes	O
that	O
have	O
housekeeping	O
-	O
type	O
promoters	O
.	O

As	O
PP2A	B-protein
exerts	O
a	O
range	O
of	O
cellular	O
functions	O
including	O
cell	O
cycle	O
regulation	O
and	O
cell	O
fate	O
determination	O
,	O
we	O
were	O
surprised	O
to	O
find	O
that	O
these	O
embryos	O
develop	O
normally	O
until	O
postimplantation	O
,	O
around	O
embryonic	O
day	O
5	O
.	O
5	O
/	O
6	O
.	O
0	O
.	O

The	O
femoral	O
artery	O
/	O
vein	O
and	O
the	O
soleus	O
and	O
gastrocnemius	O
muscles	O
were	O
examined	O
in	O
healthy	O
human	O
male	O
volunteers	O
.	O

We	O
also	O
show	O
that	O
zygotically	O
activated	O
Xretpos	O
transcripts	O
are	O
restricted	O
to	O
ventro	O
-	O
posterior	O
specific	O
regions	O
and	O
induced	O
by	O
UV	O
-	O
irradiation	O
and	O
BMP	B-protein
-	I-protein
4	I-protein
overexpression	O
in	O
cycloheximide	O
-	O
dependent	O
way	O
.	O
genesis	O
26	O
:	O
198	O
-	O
207	O
,	O
2000	O
.	O

An	O
abundant	O
1	O
.	O
1	O
-	O
kb	O
virion	O
-	O
sense	O
polyadenylated	O
RNA	O
and	O
four	O
complementary	O
-	O
sense	O
polyadenylated	O
RNAs	O
of	O
1	O
.	O
7	O
,	O
1	O
.	O
5	O
,	O
1	O
.	O
3	O
,	O
and	O
0	O
.	O
7	O
kb	O
have	O
been	O
identified	O
by	O
northern	O
blot	O
hybridization	O
,	O
confirming	O
the	O
bidirectional	O
transcription	O
strategy	O
implied	O
by	O
the	O
arrangement	O
of	O
ORFs	O
.	O

A	O
case	O
of	O
manifest	O
latent	O
nystagmus	O
of	O
late	O
onset	O
in	O
a	O
13	O
-	O
year	O
-	O
old	O
girl	O
is	O
reported	O
.	O

Tightly	O
ordered	O
proteasomal	O
degradation	O
of	O
proteins	O
critical	O
for	O
cell	O
cycle	O
control	O
implies	O
a	O
role	O
of	O
the	O
proteasome	O
in	O
maintaining	O
cell	O
proliferation	O
and	O
cell	O
survival	O
.	O

We	O
found	O
in	O
the	O
control	O
subjects	O
rCBF	O
increases	O
in	O
regions	O
associated	O
with	O
the	O
meso	O
-	O
striatal	O
and	O
meso	O
-	O
corticolimbic	O
circuits	O
in	O
response	O
to	O
both	O
monetary	O
reward	O
and	O
nonmonetary	O
reinforcement	O
.	O

Growth	O
of	O
tracheal	O
anastomoses	O
in	O
growing	O
animals	O
.	O

The	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
preferentially	O
infects	O
CD4	B-protein
+	I-protein
T	O
lymphocytes	O
and	O
may	O
exist	O
as	O
a	O
latent	O
provirus	O
within	O
these	O
cells	O
for	O
extended	O
periods	O
.	O

However	O
,	O
it	O
is	O
only	O
one	O
-	O
half	O
and	O
one	O
-	O
third	O
the	O
size	O
of	O
the	O
proteolipids	O
from	O
M	O
.	O
thermoautotrophicum	O
and	O
M	O
.	O
jannaschii	O
,	O
respectively	O
.	O
ahaK	B-protein
is	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
and	O
it	O
is	O
incorporated	O
into	O
the	O
cytoplasmic	O
membrane	O
despite	O
the	O
different	O
chemical	O
natures	O
of	O
lipids	O
from	O
archaea	O
and	O
bacteria	O
.	O

Calves	O
fed	O
MCT	O
-	O
milk	O
had	O
significantly	O
lower	O
blood	O
cholesterol	O
than	O
calves	O
fed	O
T	O
-	O
or	O
SBO	O
-	O
milk	O
.	O

Although	O
the	O
extracellular	O
domain	O
of	O
the	O
TSH	B-protein
-	I-protein
R	I-protein
is	O
sufficient	O
for	O
high	O
affinity	O
binding	O
of	O
TSH	B-protein
,	O
we	O
conclude	O
that	O
the	O
hyt	O
mutation	O
in	O
the	O
fourth	O
transmembrane	O
domain	O
eliminates	O
TSH	B-protein
binding	O
.	O

Pseudomonas	O
aeruginosa	O
strains	O
infecting	O
patients	O
with	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
acquire	O
a	O
mucoid	O
phenotype	O
due	O
to	O
overproduction	O
of	O
alginate	O
.	O

All	O
the	O
women	O
received	O
13	O
.	O
5	O
mg	O
plain	O
bupivacaine	O
via	O
subarachnoid	O
injection	O
at	O
the	O
L2	O
-	O
3	O
interspace	O
.	O

The	O
level	O
of	O
subclinical	O
infection	O
was	O
75	O
%	O
among	O
seropositive	O
dogs	O
.	O

Benztropine	O
for	O
venlafaxine	O
-	O
induced	O
night	O
sweats	O
.	O

(	O
1992	O
)	O
Genomics	O
12	O
,	O
58	O
-	O
62	O
)	O
.	O

The	O
future	O
of	O
research	O
with	O
interferon	B-protein
may	O
be	O
divided	O
into	O
three	O
areas	O
:	O
Efforts	O
must	O
be	O
made	O
to	O
determine	O
how	O
best	O
to	O
translate	O
the	O
in	O
vitro	O
synergy	O
into	O
clinically	O
meaningful	O
terms	O
;	O
in	O
order	O
to	O
exploit	O
the	O
fullest	O
potential	O
of	O
IFN	B-protein
,	O
research	O
is	O
moving	O
toward	O
using	O
this	O
agent	O
earlier	O
in	O
disease	O
either	O
as	O
an	O
adjuvant	O
after	O
tumor	O
debulking	O
or	O
after	O
initial	O
diagnosis	O
;	O
the	O
medical	O
community	O
must	O
rethink	O
the	O
natural	O
history	O
of	O
some	O
diseases	O
,	O
because	O
the	O
fullest	O
potential	O
of	O
the	O
biologic	O
agents	O
will	O
most	O
likely	O
manifest	O
itself	O
when	O
these	O
agents	O
are	O
used	O
together	O
.	O

Proteasomes	B-protein
are	O
the	O
multisubunit	O
protease	B-protein
involved	O
in	O
the	O
generation	O
of	O
peptides	O
presented	O
by	O
MHC	B-protein
class	I-protein
I	I-protein
molecules	I-protein
.	O

IFN	B-protein
-	I-protein
gamma	I-protein
was	O
elevated	O
during	O
active	O
TB	O
when	O
compared	O
with	O
healthy	O
controls	O
,	O
declining	O
during	O
and	O
after	O
treatment	O
.	O

Within	O
the	O
human	O
enhancer	O
,	O
these	O
two	O
sites	O
are	O
located	O
within	O
the	O
previously	O
defined	O
DNase	B-protein
I	I-protein
footprints	I-protein
,	O
NFAT	B-protein
-	I-protein
1	I-protein
and	O
NFIL	B-protein
-	I-protein
2B	I-protein
,	O
respectively	O
.	O

Analysis	O
of	O
SRE	O
oligonucleotide	O
gel	O
mobility	O
shift	O
assays	O
with	O
nuclear	O
extracts	O
from	O
Sertoli	O
cells	O
demonstrated	O
the	O
presence	O
of	O
both	O
the	O
SRF	B-protein
and	O
the	O
ubiquitously	O
expressed	O
bHLH	B-protein
protein	I-protein
E12	I-protein
/	I-protein
E47	I-protein
.	O

These	O
results	O
lead	O
us	O
to	O
hypothesize	O
that	O
a	O
single	O
multisubunit	B-protein
TFIID	I-protein
protein	I-protein
supports	O
transcriptional	O
stimulation	O
by	O
diverse	O
activation	O
domains	O
and	O
from	O
a	O
TATA	O
-	O
less	O
promoter	O
.	O

The	O
ZnF20	B-protein
cDNA	I-protein
hybridized	O
to	O
multiple	O
transcripts	O
in	O
a	O
thyroid	O
cancer	O
cell	O
line	O
(	O
8	O
.	O
0	O
,	O
4	O
.	O
5	O
and	O
2	O
kb	O
)	O
that	O
increased	O
after	O
cycloheximide	O
treatment	O
and	O
decayed	O
<	O
2	O
h	O
after	O
addition	O
of	O
actinomycin	O
D	O
.	O

This	O
fragment	O
contained	O
the	O
C	O
-	O
terminal	O
47	O
nucleotides	O
of	O
leuB	B-protein
,	O
encoding	O
3	B-protein
-	I-protein
isopropylmalate	I-protein
dehydrogenase	I-protein
;	O
asd	B-protein
,	O
encoding	O
aspartate	B-protein
-	I-protein
beta	I-protein
-	I-protein
semialdehyde	I-protein
dehydrogenase	I-protein
(	O
Asd	B-protein
)	O
;	O
and	O
orfA	O
,	O
whose	O
product	O
showed	O
similarity	O
to	O
the	O
Asd	B-protein
proteins	I-protein
from	I-protein
Vibrio	I-protein
spp	I-protein
.	O

Sp1	B-protein
can	O
activate	O
transcription	O
through	O
immunoglobulin	B-protein
kappa	I-protein
-	I-protein
chain	I-protein
enhancer	I-protein
or	O
P	B-protein
-	I-protein
selectin	I-protein
promoter	I-protein
NF	I-protein
-	I-protein
kappaB	I-protein
sites	I-protein
.	O
p50	B-protein
homodimers	I-protein
replace	O
Sp1	B-protein
from	O
the	O
P	B-protein
-	I-protein
selectin	I-protein
promoter	I-protein
by	O
binding	O
site	O
competition	O
and	O
thereby	O
either	O
inhibit	O
basal	O
Sp1	O
-	O
driven	O
expression	O
or	O
,	O
in	O
concert	O
with	O
Bcl	B-protein
-	I-protein
3	I-protein
,	O
stimulate	O
expression	O
.	O

Results	O
of	O
two	O
-	O
hybrid	O
assays	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
strongly	O
suggest	O
that	O
all	O
HD	B-protein
-	I-protein
Zip	I-protein
proteins	I-protein
of	O
families	O
I	O
and	O
II	O
can	O
form	O
homodimers	O
and	O
also	O
heterodimers	O
with	O
all	O
HD	B-protein
-	I-protein
Zip	I-protein
proteins	I-protein
of	O
the	O
same	O
family	O
.	O

Simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
is	O
a	O
lentivirus	O
with	O
morphological	O
and	O
antigenic	O
similarities	O
to	O
human	O
immunodeficiency	O
virus	O
,	O
the	O
causative	O
agent	O
of	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
of	O
humans	O
.	O

This	O
sequence	O
possessed	O
homology	O
with	O
a	O
methylation	O
-	O
sensitive	O
promoter	O
element	O
,	O
Enh2	B-protein
,	O
present	O
in	O
the	O
LTR	O
of	O
mouse	O
intractisternal	O
A	O
-	O
particles	O
.	O

The	O
p36	B-protein
gene	I-protein
is	O
at	O
least	O
22	O
kb	O
in	O
length	O
and	O
has	O
a	O
coding	O
sequence	O
of	O
approximately	O
1	O
kb	O
,	O
representing	O
only	O
4	O
.	O
5	O
%	O
of	O
the	O
gene	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Members	O
of	O
the	O
mitogen	B-protein
activated	I-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinase	I-protein
family	I-protein
,	O
extracellular	B-protein
signal	I-protein
-	I-protein
regulated	I-protein
kinase	I-protein
,	O
stress	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
-	I-protein
1	I-protein
/	I-protein
c	I-protein
-	I-protein
Jun	I-protein
NH2	I-protein
-	I-protein
terminal	I-protein
kinase	I-protein
,	O
and	O
p38	B-protein
,	O
are	O
central	O
elements	O
that	O
transduce	O
the	O
signal	O
generated	O
by	O
growth	B-protein
factors	I-protein
,	O
cytokines	O
,	O
and	O
stressing	O
agents	O
.	O

Fifty	O
-	O
four	O
patients	O
were	O
divided	O
into	O
groups	O
according	O
to	O
their	O
clinical	O
presentation	O
;	O
seven	O
asymptomatic	O
volunteers	O
,	O
20	O
patients	O
with	O
duodenal	O
-	O
gastric	O
reflux	O
gastropathy	O
(	O
DRG	O
)	O
,	O
16	O
patients	O
with	O
recurrent	O
ulcers	O
of	O
the	O
duodenal	O
bulb	O
(	O
RUD	O
)	O
,	O
and	O
11	O
patients	O
with	O
Moynihan	O
'	O
s	O
disease	O
.	O

If	O
this	O
is	O
unavailable	O
,	O
then	O
Supramid	O
has	O
a	O
proven	O
record	O
for	O
good	O
tissue	O
compatibility	O
and	O
resistance	O
to	O
infection	O
.	O

Recently	O
,	O
our	O
laboratory	O
developed	O
a	O
screen	O
that	O
identified	O
five	O
multicopy	O
suppressors	O
that	O
can	O
rescue	O
lethal	O
strains	O
of	O
clathrin	B-protein
heavy	O
chain	O
-	O
deficient	O
yeast	O
(	O
Chc	B-protein
-	I-protein
scd1	I-protein
-	I-protein
i	I-protein
)	O
to	O
viability	O
.	O

In	O
19	O
patients	O
vagotomy	O
not	O
only	O
curbed	O
the	O
bleeding	O
but	O
provided	O
definitive	O
therapy	O
(	O
Visick	O
I	O
-	O
II	O
)	O
;	O
4	O
patients	O
died	O
(	O
mortality	O
rate	O
16	O
%	O
)	O
.	O

Cytokine	O
-	O
induced	O
NF	B-protein
-	I-protein
kappa	I-protein
B	I-protein
DNA	O
binding	O
activity	O
,	O
RelA	B-protein
nuclear	O
translocation	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
degradation	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
serine	O
32	O
phosphorylation	O
,	O
and	O
I	B-protein
kappa	I-protein
B	I-protein
kinase	I-protein
(	O
IKK	B-protein
)	O
activity	O
were	O
blocked	O
by	O
curcumin	O
treatment	O
.	O

HPLC	O
phosphopeptide	O
mapping	O
,	O
amino	O
acid	O
sequencing	O
,	O
and	O
site	O
-	O
directed	O
mutagenesis	O
determined	O
that	O
NCLK	B-protein
phosphorylates	O
Ser	O
(	O
67	O
)	O
of	O
I	B-protein
-	I-protein
1	I-protein
.	O

Identification	O
of	O
a	O
consensus	O
cyclin	B-protein
-	I-protein
dependent	I-protein
kinase	I-protein
phosphorylation	I-protein
site	I-protein
unique	O
to	O
the	O
nuclear	O
form	O
of	O
human	B-protein
deoxyuridine	I-protein
triphosphate	I-protein
nucleotidohydrolase	I-protein
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
ability	O
of	O
pretreatment	O
and	O
post	O
-	O
treatment	O
prostate	B-protein
-	I-protein
specific	I-protein
antigen	I-protein
(	O
PSA	B-protein
)	O
measurements	O
,	O
clinical	O
tumor	O
stage	O
,	O
tumor	O
grade	O
,	O
Gleason	O
sum	O
,	O
race	O
,	O
age	O
,	O
and	O
radiation	O
dose	O
to	O
predict	O
the	O
recurrence	O
of	O
prostate	O
cancer	O
following	O
external	O
beam	O
radiation	O
therapy	O
(	O
XRT	O
)	O
since	O
the	O
introduction	O
of	O
PSA	B-protein
as	O
a	O
tumor	O
marker	O
at	O
one	O
tertiary	O
care	O
center	O
.	O

The	O
activity	O
of	O
Rac1	B-protein
leads	O
to	O
STAT3	B-protein
translocation	O
to	O
the	O
nucleus	O
coincident	O
with	O
STAT3	O
-	O
dependent	O
gene	O
expression	O
.	O

In	O
vivo	O
dimethyl	O
sulfate	O
footprinting	O
of	O
the	O
cyclin	B-protein
E	I-protein
promoter	I-protein
revealed	O
several	O
regions	O
of	O
protection	O
and	O
hypersensitivity	O
that	O
were	O
unique	O
to	O
infected	O
cells	O
.	O

Prognostic	O
value	O
of	O
a	O
treadmill	O
exercise	O
score	O
in	O
symptomatic	O
patients	O
with	O
nonspecific	O
ST	O
-	O
T	O
abnormalities	O
on	O
resting	O
ECG	O
.	O

Nonvascular	O
ophthalmic	O
and	O
neurologic	O
disorders	O
that	O
can	O
be	O
confused	O
with	O
amaurosis	O
fugax	O
are	O
listed	O
,	O
and	O
an	O
algorithm	O
for	O
evaluation	O
(	O
which	O
includes	O
ophthalmic	O
examination	O
,	O
laboratory	O
studies	O
,	O
and	O
noninvasive	O
carotid	O
artery	O
studies	O
)	O
is	O
given	O
.	O

Aspirin	O
intolerance	O
:	O
unaltered	O
susceptibility	O
of	O
platelet	B-protein
cyclo	I-protein
-	I-protein
oxygenase	I-protein
to	O
inhibition	O
by	O
aspirin	O
in	O
vitro	O
.	O

The	O
second	O
group	O
of	O
homologous	O
elements	O
is	O
present	O
in	O
the	O
upstream	O
region	O
of	O
both	O
genes	O
.	O

In	O
SN	O
-	O
48	O
neuronal	O
cells	O
that	O
express	O
MR	B-protein
,	O
GR	B-protein
,	O
and	O
5	B-protein
-	I-protein
HT1A	I-protein
receptors	I-protein
,	O
deletion	O
or	O
inactivation	O
of	O
the	O
nGRE	B-protein
(	O
negative	B-protein
GRE	I-protein
)	O
eliminated	O
negative	O
regulation	O
of	O
the	O
rat	B-protein
5	I-protein
-	I-protein
HT1A	I-protein
or	O
heterologous	O
promoters	O
by	O
corticosteroids	O
,	O
whereas	O
its	O
inclusion	O
conferred	O
corticosteroid	O
-	O
induced	O
inhibition	O
to	O
a	O
heterologous	O
promoter	O
.	O

To	O
evaluate	O
the	O
cost	O
and	O
benefits	O
of	O
screening	O
tests	O
for	O
Chlamydia	O
trachomatis	O
in	O
adolescent	O
males	O
,	O
we	O
developed	O
a	O
decision	O
analysis	O
model	O
and	O
compared	O
the	O
leukocyte	B-protein
esterase	I-protein
urine	O
dipstick	O
test	O
with	O
culture	O
,	O
with	O
direct	O
-	O
smear	O
fluorescent	O
antibody	O
(	O
DFA	O
)	O
,	O
and	O
with	O
the	O
option	O
of	O
no	O
screening	O
(	O
no	O
treatment	O
)	O
.	O

Initial	O
screening	O
of	O
a	O
rat	O
liver	O
cDNA	O
library	O
with	O
an	O
oligonucleotide	O
probe	O
derived	O
from	O
the	O
rat	O
SCP2	B-protein
protein	O
sequence	O
revealed	O
an	O
825	O
-	O
base	O
pair	O
cDNA	O
clone	O
coding	O
for	O
the	O
complete	O
SCP2	B-protein
protein	O
sequence	O
.	O

It	O
seems	O
that	O
the	O
way	O
in	O
which	O
drugs	O
modify	O
a	O
patient	O
'	O
s	O
serum	O
chemistry	O
may	O
be	O
used	O
to	O
assess	O
the	O
efficacy	O
with	O
which	O
they	O
control	O
the	O
inflammatory	O
process	O
.	O

Two	O
experiments	O
(	O
N	O
=	O
20	O
each	O
)	O
were	O
carried	O
out	O
to	O
explore	O
the	O
nature	O
of	O
ERP	O
negativities	O
in	O
a	O
visuospatial	O
memory	O
task	O
and	O
in	O
an	O
auditory	O
spatial	O
memory	O
task	O
,	O
respectively	O
.	O

A	O
coiled	O
-	O
coil	O
related	O
protein	O
specific	O
for	O
synapsed	O
regions	O
of	O
meiotic	O
prophase	O
chromosomes	O
.	O

Lack	O
of	O
sufficient	O
data	O
on	O
vibration	O
measurements	O
and	O
employment	O
durations	O
add	O
to	O
the	O
uncertainty	O
,	O
as	O
do	O
variations	O
in	O
tool	O
conditions	O
(	O
grinder	O
wheels	O
,	O
etc	O
)	O
and	O
inherent	O
difficulties	O
in	O
measurement	O
.	O

These	O
results	O
suggest	O
that	O
Thr115	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
MyoD	B-protein
function	O
under	O
conditions	O
of	O
high	O
mitogenesis	O
.	O

To	O
determine	O
whether	O
vanadate	O
could	O
inhibit	O
PEPCK	B-protein
gene	I-protein
transcription	O
,	O
a	O
series	O
of	O
chimeric	O
genes	O
containing	O
several	O
deletions	O
in	O
the	O
P	B-protein
-	I-protein
enolypyruvate	I-protein
carboxykinase	I-protein
promoter	I-protein
between	O
-	O
550	O
and	O
-	O
68	O
was	O
linked	O
to	O
the	O
structural	O
genes	O
for	O
either	O
amino	B-protein
-	I-protein
3	I-protein
-	I-protein
glycosyl	I-protein
phosphotransferase	I-protein
(	O
neo	B-protein
)	O
or	O
chloramphenicol	B-protein
acetyltransferase	I-protein
and	O
introduced	O
into	O
hepatoma	O
cells	O
using	O
three	O
methods	O
:	O
(	O
a	O
)	O
infection	O
with	O
a	O
Moloney	O
murine	O
leukemia	O
virus	O
-	O
based	O
retrovirus	O
,	O
(	O
b	O
)	O
transfection	O
and	O
stable	O
selection	O
for	O
neo	O
expression	O
,	O
or	O
(	O
c	O
)	O
transient	O
expression	O
of	O
chloroamphenicol	B-protein
acetyltransferase	I-protein
.	O

Peptide	O
sequences	O
of	O
the	O
zinc	B-protein
finger	I-protein
protein	I-protein
Ttk	I-protein
and	O
the	O
transcription	B-protein
factor	I-protein
Adf	I-protein
-	I-protein
1	I-protein
were	O
obtained	O
.	O

Both	O
resting	O
blood	O
flow	O
(	O
RBF	O
)	O
and	O
maximal	O
blood	O
flow	O
(	O
NBF	O
)	O
were	O
studied	O
by	O
Xenon	O
133	O
clearance	O
.	O

INO2	B-protein
,	O
a	O
regulatory	O
gene	O
in	O
yeast	O
phospholipid	O
biosynthesis	O
,	O
affects	O
nuclear	O
segregation	O
and	O
bud	O
pattern	O
formation	O
.	O

We	O
established	O
that	O
the	O
2	B-protein
.	I-protein
6	I-protein
kb	I-protein
mRNA	I-protein
V	I-protein
-	I-protein
1	I-protein
and	O
the	O
2	B-protein
.	I-protein
3	I-protein
kb	I-protein
GGT	I-protein
mRNA	I-protein
V	I-protein
-	I-protein
2	I-protein
derive	O
,	O
by	O
alternate	O
splicing	O
,	O
from	O
a	O
primary	O
transcript	O
initiated	O
on	O
a	O
distal	O
promoter	O
on	O
the	O
rat	B-protein
GGT	I-protein
gene	I-protein
.	O

Pulmonary	O
hypertension	O
,	O
with	O
or	O
without	O
coronary	O
arterial	O
narrowing	O
,	O
is	O
the	O
major	O
condition	O
leading	O
to	O
isolated	O
atrial	O
infarction	O
.	O

These	O
results	O
suggest	O
that	O
mitochondrial	O
presequences	O
interact	O
with	O
the	O
mt	B-protein
-	I-protein
hsp70	I-protein
during	O
or	O
after	O
mitochondrial	O
protein	O
import	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
In	O
25	O
open	O
-	O
chest	O
,	O
anesthetized	O
dogs	O
,	O
progressive	O
circumflex	O
artery	O
stenosis	O
led	O
to	O
a	O
concordant	O
decrease	O
of	O
circumflex	O
artery	O
resting	O
and	O
hyperemic	O
flow	O
,	O
coronary	O
flow	O
reserve	O
,	O
and	O
inverse	O
angiographic	O
mean	O
transit	O
time	O
Tmicro	O
-	O
1	O
(	O
P	O
<	O
.	O
01	O
)	O
.	O

Conversely	O
,	O
the	O
central	O
regions	O
are	O
highly	O
variable	O
.	O

In	O
an	O
attempt	O
to	O
understand	O
Wee1	B-protein
regulation	O
during	O
cell	O
cycle	O
,	O
yeast	O
two	O
-	O
hybrid	O
screening	O
was	O
used	O
to	O
identify	O
Wee1	B-protein
-	I-protein
binding	I-protein
protein	I-protein
(	I-protein
s	I-protein
)	I-protein
.	O

This	O
philosophy	O
was	O
instituted	O
for	O
the	O
compound	O
RP	O
73401	O
,	O
a	O
specific	O
phosphodiesterase	B-protein
IV	I-protein
inhibitor	O
,	O
that	O
was	O
being	O
developed	O
simultaneously	O
for	O
delivery	O
by	O
both	O
oral	O
and	O
pulmonary	O
routes	O
of	O
administration	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
expression	O
of	O
the	O
gene	O
for	O
the	O
reproductive	O
neuropeptide	O
,	O
GnRH	B-protein
,	O
is	O
repressed	O
by	O
the	O
glutamate	O
/	O
NO	O
/	O
cyclic	O
GMP	O
(	O
cGMP	O
)	O
signal	O
transduction	O
pathway	O
through	O
cGMP	B-protein
-	I-protein
dependent	I-protein
protein	I-protein
kinase	I-protein
in	O
the	O
hypothalamic	O
GnRH	O
-	O
secreting	O
neuronal	O
cell	O
line	O
GT1	O
-	O
7	O
.	O

To	O
evaluate	O
the	O
effects	O
of	O
HRT	O
on	O
those	O
factors	O
in	O
end	O
-	O
stage	O
renal	O
disease	O
(	O
ESRD	O
)	O
patients	O
,	O
we	O
evaluated	O
the	O
changes	O
of	O
lipid	O
profile	O
,	O
coagulation	O
and	O
fibrinolysis	O
markers	O
,	O
and	O
plasma	O
homocysteine	O
levels	O
after	O
treatment	O
.	O

Decreased	O
serum	B-protein
ceruloplasmin	I-protein
and	O
copper	O
levels	O
in	O
cervical	O
dystonia	O
.	O

The	O
encoded	O
sequence	O
revealed	O
a	O
typical	O
signal	O
peptide	O
,	O
a	O
predominantly	O
hydrophilic	O
707	O
amino	O
acid	O
residue	O
domain	O
with	O
8	O
N	O
-	O
glycosylation	O
sites	O
,	O
a	O
transmembrane	O
domain	O
,	O
and	O
a	O
C	O
-	O
terminal	O
domain	O
of	O
52	O
amino	O
acids	O
.	O

Oncogenic	O
signalling	O
by	O
E2F1	B-protein
has	O
recently	O
been	O
linked	O
to	O
stabilization	O
and	O
activation	O
of	O
the	O
tumour	O
suppressor	O
p53	B-protein
(	O
refs	O
1	O
,	O
3	O
,	O
4	O
)	O
.	O

PPD	B-protein
-	I-protein
specific	I-protein
IgG	I-protein
subclass	O
responses	O
were	O
evident	O
to	O
all	O
four	O
IgG	B-protein
subclasses	O
.	O

Biohydrogenation	O
of	O
linoleic	O
acid	O
into	O
octadecenoic	O
acid	O
was	O
observed	O
.	O

(	O
total	O
soluble	O
solids	O
)	O
and	O
organoleptic	O
characteristics	O
under	O
the	O
influence	O
of	O
different	O
treatments	O
.	O

Furthermore	O
,	O
in	O
vivo	O
and	O
in	O
vitro	O
protein	O
-	O
protein	O
interaction	O
experiments	O
have	O
shown	O
that	O
SR33	B-protein
protein	I-protein
interacts	O
with	O
itself	O
and	O
with	O
SR45	B-protein
protein	I-protein
but	O
not	O
with	O
two	O
other	O
members	O
(	O
SRZ21	B-protein
and	O
SRZ22	B-protein
)	O
of	O
the	O
SR	B-protein
family	I-protein
that	O
are	O
known	O
to	O
interact	O
with	O
the	O
Arabidopsis	O
full	O
-	O
length	O
U	B-protein
-	I-protein
70K	I-protein
only	O
.	O

The	O
prophylactic	O
use	O
of	O
new	O
medication	O
for	O
patients	O
between	O
the	O
first	O
and	O
second	O
cycle	O
of	O
chemotherapy	O
,	O
in	O
agreement	O
with	O
the	O
estimates	O
calculated	O
,	O
does	O
not	O
save	O
health	O
care	O
costs	O
but	O
may	O
improve	O
the	O
quality	O
of	O
life	O
in	O
these	O
patients	O
and	O
permit	O
the	O
continuation	O
of	O
a	O
therapeutic	O
schedule	O
without	O
interruption	O
which	O
may	O
improve	O
the	O
life	O
expectancy	O
of	O
the	O
patient	O
.	O

Alveolar	O
lymphocytes	O
were	O
surprisingly	O
increased	O
in	O
most	O
patients	O
with	O
AIDS	O
(	O
mean	O
26	O
.	O
1	O
+	O
/	O
-	O
21	O
.	O
9	O
%	O
;	O
range	O
1	O
-	O
76	O
%	O
)	O
and	O
CGL	O
(	O
mean	O
26	O
.	O
6	O
+	O
/	O
-	O
22	O
.	O
6	O
%	O
;	O
range	O
3	O
-	O
76	O
%	O
)	O
with	O
criteria	O
of	O
activation	O
contrasting	O
with	O
the	O
blood	O
lymphopenia	O
.	O

Overexpression	O
of	O
SCS1	B-protein
could	O
not	O
complement	O
an	O
HSP60	B-protein
-	I-protein
null	I-protein
allele	I-protein
,	O
indicating	O
that	O
suppression	O
was	O
not	O
due	O
to	O
the	O
bypassing	O
of	O
Hsp60	B-protein
activity	O
.	O

Eastern	O
Cooperative	O
Oncology	O
Group	O
trial	O
E3186	O
was	O
initiated	O
to	O
explore	O
this	O
question	O
.	O

Through	O
Southern	O
blot	O
analyses	O
of	O
DNA	O
from	O
backcross	O
and	O
cogenic	O
mice	O
,	O
recombinant	O
inbred	O
strains	O
,	O
and	O
somatic	O
cell	O
hybrids	O
,	O
the	O
genetic	O
loci	O
that	O
produce	O
the	O
cyclin	B-protein
B1	I-protein
-	I-protein
related	I-protein
sequences	I-protein
(	O
designated	O
loci	B-protein
Cycb1	I-protein
-	I-protein
rs1	I-protein
to	O
Cycb1	B-protein
-	I-protein
rs9	I-protein
)	O
were	O
mapped	O
on	O
mouse	O
chromosomes	O
5	O
,	O
1	O
,	O
17	O
,	O
4	O
,	O
14	O
,	O
13	O
,	O
7	O
,	O
X	O
,	O
and	O
8	O
,	O
respectively	O
.	O

The	O
diet	O
of	O
migrants	O
showed	O
both	O
positive	O
(	O
macronutrients	O
)	O
and	O
negative	O
(	O
micronutrients	O
)	O
differences	O
with	O
the	O
general	O
Dutch	O
diet	O
.	O

Greater	O
rupture	O
force	O
was	O
required	O
in	O
the	O
adult	O
pigs	O
than	O
in	O
the	O
young	O
pigs	O
.	O

Identical	O
effects	O
were	O
obtained	O
when	O
inhibitors	O
and	O
dominant	O
negative	O
mutants	O
were	O
tested	O
on	O
the	O
-	O
29	O
to	O
+	O
139	O
bp	O
region	O
of	O
the	O
cyclin	B-protein
D1	I-protein
promoter	I-protein
.	O

Recent	O
literature	O
has	O
suggested	O
that	O
beta	B-protein
-	I-protein
2	I-protein
transferrin	I-protein
can	O
also	O
be	O
used	O
as	O
a	O
clinical	O
marker	O
for	O
perilymph	O
.	O

Expression	O
of	O
the	O
human	B-protein
heat	I-protein
shock	I-protein
protein	I-protein
70	I-protein
gene	I-protein
(	O
hsp70	B-protein
)	O
is	O
induced	O
by	O
various	O
kinds	O
of	O
stress	O
and	O
by	O
oncogenes	O
.	O

We	O
have	O
investigated	O
the	O
requirements	O
of	O
the	O
CH	B-protein
gene	I-protein
switch	O
by	O
characterizing	O
two	O
rearranged	B-protein
gamma	I-protein
2b	I-protein
genes	I-protein
from	O
a	O
gamma	B-protein
2b	I-protein
producing	O
mouse	O
myeloma	O
(	O
MPC	O
-	O
11	O
)	O
.	O

Exchanging	O
the	O
human	O
propeptide	O
in	O
this	O
chimera	O
with	O
either	O
the	O
murine	B-protein
MIC	I-protein
-	I-protein
1	I-protein
or	O
TGF	B-protein
-	I-protein
beta1	I-protein
propeptide	I-protein
resulted	O
in	O
secretion	O
of	O
the	O
unprocessed	O
,	O
monomeric	O
chimera	O
,	O
suggesting	O
a	O
specific	O
interaction	O
between	O
the	O
human	B-protein
MIC	I-protein
-	I-protein
1	I-protein
propeptide	I-protein
and	O
mature	O
peptide	O
.	O

CONCLUSION	O
:	O
Although	O
quantitative	O
and	O
qualitative	O
criteria	O
for	O
diagnosing	O
fatty	O
liver	O
on	O
helical	O
CT	O
can	O
be	O
determined	O
,	O
they	O
are	O
protocol	O
-	O
specific	O
.	O

Syndecan	B-protein
-	I-protein
4	I-protein
is	O
a	O
focal	O
adhesion	O
component	O
,	O
and	O
this	O
interaction	O
may	O
both	O
localize	O
PKC	B-protein
and	O
amplify	O
its	O
activity	O
at	O
sites	O
of	O
forming	O
adhesions	O
.	O

A	O
-	O
69	O
-	O
year	O
-	O
old	O
patient	O
with	O
postoperative	O
small	O
-	O
bowel	O
obstruction	O
underwent	O
laparotomy	O
three	O
times	O
.	O

The	O
VirR	B-protein
response	I-protein
regulator	I-protein
from	O
Clostridium	O
perfringens	O
binds	O
independently	O
to	O
two	O
imperfect	O
direct	O
repeats	O
located	O
upstream	O
of	O
the	O
pfoA	B-protein
promoter	I-protein
.	O

Ion	O
injection	O
.	O

These	O
data	O
suggest	O
that	O
AP	B-protein
-	I-protein
A	I-protein
may	O
be	O
potentially	O
useful	O
in	O
the	O
management	O
of	O
heart	O
failure	O
.	O

The	O
effect	O
of	O
low	O
-	O
profile	O
serine	O
substitutions	O
in	O
the	O
V3	O
loop	O
of	O
HIV	B-protein
-	I-protein
1	I-protein
gp120	I-protein
IIIB	I-protein
/	I-protein
LAI	I-protein
on	O
the	O
immunogenicity	O
of	O
the	O
envelope	B-protein
protein	I-protein
.	O

Laboratory	O
pyrolyses	O
have	O
indeed	O
shown	O
that	O
PCBs	O
give	O
significant	O
yields	O
of	O
PCDFs	O
,	O
and	O
chlorobenzenes	O
give	O
both	O
PCDFs	O
and	O
PCDDs	O
.	O

A	O
marked	O
decrease	O
in	O
the	O
type	B-protein
1	I-protein
insulin	I-protein
-	I-protein
like	I-protein
growth	I-protein
factor	I-protein
(	I-protein
IGF	I-protein
)	I-protein
receptor	I-protein
(	O
IGF	B-protein
-	I-protein
IR	I-protein
)	O
occurs	O
in	O
prostate	O
epithelial	O
cells	O
during	O
transformation	O
from	O
the	O
benign	O
to	O
the	O
metastatic	O
state	O
.	O

Pokeweed	B-protein
antiviral	I-protein
protein	I-protein
(	O
PAP	B-protein
)	O
from	O
Phytolacca	O
americana	O
is	O
a	O
highly	O
specific	O
N	B-protein
-	I-protein
glycosidase	I-protein
removing	O
adenine	O
residues	O
(	O
A4324	O
in	O
28S	B-protein
rRNA	I-protein
and	O
A2660	O
in	O
23S	B-protein
rRNA	I-protein
)	O
from	O
intact	O
ribosomes	O
of	O
both	O
eukaryotes	O
and	O
prokaryotes	O
.	O

This	O
study	O
indicated	O
that	O
the	O
Japanese	O
quail	O
was	O
less	O
sensitive	O
to	O
particulate	O
Mn3O4	O
exposure	O
than	O
rodents	O
treated	O
comparably	O
.	O

The	O
significance	O
of	O
these	O
palindromic	O
domains	O
in	O
this	O
ORF	O
is	O
unclear	O
but	O
the	O
coincidence	O
of	O
the	O
end	O
of	O
one	O
larger	O
palindrome	O
with	O
the	O
end	O
of	O
the	O
translated	O
protein	O
sequence	O
that	O
has	O
homology	O
with	O
the	O
B	B-protein
chain	I-protein
of	O
insulin	B-protein
suggests	O
that	O
the	O
palindromes	O
may	O
divide	O
the	O
T2	B-protein
protein	I-protein
into	O
several	O
functional	O
units	O
.	O

In	O
contrast	O
,	O
when	O
the	O
isoform	O
containing	O
the	O
C	B-protein
epsilon4	I-protein
domain	I-protein
joined	O
directly	O
to	O
the	O
M2	B-protein
exon	I-protein
(	O
IgE	B-protein
grande	I-protein
)	O
is	O
expressed	O
in	O
the	O
J558L	O
cell	O
line	O
,	O
it	O
is	O
degraded	O
intracellularly	O
,	O
suggesting	O
a	O
cell	O
line	O
-	O
dependent	O
regulation	O
of	O
secretion	O
.	O

Positive	O
correlations	O
were	O
seen	O
between	O
the	O
measurements	O
for	O
protein	O
intake	O
(	O
r	O
=	O
.	O
58	O
,	O
P	O
=	O
.	O
0026	O
)	O
energy	O
intake	O
(	O
r	O
=	O
.	O
78	O
,	O
P	O
<	O
.	O
00001	O
)	O
,	O
with	O
mean	O
differences	O
of	O
.	O
066	O
g	O
/	O
kg	O
/	O
d	O
(	O
SD	O
.	O
38	O
)	O
2	O
.	O
04	O
kcal	O
/	O
kg	O
/	O
day	O
(	O
SD	O
6	O
.	O
67	O
)	O
,	O
respectively	O
.	O

SPP41	B-protein
was	O
cloned	O
and	O
sequenced	O
and	O
found	O
to	O
be	O
essential	O
.	O
spp43	B-protein
is	O
allelic	O
to	O
the	O
previously	O
identified	O
suppressor	B-protein
srn1	I-protein
,	O
which	O
encodes	O
a	O
negative	O
regulator	O
of	O
gene	O
expression	O
.	O

Thus	O
,	O
phosphodiesterase	B-protein
inhibitors	O
that	O
produce	O
an	O
opiate	O
quasi	O
-	O
withdrawal	O
syndrome	O
potentiate	O
interoceptive	O
stimuli	O
and	O
weight	O
loss	O
associated	O
with	O
the	O
withdrawal	O
syndrome	O
precipitated	O
by	O
naltrexone	O
in	O
morphine	O
-	O
dependent	O
rats	O
.	O

No	O
differences	O
in	O
fixation	O
quality	O
were	O
observed	O
between	O
cochleas	O
fixed	O
by	O
intravascular	O
perfusion	O
and	O
cochleas	O
fixed	O
by	O
intralabyrinthine	O
perfusion	O
.	O

Effects	O
of	O
diltiazem	O
on	O
netilmicin	O
-	O
induced	O
nephrotoxicity	O
in	O
rabbits	O
.	O

The	O
results	O
show	O
that	O
cognitive	O
stimulation	O
enhanced	O
performance	O
on	O
the	O
Boston	O
Naming	O
Test	O
and	O
a	O
Word	O
List	O
Recognition	O
Task	O
;	O
physical	O
intervention	O
,	O
however	O
,	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

A	O
DNA	O
fragment	O
encoding	O
the	O
DNA	O
-	O
binding	O
domain	O
(	O
amino	O
acids	O
1	O
-	O
60	O
)	O
of	O
the	O
Escherichia	B-protein
coli	I-protein
fru	I-protein
transcriptional	I-protein
regulator	I-protein
was	O
cloned	O
into	O
the	O
pGEX	O
-	O
KT	O
vector	O
and	O
expressed	O
in	O
frame	O
with	O
the	O
fused	O
gene	O
encoding	O
glutathione	B-protein
S	I-protein
-	I-protein
transferase	I-protein
.	O

It	O
is	O
believed	O
that	O
these	O
domains	O
are	O
important	O
for	O
directing	O
specific	O
protein	O
-	O
protein	O
interactions	O
necessary	O
for	O
the	O
proper	O
functioning	O
of	O
Src	B-protein
.	O

Obesity	O
was	O
strongly	O
associated	O
with	O
the	O
proportions	O
of	O
nonprotein	O
-	O
bound	O
and	O
albumin	O
-	O
bound	O
estradiol	O
,	O
and	O
inversely	O
associated	O
with	O
sex	B-protein
hormone	I-protein
binding	I-protein
globulin	I-protein
(	O
SHBG	B-protein
)	O
levels	O
and	O
the	O
proportion	O
of	O
SHBG	O
-	O
bound	O
estradiol	O
.	O

METHODS	O
:	O
We	O
obtained	O
maximal	O
inspiratory	O
and	O
expiratory	O
flow	O
-	O
volume	O
curves	O
in	O
41	O
unselected	O
patients	O
with	O
essential	O
tremor	O
(	O
14	O
males	O
,	O
27	O
females	O
,	O
age	O
61	O
.	O
7	O
+	O
/	O
-	O
2	O
.	O
14	O
years	O
)	O
.	O

This	O
correlated	O
with	O
reduced	O
levels	O
of	O
secreted	O
hepatitis	B-protein
B	I-protein
e	I-protein
antigen	I-protein
and	O
increased	O
intracellular	O
levels	O
of	O
core	B-protein
and	O
Pol	B-protein
proteins	I-protein
and	O
replicative	O
HBV	O
DNA	O
intermediates	O
.	O

Relapse	O
of	O
leukemia	O
after	O
prolonged	O
remission	O
.	O

A	O
new	O
physiopathological	O
treatment	O
of	O
HBV	O
-	O
related	O
polyarteritis	O
inspired	O
by	O
advances	O
in	O
the	O
treatment	O
of	O
chronic	O
active	O
hepatitis	O
B	O
was	O
tested	O
in	O
7	O
patients	O
.	O

Possibilities	O
of	O
needleless	O
administration	O
of	O
various	O
substances	O
to	O
animals	O
.	O

No	O
significant	O
correlation	O
was	O
found	O
between	O
LVM	O
or	O
wall	O
thickness	O
and	O
body	O
surface	O
area	O
,	O
age	O
,	O
blood	O
pressure	O
,	O
heart	O
rate	O
,	O
cardiac	O
output	O
,	O
total	O
peripheral	O
resistance	O
and	O
left	O
ventricular	O
systolic	O
wall	O
stress	O
,	O
whereas	O
CD25	O
was	O
correlated	O
with	O
urinary	O
catecholamines	O
only	O
in	O
hypertensive	O
patients	O
(	O
r	O
=	O
0	O
.	O
606	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Uses	O
of	O
orthoclone	O
OKT3	O
for	O
prophylaxis	O
of	O
rejection	O
and	O
induction	O
in	O
initial	O
nonfunction	O
in	O
kidney	O
transplantation	O
.	O

(	O
iv	O
)	O
Although	O
UCRBP	B-protein
has	O
been	O
previously	O
shown	O
to	O
act	O
as	O
a	O
transcriptional	O
repressor	O
,	O
we	O
show	O
here	O
that	O
UCRBP	B-protein
can	O
also	O
act	O
as	O
a	O
positive	O
transactivator	O
of	O
a	O
reporter	O
driven	O
by	O
UCR	B-protein
elements	I-protein
when	O
used	O
in	O
co	O
-	O
transfection	O
assays	O
.	O

Collectively	O
,	O
these	O
data	O
indicate	O
that	O
HIP	B-protein
is	O
a	O
membrane	O
-	O
associated	O
HP	O
-	O
binding	O
protein	O
expressed	O
on	O
the	O
surface	O
of	O
normal	O
human	O
uterine	O
epithelia	O
and	O
uterine	O
epithelial	O
cell	O
lines	O
.	O

The	O
second	O
mutation	O
present	O
in	O
the	O
original	O
mutant	O
proved	O
to	O
be	O
an	O
allele	O
of	O
a	O
known	O
gene	O
,	O
PBS2	B-protein
,	O
which	O
encodes	O
a	O
putative	O
protein	B-protein
kinase	I-protein
that	O
functions	O
in	O
the	O
high	O
osmolarity	O
stress	O
pathway	O
.	O

Clinical	O
implication	O
of	O
protein	O
levels	O
of	O
IL	B-protein
-	I-protein
5	I-protein
in	O
induced	O
sputum	O
in	O
asthmatic	O
patients	O
.	O

The	O
enzyme	O
displays	O
optimal	O
activity	O
at	O
about	O
0	O
.	O
5	O
mM	O
pantoate	O
(	O
k	O
(	O
cat	O
)	O
0	O
.	O
63	O
s	O
(	O
-	O
1	O
)	O
)	O
and	O
at	O
pH	O
7	O
.	O
8	O
.	O

These	O
properties	O
indicate	O
that	O
Gle1	B-protein
is	O
an	O
RNA	O
-	O
export	O
factor	O
and	O
that	O
Rev	B-protein
may	O
mediate	O
viral	O
RNA	O
export	O
by	O
mimicking	O
the	O
function	O
of	O
Gle1	B-protein
.	O

Dynamic	O
imaging	O
of	O
nuclear	O
wave	O
functions	O
with	O
ultrashort	O
UV	O
laser	O
pulses	O
.	O

Co	O
-	O
administration	O
of	O
5FU	O
,	O
angiotensin	B-protein
II	I-protein
and	O
microspheres	O
via	O
the	O
hepatic	O
artery	O
may	O
reduce	O
drug	O
exposure	O
in	O
the	O
systemic	O
compartment	O
and	O
therefore	O
may	O
increase	O
the	O
therapeutic	O
ratio	O
of	O
5FU	O
administration	O
via	O
the	O
hepatic	O
artery	O
.	O

Specific	O
binding	O
of	O
the	O
protein	O
factors	O
to	O
the	O
sites	O
,	O
possibly	O
to	O
the	O
three	O
Mt	B-protein
sequences	I-protein
,	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
coordinate	O
regulation	O
of	O
the	O
transcription	O
of	O
nuclear	O
genes	O
encoding	O
subunits	O
responsible	O
for	O
mitochondrial	O
oxidative	O
phosphorylation	O
.	O

Neutrophil	O
:	O
lymphocyte	O
ratio	O
,	O
plasma	O
haptoglobin	B-protein
,	O
and	O
CBG	B-protein
levels	O
were	O
greater	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
during	O
the	O
INITIAL	O
period	O
than	O
during	O
the	O
PRE	O
or	O
POST	O
periods	O
but	O
did	O
not	O
differ	O
between	O
treatments	O
.	O

In	O
a	O
prospective	O
randomized	O
study	O
,	O
287	O
patients	O
with	O
advanced	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
stage	O
IIIb	O
or	O
IV	O
with	O
ECOG	O
performance	O
status	O
(	O
PS	O
)	O
0	O
-	O
1	O
or	O
2	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
best	O
supportive	O
care	O
(	O
BSC	O
)	O
or	O
supportive	O
care	O
plus	O
combination	O
chemotherapy	O
(	O
IEP	O
regimen	O
:	O
ifosfamide	O
3	O
gm	O
/	O
m2	O
IV	O
with	O
mesna	O
uroprotection	O
,	O
epirubicin	O
60	O
mg	O
/	O
m2	O
IV	O
on	O
day	O
1	O
and	O
cisplatin	O
60	O
mg	O
/	O
m2	O
IV	O
on	O
day	O
2	O
;	O
or	O
MVP	O
regimen	O
:	O
mitomycin	O
-	O
C	O
8	O
mg	O
/	O
m2	O
,	O
cisplatin	O
100	O
mg	O
/	O
m2	O
IV	O
on	O
day	O
1	O
,	O
vinblastine	O
4	O
mg	O
/	O
m2	O
IV	O
on	O
days	O
1	O
and	O
15	O
)	O
.	O

In	O
gel	O
mobility	O
shift	O
assays	O
,	O
low	O
binding	O
activity	O
of	O
CBF	B-protein
to	O
the	O
wild	B-protein
-	I-protein
type	I-protein
AtpC	I-protein
promoter	I-protein
sequence	I-protein
was	O
observed	O
with	O
nuclear	O
extracts	O
from	O
tissue	O
with	O
low	O
AtpC	B-protein
expression	O
levels	O
,	O
i	O
.	O
e	O
.	O
extracts	O
from	O
etiolated	O
and	O
photobleached	O
seedlings	O
,	O
whereas	O
high	O
binding	O
activity	O
was	O
detectable	O
with	O
extracts	O
from	O
tissues	O
with	O
high	O
AtpC	B-protein
expression	O
levels	O
,	O
i	O
.	O
e	O
.	O
extracts	O
from	O
light	O
-	O
grown	O
seedlings	O
and	O
etiolated	O
seedlings	O
treated	O
with	O
cytokinin	B-protein
.	O

The	O
data	O
indicate	O
that	O
calcitonin	B-protein
induced	O
a	O
beta	B-protein
-	I-protein
endorphin	I-protein
increase	O
independent	O
of	O
enhanced	O
corticotrophin	O
-	O
cortisol	O
release	O
.	O

The	O
plasmin	B-protein
-	I-protein
derived	I-protein
D	I-protein
(	I-protein
approximately	I-protein
105	I-protein
-	I-protein
kDa	I-protein
)	I-protein
product	I-protein
,	O
however	O
,	O
could	O
be	O
cross	O
-	O
linked	O
into	O
DD	B-protein
dimers	I-protein
.	O

Furthermore	O
,	O
the	O
deletion	O
of	O
bcp	B-protein
from	O
the	O
chromosome	O
had	O
no	O
effect	O
on	O
gcv	B-protein
-	I-protein
lacZ	I-protein
expression	O
.	O

The	O
amino	O
-	O
terminal	O
region	O
of	O
E1A	B-protein
binds	O
several	O
high	O
molecular	O
weight	O
proteins	O
and	O
inhibits	O
the	O
transcriptional	O
coactivator	O
function	O
of	O
p300	B-protein
and	O
the	O
homologous	O
cAMP	B-protein
response	I-protein
element	I-protein
(	I-protein
CRE	I-protein
)	I-protein
-	I-protein
binding	I-protein
protein	I-protein
.	O

To	O
investigate	O
the	O
effects	O
of	O
exogenous	O
hyaluronic	O
acid	O
,	O
the	O
development	O
of	O
port	O
-	O
site	O
metastasis	O
was	O
examined	O
using	O
mouse	O
adenocarcinoma	O
cell	O
-	O
line	O
colon	O
26	O
cells	O
.	O

The	O
extraction	O
was	O
subsequently	O
rated	O
as	O
'	O
easy	O
'	O
or	O
'	O
difficult	O
'	O
.	O
Taking	O
Pell	O
-	O
Gregory	O
class	O
C	O
as	O
a	O
predictor	O
of	O
a	O
'	O
difficult	O
'	O
extraction	O
,	O
specificity	O
was	O
88	O
%	O
but	O
sensitivity	O
was	O
low	O
at	O
15	O
%	O
.	O

Chrispeels	O
[	O
1993	O
]	O
EMBO	O
J	O
12	O
:	O
2241	O
-	O
2247	O
)	O
.	O

Therefore	O
,	O
vitamin	O
D3	O
analogues	O
have	O
a	O
substantial	O
antipsoriatic	O
effect	O
.	O

A	O
mutant	B-protein
areA	I-protein
product	I-protein
truncated	O
immediately	O
after	O
the	O
last	O
residue	O
of	O
the	O
highly	O
conserved	O
GATA	B-protein
(	O
DNA	O
-	O
binding	O
)	O
domain	O
retains	O
partial	O
function	O
.	O

The	O
identification	O
of	O
the	O
hepatitis	O
C	O
virus	O
as	O
the	O
major	O
cause	O
of	O
liver	O
disease	O
both	O
in	O
dialysis	O
patients	O
and	O
in	O
transplant	O
patients	O
has	O
focused	O
attention	O
on	O
the	O
epidemiology	O
and	O
the	O
impact	O
of	O
continuing	O
infection	O
in	O
these	O
patient	O
groups	O
.	O

IL	B-protein
-	I-protein
1	I-protein
and	O
TNF	B-protein
increase	O
AND	B-protein
-	I-protein
34	I-protein
transcript	I-protein
levels	O
in	O
thymic	O
cortical	O
reticular	O
,	O
thymic	O
nurse	O
,	O
and	O
fibroblast	O
cell	O
lines	O
.	O

Sequence	O
divergence	O
is	O
observed	O
in	O
untranslated	O
regions	O
which	O
allows	O
the	O
definition	O
of	O
gene	O
-	O
specific	O
probes	O
.	O

This	O
site	O
is	O
upstream	O
from	O
the	O
TATA	O
box	O
used	O
in	O
somatic	O
cells	O
.	O

Furthermore	O
,	O
45Ca	O
-	O
binding	O
assays	O
revealed	O
that	O
CCaMK	B-protein
directly	O
binds	O
Ca2	O
+	O
.	O

To	O
analyze	O
the	O
regulatory	O
activity	O
of	O
Gtx	B-protein
,	O
we	O
first	O
identified	O
the	O
optimal	O
Gtx	B-protein
-	I-protein
binding	I-protein
sequence	I-protein
using	O
an	O
in	O
vitro	O
DNA	O
-	O
binding	O
assay	O
.	O

Generally	O
the	O
differences	O
between	O
short	O
gut	O
and	O
sham	O
operation	O
animals	O
disappeared	O
when	O
the	O
data	O
were	O
normalised	O
for	O
mucosal	O
weight	O
.	O

Dopaminergic	O
modulation	O
of	O
transcallosal	O
activity	O
of	O
cat	O
motor	O
cortical	O
neurons	O
.	O

An	O
increase	O
in	O
bone	O
mineral	O
density	O
at	O
the	O
spine	O
,	O
total	O
hip	O
,	O
and	O
total	O
body	O
has	O
been	O
reported	O
with	O
raloxifene	O
but	O
seems	O
to	O
be	O
less	O
than	O
that	O
seen	O
with	O
estrogen	O
or	O
alendronate	O
therapy	O
.	O

The	O
retinoid	B-protein
Z	I-protein
receptor	I-protein
beta	I-protein
(	O
RZR	B-protein
beta	I-protein
)	O
,	O
an	O
orphan	B-protein
receptor	I-protein
,	O
is	O
a	O
member	O
of	O
the	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
(	O
RAR	B-protein
)	I-protein
/	I-protein
thyroid	I-protein
hormone	I-protein
receptor	I-protein
(	O
TR	B-protein
)	O
subfamily	O
of	O
nuclear	O
receptors	O
.	O

We	O
conclude	O
that	O
grade	O
III	O
BGCT	O
can	O
be	O
treated	O
by	O
modified	O
intralesional	O
excision	O
provided	O
the	O
articular	O
surfaces	O
and	O
part	O
of	O
the	O
metaphysis	O
are	O
intact	O
.	O

A	O
reversed	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatographic	O
(	O
HPLC	O
)	O
method	O
for	O
the	O
determination	O
of	O
cocaine	O
metabolites	O
produced	O
in	O
vitro	O
by	O
serum	B-protein
and	I-protein
liver	I-protein
esterases	I-protein
is	O
described	O
.	O

Caries	O
prevention	O
in	O
the	O
dental	O
office	O
.	O

Use	O
of	O
the	O
vena	O
cava	O
to	O
extend	O
the	O
right	O
renal	O
vein	O
for	O
cadaver	O
transplantation	O
is	O
controversial	O
.	O

During	O
the	O
observation	O
period	O
of	O
0	O
.	O
4	O
-	O
30	O
weeks	O
,	O
cardiac	O
white	O
spots	O
on	O
the	O
right	O
ventricle	O
of	O
BALB	O
/	O
c	O
mice	O
were	O
first	O
detected	O
at	O
three	O
weeks	O
(	O
6	O
of	O
20	O
mice	O
;	O
30	O
%	O
)	O
,	O
and	O
the	O
maximal	O
incidence	O
of	O
cardiac	O
white	O
spots	O
was	O
obtained	O
at	O
nine	O
weeks	O
(	O
39	O
of	O
44	O
mice	O
;	O
88	O
%	O
)	O
.	O

We	O
have	O
used	O
the	O
hydrophobic	O
repeats	O
of	O
the	O
HSF1	B-protein
trimerization	I-protein
domain	I-protein
in	O
the	O
yeast	O
two	O
-	O
hybrid	O
protein	O
interaction	O
assay	O
to	O
identify	O
heat	B-protein
shock	I-protein
factor	I-protein
binding	I-protein
protein	I-protein
1	I-protein
(	O
HSBP1	B-protein
)	O
,	O
a	O
novel	O
,	O
conserved	O
,	O
76	O
-	O
amino	O
-	O
acid	O
protein	O
that	O
contains	O
two	O
extended	O
arrays	O
of	O
hydrophobic	O
repeats	O
that	O
interact	O
with	O
the	O
HSF1	B-protein
heptad	I-protein
repeats	I-protein
.	O

One	O
of	O
its	O
unique	O
features	O
appears	O
to	O
be	O
the	O
unusually	O
short	O
5	O
'	O
-	O
untranslated	O
regions	O
(	O
UTR	O
)	O
(	O
1	O
-	O
6	O
nucleotides	O
(	O
nts	O
)	O
)	O
and	O
the	O
apparent	O
absence	O
of	O
5	O
'	O
-	O
cap	O
structures	O
from	O
its	O
mRNAs	O
.	O

The	O
COP	O
-	O
PAWP	O
gradient	O
was	O
markedly	O
decreased	O
in	O
both	O
shock	O
and	O
non	O
-	O
shock	O
patients	O
with	O
pulmonary	O
edema	O
.	O

Chick	B-protein
brain	I-protein
actin	I-protein
depolymerizing	I-protein
factor	I-protein
(	O
ADF	B-protein
)	O
is	O
a	O
19	O
-	O
kDa	O
protein	O
that	O
severs	O
actin	B-protein
filaments	I-protein
and	O
binds	O
actin	B-protein
monomers	I-protein
.	O

CodY	B-protein
does	O
not	O
have	O
any	O
homologues	O
in	O
the	O
data	O
-	O
bases	O
.	O

The	O
test	O
for	O
alpha	B-protein
-	I-protein
naphthyl	I-protein
esterase	I-protein
and	O
quantitation	O
of	O
macrophages	O
(	O
absolute	O
number	O
)	O
per	O
infiltration	O
area	O
unit	O
adjacent	O
to	O
the	O
abscess	O
suggest	O
a	O
direct	O
correlation	O
between	O
the	O
absolute	O
number	O
of	O
macrophages	O
and	O
the	O
width	O
of	O
the	O
capsule	O
.	O

Here	O
,	O
we	O
have	O
more	O
closely	O
investigated	O
transactivation	O
of	O
the	O
human	B-protein
HSP70	I-protein
promoter	I-protein
by	O
Myb	B-protein
proteins	I-protein
.	O

Varieties	O
of	O
envious	O
experience	O
.	O

In	O
the	O
absence	O
of	O
histological	O
criteria	O
,	O
which	O
it	O
is	O
difficult	O
to	O
demand	O
in	O
view	O
of	O
the	O
variability	O
of	O
results	O
and	O
potential	O
dangers	O
of	O
endomyocardial	O
biopsy	O
involving	O
such	O
thin	O
and	O
fragile	O
ventricular	O
walls	O
,	O
the	O
diagnosis	O
of	O
ACRV	O
is	O
based	O
upon	O
the	O
concomitant	O
existence	O
of	O
:	O
(	O
1	O
)	O
electrophysiological	O
criteria	O
:	O
ventricular	O
arrhythmias	O
,	O
in	O
particular	O
sustained	O
monomorphous	O
VT	O
,	O
with	O
the	O
particular	O
feature	O
of	O
a	O
very	O
high	O
degree	O
of	O
sensitivity	O
to	O
adrenergic	O
stimulation	O
(	O
exercise	O
)	O
,	O
the	O
existence	O
of	O
late	O
potentials	O
on	O
the	O
high	O
amplification	O
ECG	O
,	O
a	O
highly	O
specific	O
sign	O
,	O
though	O
unfortunately	O
of	O
poor	O
sensitivity	O
in	O
localized	O
froms	O
,	O
those	O
which	O
are	O
most	O
difficult	O
to	O
identify	O
(	O
2	O
)	O
;	O
segmentary	O
morphological	O
and	O
kinetic	O
RV	O
abnormalities	O
,	O
most	O
often	O
resulting	O
in	O
localized	O
akinetic	O
or	O
dyskinetic	O
parietal	O
vaulting	O
,	O
with	O
stasis	O
`	O
`	O
in	O
situ	O
'	O
'	O
.	O

Use	O
of	O
Medi	O
-	O
Jector	O
EZ	O
dermojet	O
for	O
anesthesia	O
in	O
minor	O
surgery	O
.	O

Each	O
half	O
molecule	O
contains	O
four	O
disulfide	O
linkages	O
and	O
four	O
cis	O
peptides	O
.	O

The	O
alpha	O
-	O
subunit	O
by	O
itself	O
binds	O
to	O
telomeric	O
DNA	O
.	O

The	O
positive	O
-	O
acting	O
global	O
sulfur	O
regulatory	O
protein	O
,	O
CYS3	B-protein
,	O
of	O
Neurospora	O
crassa	O
turns	O
on	O
the	O
expression	O
of	O
a	O
family	O
of	O
unlinked	O
structural	O
genes	O
that	O
encode	O
enzymes	O
of	O
sulfur	O
catabolism	O
.	O

Cortisol	O
excretion	O
,	O
appeared	O
to	O
be	O
markedly	O
affected	O
by	O
the	O
season	O
although	O
other	O
factors	O
such	O
as	O
social	O
and	O
environmental	O
stress	O
can	O
not	O
be	O
discounted	O
.	O

The	O
minimal	O
promoter	O
of	O
the	O
RII	B-protein
beta	I-protein
gene	I-protein
was	O
composed	O
of	O
two	O
adjacent	O
functional	O
elements	O
.	O

Our	O
results	O
,	O
however	O
,	O
were	O
obtained	O
for	O
Z	O
itself	O
and	O
not	O
for	O
[	O
Z	O
]	O
.	O

Structure	O
and	O
expression	O
of	O
the	O
mouse	B-protein
growth	I-protein
hormone	I-protein
receptor	I-protein
/	I-protein
growth	I-protein
hormone	I-protein
binding	I-protein
protein	I-protein
gene	I-protein
.	O

Investigations	O
using	O
hippocampal	O
slices	O
maintained	O
in	O
vitro	O
have	O
demonstrated	O
that	O
bursts	O
of	O
oscillatory	O
field	O
potentials	O
in	O
the	O
gamma	O
frequency	O
range	O
(	O
30	O
-	O
80	O
Hz	O
)	O
are	O
followed	O
by	O
a	O
slower	O
oscillation	O
in	O
the	O
beta	O
1	O
range	O
(	O
12	O
-	O
20	O
Hz	O
)	O
.	O

We	O
suggest	O
that	O
CT	O
scan	O
be	O
preferable	O
in	O
diagnosis	O
of	O
tumors	O
in	O
that	O
area	O
.	O

Several	O
features	O
of	O
10	O
.	O
24	O
.	O
6	O
cells	O
suggest	O
that	O
the	O
mutation	O
disrupts	O
normal	O
intracellular	O
formation	O
of	O
peptide	B-protein
/	I-protein
DR	I-protein
complexes	I-protein
.	O

Human	O
antitetanus	O
serum	O
:	O
an	O
unused	O
wealth	O
.	O

Their	O
effect	O
on	O
the	O
guinea	O
pig	O
vas	O
deferens	O
.	O

This	O
enabled	O
the	O
formation	O
of	O
stem	O
-	O
loop	O
templates	O
with	O
the	O
fusion	O
point	O
of	O
the	O
chimeric	O
transcript	O
in	O
the	O
loop	O
and	O
the	O
use	O
of	O
MLL	B-protein
primers	O
in	O
two	O
-	O
sided	O
PCR	O
.	O

We	O
recently	O
reported	O
a	O
placenta	O
-	O
specific	O
enhancer	O
in	O
the	O
human	B-protein
leukemia	I-protein
inhibitory	I-protein
factor	I-protein
receptor	I-protein
(	O
LIFR	B-protein
)	O
gene	O
and	O
now	O
show	O
detailed	O
characterization	O
of	O
the	O
226	O
-	O
base	O
pair	O
enhancer	O
(	O
-	O
4625	O
/	O
-	O
4400	O
nucleotides	O
)	O
.	O

Factors	O
influencing	O
semen	O
characteristics	O
in	O
young	O
boars	O
reared	O
in	O
a	O
subtropical	O
environment	O
were	O
studied	O
.	O

The	O
studied	O
protein	O
fragments	O
consist	O
of	O
residues	O
Arg183	O
-	O
His267	O
of	O
the	O
human	B-protein
ER	I-protein
and	O
residues	O
Lys438	O
-	O
Gln520	O
of	O
the	O
rat	B-protein
GR	O
.	O

Micro	O
high	O
-	O
performance	O
liquid	O
chromatographic	O
system	O
with	O
micro	O
precolumn	O
and	O
dual	O
electrochemical	O
detector	O
for	O
direct	O
injection	O
analysis	O
of	O
catecholamines	O
in	O
body	O
fluids	O
.	O

Human	B-protein
cytomegalovirus	I-protein
immediate	I-protein
-	I-protein
early	I-protein
protein	I-protein
IE2	I-protein
tethers	O
a	O
transcriptional	O
repression	O
domain	O
to	O
p53	B-protein
.	O

Neither	O
verapamil	O
nor	O
nifedipine	O
changed	O
collateral	O
myocardial	O
blood	O
flow	O
from	O
0	O
.	O
10	O
+	O
/	O
-	O
0	O
.	O
02	O
in	O
the	O
subendocardium	O
and	O
0	O
.	O
17	O
+	O
/	O
-	O
0	O
.	O
03	O
ml	O
/	O
min	O
/	O
g	O
in	O
the	O
subepicardium	O
.	O

The	O
most	O
common	O
cause	O
of	O
renal	O
deterioration	O
in	O
the	O
spinal	O
cord	O
injured	O
patient	O
is	O
irreversible	O
vesicoureteral	O
reflux	O
.	O

Identification	O
of	O
eotaxin	B-protein
-	I-protein
3	I-protein
will	O
further	O
promote	O
our	O
understanding	O
of	O
the	O
control	O
of	O
eosinophil	O
trafficking	O
and	O
other	O
CCR3	O
-	O
mediated	O
biological	O
phenomena	O
.	O

The	O
efficacy	O
of	O
a	O
Propionibacterium	O
acnes	O
product	O
for	O
treatment	O
of	O
coliform	O
mastitis	O
was	O
evaluated	O
following	O
intramammary	O
infusion	O
of	O
Escherichia	O
coli	O
.	O

Patients	O
had	O
to	O
have	O
adequate	O
liver	O
,	O
renal	O
,	O
and	O
marrow	O
functions	O
.	O

Reconstitution	O
of	O
Raf	B-protein
-	I-protein
1	I-protein
activity	O
was	O
observed	O
only	O
with	O
kinase	B-protein
active	O
Jak1	B-protein
in	O
both	O
cell	O
lines	O
.	O

Binding	O
of	O
meAda	B-protein
is	O
necessary	O
to	O
activate	O
transcription	O
of	O
the	O
adaptive	O
response	O
genes	O
;	O
accordingly	O
,	O
in	O
vitro	O
transcription	O
of	O
aidB	B-protein
is	O
dependent	O
on	O
the	O
presence	O
of	O
meAda	B-protein
.	O

Spatiotemporal	O
expression	O
of	O
the	O
PAX3	B-protein
gene	I-protein
is	O
tightly	O
regulated	O
during	O
development	O
.	O

Neural	O
blockade	O
in	O
chronic	O
and	O
cancer	O
pain	O
.	O

Lymphoproliferative	O
disorders	O
arising	O
under	O
immunosuppression	O
with	O
FK	O
506	O
:	O
initial	O
observations	O
in	O
a	O
large	O
transplant	O
population	O
.	O

Furthermore	O
,	O
plasma	O
fibrinogen	B-protein
levels	O
increased	O
by	O
a	O
mean	O
of	O
17	O
.	O
6	O
%	O
,	O
a	O
potentially	O
adverse	O
effect	O
of	O
gemfibrozil	O
that	O
has	O
not	O
been	O
previously	O
reported	O
.	O

This	O
5	O
'	O
splice	O
site	O
sequence	O
was	O
required	O
for	O
enhanced	O
polyadenylation	O
and	O
was	O
recognized	O
by	O
both	O
U1	B-protein
small	I-protein
nuclear	I-protein
ribonucleoproteins	I-protein
(	O
snRNPs	B-protein
)	O
and	O
alternative	B-protein
splicing	I-protein
factor	I-protein
/	I-protein
splicing	I-protein
factor	I-protein
2	I-protein
(	O
ASF	B-protein
/	I-protein
SF2	I-protein
)	O
.	O

One	O
R	O
-	O
EST	O
and	O
one	O
Pto	B-protein
-	I-protein
like	I-protein
sequence	I-protein
each	O
mapped	O
to	O
two	O
locations	O
.	O

SELECTION	O
CRITERIA	O
:	O
Randomised	O
and	O
possibly	O
randomised	O
trials	O
using	O
acupuncture	O
to	O
treat	O
asthma	O
and	O
asthma	O
-	O
like	O
symptoms	O
.	O

The	O
size	O
of	O
the	O
mutant	O
molecule	O
corresponds	O
to	O
the	O
unprocessed	O
cytoplasmic	O
precursor	O
(	O
pre	B-protein
-	I-protein
super	I-protein
-	I-protein
pro	I-protein
-	I-protein
PrB	I-protein
)	O
,	O
as	O
detected	O
in	O
sec61	B-protein
mutants	I-protein
,	O
when	O
translocation	O
into	O
the	O
endoplasmic	O
reticulum	O
is	O
blocked	O
.	O

Malonate	O
decarboxylation	O
in	O
Malonomonas	O
rubra	O
involves	O
the	O
formation	O
of	O
malonyl	B-protein
-	I-protein
S	I-protein
-	I-protein
[	I-protein
acyl	I-protein
-	I-protein
carrier	I-protein
protein	I-protein
]	I-protein
from	O
acetyl	B-protein
-	I-protein
S	I-protein
-	I-protein
[	I-protein
acyl	I-protein
-	I-protein
carrier	I-protein
protein	I-protein
]	I-protein
and	O
malonate	O
,	O
carboxyltransfer	O
to	O
a	O
biotin	B-protein
protein	I-protein
and	O
its	O
decarboxylation	O
that	O
is	O
coupled	O
to	O
delta	O
mu	O
Na	O
+	O
generation	O
.	O

Production	O
of	O
C	B-protein
mu	I-protein
RNAs	I-protein
,	O
unlike	O
mu	B-protein
mRNAs	I-protein
,	O
does	O
not	O
require	O
recombination	O
with	O
the	O
joining	B-protein
region	I-protein
(	I-protein
JH	I-protein
)	I-protein
locus	I-protein
.	O

Neurons	O
were	O
held	O
at	O
-	O
67	O
mV	O
to	O
equate	O
voltage	O
-	O
dependent	O
effects	O
.	O

Prenatal	O
diagnosis	O
of	O
galactosaemia	O
[	O
letter	O
]	O
.	O

All	O
tumors	O
proved	O
histologically	O
to	O
be	O
neuroendocrine	O
in	O
origin	O
.	O

Mechanisms	O
of	O
tachyphylaxis	O
in	O
regional	O
anesthesia	O
of	O
long	O
duration	O
.	O

This	O
dynamic	O
response	O
strongly	O
suggests	O
that	O
the	O
p53	B-protein
and	O
Rb	B-protein
tumor	O
suppressor	O
pathways	O
are	O
intact	O
in	O
HeLa	O
cells	O
and	O
that	O
repression	O
of	O
HPV	B-protein
E6	I-protein
and	O
E7	B-protein
mobilizes	O
these	O
pathways	O
in	O
an	O
orderly	O
fashion	O
to	O
deliver	O
growth	O
inhibitory	O
signals	O
to	O
the	O
cells	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
prostate	O
carcinomas	O
with	O
the	O
Ras	B-protein
/	I-protein
MAPK	I-protein
pathway	O
activation	O
might	O
have	O
a	O
selective	O
growth	O
advantage	O
by	O
autocrine	O
TGF	B-protein
-	I-protein
beta1	I-protein
production	O
.	O

Optima	O
)	O
genomic	O
library	O
by	O
hybridizing	O
with	O
elicitor	O
-	O
induced	O
stilbene	B-protein
synthase	I-protein
cDNA	I-protein
as	O
a	O
probe	O
.	O

The	O
GTPase	B-protein
activity	O
of	O
CDC42Ce	B-protein
is	O
moderately	O
stimulated	O
by	O
human	B-protein
n	I-protein
-	I-protein
chimaerin	I-protein
,	O
a	O
GTPase	B-protein
-	I-protein
activating	I-protein
protein	I-protein
for	O
the	O
related	O
p21	B-protein
rac1	I-protein
.	O

The	O
CCAAT	B-protein
core	I-protein
sequence	I-protein
mutants	I-protein
in	O
which	O
both	O
CIII	B-protein
and	O
CI	B-protein
/	I-protein
CII	I-protein
were	O
abolished	O
,	O
also	O
increased	O
the	O
promoter	O
activity	O
.	O

In	O
the	O
present	O
study	O
,	O
beta	O
-	O
funaltrexamine	O
(	O
beta	O
-	O
FNA	O
)	O
and	O
naltrindole	O
(	O
NTI	O
)	O
(	O
nonequilibrium	O
mu	O
-	O
and	O
delta	O
-	O
antagonist	O
,	O
respectively	O
)	O
were	O
used	O
to	O
precipitate	O
withdrawal	O
in	O
butorphanol	O
-	O
dependent	O
rats	O
.	O

The	O
frequency	O
of	O
SPs	O
for	O
both	O
the	O
moderate	O
and	O
severe	O
groups	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
patients	O
with	O
a	O
normal	O
MMFCV	O
(	O
p	O
<	O
.	O
01	O
)	O
;	O
of	O
154	O
arms	O
with	O
a	O
normal	O
MMFCV	O
,	O
only	O
9	O
(	O
6	O
%	O
)	O
had	O
an	O
SP	O
.	O

The	O
pattern	O
and	O
timing	O
of	O
CARP	B-protein
mRNA	I-protein
expression	O
,	O
including	O
transient	O
expression	O
in	O
the	O
tongue	O
at	O
14	O
.	O
5	O
days	O
p	O
.	O
c	O
.	O
,	O
coincides	O
with	O
that	O
of	O
Nkx2	B-protein
.	I-protein
5	I-protein
/	I-protein
Csx	I-protein
(	O
a	O
putative	O
homolog	O
of	O
tinman	B-protein
,	O
the	O
Drosophila	O
melanogaster	O
gene	O
responsible	O
for	O
cardiac	O
development	O
)	O
.	O

Mechanism	O
of	O
activation	O
of	O
the	O
vav	B-protein
protooncogene	I-protein
.	O
vav	B-protein
is	O
a	O
human	O
locus	O
that	O
appears	O
to	O
be	O
specifically	O
expressed	O
in	O
cells	O
of	O
hematopoietic	O
origin	O
regardless	O
of	O
their	O
differentiation	O
lineage	O
.	O

Not	O
even	O
extensive	O
pancreatic	O
resection	O
could	O
prevent	O
pancreatic	O
remnant	O
infection	O
.	O

This	O
concept	O
is	O
supported	O
by	O
the	O
identification	O
of	O
RH	B-protein
-	I-protein
like	I-protein
genes	I-protein
in	O
non	O
human	O
primates	O
.	O

The	O
ultrastructural	O
findings	O
,	O
as	O
well	O
as	O
the	O
urinary	O
C	B-protein
-	I-protein
peptide	I-protein
excretion	O
,	O
confirmed	O
that	O
the	O
glycemic	O
effects	O
should	O
not	O
be	O
thought	O
to	O
be	O
due	O
to	O
a	O
direct	O
action	O
of	O
the	O
drugs	O
used	O
on	O
the	O
endocrine	O
pancreas	O
.	O

Both	O
functional	O
analyses	O
in	O
undifferentiated	O
and	O
differentiated	O
F9	O
cells	O
and	O
characterization	O
of	O
DNA	O
-	O
protein	O
complexes	O
in	O
vitro	O
have	O
identified	O
the	O
sequence	B-protein
motifs	I-protein
GTGACT	I-protein
(	I-protein
C	I-protein
)	I-protein
,	O
ATTGT	B-protein
,	O
and	O
GATA	B-protein
as	O
the	O
key	O
transcription	O
factor	O
binding	O
sites	O
.	O

Estrogen	O
replacement	O
therapy	O
and	O
risk	O
of	O
breast	O
cancer	O
:	O
results	O
of	O
two	O
meta	O
-	O
analyses	O
.	O

The	O
first	O
gene	O
,	O
NSR1	B-protein
,	O
a	O
previously	O
identified	O
gene	O
,	O
encodes	O
a	O
protein	O
involved	O
in	O
ribosomal	O
RNA	O
maturation	O
and	O
possibly	O
in	O
transport	O
of	O
proteins	O
into	O
the	O
nucleus	O
.	O

Northern	O
-	O
blot	O
analysis	O
of	O
mRNA	O
from	O
Avicel	O
-	O
grown	O
N	O
.	O
patriciarum	O
showed	O
that	O
xynB	B-protein
hybridized	O
to	O
a	O
3	O
.	O
4	O
kb	O
mRNA	O
species	O
.	O

To	O
assess	O
the	O
relationship	O
between	O
G	O
(	O
q	O
)	O
/	O
G	O
(	O
11	O
)	O
function	O
with	O
the	O
phosphatidylinositol	B-protein
3	I-protein
-	I-protein
kinase	I-protein
dependent	O
pathway	O
,	O
expression	O
of	O
a	O
dominant	O
-	O
interfering	O
p85	B-protein
regulatory	I-protein
subunit	I-protein
,	O
as	O
well	O
as	O
wortmannin	O
treatment	O
inhibited	O
insulin	O
-	O
stimulated	O
but	O
not	O
G	O
(	O
q	O
)	O
/	O
Q209L	O
-	O
stimulated	O
GLUT4	B-protein
-	I-protein
EGFP	I-protein
translocation	O
.	O

Changes	O
of	O
the	O
DB	B-protein
sequence	I-protein
without	O
affecting	O
the	O
postulated	O
stem	O
structure	O
led	O
to	O
drastic	O
losses	O
of	O
translation	O
efficiency	O
.	O

Northern	O
blot	O
analysis	O
of	O
LeMT	B-protein
(	I-protein
A	I-protein
)	I-protein
and	O
LeMT	B-protein
(	I-protein
B	I-protein
)	I-protein
showed	O
that	O
transcripts	O
of	O
both	O
MT	B-protein
-	I-protein
like	I-protein
genes	I-protein
were	O
more	O
abundant	O
in	O
leaves	O
than	O
roots	O
in	O
tomato	O
plants	O
grown	O
without	O
addition	O
of	O
extra	O
metal	O
ions	O
,	O
a	O
characteristic	O
of	O
type	B-protein
II	I-protein
MTs	I-protein
.	O

Blood	O
variables	O
measured	O
at	O
eight	O
intervals	O
before	O
,	O
during	O
,	O
and	O
after	O
operation	O
were	O
as	O
follows	O
:	O
seven	O
plasma	O
proteins	O
,	O
free	O
hemoglobin	B-protein
,	O
formed	O
elements	O
,	O
and	O
clotting	O
functions	O
.	O

Echo	O
modulation	O
in	O
Pr3	O
+	O
:	O
YAlO3	O
.	O

The	O
various	O
forms	O
of	O
sickle	O
cell	O
disease	O
share	O
the	O
common	O
feature	O
of	O
an	O
abnormal	O
globin	B-protein
chain	I-protein
that	O
,	O
under	O
certain	O
conditions	O
such	O
as	O
hypoxia	O
,	O
results	O
in	O
the	O
sickling	O
of	O
red	O
blood	O
cells	O
and	O
obstruction	O
of	O
blood	O
vessels	O
.	O

No	O
TATA	O
box	O
was	O
found	O
in	O
the	O
putative	O
promoter	O
region	O
,	O
but	O
multiple	O
GC	O
boxes	O
were	O
found	O
around	O
the	O
cap	O
sites	O
,	O
supporting	O
the	O
previously	O
inferred	O
housekeeping	O
nature	O
of	O
CYP51	B-protein
gene	I-protein
and	O
the	O
existence	O
of	O
the	O
multiple	O
transcription	O
initiation	O
sites	O
.	O

Sequencing	O
the	O
gene	O
for	O
an	O
imipenem	O
-	O
cefoxitin	O
-	O
hydrolyzing	O
enzyme	O
(	O
CfiA	B-protein
)	O
from	O
Bacteroides	O
fragilis	O
TAL2480	O
reveals	O
strong	O
similarity	O
between	O
CfiA	B-protein
and	O
Bacillus	B-protein
cereus	I-protein
beta	I-protein
-	I-protein
lactamase	I-protein
II	I-protein
.	O

The	O
SH2	B-protein
domain	I-protein
-	I-protein
containing	I-protein
inositol	I-protein
5	I-protein
'	I-protein
-	I-protein
phosphatase	I-protein
(	O
SHIP	B-protein
)	O
recruits	O
the	O
p85	B-protein
subunit	I-protein
of	O
phosphoinositide	B-protein
3	I-protein
-	I-protein
kinase	I-protein
during	O
FcgammaRIIb1	O
-	O
mediated	O
inhibition	O
of	O
B	B-protein
cell	I-protein
receptor	I-protein
signaling	O
.	O

In	O
the	O
face	O
of	O
the	O
outbreak	O
,	O
there	O
was	O
a	O
delay	O
before	O
vaccination	O
was	O
able	O
to	O
stop	O
deaths	O
.	O

Hydrocortisone	O
seems	O
to	O
be	O
unable	O
to	O
hinder	O
the	O
postdenervation	O
changes	O
in	O
the	O
muscle	O
membrane	O
whereas	O
high	O
doses	O
of	O
the	O
hormone	O
are	O
able	O
to	O
induce	O
changes	O
in	O
the	O
muscle	O
membrane	O
.	O

The	O
recovered	O
calves	O
were	O
tested	O
for	O
immunity	O
to	O
homologous	O
severe	O
challenge	O
,	O
50	O
or	O
73	O
days	O
after	O
the	O
first	O
infection	O
.	O

J	O
.	O

Results	O
from	O
in	O
vitro	O
transcription	O
-	O
translation	O
analysis	O
and	O
maxicell	O
experiments	O
suggested	O
that	O
the	O
447	O
-	O
bp	O
ORF	O
was	O
the	O
one	O
being	O
actively	O
expressed	O
.	O

Extensive	O
DNA	O
rearrangement	O
occurs	O
during	O
the	O
development	O
of	O
the	O
somatic	O
macronucleus	O
from	O
the	O
germ	O
line	O
micronucleus	O
in	O
ciliated	O
protozoans	O
.	O

Thus	O
,	O
dpp	B-protein
and	O
omb	B-protein
promote	O
both	O
dorsal	O
leg	O
cell	O
fate	O
as	O
well	O
as	O
transdetermination	O
-	O
competent	O
leg	O
disc	O
cells	O
.	O

Based	O
on	O
mutational	O
data	O
and	O
possible	O
mRNA	O
structure	O
,	O
we	O
hypothesized	O
about	O
the	O
effect	O
of	O
mRNA	O
structure	O
on	O
translation	O
of	O
the	O
two	O
major	O
C	B-protein
/	I-protein
EBPepsilon	I-protein
isoforms	I-protein
:	O
p32	B-protein
and	O
p30	B-protein
.	O

Moreover	O
,	O
unlike	O
control	O
rats	O
operated	O
animals	O
did	O
not	O
show	O
aversion	O
to	O
the	O
highest	O
concentrations	O
of	O
saccharin	O
solutions	O
.	O

We	O
recently	O
found	O
that	O
17	O
beta	O
-	O
estradiol	O
(	O
E2	O
)	O
not	O
only	O
suppresses	O
bone	O
resorption	O
but	O
also	O
stimulates	O
bone	O
formation	O
in	O
the	O
cancellous	O
bone	O
of	O
female	O
rats	O
.	O

Although	O
the	O
E	O
-	O
box	O
consensus	O
is	O
minimally	O
defined	O
as	O
CANNTG	B-protein
,	O
the	O
adjacent	O
nucleotides	O
of	O
functional	O
E	O
-	O
boxes	O
are	O
variable	O
for	O
genes	O
regulated	O
by	O
the	O
bHLH	B-protein
proteins	I-protein
.	O

Far	O
Western	O
blot	O
analysis	O
suggested	O
that	O
the	O
tandem	O
SH2	B-protein
domains	I-protein
of	O
SHP2	B-protein
bind	O
to	O
Gab1	B-protein
in	O
a	O
specific	O
orientation	O
,	O
in	O
which	O
the	O
N	B-protein
-	I-protein
SH2	I-protein
domain	I-protein
binds	O
to	O
phosphotyrosine	O
(	O
Tyr	O
(	O
P	O
)	O
)	O
-	O
627	O
and	O
the	O
C	B-protein
-	I-protein
SH2	I-protein
domain	I-protein
binds	O
to	O
Tyr	O
(	O
P	O
)	O
-	O
659	O
.	O

These	O
results	O
suggest	O
that	O
G	O
beta	O
gamma	O
-	O
stimulated	O
Shc	B-protein
phosphorylation	O
represents	O
an	O
early	O
step	O
in	O
the	O
pathway	O
leading	O
to	O
p21ras	B-protein
activation	O
,	O
similar	O
to	O
the	O
mechanism	O
utilized	O
by	O
growth	B-protein
factor	I-protein
tyrosine	I-protein
kinase	I-protein
receptors	I-protein
.	O

The	O
Oct	B-protein
-	I-protein
2	I-protein
glutamine	O
-	O
rich	O
and	O
proline	O
-	O
rich	O
activation	O
domains	O
can	O
synergize	O
with	O
each	O
other	O
or	O
duplicates	O
of	O
themselves	O
to	O
activate	O
transcription	O
.	O

This	O
sequence	O
also	O
confers	O
VDR	B-protein
and	O
vitamin	O
D	O
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
.	O

Processivity	O
of	O
DNA	O
synthesis	O
by	O
the	O
mutant	O
holoenzyme	O
containing	O
pcna	B-protein
-	I-protein
79	I-protein
was	O
unaffected	O
on	O
poly	O
(	O
dA	O
)	O
x	O
oligo	O
(	O
dT	O
)	O
but	O
was	O
dramatically	O
reduced	O
on	O
a	O
natural	O
template	O
with	O
secondary	O
structure	O
.	O

The	O
present	O
treatment	O
strategy	O
in	O
progressive	O
disorders	O
is	O
mainly	O
based	O
on	O
the	O
complementary	O
effect	O
of	O
intensive	O
radiochemotherapy	O
,	O
autologous	O
stem	O
-	O
cell	O
transplantation	O
and	O
the	O
rational	O
use	O
of	O
cytokines	O
,	O
mostly	O
colony	B-protein
-	I-protein
stimulating	I-protein
factors	I-protein
.	O

Competition	O
electrophoretic	O
mobility	O
shift	O
and	O
immunoshift	O
assays	O
confirmed	O
that	O
NF1	B-protein
factors	I-protein
present	O
in	O
nuclear	O
extracts	O
of	O
HeLa	O
and	O
CV	O
-	O
1	O
cells	O
bind	O
to	O
the	O
BKV	B-protein
-	I-protein
MLP	I-protein
.	O

CKbeta4GT	B-protein
-	I-protein
II	I-protein
is	O
predicted	O
to	O
encode	O
a	O
type	B-protein
II	I-protein
transmembrane	I-protein
glycoprotein	I-protein
of	O
43	O
kDa	O
with	O
five	O
potential	O
N	O
-	O
linked	O
glycosylation	O
sites	O
.	O

Plasmids	O
were	O
constructed	O
with	O
the	O
mouse	O
promoter	O
region	O
linked	O
to	O
the	O
reporter	B-protein
gene	I-protein
chloramphenicol	I-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
,	O
and	O
transiently	O
and	O
stably	O
transfected	O
in	O
the	O
INS	O
-	O
1	O
cells	O
.	O

A	O
set	O
of	O
peptides	O
corresponding	O
to	O
the	O
individual	O
elements	O
of	O
secondary	O
structure	O
derived	O
from	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
the	O
ribosomal	B-protein
protein	I-protein
L9	I-protein
have	O
been	O
synthesized	O
.	O

Both	O
can	O
be	O
elevated	O
on	O
a	O
single	O
vascular	O
pedicle	O
based	O
on	O
the	O
superficial	O
temporal	O
artery	O
,	O
the	O
double	O
-	O
layered	O
temporal	O
fascia	O
flap	O
.	O

The	O
two	O
-	O
wave	O
,	O
1995	O
-	O
1996	O
National	O
Longitudinal	O
Study	O
of	O
Adolescent	O
Health	O
uses	O
a	O
measure	O
of	O
depressive	O
symptomatology	O
across	O
a	O
12	O
-	O
month	O
interval	O
.	O

Postprandial	O
plasma	B-protein
enteroglucagon	I-protein
concentration	O
after	O
90	O
minutes	O
in	O
untreated	O
patients	O
correlated	O
positively	O
to	O
the	O
faecal	O
fat	O
excretion	O
(	O
r	O
=	O
0	O
.	O
58	O
,	O
p	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

In	O
addition	O
,	O
the	O
megabase	O
region	O
surrounding	O
the	O
dagA	B-protein
locus	I-protein
was	O
mapped	O
.	O

In	O
an	O
attempt	O
to	O
investigate	O
whether	O
the	O
intergenic	O
region	O
between	O
the	O
oleosin	B-protein
and	O
a	O
second	O
open	O
reading	O
frame	O
(	O
ORFII	O
)	O
in	O
Brassica	O
napus	O
(	O
L	O
.	O
)	O
is	O
a	O
divergent	O
promoter	O
,	O
and	O
also	O
to	O
characterize	O
the	O
ORFII	B-protein
,	O
cDNA	B-protein
clones	I-protein
homologous	I-protein
to	I-protein
ORFII	I-protein
were	O
isolated	O
from	O
a	O
leaf	O
cDNA	O
library	O
.	O

The	O
protein	O
is	O
composed	O
of	O
a	O
central	O
alpha	O
-	O
helical	O
portion	O
with	O
globular	O
domains	O
at	O
both	O
NH2	O
and	O
COOH	O
termini	O
,	O
and	O
the	O
epitope	O
to	O
the	O
monoclonal	O
antibody	O
resides	O
in	O
the	O
central	O
alpha	O
-	O
helical	O
stalk	O
.	O

Indirect	O
plasma	O
parameters	O
such	O
as	O
vitamin	O
E	O
,	O
thiol	O
and	O
uric	O
acid	O
levels	O
were	O
also	O
quantified	O
.	O

In	O
addition	O
,	O
we	O
did	O
not	O
detect	O
significant	O
differences	O
in	O
CDR3	B-protein
sequences	I-protein
of	O
endogenous	B-protein
Ig	I-protein
lambdaL	I-protein
and	O
kappaL	B-protein
chain	I-protein
gene	I-protein
loci	I-protein
cloned	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
an	O
NBS	O
patient	O
and	O
of	O
healthy	O
individuals	O
.	O

To	O
investigate	O
the	O
convergent	O
role	O
of	O
the	O
insulin	B-protein
/	I-protein
IGF	I-protein
-	I-protein
I	I-protein
effector	O
pathway	O
mediating	O
bihormonal	O
stimulation	O
of	O
LDL	B-protein
receptor	I-protein
promoter	I-protein
expression	O
,	O
transfected	O
granulosa	O
-	O
luteal	O
cells	O
were	O
pretreated	O
for	O
30	O
min	O
with	O
two	O
specific	O
inhibitors	O
of	O
phophatidylinositol	B-protein
3	I-protein
-	I-protein
kinase	I-protein
,	O
wortmannin	O
(	O
100	O
nM	O
)	O
and	O
LY	O
294002	O
(	O
10	O
microM	O
)	O
,	O
or	O
of	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
kinase	I-protein
,	O
PD	O
98059	O
(	O
50	O
microM	O
)	O
,	O
U0126	O
(	O
10	O
microM	O
)	O
,	O
or	O
the	O
latter	O
'	O
s	O
inactive	O
derivative	O
,	O
U0124	O
(	O
10	O
microM	O
)	O
.	O

Thus	O
,	O
the	O
consensus	O
sequences	O
for	O
phosphatase	B-protein
regulation	O
are	O
5	B-protein
'	I-protein
-	I-protein
GCACGTGGG	I-protein
-	I-protein
3	I-protein
'	I-protein
and	O
5	B-protein
'	I-protein
-	I-protein
GCACGTTTT	I-protein
-	I-protein
3	I-protein
'	I-protein
which	O
differ	O
from	O
the	O
binding	O
sequences	O
for	O
the	O
Cpflp	B-protein
protein	O
required	O
for	O
transcription	O
of	O
the	O
genes	O
in	O
methionine	O
biosynthesis	O
and	O
for	O
centromere	O
function	O
.	O

The	O
human	B-protein
T	I-protein
cell	I-protein
leukemia	I-protein
/	I-protein
lymphotropic	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax	I-protein
protein	I-protein
represses	O
MyoD	O
-	O
dependent	O
transcription	O
by	O
inhibiting	O
MyoD	O
-	O
binding	O
to	O
the	O
KIX	B-protein
domain	I-protein
of	O
p300	B-protein
.	O

With	O
current	O
methodology	O
beta	B-protein
-	I-protein
2	I-protein
transferrin	I-protein
does	O
not	O
appear	O
to	O
be	O
a	O
reliable	O
clinical	O
marker	O
for	O
perilymph	O
in	O
the	O
operative	O
setting	O
.	O

This	O
sequence	O
is	O
almost	O
identical	O
with	O
that	O
of	O
human	B-protein
luteinizing	I-protein
hormone	I-protein
(	O
Sairam	O
,	O
M	O
.	O

However	O
,	O
little	O
is	O
known	O
regarding	O
the	O
genomic	O
organization	O
and	O
developmental	O
expression	O
of	O
the	O
caveolin	B-protein
gene	I-protein
family	I-protein
.	O

The	O
number	O
of	O
polymerases	B-protein
active	O
in	O
vitro	O
at	O
the	O
E	B-protein
strand	I-protein
promoter	I-protein
was	O
similar	O
to	O
the	O
number	O
of	O
polymerases	B-protein
at	O
the	O
L	B-protein
strand	I-protein
promoter	I-protein
.	O

Our	O
data	O
suggest	O
that	O
it	O
may	O
be	O
possible	O
to	O
individualize	O
hCG	B-protein
administration	O
at	O
midcycle	O
by	O
determining	O
the	O
number	O
of	O
follicles	O
greater	O
than	O
1	O
cm	O
by	O
ultrasound	O
on	O
cycle	O
day	O
12	O
or	O
13	O
and	O
giving	O
hCG	B-protein
when	O
serum	O
E2	O
levels	O
reach	O
1100	O
to	O
1200	O
pmol	O
/	O
l	O
per	O
follicle	O
.	O

An	O
electrophoretic	O
mobility	O
shift	O
assay	O
was	O
performed	O
to	O
characterize	O
the	O
binding	O
property	O
of	O
TR2	B-protein
and	O
its	O
truncated	O
isoform	O
.	O

Adrenergic	O
nerve	O
function	O
,	O
noradrenaline	O
level	O
and	O
noradrenaline	O
uptake	O
in	O
cat	O
nictitating	O
membrane	O
after	O
reserpine	O
treatment	O
.	O

After	O
determining	O
isoflurane	O
MAC	O
in	O
triplicate	O
,	O
birds	O
were	O
given	O
a	O
mu	O
-	O
opioid	O
agonist	O
(	O
morphine	O
,	O
n	O
=	O
9	O
)	O
or	O
a	O
kappa	O
-	O
opioid	O
agonist	O
(	O
U50488H	O
,	O
n	O
=	O
9	O
)	O
.	O

Functional	O
disorders	O
of	O
the	O
ureter	O
following	O
gynecologic	O
surgery	O
.	O

Based	O
on	O
the	O
comparison	O
of	O
the	O
predicted	O
amino	O
acid	O
sequences	O
of	O
1	B-protein
-	I-protein
sst	I-protein
and	O
1	B-protein
-	I-protein
fft	I-protein
with	O
those	O
of	O
other	O
plant	O
fructosyl	B-protein
transferase	I-protein
genes	I-protein
,	O
we	O
postulate	O
that	O
both	O
plant	O
fructan	B-protein
genes	I-protein
have	O
evolved	O
from	O
plant	O
invertase	B-protein
genes	O
.	O

Further	O
investigations	O
are	O
necessary	O
to	O
elucidate	O
the	O
biochemical	O
and	O
physiological	O
properties	O
of	O
DLIS	O
.	O

Together	O
with	O
a	O
considerably	O
shortened	O
and	O
interrupted	O
aromatic	O
aa	O
stretch	O
in	O
this	O
region	O
,	O
these	O
differences	O
are	O
discussed	O
in	O
terms	O
of	O
the	O
peculiar	O
affinity	O
of	O
cyanobacterial	B-protein
cytochrome	I-protein
oxidases	I-protein
for	O
acidic	O
c	B-protein
-	I-protein
type	I-protein
cytochromes	I-protein
.	O

Comparison	O
of	O
sequences	O
from	O
-	O
215	O
to	O
+	O
1	O
bp	O
identified	O
consensus	O
binding	O
sites	O
for	O
the	O
homeodomain	B-protein
transcription	I-protein
factor	I-protein
thyroid	I-protein
transcription	I-protein
factor	I-protein
-	I-protein
1	I-protein
(	O
TTF	B-protein
-	I-protein
1	I-protein
)	O
.	O

An	O
approach	O
to	O
a	O
biomathematical	O
model	O
of	O
lymphocytopoiesis	O
.	O

A	O
five	O
-	O
phase	O
experiment	O
was	O
designed	O
to	O
investigate	O
(	O
a	O
)	O
whether	O
contingent	O
music	O
-	O
listening	O
would	O
act	O
as	O
a	O
reinforcer	O
to	O
increase	O
arithmetic	O
performance	O
of	O
EMR	O
children	O
and	O
(	O
b	O
)	O
whether	O
this	O
contingent	O
reinforcement	O
would	O
affect	O
preference	O
for	O
that	O
reinforcer	O
.	O

We	O
now	O
show	O
that	O
RNU2	B-protein
fragility	O
can	O
be	O
induced	O
by	O
transfection	O
with	O
an	O
expression	O
vector	O
encoding	O
Ad12	B-protein
E1B	I-protein
55	O
kDa	O
alone	O
but	O
not	O
by	O
an	O
E1	B-protein
vector	O
encoding	O
all	O
E1	B-protein
products	I-protein
(	O
3	O
E1A	B-protein
proteins	I-protein
,	O
as	O
well	O
as	O
the	O
E1B	B-protein
19	O
kDa	O
and	O
55	O
kDa	O
proteins	O
)	O
.	O

A	O
case	O
report	O
with	O
angiographic	O
follow	O
-	O
up	O
study	O
.	O

The	O
PAI	B-protein
-	I-protein
2	I-protein
gene	I-protein
is	O
one	O
of	O
the	O
most	O
TNF	B-protein
-	I-protein
responsive	I-protein
genes	I-protein
known	O
and	O
is	O
also	O
highly	O
induced	O
by	O
the	O
phorbol	O
ester	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
and	O
the	O
phosphatase	B-protein
inhibitor	O
,	O
okadaic	O
acid	O
,	O
in	O
both	O
HT	O
-	O
1080	O
fibrosarcoma	O
and	O
U	O
-	O
937	O
histiocytic	O
cells	O
.	O

Mutational	O
analyses	O
showed	O
that	O
in	O
-	O
frame	O
stop	O
codons	O
introduced	O
into	O
five	O
of	O
seven	O
RNA	B-protein
2	I-protein
ORFs	I-protein
did	O
not	O
affect	O
accumulation	O
of	O
progeny	O
LIYV	B-protein
RNA	I-protein
1	I-protein
or	O
RNA	B-protein
2	I-protein
,	O
confirming	O
that	O
RNA	B-protein
2	I-protein
does	O
not	O
encode	O
proteins	O
necessary	O
for	O
LIYV	B-protein
RNA	I-protein
replication	O
.	O

Responses	O
of	O
TLD	O
Mg2SiO4	O
:	O
Tb	O
and	O
radiophotoluminescent	O
glass	O
to	O
heavy	O
charged	O
particles	O
and	O
space	O
radiation	O
.	O

Because	O
of	O
the	O
increased	O
CPK	B-protein
activity	O
found	O
in	O
normal	O
newborns	O
,	O
screening	O
for	O
Duchenne	O
-	O
type	O
muscular	O
dystrophy	O
should	O
be	O
postponed	O
for	O
a	O
few	O
weeks	O
after	O
delivery	O
.	O

CYC2	B-protein
encodes	O
a	O
24	O
-	O
kDa	O
protein	O
that	O
has	O
sequence	O
identity	O
to	O
the	O
Neurospora	B-protein
crassa	I-protein
PREG1	I-protein
and	O
the	O
S	B-protein
.	I-protein
cerevisiae	I-protein
PHO80	I-protein
cyclin	I-protein
.	O

Similarly	O
,	O
overexpression	O
of	O
increasing	O
concentration	O
of	O
COUP	B-protein
-	I-protein
TFI	I-protein
,	O
but	O
not	O
COUP	B-protein
-	I-protein
TFI	I-protein
delta35	I-protein
,	O
can	O
squelch	O
the	O
silencing	O
activity	O
of	O
the	O
unliganded	O
TRbeta	B-protein
.	O

The	O
immuno	O
-	O
purified	O
mRNA	O
in	O
the	O
polysome	O
complex	O
was	O
used	O
to	O
prepare	O
cDNA	O
with	O
which	O
to	O
probe	O
a	O
D	O
.	O
melanogaster	O
genomic	O
library	O
.	O

Retrogradely	O
labelled	O
neurons	O
significantly	O
prevailed	O
in	O
the	O
ipsilateral	O
substantia	O
nigra	O
pars	O
compacta	O
.	O

Mechanism	O
of	O
the	O
t	O
(	O
14	O
;	O
18	O
)	O
chromosomal	O
translocation	O
:	O
structural	O
analysis	O
of	O
both	O
derivative	O
14	O
and	O
18	O
reciprocal	O
partners	O
.	O

In	O
the	O
free	O
-	O
swimming	O
rotatory	O
test	O
mice	O
spend	O
most	O
of	O
the	O
time	O
swimming	O
close	O
to	O
the	O
wall	O
of	O
the	O
container	O
attempting	O
to	O
escape	O
from	O
an	O
aversive	O
test	O
situation	O
.	O

Sequencing	O
of	O
the	O
three	O
pag	B-protein
-	I-protein
3	I-protein
alleles	I-protein
showed	O
that	O
two	O
apparent	O
null	O
alleles	O
encode	O
a	O
nonsense	O
mutation	O
before	O
the	O
zinc	O
fingers	O
and	O
a	O
missense	O
mutation	O
in	O
the	O
fourth	O
zinc	O
finger	O
that	O
changes	O
a	O
coordinating	O
histidine	O
to	O
a	O
tyrosine	O
.	O

Codon	O
usage	O
in	O
C	O
.	O
reinhardtii	O
mitochondria	O
is	O
highly	O
biased	O
,	O
with	O
eight	O
codons	O
entirely	O
absent	O
from	O
all	O
protein	O
-	O
coding	O
genes	O
;	O
however	O
,	O
even	O
though	O
codon	O
usage	O
is	O
restricted	O
,	O
it	O
appears	O
that	O
C	O
.	O
reinhardtii	O
mtDNA	O
can	O
not	O
encode	O
the	O
minimum	O
number	O
of	O
tRNAs	O
needed	O
to	O
support	O
mitochondrial	O
protein	O
synthesis	O
.	O

Dialyzable	O
transfer	B-protein
factor	I-protein
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
IL	B-protein
-	I-protein
1	I-protein
beta	I-protein
induces	O
VEGF	B-protein
gene	I-protein
expression	O
at	O
both	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
levels	O
,	O
and	O
IL	B-protein
-	I-protein
1	I-protein
beta	I-protein
evokes	O
p38	B-protein
MAPK	I-protein
and	O
JNK	B-protein
signalings	O
,	O
which	O
in	O
turn	O
stimulate	O
the	O
transcription	O
of	O
the	O
VEGF	B-protein
gene	I-protein
through	O
Sp1	B-protein
-	I-protein
binding	I-protein
sites	I-protein
.	O

We	O
report	O
here	O
the	O
discovery	O
of	O
a	O
new	O
actin	B-protein
-	I-protein
related	I-protein
gene	I-protein
in	O
this	O
organism	O
,	O
which	O
we	O
have	O
named	O
ACT4	B-protein
.	O

In	O
this	O
method	O
,	O
PLP	O
in	O
plasma	O
can	O
be	O
determined	O
with	O
high	O
sensitivity	O
using	O
derivatization	O
with	O
sodium	O
bisulfite	O
in	O
the	O
mobile	O
phase	O
.	O

Polypeptide	B-protein
growth	I-protein
factors	I-protein
and	O
cytokines	O
mediate	O
their	O
biochemical	O
functions	O
through	O
their	O
responsive	O
receptors	O
.	O

Auditory	O
clicks	O
were	O
given	O
at	O
a	O
rate	O
of	O
20	O
s	O
(	O
-	O
1	O
)	O
.	O

We	O
studied	O
the	O
functional	O
interaction	O
between	O
human	O
embryonic	O
zeta	B-protein
2	I-protein
globin	I-protein
promoter	O
and	O
the	O
alpha	B-protein
globin	I-protein
regulatory	I-protein
element	I-protein
(	O
HS	B-protein
-	I-protein
40	I-protein
)	O
located	O
40	O
kb	O
upstream	O
of	O
the	O
zeta	B-protein
2	I-protein
globin	I-protein
gene	I-protein
.	O

The	O
HiNF	B-protein
-	I-protein
D	I-protein
(	I-protein
CDP	I-protein
/	I-protein
cut	I-protein
)	I-protein
complex	I-protein
with	O
the	O
H4	B-protein
promoter	I-protein
is	O
immunoreactive	O
with	O
antibodies	O
against	O
CDP	B-protein
/	I-protein
cut	I-protein
and	O
pRB	B-protein
but	O
not	O
p107	B-protein
,	O
whereas	O
the	O
CDP	B-protein
/	I-protein
cut	I-protein
complex	I-protein
with	O
a	O
nonhistone	B-protein
promoter	I-protein
(	O
gp91	B-protein
-	I-protein
phox	I-protein
)	O
reacts	O
only	O
with	O
CDP	B-protein
and	O
p107	B-protein
antibodies	O
.	O

The	O
genome	O
of	O
all	O
retroviruses	O
consists	O
of	O
two	O
identical	O
RNAs	O
noncovalently	O
linked	O
near	O
their	O
5	O
'	O
end	O
.	O

Adding	O
phytase	B-protein
and	O
nP	O
improved	O
the	O
orderliness	O
of	O
development	O
,	O
mineralization	O
and	O
arrangement	O
of	O
cartilage	O
and	O
bone	O
cells	O
,	O
and	O
alleviated	O
the	O
effects	O
of	O
P	O
deficiency	O
on	O
the	O
histological	O
and	O
gross	O
structure	O
of	O
the	O
tibias	O
.	O

Somatostatin	B-protein
gene	I-protein
expression	O
in	O
pancreatic	O
islet	O
cells	O
is	O
directed	O
by	O
cell	O
-	O
specific	O
DNA	O
control	O
elements	O
and	O
DNA	O
-	O
binding	O
proteins	O
.	O

In	O
about	O
one	O
third	O
of	O
the	O
cases	O
this	O
operation	O
results	O
in	O
tonal	O
and	O
vocal	O
improvement	O
for	O
patients	O
suffering	O
from	O
progressive	O
perceptive	O
deafness	O
.	O

Apart	O
from	O
iron	O
regulation	O
,	O
sodA	B-protein
expression	O
was	O
affected	O
by	O
changes	O
in	O
DNA	O
topology	O
induced	O
by	O
coumermycin	O
A	O
but	O
not	O
by	O
the	O
global	O
virulence	O
regulatory	O
Bvg	B-protein
system	I-protein
.	O

Influence	O
of	O
neural	O
regulation	O
on	O
anti	O
-	O
arrhythmic	O
effects	O
of	O
GABA	O
in	O
rats	O
.	O

Nuclear	O
localization	O
and	O
protein	O
sequence	O
similarities	O
suggested	O
that	O
the	O
SPT2	B-protein
/	I-protein
SIN1	I-protein
protein	I-protein
may	O
be	O
related	O
to	O
the	O
nonhistone	B-protein
chromosomal	I-protein
protein	I-protein
HMG1	I-protein
.	O

In	O
contrast	O
with	O
previous	O
two	O
-	O
pool	O
models	O
,	O
provisions	O
were	O
made	O
for	O
folate	O
turnover	O
by	O
urinary	O
folate	O
excretion	O
(	O
as	O
measured	O
here	O
)	O
and	O
by	O
fecal	O
excretion	O
and	O
catabolic	O
processes	O
.	O

These	O
results	O
suggest	O
that	O
,	O
for	O
the	O
HML	B-protein
ARS	I-protein
cluster	I-protein
(	O
ARS303	B-protein
,	O
ARS320	B-protein
,	O
and	O
ARS302	B-protein
)	O
,	O
inactivity	O
of	O
origins	O
is	O
independent	O
of	O
local	O
transcriptional	O
silencing	O
,	O
even	O
though	O
origins	O
and	O
silencers	O
share	O
key	O
cis	O
-	O
and	O
trans	O
-	O
acting	O
components	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
C	B-protein
/	I-protein
EBP	I-protein
alpha	I-protein
can	O
also	O
active	O
the	O
GM	B-protein
-	I-protein
CSF	I-protein
receptor	I-protein
alpha	I-protein
promoter	O
in	O
nonmyeloid	O
cells	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Antibiotic	O
effect	O
of	O
the	O
mud	O
from	O
heviz	O
.	O

A	O
case	O
observed	O
in	O
Saigon	O
.	O

Sequences	O
required	O
for	O
interaction	O
of	O
mu2	B-protein
and	O
CTLA	B-protein
-	I-protein
4	I-protein
were	O
localized	O
to	O
residues	O
,	O
161TTGVY	B-protein
in	O
CTLA	B-protein
-	I-protein
4	I-protein
;	O
this	O
sequence	O
is	O
N	O
-	O
terminal	O
to	O
,	O
but	O
overlaps	O
with	O
,	O
a	O
previously	O
identified	O
SH2	B-protein
binding	I-protein
motif	I-protein
,	O
165YVKM	B-protein
,	O
involved	O
in	O
CTLA	B-protein
-	I-protein
4	I-protein
signaling	O
.	O

The	O
accuracies	O
of	O
presence	O
or	O
absence	O
of	O
neuroblastoma	O
were	O
compared	O
between	O
131I	O
-	O
MIBG	O
imaging	O
and	O
several	O
tumor	O
markers	O
.	O

We	O
determined	O
whether	O
regional	O
myocardial	O
work	O
efficiency	O
(	O
segment	O
work	O
/	O
regional	O
O2	O
consumption	O
)	O
would	O
be	O
elevated	O
by	O
surgically	O
-	O
augmented	O
inflow	O
.	O

Phylogenetic	O
analysis	O
showed	O
that	O
the	O
ToLCV	O
isolates	O
from	O
Bangalore	O
constitute	O
a	O
group	O
of	O
viruses	O
separated	O
from	O
those	O
of	O
Northern	O
India	O
.	O

Recombinant	B-protein
HRMT1L2	I-protein
protein	I-protein
encoded	O
by	O
the	O
most	O
common	O
5	O
'	O
-	O
variant	O
exhibited	O
methyltransferase	B-protein
activity	O
in	O
vitro	O
.	O

These	O
results	O
indicate	O
that	O
the	O
effect	O
of	O
the	O
isomers	O
of	O
pentobarbital	O
and	O
secobarbital	O
on	O
mult	O
FR30	O
FI600	O
responding	O
and	O
on	O
suppressed	O
responding	O
are	O
qualitatively	O
similar	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

SKP1	B-protein
-	I-protein
SnRK	I-protein
protein	I-protein
kinase	I-protein
interactions	O
mediate	O
proteasomal	O
binding	O
of	O
a	O
plant	O
SCF	B-protein
ubiquitin	I-protein
ligase	I-protein
.	O

IdB	O
1031	O
was	O
first	O
extracted	O
by	O
liquid	O
-	O
solid	O
partition	O
and	O
the	O
extracts	O
were	O
evaporated	O
and	O
analysed	O
on	O
a	O
reversed	O
-	O
phase	O
column	O
under	O
isocratic	O
conditions	O
,	O
using	O
either	O
an	O
electrochemical	O
or	O
a	O
UV	O
detector	O
.	O

This	O
study	O
represents	O
the	O
first	O
published	O
long	O
-	O
term	O
follow	O
-	O
up	O
regarding	O
this	O
mode	O
of	O
treatment	O
in	O
patients	O
with	O
alveolar	O
hypoventilation	O
.	O

Moreover	O
,	O
the	O
same	O
mutations	O
alter	O
the	O
structure	O
of	O
junB	B-protein
5	O
'	O
flanking	O
DNA	O
within	O
chromatin	O
.	O

Basal	O
FSH	B-protein
and	O
LH	B-protein
levels	O
were	O
significantly	O
lower	O
in	O
addicts	O
;	O
after	O
GnRH	B-protein
stimulation	O
the	O
addicts	O
'	O
FSH	B-protein
and	O
LH	B-protein
values	O
increased	O
but	O
not	O
significantly	O
compared	O
to	O
controls	O
.	O

Secretory	O
function	O
of	O
the	O
prostate	O
gland	O
.	O

Mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinase	I-protein
phosphatase	I-protein
-	I-protein
3	I-protein
(	O
MKP	B-protein
-	I-protein
3	I-protein
)	O
is	O
a	O
dual	O
specificity	O
phosphatase	B-protein
that	O
inactivates	O
extracellular	B-protein
signal	I-protein
-	I-protein
regulated	I-protein
kinase	I-protein
(	O
ERK	B-protein
)	O
MAP	B-protein
kinases	I-protein
.	O

It	O
is	O
clear	O
that	O
subclinical	O
and	O
silent	O
CD	O
exist	O
in	O
a	O
large	O
subgroup	O
of	O
the	O
celiac	O
population	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Palmaz	O
-	O
Schatz	O
stents	O
were	O
dip	O
-	O
coated	O
with	O
paclitaxel	O
(	O
0	O
,	O
0	O
.	O
2	O
,	O
15	O
,	O
or	O
187	O
microgram	O
/	O
stent	O
)	O
by	O
immersion	O
in	O
ethanolic	O
paclitaxel	O
and	O
evaporation	O
of	O
the	O
solvent	O
.	O

Furthermore	O
,	O
unlike	O
the	O
case	O
for	O
HIS3	B-protein
where	O
only	O
a	O
limited	O
subset	O
of	O
TATA	B-protein
-	I-protein
like	I-protein
sequences	I-protein
can	O
activate	O
transcription	O
in	O
conjunction	O
with	O
GCN4p	B-protein
,	O
many	O
divergent	O
TATA	B-protein
-	I-protein
like	I-protein
sequences	I-protein
allowed	O
GCN4p	B-protein
activation	O
of	O
TRP3	B-protein
.	O

The	O
peptide	O
sequences	O
reveal	O
that	O
the	O
factor	O
consists	O
of	O
GABP	B-protein
alpha	I-protein
and	O
GABP	B-protein
beta	I-protein
1	I-protein
with	O
Ets	B-protein
and	O
Notch	B-protein
motifs	I-protein
,	O
respectively	O
.	O

The	O
ubiquitous	O
transcription	O
factor	O
Oct	B-protein
-	I-protein
1	I-protein
forms	O
complexes	O
with	O
an	O
octamer	O
motif	O
present	O
within	O
FPIV	O
by	O
gel	O
shift	O
analysis	O
with	O
liver	O
and	O
kidney	O
extracts	O
,	O
making	O
Oct	B-protein
-	I-protein
1	I-protein
an	O
intriguing	O
candidate	O
for	O
partnership	O
in	O
androgen	O
regulation	O
.	O

These	O
two	O
mRNA	O
species	O
are	O
produced	O
by	O
differential	O
polyadenylation	O
site	O
usage	O
.	O

When	O
mixed	O
with	O
aqueous	O
solutions	O
of	O
TMT	O
-	O
55	O
,	O
aqueous	O
solutions	O
of	O
either	O
reagent	O
-	O
grade	O
zinc	O
,	O
cadmium	O
,	O
or	O
lead	O
salts	O
precipitate	O
crystalline	O
`	O
`	O
Zn	O
-	O
TMT	O
'	O
'	O
,	O
amorphous	O
or	O
crystalline	O
`	O
`	O
Cd	O
-	O
TMT	O
'	O
'	O
or	O
amorphous	O
`	O
`	O
Pb	O
-	O
TMT	O
'	O
'	O
(	O
M3	O
[	O
S3C3N3	O
]	O
2	O
.	O
nH2O	O
,	O
where	O
M	O
=	O
Cd2	O
+	O
,	O
Pb2	O
+	O
,	O
and	O
Zn2	O
+	O
and	O
n	O
>	O
or	O
=	O
0	O
)	O
that	O
may	O
eventually	O
crystallize	O
if	O
stored	O
in	O
air	O
.	O

We	O
report	O
the	O
isolation	O
of	O
genomic	O
and	O
cDNA	O
clones	O
of	O
the	O
light	O
-	O
independent	O
Sn	B-protein
:	I-protein
bol3	I-protein
allele	I-protein
.	O

Pharmacokinetics	O
of	O
FK	O
506	O
in	O
transplant	O
patients	O
.	O

Therefore	O
,	O
the	O
strD	B-protein
and	O
strE	B-protein
genes	I-protein
could	O
serve	O
as	O
universal	O
probes	O
indicative	O
of	O
the	O
presence	O
of	O
biosynthetic	O
capacity	O
for	O
6	O
-	O
deoxyhexose	O
moieties	O
.	O

The	O
1	O
,	O
2	O
,	O
3	O
and	O
4	O
year	O
survival	O
rates	O
were	O
94	O
%	O
,	O
84	O
%	O
,	O
76	O
%	O
and	O
63	O
%	O
,	O
respectively	O
.	O

For	O
the	O
study	O
of	O
the	O
transition	O
of	O
long	O
to	O
short	O
waves	O
(	O
deep	O
-	O
water	O
waves	O
)	O
a	O
closed	O
-	O
form	O
solution	O
is	O
advantageous	O
;	O
this	O
can	O
,	O
however	O
,	O
only	O
be	O
obtained	O
at	O
the	O
cost	O
of	O
further	O
simplification	O
.	O

TcPO2	O
measurement	O
appears	O
to	O
be	O
a	O
reliable	O
technique	O
that	O
can	O
influence	O
ischaemic	O
ulcer	O
management	O
.	O

Molecular	O
modelling	O
suggested	O
that	O
the	O
tetramerization	O
domain	O
was	O
a	O
four	O
-	O
helix	O
bundle	O
,	O
stabilized	O
by	O
interactions	O
of	O
seven	O
conserved	O
aromatic	O
amino	O
acids	O
.	O

It	O
is	O
concluded	O
that	O
suppression	O
of	O
elevated	O
prolactin	B-protein
levels	O
in	O
progressive	O
metastatic	O
breast	O
cancer	O
patients	O
is	O
not	O
effective	O
in	O
restoring	O
tumor	O
sensitivity	O
to	O
chemotherapy	O
.	O

Apart	O
from	O
two	O
proline	O
-	O
rich	O
regions	O
(	O
amino	O
acids	O
1	O
-	O
117	O
and	O
239	O
-	O
270	O
)	O
,	O
p230	B-protein
contains	O
a	O
very	O
high	O
frequency	O
of	O
heptad	O
repeats	O
,	O
characteristic	O
of	O
alpha	O
-	O
helices	O
that	O
form	O
dimeric	O
coiled	O
-	O
coil	O
structures	O
.	O
p230	B-protein
also	O
includes	O
the	O
sequence	B-protein
ESLALEELEL	I-protein
(	I-protein
amino	I-protein
acids	I-protein
538	I-protein
-	I-protein
546	I-protein
)	I-protein
,	O
a	O
motif	O
found	O
in	O
the	O
granin	B-protein
family	I-protein
of	O
acidic	O
proteins	O
present	O
in	O
secretory	O
granules	O
of	O
neuroendocrine	O
cells	O
.	O

Constantly	O
rectilinear	O
pressure	O
curves	O
without	O
uterine	O
activities	O
are	O
interpreted	O
as	O
characteristic	O
tocographic	O
criteria	O
of	O
an	O
advanced	O
ectopic	O
gravidity	O
.	O

Use	O
of	O
a	O
dual	O
-	O
pulse	O
lithotripter	O
to	O
generate	O
a	O
localized	O
and	O
intensified	O
cavitation	O
field	O
.	O

Critical	O
study	O
.	O

No	O
post	O
-	O
operative	O
haemorrhages	O
from	O
the	O
prostheses	O
were	O
observed	O
.	O

CONCLUSIONS	O
:	O
Adding	O
MMF	O
,	O
a	O
potent	O
topical	O
corticosteroid	O
,	O
to	O
an	O
emollient	O
cream	O
is	O
statistically	O
significantly	O
more	O
effective	O
than	O
emollient	O
cream	O
alone	O
in	O
reducing	O
acute	O
radiation	O
dermatitis	O
.	O

Yeast	B-protein
Gal11	I-protein
protein	I-protein
mediates	O
the	O
transcriptional	O
activation	O
signal	O
of	O
two	O
different	O
transacting	O
factors	O
,	O
Gal4	B-protein
and	O
general	B-protein
regulatory	I-protein
factor	I-protein
I	I-protein
/	I-protein
repressor	I-protein
/	I-protein
activator	I-protein
site	I-protein
binding	I-protein
protein	I-protein
1	I-protein
/	I-protein
translation	I-protein
upstream	I-protein
factor	I-protein
.	O

It	O
was	O
concluded	O
that	O
Scotchbond	O
2	O
and	O
Prisma	O
Universal	O
Bond	O
2	O
are	O
effective	O
and	O
are	O
the	O
dentine	O
bonding	O
agents	O
of	O
choice	O
.	O

The	O
activity	O
of	O
serum	B-protein
lipase	I-protein
and	O
amylase	B-protein
distinctly	O
increased	O
at	O
3	O
h	O
and	O
went	O
up	O
to	O
the	O
maximum	O
at	O
12	O
h	O
after	O
injection	O
of	O
Na	O
-	O
Tc	O
.	O

Characterization	O
of	O
polymorphic	O
TNRs	B-protein
in	O
novel	O
and	O
even	O
known	O
genes	O
expressed	O
in	O
human	O
spinal	O
cord	O
is	O
likely	O
to	O
help	O
in	O
the	O
identification	O
of	O
new	O
candidates	O
for	O
genes	O
involved	O
in	O
neurodegenerative	O
disorders	O
.	O

The	O
RAD18	B-protein
gene	I-protein
open	I-protein
reading	I-protein
frame	I-protein
encodes	O
a	O
protein	O
of	O
487	O
amino	O
acids	O
,	O
with	O
a	O
calculated	O
molecular	O
weight	O
of	O
55	O
,	O
512	O
.	O

In	O
the	O
10	O
patients	O
with	O
a	O
more	O
severe	O
degree	O
of	O
steatorrhea	O
the	O
decrease	O
in	O
fat	O
loss	O
approached	O
20	O
%	O
and	O
a	O
close	O
relationship	O
was	O
found	O
(	O
r	O
=	O
0	O
.	O
84	O
,	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
between	O
the	O
extent	O
of	O
the	O
fatty	O
acid	O
loss	O
on	O
placebo	O
and	O
the	O
decrease	O
of	O
this	O
loss	O
on	O
taurine	O
.	O

Laryngographic	O
changes	O
following	O
endotracheal	O
intubation	O
in	O
adults	O
.	O

The	O
partial	O
sequence	O
of	O
the	O
62	B-protein
-	I-protein
kDa	I-protein
nuclear	I-protein
pore	I-protein
glycoprotein	I-protein
shows	O
little	O
similarity	O
to	O
other	O
characterized	O
proteins	O
and	O
elucidates	O
structural	O
features	O
of	O
a	O
member	O
of	O
the	O
family	O
of	O
nuclear	B-protein
pore	I-protein
glycoproteins	I-protein
.	O

In	O
order	O
to	O
investigate	O
how	O
these	O
expression	O
patterns	O
are	O
established	O
,	O
we	O
fused	O
promoter	O
regions	O
of	O
an	O
acidic	O
and	O
a	O
basic	O
glucanase	B-protein
gene	I-protein
to	O
the	O
beta	B-protein
-	I-protein
glucuronidase	I-protein
(	O
GUS	B-protein
)	O
reporter	O
gene	O
and	O
examined	O
expression	O
of	O
these	O
constructs	O
in	O
transgenic	O
tobacco	O
plants	O
.	O

Sixty	O
-	O
five	O
patients	O
(	O
aged	O
between	O
3	O
years	O
5	O
months	O
and	O
60	O
years	O
)	O
suffering	O
from	O
medically	O
resistant	O
temporal	O
lobe	O
epilepsy	O
(	O
TLE	O
)	O
were	O
operated	O
on	O
over	O
a	O
period	O
of	O
33	O
months	O
in	O
Bethel	O
Epilepsy	O
Center	O
.	O

The	O
results	O
showed	O
that	O
IFN	B-protein
-	I-protein
gamma	I-protein
stimulated	O
the	O
rapid	O
accumulation	O
of	O
interferon	B-protein
regulated	I-protein
factor	I-protein
(	I-protein
IRF	I-protein
)	I-protein
-	I-protein
1	I-protein
mRNA	I-protein
,	O
followed	O
by	O
a	O
delayed	O
and	O
dose	O
-	O
dependent	O
inhibition	O
of	O
alpha1	B-protein
(	I-protein
I	I-protein
)	I-protein
procollagen	I-protein
mRNA	I-protein
expression	O
in	O
skin	O
fibroblasts	O
from	O
several	O
different	O
donors	O
.	O

A	O
split	O
motor	O
domain	O
in	O
a	O
cytoplasmic	B-protein
dynein	I-protein
.	O

CONCLUSIONS	O
:	O
The	O
largest	O
value	O
of	O
the	O
joint	O
space	O
may	O
be	O
used	O
when	O
evaluating	O
rheumatoid	O
AC	O
joint	O
space	O
.	O

We	O
then	O
demonstrated	O
that	O
1	O
)	O
GAL4	B-protein
-	I-protein
REV	I-protein
-	I-protein
erbA	I-protein
alpha	I-protein
chimeras	I-protein
that	O
contain	O
the	O
'	B-protein
AB	I-protein
'	I-protein
region	I-protein
and	O
lack	O
the	O
'	B-protein
E	I-protein
'	I-protein
region	I-protein
activated	O
transcription	O
of	O
GAL4	B-protein
response	I-protein
elements	I-protein
in	O
the	O
presence	O
of	O
8	O
-	O
Br	O
-	O
cAMP	O
and	O
2	O
)	O
the	O
ligand	O
-	O
binding	O
domain	O
(	O
LBD	O
)	O
contains	O
an	O
active	O
transcriptional	O
silencer	O
.	O

When	O
transfected	O
into	O
Drosophila	O
SL	O
-	O
2	O
cells	O
,	O
pCAT	O
plasmid	O
containing	O
2	O
,	O
090	O
bp	O
of	O
5	O
'	O
-	O
flanking	O
region	O
shows	O
a	O
3	O
.	O
0	O
-	O
to	O
3	O
.	O
5	O
-	O
fold	O
increase	O
in	O
chloramphenicol	B-protein
acetyltransferase	I-protein
activity	O
after	O
induction	O
with	O
retinoic	O
acid	O
and	O
/	O
or	O
8	O
-	O
bromo	O
-	O
cAMP	O
.	O

In	O
the	O
course	O
of	O
screening	O
for	O
transcription	O
factors	O
which	O
interact	O
with	O
the	O
human	B-protein
myeloperoxidase	I-protein
(	O
MPO	B-protein
)	O
promoter	O
we	O
,	O
for	O
the	O
first	O
time	O
,	O
identified	O
and	O
cloned	O
the	O
cDNA	O
and	O
genomic	O
DNA	O
for	O
human	B-protein
HBP1	I-protein
(	O
HMG	B-protein
-	I-protein
Box	I-protein
containing	I-protein
protein	I-protein
1	I-protein
)	O
,	O
a	O
member	O
of	O
the	O
high	B-protein
mobility	I-protein
group	I-protein
of	I-protein
non	I-protein
-	I-protein
histone	I-protein
chromosomal	I-protein
proteins	I-protein
.	O

The	O
first	O
contains	O
ATF	B-protein
/	I-protein
CRE	I-protein
and	O
TBP	B-protein
/	I-protein
TATA	I-protein
sequence	I-protein
motifs	I-protein
within	O
an	O
87	O
-	O
bp	O
region	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
accuracy	O
of	O
working	O
casts	O
for	O
crown	O
and	O
bridge	O
restorations	O
made	O
from	O
twin	O
mix	O
putty	O
/	O
wash	O
silicone	O
elastomeric	O
impression	O
materials	O
using	O
different	O
types	O
of	O
stock	O
tray	O
.	O

The	O
final	O
predicted	O
structure	O
has	O
an	O
overall	O
backbone	O
deviation	O
of	O
0	O
.	O
7	O
A	O
from	O
that	O
of	O
ras	B-protein
-	I-protein
p21	I-protein
.	O

As	O
a	O
consequence	O
of	O
dark	O
rearing	O
,	O
the	O
numerical	O
density	O
of	O
cortical	O
neurons	O
in	O
area	O
17	O
amounted	O
to	O
about	O
double	O
of	O
the	O
value	O
observed	O
in	O
normally	O
reared	O
kittens	O
and	O
was	O
also	O
significantly	O
higher	O
in	O
area	O
18	O
.	O

Ten	O
out	O
of	O
10	O
patients	O
with	O
progressive	O
disease	O
had	O
mast	O
cells	O
greater	O
than	O
or	O
equal	O
to	O
0	O
.	O
5	O
%	O
,	O
hyaluronan	O
greater	O
than	O
or	O
equal	O
to	O
50	O
micrograms	O
.	O
l	O
-	O
1	O
and	O
fibronectin	B-protein
greater	O
than	O
or	O
equal	O
to	O
350	O
micrograms	O
.	O
l	O
-	O
1	O
compared	O
to	O
eight	O
out	O
of	O
41	O
patients	O
with	O
stable	O
or	O
regressive	O
disease	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Since	O
1990	O
the	O
University	O
Hospital	O
of	O
Tromso	O
has	O
provided	O
local	O
hospitals	O
in	O
northern	O
Norway	O
with	O
a	O
remote	O
frozen	O
section	O
service	O
and	O
with	O
access	O
to	O
video	O
conferences	O
for	O
the	O
review	O
of	O
microscopic	O
findings	O
and	O
for	O
the	O
discussion	O
of	O
major	O
diagnostic	O
issues	O
.	O

NSCL	B-protein
-	I-protein
1	I-protein
is	O
expressed	O
in	O
a	O
larger	O
number	O
of	O
these	O
cell	O
lines	O
.	O

Both	O
of	O
these	O
dogs	O
had	O
low	O
serum	O
IgG	B-protein
(	O
3	O
.	O
5	O
to	O
7	O
.	O
2	O
mg	O
/	O
ml	O
)	O
and	O
the	O
second	O
littermate	O
also	O
had	O
reduced	O
serum	O
IgA	B-protein
(	O
<	O
0	O
.	O
1	O
to	O
0	O
.	O
15	O
mg	O
/	O
ml	O
)	O
.	O

A	O
.	O

Direct	O
proof	O
that	O
the	O
heightened	O
renal	O
cellular	O
apoptosis	O
in	O
PKD	O
is	O
not	O
occurring	O
through	O
p53	B-protein
was	O
obtained	O
by	O
successive	O
matings	O
between	O
SBM	O
and	O
p53	B-protein
(	I-protein
-	I-protein
/	I-protein
-	I-protein
)	I-protein
mice	O
.	O

Evoked	O
electromyographic	O
response	O
to	O
indirect	O
supramaximal	O
stimulation	O
at	O
1	O
Hz	O
was	O
monitored	O
in	O
ten	O
adult	O
goats	O
under	O
thiopentone	O
-	O
halothane	O
anaesthesia	O
.	O

It	O
has	O
been	O
demonstrated	O
previously	O
that	O
Pax	B-protein
-	I-protein
6	I-protein
,	O
a	O
paired	B-protein
domain	I-protein
(	I-protein
PD	I-protein
)	I-protein
/	I-protein
homeodomain	I-protein
(	I-protein
HD	I-protein
)	I-protein
transcription	I-protein
factor	I-protein
critical	O
for	O
eye	O
development	O
,	O
contributes	O
to	O
the	O
activation	O
of	O
the	O
alphaB	B-protein
-	I-protein
,	O
alphaA	B-protein
-	I-protein
,	O
delta1	B-protein
-	I-protein
,	O
and	O
zeta	B-protein
-	I-protein
crystallin	I-protein
genes	I-protein
in	O
the	O
lens	O
.	O

The	O
transverse	O
relaxation	O
time	O
(	O
T2	O
)	O
and	O
apparent	O
diffusion	O
coefficient	O
of	O
water	O
were	O
determined	O
.	O

Female	O
mice	O
were	O
significantly	O
more	O
resistant	O
to	O
infection	O
than	O
males	O
.	O

Three	O
ORFs	O
(	O
9765orfR002	B-protein
,	O
9765orfR011	B-protein
and	O
9765orfR013	B-protein
)	O
were	O
found	O
to	O
be	O
homologous	O
with	O
Schizosaccharomyces	O
pombe	O
polyadenylate	B-protein
binding	I-protein
protein	I-protein
,	O
Escherichia	O
coli	O
hypothetical	O
38	O
.	O
1	O
-	O
kDa	O
protein	O
in	O
the	O
BCR	B-protein
5	O
'	O
region	O
,	O
and	O
transcription	O
regulatory	O
protein	O
Swi3	B-protein
,	O
respectively	O
.	O

EBNA	B-protein
-	I-protein
2	I-protein
and	O
the	O
cis	O
-	O
acting	O
CD23	B-protein
element	I-protein
increased	O
TK	O
-	O
promoted	O
mRNA	O
and	O
did	O
not	O
alter	O
the	O
herpes	B-protein
simplex	I-protein
virus	I-protein
TK	I-protein
promoter	I-protein
transcription	I-protein
start	I-protein
site	I-protein
.	O

The	O
case	O
described	O
is	O
that	O
of	O
a	O
72	O
-	O
year	O
-	O
old	O
man	O
with	O
ochronosis	O
who	O
suffered	O
a	O
hyperextension	O
injury	O
to	O
his	O
spine	O
in	O
a	O
fall	O
,	O
resulting	O
in	O
a	O
fracture	O
through	O
an	O
ankylosed	O
L2	O
-	O
L3	O
disk	O
space	O
.	O

Although	O
stone	O
-	O
formers	O
were	O
not	O
found	O
to	O
display	O
any	O
features	O
of	O
magnesium	O
metabolism	O
that	O
were	O
different	O
from	O
those	O
in	O
the	O
control	O
group	O
,	O
their	O
lower	O
urinary	O
excretion	O
of	O
magnesium	O
in	O
relation	O
to	O
calcium	O
may	O
be	O
a	O
factor	O
in	O
their	O
increased	O
stone	O
-	O
forming	O
propensity	O
.	O

Phosphoamino	O
acid	O
analysis	O
of	O
radiolabeled	O
ASGPR	B-protein
subunits	I-protein
identified	O
Ser	O
(	O
P	O
)	O
as	O
the	O
predominant	O
(	O
approximately	O
95	O
%	O
)	O
and	O
Thr	O
(	O
P	O
)	O
as	O
a	O
minor	O
(	O
approximately	O
5	O
%	O
)	O
phosphoamino	O
acid	O
in	O
each	O
polypeptide	O
and	O
confirmed	O
the	O
presence	O
of	O
Tyr	O
(	O
P	O
)	O
(	O
approximately	O
1	O
%	O
)	O
in	O
RHL1	B-protein
.	O

Cheung	O
and	O
S	O
.	O

Dentalplaque	O
was	O
controlled	O
by	O
the	O
oral	O
higienic	O
index	O
of	O
the	O
whole	O
dentition	O
daily	O
,	O
after	O
staining	O
with	O
1	O
per	O
cent	O
alkaline	O
fuxin	O
.	O

The	O
antinociceptive	O
properties	O
,	O
as	O
measured	O
by	O
the	O
tail	O
-	O
flick	O
and	O
hot	O
-	O
plate	O
tests	O
,	O
and	O
the	O
motor	O
effects	O
of	O
an	O
intrathecally	O
-	O
administered	O
benzodiazepine	O
agonist	O
midazolam	O
,	O
alone	O
,	O
and	O
in	O
combination	O
with	O
morphine	O
,	O
was	O
examined	O
in	O
rats	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
the	O
successful	O
resection	O
of	O
a	O
MFH	O
originating	O
in	O
the	O
renal	O
capsular	O
tissue	O
and	O
extending	O
into	O
the	O
inferior	O
vena	O
cava	O
.	O

In	O
connective	O
tissue	O
,	O
cell	O
structure	O
contributes	O
to	O
type	B-protein
I	I-protein
collagen	I-protein
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
cloned	O
the	O
human	B-protein
DSG3	I-protein
gene	I-protein
and	O
examined	O
the	O
transcriptional	O
regulation	O
of	O
its	O
expression	O
.	O

In	O
simpler	O
organisms	O
,	O
the	O
ATP	B-protein
sulfurylase	I-protein
and	O
APS	B-protein
kinase	I-protein
reactions	O
are	O
catalyzed	O
by	O
separate	O
enzymes	O
encoded	O
by	O
two	O
or	O
three	O
genes	O
,	O
suggesting	O
that	O
a	O
fusion	O
of	O
separate	O
genes	O
during	O
the	O
course	O
of	O
evolution	O
generated	O
the	O
bifunctional	O
enzyme	O
.	O

The	O
protein	O
predicted	O
by	O
the	O
sequence	O
of	O
the	O
human	B-protein
pim	I-protein
-	I-protein
1	I-protein
proto	I-protein
-	I-protein
oncogene	I-protein
shares	O
extensive	O
homology	O
with	O
known	O
serine	B-protein
/	I-protein
threonine	I-protein
protein	I-protein
kinases	I-protein
,	O
and	O
yet	O
the	O
human	B-protein
Pim	I-protein
-	I-protein
1	I-protein
enzyme	I-protein
has	O
previously	O
been	O
reported	O
to	O
exhibit	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activity	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Compared	O
to	O
its	O
counterpart	O
in	O
the	O
GPB	B-protein
gene	I-protein
,	O
exon	O
3	O
of	O
the	O
GPE	B-protein
gene	I-protein
contains	O
several	O
point	O
mutations	O
,	O
an	O
insertion	O
of	O
24	O
bp	O
,	O
and	O
a	O
stop	O
codon	O
which	O
shortens	O
the	O
reading	O
frame	O
.	O

These	O
findings	O
demonstrate	O
that	O
signature	O
-	O
tagged	O
mutagenesis	O
is	O
a	O
viable	O
approach	O
to	O
identify	O
bacterial	O
genes	O
associated	O
with	O
the	O
ability	O
to	O
infect	O
the	O
urinary	O
tract	O
.	O

CONCLUSION	O
:	O
Monitoring	O
SpO2	O
at	O
the	O
nasal	O
septum	O
site	O
is	O
more	O
reliable	O
than	O
monitoring	O
it	O
at	O
the	O
finger	O
site	O
in	O
hypothermic	O
patients	O
.	O

Hemorrhagic	O
shock	O
and	O
bacterial	O
translocation	O
in	O
a	O
swine	O
model	O
.	O

Induction	O
of	O
the	O
CINC	B-protein
promoter	I-protein
by	O
IL	B-protein
-	I-protein
17	I-protein
in	O
IEC	O
-	O
6	O
cells	O
was	O
TNF	B-protein
receptor	I-protein
-	I-protein
associated	I-protein
factor	I-protein
-	I-protein
6	I-protein
(	O
TRAF6	B-protein
)	O
,	O
but	O
not	O
TRAF2	B-protein
,	O
dependent	O
.	O

However	O
,	O
while	O
IL	B-protein
-	I-protein
1beta	I-protein
and	O
TNF	B-protein
-	I-protein
alpha	I-protein
both	O
induced	O
nuclear	O
binding	O
of	O
the	O
Rel	B-protein
proteins	I-protein
p50	I-protein
and	O
p65	B-protein
to	O
an	O
NF	B-protein
-	I-protein
kappaB	I-protein
consensus	I-protein
oligonucleotide	I-protein
in	O
gel	O
shift	O
assays	O
and	O
caused	O
transient	O
degradation	O
of	O
inhibitor	B-protein
of	I-protein
NF	I-protein
-	I-protein
kappaB	I-protein
-	I-protein
alpha	I-protein
(	O
IkappaB	B-protein
-	I-protein
alpha	I-protein
)	O
in	O
the	O
cytoplasm	O
of	O
myofibroblasts	O
,	O
only	O
IL	B-protein
-	I-protein
1beta	I-protein
upregulated	O
PDGF	B-protein
-	I-protein
Ralpha	I-protein
.	O

Oculus	O
-	O
500	O
is	O
a	O
group	O
of	O
high	O
resolution	O
imaging	O
boards	O
for	O
use	O
with	O
IBM	O
-	O
AT	O
and	O
compatible	O
computers	O
.	O

The	O
mRNA	O
from	O
this	O
gene	O
,	O
termed	O
HES1	B-protein
,	O
is	O
ubiquitously	O
expressed	O
,	O
but	O
strongly	O
so	O
in	O
heart	O
and	O
skeletal	O
muscle	O
.	O

When	O
ligated	O
to	O
the	O
proIL	B-protein
-	I-protein
1	I-protein
beta	I-protein
cap	I-protein
site	I-protein
-	I-protein
proximal	I-protein
region	I-protein
(	O
located	O
between	O
-	O
131	O
to	O
+	O
12	O
)	O
,	O
both	O
the	O
proIL	B-protein
-	I-protein
1	I-protein
beta	I-protein
and	O
the	O
simian	B-protein
virus	I-protein
40	I-protein
enhancer	I-protein
elements	I-protein
functioned	O
more	O
efficiently	O
in	O
monocytes	O
than	O
in	O
HeLa	O
cells	O
,	O
which	O
are	O
not	O
normally	O
competent	O
for	O
IL	B-protein
-	I-protein
1	I-protein
beta	I-protein
expression	O
.	O

We	O
report	O
two	O
patients	O
receiving	O
maintenance	O
valproate	O
,	O
one	O
with	O
resolving	O
acute	O
hepatitis	O
C	O
and	O
the	O
other	O
with	O
chronic	O
persistent	O
hepatitis	O
C	O
,	O
with	O
incidental	O
microvesicular	O
steatosis	O
demonstrated	O
on	O
oil	O
-	O
red	O
O	O
stains	O
.	O

One	O
of	O
these	O
,	O
the	O
origin	O
core	O
,	O
is	O
required	O
only	O
for	O
DNA	O
replication	O
.	O

Levels	O
of	O
serum	O
IgE	B-protein
were	O
measured	O
monthly	O
,	O
and	O
nasal	O
IgE	B-protein
was	O
measured	O
at	O
the	O
height	O
and	O
end	O
of	O
the	O
season	O
.	O

PDGF	B-protein
A	I-protein
-	I-protein
chain	I-protein
levels	O
increase	O
in	O
cultured	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
SMCs	O
)	O
exposed	O
to	O
ATII	B-protein
.	O

Likewise	O
,	O
at	O
150	O
degrees	O
C	O
with	O
2	O
%	O
APS	O
the	O
surface	O
density	O
of	O
NH2	O
groups	O
reached	O
a	O
maximum	O
at	O
24	O
hr	O
and	O
remained	O
relatively	O
constant	O
up	O
to	O
96	O
hr	O
.	O

HeLa	O
and	O
Jurkat	O
cell	O
lines	O
carrying	O
the	O
nef	B-protein
gene	I-protein
linked	O
to	O
the	O
CMV	O
promoter	O
or	O
the	O
HIV	O
-	O
1	O
LTR	O
were	O
isolated	O
by	O
coselection	O
for	O
neomycin	O
resistance	O
.	O

We	O
have	O
isolated	O
and	O
characterized	O
the	O
GCD6	B-protein
and	O
GCD7	B-protein
genes	I-protein
and	O
shown	O
that	O
their	O
products	O
are	O
required	O
to	O
repress	O
GCN4	B-protein
translation	O
under	O
nonstarvation	O
conditions	O
.	O

We	O
have	O
visualized	O
DNA	O
-	O
protein	O
complexes	O
by	O
electron	O
microscopy	O
and	O
a	O
high	O
-	O
affinity	O
binding	O
site	O
of	O
WDV	B-protein
Rep	I-protein
protein	I-protein
within	O
the	O
core	O
element	O
has	O
been	O
mapped	O
to	O
approximately	O
144	O
+	O
/	O
-	O
18	O
bp	O
upstream	O
from	O
the	O
initiation	O
site	O
,	O
between	O
the	O
start	O
site	O
for	O
complementary	O
-	O
sense	O
transcription	O
and	O
the	O
TATA	O
box	O
.	O

For	O
these	O
patients	O
the	O
introduction	O
of	O
a	O
separate	O
category	O
`	O
`	O
extended	O
oligoarthritis	O
at	O
onset	O
'	O
'	O
should	O
be	O
considered	O
to	O
establish	O
comparable	O
patient	O
groups	O
.	O

The	O
number	O
of	O
bacteria	O
in	O
the	O
lung	O
,	O
peripheral	O
white	O
blood	O
cell	O
and	O
BAL	O
fluid	O
cell	O
also	O
decreased	O
by	O
the	O
administration	O
of	O
FN	B-protein
.	O

A	O
major	O
mechanism	O
by	O
which	O
estrogens	O
prevent	O
osteoporosis	O
seems	O
to	O
be	O
repression	O
of	O
transcription	O
of	O
NF	B-protein
-	I-protein
kappa	I-protein
B	I-protein
target	I-protein
genes	I-protein
,	O
such	O
as	O
the	O
osteoclast	O
-	O
activating	O
cytokines	O
interleukin	B-protein
-	I-protein
6	I-protein
and	O
interleukin	B-protein
-	I-protein
1	I-protein
.	O

Suppressors	O
of	O
defective	O
silencing	O
in	O
yeast	O
:	O
effects	O
on	O
transcriptional	O
repression	O
at	O
the	O
HMR	B-protein
locus	I-protein
,	O
cell	O
growth	O
and	O
telomere	O
structure	O
.	O

Patients	O
received	O
either	O
diltiazem	O
CD	O
180	O
mg	O
or	O
placebo	O
once	O
/	O
day	O
in	O
combination	O
with	O
existing	O
antianginal	O
therapy	O
.	O

A	O
haemolytic	O
enterotoxigenic	O
strain	O
of	O
E	O
.	O
coli	O
(	O
O149	O
:	O
K88	O
:	O
H10	O
)	O
was	O
regularly	O
recovered	O
from	O
piglets	O
with	O
PWD	O
while	O
rotavirus	O
was	O
demonstrated	O
on	O
a	O
number	O
of	O
occasions	O
.	O

These	O
findings	O
indicate	O
that	O
hypergastrinemia	O
induced	O
by	O
surgical	O
removal	O
of	O
acid	O
-	O
producing	O
mucosa	O
in	O
the	O
rat	O
has	O
the	O
same	O
effects	O
on	O
oxyntical	O
mucosal	B-protein
HDC	I-protein
activity	O
,	O
histamine	O
concentration	O
and	O
ECL	O
cell	O
density	O
as	O
hypergastrinemia	O
induced	O
by	O
continuous	O
gastrin	B-protein
infusion	O
or	O
by	O
long	O
-	O
term	O
treatment	O
with	O
effective	O
antisecretagogues	O
.	O

We	O
have	O
isolated	O
and	O
analyzed	O
human	B-protein
CTCF	I-protein
cDNA	I-protein
clones	O
and	O
show	O
here	O
that	O
the	O
ubiquitously	O
expressed	O
11	B-protein
-	I-protein
zinc	I-protein
-	I-protein
finger	I-protein
factor	I-protein
CTCF	I-protein
is	O
an	O
exceptionally	O
highly	O
conserved	O
protein	O
displaying	O
93	O
%	O
identity	O
between	O
avian	O
and	O
human	O
amino	O
acid	O
sequences	O
.	O

The	O
glucose	O
areas	O
following	O
the	O
ingestion	O
of	O
the	O
foods	O
were	O
:	O
Study	O
1	O
:	O
glucose	O
11	O
.	O
7	O
,	O
orange	O
juice	O
7	O
.	O
3	O
,	O
sucrose	O
5	O
.	O
2	O
,	O
glucose	O
+	O
fructose	O
6	O
.	O
3	O
,	O
and	O
fructose	O
0	O
.	O
7	O
mmol	O
X	O
h	O
/	O
l	O
;	O
Study	O
2	O
:	O
glucose	O
14	O
.	O
6	O
,	O
orange	O
juice	O
7	O
.	O
3	O
,	O
apples	O
5	O
.	O
5	O
,	O
and	O
apple	O
juice	O
4	O
.	O
7	O
mmol	O
X	O
h	O
/	O
l	O
;	O
Study	O
3	O
:	O
glucose	O
12	O
.	O
6	O
,	O
ice	O
cream	O
8	O
.	O
1	O
,	O
milk	O
3	O
.	O
7	O
,	O
and	O
lactose	O
4	O
.	O
1	O
mmol	O
X	O
h	O
/	O
l	O
.	O

Nevertheless	O
,	O
protein	B-protein
kinase	I-protein
A	I-protein
stimulation	O
induces	O
CREMalpha	B-protein
to	O
activate	O
the	O
complex	O
native	O
promoter	O
in	O
the	O
phosphoenolpyruvate	B-protein
carboxykinase	I-protein
(	O
PEPCK	B-protein
)	O
gene	O
.	O

The	O
calcitonin	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
HEF1	B-protein
increased	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
.	O

These	O
data	O
locate	O
the	O
aniridia	B-protein
gene	I-protein
(	O
AN2	B-protein
)	O
and	O
a	O
recurrent	O
T	B-protein
-	I-protein
cell	I-protein
leukemia	I-protein
breakpoint	I-protein
(	O
TCL2	B-protein
)	O
in	O
the	O
marker	O
sequence	O
,	O
on	O
opposite	O
sides	O
of	O
MIC1	B-protein
.	O

A	O
study	O
was	O
conducted	O
of	O
a	O
human	O
male	O
who	O
had	O
inhaled	O
a	O
mixture	O
of	O
241Am	O
and	O
Pu	O
.	O

In	O
slightly	O
older	O
embryos	O
,	O
the	O
expression	O
was	O
skewed	O
to	O
one	O
side	O
of	O
the	O
embryo	O
and	O
by	O
E6	O
.	O
5	O
,	O
at	O
the	O
onset	O
of	O
gastrulation	O
,	O
expression	O
was	O
seen	O
in	O
the	O
epiblast	O
,	O
visceral	O
endoderm	O
,	O
nascent	O
mesoderm	O
,	O
and	O
the	O
primitive	O
streak	O
.	O

As	O
for	O
31	O
stage	O
I	O
-	O
II	O
lung	O
cancer	O
patients	O
,	O
CR	O
has	O
been	O
observed	O
in	O
82	O
.	O
8	O
%	O
of	O
them	O
and	O
PR	O
in	O
13	O
.	O
8	O
%	O
;	O
the	O
response	O
was	O
always	O
assessed	O
with	O
chest	O
radiography	O
,	O
CT	O
,	O
FBS	O
,	O
cytology	O
and	O
/	O
or	O
histology	O
.	O

The	O
technique	O
of	O
the	O
TEE	O
visualization	O
of	O
the	O
proximal	O
coronary	O
arteries	O
is	O
described	O
.	O

Myogenic	O
differentiation	O
can	O
be	O
inhibited	O
by	O
the	O
adenovirus	O
E1a	B-protein
protein	I-protein
in	O
the	O
rat	O
L6	O
muscle	O
cell	O
line	O
.	O

Two	O
points	O
are	O
indicated	O
:	O
first	O
,	O
the	O
photosensitized	O
damage	O
of	O
YHPD	O
is	O
interrelated	O
to	O
not	O
only	O
1O2	O
,	O
but	O
also	O
free	O
radicals	O
(	O
O2	O
-	O
.	O
.	O
OH	O
and	O
YHPD	O
-	O
.	O
)	O
;	O
second	O
,	O
although	O
the	O
photosensitized	O
damage	O
of	O
YHPD	O
is	O
stronger	O
than	O
that	O
of	O
BHPD	O
,	O
yet	O
the	O
photosensitized	O
damage	O
is	O
negatively	O
correlated	O
to	O
the	O
yield	O
of	O
1O2	O
but	O
positively	O
correlated	O
to	O
those	O
of	O
O2	O
-	O
.	O
and	O
OH	O
.	O

Selection	O
using	O
SC	O
EPD	O
was	O
more	O
effective	O
than	O
phenotypic	O
selection	O
in	O
reducing	O
age	O
at	O
puberty	O
in	O
daughters	O
.	O

The	O
results	O
indicate	O
that	O
increased	O
pulmonary	O
blood	O
flow	O
and	O
decreased	O
pulmonary	O
vascular	O
resistance	O
with	O
advancing	O
gestation	O
are	O
due	O
to	O
an	O
increase	O
in	O
the	O
total	O
number	O
of	O
vessels	O
and	O
increased	O
vasomotor	O
reactivity	O
is	O
related	O
to	O
an	O
increase	O
in	O
the	O
total	O
amount	O
of	O
smooth	O
muscle	O
while	O
the	O
thickness	O
of	O
muscle	O
in	O
individual	O
vessels	O
remains	O
constant	O
.	O

Thirty	O
of	O
the	O
clones	O
contained	O
a	O
complete	O
340	O
base	O
-	O
pair	O
dimer	O
unit	O
of	O
the	O
repeat	O
.	O

Primer	O
extension	O
and	O
cDNA	O
cloning	O
were	O
used	O
to	O
isolate	O
the	O
complete	O
5	O
'	O
end	O
of	O
the	O
Nramp1	B-protein
mRNA	I-protein
.	O

A	O
736	O
-	O
bp	O
sequence	O
of	O
the	O
5	O
'	O
flanking	O
region	O
adjacent	O
to	O
the	O
cap	O
site	O
of	O
the	O
human	B-protein
AFP	I-protein
gene	I-protein
shows	O
a	O
61	O
%	O
similarity	O
with	O
the	O
corresponding	O
region	O
of	O
the	O
mouse	B-protein
AFP	I-protein
gene	I-protein
.	O

A	O
new	O
species	O
of	O
Euspondylus	O
is	O
described	O
based	O
on	O
a	O
female	O
(	O
taken	O
within	O
a	O
bromeliad	O
)	O
from	O
Cerro	O
El	O
Humo	O
,	O
Sucre	O
,	O
northeastern	O
Venezuela	O
.	O

The	O
Og4C3	B-protein
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
to	O
detect	O
circulating	O
Wuchereria	B-protein
bancrofti	I-protein
antigen	I-protein
uses	O
50	O
microL	O
of	O
serum	O
.	O

Pharmacological	O
desympathization	O
leads	O
to	O
the	O
development	O
of	O
hyper	O
-	O
reactivity	O
of	O
the	O
true	O
pacemakers	O
to	O
noradrenaline	O
and	O
dopamine	O
and	O
triggers	O
off	O
changes	O
in	O
the	O
regulation	O
of	O
the	O
electric	O
activity	O
of	O
these	O
cells	O
by	O
catecholamines	O
.	O

The	O
inhibition	O
of	O
focus	O
formation	O
observed	O
in	O
the	O
presence	O
of	O
C3G	B-protein
was	O
not	O
due	O
to	O
toxic	O
effects	O
on	O
cell	O
viability	O
,	O
since	O
transfected	O
C3G	B-protein
cells	O
exhibited	O
the	O
same	O
survival	O
and	O
growth	O
rates	O
as	O
untransfected	O
NIH3T3	O
cells	O
or	O
cells	O
transfected	O
with	O
plasmid	O
vector	O
alone	O
.	O

In	O
rubella	O
patients	O
with	O
serologic	O
confirmation	O
by	O
HI	O
,	O
the	O
IF	O
test	O
detected	O
significant	O
rises	O
in	O
219	O
(	O
99	O
.	O
1	O
%	O
)	O
of	O
221	O
patients	O
and	O
the	O
PHA	B-protein
test	O
detected	O
antibody	O
conversion	O
in	O
68	O
(	O
93	O
%	O
)	O
of	O
73	O
patients	O
.	O

Southern	O
blotting	O
analysis	O
implied	O
the	O
occurrence	O
of	O
multiple	O
COXVb	B-protein
genes	I-protein
in	O
the	O
rat	O
genome	O
.	O

Cryopreservation	O
straws	O
filled	O
with	O
media	O
plus	O
additive	O
are	O
emersed	O
below	O
the	O
surface	O
of	O
an	O
unprocessed	O
donor	O
ejaculate	O
.	O

Clinical	O
course	O
and	O
nursing	O
care	O
of	O
patients	O
with	O
decubitus	O
ulcer	O
-	O
-	O
use	O
of	O
pillows	O
stuffed	O
with	O
buckwheat	O
chaff	O
.	O

An	O
examination	O
was	O
performed	O
in	O
15	O
patients	O
who	O
had	O
developed	O
pronounced	O
osteomalacia	O
following	O
gastric	O
resection	O
.	O

Doppler	O
ultrasound	O
studies	O
of	O
long	O
-	O
term	O
follow	O
-	O
up	O
of	O
children	O
with	O
hemolytic	O
-	O
uremic	O
syndrome	O
.	O

The	O
contrasting	O
effects	O
of	O
dopaminergic	O
stimulation	O
on	O
the	O
motor	O
performance	O
and	O
on	O
some	O
aspects	O
of	O
cognitive	O
processing	O
suggest	O
the	O
existence	O
of	O
complex	O
interactions	O
within	O
pre	O
-	O
and	O
postsynaptic	O
brain	B-protein
dopamine	I-protein
receptors	I-protein
,	O
and	O
an	O
intervention	O
of	O
segregated	O
basal	O
ganglia	O
-	O
prefrontal	O
cortex	O
loops	O
in	O
motor	O
and	O
cognitive	O
behaviour	O
.	O

As	O
in	O
Tb	O
,	O
U6	B-protein
is	O
a	O
single	O
-	O
copy	O
gene	O
and	O
two	O
tRNA	B-protein
genes	I-protein
,	O
tRNAGln	B-protein
and	O
tRNAIle	B-protein
,	O
are	O
found	O
upstream	O
to	O
the	O
gene	O
.	O

Experimental	O
adhesion	O
prophylaxis	O
with	O
recombinant	B-protein
tissue	I-protein
plasminogen	I-protein
activator	I-protein
.	O

Cotransfection	O
analyses	O
of	O
the	O
T	B-protein
/	I-protein
EBP	I-protein
promoter	I-protein
-	I-protein
reporter	I-protein
constructs	I-protein
with	O
a	O
T	B-protein
/	I-protein
EBP	I-protein
expression	O
vector	O
into	O
human	O
HepG2	O
cells	O
,	O
which	O
do	O
not	O
express	O
T	B-protein
/	I-protein
EBP	I-protein
,	O
suggested	O
that	O
autoregulation	O
may	O
be	O
involved	O
in	O
controlling	O
both	O
rat	O
and	O
human	B-protein
T	I-protein
/	I-protein
EBP	I-protein
gene	I-protein
expression	O
.	O

A	O
newly	O
developed	O
broad	O
-	O
spectrum	O
fluoroquinolone	O
,	O
levofloxacin	O
(	O
LVFX	O
,	O
DR	O
-	O
3355	O
)	O
,	O
was	O
evaluated	O
in	O
vitro	O
and	O
in	O
vivo	O
in	O
comparison	O
with	O
ciprofloxacin	O
(	O
CPFX	O
)	O
,	O
ofloxacin	O
(	O
OFLX	O
)	O
and	O
norfloxacin	O
(	O
NFLX	O
)	O
.	O

Previous	O
studies	O
indicated	O
that	O
the	O
20S	B-protein
proteasome	I-protein
is	O
a	O
catalytic	O
core	O
of	O
the	O
26S	B-protein
proteolytic	I-protein
complex	I-protein
that	O
possesses	O
a	O
latent	O
multicatalytic	O
proteinase	B-protein
activity	O
and	O
catalyzes	O
an	O
ATP	O
-	O
dependent	O
,	O
selective	O
breakdown	O
of	O
proteins	O
ligated	O
to	O
ubiquitin	B-protein
.	O

The	O
fission	B-protein
yeast	I-protein
dsk1	I-protein
+	I-protein
gene	I-protein
,	O
a	O
multicopy	O
suppressor	O
for	O
cold	O
-	O
sensitive	O
dis1	B-protein
mutants	I-protein
,	O
encodes	O
a	O
novel	O
61	B-protein
-	I-protein
kd	I-protein
protein	I-protein
kinase	I-protein
.	O

The	O
requirement	O
of	O
different	O
essential	O
fatty	O
acids	O
in	O
patients	O
with	O
total	O
parenteral	O
nutrition	O
after	O
heavy	O
injury	O
is	O
of	O
special	O
interest	O
with	O
respect	O
to	O
the	O
development	O
and	O
prognosis	O
of	O
shock	O
,	O
sepsis	O
or	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O

These	O
consisted	O
of	O
beading	O
and	O
strictures	O
mainly	O
of	O
the	O
intrahepatic	O
biliary	O
tree	O
(	O
IHB	O
)	O
.	O

Comparison	O
of	O
the	O
genomes	O
of	O
PMTV	O
,	O
BNYVV	O
,	O
and	O
SBWMV	O
shows	O
that	O
furoviruses	O
exhibit	O
considerable	O
heterogeneity	O
in	O
genome	O
organization	O
.	O

Hybrid	O
-	O
selection	O
experiments	O
against	O
total	O
PB	O
-	O
inducible	O
RNA	O
were	O
performed	O
with	O
plasmid	O
DNA	O
derived	O
from	O
clones	O
enriched	O
in	O
PB	O
-	O
inducible	O
information	O
.	O

However	O
,	O
tyrA	B-protein
can	O
be	O
expressed	O
efficiently	O
from	O
an	O
internal	O
promoter	O
which	O
appears	O
to	O
lie	O
within	O
the	O
3	O
'	O
portion	O
of	O
aroF	B-protein
.	O

The	O
interaction	O
between	O
U	O
(	O
L	O
)	O
3	O
.	O

The	O
percutaneous	O
absorption	O
of	O
clindamycin	O
was	O
studied	O
in	O
healthy	O
male	O
volunteers	O
,	O
comparing	O
two	O
investigative	O
clindamycin	O
(	O
%	O
w	O
/	O
v	O
)	O
/	O
tretinoin	O
(	O
0	O
.	O
025	O
%	O
w	O
/	O
v	O
)	O
gels	O
,	O
containing	O
clindamycin	O
phosphate	O
ester	O
and	O
clindamycin	O
HCl	O
,	O
respectively	O
,	O
relative	O
to	O
a	O
clindamycin	O
phosphate	O
lotion	O
(	O
1	O
%	O
clindamycin	O
;	O
Dalacin	O
T	O
)	O
.	O

Urinary	B-protein
N	I-protein
-	I-protein
acetylglucosaminidase	I-protein
activity	O
per	O
mg	O
creatinine	O
did	O
not	O
differ	O
significantly	O
between	O
groups	O
.	O

Ritanserin	O
is	O
a	O
new	O
substance	O
with	O
highly	O
selective	O
blocking	O
activity	O
on	O
S2	B-protein
receptors	I-protein
for	O
5	O
-	O
HT	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Mortality	O
on	O
the	O
last	O
ranch	O
was	O
particularly	O
severe	O
among	O
certain	O
segregated	O
groups	O
of	O
turkeys	O
that	O
included	O
toms	O
,	O
heavier	O
birds	O
,	O
and	O
birds	O
undergoing	O
a	O
stressful	O
event	O
such	O
as	O
artificial	O
insemination	O
.	O

NERVTRACK	O
contains	O
4000	O
anatomical	O
data	O
items	O
arranged	O
in	O
a	O
tree	O
-	O
like	O
manner	O
reflecting	O
structural	O
and	O
functional	O
relationships	O
.	O

Myocardial	O
infarction	O
in	O
patients	O
with	O
previous	O
bypass	O
surgery	O
.	O

Management	O
of	O
hypertension	O
in	O
the	O
elderly	O
.	O

By	O
using	O
the	O
full	O
-	O
length	O
cytoplasmic	O
domain	O
and	O
mutants	O
with	O
progressive	O
carboxy	O
-	O
terminal	O
deletions	O
,	O
internal	O
deletions	O
,	O
or	O
point	O
mutations	O
,	O
we	O
identified	O
the	O
first	O
150	O
amino	O
acid	O
residues	O
of	O
LIFR	B-protein
as	O
the	O
minimal	O
region	O
necessary	O
for	O
signaling	O
.	O

In	O
the	O
predicted	O
transmembrane	O
domain	O
,	O
Casr	B-protein
-	I-protein
rs2	I-protein
and	O
Casr	B-protein
-	I-protein
rs3	I-protein
are	O
95	O
%	O
identical	O
to	O
Casr	B-protein
-	I-protein
rs1	I-protein
.	O

Serum	O
magnesium	O
in	O
79	O
patients	O
of	O
gynecologic	O
neoplasms	O
treated	O
with	O
cisplatin	O
and	O
their	O
controls	O
was	O
measured	O
.	O

In	O
order	O
to	O
overcome	O
the	O
false	O
positive	O
readings	O
that	O
are	O
possible	O
in	O
sphincter	O
manometry	O
,	O
we	O
proposed	O
to	O
use	O
secretin	B-protein
stimulated	O
endoscopic	O
ultrasound	O
(	O
SSEUS	O
)	O
to	O
measure	O
pancreatic	O
ductal	O
response	O
as	O
an	O
adjunctive	O
method	O
to	O
aid	O
and	O
supplement	O
the	O
diagnosis	O
.	O

CES4	B-protein
on	O
a	O
multicopy	O
plasmid	O
was	O
unable	O
to	O
suppress	O
tif1	B-protein
-	I-protein
A79V	I-protein
.	O

A	O
prospective	O
trial	O
was	O
undertaken	O
to	O
determine	O
(	O
1	O
)	O
clinical	O
characteristics	O
of	O
patients	O
with	O
chest	O
pain	O
;	O
(	O
2	O
)	O
value	O
of	O
cardiac	O
markers	O
troponin	B-protein
T	I-protein
,	O
myoglobin	B-protein
and	O
CK	B-protein
-	I-protein
MB	I-protein
mass	O
in	O
differentiating	O
cardiac	O
and	O
noncardiac	O
chest	O
pain	O
;	O
(	O
3	O
)	O
the	O
proportion	O
of	O
patients	O
with	O
ACS	O
in	O
whom	O
these	O
markers	O
provided	O
helpful	O
additional	O
information	O
on	O
admission	O
and	O
afterwards	O
.	O

Mutational	O
analysis	O
of	O
the	O
major	O
homology	O
region	O
of	O
Mason	O
-	O
Pfizer	O
monkey	O
virus	O
by	O
use	O
of	O
saturation	O
mutagenesis	O
.	O

STUDY	O
OBJECTIVE	O
:	O
This	O
study	O
assessed	O
several	O
methodological	O
aspects	O
related	O
to	O
the	O
quality	O
of	O
published	O
controlled	O
clinical	O
trials	O
(	O
CCTs	O
)	O
in	O
relation	O
to	O
the	O
participation	O
of	O
an	O
epidemiologist	O
/	O
biostatistician	O
(	O
E	O
/	O
B	O
)	O
.	O

Neuronal	O
signaling	O
properties	O
are	O
largely	O
determined	O
by	O
the	O
quantity	O
and	O
combination	O
of	O
ion	O
channels	O
expressed	O
.	O

Triumph	O
of	O
Leninist	O
national	O
policy	O
.	O

If	O
no	O
reply	O
was	O
received	O
,	O
telephone	O
contact	O
or	O
home	O
visits	O
were	O
made	O
.	O

A	O
cDNA	O
encoding	O
the	O
amino	O
-	O
terminal	O
17	O
%	O
of	O
apoB	B-protein
(	O
apoB17	B-protein
)	O
was	O
fused	O
to	O
a	O
cDNA	O
coding	O
for	O
the	O
last	O
37	O
amino	O
acids	O
of	O
decay	B-protein
-	I-protein
accelerating	I-protein
factor	I-protein
(	O
DAF	B-protein
)	O
,	O
which	O
contains	O
the	O
signal	O
for	O
glycosylphosphatidylinositol	O
anchor	O
attachment	O
.	O

It	O
then	O
merged	O
with	O
right	O
ventricular	O
wavefronts	O
ending	O
along	O
the	O
right	O
ventricular	O
anterior	O
atrioventricular	O
groove	O
and	O
outflow	O
tract	O
.	O

Selective	O
visual	O
attention	O
involves	O
dynamic	O
interplay	O
between	O
attentional	O
control	O
systems	O
and	O
sensory	O
brain	O
structures	O
.	O

A	O
variety	O
of	O
receptor	O
-	O
mediated	O
signaling	O
pathways	O
are	O
controlled	O
by	O
both	O
positive	O
and	O
negative	O
extracellular	O
regulators	O
.	O

Statistical	O
Analysis	O
included	O
ANOVA	O
,	O
the	O
Pearson	O
Product	O
Moment	O
Correlation	O
Coefficient	O
,	O
Principal	O
Components	O
Analysis	O
and	O
Discriminant	O
Function	O
Analysis	O
and	O
the	O
calculation	O
of	O
Cronbach	O
'	O
s	O
alpha	O
(	O
alpha	O
)	O
RESULTS	O
:	O
Both	O
Sensitivity	O
and	O
specificity	O
exceed	O
90	O
.	O
00	O
at	O
23	O
/	O
24	O
,	O
Chronbach	O
'	O
s	O
alpha	O
for	O
the	O
total	O
scale	O
was	O
equal	O
to	O
0	O
.	O
95	O
.	O

Mnt	B-protein
:	I-protein
Max	I-protein
complexes	I-protein
also	O
efficiently	O
suppress	O
Myc	O
-	O
dependent	O
activation	O
from	O
the	O
same	O
promoter	O
.	O

An	O
epidemiological	O
survey	O
of	O
rheumatic	O
valve	O
disease	O
and	O
rheumatic	O
fever	O
in	O
primary	O
and	O
secondary	O
school	O
students	O
in	O
Jiangxi	O
Province	O
.	O

Haplotype	O
mapping	O
and	O
sequence	O
analysis	O
of	O
the	O
mouse	O
Nramp	B-protein
gene	I-protein
predict	O
susceptibility	O
to	O
infection	O
with	O
intracellular	O
parasites	O
.	O

Transient	O
cotransfection	O
of	O
tat	B-protein
cDNA	I-protein
in	O
sense	O
orientation	O
(	O
tat	B-protein
/	I-protein
S	I-protein
)	O
,	O
together	O
with	O
a	O
plasmid	O
containing	O
the	O
c	B-protein
-	I-protein
fos	I-protein
promoter	I-protein
(	O
FC3	B-protein
,	O
from	O
-	O
711	O
to	O
+	O
42	O
)	O
in	O
front	O
of	O
the	O
bacterial	B-protein
chloramphenicol	I-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
gene	O
significantly	O
enhanced	O
CAT	B-protein
activity	O
in	O
Jurkat	O
cells	O
activated	O
by	O
the	O
addition	O
of	O
15	O
%	O
fetal	O
calf	O
serum	O
(	O
FCS	O
)	O
or	O
5	O
micrograms	O
/	O
mL	O
phytohemagglutinin	B-protein
plus	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
U937	O
cells	O
activated	O
by	O
15	O
%	O
FCS	O
or	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
PMA	O
.	O

The	O
most	O
important	O
one	O
among	O
them	O
is	O
Cyclosporin	O
A	O
,	O
which	O
is	O
a	O
selective	O
immunosuppressive	O
drug	O
.	O

A	O
genetic	O
complementation	O
system	O
was	O
developed	O
in	O
which	O
tobacco	B-protein
etch	I-protein
virus	I-protein
(	I-protein
TEV	I-protein
)	I-protein
polymerase	I-protein
(	O
NIb	B-protein
)	O
-	O
expressing	O
transgenic	O
plants	O
or	O
protoplasts	O
were	O
inoculated	O
with	O
NIb	O
-	O
defective	O
TEV	B-protein
mutants	I-protein
.	O

Furthermore	O
,	O
as	O
in	O
the	O
human	O
gene	O
,	O
the	O
3	O
'	O
end	O
of	O
the	O
Cacna1f	B-protein
gene	I-protein
maps	O
within	O
5	O
kb	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
mouse	B-protein
synaptophysin	I-protein
gene	I-protein
in	O
a	O
region	O
orthologous	O
to	O
Xp11	O
.	O
23	O
.	O

The	O
logistic	O
regression	O
analysis	O
of	O
the	O
manual	O
method	O
(	O
percentage	O
normal	O
morphology	O
)	O
and	O
IVOS	O
indicated	O
that	O
both	O
were	O
predictors	O
of	O
fertilization	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
BOX	B-protein
DNA	I-protein
enhances	O
transcription	O
from	O
the	O
thymidine	B-protein
kinase	I-protein
(	O
TK	B-protein
)	O
promoter	O
in	O
various	O
EC	O
cells	O
.	O

The	O
clinical	O
efficacy	O
rates	O
evaluated	O
in	O
151	O
cases	O
(	O
KS	O
-	O
R1	O
group	O
in	O
77	O
cases	O
,	O
oral	O
group	O
in	O
74	O
cases	O
)	O
on	O
standard	O
criteria	O
of	O
committee	O
members	O
were	O
88	O
.	O
3	O
%	O
for	O
the	O
KS	O
-	O
R1	O
group	O
and	O
86	O
.	O
5	O
%	O
for	O
the	O
oral	O
group	O
,	O
respectively	O
.	O

We	O
show	O
here	O
that	O
the	O
third	O
SH3	B-protein
domain	I-protein
binds	O
to	O
Sos	B-protein
,	O
a	O
guanine	B-protein
nucleotide	I-protein
exchange	I-protein
factor	I-protein
for	O
Ras	B-protein
and	O
Rac	B-protein
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

A	O
dose	O
of	O
3	O
and	O
6	O
micrograms	O
/	O
kg	O
/	O
day	O
GM	O
-	O
CSF	O
reduces	O
the	O
severity	O
of	O
neutropenia	O
and	O
thrombocytopenia	O
after	O
carboplatin	O
-	O
cyclophosphamide	O
chemotherapy	O
,	O
which	O
may	O
lead	O
to	O
more	O
effective	O
chemotherapy	O
for	O
ovarian	O
cancer	O
in	O
the	O
future	O
.	O

SH2D1A	B-protein
protein	I-protein
levels	O
are	O
up	O
-	O
regulated	O
by	O
CD40	B-protein
cross	O
-	O
linking	O
and	O
down	O
-	O
regulated	O
by	O
B	B-protein
cell	I-protein
receptor	I-protein
ligation	O
.	O

[	O
82Br	O
]	O
MISO	O
was	O
prepared	O
by	O
irradiating	O
samples	O
of	O
Br	O
-	O
MISO	O
in	O
a	O
SLOWPOKE	O
reactor	O
for	O
2	O
h	O
at	O
a	O
thermal	O
neutron	O
flux	O
of	O
10	O
(	O
12	O
)	O
n	O
cm	O
-	O
2	O
s	O
-	O
1	O
.	O

A	O
partial	O
cDNA	O
sequence	O
indicated	O
that	O
the	O
T	B-protein
lymphocyte	I-protein
early	I-protein
-	I-protein
activation	I-protein
gene	I-protein
(	O
Tea	B-protein
)	O
encodes	O
a	O
protein	O
related	O
to	O
the	O
dual	O
-	O
function	O
ecotropic	B-protein
retrovirus	I-protein
receptor	I-protein
/	I-protein
cationic	I-protein
amino	I-protein
acid	I-protein
transporter	I-protein
(	O
ecoR	B-protein
/	I-protein
CAT1	I-protein
)	O
,	O
and	O
RNA	O
blots	O
suggested	O
highest	O
Tea	B-protein
expression	O
in	O
T	O
lymphocytes	O
and	O
liver	O
(	O
MacLeod	O
,	O
C	O
.	O
L	O
.	O
,	O
Finley	O
,	O
K	O
.	O
,	O
Kakuda	O
,	O
D	O
.	O

Precipitating	O
antibodies	O
for	O
Thermophilic	O
actinomycetes	O
and	O
M	O
.	O
f	O
.	O
were	O
negative	O
.	O

UbiA	B-protein
is	O
also	O
unique	O
among	O
known	O
polyubiquitin	B-protein
genes	I-protein
in	O
containing	O
four	O
cis	O
-	O
spliced	O
introns	O
within	O
its	O
coding	O
sequence	O
.	O

Stress	B-protein
-	I-protein
inducible	I-protein
protein	I-protein
kinases	I-protein
capable	O
of	O
activating	O
c	B-protein
-	I-protein
jun	I-protein
expression	O
include	O
stress	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
/	I-protein
c	I-protein
-	I-protein
Jun	I-protein
N	I-protein
-	I-protein
terminal	I-protein
protein	I-protein
kinase	I-protein
(	O
SAPK	B-protein
/	I-protein
JNK	I-protein
)	O
and	O
p38	B-protein
members	O
of	O
the	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
superfamily	O
of	O
signaling	O
molecules	O
.	O

The	O
variable	O
regions	O
of	O
vertebrate	O
striated	O
TnT	B-protein
isoforms	I-protein
reflect	O
the	O
subsequent	O
addition	O
and	O
modification	O
of	O
genomic	O
sequences	O
to	O
give	O
rise	O
to	O
members	O
of	O
the	O
TnT	B-protein
multigene	I-protein
family	I-protein
.	O

Alternative	O
splicing	O
of	O
the	O
cytoplasmic	O
tail	O
appears	O
to	O
generate	O
multiple	O
PECAM	B-protein
-	I-protein
1	I-protein
isoforms	I-protein
that	O
may	O
regulate	O
phosphorylation	O
,	O
cytoskeletal	O
association	O
,	O
and	O
affinity	O
modulation	O
of	O
the	O
mature	O
protein	O
.	O

In	O
26	O
patients	O
with	O
angina	O
pectoris	O
,	O
the	O
changes	O
of	O
LVEF	O
,	O
LVESV	O
and	O
PSP	O
/	O
LVESV	O
were	O
more	O
sensitive	O
for	O
the	O
detection	O
of	O
exercise	O
-	O
induced	O
ischemia	O
than	O
the	O
appearance	O
of	O
chest	O
pain	O
and	O
the	O
changes	O
of	O
ECG	O
.	O

Here	O
,	O
we	O
have	O
used	O
specific	O
antibody	O
to	O
identify	O
and	O
characterize	O
the	O
SSN6	B-protein
protein	I-protein
.	O

Many	O
mammary	O
tumors	O
induced	O
by	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
contain	O
a	O
provirus	O
in	O
the	O
same	O
region	O
of	O
the	O
host	O
-	O
cell	O
genome	O
,	O
leading	O
to	O
expression	O
of	O
a	O
putative	O
cellular	O
oncogene	O
called	O
int	B-protein
-	I-protein
1	I-protein
.	O

Grossly	O
,	O
the	O
incidence	O
of	O
a	O
type	O
IIc	O
carcinoma	O
was	O
46	O
.	O
5	O
%	O
and	O
that	O
of	O
a	O
IIc	O
+	O
III	O
type	O
was	O
20	O
.	O
5	O
%	O
,	O
respectively	O
.	O

In	O
XO	O
males	O
,	O
two	O
her	B-protein
-	I-protein
1	I-protein
mRNAs	I-protein
,	O
her	B-protein
-	I-protein
1a	I-protein
and	O
her	B-protein
-	I-protein
1b	I-protein
,	O
are	O
transcribed	O
from	O
two	O
separate	O
promoters	O
:	O
P1	O
,	O
located	O
in	O
the	O
5	O
'	O
-	O
flanking	O
region	O
,	O
and	O
P2	O
,	O
located	O
in	O
the	O
large	O
second	O
intron	O
.	O

One	O
hundred	O
fifty	O
patients	O
were	O
reviewed	O
at	O
1	O
year	O
after	O
arthroplasty	O
.	O

The	O
human	B-protein
CD38	I-protein
gene	I-protein
consists	O
of	O
8	O
exons	O
that	O
extend	O
more	O
than	O
77	O
kb	O
on	O
the	O
human	O
genome	O
.	O

Screening	O
of	O
asthma	O
patients	O
by	O
determination	O
of	O
IgE	B-protein
and	O
by	O
comprehension	O
of	O
spectrum	O
of	O
allergospecific	B-protein
IgE	I-protein
antibodies	I-protein
.	O

To	O
evaluate	O
the	O
relative	O
accuracy	O
of	O
continuous	O
wave	O
(	O
CW	O
)	O
and	O
high	O
pulse	O
repetition	O
frequency	O
(	O
HPRF	O
)	O
Doppler	O
for	O
estimating	O
aortic	O
transvalvular	O
pressure	O
gradients	O
,	O
Doppler	O
examinations	O
with	O
both	O
devices	O
were	O
obtained	O
in	O
87	O
consecutive	O
patients	O
with	O
aortic	O
valve	O
disease	O
.	O

PABP	B-protein
is	O
a	O
modular	O
protein	O
,	O
with	O
four	O
N	O
-	O
terminal	O
RNA	O
-	O
binding	O
domains	O
and	O
an	O
extensive	O
C	O
terminus	O
.	O

Pit	B-protein
-	I-protein
1	I-protein
is	O
a	O
tissue	O
-	O
specific	O
POU	B-protein
domain	I-protein
factor	I-protein
obligatory	O
for	O
the	O
appearance	O
of	O
three	O
cell	O
phenotypes	O
in	O
the	O
anterior	O
pituitary	O
gland	O
.	O

Proteins	O
immunoprecipitated	O
from	O
lysates	O
of	O
control	O
-	O
and	O
VEGF	O
-	O
stimulated	O
BAEC	O
with	O
antisera	O
to	O
phospholipase	B-protein
C	I-protein
-	I-protein
gamma	I-protein
(	O
PLC	B-protein
-	I-protein
gamma	I-protein
)	O
were	O
fractionated	O
by	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
transferred	O
to	O
Immobilon	O
-	O
P	O
.	O

Dissociation	O
and	O
complexation	O
of	O
the	O
fluoroquinolone	O
antimicrobials	O
-	O
-	O
an	O
update	O
.	O

These	O
data	O
suggest	O
that	O
other	O
Ras	B-protein
effectors	I-protein
can	O
collaborate	O
with	O
PI	B-protein
3	I-protein
-	I-protein
kinase	I-protein
and	O
with	O
each	O
other	O
to	O
activate	O
Pak	B-protein
.	O

Blood	O
flow	O
and	O
velocity	O
(	O
measured	O
using	O
Doppler	O
ultrasound	O
)	O
gradually	O
decreased	O
during	O
diastole	O
and	O
ultimately	O
reversed	O
in	O
direction	O
as	O
cotyledon	O
resistance	O
was	O
increased	O
up	O
to	O
14	O
fold	O
.	O

Harel	O
,	O
E	O
.	O
M	O
.	O

Daily	O
and	O
seasonal	O
rhythmicity	O
in	O
the	O
methylation	O
of	O
pineal	O
indolic	O
compounds	O
in	O
adult	O
male	O
golden	O
hamsters	O
,	O
kept	O
under	O
natural	O
conditions	O
.	O

Seventy	O
-	O
one	O
percent	O
of	O
patients	O
treated	O
with	O
ticarcillin	O
alone	O
responded	O
favorably	O
.	O

Isolation	O
and	O
characterization	O
of	O
a	O
TATA	O
-	O
less	O
promoter	O
for	O
the	O
human	B-protein
beta	I-protein
3	I-protein
integrin	I-protein
gene	I-protein
.	O

Histopathologic	O
response	O
of	O
gingival	O
tissues	O
to	O
hemodent	O
and	O
aluminum	O
chloride	O
solutions	O
as	O
tissue	O
displacement	O
materials	O
.	O

Deglutition	O
is	O
considered	O
to	O
be	O
immature	O
in	O
infants	O
and	O
to	O
mature	O
postnatally	O
.	O

Antidepressant	O
-	O
like	O
properties	O
of	O
some	O
serotonin	B-protein
receptor	I-protein
ligands	O
and	O
calcium	O
channel	O
antagonists	O
measured	O
with	O
the	O
forced	O
swimming	O
test	O
in	O
mice	O
.	O

Regulation	O
of	O
avian	B-protein
fibroblast	I-protein
growth	I-protein
factor	I-protein
receptor	I-protein
1	I-protein
(	O
FGFR	B-protein
-	I-protein
1	I-protein
)	O
gene	O
expression	O
during	O
skeletal	O
muscle	O
differentiation	O
.	O

To	O
confirm	O
the	O
binding	O
of	O
protein	O
to	O
these	O
sites	O
in	O
cells	O
,	O
we	O
carried	O
out	O
an	O
in	O
vivo	O
genomic	O
footprinting	O
analysis	O
of	O
this	O
portion	O
of	O
the	O
TGF	B-protein
alpha	I-protein
promoter	I-protein
in	O
normal	O
and	O
transformed	O
rat	O
liver	O
epithelial	O
cell	O
lines	O
that	O
express	O
the	O
endogenous	O
gene	O
at	O
varying	O
levels	O
.	O

Grade	O
3	O
-	O
4	O
mucositis	O
was	O
present	O
in	O
13	O
%	O
of	O
the	O
cycles	O
.	O

Subdural	O
electrodes	O
may	O
yield	O
larger	O
VEP	O
amplitudes	O
than	O
skull	O
or	O
scalp	O
electrodes	O
.	O

The	O
desirability	O
function	O
is	O
based	O
on	O
the	O
search	O
for	O
a	O
global	O
optimum	O
[	O
D	O
=	O
f	O
(	O
Y1	O
,	O
Y2	O
,	O
.	O
.	O
.	O
,	O
Yn	O
)	O
]	O
by	O
the	O
transformation	O
of	O
the	O
measured	O
property	O
to	O
a	O
dimensionless	O
scale	O
for	O
each	O
criterion	O
.	O

(	O
ii	O
)	O
opening	O
of	O
KATP	O
attenuates	O
,	O
inhibition	O
of	O
the	O
channel	O
exacerbates	O
functional	O
consequences	O
of	O
coronary	O
occlusion	O
,	O
and	O
(	O
iii	O
)	O
KATP	O
opening	O
attenuates	O
reperfusion	O
-	O
induced	O
VF	O
,	O
but	O
it	O
triggers	O
ischemia	O
-	O
induced	O
VF	O
.	O

CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
:	O
Increased	O
cortical	O
thickness	O
and	O
geometric	O
properties	O
of	O
left	O
MCB	O
-	O
IV	O
and	O
-	O
V	O
of	O
Greyhounds	O
,	O
together	O
with	O
altered	O
turnover	O
and	O
orientation	O
of	O
osteons	O
in	O
the	O
dorsal	O
quadrants	O
of	O
left	O
MCB	O
,	O
are	O
site	O
-	O
specific	O
adaptive	O
responses	O
associated	O
with	O
asymmetric	O
cyclic	O
loading	O
as	O
a	O
result	O
of	O
racing	O
on	O
circular	O
tracks	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
SRm160	B-protein
/	I-protein
300	I-protein
is	O
required	O
for	O
a	O
purine	O
-	O
rich	O
ESE	B-protein
to	O
promote	O
the	O
splicing	O
of	O
a	O
pre	O
-	O
mRNA	O
derived	O
from	O
the	O
Drosophila	B-protein
doublesex	I-protein
gene	I-protein
.	O

In	O
addition	O
,	O
we	O
have	O
isolated	O
a	O
genomic	O
fragment	O
containing	O
the	O
most	O
distal	O
5	O
'	O
sequences	O
of	O
the	O
major	O
GGT	B-protein
mRNA	I-protein
in	O
HepG2	O
cells	O
.	O

(	O
5	O
)	O
No	O
changes	O
were	O
observed	O
in	O
the	O
gastric	O
venous	O
blood	O
flow	O
by	O
continuous	O
intravenous	O
injection	O
of	O
cimetidine	O
,	O
but	O
by	O
rapid	O
injection	O
both	O
the	O
flow	O
was	O
augmented	O
and	O
the	O
systemic	O
blood	O
pressure	O
decreased	O
transiently	O
.	O

To	O
determine	O
the	O
signal	B-protein
recognition	I-protein
particle	I-protein
(	I-protein
SRP	I-protein
)	I-protein
-	I-protein
SRP	I-protein
receptor	I-protein
(	I-protein
Srb	I-protein
)	I-protein
system	I-protein
in	I-protein
Bacillus	I-protein
subtilis	I-protein
(	I-protein
Bs	I-protein
)	I-protein
,	O
we	O
cloned	O
the	O
Bs	B-protein
srb	I-protein
gene	I-protein
,	O
which	O
encodes	O
a	O
homologue	O
of	O
the	O
mammalian	B-protein
SRP	I-protein
receptor	I-protein
alpha	I-protein
-	I-protein
subunit	I-protein
[	O
Oguro	O
et	O
al	O
.	O
,	O
DNA	O
Res	O
.	O

TREB7	B-protein
and	O
TREB36	B-protein
protected	O
all	O
three	O
repeats	O
of	O
the	O
21	O
bp	O
,	O
but	O
TREB5	B-protein
protected	O
only	O
the	O
second	O
repeat	O
.	O

Biol	O
.	O

OODG	O
is	O
a	O
diagnostic	O
method	O
permitting	O
assessment	O
of	O
ocular	O
pulse	O
curves	O
and	O
objective	O
determination	O
of	O
blood	O
pressures	O
in	O
the	O
ophthalmic	O
circulatory	O
system	O
(	O
retinal	O
and	O
ciliary	O
arterial	O
blood	O
pressures	O
)	O
simultaneously	O
for	O
both	O
eyes	O
,	O
without	O
dilatation	O
of	O
the	O
pupils	O
.	O

The	O
carboxyl	B-protein
-	I-protein
terminal	I-protein
CCCC	I-protein
module	I-protein
is	O
structurally	O
related	O
to	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
erythroid	B-protein
transcription	I-protein
factor	I-protein
GATA	I-protein
-	I-protein
1	I-protein
.	O

The	O
median	O
levels	O
of	O
particles	O
with	O
50	O
%	O
cut	O
-	O
off	O
aerodynamic	O
diameters	O
of	O
10	O
(	O
PM10	O
)	O
and	O
2	O
.	O
5	O
microm	O
(	O
PM2	O
.	O
5	O
)	O
were	O
170	O
(	O
range	O
103	O
-	O
613	O
)	O
and	O
95	O
(	O
range	O
61	O
-	O
218	O
)	O
micro	O
x	O
m	O
-	O
3	O
,	O
respectively	O
.	O

The	O
novel	O
approach	O
to	O
insulin	B-protein
administration	O
known	O
as	O
chronic	O
intermittent	O
intravenous	O
insulin	B-protein
therapy	O
(	O
CIIIT	O
)	O
delivers	O
insulin	B-protein
in	O
a	O
pulsatile	O
fashion	O
and	O
achieves	O
physiological	O
insulin	B-protein
concentration	O
in	O
the	O
portal	O
vein	O
.	O

The	O
shift	O
to	O
the	O
nonpermissive	O
temperature	O
is	O
accompanied	O
by	O
the	O
loss	O
of	O
guanyl	O
nucleotide	O
-	O
dependent	O
activity	O
of	O
adenylylcyclase	B-protein
in	O
vitro	O
.	O

In	O
vitro	O
translation	O
of	O
the	O
mTRF1	B-protein
cDNA	I-protein
resulted	O
in	O
a	O
56	O
kDa	O
protein	O
that	O
binds	O
to	O
TTAGGG	B-protein
repeat	I-protein
arrays	O
.	O
mTRF1	B-protein
displayed	O
the	O
same	O
sequence	O
specificity	O
as	O
hTRF1	B-protein
,	O
preferring	O
arrays	O
of	O
TTAGGG	B-protein
repeats	I-protein
as	O
a	O
binding	O
substrate	O
over	O
TTAGGC	B-protein
and	O
TTGGGG	B-protein
repeats	I-protein
.	O

4	O
.	O

Our	O
study	O
differs	O
from	O
previous	O
studies	O
in	O
that	O
it	O
is	O
limited	O
to	O
one	O
diagnostic	O
entity	O
,	O
yet	O
at	O
the	O
same	O
time	O
evaluates	O
a	O
broad	O
range	O
of	O
social	O
and	O
work	O
-	O
related	O
factors	O
in	O
disability	O
.	O

Oral	O
candidiasis	O
.	O

Intron	O
-	O
exon	O
structure	O
of	O
the	O
porcine	B-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
-	I-protein
encoding	I-protein
gene	I-protein
.	O

Interleukin	B-protein
-	I-protein
6	I-protein
(	O
IL	B-protein
-	I-protein
6	I-protein
)	O
is	O
a	O
pleiotropic	O
cytokine	O
,	O
which	O
is	O
involved	O
in	O
inflammatory	O
and	O
immune	O
responses	O
,	O
acute	O
phase	O
reactions	O
,	O
and	O
hematopoiesis	O
.	O

Bacterial	O
metabolism	O
of	O
4	O
-	O
chlorophenoxyacetate	O
.	O

The	O
character	O
of	O
specific	O
immune	O
response	O
in	O
101	O
immunized	O
children	O
and	O
in	O
12	O
adults	O
belonging	O
to	O
a	O
high	O
risk	O
group	O
with	O
respect	O
to	O
VHB	O
.	O

A	O
short	O
history	O
of	O
dermatology	O
in	O
Lagos	O
,	O
Nigeria	O
.	O

We	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
myr	B-protein
4	I-protein
(	O
myosin	B-protein
from	I-protein
rat	I-protein
)	O
,	O
the	O
first	O
mammalian	B-protein
myosin	I-protein
I	I-protein
that	O
is	O
not	O
closely	O
related	O
to	O
brush	O
border	O
myosin	B-protein
I	I-protein
.	O

Only	O
nine	O
patients	O
were	O
offered	O
surgery	O
(	O
six	O
were	O
resected	O
and	O
three	O
were	O
found	O
inoperable	O
)	O
.	O

The	O
relevance	O
of	O
these	O
elements	O
in	O
conferring	O
anaerobic	O
induction	O
of	O
gpc4	B-protein
gene	I-protein
expression	O
is	O
discussed	O
.	O

The	O
genomic	O
structure	O
and	O
chromosomal	O
location	O
of	O
the	O
human	B-protein
TR2	I-protein
orphan	I-protein
receptor	I-protein
,	O
a	O
member	O
of	O
the	O
steroid	B-protein
receptor	I-protein
superfamily	I-protein
.	O

We	O
identify	O
considerable	O
spatio	O
-	O
temporal	O
similarities	O
between	O
reported	O
expression	O
patterns	O
of	O
Ypr10	B-protein
genes	I-protein
and	O
ribonuclease	B-protein
genes	I-protein
,	O
which	O
,	O
together	O
with	O
the	O
significant	O
sequence	O
similarity	O
to	O
the	O
ginseng	B-protein
ribonuclease	I-protein
,	O
support	O
the	O
hypothesis	O
of	O
a	O
ribonuclease	B-protein
function	O
for	O
PR	B-protein
-	I-protein
10	I-protein
proteins	I-protein
and	O
allow	O
the	O
prediction	O
of	O
possible	O
biological	O
roles	O
.	O

The	O
p20	B-protein
-	I-protein
CGGBP	I-protein
gene	I-protein
is	O
conserved	O
among	O
mammals	O
but	O
shows	O
no	O
homology	O
to	O
non	O
-	O
vertebrate	O
species	O
.	O

The	O
diagnostic	O
significance	O
of	O
creatine	B-protein
phosphokinase	I-protein
antibodies	O
in	O
the	O
cardiac	O
muscle	O
in	O
non	O
-	O
coronarogenic	O
myocardial	O
diseases	O
.	O

Note	O
on	O
Slot	O
'	O
s	O
method	O
for	O
the	O
specific	O
determination	O
of	O
creatinine	O
.	O

When	O
the	O
blood	O
clot	O
is	O
formed	O
in	O
the	O
vitreous	O
cavity	O
,	O
intravitreal	O
injection	O
of	O
t	B-protein
-	I-protein
PA	I-protein
can	O
convert	O
plasminogen	B-protein
to	O
plasmin	O
and	O
remove	O
the	O
clot	O
.	O

We	O
report	O
herein	O
the	O
case	O
of	O
a	O
30	O
-	O
year	O
-	O
old	O
man	O
in	O
whom	O
ectopic	O
mediastinal	O
parathyroid	O
adenoma	O
was	O
detected	O
by	O
99mTc	O
-	O
methoxyisobutylisonitrile	O
scintigraphy	O
(	O
99mTc	O
-	O
MIBI	O
)	O
.	O

The	O
distinguishing	O
features	O
involved	O
eight	O
amino	O
acid	O
changes	O
,	O
including	O
a	O
single	O
lysine	O
deletion	O
relative	O
to	O
a	O
primate	O
consensus	O
sequence	O
in	O
the	O
first	O
complementary	O
-	O
determing	O
region	O
of	O
V1J1	B-protein
.	O

We	O
cloned	O
a	O
complete	O
cDNA	O
(	O
2	O
.	O
9	O
kb	O
)	O
for	O
HET	B-protein
from	O
an	O
MCF	O
-	O
7	O
cDNA	O
library	O
.	O

NF	B-protein
-	I-protein
kappaB	I-protein
is	O
a	O
redox	O
-	O
sensitive	O
transcription	O
factor	O
known	O
to	O
be	O
activated	O
by	O
oxidative	O
stress	O
as	O
well	O
as	O
chemical	O
and	O
biological	O
reductants	O
.	O

Many	O
of	O
the	O
important	O
genes	O
associated	O
with	O
G1	O
regulation	O
have	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
proliferation	O
,	O
differentiation	O
and	O
oncogenic	O
transformation	O
and	O
programmed	O
cell	O
death	O
(	O
apoptosis	O
)	O
.	O

Enoxacin	O
appears	O
to	O
be	O
well	O
suited	O
for	O
the	O
treatment	O
of	O
complicated	O
UTI	O
.	O

The	O
primary	O
pancreatic	O
insult	O
seemed	O
to	O
be	O
unaffected	O
by	O
the	O
treatment	O
,	O
because	O
neither	O
the	O
rise	O
in	O
plasma	B-protein
lipase	I-protein
nor	O
the	O
development	O
of	O
ascites	O
or	O
the	O
extension	O
of	O
the	O
pancreatic	O
necrosis	O
were	O
diminished	O
.	O

Detailed	O
analysis	O
of	O
alpha1	B-protein
,	I-protein
3GT	I-protein
transcripts	I-protein
revealed	O
two	O
major	O
alternative	O
splicing	O
patterns	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
(	O
5	O
'	O
-	O
UTR	O
)	O
and	O
evidence	O
for	O
minor	O
splicing	O
activity	O
that	O
occurs	O
in	O
a	O
tissue	O
-	O
specific	O
manner	O
.	O

The	O
segmental	O
and	O
regional	O
projections	O
of	O
the	O
sciatic	O
,	O
tibial	O
and	O
common	O
peroneal	O
nerves	O
to	O
the	O
substantia	O
gelatinosa	O
of	O
the	O
spinal	O
cord	O
in	O
rats	O
-	O
-	O
an	O
experimental	O
study	O
by	O
means	O
of	O
an	O
acid	B-protein
phosphatase	I-protein
(	O
ACP	B-protein
)	O
method	O
.	O

Two	O
closely	O
related	O
variants	O
of	O
Stat5	B-protein
,	O
Stat5a	B-protein
and	O
Stat5b	B-protein
,	O
are	O
encoded	O
by	O
distinct	O
genes	O
.	O

Also	O
,	O
small	O
,	O
sense	O
and	O
antisense	O
approximately	O
22	O
nt	O
RNAs	O
,	O
derived	O
from	O
the	O
satRNA	B-protein
,	O
were	O
associated	O
with	O
the	O
replicating	O
satellite	O
.	O

Induction	O
of	O
both	O
potential	O
transcripts	O
follows	O
heat	O
shock	O
in	O
vivo	O
.	O

Limb	O
allografts	O
in	O
rats	O
immunosuppressed	O
with	O
cyclosporin	O
A	O
.	O

Regulation	O
of	O
myosin	B-protein
phosphatase	I-protein
activity	O
involves	O
changes	O
in	O
subunit	O
interactions	O
,	O
although	O
molecular	O
mechanisms	O
are	O
not	O
defined	O
.	O

However	O
,	O
the	O
history	O
of	O
acute	O
severe	O
complications	O
from	O
otitis	O
media	O
revealed	O
a	O
higher	O
frequency	O
in	O
those	O
individuals	O
with	O
alpha	B-protein
1	I-protein
-	I-protein
antitrypsin	I-protein
deficiency	O
as	O
compared	O
to	O
normals	O
.	O

Unlike	O
P135gag	B-protein
-	I-protein
myb	I-protein
-	I-protein
ets	I-protein
and	O
the	O
Mr	O
75	O
,	O
000	O
translation	O
product	O
of	O
c	B-protein
-	I-protein
myb	I-protein
(	O
P75c	B-protein
-	I-protein
myb	I-protein
)	O
,	O
which	O
are	O
nuclear	O
proteins	O
,	O
P54c	B-protein
-	I-protein
ets	I-protein
was	O
found	O
to	O
be	O
predominantly	O
cytoplasmic	O
.	O

Although	O
differences	O
were	O
not	O
significant	O
,	O
infants	O
in	O
the	O
experimental	O
group	O
had	O
more	O
changes	O
in	O
the	O
intermittent	O
mandatory	O
ventilation	O
(	O
IMV	O
)	O
settings	O
during	O
transport	O
,	O
and	O
more	O
such	O
infants	O
arrived	O
at	O
the	O
receiving	O
hospital	O
with	O
acceptable	O
pH	O
and	O
PCO2	O
values	O
.	O

The	O
priming	O
activity	O
of	O
DNA	O
incised	O
by	O
either	O
of	O
the	O
Drosophila	O
enzymes	O
can	O
be	O
enhanced	O
,	O
however	O
,	O
by	O
an	O
additional	O
incubation	O
with	O
E	B-protein
.	I-protein
coli	I-protein
endonuclease	I-protein
IV	I-protein
,	O
which	O
is	O
known	O
to	O
cleave	O
depurinated	O
DNA	O
on	O
the	O
5	O
'	O
-	O
side	O
of	O
an	O
apurinic	O
site	O
.	O

Subsequently	O
,	O
these	O
coordinates	O
must	O
be	O
interpreted	O
to	O
define	O
particular	O
tissues	O
and	O
organs	O
.	O

To	O
assess	O
the	O
functional	O
importance	O
of	O
these	O
NBS	O
in	O
the	O
overall	O
drug	O
resistance	O
phenotype	O
conferred	O
by	O
mdr1	B-protein
,	O
we	O
introduced	O
amino	O
acid	O
substitutions	O
in	O
the	O
core	O
consensus	O
sequence	O
for	O
nucleotide	O
binding	O
,	O
GXGKST	B-protein
.	O

Excision	O
repair	O
at	O
the	O
level	O
of	O
the	O
nucleotide	O
in	O
the	O
Saccharomyces	B-protein
cerevisiae	I-protein
MFA2	I-protein
gene	I-protein
:	O
mapping	O
of	O
where	O
enhanced	O
repair	O
in	O
the	O
transcribed	O
strand	O
begins	O
or	O
ends	O
and	O
identification	O
of	O
only	O
a	O
partial	O
rad16	B-protein
requisite	O
for	O
repairing	O
upstream	O
control	O
sequences	O
.	O

Behavior	O
of	O
aspartate	B-protein
aminotransferase	I-protein
(	O
EC	B-protein
2	I-protein
.	I-protein
6	I-protein
.	I-protein
1	I-protein
.	I-protein
1	I-protein
)	O
and	O
alanine	B-protein
aminotransferase	I-protein
(	O
EC	B-protein
2	I-protein
.	I-protein
6	I-protein
.	I-protein
1	I-protein
.	I-protein
2	I-protein
)	O
in	O
rat	O
serum	O
during	O
the	O
course	O
of	O
acute	O
radiation	O
syndrome	O
following	O
whole	O
body	O
X	O
-	O
irradiation	O
.	O

NUP145	B-protein
was	O
previously	O
identified	O
by	O
using	O
a	O
genetic	O
synthetic	O
lethal	O
screen	O
(	O
E	O
.	O

However	O
,	O
there	O
is	O
still	O
a	O
subset	O
of	O
tumors	O
that	O
displayed	O
no	O
changes	O
in	O
these	O
genes	O
.	O

Results	O
confirmed	O
that	O
stress	O
produced	O
CA3	O
dendritic	O
atrophy	O
and	O
tianeptine	O
prevented	O
it	O
.	O

This	O
led	O
to	O
the	O
conclusion	O
that	O
the	O
metatarsal	O
artery	O
should	O
be	O
used	O
for	O
toe	O
MP	O
joint	O
grafts	O
,	O
while	O
the	O
unilateral	O
proper	O
digital	O
artery	O
is	O
suitable	O
for	O
toe	O
PIP	O
joint	O
grafts	O
,	O
together	O
with	O
concomitant	O
or	O
dorsal	O
cutaneous	O
vein	O
.	O

Clinical	O
trials	O
with	O
1	O
,	O
3	O
-	O
bis	O
(	O
2	O
-	O
chloroethyl	O
)	O
-	O
1	O
-	O
nitrosourea	O
,	O
NSC	O
-	O
409962	O
.	O

Identity	O
elements	O
in	O
tRNA	B-protein
for	O
mono	O
-	O
and	O
dimethylation	O
reactions	O
by	O
the	O
recombinant	B-protein
pfTrm1p	I-protein
were	O
identified	O
using	O
in	O
vitro	O
T7	O
transcripts	O
of	O
33	O
variants	O
of	O
tRNA	B-protein
(	I-protein
Asp	I-protein
)	I-protein
and	I-protein
tRNA	I-protein
(	I-protein
Phe	I-protein
)	I-protein
from	I-protein
yeast	I-protein
.	O

Results	O
indicate	O
that	O
KNM	O
-	O
LU	O
335	O
differs	O
from	O
both	O
human	O
and	O
chimpanzee	O
M1s	O
in	O
relative	O
distances	O
(	O
measured	O
in	O
three	O
dimensions	O
)	O
between	O
crown	O
fissure	O
termini	O
.	O

We	O
have	O
demonstrated	O
previously	O
that	O
two	O
binding	O
sites	O
in	O
the	O
-	B-protein
184	I-protein
HNF	I-protein
-	I-protein
3	I-protein
beta	I-protein
promoter	I-protein
are	O
recognized	O
by	O
widely	O
distributed	O
factors	O
and	O
that	O
there	O
is	O
also	O
a	O
critical	O
autoregulatory	O
site	O
,	O
we	O
identified	O
a	O
binding	O
site	O
for	O
a	O
cell	O
-	O
specific	O
factor	O
,	O
LF	B-protein
-	I-protein
H3	I-protein
beta	I-protein
,	O
that	O
may	O
function	O
in	O
restricting	O
HNF	B-protein
-	I-protein
3	I-protein
beta	I-protein
gene	I-protein
expression	O
to	O
hepatocytes	O
.	O

Overlapping	O
clones	O
representing	O
full	O
-	O
length	O
cDNAs	O
for	O
MMI	B-protein
alpha	I-protein
were	O
obtained	O
from	O
mouse	O
brain	O
.	O

Since	O
GAGs	O
are	O
the	O
components	O
of	O
cartilage	O
matrix	O
,	O
the	O
depletion	O
of	O
which	O
is	O
associated	O
with	O
osteoarthrosis	O
,	O
a	O
method	O
for	O
measuring	O
sulphated	O
GAG	O
synthesis	O
in	O
culture	O
has	O
been	O
investigated	O
.	O

Chagas	O
'	O
disease	O
,	O
visceral	O
leishmaniasis	O
,	O
anti	B-protein
-	I-protein
nuclear	I-protein
factor	I-protein
,	O
schistosomiasis	O
,	O
rheumatoid	B-protein
factor	I-protein
and	O
normal	O
controls	O
.	O

The	O
bcl	B-protein
-	I-protein
2	I-protein
gene	I-protein
can	O
potentially	O
encode	O
26	O
-	O
and	O
22	O
-	O
kDa	O
proteins	O
that	O
differ	O
only	O
in	O
their	O
carboxyl	O
tails	O
because	O
of	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

We	O
have	O
identified	O
a	O
strong	O
Tas	B-protein
-	I-protein
responsive	I-protein
element	I-protein
,	O
designated	O
TRE	B-protein
(	O
GP	B-protein
)	O
,	O
near	O
the	O
3	O
'	O
end	O
of	O
the	O
gag	B-protein
gene	I-protein
and	O
preceding	O
the	O
pol	B-protein
gene	I-protein
of	O
SFV	O
-	O
1	O
.	O

In	O
gel	O
mobility	O
shift	O
assays	O
,	O
factors	O
present	O
in	O
nuclear	O
extracts	O
derived	O
from	O
differentiated	O
osteoblast	O
bound	O
to	O
oligonucleotide	O
probes	O
containing	O
the	O
E	B-protein
-	I-protein
box	I-protein
1	I-protein
and	O
E	B-protein
-	I-protein
box	I-protein
2	I-protein
elements	I-protein
.	O

Induction	O
of	O
proto	B-protein
-	I-protein
oncogene	I-protein
fos	I-protein
transcription	O
through	O
the	O
adenylate	B-protein
cyclase	I-protein
pathway	I-protein
:	O
characterization	O
of	O
a	O
cAMP	B-protein
-	I-protein
responsive	I-protein
element	I-protein
.	O

We	O
conclude	O
that	O
common	O
upstream	O
signals	O
cause	O
activation	O
of	O
Ras	B-protein
and	O
TC21	B-protein
,	O
but	O
activated	O
TC21	B-protein
controls	O
cell	O
growth	O
via	O
distinct	O
Raf	O
-	O
independent	O
downstream	O
signaling	O
pathways	O
.	O

Our	O
experiments	O
suggest	O
that	O
the	O
SCL	B-protein
gene	I-protein
can	O
be	O
a	O
target	O
for	O
the	O
erythroid	B-protein
transcription	I-protein
factor	I-protein
GATA	I-protein
-	I-protein
1	I-protein
and	O
that	O
the	O
SCL	B-protein
gene	I-protein
product	I-protein
serves	O
as	O
a	O
positive	O
regulator	O
of	O
erythroid	O
differentiation	O
.	O

Because	O
GH	O
-	O
induced	O
Akt	B-protein
activation	O
was	O
completely	O
inhibited	O
in	O
both	O
cells	O
by	O
the	O
same	O
concentration	O
of	O
LY294002	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
wortmannin	O
sensitivity	O
of	O
both	O
the	O
IRS	O
-	O
1	O
-	O
independent	O
and	O
-	O
dependent	O
GH	O
-	O
induced	O
MAP	B-protein
kinase	I-protein
activation	O
may	O
reflect	O
the	O
activity	O
of	O
another	O
wortmannin	O
-	O
sensitive	O
target	O
(	O
s	O
)	O
in	O
addition	O
to	O
PI3K	B-protein
in	O
mediation	O
of	O
GH	O
-	O
induced	O
MAP	B-protein
kinase	I-protein
activation	O
in	O
these	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
Rb	B-protein
protein	I-protein
is	O
interacting	O
with	O
some	O
component	O
(	O
s	O
)	O
of	O
the	O
cell	O
cycle	O
-	O
regulatory	O
machinery	O
during	O
G2	O
phase	O
.	O

The	O
RS447	B-protein
human	I-protein
megasatellite	I-protein
tandem	I-protein
repetitive	I-protein
sequence	I-protein
encodes	O
a	O
novel	O
deubiquitinating	O
enzyme	O
with	O
a	O
functional	O
promoter	O
.	O

There	O
was	O
no	O
correlation	O
between	O
secretor	O
status	O
and	O
clinical	O
status	O
,	O
spirometry	O
measurements	O
,	O
salivary	O
and	O
serum	B-protein
lysozyme	I-protein
levels	O
or	O
rates	O
of	O
respiratory	O
tract	O
colonization	O
with	O
P	O
.	O
aeruginosa	O
and	O
S	O
.	O
aureus	O
.	O

Urine	O
specimens	O
containing	O
either	O
phencyclidine	O
(	O
PCP	O
)	O
or	O
11	O
-	O
nor	O
-	O
delta	O
9	O
-	O
tetrahydrocannabinol	O
-	O
9	O
-	O
carboxylic	O
acid	O
(	O
9	O
-	O
THC	O
-	O
COOH	O
)	O
were	O
adulterated	O
with	O
sodium	O
chloride	O
,	O
bleach	O
,	O
vinegar	O
,	O
potassium	O
hydroxide	O
,	O
liquid	O
soap	O
,	O
2	O
-	O
propanol	O
,	O
and	O
ammonia	O
.	O

We	O
sought	O
to	O
determine	O
whether	O
such	O
differences	O
in	O
polyadenylation	O
affect	O
the	O
steady	O
-	O
state	O
levels	O
of	O
DHFR	B-protein
and	O
mRNAs	O
expressed	O
from	O
either	O
allele	O
and	O
,	O
in	O
a	O
more	O
general	O
sense	O
,	O
to	O
ask	O
whether	O
differences	O
in	O
3	O
'	O
end	O
RNA	O
processing	O
in	O
a	O
gene	O
containing	O
multiple	O
poly	O
(	O
A	O
)	O
sites	O
affects	O
the	O
final	O
level	O
of	O
gene	O
expression	O
.	O

ACTH	B-protein
release	O
is	O
transiently	O
suppressed	O
in	O
some	O
children	O
after	O
exogenous	O
ACTH	B-protein
treatment	O
.	O

In	O
the	O
cell	O
-	O
free	O
import	O
assay	O
,	O
beta	B-protein
-	I-protein
catenin	I-protein
rapidly	O
migrates	O
into	O
the	O
nucleus	O
without	O
the	O
exogenous	O
addition	O
of	O
cytosol	O
,	O
Ran	B-protein
,	O
or	O
ATP	O
/	O
GTP	O
.	O

The	O
protein	O
sequence	O
contains	O
seven	O
potential	O
N	O
-	O
linked	O
glycosylation	O
sites	O
and	O
a	O
threonine	O
/	O
serine	O
-	O
rich	O
region	O
which	O
is	O
a	O
potential	O
site	O
for	O
attachment	O
of	O
O	O
-	O
linked	O
carbohydrate	O
.	O

Inverse	O
relation	O
between	O
serum	O
IgG	B-protein
concentration	O
and	O
glucose	O
and	O
xylose	O
absorption	O
in	O
Zambian	O
African	O
adults	O
.	O

The	O
authors	O
report	O
the	O
results	O
of	O
a	O
series	O
of	O
toxicological	O
tests	O
conducted	O
on	O
plastic	O
materials	O
(	O
polyethylene	O
)	O
activated	O
with	O
tetraphenylbutadiene	O
(	O
TPB	O
)	O
an	O
additive	O
recently	O
proposed	O
as	O
a	O
sensitizer	O
capable	O
of	O
photodegrading	O
plastic	O
materials	O
.	O

The	O
human	B-protein
T	I-protein
cell	I-protein
lymphotropic	I-protein
retrovirus	I-protein
type	I-protein
I	I-protein
(	I-protein
HTLV	I-protein
-	I-protein
I	I-protein
)	I-protein
trans	I-protein
-	I-protein
activator	I-protein
,	O
Tax	B-protein
,	O
interacts	O
specifically	O
with	O
the	O
basic	B-protein
-	I-protein
domain	I-protein
/	I-protein
leucine	I-protein
-	I-protein
zipper	I-protein
(	I-protein
bZip	I-protein
)	I-protein
protein	I-protein
,	O
cAMP	B-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
,	O
bound	O
to	O
the	O
viral	B-protein
Tax	I-protein
-	I-protein
responsive	I-protein
element	I-protein
consisting	O
of	O
three	O
imperfect	O
21	O
-	O
base	O
pair	O
repeats	O
,	O
each	O
with	O
a	O
cAMP	B-protein
response	I-protein
element	I-protein
core	I-protein
flanked	O
by	O
G	O
/	O
C	O
-	O
rich	O
sequences	O
.	O

METHODS	O
:	O
Von	B-protein
Willebrand	I-protein
factor	I-protein
(	O
vWF	B-protein
)	O
and	O
the	O
fibrinolytic	O
factors	O
tissue	B-protein
plasminogen	I-protein
activator	I-protein
(	O
tPA	B-protein
)	O
,	O
measured	O
as	O
tPA	B-protein
capacity	O
,	O
and	O
plasminogen	B-protein
activator	I-protein
inhibitor	I-protein
1	I-protein
(	O
PAI	B-protein
-	I-protein
1	I-protein
)	O
,	O
platelets	O
,	O
fibrinogen	B-protein
,	O
and	O
inflammatory	O
markers	O
were	O
measured	O
in	O
74	O
patients	O
with	O
active	O
seropositive	O
RA	O
.	O

Regressing	O
microaneurysms	O
in	O
5	O
cases	O
of	O
hepatitis	O
B	O
virus	O
related	O
polyarteritis	O
nodosa	O
.	O

Positron	O
emission	O
tomography	O
radioligands	O
for	O
dopamine	B-protein
transporters	I-protein
and	O
studies	O
in	O
human	O
and	O
nonhuman	O
primates	O
.	O

Several	O
cDNAs	O
corresponding	O
to	O
the	O
human	B-protein
PWP2	I-protein
gene	I-protein
were	O
identified	O
and	O
partially	O
sequenced	O
.	O

The	O
primary	O
structure	O
and	O
cotranscription	O
of	O
the	O
petCA	B-protein
genes	I-protein
encoding	O
the	O
Rieske	B-protein
-	I-protein
FeS	I-protein
(	O
nuclear	B-protein
encoded	I-protein
in	I-protein
plants	I-protein
)	O
and	O
apocytochrome	B-protein
f	I-protein
proteins	I-protein
has	O
been	O
described	O
previously	O
(	O
Kallas	O
,	O
T	O
.	O
,	O
Spiller	O
,	O
S	O
.	O
,	O
and	O
Malkin	O
,	O
R	O
.	O

Nonteratogenicity	O
in	O
rats	O
of	O
blighted	O
potatoes	O
and	O
compounds	O
contained	O
in	O
them	O
.	O

Herpes	O
virus	O
infection	O
was	O
characterized	O
by	O
inversion	O
of	O
the	O
T4	O
/	O
T8	O
ratio	O
below	O
1	O
.	O
0	O
(	O
sensitivity	O
90	O
%	O
,	O
specificity	O
88	O
%	O
)	O
,	O
caused	O
by	O
proliferation	O
of	O
the	O
T8	O
subpopulation	O
,	O
which	O
-	O
-	O
compared	O
with	O
the	O
findings	O
in	O
patients	O
with	O
rejection	O
crises	O
-	O
-	O
was	O
significantly	O
raised	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Sequence	O
analysis	O
revealed	O
significant	O
differences	O
between	O
the	O
5	O
'	O
region	O
of	O
the	O
beta	B-protein
subunit	I-protein
gene	I-protein
and	O
the	O
corresponding	O
regions	O
of	O
the	O
homologous	B-protein
GlyR	I-protein
alpha	I-protein
subunit	I-protein
genes	I-protein
;	O
it	O
also	O
identified	O
a	O
novel	O
exon	O
(	O
exon	O
0	O
)	O
that	O
encodes	O
most	O
of	O
the	O
5	O
'	O
-	O
untranslated	O
portion	O
of	O
the	O
GlyR	B-protein
beta	I-protein
mRNA	I-protein
.	O

A	O
study	O
in	O
vivo	O
of	O
adrenergic	B-protein
receptors	I-protein
in	O
the	O
rectum	O
and	O
in	O
the	O
internal	O
and	O
sphincter	O
of	O
the	O
cat	O
.	O

The	O
unfolded	O
protein	O
response	O
regulates	O
multiple	O
aspects	O
of	O
secretory	O
and	O
membrane	O
protein	O
biogenesis	O
and	O
endoplasmic	O
reticulum	O
quality	O
control	O
.	O

Molecular	O
dissection	O
of	O
the	O
multimeric	B-protein
CD3	I-protein
-	I-protein
TCR	I-protein
complex	I-protein
revealed	O
that	O
at	O
least	O
two	O
associated	O
polypeptides	O
,	O
CD3	B-protein
zeta	I-protein
and	O
CD3	B-protein
epsilon	I-protein
,	O
autonomously	O
couple	O
antigenic	O
recognition	O
event	O
to	O
early	O
and	O
late	O
events	O
of	O
the	O
intracytoplasmic	O
activation	O
cascade	O
.	O

Comparison	O
with	O
alkaline	B-protein
phosphatases	I-protein
and	O
5	B-protein
-	I-protein
nucleotidase	I-protein
.	O

The	O
GAC1	B-protein
gene	I-protein
encodes	O
the	O
regulatory	O
subunit	O
for	O
a	O
type	B-protein
1	I-protein
serine	I-protein
/	I-protein
threonine	I-protein
phosphoprotein	I-protein
phosphatase	I-protein
,	O
Glc7	B-protein
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
roles	O
that	O
CCK	B-protein
and	O
trypsin	B-protein
inhibitors	O
are	O
believed	O
to	O
play	O
in	O
the	O
negative	O
feedback	O
control	O
of	O
pancreatic	O
exocrine	O
function	O
.	O

The	O
numerous	O
tests	O
demonstrate	O
that	O
the	O
HDL	O
-	O
2M	O
can	O
be	O
extensively	O
and	O
successfully	O
used	O
for	O
therapy	O
of	O
insulin	O
-	O
dependent	O
diabetes	O
mellitus	O
in	O
clinical	O
practice	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
t	O
(	O
4	O
;	O
14	O
)	O
(	O
p16	O
.	O
3	O
;	O
q32	O
)	O
represents	O
a	O
novel	O
,	O
recurrent	O
chromosomal	O
translocation	O
in	O
MM	O
,	O
and	O
suggest	O
that	O
the	O
FGFR3	B-protein
gene	I-protein
may	O
be	O
the	O
target	O
of	O
this	O
abnormality	O
and	O
thus	O
contribute	O
to	O
tumorigenesis	O
in	O
MM	O
.	O

All	O
injections	O
of	O
CSF	B-protein
were	O
given	O
after	O
the	O
initiation	O
of	O
neutropenia	O
and	O
continued	O
until	O
the	O
occurrence	O
of	O
an	O
absolute	O
neutrophil	O
recovery	O
.	O
rHu	B-protein
GM	I-protein
-	I-protein
CSF	I-protein
and	O
rHu	B-protein
G	I-protein
-	I-protein
CSF	I-protein
,	O
administered	O
once	O
daily	O
at	O
the	O
250	O
microg	O
m	O
(	O
-	O
2	O
)	O
day	O
(	O
-	O
1	O
)	O
and	O
5	O
microg	O
kg	O
(	O
-	O
1	O
)	O
day	O
(	O
-	O
1	O
)	O
level	O
,	O
were	O
effective	O
in	O
increasing	O
the	O
absolute	O
neutrophil	O
count	O
and	O
neutrophil	O
function	O
,	O
as	O
measured	O
by	O
an	O
automated	O
chemiluminescence	O
system	O
.	O

Stringent	O
hybridization	O
of	O
EHS	B-protein
-	I-protein
1	I-protein
back	O
to	O
primate	O
genomic	O
DNA	O
indicates	O
two	O
distinct	O
EHS	B-protein
-	I-protein
1	I-protein
loci	I-protein
in	O
normal	O
human	O
DNA	O
,	O
an	O
identical	O
band	O
pattern	O
in	O
chimpanzee	O
DNA	O
,	O
and	O
a	O
single	O
locus	O
in	O
rhesus	O
monkey	O
DNA	O
.	O

The	O
results	O
suggest	O
that	O
the	O
calcium	O
antagonist	O
,	O
diltiazem	O
,	O
may	O
modify	O
the	O
effects	O
of	O
isoflurane	O
on	O
myocardial	O
function	O
.	O

Twenty	O
eligible	O
patients	O
with	O
cirrhosis	O
were	O
randomized	O
into	O
two	O
groups	O
:	O
10	O
patients	O
treated	O
with	O
6	O
million	O
units	O
of	O
natural	O
IFN	B-protein
-	I-protein
beta	I-protein
twice	O
a	O
week	O
for	O
36	O
months	O
and	O
10	O
patients	O
without	O
IFN	B-protein
therapy	O
.	O

The	O
multidomain	O
structure	O
includes	O
a	O
cysteine	O
-	O
rich	O
motif	O
resembling	O
those	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
n	B-protein
-	I-protein
chimaerin	I-protein
and	O
a	O
putative	O
pleckstrin	B-protein
homology	I-protein
domain	I-protein
.	O

For	O
the	O
sample	O
of	O
systematic	O
reviews	O
drawn	O
from	O
ACP	O
Journal	O
Club	O
(	O
n	O
=	O
103	O
)	O
,	O
the	O
PubMed	O
strategy	O
achieved	O
a	O
sensitivity	O
of	O
97	O
%	O
(	O
CI	O
,	O
91	O
%	O
to	O
99	O
%	O
)	O
.	O

Trypanosoma	O
cruzi	O
.	O

Dangers	O
in	O
use	O
of	O
live	O
-	O
virus	O
vaccines	O
[	O
letter	O
]	O
.	O

Expression	O
plasmids	O
harboring	O
full	O
-	O
length	O
or	O
kinase	O
domain	O
of	O
PKC	B-protein
alpha	I-protein
and	O
PKC	B-protein
delta	I-protein
(	O
PKC	B-protein
alpha	I-protein
K	I-protein
and	O
PKC	B-protein
delta	I-protein
K	I-protein
)	O
were	O
constructed	O
.	O

The	O
major	O
transcription	O
factors	O
controlling	O
arginine	O
metabolism	O
in	O
Escherichia	O
coli	O
and	O
Bacillus	O
subtilis	O
,	O
ArgR	B-protein
and	O
AhrC	B-protein
,	O
respectively	O
,	O
are	O
homologous	O
multimeric	O
proteins	O
that	O
form	O
l	O
-	O
arginine	O
-	O
dependent	O
DNA	O
-	O
binding	O
complexes	O
capable	O
of	O
repressing	O
transcription	O
of	O
the	O
biosynthetic	O
genes	O
(	O
both	O
)	O
,	O
activating	O
transcription	O
of	O
catabolic	O
genes	O
(	O
AhrC	B-protein
only	O
)	O
or	O
facilitating	O
plasmid	O
dimer	O
resolution	O
(	O
both	O
)	O
.	O

On	O
Cox	O
proportional	O
hazards	O
regression	O
adenocarcinoma	O
(	O
P	O
=	O
0	O
.	O
006	O
)	O
,	O
the	O
development	O
of	O
BPF	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
,	O
older	O
age	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
and	O
higher	O
pathological	O
stage	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
were	O
independent	O
adverse	O
predictors	O
of	O
survival	O
.	O

Interestingly	O
,	O
however	O
,	O
it	O
is	O
homologous	O
to	O
several	O
expressed	O
sequence	O
tags	O
(	O
EST	O
)	O
of	O
unknown	O
function	O
from	O
Caenorhabditis	O
elegans	O
,	O
Oryza	O
sativa	O
and	O
Homo	O
sapiens	O
.	O

A	O
poor	O
correlation	O
was	O
also	O
observed	O
between	O
PbB	O
and	O
ALAD	B-protein
activity	O
of	O
the	O
stearate	O
workers	O
.	O

Analysis	O
of	O
several	O
Tat	B-protein
mutants	I-protein
indicated	O
that	O
both	O
the	O
cysteine	O
-	O
rich	O
and	O
the	O
core	O
domains	O
of	O
this	O
transactivator	O
are	O
necessary	O
and	O
sufficient	O
to	O
activate	O
transcription	O
when	O
TBP	B-protein
is	O
overexpressed	O
.	O

These	O
results	O
indicate	O
that	O
both	O
N	O
-	O
and	O
C	O
-	O
terminal	O
mutations	O
are	O
required	O
to	O
inhibit	O
transrepression	O
by	O
FBR	B-protein
protein	I-protein
and	O
that	O
multiple	O
structural	O
mutations	O
accompanied	O
by	O
posttranslational	O
protein	O
modification	O
alter	O
gene	O
regulation	O
by	O
FBR	B-protein
protein	I-protein
.	O

Alveolar	O
growth	O
,	O
contemporary	O
with	O
dental	O
eruption	O
,	O
is	O
sufficient	O
to	O
compensate	O
possible	O
hypotrophy	O
of	O
maxillary	O
bone	O
bases	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
NF	B-protein
-	I-protein
kappaB	I-protein
activity	O
may	O
be	O
regulated	O
by	O
its	O
interaction	O
with	O
the	O
cell	O
cycle	O
regulatory	O
protein	O
,	O
E2F	B-protein
-	I-protein
1	I-protein
.	O

In	O
accordance	O
with	O
clinical	O
improvement	O
we	O
found	O
a	O
decrease	O
of	O
laboratory	O
indicators	O
of	O
inflammation	O
(	O
C	B-protein
-	I-protein
reactive	I-protein
protein	I-protein
,	O
alpha	B-protein
2	I-protein
-	I-protein
globuline	I-protein
,	O
prostaglandin	O
E2	O
)	O
.	O

The	O
PRB	B-protein
-	I-protein
1b	I-protein
gene	I-protein
encodes	O
for	O
a	O
basic	O
-	O
type	O
component	O
of	O
the	O
pathogenesis	O
-	O
related	O
PR	B-protein
-	I-protein
1	I-protein
protein	I-protein
family	I-protein
.	O

Two	O
-	O
dimensional	O
phosphotryptic	O
analyses	O
indicate	O
that	O
phosphorylation	O
on	O
Ser	O
-	O
12	O
and	O
Ser	O
-	O
48	O
in	O
unstimulated	O
cells	O
is	O
associated	O
with	O
the	O
ability	O
of	O
overexpressed	O
pp60c	B-protein
-	I-protein
src	I-protein
to	O
potentiate	O
beta	O
-	O
adrenergic	O
signalling	O
.	O

Methods	O
included	O
24	O
-	O
hour	O
dietary	O
recall	O
,	O
menu	O
weights	O
,	O
and	O
recipe	O
analysis	O
.	O

A	O
2	O
.	O
3	O
-	O
kb	O
full	O
-	O
length	O
cDNA	O
clone	O
of	O
an	O
Atlantic	B-protein
halibut	I-protein
Mx	I-protein
gene	I-protein
was	O
isolated	O
from	O
a	O
liver	O
cDNA	O
library	O
.	O

Mapping	O
the	O
cAMP	B-protein
receptor	I-protein
protein	I-protein
contact	I-protein
site	I-protein
on	O
the	O
alpha	O
subunit	O
of	O
Escherichia	B-protein
coli	I-protein
RNA	I-protein
polymerase	I-protein
.	O

Transforming	B-protein
growth	I-protein
factor	I-protein
(	I-protein
TGF	I-protein
)	I-protein
-	I-protein
beta1	I-protein
induces	O
extracellular	O
matrix	O
deposition	O
and	O
proliferation	O
of	O
mesenchymal	O
cells	O
.	O

Results	O
were	O
supported	O
by	O
the	O
agar	O
diffusion	O
method	O
for	O
Y	O
.	O
enterocolitica	O
,	O
whereas	O
inhibition	O
activity	O
was	O
not	O
found	O
for	O
A	O
.	O
hydrophila	O
.	O

JCAHO	O
revised	O
interpretation	O
.	O

These	O
data	O
suggest	O
that	O
mammalian	O
erythroid	O
alpha	B-protein
-	I-protein
spectrin	I-protein
evolved	O
by	O
duplication	O
and	O
rapid	O
divergence	O
from	O
an	O
ancestral	O
alpha	B-protein
-	I-protein
fodrin	I-protein
-	I-protein
like	I-protein
gene	I-protein
.	O

Immunologically	O
reactive	O
insulin	B-protein
levels	O
were	O
determined	O
in	O
freely	O
-	O
moving	O
normal	O
rats	O
offered	O
three	O
different	O
test	O
-	O
meals	O
.	O

Transcriptional	O
blockade	O
was	O
reversed	O
by	O
co	O
-	O
transfections	O
of	O
a	O
wild	B-protein
-	I-protein
type	I-protein
SRF	I-protein
expression	O
vector	O
,	O
but	O
was	O
not	O
rescued	O
by	O
the	O
expression	O
of	O
other	O
myogenic	O
factors	O
,	O
such	O
as	O
MyoD	B-protein
and	O
Mef	B-protein
-	I-protein
2C	I-protein
.	O

The	O
significance	O
of	O
structural	O
integrity	O
of	O
lymphoid	O
tissue	O
for	O
antibody	O
production	O
in	O
culture	O
in	O
vivo	O
.	O

Losartan	O
Intervention	O
For	O
Endpoint	O
.	O

In	O
the	O
evening	O
,	O
the	O
amplitude	O
of	O
the	O
responses	O
to	O
both	O
O2	O
and	O
CO2	O
increased	O
but	O
the	O
increase	O
in	O
CO2	O
sensitivity	O
was	O
proportionally	O
more	O
important	O
.	O

The	O
lethal	O
toxicity	O
of	O
inorganic	O
(	O
HgCl2	O
)	O
and	O
organic	O
(	O
CH3HgCl	O
)	O
mercury	O
chloride	O
was	O
compared	O
for	O
Coturnix	O
(	O
Japanese	O
quail	O
,	O
Coturnix	O
japonica	O
)	O
of	O
different	O
ages	O
from	O
hatch	O
through	O
adulthood	O
by	O
single	O
-	O
dose	O
acute	O
oral	O
and	O
intramuscular	O
injections	O
and	O
by	O
a	O
5	O
-	O
d	O
dietary	O
trial	O
.	O

Distal	O
tubular	O
acidification	O
and	O
the	O
threshold	O
for	O
proximal	O
tubular	O
bicarbonate	O
reabsorption	O
were	O
normal	O
,	O
as	O
was	O
urine	O
concentrating	O
capacity	O
.	O

Of	O
the	O
patients	O
in	O
each	O
regimen	O
who	O
reached	O
study	O
end	O
points	O
,	O
17	O
of	O
29	O
(	O
59	O
%	O
)	O
were	O
in	O
regimen	O
A	O
,	O
11	O
of	O
20	O
(	O
55	O
%	O
)	O
were	O
in	O
regimen	O
B	O
,	O
and	O
28	O
of	O
43	O
(	O
65	O
%	O
)	O
were	O
in	O
regimen	O
C	O
met	O
the	O
treatment	O
success	O
criterion	O
.	O

The	O
patients	O
who	O
presented	O
with	O
mucocutaneous	O
disease	O
also	O
had	O
low	O
CD4	B-protein
+	I-protein
T	O
lymphocyte	O
counts	O
,	O
and	O
most	O
of	O
them	O
had	O
AIDS	O
defining	O
illnesses	O
.	O

The	O
results	O
indicate	O
that	O
the	O
relationship	O
between	O
comprehension	O
and	O
production	O
is	O
different	O
at	O
different	O
stages	O
in	O
development	O
.	O

C	O
.	O
D2	O
-	O
Chr	O
4	O
congenic	O
strains	O
harboring	O
DBA	B-protein
/	I-protein
2	I-protein
alleles	I-protein
associated	O
with	O
the	O
Pctr1	B-protein
locus	I-protein
contained	O
DBA	B-protein
/	I-protein
2	I-protein
`	I-protein
`	I-protein
resistant	I-protein
'	I-protein
'	I-protein
alleles	I-protein
of	O
the	O
CDK4	B-protein
/	I-protein
CDK6	I-protein
inhibitors	O
p16	B-protein
and	O
p15	B-protein
.	O

Finally	O
,	O
Cas	B-protein
existed	O
mainly	O
in	O
cytosol	O
and	O
membrane	O
cytoskeleton	O
fractions	O
in	O
the	O
resting	O
state	O
,	O
and	O
remained	O
unchanged	O
during	O
platelet	O
aggregation	O
,	O
when	O
FAK	B-protein
translocated	O
to	O
the	O
cytoskeletal	O
fraction	O
.	O

On	O
the	O
basis	O
of	O
serum	B-protein
alpha1AT	I-protein
quantitation	O
,	O
newborn	O
infants	O
may	O
be	O
separated	O
into	O
two	O
groups	O
,	O
characterized	O
respectively	O
by	O
concentrations	O
above	O
or	O
below	O
150	O
mg	O
%	O
.	O

Elimination	O
of	O
bagassosis	O
in	O
Louisiana	O
paper	O
manufacturing	O
plant	O
workers	O
.	O

The	O
present	O
data	O
also	O
suggest	O
that	O
when	O
compared	O
to	O
the	O
systemic	O
vascular	O
bed	O
,	O
the	O
pulmonary	O
vascular	O
bed	O
is	O
less	O
responsive	O
to	O
bolus	O
administration	O
of	O
ET	B-protein
-	I-protein
1	I-protein
.	O

The	O
POEMS	O
syndrome	O
(	O
Polyneuropathy	O
,	O
Organomegaly	O
,	O
Endocrinopathy	O
,	O
Monoclonal	O
component	O
,	O
Skin	O
)	O
.	O

Neuronal	O
mechanisms	O
underlying	O
stimulus	O
-	O
response	O
(	O
S	O
-	O
R	O
)	O
associations	O
in	O
S	O
-	O
R	O
compatibility	O
tasks	O
were	O
identified	O
in	O
2	O
experiments	O
with	O
monkeys	O
.	O

Identification	O
of	O
Ste4	B-protein
as	O
a	O
potential	O
regulator	O
of	O
Byr2	B-protein
in	O
the	O
sexual	O
response	O
pathway	O
of	O
Schizosaccharomyces	O
pombe	O
.	O

After	O
two	O
successive	O
rounds	O
of	O
selection	O
by	O
focus	O
formation	O
assay	O
,	O
a	O
transforming	B-protein
ribozyme	I-protein
(	O
Rz007	B-protein
)	O
was	O
identified	O
.	O

This	O
work	O
unravels	O
a	O
new	O
model	O
for	O
the	O
ets	B-protein
-	I-protein
1	I-protein
/	I-protein
ets	I-protein
-	I-protein
2	I-protein
gene	O
'	O
s	O
evolution	O
,	O
based	O
for	O
the	O
first	O
time	O
on	O
both	O
structural	O
and	O
functional	O
evidences	O
.	O

Molecular	O
cloning	O
and	O
sequencing	O
of	O
a	O
cDNA	O
encoding	O
SR	B-protein
beta	I-protein
revealed	O
that	O
SR	B-protein
beta	I-protein
is	O
a	O
transmembrane	O
protein	O
and	O
,	O
like	O
SR	B-protein
alpha	I-protein
and	O
SRP54	B-protein
,	O
is	O
a	O
member	O
of	O
the	O
GTPase	B-protein
superfamily	I-protein
.	O

The	O
major	O
findings	O
of	O
our	O
studies	O
are	O
as	O
follows	O
:	O
1	O
)	O
There	O
are	O
no	O
detectable	O
signals	O
around	O
GDF	O
-	O
9	O
-	O
deficient	O
follicles	O
for	O
several	O
theca	O
cell	O
layer	O
markers	O
[	O
i	O
.	O
e	O
.	O

W	O
.	O
G	O
.	O

The	O
polyubiquitin	B-protein
gene	I-protein
was	O
transcribed	O
throughout	O
the	O
Volvox	O
life	O
cycle	O
with	O
peaks	O
in	O
the	O
1	O
.	O
6	O
-	O
kb	O
mRNA	O
levels	O
during	O
pre	O
-	O
cleavage	O
,	O
cleavage	O
,	O
and	O
post	O
-	O
inversion	O
.	O

DNase	B-protein
I	I-protein
and	O
1	O
,	O
10	O
-	O
phenanthroline	O
-	O
copper	O
footprinting	O
of	O
MURA	B-protein
-	I-protein
Mu1	I-protein
TIR	I-protein
complexes	I-protein
indicate	O
that	O
MURA	B-protein
binds	O
to	O
a	O
conserved	O
approximately	O
32	O
-	O
bp	O
region	O
in	O
the	O
TIR	B-protein
of	O
Mu1	B-protein
.	O

We	O
and	O
others	O
have	O
demonstrated	O
that	O
the	O
c	B-protein
-	I-protein
cbl	I-protein
proto	I-protein
-	I-protein
oncogene	I-protein
product	I-protein
is	O
one	O
of	O
the	O
earliest	O
targets	O
of	O
tyrosine	O
phosphorylation	O
upon	O
T	B-protein
cell	I-protein
receptor	I-protein
stimulation	O
.	O

Analysis	O
of	O
the	O
DNA	O
from	O
15	O
cases	O
of	O
sporadic	O
and	O
familial	O
Wilms	O
'	O
tumor	O
did	O
not	O
reveal	O
any	O
changes	O
,	O
indicating	O
that	O
the	O
translocation	O
breakpoint	O
does	O
not	O
reside	O
in	O
this	O
gene	O
.	O

The	O
use	O
of	O
specific	O
antibodies	O
allowed	O
the	O
identification	O
of	O
at	O
least	O
RAR	B-protein
beta	I-protein
in	O
some	O
of	O
the	O
DNA	O
-	O
protein	O
complexes	O
,	O
although	O
the	O
four	O
sequences	O
bind	O
single	O
RARs	B-protein
transfected	O
in	O
COS	O
cells	O
much	O
less	O
efficiently	O
,	O
or	O
not	O
at	O
all	O
,	O
when	O
compared	O
to	O
a	O
canonical	O
RAR	B-protein
responsive	I-protein
element	I-protein
.	O

Although	O
increased	O
expression	O
of	O
the	O
HMG	B-protein
-	I-protein
I	I-protein
/	I-protein
Y	I-protein
proteins	I-protein
is	O
associated	O
with	O
cellular	O
proliferation	O
,	O
neoplastic	O
transformation	O
,	O
and	O
several	O
human	O
cancers	O
,	O
the	O
role	O
of	O
these	O
proteins	O
in	O
the	O
pathogenesis	O
of	O
malignancy	O
remains	O
unclear	O
.	O

The	O
hydropathy	O
plot	O
revealed	O
a	O
rather	O
hydrophilic	O
N	O
-	O
terminal	O
region	O
and	O
the	O
absence	O
of	O
a	O
hydrophobic	O
signal	O
peptide	O
.	O

These	O
results	O
demonstrate	O
that	O
sequences	O
in	O
the	O
SH2	B-protein
/	I-protein
SH3	I-protein
/	I-protein
SH2	I-protein
region	I-protein
of	O
p120	B-protein
GAP	I-protein
are	O
required	O
for	O
full	O
catalytic	O
activity	O
toward	O
Ras	B-protein
.	O

The	O
effects	O
of	O
coenzyme	B-protein
Q10	I-protein
(	O
CoQ	B-protein
)	O
and	O
captopril	O
on	O
functional	O
capacity	O
,	O
hemodynamics	O
and	O
survival	O
were	O
studied	O
in	O
154	O
rats	O
that	O
recovered	O
after	O
experimental	O
myocardial	O
infarction	O
.	O

Novel	O
intronic	O
promoter	O
in	O
the	O
rat	B-protein
ER	I-protein
alpha	I-protein
gene	I-protein
responsible	O
for	O
the	O
transient	O
transcription	O
of	O
a	O
variant	O
receptor	O
.	O

In	O
assays	O
with	O
purified	O
enzymes	O
,	O
wild	O
-	O
type	O
but	O
not	O
PTPS	B-protein
-	I-protein
S19A	I-protein
was	O
a	O
specific	O
substrate	O
for	O
the	O
cGMP	B-protein
-	I-protein
dependent	I-protein
protein	I-protein
kinase	I-protein
(	I-protein
cGK	I-protein
)	I-protein
type	I-protein
I	I-protein
and	I-protein
II	O
.	O

A	O
decanucleotide	O
promoter	O
sequence	O
homologous	O
to	O
those	O
found	O
in	O
humans	O
and	O
mice	O
was	O
located	O
in	O
the	O
5	O
'	O
untranslated	O
region	O
of	O
one	O
horse	O
gene	O
.	O

Each	O
of	O
these	O
genes	O
contains	O
a	O
putative	O
upstream	O
ORF	O
,	O
while	O
STA2	B-protein
has	O
two	O
additional	O
in	O
-	O
frame	O
AUG	O
codons	O
5	O
'	O
to	O
the	O
major	O
cistron	O
.	O

BRCA1	B-protein
protein	I-protein
contains	O
an	O
amino	O
-	O
terminal	O
zinc	O
finger	O
motif	O
and	O
a	O
carboxy	O
-	O
terminal	O
acidic	O
region	O
.	O

Eleven	O
patients	O
tested	O
positive	O
for	O
the	O
hepatitis	B-protein
B	I-protein
surface	I-protein
antigen	I-protein
(	O
HBsAg	B-protein
)	O
.	O

Gel	O
-	O
mobility	O
shift	O
analysis	O
was	O
also	O
performed	O
for	O
the	O
CCAAT	O
motif	O
at	O
-	O
67	O
.	O

Hrs	B-protein
has	O
a	O
FYVE	B-protein
double	I-protein
zinc	I-protein
finger	I-protein
domain	I-protein
,	O
which	O
specifically	O
binds	O
phosphatidylinositol	O
(	O
3	O
)	O
-	O
phosphate	O
and	O
is	O
conserved	O
in	O
several	O
proteins	O
involved	O
in	O
vesicular	O
traffic	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
In	O
807	O
consecutive	O
patients	O
from	O
the	O
Chilean	O
National	O
Registry	O
of	O
Acute	O
Myocardial	O
Infarction	O
we	O
analyzed	O
the	O
resolution	O
of	O
chest	O
pain	O
and	O
ST	O
segment	O
elevation	O
over	O
50	O
%	O
within	O
the	O
first	O
90	O
min	O
,	O
abrupt	O
CK	O
rise	O
within	O
8	O
h	O
and	O
T	O
wave	O
inversion	O
in	O
infarct	O
related	O
EKG	O
leads	O
within	O
the	O
first	O
24	O
h	O
after	O
thrombolysis	O
.	O

For	O
each	O
night	O
,	O
the	O
diary	O
allowed	O
the	O
subjective	O
measurement	O
of	O
bedtime	O
,	O
wake	O
time	O
,	O
time	O
in	O
bed	O
(	O
TIB	O
)	O
,	O
sleep	O
efficiency	O
,	O
number	O
of	O
minutes	O
of	O
wake	O
after	O
sleep	O
onset	O
(	O
WASO	O
)	O
,	O
alertness	O
on	O
awakening	O
,	O
and	O
percentage	O
of	O
morning	O
needing	O
an	O
alarm	O
(	O
or	O
a	O
person	O
functioning	O
as	O
one	O
)	O
.	O

Mutational	O
analysis	O
of	O
the	O
L1	B-protein
binding	I-protein
site	I-protein
of	O
23S	B-protein
rRNA	I-protein
in	I-protein
Escherichia	I-protein
coli	I-protein
.	O

Location	O
and	O
orientation	O
of	O
an	O
activating	O
region	O
in	O
the	O
Escherichia	O
coli	O
transcription	O
factor	O
,	O
FNR	B-protein
.	O

(	O
iii	O
)	O
The	O
mRNA	O
is	O
not	O
efficiently	O
polyadenylated	O
at	O
sequences	O
in	O
the	O
3	O
'	O
end	O
of	O
the	O
DHFR	B-protein
cDNA	I-protein
but	O
rather	O
uses	O
polyadenylation	O
signals	O
downstream	O
from	O
the	O
DHFR	B-protein
cDNA	I-protein
.	O

Northern	O
blot	O
analysis	O
with	O
one	O
of	O
the	O
PARNAs	B-protein
revealed	O
a	O
highly	O
abundant	O
signal	O
of	O
approximately	O
2	O
.	O
0	O
kilobases	O
(	O
kb	O
)	O
present	O
in	O
all	O
cell	O
lines	O
tested	O
.	O

Therefore	O
,	O
the	O
impaired	O
floor	O
plate	O
development	O
in	O
oep	B-protein
mutants	I-protein
is	O
not	O
caused	O
by	O
the	O
absence	O
of	O
the	O
floor	B-protein
plate	I-protein
inducer	I-protein
shh	I-protein
.	O

The	O
gene	O
is	O
separated	O
into	O
four	O
exons	O
by	O
three	O
short	O
introns	O
,	O
and	O
the	O
open	O
reading	O
frame	O
consists	O
of	O
6660	O
base	O
pairs	O
(	O
bp	O
)	O
capable	O
of	O
encoding	O
a	O
polypeptide	O
of	O
2220	O
amino	O
acid	O
residues	O
.	O

METHODS	O
:	O
IgG	B-protein
antibodies	I-protein
vs	O
HHV	O
-	O
6	O
(	O
anti	B-protein
-	I-protein
HHV	I-protein
-	I-protein
6	I-protein
-	I-protein
IgG	I-protein
)	O
were	O
determined	O
by	O
indirect	O
immunofluorescence	O
in	O
100	O
IVDA	O
(	O
29	O
seronegative	O
and	O
71	O
seropositive	O
for	O
HIV	O
-	O
1	O
of	O
which	O
45	O
were	O
in	O
stage	O
II	O
and	O
26	O
in	O
IV	O
-	O
C1	O
of	O
CDC	O
)	O
as	O
well	O
as	O
in	O
100	O
healthy	O
subjects	O
of	O
a	O
similar	O
age	O
(	O
control	O
group	O
)	O
.	O

An	O
analysis	O
of	O
sequence	O
of	O
the	O
mutant	B-protein
recN	I-protein
gene	I-protein
revealed	O
a	O
G	O
:	O
C	O
to	O
T	O
:	O
A	O
transversion	O
near	O
the	O
3	O
'	O
end	O
of	O
the	O
coding	O
region	O
.	O

Overexpression	O
of	O
Sed5p	B-protein
allowed	O
growth	O
in	O
the	O
absence	O
of	O
Vti1p	B-protein
.	O

Kodak	O
XV	O
-	O
2	O
film	O
is	O
wrapped	O
around	O
a	O
cylindrical	O
water	O
-	O
filled	O
phantom	O
and	O
the	O
dose	O
distribution	O
is	O
recorded	O
.	O

When	O
two	O
-	O
dimensional	O
polyacrylamide	O
gel	O
electrophoretic	O
patterns	O
of	O
[	O
35S	O
]	O
methionine	O
-	O
labeled	O
proteins	O
secreted	O
from	O
cells	O
infected	O
with	O
parental	O
and	O
recombinant	O
viruses	O
were	O
compared	O
,	O
a	O
spot	O
missing	O
from	O
the	O
latter	O
corresponded	O
in	O
molecular	O
weigh	O
and	O
isoelectric	O
point	O
with	O
that	O
predicted	O
from	O
the	O
N1L	B-protein
ORF	I-protein
.	O

T	O
cells	O
express	O
two	O
isoforms	O
of	O
S6k1	B-protein
:	O
a	O
70	B-protein
kDa	I-protein
cytoplasmic	I-protein
kinase	I-protein
and	O
an	O
85	O
kDa	O
isoform	O
that	O
has	O
a	O
classic	O
nuclear	O
localisation	O
.	O

Western	O
blot	O
analysis	O
showed	O
a	O
rapid	O
corresponding	O
increase	O
in	O
p21WAF1	B-protein
/	I-protein
CIP1	I-protein
protein	I-protein
,	O
whereas	O
protein	O
levels	O
of	O
another	O
member	O
of	O
the	O
cyclin	B-protein
-	I-protein
dependent	I-protein
kinase	I-protein
inhibitor	I-protein
family	I-protein
,	O
p27kip1	B-protein
,	O
were	O
unchanged	O
.	O

Effects	O
of	O
beta	B-protein
-	I-protein
adrenergic	I-protein
receptor	I-protein
blockade	O
on	O
airway	O
conductance	O
and	O
lung	O
volume	O
in	O
normal	O
and	O
asthmatic	O
subjects	O
.	O

Co	O
-	O
transfection	O
of	O
the	O
Sp1	B-protein
expression	O
plasmid	O
and	O
the	O
-	O
58	O
promoter	O
construct	O
into	O
Drosophila	O
Schneider	O
cells	O
revealed	O
that	O
Sp1	B-protein
contributed	O
to	O
the	O
kinase	B-protein
basal	I-protein
promoter	I-protein
activity	O
by	O
binding	O
to	O
the	O
non	O
-	O
consensus	O
site	O
in	O
the	O
-	O
58	O
region	O
.	O

Incidental	O
findings	O
in	O
the	O
epidermis	O
and	O
in	O
the	O
intraepidermal	O
eccrine	O
sweat	O
duct	O
units	O
.	O

Protein	O
sequence	O
analysis	O
reveals	O
that	O
MAN1	B-protein
shares	O
a	O
conserved	O
globular	O
domain	O
of	O
approximately	O
40	O
amino	O
acids	O
,	O
which	O
we	O
term	O
the	O
LEM	B-protein
module	I-protein
,	O
with	O
inner	O
nuclear	O
membrane	O
proteins	O
lamina	B-protein
-	I-protein
associated	I-protein
polypeptide	I-protein
2	I-protein
and	O
emerin	B-protein
.	O

Based	O
on	O
these	O
results	O
and	O
because	O
Cdc68	B-protein
has	O
been	O
implicated	O
as	O
a	O
regulator	O
of	O
chromatin	O
structure	O
,	O
we	O
postulate	O
that	O
polymerase	B-protein
alpha	I-protein
may	O
interact	O
with	O
these	O
proteins	O
to	O
gain	O
access	O
to	O
its	O
template	O
or	O
to	O
origins	O
of	O
replication	O
in	O
vivo	O
.	O

Mutants	O
lacking	O
any	O
tyrosine	O
residues	O
in	O
the	O
cytoplasmic	O
domain	O
maintain	O
their	O
ability	O
to	O
activate	O
STAT5	B-protein
and	O
STAT1	B-protein
but	O
can	O
not	O
activate	O
STAT3	B-protein
,	O
implying	O
that	O
STAT5	B-protein
and	O
STAT1	B-protein
activation	O
does	O
not	O
require	O
receptor	O
tyrosine	O
phosphorylation	O
.	O

Tyrosine	O
112	O
of	O
latent	B-protein
membrane	I-protein
protein	I-protein
2A	I-protein
is	O
essential	O
for	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
loading	O
and	O
regulation	O
of	O
Epstein	O
-	O
Barr	O
virus	O
latency	O
.	O

The	O
status	O
of	O
education	O
and	O
training	O
programs	O
in	O
speech	O
pathology	O
and	O
audiology	O
-	O
-	O
1971	O
-	O
72	O
.	O

Recently	O
,	O
an	O
alternatively	O
spliced	O
form	O
of	O
c	B-protein
-	I-protein
myb	I-protein
-	I-protein
encoded	I-protein
mRNA	I-protein
has	O
been	O
identified	O
in	O
murine	O
cells	O
containing	O
either	O
normal	O
or	O
rearranged	O
c	B-protein
-	I-protein
myb	I-protein
genes	I-protein
.	O

A	O
comparative	O
study	O
was	O
undertaken	O
between	O
an	O
enzymatic	O
immunohistochemical	O
technique	O
(	O
EIT	O
)	O
developed	O
for	O
the	O
diagnosis	O
of	O
human	O
trichinellosis	O
and	O
the	O
indirect	O
immunofluorescence	O
test	O
(	O
IIF	O
)	O
,	O
analysing	O
sera	O
from	O
outbreaks	O
of	O
human	O
trichinellosis	O
in	O
Argentina	O
.	O

Endogenous	O
RMP	B-protein
was	O
immunologically	O
detected	O
interacting	O
with	O
assembled	O
RPB5	B-protein
in	O
RNA	B-protein
polymerase	I-protein
in	O
mammalian	O
cells	O
.	O

Transcriptional	O
activation	O
by	O
thyroid	O
hormone	O
(	O
T3	O
)	O
requires	O
interactions	O
between	O
the	O
T3	B-protein
receptor	I-protein
(	O
TR	B-protein
)	O
and	O
T3	B-protein
response	I-protein
elements	I-protein
(	O
TREs	B-protein
)	O
composed	O
of	O
two	O
copies	O
of	O
sequences	O
related	O
to	O
AGGTCA	B-protein
.	O

Rhizobium	O
meliloti	O
large	O
plasmid	O
pRmeGR4b	O
carries	O
the	O
nodulation	O
competitiveness	O
locus	O
nfe	B-protein
responsible	O
for	O
the	O
nodulation	O
efficiency	O
and	O
competitive	O
ability	O
of	O
strain	O
GR4	O
on	O
alfalfa	O
roots	O
.	O

Sp1	B-protein
binds	O
the	O
CTC	O
repeat	O
with	O
an	O
affinity	O
,	O
KD	O
=	O
0	O
.	O
37	O
nM	O
,	O
at	O
least	O
as	O
high	O
as	O
the	O
consensus	O
GC	O
box	O
.	O

Clinical	O
aspects	O
of	O
early	O
increase	O
in	O
serum	O
gamma	B-protein
-	I-protein
glutamyl	I-protein
transferase	I-protein
in	O
cerebral	O
infarction	O
.	O

However	O
,	O
bilateral	O
diffuse	O
pulmonary	O
infiltrations	O
developed	O
21	O
days	O
later	O
.	O

The	O
physical	O
linkage	O
of	O
the	O
FHR2	B-protein
and	O
the	O
factor	B-protein
H	I-protein
genes	I-protein
provides	O
additional	O
evidence	O
for	O
a	O
close	O
relatedness	O
of	O
complement	B-protein
factor	I-protein
H	I-protein
and	O
the	O
factor	B-protein
H	I-protein
-	I-protein
related	I-protein
proteins	I-protein
.	O

Protein	B-protein
kinase	I-protein
A	I-protein
-	I-protein
Ialpha	I-protein
subunit	O
-	O
directed	O
antisense	O
inhibition	O
of	O
ovarian	O
cancer	O
cell	O
growth	O
:	O
crosstalk	O
with	O
tyrosine	B-protein
kinase	I-protein
signaling	O
pathway	O
.	O

BiP670	B-protein
retains	O
basal	O
and	O
Ca2	O
+	O
ionophore	O
A23187	O
-	O
inducible	O
activities	O
.	O

This	O
is	O
in	O
contrast	O
to	O
PPARgamma2	B-protein
,	O
which	O
was	O
previously	O
shown	O
to	O
be	O
phosphorylated	O
at	O
a	O
single	O
site	O
in	O
a	O
motif	O
that	O
is	O
not	O
homologous	O
to	O
the	O
sites	O
now	O
described	O
in	O
PPARalpha	B-protein
.	O

Also	O
,	O
the	O
EWS	B-protein
protein	I-protein
stimulates	O
transcription	O
mediated	O
by	O
the	O
COOH	O
-	O
terminal	O
transactivation	O
domain	O
of	O
the	O
cofactor	O
CREB	B-protein
-	I-protein
binding	I-protein
protein	I-protein
(	O
CBP	B-protein
)	O
.	O

This	O
is	O
the	O
first	O
study	O
in	O
which	O
mutation	O
screening	O
has	O
been	O
performed	O
for	O
both	O
the	O
EXT1	B-protein
and	O
EXT2	B-protein
genes	I-protein
prior	O
to	O
any	O
linkage	O
analysis	O
.	O

In	O
a	O
stepwise	O
logistic	O
regression	O
analysis	O
of	O
SPT	O
and	O
RAST	O
data	O
,	O
the	O
occurrence	O
of	O
serum	B-protein
IgE	I-protein
antibodies	I-protein
to	I-protein
P	I-protein
.	I-protein
orbiculare	I-protein
had	O
the	O
highest	O
explanatory	O
value	O
for	O
current	O
eczema	O
.	O

Group	O
I	O
consisted	O
of	O
six	O
noncholestatic	O
patients	O
;	O
group	O
II	O
consisted	O
of	O
nine	O
mildly	O
cholestatic	O
patients	O
with	O
mild	O
hepatic	O
impairment	O
(	O
conjugated	O
bilirubin	O
,	O
47	O
mumol	O
liter	O
-	O
1	O
;	O
alkaline	B-protein
phosphatase	I-protein
,	O
280	O
IU	O
liter	O
-	O
1	O
;	O
gamma	B-protein
-	I-protein
glutamyltranspeptidase	I-protein
,	O
190	O
IU	O
liter	O
-	O
1	O
)	O
;	O
group	O
III	O
consisted	O
of	O
six	O
benign	O
intrahepatic	O
cholestatic	O
patients	O
with	O
high	O
isolated	O
conjugated	O
hyperbilirubinemia	O
(	O
98	O
.	O
1	O
mumol	O
liter	O
-	O
1	O
)	O
.	O

To	O
understand	O
the	O
function	O
of	O
receptor	B-protein
-	I-protein
linked	I-protein
tyrosine	I-protein
phosphatases	I-protein
in	O
neural	O
development	O
,	O
we	O
sought	O
to	O
identify	O
LAR	B-protein
isoforms	I-protein
preferentially	O
expressed	O
in	O
the	O
nervous	O
system	O
and	O
cellular	O
processes	O
regulating	O
LAR	B-protein
alternative	O
splicing	O
.	O

There	O
was	O
a	O
positive	O
correlation	O
between	O
pyridinium	O
cross	O
-	O
link	O
excretion	O
and	O
thyroid	O
hormone	O
concentrations	O
.	O

An	O
analysis	O
of	O
the	O
steady	O
state	O
RNA	O
levels	O
in	O
T	O
-	O
lymphoid	O
cell	O
lines	O
showed	O
that	O
at	O
least	O
three	O
different	O
incomplete	O
proviral	O
transcripts	O
and	O
their	O
spliced	O
products	O
made	O
up	O
the	O
majority	O
of	O
expressed	O
RD	B-protein
-	I-protein
114	I-protein
mRNA	I-protein
,	O
and	O
further	O
demonstrated	O
that	O
partially	O
deleted	O
proviral	O
loci	O
have	O
the	O
potential	O
to	O
be	O
transcriptionally	O
vigorous	O
in	O
certain	O
feline	O
cell	O
types	O
.	O

The	O
ATR	O
-	O
X	O
syndrome	O
results	O
from	O
mutations	O
of	O
the	O
XH2	B-protein
gene	I-protein
,	O
located	O
on	O
the	O
X	O
chromosome	O
(	O
Xq13	O
.	O
3	O
)	O
and	O
coding	O
for	O
a	O
transacting	O
factor	O
which	O
regulates	O
gene	O
expression	O
.	O

These	O
data	O
establish	O
Smd1p	B-protein
as	O
a	O
required	O
component	O
of	O
the	O
cellular	O
splicing	O
apparatus	O
and	O
a	O
factor	O
in	O
snRNA	O
maturation	O
and	O
stability	O
.	O

Erratum	O
to	O
:	O
corticostriatal	O
and	O
corticosubthalamic	O
input	O
zones	O
from	O
the	O
presupplementary	O
motor	O
area	O
in	O
the	O
macaque	O
monkey	O
:	O
comparison	O
with	O
the	O
input	O
zones	O
from	O
the	O
supplementary	O
motor	O
area	O
.	O

Their	O
use	O
resulted	O
in	O
a	O
sensitivity	O
of	O
73	O
%	O
and	O
a	O
specificity	O
of	O
74	O
%	O
with	O
regard	O
to	O
predictability	O
of	O
ALT	B-protein
levels	O
increasing	O
during	O
the	O
trial	O
.	O

It	O
contains	O
25	O
exons	O
coding	O
for	O
a	O
4	O
.	O
7kb	O
transcript	O
including	O
large	O
5	O
'	O
-	O
and	O
3	O
'	O
-	O
(	O
1218bp	O
and	O
701bp	O
,	O
respectively	O
)	O
untranslated	O
regions	O
(	O
UTRs	O
)	O
.	O

These	O
results	O
were	O
corroborated	O
in	O
a	O
subsequent	O
study	O
in	O
which	O
30	O
hypogonadal	O
men	O
were	O
supplemented	O
with	O
SLT	O
5	O
mg	O
three	O
times	O
daily	O
for	O
6	O
months	O
.	O

We	O
demonstrate	O
here	O
that	O
the	O
-	B-protein
DEDDDL	I-protein
sequence	I-protein
stabilizes	O
GDP	O
binding	O
to	O
Ran	B-protein
,	O
and	O
that	O
the	O
domain	O
is	O
required	O
for	O
high	O
affinity	O
interaction	O
with	O
a	O
Ran	B-protein
-	I-protein
binding	I-protein
protein	I-protein
,	O
HTF9A	B-protein
/	I-protein
RanBP1	I-protein
.	O

We	O
conclude	O
that	O
c	B-protein
-	I-protein
Abl	I-protein
activates	O
c	B-protein
-	I-protein
myc	I-protein
transcription	O
indirectly	O
with	O
no	O
requirement	O
for	O
DNA	O
binding	O
by	O
c	B-protein
-	I-protein
Abl	I-protein
.	O

Differential	O
regulation	O
of	O
the	O
pre	O
-	O
C	O
and	O
pregenomic	O
promoters	O
of	O
human	O
hepatitis	O
B	O
virus	O
by	O
members	O
of	O
the	O
nuclear	B-protein
receptor	I-protein
superfamily	I-protein
.	O

Multiple	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
signaling	O
pathways	O
connect	O
the	O
cot	B-protein
oncoprotein	I-protein
to	O
the	O
c	B-protein
-	I-protein
jun	I-protein
promoter	I-protein
and	O
to	O
cellular	O
transformation	O
.	O

Inspection	O
of	O
enhancer	O
mutants	O
suggests	O
that	O
trans	O
-	O
activation	O
by	O
hLEF	B-protein
/	I-protein
GAL4	I-protein
is	O
especially	O
dependent	O
on	O
TCF	B-protein
-	I-protein
2	I-protein
,	O
a	O
distinct	O
T	O
-	O
cell	O
-	O
enriched	O
protein	O
that	O
binds	O
to	O
sequences	O
flanking	O
the	O
hLEF	B-protein
-	I-protein
binding	I-protein
site	I-protein
in	O
the	O
enhancer	O
.	O

Mapping	O
features	O
of	O
HIV	B-protein
-	I-protein
1	I-protein
integrase	I-protein
near	O
selected	O
sites	O
on	O
viral	O
and	O
target	O
DNA	O
molecules	O
in	O
an	O
active	O
enzyme	O
-	O
DNA	O
complex	O
by	O
photo	O
-	O
cross	O
-	O
linking	O
.	O

Surprisingly	O
,	O
calf	B-protein
thymus	I-protein
CstF	I-protein
contained	O
an	O
additional	O
,	O
novel	O
form	O
of	O
the	O
64	O
-	O
kDa	O
subunit	O
with	O
a	O
molecular	O
mass	O
of	O
70	O
kDa	O
.	O

In	O
vitro	O
DNase	B-protein
I	I-protein
footprinting	O
showed	O
that	O
OxyR	B-protein
-	I-protein
C199S	I-protein
protected	O
Pmom	B-protein
from	O
-	O
104	O
to	O
-	O
46	O
on	O
the	O
top	O
strand	O
and	O
produced	O
a	O
protection	O
pattern	O
characteristic	O
of	O
reduced	B-protein
wild	I-protein
-	I-protein
type	I-protein
OxyR	I-protein
.	O

Growth	B-protein
factors	I-protein
induce	O
the	O
expression	O
of	O
the	O
immediate	B-protein
early	I-protein
gene	I-protein
products	I-protein
MAP	I-protein
kinase	I-protein
phosphatase	I-protein
-	I-protein
1	I-protein
(	O
MKP	B-protein
-	I-protein
1	I-protein
)	O
,	O
c	B-protein
-	I-protein
Fos	I-protein
and	O
c	B-protein
-	I-protein
Jun	I-protein
.	O

There	O
are	O
regions	O
with	O
long	O
runs	O
of	O
up	O
to	O
45	O
%	O
C	O
or	O
35	O
%	O
G	O
residues	O
.	O

7	O
.	O

The	O
corresponding	O
inhibition	O
of	O
acid	B-protein
phosphatase	I-protein
activity	O
in	O
control	O
male	O
and	O
female	O
guinea	O
pigs	O
was	O
15	O
.	O
91	O
%	O
and	O
20	O
.	O
33	O
%	O
respectively	O
.	O

It	O
also	O
contains	O
a	O
picornaviral	B-protein
3C	I-protein
-	I-protein
like	I-protein
protease	I-protein
domain	I-protein
and	O
two	O
papain	B-protein
-	I-protein
like	I-protein
protease	I-protein
domains	I-protein
.	O

It	O
is	O
concluded	O
that	O
stereotypy	O
can	O
be	O
evoked	O
also	O
in	O
the	O
case	O
when	O
the	O
striatal	O
dopaminergic	O
tone	O
is	O
normal	O
or	O
even	O
below	O
normal	O
:	O
it	O
is	O
the	O
equilibrium	O
of	O
the	O
striatal	O
cholinergic	O
-	O
dopaminergic	O
systems	O
which	O
must	O
be	O
shifted	O
towards	O
dopamine	O
,	O
which	O
is	O
necessary	O
for	O
the	O
development	O
of	O
this	O
behavioral	O
manifestation	O
.	O

All	O
other	O
normal	O
and	O
transformed	O
lymphoid	O
and	O
nonlymphoid	O
cell	O
lines	O
and	O
normal	O
tissues	O
were	O
negative	O
for	O
PANG	B-protein
expression	O
except	O
for	O
the	O
brain	O
,	O
wherein	O
unique	O
4	O
.	O
0	O
-	O
and	O
6	O
.	O
1	O
-	O
kb	O
transcripts	O
were	O
detected	O
.	O

The	O
main	O
aim	O
of	O
the	O
contribution	O
,	O
which	O
opens	O
an	O
arena	O
for	O
discussion	O
on	O
the	O
Rivista	O
dell	O
'	O
Infermiere	O
is	O
to	O
critically	O
appraise	O
published	O
research	O
works	O
focusing	O
both	O
on	O
strengths	O
and	O
novelty	O
and	O
weaknesses	O
in	O
the	O
hypothesis	O
formulation	O
,	O
methods	O
and	O
instruments	O
used	O
,	O
discussion	O
of	O
results	O
.	O

The	O
result	O
suggests	O
that	O
this	O
non	O
-	O
invasive	O
TTD	O
method	O
is	O
easily	O
available	O
and	O
useful	O
in	O
monitoring	O
the	O
intraoperative	O
cardiac	O
output	O
.	O

The	O
HGF	O
-	O
induced	O
cell	O
motility	O
was	O
mimicked	O
by	O
12	O
-	O
0	O
-	O
tetradecanoyl	O
-	O
phorbol	O
-	O
13	O
-	O
acetate	O
,	O
a	O
protein	B-protein
kinase	I-protein
C	O
-	O
activating	O
phorbol	O
ester	O
,	O
but	O
not	O
by	O
Ca2	O
+	O
ionophore	O
.	O

These	O
results	O
demonstrate	O
that	O
a	O
class	O
of	O
proline	O
-	O
rich	O
activator	O
proteins	O
and	O
RNA	B-protein
polymerase	I-protein
II	I-protein
possess	O
a	O
common	O
structural	O
and	O
functional	O
component	O
which	O
can	O
interact	O
with	O
the	O
same	O
target	O
in	O
the	O
general	O
transcription	O
machinery	O
.	O

Another	O
mutant	O
,	O
T255A	O
,	O
lost	O
the	O
ability	O
to	O
bind	O
E4orf6	B-protein
,	O
but	O
unexpectedly	O
,	O
viral	O
late	O
-	O
gene	O
expression	O
was	O
not	O
affected	O
.	O

In	O
addition	O
,	O
they	O
display	O
common	O
features	O
that	O
make	O
them	O
strikingly	O
related	O
to	O
snoRNA	B-protein
U14	I-protein
.	O

The	O
second	O
class	O
of	O
cDNA	O
hybridized	O
to	O
a	O
13	O
kb	O
transcript	O
,	O
which	O
was	O
approximately	O
twice	O
as	O
large	O
as	O
the	O
mammalian	B-protein
lactase	I-protein
mRNA	I-protein
.	O

Five	O
modalities	O
of	O
nonpharmacologic	O
approaches	O
are	O
recommended	O
at	O
present	O
for	O
lifestyle	O
modification	O
and	O
control	O
of	O
arterial	O
blood	O
pressure	O
elevation	O
:	O
1	O
)	O
weight	O
reduction	O
to	O
ideal	O
body	O
weight	O
,	O
since	O
it	O
reduces	O
risk	O
of	O
hypertension	O
as	O
well	O
as	O
overall	O
cardiovascular	O
morbidity	O
and	O
mortality	O
;	O
2	O
)	O
dietary	O
sodium	O
restriction	O
to	O
less	O
than	O
2	O
g	O
a	O
day	O
,	O
without	O
assurance	O
that	O
it	O
will	O
normalize	O
arterial	O
pressure	O
although	O
it	O
may	O
help	O
reduce	O
dosage	O
and	O
numbers	O
of	O
prescribed	O
antihypertensive	O
drugs	O
;	O
3	O
)	O
moderation	O
of	O
alcohol	O
consumption	O
to	O
less	O
than	O
1	O
ounce	O
a	O
day	O
;	O
4	O
)	O
a	O
regular	O
isotonic	O
exercise	O
program	O
;	O
and	O
5	O
)	O
cessation	O
of	O
tobacco	O
consumption	O
.	O

Deletion	O
mapping	O
of	O
the	O
human	B-protein
presenilin	I-protein
-	I-protein
1	I-protein
(	O
PS1	B-protein
)	O
promoter	O
delineated	O
the	O
most	O
active	O
fragment	O
from	O
-	O
118	O
to	O
+	O
178	O
in	O
relation	O
to	O
the	O
transcription	O
start	O
site	O
mapped	O
in	O
this	O
study	O
,	O
in	O
both	O
human	O
neuroblastoma	O
SK	O
-	O
N	O
-	O
SH	O
and	O
hepatoma	O
HepG2	O
cells	O
.	O

Ariga	O
,	O
Biochem	O
.	O

The	O
feed	O
given	O
to	O
young	O
broiler	O
chickens	O
was	O
contaminated	O
artificially	O
with	O
Salmonella	O
kedougou	O
,	O
a	O
serotype	O
associated	O
with	O
both	O
subclinical	O
infections	O
in	O
commercially	O
reared	O
chickens	O
and	O
food	O
poisoning	O
in	O
humans	O
.	O

Src	B-protein
homology	I-protein
(	O
SH	B-protein
)	O
domain	O
dependent	O
protein	O
-	O
protein	O
interactions	O
are	O
important	O
to	O
tyrosine	B-protein
kinase	I-protein
receptor	I-protein
signal	O
transduction	O
.	O

It	O
suggests	O
a	O
sequence	O
of	O
surgical	O
planning	O
that	O
can	O
prevent	O
them	O
and	O
also	O
offers	O
ways	O
of	O
dealing	O
with	O
the	O
problems	O
should	O
they	O
occur	O
.	O

To	O
gain	O
insight	O
into	O
the	O
possible	O
involvement	O
of	O
p21	B-protein
in	O
liver	O
cell	O
growth	O
,	O
the	O
expression	O
and	O
regulation	O
of	O
the	O
p21	B-protein
gene	I-protein
was	O
evaluated	O
in	O
rodent	O
models	O
of	O
liver	O
regeneration	O
and	O
specimens	O
of	O
human	O
liver	O
diseases	O
.	O

In	O
a	O
randomised	O
double	O
-	O
blind	O
study	O
,	O
46	O
first	O
episode	O
schizophrenics	O
were	O
given	O
pimozide	O
or	O
flupenthixol	O
for	O
up	O
to	O
5	O
weeks	O
;	O
the	O
mean	O
daily	O
dose	O
at	O
the	O
end	O
was	O
18	O
.	O
8	O
mg	O
pimozide	O
and	O
20	O
mg	O
flupenthixol	O
.	O

A	O
limited	O
study	O
in	O
a	O
glassware	O
factory	O
(	O
As2O3	O
exposure	O
)	O
involving	O
the	O
measurement	O
of	O
total	O
airborne	O
arsenic	O
,	O
the	O
determination	O
of	O
urinary	O
arsenic	O
,	O
and	O
the	O
evaluation	O
of	O
hand	O
and	O
mouth	O
contamination	O
by	O
arsenic	O
before	O
and	O
after	O
the	O
workshift	O
suggests	O
that	O
the	O
high	O
urinary	O
arsenic	O
levels	O
(	O
300	O
microgram	O
/	O
g	O
creatinine	O
)	O
are	O
likely	O
to	O
be	O
more	O
related	O
to	O
an	O
increased	O
oral	O
intake	O
from	O
contaminated	O
hands	O
than	O
to	O
an	O
increased	O
absorption	O
from	O
the	O
lungs	O
.	O

A	O
central	O
finding	O
is	O
the	O
identification	O
of	O
a	O
GC	O
-	O
rich	O
sequence	O
in	O
the	O
-	O
99	O
/	O
-	O
91	O
Cp	O
region	O
that	O
is	O
essential	O
for	O
oriPI	O
-	O
EBNA1	O
-	O
independent	O
as	O
well	O
as	O
oriPI	O
-	O
EBNA1	O
-	O
dependent	O
activity	O
of	O
the	O
promoter	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
cyclin	B-protein
E	I-protein
,	O
in	O
contrast	O
to	O
cyclin	B-protein
D1	I-protein
,	O
was	O
required	O
for	O
the	O
G1	O
/	O
S	O
transition	O
even	O
in	O
cells	O
lacking	O
retinoblastoma	B-protein
protein	I-protein
function	O
.	O

In	O
patients	O
resistant	O
to	O
VAD	O
,	O
high	O
-	O
dose	O
therapies	O
with	O
intravenous	O
melphalan	O
,	O
a	O
CBV	O
combination	O
(	O
cyclophosphamide	O
-	O
BCNU	O
-	O
VP	O
-	O
16	O
)	O
or	O
an	O
EDAP	O
regimen	O
(	O
VP	O
-	O
16	O
-	O
platinum	O
)	O
produced	O
responses	O
in	O
about	O
40	O
%	O
of	O
patients	O
.	O

Whereas	O
p82	B-protein
expression	O
had	O
no	O
effect	O
on	O
ERK2	B-protein
activation	O
by	O
p126	B-protein
,	O
p70	B-protein
completely	O
abrogated	O
this	O
activity	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
competition	O
experiments	O
showed	O
that	O
site	O
A	O
is	O
recognized	O
by	O
an	O
NF1	B-protein
protein	I-protein
.	O

Drosophila	B-protein
orthodenticle	I-protein
(	O
otd	B-protein
)	O
and	O
murine	B-protein
Otx	I-protein
genes	I-protein
exemplify	O
this	O
,	O
both	O
in	O
terms	O
of	O
expression	O
patterns	O
and	O
mutant	O
phenotypes	O
.	O

The	O
ARG	B-protein
SH2	I-protein
domain	I-protein
exhibited	O
relatively	O
weak	O
affinity	O
for	O
BCR	B-protein
and	O
was	O
determined	O
to	O
bind	O
about	O
10	O
-	O
fold	O
less	O
strongly	O
than	O
the	O
ABL	B-protein
SH2	I-protein
domain	I-protein
.	O

At	O
an	O
ambient	O
temperature	O
of	O
25	O
degrees	O
C	O
,	O
the	O
responses	O
to	O
spinal	O
cooling	O
are	O
reduced	O
during	O
the	O
dark	O
phase	O
.	O

Liver	O
TG	O
and	O
serum	O
NEFA	O
concentrations	O
were	O
positively	O
correlated	O
.	O

We	O
show	O
that	O
HRI	B-protein
and	O
dsRNA	B-protein
-	I-protein
PK	I-protein
phosphorylate	O
yeast	B-protein
eIF	I-protein
-	I-protein
2	I-protein
alpha	I-protein
in	O
vitro	O
and	O
in	O
vivo	O
and	O
functionally	O
substitute	O
for	O
GCN2	B-protein
protein	I-protein
to	O
stimulate	O
GCN4	B-protein
translation	O
in	O
yeast	O
.	O

Two	O
soybean	O
cDNA	O
clones	O
,	O
SPK	B-protein
-	I-protein
3	I-protein
and	O
SPK	B-protein
-	I-protein
4	I-protein
,	O
encoding	O
putative	O
protein	B-protein
kinases	I-protein
were	O
isolated	O
and	O
characterized	O
.	O

At	O
60	O
days	O
the	O
amount	O
of	O
gangliosides	O
was	O
on	O
average	O
lower	O
in	O
females	O
than	O
in	O
males	O
,	O
even	O
if	O
with	O
some	O
exception	O
.	O

Eleven	O
strains	O
of	O
Fusarium	O
poae	O
and	O
F	O
.	O
sporotrichioides	O
from	O
the	O
U	O
.	O
S	O
.	O
S	O
.	O
R	O
.	O
and	O
7	O
strains	O
of	O
these	O
species	O
and	O
one	O
of	O
F	O
.	O
sporotrichioides	O
var	O
.	O
tricinctum	O
from	O
U	O
.	O
S	O
.	O
A	O
.	O
and	O
France	O
have	O
been	O
compared	O
as	O
to	O
their	O
capacity	O
to	O
yield	O
T	B-protein
-	I-protein
2	I-protein
toxin	I-protein
.	O

In	O
a	O
randomized	O
double	O
-	O
blind	O
cross	O
-	O
over	O
study	O
,	O
the	O
subjects	O
received	O
theophylline	O
5	O
mg	O
.	O
kg	O
-	O
1	O
per	O
day	O
with	O
omeprazole	O
20	O
mg	O
per	O
day	O
or	O
identical	O
placebo	O
during	O
two	O
periods	O
,	O
each	O
of	O
7	O
days	O
,	O
separated	O
by	O
a	O
washout	O
period	O
of	O
7	O
days	O
.	O

This	O
conclusion	O
was	O
confirmed	O
by	O
Northern	O
blotting	O
analysis	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
CAD	B-protein
gene	I-protein
.	O

The	O
ARF	B-protein
promoter	I-protein
was	O
also	O
found	O
to	O
be	O
highly	O
responsive	O
to	O
E2F1	B-protein
expression	O
,	O
in	O
keeping	O
with	O
previous	O
results	O
at	O
the	O
RNA	O
level	O
.	O

Radiation	O
therapy	O
was	O
effective	O
in	O
controlling	O
symptomatic	O
metastasis	O
in	O
all	O
three	O
patients	O
.	O

Further	O
analysis	O
of	O
this	O
DNA	O
fragment	O
showed	O
that	O
four	O
genes	O
are	O
present	O
encoding	O
proteins	O
of	O
16	O
,	O
18	O
.	O
5	O
,	O
21	O
and	O
89	O
kDal	O
.	O

Since	O
the	O
integrated	O
13h00	O
-	O
16h00	O
plasma	O
cortisol	O
estimation	O
is	O
cheaper	O
and	O
simpler	O
than	O
the	O
mean	O
13h00	O
-	O
16h00	O
plasma	O
cortisol	O
estimation	O
,	O
we	O
recommend	O
it	O
as	O
an	O
adjunct	O
in	O
the	O
diagnosis	O
of	O
Cushing	O
'	O
s	O
syndrome	O
.	O

Using	O
an	O
interspecific	O
backcross	O
panel	O
,	O
we	O
localized	O
both	O
Gng3	B-protein
and	O
Gng3lg	B-protein
to	O
the	O
same	O
locus	O
on	O
chromosome	O
19	O
.	O

An	O
ELISA	O
procedure	O
was	O
developed	O
for	O
monitoring	O
the	O
specific	O
IgE	B-protein
response	O
in	O
dogs	O
to	O
Dirofilaria	O
immitis	O
infection	O
.	O

The	O
malignity	O
of	O
nevoid	O
lentigo	O
.	O

In	O
adherent	O
macrophages	O
,	O
absence	O
of	O
CD45	B-protein
led	O
to	O
the	O
hyperphosphorylation	O
and	O
hyperactivation	O
of	O
p56	B-protein
/	I-protein
59	I-protein
(	I-protein
hck	I-protein
)	I-protein
and	O
p53	B-protein
/	I-protein
56	I-protein
(	I-protein
lyn	I-protein
)	I-protein
,	O
but	O
not	O
of	O
p58	B-protein
(	I-protein
c	I-protein
-	I-protein
fgr	I-protein
)	I-protein
.	O

Additionally	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
,	O
but	O
not	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
also	O
prevented	O
the	O
binding	O
of	O
Rel	B-protein
to	O
the	O
kappa	B-protein
B	I-protein
site	I-protein
.	O

Exploratory	O
-	O
motor	O
task	O
to	O
evaluate	O
right	O
frontal	O
lobe	O
damage	O
.	O

Study	O
of	O
the	O
alterations	O
of	O
intestinal	O
absorption	O
,	O
by	O
means	O
of	O
I	O
-	O
131	O
-	O
triolein	O
,	O
in	O
the	O
whole	O
body	O
irradiated	O
rat	O
.	O

Cortisone	O
induced	O
bone	O
changes	O
and	O
its	O
response	O
to	O
lipid	O
clearing	O
agents	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
reliable	O
and	O
culturally	O
meaningful	O
exercise	O
self	O
-	O
efficacy	O
questionnaire	O
for	O
older	O
Mexican	O
American	O
women	O
.	O

However	O
,	O
in	O
the	O
subgroup	O
with	O
normal	O
Ht	O
(	O
<	O
0	O
.	O
45	O
l	O
/	O
l	O
;	O
n	O
=	O
201	O
)	O
there	O
was	O
a	O
significant	O
reduction	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
of	O
the	O
mortality	O
after	O
3	O
months	O
(	O
27	O
%	O
and	O
16	O
%	O
,	O
respectively	O
)	O
and	O
an	O
increase	O
of	O
independence	O
at	O
home	O
(	O
35	O
%	O
and	O
48	O
%	O
,	O
respectively	O
)	O
due	O
to	O
a	O
reduction	O
of	O
the	O
viscosity	O
by	O
means	O
of	O
haemodilution	O
with	O
albumin	B-protein
(	O
a	O
specific	O
viscosity	O
effect	O
in	O
the	O
normovolaemic	O
group	O
)	O
.	O

A	O
stable	O
heterologous	O
cell	O
line	O
containing	O
the	O
mouse	B-protein
TRH	I-protein
receptor	I-protein
was	O
constructed	O
by	O
transfection	O
of	O
nonexcitable	O
293	O
cells	O
,	O
which	O
lack	O
L	O
channel	O
activity	O
.	O

These	O
data	O
suggest	O
that	O
the	O
function	O
of	O
the	O
DS2	B-protein
may	O
be	O
the	O
protection	O
of	O
the	O
nuclear	O
DNA	O
from	O
desiccation	O
.	O

A	O
recently	O
described	O
protein	O
,	O
metaxin	B-protein
1	I-protein
,	O
serves	O
as	O
a	O
component	O
of	O
a	O
preprotein	O
import	O
complex	O
in	O
the	O
outer	O
membrane	O
of	O
the	O
mammalian	O
mitochondrion	O
.	O

RESULTS	O
:	O
The	O
age	O
distribution	O
was	O
28	O
to	O
83	O
years	O
old	O
(	O
mean	O
was	O
54	O
.	O
1	O
years	O
)	O
.	O

Univariate	O
statistical	O
analysis	O
based	O
on	O
Kaplan	O
-	O
Meier	O
-	O
estimates	O
and	O
Log	O
-	O
Rank	O
-	O
Test	O
showed	O
the	O
following	O
prognostically	O
beneficial	O
factors	O
:	O
Limited	O
disease	O
stage	O
(	O
p	O
=	O
0	O
.	O
009	O
)	O
,	O
NSE	O
serum	O
level	O
less	O
than	O
25	O
micrograms	O
/	O
l	O
(	O
p	O
=	O
0	O
.	O
016	O
)	O
,	O
serum	O
alkaline	B-protein
phosphatase	I-protein
less	O
than	O
200	O
U	O
/	O
l	O
(	O
p	O
=	O
0	O
.	O
035	O
)	O
,	O
normal	O
serum	O
albumin	B-protein
(	O
p	O
=	O
0	O
.	O
003	O
)	O
and	O
activity	O
index	O
of	O
minimum	O
of	O
70	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

GAP	O
JUNCTIONS	O
IN	O
THE	O
BRAIN	O
:	O
PREFACE	O
.	O

The	O
new	O
semi	O
-	O
synthetic	O
oral	O
cephalosporin	O
,	O
CGP	O
9	O
,	O
000	O
,	O
has	O
been	O
evaluated	O
in	O
a	O
large	O
number	O
of	O
hospitalized	O
patients	O
with	O
urinary	O
infections	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
with	O
each	O
of	O
these	O
sequences	O
demonstrated	O
complexes	O
with	O
mobilities	O
identical	O
to	O
those	O
of	O
the	O
NF	B-protein
-	I-protein
kappa	I-protein
B	I-protein
site	I-protein
from	O
the	O
kappa	B-protein
light	I-protein
-	I-protein
chain	I-protein
gene	I-protein
.	O

Taken	O
together	O
,	O
these	O
findings	O
show	O
that	O
16K	B-protein
hPRL	I-protein
inhibits	O
the	O
VEGF	O
-	O
induced	O
Ras	B-protein
activation	O
;	O
this	O
antagonism	O
represents	O
a	O
novel	O
and	O
potentially	O
important	O
mechanism	O
for	O
the	O
control	O
of	O
angiogenesis	O
.	O

Transfection	O
with	O
a	O
CSF	B-protein
-	I-protein
1R	I-protein
expression	O
plasmid	O
permitted	O
CSF	O
-	O
1	O
-	O
dependent	O
activation	O
of	O
the	O
signalling	O
pathway	O
targeting	O
an	O
Ets	B-protein
/	I-protein
AP1	I-protein
(	O
activator	B-protein
protein	I-protein
1	I-protein
)	O
element	O
in	O
the	O
uPA	B-protein
promoter	I-protein
that	O
has	O
been	O
shown	O
previously	O
to	O
be	O
a	O
target	O
of	O
oncogenic	B-protein
ras	I-protein
and	O
protein	B-protein
kinase	I-protein
C	I-protein
pathways	I-protein
.	O

During	O
the	O
1980	O
'	O
s	O
,	O
quantifications	O
of	O
immunoserological	O
testings	O
,	O
especially	O
C	B-protein
reactive	I-protein
protein	I-protein
,	O
rheumatoid	B-protein
factor	I-protein
and	O
antistreptolysin	B-protein
O	I-protein
,	O
progressed	O
rapidly	O
.	O

Evidence	O
that	O
therapeutic	O
alterations	O
of	O
a	O
circadian	O
rhythm	O
for	O
gastric	O
emptying	O
response	O
may	O
be	O
possible	O
.	O

It	O
is	O
the	O
human	O
homolog	O
of	O
the	O
mouse	B-protein
Mx	I-protein
protein	I-protein
involved	O
in	O
resistance	O
to	O
influenza	O
virus	O
.	O

Accumulations	O
of	O
Tl	O
+	O
1	O
(	O
202Tl	O
label	O
)	O
were	O
6	O
times	O
those	O
for	O
Ga	O
or	O
In	O
in	O
the	O
brain	O
and	O
muscles	O
,	O
and	O
.	O
1	O
times	O
in	O
plasma	O
.	O

These	O
results	O
indicate	O
that	O
during	O
pregnancy	O
there	O
are	O
increases	O
in	O
bone	O
formation	O
rates	O
contributing	O
to	O
the	O
increases	O
in	O
skeletal	O
mass	O
.	O

In	O
a	O
recent	O
measles	O
epidemic	O
in	O
El	O
Paso	O
,	O
TX	O
,	O
120	O
,	O
000	O
records	O
were	O
screened	O
using	O
these	O
criteria	O
,	O
and	O
as	O
a	O
result	O
13	O
,	O
000	O
students	O
were	O
vaccinated	O
.	O

Recently	O
,	O
we	O
have	O
reported	O
the	O
cloning	O
of	O
the	O
germ	O
cell	O
-	O
specific	O
,	O
nuclear	B-protein
orphan	I-protein
receptor	I-protein
germ	I-protein
cell	I-protein
nuclear	I-protein
factor	I-protein
(	I-protein
GCNF	I-protein
)	I-protein
/	I-protein
RTR	I-protein
.	O

(	O
1991	O
)	O
.	O

Appropriate	O
restriction	O
sites	O
allow	O
one	O
to	O
insert	O
virtually	O
any	O
desired	O
cDNA	O
fragment	O
directly	O
behind	O
the	O
epitope	O
-	O
specific	O
sequence	O
and	O
before	O
a	O
long	O
poly	O
(	O
A	O
)	O
tail	O
.	O

The	O
promoter	O
activity	O
of	O
the	O
proximal	O
region	O
was	O
found	O
to	O
be	O
restricted	O
to	O
a	O
subset	O
of	O
prestalk	O
cells	O
.	O

Such	O
an	O
increase	O
in	O
the	O
steady	O
-	O
state	O
testicular	B-protein
TIMP	I-protein
-	I-protein
2	I-protein
mRNA	I-protein
level	O
apparently	O
is	O
not	O
the	O
result	O
of	O
an	O
up	O
-	O
regulation	O
by	O
germ	O
cells	O
because	O
germ	O
cells	O
cocultured	O
with	O
Sertoli	O
cells	O
failed	O
to	O
elicit	O
an	O
increase	O
in	O
the	O
Sertoli	O
cell	O
steady	O
-	O
state	O
TIMP	B-protein
-	I-protein
2	I-protein
mRNA	I-protein
level	O
.	O

Transgenic	O
mice	O
harboring	O
the	O
rat	B-protein
TnI	I-protein
-	I-protein
CAT	I-protein
fusion	I-protein
gene	I-protein
expressed	O
the	O
reporter	O
specifically	O
in	O
the	O
skeletal	O
muscle	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
indicate	O
that	O
the	O
C	O
-	O
terminal	O
24	O
amino	O
acids	O
are	O
sufficient	O
for	O
NodO	B-protein
secretion	O
although	O
the	O
region	O
adjacent	O
to	O
this	O
domain	O
appears	O
to	O
affect	O
secretion	O
efficiency	O
.	O

Substantial	O
evidence	O
supports	O
a	O
critical	O
role	O
for	O
the	O
activation	O
of	O
the	O
Raf	B-protein
-	I-protein
1	I-protein
/	I-protein
MEK	I-protein
/	I-protein
mitogen	I-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
pathway	I-protein
in	O
oncogenic	O
Ras	O
-	O
mediated	O
transformation	O
.	O

The	O
3	O
'	O
fragment	O
was	O
shown	O
to	O
accumulate	O
as	O
full	O
-	O
length	O
mRNA	O
disappeared	O
in	O
actinomycin	O
D	O
-	O
treated	O
cells	O
,	O
indicating	O
a	O
precursor	O
-	O
product	O
relationship	O
.	O

Relation	O
between	O
mixing	O
ratio	O
of	O
raw	O
materials	O
and	O
composition	O
of	O
products	O
in	O
the	O
synthesis	O
of	O
aluminosilicates	O
.	O

I	O
.	O

The	O
course	O
of	O
endotoxin	B-protein
fever	O
remained	O
uninfluenced	O
by	O
ALS	O
.	O

The	O
brackets	O
were	O
bonded	O
to	O
100	O
freshly	O
extracted	O
bovine	O
incisors	O
,	O
and	O
,	O
after	O
storage	O
in	O
tap	O
water	O
at	O
room	O
temperature	O
for	O
24	O
hours	O
,	O
they	O
were	O
subsequently	O
tested	O
in	O
a	O
shear	O
mode	O
using	O
a	O
universal	O
testing	O
machine	O
.	O

Potential	O
consensus	O
sequences	O
for	O
early	O
and	O
late	O
regulatory	O
elements	O
were	O
identified	O
.	O

Sequencing	O
of	O
a	O
1	O
.	O
3	O
-	O
kilobase	O
fragment	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
TSG6	B-protein
gene	I-protein
identified	O
TATA	O
-	O
like	O
and	O
CAAT	O
sequences	O
near	O
the	O
transcription	O
start	O
site	O
.	O

When	O
the	O
downstream	O
operator	O
was	O
altered	O
,	O
there	O
was	O
a	O
fourfold	O
reduction	O
in	O
reporter	O
enzyme	O
levels	O
.	O

Tyrosine	O
phosphorylated	O
STATs	B-protein
dimerize	O
and	O
translocate	O
into	O
the	O
nucleus	O
to	O
activate	O
specific	O
genes	O
.	O

The	O
fepA	B-protein
-	I-protein
entD	I-protein
and	O
fes	B-protein
-	I-protein
entF	I-protein
operons	I-protein
in	O
the	O
enterobactin	O
synthesis	O
and	O
transport	O
system	O
are	O
divergently	O
transcribed	O
from	O
overlapping	O
promoters	O
,	O
and	O
both	O
are	O
inhibited	O
by	O
the	O
Fur	B-protein
repressor	I-protein
protein	I-protein
under	O
iron	O
-	O
replete	O
conditions	O
.	O

Results	O
from	O
transient	O
assays	O
using	O
these	O
mutants	O
showed	O
that	O
the	O
DE1	B-protein
received	O
signals	O
from	O
phytochromes	O
A	O
and	O
B	O
,	O
demonstrating	O
that	O
this	O
element	O
is	O
indeed	O
a	O
light	O
-	O
responsive	O
element	O
.	O

After	O
1	O
.	O
5	O
years	O
of	O
such	O
photoperiodic	O
control	O
,	O
all	O
ewes	O
were	O
blinded	O
by	O
bilateral	O
orbital	O
enucleation	O
.	O

Refined	O
Cox	O
models	O
using	O
a	O
CD4	B-protein
count	O
of	O
150	O
/	O
microL	O
rather	O
than	O
200	O
/	O
microL	O
to	O
distinguish	O
I0	O
and	O
I1	O
yielded	O
a	O
simplified	O
model	O
with	O
better	O
fit	O
to	O
the	O
observed	O
data	O
.	O

The	O
RPO1	B-protein
of	O
LCDV	O
shows	O
the	O
highest	O
similarity	O
to	O
the	O
RPO1	B-protein
of	O
IIV6	O
and	O
significant	O
lower	O
similarity	O
to	O
the	O
eukaryotic	B-protein
polymerases	I-protein
II	I-protein
and	I-protein
III	I-protein
as	O
well	O
as	O
to	O
the	O
archaebacteral	O
subunit	O
.	O

Other	O
assays	O
also	O
distinguished	O
the	O
processive	O
replication	O
of	O
pNeo	O
.	O
Myc	B-protein
-	I-protein
2	I-protein
.	O
4	O
from	O
the	O
dispersive	O
labeling	O
of	O
control	O
plasmids	O
.	O

Thus	O
adaptation	O
to	O
continuous	O
mild	O
stress	O
has	O
a	O
potent	O
antiarrhythmic	O
effect	O
which	O
occurs	O
due	O
to	O
the	O
increased	O
vagal	O
tone	O
.	O

Because	O
Trp53	B-protein
(	O
the	O
mouse	B-protein
homolog	I-protein
of	I-protein
human	I-protein
TP53	I-protein
)	O
is	O
located	O
with	O
Tk1	B-protein
on	O
chromosome	O
11	O
and	O
is	O
critical	O
in	O
regulating	O
cellular	O
responses	O
following	O
exposure	O
to	O
DNA	O
damaging	O
agents	O
,	O
we	O
wanted	O
to	O
determine	O
if	O
these	O
mouse	O
lymphoma	O
cells	O
harbor	O
mutations	O
in	O
Trp53	B-protein
.	O

We	O
concluded	O
that	O
activation	O
of	O
c	B-protein
-	I-protein
fosER	I-protein
mediated	O
transcriptional	O
inhibition	O
of	O
p21	B-protein
(	I-protein
Cip1	I-protein
/	I-protein
WAF1	I-protein
)	I-protein
through	O
a	O
previously	O
uncharacterized	O
AP	B-protein
-	I-protein
1	I-protein
site	I-protein
,	O
revealing	O
an	O
important	O
role	O
for	O
c	B-protein
-	I-protein
fos	I-protein
in	O
negative	O
control	O
of	O
cell	O
cycle	O
regulatory	O
genes	O
.	O

On	O
the	O
other	O
hand	O
,	O
phosphatidyl	O
inositol	O
4	O
,	O
5	O
bisphosphate	O
(	O
PIP2	O
)	O
hydrolysis	O
requires	O
direct	O
phosphorylation	O
at	O
tyrosine	O
residue	O
of	O
the	O
PLC	B-protein
-	I-protein
gamma1	I-protein
isozyme	I-protein
.	O

The	O
actA	B-protein
gene	I-protein
is	O
present	O
as	O
a	O
single	O
copy	O
in	O
the	O
genome	O
of	O
A	O
.	O
chrysogenum	O
;	O
and	O
its	O
expression	O
level	O
,	O
opposite	O
to	O
pcbC	B-protein
and	O
cefEF	B-protein
cephalosporin	I-protein
biosynthetic	I-protein
genes	I-protein
,	O
was	O
steady	O
during	O
cephalosporin	B-protein
fermentation	O
,	O
showing	O
a	O
single	O
1	O
.	O
4	O
-	O
kb	O
transcript	O
.	O

The	O
antibody	O
titer	O
of	O
202	O
chickens	O
to	O
SA	O
-	O
11	O
rotavirus	O
was	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
blocking	O
assay	O
.	O

Therefore	O
,	O
recombinant	O
human	O
Ads	O
that	O
express	O
noninfectious	O
HIV	O
or	O
other	O
microbial	O
proteins	O
are	O
attractive	O
vaccine	O
candidates	O
.	O

Based	O
on	O
a	O
morphological	O
study	O
of	O
the	O
resin	O
-	O
dentine	O
interface	O
,	O
a	O
broad	O
selection	O
of	O
dentine	O
adhesive	O
systems	O
was	O
classified	O
following	O
their	O
adhesion	O
-	O
strategy	O
.	O

These	O
women	O
should	O
not	O
be	O
given	O
the	O
current	O
estrogen	O
PPI	O
,	O
which	O
was	O
designed	O
to	O
warn	O
women	O
of	O
the	O
risks	O
of	O
long	O
-	O
term	O
estrogen	O
use	O
;	O
a	O
PPI	O
should	O
be	O
written	O
specifically	O
for	O
patients	O
receiving	O
short	O
courses	O
.	O

For	O
SMX	O
at	O
pH	O
7	O
.	O
0	O
,	O
a	O
1	O
:	O
1	O
complex	O
is	O
formed	O
,	O
but	O
at	O
pH	O
7	O
.	O
5	O
HPCD	O
has	O
little	O
effect	O
on	O
the	O
solubility	O
of	O
the	O
highly	O
ionized	O
SMX	O
,	O
presumably	O
since	O
only	O
un	O
-	O
ionized	O
molecules	O
can	O
form	O
inclusion	O
complexes	O
with	O
the	O
HPCD	O
.	O

With	O
such	O
analysis	O
,	O
one	O
can	O
test	O
hypotheses	O
about	O
the	O
structure	O
of	O
latent	O
variability	O
within	O
a	O
given	O
data	O
set	O
.	O

Here	O
,	O
we	O
propose	O
that	O
an	O
antagonistic	O
,	O
BMP	O
/	O
ALK2	O
/	O
Smad	O
-	O
mediated	O
signaling	O
pathway	O
is	O
active	O
on	O
the	O
right	O
side	O
of	O
the	O
Xenopus	O
embryo	O
.	O

The	O
process	O
has	O
been	O
applied	O
to	O
the	O
river	O
reclamation	O
in	O
Yangpu	O
District	O
of	O
Shanghai	O
City	O
,	O
China	O
.	O

FK	O
33	O
-	O
824	O
,	O
a	O
methionine	O
-	O
enkephalin	O
analogue	O
,	O
suppressed	O
plasma	O
ACTH	B-protein
to	O
85	O
%	O
of	O
basal	O
level	O
,	O
while	O
bromocriptine	O
(	O
CB	O
-	O
154	O
)	O
caused	O
no	O
significant	O
change	O
.	O

Most	O
of	O
the	O
patients	O
had	O
locally	O
advanced	O
lesions	O
(	O
63	O
T3	O
-	O
4	O
:	O
91	O
.	O
5	O
%	O
)	O
according	O
to	O
the	O
adopted	O
TNM	O
system	O
(	O
Lederman	O
-	O
Gadeberg	O
,	O
Sisson	O
-	O
Jesse	O
)	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
SNF2	B-protein
,	O
SNF5	B-protein
,	O
and	O
SNF6	B-protein
function	O
interdependently	O
in	O
transcriptional	O
activation	O
,	O
possibly	O
forming	O
a	O
heteromeric	O
complex	O
.	O

Sinusoidal	O
oscillations	O
of	O
a	O
gas	O
dilution	O
indicator	O
.	O

Shoulder	O
forearm	O
support	O
for	O
the	O
subluxed	O
shoulder	O
.	O

The	O
effects	O
of	O
glutaraldehyde	O
on	O
dimensions	O
and	O
ultrastructure	O
of	O
microvascular	O
beds	O
in	O
rat	O
mesentery	O
were	O
studied	O
in	O
two	O
kinds	O
of	O
experiment	O
,	O
administering	O
the	O
fixative	O
by	O
intra	O
-	O
arterial	O
perfusion	O
at	O
a	O
pressure	O
of	O
80	O
mm	O
Hg	O
and	O
by	O
superfusion	O
of	O
the	O
exteriorized	O
mesenteric	O
membrane	O
.	O

METHODS	O
:	O
Rats	O
received	O
continuous	O
intragastric	O
infusion	O
of	O
elemental	O
diet	O
or	O
with	O
supplementation	O
of	O
oatbase	O
,	O
Lactobacillus	O
reuteri	O
R2LC	O
,	O
and	O
Lactobacillus	O
plantarum	O
DSM	O
9843	O
,	O
with	O
and	O
without	O
fermentation	O
,	O
from	O
the	O
beginning	O
of	O
the	O
study	O
.	O

The	O
Ntl1	B-protein
gene	I-protein
is	O
present	O
as	O
a	O
unique	O
copy	O
in	O
the	O
diploid	O
N	O
.	O
plumbaginifolia	O
species	O
.	O

Overexpression	O
of	O
PTTG	B-protein
in	O
transfected	O
NIH	O
3T3	O
cells	O
also	O
stimulated	O
expression	O
and	O
secretion	O
of	O
basic	B-protein
fibroblast	I-protein
growth	I-protein
factor	I-protein
,	O
a	O
human	O
pituitary	O
tumor	O
growth	O
-	O
regulating	O
factor	O
.	O

Apropos	O
of	O
a	O
case	O
.	O

After	O
age	O
30	O
,	O
mean	O
hemoglobin	B-protein
levels	O
for	O
men	O
gradually	O
declined	O
,	O
while	O
those	O
in	O
women	O
rose	O
,	O
so	O
that	O
the	O
sex	O
difference	O
diminished	O
after	O
60	O
years	O
of	O
age	O
.	O

Biol	O
.	O

Among	O
unusual	O
features	O
,	O
we	O
report	O
numerous	O
large	O
G	O
+	O
C	O
-	O
rich	O
conserved	O
sequences	O
located	O
in	O
the	O
first	O
intron	O
.	O

The	O
Nur77	B-protein
protein	I-protein
can	O
act	O
as	O
a	O
potent	O
transcription	O
activator	O
and	O
may	O
function	O
to	O
regulate	O
the	O
expression	O
of	O
downstream	O
genes	O
in	O
response	O
to	O
extracellular	O
stimuli	O
.	O

DNase	B-protein
I	I-protein
footprinting	O
with	O
rat	O
liver	O
nuclear	O
extracts	O
identified	O
7	O
major	O
protein	O
-	O
binding	O
domains	O
termed	O
P1	B-protein
through	O
P7	B-protein
in	O
a	O
796	O
base	O
pair	O
DNA	O
fragment	O
(	O
base	O
pairs	O
-	O
763	O
to	O
+	O
33	O
)	O
.	O

This	O
element	O
,	O
termed	O
CREsp	B-protein
-	I-protein
a	I-protein
(	O
TGACCTCA	B-protein
)	O
,	O
differs	O
by	O
one	O
nucleotide	O
from	O
a	O
palindromic	O
CRE	B-protein
(	O
CREpal	B-protein
,	O
TGACGTCA	B-protein
)	O
,	O
which	O
is	O
known	O
to	O
bind	O
CREB	B-protein
as	O
a	O
homodimer	O
.	O

Its	O
vasodilatory	O
,	O
anti	O
-	O
vasopressor	O
,	O
and	O
platelet	O
stabilizing	O
effects	O
could	O
be	O
expected	O
to	O
counteract	O
the	O
placental	O
ischemia	O
,	O
hypertension	O
and	O
excessive	O
coagulation	O
that	O
are	O
seen	O
in	O
pre	O
-	O
eclampsia	O
.	O

Transient	O
transfection	O
assays	O
using	O
P19	O
cells	O
revealed	O
that	O
expression	O
of	O
NDRF	B-protein
/	I-protein
NeuroD2	I-protein
increased	O
the	O
transactivation	O
of	O
the	O
rat	B-protein
insulin	I-protein
promoter	I-protein
element	I-protein
3	I-protein
(	O
RIPE3	B-protein
)	O
enhancer	O
up	O
to	O
approximately	O
12	O
-	O
fold	O
and	O
that	O
co	O
-	O
expression	O
of	O
catalytically	O
active	O
form	O
of	O
PKN	B-protein
,	O
but	O
not	O
kinase	O
-	O
deficient	O
derivative	O
,	O
resulted	O
in	O
a	O
further	O
threefold	O
increase	O
of	O
NDRF	O
/	O
NeuroD2	O
-	O
mediated	O
transcription	O
.	O

Platelet	O
aggregation	O
in	O
response	O
to	O
10	O
micrograms	O
collagen	O
/	O
ml	O
was	O
decreased	O
in	O
parallel	O
after	O
treatment	O
with	O
ASA	O
.	O

Arhythmacanthus	O
Yamaguti	O
,	O
1935	O
is	O
maintained	O
as	O
a	O
synonym	O
of	O
Heterosentis	O
because	O
the	O
distinction	O
between	O
two	O
and	O
three	O
hook	O
types	O
is	O
made	O
equivocal	O
when	O
the	O
transition	O
between	O
the	O
apical	O
and	O
subapical	O
hooks	O
is	O
gradual	O
.	O

Autorosette	O
-	O
forming	O
cells	O
are	O
characterized	O
by	O
a	O
high	O
activity	O
of	O
alkaline	B-protein
and	I-protein
acid	I-protein
phosphatases	I-protein
and	O
low	O
NBT	O
-	O
test	O
values	O
.	O

The	O
spectrum	O
of	O
histologically	O
diagnosed	O
malignant	O
neoplasms	O
in	O
Sabah	O
,	O
1983	O
-	O
1988	O
.	O

Eight	O
recombinant	O
DNA	O
clones	O
of	O
endogenous	O
murine	O
leukemia	O
virus	O
(	O
MuLV	O
)	O
-	O
related	O
DNA	O
sequences	O
have	O
been	O
isolated	O
from	O
a	O
lambdaphage	O
genomic	O
library	O
of	O
Balb	O
/	O
c	O
mouse	O
DNA	O
.	O

When	O
transiently	O
transfected	O
into	O
K562	O
cells	O
,	O
this	O
Lg	B-protein
genomic	O
clone	O
is	O
actively	O
transcribed	O
,	O
suggesting	O
that	O
,	O
although	O
it	O
possesses	O
the	O
characteristics	O
of	O
a	O
processed	O
pseudogene	O
,	O
it	O
is	O
likely	O
to	O
correspond	O
to	O
the	O
gene	O
encoding	O
this	O
new	O
ferritin	B-protein
subunit	I-protein
.	O

The	O
murine	B-protein
Htf9	I-protein
-	I-protein
a	I-protein
/	I-protein
RanBP1	I-protein
and	O
Htf9	B-protein
-	I-protein
c	I-protein
genes	I-protein
are	O
divergently	O
transcribed	O
from	O
a	O
shared	O
TATA	O
-	O
less	O
promoter	O
.	O

Under	O
these	O
schedules	O
,	O
a	O
reinforced	O
response	O
run	O
consisted	O
of	O
responding	O
between	O
eight	O
and	O
12	O
times	O
on	O
one	O
response	O
key	O
(	O
work	O
key	O
)	O
and	O
then	O
responding	O
once	O
on	O
a	O
second	O
response	O
key	O
(	O
reinforced	O
key	O
)	O
.	O

AIMS	O
:	O
To	O
evaluate	O
the	O
role	O
of	O
environmental	O
intra	O
-	O
uterine	O
factors	O
in	O
determining	O
the	O
birthweights	O
of	O
twins	O
with	O
increased	O
susceptibility	O
to	O
diabetes	O
and	O
discordant	O
for	O
abnormal	O
responses	O
to	O
the	O
oral	O
glucose	O
tolerance	O
test	O
(	O
OGTT	O
)	O
and	O
verify	O
the	O
possible	O
association	O
of	O
within	O
-	O
pair	O
birthweight	O
differences	O
and	O
metabolic	O
abnormalities	O
in	O
adult	O
life	O
.	O

Amino	O
acid	O
sequence	O
comparison	O
revealed	O
significant	O
homology	O
between	O
the	O
yeast	B-protein
and	I-protein
Escherichia	I-protein
coli	I-protein
gamma	I-protein
-	I-protein
glutamyl	I-protein
kinases	I-protein
throughout	O
their	O
lengths	O
.	O

Tumours	O
of	O
the	O
cavum	O
oris	O
and	O
oropharynx	O
of	O
T1	O
-	O
stage	O
are	O
possible	O
only	O
in	O
1	O
of	O
3	O
cases	O
.	O

Expression	O
and	O
regulation	O
by	O
interferon	O
of	O
a	O
double	B-protein
-	I-protein
stranded	I-protein
-	I-protein
RNA	I-protein
-	I-protein
specific	I-protein
adenosine	I-protein
deaminase	I-protein
from	O
human	O
cells	O
:	O
evidence	O
for	O
two	O
forms	O
of	O
the	O
deaminase	B-protein
.	O

The	O
ZNF274	B-protein
gene	I-protein
is	O
mapped	O
distal	O
to	O
marker	O
RP	O
S28	O
1	O
in	O
the	O
human	O
chromosome	O
19qter	O
region	O
,	O
by	O
RH	O
mapping	O
.	O

Gene	O
constructs	O
possessing	O
the	O
complete	B-protein
tat	I-protein
,	O
rev	B-protein
(	O
tat	B-protein
+	I-protein
rev	I-protein
+	I-protein
)	O
and	O
env	B-protein
genes	I-protein
were	O
transiently	O
expressed	O
in	O
COS	O
-	O
1	O
cells	O
as	O
precursor	B-protein
SU	I-protein
-	I-protein
TM	I-protein
(	O
gp160	B-protein
)	O
,	O
SU	B-protein
.	I-protein
TM	I-protein
(	O
gp120	B-protein
x	I-protein
41	I-protein
)	O
,	O
and	O
nucleolar	B-protein
rev	I-protein
protein	I-protein
.	O

The	O
population	O
studied	O
comprised	O
4472	O
men	O
and	O
5212	O
women	O
aged	O
30	O
-	O
74	O
years	O
,	O
without	O
coronary	O
heart	O
disease	O
,	O
who	O
had	O
CRP	O
measurements	O
in	O
the	O
Third	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
NHANES	O
III	O
)	O
.	O

V	O
.	O

Disruption	O
of	O
ARF2	B-protein
causes	O
no	O
detectable	O
phenotype	O
.	O

The	O
specific	O
electrical	O
resistance	O
of	O
the	O
cerebrospinal	O
fluid	O
was	O
measured	O
by	O
means	O
of	O
conductometry	O
in	O
14	O
cases	O
of	O
meningitis	O
purulenta	O
,	O
17	O
cases	O
of	O
meningitis	O
serosa	O
,	O
10	O
cases	O
of	O
encephalitis	O
and	O
in	O
32	O
control	O
subjects	O
.	O

Incubation	O
of	O
the	O
purified	O
fusion	O
proteins	O
with	O
[	O
gamma	O
-	O
32P	O
]	O
ATP	O
in	O
an	O
in	O
vitro	O
assay	O
showed	O
that	O
both	O
proteins	O
were	O
capable	O
of	O
autophosphorylation	O
.	O

Overall	O
,	O
our	O
results	O
suggest	O
that	O
resistant	O
genotypes	O
exist	O
among	O
the	O
WAD	O
goat	O
population	O
.	O

Complete	O
nucleotide	O
sequence	O
of	O
the	O
bacteriophage	B-protein
K1F	I-protein
tail	I-protein
gene	I-protein
encoding	O
endo	B-protein
-	I-protein
N	I-protein
-	I-protein
acylneuraminidase	I-protein
(	O
endo	B-protein
-	I-protein
N	I-protein
)	O
and	O
comparison	O
to	O
an	O
endo	B-protein
-	I-protein
N	I-protein
homolog	I-protein
in	O
bacteriophage	O
PK1E	O
.	O

It	O
was	O
argued	O
that	O
this	O
arose	O
from	O
the	O
possibility	O
that	O
the	O
nature	O
of	O
blue	O
collar	O
jobs	O
was	O
physical	O
,	O
and	O
that	O
loss	O
of	O
myocardial	O
tissue	O
might	O
be	O
expected	O
to	O
more	O
markedly	O
interfere	O
with	O
their	O
work	O
efficiency	O
(	O
on	O
returning	O
to	O
work	O
)	O
than	O
it	O
would	O
the	O
efficiency	O
of	O
the	O
more	O
sedentary	O
jobs	O
of	O
white	O
collar	O
workers	O
.	O

Based	O
on	O
the	O
occurrence	O
of	O
several	O
transcription	O
signals	O
in	O
the	O
Thermus	B-protein
pyr	I-protein
promoter	I-protein
region	I-protein
and	O
strong	O
amino	O
acid	O
sequence	O
identities	O
(	O
about	O
60	O
%	O
)	O
between	O
Thermus	B-protein
PyrR	I-protein
and	O
the	O
PyrR	B-protein
attenuation	I-protein
proteins	I-protein
of	O
two	O
Bacillus	O
sp	O
.	O
,	O
we	O
propose	O
a	O
regulatory	O
mechanism	O
involving	O
transcriptional	O
attenuation	O
to	O
control	O
pyr	B-protein
gene	I-protein
expression	O
in	O
Thermus	O
.	O

The	O
sensitivity	O
of	O
human	O
neuroblastoma	O
cells	O
SK	O
-	O
N	O
-	O
SH	O
to	O
undergo	O
apoptosis	O
induced	O
by	O
thapsigargin	O
was	O
examined	O
.	O

Detection	O
of	O
airborne	O
Mycobacterium	O
tuberculosis	O
by	O
air	O
filtration	O
and	O
polymerase	B-protein
chain	O
reaction	O
.	O

The	O
bHLH	B-protein
proteins	I-protein
function	O
as	O
potent	O
transcriptional	O
activators	O
of	O
tissue	O
-	O
specific	O
genes	O
by	O
forming	O
heterodimers	O
between	O
ubiquitous	O
and	O
cell	O
-	O
restricted	O
family	O
members	O
.	O

Evoked	O
potential	O
and	O
single	O
unit	O
responses	O
to	O
olfactory	O
nerve	O
volleys	O
in	O
the	O
isolated	O
turtle	O
olfactory	O
bulb	O
.	O

Selection	O
was	O
based	O
on	O
expression	O
of	O
an	O
integrated	O
DNA	O
fragment	O
containing	O
the	O
con	B-protein
-	I-protein
10	I-protein
promoter	I-protein
-	I-protein
regulatory	I-protein
region	I-protein
followed	O
by	O
the	O
initial	O
segment	O
of	O
the	O
con	B-protein
-	I-protein
10	I-protein
open	I-protein
reading	I-protein
frame	I-protein
fused	O
in	O
frame	O
with	O
the	O
bacterial	B-protein
hygromycin	I-protein
B	I-protein
phosphotransferase	I-protein
structural	I-protein
gene	I-protein
(	O
con10	B-protein
'	I-protein
-	I-protein
'	I-protein
hph	I-protein
)	O
.	O

3	O
Significant	O
reductions	O
in	O
lying	O
mean	O
arterial	O
blood	O
pressure	O
were	O
observed	O
with	O
daily	O
doses	O
of	O
200	O
mg	O
(	O
-	O
9	O
%	O
)	O
,	O
400	O
mg	O
(	O
-	O
10	O
%	O
)	O
and	O
800	O
mg	O
(	O
-	O
14	O
%	O
)	O
,	O
and	O
were	O
associated	O
with	O
significant	O
decreases	O
in	O
heart	O
rate	O
and	O
plasma	B-protein
renin	I-protein
activity	O
.	O

All	O
33	O
subjects	O
were	O
given	O
psychometric	O
instruments	O
for	O
measuring	O
various	O
components	O
of	O
anger	O
and	O
anxiety	O
:	O
Spielberger	O
'	O
s	O
State	O
-	O
Trait	O
Personality	O
Inventory	O
,	O
the	O
Anger	O
Expression	O
Scale	O
,	O
and	O
the	O
State	O
Anger	O
Reaction	O
Scale	O
.	O

The	O
data	O
suggest	O
that	O
like	O
in	O
yeast	O
,	O
in	O
plants	O
a	O
certain	O
subfamily	O
of	O
UBC	B-protein
is	O
specifically	O
involved	O
in	O
the	O
proteolytic	O
degradation	O
of	O
abnormal	O
proteins	O
as	O
result	O
of	O
stress	O
.	O

1	O
)	O
CFDN	O
,	O
AMPC	O
and	O
MNZ	O
showed	O
a	O
potent	O
antimicrobial	O
activity	O
against	O
H	O
.	O
pylori	O
,	O
and	O
especially	O
,	O
AMPC	O
showed	O
a	O
marked	O
bactericidal	O
activity	O
in	O
a	O
short	O
time	O
.	O

Tributyltin	O
and	O
its	O
breakdown	O
products	O
,	O
mono	O
-	O
and	O
di	O
-	O
butyltin	O
,	O
were	O
determined	O
in	O
water	O
birds	O
collected	O
from	O
Lake	O
Huron	O
(	O
the	O
Great	O
Lakes	O
)	O
,	O
marine	O
coastal	O
United	O
States	O
,	O
and	O
the	O
west	O
coast	O
of	O
British	O
Columbia	O
,	O
Canada	O
.	O

This	O
motif	O
,	O
first	O
described	O
for	O
the	O
Drosophila	B-protein
homeobox	I-protein
activator	I-protein
DEAF	I-protein
-	I-protein
1	I-protein
,	O
identifies	O
an	O
emerging	O
group	O
of	O
metazoan	O
transcriptional	O
modulators	O
.	O

Therefore	O
,	O
PC	B-protein
-	I-protein
PLC	I-protein
is	O
a	O
component	O
of	O
a	O
signal	O
transduction	O
pathway	O
leading	O
to	O
transcription	O
of	O
c	B-protein
-	I-protein
fos	I-protein
and	O
junB	B-protein
that	O
collaborates	O
with	O
c	B-protein
-	I-protein
myc	I-protein
and	O
is	O
independent	O
of	O
PKC	B-protein
-	I-protein
delta	I-protein
and	O
Ras	B-protein
activation	O
.	O

Peripheral	O
and	O
preemptive	O
opioid	O
antinociception	O
in	O
a	O
mouse	O
visceral	O
pain	O
model	O
.	O

G	B-protein
-	I-protein
DNA	I-protein
is	O
a	O
four	O
-	O
stranded	O
DNA	O
structure	O
with	O
diverse	O
putative	O
biological	O
roles	O
.	O

Negatively	O
supercoiled	O
plasmid	O
pUC19	O
did	O
not	O
compete	O
,	O
whereas	O
an	O
otherwise	O
identical	O
plasmid	O
pUC19	O
(	O
CG	O
)	O
,	O
which	O
contained	O
a	O
(	O
dG	O
-	O
dC	O
)	O
7	O
segment	O
in	O
the	O
Z	O
-	O
form	O
was	O
an	O
excellent	O
competitor	O
.	O

Deletion	O
of	O
the	O
proximal	O
octanucleotide	O
motif	O
from	O
the	O
plasmid	O
containing	O
the	O
-	O
461	O
fragment	O
of	O
the	O
LPL	B-protein
promoter	I-protein
,	O
resulted	O
in	O
a	O
79	O
and	O
76	O
%	O
decrease	O
in	O
the	O
level	O
of	O
expression	O
in	O
transfected	O
3T3	O
-	O
L1	O
adipocytes	O
and	O
HepG2	O
hepatocytes	O
,	O
respectively	O
.	O

Whereas	O
MARTA1	B-protein
is	O
clearly	O
detectable	O
in	O
crude	O
lysates	O
,	O
cytosolic	O
and	O
ribosomal	O
salt	O
-	O
wash	O
fractions	O
,	O
and	O
in	O
nuclear	O
extracts	O
,	O
MARTA2	B-protein
is	O
preferentially	O
found	O
in	O
the	O
ribosomal	O
salt	O
-	O
wash	O
preparation	O
.	O

Blood	B-protein
serum	I-protein
erythropoietin	I-protein
level	O
and	O
basic	O
hematological	O
indices	O
during	O
the	O
adaptation	O
of	O
healthy	O
newborn	O
infants	O
.	O

SETTING	O
-	O
-	O
Women	O
,	O
Infants	O
,	O
and	O
Children	O
clinics	O
in	O
Minneapolis	O
,	O
Minn	O
.	O

The	O
transit	O
time	O
was	O
significantly	O
shortened	O
.	O

Roles	O
of	O
the	O
Candida	B-protein
albicans	I-protein
mitogen	I-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
homolog	I-protein
,	O
Cek1p	B-protein
,	O
in	O
hyphal	O
development	O
and	O
systemic	O
candidiasis	O
.	O

By	O
using	O
reporter	O
gene	O
constructs	O
,	O
it	O
is	O
shown	O
that	O
upstream	O
sequences	O
of	O
the	O
P1	B-protein
promoter	I-protein
contain	O
several	O
regions	O
that	O
modulate	O
the	O
expression	O
either	O
positively	O
or	O
negatively	O
.	O

Gentamicin	O
given	O
by	O
DPI	O
and	O
SVN	O
significantly	O
decreased	O
the	O
sputum	O
Psa	O
density	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
by	O
almost	O
one	O
order	O
of	O
magnitude	O
.	O

The	O
210	O
kDa	O
precursor	O
is	O
converted	O
slowly	O
(	O
t	O
1	O
/	O
2	O
=	O
2	O
h	O
)	O
by	O
proteolytic	O
processing	O
into	O
a	O
125	O
kDa	O
(	O
alpha	O
'	O
)	O
and	O
83	O
kDa	O
(	O
beta	O
'	O
)	O
species	O
.	O

TATA	O
and	O
CCAAT	O
boxes	O
are	O
located	O
34	O
-	O
bp	O
and	O
68	O
-	O
bp	O
,	O
respectively	O
,	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
,	O
the	O
5	O
'	O
-	O
untranslated	O
leader	O
is	O
78	O
nucleotides	O
long	O
,	O
and	O
the	O
intronless	O
gene	O
has	O
at	O
least	O
two	O
different	O
polyadenylation	O
sites	O
.	O

We	O
speculate	O
that	O
the	O
human	O
papillomavirus	O
late	O
mRNAs	O
,	O
produced	O
from	O
several	O
hundred	O
copies	O
of	O
the	O
virus	O
genome	O
present	O
in	O
infected	O
cells	O
,	O
compete	O
with	O
the	O
c	B-protein
-	I-protein
fos	I-protein
mRNAs	I-protein
for	O
destabilizing	O
cellular	O
factors	O
and	O
that	O
this	O
may	O
lead	O
to	O
elevated	O
Fos	B-protein
protein	I-protein
levels	O
in	O
human	O
papillomavirus	O
infected	O
cells	O
.	O

PET	O
activation	O
studies	O
are	O
performed	O
widely	O
to	O
study	O
human	O
brain	O
function	O
.	O

Deterministic	O
effects	O
.	O

Regulation	O
of	O
mitochondrial	B-protein
single	I-protein
-	I-protein
stranded	I-protein
DNA	I-protein
-	I-protein
binding	I-protein
protein	I-protein
gene	I-protein
expression	O
links	O
nuclear	O
and	O
mitochondrial	O
DNA	O
replication	O
in	O
drosophila	O
.	O

In	O
mitogen	O
-	O
stimulated	O
splenocytes	O
,	O
Gfi	B-protein
-	I-protein
1	I-protein
expression	O
begins	O
to	O
rise	O
at	O
12	O
h	O
after	O
stimulation	O
and	O
reaches	O
very	O
high	O
levels	O
after	O
50	O
h	O
,	O
suggesting	O
that	O
it	O
may	O
be	O
functionally	O
involved	O
in	O
events	O
occurring	O
after	O
the	O
interaction	O
of	O
IL	B-protein
-	I-protein
2	I-protein
with	O
its	O
receptor	O
,	O
perhaps	O
during	O
the	O
transition	O
from	O
the	O
G1	O
to	O
the	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Several	O
authors	O
have	O
recently	O
reported	O
interference	O
in	O
theophylline	O
analysis	O
by	O
paraxanthine	O
(	O
1	O
,	O
7	O
-	O
dimethylxanthine	O
)	O
,	O
an	O
important	O
metabolite	O
of	O
caffeine	O
.	O

An	O
immunoperoxidase	B-protein
reaction	O
,	O
PAP	B-protein
method	O
,	O
with	O
the	O
antiserum	O
of	O
Factor	B-protein
VIII	I-protein
as	O
the	O
primary	O
antibody	O
,	O
was	O
carried	O
out	O
in	O
the	O
endometrial	O
biopsies	O
to	O
detect	O
the	O
Factor	B-protein
VIII	I-protein
activity	O
in	O
the	O
endometrial	O
endothelium	O
before	O
and	O
after	O
insertion	O
of	O
LNG	O
-	O
IUD	O
-	O
20	O
.	O

Age	O
was	O
categorized	O
into	O
four	O
groups	O
:	O
20	O
-	O
44	O
,	O
45	O
-	O
64	O
,	O
65	O
-	O
74	O
,	O
and	O
75	O
+	O
.	O
RESULTS	O
:	O
At	O
the	O
initiation	O
of	O
dialysis	O
PD	O
patients	O
were	O
approximately	O
6	O
years	O
younger	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
than	O
HD	O
patients	O
.	O

UPMC	O
is	O
not	O
the	O
only	O
organization	O
pursuing	O
controlled	O
NHBC	O
organ	O
procurement	O
,	O
however	O
.	O

Functional	O
analysis	O
of	O
DNase	B-protein
-	I-protein
I	I-protein
hypersensitive	O
sites	O
at	O
the	O
mouse	B-protein
porphobilinogen	I-protein
deaminase	I-protein
gene	I-protein
locus	I-protein
.	O

The	O
synthetic	O
DNA	O
sequence	O
was	O
constructed	O
to	O
achieve	O
efficient	O
base	O
pairing	O
with	O
Escherichia	B-protein
coli	I-protein
16S	I-protein
ribosomal	I-protein
RNA	I-protein
,	O
avoidance	O
of	O
internal	O
secondary	O
structure	O
,	O
and	O
optimal	O
codon	O
usage	O
for	O
high	O
-	O
level	O
protein	O
expression	O
in	O
accord	O
with	O
the	O
known	O
preferences	O
in	O
E	O
.	O
coli	O
.	O

Similarly	O
,	O
the	O
sequence	O
of	O
the	O
U2	B-protein
RNA	I-protein
region	I-protein
shown	O
to	O
be	O
involved	O
in	O
pre	O
-	O
mRNA	O
branchpoint	O
recognition	O
in	O
yeast	O
,	O
and	O
exactly	O
conserved	O
in	O
metazoan	B-protein
U2	I-protein
RNAs	I-protein
,	O
was	O
totally	O
divergent	O
in	O
trypanosomes	O
.	O

The	O
Ras	B-protein
-	I-protein
related	I-protein
GTPases	I-protein
are	O
small	O
,	O
20	O
-	O
to	O
25	O
-	O
kDa	O
proteins	O
which	O
cycle	O
between	O
an	O
inactive	O
GDP	O
-	O
bound	O
form	O
and	O
an	O
active	O
GTP	O
-	O
bound	O
state	O
.	O

The	O
most	O
common	O
characteristics	O
of	O
VRE	O
patients	O
were	O
recent	O
prior	O
vancomycin	O
use	O
,	O
recent	O
prior	O
susceptible	O
enterococcal	O
infection	O
,	O
coinfection	O
with	O
other	O
microbial	O
pathogens	O
,	O
and	O
concurrent	O
fungal	O
infection	O
.	O

Northern	O
and	O
Western	O
blot	O
analyses	O
demonstrated	O
that	O
Graf	B-protein
2	I-protein
is	O
expressed	O
in	O
several	O
tissues	O
,	O
with	O
the	O
highest	O
expression	O
in	O
skeletal	O
muscle	O
.	O

3D	O
image	O
-	O
processing	O
permits	O
to	O
analyse	O
ultrasound	O
data	O
interactively	O
in	O
three	O
orthogonal	O
planes	O
(	O
section	O
mode	O
)	O
or	O
in	O
realistic	O
3D	O
views	O
(	O
rendering	O
mode	O
)	O
.	O

Lac	O
operators	O
were	O
introduced	O
into	O
several	O
positions	O
within	O
the	O
CAB	B-protein
promoter	I-protein
and	O
operator	O
-	O
free	O
plasmid	O
was	O
used	O
as	O
control	O
.	O

However	O
,	O
if	O
EMPD	O
involves	O
the	O
glans	O
penis	O
or	O
perianal	O
area	O
,	O
a	O
search	O
for	O
internal	O
malignancy	O
is	O
still	O
warranted	O
.	O

There	O
was	O
a	O
significant	O
effect	O
of	O
hematocrit	O
on	O
the	O
General	O
Health	O
scale	O
on	O
the	O
SF	O
-	O
36	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

The	O
function	O
of	O
the	O
C	O
-	O
terminal	O
tail	O
in	O
telomere	O
maintenance	O
is	O
not	O
mediated	O
through	O
the	O
RAP1	B-protein
interacting	I-protein
factor	I-protein
RIF1	I-protein
:	O
rap1	B-protein
alleles	I-protein
defective	O
in	O
both	O
the	O
C	O
-	O
terminal	O
tail	O
and	O
RIF1	B-protein
interaction	I-protein
domains	I-protein
have	O
additive	O
effects	O
on	O
telomere	O
length	O
.	O

Cloning	O
by	O
complementation	O
and	O
subsequent	O
physical	O
and	O
genetic	O
analysis	O
revealed	O
that	O
it	O
maps	O
to	O
RAF1	B-protein
.	O

These	O
single	O
mutational	O
defects	O
in	O
the	O
eRF1	B-protein
-	I-protein
eRF3	I-protein
interaction	O
became	O
evident	O
when	O
either	O
truncated	O
protein	O
eRF3C	B-protein
or	O
C	O
-	O
terminally	O
altered	O
eRF1	B-protein
proteins	O
were	O
used	O
for	O
the	O
authentic	O
protein	O
,	O
providing	O
further	O
support	O
for	O
the	O
presence	O
of	O
a	O
C	O
-	O
terminal	O
interaction	O
.	O

Eight	O
-	O
four	O
ACOAs	O
were	O
tested	O
in	O
order	O
to	O
examine	O
the	O
fit	O
of	O
the	O
model	O
to	O
the	O
data	O
by	O
path	O
analysis	O
with	O
LISREL	O
VII	O
.	O

In	O
conclusion	O
,	O
marmoset	B-protein
monkey	I-protein
LHR	I-protein
seems	O
to	O
lack	O
the	O
sequence	O
corresponding	O
to	O
exon	O
10	O
of	O
the	O
LHR	B-protein
gene	I-protein
in	O
other	O
mammalian	O
species	O
.	O

By	O
deletion	O
analysis	O
of	O
the	O
MLS1	B-protein
control	O
region	O
,	O
we	O
identified	O
two	O
sites	O
,	O
UAS1	B-protein
and	O
UAS2	B-protein
,	O
as	O
important	O
for	O
efficient	O
derepression	O
of	O
the	O
gene	O
.	O

Human	O
neutrophil	O
response	O
to	O
short	O
-	O
term	O
exposure	O
to	O
F	O
-	O
75	O
cobalt	O
-	O
based	O
alloy	O
.	O

Overexpressing	O
the	O
coactivator	O
,	O
SRC1a	B-protein
or	O
GRIP1	B-protein
,	O
further	O
enhances	O
ERRalpha1	O
-	O
induced	O
transcriptional	O
activity	O
.	O

Individuals	O
attending	O
the	O
GUM	O
Department	O
in	O
the	O
Royal	O
Infirmary	O
of	O
Edinburgh	O
between	O
1990	O
and	O
1994	O
with	O
the	O
diagnosis	O
of	O
HIV	O
infection	O
,	O
genital	O
warts	O
,	O
genital	O
herpes	O
,	O
non	O
-	O
specific	O
genital	O
infection	O
(	O
NSGI	O
)	O
,	O
gonorrhoea	O
and	O
syphilis	O
were	O
included	O
in	O
the	O
study	O
.	O

DMI	O
and	O
2	O
-	O
OH	O
-	O
DMI	O
concentrations	O
were	O
determined	O
in	O
a	O
similar	O
group	O
of	O
61	O
DMI	O
-	O
treated	O
patients	O
.	O

A	O
rate	O
-	O
decreasing	O
dose	O
of	O
physostigmine	O
,	O
an	O
acetylcholinesterase	B-protein
inhibitor	O
,	O
was	O
studied	O
in	O
combination	O
with	O
the	O
range	O
of	O
atropine	O
doses	O
.	O

(	O
5	O
)	O
An	O
increase	O
in	O
leukocyte	O
-	O
counts	O
occurred	O
on	O
the	O
administration	O
of	O
serum	O
obtained	O
from	O
rabbit	O
during	O
phase	O
-	O
2	O
.	O

In	O
addition	O
,	O
we	O
identified	O
a	O
novel	O
type	O
of	O
inhibitory	O
domain	O
in	O
the	O
N	O
-	O
terminal	O
60	O
amino	O
acids	O
of	O
IRF	B-protein
-	I-protein
1	I-protein
which	O
strongly	O
inhibits	O
its	O
transcriptional	O
activity	O
.	O

Similarly	O
,	O
expression	O
of	O
a	O
transiently	O
transfected	O
wild	B-protein
-	I-protein
type	I-protein
prothymosin	I-protein
alpha	I-protein
gene	I-protein
as	O
the	O
reporter	O
was	O
not	O
affected	O
by	O
a	O
repertoire	O
of	O
myc	B-protein
-	I-protein
derived	I-protein
genes	I-protein
,	O
including	O
myc	B-protein
itself	O
and	O
dominant	O
or	O
recessive	O
negative	O
myc	B-protein
mutants	I-protein
.	O

In	O
this	O
paper	O
,	O
a	O
comparison	O
between	O
the	O
number	O
and	O
shape	O
of	O
corneal	O
endothelial	O
cells	O
has	O
been	O
performed	O
in	O
25	O
patients	O
before	O
and	O
6	O
months	O
after	O
PRK	O
.	O

Experimental	O
study	O
of	O
ta	O
chengchi	O
tang	O
decoction	O
for	O
relieving	O
lung	O
injury	O
during	O
acute	O
necrotizing	O
pancreatitis	O
The	O
objectives	O
of	O
the	O
study	O
were	O
to	O
investigate	O
the	O
changes	O
of	O
leukocyte	O
adhesiveness	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
in	O
the	O
early	O
stage	O
of	O
acute	O
necrotizing	O
pancreatitis	O
(	O
ANP	O
)	O
,	O
to	O
go	O
further	O
into	O
the	O
relation	O
of	O
those	O
changes	O
to	O
lung	O
injury	O
of	O
ANP	O
,	O
and	O
to	O
evaluate	O
the	O
prohibitive	O
effect	O
of	O
ta	O
chengchi	O
tang	O
Decoction	O
on	O
leukocyte	O
adhesion	O
and	O
TNF	B-protein
secretion	O
.	O

Processing	O
of	O
the	O
NS3	B-protein
'	I-protein
-	I-protein
5B	I-protein
polyprotein	I-protein
was	O
complex	O
and	O
occurred	O
rapidly	O
.	O

Sequential	O
cleavage	O
by	O
metallopeptidases	B-protein
and	O
proteasomes	O
is	O
involved	O
in	O
processing	O
HIV	B-protein
-	I-protein
1	I-protein
ENV	I-protein
epitope	I-protein
for	O
endogenous	O
MHC	B-protein
class	I-protein
I	I-protein
antigen	I-protein
presentation	O
.	O

Identification	O
of	O
a	O
new	O
gene	O
in	O
the	O
streptococcal	O
plasmid	O
pLS1	O
:	O
the	O
rnaI	B-protein
gene	I-protein
.	O

We	O
recommend	O
that	O
ovarian	O
stimulation	O
is	O
done	O
only	O
if	O
there	O
is	O
a	O
valid	O
indication	O
after	O
proper	O
assessment	O
of	O
the	O
ovaries	O
,	O
and	O
that	O
women	O
who	O
have	O
had	O
ovarian	O
stimulation	O
are	O
followed	O
for	O
longer	O
than	O
at	O
present	O
.	O

In	O
Experiment	O
1	O
,	O
pups	O
that	O
had	O
received	O
an	O
injection	O
of	O
the	O
noncompetitive	O
N	B-protein
-	I-protein
methyl	I-protein
-	I-protein
D	I-protein
-	I-protein
aspartate	I-protein
receptor	I-protein
antagonist	O
MK	O
-	O
801	O
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
either	O
30	O
min	O
before	O
or	O
immediately	O
after	O
conditioning	O
spent	O
less	O
time	O
over	O
the	O
conditioned	O
odor	O
than	O
saline	O
-	O
treated	O
controls	O
.	O

Group	O
A	O
was	O
treated	O
with	O
three	O
or	O
four	O
doses	O
of	O
hepatitis	B-protein
B	I-protein
immune	I-protein
globulin	I-protein
(	O
HBIG	B-protein
)	O
in	O
one	O
of	O
three	O
different	O
schedules	O
.	O

Vestibular	O
adaptation	O
exercises	O
and	O
recovery	O
:	O
acute	O
stage	O
after	O
acoustic	O
neuroma	O
resection	O
.	O

SEA	O
was	O
recorded	O
with	O
bidirectional	O
filters	O
at	O
25	O
-	O
250	O
HZ	O
and	O
40	O
-	O
250	O
Hz	O
using	O
Simson	O
method	O
.	O

(	O
Cactaceae	O
)	O
waste	O
matter	O
.	O

During	O
chronic	O
treatment	O
,	O
when	O
plasma	O
concentrations	O
fluctuated	O
between	O
23	O
.	O
5	O
ng	O
.	O
ml	O
-	O
1	O
at	O
8	O
h	O
and	O
14	O
ng	O
.	O
ml	O
-	O
1	O
at	O
24	O
h	O
post	O
-	O
dosing	O
,	O
ST	O
segment	O
depression	O
at	O
an	O
individually	O
comparable	O
workload	O
was	O
significantly	O
decreased	O
by	O
28	O
%	O
compared	O
with	O
placebo	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
at	O
both	O
points	O
in	O
time	O
.	O

Immunoblotting	O
of	O
expressed	O
recombinant	O
proteins	O
with	O
the	O
monoclonal	B-protein
08L	I-protein
antibody	I-protein
localized	O
the	O
08L	B-protein
epitope	O
to	O
the	O
carboxyl	O
end	O
of	O
the	O
protein	O
.	O

Consistently	O
,	O
activation	O
of	O
c	B-protein
-	I-protein
Jun	I-protein
N	I-protein
-	I-protein
terminal	I-protein
kinase	I-protein
downstream	O
of	O
Rho	B-protein
family	I-protein
GTP	I-protein
-	I-protein
binding	I-protein
proteins	I-protein
was	O
also	O
enhanced	O
when	O
Dbl	B-protein
was	O
tyrosine	O
-	O
phosphorylated	O
.	O

However	O
,	O
both	O
TPN	O
groups	O
showed	O
a	O
marked	O
increase	O
in	O
activities	O
of	O
liver	B-protein
lysosomal	I-protein
enzymes	I-protein
.	O

267	O
,	O
4870	O
-	O
4877	O
)	O
)	O
indicates	O
an	O
overall	O
identity	O
of	O
58	O
and	O
56	O
%	O
,	O
respectively	O
,	O
with	O
a	O
91	O
and	O
92	O
%	O
identity	O
in	O
the	O
highly	O
conserved	O
transmembrane	O
and	O
cytoplasmic	O
domains	O
.	O

Nuclear	B-protein
beta	I-protein
II	I-protein
PKC	I-protein
,	O
like	O
p34cdc2	B-protein
kinase	I-protein
,	O
may	O
function	O
to	O
regulate	O
nuclear	O
lamina	O
structural	O
stability	O
during	O
cell	O
cycle	O
.	O

When	O
Hy	O
-	O
Vac	O
SPF	O
type	O
V	O
embryos	O
were	O
exposed	O
to	O
either	O
0	O
.	O
20	O
ml	O
50	O
%	O
ethanol	O
in	O
CRS	O
or	O
to	O
0	O
.	O
20	O
ml	O
CRS	O
(	O
controls	O
)	O
,	O
ethanol	O
-	O
treated	O
embryos	O
showed	O
a	O
VSD	O
incidence	O
of	O
34	O
.	O
1	O
%	O
compared	O
with	O
a	O
3	O
.	O
6	O
%	O
incidence	O
in	O
the	O
controls	O
(	O
P	O
=	O
0	O
.	O
0017	O
)	O
.	O

Gains	O
increased	O
3	O
.	O
5	O
%	O
(	O
P	O
less	O
than	O
.	O
10	O
)	O
and	O
feed	O
conversion	O
improved	O
5	O
.	O
9	O
%	O
(	O
P	O
less	O
than	O
.	O
07	O
)	O
in	O
steers	O
fed	O
.	O
28	O
%	O
AS	O
-	O
VFA	O
compared	O
with	O
gain	O
and	O
feed	O
conversion	O
of	O
the	O
control	O
steers	O
.	O

Endocrine	O
cells	O
were	O
studied	O
by	O
means	O
of	O
Grimelius	O
'	O
silver	O
staining	O
and	O
immunostaining	O
for	O
chromogranin	B-protein
,	O
a	O
general	O
marker	O
of	O
endocrine	O
cells	O
.	O

Genetic	O
and	O
molecular	O
data	O
indicate	O
that	O
wild	B-protein
-	I-protein
type	I-protein
Pan	I-protein
and	O
CiD	B-protein
compete	O
for	O
binding	O
to	O
Arm	B-protein
,	O
leading	O
to	O
a	O
compromised	O
transduction	O
of	O
the	O
Wg	B-protein
signal	O
in	O
heterozygous	O
ciD	B-protein
/	I-protein
+	I-protein
animals	O
and	O
to	O
a	O
dramatic	O
enhancement	O
of	O
the	O
gain	O
-	O
of	O
-	O
function	O
activity	O
of	O
CiD	B-protein
in	O
homozygous	O
mutants	O
.	O

Our	O
data	O
therefore	O
indicate	O
that	O
it	O
is	O
possible	O
to	O
engineer	O
the	O
HA	B-protein
envelope	I-protein
glycoprotein	I-protein
by	O
fusing	O
ligands	O
to	O
its	O
amino	O
-	O
terminal	O
end	O
without	O
affecting	O
its	O
fusion	O
activity	O
.	O

Drug	O
and	O
nutrient	O
interactions	O
.	O

The	O
protein	O
first	O
identified	O
by	O
the	O
monoclonal	B-protein
antibody	I-protein
Q18	I-protein
is	O
encoded	O
by	O
a	O
gene	O
located	O
in	O
57A	O
on	O
polytene	O
chromosomes	O
and	O
has	O
been	O
consequently	O
named	O
Hrb57A	B-protein
.	O

On	O
admission	O
to	O
our	O
department	O
in	O
September	O
,	O
1987	O
,	O
the	O
patient	O
was	O
alert	O
and	O
had	O
spastic	O
paraparesis	O
,	O
the	O
impairment	O
of	O
all	O
sensory	O
modalities	O
below	O
the	O
level	O
of	O
Th	O
10	O
and	O
urinary	O
disturbance	O
.	O

In	O
conclusion	O
,	O
changes	O
in	O
carotid	O
sinus	O
stimulation	O
alters	O
blood	O
flow	O
to	O
the	O
hindlimb	O
through	O
changes	O
in	O
both	O
Pcrit	O
and	O
Ra	O
.	O

This	O
R	O
-	O
domain	O
may	O
modulate	O
the	O
interaction	O
with	O
SRF	B-protein
,	O
providing	O
a	O
mechanism	O
that	O
would	O
be	O
unique	O
to	O
FLI1	B-protein
and	O
EWS	B-protein
-	I-protein
FLI1	I-protein
,	O
thus	O
implicating	O
a	O
novel	O
function	O
for	O
these	O
ETS	B-protein
transcription	I-protein
factors	I-protein
in	O
the	O
regulation	O
of	O
the	O
Egr1	B-protein
gene	I-protein
.	O

A	O
new	O
generation	O
of	O
information	O
retrieval	O
tools	O
for	O
biologists	O
:	O
the	O
example	O
of	O
the	O
ExPASy	O
WWW	O
server	O
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
the	O
mouse	B-protein
NMO1	I-protein
cDNA	I-protein
,	O
which	O
encodes	O
the	O
NAD	B-protein
(	I-protein
P	I-protein
)	I-protein
H	I-protein
:	I-protein
menadione	I-protein
oxidoreductase	I-protein
[	O
also	O
called	O
NAD	B-protein
(	I-protein
P	I-protein
)	I-protein
H	I-protein
:	I-protein
(	I-protein
quinone	I-protein
acceptor	I-protein
)	I-protein
oxidoreductase	I-protein
;	I-protein
quinone	I-protein
reductase	I-protein
;	O
azo	B-protein
dye	I-protein
reductase	I-protein
;	O
DT	B-protein
diaphorase	I-protein
;	O
EC	B-protein
1	I-protein
.	I-protein
6	I-protein
.	I-protein
99	I-protein
.	I-protein
2	I-protein
]	I-protein
.	O

Type	O
I	O
cysts	O
(	O
with	O
a	O
high	O
K	O
+	O
/	O
Na	O
+	O
ratio	O
)	O
tend	O
to	O
have	O
higher	O
total	O
PSA	B-protein
than	O
Type	O
II	O
cysts	O
.	O

The	O
presence	O
of	O
local	O
abnormalities	O
in	O
both	O
patients	O
can	O
support	O
the	O
hypothesis	O
that	O
the	O
cortex	O
,	O
especially	O
of	O
the	O
temporal	O
anterior	O
lobe	O
,	O
is	O
involved	O
in	O
the	O
origin	O
of	O
the	O
laughing	O
seizures	O
.	O

In	O
summary	O
,	O
WT1	B-protein
is	O
enriched	O
by	O
oligo	O
(	O
dT	O
)	O
chromatography	O
,	O
as	O
are	O
U2AF65	B-protein
,	O
the	O
U5	B-protein
small	I-protein
nuclear	I-protein
RNP	I-protein
-	I-protein
associated	I-protein
protein	I-protein
p116	I-protein
and	O
hnRNP	B-protein
A1	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
coimmunoprecipitation	O
studies	O
suggest	O
that	O
homo	O
-	O
and	O
heterodimerization	O
occurs	O
between	O
cKrox	B-protein
family	I-protein
members	I-protein
.	O

A	O
new	O
bioencapsulation	O
technology	O
for	O
microbial	O
inoculants	O
.	O

This	O
indicates	O
that	O
recruitment	O
of	O
large	B-protein
T	I-protein
antigen	I-protein
to	O
the	O
rRNA	O
promoter	O
by	O
SL1	B-protein
constitutes	O
a	O
crucial	O
step	O
in	O
the	O
activation	O
process	O
.	O

Anatomy	O
of	O
the	O
RNA	O
and	O
gene	O
products	O
of	O
MC29	O
and	O
MH2	O
,	O
two	O
defective	O
avian	O
tumor	O
viruses	O
causing	O
acute	O
leukemia	O
and	O
carcinoma	O
:	O
evidence	O
for	O
a	O
new	O
class	O
of	O
transforming	O
genes	O
.	O

NO	O
metabolites	O
were	O
determined	O
by	O
the	O
measurement	O
of	O
nitrate	O
/	O
nitrite	O
(	O
NOx	O
,	O
micromol	O
/	O
mmol	O
creatinine	O
)	O
and	O
cyclic	O
guanosine	O
monophosphate	O
(	O
cGMP	O
,	O
nmol	O
/	O
mmol	O
creatinine	O
)	O
in	O
plasma	O
and	O
urine	O
.	O

The	O
therapeutic	O
protocole	O
used	O
at	O
the	O
Gustave	O
Roussy	O
Institute	O
for	O
invasive	O
epithelioma	O
of	O
the	O
uterine	O
cervix	O
rests	O
,	O
for	O
limited	O
forms	O
(	O
T1B	O
-	O
T2	O
proximal	O
)	O
,	O
on	O
combined	O
radiology	O
and	O
surgery	O
.	O

Thus	O
,	O
NART	O
-	O
R	O
performance	O
may	O
not	O
be	O
a	O
valid	O
estimate	O
of	O
baseline	O
IQ	O
for	O
patients	O
with	O
neurologic	O
disorders	O
with	O
suspected	O
language	O
impairment	O
.	O

Staphylococcal	B-protein
enterotoxin	I-protein
A	I-protein
involvement	O
in	O
the	O
illness	O
of	O
a	O
20	O
-	O
month	O
-	O
old	O
burn	O
patient	O
.	O

Importantly	O
,	O
concomitant	O
expression	O
of	O
constitutive	O
activated	O
Raf	B-protein
and	O
V12N38	B-protein
Ras	I-protein
results	O
in	O
almost	O
complete	O
loss	O
of	O
TTF	B-protein
-	I-protein
1	I-protein
activity	O
.	O

Using	O
an	O
audiotape	O
cassette	O
and	O
headphones	O
the	O
duration	O
of	O
the	O
hallucinations	O
decreased	O
significantly	O
.	O

These	O
studies	O
indicate	O
that	O
the	O
acidimetric	O
test	O
was	O
less	O
sensitive	O
than	O
the	O
chromogenic	O
cephalosporin	O
substrates	O
and	O
that	O
nitrocefin	O
and	O
S1	O
could	O
be	O
used	O
to	O
screen	O
for	O
beta	B-protein
-	I-protein
lactamase	I-protein
production	O
in	O
these	O
tested	O
species	O
.	O

We	O
performed	O
the	O
present	O
study	O
to	O
clarify	O
the	O
relationship	O
between	O
the	O
DOX	O
binding	O
ability	O
(	O
%	O
DB	O
)	O
and	O
the	O
histologic	O
response	O
,	O
rate	O
of	O
decrease	O
in	O
tumor	O
volume	O
of	O
malignant	O
soft	O
tissue	O
tumors	O
after	O
preoperative	O
chemotherapy	O
and	O
prognosis	O
.	O

2000	O
update	O
of	O
recommendations	O
for	O
the	O
use	O
of	O
hematopoietic	B-protein
colony	I-protein
-	I-protein
stimulating	I-protein
factors	I-protein
:	O
evidence	O
-	O
based	O
,	O
clinical	O
practice	O
guidelines	O
.	O

The	O
beta	O
chain	O
contains	O
five	O
potential	O
N	O
-	O
linked	O
glycosylation	O
sites	O
,	O
and	O
endoglycosidase	B-protein
digestion	O
suggested	O
that	O
the	O
beta	O
chain	O
contained	O
multiple	O
complex	O
carbohydrate	O
side	O
chains	O
.	O

Rapid	O
detection	O
of	O
this	O
mutation	O
is	O
achieved	O
by	O
restriction	O
digestion	O
of	O
PCR	O
-	O
amplified	O
genomic	O
DNA	O
;	O
a	O
mismatch	O
primer	O
combined	O
with	O
the	O
point	O
mutation	O
creates	O
a	O
Tru9I	B-protein
restriction	I-protein
site	I-protein
.	O

Transactivation	O
domain	O
is	O
located	O
downstream	O
of	O
the	O
128	B-protein
-	I-protein
amino	I-protein
-	I-protein
acid	I-protein
runt	I-protein
homology	I-protein
region	I-protein
,	O
referred	O
to	O
as	O
the	O
Runt	B-protein
domain	I-protein
.	O

Mutational	O
analysis	O
showed	O
that	O
the	O
U	O
-	O
box	O
,	O
like	O
the	O
RING	O
finger	O
in	O
other	O
proteins	O
,	O
forms	O
the	O
physical	O
basis	O
for	O
the	O
interaction	O
with	O
E2	B-protein
enzymes	I-protein
.	O

Pb	O
foil	O
(	O
0	O
.	O
55	O
gcm	O
-	O
2	O
)	O
provided	O
the	O
best	O
overall	O
improvement	O
.	O

This	O
article	O
reviews	O
recent	O
information	O
on	O
the	O
frequency	O
,	O
characteristics	O
,	O
and	O
possible	O
pathogenic	O
mechanisms	O
of	O
the	O
vasculitides	O
occurring	O
in	O
patients	O
with	O
the	O
main	O
connective	O
tissue	O
diseases	O
.	O

During	O
activity	O
III	O
,	O
one	O
patient	O
developed	O
angina	O
.	O

Eight	O
hr	O
of	O
acidosis	O
caused	O
a	O
significant	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
decrease	O
in	O
P50	O
in	O
vitro	O
which	O
fell	O
from	O
29	O
.	O
0	O
to	O
24	O
.	O
4	O
torr	O
.	O

Neutron	O
scattering	O
measurements	O
of	O
critical	O
exponents	O
in	O
CsMnBr3	O
:	O
A	O
Z2	O
>	O
=	O
1	O
antiferromagnet	O
.	O

Thus	O
,	O
the	O
B	O
-	O
S	O
mutant	O
does	O
not	O
mimic	O
efficiently	O
the	O
chloroplastic	B-protein
GAPDHs	I-protein
,	O
and	O
long	O
-	O
range	O
and	O
/	O
or	O
second	O
-	O
layer	O
effects	O
,	O
not	O
easily	O
predictable	O
from	O
visual	O
inspection	O
of	O
three	O
-	O
dimensional	O
structures	O
,	O
need	O
to	O
be	O
taken	O
into	O
account	O
for	O
designing	O
a	O
true	O
`	O
`	O
chloroplastic	O
-	O
like	O
'	O
'	O
mutant	O
of	O
cytosolic	B-protein
GAPDH	I-protein
.	O

It	O
has	O
been	O
proposed	O
that	O
the	O
parCBA	B-protein
operon	I-protein
encodes	O
a	O
plasmid	O
partitioning	O
system	O
(	O
M	O
.	O

Genome	O
plasticity	O
in	O
the	O
distal	B-protein
tail	I-protein
fiber	I-protein
locus	I-protein
of	O
the	O
T	O
-	O
even	O
bacteriophage	O
:	O
recombination	O
between	O
conserved	O
motifs	O
swaps	O
adhesin	B-protein
specificity	O
.	O

Because	O
of	O
its	O
great	O
reliability	O
,	O
conventional	O
arteriography	O
occupies	O
a	O
place	O
of	O
choice	O
among	O
the	O
medical	O
imaging	O
techniques	O
.	O

They	O
were	O
checked	O
for	O
anti	B-protein
-	I-protein
HCV	I-protein
(	O
anti	B-protein
-	I-protein
C100	I-protein
-	I-protein
3	I-protein
)	O
with	O
HCV	O
EIA	O
kit	O
(	O
Abbott	O
Lab	O
.	O
,	O
North	O
Chicago	O
,	O
IL	O
)	O
.	O

Therefore	O
more	O
active	O
and	O
tolerable	O
salvage	O
regimens	O
are	O
needed	O
.	O

A	O
variety	O
of	O
professional	O
and	O
self	O
-	O
applied	O
fluoride	O
products	O
are	O
available	O
and	O
new	O
fluoride	O
delivery	O
systems	O
have	O
recently	O
entered	O
the	O
market	O
.	O

These	O
results	O
indicate	O
that	O
K	B-protein
-	I-protein
glypican	I-protein
is	O
a	O
novel	O
GPI	B-protein
-	I-protein
anchored	I-protein
HSPG	I-protein
involved	O
in	O
embryonic	O
development	O
.	O

Serum	O
gastrin	B-protein
levels	O
did	O
not	O
change	O
in	O
either	O
group	O
;	O
however	O
,	O
background	O
serum	O
gastrin	B-protein
concentrations	O
were	O
significantly	O
greater	O
for	O
V	O
@	O
P	O
patients	O
than	O
V	O
@	O
A	O
patients	O
throughout	O
the	O
study	O
.	O

These	O
residues	O
,	O
Ile244	O
at	O
the	O
extracellular	O
end	O
of	O
transmembrane	O
helix	O
3	O
,	O
and	O
Tyr318	O
at	O
the	O
COOH	O
-	O
terminal	O
portion	O
of	O
extracellular	O
loop	O
2	O
,	O
are	O
replaced	O
by	O
Leu	O
and	O
Ile	O
in	O
the	O
PTH	B-protein
-	I-protein
1	I-protein
receptor	I-protein
,	O
respectively	O
.	O

Viable	O
flap	O
areas	O
were	O
established	O
following	O
vascular	O
pedicle	O
ligation	O
(	O
both	O
vessels	O
or	O
only	O
artery	O
or	O
vein	O
)	O
,	O
on	O
the	O
third	O
day	O
after	O
flap	O
replantation	O
in	O
both	O
island	O
and	O
free	O
flaps	O
.	O

Using	O
backcross	O
analysis	O
,	O
both	O
exons	O
1	O
and	O
4	O
mapped	O
to	O
a	O
proximal	O
region	O
of	O
murine	O
Chromosome	O
4	O
indistinguishable	O
from	O
the	O
vacillans	B-protein
gene	I-protein
.	O

It	O
was	O
found	O
that	O
under	O
the	O
selected	O
conditions	O
a	O
linear	O
dependence	O
exists	O
between	O
the	O
betaI	O
%	O
value	O
and	O
lgC	O
within	O
the	O
range	O
of	O
0	O
.	O
5	O
-	O
-	O
10	O
mug	O
ruscogenin	O
.	O

Characterization	O
of	O
the	O
transcription	B-protein
factor	I-protein
MTF	I-protein
-	I-protein
1	I-protein
from	O
the	O
Japanese	O
pufferfish	O
(	O
Fugu	O
rubripes	O
)	O
reveals	O
evolutionary	O
conservation	O
of	O
heavy	O
metal	O
stress	O
response	O
.	O

Furthermore	O
,	O
no	O
Shine	O
-	O
Dalgarno	O
sequences	O
are	O
present	O
upstream	O
of	O
the	O
presumed	O
translational	O
start	O
codons	O
.	O

Holger	O
v	O
.	O

Tolerance	O
to	O
ADAL	O
-	O
2	O
was	O
similar	O
to	O
that	O
of	O
Vicryl	O
suture	O
and	O
tolerance	O
to	O
ADAL	O
-	O
2	O
was	O
superior	O
to	O
that	O
to	O
Tisuacryl	O
.	O

PKNbeta	B-protein
had	O
high	O
sequence	O
homology	O
with	O
PKNalpha	B-protein
,	O
originally	O
isolated	O
PKN	B-protein
,	O
especially	O
in	O
the	O
repeats	O
of	O
charged	O
amino	O
acid	O
-	O
rich	O
region	O
with	O
leucine	O
-	O
zipper	O
like	O
sequences	O
(	O
CZ	B-protein
region	I-protein
/	I-protein
HR1	I-protein
)	O
,	O
in	O
the	O
carboxyl	O
-	O
terminal	O
catalytic	O
domain	O
,	O
and	O
in	O
approximately	O
130	O
amino	O
acid	O
stretch	O
(	O
D	B-protein
region	I-protein
/	I-protein
HR2	I-protein
)	O
,	O
located	O
between	O
CZ	B-protein
region	I-protein
/	I-protein
HR1	I-protein
and	O
the	O
catalytic	O
domain	O
.	O

[	O
figure	O
:	O
see	O
text	O
]	O
The	O
Stille	O
coupling	O
reaction	O
has	O
been	O
performed	O
in	O
1	O
-	O
butyl	O
-	O
3	O
-	O
methylimidazolium	O
tetrafluoroborate	O
(	O
BMIM	O
BF4	O
)	O
,	O
a	O
room	O
-	O
temperature	O
ionic	O
liquid	O
(	O
RTIL	O
)	O
.	O

In	O
general	O
,	O
the	O
values	O
obtained	O
by	O
the	O
two	O
methods	O
were	O
in	O
agreement	O
for	O
each	O
species	O
of	O
epidermal	B-protein
growth	I-protein
factor	I-protein
and	O
followed	O
the	O
order	O
:	O
wild	O
type	O
greater	O
than	O
Glu24	O
-	O
-	O
-	O
-	O
Gly	O
greater	O
than	O
Asp27	O
-	O
-	O
-	O
-	O
Gly	O
much	O
greater	O
than	O
Pro7	O
-	O
-	O
-	O
-	O
Thr	O
greater	O
than	O
Tyr29	O
-	O
-	O
-	O
-	O
Gly	O
greater	O
than	O
Leu47	O
-	O
-	O
-	O
-	O
His	O
.	O

The	O
ensembles	O
are	O
considered	O
to	O
be	O
one	O
of	O
the	O
forms	O
of	O
activity	O
of	O
the	O
structured	O
morphofunctional	O
cortical	O
units	O
,	O
i	O
.	O
e	O
.	O
the	O
columns	O
.	O

The	O
mouse	B-protein
platelet	I-protein
-	I-protein
derived	I-protein
growth	I-protein
factor	I-protein
(	I-protein
PDGF	I-protein
)	I-protein
beta	I-protein
-	I-protein
receptor	I-protein
promoter	I-protein
contains	O
a	O
CCAAT	O
motif	O
,	O
and	O
NF	B-protein
-	I-protein
Y	I-protein
plays	O
an	O
essential	O
role	O
in	O
its	O
transcription	O
.	O

The	O
growth	O
-	O
promoting	O
properties	O
of	O
the	O
retroviral	B-protein
v	I-protein
-	I-protein
erbA	I-protein
oncogene	I-protein
,	O
a	O
highly	O
mutated	O
version	O
of	O
the	O
chicken	B-protein
thyroid	I-protein
hormone	I-protein
receptor	I-protein
(	I-protein
TR	I-protein
)	I-protein
alpha	I-protein
,	O
have	O
so	O
far	O
exclusively	O
been	O
linked	O
to	O
dominant	O
repression	O
of	O
the	O
antimitogenic	O
roles	O
of	O
TR	B-protein
and	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
.	O

With	O
a	O
population	O
of	O
853	O
million	O
there	O
should	O
be	O
51	O
,	O
204	O
patients	O
with	O
hemophilia	O
A	O
in	O
India	O
assuming	O
a	O
prevalence	O
of	O
6	O
/	O
100	O
,	O
000	O
population	O
.	O

Restriction	O
enzyme	O
mapping	O
and	O
Southern	O
analysis	O
indicated	O
further	O
that	O
the	O
human	B-protein
MZF	I-protein
-	I-protein
1	I-protein
gene	I-protein
is	O
a	O
single	O
-	O
copy	O
gene	O
.	O

Anti	B-protein
-	I-protein
CRK	I-protein
antibodies	I-protein
detect	O
a	O
53kDa	O
protein	O
in	O
extracts	O
of	O
C	O
.	O
fasciculata	O
in	O
agreement	O
with	O
the	O
size	O
predicted	O
from	O
the	O
nucleotide	O
sequence	O
of	O
the	O
cloned	O
gene	O
.	O

We	O
developed	O
a	O
system	O
for	O
domain	O
shuffling	O
to	O
establish	O
the	O
function	O
of	O
C1	B-protein
domains	I-protein
from	O
human	B-protein
Raf	I-protein
kinase	I-protein
and	O
rat	B-protein
PKC	I-protein
eta	I-protein
in	O
yeast	O
.	O

This	O
survey	O
included	O
3000	O
randomly	O
selected	O
Norwegians	O
above	O
18	O
years	O
of	O
age	O
who	O
received	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Core	O
Quality	O
of	O
Life	O
Questionnaire	O
(	O
EORTC	O
QLQ	O
-	O
C30	O
(	O
+	O
3	O
)	O
by	O
mail	O
.	O

To	O
isolate	O
this	O
gene	O
,	O
a	O
P	O
-	O
1	O
artificial	O
chromosome	O
(	O
PAC	O
)	O
library	O
was	O
screened	O
with	O
a	O
full	B-protein
length	I-protein
UGT2B7	I-protein
probe	O
and	O
a	O
clone	O
of	O
approximately	O
100	O
kb	O
in	O
length	O
was	O
isolated	O
.	O

Simple	O
method	O
for	O
determination	O
of	O
the	O
cephalosporin	O
DQ	O
-	O
2556	O
in	O
biological	O
fluids	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
.	O

Two	O
new	O
flavone	O
glucosides	O
,	O
nevadensin	O
5	O
-	O
O	O
-	O
beta	O
-	O
D	O
-	O
glucoside	O
and	O
nevadensin	O
5	O
-	O
O	O
-	O
beta	O
-	O
D	O
-	O
glucosyl	O
(	O
1	O
-	O
-	O
>	O
6	O
)	O
beta	O
-	O
D	O
-	O
glucoside	O
,	O
have	O
been	O
isolated	O
from	O
the	O
aerial	O
parts	O
of	O
Lysionotus	O
pauciflorus	O
.	O

Molecule	O
(	O
s	O
)	O
secreted	O
by	O
neuronal	O
cultures	O
contribute	O
to	O
this	O
induction	O
of	O
GLT	B-protein
-	I-protein
1	I-protein
,	O
but	O
little	O
is	O
known	O
about	O
the	O
signaling	O
pathways	O
mediating	O
this	O
regulation	O
.	O

The	O
six	O
commonest	O
causes	O
of	O
death	O
varied	O
in	O
the	O
three	O
ethnic	O
groups	O
.	O

These	O
`	O
`	O
nucleocapsid	O
-	O
like	O
'	O
'	O
structures	O
were	O
readily	O
purified	O
by	O
density	O
gradient	O
centrifugation	O
.	O

Montelukast	O
reduces	O
airway	O
eosinophilic	O
inflammation	O
in	O
asthma	O
:	O
a	O
randomized	O
,	O
controlled	O
trial	O
.	O

This	O
is	O
particularly	O
intriguing	O
because	O
SKUT	O
-	O
1B	O
-	O
20	O
cells	O
lack	O
the	O
transcription	O
factor	O
Pit	B-protein
-	I-protein
1	I-protein
.	O

Surprisingly	O
,	O
a	O
C	O
to	O
G	O
transversion	O
at	O
the	O
first	O
residue	O
of	O
the	O
CAT	B-protein
pentanucleotide	I-protein
,	O
which	O
severely	O
impairs	O
the	O
activity	O
of	O
both	O
promoters	O
,	O
appears	O
to	O
increase	O
affinity	O
of	O
the	O
CAT	B-protein
binding	I-protein
protein	I-protein
.	O

Using	O
a	O
polymerase	B-protein
chain	O
reaction	O
-	O
based	O
approach	O
,	O
we	O
cloned	O
a	O
150	O
-	O
base	O
pair	O
fragment	O
of	O
a	O
new	O
sialymotif	O
from	O
human	O
placenta	O
mRNA	O
,	O
which	O
was	O
then	O
used	O
as	O
a	O
probe	O
to	O
clone	O
the	O
complete	O
coding	O
sequence	O
of	O
the	O
corresponding	O
gene	O
from	O
a	O
cDNA	O
library	O
.	O

The	O
biosynthesis	O
and	O
stability	O
of	O
the	O
three	O
mutant	O
proteins	O
were	O
similar	O
to	O
those	O
of	O
the	O
wild	B-protein
-	I-protein
type	I-protein
erbB	I-protein
protein	I-protein
,	O
and	O
all	O
three	O
retained	O
the	O
ability	O
to	O
transform	O
chicken	O
embryo	O
fibroblasts	O
.	O

The	O
results	O
indicate	O
that	O
rep	B-protein
strongly	O
enhances	O
the	O
function	O
of	O
negative	O
regulatory	O
elements	O
of	O
the	O
LTR	O
.	O

A	O
genetic	O
system	O
was	O
devised	O
to	O
select	O
for	O
pi	B-protein
protein	I-protein
mutants	I-protein
which	O
discriminate	O
between	O
IR	O
and	O
DR	O
(	O
York	O
et	O
al	O
.	O
,	O
Gene	O
(	O
Amst	O
.	O
)	O
116	O
,	O
7	O
-	O
12	O
,	O
1992	O
;	O
York	O
and	O
Filutowicz	O
,	O
J	O
.	O

Mitochondria	O
-	O
lytic	O
action	O
of	O
warfarin	O
in	O
lymphocytes	O
.	O

Zarix	O
expected	O
patient	O
enrollment	O
in	O
Canadian	O
clinical	O
sites	O
to	O
begin	O
in	O
Spring	O
2001	O
[	O
397955	O
]	O
,	O
[	O
405928	O
]	O
.	O

Members	O
of	O
SVA	B-protein
are	O
also	O
present	O
in	O
the	O
complement	B-protein
C2	I-protein
gene	I-protein
located	O
about	O
20	O
kilobases	O
upstream	O
of	O
RP1	B-protein
in	O
the	O
HLA	B-protein
and	O
in	O
the	O
cytochrome	B-protein
CYP1A1	I-protein
gene	I-protein
.	O

The	O
reduced	O
efficiency	O
in	O
the	O
glycosylase	B-protein
activity	O
is	O
also	O
reflected	O
in	O
a	O
reduced	O
ability	O
of	O
S120K	B-protein
MutY	I-protein
to	O
prevent	O
DNA	O
mutations	O
in	O
vivo	O
.	O

The	O
plasma	O
half	O
-	O
life	O
of	O
slow	O
disposition	O
phase	O
t1	O
/	O
2	O
beta	O
,	O
increases	O
from	O
0	O
.	O
26	O
hour	O
in	O
rabbits	O
with	O
normal	O
renal	O
function	O
to	O
5	O
.	O
41	O
hours	O
in	O
rabbits	O
with	O
severe	O
renal	O
impairment	O
.	O

TOR2	B-protein
is	O
part	O
of	O
two	O
related	O
signaling	O
pathways	O
coordinating	O
cell	O
growth	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
T	B-protein
-	I-protein
cyt	I-protein
promoter	I-protein
,	O
although	O
of	O
bacterial	O
origin	O
is	O
active	O
in	O
planta	O
and	O
the	O
30	B-protein
bp	I-protein
cyt	I-protein
-	I-protein
1	I-protein
element	I-protein
is	O
located	O
within	O
a	O
region	O
that	O
is	O
essential	O
for	O
T	B-protein
-	I-protein
cyt	I-protein
promotor	I-protein
activity	O
in	O
leaf	O
,	O
stem	O
and	O
root	O
cells	O
of	O
tobacco	O
plants	O
.	O

The	O
weak	O
base	O
ketoconazole	O
showed	O
complete	O
dissolution	O
from	O
a	O
tablet	O
formulation	O
in	O
Simulated	O
Gastric	O
Fluid	O
without	O
pepsin	B-protein
(	O
SGFsp	O
)	O
within	O
30	O
minutes	O
,	O
70	O
%	O
dissolution	O
in	O
2	O
hours	O
under	O
fed	O
state	O
simulated	O
upper	O
jejunal	O
conditions	O
but	O
only	O
6	O
%	O
dissolution	O
in	O
2	O
hours	O
under	O
fasted	O
state	O
conditions	O
.	O

Phosphorylation	O
analyses	O
indicated	O
that	O
inhibition	O
of	O
ERK	B-protein
-	I-protein
1	I-protein
/	I-protein
2	I-protein
decreased	O
okadaic	O
acid	O
-	O
elevated	O
phosphorylation	O
of	O
JunD	B-protein
and	O
FosB	B-protein
.	O

A	O
total	O
of	O
174	O
primer	O
pairs	O
gave	O
interpretable	O
banding	O
patterns	O
,	O
137	O
(	O
79	O
%	O
)	O
of	O
which	O
revealed	O
at	O
least	O
two	O
alleles	O
on	O
native	O
polyacrylamide	O
gels	O
.	O

All	O
problems	O
were	O
associated	O
with	O
fractured	O
or	O
lost	O
screws	O
.	O

Following	O
baseline	O
clinical	O
examination	O
and	O
initial	O
periodontal	O
therapy	O
,	O
32	O
patients	O
received	O
mucogingival	O
surgery	O
with	O
free	O
gingival	O
grafts	O
for	O
treatment	O
of	O
insufficient	O
attached	O
gingiva	O
.	O

This	O
effect	O
was	O
not	O
seen	O
in	O
conjunction	O
with	O
oxycodone	O
,	O
a	O
morphine	B-protein
-	I-protein
like	I-protein
mu	I-protein
-	I-protein
receptor	I-protein
agonist	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
mechanism	O
of	O
activation	O
of	O
HIF	B-protein
-	I-protein
1alpha	I-protein
is	O
a	O
multi	O
-	O
step	O
process	O
which	O
includes	O
hypoxia	O
-	O
dependent	O
nuclear	O
import	O
and	O
activation	O
(	O
derepression	O
)	O
of	O
the	O
transactivation	O
domain	O
,	O
resulting	O
in	O
recruitment	O
of	O
the	O
CREB	B-protein
-	I-protein
binding	I-protein
protein	I-protein
(	O
CBP	B-protein
)	O
/	B-protein
p300	I-protein
coactivator	I-protein
.	O

There	O
were	O
15	O
deaths	O
,	O
seven	O
of	O
which	O
were	O
felt	O
to	O
be	O
avoidable	O
.	O

Sequence	O
comparison	O
of	O
cytochromes	B-protein
bd	I-protein
and	O
their	O
homologs	O
from	O
various	O
organisms	O
demonstrates	O
that	O
the	O
proteins	O
can	O
be	O
classified	O
into	O
two	O
subfamilies	O
,	O
a	O
proteobacterial	O
type	O
including	O
E	B-protein
.	I-protein
coli	I-protein
bd	I-protein
and	O
a	O
more	O
widely	O
distributed	O
type	O
including	O
the	O
B	O
.	O
stearothermophilus	O
enzyme	O
,	O
suggesting	O
that	O
the	O
latter	O
type	O
is	O
evolutionarily	O
older	O
.	O

The	O
beta	O
subunit	O
of	O
the	O
heterotrimeric	B-protein
G	I-protein
proteins	I-protein
that	O
transduce	O
signals	O
across	O
the	O
plasma	O
membrane	O
is	O
made	O
up	O
of	O
an	O
amino	O
-	O
terminal	O
alpha	O
-	O
helical	O
segment	O
followed	O
by	O
seven	O
repeating	O
units	O
called	O
WD	O
(	O
Trp	O
-	O
Asp	O
)	O
repeats	O
that	O
occur	O
in	O
about	O
140	O
different	O
proteins	O
.	O

Administration	O
of	O
RIFA	O
at	O
200	O
mg	O
/	O
kg	O
/	O
day	O
in	O
combination	O
with	O
ATO	O
at	O
100	O
mg	O
/	O
kg	O
/	O
day	O
resulted	O
in	O
a	O
marked	O
prolongation	O
of	O
survival	O
compared	O
with	O
that	O
for	O
mice	O
that	O
received	O
ATO	O
or	O
RIFA	O
alone	O
.	O

The	O
patients	O
and	O
their	O
families	O
were	O
closely	O
questioned	O
,	O
and	O
full	O
clinical	O
examination	O
included	O
a	O
test	O
for	O
orthostasia	O
.	O

Thyroid	O
lymphoma	O
and	O
its	O
management	O
.	O

In	O
eukaryotic	O
cells	O
,	O
premature	O
termination	O
of	O
translation	O
at	O
nonsense	O
codons	O
has	O
been	O
implicated	O
as	O
the	O
cause	O
of	O
a	O
variety	O
of	O
posttranscriptional	O
events	O
,	O
including	O
rapid	O
mRNA	O
decay	O
in	O
the	O
cytoplasm	O
or	O
the	O
nucleus	O
,	O
altered	O
splice	O
site	O
selection	O
,	O
and	O
exon	O
skipping	O
.	O

Thus	O
,	O
the	O
N	B-protein
-	I-protein
Nus	I-protein
complex	I-protein
may	O
be	O
affected	O
through	O
contacts	O
with	O
the	O
CTD	O
of	O
the	O
alpha	O
subunit	O
of	O
RNA	B-protein
polymerase	I-protein
,	O
as	O
is	O
a	O
group	O
of	O
regulatory	O
proteins	O
that	O
influences	O
initiation	O
of	O
transcription	O
.	O

The	O
highly	O
amyloidogenic	O
42	O
-	O
residue	O
form	O
of	O
Abeta	B-protein
(	O
Abeta42	B-protein
)	O
is	O
the	O
first	O
species	O
to	O
be	O
deposited	O
in	O
both	O
sporadic	O
and	O
familial	O
AD	O
.	O

Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
viral	B-protein
interferon	I-protein
regulatory	I-protein
factor	I-protein
confers	O
resistance	O
to	O
the	O
antiproliferative	O
effect	O
of	O
interferon	B-protein
-	I-protein
alpha	I-protein
.	O

Regulatory	O
motifs	O
for	O
gene	O
expression	O
such	O
as	O
nuclear	B-protein
-	I-protein
factor	I-protein
-	I-protein
kappaB	I-protein
-	I-protein
binding	I-protein
-	I-protein
site	I-protein
-	I-protein
like	I-protein
sequence	I-protein
(	O
kappaB	B-protein
site	I-protein
)	O
and	O
nuclear	B-protein
-	I-protein
factor	I-protein
-	I-protein
interleukin	I-protein
-	I-protein
6	I-protein
-	I-protein
binding	I-protein
-	I-protein
site	I-protein
-	I-protein
like	I-protein
sequence	I-protein
(	O
NF	B-protein
-	I-protein
IL	I-protein
-	I-protein
6	I-protein
site	I-protein
)	O
were	O
found	O
in	O
the	O
5	O
'	O
-	O
upstream	O
regulatory	O
region	O
.	O

Nuclear	B-protein
factor	I-protein
III	I-protein
(	O
NFIII	B-protein
)	O
is	O
a	O
protein	O
from	O
HeLa	O
cells	O
that	O
stimulates	O
the	O
initiation	O
of	O
adenovirus	O
type	O
2	O
(	O
Ad2	O
)	O
DNA	O
replication	O
by	O
binding	O
to	O
a	O
specific	O
nucleotide	O
sequence	O
in	O
the	O
origin	O
,	O
adjacent	O
to	O
the	O
nuclear	B-protein
factor	I-protein
I	I-protein
recognition	I-protein
site	I-protein
.	O

We	O
have	O
measured	O
the	O
kinetics	O
of	O
the	O
recovery	O
of	O
mRNA	O
synthesis	O
in	O
the	O
inducible	O
GAL10	B-protein
and	O
RNR3	B-protein
genes	I-protein
after	O
exposure	O
of	O
yeast	O
cells	O
to	O
ultraviolet	O
(	O
UV	O
)	O
radiation	O
.	O

These	O
data	O
define	O
a	O
conserved	O
pathway	O
wherein	O
sequential	O
histone	B-protein
modifications	O
establish	O
a	O
`	O
`	O
histone	O
code	O
'	O
'	O
essential	O
for	O
the	O
epigenetic	O
inheritance	O
of	O
heterochromatin	O
assembly	O
.	O

UGA	O
codon	O
position	O
affects	O
the	O
efficiency	O
of	O
selenocysteine	O
incorporation	O
into	O
glutathione	B-protein
peroxidase	I-protein
-	I-protein
1	I-protein
.	O

The	O
regions	O
of	O
the	O
tooth	O
fracture	O
are	O
determined	O
.	O

It	O
consists	O
of	O
2185	O
amino	O
acid	O
residues	O
encoded	O
by	O
a	O
9	O
-	O
kilobase	O
pair	O
mRNA	O
;	O
several	O
splice	O
variants	O
have	O
been	O
detected	O
in	O
human	O
and	O
rat	O
cDNA	O
libraries	O
.	O

A	O
correlation	O
coefficient	O
was	O
used	O
for	O
assessing	O
the	O
similarity	O
of	O
each	O
map	O
pattern	O
with	O
the	O
normal	O
mean	O
IQRST	O
map	O
.	O

Furthermore	O
,	O
this	O
element	O
confers	O
p53	B-protein
induction	O
to	O
the	O
otherwise	O
nonresponsive	O
adenovirus	O
major	O
late	O
promoter	O
.	O

Systemic	O
impact	O
of	O
risk	O
-	O
sharing	O
arrangements	O
.	O

By	O
screening	O
a	O
cDNA	O
library	O
with	O
a	O
probe	O
derived	O
from	O
sequences	O
downstream	O
of	O
the	O
p53p2	B-protein
start	O
site	O
,	O
we	O
have	O
cloned	O
and	O
characterized	O
a	O
cDNA	O
that	O
represents	O
a	O
mRNA	O
that	O
appears	O
to	O
have	O
been	O
initiated	O
from	O
the	O
p53p2	B-protein
promoter	I-protein
.	O

Manipulation	O
of	O
the	O
checkpoint	O
regulators	O
involved	O
in	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
may	O
thus	O
provide	O
a	O
novel	O
strategy	O
to	O
cancer	O
therapy	O
.	O

Induction	O
was	O
reversed	O
by	O
coexpression	O
of	O
A	B-protein
-	I-protein
Fos	I-protein
,	O
a	O
dominant	O
negative	O
to	O
AP	B-protein
-	I-protein
1	I-protein
.	O

Conservation	O
of	O
function	O
of	O
Drosophila	B-protein
melanogaster	I-protein
abl	I-protein
and	O
murine	B-protein
v	I-protein
-	I-protein
abl	I-protein
proteins	I-protein
in	O
transformation	O
of	O
mammalian	O
cells	O
.	O

There	O
are	O
,	O
however	O
,	O
several	O
differences	O
between	O
the	O
two	O
new	O
ars	B-protein
sequences	I-protein
.	O

These	O
sorting	B-protein
nexins	I-protein
also	O
associated	O
with	O
the	O
long	O
isoform	O
of	O
the	O
leptin	B-protein
receptor	I-protein
but	O
not	O
with	O
the	O
short	O
and	O
medium	O
isoforms	O
.	O

Molecular	O
cloning	O
of	O
the	O
polypeptide	O
component	O
of	O
the	O
Rel	B-protein
-	I-protein
related	I-protein
human	I-protein
p75	I-protein
nucleoprotein	I-protein
complex	I-protein
has	O
revealed	O
its	O
identity	O
with	O
the	O
65	O
-	O
kDa	O
(	O
p65	B-protein
)	O
subunit	O
of	O
NF	B-protein
-	I-protein
kappa	I-protein
B	I-protein
.	O

We	O
find	O
that	O
3T1	O
-	O
3T2	O
mixing	O
has	O
a	O
pronounced	O
effect	O
on	O
the	O
line	O
shape	O
and	O
radiative	O
decay	O
rate	O
of	O
emission	O
from	O
the	O
3T2	O
state	O
and	O
that	O
the	O
extent	O
of	O
mixing	O
depends	O
critically	O
on	O
the	O
magnitude	O
of	O
nontetrahedral	O
distortions	O
.	O

This	O
cohort	O
of	O
patients	O
was	O
selected	O
on	O
the	O
basis	O
of	O
clinical	O
stage	O
.	O

Systemic	O
lupus	O
erythematosus	O
was	O
diagnosed	O
.	O

We	O
describe	O
the	O
identification	O
and	O
initial	O
characterization	O
of	O
neurobeachin	B-protein
,	O
a	O
neuron	O
-	O
specific	O
multidomain	O
protein	O
of	O
327	O
kDa	O
with	O
a	O
high	O
-	O
affinity	O
binding	O
site	O
(	O
K	O
(	O
d	O
)	O
,	O
10	O
nm	O
)	O
for	O
the	O
type	B-protein
II	I-protein
regulatory	I-protein
subunit	I-protein
of	I-protein
protein	I-protein
kinase	I-protein
A	I-protein
(	O
PKA	B-protein
RII	I-protein
)	O
.	O

Intron	O
1	O
is	O
6	O
.	O
5	O
kb	O
long	O
,	O
and	O
the	O
minimal	O
sizes	O
of	O
introns	O
2	O
and	O
3	O
are	O
estimated	O
to	O
be	O
32	O
kb	O
each	O
.	O

In	O
3Y1	O
and	O
3Y1	O
v	O
-	O
crk	O
-	O
transformed	O
fibroblasts	O
,	O
almost	O
all	O
of	O
the	O
total	O
PTP1B	B-protein
and	O
about	O
40	O
%	O
of	O
total	O
p130	B-protein
(	I-protein
Cas	I-protein
)	I-protein
co	O
-	O
sediment	O
with	O
membranes	O
composed	O
primarily	O
of	O
endoplasmic	O
reticulum	O
.	O

Several	O
agents	O
have	O
been	O
tried	O
for	O
treatment	O
,	O
often	O
limited	O
by	O
toxic	O
side	O
effects	O
.	O

These	O
studies	O
have	O
shown	O
that	O
the	O
majority	O
of	O
tested	O
staphylococci	O
were	O
resistant	O
to	O
penicillin	O
G	O
,	O
erythromycin	O
,	O
and	O
produced	O
beta	B-protein
-	I-protein
lactamase	I-protein
.	O

19	O
-	O
32	O
.	O

Treatment	O
with	O
amphotericin	O
B	O
and	O
flucytosine	O
led	O
to	O
improvement	O
of	O
the	O
symptoms	O
but	O
did	O
not	O
eradicate	O
the	O
micro	O
-	O
organisms	O
from	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
.	O

The	O
yeast	O
silent	B-protein
information	I-protein
regulator	I-protein
Sir4p	I-protein
anchors	O
and	O
partitions	O
plasmids	O
.	O

Antituberculosis	O
agents	O
.	O

SRY	B-protein
-	I-protein
related	I-protein
cDNA	I-protein
encoding	O
a	O
protein	O
with	O
a	O
high	B-protein
-	I-protein
mobility	I-protein
-	I-protein
group	I-protein
(	O
HMG	B-protein
)	O
box	O
and	O
a	O
leucine	O
zipper	O
motif	O
,	O
which	O
was	O
designated	O
SOX	B-protein
-	I-protein
LZ	I-protein
,	O
was	O
isolated	O
from	O
a	O
rainbow	O
trout	O
testis	O
cDNA	O
library	O
.	O

These	O
results	O
indicate	O
a	O
possible	O
involvement	O
of	O
endogenous	B-protein
opioid	I-protein
peptides	I-protein
in	O
the	O
cardiac	O
effects	O
due	O
to	O
myocardial	O
ischaemia	O
and	O
reperfusion	O
,	O
mediated	O
by	O
opiate	B-protein
receptors	I-protein
through	O
opiate	O
antagonism	O
.	O

In	O
addition	O
,	O
a	O
wild	O
-	O
type	O
strain	O
containing	O
a	O
temperature	B-protein
-	I-protein
sensitive	I-protein
threonyl	I-protein
-	I-protein
tRNA	I-protein
synthetase	I-protein
mutation	I-protein
showed	O
increased	O
thr	B-protein
operon	I-protein
expression	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
,	O
whereas	O
none	O
of	O
the	O
mutants	O
showed	O
any	O
change	O
.	O

Ten	O
patients	O
with	O
advanced	O
,	O
diffuse	O
Hodgkin	O
'	O
s	O
and	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphomas	O
responding	O
poorly	O
to	O
the	O
most	O
widely	O
employed	O
primary	O
chemotherapy	O
regimens	O
were	O
treated	O
with	O
a	O
high	O
-	O
dose	O
chemotherapy	O
(	O
HDC	O
)	O
followed	O
by	O
rescue	O
with	O
non	O
-	O
frozen	O
autologous	O
bone	O
marrow	O
infusion	O
(	O
ABMT	O
)	O
.	O

All	O
four	O
doubly	O
tyrosine	O
phosphorylated	O
TAM	B-protein
peptides	I-protein
cross	O
-	O
compete	O
with	O
each	O
other	O
for	O
binding	O
to	O
the	O
tandem	O
SH2	B-protein
domains	I-protein
of	O
ZAP	B-protein
-	I-protein
70	I-protein
.	O

Axillary	O
nodal	O
status	O
,	O
tumour	O
progesterone	B-protein
receptor	I-protein
status	O
,	O
and	O
season	O
of	O
tumour	O
detection	O
significantly	O
influenced	O
survival	O
in	O
both	O
older	O
(	O
greater	O
than	O
50	O
yrs	O
)	O
and	O
younger	O
(	O
less	O
than	O
50	O
yrs	O
)	O
patients	O
.	O

Adjustment	O
for	O
age	O
,	O
total	O
cholesterol	O
,	O
HDL	O
cholesterol	O
,	O
triglycerides	O
,	O
current	O
smoking	O
,	O
and	O
systolic	O
pressure	O
slightly	O
reduced	O
the	O
association	O
between	O
fibrinogen	B-protein
and	O
atherosclerosis	O
.	O

However	O
,	O
a	O
cosmid	O
clone	O
containing	O
the	O
entire	O
mouse	B-protein
alpha	I-protein
1	I-protein
(	I-protein
I	I-protein
)	I-protein
gene	I-protein
,	O
including	O
3	O
.	O
7	O
kb	O
of	O
5	O
'	O
-	O
and	O
4	O
kb	O
of	O
3	O
'	O
-	O
flanking	O
DNA	O
,	O
was	O
expressed	O
at	O
reduced	O
levels	O
in	O
fibroblasts	O
overexpressing	O
oncogenic	B-protein
ras	I-protein
.	O

To	O
understand	O
the	O
regulatory	O
mechanism	O
controlling	O
its	O
expression	O
at	O
low	O
temperature	O
,	O
the	O
promoter	O
region	O
has	O
been	O
characterized	O
.	O

2	O
.	O
-	O
-	O
concepts	O
of	O
higher	O
nervous	O
function	O
in	O
the	O
USSR	O
.	O

The	O
mature	O
AP	B-protein
-	I-protein
2	I-protein
mRNA	I-protein
is	O
spliced	O
from	O
7	O
exons	O
distributed	O
over	O
a	O
region	O
of	O
18	O
kb	O
genomic	O
DNA	O
.	O

Nonsynonymous	O
substitution	O
in	O
abalone	O
sperm	O
fertilization	O
genes	O
exceeds	O
substitution	O
in	O
introns	O
and	O
mitochondrial	O
DNA	O
.	O

202	O
-	O
8	O
.	O

There	O
were	O
differences	O
between	O
males	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
for	O
most	O
of	O
the	O
characteristics	O
studied	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
strongyloidiasis	O
was	O
the	O
cause	O
of	O
sudden	O
death	O
.	O

Many	O
canonical	O
TATA	O
sequences	O
are	O
present	O
upstream	O
from	O
these	O
VZV	O
transcriptional	O
start	O
sites	O
but	O
,	O
apparently	O
,	O
are	O
not	O
used	O
.	O

A	O
comparative	O
study	O
of	O
the	O
cortical	O
end	O
of	O
the	O
auditory	O
analyzer	O
during	O
postnatal	O
ontogenesis	O
in	O
lower	O
monkeys	O
and	O
man	O
.	O

Constitutive	O
function	O
of	O
a	O
positively	O
regulated	O
promoter	O
reveals	O
new	O
sequences	O
essential	O
for	O
activity	O
.	O

Analysis	O
in	O
3	O
groups	O
of	O
patients	O
suffering	O
from	O
simple	O
acute	O
and	O
pernicious	O
malarial	O
flare	O
-	O
ups	O
.	O

The	O
mobility	O
shift	O
assay	O
of	O
the	O
65	O
bp	O
(	O
-	O
318	O
/	O
-	O
254	O
)	O
fragment	O
with	O
nuclear	O
extract	O
from	O
the	O
dark	O
-	O
adapted	O
sample	O
showed	O
an	O
additional	O
band	O
,	O
not	O
seen	O
with	O
the	O
light	O
-	O
grown	O
sample	O
.	O

Feed	O
intake	O
was	O
not	O
affected	O
by	O
dietary	O
KCl	O
or	O
NaHCO3	O
supplementation	O
,	O
but	O
average	O
daily	O
gain	O
increased	O
with	O
increased	O
K	O
and	O
tended	O
to	O
be	O
reduced	O
by	O
dietary	O
NaHCO3	O
.	O

The	O
high	O
degree	O
of	O
sequence	O
identity	O
(	O
96	O
%	O
)	O
between	O
hydrolase	B-protein
B	I-protein
and	I-protein
C	I-protein
,	O
particularly	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
,	O
suggests	O
that	O
the	O
genes	O
encoding	O
these	O
two	O
carboxylesterases	B-protein
evolved	O
by	O
duplication	O
and	O
divergence	O
of	O
a	O
common	O
ancestral	O
gene	O
.	O

Hypotension	O
was	O
produced	O
by	O
head	O
up	O
tilt	O
.	O

Immunodepression	O
was	O
combined	O
with	O
the	O
increase	O
of	O
glucocorticoid	O
activity	O
of	O
adrenal	O
cortex	O
,	O
while	O
no	O
significant	O
changes	O
in	O
thyroid	O
hormones	O
were	O
registered	O
.	O

Enhanced	O
period	O
-	O
peak	O
analysis	O
of	O
electro	O
-	O
encephalograms	O
using	O
a	O
fast	O
sinc	O
function	O
.	O

These	O
sequence	O
analyses	O
suggest	O
that	O
xIRS	B-protein
-	I-protein
u	I-protein
is	O
a	O
novel	O
member	O
of	O
the	O
IRS	B-protein
family	I-protein
rather	O
than	O
a	O
Xenopus	O
homolog	O
of	O
an	O
existing	O
member	O
.	O

Analysis	O
with	O
additional	O
anti	O
-	O
peptide	O
antibodies	O
specific	O
for	O
alpha	B-protein
,	I-protein
beta	I-protein
,	I-protein
or	I-protein
gamma	I-protein
PKC	I-protein
indicated	O
that	O
all	O
three	O
types	O
of	O
PKC	B-protein
are	O
expressed	O
in	O
JK	O
cells	O
;	O
however	O
,	O
JKPE	O
cells	O
lost	O
a	O
major	O
approximately	O
82	O
kDa	O
immunoreactive	O
cytosolic	O
protein	O
detectable	O
with	O
anti	B-protein
-	I-protein
PKC	I-protein
alpha	I-protein
antibody	I-protein
.	O

Reverse	O
transcription	O
(	O
RT	O
)	O
-	O
PCR	O
products	O
were	O
synthesized	O
with	O
two	O
degenerate	O
primers	O
derived	O
from	O
the	O
conserved	O
motifs	O
of	O
various	O
tyrosine	B-protein
kinases	I-protein
.	O

Mutations	O
in	O
a	O
region	O
located	O
15	O
to	O
30	O
bp	O
downstream	O
from	O
the	O
major	O
transcription	O
start	O
site	O
that	O
shows	O
good	O
homology	O
to	O
a	O
sequence	O
in	O
the	O
first	O
exon	O
of	O
c	B-protein
-	I-protein
fos	I-protein
implicated	O
as	O
a	O
negative	O
regulatory	O
element	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
basal	O
gene	O
expression	O
but	O
did	O
not	O
affect	O
regulation	O
.	O

After	O
all	O
doses	O
of	O
d	O
-	O
amphetamine	O
,	O
responding	O
occurred	O
largely	O
on	O
the	O
saline	O
key	O
under	O
both	O
schedules	O
.	O

Thrombosis	O
of	O
the	O
renal	O
vein	O
may	O
be	O
dramatic	O
and	O
include	O
renal	O
failure	O
.	O

The	O
experimental	O
group	O
consisted	O
of	O
61	O
examinees	O
class	O
II	O
/	O
2	O
orthodontic	O
anomalies	O
.	O

Contrary	O
to	O
expectations	O
,	O
we	O
find	O
a	O
relatively	O
high	O
level	O
of	O
variation	O
in	O
the	O
stripe	B-protein
2	I-protein
enhancer	I-protein
region	I-protein
,	O
including	O
point	O
substitutions	O
and	O
insertion	O
/	O
deletions	O
in	O
binding	O
sites	O
,	O
and	O
a	O
comparable	O
level	O
of	O
variation	O
in	O
the	O
other	O
noncoding	O
regions	O
.	O

Thyreoliberin	O
VUFB	O
in	O
thyroid	O
gammagraphy	O
.	O

A	O
soluble	O
62	O
-	O
kDa	O
protein	O
was	O
produced	O
without	O
the	O
proteolytic	O
processing	O
by	O
inserting	O
the	O
coding	O
sequence	O
of	O
amino	O
acids	O
112	O
to	O
660	O
of	O
ORF	O
-	O
2	O
in	O
a	O
baculovirus	O
expression	O
vector	O
and	O
using	O
the	O
corresponding	O
virus	O
to	O
infect	O
Sf9	O
cells	O
.	O

While	O
these	O
findings	O
may	O
reflect	O
the	O
sensitivity	O
of	O
a	O
thick	O
myocardial	O
wall	O
to	O
ischaemia	O
during	O
surgery	O
,	O
the	O
postoperative	O
recovery	O
was	O
not	O
related	O
to	O
the	O
serum	B-protein
CK	I-protein
-	I-protein
MB	I-protein
level	O
.	O

Model	O
predictions	O
were	O
in	O
accord	O
with	O
the	O
nine	O
-	O
year	O
survival	O
experience	O
of	O
women	O
in	O
the	O
HIP	O
trial	O
,	O
and	O
,	O
with	O
the	O
exception	O
of	O
women	O
40	O
-	O
44	O
years	O
old	O
,	O
with	O
HIP	O
data	O
on	O
18	O
-	O
year	O
survival	O
.	O

Eleven	O
biopsy	O
specimens	O
(	O
five	O
papules	O
and	O
six	O
dusky	O
or	O
crusted	O
lesions	O
)	O
from	O
four	O
patients	O
with	O
pityriasis	O
lichenoides	O
et	O
varioliformis	O
acuta	O
(	O
PLEVA	O
)	O
were	O
studied	O
by	O
direct	O
immunofluorescence	O
and	O
immunoperoxidase	O
technics	O
.	O

Detection	O
of	O
poisoning	O
by	O
Impila	O
(	O
Callilepis	O
laureola	O
)	O
in	O
a	O
mother	O
and	O
child	O
.	O

Screening	O
,	O
counseling	O
,	O
and	O
treatment	O
for	O
alcohol	O
and	O
illicit	O
drug	O
use	O
should	O
be	O
essential	O
components	O
in	O
comprehensive	O
HBP	O
care	O
.	O

The	O
serum	O
levels	O
of	O
IgE	B-protein
,	O
and	O
asIgE	B-protein
and	O
IgG	B-protein
-	I-protein
4	I-protein
against	O
14	O
common	O
food	O
allergens	O
were	O
determined	O
.	O

Also	O
,	O
the	O
amplitude	O
of	O
the	O
oscillatory	O
potentials	O
(	O
O1	O
+	O
O2	O
+	O
O3	O
+	O
O4	O
)	O
was	O
significantly	O
reduced	O
in	O
the	O
early	O
postoperative	O
period	O
.	O

Differential	O
expression	O
of	O
the	O
`	O
`	O
B	O
'	O
'	O
subunit	O
of	O
the	O
vacuolar	B-protein
H	I-protein
(	I-protein
+	I-protein
)	I-protein
-	I-protein
ATPase	I-protein
in	O
bovine	O
tissues	O
.	O

Pediatric	O
medical	O
emergencies	O
in	O
a	O
regional	O
hospital	O
:	O
appropriate	O
locale	O
?	O

Trichloroethylene	O
,	O
in	O
turn	O
,	O
increased	O
the	O
AUC	O
5	O
.	O
0	O
(	O
1	O
.	O
9	O
-	O
13	O
.	O
4	O
)	O
,	O
25	O
.	O
8	O
(	O
8	O
.	O
2	O
-	O
80	O
.	O
8	O
)	O
and	O
2	O
.	O
9	O
(	O
1	O
.	O
6	O
-	O
5	O
.	O
4	O
)	O
,	O
respectively	O
,	O
whereas	O
the	O
corresponding	O
values	O
for	O
n	O
-	O
hexane	O
were	O
1	O
.	O
9	O
(	O
0	O
.	O
7	O
-	O
5	O
.	O
1	O
)	O
,	O
1	O
.	O
5	O
(	O
0	O
.	O
5	O
-	O
4	O
.	O
6	O
)	O
,	O
and	O
3	O
.	O
2	O
(	O
1	O
.	O
8	O
-	O
5	O
.	O
9	O
)	O
.	O

The	O
interaction	O
of	O
U1	B-protein
-	I-protein
70K	I-protein
with	O
the	O
SRZ	B-protein
proteins	I-protein
is	O
confirmed	O
further	O
in	O
vitro	O
using	O
a	O
blot	O
overlay	O
assay	O
.	O

Analysis	O
of	O
various	O
deletion	O
mutants	O
indicates	O
that	O
the	O
sequence	O
requirements	O
for	O
binding	O
by	O
QBP	B-protein
in	O
vitro	O
are	O
indistinguishable	O
from	O
those	O
necessary	O
for	O
Q	B-protein
activity	O
in	O
vivo	O
,	O
strongly	O
suggesting	O
that	O
QBP	B-protein
is	O
required	O
for	O
the	O
function	O
of	O
this	O
TATA	O
-	O
independent	O
promoter	O
.	O

Common	O
history	O
and	O
prospects	O
in	O
surgical	O
gynecology	O
of	O
the	O
Charite	O
and	O
the	O
Vienna	O
University	O
Clinic	O
.	O

CONCLUSIONS	O
:	O
Under	O
current	O
immunization	O
practices	O
,	O
the	O
authors	O
estimate	O
that	O
nearly	O
13	O
,	O
000	O
Asian	O
and	O
Pacific	O
Islander	O
children	O
living	O
in	O
the	O
United	O
States	O
today	O
will	O
become	O
infected	O
with	O
HBV	O
in	O
the	O
future	O
,	O
resulting	O
in	O
more	O
than	O
600	O
liver	O
carcinoma	O
deaths	O
.	O

Steroids	O
in	O
germfree	O
and	O
conventional	O
rats	O
.	O

Cardiac	O
output	O
at	O
anaerobic	O
threshold	O
(	O
COAT	O
)	O
<	O
or	O
=	O
7	O
.	O
3	O
L	O
/	O
min	O
was	O
the	O
best	O
cutoff	O
value	O
for	O
identifying	O
multivessel	O
coronary	O
artery	O
disease	O
(	O
relative	O
risk	O
,	O
3	O
.	O
1	O
)	O
.	O

We	O
show	O
that	O
cytR	B-protein
expression	O
is	O
negatively	O
controlled	O
by	O
the	O
CytR	B-protein
protein	I-protein
and	O
positively	O
affected	O
by	O
the	O
cAMP	B-protein
/	I-protein
CAP	I-protein
complex	I-protein
.	O

SSG1	B-protein
,	O
a	O
gene	O
encoding	O
a	O
sporulation	B-protein
-	I-protein
specific	I-protein
1	I-protein
,	I-protein
3	I-protein
-	I-protein
beta	I-protein
-	I-protein
glucanase	I-protein
in	O
Saccharomyces	O
cerevisiae	O
.	O

T4	O
and	O
FT4I	O
followed	O
parallel	O
courses	O
in	O
both	O
groups	O
;	O
during	O
the	O
first	O
45	O
days	O
,	O
however	O
,	O
the	O
values	O
were	O
significantly	O
lower	O
in	O
premature	O
infants	O
under	O
34	O
weeks	O
'	O
EGA	O
than	O
in	O
term	O
infants	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Multiple	O
regression	O
analysis	O
performed	O
between	O
these	O
long	O
-	O
term	O
abiotic	O
factors	O
and	O
nymphal	O
abundance	O
in	O
positive	O
sites	O
showed	O
high	O
relationship	O
(	O
R2	O
coefficients	O
)	O
for	O
every	O
habitat	O
category	O
and	O
explained	O
>	O
50	O
%	O
of	O
the	O
variation	O
in	O
tick	O
abundance	O
.	O

The	O
regulation	O
of	O
PGHS	B-protein
-	I-protein
2	I-protein
mRNA	I-protein
and	O
protein	O
was	O
studied	O
in	O
primary	O
cultures	O
of	O
bovine	O
uterine	O
stromal	O
cells	O
stimulated	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
;	O
100	O
nM	O
)	O
.	O

Moreover	O
,	O
the	O
ability	O
to	O
selectivity	O
arrest	O
elongation	O
by	O
polIII	B-protein
at	O
defined	O
positions	O
within	O
the	O
tRNA	B-protein
gene	I-protein
transcription	I-protein
unit	I-protein
has	O
permitted	O
the	O
identification	O
of	O
discrete	O
functional	O
properties	O
of	O
paused	O
mammalian	B-protein
polIII	I-protein
ternary	I-protein
complexes	I-protein
.	O

The	O
effect	O
of	O
food	O
on	O
procainamide	O
absorption	O
.	O

Approximately	O
50	O
%	O
of	O
the	O
ribosomal	O
DNA	O
(	O
rDNA	O
)	O
units	O
of	O
Drosophila	O
melanogaster	O
are	O
inactivated	O
by	O
two	O
different	O
28	B-protein
S	I-protein
RNA	I-protein
ribosomal	I-protein
gene	I-protein
insertions	O
(	O
type	O
I	O
and	O
type	O
II	O
)	O
.	O

Based	O
on	O
restriction	O
enzyme	O
analysis	O
,	O
Southern	O
blots	O
,	O
polymerase	O
chain	O
reaction	O
analysis	O
and	O
DNA	O
sequencing	O
,	O
it	O
was	O
confirmed	O
that	O
the	O
three	O
overlapping	O
clones	O
isolated	O
cover	O
the	O
entire	O
cHO	B-protein
-	I-protein
1	I-protein
gene	I-protein
,	O
as	O
well	O
as	O
approximately	O
10	O
kb	O
of	O
the	O
flanking	O
regions	O
on	O
both	O
ends	O
.	O

The	O
pharmacokinetics	O
of	O
each	O
tetracycline	O
in	O
serum	O
and	O
dermal	O
,	O
suction	O
blister	O
fluid	O
were	O
determined	O
after	O
oral	O
doses	O
of	O
300	O
mg	O
lymecycline	O
or	O
100	O
mg	O
doxycycline	O
on	O
the	O
3rd	O
day	O
.	O

Defects	O
in	O
the	O
Schizosaccharomyces	O
pombe	O
(	O
Sp	O
)	O
cell	O
cycle	O
-	O
controlling	O
genes	O
prevent	O
the	O
cell	O
cycle	O
progression	O
.	O

Problems	O
remain	O
to	O
be	O
resolved	O
in	O
the	O
area	O
of	O
quantitative	O
risk	O
assessment	O
.	O

The	O
binding	O
of	O
transcription	O
factor	O
AP	B-protein
-	I-protein
1	I-protein
and	O
vitamin	B-protein
D	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
to	O
the	O
composite	O
AP	B-protein
-	I-protein
1	I-protein
plus	O
vitamin	B-protein
-	I-protein
D	I-protein
-	I-protein
responsive	I-protein
promoter	I-protein
region	I-protein
(	O
AP	B-protein
-	I-protein
1	I-protein
+	I-protein
VDRE	I-protein
)	O
of	O
the	O
human	B-protein
osteocalcin	I-protein
gene	I-protein
was	O
characterized	O
in	O
osteocalcin	O
-	O
producing	O
(	O
MG	O
-	O
63	O
)	O
and	O
non	O
-	O
producing	O
(	O
U2	O
-	O
Os	O
,	O
SaOs	O
-	O
2	O
)	O
human	O
osteosarcoma	O
cell	O
lines	O
.	O

To	O
examine	O
the	O
role	O
of	O
this	O
CE2	B-protein
element	I-protein
in	O
regulating	O
Hoxa1	B-protein
expression	O
in	O
vivo	O
,	O
transgenic	O
mice	O
were	O
generated	O
which	O
express	O
a	O
Hoxa1	B-protein
beta	I-protein
-	I-protein
galactosidase	I-protein
reporter	O
gene	O
that	O
contains	O
a	O
mutation	O
in	O
the	O
CE2	B-protein
element	I-protein
.	O

We	O
produced	O
transgenic	O
plants	O
expressing	O
the	O
antisense	B-protein
Arabidopsis	I-protein
HD	I-protein
(	O
AtHD1	B-protein
)	O
gene	O
.	O

To	O
determine	O
the	O
relationship	O
of	O
these	O
viruses	O
,	O
the	O
complete	O
DNA	O
sequence	O
of	O
KV	O
consisting	O
of	O
4754	O
bp	O
was	O
determined	O
.	O

We	O
have	O
investigated	O
the	O
role	O
of	O
cellular	B-protein
p21ras	I-protein
protein	I-protein
in	O
insulin	B-protein
and	O
insulin	B-protein
-	I-protein
like	I-protein
growth	I-protein
factor	I-protein
-	I-protein
I	I-protein
(	O
IGF	B-protein
-	I-protein
I	I-protein
)	O
signaling	O
pathways	O
.	O

A	O
stable	O
interface	O
depends	O
on	O
overall	O
stress	O
and	O
microstress	O
distribution	O
on	O
the	O
bone	O
,	O
particularly	O
trabecular	O
bone	O
.	O

Variation	O
in	O
the	O
temporal	O
-	O
spatial	O
distribution	O
of	O
228Ra	O
and	O
224Ra	O
in	O
the	O
RES	O
and	O
marrow	O
-	O
free	O
skeleton	O
after	O
incorporation	O
of	O
colloidal	O
ThO2	O
.	O

Hypoglycemic	O
and	O
antidiabetic	O
properties	O
.	O

The	O
method	O
is	O
applied	O
to	O
determine	O
aberration	O
constants	O
of	O
a	O
CM300	O
FEG	O
/	O
UT	O
microscope	O
with	O
correction	O
of	O
the	O
three	O
-	O
fold	O
astigmatism	O
.	O

Gel	O
retardation	O
assays	O
detected	O
ZiaR	O
-	O
dependent	O
complexes	O
forming	O
with	O
the	O
zia	B-protein
operator	I-protein
-	I-protein
promoter	I-protein
and	O
ZiaR	O
-	O
DNA	O
binding	O
was	O
enhanced	O
by	O
treatment	O
with	O
a	O
metal	O
-	O
chelator	O
in	O
vitro	O
.	O

Similarly	O
,	O
co	O
-	O
expression	O
of	O
a	O
dominant	O
-	O
negative	O
mutant	O
of	O
p38alpha	B-protein
,	O
but	O
not	O
of	O
ERK1	B-protein
,	O
ERK2	B-protein
,	O
JNK1	B-protein
,	O
or	O
JNK2	B-protein
,	O
reduces	O
basal	O
and	O
cadmium	O
-	O
induced	O
pE1	B-protein
-	I-protein
luc	I-protein
activity	O
.	O

A	O
contiguous	O
and	O
sequentially	O
occupied	O
secondary	O
Fur	B-protein
-	I-protein
binding	I-protein
site	I-protein
in	O
entC	B-protein
was	O
protected	O
at	O
higher	O
Fur	B-protein
concentrations	O
,	O
extending	O
the	O
protected	O
region	O
to	O
+	O
49	O
,	O
and	O
sequestering	O
the	O
putative	O
Shine	O
-	O
Dalgarno	O
sequence	O
.	O

The	O
biochemistry	O
of	O
amniotic	O
fluid	O
with	O
poor	O
fetal	O
growth	O
.	O

Application	O
of	O
the	O
2	O
-	O
deoxy	O
-	O
D	O
-	O
glucose	O
method	O
to	O
the	O
coupling	O
of	O
cerebral	O
metabolism	O
and	O
blood	O
flow	O
.	O

Genetic	O
analysis	O
has	O
subsequently	O
identified	O
subpathways	O
of	O
the	O
DNA	O
structure	O
checkpoints	O
,	O
including	O
the	O
reversible	O
arrest	O
of	O
DNA	O
synthesis	O
.	O

One	O
linker	O
-	O
peptide	O
insertion	O
in	O
the	O
RsaA	B-protein
C	I-protein
terminus	I-protein
(	I-protein
amino	I-protein
acid	I-protein
784	I-protein
)	I-protein
had	O
no	O
effect	O
on	O
S	O
-	O
layer	O
biogenesis	O
,	O
while	O
another	O
(	O
amino	O
acid	O
907	O
)	O
disrupted	O
secretion	O
of	O
the	O
protein	O
,	O
suggesting	O
that	O
RsaA	B-protein
possesses	O
a	O
secretion	O
signal	O
lying	O
C	O
terminal	O
to	O
amino	O
acid	O
784	O
,	O
near	O
or	O
including	O
amino	O
acid	O
907	O
.	O

Dipetalonema	O
(	O
Alafilaria	O
)	O
hydrochoerus	O
subgen	O
.	O
et	O
sp	O
.	O
n	O
.	O

356	O
,	O
93	O
-	O
98	O
]	O
.	O

DESIGN	O
AND	O
METHODS	O
:	O
Case	O
study	O
.	O

Like	O
pineal	O
melatonin	O
,	O
serum	O
melatonin	O
was	O
high	O
at	O
mid	O
-	O
dark	O
and	O
low	O
at	O
mid	O
-	O
light	O
.	O

After	O
an	O
initial	O
titration	O
period	O
and	O
adjustment	O
of	O
the	O
therapeutic	O
dose	O
,	O
the	O
individual	O
doses	O
were	O
from	O
21	O
to	O
500	O
micrograms	O
/	O
24	O
hrs	O
(	O
mean	O
160	O
micrograms	O
/	O
24	O
hrs	O
)	O
.	O

The	O
model	O
indicates	O
that	O
a	O
0	O
.	O
076	O
%	O
reduction	O
in	O
cigarette	O
consumption	O
is	O
associated	O
with	O
the	O
availability	O
of	O
nicotine	O
patches	O
after	O
1992	O
.	O

E1	B-protein
,	O
a	O
DNA	B-protein
helicase	I-protein
,	O
collaborates	O
with	O
the	O
HPV	B-protein
E2	I-protein
protein	I-protein
in	O
ori	O
-	O
dependent	O
replication	O
.	O

Tec	B-protein
kinase	I-protein
signaling	O
in	O
T	O
cells	O
is	O
regulated	O
by	O
phosphatidylinositol	B-protein
3	I-protein
-	I-protein
kinase	I-protein
and	O
the	O
Tec	B-protein
pleckstrin	I-protein
homology	I-protein
domain	I-protein
.	O

Together	O
,	O
our	O
results	O
show	O
that	O
tinman	B-protein
is	O
controlled	O
by	O
an	O
array	O
of	O
discrete	O
enhancer	O
elements	O
that	O
are	O
activated	O
successively	O
by	O
differential	O
genetic	O
inputs	O
,	O
as	O
well	O
as	O
by	O
closely	O
linked	O
activator	O
and	O
repressor	O
binding	O
sites	O
within	O
an	O
early	O
-	O
acting	O
enhancer	O
,	O
which	O
restrict	O
twist	B-protein
activity	O
to	O
specific	O
areas	O
within	O
the	O
twist	B-protein
expression	I-protein
domain	I-protein
.	O

Infant	O
aged	O
3	O
.	O
5	O
years	O
presents	O
persistence	O
of	O
primordial	O
vitreous	O
body	O
with	O
crystalline	O
dislocation	O
in	O
the	O
camera	O
aquosa	O
and	O
secondary	O
buphthalmos	O
of	O
the	O
left	O
eye	O
and	O
microphthalmos	O
with	O
dislocation	O
of	O
the	O
crystalline	O
in	O
the	O
vitreous	O
body	O
of	O
the	O
right	O
eye	O
.	O

The	O
scr	B-protein
regulon	I-protein
of	O
pUR400	O
and	O
the	O
chromosomally	B-protein
encoded	I-protein
scr	I-protein
regulon	I-protein
of	I-protein
Klebsiella	I-protein
pneumoniae	I-protein
KAY2026	I-protein
are	O
both	O
negatively	O
controlled	O
by	O
a	O
specific	O
repressor	O
(	O
ScrR	B-protein
)	O
.	O

A	O
215	O
-	O
base	O
-	O
pair	O
(	O
bp	O
)	O
region	O
of	O
the	O
mouse	B-protein
MOPC	I-protein
41	I-protein
kappa	I-protein
light	I-protein
-	I-protein
chain	I-protein
immunoglobulin	I-protein
gene	I-protein
enhancer	I-protein
has	O
been	O
analyzed	O
for	O
specific	O
binding	O
of	O
lymphoid	O
and	O
nonlymphoid	O
nuclear	O
factors	O
.	O

These	O
mutants	O
had	O
deletions	O
of	O
the	O
extreme	O
amino	O
-	O
terminal	O
residues	O
as	O
far	O
as	O
amino	O
acid	O
residue	O
30	O
.	O

She	O
was	O
able	O
to	O
stand	O
unaided	O
by	O
3	O
years	O
of	O
age	O
with	O
then	O
progressive	O
worsening	O
of	O
motor	O
abilities	O
.	O

These	O
RZR	B-protein
subtypes	O
represent	O
members	O
of	O
a	O
new	O
family	O
of	O
orphan	B-protein
nuclear	I-protein
receptors	I-protein
that	O
most	O
likely	O
regulate	O
specific	O
gene	O
expression	O
.	O

To	O
study	O
the	O
in	O
vivo	O
role	O
of	O
p16	B-protein
.	I-protein
7	I-protein
,	O
a	O
phi29	O
mutant	O
containing	O
a	O
suppressible	O
mutation	O
in	O
gene	B-protein
16	I-protein
.	I-protein
7	I-protein
was	O
constructed	O
.	O

In	O
an	O
in	O
vitro	O
study	O
,	O
10	O
/	O
0	O
nylon	O
was	O
found	O
to	O
require	O
a	O
significantly	O
lower	O
laser	O
energy	O
density	O
to	O
produce	O
suture	O
lysis	O
following	O
a	O
single	O
shot	O
than	O
either	O
10	O
/	O
0	O
Dacron	O
or	O
10	O
/	O
0	O
prolene	O
.	O

A	O
decamer	O
sequence	O
,	O
5	B-protein
'	I-protein
-	I-protein
CGA	I-protein
-	I-protein
CCCCUCC	I-protein
-	I-protein
3	I-protein
'	I-protein
,	O
complementary	O
to	O
a	O
conserved	O
sequence	O
adjacent	O
to	O
the	O
enzymatic	O
cleavage	O
site	O
on	O
the	O
mitochondrial	O
RNA	O
substrate	O
,	O
is	O
present	O
in	O
the	O
RNAase	B-protein
MRP	I-protein
RNA	I-protein
.	O

In	O
vitro	O
translation	O
of	O
RNA	O
synthesized	O
from	O
the	O
cloned	O
cDNAs	O
predicts	O
that	O
P0	B-protein
transcripts	I-protein
are	O
translated	O
into	O
a	O
novel	O
12	O
.	O
5	O
-	O
kilodalton	O
protein	O
corresponding	O
to	O
the	O
first	O
open	O
reading	O
frame	O
.	O

In	O
the	O
remaining	O
case	O
,	O
the	O
aneurysm	O
originated	O
from	O
the	O
proximal	O
end	O
of	O
the	O
associated	O
A1	O
fenestration	O
.	O

The	O
diagnosis	O
of	O
amyloidosis	O
was	O
determined	O
from	O
a	O
labial	O
salivary	O
gland	O
biopsy	O
.	O

We	O
further	O
found	O
that	O
KmMig1p	B-protein
is	O
fully	O
functional	O
when	O
expressed	O
in	O
S	O
.	O
cerevisiae	O
.	O

It	O
has	O
repeatedly	O
been	O
shown	O
that	O
HCMV	B-protein
IE1	I-protein
/	I-protein
IE2	I-protein
can	O
independently	O
transactivate	O
HIV	B-protein
-	I-protein
1	I-protein
LTR	I-protein
.	O

Terbutaline	O
;	O
a	O
beta2	O
-	O
adrenergic	O
agonist	O
,	O
and	O
aminophyllin	O
,	O
a	O
phosphodiesterase	B-protein
inhibitor	O
,	O
were	O
given	O
separately	O
,	O
or	O
in	O
combination	O
,	O
to	O
rabbit	O
fetuses	O
on	O
the	O
28th	O
day	O
of	O
gestation	O
.	O

Comparison	O
to	O
other	O
coxI	B-protein
genes	I-protein
revealed	O
a	O
966	B-protein
-	I-protein
bp	I-protein
group	I-protein
I	I-protein
intron	I-protein
,	O
which	O
,	O
based	O
on	O
homology	O
with	O
the	O
related	O
yeast	B-protein
coxI	I-protein
intron	I-protein
aI4	I-protein
,	O
potentially	O
encodes	O
a	O
279	B-protein
-	I-protein
amino	I-protein
-	I-protein
acid	I-protein
site	I-protein
-	I-protein
specific	I-protein
DNA	I-protein
endonuclease	I-protein
.	O

Antipyretic	O
therapy	O
:	O
physiologic	O
rationale	O
,	O
diagnostic	O
implications	O
,	O
and	O
clinical	O
consequences	O
.	O

Upon	O
analysis	O
of	O
the	O
tissue	O
distribution	O
of	O
AAMP	B-protein
,	O
it	O
was	O
found	O
to	O
be	O
expressed	O
strongly	O
in	O
endothelial	O
cells	O
,	O
cytotrophoblasts	O
,	O
and	O
poorly	O
differentiated	O
colon	O
adenocarcinoma	O
cells	O
found	O
in	O
lymphatics	O
.	O

We	O
propose	O
that	O
noi	B-protein
/	I-protein
pax2	I-protein
.	I-protein
1	I-protein
participates	O
in	O
sequential	O
signaling	O
processes	O
as	O
a	O
key	O
integrator	O
of	O
midbrain	O
-	O
hindbrain	O
boundary	O
development	O
.	O

Finally	O
,	O
over	O
a	O
similar	O
range	O
of	O
QO2	O
,	O
oxygen	O
extraction	O
was	O
greater	O
in	O
patients	O
with	O
ARDS	O
compared	O
to	O
patients	O
with	O
non	O
-	O
ARDS	O
respiratory	O
failure	O
(	O
r	O
=	O
-	O
0	O
.	O
67	O
and	O
slope	O
=	O
-	O
0	O
.	O
62	O
vs	O
r	O
=	O
-	O
0	O
.	O
45	O
and	O
slope	O
=	O
-	O
0	O
.	O
35	O
;	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Inhibition	O
of	O
histalog	O
-	O
stimulated	O
gastric	O
secretion	O
by	O
40	O
749	O
RP	O
,	O
a	O
new	O
long	O
-	O
acting	O
gastric	O
antisecretory	O
agent	O
.	O

The	O
HMG	B-protein
CoA	I-protein
reductase	I-protein
inhibitors	O
are	O
the	O
most	O
effective	O
cholesterol	O
-	O
lowering	O
agents	O
currently	O
available	O
.	O

The	O
activity	O
of	O
the	O
EGF	B-protein
receptor	I-protein
promoter	I-protein
can	O
be	O
modulated	O
by	O
E1A	B-protein
protein	I-protein
and	O
receptor	O
RNA	O
levels	O
increased	O
by	O
stimulation	O
with	O
phorbol	O
ester	O
or	O
fetal	O
calf	O
serum	O
.	O

Moreover	O
,	O
the	O
observation	O
of	O
enhanced	O
luteal	B-protein
HSP	I-protein
-	I-protein
27	I-protein
phosphorylation	O
in	O
vivo	O
,	O
in	O
late	O
pregnancy	O
,	O
when	O
PKC	B-protein
-	I-protein
delta	I-protein
is	O
abundant	O
and	O
active	O
,	O
suggests	O
that	O
select	O
PKC	B-protein
family	I-protein
members	I-protein
contribute	O
to	O
sHSP	B-protein
phosphorylation	O
events	O
in	O
vivo	O
.	O

Sural	O
nerve	O
biopsy	O
showed	O
mild	O
thickening	O
of	O
the	O
perineurium	O
,	O
vascular	O
alterations	O
with	O
inflammatory	O
cell	O
infiltration	O
in	O
the	O
perineurium	O
,	O
and	O
remarkable	O
loss	O
of	O
large	O
and	O
small	O
myelinated	O
fibers	O
.	O

Family	O
environment	O
was	O
an	O
important	O
influence	O
on	O
interpersonal	O
relationships	O
,	O
substance	O
use	O
,	O
and	O
social	O
support	O
.	O

Finally	O
,	O
we	O
compared	O
the	O
differential	O
screening	O
techniques	O
in	O
terms	O
of	O
sensitivity	O
,	O
efficiency	O
and	O
occurrence	O
of	O
false	O
positives	O
.	O

There	O
has	O
been	O
similar	O
improvement	O
in	O
treating	O
ampullary	O
and	O
periampullary	O
cancer	O
,	O
gallbladder	O
cancer	O
,	O
or	O
extrahepatic	O
bile	O
duct	O
cancer	O
.	O

Editorial	O
:	O
Low	O
-	O
dose	O
heparin	O
and	O
the	O
prevention	O
of	O
venous	O
thromboembolic	O
disease	O
.	O

These	O
genes	O
were	O
expressed	O
in	O
a	O
Saccharomyces	O
cerevisiae	O
mutant	O
in	O
which	O
the	O
endogenous	B-protein
ferrochelatase	I-protein
gene	I-protein
(	O
HEM15	B-protein
)	O
had	O
been	O
deleted	O
,	O
and	O
the	O
phenotypes	O
of	O
the	O
transformants	O
were	O
characterized	O
.	O

Lyn	B-protein
kinase	I-protein
immunoprecipitated	O
from	O
lysates	O
of	O
irradiated	O
BCP	O
as	O
well	O
as	O
a	O
full	B-protein
-	I-protein
length	I-protein
glutathione	I-protein
S	I-protein
-	I-protein
transferase	I-protein
(	O
GST	B-protein
)	O
-	O
Lyn	O
fusion	O
protein	O
-	O
phosphorylated	O
recombinant	B-protein
human	I-protein
p34cdc2	I-protein
on	O
tyrosine	O
15	O
.	O

Computer	O
-	O
aided	O
`	O
`	O
FRAME	O
'	O
'	O
analysis	O
revealed	O
four	O
possible	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
,	O
three	O
in	O
one	O
direction	O
and	O
one	O
in	O
the	O
opposite	O
direction	O
.	O

I	O
.	O

The	O
corresponding	O
orifice	O
voltages	O
for	O
the	O
three	O
instruments	O
were	O
20	O
/	O
50	O
/	O
80	O
V	O
(	O
API	O
365	O
)	O
,	O
30	O
/	O
90	O
/	O
130	O
V	O
(	O
API	O
2000	O
)	O
and	O
40	O
/	O
80	O
/	O
120	O
V	O
(	O
API	O
3000	O
)	O
.	O

Schnell	O
,	O
J	O
.	O

Continued	O
development	O
of	O
the	O
rat	O
conditioning	O
paradigm	O
is	O
especially	O
warranted	O
because	O
of	O
the	O
ability	O
to	O
record	O
sympathetic	O
nerve	O
activity	O
in	O
intact	O
,	O
awake	O
subjects	O
and	O
the	O
large	O
number	O
of	O
readily	O
available	O
genetic	O
strains	O
,	O
which	O
model	O
human	O
pathological	O
states	O
.	O

Patients	O
who	O
have	O
undergone	O
thyroidectomy	O
for	O
thyroid	O
carcinoma	O
are	O
frequently	O
subjected	O
to	O
periods	O
of	O
induced	O
severe	O
hypothyroidism	O
in	O
preparation	O
for	O
131I	O
whole	O
body	O
scanning	O
and	O
measurement	O
of	O
serum	O
TG	O
.	O

In	O
metabolic	O
acidosis	O
there	O
was	O
a	O
marked	O
stimulation	O
when	O
clamped	O
at	O
-	O
10	O
to	O
-	O
100	O
mV	O
.	O

Synergistic	O
transactivation	O
of	O
the	O
BMRF1	B-protein
promoter	I-protein
by	O
the	O
Z	B-protein
/	I-protein
c	I-protein
-	I-protein
myb	I-protein
combination	O
appears	O
to	O
involve	O
direct	O
binding	O
by	O
the	O
Z	B-protein
protein	I-protein
but	O
not	O
the	O
c	B-protein
-	I-protein
myb	I-protein
protein	I-protein
.	O

Insulin	B-protein
-	I-protein
like	I-protein
growth	I-protein
factor	I-protein
-	I-protein
I	I-protein
induces	O
bcl	B-protein
-	I-protein
2	I-protein
promoter	I-protein
through	O
the	O
transcription	O
factor	O
cAMP	B-protein
-	I-protein
response	I-protein
element	I-protein
-	I-protein
binding	I-protein
protein	I-protein
.	O

Long	O
-	O
range	O
comparison	O
of	O
human	B-protein
and	I-protein
mouse	I-protein
SCL	I-protein
loci	I-protein
:	O
localized	O
regions	O
of	O
sensitivity	O
to	O
restriction	B-protein
endonucleases	I-protein
correspond	O
precisely	O
with	O
peaks	O
of	O
conserved	O
noncoding	O
sequences	O
.	O

In	O
TNF	O
-	O
resistant	O
T24	O
bladder	O
carcinoma	O
cells	O
,	O
TNF	B-protein
failed	O
to	O
alter	O
EGF	B-protein
-	I-protein
R	I-protein
tyrosine	I-protein
protein	I-protein
kinase	I-protein
activity	O
although	O
both	O
EGF	B-protein
and	O
phorbol	O
ester	O
were	O
shown	O
to	O
modulate	O
the	O
enzymatic	O
activity	O
of	O
the	O
receptor	O
in	O
these	O
cells	O
.	O

We	O
isolated	O
a	O
ribosomal	B-protein
protein	I-protein
L18	I-protein
by	O
interaction	O
with	O
PKR	B-protein
.	O

Sequence	O
determination	O
of	O
isolated	O
peptides	O
suggested	O
that	O
Asn120	O
is	O
glycosylated	O
,	O
Asn65	O
and	O
Asn109	O
glycosylated	O
in	O
some	O
molecules	O
but	O
not	O
in	O
others	O
,	O
and	O
Asn72	O
not	O
glycosylated	O
.	O

Insertional	O
inactivation	O
of	O
sms	B-protein
led	O
to	O
increased	O
sensitivity	O
to	O
the	O
alkylating	O
agent	O
methylmethane	O
sulfonate	O
,	O
but	O
not	O
to	O
a	O
requirement	O
for	O
serine	O
or	O
other	O
metabolites	O
.	O

Since	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
this	O
gene	O
is	O
likely	O
involved	O
in	O
hormonal	O
regulation	O
of	O
its	O
expression	O
,	O
we	O
have	O
isolated	O
and	O
partially	O
characterized	O
an	O
avian	O
fatty	B-protein
acid	I-protein
synthase	I-protein
gene	O
.	O

Improved	O
cosmesis	O
,	O
extension	O
of	O
the	O
scope	O
of	O
the	O
problems	O
that	O
can	O
be	O
addressed	O
with	O
this	O
repair	O
(	O
including	O
treatment	O
of	O
a	O
distal	O
urethrocutaneous	O
fistula	O
)	O
and	O
the	O
ease	O
with	O
which	O
the	O
Arap	O
procedure	O
can	O
be	O
performed	O
are	O
the	O
advantages	O
that	O
this	O
operation	O
has	O
over	O
other	O
1	O
-	O
stage	O
distal	O
hypospadias	O
repairs	O
.	O

Thirty	O
percent	O
of	O
patients	O
were	O
tapered	O
off	O
all	O
steroids	O
,	O
and	O
the	O
average	O
steroid	O
dose	O
in	O
the	O
group	O
who	O
received	O
steroids	O
was	O
8	O
.	O
6	O
mg	O
of	O
prednisone	O
per	O
day	O
.	O

Spontaneous	O
recovery	O
occurs	O
within	O
30	O
min	O
to	O
2	O
hrs	O
.	O

A	O
p21	B-protein
peptide	I-protein
spanning	O
amino	O
acids	O
139	O
-	O
164	O
was	O
found	O
to	O
bind	O
PCNA	B-protein
in	O
a	O
filter	O
binding	O
assay	O
and	O
this	O
peptide	O
suppressed	O
recombinant	B-protein
p21	I-protein
-	I-protein
PCNA	I-protein
interaction	O
.	O

Molecular	O
characterization	O
of	O
malignant	O
melanoma	O
of	O
soft	O
parts	O
or	O
soft	O
tissue	O
clear	O
cell	O
sarcoma	O
which	O
shares	O
t	O
(	O
12	O
;	O
22	O
)	O
chromosome	O
translocation	O
revealed	O
fusion	O
of	O
EWS	B-protein
with	O
a	O
transcriptional	O
factor	O
gene	B-protein
ATF	I-protein
-	I-protein
1	I-protein
.	O

Thus	O
,	O
these	O
studies	O
on	O
rat	B-protein
Std	I-protein
promoter	I-protein
function	O
indicate	O
that	O
(	O
i	O
)	O
HNF1	B-protein
and	O
C	B-protein
/	I-protein
EBP	I-protein
are	O
responsible	O
for	O
liver	O
specificity	O
of	O
the	O
rat	B-protein
Std	I-protein
gene	I-protein
;	O
(	O
ii	O
)	O
androgenic	O
repression	O
of	O
the	O
gene	O
requires	O
the	O
presence	O
of	O
all	O
of	O
the	O
OCT	B-protein
-	I-protein
1	I-protein
and	O
C	B-protein
/	I-protein
EBP	I-protein
elements	I-protein
between	O
positions	O
-	O
231	O
and	O
-	O
292	O
;	O
and	O
(	O
iii	O
)	O
AR	B-protein
may	O
exert	O
its	O
negative	O
regulatory	O
effect	O
indirectly	O
through	O
transcriptional	O
interference	O
of	O
OCT	B-protein
-	I-protein
1	I-protein
and	O
C	B-protein
/	I-protein
EBP	I-protein
rather	O
than	O
through	O
a	O
direct	O
DNA	B-protein
-	I-protein
AR	I-protein
interaction	O
.	O

Competition	O
EMSA	O
established	O
that	O
constitutively	O
expressed	O
nuclear	O
proteins	O
bound	O
the	O
KCS	B-protein
element	I-protein
selectively	O
;	O
KCS	B-protein
protein	I-protein
binding	O
activity	O
correlated	O
with	O
promoter	O
activity	O
in	O
the	O
transient	O
transfection	O
reporter	O
assay	O
.	O

CONCLUSION	O
:	O
In	O
Cdks	B-protein
functioning	O
throughout	O
the	O
cell	O
cycle	O
,	O
tyrosine	O
phosphorylation	O
is	O
inhibitory	O
to	O
the	O
activation	O
of	O
kinase	O
,	O
whereas	O
the	O
phosphorylation	O
of	O
threonine	O
in	O
the	O
T	O
-	O
loop	O
is	O
essential	O
for	O
activation	O
.	O

For	O
the	O
first	O
time	O
we	O
describe	O
deletion	O
and	O
point	O
mutations	O
within	O
the	O
plasma	B-protein
membrane	I-protein
family	I-protein
of	I-protein
guanylyl	I-protein
cyclase	I-protein
receptors	I-protein
that	O
result	O
in	O
the	O
formation	O
of	O
effective	O
dominant	O
negative	O
proteins	O
.	O

No	O
difference	O
in	O
the	O
clinical	O
acceptability	O
could	O
be	O
ascertained	O
between	O
the	O
two	O
groups	O
.	O

The	O
clinical	O
picture	O
of	O
the	O
disease	O
was	O
significantly	O
different	O
from	O
anthropogenic	O
cutaneous	O
leishmaniasis	O
caused	O
by	O
L	O
.	O
tropica	O
but	O
similar	O
to	O
cutaneous	O
patterns	O
caused	O
by	O
L	O
.	O
infantum	O
which	O
was	O
a	O
prevalent	O
pattern	O
in	O
the	O
southern	O
France	O
.	O

The	O
human	B-protein
2	I-protein
'	I-protein
,	I-protein
5	I-protein
'	I-protein
-	I-protein
oligoadenylate	I-protein
(	I-protein
2	I-protein
-	I-protein
5A	I-protein
)	I-protein
synthetases	I-protein
are	O
members	O
of	O
a	O
family	O
interferon	B-protein
(	O
IFN	B-protein
)	O
-	O
inducible	O
anti	B-protein
-	I-protein
viral	I-protein
proteins	I-protein
.	O

Taken	O
together	O
,	O
we	O
provide	O
evidence	O
for	O
the	O
existence	O
of	O
an	O
activator	O
,	O
NFE	B-protein
,	O
which	O
in	O
combination	O
with	O
the	O
p50	B-protein
and	O
c	B-protein
-	I-protein
Rel	I-protein
proteins	I-protein
,	O
are	O
part	O
of	O
the	O
transcription	O
factor	O
machinery	O
that	O
regulates	O
3	O
'	O
enhancer	O
activity	O
,	O
and	O
thus	O
the	O
control	O
of	O
the	O
IgH	B-protein
locus	I-protein
in	O
late	O
B	O
lymphocyte	O
development	O
.	O

We	O
show	O
that	O
the	O
mouse	O
genome	O
contains	O
four	O
copies	O
of	O
the	O
ubc	B-protein
-	I-protein
9	I-protein
gene	I-protein
.	O

In	O
resting	O
3T3	O
cells	O
,	O
jun	B-protein
-	I-protein
D	I-protein
is	O
expressed	O
at	O
a	O
higher	O
level	O
compared	O
to	O
c	B-protein
-	I-protein
jun	I-protein
and	O
jun	B-protein
-	I-protein
B	I-protein
,	O
and	O
its	O
transcription	O
is	O
stimulated	O
only	O
slightly	O
by	O
serum	O
growth	B-protein
factors	I-protein
.	O

A	O
method	O
is	O
described	O
for	O
the	O
simultaneous	O
determination	O
of	O
1	O
,	O
alpha	O
-	O
acetylmethadol	O
(	O
LAAM	O
)	O
and	O
five	O
active	O
metabolites	O
-	O
-	O
noracetylmethadol	O
,	O
dinoracetylmethadol	O
,	O
methadol	O
,	O
normethadol	O
,	O
and	O
dinormethadol	O
-	O
-	O
in	O
biofluids	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
using	O
a	O
normal	O
-	O
phase	O
column	O
and	O
a	O
UV	O
detector	O
at	O
218	O
nm	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
identify	O
neuronal	O
cell	O
cultures	O
that	O
express	O
RC3	B-protein
/	I-protein
neurogranin	I-protein
,	O
to	O
check	O
whether	O
they	O
are	O
sensitive	O
to	O
T3	O
,	O
and	O
to	O
examine	O
the	O
mechanism	O
of	O
regulation	O
.	O

Self	O
-	O
emasculation	O
is	O
the	O
end	O
result	O
of	O
an	O
unusual	O
psychiatric	O
disorder	O
,	O
which	O
initially	O
requires	O
surgical	O
treatment	O
.	O

Reovirus	O
mRNAs	O
are	O
efficiently	O
translated	O
within	O
host	O
cells	O
despite	O
the	O
absence	O
of	O
3	O
'	O
polyadenylated	O
tails	O
.	O

The	O
disturbance	O
of	O
pulmonary	O
gas	O
exchange	O
,	O
as	O
revealed	O
by	O
the	O
high	O
value	O
of	O
AaDO2	O
,	O
existed	O
without	O
left	O
ventricular	O
dysfunction	O
,	O
and	O
AaDO2	O
had	O
no	O
significant	O
relationship	O
with	O
any	O
of	O
the	O
hemodynamic	O
parameters	O
including	O
the	O
difference	O
between	O
plasma	O
colloid	O
osmotic	O
pressure	O
and	O
PCW	O
.	O

Transfection	O
of	O
cDNAs	O
for	O
three	O
mutant	O
enzymes	O
into	O
FPGS	O
-	O
null	O
Chinese	O
hamster	O
ovary	O
cells	O
restored	O
a	O
reduced	O
level	O
of	O
clonal	O
growth	O
,	O
whereas	O
a	O
T339I	O
mutant	O
supported	O
growth	O
at	O
a	O
level	O
comparable	O
to	O
that	O
of	O
the	O
wild	O
-	O
type	O
enzyme	O
.	O

A	O
vector	O
containing	O
a	O
transcriptionally	O
inactive	O
neomycin	B-protein
phosphotransferase	I-protein
II	I-protein
gene	I-protein
was	O
used	O
to	O
select	O
promoter	O
sequences	O
from	O
a	O
pool	O
of	O
random	O
genomic	O
DNA	O
fragments	O
.	O

In	O
co	O
-	O
transfection	O
studies	O
,	O
the	O
expression	O
of	O
c	B-protein
-	I-protein
Jun	I-protein
plus	O
c	B-protein
-	I-protein
Fos	I-protein
enhanced	O
the	O
transactivation	O
of	O
oIFNtau	B-protein
-	I-protein
CAT	I-protein
but	O
the	O
expression	O
of	O
GATA	B-protein
-	I-protein
1	I-protein
,	O
GATA	B-protein
-	I-protein
2	I-protein
or	O
GATA	B-protein
-	I-protein
3	I-protein
did	O
not	O
.	O

In	O
the	O
DNAs	O
of	O
all	O
Ph1	O
-	O
positive	O
chronic	O
myelocytic	O
leukemia	O
patients	O
studied	O
to	O
date	O
,	O
a	O
breakpoint	O
on	O
chromosome	O
22	O
(	O
the	O
Ph1	O
chromosome	O
)	O
can	O
be	O
demonstrated	O
with	O
a	O
probe	O
from	O
the	O
bcr	O
(	O
breakpoint	O
cluster	O
region	O
)	O
.	O

The	O
bactericidal	O
effect	O
of	O
disinfectants	O
against	O
biofilm	O
cells	O
was	O
found	O
to	O
be	O
considerably	O
enhanced	O
by	O
increasing	O
the	O
concentrations	O
of	O
the	O
disinfectants	O
.	O

Domain	O
II	O
is	O
highly	O
homologous	O
to	O
the	O
LDL	B-protein
receptor	I-protein
and	O
contains	O
four	O
repeats	O
with	O
perfect	O
conservation	O
of	O
all	O
6	O
consecutive	O
cysteines	O
.	O

Sequencing	O
of	O
a	O
40	O
-	O
kb	O
DNA	O
segment	O
of	O
the	O
FK506	B-protein
gene	I-protein
cluster	O
from	O
Streptomyces	O
sp	O
.	O

Thus	O
,	O
replication	O
fork	O
movement	O
near	O
HML	B-protein
pauses	O
at	O
a	O
silent	O
origin	O
which	O
is	O
competent	O
for	O
replication	O
initiation	O
but	O
kept	O
silent	O
through	O
Orc2p	B-protein
,	O
a	O
component	O
of	O
the	O
replication	O
initiator	O
.	O

Assessment	O
of	O
nutrient	O
media	O
in	O
the	O
diagnosis	O
of	O
diptheria	O
.	O

Histological	O
changes	O
,	O
including	O
cortical	O
cell	O
involution	O
and	O
hemorrhage	O
occurring	O
during	O
the	O
neonatal	O
period	O
,	O
would	O
seem	O
to	O
have	O
crucial	O
relevance	O
to	O
the	O
remodeling	O
of	O
the	O
adrenal	O
vasculature	O
.	O

The	O
Gap69C	B-protein
is	O
a	O
single	O
-	O
copy	O
gene	O
producing	O
a	O
major	O
2	O
.	O
1	O
-	O
kb	O
mRNA	O
throughout	O
development	O
,	O
but	O
its	O
amount	O
is	O
decreased	O
in	O
larvae	O
.	O

The	O
relationship	O
of	O
the	O
factor	B-protein
V	I-protein
Leiden	I-protein
mutation	I-protein
or	O
the	O
deletion	O
-	O
deletion	O
polymorphism	O
of	O
the	O
angiotensin	B-protein
converting	I-protein
enzyme	I-protein
to	O
postoperative	O
thromboembolic	O
events	O
following	O
total	O
joint	O
arthroplasty	O
.	O

End	O
-	O
tidal	O
PO2	O
and	O
the	O
ratio	O
of	O
minute	O
ventilation	O
to	O
oxygen	O
consumption	O
(	O
VE	O
/	O
VO2	O
)	O
were	O
lower	O
while	O
PETCO2	O
was	O
higher	O
for	O
Hyp	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
.	O

Considering	O
these	O
sources	O
of	O
error	O
some	O
of	O
the	O
variability	O
in	O
the	O
present	O
investigation	O
might	O
be	O
avoided	O
by	O
systematic	O
instructions	O
.	O

Diagnosis	O
of	O
prostatic	O
carcinoma	O
:	O
the	O
yield	O
of	O
serum	B-protein
prostate	I-protein
specific	I-protein
antigen	I-protein
,	O
digital	O
rectal	O
examination	O
and	O
transrectal	O
ultrasonography	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
LvUSF2	B-protein
is	O
nearly	O
identical	O
to	O
LvUSF1	B-protein
except	O
at	O
the	O
amino	O
end	O
,	O
where	O
they	O
are	O
sharply	O
divergent	O
.	O

In	O
retrospect	O
,	O
the	O
diagnoses	O
were	O
reconsidered	O
applying	O
strict	O
criteria	O
.	O

A	O
consensus	O
sequence	O
indicates	O
a	O
highly	O
conserved	O
lysine	O
residue	O
,	O
K120	O
of	O
endonuclease	B-protein
III	I-protein
or	O
K241	O
of	O
Ogg1	B-protein
,	O
respectively	O
.	O

The	O
data	O
show	O
conclusively	O
that	O
phosphorylation	O
of	O
His	O
-	O
304	O
is	O
not	O
essential	O
for	O
any	O
of	O
the	O
known	O
functions	O
of	O
A	B-protein
.	I-protein
vinelandii	I-protein
NifL	I-protein
.	O

The	O
maximal	O
effect	O
was	O
seen	O
at	O
100	O
ng	O
/	O
ml	O
EGF	B-protein
,	O
with	O
a	O
time	O
lag	O
of	O
about	O
5	O
h	O
.	O

Effects	O
of	O
aerosol	O
-	O
vapor	O
JP	O
-	O
8	O
jet	O
fuel	O
on	O
the	O
functional	O
observational	O
battery	O
,	O
and	O
learning	O
and	O
memory	O
in	O
the	O
rat	O
.	O

The	O
Saccharomyces	B-protein
cerevisiae	I-protein
GAL1	I-protein
and	O
GAL10	B-protein
genes	I-protein
are	O
controlled	O
in	O
response	O
to	O
the	O
availability	O
of	O
galactose	O
and	O
glucose	O
by	O
multiple	O
activating	O
and	O
repressing	O
proteins	O
bound	O
at	O
adjacent	O
or	O
overlapping	O
sites	O
in	O
UASG	B-protein
.	O

When	O
differentiated	O
G0	O
-	O
arrested	O
leaf	O
cells	O
were	O
induced	O
to	O
resume	O
cell	O
division	O
by	O
treatment	O
with	O
plant	O
hormones	O
,	O
cycMs4	B-protein
transcription	O
was	O
induced	O
before	O
the	O
onset	O
of	O
DNA	O
synthesis	O
.	O

Also	O
,	O
component	O
I	O
significantly	O
correlated	O
with	O
fasting	O
insulin	B-protein
and	O
VO2	O
max	O
for	O
both	O
sexes	O
and	O
with	O
basal	O
metabolism	O
and	O
HDL	B-protein
-	I-protein
cholesterol	I-protein
for	O
females	O
and	O
males	O
,	O
respectively	O
.	O

Desmethyltrimebutine	O
was	O
inactive	O
.	O

The	O
antibodies	O
inhibited	O
specifically	O
the	O
transcription	O
of	O
DNA	B-protein
polymerase	I-protein
alpha	I-protein
promoter	O
in	O
vitro	O
.	O

RNase	B-protein
protection	O
experiments	O
confirmed	O
the	O
presence	O
of	O
the	O
GHR1	B-protein
-	I-protein
279	I-protein
variant	I-protein
in	O
IM	O
-	O
9	O
cells	O
and	O
human	O
liver	O
.	O

The	O
open	O
reading	O
frames	O
of	O
rbsD	B-protein
,	O
rbsA	B-protein
,	O
and	O
rbsC	B-protein
encode	O
proteins	O
of	O
139	O
,	O
501	O
,	O
and	O
321	O
amino	O
acid	O
residues	O
,	O
respectively	O
.	O

Sucrose	O
-	O
specific	O
regulation	O
of	O
scrB	B-protein
was	O
also	O
lost	O
upon	O
deletion	O
of	O
4	O
bp	O
of	O
a	O
palindromic	O
sequence	O
(	O
OB	O
)	O
covering	O
positions	O
+	O
6	O
to	O
+	O
21	O
downstream	O
of	O
the	O
scrB	B-protein
transcriptional	O
start	O
site	O
.	O

High	O
concentrations	O
of	O
tumor	O
-	O
associated	O
trypsin	B-protein
inhibitor	O
in	O
hemodialyzed	O
patients	O
.	O

There	O
was	O
a	O
gradual	O
increase	O
in	O
the	O
myocyte	O
diameter	O
according	O
to	O
age	O
in	O
the	O
biopsy	O
and	O
autopsy	O
specimens	O
.	O

Mutation	O
of	O
the	O
Sp1	B-protein
element	I-protein
,	O
which	O
abolishes	O
Sp1	B-protein
binding	O
,	O
results	O
in	O
a	O
6	O
-	O
10	O
-	O
fold	O
reduction	O
in	O
reporter	O
activity	O
.	O

INTERVENTIONS	O
:	O
Subcutaneous	O
tissue	O
PO2	O
and	O
PCO2	O
tensions	O
were	O
measured	O
directly	O
in	O
patients	O
with	O
necrotising	O
fasciitis	O
and	O
in	O
healthy	O
volunteers	O
during	O
normobaric	O
and	O
hyperbaric	O
conditions	O
.	O

Because	O
of	O
the	O
potential	O
implications	O
of	O
these	O
findings	O
in	O
human	O
physiology	O
,	O
we	O
cloned	O
the	O
hPACAP	B-protein
-	I-protein
R	I-protein
gene	I-protein
.	O

Modifications	O
of	O
the	O
involuntary	O
postcontraction	O
in	O
diseased	O
people	O
.	O

Although	O
noninhibitory	O
fluid	O
had	O
higher	O
mean	O
concentrations	O
of	O
phosphorus	O
and	O
zinc	O
,	O
these	O
differences	O
did	O
not	O
hold	O
after	O
meconium	O
-	O
stained	O
samples	O
were	O
excluded	O
.	O

Normal	O
baseline	O
(	O
day	O
-	O
8	O
)	O
PC	O
levels	O
(	O
86	O
and	O
89	O
%	O
)	O
were	O
markedly	O
reduced	O
in	O
both	O
patients	O
at	O
the	O
time	O
of	O
VOD	O
manifestation	O
on	O
day	O
20	O
and	O
40	O
,	O
respectively	O
(	O
26	O
and	O
31	O
%	O
)	O
.	O

The	O
sequence	O
upstream	O
of	O
the	O
rhlA	B-protein
promoter	I-protein
contains	O
two	O
inverted	O
repeats	O
which	O
define	O
putative	O
binding	O
sites	O
for	O
the	O
RhlR	B-protein
regulator	I-protein
.	O

A	O
second	O
aim	O
was	O
to	O
determine	O
whether	O
the	O
decrease	O
in	O
muscle	O
-	O
tendon	O
unit	O
rest	O
length	O
produced	O
by	O
prolonged	O
immobilisation	O
in	O
a	O
shortened	O
position	O
is	O
mediated	O
primarily	O
by	O
adaptations	O
of	O
the	O
muscle	O
or	O
tendon	O
.	O

Analysis	O
of	O
clearance	O
curve	O
of	O
rose	O
bengal	O
-	O
I	O
-	O
131	O
.	O

Intravenous	O
administration	O
(	O
25	O
mg	O
/	O
kg	O
)	O
of	O
carbonic	B-protein
anhydrase	I-protein
inhibitors	O
(	O
acetazolamide	O
,	O
methazolamide	O
,	O
dichlorphenamide	O
,	O
sulthiame	O
)	O
induced	O
an	O
early	O
important	O
rise	O
of	O
cortical	O
p	O
O2	O
,	O
which	O
is	O
not	O
dependent	O
on	O
increase	O
of	O
p	O
O2	O
and	O
p	O
CO2	O
and	O
decrease	O
of	O
pH	O
in	O
arterial	O
blood	O
.	O

Cholinesterase	B-protein
.	O

Moritta	O
)	O
and	O
contains	O
Bis	O
-	O
GMA	O
.	O

Single	O
amino	O
acid	O
substitutions	O
at	O
the	O
acyl	O
-	O
CoA	O
-	O
binding	O
domain	O
interrupt	O
14	O
[	O
C	O
]	O
palmitoyl	O
-	O
CoA	O
binding	O
of	O
ACBP2	B-protein
,	O
an	O
Arabidopsis	O
acyl	B-protein
-	I-protein
CoA	I-protein
-	I-protein
binding	I-protein
protein	I-protein
with	O
ankyrin	B-protein
repeats	O
.	O

Expression	O
of	O
GlcNAc	B-protein
-	I-protein
TI	I-protein
mRNA	I-protein
in	O
tobacco	O
leaves	O
was	O
detected	O
using	O
RT	O
-	O
PCR	O
.	O

At	O
a	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
of	O
60	O
mmHg	O
,	O
C02	O
responsiveness	O
was	O
abolished	O
,	O
but	O
was	O
maintained	O
at	O
higher	O
levels	O
of	O
BP	O
.	O

Colorectal	O
cancer	O
was	O
shown	O
to	O
disproportionately	O
overburden	O
Ashkenazi	O
Jews	O
,	O
who	O
may	O
also	O
be	O
at	O
increased	O
risk	O
for	O
ovarian	O
,	O
pancreatic	O
and	O
stomach	O
cancer	O
,	O
and	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
.	O

HIV	O
-	O
1	O
and	O
hepatitis	O
B	O
virus	O
infections	O
in	O
adolescents	O
lodged	O
in	O
security	O
institutes	O
of	O
Buenos	O
Aires	O
.	O

Covalent	O
modification	O
of	O
the	O
transactivator	B-protein
protein	I-protein
IE2	I-protein
-	I-protein
p86	I-protein
of	O
human	O
cytomegalovirus	O
by	O
conjugation	O
to	O
the	O
ubiquitin	B-protein
-	I-protein
homologous	I-protein
proteins	I-protein
SUMO	I-protein
-	I-protein
1	I-protein
and	O
hSMT3b	B-protein
.	O

The	O
full	O
protocol	O
was	O
completed	O
by	O
33	O
patients	O
(	O
45	O
%	O
of	O
original	O
cohort	O
)	O
.	O

TaqMan	O
analysis	O
of	O
gene	O
expression	O
following	O
chronic	O
FA	O
treatment	O
showed	O
neither	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
leptin	B-protein
receptor	I-protein
(	O
Ob	B-protein
-	I-protein
R	I-protein
)	O
mRNA	O
,	O
nor	O
an	O
increase	O
in	O
the	O
negative	O
regulators	O
of	O
STAT	B-protein
signalling	O
,	O
SOCS3	B-protein
(	O
suppressors	B-protein
of	I-protein
cytokine	I-protein
signalling	I-protein
)	O
or	O
cytokine	B-protein
inducible	I-protein
sequence	I-protein
(	O
CIS	B-protein
)	O
.	O

It	O
was	O
shown	O
by	O
transient	O
expression	O
assay	O
that	O
HS	B-protein
-	I-protein
40	I-protein
behaved	O
as	O
an	O
authentic	O
enhancer	O
for	O
high	O
-	O
level	O
zeta	B-protein
2	I-protein
globin	I-protein
promoter	I-protein
activity	O
in	O
K562	O
cells	O
,	O
an	O
erythroid	O
cell	O
line	O
of	O
embryonic	O
and	O
/	O
or	O
fetal	O
origin	O
.	O

Despite	O
the	O
presence	O
of	O
one	O
additional	O
ribonucleotide	B-protein
reductase	I-protein
,	O
the	O
nrdAB	B-protein
-	I-protein
encoded	I-protein
enzyme	I-protein
is	O
essential	O
to	O
the	O
aerobic	O
growth	O
of	O
the	O
cell	O
because	O
nrdAB	B-protein
-	I-protein
defective	I-protein
mutants	I-protein
of	O
both	O
species	O
are	O
not	O
viable	O
in	O
the	O
presence	O
of	O
oxygen	O
.	O

We	O
studied	O
the	O
human	O
vestibulo	O
-	O
ocular	O
reflex	O
(	O
VOR	O
)	O
in	O
response	O
to	O
head	O
'	O
impulses	O
'	O
:	O
brief	O
,	O
unpredictable	O
,	O
passive	O
,	O
high	O
-	O
acceleration	O
(	O
up	O
to	O
4000	O
degrees	O
/	O
s2	O
)	O
,	O
low	O
-	O
amplitude	O
(	O
20	O
-	O
30	O
degrees	O
)	O
head	O
rotations	O
.	O

CXCR4	B-protein
is	O
a	O
chemokine	B-protein
receptor	I-protein
and	O
a	O
coreceptor	O
for	O
T	O
-	O
cell	O
-	O
line	O
-	O
tropic	O
(	O
X4	O
)	O
and	O
dual	O
-	O
tropic	O
(	O
R5X4	O
)	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
isolates	O
.	O

Implication	O
of	O
PAF	B-protein
and	O
acetylhydrolase	B-protein
(	O
PAF	B-protein
-	I-protein
AH	I-protein
)	O
activity	O
in	O
periodontal	O
disease	O
.	O

Coactivation	O
of	O
endogenous	O
or	O
exogenous	O
G	B-protein
(	I-protein
q	I-protein
)	I-protein
-	I-protein
coupled	I-protein
receptors	I-protein
with	O
the	O
delta	B-protein
-	I-protein
opioid	I-protein
receptor	I-protein
produced	O
strong	O
stimulations	O
of	O
PLCbeta	B-protein
and	O
such	O
responses	O
could	O
be	O
partially	O
blocked	O
by	O
pertussis	B-protein
toxin	I-protein
.	O

CONCLUSION	O
:	O
The	O
results	O
demonstrate	O
that	O
at	O
the	O
site	O
of	O
lumbar	O
disc	O
herniation	O
,	O
inflammatory	O
cytokines	O
such	O
as	O
interleukin	B-protein
-	I-protein
1	I-protein
alpha	I-protein
are	O
produced	O
,	O
which	O
increases	O
prostaglandin	O
E2	O
production	O
.	O

Here	O
,	O
we	O
report	O
the	O
complete	O
structure	O
of	O
the	O
human	B-protein
topoisomerase	I-protein
IIalpha	I-protein
gene	I-protein
,	O
which	O
consists	O
of	O
35	O
exons	O
spanning	O
27	O
.	O
5	O
kb	O
.	O

100	O
of	O
the	O
patients	O
who	O
would	O
have	O
died	O
survive	O
.	O

Calcitonin	B-protein
simultaneously	O
regulates	O
both	O
periosteal	O
hyperostosis	O
and	O
trabecular	O
osteopenia	O
in	O
the	O
spinal	O
hyperostotic	O
mouse	O
(	O
twy	B-protein
/	I-protein
twy	I-protein
)	O
in	O
vivo	O
.	O

SCA	B-protein
was	O
resistant	O
to	O
inhibitors	O
of	O
serine	O
,	O
aspartyl	O
,	O
and	O
metalloproteases	B-protein
,	O
but	O
it	O
was	O
sensitive	O
to	O
N	O
-	O
ethylmaleimide	O
.	O

The	O
failures	O
frequently	O
were	O
related	O
to	O
patient	O
intolerance	O
or	O
poor	O
mechanical	O
fit	O
and	O
occurred	O
in	O
the	O
first	O
few	O
days	O
or	O
first	O
few	O
months	O
after	O
insertion	O
.	O

Recovery	O
of	O
radiolabelled	O
BA	O
through	O
urine	O
(	O
28	O
%	O
)	O
and	O
faeces	O
(	O
22	O
%	O
)	O
up	O
to	O
96	O
hrs	O
averaged	O
50	O
%	O
,	O
whereas	O
residual	O
radioactivity	O
in	O
liver	O
and	O
testis	O
experienced	O
a	O
recovery	O
of	O
29	O
%	O
in	O
scorbutic	O
animals	O
.	O

Epstein	B-protein
-	I-protein
Barr	I-protein
virus	I-protein
nuclear	I-protein
protein	I-protein
2	I-protein
(	I-protein
EBNA2	I-protein
)	I-protein
binds	O
to	O
a	O
component	O
of	O
the	O
human	B-protein
SNF	I-protein
-	I-protein
SWI	I-protein
complex	I-protein
,	O
hSNF5	B-protein
/	I-protein
Ini1	I-protein
.	O

HIV	O
-	O
1	O
C	O
subtype	O
in	O
IDUs	O
accounted	O
for	O
61	O
.	O
3	O
%	O
.	O

METHODS	O
:	O
rHb1	B-protein
.	I-protein
1	I-protein
or	O
human	B-protein
serum	I-protein
albumin	I-protein
was	O
administered	O
intravenously	O
to	O
fasting	O
male	O
volunteers	O
.	O

EsaR	B-protein
can	O
repress	O
its	O
own	O
expression	O
but	O
seems	O
not	O
to	O
regulate	O
the	O
expression	O
of	O
esaI	B-protein
.	O

Administration	O
of	O
dexamethasone	O
was	O
associated	O
with	O
progressive	O
rises	O
in	O
plasma	O
17	O
alpha	O
OH	O
progesterone	O
,	O
11	O
beta	O
-	O
desoxycortisol	O
,	O
DHEA	O
sulphate	O
,	O
androstenedione	O
and	O
testosterone	O
,	O
together	O
with	O
increased	O
urinary	O
excretion	O
of	O
androsterone	O
,	O
11	O
beta	O
OH	O
androsterone	O
,	O
etiocholanolone	O
,	O
DHEA	O
,	O
and	O
16	O
alpha	O
OH	O
DHEA	O
.	O

In	O
the	O
course	O
of	O
investigating	O
the	O
mechanisms	O
by	O
which	O
OF5	B-protein
and	O
OF3	B-protein
regulated	O
CYP11A1	B-protein
transcription	O
,	O
we	O
found	O
that	O
OF5	B-protein
and	O
OF3	B-protein
bound	O
Sp1	B-protein
and	O
Sp3	B-protein
in	O
JEG	O
-	O
3	O
cells	O
.	O

Several	O
secondary	O
structure	O
elements	O
were	O
identified	O
.	O

Streptococcal	O
preparation	O
(	O
OK	O
-	O
432	O
)	O
,	O
a	O
new	O
type	O
of	O
anti	O
-	O
cancer	O
agent	O
,	O
was	O
given	O
to	O
the	O
patients	O
with	O
advanced	O
cancer	O
in	O
combination	O
with	O
Mitomycin	O
-	O
C	O
,	O
5	O
-	O
FU	O
and	O
Cytosine	O
arabinoside	O
.	O

The	O
genomic	O
fragments	O
were	O
fused	O
upstream	O
of	O
the	O
luciferase	B-protein
reporter	I-protein
gene	I-protein
.	O

At	O
1	O
,	O
5	O
,	O
and	O
9	O
months	O
after	O
initial	O
isolation	O
of	O
C	O
.	O
kutscheri	O
from	O
the	O
oral	O
cavity	O
,	O
hamsters	O
were	O
euthanatized	O
,	O
and	O
attempts	O
were	O
made	O
to	O
culture	O
C	O
.	O
kutscheri	O
from	O
13	O
additional	O
sites	O
.	O

Incidence	O
rate	O
ranging	O
between	O
122	O
/	O
100	O
,	O
000	O
/	O
year	O
and	O
190	O
/	O
100	O
,	O
000	O
/	O
year	O
were	O
found	O
(	O
minimum	O
,	O
estimated	O
and	O
raw	O
datasets	O
)	O
.	O

An	O
automated	O
method	O
for	O
the	O
quantitative	O
analysis	O
of	O
the	O
polyamines	O
putrescine	O
,	O
spermidine	O
and	O
spermine	O
in	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
was	O
used	O
to	O
analyze	O
CSF	O
samples	O
from	O
37	O
patients	O
with	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
tumors	O
and	O
from	O
13	O
patients	O
without	O
tumors	O
.	O

Further	O
studies	O
established	O
that	O
the	O
Ep	O
-	O
induced	O
increase	O
in	O
beta	B-protein
-	I-protein
globin	I-protein
mRNA	I-protein
could	O
be	O
inhibited	O
by	O
the	O
tyrosine	B-protein
kinase	I-protein
inhibitor	O
genistein	O
and	O
the	O
protein	B-protein
kinase	I-protein
C	I-protein
inhibitor	O
Compound	O
3	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
relationship	O
between	O
estrogenic	O
properties	O
of	O
Tamoxifen	O
and	O
breast	O
cancer	O
management	O
is	O
discussed	O
.	O

In	O
PC	O
,	O
rare	O
MNGCs	O
had	O
intranuclear	O
inclusions	O
and	O
grooves	O
.	O

The	O
costs	O
were	O
DM	O
11	O
,	O
562	O
for	O
a	O
PE	O
,	O
DM	O
12	O
,	O
477	O
for	O
a	O
VR	O
and	O
DM	O
7	O
,	O
532	O
for	O
a	O
MR	O
.	O

The	O
provisional	O
reports	O
are	O
based	O
mainly	O
upon	O
macroscopic	O
findings	O
,	O
whereas	O
the	O
final	O
reports	O
include	O
the	O
information	O
provided	O
by	O
supplementary	O
investigations	O
such	O
as	O
microscopy	O
,	O
histochemistry	O
,	O
more	O
rarely	O
electron	O
microscopy	O
,	O
immunohistochemistry	O
and	O
/	O
or	O
microbiology	O
.	O

Cells	O
containing	O
alpha	O
subunits	O
that	O
lacked	O
a	O
distal	B-protein
domain	O
(	O
term	B-protein
-	I-protein
3	I-protein
)	O
or	O
had	O
the	O
alternatively	O
spliced	O
alpha	B-protein
-	I-protein
2	I-protein
distal	I-protein
domain	I-protein
showed	O
markedly	O
decreased	O
ability	O
to	O
support	O
tyrosine	O
phosphorylation	O
of	O
Jak	B-protein
-	I-protein
2	I-protein
and	O
its	O
substrates	O
or	O
to	O
up	O
-	O
regulate	O
CD86	B-protein
.	O

Abundant	O
infiltration	O
of	O
lymphocytes	O
and	O
plasma	O
cells	O
was	O
also	O
wide	O
-	O
spread	O
beneath	O
the	O
carcinoma	O
in	O
situ	O
,	O
together	O
with	O
the	O
lymphoid	O
follicles	O
.	O

Addition	O
of	O
Rap	O
or	O
KN62	O
after	O
exposure	O
of	O
cells	O
to	O
progesterone	O
agonist	O
Org	O
2058	O
had	O
no	O
effect	O
on	O
induction	O
of	O
CAT	B-protein
activity	O
.	O

Teicoplanin	O
was	O
given	O
most	O
often	O
because	O
of	O
persistent	O
fever	O
or	O
initial	O
Gram	O
-	O
positive	O
bacteraemia	O
and	O
only	O
one	O
-	O
third	O
of	O
these	O
cases	O
responded	O
.	O

A	O
peculiar	O
people	O
:	O
`	O
`	O
the	O
physiological	O
aspects	O
of	O
Mormonism	O
1850	O
-	O
1975	O
.	O
`	O
`	O

Keck	O
,	O
C	O
.	O
J	O
.	O

E2F	B-protein
-	I-protein
1	I-protein
is	O
a	O
transcription	O
factor	O
that	O
regulates	O
cell	O
cycle	O
progression	O
into	O
S	O
-	O
phase	O
.	O

L3	O
-	O
L4	O
compressive	O
load	O
was	O
calculated	O
using	O
a	O
model	O
of	O
the	O
anatomy	O
of	O
the	O
trunk	O
musculoskeletal	O
system	O
.	O

Transactivation	O
of	O
oIFNtau	B-protein
enhancer	O
-	O
reporter	O
constructs	O
was	O
primarily	O
regulated	O
by	O
three	O
regions	O
containing	O
AP	B-protein
-	I-protein
1	I-protein
site	I-protein
,	O
GATA	B-protein
like	O
sequence	O
and	O
site	O
(	O
s	O
)	O
unidentified	O
.	O

The	O
lengths	O
of	O
the	O
complete	O
polypeptide	O
chain	O
of	O
the	O
recombinant	O
enzyme	O
and	O
its	O
transit	O
peptide	O
are	O
388	O
and	O
53	O
residues	O
,	O
respectively	O
.	O

Transfection	O
analyses	O
indicate	O
that	O
mutation	O
of	O
any	O
one	O
of	O
these	O
TGACCT	B-protein
motifs	I-protein
or	O
truncation	O
of	O
the	O
entire	O
HD	B-protein
PPRE	I-protein
into	O
a	O
separate	O
DR1	B-protein
and	O
DR2	B-protein
element	I-protein
significantly	O
reduced	O
the	O
transcriptional	O
response	O
of	O
HD	B-protein
PPRE	I-protein
to	O
peroxisome	O
proliferators	O
.	O

The	O
amino	O
acid	O
changes	O
D206A	O
and	O
D208A	O
abolish	O
singly	O
or	O
in	O
combination	O
the	O
exonuclease	B-protein
activity	O
in	O
vivo	O
.	O

Chem	O
.	O

A	O
case	O
of	O
AIDS	O
-	O
related	O
complex	O
(	O
ARC	O
/	O
LAS	O
)	O
in	O
a	O
health	O
worker	O
.	O

There	O
occurred	O
a	O
linear	O
relationship	O
between	O
the	O
drop	O
in	O
glucose	B-protein
-	I-protein
6	I-protein
-	I-protein
phosphatase	I-protein
dehydrogenase	I-protein
activity	O
and	O
in	O
vitamin	O
E	O
level	O
,	O
on	O
one	O
hand	O
,	O
and	O
the	O
duration	O
of	O
poisoning	O
with	O
sodium	O
nitrite	O
.	O

A	O
cis	O
-	O
acting	O
DNA	O
element	O
located	O
between	O
TATA	O
box	O
and	O
transcription	O
initiation	O
site	O
is	O
critical	O
in	O
response	O
to	O
regulatory	O
sequences	O
in	O
human	O
angiotensinogen	B-protein
gene	I-protein
.	O

Hepatic	O
oxygen	O
supply	O
and	O
selected	O
blood	O
parameters	O
were	O
recorded	O
in	O
fasted	O
male	O
rates	O
given	O
20	O
-	O
-	O
30	O
mg	O
/	O
kg	O
Escherichia	B-protein
coli	I-protein
endotoxin	I-protein
intraperitoneally	O
.	O

Branch	O
occlusion	O
of	O
Heubner	O
'	O
s	O
artery	O
,	O
or	O
perforators	O
from	O
the	O
proximal	O
anterior	O
or	O
middle	O
cerebral	O
arteries	O
were	O
the	O
posited	O
mechanism	O
of	O
infarction	O
.	O

We	O
propose	O
that	O
Gly84	O
is	O
part	O
of	O
a	O
putative	O
`	O
`	O
oxyanion	O
hole	O
'	O
'	O
involved	O
in	O
the	O
stabilization	O
of	O
the	O
transition	O
state	O
similar	O
to	O
the	O
C	B-protein
group	I-protein
of	O
the	O
esterase	B-protein
/	I-protein
lipase	I-protein
family	I-protein
.	O

While	O
important	O
for	O
ligand	O
-	O
dependent	O
transactivation	O
,	O
this	O
interaction	O
surface	O
is	O
not	O
directly	O
involved	O
in	O
transrepression	O
of	O
AP	B-protein
-	I-protein
1	I-protein
activity	O
.	O

To	O
elucidate	O
whether	O
potential	O
endocrine	O
changes	O
resulted	O
from	O
acute	O
hypoxaemia	O
alone	O
,	O
the	O
underlying	O
disease	O
,	O
or	O
unspecific	O
influences	O
connected	O
with	O
the	O
ICU	O
setting	O
,	O
all	O
measurements	O
were	O
compared	O
to	O
those	O
of	O
a	O
completely	O
healthy	O
reference	O
group	O
(	O
REF	O
)	O
with	O
comparable	O
acute	O
experimental	O
hypoxaemia	O
.	O

Their	O
function	O
is	O
not	O
only	O
to	O
recruit	O
Pho2	B-protein
to	O
the	O
promoter	O
but	O
to	O
allow	O
cooperative	O
binding	O
of	O
Pho4	B-protein
together	O
with	O
Pho2	B-protein
.	O

EUK	O
-	O
8	O
is	O
a	O
novel	O
,	O
synthetic	O
,	O
low	O
-	O
molecular	O
-	O
weight	O
salen	O
-	O
manganese	O
complex	O
that	O
exhibits	O
both	O
superoxide	B-protein
dismutase	I-protein
and	O
catalase	B-protein
activities	O
in	O
vitro	O
.	O

Ras	B-protein
p21Val	I-protein
inhibits	O
myogenesis	O
without	O
altering	O
the	O
DNA	O
binding	O
or	O
transcriptional	O
activities	O
of	O
the	O
myogenic	B-protein
basic	I-protein
helix	I-protein
-	I-protein
loop	I-protein
-	I-protein
helix	I-protein
factors	I-protein
.	O

The	O
patient	O
underwent	O
two	O
intracytoplasmic	O
sperm	O
injection	O
cycles	O
with	O
thawed	O
epididymal	O
spermatozoa	O
,	O
in	O
which	O
,	O
due	O
to	O
a	O
pharmacist	O
'	O
s	O
mistake	O
,	O
ovarian	O
stimulation	O
was	O
carried	O
out	O
by	O
a	O
combination	O
of	O
long	O
-	O
acting	O
gonadotrophin	B-protein
-	I-protein
releasing	I-protein
hormone	I-protein
agonist	O
(	O
leuprolide	O
depot	O
)	O
and	O
gonadotrophins	B-protein
.	O

These	O
findings	O
suggest	O
that	O
an	O
intracellular	B-protein
WT1	I-protein
/	I-protein
Hsal	I-protein
2	I-protein
pathway	O
may	O
play	O
a	O
role	O
in	O
development	O
and	O
hematopoiesis	O
.	O

Adjuvant	O
and	O
neoadjuvant	O
treatment	O
of	O
breast	O
cancer	O
.	O

This	O
was	O
obtained	O
with	O
the	O
thermal	O
neutron	O
fluency	O
2	O
.	O
0	O
x	O
10	O
(	O
10	O
)	O
n	O
/	O
cm2	O
.	O

In	O
contrast	O
to	O
T	O
cells	O
,	O
in	O
fibroblasts	O
PILOT	B-protein
gene	I-protein
expression	O
requires	O
only	O
one	O
signal	O
(	O
PMA	O
)	O
and	O
is	O
not	O
affected	O
by	O
CyA	O
.	O

The	O
findings	O
are	O
compatible	O
with	O
the	O
idea	O
that	O
the	O
genes	O
encoding	O
PDGF	B-protein
receptors	I-protein
in	O
glioma	O
cells	O
are	O
regulated	O
in	O
concert	O
with	O
other	O
genes	O
,	O
the	O
expression	O
of	O
which	O
may	O
reflect	O
the	O
developmental	O
program	O
of	O
normal	O
glia	O
cell	O
lineages	O
.	O

Current	O
clinical	O
trials	O
should	O
answer	O
the	O
question	O
of	O
which	O
of	O
the	O
therapeutic	O
options	O
impairs	O
quality	O
of	O
life	O
less	O
.	O

Several	O
genes	O
or	O
transcriptional	O
units	O
were	O
identified	O
,	O
including	O
the	O
3	O
'	O
end	O
of	O
ribosomal	B-protein
s6	I-protein
kinase	I-protein
(	O
Rsk3	B-protein
)	O
;	O
two	O
apparently	O
intronless	O
and	O
ORF	O
-	O
less	O
genes	O
;	O
and	O
Gpr31	B-protein
,	O
an	O
intronless	O
,	O
putative	O
G	B-protein
-	I-protein
protein	I-protein
coupled	I-protein
receptor	I-protein
.	O

Using	O
gel	O
retardation	O
assays	O
with	O
HepG2	O
nuclear	O
extract	O
,	O
we	O
demonstrated	O
the	O
presence	O
of	O
a	O
specific	O
protein	O
which	O
bound	O
to	O
the	O
NRE	B-protein
fragment	O
.	O

In	O
contrast	O
,	O
a	O
similar	O
fragment	O
lacking	O
the	O
38	O
-	O
base	O
-	O
pair	O
region	O
had	O
no	O
such	O
stabilizing	O
effect	O
.	O

Here	O
,	O
we	O
describe	O
a	O
tyrosine	O
-	O
phosphorylated	O
nuclear	O
protein	O
,	O
YT521	B-protein
-	I-protein
B	I-protein
,	O
and	O
show	O
that	O
it	O
interacts	O
with	O
the	O
nuclear	B-protein
transcriptosomal	I-protein
component	I-protein
scaffold	I-protein
attachment	I-protein
factor	I-protein
B	I-protein
,	O
and	O
the	O
68	B-protein
-	I-protein
kDa	I-protein
Src	I-protein
substrate	O
associated	O
during	O
mitosis	O
,	O
Sam68	B-protein
.	O

The	O
exon	O
:	O
intron	O
structure	O
of	O
chicken	B-protein
IL8	I-protein
corresponds	O
almost	O
exactly	O
to	O
that	O
of	O
human	B-protein
IL8	I-protein
and	O
differs	O
from	O
those	O
of	O
other	O
known	O
mammalian	B-protein
CXC	I-protein
chemokine	I-protein
genes	I-protein
.	O

Brain	O
scan	O
with	O
99mTc	O
-	O
labelled	O
macroaggregated	O
albumin	B-protein
(	O
MAA	O
brain	O
scan	O
)	O
and	O
computed	O
tomography	O
studies	O
(	O
CT	O
)	O
were	O
performed	O
on	O
78	O
patients	O
with	O
intracranial	O
diseases	O
.	O

First	O
,	O
each	O
lung	O
was	O
cut	O
into	O
slices	O
,	O
from	O
which	O
primary	O
disectors	O
were	O
sampled	O
systematically	O
with	O
a	O
known	O
sampling	O
fraction	O
.	O

Tumor	O
cells	O
were	O
focally	O
immunoreactive	O
for	O
neuron	B-protein
-	I-protein
specific	I-protein
enolase	I-protein
,	O
insulin	B-protein
,	O
glucagon	B-protein
and	O
VIP	B-protein
.	O

Analysis	O
of	O
viral	O
mutants	O
in	O
vivo	O
demonstrated	O
that	O
the	O
NFIII	B-protein
/	I-protein
OCT	I-protein
-	I-protein
1	I-protein
binding	I-protein
site	I-protein
and	O
a	O
conserved	O
ATF	B-protein
motif	I-protein
were	O
important	O
for	O
efficient	O
viral	O
growth	O
.	O

E1A	B-protein
autoactivation	O
mediated	O
by	O
these	O
sites	O
was	O
about	O
twofold	O
compared	O
with	O
a	O
ninefold	O
activation	O
described	O
for	O
the	O
complete	O
E1A	B-protein
promoter	I-protein
.	O

In	O
a	O
second	O
patient	O
the	O
VT	O
became	O
nonsustained	O
.	O

Further	O
,	O
the	O
PIP2	O
content	O
of	O
the	O
85	O
-	O
90	O
kDa	O
protein	O
appeared	O
to	O
decrease	O
with	O
CSF	B-protein
-	I-protein
1	I-protein
treatment	O
.	O

The	O
epitope	O
-	O
protected	O
lysine	O
(	O
K	O
)	O
was	O
present	O
in	O
a	O
30	B-protein
-	I-protein
aa	I-protein
TPO	I-protein
fragment	I-protein
that	O
,	O
by	O
N	O
-	O
terminal	O
sequencing	O
,	O
was	O
found	O
to	O
be	O
K713	O
.	O

Therefore	O
,	O
magnetic	O
resonance	O
imaging	O
was	O
used	O
to	O
determine	O
liver	O
volume	O
in	O
pediatric	O
and	O
adolescent	O
patients	O
,	O
in	O
whom	O
systemic	O
clearance	O
of	O
three	O
model	O
substrates	O
[	O
lorazepam	O
(	O
0	O
.	O
03	O
mg	O
/	O
kg	O
)	O
,	O
antipyrine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
and	O
indocyanine	O
green	O
(	O
ICG	O
;	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
]	O
was	O
also	O
determined	O
.	O

Like	O
scrotal	O
testes	O
,	O
undescended	O
testes	O
were	O
hypointense	O
to	O
fat	O
on	O
sequences	O
with	O
a	O
short	O
repetition	O
time	O
(	O
TR	O
)	O
and	O
echo	O
time	O
(	O
TE	O
)	O
in	O
all	O
cases	O
,	O
and	O
hyperintense	O
or	O
isointense	O
to	O
fat	O
on	O
long	O
TR	O
/	O
TE	O
sequences	O
in	O
all	O
but	O
two	O
cases	O
.	O

Samples	O
from	O
1415	O
neurological	O
patients	O
were	O
used	O
to	O
study	O
the	O
diagnostic	O
value	O
of	O
acid	B-protein
alpha	I-protein
1	I-protein
-	I-protein
glycoprotein	I-protein
in	O
the	O
lumbar	O
cerebrospinal	O
fluid	O
.	O

In	O
addition	O
,	O
a	O
comparison	O
of	O
the	O
hCHLR	B-protein
gene	I-protein
sequences	I-protein
with	O
available	O
databases	O
indicates	O
that	O
a	O
large	O
portion	O
of	O
these	O
genes	O
,	O
including	O
exons	O
encoding	O
two	O
functional	O
domains	O
of	O
the	O
carboxyl	O
-	O
terminal	O
region	O
of	O
these	O
proteins	O
,	O
has	O
been	O
duplicated	O
as	O
part	O
of	O
a	O
larger	O
human	O
telomeric	O
repeat	O
sequence	O
found	O
on	O
many	O
human	O
chromosomes	O
.	O

The	O
pulmonary	O
effects	O
observed	O
,	O
became	O
more	O
pronounced	O
with	O
increasing	O
NO2	O
concentrations	O
(	O
0	O
,	O
25	O
,	O
75	O
,	O
125	O
,	O
175	O
or	O
200	O
ppm	O
,	O
1	O
ppm	O
NO2	O
=	O
1	O
.	O
88	O
mg	O
m	O
-	O
3	O
NO2	O
)	O
and	O
exposure	O
times	O
(	O
5	O
,	O
10	O
,	O
20	O
or	O
30	O
min	O
)	O
.	O

Type	B-protein
2	I-protein
deiodinase	I-protein
(	O
D2	B-protein
)	O
catalyzes	O
the	O
5	O
'	O
-	O
deiodination	O
of	O
thyroxine	O
to	O
form	O
3	O
,	O
5	O
,	O
3	O
'	O
-	O
triiodothyronine	O
.	O

Comparison	O
of	O
genomic	O
sequence	O
shows	O
that	O
the	O
ph	B-protein
locus	I-protein
has	O
been	O
duplicated	O
,	O
and	O
that	O
it	O
contains	O
proximal	O
and	O
distal	O
transcription	O
units	O
.	O

Pao2	O
increased	O
from	O
15	O
.	O
5	O
+	O
/	O
-	O
5	O
.	O
6	O
kPa	O
(	O
116	O
+	O
/	O
-	O
42	O
mm	O
Hg	O
)	O
to	O
17	O
.	O
3	O
+	O
/	O
-	O
6	O
.	O
3	O
kPa	O
(	O
130	O
+	O
/	O
-	O
47	O
mm	O
Hg	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
efficacy	O
and	O
safety	O
of	O
a	O
novel	O
percutaneous	O
anaesthetic	O
preparation	O
based	O
on	O
amethocaine	O
has	O
been	O
investigated	O
in	O
the	O
paediatric	O
clinical	O
environment	O
.	O

Cell	O
.	O

The	O
drug	O
sensitivity	O
was	O
100	O
%	O
for	O
vancomycin	O
(	O
VCM	O
)	O
,	O
30	O
%	O
for	O
imipenam	O
(	O
IMP	O
)	O
,	O
31	O
%	O
for	O
minomycin	O
(	O
MINO	O
)	O
,	O
31	O
%	O
for	O
amikacin	O
(	O
AMK	O
)	O
,	O
and	O
7	O
%	O
for	O
fosfomycin	O
(	O
FOM	O
)	O
.	O

Induction	O
of	O
CD86	B-protein
expression	O
by	O
stimulation	O
of	O
U937	O
cells	O
with	O
IFN	B-protein
-	I-protein
gamma	I-protein
revealed	O
the	O
presence	O
of	O
two	O
functional	O
GAS	B-protein
(	O
gamma	B-protein
-	I-protein
interferon	I-protein
activation	I-protein
site	I-protein
)	O
elements	O
.	O

Measurements	O
of	O
perfusion	O
also	O
showed	O
significantly	O
higher	O
values	O
under	O
active	O
therapy	O
.	O

Serum	O
and	O
peritoneal	O
dialysis	O
fluid	O
(	O
PDF	O
)	O
were	O
collected	O
for	O
assay	O
throughout	O
the	O
course	O
of	O
the	O
study	O
and	O
for	O
5	O
days	O
thereafter	O
.	O

These	O
results	O
show	O
that	O
Ski	B-protein
is	O
a	O
component	O
of	O
the	O
HDAC	B-protein
complex	I-protein
and	O
that	O
Ski	B-protein
is	O
required	O
for	O
the	O
transcriptional	O
repression	O
mediated	O
by	O
this	O
complex	O
.	O

Theory	O
and	O
applications	O
of	O
pulse	O
dosing	O
:	O
a	O
summary	O
of	O
the	O
symposium	O
.	O

The	O
structural	O
genes	O
encoding	O
glyceraldehyde	B-protein
-	I-protein
3	I-protein
-	I-protein
phosphate	I-protein
dehydrogenase	I-protein
(	O
GAPDH	B-protein
)	O
,	O
3	B-protein
-	I-protein
phosphoglycerate	I-protein
kinase	I-protein
(	O
PGK	B-protein
)	O
and	O
the	O
N	O
-	O
terminal	O
part	O
of	O
triosephosphate	B-protein
isomerase	I-protein
(	O
TIM	B-protein
)	O
from	O
mesophilic	O
Bacillus	O
megaterium	O
DSM319	O
have	O
been	O
cloned	O
as	O
a	O
gene	O
cluster	O
(	O
gap	B-protein
operon	I-protein
)	O
by	O
complementation	O
of	O
an	O
Escherichia	O
coli	O
gap	B-protein
amber	I-protein
mutant	I-protein
.	O

1	O
-	O
(	O
m	O
-	O
Chlorophenyl	O
)	O
piperazine	O
(	O
mCPP	O
,	O
0	O
.	O
1	O
-	O
3	O
.	O
0	O
mg	O
/	O
kg	O
)	O
and	O
1	O
-	O
(	O
m	O
-	O
trifluoromethylphenyl	O
)	O
piperazine	O
(	O
TFMPP	O
,	O
0	O
.	O
1	O
-	O
3	O
.	O
0	O
mg	O
/	O
kg	O
)	O
,	O
both	O
thought	O
to	O
act	O
primarily	O
at	O
5	B-protein
-	I-protein
HT1	I-protein
sites	I-protein
,	O
also	O
decreased	O
responding	O
and	O
this	O
effect	O
was	O
blocked	O
by	O
methysergide	O
and	O
by	O
1	O
-	O
NP	O
,	O
but	O
not	O
by	O
ketanserin	O
.	O

METHOD	O
:	O
The	O
sample	O
of	O
subjects	O
was	O
drawn	O
from	O
the	O
Suffolk	O
County	O
Mental	O
Health	O
Project	O
,	O
a	O
longitudinal	O
epidemiologic	O
study	O
of	O
first	O
-	O
hospitalized	O
subjects	O
with	O
psychotic	O
disorders	O
;	O
the	O
present	O
study	O
focused	O
on	O
patients	O
with	O
schizophrenic	O
disorders	O
.	O

The	O
temporal	O
component	O
lacked	O
a	O
mandibular	O
fossa	O
as	O
well	O
as	O
articular	O
eminence	O
.	O

Ang	B-protein
II	I-protein
-	I-protein
induced	I-protein
fibronectin	I-protein
mRNA	I-protein
was	O
not	O
affected	O
by	O
PKC	B-protein
inhibitors	O
or	O
PKC	B-protein
depletion	O
,	O
whereas	O
specific	O
inhibition	O
of	O
EGF	B-protein
-	I-protein
R	I-protein
function	O
by	O
a	O
dominant	B-protein
negative	I-protein
EGF	I-protein
-	I-protein
R	I-protein
mutant	I-protein
and	O
tyrphostin	O
AG1478	O
abolished	O
induction	O
of	O
fibronectin	B-protein
mRNA	I-protein
.	O

Furthermore	O
,	O
although	O
the	O
regional	O
distribution	O
of	O
lean	O
tissue	O
mass	O
in	O
the	O
trunk	O
and	O
legs	O
remained	O
fairly	O
constant	O
at	O
different	O
pubertal	O
stages	O
,	O
the	O
regional	O
distribution	O
of	O
fat	O
was	O
altered	O
significantly	O
,	O
becoming	O
more	O
central	O
and	O
less	O
peripheral	O
.	O

Coliphage	B-protein
186	I-protein
B	I-protein
is	O
a	O
72	O
-	O
amino	O
acid	O
protein	O
belonging	O
to	O
the	O
Ogr	B-protein
family	O
of	O
analogous	O
transcription	O
factors	O
present	O
in	O
P2	O
-	O
like	O
phage	O
,	O
which	O
contain	O
a	O
Cys	O
-	O
X2	O
-	O
Cys	O
-	O
X22	O
-	O
Cys	O
-	O
X4	O
-	O
Cys	O
presumptive	O
zinc	O
-	O
finger	O
motif	O
.	O

In	O
a	O
maxicell	O
system	O
a	O
protein	O
with	O
an	O
approximate	O
molecular	O
weight	O
of	O
36	O
,	O
000	O
was	O
synthesized	O
.	O

Vac1p	B-protein
was	O
found	O
to	O
bind	O
the	O
Sec1p	B-protein
homologue	I-protein
Vps45p	I-protein
.	O

The	O
Aie1	B-protein
locus	I-protein
was	O
mapped	O
to	O
mouse	O
chromosome	O
7A2	O
-	O
A3	O
by	O
fluorescent	O
in	O
situ	O
hybridization	O
.	O

Effects	O
of	O
point	O
defects	O
on	O
lattice	O
parameters	O
of	O
semiconductors	O
.	O

There	O
was	O
no	O
difference	O
in	O
apnea	O
duration	O
between	O
the	O
supine	O
and	O
prone	O
positions	O
.	O

Cell	O
49	O
,	O
753	O
-	O
761	O
]	O
.	O

After	O
PTCA	O
,	O
ejection	O
fraction	O
increased	O
from	O
54	O
+	O
/	O
-	O
8	O
%	O
to	O
59	O
+	O
/	O
-	O
8	O
%	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
regional	O
function	O
improved	O
significantly	O
(	O
maximal	O
standard	O
deviation	O
before	O
PTCA	O
:	O
2	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
8	O
;	O
after	O
PTCA	O
:	O
1	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
9	O
-	O
segments	O
below	O
the	O
first	O
standard	O
deviation	O
before	O
PTCA	O
:	O
31	O
+	O
/	O
-	O
16	O
;	O
after	O
PTCA	O
:	O
19	O
+	O
/	O
-	O
17	O
)	O
.	O

The	O
concentrations	O
of	O
plasma	O
ACTH	B-protein
and	O
cortisol	O
increased	O
by	O
40	O
%	O
and	O
60	O
%	O
after	O
MPTP	O
treatment	O
,	O
respectively	O
.	O

This	O
distribution	O
parallels	O
that	O
of	O
the	O
neurotransmitters	O
glutamate	O
and	O
aspartate	O
;	O
however	O
,	O
neither	O
of	O
these	O
excitatory	O
amino	O
acids	O
is	O
a	O
substrate	O
for	O
transport	O
.	O

Only	O
two	O
of	O
the	O
isoforms	O
possess	O
the	O
N	O
-	O
terminal	O
zinc	O
finger	O
domain	O
that	O
is	O
necessary	O
and	O
sufficient	O
for	O
TdT	B-protein
promoter	I-protein
binding	O
.	O

This	O
demonstrates	O
that	O
treatment	O
of	O
the	O
graft	O
recipient	O
for	O
a	O
relatively	O
short	O
period	O
during	O
and	O
after	O
surgery	O
has	O
a	O
favorable	O
effect	O
on	O
the	O
survival	O
of	O
grafted	O
dopaminergic	O
neurons	O
.	O

Three	O
-	O
dimensional	O
structural	O
studies	O
using	O
electron	O
cryomicroscopy	O
showed	O
that	O
the	O
binding	O
of	O
one	O
Fab	B-protein
(	O
8H2	O
/	O
G5	O
)	O
does	O
not	O
affect	O
the	O
conformation	O
of	O
the	O
capsid	O
,	O
and	O
the	O
efficiency	O
of	O
mRNA	O
production	O
is	O
similar	O
to	O
that	O
of	O
the	O
native	O
subviral	O
particle	O
.	O

Femoral	O
strain	O
adaptation	O
after	O
total	O
hip	O
replacement	O
:	O
a	O
comparison	O
of	O
cemented	O
and	O
porous	O
ingrowth	O
components	O
in	O
canines	O
.	O

The	O
ability	O
of	O
chronic	O
UM	O
-	O
272	O
(	O
dimethylpropranolol	O
)	O
treatment	O
to	O
prevent	O
the	O
induction	O
of	O
reentrant	O
ventricular	O
tachyarrhythmias	O
was	O
assessed	O
in	O
the	O
conscious	O
dog	O
subjected	O
to	O
serial	O
programmed	O
electrical	O
stimulation	O
on	O
days	O
3	O
-	O
-	O
5	O
after	O
myocardial	O
infarction	O
.	O

MR	O
imaging	O
of	O
traumatic	O
head	O
injuries	O
using	O
FLAIR	O
technique	O
.	O

With	O
0	O
.	O
5	O
vol	O
.	O
-	O
%	O
,	O
the	O
corresponding	O
values	O
were	O
345	O
mumol	O
/	O
1	O
(	O
5	O
.	O
72	O
mg	O
/	O
100	O
ml	O
)	O
and	O
137	O
mumol	O
/	O
1	O
(	O
2	O
.	O
25	O
mg	O
/	O
100	O
ml	O
)	O
respectively	O
.	O

Given	O
its	O
relative	O
longevity	O
on	O
the	O
Web	O
,	O
TIE	O
researchers	O
have	O
been	O
in	O
a	O
unique	O
position	O
to	O
observe	O
trends	O
in	O
telemedicine	O
.	O

She	O
improved	O
with	O
a	O
combination	O
of	O
benzodiazepines	O
and	O
the	O
acetylcholinesterase	B-protein
inhibitor	O
physostigmine	O
.	O

Those	O
radiological	O
aspects	O
were	O
distributed	O
in	O
two	O
categories	O
:	O
1	O
)	O
type	O
I	O
-	O
presenting	O
variable	O
sinusoidal	O
filling	O
.	O

Since	O
we	O
have	O
observed	O
effects	O
of	O
growth	B-protein
factors	I-protein
and	O
cAMP	O
as	O
well	O
as	O
estradiol	O
(	O
E2	O
)	O
on	O
regulation	O
of	O
expression	O
of	O
some	O
genes	O
stimulated	O
by	O
the	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
,	O
we	O
have	O
undertaken	O
studies	O
to	O
examine	O
directly	O
whether	O
activators	O
of	O
protein	B-protein
kinases	I-protein
can	O
modulate	O
transcriptional	O
activity	O
of	O
the	O
ER	B-protein
.	O

BCL	B-protein
-	I-protein
2	I-protein
,	O
an	O
inhibitor	O
of	O
apoptosis	O
in	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
,	O
has	O
been	O
reported	O
to	O
prevent	O
oxidative	O
stress	O
-	O
induced	O
cell	O
death	O
.	O

This	O
mechanism	O
is	O
not	O
due	O
to	O
the	O
observed	O
grain	O
boundary	O
precipitates	O
.	O

Taste	O
reactivity	O
tests	O
were	O
used	O
to	O
examine	O
the	O
orofacial	O
responses	O
of	O
alcohol	O
preferring	O
(	O
P	O
)	O
rats	O
and	O
alcohol	O
nonpreferring	O
(	O
NP	O
)	O
rats	O
to	O
the	O
taste	O
of	O
alcohol	O
.	O

On	O
the	O
other	O
side	O
,	O
when	O
the	O
aortic	O
ring	O
was	O
perfused	O
with	O
L	O
-	O
NNA	O
(	O
NO	O
-	O
synthesis	O
inhibitor	O
)	O
or	O
methylene	O
blue	O
(	O
soluble	O
cGMPase	B-protein
inhibitor	O
)	O
,	O
the	O
changes	O
could	O
be	O
attenuated	O
.	O

Effects	O
of	O
verapamil	O
and	O
propranolol	O
on	O
early	O
afterdepolarizations	O
and	O
ventricular	O
arrhythmias	O
induced	O
by	O
epinephrine	O
in	O
congenital	O
long	O
QT	O
syndrome	O
.	O

This	O
implies	O
that	O
the	O
groups	O
do	O
not	O
just	O
differ	O
along	O
one	O
dimension	O
,	O
but	O
along	O
three	O
dimensions	O
.	O

Poor	O
response	O
when	O
laboratory	O
recommended	O
range	O
for	O
serum	O
lithium	O
is	O
changed	O
.	O

Hydrocoele	O
is	O
common	O
in	O
men	O
in	O
Wuchereria	O
bancrofti	O
-	O
endemic	O
areas	O
,	O
the	O
treatment	O
for	O
which	O
is	O
currently	O
surgical	O
intervention	O
.	O

Replication	O
of	O
bovine	O
papillomavirus	O
-	O
1	O
(	O
BPV	O
-	O
1	O
)	O
DNA	O
requires	O
two	O
viral	O
gene	O
products	O
,	O
the	O
E1	B-protein
protein	I-protein
and	O
the	O
full	B-protein
-	I-protein
length	I-protein
E2	I-protein
protein	I-protein
.	O

We	O
have	O
been	O
able	O
to	O
map	O
specific	O
DNA	O
fragments	O
at	O
the	O
bases	O
of	O
chromatin	O
loops	O
with	O
the	O
help	O
of	O
a	O
novel	O
extraction	O
procedure	O
by	O
using	O
lithium	O
-	O
3	O
'	O
,	O
5	O
'	O
-	O
diiodosalicylate	O
.	O

One	O
month	O
after	O
the	O
DTaP	O
booster	O
vaccination	O
,	O
both	O
groups	O
had	O
6	O
-	O
to	O
40	O
-	O
fold	O
increases	O
in	O
serum	O
antibody	O
concentrations	O
to	O
all	O
antigens	O
tested	O
;	O
the	O
concentrations	O
against	O
the	O
three	O
pertussis	B-protein
antigens	I-protein
were	O
higher	O
in	O
the	O
DTaP	O
-	O
primed	O
children	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
iron	O
dependence	O
of	O
transcription	O
and	O
expression	O
of	O
cvaA	B-protein
,	O
which	O
encodes	O
a	O
transporter	O
accessory	O
protein	O
,	O
and	O
cvi	B-protein
,	O
encoding	O
the	O
colicin	B-protein
V	I-protein
immunity	I-protein
protein	I-protein
,	O
was	O
assessed	O
under	O
conditions	O
of	O
iron	O
excess	O
or	O
depletion	O
.	O

Synthetic	O
ligands	O
have	O
been	O
identified	O
that	O
reset	O
and	O
amplify	O
the	O
cycle	O
of	O
pulsatile	O
GH	B-protein
secretion	O
by	O
interacting	O
with	O
the	O
orphan	B-protein
GH	I-protein
-	I-protein
secretagogue	I-protein
receptor	I-protein
(	O
GHS	B-protein
-	I-protein
R	I-protein
)	O
.	O

Self	O
-	O
heating	O
after	O
deep	O
hypothermia	O
(	O
20	O
degrees	O
C	O
)	O
causes	O
a	O
considerable	O
increase	O
in	O
the	O
brain	O
tissues	O
glutaminase	B-protein
activity	O
at	O
all	O
studied	O
incubation	O
temperatures	O
(	O
37	O
,	O
30	O
,	O
20	O
and	O
10	O
degrees	O
C	O
)	O
as	O
compared	O
to	O
control	O
rats	O
and	O
rats	O
under	O
hypothermia	O
.	O

HFA	O
134a	O
had	O
a	O
greater	O
tendency	O
to	O
take	O
up	O
moisture	O
from	O
the	O
environment	O
than	O
did	O
HFA	O
227	O
.	O

We	O
also	O
show	O
that	O
in	O
fusions	O
with	O
the	O
DNA	O
binding	O
domain	O
of	O
GAL4	B-protein
,	O
full	O
activity	O
requires	O
the	O
entire	O
BHV	B-protein
-	I-protein
alpha	I-protein
TIF	I-protein
,	O
although	O
both	O
amino	O
and	O
carboxyl	O
termini	O
display	O
some	O
activity	O
on	O
their	O
own	O
.	O

Effects	O
of	O
a	O
booster	O
dose	O
of	O
tetanus	O
toxoid	O
after	O
different	O
primary	O
courses	O
of	O
vaccination	O
:	O
implications	O
on	O
the	O
use	O
of	O
immune	B-protein
globulin	I-protein
.	O

In	O
Xenopus	O
,	O
BMPs	B-protein
act	O
as	O
epidermal	O
inducers	O
and	O
also	O
as	O
negative	O
regulators	O
of	O
neurogenesis	O
.	O

Characterization	O
of	O
fus1	B-protein
of	O
Schizosaccharomyces	O
pombe	O
:	O
a	O
developmentally	O
controlled	O
function	O
needed	O
for	O
conjugation	O
.	O

Southern	O
analysis	O
on	O
genomic	O
DNA	O
isolated	O
from	O
tissues	O
and	O
cell	O
lines	O
from	O
several	O
mouse	O
strains	O
using	O
mCD22	B-protein
cDNA	I-protein
demonstrated	O
that	O
the	O
Cd22	B-protein
locus	I-protein
encoding	O
mCD22	B-protein
is	O
a	O
single	O
copy	O
gene	O
of	O
<	O
or	O
=	O
30	O
kb	O
.	O

Importance	O
of	O
determining	O
the	O
blood	O
sulfhydryl	O
groups	O
in	O
fractures	O
of	O
the	O
long	O
tubular	O
bones	O
complicated	O
by	O
infection	O
.	O

Similar	O
observations	O
have	O
been	O
made	O
previously	O
for	O
other	O
genes	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
DnaA	B-protein
may	O
contact	O
the	O
beta	O
subunit	O
of	O
RNA	B-protein
polymerase	I-protein
during	O
activation	O
of	O
the	O
pR	B-protein
promoter	I-protein
.	O

Letter	O
:	O
Salmonella	O
detection	O
.	O

Fourth	O
,	O
the	O
3	O
'	O
-	O
region	O
splice	O
junctions	O
of	O
the	O
MSRs	B-protein
during	O
latent	O
and	O
productive	O
infection	O
were	O
determined	O
by	O
sequencing	O
RNA	O
-	O
PCR	O
products	O
generated	O
with	O
primers	O
that	O
flank	O
the	O
3	O
'	O
splice	O
region	O
.	O

A	O
neuropsychological	O
test	O
battery	O
was	O
used	O
that	O
contained	O
the	O
Wisconsin	O
card	O
sorting	O
test	O
,	O
Street	O
completion	O
test	O
,	O
Stroop	O
test	O
,	O
a	O
dichotic	O
memory	O
listening	O
test	O
,	O
and	O
a	O
facial	O
recognition	O
test	O
.	O

Treatment	O
of	O
hypertension	O
with	O
a	O
combination	O
of	O
the	O
adrenergic	B-protein
beta	I-protein
receptor	I-protein
blockader	O
,	O
obsidan	O
,	O
and	O
the	O
vasodilator	O
,	O
apressin	O
.	O

The	O
results	O
of	O
these	O
studies	O
demonstrate	O
that	O
the	O
rat	B-protein
HDL	I-protein
receptor	I-protein
SR	I-protein
-	I-protein
BI	I-protein
promoter	I-protein
contains	O
two	O
sterol	B-protein
response	I-protein
elements	I-protein
(	O
pSRE	B-protein
and	O
dSRE	B-protein
)	O
through	O
which	O
SREBP	B-protein
-	I-protein
1a	I-protein
can	O
bind	O
and	O
activate	O
transcription	O
of	O
this	O
gene	O
.	O

Disruption	O
demonstrates	O
that	O
CDC14	B-protein
is	O
an	O
essential	O
gene	O
.	O

The	O
sites	O
targeted	O
for	O
mutagenesis	O
,	O
residues	O
60	O
,	O
61	O
,	O
and	O
66	O
,	O
are	O
located	O
within	O
a	O
putative	O
helical	O
loop	O
structure	O
which	O
may	O
be	O
involved	O
in	O
substrate	O
recognition	O
by	O
the	O
enzyme	O
.	O

The	O
amino	O
acid	O
sequences	O
of	O
the	O
yeast	O
and	O
mammalian	O
mitochondrial	O
targeting	O
sequences	O
are	O
similar	O
but	O
less	O
related	O
than	O
the	O
mature	O
polypeptides	O
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
SHP	B-protein
-	I-protein
1	I-protein
,	O
a	O
SH2	B-protein
domain	I-protein
-	I-protein
containing	I-protein
protein	I-protein
-	I-protein
tyrosine	I-protein
phosphatase	I-protein
,	O
is	O
expressed	O
not	O
only	O
in	O
cells	O
of	O
hematopoietic	O
lineages	O
,	O
but	O
also	O
in	O
many	O
non	O
-	O
hematopoietic	O
cells	O
under	O
the	O
control	O
of	O
an	O
alternative	O
tissue	O
-	O
specific	O
promoter	O
,	O
P1	B-protein
.	O

Owing	O
to	O
parental	O
attitude	O
,	O
a	O
low	O
protein	O
diet	O
(	O
1	O
-	O
5	O
g	O
/	O
kg	O
)	O
was	O
introduced	O
only	O
late	O
.	O

Current	O
status	O
of	O
telepathology	O
.	O

Effects	O
of	O
dioxins	O
on	O
thyroid	O
function	O
in	O
newborn	O
babies	O
.	O

Potentiation	O
of	O
the	O
thrombolytic	O
efficacy	O
of	O
single	B-protein
-	I-protein
chain	I-protein
urokinase	I-protein
(	O
Pro	B-protein
-	I-protein
urokinase	I-protein
)	O
by	O
heparin	O
.	O

Effect	O
of	O
biliary	O
obstruction	O
and	O
cholangitis	O
on	O
serum	B-protein
SPan	I-protein
-	I-protein
1	I-protein
level	O
.	O

The	O
overexpressed	O
His6	B-protein
-	I-protein
tagged	I-protein
GrsA	I-protein
derivatives	I-protein
were	O
affinity	O
-	O
purified	O
,	O
and	O
the	O
catalytic	O
properties	O
of	O
the	O
deletion	O
mutants	O
were	O
examined	O
by	O
biochemical	O
studies	O
including	O
ATP	O
-	O
dependent	O
amino	O
acid	O
activation	O
,	O
carboxyl	O
thioester	O
formation	O
,	O
and	O
the	O
ability	O
to	O
racemize	O
the	O
covalently	O
bound	O
phenylalanine	O
from	O
L	O
-	O
to	O
the	O
D	O
-	O
isomer	O
.	O

Fatal	O
encephalitis	O
in	O
a	O
patient	O
with	O
chronic	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
.	O

The	O
need	O
in	O
the	O
small	O
hospital	O
.	O

Mechanical	O
ventilation	O
in	O
control	O
lungs	O
produced	O
a	O
47	O
%	O
decrease	O
in	O
chord	O
compliance	O
,	O
an	O
increase	O
in	O
lung	O
lavage	O
levels	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-	I-protein
alpha	I-protein
(	O
722	O
+	O
/	O
-	O
306	O
pg	O
/	O
ml	O
)	O
,	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-	I-protein
1beta	I-protein
(	O
902	O
+	O
/	O
-	O
322	O
pg	O
/	O
ml	O
)	O
,	O
and	O
macrophage	B-protein
inflammatory	I-protein
protein	I-protein
-	I-protein
2	I-protein
(	O
MIP	B-protein
-	I-protein
2	I-protein
)	O
(	O
363	O
+	O
/	O
-	O
104	O
pg	O
/	O
ml	O
)	O
as	O
compared	O
with	O
low	O
levels	O
of	O
cytokines	O
detected	O
in	O
preventilation	O
data	O
,	O
and	O
no	O
change	O
in	O
percentage	O
of	O
surfactant	O
large	O
aggregates	O
(	O
LA	O
)	O
.	O

Of	O
the	O
compounds	O
tested	O
,	O
alpha	O
-	O
(	O
3	O
-	O
methyl	O
-	O
2	O
-	O
quinoxalinyl	O
)	O
-	O
N	O
-	O
methylnitrone	O
1	O
,	O
4	O
-	O
dioxide	O
(	O
2	O
)	O
was	O
the	O
most	O
active	O
agent	O
in	O
vivo	O
against	O
the	O
gram	O
-	O
negative	O
and	O
the	O
gram	O
-	O
positive	O
organisms	O
.	O

Immunohistochemical	O
studies	O
revealed	O
positive	O
staining	O
for	O
S100	B-protein
protein	I-protein
in	O
all	O
the	O
granular	O
cell	O
tumors	O
of	O
the	O
adult	O
but	O
in	O
none	O
of	O
the	O
congenital	O
granular	O
cell	O
epulides	O
.	O

In	O
a	O
prospective	O
,	O
randomized	O
clinical	O
trial	O
we	O
compared	O
the	O
efficacy	O
of	O
subcutaneously	O
(	O
SC	O
)	O
administered	O
(	O
every	O
8	O
h	O
)	O
calcium	O
heparin	O
to	O
intravenous	O
(	O
IV	O
)	O
sodium	O
heparin	O
in	O
the	O
treatment	O
of	O
proximal	O
deep	O
-	O
vein	O
thrombosis	O
(	O
DVT	O
)	O
.	O

Mean	O
increase	O
of	O
milk	O
protein	O
yield	O
was	O
46	O
g	O
/	O
d	O
with	O
Met	O
plus	O
Lys	O
,	O
and	O
mean	O
increase	O
of	O
true	O
protein	O
content	O
was	O
1	O
.	O
1	O
g	O
/	O
kg	O
of	O
milk	O
.	O

V	O
.	O

Mss4	B-protein
also	O
acts	O
as	O
a	O
relatively	O
inefficient	O
guanine	B-protein
nucleotide	I-protein
exchange	I-protein
factor	I-protein
(	O
GEF	B-protein
)	O
.	O

Treatment	O
of	O
Graves	O
'	O
disease	O
.	O

Some	O
artificial	O
promoter	O
constructs	O
containing	O
multiple	O
Sp1	B-protein
sites	I-protein
were	O
highly	O
responsive	O
to	O
ethanol	O
,	O
but	O
others	O
were	O
not	O
,	O
suggesting	O
that	O
the	O
organization	O
of	O
the	O
proximal	O
promoter	O
region	O
was	O
an	O
additional	O
factor	O
that	O
affected	O
the	O
ethanol	O
response	O
.	O

Polysome	B-protein
and	O
40S	B-protein
ribosome	I-protein
fractions	O
were	O
severely	O
decreased	O
in	O
the	O
krr1	B-protein
mutant	I-protein
and	O
Kri1p	O
-	O
depleted	O
cells	O
.	O

Atopic	O
allergy	O
and	O
other	O
hypersensitivities	O
.	O

Reaction	O
time	O
(	O
RT	O
)	O
and	O
P300	O
were	O
collected	O
simultaneously	O
.	O

There	O
was	O
no	O
evidence	O
of	O
any	O
persistent	O
oscillation	O
within	O
the	O
ULF	O
band	O
.	O

From	O
March	O
5	O
through	O
October	O
26	O
,	O
1991	O
,	O
eight	O
persons	O
were	O
diagnosed	O
with	O
elevated	O
blood	O
lead	O
levels	O
(	O
BLLs	O
)	O
at	O
a	O
local	O
hospital	O
and	O
were	O
reported	O
to	O
the	O
notifiable	O
disease	O
surveillance	O
system	O
maintained	O
by	O
the	O
Alabama	O
Department	O
of	O
Public	O
Health	O
(	O
ADPH	O
)	O
.	O

The	O
cloned	O
alcR	B-protein
gene	I-protein
provided	O
in	O
trans	O
restored	O
these	O
siderophore	O
system	O
activities	O
to	O
the	O
mutants	O
.	O

Amikacin	O
concentrations	O
in	O
serum	O
and	O
blister	O
fluid	O
in	O
healthy	O
volunteers	O
and	O
in	O
patients	O
with	O
renal	O
impairment	O
.	O

We	O
conclude	O
that	O
the	O
gp54	B-protein
structural	I-protein
gene	I-protein
is	O
required	O
for	O
initiation	O
or	O
amplification	O
of	O
the	O
splenic	O
erythroblast	O
hyperplasia	O
which	O
characterizes	O
the	O
preleukemic	O
phase	O
of	O
Rauscher	O
disease	O
.	O

With	O
Sair	O
and	O
So2	O
,	O
mean	O
vital	O
capacity	O
was	O
reduced	O
by	O
44	O
%	O
from	O
control	O
.	O

Transcription	O
of	O
the	O
first	O
operon	O
coding	O
for	O
m	O
-	O
xylene	O
-	O
degrading	O
enzymes	O
on	O
the	O
TOL	O
plasmid	O
of	O
Pseudomonas	O
putida	O
is	O
activated	O
by	O
the	O
xylR	B-protein
gene	I-protein
product	I-protein
in	O
the	O
presence	O
of	O
m	O
-	O
xylene	O
.	O

Three	O
patients	O
received	O
additional	O
cycles	O
of	O
5	O
-	O
fluorouracil	O
+	O
/	O
-	O
leucovorin	O
as	O
maintenance	O
chemotherapy	O
.	O
RESULTS	O
:	O
Thirty	O
males	O
and	O
21	O
females	O
with	O
a	O
median	O
age	O
of	O
55	O
years	O
(	O
range	O
31	O
-	O
-	O
73	O
years	O
)	O
were	O
treated	O
.	O

Epididymal	O
growth	O
was	O
retarded	O
in	O
animals	O
maintained	O
solely	O
on	O
chickpea	O
haulm	O
and	O
improved	O
with	O
supplementation	O
.	O

The	O
mean	O
extracted	O
concentration	O
of	O
flucloxacillin	O
obtained	O
at	O
operation	O
was	O
12	O
.	O
9	O
micrograms	O
/	O
ml	O
(	O
SD	O
5	O
.	O
25	O
)	O
in	O
synovial	O
fluid	O
;	O
2	O
.	O
9	O
micrograms	O
/	O
g	O
(	O
SD	O
3	O
.	O
59	O
)	O
in	O
synovium	O
;	O
2	O
.	O
0	O
micrograms	O
/	O
g	O
(	O
SD	O
1	O
.	O
48	O
)	O
in	O
cancellous	O
bone	O
and	O
1	O
.	O
3	O
micrograms	O
/	O
g	O
(	O
SD	O
1	O
.	O
25	O
)	O
in	O
cortical	O
bone	O
.	O

Interestingly	O
,	O
segment	O
nesting	O
differentially	O
increases	O
the	O
copy	O
number	O
of	O
genes	O
encoded	O
by	O
segment	O
W	O
,	O
suggesting	O
that	O
the	O
unusual	O
genomic	O
organization	O
of	O
PDVs	O
may	O
be	O
directly	O
linked	O
to	O
the	O
unique	O
functions	O
of	O
this	O
virus	O
in	O
its	O
obligate	O
mutualistic	O
association	O
with	O
parasitic	O
wasps	O
.	O

Molecular	O
mimicry	O
of	O
human	O
cytokine	O
and	O
cytokine	O
response	O
pathway	O
genes	O
by	O
KSHV	O
.	O

The	O
insulin	B-protein
therapy	O
regimen	O
did	O
not	O
affect	O
the	O
evolution	O
of	O
the	O
patients	O
and	O
no	O
significant	O
relationship	O
existed	O
between	O
the	O
age	O
at	O
diagnosis	O
,	O
duration	O
of	O
diabetes	O
,	O
daily	O
insulin	B-protein
dosage	O
or	O
metabolic	O
control	O
and	O
height	O
or	O
BMI	O
.	O

Cutis	O
aplasia	O
.	O

Two	O
alternatively	O
spliced	O
5	O
'	O
UTRs	O
,	O
designated	O
type	O
I	O
and	O
type	O
II	O
,	O
of	O
222	O
and	O
115	O
bp	O
,	O
respectively	O
,	O
were	O
found	O
associated	O
with	O
PFP	B-protein
.	O

Our	O
data	O
,	O
combined	O
with	O
those	O
of	O
Hershey	O
and	O
co	O
-	O
workers	O
,	O
suggest	O
that	O
mammalian	B-protein
eIF3	I-protein
is	O
composed	O
of	O
at	O
least	O
10	O
subunits	O
:	O
p170	B-protein
,	O
p116	B-protein
(	O
hPrt1	B-protein
)	O
,	O
p110	B-protein
,	O
p66	B-protein
,	O
p48	B-protein
,	O
p47	B-protein
,	O
p44	B-protein
,	O
p40	B-protein
,	O
p36	B-protein
,	O
and	O
p35	B-protein
.	O

A	O
controlled	O
trial	O
of	O
recombinant	B-protein
human	I-protein
granulocyte	I-protein
-	I-protein
macrophage	I-protein
colony	I-protein
-	I-protein
stimulating	I-protein
factor	I-protein
after	O
total	O
body	O
irradiation	O
,	O
high	O
-	O
dose	O
chemotherapy	O
,	O
and	O
autologous	O
bone	O
marrow	O
transplantation	O
for	O
acute	O
lymphoblastic	O
leukemia	O
or	O
malignant	O
lymphoma	O
.	O

The	O
development	O
of	O
a	O
data	O
base	O
is	O
described	O
which	O
can	O
be	O
used	O
as	O
common	O
reference	O
for	O
ECG	O
computer	O
programs	O
analyzing	O
12	O
or	O
15	O
simultaneously	O
recorded	O
leads	O
.	O

The	O
ability	O
of	O
sodium	O
phenobarbital	O
(	O
60	O
mg	O
/	O
kg	O
)	O
and	O
sodium	O
barbital	O
(	O
80	O
mg	O
/	O
kg	O
)	O
to	O
produce	O
a	O
taste	O
aversion	O
in	O
23	O
hr	O
fluid	O
deprived	O
rats	O
was	O
examined	O
using	O
a	O
discrimination	O
or	O
two	O
bottle	O
taste	O
aversion	O
task	O
(	O
0	O
.	O
125	O
%	O
sodium	O
saccharin	O
solution	O
or	O
water	O
)	O
.	O

Study	O
on	O
the	O
evagination	O
of	O
Cysticercus	O
pisiformis	O
.	O

Gaucher	O
'	O
s	O
disease	O
is	O
a	O
rare	O
metabolic	O
disorder	O
characterized	O
by	O
the	O
lack	O
of	O
beta	B-protein
-	I-protein
glucocerebrosidase	I-protein
enzyme	I-protein
.	O

In	O
order	O
to	O
infer	O
shape	O
from	O
contour	O
,	O
the	O
human	O
visual	O
system	O
must	O
selectively	O
integrate	O
fragments	O
projecting	O
from	O
a	O
common	O
object	O
while	O
keeping	O
fragments	O
from	O
different	O
objects	O
separate	O
.	O

The	O
NIT2	B-protein
protein	I-protein
is	O
localised	O
in	O
nuclei	O
and	O
could	O
not	O
be	O
detected	O
in	O
the	O
cytoplasmic	O
fraction	O
of	O
cells	O
subjected	O
to	O
nitrogen	O
derepression	O
or	O
nitrogen	O
repression	O
,	O
indicating	O
that	O
the	O
nuclear	O
import	O
of	O
NIT2	B-protein
is	O
not	O
regulated	O
.	O

Prostaglandins	O
F	O
(	O
PGF	O
)	O
were	O
measured	O
in	O
uterine	O
vein	O
,	O
ovarian	O
artery	O
,	O
and	O
jugular	O
vein	O
plasma	O
and	O
in	O
the	O
endometrial	O
tissues	O
at	O
various	O
times	O
during	O
the	O
bovine	O
estrous	O
cycle	O
,	O
and	O
were	O
compared	O
to	O
peripheral	O
plasma	O
progesterone	O
levels	O
.	O

SELECTION	O
CRITERIA	O
:	O
Randomised	O
trials	O
comparing	O
children	O
undergoing	O
systematic	O
therapy	O
focusing	O
on	O
the	O
family	O
in	O
conjunction	O
with	O
asthma	O
medication	O
,	O
with	O
children	O
taking	O
asthma	O
medication	O
only	O
.	O

All	O
numbers	O
refer	O
to	O
nucleotide	O
positions	O
on	O
the	O
wild	O
-	O
type	O
HIV	O
-	O
1	O
transcript	O
.	O

PLUS	O
-	O
3	O
is	O
a	O
new	O
Swedish	O
protocol	O
of	O
natural	O
speech	O
in	O
3	O
-	O
year	O
-	O
old	O
children	O
.	O

Transfection	O
of	O
increasing	O
amounts	O
of	O
delta5ERalpha	B-protein
expression	O
vector	O
into	O
[	O
ERalpha	O
+	O
]	O
OS	O
cells	O
resulted	O
in	O
potentiation	O
of	O
E2	O
-	O
stimulated	O
ERELuc	B-protein
activity	O
in	O
a	O
synergistic	O
,	O
dose	O
-	O
dependent	O
manner	O
.	O

Specialist	O
in	O
family	O
practice	O
-	O
-	O
prototype	O
of	O
a	O
doctor	O
.	O

The	O
effect	O
of	O
low	O
dosage	O
radiation	O
on	O
metabolism	O
and	O
function	O
of	O
the	O
rat	O
kidney	O
damaged	O
by	O
ischemia	O
.	O

Transformation	O
of	O
the	O
sconC3	B-protein
mutant	I-protein
with	O
sconB	B-protein
+	I-protein
restores	O
the	O
wild	O
-	O
type	O
phenotype	O
.	O

We	O
have	O
attempted	O
to	O
clone	O
two	O
recessive	O
extragenic	O
suppressors	O
of	O
such	O
ts	O
mutants	O
(	O
sdp1	O
for	O
mutation	B-protein
pol3	I-protein
-	I-protein
14	I-protein
and	O
sdp5	O
-	O
1	O
for	O
mutation	B-protein
pol3	I-protein
-	I-protein
11	I-protein
)	O
by	O
transforming	O
thermoresistant	O
haploid	O
strains	O
pol3	B-protein
-	I-protein
14	I-protein
sdp1	I-protein
and	O
pol3	B-protein
-	I-protein
11	I-protein
sdp5	I-protein
-	I-protein
1	I-protein
with	O
wild	O
-	O
type	O
genomic	O
libraries	O
in	O
singlecopy	O
or	O
multicopy	O
vectors	O
.	O

Alternative	O
splicing	O
of	O
CDC25B	B-protein
may	O
therefore	O
contribute	O
to	O
the	O
control	O
of	O
cell	O
proliferation	O
.	O

After	O
i	O
.	O
v	O
.	O
administration	O
of	O
500	O
mg	O
acetazolamide	O
and	O
disinfection	O
of	O
the	O
conjunctiva	O
,	O
50	O
micrograms	O
rt	O
-	O
PA	O
in	O
0	O
.	O
1	O
ml	O
(	O
BSS	O
)	O
and	O
0	O
.	O
5	O
ml	O
SF6	O
were	O
injected	O
intravitreally	O
.	O

Enhancer	O
and	O
promoter	O
elements	O
directing	O
activation	O
and	O
glucocorticoid	O
repression	O
of	O
the	O
alpha	B-protein
1	I-protein
-	I-protein
fetoprotein	I-protein
gene	I-protein
in	O
hepatocytes	O
.	O

The	O
terminator	O
region	O
supported	O
termination	O
of	O
transcripts	O
initiated	O
by	O
RNA	B-protein
polymerase	I-protein
I	I-protein
in	O
vivo	O
.	O

The	O
level	O
of	O
the	O
SUP4A53T61	B-protein
transcript	I-protein
was	O
threefold	O
higher	O
in	O
the	O
tap1	B-protein
-	I-protein
1	I-protein
mutant	I-protein
than	O
in	O
the	O
wild	O
type	O
.	O

However	O
,	O
for	O
the	O
evaluable	O
cases	O
,	O
the	O
performances	O
of	O
the	O
CD3500	O
and	O
the	O
STKS	O
were	O
broadly	O
similar	O
and	O
generally	O
correlated	O
well	O
with	O
the	O
manual	O
reference	O
procedure	O
.	O

Familial	O
juvenile	O
nephronophthisis	O
.	O

A	O
note	O
on	O
some	O
consequences	O
of	O
UV	O
vision	O
in	O
birds	O
.	O

Biol	O
.	O

The	O
data	O
indicates	O
the	O
presence	O
of	O
5	B-protein
-	I-protein
HT2	I-protein
serotonergic	I-protein
receptors	I-protein
in	O
the	O
bronchial	O
artery	O
of	O
these	O
species	O
.	O

At	O
4	O
wk	O
however	O
,	O
tumor	O
relapse	O
was	O
noted	O
in	O
6	O
of	O
7	O
group	O
4	O
responders	O
,	O
10	O
of	O
12	O
in	O
group	O
5	O
,	O
13	O
of	O
16	O
in	O
group	O
7	O
,	O
but	O
only	O
4	O
of	O
19	O
group	O
8	O
responders	O
(	O
p	O
less	O
than	O
.	O
001	O
group	O
8	O
versus	O
4	O
,	O
5	O
,	O
7	O
)	O
.	O

This	O
study	O
shows	O
that	O
C	B-protein
/	I-protein
EBPbeta	I-protein
is	O
the	O
predominant	O
C	B-protein
/	I-protein
EBP	I-protein
isoform	I-protein
found	O
in	O
activated	O
stellate	O
cells	O
and	O
that	O
increased	O
C	B-protein
/	I-protein
EBPbeta	I-protein
protein	I-protein
and	O
C	B-protein
/	I-protein
EBPbeta	I-protein
binding	O
to	O
a	O
proximal	O
C	B-protein
/	I-protein
EBP	I-protein
binding	I-protein
site	I-protein
in	O
the	O
promoter	O
mediates	O
the	O
activating	O
effect	O
of	O
acetaldehyde	O
.	O

The	O
mean	O
thickness	O
of	O
the	O
visceral	O
peritoneum	O
was	O
comparable	O
in	O
both	O
groups	O
of	O
animals	O
,	O
but	O
,	O
macroscopically	O
,	O
more	O
severe	O
fibrosis	O
was	O
found	O
in	O
the	O
peritoneum	O
of	O
rats	O
exposed	O
to	O
CAPD	O
3	O
as	O
compared	O
with	O
animals	O
treated	O
with	O
CAPD	O
3	O
Balance	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Hence	O
temperature	O
and	O
virF	B-protein
are	O
both	O
required	O
for	O
the	O
induction	O
of	O
the	O
yop	B-protein
regulon	I-protein
.	O

Lymphatics	O
in	O
the	O
aorta	O
of	O
rats	O
treated	O
with	O
a	O
soy	O
-	O
bean	O
oil	O
extract	O
(	O
lipofundin	O
)	O
.	O

Two	O
distinct	O
recessive	O
susceptibility	O
loci	O
for	O
vasculitis	O
were	O
mapped	O
on	O
chromosome	O
(	O
Chr	O
)	O
4	O
at	O
D4Mit89	B-protein
and	O
D4Mit147	B-protein
in	O
both	O
progenies	O
.	O

These	O
cell	O
lines	O
,	O
selected	O
for	O
the	O
ability	O
to	O
support	O
the	O
replication	O
of	O
a	O
temperature	O
-	O
sensitive	O
VP5	B-protein
mutant	I-protein
,	O
were	O
used	O
to	O
isolate	O
VP5	B-protein
and	O
VP23	B-protein
null	O
mutants	O
.	O

The	O
toxicological	O
evaluation	O
of	O
chlorofluorocarbon	O
22	O
(	O
CFC	O
22	O
)	O
.	O

The	O
cochlear	O
compromise	O
.	O

The	O
Cut9	B-protein
subunit	I-protein
is	O
likely	O
to	O
be	O
a	O
target	O
for	O
regulating	O
APC	B-protein
/	I-protein
cyclosome	I-protein
function	O
through	O
protein	O
-	O
protein	O
interactions	O
and	O
phosphorylation	O
.	O

Bacteria	O
can	O
also	O
cause	O
a	O
labyrinthitis	O
acting	O
directly	O
on	O
the	O
inner	O
ear	O
:	O
among	O
these	O
,	O
Treponemas	O
Pallidum	O
,	O
a	O
spirochaete	O
which	O
causes	O
syphilis	O
and	O
Borrelia	O
Burgdorferi	O
,	O
a	O
spirochaete	O
that	O
causes	O
Lyme	O
Disease	O
,	O
must	O
be	O
mentioned	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
two	O
recombination	O
-	O
and	O
repair	O
-	O
defective	O
mutations	O
,	O
rad1	B-protein
and	O
rad52	B-protein
,	O
on	O
direct	O
repeat	O
recombination	O
in	O
transcriptionally	O
active	O
and	O
inactive	O
sequences	O
.	O

The	O
harpin	O
-	O
encoding	O
hrpZ	B-protein
gene	I-protein
is	O
located	O
in	O
an	O
operon	O
that	O
also	O
encodes	O
Hrp	B-protein
secretion	I-protein
pathway	I-protein
components	I-protein
and	O
is	O
part	O
of	O
the	O
functional	O
cluster	O
of	O
hrp	B-protein
genes	I-protein
carried	O
on	O
cosmid	O
pHIR11	O
that	O
enables	O
saprophytic	O
bacteria	O
like	O
Escherichia	O
coli	O
and	O
Pseudomonas	O
fluorescens	O
to	O
elicit	O
the	O
HR	O
in	O
tobacco	O
leaves	O
.	O

Lactation	O
of	O
baboons	O
fed	O
a	O
low	O
protein	O
maintenance	O
diet	O
.	O

We	O
present	O
here	O
a	O
detailed	O
genomic	O
sequencing	O
analysis	O
of	O
the	O
cytosine	O
methylation	O
patterns	O
of	O
the	O
transposase	O
binding	O
sites	O
within	O
both	O
Ac	B-protein
ends	O
in	O
the	O
wx	B-protein
-	I-protein
m9	I-protein
:	O
:	O
Ac	B-protein
allele	I-protein
,	O
where	O
Ac	B-protein
is	O
inserted	O
into	O
the	O
tenth	O
exon	O
of	O
the	O
Waxy	B-protein
gene	I-protein
.	O

During	O
an	O
8	O
-	O
wk	O
follow	O
-	O
up	O
,	O
parasites	O
reappeared	O
in	O
10	O
patients	O
,	O
5	O
after	O
each	O
drug	O
,	O
between	O
1	O
and	O
7	O
wk	O
after	O
treatment	O
.	O

Pure	O
T1	O
and	O
dual	O
-	O
T1	O
images	O
were	O
visually	O
evaluated	O
for	O
image	O
quality	O
(	O
IQ	O
)	O
on	O
a	O
five	O
-	O
point	O
scale	O
(	O
0	O
=	O
unacceptable	O
to	O
4	O
=	O
excellent	O
)	O
.	O

Changing	O
and	O
predicting	O
doses	O
of	O
Cs137	O
irradiation	O
.	O

Thus	O
,	O
the	O
positive	O
effect	O
of	O
NS1	B-protein
on	O
the	O
steady	O
-	O
state	O
levels	O
of	O
P4	B-protein
transcripts	I-protein
depends	O
on	O
the	O
amplification	O
of	O
gene	O
copy	O
number	O
and	O
the	O
integrity	O
of	O
the	O
terminal	O
repeats	O
.	O

However	O
,	O
the	O
requirement	O
of	O
rev3	B-protein
for	O
the	O
production	O
of	O
G	O
.	O
C	O
-	O
-	O
>	O
T	O
.	O
A	O
transversions	O
by	O
the	O
rad18	B-protein
mutator	I-protein
,	O
which	O
induces	O
only	O
these	O
substitutions	O
,	O
was	O
similar	O
to	O
that	O
for	O
rad6	O
-	O
mediated	O
G	O
.	O
C	O
-	O
-	O
>	O
T	O
.	O
A	O
transversion	O
.	O

METHODS	O
:	O
The	O
passive	O
and	O
active	O
transport	O
of	O
fluorescein	O
through	O
the	O
BRB	O
was	O
quantitated	O
by	O
vitreous	O
fluorometry	O
.	O

As	O
a	O
result	O
,	O
the	O
subendocardial	O
/	O
subepicardial	O
blood	O
flow	O
ratio	O
(	O
ENDO	O
/	O
EPI	O
)	O
increased	O
from	O
0	O
.	O
44	O
+	O
/	O
-	O
0	O
.	O
09	O
during	O
control	O
stenosis	O
to	O
0	O
.	O
85	O
+	O
/	O
-	O
0	O
.	O
13	O
after	O
ITF	O
1129	O
(	O
10	O
micrograms	O
/	O
kg	O
/	O
min	O
i	O
.	O
v	O
.	O
)	O
and	O
to	O
0	O
.	O
81	O
+	O
/	O
-	O
0	O
.	O
12	O
after	O
NTG	O
.	O

The	O
risk	O
factors	O
for	O
hematuria	O
in	O
patients	O
with	O
renal	O
hypouricemia	O
are	O
the	O
elevation	O
of	O
urinary	O
urate	O
concentration	O
and	O
the	O
subtypes	O
of	O
Post	O
and	O
Secretion	O
.	O

Results	O
demonstrated	O
that	O
the	O
presence	O
of	O
myofibroblasts	O
varied	O
considerably	O
from	O
case	O
to	O
case	O
and	O
was	O
always	O
related	O
to	O
smooth	O
muscle	O
cell	O
dispersion	O
,	O
which	O
occurred	O
around	O
medium	O
-	O
sized	O
damaged	O
portal	O
vein	O
branches	O
.	O

The	O
N1	O
and	O
P2	O
were	O
comparable	O
in	O
amplitude	O
and	O
both	O
had	O
prolonged	O
refractory	O
periods	O
.	O

These	O
human	O
IFN	O
-	O
beta	O
-	O
transformed	O
cell	O
populations	O
have	O
acquired	O
a	O
low	O
,	O
constitutive	O
production	O
of	O
human	B-protein
IFN	I-protein
,	O
while	O
replicating	O
at	O
a	O
rate	O
similar	O
to	O
that	O
of	O
untransformed	O
cells	O
and	O
of	O
cells	O
transformed	O
with	O
the	O
control	O
vector	O
carrying	O
a	O
human	B-protein
IFN	I-protein
-	I-protein
beta	I-protein
sequence	I-protein
encoding	O
an	O
inactive	O
,	O
mutated	O
protein	O
.	O

Thirty	O
-	O
five	O
strains	O
of	O
Legionnaires	O
'	O
disease	O
bacteria	O
were	O
shown	O
to	O
belong	O
in	O
four	O
distinct	O
serologic	O
groups	O
on	O
the	O
basis	O
of	O
findings	O
obtained	O
with	O
direct	O
fluorescent	O
antibody	O
testing	O
.	O

An	O
additional	O
advantage	O
is	O
that	O
the	O
resin	O
can	O
be	O
removed	O
and	O
the	O
immunoperoxidase	O
technique	O
carried	O
out	O
on	O
thin	O
sections	O
.	O

The	O
alternative	O
exon	O
introduces	O
the	O
novel	O
carboxyl	O
terminus	O
and	O
a	O
new	O
translation	O
stop	O
signal	O
,	O
while	O
simultaneously	O
converting	O
the	O
coding	O
sequence	O
for	O
40	O
carboxyl	O
-	O
terminal	O
residues	O
in	O
CeCAT	B-protein
alpha	I-protein
into	O
3	O
'	O
-	O
untranslated	O
nucleotides	O
.	O

Studies	O
on	O
alcoholic	O
liver	O
injury	O
.	O

However	O
,	O
the	O
serum	B-protein
TNF	I-protein
-	I-protein
a	I-protein
concentration	O
decreased	O
significantly	O
in	O
patients	O
receiving	O
pentoxifylline	O
(	O
basal	O
623	O
+	O
/	O
-	O
366	O
pg	O
/	O
ml	O
;	O
6th	O
month	O
562	O
+	O
/	O
-	O
358	O
pg	O
/	O
ml	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
but	O
not	O
in	O
the	O
control	O
group	O
.	O

While	O
no	O
significant	O
differences	O
in	O
the	O
tensile	O
responses	O
or	O
failure	O
characteristics	O
were	O
noted	O
for	O
irradiated	O
and	O
nonirradiated	O
grafts	O
in	O
the	O
drip	O
,	O
in	O
the	O
bath	O
environment	O
the	O
nonirradiated	O
tissues	O
had	O
greater	O
strength	O
and	O
modulus	O
.	O

Pretreatment	O
of	O
cells	O
with	O
the	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
-	I-protein
extracellular	I-protein
signal	I-protein
-	I-protein
regulated	I-protein
kinase	I-protein
kinase	I-protein
(	O
MEK	B-protein
)	O
inhibitor	O
U0126	O
inhibited	O
S6K2	B-protein
activation	O
to	O
a	O
greater	O
extent	O
than	O
S6K1	B-protein
.	O

No	O
symptomatic	O
abnormality	O
has	O
been	O
noted	O
in	O
the	O
neonatal	O
period	O
except	O
periventricular	O
calcifications	O
.	O

The	O
differences	O
were	O
as	O
follows	O
:	O
for	O
overall	O
response	O
rate	O
p	O
=	O
0	O
.	O
004	O
;	O
power	O
(	O
for	O
p	O
=	O
0	O
.	O
05	O
)	O
85	O
%	O
;	O
for	O
survival	O
p	O
=	O
0	O
.	O
09	O
;	O
for	O
grade	O
IV	O
granulocytopenia	O
p	O
=	O
0	O
.	O
3	O
;	O
and	O
for	O
febrile	O
neutropenia	O
p	O
=	O
0	O
.	O
61	O
.	O

The	O
N	O
-	O
terminal	O
amino	O
acid	O
sequence	O
of	O
Mop	B-protein
has	O
sequence	O
homology	O
with	O
DNA	O
binding	O
proteins	O
.	O

Nutritional	O
status	O
in	O
adults	O
on	O
an	O
alternative	O
or	O
traditional	O
diet	O
BACKGROUND	O
:	O
Plant	O
food	O
lacks	O
vitamin	O
B12	O
,	O
vitamin	O
D	O
and	O
higher	O
n	O
-	O
3	O
polyunsaturated	O
fatty	O
acids	O
.	O

Thus	O
,	O
the	O
effects	O
of	O
father	O
absence	O
under	O
routine	O
conditions	O
in	O
relatively	O
healthy	O
samples	O
may	O
exert	O
no	O
significant	O
effects	O
independent	O
of	O
intervening	O
family	O
stressors	O
or	O
maternal	O
psychopathology	O
.	O

Common	O
foot	O
pathologies	O
are	O
heel	O
pain	O
,	O
metatarsalgia	O
,	O
hammertoes	O
and	O
clawtoes	O
,	O
bunions	O
,	O
hallux	O
rigidus	O
,	O
corns	O
and	O
calluses	O
,	O
nail	O
pathologies	O
,	O
arthritis	O
,	O
and	O
neuropathies	O
.	O

Using	O
an	O
oligomer	O
duplex	O
5	B-protein
'	I-protein
-	I-protein
A	I-protein
(	I-protein
GGGTTA	I-protein
)	I-protein
(	I-protein
5	I-protein
)	I-protein
-	I-protein
3	I-protein
'	I-protein
/	I-protein
5	I-protein
'	I-protein
-	I-protein
(	I-protein
TAACCC	I-protein
)	I-protein
(	I-protein
5	I-protein
)	I-protein
T	I-protein
-	I-protein
3	I-protein
'	I-protein
as	O
a	O
template	O
-	O
primer	O
,	O
we	O
show	O
that	O
both	O
the	O
Klenow	B-protein
fragment	I-protein
of	I-protein
Escherichia	I-protein
coli	I-protein
DNA	I-protein
polymerase	I-protein
I	I-protein
and	O
HIV	B-protein
reverse	I-protein
transcriptase	I-protein
could	O
expand	O
telomere	O
DNA	O
sequences	O
as	O
well	O
,	O
giving	O
products	O
greater	O
than	O
the	O
size	O
of	O
the	O
template	O
DNA	O
.	O

Endotoxemia	O
induced	O
by	O
gram	O
-	O
negative	O
bacteria	O
leads	O
to	O
endotoxic	O
shock	O
pathogenetically	O
stemming	O
from	O
the	O
integral	O
component	O
of	O
the	O
bacterial	O
wall	O
-	O
-	O
lipid	O
A	O
.	O

Constitutive	O
phosphorylation	O
of	O
the	O
CD30v	B-protein
protein	I-protein
was	O
demonstrated	O
by	O
in	O
vitro	O
labeling	O
with	O
[	O
32P	O
]	O
.	O

Baseline	O
BMD	O
values	O
were	O
significantly	O
lower	O
in	O
the	O
oligo	O
-	O
amenorrheic	O
group	O
than	O
in	O
the	O
two	O
others	O
at	O
the	O
level	O
of	O
lumbar	O
spine	O
(	O
anteroposterior	O
view	O
:	O
0	O
.	O
941	O
+	O
/	O
-	O
0	O
.	O
039	O
in	O
oligo	O
-	O
amenorrheic	O
vs	O
1	O
.	O
077	O
+	O
/	O
-	O
0	O
.	O
029	O
or	O
1	O
.	O
051	O
+	O
/	O
-	O
0	O
.	O
017	O
g	O
x	O
cm	O
(	O
-	O
2	O
)	O
,	O
P	O
<	O
0	O
.	O
005	O
,	O
in	O
the	O
eumenorrheic	O
and	O
contraceptive	O
user	O
groups	O
,	O
respectively	O
)	O
but	O
not	O
in	O
weight	O
-	O
bearing	O
bone	O
such	O
as	O
proximal	O
and	O
midshaft	O
femur	O
.	O

Antithrombin	B-protein
III	I-protein
(	O
AT	B-protein
III	I-protein
)	O
is	O
a	O
plasma	O
protein	O
which	O
acts	O
as	O
the	O
principal	O
inhibitor	O
of	O
thrombin	B-protein
and	O
is	O
a	O
major	O
modulator	O
of	O
intravascular	O
coagulation	O
.	O

These	O
defects	O
no	O
doubt	O
impair	O
the	O
folding	O
and	O
configuration	O
necessary	O
for	O
normal	O
processing	O
of	O
the	O
AVP	B-protein
gene	I-protein
precursor	I-protein
.	O

The	O
results	O
presented	O
here	O
show	O
that	O
AR1	B-protein
of	O
the	O
promoter	O
-	O
proximal	O
CAP	B-protein
subunit	I-protein
was	O
required	O
for	O
papBA	B-protein
transcription	O
even	O
in	O
the	O
absence	O
of	O
the	O
histone	B-protein
-	I-protein
like	I-protein
protein	I-protein
H	I-protein
-	I-protein
NS	I-protein
.	O

In	O
Ka13	O
cells	O
,	O
CoCl	O
(	O
2	O
)	O
stimulated	O
expression	O
of	O
a	O
luciferase	B-protein
reporter	I-protein
gene	I-protein
under	O
the	O
control	O
of	O
a	O
15	B-protein
-	I-protein
kilobase	I-protein
pair	I-protein
mouse	I-protein
ho	I-protein
-	I-protein
1	I-protein
promoter	I-protein
(	O
pHO15luc	B-protein
)	O
.	O

Hybridization	O
data	O
indicate	O
that	O
6F6	B-protein
.	I-protein
2	I-protein
corresponds	O
to	O
the	O
previously	O
characterized	O
m6F6	B-protein
cDNA	I-protein
clone	I-protein
and	O
that	O
6F6	B-protein
.	I-protein
1	I-protein
and	O
6F6	B-protein
.	I-protein
3	I-protein
,	O
but	O
not	O
6F6	B-protein
.	I-protein
2	I-protein
,	O
are	O
adjacent	O
to	O
alpha	B-protein
-	I-protein
type	I-protein
genes	I-protein
.	O

The	O
test	O
was	O
not	O
performed	O
in	O
3923	O
patients	O
because	O
of	O
contraindications	O
.	O

The	O
viral	B-protein
oncoprotein	I-protein
E1A	I-protein
inhibits	O
NFAT	O
-	O
dependent	O
transactivation	O
in	O
a	O
p300	O
-	O
dependent	O
manner	O
.	O

EEG	O
theta	O
waves	O
and	O
psychological	O
phenomena	O
:	O
a	O
review	O
and	O
analysis	O
.	O

Correlation	O
between	O
intraocular	O
involvement	O
and	O
systemic	O
outcome	O
was	O
poor	O
.	O

Genomic	O
DNA	O
clones	O
containing	O
the	O
T	B-protein
-	I-protein
cell	I-protein
-	I-protein
specific	I-protein
human	I-protein
MAL	I-protein
gene	I-protein
were	O
isolated	O
.	O

Hematopoietic	B-protein
growth	I-protein
factors	I-protein
have	O
already	O
had	O
an	O
enormous	O
impact	O
on	O
transfusion	O
practice	O
by	O
eliminating	O
or	O
reducing	O
the	O
need	O
for	O
red	O
blood	O
cell	O
transfusions	O
in	O
a	O
variety	O
of	O
anemic	O
states	O
characterized	O
by	O
an	O
absolute	O
or	O
relative	O
decrease	O
in	O
erythropoietin	B-protein
.	O

Increased	O
blood	O
pressure	O
during	O
CyA	O
treatment	O
was	O
independent	O
of	O
circulating	O
ET	B-protein
-	I-protein
1	I-protein
levels	O
.	O

An	O
NF1	B-protein
-	I-protein
related	I-protein
vitellogenin	I-protein
activator	I-protein
element	I-protein
mediates	O
transcription	O
from	O
the	O
estrogen	O
-	O
regulated	O
Xenopus	B-protein
laevis	I-protein
vitellogenin	I-protein
promoter	I-protein
.	O

As	O
an	O
extension	O
of	O
our	O
structural	O
characterization	O
of	O
the	O
exon	O
-	O
intron	O
organization	O
of	O
the	O
mouse	B-protein
Pkr	I-protein
gene	I-protein
,	O
we	O
now	O
have	O
isolated	O
and	O
characterized	O
the	O
mouse	B-protein
Pkr	I-protein
promoter	I-protein
region	I-protein
required	O
for	O
IFN	O
-	O
inducible	O
transcription	O
.	O

Therefore	O
the	O
binding	O
sites	O
for	O
liver	O
-	O
enriched	O
factors	O
,	O
present	O
in	O
the	O
hamster	B-protein
CYP7A1	I-protein
proximal	I-protein
promoter	I-protein
in	O
close	O
vicinity	O
and	O
conserved	O
between	O
species	O
,	O
constitute	O
a	O
regulatory	O
unit	O
important	O
for	O
basal	O
hepatic	O
expression	O
and	O
tissue	O
restriction	O
of	O
the	O
action	O
of	O
hormones	O
such	O
as	O
insulin	B-protein
.	O

I	O
.	O

Although	O
antisperm	B-protein
antibodies	I-protein
are	O
associated	O
with	O
infertility	O
,	O
many	O
hospital	O
laboratories	O
do	O
not	O
test	O
for	O
these	O
antibodies	O
.	O

Is	O
desensitization	O
'	O
for	O
ragweed	O
hay	O
fever	O
immunologically	O
specific	O
?	O

Here	O
we	O
show	O
that	O
calpeptin	B-protein
inhibits	O
tyrosine	B-protein
phosphatases	I-protein
,	O
enhancing	O
tyrosine	O
phosphorylation	O
particularly	O
of	O
paxillin	B-protein
.	O

We	O
show	O
here	O
that	O
the	O
LIM	B-protein
domain	I-protein
homeobox	I-protein
protein	I-protein
isl	I-protein
-	I-protein
1	I-protein
activates	O
the	O
rat	B-protein
amylin	I-protein
promoter	I-protein
in	O
both	O
fibroblast	O
and	O
islet	O
cell	O
lines	O
.	O

The	O
ability	O
of	O
spt2	B-protein
mutations	I-protein
to	O
suppress	O
the	O
transcriptional	O
interference	O
caused	O
by	O
the	O
delta	B-protein
promoter	I-protein
insertion	I-protein
his	I-protein
-	I-protein
4	I-protein
-	I-protein
912	I-protein
delta	I-protein
correlates	O
with	O
an	O
increase	O
in	O
wild	B-protein
-	I-protein
type	I-protein
HIS4	I-protein
mRNA	I-protein
levels	O
.	O

The	O
proportion	O
of	O
the	O
biopsies	O
found	O
to	O
be	O
seropositive	O
for	O
HBs	O
antigen	O
was	O
27	O
.	O
9	O
%	O
,	O
and	O
these	O
showed	O
either	O
MGN	O
or	O
MPGN	O
pattern	O
.	O

A	O
sterol	B-protein
-	I-protein
regulated	I-protein
protease	I-protein
initiates	O
release	O
of	O
the	O
NH2	O
-	O
terminal	O
segments	O
of	O
sterol	B-protein
regulatory	I-protein
element	I-protein
-	I-protein
binding	I-protein
proteins	I-protein
(	O
SREBPs	B-protein
)	O
from	O
cell	O
membranes	O
,	O
thereby	O
allowing	O
them	O
to	O
enter	O
the	O
nucleus	O
and	O
to	O
stimulate	O
transcription	O
of	O
genes	O
involved	O
in	O
the	O
uptake	O
and	O
synthesis	O
of	O
cholesterol	O
and	O
fatty	O
acids	O
.	O

Initial	O
experience	O
with	O
a	O
microprocessor	O
controlled	O
current	O
based	O
defibrillator	O
.	O

The	O
following	O
technique	O
describes	O
a	O
modification	O
to	O
a	O
bar	O
superstructure	O
that	O
provided	O
the	O
advantages	O
of	O
convenience	O
,	O
security	O
,	O
and	O
consistent	O
positioning	O
even	O
though	O
one	O
implant	O
was	O
lost	O
and	O
the	O
angulation	O
of	O
implants	O
limited	O
accuracy	O
.	O

Phase	O
II	O
study	O
of	O
paclitaxel	O
and	O
oral	O
etoposide	O
in	O
patients	O
with	O
locally	O
advanced	O
or	O
metastatic	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

After	O
termination	O
of	O
medication	O
the	O
animals	O
were	O
kindled	O
electrically	O
in	O
the	O
nucleus	O
amygdala	O
.	O

Account	O
was	O
taken	O
of	O
noncellular	O
and	O
nonhuman	O
elements	O
in	O
the	O
smears	O
;	O
they	O
included	O
mucus	O
,	O
Charcot	O
-	O
Layden	O
crystals	O
,	O
pollen	O
grains	O
,	O
vegetal	O
fragments	O
and	O
fungi	O
.	O

We	O
have	O
now	O
identified	O
,	O
after	O
21	O
serial	O
undiluted	O
passages	O
of	O
MHV	O
,	O
a	O
small	B-protein
DI	I-protein
RNA	I-protein
,	O
DIssF	B-protein
,	O
which	O
is	O
efficiently	O
packaged	O
into	O
virions	O
.	O

Physical	O
principles	O
in	O
therapeutic	O
apheresis	O
.	O

E2F	B-protein
is	O
a	O
heterodimeric	O
complex	O
consisting	O
of	O
E2F	B-protein
family	I-protein
members	I-protein
(	I-protein
1	I-protein
-	I-protein
5	I-protein
)	I-protein
and	O
DP	B-protein
proteins	I-protein
(	I-protein
1	I-protein
-	I-protein
3	I-protein
)	I-protein
.	O

We	O
screened	O
a	O
K562	O
cDNA	O
library	O
and	O
identified	O
novel	O
transcripts	O
,	O
MZF1B	B-protein
and	O
MZF1C	B-protein
.	O

Ischemic	O
stroke	O
due	O
to	O
protein	B-protein
C	I-protein
deficiency	O
.	O

The	O
kinase	B-protein
is	O
essential	O
in	O
vivo	O
for	O
normal	O
phosphorylation	O
of	O
the	O
CTD	O
and	O
for	O
normal	O
growth	O
and	O
differentiation	O
.	O

The	O
hit1	B-protein
-	I-protein
1	I-protein
mutation	O
caused	O
a	O
defect	O
in	O
synthesis	O
of	O
a	O
74	B-protein
-	I-protein
kD	I-protein
heat	I-protein
shock	I-protein
protein	I-protein
.	O

A	O
new	O
DNA	B-protein
repair	I-protein
gene	I-protein
from	I-protein
Schizosaccharomyces	I-protein
pombe	I-protein
with	O
homology	O
to	O
RecA	B-protein
was	O
identified	O
and	O
characterized	O
.	O

Recombinant	O
,	O
bacterially	O
expressed	O
PIP5KIalpha	B-protein
possessed	O
PIP5K	B-protein
activity	O
and	O
was	O
immunoreactive	O
with	O
erythroid	B-protein
PIP5KI	I-protein
antibodies	I-protein
.	O

The	O
results	O
show	O
that	O
ROS	O
production	O
by	O
viable	O
spermatozoa	O
is	O
highly	O
correlated	O
with	O
the	O
concentration	O
of	O
PMN	B-protein
elastase	I-protein
and	O
the	O
number	O
of	O
both	O
peroxidase	O
-	O
positive	O
and	O
round	O
cells	O
.	O

Recombinant	O
unr	B-protein
acts	O
synergistically	O
with	O
recombinant	O
PTB	B-protein
to	O
stimulate	O
translation	O
dependent	O
on	O
the	O
rhinovirus	O
IRES	O
.	O

GATA	B-protein
-	I-protein
1	I-protein
mRNA	I-protein
was	O
present	O
in	O
equivalent	O
levels	O
in	O
both	O
erythroid	O
cell	O
lines	O
,	O
but	O
at	O
a	O
low	O
level	O
in	O
FDC	O
-	O
P1	O
cells	O
.	O

DNA	O
sequence	O
and	O
evolution	O
of	O
the	O
CPS	B-protein
domain	I-protein
of	O
the	O
Syrian	B-protein
hamster	I-protein
multifunctional	I-protein
protein	I-protein
CAD	I-protein
.	O

Together	O
,	O
these	O
data	O
support	O
a	O
model	O
in	O
which	O
Tax	B-protein
anchors	O
CBP	B-protein
to	O
the	O
HTLV	B-protein
-	I-protein
1	I-protein
promoter	I-protein
,	O
with	O
strong	O
transcriptional	O
activation	O
resulting	O
from	O
the	O
CBP	O
-	O
associated	O
activities	O
of	O
nucleosome	O
remodeling	O
and	O
recruitment	O
of	O
the	O
general	O
transcription	O
machinery	O
.	O

ORF	B-protein
E8	I-protein
colinear	O
with	O
ORF	B-protein
E6	I-protein
,	O
which	O
could	O
generate	O
a	O
50	O
-	O
amino	O
-	O
acid	O
protein	O
with	O
a	O
hydrophobic	O
segment	O
,	O
did	O
not	O
transform	O
cells	O
when	O
cloned	O
into	O
the	O
pZipNeo	O
vector	O
.	O

Rep	B-protein
-	I-protein
Rep	I-protein
protein	I-protein
interaction	O
was	O
confirmed	O
in	O
vitro	O
through	O
coimmunoprecipitation	O
experiments	O
with	O
a	O
bacterially	O
expressed	O
maltose	B-protein
-	I-protein
binding	I-protein
protein	I-protein
-	I-protein
Rep78	I-protein
fusion	I-protein
protein	I-protein
in	O
combination	O
with	O
[	O
35S	O
]	O
methionine	O
-	O
labeled	O
Rep78	B-protein
synthesized	O
in	O
a	O
coupled	O
in	O
vitro	O
transcription	O
-	O
translation	O
system	O
.	O

The	O
repression	O
domain	O
,	O
and	O
indeed	O
the	O
entire	O
Cdc68	B-protein
protein	I-protein
,	O
is	O
highly	O
conserved	O
,	O
as	O
shown	O
by	O
the	O
sequence	O
of	O
the	O
Cdc68	B-protein
functional	I-protein
homolog	I-protein
from	O
the	O
yeast	O
Kluyveromyces	O
lactis	O
and	O
by	O
database	O
searches	O
.	O

(	O
2	O
)	O
Erythroid	O
32D	O
Epo1	B-protein
cells	O
showed	O
a	O
lower	O
level	O
of	O
bulk	O
PKC	B-protein
catalytic	O
activity	O
,	O
lacked	O
the	O
expression	O
of	O
epsilon	B-protein
and	O
eta	B-protein
PKC	I-protein
isoforms	I-protein
,	O
and	O
showed	O
a	O
weak	O
or	O
absent	O
upregulation	O
of	O
the	O
remaining	O
isoforms	O
,	O
except	O
betaI	B-protein
,	O
upon	O
readdition	O
of	O
Epo	B-protein
to	O
growth	O
factor	O
-	O
starved	O
cells	O
.	O

Downstream	O
of	O
the	O
G	O
-	O
A	O
anastomosis	O
,	O
the	O
RD	O
,	O
CC	O
,	O
E	O
(	O
p	O
)	O
and	O
loop	O
areas	O
were	O
significantly	O
different	O
from	O
REF	O
,	O
but	O
significantly	O
different	O
from	O
A	O
-	O
A	O
.	O

Secretion	O
in	O
milk	O
and	O
transplacental	O
transfer	O
of	O
two	O
iodized	O
oils	O
,	O
Lipiodol	O
UF	O
and	O
Oriodol	O
,	O
in	O
rabbits	O
.	O

Catecholamines	O
and	O
aversive	O
learning	O
:	O
a	O
review	O
.	O

LMP2A	B-protein
enhances	O
Lyn	B-protein
and	O
Syk	B-protein
ubiquitination	O
in	O
vivo	O
in	O
a	O
fashion	O
that	O
depends	O
on	O
the	O
activity	O
of	O
Nedd4	B-protein
family	O
members	O
and	O
correlates	O
with	O
destabilization	O
of	O
the	O
Lyn	B-protein
tyrosine	I-protein
kinase	I-protein
.	O

Amyloid	B-protein
beta	I-protein
-	I-protein
protein	I-protein
(	O
Abeta	B-protein
)	O
is	O
the	O
main	O
constituent	O
of	O
amyloid	O
fibrils	O
found	O
in	O
senile	O
plaques	O
and	O
cerebral	O
vessels	O
in	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
and	O
is	O
derived	O
by	O
proteolysis	O
from	O
the	O
beta	B-protein
-	I-protein
amyloid	I-protein
precursor	I-protein
protein	I-protein
(	O
APP	B-protein
)	O
.	O

Drug	O
interactions	O
have	O
been	O
found	O
with	O
drugs	O
that	O
compete	O
for	O
the	O
same	O
CYP450	B-protein
isoenzymes	I-protein
as	O
statins	B-protein
.	O

The	O
Clb5	B-protein
kinase	I-protein
,	O
which	O
promotes	O
S	O
phase	O
,	O
remains	O
active	O
during	O
the	O
G2	O
-	O
phase	O
arrest	O
of	O
cells	O
of	O
the	O
parental	O
strain	O
,	O
but	O
its	O
activity	O
declines	O
rapidly	O
in	O
sim	B-protein
mutants	I-protein
.	O

A	O
site	O
-	O
directed	O
R618K	B-protein
mutation	I-protein
in	O
the	O
Stat5	B-protein
SH2	I-protein
domain	I-protein
abolished	O
the	O
phosphorylation	O
by	O
Jak2	B-protein
,	O
while	O
deletion	O
of	O
the	O
C	O
terminus	O
led	O
to	O
Stat5	B-protein
hyperphosphorylation	O
.	O

Another	O
putative	O
HNF3	B-protein
site	I-protein
in	O
close	O
apposition	O
to	O
a	O
NF1	B-protein
/	I-protein
CTF	I-protein
site	I-protein
was	O
localized	O
upstream	O
of	O
the	O
silencer	B-protein
-	I-protein
like	I-protein
element	I-protein
.	O

In	O
patients	O
with	O
complete	O
or	O
partial	O
remission	O
of	O
the	O
tumor	O
,	O
the	O
neopterine	O
excretion	O
dropped	O
to	O
normal	O
values	O
.	O

The	O
child	O
left	O
behind	O
.	O

Electrocardiograms	O
of	O
the	O
month	O
.	O

Symposium	O
on	O
presenile	O
spongy	O
encephalopathies	O
.	O

The	O
hIGF	B-protein
-	I-protein
I	I-protein
gene	I-protein
has	O
two	O
promoters	O
,	O
P1	O
and	O
P2	O
.	O

In	O
this	O
animal	O
,	O
infected	O
with	O
what	O
was	O
judged	O
previously	O
to	O
be	O
the	O
less	O
virulent	O
of	O
the	O
two	O
T	O
.	O
cruzi	O
stocks	O
used	O
(	O
'	O
strain	O
7	O
'	O
)	O
,	O
there	O
was	O
severe	O
myocarditis	O
,	O
with	O
myofibre	O
degeneration	O
,	O
and	O
lesions	O
of	O
the	O
oesophagus	O
.	O

3	O
)	O
and	O
one	O
distal	O
(	O
-	O
11	O
.	O
8	O
/	O
-	O
10	O
.	O
9	O
)	O
,	O
presented	O
an	O
enhancer	O
activity	O
in	O
pituitary	O
cells	O
when	O
placed	O
upstream	O
of	O
the	O
SV40	O
promoter	O
.	O

RESULTS	O
:	O
There	O
is	O
a	O
considerable	O
amount	O
of	O
variation	O
between	O
the	O
results	O
of	O
TRA1	O
and	O
TRA2	O
and	O
between	O
the	O
results	O
of	O
both	O
TRA	O
'	O
s	O
and	O
the	O
door	O
-	O
to	O
-	O
door	O
survey	O
.	O

Clinical	O
use	O
of	O
absorbable	O
polyglycolic	O
acid	O
suture	O
in	O
Blalock	O
-	O
Taussig	O
'	O
s	O
operation	O
.	O

The	O
standard	O
dosage	O
of	O
anti	B-protein
-	I-protein
D	I-protein
currently	O
given	O
at	O
all	O
gestational	O
ages	O
is	O
1	O
ampoule	O
containing	O
125	O
micrograms	O
of	O
anti	B-protein
-	I-protein
D	I-protein
.	O

Mean	O
ROI	O
-	O
A	O
/	O
B	O
ratio	O
was	O
49	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
7	O
%	O
in	O
the	O
diabetic	O
group	O
,	O
significantly	O
lower	O
than	O
the	O
57	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
6	O
%	O
at	O
the	O
nondiabetic	O
group	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
.	O

Recovery	O
of	O
carbimazole	O
-	O
induced	O
agranulocytosis	O
following	O
recombinant	B-protein
granulocyte	I-protein
-	I-protein
macrophage	I-protein
colony	I-protein
stimulating	I-protein
factor	I-protein
(	O
rhGM	B-protein
-	I-protein
CSF	I-protein
)	O
administration	O
.	O

This	O
locus	O
maps	O
approximately	O
160	O
kbp	O
from	O
the	O
genes	O
encoding	O
cytadherence	O
-	O
associated	O
proteins	O
HMW1	B-protein
and	O
HMW3	B-protein
,	O
and	O
yet	O
insertions	O
therein	O
result	O
in	O
loss	O
of	O
these	O
proteins	O
and	O
a	O
hemadsorption	O
-	O
negative	O
(	O
HA	O
-	O
)	O
phenotype	O
,	O
prompting	O
the	O
designation	O
cytadherence	B-protein
-	I-protein
regulatory	I-protein
locus	I-protein
(	O
crl	B-protein
)	O
.	O

The	O
effect	O
of	O
diffusion	O
limitation	O
was	O
quantified	O
in	O
terms	O
of	O
the	O
ratio	O
O2	O
uptake	O
/	O
O2	O
requirement	O
(	O
=	O
fraction	O
of	O
cross	O
-	O
sectional	O
area	O
supplied	O
with	O
O2	O
)	O
,	O
assuming	O
local	O
O2	O
requirement	O
per	O
unit	O
volume	O
to	O
be	O
constant	O
and	O
independent	O
of	O
PO2	O
at	O
PO2	O
greater	O
than	O
0	O
.	O

Here	O
we	O
investigate	O
the	O
role	O
of	O
c	B-protein
-	I-protein
Cbl	I-protein
in	O
development	O
and	O
homeostasis	O
in	O
mice	O
by	O
targeted	O
disruption	O
of	O
the	O
c	B-protein
-	I-protein
Cbl	I-protein
locus	I-protein
.	O
c	O
-	O
Cbl	O
-	O
deficient	O
mice	O
were	O
viable	O
,	O
fertile	O
,	O
and	O
outwardly	O
normal	O
in	O
appearance	O
.	O

Acoust	O
.	O

The	O
modification	O
of	O
P32	O
uptake	O
into	O
the	O
Jensen	O
sarcoma	O
in	O
vitro	O
by	O
adding	O
of	O
peroxide	O
to	O
the	O
nutritive	O
medium	O
.	O

Detailed	O
molecular	O
organization	O
of	O
the	O
coding	O
and	O
upstream	O
regulatory	O
regions	O
of	O
the	O
murine	O
homeodomain	O
-	O
containing	O
gene	O
,	O
Msx	B-protein
-	I-protein
1	I-protein
,	O
is	O
reported	O
.	O

Studies	O
are	O
necessary	O
to	O
assess	O
the	O
source	O
of	O
contamination	O
and	O
potential	O
role	O
of	O
MRSA	O
-	O
contaminated	O
milk	O
in	O
the	O
transmission	O
of	O
MRSA	O
to	O
neonates	O
.	O

A	O
suspected	O
new	O
storage	O
disease	O
in	O
cattle	O
.	O

Reduced	O
NK	O
activity	O
correlates	O
with	O
active	O
disease	O
in	O
HIV	O
-	O
patients	O
with	O
multidrug	O
-	O
resistant	O
pulmonary	O
tuberculosis	O
.	O

These	O
results	O
indicate	O
that	O
evaluation	O
of	O
exposure	O
to	O
S	O
.	O
neurona	O
by	O
WB	O
analysis	O
of	O
serum	O
may	O
be	O
misleading	O
in	O
young	O
horses	O
.	O

The	O
PC2	B-protein
protein	I-protein
also	O
shows	O
great	O
similarity	O
to	O
the	O
incomplete	O
NH2	O
-	O
terminal	O
sequence	O
of	O
the	O
human	B-protein
furin	I-protein
gene	I-protein
product	I-protein
,	O
a	O
putative	O
membrane	O
-	O
inserted	O
receptor	O
-	O
like	O
molecule	O
.	O

Difficulties	O
bound	O
to	O
measuring	O
of	O
sputum	O
viscosity	O
.	O

Whether	O
or	O
not	O
there	O
are	O
sequences	O
conferring	O
cAMP	O
responsiveness	O
which	O
are	O
common	O
both	O
to	O
P	B-protein
-	I-protein
450scc	I-protein
and	O
the	O
other	O
steroidogenic	O
P	B-protein
-	I-protein
450	I-protein
genes	I-protein
remains	O
to	O
be	O
established	O
.	O

We	O
have	O
also	O
tested	O
Src	B-protein
SH2	I-protein
mutants	I-protein
for	O
their	O
binding	O
properties	O
and	O
have	O
interpreted	O
our	O
results	O
in	O
light	O
of	O
the	O
recent	O
crystal	O
structure	O
solution	O
for	O
the	O
Src	B-protein
SH2	I-protein
domain	I-protein
.	O

We	O
linked	O
hypersensitivity	B-protein
site	I-protein
2	I-protein
(	O
HS2	B-protein
)	O
from	O
the	O
locus	O
control	O
region	O
(	O
LCR	O
)	O
to	O
a	O
A	B-protein
gamma	I-protein
-	I-protein
globin	I-protein
gene	O
(	O
A	B-protein
gamma	I-protein
*	I-protein
)	O
mutationally	O
marked	O
to	O
allow	O
its	O
transcript	O
to	O
be	O
distinguished	O
from	O
endogenous	O
gamma	B-protein
-	I-protein
globin	I-protein
mRNA	O
.	O

In	O
controls	O
,	O
only	O
modest	O
differences	O
were	O
observed	O
.	O

Our	O
results	O
suggest	O
that	O
a	O
sequence	O
match	O
between	O
enhancers	O
and	O
certain	O
promoter	O
elements	O
is	O
critical	O
.	O

A	O
conserved	O
role	O
for	O
L1	B-protein
as	O
a	O
transmembrane	O
link	O
between	O
neuronal	O
adhesion	O
and	O
membrane	O
cytoskeleton	O
assembly	O
.	O

Cicatricial	O
pemphigoid	O
is	O
an	O
autoimmune	O
systemic	O
disease	O
characterized	O
by	O
chronic	O
conjunctival	O
cicatrization	O
.	O

1	O
.	O

We	O
conclude	O
that	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
telomere	B-protein
-	I-protein
binding	I-protein
protein	I-protein
,	O
like	O
many	O
transcription	O
factors	O
,	O
has	O
separable	O
DNA	O
-	O
binding	O
and	O
protein	O
-	O
protein	O
interaction	O
domains	O
.	O

In	O
the	O
electrophoresis	O
mobility	O
shift	O
assay	O
using	O
nuclear	O
extracts	O
of	O
the	O
myogenic	O
cells	O
,	O
MyoD	B-protein
and	O
myogenin	B-protein
bound	O
to	O
the	O
right	O
E	O
-	O
box	O
in	O
the	O
enhancer	O
region	O
of	O
the	O
MCK	B-protein
gene	I-protein
even	O
in	O
the	O
presence	O
of	O
BMP	B-protein
-	I-protein
2	I-protein
.	O

1	O
,	O
3	O
-	O
bis	O
(	O
2	O
-	O
chloroethyl	O
)	O
-	O
1	O
-	O
nitrosourea	O
(	O
bcnu	O
)	O
and	O
other	O
nitrosoureas	O
in	O
cancer	O
treatment	O
:	O
a	O
review	O
.	O

9	O
,	O
1498	O
-	O
1506	O
)	O
.	O

Therefore	O
,	O
to	O
understand	O
how	O
ErbB1	B-protein
/	I-protein
ErbB2	I-protein
signaling	O
contributes	O
to	O
this	O
process	O
,	O
we	O
used	O
the	O
ErbB	B-protein
kinase	I-protein
inhibitor	O
AG1478in	O
ErbB2	O
-	O
dependent	O
BT	O
-	O
474	O
and	O
SKBR	O
-	O
3	O
human	O
breast	O
cancer	O
cells	O
.	O

Infants	O
who	O
died	O
in	O
the	O
first	O
12	O
hours	O
from	O
'	O
IVH	O
only	O
'	O
had	O
suffered	O
severe	O
birth	O
asphyxia	O
but	O
in	O
those	O
who	O
died	O
later	O
the	O
main	O
symptom	O
was	O
recurrent	O
apnoea	O
.	O

When	O
vascular	O
pressure	O
(	O
Pvas	O
)	O
was	O
raised	O
abruptly	O
from	O
-	O
5	O
to	O
+	O
25	O
cmH2O	O
by	O
air	O
inflation	O
for	O
60	O
min	O
,	O
Px	O
(	O
f	O
)	O
became	O
abruptly	O
less	O
negative	O
,	O
then	O
remained	O
stable	O
.	O

Consistent	O
with	O
this	O
finding	O
,	O
beta	B-protein
-	I-protein
catenin	I-protein
interacted	O
directly	O
with	O
the	O
RA	B-protein
receptor	I-protein
(	O
RAR	B-protein
)	O
in	O
a	O
retinoid	O
-	O
dependent	O
manner	O
,	O
but	O
not	O
with	O
the	O
retinoid	B-protein
X	I-protein
receptor	I-protein
(	O
RXR	B-protein
)	O
,	O
and	O
RAR	B-protein
competed	O
with	O
TCF	B-protein
for	O
beta	B-protein
-	I-protein
catenin	I-protein
binding	O
.	O

Measurement	O
of	O
anti	B-protein
-	I-protein
HCV	I-protein
IgM	I-protein
antibodies	I-protein
with	O
an	O
experimental	O
kit	O
.	O

In	O
three	O
cases	O
(	O
21	O
.	O
4	O
%	O
)	O
,	O
the	O
MR	O
imaging	O
was	O
interpreted	O
as	O
negative	O
,	O
but	O
microscopic	O
tumor	O
was	O
shown	O
around	O
seroma	O
on	O
reexcision	O
.	O

Protein	B-protein
phosphatase	I-protein
2A	I-protein
is	O
a	O
critical	O
regulator	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
zeta	I-protein
signaling	O
targeted	O
by	O
SV40	B-protein
small	I-protein
t	I-protein
to	O
promote	O
cell	O
growth	O
and	O
NF	B-protein
-	I-protein
kappaB	I-protein
activation	O
.	O

The	O
homology	O
to	O
v	B-protein
-	I-protein
mil	I-protein
starts	O
within	O
the	O
coding	O
sequence	O
of	O
exon	O
1	O
and	O
ends	O
within	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
exon	O
11	O
,	O
12	O
nucleotides	O
downstream	O
from	O
the	O
nonsense	O
codon	O
terminating	O
the	O
large	O
open	O
reading	O
frame	O
shared	O
between	O
c	B-protein
-	I-protein
mil	I-protein
and	O
v	B-protein
-	I-protein
mil	I-protein
.	O

DESIGN	O
:	O
Retrospective	O
study	O
.	O

The	O
R2	O
between	O
MFI	O
of	O
fresh	O
and	O
frozen	O
muscle	O
was	O
0	O
.	O
94	O
and	O
0	O
.	O
92	O
for	O
lamb	O
and	O
pork	O
longissimus	O
,	O
respectively	O
.	O

The	O
spectrum	O
of	O
age	O
-	O
associated	O
brain	O
abnormalities	O
:	O
their	O
measurement	O
and	O
histopathological	O
correlates	O
.	O

The	O
mechanism	O
of	O
action	O
is	O
explored	O
in	O
some	O
detail	O
,	O
specifically	O
as	O
it	O
relates	O
to	O
reticuloendothelial	O
system	O
(	O
RES	O
)	O
Fc	B-protein
receptor	I-protein
blockade	O
and	O
suppression	O
of	O
antiplatelet	O
antibody	O
synthesis	O
.	O

During	O
this	O
period	O
,	O
administration	O
of	O
additional	O
exogenous	B-protein
PRL	I-protein
did	O
not	O
stimulate	O
further	O
activation	O
(	O
binding	O
)	O
of	O
the	O
Stat	B-protein
factors	I-protein
.	O

Differential	O
screening	O
of	O
mitochondrial	O
cDNA	O
libraries	O
from	O
male	O
-	O
fertile	O
and	O
cytoplasmic	O
male	O
-	O
sterile	O
sugar	O
-	O
beet	O
reveals	O
genome	O
rearrangements	O
at	O
atp6	B-protein
and	O
atpA	B-protein
loci	I-protein
.	O

No	O
patient	O
had	O
a	O
history	O
of	O
excess	O
alcohol	O
intake	O
,	O
or	O
prolonged	O
intake	O
of	O
hepatotoxic	O
drugs	O
and	O
steroids	O
,	O
and	O
were	O
not	O
obese	O
or	O
malnourished	O
.	O

Chaperones	B-protein
/	I-protein
HSPs	I-protein
thus	O
play	O
important	O
roles	O
within	O
cell	O
cycle	O
processes	O
.	O

Experiences	O
with	O
the	O
clinical	O
and	O
experimental	O
use	O
of	O
Urat	O
-	O
I	O
lithotriptor	O
.	O

Under	O
resting	O
conditions	O
,	O
activity	O
levels	O
of	O
cardiac	O
vagal	O
and	O
sympathetic	O
outflows	O
are	O
not	O
related	O
across	O
young	O
,	O
healthy	O
human	O
subjects	O
and	O
peripheral	O
interaction	O
is	O
not	O
manifest	O
between	O
the	O
autonomic	O
divisions	O
.	O

This	O
study	O
describes	O
a	O
new	O
MADS	B-protein
box	I-protein
gene	I-protein
,	O
nmhC5	B-protein
,	O
which	O
along	O
with	O
nmh7	B-protein
(	O
J	O
.	O

To	O
explore	O
the	O
functional	O
significance	O
of	O
these	O
subdomains	O
in	O
PRL	B-protein
binding	O
and	O
signal	O
transduction	O
,	O
deletion	O
mutants	O
of	O
S1	B-protein
or	O
/	O
and	O
S2	B-protein
subdomains	I-protein
were	O
constructed	O
.	O

A	O
second	O
large	O
group	O
of	O
disorders	O
in	O
pregnancy	O
is	O
caused	O
by	O
effects	O
of	O
infections	O
of	O
the	O
mother	O
without	O
pathogens	O
being	O
transmitted	O
to	O
the	O
embryo	O
or	O
the	O
placenta	O
.	O

Melatonin	O
and	O
seasonality	O
:	O
filling	O
the	O
gap	O
.	O

Our	O
laboratory	O
has	O
recently	O
identified	O
two	O
phosducin	B-protein
-	I-protein
like	I-protein
orphan	I-protein
proteins	I-protein
(	O
PhLOP1	B-protein
and	O
PhLOP2	B-protein
)	O
that	O
lack	O
the	O
ability	O
to	O
interact	O
with	O
Gbetagamma	B-protein
.	O

In	O
18	O
%	O
lymphography	O
was	O
clearly	O
positive	O
and	O
CT	O
negative	O
.	O

Surprisingly	O
,	O
double	O
mutants	O
of	O
the	O
shy2	B-protein
-	I-protein
1D	I-protein
mutant	I-protein
with	O
the	O
phytochrome	O
-	O
deficient	O
mutants	O
hy2	B-protein
,	O
hy3	B-protein
(	I-protein
phyB	I-protein
-	I-protein
1	I-protein
)	I-protein
and	O
fre1	B-protein
-	I-protein
1	I-protein
(	I-protein
phyA	I-protein
-	I-protein
201	I-protein
)	I-protein
showed	O
reduced	O
photomorphogenic	O
response	O
in	O
darkness	O
with	O
a	O
longer	O
hypocotyl	O
,	O
a	O
longer	O
inflorescence	O
stem	O
,	O
and	O
a	O
lower	O
level	O
expression	O
of	O
the	O
CAB	B-protein
gene	I-protein
than	O
the	O
shy2	B-protein
-	I-protein
1D	I-protein
single	I-protein
mutant	I-protein
.	O

1	O
.	O

During	O
the	O
CR	O
/	O
PP	O
diet	O
only	O
the	O
HS	O
subjects	O
did	O
not	O
show	O
the	O
stress	O
-	O
induced	O
rise	O
in	O
depression	O
,	O
decline	O
in	O
vigour	O
and	O
cortisol	O
elevation	O
that	O
they	O
showed	O
after	O
the	O
PR	O
/	O
CP	O
diet	O
.	O

Overexpression	O
of	O
RORgamma	B-protein
has	O
been	O
shown	O
to	O
inhibit	O
T	O
cell	O
receptor	O
-	O
mediated	O
apoptosis	O
in	O
T	O
cell	O
hybridomas	O
and	O
to	O
repress	O
the	O
induction	O
of	O
Fas	B-protein
-	I-protein
ligand	I-protein
and	O
interleukin	B-protein
2	I-protein
.	O

Circularized	B-protein
Ac	I-protein
/	I-protein
Ds	I-protein
transposons	I-protein
:	O
formation	O
,	O
structure	O
and	O
fate	O
.	O

Since	O
the	O
latter	O
is	O
very	O
small	O
for	O
physiological	O
flows	O
,	O
the	O
result	O
is	O
that	O
alpha	O
<	O
1	O
even	O
at	O
relatively	O
high	O
values	O
of	O
the	O
Reynolds	O
number	O
(	O
i	O
.	O
e	O
.	O
,	O
for	O
non	O
-	O
negligible	O
inertia	O
)	O
and	O
we	O
validate	O
our	O
perturbation	O
theory	O
results	O
by	O
comparison	O
with	O
a	O
numerical	O
integration	O
of	O
the	O
full	O
model	O
.	O

The	O
study	O
enrolled	O
994	O
people	O
co	O
-	O
infected	O
with	O
CMV	O
and	O
HIV	O
,	O
with	O
at	O
least	O
one	O
CD4	B-protein
count	O
recorded	O
<	O
100	O
x	O
10	O
(	O
6	O
)	O
cells	O
/	O
l	O
.	O

UK	O
'	O
s	O
biotechnology	O
lacking	O
specialists	O
.	O

Expression	O
of	O
a	O
dominant	B-protein
-	I-protein
negative	I-protein
ras	I-protein
gene	I-protein
also	O
blocks	O
TIS10	B-protein
/	I-protein
PGS2	I-protein
induction	O
by	O
v	B-protein
-	I-protein
src	I-protein
.	O

High	O
-	O
affinity	O
binding	O
sites	O
for	O
both	O
GR	B-protein
and	O
AP	B-protein
-	I-protein
1	I-protein
nucleoproteins	I-protein
were	O
identified	O
at	O
adjacent	O
elements	O
within	O
the	O
nGRE	B-protein
.	O

The	O
nucleotide	O
sequence	O
of	O
3874	O
bp	O
of	O
cloned	O
R	O
.	O
sphaeroides	O
chromosomal	O
DNA	O
,	O
including	O
the	O
three	O
structural	O
genes	O
fbcF	B-protein
,	O
fbcB	B-protein
and	O
fbcC	B-protein
has	O
been	O
determined	O
.	O

We	O
obtained	O
quantitative	O
evidence	O
on	O
the	O
coding	O
of	O
interaural	O
time	O
differences	O
(	O
ITDs	O
)	O
of	O
click	O
stimuli	O
by	O
40	O
single	O
neurons	O
in	O
the	O
auditory	O
cortex	O
of	O
anesthetized	O
albino	O
rats	O
.	O

Renal	O
cell	O
carcinoma	O
in	O
children	O
:	O
a	O
single	O
institution	O
'	O
s	O
experience	O
.	O

What	O
to	O
look	O
for	O
during	O
a	O
compliance	O
review	O
:	O
10	O
common	O
mistakes	O
made	O
by	O
SNFs	O
.	O

Following	O
chondroitinase	B-protein
AC	I-protein
and	O
ABC	B-protein
digestion	O
,	O
staining	O
reactions	O
suggested	O
that	O
the	O
highest	O
levels	O
of	O
dermatan	O
sulfate	O
were	O
in	O
the	O
diabetes	O
resistant	O
group	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
compared	O
to	O
diabetic	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
compared	O
to	O
diabetes	O
prone	O
)	O
and	O
the	O
highest	O
levels	O
of	O
chondroitin	O
sulfates	O
were	O
in	O
the	O
diabetes	O
prone	O
group	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

In	O
this	O
paper	O
we	O
report	O
that	O
ligand	O
binding	O
induced	O
tyrosine	O
phosphorylation	O
in	O
BaF3	O
cells	O
engineered	O
to	O
express	O
the	O
murine	B-protein
Mpl	I-protein
receptor	I-protein
(	O
BaF3	B-protein
/	I-protein
mMpl	I-protein
)	O
.	O

New	O
and	O
successful	O
steps	O
have	O
been	O
made	O
in	O
immunodiagnostics	O
,	O
immunotherapy	O
,	O
and	O
immunoprophylaxis	O
of	O
immunologically	O
conditioned	O
infertility	O
.	O

Localization	O
of	O
the	O
intronless	O
gene	O
coding	O
for	O
calmodulin	B-protein
-	I-protein
like	I-protein
protein	I-protein
CLP	I-protein
to	O
human	O
chromosome	O
10p13	O
-	O
ter	O
.	O

Uroflowmetry	O
can	O
detect	O
dysuria	O
,	O
which	O
may	O
be	O
poorly	O
perceived	O
or	O
even	O
unknown	O
to	O
the	O
subjects	O
themselves	O
.	O

Removal	O
of	O
lipid	O
fractions	O
of	O
plant	O
extractions	O
with	O
hexane	O
is	O
recommended	O
to	O
avoid	O
damage	O
to	O
the	O
HPLC	O
column	O
.	O

However	O
,	O
the	O
signaling	O
cascade	O
utilized	O
by	O
the	O
urokinase	B-protein
receptor	I-protein
is	O
only	O
incompletely	O
understood	O
.	O

Substrate	O
specificity	O
of	O
the	O
RNase	B-protein
activity	O
of	O
yeast	B-protein
RNA	I-protein
polymerase	I-protein
III	I-protein
.	O

The	O
rear	O
silver	O
liquid	O
chamber	O
was	O
threefold	O
thick	O
to	O
17	O
MeV	O
protons	O
in	O
water	O
and	O
it	O
efficiently	O
produced	O
either	O
13N	O
by	O
the	O
16O	O
(	O
p	O
,	O
alpha	O
)	O
13N	O
reaction	O
or	O
[	O
18F	O
]	O
fluoride	O
ion	O
by	O
the	O
18O	O
(	O
p	O
,	O
n	O
)	O
18F	O
reaction	O
.	O

Furthermore	O
,	O
analysis	O
of	O
deletion	O
promoter	O
-	O
reporter	O
constructs	O
found	O
that	O
the	O
basal	O
activity	O
of	O
P2	O
resided	O
in	O
the	O
proximal	O
region	O
of	O
P2	O
.	O

We	O
introduced	O
the	O
gel	O
technique	O
as	O
a	O
routine	O
assay	O
for	O
antibody	O
detection	O
and	O
identification	O
in	O
1993	O
.	O

Their	O
conduction	O
velocity	O
ranged	O
from	O
0	O
.	O
23	O
to	O
0	O
.	O
98	O
m	O
/	O
sec	O
(	O
group	O
C	O
)	O
.	O

Fasting	O
gastrin	B-protein
levels	O
(	O
normal	O
range	O
:	O
25	O
-	O
110	O
mU	O
/	O
L	O
)	O
varied	O
from	O
48	O
.	O
78	O
mU	O
/	O
L	O
-	O
168	O
.	O
20	O
(	O
mean	O
:	O
85	O
.	O
23	O
mU	O
/	O
L	O
)	O
.	O

CONCLUSION	O
:	O
Sonographic	O
angiography	O
has	O
a	O
possible	O
role	O
in	O
the	O
detection	O
of	O
small	O
nodules	O
in	O
patients	O
with	O
CRF	O
.	O

To	O
examine	O
transcriptional	O
regulation	O
of	O
the	O
rat	B-protein
eIF4E	I-protein
gene	I-protein
,	O
2	O
.	O
1	O
kB	O
of	O
the	O
rat	B-protein
eIF4E	I-protein
promoter	I-protein
region	I-protein
was	O
cloned	O
and	O
the	O
contribution	O
of	O
specific	O
elements	O
in	O
regulating	O
transcription	O
was	O
determined	O
in	O
primary	O
cultures	O
of	O
rat	O
cardiocytes	O
and	O
in	O
a	O
murine	O
C	O
(	O
2	O
)	O
C	O
(	O
12	O
)	O
myoblast	O
cell	O
line	O
.	O

Cytochrome	B-protein
b	I-protein
in	O
human	B-protein
complex	I-protein
II	I-protein
(	O
succinate	B-protein
-	I-protein
ubiquinone	I-protein
oxidoreductase	I-protein
)	O
:	O
cDNA	O
cloning	O
of	O
the	O
components	O
in	O
liver	O
mitochondria	O
and	O
chromosome	O
assignment	O
of	O
the	O
genes	O
for	O
the	O
large	O
(	O
SDHC	B-protein
)	O
and	O
small	O
(	O
SDHD	B-protein
)	O
subunits	O
to	O
1q21	O
and	O
11q23	O
.	O

During	O
latency	O
,	O
more	O
than	O
1	O
%	O
of	O
neurons	O
in	O
ganglia	O
that	O
innervate	O
the	O
footpad	O
expressed	O
beta	B-protein
-	I-protein
galactosidase	I-protein
,	O
with	O
the	O
number	O
of	O
positive	O
cells	O
remaining	O
constant	O
for	O
at	O
least	O
5	O
months	O
.	O

Using	O
a	O
novel	O
method	O
combining	O
chromatin	O
immunoprecipitation	O
and	O
genomic	O
array	O
hybridization	O
,	O
we	O
have	O
identified	O
a	O
460	B-protein
-	I-protein
kb	I-protein
CENP	I-protein
-	I-protein
A	I-protein
-	I-protein
binding	I-protein
DNA	I-protein
domain	I-protein
of	O
a	O
neocentromere	O
derived	O
from	O
the	O
20p12	O
region	O
of	O
an	O
invdup	O
(	O
20p	O
)	O
human	O
marker	O
chromosome	O
.	O

The	O
effects	O
of	O
oral	O
vanadyl	O
sulfate	O
(	O
VOSO4	O
)	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
)	O
on	O
anthropometry	O
,	O
body	O
composition	O
,	O
and	O
performance	O
were	O
investigated	O
in	O
a	O
12	O
-	O
week	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
involving	O
weight	O
-	O
training	O
volunteers	O
.	O

A	O
new	O
instrument	O
has	O
been	O
designed	O
for	O
freeze	O
-	O
fracturing	O
of	O
biological	O
material	O
in	O
ultra	O
high	O
vacuum	O
.	O

Antibodies	O
against	O
this	O
purified	O
protein	O
localize	O
RIM1	B-protein
to	O
mitochondria	O
.	O

RESULTS	O
:	O
Of	O
the	O
29	O
patients	O
who	O
received	O
concurrent	O
chemotherapy	O
and	O
G	B-protein
-	I-protein
CSF	I-protein
,	O
ten	O
(	O
34	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
17	O
.	O
9	O
to	O
54	O
.	O
3	O
%	O
)	O
were	O
believed	O
to	O
have	O
clinically	O
significant	O
bleomycin	O
toxicity	O
.	O

The	O
growth	O
of	O
Aer	O
.	O
hydrophila	O
in	O
filter	O
-	O
sterilized	O
lettuce	O
extract	O
was	O
completely	O
inhibited	O
by	O
0	O
.	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
BMC	O
whereas	O
that	O
of	O
Ps	O
.	O
fluorescens	O
was	O
not	O
significantly	O
affected	O
by	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
BMC	O
.	O

Crystal	O
structure	O
of	O
an	O
oligomer	O
of	O
proteolytic	B-protein
zymogens	I-protein
:	O
detailed	O
conformational	O
analysis	O
of	O
the	O
bovine	O
ternary	O
complex	O
and	O
implications	O
for	O
their	O
activation	O
.	O

Maize	B-protein
rbcS	I-protein
promoter	I-protein
activity	O
depends	O
on	O
sequence	O
elements	O
not	O
found	O
in	O
dicot	B-protein
rbcS	I-protein
promoters	I-protein
.	O

COUP	B-protein
transcription	I-protein
factor	I-protein
is	O
a	O
member	O
of	O
the	O
steroid	B-protein
receptor	I-protein
superfamily	I-protein
.	O

When	O
a	O
plateau	O
of	O
enhancement	O
was	O
reached	O
,	O
a	O
single	O
lesion	O
in	O
each	O
patient	O
was	O
imaged	O
using	O
five	O
different	O
continuous	O
scanning	O
modes	O
,	O
fundamental	O
grey	O
scale	O
(	O
FGS	O
)	O
;	O
fundamental	O
colour	O
Doppler	O
(	O
FCD	O
)	O
;	O
fundamental	O
power	O
Doppler	O
(	O
FPD	O
)	O
;	O
second	O
harmonic	O
grey	O
scale	O
(	O
HGS	O
)	O
;	O
and	O
pulse	O
inversion	O
mode	O
(	O
Pim	O
)	O
using	O
an	O
HDI5000	O
scanner	O
and	O
C5	O
-	O
2	O
probe	O
(	O
ATL	O
,	O
Bothell	O
,	O
WA	O
)	O
.	O

Cat	B-protein
proteins	I-protein
are	O
tyrosine	O
-	O
phosphorylated	O
when	O
co	O
-	O
expressed	O
in	O
cells	O
with	O
the	O
focal	B-protein
adhesion	I-protein
kinase	I-protein
Fak	I-protein
and	O
Src	B-protein
.	O

From	O
Pap	O
to	O
ApUp	O
.	O

This	O
transcriptional	O
regulation	O
occurs	O
through	O
modulation	O
of	O
the	O
forkhead	B-protein
transcription	I-protein
factor	I-protein
FKHR	I-protein
-	I-protein
L1	I-protein
,	O
and	O
IL	B-protein
-	I-protein
3	I-protein
inhibited	O
FKHR	B-protein
-	I-protein
L1	I-protein
activity	O
in	O
a	O
PI3K	O
-	O
dependent	O
manner	O
.	O

Utero	O
-	O
placental	O
blood	O
flow	O
and	O
the	O
effect	O
of	O
beta	B-protein
2	I-protein
-	I-protein
adrenoceptor	I-protein
stimulating	O
drugs	O
.	O

Intron	O
8	O
harbored	O
a	O
strong	O
erythroid	O
-	O
specific	O
enhancer	O
activity	O
which	O
was	O
orientation	O
-	O
dependent	O
.	O

Hodgkin	O
'	O
s	O
disease	O
.	O

The	O
relationship	O
between	O
the	O
rare	O
complications	O
mentioned	O
above	O
and	O
the	O
pathophysiology	O
of	O
Bartter	O
'	O
s	O
syndrome	O
is	O
still	O
obscure	O
.	O

Examination	O
of	O
the	O
mitochondrial	B-protein
bc1	I-protein
complex	I-protein
crystal	I-protein
structure	I-protein
[	O
Zhang	O
,	O
Z	O
.	O
,	O
Huang	O
,	O
L	O
.	O
,	O
Shulmeister	O
,	O
V	O
.	O

Sequence	O
analysis	O
of	O
the	O
sMtCK	B-protein
genomic	I-protein
upstream	I-protein
sequences	I-protein
reveals	O
a	O
typical	O
TATAA	O
box	O
within	O
the	O
80	O
base	O
pairs	O
(	O
bp	O
)	O
that	O
,	O
by	O
transfection	O
experiments	O
,	O
are	O
sufficient	O
to	O
promote	O
expression	O
of	O
chimeric	O
plasmids	O
with	O
the	O
chloramphenicol	B-protein
acetyltransferase	I-protein
reporter	I-protein
.	O

The	O
MAP	B-protein
kinase	I-protein
cascade	I-protein
is	O
highly	O
conserved	O
in	O
all	O
eukaryotes	O
and	O
involved	O
in	O
numerous	O
cellular	O
responses	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
indicate	O
that	O
inhibition	O
of	O
p27	B-protein
(	I-protein
KIP1	I-protein
)	I-protein
transcription	O
through	O
PI3K	B-protein
-	I-protein
induced	I-protein
FKHR	I-protein
-	I-protein
L1	I-protein
phosphorylation	O
provides	O
a	O
novel	O
mechanism	O
of	O
regulating	O
cytokine	O
-	O
mediated	O
survival	O
and	O
proliferation	O
.	O

The	O
effects	O
of	O
c	B-protein
-	I-protein
myc	I-protein
were	O
further	O
dissected	O
by	O
showing	O
that	O
c	B-protein
-	I-protein
myc	I-protein
can	O
inhibit	O
differentiation	O
independently	O
of	O
Id	B-protein
,	O
a	O
negative	O
regulator	O
of	O
muscle	O
differentiation	O
.	O

Statement	O
of	O
the	O
American	O
Academy	O
of	O
Implant	O
Dentistry	O
.	O

Other	O
adverse	O
events	O
with	O
incidences	O
significantly	O
higher	O
than	O
with	O
placebo	O
were	O
dizziness	O
,	O
constipation	O
,	O
sweating	O
,	O
nervousness	O
,	O
and	O
abnormal	O
ejaculation	O
.	O

Bacillus	O
cereus	O
cross	O
-	O
infection	O
in	O
a	O
maternity	O
-	O
unit	O
.	O

The	O
effect	O
of	O
smoking	O
was	O
not	O
examined	O
in	O
this	O
study	O
,	O
as	O
such	O
data	O
were	O
not	O
available	O
.	O

The	O
S229A	O
variant	O
can	O
better	O
flip	O
modified	O
bases	O
but	O
does	O
not	O
tightly	O
lock	O
the	O
flipped	O
base	O
into	O
the	O
adenine	O
-	O
binding	O
pocket	O
,	O
suggesting	O
that	O
Ser229	O
could	O
form	O
a	O
contact	O
to	O
the	O
flipped	O
adenine	O
.	O

Characterization	O
and	O
hormonal	O
regulation	O
of	O
the	O
promoter	O
of	O
the	O
rat	B-protein
prostaglandin	I-protein
endoperoxide	I-protein
synthase	I-protein
2	I-protein
gene	I-protein
in	O
granulosa	O
cells	O
.	O

Cerebral	O
flow	O
and	O
resistance	O
showed	O
minor	O
reductions	O
with	O
HD	O
.	O

Losses	O
of	O
dichlofluanid	O
(	O
54	O
%	O
)	O
,	O
chlozolinate	O
(	O
22	O
%	O
)	O
,	O
and	O
etridiazole	O
(	O
40	O
%	O
)	O
,	O
previously	O
reported	O
to	O
occur	O
during	O
ambient	O
processing	O
of	O
apples	O
,	O
were	O
reduced	O
to	O
barely	O
significant	O
levels	O
(	O
10	O
,	O
17	O
,	O
and	O
14	O
%	O
,	O
respectively	O
)	O
by	O
cryogenic	O
processing	O
.	O

Further	O
studies	O
of	O
mandibular	O
movement	O
at	O
initial	O
tooth	O
contact	O
.	O

This	O
finding	O
is	O
consistent	O
with	O
the	O
notion	O
that	O
the	O
dsRNA	O
binding	O
domains	O
may	O
be	O
composed	O
of	O
two	O
separate	O
functional	O
subdomains	O
.	O

The	O
molecular	O
basis	O
for	O
commitment	O
of	O
progenitors	O
to	O
the	O
eosinophil	O
lineage	O
and	O
mechanisms	O
by	O
which	O
eosinophil	O
-	O
specific	O
genes	O
are	O
expressed	O
and	O
regulated	O
during	O
differentiation	O
is	O
unknown	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
these	O
elements	O
are	O
required	O
for	O
promoter	O
activity	O
,	O
we	O
compared	O
the	O
reporter	O
expression	O
activity	O
of	O
segments	O
containing	O
mutations	O
of	O
these	O
elements	O
with	O
activity	O
of	O
the	O
parent	B-protein
Hlx	I-protein
promoter	I-protein
sequence	I-protein
.	O

2	O
:	O
The	O
dynamic	O
moduli	O
of	O
microcrystalline	B-protein
cellulose	I-protein
.	O

Glomerular	O
lesions	O
in	O
renal	O
allografts	O
.	O

At	O
the	O
genomic	O
level	O
,	O
the	O
sequences	O
of	O
two	O
members	O
of	O
this	O
family	O
are	O
known	O
in	O
the	O
rat	O
Rattus	O
norvegicus	O
:	O
the	O
VCSA1	B-protein
gene	I-protein
,	O
encoding	O
the	O
prohormone	B-protein
-	I-protein
like	I-protein
polypeptide	I-protein
SMR1	I-protein
,	O
and	O
the	O
VCSB1	B-protein
gene	I-protein
,	O
encoding	O
a	O
salivary	O
Pro	O
-	O
rich	O
polypeptide	O
.	O

Angiotensin	B-protein
effect	O
in	O
the	O
human	O
kidney	O
.	O

The	O
RNA	O
genome	O
of	O
rabbit	O
hemorrhagic	O
disease	O
virus	O
(	O
RHDV	O
)	O
was	O
molecularly	O
cloned	O
.	O

Increased	O
p53	B-protein
activity	O
induced	O
by	O
OP	O
is	O
not	O
due	O
to	O
elevated	O
p53	B-protein
mRNA	I-protein
nor	O
to	O
protein	O
levels	O
.	O

In	O
an	O
ongoing	O
study	O
the	O
performance	O
of	O
the	O
SMSP	O
is	O
being	O
compared	O
with	O
that	O
of	O
the	O
Mini	O
Speech	O
Processor	O
(	O
MSP	O
)	O
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
is	O
reported	O
to	O
cause	O
a	O
shock	O
syndrome	O
similar	O
to	O
that	O
produced	O
by	O
endotoxin	B-protein
(	O
LPS	B-protein
)	O
.	O

Phylogenetic	O
analyses	O
of	O
19	O
amino	O
acid	O
sequences	O
of	O
6	O
related	O
protein	O
types	O
indicate	O
that	O
actin	O
-	O
associated	O
proteins	O
related	O
to	O
gelsolin	B-protein
are	O
monophyletic	O
to	O
a	O
common	O
ancestor	O
and	O
include	O
flightless	B-protein
proteins	I-protein
.	O

Anoxia	O
was	O
introduced	O
by	O
perfusing	O
the	O
gill	O
with	O
water	O
deprived	O
of	O
oxygen	O
or	O
by	O
halting	O
the	O
water	O
flow	O
to	O
the	O
gill	O
.	O

Alternative	O
splicing	O
of	O
ClC	B-protein
-	I-protein
6	I-protein
(	O
a	O
member	O
of	O
the	O
CIC	B-protein
chloride	I-protein
-	I-protein
channel	I-protein
family	I-protein
)	O
transcripts	O
generates	O
three	O
truncated	O
isoforms	O
one	O
of	O
which	O
,	O
ClC	B-protein
-	I-protein
6c	I-protein
,	O
is	O
kidney	O
-	O
specific	O
.	O

Strategies	O
for	O
blood	O
screening	O
for	O
the	O
hepatitis	O
C	O
virus	O
and	O
for	O
the	O
human	O
immunodeficiency	O
virus	O
in	O
high	O
risk	O
groups	O
.	O

We	O
purified	O
both	O
proteins	O
from	O
human	O
platelet	O
membranes	O
using	O
DEAE	O
-	O
Sepharose	O
chromatography	O
followed	O
by	O
mAb	B-protein
F11	I-protein
affinity	O
chromatography	O
.	O

5	O
)	O
Before	O
and	O
ten	O
days	O
after	O
DOTC	O
infusion	O
,	O
laboratory	O
tests	O
for	O
liver	O
and	O
renal	O
functions	O
and	O
blood	O
were	O
performed	O
.	O

A	O
recombinant	O
with	O
a	O
5	O
'	O
end	O
from	O
src	B-protein
and	O
a	O
3	O
'	O
end	O
from	O
ros	B-protein
,	O
called	O
SRC	B-protein
x	O
ROS	B-protein
,	O
transformed	O
chicken	O
embryo	O
fibroblasts	O
(	O
CEF	O
)	O
to	O
a	O
spindle	O
shape	O
morphology	O
,	O
mimicking	O
that	O
of	O
UR2	B-protein
.	O

After	O
one	O
accommodation	O
night	O
,	O
sleep	O
EEG	O
recordings	O
were	O
performed	O
during	O
three	O
consecutive	O
nights	O
in	O
ten	O
drug	O
-	O
free	O
inpatients	O
presenting	O
generalized	O
anxiety	O
disorder	O
(	O
GAD	O
)	O
with	O
significant	O
depression	O
,	O
compared	O
with	O
a	O
age	O
-	O
and	O
sex	O
-	O
matched	O
group	O
of	O
patients	O
with	O
GAD	O
and	O
a	O
group	O
of	O
primary	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
patients	O
.	O

S6	B-protein
kinase	I-protein
activation	O
requires	O
displacement	O
of	O
this	O
inhibitory	O
segment	O
,	O
which	O
is	O
proposed	O
to	O
occur	O
consequent	O
to	O
its	O
multiple	O
phosphorylation	O
.	O

Most	O
recently	O
,	O
the	O
use	O
of	O
the	O
product	O
of	O
brain	O
weight	O
and	O
clearance	O
has	O
been	O
proposed	O
.	O

Purified	B-protein
P7	I-protein
could	O
be	O
assembled	O
onto	O
particles	O
lacking	O
P7	B-protein
and	O
particles	O
lacking	O
both	O
P2	B-protein
(	O
RNA	B-protein
polymerase	I-protein
)	O
and	O
P7	O
.	O

Deletion	O
analyses	O
of	O
the	O
pCD41	B-protein
ORF	I-protein
-	I-protein
A	I-protein
and	O
the	O
use	O
of	O
promoter	O
constructs	O
further	O
mapped	O
an	O
internal	O
functional	O
promoter	O
within	O
the	O
pCD41	B-protein
sequence	I-protein
that	O
can	O
direct	O
the	O
synthesis	O
of	O
the	O
trans	O
-	O
activating	O
protein	O
.	O

Reproductive	O
period	O
affects	O
water	O
intake	O
in	O
heat	O
-	O
stressed	O
dehydrated	O
goats	O
.	O

The	O
mRNA	O
expression	O
of	O
RFX1	B-protein
,	O
RFX2	B-protein
,	O
and	O
RFX3	B-protein
was	O
detected	O
ubiquitously	O
,	O
but	O
in	O
transient	O
-	O
transfection	O
assays	O
,	O
multimerized	B-protein
RFX	I-protein
binding	I-protein
sites	I-protein
in	O
front	O
of	O
a	O
basal	O
promoter	O
efficiently	O
functioned	O
in	O
a	O
tissue	O
-	O
and	O
lineage	O
-	O
specific	O
manner	O
.	O

To	O
study	O
the	O
role	O
of	O
heavy	B-protein
chain	I-protein
motifs	I-protein
in	O
substrate	O
recognition	O
,	O
secreted	O
variants	O
of	O
recombinant	B-protein
bovine	I-protein
proenteropeptidase	I-protein
were	O
constructed	O
by	O
replacing	O
the	O
transmembrane	O
domain	O
with	O
a	O
signal	O
peptide	O
.	O

The	O
centromedial	O
amygdala	O
and	O
gastric	O
pathology	O
in	O
rats	O
.	O

The	O
p53	B-protein
-	I-protein
homolog	I-protein
p73beta	I-protein
also	O
activated	O
the	O
PIG3	B-protein
promoter	I-protein
,	O
but	O
in	O
contrast	O
to	O
p53	B-protein
,	O
the	O
proline	O
-	O
rich	O
domain	O
of	O
p73beta	B-protein
(	I-protein
residues	I-protein
81	I-protein
-	I-protein
113	I-protein
)	I-protein
was	O
dispensable	O
to	O
induce	O
the	O
PIG3	B-protein
promoter	I-protein
.	O

The	O
DRF	B-protein
-	I-protein
2	I-protein
nuclear	I-protein
protein	I-protein
has	O
characteristics	O
similar	O
to	O
those	O
of	O
the	O
muscle	O
-	O
specific	O
regulatory	O
factor	O
,	O
MEF	B-protein
-	I-protein
2	I-protein
(	O
Buskin	O
and	O
Hauschka	O
1989	O
;	O
Gossett	O
et	O
al	O
.	O
,	O
1989	O
)	O
.	O

Pulmonary	O
vein	O
varix	O
in	O
association	O
with	O
bilateral	O
pulmonary	O
vein	O
stenosis	O
.	O

RESULTS	O
:	O
At	O
the	O
beginning	O
of	O
the	O
QA	O
/	O
QI	O
process	O
,	O
monitoring	O
of	O
blood	O
administration	O
practices	O
revealed	O
that	O
a	O
variance	O
from	O
institutional	O
blood	O
administration	O
policy	O
occurred	O
during	O
50	O
percent	O
of	O
blood	O
and	O
component	O
transfusions	O
.	O

TNFalpha	B-protein
and	O
IL	B-protein
-	I-protein
6	I-protein
levels	O
were	O
determined	O
in	O
the	O
culture	O
supernatants	O
.	O

In	O
two	O
further	O
cases	O
(	O
one	O
type	O
I	O
and	O
one	O
type	O
III	O
SMA	O
)	O
,	O
de	O
novo	O
deletions	O
of	O
only	O
one	O
copy	O
of	O
Ag1	B-protein
-	I-protein
CA	I-protein
and	O
C212	B-protein
were	O
found	O
.	O

In	O
supine	O
position	O
,	O
plasma	O
ANP	B-protein
levels	O
ranged	O
from	O
12	O
pg	O
/	O
ml	O
to	O
51	O
.	O
5	O
pg	O
/	O
ml	O
,	O
with	O
an	O
average	O
level	O
of	O
35	O
.	O
3	O
+	O
/	O
-	O
11	O
.	O
5	O
pg	O
/	O
ml	O
.	O

NIK	O
-	O
244	O
suppressed	O
coronary	O
ligation	O
-	O
and	O
digitalis	O
-	O
induced	O
arrhythmias	O
,	O
and	O
the	O
minimum	O
effective	O
plasma	O
concentrations	O
for	O
arrhythmias	O
induced	O
by	O
24	O
-	O
h	O
and	O
48	O
-	O
h	O
coronary	O
ligation	O
and	O
digitalis	O
were	O
0	O
.	O
41	O
+	O
/	O
-	O
0	O
.	O
10	O
(	O
by	O
1	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
,	O
0	O
.	O
70	O
+	O
/	O
-	O
0	O
.	O
13	O
(	O
by	O
1	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
,	O
and	O
0	O
.	O
21	O
+	O
/	O
-	O
0	O
.	O
08	O
(	O
by	O
0	O
.	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
microgram	O
/	O
ml	O
,	O
respectively	O
(	O
mean	O
+	O
/	O
-	O
SD	O
of	O
the	O
mean	O
,	O
n	O
=	O
6	O
)	O
.	O

The	O
5	O
'	O
external	O
transcribed	O
spacer	O
(	O
ETS	O
)	O
region	O
of	O
the	O
pre	O
-	O
rRNA	O
in	O
Saccharomyces	O
cerevisiae	O
contains	O
a	O
sequence	O
with	O
10	O
bp	O
of	O
perfect	O
complementarity	O
to	O
the	O
U3	B-protein
snoRNA	I-protein
.	O

To	O
further	O
define	O
the	O
structural	O
requirements	O
for	O
ZAP	B-protein
-	I-protein
70	I-protein
interaction	O
with	O
the	O
TCR	B-protein
,	O
we	O
developed	O
a	O
binding	O
assay	O
using	O
immobilized	O
glutathione	B-protein
S	I-protein
-	I-protein
transferase	I-protein
fusion	I-protein
proteins	I-protein
containing	O
the	O
NH2	O
-	O
and	O
/	O
or	O
COOH	B-protein
-	I-protein
terminal	I-protein
SH2	I-protein
domains	I-protein
of	O
ZAP	B-protein
-	I-protein
70	I-protein
,	O
and	O
soluble	O
synthetic	O
peptides	O
with	O
the	O
sequence	O
of	O
the	O
cytoplasmic	O
region	O
of	O
the	O
TCR	B-protein
zeta	I-protein
chain	I-protein
(	O
TCR	B-protein
zeta	I-protein
cyt	I-protein
)	O
or	O
individual	O
TCR	B-protein
zeta	I-protein
and	O
CD3	B-protein
epsilon	I-protein
TAM	I-protein
motifs	I-protein
.	O

The	O
inspiratory	O
oxygen	O
concentration	O
needed	O
(	O
FiO2	O
)	O
and	O
the	O
Horowitz	O
quotient	O
differed	O
in	O
a	O
highly	O
significant	O
manner	O
beginning	O
on	O
the	O
1st	O
day	O
after	O
trauma	O
.	O

The	O
sera	O
and	O
nasal	O
secretions	O
of	O
142	O
patients	O
,	O
who	O
were	O
positive	O
in	O
HD	O
or	O
mites	O
skin	O
test	O
,	O
were	O
subjected	O
to	O
a	O
radioallergosorbent	O
test	O
(	O
RAST	O
)	O
for	O
estimating	O
the	O
specific	O
IgE	B-protein
antibody	I-protein
activity	O
to	O
mites	O
.	O

This	O
organization	O
suggests	O
that	O
duplication	O
events	O
that	O
have	O
generated	O
the	O
primate	B-protein
FUT3	I-protein
-	I-protein
FUT5	I-protein
-	I-protein
FUT6	I-protein
cluster	I-protein
might	O
have	O
occurred	O
through	O
a	O
long	O
-	O
interspersed	O
-	O
nuclear	O
-	O
element	O
-	O
based	O
mechanism	O
of	O
unequal	O
crossing	O
over	O
,	O
as	O
described	O
for	O
the	O
globin	B-protein
cluster	I-protein
.	O

BACKGROUND	O
:	O
In	O
the	O
ubiquitin	O
-	O
dependent	O
proteolysis	O
pathway	O
,	O
a	O
ubiquitin	B-protein
ligase	I-protein
(	O
E3	B-protein
)	O
is	O
responsible	O
for	O
substrate	O
selectivity	O
and	O
timing	O
of	O
degradation	O
.	O

The	O
initial	O
phase	O
of	O
increased	O
vascular	O
permeability	O
in	O
the	O
peritoneal	O
cavity	O
and	O
LTB4	O
production	O
was	O
dose	O
dependently	O
inhibited	O
by	O
the	O
5	O
-	O
LO	O
inhibitors	O
phenidone	O
,	O
BW	O
A4C	O
,	O
A63162	O
,	O
and	O
ICI	O
207	O
968	O
but	O
not	O
by	O
dexamethasone	O
or	O
colchicine	O
.	O

Circulatory	O
arrest	O
in	O
the	O
operating	O
room	O
.	O

This	O
study	O
is	O
a	O
further	O
and	O
more	O
extensive	O
validation	O
of	O
the	O
clinician	O
rated	O
NIMH	O
-	O
LCM	O
-	O
p	O
.	O

Left	O
atrial	O
volumes	O
were	O
greater	O
in	O
old	O
compared	O
with	O
young	O
subjects	O
(	O
maximal	O
:	O
31	O
+	O
/	O
-	O
10	O
cm3	O
/	O
m2	O
vs	O
24	O
+	O
/	O
-	O
8	O
cm3	O
/	O
m2	O
,	O
p	O
=	O
0	O
.	O
02	O
;	O
at	O
onset	O
of	O
atrial	O
systole	O
:	O
23	O
+	O
/	O
-	O
8	O
cm3	O
/	O
m2	O
vs	O
15	O
+	O
/	O
-	O
5	O
cm3	O
/	O
m2	O
,	O
p	O
=	O
0	O
.	O
0002	O
;	O
minimal	O
:	O
13	O
+	O
/	O
-	O
5	O
cm3	O
/	O
m2	O
vs	O
9	O
+	O
/	O
-	O
4	O
cm3	O
/	O
m2	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

This	O
article	O
describes	O
the	O
collaborative	O
care	O
of	O
the	O
woman	O
participating	O
in	O
maternal	O
blood	O
donation	O
for	O
intrauterine	O
transfusion	O
.	O

Gestational	O
trophoblastic	O
diseases	O
:	O
recent	O
advances	O
in	O
the	O
understanding	O
of	O
cytogenetics	O
,	O
histopathology	O
,	O
and	O
natural	O
history	O
.	O

A	O
genetic	O
screen	O
applied	O
to	O
mutants	O
in	O
the	O
branch	O
site	O
region	O
shows	O
that	O
all	O
positions	O
in	O
the	O
conserved	O
TACTAAC	O
sequence	O
are	O
important	O
for	O
intron	O
recognition	O
.	O

The	O
system	O
consisted	O
of	O
the	O
intact	O
canine	O
heart	O
connected	O
to	O
a	O
microcomputer	O
that	O
operated	O
as	O
the	O
modulated	O
parasystolic	O
pacemaker	O
.	O

Immunological	O
and	O
biochemical	O
characterization	O
of	O
streptococcal	B-protein
pyrogenic	I-protein
exotoxins	I-protein
I	I-protein
and	I-protein
J	I-protein
(	O
SPE	B-protein
-	I-protein
I	I-protein
and	O
SPE	B-protein
-	I-protein
J	I-protein
)	O
from	O
Streptococcus	O
pyogenes	O
.	O

Patients	O
with	O
an	O
enzymatic	O
activity	O
below	O
X	O
-	O
-	O
1	O
manifested	O
a	O
decrease	O
of	O
the	O
content	O
of	O
IgA	B-protein
,	O
IgG	B-protein
,	O
IgM	B-protein
,	O
T	O
and	O
B	O
lymphocytes	O
,	O
and	O
of	O
phagocytic	O
activity	O
of	O
neutrophils	O
as	O
compared	O
to	O
patients	O
exhibiting	O
a	O
high	O
enzymatic	O
activity	O
.	O

These	O
data	O
suggest	O
that	O
the	O
combined	O
treatment	O
with	O
a	O
thromboxane	B-protein
synthetase	I-protein
inhibitor	O
and	O
a	O
thromboxane	B-protein
receptor	I-protein
antagonist	O
provides	O
a	O
better	O
protection	O
against	O
digoxin	O
intoxication	O
than	O
with	O
either	O
agent	O
alone	O
.	O

These	O
are	O
the	O
long	B-protein
terminal	I-protein
repeat	I-protein
(	I-protein
LTR	I-protein
)	I-protein
promoter	I-protein
,	O
which	O
regulates	O
expression	O
of	O
the	O
viral	O
structural	O
proteins	O
,	O
and	O
a	O
second	O
internal	O
promoter	O
,	O
located	O
towards	O
the	O
3	O
'	O
end	O
of	O
the	O
env	B-protein
gene	I-protein
,	O
that	O
directs	O
expression	O
of	O
the	O
viral	O
auxiliary	O
proteins	O
.	O

The	O
1	O
.	O
1	O
-	O
and	O
1	O
.	O
3	O
-	O
kb	O
mRNA	O
species	O
were	O
found	O
only	O
in	O
the	O
heart	O
,	O
and	O
the	O
2	O
.	O
6	O
-	O
kb	O
species	O
was	O
found	O
in	O
the	O
heart	O
,	O
kidney	O
and	O
brain	O
,	O
but	O
not	O
in	O
skeletal	O
muscle	O
or	O
liver	O
.	O

It	O
has	O
been	O
reported	O
that	O
rat	O
blood	O
chloroform	O
levels	O
were	O
significantly	O
decreased	O
after	O
treatment	O
with	O
ClO2	O
.	O

A	O
DNA	O
motif	O
related	O
to	O
the	O
cAMP	B-protein
-	I-protein
responsive	I-protein
element	I-protein
and	O
an	O
exon	B-protein
-	I-protein
located	I-protein
activator	I-protein
protein	I-protein
-	I-protein
2	I-protein
binding	I-protein
site	I-protein
in	O
the	O
human	B-protein
tissue	I-protein
-	I-protein
type	I-protein
plasminogen	I-protein
activator	I-protein
gene	I-protein
promoter	I-protein
cooperate	O
in	O
basal	O
expression	O
and	O
convey	O
activation	O
by	O
phorbol	O
ester	O
and	O
cAMP	O
.	O

Band	O
structure	O
effects	O
of	O
transport	O
properties	O
in	O
icosahedral	O
quasicrystals	O
.	O

Each	O
dietary	O
treatment	O
was	O
fed	O
to	O
six	O
pen	O
replicates	O
of	O
five	O
chicks	O
per	O
pen	O
for	O
21	O
d	O
.	O

Repression	O
of	O
glucocorticoid	O
receptor	O
-	O
mediated	O
transcriptional	O
activation	O
by	O
unliganded	O
thyroid	B-protein
hormone	I-protein
receptor	I-protein
(	O
TR	B-protein
)	O
is	O
TR	B-protein
isoform	O
-	O
specific	O
.	O

cDNA	O
encoding	O
a	O
functional	O
feline	B-protein
liver	I-protein
/	I-protein
bone	I-protein
/	I-protein
kidney	I-protein
-	I-protein
type	I-protein
alkaline	I-protein
phosphatase	I-protein
.	O

RNase	B-protein
protection	O
assays	O
revealed	O
a	O
correlation	O
between	O
the	O
levels	O
of	O
dorsal	O
and	O
ventral	O
skin	O
expression	O
with	O
pigmentation	O
/	O
phaeomelanin	O
phenotypes	O
.	O

Because	O
chromosome	O
X	O
is	O
frequently	O
involved	O
in	O
structural	O
alterations	O
in	O
neoplastic	O
Syrian	O
hamster	O
cells	O
transformed	O
by	O
chemical	O
carcinogens	O
and	O
oncogenic	O
viruses	O
,	O
the	O
localization	O
of	O
the	O
cph	B-protein
locus	I-protein
on	O
this	O
chromosome	O
supports	O
the	O
notion	O
that	O
the	O
cph	B-protein
oncogene	I-protein
plays	O
a	O
role	O
in	O
the	O
malignant	O
conversion	O
of	O
chemically	O
transformed	O
hamster	O
fibroblasts	O
.	O

In	O
this	O
paper	O
,	O
the	O
current	O
status	O
of	O
the	O
understanding	O
of	O
the	O
interaction	O
mechanisms	O
of	O
ultrasound	O
with	O
biological	O
media	O
and	O
the	O
factors	O
that	O
govern	O
different	O
biological	O
effects	O
are	O
surveyed	O
.	O

Most	O
of	O
the	O
phenomena	O
of	O
azotaemic	O
osteodystrophy	O
are	O
encountered	O
in	O
simple	O
vitamin	O
D	O
deficiency	O
;	O
as	O
in	O
that	O
condition	O
,	O
deficiency	O
of	O
1	O
,	O
25	O
-	O
dihydroxycholecalciferol	O
may	O
be	O
of	O
primary	O
significance	O
in	O
causing	O
secondary	O
hyperparathyroidism	O
in	O
renal	O
failure	O
.	O

Diabetes	O
care	O
:	O
a	O
guideline	O
to	O
the	O
facilities	O
needed	O
to	O
support	O
internationally	O
endorsed	O
standards	O
.	O

However	O
,	O
the	O
N63S	O
mutation	O
in	O
the	O
wild	B-protein
-	I-protein
type	I-protein
VP5	I-protein
background	O
increased	O
the	O
interaction	O
,	O
as	O
judged	O
by	O
the	O
beta	B-protein
-	I-protein
galactosidase	I-protein
activity	O
,	O
by	O
a	O
factor	O
of	O
9	O
relative	O
to	O
when	O
the	O
PR7	O
mutation	O
was	O
present	O
.	O

The	O
possibility	O
of	O
a	O
hereditary	O
disorder	O
leading	O
to	O
a	O
minor	O
defect	O
in	O
elastic	O
fibre	O
structure	O
which	O
could	O
be	O
responsible	O
for	O
the	O
spontaneous	O
lesions	O
is	O
discussed	O
.	O

The	O
binding	O
of	O
PH	B-protein
domains	I-protein
to	O
Gbetagamma	B-protein
was	O
inhibited	O
by	O
preincubation	O
of	O
Gbetagamma	B-protein
with	O
the	O
GDP	O
-	O
bound	O
but	O
not	O
the	O
GTP	O
-	O
bound	O
form	O
of	O
Gialpha	B-protein
.	O

False	O
positive	O
amniotic	B-protein
fluid	I-protein
alpha	I-protein
fetoprotein	I-protein
levels	O
resulting	O
from	O
contamination	O
with	O
fetal	O
blood	O
:	O
results	O
of	O
an	O
experiment	O
.	O

Piperacillin	O
-	O
tazobactam	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
infections	O
caused	O
by	O
gram	O
-	O
negative	O
,	O
gram	O
-	O
positive	O
,	O
aerobic	O
,	O
and	O
anaerobic	O
bacteria	O
.	O

Identification	O
of	O
RNase	B-protein
T	I-protein
as	O
a	O
high	O
-	O
copy	O
suppressor	O
of	O
the	O
UV	O
sensitivity	O
associated	O
with	O
single	B-protein
-	I-protein
strand	I-protein
DNA	I-protein
exonuclease	I-protein
deficiency	O
in	O
Escherichia	O
coli	O
.	O

All	O
patients	O
had	O
elevated	O
levels	O
of	O
serum	B-protein
IgE	I-protein
antibodies	I-protein
to	O
the	O
crude	O
soybean	O
extract	O
;	O
binding	O
values	O
ranged	O
from	O
2	O
.	O
3	O
to	O
28	O
.	O
1	O
times	O
that	O
of	O
a	O
negative	O
control	O
serum	O
.	O

DNA	B-protein
polymerase	I-protein
E	I-protein
,	O
DNA	B-protein
ligase	I-protein
III	I-protein
and	O
a	O
DNA	B-protein
structure	I-protein
-	I-protein
specific	I-protein
endonuclease	I-protein
co	O
-	O
purify	O
with	O
the	O
five	O
polypeptide	O
complex	O
.	O

Yeast	B-protein
U1	I-protein
snRNP	I-protein
therefore	O
contains	O
16	O
different	O
proteins	O
,	O
including	O
seven	O
snRNP	B-protein
core	I-protein
proteins	I-protein
,	O
three	O
homologues	O
of	O
the	O
metazoan	B-protein
U1	I-protein
snRNP	I-protein
-	I-protein
specific	I-protein
proteins	I-protein
,	O
and	O
six	O
yeast	B-protein
-	I-protein
specific	I-protein
U1	I-protein
snRNP	I-protein
proteins	I-protein
.	O

Strontium	O
chloride	O
Sr	O
89	O
is	O
costly	O
,	O
but	O
preliminary	O
analysis	O
indicates	O
that	O
it	O
may	O
reduce	O
management	O
expenditures	O
overall	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Measurement	O
of	O
magnesium	O
absorption	O
in	O
man	O
using	O
stable	O
26Mg	O
as	O
a	O
tracer	O
.	O

The	O
frameshift	O
initiated	O
by	O
ADEx2	O
is	O
believed	O
to	O
alter	O
the	O
regular	O
coding	O
sequence	O
,	O
acting	O
as	O
a	O
loss	O
-	O
of	O
-	O
function	O
ASIP	B-protein
mutation	I-protein
.	O

Distant	O
spread	O
was	O
found	O
in	O
46	O
patients	O
(	O
34	O
%	O
)	O
,	O
42	O
of	O
whom	O
had	O
serum	O
Tg	O
greater	O
than	O
10	O
micrograms	O
/	O
l	O
.	O

METHODS	O
:	O
Out	O
of	O
171	O
patients	O
receiving	O
anticoagulation	O
between	O
July	O
1992	O
and	O
December	O
1993	O
,	O
83	O
patients	O
with	O
hemispheric	O
embolisms	O
received	O
heparin	O
within	O
72	O
hours	O
from	O
onset	O
(	O
activated	O
partial	O
thromboplastin	B-protein
time	O
[	O
aPTT	O
]	O
1	O
.	O
5	O
times	O
control	O
value	O
)	O
.	O

These	O
probable	O
border	O
sequences	O
are	O
closely	O
related	O
to	O
those	O
of	O
other	O
known	O
T	O
-	O
regions	O
and	O
define	O
a	O
second	O
T	O
-	O
region	O
of	O
pTiChry5	O
,	O
called	O
T	O
-	O
right	O
(	O
TR	O
)	O
,	O
that	O
confers	O
production	O
of	O
the	O
Amadoriopines	O
.	O

The	O
structural	O
changes	O
in	O
intra	O
-	O
acinar	O
artery	O
manifested	O
mainly	O
by	O
an	O
increase	O
in	O
number	O
of	O
muscular	O
artery	O
resulting	O
from	O
muscularization	O
of	O
precursor	O
cells	O
(	O
pericytes	O
and	O
intermediate	O
cells	O
)	O
located	O
within	O
partially	O
muscular	O
and	O
nonmuscular	O
arterial	O
wall	O
to	O
smooth	O
muscle	O
cell	O
,	O
and	O
by	O
the	O
medial	O
wall	O
thickened	O
due	O
to	O
hypertrophy	O
and	O
hyperplasia	O
of	O
smooth	O
muscle	O
cells	O
as	O
well	O
as	O
accumulation	O
of	O
a	O
large	O
amount	O
of	O
collagen	B-protein
,	O
especially	O
the	O
type	B-protein
1	I-protein
collagen	I-protein
.	O

In	O
subjects	O
(	O
n	O
=	O
5	O
)	O
with	O
quadriplegia	O
and	O
reduced	O
sympathetic	O
tone	O
secondary	O
to	O
cervical	O
cord	O
trauma	O
,	O
TcpO2	O
at	O
42	O
degrees	O
C	O
and	O
vasodilation	O
index	O
were	O
increased	O
(	O
45	O
.	O
0	O
mmHg	O
and	O
0	O
.	O
61	O
)	O
;	O
TcpO2	O
at	O
45	O
degrees	O
C	O
did	O
not	O
change	O
.	O

Letter	O
:	O
Is	O
actinic	O
(	O
solar	O
)	O
damage	O
the	O
provoking	O
cause	O
of	O
'	O
post	O
-	O
inflammatory	O
elastolysis	O
and	O
cutis	O
laxa	O
(	O
PECL	O
)	O
'	O
?	O

The	O
size	O
discrepancy	O
is	O
not	O
due	O
to	O
glycosylation	O
or	O
phosphorylation	O
of	O
Ag35	B-protein
but	O
may	O
result	O
from	O
a	O
proline	O
-	O
rich	O
sequence	O
which	O
occurs	O
in	O
this	O
polypeptide	O
.	O

Moreover	O
,	O
LD50	O
in	O
mice	O
of	O
RP	O
-	O
170	O
(	O
4	O
.	O
3	O
g	O
/	O
kg	O
on	O
i	O
.	O
v	O
.	O
)	O
was	O
increased	O
to	O
5	O
.	O
2	O
g	O
/	O
kg	O
by	O
oral	O
administration	O
.	O

The	O
co	O
-	O
existence	O
of	O
TE	B-protein
domains	I-protein
within	O
modular	O
PKSs	B-protein
along	O
with	O
physically	O
separated	O
,	O
monofunctional	O
TEs	B-protein
(	O
TE	B-protein
IIs	I-protein
)	O
has	O
been	O
reported	O
for	O
a	O
number	O
of	O
modular	O
polyketide	O
and	O
non	B-protein
-	I-protein
ribosomal	I-protein
peptide	I-protein
synthases	I-protein
(	O
NRPS	B-protein
)	O
.	O

The	O
complete	O
circular	O
TTV	O
genome	O
contained	O
a	O
novel	O
sequence	O
of	O
113	O
nt	O
(	O
nt	O
3740	O
to	O
3852	O
[	O
=	O
0	O
]	O
)	O
in	O
between	O
the	O
known	O
3	O
'	O
-	O
and	O
5	O
'	O
-	O
end	O
arms	O
,	O
forming	O
a	O
117	O
-	O
nt	O
GC	O
-	O
rich	O
stretch	O
(	O
GC	O
content	O
,	O
90	O
.	O
6	O
%	O
at	O
nt	O
3736	O
to	O
3852	O
)	O
.	O

SNAP	B-protein
-	I-protein
23	I-protein
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
vesicle	O
trafficking	O
in	O
mammalian	O
cells	O
.	O

Surprisingly	O
,	O
there	O
is	O
no	O
sequence	O
homology	O
between	O
this	O
region	O
of	O
Ly	B-protein
-	I-protein
6E	I-protein
and	O
the	O
established	O
consensus	O
for	O
the	O
interferon	B-protein
-	I-protein
stimulated	I-protein
response	I-protein
element	I-protein
,	O
which	O
has	O
been	O
shown	O
functionally	O
important	O
to	O
all	O
previously	O
characterized	O
alpha	B-protein
/	I-protein
beta	I-protein
interferon	I-protein
-	I-protein
inducible	I-protein
promoters	I-protein
.	O

Ectopic	O
expression	O
of	O
the	O
dominant	B-protein
mutant	I-protein
Lg3	I-protein
allele	I-protein
is	O
believed	O
to	O
cause	O
the	O
phenotype	O
.	O

Expression	O
of	O
the	O
dibasic	O
proprotein	O
processing	O
enzyme	O
furin	B-protein
is	O
directed	O
by	O
multiple	O
promoters	O
.	O

Structural	O
changes	O
in	O
the	O
kinetically	O
more	O
damaged	O
E44D	O
mutant	O
detected	O
in	O
(	O
1	O
)	O
H	O
-	O
(	O
15	O
)	O
N	O
HSQC	O
spectra	O
were	O
largely	O
limited	O
to	O
the	O
loop	O
I	O
-	O
helix	O
I	O
motif	O
,	O
suggesting	O
that	O
Glu	O
-	O
44	O
stabilizes	O
the	O
active	O
site	O
region	O
.	O

Between	O
1967	O
and	O
1994	O
,	O
495	O
patients	O
underwent	O
surgery	O
for	O
primary	O
PTC	O
at	O
the	O
Department	O
of	O
Surgery	O
,	O
Helsinki	O
University	O
Central	O
Hospital	O
.	O

According	O
to	O
the	O
literature	O
,	O
second	O
malignant	O
epithelial	O
tumours	O
are	O
,	O
in	O
contrast	O
to	O
mesenchymal	O
tumours	O
such	O
as	O
osteosarcoma	O
,	O
very	O
rare	O
in	O
retinoblastoma	O
survivors	O
.	O

In	O
patients	O
,	O
the	O
effect	O
of	O
CCK	O
-	O
PZ	O
on	O
the	O
movement	O
of	O
the	O
terminal	O
part	O
of	O
the	O
bile	O
duct	O
was	O
measured	O
with	O
a	O
pressure	O
sensor	O
using	O
a	O
duodenofiberscope	O
.	O

Intestinal	O
adaptation	O
(	O
first	O
of	O
two	O
parts	O
)	O
.	O

Tissue	O
samples	O
were	O
obtained	O
either	O
from	O
rats	O
that	O
had	O
been	O
exposed	O
to	O
opiate	O
withdrawal	O
following	O
a	O
seven	O
day	O
morphine	O
infusion	O
or	O
sham	O
treated	O
control	O
subjects	O
.	O

The	O
optimal	O
sequence	O
for	O
interaction	O
with	O
mu	B-protein
2	I-protein
and	O
with	O
AP	B-protein
-	I-protein
2	I-protein
has	O
tyrosine	O
as	O
an	O
anchor	O
and	O
prefers	O
arginine	O
at	O
position	O
Y	O
+	O
2	O
and	O
leucine	O
at	O
position	O
Y	O
+	O
3	O
.	O

Unlike	O
most	O
other	O
small	B-protein
G	I-protein
proteins	I-protein
which	O
are	O
expressed	O
ubiquitously	O
,	O
TTF	B-protein
was	O
transcribed	O
only	O
in	O
hemopoietic	O
cells	O
as	O
a	O
2	O
.	O
2	O
kb	O
transcript	O
.	O

The	O
generally	O
adopted	O
criteria	O
enabling	O
to	O
classify	O
the	O
examined	O
persons	O
into	O
the	O
following	O
3	O
groups	O
have	O
been	O
used	O
:	O
(	O
a	O
)	O
diseased	O
of	O
BEN	O
;	O
(	O
b	O
)	O
suspect	O
to	O
be	O
diseased	O
of	O
BEN	O
,	O
and	O
(	O
c	O
)	O
individuals	O
without	O
signs	O
of	O
a	O
renal	O
disease	O
.	O

No	O
changes	O
were	O
evident	O
in	O
the	O
FR	O
-	O
task	O
performance	O
of	O
controls	O
that	O
received	O
daily	O
saline	O
injections	O
.	O

Of	O
165	O
women	O
with	O
non	O
-	O
malignant	O
diagnoses	O
26	O
(	O
16	O
%	O
)	O
had	O
CA	B-protein
125	I-protein
levels	O
in	O
excess	O
of	O
35	O
U	O
/	O
ml	O
and	O
8	O
(	O
5	O
%	O
)	O
greater	O
than	O
65	O
U	O
/	O
ml	O
.	O

P	B-protein
-	I-protein
CIP1	I-protein
,	O
a	O
novel	O
protein	O
that	O
interacts	O
with	O
the	O
cytosolic	O
domain	O
of	O
peptidylglycine	B-protein
alpha	I-protein
-	I-protein
amidating	I-protein
monooxygenase	I-protein
,	O
is	O
associated	O
with	O
endosomes	O
.	O

Contagious	O
bovine	O
pleuropneumonia	O
is	O
a	O
major	O
threat	O
for	O
cattle	O
in	O
Africa	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
investigated	O
the	O
regulatory	O
mechanism	O
for	O
CD95L	B-protein
expression	O
.	O

SELECTION	O
CRITERIA	O
:	O
All	O
randomised	O
controlled	O
trials	O
comparing	O
IUSs	O
with	O
other	O
forms	O
of	O
reversible	O
contraceptives	O
and	O
reporting	O
on	O
pre	O
-	O
determined	O
outcomes	O
in	O
women	O
of	O
reproductive	O
years	O
.	O

The	O
experimental	O
design	O
incorporated	O
a	O
multiple	O
regression	O
model	O
,	O
sequential	O
treatments	O
and	O
a	O
proportional	O
end	O
point	O
(	O
95	O
%	O
)	O
for	O
protection	O
time	O
.	O

In	O
conclusion	O
,	O
we	O
observed	O
a	O
great	O
regeneration	O
ability	O
following	O
mechanical	O
injury	O
in	O
the	O
nasal	O
mucosa	O
.	O

Full	B-protein
-	I-protein
length	I-protein
FLAP	I-protein
clones	O
were	O
isolated	O
from	O
a	O
mouse	O
skeletal	O
muscle	O
cDNA	O
library	O
.	O

Liver	O
dysfunction	O
in	O
the	O
presence	O
of	O
different	O
adverse	O
reactions	O
presented	O
with	O
a	O
higher	O
activity	O
in	O
the	O
blood	O
serum	O
of	O
indicator	O
liver	O
enzymes	O
and	O
its	O
impaired	O
protein	O
-	O
forming	O
function	O
.	O

Regulation	O
of	O
the	O
Raf	B-protein
kinase	I-protein
in	O
T	O
cells	O
differs	O
from	O
findings	O
with	O
a	O
variety	O
of	O
cell	O
lines	O
that	O
the	O
catalytic	B-protein
domain	I-protein
of	I-protein
Raf	I-protein
(	O
Raf	B-protein
(	I-protein
delta26	I-protein
-	I-protein
303	I-protein
)	O
)	O
shows	O
no	O
activity	O
.	O

The	O
experience	O
of	O
the	O
lateral	O
rhinotomy	O
approach	O
in	O
transsphenoidal	O
surgery	O
of	O
acromegaly	O
has	O
been	O
favourable	O
.	O

BACKGROUND	O
:	O
Measurement	O
of	O
stereoacuity	O
at	O
varying	O
distances	O
,	O
by	O
real	O
or	O
simulated	O
depth	O
stereoacuity	O
tests	O
,	O
is	O
helpful	O
in	O
the	O
evaluation	O
of	O
patients	O
with	O
binocular	O
imbalance	O
or	O
strabismus	O
.	O

A	O
comparison	O
of	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
T	O
.	O
thermophilus	O
enzyme	O
with	O
that	O
of	O
the	O
Escherichia	O
coli	O
enzyme	O
showed	O
(	O
i	O
)	O
a	O
37	O
%	O
overall	O
similarity	O
;	O
(	O
ii	O
)	O
the	O
conservation	O
of	O
the	O
Ser	O
residue	O
,	O
which	O
is	O
known	O
to	O
be	O
phosphorylated	O
in	O
the	O
E	O
.	O
coli	O
enzyme	O
,	O
and	O
of	O
the	O
surrounding	O
sequence	O
;	O
and	O
(	O
iii	O
)	O
the	O
presence	O
of	O
141	O
extra	O
residues	O
at	O
the	O
C	O
terminus	O
of	O
the	O
T	O
.	O
thermophilus	O
enzyme	O
.	O

The	O
range	O
of	O
serum	O
concentrations	O
,	O
mean	O
values	O
,	O
median	O
values	O
,	O
and	O
standard	O
deviations	O
for	O
each	O
analyte	O
are	O
reported	O
for	O
males	O
and	O
females	O
and	O
for	O
three	O
age	O
groups	O
(	O
25	O
-	O
44	O
,	O
45	O
-	O
59	O
,	O
60	O
-	O
70	O
)	O
.	O

Therapeutic	O
effects	O
of	O
cefpirome	O
(	O
HR	O
810	O
)	O
on	O
experimental	O
mixed	O
infections	O
with	O
Enterococcus	O
faecalis	O
and	O
Escherichia	O
coli	O
in	O
mice	O
.	O

This	O
is	O
a	O
challenging	O
task	O
insofar	O
as	O
direct	O
measures	O
of	O
ISF	O
glucose	O
are	O
not	O
readily	O
available	O
.	O

These	O
results	O
suggest	O
that	O
both	O
transcription	O
activators	O
depend	O
on	O
or	O
interact	O
with	O
different	O
subunits	O
of	O
RNA	B-protein
polymerase	I-protein
,	O
although	O
their	O
role	O
in	O
formation	O
of	O
proper	O
DNA	O
geometry	O
may	O
also	O
be	O
crucial	O
.	O

Inhibition	O
assays	O
performed	O
with	O
over	O
30	O
different	O
natural	O
and	O
synthetic	O
sialylated	O
and	O
/	O
or	O
sulfated	O
compounds	O
are	O
utilized	O
to	O
define	O
in	O
greater	O
detail	O
specific	O
structural	O
features	O
involved	O
in	O
oligosaccharide	O
-	O
protein	O
binding	O
.	O

Molecular	O
cloning	O
of	O
a	O
cDNA	O
encoding	O
rat	B-protein
NADH	I-protein
-	I-protein
cytochrome	I-protein
b5	I-protein
reductase	I-protein
and	O
the	O
corresponding	O
gene	O
.	O

We	O
also	O
localized	O
the	O
Fra	B-protein
-	I-protein
2	I-protein
phosphorylation	I-protein
sites	I-protein
by	O
MAPK	B-protein
to	O
three	O
threonine	O
and	O
three	O
serine	O
residues	O
in	O
the	O
COOH	O
-	O
terminal	O
region	O
by	O
means	O
of	O
site	O
-	O
directed	O
mutagenesis	O
and	O
showed	O
that	O
the	O
threonine	O
residues	O
were	O
more	O
susceptible	O
to	O
MAPK	B-protein
.	O

Deletion	O
mapping	O
studies	O
revealed	O
that	O
the	O
upstream	O
DNA	O
sequences	O
up	O
to	O
-	O
86	O
were	O
sufficient	O
for	O
the	O
optimal	O
basal	O
level	O
transcription	O
in	O
HeLa	O
cells	O
and	O
also	O
for	O
the	O
EIA	O
-	O
induced	O
transcription	O
.	O

The	O
QT	O
interval	O
was	O
related	O
to	O
various	O
components	O
of	O
the	O
insulin	B-protein
resistance	O
syndrome	O
,	O
including	O
BP	O
and	O
insulin	B-protein
sensitivity	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
nebulized	O
ipratropium	O
in	O
patients	O
with	O
acute	O
asthma	O
in	O
order	O
to	O
determine	O
whether	O
it	O
augments	O
the	O
bronchodilator	O
effect	O
of	O
a	O
beta	O
agonist	O
drug	O
.	O

Ongoing	O
and	O
future	O
investigations	O
may	O
better	O
define	O
the	O
optimal	O
approach	O
for	O
local	O
control	O
,	O
the	O
optimal	O
duration	O
of	O
maintenance	O
chemotherapy	O
,	O
and	O
the	O
possible	O
role	O
of	O
biologic	O
response	O
modifiers	O
and	O
growth	B-protein
factors	I-protein
in	O
further	O
improving	O
the	O
outcome	O
for	O
patients	O
with	O
this	O
disease	O
.	O

Effects	O
of	O
long	O
-	O
term	O
parenteral	O
nutrition	O
on	O
gastrin	B-protein
release	O
in	O
dogs	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
SGC1	B-protein
gene	I-protein
product	I-protein
includes	O
a	O
region	O
with	O
substantial	O
similarity	O
to	O
the	O
basic	O
-	O
helix	O
-	O
loop	O
-	O
helix	O
domain	O
of	O
the	O
Myc	B-protein
family	I-protein
of	O
DNA	O
-	O
binding	O
proteins	O
.	O

Evidence	O
suggests	O
that	O
PHACES	O
syndrome	O
is	O
not	O
a	O
random	O
association	O
but	O
a	O
true	O
phakomatosis	O
;	O
further	O
studies	O
are	O
awaited	O
to	O
shed	O
light	O
on	O
a	O
possible	O
genetic	O
background	O
.	O

Monitoring	O
patients	O
with	O
acute	O
leukemia	O
for	O
IL	B-protein
-	I-protein
1	I-protein
and	O
TNF	B-protein
levels	O
throughout	O
the	O
clinical	O
course	O
of	O
disease	O
may	O
help	O
clarify	O
the	O
causes	O
of	O
febrile	O
episodes	O
.	O

Virol	O
.	O

The	O
P131	B-protein
ORF	I-protein
is	O
followed	O
in	O
-	O
frame	O
by	O
a	O
second	O
ORF	O
which	O
is	O
probably	O
expressed	O
by	O
partial	O
readthrough	O
of	O
the	O
UGA	O
termination	O
codon	O
of	O
the	O
P131	B-protein
ORF	I-protein
to	O
produce	O
a	O
polypeptide	O
of	O
M	O
(	O
r	O
)	O
191044	O
(	O
P191	B-protein
)	O
.	O

The	O
CANNTG	B-protein
motifs	I-protein
were	O
found	O
to	O
bind	O
MyoD	B-protein
and	O
myogenin	B-protein
fusion	I-protein
proteins	I-protein
and	O
to	O
interact	O
with	O
proteins	O
in	O
nuclear	O
extracts	O
from	O
cultured	O
myotubes	O
.	O

D3S1261	B-protein
is	O
physically	O
located	O
at	O
or	O
near	O
the	O
MITF	B-protein
locus	I-protein
,	O
while	O
D3S2465	B-protein
and	O
D3S1766	B-protein
are	O
flanking	O
the	O
locus	O
at	O
about	O
17	O
.	O
5	O
cM	O
genetic	O
distance	O
each	O
side	O
.	O

CyIIa	B-protein
transcription	O
follows	O
,	O
and	O
is	O
therefore	O
downstream	O
of	O
,	O
the	O
initial	O
specification	O
of	O
these	O
embryonic	O
domains	O
.	O

Determination	O
of	O
diquat	O
in	O
biological	O
materials	O
by	O
electron	O
spin	O
resonance	O
spectroscopy	O
.	O

As	O
no	O
complete	O
PPARgamma	B-protein
antagonists	O
have	O
been	O
described	O
hitherto	O
,	O
we	O
have	O
constructed	O
a	O
dominant	O
-	O
negative	O
mutant	O
receptor	O
to	O
inhibit	O
wild	O
-	O
type	O
PPARgamma	B-protein
action	O
.	O

PCNA	B-protein
mRNA	I-protein
has	O
a	O
3	O
'	O
UTR	O
antisense	O
to	O
yellow	O
crescent	O
RNA	O
and	O
is	O
localized	O
in	O
ascidian	O
eggs	O
and	O
embryos	O
.	O

Anti	B-protein
-	I-protein
PTB	I-protein
antibodies	I-protein
did	O
not	O
inhibit	O
the	O
binding	O
of	O
PTB	B-protein
to	O
RNA	O
because	O
they	O
were	O
able	O
to	O
supershift	O
RNA	B-protein
-	I-protein
PTB	I-protein
complexes	I-protein
.	O

Influence	O
of	O
different	O
methods	O
of	O
chemical	O
disinfection	O
on	O
the	O
physical	O
properties	O
of	O
type	O
IV	O
and	O
V	O
gypsum	O
dies	O
Several	O
instruments	O
and	O
materials	O
frequently	O
used	O
in	O
prosthodontics	O
-	O
-	O
such	O
as	O
stone	O
casts	O
,	O
dental	O
impressions	O
,	O
interocclusal	O
records	O
-	O
-	O
are	O
classified	O
,	O
by	O
the	O
dental	O
literature	O
,	O
as	O
vehicles	O
of	O
transmission	O
of	O
infectious	O
diseases	O
to	O
those	O
who	O
handle	O
them	O
.	O

Spectrophotometric	O
microanalysis	O
of	O
ethylenediaminotetracetic	O
acid	O
in	O
pharmaceutical	O
preparations	O
.	O

Pacing	O
the	O
Roux	O
limb	O
abolished	O
the	O
ectopic	O
pacemakers	O
,	O
restored	O
the	O
slow	O
emptying	O
of	O
liquids	O
to	O
the	O
more	O
rapid	O
rate	O
found	O
in	O
the	O
Billroth	O
dogs	O
(	O
t1	O
/	O
2	O
:	O
paced	O
Roux	O
,	O
72	O
+	O
/	O
-	O
15	O
minutes	O
;	O
Billroth	O
,	O
43	O
+	O
/	O
-	O
9	O
minutes	O
;	O
p	O
greater	O
than	O
0	O
.	O
05	O
)	O
and	O
did	O
not	O
change	O
emptying	O
of	O
solids	O
.	O

Staining	O
with	O
IF	B-protein
MoAB	O
alone	O
of	O
BAL	O
fluid	O
only	O
seemed	O
to	O
be	O
even	O
more	O
sensitive	O
than	O
silver	O
methenamine	O
staining	O
of	O
BAL	O
,	O
TBB	O
and	O
brushing	O
material	O
.	O

Evidence	O
for	O
the	O
involvement	O
of	O
the	O
Glc7	B-protein
-	I-protein
Reg1	I-protein
phosphatase	I-protein
and	O
the	O
Snf1	B-protein
-	I-protein
Snf4	I-protein
kinase	I-protein
in	O
the	O
regulation	O
of	O
INO1	B-protein
transcription	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
effects	O
of	O
social	O
isolation	O
on	O
morphine	O
-	O
induced	O
locomotor	O
activity	O
were	O
compared	O
in	O
:	O
(	O
i	O
)	O
animals	O
with	O
an	O
intact	O
hypothalamo	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
;	O
(	O
ii	O
)	O
animals	O
in	O
which	O
stress	O
-	O
induced	O
corticosterone	O
secretion	O
was	O
blocked	O
by	O
adrenalectomy	O
.	O

255	O
-	O
61	O
.	O

Drug	O
and	O
personnel	O
costs	O
were	O
reduced	O
when	O
batch	O
manufacturing	O
with	O
40	O
-	O
mL	O
multidose	O
vials	O
was	O
compared	O
with	O
extemporaneous	O
compounding	O
with	O
unit	O
-	O
dose	O
vials	O
.	O

The	O
MSL	B-protein
complex	I-protein
is	O
specifically	O
localized	O
on	O
the	O
male	O
X	O
chromosome	O
to	O
increase	O
its	O
expression	O
approximately	O
2	O
-	O
fold	O
.	O

Transfer	O
also	O
correlated	O
inversely	O
with	O
gastric	O
juice	O
pH	O
(	O
r	O
=	O
-	O
0	O
.	O
619	O
,	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
that	O
CAP1	B-protein
is	O
involved	O
in	O
multidrug	O
resistance	O
and	O
oxidative	O
stress	O
response	O
in	O
C	O
.	O
albicans	O
.	O

Sequence	O
analysis	O
and	O
identification	O
of	O
two	O
hyp	B-protein
regulatory	I-protein
mutants	I-protein
.	O

Acute	O
pancreatitis	O
is	O
a	O
rather	O
common	O
abdominal	O
disorder	O
.	O

Using	O
Scheffe	O
'	O
s	O
procedure	O
as	O
an	O
illustration	O
,	O
comparisons	O
are	O
made	O
to	O
usual	O
sample	O
size	O
methods	O
that	O
incorrectly	O
ignore	O
the	O
stochastic	O
nature	O
of	O
S2p	O
.	O

Recently	O
,	O
cell	O
-	O
surface	O
TRAIL	B-protein
has	O
been	O
shown	O
to	O
be	O
expressed	O
by	O
activated	O
human	O
and	O
mouse	O
T	O
lymphocytes	O
,	O
raising	O
the	O
possibility	O
that	O
TRAIL	B-protein
might	O
be	O
involved	O
in	O
T	O
cell	O
-	O
mediated	O
cytotoxicity	O
and	O
/	O
or	O
immune	O
regulation	O
.	O

Classical	O
ligand	B-protein
-	I-protein
activated	I-protein
nuclear	I-protein
receptors	I-protein
(	O
e	O
.	O
g	O
.	O
thyroid	B-protein
hormone	I-protein
receptor	I-protein
,	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
)	O
,	O
orphan	B-protein
nuclear	I-protein
receptors	I-protein
(	O
e	O
.	O
g	O
.	O

Therefore	O
the	O
procedure	O
of	O
Lich	O
-	O
Gregoir	O
is	O
not	O
to	O
be	O
recommended	O
in	O
adults	O
.	O

In	O
the	O
posthospital	O
phase	O
of	O
AMI	O
,	O
as	O
well	O
as	O
in	O
CCHD	O
,	O
the	O
occurrence	O
of	O
high	O
-	O
grade	O
VPBs	O
usually	O
indicates	O
more	O
advanced	O
degrees	O
of	O
both	O
coronary	O
and	O
left	O
ventricular	O
disease	O
as	O
well	O
as	O
the	O
possibility	O
of	O
cardiac	O
and	O
/	O
or	O
sudden	O
death	O
.	O

Kinetics	O
of	O
calcium	O
metabolism	O
.	O

However	O
,	O
essential	O
contrast	O
differences	O
existing	O
between	O
the	O
FSE	O
sequences	O
and	O
their	O
routine	O
asymmetric	O
dual	O
SE	O
counterpart	O
can	O
be	O
identified	O
.	O

Management	O
of	O
postvitrectomy	O
diabetic	O
vitreous	O
hemorrhage	O
with	O
tissue	B-protein
plasminogen	I-protein
activator	I-protein
(	O
t	B-protein
-	I-protein
PA	I-protein
)	O
and	O
volume	O
homeostatic	O
fluid	O
-	O
fluid	O
exchanger	O
.	O

After	O
peripheral	O
administration	O
of	O
both	O
CRF	B-protein
and	O
TRH	B-protein
,	O
ACTH	B-protein
levels	O
were	O
significantly	O
higher	O
on	O
the	O
tumor	O
side	O
in	O
all	O
patients	O
.	O

The	O
leader	O
sequence	O
of	O
the	O
isolated	O
cDNA	O
clone	O
contains	O
several	O
small	O
open	O
reading	O
frames	O
upstream	O
of	O
the	O
initiation	O
codon	O
of	O
the	O
largest	O
open	O
reading	O
frame	O
coding	O
for	O
the	O
homeodomain	O
protein	O
.	O

The	O
foregoing	O
results	O
show	O
that	O
CXD	O
has	O
high	O
efficacy	O
and	O
safety	O
and	O
it	O
can	O
be	O
said	O
that	O
it	O
is	O
a	O
drug	O
required	O
in	O
the	O
pediatric	O
field	O
.	O

Three	O
mutants	O
were	O
isolated	O
from	O
the	O
widely	O
used	O
strain	O
,	O
PAO1	O
.	O

No	O
anisotropism	O
was	O
recorded	O
in	O
a	O
tetrahydrofuran	O
solution	O
.	O

The	O
moduli	O
of	O
elasticity	O
of	O
the	O
gray	O
and	O
white	O
matter	O
were	O
3	O
.	O
4	O
+	O
/	O
-	O
1	O
.	O
4	O
kPa	O
(	O
mean	O
+	O
/	O
-	O
standard	O
deviation	O
)	O
and	O
3	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
9	O
kPa	O
in	O
the	O
axial	O
section	O
,	O
3	O
+	O
/	O
-	O
0	O
.	O
3	O
kPa	O
and	O
3	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
5	O
kPa	O
in	O
the	O
frontal	O
section	O
,	O
and	O
3	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
9	O
kPa	O
and	O
2	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
4	O
kPa	O
in	O
the	O
sagittal	O
section	O
,	O
respectively	O
.	O

The	O
NF1	B-protein
locus	I-protein
encodes	O
a	O
protein	O
functionally	O
related	O
to	O
mammalian	B-protein
GAP	I-protein
and	O
yeast	B-protein
IRA	I-protein
proteins	I-protein
.	O

In	O
the	O
second	O
experiment	O
,	O
a	O
stable	O
nickel	O
isotope	O
,	O
61Ni	O
,	O
was	O
given	O
in	O
drinking	O
water	O
to	O
20	O
nickel	O
-	O
sensitized	O
women	O
and	O
20	O
age	O
-	O
matched	O
controls	O
,	O
both	O
groups	O
having	O
vesicular	O
hand	O
eczema	O
of	O
the	O
pompholyx	O
type	O
.	O

Subsequent	O
to	O
their	O
secretion	O
,	O
the	O
IGF	B-protein
-	I-protein
II	I-protein
in	O
xz97	O
and	O
G11	O
cells	O
accumulated	O
in	O
the	O
conditioned	O
medium	O
mostly	O
as	O
two	O
partially	O
processed	O
species	O
with	O
appMr	O
,	O
of	O
17K	O
and	O
14K	O
,	O
respectively	O
.	O

Cold	O
cardioplegia	O
was	O
administered	O
at	O
45	O
mm	O
Hg	O
every	O
20	O
minutes	O
for	O
2	O
hours	O
.	O

Experimental	O
data	O
showed	O
that	O
these	O
abnormal	O
proteins	O
are	O
constitutively	O
localized	O
in	O
the	O
nucleus	O
,	O
have	O
lost	O
the	O
transcriptional	O
repressor	O
functions	O
typical	O
of	O
normal	O
NF	B-protein
-	I-protein
kappa	I-protein
B2p52	I-protein
and	O
may	O
be	O
capable	O
of	O
transactivation	O
activity	O
.	O

Ultrastructure	O
of	O
the	O
heart	O
muscle	O
in	O
experimental	O
myocardial	O
infarct	O
following	O
physical	O
training	O
.	O

By	O
using	O
lacZ	B-protein
fusions	I-protein
,	O
it	O
was	O
possible	O
to	O
localize	O
the	O
DNA	O
sequences	O
required	O
to	O
mediate	O
nitrate	O
repression	O
to	O
the	O
pfl	B-protein
promoter	I-protein
-	I-protein
regulatory	I-protein
region	I-protein
.	O

Splicing	O
of	O
the	O
K	B-protein
-	I-protein
SAM	I-protein
alternative	O
exon	O
of	O
the	O
fibroblast	B-protein
growth	I-protein
factor	I-protein
receptor	I-protein
2	I-protein
gene	I-protein
is	O
heavily	O
dependent	O
on	O
the	O
U	O
-	O
rich	O
sequence	O
IAS1	B-protein
lying	O
immediately	O
downstream	O
from	O
its	O
5	O
'	O
splice	O
site	O
.	O

Biochemical	O
examinations	O
of	O
calcium	O
-	O
phosphorus	O
metabolism	O
included	O
ions	O
and	O
PTH	B-protein
concentrations	O
in	O
blood	O
serum	O
,	O
and	O
the	O
activity	O
of	O
bone	O
isoenzyme	O
of	O
AP	B-protein
.	O

Changes	O
in	O
prognosis	O
of	O
twin	O
births	O
over	O
20	O
years	O
.	O

Losses	O
during	O
the	O
complete	O
procedure	O
are	O
corrected	O
for	O
using	O
radioactive	O
estrogen	O
conjugates	O
during	O
the	O
first	O
steps	O
and	O
later	O
by	O
adding	O
deuterated	O
internal	O
standards	O
of	O
all	O
compounds	O
measured	O
(	O
matairesinol	O
,	O
enterodiol	O
,	O
enterolactone	O
,	O
daidzein	O
,	O
O	O
-	O
desmethylangolensin	O
,	O
equol	O
,	O
and	O
genistein	O
)	O
.	O

Regionalization	O
of	O
drug	O
delivery	O
is	O
a	O
potential	O
method	O
to	O
avoid	O
this	O
problem	O
.	O

Restriction	O
mapping	O
analysis	O
localized	O
this	O
cDNA	O
to	O
the	O
HHV	B-protein
-	I-protein
6A	I-protein
(	I-protein
U1102	I-protein
)	I-protein
genomic	I-protein
BamHI	I-protein
G	I-protein
fragment	I-protein
,	O
at	O
the	O
right	O
end	O
of	O
the	O
unique	O
long	O
segment	O
of	O
the	O
genome	O
and	O
to	O
the	O
SalI	B-protein
L	I-protein
and	O
SalI	B-protein
O	I-protein
fragments	I-protein
within	O
the	O
left	O
and	O
right	O
terminal	O
direct	O
repeat	O
regions	O
,	O
respectively	O
.	O

Fowlpox	O
virus	O
encodes	O
nonessential	O
homologs	O
of	O
cellular	B-protein
alpha	I-protein
-	I-protein
SNAP	I-protein
,	O
PC	B-protein
-	I-protein
1	I-protein
,	O
and	O
an	O
orphan	O
human	O
homolog	O
of	O
a	O
secreted	O
nematode	O
protein	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
temporal	O
characteristics	O
and	O
the	O
spatial	O
mapping	O
of	O
the	O
independent	O
components	O
identified	O
by	O
ICA	O
when	O
the	O
subject	O
performs	O
a	O
finger	O
-	O
tapping	O
task	O
.	O

Antiviral	O
agents	O
.	O

The	O
maintenance	O
of	O
increased	O
myocardial	O
capillary	O
density	O
required	O
a	O
similar	O
amount	O
of	O
exercise	O
,	O
and	O
at	O
least	O
1	O
h	O
of	O
exercise	O
once	O
a	O
week	O
was	O
necessary	O
to	O
maintain	O
the	O
enlargement	O
of	O
ECA	O
.	O
20	O

RESULTS	O
AND	O
CONCLUSIONS	O
:	O
Brandt	O
'	O
s	O
double	O
cuff	O
-	O
tubes	O
(	O
G2	O
)	O
succeed	O
in	O
avoiding	O
uncontrolled	O
increase	O
of	O
cuff	O
-	O
pressure	O
during	O
anaesthesia	O
with	O
N2O	O
.	O

The	O
effects	O
produced	O
by	O
oral	O
administration	O
of	O
500	O
mg	O
/	O
kg	O
p	O
-	O
xylene	O
or	O
toluene	O
lasted	O
at	O
least	O
8	O
hr	O
,	O
while	O
the	O
effect	O
of	O
inhaled	O
p	O
-	O
xylene	O
dissipated	O
within	O
75	O
min	O
of	O
removal	O
from	O
the	O
exposure	O
.	O

This	O
combined	O
intravenous	O
anaesthetic	O
regimen	O
gave	O
good	O
anaesthesia	O
and	O
analgesia	O
to	O
pigs	O
for	O
up	O
to	O
2	O
h	O
as	O
monitored	O
by	O
clinical	O
signs	O
.	O

Serum	O
E2	O
concentrations	O
increased	O
numerically	O
two	O
-	O
to	O
threefold	O
from	O
d	O
56	O
to	O
140	O
in	O
controls	O
fed	O
MGA	O
,	O
compared	O
with	O
controls	O
not	O
fed	O
MGA	O
.	O

The	O
coding	O
sequences	O
of	O
the	O
Crry	B-protein
gene	I-protein
encompass	O
over	O
25	O
kb	O
of	O
DNA	O
,	O
whereas	O
the	O
Crry	B-protein
-	I-protein
ps	I-protein
sequences	I-protein
are	O
included	O
within	O
a	O
single	O
5	B-protein
.	I-protein
6	I-protein
-	I-protein
kb	I-protein
Eco	I-protein
-	I-protein
R1	I-protein
fragment	I-protein
.	O

A	O
note	O
on	O
the	O
phase	O
-	O
plane	O
technique	O
representation	O
of	O
cardiac	O
action	O
potentials	O
.	O

The	O
amino	O
acid	O
sequence	O
was	O
determined	O
to	O
be	O
residues	O
716	O
-	O
724	O
and	O
hence	O
lysine	O
residue	O
721	O
is	O
located	O
within	O
the	O
ATP	O
-	O
binding	O
site	O
.	O

Thus	O
,	O
hGRbeta	B-protein
potentially	O
functions	O
as	O
a	O
dominant	O
negative	O
inhibitor	O
of	O
hGRalpha	B-protein
activity	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
RSTD	O
predicts	O
coronary	O
anatomy	O
during	O
acute	O
coronary	O
occlusion	O
.	O

Alignment	O
of	O
the	O
cervical	O
spine	O
,	O
vertebral	O
abnormalities	O
,	O
and	O
disc	O
changes	O
also	O
were	O
evaluated	O
.	O

There	O
are	O
two	O
immunogenic	O
sites	O
on	O
the	O
type	B-protein
A	I-protein
influenza	I-protein
A	I-protein
/	I-protein
Japan	I-protein
/	I-protein
57	I-protein
(	I-protein
H2N2	I-protein
)	I-protein
hemagglutinin	I-protein
(	O
HA	B-protein
)	O
that	O
can	O
be	O
recognized	O
by	O
class	B-protein
I	I-protein
major	I-protein
histocompatibility	I-protein
complex	I-protein
(	O
MHC	B-protein
)	O
,	O
H	O
-	O
2Kd	O
-	O
restricted	O
cytolytic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
.	O

However	O
,	O
after	O
PRK	O
at	O
5	O
weeks	O
of	O
age	O
,	O
partial	O
retreatment	O
may	O
be	O
necessary	O
due	O
to	O
regression	O
of	O
the	O
PRK	O
effect	O
.	O

One	O
maternal	O
death	O
,	O
reduced	O
body	O
weight	O
,	O
and	O
reduced	O
weight	O
gain	O
were	O
noted	O
at	O
the	O
high	O
dose	O
;	O
confirmed	O
pregnancy	O
rates	O
were	O
84	O
to	O
100	O
%	O
for	O
each	O
group	O
.	O

Entry	O
of	O
yeast	O
cells	O
into	O
the	O
mitotic	O
cell	O
cycle	O
(	O
Start	O
)	O
involves	O
a	O
form	O
of	O
the	O
CDC28	B-protein
kinase	I-protein
that	O
associates	O
with	O
G1	O
-	O
specific	O
cyclins	B-protein
encoded	O
by	O
CLN1	B-protein
and	O
CLN2	B-protein
(	O
ref	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
STAT	B-protein
activation	O
in	O
a	O
panel	O
of	O
rodent	O
fibroblast	O
cell	O
lines	O
stably	O
transformed	O
by	O
diverse	O
viral	O
oncoproteins	O
.	O

Comparison	O
with	O
the	O
crystal	O
structure	O
of	O
Desulfovibrio	O
gigas	O
,	O
Dg	O
,	O
Fd	O
(	O
Kissinger	O
et	O
al	O
.	O
,	O
1991	O
)	O
reveals	O
a	O
very	O
similar	O
folding	O
topology	O
,	O
although	O
several	O
secondary	O
structural	O
elements	O
are	O
extended	O
in	O
Pf	O
relative	O
to	O
Dg	O
Fd	O
.	O

Thus	O
,	O
elongin	B-protein
C	I-protein
is	O
found	O
to	O
oligomerize	O
in	O
solution	O
and	O
to	O
undergo	O
significant	O
structural	O
rearrangements	O
upon	O
binding	O
of	O
two	O
different	O
partner	O
proteins	O
.	O

The	O
gene	B-protein
lac	I-protein
-	I-protein
1	I-protein
,	O
encoding	O
the	O
enzyme	O
laccase	B-protein
,	O
is	O
the	O
best	O
characterized	O
of	O
a	O
number	O
of	O
genes	O
in	O
the	O
chestnut	O
blight	O
fungus	O
,	O
Cryphonectria	O
parasitica	O
,	O
that	O
are	O
repressed	O
by	O
hypoviruses	O
,	O
a	O
group	O
of	O
virulence	O
-	O
attenuating	O
mycoviruses	O
.	O
lac	B-protein
-	I-protein
1	I-protein
has	O
also	O
been	O
shown	O
to	O
be	O
transcriptionally	O
activated	O
by	O
low	O
concentrations	O
of	O
the	O
translational	O
inhibitor	O
cycloheximide	O
(	O
CHX	O
)	O
and	O
by	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
.	O

Using	O
sequence	O
information	O
from	O
human	B-protein
BMAL1	I-protein
(	O
hBMAL1	B-protein
)	O
cDNAs	O
previously	O
reported	O
by	O
our	O
laboratory	O
,	O
we	O
have	O
isolated	O
and	O
characterized	O
cDNAs	O
encoding	O
three	O
splice	O
variants	O
of	O
the	O
mouse	B-protein
BMAL1	I-protein
(	O
mBMAL1	B-protein
)	O
gene	O
.	O

In	O
support	O
of	O
a	O
role	O
at	O
the	O
spindle	O
,	O
two	O
-	O
hybrid	O
library	O
screening	O
with	O
HEF1	B-protein
identifies	O
the	O
human	O
homolog	O
of	O
the	O
G2	B-protein
/	I-protein
M	I-protein
spindle	I-protein
-	I-protein
regulatory	I-protein
protein	I-protein
Dim1p	I-protein
as	O
a	O
specific	O
interactor	O
with	O
a	O
region	O
of	O
HEF1	B-protein
encompassed	O
in	O
p55	B-protein
(	I-protein
HEF1	I-protein
)	I-protein
.	O

An	O
endogenous	O
mammalian	O
regulator	O
of	O
this	O
process	O
,	O
named	O
Usurpin	B-protein
,	O
has	O
been	O
identified	O
(	O
aliases	O
for	O
Usurpin	B-protein
include	O
CASH	B-protein
,	O
Casper	B-protein
,	O
CLARP	B-protein
,	O
FLAME	B-protein
-	I-protein
1	I-protein
,	O
FLIP	B-protein
,	O
I	B-protein
-	I-protein
FLICE	I-protein
and	O
MRIT	B-protein
)	O
.	O

In	O
a	O
similar	O
fashion	O
to	O
adipose	O
stromal	O
cells	O
,	O
serum	O
potentiated	O
the	O
response	O
to	O
dexamethasone	O
but	O
had	O
no	O
effect	O
on	O
phorbol	O
ester	O
-	O
stimulated	O
activity	O
.	O

AGO1	B-protein
is	O
similar	O
to	O
QDE	B-protein
-	I-protein
2	I-protein
required	O
for	O
quelling	O
and	O
RDE	B-protein
-	I-protein
1	I-protein
required	O
for	O
RNAi	O
.	O

METHODS	O
:	O
Fifty	O
-	O
eight	O
patients	O
who	O
underwent	O
a	O
curative	O
hepatic	O
resection	O
for	O
HCC	O
and	O
whose	O
preoperative	O
AFP	B-protein
levels	O
were	O
>	O
100	O
ng	O
/	O
ml	O
,	O
were	O
selected	O
for	O
this	O
study	O
.	O

Significant	O
alterations	O
in	O
the	O
vasectomized	O
rats	O
from	O
sham	O
rats	O
included	O
:	O
testicular	O
and	O
epididymal	O
hypertrophy	O
,	O
formation	O
of	O
pathologic	O
vas	O
deferens	O
granulomas	O
,	O
decreased	O
total	O
serum	O
protein	O
,	O
lowered	O
alpha	B-protein
-	I-protein
globulin	I-protein
levels	O
as	O
shown	O
by	O
serum	O
electrophoresis	O
,	O
and	O
increased	O
sperm	O
agglutinin	O
antibody	O
titers	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
hormone	O
receptor	O
status	O
between	O
the	O
cases	O
without	O
lymph	O
node	O
metastases	O
and	O
with	O
lymph	O
node	O
metastases	O
,	O
'	O
clandestine	O
'	O
or	O
macrometastases	O
.	O

Comparative	O
mapping	O
of	O
the	O
Brassica	B-protein
S	I-protein
locus	I-protein
region	I-protein
and	O
its	O
homeolog	O
in	O
Arabidopsis	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
the	O
expression	O
of	O
individual	O
members	O
of	O
one	O
subfamily	O
of	O
KRAB	B-protein
zinc	I-protein
finger	I-protein
genes	I-protein
is	O
restricted	O
to	O
specific	O
hematopoietic	O
cell	O
lineages	O
.	O

Two	O
of	O
the	O
ORFs	O
are	O
completely	O
internal	O
to	O
longer	O
ones	O
and	O
a	O
third	O
is	O
partially	O
embedded	O
in	O
G2850	B-protein
.	O

Fast	O
goal	O
-	O
directed	O
voluntary	O
movements	O
of	O
the	O
human	O
upper	O
extremity	O
are	O
known	O
to	O
be	O
associated	O
with	O
three	O
distinct	O
bursts	O
of	O
EMG	O
activity	O
in	O
antagonistic	O
muscles	O
.	O

Nevertheless	O
,	O
antibodies	O
directed	O
against	O
an	O
epitope	O
-	O
tagged	O
version	O
of	O
Prp42p	B-protein
specifically	O
precipitate	O
U1	B-protein
snRNA	I-protein
from	O
yeast	O
extracts	O
.	O

They	O
lack	O
a	O
predicted	O
single	O
stranded	O
(	O
ss	O
)	O
DNA	O
binding	O
motif	O
that	O
is	O
unique	O
the	O
large	O
terminase	B-protein
proteins	I-protein
in	O
T4	B-protein
gp17	I-protein
,	O
and	O
that	O
has	O
been	O
implicated	O
in	O
recognizing	O
ssDNA	O
regions	O
in	O
replicating	O
and	O
recombining	O
T4DNA	O
destined	O
to	O
be	O
packaged	O
.	O

The	O
Tullio	O
phenomenon	O
,	O
fistula	O
test	O
,	O
and	O
Hennebert	O
'	O
s	O
sign	O
:	O
clinical	O
significance	O
.	O

The	O
ORF3	O
mutant	O
produced	O
reduced	O
levels	O
of	O
tabtoxin	B-protein
,	O
indicating	O
that	O
ORF3	O
may	O
have	O
a	O
role	O
in	O
T	B-protein
beta	I-protein
L	I-protein
biosynthesis	O
.	O

Interferon	B-protein
stimulated	I-protein
gene	I-protein
factor	I-protein
3	I-protein
(	O
ISGF3	B-protein
)	O
is	O
a	O
trimeric	O
transcription	O
factor	O
activated	O
on	O
treatment	O
of	O
cells	O
with	O
interferon	B-protein
-	I-protein
alpha	I-protein
and	I-protein
beta	I-protein
(	O
type	B-protein
I	I-protein
IFNs	I-protein
)	O
.	O

Although	O
heart	O
rate	O
and	O
diastolic	O
pressure	O
rose	O
in	O
some	O
degree	O
1	O
min	O
after	O
intubation	O
,	O
free	O
and	O
total	O
CA	O
concentrations	O
did	O
not	O
increase	O
during	O
study	O
period	O
.	O

Biol	O
.	O

Activation	O
of	O
c	B-protein
-	I-protein
fos	I-protein
gene	I-protein
expression	O
by	O
a	O
kinase	O
-	O
deficient	O
epidermal	B-protein
growth	I-protein
factor	I-protein
receptor	I-protein
.	O

The	O
effects	O
of	O
procedural	O
variations	O
on	O
lateralized	O
Stroop	O
effects	O
.	O

Host	O
lipids	O
in	O
tuberculous	O
infection	O
.	O

However	O
,	O
in	O
those	O
studies	O
due	O
to	O
the	O
presence	O
of	O
thiol	O
agents	O
in	O
the	O
PKC	B-protein
preparations	O
,	O
the	O
sensitive	O
reaction	O
of	O
BPO	O
with	O
redox	O
-	O
active	O
cysteine	O
residues	O
in	O
PKC	B-protein
was	O
not	O
observed	O
.	O

Increasing	O
the	O
cut	O
-	O
off	O
point	O
to	O
3	O
positive	O
responses	O
decreased	O
the	O
sensitivity	O
to	O
81	O
%	O
and	O
increased	O
the	O
specificity	O
to	O
94	O
%	O
.	O

The	O
3	O
'	O
stem	O
-	O
loop	O
is	O
highly	O
divergent	O
in	O
structure	O
among	O
species	O
and	O
lies	O
immediately	O
upstream	O
of	O
the	O
binding	O
site	O
for	O
Sm	B-protein
proteins	I-protein
.	O

The	O
C	O
-	O
terminal	O
domains	O
(	O
CTDs	O
)	O
of	O
the	O
RPase	B-protein
beta	I-protein
subunit	I-protein
and	O
DNA	B-protein
primase	I-protein
(	O
dnaG	B-protein
protein	I-protein
)	O
were	O
not	O
only	O
strongly	O
homologous	O
to	O
each	O
other	O
but	O
also	O
considerably	O
homologous	O
to	O
the	O
RPase	B-protein
alpha	I-protein
,	O
suggesting	O
that	O
an	O
alpha	O
subunit	O
-	O
like	O
enzyme	O
must	O
have	O
been	O
commonly	O
ancestral	O
to	O
core	B-protein
enzyme	I-protein
subunits	I-protein
and	O
primase	B-protein
.	O

In	O
these	O
cases	O
,	O
asbestos	O
or	O
erionite	O
-	O
tissue	O
burden	O
followed	O
by	O
fibrosis	O
was	O
frequently	O
observed	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
amphotericin	O
B	O
oral	O
suspension	O
(	O
ABOS	O
)	O
for	O
the	O
treatment	O
of	O
fluconazole	O
refractory	O
oral	O
candidiasis	O
in	O
persons	O
with	O
HIV	O
infection	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
evaluate	O
how	O
couplers	O
and	O
their	O
placement	O
affect	O
the	O
ALGO2	O
click	O
spectral	O
properties	O
.	O

III	O
.	O

The	O
arrangement	O
of	O
these	O
cutoff	O
-	O
levels	O
leads	O
to	O
a	O
sensitivity	O
of	O
85	O
%	O
at	O
a	O
specificity	O
of	O
55	O
%	O
for	O
Protein	B-protein
S100	I-protein
when	O
measured	O
by	O
RIA	O
,	O
and	O
to	O
a	O
sensitivity	O
of	O
77	O
%	O
at	O
a	O
specificity	O
of	O
61	O
%	O
when	O
measured	O
by	O
LIA	O
.	O

In	O
memory	O
of	O
Magdelaine	O
Comtesse	O
.	O

The	O
study	O
made	O
to	O
define	O
the	O
ability	O
of	O
lipid	B-protein
A	I-protein
monoclonal	I-protein
antibodies	I-protein
to	O
correct	O
hemodynamic	O
disturbances	O
due	O
to	O
endotoxemia	O
in	O
dog	O
experiments	O
showed	O
the	O
efficacy	O
of	O
the	O
antibodies	O
administration	O
.	O

Data	O
on	O
prosthesis	O
use	O
are	O
encouraging	O
,	O
although	O
a	O
follow	O
-	O
up	O
study	O
is	O
required	O
to	O
determine	O
the	O
functional	O
outcome	O
for	O
prosthesis	O
users	O
and	O
non	O
-	O
users	O
.	O

HBx	B-protein
strongly	O
elevates	O
levels	O
of	O
GTP	O
-	O
bound	O
Ras	B-protein
,	O
activated	O
and	O
phosphorylated	O
Raf	B-protein
,	O
and	O
tyrosine	O
-	O
phosphorylated	O
and	O
activated	O
MAP	B-protein
kinase	I-protein
.	O

These	O
studies	O
indicate	O
that	O
in	O
vitro	O
and	O
in	O
vivo	O
electrical	O
stimulation	O
generate	O
reactive	O
oxygen	O
species	O
and	O
affect	O
SOD	B-protein
activity	O
,	O
which	O
in	O
part	O
are	O
responsible	O
for	O
decreased	O
sperm	O
motion	O
and	O
viability	O
.	O

Finally	O
,	O
the	O
mechanism	O
of	O
ASK1	B-protein
activation	O
involves	O
,	O
in	O
part	O
,	O
homo	O
-	O
oligomerization	O
.	O

A	O
third	O
one	O
is	O
homologous	O
in	O
half	O
of	O
its	O
length	O
to	O
the	O
prokaryotic	B-protein
hydantoinase	I-protein
HyuA	I-protein
and	O
in	O
the	O
other	O
half	O
to	O
hydatoinase	B-protein
HyuB	I-protein
.	O

One	O
of	O
the	O
most	O
relevant	O
aspects	O
in	O
achieving	O
the	O
consistent	O
survival	O
of	O
an	O
animal	O
undergoing	O
the	O
experimental	O
implantation	O
of	O
a	O
total	O
artificial	O
heart	O
is	O
obviously	O
related	O
to	O
the	O
correct	O
anatomic	O
placement	O
of	O
prosthetic	O
ventricles	O
inside	O
the	O
chest	O
.	O

In	O
addition	O
serum	B-protein
IgE	I-protein
concentrations	O
were	O
not	O
statistically	O
different	O
.	O

H	O
-	O
7	O
,	O
which	O
specifically	O
,	O
although	O
weakly	O
,	O
inhibited	O
PKC	B-protein
activation	O
,	O
had	O
no	O
effect	O
on	O
tyrosine	O
phosphorylation	O
and	O
PtdIns	O
(	O
3	O
,	O
4	O
)	O
P2	O
production	O
.	O

CONCLUSION	O
:	O
Extrusion	O
cooking	O
is	O
effective	O
for	O
the	O
inactivation	O
of	O
DON	O
but	O
is	O
of	O
limited	O
value	O
for	O
AFB1	O
,	O
even	O
if	O
metabisulphite	O
is	O
added	O
.	O

Efforts	O
were	O
made	O
to	O
determine	O
the	O
amount	O
of	O
time	O
required	O
for	O
kidney	O
lesions	O
to	O
develop	O
and	O
,	O
if	O
possible	O
,	O
to	O
delineate	O
the	O
potential	O
site	O
of	O
action	O
of	O
PBB	O
.	O

In	O
summary	O
,	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
activation	O
of	O
NO	O
production	O
mediates	O
apoptosis	O
after	O
TG	O
exposure	O
in	O
JT	O
/	O
Neo	O
cells	O
.	O

Saccharomyces	O
cerevisiae	O
contains	O
four	O
known	O
acyl	B-protein
-	I-protein
CoA	I-protein
synthetases	I-protein
(	O
fatty	B-protein
acid	I-protein
activation	I-protein
proteins	I-protein
,	O
Faaps	B-protein
)	O
.	O

Specific	O
requirements	O
for	O
branched	O
-	O
chain	O
amino	O
acids	O
,	O
glutamine	O
,	O
and	O
arginine	O
are	O
evaluated	O
.	O

The	O
corn	O
and	O
mineral	O
oil	O
emulsions	O
were	O
almost	O
as	O
effective	O
as	O
milk	O
but	O
less	O
effective	O
than	O
sucrose	O
(	O
0	O
.	O
3M	O
)	O
in	O
stimulating	O
ingestion	O
.	O

In	O
both	O
shoots	O
and	O
roots	O
,	O
GT	B-protein
-	I-protein
2	I-protein
protein	I-protein
is	O
undetectable	O
in	O
meristematic	O
tissue	O
but	O
becomes	O
expressed	O
at	O
later	O
stages	O
of	O
cellular	O
development	O
,	O
consistent	O
with	O
a	O
role	O
in	O
contributing	O
to	O
the	O
pattern	O
of	O
phytochrome	B-protein
A	I-protein
gene	I-protein
expression	O
.	O

A	O
cDNA	O
library	O
of	O
tumour	O
cells	O
was	O
screened	O
with	O
an	O
interleukin	B-protein
2	I-protein
gene	O
-	O
specific	O
probe	O
.	O

An	O
element	O
within	O
the	O
5	O
'	O
untranslated	O
region	O
of	O
human	B-protein
Hsp70	I-protein
mRNA	I-protein
which	O
acts	O
as	O
a	O
general	O
enhancer	O
of	O
mRNA	O
translation	O
.	O

The	O
ARX2	O
procedure	O
models	O
the	O
recorded	O
signal	O
as	O
the	O
sum	O
of	O
three	O
signals	O
:	O
(	O
a	O
)	O
the	O
background	O
EEG	O
activity	O
,	O
modelled	O
as	O
an	O
autoregressive	O
process	O
driven	O
by	O
a	O
white	O
noise	O
;	O
(	O
b	O
)	O
a	O
filtered	O
version	O
of	O
a	O
reference	O
signal	O
carrying	O
the	O
average	O
information	O
contained	O
in	O
each	O
sweep	O
;	O
(	O
c	O
)	O
a	O
signal	O
due	O
to	O
the	O
ocular	O
artefact	O
propagation	O
.	O

Diagnosis	O
and	O
treatment	O
of	O
insulin	O
-	O
secreting	O
tumours	O
.	O

In	O
contrast	O
,	O
recent	O
evidence	O
suggests	O
that	O
children	O
with	O
sickle	B-protein
-	I-protein
hemoglobin	I-protein
C	I-protein
disease	O
do	O
not	O
develop	O
functional	O
asplenia	O
before	O
3	O
to	O
4	O
years	O
of	O
age	O
and	O
thus	O
may	O
not	O
benefit	O
from	O
penicillin	O
prophylaxis	O
.	O

Contraction	O
of	O
the	O
tracheal	O
muscle	O
and	O
the	O
activity	O
of	O
stretch	O
receptors	O
in	O
the	O
trachea	O
.	O

Imaging	O
of	O
D2	B-protein
dopamine	I-protein
receptor	I-protein
.	O

Modification	O
of	O
enteral	O
resorption	O
by	O
cytostatic	O
therapy	O
.	O

The	O
production	O
of	O
ceramide	O
is	O
emerging	O
as	O
a	O
fixture	O
of	O
programmed	O
cell	O
death	O
.	O

Foveating	O
saccades	O
,	O
therefore	O
,	O
can	O
be	O
distinguished	O
from	O
other	O
FEMs	O
on	O
the	O
basis	O
of	O
speed	O
.	O

RESULTS	O
:	O
In	O
the	O
AGA	O
group	O
,	O
both	O
fetal	O
and	O
maternal	O
serum	O
prolactin	B-protein
concentration	O
increased	O
significantly	O
with	O
gestation	O
(	O
P	O
<	O
0	O
.	O
001	O
and	O
P	O
<	O
0	O
.	O
01	O
,	O
respectively	O
)	O
.	O

Colorimetric	O
determination	O
of	O
urinary	O
iron	O
,	O
chelated	O
with	O
deferoxamine	O
B	O
,	O
using	O
a	O
single	O
reagent	O
.	O

The	O
maps	O
of	O
Case	O
2	O
showed	O
that	O
a	O
maximum	O
first	O
appeared	O
on	O
the	O
upper	O
right	O
back	O
and	O
then	O
moved	O
down	O
the	O
right	O
side	O
of	O
the	O
posterior	O
thorax	O
.	O

Assembly	O
of	O
a	O
complex	O
between	O
FAK	B-protein
and	O
Src	B-protein
kinases	I-protein
may	O
serve	O
to	O
regulate	O
the	O
subcellular	O
localization	O
and	O
the	O
enzymatic	O
activity	O
of	O
members	O
of	O
the	O
Src	B-protein
family	I-protein
of	O
kinases	B-protein
.	O

Naphthalene	O
and	O
paradichlorobenzene	O
in	O
clinical	O
toxicology	O
.	O

Role	O
of	O
the	O
transcription	O
start	O
site	O
core	O
region	O
and	O
transcription	B-protein
factor	I-protein
YY1	I-protein
in	O
Rous	B-protein
sarcoma	I-protein
virus	I-protein
long	I-protein
terminal	I-protein
repeat	I-protein
promoter	I-protein
activity	O
.	O

These	O
overall	O
results	O
indicate	O
that	O
there	O
is	O
generally	O
one	O
PERV	O
copy	O
per	O
integration	O
site	O
.	O

Until	O
now	O
,	O
each	O
of	O
these	O
loci	O
was	O
considered	O
to	O
contain	O
three	O
genes	O
(	O
for	O
regulator	B-protein
,	O
permease	B-protein
and	O
alpha	B-protein
-	I-protein
glucosidase	I-protein
)	O
,	O
but	O
a	O
fourth	O
gene	O
,	O
presumably	O
an	O
extra	O
alpha	B-protein
-	I-protein
glucosidase	I-protein
gene	I-protein
,	O
was	O
found	O
at	O
MAL1	B-protein
adjacent	O
to	O
the	O
usual	O
cluster	O
of	O
three	O
genes	O
.	O

In	O
patients	O
with	O
type	O
II	O
tumors	O
,	O
the	O
pattern	O
of	O
lymphatic	O
spread	O
was	O
primarily	O
directed	O
toward	O
the	O
paracardial	O
,	O
lesser	O
curvature	O
,	O
and	O
left	O
gastric	O
artery	O
nodes	O
;	O
esophagectomy	O
offered	O
no	O
survival	O
benefit	O
over	O
extended	O
gastrectomy	O
in	O
these	O
patients	O
.	O

INF	B-protein
-	I-protein
alpha	I-protein
therapy	O
has	O
been	O
a	O
major	O
development	O
in	O
the	O
treatment	O
of	O
CML	O
.	O

The	O
cAMP	O
-	O
dependent	O
mitogenic	O
pathway	O
is	O
unique	O
as	O
it	O
is	O
independent	O
of	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
activation	O
and	O
differs	O
from	O
growth	O
factor	O
-	O
dependent	O
pathways	O
at	O
the	O
level	O
of	O
the	O
expression	O
of	O
several	O
protooncogenes	O
/	O
transcription	O
factors	O
.	O

If	O
NCR	O
-	O
sensitive	O
gene	O
expression	O
occurs	O
exclusively	O
by	O
this	O
pathway	O
,	O
as	O
has	O
been	O
thought	O
to	O
be	O
the	O
case	O
,	O
then	O
the	O
NCR	O
sensitivity	O
of	O
a	O
gene	O
'	O
s	O
expression	O
should	O
be	O
abolished	O
by	O
a	O
ure2	B-protein
delta	I-protein
mutation	I-protein
.	O

These	O
data	O
show	O
that	O
heterologous	O
virus	O
RNAs	O
(	O
BSMV	O
)	O
can	O
serve	O
as	O
primer	O
donors	O
for	O
MStV	O
mRNA	O
capped	O
RNA	O
-	O
primed	O
transcription	O
in	O
doubly	O
infected	O
plants	O
.	O

With	O
certain	O
exceptions	O
the	O
method	O
was	O
considered	O
suitable	O
in	O
the	O
routine	O
intravenous	O
cholangiography	O
.	O

Four	O
possible	O
isoforms	O
(	O
hGli2	B-protein
alpha	I-protein
,	I-protein
beta	I-protein
,	I-protein
gamma	I-protein
,	I-protein
and	I-protein
delta	I-protein
)	O
are	O
formed	O
by	O
combinations	O
of	O
two	O
independent	O
alternative	O
splicings	O
,	O
and	O
all	O
the	O
isoforms	O
could	O
bind	O
to	O
a	O
DNA	O
motif	O
,	O
TRE2S	B-protein
,	O
in	O
the	O
LTR	O
.	O

When	O
the	O
E1A	B-protein
N	I-protein
-	I-protein
terminus	I-protein
is	O
used	O
as	O
a	O
competitor	O
in	O
squelshing	O
experiments	O
it	O
abolishes	O
CBP	O
-	O
induced	O
activation	O
of	O
E2F1	B-protein
/	I-protein
DP1	I-protein
,	O
whereas	O
an	O
E1A	B-protein
mutant	I-protein
lacking	O
CBP	B-protein
binding	O
ability	O
fails	O
to	O
do	O
so	O
.	O

Specialized	O
actin	B-protein
tails	O
that	O
propel	O
IEV	O
particles	O
to	O
the	O
periphery	O
and	O
virus	O
-	O
tipped	O
microvilli	O
(	O
both	O
common	O
in	O
wild	O
-	O
type	O
-	O
infected	O
cells	O
)	O
were	O
absent	O
in	O
cells	O
infected	O
with	O
vA33delta	O
.	O

(	O
1996a	O
)	O
Biochemistry	O
35	O
,	O
1589	O
-	O
1598	O
]	O
.	O

TGF	B-protein
beta	I-protein
1	I-protein
expression	O
is	O
largely	O
governed	O
by	O
three	O
AP	B-protein
-	I-protein
1	I-protein
binding	I-protein
sites	I-protein
located	O
in	O
two	O
different	O
promoters	O
of	O
this	O
gene	O
.	O

The	O
pyramidal	O
tract	O
and	O
Mesencephalic	O
Reticular	O
Formation	O
(	O
MRF	O
)	O
were	O
stimulated	O
before	O
and	O
after	O
the	O
transection	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
EF	O
between	O
the	O
two	O
studies	O
,	O
both	O
at	O
rest	O
(	O
56	O
.	O
0	O
+	O
/	O
-	O
13	O
.	O
8	O
%	O
vs	O
58	O
.	O
2	O
+	O
/	O
-	O
11	O
.	O
7	O
%	O
,	O
p	O
=	O
NS	O
)	O
and	O
with	O
exercise	O
(	O
51	O
.	O
1	O
+	O
/	O
-	O
17	O
.	O
6	O
%	O
vs	O
54	O
.	O
3	O
+	O
/	O
-	O
17	O
.	O
6	O
%	O
,	O
p	O
=	O
NS	O
)	O
and	O
a	O
highly	O
significant	O
correlation	O
was	O
shown	O
between	O
the	O
two	O
groups	O
of	O
values	O
(	O
rest	O
r	O
=	O
0	O
.	O
90	O
,	O
exercise	O
r	O
=	O
0	O
.	O
93	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Serum	O
levels	O
of	O
testosterone	O
also	O
showed	O
no	O
significant	O
changes	O
by	O
exposure	O
to	O
p	O
,	O
p	O
'	O
-	O
DDE	O
under	O
the	O
conditions	O
of	O
this	O
study	O
.	O

CONCLUSIONS	O
:	O
ChromaFlo	O
-	O
enhanced	O
IVUS	O
demonstrates	O
colorized	O
blood	O
flow	O
inside	O
the	O
vessel	O
lumen	O
,	O
which	O
is	O
helpful	O
in	O
distinguishing	O
echolucent	O
disease	O
from	O
luminal	O
blood	O
flow	O
and	O
can	O
also	O
be	O
used	O
to	O
perform	O
peripheral	O
interventions	O
in	O
patients	O
with	O
renal	O
failure	O
or	O
allergy	O
,	O
avoiding	O
the	O
use	O
of	O
contrast	O
media	O
.	O

Disruption	O
of	O
microtubules	O
did	O
not	O
affect	O
the	O
fidelity	O
or	O
kinetics	O
of	O
vacuolar	O
protein	O
sorting	O
,	O
indicating	O
that	O
Vps1p	B-protein
function	O
is	O
not	O
dependent	O
on	O
microtubules	O
.	O

Transcription	O
start	O
sites	O
of	O
the	O
plastid	O
ACCase	B-protein
genes	I-protein
were	O
estimated	O
from	O
the	O
longest	O
cDNA	O
clones	O
obtained	O
by	O
5	O
'	O
-	O
RACE	O
(	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
)	O
.	O

MKK3	B-protein
autophosphorylation	O
and	O
activation	O
of	O
p38	B-protein
was	O
also	O
observed	O
following	O
coexpression	O
of	O
MKK3	B-protein
with	O
MEKK3	B-protein
,	O
but	O
not	O
with	O
MEKK2	B-protein
.	O

We	O
investigate	O
the	O
reaction	O
kinetics	O
of	O
small	O
spherical	O
particles	O
with	O
inertia	O
,	O
obeying	O
coalescence	O
type	O
of	O
reaction	O
,	O
B	O
+	O
B	O
-	O
-	O
>	O
B	O
,	O
and	O
being	O
advected	O
by	O
hydrodynamical	O
flows	O
with	O
time	O
-	O
periodic	O
forcing	O
.	O

These	O
striations	O
were	O
caused	O
by	O
contact	O
between	O
the	O
sharp	O
edge	O
of	O
the	O
upper	O
canine	O
and	O
the	O
P3	O
during	O
honing	O
(	O
canine	O
/	O
premolar	O
complex	O
)	O
.	O

At	O
the	O
very	O
high	O
dose	O
levels	O
used	O
,	O
sodium	O
saccharin	O
and	O
sodium	O
cyclamate	O
were	O
weak	O
solitary	O
carcinogens	O
producing	O
4	O
/	O
253	O
and	O
3	O
/	O
228	O
bladder	O
tumours	O
respectively	O
,	O
and	O
the	O
first	O
of	O
these	O
tumours	O
did	O
not	O
appear	O
for	O
more	O
than	O
80	O
weeks	O
.	O

Our	O
analysis	O
of	O
nonsense	O
mutations	O
indicates	O
that	O
the	O
C	O
terminus	O
of	O
eIF2Bepsilon	B-protein
(	I-protein
residues	I-protein
518	I-protein
to	I-protein
712	I-protein
)	I-protein
is	O
required	O
for	O
both	O
catalytic	O
activity	O
and	O
interaction	O
with	O
eIF2	B-protein
.	O

While	O
these	O
results	O
are	O
consistent	O
with	O
previously	O
reported	O
effects	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
on	O
nucleotide	O
binding	O
,	O
they	O
also	O
demonstrate	O
that	O
interactions	O
with	O
the	O
N	O
-	O
terminal	O
domains	O
are	O
necessary	O
to	O
inhibit	O
proton	O
transport	O
.	O

In	O
contrast	O
,	O
the	O
loss	O
of	O
MAD2	B-protein
staining	O
in	O
meiosis	O
was	O
not	O
correlated	O
with	O
initial	O
microtubule	O
attachment	O
but	O
was	O
correlated	O
with	O
a	O
measure	O
of	O
tension	O
:	O
the	O
distance	O
between	O
homologous	O
or	O
sister	O
kinetochores	O
(	O
in	O
meiosis	O
I	O
and	O
II	O
,	O
respectively	O
)	O
.	O

Furthermore	O
,	O
Rac1	B-protein
activation	O
of	O
JNK	B-protein
or	O
SRF	B-protein
,	O
or	O
induction	O
of	O
lamellipodia	O
,	O
was	O
neither	O
necessary	O
nor	O
sufficient	O
for	O
Rac1	B-protein
transforming	O
activity	O
.	O

It	O
is	O
suggested	O
that	O
the	O
observed	O
clinical	O
phenomena	O
in	O
response	O
to	O
morphine	O
can	O
be	O
explained	O
by	O
differences	O
in	O
expression	O
and	O
sensitivity	O
of	O
some	O
opioid	B-protein
receptor	I-protein
subtypes	O
in	O
migraine	O
.	O

These	O
protective	O
influences	O
were	O
observed	O
throughout	O
the	O
range	O
of	O
filling	O
pressures	O
measured	O
,	O
from	O
0	O
to	O
30	O
mmHg	O
.	O

The	O
levels	O
of	O
galactosyltransferase	B-protein
activity	O
in	O
sera	O
from	O
normal	O
children	O
and	O
patients	O
with	O
cystic	O
fibrosis	O
.	O

SSF	O
experiments	O
were	O
carried	O
out	O
in	O
bench	O
-	O
scale	O
bioreactors	O
(	O
equipped	O
with	O
CO2	O
and	O
volatile	O
organic	O
traps	O
)	O
containing	O
a	O
mixture	O
of	O
lignocellulosic	O
materials	O
and	O
a	O
radiolabeled	O
pesticide	O
.	O

Since	O
CENP	B-protein
-	I-protein
B	I-protein
gene	I-protein
is	O
conserved	O
in	O
mammalian	O
species	O
and	O
CENP	B-protein
-	I-protein
B	I-protein
boxes	I-protein
are	O
found	O
also	O
in	O
mouse	O
centromere	O
satellite	O
DNA	O
(	O
minor	O
satellite	O
)	O
,	O
this	O
sequence	O
-	O
specific	O
DNA	O
-	O
protein	O
interaction	O
may	O
be	O
important	O
for	O
some	O
kind	O
of	O
common	O
centromere	O
function	O
.	O

The	O
paper	O
is	O
concerned	O
with	O
the	O
data	O
on	O
change	O
in	O
the	O
blood	O
level	O
of	O
ACTH	B-protein
,	O
STH	B-protein
,	I-protein
TSH	I-protein
,	O
cortisol	O
,	O
T3	O
,	O
insulin	B-protein
,	O
C	B-protein
-	I-protein
peptide	I-protein
during	O
a	O
25	O
-	O
minute	O
session	O
of	O
respiration	O
using	O
a	O
gaseous	O
hypoxic	O
mixture	O
with	O
10	O
%	O
oxygen	O
(	O
GHM	O
-	O
10	O
)	O
.	O

Testing	O
blood	O
donors	O
for	O
non	O
-	O
A	O
,	O
non	O
-	O
B	O
hepatitis	O
:	O
irrational	O
,	O
perhaps	O
,	O
but	O
inescapable	O
.	O

Raes	O
,	O
P	O
.	O

Blocked	O
shift	O
/	O
supershift	O
analysis	O
indicates	O
that	O
Fos	B-protein
family	I-protein
member	O
proteins	O
especially	O
Fra	B-protein
-	I-protein
1	I-protein
and	O
Fra	B-protein
-	I-protein
2	I-protein
are	O
related	O
to	O
progression	O
and	O
no	O
changes	O
found	O
in	O
the	O
Jun	B-protein
family	I-protein
member	O
proteins	O
although	O
they	O
are	O
present	O
in	O
the	O
AP	B-protein
-	I-protein
1	I-protein
/	I-protein
DNA	I-protein
binding	I-protein
complex	I-protein
.	O

To	O
investigate	O
the	O
regulation	O
of	O
Spec	B-protein
gene	I-protein
activity	O
,	O
the	O
region	O
around	O
the	O
Spec1	B-protein
transcriptional	I-protein
initiation	I-protein
site	I-protein
was	O
analyzed	O
for	O
sites	O
of	O
protein	O
-	O
DNA	O
interaction	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
Sp1	B-protein
and	O
Sp3	B-protein
as	O
major	O
factors	O
binding	O
to	O
the	O
Sp1	B-protein
sites	I-protein
of	O
the	O
p21	B-protein
/	I-protein
WAF1	I-protein
/	I-protein
Cip1	I-protein
promoter	I-protein
in	O
MG63	O
cells	O
through	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
showed	O
that	O
TSA	O
treatment	O
did	O
not	O
change	O
their	O
binding	O
activities	O
.	O

Experience	O
with	O
the	O
restoration	O
of	O
agglutination	O
properties	O
of	O
non	O
-	O
agglutinating	O
dysenterial	O
cultures	O
with	O
the	O
use	O
of	O
Rzhaninov	O
'	O
s	O
method	O
.	O

Vitiligo	O
in	O
diabetes	O
mellitus	O
.	O

Therefore	O
,	O
we	O
studied	O
ninety	O
coagulopathic	O
patients	O
with	O
the	O
aim	O
of	O
determining	O
the	O
prevalence	O
of	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
antibodies	O
using	O
the	O
ELISA	O
and	O
RIBA	O
methods	O
.	O

Direct	O
superoxide	O
scavenging	O
activity	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
:	O
determination	O
by	O
electron	O
spin	O
resonance	O
using	O
the	O
spin	O
trap	O
method	O
.	O

Low	O
affinity	O
binding	O
of	O
Rab6A	B-protein
-	I-protein
GTP	I-protein
was	O
also	O
observed	O
(	O
K	O
(	O
d	O
)	O
=	O
16	O
@	O
mgr	O
;	O
m	O
)	O
,	O
whereas	O
Rab1B	B-protein
,	I-protein
-	I-protein
5	I-protein
,	I-protein
-	I-protein
7	I-protein
,	I-protein
-	I-protein
8	I-protein
,	I-protein
or	I-protein
-	I-protein
11A	I-protein
did	O
not	O
bind	O
.	O

CM	B-protein
-	I-protein
ACO3	I-protein
is	O
expressed	O
in	O
flowers	O
and	O
is	O
not	O
induced	O
by	O
any	O
of	O
the	O
stimuli	O
tested	O
.	O

PCR	O
analysis	O
indicates	O
that	O
this	O
new	O
beta	B-protein
-	I-protein
adducin	I-protein
isoform	I-protein
is	O
expressed	O
in	O
fetal	O
brain	O
and	O
liver	O
,	O
bone	O
marrow	O
,	O
and	O
NT	O
-	O
2	O
(	O
neuroepithelial	O
)	O
cells	O
,	O
but	O
is	O
not	O
detected	O
in	O
several	O
other	O
tissues	O
.	O

Both	O
PPC	O
-	O
1	O
and	O
ALVA	O
-	O
31	O
cells	O
display	O
tumorigenesis	O
and	O
invasiveness	O
in	O
nude	O
mice	O
,	O
whereas	O
LNCap	O
cells	O
exhibit	O
a	O
less	O
malignant	O
phenotype	O
,	O
suggesting	O
a	O
correlation	O
between	O
CD44	B-protein
variant	I-protein
(	O
CD44v	B-protein
)	O
expression	O
and	O
aggressive	O
prostate	O
tumor	O
behavior	O
.	O

The	O
mMIWC1	B-protein
promoter	I-protein
was	O
identified	O
and	O
contained	O
TATA	O
,	O
CAAT	O
,	O
GATA	B-protein
,	O
and	O
AP	B-protein
-	I-protein
2	I-protein
elements	I-protein
;	O
primer	O
extension	O
revealed	O
mMIWC	B-protein
transcription	O
initiation	O
at	O
621	O
bp	O
upstream	O
from	O
the	O
mMIWC1	B-protein
translational	O
initiation	O
site	O
.	O

RESULTS	O
:	O
CK	B-protein
-	I-protein
MB	I-protein
elevation	O
was	O
detected	O
in	O
313	O
patients	O
(	O
18	O
.	O
7	O
%	O
)	O
,	O
with	O
1	O
-	O
3x	O
in	O
12	O
.	O
8	O
%	O
,	O
3	O
-	O
5x	O
in	O
3	O
.	O
5	O
%	O
and	O
>	O
5x	O
normal	O
in	O
2	O
.	O
4	O
%	O
of	O
patients	O
.	O

This	O
gene	O
joins	O
the	O
group	O
of	O
genes	O
whose	O
members	O
are	O
rapidly	O
transcribed	O
in	O
response	O
to	O
insulin	B-protein
and	O
other	O
mitogens	O
.	O

The	O
deleted	O
nucleotide	O
sequence	O
corresponded	O
to	O
sequences	O
that	O
,	O
by	O
analogy	O
to	O
the	O
organization	O
of	O
the	O
type	B-protein
I	I-protein
collagen	I-protein
genes	I-protein
,	O
should	O
be	O
precisely	O
encoded	O
by	O
exon	O
41	O
of	O
the	O
COL3A1	B-protein
gene	I-protein
.	O

A	O
highly	O
significant	O
correlation	O
was	O
found	O
between	O
the	O
presence	O
of	O
fibrinolytic	O
degradation	O
products	O
(	O
FDP	O
)	O
and	O
the	O
incidence	O
of	O
nephropathy	O
and	O
renal	O
insufficiency	O
,	O
as	O
well	O
as	O
between	O
the	O
presence	O
of	O
fibrin	B-protein
monomers	I-protein
(	O
Godal	O
'	O
s	O
ethanol	O
-	O
gelification	O
test	O
)	O
and	O
the	O
evolutive	O
signs	O
of	O
the	O
primary	O
disease	O
(	O
fever	O
,	O
accelerated	O
ESR	O
)	O
.	O

The	O
perifascicular	O
connective	O
tissue	O
sheath	O
is	O
important	O
in	O
organising	O
the	O
contraction	O
of	O
the	O
myocardium	O
by	O
preventing	O
lateral	O
spread	O
of	O
conduction	O
and	O
by	O
permitting	O
transmission	O
of	O
the	O
impulse	O
only	O
at	O
the	O
termination	O
of	O
the	O
purkinje	O
fibre	O
.	O

During	O
the	O
past	O
decade	O
,	O
different	O
types	O
of	O
endogenous	O
retroviral	O
sequences	O
have	O
been	O
defined	O
in	O
the	O
human	O
genome	O
usually	O
by	O
low	O
stringency	O
hybridization	O
employing	O
DNA	O
probes	O
of	O
evolutionary	O
conserved	O
animal	O
retrovirus	O
genes	O
.	O

Previous	O
work	O
showed	O
that	O
repA	B-protein
(	O
initiator	B-protein
protein	I-protein
)	O
expression	O
requires	O
tap	B-protein
(	O
leader	B-protein
peptide	I-protein
)	O
translation	O
.	O

In	O
addition	O
,	O
IgM	B-protein
can	O
be	O
absent	O
in	O
children	O
with	O
congenital	O
toxoplasmosis	O
or	O
subjects	O
with	O
secondary	O
reactivation	O
.	O

The	O
high	O
level	O
of	O
transformation	O
-	O
associated	O
deletions	O
in	O
the	O
human	O
YACs	O
was	O
reduced	O
over	O
10	O
-	O
fold	O
when	O
the	O
host	O
was	O
a	O
recombination	O
-	O
deficient	O
strain	O
deleted	O
for	O
the	O
RAD52	B-protein
gene	I-protein
.	O

Total	O
body	O
water	O
,	O
rhodanide	O
space	O
and	O
I	B-protein
-	I-protein
131	I-protein
-	I-protein
albumin	I-protein
space	O
under	O
the	O
acute	O
effect	O
of	O
furosemide	O
.	O

Furthermore	O
,	O
an	O
upstream	O
element	O
,	O
collagen	B-protein
element	I-protein
I	I-protein
(	I-protein
-	I-protein
370	I-protein
/	I-protein
-	I-protein
344	I-protein
)	I-protein
,	O
which	O
shares	O
homology	O
with	O
the	O
LAP	B-protein
binding	O
cis	O
-	O
element	O
of	O
the	O
albumin	B-protein
promoter	I-protein
(	O
9	O
of	O
13	O
bp	O
)	O
is	O
described	O
.	O

Cut	O
-	O
off	O
levels	O
that	O
define	O
abnormality	O
are	O
rather	O
arbitrary	O
and	O
this	O
decreases	O
the	O
specificity	O
of	O
the	O
test	O
in	O
apparently	O
healthy	O
patients	O
.	O

The	O
Oct	B-protein
-	I-protein
3	I-protein
/	I-protein
4	I-protein
gene	I-protein
product	I-protein
,	O
which	O
belongs	O
to	O
the	O
POU	B-protein
family	I-protein
of	I-protein
transcription	I-protein
factors	I-protein
,	O
is	O
a	O
good	O
candidate	O
for	O
regulating	O
initial	O
differentiation	O
decisions	O
.	O

Value	O
of	O
Normotest	O
and	O
antithrombin	B-protein
3	I-protein
in	O
the	O
assessment	O
of	O
liver	O
function	O
.	O

Orthop	O
.	O

Recombinant	B-protein
Ffh	I-protein
has	O
a	O
melting	O
point	O
of	O
tm	O
=	O
89	O
degreesC	O
.	O

In	O
a	O
similar	O
experiment	O
,	O
simultaneous	O
nitrofurazone	O
administration	O
and	O
S	O
.	O
enteritidis	O
challenge	O
resulted	O
in	O
no	O
significant	O
differences	O
in	O
S	O
.	O
enteritidis	O
isolation	O
frequency	O
.	O

Normocapnic	O
(	O
PACO2	O
=	O
40	O
mm	O
Hg	O
)	O
ventilatory	O
drive	O
increased	O
significantly	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
in	O
six	O
subjects	O
(	O
Type	O
1	O
response	O
)	O
and	O
decreased	O
substantially	O
in	O
the	O
others	O
(	O
Type	O
2	O
response	O
)	O
;	O
with	O
hypercapnia	O
,	O
the	O
changes	O
in	O
drive	O
were	O
attenuated	O
in	O
both	O
groups	O
.	O

MOP5	B-protein
contained	O
the	O
characteristic	O
PAS	B-protein
domain	I-protein
and	O
a	O
variable	O
C	O
terminus	O
;	O
it	O
is	O
possible	O
that	O
the	O
cDNA	O
contains	O
a	O
bHLH	B-protein
domain	O
,	O
but	O
the	O
entire	O
open	O
reading	O
frame	O
has	O
yet	O
to	O
be	O
completed	O
.	O

Sequence	O
analysis	O
of	O
the	O
5	O
'	O
flanking	O
region	O
revealed	O
several	O
GC	O
boxes	O
but	O
no	O
identifiable	O
TATA	O
box	O
.	O

Drug	O
use	O
in	O
trauma	O
victims	O
.	O

It	O
applies	O
Udry	O
'	O
s	O
biosocial	O
perspective	O
,	O
which	O
attempts	O
to	O
reconcile	O
the	O
biological	O
and	O
sociological	O
models	O
of	O
premarital	O
sexual	O
and	O
reproductive	O
behaviour	O
.	O

We	O
conclude	O
that	O
(	O
i	O
)	O
we	O
have	O
identified	O
several	O
candidate	O
latency	O
genes	O
of	O
murine	O
gammaHV68	O
,	O
(	O
ii	O
)	O
expression	O
of	O
genes	O
during	O
latency	O
may	O
be	O
different	O
in	O
different	O
organs	O
,	O
consistent	O
with	O
multiple	O
latency	O
programs	O
and	O
/	O
or	O
multiple	O
cellular	O
sites	O
of	O
latency	O
,	O
and	O
(	O
iii	O
)	O
regions	O
of	O
the	O
viral	O
genome	O
(	O
v	B-protein
-	I-protein
bcl	I-protein
-	I-protein
2	I-protein
gene	I-protein
,	O
v	B-protein
-	I-protein
GCR	I-protein
gene	I-protein
,	O
and	O
gene	B-protein
73	I-protein
)	O
are	O
transcribed	O
during	O
latency	O
with	O
both	O
gammaHV68	O
and	O
primate	O
gammaherpesviruses	O
.	O

Co	O
-	O
immunoprecipitation	O
and	O
DNA	O
affinity	O
chromatography	O
prove	O
that	O
Sp1	B-protein
heterodimerizes	O
with	O
ZBP	B-protein
-	I-protein
89	I-protein
when	O
bound	O
to	O
the	O
silencer	O
element	O
to	O
yield	O
a	O
DNA	O
-	O
protein	O
complex	O
whose	O
mobility	O
is	O
indistinguishable	O
from	O
that	O
displayed	O
by	O
HeLa	O
nuclear	O
extract	O
in	O
band	O
shift	O
assays	O
.	O

The	O
location	O
of	O
multiple	O
GRK2	B-protein
and	O
GRK5	B-protein
phosphoacceptor	I-protein
sites	I-protein
at	O
the	O
extreme	O
carboxyl	O
terminus	O
of	O
the	O
beta2AR	B-protein
is	O
highly	O
reminiscent	O
of	O
GRK1	O
-	O
mediated	O
phosphorylation	O
of	O
rhodopsin	B-protein
.	O

Focused	O
beams	O
of	O
classical	O
light	O
ablate	O
elements	O
of	O
the	O
cell	O
division	O
machinery	O
and	O
switch	O
the	O
beating	O
of	O
hearts	O
on	O
a	O
cellular	O
basis	O
.	O

In	O
Exp	O
.	O

This	O
last	O
region	O
contains	O
two	O
sites	O
that	O
bind	O
Ets	B-protein
-	I-protein
related	I-protein
proteins	I-protein
present	O
in	O
liver	O
nuclear	O
extracts	O
as	O
well	O
as	O
recombinant	B-protein
purified	I-protein
Ets	I-protein
-	I-protein
1	I-protein
protein	I-protein
.	O

Sequence	O
analysis	O
of	O
the	O
promoter	O
region	O
showed	O
no	O
TATA	O
box	O
but	O
identified	O
consensus	O
binding	O
motifs	O
for	O
Sp1	B-protein
,	O
CREB	B-protein
,	O
and	O
half	O
sites	O
of	O
the	O
estrogen	B-protein
receptor	I-protein
binding	I-protein
site	I-protein
.	O

Cytohesin	B-protein
-	I-protein
1	I-protein
,	O
a	O
protein	O
abundant	O
in	O
cells	O
of	O
the	O
immune	O
system	O
,	O
has	O
been	O
proposed	O
to	O
be	O
a	O
human	O
homolog	O
of	O
the	O
Saccharomyces	B-protein
cerevisiae	I-protein
Sec7	I-protein
gene	I-protein
product	I-protein
,	O
which	O
is	O
crucial	O
in	O
protein	O
transport	O
.	O

Also	O
in	O
the	O
spectrum	O
of	O
mutants	O
with	O
TGN	O
sorting	O
defects	O
are	O
isolates	O
with	O
mutations	O
in	O
the	O
following	O
:	O
RIC1	B-protein
,	O
encoding	O
a	O
product	O
originally	O
proposed	O
to	O
participate	O
in	O
ribosome	O
biogenesis	O
;	O
LUV1	B-protein
,	O
encoding	O
a	O
product	O
potentially	O
involved	O
in	O
vacuole	O
and	O
microtubule	O
organization	O
;	O
and	O
INP53	B-protein
,	O
encoding	O
a	O
synaptojanin	B-protein
-	I-protein
like	I-protein
inositol	I-protein
polyphosphate	I-protein
5	I-protein
-	I-protein
phosphatase	I-protein
.	O

Transcriptional	O
activation	O
by	O
the	O
HIV	B-protein
-	I-protein
1	I-protein
Tat	I-protein
protein	I-protein
requires	O
specific	O
residues	O
in	O
the	O
hexanucleotide	O
loop	O
and	O
trinucleotide	O
bulge	O
of	O
the	O
TAR	B-protein
RNA	I-protein
stem	O
-	O
loop	O
structure	O
found	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
leader	O
of	O
all	O
viral	O
transcripts	O
.	O

Ligand	O
-	O
independent	O
activation	O
of	O
platelet	B-protein
-	I-protein
derived	I-protein
growth	I-protein
factor	I-protein
receptor	I-protein
is	O
a	O
necessary	O
intermediate	O
in	O
lysophosphatidic	O
,	O
acid	O
-	O
stimulated	O
mitogenic	O
activity	O
in	O
L	O
cells	O
.	O

Since	O
August	O
1994	O
,	O
the	O
ENRP	O
has	O
retained	O
70	O
.	O
3	O
metric	O
tons	O
of	O
TP	O
that	O
otherwise	O
would	O
have	O
entered	O
the	O
Everglades	O
.	O

These	O
findings	O
suggest	O
a	O
functional	O
cross	O
-	O
talk	O
between	O
RB	B-protein
protein	I-protein
and	O
p21ras	B-protein
,	O
which	O
balances	O
the	O
cell	O
phenotype	O
between	O
normal	O
and	O
transformed	O
states	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
tissue	O
-	O
restricted	O
transcription	O
factors	O
including	O
PU	B-protein
.	I-protein
1	I-protein
and	O
PU	B-protein
.	I-protein
1	I-protein
interaction	I-protein
partner	I-protein
(	O
PIP	B-protein
)	O
function	O
synergistically	O
with	O
c	B-protein
-	I-protein
Fos	I-protein
plus	O
c	B-protein
-	I-protein
Jun	I-protein
to	O
stimulate	O
the	O
kappaE3	B-protein
'	I-protein
-	I-protein
enhancer	I-protein
in	O
3T3	O
cells	O
.	O

The	O
origins	O
of	O
reflected	O
light	O
changes	O
associated	O
with	O
neuronal	O
activity	O
(	O
optical	O
signals	O
)	O
were	O
investigated	O
in	O
rat	O
somatosensory	O
cortex	O
with	O
optical	O
imaging	O
,	O
microspectrophotometry	O
,	O
and	O
laser	O
-	O
Doppler	O
flowmetry	O
,	O
and	O
dynamic	O
changes	O
in	O
local	O
hemoglobin	B-protein
concentration	O
and	O
oxygenation	O
were	O
focused	O
on	O
.	O

This	O
reveals	O
a	O
new	O
test	O
for	O
short	O
saphenous	O
incompetence	O
and	O
shows	O
that	O
14	O
per	O
cent	O
of	O
varices	O
stem	O
from	O
a	O
saphenopopliteal	O
reflux	O
.	O

These	O
observations	O
,	O
together	O
with	O
the	O
occurrence	O
of	O
putative	O
4	O
'	O
-	O
phosphopantetheine	O
-	O
attachment	O
sites	O
and	O
a	O
putative	O
thioesterase	B-protein
site	I-protein
,	O
are	O
discussed	O
with	O
reference	O
to	O
the	O
reaction	O
sequence	O
leading	O
to	O
production	O
of	O
the	O
ACV	B-protein
tripeptide	I-protein
.	O

Examination	O
of	O
DNA	O
:	O
protein	O
binding	O
complexes	O
by	O
gel	O
-	O
shift	O
analysis	O
indicated	O
that	O
nuclear	O
factors	O
from	O
both	O
proliferative	O
and	O
growth	O
-	O
arrested	O
cells	O
bound	O
to	O
the	O
DNA	O
fragment	O
spanning	O
-	O
949	O
-	O
-	O
722	O
bp	O
.	O

The	O
pharmacokinetic	O
patterns	O
of	O
estradiol	O
(	O
CAS	O
50	O
-	O
28	O
-	O
2	O
)	O
and	O
of	O
estrone	O
(	O
CAS	O
53	O
-	O
16	O
-	O
7	O
)	O
were	O
investigated	O
in	O
18	O
women	O
in	O
natural	O
or	O
surgical	O
menopause	O
during	O
the	O
application	O
of	O
a	O
new	O
estradiol	O
transdermal	O
patch	O
with	O
active	O
matrix	O
and	O
without	O
absorption	O
enhancers	O
designed	O
for	O
epicutaneous	O
applications	O
of	O
7	O
days	O
(	O
hereinafter	O
called	O
`	O
`	O
patch	O
7D	O
'	O
'	O
)	O
.	O

The	O
capacity	O
to	O
repair	O
8	O
-	O
OxoG	O
has	O
been	O
measured	O
in	O
cell	O
-	O
free	O
extracts	O
of	O
wild	O
-	O
type	O
and	O
ogg1	B-protein
strains	O
using	O
a	O
34mer	O
DNA	O
fragment	O
containing	O
a	O
single	O
8	O
-	O
OxoG	O
residue	O
paired	O
with	O
a	O
cytosine	O
(	O
8	O
-	O
OxoG	O
/	O
C	O
)	O
as	O
a	O
substrate	O
.	O

The	O
maximum	O
stress	O
due	O
to	O
the	O
hygroscopic	O
examination	O
of	O
the	O
composite	O
was	O
0	O
.	O
74	O
kg	O
/	O
mm2	O
at	O
equilibrium	O
of	O
the	O
water	O
absorbed	O
of	O
the	O
composite	O
.	O

VirD2	B-protein
is	O
one	O
of	O
the	O
key	O
Agrobacterium	O
tumefaciens	O
proteins	O
involved	O
in	O
T	O
-	O
DNA	O
processing	O
and	O
transfer	O
.	O

The	O
dnaK	B-protein
operon	I-protein
of	I-protein
Bacillus	I-protein
subtilis	I-protein
is	O
heptacistronic	O
.	O

Alterations	O
in	O
DNase	B-protein
I	I-protein
reactivity	O
of	O
the	O
GC	O
-	O
response	O
element	O
region	O
suggest	O
that	O
GC	B-protein
receptor	I-protein
-	I-protein
GC	I-protein
complexes	I-protein
may	O
associate	O
,	O
in	O
a	O
transient	O
manner	O
,	O
with	O
the	O
promoter	O
in	O
the	O
actively	O
transcribing	O
control	O
state	O
.	O

Reconstitution	O
of	O
complexes	O
containing	O
p62	B-protein
and	O
the	O
src	B-protein
family	I-protein
kinase	I-protein
p59fyn	I-protein
in	O
HeLa	O
cells	O
demonstrated	O
that	O
complex	O
formation	O
resulted	O
in	O
tyrosine	O
phosphorylation	O
of	O
p62	B-protein
and	O
was	O
mediated	O
by	O
both	O
the	O
SH3	B-protein
and	O
SH2	B-protein
domains	I-protein
of	O
p59fyn	B-protein
.	O

Sixteen	O
out	O
of	O
52	O
seropositive	O
MS	O
patients	O
(	O
30	O
.	O
8	O
%	O
)	O
showed	O
intrathecal	O
synthesis	O
of	O
C	B-protein
.	I-protein
pneumoniae	I-protein
-	I-protein
specific	I-protein
IgG	I-protein
but	O
only	O
one	O
of	O
43	O
seropositive	O
controls	O
(	O
2	O
.	O
3	O
%	O
)	O
.	O

The	O
N	O
-	O
terminus	O
of	O
another	O
open	O
reading	O
frame	O
was	O
found	O
3	O
'	O
from	O
nifA	B-protein
and	O
tentatively	O
identified	O
as	O
nifB	B-protein
by	O
amino	O
acid	O
sequence	O
comparison	O
.	O

Cortical	O
dysplasias	O
,	O
genetics	O
,	O
and	O
epileptogenesis	O
.	O

In	O
addition	O
to	O
homologues	O
of	O
the	O
human	B-protein
genes	I-protein
PSMB5	I-protein
through	O
PSMB9	B-protein
,	O
two	O
new	O
genes	O
,	O
PSMB11	B-protein
and	O
PSMB12	B-protein
,	O
have	O
been	O
found	O
for	O
which	O
there	O
are	O
no	O
known	O
corresponding	O
genes	O
in	O
humans	O
.	O

We	O
conclude	O
that	O
the	O
conservation	O
of	O
nucleotides	O
154	O
to	O
156	O
is	O
likely	O
to	O
be	O
a	O
consequence	O
of	O
their	O
role	O
as	O
a	O
sequence	O
-	O
specific	O
recognition	O
element	O
for	O
the	O
SRP54	B-protein
protein	I-protein
.	O

The	O
genetic	O
basis	O
for	O
the	O
expression	O
of	O
a	O
latent	O
VH	B-protein
allotype	I-protein
in	O
the	O
rabbit	O
was	O
investigated	O
.	O

Administration	O
of	O
a	O
second	O
dose	O
of	O
vaccine	O
during	O
the	O
outbreak	O
was	O
not	O
protective	O
.	O

Clipping	O
resulted	O
in	O
a	O
serious	O
mislocalization	O
of	O
the	O
position	O
of	O
the	O
peak	O
of	O
the	O
epicortical	O
potential	O
field	O
.	O

Unexpectedly	O
,	O
Arg1	O
-	O
expressing	O
COS1	O
cells	O
showed	O
no	O
significant	O
proteinase	B-protein
activity	O
to	O
various	O
synthesized	O
substrates	O
under	O
neutral	O
or	O
acidic	O
conditions	O
in	O
this	O
study	O
.	O

In	O
the	O
duodenum	O
a	O
small	O
part	O
of	O
the	O
administered	O
dose	O
was	O
transformed	O
to	O
3H	O
-	O
alpha	O
-	O
acetyldigoxin	O
.	O

These	O
findings	O
suggest	O
one	O
potential	O
mechanism	O
for	O
direct	O
recruitment	O
of	O
distal	O
regulatory	O
regions	O
of	O
the	O
globin	B-protein
loci	I-protein
to	O
the	O
individual	O
promoters	O
.	O

GETS	B-protein
-	I-protein
1	I-protein
is	O
expressed	O
in	O
many	O
tissues	O
,	O
but	O
is	O
enriched	O
in	O
retina	O
and	O
brain	O
.	O

A	O
second	O
isotype	O
of	O
Raja	B-protein
immunoglobulin	I-protein
heavy	I-protein
chain	I-protein
genes	I-protein
has	O
been	O
detected	O
by	O
screening	O
a	O
spleen	O
cDNA	O
library	O
with	O
homologous	O
Raja	O
VH	O
-	O
and	O
CH1	O
-	O
specific	O
probes	O
complementing	O
the	O
respective	O
regions	O
of	O
the	O
mu	B-protein
-	I-protein
like	I-protein
isotype	I-protein
.	O

Thereafter	O
,	O
the	O
aggregation	O
rose	O
to	O
the	O
initial	O
100	O
%	O
value	O
4	O
h	O
after	O
drug	O
application	O
and	O
remained	O
at	O
this	O
level	O
during	O
the	O
observation	O
period	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

At	O
the	O
time	O
of	O
the	O
seizure	O
,	O
the	O
patient	O
was	O
asked	O
to	O
read	O
a	O
test	O
phrase	O
aloud	O
until	O
it	O
was	O
read	O
correctly	O
and	O
clearly	O
.	O

Two	O
new	O
artifacts	O
in	O
automated	O
coagulation	O
testing	O
.	O

This	O
study	O
examines	O
the	O
cooperative	O
effects	O
of	O
a	O
human	O
estrogen	B-protein
receptor	I-protein
-	I-protein
alpha	I-protein
(	O
ERalpha	B-protein
)	O
isoform	O
on	O
estrogen	B-protein
(	O
E2	B-protein
)	O
-	O
mediated	O
gene	O
activation	O
in	O
U2	O
-	O
OS	O
osteosarcoma	O
cells	O
.	O

Three	O
mog	B-protein
-	I-protein
1	I-protein
alleles	I-protein
possess	O
premature	O
stop	O
codons	O
and	O
are	O
likely	O
to	O
be	O
null	O
alleles	O
,	O
and	O
one	O
is	O
a	O
missense	O
mutation	O
and	O
is	O
likely	O
to	O
retain	O
residual	O
activity	O
.	O
mog	B-protein
-	I-protein
1	I-protein
mRNA	I-protein
is	O
expressed	O
in	O
both	O
germ	O
line	O
and	O
somatic	O
tissues	O
and	O
appears	O
to	O
be	O
ubiquitous	O
.	O

Marked	O
hemolysis	O
significantly	O
increased	O
plasma	O
values	O
of	O
potassium	O
,	O
phosphorus	O
,	O
total	O
protein	O
,	O
and	O
aspartate	B-protein
aminotransferase	I-protein
.	O

The	O
regurgitation	O
of	O
large	O
vitreous	O
injections	O
.	O

Assessment	O
of	O
the	O
carcinogenicity	O
of	O
non	O
-	O
nutritive	O
sweetners	O
II	O
:	O
Cyclamates	O
and	O
cyclohexylamine	O
.	O

Blood	O
from	O
dams	O
was	O
collected	O
prior	O
to	O
inoculation	O
and	O
at	O
time	O
of	O
necropsy	O
for	O
measurement	O
of	O
IgM	B-protein
and	O
IgG	B-protein
antibodies	I-protein
to	O
M	O
.	O
pulmonis	O
.	O

Effects	O
of	O
cisapride	O
on	O
upper	O
-	O
gastrointestinal	O
motility	O
and	O
digestive	O
hormones	O
.	O

The	O
cDNAs	O
cross	O
-	O
hybridize	O
with	O
genomic	O
sequences	O
in	O
rat	O
,	O
human	O
,	O
and	O
chicken	O
DNA	O
,	O
but	O
not	O
with	O
DNA	O
from	O
frog	O
,	O
Drosophila	O
,	O
or	O
sea	O
urchin	O
.	O

Trials	O
of	O
sevine	O
activity	O
against	O
mosquito	O
larvae	O
.	O

Immediately	O
before	O
surgery	O
patients	O
received	O
either	O
intravenous	O
hydrocortisone	O
100	O
mg	O
or	O
placebo	O
in	O
random	O
,	O
double	O
-	O
blind	O
order	O
.	O

In	O
some	O
early	O
B	O
cells	O
and	O
Abelson	O
murine	O
leukemia	O
virus	O
-	O
transformed	O
pre	O
-	O
B	O
-	O
cell	O
lines	O
,	O
LT	B-protein
mRNA	I-protein
is	O
constitutively	O
expressed	O
.	O

Substitution	O
of	O
bulky	O
hydrophobic	O
residues	O
with	O
charged	O
residues	O
within	O
PEP1	B-protein
affects	O
the	O
fusion	O
activity	O
of	O
the	O
S	B-protein
protein	I-protein
without	O
affecting	O
processing	O
and	O
surface	O
expression	O
.	O

The	O
dying	O
tTG	O
-	O
transfected	O
cells	O
exhibit	O
both	O
cytoplasmic	O
and	O
nuclear	O
changes	O
characteristic	O
of	O
cells	O
undergoing	O
apoptosis	O
.	O

Roizman	O
,	O
J	O
.	O

There	O
are	O
four	O
polyglutamine	O
motifs	O
interspersed	O
with	O
histidine	O
-	O
rich	O
regions	O
.	O

SL1	B-protein
trans	O
-	O
splicing	O
specified	O
by	O
AU	O
-	O
rich	O
synthetic	O
RNA	O
inserted	O
at	O
the	O
5	O
'	O
end	O
of	O
Caenorhabditis	O
elegans	O
pre	O
-	O
mRNA	O
.	O

When	O
CSF	O
[	O
HCO3	O
-	O
]	O
is	O
shown	O
as	O
a	O
function	O
of	O
CSF	O
PCO2	O
the	O
data	O
of	O
K	O
-	O
depleted	O
rats	O
are	O
no	O
longer	O
displaced	O
when	O
compared	O
to	O
controls	O
but	O
still	O
have	O
a	O
significantly	O
greater	O
slope	O
(	O
1	O
.	O
21	O
+	O
/	O
-	O
0	O
.	O
23	O
vs	O
.	O

The	O
patient	O
with	O
a	O
prolonged	O
fever	O
caused	O
by	O
dissecting	O
aneurysm	O
of	O
the	O
aorta	O
in	O
whom	O
pleuropneumonia	O
masked	O
the	O
real	O
diseases	O
has	O
been	O
presented	O
.	O

ENV	B-protein
also	O
was	O
secreted	O
from	O
P	O
.	O
pastoris	O
using	O
the	O
S	B-protein
.	I-protein
cerevisiae	I-protein
alpha	I-protein
-	I-protein
factor	I-protein
prepro	I-protein
secretion	I-protein
leader	I-protein
and	O
the	O
S	B-protein
.	I-protein
cerevisiae	I-protein
invertase	I-protein
signal	I-protein
sequence	I-protein
.	O

Androgens	O
and	O
growth	O
.	O

Arterial	O
blood	O
gas	O
tensions	O
were	O
similar	O
across	O
all	O
ventilation	O
modes	O
.	O

Accordingly	O
,	O
no	O
Ha	B-protein
-	I-protein
ras	I-protein
codon	I-protein
12	I-protein
mutations	O
are	O
found	O
in	O
the	O
EtNU	O
-	O
induced	O
mammary	O
tumors	O
.	O

Functional	O
postnatal	O
development	O
of	O
the	O
rat	O
primary	O
visual	O
cortex	O
and	O
the	O
role	O
of	O
visual	O
experience	O
:	O
dark	O
rearing	O
and	O
monocular	O
deprivation	O
.	O

The	O
patients	O
in	O
one	O
group	O
had	O
intrauterine	O
catheters	O
inserted	O
and	O
oxytocin	O
was	O
titrated	O
to	O
achieve	O
the	O
75th	O
percentile	O
of	O
uterine	O
activity	O
observed	O
in	O
spontaneous	O
normal	O
labour	O
according	O
to	O
parity	O
.	O

A	O
mouse	B-protein
brain	I-protein
beta	I-protein
-	I-protein
spectrin	I-protein
of	O
cDNA	O
was	O
identified	O
within	O
a	O
lambda	O
Gt11	O
expression	O
library	O
using	O
an	O
antibody	O
which	O
specifically	O
binds	O
with	O
the	O
235	B-protein
kDa	I-protein
spectrin	I-protein
beta	I-protein
-	I-protein
subunit	I-protein
.	O

Renal	O
and	O
extrarenal	O
arterial	O
fibromuscular	O
hyperplasia	O
with	O
hypertension	O
.	O

The	O
other	O
transmembrane	O
regions	O
as	O
well	O
as	O
the	O
nucleoplasmic	O
domain	O
are	O
not	O
required	O
for	O
sorting	O
.	O

The	O
major	O
pathological	O
findings	O
of	O
the	O
placenta	O
were	O
prematuration	O
and	O
hypoplasia	O
.	O

Viral	O
genomic	O
RNA	O
for	O
these	O
reactions	O
was	O
obtained	O
directly	O
from	O
fecal	O
specimens	O
of	O
infected	O
infant	O
rats	O
.	O

In	O
two	O
experiments	O
,	O
neonatal	O
female	O
BALB	O
/	O
cCrgl	O
or	O
BALB	O
/	O
cfC3HCrgl	O
mice	O
were	O
given	O
subcutaneous	O
injections	O
of	O
5	O
micrograms	O
17	O
beta	O
-	O
estradiol	O
or	O
sesame	O
oil	O
for	O
the	O
first	O
3	O
days	O
of	O
life	O
and	O
were	O
ovariectomized	O
at	O
60	O
days	O
of	O
age	O
,	O
at	O
which	O
time	O
vaginal	O
concretions	O
(	O
Experiments	O
I	O
and	O
II	O
)	O
or	O
silica	O
(	O
Experiment	O
II	O
)	O
were	O
implanted	O
intravaginally	O
.	O

Human	B-protein
thyroid	I-protein
stimulator	I-protein
(	O
HTS	B-protein
)	O
in	O
thyroid	O
diseases	O
.	O

Substituting	O
a	O
Ser	O
for	O
Gly69	O
or	O
a	O
Glu	O
for	O
Lys	O
71	O
in	O
the	O
conserved	O
TGEK	B-protein
tetrapeptide	I-protein
in	O
finger	O
II	O
of	O
TFIIIA	B-protein
resulted	O
in	O
the	O
loss	O
of	O
DNA	O
binding	O
.	O

Plasma	O
thrombomodulin	B-protein
:	O
a	O
marker	O
for	O
microvascular	O
complications	O
in	O
diabetes	O
mellitus	O
.	O

Thus	O
,	O
the	O
L45	B-protein
sequence	I-protein
between	O
kinase	B-protein
subdomains	I-protein
IV	I-protein
and	I-protein
V	I-protein
specifies	O
TGF	B-protein
-	I-protein
beta	I-protein
responsiveness	O
of	O
the	O
type	B-protein
I	I-protein
receptor	I-protein
.	O

Epitopes	O
of	O
adhesion	O
-	O
perturbing	O
monoclonal	O
antibodies	O
map	O
within	O
a	O
predicted	O
alpha	O
-	O
helical	O
domain	O
of	O
the	O
integrin	B-protein
beta	I-protein
1	I-protein
subunit	I-protein
.	O

In	O
addition	O
,	O
the	O
transcription	O
of	O
c	B-protein
-	I-protein
IAP2	I-protein
promoter	I-protein
was	O
strongly	O
up	O
-	O
regulated	O
when	O
CD40	B-protein
or	O
Epstein	B-protein
-	I-protein
Barr	I-protein
virus	I-protein
latent	I-protein
membrane	I-protein
protein	I-protein
1	I-protein
was	O
overexpressed	O
.	O

A	O
local	O
,	O
high	O
-	O
density	O
,	O
single	O
-	O
nucleotide	O
polymorphism	O
map	O
used	O
to	O
clone	O
Caenorhabditis	B-protein
elegans	I-protein
cdf	I-protein
-	I-protein
1	I-protein
.	O

Tiaprofenic	O
acid	O
overdose	O
.	O

Fentanyl	O
,	O
a	O
prototypic	O
mu	B-protein
-	I-protein
opiate	I-protein
receptor	I-protein
agonist	O
,	O
has	O
been	O
previously	O
shown	O
to	O
produce	O
a	O
syndrome	O
characterized	O
by	O
marked	O
analgesia	O
and	O
locomotor	O
stimulation	O
as	O
well	O
as	O
tachycardia	O
,	O
tachypnoea	O
and	O
behavioural	O
arousal	O
.	O

CONCLUSIONS	O
:	O
In	O
our	O
patients	O
and	O
within	O
the	O
range	O
of	O
treatment	O
variables	O
studied	O
,	O
age	O
,	O
Karnofsky	O
index	O
,	O
and	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
are	O
the	O
most	O
important	O
factors	O
related	O
with	O
early	O
mortality	O
.	O

Once	O
P	B-protein
-	I-protein
450scc	I-protein
mRNA	I-protein
is	O
induced	O
as	O
a	O
consequence	O
of	O
the	O
LH	B-protein
/	I-protein
hCG	I-protein
surge	O
it	O
is	O
constitutively	O
maintained	O
by	O
luteinized	O
cells	O
in	O
vivo	O
(	O
0	O
-	O
4	O
days	O
)	O
and	O
in	O
vitro	O
(	O
0	O
-	O
9	O
days	O
)	O
in	O
the	O
absence	O
of	O
gonadotropins	B-protein
,	O
is	O
susceptible	O
to	O
modulation	O
by	O
prolactin	B-protein
and	O
is	O
no	O
longer	O
regulated	O
by	O
cAMP	O
.	O

Effects	O
of	O
3	O
'	O
terminus	O
modifications	O
on	O
mRNA	O
functional	O
decay	O
during	O
in	O
vitro	O
protein	O
synthesis	O
.	O

The	O
maximum	O
period	O
of	O
treatment	O
was	O
73	O
(	O
oral	O
)	O
,	O
73	O
(	O
intraperitoneal	O
)	O
or	O
75	O
(	O
dermal	O
)	O
weeks	O
.	O

Sequence	O
analysis	O
of	O
the	O
47	B-protein
-	I-protein
kilodalton	I-protein
major	I-protein
integral	I-protein
membrane	I-protein
immunogen	I-protein
of	I-protein
Treponema	I-protein
pallidum	I-protein
.	O

By	O
using	O
total	O
-	O
protein	O
extracts	O
from	O
mycelia	O
grown	O
under	O
penicillin	O
producing	O
conditions	O
we	O
have	O
detected	O
a	O
DNA	O
-	O
binding	O
activity	O
that	O
specifically	O
shifts	O
a	O
promoter	O
fragment	O
located	O
between	O
-	O
654	O
and	O
-	O
455	O
(	O
relative	O
to	O
IPNS	B-protein
tsp	I-protein
)	O
.	O

The	O
RF	O
values	O
correlated	O
well	O
with	O
the	O
angiographic	O
semiquantitative	O
scale	O
of	O
severity	O
of	O
aortal	O
insufficiency	O
(	O
r	O
=	O
0	O
.	O
805	O
;	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
although	O
they	O
enabled	O
the	O
authors	O
only	O
to	O
make	O
a	O
partial	O
differentiation	O
of	O
haemodynamically	O
severe	O
regurgitations	O
and	O
mild	O
or	O
insignificant	O
ones	O
.	O

Hb	B-protein
levels	O
remained	O
adequate	O
(	O
Hb	B-protein
=	O
10	O
.	O
68	O
+	O
/	O
-	O
0	O
.	O
77	O
g	O
/	O
dl	O
)	O
after	O
14	O
.	O
6	O
+	O
/	O
-	O
7	O
.	O
64	O
months	O
.	O

Their	O
numbers	O
have	O
regularly	O
increased	O
since	O
the	O
mid	O
-	O
1970s	O
.	O

An	O
unusual	O
cysteine	O
triplet	O
conserved	O
in	O
the	O
sequences	O
of	O
TB	B-protein
domains	I-protein
is	O
localized	O
to	O
the	O
hydrophobic	O
core	O
,	O
at	O
the	O
C	O
-	O
terminus	O
of	O
an	O
alpha	O
-	O
helix	O
.	O

BIM	O
130	O
.	O

Prostate	B-protein
specific	I-protein
antigen	I-protein
shows	O
the	O
metastatic	O
cases	O
better	O
[	O
correction	O
of	O
worse	O
]	O
than	O
prostatic	B-protein
acid	I-protein
phosphatase	I-protein
.	O

An	O
industry	O
-	O
wide	O
retrospective	O
cohort	O
mortality	O
study	O
was	O
conducted	O
on	O
6	O
,	O
152	O
chemical	O
workers	O
(	O
2	O
,	O
460	O
exposed	O
and	O
3	O
,	O
692	O
nonexposed	O
)	O
engaged	O
in	O
chloromethyl	O
ether	O
manufacture	O
at	O
7	O
major	O
U	O
.	O
S	O
.	O
companies	O
between	O
1948	O
and	O
1980	O
.	O

The	O
cwg2	B-protein
-	I-protein
1	I-protein
mutation	I-protein
was	O
identified	O
as	O
a	O
guanine	O
to	O
adenine	O
substitution	O
at	O
nucleotide	O
604	O
of	O
the	O
coding	O
region	O
,	O
originating	O
the	O
change	O
A202T	O
in	O
the	O
cwg2p	B-protein
.	O

Closure	O
of	O
an	O
open	O
high	O
below	O
-	O
knee	O
guillotine	O
amputation	O
wound	O
using	O
a	O
skin	O
-	O
stretching	O
device	O
.	O

Large	B-protein
T	I-protein
antigen	I-protein
was	O
coimmunoprecipitated	O
by	O
antibodies	O
to	O
epitope	O
-	O
tagged	O
TBP	B-protein
,	O
endogenous	O
TBP	B-protein
,	O
hTAF	B-protein
(	I-protein
II	I-protein
)	I-protein
100	I-protein
,	O
hTAF	B-protein
(	I-protein
II	I-protein
)	I-protein
130	I-protein
,	O
and	O
hTAF	B-protein
(	I-protein
II	I-protein
)	I-protein
250	I-protein
,	O
under	O
conditions	O
where	O
holo	B-protein
-	I-protein
TFIID	I-protein
would	O
be	O
precipitated	O
.	O

CONCLUSIONS	O
:	O
This	O
randomized	O
study	O
shows	O
that	O
Vivostat	O
fibrin	B-protein
sealant	O
is	O
effective	O
in	O
preventing	O
air	O
leakage	O
after	O
small	O
lung	O
resections	O
in	O
pigs	O
,	O
even	O
at	O
high	O
inspiratory	O
pressures	O
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
Sro7	B-protein
function	O
is	O
involved	O
in	O
the	O
targeting	O
of	O
the	O
myosin	B-protein
proteins	I-protein
to	O
their	O
intrinsic	O
pathways	O
.	O

The	O
response	O
properties	O
of	O
cat	O
horizontal	O
canal	O
afferents	O
(	O
N	O
=	O
81	O
)	O
were	O
characterized	O
by	O
three	O
parameters	O
:	O
their	O
long	O
time	O
constants	O
(	O
tau	O
)	O
,	O
low	O
frequency	O
gain	O
constants	O
(	O
G1	O
)	O
,	O
and	O
middle	O
frequency	O
gain	O
constants	O
(	O
Gm	O
)	O
.	O

We	O
have	O
applied	O
the	O
mRNA	O
differential	O
display	O
method	O
to	O
compare	O
and	O
analyze	O
mRNAs	O
prepared	O
from	O
five	O
normal	O
nasopharyngeal	O
epithelial	O
cell	O
cultures	O
and	O
five	O
nasopharyngeal	O
carcinoma	O
cell	O
lines	O
.	O

Lung	O
and	O
multi	O
-	O
system	O
damage	O
were	O
early	O
indicators	O
of	O
poor	O
outcome	O
in	O
severe	O
non	O
-	O
fatal	O
disease	O
.	O

Histological	O
slides	O
of	O
one	O
biopsy	O
of	O
each	O
patient	O
(	O
formalin	O
-	O
fixed	O
and	O
paraffin	O
-	O
embedded	O
)	O
were	O
stained	O
with	O
a	O
Modified	O
Giemsa	O
(	O
MG	O
)	O
,	O
the	O
Warthin	O
-	O
Starry	O
(	O
WS	O
)	O
,	O
and	O
an	O
immunohistochemical	O
method	O
(	O
IMM	O
)	O
using	O
purified	O
polyclonal	O
H	O
.	O
pylori	O
antiserum	O
(	O
DAKO	O
B471	O
)	O
.	O

BACKGROUND	O
:	O
Chemicals	O
vary	O
considerably	O
in	O
their	O
intrinsic	O
ability	O
to	O
cause	O
allergic	O
contact	O
dermatitis	O
.	O

In	O
one	O
acromegalic	O
patient	O
visual	O
improvement	O
was	O
obtained	O
while	O
the	O
abnormal	O
GH	B-protein
secretion	O
remained	O
unaltered	O
.	O

When	O
the	O
blood	O
pressure	O
increase	O
in	O
response	O
to	O
smoking	O
was	O
blunted	O
by	O
nitroprusside	O
infusion	O
,	O
there	O
was	O
a	O
striking	O
increase	O
in	O
muscle	O
SNA	O
.	O

Multiple	O
single	O
-	O
stranded	O
cis	O
elements	O
are	O
associated	O
with	O
activated	O
chromatin	O
of	O
the	O
human	B-protein
c	I-protein
-	I-protein
myc	I-protein
gene	I-protein
in	O
vivo	O
.	O

Removal	O
of	O
thick	O
,	O
permanently	O
altered	O
mucoas	O
is	O
recommended	O
even	O
in	O
the	O
absence	O
of	O
squamous	O
epithelium	O
.	O

High	O
-	O
pressure	O
effects	O
on	O
ultrafast	O
-	O
relaxation	O
kinetics	O
of	O
excitons	O
in	O
polydiacetylene	O
4BCMU	O
.	O

Interestingly	O
,	O
we	O
find	O
that	O
the	O
interaction	O
between	O
Tat	B-protein
and	O
hCycT1	B-protein
requires	O
zinc	O
as	O
well	O
as	O
essential	O
cysteine	O
residues	O
in	O
both	O
proteins	O
.	O

Treatment	O
of	O
2	O
patients	O
with	O
pseudohypoparathyroidism	O
type	O
I	O
with	O
vitamin	O
-	O
D	O
-	O
3	O
and	O
1	O
alpha	O
-	O
Hydroxycholecalciferol	O
consecutively	O
resulted	O
in	O
a	O
nonuniform	O
response	O
with	O
regard	O
to	O
the	O
normalisation	O
of	O
serum	O
-	O
calcium	O
.	O

Tumour	B-protein
necrosis	I-protein
factor	I-protein
and	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O

Biological	O
evaluation	O
of	O
mibolerone	O
in	O
the	O
female	O
Beagle	O
.	O

These	O
results	O
suggest	O
that	O
Rho1p	B-protein
regulates	O
cytoskeletal	O
reorganization	O
at	O
least	O
through	O
Bni1p	B-protein
and	O
Pkc1p	B-protein
.	O

This	O
protein	O
-	O
protein	O
interaction	O
does	O
not	O
require	O
the	O
simultaneous	O
binding	O
of	O
Oct	B-protein
proteins	I-protein
to	O
DNA	O
,	O
and	O
high	O
resolution	O
footprinting	O
of	O
the	O
Oct	B-protein
-	I-protein
DNA	I-protein
interaction	O
reveals	O
that	O
binding	O
of	O
BOB	B-protein
.	I-protein
1	I-protein
/	I-protein
OBF	I-protein
.	I-protein
1	I-protein
to	O
Oct1	B-protein
or	O
Oct2	B-protein
does	O
not	O
alter	O
the	O
interaction	O
with	O
DNA	O
.	O

The	O
lytic	O
cycle	O
of	O
KSHV	O
,	O
probably	O
under	O
the	O
initial	O
control	O
of	O
the	O
KSHV	B-protein
/	I-protein
Rta	I-protein
gene	I-protein
,	O
may	O
directly	O
contribute	O
to	O
tumor	O
pathogenesis	O
.	O

Perfusion	O
washout	O
:	O
increasing	O
a	O
microvascular	O
free	O
flap	O
tolerance	O
to	O
ischemia	O
.	O

A	O
case	O
of	O
M	O
hemoglobinosis	O
.	O

The	O
location	O
and	O
approximate	O
length	O
of	O
the	O
intron	O
are	O
conserved	O
in	O
both	O
the	O
tomato	O
and	O
Arabidopsis	O
genes	O
,	O
with	O
the	O
intron	O
separating	O
the	O
'	O
nose	O
'	O
region	O
(	O
encoded	O
by	O
exon	O
1	O
)	O
from	O
the	O
central	O
globular	O
domain	O
(	O
exon	O
2	O
)	O
.	O

Thus	O
,	O
the	O
bovine	B-protein
PEDF	I-protein
cDNA	I-protein
isolated	O
here	O
codes	O
for	O
a	O
functional	O
soluble	O
secreted	B-protein
PEDF	I-protein
glycoprotein	I-protein
.	O

However	O
,	O
the	O
element	O
proximal	O
to	O
the	O
transcription	O
start	O
site	O
is	O
dependent	O
on	O
the	O
SRE	B-protein
-	I-protein
1	I-protein
.	O

Klebsiella	O
oxytoca	O
can	O
assimilate	O
nitrate	O
and	O
nitrite	O
by	O
using	O
enzymes	O
encoded	O
by	O
the	O
nasFEDCBA	B-protein
operon	I-protein
.	O

Use	O
of	O
the	O
immunofluorescence	O
method	O
for	O
identification	O
of	O
enteroviruses	O
in	O
cell	O
cultures	O
.	O

Atcys1	B-protein
,	O
Athyp1	B-protein
,	O
AKin10	B-protein
and	O
the	O
ORF	O
are	O
very	O
close	O
to	O
each	O
other	O
and	O
organized	O
in	O
the	O
same	O
polarity	O
;	O
hence	O
,	O
the	O
intergenic	O
regions	O
probably	O
contain	O
,	O
within	O
less	O
than	O
0	O
.	O
5	O
kb	O
,	O
all	O
the	O
regulatory	O
elements	O
necessary	O
to	O
govern	O
initiation	O
and	O
termination	O
of	O
transcription	O
.	O

(	O
ii	O
)	O
An	O
AF	O
G	B-protein
-	I-protein
CSF	I-protein
level	O
>	O
2000	O
pg	O
/	O
ml	O
is	O
a	O
strong	O
positive	O
predictor	O
of	O
CAM	O
.	O

I	O
report	O
here	O
that	O
induction	O
of	O
HSP82	B-protein
is	O
regulated	O
by	O
the	O
early	O
meiotic	O
IME1	B-protein
-	I-protein
IME2	I-protein
transcriptional	O
cascade	O
.	O

We	O
now	O
report	O
the	O
isolation	O
and	O
expression	O
of	O
cDNAs	O
encoding	O
PTF	B-protein
gamma	I-protein
and	O
PTF	B-protein
delta	I-protein
,	O
as	O
well	O
as	O
functional	O
studies	O
with	O
cognate	O
antibodies	O
that	O
recognize	O
the	O
native	O
PTF	B-protein
complex	I-protein
in	O
HeLa	O
extracts	O
.	O

Primers	O
for	O
subsequent	O
rounds	O
of	O
RACE	O
were	O
designed	O
from	O
the	O
5	O
'	O
-	O
ends	O
of	O
amplified	O
RACE	B-protein
products	I-protein
.	O

Several	O
free	O
2nd	O
-	O
generation	O
schizonts	O
,	O
which	O
varied	O
in	O
diameter	O
from	O
11	O
to	O
21	O
.	O
6	O
micrometer	O
,	O
were	O
found	O
on	O
the	O
epithelial	O
surface	O
of	O
the	O
cecum	O
.	O

Active	O
lambda	B-protein
and	I-protein
kappa	I-protein
antibody	I-protein
gene	I-protein
rearrangement	O
in	O
Abelson	O
murine	O
leukemia	O
virus	O
-	O
transformed	O
pre	O
-	O
B	O
cell	O
lines	O
.	O

Brainstem	O
auditory	O
evoked	O
responses	O
(	O
BAERs	O
)	O
and	O
quantitative	O
saccadic	O
eye	O
movement	O
studies	O
provide	O
information	O
on	O
the	O
integrity	O
of	O
pathways	O
traversing	O
the	O
brainstem	O
.	O

Spinal	O
cord	O
representation	O
of	O
the	O
micturition	O
reflex	O
.	O

Glycemic	O
response	O
to	O
malted	O
,	O
popped	O
and	O
roller	O
dried	O
wheat	O
-	O
legume	O
based	O
foods	O
in	O
normal	O
subjects	O
.	O

Sterol	O
-	O
mediated	O
suppression	O
of	O
cleavage	O
of	O
SREBP	B-protein
-	I-protein
1	I-protein
was	O
found	O
to	O
be	O
dependent	O
on	O
the	O
extreme	O
COOH	O
-	O
terminal	O
region	O
(	O
residue	O
1034	O
to	O
the	O
COOH	O
terminus	O
)	O
,	O
which	O
exists	O
in	O
two	O
forms	O
as	O
a	O
result	O
of	O
alternative	O
splicing	O
.	O

The	O
difference	O
between	O
the	O
patients	O
and	O
the	O
controls	O
was	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O

The	O
coefficient	O
of	O
determination	O
,	O
r2	O
,	O
of	O
the	O
other	O
scores	O
ranged	O
from	O
0	O
.	O
56	O
to	O
0	O
.	O
61	O
.	O

A	O
yeast	O
DNA	O
fragment	O
carrying	O
the	O
gene	B-protein
CP	I-protein
A1	I-protein
encoding	O
the	O
small	O
subunit	O
of	O
the	O
arginine	O
pathway	O
carbamoyl	B-protein
-	I-protein
phosphate	I-protein
synthetase	I-protein
has	O
been	O
sequenced	O
.	O

In	O
an	O
effort	O
to	O
identify	O
the	O
USH1C	B-protein
disease	I-protein
gene	I-protein
we	O
have	O
isolated	O
the	O
region	O
between	O
these	O
markers	O
in	O
yeast	O
artificial	O
chromosomes	O
(	O
YACs	O
)	O
using	O
a	O
combination	O
of	O
STS	O
content	O
mapping	O
and	O
Alu	O
-	O
PCR	O
hybridization	O
.	O

Critical	O
residues	O
required	O
for	O
repression	O
are	O
located	O
within	O
the	O
C	O
-	O
terminal	O
27	O
amino	O
acids	O
of	O
c	B-protein
-	I-protein
Fos	I-protein
,	O
since	O
v	B-protein
-	I-protein
Fos	I-protein
and	O
C	O
-	O
terminal	O
truncations	O
of	O
c	B-protein
-	I-protein
Fos	I-protein
did	O
not	O
down	O
regulate	O
.	O

Altogether	O
these	O
results	O
indicate	O
that	O
the	O
Syn	B-protein
5	I-protein
locus	I-protein
segregates	O
from	O
the	O
gene	O
specifying	O
gH	B-protein
,	O
to	O
a	O
region	O
encompassing	O
portions	O
of	O
the	O
TK	B-protein
and	O
UL	B-protein
24	I-protein
genes	I-protein
,	O
and	O
that	O
the	O
syn	B-protein
mutation	I-protein
does	O
not	O
affect	O
the	O
expression	O
or	O
activity	O
of	O
TK	O
.	O

2	O
.	O

Upon	O
analysis	O
of	O
various	O
deletion	O
and	O
point	O
-	O
mutated	O
variants	O
of	O
the	O
human	B-protein
IL	I-protein
-	I-protein
6	I-protein
gene	I-protein
promoter	I-protein
coupled	O
to	O
a	O
reporter	O
gene	O
,	O
we	O
screened	O
for	O
possible	O
cooperating	O
transcription	O
factors	O
.	O

Characterization	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
growth	O
-	O
regulated	O
Syrian	B-protein
hamster	I-protein
CAD	I-protein
gene	I-protein
.	O

Horvath	O
,	O
I	O
.	O

Analysis	O
of	O
the	O
gag	B-protein
and	O
rev	B-protein
proteins	I-protein
in	O
the	O
transfected	O
cells	O
demonstrated	O
that	O
these	O
proteins	O
were	O
not	O
detectable	O
in	O
cells	O
transfected	O
with	O
the	O
tat	B-protein
mutants	I-protein
but	O
could	O
be	O
readily	O
detected	O
when	O
the	O
mutations	O
were	O
complemented	O
in	O
trans	O
with	O
a	O
tat	B-protein
expression	O
vector	O
.	O

However	O
,	O
the	O
BCH	O
group	O
showed	O
inferior	O
gross	O
motor	O
performance	O
on	O
the	O
Bruininks	O
-	O
Oseretsky	O
Test	O
of	O
Motor	O
Proficiency	O
(	O
Bruininks	O
1978	O
)	O
.	O

Repression	O
is	O
alleviated	O
when	O
the	O
two	O
(	O
for	O
E2	B-protein
)	O
or	O
three	O
(	O
for	O
E2	B-protein
-	I-protein
C	I-protein
)	O
promoter	O
-	O
proximal	O
copies	O
of	O
E2	B-protein
-	I-protein
RS	I-protein
are	O
mutated	O
.	O

Our	O
findings	O
suggest	O
that	O
striatal	O
FDG	O
and	O
particularly	O
RACLO	O
are	O
sensitive	O
and	O
effective	O
measures	O
of	O
striatal	O
function	O
and	O
may	O
help	O
characterizing	O
patients	O
with	O
multiple	O
system	O
atrophy	O
.	O

Serum	B-protein
Fibrin	I-protein
Degradation	O
Products	O
(	O
FDP	O
)	O
were	O
determined	O
in	O
50	O
oral	O
cancer	O
patients	O
and	O
50	O
normal	O
individuals	O
prior	O
to	O
any	O
kind	O
of	O
treatment	O
.	O

Among	O
these	O
360	O
ZFPs	B-protein
,	O
a	O
novel	O
ZFP	B-protein
cDNA	I-protein
named	O
HFHZ	B-protein
(	O
human	B-protein
fetal	I-protein
heart	I-protein
ZFP	I-protein
)	O
with	O
sequence	O
homology	O
to	O
a	O
Kruppel	B-protein
-	I-protein
associated	I-protein
box	I-protein
(	O
KRAB	B-protein
)	O
was	O
identified	O
.	O

Such	O
a	O
mechanism	O
may	O
allow	O
acceleration	O
of	O
degenerative	O
joint	O
conditions	O
,	O
and	O
may	O
account	O
for	O
the	O
increased	O
prevalence	O
of	O
such	O
conditions	O
seen	O
with	O
HMS	O
subjects	O
.	O

Furthermore	O
,	O
stable	O
expression	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
chicken	O
Notch1	B-protein
or	O
Notch2	B-protein
in	O
a	O
B	O
cell	O
line	O
results	O
in	O
a	O
down	O
-	O
regulation	O
of	O
surface	O
IgM	B-protein
expression	O
,	O
which	O
is	O
accompanied	O
by	O
the	O
reduction	O
of	O
IgH	B-protein
gene	I-protein
transcripts	I-protein
.	O

A	O
case	O
of	O
chronic	O
hepatitis	O
C	O
with	O
primary	O
hypothyroidism	O
manifested	O
during	O
interferon	B-protein
treatment	O
.	O

For	O
this	O
purpose	O
,	O
a	O
segment	O
of	O
dxr	B-protein
was	O
amplified	O
from	O
Synechococcus	O
leopoliensis	O
SAUG	O
1402	O
-	O
1	O
DNA	O
via	O
PCR	O
using	O
oligonucleotides	O
for	O
conserved	O
regions	O
.	O

This	O
result	O
indicates	O
that	O
separate	O
complexes	O
exist	O
containing	O
ankyrin	B-protein
and	O
fodrin	B-protein
with	O
either	O
uvomorulin	B-protein
or	O
Na	B-protein
+	I-protein
,	I-protein
K	I-protein
+	I-protein
-	I-protein
ATPase	I-protein
.	O

Nerve	B-protein
growth	I-protein
factor	I-protein
(	O
NGF	B-protein
)	O
and	O
retinoic	O
acid	O
(	O
RA	O
)	O
exert	O
important	O
actions	O
on	O
PC12	O
cells	O
.	O

Because	O
of	O
its	O
wide	O
spectrum	O
of	O
activity	O
particularly	O
against	O
ampicillin	O
resistant	O
strains	O
of	O
H	O
.	O
influenzae	O
and	O
because	O
of	O
its	O
good	O
tolerance	O
Cefaclor	O
is	O
very	O
useful	O
in	O
treatment	O
of	O
respiratory	O
tract	O
infections	O
in	O
children	O
.	O

Using	O
purified	O
recombinant	B-protein
HMG	I-protein
I	I-protein
,	O
we	O
have	O
identified	O
several	O
high	O
-	O
affinity	O
binding	O
sites	O
which	O
overlap	O
important	O
transcription	O
factor	O
binding	O
sites	O
.	O

BCL6	B-protein
encodes	O
a	O
POZ	B-protein
/	I-protein
Zn	I-protein
finger	I-protein
protein	I-protein
,	O
a	O
structure	O
similar	O
to	O
that	O
of	O
many	O
Drosophila	O
developmental	O
regulators	O
and	O
to	O
another	O
protein	O
involved	O
in	O
a	O
human	O
hematopoietic	O
malignancy	O
,	O
PLZF	B-protein
.	O

The	O
level	O
of	O
contamination	O
in	O
the	O
wound	O
can	O
be	O
determined	O
with	O
the	O
rapid	O
biopsy	O
fixation	O
technique	O
.	O

The	O
presence	O
of	O
PDZ	B-protein
and	O
SAM	B-protein
domains	I-protein
in	O
the	O
KS5	B-protein
protein	I-protein
suggests	O
that	O
it	O
may	O
act	O
as	O
a	O
molecular	O
adaptor	O
,	O
promoting	O
and	O
relaying	O
information	O
in	O
a	O
signal	O
transduction	O
pathway	O
.	O

An	O
IgG	B-protein
monoclonal	O
gammopathy	O
was	O
present	O
in	O
the	O
serum	O
of	O
4	O
patients	O
and	O
Bence	O
-	O
Joanes	O
proteinuria	O
was	O
found	O
in	O
1	O
patient	O
.	O

The	O
eluting	O
solvent	O
was	O
methanol	O
-	O
chloroform	O
(	O
10	O
+	O
90	O
)	O
at	O
a	O
flow	O
rate	O
of	O
2	O
.	O
0	O
ml	O
/	O
min	O
.	O

HLA	B-protein
-	I-protein
A	I-protein
and	I-protein
B	I-protein
phenotypes	O
of	O
105	O
patients	O
suffering	O
from	O
malignant	O
melanomas	O
were	O
determined	O
,	O
with	O
special	O
regard	O
for	O
metastatic	O
form	O
or	O
relapse	O
.	O

Further	O
investigation	O
on	O
the	O
chemotactic	O
influence	O
of	O
thymic	B-protein
hormone	I-protein
on	O
lymphocytes	O
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
,	O
the	O
cytokine	O
that	O
participates	O
in	O
the	O
autocrine	O
growth	O
control	O
of	O
hairy	O
cell	O
leukemia	O
has	O
strong	O
bone	O
resorptive	O
properties	O
.	O

This	O
rapid	O
and	O
extensive	O
penetration	O
of	O
intrathecally	O
administered	O
chemotherapy	O
may	O
offer	O
insight	O
into	O
the	O
myelopathy	O
observed	O
with	O
these	O
treatments	O
.	O

The	O
'	O
field	O
of	O
stress	O
'	O
of	O
the	O
supervisory	O
nurse	O
.	O

Its	O
role	O
in	O
these	O
processes	O
suggests	O
that	O
the	O
function	O
of	O
c	B-protein
-	I-protein
Myb	I-protein
may	O
be	O
important	O
early	O
in	O
the	O
establishment	O
of	O
the	O
hematopoietic	O
lineage	O
.	O

The	O
development	O
and	O
distribution	O
of	O
Trypanosoma	O
congolense	O
,	O
T	O
vivax	O
and	O
T	O
brucei	O
in	O
the	O
skin	O
of	O
goats	O
was	O
examined	O
after	O
the	O
animals	O
were	O
bitten	O
by	O
infected	O
Glossina	O
morsitans	O
centralis	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
twofold	O
:	O
(	O
1	O
)	O
to	O
present	O
a	O
parallel	O
form	O
of	O
the	O
Gudjonsson	O
Suggestibility	O
Scale	O
(	O
GSS	O
,	O
Form	O
1	O
)	O
;	O
(	O
2	O
)	O
to	O
study	O
test	O
-	O
retest	O
reliabilities	O
of	O
interrogative	O
suggestibility	O
.	O

Antimicrobial	O
Susceptibility	O
of	O
Klebsiella	O
pneumoniae	O
Producing	O
Extended	B-protein
-	I-protein
Spectrum	I-protein
beta	I-protein
-	I-protein
lactamase	I-protein
(	O
ESBL	B-protein
)	O
Isolated	O
in	O
Hospitals	O
in	O
Brazil	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
imply	O
that	O
eotaxin	O
either	O
is	O
mechanistically	O
involved	O
in	O
acute	O
asthma	O
or	O
serves	O
as	O
a	O
biomarker	O
for	O
activity	O
of	O
the	O
CCR3	B-protein
receptor	I-protein
ligand	I-protein
system	O
,	O
which	O
is	O
functionally	O
linked	O
to	O
asthma	O
.	O

GH	B-protein
failed	O
to	O
stimulate	O
phosphorylation	O
or	O
activation	O
of	O
Jun	B-protein
N	I-protein
-	I-protein
terminal	I-protein
kinase	I-protein
under	O
the	O
conditions	O
used	O
.	O

Surgical	O
treatment	O
of	O
pulmonary	O
metastases	O
.	O

We	O
found	O
that	O
the	O
expression	O
of	O
the	O
protein	O
was	O
maximum	O
in	O
mitosis	O
and	O
minimum	O
in	O
G1	O
,	O
which	O
correlated	O
with	O
the	O
expression	O
of	O
its	O
messenger	O
RNA	O
.	O

The	O
existence	O
of	O
threshold	O
concentrations	O
,	O
above	O
which	O
certain	O
phenomena	O
may	O
occur	O
,	O
strengthens	O
the	O
role	O
of	O
sentinels	O
.	O

Our	O
results	O
indicate	O
that	O
Gab1	B-protein
is	O
involved	O
in	O
the	O
control	O
of	O
egr	B-protein
-	I-protein
1	I-protein
expression	O
regulated	O
by	O
insulin	B-protein
.	O

Object	O
relations	O
,	O
affect	O
management	O
,	O
and	O
psychic	O
structure	O
formation	O
.	O

The	O
molecular	O
weight	O
of	O
in	O
vivo	O
-	O
labeled	O
proteins	O
was	O
increased	O
relative	O
to	O
that	O
of	O
in	O
vitro	O
-	O
translated	O
proteins	O
,	O
indicating	O
that	O
a	O
posttranslational	O
modification	O
had	O
occurred	O
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
HSF	B-protein
in	O
the	O
fission	O
yeast	O
Schizosaccharomyces	O
pombe	O
.	O

Role	O
of	O
secondary	O
structure	O
in	O
discrimination	O
between	O
constitutive	O
and	O
inducible	O
activators	O
.	O

A	O
study	O
of	O
the	O
E	O
.	O
O	O
.	O
R	O
.	O
T	O
.	O
C	O
.	O

METHODS	O
:	O
The	O
most	O
distal	O
muscle	O
fibres	O
from	O
the	O
deep	O
and	O
superficial	O
finger	O
flexors	O
were	O
measured	O
relative	O
to	O
the	O
pisiform	O
bone	O
in	O
18	O
cadaveric	O
specimens	O
.	O

A	O
new	O
,	O
flexible	O
fiberoptic	O
ventriculoscope	O
for	O
observation	O
of	O
the	O
ventricles	O
and	O
major	O
cisterns	O
is	O
reported	O
.	O

The	O
highly	O
conserved	O
ninth	O
heptad	O
,	O
which	O
is	O
involved	O
in	O
heterodimerization	O
,	O
appears	O
to	O
participate	O
in	O
the	O
receptor	O
-	O
inhibitor	O
interaction	O
,	O
suggesting	O
that	O
the	O
inhibitor	O
is	O
a	O
related	O
member	O
of	O
the	O
receptor	O
gene	O
family	O
.	O

The	O
human	B-protein
eps15	I-protein
gene	I-protein
,	O
encoding	O
a	O
tyrosine	B-protein
kinase	I-protein
substrate	O
,	O
is	O
conserved	O
in	O
evolution	O
and	O
maps	O
to	O
1p31	O
-	O
p32	O
.	O

The	O
rate	O
of	O
decrement	O
in	O
DPOAE	O
amplitude	O
over	O
a	O
prescribed	O
time	O
period	O
was	O
utilized	O
as	O
a	O
measure	O
of	O
susceptibility	O
to	O
the	O
acoustic	O
trauma	O
.	O

Expression	O
of	O
six	O
genes	O
,	O
ipaB	B-protein
,	O
ipaC	B-protein
,	O
invE	B-protein
,	O
invG	B-protein
,	O
invJ	B-protein
,	O
and	O
invK	B-protein
,	O
was	O
apparently	O
regulated	O
by	O
the	O
positive	O
regulator	O
virF	B-protein
.	O

These	O
combined	O
observations	O
define	O
a	O
promoter	O
and	O
an	O
enhancer	O
for	O
the	O
chicken	B-protein
L	I-protein
-	I-protein
CAM	I-protein
gene	I-protein
.	O

METHODS	O
:	O
Fifty	O
-	O
one	O
healthy	O
eyes	O
,	O
169	O
ocular	O
hypertensive	O
eyes	O
with	O
normal	O
visual	O
fields	O
,	O
and	O
132	O
glaucomatous	O
eyes	O
with	O
early	O
visual	O
field	O
defects	O
were	O
evaluated	O
with	O
qualitative	O
and	O
quantitative	O
measures	O
of	O
structural	O
damage	O
to	O
the	O
optic	O
nerve	O
and	O
nerve	O
fiber	O
layer	O
.	O

From	O
these	O
results	O
,	O
CBF	B-protein
-	I-protein
A	I-protein
is	O
a	O
novel	O
CArG	O
box	O
-	O
,	O
ssDNA	B-protein
-	I-protein
and	I-protein
RNA	I-protein
-	I-protein
binding	I-protein
protein	I-protein
,	O
as	O
well	O
as	O
a	O
repressive	O
transcriptional	O
factor	O
.	O

Overexpression	O
of	O
wild	B-protein
-	I-protein
type	I-protein
p53	I-protein
also	O
induces	O
apoptosis	O
in	O
an	O
LCL	O
.	O

RESULTS	O
:	O
The	O
medians	O
of	O
average	O
daily	O
CD34	B-protein
+	I-protein
cell	O
yields	O
for	O
patients	O
who	O
received	O
paclitaxel	O
plus	O
CY	O
,	O
CE	O
,	O
and	O
CEP	O
with	O
G	B-protein
-	I-protein
CSF	I-protein
were	O
12	O
.	O
9	O
,	O
11	O
.	O
03	O
,	O
and	O
5	O
.	O
37	O
x	O
10	O
(	O
6	O
)	O
/	O
kg	O
,	O
respectively	O
,	O
compared	O
with	O
2	O
.	O
02	O
x	O
10	O
(	O
6	O
)	O
/	O
kg	O
in	O
the	O
reference	O
group	O
that	O
received	O
CY	O
with	O
G	B-protein
-	I-protein
CSF	I-protein
(	O
P	O
=	O
<	O
.	O
0001	O
,	O
.	O
002	O
,	O
and	O
.	O
09	O
,	O
respectively	O
)	O
.	O

The	O
calculated	O
pD2	O
values	O
were	O
8	O
.	O
8	O
for	O
E	O
,	O
8	O
.	O
6	O
for	O
DHE	O
and	O
6	O
.	O
6	O
for	O
M	O
.	O

Significant	O
intergroup	O
differences	O
are	O
highlighted	O
for	O
both	O
selected	O
dentoskeletal	O
and	O
soft	O
tissue	O
profile	O
variables	O
.	O

B	O
cell	O
-	O
specific	O
mb	B-protein
-	I-protein
1	I-protein
and	O
B29	B-protein
genes	I-protein
encode	O
the	O
alpha	O
/	O
beta	O
components	O
of	O
the	O
BCR	B-protein
-	I-protein
associated	I-protein
complex	I-protein
in	O
mature	O
sIgM	B-protein
+	I-protein
B	O
cells	O
.	O

Comparative	O
DNA	O
sequence	O
analysis	O
showed	O
the	O
Genethon	O
microsatellite	B-protein
D19S596	I-protein
lies	O
2	O
.	O
2	O
kb	O
downstream	O
of	O
the	O
coding	O
region	O
of	O
FUT1	B-protein
,	O
indicating	O
that	O
the	O
cluster	O
comprising	O
the	O
closely	O
linked	O
FUT1	B-protein
and	O
FUT2	B-protein
genes	I-protein
is	O
located	O
4	O
cM	O
distal	O
to	O
D19S412	B-protein
(	O
lod	O
score	O
13	O
.	O
7	O
)	O
and	O
9	O
cM	O
proximal	O
to	O
D19S571	B-protein
(	O
lod	O
score	O
11	O
.	O
7	O
)	O
.	O

Only	O
17	O
%	O
of	O
all	O
patients	O
admitted	O
it	O
at	O
all	O
times	O
.	O

The	O
c	B-protein
-	I-protein
myc	I-protein
gene	I-protein
is	O
overexpressed	O
in	O
a	O
variety	O
of	O
tumor	O
types	O
and	O
appears	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
abnormal	O
growth	O
of	O
a	O
number	O
of	O
cell	O
types	O
.	O

Twenty	O
-	O
six	O
(	O
55	O
%	O
)	O
(	O
95	O
%	O
CI	O
,	O
41	O
-	O
69	O
%	O
)	O
patients	O
experienced	O
>	O
or	O
=	O
grade	O
3	O
acute	O
toxicity	O
(	O
RTOG	O
)	O
.	O

To	O
estimate	O
the	O
locations	O
of	O
sources	O
with	O
the	O
TF	O
-	O
MUSIC	O
algorithm	O
,	O
we	O
first	O
set	O
the	O
target	O
region	O
on	O
the	O
spectrogram	O
of	O
the	O
somatosensory	O
responses	O
.	O

A	O
microsporidian	O
,	O
Nosema	O
algerae	O
Vavra	O
and	O
undeen	O
,	O
was	O
found	O
parasitizing	O
larvae	O
and	O
adults	O
of	O
a	O
laboratory	O
colony	O
of	O
Culex	O
pipiens	O
L	O
.	O
originated	O
from	O
Gharbia	O
Governorate	O
.	O

Serological	O
studies	O
of	O
antibodies	O
to	O
Epstein	O
-	O
Barr	O
virus	O
in	O
infectious	O
mononucleosis	O
.	O

We	O
have	O
also	O
isolated	O
and	O
analyzed	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
pea	O
33RNP	B-protein
gene	I-protein
.	O

We	O
conclude	O
that	O
for	O
mono	O
-	O
intronic	O
precursors	O
in	O
which	O
there	O
is	O
only	O
one	O
choice	O
of	O
splice	O
sites	O
,	O
most	O
of	O
the	O
exon	O
sequences	O
are	O
not	O
mechanistically	O
involved	O
in	O
the	O
splicing	O
process	O
.	O

Identification	O
and	O
characterization	O
of	O
two	O
putative	O
human	B-protein
arginine	I-protein
methyltransferases	I-protein
(	O
HRMT1L1	B-protein
and	O
HRMT1L2	B-protein
)	O
.	O

The	O
contraceptive	O
pattern	O
of	O
157	O
women	O
was	O
analysed	O
and	O
13	O
.	O
8	O
percent	O
were	O
using	O
inefficient	O
methods	O
.	O

Patients	O
at	O
risk	O
of	O
hypothyroidism	O
.	O

Thus	O
,	O
included	O
in	O
the	O
KG1a	O
EST	O
dataset	O
are	O
candidates	O
for	O
new	O
human	O
genes	O
that	O
may	O
play	O
roles	O
in	O
hematopoietic	O
differentiative	O
progression	O
and	O
lineage	O
commitment	O
.	O

Restoration	O
of	O
opponens	O
function	O
with	O
transplantation	O
of	O
free	O
composites	O
dorsal	O
pedal	O
skin	O
flap	O
containing	O
m	O
.	O
extensor	O
hallucis	O
brevis	O
.	O

They	O
also	O
interact	O
with	O
GTPase	B-protein
activating	I-protein
proteins	I-protein
encoded	O
by	O
IRA1	B-protein
and	O
IRA2	B-protein
.	O

GLRaV	O
-	O
2	O
is	O
the	O
only	O
closterovirus	O
,	O
so	O
far	O
,	O
that	O
matches	O
the	O
genome	O
organization	O
of	O
the	O
type	O
member	O
of	O
the	O
group	O
,	O
BYV	O
,	O
and	O
thus	O
can	O
be	O
unambiguously	O
classified	O
as	O
a	O
definitive	O
member	O
of	O
the	O
genus	O
Closterovirus	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
promoter	O
and	O
enhancer	O
regions	O
identified	O
here	O
are	O
essential	O
for	O
maintaining	O
the	O
efficient	O
promoter	O
activity	O
of	O
the	O
human	B-protein
activin	I-protein
betaA	I-protein
subunit	I-protein
gene	I-protein
.	O

CONCLUSIONS	O
:	O
Significant	O
elevations	O
of	O
IL	B-protein
-	I-protein
1alpha	I-protein
and	O
IL	B-protein
-	I-protein
1beta	I-protein
occur	O
in	O
patients	O
with	O
bacterial	O
cystitis	O
and	O
microscopic	O
hematuria	O
.	O

Recent	O
work	O
in	O
this	O
laboratory	O
has	O
shown	O
that	O
the	O
gene	O
coding	O
for	O
acetate	B-protein
kinase	I-protein
(	O
ackA	B-protein
)	O
in	O
Sinorhizobium	O
meliloti	O
is	O
up	O
-	O
regulated	O
in	O
response	O
to	O
phosphate	O
limitation	O
.	O

Autoimmune	O
neutropenia	O
(	O
AIN	O
)	O
is	O
a	O
frequent	O
cause	O
of	O
chronic	O
neutropenia	O
especially	O
in	O
youngest	O
children	O
.	O

Comparison	O
of	O
the	O
amino	O
acid	O
sequences	O
of	O
the	O
RPO1	B-protein
polypeptides	I-protein
of	I-protein
IIV6	I-protein
,	I-protein
LCDV	I-protein
,	I-protein
and	I-protein
MCV	I-protein
-	I-protein
1	I-protein
with	O
the	O
corresponding	O
prokaryotic	O
,	O
eukaryotic	O
,	O
and	O
viral	O
proteins	O
revealed	O
differences	O
in	O
amino	O
acid	O
similarity	O
and	O
phylogenetic	O
relationships	O
.	O

Intravenous	O
antibiotic	O
therapy	O
in	O
cystic	O
fibrosis	O
:	O
in	O
hospital	O
or	O
at	O
home	O
?	O

Concordantly	O
,	O
it	O
was	O
shown	O
that	O
the	O
dnHLH	B-protein
protein	I-protein
Id1	I-protein
inhibits	O
differentiation	O
of	O
muscle	O
and	O
myeloid	O
cells	O
in	O
vitro	O
.	O

The	O
Drosophila	B-protein
melanogaster	I-protein
suppressor	I-protein
of	I-protein
sable	I-protein
gene	I-protein
,	O
su	B-protein
(	I-protein
s	I-protein
)	I-protein
,	O
encodes	O
a	O
novel	O
,	O
150	O
-	O
kDa	O
nuclear	O
RNA	O
binding	O
protein	O
,	O
SU	B-protein
(	I-protein
S	I-protein
)	I-protein
,	O
that	O
negatively	O
regulates	O
RNA	O
accumulation	O
from	O
mutant	O
alleles	O
of	O
other	O
genes	O
that	O
have	O
transposon	O
insertions	O
in	O
the	O
5	O
'	O
transcribed	O
region	O
.	O

0	O
.	O
61	O
+	O
/	O
-	O
0	O
.	O
04	O
)	O
.	O

In	O
addition	O
,	O
both	O
the	O
exon	O
1	O
-	O
and	O
exon	O
2	O
-	O
initiated	O
forms	O
of	O
the	O
c	B-protein
-	I-protein
Myc	I-protein
protein	I-protein
stimulated	O
transcription	O
of	O
a	O
Myc	B-protein
/	I-protein
Max	I-protein
-	I-protein
responsive	I-protein
reporter	I-protein
construct	I-protein
to	O
a	O
similar	O
level	O
.	O

Productive	O
growth	O
of	O
phage	O
P22	O
in	O
wild	O
-	O
type	O
Salmonella	O
typhimurium	O
correlates	O
with	O
the	O
presence	O
of	O
Abc2	B-protein
,	O
but	O
is	O
independent	O
of	O
the	O
absolute	O
level	O
of	O
ATP	B-protein
-	I-protein
dependent	I-protein
nuclease	I-protein
activity	O
,	O
suggesting	O
a	O
qualitative	O
change	O
in	O
the	O
nature	O
of	O
Abc2	O
-	O
modified	O
RecBCD	B-protein
nuclease	I-protein
activity	O
relative	O
to	O
the	O
native	O
enzyme	O
.	O

Thus	O
,	O
endemic	O
cumlations	O
of	O
hepatitis	O
A	O
diseases	O
are	O
possible	O
.	O

Systematic	O
review	O
of	O
diagnostic	O
tests	O
for	O
vaginal	O
trichomoniasis	O
.	O

Modification	O
by	O
this	O
latter	O
compound	O
was	O
so	O
extensive	O
that	O
the	O
amount	O
of	O
membrane	O
-	O
associated	O
N	O
-	O
myristoylated	O
protein	O
was	O
decreased	O
.	O

Rearrangements	O
of	O
the	O
NFKB2	B-protein
gene	I-protein
are	O
associated	O
with	O
lymphoid	O
malignancies	O
,	O
but	O
the	O
functional	O
significance	O
of	O
these	O
alterations	O
is	O
not	O
known	O
.	O

Thus	O
,	O
in	O
the	O
presence	O
of	O
active	B-protein
S	I-protein
-	I-protein
CDKs	I-protein
and	O
Dbf4	B-protein
/	I-protein
Cdc7	I-protein
,	O
Mcms	B-protein
may	O
open	O
origins	O
and	O
thereby	O
facilitate	O
the	O
loading	O
of	O
RPA	B-protein
.	O

In	O
canrenoate	O
-	O
treated	O
rats	O
,	O
ANP	B-protein
infusion	O
caused	O
greater	O
increases	O
in	O
sodium	O
excretion	O
(	O
FENA	O
from	O
3	O
.	O
05	O
+	O
/	O
-	O
0	O
.	O
71	O
to	O
7	O
.	O
21	O
+	O
/	O
-	O
0	O
.	O
45	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
;	O
n	O
=	O
8	O
)	O
than	O
saline	O
infusion	O
(	O
FENA	O
from	O
4	O
.	O
16	O
+	O
/	O
-	O
1	O
.	O
11	O
to	O
5	O
.	O
47	O
+	O
/	O
-	O
0	O
.	O
66	O
%	O
;	O
n	O
=	O
6	O
)	O
,	O
despite	O
the	O
hypocapnia	O
.	O

RT	O
-	O
PCR	O
analysis	O
showed	O
that	O
PLP	B-protein
-	I-protein
H	I-protein
as	O
well	O
as	O
PLP	B-protein
-	I-protein
C	I-protein
and	O
PLP	B-protein
-	I-protein
D	I-protein
are	O
expressed	O
in	O
all	O
rat	O
strains	O
examined	O
,	O
confirming	O
that	O
PLP	B-protein
diversity	O
is	O
not	O
due	O
to	O
strain	O
differences	O
.	O

In	O
rats	O
bearing	O
Walker	O
-	O
256	O
-	O
carcinosarcoma	O
4	O
-	O
EPI	O
was	O
effective	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

This	O
makes	O
these	O
compounds	O
attractive	O
as	O
vehicles	O
for	O
these	O
and	O
other	O
gases	O
in	O
-	O
vivo	O
and	O
in	O
-	O
vitro	O
.	O

Chem	O
.	O

We	O
now	O
show	O
that	O
the	O
BAT1	B-protein
translation	I-protein
product	I-protein
is	O
the	O
homolog	O
of	O
the	O
rat	B-protein
p47	I-protein
nuclear	I-protein
protein	I-protein
,	O
the	O
WM6	B-protein
Drosophila	I-protein
gene	I-protein
product	I-protein
,	O
and	O
probably	O
also	O
Ce08102	B-protein
of	O
Caenorhabditis	O
elegans	O
,	O
all	O
members	O
of	O
the	O
DEAD	B-protein
protein	I-protein
family	I-protein
of	O
ATP	B-protein
-	I-protein
dependent	I-protein
RNA	I-protein
helicases	I-protein
.	O

In	O
synchronized	O
HeLa	O
cells	O
,	O
expression	O
of	O
luciferase	B-protein
activity	O
was	O
induced	O
at	O
the	O
beginning	O
of	O
DNA	O
synthesis	O
and	O
was	O
dependent	O
on	O
the	O
presence	O
of	O
an	O
E2F	B-protein
-	I-protein
binding	I-protein
site	I-protein
in	O
the	O
H2A	B-protein
.	I-protein
1	I-protein
promoter	I-protein
.	O

Seventy	O
-	O
one	O
supplementary	O
doses	O
of	O
vecuronium	O
were	O
used	O
for	O
muscle	O
relaxation	O
during	O
a	O
22	O
-	O
h	O
-	O
long	O
NLA	O
II	O
anaesthesia	O
.	O

Strikingly	O
,	O
these	O
cells	O
contain	O
a	O
missense	O
mutation	O
of	O
the	O
p53	B-protein
gene	I-protein
at	O
codon	O
242	O
(	O
p53	O
(	O
242	O
)	O
)	O
,	O
which	O
substitutes	O
alanine	O
for	O
glycine	O
.	O

The	O
mapping	O
was	O
completed	O
with	O
Southern	O
blotting	O
and	O
restriction	O
analysis	O
.	O

Together	O
,	O
the	O
data	O
suggest	O
that	O
cAMP	O
-	O
dependent	O
control	O
of	O
the	O
amounts	O
of	O
the	O
activator	O
SF	B-protein
-	I-protein
1	I-protein
vs	O
.	O
the	O
repressor	O
COUP	B-protein
-	I-protein
TF	I-protein
could	O
influence	O
CRS2	O
-	O
dependent	O
transcription	O
.	O

The	O
findings	O
are	O
discussed	O
in	O
the	O
context	O
of	O
known	O
properties	O
of	O
cortical	O
-	O
bar	O
detectors	O
.	O

Human	B-protein
alpha	I-protein
-	I-protein
galactosidase	I-protein
A	I-protein
:	O
nucleotide	O
sequence	O
of	O
a	O
cDNA	O
clone	O
encoding	O
the	O
mature	O
enzyme	O
.	O

In	O
the	O
absence	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
,	O
purified	B-protein
soluble	I-protein
D10	I-protein
TCR	I-protein
bound	O
to	O
Staphylococcus	B-protein
aureus	I-protein
enterotoxin	I-protein
C2	I-protein
with	O
an	O
association	O
rate	O
of	O
1	O
.	O
69	O
+	O
/	O
-	O
0	O
.	O
12	O
x	O
10	O
(	O
4	O
)	O
M	O
(	O
-	O
1	O
)	O
sec	O
(	O
-	O
1	O
)	O
and	O
a	O
dissociation	O
rate	O
of	O
1	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
47	O
x	O
10	O
(	O
-	O
2	O
)	O
sec	O
(	O
-	O
1	O
)	O
,	O
giving	O
a	O
dissociation	O
constant	O
of	O
1	O
.	O
1	O
microM	O
.	O

The	O
case	O
for	O
completing	O
the	O
lymphadenectomy	O
when	O
positive	O
lymph	O
nodes	O
are	O
found	O
during	O
radical	O
hysterectomy	O
for	O
cervical	O
carcinoma	O
.	O

When	O
expressed	O
per	O
kilogram	O
body	O
weight	O
,	O
mean	O
GIT	O
increased	O
in	O
the	O
dF	O
group	O
from	O
0	O
.	O
14	O
%	O
to	O
0	O
.	O
16	O
%	O
above	O
RMR	O
,	O
with	O
a	O
significant	O
decrease	O
from	O
0	O
.	O
15	O
%	O
to	O
0	O
.	O
13	O
%	O
in	O
the	O
P	O
group	O
.	O

The	O
mature	O
chromosome	O
4	O
FRG1	B-protein
transcript	I-protein
is	O
1042	O
bp	O
in	O
length	O
and	O
contains	O
nine	O
exons	O
which	O
encode	O
a	O
putative	O
protein	O
of	O
258	O
amino	O
acid	O
residues	O
.	O

Various	O
transcripts	O
are	O
generated	O
from	O
the	O
VCSA1	B-protein
gene	I-protein
by	O
alternative	O
splicing	O
and	O
poly	O
(	O
A	O
)	O
processing	O
in	O
the	O
rat	O
submandibular	O
gland	O
.	O

A	O
stochastic	O
version	O
of	O
Kernell	O
'	O
s	O
(	O
1968	O
,	O
1972	O
)	O
model	O
with	O
cumulative	O
afterhyperpolarization	O
(	O
AHP	O
)	O
was	O
simulated	O
.	O

This	O
hypothesis	O
was	O
tested	O
by	O
introducing	O
mutations	O
at	O
each	O
of	O
the	O
three	O
histidine	O
pairs	O
,	O
the	O
H382	B-protein
-	I-protein
X2	I-protein
-	I-protein
H385	I-protein
pair	I-protein
,	O
the	O
H411	B-protein
-	I-protein
X2	I-protein
-	I-protein
H414	I-protein
pair	I-protein
and	O
the	O
H430	B-protein
-	I-protein
X5	I-protein
-	I-protein
H436	I-protein
pair	I-protein
,	O
which	O
constitute	O
the	O
histidine	O
-	O
rich	O
region	O
near	O
the	O
C	O
terminus	O
of	O
gp17	B-protein
.	O

The	O
isolated	O
plasmin	O
fragments	O
of	O
VEGF	B-protein
were	O
compared	O
with	O
respect	O
to	O
heparin	O
binding	O
,	O
interaction	O
with	O
soluble	O
VEGF	B-protein
receptors	I-protein
,	O
and	O
ability	O
to	O
promote	O
endothelial	O
cell	O
mitogenesis	O
.	O

Hepatitis	O
A	O
infected	O
food	O
handler	O
at	O
an	O
Edmonton	O
,	O
Alberta	O
retail	O
food	O
facility	O
:	O
public	O
health	O
protection	O
strategies	O
.	O

METHODS	O
:	O
126	O
patients	O
with	O
histologically	O
confirmed	O
MFH	O
were	O
analyzed	O
.	O

Our	O
purpose	O
was	O
to	O
determine	O
if	O
intact	O
perianal	O
(	O
S4	O
-	O
5	O
)	O
pin	O
sensation	O
(	O
PPS	O
)	O
and	O
bulbocavernosus	O
(	O
S2	O
-	O
4	O
)	O
reflex	O
(	O
BCR	O
)	O
shortly	O
after	O
spinal	O
cord	O
injury	O
(	O
SCI	O
)	O
are	O
predictive	O
of	O
bladder	O
function	O
recovery	O
.	O

Further	O
studies	O
demonstrated	O
that	O
the	O
PPARalpha	B-protein
ligand	O
8	O
(	O
S	O
)	O
-	O
hydroxyeicosatetraenoic	O
acid	O
strongly	O
promotes	O
the	O
interaction	O
of	O
PPARalpha	B-protein
with	O
the	O
co	O
-	O
activator	O
RIP	B-protein
-	I-protein
140	I-protein
but	O
decreases	O
the	O
interaction	O
of	O
PPARalpha	B-protein
with	O
the	O
co	O
-	O
repressor	O
SMRT	B-protein
.	O

When	O
O2	O
therapy	O
was	O
controlled	O
for	O
,	O
the	O
association	O
between	O
RBT	O
and	O
RLF	O
did	O
not	O
achieve	O
statistical	O
significance	O
(	O
P	O
=	O
.	O
07	O
)	O
.	O

In	O
the	O
brain	O
,	O
muscarinic	B-protein
receptors	I-protein
mediate	O
motor	O
and	O
memory	O
function	O
by	O
interaction	O
with	O
their	O
ligand	O
acetylcholine	O
.	O

Management	O
often	O
involves	O
beta	O
-	O
and	O
calcium	O
channel	O
blocking	O
drugs	O
or	O
type	O
IC	O
antiarrhythmic	O
drugs	O
.	O

Sensitivity	O
and	O
specificity	O
was	O
established	O
for	O
the	O
Pharmacia	O
CAP	O
System	O
and	O
the	O
DPC	O
AlaSTAT	O
System	O
by	O
comparison	O
with	O
results	O
of	O
the	O
skin	O
prick	O
test	O
.	O

The	O
interferon	O
-	O
inducible	O
protein	B-protein
kinase	I-protein
PKR	I-protein
modulates	O
the	O
transcriptional	O
activation	O
of	O
immunoglobulin	B-protein
kappa	I-protein
gene	I-protein
.	O

We	O
report	O
a	O
case	O
of	O
vasculitis	O
(	O
cutaneous	O
and	O
neurologic	O
)	O
which	O
led	O
to	O
the	O
discovery	O
of	O
a	O
selective	O
immunodeficit	O
towards	O
EBV	O
,	O
similar	O
to	O
Purtilo	O
'	O
s	O
syndrome	O
.	O

Inhibition	O
appears	O
to	O
result	O
from	O
titration	O
of	O
general	O
transcription	O
factors	O
because	O
MDM2	B-protein
overexpression	O
inhibits	O
c	B-protein
-	I-protein
fos	I-protein
as	O
well	O
as	O
other	O
promoters	O
in	O
vivo	O
and	O
basal	O
transcription	O
in	O
vitro	O
.	O

A	O
13	O
-	O
bp	O
cis	O
-	O
regulatory	O
element	O
in	O
the	O
LTR	O
promoter	O
of	O
the	O
tobacco	B-protein
retrotransposon	I-protein
Tto1	I-protein
is	O
involved	O
in	O
responsiveness	O
to	O
tissue	O
culture	O
,	O
wounding	O
,	O
methyl	O
jasmonate	O
and	O
fungal	O
elicitors	O
.	O

Serum	O
leptin	B-protein
concentrations	O
in	O
women	O
during	O
gonadotropin	B-protein
stimulation	O
cycles	O
.	O

In	O
this	O
study	O
,	O
we	O
purified	O
and	O
characterized	O
the	O
recombinant	B-protein
furin	I-protein
from	O
the	O
conditioned	O
medium	O
of	O
these	O
cells	O
.	O

Moreover	O
,	O
the	O
effect	O
exerted	O
by	O
TIS1	B-protein
appeared	O
to	O
be	O
selective	O
for	O
the	O
MCK	B-protein
promoter	I-protein
.	O

CD7	B-protein
+	I-protein
/	I-protein
CD3	I-protein
-	I-protein
T	O
-	O
cell	O
precursors	O
exhibit	O
V	B-protein
delta	I-protein
2D	I-protein
delta	I-protein
3	I-protein
rearrangements	I-protein
.	O

GCR1	B-protein
gene	I-protein
function	O
is	O
required	O
for	O
high	O
-	O
level	O
glycolytic	O
gene	O
expression	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Crohn	O
'	O
s	O
disease	O
in	O
prolonged	O
remission	O
:	O
should	O
one	O
augment	O
protein	O
-	O
calorie	O
intake	O
as	O
compared	O
to	O
healthy	O
subjects	O
?	O
The	O
aim	O
of	O
our	O
two	O
year	O
prospective	O
study	O
was	O
to	O
evaluate	O
whether	O
adult	O
Crohn	O
'	O
s	O
disease	O
patients	O
in	O
prolonged	O
remission	O
(	O
CDAI	O
<	O
150	O
)	O
,	O
in	O
order	O
to	O
maintain	O
their	O
body	O
weight	O
as	O
close	O
as	O
possible	O
to	O
the	O
ideal	O
one	O
,	O
need	O
a	O
protein	O
-	O
calorie	O
intake	O
higher	O
than	O
the	O
predicted	O
one	O
and	O
that	O
of	O
healthy	O
controls	O
.	O

Thus	O
,	O
this	O
study	O
provides	O
evidence	O
that	O
a	O
novel	O
,	O
ubiquitous	O
factor	O
(	O
HF	B-protein
-	I-protein
1a	I-protein
)	O
and	O
a	O
muscle	O
factor	O
(	O
HF	B-protein
-	I-protein
1b	I-protein
/	I-protein
MEF	I-protein
-	I-protein
2	I-protein
)	O
can	O
form	O
a	O
novel	O
,	O
E	O
-	O
box	O
-	O
independent	O
pathway	O
for	O
muscle	O
-	O
specific	O
expression	O
in	O
ventricular	O
cardiac	O
muscle	O
cells	O
.	O

Thyroid	O
function	O
tests	O
were	O
performed	O
on	O
300	O
admissions	O
,	O
leaving	O
707	O
untested	O
.	O

Molecular	O
cloning	O
and	O
expression	O
of	O
RPE65	B-protein
,	O
a	O
novel	O
retinal	O
pigment	O
epithelium	O
-	O
specific	O
microsomal	O
protein	O
that	O
is	O
post	O
-	O
transcriptionally	O
regulated	O
in	O
vitro	O
.	O

The	O
concentrations	O
of	O
apo	B-protein
A	I-protein
-	I-protein
I	I-protein
and	O
apo	B-protein
A	I-protein
-	I-protein
II	I-protein
of	O
abstainers	O
decreased	O
significantly	O
compared	O
with	O
the	O
corresponding	O
changes	O
in	O
controls	O
.	O

These	O
results	O
provide	O
the	O
first	O
demonstration	O
that	O
an	O
SR	B-protein
protein	I-protein
can	O
influence	O
splicing	O
of	O
specific	O
pre	O
-	O
mRNAs	O
in	O
vivo	O
.	O

Yeast	O
mutants	O
assigned	O
to	O
the	O
pet	O
complementation	O
group	O
G104	O
were	O
found	O
to	O
lack	O
alpha	B-protein
-	I-protein
ketoglutarate	I-protein
dehydrogenase	I-protein
activity	O
as	O
a	O
result	O
of	O
mutations	O
in	O
the	O
dihydrolipoyl	B-protein
transsuccinylase	I-protein
(	O
KE2	B-protein
)	O
component	O
of	O
the	O
complex	O
.	O

We	O
show	O
,	O
by	O
injection	O
of	O
synthetic	O
mRNAs	O
,	O
that	O
the	O
cis	O
-	O
acting	O
sequences	O
responsible	O
for	O
repression	O
of	O
cyclin	B-protein
B1	I-protein
mRNA	I-protein
reside	O
within	O
its	O
3	O
'	O
UTR	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
sensitivity	O
and	O
specificity	O
of	O
AMP	O
CT	O
(	O
Gen	O
-	O
Probe	O
Incorporated	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
on	O
urogenital	O
specimens	O
taken	O
from	O
symptomatic	O
patients	O
and	O
on	O
first	O
void	O
urine	O
(	O
FVU	O
)	O
specimens	O
from	O
asymptomatic	O
patients	O
.	O

There	O
were	O
35	O
boys	O
and	O
15	O
girls	O
,	O
with	O
a	O
mean	O
age	O
of	O
five	O
and	O
a	O
half	O
years	O
.	O

Analysis	O
of	O
mig	B-protein
/	I-protein
CAT	I-protein
chimeric	O
constructs	O
transiently	O
transfected	O
into	O
the	O
RAW	O
264	O
.	O
7	O
mouse	O
monocytic	O
cell	O
line	O
revealed	O
a	O
unique	O
IFN	B-protein
-	I-protein
gamma	I-protein
-	I-protein
responsive	I-protein
element	I-protein
(	O
gamma	B-protein
RE	I-protein
-	I-protein
1	I-protein
)	O
.	O

In	O
most	O
cases	O
,	O
DR4	O
-	O
homozygous	O
,	O
DRB1	O
-	O
heterozygous	O
individuals	O
could	O
be	O
genotyped	O
with	O
the	O
panel	O
of	O
probes	O
.	O

In	O
study	O
2	O
,	O
the	O
correlation	O
coefficients	O
between	O
the	O
ISO2	O
measurements	O
obtained	O
at	O
the	O
ulcer	O
margin	O
and	O
at	O
the	O
adjacent	O
normal	O
mucosa	O
,	O
and	O
delta	O
ISO2	O
obtained	O
by	O
the	O
experienced	O
observer	O
and	O
one	O
of	O
the	O
three	O
learners	O
were	O
0	O
.	O
94	O
,	O
0	O
.	O
97	O
,	O
and	O
0	O
.	O
94	O
,	O
respectively	O
.	O

Much	O
evidence	O
indicates	O
that	O
p38	B-protein
is	O
an	O
activator	O
of	O
MyoD	B-protein
:	O
(	O
i	O
)	O
p38	B-protein
kinase	I-protein
activity	O
is	O
required	O
for	O
the	O
expression	O
of	O
MyoD	B-protein
-	I-protein
responsive	I-protein
genes	I-protein
,	O
(	O
ii	O
)	O
enforced	O
induction	O
of	O
p38	B-protein
stimulates	O
the	O
transcriptional	O
activity	O
of	O
a	O
Gal4	B-protein
-	I-protein
MyoD	I-protein
fusion	I-protein
protein	I-protein
and	O
allows	O
efficient	O
activation	O
of	O
chromatin	O
-	O
integrated	O
reporters	O
by	O
MyoD	B-protein
,	O
and	O
(	O
iii	O
)	O
MyoD	O
-	O
dependent	O
myogenic	O
conversion	O
is	O
reduced	O
in	O
mouse	O
embryonic	O
fibroblasts	O
derived	O
from	O
p38alpha	B-protein
(	I-protein
-	I-protein
/	I-protein
-	I-protein
)	I-protein
embryos	O
.	O

Magnetic	O
storm	O
indicators	O
could	O
be	O
used	O
in	O
medicine	O
,	O
in	O
geophysics	O
and	O
for	O
special	O
purposes	O
.	O

However	O
,	O
a	O
strongly	O
increased	O
frequency	O
of	O
CpG	O
dinucleotides	O
was	O
found	O
.	O

Thus	O
,	O
as	O
expected	O
,	O
trans	O
-	O
splicing	O
depends	O
on	O
the	O
integrity	O
of	O
U2	B-protein
,	O
U4	B-protein
,	O
and	O
U6	B-protein
snRNAs	I-protein
.	O

The	O
protein	O
folds	O
correctly	O
with	O
two	O
disulfide	O
bonds	O
and	O
a	O
free	O
thiol	O
group	O
at	O
Cys25	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
footprinting	O
and	O
gel	O
mobility	O
retardation	O
assays	O
to	O
reveal	O
that	O
bacterially	O
synthesized	O
Zta	B-protein
fusion	I-protein
proteins	I-protein
bound	O
directly	O
to	O
six	O
TGTGCAA	B-protein
-	I-protein
like	I-protein
motifs	I-protein
within	O
DSL	B-protein
.	O

Dsh	B-protein
is	O
required	O
for	O
two	O
different	O
pathways	O
,	O
the	O
Wnt	B-protein
pathway	O
and	O
planar	O
polarity	O
pathway	O
in	O
Drosophila	O
.	O

The	O
C2C	B-protein
-	I-protein
Prx	I-protein
is	O
encoded	O
as	O
a	O
preprotein	O
of	O
273	O
amino	O
acids	O
containing	O
a	O
putative	O
chloroplast	O
-	O
targeting	O
signal	O
of	O
65	O
amino	O
acids	O
at	O
its	O
N	O
-	O
terminus	O
.	O

Here	O
we	O
show	O
in	O
mouse	O
fibroblasts	O
stably	O
transformed	O
by	O
v	B-protein
-	I-protein
Src	I-protein
that	O
mRNA	O
and	O
protein	O
levels	O
of	O
p21	B-protein
(	O
WAF1	B-protein
/	I-protein
CIP1	I-protein
)	O
,	O
cyclin	B-protein
D1	I-protein
,	O
and	O
cyclin	B-protein
E	I-protein
are	O
elevated	O
.	O

These	O
experiments	O
confirm	O
that	O
the	O
6	O
-	O
S	O
liganded	O
form	O
of	O
the	O
receptor	O
identified	O
in	O
nuclear	O
extracts	O
of	O
cells	O
treated	O
with	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
(	O
TCDD	O
)	O
contains	O
the	O
Ah	B-protein
receptor	I-protein
protein	I-protein
and	O
ARNT	B-protein
but	O
not	O
the	O
90	B-protein
-	I-protein
kDa	I-protein
heat	I-protein
shock	I-protein
protein	I-protein
.	O

These	O
children	O
were	O
grouped	O
into	O
four	O
diagnostic	O
categories	O
:	O
1	O
)	O
idiopathic	O
GH	B-protein
deficiency	O
(	O
n	O
=	O
10	O
)	O
;	O
2	O
)	O
organic	O
hypopituitarism	O
(	O
n	O
=	O
7	O
)	O
;	O
3	O
)	O
intrauterine	O
growth	O
retardation	O
(	O
n	O
=	O
5	O
)	O
;	O
and	O
4	O
)	O
constitutional	O
delay	O
of	O
growth	O
and	O
/	O
or	O
familial	O
short	O
stature	O
(	O
n	O
=	O
18	O
)	O
,	O
by	O
standard	O
clinical	O
criteria	O
and	O
physiological	O
and	O
pharmacological	O
tests	O
of	O
GH	B-protein
reserve	O
.	O

A	O
total	O
of	O
125	O
acute	O
leukemia	O
adult	O
patients	O
were	O
autografted	O
with	O
bone	O
marrow	O
(	O
BM	O
)	O
purged	O
by	O
mafosfamide	O
(	O
ASTA	O
Z	O
)	O
during	O
the	O
period	O
of	O
January	O
1983	O
to	O
January	O
1993	O
.	O

We	O
have	O
investigated	O
the	O
contribution	O
of	O
specific	O
TATA	B-protein
-	I-protein
binding	I-protein
protein	I-protein
(	O
TBP	B-protein
)	O
-	O
TATA	O
interactions	O
to	O
the	O
promoter	O
activity	O
of	O
a	O
constitutively	O
expressed	O
silkworm	B-protein
tRNA	I-protein
(	I-protein
C	I-protein
)	I-protein
(	I-protein
Ala	I-protein
)	I-protein
gene	I-protein
and	O
have	O
also	O
asked	O
whether	O
the	O
lack	O
of	O
similar	O
interactions	O
accounts	O
for	O
the	O
low	O
promoter	O
activity	O
of	O
a	O
silk	B-protein
gland	I-protein
-	I-protein
specific	I-protein
tRNA	I-protein
(	I-protein
SG	I-protein
)	I-protein
(	I-protein
Ala	I-protein
)	I-protein
gene	I-protein
.	O

Differences	O
in	O
the	O
clinical	O
presentation	O
and	O
the	O
gross	O
appearance	O
of	O
the	O
two	O
cases	O
are	O
described	O
,	O
and	O
similarities	O
in	O
the	O
microscopic	O
features	O
are	O
discussed	O
.	O

Superoxide	B-protein
dismutase	I-protein
(	O
SOD	B-protein
)	O
activity	O
decreased	O
significantly	O
in	O
sperm	O
subjected	O
to	O
direct	O
electric	O
current	O
in	O
comparison	O
to	O
the	O
control	O
or	O
the	O
sample	O
incubated	O
with	O
electrolyzed	O
medium	O
.	O

Thus	O
,	O
in	O
normal	O
intestinal	O
epithelial	O
goblet	O
cells	O
,	O
TbetaRI	B-protein
and	O
TbetaRII	B-protein
can	O
respond	O
to	O
autocrine	O
but	O
not	O
exogenous	O
TGF	B-protein
-	I-protein
beta	I-protein
without	O
the	O
participation	O
of	O
TbetaRIII	B-protein
.	O

A	O
full	B-protein
-	I-protein
length	I-protein
PRL	I-protein
receptor	I-protein
(	O
PRLR	B-protein
)	O
complementary	O
DNA	O
from	O
pigeons	O
was	O
obtained	O
by	O
screening	O
pigeon	O
crop	O
sac	O
libraries	O
and	O
by	O
reverse	O
transcription	O
coupled	O
with	O
polymerase	B-protein
chain	O
reaction	O
.	O

Individual	O
mutations	O
in	O
motifs	B-protein
III	I-protein
,	I-protein
IV	I-protein
,	I-protein
and	I-protein
V	I-protein
had	O
distinctive	O
effects	O
on	O
the	O
affinity	O
of	O
enzyme	O
for	O
GTP	O
,	O
the	O
rate	O
of	O
covalent	O
catalysis	O
(	O
EpG	O
formation	O
)	O
,	O
or	O
the	O
transfer	O
of	O
GMP	O
from	O
enzyme	O
to	O
RNA	O
.	O

Mutagenesis	O
of	O
each	O
NRF	B-protein
-	I-protein
1	I-protein
motif	I-protein
in	O
the	O
ALAS	B-protein
promoter	I-protein
gave	O
substantially	O
lowered	O
levels	O
of	O
chloramphenicol	B-protein
acetyltransferase	I-protein
expression	O
,	O
whereas	O
mutagenesis	O
of	O
both	O
NRF	B-protein
-	I-protein
1	I-protein
motifs	I-protein
resulted	O
in	O
the	O
almost	O
complete	O
loss	O
of	O
expression	O
.	O

The	O
C	O
-	O
terminal	O
mutants	O
were	O
strongly	O
dominant	O
over	O
TraR	B-protein
,	O
suggesting	O
that	O
they	O
can	O
form	O
heteromultimers	O
with	O
the	O
wild	O
-	O
type	O
activator	O
.	O

Gel	O
mobility	O
shift	O
assays	O
using	O
a	O
synthetic	O
E6	B-protein
motif	I-protein
detected	O
a	O
B	O
-	O
cell	O
-	O
specific	O
complex	O
in	O
addition	O
to	O
a	O
ubiquitous	O
band	O
found	O
also	O
in	O
T	O
cells	O
and	O
HeLa	O
cells	O
.	O

Mutations	O
in	O
either	O
gene	O
block	O
some	O
crucial	O
late	O
step	O
in	O
assembly	O
of	O
F1	B-protein
,	O
causing	O
the	O
alpha	O
and	O
beta	O
subunits	O
to	O
accumulate	O
in	O
mitochondria	O
as	O
inactive	O
aggregates	O
(	O
Ackerman	O
,	O
S	O
.	O

Sp1	B-protein
and	O
two	O
Sp3	B-protein
isoforms	I-protein
were	O
detected	O
as	O
the	O
primary	O
cellular	O
constituents	O
of	O
DNA	O
-	O
protein	O
complexes	O
formed	O
with	O
the	O
NF	B-protein
-	I-protein
kappaB	I-protein
-	I-protein
proximal	I-protein
site	I-protein
.	O

Strains	O
bearing	O
the	O
drs2	B-protein
mutation	I-protein
process	O
the	O
20S	B-protein
precursor	I-protein
of	O
the	O
mature	B-protein
18S	I-protein
rRNA	I-protein
slowly	O
and	O
are	O
deficient	O
in	O
40S	B-protein
ribosomal	I-protein
subunits	I-protein
.	O

The	O
recovery	O
of	O
labelled	O
methoxydextrane	O
is	O
98	O
+	O
/	O
-	O
7	O
%	O
.	O

RESULTS	O
:	O
The	O
overall	O
FNF	O
for	O
1992	O
was	O
12	O
.	O
3	O
%	O
and	O
was	O
19	O
.	O
1	O
%	O
,	O
22	O
.	O
2	O
%	O
,	O
3	O
.	O
8	O
%	O
and	O
6	O
.	O
1	O
%	O
per	O
successive	O
quarters	O
in	O
1992	O
.	O

In	O
cerebrospinal	O
fluid	O
,	O
an	O
ADA	B-protein
catalytic	O
concentration	O
above	O
0	O
.	O
15	O
mu	O
kat	O
/	O
L	O
strongly	O
suggests	O
tuberculous	O
meningitis	O
in	O
patients	O
older	O
than	O
7	O
years	O
(	O
sensitivity	O
1	O
.	O
00	O
,	O
specificity	O
0	O
.	O
99	O
and	O
efficiency	O
0	O
.	O
99	O
)	O
.	O

Along	O
with	O
previously	O
mapped	O
genes	O
including	O
Ly	B-protein
-	I-protein
1	I-protein
and	O
CD20	B-protein
,	O
OSBP	B-protein
defines	O
a	O
new	O
conserved	O
syntenic	O
group	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
11	O
in	O
the	O
human	O
and	O
the	O
proximal	O
end	O
of	O
chromosome	O
19	O
in	O
the	O
mouse	O
.	O

The	O
conserved	O
ninth	O
C	O
-	O
terminal	O
heptad	O
in	O
thyroid	O
hormone	O
and	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
mediates	O
diverse	O
responses	O
by	O
affecting	O
heterodimer	O
but	O
not	O
homodimer	O
formation	O
.	O

Secondly	O
,	O
an	O
ethanol	B-protein
repression	I-protein
autoregulation	I-protein
(	I-protein
ERA	I-protein
)	I-protein
/	I-protein
twelve	I-protein
-	I-protein
fold	I-protein
TA	I-protein
repeat	I-protein
(	I-protein
TAB	I-protein
)	I-protein
repressor	I-protein
element	I-protein
was	O
identified	O
within	O
the	O
promoter	O
region	O
of	O
the	O
GLK1	B-protein
gene	I-protein
.	O

With	O
a	O
sample	O
of	O
mothers	O
of	O
healthy	O
infants	O
,	O
all	O
three	O
subscales	O
of	O
the	O
revised	O
instrument	O
,	O
WPL	O
-	O
R	O
,	O
had	O
acceptable	O
levels	O
of	O
internal	O
consistency	O
at	O
7	O
,	O
30	O
,	O
and	O
90	O
days	O
postpartum	O
,	O
and	O
stability	O
across	O
administrations	O
.	O

These	O
results	O
implicate	O
a	O
precursor	O
-	O
specific	O
base	O
-	O
paired	O
structure	O
involving	O
sequences	O
on	O
both	O
sides	O
of	O
the	O
mature	O
cleavage	O
site	O
in	O
the	O
3	O
'	O
processing	O
of	O
human	B-protein
U2	I-protein
RNA	I-protein
.	O

It	O
corresponds	O
to	O
the	O
complete	O
mitochondrial	O
presequence	O
and	O
the	O
lipoyl	O
-	O
bearing	O
domain	O
that	O
are	O
encoded	O
by	O
exons	O
I	O
through	O
IV	O
of	O
the	O
functional	O
E2	B-protein
gene	I-protein
.	O

Viscosity	O
experiments	O
on	O
the	O
catalytic	O
fragment	O
kinase	B-protein
reaction	O
demonstrated	O
that	O
the	O
chemical	O
(	O
phosphoryl	O
transfer	O
)	O
step	O
had	O
a	O
reduced	O
rate	O
.	O

To	O
define	O
the	O
mechanism	O
responsible	O
for	O
the	O
loss	O
of	O
transcription	O
elongation	O
blockage	O
and	O
resulting	O
c	B-protein
-	I-protein
myc	I-protein
deregulation	O
in	O
Burkitt	O
'	O
s	O
lymphoma	O
,	O
we	O
analyzed	O
transcription	O
patterns	O
after	O
transfer	O
of	O
normal	O
and	O
Burkitt	O
'	O
s	O
lymphoma	O
c	B-protein
-	I-protein
myc	I-protein
alleles	O
into	O
murine	O
cells	O
and	O
Xenopus	O
oocyte	O
germinal	O
vesicles	O
.	O

Mutation	O
analyses	O
identified	O
the	O
cobalt	O
-	O
responsive	O
sequences	O
as	O
the	O
stress	B-protein
-	I-protein
response	I-protein
elements	I-protein
(	O
StREs	B-protein
)	O
.	O

Molecular	O
characterization	O
of	O
type	B-protein
-	I-protein
specific	I-protein
capsular	I-protein
polysaccharide	I-protein
biosynthesis	I-protein
genes	I-protein
of	I-protein
Streptococcus	I-protein
agalactiae	I-protein
type	I-protein
Ia	O
.	O

The	O
model	O
also	O
predicts	O
that	O
blood	O
flow	O
shunt	O
fraction	O
(	O
Qs	O
/	O
QT	O
)	O
is	O
directly	O
related	O
to	O
the	O
oxygen	O
sine	O
-	O
wave	O
amplitude	O
perturbations	O
transmitted	O
to	O
end	O
-	O
expired	O
air	O
and	O
arterial	O
and	O
mixed	O
-	O
venous	O
blood	O
through	O
two	O
simple	O
equations	O
.	O

Filter	O
and	O
cytocentrifuge	O
preparations	O
of	O
the	O
urine	O
were	O
studied	O
and	O
all	O
cases	O
displayed	O
numerous	O
scattered	O
aggregates	O
or	O
single	O
tumor	O
cells	O
in	O
an	O
inflammatory	O
background	O
.	O

Mean	O
longitudinal	O
extension	O
of	O
the	O
epidural	O
lesion	O
was	O
2	O
.	O
6	O
vertebral	O
segments	O
.	O

Cis	O
-	O
acting	O
CCAAT	B-protein
elements	I-protein
are	O
frequently	O
found	O
in	O
eukaryotic	O
promoter	O
regions	O
.	O

Expression	O
of	O
Bcl	B-protein
-	I-protein
XL	I-protein
inhibited	O
the	O
association	O
of	O
Apaf	B-protein
-	I-protein
1	I-protein
with	O
caspase	B-protein
-	I-protein
9	I-protein
in	O
mammalian	O
cells	O
.	O

SF	B-protein
-	I-protein
1	I-protein
does	O
not	O
have	O
an	O
N	B-protein
-	I-protein
terminal	I-protein
AF1	I-protein
domain	I-protein
.	O

Basing	O
on	O
experimental	O
toxicity	O
research	O
it	O
was	O
established	O
that	O
,	O
out	O
of	O
50	O
atmosphere	O
metal	O
corrosion	O
inhibitors	O
,	O
some	O
14	O
per	O
cent	O
were	O
found	O
extremely	O
hazardous	O
,	O
42	O
per	O
cent	O
-	O
-	O
of	O
high	O
level	O
hazardous	O
,	O
33	O
percent	O
-	O
-	O
of	O
moderate	O
and	O
11	O
per	O
cent	O
-	O
-	O
of	O
low	O
hazardous	O
.	O

Azygos	O
vein	O
abutting	O
the	O
posterior	O
wall	O
of	O
the	O
right	O
main	O
and	O
upper	O
lobe	O
bronchi	O
:	O
a	O
normal	O
CT	O
variant	O
.	O

We	O
also	O
report	O
that	O
AHR	B-protein
interacts	O
with	O
COUP	B-protein
-	I-protein
TF	I-protein
in	O
transfected	O
CV	O
-	O
1	O
cells	O
.	O

Acute	O
pancreatitis	O
as	O
a	O
complication	O
of	O
polyarteritis	O
nodosa	O
.	O

Cluster	O
formation	O
of	O
E	B-protein
-	I-protein
cadherin	I-protein
on	O
the	O
cell	O
surface	O
is	O
believed	O
to	O
be	O
of	O
major	O
importance	O
for	O
cell	O
-	O
cell	O
adhesion	O
.	O

Following	O
seven	O
days	O
'	O
incubation	O
both	O
at	O
20	O
degrees	O
C	O
and	O
28	O
degrees	O
C	O
,	O
Ae	O
.	O
vexans	O
nip	O
.	O
was	O
capable	O
of	O
transmitting	O
the	O
virus	O
.	O

Interplane	O
coupling	O
in	O
the	O
superconductor	O
Y2Ba4Cu7O15	O
as	O
revealed	O
by	O
NQR	O
spin	O
-	O
echo	O
double	O
resonance	O
.	O

The	O
evidence	O
in	O
support	O
of	O
this	O
was	O
derived	O
from	O
the	O
fact	O
that	O
the	O
affinity	O
or	O
interaction	O
between	O
the	O
two	O
subunits	O
was	O
impaired	O
as	O
indicated	O
by	O
the	O
first	O
order	O
rate	O
constant	O
of	O
hCG	B-protein
alpha	I-protein
1	I-protein
beta	I-protein
(	O
km	O
=	O
4	O
.	O
1	O
x	O
10	O
(	O
-	O
2	O
)	O
min	O
-	O
1	O
)	O
at	O
pH	O
3	O
.	O
0	O
at	O
23	O
degrees	O
C	O
which	O
is	O
one	O
order	O
of	O
magnitude	O
greater	O
relative	O
to	O
rehCG	B-protein
(	O
kw	O
=	O
4	O
.	O
6	O
x	O
10	O
(	O
-	O
3	O
)	O
min	O
-	O
1	O
)	O
.	O

Correlation	O
coefficients	O
between	O
the	O
reference	O
methods	O
and	O
NIT	O
were	O
>	O
or	O
=	O
0	O
.	O
95	O
for	O
water	O
,	O
fat	O
,	O
crude	O
protein	O
and	O
connective	O
-	O
tissue	O
-	O
protein	O
frei	O
meat	O
protein	O
,	O
and	O
>	O
or	O
=	O
0	O
.	O
86	O
for	O
connective	O
-	O
tissue	O
-	O
protein	O
.	O

Sci	O
.	O

A	O
miracle	O
cure	O
and	O
its	O
solution	O
.	O

The	O
human	B-protein
SHBG	I-protein
proximal	I-protein
promoter	I-protein
was	O
analyzed	O
by	O
DNase	B-protein
I	I-protein
footprinting	O
,	O
and	O
the	O
functional	O
significance	O
of	O
6	O
footprinted	O
regions	O
(	O
FP1	O
-	O
FP6	O
)	O
within	O
the	O
proximal	O
promoter	O
was	O
studied	O
in	O
human	O
HepG2	O
hepatoblastoma	O
cells	O
.	O

Two	O
activities	O
of	O
the	O
D	B-protein
protein	I-protein
of	O
the	O
miniF	O
plasmid	O
have	O
been	O
found	O
.	O

After	O
nitric	O
oxide	O
inhalation	O
,	O
the	O
results	O
showed	O
moderate	O
increases	O
in	O
PaO2	O
and	O
SaO2	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
and	O
a	O
significant	O
decrease	O
in	O
Qs	O
/	O
Q	O
tau	O
ratio	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
mass	O
of	O
UO2	O
in	O
the	O
extrapulmonary	O
bronchi	O
and	O
first	O
bifurcation	O
decreased	O
more	O
slowly	O
over	O
0	O
-	O
-	O
8	O
d	O
after	O
inhalation	O
than	O
the	O
corresponding	O
mass	O
on	O
the	O
trachea	O
.	O

This	O
region	O
is	O
required	O
for	O
activation	O
of	O
DNA	O
binding	O
of	O
MyoD	B-protein
and	O
E12	B-protein
homodimers	I-protein
and	O
E12	B-protein
/	I-protein
MyoD	I-protein
heterodimers	I-protein
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
a	O
detailed	O
study	O
of	O
the	O
structure	O
and	O
the	O
functional	O
role	O
of	O
the	O
MalT	B-protein
binding	I-protein
sites	I-protein
located	O
in	O
the	O
adjacent	O
and	O
divergent	O
pulAp	B-protein
and	O
pulCp	B-protein
promoters	I-protein
.	O

Interestingly	O
,	O
EGF	B-protein
,	O
but	O
not	O
insulin	B-protein
,	O
stimulated	O
tyrosine	O
phosphorylation	O
of	O
c	B-protein
-	I-protein
cbl	I-protein
and	O
its	O
association	O
with	O
Crk	B-protein
-	I-protein
II	I-protein
.	O

Interferon	B-protein
-	I-protein
alpha	I-protein
may	O
exacerbate	O
cryoblobulinemia	O
-	O
related	O
ischemic	O
manifestations	O
:	O
an	O
adverse	O
effect	O
potentially	O
related	O
to	O
its	O
anti	O
-	O
angiogenic	O
activity	O
.	O

Two	O
such	O
genes	O
,	O
designated	O
hsiggll150	B-protein
and	O
hsiggll295	B-protein
,	O
were	O
cloned	O
and	O
sequenced	O
from	O
genomic	O
DNA	O
.	O

Cyclin	B-protein
D1	I-protein
could	O
not	O
be	O
displaced	O
from	O
cdk4	B-protein
in	O
the	O
resistant	O
184A1L5R	O
cell	O
lysates	O
.	O

RESULTS	O
:	O
Patients	O
in	O
Group	O
A	O
had	O
a	O
higher	O
incidence	O
of	O
posterolateral	O
wall	O
motion	O
abnormalities	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
on	O
radionuclide	O
ventriculography	O
,	O
a	O
larger	O
infarct	O
area	O
(	O
as	O
evidenced	O
by	O
higher	O
peak	O
creatine	B-protein
kinase	I-protein
levels	O
)	O
(	O
p	O
<	O
0	O
.	O
02	O
)	O
and	O
a	O
lower	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
at	O
hospital	O
discharge	O
(	O
p	O
<	O
0	O
.	O
008	O
)	O
than	O
those	O
in	O
Group	O
B	O
.	O

The	O
incompatibility	O
group	O
W	O
plasmid	O
pSa	O
suppresses	O
Agrobacterium	O
tumefaciens	O
oncogenicity	O
(	O
J	O
.	O

In	O
this	O
report	O
,	O
we	O
identify	O
and	O
characterize	O
two	O
overlapping	O
ELL	B-protein
functional	I-protein
domains	I-protein
that	O
govern	O
its	O
interaction	O
with	O
RNA	B-protein
polymerase	I-protein
II	I-protein
and	O
the	O
ternary	O
elongation	O
complex	O
.	O

The	O
Spo0F	B-protein
residues	I-protein
making	O
up	O
the	O
hydrophobic	O
patch	O
are	O
very	O
similar	O
in	O
all	O
response	O
regulators	O
suggesting	O
that	O
the	O
binding	O
is	O
initiated	O
through	O
the	O
same	O
residues	O
in	O
all	O
interacting	O
response	O
regulator	O
-	O
kinase	O
pairs	O
.	O

The	O
so	O
-	O
called	O
`	B-protein
`	I-protein
SH3	I-protein
'	I-protein
'	I-protein
segment	I-protein
of	O
the	O
linker	O
domain	O
,	O
in	O
contrast	O
,	O
shows	O
species	O
-	O
specific	O
sequence	O
identity	O
in	O
all	O
but	O
one	O
amino	O
acid	O
residues	O
in	O
both	O
factors	O
,	O
in	O
cattle	O
,	O
human	O
,	O
and	O
mouse	O
.	O

Early	O
indicators	O
of	O
the	O
effect	O
of	O
a	O
breast	O
cancer	O
screening	O
program	O
for	O
low	O
-	O
income	O
women	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
developmental	O
scores	O
at	O
9	O
or	O
18	O
months	O
,	O
although	O
PDF	O
infants	O
had	O
a	O
2	O
.	O
8	O
(	O
-	O
1	O
.	O
3	O
-	O
6	O
.	O
8	O
)	O
point	O
advantage	O
in	O
Bayley	O
motor	O
score	O
scales	O
.	O

Analysis	O
of	O
its	O
genomic	O
region	O
revealed	O
that	O
the	O
13	O
-	O
kb	O
Cdc6	B-protein
gene	I-protein
is	O
divided	O
into	O
12	O
exons	O
by	O
11	O
introns	O
.	O

Private	O
hospital	O
accreditation	O
.	O

One	O
of	O
these	O
is	O
located	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
,	O
and	O
may	O
encode	O
regulatory	O
sequences	O
.	O

Glomerular	O
mesangial	O
cells	O
expressed	O
an	O
abundant	O
1	O
.	O
1	O
kb	O
mRNA	O
transcript	O
for	O
Id1	B-protein
,	O
but	O
in	O
contrast	O
to	O
other	O
cell	O
types	O
Id1	B-protein
mRNA	I-protein
was	O
expressed	O
in	O
both	O
randomly	O
cycling	O
cells	O
and	O
in	O
serum	O
-	O
deprived	O
,	O
quiescent	O
cultures	O
.	O

CNS	O
effects	O
of	O
local	O
anesthetics	O
only	O
partially	O
dependent	O
on	O
biogenic	O
amine	O
mechanisms	O
.	O

Transcriptional	O
activity	O
was	O
measured	O
by	O
slot	O
-	O
blot	O
hybridization	O
with	O
steady	O
-	O
state	O
RNA	O
isolated	O
from	O
lacZ	B-protein
+	I-protein
M	I-protein
.	I-protein
smegmatis	I-protein
clones	O
.	O

CONCLUSION	O
:	O
The	O
MTD	O
for	O
CPT	O
-	O
11	O
administered	O
in	O
a	O
3	O
consecutive	O
-	O
days	O
-	O
every	O
-	O
3	O
weeks	O
schedule	O
in	O
this	O
patient	O
population	O
is	O
115	O
mg	O
/	O
m2	O
/	O
day	O
.	O

4	O
.	O

ICP4	B-protein
has	O
been	O
shown	O
to	O
form	O
tripartite	O
complexes	O
cooperatively	O
with	O
the	O
TATA	B-protein
box	I-protein
-	I-protein
binding	I-protein
protein	I-protein
and	O
TFIIB	B-protein
on	O
DNA	O
containing	O
an	O
ICP4	B-protein
binding	I-protein
site	I-protein
and	O
a	O
TATA	O
box	O
(	O
C	O
.	O

OBJECTIVE	O
:	O
Our	O
purpose	O
was	O
to	O
determine	O
the	O
simultaneous	O
concentrations	O
of	O
serum	O
cotinine	O
in	O
both	O
fetal	O
and	O
maternal	O
blood	O
.	O

Records	O
of	O
31	O
children	O
with	O
AIDS	O
or	O
AIDS	O
-	O
related	O
complex	O
admitted	O
to	O
the	O
pediatric	O
intensive	O
care	O
unit	O
for	O
acute	O
respiratory	O
failure	O
throughout	O
a	O
46	O
-	O
month	O
period	O
were	O
reviewed	O
.	O

The	O
artery	O
cuff	O
was	O
slightly	O
superior	O
to	O
the	O
fat	O
wrap	O
,	O
particularly	O
in	O
having	O
fewer	O
adhesions	O
and	O
a	O
better	O
histological	O
picture	O
.	O

Liquid	O
chromatographic	O
separation	O
was	O
achieved	O
on	O
a	O
Zorbax	O
RX	O
C8	O
analytical	O
column	O
using	O
gradient	O
elution	O
.	O

A	O
cDNA	O
clone	O
corresponding	O
to	O
the	O
putative	O
GA	B-protein
20	I-protein
-	I-protein
oxidase	I-protein
genomic	I-protein
sequence	I-protein
was	O
constructed	O
with	O
the	O
reverse	O
transcription	O
-	O
PCR	O
method	O
,	O
and	O
the	O
identity	O
of	O
the	O
cDNA	O
clone	O
was	O
confirmed	O
by	O
analyzing	O
the	O
capability	O
of	O
the	O
fusion	O
protein	O
expressed	O
in	O
Escherichia	O
coli	O
to	O
convert	O
GA53	B-protein
to	O
GA44	B-protein
and	O
GA19	B-protein
to	O
GA20	B-protein
.	O

The	O
incidence	O
of	O
DNCB	O
reactions	O
was	O
78	O
per	O
cent	O
for	O
Stage	O
I	O
and	O
II	O
cancers	O
(	O
37	O
patinets	O
)	O
,	O
73	O
per	O
cent	O
for	O
resectable	O
Stage	O
III	O
cancer	O
(	O
22	O
patients	O
)	O
,	O
and	O
66	O
per	O
cent	O
in	O
patients	O
with	O
unresectable	O
or	O
inoperable	O
Stage	O
III	O
cancer	O
.	O

An	O
analysis	O
of	O
the	O
dynamics	O
is	O
performed	O
of	O
exactly	O
solvable	O
models	O
for	O
fragile	O
and	O
strong	O
glasses	O
,	O
exploiting	O
the	O
partitioning	O
of	O
the	O
free	O
-	O
energy	O
landscape	O
in	O
inherent	O
structures	O
.	O

Moreover	O
,	O
elderly	O
men	O
with	O
bioavailable	O
estradiol	O
levels	O
below	O
the	O
median	O
[	O
40	O
pmol	O
/	O
liter	O
(	O
11	O
pg	O
/	O
ml	O
)	O
]	O
had	O
significantly	O
higher	O
rates	O
of	O
bone	O
loss	O
and	O
levels	O
of	O
bone	O
resorption	O
markers	O
than	O
men	O
with	O
bioavailable	O
estradiol	O
levels	O
above	O
40	O
pmol	O
/	O
liter	O
.	O

Replacing	O
residues	O
405	O
-	O
419	O
on	O
delta419	O
with	O
the	O
conserved	O
AF	B-protein
-	I-protein
2	I-protein
domain	I-protein
from	O
the	O
vitamin	B-protein
D3	I-protein
receptor	I-protein
or	O
the	O
estrogen	B-protein
receptor	I-protein
results	O
in	O
a	O
receptor	O
with	O
wild	O
-	O
type	O
or	O
low	O
transcriptional	O
activity	O
,	O
respectively	O
.	O

Psychological	O
disturbance	O
was	O
greater	O
in	O
the	O
high	O
life	O
stress	O
group	O
as	O
indicated	O
by	O
significant	O
elevations	O
on	O
the	O
global	O
severity	O
index	O
of	O
the	O
Symptom	O
Checklist	O
-	O
90	O
and	O
elevations	O
on	O
somatization	O
,	O
obsessive	O
compulsive	O
,	O
interpersonal	O
sensitivity	O
,	O
depression	O
,	O
anxiety	O
and	O
psychoticism	O
subscales	O
.	O

Since	O
electrical	O
stimulation	O
of	O
neurones	O
may	O
activate	O
not	O
only	O
cell	O
bodies	O
but	O
also	O
neuronal	O
fibres	O
,	O
this	O
study	O
aimed	O
to	O
test	O
a	O
selectively	O
cholinergic	O
neurochemical	O
stimulation	O
of	O
the	O
rat	O
substantia	O
innominata	O
(	O
SI	O
)	O
by	O
the	O
local	O
microinjection	O
of	O
carbachol	O
;	O
the	O
effects	O
of	O
this	O
acetylcholine	O
agonist	O
were	O
compared	O
with	O
glutamate	O
.	O

Eucaryotic	O
transcription	O
factors	O
that	O
stimulate	O
RNA	B-protein
polymerase	I-protein
II	I-protein
by	O
increasing	O
the	O
efficiency	O
of	O
elongation	O
of	O
specifically	O
or	O
randomly	O
initiated	O
RNA	O
chains	O
have	O
been	O
isolated	O
and	O
characterized	O
.	O

We	O
used	O
a	O
rev	O
-	O
and	O
RRE	O
-	O
defective	O
HIV	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
molecular	O
clone	O
in	O
complementation	O
experiments	O
to	O
establish	O
a	O
method	O
for	O
the	O
rapid	O
isolation	O
of	O
posttranscriptional	O
regulatory	O
elements	O
from	O
the	O
mammalian	O
genome	O
by	O
selecting	O
for	O
rescue	O
of	O
virus	O
replication	O
.	O

Evolutionary	O
conservation	O
of	O
homeodomain	B-protein
-	I-protein
binding	I-protein
sites	I-protein
and	O
other	O
sequences	O
upstream	O
and	O
within	O
the	O
major	O
transcription	O
unit	O
of	O
the	O
Drosophila	B-protein
segmentation	I-protein
gene	I-protein
engrailed	I-protein
.	O

Furthermore	O
,	O
the	O
NH2	O
-	O
terminal	O
portion	O
of	O
the	O
homologue	O
was	O
not	O
translocated	O
into	O
the	O
outer	O
membrane	O
without	O
its	O
COOH	O
-	O
terminal	O
part	O
.	O

The	O
5	O
'	O
flanking	O
regions	O
of	O
both	O
pelA	B-protein
and	O
pelB	B-protein
were	O
translationally	O
fused	O
to	O
the	O
beta	B-protein
-	I-protein
glucuronidase	I-protein
gene	I-protein
and	O
introduced	O
into	O
F	O
.	O
solani	O
f	O
.	O
sp	O
.	O
pisi	O
,	O
and	O
beta	B-protein
-	I-protein
glucuronidase	I-protein
activities	O
of	O
the	O
transformants	O
were	O
measured	O
.	O

A	O
human	O
recombinant	O
cDNA	O
clone	O
that	O
encoded	O
253	O
amino	O
acids	O
residues	O
of	O
a	O
zinc	B-protein
-	I-protein
finger	I-protein
protein	I-protein
(	O
THZif	B-protein
-	I-protein
1	I-protein
)	O
was	O
cloned	O
by	O
screening	O
a	O
cDNA	O
library	O
prepared	O
from	O
human	O
promyelocytic	O
leukemia	O
HL60	O
cells	O
with	O
synthetic	O
oligodeoxynucleotide	O
probes	O
that	O
corresponded	O
to	O
the	O
amino	O
acid	O
sequences	O
of	O
tryptic	O
peptides	O
derived	O
from	O
the	O
DNA	O
-	O
binding	O
protein	O
specific	O
for	O
the	O
nuclease	B-protein
-	I-protein
hypersensitive	I-protein
element	I-protein
(	O
NHE	B-protein
)	O
of	O
the	O
human	B-protein
c	I-protein
-	I-protein
myc	I-protein
gene	I-protein
.	O

Human	B-protein
papillomavirus	I-protein
type	I-protein
31b	I-protein
late	I-protein
gene	I-protein
expression	O
is	O
regulated	O
through	O
protein	B-protein
kinase	I-protein
C	O
-	O
mediated	O
changes	O
in	O
RNA	O
processing	O
.	O

Amino	O
acid	O
residues	O
of	O
beta	O
1	O
'	O
,	O
alpha	O
A	O
'	O
,	O
alpha	O
B	O
'	O
,	O
and	O
the	O
loop	O
containing	O
His539	O
of	O
the	O
RNase	B-protein
H	I-protein
domain	I-protein
interact	O
with	O
the	O
primer	O
strand	O
of	O
the	O
dsDNA	O
.	O

Regulated	O
activity	O
of	O
the	O
distal	O
promoter	O
-	O
like	O
element	O
of	O
the	O
human	B-protein
corticotropin	I-protein
-	I-protein
releasing	I-protein
hormone	I-protein
gene	I-protein
and	O
secondary	O
structural	O
features	O
of	O
its	O
corresponding	O
transcripts	O
.	O

The	O
60A	B-protein
transcripts	I-protein
and	O
protein	O
are	O
first	O
detected	O
at	O
the	O
onset	O
of	O
gastrulation	O
,	O
primarily	O
in	O
the	O
mesoderm	O
of	O
the	O
extending	O
germ	O
band	O
.	O

An	O
11	O
-	O
month	O
-	O
old	O
girl	O
suffering	O
from	O
Dandy	O
-	O
Walker	O
malformation	O
(	O
DWM	O
)	O
associated	O
with	O
tetralogy	O
of	O
Fallot	O
(	O
TOF	O
)	O
is	O
presented	O
.	O

Determination	O
of	O
transaminases	B-protein
with	O
an	O
autoanalyzer	O
.	O

The	O
proteins	O
encoded	O
downstream	O
of	O
rpoN	B-protein
are	O
known	O
to	O
negatively	O
regulate	O
sigma	B-protein
54	I-protein
activity	O
.	O

The	O
genomic	O
and	O
transcriptional	O
complexity	O
of	O
the	O
Crry	B-protein
and	O
Crry	B-protein
-	I-protein
ps	I-protein
genes	I-protein
.	O

The	O
apparatus	O
consists	O
of	O
an	O
Am	O
-	O
241	O
exciting	O
source	O
(	O
300	O
mCi	O
)	O
and	O
pure	O
Ge	O
detector	O
(	O
50	O
mm2	O
X	O
5	O
mm	O
)	O
for	O
measuring	O
K	O
alpha	O
fluorescent	O
x	O
-	O
rays	O
(	O
28	O
.	O
3	O
and	O
28	O
.	O
6	O
KeV	O
)	O
emitted	O
from	O
exited	O
iodine	O
.	O

The	O
potentially	O
SLE	O
-	O
inducing	O
drugs	O
are	O
reviewed	O
.	O

In	O
this	O
study	O
,	O
we	O
sought	O
to	O
identify	O
mechanisms	O
that	O
could	O
account	O
for	O
the	O
antimitogenic	O
effects	O
of	O
IL	B-protein
-	I-protein
4	I-protein
.	O

Subsequent	O
cloning	O
and	O
nucleotide	O
sequence	O
analysis	O
of	O
the	O
S	B-protein
.	I-protein
pombe	I-protein
adenylate	I-protein
kinase	I-protein
gene	I-protein
,	O
adk1	B-protein
,	O
revealed	O
a	O
coding	O
region	O
of	O
660	O
nucleotides	O
.	O

Three	O
subgenomes	O
also	O
comprised	O
15	O
to	O
75	O
nucleotides	O
derived	O
from	O
the	O
5	O
'	O
part	O
of	O
the	O
NS2	B-protein
gene	I-protein
.	O

The	O
present	O
investigation	O
sought	O
to	O
identify	O
the	O
principal	O
dimensions	O
of	O
the	O
Framingham	O
Type	O
A	O
scale	O
(	O
FTAS	O
)	O
and	O
then	O
to	O
examine	O
their	O
physiological	O
and	O
psychological	O
correlates	O
.	O

SCL	O
prolonged	O
promptly	O
after	O
verapamil	O
,	O
and	O
sinus	O
arrest	O
developed	O
in	O
two	O
of	O
10	O
group	O
2	O
and	O
two	O
of	O
five	O
group	O
3	O
animals	O
.	O

Enhanced	O
hepatic	O
portal	O
blood	O
flow	O
induced	O
by	O
prostaglandin	O
E1	O
following	O
liver	O
transplantation	O
in	O
pigs	O
.	O

The	O
promoter	O
of	O
the	O
rat	B-protein
PGS	I-protein
-	I-protein
2	I-protein
gene	I-protein
contains	O
a	O
CAAT	B-protein
enhancer	I-protein
-	I-protein
binding	I-protein
protein	I-protein
consensus	I-protein
site	I-protein
(	I-protein
CAAT	I-protein
box	I-protein
)	I-protein
which	O
can	O
confer	O
hormone	O
inducibility	O
to	O
a	O
PGS	B-protein
-	I-protein
2	I-protein
.	I-protein
CAT	I-protein
reporter	I-protein
gene	I-protein
,	O
as	O
well	O
as	O
a	O
putative	O
E	O
-	O
box	O
region	O
.	O

A	O
3	O
-	O
week	O
regimen	O
of	O
erythropoietin	B-protein
may	O
help	O
prevent	O
the	O
donor	O
'	O
s	O
need	O
to	O
receive	O
allogeneic	O
blood	O
transfusion	O
,	O
when	O
the	O
initial	O
Hb	B-protein
levels	O
were	O
below	O
130	O
milligrams	O
.	O

Nutritional	O
cataracts	O
in	O
timber	O
wolves	O
.	O

Molecular	O
and	O
functional	O
characterization	O
of	O
the	O
promoter	O
of	O
ETS2	B-protein
,	O
the	O
human	O
c	B-protein
-	I-protein
ets	I-protein
-	I-protein
2	I-protein
gene	O
.	O

Calcification	O
of	O
a	O
cariogenic	O
Streptococcus	O
and	O
of	O
Corynebacterium	O
(	O
Bacterionema	O
)	O
matruchotii	O
.	O

E	O
.	O
,	O
Scott	O
,	O
J	O
.	O

These	O
results	O
suggest	O
that	O
HAC1	B-protein
may	O
also	O
be	O
one	O
of	O
the	O
meiotic	O
genes	O
.	O

In	O
some	O
of	O
the	O
cases	O
of	O
solitary	O
lesion	O
,	O
serum	B-protein
TSH	I-protein
levels	O
,	O
serum	B-protein
thyroglobulin	I-protein
values	O
,	O
and	O
131I	O
protein	O
bounded	O
iodine	O
(	O
131I	O
-	O
PBI	O
)	O
were	O
measured	O
,	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
successful	O
and	O
unsuccessful	O
therapy	O
.	O

RESULTS	O
:	O
Each	O
year	O
,	O
on	O
average	O
39	O
%	O
of	O
cases	O
seen	O
in	O
Sardinia	O
are	O
notified	O
;	O
646	O
(	O
40	O
%	O
)	O
of	O
the	O
1591	O
patients	O
notified	O
during	O
the	O
study	O
period	O
were	O
never	O
seen	O
by	O
regional	O
medical	O
centres	O
.	O

Northern	O
blot	O
and	O
in	O
situ	O
hybridization	O
analyses	O
revealed	O
GPR34	B-protein
mRNA	I-protein
transcripts	I-protein
in	O
several	O
human	O
and	O
rat	O
brain	O
regions	O
.	O

A	O
high	O
reactor	O
pH	O
(	O
+	O
/	O
-	O
8	O
)	O
,	O
a	O
short	O
solid	O
retention	O
time	O
(	O
<	O
150	O
days	O
)	O
,	O
and	O
the	O
presence	O
of	O
a	O
substantial	O
SRB	O
population	O
in	O
the	O
inoculum	O
may	O
considerably	O
reduce	O
the	O
time	O
required	O
for	O
acetate	O
-	O
utilising	O
SRB	O
to	O
outcompete	O
MB	O
.	O

Five	O
of	O
the	O
patients	O
with	O
increased	O
L	O
-	O
L	O
size	O
had	O
a	O
normal	O
A	O
-	O
P	O
diameter	O
.	O

Antibodies	O
directed	O
against	O
the	O
SNM1	B-protein
protein	I-protein
immunoprecipitated	O
RNase	B-protein
MRP	I-protein
RNA	I-protein
from	O
whole	O
-	O
cell	O
extracts	O
without	O
precipitating	O
the	O
structurally	O
and	O
functionally	O
related	O
RNase	B-protein
P	I-protein
RNA	I-protein
.	O

METHOD	O
:	O
50	O
consecutive	O
children	O
aged	O
from	O
6	O
months	O
to	O
17	O
years	O
were	O
included	O
into	O
the	O
study	O
which	O
comprised	O
questionnaires	O
of	O
patient	O
and	O
family	O
histories	O
,	O
serological	O
screening	O
tests	O
for	O
common	O
inhalational	O
allergens	O
(	O
CAP	O
SX1	O
)	O
,	O
and	O
determination	O
of	O
total	O
serum	B-protein
immunoglobulin	I-protein
E	I-protein
(	O
IgE	B-protein
)	O
and	O
of	O
latex	O
-	O
specific	O
serum	B-protein
IgE	I-protein
by	O
solid	O
-	O
phase	O
immunoassays	O
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
COX12	B-protein
,	O
the	O
nuclear	O
gene	O
for	O
subunit	B-protein
VIb	I-protein
of	O
Saccharomyces	B-protein
cerevisiae	I-protein
cytochrome	I-protein
c	I-protein
oxidase	I-protein
.	O

The	O
efficacy	O
of	O
these	O
immunosuppressive	O
drugs	O
is	O
clinical	O
proven	O
.	O

Neonatal	O
lupus	O
erythematosus	O
is	O
most	O
often	O
associated	O
with	O
autoantibodies	O
against	O
Ro	B-protein
and	O
La	B-protein
antigens	O
.	O

The	O
etiology	O
,	O
pathology	O
,	O
brain	O
CT	O
scan	O
features	O
,	O
clinical	O
manifestations	O
and	O
treatment	O
of	O
these	O
accidents	O
were	O
discussed	O
.	O

Among	O
booked	O
patients	O
the	O
maternal	O
mortality	O
rate	O
was	O
0	O
.	O
32	O
and	O
among	O
unbooked	O
patients	O
11	O
.	O
13	O
per	O
1000	O
deliveries	O
.	O

Effect	O
of	O
nitrous	O
oxide	O
(	O
N2O	O
)	O
on	O
the	O
somatosympathetic	O
A	O
-	O
and	O
C	O
-	O
reflexes	O
was	O
investigated	O
using	O
artificially	O
ventilated	O
rats	O
anesthetized	O
with	O
alpha	O
-	O
chloralose	O
and	O
urethane	O
.	O

The	O
sensitivity	O
of	O
the	O
vas	O
deferens	O
to	O
adrenaline	O
was	O
also	O
reduced	O
in	O
scorbutic	O
guinea	O
pigs	O
,	O
thus	O
decreasing	O
their	O
fertility	O
rate	O
.	O

An	O
amino	O
-	O
acid	O
sequence	O
comparison	O
revealed	O
that	O
Bacillus	B-protein
YM55	I-protein
-	I-protein
1	I-protein
aspartase	I-protein
shared	O
71	O
%	O
homology	O
with	O
Bacillus	B-protein
subtilis	I-protein
aspartase	I-protein
and	O
49	O
%	O
with	O
Escherichia	O
coli	O
and	O
Pseudomonas	B-protein
fluorescens	I-protein
aspartases	I-protein
.	O

In	O
contrast	O
,	O
the	O
full	O
mu	O
-	O
opioid	O
agonists	O
fentanyl	O
,	O
morphine	O
,	O
I	O
-	O
methadone	O
and	O
levorphanol	O
produced	O
50	O
%	O
fentanyl	O
-	O
appropriate	O
responding	O
at	O
doses	O
only	O
1	O
.	O
3	O
to	O
10	O
.	O
9	O
times	O
smaller	O
than	O
those	O
required	O
to	O
decrease	O
response	O
rates	O
by	O
50	O
%	O
.	O

A	O
portion	O
of	O
p193	B-protein
is	O
nuclear	O
and	O
localizes	O
to	O
the	O
mitotic	O
spindle	O
.	O

Evolutive	O
morphology	O
of	O
the	O
olfactory	O
bulb	O
in	O
man	O
and	O
certain	O
non	O
-	O
human	O
mammals	O
.	O

The	O
core	O
promoter	O
of	O
human	B-protein
thioredoxin	I-protein
reductase	I-protein
1	I-protein
.	I-protein
cloning	O
,	O
transcriptional	O
activity	O
,	O
and	O
oct	B-protein
-	I-protein
1	I-protein
,	O
sp1	B-protein
,	O
and	O
sp3	B-protein
binding	O
reveal	O
a	O
housekeeping	O
-	O
type	O
promoter	O
for	O
the	O
au	O
-	O
rich	O
element	O
-	O
regulated	O
gene	O
.	O

The	O
five	O
-	O
drug	O
combination	O
of	O
fluorouracil	O
imidazole	O
carboxamide	O
dimethyl	O
triazeno	O
,	O
vincristine	O
,	O
bis	O
-	O
chloroethyl	O
nitrosourea	O
,	O
and	O
prednisone	O
(	O
FIVB	O
+	O
P	O
)	O
was	O
given	O
to	O
120	O
women	O
with	O
metastatic	O
breast	O
cancer	O
.	O

Here	O
,	O
we	O
correlate	O
Dox	O
effects	O
on	O
cell	O
cycle	O
with	O
changes	O
of	O
E2F	B-protein
/	I-protein
DP	I-protein
complexes	I-protein
and	O
activity	O
in	O
differentiating	O
C2C12	B-protein
myocytes	O
.	O

We	O
have	O
determined	O
the	O
structure	O
of	O
the	O
WNT	B-protein
-	I-protein
2B	I-protein
gene	I-protein
.	O

Positive	O
genetic	O
selections	O
for	O
inhibition	O
of	O
cyclin	B-protein
/	I-protein
CDK	I-protein
function	O
were	O
characterized	O
using	O
the	O
E	B-protein
.	I-protein
coli	I-protein
neo	I-protein
and	O
yeast	B-protein
LEU2	I-protein
genes	I-protein
.	O

Finger	B-protein
associated	I-protein
box	I-protein
-	I-protein
zinc	I-protein
finger	I-protein
proteins	I-protein
(	O
FAX	B-protein
-	I-protein
ZFPs	I-protein
)	O
constitute	O
a	O
subfamily	O
of	O
the	O
many	O
C2H2	B-protein
type	I-protein
ZFPs	I-protein
in	O
Xenopus	O
laevis	O
.	O

This	O
report	O
has	O
reviewed	O
some	O
of	O
the	O
reasons	O
for	O
treatment	O
failures	O
and	O
has	O
presented	O
a	O
philosophy	O
for	O
their	O
management	O
.	O

Ceftazidime	O
shows	O
promise	O
as	O
single	O
-	O
agent	O
therapy	O
for	O
serious	O
gram	O
-	O
negative	O
bacillary	O
infections	O
.	O

Anti	O
-	O
anxiety	O
action	O
of	O
diazepam	O
after	O
intra	O
-	O
amygdaloid	O
application	O
in	O
the	O
rat	O
.	O

The	O
Ogg1	B-protein
protein	I-protein
efficiently	O
cleaves	O
a	O
DNA	O
duplex	O
where	O
a	O
preformed	O
AP	B-protein
site	I-protein
is	O
placed	O
opposite	O
a	O
cytosine	O
(	O
AP	O
/	O
C	O
)	O
.	O

Molecular	O
structure	O
and	O
evolutionary	O
origin	O
of	O
human	B-protein
cardiac	I-protein
muscle	I-protein
actin	I-protein
gene	I-protein
.	O

Serine	O
phosphorylation	O
of	O
STAT3	B-protein
was	O
only	O
apparent	O
after	O
somatostatin	B-protein
treatment	O
and	O
was	O
abolished	O
by	O
pertussis	B-protein
toxin	I-protein
or	O
PD	O
98059	O
,	O
together	O
with	O
the	O
associated	O
increases	O
in	O
proliferation	O
.	O

The	O
genome	O
of	O
avian	O
erythroblastosis	O
virus	O
contains	O
two	O
independently	O
expressed	O
genetic	O
loci	O
(	O
v	B-protein
-	I-protein
erbA	I-protein
and	O
v	B-protein
-	I-protein
erbB	I-protein
)	O
whose	O
activities	O
are	O
probably	O
responsible	O
for	O
oncogenesis	O
by	O
the	O
virus	O
.	O

This	O
phenomenon	O
did	O
not	O
require	O
DNA	O
binding	O
by	O
the	O
`	O
`	O
interfering	O
'	O
'	O
receptor	O
but	O
required	O
it	O
to	O
be	O
hormone	O
-	O
bound	O
,	O
indicating	O
that	O
a	O
transcriptionally	O
active	O
form	O
of	O
the	O
interfering	O
receptor	O
is	O
essential	O
for	O
the	O
interfering	O
effect	O
.	O

We	O
recommend	O
that	O
paracervical	O
block	O
with	O
lignocaine	O
should	O
be	O
used	O
in	O
conjunction	O
with	O
i	O
.	O
v	O
.	O
sedation	O
/	O
analgesia	O
during	O
egg	O
collection	O
performed	O
through	O
the	O
transvaginal	O
route	O
under	O
ultrasound	O
guidance	O
(	O
TUGOR	O
)	O
to	O
reduce	O
the	O
pain	O
of	O
the	O
procedure	O
.	O

Thyroid	O
disease	O
and	O
pregnancy	O
.	O

To	O
study	O
retinoid	O
signalling	O
in	O
zebrafish	O
embryos	O
,	O
we	O
developed	O
a	O
novel	O
method	O
to	O
detect	O
endogenous	O
retinoids	O
in	O
situ	O
in	O
embryos	O
,	O
using	O
a	O
fusion	O
protein	O
of	O
the	O
ligand	O
inducible	O
transactivation	O
domain	O
of	O
a	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
and	O
a	O
heterologous	O
DNA	O
binding	O
domain	O
.	O

Northern	O
blot	O
analysis	O
revealed	O
that	O
mlt	B-protein
1	I-protein
is	O
normally	O
expressed	O
in	O
brain	O
,	O
spleen	O
,	O
stom	O
ach	O
,	O
and	O
liver	O
.	O

This	O
distinction	O
was	O
based	O
upon	O
whether	O
the	O
diagnosis	O
provided	O
a	O
straightforward	O
range	O
of	O
prognoses	O
or	O
an	O
ambiguous	O
clinical	O
implication	O
.	O

However	O
,	O
vancomycin	O
and	O
fosfomycin	O
,	O
which	O
revealed	O
suboptimal	O
in	O
vitro	O
bactericidal	O
activity	O
,	O
proved	O
as	O
efficacious	O
as	O
penicillin	O
G	O
and	O
imipenem	O
in	O
an	O
experimental	O
mode	O
of	O
murine	O
gas	O
gangrene	O
.	O

For	O
HeLa	O
,	O
293	O
,	O
U937	O
,	O
and	O
A549	O
cells	O
,	O
participation	O
of	O
E2F	B-protein
-	I-protein
1	I-protein
,	O
DP	B-protein
-	I-protein
1	I-protein
,	O
cyclin	B-protein
A	I-protein
,	O
and	O
RB	B-protein
was	O
involved	O
in	O
formation	O
of	O
some	O
complexes	O
only	O
,	O
assuming	O
participation	O
of	O
factors	O
different	O
from	O
E2F	B-protein
-	I-protein
1	I-protein
or	O
DP	B-protein
-	I-protein
1	I-protein
in	O
others	O
.	O

The	O
severity	O
of	O
clinical	O
course	O
was	O
expressed	O
by	O
means	O
of	O
SOFA	O
score	O
(	O
group	O
A	O
0	O
.	O
3	O
-	O
1	O
-	O
1	O
.	O
3	O
point	O
,	O
group	O
B	O
2	O
.	O
2	O
-	O
2	O
.	O
9	O
-	O
2	O
.	O
6	O
point	O
,	O
group	O
C	O
7	O
.	O
4	O
-	O
8	O
.	O
3	O
-	O
7	O
.	O
7	O
point	O
)	O
and	O
APACHE	O
II	O
score	O
(	O
group	O
A	O
3	O
.	O
7	O
-	O
7	O
.	O
6	O
-	O
8	O
.	O
1	O
point	O
,	O
group	O
B	O
8	O
.	O
6	O
-	O
11	O
.	O
1	O
-	O
10	O
.	O
5	O
point	O
,	O
group	O
C	O
16	O
.	O
3	O
-	O
15	O
.	O
2	O
-	O
14	O
.	O
3	O
point	O
)	O
.	O

Partial	O
N	O
-	O
terminal	O
amino	O
acid	O
sequence	O
analysis	O
showed	O
that	O
the	O
43K	B-protein
and	I-protein
42K	I-protein
T	I-protein
antigens	I-protein
contain	O
methionine	O
at	O
residues	O
1	O
and	O
5	O
,	O
as	O
predicted	O
from	O
the	O
DNA	O
sequence	O
,	O
whereas	O
no	O
methionine	O
was	O
released	O
from	O
the	O
39K	B-protein
T	I-protein
antigen	I-protein
during	O
the	O
first	O
six	O
cycles	O
of	O
Edman	O
degradation	O
.	O

A	O
new	O
Onchocerca	O
species	O
,	O
a	O
parasite	O
of	O
domestic	O
cattle	O
,	O
in	O
Senegal	O
.	O

Ga	O
-	O
67	O
and	O
Tl	O
-	O
201	O
scintigraphy	O
in	O
extramedullary	O
plasmacytoma	O
:	O
a	O
case	O
report	O
.	O

The	O
addition	O
of	O
diatrizoate	O
to	O
the	O
IPRK	O
led	O
to	O
a	O
dose	O
-	O
dependent	O
biphasic	O
change	O
in	O
RPF	O
and	O
GFR	O
characterized	O
by	O
an	O
initial	O
transient	O
increase	O
followed	O
by	O
a	O
marked	O
and	O
sustained	O
decrease	O
.	O

Chemical	O
stability	O
tests	O
and	O
site	O
-	O
specific	O
mutagenesis	O
identified	O
amino	O
acids	O
H219	O
and	O
D63	O
of	O
RegS	B-protein
and	O
RegR	B-protein
,	O
respectively	O
,	O
as	O
the	O
phosphorylated	O
residues	O
.	O

Prostacyclin	O
formation	O
,	O
reflected	O
by	O
the	O
excretion	O
rate	O
of	O
its	O
stable	O
metabolite	O
6	O
-	O
keto	O
-	O
prostaglandin	O
F1	O
alpha	O
,	O
was	O
measured	O
by	O
means	O
of	O
radioimmunoassay	O
in	O
4	O
-	O
hour	O
urine	O
specimens	O
obtained	O
during	O
a	O
smoking	O
-	O
free	O
period	O
and	O
after	O
participants	O
had	O
inhaled	O
smoke	O
from	O
four	O
high	O
-	O
nicotine	O
cigarettes	O
.	O

There	O
were	O
gene	O
clusters	O
encoding	O
photosynthesis	O
components	O
such	O
as	O
the	O
psbB	B-protein
-	I-protein
psbH	I-protein
-	I-protein
petB	I-protein
-	I-protein
petD	I-protein
and	O
the	O
psbE	B-protein
-	I-protein
psbF	I-protein
clusters	I-protein
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
EGF	B-protein
/	I-protein
Ras	I-protein
/	I-protein
Raf	I-protein
induces	O
transcription	O
via	O
combined	O
activation	O
of	O
ATF3	B-protein
/	I-protein
c	I-protein
-	I-protein
Jun	I-protein
and	O
a	O
52	O
-	O
kDa	O
nuclear	O
factor	O
,	O
whereas	O
JunD	B-protein
acts	O
as	O
a	O
repressor	O
of	O
this	O
response	O
.	O

The	O
SR	B-protein
protein	I-protein
family	I-protein
is	O
involved	O
in	O
constitutive	O
and	O
regulated	O
pre	O
-	O
mRNA	O
splicing	O
and	O
has	O
been	O
found	O
to	O
be	O
evolutionarily	O
conserved	O
in	O
metazoan	O
organisms	O
.	O

Here	O
we	O
describe	O
and	O
map	O
two	O
more	O
new	O
genes	O
identified	O
as	O
allele	O
-	O
specific	O
suppressors	O
that	O
compensate	O
for	O
carboxy	O
-	O
terminal	O
truncation	O
of	O
PET122	B-protein
.	O

2	O
.	O

Analysis	O
of	O
Msy2	B-protein
mRNA	I-protein
expression	O
in	O
prepubertal	O
and	O
adult	O
mouse	O
testes	O
,	O
and	O
in	O
isolated	O
populations	O
of	O
germ	O
cells	O
,	O
reveals	O
maximal	O
expression	O
in	O
postmeiotic	O
round	O
spermatids	O
,	O
a	O
cell	O
type	O
with	O
abundant	O
amounts	O
of	O
stored	O
messenger	O
ribonucleoproteins	O
.	O

In	O
vitro	O
metabolism	O
of	O
progesterone	O
by	O
the	O
human	O
undescended	O
testis	O
.	O

Asthmatic	O
patients	O
showed	O
greater	O
responses	O
of	O
both	O
parameters	O
to	O
adrenaline	O
than	O
controls	O
indicating	O
that	O
long	O
-	O
term	O
corticosteroid	O
treatment	O
enhances	O
the	O
acute	O
responses	O
of	O
plasminogen	B-protein
activator	I-protein
and	O
clotting	B-protein
factor	I-protein
VIII	I-protein
to	O
adrenaline	O
infusion	O
.	O

The	O
heart	O
rate	O
,	O
respiratory	O
rate	O
,	O
arterial	O
O2	O
and	O
systemic	O
vascular	O
resistance	O
were	O
not	O
significantly	O
altered	O
.	O

National	O
abortion	O
laws	O
usually	O
do	O
not	O
allow	O
abortion	O
when	O
a	O
foetus	O
is	O
independently	O
viable	O
,	O
i	O
.	O
e	O
.	O
from	O
a	O
gestational	O
age	O
of	O
about	O
24	O
weeks	O
.	O

Although	O
E2FBP1	B-protein
lacks	O
the	O
transactivation	O
domain	O
,	O
it	O
stimulates	O
E2F	B-protein
site	O
-	O
dependent	O
transcription	O
in	O
cooperation	O
with	O
E2F	B-protein
-	I-protein
1	I-protein
.	O

Although	O
olfactory	O
associative	O
conditioning	O
in	O
newborn	O
rats	O
produces	O
marked	O
structural	O
and	O
functional	O
changes	O
in	O
the	O
olfactory	O
bulb	O
,	O
recent	O
evidence	O
suggests	O
that	O
extrabulbar	O
circuits	O
must	O
be	O
involved	O
in	O
storing	O
these	O
early	O
memories	O
.	O

The	O
3	O
'	O
region	O
,	O
GA2	B-protein
,	O
is	O
necessary	O
for	O
maximal	O
expression	O
.	O

There	O
was	O
no	O
clear	O
correlation	O
between	O
the	O
MFA	O
and	O
the	O
severity	O
of	O
the	O
UTS	O
phenotype	O
.	O

Encouraged	O
by	O
a	O
Dutch	O
study	O
using	O
etidronate	O
/	O
fluoride	O
in	O
corticoid	O
-	O
induced	O
osteoporosis	O
,	O
we	O
performed	O
a	O
pilot	O
study	O
in	O
33	O
men	O
with	O
severe	O
established	O
primary	O
osteoporosis	O
giving	O
cyclically	O
etidronate	O
for	O
14	O
days	O
followed	O
by	O
fluoride	O
plus	O
calcium	O
/	O
vitamin	O
D	O
for	O
76	O
days	O
.	O

The	O
prevalence	O
of	O
malnutrition	O
was	O
30	O
%	O
in	O
the	O
47	O
patients	O
without	O
CVD	O
and	O
was	O
significantly	O
higher	O
(	O
70	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
the	O
70	O
patients	O
with	O
CVD	O
,	O
who	O
also	O
had	O
lower	O
tHcy	O
,	O
SAlb	O
,	O
plasma	B-protein
IGF	I-protein
-	I-protein
1	I-protein
,	O
serum	O
creatinine	O
(	O
SCr	O
)	O
,	O
and	O
blood	B-protein
hemoglobin	I-protein
.	O

The	O
assay	O
exhibits	O
a	O
dynamic	O
range	O
of	O
0	O
.	O
1	O
-	O
100	O
micrograms	O
l	O
-	O
1	O
using	O
a	O
monoclonal	O
antibody	O
or	O
alternatively	O
10	O
micrograms	O
l	O
-	O
1	O
to	O
10	O
mg	O
l	O
-	O
1	O
using	O
commercially	O
available	O
antiserum	O
.	O

Mapping	O
results	O
suggested	O
that	O
the	O
complementation	O
group	O
identified	O
by	O
these	O
mutants	O
is	O
allelic	O
to	O
the	O
ag	B-protein
alpha	I-protein
1	I-protein
mutation	O
identified	O
previously	O
.	O

3	O
.	O
04	O
+	O
/	O
-	O
1	O
.	O
2	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
,	O
large	O
accelerations	O
/	O
30	O
min	O
(	O
1	O
.	O
46	O
+	O
/	O
-	O
1	O
.	O
96	O
vs	O
.	O

We	O
describe	O
a	O
total	O
of	O
39	O
DEAH	B-protein
helicases	I-protein
in	O
these	O
four	O
species	O
.	O

Quantitation	O
of	O
exocrine	B-protein
IgA	I-protein
in	O
human	O
serum	O
in	O
health	O
and	O
disease	O
.	O

For	O
228	O
of	O
425	O
deaths	O
(	O
54	O
%	O
)	O
occurring	O
among	O
26	O
100	O
people	O
of	O
known	O
age	O
in	O
the	O
Malumfashi	O
area	O
of	O
northern	O
Nigeria	O
,	O
data	O
were	O
collected	O
on	O
symptoms	O
present	O
prior	O
to	O
death	O
.	O

As	O
regards	O
lipid	O
metabolism	O
,	O
the	O
mean	O
values	O
for	O
total	O
triglycerides	O
,	O
cholesterol	O
,	O
LDL	O
-	O
cholesterol	O
and	O
HDL	O
-	O
cholesterol	O
seen	O
at	O
the	O
end	O
of	O
five	O
years	O
of	O
Norplant	O
-	O
2	O
rod	O
use	O
and	O
six	O
months	O
postremoval	O
were	O
similar	O
to	O
the	O
preinsertion	O
mean	O
.	O

We	O
have	O
recently	O
shown	O
that	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
RAR	B-protein
beta	I-protein
2	I-protein
gene	I-protein
in	I-protein
mouse	I-protein
embryos	I-protein
is	O
regulated	O
at	O
the	O
translational	O
level	O
by	O
short	O
upstream	O
open	O
reading	O
frames	O
(	O
uORFs	O
)	O
In	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
(	O
Zimmer	O
,	O
A	O
.	O
,	O
A	O
.	O
M	O
.	O

Frequent	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
of	O
>	O
30	O
%	O
of	O
the	O
informative	O
cases	O
was	O
observed	O
on	O
chromosomes	O
3p	O
(	O
41	O
.	O
1	O
%	O
)	O
,	O
5q	O
(	O
52	O
.	O
6	O
%	O
)	O
,	O
6p	O
(	O
30	O
.	O
4	O
%	O
)	O
,	O
8p	O
(	O
33	O
.	O
3	O
%	O
)	O
,	O
9p	O
(	O
35	O
.	O
7	O
%	O
)	O
,	O
9q	O
(	O
30	O
.	O
8	O
%	O
)	O
,	O
11p	O
(	O
32	O
.	O
4	O
%	O
)	O
,	O
13q	O
(	O
52	O
.	O
7	O
%	O
)	O
,	O
17p	O
(	O
55	O
.	O
2	O
%	O
)	O
,	O
17q	O
(	O
33	O
.	O
3	O
%	O
)	O
,	O
18q	O
(	O
45	O
.	O
7	O
%	O
)	O
,	O
and	O
19q	O
(	O
30	O
.	O
4	O
%	O
)	O
.	O

PowerBLAST	O
analysis	O
identified	O
six	O
clusters	O
of	O
expressed	O
sequence	O
tags	O
(	O
ESTs	O
)	O
,	O
two	O
known	O
genes	O
(	O
BIR	B-protein
,	O
SUR1	B-protein
)	O
mapped	O
previously	O
to	O
this	O
region	O
,	O
and	O
a	O
previously	O
characterized	O
but	O
unmapped	O
gene	B-protein
NEFA	I-protein
(	O
DNA	B-protein
binding	I-protein
/	I-protein
EF	I-protein
hand	I-protein
/	I-protein
acidic	I-protein
amino	I-protein
-	I-protein
acid	I-protein
-	I-protein
rich	I-protein
)	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
The	O
two	O
groups	O
were	O
similar	O
on	O
entry	O
into	O
the	O
study	O
,	O
including	O
mean	O
FEV1	O
measurements	O
(	O
0	O
.	O
70	O
L	O
atropine	O
/	O
0	O
.	O
60	O
L	O
metaproterenol	O
,	O
P	O
greater	O
than	O
.	O
05	O
)	O
.	O

Decreased	O
levels	O
of	O
alpha2	B-protein
-	I-protein
antiplasmin	I-protein
were	O
also	O
observed	O
in	O
the	O
mediastinum	O
(	O
0	O
.	O
50	O
versus	O
0	O
.	O
61	O
U	O
/	O
mL	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Postnatal	O
volumetric	O
development	O
of	O
the	O
prefrontal	O
cortex	O
in	O
the	O
rat	O
.	O

There	O
was	O
no	O
significant	O
correlation	O
between	O
baseline	O
PC40	O
methacholine	O
and	O
the	O
maximal	O
fall	O
in	O
Vp30	O
after	O
either	O
the	O
first	O
(	O
12	O
micrograms	O
)	O
or	O
the	O
second	O
dose	O
(	O
24	O
micrograms	O
)	O
of	O
platelet	B-protein
activating	I-protein
factor	I-protein
.	O

Long	O
-	O
range	O
mapping	O
of	O
the	O
11q23	O
region	O
involved	O
in	O
chromosome	O
aberrations	O
in	O
human	O
tumors	O
by	O
pulsed	O
-	O
field	O
gel	O
electrophoresis	O
with	O
a	O
yeast	O
artificial	O
chromosome	O
.	O

An	O
implant	O
may	O
release	O
a	O
drug	O
either	O
by	O
diffusion	O
concurrent	O
with	O
dissolution	O
of	O
the	O
polymeric	O
implant	O
material	O
without	O
depolymerization	O
(	O
Type	O
A	O
)	O
or	O
by	O
bioerosion	O
involving	O
depolymerization	O
(	O
Type	O
B	O
)	O
.	O

Plasma	B-protein
secretin	I-protein
,	O
pancreozymin	B-protein
,	O
and	O
somatostatin	B-protein
-	I-protein
like	I-protein
hormone	I-protein
in	O
chronic	O
renal	O
failure	O
patients	O
.	O

Insertion	O
of	O
4	O
bp	O
reduced	O
SV40	O
early	O
promoter	O
-	O
dependent	O
chloramphenicol	B-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
expression	O
by	O
six	O
-	O
to	O
eightfold	O
.	O

Lewis	O
,	O
N	O
.	O

The	O
preferences	O
were	O
for	O
intact	O
vis	O
-	O
a	O
-	O
vis	O
castrated	O
males	O
,	O
though	O
injections	O
of	O
TP	O
restored	O
the	O
castrates	O
'	O
attractiveness	O
to	O
the	O
females	O
.	O

This	O
animal	O
model	O
of	O
dystonia	O
appears	O
to	O
be	O
a	O
model	O
of	O
NAD	O
in	O
man	O
from	O
the	O
viewpoint	O
of	O
treatment	O
-	O
response	O
.	O

These	O
changes	O
correlate	O
directly	O
with	O
an	O
increase	O
in	O
the	O
acetylation	O
levels	O
of	O
all	O
four	O
core	B-protein
histones	I-protein
in	O
vivo	O
.	O

Coronary	O
flow	O
was	O
reduced	O
by	O
10	O
%	O
in	O
the	O
phosphocreatine	O
and	O
by	O
18	O
%	O
in	O
the	O
control	O
group	O
.	O

In	O
vivo	O
,	O
MyoD	B-protein
requires	O
this	O
tryptophan	O
motif	O
to	O
evoke	O
chromatin	O
remodeling	O
in	O
the	O
Myogenin	B-protein
promoter	I-protein
and	O
to	O
activate	O
Myogenin	B-protein
transcription	O
.	O

Using	O
autoantibodies	O
from	O
a	O
Sjogren	O
'	O
s	O
syndrome	O
patient	O
,	O
we	O
have	O
previously	O
identified	O
a	O
230	O
-	O
kDa	O
peripheral	O
membrane	O
protein	O
associated	O
with	O
the	O
cytosolic	O
face	O
of	O
the	O
trans	O
-	O
Golgi	O
(	O
Kooy	O
,	O
J	O
.	O
,	O
Toh	O
,	O
B	O
.	O

The	O
single	O
strandedness	O
is	O
manifested	O
as	O
a	O
terminal	O
extension	O
of	O
the	O
G	O
-	O
rich	O
strand	O
(	O
G	O
tails	O
)	O
that	O
can	O
occur	O
independently	O
of	O
telomerase	B-protein
,	O
suggesting	O
that	O
cdc17	B-protein
/	I-protein
pol1	I-protein
mutants	I-protein
exhibit	O
defects	O
in	O
telomeric	O
lagging	O
-	O
strand	O
synthesis	O
.	O

Group	O
6	O
was	O
given	O
physostigmine	O
,	O
0	O
.	O
1	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
,	O
known	O
to	O
inhibit	O
cholinesterase	B-protein
degradation	O
,	O
5	O
min	O
before	O
bupivacaine	O
administration	O
,	O
and	O
Group	O
7	O
received	O
a	O
combination	O
of	O
physostigmine	O
pretreatment	O
and	O
electrical	O
vagal	O
stimulation	O
.	O

We	O
conclude	O
that	O
,	O
with	O
autonomic	O
nervous	O
system	O
activity	O
intact	O
,	O
carotid	O
chemoreceptor	O
reflex	O
activation	O
can	O
elicit	O
an	O
absolute	O
reflexly	O
mediated	O
reduction	O
in	O
coronary	O
blood	O
flow	O
in	O
the	O
normal	O
,	O
conscious	O
dog	O
,	O
despite	O
an	O
increase	O
in	O
arterial	O
pressure	O
.	O

Furthermore	O
,	O
in	O
the	O
ischemia	O
/	O
angiotension	O
II	O
-	O
induced	O
AHF	O
model	O
,	O
NIC	O
decreased	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
(	O
LVEDP	O
)	O
.	O

These	O
results	O
suggest	O
that	O
decreased	O
class	B-protein
I	I-protein
enhancer	I-protein
activity	O
in	O
Ad12	O
-	O
transformed	O
cells	O
may	O
,	O
at	O
least	O
in	O
part	O
,	O
be	O
due	O
to	O
the	O
higher	O
levels	O
of	O
an	O
enhancer	O
-	O
specific	O
factor	O
,	O
possibly	O
acting	O
as	O
a	O
repressor	O
.	O

Combined	O
expression	O
of	O
c	B-protein
-	I-protein
Jun	I-protein
and	O
p65	B-protein
induced	O
vigorous	O
transcription	O
of	O
IL	B-protein
-	I-protein
2	I-protein
promoter	O
-	O
and	O
CD28RE	B-protein
-	I-protein
driven	I-protein
reporter	I-protein
constructs	I-protein
in	O
both	O
LFA	O
-	O
3	O
-	O
and	O
B7	O
-	O
1	O
-	O
costimulated	O
Jurkat	O
cells	O
.	O

Treadmill	O
training	O
at	O
least	O
for	O
2	O
weeks	O
can	O
reduce	O
the	O
infarction	O
size	O
and	O
edema	O
caused	O
by	O
MCA	O
occlusion	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

However	O
,	O
unlike	O
the	O
SIN3	B-protein
gene	I-protein
of	O
Saccharomyces	O
cerevisiae	O
,	O
pst1	B-protein
(	I-protein
+	I-protein
)	I-protein
is	O
essential	O
for	O
cell	O
viability	O
.	O

Calmodulin	B-protein
-	I-protein
binding	I-protein
peptide	I-protein
(	O
CBP	B-protein
)	O
,	O
a	O
peptide	O
of	O
26	O
amino	O
acids	O
derived	O
from	O
muscle	B-protein
myosin	I-protein
light	I-protein
chain	I-protein
kinase	I-protein
(	O
MLCK	B-protein
)	O
,	O
binds	O
to	O
calmodulin	B-protein
with	O
nanomolar	O
affinity	O
.	O

ATP	O
gamma	O
S	O
inhibition	O
can	O
be	O
overcome	O
by	O
high	O
concentrations	O
of	O
ATP	O
,	O
dATP	O
,	O
araATP	O
,	O
or	O
ddATP	O
.	O

The	O
gene	O
encodes	O
an	O
ATP	B-protein
-	I-protein
binding	I-protein
cassette	I-protein
,	I-protein
ABC	I-protein
transporter	I-protein
.	O

Muscle	B-protein
GSH	I-protein
-	I-protein
Px	I-protein
activity	O
after	O
prolonged	O
exercise	O
,	O
training	O
,	O
and	O
selenium	O
supplementation	O
.	O

RESULTS	O
:	O
The	O
bovine	O
cDNA	O
insert	O
sequence	O
was	O
273	O
nucleotides	O
in	O
length	O
for	O
the	O
entire	O
mRNA	O
coding	O
region	O
,	O
212	O
nucleotides	O
in	O
the	O
5	O
'	O
untranslated	O
region	O
,	O
83	O
nucleotides	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
and	O
a	O
poly	O
(	O
A	O
)	O
tail	O
.	O

Toxicity	O
was	O
mild	O
,	O
mainly	O
consisting	O
of	O
emesis	O
(	O
81	O
%	O
of	O
the	O
patients	O
;	O
66	O
%	O
of	O
the	O
courses	O
)	O
,	O
leukopenia	O
of	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
grade	O
1	O
to	O
2	O
(	O
47	O
%	O
of	O
the	O
patients	O
;	O
18	O
%	O
of	O
the	O
courses	O
)	O
,	O
and	O
thrombocytopenia	O
(	O
12	O
%	O
of	O
the	O
patients	O
;	O
3	O
%	O
of	O
the	O
courses	O
)	O
.	O

Refractory	O
periods	O
of	O
the	O
AV	O
junction	O
were	O
altered	O
in	O
a	O
comparable	O
fashion	O
to	O
conduction	O
through	O
the	O
AV	O
node	O
.	O

Development	O
of	O
a	O
yeast	O
system	O
to	O
assay	O
mutational	O
specificity	O
.	O

Although	O
some	O
residues	O
are	O
found	O
reactive	O
toward	O
dimethylsulphate	O
and	O
kethoxal	O
in	O
regions	O
predicted	O
to	O
be	O
unpaired	O
by	O
the	O
phylogenetic	O
secondary	O
structure	O
model	O
of	O
4	B-protein
.	I-protein
5S	I-protein
RNA	I-protein
,	O
generally	O
the	O
reactivity	O
is	O
low	O
,	O
and	O
some	O
residues	O
in	O
internal	O
loops	O
are	O
not	O
reactive	O
at	O
all	O
.	O

Fasting	O
plasma	O
and	O
lipoprotein	O
lipid	O
concentrations	O
,	O
adipose	B-protein
tissue	I-protein
lipoprotein	I-protein
lipase	I-protein
activity	O
,	O
anthropometric	O
data	O
,	O
alcohol	O
consumption	O
,	O
smoking	O
habits	O
,	O
weekly	O
mileage	O
run	O
and	O
performance	O
on	O
a	O
bicycle	O
ergometer	O
were	O
recorded	O
before	O
and	O
after	O
the	O
training	O
period	O
.	O

The	O
presence	O
of	O
circulating	O
platelet	O
aggregates	O
and	O
elevated	O
levels	O
of	O
fibrinopeptide	B-protein
A	I-protein
(	O
a	O
cleavage	O
product	O
of	O
fibrin	B-protein
)	O
suggests	O
that	O
platelet	O
activation	O
and	O
fibrin	B-protein
deposition	O
may	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
this	O
disorder	O
.	O

Additionally	O
in	O
seven	O
subjects	O
adrenaline	O
(	O
A	O
)	O
and	O
noradrenaline	O
(	O
NA	O
)	O
concentrations	O
were	O
determined	O
.	O

Direct	O
current	O
polarography	O
and	O
differential	O
pulse	O
polarographic	O
methods	O
have	O
been	O
developed	O
for	O
the	O
qualitative	O
as	O
well	O
as	O
quantitative	O
analysis	O
of	O
vitamin	O
B1	O
,	O
B2	O
and	O
B6	O
.	O

Induction	O
of	O
Jurkat	O
leukemic	O
T	O
cells	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
and	O
ionomycin	O
did	O
not	O
affect	O
the	O
level	O
of	O
FKBP	B-protein
mRNA	I-protein
.	O

Because	O
the	O
DPPD	B-protein
gene	I-protein
is	O
not	O
present	O
in	O
non	O
-	O
tuberculous	O
bacilli	O
,	O
these	O
results	O
suggest	O
that	O
this	O
molecule	O
can	O
be	O
an	O
additional	O
tool	O
for	O
a	O
more	O
specific	O
diagnosis	O
of	O
tuberculosis	O
.	O

Mo	O
+	O
SV	O
M	O
-	O
MuLV	O
-	O
inoculated	O
animals	O
became	O
moribund	O
at	O
3	O
to	O
13	O
months	O
postinoculation	O
,	O
whereas	O
delta	O
Mo	O
+	O
SV	O
M	O
-	O
MuLV	O
-	O
inoculated	O
animals	O
became	O
moribund	O
at	O
6	O
to	O
24	O
months	O
postinoculation	O
.	O

Cowpox	O
virus	O
contains	O
two	O
copies	O
of	O
an	O
early	O
gene	O
encoding	O
a	O
soluble	O
secreted	O
form	O
of	O
the	O
type	B-protein
II	I-protein
TNF	I-protein
receptor	I-protein
.	O

Gas6	B-protein
contains	O
an	O
NH2	O
-	O
terminal	O
Gla	O
domain	O
followed	O
by	O
four	O
epidermal	B-protein
growth	I-protein
factor	I-protein
-	I-protein
like	I-protein
repeats	I-protein
and	O
tandem	O
globular	O
(	O
G	O
)	O
domains	O
.	O

As	O
control	O
,	O
the	O
cells	O
were	O
transfected	O
with	O
DNA	O
mixtures	O
containing	O
vector	O
mU6	O
-	O
C1	O
or	O
mU6	O
-	O
C2	O
.	O

This	O
result	O
suggests	O
that	O
phosphorylation	O
of	O
Thr	O
14	O
and	O
/	O
or	O
Tyr	O
15	O
inhibits	O
p34cdc2	B-protein
kinase	I-protein
activity	O
,	O
in	O
line	O
with	O
the	O
location	O
of	O
these	O
residues	O
within	O
the	O
putative	O
ATP	O
binding	O
site	O
of	O
the	O
kinase	B-protein
.	O

We	O
have	O
previously	O
identified	O
a	O
liver	O
-	O
enriched	O
transcription	O
factor	O
,	O
HNF	B-protein
-	I-protein
6	I-protein
,	O
which	O
is	O
required	O
for	O
HNF	B-protein
-	I-protein
3	I-protein
beta	I-protein
promoter	I-protein
activity	O
and	O
also	O
recognizes	O
the	O
regulatory	O
region	O
of	O
numerous	O
hepatocyte	O
-	O
specific	O
genes	O
.	O

An	O
ion	O
chromatographic	O
method	O
was	O
used	O
to	O
determine	O
Br	O
ion	O
in	O
the	O
urine	O
of	O
Greyhounds	O
.	O

On	O
the	O
other	O
hand	O
,	O
knowledge	O
of	O
the	O
epidemiology	O
of	O
Parkinson	O
'	O
s	O
disease	O
is	O
necessary	O
in	O
creating	O
etiological	O
hypotheses	O
,	O
since	O
only	O
hypotheses	O
consistent	O
with	O
the	O
epidemiological	O
profile	O
deserve	O
careful	O
testing	O
.	O

To	O
define	O
transcriptional	O
control	O
elements	O
responsible	O
for	O
muscle	O
-	O
specific	O
expression	O
of	O
the	O
human	B-protein
myoglobin	I-protein
gene	I-protein
,	O
we	O
performed	O
mutational	O
analysis	O
of	O
upstream	O
sequences	O
(	O
nucleotide	O
positions	O
-	O
373	O
to	O
+	O
7	O
relative	O
to	O
the	O
transcriptional	O
start	O
site	O
)	O
linked	O
to	O
a	O
firefly	B-protein
luciferase	I-protein
gene	I-protein
.	O

A	O
DNA	O
fragment	O
carrying	O
1	O
,	O
100	O
nucleotides	O
derived	O
from	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
UGT1A1	B-protein
gene	I-protein
was	O
enough	O
for	O
MC	O
induction	O
.	O

Limits	O
of	O
energy	O
turnover	O
in	O
relation	O
to	O
physical	O
performance	O
were	O
addressed	O
in	O
terms	O
of	O
upper	O
and	O
lower	O
limit	O
,	O
changes	O
during	O
a	O
training	O
programme	O
and	O
how	O
to	O
regulate	O
energy	O
balance	O
at	O
a	O
changing	O
energy	O
turnover	O
.	O

Non	O
-	O
poliomyelitis	O
AFP	O
rate	O
had	O
increased	O
from	O
0	O
.	O
9	O
in	O
1997	O
to	O
2	O
.	O
8	O
in	O
1998	O
.	O

Most	O
yeast	B-protein
peroxisomal	I-protein
matrix	I-protein
proteins	I-protein
contain	O
a	O
type	B-protein
1C	I-protein
-	I-protein
terminal	I-protein
peroxisomal	I-protein
targeting	I-protein
signal	I-protein
(	O
PTS1	B-protein
)	O
consisting	O
of	O
the	O
tripeptide	B-protein
SKL	I-protein
or	O
a	O
conservative	O
variant	O
thereof	O
.	O

On	O
the	O
basis	O
of	O
these	O
relations	O
,	O
a	O
risk	O
factor	O
-	O
selection	O
scale	O
(	O
RFSS	O
)	O
(	O
range	O
,	O
0	O
to	O
10	O
)	O
was	O
developed	O
by	O
computing	O
appropriate	O
weights	O
for	O
each	O
risk	O
factor	O
.	O

GRFI	B-protein
bound	O
to	O
sequences	O
at	O
the	O
negative	O
regulatory	O
elements	O
(	O
silencers	O
)	O
of	O
the	O
silent	B-protein
mating	I-protein
type	I-protein
loci	I-protein
HML	I-protein
E	I-protein
and	O
HMR	B-protein
E	I-protein
and	O
to	O
the	O
upstream	B-protein
activating	I-protein
sequence	I-protein
(	O
UAS	B-protein
)	O
required	O
for	O
transcription	O
of	O
the	O
MAT	B-protein
alpha	I-protein
genes	I-protein
.	O

Large	O
-	O
scale	O
sequencing	O
of	O
two	O
regions	O
in	O
human	O
chromosome	O
7q22	O
:	O
analysis	O
of	O
650	O
kb	O
of	O
genomic	O
sequence	O
around	O
the	O
EPO	B-protein
and	O
CUTL1	B-protein
loci	I-protein
reveals	O
17	O
genes	O
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
the	O
FCR1	B-protein
gene	I-protein
behaves	O
as	O
a	O
negative	O
regulator	O
of	O
drug	O
resistance	O
in	O
C	O
.	O
albicans	O
and	O
constitute	O
the	O
first	O
evidence	O
that	O
FCZ	O
resistance	O
can	O
result	O
from	O
the	O
inactivation	O
of	O
a	O
regulatory	O
factor	O
such	O
as	O
Fcr1p	B-protein
.	O

This	O
emancipation	O
of	O
the	O
ability	O
to	O
copulate	O
from	O
hormonal	O
influence	O
makes	O
female	O
sexual	O
motivation	O
the	O
primary	O
regulator	O
of	O
mating	O
in	O
primates	O
.	O

The	O
Saccharomyces	B-protein
cerevisiae	I-protein
APS1	I-protein
gene	I-protein
encodes	O
a	O
homolog	O
of	O
the	O
small	O
subunit	O
of	O
the	O
mammalian	B-protein
clathrin	I-protein
AP	I-protein
-	I-protein
1	I-protein
complex	I-protein
:	O
evidence	O
for	O
functional	O
interaction	O
with	O
clathrin	B-protein
at	O
the	O
Golgi	O
complex	O
.	O

In	O
girls	O
prolactin	B-protein
levels	O
rise	O
at	O
stage	O
2	O
,	O
and	O
are	O
higher	O
after	O
menarche	O
;	O
in	O
boys	O
there	O
is	O
no	O
change	O
in	O
prolactin	B-protein
levels	O
.	O

Spasmus	O
nutans	O
:	O
a	O
syndrome	O
of	O
auto	O
-	O
arousal	O
.	O

The	O
effects	O
of	O
diltiazem	O
were	O
stereoselective	O
,	O
thus	O
the	O
potentiation	O
induced	O
by	O
d	O
-	O
cis	O
diltiazem	O
was	O
significantly	O
greater	O
in	O
all	O
cases	O
than	O
that	O
induced	O
by	O
l	O
-	O
cis	O
diltiazem	O
,	O
which	O
suggests	O
that	O
calcium	O
channel	O
blockade	O
plays	O
a	O
role	O
in	O
these	O
interactions	O
.	O

Dorsal	O
foot	O
TcpO2	O
was	O
measured	O
by	O
using	O
oxygen	O
-	O
sensing	O
electrodes	O
with	O
surface	O
temperatures	O
of	O
42	O
degrees	O
C	O
and	O
45	O
degrees	O
C	O
;	O
in	O
theory	O
,	O
changes	O
in	O
sympathetic	O
activity	O
should	O
affect	O
vasomotor	O
tone	O
and	O
TcpO2	O
in	O
skin	O
beneath	O
an	O
electrode	O
at	O
42	O
degrees	O
C	O
(	O
submaximal	O
vasodilation	O
)	O
,	O
but	O
not	O
at	O
45	O
degrees	O
C	O
(	O
maximal	O
vasodilation	O
)	O
.	O

The	O
84	B-protein
.	I-protein
1C	I-protein
mAb	I-protein
recognizes	O
a	O
site	O
on	O
IgE	B-protein
which	O
is	O
identical	O
or	O
very	O
close	O
to	O
the	O
Fc	B-protein
epsilon	I-protein
R	I-protein
binding	I-protein
site	I-protein
,	O
and	O
95	O
.	O
3	O
recognizes	O
a	O
site	O
on	O
IgE	B-protein
which	O
is	O
related	O
,	O
but	O
not	O
identical	O
to	O
the	O
Fc	B-protein
epsilon	I-protein
R	I-protein
binding	I-protein
site	I-protein
.	O

Previous	O
studies	O
have	O
shown	O
that	O
the	O
pro	O
-	O
inflammatory	O
cytokines	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
and	O
interferon	B-protein
gamma	I-protein
reduce	O
the	O
expression	O
of	O
the	O
cystic	B-protein
fibrosis	I-protein
transmembrane	I-protein
conductance	I-protein
regulator	I-protein
(	O
CFTR	B-protein
)	O
gene	O
(	O
CFTR	B-protein
)	O
in	O
HT	O
-	O
29	O
and	O
T84	O
cells	O
by	O
acting	O
post	O
-	O
transcriptionally	O
.	O

Therefore	O
,	O
we	O
propose	O
that	O
p27	B-protein
represents	O
a	O
crucial	O
molecule	O
in	O
HMBA	O
signaling	O
that	O
can	O
not	O
be	O
replaced	O
by	O
p21	B-protein
.	O

The	O
injection	O
of	O
XDRP1	B-protein
protein	I-protein
into	O
fertilized	O
Xenopus	O
eggs	O
blocked	O
embryonic	O
cell	O
division	O
.	O

Lck	B-protein
has	O
been	O
postulated	O
to	O
dimerize	O
through	O
the	O
SH2	B-protein
and	O
SH3	B-protein
domains	I-protein
.	O

The	O
kinase	O
activity	O
of	O
PfPK6	B-protein
is	O
sensitive	O
to	O
CDK	B-protein
inhibitors	O
such	O
as	O
olomoucine	O
and	O
roscovitine	O
.	O

Both	O
HERV	O
-	O
K	O
type	O
1	O
and	O
2	O
clones	O
were	O
isolated	O
.	O

Human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
Vpr	I-protein
is	O
a	O
virion	O
-	O
associated	O
,	O
regulatory	O
protein	O
that	O
is	O
required	O
for	O
efficient	O
viral	O
replication	O
in	O
monocytes	O
/	O
macrophages	O
.	O

Treatment	O
of	O
Paget	O
'	O
s	O
disease	O
.	O

Furthermore	O
,	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
from	O
LAT	O
-	O
deficient	O
mice	O
displayed	O
reduced	O
phagocytic	O
efficiency	O
in	O
comparison	O
to	O
the	O
macrophages	O
from	O
wild	O
-	O
type	O
mice	O
.	O

SETTING	O
:	O
University	O
of	O
Paris	O
VII	O
hospital	O
.	O
Patient	O
(	O
s	O
)	O
:	O
Nine	O
women	O
had	O
embolization	O
for	O
symptomatic	O
myoma	O
,	O
with	O
12	O
pregnancies	O
observed	O
.	O

Nuclear	B-protein
receptors	I-protein
(	O
NRs	B-protein
)	O
can	O
function	O
as	O
ligandinducible	O
transregulators	O
in	O
both	O
mammalian	O
and	O
yeast	O
cells	O
,	O
indicating	O
that	O
important	O
features	O
of	O
transcriptional	O
control	O
have	O
been	O
conserved	O
throughout	O
evolution	O
.	O

Mn2	O
+	O
increased	O
both	O
the	O
junction	O
binding	O
and	O
cleaving	O
activities	O
of	O
the	O
mutant	O
proteins	O
.	O

The	O
Drosophila	B-protein
suppressor	I-protein
of	I-protein
sable	I-protein
gene	I-protein
encodes	O
a	O
polypeptide	O
with	O
regions	O
similar	O
to	O
those	O
of	O
RNA	O
-	O
binding	O
proteins	O
.	O

High	O
resolution	O
computed	O
tomography	O
of	O
the	O
lungs	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
.	O

In	O
our	O
opinion	O
,	O
the	O
SM	O
-	O
CMA	O
system	O
is	O
,	O
despite	O
some	O
shortcomings	O
in	O
its	O
user	O
-	O
interface	O
,	O
a	O
useful	O
and	O
versatile	O
instrument	O
for	O
examination	O
of	O
human	O
semen	O
samples	O
,	O
with	O
desirable	O
features	O
.	O

These	O
results	O
support	O
the	O
diagnostic	O
validity	O
of	O
NFPD	O
in	O
CP	O
/	O
NCA	O
patients	O
,	O
because	O
such	O
patients	O
had	O
a	O
family	O
history	O
of	O
panic	O
disorder	O
similar	O
to	O
patients	O
with	O
a	O
more	O
classical	O
panic	O
disorder	O
presentation	O
.	O

On	O
the	O
basis	O
of	O
histopathological	O
findings	O
,	O
the	O
origin	O
of	O
amyloid	O
appeared	O
to	O
be	O
closely	O
related	O
to	O
the	O
fibroblasts	O
.	O

We	O
have	O
isolated	O
a	O
Drosophila	O
melanogaster	O
(	O
Dm	O
)	O
cDNA	O
encoding	O
a	O
polypeptide	O
that	O
has	O
extensive	O
sequence	O
similarity	O
to	O
the	O
mammalian	B-protein
MAPKAPK	I-protein
-	I-protein
2	I-protein
.	O

Inhibition	O
of	O
RNA2	B-protein
translation	O
was	O
selective	O
,	O
with	O
no	O
effect	O
on	O
general	O
cellular	O
translation	O
or	O
translation	O
of	O
BMV	O
RNA1	B-protein
-	I-protein
encoded	I-protein
replication	I-protein
factor	I-protein
1a	I-protein
,	O
and	O
was	O
independent	O
of	O
p20	B-protein
,	O
a	O
cellular	O
antagonist	O
of	O
DED1	B-protein
function	O
in	O
translation	O
.	O

Clinical	O
and	O
anatomical	O
considerations	O
.	O

Salazopyrine	O
desensitization	O
.	O

Despite	O
the	O
favourable	O
natural	O
history	O
of	O
acute	O
BI	O
,	O
mild	O
,	O
moderate	O
,	O
and	O
severe	O
posttraumatic	O
changes	O
were	O
shown	O
to	O
appear	O
as	O
cicatricial	O
-	O
adhesive	O
and	O
atrophic	O
processes	O
,	O
intracerebral	O
cysts	O
,	O
porencephaly	O
,	O
which	O
result	O
in	O
posttraumatic	O
epilepsy	O
,	O
hydrocephalus	O
,	O
etc	O
.	O

Under	O
our	O
conditions	O
,	O
the	O
combination	O
O3	O
/	O
UV	O
did	O
not	O
improve	O
the	O
degradation	O
rate	O
obtained	O
by	O
ozonation	O
.	O

For	O
sputum	B-protein
interleukin	I-protein
-	I-protein
8	I-protein
there	O
was	O
an	O
estimated	O
true	O
treatment	O
median	O
difference	O
of	O
142	O
pg	O
/	O
ml	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
8	O
to	O
2866	O
pg	O
/	O
ml	O
)	O
in	O
favour	O
of	O
placebo	O
;	O
while	O
for	O
maximal	O
expiratory	O
flow	O
at	O
25	O
%	O
(	O
MEF25	O
%	O
)	O
remaining	O
forced	O
vital	O
capacity	O
predicted	O
for	O
sex	O
and	O
height	O
there	O
was	O
a	O
15	O
percentage	O
points	O
(	O
pp	O
)	O
(	O
95	O
%	O
CI	O
4	O
to	O
26	O
pp	O
)	O
mean	O
treatment	O
difference	O
in	O
favour	O
of	O
placebo	O
.	O

Genetic	O
alterations	O
in	O
elements	O
of	O
normal	O
signal	O
transduction	O
mechanisms	O
are	O
known	O
to	O
be	O
oncogenic	O
events	O
often	O
resulting	O
in	O
aberrant	O
activation	O
of	O
programs	O
of	O
gene	O
transcription	O
.	O

In	O
the	O
diabetics	O
,	O
Ca2	O
+	O
infusions	O
induced	O
a	O
rise	O
of	O
plasma	O
Ca2	O
+	O
up	O
to	O
3	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
mmol	O
/	O
1	O
and	O
a	O
fall	O
of	O
circulating	O
glucagon	B-protein
(	O
-	O
26	O
.	O
4	O
+	O
/	O
-	O
5	O
.	O
7	O
%	O
;	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
glucose	O
(	O
-	O
23	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
%	O
;	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

They	O
observed	O
depressed	O
protein	B-protein
C	I-protein
activity	O
that	O
significantly	O
(	O
p	O
<	O
0	O
.	O
005	O
)	O
increased	O
and	O
became	O
normal	O
immediately	O
after	O
hemodialysis	O
while	O
factor	B-protein
X	I-protein
and	O
factor	B-protein
VII	I-protein
increased	O
(	O
p	O
<	O
0	O
.	O
01	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
despite	O
heparinization	O
together	O
with	O
amount	O
of	O
serum	B-protein
lipoprotein	I-protein
(	I-protein
a	I-protein
)	I-protein
.	O

The	O
data	O
presented	O
in	O
this	O
work	O
indicate	O
that	O
thi1	B-protein
may	O
also	O
be	O
involved	O
in	O
DNA	O
damage	O
tolerance	O
in	O
plant	O
cells	O
.	O

For	O
the	O
5HT5A	B-protein
receptor	I-protein
the	O
addition	O
of	O
yohimbine	O
resulted	O
in	O
a	O
similar	O
but	O
smaller	O
effect	O
.	O

Sequence	O
comparisons	O
have	O
shown	O
that	O
Aps1p	B-protein
is	O
more	O
similar	O
to	O
the	O
sigma	O
subunit	O
of	O
the	O
Golgi	O
-	O
localized	O
mammalian	O
AP	B-protein
-	I-protein
1	I-protein
complex	I-protein
than	O
Aps2p	B-protein
,	O
which	O
is	O
more	O
related	O
to	O
the	O
plasma	O
membrane	O
AP	B-protein
-	I-protein
2	I-protein
sigma	I-protein
subunit	O
.	O

Another	O
group	O
of	O
HIPP	O
-	O
and	O
HCX	O
-	O
lesioned	O
animals	O
trained	O
on	O
the	O
tasks	O
after	O
the	O
lesion	O
showed	O
reduced	O
impairments	O
of	O
the	O
type	O
described	O
above	O
,	O
suggesting	O
that	O
extrahippocampal	O
structures	O
trained	O
after	O
the	O
lesion	O
can	O
assume	O
the	O
role	O
of	O
the	O
hippocampus	O
to	O
some	O
degree	O
.	O

Two	O
domains	O
of	O
EBNA2	B-protein
defined	O
by	O
deletion	O
of	O
amino	O
acids	O
247	O
-	O
337	O
and	O
437	O
-	O
476	O
were	O
found	O
to	O
be	O
important	O
for	O
the	O
activation	O
of	O
both	O
promoters	O
,	O
while	O
two	O
different	O
domains	O
corresponding	O
to	O
residues	O
4	O
-	O
18	O
and	O
118	O
-	O
198	O
were	O
required	O
solely	O
for	O
the	O
LMP1	B-protein
promoter	I-protein
.	O

These	O
results	O
indicate	O
that	O
the	O
total	O
number	O
of	O
subunit	O
c	O
in	O
F0	B-protein
should	O
be	O
a	O
multiple	O
of	O
2	O
and	O
3	O
.	O

At	O
termination	O
(	O
gd	O
20	O
)	O
,	O
confirmed	O
-	O
pregnant	O
females	O
(	O
21	O
to	O
25	O
per	O
group	O
)	O
were	O
evaluated	O
for	O
clinical	O
status	O
and	O
gestational	O
outcome	O
;	O
live	O
fetuses	O
were	O
examined	O
for	O
external	O
,	O
visceral	O
,	O
and	O
skeletal	O
malformations	O
.	O

To	O
determine	O
which	O
region	O
of	O
SulA	B-protein
is	O
essential	O
for	O
the	O
inhibition	O
of	O
cell	O
division	O
,	O
we	O
constructed	O
a	O
series	O
of	O
N	O
-	O
terminal	O
and	O
C	O
-	O
terminal	O
deletions	O
of	O
SulA	B-protein
and	O
a	O
series	O
of	O
alanine	O
substitution	O
mutants	O
.	O

Shape	O
factor	O
correlated	O
well	O
with	O
hemodynamic	O
data	O
for	O
RV	O
/	O
LV	O
systolic	O
pressure	O
ratios	O
(	O
r	O
=	O
0	O
.	O
93	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
for	O
normalized	O
interventricular	O
pressure	O
differences	O
(	O
r	O
=	O
-	O
0	O
.	O
95	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

The	O
mutation	O
experiments	O
showed	O
that	O
the	O
most	O
critical	O
sequence	O
for	O
the	O
repression	O
of	O
PTH	B-protein
was	O
5	B-protein
'	I-protein
-	I-protein
GGGGGAGGGGAG	I-protein
-	I-protein
3	I-protein
'	I-protein
(	I-protein
+	I-protein
1	I-protein
to	I-protein
+	I-protein
12	I-protein
)	I-protein
of	O
PTHSR	B-protein
.	O

In	O
general	O
,	O
the	O
filtration	O
rate	O
in	O
relevant	O
areas	O
appears	O
to	O
be	O
an	O
integrative	O
and	O
easily	O
determined	O
parameter	O
,	O
reflecting	O
hormonal	O
and	O
neurogenic	O
vascular	O
as	O
well	O
as	O
local	O
interstitial	O
control	O
of	O
the	O
Starling	O
forces	O
.	O

Crosstalk	O
among	O
the	O
pathways	O
may	O
explain	O
how	O
some	O
forms	O
of	O
stress	O
can	O
contribute	O
to	O
the	O
development	O
of	O
a	O
malignancy	O
.	O

Analysis	O
of	O
electrically	O
evoked	O
response	O
(	O
EER	O
)	O
in	O
relation	O
to	O
the	O
central	O
visual	O
pathway	O
of	O
the	O
cat	O
(	O
1	O
)	O
.	O

The	O
effectiveness	O
of	O
alpha	O
-	O
mercapto	O
-	O
beta	O
-	O
(	O
2	O
-	O
furyl	O
)	O
acrylic	O
acid	O
(	O
MFA	O
)	O
and	O
N	O
-	O
benzyl	O
-	O
N	O
-	O
dithiocarboxy	O
-	O
D	O
-	O
glucamine	O
(	O
NaB	O
)	O
,	O
used	O
in	O
combination	O
,	O
in	O
the	O
mobilization	O
and	O
excretion	O
of	O
lead	O
was	O
investigated	O
in	O
rats	O
.	O

The	O
319	O
base	O
pair	O
region	O
immediately	O
upstream	O
of	O
the	O
CAP	O
site	O
is	O
characterized	O
by	O
the	O
lack	O
of	O
a	O
proximal	O
TATA	O
box	O
and	O
the	O
presence	O
of	O
sequences	O
similar	O
to	O
GC	O
boxes	O
,	O
CACCC	O
boxes	O
,	O
CCAAT	O
boxes	O
,	O
activator	B-protein
protein	I-protein
2	I-protein
(	O
Ap	B-protein
-	I-protein
2	I-protein
)	O
sites	O
,	O
partial	O
glucocorticoid	B-protein
response	I-protein
elements	I-protein
(	O
GREs	B-protein
)	O
,	O
and	O
partial	O
cyclic	B-protein
AMP	I-protein
response	I-protein
elements	I-protein
(	O
CREs	B-protein
)	O
.	O

Vitamin	O
D3	O
and	O
calcium	O
absorption	O
in	O
the	O
chick	O
.	O

Far	O
from	O
this	O
being	O
the	O
case	O
,	O
however	O
,	O
the	O
measurement	O
of	O
apo	B-protein
B	I-protein
has	O
met	O
every	O
reasonable	O
standard	O
of	O
laboratory	O
precision	O
and	O
reliability	O
to	O
allow	O
its	O
widespread	O
introduction	O
in	O
clinical	O
laboratories	O
.	O

Under	O
halothane	O
anesthesia	O
,	O
the	O
flow	O
pneumocardiogram	O
(	O
PnCG	O
)	O
and	O
its	O
time	O
derivative	O
(	O
acceleration	O
pneumocardiogram	O
or	O
dPn	O
/	O
dt	O
)	O
were	O
transduced	O
during	O
apnea	O
by	O
a	O
small	O
high	O
-	O
gain	O
pneumotachograph	O
.	O

Phosphorylation	O
of	O
myosin	B-protein
-	I-protein
binding	I-protein
subunit	I-protein
(	O
MBS	B-protein
)	O
of	O
myosin	B-protein
phosphatase	I-protein
by	O
Rho	B-protein
-	I-protein
kinase	I-protein
in	O
vivo	O
.	O

We	O
have	O
generated	O
various	O
base	O
substitutions	O
and	O
internal	O
deletions	O
in	O
and	O
around	O
DRE	B-protein
(	O
nucleotide	O
positions	O
-	O
93	O
to	O
-	O
100	O
with	O
respect	O
to	O
the	O
transcription	O
initiation	O
site	O
)	O
of	O
the	O
PCNA	B-protein
gene	I-protein
in	O
vitro	O
and	O
subsequently	O
examined	O
their	O
effects	O
on	O
the	O
binding	O
to	O
DREF	B-protein
(	O
DRE	B-protein
-	I-protein
binding	I-protein
factor	I-protein
)	O
and	O
PCNA	B-protein
gene	I-protein
promote	O
activity	O
in	O
cultured	O
Drosophila	O
Kc	O
cells	O
as	O
well	O
as	O
in	O
living	O
flies	O
.	O

Transient	O
transfections	O
showed	O
that	O
a	O
single	O
mutation	O
(	O
556M	O
)	O
decreased	O
TBLV	B-protein
enhancer	I-protein
activity	O
at	O
least	O
20	O
-	O
fold	O
in	O
two	O
different	O
T	O
-	O
cell	O
lines	O
.	O

Fas	B-protein
has	O
been	O
shown	O
to	O
require	O
ICE	B-protein
(	O
interleukin	B-protein
-	I-protein
1	I-protein
beta	I-protein
-	I-protein
converting	I-protein
enzyme	I-protein
)	O
family	O
proteases	O
to	O
induce	O
apoptosis	O
from	O
studies	O
utilizing	O
the	O
cowpox	O
ICE	B-protein
inhibitor	I-protein
protein	I-protein
CrmA	I-protein
,	O
the	O
synthetic	O
tetrapeptide	O
ICE	B-protein
inhibitor	O
YVAD	B-protein
-	I-protein
CMK	I-protein
,	O
and	O
the	O
tripeptide	O
pan	O
-	O
ICE	O
inhibitor	O
Z	B-protein
-	I-protein
VAD	I-protein
-	I-protein
FMK	I-protein
.	O

However	O
,	O
the	O
lens	O
dose	O
(	O
3	O
.	O
6	O
Gy	O
/	O
25	O
fractions	O
)	O
was	O
higher	O
compared	O
to	O
the	O
other	O
techniques	O
.	O

Studies	O
using	O
a	O
reporter	O
plasmid	O
with	O
a	O
functionally	O
disrupted	O
sterol	B-protein
-	I-protein
responsive	I-protein
element	I-protein
(	O
SRE	B-protein
)	O
-	O
1	O
revealed	O
a	O
reduced	O
stimulatory	O
response	O
to	O
IL	B-protein
-	I-protein
6	I-protein
.	O

The	O
proposed	O
algorithm	O
consists	O
of	O
several	O
steps	O
.	O

Ganciclovir	O
and	O
foscarnet	O
efficacy	O
in	O
AIDS	O
-	O
related	O
CMV	O
polyradiculopathy	O
.	O

A	O
.	O

This	O
report	O
presents	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
(	O
1	O
.	O
2	O
kb	O
)	O
and	O
exon	O
1	O
of	O
the	O
human	B-protein
RII	I-protein
alpha	I-protein
gene	I-protein
.	O

It	O
is	O
also	O
homologous	O
to	O
other	O
sugar	O
carriers	O
from	O
human	O
,	O
mouse	O
and	O
Escherichia	O
coli	O
.	O

Our	O
results	O
confirm	O
the	O
participation	O
of	O
intron	O
1	O
in	O
transcriptional	O
regulation	O
of	O
the	O
c	B-protein
-	I-protein
myb	I-protein
gene	I-protein
(	O
in	O
mouse	O
and	O
human	O
)	O
and	O
implicate	O
multiple	O
and	O
complex	O
regulatory	O
mechanisms	O
of	O
activation	O
during	O
myelomonocytic	O
differentiation	O
and	O
leukemic	O
cell	O
growth	O
control	O
.	O

There	O
was	O
a	O
general	O
broadening	O
of	O
proton	O
resonances	O
for	O
a	O
three	O
-	O
nucleotide	O
segment	O
centered	O
about	O
the	O
lesion	O
site	O
which	O
resulted	O
in	O
a	O
tentative	O
assignment	O
for	O
the	O
sugar	O
protons	O
of	O
the	O
C7	O
residue	O
in	O
the	O
spectrum	O
of	O
the	O
adduct	O
duplex	O
.	O

The	O
accumulated	O
products	O
of	O
ancient	O
duplication	O
events	O
can	O
be	O
readily	O
observed	O
among	O
the	O
genes	O
encoding	O
voltage	O
-	O
dependent	O
Ca	O
(	O
2	O
+	O
)	O
ion	O
channels	O
.	O

On	O
the	O
other	O
hand	O
,	O
lack	O
of	O
conservation	O
of	O
the	O
membrane	B-protein
attachment	I-protein
sequence	I-protein
arginine	I-protein
-	I-protein
glycine	I-protein
-	I-protein
aspartic	I-protein
acid	I-protein
argues	O
against	O
its	O
functional	O
importance	O
in	O
CgA	B-protein
.	O

The	O
hcKrox	B-protein
gene	O
family	O
regulates	O
multiple	O
extracellular	O
matrix	O
genes	O
.	O

A	O
noncatalytic	O
domain	O
conserved	O
among	O
cytoplasmic	B-protein
protein	I-protein
-	I-protein
tyrosine	I-protein
kinases	I-protein
modifies	O
the	O
kinase	O
function	O
and	O
transforming	O
activity	O
of	O
Fujinami	B-protein
sarcoma	I-protein
virus	I-protein
P130gag	I-protein
-	I-protein
fps	I-protein
.	O

A	O
unified	O
approach	O
to	O
the	O
standardization	O
of	O
allergens	O
.	O

Sevelamer	O
hydrochloride	O
(	O
Renagel	O
)	O
is	O
a	O
nonabsorbed	O
phosphate	O
-	O
binding	O
polymer	O
marketed	O
for	O
the	O
treatment	O
of	O
hyperphosphatemia	O
in	O
adult	O
patients	O
receiving	O
hemodialysis	O
.	O

Here	O
we	O
show	O
that	O
messenger	O
RNAs	O
encoding	O
trans	B-protein
-	I-protein
sialidases	I-protein
containing	O
the	O
repeats	O
are	O
not	O
present	O
in	O
epimastigotes	O
but	O
are	O
abundant	O
in	O
trypomastigotes	O
.	O

Doctor	O
Berglund	O
warns	O
members	O
of	O
union	O
pitfalls	O
.	O

Molecular	O
characterization	O
and	O
expression	O
of	O
the	O
Erwinia	B-protein
carotovora	I-protein
hrpNEcc	I-protein
gene	I-protein
,	O
which	O
encodes	O
an	O
elicitor	O
of	O
the	O
hypersensitive	O
reaction	O
.	O

CONCLUSIONS	O
:	O
Although	O
the	O
levels	O
of	O
oxLDL	B-protein
antibodies	I-protein
might	O
be	O
modified	O
in	O
early	O
hypertension	O
,	O
once	O
advanced	O
coronary	O
artery	O
disease	O
has	O
developed	O
the	O
presence	O
of	O
hypertension	O
does	O
not	O
affect	O
anti	B-protein
-	I-protein
oxLDL	I-protein
levels	O
.	O

The	O
strategy	O
has	O
been	O
used	O
to	O
determine	O
2	O
.	O
6	O
kilobases	O
of	O
nucleotide	O
sequence	O
in	O
the	O
Saccharomyces	B-protein
cerevisiae	I-protein
ADE	I-protein
1	I-protein
locus	I-protein
.	O

A	O
subset	O
of	O
mutations	O
in	O
the	O
Psi	B-protein
synthase	I-protein
domain	I-protein
impairs	O
association	O
of	O
the	O
altered	O
Cbf5p	B-protein
proteins	I-protein
with	O
selected	O
box	O
H	B-protein
/	I-protein
ACA	I-protein
snoRNAs	I-protein
,	O
suggesting	O
that	O
the	O
functional	O
catalytic	O
domain	O
is	O
essential	O
for	O
that	O
interaction	O
.	O

They	O
share	O
many	O
downstream	O
targets	O
,	O
including	O
remodeling	O
of	O
the	O
actin	B-protein
cytoskeleton	O
,	O
activation	O
of	O
p70	B-protein
(	I-protein
S6	I-protein
)	I-protein
kinase	I-protein
and	O
c	B-protein
-	I-protein
jun	I-protein
N	I-protein
-	I-protein
terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
,	O
and	O
regulation	O
of	O
transcription	O
and	O
cell	O
proliferation	O
.	O

272	O
,	O
19107	O
-	O
19110	O
)	O
.	O

In	O
the	O
further	O
development	O
of	O
bladder	O
neck	O
suspension	O
according	O
to	O
Stamey	O
-	O
Pereyra	O
,	O
the	O
use	O
of	O
miniature	O
bone	O
anchors	O
received	O
considerable	O
support	O
.	O

GHB	O
,	O
2	O
CB	O
,	O
HMB	O
,	O
are	O
some	O
of	O
these	O
recent	O
substances	O
.	O

Control	O
of	O
fatty	O
liver	O
syndrome	O
in	O
a	O
Jersey	O
herd	O
by	O
a	O
change	O
of	O
diet	O
and	O
the	O
use	O
of	O
recombinant	O
bovine	O
somatotrophin	B-protein
.	O

A	O
comparison	O
of	O
physical	O
and	O
cytogenetic	O
estimates	O
of	O
radiation	O
dose	O
in	O
patients	O
treated	O
with	O
iodine	O
-	O
131	O
for	O
thyroid	O
carcinoma	O
.	O

Initial	O
experience	O
with	O
the	O
new	O
technology	O
indicates	O
that	O
SieScape	O
is	O
an	O
alternative	O
to	O
other	O
methods	O
such	O
as	O
CT	O
and	O
MRI	O
.	O

To	O
map	O
this	O
regulatory	O
serine	O
phosphorylation	O
site	O
we	O
developed	O
a	O
baculovirus	O
-	O
mediated	O
expression	O
system	O
for	O
wild	B-protein
-	I-protein
type	I-protein
annexin	I-protein
II	I-protein
and	O
for	O
a	O
series	O
of	O
annexin	B-protein
II	I-protein
mutants	I-protein
which	O
contained	O
substitutions	O
in	O
one	O
or	O
more	O
serine	O
residues	O
present	O
in	O
the	O
N	O
-	O
terminal	O
domain	O
.	O

CONCLUSIONS	O
:	O
In	O
healthy	O
individuals	O
,	O
whole	O
body	O
insulin	B-protein
sensitivity	O
is	O
related	O
,	O
or	O
`	O
`	O
coupled	O
,	O
`	O
`	O
to	O
the	O
anaerobic	O
threshold	O
.	O

The	O
survival	O
rate	O
at	O
forty	O
months	O
in	O
15	O
patients	O
with	O
N2	O
disease	O
who	O
underwent	O
R2b	O
operation	O
was	O
51	O
%	O
.	O

Furthermore	O
,	O
we	O
have	O
identified	O
a	O
43	O
-	O
bp	O
region	O
of	O
the	O
24p3	B-protein
promoter	I-protein
required	O
for	O
the	O
Dex	O
responsiveness	O
.	O

Histamine	O
reactivity	O
was	O
significantly	O
reduced	O
after	O
the	O
nifedipine	O
aerosol	O
,	O
the	O
geometric	O
mean	O
provocative	O
concentration	O
causing	O
a	O
35	O
%	O
fall	O
in	O
specific	O
airway	O
conductance	O
,	O
rising	O
from	O
5	O
.	O
0	O
to	O
10	O
.	O
9	O
mg	O
/	O
ml	O
of	O
histamine	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

By	O
applying	O
the	O
potentiometric	O
method	O
,	O
in	O
aqueous	O
medium	O
of	O
ionic	O
strength	O
mu	O
=	O
0	O
.	O
2	O
,	O
the	O
stability	O
constants	O
,	O
log	O
beta	O
1	O
=	O
4	O
.	O
42	O
and	O
log	O
beta	O
2	O
=	O
8	O
.	O
57	O
were	O
obtained	O
.	O

Induction	O
of	O
B	O
cell	O
apoptosis	O
by	O
co	O
-	O
cross	O
-	O
linking	O
CD23	B-protein
and	O
sIg	B-protein
involves	O
aberrant	O
regulation	O
of	O
c	B-protein
-	I-protein
myc	I-protein
and	O
is	O
inhibited	O
by	O
bcl	B-protein
-	I-protein
2	I-protein
.	O

SAECG	O
,	O
echocardiography	O
and	O
thallium	O
-	O
201	O
imaging	O
were	O
performed	O
before	O
and	O
1	O
month	O
after	O
attempted	O
angioplasty	O
.	O

Our	O
results	O
suggest	O
that	O
protein	O
binding	O
to	O
the	O
E2F	B-protein
-	I-protein
like	I-protein
sequences	I-protein
may	O
act	O
to	O
reduce	O
expression	O
.	O

The	O
genomic	O
structure	O
of	O
four	O
members	O
of	O
the	O
SRC	B-protein
-	I-protein
family	I-protein
revealed	O
nearly	O
identical	O
exon	O
/	O
intron	O
boundaries	O
within	O
the	O
catalytic	O
domain	O
of	O
this	O
family	O
.	O

The	O
students	O
who	O
had	O
abnormal	O
urine	O
screening	O
results	O
at	O
the	O
first	O
time	O
received	O
a	O
second	O
urine	O
analysis	O
10	O
to	O
15	O
days	O
later	O
to	O
confirm	O
the	O
abnormal	O
urine	O
analysis	O
.	O

However	O
,	O
addition	O
of	O
core	B-protein
DNA	I-protein
polymerase	I-protein
III	I-protein
to	O
preinitiation	O
complex	O
,	O
fully	O
reconstituting	O
holoenzyme	O
resulted	O
in	O
replacement	O
of	O
gamma	O
by	O
alpha	O
at	O
the	O
primer	O
terminus	O
.	O

Characterisation	O
of	O
the	O
chicken	B-protein
apolipoprotein	I-protein
A	I-protein
-	I-protein
I	I-protein
gene	I-protein
5	O
'	O
-	O
flanking	O
region	O
.	O

All	O
of	O
these	O
data	O
suggest	O
that	O
replication	O
of	O
UV	O
-	O
damaged	O
templates	O
occurs	O
in	O
vitro	O
as	O
it	O
does	O
in	O
vivo	O
and	O
that	O
this	O
replication	O
results	O
in	O
mutation	O
fixation	O
.	O

In	O
group	O
I	O
adults	O
both	O
of	O
these	O
variables	O
increased	O
.	O

The	O
plasma	B-protein
growth	I-protein
hormone	I-protein
concentration	O
of	O
the	O
foetal	O
lamb	O
.	O

Despite	O
resolution	O
of	O
the	O
solid	O
portion	O
of	O
the	O
tumor	O
,	O
serial	O
MRI	O
showed	O
enlargement	O
of	O
a	O
bilobar	O
tumor	O
cyst	O
3	O
years	O
after	O
the	O
original	O
diagnosis	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
using	O
crude	O
extracts	O
from	O
FREJ4	O
cells	O
revealed	O
the	O
binding	O
of	O
a	O
member	O
(	O
s	O
)	O
of	O
the	O
Ets	B-protein
family	I-protein
of	I-protein
transcription	I-protein
factors	I-protein
to	O
the	O
P4	B-protein
EBS	I-protein
,	O
as	O
well	O
as	O
the	O
interaction	O
of	O
two	O
members	O
of	O
the	O
Sp1	B-protein
family	I-protein
,	O
Sp1	B-protein
and	O
Sp3	B-protein
,	O
with	O
the	O
adjacent	O
GC	O
box	O
.	O

The	O
binary	O
and	O
tertiary	O
combinations	O
of	O
plant	O
-	O
derived	O
molluscicides	O
Azadirachta	O
indica	O
and	O
Cedrus	O
deodara	O
oil	O
with	O
synergists	O
MGK	O
-	O
264	O
,	O
piperonyl	O
butoxide	O
(	O
PB	O
)	O
and	O
fruit	O
powder	O
of	O
Embelia	O
ribes	O
were	O
used	O
against	O
the	O
Lymnaea	O
acuminata	O
.	O

The	O
known	O
B1	O
-	O
deficiency	O
reaches	O
excessive	O
high	O
values	O
with	O
light	O
exercise	O
.	O

The	O
rate	O
of	O
enzymic	O
stimulation	O
induced	O
by	O
a	O
given	O
nitrate	O
correlates	O
closely	O
with	O
the	O
rate	O
of	O
measured	O
NO	O
production	O
from	O
the	O
nitrate	O
molecule	O
.	O

Experiments	O
were	O
performed	O
in	O
which	O
brain	O
-	O
stem	O
auditory	O
-	O
evoked	O
responses	O
(	O
BAERs	O
)	O
were	O
elicited	O
by	O
two	O
types	O
of	O
pseudorandom	O
pulse	O
trains	O
:	O
maximum	O
length	O
sequences	O
(	O
MLS	O
)	O
and	O
Legendre	O
sequences	O
(	O
LGS	O
)	O
.	O

Six	O
patients	O
with	O
the	O
diagnosis	O
of	O
acute	O
mania	O
were	O
treated	O
with	O
high	O
doses	O
of	O
the	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
propranolol	O
.	O

PKA	B-protein
phosphorylated	O
WT1	B-protein
at	O
Ser	O
-	O
365	O
and	O
Ser	O
-	O
393	O
in	O
vitro	O
,	O
as	O
well	O
as	O
at	O
additional	O
sites	O
,	O
and	O
this	O
phosphorylation	O
abolished	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
WT1	B-protein
in	O
vitro	O
.	O

The	O
color	O
-	O
word	O
interference	O
effect	O
previously	O
reported	O
with	O
normal	O
populations	O
when	O
given	O
the	O
Stroop	O
test	O
was	O
demonstrated	O
for	O
this	O
retarded	O
sample	O
using	O
a	O
special	O
format	O
.	O

Use	O
of	O
Selenastrum	O
capricornutum	O
and	O
Microfeast	O
as	O
food	O
for	O
Daphnia	O
pulex	O
.	O

The	O
other	O
is	O
located	O
at	O
-	O
1335	O
,	O
outside	O
this	O
highly	O
conserved	O
region	O
.	O

No	O
consistent	O
correlation	O
between	O
blood	O
pressure	O
change	O
and	O
SCR	O
-	O
change	O
was	O
seen	O
.	O

Although	O
YopH	B-protein
is	O
a	O
highly	O
active	O
PTP	B-protein
,	O
it	O
preferentially	O
targets	O
a	O
subset	O
of	O
tyrosine	O
-	O
phosphorylated	O
proteins	O
in	O
host	O
cells	O
,	O
including	O
p130Cas	B-protein
.	O

The	O
carboxyl	O
-	O
terminal	O
proline	O
-	O
rich	O
domain	O
of	O
SOS1	B-protein
is	O
involved	O
in	O
the	O
interaction	O
with	O
the	O
PLC	B-protein
-	I-protein
gamma1	I-protein
SH3	I-protein
domain	I-protein
.	O

The	O
pilE	B-protein
gene	I-protein
product	I-protein
of	I-protein
Pseudomonas	I-protein
aeruginosa	I-protein
,	O
required	O
for	O
pilus	O
biogenesis	O
,	O
shares	O
amino	O
acid	O
sequence	O
identity	O
with	O
the	O
N	O
-	O
termini	O
of	O
type	B-protein
4	I-protein
prepilin	I-protein
proteins	I-protein
.	O

In	O
contrast	O
to	O
the	O
signaling	O
triggered	O
by	O
surface	O
Ig	O
engagement	O
in	O
B	O
lymphocytes	O
,	O
CD38	B-protein
ligation	O
did	O
not	O
appear	O
to	O
induce	O
tyrosine	O
phosphorylation	O
of	O
the	O
src	B-protein
-	I-protein
like	I-protein
protein	I-protein
tyrosine	I-protein
kinases	I-protein
lyn	I-protein
,	O
fyn	B-protein
,	O
and	O
btk	B-protein
,	O
or	O
of	O
vav	O
-	O
and	O
ras	B-protein
-	I-protein
GTPase	I-protein
-	I-protein
activating	I-protein
protein	I-protein
,	O
nor	O
did	O
it	O
induce	O
detectable	O
changes	O
in	O
cytosolic	O
CA2	O
+	O
concentrations	O
.	O

A	O
total	O
of	O
57	O
patients	O
with	O
Hodgkin	O
'	O
s	O
disease	O
limited	O
to	O
above	O
the	O
diaphragm	O
(	O
Stages	O
I	O
and	O
II	O
,	O
A	O
and	O
B	O
)	O
were	O
treated	O
with	O
radiation	O
therapy	O
alone	O
at	O
the	O
University	O
of	O
Florida	O
between	O
1964	O
and	O
1974	O
.	O

The	O
ns2	B-protein
gene	I-protein
comprises	O
an	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
encoding	O
a	O
putative	O
nonstructural	O
(	O
ns	O
)	O
protein	O
of	O
279	O
amino	O
acids	O
with	O
a	O
predicted	O
molecular	O
mass	O
of	O
32	O
-	O
kDa	O
.	O

These	O
cognitive	O
deficits	O
were	O
prevented	O
in	O
animals	O
treated	O
with	O
MK	O
-	O
801	O
during	O
SE	O
.	O

We	O
previously	O
showed	O
that	O
v	B-protein
-	I-protein
Rel	I-protein
,	O
the	O
oncoprotein	O
of	O
the	O
avian	O
retrovirus	O
Rev	O
-	O
T	O
,	O
can	O
increase	O
expression	O
from	O
promoters	O
containing	O
binding	O
sites	O
for	O
the	O
cellular	O
transcription	O
factor	O
Sp1	B-protein
in	O
chicken	O
embryo	O
fibroblasts	O
(	O
S	O
.	O

Allergic	O
reaction	O
to	O
Patent	O
Blue	O
Violet	O
during	O
lymphography	O
.	O

NuA4	B-protein
has	O
an	O
apparent	O
molecular	O
mass	O
of	O
1	O
.	O
3	O
MDa	O
.	O

We	O
also	O
raised	O
a	O
polyclonal	O
antibody	O
against	O
the	O
glutathione	B-protein
S	I-protein
-	I-protein
transferase	I-protein
fusion	I-protein
protein	I-protein
containing	O
the	O
NH2	O
-	O
terminal	O
86	O
amino	O
acids	O
of	O
human	B-protein
NRAMP2	I-protein
.	O

The	O
protein	O
coding	O
region	O
,	O
1	O
,	O
696	O
bps	O
long	O
,	O
is	O
divided	O
by	O
an	O
intron	O
into	O
two	O
exons	O
.	O

Transcription	O
of	O
the	O
gene	O
for	O
ivanolysin	B-protein
O	I-protein
and	O
expression	O
of	O
other	O
genes	O
of	O
the	O
virulence	B-protein
gene	I-protein
cluster	I-protein
in	I-protein
L	I-protein
.	I-protein
ivanovii	I-protein
were	O
dependent	O
on	O
PrfA	B-protein
.	O

The	O
nm23	B-protein
-	I-protein
H1	I-protein
/	I-protein
nm23	I-protein
-	I-protein
H2	I-protein
gene	I-protein
transcriptional	O
activity	O
ratio	O
varied	O
depending	O
on	O
the	O
cell	O
line	O
.	O

Experimentally	O
in	O
green	O
monkeys	O
,	O
Syrian	O
hamsters	O
and	O
white	O
mice	O
the	O
authors	O
studied	O
the	O
pathogenic	O
properties	O
of	O
a	O
new	O
virus	O
Issyk	O
-	O
Kul	O
.	O

METHODS	O
:	O
Millipore	O
ultrafiltration	O
membranes	O
of	O
three	O
different	O
pore	O
sizes	O
were	O
used	O
as	O
model	O
lenticule	O
materials	O
.	O
The	O
nominal	O
membrane	O
pore	O
sizes	O
were	O
0	O
.	O
1	O
microm	O
,	O
0	O
.	O
45	O
microm	O
,	O
and	O
3	O
microm	O
;	O
the	O
surface	O
roughness	O
increased	O
in	O
the	O
same	O
order	O
The	O
membranes	O
were	O
coated	O
with	O
a	O
thin	O
layer	O
of	O
collagen	B-protein
I	I-protein
and	O
implanted	O
in	O
a	O
circular	O
pocket	O
of	O
the	O
anterior	O
cornea	O
of	O
adult	O
cats	O
,	O
and	O
were	O
clinically	O
evaluated	O
for	O
the	O
extent	O
of	O
epithelialization	O
and	O
the	O
persistence	O
of	O
epithelial	O
attachment	O
.	O

Comparative	O
study	O
on	O
acute	O
oral	O
overload	O
using	O
tolbutamide	O
and	O
tolazamide	O
in	O
normal	O
and	O
diabetic	O
subjects	O
.	O

According	O
to	O
the	O
changes	O
of	O
perfusion	O
defects	O
between	O
Ex	O
,	O
RD	O
and	O
ReI	O
images	O
,	O
they	O
were	O
classified	O
into	O
3	O
types	O
:	O
Type	O
I	O
;	O
perfusion	O
defect	O
on	O
the	O
RD	O
image	O
was	O
identical	O
to	O
ReI	O
image	O
(	O
75	O
%	O
)	O
Type	O
I	O
was	O
divided	O
into	O
2	O
subgroups	O
whether	O
perfusion	O
defect	O
at	O
Ex	O
was	O
unchanged	O
(	O
Ia	O
,	O
42	O
%	O
)	O
or	O
improved	O
(	O
Ib	O
,	O
33	O
%	O
)	O
on	O
the	O
RD	O
image	O
.	O

The	O
associations	O
between	O
sex	B-protein
-	I-protein
hormone	I-protein
-	I-protein
binding	I-protein
globulin	I-protein
capacity	O
(	O
SHBG	B-protein
)	O
,	O
age	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
and	O
physical	O
fitness	O
have	O
been	O
studied	O
in	O
34	O
men	O
and	O
36	O
women	O
.	O

In	O
Malmo	O
,	O
Sweden	O
,	O
17	O
,	O
181	O
school	O
children	O
born	O
in	O
the	O
years	O
1961	O
-	O
1965	O
were	O
screened	O
for	O
scoliosis	O
once	O
a	O
year	O
between	O
the	O
ages	O
of	O
7	O
and	O
16	O
years	O
,	O
during	O
1971	O
-	O
1980	O
.	O

A	O
platelet	B-protein
-	I-protein
derived	I-protein
growth	I-protein
factor	I-protein
receptor	I-protein
(	O
PDGF	B-protein
-	I-protein
R	I-protein
)	O
phosphopeptide	O
containing	O
Tyr	O
-	O
857	O
does	O
not	O
bind	O
appreciably	O
to	O
the	O
Src	B-protein
SH2	I-protein
domain	I-protein
,	O
suggesting	O
it	O
is	O
not	O
the	O
PDGF	B-protein
-	I-protein
R	I-protein
binding	O
site	O
for	O
Src	B-protein
as	O
previously	O
reported	O
.	O

Here	O
we	O
have	O
tested	O
the	O
hypothesis	O
that	O
the	O
short	O
transcripts	O
,	O
or	O
proteins	O
translated	O
from	O
the	O
short	O
transcripts	O
,	O
are	O
also	O
required	O
for	O
respiration	O
.	O

Also	O
,	O
the	O
human	B-protein
glycoprotein	I-protein
alpha	I-protein
-	I-protein
subunit	I-protein
promoter	I-protein
was	O
induced	O
10	O
-	O
fold	O
by	O
FSK	B-protein
in	O
GH4	O
rat	O
pituitary	O
cells	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Three	O
chromosomal	B-protein
crsA	I-protein
mutations	I-protein
,	O
crsA1	B-protein
,	O
crsA4	B-protein
,	O
and	O
crsA47	B-protein
,	O
were	O
transferred	O
by	O
the	O
`	O
`	O
gene	O
conversion	O
'	O
'	O
process	O
to	O
B	O
.	O
subtilis	O
plasmid	O
pRPD11	O
,	O
which	O
consists	O
of	O
the	O
entire	O
wild	B-protein
-	I-protein
type	I-protein
rpoD	I-protein
coding	I-protein
sequence	I-protein
,	O
encoding	O
the	O
major	B-protein
sigma	I-protein
43	I-protein
factor	I-protein
of	I-protein
B	I-protein
.	I-protein
subtilis	I-protein
RNA	I-protein
polymerase	I-protein
,	O
and	O
pUB110	O
.	O

Lymphocytes	O
from	O
all	O
3	O
species	O
yielded	O
maximum	O
responses	O
with	O
a	O
48	O
-	O
hour	O
prelabel	O
and	O
12	O
-	O
to	O
-	O
16	O
hour	O
postlabel	O
incubation	O
period	O
at	O
41	O
C	O
and	O
1	O
:	O
20	O
blood	O
dilution	O
.	O

Unlike	O
class	B-protein
II	I-protein
-	I-protein
and	I-protein
III	I-protein
-	I-protein
specific	I-protein
TBP	I-protein
-	I-protein
TAF	I-protein
complexes	I-protein
,	O
the	O
corresponding	O
murine	O
and	O
human	B-protein
class	I-protein
I	I-protein
-	I-protein
specific	I-protein
transcription	I-protein
initiation	I-protein
factor	I-protein
TIF	I-protein
-	I-protein
IB	I-protein
/	I-protein
SL1	I-protein
exhibits	O
a	O
pronounced	O
selectivity	O
for	O
its	O
homologous	O
promoter	O
.	O

The	O
suppression	O
was	O
also	O
demonstrated	O
in	O
a	O
transient	O
expression	O
assay	O
in	O
vivo	O
using	O
isolated	O
barley	O
endosperms	O
.	O

CREST	O
syndrome	O
;	O
a	O
changing	O
clinical	O
significance	O
.	O

Hormonal	O
regulation	O
of	O
multiple	O
promoters	O
of	O
the	O
rat	B-protein
mitochondrial	I-protein
glycerol	I-protein
-	I-protein
3	I-protein
-	I-protein
phosphate	I-protein
dehydrogenase	I-protein
gene	I-protein
:	O
identification	O
of	O
a	O
complex	O
hormone	B-protein
-	I-protein
response	I-protein
element	I-protein
in	O
the	O
ubiquitous	O
promoter	O
B	O
.	O

Isolation	O
and	O
characterization	O
of	O
a	O
vinculin	B-protein
cDNA	I-protein
from	I-protein
chick	I-protein
-	I-protein
embryo	I-protein
fibroblasts	I-protein
.	O

Long	O
-	O
term	O
effects	O
of	O
clofibrate	O
(	O
Atromid	O
-	O
S	O
)	O
on	O
serum	O
lipids	O
in	O
man	O
.	O

Drosophila	O
230	O
-	O
kD	O
TFIID	B-protein
subunit	O
,	O
a	O
functional	O
homolog	O
of	O
the	O
human	O
cell	O
cycle	O
gene	O
product	O
,	O
negatively	O
regulates	O
DNA	O
binding	O
of	O
the	O
TATA	B-protein
box	I-protein
-	I-protein
binding	I-protein
subunit	I-protein
of	I-protein
TFIID	I-protein
.	O

Recent	O
investigations	O
have	O
shown	O
that	O
Grenz	O
rays	O
can	O
suppress	O
the	O
allergic	O
contact	O
dermatitis	O
reaction	O
completely	O
and	O
that	O
Langerhans	O
cells	O
,	O
identified	O
by	O
OKT6	B-protein
antibodies	I-protein
and	O
electron	O
microscopy	O
,	O
disappear	O
from	O
the	O
epidermis	O
at	O
the	O
same	O
time	O
.	O

Recombinant	B-protein
Leishmania	I-protein
surface	I-protein
glycoprotein	I-protein
GP63	I-protein
is	O
secreted	O
in	O
the	O
baculovirus	O
expression	O
system	O
as	O
a	O
latent	O
metalloproteinase	B-protein
.	O

The	O
mean	O
jitter	O
and	O
the	O
fiber	O
density	O
did	O
not	O
change	O
significantly	O
from	O
day	O
0	O
(	O
30	O
.	O
1	O
+	O
/	O
-	O
3	O
.	O
6	O
microseconds	O
;	O
1	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
07	O
)	O
to	O
day	O
30	O
(	O
34	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
7	O
microseconds	O
;	O
1	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
13	O
)	O
.	O

9	O
,	O
11	O
-	O
Seco	O
steroids	O
derived	O
from	O
estradiol	O
3	O
-	O
methyl	O
ether	O
.	O

Several	O
demographic	O
indices	O
of	O
isolated	O
populations	O
in	O
Uzbekistan	O
.	O

Our	O
findings	O
confirm	O
the	O
high	O
frequency	O
of	O
proximal	O
nerve	O
lesions	O
in	O
early	O
GBS	O
and	O
CIDP	O
,	O
not	O
all	O
of	O
which	O
are	O
associated	O
with	O
distal	O
motor	O
conduction	O
abnormalities	O
,	O
and	O
suggest	O
that	O
assessment	O
of	O
multiple	O
F	O
wave	O
parameters	O
,	O
in	O
particular	O
chronodispersion	O
,	O
mean	O
latency	O
and	O
mean	O
amplitude	O
(	O
in	O
addition	O
to	O
absence	O
and	O
minimum	O
latency	O
)	O
,	O
increases	O
the	O
yield	O
of	O
F	O
wave	O
studies	O
.	O

Each	O
causative	O
organism	O
has	O
a	O
species	O
-	O
specific	O
preference	O
and	O
requirement	O
for	O
temperature	O
,	O
salinity	O
,	O
pH	O
,	O
the	O
basic	O
nutrients	O
,	O
and	O
growth	B-protein
factors	I-protein
,	O
and	O
the	O
toxin	O
formation	O
is	O
affected	O
by	O
these	O
environmental	O
factors	O
.	O

Structural	O
analysis	O
and	O
characterization	O
of	O
tissue	O
and	O
hormonal	O
responsive	O
expression	O
of	O
the	O
avian	B-protein
bone	I-protein
sialoprotein	I-protein
(	O
BSP	B-protein
)	O
gene	O
.	O

I	O
.	O

Identical	O
results	O
were	O
obtained	O
when	O
transfections	O
and	O
mobility	O
shift	O
assays	O
were	O
performed	O
in	O
primary	O
rat	O
hepatocytes	O
in	O
which	O
the	O
endogenous	O
ALS	B-protein
gene	I-protein
is	O
expressed	O
.	O

Elimination	O
of	O
gamma	O
-	O
irradiation	O
induced	O
oxidation	O
in	O
aqueous	O
drug	O
preparations	O
.	O

The	O
timing	O
of	O
fla	B-protein
gene	I-protein
expression	O
in	O
the	O
cell	O
cycle	O
is	O
determined	O
by	O
specialized	O
forms	O
of	O
RNA	B-protein
polymerase	I-protein
and	O
the	O
appearance	O
and	O
/	O
or	O
activation	O
of	O
regulatory	O
proteins	O
.	O

Growth	O
,	O
4	O
-	O
PA	O
and	O
14C	O
turnover	O
data	O
indicated	O
that	O
WB	O
contributed	O
to	O
B	O
-	O
6	O
intake	O
of	O
these	O
rats	O
.	O

Advances	O
in	O
the	O
management	O
of	O
gynecologic	O
cancer	O
-	O
-	O
radiation	O
therapy	O
.	O

To	O
test	O
the	O
role	O
of	O
ML	O
in	O
human	O
reproductive	O
axis	O
,	O
128	O
healthy	O
children	O
,	O
68	O
boys	O
and	O
60	O
girls	O
,	O
were	O
studied	O
.	O

It	O
has	O
been	O
suggested	O
that	O
members	O
of	O
this	O
protein	O
family	O
exhibit	O
both	O
prolyl	B-protein
isomerase	I-protein
and	O
chaperone	O
activity	O
.	O

Recently	O
,	O
identical	O
RBE	B-protein
sequences	I-protein
have	O
been	O
identified	O
at	O
other	O
locations	O
in	O
the	O
human	O
genome	O
.	O

Increased	O
granulocyte	B-protein
-	I-protein
colony	I-protein
stimulating	I-protein
factor	I-protein
(	O
G	B-protein
-	I-protein
CSF	I-protein
)	O
levels	O
in	O
neonates	O
with	O
perinatal	O
complications	O
.	O

In	O
some	O
instances	O
,	O
this	O
is	O
partly	O
mediated	O
by	O
the	O
expression	O
of	O
virally	O
encoded	O
proteases	B-protein
which	O
lead	O
to	O
the	O
cleavage	O
of	O
initiation	B-protein
factor	I-protein
eIF4G	I-protein
.	O

In	O
contrast	O
,	O
tobacco	B-protein
GS	I-protein
-	I-protein
2	I-protein
is	O
composed	O
of	O
subunits	O
of	O
identical	O
size	O
in	O
all	O
organs	O
examined	O
.	O

Women	O
'	O
s	O
opportunities	O
for	O
paid	O
work	O
outside	O
the	O
home	O
are	O
constrained	O
by	O
their	O
role	O
as	O
primary	O
carer	O
within	O
the	O
family	O
,	O
writes	O
Trudy	O
Wynne	O
.	O

The	O
mean	O
percentage	O
of	O
linoleic	O
acid	O
in	O
the	O
triglycerides	O
of	O
the	O
subcutaneous	O
adipose	O
tissue	O
(	O
PLASAT	O
)	O
of	O
these	O
subjects	O
was	O
substantially	O
higher	O
than	O
that	O
in	O
a	O
similar	O
group	O
examined	O
in	O
1975	O
-	O
1976	O
.	O

However	O
,	O
the	O
ratio	O
M	O
/	O
Pc	O
provides	O
a	O
useful	O
index	O
that	O
seems	O
to	O
be	O
independent	O
of	O
the	O
metabolic	O
demand	O
.	O

Cys	O
-	O
757	O
within	O
the	O
(	B-protein
Fe4S4	I-protein
)	I-protein
-	I-protein
siroheme	I-protein
-	I-protein
binding	I-protein
domain	I-protein
was	O
essential	O
for	O
native	O
enzyme	O
activity	O
.	O

The	O
amplitude	O
of	O
detrusor	O
contractions	O
at	O
6	O
,	O
12	O
,	O
and	O
24	O
hours	O
showed	O
no	O
significant	O
difference	O
from	O
that	O
in	O
the	O
controls	O
.	O

Zebrafish	O
cyclops	B-protein
(	O
cyc	B-protein
)	O
encodes	O
a	O
Transforming	B-protein
Growth	I-protein
Factor	I-protein
beta	I-protein
(	O
TGFbeta	B-protein
)	O
signaling	O
factor	O
closely	O
related	O
to	O
mouse	O
Nodal	B-protein
.	O

Breitbart	O
,	O
L	O
.	O

A	O
newly	O
synthesized	O
anti	O
-	O
inflammatory	O
agent	O
,	O
Y	O
-	O
8004	O
demonstrated	O
a	O
greater	O
inhibition	O
than	O
did	O
indomethacin	O
(	O
IM	O
)	O
.	O
on	O
inflammatory	O
response	O
such	O
as	O
ultraviolet	O
erythema	O
in	O
guinea	O
pigs	O
,	O
carrageenin	O
edema	O
,	O
evans	O
blue	O
and	O
carrageenin	O
-	O
induced	O
pleuritis	O
and	O
acetic	O
acid	O
-	O
induced	O
peritonitis	O
in	O
rats	O
.	O

Polyvinyl	O
alcohol	O
as	O
a	O
solution	O
mediator	O
.	O

Ovaries	O
of	O
10	O
animals	O
per	O
group	O
from	O
16	O
studies	O
in	O
CD	O
-	O
1	O
mice	O
and	O
1	O
study	O
each	O
in	O
C3H	O
and	O
C57BL	O
/	O
6	O
mice	O
were	O
sectioned	O
serially	O
at	O
6	O
@	O
mgr	O
;	O
m	O
.	O

5	O
'	O
-	O
RACE	O
analysis	O
suggested	O
a	O
single	O
transcription	O
initiation	O
site	O
187	O
bp	O
upstream	O
from	O
the	O
translational	O
start	O
site	O
.	O

Treatment	O
also	O
led	O
to	O
a	O
significant	O
dose	O
dependent	O
reduction	O
in	O
the	O
sum	O
of	O
ST	O
segment	O
depression	O
at	O
both	O
trough	O
and	O
peak	O
concentrations	O
.	O

Our	O
data	O
demonstrate	O
directly	O
that	O
Rpm1r	B-protein
is	O
transcribed	O
with	O
its	O
substrates	O
,	O
tRNA	B-protein
met	I-protein
f	I-protein
and	O
tRNAPro	B-protein
,	O
from	O
a	O
promoter	O
located	O
upstream	O
of	O
the	O
tRNA	B-protein
met	I-protein
f	I-protein
gene	I-protein
and	O
suggest	O
that	O
a	O
portion	O
also	O
originates	O
from	O
a	O
second	O
promoter	O
,	O
located	O
between	O
the	O
tRNA	B-protein
met	I-protein
f	I-protein
gene	I-protein
and	O
RPM1	B-protein
.	O

Retinoid	O
-	O
dependent	O
activation	O
of	O
the	O
tissue	B-protein
transglutaminase	I-protein
promoter	I-protein
depends	O
on	O
both	O
a	O
proximal	O
regulatory	O
region	O
containing	O
sequences	O
highly	O
conserved	O
between	O
the	O
human	O
and	O
the	O
mouse	B-protein
tissue	I-protein
transglutaminase	I-protein
promoters	I-protein
and	O
a	O
distal	O
region	O
that	O
includes	O
a	O
30	B-protein
-	I-protein
base	I-protein
pair	I-protein
retinoid	I-protein
response	I-protein
element	I-protein
(	I-protein
mTGRRE1	I-protein
)	I-protein
.	O
mTGRRE1	B-protein
contains	O
three	O
hexanucleotide	O
half	O
-	O
sites	O
(	O
two	O
canonical	O
and	O
one	O
non	O
-	O
canonical	O
)	O
in	O
a	O
DR7	B-protein
/	I-protein
DR5	I-protein
motif	I-protein
that	O
bind	O
both	O
RAR	B-protein
*	I-protein
RXR	I-protein
heterodimers	I-protein
and	O
RXR	B-protein
homodimers	I-protein
.	O

However	O
,	O
the	O
published	O
reports	O
consist	O
of	O
a	O
small	O
number	O
of	O
patients	O
and	O
limited	O
data	O
.	O

Relationship	O
between	O
mitochondrial	B-protein
NADH	I-protein
-	I-protein
ubiquinone	I-protein
reductase	I-protein
and	O
a	O
bacterial	B-protein
NAD	I-protein
-	I-protein
reducing	I-protein
hydrogenase	I-protein
.	O

The	O
combination	O
of	O
hydralazine	O
hydrochloride	O
and	O
isosorbide	O
dinitrate	O
also	O
improves	O
survival	O
,	O
but	O
direct	O
comparison	O
of	O
both	O
regimens	O
provided	O
evidence	O
for	O
a	O
less	O
favourable	O
effect	O
than	O
that	O
of	O
the	O
ACE	B-protein
inhibitors	O
.	O

In	O
fact	O
,	O
families	O
of	O
polypeptides	O
were	O
produced	O
by	O
initiation	O
of	O
translation	O
at	O
AUG	O
codons	O
within	O
sequences	O
coding	O
for	O
VP1	B-protein
and	O
T	B-protein
,	O
presumably	O
as	O
a	O
result	O
of	O
transcription	O
initiation	O
events	O
that	O
generated	O
5	O
'	O
ends	O
immediately	O
upstream	O
from	O
these	O
AUGs	O
.	O

Although	O
the	O
expression	O
of	O
the	O
4E	B-protein
-	I-protein
BP1	I-protein
gene	I-protein
alone	O
has	O
not	O
yet	O
been	O
accomplished	O
,	O
the	O
gene	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
[	O
BL21	O
(	O
DE3	O
)	O
]	O
as	O
a	O
fusion	O
gene	O
with	O
the	O
glutathione	B-protein
-	I-protein
S	I-protein
-	I-protein
transferase	I-protein
(	O
GST	B-protein
)	O
gene	O
using	O
a	O
prokaryotic	O
gene	O
fusion	O
vector	O
(	O
pGEX	O
-	O
4T	O
-	O
2	O
)	O
,	O
which	O
contains	O
a	O
gene	O
sequence	O
coding	O
the	O
cleavage	O
site	O
for	O
a	O
specific	O
protease	B-protein
,	O
alpha	B-protein
-	I-protein
thrombin	I-protein
.	O

Reporter	O
gene	O
expression	O
analyses	O
indicate	O
that	O
both	O
WASP	B-protein
promoters	I-protein
show	O
high	O
levels	O
of	O
expression	O
in	O
different	O
hematopoietic	O
cell	O
lines	O
.	O

The	O
geometric	O
mean	O
hemagglutination	O
-	O
inhibition	O
antibody	O
titers	O
(	O
GMT	O
)	O
of	O
non	O
-	O
immunized	O
,	O
once	O
-	O
immunized	O
,	O
and	O
twice	O
-	O
immunized	O
chickens	O
were	O
compared	O
at	O
2	O
-	O
week	O
intervals	O
following	O
primary	O
immunization	O
,	O
secondary	O
immunization	O
,	O
and	O
challenge	O
.	O

The	O
micturition	O
pressure	O
was	O
significantly	O
decreased	O
only	O
after	O
injection	O
with	O
BUP	O
-	O
4	O
in	O
both	O
normal	O
and	O
obstructed	O
rats	O
.	O

We	O
have	O
previously	O
isolated	O
a	O
cDNA	O
for	O
a	O
transcription	O
factor	O
referred	O
to	O
as	O
Zfhep	B-protein
(	O
zinc	B-protein
finger	I-protein
homeodomain	I-protein
enhancer	I-protein
-	I-protein
binding	I-protein
protein	I-protein
)	O
containing	O
two	O
separate	O
zinc	O
finger	O
domains	O
,	O
ZD1	B-protein
and	O
ZD2	B-protein
,	O
each	O
of	O
which	O
binds	O
DNA	O
,	O
and	O
a	O
homeodomain	O
.	O

Inactivation	O
of	O
p53	B-protein
but	O
not	O
p73	B-protein
by	O
adenovirus	B-protein
type	I-protein
5	I-protein
E1B	I-protein
55	I-protein
-	I-protein
kilodalton	I-protein
and	I-protein
E4	I-protein
34	I-protein
-	I-protein
kilodalton	I-protein
oncoproteins	I-protein
.	O

Following	O
EPI	O
-	O
C0401	O
,	O
but	O
not	O
saline	O
or	O
DepoFoam	O
vehicle	O
,	O
there	O
were	O
transient	O
(	O
<	O
72	O
hr	O
)	O
decreases	O
in	O
food	O
consumption	O
,	O
arousal	O
,	O
hindlimb	O
muscle	O
tone	O
,	O
and	O
body	O
temperature	O
.	O

Deletion	O
studies	O
identified	O
a	O
distal	O
response	O
element	O
that	O
is	O
responsible	O
for	O
the	O
cytokine	O
response	O
and	O
has	O
properties	O
of	O
an	O
inducible	O
transcriptional	O
enhancer	O
.	O

195mPt	O
-	O
labeled	O
cisplatin	O
was	O
administered	O
iv	O
and	O
ip	O
to	O
control	O
mice	O
and	O
to	O
mice	O
bearing	O
Sarcoma	O
180	O
.	O

Both	O
groups	O
rejected	O
pops	O
with	O
added	O
SOA	O
,	O
decreasing	O
mouthing	O
times	O
as	O
SOA	O
concentration	O
increased	O
.	O

One	O
millimolar	O
ouabain	O
completely	O
inhibited	O
net	O
HCO3	O
-	O
secretion	O
.	O

The	O
uncomplicated	O
cases	O
of	O
typhoid	O
fever	O
were	O
found	O
to	O
have	O
an	O
intact	O
CMIR	O
as	O
compared	O
to	O
the	O
complicated	O
cases	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Zatebradine	O
weakly	O
depressed	O
the	O
ectopic	O
ventricular	O
rate	O
but	O
not	O
the	O
arrhythmic	O
ratio	O
of	O
the	O
ventricular	O
arrhythmias	O
induced	O
by	O
two	O
-	O
stage	O
coronary	O
ligation	O
24	O
h	O
after	O
the	O
ligation	O
in	O
conscious	O
dogs	O
.	O

The	O
sense	O
of	O
self	O
.	O

The	O
existence	O
of	O
these	O
two	O
categories	O
of	O
strains	O
offers	O
a	O
new	O
genetic	O
system	O
in	O
which	O
the	O
properties	O
of	O
a	O
potential	O
invertebrate	O
retrovirus	O
can	O
be	O
tested	O
.	O

(	O
ii	O
)	O
ICP27	B-protein
binds	O
preferentially	O
to	O
less	O
modified	O
forms	O
of	O
ICP4	B-protein
,	O
a	O
protein	O
that	O
is	O
extensively	O
modified	O
posttranslationally	O
.	O

To	O
prepare	O
for	O
analyses	O
with	O
the	O
family	O
variables	O
,	O
we	O
next	O
present	O
descriptive	O
data	O
based	O
on	O
separate	O
principal	O
components	O
analysis	O
(	O
PCA	O
)	O
and	O
multidimensional	O
scaling	O
analysis	O
(	O
MDS	O
)	O
of	O
14	O
self	O
-	O
reported	O
health	O
scores	O
for	O
husbands	O
and	O
for	O
wives	O
.	O

Based	O
on	O
16S	B-protein
rRNA	I-protein
gene	I-protein
sequence	I-protein
analysis	O
,	O
the	O
11	O
species	O
having	O
two	O
tuf	B-protein
genes	I-protein
all	O
have	O
a	O
common	O
ancestor	O
,	O
while	O
the	O
six	O
species	O
having	O
only	O
one	O
copy	O
diverged	O
from	O
the	O
enterococcal	O
lineage	O
before	O
that	O
common	O
ancestor	O
.	O

The	O
locus	O
encoding	O
the	O
XD	B-protein
gene	I-protein
(	O
designated	O
Xd	B-protein
)	O
was	O
mapped	O
to	O
the	O
distal	O
part	O
of	O
mouse	O
chromosome	O
17	O
by	O
haplotype	O
analysis	O
of	O
114	O
interspecific	O
backcross	O
mice	O
.	O

Merosin	B-protein
positive	O
congenital	O
muscular	O
dystrophy	O
with	O
mental	O
deficiency	O
,	O
epilepsy	O
and	O
MRI	O
changes	O
in	O
the	O
cerebral	O
white	O
matter	O
.	O

Lacrimal	O
secretion	O
in	O
hyperthyroidism	O
.	O

Once	O
ICP	O
reaches	O
critical	O
values	O
(	O
>	O
30	O
mm	O
Hg	O
)	O
herniation	O
occurs	O
,	O
usually	O
within	O
2	O
to	O
5	O
days	O
.	O

Changes	O
following	O
periodontal	O
surgery	O
.	O

Pro	O
-	O
inflammatory	O
cytokine	O
,	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
-	I-protein
alpha	I-protein
(	O
TNF	B-protein
-	I-protein
alpha	I-protein
)	O
,	O
produced	O
from	O
adipose	O
tissues	O
in	O
obese	O
subjects	O
,	O
is	O
known	O
to	O
play	O
a	O
predominant	O
role	O
in	O
inducing	O
insulin	B-protein
resistance	O
.	O

Below	O
50	O
%	O
decrease	O
of	O
PaO2	O
,	O
NADH	O
was	O
reduced	O
largely	O
.	O

In	O
all	O
cases	O
,	O
high	O
-	O
level	O
expression	O
of	O
the	O
truncated	B-protein
avian	I-protein
integrins	I-protein
was	O
obtained	O
.	O

A	O
system	O
is	O
described	O
in	O
which	O
the	O
volume	O
flow	O
rate	O
of	O
blood	O
in	O
a	O
vessel	O
is	O
determined	O
using	O
transverse	O
colour	O
Doppler	O
ultrasound	O
imaging	O
.	O

Studies	O
of	O
lipogenesis	O
by	O
labelled	O
precursors	O
in	O
the	O
pregnant	O
rat	O
.	O

A	O
prospective	O
trial	O
was	O
carried	O
out	O
in	O
156	O
unselected	O
patients	O
(	O
41	O
men	O
,	O
mean	O
age	O
67	O
.	O
5	O
years	O
,	O
115	O
women	O
,	O
mean	O
age	O
71	O
.	O
4	O
years	O
)	O
who	O
had	O
undergone	O
total	O
hip	O
joint	O
replacement	O
because	O
of	O
degenerative	O
or	O
inflammatory	O
arthritis	O
or	O
fracture	O
of	O
the	O
neck	O
of	O
the	O
femur	O
.	O

Nucleotide	O
sequence	O
and	O
transcriptional	O
analysis	O
of	O
the	O
DNA	B-protein
polymerase	I-protein
gene	I-protein
of	I-protein
Bombyx	I-protein
mori	I-protein
nuclear	I-protein
polyhedrosis	I-protein
virus	I-protein
.	O

Sequence	O
analysis	O
of	O
a	O
6	O
.	O
3	O
-	O
kbp	O
genomic	O
EcoRI	O
-	O
fragment	O
of	O
Alcaligenes	O
eutrophus	O
,	O
which	O
was	O
recently	O
identified	O
by	O
using	O
a	O
dihydrolipoamide	O
dehydrogenase	O
-	O
specific	O
DNA	O
probe	O
(	O
A	O
.	O

Polysome	O
analysis	O
further	O
indicated	O
that	O
these	O
germ	B-protein
cell	I-protein
-	I-protein
specific	I-protein
Sp1	I-protein
mRNAs	I-protein
are	O
translated	O
,	O
albeit	O
with	O
a	O
lower	O
efficiency	O
than	O
the	O
somatic	O
transcript	O
.	O

Transgenic	O
tobacco	O
plants	O
(	O
ppa	O
-	O
1	O
)	O
constitutively	O
expressing	O
Escherichia	B-protein
coli	I-protein
pyrophosphatase	I-protein
behind	O
the	O
35S	B-protein
CaMV	I-protein
promoter	I-protein
accumulate	O
high	O
levels	O
of	O
soluble	O
sugars	O
in	O
their	O
leaves	O
[	O
27	O
]	O
.	O

Deletions	O
were	O
examined	O
in	O
the	O
LYS2	B-protein
gene	I-protein
,	O
using	O
a	O
set	O
of	O
31	O
-	O
to	O
156	O
-	O
bp	O
inserts	O
that	O
included	O
inserts	O
with	O
no	O
apparent	O
potential	O
for	O
secondary	O
structure	O
as	O
well	O
as	O
two	O
quasipalindromes	O
.	O

Diagnosis	O
and	O
differential	O
diagnosis	O
.	O

In	O
addition	O
,	O
the	O
utility	O
of	O
beta	B-protein
2	I-protein
transferrin	I-protein
assay	O
in	O
the	O
diagnosis	O
of	O
cerebrospinal	O
fluid	O
otorrhea	O
is	O
presented	O
.	O

We	O
show	O
here	O
that	O
,	O
despite	O
their	O
structural	O
and	O
functional	O
similarities	O
,	O
the	O
pop1	B-protein
and	O
pop2	B-protein
genes	I-protein
fail	O
to	O
complement	O
each	O
other	O
'	O
s	O
deletion	O
phenotypes	O
,	O
indicating	O
that	O
they	O
perform	O
non	O
-	O
redundant	O
,	O
but	O
potentially	O
interdependent	O
,	O
functions	O
in	O
proteolysis	O
.	O

To	O
identify	O
the	O
precise	O
location	O
of	O
the	O
phosphorylation	O
site	O
on	O
the	O
64	O
-	O
kDa	O
protein	O
,	O
a	O
step	O
-	O
by	O
-	O
step	O
mutagenesis	O
procedures	O
was	O
followed	O
.	O

To	O
better	O
understand	O
the	O
role	O
of	O
Ets	B-protein
proteins	I-protein
in	O
Ras	B-protein
transformation	O
,	O
we	O
have	O
now	O
analyzed	O
the	O
effects	O
of	O
stably	O
expressing	O
a	O
variety	O
of	O
Ets2	B-protein
constructs	I-protein
in	O
Ras	O
-	O
transformed	O
NIH3T3	O
(	O
DT	O
)	O
cells	O
.	O

They	O
were	O
randomly	O
allocated	O
to	O
receive	O
either	O
625	O
mg	O
of	O
calcium	O
carbonate	O
(	O
250	O
mg	O
of	O
elemental	O
calcium	O
)	O
at	O
the	O
end	O
of	O
a	O
meal	O
three	O
times	O
a	O
day	O
(	O
group	O
A	O
,	O
n	O
=	O
26	O
)	O
or	O
calcium	O
carbonate	O
in	O
the	O
same	O
manner	O
plus	O
0	O
.	O
625	O
mg	O
/	O
day	O
of	O
conjugated	O
equine	O
estrogen	O
and	O
5	O
mg	O
medrogestone	O
acetate	O
from	O
day	O
1	O
-	O
12	O
each	O
month	O
(	O
group	O
B	O
,	O
n	O
=	O
30	O
)	O
.	O

In	O
addition	O
to	O
the	O
signals	O
obtained	O
by	O
ligation	O
of	O
the	O
TCR	B-protein
,	O
T	O
cells	O
need	O
additional	O
,	O
co	O
-	O
stimulatory	O
signals	O
to	O
be	O
activated	O
.	O

However	O
,	O
most	O
produced	O
significant	O
alteration	O
of	O
small	O
intestinal	O
permeability	O
.	O

Synthetic	O
enantiomers	O
of	O
drugs	O
.	O

Furthermore	O
,	O
in	O
vitro	O
decay	O
reaction	O
mixtures	O
supplemented	O
with	O
the	O
20	O
-	O
nt	O
sense	O
RNA	O
transcript	O
resulted	O
in	O
stabilization	O
of	O
R2	B-protein
message	I-protein
.	O

The	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
sequences	O
contain	O
characteristic	O
sequences	O
that	O
are	O
involved	O
in	O
the	O
initiation	O
and	O
termination	O
of	O
transcription	O
,	O
including	O
two	O
possible	O
promoters	O
,	O
one	O
of	O
which	O
may	O
contain	O
two	O
overlapping	O
-	O
10	O
sequences	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
inducible	O
expression	O
of	O
the	O
flt	B-protein
-	I-protein
1	I-protein
gene	I-protein
during	O
the	O
activation	O
of	O
THP	O
-	O
1	O
cells	O
.	O

A	O
protocol	O
is	O
elaborated	O
for	O
the	O
preparation	O
and	O
characterization	O
of	O
a	O
quality	O
control	O
material	O
(	O
QCM	O
)	O
containing	O
intrinsic	O
concentration	O
of	O
cadmium	O
(	O
Cd	O
)	O
(	O
0	O
.	O
8	O
microgram	O
/	O
L	O
)	O
and	O
lead	O
(	O
Pb	O
)	O
(	O
13	O
.	O
4	O
micrograms	O
/	O
dL	O
)	O
from	O
bovine	O
blood	O
and	O
an	O
elevated	O
QCM	O
containing	O
Cd	O
(	O
5	O
.	O
0	O
micrograms	O
/	O
L	O
)	O
,	O
mercury	O
(	O
Hg	O
)	O
(	O
11	O
.	O
2	O
micrograms	O
/	O
L	O
)	O
,	O
and	O
Pb	O
(	O
34	O
.	O
5	O
micrograms	O
/	O
dL	O
)	O
from	O
bovine	O
blood	O
spiked	O
with	O
aqueous	O
spiking	O
-	O
solutions	O
prepared	O
with	O
salts	O
of	O
Cd	O
,	O
Hg	O
,	O
and	O
Pb	O
.	O

Gab2	B-protein
,	O
a	O
new	O
pleckstrin	B-protein
homology	O
domain	O
-	O
containing	O
adapter	O
protein	O
,	O
acts	O
to	O
uncouple	O
signaling	O
from	O
ERK	B-protein
kinase	I-protein
to	O
Elk	B-protein
-	I-protein
1	I-protein
.	O

In	O
HeLa	O
cells	O
,	O
it	O
activated	O
transcription	O
from	O
the	O
herpes	B-protein
simplex	I-protein
virus	I-protein
type	I-protein
1	I-protein
thymidine	I-protein
kinase	I-protein
promoter	I-protein
linked	O
to	O
the	O
chloramphenicol	B-protein
acetyltransferase	I-protein
gene	I-protein
when	O
located	O
in	O
inverted	O
orientation	O
upstream	O
of	O
the	O
thymidine	B-protein
kinase	I-protein
promoter	I-protein
or	O
downstream	O
of	O
the	O
chloramphenicol	B-protein
acetyltransferase	I-protein
gene	I-protein
coding	I-protein
sequence	I-protein
.	O

Guiding	O
patients	O
in	O
the	O
decision	O
should	O
involve	O
a	O
multidisciplinary	O
team	O
composed	O
of	O
a	O
surgical	O
oncologist	O
,	O
geneticist	O
,	O
pathologist	O
,	O
psychotherapist	O
and	O
plastic	O
surgeon	O
.	O

Treatment	O
of	O
ovarian	O
neoplasms	O
.	O

The	O
variable	O
HMG	B-protein
dosage	O
regimen	O
was	O
found	O
to	O
offer	O
no	O
advantages	O
when	O
compared	O
with	O
our	O
standard	O
daily	O
dosage	O
regimen	O
.	O

The	O
improved	O
CSF	O
outflow	O
conductance	O
may	O
increase	O
the	O
intracranial	O
compliance	O
and	O
thereby	O
dampen	O
a	O
pathological	O
ICP	O
waveform	O
.	O

The	O
sequence	O
of	O
this	O
region	O
shows	O
high	O
G	O
+	O
C	O
content	O
(	O
62	O
%	O
)	O
,	O
which	O
is	O
particularly	O
emphasized	O
in	O
the	O
200	O
bp	O
upstream	O
from	O
the	O
mRNA	O
start	O
(	O
80	O
%	O
G	O
+	O
C	O
)	O
.	O

Expression	O
,	O
nucleotide	O
sequence	O
and	O
mutational	O
analysis	O
of	O
two	O
open	O
reading	O
frames	O
in	O
the	O
nif	B-protein
gene	I-protein
region	I-protein
of	I-protein
Anabaena	I-protein
sp	I-protein
.	I-protein
strain	I-protein
PCC7120	I-protein
.	O

We	O
postulate	O
that	O
CaM	B-protein
binding	O
by	O
HIV	B-protein
envelope	I-protein
proteins	I-protein
is	O
likely	O
to	O
exert	O
diverse	O
modulatory	O
effects	O
,	O
and	O
the	O
mechanism	O
for	O
HIV	O
-	O
induced	O
cytotoxicity	O
may	O
involve	O
,	O
in	O
part	O
,	O
inhibition	O
of	O
CaM	O
-	O
regulated	O
cellular	O
functions	O
.	O

Both	O
of	O
these	O
domains	O
have	O
striking	O
sequence	O
homology	O
with	O
human	O
SIM	B-protein
and	O
Drosophila	O
SIM	B-protein
proteins	O
.	O

Truncations	O
composed	O
of	O
78	O
and	O
64	O
amino	O
acids	O
were	O
translocated	O
across	O
the	O
endoplasmic	O
reticulum	O
membrane	O
,	O
and	O
translocation	O
was	O
found	O
to	O
be	O
strictly	O
co	O
-	O
translational	O
and	O
SRP	O
-	O
dependent	O
.	O

6	O
.	O

The	O
uterine	O
response	O
to	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
and	O
prostaglandin	O
F2alpha	O
(	O
administered	O
by	O
intravenous	O
and	O
intrauterine	O
routes	O
)	O
was	O
evaluated	O
during	O
different	O
phases	O
of	O
the	O
menstrual	O
cycle	O
in	O
five	O
functionally	O
infertile	O
women	O
.	O

Shift	O
-	O
down	O
experiments	O
indicated	O
that	O
the	O
10	O
(	O
4	O
)	O
-	O
to	O
10	O
(	O
5	O
)	O
-	O
fold	O
reduction	O
in	O
virus	O
yield	O
at	O
the	O
nonpermissive	O
temperature	O
was	O
due	O
to	O
the	O
disfunction	O
of	O
alpha	B-protein
TIF	I-protein
late	O
in	O
infection	O
,	O
presumably	O
in	O
virion	O
maturation	O
.	O

Specifically	O
,	O
the	O
deduced	O
FR	B-protein
-	I-protein
19	I-protein
amino	I-protein
acid	I-protein
sequence	I-protein
has	O
approximately89	O
,	O
77	O
,	O
and	O
68	O
%	O
overall	O
identity	O
to	O
chicken	B-protein
TEF	I-protein
-	I-protein
1A	I-protein
,	O
mouse	B-protein
TEF	I-protein
-	I-protein
1	I-protein
,	O
and	O
mouse	B-protein
embryonic	I-protein
TEA	I-protein
domain	I-protein
-	I-protein
containing	I-protein
factor	I-protein
,	O
respectively	O
.	O

Two	O
classes	O
of	O
mutations	O
were	O
obtained	O
:	O
(	O
i	O
)	O
those	O
that	O
altered	O
the	O
coding	O
region	O
of	O
HOL1	B-protein
,	O
conferring	O
the	O
ability	O
to	O
take	O
up	O
histidinol	O
;	O
and	O
(	O
ii	O
)	O
cis	O
-	O
acting	O
mutations	O
(	O
selected	O
in	O
a	O
mutant	O
HOL1	B-protein
-	I-protein
1	I-protein
background	O
)	O
that	O
increased	O
expression	O
of	O
the	O
Hol1	B-protein
protein	I-protein
.	O

INTERVENTION	O
(	O
S	O
)	O
:	O
Twenty	O
-	O
six	O
hemostasis	O
parameters	O
evaluated	O
repeatedly	O
in	O
patients	O
undergoing	O
IVF	O
-	O
ET	O
.	O

NF	B-protein
kappa	I-protein
B	I-protein
was	O
activated	O
to	O
a	O
much	O
greater	O
extent	O
by	O
roscovitine	O
in	O
the	O
WT	O
cells	O
than	O
in	O
Y8	O
cells	O
.	O

Although	O
pathological	O
thyroid	O
function	O
is	O
related	O
to	O
changes	O
in	O
energy	O
expenditure	O
and	O
body	O
composition	O
,	O
its	O
possible	O
influence	O
on	O
leptin	B-protein
levels	O
remains	O
to	O
be	O
determined	O
.	O

A	O
coiled	O
-	O
coil	O
domain	O
,	O
conserved	O
within	O
each	O
encoded	O
protein	O
,	O
serves	O
as	O
a	O
potential	O
interaction	O
motif	O
for	O
FLI	B-protein
LRR	I-protein
.	O

We	O
have	O
identified	O
two	O
Marek	O
'	O
s	O
Disease	O
Virus	O
(	O
MDV	O
)	O
genes	O
within	O
the	O
EcoRI	B-protein
-	I-protein
B	I-protein
fragment	I-protein
of	O
MDV	O
-	O
GA	O
genomic	O
DNA	O
.	O

Twenty	O
-	O
eight	O
were	O
excluded	O
as	O
gallstones	O
were	O
not	O
proved	O
:	O
of	O
the	O
remainder	O
,	O
21	O
patients	O
received	O
glucagon	B-protein
and	O
22	O
placebo	O
.	O

Fibrinogen	B-protein
determination	O
using	O
the	O
KZM	O
-	O
1	O
meter	O
.	O

The	O
effect	O
of	O
echothiophate	O
on	O
the	O
biphasic	O
response	O
of	O
rabbit	O
ocular	O
pressure	O
to	O
dipivefrin	O
.	O

At	O
the	O
time	O
of	O
the	O
blind	O
therapeutic	O
doses	O
,	O
Tg	O
-	O
off	O
values	O
ranged	O
from	O
8	O
to	O
608	O
microg	O
/	O
l	O
.	O

We	O
report	O
here	O
the	O
cloning	O
of	O
the	O
murine	B-protein
p44	I-protein
MAP	I-protein
kinase	I-protein
(	O
extracellular	B-protein
signal	I-protein
-	I-protein
regulated	I-protein
kinase	I-protein
1	I-protein
)	O
gene	O
,	O
the	O
determination	O
of	O
its	O
intron	O
/	O
exon	O
boundaries	O
,	O
and	O
the	O
characterization	O
of	O
its	O
promoter	O
.	O

Besides	O
,	O
we	O
found	O
in	O
3	O
patients	O
increased	O
serum	O
immunoglobulins	O
,	O
chiefly	O
IgG	B-protein
,	O
as	O
first	O
Russe	O
,	O
Busey	O
and	O
Barbeau	O
demonstrated	O
in	O
a	O
large	O
French	O
-	O
Canadian	O
family	O
.	O

A	O
rapid	O
staining	O
technique	O
for	O
Leishmania	O
parasites	O
in	O
splenic	O
aspirate	O
smears	O
.	O

Role	O
of	O
superoxide	B-protein
dismutase	I-protein
in	O
cellular	O
oxidative	O
processes	O
and	O
method	O
of	O
its	O
determination	O
in	O
biological	O
materials	O
.	O

This	O
study	O
analyzed	O
whether	O
the	O
localization	O
of	O
an	O
accessory	O
pathway	O
could	O
be	O
predicted	O
by	O
using	O
the	O
polarity	O
of	O
the	O
QRS	O
complex	O
during	O
sinus	O
rhythm	O
on	O
the	O
surface	O
ECG	O
,	O
instead	O
of	O
the	O
delta	O
wave	O
polarity	O
as	O
used	O
in	O
many	O
reports	O
.	O

Here	O
we	O
show	O
that	O
phosphorylation	O
-	O
induced	O
loss	O
of	O
the	O
protein	B-protein
kinase	I-protein
activity	O
of	O
DNA	B-protein
-	I-protein
PK	I-protein
is	O
restored	O
by	O
the	O
addition	O
of	O
the	O
purified	O
catalytic	O
subunit	O
of	O
either	O
protein	B-protein
phosphatase	I-protein
1	I-protein
or	O
protein	B-protein
phosphatase	I-protein
2A	I-protein
(	O
PP2A	B-protein
)	O
and	O
that	O
this	O
reactivation	O
is	O
blocked	O
by	O
the	O
potent	O
protein	B-protein
phosphatase	I-protein
inhibitor	O
,	O
microcystin	O
.	O

Control	O
of	O
transcription	O
of	O
the	O
erbB	B-protein
-	I-protein
2	I-protein
gene	I-protein
is	O
an	O
important	O
determinant	O
of	O
receptor	O
expression	O
.	O

The	O
incidence	O
of	O
second	O
malignant	O
neoplasms	O
was	O
lower	O
(	O
1	O
.	O
3	O
%	O
)	O
in	O
the	O
group	O
treated	O
with	O
5	O
-	O
fluorouracil	O
,	O
doxorubicin	O
,	O
and	O
cyclophosphamide	O
than	O
in	O
the	O
historical	O
control	O
group	O
(	O
4	O
.	O
8	O
%	O
)	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
antimicrobial	O
susceptibility	O
to	O
10	O
currently	O
used	O
antimicrobial	O
agents	O
of	O
50	O
strains	O
of	O
P	O
.	O
acnes	O
isolated	O
from	O
acne	O
lesions	O
and	O
identified	O
using	O
a	O
Rap	O
ID	O
ANA	O
II	O
panel	O
.	O

Polyhomeotic	B-protein
and	I-protein
Posterior	I-protein
Sex	I-protein
Combs	I-protein
may	O
participate	O
in	O
a	O
more	O
general	O
transcriptional	O
mechanism	O
that	O
causes	O
modulated	O
gene	O
repression	O
,	O
whereas	O
the	O
inclusion	O
of	O
Polycomb	B-protein
protein	I-protein
in	O
the	O
complex	O
at	O
PREs	B-protein
leads	O
to	O
stable	O
silencing	O
.	O

Unitary	O
-	O
group	O
approach	O
to	O
spin	O
-	O
dependent	O
operators	O
.	O

The	O
transcription	O
factor	O
E2F	B-protein
plays	O
an	O
important	O
role	O
in	O
G	O
(	O
1	O
)	O
to	O
S	O
phase	O
transition	O
in	O
the	O
higher	O
eukaryotic	O
cell	O
cycle	O
.	O

The	O
RMR	O
was	O
measured	O
twice	O
in	O
each	O
phase	O
and	O
found	O
to	O
be	O
similar	O
(	O
F	O
(	O
1	O
,	O
18	O
)	O
=	O
0	O
.	O
863	O
)	O
across	O
the	O
follicular	O
(	O
5018	O
kJ	O
/	O
24	O
h	O
)	O
and	O
the	O
luteal	O
(	O
5098	O
kJ	O
/	O
24	O
h	O
)	O
phases	O
.	O

Inductively	O
coupled	O
plasma	O
atomic	O
emission	O
spectroscopy	O
was	O
employed	O
to	O
obtain	O
the	O
tissue	O
silicon	O
measurements	O
.	O

Zn	B-protein
(	I-protein
II	I-protein
)	I-protein
coordination	I-protein
domain	I-protein
mutants	O
of	O
T4	O
gene	B-protein
32	I-protein
protein	O
.	O

Deletion	O
of	O
the	O
NF	B-protein
-	I-protein
IL6	I-protein
beta	I-protein
leucine	I-protein
zipper	I-protein
domain	I-protein
also	O
greatly	O
diminished	O
the	O
interaction	O
between	O
these	O
two	O
proteins	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
increase	O
in	O
V	O
O2	O
may	O
have	O
been	O
a	O
consequence	O
of	O
the	O
increase	O
in	O
Q	O
O2	O
rather	O
than	O
a	O
response	O
to	O
the	O
procedure	O
itself	O
.	O

Significant	O
alterations	O
in	O
CBC	O
results	O
and	O
serum	B-protein
CRP	I-protein
concentration	O
,	O
compared	O
with	O
baseline	O
values	O
,	O
were	O
lacking	O
in	O
dogs	O
of	O
the	O
control	O
group	O
.	O

The	O
tetraphasic	O
action	O
of	O
lidocaine	O
on	O
CNS	O
electrical	O
activity	O
and	O
behavior	O
in	O
cats	O
.	O

An	O
analytic	O
method	O
for	O
comparative	O
parameter	O
weighting	O
in	O
magnetic	O
resonance	O
(	O
MR	O
)	O
imaging	O
has	O
been	O
developed	O
using	O
the	O
concept	O
of	O
`	O
`	O
fractional	O
sensitivity	O
.	O
`	O
`	O
This	O
new	O
approach	O
results	O
in	O
easily	O
calculated	O
indexes	O
for	O
T1	O
,	O
T2	O
,	O
and	O
hydrogen	O
weighting	O
.	O

Here	O
we	O
report	O
the	O
purification	O
of	O
this	O
larger	O
form	O
as	O
an	O
approximately	O
320	O
-	O
kDa	O
particle	O
that	O
contains	O
mRNP3	B-protein
+	I-protein
4	I-protein
and	O
nine	O
additional	O
polypeptides	O
,	O
including	O
mRNA	B-protein
-	I-protein
binding	I-protein
polypeptides	I-protein
of	I-protein
34	I-protein
and	I-protein
36	I-protein
kDa	I-protein
and	O
a	O
doublet	O
of	O
110	O
/	O
105	O
kDa	O
that	O
proved	O
to	O
be	O
nucleolin	B-protein
.	O

SIP1	B-protein
(	O
Smad	B-protein
interacting	I-protein
protein	I-protein
1	I-protein
)	O
and	O
deltaEF1	B-protein
(	O
delta	B-protein
-	I-protein
crystallin	I-protein
enhancer	I-protein
binding	I-protein
factor	I-protein
)	O
are	O
structurally	O
similar	O
transcriptional	O
repressors	O
.	O

Overproduction	O
of	O
HrcA	B-protein
protein	I-protein
from	O
a	O
second	O
copy	O
of	O
hrcA	B-protein
derived	O
from	O
a	O
plasmid	O
(	O
phrcA	O
+	O
)	O
in	O
B	O
.	O
subtilis	O
wild	O
-	O
type	O
and	O
delta	O
hrcA	B-protein
strains	O
prevented	O
heat	O
shock	O
induction	O
of	O
the	O
dnaK	B-protein
and	O
groE	B-protein
operons	I-protein
at	O
the	O
level	O
of	O
transcription	O
almost	O
completely	O
and	O
strongly	O
reduced	O
the	O
amounts	O
of	O
mRNA	O
at	O
a	O
low	O
temperature	O
as	O
well	O
.	O

The	O
construct	O
was	O
introduced	O
into	O
BW2001	O
(	O
xth	O
-	O
11	O
,	O
nfo	O
-	O
2	O
)	O
strain	O
cells	O
of	O
Escherichia	O
coli	O
.	O

These	O
data	O
suggest	O
that	O
:	O
(	O
a	O
)	O
proSRIF	B-protein
cleavage	O
is	O
initiated	O
in	O
the	O
TGN	O
,	O
and	O
(	O
b	O
)	O
this	O
reaction	O
requires	O
an	O
acidic	O
pH	O
which	O
is	O
facilitated	O
by	O
a	O
Golgi	B-protein
-	I-protein
associated	I-protein
vacuolar	I-protein
-	I-protein
type	I-protein
ATPase	I-protein
.	O

High	O
-	O
resolution	O
structure	O
of	O
the	O
diphtheria	B-protein
toxin	I-protein
repressor	I-protein
complexed	O
with	O
cobalt	O
and	O
manganese	O
reveals	O
an	O
SH3	B-protein
-	I-protein
like	I-protein
third	O
domain	O
and	O
suggests	O
a	O
possible	O
role	O
of	O
phosphate	O
as	O
co	O
-	O
corepressor	O
.	O

In	O
spite	O
of	O
this	O
and	O
other	O
complications	O
of	O
corticosteroids	O
,	O
she	O
made	O
a	O
full	O
recovery	O
from	O
the	O
fungal	O
infection	O
following	O
treatment	O
with	O
amphotericin	O
B	O
and	O
surgical	O
excision	O
of	O
the	O
lung	O
abscess	O
.	O

The	O
GALT	O
-	O
primed	O
calves	O
had	O
increased	O
serum	O
IgG	B-protein
,	O
lavage	O
IgG	B-protein
and	O
IgA	B-protein
and	O
increased	O
LNA	B-protein
titers	O
in	O
both	O
lavage	O
fluids	O
and	O
serum	O
following	O
the	O
SC	O
dose	O
of	O
killed	O
bacteria	O
.	O

We	O
describe	O
a	O
case	O
of	O
a	O
perinephric	O
abscess	O
treated	O
with	O
amphotericin	O
B	O
and	O
nephrectomy	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
binding	O
of	O
CBF	B-protein
/	I-protein
NF	I-protein
-	I-protein
Y	I-protein
to	O
the	O
inverted	O
CCAAT	O
box	O
is	O
responsible	O
for	O
transcriptional	O
activation	O
of	O
the	O
nTPH	B-protein
gene	I-protein
.	O

There	O
were	O
27	O
men	O
and	O
156	O
women	O
.	O

A	O
new	O
set	O
of	O
cDNA	O
clones	O
spanning	O
approximately	O
3	O
.	O
2	O
kb	O
was	O
isolated	O
from	O
a	O
lambda	O
-	O
ZAP	O
goose	O
liver	O
cDNA	O
library	O
using	O
the	O
5	O
'	O
-	O
most	O
exon	O
-	O
containing	O
fragment	O
of	O
the	O
5	O
'	O
-	O
most	O
genomic	O
DNA	O
clone	O
.	O

The	O
sequence	O
contains	O
an	O
open	O
reading	O
frame	O
of	O
1744	O
nt	O
in	O
the	O
virus	O
-	O
sense	O
strand	O
,	O
a	O
3	O
'	O
untranslated	O
region	O
of	O
1360	O
nt	O
and	O
a	O
3	O
'	O
poly	O
(	O
A	O
)	O
tail	O
.	O

We	O
found	O
that	O
total	O
PSA	B-protein
can	O
be	O
detected	O
in	O
all	O
cyst	O
fluids	O
and	O
in	O
about	O
75	O
%	O
of	O
female	O
sera	O
.	O

Human	O
adenovirus	O
type	O
41	O
contains	O
two	O
fibers	O
.	O

The	O
likelihood	O
that	O
a	O
common	O
region	O
of	O
deletions	O
would	O
contain	O
a	O
tumor	O
suppressor	O
is	O
strongly	O
enhanced	O
by	O
coincidence	O
of	O
that	O
region	O
with	O
a	O
chromosome	O
fragment	O
suppressing	O
tumorigenicity	O
upon	O
introduction	O
in	O
tumor	O
cells	O
.	O

Denaturation	O
of	O
the	O
simian	O
virus	O
40	O
origin	O
of	O
replication	O
mediated	O
by	O
human	B-protein
replication	I-protein
protein	I-protein
A	O
.	O

In	O
both	O
these	O
respects	O
,	O
however	O
,	O
the	O
DBP	B-protein
mRNA	I-protein
resembles	O
the	O
late	O
messengers	O
of	O
SV40	O
and	O
polyoma	O
viruses	O
.	O

Type	O
2	O
genomes	O
containing	O
this	O
sequence	O
presumably	O
more	O
closely	O
reflect	O
the	O
structure	O
of	O
the	O
infectious	O
,	O
replication	O
-	O
competent	O
retrovirus	O
ancestors	O
of	O
the	O
HERV	O
-	O
K	O
family	O
than	O
do	O
type	O
1	O
genomes	O
that	O
lack	O
the	O
sequence	O
.	O

Multidrug	O
resistance	O
in	O
Saccharomyces	O
cerevisiae	O
mainly	O
results	O
from	O
the	O
overexpression	O
of	O
genes	O
coding	O
for	O
the	O
membrane	O
efflux	O
pumps	O
,	O
the	O
major	O
facilitators	O
and	O
the	O
ABC	B-protein
binding	I-protein
cassette	I-protein
transporters	I-protein
,	O
under	O
the	O
control	O
of	O
key	O
transcription	O
regulators	O
encoded	O
by	O
the	O
PDR1	B-protein
and	O
PDR3	B-protein
genes	I-protein
.	O

In	O
the	O
Oct	B-protein
-	I-protein
1	I-protein
crystal	O
,	O
the	O
POU	B-protein
-	I-protein
specific	I-protein
domain	I-protein
recognizes	O
a	O
GCAT	B-protein
half	I-protein
-	I-protein
site	I-protein
,	O
while	O
the	O
corresponding	O
sequence	O
recognized	O
by	O
the	O
Pit	B-protein
-	I-protein
1	I-protein
POU	I-protein
-	I-protein
specific	I-protein
domain	I-protein
,	O
GTAT	B-protein
,	O
is	O
on	O
the	O
opposing	O
strand	O
.	O

Blood	O
samples	O
were	O
obtained	O
daily	O
during	O
this	O
supplementation	O
period	O
and	O
5	O
d	O
thereafter	O
(	O
d	O
11	O
to	O
15	O
)	O
.	O

The	O
in	O
vitro	O
antibacterial	O
potency	O
is	O
greatest	O
when	O
the	O
1	O
-	O
substituent	O
is	O
2	O
,	O
4	O
-	O
difluorophenyl	O
and	O
the	O
7	O
-	O
substituent	O
is	O
a	O
3	O
-	O
amino	O
-	O
1	O
-	O
pyrrolidinyl	O
group	O
.	O

Previous	O
analysis	O
of	O
the	O
98	O
-	O
bp	O
sequence	O
has	O
delineated	O
several	O
protein	O
-	O
binding	O
domains	O
that	O
are	O
recognized	O
by	O
nuclear	O
factors	O
present	O
in	O
human	O
brain	O
cells	O
.	O

There	O
is	O
no	O
correlation	O
between	O
C2	O
-	O
C3	O
disk	O
morphology	O
and	O
the	O
diskographically	O
provoked	O
response	O
.	O

In	O
experiment	O
2	O
the	O
rats	O
had	O
free	O
access	O
to	O
two	O
bottles	O
,	O
one	O
of	O
which	O
contained	O
tap	O
water	O
,	O
and	O
the	O
other	O
contained	O
either	O
an	O
ethanol	O
(	O
6	O
%	O
)	O
or	O
a	O
sucrose	O
(	O
5	O
%	O
)	O
solution	O
.	O

Here	O
we	O
describe	O
a	O
mutant	O
alpha	O
subunit	O
designed	O
to	O
inhibit	O
receptor	O
-	O
mediated	O
hormonal	O
activation	O
of	O
Gs	B-protein
,	O
the	O
stimulatory	O
regulator	O
of	O
adenylyl	B-protein
cyclase	I-protein
.	O

An	O
inactive	O
analog	O
of	O
wortmannin	O
,	O
WM12	O
,	O
did	O
not	O
affect	O
TCR	O
/	O
CD3	O
-	O
induced	O
Erk2	B-protein
activation	O
,	O
and	O
wortmannin	O
had	O
no	O
effect	O
on	O
the	O
activity	O
of	O
Erk2	B-protein
when	O
added	O
directly	O
to	O
the	O
in	O
vitro	O
assays	O
.	O

Concordance	O
of	O
IBDQ	O
scores	O
was	O
tested	O
in	O
280	O
stable	O
subjects	O
.	O

The	O
UCR	B-protein
core	I-protein
sequence	I-protein
,	O
CGCCATTTT	B-protein
,	O
binds	O
a	O
ubiquitous	O
nuclear	O
factor	O
and	O
mediates	O
negative	O
regulation	O
of	O
MuLV	O
promoter	O
activity	O
.	O

The	O
effects	O
of	O
Codonopsis	O
pilosula	O
oral	O
liquor	O
(	O
CPOL	O
)	O
on	O
tissue	B-protein
-	I-protein
type	I-protein
plasminogen	I-protein
activator	I-protein
(	O
t	B-protein
-	I-protein
PA	I-protein
)	O
and	O
plasminogen	B-protein
activator	I-protein
inhibitor	I-protein
(	O
PAI	B-protein
)	O
in	O
the	O
plasma	O
of	O
25	O
patients	O
of	O
coronary	O
heart	O
disease	O
with	O
blood	O
stasis	O
were	O
studied	O
.	O

Here	O
,	O
the	O
PEX5	B-protein
-	I-protein
TPR	I-protein
domains	I-protein
from	O
human	O
,	O
tobacco	O
,	O
and	O
nematode	O
were	O
inserted	O
into	O
a	O
TPR	O
-	O
less	O
yeast	O
Pex5p	B-protein
construct	O
to	O
generate	O
Pex5p	B-protein
chimaeras	O
.	O

Despite	O
total	O
tumor	O
resection	O
,	O
multiple	O
intraperitoneal	O
tumor	O
nodules	O
of	O
varying	O
sizes	O
were	O
found	O
and	O
resected	O
six	O
months	O
and	O
one	O
year	O
later	O
.	O

Primary	O
adrenal	O
hypersensitivity	O
to	O
ACTH	B-protein
drive	O
in	O
obesity	O
has	O
also	O
been	O
suggested	O
.	O

To	O
determine	O
which	O
sequences	O
in	O
the	O
rat	B-protein
P450c17	I-protein
promoter	I-protein
may	O
be	O
responsible	O
for	O
basal	O
and	O
cAMP	O
-	O
stimulated	O
gene	O
transcription	O
,	O
deletion	O
constructs	O
containing	O
between	O
-	O
1	O
,	O
560	O
and	O
-	O
53	O
base	O
pairs	O
of	O
5	O
'	O
-	O
flanking	O
DNA	O
from	O
the	O
rat	B-protein
P450c17	I-protein
gene	I-protein
were	O
ligated	O
to	O
plasmids	O
expressing	O
the	O
reporter	O
gene	O
luciferase	B-protein
and	O
transfected	O
into	O
two	O
mouse	O
cell	O
lines	O
,	O
adrenal	O
Y	O
-	O
1	O
cells	O
,	O
and	O
testicular	O
Leydig	O
MA	O
-	O
10	O
cells	O
.	O

Eliminating	O
any	O
subset	O
of	O
ASCUS	O
reduces	O
the	O
ASCUS	O
/	O
SIL	O
ratio	O
but	O
also	O
significantly	O
diminishes	O
the	O
sensitivity	O
of	O
the	O
Papanicolaou	O
test	O
.	O

However	O
,	O
besides	O
the	O
kinase	O
catalytic	O
domain	O
and	O
double	O
leucine	O
/	O
isoleucine	O
zippers	O
,	O
there	O
was	O
no	O
significant	O
homology	O
with	O
known	O
proteins	O
.	O

We	O
characterized	O
the	O
structure	O
of	O
this	O
leader	O
mRNA	O
by	O
using	O
the	O
program	O
Mfold	O
and	O
a	O
combination	O
of	O
nested	O
and	O
internal	O
deletions	O
transcriptionally	O
fused	O
to	O
a	O
promoterless	O
lac	B-protein
operon	I-protein
.	O

Signal	O
transduction	O
via	O
modulation	O
of	O
phosphorylation	O
after	O
selective	O
inhibition	O
of	O
protein	B-protein
phosphatase	I-protein
(	I-protein
PP	I-protein
)	I-protein
1	I-protein
and	O
/	O
or	O
PP2A	B-protein
appears	O
to	O
play	O
a	O
role	O
in	O
okadaic	O
acid	O
(	O
OA	O
)	O
-	O
mediated	O
effects	O
.	O

The	O
dual	O
specificity	O
kinases	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
(	I-protein
MAPK	I-protein
)	I-protein
kinase	I-protein
(	O
MKK	B-protein
)	O
7	O
and	O
MKK4	B-protein
are	O
the	O
only	O
molecules	O
known	O
to	O
directly	O
activate	O
the	O
stress	B-protein
kinases	I-protein
stress	I-protein
-	I-protein
activated	I-protein
protein	I-protein
kinases	I-protein
(	O
SAPKs	B-protein
)	O
/	B-protein
c	I-protein
-	I-protein
Jun	I-protein
N	I-protein
-	I-protein
terminal	I-protein
kinases	I-protein
(	O
JNKs	B-protein
)	O
in	O
response	O
to	O
environmental	O
or	O
mitogenic	O
stimuli	O
.	O

After	O
2	O
min	O
of	O
dobutamine	O
injection	O
,	O
or	O
after	O
20	O
min	O
of	O
pimobendan	O
injection	O
,	O
the	O
myocardium	O
was	O
removed	O
,	O
and	O
used	O
for	O
determination	O
of	O
the	O
tissue	O
levels	O
of	O
metabolites	O
of	O
energy	O
and	O
carbohydrate	O
metabolism	O
.	O

Quantitative	O
evaluation	O
of	O
the	O
steady	O
state	O
kinetics	O
of	O
MEK	B-protein
inhibition	O
by	O
these	O
compounds	O
reveals	O
that	O
U0126	O
has	O
approximately	O
100	O
-	O
fold	O
higher	O
affinity	O
for	O
deltaN3	B-protein
-	I-protein
S218E	I-protein
/	I-protein
S222D	I-protein
MEK	I-protein
than	O
does	O
PD098059	O
.	O

Although	O
there	O
was	O
a	O
high	O
correlation	O
between	O
sap	O
flux	O
densities	O
registered	O
by	O
the	O
old	O
and	O
new	O
sensors	O
,	O
significant	O
differences	O
in	O
sap	O
flux	O
densities	O
between	O
the	O
duplicated	O
sensors	O
were	O
detected	O
.	O

Modern	O
cancer	O
therapy	O
has	O
included	O
surgery	O
,	O
radiotherapy	O
,	O
chemotherapy	O
,	O
and	O
most	O
recently	O
,	O
immunotherapy	O
and	O
hyperthermia	O
.	O

One	O
skull	O
does	O
not	O
a	O
species	O
make	O
.	O

Clones	O
33F	O
and	O
34B	O
encoded	O
identical	O
aromatase	B-protein
proteins	I-protein
of	O
503	O
amino	O
acids	O
,	O
but	O
differed	O
in	O
size	O
due	O
to	O
alternative	O
polyadenylation	O
signal	O
usage	O
for	O
the	O
corresponding	O
mRNAs	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
risk	O
factors	O
for	O
background	O
diabetic	O
retinopathy	O
(	O
BDR	O
)	O
and	O
PDR	O
by	O
following	O
394	O
Japanese	O
patients	O
with	O
early	O
-	O
onset	O
type	O
2	O
diabetes	O
diagnosed	O
before	O
30	O
years	O
of	O
age	O
(	O
mean	O
age	O
27	O
,	O
mean	O
blood	O
pressure	O
at	O
entry	O
116	O
/	O
73	O
mm	O
Hg	O
)	O
.	O

The	O
possible	O
benefits	O
of	O
LMW	O
heparin	O
(	O
reduced	O
frequency	O
of	O
bleeding	O
,	O
alleviation	O
of	O
hypertriglyceridemia	O
)	O
were	O
not	O
,	O
however	O
,	O
apparent	O
,	O
possibly	O
because	O
of	O
the	O
short	O
observation	O
period	O
and	O
the	O
low	O
incidence	O
of	O
hemorrhagic	O
complications	O
in	O
routine	O
dialyses	O
.	O

Percentages	O
of	O
recovery	O
for	O
overload	O
and	O
dilution	O
tests	O
were	O
between	O
87	O
and	O
120	O
%	O
.	O

Different	O
cortical	O
malformations	O
were	O
produced	O
in	O
rats	O
by	O
a	O
single	O
dose	O
of	O
X	O
-	O
rays	O
(	O
200	O
cGy	O
)	O
given	O
on	O
different	O
days	O
during	O
gestation	O
.	O

The	O
yeast	O
gene	O
that	O
encodes	O
eIF	B-protein
-	I-protein
5	I-protein
,	O
designated	O
TIF5	B-protein
,	O
has	O
been	O
isolated	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
to	O
yield	O
a	O
catalytically	O
active	O
eIF	B-protein
-	I-protein
5	I-protein
protein	I-protein
.	O

After	O
nerve	O
injury	O
,	O
the	O
nociceptive	O
responses	O
through	O
type	O
I	O
neurons	O
,	O
which	O
are	O
polymodal	O
C	O
-	O
fibers	O
and	O
drive	O
NK1	B-protein
-	I-protein
receptor	I-protein
mechanisms	O
in	O
spinal	O
pain	O
transmission	O
,	O
were	O
completely	O
lost	O
,	O
but	O
without	O
changes	O
in	O
type	O
II	O
ones	O
,	O
which	O
are	O
polymodal	O
C	O
-	O
fibers	O
and	O
drive	O
NMDA	O
receptor	O
-	O
mechanisms	O
,	O
while	O
type	O
III	O
ones	O
,	O
which	O
are	O
capsaicin	O
-	O
insensitive	O
(	O
possibly	O
A	O
-	O
fibers	O
)	O
and	O
drive	O
NMDA	B-protein
-	I-protein
receptor	I-protein
mechanisms	O
,	O
were	O
markedly	O
enhanced	O
.	O

Respondents	O
who	O
lived	O
with	O
a	O
spouse	O
/	O
partner	O
only	O
were	O
less	O
likely	O
to	O
have	O
an	O
unfavorable	O
BMI	O
status	O
than	O
people	O
in	O
the	O
other	O
two	O
groups	O
.	O

Catalytic	O
activation	O
of	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinase	I-protein
phosphatase	I-protein
-	I-protein
1	I-protein
by	O
binding	O
to	O
p38	B-protein
MAP	I-protein
kinase	I-protein
:	O
critical	O
role	O
of	O
the	O
p38	B-protein
C	I-protein
-	I-protein
terminal	I-protein
domain	I-protein
in	O
its	O
negative	O
regulation	O
.	O

Whereas	O
a	O
PR55	B-protein
beta	I-protein
transcript	I-protein
of	O
about	O
2	O
.	O
3	O
kb	O
was	O
detected	O
at	O
high	O
levels	O
in	O
the	O
neuroblastoma	O
derived	O
cell	O
line	O
LA	O
-	O
N	O
-	O
1	O
,	O
the	O
level	O
of	O
the	O
mRNA	O
was	O
very	O
low	O
in	O
the	O
other	O
human	O
cell	O
lines	O
analyzed	O
.	O

These	O
observations	O
indicate	O
that	O
there	O
are	O
multiple	O
mechanisms	O
by	O
which	O
an	O
individual	O
transcript	O
can	O
be	O
degraded	O
following	O
deadenylation	O
.	O

Total	O
PGE	O
levels	O
in	O
synovial	O
fluid	O
remained	O
significantly	O
depressed	O
in	O
the	O
patient	O
group	O
for	O
24	O
hours	O
after	O
the	O
400	O
-	O
mg	O
test	O
dose	O
of	O
tolmetin	O
on	O
day	O
8	O
.	O

Mutually	O
exclusive	O
interaction	O
of	O
the	O
adenovirus	B-protein
E4	I-protein
-	I-protein
6	I-protein
/	I-protein
7	I-protein
protein	I-protein
and	O
the	O
retinoblastoma	B-protein
gene	I-protein
product	I-protein
with	O
internal	O
domains	O
of	O
E2F	B-protein
-	I-protein
1	I-protein
and	O
DP	B-protein
-	I-protein
1	I-protein
.	O

These	O
results	O
indicate	O
that	O
mutL	B-protein
,	O
miaA	B-protein
,	O
and	O
hfq	B-protein
expression	O
could	O
be	O
regulated	O
by	O
multiple	O
mechanisms	O
,	O
including	O
degree	O
of	O
cotranscription	O
from	O
upstream	O
genes	O
,	O
modulation	O
of	O
internal	O
promoter	O
strength	O
,	O
and	O
by	O
RNase	B-protein
E	I-protein
activity	O
.	O

Transfection	O
and	O
in	O
vitro	O
binding	O
studies	O
identified	O
within	O
HEFT1	B-protein
a	I-protein
promoter	I-protein
whose	O
basal	O
activity	O
required	O
a	O
GC	O
box	O
activated	O
by	O
Sp1	B-protein
or	O
Sp3	B-protein
.	O

The	O
RAS	B-protein
-	I-protein
cyclic	I-protein
AMP	I-protein
-	I-protein
dependent	I-protein
protein	I-protein
kinase	I-protein
cAPK	I-protein
pathway	O
prevents	O
the	O
UAS	B-protein
activity	O
of	O
IREu	B-protein
in	O
the	O
presence	O
of	O
glucose	O
as	O
the	O
sole	O
carbon	O
source	O
,	O
while	O
the	O
transcriptional	O
activators	O
Msn2p	B-protein
and	O
Msn4p	B-protein
promote	O
the	O
UAS	B-protein
activity	O
of	O
this	O
repeat	O
in	O
the	O
presence	O
of	O
acetate	O
.	O

CONCLUSIONS	O
:	O
In	O
essential	O
hypertension	O
an	O
acute	O
protein	O
load	O
induces	O
a	O
decrease	O
in	O
GFR	O
that	O
may	O
normalize	O
under	O
antihypertensive	O
treatment	O
.	O

Beta	O
blocking	O
agents	O
.	O

There	O
was	O
no	O
further	O
increase	O
in	O
oxygen	O
consumption	O
when	O
these	O
subjects	O
breathed	O
with	O
inspiratory	O
pressures	O
above	O
SIP	O
.	O

This	O
dimer	O
interface	O
is	O
likely	O
important	O
for	O
increasing	O
the	O
DNA	O
-	O
binding	O
specificity	O
and	O
affinity	O
of	O
the	O
trimeric	O
form	O
of	O
HSF	B-protein
,	O
as	O
well	O
as	O
for	O
increasing	O
cooperativity	O
between	O
adjacent	O
trimers	O
.	O

Three	O
missense	O
mutants	O
in	O
subunit	O
a	O
of	O
the	O
Escherichia	B-protein
coli	I-protein
F1F0	I-protein
-	I-protein
ATPase	I-protein
were	O
isolated	O
and	O
characterized	O
after	O
hydroxylamine	O
mutagenesis	O
of	O
a	O
plasmid	O
carrying	O
the	O
uncB	B-protein
(	I-protein
subunit	I-protein
a	I-protein
)	I-protein
gene	I-protein
.	O

The	O
predicted	O
DNA	O
-	O
binding	O
,	O
zinc	O
finger	O
domain	O
protein	O
sequence	O
was	O
strictly	O
conserved	O
.	O

In	O
transient	O
cotransfection	O
assays	O
using	O
Chang	O
liver	O
cells	O
(	O
CCL	O
13	O
)	O
,	O
pM1	O
DNA	O
exerts	O
a	O
6	O
-	O
to	O
10	O
-	O
fold	O
trans	O
-	O
activating	O
effect	O
on	O
the	O
expression	O
of	O
the	O
pSV2CAT	O
reporter	O
plasmid	O
.	O

During	O
treatment	O
,	O
the	O
phosphorylation	O
state	O
of	O
Rb	B-protein
shifted	O
to	O
a	O
hypophosphorylated	O
form	O
.	O
mRNA	O
for	O
the	O
HPV	B-protein
E6	I-protein
/	I-protein
E7	I-protein
genes	I-protein
decreased	O
;	O
however	O
,	O
significant	O
changes	O
in	O
the	O
E7	B-protein
protein	I-protein
were	O
not	O
observed	O
,	O
while	O
increased	O
levels	O
of	O
Rb	B-protein
immunoprecipitated	O
with	O
anti	B-protein
-	I-protein
E7	I-protein
antibodies	I-protein
were	O
observed	O
.	O

51	O
.	O
9	O
%	O
(	O
P	O
=	O
0	O
.	O
0006	O
)	O
in	O
the	O
MMF	O
versus	O
the	O
AZA	O
groups	O
,	O
respectively	O
.	O

Velocity	O
sedimentation	O
,	O
cross	O
-	O
linking	O
,	O
and	O
immunoprecipitation	O
analyses	O
of	O
detergent	O
-	O
solubilized	O
rat	O
brain	O
revealed	O
that	O
the	O
32	O
and	O
34	O
kDa	O
polypeptides	O
reside	O
within	O
heterotetramers	O
.	O

Characterization	O
of	O
the	O
3	O
'	O
ends	O
of	O
the	O
plus	O
-	O
strand	O
DNA	O
fragments	O
reveals	O
(	O
1	O
)	O
that	O
the	O
upstream	O
fragment	O
is	O
elongated	O
beyond	O
PPT2	B-protein
creating	O
a	O
plus	O
-	O
strand	O
overlap	O
and	O
(	O
2	O
)	O
that	O
the	O
majority	O
of	O
plus	O
-	O
strand	O
strong	O
-	O
stop	O
DNA	O
fragments	O
bear	O
a	O
copy	O
of	O
the	O
minus	O
-	O
strand	O
primer	O
binding	O
site	O
in	O
agreement	O
with	O
the	O
accepted	O
model	O
of	O
retroviral	O
genomic	O
RNA	O
reverse	O
transcription	O
.	O

Further	O
,	O
they	O
are	O
consistent	O
with	O
the	O
suggestion	O
that	O
sites	O
homologous	O
to	O
the	O
CAR1	B-protein
URS	I-protein
may	O
be	O
situated	O
in	O
the	O
5	O
'	O
-	O
flanking	O
regions	O
of	O
multiple	O
unrelated	O
yeast	O
genes	O
.	O

A23187	O
did	O
not	O
induce	O
any	O
modifications	O
of	O
the	O
endolymphatic	O
potential	O
,	O
the	O
ampullar	O
direct	O
current	O
or	O
the	O
frequency	O
of	O
the	O
evoked	O
afferent	O
spikes	O
.	O

GnRH	B-protein
treatment	O
was	O
found	O
to	O
increase	O
the	O
phosphorylation	O
of	O
tyrosine	O
residues	O
of	O
MAPK	B-protein
and	O
to	O
increase	O
MAPK	B-protein
activity	O
,	O
as	O
determined	O
by	O
an	O
immune	O
complex	O
kinase	B-protein
assay	O
.	O

Hemodynamics	O
changes	O
in	O
man	O
during	O
flight	O
.	O

Nasal	O
absorption	O
was	O
rapid	O
,	O
nasal	O
bioavailability	O
was	O
43	O
%	O
,	O
and	O
the	O
iv	O
and	O
nasal	O
elimination	O
profiles	O
were	O
similar	O
.	O

In	O
experiment	O
2	O
,	O
no	O
difference	O
in	O
gastric	O
emptying	O
of	O
40	O
%	O
peptone	O
or	O
25	O
%	O
glucose	O
was	O
found	O
between	O
rats	O
receiving	O
TPN	O
and	O
those	O
receiving	O
intragastric	O
nutrition	O
for	O
10	O
to	O
12	O
days	O
.	O

Analysis	O
of	O
chromosomal	O
DNA	O
sequence	O
immediately	O
downstream	O
of	O
the	O
transposon	O
insertion	O
identified	O
two	O
open	O
reading	O
frames	O
,	O
designated	O
csrR	B-protein
and	O
csrS	B-protein
,	O
which	O
exhibited	O
sequence	O
similarity	O
to	O
bacterial	O
two	O
-	O
component	O
regulatory	O
systems	O
.	O

Rev	B-protein
-	I-protein
erbAalpha	I-protein
/	I-protein
beta	I-protein
)	I-protein
,	O
Mxi	B-protein
-	I-protein
1	I-protein
and	O
Mad	B-protein
bHLH	I-protein
-	I-protein
zip	I-protein
proteins	I-protein
and	O
the	O
oncoproteins	O
PLZF	B-protein
and	O
LAZ3	B-protein
/	I-protein
BCL6	I-protein
is	O
mediated	O
by	O
the	O
corepressors	O
N	B-protein
-	I-protein
CoR	I-protein
and	O
SMRT	B-protein
.	O

Reporting	O
of	O
adverse	O
events	O
occurring	O
during	O
clinical	O
trials	O
of	O
investigational	O
drugs	O
is	O
a	O
complex	O
and	O
controversial	O
issue	O
.	O

The	O
effects	O
of	O
two	O
levels	O
of	O
caffeine	O
ingestion	O
on	O
excess	O
postexercise	O
oxygen	O
consumption	O
in	O
untrained	O
women	O
.	O

Unfortunately	O
,	O
these	O
preservatives	O
may	O
also	O
interfere	O
with	O
microbiological	O
assays	O
used	O
to	O
determine	O
product	O
sterility	O
or	O
bioburden	O
levels	O
.	O

Where	O
UMDNJ	O
is	O
headed	O
.	O

Serum	B-protein
relaxin	I-protein
levels	O
in	O
prostaglandin	O
E2	O
induced	O
abortions	O
.	O

Human	B-protein
GATA	I-protein
-	I-protein
3	I-protein
:	O
a	O
lineage	O
-	O
restricted	O
transcription	O
factor	O
that	O
regulates	O
the	O
expression	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
alpha	I-protein
gene	I-protein
.	O

Telomeres	O
prevent	O
end	O
-	O
to	O
-	O
end	O
fusions	O
and	O
exonucleolytic	O
degradation	O
,	O
enable	O
the	O
end	O
of	O
the	O
linear	O
DNA	O
molecule	O
to	O
replicate	O
,	O
and	O
function	O
in	O
cell	O
division	O
.	O

Specifically	O
,	O
by	O
the	O
type	O
of	O
adjuvant	O
therapy	O
,	O
the	O
median	O
disease	O
-	O
free	O
interval	O
and	O
survival	O
from	O
stage	O
IVA	O
for	O
23	O
patients	O
receiving	O
Corynebacterium	O
parvum	O
were	O
6	O
.	O
9	O
and	O
19	O
months	O
;	O
for	O
39	O
patients	O
receiving	O
BCG	O
,	O
eight	O
months	O
and	O
26	O
months	O
;	O
for	O
24	O
patients	O
receiving	O
BCG	O
+	O
DTIC	O
,	O
eight	O
and	O
17	O
.	O
4	O
months	O
;	O
and	O
for	O
all	O
51	O
DTIC	O
treated	O
patients	O
6	O
.	O
3	O
and	O
17	O
.	O
8	O
months	O
,	O
respectively	O
.	O

Merr	O
.	O
)	O
embryo	O
library	O
.	O

Altogether	O
,	O
we	O
confirm	O
that	O
all	O
genes	O
of	O
the	O
Rad52	B-protein
recombinational	I-protein
repair	I-protein
pathway	I-protein
are	O
required	O
for	O
the	O
survival	O
of	O
rad27	B-protein
Delta	I-protein
strains	O
at	O
both	O
permissive	O
(	O
23	O
degrees	O
C	O
)	O
and	O
semipermissive	O
(	O
30	O
degrees	O
C	O
)	O
temperatures	O
for	O
growth	O
.	O

Improving	O
the	O
evidence	O
base	O
for	O
anaesthesia	O
.	O

Seven	O
of	O
these	O
had	O
counterparts	O
in	O
the	O
US	O
of	O
herpes	O
simplex	O
type	O
1	O
(	O
HSV	O
-	O
1	O
)	O
,	O
pseudorabies	O
virus	O
(	O
PRV	O
)	O
,	O
and	O
equine	O
herpesvirus	O
type	O
1	O
(	O
EHV	O
-	O
1	O
)	O
.	O

Since	O
high	O
levels	O
of	O
immunoglobulin	B-protein
G	I-protein
were	O
demonstrated	O
against	O
the	O
surface	O
of	O
the	O
NVS	O
after	O
immunization	O
,	O
passive	O
transfer	O
experiments	O
were	O
initiated	O
.	O

Our	O
results	O
show	O
that	O
CVN	B-protein
specifically	O
recognizes	O
with	O
nanomolar	O
affinity	O
Man	B-protein
(	I-protein
9	I-protein
)	I-protein
GlcNAc	I-protein
(	I-protein
2	I-protein
)	I-protein
and	O
the	O
D1D3	B-protein
isomer	I-protein
of	O
Man	B-protein
(	I-protein
8	I-protein
)	I-protein
GlcNAc	I-protein
(	I-protein
2	I-protein
)	I-protein
.	O

Out	O
of	O
these	O
families	O
74	O
,	O
3	O
%	O
planned	O
next	O
pregnancy	O
(	O
table	O
IX	O
)	O
,	O
57	O
,	O
6	O
%	O
wanted	O
to	O
have	O
prenatal	O
diagnosis	O
(	O
table	O
VI	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
special	O
clinical	O
presentation	O
of	O
our	O
case	O
of	O
possible	O
Gardner	O
'	O
s	O
syndrome	O
is	O
discussed	O
.	O

Interestingly	O
,	O
addition	O
of	O
purified	O
CBP	B-protein
to	O
the	O
nuclear	O
extracts	O
of	O
T47D	O
cells	O
markedly	O
stimulated	O
progesterone	O
-	O
and	O
PR	O
-	O
dependent	O
transcription	O
from	O
a	O
nucleosome	O
-	O
free	O
,	O
progesterone	B-protein
response	I-protein
element	I-protein
(	O
PRE	B-protein
)	O
-	O
linked	O
reporter	O
DNA	O
template	O
.	O

Therefore	O
,	O
it	O
was	O
concluded	O
that	O
thrombotic	O
tendency	O
certainly	O
existed	O
in	O
patients	O
with	O
MS	O
compared	O
to	O
those	O
with	O
non	O
RHD	O
and	O
that	O
it	O
was	O
one	O
of	O
the	O
causes	O
of	O
the	O
significantly	O
high	O
incidence	O
of	O
thromboembolism	O
in	O
comparison	O
with	O
non	O
RHD	O
.	O

Routine	O
psychometric	O
screening	O
of	O
IHD	O
patients	O
may	O
provide	O
a	O
cost	O
-	O
effective	O
means	O
of	O
alerting	O
cardiologists	O
and	O
internists	O
to	O
the	O
relatively	O
high	O
levels	O
of	O
distress	O
among	O
their	O
patients	O
.	O

In	O
addition	O
,	O
computer	O
analysis	O
suggests	O
that	O
sequences	O
similar	O
to	O
the	O
A	O
stem	O
element	O
are	O
present	O
within	O
the	O
three	O
AAV	B-protein
promoter	I-protein
regions	O
.	O

Another	O
cis	O
-	O
acting	O
element	O
,	O
exonic	B-protein
splicing	I-protein
suppressor	I-protein
1	I-protein
(	O
ESS1	B-protein
)	O
,	O
represses	O
use	O
of	O
the	O
nt	O
3225	O
3	O
'	O
splice	O
site	O
.	O

After	O
hemodynamic	O
stabilization	O
,	O
the	O
goal	O
of	O
therapy	O
is	O
to	O
diminish	O
the	O
chance	O
that	O
an	O
ulcer	O
will	O
continue	O
to	O
bleed	O
or	O
will	O
rebleed	O
.	O

Our	O
results	O
suggest	O
that	O
while	O
many	O
muscle	O
gene	O
E	O
-	O
boxes	O
are	O
capable	O
of	O
binding	O
the	O
previously	O
characterized	O
spectrum	O
of	O
MDF	B-protein
/	I-protein
bH	I-protein
-	I-protein
L	I-protein
-	I-protein
H	I-protein
heterodimers	I-protein
in	O
vitro	O
,	O
MCK	B-protein
-	I-protein
L	I-protein
type	O
E	O
-	O
boxes	O
probably	O
bind	O
qualitatively	O
different	O
factors	O
in	O
vivo	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
matrilysin	B-protein
-	I-protein
2	I-protein
also	O
contains	O
a	O
threonine	O
residue	O
adjacent	O
to	O
the	O
Zn	O
-	O
binding	O
site	O
that	O
has	O
been	O
defined	O
as	O
a	O
specific	O
feature	O
of	O
matrilysin	B-protein
.	O

Value	O
of	O
determination	O
of	O
alkaline	B-protein
phosphatase	I-protein
isoenzymes	I-protein
for	O
differential	O
diagnosis	O
of	O
obstructive	O
jaundice	O
and	O
biliary	O
liver	O
cirrhosis	O
.	O

Aedes	O
aegypti	O
(	O
L	O
.	O
)	O
and	O
Aedes	O
albopictus	O
(	O
Skuse	O
)	O
in	O
Singapore	O
City	O
.	O

CONCLUSIONS	O
:	O
Lymphoscintigraphy	O
of	O
the	O
cynomolgus	O
monkey	O
eyelids	O
reveals	O
discrete	O
lymphatic	O
drainage	O
pathways	O
for	O
the	O
upper	O
and	O
lower	O
eyelids	O
and	O
a	O
dual	O
pathway	O
for	O
the	O
central	O
upper	O
eyelid	O
.	O

Regional	O
blood	O
blow	O
was	O
measured	O
by	O
means	O
of	O
microspheres	O
in	O
predefined	O
regions	O
of	O
the	O
C6	O
,	O
T11	O
,	O
and	O
L6	O
vertebrae	O
.	O

CMV	O
hyperimmunoglobulin	B-protein
treatment	O
(	O
Cytotect	O
,	O
Biotest	O
)	O
was	O
started	O
(	O
2	O
ml	O
/	O
kg	O
bw	O
on	O
day	O
1	O
and	O
3	O
,	O
and	O
1	O
ml	O
/	O
kg	O
on	O
days	O
5	O
,	O
7	O
and	O
9	O
)	O
,	O
which	O
led	O
to	O
the	O
eradication	O
of	O
the	O
residual	O
infiltrate	O
and	O
CMV	O
-	O
DNA	O
in	O
the	O
myocardium	O
.	O

The	O
ewes	O
were	O
returned	O
to	O
normoxia	O
,	O
and	O
monitoring	O
was	O
continued	O
for	O
1	O
h	O
.	O

Interestingly	O
,	O
in	O
the	O
adult	O
,	O
transgene	O
expression	O
patterns	O
within	O
the	O
cerebellum	O
in	O
two	O
lines	O
appeared	O
to	O
mark	O
distinct	O
anterior	O
-	O
posterior	O
compartments	O
.	O

Heterogeneous	B-protein
nuclear	I-protein
ribonucleoprotein	I-protein
A1	I-protein
binds	O
to	O
the	O
transcription	O
-	O
regulatory	O
region	O
of	O
mouse	O
hepatitis	O
virus	O
RNA	O
.	O

In	O
17	O
patients	O
with	O
deletions	O
,	O
the	O
parental	O
origin	O
of	O
deletion	O
was	O
determined	O
.	O

Clinical	O
accuracy	O
of	O
updated	O
version	O
of	O
the	O
Phadebas	O
RAST	O
test	O
.	O

The	O
detection	O
ratio	O
peaked	O
at	O
ages	O
30	O
to	O
34	O
and	O
decreased	O
heavily	O
during	O
the	O
next	O
15	O
years	O
of	O
age	O
.	O

Phase	O
II	O
trial	O
of	O
the	O
anti	B-protein
-	I-protein
G	I-protein
(	I-protein
D2	I-protein
)	I-protein
monoclonal	I-protein
antibody	I-protein
3F8	I-protein
and	O
granulocyte	B-protein
-	I-protein
macrophage	I-protein
colony	I-protein
-	I-protein
stimulating	I-protein
factor	I-protein
for	O
neuroblastoma	O
.	O

Another	O
ORF	O
,	O
dda	B-protein
.	I-protein
2	I-protein
located	O
between	O
modA	B-protein
and	O
dda	B-protein
,	O
shares	O
sequence	O
similarity	O
with	O
sigma70	B-protein
,	O
and	O
we	O
call	O
it	O
srd	B-protein
.	O

The	O
authors	O
present	O
the	O
only	O
two	O
studies	O
that	O
have	O
proved	O
successful	O
in	O
treating	O
animal	O
models	O
of	O
osteoarthritis	O
using	O
gene	O
therapy	O
,	O
and	O
propose	O
an	O
overview	O
of	O
several	O
strategies	O
for	O
the	O
development	O
of	O
gene	O
therapy	O
in	O
osteoarthritis	O
treatment	O
in	O
the	O
future	O
.	O

A	O
gene	O
in	O
Drosophila	O
melanogaster	O
that	O
maps	O
cytologically	O
to	O
2C1	O
-	O
3	O
on	O
the	O
distal	O
portion	O
of	O
the	O
X	O
-	O
chromosome	O
encodes	O
a	O
member	O
of	O
the	O
steroid	B-protein
/	I-protein
thyroid	I-protein
hormone	I-protein
receptor	I-protein
superfamily	I-protein
.	O

We	O
investigated	O
the	O
diagnostic	O
value	O
of	O
a	O
new	O
in	O
vitro	O
test	O
,	O
Pharmacia	O
CAP	O
System	O
(	O
Pharmacia	O
Diagnostics	O
AB	O
,	O
Uppsala	O
,	O
Sweden	O
)	O
,	O
for	O
the	O
quantitative	O
measurement	O
of	O
allergen	B-protein
-	I-protein
specific	I-protein
IgE	I-protein
antibodies	I-protein
by	O
comparison	O
with	O
RAST	O
in	O
2	O
groups	O
of	O
patients	O
,	O
71	O
atopic	O
and	O
48	O
non	O
-	O
atopic	O
.	O

One	O
complex	O
containing	O
a	O
70	O
D	O
protein	O
was	O
found	O
to	O
be	O
associated	O
specifically	O
with	O
transcriptionally	O
active	O
leukemia	O
cells	O
.	O

This	O
finding	O
suggested	O
that	O
the	O
PI3K	B-protein
-	I-protein
Akt	I-protein
activation	I-protein
pathway	I-protein
plays	O
some	O
role	O
in	O
the	O
antiapoptotic	O
effect	O
of	O
EPO	B-protein
.	O

Strikingly	O
,	O
this	O
subdomain	O
is	O
also	O
present	O
in	O
the	O
otherwise	O
unrelated	O
N	O
-	O
terminal	O
activating	O
region	O
of	O
p58c	B-protein
-	I-protein
ets	I-protein
-	I-protein
2	I-protein
and	O
was	O
thus	O
named	O
BEC	B-protein
for	O
Ets	B-protein
-	I-protein
1	I-protein
-	I-protein
beta	I-protein
/	I-protein
Ets	I-protein
-	I-protein
2	I-protein
-	I-protein
Conserved	I-protein
sequence	I-protein
.	O

Consistent	O
with	O
the	O
hepatic	O
and	O
epidermal	O
expression	O
of	O
histidase	B-protein
,	O
this	O
finding	O
suggests	O
that	O
histidase	B-protein
transcription	O
may	O
be	O
regulated	O
by	O
these	O
factors	O
.	O

The	O
respiratory	O
rate	O
was	O
13	O
+	O
/	O
-	O
1	O
breaths	O
/	O
min	O
with	O
52	O
+	O
/	O
-	O
4	O
%	O
of	O
the	O
respiratory	O
cycle	O
spent	O
in	O
inspiration	O
;	O
end	O
-	O
tidal	O
CO2	O
pressure	O
increased	O
by	O
3	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
0	O
Torr	O
during	O
runs	O
at	O
SIP	O
.	O

Previous	O
studies	O
have	O
indicated	O
that	O
a	O
hamster	O
cell	O
line	O
(	O
ts13	O
)	O
with	O
a	O
point	O
mutation	O
in	O
the	O
TAF	B-protein
(	I-protein
II	I-protein
)	I-protein
250	I-protein
/	I-protein
CCG1	I-protein
(	O
TAF	B-protein
(	I-protein
II	I-protein
)	I-protein
250	I-protein
)	O
gene	O
shows	O
temperature	O
-	O
sensitive	O
expression	O
of	O
a	O
subset	O
of	O
genes	O
and	O
arrests	O
in	O
late	O
G1	O
at	O
39	O
.	O
5	O
degrees	O
C	O
.	O

A	O
hydrodynamic	O
description	O
of	O
the	O
osmotic	O
reflection	O
coefficient	O
with	O
application	O
to	O
the	O
pore	O
theory	O
of	O
transcapillary	O
exchange	O
.	O

Sequential	O
MR	O
examinations	O
of	O
the	O
nasal	O
cavity	O
and	O
paranasal	O
sinuses	O
were	O
performed	O
within	O
a	O
6	O
-	O
8	O
h	O
period	O
in	O
five	O
normal	O
volunteers	O
.	O

Comparison	O
of	O
patients	O
receiving	O
phenytoin	O
and	O
those	O
who	O
were	O
not	O
showed	O
significantly	O
lower	O
serum	O
folate	O
in	O
the	O
sub	O
-	O
group	O
receiving	O
phenytoin	O
,	O
but	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
sub	O
-	O
groups	O
with	O
respect	O
to	O
vitamin	O
B12	O
or	O
behaviour	O
problem	O
rating	O
.	O

Jerseys	O
had	O
higher	O
hepatic	O
Cu	O
concentrations	O
than	O
did	O
Holsteins	O
on	O
d	O
60	O
(	O
346	O
vs	O
.	O

We	O
also	O
found	O
that	O
the	O
same	O
males	O
,	O
breeding	O
in	O
different	O
years	O
on	O
the	O
same	O
territories	O
,	O
had	O
significantly	O
larger	O
harems	O
in	O
the	O
years	O
they	O
had	O
familiar	O
neighbors	O
.	O

Galoyan	O
has	O
summarized	O
the	O
results	O
of	O
his	O
discovery	O
of	O
cardioactive	O
neurohormones	O
.	O

The	O
authors	O
proposed	O
that	O
the	O
highly	O
convergent	O
inputs	O
to	O
the	O
entorhinal	O
cortex	O
indicate	O
this	O
region	O
may	O
be	O
particularly	O
important	O
for	O
selecting	O
or	O
compressing	O
information	O
.	O

Serum	B-protein
TNF	I-protein
concentrations	O
were	O
elevated	O
at	O
diagnosis	O
and	O
gradually	O
decreased	O
toward	O
the	O
reference	O
limits	O
by	O
week	O
16	O
.	O

The	O
importance	O
of	O
selective	O
renal	O
vein	O
phlebography	O
in	O
the	O
evaluation	O
of	O
unexplained	O
hematuria	O
and	O
filing	O
defects	O
in	O
the	O
excretory	O
urogram	O
is	O
illustrated	O
.	O

Gluzman	O
,	O
EMBO	O
J	O
.	O

Comparison	O
was	O
made	O
with	O
other	O
neuroradiological	O
imaging	O
modalities	O
including	O
CT	O
,	O
myelography	O
,	O
CT	O
ventriculography	O
,	O
and	O
CT	O
myelocisternography	O
.	O

The	O
best	O
regression	O
model	O
for	O
predicting	O
changes	O
in	O
the	O
WCXR	O
included	O
time	O
to	O
first	O
positive	O
culture	O
and	O
antibody	O
titer	O
for	O
Pa	B-protein
elastase	I-protein
.	O

A	O
possible	O
role	O
for	O
the	O
mixed	O
function	O
oxidase	B-protein
enzyme	I-protein
system	I-protein
in	O
the	O
requirement	O
for	O
selenium	O
in	O
the	O
rat	O
.	O

Monospecific	O
antibodies	O
raised	O
against	O
rat	B-protein
cytochrome	I-protein
P	I-protein
-	I-protein
450	I-protein
1A1	I-protein
recognized	O
a	O
protein	O
in	O
the	O
hepatic	O
microsomes	O
of	O
the	O
double	O
-	O
crested	O
cormorant	O
,	O
and	O
also	O
in	O
those	O
of	O
the	O
great	O
blue	O
heron	O
(	O
Ardea	O
herodias	O
)	O
,	O
using	O
immunoblotting	O
.	O

Blood	O
sampling	O
procedures	O
were	O
videotaped	O
.	O

Calcimimetic	O
agents	O
directly	O
inhibit	O
PTH	B-protein
secretion	O
by	O
activating	O
the	O
calcium	O
-	O
sensing	O
receptor	O
in	O
the	O
parathyroid	O
glands	O
,	O
but	O
clinical	O
experience	O
with	O
them	O
is	O
limited	O
.	O

Taken	O
together	O
,	O
differences	O
in	O
signaling	O
and	O
tissue	O
expression	O
suggest	O
that	O
the	O
human	B-protein
intermediate	I-protein
PRLr	I-protein
differs	O
from	O
the	O
long	B-protein
PRLr	I-protein
in	O
physiological	O
function	O
.	O

Conservative	O
treatment	O
of	O
bladder	O
carcinoma	O
by	O
partial	O
cystectomy	O
and	O
interstitial	O
iridium	O
192	O
.	O

This	O
fragment	O
can	O
bind	O
several	O
trans	O
-	O
acting	O
factors	O
in	O
vitro	O
,	O
including	O
GATA	B-protein
-	I-protein
1	I-protein
and	O
members	O
of	O
the	O
Ets	B-protein
family	I-protein
.	O

This	O
study	O
determined	O
the	O
arthritogenic	O
potential	O
of	O
silicone	O
gel	O
by	O
either	O
mixing	O
it	O
with	O
bovine	B-protein
collagen	I-protein
II	I-protein
(	O
BII	B-protein
)	O
or	O
by	O
injecting	O
silicone	O
gel	O
alone	O
in	O
DA	O
rats	O
.	O

Group	O
I	O
comprised	O
5	O
adult	O
Collies	O
that	O
received	O
at	O
least	O
400	O
microg	O
/	O
kg	O
ivermectin	O
p	O
.	O
o	O
.	O
and	O
were	O
presented	O
to	O
the	O
VMTH	O
3	O
hours	O
after	O
intoxication	O
.	O

At	O
cuticular	O
positions	O
exhibiting	O
the	O
Brd	B-protein
bristle	I-protein
loss	I-protein
phenotype	I-protein
,	O
we	O
have	O
found	O
that	O
the	O
progeny	O
of	O
the	O
multiplied	O
SOPs	O
develop	O
aberrantly	O
,	O
in	O
that	O
neurons	O
and	O
thecogen	O
(	O
sheath	O
)	O
cells	O
appear	O
but	O
not	O
trichogen	O
(	O
shaft	O
)	O
and	O
tormogen	O
(	O
socket	O
)	O
cells	O
.	O

Optimal	O
activation	O
of	O
T	O
cells	O
requires	O
at	O
least	O
two	O
signals	O
.	O

Use	O
of	O
free	O
-	O
access	O
minerals	O
.	O

Purified	B-protein
Pra	I-protein
was	O
also	O
shown	O
to	O
physically	O
interact	O
with	O
pyruvate	B-protein
kinase	I-protein
(	O
Pk	B-protein
)	O
;	O
Pk	B-protein
and	O
Pra	B-protein
can	O
form	O
a	O
complex	O
,	O
but	O
when	O
the	O
12	B-protein
-	I-protein
kDa	I-protein
Ndk	I-protein
,	O
Pk	B-protein
,	O
and	O
Pra	B-protein
are	O
all	O
present	O
,	O
Pk	B-protein
has	O
a	O
higher	O
affinity	O
than	O
Pra	B-protein
for	O
forming	O
a	O
complex	O
with	O
the	O
12	B-protein
-	I-protein
kDa	I-protein
Ndk	I-protein
.	O

The	O
data	O
suggest	O
that	O
plasminogen	B-protein
,	O
alpha	B-protein
2AP	I-protein
,	O
and	O
C1	B-protein
-	I-protein
INH	I-protein
,	O
should	O
be	O
considered	O
equine	B-protein
acute	I-protein
-	I-protein
phase	I-protein
proteins	I-protein
.	O

We	O
here	O
demonstrate	O
that	O
a	O
temperature	O
-	O
sensitive	O
fission	O
yeast	O
mutant	O
which	O
has	O
a	O
mutation	O
in	O
a	O
homologous	O
gene	O
,	O
and	O
two	O
of	O
three	O
additional	O
(	O
mtr1	B-protein
/	I-protein
prp20	I-protein
/	I-protein
srm1	I-protein
)	O
mutants	O
accumulate	O
nuclear	O
poly	O
(	O
A	O
)	O
+	O
RNA	O
at	O
37	O
degrees	O
C	O
.	O

Grossly	O
,	O
the	O
experimental	O
vulvitis	O
was	O
identical	O
to	O
the	O
field	O
condition	O
,	O
and	O
bacteria	O
indistinguishable	O
from	O
the	O
inoculated	O
strains	O
were	O
reisolated	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
PHO85	B-protein
encodes	O
a	O
cyclin	B-protein
-	I-protein
dependent	I-protein
protein	I-protein
kinase	I-protein
(	O
Cdk	B-protein
)	O
catalytic	O
subunit	O
with	O
multiple	O
regulatory	O
roles	O
thought	O
to	O
be	O
specified	O
by	O
association	O
with	O
different	O
cyclin	B-protein
partners	O
(	O
Pcls	B-protein
)	O
.	O

Tonometry	O
of	O
blood	O
samples	O
from	O
patients	O
may	O
also	O
be	O
used	O
in	O
the	O
determination	O
of	O
acid	O
-	O
base	O
quantities	O
and	O
hemoglobin	O
-	O
oxygen	O
affinity	O
e	O
.	O
g	O
.	O
p50	O
.	O

The	O
natural	O
history	O
of	O
these	O
lesions	O
,	O
locoregional	O
efficiency	O
of	O
the	O
different	O
treatments	O
used	O
,	O
the	O
part	O
played	O
by	O
chemotherapy	O
,	O
survival	O
,	O
causes	O
of	O
death	O
and	O
therapeutic	O
modalities	O
used	O
as	O
a	O
last	O
measure	O
,	O
have	O
been	O
analysed	O
.	O

The	O
homologies	O
between	O
RAD16	B-protein
,	O
RAD54	B-protein
and	O
SNF2	B-protein
are	O
also	O
shared	O
by	O
several	O
additional	O
,	O
recently	O
isolated	O
yeast	O
and	O
Drosophila	O
genes	O
.	O

Background	O
/	O
Aims	O
:	O
Hepatitis	O
C	O
and	O
nonalcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFL	O
)	O
are	O
the	O
two	O
most	O
common	O
forms	O
of	O
liver	O
disease	O
in	O
the	O
United	O
States	O
.	O

The	O
progression	O
of	O
acute	O
bronchitis	O
is	O
associated	O
with	O
elevated	O
blood	O
concentrations	O
of	O
acute	B-protein
-	I-protein
phase	I-protein
proteins	I-protein
,	O
KKS	B-protein
activation	O
in	O
the	O
blood	O
and	O
high	O
serotonin	O
and	O
lactic	O
acid	O
content	O
in	O
the	O
humor	O
condensated	O
from	O
the	O
exhaled	O
air	O
.	O

Topical	O
1	O
percent	O
isoproterenol	O
in	O
the	O
presence	O
of	O
the	O
phosphodiesterase	B-protein
inhibitor	O
theophylline	O
was	O
tested	O
for	O
its	O
ability	O
to	O
stimulate	O
the	O
rate	O
of	O
aqueous	O
humor	O
flow	O
through	O
the	O
anterior	O
chamber	O
of	O
the	O
normal	O
and	O
the	O
partially	O
adrenergically	O
denervated	O
human	O
eye	O
(	O
Horner	O
'	O
s	O
syndrome	O
)	O
.	O

Copyright	O
2000	O
Academic	O
Press	O
.	O

The	O
sequencing	O
of	O
Stellate	B-protein
copies	O
located	O
along	O
the	O
discontinuous	O
cluster	O
revealed	O
a	O
complex	O
pattern	O
of	O
diversification	O
.	O

These	O
results	O
suggest	O
that	O
the	O
phenotype	O
of	O
XLP	O
may	O
result	O
from	O
perturbed	O
signaling	O
not	O
only	O
through	O
SLAM	B-protein
,	O
but	O
also	O
other	O
cell	O
surface	O
molecules	O
that	O
utilize	O
SAP	B-protein
as	O
a	O
signaling	O
adaptor	O
protein	O
.	O

Only	O
one	O
ADR	O
was	O
related	O
definitely	O
to	O
ciprofloxacin	O
therapy	O
.	O

Here	O
,	O
a	O
case	O
of	O
Sjogren	O
'	O
s	O
syndrome	O
is	O
presented	O
that	O
was	O
initially	O
diagnosed	O
because	O
of	O
dental	O
complaints	O
,	O
and	O
long	O
-	O
term	O
treatment	O
of	O
Sjogren	O
'	O
s	O
patients	O
is	O
discussed	O
.	O

Second	O
,	O
the	O
wild	B-protein
-	I-protein
type	I-protein
m8	I-protein
3	I-protein
'	I-protein
UTR	I-protein
strongly	O
reduces	O
accumulation	O
of	O
heterologous	O
transcripts	O
in	O
vivo	O
,	O
an	O
activity	O
that	O
requires	O
its	O
K	O
box	O
sequences	O
.	O

Thus	O
it	O
appears	O
that	O
insertion	O
of	O
a	O
transposable	O
element	O
near	O
the	O
5	O
'	O
terminus	O
of	O
the	O
structural	O
gene	O
can	O
produce	O
constitutive	O
expression	O
of	O
a	O
normally	O
glucose	O
-	O
repressed	O
enzyme	O
.	O

The	O
IE13	O
.	O
1	O
cell	O
line	O
was	O
able	O
to	O
complement	O
a	O
recombinant	O
virus	O
in	O
which	O
both	O
copies	O
of	O
the	O
IE	B-protein
gene	I-protein
were	O
replaced	O
by	O
insertion	O
of	O
the	O
Escherichia	B-protein
coli	I-protein
lacZ	I-protein
gene	I-protein
.	O

After	O
taking	O
smears	O
from	O
lesions	O
of	O
the	O
oral	O
mucosa	O
(	O
tongue	O
,	O
cheeks	O
,	O
palate	O
)	O
and	O
the	O
contiguous	O
denture	O
surface	O
by	O
cotton	O
wool	O
swabs	O
and	O
inoculating	O
them	O
onto	O
Sabouraud	O
glucose	O
agar	O
and	O
CHROMagar	O
Candida	O
,	O
individual	O
yeast	O
species	O
were	O
identified	O
by	O
a	O
germ	O
tube	O
,	O
filamentous	O
,	O
and	O
assimilation	O
tests	O
employing	O
the	O
commercial	O
kit	O
AuxaColor	O
.	O

A	O
genomic	O
clone	O
was	O
isolated	O
that	O
contained	O
12	O
.	O
5	O
kb	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
and	O
the	O
first	O
exon	O
of	O
the	O
p69	B-protein
/	I-protein
71	I-protein
2	I-protein
-	I-protein
5A	I-protein
synthetase	I-protein
gene	I-protein
.	O

Here	O
we	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
Xenopus	B-protein
Pax	I-protein
-	I-protein
5	I-protein
and	O
Pax	B-protein
-	I-protein
8	I-protein
,	O
two	O
orthologues	O
of	O
the	O
Pax	B-protein
-	I-protein
2	I-protein
/	I-protein
5	I-protein
/	I-protein
8	I-protein
gene	I-protein
family	I-protein
.	O

However	O
,	O
cotransfection	O
studies	O
indicate	O
that	O
RVR	B-protein
does	O
not	O
activate	O
transcription	O
when	O
this	O
hormone	B-protein
response	I-protein
element	I-protein
is	O
linked	O
to	O
a	O
reporter	O
gene	O
but	O
rather	O
acts	O
as	O
a	O
potent	O
competitive	O
repressor	O
of	O
ROR	B-protein
alpha	I-protein
function	O
.	O

The	O
level	O
of	O
carboxyl	B-protein
-	I-protein
terminal	I-protein
parathyroid	I-protein
hormone	I-protein
in	O
the	O
patients	O
with	O
thyroid	O
carcinoma	O
was	O
higher	O
than	O
that	O
in	O
the	O
patients	O
without	O
thyroid	O
carcinoma	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
correct	O
termination	O
of	O
retroviral	O
transcripts	O
at	O
the	O
3	O
'	O
LTR	B-protein
R	I-protein
/	I-protein
U5	I-protein
junction	I-protein
is	O
primarily	O
dependent	O
on	O
the	O
canonical	O
AAUAAA	B-protein
polyadenylation	O
signal	O
,	O
so	O
we	O
have	O
analyzed	O
the	O
effect	O
of	O
mutating	O
the	O
polyadenylation	O
signal	O
sequences	O
on	O
the	O
properties	O
of	O
a	O
selectable	O
murine	O
retroviral	O
vector	O
.	O

When	O
the	O
coronary	O
sinus	O
pressure	O
reached	O
15	O
torr	O
,	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
cardiac	O
index	O
(	O
3	O
.	O
60	O
+	O
/	O
-	O
0	O
.	O
5	O
to	O
2	O
.	O
70	O
+	O
/	O
-	O
0	O
.	O
6	O
L	O
/	O
min	O
/	O
m2	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
coronary	O
blood	O
flow	O
(	O
13	O
.	O
7	O
+	O
/	O
-	O
3	O
.	O
1	O
to	O
7	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
ml	O
/	O
min	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
rate	O
of	O
rise	O
of	O
left	O
ventricular	O
pressure	O
(	O
1	O
,	O
567	O
+	O
/	O
-	O
275	O
to	O
1	O
,	O
331	O
+	O
/	O
-	O
314	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
and	O
an	O
increase	O
in	O
coronary	O
arteriovenous	O
difference	O
(	O
62	O
.	O
8	O
%	O
+	O
/	O
-	O
9	O
.	O
3	O
%	O
to	O
70	O
.	O
5	O
%	O
+	O
/	O
-	O
5	O
.	O
4	O
%	O
saturation	O
,	O
p	O
less	O
than	O
0	O
.	O
03	O
)	O
.	O

These	O
results	O
suggest	O
that	O
ULK2	B-protein
is	O
involved	O
in	O
a	O
previously	O
uncharacterized	O
signaling	O
pathway	O
in	O
mammalian	O
cells	O
.	O

We	O
compared	O
previously	O
the	O
methylation	O
status	O
between	O
normal	O
liver	O
and	O
liver	O
tumors	O
in	O
SV40	B-protein
T	I-protein
/	I-protein
t	I-protein
antigen	I-protein
transgenic	O
mice	O
(	O
MT	O
-	O
D2	O
mice	O
)	O
using	O
Restriction	O
Landmark	O
Genomic	O
Scanning	O
for	O
Methylation	O
(	O
RLGS	O
-	O
M	O
)	O
and	O
identified	O
several	O
loci	O
/	O
spots	O
that	O
appeared	O
to	O
be	O
methylated	O
frequently	O
in	O
liver	O
tumors	O
.	O

Additionally	O
,	O
observations	O
that	O
patients	O
with	O
mitral	O
versus	O
aortic	O
regurgitation	O
respond	O
differently	O
to	O
valve	O
replacement	O
suggest	O
that	O
differences	O
exist	O
preoperatively	O
between	O
these	O
two	O
types	O
of	O
volume	O
overload	O
.	O

GH	B-protein
deficiency	O
may	O
be	O
absolute	O
,	O
but	O
often	O
is	O
not	O
and	O
the	O
diagnosis	O
may	O
be	O
complicated	O
by	O
a	O
constellation	O
of	O
physical	O
and	O
hormonal	O
findings	O
that	O
are	O
along	O
a	O
spectrum	O
from	O
low	O
normal	O
GH	B-protein
sufficiency	O
to	O
absent	O
GH	B-protein
secretion	O
.	O

The	O
bovine	B-protein
PGHS	I-protein
-	I-protein
2	I-protein
cDNA	I-protein
was	O
cloned	O
by	O
a	O
combination	O
of	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
cDNA	O
library	O
screening	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
moderate	O
cooling	O
increases	O
the	O
responsiveness	O
of	O
vascular	B-protein
alpha2	I-protein
-	I-protein
adrenoceptors	I-protein
.	O

Stable	O
association	O
of	O
U2	B-protein
snRNP	I-protein
with	O
the	O
branchpoint	O
sequence	O
of	O
mammalian	O
pre	O
-	O
mRNAs	O
requires	O
binding	O
of	O
a	O
non	B-protein
-	I-protein
snRNP	I-protein
protein	I-protein
to	O
the	O
polypyrimidine	O
tract	O
.	O

Patterns	O
defined	O
by	O
combinations	O
of	O
normal	O
and	O
abnormal	O
laboratory	O
results	O
had	O
decreased	O
the	O
likelihood	O
of	O
PEM	O
from	O
an	O
all	O
-	O
2	O
to	O
all	O
-	O
0	O
pattern	O
.	O

Nucleotide	O
sequencing	O
indicates	O
that	O
this	O
E1	B-protein
alpha	I-protein
cDNA	I-protein
clone	O
is	O
1821	O
base	O
pairs	O
(	O
bp	O
)	O
in	O
length	O
with	O
an	O
open	O
reading	O
frame	O
of	O
1365	O
bp	O
and	O
a	O
3	O
'	O
-	O
untranslated	O
region	O
of	O
356	O
bp	O
.	O

Retinoblastoma	O
:	O
a	O
study	O
of	O
natural	O
history	O
and	O
prognosis	O
of	O
268	O
cases	O
.	O

The	O
results	O
suggest	O
that	O
the	O
role	O
of	O
S	O
.	O
argyrostoma	O
in	O
the	O
dissemination	O
of	O
Trichinella	O
larvae	O
in	O
nature	O
is	O
limited	O
in	O
comparison	O
to	O
the	O
role	O
played	O
by	O
mammals	O
with	O
scavenger	O
and	O
cannibalistic	O
behavior	O
.	O

Karger	O
AG	O
,	O
Basel	O

Proceedings	O
:	O
Reversible	O
complete	O
heart	O
block	O
following	O
surgery	O
of	O
congenital	O
heart	O
defects	O
.	O

GABA	B-protein
(	I-protein
B	I-protein
)	I-protein
R1g	I-protein
was	O
expressed	O
in	O
both	O
brain	O
and	O
peripheral	O
tissues	O
.	O

To	O
assess	O
the	O
health	O
significance	O
of	O
the	O
early	O
renal	O
changes	O
after	O
chronic	O
exposure	O
to	O
cadmium	O
,	O
23	O
workers	O
removed	O
from	O
exposure	O
because	O
of	O
the	O
discovery	O
of	O
an	O
increased	O
urinary	O
excretion	O
of	O
beta	B-protein
2	I-protein
-	I-protein
microglobulin	I-protein
or	O
retinol	B-protein
binding	I-protein
protein	I-protein
,	O
or	O
both	O
,	O
have	O
been	O
examined	O
once	O
a	O
year	O
for	O
five	O
years	O
.	O

We	O
have	O
examined	O
reporter	O
gene	O
(	O
beta	B-protein
-	I-protein
gal	I-protein
)	O
expression	O
directed	O
by	O
human	B-protein
heat	I-protein
shock	I-protein
transcription	I-protein
factors	I-protein
1	I-protein
and	I-protein
2	I-protein
(	O
HSF1	B-protein
and	O
HSF2	B-protein
)	O
in	O
HeLa	O
cells	O
and	O
in	O
yeast	O
(	O
Saccharomyces	O
cerevisiae	O
)	O
.	O

Therefore	O
,	O
use	O
of	O
presaturation	O
is	O
recommended	O
for	O
myocardial	O
motion	O
studies	O
using	O
cine	O
PC	O
velocity	O
data	O
.	O

The	O
histological	O
grading	O
was	O
certified	O
in	O
68	O
cases	O
:	O
12	O
G1	O
,	O
39	O
G2	O
,	O
17	O
G3	O
;	O
extracapsular	O
spread	O
was	O
found	O
in	O
20	O
/	O
54	O
cases	O
(	O
37	O
%	O
)	O
.	O

Expression	O
of	O
Msp	B-protein
was	O
toxic	O
to	O
E	O
.	O
coli	O
when	O
the	O
entire	O
msp	B-protein
gene	I-protein
was	O
present	O
.	O

High	B-protein
-	I-protein
mobility	I-protein
-	I-protein
group	I-protein
protein	I-protein
I	I-protein
can	O
modulate	O
binding	O
of	O
transcription	O
factors	O
to	O
the	O
U5	B-protein
region	I-protein
of	O
the	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
proviral	I-protein
promoter	I-protein
.	O

There	O
was	O
a	O
significant	O
correlation	O
between	O
tubular	O
diameter	O
and	O
spg	O
(	O
r	O
=	O
0	O
.	O
68	O
,	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
suggesting	O
that	O
tubular	O
diameter	O
measurements	O
in	O
histological	O
sections	O
could	O
be	O
used	O
to	O
predict	O
sperm	O
production	O
.	O

The	O
rho	B-protein
genes	I-protein
comprise	O
an	O
evolutionarily	O
conserved	O
family	O
with	O
significant	O
homology	O
to	O
the	O
ras	B-protein
oncogene	I-protein
family	I-protein
.	O

The	O
syndrome	O
of	O
resistance	O
to	O
thyroid	O
hormone	O
is	O
characterized	O
by	O
elevated	O
serum	O
free	O
thyroid	O
hormones	O
,	O
failure	O
to	O
suppress	O
pituitary	B-protein
thyrotropin	I-protein
secretion	O
,	O
and	O
variable	O
peripheral	O
refractoriness	O
to	O
hormone	O
action	O
.	O

Survival	O
rates	O
for	O
the	O
original	O
treatment	O
group	O
were	O
84	O
.	O
5	O
%	O
and	O
57	O
.	O
6	O
%	O
at	O
12	O
and	O
21	O
months	O
,	O
respectively	O
;	O
for	O
the	O
delayed	O
treatment	O
group	O
,	O
78	O
.	O
8	O
%	O
and	O
64	O
.	O
6	O
%	O
at	O
12	O
and	O
21	O
months	O
,	O
respectively	O
,	O
and	O
78	O
.	O
8	O
%	O
and	O
47	O
.	O
5	O
%	O
at	O
12	O
and	O
21	O
months	O
,	O
respectively	O
,	O
for	O
77	O
subjects	O
with	O
AIDS	O
and	O
93	O
.	O
0	O
%	O
and	O
71	O
.	O
8	O
%	O
,	O
respectively	O
,	O
for	O
50	O
subjects	O
with	O
AIDS	O
-	O
related	O
complex	O
in	O
the	O
original	O
treatment	O
group	O
.	O

The	O
signalling	O
molecules	O
Wnt1	B-protein
and	O
Sonic	B-protein
hedgehog	I-protein
,	O
implicated	O
in	O
the	O
activation	O
of	O
Myf5	B-protein
in	O
myogenic	O
progenitor	O
cells	O
in	O
the	O
somite	O
,	O
are	O
also	O
produced	O
in	O
the	O
viscinity	O
of	O
the	O
Myf5	B-protein
expression	I-protein
domain	I-protein
in	O
the	O
mesencephalon	O
.	O

Sequence	O
analysis	O
of	O
this	O
100	O
-	O
bp	O
Col2a1	B-protein
enhancer	I-protein
revealed	O
several	O
sequence	O
motifs	O
similar	O
to	O
motifs	O
present	O
within	O
the	O
regulatory	O
region	O
of	O
the	O
link	B-protein
protein	I-protein
gene	I-protein
,	O
another	O
cartilage	O
gene	O
.	O

Mental	O
development	O
is	O
generally	O
normal	O
.	O

Reactivities	O
to	O
horse	B-protein
anti	I-protein
-	I-protein
lymphocyte	I-protein
globulin	I-protein
.	O

Further	O
studies	O
in	O
T	O
-	O
24	O
cells	O
demonstrated	O
that	O
HA	O
fragments	O
also	O
induced	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
phosphorylation	O
and	O
degradation	O
,	O
kappa	B-protein
B	I-protein
-	I-protein
linked	I-protein
reporter	I-protein
gene	I-protein
expression	O
,	O
and	O
ICAM	B-protein
-	I-protein
1	I-protein
promoter	I-protein
activity	O
in	O
an	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
manner	O
.	O

Acetoin	O
can	O
be	O
reused	O
by	O
the	O
bacteria	O
during	O
stationary	O
phase	O
when	O
other	O
carbon	O
sources	O
have	O
been	O
depleted	O
.	O

Transformations	O
in	O
the	O
morphine	O
series	O
.	O

Morphology	O
of	O
bacteriophages	O
of	O
Klebsiella	O
bacilli	O
.	O

During	O
the	O
biosynthesis	O
of	O
all	O
three	O
mutant	O
polypeptides	O
,	O
the	O
signal	O
peptide	O
is	O
efficiently	O
and	O
accurately	O
cleaved	O
from	O
the	O
nascent	O
protein	O
,	O
even	O
though	O
in	O
mutants	O
X2	O
and	O
X3	O
the	O
cleavage	O
site	O
itself	O
has	O
been	O
altered	O
.	O

Influence	O
of	O
cyclo	B-protein
-	I-protein
oxygenase	I-protein
inhibition	O
and	O
of	O
leukotriene	B-protein
receptor	I-protein
blockade	O
on	O
pulmonary	O
vascular	O
pressure	O
/	O
cardiac	O
index	O
relationships	O
in	O
hyperoxic	O
and	O
in	O
hypoxic	O
dogs	O
.	O

Polysorbate	O
80	O
did	O
not	O
have	O
a	O
direct	O
stimulant	O
or	O
relaxant	O
effect	O
on	O
either	O
guinea	O
pig	O
ileum	O
or	O
rat	O
uterus	O
,	O
however	O
,	O
it	O
antagonised	O
the	O
contractions	O
induced	O
by	O
acetylcholine	O
,	O
histamine	O
,	O
barium	O
,	O
5	O
-	O
hydroxytryptamine	O
and	O
carbachol	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
molecular	O
mechanism	O
by	O
which	O
Gle2p	B-protein
and	O
the	O
Gle2p	B-protein
-	I-protein
Nup116p	I-protein
interaction	O
function	O
in	O
mRNA	O
export	O
is	O
unknown	O
.	O

The	O
C4BP	B-protein
alpha	I-protein
gene	I-protein
is	O
organized	O
as	O
follows	O
:	O
the	O
first	O
exon	O
codes	O
for	O
the	O
first	O
198	O
nucleotides	O
of	O
the	O
5	O
'	O
UTR	O
.	O

EXERCISE	O
IN	O
THE	O
TERRESTRIAL	O
CHRISTMAS	O
ISLAND	O
RED	O
CRAB	O
GECARCOIDEA	O
NATALIS	O
-	O
ENERGETICS	O
OF	O
LOCOMOTION	O
.	O

Acta	O
572	O
,	O
113	O
-	O
120	O
]	O
.	O

The	O
RNA	B-protein
polymerase	I-protein
III	I-protein
-	I-protein
recruiting	I-protein
factor	I-protein
TFIIIB	I-protein
induces	O
a	O
DNA	O
bend	O
between	O
the	O
TATA	O
box	O
and	O
the	O
transcriptional	O
start	O
site	O
.	O

To	O
search	O
for	O
genes	O
that	O
interact	O
with	O
the	O
SLK1	B-protein
-	I-protein
SLT2	I-protein
pathway	O
,	O
a	O
synthetic	O
lethal	O
suppression	O
screen	O
was	O
carried	O
out	O
.	O

Scotchbond	O
2	O
showed	O
the	O
least	O
dye	O
penetration	O
but	O
not	O
statistically	O
less	O
than	O
the	O
XR	O
bond	O
/	O
Silus	O
Plus	O
combination	O
.	O

Pitx2	B-protein
rescues	O
the	O
GABAergic	O
differentiation	O
defect	O
and	O
partially	O
rescues	O
the	O
axon	O
guidance	O
and	O
behavioral	O
phenotypes	O
of	O
unc	B-protein
-	I-protein
30	I-protein
mutants	I-protein
,	O
indicating	O
a	O
high	O
degree	O
of	O
functional	O
conservation	O
between	O
these	O
evolutionarily	O
related	O
genes	O
.	O

These	O
data	O
strongly	O
implicate	O
the	O
normal	O
product	O
of	O
the	O
int	B-protein
-	I-protein
2	I-protein
gene	I-protein
,	O
which	O
is	O
related	O
to	O
the	O
fibroblast	B-protein
growth	I-protein
factor	I-protein
family	I-protein
,	O
as	O
a	O
contributory	O
factor	O
in	O
virally	O
induced	O
mammary	O
tumors	O
.	O

Similarity	O
of	O
DNA	O
binding	O
and	O
transcriptional	O
regulation	O
by	O
Caenorhabditis	B-protein
elegans	I-protein
MAB	I-protein
-	I-protein
3	I-protein
and	O
Drosophila	B-protein
melanogaster	I-protein
DSX	I-protein
suggests	O
conservation	O
of	O
sex	O
determining	O
mechanisms	O
.	O

Serum	O
gastrin	B-protein
and	O
AFP	B-protein
levels	O
had	O
the	O
same	O
evolution	O
and	O
appear	O
to	O
have	O
the	O
same	O
interest	O
to	O
follow	O
the	O
course	O
of	O
the	O
disease	O
.	O

The	O
same	O
trend	O
was	O
noted	O
between	O
YG	O
4	O
.	O
5	O
heifers	O
and	O
YG	O
5	O
.	O
5	O
steers	O
,	O
indicating	O
a	O
sex	O
-	O
related	O
deposition	O
of	O
seam	O
fat	O
in	O
fed	O
cattle	O
.	O

Nucleoprotein	O
(	O
N	O
)	O
expressed	O
by	O
both	O
recombinant	O
vaccinia	O
virus	O
and	O
TGEV	O
had	O
a	O
relative	O
molecular	O
mass	O
(	O
Mr	O
)	O
of	O
47	O
,	O
000	O
and	O
was	O
susceptible	O
to	O
degradation	O
at	O
the	O
C	O
-	O
terminus	O
yielding	O
discrete	O
breakdown	O
products	O
.	O

A	O
herpesvirus	B-protein
proteinase	I-protein
activity	O
has	O
been	O
identified	O
and	O
partially	O
characterized	O
by	O
using	O
the	O
cloned	O
enzyme	O
and	O
substrate	O
genes	O
in	O
transient	O
transfection	O
assays	O
.	O

Molecular	O
cloning	O
and	O
expression	O
of	O
human	B-protein
UDP	I-protein
-	I-protein
d	I-protein
-	I-protein
Xylose	I-protein
:	I-protein
proteoglycan	I-protein
core	I-protein
protein	I-protein
beta	I-protein
-	I-protein
d	I-protein
-	I-protein
xylosyltransferase	I-protein
and	O
its	O
first	O
isoform	B-protein
XT	I-protein
-	I-protein
II	I-protein
.	O

These	O
results	O
suggest	O
that	O
less	O
antidopaminergic	O
activity	O
of	O
RHAL	O
in	O
this	O
neuroleptic	O
test	O
might	O
be	O
explained	O
by	O
the	O
lesser	O
conversion	O
of	O
RHAL	O
to	O
HAL	O
.	O

All	O
patients	O
had	O
the	O
CA	B-protein
125	I-protein
assay	O
performed	O
within	O
one	O
week	O
before	O
their	O
second	O
-	O
look	O
operation	O
.	O

Early	O
disagnosis	O
of	O
cancer	O
-	O
-	O
50	O
per	O
cent	O
of	O
all	O
patients	O
could	O
be	O
cured	O
.	O

Thiopentone	O
sodium	O
administered	O
at	O
30	O
and	O
10	O
min	O
before	O
or	O
5	O
,	O
10	O
and	O
15	O
min	O
after	O
exposure	O
to	O
NOC	O
-	O
5	O
,	O
but	O
not	O
thereafter	O
,	O
significantly	O
attenuated	O
NO	O
-	O
induced	O
neurotoxicity	O
compared	O
with	O
controls	O
.	O

Microscopic	O
anatomy	O
and	O
cell	O
population	O
dynamics	O
.	O

Angina	O
(	O
Q	O
)	O
persistence	O
showed	O
marked	O
associations	O
with	O
previous	O
myocardial	O
infarction	O
,	O
diagnosed	O
angina	O
,	O
electrocardiogram	O
ischemia	O
,	O
and	O
subsequent	O
major	O
ischemic	O
heart	O
disease	O
events	O
from	O
Q5	O
onward	O
.	O

We	O
propose	O
that	O
Mad	B-protein
and	O
Medea	B-protein
encode	O
rate	O
-	O
limiting	O
components	O
integral	O
to	O
dpp	B-protein
pathways	I-protein
throughout	O
development	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
transcription	O
from	O
the	O
MMTV	B-protein
5	I-protein
'	I-protein
LTR	I-protein
is	O
highly	O
active	O
in	O
the	O
absence	O
of	O
Stat5a	B-protein
,	O
a	O
transcription	O
factor	O
that	O
had	O
been	O
shown	O
previously	O
to	O
be	O
required	O
for	O
transcription	O
from	O
the	O
MMTV	B-protein
LTR	I-protein
.	O

Viral	O
infections	O
have	O
long	O
been	O
suspected	O
to	O
be	O
causative	O
agents	O
in	O
a	O
number	O
of	O
inner	O
ear	O
dysfunctions	O
.	O

Microdetermination	O
of	O
adrenocortical	O
steroids	O
by	O
double	O
isotope	O
method	O
.	O

STUDY	O
DESIGN	O
:	O
Salivary	B-protein
immunoglobulin	I-protein
A	I-protein
levels	O
of	O
each	O
of	O
20	O
subjects	O
were	O
determined	O
on	O
3	O
occasions	O
:	O
first	O
,	O
while	O
the	O
subject	O
was	O
still	O
smoking	O
;	O
second	O
,	O
7	O
days	O
after	O
cessation	O
of	O
smoking	O
;	O
third	O
,	O
on	O
the	O
14th	O
day	O
after	O
cessation	O
.	O

Practical	O
interest	O
of	O
such	O
studies	O
is	O
limited	O
since	O
the	O
pharmacokinetic	O
parameters	O
are	O
systematically	O
evaluated	O
in	O
man	O
during	O
phase	O
I	O
trials	O
.	O

40	O
,	O
000	O
)	O
.	O

These	O
results	O
also	O
suggest	O
the	O
involvement	O
of	O
additional	O
elements	O
in	O
the	O
UPR	O
.	O

RESULTS	O
:	O
Abnormal	O
color	O
perception	O
was	O
found	O
in	O
32	O
%	O
of	O
the	O
epilepsy	O
patients	O
treated	O
with	O
vigabatrin	O
monotherapy	O
and	O
28	O
%	O
of	O
the	O
epilepsy	O
patients	O
treated	O
with	O
carbamazepine	O
monotherapy	O
.	O

Cramps	O
in	O
extrapyramidal	O
disorders	O
.	O

Each	O
of	O
these	O
spliced	O
mRNAs	O
has	O
an	O
untranslated	O
leader	O
sequence	O
of	O
249	O
bases	O
and	O
a	O
single	O
intron	O
of	O
approximately	O
540	O
bases	O
which	O
are	O
contained	O
entirely	O
within	O
TRs	O
/	O
IRs	O
sequences	O
.	O

We	O
previously	O
described	O
the	O
purification	O
of	O
an	O
83	B-protein
-	I-protein
kDa	I-protein
phosphatidic	I-protein
acid	I-protein
phosphatase	I-protein
(	O
PAP	B-protein
)	O
from	O
the	O
porcine	O
thymus	O
membranes	O
(	O
Kanoh	O
,	O
H	O
.	O
,	O
Imai	O
,	O
S	O
.	O
-	O
i	O
.	O
,	O
Yamada	O
,	O
K	O
.	O
and	O
Sakane	O
,	O
F	O
.	O
(	O
1992	O
)	O
J	O
.	O

Tilmicosin	O
is	O
a	O
novel	O
macrolide	O
antibiotic	O
developed	O
for	O
exclusive	O
use	O
in	O
veterinary	O
medicine	O
.	O

TSC1	B-protein
mutations	I-protein
include	O
two	O
nonsense	O
mutations	O
,	O
four	O
insertions	O
,	O
and	O
three	O
splice	O
mutations	O
.	O

Fenfluramine	O
(	O
in	O
doses	O
ranging	O
from	O
0	O
.	O
0625	O
-	O
4	O
.	O
0	O
mg	O
/	O
kg	O
/	O
infusion	O
)	O
did	O
not	O
maintain	O
self	O
-	O
administration	O
behavior	O
at	O
or	O
above	O
the	O
minimum	O
requirement	O
(	O
FR	O
30	O
)	O
.	O

No	O
difference	O
in	O
telomere	O
length	O
was	O
seen	O
in	O
mutants	O
affected	O
in	O
the	O
regulation	O
of	O
Cdc2	B-protein
,	O
whereas	O
some	O
of	O
the	O
DNA	O
repair	O
mutants	O
examined	O
had	O
slightly	O
longer	O
telomeres	O
than	O
did	O
the	O
wild	O
type	O
.	O

Using	O
an	O
opsonophagocytic	O
bacterial	O
assay	O
and	O
a	O
suckling	O
rat	O
model	O
of	O
GBS	O
sepsis	O
,	O
we	O
analyzed	O
a	O
modified	O
human	B-protein
immunoglobulin	I-protein
for	O
opsonic	O
and	O
protective	O
antibody	O
.	O

Near	O
term	O
,	O
under	O
experimental	O
conditions	O
,	O
maternal	O
and	O
fetal	O
blood	O
gases	O
,	O
pH	O
,	O
uterine	O
and	O
umbilical	O
blood	O
flows	O
were	O
measured	O
or	O
calculated	O
.	O

Cloning	O
,	O
expression	O
,	O
and	O
nucleotide	O
sequence	O
of	O
rat	B-protein
liver	I-protein
sterol	I-protein
carrier	I-protein
protein	I-protein
2	I-protein
cDNAs	I-protein
.	O

Just	O
before	O
inserting	O
on	O
the	O
anterior	O
margin	O
and	O
apex	O
of	O
the	O
iliac	O
crest	O
it	O
widens	O
,	O
assuming	O
the	O
aspect	O
of	O
a	O
small	O
cone	O
.	O

Integrated	O
mapping	O
analysis	O
of	O
the	O
Werner	B-protein
syndrome	I-protein
region	I-protein
of	O
chromosome	O
8	O
.	O

The	O
cis	O
-	O
acting	O
regulatory	O
properties	O
of	O
an	O
872	O
bp	O
promoter	O
fragment	O
of	O
a	O
B	O
.	O
napus	O
oleosin	B-protein
gene	I-protein
were	O
examined	O
by	O
analysis	O
of	O
beta	B-protein
-	I-protein
glucuronidase	I-protein
(	O
GUS	B-protein
)	O
expression	O
in	O
transgenic	O
tobacco	O
plants	O
containing	O
an	O
oleosin	B-protein
promoter	I-protein
-	I-protein
GUS	I-protein
transcriptional	I-protein
fusion	I-protein
.	O

39	O
-	O
47	O
.	O

In	O
the	O
first	O
group	O
,	O
0	O
.	O
02	O
%	O
Prazosin	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
was	O
administered	O
intravenously	O
for	O
1	O
.	O
5	O
hours	O
before	O
the	O
application	O
of	O
Oxy	O
-	O
Hb	O
or	O
PGF2	B-protein
alpha	I-protein
.	O

Based	O
on	O
previous	O
mapping	O
of	O
the	O
G	B-protein
beta	I-protein
gamma	I-protein
binding	I-protein
region	I-protein
of	O
beta	B-protein
ARK	I-protein
,	O
and	O
conserved	O
residues	O
within	O
the	O
PH	B-protein
domain	I-protein
,	O
we	O
have	O
constructed	O
a	O
series	O
of	O
mutants	O
in	O
the	O
carboxyl	O
terminus	O
of	O
beta	B-protein
ARK	I-protein
in	O
order	O
to	O
determine	O
important	O
residues	O
involved	O
in	O
G	B-protein
beta	I-protein
gamma	I-protein
and	O
PIP2	O
binding	O
.	O

Altogether	O
,	O
the	O
results	O
demonstrate	O
that	O
the	O
two	O
isoforms	O
elicit	O
similar	O
responses	O
in	O
vivo	O
despite	O
differences	O
in	O
their	O
regulation	O
.	O

Zinc	O
fingers	O
(	O
Zf	O
)	O
are	O
a	O
common	O
structural	O
motif	O
found	O
in	O
many	O
nucleic	O
acid	O
-	O
binding	O
proteins	O
.	O

When	O
normalized	O
for	O
imaging	O
time	O
,	O
all	O
parameters	O
are	O
significantly	O
higher	O
with	O
RASE	O
,	O
with	O
a	O
C	O
/	O
A	O
per	O
unit	O
time	O
that	O
was	O
338	O
%	O
higher	O
.	O

The	O
levels	O
of	O
NPY	B-protein
-	I-protein
ir	I-protein
in	O
the	O
rat	O
vas	O
deferens	O
were	O
not	O
affected	O
by	O
either	O
surgical	O
or	O
pharmacological	O
treatment	O
.	O

Gimpl	O
,	O
F	O
.	O

Mono	O
-	O
ADP	O
-	O
ribosylation	O
is	O
a	O
reversible	O
modification	O
of	O
proteins	O
,	O
with	O
NAD	O
:	O
arginine	B-protein
ADP	I-protein
-	I-protein
ribosyltransferases	I-protein
(	O
EC	B-protein
2	I-protein
.	I-protein
4	I-protein
.	I-protein
2	I-protein
.	I-protein
31	I-protein
)	O
and	O
ADP	B-protein
-	I-protein
ribosylarginine	I-protein
hydrolases	I-protein
(	O
EC	B-protein
3	I-protein
.	I-protein
2	I-protein
.	I-protein
2	I-protein
.	I-protein
19	I-protein
)	O
catalyzing	O
the	O
opposing	O
reactions	O
in	O
an	O
ADP	O
-	O
ribosylation	O
cycle	O
.	O

A	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
exon	O
2	O
,	O
which	O
is	O
tightly	O
liked	O
to	O
another	O
SNP	O
(	O
GTG83	O
/	O
ATG83	O
)	O
,	O
creates	O
an	O
additional	O
alternative	O
in	O
-	O
frame	O
AUG	O
in	O
B	B-protein
-	I-protein
type	I-protein
MTH1	I-protein
mRNAs	I-protein
yielding	O
the	O
fourth	O
MTH1	B-protein
polypeptide	I-protein
,	O
p26	B-protein
that	O
possesses	O
an	O
additional	O
mitochondrial	O
targeting	O
signal	O
.	O

Ovulation	O
was	O
induced	O
in	O
8	O
(	O
56	O
.	O
7	O
%	O
)	O
patients	O
who	O
conceived	O
.	O

In	O
contrast	O
,	O
despite	O
external	O
radiation	O
therapy	O
,	O
brain	O
metastases	O
proved	O
fatal	O
.	O

Analysis	O
of	O
liver	O
biopsy	O
specimens	O
from	O
patients	O
with	O
hepatitis	O
showed	O
a	O
large	O
variation	O
in	O
the	O
mean	O
iron	O
content	O
of	O
the	O
liver	O
ferritin	B-protein
molecules	O
.	O

Electrical	O
activity	O
was	O
evaluated	O
by	O
monitoring	O
the	O
general	O
electrocorticogram	O
(	O
ECoG	O
)	O
as	O
well	O
as	O
local	O
DC	O
steady	O
potential	O
(	O
two	O
sites	O
)	O
.	O

The	O
antigen	B-protein
-	I-protein
specific	I-protein
IgG4	I-protein
antibody	I-protein
seems	O
to	O
be	O
an	O
index	O
in	O
evaluating	O
immunotherapy	O
objectively	O
.	O

BACKGROUND	O
:	O
The	O
c	B-protein
-	I-protein
myc	I-protein
proto	I-protein
-	I-protein
oncogene	I-protein
has	O
been	O
suggested	O
to	O
play	O
key	O
roles	O
in	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
transformation	O
and	O
apoptosis	O
.	O

T7	O
transcription	O
could	O
be	O
manipulated	O
to	O
achieve	O
different	O
levels	O
of	O
constitutive	O
expression	O
,	O
through	O
the	O
use	O
of	O
promoter	O
mutations	O
.	O

Interferon	B-protein
beta	I-protein
therapy	O
was	O
discontinued	O
for	O
4	O
weeks	O
.	O

Deletion	O
analysis	O
indicates	O
that	O
TBP	B-protein
and	O
hTAFII18	B-protein
bind	O
to	O
distinct	O
domains	O
of	O
hTAFII28	B-protein
.	O
hTAFII18	B-protein
also	O
interacts	O
with	O
TBP	B-protein
,	O
but	O
it	O
interacts	O
more	O
strongly	O
with	O
hTAFII28	B-protein
and	O
hTAFII30	B-protein
.	O

The	O
coding	O
region	O
of	O
mkh1	B-protein
is	O
contained	O
within	O
a	O
single	O
exon	O
encoding	O
a	O
1	O
,	O
116	O
-	O
amino	O
-	O
acid	O
protein	O
.	O

Clinical	O
research	O
of	O
non	O
-	O
A	O
,	O
non	O
-	O
B	O
post	O
-	O
transfusion	O
hepatitis	O
.	O

The	O
highest	O
postoperative	O
CK	B-protein
-	I-protein
MB	I-protein
level	O
was	O
less	O
after	O
BC	O
(	O
BC	O
,	O
31	O
+	O
/	O
-	O
17	O
U	O
/	O
L	O
;	O
CC	O
,	O
56	O
+	O
/	O
-	O
13	O
U	O
/	O
L	O
;	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
current	O
study	O
defines	O
the	O
vinculin	B-protein
-	I-protein
and	O
FAK	B-protein
-	I-protein
interaction	I-protein
domains	I-protein
on	O
paxillin	B-protein
and	O
identifies	O
the	O
principal	O
paxillin	B-protein
focal	I-protein
adhesion	I-protein
targeting	I-protein
motif	I-protein
.	O

In	O
44	O
evaluable	O
patients	O
the	O
response	O
rate	O
was	O
50	O
%	O
,	O
with	O
one	O
complete	O
response	O
.	O

NF	B-protein
-	I-protein
kappaB	I-protein
,	O
which	O
is	O
probably	O
important	O
for	O
basal	O
activity	O
of	O
the	O
human	B-protein
NOS	I-protein
II	I-protein
promoter	I-protein
,	O
is	O
unlikely	O
to	O
function	O
as	O
a	O
major	O
effector	O
of	O
CM	O
in	O
DLD	O
-	O
1	O
cells	O
.	O

A	O
false	O
positive	O
marker	O
screen	O
was	O
associated	O
with	O
the	O
occurrence	O
of	O
hand	O
-	O
foot	O
syndrome	O
even	O
when	O
the	O
effect	O
of	O
regimen	O
was	O
accounted	O
for	O
by	O
stratification	O
(	O
p	O
=	O
.	O
01	O
)	O
.	O

With	O
the	O
exception	O
of	O
virus	O
assay	O
and	O
quantitation	O
,	O
these	O
methods	O
are	O
simple	O
and	O
inexpensive	O
enough	O
to	O
be	O
done	O
in	O
typical	O
shellfish	O
microbiology	O
laboratories	O
.	O

Pulmonary	O
vascular	O
resistance	O
was	O
not	O
altered	O
,	O
ejection	O
fraction	O
remained	O
unchanged	O
and	O
isovolumic	O
relaxation	O
period	O
was	O
lengthened	O
(	O
119	O
+	O
/	O
-	O
20	O
.	O
1	O
to	O
147	O
.	O
39	O
+	O
/	O
-	O
21	O
.	O
15	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Through	O
a	O
stretch	O
of	O
56	O
amino	O
acids	O
,	O
constituting	O
the	O
MADS	B-protein
domain	I-protein
,	O
the	O
two	O
proteins	O
are	O
identical	O
except	O
for	O
two	O
conservative	O
amino	O
acid	O
substitutions	O
.	O

The	O
ability	O
of	O
SMRT	B-protein
to	O
associate	O
with	O
these	O
transcription	O
factors	O
and	O
thereby	O
to	O
mediate	O
repression	O
is	O
strongly	O
inhibited	O
by	O
activation	O
of	O
tyrosine	B-protein
kinase	I-protein
signaling	O
pathways	O
,	O
such	O
as	O
that	O
represented	O
by	O
the	O
epidermal	B-protein
growth	I-protein
factor	I-protein
receptor	I-protein
.	O

Finally	O
,	O
we	O
determined	O
that	O
the	O
P68	B-protein
amino	O
terminus	O
was	O
both	O
necessary	O
and	O
sufficient	O
for	O
binding	O
dsRNA	O
as	O
we	O
were	O
able	O
to	O
transfer	O
dsRNA	O
-	O
binding	O
properties	O
to	O
a	O
reporter	O
gene	O
product	O
previously	O
unable	O
to	O
bind	O
RNA	O
.	O

METHODS	O
:	O
A	O
total	O
of	O
15	O
pigs	O
were	O
randomised	O
to	O
ligation	O
of	O
left	O
marginal	O
arteries	O
(	O
infarction	O
group	O
,	O
n	O
=	O
5	O
)	O
,	O
to	O
TMLR	O
of	O
the	O
left	O
lateral	O
wall	O
using	O
a	O
holmium	O
:	O
yttrium	O
-	O
aluminium	O
garnet	O
(	O
Ho	O
:	O
YAG	O
)	O
laser	O
(	O
laser	O
group	O
,	O
n	O
=	O
5	O
)	O
,	O
and	O
to	O
both	O
(	O
laser	O
-	O
infarction	O
group	O
,	O
n	O
=	O
5	O
)	O
.	O

Further	O
research	O
is	O
recommended	O
to	O
identify	O
the	O
coping	O
styles	O
associated	O
with	O
the	O
high	O
EE	O
/	O
low	O
EE	O
research	O
classification	O
.	O

Curiously	O
,	O
testololactone	O
was	O
earlier	O
and	O
more	O
widely	O
used	O
than	O
aminoglutethimide	O
in	O
treating	O
advanced	O
breast	O
carcinoma	O
.	O

Responses	O
to	O
the	O
Plowright	O
Rinderpest	O
vaccine	O
by	O
43	O
calves	O
and	O
70	O
adult	O
cattle	O
in	O
Uganda	O
in	O
1990	O
,	O
through	O
the	O
production	O
of	O
IgG	B-protein
antibodies	I-protein
,	O
were	O
monitored	O
for	O
4	O
weeks	O
using	O
the	O
ELISA	O
assay	O
.	O

Fifty	O
-	O
one	O
patients	O
with	O
primary	O
refractory	O
or	O
relapsed	O
malignant	O
lymphoma	O
(	O
47	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
and	O
four	O
Hodgkin	O
'	O
s	O
disease	O
)	O
were	O
treated	O
with	O
a	O
new	O
chemotherapeutic	O
regimen	O
(	O
cisplatinum	O
,	O
methyl	O
GAG	O
,	O
bleomocyin	O
,	O
methyl	O
prednisolon	O
)	O
.	O

These	O
two	O
contigs	O
contain	O
a	O
total	O
of	O
163	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
in	O
26	O
-	O
29	O
putative	O
operons	O
;	O
56	O
ORFs	O
could	O
be	O
identified	O
with	O
reasonable	O
certainty	O
.	O

Toxicity	O
was	O
significant	O
in	O
selected	O
cases	O
;	O
three	O
patients	O
developed	O
WBC	O
counts	O
less	O
than	O
1	O
,	O
000	O
/	O
mm3	O
and	O
one	O
of	O
these	O
patients	O
died	O
with	O
sepsis	O
.	O

Over	O
-	O
expression	O
of	O
the	O
cofactor	O
p300	B-protein
,	O
which	O
functions	O
as	O
a	O
coactivator	O
of	O
myoD	O
-	O
mediated	O
transcription	O
,	O
alleviated	O
repression	O
by	O
COUP	B-protein
-	I-protein
TF	I-protein
II	I-protein
.	O

Interaction	O
of	O
the	O
Fur	B-protein
repressor	I-protein
with	O
a	O
150	O
-	O
bp	O
fragment	O
encompassing	O
the	O
pvdS	B-protein
promoter	I-protein
was	O
demonstrated	O
in	O
vivo	O
by	O
the	O
Fur	B-protein
titration	O
assay	O
and	O
confirmed	O
in	O
vitro	O
by	O
gel	O
retardation	O
experiments	O
with	O
a	O
partially	O
purified	O
Fur	B-protein
preparation	O
.	O

IFN	B-protein
alpha	I-protein
and	O
IFN	B-protein
gamma	I-protein
inducibility	O
is	O
mediated	O
by	O
a	O
single	O
element	O
:	O
a	O
high	O
affinity	O
,	O
nearly	O
palindromic	O
version	O
of	O
the	O
IFN	B-protein
gamma	I-protein
activation	I-protein
site	I-protein
(	O
GAS	B-protein
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
characterized	O
cis	O
-	O
elements	O
of	O
the	O
human	B-protein
PCI	I-protein
gene	I-protein
required	O
for	O
expression	O
in	O
the	O
hepatoma	O
-	O
derived	O
cell	O
line	O
,	O
HepG2	O
cells	O
,	O
and	O
also	O
evaluated	O
rat	B-protein
PCI	I-protein
mRNA	I-protein
expression	O
,	O
particularly	O
on	O
the	O
effect	O
of	O
androgen	O
in	O
rat	O
reproductive	O
tissues	O
.	O

The	O
transcription	B-protein
factor	I-protein
CHOP	I-protein
(	O
C	B-protein
/	I-protein
EBP	I-protein
homologous	I-protein
protein	I-protein
10	I-protein
)	O
is	O
a	O
bZIP	B-protein
protein	I-protein
induced	O
by	O
a	O
variety	O
of	O
stimuli	O
that	O
evoke	O
cellular	O
stress	O
responses	O
and	O
has	O
been	O
shown	O
to	O
arrest	O
cell	O
growth	O
and	O
to	O
promote	O
programmed	O
cell	O
death	O
.	O

All	O
ribosomal	B-protein
protein	I-protein
(	O
rp	B-protein
)	O
gene	O
promoters	O
from	O
Saccharomyces	O
cerevisiae	O
studied	O
so	O
far	O
contain	O
either	O
(	O
usually	O
two	O
)	O
binding	O
sites	O
for	O
the	O
global	O
gene	O
regulator	O
Rap1p	B-protein
or	O
one	O
binding	O
site	O
for	O
another	O
global	O
factor	O
,	O
Abf1p	B-protein
.	O

Seventeen	O
of	O
them	O
were	O
on	O
treatment	O
with	O
systemic	O
steroids	O
.	O

In	O
contrast	O
,	O
c	B-protein
-	I-protein
Src	I-protein
activated	O
by	O
isoproterenol	O
led	O
to	O
tyrosine	O
phosphorylation	O
of	O
Shc	B-protein
and	O
subsequent	O
Erk	B-protein
activation	O
,	O
but	O
not	O
tyrosine	O
phosphorylation	O
of	O
cortactin	B-protein
or	O
Stat3	B-protein
.	O

Identity	O
of	O
GABP	B-protein
with	O
NRF	B-protein
-	I-protein
2	I-protein
,	O
a	O
multisubunit	O
activator	O
of	O
cytochrome	B-protein
oxidase	I-protein
expression	O
,	O
reveals	O
a	O
cellular	O
role	O
for	O
an	O
ETS	B-protein
domain	I-protein
activator	O
of	O
viral	O
promoters	O
.	O

Thus	O
it	O
appears	O
that	O
the	O
management	O
of	O
blood	O
,	O
including	O
washing	O
is	O
of	O
great	O
importance	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Associations	O
of	O
factor	O
analysis	O
-	O
derived	O
syndromes	O
with	O
risk	O
factors	O
for	O
chemical	O
interactions	O
that	O
inhibit	O
butyrylcholinesterase	B-protein
and	O
neuropathy	O
target	O
esterase	B-protein
.	O

State	O
of	O
the	O
body	O
in	O
disorders	O
of	O
diurnal	O
physiological	O
rhythms	O
and	O
long	O
-	O
term	O
hypokinesia	O
.	O

OsBBPI	B-protein
was	O
found	O
to	O
be	O
rapidly	O
induced	O
in	O
rice	O
seedling	O
leaf	O
in	O
response	O
to	O
cut	B-protein
,	O
exogenous	O
jasmonic	O
acid	O
(	O
JA	O
)	O
,	O
and	O
two	O
potent	O
protein	B-protein
phosphatase	I-protein
2A	I-protein
(	O
PP2A	B-protein
)	O
inhibitors	O
,	O
cantharidin	O
(	O
CN	O
)	O
and	O
endothall	O
(	O
EN	O
)	O
,	O
in	O
a	O
light	O
/	O
dark	O
-	O
,	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
;	O
this	O
induction	O
was	O
completely	O
inhibited	O
by	O
cycloheximide	O
(	O
CHX	O
)	O
,	O
indicating	O
a	O
requirement	O
for	O
de	O
novo	O
protein	O
synthesis	O
in	O
its	O
induction	O
.	O

Moreover	O
,	O
a	O
high	O
proportion	O
of	O
blood	O
samples	O
from	O
a	O
random	O
sample	O
of	O
the	O
rest	O
of	O
the	O
suspects	O
tested	O
positive	O
for	O
trypanosome	O
-	O
specific	O
DNA	O
by	O
PCR	O
(	O
79	O
.	O
9	O
%	O
for	O
T	O
.	O
b	O
.	O
gambiense	O
and	O
13	O
.	O
9	O
%	O
for	O
T	O
.	O
b	O
.	O
rhodesiense	O
)	O
.	O

Increased	O
dietary	O
energy	O
decreased	O
PAB	O
and	O
the	O
use	O
of	O
added	O
dietary	O
CO	O
rather	O
than	O
PF	O
decreased	O
PSHL	O
in	O
broiler	O
breeders	O
between	O
26	O
and	O
47	O
wk	O
of	O
age	O
.	O

Our	O
data	O
showed	O
that	O
activation	O
of	O
the	O
raf	B-protein
-	I-protein
ERK	I-protein
pathway	O
led	O
to	O
activation	O
of	O
TF	B-protein
expression	O
in	O
breast	O
carcinoma	O
cells	O
and	O
suggested	O
that	O
constitutive	O
activation	O
of	O
this	O
pathway	O
leads	O
to	O
high	O
TF	B-protein
expression	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
.	O

As	O
expected	O
,	O
homologous	B-protein
loxP	I-protein
sequences	I-protein
efficiently	O
underwent	O
Cre	O
-	O
mediated	O
recombination	O
.	O

IL	B-protein
-	I-protein
1beta	I-protein
was	O
significantly	O
higher	O
in	O
endometrioma	O
than	O
in	O
lesions	O
of	O
other	O
localizations	O
.	O

To	O
get	O
further	O
insights	O
into	O
the	O
molecular	O
mechanisms	O
that	O
control	O
tal	B-protein
-	I-protein
1	I-protein
expression	O
,	O
we	O
have	O
isolated	O
5	O
'	O
sequences	O
of	O
the	O
murine	O
gene	O
and	O
compared	O
them	O
to	O
their	O
human	O
counterparts	O
.	O

Serum	O
antibody	O
titre	O
was	O
not	O
significantly	O
associated	O
with	O
the	O
recurrence	O
rate	O
or	O
the	O
duration	O
of	O
infection	O
.	O

A	O
series	O
of	O
5	O
'	O
-	O
deletions	O
revealed	O
that	O
the	O
fragment	O
-	O
218	O
to	O
+	O
4	O
from	O
the	O
TSS	O
had	O
the	O
highest	O
promoter	O
activity	O
,	O
nearly	O
1000	O
-	O
fold	O
greater	O
than	O
the	O
promoterless	O
chloramphenicol	B-protein
acetyltransferase	I-protein
construct	I-protein
.	O

Areas	O
with	O
significantly	O
greater	O
rCBF	O
for	O
targeting	O
were	O
the	O
left	O
motor	O
cortex	O
,	O
left	O
intraparietal	O
sulcus	O
,	O
and	O
left	O
caudate	O
.	O

Finally	O
,	O
using	O
in	O
vitro	O
binding	O
studies	O
,	O
we	O
showed	O
that	O
SREBP2	B-protein
was	O
able	O
to	O
displace	O
ADD1	B-protein
/	I-protein
SREBP1	I-protein
binding	O
from	O
the	O
sterol	B-protein
regulatory	I-protein
element	I-protein
(	O
SRE	B-protein
)	O
site	O
.	O

Chronic	O
nutritional	O
diseases	O
of	O
infectious	O
origin	O
:	O
an	O
assessment	O
of	O
a	O
nascent	O
field	O
.	O

Isolation	O
and	O
characterization	O
of	O
the	O
rat	O
chromosomal	O
gene	O
for	O
a	O
polypeptide	O
(	O
pS1	B-protein
)	O
antigenically	O
related	O
to	O
statin	B-protein
.	O

Deformities	O
of	O
the	O
tip	O
of	O
the	O
olecranon	O
and	O
of	O
the	O
coronoid	O
process	O
are	O
also	O
described	O
(	O
De	O
Palma	O
1956	O
,	O
Jordan	O
1958	O
,	O
Ahlberg	O
1965	O
,	O
Weseloh	O
1973	O
)	O
.	O

Secretion	O
of	O
interleukin	B-protein
-	I-protein
8	I-protein
,	O
RANTES	B-protein
,	O
macrophage	B-protein
inflammatory	I-protein
protein	I-protein
1alpha	I-protein
,	O
and	O
10	B-protein
-	I-protein
kappaDa	I-protein
IFN	I-protein
-	I-protein
gamma	I-protein
-	I-protein
inducible	I-protein
protein	I-protein
were	O
increased	O
in	O
differentiating	O
keratinocytes	O
by	O
E6	B-protein
.	O

Stimulation	O
of	O
the	O
caudate	O
nucleus	O
'	O
dophamine	O
-	O
reactive	O
system	O
in	O
dogs	O
by	O
means	O
of	O
administration	O
of	O
dophamine	O
(	O
60	O
micrograms	O
)	O
and	O
phenamine	O
led	O
to	O
deterioration	O
of	O
conditioned	O
and	O
unconditioned	O
components	O
of	O
feeding	O
behaviour	O
.	O

Binding	O
to	O
sulphatides	O
and	O
the	O
alpha	B-protein
-	I-protein
dystroglycan	I-protein
receptor	I-protein
was	O
much	O
stronger	O
and	O
required	O
at	O
least	O
two	O
LG	B-protein
modules	I-protein
.	O

The	O
immune	O
response	O
of	O
past	O
-	O
infection	O
of	O
cytomegalovirus	O
in	O
the	O
patients	O
of	O
RTID	O
is	O
rather	O
remarkable	O
.	O

Reverse	B-protein
transcriptase	I-protein
and	O
protease	B-protein
activities	O
of	O
avian	O
leukosis	O
virus	O
Gag	B-protein
-	I-protein
Pol	I-protein
fusion	I-protein
proteins	I-protein
expressed	O
in	O
insect	O
cells	O
.	O

Erythrocytic	O
stages	O
of	O
mammalian	O
malarial	O
parasites	O
contain	O
acristate	O
mitochondria	O
whose	O
functions	O
are	O
not	O
well	O
understood	O
.	O

New	O
techniques	O
for	O
the	O
mass	O
spectrometry	O
of	O
natural	O
products	O
.	O

Thromboxane	B-protein
B2	I-protein
increased	O
(	O
97	O
+	O
/	O
-	O
105	O
versus	O
40	O
+	O
/	O
-	O
26	O
pg	O
/	O
ml	O
)	O
and	O
was	O
significantly	O
higher	O
during	O
heparin	O
free	O
hemodialysis	O
than	O
during	O
hemodialysis	O
with	O
heparin	O
(	O
p	O
=	O
0	O
.	O
01	O
,	O
Wilcoxon	O
matched	O
pairs	O
signed	O
rank	O
test	O
)	O
.	O

D	O
.	O

This	O
0	O
.	O
74	O
kb	O
cDNA	O
contains	O
an	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
of	O
477	O
bp	O
encoding	O
a	O
polypeptide	O
of	O
159	O
amino	O
acids	O
(	O
aa	O
)	O
which	O
differs	O
at	O
only	O
one	O
position	O
(	O
position	O
65	O
)	O
from	O
the	O
human	B-protein
U1	I-protein
-	I-protein
C	I-protein
protein	I-protein
.	O

Our	O
results	O
demonstrated	O
that	O
50	O
%	O
of	O
the	O
hepatic	O
artery	O
-	O
alone	O
ALT	O
graft	O
showed	O
almost	O
normal	O
structure	O
histologically	O
at	O
1	O
month	O
after	O
grafting	O
,	O
with	O
bile	O
secretion	O
preserved	O
.	O

Human	B-protein
bcl3	I-protein
protein	I-protein
specifically	O
displaces	O
(	B-protein
p50	I-protein
)	I-protein
2	I-protein
-	I-protein
DNA	I-protein
complexes	I-protein
.	O

Videonystagmoscopy	O
has	O
been	O
used	O
to	O
subjectively	O
observe	O
the	O
responses	O
of	O
the	O
vestibular	O
system	O
in	O
a	O
population	O
of	O
patients	O
with	O
vestibular	O
deficits	O
.	O

In	O
conclusion	O
,	O
these	O
studies	O
indicate	O
that	O
LiCl	O
(	O
1	O
)	O
decreases	O
histamine	O
-	O
stimulated	O
gastric	O
acid	O
secretion	O
,	O
and	O
(	O
2	O
)	O
diminishes	O
bile	O
-	O
induced	O
disruption	O
of	O
the	O
gastric	O
mucosal	O
barrier	O
in	O
the	O
canine	O
Heidenhain	O
pouch	O
.	O

We	O
have	O
previously	O
reported	O
that	O
high	O
level	O
human	B-protein
desmin	I-protein
expression	O
depends	O
on	O
a	O
280	O
-	O
base	O
pair	O
muscle	O
-	O
specific	O
enhancer	O
which	O
can	O
function	O
not	O
only	O
in	O
myotubes	O
,	O
but	O
can	O
also	O
activate	O
gene	O
expression	O
in	O
myoblasts	O
.	O

Treatment	O
of	O
human	O
myeloid	O
cell	O
lines	O
HL	O
-	O
60	O
and	O
U937	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
increased	O
within	O
2	O
h	O
cellular	O
levels	O
of	O
the	O
RNA	O
hybridizable	O
to	O
LD78	B-protein
cDNA	I-protein
.	O

We	O
have	O
examined	O
the	O
regulation	O
of	O
the	O
FGFR	B-protein
-	I-protein
1	I-protein
gene	I-protein
(	O
cek	B-protein
-	I-protein
1	I-protein
)	O
in	O
avian	O
myogenic	O
cultures	O
by	O
immunocytochemistry	O
and	O
Northern	O
blot	O
analysis	O
.	O

A	O
low	O
aspirin	B-protein
esterase	I-protein
activity	O
may	O
be	O
a	O
contributory	O
factor	O
in	O
precipitating	O
these	O
aspirin	O
sensitive	O
reactions	O
.	O

On	O
the	O
character	O
of	O
changes	O
in	O
the	O
enzyme	O
activity	O
in	O
the	O
brain	O
tissue	O
during	O
reflex	O
epilepsy	O
.	O

Localized	O
fluorescence	O
was	O
detectable	O
only	O
in	O
cells	O
containing	O
a	O
visible	O
midcell	O
constriction	O
,	O
suggesting	O
that	O
FtsK	B-protein
targeting	O
normally	O
occurs	O
only	O
at	O
a	O
late	O
stage	O
of	O
septation	O
.	O

Chloramphenicol	B-protein
acetyltransferase	I-protein
assays	O
examining	O
the	O
ability	O
of	O
IE86	B-protein
to	O
repress	O
activity	O
from	O
the	O
HCMV	O
major	O
IE	B-protein
promoter	I-protein
or	O
activate	O
the	O
HCMV	B-protein
early	I-protein
promoter	I-protein
for	O
the	O
2	O
.	O
2	O
-	O
kb	O
class	O
of	O
RNAs	O
demonstrated	O
the	O
functional	O
integrity	O
of	O
the	O
IE86	B-protein
protein	I-protein
.	O

Piroximone	O
is	O
a	O
new	O
phosphodiesterase	B-protein
III	I-protein
inhibitor	O
that	O
combines	O
inotropic	O
and	O
vasodilator	O
properties	O
.	O

This	O
enzyme	O
is	O
designated	O
(	B-protein
1	I-protein
-	I-protein
-	I-protein
>	I-protein
4	I-protein
)	I-protein
-	I-protein
beta	I-protein
-	I-protein
xylan	I-protein
endohydrolase	I-protein
isoenzyme	I-protein
X	I-protein
-	I-protein
I	I-protein
.	O

Because	O
the	O
number	O
of	O
parameters	O
required	O
by	O
a	O
Volterra	O
series	O
grows	O
rapidly	O
with	O
both	O
the	O
length	O
of	O
its	O
memory	O
and	O
the	O
order	O
of	O
its	O
nonlinearity	O
,	O
methods	O
for	O
identifying	O
these	O
models	O
from	O
measurements	O
of	O
input	O
/	O
output	O
data	O
are	O
limited	O
to	O
low	O
-	O
order	O
systems	O
with	O
relatively	O
short	O
memories	O
.	O

Both	O
normal	O
and	O
transforming	O
PCPH	B-protein
proteins	I-protein
have	O
guanosine	B-protein
diphosphatase	I-protein
activity	O
but	O
only	O
the	O
oncoprotein	O
cooperates	O
with	O
Ras	B-protein
in	O
activating	O
extracellular	B-protein
signal	I-protein
-	I-protein
regulated	I-protein
kinase	I-protein
ERK1	I-protein
.	O

New	O
Langevin	O
equations	O
for	O
a	O
translating	O
and	O
simultaneously	O
rotating	O
asymmetric	O
top	O
.	O

The	O
early	O
dg	O
.	O
of	O
rejection	O
and	O
especially	O
acute	O
rejection	O
,	O
it	O
'	O
s	O
adequate	O
management	O
,	O
decreased	O
risk	O
for	O
the	O
future	O
chronic	O
rejection	O
nephropathy	O
.	O

Improvement	O
of	O
the	O
CRT	O
display	O
of	O
an	O
averager	O
.	O

Seventy	O
-	O
two	O
of	O
73	O
negative	O
controls	O
and	O
all	O
positive	O
blocks	O
as	O
seen	O
on	O
soft	O
tissue	O
radiographs	O
(	O
STRs	O
)	O
were	O
correctly	O
coded	O
(	O
specificity	O
98	O
.	O
6	O
%	O
,	O
sensitivity	O
100	O
%	O
)	O
.	O

The	O
method	O
requires	O
a	O
reversed	O
-	O
phase	O
column	O
and	O
a	O
paired	O
-	O
ion	O
technique	O
to	O
separate	O
docusate	O
sodium	O
from	O
other	O
components	O
.	O

This	O
study	O
was	O
aimed	O
at	O
assessing	O
whether	O
c	O
-	O
DDP	O
administration	O
immediately	O
before	O
radiotherapy	O
could	O
increase	O
frequency	O
and	O
duration	O
of	O
objective	O
responses	O
,	O
as	O
well	O
as	O
survival	O
,	O
in	O
patients	O
affected	O
with	O
locally	O
advanced	O
stages	O
of	O
squamous	O
carcinomas	O
of	O
the	O
head	O
and	O
neck	O
.	O

Chem	O
.	O

In	O
contrast	O
,	O
cotransfection	O
of	O
TFIIB	B-protein
and	O
IRF	B-protein
-	I-protein
1	I-protein
into	O
NIH	O
3T3	O
cells	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
repression	O
of	O
promoter	O
activation	O
which	O
occurred	O
in	O
a	O
TATA	O
-	O
dependent	O
manner	O
.	O

Fetal	O
lung	O
volume	O
:	O
estimation	O
at	O
MR	O
imaging	O
-	O
initial	O
results	O
.	O

It	O
contains	O
three	O
putative	O
binding	O
sites	O
for	O
transcription	B-protein
factor	I-protein
Sp1	I-protein
as	O
well	O
as	O
several	O
short	O
sequences	O
that	O
are	O
similar	O
to	O
known	O
cis	O
-	O
acting	O
enhancers	O
or	O
binding	O
sites	O
for	O
transcription	O
factors	O
.	O

Thus	O
,	O
the	O
system	O
can	O
be	O
used	O
to	O
detect	O
and	O
study	O
dynamic	O
perfusion	O
changes	O
from	O
the	O
brain	O
surface	O
with	O
minimal	O
tissue	O
damage	O
.	O

Addition	O
of	O
soluble	O
recombinant	B-protein
human	I-protein
SLF	I-protein
to	O
SI4	O
-	O
h220	O
cultures	O
enhanced	O
reduction	O
of	O
cell	O
-	O
surface	O
c	B-protein
-	I-protein
kit	I-protein
expression	O
and	O
its	O
protein	O
degradation	O
.	O

Transcription	O
factors	O
containing	O
a	O
basic	B-protein
helix	I-protein
-	I-protein
loop	I-protein
-	I-protein
helix	I-protein
(	I-protein
bHLH	I-protein
)	I-protein
motif	I-protein
regulate	O
the	O
expression	O
of	O
tissue	O
-	O
specific	O
genes	O
in	O
a	O
number	O
of	O
mammalian	O
and	O
insect	O
systems	O
.	O

Also	O
,	O
transient	O
overexpression	O
of	O
this	O
protein	O
in	O
C2C12	O
cells	O
reduced	O
the	O
transcription	O
of	O
a	O
CAT	B-protein
-	I-protein
reporter	I-protein
regulated	O
by	O
an	O
E12	B-protein
/	I-protein
MyoD	I-protein
driven	I-protein
enhancer	I-protein
.	O

Two	O
patients	O
were	O
treated	O
with	O
both	O
regimens	O
.	O

A	O
1	O
.	O
8	O
-	O
kb	O
cDNA	O
clone	O
(	O
designed	O
hKID	O
,	O
gene	B-protein
symbol	I-protein
AQP2L	I-protein
)	O
with	O
homology	O
to	O
the	O
aquaporins	B-protein
was	O
isolated	O
from	O
a	O
human	O
kidney	O
cDNA	O
library	O
.	O

The	O
Lm	O
increased	O
and	O
the	O
alveoli	O
/	O
mm2	O
and	O
elastic	O
recoil	O
pressure	O
decreased	O
.	O

Serum	O
-	O
ferritin	O
in	O
diagnosis	O
of	O
haemochromatosis	O
.	O

Comparison	O
of	O
1	O
.	O
5	O
Tesla	O
and	O
0	O
.	O
35	O
Tesla	O
field	O
strength	O
magnetic	O
resonance	O
imaging	O
scans	O
in	O
the	O
morphometric	O
evaluation	O
of	O
the	O
lumbar	O
intervertebral	O
foramina	O
.	O

Chronic	O
endotoxemia	O
appears	O
to	O
be	O
associated	O
with	O
an	O
elevated	O
pulmonary	O
microvascular	O
permeability	O
and	O
a	O
tendency	O
toward	O
a	O
hyperdynamic	O
circulation	O
but	O
with	O
an	O
appreciable	O
degree	O
of	O
refractoriness	O
associated	O
with	O
regional	O
hemodynamics	O
and	O
eicosanoid	O
biosynthesis	O
.	O

These	O
rearrangements	O
result	O
in	O
the	O
formation	O
of	O
chimeric	O
genes	O
showing	O
the	O
tyrosine	B-protein
kinase	I-protein
domain	I-protein
of	O
ret	B-protein
fused	O
with	O
the	O
5	O
'	O
end	O
sequences	O
of	O
different	O
genes	O
.	O

The	O
TATA	B-protein
box	I-protein
-	I-protein
binding	I-protein
protein	I-protein
(	O
TBP	B-protein
)	O
plays	O
an	O
essential	O
role	O
in	O
transcription	O
by	O
all	O
three	O
eukaryotic	O
nuclear	B-protein
RNA	I-protein
polymerases	I-protein
,	O
polymerases	B-protein
(	I-protein
Pol	I-protein
)	I-protein
I	I-protein
,	I-protein
II	I-protein
,	I-protein
and	I-protein
III	I-protein
.	O

Mutation	O
of	O
nucleotides	O
adjacent	O
to	O
the	O
AP	B-protein
-	I-protein
1	I-protein
cis	I-protein
-	I-protein
response	I-protein
elements	I-protein
had	O
no	O
effect	O
on	O
trans	O
-	O
activation	O
.	O

Dual	O
innervation	O
of	O
fast	O
fibers	O
in	O
trunk	O
muscles	O
of	O
lamprey	O
larvae	O
.	O

Mucolipidosis	O
type	O
IV	O
:	O
clinical	O
spectrum	O
and	O
natural	O
history	O
.	O

At	O
necropsy	O
28	O
days	O
post	O
-	O
inoculation	O
,	O
F344	O
rats	O
had	O
no	O
gross	O
lung	O
lesions	O
,	O
even	O
those	O
given	O
the	O
maximum	O
dose	O
of	O
1	O
.	O
4	O
X	O
10	O
(	O
9	O
)	O
colony	O
-	O
forming	O
units	O
of	O
M	O
.	O
pulmonis	O
.	O

The	O
Epstein	B-protein
-	I-protein
Barr	I-protein
virus	I-protein
transactivator	I-protein
Zta	I-protein
triggers	O
lytic	O
gene	O
expression	O
and	O
is	O
essential	O
for	O
replication	O
of	O
the	O
lytic	O
origin	O
,	O
oriLyt	B-protein
.	O

We	O
have	O
determined	O
the	O
molecular	O
lesions	O
of	O
nine	O
Scm	B-protein
mutant	I-protein
alleles	I-protein
,	O
which	O
identify	O
functional	O
requirements	O
for	O
specific	O
domains	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
Of	O
the	O
17	O
men	O
and	O
17	O
women	O
,	O
who	O
were	O
21	O
to	O
80	O
years	O
of	O
age	O
,	O
27	O
had	O
hereditary	O
motor	O
and	O
sensory	O
neuropathy	O
type	O
I	O
and	O
7	O
had	O
acquired	O
demyelinating	O
polyneuropathy	O
.	O

Anti	B-protein
-	I-protein
B	I-protein
.	I-protein
burgdorferi	I-protein
,	O
anti	B-protein
-	I-protein
B	I-protein
.	I-protein
turicatae	I-protein
and	O
anti	B-protein
-	I-protein
B	I-protein
.	I-protein
parkeri	I-protein
antibodies	I-protein
,	O
tested	O
by	O
the	O
indirect	O
immunofluorescent	O
assay	O
(	O
IFA	O
)	O
,	O
were	O
detected	O
in	O
10	O
.	O
8	O
,	O
16	O
.	O
1	O
and	O
8	O
.	O
2	O
%	O
of	O
the	O
serum	O
samples	O
tested	O
,	O
and	O
confirmed	O
by	O
IFA	O
-	O
ABS	O
in	O
1	O
.	O
3	O
,	O
1	O
.	O
3	O
and	O
1	O
.	O
0	O
%	O
,	O
respectively	O
.	O

Tobramycin	O
60	O
mg	O
did	O
not	O
show	O
any	O
remarkable	O
effect	O
,	O
but	O
dibecacin	O
100	O
mg	O
produced	O
a	O
slight	O
potentiating	O
effect	O
on	O
the	O
action	O
of	O
d	O
-	O
tubocurarine	O
.	O

OBJECTIVE	O
:	O
1998	O
Surveillance	O
,	O
Epidemiology	O
,	O
and	O
End	O
Results	O
(	O
SEER	O
)	O
data	O
estimate	O
an	O
83	O
.	O
1	O
%	O
5	O
-	O
year	O
survival	O
rate	O
for	O
corpus	O
uteri	O
adenocarcinoma	O
FIGO	O
stage	O
II	O
.	O

Intron	O
K1	B-protein
cox1	I-protein
.	I-protein
2	I-protein
is	O
not	O
found	O
in	O
S	O
.	O
cerevisiae	O
and	O
appears	O
at	O
an	O
unique	O
location	O
in	O
K	O
.	O
lactis	O
.	O

In	O
B	O
cells	O
,	O
HEF1	B-protein
is	O
phosphorylated	O
by	O
a	O
cytoskeleton	O
-	O
dependent	O
mechanism	O
that	O
is	O
triggered	O
by	O
integrin	B-protein
ligation	O
.	O

Attenuation	O
from	O
the	O
vit	B-protein
A2	I-protein
consensus	O
ERE	B-protein
is	O
not	O
necessarily	O
dependent	O
on	O
DNA	O
binding	O
as	O
the	O
TR	B-protein
alpha	I-protein
DNA	O
binding	O
mutant	O
was	O
still	O
able	O
to	O
inhibit	O
E	O
-	O
dependent	O
transactivation	O
.	O

The	O
data	O
indicate	O
that	O
the	O
minimal	O
catalytic	O
domain	O
of	O
Nmt1p	B-protein
is	O
located	O
between	O
Ile59	O
-	O
-	O
>	O
Phe96	O
and	O
Gly451	O
-	O
-	O
>	O
Leu455	O
.	O

This	O
family	O
of	O
proteins	O
binds	O
GC	O
-	O
rich	O
motifs	O
widely	O
distributed	O
in	O
gene	O
promoters	O
,	O
resulting	O
in	O
distinct	O
activation	O
or	O
repression	O
of	O
transcriptional	O
activities	O
.	O

Rare	O
neurogenic	O
tumor	O
with	O
metastasis	O
to	O
mouth	O
,	O
jaw	O
and	O
face	O
regions	O
.	O

Studies	O
using	O
an	O
inhibitor	O
or	O
a	O
mutant	B-protein
Lb	I-protein
proteinase	I-protein
indicated	O
that	O
stimulation	O
of	O
IRES	O
-	O
driven	O
translation	O
is	O
mediated	O
via	O
proteolysis	O
of	O
some	O
cellular	O
component	O
(	O
s	O
)	O
.	O

The	O
newly	O
defined	O
region	O
contains	O
an	O
intron	O
that	O
may	O
be	O
alternatively	O
spliced	O
and	O
seven	O
polyadenylation	O
signal	O
sequences	O
.	O

The	O
psaD	B-protein
,	O
psaF	B-protein
,	O
psaH	B-protein
,	O
and	O
psaL	B-protein
products	I-protein
have	O
two	O
isoforms	O
each	O
that	O
are	O
distinguished	O
by	O
different	O
mobilities	O
in	O
polyacrylamide	O
gel	O
electrophoresis	O
,	O
and	O
the	O
psaE	B-protein
product	I-protein
has	O
four	O
isoforms	O
.	O

Fans	O
in	O
tunnels	O
and	O
open	O
windows	O
at	O
aboveground	O
locations	O
appeared	O
to	O
greatly	O
reduce	O
the	O
likelihood	O
of	O
high	O
PH3	O
concentrations	O
in	O
enclosed	O
areas	O
.	O

These	O
well	O
-	O
characterized	O
brain	O
regions	O
may	O
provide	O
a	O
basis	O
for	O
future	O
studies	O
of	O
RPTP	B-protein
-	I-protein
kappa	I-protein
function	O
.	O

A	O
sequence	O
representing	O
about	O
50	O
%	O
of	O
the	O
expected	O
complete	O
sequence	O
was	O
obtained	O
by	O
translation	O
of	O
the	O
two	O
open	O
reading	O
frames	O
present	O
on	O
a	O
1	O
.	O
6	O
kb	O
DNA	O
genomic	O
fragment	O
.	O

Drosophila	B-protein
UbcD1	I-protein
encodes	O
a	O
highly	O
conserved	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
involved	O
in	O
selective	O
protein	O
degradation	O
.	O

In	O
vitro	O
expression	O
of	O
four	O
different	O
naturally	O
occurring	O
nonsense	O
and	O
missense	O
mutations	O
revealed	O
a	O
dramatically	O
altered	O
subcellular	O
location	O
of	O
the	O
protein	O
in	O
cultured	O
cells	O
.	O

Five	O
of	O
these	O
eight	O
patients	O
in	O
group	O
II	O
also	O
received	O
8	O
-	O
in	O
-	O
1	O
chemotherapy	O
.	O

The	O
controversy	O
of	O
significance	O
testing	O
:	O
misconceptions	O
and	O
alternatives	O
.	O

These	O
results	O
indicate	O
that	O
the	O
p33	B-protein
subunit	I-protein
of	O
eIF3	B-protein
plays	O
an	O
important	O
role	O
in	O
the	O
initiation	O
phase	O
of	O
protein	O
synthesis	O
and	O
that	O
its	O
RNA	O
-	O
binding	O
domain	O
is	O
required	O
for	O
optimal	O
activity	O
.	O

It	O
has	O
been	O
shown	O
in	O
experiments	O
in	O
vitro	O
that	O
the	O
hepatotrophic	O
organic	O
anions	O
,	O
the	O
radiographic	O
contrast	O
agent	O
(	O
RCA	O
)	O
bilignost	O
used	O
in	O
cholecystography	O
and	O
Bengal	O
pink	O
,	O
have	O
an	O
affinity	O
,	O
unlike	O
the	O
urographic	O
RCA	O
triombrin	O
and	O
renotrophic	O
dye	O
indigo	O
-	O
carmine	O
,	O
for	O
the	O
plasmatic	O
membranes	O
(	O
PM	O
)	O
of	O
liver	O
cells	O
.	O

The	O
alpha	B-protein
7A	I-protein
form	I-protein
RNA	I-protein
contains	O
an	O
additional	O
113	O
nucleotides	O
compared	O
to	O
the	O
B	O
form	O
,	O
and	O
a	O
common	O
coding	O
region	O
in	O
the	O
A	O
and	O
B	O
form	O
RNAs	O
is	O
used	O
in	O
alternate	O
reading	O
frames	O
.	O

A	O
Bub2p	O
-	O
dependent	O
spindle	O
checkpoint	O
pathway	O
regulates	O
the	O
Dbf2p	B-protein
kinase	I-protein
in	I-protein
budding	I-protein
yeast	I-protein
.	O

All	O
six	O
ARF	B-protein
cDNAs	I-protein
are	O
more	O
similar	O
to	O
each	O
other	O
than	O
to	O
other	O
approximately	O
20	B-protein
-	I-protein
kDa	I-protein
guanine	I-protein
nucleotide	I-protein
-	I-protein
binding	I-protein
proteins	I-protein
.	O

We	O
have	O
subcloned	O
into	O
pBR322	O
deoxyribonucleic	O
acid	O
(	O
DNA	O
)	O
sequences	O
mapping	O
either	O
in	O
the	O
coding	O
region	O
,	O
the	O
5	O
'	O
spacer	O
,	O
or	O
the	O
3	O
'	O
spacer	O
of	O
the	O
H2B	B-protein
histone	I-protein
gene	I-protein
.	O

The	O
rrd1	B-protein
,	I-protein
2delta	I-protein
mutant	I-protein
was	O
partially	O
rescued	O
by	O
inactivation	O
of	O
HOG1	B-protein
or	O
PBS2	B-protein
,	O
suggesting	O
an	O
interaction	O
between	O
the	O
RRD	B-protein
genes	I-protein
and	O
the	O
Hog1p	B-protein
signal	I-protein
transduction	I-protein
pathway	I-protein
.	O

The	O
negative	O
predictive	O
value	O
is	O
92	O
%	O
,	O
vs	O
80	O
%	O
for	O
the	O
NCEP	O
I	O
.	O

The	O
matrix	O
surrounding	O
the	O
clusters	O
either	O
showed	O
a	O
normal	O
morphology	O
or	O
a	O
homogeneous	O
appearance	O
,	O
within	O
which	O
faint	O
cross	O
striations	O
but	O
no	O
distinctly	O
fibrillar	O
outlines	O
could	O
be	O
identified	O
.	O

The	O
muskox	O
is	O
a	O
new	O
host	O
record	O
for	O
T	O
.	O
gondii	O
.	O

The	O
patient	O
'	O
s	O
role	O
,	O
organized	O
by	O
the	O
prerequisites	O
of	O
expressive	O
freedom	O
,	O
is	O
counter	O
posed	O
with	O
the	O
psychoanalyst	O
'	O
s	O
,	O
which	O
is	O
structured	O
to	O
empower	O
listening	O
and	O
understanding	O
.	O

Immunoreactive	O
AR	B-protein
content	O
in	O
transfected	O
COS	O
-	O
1	O
cells	O
was	O
not	O
influenced	O
by	O
exposure	O
to	O
8	O
-	O
Br	O
-	O
cAMP	O
.	O

Erythrocyte	O
protoporphyrin	O
concentration	O
increased	O
significantly	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
by	O
14	O
days	O
in	O
dogs	O
fed	O
the	O
basal	O
diet	O
,	O
and	O
remained	O
significantly	O
high	O
relative	O
to	O
that	O
in	O
dogs	O
of	O
the	O
other	O
dietary	O
groups	O
for	O
the	O
remainder	O
of	O
the	O
study	O
.	O

A	O
case	O
of	O
Goodpasture	O
'	O
s	O
syndrome	O
.	O

RXR	B-protein
-	I-protein
gamma	I-protein
expression	O
produced	O
significant	O
reduction	O
in	O
levels	O
of	O
RA	O
-	O
responsive	O
genes	O
including	O
the	O
cyclin	B-protein
-	I-protein
dependent	I-protein
kinase	I-protein
inhibitors	I-protein
p21Cip1	I-protein
/	I-protein
WAF1	I-protein
and	O
p27Kip1	B-protein
,	O
resulting	O
in	O
increased	O
cdc2	B-protein
and	O
cdk2	B-protein
kinase	I-protein
activity	O
and	O
RB	B-protein
phosphorylation	O
.	O

Insulin	B-protein
-	I-protein
like	I-protein
growth	I-protein
factor	I-protein
II	I-protein
(	O
IGFII	B-protein
)	O
is	O
a	O
mitogenic	O
polypeptide	O
,	O
the	O
mRNAs	O
of	O
which	O
are	O
present	O
in	O
multiple	O
forms	O
,	O
despite	O
derivation	O
from	O
a	O
single	O
gene	O
.	O

The	O
more	O
traditional	O
SERMS	O
,	O
clomiphene	O
citrate	O
and	O
tamoxifen	O
,	O
will	O
be	O
reviewed	O
along	O
with	O
such	O
modern	O
drugs	O
as	O
raloxifene	O
and	O
faslodex	O
,	O
with	O
emphasis	O
upon	O
their	O
actions	O
on	O
breast	O
,	O
uterus	O
,	O
bone	O
and	O
lipids	O
.	O

We	O
have	O
cloned	O
cDNA	O
and	O
genomic	O
DNA	O
for	O
a	O
mouse	O
gene	O
encoding	O
a	O
protein	O
with	O
significant	O
sequence	O
similarity	O
to	O
conserved	O
domains	O
found	O
in	O
proteins	O
of	O
the	O
Spo11p	B-protein
family	I-protein
.	O

If	O
E	O
.	O
coli	O
is	O
present	O
in	O
any	O
source	O
water	O
sample	O
,	O
the	O
borehole	O
and	O
any	O
directly	O
connected	O
borehole	O
should	O
be	O
embargoed	O
.	O

An	O
important	O
mechanism	O
by	O
which	O
the	O
tumor	O
suppressor	O
p53	B-protein
maintains	O
genomic	O
stability	O
is	O
to	O
induce	O
cell	O
cycle	O
arrest	O
through	O
activation	O
of	O
the	O
cyclin	B-protein
-	I-protein
dependent	I-protein
kinase	I-protein
inhibitor	I-protein
p21	I-protein
(	I-protein
WAF1	I-protein
/	I-protein
Cip1	I-protein
)	I-protein
gene	I-protein
.	O

However	O
,	O
the	O
mouse	O
has	O
previously	O
been	O
shown	O
to	O
possess	O
only	O
three	O
forms	O
of	O
ADH	B-protein
.	O

The	O
effect	O
of	O
antilymphocyte	O
sera	O
on	O
formation	O
of	O
transplantation	O
and	O
anti	O
-	O
infection	O
immunity	O
in	O
mice	O
.	O

The	O
quantity	O
of	O
each	O
population	O
(	O
L	O
.	O
bulgaricus	O
,	O
S	O
.	O
thermophilus	O
)	O
was	O
then	O
estimated	O
in	O
the	O
pellet	O
by	O
PyMS	O
,	O
and	O
the	O
data	O
were	O
analysed	O
by	O
artificial	O
neural	O
networks	O
(	O
ANNs	O
)	O
.	O

Experiments	O
on	O
narcotized	O
cats	O
demonstrated	O
that	O
the	O
derivatives	O
of	O
2	O
-	O
mercaptobenzimidazole	O
possessing	O
the	O
properties	O
of	O
specific	O
bradycardic	O
agents	O
and	O
coded	O
as	O
CM	O
-	O
251	O
,	O
CM	O
-	O
266	O
,	O
and	O
CM	O
-	O
345	O
,	O
reduce	O
the	O
mean	O
rise	O
of	O
segment	O
ST	O
on	O
numerous	O
leads	O
of	O
the	O
epicardial	O
electrogram	O
during	O
5	O
-	O
min	O
occlusion	O
of	O
the	O
anterior	O
descending	O
branch	O
of	O
the	O
left	O
coronary	O
artery	O
.	O

Ten	O
weeks	O
after	O
reconstruction	O
,	O
the	O
regenerating	O
nerves	O
already	O
resembled	O
normal	O
nerves	O
.	O

Franz	O
Schubert	O
-	O
-	O
his	O
life	O
,	O
music	O
and	O
diseases	O
.	O

The	O
emerging	O
view	O
based	O
on	O
studies	O
in	O
yeast	O
is	O
that	O
each	O
class	O
of	O
snoRNPs	B-protein
is	O
composed	O
of	O
a	O
unique	O
set	O
of	O
proteins	O
.	O

Svensson	O
et	O
al	O
.	O

This	O
study	O
suggests	O
that	O
BSPMs	O
are	O
useful	O
in	O
the	O
assessment	O
of	O
AMI	O
in	O
terms	O
of	O
diagnosis	O
,	O
location	O
and	O
extent	O
of	O
myocardial	O
infarct	O
.	O

Erratum	O
:	O
Absence	O
of	O
precursor	O
effects	O
above	O
the	O
martensitic	O
transformation	O
in	O
a	O
virgin	O
crystal	O
of	O
Li	O
metal	O
[	O
Phys	O
.	O

B	B-protein
-	I-protein
myb	I-protein
is	O
essential	O
for	O
G1	O
/	O
S	O
transition	O
and	O
has	O
been	O
shown	O
to	O
be	O
phosphorylated	O
by	O
the	O
cyclin	B-protein
A2	I-protein
/	I-protein
cdk2	I-protein
complex	I-protein
.	O

Its	O
neuromuscular	O
effects	O
are	O
similar	O
to	O
a	O
single	O
ED90	O
dose	O
of	O
vecuronium	O
.	O

The	O
hp55	B-protein
gamma	I-protein
protein	I-protein
interacts	O
strongly	O
with	O
the	O
activated	O
IGFIR	B-protein
but	O
not	O
with	O
the	O
kinase	O
-	O
negative	O
mutant	O
receptor	O
.	O
hp55	B-protein
gamma	I-protein
also	O
interacts	O
with	O
the	O
insulin	B-protein
receptor	I-protein
(	O
IR	B-protein
)	O
in	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
.	O

In	O
humans	O
,	O
four	O
AMP	B-protein
deaminase	I-protein
variants	I-protein
,	O
termed	O
M	O
(	O
muscle	O
)	O
,	O
L	O
(	O
liver	O
)	O
,	O
E1	B-protein
,	O
and	O
E2	B-protein
(	O
erythrocyte	O
)	O
can	O
be	O
distinguished	O
by	O
a	O
variety	O
of	O
biochemical	O
and	O
immunological	O
criteria	O
.	O

In	O
a	O
longitudinal	O
study	O
,	O
14	O
low	O
-	O
risk	O
fetuses	O
were	O
studied	O
at	O
2	O
-	O
week	O
intervals	O
from	O
32	O
weeks	O
of	O
gestation	O
onward	O
.	O

C	B-protein
.	I-protein
elegans	I-protein
KLP	I-protein
-	I-protein
11	I-protein
/	I-protein
OSM	I-protein
-	I-protein
3	I-protein
/	I-protein
KAP	I-protein
-	I-protein
1	I-protein
:	O
orthologs	O
of	O
the	O
sea	B-protein
urchin	I-protein
kinesin	I-protein
-	I-protein
II	I-protein
,	O
and	O
mouse	B-protein
KIF3A	I-protein
/	I-protein
KIFB	I-protein
/	I-protein
KAP3	I-protein
kinesin	I-protein
complexes	I-protein
.	O

Increase	O
in	O
blood	O
NEFA	O
was	O
further	O
augmented	O
by	O
fat	O
plus	O
AA	O
supplementation	O
,	O
but	O
no	O
changes	O
in	O
concentrations	O
of	O
Lys	O
or	O
Met	O
in	O
blood	O
were	O
found	O
.	O

Most	O
eukaryotic	O
mRNAs	O
are	O
translated	O
by	O
a	O
`	O
`	O
scanning	O
ribosome	O
'	O
'	O
mechanism	O
.	O

According	O
to	O
the	O
biochemical	O
tests	O
,	O
high	O
activity	O
(	O
over	O
200	O
U	O
/	O
l	O
)	O
of	O
alkaline	B-protein
phosphatase	I-protein
was	O
recorded	O
exclusively	O
in	O
patients	O
with	O
the	O
lymphogranulomatosis	O
-	O
induced	O
liver	O
damage	O
.	O

The	O
incidence	O
of	O
HSV	O
-	O
2	O
positive	O
subjects	O
(	O
HSV	B-protein
-	I-protein
2	I-protein
/	I-protein
HSV	I-protein
-	I-protein
1	I-protein
antibody	I-protein
ratio	O
>	O
or	O
=	O
1	O
)	O
was	O
low	O
in	O
the	O
Jewish	O
Israeli	O
population	O
,	O
compared	O
to	O
other	O
demographic	O
areas	O
.	O

The	O
sorption	O
mechanisms	O
changed	O
from	O
adsorption	O
to	O
partition	O
in	O
the	O
process	O
of	O
repetitious	O
sorption	O
.	O

According	O
to	O
their	O
staining	O
affinity	O
for	O
anti	B-protein
-	I-protein
T	I-protein
antibodies	I-protein
,	O
the	O
glandular	O
tissue	O
cells	O
were	O
classified	O
as	O
T	O
-	O
,	O
T	O
+	O
,	O
T	O
+	O
+	O
,	O
and	O
T	O
and	O
the	O
annual	O
changes	O
in	O
the	O
numbers	O
of	O
these	O
cell	O
populations	O
,	O
as	O
well	O
as	O
in	O
the	O
volume	O
occupied	O
by	O
the	O
glandular	O
tissue	O
,	O
were	O
calculated	O
.	O

Cardiac	O
preservation	O
.	O

Karger	O
AG	O
,	O
Basel	O

The	O
cloned	O
alcR	B-protein
gene	I-protein
provided	O
in	O
trans	O
restored	O
these	O
siderophore	O
system	O
activities	O
to	O
the	O
mutants	O
.	O

Study	O
of	O
bacterial	O
motility	O
and	O
rate	O
of	O
movement	O
using	O
a	O
closed	O
circuit	O
television	O
.	O

Analysis	O
of	O
lacZ	B-protein
transcriptional	I-protein
fusions	I-protein
shows	O
that	O
the	O
KdgR	B-protein
-	I-protein
binding	I-protein
sites	I-protein
negatively	O
affect	O
the	O
expression	O
of	O
rsmB	B-protein
.	O

In	O
addition	O
,	O
a	O
21	O
-	O
mer	O
subrepeat	O
structure	O
is	O
also	O
present	O
in	O
each	O
unit	O
.	O

Intravenous	O
glucose	O
tolerance	O
tests	O
were	O
performed	O
before	O
operation	O
,	O
before	O
starting	O
CyA	O
and	O
after	O
3	O
weeks	O
.	O

Modulation	O
of	O
AUUUA	B-protein
response	I-protein
element	I-protein
binding	O
by	O
heterogeneous	B-protein
nuclear	I-protein
ribonucleoprotein	I-protein
A1	I-protein
in	O
human	O
T	O
lymphocytes	O
.	O

The	O
data	O
provide	O
strong	O
evidence	O
that	O
ThlA	B-protein
is	O
involved	O
in	O
the	O
metabolism	O
of	O
both	O
acid	O
and	O
solvent	O
formation	O
,	O
whereas	O
the	O
physiological	O
function	O
of	O
ThlB	B-protein
has	O
yet	O
to	O
be	O
elucidated	O
.	O

We	O
also	O
observed	O
that	O
cell	B-protein
surface	I-protein
CD4	I-protein
(	I-protein
-	I-protein
)	I-protein
CD8	I-protein
(	I-protein
-	I-protein
)	I-protein
CD3	I-protein
(	I-protein
-	I-protein
)	I-protein
cells	O
with	O
rearranged	B-protein
TCR	I-protein
genes	I-protein
developed	O
from	O
Id3	O
-	O
transduced	O
but	O
not	O
from	O
control	O
-	O
transduced	O
pre	O
-	O
T	O
cells	O
in	O
an	O
FTOC	O
.	O

In	O
order	O
to	O
define	O
potential	O
candidate	O
genes	O
for	O
inherited	O
disorders	O
characterized	O
by	O
aberrant	O
gene	O
expression	O
,	O
we	O
utilized	O
Kruppel	B-protein
-	I-protein
related	I-protein
sequences	I-protein
to	O
isolate	O
zinc	O
finger	O
-	O
containing	O
cDNAs	O
.	O

Praziquantel	O
and	O
Albendazole	O
were	O
found	O
effective	O
in	O
the	O
treatment	O
of	O
neurocysticercosis	O
,	O
but	O
because	O
of	O
serious	O
side	O
effects	O
encountered	O
in	O
some	O
cases	O
,	O
the	O
drugs	O
should	O
be	O
used	O
cautiously	O
in	O
selected	O
cases	O
only	O
.	O

The	O
results	O
raise	O
the	O
possibility	O
that	O
pH	O
induced	O
post	O
-	O
translational	O
modifications	O
of	O
DdRPA	B-protein
are	O
involved	O
in	O
events	O
that	O
halt	O
cell	O
proliferation	O
and	O
induce	O
differentiation	O
in	O
Dictyostelium	O
.	O

At	O
different	O
times	O
of	O
the	O
surgical	O
procedures	O
(	O
thorax	O
opening	O
and	O
closure	O
,	O
period	O
of	O
cardiopulmonary	O
bypass	O
)	O
67	O
to	O
100	O
%	O
of	O
the	O
patients	O
in	O
group	O
1	O
had	O
vancomycin	O
concentrations	O
in	O
the	O
studied	O
tissues	O
above	O
the	O
MIC	O
90	O
for	O
Staphylococcus	O
aureus	O
(	O
1	O
microgram	O
/	O
g	O
)	O
and	O
Staphylococcus	O
epidermidis	O
(	O
2	O
micrograms	O
/	O
g	O
)	O
.	O

Ent	B-protein
-	I-protein
kaurene	I-protein
synthase	I-protein
from	I-protein
the	I-protein
fungus	I-protein
Phaeosphaeria	I-protein
sp	O
.	O

Data	O
Management	O
in	O
Practice	O
-	O
based	O
Research	O
.	O

The	O
incidence	O
of	O
cardiac	O
death	O
(	O
one	O
per	O
group	O
)	O
,	O
Q	O
wave	O
MI	O
(	O
propofol	O
,	O
n	O
=	O
7	O
;	O
midazolam	O
,	O
n	O
=	O
3	O
;	O
P	O
=	O
0	O
.	O
27	O
)	O
,	O
or	O
non	O
Q	O
wave	O
MI	O
(	O
propofol	O
,	O
n	O
=	O
16	O
;	O
midazolam	O
,	O
n	O
=	O
18	O
;	O
P	O
=	O
0	O
.	O
81	O
)	O
did	O
not	O
differ	O
between	O
treatment	O
groups	O
.	O

Here	O
,	O
we	O
alter	O
the	O
dimerization	O
specificity	O
of	O
Fos	B-protein
by	O
precisely	O
replacing	O
its	O
leucine	O
zipper	O
with	O
that	O
from	O
GCN4	B-protein
.	O

We	O
confirmed	O
the	O
interaction	O
between	O
TLS	B-protein
and	O
p65	B-protein
by	O
the	O
pull	O
-	O
down	O
assay	O
in	O
vitro	O
and	O
by	O
a	O
coimmunoprecipitation	O
experiment	O
followed	O
by	O
Western	O
blot	O
of	O
the	O
cultured	O
cell	O
in	O
vivo	O
.	O

The	O
cycle	O
length	O
of	O
induced	O
VT	O
(	O
n	O
=	O
10	O
VTs	O
)	O
was	O
380	O
+	O
/	O
-	O
41	O
msec	O
.	O

Nucleotide	O
sequence	O
,	O
genome	O
organization	O
and	O
phylogenetic	O
analysis	O
of	O
pineapple	O
mealybug	O
wilt	O
-	O
associated	O
virus	O
-	O
2	O
.	O

Stimulation	O
of	O
[	O
3H	O
]	O
PA	O
production	O
upon	O
CD3	B-protein
cross	O
-	O
linking	O
was	O
77	O
%	O
lower	O
in	O
permeabilized	O
CD45	B-protein
-	I-protein
cells	O
than	O
in	O
CD45	B-protein
+	I-protein
cells	O
,	O
consistent	O
with	O
the	O
reduced	O
activity	O
of	O
p59fyn	B-protein
in	O
CD45	B-protein
-	I-protein
cells	O
.	O

In	O
a	O
series	O
of	O
402	O
consecutive	O
autopsies	O
,	O
parietal	O
pleural	O
plaques	O
(	O
PP	O
)	O
were	O
found	O
in	O
68	O
individuals	O
above	O
40	O
years	O
of	O
age	O
.	O

In	O
contrast	O
,	O
high	O
COUP	B-protein
-	I-protein
TFI	I-protein
expression	O
impeded	O
the	O
neuronal	O
differentiation	O
of	O
P19	O
cells	O
induced	O
with	O
RA	O
,	O
resulting	O
in	O
cell	O
cultures	O
lacking	O
neurons	O
.	O

We	O
show	O
that	O
several	O
heme	O
-	O
responsive	O
mechanisms	O
combine	O
to	O
regulate	O
DAN	B-protein
/	I-protein
TIR	I-protein
gene	I-protein
expression	O
.	O

The	O
FFA	O
levels	O
were	O
not	O
affected	O
(	O
P	O
greater	O
than	O
.	O
1	O
)	O
by	O
meal	O
interval	O
.	O

A	O
survey	O
is	O
given	O
of	O
the	O
pharmacological	O
backgrounds	O
that	O
are	O
relevant	O
for	O
the	O
drug	O
treatment	O
of	O
essential	O
hypertension	O
in	O
the	O
elderly	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
minimal	O
requirements	O
for	O
induction	O
of	O
PEPCK	B-protein
by	O
PKA	B-protein
and	O
inhibition	O
by	O
insulin	B-protein
include	O
:	O
1	O
)	O
the	O
CREB	B-protein
activation	I-protein
domain	I-protein
,	O
2	O
)	O
the	O
PEPCK	B-protein
TATA	I-protein
sequence	I-protein
,	O
and	O
3	O
)	O
insulin	O
-	O
responsive	O
hepatoma	O
cells	O
.	O

The	O
Drosophila	B-protein
melanogaster	I-protein
Gart	I-protein
gene	I-protein
encodes	O
three	O
enzymatic	O
activities	O
in	O
the	O
pathway	O
for	O
purine	O
de	O
novo	O
synthesis	O
.	O

Unlike	O
the	O
mammalian	O
proteins	O
,	O
XFGF3	B-protein
is	O
efficiently	O
secreted	O
as	O
a	O
Mr	O
31	O
,	O
000	O
glycoprotein	O
,	O
gp31	B-protein
,	O
which	O
undergoes	O
proteolytic	O
cleavage	O
to	O
produce	O
an	O
NH2	O
-	O
terminally	O
truncated	O
product	O
,	O
gp27	B-protein
.	O

Enhancement	O
of	O
the	O
immune	O
response	O
by	O
aspecific	O
action	O
of	O
vaccine	O
additives	O
in	O
the	O
aerogenic	O
immunization	O
of	O
swine	O
against	O
swine	O
plague	O
.	O

The	O
effect	O
of	O
six	O
arginine	O
mutations	O
of	O
oxidative	O
phosphorylation	O
and	O
AAC	B-protein
expression	O
.	O

Neuregulin	B-protein
stimulates	O
ErbB2	B-protein
,	O
ErbB3	B-protein
,	O
and	O
ErbB4	B-protein
,	O
members	O
of	O
the	O
ErbB	B-protein
family	I-protein
of	O
receptor	B-protein
tyrosine	I-protein
kinases	I-protein
.	O

Furthermore	O
,	O
cpxA	B-protein
*	I-protein
mutations	O
suppress	O
the	O
toxicity	O
conferred	O
by	O
the	O
LamB	B-protein
-	I-protein
LacZ	I-protein
hybrid	I-protein
protein	I-protein
,	O
which	O
exerts	O
its	O
effects	O
in	O
the	O
cytoplasm	O
,	O
sequestered	O
from	O
DegP	B-protein
.	O

They	O
include	O
genes	O
encoding	O
three	O
subunits	O
of	O
the	O
cytochrome	B-protein
oxidase	I-protein
(	O
cox1	B-protein
to	I-protein
3	I-protein
)	O
,	O
apocytochrome	B-protein
b	I-protein
(	O
cob	B-protein
)	O
,	O
seven	O
subunits	O
of	O
the	O
NADH	B-protein
dehydrogenase	I-protein
complex	I-protein
(	O
nad1	B-protein
to	I-protein
6	I-protein
,	O
nad4L	B-protein
)	O
,	O
two	O
ATPase	B-protein
subunits	O
(	O
atp6	B-protein
and	O
atp9	B-protein
)	O
,	O
three	O
ribosomal	O
RNAs	O
(	O
rrn5	B-protein
,	O
srn	B-protein
and	O
lrn	B-protein
)	O
,	O
23	O
tRNAs	O
and	O
four	O
ribosomal	B-protein
proteins	I-protein
(	O
rps3	B-protein
,	O
rps11	B-protein
,	O
rps12	B-protein
and	O
rpl16	B-protein
)	O
.	O

OUTCOME	O
:	O
Acetylcholine	B-protein
receptor	I-protein
antibodies	I-protein
and	O
single	O
-	O
fibre	O
electromyogram	O
were	O
useful	O
in	O
the	O
diagnosis	O
of	O
myasthenia	O
gravis	O
.	O

In	O
the	O
PMR	O
target	O
area	O
but	O
not	O
in	O
the	O
nontreated	O
area	O
an	O
improvement	O
in	O
regional	O
myocardial	O
flow	O
reserve	O
occurs	O
in	O
wall	O
segments	O
with	O
initially	O
severely	O
or	O
moderately	O
reduced	O
stress	O
perfusion	O
.	O

Blood	O
eosinophils	O
in	O
patients	O
with	O
Taenia	O
saginata	O
taeniasis	O
.	O

Our	O
results	O
suggest	O
that	O
WASP	B-protein
activates	O
transcription	O
following	O
TCR	B-protein
stimulation	O
in	O
a	O
manner	O
that	O
is	O
independent	O
of	O
its	O
role	O
in	O
Arp2	B-protein
/	O
3	O
-	O
directed	O
actin	B-protein
polymerization	O
.	O

O2	O
and	O
CO2	O
in	O
the	O
tracheostomy	O
tube	O
were	O
continuously	O
monitored	O
by	O
mass	O
spectrometry	O
using	O
a	O
special	O
sample	O
-	O
hold	O
phase	O
-	O
locked	O
sampling	O
technique	O
.	O

Removal	O
of	O
the	O
carboxyl	O
region	O
severely	O
reduced	O
transcriptional	O
activation	O
.	O

Using	O
a	O
3	O
'	O
-	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
strategy	O
,	O
we	O
have	O
cloned	O
cDNAs	O
representing	O
the	O
3	O
'	O
-	O
termini	O
of	O
both	O
the	O
native	O
and	O
mutant	O
transcripts	O
from	O
both	O
P388	O
/	O
ADR	O
/	O
3	O
and	O
P388	O
/	O
ADR	O
/	O
7	O
cells	O
.	O

Mutations	O
at	O
three	O
sites	O
have	O
larger	O
effects	O
in	O
muscle	O
than	O
nonmuscle	O
cells	O
;	O
an	O
A	O
/	O
T	O
-	O
rich	O
site	O
mutation	O
has	O
a	O
pronounced	O
effect	O
in	O
both	O
striated	O
muscle	O
types	O
,	O
mutations	O
at	O
the	O
MEF1	B-protein
(	I-protein
Right	I-protein
E	I-protein
-	I-protein
box	I-protein
)	I-protein
site	I-protein
are	O
relatively	O
specific	O
to	O
expression	O
in	O
skeletal	O
muscle	O
,	O
and	O
mutations	O
at	O
the	O
CArG	O
site	O
are	O
relatively	O
specific	O
to	O
expression	O
in	O
cardiac	O
muscle	O
.	O

Therefore	O
,	O
in	O
our	O
in	O
vitro	O
model	O
,	O
the	O
localization	O
of	O
the	O
mutation	O
in	O
the	O
K	B-protein
-	I-protein
ras	I-protein
gene	I-protein
predisposes	O
to	O
a	O
different	O
level	O
of	O
aggressiveness	O
in	O
the	O
transforming	O
phenotype	O
.	O

Induction	O
of	O
anaesthesia	O
was	O
standardised	O
:	O
fentanyl	O
(	O
3	O
micrograms	O
/	O
kg	O
)	O
,	O
thiopentone	O
(	O
5	O
mg	O
/	O
kg	O
)	O
,	O
atracurium	O
(	O
0	O
.	O
4	O
mg	O
/	O
kg	O
)	O
.	O

In	O
on	O
-	O
going	O
screening	O
programmes	O
,	O
the	O
Haemoccult	O
test	O
consists	O
of	O
six	O
slides	O
and	O
a	O
test	O
is	O
considered	O
positive	O
if	O
at	O
least	O
one	O
slide	O
is	O
coloured	O
.	O

The	O
results	O
obtained	O
were	O
as	O
follows	O
:	O
The	O
mitral	O
valve	O
orifice	O
area	O
(	O
MVA	O
)	O
was	O
significantly	O
smaller	O
in	O
patients	O
with	O
type	O
III	O
of	O
the	O
LVIT	O
flow	O
velocity	O
pattern	O
than	O
in	O
patients	O
with	O
type	O
I	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Our	O
data	O
indicate	O
that	O
SIP1	B-protein
is	O
required	O
to	O
confine	O
XBra	B-protein
gene	I-protein
expression	O
to	O
the	O
mesoderm	O
.	O

Menstrual	O
-	O
cycle	O
phase	O
did	O
not	O
significantly	O
affect	O
personality	O
variables	O
in	O
either	O
group	O
.	O

Administration	O
of	O
anticoagulants	O
,	O
i	O
.	O
e	O
.	O
,	O
heparin	O
,	O
prostaglandin	O
E1	O
and	O
ticlopidine	O
seems	O
to	O
be	O
effective	O
in	O
alleviating	O
symptoms	O
and	O
might	O
prevent	O
further	O
deterioration	O
.	O

Both	O
tear	O
volume	O
and	O
tear	O
flow	O
were	O
found	O
to	O
be	O
significantly	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
decreased	O
up	O
to	O
6	O
h	O
after	O
instillation	O
,	O
reaching	O
a	O
minimum	O
90	O
min	O
after	O
application	O
(	O
tear	O
volume	O
:	O
-	O
63	O
%	O
;	O
tear	O
flow	O
:	O
-	O
71	O
%	O
)	O
.	O

Experimental	O
reproduction	O
of	O
malignant	O
catarrhal	O
fever	O
in	O
Bali	O
cattle	O
.	O

Deletion	O
analysis	O
was	O
carried	O
out	O
within	O
a	O
part	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
showing	O
homology	O
to	O
the	O
upstream	O
region	O
of	O
the	O
yeast	B-protein
CYC1	I-protein
gene	I-protein
.	O

Class	B-protein
I	I-protein
alpha1	I-protein
,	I-protein
2	I-protein
-	I-protein
mannosidases	I-protein
play	O
an	O
essential	O
role	O
in	O
the	O
elaboration	O
of	O
complex	O
and	O
hybrid	O
N	O
-	O
glycans	O
in	O
mammalian	O
cells	O
.	O

Recent	O
developments	O
in	O
drugs	O
antagonistic	O
to	O
factors	O
causing	O
peptic	O
ulcer	O
-	O
-	O
clinical	O
efficacy	O
and	O
problems	O
;	O
gastrin	B-protein
receptor	I-protein
blockaders	O
.	O

SCOB	O
testing	O
of	O
food	O
-	O
restricted	O
animals	O
,	O
using	O
a	O
multiple	O
fixed	O
ratio	O
(	O
FR	O
)	O
/	O
fixed	O
interval	O
(	O
FI	O
)	O
schedule	O
(	O
FR20	O
:	O
FI120	O
)	O
,	O
was	O
conducted	O
prior	O
to	O
each	O
exposure	O
to	O
maintain	O
the	O
operant	O
behavior	O
;	O
the	O
data	O
from	O
Weeks	O
-	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
13	O
were	O
evaluated	O
for	O
evidence	O
of	O
neurotoxicity	O
.	O

Two	O
overlapping	O
clones	O
contained	O
the	O
complete	O
Adh	B-protein
-	I-protein
2	I-protein
gene	I-protein
composed	O
of	O
nine	O
exons	O
in	O
a	O
12	O
-	O
kb	O
region	O
,	O
with	O
the	O
placement	O
of	O
introns	O
matching	O
that	O
observed	O
in	O
other	O
mammalian	B-protein
ADH	I-protein
genes	I-protein
.	O

The	O
strong	O
conservation	O
of	O
the	O
inverted	O
terminal	O
repeat	O
sequence	O
may	O
reflect	O
a	O
common	O
integration	O
mechanism	O
for	O
VL30	B-protein
elements	I-protein
and	O
MuLV	O
proviruses	O
.	O

A	O
method	O
of	O
three	O
-	O
station	O
three	O
-	O
dimensional	O
magnetic	O
resonance	O
(	O
MR	O
)	O
angiography	O
of	O
the	O
lower	O
extremities	O
with	O
segmented	O
volume	O
acquisition	O
is	O
presented	O
.	O

The	O
presence	O
of	O
unidentified	O
macroscopic	O
or	O
microscopic	O
clusters	O
of	O
neoplastic	O
cells	O
,	O
lying	O
around	O
,	O
more	O
or	O
less	O
close	O
to	O
,	O
the	O
line	O
of	O
insertion	O
of	O
lesion	O
,	O
could	O
render	O
any	O
attempt	O
to	O
gain	O
a	O
`	O
`	O
radical	O
'	O
'	O
excision	O
useless	O
.	O

Psychological	O
examinations	O
in	O
patients	O
with	O
chronic	O
kidney	O
insufficiency	O
.	O

After	O
the	O
first	O
cycle	O
,	O
18	O
cases	O
were	O
treated	O
at	O
dose	O
level	O
1	O
,	O
after	O
a	O
second	O
cycle	O
,	O
13	O
cases	O
were	O
treated	O
at	O
dose	O
level	O
2	O
.	O

Their	O
hydropathic	O
plots	O
are	O
very	O
similar	O
and	O
both	O
possess	O
three	O
hydrophobic	O
segments	O
that	O
are	O
likely	O
alpha	O
-	O
helical	O
transmembrane	O
segments	O
.	O

We	O
propose	O
that	O
Mnt	B-protein
:	O
Max	B-protein
:	O
Sin3	B-protein
complexes	O
normally	O
function	O
to	O
restrict	O
Myc	B-protein
:	O
Max	B-protein
activities	O
associated	O
with	O
cell	O
proliferation	O
.	O

We	O
recently	O
characterized	O
a	O
single	O
yeast	B-protein
hnRNP	I-protein
methyltransferase	I-protein
(	O
HMT1	B-protein
)	O
.	O

Complexes	O
of	O
qTBP42	B-protein
with	O
each	O
complementary	O
strand	O
of	O
telomeric	O
DNA	O
and	O
with	O
quadruplex	O
forms	O
of	O
the	O
guanine	O
-	O
rich	O
strand	O
had	O
3	O
.	O
7	O
-	O
14	O
.	O
6	O
nM	O
dissociation	O
constants	O
,	O
Kd	O
,	O
whereas	O
complexes	O
with	O
double	O
-	O
stranded	O
telomeric	O
DNA	O
had	O
up	O
to	O
100	O
-	O
fold	O
higher	O
Kd	O
values	O
.	O

Between	O
the	O
subgroups	O
of	O
dementia	O
disorders	O
there	O
were	O
no	O
significant	O
differences	O
in	O
basal	O
cortisol	O
levels	O
.	O

Certain	O
characteristics	O
of	O
eye	O
changes	O
in	O
patients	O
with	O
pheochromocytoma	O
including	O
Sipple	O
'	O
s	O
syndrome	O
.	O

Proteomic	O
patterns	O
of	O
nipple	O
aspirate	O
fluids	O
obtained	O
by	O
SELDI	O
-	O
TOF	O
:	O
potential	O
for	O
new	O
biomarkers	O
to	O
aid	O
in	O
the	O
diagnosis	O
of	O
breast	O
cancer	O
.	O

An	O
intact	O
5	O
.	O
7	O
-	O
kb	O
provirus	O
of	O
the	O
avian	O
erythroblastosis	O
virus	O
E26	O
has	O
been	O
molecularly	O
cloned	O
for	O
comparisons	O
with	O
avian	O
myeloblastosis	O
virus	O
(	O
AMV	O
)	O
and	O
other	O
avian	O
tumor	O
viruses	O
.	O

RESULTS	O
:	O
For	O
E1	O
,	O
itraconazole	O
plasma	O
drug	O
concentration	O
extrapolated	O
to	O
time	O
zero	O
(	O
IV	O
dose	O
)	O
was	O
5	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
4	O
micrograms	O
/	O
ml	O
,	O
and	O
mean	O
residence	O
time	O
(	O
MRT	O
)	O
was	O
37	O
+	O
/	O
-	O
16	O
hours	O
.	O

It	O
was	O
shown	O
that	O
administration	O
of	O
immunomodulator	O
neurotropin	B-protein
(	O
NSP	B-protein
)	O
results	O
in	O
more	O
steady	O
consolidation	O
and	O
retention	O
of	O
feeding	O
and	O
avoidance	O
behavior	O
,	O
and	O
some	O
neurophysiological	O
mechanisms	O
of	O
that	O
phenomena	O
were	O
revealed	O
.	O

Intriguingly	O
,	O
three	O
hypomorphic	O
Scm	B-protein
mutations	O
,	O
which	O
map	O
within	O
an	O
mbt	B-protein
repeat	I-protein
,	O
interact	O
with	O
PcG	B-protein
mutations	I-protein
more	O
strongly	O
than	O
do	O
Scm	B-protein
null	O
alleles	O
.	O

Dynamic	O
decision	O
making	O
:	O
human	O
control	O
of	O
complex	O
systems	O
.	O

Autopsy	O
demonstrated	O
good	O
survival	O
of	O
the	O
transplanted	O
cells	O
with	O
good	O
integration	O
with	O
the	O
brain	O
of	O
the	O
recipient	O
and	O
traces	O
of	O
positive	O
immunocytochemical	O
reaction	O
for	O
tyrosine	B-protein
hydroxylase	I-protein
.	O

After	O
profound	O
normovolemic	O
hemodilution	O
(	O
Hct	O
9	O
%	O
)	O
superiority	O
of	O
LV	O
MC	O
and	O
LV	O
diastolic	O
properties	O
was	O
found	O
,	O
when	O
myocardial	O
oxygenation	O
was	O
supported	O
by	O
i	O
.	O
v	O
.	O
perflubron	O
emulsion	O
,	O
a	O
temporary	O
O2	O
carrier	O
.	O

The	O
inner	O
ears	O
were	O
exposed	O
by	O
microdissection	O
,	O
and	O
the	O
vestibular	O
sensory	O
regions	O
were	O
either	O
sectioned	O
and	O
studied	O
with	O
light	O
or	O
electron	O
microscopy	O
,	O
or	O
prepared	O
and	O
studied	O
with	O
the	O
surface	O
specimen	O
technique	O
.	O

The	O
domain	O
structure	O
of	O
bovine	B-protein
LTBP	I-protein
-	I-protein
2	I-protein
is	O
very	O
similar	O
to	O
that	O
of	O
the	O
human	B-protein
LTBP	I-protein
-	I-protein
2	I-protein
,	O
containing	O
20	O
examples	O
of	O
6	O
-	O
cysteine	O
epidermal	B-protein
growth	I-protein
factor	I-protein
-	I-protein
like	I-protein
repeats	I-protein
,	O
16	O
of	O
which	O
have	O
the	O
consensus	O
sequence	O
for	O
calcium	O
binding	O
,	O
together	O
with	O
4	O
examples	O
of	O
8	B-protein
-	I-protein
cysteine	I-protein
motifs	I-protein
characteristic	O
of	O
fibrillins	B-protein
and	O
LTBP	B-protein
-	I-protein
1	I-protein
.	O

Stat	B-protein
activation	O
in	O
response	O
to	O
GH	B-protein
and	O
IL	B-protein
-	I-protein
6	I-protein
was	O
determined	O
by	O
reporter	O
gene	O
induction	O
.	O

During	O
early	O
neurogenesis	O
,	O
Vnd	B-protein
protein	I-protein
is	O
restricted	O
to	O
ventral	O
column	O
neuroectoderm	O
and	O
neuroblasts	O
;	O
later	O
it	O
is	O
detected	O
in	O
a	O
complex	O
pattern	O
of	O
neurons	O
.	O

The	O
median	O
post	O
-	O
treatment	O
,	O
pre	O
-	O
operative	O
serum	B-protein
PSA	I-protein
was	O
0	O
.	O
4	O
ng	O
/	O
ml	O
.	O

Thus	O
,	O
despite	O
the	O
potential	O
for	O
common	O
regulatory	O
mechanisms	O
,	O
the	O
available	O
evidence	O
indicates	O
that	O
the	O
Mtx	B-protein
minimal	I-protein
promoter	I-protein
does	O
not	O
significantly	O
affect	O
Thbs3	B-protein
gene	I-protein
expression	O
.	O

Phosphatidylinositol	B-protein
3	I-protein
-	I-protein
kinase	I-protein
potentiates	O
,	O
but	O
does	O
not	O
trigger	O
,	O
T	O
cell	O
proliferation	O
mediated	O
by	O
the	O
IL	B-protein
-	I-protein
2	I-protein
receptor	I-protein
.	O

Value	O
of	O
the	O
EMG	O
in	O
the	O
diagnosis	O
of	O
a	O
cardiomyopathy	O
associated	O
with	O
a	O
myotonic	O
myopathy	O
.	O

As	O
a	O
result	O
of	O
alternative	O
splicing	O
,	O
the	O
BGP	B-protein
gene	I-protein
is	O
transcribed	O
into	O
at	O
least	O
seven	O
distinct	O
mRNA	O
species	O
.	O

Three	O
different	O
site	O
-	O
directed	O
mutations	O
of	O
the	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element	I-protein
each	O
reduced	O
the	O
nerve	B-protein
growth	I-protein
factor	I-protein
effect	O
by	O
>	O
90	O
%	O
.	O

Significant	O
GMBF	O
reductions	O
occurred	O
in	O
early	O
shock	O
in	O
both	O
treatment	O
groups	O
.	O

HBB	O
concentration	O
in	O
the	O
fetuses	O
indicated	O
little	O
,	O
if	O
any	O
accumulation	O
.	O

SPP	B-protein
also	O
induced	O
transient	O
tyrosine	O
phosphorylation	O
of	O
focal	B-protein
adhesion	I-protein
kinase	I-protein
(	O
p125	B-protein
(	I-protein
FAK	I-protein
)	I-protein
)	O
,	O
a	O
cytosolic	B-protein
tyrosine	I-protein
kinase	I-protein
that	O
localizes	O
in	O
focal	O
adhesions	O
,	O
and	O
of	O
the	O
cytoskeleton	B-protein
-	I-protein
associated	I-protein
protein	I-protein
paxillin	I-protein
.	O

Changes	O
induced	O
in	O
the	O
gills	O
of	O
milkfish	O
(	O
Chanos	O
chanos	O
Forsskal	O
)	O
fingerlings	O
after	O
acute	O
exposure	O
to	O
nifurpirinol	O
(	O
Furanace	O
;	O
P	O
-	O
7138	O
)	O
.	O

In	O
agreement	O
with	O
these	O
data	O
,	O
western	O
blot	O
experiments	O
using	O
an	O
antibody	O
directed	O
against	O
the	O
carboxy	O
-	O
terminal	O
portion	O
of	O
the	O
mouse	O
c	B-protein
-	I-protein
kit	I-protein
protein	I-protein
showed	O
that	O
a	O
polypeptide	O
,	O
of	O
the	O
size	O
predicted	O
by	O
the	O
open	O
reading	O
frame	O
of	O
the	O
spermatid	B-protein
-	I-protein
specific	I-protein
c	I-protein
-	I-protein
kit	I-protein
cDNA	I-protein
,	O
accumulates	O
in	O
the	O
latest	O
stages	O
of	O
spermatogenesis	O
and	O
in	O
epididymal	O
spermatozoa	O
.	O

Both	O
the	O
presence	O
of	O
arginine	O
and	O
anaerobiosis	O
are	O
needed	O
to	O
trigger	O
induction	O
of	O
the	O
pathway	O
.	O

The	O
relatively	O
mild	O
defects	O
observed	O
in	O
Rpd3	B-protein
mutants	I-protein
suggest	O
that	O
the	O
recently	O
identified	O
Groucho	B-protein
and	O
dCtBP	B-protein
corepressor	I-protein
proteins	I-protein
do	O
not	O
function	O
solely	O
through	O
the	O
recruitment	O
of	O
histone	B-protein
deacetylases	I-protein
.	O

Nonreturn	O
rates	O
can	O
be	O
used	O
to	O
derive	O
more	O
elementary	O
biological	O
measures	O
for	O
reproductive	O
efficiency	O
,	O
such	O
as	O
conception	O
rate	O
and	O
calving	O
rate	O
,	O
which	O
separately	O
might	O
be	O
more	O
reliable	O
than	O
nonreturn	O
rate	O
itself	O
to	O
evaluate	O
the	O
fertility	O
of	O
a	O
bull	O
or	O
the	O
performance	O
of	O
an	O
AI	O
technician	O
.	O

Waves	O
N1	O
,	O
P3	O
and	O
CNV	O
were	O
recorded	O
during	O
a	O
CNV	O
paradigm	O
in	O
a	O
simple	O
reaction	O
time	O
task	O
with	O
a	O
constant	O
interstimulus	O
interval	O
(	O
ISI	O
)	O
of	O
1	O
sec	O
.	O

In	O
the	O
B6	O
-	O
derived	O
Db	B-protein
mutant	I-protein
B6	I-protein
.	I-protein
CH	I-protein
-	I-protein
2bm13	I-protein
(	I-protein
bm13	I-protein
)	I-protein
strain	O
,	O
part	O
of	O
the	O
class	B-protein
I	I-protein
Db	I-protein
antigen	I-protein
-	I-protein
presenting	I-protein
groove	I-protein
is	O
shaped	O
by	O
a	O
class	B-protein
I	I-protein
Kb	I-protein
-	I-protein
encoded	I-protein
sequence	I-protein
.	O

The	O
stability	O
of	O
isoniazid	O
solutions	O
increases	O
markedly	O
with	O
increasing	O
NTA	O
or	O
EDTA	O
concentration	O
up	O
to	O
1	O
mmol	O
/	O
l	O
.	O

The	O
dynamic	O
properties	O
of	O
this	O
protein	O
fragment	O
were	O
measured	O
and	O
analyzed	O
using	O
both	O
isotropic	O
and	O
anisotropic	O
models	O
of	O
molecular	O
motion	O
.	O

The	O
original	O
technique	O
was	O
developed	O
in	O
the	O
1960	O
'	O
s	O
to	O
analyze	O
the	O
inner	O
ear	O
fluid	O
as	O
a	O
diagnostic	O
procedure	O
(	O
i	O
.	O
e	O
.	O
,	O
diagnostic	O
labyrinthotomy	O
)	O
in	O
acoustic	O
neuroma	O
suspects	O
.	O

This	O
study	O
utilizes	O
the	O
mammalian	O
two	O
-	O
hybrid	O
system	O
to	O
examine	O
the	O
role	O
of	O
ligand	O
in	O
the	O
dimerization	O
of	O
human	B-protein
progesterone	I-protein
receptor	I-protein
(	O
hPR	B-protein
)	O
.	O

No	O
mutation	O
of	O
the	O
NRL	B-protein
gene	I-protein
was	O
found	O
in	O
any	O
of	O
the	O
two	O
families	O
.	O

Several	O
distinct	O
apoptotic	O
stimuli	O
induce	O
the	O
expression	O
and	O
caspase	O
-	O
dependent	O
cleavage	O
of	O
hTAF	B-protein
(	I-protein
II	I-protein
)	I-protein
80	I-protein
delta	I-protein
.	O
hTAF	B-protein
(	I-protein
II	I-protein
)	I-protein
80	I-protein
delta	I-protein
,	O
unlike	O
hTAF	B-protein
(	I-protein
II	I-protein
)	I-protein
80	I-protein
,	O
forms	O
a	O
TFIID	B-protein
-	I-protein
like	I-protein
complex	I-protein
lacking	O
hTAF	B-protein
(	I-protein
II	I-protein
)	I-protein
31	I-protein
.	O

A	O
computed	O
tomographic	O
scan	O
obtained	O
after	O
EOE	O
-	O
13	O
infusion	O
accurately	O
showed	O
the	O
perfusion	O
pattern	O
of	O
the	O
implanted	O
catheter	O
.	O

Therefore	O
,	O
in	O
conjunction	O
with	O
a	O
positive	O
pregnancy	O
test	O
and	O
the	O
patient	O
'	O
s	O
clinical	O
history	O
,	O
a	O
severely	O
depressed	O
or	O
absent	O
serum	O
PAPP	B-protein
-	I-protein
A	I-protein
level	O
may	O
aid	O
in	O
the	O
diagnosis	O
of	O
extrauterine	O
pregnancy	O
.	O

Aneurysmal	O
bone	O
cyst	O
of	O
the	O
jaws	O
:	O
analysis	O
of	O
11	O
cases	O
.	O

However	O
,	O
the	O
a1	B-protein
isoform	I-protein
is	O
expressed	O
most	O
heavily	O
in	O
brain	O
and	O
heart	O
,	O
a2	B-protein
in	O
liver	O
and	O
kidney	O
,	O
and	O
a3	B-protein
in	O
liver	O
,	O
lung	O
,	O
heart	O
,	O
brain	O
,	O
spleen	O
,	O
and	O
kidney	O
.	O

The	O
R2	B-protein
region	I-protein
within	O
the	O
class	B-protein
I	I-protein
enhancer	I-protein
acts	O
as	O
a	O
negative	O
element	O
in	O
Ad12	O
-	O
transformed	O
cells	O
and	O
exhibits	O
a	O
stronger	O
binding	O
activity	O
than	O
is	O
observed	O
in	O
nontumorigenic	O
Ad5	O
-	O
transformed	O
cells	O
,	O
which	O
are	O
not	O
reduced	O
in	O
class	B-protein
I	I-protein
expression	O
.	O

Diverse	O
endogenous	O
light	O
chains	O
contribute	O
to	O
basement	O
membrane	O
reactivity	O
in	O
nonautoimmune	O
mice	O
transgenic	O
for	O
an	O
anti	B-protein
-	I-protein
laminin	I-protein
Ig	I-protein
heavy	I-protein
chain	I-protein
.	O

UF	O
-	O
021	O
ophthalmic	O
solution	O
(	O
0	O
.	O
03	O
to	O
0	O
.	O
24	O
%	O
)	O
,	O
when	O
topically	O
applied	O
to	O
the	O
eyes	O
of	O
rabbits	O
,	O
caused	O
dose	O
-	O
dependent	O
IOP	O
reduction	O
(	O
2	O
.	O
8	O
to	O
5	O
.	O
2	O
mmHg	O
)	O
,	O
without	O
transient	O
IOP	O
rise	O
.	O

This	O
slope	O
tended	O
to	O
be	O
higher	O
(	O
approximately	O
1	O
.	O
6	O
dB	O
/	O
dB	O
)	O
for	O
L1	O
=	O
L2	O
greater	O
than	O
80	O
dB	O
.	O

Another	O
stem	O
-	O
loop	O
called	O
structure	O
III	O
near	O
the	O
3	O
'	O
-	O
end	O
of	O
repY	B-protein
sequesters	O
both	O
the	O
5	B-protein
'	I-protein
-	I-protein
rCGCC	I-protein
-	I-protein
3	I-protein
'	I-protein
sequence	I-protein
and	O
the	O
repZ	B-protein
ribosome	I-protein
-	I-protein
binding	I-protein
site	I-protein
.	O

We	O
further	O
studied	O
the	O
effects	O
of	O
SIE	B-protein
-	I-protein
1	I-protein
hypermethylation	O
on	O
p21WAF1	B-protein
induction	O
by	O
STAT	B-protein
activation	O
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
-	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
,	O
a	O
proinflammatory	O
cytokine	O
,	O
inhibits	O
cAMP	O
-	O
stimulated	O
testosterone	O
production	O
in	O
mouse	O
Leydig	O
cells	O
.	O

To	O
explore	O
the	O
functional	O
properties	O
of	O
the	O
protein	O
encoded	O
by	O
neu	B-protein
,	O
we	O
created	O
a	O
fusion	O
gene	O
that	O
joins	O
the	O
cytoplasmic	O
domain	O
of	O
neu	B-protein
to	O
the	O
extracellular	O
portion	O
of	O
an	O
immunoglobulin	B-protein
heavy	I-protein
chain	I-protein
.	O

Dermal	O
toxicity	O
and	O
carcinogenicity	O
of	O
4	O
-	O
vinyl	O
-	O
1	O
-	O
cyclohexene	O
diepoxide	O
in	O
Fischer	O
rats	O
and	O
B6C3F1	O
mice	O
.	O

Radiogallium	O
imaging	O
is	O
thus	O
of	O
limited	O
use	O
in	O
evaluation	O
of	O
suspected	O
giant	O
cell	O
tumors	O
of	O
bone	O
.	O

In	O
vivo	O
epiluminescence	O
microscopy	O
of	O
pigmented	O
skin	O
lesions	O
.	O

Here	O
we	O
localize	O
a	O
transferable	O
40	O
-	O
amino	O
acid	O
region	O
within	O
the	O
LBDs	B-protein
of	O
RXR	B-protein
,	O
RAR	B-protein
,	O
TR	B-protein
,	O
and	O
chicken	B-protein
ovalbumin	I-protein
upstream	I-protein
promoter	I-protein
transcription	I-protein
factor	I-protein
that	O
is	O
critical	O
for	O
determining	O
identity	O
in	O
the	O
heterodimeric	O
interaction	O
and	O
for	O
high	O
-	O
affinity	O
DNA	O
binding	O
.	O

Recently	O
,	O
the	O
3	B-protein
.	I-protein
6	I-protein
-	I-protein
kb	I-protein
full	I-protein
-	I-protein
length	I-protein
alpha	I-protein
-	I-protein
GalNAc	I-protein
cDNA	I-protein
sequence	I-protein
was	O
isolated	O
and	O
found	O
to	O
have	O
remarkable	O
nucleotide	O
and	O
predicted	O
amino	O
acid	O
homology	O
(	O
55	O
.	O
8	O
and	O
46	O
.	O
9	O
%	O
,	O
respectively	O
)	O
with	O
the	O
human	B-protein
alpha	I-protein
-	I-protein
galactosidase	I-protein
A	I-protein
(	O
alpha	B-protein
-	I-protein
Gal	I-protein
A	I-protein
)	O
cDNA	O
.	O

Re	O
-	O
examination	O
of	O
the	O
ED01	O
study	O
.	O

In	O
the	O
treatment	O
of	O
opioid	O
naive	O
patients	O
who	O
underwent	O
surgery	O
and	O
received	O
opioids	O
for	O
acute	O
pain	O
,	O
oral	O
ADL	O
8	O
-	O
2698	O
(	O
6	O
.	O
0	O
mg	O
)	O
improved	O
the	O
management	O
of	O
postoperative	O
ileus	O
(	O
POI	O
)	O
by	O
shortening	O
the	O
time	O
to	O
achieve	O
normal	O
bowel	O
function	O
and	O
,	O
ultimately	O
,	O
hospital	O
stay	O
.	O

Latanoprost	O
produces	O
an	O
additional	O
reduction	O
of	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
when	O
used	O
in	O
combination	O
with	O
timolol	O
,	O
pilocarpine	O
,	O
acetazolamide	O
and	O
dipivefrin	O
.	O

The	O
inhibitory	O
response	O
to	O
taps	O
is	O
essentially	O
a	O
protective	O
reflex	O
which	O
probably	O
serves	O
to	O
reduce	O
the	O
activity	O
of	O
the	O
jaw	O
-	O
closing	O
muscles	O
when	O
one	O
bites	O
unexpectedly	O
on	O
hard	O
objects	O
.	O

A	O
flow	O
rate	O
of	O
at	O
least	O
5	O
mL	O
/	O
h	O
is	O
required	O
through	O
the	O
receptor	O
(	O
volume	O
,	O
0	O
.	O
4	O
mL	O
)	O
for	O
accurate	O
results	O
.	O

We	O
conclude	O
that	O
Hansel	O
'	O
s	O
stain	O
substantially	O
improves	O
the	O
recognition	O
of	O
eosinophiluria	O
as	O
compared	O
with	O
Wright	O
'	O
s	O
stain	O
.	O

These	O
changes	O
in	O
virus	O
entry	O
features	O
may	O
result	O
in	O
coronaviruses	O
with	O
novel	O
pathogenic	O
properties	O
.	O

Allelic	O
variation	O
in	O
HLA	B-protein
-	I-protein
B	I-protein
and	O
HLA	B-protein
-	I-protein
C	I-protein
sequences	I-protein
and	O
the	O
evolution	O
of	O
the	O
HLA	B-protein
-	I-protein
B	I-protein
alleles	I-protein
.	O

Nephrectomy	O
applied	O
to	O
cattle	O
.	O

Structure	O
and	O
localization	O
of	O
the	O
human	B-protein
gene	I-protein
encoding	I-protein
SR	I-protein
-	I-protein
BI	I-protein
/	I-protein
CLA	I-protein
-	I-protein
1	I-protein
.	O

We	O
cloned	O
and	O
sequenced	O
the	O
cDNAs	O
against	O
genomic	O
RNA	O
and	O
mRNA	O
for	O
phosphoprotein	O
(	O
P	O
)	O
of	O
human	O
parainfluenza	O
type	O
2	O
virus	O
(	O
PIV	O
-	O
2	O
)	O
.	O
cDNA	O
clone	O
from	O
genomic	O
RNA	O
was	O
1439	O
nucleotides	O
in	O
length	O
excluding	O
poly	O
(	O
A	O
)	O
and	O
was	O
found	O
to	O
have	O
two	O
small	O
open	O
reading	O
frames	O
encoding	O
proteins	O
of	O
233	O
and	O
249	O
amino	O
acids	O
.	O

Also	O
,	O
samples	O
of	O
serum	O
were	O
absorbed	O
with	O
the	O
various	O
solid	O
-	O
phase	O
allergens	O
and	O
the	O
reactivity	O
of	O
the	O
remaining	O
IgE	B-protein
antibodies	I-protein
was	O
determined	O
.	O

This	O
study	O
demonstrates	O
that	O
alteration	O
of	O
CDKN2	B-protein
is	O
one	O
of	O
the	O
most	O
frequent	O
genetic	O
abnormalities	O
in	O
prostate	O
cancer	O
and	O
may	O
contribute	O
to	O
prostate	O
carcinogenesis	O
.	O

The	O
chick	O
axon	O
-	O
associated	O
surface	O
glycoprotein	O
neurofascin	B-protein
is	O
implicated	O
in	O
axonal	O
growth	O
and	O
fasciculation	O
as	O
revealed	O
by	O
antibody	O
perturbation	O
experiments	O
.	O

The	O
unilateral	O
vestibular	O
hypofunction	O
.	O

The	O
lysozyme	B-protein
FEF	I-protein
site	I-protein
is	O
immediately	O
5	O
'	O
to	O
a	O
PU	B-protein
.	O

The	O
authors	O
have	O
tested	O
the	O
interference	O
of	O
the	O
hemoglobin	B-protein
by	O
two	O
routine	O
methods	O
(	O
Berthelot	O
classic	O
and	O
Berthelot	O
modified	O
)	O
for	O
the	O
determination	O
of	O
plasmatic	O
urea	O
.	O

The	O
nit	B-protein
-	I-protein
3	I-protein
gene	I-protein
of	I-protein
the	I-protein
filamentous	I-protein
fungus	I-protein
Neurospora	I-protein
crassa	I-protein
encodes	O
nitrate	B-protein
reductase	I-protein
,	O
the	O
enzyme	O
which	O
catalyzes	O
the	O
first	O
step	O
in	O
nitrate	O
assimilation	O
.	O

GAL4	O
-	O
VP16	O
-	O
mediated	O
antirepression	O
required	O
an	O
auxiliary	O
factor	O
,	O
denoted	O
as	O
a	O
co	O
-	O
antirepressor	O
,	O
which	O
was	O
partially	O
purified	O
from	O
Drosophila	O
embryos	O
.	O

A	O
consensus	O
binding	O
site	O
for	O
the	O
transcription	O
factor	O
SP1	B-protein
was	O
identified	O
in	O
intron	O
As	O
downstream	O
of	O
the	O
proenkephalin	B-protein
germ	I-protein
cell	I-protein
cap	I-protein
site	I-protein
region	I-protein
.	O

The	O
isolation	O
of	O
this	O
gene	O
was	O
based	O
on	O
the	O
identification	O
of	O
the	O
Y	O
-	O
231	O
cosmid	O
that	O
contains	O
CpG	O
rich	O
sequences	O
(	O
HTF	B-protein
islands	I-protein
)	O
in	O
its	O
human	O
insert	O
.	O

Sulfuric	O
acid	O
concentration	O
in	O
the	O
catalyzed	O
breathalyzer	O
ampules	O
.	O

For	O
this	O
reason	O
,	O
the	O
particle	O
forming	O
capacity	O
of	O
derivatives	O
of	O
the	O
HIV	B-protein
-	I-protein
1	I-protein
group	I-protein
specific	I-protein
core	I-protein
antigen	I-protein
p55	I-protein
gag	I-protein
was	O
assayed	O
and	O
compared	O
dependent	O
on	O
various	O
expression	O
systems	O
:	O
recombinant	O
bacteria	O
,	O
vaccinia	O
-	O
and	O
baculoviruses	O
were	O
established	O
encoding	O
the	O
entire	O
core	B-protein
protein	I-protein
p55	I-protein
either	O
in	O
its	O
authentic	O
sequence	O
or	O
lacking	O
the	O
myristylation	O
consensus	O
signal	O
.	O

Ketanserin	O
,	O
a	O
hypotensive	O
drug	O
with	O
5	B-protein
-	I-protein
HT2	I-protein
receptor	I-protein
antagonism	O
,	O
when	O
administered	O
by	O
topical	O
infusion	O
of	O
a	O
0	O
.	O
25	O
%	O
w	O
/	O
v	O
solution	O
by	O
corneal	O
and	O
scleral	O
applications	O
,	O
was	O
found	O
to	O
lower	O
intraocular	O
pressure	O
with	O
four	O
times	O
more	O
activity	O
than	O
its	O
metabolite	O
,	O
ketanserinol	O
.	O

The	O
starting	O
point	O
is	O
the	O
consideration	O
that	O
the	O
conceptions	O
underlying	O
the	O
ICIDH	O
are	O
not	O
suitable	O
to	O
serve	O
as	O
a	O
mainstay	O
of	O
a	O
model	O
for	O
diagnostics	O
in	O
rehabilitation	O
because	O
they	O
do	O
not	O
reflect	O
essential	O
characteristics	O
of	O
the	O
diagnostic	O
process	O
which	O
is	O
the	O
basis	O
for	O
intervention	O
.	O

Analysis	O
of	O
the	O
entire	O
16	O
.	O
7	O
-	O
kb	O
mt	O
genome	O
determined	O
that	O
a	O
MDP1	B-protein
mediates	O
cleavage	O
of	O
chick	O
mtDNA	O
in	O
vitro	O
at	O
three	O
H	O
-	O
and	O
two	O
L	O
-	O
strand	O
sequence	O
-	O
specific	O
target	O
sites	O
located	O
within	O
a	O
90	O
-	O
bp	O
A	O
+	O
T	O
-	O
rich	O
genomic	O
tract	O
,	O
theoretically	O
capable	O
of	O
forming	O
stable	O
secondary	O
structures	O
,	O
approximately	O
200	O
bases	O
upstream	O
from	O
the	O
H	O
-	O
strand	O
origin	O
(	O
OH	O
)	O
of	O
replication	O
.	O

The	O
3	O
'	O
UTR	O
has	O
several	O
stable	O
hairpins	O
that	O
are	O
flanked	O
by	O
single	B-protein
-	I-protein
stranded	I-protein
(	I-protein
A	I-protein
/	I-protein
U	I-protein
)	I-protein
UGC	I-protein
sequences	I-protein
.	O

Terazosin	O
,	O
a	O
structural	O
analog	O
of	O
prazosin	O
,	O
also	O
inhibits	O
alpha	B-protein
1	I-protein
adrenoceptors	I-protein
and	O
is	O
recommended	O
as	O
once	O
or	O
twice	O
-	O
daily	O
therapy	O
.	O

The	O
extraction	O
measurements	O
were	O
used	O
to	O
test	O
for	O
extracerebral	O
contamination	O
of	O
venous	O
outflow	O
.	O

The	O
patients	O
are	O
two	O
healthy	O
adult	O
males	O
.	O

Treatment	O
of	O
recurrent	O
FSGS	O
has	O
included	O
high	O
-	O
dose	O
steroids	O
,	O
high	O
-	O
dose	O
cyclosporine	O
(	O
CSA	O
)	O
,	O
plasmapheresis	O
,	O
and	O
ACE	B-protein
inhibitors	O
with	O
mixed	O
results	O
.	O

Effect	O
of	O
proteolytic	O
enzymes	O
and	O
polypeptides	O
on	O
the	O
antacid	O
activity	O
of	O
almagate	O
and	O
other	O
antacids	O
.	O

We	O
propose	O
that	O
the	O
ambiguous	O
discrimination	O
required	O
a	O
greater	O
time	O
for	O
simulus	O
evaluation	O
and	O
that	O
this	O
was	O
reflected	O
in	O
the	O
delayed	O
P3	O
latencies	O
.	O

The	O
median	O
preoperative	O
best	O
-	O
corrected	O
visual	O
acuity	O
of	O
0	O
.	O
08	O
(	O
range	O
hand	O
motions	O
/	O
0	O
.	O
003	O
to	O
0	O
.	O
4	O
)	O
,	O
improved	O
by	O
5	O
lines	O
to	O
a	O
median	O
final	O
postoperative	O
best	O
-	O
corrected	O
visual	O
acuity	O
of	O
0	O
.	O
25	O
(	O
range	O
0	O
.	O
025	O
-	O
0	O
.	O
5	O
)	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

The	O
colony	B-protein
-	I-protein
stimulating	I-protein
factors	I-protein
(	O
CSFs	B-protein
)	O
principally	O
involved	O
in	O
the	O
production	O
of	O
neutrophils	O
and	O
monocytes	O
are	O
granulocyte	B-protein
CSF	I-protein
,	O
granulocyte	B-protein
-	I-protein
macrophage	I-protein
CSF	I-protein
,	O
macrophage	B-protein
CSF	I-protein
,	O
and	O
interleukin	B-protein
3	I-protein
(	O
sometimes	O
called	O
multi	B-protein
-	I-protein
CSF	I-protein
)	O
.	O

By	O
treating	O
monkey	O
COS	O
cells	O
with	O
oligonucleotides	O
linked	O
to	O
psoralen	O
,	O
we	O
have	O
generated	O
targeted	O
mutations	O
in	O
a	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
vector	O
contained	O
within	O
the	O
cells	O
via	O
intracellular	O
triple	O
helix	O
formation	O
.	O

Deltamethrin	O
was	O
most	O
effective	O
on	O
the	O
thatched	O
surface	O
and	O
produced	O
100	O
%	O
mortality	O
of	O
An	O
.	O
culicifacies	O
adults	O
up	O
to	O
12	O
weeks	O
,	O
even	O
when	O
exposed	O
at	O
the	O
lowest	O
dose	O
/	O
12	O
.	O
5	O
mg	O
/	O
m2	O
.	O

The	O
DNA	O
sequence	O
adjacent	O
to	O
the	O
lacZ	B-protein
gene	I-protein
has	O
been	O
determined	O
for	O
91	O
vegetative	O
fusion	O
genes	O
whose	O
products	O
have	O
been	O
localized	O
and	O
for	O
43	O
meiotically	O
induced	O
fusions	O
.	O

RESULTS	O
:	O
Neither	O
basal	O
FSH	B-protein
level	O
nor	O
stimulated	O
FSH	B-protein
level	O
alone	O
were	O
statistically	O
significant	O
predictors	O
of	O
IVF	O
success	O
;	O
however	O
,	O
no	O
patient	O
with	O
a	O
day	O
3	O
FSH	B-protein
level	O
>	O
11	O
.	O
1	O
mIU	O
/	O
ml	O
or	O
a	O
stimulated	O
day	O
10	O
FSH	B-protein
level	O
>	O
13	O
.	O
5	O
mIU	O
/	O
ml	O
conceived	O
and	O
carried	O
a	O
pregnancy	O
.	O

The	O
serum	B-protein
insulin	I-protein
response	O
can	O
not	O
.	O

Significant	O
correlations	O
were	O
obtained	O
between	O
changes	O
in	O
SSEP	O
in	O
response	O
to	O
AS	O
and	O
the	O
presence	O
of	O
not	O
deep	O
residual	O
-	O
organic	O
disturbances	O
,	O
so	O
-	O
called	O
`	O
`	O
ground	O
'	O
'	O
in	O
psychogenic	O
disorders	O
.	O

In	O
rats	O
,	O
we	O
examined	O
the	O
effect	O
of	O
an	O
omentum	O
wrapping	O
on	O
the	O
vascularization	O
of	O
the	O
trachea	O
and	O
on	O
regeneration	O
of	O
the	O
mucosal	O
epithelium	O
in	O
the	O
very	O
early	O
stage	O
after	O
free	O
tracheal	O
grafting	O
.	O

Composites	O
as	O
restoration	O
materials	O
.	O

The	O
high	O
selectivity	O
of	O
arrestins	B-protein
for	O
this	O
particular	O
functional	O
form	O
of	O
receptor	O
ensures	O
their	O
timely	O
binding	O
and	O
dissociation	O
.	O

Primary	O
invasive	O
Haemophilus	O
influenzae	O
type	O
b	O
disease	O
:	O
a	O
population	O
-	O
based	O
assessment	O
of	O
risk	O
factors	O
.	O

However	O
,	O
while	O
the	O
sequence	O
similarity	O
between	O
the	O
membrane	O
exons	O
of	O
avian	B-protein
mIgY	I-protein
and	O
mammalian	B-protein
mIgG	I-protein
and	I-protein
IgE	I-protein
is	O
striking	O
,	O
the	O
overall	O
similarity	O
with	O
Xenopus	B-protein
mIgY	I-protein
is	O
very	O
low	O
.	O

VP5	B-protein
,	O
which	O
encodes	O
the	O
major	B-protein
capsid	I-protein
protein	I-protein
,	O
each	O
fused	O
to	O
the	O
chloramphenicol	B-protein
acetyltransferase	I-protein
gene	I-protein
.	O

Alternative	O
splicing	O
of	O
RNA	O
transcripts	O
encoded	O
by	O
the	O
murine	B-protein
p105	I-protein
NF	I-protein
-	I-protein
kappa	I-protein
B	I-protein
gene	I-protein
generates	O
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
isoforms	I-protein
with	O
different	O
inhibitory	O
activities	O
.	O

Elevation	O
of	O
the	O
tissues	O
of	O
the	O
face	O
is	O
essentially	O
vertical	O
and	O
acts	O
on	O
the	O
forehead	O
,	O
temporal	O
region	O
,	O
gaze	O
and	O
cheekbones	O
.	O

If	O
facilities	O
for	O
measurements	O
of	O
O2	O
consumption	O
and	O
hence	O
metabolic	O
rate	O
are	O
available	O
,	O
these	O
should	O
be	O
utilized	O
.	O

Patients	O
with	O
moderate	O
PDDAT	O
were	O
impaired	O
on	O
all	O
serial	O
positions	O
for	O
both	O
spatial	O
order	O
and	O
spatial	O
recognition	O
memory	O
.	O

At	O
the	O
time	O
of	O
the	O
13	O
latest	O
BPVs	O
,	O
age	O
ranged	O
from	O
three	O
days	O
to	O
13	O
.	O
1	O
years	O
(	O
mean	O
5	O
.	O
7	O
+	O
/	O
-	O
SD	O
4	O
.	O
8	O
years	O
)	O
.	O

Stably	O
transfected	O
human	O
kidney	O
293	O
cells	O
expressing	O
the	O
wild	B-protein
type	I-protein
rat	I-protein
LH	I-protein
/	I-protein
CG	I-protein
receptor	I-protein
(	O
rLHR	B-protein
)	O
or	O
receptors	O
with	O
C	O
-	O
terminal	O
tails	O
truncated	O
at	O
residues	O
653	O
,	O
631	O
,	O
or	O
628	O
(	O
designated	O
rLHR	B-protein
-	I-protein
t653	I-protein
,	O
rLHR	B-protein
-	I-protein
t631	I-protein
,	O
and	O
rLHR	B-protein
-	I-protein
t628	I-protein
)	O
were	O
used	O
to	O
probe	O
the	O
importance	O
of	O
this	O
region	O
on	O
the	O
regulation	O
of	O
hormonal	O
responsiveness	O
.	O

We	O
examined	O
the	O
hypothesis	O
that	O
the	O
coronary	O
vasomotor	O
responses	O
to	O
etomidate	O
(	O
ETO	O
)	O
,	O
propofol	O
(	O
PRO	O
)	O
,	O
and	O
sodium	O
thiopental	O
(	O
STP	O
)	O
are	O
mediated	O
through	O
contrasting	O
effects	O
on	O
the	O
resting	O
nitric	O
oxide	O
(	O
NO	O
)	O
-	O
dependent	O
vasodilator	O
tone	O
that	O
opposes	O
adrenergic	O
vasoconstrictor	O
activity	O
in	O
the	O
intact	O
dog	O
.	O

In	O
this	O
study	O
we	O
examined	O
hepatic	O
stellate	O
cell	O
regulation	O
of	O
M6P	B-protein
/	I-protein
IGFIIR	I-protein
expression	O
and	O
found	O
that	O
M6P	B-protein
/	I-protein
IGFIIR	I-protein
mRNA	I-protein
transcript	I-protein
levels	O
increased	O
in	O
stellate	O
cells	O
from	O
rats	O
exposed	O
to	O
carbon	O
tetrachloride	O
(	O
CCl4	O
)	O
,	O
a	O
potent	O
fibrogenic	O
stimulant	O
.	O

However	O
,	O
other	O
regions	O
of	O
the	O
plasmid	O
are	O
also	O
efficiently	O
repaired	O
.	O

Lack	O
of	O
effect	O
of	O
the	O
appetite	O
stimulant	O
pizotifen	O
(	O
BC	O
105	O
)	O
on	O
the	O
absorption	O
of	O
isonicotinylhydrazine	O
.	O

We	O
have	O
improved	O
our	O
system	O
for	O
nuclear	O
contour	O
digitization	O
and	O
determined	O
its	O
theoretical	O
limitations	O
by	O
digitizing	O
standardized	O
objects	O
.	O

2	O
.	O

These	O
corrections	O
do	O
not	O
involve	O
sequences	O
predicted	O
to	O
function	O
as	O
transcription	O
factor	O
binding	O
sites	O
.	O

Our	O
results	O
showed	O
that	O
compared	O
to	O
the	O
primary	O
photon	O
fluence	O
,	O
the	O
extra	O
-	O
focal	O
photon	O
fluence	O
from	O
the	O
primary	O
collimator	O
and	O
the	O
flattening	O
filter	O
was	O
11	O
%	O
-	O
16	O
%	O
at	O
the	O
isocenter	O
,	O
among	O
which	O
70	O
%	O
was	O
contributed	O
by	O
the	O
flattening	O
filter	O
.	O

In	O
men	O
with	O
BMI	O
<	O
30	O
,	O
the	O
OR	O
was	O
1	O
.	O
83	O
for	O
postprandial	O
TG	O
(	O
P	O
=	O
.	O
041	O
)	O
and	O
2	O
.	O
77	O
for	O
postprandial	O
RP	O
(	O
P	O
=	O
.	O
032	O
)	O
in	O
models	O
that	O
included	O
fasting	O
TG	O
,	O
LDL	O
-	O
C	O
,	O
and	O
hypertension	O
.	O

The	O
histochemistry	O
and	O
ultrastructure	O
of	O
calcified	O
cerebellar	O
deposits	O
described	O
by	O
Tonge	O
et	O
al	O
.	O

Three	O
of	O
these	O
subunits	O
are	O
also	O
homologous	O
to	O
the	O
dimeric	O
POR	B-protein
from	O
a	O
mesophilic	O
archaeon	O
,	O
Halobacterium	O
halobium	O
(	O
21	O
%	O
identity	O
)	O
.	O

The	O
RNA	O
transcripts	O
structurally	O
equivalent	O
to	O
I	B-protein
(	I-protein
2	I-protein
)	I-protein
sgRNAs	I-protein
of	O
TMV	O
U1	O
and	O
crTMV	B-protein
,	O
but	O
containing	O
a	O
hairpin	O
structure	O
(	O
H	O
)	O
immediately	O
upstream	O
of	O
IRES	B-protein
(	I-protein
MP	I-protein
,	I-protein
75	I-protein
)	I-protein
(	I-protein
HIRES	I-protein
(	I-protein
MP	I-protein
)	I-protein
,	I-protein
(	I-protein
75	I-protein
)	I-protein
(	I-protein
CR	I-protein
)	I-protein
-	I-protein
MP	I-protein
-	I-protein
CP	I-protein
-	I-protein
3	I-protein
'	I-protein
UTR	I-protein
;	O
HIRES	B-protein
(	I-protein
MP	I-protein
,	I-protein
75	I-protein
)	I-protein
(	I-protein
U1	I-protein
)	I-protein
-	I-protein
MP	I-protein
-	I-protein
CP	I-protein
-	I-protein
3	I-protein
'	I-protein
UTR	I-protein
)	O
,	O
were	O
able	O
to	O
express	O
the	O
MP	B-protein
gene	I-protein
in	O
vitro	O
.	O

In	O
addition	O
a	O
greater	O
proportion	O
of	O
women	O
in	O
the	O
sweeping	O
group	O
had	O
a	O
cervical	O
dilatation	O
of	O
4	O
cm	O
or	O
more	O
at	O
the	O
first	O
vaginal	O
examination	O
in	O
the	O
labour	O
ward	O
(	O
16	O
/	O
33	O
(	O
49	O
%	O
)	O
vs	O
5	O
/	O
32	O
(	O
16	O
%	O
)	O
;	O
OR	O
4	O
.	O
39	O
;	O
95	O
%	O
CI	O
1	O
.	O
56	O
to	O
12	O
.	O
32	O
;	O
P	O
=	O
0	O
.	O
005	O
)	O
.	O

We	O
report	O
the	O
preliminary	O
biochemical	O
characterization	O
of	O
the	O
T	B-protein
antigens	I-protein
encoded	O
by	O
three	O
SV40	O
mutants	O
,	O
5030	O
,	O
5031	O
,	O
and	O
5061	O
,	O
each	O
of	O
which	O
have	O
altered	O
residues	O
within	O
or	O
near	O
the	O
ATP	O
binding	O
pocket	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
showed	O
that	O
two	O
adjacent	O
SP1	B-protein
sites	I-protein
proximal	O
to	O
exon	O
1	O
were	O
equally	O
important	O
in	O
sustaining	O
basal	O
promoter	O
activity	O
.	O

Taken	O
together	O
,	O
these	O
results	O
are	O
consistent	O
with	O
the	O
possibility	O
that	O
p202	B-protein
protein	I-protein
contributes	O
to	O
the	O
cell	O
growth	O
retardation	O
activity	O
of	O
the	O
IFNs	B-protein
,	O
at	O
least	O
in	O
part	O
,	O
by	O
modulating	O
p21	B-protein
protein	I-protein
levels	O
.	O

Genomic	O
organization	O
of	O
the	O
human	O
phosphodiesterase	B-protein
PDE11A	I-protein
gene	I-protein
.	O

In	O
Mv1Lu	O
lung	O
epithelial	O
cells	O
,	O
ActR	B-protein
-	I-protein
IB	I-protein
and	O
T	B-protein
beta	I-protein
R	I-protein
-	I-protein
I	I-protein
signal	O
a	O
common	O
set	O
of	O
growth	O
-	O
inhibitory	O
and	O
transcriptional	O
responses	O
in	O
association	O
with	O
their	O
corresponding	O
ligands	O
and	O
type	B-protein
II	I-protein
receptors	I-protein
.	O

The	O
observed	O
phenotypes	O
may	O
be	O
explained	O
by	O
(	O
i	O
)	O
a	O
selective	O
disruption	O
of	O
very	B-protein
-	I-protein
low	I-protein
-	I-protein
density	I-protein
lipoprotein	I-protein
secretion	O
due	O
to	O
decreased	O
expression	O
of	O
genes	O
encoding	O
apolipoprotein	B-protein
B	I-protein
and	O
microsomal	B-protein
triglyceride	I-protein
transfer	I-protein
protein	I-protein
,	O
(	O
ii	O
)	O
an	O
increase	O
in	O
hepatic	O
cholesterol	O
uptake	O
due	O
to	O
increased	O
expression	O
of	O
the	O
major	O
high	B-protein
-	I-protein
density	I-protein
lipoprotein	I-protein
receptor	I-protein
,	O
scavenger	B-protein
receptor	I-protein
BI	I-protein
,	O
and	O
(	O
iii	O
)	O
a	O
decrease	O
in	O
bile	O
acid	O
uptake	O
to	O
the	O
liver	O
due	O
to	O
down	O
-	O
regulation	O
of	O
the	O
major	O
basolateral	B-protein
bile	I-protein
acid	I-protein
transporters	I-protein
sodium	I-protein
taurocholate	I-protein
cotransporter	I-protein
protein	I-protein
and	O
organic	B-protein
anion	I-protein
transporter	I-protein
protein	I-protein
1	O
.	O

Two	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
isoforms	O
with	O
different	O
estrogen	O
dependencies	O
are	O
generated	O
from	O
the	O
trout	B-protein
ER	I-protein
gene	I-protein
.	O

In	O
the	O
context	O
of	O
the	O
ADH2	B-protein
upstream	I-protein
regulatory	I-protein
region	I-protein
,	O
including	O
UAS1	B-protein
,	O
working	O
in	O
concert	O
with	O
the	O
ADH2	B-protein
basal	I-protein
promoter	I-protein
elements	I-protein
,	O
UAS2	O
-	O
dependent	O
gene	O
activation	O
was	O
dependent	O
on	O
orientation	O
,	O
copy	O
number	O
,	O
and	O
helix	O
phase	O
.	O

Paracrine	O
activation	O
of	O
the	O
HIV	B-protein
-	I-protein
1	I-protein
LTR	I-protein
promoter	I-protein
by	O
the	O
viral	B-protein
Tat	I-protein
protein	I-protein
is	O
mechanistically	O
similar	O
to	O
trans	O
-	O
activation	O
within	O
a	O
cell	O
.	O

Furthermore	O
,	O
binding	O
of	O
recombinant	B-protein
Myb	I-protein
and	O
Ets	B-protein
-	I-protein
2	I-protein
protein	I-protein
to	O
these	O
fragments	O
could	O
be	O
competed	O
with	O
an	O
excess	O
of	O
double	O
stranded	O
oligodeoxynucleotides	O
containing	O
canonical	O
,	O
but	O
not	O
mutated	O
,	O
Myb	O
-	O
or	O
Ets	B-protein
-	I-protein
binding	I-protein
sites	I-protein
.	O

A	O
total	O
of	O
117	O
EVS	O
treatments	O
were	O
performed	O
on	O
34	O
patients	O
.	O

O	B-protein
.	I-protein
novo	I-protein
-	I-protein
ulmi	I-protein
RNA	I-protein
-	I-protein
7	I-protein
,	O
previously	O
believed	O
to	O
be	O
a	O
satellite	O
-	O
like	O
RNA	O
,	O
is	O
shown	O
to	O
be	O
a	O
defective	O
RNA	O
,	O
derived	O
from	O
OnuMV4	B-protein
-	I-protein
Ld	I-protein
RNA	I-protein
by	O
multiple	O
internal	O
deletions	O
.	O

Successful	O
treatment	O
with	O
nasal	O
continuous	O
positive	O
airway	O
pressure	O
(	O
8	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
5	O
cmH2O	O
)	O
for	O
3	O
days	O
caused	O
a	O
significant	O
decrease	O
in	O
mean	O
blood	O
pressure	O
in	O
OSAS	O
.	O

DNA	O
binding	O
assays	O
confirmed	O
the	O
interference	O
of	O
p30	B-protein
(	I-protein
II	I-protein
)	I-protein
with	O
the	O
assembly	O
of	O
CREB	B-protein
-	I-protein
Tax	I-protein
-	I-protein
p300	I-protein
/	I-protein
CBP	I-protein
multiprotein	I-protein
complexes	I-protein
on	O
21	O
-	O
bp	O
repeat	O
oligonucleotides	O
in	O
vitro	O
.	O

Full	B-protein
-	I-protein
length	I-protein
AT	I-protein
-	I-protein
PHH1	I-protein
,	O
and	O
both	O
AT	B-protein
-	I-protein
PHH1	I-protein
and	O
AT	B-protein
-	I-protein
PHH1	I-protein
delta	I-protein
C	I-protein
-	I-protein
513	I-protein
(	O
truncated	O
to	O
be	O
approximately	O
the	O
size	O
of	O
microbial	B-protein
photolyase	I-protein
genes	I-protein
)	O
cDNAs	O
,	O
were	O
overexpressed	O
,	O
respectively	O
,	O
in	O
yeast	O
and	O
Escherichia	O
coli	O
mutants	O
hypersensitive	O
to	O
ultraviolet	O
light	O
.	O

GAP	B-protein
-	I-protein
N	I-protein
bound	O
constitutively	O
to	O
p190	B-protein
in	O
both	O
serum	O
-	O
deprived	O
and	O
growth	O
factor	O
-	O
stimulated	O
cells	O
.	O

Muscular	O
pathology	O
.	O

Further	O
,	O
the	O
ORFs	O
of	O
components	O
3	O
and	O
5	O
potentially	O
encoded	O
proteins	O
of	O
about	O
20	O
kDa	O
,	O
the	O
size	O
of	O
the	O
BBTV	B-protein
coat	I-protein
protein	I-protein
.	O

This	O
computation	O
is	O
performed	O
by	O
a	O
parallel	O
network	O
of	O
locally	O
connected	O
neuron	O
-	O
like	O
elements	O
.	O

SFP	O
was	O
significantly	O
elevated	O
in	O
Hn	O
(	O
s	O
)	O
.	O

Linkage	O
studies	O
have	O
shown	O
locus	O
heterogeneity	O
with	O
one	O
TSC	B-protein
gene	I-protein
mapped	O
to	O
chromosome	O
9q34	O
and	O
a	O
second	O
to	O
16p13	O
.	O
3	O
.	O

These	O
results	O
suggest	O
KCC3	B-protein
is	O
a	O
new	O
member	O
of	O
the	O
KCC	B-protein
family	I-protein
that	O
is	O
under	O
distinct	O
regulation	O
from	O
KCC1	B-protein
.	O

The	O
primary	O
structure	O
of	O
a	O
2671	O
bp	O
DNA	O
fragment	O
between	O
the	O
pla	B-protein
gene	I-protein
(	O
encoding	O
plasminogen	B-protein
activator	I-protein
)	O
and	O
the	O
origin	O
of	O
replication	O
of	O
the	O
wild	O
-	O
type	O
Yersinia	O
pestis	O
plasmid	O
pYP358	O
was	O
determined	O
.	O

A	O
single	O
amino	O
acid	O
difference	O
in	O
the	O
C	O
-	O
terminal	O
region	O
influences	O
dominant	O
negative	O
activity	O
and	O
receptor	O
dimer	O
formation	O
.	O

EEA1	B-protein
is	O
a	O
conserved	O
alpha	O
-	O
helical	O
peripheral	O
membrane	O
protein	O
flanked	O
by	O
cysteine	O
`	O
`	O
fingers	O
'	O
'	O
and	O
contains	O
a	O
calmodulin	B-protein
-	I-protein
binding	I-protein
IQ	I-protein
motif	I-protein
.	O

In	O
a	O
series	O
of	O
16	O
full	O
-	O
scale	O
fire	O
tests	O
,	O
investigators	O
at	O
the	O
IIT	O
Research	O
Institute	O
have	O
concluded	O
that	O
automatic	O
door	O
control	O
in	O
the	O
room	O
of	O
fire	O
origin	O
can	O
significantly	O
reduce	O
the	O
spread	O
of	O
toxic	O
smoke	O
and	O
gases	O
.	O

Two	O
studies	O
on	O
the	O
relationship	O
between	O
taking	O
a	O
commercial	O
coaching	O
course	O
and	O
performance	O
on	O
the	O
Medical	O
College	O
Admission	O
Test	O
(	O
MCAT	O
)	O
are	O
reported	O
.	O

However	O
,	O
in	O
some	O
of	O
them	O
either	O
pattern	O
may	O
predominate	O
or	O
be	O
exclusively	O
present	O
.	O

One	O
form	O
of	O
the	O
SBEI	B-protein
gene	I-protein
transcript	I-protein
in	O
12	O
-	O
day	O
old	O
kernels	O
contained	O
the	O
exon	O
I	O
+	O
II	O
+	O
III	O
combination	O
at	O
the	O
5	O
'	O
end	O
,	O
whereas	O
other	O
forms	O
differed	O
by	O
inclusion	O
of	O
intron	O
1	O
or	O
exclusion	O
of	O
exon	O
II	O
sequences	O
.	O

CHAP	O
and	O
the	O
Department	O
of	O
Veterans	O
Affairs	O
.	O

The	O
remainder	O
(	O
18	O
.	O
4	O
%	O
)	O
was	O
with	O
IgA	B-protein
nephropathy	O
,	O
which	O
was	O
histologically	O
mild	O
.	O

Cardiac	O
output	O
(	O
CO	O
)	O
was	O
significantly	O
higher	O
(	O
p	O
less	O
than	O
0	O
.	O
0005	O
)	O
in	O
the	O
MBBF	O
group	O
.	O

Among	O
eight	O
graminaceous	O
species	O
tested	O
,	O
Ids3	B-protein
expression	O
was	O
observed	O
only	O
in	O
Fe	O
-	O
deficient	O
roots	O
of	O
H	O
.	O
vulgare	O
and	O
Secale	O
cereale	O
.	O
which	O
not	O
only	O
secrete	O
2	O
'	O
-	O
deoxymugineic	O
acid	O
(	O
DMA	O
)	O
,	O
but	O
also	O
mugineic	O
acid	O
(	O
MA	O
)	O
and	O
3	O
-	O
epihydroxymugineic	O
acid	O
(	O
epiHMA	O
,	O
H	O
.	O
vulgare	O
)	O
,	O
and	O
3	O
-	O
hydroxymugineic	O
acid	O
(	O
HMA	O
,	O
S	O
.	O
cereale	O
)	O
.	O

We	O
also	O
found	O
that	O
environmental	O
conditions	O
for	O
meiosis	O
finely	O
regulate	O
the	O
transcript	O
levels	O
of	O
KIN28	B-protein
and	O
CCL1	B-protein
,	O
such	O
that	O
nitrogen	O
starvation	O
first	O
elevates	O
them	O
but	O
subsequent	O
alkalization	O
of	O
medium	O
decreases	O
them	O
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
effects	O
of	O
hypercholesterolemia	O
and	O
atherosclerosis	O
-	O
induced	O
chronic	O
cavernosal	O
arterial	O
insufficiency	O
on	O
cavernosal	O
smooth	O
muscle	O
tone	O
,	O
nitric	B-protein
oxide	I-protein
synthase	I-protein
(	O
NOS	B-protein
)	O
activity	O
and	O
cavernosal	O
tissue	O
synthesis	O
of	O
constrictor	O
eicosanoids	O
.	O

The	O
multiple	O
factors	O
affecting	O
plasma	O
renin	B-protein
activity	O
in	O
essential	O
hypertension	O
.	O

We	O
suggest	O
that	O
ventriculopleural	O
shunting	O
should	O
be	O
considered	O
as	O
the	O
preferred	O
alternative	O
to	O
peritoneal	O
drainage	O
in	O
children	O
with	O
intra	O
-	O
abdominal	O
adhesions	O
or	O
with	O
a	O
history	O
of	O
recent	O
peritoneal	O
infection	O
.	O

We	O
have	O
obtained	O
the	O
human	B-protein
EP4	I-protein
receptor	I-protein
gene	I-protein
sequence	I-protein
and	O
determined	O
its	O
structure	O
relative	O
to	O
EP4R	B-protein
cDNA	I-protein
synthesized	O
from	O
peripheral	O
blood	O
lymphocytes	O
.	O

Model	O
IV	O
:	O
primary	O
abutments	O
with	O
the	O
lateral	O
incisor	O
and	O
the	O
second	O
molar	O
as	O
secondary	O
abutments	O
.	O

Skeletal	O
muscle	O
metaboreceptor	O
exercise	O
responses	O
are	O
attenuated	O
in	O
heart	O
failure	O
.	O

The	O
maximum	O
amplitude	O
of	O
evoked	O
responses	O
in	O
the	O
cervical	O
sympathetic	O
trunk	O
was	O
obtained	O
when	O
the	O
T2	O
white	O
ramus	O
was	O
stimulated	O
and	O
decreased	O
gradually	O
when	O
followed	O
by	O
the	O
stimulation	O
of	O
T1	O
,	O
T3	O
,	O
T4	O
and	O
T5	O
white	O
rami	O
.	O

CONCLUSION	O
:	O
Local	O
control	O
was	O
highest	O
with	O
Preop	O
in	O
patients	O
presenting	O
primarily	O
with	O
gross	O
disease	O
,	O
and	O
with	O
Postop	O
in	O
patients	O
presenting	O
primarily	O
following	O
gross	O
total	O
excision	O
.	O

Studies	O
of	O
lipoprotein	B-protein
-	I-protein
X	I-protein
(	O
LP	B-protein
-	I-protein
X	I-protein
)	O
and	O
bile	O
acids	O
in	O
familial	O
LCAT	B-protein
deficiency	O
.	O

Oligonucleotide	O
mutagenesis	O
of	O
these	O
binding	O
domains	O
indicated	O
their	O
importance	O
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
E3	B-protein
promoter	I-protein
in	O
yeast	O
cells	O
.	O

Neither	O
Ha	B-protein
-	I-protein
Ras	I-protein
(	O
G12V	O
,	O
T35S	O
)	O
(	O
Ha	B-protein
-	I-protein
RasV12S35	I-protein
)	O
,	O
which	O
activates	O
the	O
Rafl	B-protein
signaling	O
pathway	O
,	O
nor	O
Ha	B-protein
-	I-protein
Ras	I-protein
(	I-protein
G12V	I-protein
,	I-protein
E37G	I-protein
)	I-protein
(	O
Ha	B-protein
-	I-protein
RasV12G37	I-protein
)	O
,	O
which	O
stimulates	O
the	O
RalGDS	B-protein
pathway	O
,	O
did	O
not	O
have	O
significant	O
effects	O
on	O
factor	O
-	O
withdrawal	O
apoptosis	O
of	O
myeloid	O
cells	O
.	O

Effects	O
of	O
ionizing	O
radiation	O
in	O
the	O
human	O
oral	O
cavity	O
and	O
oropharynx	O
:	O
results	O
of	O
a	O
survey	O
.	O

This	O
report	O
describes	O
the	O
identification	O
of	O
a	O
gene	O
of	O
related	O
function	O
,	O
SMD1	B-protein
,	O
located	O
immediately	O
3	O
'	O
to	O
PRP38	B-protein
.	O

Preventive	O
effect	O
of	O
ONO	O
-	O
3708	O
on	O
thrombosis	O
and	O
vasospasms	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Water	O
content	O
and	O
equilibrium	O
water	O
partition	O
in	O
immature	O
cartilage	O
.	O

A	O
novel	O
cDNA	O
clone	O
termed	O
R2	O
was	O
isolated	O
by	O
subtractive	O
hybridization	O
of	O
a	O
cDNA	O
library	O
of	O
phytohemagglutinin	B-protein
(	O
PHA	B-protein
)	O
/	O
phorbol	O
myristate	O
acetate	O
-	O
stimulated	O
Jurkat	O
cells	O
and	O
by	O
rescreening	O
a	O
cDNA	O
library	O
of	O
PHA	O
-	O
stimulated	O
peripheral	O
blood	O
lymphocytes	O
.	O

Diltiazem	O
decreased	O
the	O
total	O
body	O
clearance	O
from	O
34	O
.	O
0	O
+	O
/	O
-	O
8	O
.	O
0	O
to	O
28	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
1	O
mL	O
/	O
min	O
(	O
P	O
less	O
than	O
.	O
01	O
)	O
,	O
and	O
prolonged	O
the	O
elimination	O
half	O
-	O
life	O
from	O
12	O
.	O
6	O
+	O
/	O
-	O
3	O
.	O
0	O
to	O
14	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
5	O
hours	O
(	O
P	O
less	O
than	O
.	O
01	O
)	O
of	O
antipyrine	O
without	O
any	O
changes	O
in	O
volume	O
of	O
distribution	O
.	O

The	O
yeast	B-protein
RER2	I-protein
gene	I-protein
,	O
identified	O
by	O
endoplasmic	O
reticulum	O
protein	O
localization	O
mutations	O
,	O
encodes	O
cis	B-protein
-	I-protein
prenyltransferase	I-protein
,	O
a	O
key	O
enzyme	O
in	O
dolichol	O
synthesis	O
.	O

We	O
characterized	O
three	O
Arabidopsis	O
thaliana	O
cDNA	O
clones	O
that	O
could	O
rescue	O
the	O
sterile	O
phenotype	O
of	O
the	O
Schizosaccharomyces	B-protein
pombe	I-protein
pde1	I-protein
mutant	I-protein
,	O
which	O
is	O
defective	O
in	O
cAMP	B-protein
phosphodiesterase	I-protein
.	O

Cortical	O
afferents	O
to	O
the	O
entorhinal	O
cortex	O
of	O
the	O
Rhesus	O
monkey	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
entire	O
rat	B-protein
GSTA3	I-protein
(	O
rGST	B-protein
Yc1	I-protein
)	O
subunit	O
gene	O
.	O

Ras2p	B-protein
activates	O
invasive	O
growth	O
using	O
either	O
of	O
two	O
downstream	O
signaling	O
pathways	O
,	O
the	O
filamentation	O
MAPK	B-protein
(	O
Cdc42p	B-protein
/	I-protein
Ste20p	I-protein
/	I-protein
MAPK	I-protein
)	O
cascade	O
or	O
the	O
cAMP	B-protein
-	I-protein
dependent	I-protein
protein	I-protein
kinase	I-protein
(	O
Cyr1p	B-protein
/	I-protein
cAMP	I-protein
/	I-protein
PKA	I-protein
)	O
pathway	O
.	O

CONCLUSIONS	O
:	O
Use	O
of	O
the	O
first	O
method	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
the	O
time	O
patients	O
remained	O
in	O
the	O
ICU	O
before	O
transfer	O
to	O
another	O
unit	O
and	O
savings	O
in	O
nursing	O
time	O
,	O
but	O
the	O
two	O
methods	O
did	O
not	O
differ	O
according	O
to	O
clinical	O
outcomes	O
.	O

In	O
part	O
as	O
a	O
result	O
of	O
its	O
inability	O
to	O
sustain	O
radiative	O
loses	O
,	O
the	O
BB	O
resonator	O
has	O
extremely	O
low	O
RF	O
power	O
requirements	O
.	O

Hypoxic	O
ventilatory	O
responses	O
were	O
-	O
1	O
.	O
99	O
+	O
/	O
-	O
0	O
.	O
37	O
L	O
/	O
min	O
/	O
%	O
SaO2	O
in	O
the	O
relatives	O
and	O
-	O
1	O
.	O
54	O
+	O
/	O
-	O
0	O
.	O
25	O
L	O
/	O
min	O
/	O
%	O
SaO2	O
in	O
the	O
control	O
subjects	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

They	O
also	O
discuss	O
the	O
existing	O
nomenclature	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
hGCN5	B-protein
is	O
also	O
an	O
HAT	B-protein
and	O
has	O
the	O
same	O
substrate	O
specificity	O
as	O
yGCN5	B-protein
.	O

Instead	O
,	O
some	O
small	O
negative	O
effects	O
are	O
observed	O
,	O
particularly	O
involving	O
effects	O
of	O
husbands	O
'	O
retirement	O
on	O
the	O
marital	O
satisfaction	O
of	O
employed	O
wives	O
.	O

We	O
previously	O
described	O
two	O
alanine	O
cluster	O
mutations	O
,	O
R77	O
to	O
A	O
(	O
R77A	O
)	O
-	O
K79A	O
and	O
E192A	O
-	O
E194A	O
,	O
which	O
selectively	O
inactivated	O
the	O
triphosphatase	B-protein
component	I-protein
.	O

CKII	B-protein
as	O
a	O
CD44	B-protein
-	I-protein
associated	I-protein
serine	I-protein
kinase	I-protein
therefore	O
may	O
serve	O
as	O
an	O
important	O
molecule	O
in	O
a	O
signaling	O
cascade	O
that	O
produces	O
a	O
variety	O
of	O
cellular	O
responses	O
in	O
MDA231	O
breast	O
cancer	O
cells	O
.	O

To	O
investigate	O
the	O
requirements	O
for	O
CBF2	B-protein
binding	O
,	O
we	O
synthesized	O
a	O
series	O
of	O
oligonucleotides	O
carrying	O
double	O
transversion	O
mutations	O
spanning	O
both	O
the	O
conserved	O
core	O
sequence	O
and	O
outside	O
flanking	O
sequences	O
.	O

Biol	O
.	O

Replacement	O
of	O
the	O
wild	O
-	O
type	O
5	O
'	O
-	O
regulatory	O
region	O
with	O
either	O
of	O
the	O
mutants	O
'	O
cis	O
-	O
acting	O
regulatory	O
element	O
resulted	O
in	O
the	O
anaerobic	O
expression	O
of	O
active	B-protein
Mn	I-protein
-	I-protein
superoxide	I-protein
dismutase	I-protein
.	O

To	O
study	O
the	O
functional	O
differences	O
between	O
cutaneous	O
HPV5	O
and	O
HPV8	O
E7s	B-protein
and	O
genital	B-protein
HPV16	I-protein
E7	I-protein
,	O
we	O
cloned	O
each	O
of	O
the	O
E7	B-protein
open	O
reading	O
frames	O
and	O
tested	O
their	O
immortalizing	O
and	O
transforming	O
activities	O
,	O
the	O
binding	O
ability	O
of	O
their	O
products	O
with	O
retinoblastoma	B-protein
protein	I-protein
(	O
RB	B-protein
)	O
and	O
their	O
complementation	O
activity	O
of	O
a	O
RB	B-protein
-	I-protein
nonbinding	I-protein
adenovirus	I-protein
E1A	I-protein
mutant	I-protein
.	O

Pneumothorax	O
complicated	O
by	O
chronic	O
steroid	O
treatment	O
.	O

The	O
response	O
of	O
the	O
plasma	B-protein
fibrinogen	I-protein
level	O
to	O
the	O
subucutaneous	O
injection	O
of	O
turpentine	O
and	O
to	O
the	O
intravenous	O
injection	O
of	O
endotoxin	O
was	O
measured	O
in	O
normal	O
rabbits	O
and	O
in	O
rabbits	O
made	O
granulocytopenic	O
and	O
thrombocytopenic	O
with	O
busulfan	O
.	O

The	O
spleen	O
rate	O
of	O
about	O
600	O
villagers	O
of	O
RK	O
I	O
examined	O
was	O
54	O
.	O
3	O
%	O
and	O
the	O
parasite	O
rate	O
13	O
.	O
2	O
%	O
before	O
the	O
drug	O
intervention	O
.	O

A	O
thermal	O
Kubo	O
-	O
Martin	O
-	O
Schwinger	O
condition	O
arises	O
due	O
to	O
the	O
coupling	O
of	O
a	O
computer	O
to	O
a	O
strong	O
periodic	O
source	O
,	O
namely	O
,	O
the	O
daily	O
and	O
weekly	O
usage	O
patterns	O
of	O
the	O
system	O
.	O

Among	O
the	O
LE6	B-protein
deletions	O
,	O
only	O
one	O
had	O
a	O
reduced	O
transformation	O
efficiency	O
,	O
while	O
seven	O
transformed	O
cells	O
at	O
least	O
as	O
efficiently	O
as	O
wild	B-protein
-	I-protein
type	I-protein
LE6	I-protein
.	O

Changes	O
of	O
plasma	O
cortisol	O
level	O
in	O
late	O
asthmatic	O
responses	O
.	O

All	O
patients	O
with	O
deterioriation	O
in	O
mental	O
status	O
showed	O
a	O
marked	O
increase	O
in	O
liver	O
enzymes	O
(	O
aspartate	B-protein
and	I-protein
alanine	I-protein
aminotransaminases	I-protein
)	O
and	O
severe	O
coagulopathy	O
.	O

The	O
results	O
also	O
showed	O
that	O
although	O
oyster	O
shell	O
supplementation	O
generally	O
increased	O
alkaline	B-protein
phosphatase	I-protein
activity	O
,	O
bone	O
mineralization	O
was	O
relatively	O
uninfluenced	O
as	O
judged	O
by	O
the	O
low	O
coefficients	O
of	O
variation	O
(	O
CV	O
)	O
of	O
3	O
.	O
14	O
-	O
3	O
.	O
51	O
%	O
and	O
3	O
.	O
39	O
-	O
4	O
.	O
82	O
%	O
for	O
calcium	O
and	O
phosphorus	O
content	O
in	O
the	O
femur	O
and	O
tibia	O
respectively	O
.	O

Treating	O
renal	O
anaemia	O
with	O
recombinant	O
human	O
erythropoietin	B-protein
.	O

The	O
resulting	O
clone	O
pKB11	B-protein
,	O
which	O
has	O
a	O
1369	O
-	O
base	O
pair	O
(	O
bp	O
)	O
cDNA	O
insert	O
,	O
overlapping	O
pCAD142	B-protein
by	O
781	O
bp	O
,	O
was	O
identified	O
by	O
hybridization	O
methods	O
and	O
sequence	O
analysis	O
and	O
found	O
to	O
contain	O
the	O
entire	O
cDNA	O
sequence	O
for	O
the	O
amino	O
end	O
of	O
the	O
CAD	B-protein
polypeptide	I-protein
.	O

Treatment	O
of	O
unstable	O
angina	O
:	O
role	O
of	O
antithrombotic	O
therapy	O
.	O

Acad	O
.	O

Recognition	O
of	O
emphysema	O
was	O
poor	O
when	O
radiographs	O
of	O
inadequate	O
quality	O
were	O
included	O
(	O
anteroposterior	O
films	O
or	O
films	O
from	O
patients	O
with	O
acute	O
or	O
chronic	O
lung	O
disease	O
)	O
.	O

Vasopressin	B-protein
(	O
AVP	B-protein
)	O
,	O
the	O
antidiuretic	O
hormone	O
,	O
is	O
a	O
cyclic	O
nonapeptide	O
that	O
acts	O
through	O
binding	O
to	O
G	B-protein
protein	I-protein
-	I-protein
coupled	I-protein
specific	I-protein
membrane	I-protein
receptors	I-protein
pharmacologically	O
divided	O
into	O
three	O
subtypes	O
(	O
V1a	B-protein
,	O
V1b	B-protein
,	O
and	O
V2	B-protein
)	O
linked	O
to	O
distinct	O
second	O
messengers	O
.	O

Immunofluorescence	O
studies	O
in	O
C2C12	O
myotubes	O
show	O
that	O
Smad2	B-protein
and	O
MEF2A	B-protein
co	O
-	O
localise	O
in	O
the	O
nucleus	O
of	O
multinuclear	O
myotubes	O
during	O
differentiation	O
.	O

Homozygous	O
mutation	O
in	O
two	O
children	O
led	O
to	O
amputation	O
of	O
legs	O
due	O
to	O
purpura	O
fulminans	O
.	O

Studies	O
in	O
mammalian	O
cells	O
have	O
correlated	O
induction	O
of	O
inhibitory	O
tyrosine	O
15	O
(	O
Y15	O
)	O
phosphorylation	O
on	O
p34cdc2	B-protein
with	O
the	O
response	O
to	O
DNA	O
damage	O
.	O

Altogether	O
46	O
phase	O
III	O
activities	O
were	O
recorded	O
.	O

Using	O
a	O
battery	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
mutants	I-protein
,	O
we	O
show	O
that	O
(	O
i	O
)	O
a	O
dimer	O
binds	O
a	O
single	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
molecule	I-protein
,	O
(	O
ii	O
)	O
the	O
acidic	O
C	O
-	O
terminal	O
region	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
not	O
required	O
for	O
protein	O
-	O
protein	O
binding	O
and	O
does	O
not	O
mask	O
the	O
nuclear	O
localization	O
signal	O
of	O
the	O
dimer	O
,	O
(	O
iii	O
)	O
the	O
same	O
C	O
-	O
terminal	O
region	O
is	O
required	O
for	O
inhibition	O
of	O
DNA	O
binding	O
,	O
and	O
(	O
iv	O
)	O
this	O
inhibition	O
may	O
be	O
accomplished	O
by	O
direct	O
interaction	O
between	O
the	O
PEST	B-protein
-	I-protein
like	I-protein
region	I-protein
and	O
the	O
DNA	O
-	O
binding	O
region	O
of	O
one	O
of	O
the	O
subunits	O
of	O
the	O
dimer	O
.	O

Activation	O
mediated	O
by	O
Cat8p	B-protein
was	O
no	O
longer	O
detectable	O
in	O
a	O
cat1	B-protein
mutant	I-protein
.	O

Of	O
those	O
injuries	O
,	O
143	O
cases	O
were	O
snowboard	O
related	O
and	O
158	O
cases	O
were	O
ski	O
related	O
.	O

Diacylglycerol	B-protein
kinase	I-protein
(	O
DGK	B-protein
)	O
attenuates	O
levels	O
of	O
second	O
messenger	O
diacylglycerol	O
in	O
cells	O
and	O
produces	O
another	O
(	O
putative	O
)	O
messenger	O
,	O
phosphatidic	O
acid	O
.	O

Unusual	O
course	O
of	O
plasmocytosis	O
.	O

4	O
)	O
PU	B-protein
and	O
PD	B-protein
lacked	O
the	O
canonical	O
TATA	O
or	O
CAAT	O
motifs	O
,	O
and	O
are	O
AT	O
-	O
rich	O
.	O

We	O
have	O
found	O
that	O
PEA2	B-protein
is	O
also	O
required	O
for	O
the	O
bipolar	O
budding	O
pattern	O
and	O
that	O
it	O
encodes	O
a	O
novel	O
protein	O
with	O
a	O
predicted	O
coiled	O
-	O
coil	O
domain	O
.	O

The	O
most	O
important	O
finding	O
,	O
however	O
,	O
was	O
that	O
IMT	O
values	O
were	O
related	O
with	O
24	O
h	O
SBP	O
or	O
PP	O
standard	O
deviation	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
a	O
measure	O
of	O
overall	O
SBP	O
or	O
PP	O
variability	O
.	O

We	O
recently	O
found	O
that	O
the	O
p72syk	B-protein
protein	I-protein
tyrosine	I-protein
kinase	I-protein
is	O
physically	O
associated	O
with	O
the	O
TCR	B-protein
/	I-protein
CD3	I-protein
complex	I-protein
and	O
is	O
rapidly	O
tyrosine	O
phosphorylated	O
and	O
activated	O
by	O
receptor	O
triggering	O
also	O
in	O
T	O
cells	O
lacking	O
p56lck	B-protein
.	O

Similar	O
synergistic	O
activation	O
was	O
observed	O
in	O
the	O
IL	B-protein
-	I-protein
8	I-protein
promoter	I-protein
,	O
which	O
also	O
contains	O
both	O
NF	B-protein
-	I-protein
IL6	I-protein
and	O
NF	B-protein
-	I-protein
kappa	I-protein
B	I-protein
binding	I-protein
sites	I-protein
.	O

Stable	O
transfection	O
of	O
the	O
truncated	O
reduced	B-protein
folate	I-protein
carrier	I-protein
cDNA	I-protein
into	O
mouse	O
L1210	O
leukemia	O
cells	O
:	O
increased	O
folate	O
accumulation	O
,	O
decreased	O
their	O
leucovorin	O
and	O
folic	O
acid	O
growth	O
requirements	O
,	O
and	O
increased	O
their	O
sensitivity	O
to	O
methotrexate	O
.	O

Instead	O
,	O
TRPS1	B-protein
potently	O
and	O
specifically	O
represses	O
transcriptional	O
activation	O
mediated	O
by	O
other	O
GATA	B-protein
factors	I-protein
.	O

Hyaluronan	O
treatment	O
stimulated	O
collagen	B-protein
remodeling	O
in	O
the	O
peripheral	O
region	O
and	O
inhibited	O
swelling	O
of	O
the	O
meniscus	O
repaired	O
in	O
the	O
inner	O
region	O
.	O

Recombinant	B-protein
human	I-protein
TFIID	I-protein
supported	O
weak	O
basal	O
transcription	O
in	O
heat	O
-	O
treated	O
nuclear	O
extracts	O
whereas	O
a	O
partially	O
purified	O
TFIID	B-protein
fraction	O
from	O
HeLa	O
cells	O
reconstituted	O
a	O
maximal	O
level	O
of	O
transcription	O
.	O

X	O
-	O
ray	O
crystallographic	O
data	O
show	O
that	O
the	O
PLZF	B-protein
BTB	I-protein
/	I-protein
POZ	I-protein
domain	I-protein
forms	O
an	O
obligate	O
homodimer	O
via	O
an	O
extensive	O
interface	O
.	O

We	O
have	O
previously	O
identified	O
mouse	B-protein
and	I-protein
human	I-protein
cDNAs	I-protein
encoding	I-protein
UNC	I-protein
-	I-protein
51	I-protein
-	I-protein
like	I-protein
kinase	I-protein
(	O
ULK1	B-protein
)	O
.	O

Sequencing	O
of	O
zebrafish	O
(	O
Danio	O
rerio	O
)	O
bacterial	O
artificial	O
chromosome	O
and	O
P1	O
artificial	O
chromosome	O
genomic	O
clone	O
fragments	O
and	O
of	O
cDNA	O
clones	O
has	O
led	O
to	O
the	O
identification	O
of	O
five	O
new	O
loci	O
coding	O
for	O
beta	B-protein
subunits	I-protein
of	I-protein
proteasomes	I-protein
(	O
PSMB	B-protein
)	O
.	O

Penicillin	B-protein
acylase	I-protein
(	O
PA	B-protein
)	O
from	O
Escherichia	O
coli	O
ATCC11105	O
is	O
a	O
periplasmic	O
heterodimer	O
consisting	O
of	O
a	O
24	O
kDa	O
small	O
subunit	O
and	O
a	O
65	O
kDa	O
large	O
subunit	O
.	O

There	O
was	O
a	O
significant	O
but	O
similar	O
elevation	O
of	O
mean	O
O2	O
uptake	O
during	O
40	O
min	O
postexercise	O
by	O
13	O
.	O
6	O
%	O
in	O
both	O
the	O
fasted	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
fed	O
state	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Intracellular	O
localization	O
studies	O
using	O
the	O
mDAP	B-protein
-	I-protein
3	I-protein
/	I-protein
EGFP	I-protein
fusion	I-protein
protein	I-protein
,	O
cell	O
fractionation	O
and	O
protease	O
protection	O
experiments	O
localized	O
mDAP	B-protein
-	I-protein
3	I-protein
to	O
the	O
mitochondrial	O
matrix	O
.	O

CONCLUSION	O
:	O
The	O
study	O
demonstrates	O
that	O
transvaginal	O
ultrasonography	O
has	O
an	O
efficiency	O
of	O
88	O
%	O
in	O
differentiating	O
endometriomas	O
from	O
other	O
ovarian	O
masses	O
with	O
a	O
specificity	O
of	O
90	O
%	O
.	O

Two	O
polyadenylation	O
sites	O
were	O
used	O
,	O
one	O
at	O
the	O
end	O
of	O
the	O
early	B-protein
(	I-protein
E	I-protein
)	I-protein
region	I-protein
of	O
the	O
viral	O
DNA	O
,	O
the	O
other	O
at	O
the	O
end	O
of	O
the	O
late	B-protein
(	I-protein
L	I-protein
)	I-protein
region	I-protein
.	O

The	O
carcass	O
of	O
a	O
great	O
horned	O
owl	O
(	O
Bubo	O
virginianus	O
)	O
,	O
which	O
had	O
been	O
found	O
moribund	O
in	O
southern	O
Ontario	O
,	O
was	O
presented	O
for	O
necropsy	O
.	O

NGF	B-protein
elicits	O
a	O
more	O
delayed	O
and	O
sustained	O
ERK	B-protein
phosphorylation	O
than	O
EGF	B-protein
,	O
consistent	O
with	O
previous	O
reports	O
.	O

Compound	O
1	O
is	O
either	O
21	O
-	O
O	O
-	O
angeloyl	O
,	O
22	O
-	O
O	O
-	O
tigloyl	O
R1	O
-	O
barrigenol	O
,	O
or	O
21	O
-	O
O	O
-	O
tigloyl	O
,	O
22	O
-	O
O	O
-	O
angeloyl	O
R1	O
-	O
barrigenol	O
.	O

The	O
enhancer	O
region	O
of	O
Akv	O
murine	O
leukemia	O
virus	O
contains	O
the	O
sequence	B-protein
motif	I-protein
ACAGATGG	I-protein
.	O

Immuno	O
-	O
cytochemistry	O
,	O
using	O
antisera	O
against	O
Campylobacter	O
jejuni	O
,	O
showed	O
that	O
the	O
positive	O
staining	O
in	O
altered	O
epithelial	O
cells	O
were	O
restricted	O
to	O
intracellular	O
organisms	O
having	O
a	O
structure	O
resembling	O
Campylobacter	O
spp	O
.	O

The	O
translation	O
products	O
of	O
both	O
clones	O
are	O
highly	O
homologous	O
to	O
APS1	B-protein
(	O
66	O
and	O
86	O
%	O
identity	O
,	O
respectively	O
)	O
over	O
their	O
entire	O
lengths	O
,	O
including	O
amino	O
terminal	O
sequences	O
resembling	O
transit	O
peptides	O
for	O
plastid	O
localization	O
.	O

Organization	O
of	O
the	O
human	B-protein
LU	I-protein
gene	I-protein
and	O
molecular	O
basis	O
of	O
the	O
Lu	B-protein
(	I-protein
a	I-protein
)	I-protein
/	I-protein
Lu	I-protein
(	I-protein
b	I-protein
)	I-protein
blood	I-protein
group	I-protein
polymorphism	I-protein
.	O

The	O
MCA	O
and	O
UA	O
PI	O
values	O
showed	O
the	O
greatest	O
deviation	O
for	O
any	O
single	O
-	O
vessel	O
parameter	O
.	O

Progressive	O
100	O
-	O
mmHg	O
stepwise	O
decreases	O
in	O
superfusate	O
oxygen	O
partial	O
pressure	O
(	O
PO2	O
)	O
from	O
control	O
(	O
95	O
%	O
O2	O
aeration	O
,	O
PO2	O
,	O
620	O
-	O
650	O
mmHg	O
)	O
were	O
produced	O
,	O
and	O
subsequent	O
changes	O
in	O
isometric	O
active	O
and	O
resting	O
tension	O
were	O
measured	O
.	O

Results	O
of	O
the	O
long	O
-	O
term	O
observation	O
and	O
treatment	O
of	O
patients	O
with	O
arterial	O
hypertension	O
.	O

Jean	O
Klig	O
reviews	O
recent	O
literature	O
about	O
lower	O
respiratory	O
tract	O
infection	O
in	O
children	O
.	O

In	O
particular	O
,	O
the	O
highly	O
expressed	O
ADH1	B-protein
gene	I-protein
is	O
represented	O
in	O
this	O
database	O
by	O
no	O
less	O
than	O
20	O
EST	O
sequences	O
.	O

In	O
some	O
cases	O
,	O
factor	O
-	O
induced	O
Rac	B-protein
activation	O
results	O
in	O
Rho	B-protein
activation	O
,	O
and	O
factor	O
-	O
induced	O
Cdc42	B-protein
activation	O
leads	O
to	O
Rac	B-protein
activation	O
,	O
as	O
determined	O
by	O
specific	O
morphological	O
changes	O
.	O

A	O
sequence	O
comparison	O
reveals	O
two	O
CCAAT	B-protein
/	I-protein
enhancer	I-protein
binding	I-protein
protein	I-protein
(	O
C	B-protein
/	I-protein
EBP	I-protein
)	O
consensus	O
sequences	O
,	O
basic	O
DNA	O
binding	O
region	O
and	O
leucine	O
zippers	O
1	O
and	O
2	O
(	O
bZIP1	O
and	O
bZIP2	O
)	O
,	O
within	O
this	O
region	O
.	O

In	O
the	O
lattice	O
,	O
23	O
%	O
of	O
the	O
sites	O
are	O
occupied	O
,	O
95	O
%	O
of	O
the	O
atoms	O
are	O
in	O
the	O
lowest	O
energy	O
magnetic	O
sublevel	O
,	O
and	O
37	O
%	O
are	O
in	O
the	O
lowest	O
3D	O
vibrational	O
state	O
.	O

Arsenic	O
contents	O
in	O
native	O
copper	O
.	O

Analysis	O
of	O
human	O
genomic	O
DNA	O
reveals	O
an	O
intronless	O
sequence	O
with	O
strong	O
homology	O
to	O
human	B-protein
G	I-protein
alpha	I-protein
q	I-protein
cDNA	I-protein
.	O

The	O
risk	O
factors	O
studied	O
were	O
male	O
sex	O
,	O
hypertension	O
,	O
diabetes	O
mellitus	O
,	O
hypercholesterolemia	O
,	O
cigarette	O
smoking	O
,	O
sedentary	O
life	O
-	O
style	O
,	O
and	O
family	O
history	O
.	O

CONCLUSIONS	O
:	O
Pretreatment	O
with	O
OCs	O
prior	O
to	O
pituitary	O
suppression	O
in	O
the	O
early	O
follicular	O
phase	O
decreases	O
ovarian	O
cyst	O
formation	O
,	O
without	O
an	O
apparent	O
effect	O
on	O
subsequent	O
follicular	O
recruitment	O
or	O
pregnancy	O
rates	O
.	O

SV1	B-protein
has	O
a	O
33	O
-	O
amino	O
acid	O
insert	O
in	O
the	O
S1	B-protein
transmembrane	I-protein
domain	I-protein
that	O
does	O
not	O
alter	O
S1	B-protein
overall	O
hydrophobicity	O
,	O
but	O
makes	O
the	O
S0	B-protein
-	I-protein
S1	I-protein
linker	I-protein
longer	O
.	O

The	O
small	O
size	O
and	O
placement	O
of	O
the	O
mutagenesis	O
marker	O
(	O
the	O
supF	B-protein
suppressor	I-protein
tRNA	I-protein
gene	I-protein
from	I-protein
Escherichia	I-protein
coli	I-protein
)	O
within	O
the	O
vector	O
substantially	O
reduced	O
the	O
frequency	O
of	O
spontaneous	O
mutations	O
normally	O
observed	O
after	O
transfection	O
of	O
mammalian	O
cells	O
with	O
plasmid	O
DNA	O
;	O
hence	O
,	O
UV	O
-	O
induced	O
mutations	O
were	O
easily	O
identified	O
above	O
the	O
spontaneous	O
background	O
.	O

Although	O
not	O
consistently	O
identified	O
in	O
all	O
samples	O
,	O
secondary	O
Academic	O
,	O
Personal	O
Responsibility	O
,	O
and	O
Community	O
/	O
Vocational	O
dimensions	O
were	O
also	O
identified	O
.	O

It	O
can	O
be	O
concluded	O
that	O
in	O
normotensive	O
subjects	O
,	O
uric	O
acid	O
and	O
xanthine	B-protein
oxidase	I-protein
have	O
significant	O
association	O
with	O
blood	O
pressure	O
and	O
thus	O
are	O
one	O
of	O
the	O
many	O
factors	O
which	O
are	O
involved	O
in	O
the	O
cause	O
or	O
effect	O
of	O
hypertension	O
.	O

Hybridization	O
analysis	O
showed	O
that	O
the	O
size	O
of	O
the	O
mRNA	O
is	O
about	O
1	O
.	O
4	O
kilobases	O
.	O

Canadian	O
survey	O
reveals	O
widespread	O
dissatisfaction	O
among	O
physicians	O
.	O

Topoisomerase	B-protein
II	I-protein
is	O
a	O
major	O
target	O
of	O
the	O
protein	B-protein
kinase	I-protein
casein	I-protein
kinase	I-protein
2	I-protein
(	O
PK	B-protein
CK2	I-protein
)	O
in	O
vivo	O
.	O

Its	O
transcription	O
product	O
,	O
a	O
1	O
.	O
3	O
kb	O
mRNA	O
,	O
is	O
polyadenylated	O
at	O
a	O
site	O
containing	O
consensus	O
eukaryotic	O
polyadenylation	O
signals	O
and	O
mapping	O
87	O
bp	O
downstream	O
of	O
the	O
translation	O
termination	O
codon	O
for	O
CG30	B-protein
.	O

The	O
AL	O
-	O
R8	O
SI	O
:	O
the	O
next	O
generation	O
staging	O
container	O
for	O
plutonium	O
pits	O
at	O
the	O
USDOE	O
Pantex	O
Plant	O
.	O

Seven	O
patients	O
(	O
8	O
.	O
3	O
percent	O
)	O
had	O
latent	O
hypothyroidism	O
only	O
discovered	O
by	O
hormonal	O
determinations	O
.	O

In	O
contrast	O
to	O
other	O
known	O
retroviruses	O
,	O
the	O
FV	B-protein
pol	I-protein
genes	I-protein
are	O
expressed	O
via	O
spliced	O
transcripts	O
.	O

Two	O
basic	O
patterns	O
of	O
locomotor	O
behavior	O
and	O
corresponding	O
torso	O
morphology	O
exist	O
among	O
extant	O
anthropoids	O
.	O

Collagen	B-protein
was	O
extracted	O
from	O
the	O
skin	O
,	O
and	O
the	O
lack	O
of	O
type	B-protein
III	I-protein
collagen	I-protein
was	O
determined	O
by	O
means	O
of	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
.	O

Cooperative	O
roles	O
of	O
Bozozok	B-protein
/	I-protein
Dharma	I-protein
and	O
Nodal	B-protein
-	I-protein
related	I-protein
proteins	I-protein
in	O
the	O
formation	O
of	O
the	O
dorsal	O
organizer	O
in	O
zebrafish	O
.	O

Newcastle	O
disease	O
virus	O
surveillance	O
in	O
Hong	O
Kong	O
on	O
local	O
and	O
imported	O
poultry	O
.	O

RESULTS	O
:	O
Auditory	O
thresholds	O
collected	O
during	O
audiometric	O
tests	O
increased	O
gradually	O
in	O
proportion	O
with	O
age	O
,	O
especially	O
in	O
the	O
hypertensive	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
this	O
case	O
the	O
degree	O
of	O
promoter	O
methylation	O
,	O
which	O
could	O
extend	O
beyond	O
the	O
T	O
-	O
DNA	O
borders	O
,	O
was	O
not	O
correlated	O
with	O
the	O
reduction	O
in	O
steady	O
-	O
state	O
poly	O
(	O
A	O
)	O
+	O
mRNA	O
levels	O
,	O
the	O
silenced	O
state	O
was	O
transmitted	O
through	O
meiosis	O
and	O
reactivation	O
lasted	O
several	O
generations	O
.	O

We	O
report	O
the	O
use	O
of	O
a	O
new	O
technetium	O
-	O
99m	O
-	O
albumin	O
colloid	O
white	O
blood	O
cell	O
(	O
TAC	O
-	O
WBC	O
)	O
scan	O
in	O
the	O
evaluation	O
of	O
appendicitis	O
.	O

Thus	O
,	O
SOX8	B-protein
is	O
a	O
good	O
candidate	O
gene	O
contributing	O
to	O
the	O
mental	O
retardation	O
phenotype	O
seen	O
in	O
ATR	O
-	O
16	O
patients	O
.	O

The	O
concentrations	O
of	O
C4	B-protein
and	O
C1	B-protein
-	I-protein
INH	I-protein
increased	O
with	O
advancing	O
stage	O
of	O
disease	O
and	O
were	O
above	O
normal	O
mean	O
values	O
in	O
all	O
stages	O
.	O

We	O
measured	O
serum	B-protein
hepatocyte	I-protein
growth	I-protein
factor	I-protein
(	O
HGF	B-protein
)	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
,	O
angina	O
pectoris	O
,	O
and	O
other	O
heart	O
diseases	O
.	O

Cranio	O
-	O
caudal	O
differences	O
in	O
granulation	O
tissue	O
formation	O
:	O
an	O
experimental	O
study	O
in	O
the	O
rat	O
.	O

Here	O
we	O
show	O
that	O
for	O
expression	O
of	O
snRNA	O
genes	O
in	O
maize	O
,	O
a	O
monocotyledonous	O
plant	O
,	O
the	O
USE	O
and	O
TATA	O
elements	O
are	O
essential	O
,	O
but	O
not	O
sufficient	O
,	O
for	O
transcription	O
.	O

The	O
PETCO2	O
measurement	O
during	O
precordial	O
compression	O
predicted	O
the	O
success	O
of	O
defibrillation	O
with	O
return	O
of	O
spontaneous	O
circulation	O
.	O

RESULTS	O
:	O
The	O
binding	O
of	O
99mTc	O
d	O
,	O
1	O
-	O
HMPAO	O
to	O
human	O
placenta	O
ranged	O
from	O
2	O
.	O
95	O
%	O
+	O
/	O
-	O
1	O
.	O
5	O
%	O
to	O
5	O
.	O
82	O
%	O
+	O
/	O
-	O
0	O
.	O
3	O
%	O
per	O
1	O
ml	O
standard	O
solution	O
.	O

These	O
results	O
suggest	O
that	O
indoramin	O
may	O
have	O
Class	O
III	O
antiarrhythmic	O
activity	O
.	O

A	O
9	B-protein
.	I-protein
5	I-protein
-	I-protein
kb	I-protein
KpnI	I-protein
-	I-protein
SalI	I-protein
fragment	I-protein
,	O
where	O
all	O
the	O
DNA	O
changes	O
associated	O
with	O
su	B-protein
(	I-protein
Hw	I-protein
)	I-protein
mutations	I-protein
were	O
mapped	O
,	O
was	O
able	O
to	O
rescue	O
the	O
su	B-protein
(	I-protein
Hw	I-protein
)	I-protein
mutant	I-protein
phenotype	O
after	O
P	O
-	O
element	O
-	O
mediated	O
germ	O
-	O
line	O
transformation	O
.	O

A	O
panel	O
of	O
pharmacologic	O
inhibitors	O
was	O
used	O
to	O
investigate	O
the	O
signal	O
transduction	O
pathways	O
involved	O
in	O
TRAIL	B-protein
gene	I-protein
induction	O
following	O
T	O
lymphocyte	O
activation	O
.	O

Scanning	O
electron	O
microscopic	O
investigations	O
on	O
the	O
formation	O
of	O
Reissner	O
'	O
s	O
fiber	O
in	O
Rattus	O
rattus	O
.	O

The	O
sample	O
is	O
deproteinized	O
and	O
after	O
centrifugation	O
valproic	O
acid	O
in	O
the	O
supernatant	O
is	O
measured	O
in	O
the	O
free	O
form	O
by	O
direct	O
injection	O
into	O
the	O
gas	O
chromatograph	O
.	O

Further	O
,	O
intracerebroventricular	O
injections	O
of	O
KA	O
resulted	O
in	O
the	O
substantial	O
loss	O
of	O
pyramidal	O
cells	O
in	O
the	O
whole	O
CA3	O
field	O
of	O
the	O
hippocampus	O
.	O

Gabapentin	O
for	O
opiod	O
-	O
related	O
myoclonus	O
in	O
cancer	O
patients	O
.	O

Heterogeneous	O
electron	O
transfer	O
of	O
cytochrome	B-protein
c	I-protein
facilitated	O
by	O
polypyrrole	O
and	O
methylene	O
blue	O
polypyrrole	O
film	O
modified	O
electrodes	O
.	O

Epithelial	O
damage	O
was	O
not	O
observed	O
in	O
any	O
controls	O
but	O
was	O
in	O
all	O
tissues	O
exposed	O
to	O
SO2	O
.	O

Distribution	O
and	O
correlations	O
of	O
serum	O
uric	O
-	O
acid	O
in	O
two	O
French	O
adult	O
populations	O
:	O
13	O
,	O
885	O
men	O
and	O
6	O
,	O
861	O
women	O
.	O

Effects	O
of	O
cortisone	O
,	O
starvation	O
,	O
and	O
rickets	O
on	O
oxidative	O
enzyme	O
activities	O
of	O
epiphyseal	O
cartilage	O
from	O
rats	O
.	O

Transient	O
overexpression	O
of	O
mutant	B-protein
EphB1	I-protein
receptors	I-protein
(	O
Y594F	B-protein
)	O
blocked	O
Nck	B-protein
recruitment	O
to	O
EphB1	B-protein
,	O
attenuated	O
downstream	O
JNK	B-protein
activation	O
,	O
and	O
blocked	O
cell	O
attachment	O
responses	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
expression	O
of	O
Cktsf1b1	B-protein
,	O
a	O
gene	O
associated	O
with	O
early	O
development	O
and	O
cell	O
transformation	O
,	O
is	O
sensitive	O
to	O
MKK	B-protein
levels	O
and	O
may	O
be	O
regulated	O
via	O
multiple	O
transcription	O
factor	O
complexes	O
.	O

Drugs	O
suppressed	O
>	O
or	O
=	O
75	O
%	O
of	O
the	O
total	O
premature	O
ventricular	O
contractions	O
in	O
all	O
patients	O
who	O
had	O
both	O
use	O
-	O
dependent	O
QRS	O
prolongation	O
and	O
reverse	O
use	O
-	O
dependent	O
QT	O
prolongation	O
,	O
in	O
79	O
%	O
of	O
patients	O
with	O
use	O
-	O
dependent	O
QRS	O
prolongation	O
alone	O
,	O
in	O
70	O
%	O
with	O
reverse	O
use	O
-	O
dependent	O
QT	O
prolongation	O
alone	O
,	O
and	O
in	O
11	O
%	O
with	O
neither	O
use	O
-	O
dependent	O
QRS	O
prolongation	O
nor	O
reverse	O
use	O
-	O
dependent	O
QT	O
prolongation	O
.	O

CONCLUSION	O
:	O
NBP	O
pre	O
-	O
treatment	O
or	O
post	O
-	O
treatment	O
markedly	O
enhanced	O
the	O
rCBF	O
to	O
striatum	O
in	O
RMCAO	O
rats	O
.	O

Thioredoxin	B-protein
(	O
TR	B-protein
)	O
is	O
a	O
small	O
ubiquitous	O
dithiol	B-protein
-	I-protein
reductase	I-protein
enzyme	I-protein
first	O
identified	O
in	O
bacteria	O
and	O
plants	O
.	O

We	O
have	O
partially	O
sequenced	O
the	O
RAP74	B-protein
protein	I-protein
from	O
purified	O
HeLa	O
cells	O
,	O
cloned	O
its	O
complementary	O
DNA	O
and	O
shown	O
that	O
its	O
translation	O
product	O
can	O
interact	O
with	O
RAP30	B-protein
in	O
vitro	O
as	O
well	O
as	O
in	O
vivo	O
.	O

Regulation	O
of	O
the	O
human	B-protein
p21	I-protein
/	I-protein
WAF1	I-protein
/	I-protein
Cip1	I-protein
promoter	I-protein
in	O
hepatic	O
cells	O
by	O
functional	O
interactions	O
between	O
Sp1	B-protein
and	O
Smad	B-protein
family	I-protein
members	I-protein
.	O

Nonetheless	O
,	O
that	O
ventricular	O
afferents	O
,	O
in	O
certain	O
special	O
settings	O
,	O
are	O
able	O
to	O
induce	O
e	O
.	O
g	O
.	O
generalised	O
vasodilation	O
and	O
hypotension	O
can	O
not	O
be	O
excluded	O
.	O

A	O
comparison	O
of	O
the	O
nucleotide	O
and	O
deduced	O
amino	O
acid	O
sequences	O
of	O
the	O
core	O
regions	O
of	O
the	O
RNA	B-protein
-	I-protein
dependent	I-protein
RNA	I-protein
polymerase	I-protein
domains	I-protein
found	O
in	O
these	O
three	O
dsRNAs	B-protein
suggested	O
that	O
these	O
dsRNAs	B-protein
probably	O
evolved	O
independently	O
within	O
each	O
host	O
plant	O
from	O
a	O
common	O
ancestor	O
.	O

The	O
small	B-protein
GTPase	I-protein
Rho	I-protein
is	O
implicated	O
in	O
physiological	O
functions	O
associated	O
with	O
actin	O
-	O
myosin	O
filaments	O
such	O
as	O
cytokinesis	O
,	O
cell	O
motility	O
,	O
and	O
smooth	O
muscle	O
contraction	O
.	O

Canine	O
reproduction	O
:	O
effects	O
of	O
a	O
single	O
injection	O
of	O
medroxyprogesterone	O
acetate	O
on	O
the	O
reproductive	O
organs	O
of	O
the	O
bitch	O
.	O

The	O
size	O
of	O
the	O
infarct	O
was	O
determined	O
using	O
the	O
creatine	B-protein
kinase	I-protein
integral	O
method	O
.	O

The	O
identified	O
isolates	O
of	O
CSF	O
(	O
20	O
of	O
29	O
)	O
were	O
:	O
ECHO	O
30	O
(	O
9	O
)	O
,	O
ECHO	O
11	O
(	O
7	O
)	O
,	O
ECHO	O
9	O
(	O
3	O
)	O
and	O
ECHO	O
7	O
(	O
1	O
)	O
.	O

RESULTS	O
:	O
Plasma	B-protein
AVP	I-protein
responses	O
to	O
osmotic	O
stimulation	O
,	O
and	O
non	O
-	O
osmotic	O
inhibition	O
by	O
drinking	O
,	O
were	O
normal	O
in	O
patients	O
with	O
compulsive	O
water	O
drinking	O
.	O

Moreover	O
,	O
in	O
rats	O
allowed	O
to	O
choose	O
in	O
a	O
T	O
-	O
maze	O
between	O
immediate	O
-	O
but	O
-	O
small	O
vs	O
.	O
delayed	O
-	O
but	O
-	O
large	O
reward	O
,	O
BZP	O
significantly	O
decreased	O
the	O
frequency	O
with	O
which	O
the	O
delayed	O
reward	O
was	O
chosen	O
,	O
with	O
5	O
-	O
HT	O
uptake	O
blockers	O
producing	O
opposite	O
effects	O
.	O

Both	O
the	O
intact	B-protein
A1	I-protein
protein	I-protein
and	O
its	O
proteolytic	O
fragment	O
,	O
the	O
UP1	B-protein
protein	I-protein
,	O
can	O
be	O
cleaved	O
by	O
Staphylococcus	B-protein
aureus	I-protein
V	I-protein
-	I-protein
8	I-protein
protease	I-protein
to	O
produce	O
two	O
polypeptides	O
of	O
92	O
amino	O
acids	O
.	O

The	O
human	B-protein
p100	I-protein
protein	I-protein
was	O
recently	O
identified	O
as	O
a	O
coactivator	O
of	O
the	O
Epstein	B-protein
-	I-protein
Barr	I-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
.	O

SAM	O
-	O
TR	O
-	O
68	O
-	O
54	O
.	O

Consistent	O
with	O
the	O
hypothesis	O
that	O
it	O
acts	O
as	O
transcriptional	O
regulator	O
,	O
wild	B-protein
-	I-protein
type	I-protein
p53	I-protein
protein	I-protein
binds	O
DNA	O
and	O
activates	O
transcription	O
of	O
several	O
promoters	O
.	O

Critique	O
of	O
`	O
`	O
Interactive	O
Effects	O
of	O
Test	O
Anxiety	O
and	O
Credit	O
/	O
No	O
Credit	O
or	O
A	O
-	O
F	O
Grade	O
Condition	O
upon	O
Short	O
-	O
term	O
and	O
Long	O
-	O
term	O
Recall	O
of	O
Course	O
Information	O
.	O

The	O
distribution	O
of	O
red	O
rice	O
cultivation	O
in	O
Sri	O
Lanka	O
is	O
coincident	O
with	O
the	O
HIDD	O
villages	O
.	O

The	O
E1	B-protein
replication	I-protein
protein	I-protein
of	O
bovine	O
papillomavirus	O
type	O
1	O
contains	O
an	O
extended	O
nuclear	O
localization	O
signal	O
that	O
includes	O
a	O
p34cdc2	B-protein
phosphorylation	O
site	O
.	O

Stoichiometric	O
phosphorylation	O
of	O
human	B-protein
p53	I-protein
at	O
Ser315	O
stimulates	O
p53	O
-	O
dependent	O
transcription	O
.	O
p53	B-protein
protein	I-protein
activity	O
as	O
a	O
transcription	O
factor	O
can	O
be	O
activated	O
in	O
vivo	O
by	O
antibodies	O
that	O
target	O
its	O
C	O
-	O
terminal	O
negative	O
regulatory	O
domain	O
suggesting	O
that	O
cellular	O
enzymes	O
that	O
target	O
this	O
domain	O
may	O
play	O
a	O
role	O
in	O
stimulating	O
p53	O
-	O
dependent	O
gene	O
expression	O
.	O

Commutative	O
saccadic	O
generator	O
is	O
sufficient	O
to	O
control	O
a	O
3	O
-	O
D	O
ocular	O
plant	O
with	O
pulleys	O
.	O

Measurements	O
in	O
the	O
LWS	O
p	O
.	O
a	O
.	O
,	O
LWS	O
lat	O
.	O
and	O
at	O
Ward	O
'	O
s	O
triangle	O
were	O
made	O
in	O
a	O
total	O
of	O
100	O
patients	O
.	O

Elledge	O
,	O
P	O
.	O

With	O
the	O
modified	O
fingertip	O
-	O
to	O
-	O
floor	O
(	O
MFTF	O
)	O
method	O
,	O
patients	O
stand	O
on	O
a	O
stool	O
and	O
forward	O
bend	O
so	O
that	O
measurements	O
can	O
be	O
taken	O
on	O
patients	O
who	O
are	O
able	O
to	O
touch	O
the	O
floor	O
or	O
reach	O
beyond	O
the	O
level	O
of	O
the	O
floor	O
.	O

Clicking	O
on	O
`	O
`	O
Examples	O
and	O
Explanations	O
of	O
APA	O
Form	O
'	O
'	O
provides	O
a	O
help	O
system	O
with	O
examples	O
of	O
the	O
various	O
sections	O
of	O
a	O
review	O
article	O
,	O
journal	O
article	O
that	O
has	O
one	O
experiment	O
,	O
or	O
journal	O
article	O
that	O
has	O
two	O
or	O
more	O
experiments	O
.	O

This	O
proposed	O
method	O
is	O
similar	O
in	O
principle	O
to	O
the	O
sets	O
technique	O
but	O
is	O
shown	O
to	O
have	O
much	O
better	O
expected	O
time	O
to	O
alarm	O
properties	O
.	O

Morphine	O
produced	O
a	O
dose	O
-	O
dependent	O
bradycardia	O
followed	O
by	O
tachycardia	O
.	O

For	O
the	O
first	O
30	O
min	O
following	O
insulin	B-protein
administration	O
,	O
the	O
rate	O
of	O
change	O
in	O
glucose	O
levels	O
was	O
significantly	O
less	O
among	O
the	O
patients	O
with	O
major	O
depressive	O
disorder	O
than	O
among	O
either	O
the	O
patients	O
with	O
dysthymic	O
disorder	O
or	O
the	O
normal	O
control	O
subjects	O
.	O

The	O
expression	O
of	O
chloramphenicol	B-protein
acetyltransferase	I-protein
was	O
detected	O
within	O
1	O
h	O
after	O
infection	O
of	O
cells	O
with	O
recombinant	O
virus	O
,	O
reflecting	O
the	O
early	O
nature	O
of	O
the	O
promoters	O
used	O
.	O

Bioplastique	O
granuloma	O
presents	O
with	O
irregularly	O
shaped	O
cystic	O
spaces	O
of	O
varying	O
size	O
containing	O
jagged	O
,	O
translucent	O
,	O
nonbirefringent	O
foreign	O
bodies	O
whereas	O
Artecoll	O
granuloma	O
shows	O
numerous	O
round	O
vacuoles	O
nearly	O
identical	O
in	O
size	O
and	O
shape	O
enclosing	O
round	O
and	O
sharply	O
circumscribed	O
,	O
translucent	O
,	O
nonbirefringent	O
foreign	O
bodies	O
.	O

Two	O
transcripts	O
of	O
1	O
.	O
6	O
kb	O
and	O
5	O
.	O
8	O
kb	O
are	O
5	O
'	O
coterminal	O
and	O
may	O
both	O
encode	O
the	O
novel	O
glycoprotein	B-protein
gene	I-protein
EUS4	I-protein
.	O

A	O
randomised	O
,	O
controlled	O
trial	O
was	O
undertaken	O
in	O
40	O
patients	O
with	O
active	O
Crohn	O
'	O
s	O
disease	O
to	O
evaluate	O
clinical	O
and	O
nutritional	O
outcomes	O
after	O
an	O
amino	O
acid	O
based	O
diet	O
containing	O
3	O
%	O
fat	O
was	O
given	O
by	O
a	O
feeding	O
tube	O
compared	O
with	O
a	O
peptide	O
based	O
diet	O
containing	O
33	O
%	O
fat	O
.	O

Recombinant	B-protein
human	I-protein
erythropoietin	I-protein
(	O
epoetin	B-protein
)	O
is	O
approved	O
to	O
be	O
administered	O
by	O
the	O
intravenous	O
(	O
i	O
.	O
v	O
.	O
)	O
or	O
subcutaneous	O
(	O
SC	O
)	O
route	O
.	O

We	O
speculate	O
that	O
mast	O
cell	O
degranulation	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
necrobiosis	O
by	O
altering	O
fibroblast	O
enzyme	O
activity	O
and	O
/	O
or	O
producing	O
prolonged	O
inflammatory	O
reactions	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
a	O
cDNA	O
,	O
CHEMR1	B-protein
,	O
encoding	O
a	O
chemokine	B-protein
receptor	I-protein
with	O
a	O
homology	O
to	O
the	O
human	B-protein
C	I-protein
-	I-protein
C	I-protein
chemokine	I-protein
receptor	I-protein
,	O
CCR	B-protein
-	I-protein
4	I-protein
.	O

To	O
achieve	O
complete	O
dissection	O
of	O
the	O
anterior	O
vitreous	O
,	O
we	O
remove	O
even	O
a	O
clear	O
lens	O
during	O
the	O
first	O
surgical	O
intervention	O
in	O
selected	O
cases	O
.	O

Suggestive	O
evidence	O
was	O
obtained	O
that	O
cstA	B-protein
is	O
involved	O
in	O
peptide	O
utilization	O
.	O

QBMDs	O
for	O
a	O
5	O
%	O
change	O
in	O
response	O
(	O
QBMD05	O
)	O
were	O
6	O
-	O
fold	O
lower	O
,	O
on	O
average	O
,	O
than	O
the	O
corresponding	O
NOAEL	O
.	O

Using	O
the	O
polymerase	B-protein
chain	O
reaction	O
,	O
Whipple	B-protein
-	I-protein
specific	I-protein
DNA	I-protein
fragments	I-protein
of	O
284	O
base	O
pairs	O
from	O
the	O
genome	O
of	O
the	O
Whipple	O
bacterium	O
(	O
Tropheryma	O
whippelii	O
)	O
were	O
demonstrated	O
.	O

We	O
have	O
previously	O
reported	O
that	O
depletion	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
by	O
long	O
-	O
term	O
treatment	O
of	O
B16	O
mouse	O
melanoma	O
cells	O
with	O
phorbol	O
dibutyrate	O
(	O
PDBu	O
)	O
prevented	O
cell	O
density	O
-	O
dependent	O
melanogenesis	O
.	O

PM	O
12	O
or	O
18	O
mg	O
/	O
kg	O
daily	O
plus	O
a	O
standard	O
dose	O
of	O
SB	O
for	O
21	O
days	O
was	O
statistically	O
more	O
effective	O
than	O
SB	O
in	O
producing	O
a	O
final	O
cure	O
for	O
patients	O
with	O
VL	O
in	O
Bihar	O
,	O
India	O
.	O

Visidex	O
I	O
is	O
unsuitable	O
for	O
storage	O
and	O
re	O
-	O
reading	O
.	O

Silicosis	O
mortality	O
.	O

Rats	O
with	O
one	O
olfactory	O
bulb	O
removed	O
and	O
the	O
contralateral	O
naris	O
closed	O
can	O
detect	O
odors	O
.	O

Specimen	O
mass	O
reduction	O
increased	O
with	O
irradiance	O
from	O
19	O
to	O
72	O
%	O
of	O
the	O
initial	O
mass	O
for	O
9	O
-	O
-	O
31	O
W	O
/	O
cm	O
(	O
2	O
)	O
,	O
respectively	O
.	O

The	O
transcription	O
factor	O
Jun	B-protein
(	O
c	B-protein
-	I-protein
Jun	I-protein
)	O
functions	O
as	O
a	O
recipient	O
of	O
extracellular	O
growth	O
signals	O
and	O
converts	O
them	O
into	O
patterns	O
of	O
gene	O
expression	O
.	O

We	O
now	O
describe	O
the	O
identification	O
of	O
DEK	B-protein
as	O
this	O
43	B-protein
-	I-protein
kDa	I-protein
pets	I-protein
factor	I-protein
.	O

TH	B-protein
-	I-protein
SH3	I-protein
binding	O
in	O
vitro	O
is	O
abolished	O
by	O
specific	O
,	O
single	O
amino	O
acid	O
substitutions	O
within	O
the	O
Btk	B-protein
TH	I-protein
domain	I-protein
or	O
the	O
Fyn	B-protein
SH3	I-protein
domain	I-protein
.	O

Nuclear	O
extracts	O
prepared	O
from	O
both	O
neural	O
and	O
non	O
-	O
neural	O
cell	O
lines	O
,	O
mouse	O
brain	O
,	O
and	O
mouse	O
liver	O
contain	O
proteins	O
that	O
recognize	O
and	O
bind	O
to	O
the	O
PROX	B-protein
and	O
PAL	B-protein
sequences	I-protein
indicating	O
that	O
proteins	O
which	O
bind	O
to	O
these	O
target	O
sequences	O
are	O
widespread	O
.	O

The	O
exon	O
-	O
intron	O
distribution	O
of	O
Cdebp	B-protein
appears	O
strikingly	O
similar	O
to	O
that	O
of	O
the	O
App	B-protein
gene	I-protein
in	O
the	O
regions	O
encoding	O
the	O
conserved	O
domains	O
,	O
with	O
a	O
divergent	O
structure	O
in	O
the	O
other	O
parts	O
.	O

We	O
also	O
review	O
the	O
role	O
of	O
grains	O
in	O
the	O
formation	O
of	O
complex	O
molecules	O
in	O
interstellar	O
molecular	O
clouds	O
.	O

Identification	O
of	O
an	O
enhancer	O
and	O
an	O
alternative	O
promoter	O
in	O
the	O
first	O
intron	O
of	O
the	O
alpha	B-protein
-	I-protein
fetoprotein	I-protein
gene	I-protein
.	O

Spontaneous	O
burst	O
firing	O
in	O
cat	O
primary	O
auditory	O
cortex	O
:	O
age	O
and	O
depth	O
dependence	O
and	O
its	O
effect	O
on	O
neural	O
interaction	O
measures	O
.	O

Second	O
,	O
plasmid	O
-	O
derived	O
transgenes	O
and	O
gene	O
targeting	O
of	O
the	O
endogenous	B-protein
Hnf3g	I-protein
gene	I-protein
locus	I-protein
were	O
used	O
to	O
demonstrate	O
that	O
the	O
3	O
'	O
-	O
flanking	O
region	O
of	O
the	O
gene	O
is	O
necessary	O
and	O
sufficient	O
to	O
direct	O
reporter	O
gene	O
expression	O
in	O
liver	O
,	O
pancreas	O
,	O
stomach	O
and	O
small	O
intestine	O
.	O

Consistent	O
with	O
a	O
possible	O
role	O
in	O
transcription	O
,	O
Paf1p	B-protein
is	O
localized	O
to	O
the	O
nucleus	O
.	O

However	O
,	O
if	O
the	O
spatial	O
resolution	O
is	O
not	O
critical	O
and	O
interest	O
is	O
to	O
compare	O
a	O
pathologic	O
area	O
with	O
a	O
contralateral	O
VOI	O
,	O
then	O
the	O
acquisition	O
of	O
two	O
single	O
-	O
voxel	O
spectra	O
may	O
be	O
preferred	O
.	O

Angiographic	O
work	O
-	O
up	O
in	O
a	O
patient	O
with	O
late	O
vaginal	O
metastasis	O
from	O
a	O
renal	O
carcinoma	O
.	O

Adaptation	O
of	O
taurocholate	O
transport	O
maximum	O
to	O
increased	O
secretory	O
load	O
in	O
the	O
rat	O
.	O

This	O
suggested	O
that	O
delta	O
6	O
and	O
delta	O
5	O
desaturation	O
activities	O
are	O
normal	O
in	O
these	O
conditions	O
with	O
this	O
C18	O
:	O
2w6	O
supply	O
.	O

The	O
mean	O
values	O
of	O
the	O
first	O
three	O
components	O
were	O
not	O
significantly	O
different	O
in	O
ARVD	O
patients	O
and	O
control	O
subjects	O
.	O

Additional	O
information	O
including	O
echocardiographic	O
sequences	O
,	O
perioperative	O
video	O
sequences	O
,	O
x	O
-	O
ray	O
analysis	O
,	O
angiograms	O
,	O
etc	O
.	O
is	O
represented	O
in	O
the	O
program	O
.	O

Classification	O
according	O
to	O
the	O
ILAR	O
criteria	O
was	O
possible	O
in	O
321	O
patients	O
;	O
290	O
patients	O
had	O
a	O
disease	O
duration	O
>	O
or	O
=	O
3	O
months	O
and	O
were	O
classified	O
according	O
to	O
the	O
EULAR	O
criteria	O
.	O

In	O
order	O
to	O
delineate	O
structural	O
motifs	O
regulating	O
substrate	O
affinity	O
and	O
recognition	O
for	O
the	O
human	B-protein
dopamine	I-protein
transporter	I-protein
(	O
DAT	B-protein
)	O
,	O
we	O
assessed	O
[	O
3H	O
]	O
dopamine	O
uptake	O
kinetics	O
and	O
[	O
3H	O
]	O
CFT	O
binding	O
characteristics	O
of	O
COS	O
-	O
7	O
cells	O
transiently	O
expressing	O
mutant	B-protein
DATs	I-protein
in	O
which	O
the	O
COOH	O
terminus	O
was	O
truncated	O
or	O
substituted	O
.	O

Thus	O
,	O
methylation	O
of	O
Pph21p	B-protein
is	O
important	O
for	O
formation	O
of	O
PP2A	B-protein
trimeric	I-protein
and	I-protein
dimeric	I-protein
complexes	I-protein
,	O
and	O
consequently	O
,	O
for	O
PP2A	B-protein
function	O
.	O

157	O
+	O
/	O
-	O
16	O
mg	O
/	O
dl	O
;	O
NS	O
)	O
,	O
glucose	O
levels	O
,	O
and	O
basal	O
(	O
17	O
+	O
/	O
-	O
4	O
vs	O
.	O

Collectively	O
,	O
these	O
experiments	O
demonstrate	O
that	O
CFTR	B-protein
'	I-protein
s	I-protein
NBF1	I-protein
+	I-protein
R	I-protein
region	I-protein
and	O
its	O
NBF2	B-protein
domain	I-protein
,	O
after	O
folding	O
separately	O
as	O
distinct	O
units	O
,	O
have	O
a	O
strong	O
propensity	O
to	O
interact	O
and	O
that	O
this	O
interaction	O
is	O
stable	O
in	O
the	O
absence	O
of	O
added	O
nucleotides	O
or	O
exogenously	O
induced	O
phosphorylation	O
.	O

In	O
patients	O
who	O
were	O
not	O
vented	O
,	O
there	O
was	O
overall	O
significant	O
depression	O
of	O
function	O
(	O
67	O
+	O
/	O
-	O
5	O
%	O
of	O
control	O
;	O
range	O
,	O
91	O
-	O
-	O
45	O
%	O
,	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Value	O
of	O
the	O
method	O
of	O
passive	O
hemagglutination	O
with	O
polysaccharide	O
C	O
in	O
detecting	O
C	B-protein
-	I-protein
reactive	I-protein
protein	I-protein
as	O
compared	O
to	O
precipitation	O
in	O
capillaries	O
and	O
slide	O
latex	O
test	O
with	O
anti	B-protein
-	I-protein
CRP	I-protein
serum	O
.	O

2	O
new	O
Algerian	O
cases	O
.	O

Expression	O
of	O
the	O
src	B-protein
homology	I-protein
3	I-protein
(	O
SH3	B-protein
)	O
-	O
encoding	O
,	O
expressed	O
in	O
tumorigenic	O
astrocytes	O
(	O
SETA	O
)	O
gene	O
is	O
associated	O
with	O
astrocyte	O
transformation	O
in	O
culture	O
and	O
tumors	O
in	O
the	O
adult	O
brain	O
.	O

We	O
have	O
recently	O
detected	O
high	O
levels	O
of	O
CKB	B-protein
mRNA	I-protein
in	O
HeLa	O
cells	O
and	O
,	O
in	O
this	O
study	O
,	O
have	O
tested	O
whether	O
this	O
may	O
be	O
due	O
to	O
the	O
extremely	O
low	O
amounts	O
of	O
p53	B-protein
protein	I-protein
present	O
in	O
HeLa	O
cells	O
.	O

Video	O
images	O
of	O
the	O
nostrils	O
were	O
captured	O
and	O
then	O
analyzed	O
for	O
area	O
,	O
perimeter	O
,	O
centroid	O
,	O
principal	O
axis	O
,	O
moments	O
about	O
the	O
major	O
and	O
minor	O
axes	O
(	O
I11	O
,	O
I22	O
)	O
,	O
anisometry	O
,	O
bulkiness	O
,	O
lateral	O
offset	O
,	O
internostril	O
angle	O
,	O
and	O
rotational	O
angle	O
.	O

A	O
randomized	O
mix	O
of	O
180	O
sections	O
(	O
10	O
samples	O
x	O
3	O
tissues	O
x	O
3	O
stains	O
x	O
2	O
)	O
gave	O
90	O
matched	O
pairs	O
.	O

Four	O
out	O
of	O
10	O
patients	O
showed	O
clinical	O
improvement	O
according	O
to	O
Ritchie	O
-	O
Index	O
,	O
pain	O
score	O
,	O
ESR	O
and	O
CRP	O
.	O

Experiments	O
with	O
recombinant	O
proteins	O
showed	O
that	O
p50	B-protein
/	I-protein
p65	I-protein
and	O
high	B-protein
-	I-protein
mobility	I-protein
-	I-protein
group	I-protein
I	I-protein
(	I-protein
Y	I-protein
)	I-protein
protein	I-protein
cooperatively	O
facilitated	O
the	O
binding	O
of	O
IRF	B-protein
-	I-protein
1	I-protein
to	O
the	O
VCAM1	B-protein
IRF	I-protein
binding	I-protein
site	I-protein
and	O
that	O
IRF	B-protein
-	I-protein
1	I-protein
physically	O
interacted	O
with	O
p50	B-protein
and	O
with	O
high	B-protein
-	I-protein
mobility	I-protein
-	I-protein
group	I-protein
I	I-protein
(	I-protein
Y	I-protein
)	I-protein
protein	I-protein
.	O

Control	O
intact	O
rats	O
were	O
age	O
-	O
matched	O
to	O
the	O
different	O
treated	O
groups	O
.	O

Platelet	O
function	O
and	O
platelet	O
-	O
polymorphonuclear	O
-	O
neutrophil	O
interaction	O
in	O
patients	O
with	O
deficient	O
platelet	B-protein
lipoxygenase	I-protein
activity	O
.	O

This	O
machine	O
drift	O
,	O
which	O
was	O
not	O
associated	O
with	O
a	O
rise	O
in	O
water	O
phantom	O
temperature	O
and	O
did	O
not	O
consistently	O
correlate	O
with	O
estimated	O
x	O
-	O
ray	O
tube	O
heat	O
,	O
could	O
result	O
in	O
a	O
significant	O
overestimation	O
of	O
regional	O
cerebral	O
blood	O
flow	O
(	O
rCBF	O
)	O
for	O
a	O
xenon	O
/	O
CT	O
rCBF	O
protocol	O
involving	O
5	O
-	O
7	O
sequential	O
scans	O
obtained	O
at	O
1	O
-	O
min	O
interscan	O
intervals	O
.	O

In	O
this	O
report	O
,	O
we	O
present	O
two	O
lines	O
of	O
evidence	O
that	O
all	O
ribosomes	O
which	O
synthesize	O
GCN4	B-protein
have	O
previously	O
translated	O
uORF1	B-protein
,	O
resumed	O
scanning	O
,	O
and	O
reinitiated	O
at	O
the	O
GCN4	B-protein
start	O
site	O
.	O

A	O
36	O
year	O
-	O
old	O
woman	O
was	O
given	O
Ergotamine	O
Tartrate	O
4	O
.	O
5	O
mg	O
p	O
.	O
d	O
.	O
during	O
seven	O
days	O
,	O
after	O
an	O
abortion	O
(	O
a	O
still	O
birth	O
)	O
.	O

An	O
economic	O
analysis	O
using	O
West	O
of	O
Scotland	O
Coronary	O
Prevention	O
Study	O
(	O
WOSCOPS	O
)	O
findings	O
indicates	O
that	O
statin	O
treatment	O
would	O
have	O
prevented	O
318	O
events	O
per	O
10	O
,	O
000	O
patients	O
in	O
a	O
population	O
similar	O
to	O
that	O
in	O
WOSCOPS	O
(	O
average	O
1	O
.	O
5	O
%	O
annual	O
risk	O
of	O
a	O
cardiovascular	O
event	O
)	O
at	O
a	O
discounted	O
cost	O
per	O
life	O
-	O
year	O
gained	O
of	O
pound20	O
,	O
375	O
(	O
$	O
31	O
,	O
818	O
)	O
.	O

The	O
titer	O
of	O
TSH	B-protein
binding	I-protein
inhibitor	I-protein
immunoglobulin	I-protein
(	O
TBII	B-protein
)	O
,	O
which	O
had	O
been	O
8	O
.	O
6	O
%	O
at	O
initial	O
presentation	O
,	O
rose	O
to	O
14	O
.	O
9	O
%	O
in	O
2	O
weeks	O
.	O

A	O
possible	O
decrease	O
in	O
theophylline	O
'	O
s	O
volume	O
of	O
distribution	O
at	O
4	O
days	O
,	O
but	O
not	O
immediately	O
,	O
after	O
administration	O
of	O
chloroquine	O
was	O
suggested	O
,	O
although	O
this	O
just	O
failed	O
to	O
achieve	O
statistical	O
significance	O
(	O
p	O
=	O
0	O
.	O
055	O
)	O
.	O

There	O
was	O
no	O
correlation	O
between	O
secretor	O
status	O
and	O
clinical	O
status	O
,	O
spirometry	O
measurements	O
,	O
salivary	B-protein
and	I-protein
serum	I-protein
lysozyme	I-protein
levels	O
or	O
rates	O
of	O
respiratory	O
tract	O
colonization	O
with	O
P	O
.	O
aeruginosa	O
and	O
S	O
.	O
aureus	O
.	O

The	O
results	O
presented	O
in	O
this	O
report	O
suggest	O
that	O
the	O
SV40	O
G	O
-	O
C	O
-	O
rich	O
sequences	O
can	O
function	O
as	O
independent	O
RNA	B-protein
polymerase	I-protein
II	I-protein
transcriptional	O
-	O
control	O
elements	O
.	O

To	O
determine	O
if	O
signing	O
,	O
when	O
established	O
,	O
would	O
compete	O
with	O
SIB	O
when	O
both	O
were	O
reinforced	O
,	O
extinction	O
was	O
then	O
withdrawn	O
.	O

Fructokinase	B-protein
activity	O
is	O
elevated	O
up	O
to	O
twofold	O
when	O
Z	O
.	O
mobilis	O
was	O
grown	O
on	O
fructose	O
instead	O
of	O
glucose	O
,	O
and	O
there	O
was	O
a	O
parallel	O
increase	O
in	O
frk	B-protein
mRNA	I-protein
levels	O
.	O

Mycoplasma	O
pneumoniae	O
was	O
isolated	O
from	O
the	O
pleural	O
fluid	O
of	O
this	O
patient	O
.	O

We	O
found	O
that	O
T3	B-protein
(	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
selectively	O
stimulates	O
transcription	O
from	O
rGH	O
-	O
TRE	O
-	O
and	O
TREpal	O
-	O
,	O
but	O
not	O
ME	O
-	O
TRE	O
-	O
and	O
F2	O
-	O
TRE	O
-	O
,	O
containing	O
templates	O
in	O
which	O
these	O
TREs	O
are	O
linked	O
in	O
front	O
of	O
the	O
rGH	B-protein
minimal	I-protein
promoter	I-protein
containing	O
only	O
the	O
TATA	B-protein
box	I-protein
binding	I-protein
protein	I-protein
,	O
but	O
not	O
any	O
other	O
proximal	O
binding	O
protein	O
,	O
sequence	O
.	O

On	O
the	O
basis	O
of	O
a	O
patient	O
'	O
s	O
report	O
of	O
one	O
inaccurate	O
Clinitemp	O
,	O
we	O
undertook	O
to	O
investigate	O
the	O
accuracy	O
of	O
this	O
thermometer	O
.	O

However	O
,	O
three	O
Hm1	B-protein
mutants	I-protein
that	O
were	O
moderately	O
deficient	O
in	O
stimulating	O
PI	O
turnover	O
displayed	O
normal	O
sequestration	O
,	O
suggesting	O
distinct	O
mechanisms	O
.	O

Therefore	O
,	O
it	O
would	O
be	O
advantageous	O
to	O
identify	O
such	O
persons	O
and	O
treat	O
them	O
preferentially	O
.	O

Large	O
scale	O
electronic	O
structure	O
calculations	O
.	O

Southern	O
blot	O
hybridization	O
experiments	O
suggest	O
the	O
presence	O
of	O
one	O
copy	O
of	O
Atcys1	B-protein
,	O
Athyp1	B-protein
and	O
AKin10	B-protein
per	O
haploid	O
genome	O
,	O
and	O
Northern	O
blot	O
analysis	O
demonstrates	O
that	O
the	O
three	O
genes	O
are	O
differentially	O
expressed	O
in	O
roots	O
,	O
shoots	O
and	O
leaves	O
.	O

Indeed	O
the	O
predicted	O
folding	O
of	O
the	O
5	O
'	O
and	O
3	O
'	O
-	O
untranslated	O
regions	O
revealed	O
patterns	O
of	O
stem	O
and	O
loop	O
structures	O
conserved	O
for	O
all	O
tick	O
-	O
borne	O
flaviviruses	O
suggesting	O
a	O
purifying	O
selection	O
for	O
preservation	O
of	O
essential	O
RNA	O
secondary	O
structures	O
which	O
could	O
be	O
involved	O
in	O
translational	O
control	O
and	O
replication	O
.	O

Taurine	O
deficiency	O
significantly	O
depressed	O
the	O
amplitude	O
of	O
OP1	O
and	O
OP4	O
.	O

The	O
promoter	O
region	O
showed	O
no	O
consensus	O
TATA	O
box	O
but	O
it	O
contains	O
CCAAT	O
and	O
CreA	B-protein
boxes	I-protein
known	O
to	O
be	O
involved	O
in	O
both	O
stress	O
and	O
carbon	O
-	O
catabolite	O
regulation	O
of	O
fungal	O
promoters	O
.	O

We	O
remain	O
convinced	O
that	O
antilymphocyte	B-protein
globulin	I-protein
(	O
ALG	B-protein
)	O
is	O
a	O
potent	O
immunosuppressive	O
agent	O
in	O
humans	O
.	O

An	O
increase	O
in	O
hypothalamic	O
expression	O
of	O
at	O
least	O
two	O
of	O
the	O
erbB	B-protein
receptors	I-protein
is	O
initiated	O
before	O
the	O
pubertal	O
augmentation	O
of	O
gonadal	O
steroid	O
secretion	O
and	O
is	O
completed	O
on	O
the	O
day	O
of	O
the	O
first	O
preovulatory	O
surge	O
of	O
gonadotropins	B-protein
.	O

These	O
data	O
indicate	O
that	O
phosphorylation	O
of	O
M	B-protein
protein	I-protein
at	O
the	O
major	O
in	O
vivo	O
sites	O
is	O
not	O
essential	O
for	O
virus	O
assembly	O
.	O

Aviators	O
from	O
the	O
Light	O
Attack	O
Wing	O
,	O
Pacific	O
were	O
surveyed	O
and	O
the	O
results	O
were	O
categorized	O
by	O
aircraft	O
type	O
.	O

Identification	O
of	O
mutations	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
proto	B-protein
-	I-protein
oncogene	I-protein
c	I-protein
-	I-protein
kit	I-protein
in	O
a	O
human	O
mast	O
cell	O
leukemia	O
cell	O
line	O
causing	O
ligand	O
-	O
independent	O
activation	O
of	O
c	B-protein
-	I-protein
kit	I-protein
product	I-protein
.	O

73	O
:	O
658	O
-	O
666	O
,	O
1999	O
)	O
.	O

A	O
patient	O
is	O
described	O
with	O
skin	O
lesions	O
resembling	O
Kaposi	O
'	O
s	O
sarcoma	O
(	O
KS	O
)	O
.	O

Such	O
mutations	O
are	O
thought	O
to	O
exert	O
their	O
dominant	O
phenotype	O
by	O
sequestration	O
of	O
the	O
guanine	B-protein
nucleotide	I-protein
exchange	I-protein
factor	I-protein
(	O
GNEF	B-protein
)	O
.	O

Induction	O
of	O
AtP5CS1	B-protein
mRNA	I-protein
accumulation	O
in	O
salt	O
-	O
treated	O
seedlings	O
involves	O
an	O
immediate	O
early	O
transcriptional	O
response	O
regulated	O
by	O
ABA	B-protein
signalling	O
that	O
is	O
not	O
inhibited	O
by	O
cycloheximide	O
,	O
but	O
abolished	O
by	O
the	O
deficiency	O
of	O
ABA	B-protein
biosynthesis	O
in	O
the	O
aba1	B-protein
Arabidopsis	I-protein
mutant	I-protein
.	O

L	O
-	O
canavanine	O
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
inducible	O
nitric	B-protein
oxide	I-protein
synthase	I-protein
,	O
increases	O
the	O
mean	O
systemic	O
filling	O
pressure	O
,	O
thereby	O
improving	O
venous	O
return	O
,	O
under	O
these	O
conditions	O
.	O

One	O
of	O
these	O
SEBPs	B-protein
,	O
SEBP2	B-protein
,	O
was	O
shown	O
to	O
be	O
the	O
product	O
of	O
the	O
homeotic	B-protein
gene	I-protein
fork	I-protein
head	I-protein
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
using	O
purified	O
glucocorticoid	B-protein
receptor	I-protein
DNA	I-protein
binding	I-protein
domain	I-protein
(	O
DBD	O
)	O
demonstrated	O
that	O
both	O
GRE	B-protein
-	I-protein
2	I-protein
and	I-protein
-	I-protein
3	I-protein
motifs	I-protein
interact	O
with	O
DBD	O
and	O
oligonucleotide	O
competition	O
experiments	O
established	O
that	O
these	O
have	O
different	O
affinities	O
for	O
DBD	O
.	O

Human	B-protein
T	I-protein
-	I-protein
cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
I	I-protein
(	I-protein
HTLV	I-protein
-	I-protein
I	I-protein
)	I-protein
Tax	I-protein
is	O
a	O
potent	O
transcriptional	O
regulator	O
that	O
can	O
activate	O
or	O
repress	O
specific	O
cellular	O
genes	O
and	O
that	O
has	O
been	O
proposed	O
to	O
contribute	O
to	O
leukemogenesis	O
in	O
adult	O
T	O
-	O
cell	O
leukemia	O
.	O

CONCLUSION	O
:	O
Presence	O
of	O
APOE	B-protein
epsilon4	I-protein
/	I-protein
*	I-protein
seems	O
to	O
increase	O
the	O
risk	O
for	O
dementia	O
and	O
AD	O
independently	O
of	O
its	O
effect	O
on	O
dyslipidemia	O
and	O
atherogenesis	O
.	O

Experimental	O
pancreatitis	O
in	O
pigs	O
.	O

These	O
IgG	B-protein
antibodies	I-protein
in	O
the	O
babies	O
diminished	O
rapidly	O
after	O
delivery	O
,	O
and	O
were	O
detectable	O
only	O
in	O
3	O
cases	O
at	O
2	O
,	O
3	O
,	O
and	O
5	O
months	O
of	O
ages	O
out	O
of	O
38	O
babies	O
up	O
to	O
21	O
months	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
One	O
hundred	O
eighty	O
-	O
four	O
chemotherapy	O
-	O
naive	O
patients	O
receiving	O
high	O
-	O
dose	O
cisplatin	O
(	O
81	O
to	O
120	O
mg	O
/	O
m2	O
)	O
were	O
randomized	O
to	O
receive	O
one	O
of	O
four	O
granisetron	O
doses	O
(	O
5	O
,	O
10	O
,	O
20	O
,	O
or	O
40	O
micrograms	O
/	O
kg	O
)	O
administered	O
before	O
chemotherapy	O
.	O

Subtraction	O
hybridization	O
identified	O
melanoma	B-protein
differentiation	I-protein
associated	I-protein
gene	I-protein
-	I-protein
7	I-protein
(	O
mda	B-protein
-	I-protein
7	I-protein
)	O
,	O
as	O
a	O
gene	O
induced	O
during	O
these	O
physiological	O
changes	O
in	O
human	O
melanoma	O
cells	O
.	O

The	O
euglobulin	O
clot	O
lysis	O
time	O
was	O
slightly	O
longer	O
in	O
the	O
smokers	O
than	O
in	O
the	O
non	O
-	O
smokers	O
in	O
all	O
three	O
experimental	O
situations	O
,	O
but	O
the	O
differences	O
were	O
not	O
significant	O
.	O

The	O
two	O
IL6	B-protein
mRNA	I-protein
species	O
are	O
generated	O
by	O
alternative	O
polyadenylation	O
at	O
sites	O
separated	O
by	O
a	O
distance	O
of	O
1	O
.	O
2	O
kilobases	O
.	O

We	O
previously	O
reported	O
that	O
Tax	B-protein
induced	O
cell	O
cycle	O
progression	O
from	O
G0	O
/	O
G1	O
phase	O
to	O
S	O
and	O
G2	O
/	O
M	O
phases	O
in	O
human	O
T	O
-	O
cell	O
line	O
Kit	O
225	O
cells	O
.	O

In	O
the	O
last	O
20	O
years	O
,	O
the	O
therapeutic	O
uses	O
of	O
botulinum	B-protein
toxin	I-protein
,	O
a	O
potent	O
neurotoxin	O
,	O
have	O
been	O
investigated	O
.	O

Obstruction	O
of	O
the	O
ERF	B-protein
repressor	I-protein
function	O
by	O
the	O
transactivating	O
members	O
of	O
the	O
ets	B-protein
family	I-protein
of	O
genes	O
(	O
i	O
.	O
e	O
.	O
gag	O
-	O
myb	O
-	O
ets	O
)	O
may	O
be	O
essential	O
for	O
the	O
control	O
of	O
genes	O
involved	O
in	O
cell	O
proliferation	O
and	O
may	O
also	O
underlie	O
their	O
tumorigenic	O
effects	O
.	O

Intraventricular	O
injection	O
of	O
(	O
2S	O
,	O
1	O
'	O
R	O
,	O
2	O
'	O
R	O
,	O
3	O
'	O
R	O
)	O
-	O
2	O
-	O
(	O
2	O
,	O
3	O
-	O
dicarboxycyclopropyl	O
)	O
glycine	O
(	O
DCG	O
-	O
IV	O
)	O
,	O
a	O
potent	O
agonist	O
for	O
metabotropic	O
glutamate	B-protein
receptors	I-protein
,	O
to	O
rats	O
retarded	O
dose	O
-	O
dependently	O
the	O
recovery	O
from	O
halothane	O
anesthesia	O
at	O
a	O
dose	O
range	O
from	O
30	O
to	O
300	O
pmol	O
/	O
rat	O
.	O

The	O
single	O
most	O
important	O
element	O
,	O
by	O
linker	O
-	O
scanning	O
analysis	O
,	O
is	O
a	O
10	O
-	O
bp	O
region	O
that	O
contains	O
a	O
CCAAT	O
motif	O
.	O

We	O
took	O
advantage	O
of	O
the	O
high	O
degree	O
of	O
aa	O
sequence	O
homology	O
between	O
DAHPSs	B-protein
from	O
several	O
species	O
to	O
isolate	O
ARO3	B-protein
homologues	I-protein
from	O
the	O
pathogenic	O
yeast	O
Candida	O
albicans	O
.	O

The	O
serum	O
levels	O
of	O
beta	B-protein
-	I-protein
human	I-protein
chorionic	I-protein
gonadotropin	I-protein
(	O
HCG	B-protein
)	O
and	O
placental	B-protein
alkaline	I-protein
phosphatase	I-protein
(	O
PLAP	B-protein
)	O
were	O
not	O
elevated	O
.	O

Effects	O
of	O
aging	O
and	O
beta	O
-	O
adrenergic	O
-	O
blockade	O
on	O
standing	O
-	O
induced	O
QT	O
/	O
QS2	O
changes	O
.	O

Several	O
nuclear	O
factors	O
that	O
interact	O
with	O
sequences	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
mouse	B-protein
tyrosinase	I-protein
gene	I-protein
were	O
identified	O
using	O
band	O
shift	O
and	O
methylation	O
interference	O
assays	O
.	O

All	O
corneal	O
buttons	O
were	O
processed	O
for	O
histopathologic	O
and	O
electron	O
microscopic	O
studies	O
.	O

In	O
gel	O
mobility	O
shift	O
assays	O
,	O
we	O
found	O
no	O
evidence	O
for	O
VDR	B-protein
-	I-protein
TR	I-protein
heterodimer	I-protein
interaction	O
with	O
any	O
tested	O
element	O
.	O

A	O
combined	O
series	O
of	O
patients	O
experienced	O
a	O
TOL	O
after	O
two	O
or	O
more	O
previous	O
cesarean	O
deliveries	O
;	O
the	O
rate	O
of	O
vaginal	O
delivery	O
was	O
66	O
%	O
,	O
and	O
there	O
was	O
virtually	O
no	O
morbidity	O
.	O

The	O
two	O
drugs	O
increase	O
the	O
rate	O
of	O
early	O
diastolic	O
filling	O
.	O

3	O
-	O
-	O
It	O
is	O
necessary	O
to	O
think	O
about	O
cosmetic	O
consequences	O
of	O
the	O
chinese	O
flap	O
and	O
consider	O
other	O
possibilities	O
of	O
the	O
flap	O
choice	O
.	O

The	O
HPLC	O
method	O
involves	O
an	O
octadecylsilane	O
column	O
at	O
55	O
degrees	O
C	O
,	O
a	O
mixture	O
of	O
water	O
-	O
acetonitrile	O
-	O
orthophosphoric	O
acid	O
(	O
779	O
:	O
220	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
as	O
mobile	O
phase	O
and	O
detection	O
at	O
226	O
nm	O
.	O

The	O
results	O
indicate	O
that	O
hrpRS	B-protein
and	O
hrpL	B-protein
are	O
part	O
of	O
a	O
regulatory	O
cascade	O
in	O
which	O
HrpR	B-protein
and	O
HrpS	B-protein
activate	O
expression	O
of	O
hrpL	B-protein
and	O
HrpL	B-protein
,	O
a	O
putative	O
sigma	B-protein
factor	I-protein
,	O
induces	O
expression	O
of	O
HrpL	B-protein
-	I-protein
responsive	I-protein
genes	I-protein
.	O

In	O
Xenopus	O
embryos	O
,	O
the	O
engineered	B-protein
PDGF	I-protein
receptor	I-protein
protein	I-protein
induced	O
the	O
formation	O
of	O
mesoderm	O
from	O
animal	O
-	O
pole	O
explants	O
in	O
an	O
FK1012	O
-	O
dependent	O
manner	O
.	O

In	O
particular	O
,	O
Western	O
,	O
supershift	O
,	O
and	O
promoter	O
deletion	O
analyses	O
suggested	O
a	O
role	O
for	O
CCAAT	B-protein
/	I-protein
enhancer	I-protein
-	I-protein
binding	I-protein
protein	I-protein
-	I-protein
beta	I-protein
(	O
C	B-protein
/	I-protein
EBP	I-protein
-	I-protein
beta	I-protein
)	O
binding	O
site	O
between	O
-	O
2010	O
and	O
-	O
1954	O
in	O
regulating	O
transcription	O
of	O
collagenase	B-protein
-	I-protein
1	I-protein
in	O
monocytic	O
cells	O
.	O

Mus81p	B-protein
also	O
shares	O
homology	O
with	O
motifs	O
found	O
in	O
the	O
XPF	B-protein
endonuclease	I-protein
superfamily	I-protein
.	O

In	O
the	O
Rett	O
syndrome	O
we	O
,	O
therefore	O
,	O
suspect	O
there	O
are	O
disturbances	O
in	O
the	O
brain	O
stem	O
functions	O
especially	O
in	O
the	O
ascending	O
reticular	O
activating	O
system	O
which	O
is	O
related	O
to	O
elevation	O
of	O
the	O
conscious	O
level	O
.	O

Multistep	O
transformation	O
by	O
defined	O
fragments	O
of	O
herpes	B-protein
simplex	I-protein
virus	I-protein
type	I-protein
2	I-protein
DNA	I-protein
:	I-protein
oncogenic	I-protein
region	I-protein
and	O
its	O
gene	O
product	O
.	O

Similarly	O
,	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
activator	B-protein
protein	I-protein
1	I-protein
(	O
AP	B-protein
-	I-protein
1	I-protein
)	O
is	O
modified	O
by	O
a	O
DNA	B-protein
repair	I-protein
enzyme	I-protein
,	O
redox	B-protein
factor	I-protein
1	I-protein
(	O
Ref	B-protein
-	I-protein
1	I-protein
)	O
,	O
which	O
is	O
identical	O
to	O
a	O
DNA	B-protein
repair	I-protein
enzyme	I-protein
,	O
AP	B-protein
endonuclease	I-protein
.	O

Stereotactic	O
radiofrequency	O
lesioning	O
of	O
the	O
hamartoma	O
resulted	O
in	O
seizure	O
remission	O
without	O
complications	O
20	O
months	O
after	O
surgery	O
.	O

Gastric	O
CO2	O
/	O
HCO3	O
was	O
determined	O
in	O
absence	O
of	O
simultaneous	O
inhibition	O
of	O
acid	O
secretion	O
by	O
intra	O
-	O
and	O
extragastric	O
pCO2	O
/	O
pH	O
measurements	O
in	O
23	O
persons	O
and	O
calculated	O
using	O
the	O
equation	O
of	O
Henderson	O
-	O
Hasselbalch	O
.	O
pCO2	O
was	O
measured	O
with	O
use	O
of	O
a	O
new	O
electrode	O
.	O

The	O
microdensitometric	O
scores	O
and	O
their	O
side	O
-	O
to	O
-	O
side	O
differences	O
in	O
patients	O
correlated	O
negatively	O
with	O
the	O
serum	O
25	O
-	O
OHD	O
concentration	O
and	O
positively	O
with	O
the	O
degree	O
of	O
paralysis	O
.	O

Immunofluoresence	O
data	O
indicated	O
that	O
once	O
bound	O
to	O
the	O
mutant	O
receptor	O
,	O
fluorescent	O
-	O
labeled	O
RAP	B-protein
co	O
-	O
localized	O
with	O
markers	O
of	O
the	O
endosomal	O
pathway	O
,	O
whereas	O
,	O
in	O
cells	O
expressing	O
the	O
wild	O
-	O
type	O
receptor	O
,	O
RAP	B-protein
fluorescence	O
co	O
-	O
localized	O
with	O
lysosomal	O
markers	O
.	O

In	O
14	O
patients	O
whose	O
PaCO2	O
was	O
greater	O
than	O
or	O
equal	O
to	O
39	O
torr	O
(	O
range	O
39	O
to	O
58	O
torr	O
)	O
and	O
clinical	O
asthma	O
score	O
was	O
6	O
or	O
greater	O
,	O
PaCO2	O
decreased	O
a	O
mean	O
of	O
11	O
.	O
7	O
torr	O
during	O
a	O
mean	O
of	O
8	O
.	O
1	O
hours	O
.	O

Deletion	O
analysis	O
revealed	O
that	O
the	O
essential	O
domain	O
of	O
this	O
promoter	O
,	O
termed	O
the	O
ORF5	B-protein
/	I-protein
deltaX	I-protein
transcript	I-protein
promoter	I-protein
,	O
mapped	O
to	O
nucleotides	O
1525	O
-	O
1625	O
.	O

The	O
need	O
for	O
including	O
forensic	O
medical	O
expertise	O
in	O
the	O
list	O
of	O
urgent	O
criminal	O
investigative	O
actions	O
.	O

By	O
using	O
interleukin	O
-	O
3	O
-	O
dependent	O
cells	O
that	O
ectopically	O
express	O
the	O
three	O
ErbB	B-protein
proteins	I-protein
or	O
their	O
combinations	O
,	O
we	O
found	O
that	O
ErbB	B-protein
-	I-protein
3	I-protein
is	O
devoid	O
of	O
any	O
biological	O
activity	O
but	O
both	O
ErbB	B-protein
-	I-protein
1	I-protein
and	O
ErbB	B-protein
-	I-protein
2	I-protein
can	O
reconstitute	O
its	O
extremely	O
potent	O
mitogenic	O
activity	O
.	O

This	O
suggests	O
that	O
while	O
underpredictions	O
of	O
pain	O
do	O
not	O
hurt	O
more	O
,	O
disruption	O
on	O
primary	O
tasks	O
and	O
physiological	O
impact	O
are	O
higher	O
.	O

Marine	O
oils	O
and	O
cardiovascular	O
reactivity	O
.	O

Psychiatry	O
and	O
the	O
skin	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
identified	O
a	O
strong	O
positive	O
cis	O
-	O
regulatory	O
element	O
at	O
-	O
70	O
bp	O
to	O
-	O
75	O
bp	O
in	O
the	O
LpS1	B-protein
beta	I-protein
promoter	I-protein
with	O
the	O
sequence	O
(	O
G	O
)	O
6	O
and	O
a	O
similar	O
,	O
more	O
distal	O
cis	O
-	O
element	O
at	O
-	O
721	O
bp	O
to	O
-	O
726	O
bp	O
.	O

Several	O
artifacts	O
occurred	O
that	O
interfered	O
with	O
visualization	O
of	O
the	O
diaphragm	O
.	O

Developmental	O
follow	O
-	O
up	O
at	O
age	O
2	O
years	O
was	O
performed	O
.	O

On	O
the	O
third	O
occasion	O
water	O
(	O
W	O
)	O
was	O
ingested	O
throughout	O
the	O
run	O
.	O

Both	O
pancreatic	O
and	O
intestinal	O
cell	O
lines	O
were	O
found	O
to	O
express	O
a	O
number	O
of	O
POU	B-protein
(	O
OCT	O
binding	O
)	O
homeodomain	B-protein
proteins	I-protein
examined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Sequencing	O
of	O
the	O
16p	O
11	O
.	O
1	O
/	O
Xq28	O
duplication	O
breakpoints	O
has	O
revealed	O
the	O
presence	O
of	O
repetitive	O
immunoglobulin	B-protein
-	I-protein
like	I-protein
CAGGG	I-protein
pentamer	I-protein
sequences	I-protein
at	O
or	O
near	O
the	O
paralogy	O
boundaries	O
.	O

Thus	O
,	O
the	O
synergistic	O
effects	O
of	O
HNF	B-protein
-	I-protein
1beta	I-protein
and	O
the	O
GR	B-protein
on	O
dexamethasone	O
-	O
stimulated	O
promoter	O
activity	O
require	O
that	O
they	O
are	O
bound	O
to	O
the	O
HNF	B-protein
-	I-protein
1	I-protein
site	I-protein
and	O
the	O
GRE	B-protein
,	O
respectively	O
,	O
and	O
may	O
involve	O
protein	O
-	O
protein	O
interactions	O
between	O
the	O
transcription	O
factors	O
,	O
or	O
between	O
them	O
and	O
the	O
basal	O
transcription	O
machinery	O
or	O
a	O
steroid	B-protein
receptor	I-protein
coactivator	I-protein
.	O

In	O
the	O
control	O
preparation	O
before	O
weight	O
was	O
allowed	O
to	O
increase	O
,	O
isogravimetric	O
capillary	O
pressure	O
(	O
Pci	O
)	O
averaged	O
8	O
mmHg	O
lower	O
than	O
colloid	O
osmotic	O
pressure	O
of	O
the	O
plasma	O
(	O
IIp	O
)	O
.	O

The	O
occurrence	O
,	O
maintenance	O
and	O
possible	O
involvement	O
of	O
these	O
repeated	O
sequences	O
,	O
capable	O
of	O
forming	O
stable	O
secondary	O
structures	O
,	O
are	O
discussed	O
in	O
relation	O
to	O
their	O
location	O
in	O
the	O
region	O
of	O
control	O
signals	O
.	O

This	O
subfamily	O
of	O
genes	O
all	O
have	O
a	O
single	O
ATP	O
-	O
binding	O
domain	O
at	O
the	O
N	O
-	O
terminus	O
and	O
a	O
single	O
C	O
-	O
terminal	O
set	O
of	O
transmembrane	O
segments	O
.	O

Approximately	O
65	O
%	O
of	O
the	O
total	O
cAMP	B-protein
-	I-protein
dependent	I-protein
phosphotransferase	I-protein
activity	O
is	O
recovered	O
in	O
particulate	O
fractions	O
of	O
homogenates	O
prepared	O
from	O
asynchronous	O
populations	O
of	O
C	O
.	O
elegans	O
.	O

The	O
various	O
available	O
data	O
strongly	O
suggesting	O
an	O
environmental	O
toxic	O
origin	O
for	O
the	O
`	O
`	O
sperm	O
fall	O
'	O
'	O
will	O
be	O
presented	O
as	O
well	O
as	O
the	O
most	O
frequently	O
suspected	O
class	O
of	O
substances	O
,	O
the	O
xenoestrogens	O
.	O

DNA	O
recognition	O
by	O
F	B-protein
factor	I-protein
TraI36	I-protein
:	O
highly	O
sequence	O
-	O
specific	O
binding	O
of	O
single	O
-	O
stranded	O
DNA	O
.	O

We	O
have	O
followed	O
37	O
phenytoin	O
-	O
treated	O
patients	O
with	O
reduced	O
serum	B-protein
IgA	I-protein
concentrations	O
for	O
2	O
-	O
7	O
years	O
.	O

Erythema	O
exsudativum	O
multiforme	O
induced	O
by	O
granulocyte	B-protein
colony	I-protein
-	I-protein
stimulating	I-protein
factor	I-protein
in	O
an	O
allogeneic	O
peripheral	O
blood	O
stem	O
cell	O
donor	O
.	O

The	O
expression	O
of	O
the	O
first	O
two	O
genes	O
located	O
in	O
this	O
unit	O
(	O
c	B-protein
-	I-protein
gvpD	I-protein
and	O
c	B-protein
-	I-protein
gvpE	I-protein
)	O
was	O
also	O
monitored	O
by	O
Western	O
blot	O
(	O
immunoblot	O
)	O
analyses	O
using	O
antisera	O
raised	O
against	O
these	O
proteins	O
synthesized	O
in	O
Escherichia	O
coli	O
.	O

In	O
summary	O
,	O
at	O
equianesthetic	O
concentrations	O
,	O
desflurane	O
and	O
isoflurane	O
produced	O
similar	O
hemodynamic	O
effects	O
;	O
however	O
,	O
in	O
the	O
absence	O
of	O
drugs	O
that	O
inhibit	O
autonomic	O
reflexes	O
,	O
desflurane	O
had	O
less	O
negative	O
inotropic	O
activity	O
and	O
produced	O
less	O
decrease	O
in	O
arterial	O
pressure	O
.	O

Sparfloxacin	O
and	O
clinafloxacin	O
were	O
evaluated	O
against	O
Enterococcus	O
faecium	O
SF2149	O
and	O
Enterococcus	O
faecalis	O
WH245	O
,	O
respectively	O
.	O

A	O
330	O
-	O
kb	O
YAC	O
,	O
A148A7	O
,	O
spanned	O
from	O
the	O
HLA	B-protein
-	I-protein
DQA1	I-protein
locus	I-protein
through	O
the	O
Y3	B-protein
/	I-protein
Ring	I-protein
4	I-protein
locus	I-protein
and	O
extended	O
at	O
least	O
130	O
kb	O
centromeric	O
of	O
YAC	O
B1D12	O
.	O

Modification	O
of	O
dopamine	B-protein
D2	I-protein
receptor	I-protein
activity	O
by	O
pergolide	O
in	O
Parkinson	O
'	O
s	O
disease	O
:	O
an	O
in	O
vivo	O
study	O
by	O
PET	O
.	O

National	O
certification	O
:	O
a	O
vital	O
component	O
of	O
quality	O
assurance	O
.	O

Effects	O
of	O
dopamine	O
and	O
of	O
a	O
dopaminergic	O
blocker	O
,	O
haloperidol	O
,	O
on	O
the	O
responses	O
of	O
carotid	O
body	O
chemoreceptors	O
to	O
hypoxia	O
and	O
hypercapnia	O
were	O
investigated	O
in	O
16	O
anesthetized	O
cats	O
.	O

Mutational	O
analysis	O
of	O
a	O
DNA	O
sequence	O
involved	O
in	O
linking	O
gene	O
expression	O
to	O
the	O
cell	O
cycle	O
.	O

PCR	O
/	O
Southern	O
blot	O
analysis	O
of	O
human	O
kidney	O
cDNA	O
using	O
primers	O
flanking	O
the	O
hKID	B-protein
coding	I-protein
sequence	I-protein
revealed	O
expression	O
of	O
a	O
full	O
-	O
length	O
mRNA	O
and	O
short	O
transcripts	O
with	O
partial	O
exon	O
1	O
and	O
partial	O
exon	O
4	O
deletions	O
.	O

The	O
NF	B-protein
-	I-protein
kappaB	I-protein
responsive	O
reporter	O
construct	O
,	O
(	B-protein
PRDII	I-protein
)	I-protein
(	I-protein
4	I-protein
)	I-protein
-	I-protein
CAT	I-protein
,	O
was	O
used	O
to	O
explore	O
transcription	O
resulting	O
from	O
NF	B-protein
-	I-protein
kappaB	I-protein
activated	O
by	O
Tat	B-protein
.	O

Transcriptional	O
regulation	O
of	O
fbp1	B-protein
promoter	I-protein
constructs	I-protein
containing	O
only	O
UAS1	B-protein
or	O
UAS2	B-protein
confirms	O
that	O
the	O
PKA	B-protein
and	O
MAPK	B-protein
regulation	O
is	O
targeted	O
to	O
both	O
sites	O
.	O

Furthermore	O
,	O
formation	O
of	O
foci	O
of	O
transformed	O
RECs	O
by	O
the	O
c	B-protein
-	I-protein
jun	I-protein
/	I-protein
ras	I-protein
combination	I-protein
was	O
augmented	O
3	O
-	O
fold	O
by	O
the	O
tumor	O
promoter	O
phorbol	O
12	O
-	O
tetradecanoate	O
13	O
-	O
acetate	O
.	O

Commonly	O
used	O
stressors	O
are	O
mental	O
arithmetics	O
,	O
speech	O
tasks	O
,	O
the	O
Stroop	O
test	O
,	O
videogame	O
playing	O
,	O
films	O
or	O
videotapes	O
and	O
interviews	O
.	O

It	O
was	O
proposed	O
that	O
the	O
synthetase	O
-	O
related	O
sequences	O
of	O
GCN2	B-protein
stimulate	O
the	O
activity	O
of	O
the	O
kinase	O
by	O
interacting	O
directly	O
with	O
uncharged	O
tRNA	O
that	O
accumulates	O
during	O
amino	O
acid	O
limitation	O
.	O

99mTc	O
phytate	O
,	O
198Au	O
colloid	O
,	O
and	O
99mTc	O
antimony	O
sulfide	O
have	O
been	O
used	O
;	O
the	O
last	O
appears	O
to	O
have	O
been	O
the	O
most	O
satisfactory	O
.	O

Invited	O
editorial	O
on	O
`	O
`	O
Acute	O
and	O
chronic	O
effects	O
of	O
exercise	O
on	O
leptin	B-protein
levels	O
in	O
humans	O
'	O
'	O
.	O

Pharmacologic	O
properties	O
of	O
serotonergic	O
agents	O
and	O
antidepressant	O
drugs	O
.	O

Retinoids	O
participate	O
in	O
the	O
onset	O
of	O
differentiation	O
,	O
apoptosis	O
and	O
the	O
inhibition	O
of	O
growth	O
in	O
a	O
wide	O
variety	O
of	O
normal	O
and	O
cancerous	O
cells	O
.	O

The	O
results	O
revealed	O
a	O
hierarchy	O
of	O
ligand	O
affinities	O
that	O
mirrored	O
their	O
adhesive	O
activity	O
(	O
rsVCAM	B-protein
-	I-protein
1	I-protein
>	O
fibronectin	B-protein
variants	I-protein
containing	O
CS1	B-protein
>	O
>	O
other	O
fibronectin	B-protein
variants	I-protein
)	O
.	O

The	O
diagnosis	O
of	O
miliary	O
tuberculosis	O
should	O
be	O
systematically	O
considered	O
in	O
ARDS	O
of	O
unknown	O
origin	O
.	O

After	O
giving	O
a	O
survey	O
on	O
the	O
situation	O
of	O
antibiotic	O
resistance	O
in	O
the	O
region	O
of	O
Northern	O
Bavaria	O
during	O
1973	O
/	O
74	O
and	O
comparing	O
the	O
activity	O
of	O
a	O
sulfamethoxazole	O
(	O
SMZ	O
)	O
trimethoprim	O
(	O
TMP	O
)	O
combination	O
to	O
other	O
commonly	O
used	O
antibiotics	O
and	O
chemotherapeutic	O
agents	O
,	O
the	O
results	O
of	O
tests	O
with	O
the	O
new	O
combination	O
of	O
N1	O
-	O
(	O
4	O
,	O
5	O
-	O
dimethyl	O
-	O
2	O
-	O
oxazolyl	O
)	O
-	O
sulfanilamide	O
)	O
(	O
sulfamoxole	O
)	O
and	O
2	O
,	O
4	O
-	O
diamino	O
-	O
5	O
-	O
(	O
3	O
,	O
4	O
,	O
5	O
-	O
trimethoxy	O
-	O
benzyl	O
)	O
-	O
pyrimidine	O
(	O
trimethoprim	O
)	O
at	O
a	O
ratio	O
of	O
5	O
:	O
1	O
(	O
CN	O
3123	O
;	O
Nevin	O
,	O
Supristol	O
)	O
are	O
compared	O
to	O
those	O
of	O
tests	O
with	O
TMP	O
/	O
SMZ	O
.	O

Coronary	O
vasoconstriction	O
caused	O
by	O
endothelin	B-protein
-	I-protein
1	I-protein
is	O
enhanced	O
by	O
ischemia	O
-	O
reperfusion	O
and	O
by	O
norepinephrine	O
present	O
in	O
concentrations	O
typically	O
observed	O
after	O
neonatal	O
cardiopulmonary	O
bypass	O
.	O

The	O
plasmid	O
shuffle	O
technique	O
was	O
used	O
to	O
replace	O
the	O
wild	O
-	O
type	O
gene	O
with	O
the	O
mutant	O
form	O
,	O
resulting	O
in	O
failure	O
of	O
the	O
yeast	O
cells	O
to	O
grow	O
.	O

Late	O
mRNA	O
selected	O
by	O
a	O
cDNA	O
homologous	O
to	O
the	O
HindIII	B-protein
-	I-protein
P	I-protein
/	I-protein
EcoRI	I-protein
-	I-protein
B	I-protein
region	I-protein
of	O
the	O
AcNPV	O
map	O
directed	O
the	O
synthesis	O
of	O
31K	O
and	O
30K	O
proteins	O
which	O
comigrated	O
with	O
the	O
31K	O
and	O
30K	O
proteins	O
translated	O
from	O
RNA	O
selected	O
by	O
the	O
HindIII	B-protein
-	I-protein
A	I-protein
/	I-protein
EcoRI	I-protein
-	I-protein
C	I-protein
/	I-protein
SstI	I-protein
-	I-protein
G	I-protein
cDNA	I-protein
.	O

To	O
determine	O
whether	O
the	O
NTP	O
-	O
binding	O
motif	O
is	O
important	O
for	O
Rad24	B-protein
function	O
,	O
we	O
mutated	O
the	O
conserved	O
lysine	O
(	O
115	O
)	O
residue	O
in	O
this	O
motif	O
.	O

Constitutive	O
activation	O
of	O
Rac1	B-protein
and	O
RhoA	B-protein
causes	O
tumorigenic	O
transformation	O
of	O
NIH	O
3T3	O
cells	O
,	O
and	O
their	O
functions	O
may	O
be	O
required	O
for	O
full	O
Ras	B-protein
transformation	O
.	O

Proposals	O
on	O
authorization	O
;	O
by	O
a	O
group	O
of	O
nurses	O
from	O
psychiatric	O
hospitals	O
.	O

RESULTS	O
:	O
The	O
cardiac	O
index	O
significantly	O
changed	O
with	O
varying	O
PaCO2	O
levels	O
(	O
hypocapnia	O
,	O
-	O
9	O
%	O
;	O
hypercapnia	O
,	O
13	O
%	O
)	O
.	O

The	O
DNA	O
sequence	O
of	O
the	O
sulfate	B-protein
activation	I-protein
locus	I-protein
from	O
Escherichia	O
coli	O
K	O
-	O
12	O
has	O
been	O
determined	O
.	O

Epstein	B-protein
-	I-protein
Barr	I-protein
virus	I-protein
-	I-protein
encoded	I-protein
latent	I-protein
membrane	I-protein
protein	I-protein
1	I-protein
activates	O
the	O
JNK	B-protein
pathway	O
through	O
its	O
extreme	O
C	O
terminus	O
via	O
a	O
mechanism	O
involving	O
TRADD	B-protein
and	O
TRAF2	B-protein
.	O

WA	O
constructs	O
afforded	O
relaxed	O
and	O
positive	O
topoisomers	O
,	O
and	O
cyclization	O
kinetics	O
indicated	O
slow	O
interconversion	O
of	O
precursors	O
to	O
the	O
two	O
topoisomers	O
.	O

These	O
changes	O
may	O
be	O
the	O
result	O
of	O
,	O
on	O
the	O
one	O
hand	O
,	O
an	O
increased	O
sensitivity	O
of	O
the	O
neuromuscular	O
transmission	O
and	O
/	O
or	O
decreased	O
muscle	O
contractility	O
and	O
,	O
on	O
the	O
other	O
hand	O
,	O
the	O
result	O
of	O
a	O
reduced	O
plasma	O
clearance	O
during	O
hypothermia	O
.	O

G	O
-	O
box	O
-	O
directed	O
expression	O
in	O
leaves	O
required	O
the	O
presence	O
of	O
an	O
enhancer	O
region	O
from	O
the	O
cauliflower	O
mosaic	O
virus	O
(	O
CaMV	O
)	O
35S	B-protein
promoter	I-protein
.	O

Different	O
thermoluminescent	O
detectors	O
(	O
TLD	O
)	O
have	O
been	O
used	O
to	O
measure	O
the	O
contribution	O
of	O
the	O
low	O
linear	O
energy	O
transfer	O
component	O
(	O
LET	O
<	O
10	O
keV	O
/	O
micrometer	O
)	O
and	O
plastic	O
nuclear	O
track	O
detectors	O
(	O
PNTD	O
)	O
for	O
the	O
high	O
linear	O
energy	O
tranfer	O
(	O
LET	O
)	O
component	O
.	O

Deletion	O
mapping	O
experiments	O
determined	O
that	O
the	O
sequences	O
required	O
for	O
full	O
activity	O
in	O
MSC	O
-	O
1	O
cells	O
were	O
included	O
within	O
619	O
bp	O
of	O
the	O
start	O
site	O
and	O
identified	O
several	O
regions	O
that	O
demonstrated	O
increased	O
luciferase	B-protein
activity	O
:	O
the	O
-	O
583	O
bp	O
to	O
-	O
564	O
bp	O
,	O
-	O
503	O
bp	O
to	O
-	O
484	O
bp	O
,	O
and	O
-	O
114	O
bp	O
to	O
-	O
65	O
regions	O
.	O

Like	O
the	O
p190	B-protein
-	I-protein
B	I-protein
exon	O
,	O
the	O
first	O
exon	O
of	O
p190	B-protein
-	I-protein
A	I-protein
is	O
extremely	O
large	O
(	O
3	O
.	O
7	O
kb	O
in	O
length	O
)	O
,	O
encoding	O
both	O
the	O
GTPase	B-protein
and	O
middle	O
domains	O
(	O
residues	O
1	O
-	O
1228	O
)	O
,	O
but	O
not	O
the	O
remaining	O
GAP	B-protein
domain	I-protein
,	O
suggesting	O
a	O
high	O
conservation	O
of	O
genomic	O
structure	O
between	O
two	O
p190	B-protein
genes	I-protein
.	O

We	O
have	O
cloned	O
a	O
novel	O
mouse	O
protein	O
,	O
TAF	B-protein
(	I-protein
II	I-protein
)	I-protein
140	I-protein
,	O
containing	O
an	O
HFD	B-protein
and	O
a	O
plant	B-protein
homeodomain	I-protein
(	O
PHD	B-protein
)	O
finger	O
,	O
which	O
we	O
demonstrated	O
by	O
immunoprecipitation	O
to	O
be	O
a	O
mammalian	B-protein
TFIID	I-protein
component	I-protein
.	O

Dopamine	B-protein
beta	I-protein
-	I-protein
hydroxylase	I-protein
(	O
DBH	B-protein
)	O
catalyzes	O
the	O
conversion	O
of	O
dopamine	O
to	O
noradrenaline	O
and	O
is	O
selectively	O
expressed	O
in	O
noradrenergic	O
and	O
adrenergic	O
neurons	O
and	O
neuroendocrine	O
cells	O
.	O

Cooperative	O
dimerization	O
of	O
paired	O
class	O
homeo	O
domains	O
on	O
DNA	O
.	O

G	O
.	O
,	O
and	O
Hyde	O
,	O
C	O
.	O

The	O
cellular	O
part	O
of	O
the	O
third	O
chimeric	O
clone	O
shows	O
significant	O
homology	O
to	O
an	O
exon	O
of	O
the	O
human	B-protein
tyrosine	I-protein
phosphatase	I-protein
1	I-protein
gene	I-protein
,	O
although	O
oriented	O
in	O
the	O
antisense	O
direction	O
compared	O
to	O
the	O
adjacent	O
LTR	O
.	O

Both	O
parents	O
are	O
clinically	O
normal	O
and	O
unrelated	O
.	O

The	O
results	O
show	O
that	O
the	O
structure	O
of	O
the	O
decorin	B-protein
gene	I-protein
promoter	I-protein
is	O
different	O
from	O
that	O
of	O
any	O
other	O
proteoglycan	O
promoter	O
characterized	O
so	O
far	O
and	O
indicate	O
that	O
the	O
pur	O
/	O
pyr	O
segment	O
plays	O
a	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
transcription	O
.	O

Ammonia	O
concentration	O
dropped	O
significantly	O
in	O
all	O
treatments	O
,	O
a	O
finding	O
which	O
suggests	O
a	O
protective	O
effect	O
on	O
protein	O
nitrogen	O
degradation	O
to	O
non	O
-	O
protein	O
nitrogen	O
(	O
NH3	O
)	O
.	O

Thus	O
,	O
IRF	B-protein
-	I-protein
7	I-protein
exhibits	O
functional	O
similarity	O
to	O
IRF	B-protein
-	I-protein
3	I-protein
;	O
however	O
,	O
the	O
preferential	O
expression	O
of	O
IRF	B-protein
-	I-protein
7	I-protein
in	O
lymphoid	O
cells	O
(	O
the	O
cell	O
type	O
that	O
expresses	O
IFNA	B-protein
)	O
suggests	O
that	O
IRF	B-protein
-	I-protein
7	I-protein
may	O
play	O
a	O
critical	O
role	O
in	O
regulating	O
the	O
IFNA	B-protein
gene	I-protein
expression	O
.	O

All	O
stimulations	O
were	O
down	O
-	O
regulated	O
with	O
GnRH	B-protein
-	I-protein
a	I-protein
commenced	O
on	O
day	O
21	O
in	O
a	O
long	O
protocol	O
before	O
gonadotropin	B-protein
stimulation	O
.	O

The	O
consensus	O
highlights	O
the	O
importance	O
of	O
residues	O
other	O
than	O
the	O
eight	O
motifs	O
that	O
are	O
often	O
associated	O
with	O
DEAD	B-protein
-	I-protein
box	I-protein
RNA	I-protein
helicases	I-protein
,	O
as	O
well	O
as	O
de	O
-	O
emphasising	O
the	O
importance	O
of	O
the	O
`	O
`	O
A	O
'	O
'	O
residue	O
within	O
the	O
`	B-protein
`	I-protein
DEAD	I-protein
'	I-protein
'	I-protein
motif	I-protein
.	O

Fortunately	O
DDT	O
-	O
,	O
HCH	O
-	O
and	O
HCB	O
-	O
levels	O
decreased	O
in	O
breast	O
milk	O
during	O
the	O
last	O
years	O
.	O

Two	O
other	O
peptides	O
,	O
either	O
partially	O
or	O
totally	O
lacking	O
the	O
basic	O
region	O
,	O
but	O
containing	O
the	O
intact	O
leucine	O
zipper	O
domain	O
,	O
readily	O
form	O
dimers	O
but	O
do	O
not	O
bind	O
to	O
the	O
CRE	B-protein
.	O

We	O
detected	O
mos	B-protein
transcripts	I-protein
by	O
Northern	O
(	O
RNA	O
)	O
analyses	O
in	O
RNA	O
prepared	O
from	O
chicken	O
and	O
quail	O
ovaries	O
and	O
testes	O
.	O

Nursing	O
home	O
discharges	O
in	O
clinical	O
practice	O
.	O

Seven	O
clones	O
encoding	O
interferon	B-protein
response	I-protein
element	I-protein
binding	I-protein
factors	I-protein
have	O
been	O
isolated	O
from	O
a	O
mouse	O
fibroblast	O
lambda	O
gt11	O
cDNA	O
library	O
by	O
using	O
a	O
32P	O
end	O
-	O
labeled	O
tandem	O
trimer	O
of	O
the	O
mouse	B-protein
(	I-protein
2	I-protein
'	I-protein
-	I-protein
5	I-protein
'	I-protein
)	I-protein
oligoadenylate	I-protein
synthetase	I-protein
gene	I-protein
interferon	I-protein
response	I-protein
element	I-protein
as	O
a	O
probe	O
.	O

The	O
patient	O
initially	O
attained	O
complete	O
remission	O
(	O
CR1	O
)	O
with	O
conventional	O
chemotherapy	O
and	O
then	O
relapsed	O
14	O
months	O
later	O
.	O

Recombinant	B-protein
I	I-protein
-	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
inhibited	O
kappa	B-protein
B	I-protein
motif	I-protein
binding	O
by	O
nuclear	B-protein
factor	I-protein
-	I-protein
kappa	I-protein
B1	I-protein
,	O
RelA	B-protein
,	O
and	O
c	B-protein
-	I-protein
Rel	I-protein
as	O
indicated	O
by	O
studies	O
using	O
UV	O
radiation	O
-	O
induced	O
covalent	O
cross	O
-	O
linking	O
to	O
a	O
bromodeoxyuridine	O
-	O
substituted	O
kappa	B-protein
B	I-protein
oligonucleotide	I-protein
.	O

Cells	O
lacking	O
p116	B-protein
exhibit	O
a	O
striking	O
defect	O
in	O
the	O
formation	O
of	O
these	O
macropinocytic	O
structures	O
,	O
a	O
concomitant	O
reduction	O
in	O
the	O
rate	O
of	O
fluid	O
phase	O
pinocytosis	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
efficiency	O
of	O
chemotactic	O
aggregation	O
,	O
and	O
a	O
decrease	O
in	O
cellular	O
F	B-protein
-	I-protein
actin	I-protein
content	O
.	O

Promoter	O
region	O
of	O
the	O
transcriptional	O
unit	O
for	O
human	B-protein
alpha	I-protein
1	I-protein
-	I-protein
chimaerin	I-protein
,	O
a	O
neuron	B-protein
-	I-protein
specific	I-protein
GTPase	I-protein
-	I-protein
activating	I-protein
protein	I-protein
for	O
p21rac	B-protein
.	O
alpha	B-protein
1	I-protein
-	I-protein
chimaerin	I-protein
is	O
a	O
neuron	B-protein
-	I-protein
specific	I-protein
GTPase	I-protein
-	I-protein
activating	I-protein
protein	I-protein
for	O
p21rac	B-protein
,	O
a	O
protein	O
involved	O
in	O
morphological	O
events	O
.	O

Surprisingly	O
,	O
the	O
COOH	O
-	O
terminal	O
domain	O
of	O
RanGAP1	B-protein
was	O
also	O
found	O
to	O
harbor	O
a	O
nuclear	O
localization	O
signal	O
.	O

For	O
EPV	O
3	O
,	O
10	O
,	O
or	O
40	O
,	O
the	O
bias	O
exceeded	O
25	O
%	O
for	O
7	O
,	O
3	O
,	O
and	O
1	O
in	O
the	O
8	O
-	O
predictor	O
model	O
respectively	O
,	O
when	O
a	O
conventional	O
selection	O
criterion	O
was	O
used	O
(	O
alpha	O
=	O
0	O
.	O
05	O
)	O
.	O

Position	O
22	O
is	O
an	O
isoleucine	O
in	O
the	O
complete	B-protein
SsoL12	I-protein
protein	I-protein
sequence	I-protein
,	O
coded	O
by	O
an	O
AUA	O
codon	O
.	O

Plasma	O
concentrations	O
of	O
ANF	B-protein
(	O
pANF	B-protein
)	O
,	O
aldosterone	O
(	O
PAC	O
)	O
and	O
renin	B-protein
(	O
PRC	B-protein
)	O
were	O
measured	O
daily	O
,	O
as	O
were	O
hemodynamic	O
parameters	O
.	O

Immunochemical	O
studies	O
with	O
filarial	O
antigens	O
.	O

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
case	O
in	O
which	O
a	O
probable	O
association	O
between	O
cholelithiasis	O
and	O
Wildervanck	O
'	O
s	O
syndrome	O
has	O
been	O
recorded	O
.	O

The	O
results	O
are	O
discussed	O
in	O
relation	O
to	O
acoustical	O
models	O
of	O
sound	O
propagation	O
and	O
physiology	O
,	O
and	O
it	O
is	O
suggested	O
that	O
height	O
-	O
dependent	O
degradation	O
within	O
a	O
forest	O
is	O
an	O
important	O
selection	O
pressure	O
for	O
transmissibility	O
in	O
avian	O
communication	O
.	O

To	O
identify	O
the	O
important	O
cis	O
-	O
DNA	O
regulatory	O
element	O
(	O
s	O
)	O
involved	O
in	O
the	O
tissue	O
-	O
,	O
region	O
-	O
,	O
and	O
cell	O
-	O
specific	O
expression	O
of	O
the	O
mE	B-protein
-	I-protein
RABP	I-protein
gene	I-protein
,	O
the	O
5	O
-	O
kb	O
DNA	O
fragment	O
was	O
sequenced	O
.	O

The	O
two	O
larger	O
peptides	O
,	O
one	O
containing	O
amino	O
acids	O
1	O
-	O
228	O
and	O
the	O
other	O
containing	O
amino	O
acids	O
85	O
-	O
228	O
,	O
formed	O
dimers	O
in	O
solution	O
and	O
bound	O
DNA	O
specifically	O
as	O
a	O
dimer	O
.	O

Mechanism	O
of	O
enhancement	O
of	O
DNA	O
expression	O
consequent	O
to	O
cointernalization	O
of	O
a	O
replication	O
-	O
deficient	O
adenovirus	O
and	O
unmodified	O
plasmid	O
DNA	O
.	O

Using	O
this	O
method	O
,	O
VLPs	O
were	O
obtained	O
in	O
quantities	O
sufficient	O
for	O
further	O
characterization	O
.	O

Lactate	O
accumulation	O
peak	O
was	O
unaffected	O
by	O
supplementation	O
(	O
HMB	O
,	O
8	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
1	O
mM	O
;	O
LEU	O
,	O
6	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
8	O
mM	O
;	O
CON	O
,	O
7	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
3	O
mM	O
)	O
.	O

W	O
.	O

Exons	O
III	O
to	O
VIII	O
,	O
which	O
cover	O
the	O
coding	O
region	O
and	O
the	O
3	O
'	O
untranslated	O
region	O
,	O
are	O
almost	O
identical	O
in	O
all	O
types	O
of	O
PST	B-protein
or	O
AST	B-protein
cDNAs	I-protein
.	O

Alena	O
is	O
a	O
nurse	O
in	O
Prague	O
-	O
-	O
she	O
dreams	O
of	O
higher	O
wages	O
and	O
a	O
trip	O
across	O
the	O
ocean	O
.	O

An	O
experiment	O
examined	O
the	O
effects	O
of	O
treatment	O
with	O
gonadotrophin	O
releasing	O
hormone	O
(	O
100	O
micrograms	O
GnRH	B-protein
injected	O
24	O
h	O
after	O
progestagen	O
sponge	O
removal	O
)	O
,	O
season	O
of	O
treatment	O
(	O
autumn	O
v	O
.	O
spring	O
)	O
,	O
the	O
effect	O
of	O
supplementary	O
feeding	O
with	O
lupin	O
grain	O
(	O
in	O
autumn	O
only	O
,	O
from	O
12	O
days	O
before	O
until	O
8	O
days	O
after	O
sponge	O
removal	O
)	O
on	O
the	O
time	O
of	O
ovulation	O
in	O
182	O
mature	O
Merino	O
ewes	O
superovulated	O
with	O
a	O
combination	O
of	O
400	O
I	O
.	O
U	O
.	O
pregnant	B-protein
mare	I-protein
serum	I-protein
gonadotrophin	I-protein
(	O
PMSG	B-protein
)	O
and	O
12	O
mg	O
follicle	B-protein
stimulating	I-protein
hormone	I-protein
(	O
FSH	B-protein
-	I-protein
P	I-protein
)	O
.	O

The	O
early	O
lethality	O
of	O
the	O
left	O
-	O
sided	O
resectio	O
was	O
0	O
%	O
and	O
the	O
postoperative	O
survival	O
-	O
-	O
5	O
-	O
10	O
months	O
.	O

In	O
the	O
context	O
of	O
liver	O
allograft	O
shortage	O
,	O
our	O
results	O
suggest	O
that	O
an	O
ELT	O
should	O
not	O
be	O
performed	O
in	O
patients	O
with	O
cardiac	O
failure	O
,	O
more	O
than	O
two	O
OSF	O
,	O
or	O
an	O
APACHE	O
II	O
score	O
higher	O
than	O
30	O
.	O

If	O
no	O
alloantibodies	O
are	O
detected	O
,	O
further	O
analysis	O
to	O
define	O
a	O
role	O
of	O
drug	O
-	O
related	O
or	O
autoantibodies	O
is	O
required	O
.	O

The	O
protein	O
mixtures	O
of	O
sesame	O
flour	O
and	O
soybean	O
flour	O
were	O
well	O
accepted	O
.	O

The	O
site	O
of	O
autophosphorylation	O
is	O
Tyr397	O
which	O
corresponds	O
to	O
the	O
consensus	O
autophosphorylation	O
site	O
of	O
other	O
Src	B-protein
family	I-protein
tyrosine	I-protein
kinases	I-protein
.	O

Infrared	O
measurements	O
of	O
temperature	O
changes	O
and	O
estimates	O
of	O
the	O
heating	O
produced	O
at	O
the	O
mical	O
.	O

Northern	O
blot	O
and	O
reverse	O
transcription	O
-	O
PCR	O
analyses	O
of	O
human	O
mRNA	O
samples	O
demonstrate	O
that	O
RNR	B-protein
is	O
expressed	O
exclusively	O
in	O
the	O
retina	O
,	O
with	O
transcripts	O
of	O
approximately	O
7	O
.	O
5	O
kb	O
,	O
approximately	O
3	O
.	O
0	O
kb	O
,	O
and	O
approximately	O
2	O
.	O
3	O
kb	O
by	O
Northern	O
blot	O
analysis	O
.	O

One	O
group	O
of	O
six	O
cDNA	O
clones	O
was	O
derived	O
from	O
a	O
2	O
.	O
9	O
-	O
kilobase	O
early	O
transcript	O
encoded	O
by	O
the	O
IR2	B-protein
repeat	I-protein
element	I-protein
and	O
showed	O
restriction	O
site	O
polymorphism	O
for	O
the	O
enzyme	B-protein
SmaI	I-protein
.	O

Compared	O
to	O
controls	O
,	O
both	O
UB	O
and	O
OCS	O
rats	O
showed	O
a	O
small	O
but	O
significant	O
post	O
-	O
operative	O
reduction	O
in	O
the	O
nocturnality	O
of	O
drinking	O
.	O

These	O
data	O
suggest	O
that	O
proper	O
direct	O
binding	O
of	O
Nhp2p	B-protein
to	O
H	B-protein
/	I-protein
ACA	I-protein
snoRNAs	I-protein
is	O
required	O
for	O
the	O
assembly	O
of	O
H	B-protein
/	I-protein
ACA	I-protein
snoRNPs	I-protein
and	O
hence	O
for	O
the	O
stability	O
of	O
some	O
of	O
their	O
components	O
.	O

This	O
mode	O
of	O
ternary	O
complex	O
formation	O
is	O
in	O
contrast	O
to	O
the	O
one	O
seen	O
in	O
the	O
promoter	O
of	O
the	O
c	B-protein
-	I-protein
fos	I-protein
protooncogene	I-protein
,	O
where	O
formation	O
of	O
the	O
ternary	O
complex	O
is	O
dependent	O
on	O
the	O
prior	O
assembly	O
of	O
the	O
serum	B-protein
response	I-protein
factor	I-protein
-	I-protein
DNA	I-protein
binary	I-protein
complex	I-protein
.	O

Bile	O
bilirubin	O
did	O
not	O
rise	O
within	O
12	O
h	O
after	O
haem	O
infusion	O
a	O
finding	O
which	O
warrants	O
further	O
investigation	O
.	O

Following	O
intravenous	O
administration	O
,	O
the	O
myocardial	O
concentration	O
of	O
tracer	O
thallium	O
-	O
201	O
,	O
potassium	O
-	O
43	O
,	O
and	O
rubidium	O
-	O
81	O
were	O
determined	O
in	O
mice	O
;	O
thallium	O
was	O
present	O
in	O
the	O
greatest	O
concentration	O
in	O
the	O
myocardium	O
(	O
2	O
.	O
08	O
%	O
compared	O
1	O
.	O
25	O
%	O
for	O
potassium	O
and	O
1	O
.	O
15	O
%	O
for	O
rubidium	O
at	O
10	O
minutes	O
)	O
.	O

The	O
mutation	O
within	O
the	O
asgB480	B-protein
allele	I-protein
was	O
identified	O
as	O
an	O
A	O
-	O
to	O
-	O
G	O
transition	O
that	O
results	O
in	O
a	O
threonine	O
-	O
to	O
-	O
alanine	O
substitution	O
in	O
the	O
predicted	O
protein	O
product	O
.	O

Nucleotide	O
sequence	O
and	O
transcriptional	O
analysis	O
of	O
the	O
polyhedrin	B-protein
gene	I-protein
of	O
Spodoptera	O
exigua	O
nuclear	O
polyhedrosis	O
virus	O
.	O

In	O
12	O
cases	O
(	O
3	O
.	O
1	O
%	O
)	O
,	O
a	O
change	O
in	O
stage	O
resulted	O
.	O

Inherent	O
hematology	O
of	O
old	O
age	O
.	O

A	O
multi	O
-	O
centre	O
evaluation	O
of	O
the	O
card	O
indirect	O
agglutination	O
test	O
for	O
trypanosomiasis	O
(	O
TrypTect	O
CIATT	O
)	O
.	O

Indeed	O
,	O
A	O
-	O
MuLV	O
pseudotyped	O
with	O
some	O
viruses	O
,	O
such	O
as	O
the	O
Moloney	O
MuLV	O
,	O
has	O
been	O
shown	O
to	O
be	O
highly	O
lymphogenic	O
,	O
whereas	O
A	O
-	O
MuLV	O
pseudotyped	O
with	O
other	O
viruses	O
,	O
such	O
as	O
the	O
BALB	O
/	O
c	O
endogenous	O
N	O
-	O
tropic	O
MuLV	O
,	O
has	O
been	O
shown	O
to	O
be	O
devoid	O
of	O
lymphogenic	O
potential	O
(	O
N	O
.	O

Whole	O
-	O
mount	O
in	O
situ	O
hybridization	O
to	O
early	O
mouse	O
embryos	O
of	O
9	O
.	O
5	O
-	O
10	O
.	O
5	O
days	O
indicated	O
a	O
complex	O
pattern	O
of	O
Arp1	B-protein
expression	O
spatially	O
overlapping	O
with	O
the	O
expression	O
of	O
All1	B-protein
.	O

Conjugated	O
estrogens	O
shorten	O
bleeding	O
time	O
in	O
uraemia	O
:	O
a	O
possible	O
role	O
of	O
serotonin	O
?	O

US	O
-	O
Doppler	O
has	O
recently	O
gained	O
attention	O
as	O
a	O
noninvasive	O
method	O
for	O
the	O
functional	O
evaluation	O
of	O
arteriovenous	O
fistulas	O
(	O
FAV	O
)	O
.	O

The	O
physical	O
and	O
chemical	O
stability	O
of	O
a	O
combination	O
of	O
drugs	O
commonly	O
administered	O
into	O
the	O
epidural	O
or	O
intrathecal	O
space	O
for	O
the	O
treatment	O
of	O
chronic	O
pain	O
was	O
investigated	O
.	O

Are	O
low	O
P300	O
amplitudes	O
a	O
marker	O
for	O
schizophrenia	O
.	O

The	O
human	O
pathogenic	O
bacterium	O
group	O
A	O
Streptococcus	O
produces	O
an	O
extracellular	B-protein
cysteine	I-protein
protease	I-protein
[	I-protein
streptococcal	I-protein
pyrogenic	I-protein
exotoxin	I-protein
B	I-protein
(	O
SpeB	B-protein
)	O
]	O
that	O
is	O
a	O
critical	O
virulence	O
factor	O
for	O
invasive	O
disease	O
episodes	O
.	O

Another	O
full	O
ORF	O
was	O
found	O
on	O
the	O
opposite	O
strand	O
downstream	O
from	O
the	O
nspC	B-protein
gene	I-protein
.	O

These	O
two	O
mAbs	O
used	O
the	O
same	O
V	B-protein
(	I-protein
H	I-protein
)	I-protein
and	O
J	B-protein
(	I-protein
H	I-protein
)	I-protein
gene	I-protein
segments	I-protein
,	O
but	O
different	O
D	B-protein
,	O
Vkappa	B-protein
,	O
and	O
Jkappa	B-protein
genes	I-protein
.	O

Similarity	O
is	O
most	O
striking	O
in	O
the	O
zinc	B-protein
knuckle	I-protein
region	I-protein
,	O
a	O
region	O
characteristic	O
of	O
gag	B-protein
genes	I-protein
of	O
most	O
replication	O
-	O
competent	O
retroelements	O
.	O

The	O
up	O
-	O
regulation	O
of	O
E	B-protein
-	I-protein
selectin	I-protein
,	O
one	O
of	O
the	O
adhesion	O
molecules	O
on	O
the	O
endothelium	O
,	O
is	O
an	O
important	O
event	O
in	O
the	O
mediation	O
of	O
the	O
inflammatory	O
response	O
.	O

Side	O
effect	O
including	O
subjective	O
and	O
objective	O
symptoms	O
were	O
strictly	O
evaluated	O
in	O
163	O
cases	O
(	O
KS	O
-	O
R1	O
group	O
in	O
83	O
cases	O
,	O
oral	O
group	O
in	O
80	O
cases	O
)	O
,	O
but	O
the	O
incidence	O
rate	O
which	O
was	O
22	O
.	O
9	O
%	O
for	O
the	O
KS	O
-	O
R1	O
group	O
and	O
23	O
.	O
8	O
%	O
for	O
the	O
oral	O
group	O
showed	O
no	O
significant	O
difference	O
.	O

Increased	O
plasma	O
IgE	B-protein
was	O
also	O
confirmed	O
in	O
the	O
NC	O
mice	O
,	O
and	O
treatment	O
with	O
FK506	O
ointment	O
reduced	O
the	O
plasma	O
IgE	B-protein
level	O
.	O

We	O
found	O
that	O
the	O
amplitude	O
of	O
the	O
cortical	O
evoked	O
potentials	O
(	O
amplitude	O
of	O
the	O
N2	O
/	O
P2	O
peak	O
)	O
increased	O
from	O
5	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
7	O
microV	O
at	O
5	O
mA	O
to	O
16	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
1	O
microV	O
at	O
20	O
mA	O
.	O

Disruption	O
of	O
RB	B-protein
/	I-protein
E2F	I-protein
-	I-protein
1	I-protein
interaction	O
by	O
single	O
point	O
mutations	O
in	O
E2F	B-protein
-	I-protein
1	I-protein
enhances	O
S	O
-	O
phase	O
entry	O
and	O
apoptosis	O
.	O

Plots	O
of	O
RV	O
,	O
LV	O
+	O
S	O
and	O
2A	O
weight	O
vs	O
real	O
hematocrit	O
showed	O
sharp	O
upward	O
inflections	O
at	O
real	O
hematocrit	O
65	O
%	O
,	O
suggesting	O
a	O
possible	O
role	O
of	O
increased	O
viscosity	O
in	O
CO	O
cardiomegaly	O
at	O
the	O
higher	O
hematocrit	O
.	O

We	O
conclude	O
that	O
DNA	O
ploidy	O
is	O
a	O
major	O
objective	O
prognostic	O
factor	O
and	O
therapeutic	O
determinant	O
for	O
endometrial	O
carcinoma	O
.	O

When	O
phosphorylation	O
of	O
exogenous	O
peptide	O
substrates	O
was	O
measured	O
as	O
a	O
function	O
of	O
receptor	O
self	O
-	O
phosphorylation	O
,	O
tyrosine	B-protein
kinase	I-protein
activity	O
was	O
found	O
to	O
be	O
enhanced	O
two	O
to	O
threefold	O
at	O
1	O
-	O
2	O
mol	O
of	O
phosphate	O
per	O
mol	O
of	O
receptor	O
.	O

It	O
is	O
exclusively	O
observed	O
in	O
smooth	O
muscle	O
cells	O
by	O
Northern	O
blotting	O
and	O
immunohistochemical	O
analysis	O
and	O
therefore	O
designated	O
`	B-protein
`	I-protein
smoothelin	I-protein
.	I-protein
`	I-protein
`	I-protein
A	O
human	O
smooth	O
muscle	O
cDNA	O
library	O
was	O
screened	O
with	O
the	O
monoclonal	B-protein
antibody	I-protein
R4A	I-protein
,	O
and	O
a	O
full	O
-	O
size	O
cDNA	O
of	O
the	O
protein	O
was	O
selected	O
.	O

Sodium	O
polystyrene	O
sulfonate	O
treatment	O
for	O
lithium	O
toxicity	O
:	O
effects	O
on	O
serum	O
potassium	O
concentrations	O
.	O

BACKGROUND	O
:	O
We	O
conducted	O
a	O
phase	O
I	O
study	O
with	O
MDL	O
73	O
,	O
147EF	O
,	O
a	O
new	O
5	B-protein
hydroxytryptamine	I-protein
3	I-protein
(	I-protein
5	I-protein
-	I-protein
HT3	I-protein
)	I-protein
receptor	I-protein
antagonist	O
,	O
in	O
25	O
patients	O
requiring	O
emetogenic	O
chemotherapy	O
.	O

We	O
examined	O
Akt	B-protein
activation	O
in	O
Lyn	O
-	O
,	O
Syk	O
-	O
and	O
Btk	O
-	O
deficient	O
DT40	O
cells	O
and	O
B	O
cells	O
from	O
Lyn	B-protein
(	I-protein
-	I-protein
/	I-protein
-	I-protein
)	I-protein
mice	O
.	O

Large	O
strain	O
differences	O
were	O
found	O
for	O
all	O
variables	O
recorded	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
proportion	O
of	O
attacking	O
males	O
,	O
the	O
time	O
spent	O
in	O
the	O
brightly	O
lit	O
box	O
,	O
and	O
the	O
number	O
of	O
transitions	O
between	O
the	O
lit	O
and	O
the	O
dark	O
boxes	O
.	O

Twenty	O
-	O
two	O
of	O
the	O
24	O
patients	O
had	O
a	O
rise	O
in	O
the	O
total	O
serum	O
amylase	B-protein
following	O
ERCP	O
.	O

MCh	O
infusion	O
caused	O
a	O
concentration	O
-	O
dependent	O
increase	O
in	O
airway	O
resistance	O
at	O
constant	O
QBA	O
.	O

We	O
obtained	O
the	O
prevalence	O
of	O
IgG	B-protein
antibodies	I-protein
against	O
Trypanosoma	O
cruzi	O
among	O
1076	O
blood	O
donors	O
at	O
the	O
Instituto	O
Nacional	O
de	O
Cardiologia	O
`	O
`	O
Ignacio	O
Chavez	O
'	O
'	O
in	O
Mexico	O
City	O
.	O

In	O
particular	O
,	O
the	O
potential	O
for	O
prostate	O
cancer	O
chemoprevention	O
using	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
cyclo	B-protein
-	I-protein
oxygenase	I-protein
inhibitors	O
;	O
NSAIDs	O
)	O
has	O
received	O
little	O
attention	O
.	O

Anamnestic	O
data	O
were	O
obtained	O
from	O
case	O
history	O
,	O
smoking	O
habits	O
were	O
not	O
known	O
in	O
collective	O
A	O
and	O
C	O
.	O

Using	O
a	O
conditional	O
-	O
lethal	O
mutant	O
allele	O
of	O
SUP45	B-protein
(	O
sup45	B-protein
-	I-protein
2	I-protein
)	O
and	O
a	O
combination	O
of	O
in	O
vivo	O
and	O
in	O
vitro	O
approaches	O
,	O
we	O
demonstrate	O
that	O
the	O
product	O
of	O
the	O
SUP45	B-protein
gene	I-protein
(	O
Sup45p	B-protein
or	O
eRF1	B-protein
)	O
is	O
a	O
factor	O
required	O
for	O
translation	O
termination	O
in	O
yeast	O
.	O

Large	O
differences	O
between	O
the	O
groups	O
were	O
not	O
observed	O
in	O
HA	O
-	O
synthesizing	O
enzyme	O
activity	O
,	O
but	O
degradative	O
enzyme	O
activity	O
was	O
much	O
higher	O
in	O
aspirin	O
-	O
induced	O
asthma	O
-	O
related	O
polyps	O
than	O
in	O
other	O
types	O
of	O
nasal	O
polyps	O
tested	O
.	O

The	O
progression	O
of	O
non	O
-	O
A	O
,	O
non	O
-	O
B	O
hepatitis	O
to	O
chronic	O
diseases	O
,	O
and	O
the	O
transformation	O
to	O
hepatocellular	O
carcinoma	O
.	O

The	O
results	O
show	O
that	O
both	O
the	O
amino	O
and	O
carboxy	O
termini	O
of	O
the	O
NS1	B-protein
protein	I-protein
molecule	I-protein
and	O
the	O
cysteines	O
at	O
residues	O
337	O
and	O
340	O
are	O
essential	O
for	O
tubule	O
formation	O
.	O

Several	O
cytokines	O
exhibit	O
a	O
high	O
degree	O
of	O
temporal	O
regulation	O
as	O
well	O
as	O
somnogenic	O
potency	O
(	O
e	O
.	O
g	O
.	O
,	O
interleukin	B-protein
-	I-protein
1	I-protein
[	I-protein
IL	I-protein
-	I-protein
1	I-protein
]	I-protein
,	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
-	I-protein
alpha	I-protein
[	I-protein
TNF	I-protein
-	I-protein
alpha	I-protein
]	I-protein
)	O
.	O

Effects	O
of	O
single	O
and	O
combined	O
maltose	O
tetrapalmitate	O
immunotherapy	O
,	O
cyclophosphamide	O
chemotherapy	O
and	O
radiotherapy	O
on	O
ethyl	O
carbamate	O
accelerated	O
primary	O
lung	O
cancer	O
in	O
A	O
/	O
J	O
mice	O
.	O

The	O
authors	O
evaluate	O
the	O
clinical	O
efficacy	O
of	O
EMB	O
AZS	O
in	O
recurrent	O
ulcer	O
after	O
operation	O
on	O
the	O
stomach	O
caused	O
by	O
a	O
high	O
level	O
of	O
acid	O
production	O
and	O
ulcerative	O
gastroduodenal	O
bleeding	O
.	O

Successive	O
abdominal	O
scintillation	O
with	O
131	O
-	O
I	O
-	O
tagged	O
BSP	O
-	O
-	O
description	O
of	O
the	O
thyroid	O
gland	O
,	O
kidney	O
and	O
spleen	O
(	O
comparison	O
with	O
131	O
-	O
I	O
-	O
RB	O
)	O
.	O

The	O
operation	O
recommended	O
is	O
excision	O
of	O
3	O
mm	O
of	O
central	O
slip	O
followed	O
by	O
end	O
-	O
to	O
-	O
end	O
repair	O
of	O
the	O
tendon	O
.	O

The	O
Scales	O
of	O
Cognitive	O
Impairment	O
Rated	O
From	O
Institutional	O
Records	O
(	O
SCIRFIR	O
)	O
,	O
a	O
battery	O
based	O
on	O
commonly	O
used	O
dementia	O
rating	O
instruments	O
,	O
was	O
tested	O
on	O
the	O
records	O
of	O
26	O
chronically	O
institutionalized	O
,	O
elderly	O
schizophrenia	O
patients	O
,	O
for	O
the	O
purpose	O
of	O
retrospectively	O
evaluating	O
the	O
long	O
-	O
term	O
course	O
of	O
cognitive	O
change	O
in	O
schizophrenia	O
and	O
relating	O
it	O
to	O
available	O
autopsy	O
materials	O
.	O

We	O
report	O
an	O
odd	O
case	O
of	O
marked	O
enlargement	O
of	O
suprapineal	O
recess	O
in	O
a	O
patient	O
with	O
triventricular	O
hydrocephalus	O
.	O

Cross	O
-	O
talking	O
among	O
Drosophila	B-protein
nuclear	I-protein
receptors	I-protein
at	O
the	O
promiscuous	B-protein
response	I-protein
element	I-protein
of	O
the	O
ng	B-protein
-	I-protein
1	I-protein
and	O
ng	B-protein
-	I-protein
2	I-protein
intermolt	I-protein
genes	I-protein
.	O

The	O
results	O
of	O
supershift	O
analysis	O
using	O
specific	O
antibodies	O
against	O
transcription	O
factors	O
suggested	O
that	O
both	O
binding	O
complexes	O
contained	O
the	O
NF	B-protein
-	I-protein
kappaB	I-protein
components	O
p50	B-protein
and	O
p65	B-protein
,	O
and	O
did	O
not	O
contain	O
other	O
NF	B-protein
-	I-protein
kappaB	I-protein
proteins	I-protein
(	O
p52	B-protein
,	O
c	B-protein
-	I-protein
Rel	I-protein
,	O
Rel	B-protein
B	I-protein
)	O
,	O
AP	B-protein
-	I-protein
1	I-protein
proteins	I-protein
(	O
c	B-protein
-	I-protein
Fos	I-protein
,	O
C	B-protein
-	I-protein
Jun	I-protein
)	O
,	O
CREB	B-protein
or	O
C	B-protein
/	I-protein
EBPbeta	I-protein
(	O
NF	B-protein
-	I-protein
IL6	I-protein
)	O
.	O

The	O
COOH	O
-	O
terminal	O
46	O
codons	O
of	O
slyD	B-protein
encode	O
a	O
remarkable	O
histidine	O
-	O
rich	O
peptide	O
sequence	O
which	O
is	O
at	O
least	O
partly	O
dispensable	O
for	O
slyD	B-protein
function	O
in	O
E	O
-	O
mediated	O
lysis	O
.	O

These	O
results	O
confirmed	O
that	O
cleavage	O
of	O
the	O
leader	O
peptide	O
is	O
the	O
last	O
step	O
in	O
nisin	B-protein
maturation	O
and	O
is	O
necessary	O
to	O
generate	O
a	O
biologically	O
active	O
peptide	O
.	O

Under	O
these	O
conditions	O
,	O
transfections	O
with	O
cDNAs	O
of	O
the	O
NF	B-protein
-	I-protein
kappa	I-protein
B	I-protein
p50	I-protein
and	O
serum	B-protein
response	I-protein
factor	I-protein
(	O
SRF	B-protein
)	O
produced	O
a	O
factor	O
(	O
s	O
)	O
that	O
mediated	O
Tax	B-protein
binding	O
to	O
the	O
NF	B-protein
-	I-protein
kappa	I-protein
B	I-protein
site	I-protein
and	O
the	O
CArG	B-protein
box	I-protein
respectively	O
.	O

Here	O
we	O
report	O
that	O
Dbp5p	B-protein
and	O
Rat7p	B-protein
interact	O
through	O
their	O
Nterminal	O
domains	O
.	O

Comparisons	O
with	O
the	O
available	O
amino	O
acid	O
residue	O
(	O
aa	O
)	O
sequence	O
information	O
from	O
the	O
complete	O
CPMV	B-protein
RNA	I-protein
1	I-protein
sequence	I-protein
and	O
the	O
partial	O
sequence	O
of	O
red	B-protein
clover	I-protein
mottle	I-protein
virus	I-protein
RNA	I-protein
1	I-protein
suggest	O
that	O
CPSMV	B-protein
RNA	I-protein
1	I-protein
specifies	O
the	O
expected	O
set	O
of	O
five	O
mature	O
proteins	O
:	O
32K	B-protein
proteinase	I-protein
cofactor	I-protein
,	O
58K	B-protein
presumed	I-protein
helicase	I-protein
,	O
VPg	B-protein
5	I-protein
'	I-protein
-	I-protein
linked	I-protein
protein	I-protein
of	O
the	O
genomic	O
RNAs	O
,	O
24K	B-protein
proteinase	I-protein
,	O
and	O
87K	B-protein
presumed	I-protein
polymerase	I-protein
,	O
separated	O
by	O
four	O
cleavage	O
sites	O
.	O

Reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
assays	O
showed	O
that	O
PKRDeltaE7	B-protein
is	O
expressed	O
in	O
a	O
broad	O
range	O
of	O
human	O
tissues	O
at	O
variable	O
levels	O
.	O

The	O
mean	O
serum	O
creatinine	O
levels	O
were	O
similar	O
at	O
one	O
year	O
(	O
SPK	O
1	O
.	O
8	O
,	O
KTA	O
1	O
.	O
9	O
mg	O
/	O
d	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Urinary	O
excretion	O
of	O
oestrone	O
,	O
oestradiol	O
-	O
17	O
beta	O
and	O
oestriol	O
in	O
pregnancies	O
complicated	O
by	O
steroid	B-protein
sulphatase	I-protein
deficiency	O
.	O

Although	O
a	O
great	O
deal	O
is	O
understood	O
about	O
how	O
bHLH	B-protein
factors	I-protein
activate	O
gene	O
transcription	O
via	O
E	O
-	O
box	O
DNA	O
consensus	O
sequences	O
,	O
studies	O
of	O
bHLH	B-protein
factor	I-protein
function	O
in	O
higher	O
eukaryotes	O
often	O
have	O
been	O
hindered	O
by	O
the	O
presence	O
of	O
multiple	O
family	O
members	O
.	O

However	O
these	O
search	O
engines	O
respond	O
with	O
such	O
cumbersome	O
results	O
that	O
domain	O
specific	O
experts	O
can	O
not	O
tolerate	O
.	O

According	O
to	O
symptoms	O
,	O
signs	O
,	O
imaging	O
features	O
,	O
operation	O
findings	O
,	O
the	O
original	O
places	O
and	O
the	O
expansive	O
directions	O
of	O
the	O
tumor	O
,	O
they	O
were	O
divided	O
into	O
four	O
clinical	O
types	O
:	O
sellar	O
,	O
clival	O
,	O
occipito	O
-	O
temporal	O
and	O
extent	O
.	O

ID	O
-	O
PaGIA	O
diphtheria	B-protein
toxin	I-protein
polymer	O
particle	O
diagnostic	O
agent	O
manufactured	O
by	O
DiaMed	O
AG	O
,	O
Switzerland	O
,	O
was	O
tried	O
at	O
bacteriological	O
laboratory	O
of	O
Institute	O
of	O
Childhood	O
Infections	O
in	O
St	O
.	O

The	O
localization	O
of	O
ZAP	B-protein
-	I-protein
70	I-protein
to	O
the	O
cell	O
cortex	O
is	O
,	O
therefore	O
,	O
regulated	O
by	O
the	O
activity	O
of	O
SRC	B-protein
-	I-protein
family	I-protein
kinases	I-protein
,	O
independently	O
of	O
their	O
ability	O
to	O
phosphorylate	O
immunoreceptor	O
tyrosine	O
-	O
based	O
activation	O
motifs	O
of	O
the	O
TCR	B-protein
.	O

Revascularization	O
after	O
anterior	O
maxillary	O
and	O
mandibular	O
osteotomy	O
.	O

RESULTS	O
:	O
Fournier	O
'	O
s	O
gangrene	O
occurs	O
worldwide	O
.	O

Kindling	O
of	O
the	O
primary	O
visual	O
cortex	O
(	O
VC	O
)	O
was	O
compared	O
with	O
that	O
of	O
the	O
amygdala	O
in	O
cats	O
.	O

To	O
study	O
the	O
regulation	O
of	O
its	O
expression	O
,	O
the	O
human	B-protein
aldehyde	I-protein
reductase	I-protein
gene	I-protein
and	O
promoter	O
were	O
cloned	O
and	O
characterized	O
.	O

Serodiagnosis	O
of	O
trypanosomiasis	O
in	O
dromedary	O
camels	O
using	O
a	O
card	O
agglutination	O
test	O
set	O
(	O
Testryp	O
CATT	O
)	O
.	O

RESULTS	O
:	O
The	O
bilinear	O
model	O
provided	O
a	O
significantly	O
better	O
fit	O
to	O
the	O
acuity	O
outcome	O
data	O
.	O

Atherosclerosis	O
.	O

Tobacco	O
mosaic	O
virus	O
-	O
infected	O
tobacco	O
(	O
Nicotiana	O
tabacum	O
var	O
.	O

The	O
long	O
-	O
term	O
prediction	O
is	O
based	O
on	O
an	O
algorithm	O
for	O
R	O
-	O
R	O
interval	O
estimation	O
.	O

Diffuse	O
white	O
matter	O
injury	O
can	O
be	O
attributed	O
to	O
radiation	O
and	O
associated	O
with	O
neurological	O
deficits	O
,	O
but	O
leukoencephalopathy	O
is	O
rarely	O
observed	O
in	O
the	O
absence	O
of	O
chemotherapy	O
.	O

The	O
biology	O
of	O
Hyostrongylus	O
ruidus	O
.	O

This	O
observation	O
can	O
not	O
be	O
explained	O
by	O
the	O
scanning	O
model	O
for	O
ribosomal	O
initiation	O
and	O
suggests	O
that	O
ribosomes	O
may	O
be	O
binding	O
directly	O
at	O
an	O
internal	O
mRNA	O
site	O
at	O
or	O
near	O
the	O
initiator	O
AUG	O
codon	O
for	O
the	O
C	B-protein
protein	I-protein
.	O

Several	O
new	O
techniques	O
are	O
available	O
for	O
monitoring	O
control	O
of	O
diabetes	O
.	O

Large	O
ones	O
were	O
similar	O
in	O
size	O
to	O
the	O
main	O
lobe	O
and	O
small	O
ones	O
were	O
approximately	O
1	O
/	O
4	O
of	O
the	O
length	O
of	O
the	O
main	O
lobe	O
.	O

Two	O
families	O
with	O
concordant	O
inheritance	O
of	O
DNAH9	B-protein
alleles	I-protein
in	O
affected	O
individuals	O
were	O
observed	O
.	O

Serum	B-protein
IgM	I-protein
and	O
IgE	B-protein
concentrations	O
,	O
allergen	B-protein
-	I-protein
specific	I-protein
IgE	I-protein
scores	O
,	O
and	O
the	O
tumor	O
E2R	B-protein
status	O
were	O
combined	O
to	O
construct	O
a	O
three	O
-	O
level	O
risk	O
classification	O
that	O
was	O
more	O
prognostic	O
than	O
any	O
of	O
the	O
individual	O
components	O
.	O

Hyperprolactinaemia	O
,	O
moderate	O
hypogonadism	O
,	O
infraclinical	O
neuropathies	O
,	O
arterial	O
stenoses	O
and	O
moderate	O
venous	O
leakages	O
seem	O
to	O
play	O
a	O
partial	O
role	O
of	O
organic	O
starter	O
or	O
cofactor	O
,	O
the	O
sexual	O
consequences	O
of	O
which	O
are	O
amplified	O
by	O
psychological	O
factors	O
,	O
partly	O
secondary	O
to	O
the	O
initial	O
sexual	O
failures	O
.	O

The	O
spectrum	O
of	O
phenotypes	O
caused	O
by	O
these	O
mutations	O
was	O
strikingly	O
different	O
than	O
mutations	O
in	O
the	O
adaptor	O
for	O
the	O
VP16	B-protein
activation	I-protein
domain	I-protein
.	O

CONCLUSIONS	O
:	O
Congenital	O
horizontal	O
tarsal	O
kink	O
is	O
rare	O
and	O
its	O
cause	O
is	O
unknown	O
.	O

The	O
transforming	O
gene	O
of	O
the	O
avian	B-protein
sarcoma	I-protein
virus	I-protein
CT10	I-protein
encodes	O
a	O
fusion	O
protein	O
(	O
p47gag	B-protein
-	I-protein
crk	I-protein
or	O
v	B-protein
-	I-protein
Crk	I-protein
)	O
containing	O
viral	B-protein
Gag	I-protein
sequences	I-protein
fused	O
to	O
cellular	O
sequences	O
consisting	O
primarily	O
of	O
Src	B-protein
homology	I-protein
regions	I-protein
2	I-protein
and	I-protein
3	I-protein
(	O
SH2	B-protein
and	O
SH3	B-protein
sequences	I-protein
)	O
.	O

It	O
is	O
likely	O
that	O
other	O
pathways	O
involve	O
alternate	O
signal	O
transduction	O
events	O
(	O
e	O
.	O
g	O
.	O
,	O
calcium	O
mobilization	O
)	O
and	O
promoter	O
response	O
elements	O
(	O
e	O
.	O
g	O
.	O
,	O
SRE	O
)	O
.	O

The	O
ORF3	O
probe	O
also	O
hybridized	O
to	O
a	O
540	O
bp	O
transcript	O
consistent	O
with	O
the	O
size	O
of	O
ORF3	O
alone	O
and	O
supportive	O
of	O
the	O
mutagenesis	O
data	O
of	O
non	O
-	O
linkage	O
.	O

In	O
these	O
cases	O
,	O
greatly	O
increased	O
human	B-protein
chorionic	I-protein
gonadotropin	I-protein
(	O
hCG	B-protein
)	O
levels	O
and	O
suppressed	O
TSH	B-protein
levels	O
suggest	O
that	O
hCG	B-protein
has	O
thyrotropic	O
activity	O
.	O

Disturbance	O
of	O
regeneration	O
in	O
the	O
above	O
pathological	O
condition	O
results	O
from	O
the	O
damage	O
to	O
tunica	O
propria	O
and	O
loss	O
of	O
its	O
function	O
for	O
the	O
support	O
of	O
structural	O
homeostasis	O
.	O

However	O
,	O
a	O
correlation	O
was	O
observed	O
between	O
SF	O
levels	O
of	O
IL	B-protein
-	I-protein
8	I-protein
with	O
those	O
of	O
lactate	O
,	O
LDH	B-protein
,	O
beta	B-protein
2	I-protein
-	I-protein
microglobulin	I-protein
and	O
glucose	O
.	O

Substrates	O
for	O
p210	B-protein
(	I-protein
bcr	I-protein
-	I-protein
abl	I-protein
)	I-protein
are	O
likely	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
CML	O
.	O

Comparison	O
of	O
cDNA	O
sequences	O
revealed	O
that	O
the	O
two	O
mRNA	O
species	O
arise	O
as	O
a	O
result	O
of	O
alternate	O
use	O
of	O
poly	O
(	O
A	O
)	O
-	O
addition	O
sites	O
.	O

Polyprotein	O
processing	O
in	O
Southampton	O
virus	O
:	O
identification	O
of	O
3C	B-protein
-	I-protein
like	I-protein
protease	I-protein
cleavage	O
sites	O
by	O
in	O
vitro	O
mutagenesis	O
.	O

Assay	O
of	O
serum	B-protein
immunoreactive	I-protein
trypsin	I-protein
in	O
dried	O
blood	O
spots	O
and	O
the	O
early	O
detection	O
of	O
cystic	O
fibrosis	O
.	O

Implications	O
of	O
this	O
observation	O
for	O
pediatrics	O
are	O
discussed	O
.	O

At	O
some	O
sites	O
,	O
%	O
T	O
is	O
greatly	O
increased	O
by	O
Cl	O
-	O
concentrations	O
up	O
to	O
1	O
M	O
,	O
while	O
at	O
other	O
sites	O
%	O
T	O
is	O
reduced	O
or	O
unaffected	O
by	O
these	O
conditions	O
.	O

Northern	O
blot	O
analysis	O
demonstrated	O
the	O
ubiquitous	O
expression	O
of	O
2	O
.	O
9	O
kb	O
and	O
3	O
.	O

Objective	O
responses	O
also	O
occurred	O
in	O
studies	O
that	O
explored	O
sequential	O
use	O
of	O
exemestane	O
after	O
failure	O
of	O
aminoglutethimide	O
(	O
26	O
%	O
with	O
exemestane	O
200	O
mg	O
/	O
day	O
)	O
or	O
other	O
nonsteroidal	O
aromatase	B-protein
inhibitors	O
(	O
6	O
.	O
6	O
%	O
with	O
exemestane	O
25	O
mg	O
/	O
day	O
)	O
.	O

Such	O
a	O
concept	O
is	O
crucial	O
to	O
our	O
understanding	O
of	O
the	O
pathology	O
of	O
ageing	O
in	O
general	O
.	O

After	O
the	O
application	O
of	O
RS	O
86	O
,	O
REM	O
latency	O
was	O
shortened	O
in	O
all	O
groups	O
under	O
investigation	O
.	O

Two	O
additional	O
cis	O
-	O
acting	O
sequences	O
,	O
conserved	O
in	O
both	O
the	O
region	O
1	O
and	O
3	O
promoters	O
,	O
were	O
identified	O
,	O
suggesting	O
a	O
role	O
for	O
these	O
sequences	O
in	O
the	O
coordinate	O
regulation	O
of	O
transcription	O
from	O
these	O
promoters	O
.	O

BRCA1	B-protein
,	O
a	O
familial	O
breast	O
and	O
ovarian	O
cancer	O
susceptibility	O
gene	O
encodes	O
nuclear	O
phosphoproteins	O
that	O
function	O
as	O
tumor	O
suppressors	O
in	O
human	O
breast	O
cancer	O
cells	O
.	O

In	O
contrast	O
,	O
both	O
Sp1	B-protein
and	O
ETS	B-protein
proteins	I-protein
are	O
required	O
to	O
bring	O
about	O
full	O
promoter	O
activity	O
in	O
the	O
Surf	B-protein
-	I-protein
1	I-protein
direction	O
.	O

The	O
epidemic	O
occurred	O
in	O
a	O
group	O
of	O
26	O
community	O
members	O
(	O
23	O
men	O
and	O
3	O
women	O
,	O
mean	O
age	O
,	O
28	O
.	O
9	O
-	O
-	O
3	O
years	O
)	O
living	O
and	O
working	O
together	O
,	O
who	O
underwent	O
acute	O
and	O
convalescent	O
serologic	O
tests	O
for	O
Mycoplasma	O
pneumoniae	O
,	O
Legionella	O
pneumophila	O
,	O
cytomegalovirus	O
,	O
adenovirus	O
,	O
Coxiella	O
burnetii	O
,	O
and	O
Chlamydia	O
pneumoniae	O
.	O

We	O
found	O
strand	O
selective	O
repair	O
in	O
DNA	O
fragments	O
within	O
two	O
active	O
genes	O
,	O
DHFR	B-protein
and	O
an	O
unknown	O
gene	O
adjacent	O
to	O
DHFR	B-protein
.	O

Six	O
(	O
four	O
FAP	O
;	O
two	O
primary	O
amyloidosis	O
)	O
also	O
had	O
diffusely	O
positive	O
myocardial	O
uptakes	O
,	O
but	O
the	O
intensity	O
was	O
less	O
than	O
that	O
of	O
the	O
sternum	O
.	O

The	O
major	O
phenotypes	O
resulting	O
from	O
Fab1p	B-protein
kinase	I-protein
inactivation	O
include	O
temperature	O
-	O
sensitive	O
growth	O
,	O
vacuolar	O
acidification	O
defects	O
,	O
and	O
dramatic	O
increases	O
in	O
vacuolar	O
size	O
.	O

These	O
results	O
demonstrate	O
Ras	O
-	O
and	O
Raf	O
-	O
independent	O
ERK	B-protein
MAPK	I-protein
activation	O
maintains	O
cell	O
viability	O
following	O
heat	O
shock	O
.	O

Initial	O
control	O
of	O
bleeding	O
is	O
similar	O
,	O
but	O
eradication	O
is	O
achieved	O
in	O
fewer	O
sessions	O
with	O
EVL	O
.	O

Naloxone	O
(	O
2	O
mg	O
/	O
kg	O
bolus	O
+	O
2	O
mg	O
X	O
kg	O
-	O
1	O
X	O
h	O
-	O
1	O
)	O
was	O
given	O
with	O
one	O
of	O
the	O
two	O
doses	O
of	O
the	O
lipopolysaccharide	O
.	O

Action	O
of	O
strontium	O
-	O
90	O
and	O
metaphos	O
on	O
Cyprinus	O
carpio	O
.	O

In	O
the	O
pRb	B-protein
(	I-protein
-	I-protein
)	I-protein
SAOS	O
-	O
2	O
cell	O
line	O
transiently	O
transfected	O
with	O
a	O
reporter	O
plasmid	O
containing	O
six	O
tal	B-protein
-	I-protein
1	I-protein
binding	I-protein
site	I-protein
,	O
pRb	B-protein
enhances	O
the	O
transcriptional	O
activity	O
of	O
tal	B-protein
-	I-protein
1	I-protein
-	I-protein
E12	I-protein
-	I-protein
Lmo2	I-protein
and	O
tal	B-protein
-	I-protein
1	I-protein
-	I-protein
E12	I-protein
-	I-protein
Lmo2	I-protein
-	I-protein
Ldb1	I-protein
complexes	I-protein
but	O
not	O
that	O
of	O
a	O
tal	B-protein
-	I-protein
1	I-protein
-	I-protein
E12	I-protein
heterodimer	I-protein
.	O

The	O
flux	O
rates	O
of	O
p	O
-	O
toluidine	O
decreased	O
as	O
the	O
pH	O
value	O
in	O
the	O
donor	O
solution	O
increased	O
.	O

Using	O
immunochemical	O
co	O
-	O
precipitation	O
methods	O
,	O
we	O
also	O
found	O
that	O
the	O
two	O
proteins	O
are	O
bound	O
in	O
vivo	O
.	O

Anesthesiologists	O
often	O
use	O
more	O
than	O
one	O
drug	O
in	O
a	O
patient	O
to	O
achieve	O
a	O
target	O
response	O
,	O
such	O
as	O
a	O
desired	O
blood	O
pressure	O
.	O

Aneurysmectomy	O
and	O
the	O
performance	O
of	O
CABG	O
were	O
not	O
significantly	O
associated	O
with	O
postoperative	O
ECG	O
changes	O
,	O
but	O
more	O
bypass	O
grafts	O
per	O
patient	O
grafted	O
appeared	O
in	O
the	O
group	O
with	O
postoperative	O
ECG	O
changes	O
,	O
suggesting	O
that	O
coronary	O
artery	O
disease	O
may	O
be	O
more	O
severe	O
in	O
that	O
group	O
.	O

The	O
average	O
values	O
were	O
199	O
and	O
424	O
revertants	O
/	O
g	O
for	O
the	O
hamburgers	O
and	O
hot	O
dogs	O
,	O
respectively	O
.	O

Of	O
208	O
eligible	O
subjects	O
,	O
82	O
received	O
supervised	O
IPT	O
at	O
a	O
dose	O
of	O
900	O
mg	O
twice	O
weekly	O
for	O
6	O
mo	O
(	O
Regimen	O
A	O
)	O
,	O
73	O
received	O
unsupervised	O
IPT	O
900	O
mg	O
twice	O
weekly	O
for	O
6	O
mo	O
(	O
Regimen	O
B	O
)	O
,	O
and	O
53	O
received	O
unsupervised	O
IPT	O
300	O
mg	O
daily	O
for	O
6	O
mo	O
(	O
Regimen	O
C	O
)	O
.	O

Plasma	O
and	O
erthrocyte	O
lipid	O
profile	O
and	O
lipoprotein	B-protein
lipase	I-protein
activity	O
in	O
postheparin	O
plasma	O
on	O
vasectomized	O
rabbits	O
were	O
studied	O
and	O
also	O
the	O
incidence	O
of	O
atherosclerosis	O
in	O
different	O
arterial	O
beds	O
.	O

Treatment	O
of	O
meat	O
muscle	O
800	O
V	O
for	O
45	O
s	O
reduced	O
weeping	O
but	O
increased	O
slightly	O
the	O
rate	O
of	O
autoxidation	O
of	O
lipids	O
.	O

The	O
single	O
-	O
stranded	O
DNA	O
Pur	B-protein
alpha	I-protein
recognition	I-protein
element	I-protein
disrupts	O
these	O
complexes	O
.	O

Our	O
data	O
provide	O
a	O
biochemical	O
explanation	O
for	O
the	O
similarity	O
in	O
phenotype	O
between	O
A	O
-	O
T	O
and	O
NBS	O
.	O

The	O
extended	O
rat	B-protein
SP	I-protein
-	I-protein
A	I-protein
isoforms	I-protein
were	O
enriched	O
in	O
the	O
more	O
fully	O
glycosylated	O
and	O
multimeric	O
SP	B-protein
-	I-protein
A	I-protein
species	O
separated	O
on	O
SDS	O
-	O
PAGE	O
gels	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
We	O
report	O
our	O
experience	O
with	O
seven	O
children	O
with	O
active	O
small	O
bowel	O
Crohn	O
'	O
s	O
disease	O
given	O
a	O
casein	O
-	O
based	O
,	O
polymeric	O
feed	O
rich	O
in	O
TGF	B-protein
-	I-protein
beta	I-protein
2	I-protein
(	O
Specific	O
Polymeric	O
Diet	O
;	O
Nestle	O
-	O
Clintec	O
;	O
Vevey	O
,	O
Switzerland	O
)	O
as	O
complete	O
nutrition	O
for	O
8	O
weeks	O
.	O

The	O
action	O
of	O
nef	O
was	O
specific	O
to	O
the	O
LTR	O
,	O
as	O
expression	O
of	O
nef	B-protein
had	O
no	O
effect	O
on	O
the	O
activity	O
of	O
the	O
simian	O
virus	O
40	O
,	O
c	B-protein
-	I-protein
fms	I-protein
,	O
urokinase	B-protein
plasminogen	I-protein
activator	I-protein
,	O
or	O
type	B-protein
5	I-protein
acid	I-protein
phosphatase	I-protein
promoter	I-protein
.	O
trans	O
-	O
activating	O
activity	O
was	O
also	O
manifested	O
by	O
a	O
frameshift	O
mutant	O
expressing	O
only	O
the	O
first	O
35	O
amino	O
acids	O
of	O
the	O
protein	O
.	O

Kf	O
,	O
c	O
and	O
CT	O
(	O
referenced	O
to	O
the	O
initial	O
lung	O
mass	O
)	O
decreased	O
linearly	O
with	O
reductions	O
in	O
lung	O
mass	O
%	O
delta	O
Kf	O
,	O
c	O
=	O
1	O
.	O
26	O
-	O
0	O
.	O
98	O
%	O
mass	O
removed	O
(	O
r	O
=	O
0	O
.	O
90	O
,	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
%	O
delta	O
CT	O
=	O
-	O
3	O
.	O
99	O
-	O
0	O
.	O
98	O
%	O
mass	O
removed	O
(	O
r	O
=	O
0	O
.	O
82	O
,	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
relationships	O
that	O
were	O
not	O
altered	O
by	O
blocker	O
pretreatment	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
Wilms	B-protein
'	I-protein
tumour	I-protein
suppressor	I-protein
protein	I-protein
(	O
WT1	B-protein
)	O
is	O
a	O
putative	O
transcriptional	O
regulatory	O
protein	O
with	O
four	O
zinc	O
fingers	O
,	O
the	O
last	O
three	O
of	O
which	O
have	O
extensive	O
sequence	O
homology	O
to	O
the	O
early	B-protein
growth	I-protein
response	I-protein
-	I-protein
1	I-protein
(	O
EGR	B-protein
-	I-protein
1	I-protein
)	O
protein	O
.	O

This	O
study	O
demonstrates	O
secretion	O
of	O
bicarbonate	O
by	O
the	O
human	O
stomach	O
in	O
vivo	O
at	O
a	O
rate	O
equivalent	O
to	O
10	O
-	O
-	O
20	O
%	O
of	O
basal	O
acid	O
secretion	O
.	O

Commonly	O
observed	O
systemic	O
toxic	O
effects	O
(	O
bone	O
marrow	O
,	O
gastrointestinal	O
tract	O
,	O
and	O
heart	O
)	O
were	O
not	O
seen	O
in	O
this	O
study	O
.	O

Correlating	O
with	O
the	O
previous	O
observation	O
that	O
CBF	B-protein
binding	O
to	O
the	O
78C1	O
site	O
is	O
enhanced	O
by	O
EGTA	O
and	O
EDTA	O
,	O
these	O
divalent	O
cation	O
chelators	O
specifically	O
stimulate	O
78C1	O
-	O
directed	O
transcription	O
.	O

The	O
methylation	O
of	O
nuclear	O
and	O
chloroplast	O
DNAs	O
has	O
been	O
examined	O
in	O
relation	O
to	O
the	O
known	O
differential	O
expression	O
of	O
C4	B-protein
photosynthesis	I-protein
genes	I-protein
in	O
the	O
bundle	O
sheath	O
and	O
mesophyll	O
cells	O
of	O
etiolated	O
,	O
greening	O
,	O
and	O
fully	O
green	O
maize	O
leaves	O
.	O

Marinol	O
/	O
marijuana	O
usage	O
was	O
associated	O
with	O
depressed	O
CD4	B-protein
+	I-protein
counts	O
and	O
elevated	O
amylase	B-protein
levels	O
within	O
the	O
DDI	O
subgroup	O
.	O

Two	O
Pax2	B-protein
/	I-protein
5	I-protein
/	I-protein
8	I-protein
-	I-protein
binding	I-protein
sites	I-protein
in	O
Engrailed2	B-protein
are	O
required	O
for	O
proper	O
initiation	O
of	O
endogenous	O
mid	O
-	O
hindbrain	O
expression	O
.	O

The	O
SH3	B-protein
domains	I-protein
of	O
Grb2	B-protein
bound	O
in	O
vitro	O
to	O
specific	O
proline	O
-	O
rich	O
motifs	O
in	O
the	O
HPK1	B-protein
tail	O
and	O
functioned	O
synergistically	O
to	O
direct	O
the	O
stable	O
binding	O
of	O
Grb2	B-protein
to	O
HPK1	B-protein
in	O
transfected	O
Cos1	O
cells	O
.	O

The	O
immunophilin	B-protein
,	O
which	O
can	O
be	O
of	O
the	O
FK506	O
-	O
or	O
cyclosporin	O
A	O
-	O
binding	O
class	O
,	O
binds	O
to	O
hsp90	B-protein
via	O
its	O
tetratricopeptide	O
repeat	O
(	O
TPR	O
)	O
domain	O
,	O
and	O
different	O
receptor	O
heterocomplexes	O
exist	O
depending	O
upon	O
which	O
immunophilin	B-protein
occupies	O
the	O
TPR	B-protein
-	I-protein
binding	I-protein
region	I-protein
of	O
hsp90	B-protein
.	O

Cocaine	O
-	O
treated	O
rats	O
acquired	O
a	O
preference	O
for	O
cocaine	O
-	O
associated	O
contextual	O
stimuli	O
(	O
CS	O
)	O
relative	O
to	O
saline	O
-	O
injected	O
control	O
rats	O
.	O

Primer	O
extension	O
and	O
S1	B-protein
nuclease	I-protein
mapping	O
experiments	O
were	O
used	O
to	O
locate	O
the	O
transcription	O
initiation	O
site	O
of	O
Nramp1	B-protein
and	O
revealed	O
the	O
presence	O
of	O
one	O
major	O
and	O
several	O
minor	O
initiation	O
sites	O
.	O

Feeding	O
behavior	O
,	O
circannual	O
body	O
weight	O
and	O
hibernation	O
rhythms	O
in	O
European	O
hamsters	O
lesioned	O
in	O
the	O
noradrenergic	O
ascending	O
bundles	O
.	O

We	O
have	O
identified	O
two	O
overlapping	O
expressed	O
sequence	O
tag	O
clones	O
,	O
which	O
contain	O
the	O
missing	O
4	O
.	O
4	O
-	O
kb	O
3	O
'	O
-	O
UTR	O
of	O
the	O
human	B-protein
D2	I-protein
(	O
hD2	B-protein
)	O
cDNA	O
.	O

Eight	O
induced	O
cDNA	O
sequences	O
were	O
identified	O
and	O
designated	O
message	B-protein
up	I-protein
-	I-protein
regulated	I-protein
during	I-protein
death	I-protein
(	O
mud	B-protein
)	O
-	O
1	O
-	O
8	O
.	O

Several	O
highly	O
conserved	O
regions	O
were	O
identified	O
at	O
the	O
near	O
N	O
terminus	O
,	O
middle	O
and	O
C	O
terminus	O
.	O

S	O
.	O
,	O
K	O
.	O

Deletion	O
and	O
mutational	O
analyses	O
revealed	O
two	O
positive	O
cis	O
-	O
regulatory	O
elements	O
in	O
this	O
region	O
that	O
are	O
essential	O
for	O
CSX1	B-protein
expression	O
in	O
cardiomyocytes	O
.	O

This	O
mechanism	O
is	O
in	O
contrast	O
to	O
other	O
cases	O
of	O
splicing	O
regulation	O
by	O
PTB	B-protein
,	O
in	O
which	O
the	O
protein	O
represses	O
the	O
splice	O
site	O
to	O
which	O
it	O
binds	O
.	O

Time	O
shifts	O
increase	O
growth	B-protein
hormone	I-protein
release	O
.	O

The	O
pharmacological	O
effects	O
of	O
the	O
novel	O
compound	O
WEB	O
1881	O
FU	O
(	O
4	O
-	O
amino	O
-	O
methyl	O
-	O
1	O
-	O
benzyl	O
-	O
pyrrolidine	O
-	O
2	O
-	O
one	O
-	O
fumarate	O
)	O
were	O
investigated	O
.	O

Salzburg	O
,	O
9	O
-	O
12	O
September	O
1987	O
.	O

There	O
was	O
a	O
trend	O
in	O
all	O
studies	O
favouring	O
PVI	O
.	O

Estimation	O
of	O
L	O
-	O
alanine	O
in	O
serum	O
or	O
plasma	O
using	O
the	O
LKB	O
reaction	O
rate	O
analyser	O
.	O

We	O
have	O
carried	O
out	O
a	O
comprehensive	O
and	O
systematic	O
mutagenesis	O
of	O
the	O
Cse4p	B-protein
N	I-protein
terminus	I-protein
to	O
analyze	O
its	O
function	O
.	O

HL	B-protein
-	I-protein
A	I-protein
antibodies	I-protein
in	O
polytransfused	O
patients	O
.	O

Analysis	O
of	O
cell	O
cycle	O
regulation	O
in	O
the	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
has	O
shown	O
that	O
a	O
central	O
regulatory	O
protein	B-protein
kinase	I-protein
,	O
Cdc28	B-protein
,	O
undergoes	O
changes	O
in	O
activity	O
through	O
the	O
cell	O
cycle	O
by	O
associating	O
with	O
distinct	O
groups	O
of	O
cyclins	B-protein
that	O
accumulate	O
at	O
different	O
times	O
.	O

Ischaemia	O
was	O
induced	O
by	O
a	O
low	O
flow	O
rate	O
of	O
0	O
.	O
8	O
mL	O
min	O
-	O
1	O
for	O
30	O
min	O
,	O
and	O
was	O
followed	O
by	O
a	O
40	O
-	O
minute	O
reperfusion	O
.	O

They	O
also	O
indicate	O
that	O
direct	O
interactions	O
between	O
C	B-protein
/	I-protein
EBPs	I-protein
and	O
specific	O
Ets	B-protein
family	O
members	O
,	O
together	O
with	O
GATA	B-protein
-	I-protein
1	I-protein
,	O
are	O
important	O
for	O
eosinophil	O
lineage	O
determination	O
.	O

To	O
begin	O
to	O
understand	O
this	O
role	O
,	O
we	O
overexpressed	O
ATF	B-protein
-	I-protein
2	I-protein
in	O
a	O
human	O
cancer	O
cell	O
line	O
.	O

CD	O
was	O
determined	O
using	O
the	O
Farnsworth	O
D	O
-	O
15	O
method	O
.	O

During	O
insulin	B-protein
infusion	O
,	O
a	O
20	O
%	O
dextrose	O
solution	O
was	O
infused	O
by	O
a	O
Biostator	O
in	O
order	O
to	O
maintain	O
the	O
patient	O
'	O
s	O
glycemia	O
at	O
90	O
mg	O
/	O
dl	O
.	O

An	O
approximately	O
2	O
-	O
kilobase	O
B2	O
transcript	O
was	O
expressed	O
in	O
all	O
alfalfa	O
organs	O
tested	O
.	O

A	O
cohort	O
of	O
Swedish	O
children	O
was	O
monitored	O
from	O
6	O
months	O
to	O
11	O
years	O
of	O
age	O
.	O

We	O
provide	O
community	O
metabolic	O
data	O
that	O
indicate	O
that	O
large	O
changes	O
in	O
CO2	O
concentration	O
can	O
occur	O
in	O
coral	O
reef	O
waters	O
via	O
biogeochemical	O
processes	O
not	O
directly	O
associated	O
with	O
photosynthesis	O
,	O
respiration	O
,	O
calcification	O
,	O
and	O
CaCO3	O
dissolution	O
.	O

Effect	O
of	O
aging	O
on	O
respiratory	O
skeletal	O
muscles	O
.	O

Mutational	O
analysis	O
of	O
yeast	B-protein
CEG1	I-protein
demonstrated	O
that	O
four	O
of	O
the	O
five	O
conserved	O
motifs	O
are	O
essential	O
for	O
capping	O
enzyme	O
function	O
in	O
vivo	O
.	O

Abbreviations	O
:	O
CAS	B-protein
,	O
CRK	B-protein
-	I-protein
associated	I-protein
substrate	I-protein
;	O
CH	B-protein
,	O
calponin	B-protein
-	I-protein
homology	I-protein
domain	I-protein
;	O
CSK	B-protein
,	O
C	B-protein
-	I-protein
terminal	I-protein
SRC	I-protein
kinase	I-protein
;	O
E6	B-protein
,	O
Papillomavirus	B-protein
E6	I-protein
protein	I-protein
;	O
FAK	B-protein
,	O
focal	B-protein
adhesion	I-protein
kinase	I-protein
;	O
GIT	B-protein
,	O
GRK	B-protein
interacter	I-protein
;	O
GPCR	B-protein
,	O
heterotrimeric	B-protein
-	I-protein
G	I-protein
-	I-protein
protein	I-protein
-	I-protein
coupled	I-protein
receptor	I-protein
;	O
GRK	B-protein
,	O
G	B-protein
-	I-protein
protein	I-protein
-	I-protein
coupled	I-protein
-	I-protein
receptor	I-protein
kinase	I-protein
;	O
MAPK	B-protein
,	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
(	O
ERK	B-protein
,	O
p38	B-protein
,	O
JNK	B-protein
)	O
;	O
PAK	B-protein
,	O
p21	B-protein
-	I-protein
activated	I-protein
kinase	I-protein
;	O
PBS	B-protein
,	O
paxillin	B-protein
-	I-protein
binding	I-protein
subdomain	I-protein
;	O
PIX	B-protein
,	O
PAK	B-protein
-	I-protein
interacting	I-protein
exchange	I-protein
factor	I-protein
;	O
PKL	B-protein
,	O
paxillin	B-protein
kinase	I-protein
linker	I-protein
;	O
POR1	B-protein
,	O
partner	B-protein
of	I-protein
Rac	I-protein
;	O
PS	O
,	O
phosphoserine	O
;	O
PT	O
,	O
phosphothreonine	O
;	O
PY	O
,	O
phosphotyrosine	O
;	O
RTK	B-protein
,	O
growth	B-protein
factor	I-protein
receptor	I-protein
tyrosine	I-protein
kinase	I-protein
;	O
SH	B-protein
,	O
SRC	B-protein
-	I-protein
homology	I-protein
domain	I-protein
.	O

We	O
have	O
identified	O
SWI5	O
'	O
s	O
nuclear	O
localization	O
signal	O
(	O
NLS	O
)	O
and	O
show	O
that	O
it	O
can	O
confer	O
cell	O
cycle	O
-	O
dependent	O
nuclear	O
entry	O
to	O
a	O
heterologous	O
protein	O
.	O

We	O
found	O
that	O
PML	B-protein
was	O
expressed	O
at	O
a	O
lower	O
level	O
in	O
S	O
,	O
G2	O
,	O
and	O
M	O
phases	O
and	O
at	O
a	O
significantly	O
higher	O
level	O
in	O
G1	O
phase	O
.	O

Electroglottography	O
is	O
a	O
useful	O
,	O
non	O
-	O
invasive	O
technique	O
that	O
can	O
assist	O
in	O
the	O
assessment	O
of	O
vocal	O
fold	O
dysfunction	O
.	O

Metformin	O
plasma	O
concentrations	O
remained	O
unchanged	O
except	O
for	O
patients	O
transferred	O
from	O
1	O
.	O
5	O
to	O
2	O
.	O
0	O
g	O
daily	O
to	O
850	O
mg	O
twice	O
daily	O
;	O
in	O
these	O
patients	O
plasma	O
concentrations	O
increased	O
from	O
1	O
.	O
83	O
+	O
/	O
-	O
0	O
.	O
87	O
to	O
2	O
.	O
50	O
+	O
/	O
-	O
0	O
.	O
89	O
micrograms	O
/	O
l	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

From	O
the	O
National	O
Institutes	O
of	O
Health	O
.	O

The	O
TYAC	O
/	O
P1	O
resource	O
,	O
derivative	O
STSs	O
,	O
and	O
polymorphisms	O
constitute	O
an	O
enabling	O
resource	O
to	O
further	O
studies	O
of	O
telomere	O
structure	O
and	O
function	O
and	O
a	O
means	O
for	O
physical	O
and	O
genetic	O
map	O
integration	O
and	O
closure	O
.	O

One	O
complex	O
most	O
likely	O
contained	O
Sp1	B-protein
,	O
and	O
another	O
complex	O
showed	O
S	O
-	O
phase	O
-	O
specific	O
binding	O
,	O
suggesting	O
a	O
direct	O
role	O
in	O
the	O
cell	O
-	O
cycle	O
-	O
dependent	O
R1	B-protein
gene	I-protein
expression	O
.	O

The	O
cell	O
cycle	O
-	O
regulated	O
transcription	O
factor	O
E2F	B-protein
is	O
also	O
known	O
to	O
bend	O
DNA	O
upon	O
binding	O
.	O

In	O
11	O
patients	O
with	O
Horton	O
'	O
s	O
headache	O
morphological	O
investigations	O
(	O
differential	O
white	O
blood	O
cell	O
count	O
)	O
,	O
cytoenzymatic	O
determinations	O
(	O
alkaline	B-protein
and	I-protein
acid	I-protein
phosphatase	I-protein
,	O
non	B-protein
-	I-protein
specific	I-protein
esterase	I-protein
)	O
and	O
cytoimmunological	O
tests	O
(	O
IgM	B-protein
and	O
IgG	B-protein
binding	O
)	O
were	O
carried	O
out	O
on	O
capillary	O
blood	O
neutrophils	O
obtained	O
from	O
the	O
area	O
of	O
pain	O
,	O
non	O
-	O
painful	O
area	O
of	O
the	O
skin	O
on	O
the	O
head	O
on	O
the	O
contralateral	O
side	O
,	O
and	O
from	O
the	O
finger	O
.	O

The	O
oxygen	O
uptake	O
(	O
VO2	O
)	O
,	O
carbon	O
dioxide	O
output	O
(	O
VCO2	O
)	O
,	O
respiratory	O
rate	O
(	O
fR	O
)	O
,	O
minute	O
ventilation	O
(	O
VE	O
)	O
,	O
alveolar	O
ventilation	O
(	O
VA	O
)	O
,	O
alveolar	O
oxygen	O
pressure	O
(	O
PAO2	O
)	O
,	O
and	O
VE	O
/	O
VO2	O
ratio	O
were	O
higher	O
in	O
the	O
cows	O
,	O
while	O
the	O
tidal	O
volume	O
(	O
VT	O
)	O
and	O
physiological	O
dead	O
space	O
(	O
VD	O
)	O
were	O
larger	O
in	O
the	O
horses	O
.	O

Two	O
cDNAs	O
encoding	O
casein	B-protein
kinase	I-protein
-	I-protein
1	I-protein
have	O
been	O
isolated	O
from	O
a	O
yeast	O
cDNA	O
library	O
and	O
termed	O
CKI1	B-protein
and	O
CKI2	B-protein
.	O

These	O
observations	O
of	O
elevated	O
serum	B-protein
lipase	I-protein
and	O
serum	O
CA	B-protein
19	I-protein
-	I-protein
9	I-protein
in	O
Sjogren	O
'	O
s	O
syndrome	O
without	O
evidence	O
of	O
malignancy	O
may	O
reflect	O
pancreatic	O
involvement	O
in	O
this	O
disorder	O
.	O

These	O
results	O
confirming	O
the	O
high	O
validity	O
of	O
NOM	O
inhibiting	O
test	O
in	O
the	O
diagnosis	O
of	O
tumoural	O
hyperprolactinemic	O
states	O
,	O
reveal	O
contradictory	O
responses	O
to	O
CD	O
/	O
LD	O
,	O
LD	O
and	O
DOM	O
,	O
with	O
sustain	O
the	O
existence	O
of	O
2	O
sub	O
-	O
group	O
of	O
Prolactinomas	O
:	O
with	O
or	O
without	O
a	O
maintained	O
DA	O
central	O
tonus	O
supporting	O
the	O
possibility	O
of	O
different	O
etiopathogenetical	O
factors	O
in	O
inducing	O
a	O
tumoural	O
hyperprolactinemic	O
states	O
.	O

Efficacy	O
of	O
first	O
-	O
generation	O
Cavermap	O
to	O
verify	O
location	O
and	O
function	O
of	O
cavernous	O
nerves	O
during	O
radical	O
prostatectomy	O
:	O
a	O
multi	O
-	O
institutional	O
evaluation	O
by	O
experienced	O
surgeons	O
.	O

In	O
order	O
to	O
characterize	O
the	O
functional	O
elements	O
of	O
the	O
promoter	O
that	O
in	O
some	O
way	O
must	O
respond	O
to	O
these	O
regulatory	O
signals	O
,	O
a	O
number	O
of	O
promoter	O
mutations	O
were	O
constructed	O
,	O
including	O
a	O
set	O
of	O
linker	O
-	O
scanning	O
mutations	O
across	O
the	O
entire	O
promoter	O
region	O
.	O

Structural	O
basis	O
for	O
activation	O
of	O
human	B-protein
lymphocyte	I-protein
kinase	I-protein
Lck	I-protein
upon	O
tyrosine	O
phosphorylation	O
.	O

Among	O
them	O
,	O
26	O
cases	O
were	O
benign	O
and	O
34	O
malignant	O
.	O

Such	O
transgenic	O
plants	O
should	O
enable	O
not	O
only	O
the	O
mutational	O
analysis	O
of	O
sequence	O
elements	O
within	O
the	O
replication	O
origin	O
region	O
,	O
but	O
also	O
the	O
construction	O
of	O
a	O
new	O
generation	O
of	O
vectors	O
for	O
gene	O
amplification	O
in	O
plants	O
,	O
based	O
on	O
a	O
minimal	O
virus	O
replicon	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
revealed	O
that	O
two	O
clusters	O
of	O
basic	O
amino	O
acids	O
within	O
a	O
conserved	O
basic	O
region	O
and	O
two	O
amphipathic	O
helices	O
within	O
the	O
adjacent	O
HLH	B-protein
domain	I-protein
are	O
essential	O
for	O
sequence	O
-	O
specific	O
DNA	O
binding	O
and	O
hetero	O
-	O
oligomerization	O
,	O
respectively	O
.	O

At	O
this	O
stage	O
,	O
the	O
eventual	O
high	O
mortality	O
of	O
acute	O
ischemia	O
is	O
established	O
whatever	O
the	O
urgency	O
of	O
the	O
operation	O
or	O
the	O
skill	O
with	O
which	O
it	O
is	O
performed	O
.	O

The	O
relation	O
between	O
VE	O
/	O
VO2	O
and	O
Q	O
/	O
VO2	O
showed	O
a	O
significant	O
negative	O
correlation	O
(	O
r	O
=	O
-	O
0	O
.	O
93	O
,	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Indoor	O
concentrations	O
were	O
only	O
weakly	O
correlated	O
with	O
outdoor	O
concentrations	O
,	O
however	O
,	O
and	O
personal	O
exposures	O
were	O
even	O
more	O
poorly	O
correlated	O
with	O
outdoor	O
concentrations	O
.	O

However	O
,	O
when	O
a	O
second	O
,	O
upstream	B-protein
IRE	I-protein
-	I-protein
like	I-protein
sequence	I-protein
was	O
evaluated	O
by	O
EMSA	O
,	O
a	O
DNA	O
binding	O
pattern	O
distinct	O
from	O
that	O
seen	O
following	O
exposure	O
to	O
IFN	B-protein
-	I-protein
gamma	I-protein
alone	O
was	O
observed	O
after	O
prolonged	O
stimulation	O
with	O
both	O
IFN	B-protein
-	I-protein
alpha	I-protein
and	O
IFN	B-protein
-	I-protein
gamma	I-protein
.	O

Clone	O
4c	O
(	O
2681	O
bp	O
)	O
had	O
a	O
coding	O
region	O
identical	O
to	O
that	O
of	O
clone	O
22c	O
but	O
it	O
included	O
a	O
putative	O
intron	O
of	O
959	O
bp	O
.	O

These	O
results	O
indicate	O
that	O
an	O
internal	O
short	O
element	O
located	O
at	O
the	O
very	O
5	O
'	O
terminal	O
of	O
L1	B-protein
sequence	I-protein
and	O
the	O
nuclear	O
factor	O
binding	O
to	O
the	O
element	O
play	O
a	O
crucial	O
role	O
in	O
the	O
transcription	O
of	O
human	B-protein
L1	O
.	O

E47	B-protein
protein	I-protein
levels	O
remain	O
high	O
until	O
the	O
double	O
positive	O
developmental	O
stage	O
,	O
at	O
which	O
point	O
they	O
drop	O
to	O
relatively	O
moderate	O
levels	O
,	O
and	O
are	O
further	O
downregulated	O
upon	O
transition	O
to	O
the	O
single	O
positive	O
stage	O
.	O

Laboratory	O
aspects	O
with	O
particular	O
reference	O
to	O
chemotherapy	O
and	O
control	O
.	O

The	O
plant	O
protein	O
maintains	O
all	O
the	O
functional	O
domains	O
found	O
in	O
the	O
other	O
proteins	O
,	O
including	O
nuclear	O
localization	O
signal	O
,	O
DNA	O
-	O
binding	O
domain	O
and	O
helicase	B-protein
motifs	I-protein
,	O
suggesting	O
that	O
it	O
might	O
also	O
act	O
as	O
part	O
of	O
the	O
RNA	O
transcription	O
apparatus	O
,	O
as	O
well	O
as	O
nucleotide	O
excision	O
repair	O
in	O
plant	O
cells	O
.	O

SELECTION	O
CRITERIA	O
:	O
All	O
controlled	O
trials	O
where	O
adults	O
with	O
schizophrenia	O
or	O
similar	O
illnesses	O
were	O
randomised	O
to	O
quetiapine	O
,	O
placebo	O
or	O
other	O
neuroleptic	O
drugs	O
and	O
where	O
clinically	O
relevant	O
outcomes	O
were	O
reported	O
.	O

Transcriptional	O
control	O
signals	O
of	O
a	O
herpes	B-protein
simplex	I-protein
virus	I-protein
type	I-protein
1	I-protein
late	I-protein
(	I-protein
gamma	I-protein
2	I-protein
)	I-protein
gene	I-protein
lie	O
within	O
bases	O
-	O
34	O
to	O
+	O
124	O
relative	O
to	O
the	O
5	O
'	O
terminus	O
of	O
the	O
mRNA	O
.	O

Although	O
it	O
has	O
been	O
shown	O
that	O
it	O
is	O
possible	O
to	O
use	O
orally	O
administered	O
testosterone	O
to	O
maintain	O
se	O
-	O
T	O
levels	O
in	O
the	O
normal	O
male	O
range	O
,	O
the	O
convenience	O
to	O
the	O
patient	O
must	O
be	O
balanced	O
against	O
the	O
cost	O
and	O
possible	O
side	O
effects	O
of	O
the	O
large	O
doses	O
required	O
.	O

The	O
recovery	O
value	O
of	O
systolic	O
pressure	O
was	O
higher	O
than	O
diastolic	O
pressure	O
and	O
pulse	O
pressure	O
increased	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
encodes	O
a	O
40	O
-	O
kDa	O
nuclear	O
protein	O
,	O
Tax	B-protein
,	O
which	O
stimulates	O
transcription	O
from	O
three	O
21	O
-	O
base	O
pair	O
(	O
bp	O
)	O
repeats	O
in	O
its	O
U3	B-protein
region	I-protein
.	O

The	O
effect	O
of	O
ligustrazine	O
hydrochloride	O
(	O
LTH	O
)	O
on	O
depressing	O
pulmonary	O
artery	O
hypertension	O
has	O
been	O
proved	O
in	O
recent	O
studies	O
.	O

Band	O
-	O
shift	O
assays	O
were	O
performed	O
using	O
the	O
LPS	B-protein
-	I-protein
and	I-protein
IL	I-protein
-	I-protein
1	I-protein
-	I-protein
responsive	I-protein
element	I-protein
(	O
LILRE	B-protein
)	O
oligonucleotide	O
,	O
a	O
gamma	B-protein
interferon	I-protein
activation	I-protein
site	I-protein
-	I-protein
like	I-protein
site	I-protein
that	O
is	O
present	O
in	O
the	O
human	B-protein
IL	I-protein
-	I-protein
1beta	I-protein
promoter	I-protein
.	O

A	O
protein	O
footprint	O
also	O
was	O
identified	O
for	O
a	O
GC	O
box	O
element	O
at	O
nucleotides	O
-	O
59	O
to	O
-	O
45	O
.	O

Thus	O
,	O
we	O
have	O
identified	O
a	O
GRE	B-protein
sufficient	O
to	O
account	O
for	O
full	O
glucocorticoid	O
inducibility	O
and	O
an	O
HNF	B-protein
-	I-protein
1	I-protein
site	I-protein
close	O
to	O
the	O
promoter	O
that	O
are	O
major	O
determinants	O
of	O
transcriptional	O
control	O
of	O
the	O
Xenopus	B-protein
fibrinogen	I-protein
B	I-protein
beta	I-protein
subunit	I-protein
gene	I-protein
in	O
cells	O
from	O
normal	O
liver	O
tissue	O
.	O

Here	O
we	O
present	O
genetic	O
evidence	O
suggesting	O
that	O
PP2A	B-protein
functions	O
downstream	O
of	O
Ras1	B-protein
in	O
the	O
Sevenless	B-protein
receptor	I-protein
tyrosine	I-protein
kinase	I-protein
(	O
RTK	B-protein
)	O
signal	O
transduction	O
pathway	O
that	O
specifies	O
R7	O
photoreceptor	O
cell	O
fate	O
in	O
the	O
developing	O
Drosophila	O
eye	O
.	O

CONCLUSION	O
:	O
In	O
our	O
animal	O
model	O
,	O
blood	O
-	O
brain	O
barrier	O
disruption	O
was	O
a	O
reproducible	O
,	O
integral	O
finding	O
of	O
single	O
-	O
fraction	O
,	O
high	O
-	O
dose	O
irradiation	O
injury	O
.	O

Mean	O
Hg	O
concentrations	O
in	O
the	O
livers	O
of	O
mice	O
at	O
some	O
sites	O
in	O
Isle	O
Royale	O
are	O
not	O
significantly	O
lower	O
(	O
P	O
=	O
0	O
.	O
62	O
)	O
than	O
Hg	O
concentrations	O
considered	O
by	O
some	O
government	O
agencies	O
to	O
be	O
unhealthy	O
for	O
human	O
consumption	O
.	O

axl	O
,	O
a	O
transforming	O
gene	O
isolated	O
from	O
primary	O
human	O
myeloid	O
leukemia	O
cells	O
,	O
encodes	O
a	O
novel	O
receptor	B-protein
tyrosine	I-protein
kinase	I-protein
.	O

In	O
E	O
.	O
coli	O
,	O
CheW	B-protein
mediates	O
the	O
physical	O
coupling	O
of	O
the	O
receptors	O
to	O
the	O
kinase	B-protein
CheA	I-protein
.	O

We	O
argue	O
that	O
this	O
is	O
the	O
general	O
property	O
of	O
QSAR	O
models	O
developed	O
using	O
LOO	O
cross	O
-	O
validation	O
.	O

The	O
equivalent	O
of	O
the	O
third	O
ligand	O
,	O
H	B-protein
-	I-protein
87	I-protein
,	O
is	O
T	O
-	O
47	O
in	O
the	O
PSTAIRE	B-protein
sequence	I-protein
motif	I-protein
.	O

In	O
all	O
eight	O
cases	O
,	O
neither	O
FL	O
nor	O
DLL	O
cells	O
showed	O
alterations	O
of	O
bcl	B-protein
-	I-protein
2	I-protein
gene	I-protein
sequences	I-protein
in	O
the	O
breakpoint	O
region	O
,	O
suggesting	O
high	O
conservation	O
of	O
the	O
bcl	B-protein
-	I-protein
2	I-protein
gene	I-protein
during	O
both	O
t	O
(	O
14	O
;	O
18	O
)	O
translocation	O
and	O
morphologic	O
transformation	O
of	O
the	O
FL	O
cells	O
.	O

The	O
transcriptional	O
activity	O
of	O
PPARgamma	B-protein
is	O
positively	O
modulated	O
by	O
ligand	O
binding	O
and	O
negatively	O
regulated	O
by	O
phosphorylation	O
mediated	O
by	O
the	O
MEK	B-protein
/	I-protein
ERK	I-protein
signaling	I-protein
pathway	I-protein
.	O

Furthermore	O
,	O
the	O
insertion	O
of	O
the	O
ColE1	B-protein
cer	I-protein
site	I-protein
into	O
the	O
RK2	O
plasmid	O
deleted	O
for	O
the	O
par	O
region	O
failed	O
to	O
stabilize	O
the	O
plasmid	O
in	O
the	O
MC1061K	O
strain	O
,	O
indicating	O
that	O
the	O
multimer	O
resolution	O
activity	O
encoded	O
by	O
parCBA	B-protein
is	O
not	O
by	O
itself	O
responsible	O
for	O
the	O
stabilization	O
activity	O
observed	O
for	O
this	O
operon	O
.	O

No	O
local	O
destruction	O
by	O
tumor	O
or	O
infection	O
could	O
be	O
demonstrated	O
apart	O
from	O
HIV	O
infection	O
.	O

We	O
have	O
identified	O
three	O
binding	O
sites	O
for	O
protein	O
complexes	O
:	O
a	O
palindrome	O
,	O
a	O
direct	O
repeat	O
,	O
and	O
a	O
C	O
+	O
T	O
sequence	O
that	O
corresponds	O
to	O
seven	O
GAGA	B-protein
motifs	I-protein
on	O
the	O
transcribed	O
strand	O
.	O

These	O
results	O
indicate	O
that	O
the	O
sulfhydryl	O
group	O
of	O
certain	O
angiotensin	B-protein
converting	I-protein
enzyme	I-protein
inhibitors	O
can	O
potentiate	O
their	O
effect	O
on	O
the	O
endogenous	O
nitrovasodilator	O
EDRF	B-protein
.	O

Selenium	O
,	O
as	O
a	O
constituent	O
of	O
glutathione	B-protein
peroxidase	I-protein
,	O
plays	O
a	O
role	O
in	O
the	O
antioxidant	O
defense	O
systems	O
of	O
the	O
body	O
,	O
but	O
other	O
metabolic	O
roles	O
for	O
selenium	O
may	O
yet	O
be	O
discovered	O
.	O

HVH2	B-protein
mRNA	I-protein
showed	O
an	O
expression	O
pattern	O
distinct	O
from	O
CL100	B-protein
(	O
human	B-protein
homologue	I-protein
of	I-protein
mouse	I-protein
MKP1	I-protein
)	O
and	O
PAC1	B-protein
,	O
two	O
previously	O
identified	O
MAP	B-protein
kinase	I-protein
phosphatases	I-protein
.	O

In	O
ciliates	O
,	O
both	O
mechanisms	O
are	O
readily	O
observed	O
.	O

We	O
have	O
studied	O
the	O
biokinetics	O
of	O
BLM	O
labeled	O
with	O
indium	O
-	O
111	O
(	O
In	O
-	O
111	O
)	O
.	O

Exon	O
A	O
is	O
located	O
approximately	O
7	O
kb	O
5	O
'	O
to	O
the	O
HSL	B-protein
translation	I-protein
start	I-protein
site	I-protein
.	O

SETTING	O
:	O
A	O
division	O
of	O
a	O
large	O
tea	O
plantation	O
in	O
Kandy	O
.	O

Imaging	O
features	O
of	O
splenic	O
epidermoid	O
cyst	O
with	O
pathologic	O
correlation	O
.	O

One	O
of	O
these	O
genes	O
,	O
REC114	B-protein
,	O
is	O
described	O
here	O
,	O
and	O
the	O
data	O
confirm	O
that	O
REC114	B-protein
is	O
a	O
meiosis	O
-	O
specific	O
recombination	O
gene	O
with	O
no	O
detectable	O
function	O
in	O
mitosis	O
.	O

2	O
)	O
The	O
time	O
-	O
sharing	O
principle	O
was	O
applied	O
to	O
gain	O
high	O
stability	O
.	O

In	O
patients	O
with	O
limited	O
disease	O
,	O
the	O
survival	O
in	O
the	O
alternating	O
arm	O
was	O
significantly	O
superior	O
to	O
the	O
survival	O
in	O
the	O
CAV	O
arm	O
(	O
P	O
=	O
.	O
014	O
)	O
or	O
the	O
survival	O
in	O
the	O
PE	O
arm	O
(	O
P	O
=	O
.	O
023	O
)	O
.	O

Analysis	O
of	O
disassociation	O
rates	O
indicates	O
that	O
the	O
Grf10	B-protein
-	I-protein
Swi5	I-protein
-	I-protein
DNA	I-protein
complex	I-protein
has	O
a	O
longer	O
half	O
-	O
life	O
than	O
protein	O
-	O
DNA	O
complexes	O
that	O
contain	O
only	O
Swi5	B-protein
or	O
Grf10	B-protein
.	O

Constructs	O
were	O
made	O
in	O
which	O
an	O
AATAAA	O
and	O
the	O
GT	O
-	O
rich	O
region	O
were	O
separated	O
by	O
various	O
distances	O
ranging	O
from	O
7	O
to	O
43	O
bp	O
.	O

The	O
prevalence	O
of	O
hepatitis	B-protein
B	I-protein
surface	I-protein
antigen	I-protein
(	O
HBsAg	B-protein
)	O
and	O
anti	B-protein
-	I-protein
HBs	I-protein
was	O
determined	O
by	O
a	O
sensitive	O
double	O
-	O
antibody	O
radio	O
-	O
immunoassay	O
technique	O
in	O
a	O
series	O
of	O
patients	O
with	O
chronic	O
liver	O
diseases	O
.	O

Based	O
on	O
these	O
results	O
the	O
minimal	O
control	O
element	O
(	O
AX	B-protein
470	I-protein
)	O
specifying	O
the	O
anterior	O
boundary	O
of	O
Hox	B-protein
expression	O
was	O
designated	O
as	O
Hoxa	B-protein
-	I-protein
7	I-protein
enhancer	I-protein
.	O

There	O
have	O
been	O
five	O
problems	O
(	O
extravasation	O
2	O
,	O
suspected	O
sepsis	O
1	O
,	O
and	O
hematoma	O
2	O
)	O
during	O
a	O
total	O
of	O
2	O
,	O
927	O
days	O
of	O
exposure	O
.	O

Plasma	O
lipid	O
and	O
lipoprotein	O
profiles	O
were	O
compared	O
in	O
elderly	O
female	O
runners	O
(	O
RU	O
:	O
n	O
=	O
15	O
,	O
aged	O
66	O
+	O
/	O
-	O
5	O
years	O
,	O
body	O
fat	O
20	O
+	O
/	O
-	O
4	O
%	O
,	O
training	O
distance	O
35	O
+	O
/	O
-	O
15	O
km	O
week	O
-	O
1	O
,	O
VO2max	O
36	O
+	O
/	O
-	O
4	O
ml	O
kg	O
-	O
1	O
min	O
-	O
1	O
,	O
mean	O
+	O
/	O
-	O
SD	O
)	O
and	O
age	O
-	O
matched	O
untrained	O
women	O
(	O
UT	O
:	O
n	O
=	O
28	O
,	O
66	O
+	O
/	O
-	O
4	O
years	O
,	O
body	O
fat	O
26	O
+	O
/	O
-	O
6	O
%	O
,	O
VO2max	O
26	O
+	O
/	O
-	O
3	O
ml	O
kg	O
-	O
1	O
min	O
-	O
1	O
)	O
.	O

Dementia	O
is	O
being	O
avoided	O
in	O
NHS	O
and	O
social	O
care	O
.	O

Two	O
independent	O
transgenic	O
lines	O
were	O
produced	O
,	O
and	O
both	O
showed	O
expression	O
of	O
the	O
Gus	B-protein
gene	I-protein
specifically	O
in	O
the	O
endosperm	O
during	O
mid	O
-	O
development	O
(	O
first	O
detected	O
10	O
-	O
12	O
d	O
after	O
anthesis	O
)	O
.	O

The	O
second	O
complex	O
,	O
when	O
purified	O
,	O
contained	O
four	O
protein	O
components	O
including	O
the	O
36	O
-	O
kDa	O
protein	O
.	O

Histopathologic	O
observations	O
showed	O
that	O
both	O
somatostatin	B-protein
and	O
triamcinolone	O
acetonide	O
reduced	O
the	O
inflammatory	O
signs	O
in	O
the	O
joint	O
structures	O
,	O
although	O
triamcinolone	O
acetonide	O
appeared	O
to	O
be	O
more	O
effective	O
.	O

Induction	O
in	O
AP	B-protein
-	I-protein
1	I-protein
DNA	O
binding	O
correlates	O
with	O
a	O
concomitant	O
GH	B-protein
trans	O
-	O
activation	O
of	O
c	B-protein
-	I-protein
jun	I-protein
and	O
c	B-protein
-	I-protein
fos	I-protein
genes	I-protein
described	O
previously	O
.	O

We	O
have	O
generated	O
a	O
computer	O
model	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
434	O
repressor	O
based	O
on	O
the	O
crystal	O
structure	O
of	O
the	O
homologous	B-protein
UmuD	I-protein
'	I-protein
protein	I-protein
.	O

Activation	O
of	O
a	O
CRE	B-protein
-	I-protein
dependent	I-protein
junB	I-protein
promoter	I-protein
/	I-protein
chloramphenicol	I-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
reporter	O
gene	O
by	O
the	O
BCR	B-protein
was	O
also	O
blocked	O
by	O
SB203580	O
.	O

Oxygen	O
delivery	O
and	O
consumption	O
and	O
P50	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
.	O

The	O
tyrosine	B-protein
hydroxylase	I-protein
gene	I-protein
(	O
TH	B-protein
)	O
contains	O
a	O
single	O
copy	O
of	O
a	O
consensus	O
CRE	B-protein
at	O
-	O
45	O
to	O
-	O
38	O
base	O
pair	O
(	O
bp	O
)	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
.	O

In	O
C	O
.	O
albicans	O
,	O
HST6	B-protein
is	O
expressed	O
constitutively	O
at	O
high	O
levels	O
in	O
the	O
different	O
cell	O
types	O
analysed	O
(	O
yeast	O
,	O
hyphae	O
,	O
white	O
and	O
opaque	O
)	O
,	O
demonstrating	O
that	O
HST6	B-protein
transcription	O
is	O
not	O
repressed	O
in	O
this	O
diploid	O
yeast	O
,	O
unlike	O
in	O
diploid	O
S	O
.	O
cerevisiae	O
,	O
and	O
suggesting	O
a	O
basic	O
biological	O
function	O
for	O
the	O
Hst6p	B-protein
transporter	O
in	O
C	O
.	O
albicans	O
.	O

Ketamine	O
in	O
the	O
treatment	O
of	O
bronchospasm	O
during	O
mechanical	O
ventilation	O
.	O

It	O
is	O
concluded	O
that	O
the	O
plasma	B-protein
prolactin	I-protein
response	O
to	O
12	O
.	O
5	O
micrograms	O
i	O
.	O
v	O
.	O

But	O
no	O
influence	O
was	O
observed	O
at	O
lower	O
concentrations	O
than	O
1	O
/	O
4	O
MIC	O
of	O
AMK	O
.	O

Oxygen	O
tension	O
of	O
the	O
small	O
lymph	O
vessels	O
(	O
PLO2	O
)	O
of	O
the	O
rabbit	O
hind	O
limb	O
was	O
measured	O
with	O
both	O
a	O
flow	O
-	O
through	O
micro	O
chamber	O
and	O
a	O
polarographic	O
catheter	O
-	O
tip	O
oxygen	O
electrode	O
to	O
obtain	O
experimental	O
data	O
on	O
the	O
source	O
of	O
oxygen	O
in	O
the	O
lymph	O
.	O

The	O
smaller	O
uptake	O
rate	O
and	O
faster	O
clearance	O
rate	O
resulted	O
in	O
the	O
lower	O
BCF	O
for	O
SWA	O
killifish	O
.	O

The	O
second	O
functional	O
pair	O
of	O
CreA	B-protein
sites	I-protein
is	O
located	O
between	O
the	O
two	O
transcription	O
initiation	O
sites	O
.	O

Six	O
out	O
of	O
ten	O
hearts	O
from	O
macerated	O
stillborn	O
infants	O
showed	O
varying	O
degrees	O
of	O
positive	O
staining	O
.	O

In	O
vitro	O
transcription	O
results	O
indicate	O
that	O
this	O
5	O
'	O
structure	O
functions	O
in	O
the	O
attenuation	O
mechanism	O
,	O
since	O
deletion	O
of	O
the	O
stem	O
-	O
loop	O
caused	O
an	O
increase	O
in	O
transcription	O
readthrough	O
.	O

Northern	O
blotting	O
showed	O
that	O
MDMX	B-protein
,	O
like	O
MDM2	B-protein
,	O
is	O
expressed	O
in	O
all	O
tissues	O
tested	O
,	O
and	O
that	O
several	O
mRNAs	O
for	O
MDMX	B-protein
can	O
be	O
detected	O
.	O

The	O
mean	O
serum	O
creatinine	O
level	O
did	O
not	O
change	O
during	O
the	O
first	O
6	O
months	O
after	O
withdrawal	O
of	O
MMF	O
.	O

Control	O
subjects	O
'	O
evoked	O
potentials	O
(	O
EPs	O
)	O
were	O
characterized	O
by	O
an	O
initial	O
positivity	O
in	O
the	O
90	O
-	O
140	O
ms	O
range	O
(	O
P1	O
)	O
at	O
the	O
temporo	O
-	O
occipital	O
site	O
.	O

Gel	O
filtration	O
,	O
sedimentation	O
velocity	O
,	O
and	O
immunoprecipitation	O
experiments	O
revealed	O
that	O
beta4	B-protein
is	O
a	O
component	O
of	O
a	O
multisubunit	O
complex	O
(	O
AP	B-protein
-	I-protein
4	I-protein
)	O
that	O
also	O
contains	O
the	O
sigma4	B-protein
polypeptide	I-protein
and	O
two	O
additional	O
adaptor	O
subunit	O
homologs	O
named	O
mu4	B-protein
(	O
mu	B-protein
-	I-protein
ARP2	I-protein
)	O
and	O
epsilon	B-protein
.	O

Hexsyn	O
is	O
the	O
Goodyear	O
Tire	O
and	O
Rubber	O
Company	O
tradename	O
for	O
a	O
polyolefin	O
rubber	O
synthesized	O
from	O
1	O
-	O
hexene	O
with	O
3	O
-	O
5	O
%	O
methylhexadiene	O
as	O
the	O
source	O
of	O
residual	O
double	O
bonds	O
for	O
vulcanization	O
.	O

The	O
recessive	O
hos1	B-protein
mutation	O
causes	O
enhanced	O
induction	O
of	O
the	O
CBF	B-protein
transcription	I-protein
factors	I-protein
by	O
low	O
temperature	O
as	O
well	O
as	O
of	O
their	O
downstream	O
cold	O
-	O
responsive	O
genes	O
.	O

This	O
mutant	O
was	O
identified	O
by	O
screening	O
with	O
a	O
TGF	O
-	O
beta	O
-	O
inducible	O
vector	O
a	O
series	O
of	O
mink	O
lung	O
epithelial	O
cell	O
clones	O
that	O
have	O
normal	O
TGF	B-protein
-	I-protein
beta	I-protein
binding	O
activity	O
but	O
have	O
lost	O
antiproliferative	O
and	O
transcriptional	O
responses	O
to	O
TGF	B-protein
-	I-protein
beta	I-protein
.	O

GlcNAc	O
-	O
and	O
GlcNAc2	B-protein
-	I-protein
PP	I-protein
-	I-protein
Dolichol	I-protein
biosynthesis	O
could	O
be	O
shown	O
with	O
isolated	O
S	O
.	O
cerevisiae	O
membranes	O
from	O
cells	O
harboring	O
the	O
recombinant	O
plasmid	O
and	O
grown	O
on	O
glucose	O
thus	O
suppressing	O
transcription	O
of	O
the	O
endogenous	O
gene	O
.	O

The	O
predicted	O
domain	O
structures	O
of	O
FkbB	B-protein
and	O
FkbC	B-protein
are	O
analogous	O
to	O
that	O
of	O
FkbA	B-protein
and	O
comprise	O
30	O
fatty	B-protein
-	I-protein
acid	I-protein
-	I-protein
synthase	I-protein
(	I-protein
FAS	I-protein
)	I-protein
-	I-protein
like	I-protein
domains	I-protein
arranged	O
in	O
6	O
modules	O
.	O

The	O
observation	O
that	O
beta	B-protein
2m	I-protein
with	O
covalently	O
attached	O
peptide	O
can	O
effectively	O
create	O
CTL	O
target	O
structures	O
in	O
vitro	O
offers	O
new	O
possibilities	O
for	O
the	O
in	O
vivo	O
induction	O
of	O
epitope	O
-	O
specific	O
CTL	O
responses	O
by	O
either	O
DNA	O
immunization	O
or	O
injection	O
of	O
the	O
purified	O
epitope	O
-	O
linked	O
beta	B-protein
2m	O
.	O

The	O
mechanistic	O
implications	O
of	O
aromatic	O
non	O
-	O
responsiveness	O
of	O
autonomously	O
expressed	O
A	O
-	O
domain	O
,	O
despite	O
its	O
demonstrated	O
ability	O
to	O
bind	O
phenol	O
,	O
are	O
discussed	O
.	O

Computerized	O
detection	O
of	O
abnormal	O
asymmetry	O
in	O
digital	O
chest	O
radiographs	O
.	O

When	O
pollen	O
allergen	O
from	O
three	O
grass	O
species	O
were	O
used	O
,	O
The	O
RAST	O
-	O
test	O
results	O
did	O
not	O
differ	O
from	O
duplicate	O
values	O
either	O
.	O

In	O
1990	O
,	O
an	O
International	O
Commission	O
for	O
the	O
Certification	O
of	O
Eradication	O
of	O
Poliomyelitis	O
Eradication	O
(	O
ICCPE	O
)	O
was	O
established	O
by	O
the	O
Pan	O
American	O
Health	O
Organization	O
to	O
eventually	O
determine	O
if	O
transmission	O
was	O
interrupted	O
.	O

New	O
diagnostic	O
strategies	O
for	O
lupus	O
anticoagulants	O
and	O
antiphospholipid	B-protein
antibodies	I-protein
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
SNTCS	O
is	O
highly	O
malignant	O
.	O

Motile	O
nocardoid	O
Actinomycetales	O
.	O

Our	O
data	O
complement	O
other	O
studies	O
of	O
circumpolar	O
populations	O
and	O
reinforce	O
the	O
reported	O
high	O
prevalences	O
of	O
SPA	O
and	O
HLA	B-protein
-	I-protein
B27	I-protein
among	O
those	O
populations	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
transfected	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cell	O
line	O
expressing	O
a	O
murine	B-protein
CD4	I-protein
fragment	I-protein
containing	O
the	O
first	O
two	O
N	O
-	O
terminal	O
domains	O
secretes	O
both	O
monomeric	O
molecules	O
and	O
disulfide	O
-	O
linked	O
multimers	O
.	O

In	O
reviewing	O
a	O
number	O
of	O
the	O
most	O
intensely	O
studied	O
environmentally	O
inducible	O
promoters	O
it	O
becomes	O
clear	O
that	O
the	O
presence	O
of	O
two	O
cis	O
-	O
acting	O
elements	O
are	O
critical	O
for	O
promoter	O
activity	O
,	O
one	O
of	O
which	O
is	O
the	O
G	O
-	O
box	O
(	O
CCACGTGG	B-protein
)	O
.	O

Nodular	O
involvement	O
of	O
the	O
left	O
lung	O
and	O
infiltration	O
of	O
the	O
mucosa	O
of	O
the	O
left	O
lower	O
lobe	O
bronchus	O
followed	O
very	O
gradually	O
and	O
a	O
monoclonal	O
gammopathy	O
(	O
IgA	B-protein
-	I-protein
-	I-protein
Type	I-protein
Kappa	I-protein
)	O
was	O
demonstrated	O
.	O

Beta	B-protein
-	I-protein
endorphin	I-protein
,	O
ACTH	B-protein
and	O
cortisol	O
secretion	O
were	O
measured	O
in	O
twelve	O
healthy	O
adult	O
males	O
after	O
nasal	O
spray	O
administration	O
200	O
IU	O
salmon	B-protein
calcitonin	I-protein
.	O

Transcription	O
from	O
the	O
promoter	O
containing	O
the	O
mutated	O
direct	O
repeats	O
was	O
increased	O
greatly	O
,	O
consistent	O
with	O
the	O
conclusion	O
that	O
these	O
motifs	O
functions	O
in	O
vivo	O
to	O
repress	O
GPT	B-protein
gene	I-protein
expression	O
.	O

Analysis	O
of	O
1	O
Mb	O
of	O
published	O
sequence	O
from	O
the	O
region	O
of	O
conserved	O
synteny	O
on	O
human	O
chromosome	O
5q31	O
-	O
q33	O
identified	O
45	O
gene	O
candidates	O
,	O
including	O
35	O
expressed	O
genes	O
in	O
the	O
human	B-protein
IL	I-protein
-	I-protein
4	I-protein
cytokine	I-protein
gene	I-protein
cluster	I-protein
.	O

If	O
this	O
is	O
present	O
,	O
such	O
patients	O
should	O
be	O
closely	O
monitored	O
,	O
and	O
any	O
atypical	O
lesions	O
biopsied	O
.	O

Analysis	O
of	O
the	O
sequence	O
identified	O
four	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
which	O
are	O
designated	O
UL1	B-protein
,	O
UL2	B-protein
,	O
UL3	B-protein
,	O
and	O
UL3	B-protein
.	I-protein
5	I-protein
based	O
on	O
their	O
homology	O
with	O
proteins	O
of	O
herpes	O
simplex	O
virus	O
-	O
1	O
(	O
HSV	O
-	O
1	O
)	O
,	O
pseudorabies	O
virus	O
(	O
PRV	O
)	O
,	O
equine	O
herpesvirus	O
-	O
1	O
,	O
and	O
varicella	O
-	O
zoster	O
virus	O
.	O

Diary	O
.	O

Cell	O
lines	O
are	O
checked	O
to	O
find	O
out	O
whether	O
they	O
develop	O
tumors	O
in	O
nude	O
mice	O
followed	O
by	O
an	O
analysis	O
of	O
the	O
karyotype	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Between	O
June	O
1991	O
and	O
December	O
1996	O
,	O
we	O
administered	O
the	O
nucleoside	O
analog	O
2	O
-	O
chlorodeoxyadenosine	O
(	O
2	O
-	O
CDA	O
)	O
to	O
73	O
children	O
with	O
primary	O
AML	O
and	O
20	O
children	O
with	O
secondary	O
AML	O
or	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
.	O

First	O
,	O
the	O
finding	O
of	O
a	O
monomeric	B-protein
Alu	I-protein
family	I-protein
repeat	I-protein
at	O
the	O
junction	O
between	O
nonhomology	O
block	O
I	O
and	O
homology	O
block	O
Y	O
of	O
the	O
alpha	B-protein
2	I-protein
gene	I-protein
-	I-protein
containing	I-protein
unit	I-protein
in	I-protein
rhesus	I-protein
macaque	I-protein
suggests	O
that	O
the	O
dimeric	B-protein
Alu	I-protein
family	I-protein
repeat	I-protein
,	O
Alu	B-protein
3	I-protein
,	O
at	O
the	O
orthologous	O
position	O
in	O
human	O
was	O
generated	O
by	O
insertion	O
of	O
a	O
monomeric	B-protein
Alu	I-protein
family	I-protein
repeat	I-protein
into	O
the	O
3	O
'	O
end	O
of	O
another	O
preexisting	O
Alu	B-protein
family	I-protein
repeat	I-protein
.	O

Vertebrate	B-protein
synapsins	I-protein
constitute	O
a	O
family	O
of	O
synaptic	O
proteins	O
that	O
participate	O
in	O
the	O
regulation	O
of	O
neurotransmitter	O
release	O
.	O

Within	O
-	O
subject	O
BP	O
differences	O
between	O
fish	O
oil	O
and	O
corn	O
oil	O
treatment	O
were	O
similar	O
for	O
Dinamap	O
(	O
3	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
8	O
/	O
2	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
0	O
mm	O
Hg	O
)	O
and	O
for	O
24	O
-	O
h	O
ABP	O
(	O
2	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
0	O
/	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
8	O
mm	O
Hg	O
)	O
,	O
but	O
were	O
more	O
significant	O
with	O
the	O
latter	O
.	O

Steroid	O
glucuronides	O
in	O
amniotic	O
fluid	O
at	O
term	O
.	O

Phd	B-protein
antibody	O
-	O
immunoreactive	O
peptides	O
are	O
seen	O
in	O
light	O
-	O
adapted	O
mouse	O
retinal	O
cytosolic	O
and	O
nuclear	O
extracts	O
.	O

Serotonin	B-protein
5	I-protein
-	I-protein
HT2	I-protein
receptor	I-protein
binding	O
on	O
blood	O
platelets	O
as	O
a	O
state	O
dependent	O
marker	O
in	O
major	O
affective	O
disorder	O
.	O

Hematocrit	O
and	O
PaO2	O
did	O
not	O
change	O
.	O

Fibrin	B-protein
gels	O
and	O
their	O
possible	O
implication	O
for	O
surface	O
hemorheology	O
in	O
health	O
and	O
disease	O
.	O

Standard	O
reference	O
sources	O
indicate	O
that	O
an	O
able	O
-	O
bodied	O
11	O
-	O
year	O
-	O
old	O
child	O
of	O
comparable	O
height	O
requires	O
1	O
,	O
493	O
kcal	O
/	O
d	O
for	O
support	O
of	O
basal	O
metabolic	O
functions	O
.	O

The	O
intron	O
RNA	O
consists	O
of	O
2492	O
nucleotides	O
which	O
can	O
be	O
folded	O
into	O
a	O
secondary	O
structure	O
with	O
all	O
the	O
expected	O
sequence	O
motifs	O
of	O
subgroup	O
-	O
IIA1	O
introns	O
(	O
Michel	O
et	O
al	O
.	O

It	O
was	O
also	O
suggested	O
that	O
the	O
biological	O
activities	O
of	O
5	O
-	O
FU	O
,	O
ADM	O
and	O
MMC	O
in	O
FAMLIP	O
were	O
stable	O
in	O
FULIP	O
,	O
ADRLIP	O
and	O
MMCLIP	O
.	O

The	O
neural	O
mechanism	O
of	O
parkinsonian	O
motor	O
symptoms	O
,	O
i	O
.	O
e	O
.	O
,	O
rigidity	O
,	O
tremor	O
and	O
akinesia	O
,	O
which	O
are	O
the	O
result	O
of	O
nigrostriatal	O
dopamine	O
deficiency	O
,	O
is	O
interpreted	O
from	O
long	O
-	O
term	O
observations	O
on	O
the	O
effect	O
of	O
surgical	O
and	O
pharmacological	O
treatment	O
of	O
the	O
disease	O
in	O
relation	O
to	O
the	O
neuropathological	O
findings	O
within	O
the	O
substantia	O
nigra	O
zona	O
compacta	O
(	O
SNc	O
)	O
.	O

We	O
have	O
designated	O
the	O
protein	O
`	B-protein
`	I-protein
cellular	I-protein
NBP	I-protein
'	I-protein
'	I-protein
(	O
CNBP	B-protein
)	O
.	O

After	O
description	O
of	O
his	O
short	O
life	O
and	O
an	O
explanation	O
of	O
the	O
light	O
conductor	O
Bozzini	O
'	O
s	O
merit	O
is	O
emphasized	O
,	O
by	O
his	O
invention	O
as	O
first	O
physician	O
to	O
have	O
made	O
accessible	O
to	O
medicine	O
endoscopic	O
diagnostic	O
possibilities	O
.	O

We	O
have	O
earlier	O
evolved	O
an	O
experimental	O
model	O
by	O
means	O
of	O
which	O
changes	O
identical	O
to	O
the	O
microembolism	O
syndrome	O
can	O
be	O
induced	O
from	O
a	O
reproducible	O
musculo	O
-	O
skeletal	O
trauma	O
in	O
pigs	O
observed	O
under	O
long	O
-	O
term	O
anesthesia	O
under	O
standardized	O
conditions	O
.	O

The	O
results	O
suggest	O
followings	O
-	O
-	O
1	O
)	O
both	O
eosinophils	O
and	O
neutrophils	O
participate	O
in	O
hypersecretion	O
of	O
type	O
Ib	O
in	O
atopic	O
cases	O
,	O
and	O
only	O
eosinophils	O
in	O
non	O
-	O
atopic	O
cases	O
.	O

In	O
budding	O
yeast	O
,	O
this	O
latter	O
checkpoint	O
response	O
involves	O
the	O
proteins	O
Mad1	B-protein
,	I-protein
2	I-protein
,	I-protein
3	I-protein
,	O
Bub1	B-protein
and	O
Bub3	B-protein
,	O
whose	O
vertebrate	O
counterparts	O
localize	O
to	O
unattached	O
kinetochores	O
.	O

A	O
transcript	O
of	O
about	O
2	O
kb	O
is	O
expected	O
for	O
each	O
PPO	B-protein
.	O

In	O
Wnt	B-protein
signaling	O
,	O
beta	B-protein
-	I-protein
catenin	I-protein
and	O
plakoglobin	B-protein
transduce	O
signals	O
to	O
the	O
nucleus	O
through	O
interactions	O
with	O
TCF	B-protein
-	I-protein
type	I-protein
transcription	I-protein
factors	I-protein
.	O

Microstructure	O
and	O
conductivity	O
of	O
hierarchical	O
laminate	O
composites	O
.	O

There	O
is	O
no	O
TATA	O
box	O
around	O
the	O
transcriptional	O
start	O
points	O
(	O
tsp	O
)	O
,	O
as	O
determined	O
by	O
primer	O
extension	O
analysis	O
.	O

VE	O
-	O
DEF	O
animals	O
had	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
levels	O
of	O
myocardial	O
lipid	O
peroxidation	O
and	O
lower	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
protein	O
thiols	O
following	O
I	O
-	O
R	O
compared	O
to	O
the	O
CON	O
animals	O
.	O

Changes	O
in	O
ionic	O
content	O
of	O
the	O
mucous	O
suggest	O
that	O
cholinergic	O
mechanisms	O
affect	O
pressure	O
in	O
the	O
excretory	O
duct	O
of	O
the	O
gland	O
.	O

Application	O
of	O
the	O
method	O
to	O
a	O
representative	O
set	O
of	O
50	O
known	O
genes	O
from	O
Arabidopsis	O
thaliana	O
showed	O
significant	O
improvement	O
in	O
prediction	O
accuracy	O
compared	O
to	O
previous	O
spliced	O
alignment	O
methods	O
.	O

All	O
adults	O
attending	O
the	O
outpatient	O
clinics	O
of	O
a	O
dermatological	O
hospital	O
on	O
predetermined	O
days	O
were	O
given	O
the	O
12	O
-	O
item	O
General	O
Health	O
Questionnaire	O
.	O

The	O
BAL	O
-	O
to	O
-	O
plasma	O
specific	O
activity	O
of	O
urea	O
was	O
about	O
twice	O
that	O
of	O
Na	O
+	O
,	O
indicating	O
that	O
urea	O
diffused	O
into	O
the	O
ELF	O
more	O
rapidly	O
than	O
Na	O
+	O
during	O
the	O
70	O
s	O
that	O
elapsed	O
between	O
the	O
time	O
the	O
radioactive	O
urea	O
and	O
Na	O
+	O
were	O
injected	O
into	O
the	O
circulation	O
and	O
the	O
time	O
when	O
lavage	O
was	O
complete	O
.	O

Multiple	O
dosing	O
four	O
times	O
daily	O
for	O
7	O
days	O
of	O
indoprofen	O
200	O
mg	O
,	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
with	O
a	O
short	O
half	O
-	O
life	O
(	O
t1	O
/	O
2	O
)	O
,	O
revealed	O
drug	O
accumulation	O
in	O
eight	O
elderly	O
subjects	O
.	O

The	O
standard	O
method	O
for	O
calculating	O
the	O
composite	O
score	O
on	O
the	O
S	O
-	O
B	O
IV	O
excludes	O
subtests	O
with	O
a	O
raw	O
score	O
of	O
0	O
,	O
which	O
overestimates	O
cognitive	O
functioning	O
in	O
young	O
biologically	O
high	O
risk	O
children	O
.	O

A	O
multicentre	O
study	O
involving	O
9	O
Italian	O
institutions	O
was	O
carried	O
out	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
ranitidine	O
150	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
and	O
ranitidine	O
300	O
mg	O
nocte	O
in	O
the	O
treatment	O
of	O
reflux	O
oesophagitis	O
.	O

The	O
astronaut	O
crew	O
operates	O
the	O
payload	O
and	O
documents	O
its	O
operation	O
.	O

The	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
CREB	I-protein
is	O
regulated	O
by	O
extracellular	O
stimuli	O
that	O
result	O
in	O
its	O
phosphorylation	O
at	O
a	O
critical	O
serine	O
residue	O
,	O
Ser133	O
.	O

A	O
randomized	O
,	O
multicenter	O
study	O
comparing	O
the	O
efficacy	O
and	O
tolerability	O
of	O
tropisetron	O
,	O
a	O
new	O
5	B-protein
-	I-protein
HT3	I-protein
receptor	I-protein
antagonist	O
,	O
with	O
a	O
metoclopramide	O
-	O
containing	O
antiemetic	O
cocktail	O
in	O
the	O
prevention	O
of	O
cisplatin	O
-	O
induced	O
emesis	O
.	O

In	O
studies	O
of	O
many	O
different	O
phenotypically	O
distinct	O
cells	O
,	O
the	O
CRE	B-protein
of	O
the	O
somatostatin	B-protein
gene	I-protein
promoter	I-protein
is	O
a	O
prototype	O
of	O
a	O
highly	O
cAMP	B-protein
-	I-protein
responsive	I-protein
element	I-protein
regulated	O
by	O
CREB	B-protein
.	O

Capsular	O
antigens	O
of	O
Staphylococcus	O
aureus	O
.	O

Althoug	O
RBF	O
tended	O
to	O
increase	O
after	O
the	O
therapy	O
,	O
there	O
was	O
no	O
statistically	O
significant	O
change	O
in	O
RBF	O
,	O
GFR	O
and	O
cardiac	O
output	O
.	O

We	O
suggest	O
that	O
apart	O
from	O
the	O
World	O
Summit	O
for	O
Children	O
'	O
s	O
under	O
-	O
five	O
mortality	O
target	O
for	O
the	O
year	O
2000	O
,	O
intraregional	O
targets	O
to	O
reduce	O
geographical	O
inequalities	O
in	O
under	O
-	O
five	O
mortality	O
should	O
be	O
specified	O
.	O

A	O
114	O
-	O
base	O
pair	O
sequence	O
of	O
predominantly	O
repeating	O
purine	O
-	O
pyrimidine	O
nucleotides	O
separates	O
these	O
two	O
d	O
(	O
AC	O
)	O
repeats	O
.	O

The	O
ERH	B-protein
expression	O
profile	O
is	O
similar	O
,	O
to	O
that	O
of	O
An3	B-protein
,	O
which	O
localizes	O
to	O
the	O
animal	O
hemisphere	O
of	O
oocytes	O
and	O
is	O
abundantly	O
expressed	O
in	O
the	O
embryo	O
.	O

By	O
comparison	O
,	O
in	O
nontumorigenic	O
Ad5	O
cells	O
,	O
class	B-protein
I	I-protein
expression	O
is	O
high	O
due	O
to	O
negligible	O
binding	O
of	O
COUP	B-protein
-	I-protein
TF	I-protein
and	O
strong	O
binding	O
of	O
NF	B-protein
-	I-protein
kappaB	I-protein
.	O

After	O
surgery	O
,	O
patients	O
self	O
administered	O
one	O
of	O
three	O
possible	O
postsurgical	O
medications	O
,	O
which	O
included	O
placebo	O
,	O
codeine	O
60	O
mg	O
,	O
and	O
ibuprofen	O
400	O
mg	O
,	O
when	O
their	O
pain	O
reached	O
a	O
moderate	O
or	O
severe	O
intensity	O
.	O

A	O
short	O
open	O
reading	O
frame	O
(	O
ORF2	O
)	O
,	O
of	O
unknown	O
function	O
,	O
is	O
present	O
in	O
all	O
FIV	O
isolates	O
.	O

Probable	O
progressive	O
multifocal	O
leukoencephalopathy	O
(	O
PML	O
)	O
was	O
diagnosed	O
on	O
the	O
basis	O
of	O
clinical	O
picture	O
and	O
magnetic	O
resonance	O
imaging	O
in	O
a	O
63	O
-	O
year	O
-	O
old	O
man	O
with	O
a	O
complete	O
remission	O
of	O
a	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
.	O

High	O
radial	O
r	O
values	O
with	O
small	O
standard	O
deviations	O
were	O
observed	O
in	O
normal	O
LV	O
(	O
0	O
.	O
972	O
+	O
/	O
-	O
0	O
.	O
016	O
)	O
and	O
in	O
non	O
-	O
MI	O
regions	O
(	O
0	O
.	O
964	O
+	O
/	O
-	O
0	O
.	O
018	O
)	O
,	O
indicating	O
temporally	O
homogeneous	O
radial	O
shortening	O
.	O

Foreigners	O
return	O
.	O

Catha	O
edulis	O
,	O
a	O
plant	O
that	O
has	O
amphetamine	O
effects	O
.	O

Observation	O
of	O
dipolar	O
interactions	O
between	O
Pb0	O
defects	O
at	O
the	O
(	O
111	O
)	O
Si	O
/	O
SiO2	O
interface	O
.	O

Consequently	O
,	O
significant	O
differences	O
between	O
the	O
measured	O
and	O
calculated	O
methods	O
were	O
noted	O
in	O
oxygen	O
uptake	O
(	O
213	O
+	O
/	O
-	O
41	O
ml	O
/	O
min	O
vs	O
193	O
+	O
/	O
-	O
25	O
ml	O
/	O
min	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
oxygen	O
delivery	O
(	O
780	O
+	O
/	O
-	O
297	O
ml	O
/	O
min	O
vs	O
716	O
+	O
/	O
-	O
296	O
ml	O
/	O
min	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
cardiac	O
output	O
(	O
5	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
2	O
L	O
/	O
min	O
vs	O
5	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
8	O
L	O
/	O
min	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Transcription	O
readthrough	O
into	O
the	O
inverted	O
repeats	O
has	O
little	O
effect	O
on	O
this	O
event	O
.	O

PATIENTS	O
and	O
METHODS	O
:	O
Thallium	O
-	O
201	O
myocardial	O
scintigraphy	O
was	O
performed	O
at	O
rest	O
and	O
after	O
0	O
.	O
56	O
mg	O
/	O
kg	O
intravenous	O
dipyridamole	O
during	O
four	O
minutes	O
in	O
16	O
patients	O
with	O
sarcoidosis	O
.	O

Previously	O
,	O
we	O
identified	O
a	O
51	O
-	O
bp	O
promoter	O
fragment	O
,	O
oligo31	B-protein
/	I-protein
32	I-protein
,	O
which	O
conferred	O
heat	O
shock	O
inducibility	O
on	O
the	O
heterologous	O
CYC1	B-protein
-	I-protein
lacZ	I-protein
reporter	I-protein
gene	I-protein
in	O
S	O
.	O
cerevisiae	O
(	O
N	O
.	O

Northern	O
analysis	O
revealed	O
no	O
detectable	O
expression	O
of	O
the	O
transcript	O
in	O
diapause	O
-	O
or	O
nondiapause	O
-	O
programmed	O
wandering	O
larvae	O
,	O
and	O
only	O
trace	O
expression	O
in	O
nondiapausing	O
pupae	O
.	O

Such	O
an	O
intervention	O
may	O
be	O
of	O
considerable	O
use	O
for	O
the	O
treatment	O
of	O
angiogenesis	O
-	O
dependent	O
diseases	O
involving	O
FGF	B-protein
-	I-protein
2	I-protein
.	O

Differential	O
expression	O
of	O
AP	B-protein
-	I-protein
2alpha	I-protein
and	O
AP	B-protein
-	I-protein
2beta	I-protein
in	O
the	O
developing	O
chick	O
retina	O
:	O
repression	O
of	O
R	B-protein
-	I-protein
FABP	I-protein
promoter	I-protein
activity	O
by	O
AP	B-protein
-	I-protein
2	I-protein
.	O

A	O
specific	O
distal	O
promoter	O
controls	O
gamma	B-protein
-	I-protein
glutamyl	I-protein
transpeptidase	I-protein
gene	I-protein
expression	O
in	O
undifferentiated	O
rat	O
transformed	O
liver	O
cells	O
.	O

We	O
analyzed	O
an	O
EBV	O
B	O
-	O
cell	O
clone	O
,	O
E29	O
.	O
1	O
,	O
derived	O
from	O
an	O
11	O
week	O
-	O
old	O
embryo	O
,	O
and	O
secreting	O
both	O
IgM	B-protein
kappa	I-protein
and	O
IgM	B-protein
lambda	I-protein
.	O

The	O
maximum	O
deflections	O
of	O
phase	O
IV	O
for	O
Ar	O
and	O
N2	O
from	O
extrapolated	O
phase	O
III	O
slopes	O
were	O
smaller	O
in	O
the	O
prone	O
position	O
,	O
suggesting	O
more	O
uniform	O
tracer	O
gas	O
concentrations	O
across	O
the	O
lungs	O
.	O

The	O
present	O
paper	O
elucidates	O
the	O
existing	O
discrepancies	O
,	O
and	O
offers	O
a	O
consistent	O
terminology	O
incorporating	O
also	O
such	O
terms	O
as	O
`	O
`	O
additivity	O
'	O
'	O
,	O
`	O
`	O
potentiation	O
'	O
'	O
,	O
and	O
`	O
`	O
simple	O
similarity	O
'	O
'	O
.	O

Human	B-protein
ESP1	I-protein
/	I-protein
CRP2	I-protein
protein	I-protein
has	O
two	O
LIM	B-protein
domains	I-protein
,	O
and	O
each	O
shares	O
35	O
.	O
1	O
%	O
and	O
77	O
or	O
79	O
%	O
identical	O
residues	O
with	O
human	B-protein
cysteine	I-protein
-	I-protein
rich	I-protein
protein	I-protein
(	O
CRP	B-protein
)	O
and	O
rat	B-protein
CRIP	I-protein
,	O
respectively	O
.	O

However	O
,	O
patients	O
with	O
isolated	O
office	O
hypertension	O
had	O
fewer	O
previous	O
cardiovascular	O
complications	O
.	O

Sequence	O
analysis	O
indicates	O
that	O
in	O
addition	O
to	O
an	O
ATA	O
and	O
GC	O
box	O
,	O
this	O
region	O
contains	O
domains	O
that	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
other	O
muscle	O
-	O
specific	O
genes	O
:	O
a	O
CArG	O
box	O
at	O
-	O
91	O
bp	O
;	O
myocyte	B-protein
-	I-protein
specific	I-protein
enhancer	I-protein
-	I-protein
binding	I-protein
nuclear	I-protein
factor	I-protein
1	I-protein
binding	I-protein
site	I-protein
homologies	O
at	O
-	O
58	O
,	O
-	O
535	O
,	O
and	O
-	O
583	O
bp	O
;	O
and	O
a	O
muscle	O
-	O
CAAT	O
consensus	O
sequence	O
at	O
-	O
394	O
bp	O
relative	O
to	O
the	O
cap	O
site	O
.	O

Feed	O
intake	O
and	O
BW	O
gains	O
were	O
decreased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
by	O
dietary	O
treatments	O
containing	O
M	O
.	O

In	O
nondiabetics	O
the	O
response	O
of	O
tcPO2	O
but	O
not	O
of	O
LDF	O
was	O
influenced	O
by	O
the	O
values	O
at	O
rest	O
.	O

Phenylephrine	O
is	O
a	O
pure	O
alpha	B-protein
-	I-protein
1	I-protein
adrenoreceptor	I-protein
agonist	O
known	O
to	O
produce	O
marked	O
systemic	O
vasoconstriction	O
and	O
associated	O
hypertension	O
with	O
occasional	O
profound	O
reflex	O
bradycardia	O
.	O

Before	O
turnout	O
,	O
a	O
morantel	O
sustained	O
release	O
bolus	O
(	O
MSRB	O
)	O
was	O
administered	O
to	O
each	O
animal	O
in	O
the	O
`	O
`	O
treated	O
'	O
'	O
category	O
.	O

Similar	O
waves	O
were	O
seen	O
on	O
cross	O
-	O
correlating	O
a	O
motor	O
unit	O
with	O
an	O
electronic	O
oscillator	O
,	O
confirming	O
that	O
their	O
occurrence	O
does	O
not	O
necessarily	O
demonstrate	O
the	O
existence	O
of	O
active	O
neural	O
interactions	O
.	O

Another	O
sequence	O
,	O
GGGXGGAG	B-protein
,	O
which	O
is	O
repeated	O
several	O
times	O
in	O
many	O
polyomaviruses	O
and	O
adenoviruses	O
,	O
and	O
which	O
is	O
thought	O
to	O
play	O
a	O
role	O
in	O
DNA	O
replication	O
and	O
/	O
or	O
transcription	O
,	O
is	O
not	O
found	O
in	O
the	O
JCV	B-protein
sequence	I-protein
presented	O
.	O

A	O
study	O
of	O
human	O
genes	O
coding	O
for	O
U4	B-protein
small	I-protein
nuclear	I-protein
RNA	I-protein
is	O
presented	O
.	O

A	O
cAMP	B-protein
response	I-protein
element	I-protein
(	O
CRE	B-protein
)	O
consensus	O
signal	O
was	O
identified	O
in	O
the	O
5	O
'	O
-	O
noncoding	O
region	O
.	O
cAMP	O
regulates	O
the	O
expression	O
of	O
Kv1	B-protein
.	I-protein
5	I-protein
gene	I-protein
in	O
a	O
cell	O
-	O
specific	O
manner	O
.	O

A	O
hypothesis	O
.	O

Acute	O
decrease	O
in	O
body	O
temperature	O
(	O
TB	O
)	O
lowered	O
PaCO2	O
(	O
32	O
.	O
5	O
to	O
14	O
.	O
5	O
mmHg	O
)	O
and	O
[	O
HCO3	O
-	O
]	O
a	O
(	O
24	O
.	O
20	O
mEq	O
/	O
L	O
to	O
17	O
.	O
56	O
mEq	O
/	O
L	O
)	O
,	O
increased	O
pHa	O
(	O
7	O
.	O
481	O
to	O
7	O
.	O
608	O
)	O
and	O
diminished	O
the	O
[	O
OH	O
-	O
]	O
/	O
[	O
H	O
+	O
]	O
ratio	O
,	O
but	O
had	O
no	O
significant	O
effect	O
on	O
[	O
SID	O
]	O
or	O
[	O
Atot	O
]	O
,	O
although	O
both	O
total	O
phosphorus	O
[	O
PT	O
]	O
and	O
inorganic	O
phosphate	O
[	O
Pi	O
]	O
increased	O
.	O

As	O
a	O
complement	O
to	O
genome	O
-	O
wide	O
mapping	O
and	O
sequencing	O
efforts	O
,	O
it	O
is	O
often	O
important	O
to	O
generate	O
detailed	O
maps	O
and	O
sequence	O
data	O
for	O
specific	O
regions	O
of	O
interest	O
.	O

Rats	O
underwent	O
either	O
a	O
90	O
-	O
95	O
%	O
JIB	O
or	O
a	O
sham	O
operation	O
.	O

Ig	B-protein
D	I-protein
-	I-protein
JH	I-protein
recombinations	O
may	O
precede	O
TcR	B-protein
gene	I-protein
recombination	O
in	O
these	O
early	O
T	O
cell	O
lines	O
,	O
and	O
some	O
but	O
not	O
all	O
express	O
sterile	O
Cmu	B-protein
transcripts	I-protein
.	O

We	O
have	O
previously	O
shown	O
that	O
ARNO	B-protein
localizes	O
to	O
the	O
plasma	O
membrane	O
in	O
vivo	O
and	O
efficiently	O
catalyzes	O
ARF6	B-protein
nucleotide	O
exchange	O
in	O
vitro	O
.	O

Among	O
these	O
,	O
ACT1	B-protein
was	O
isolated	O
four	O
times	O
,	O
and	O
NSR1	B-protein
three	O
times	O
.	O

An	O
unusual	O
feature	O
of	O
these	O
replicative	O
genes	O
is	O
that	O
the	O
smaller	O
mRNA	O
begins	O
within	O
a	O
long	O
open	O
reading	O
frame	O
of	O
the	O
larger	O
mRNA	O
.	O

LDL	O
cholesterol	O
decreased	O
from	O
4	O
.	O
74	O
+	O
/	O
-	O
0	O
.	O
87	O
to	O
3	O
.	O
78	O
+	O
/	O
-	O
0	O
.	O
78	O
mmol	O
/	O
l	O
after	O
8	O
weeks	O
on	O
simvastatin	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
apo	B-protein
B	I-protein
fell	O
from	O
142	O
+	O
/	O
-	O
31	O
to	O
112	O
+	O
/	O
-	O
22	O
mg	O
/	O
dl	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Defective	O
provirus	O
genomes	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
are	O
frequently	O
detected	O
in	O
lymphocytes	O
from	O
infected	O
individuals	O
and	O
in	O
infected	O
cell	O
lines	O
.	O

This	O
result	O
suggested	O
that	O
mutant	B-protein
I299	I-protein
has	O
diminished	O
cap	O
-	O
binding	O
activity	O
.	O

The	O
volume	O
of	O
blood	O
to	O
the	O
flap	O
ranges	O
from	O
1	O
to	O
2	O
ml	O
/	O
min	O
,	O
collateral	O
circulation	O
to	O
the	O
flap	O
exists	O
,	O
but	O
is	O
negligible	O
,	O
and	O
there	O
is	O
little	O
change	O
in	O
the	O
capillary	O
blood	O
flow	O
as	O
the	O
flap	O
ages	O
.	O

Serum	O
induction	O
of	O
a	O
MEF2	B-protein
reporter	I-protein
gene	I-protein
was	O
not	O
observed	O
in	O
a	O
line	O
of	O
NIH	O
3T3	O
cells	O
which	O
contain	O
low	O
MEF2	B-protein
site	I-protein
binding	O
activity	O
.	O

The	O
rate	O
of	O
resectability	O
is	O
low	O
and	O
5	O
-	O
year	O
survival	O
is	O
very	O
poor	O
.	O

Effects	O
of	O
a	O
selective	O
monoamine	B-protein
oxidase	I-protein
(	I-protein
MAO	I-protein
)	I-protein
-	I-protein
-	I-protein
A	I-protein
inhibitor	O
,	O
clorgyline	O
,	O
a	O
selective	O
MAO	B-protein
-	I-protein
B	I-protein
inhibitor	O
,	O
deprenyl	O
,	O
and	O
a	O
non	O
-	O
selective	O
MAO	B-protein
inhibitor	O
,	O
nialamide	O
,	O
were	O
investigated	O
on	O
footshock	O
-	O
induced	O
aggression	O
(	O
FIA	O
)	O
in	O
paired	O
rats	O
.	O

IFI	B-protein
16	I-protein
mRNA	I-protein
was	O
found	O
to	O
be	O
constitutively	O
expressed	O
in	O
lymphoid	O
cells	O
and	O
in	O
cell	O
lines	O
of	O
both	O
the	O
T	O
and	O
B	O
lineages	O
.	O

1	O
-	O
(	O
1	O
-	O
Naphthyl	O
)	O
piperazine	O
(	O
1	O
-	O
NP	O
)	O
has	O
been	O
reported	O
to	O
have	O
serotonin	O
antagonist	O
properties	O
at	O
the	O
5	B-protein
-	I-protein
HT2	I-protein
subtype	I-protein
of	O
receptor	O
,	O
and	O
it	O
has	O
been	O
suggested	O
that	O
it	O
may	O
have	O
agonist	O
actions	O
at	O
the	O
5	B-protein
-	I-protein
HT1	I-protein
site	I-protein
.	O

`	O
`	O
In	O
vitro	O
'	O
'	O
study	O
of	O
dentin	B-protein
adhesion	O
to	O
adhesives	O
made	O
from	O
urethane	O
molecules	O
with	O
free	O
groups	O
of	O
isocyanate	O
.	O

Both	O
HEF1	B-protein
and	O
Cas	B-protein
were	O
found	O
to	O
complex	O
with	O
the	O
related	B-protein
adhesion	I-protein
focal	I-protein
tyrosine	I-protein
kinase	I-protein
(	O
RAFTK	B-protein
)	O
,	O
and	O
when	O
tyrosine	O
phosphorylated	O
,	O
with	O
the	O
adapter	O
molecule	O
CrkL	B-protein
.	O

Statistical	O
analysis	O
of	O
the	O
degrees	O
of	O
secondary	O
spinal	O
cord	O
compression	O
was	O
performed	O
in	O
group	O
-	O
1	O
dogs	O
by	O
measuring	O
and	O
comparing	O
ratios	O
of	O
the	O
vertical	O
to	O
the	O
horizontal	O
diameters	O
of	O
the	O
transverse	O
spinal	O
cord	O
sections	O
from	O
locations	O
within	O
(	O
T12	O
to	O
L1	O
)	O
and	O
out	O
of	O
(	O
T11	O
,	O
T11	O
-	O
12	O
,	O
L1	O
-	O
2	O
,	O
and	O
L2	O
)	O
the	O
region	O
of	O
surgical	O
intervention	O
.	O

The	O
nucleotide	O
sequences	O
of	O
the	O
human	B-protein
and	I-protein
murine	I-protein
ornithine	I-protein
decarboxylase	I-protein
mRNAs	I-protein
share	O
an	O
85	O
%	O
homology	O
,	O
even	O
in	O
their	O
3	O
'	O
-	O
noncoding	O
regions	O
.	O

These	O
studies	O
show	O
that	O
UCRBP	B-protein
binds	O
to	O
various	O
target	O
motifs	O
that	O
are	O
distinct	O
from	O
the	O
UCR	B-protein
motif	I-protein
:	O
the	O
adeno	B-protein
-	I-protein
associated	I-protein
virus	I-protein
P5	I-protein
promoter	I-protein
and	O
elements	O
in	O
the	O
immunoglobulin	B-protein
light	I-protein
-	I-protein
and	I-protein
heavy	I-protein
-	I-protein
chain	I-protein
genes	I-protein
,	O
as	O
well	O
as	O
elements	O
in	O
ribosomal	B-protein
protein	I-protein
genes	I-protein
.	O

PACAP	B-protein
mRNA	I-protein
was	O
widely	O
expressed	O
in	O
most	O
human	O
tissues	O
;	O
in	O
transfected	O
cells	O
,	O
PACAP	B-protein
was	O
diffusely	O
expressed	O
in	O
the	O
cytoplasm	O
.	O

Malignant	O
lymphoma	O
is	O
very	O
heterogeneous	O
in	O
terms	O
of	O
its	O
biological	O
behavior	O
.	O

Number	O
and	O
size	O
of	O
silver	O
-	O
stained	O
nucleoli	O
(	O
Ag	O
-	O
NOR	O
clusters	O
)	O
in	O
canine	O
seminomas	O
:	O
correlation	O
with	O
histological	O
features	O
and	O
tumour	O
behaviour	O
.	O

These	O
data	O
further	O
define	O
a	O
role	O
for	O
TRADD	B-protein
and	O
TRAF2	B-protein
in	O
JNK	B-protein
activation	O
and	O
confirm	O
that	O
LMP1	B-protein
utilizes	O
signalling	O
mechanisms	O
used	O
by	O
the	O
TNF	B-protein
receptor	I-protein
/	I-protein
CD40	I-protein
family	I-protein
to	O
elicit	O
its	O
pleiotropic	O
activities	O
.	O

H19	B-protein
and	O
Igf2	B-protein
monoallelic	O
expression	O
is	O
regulated	O
in	O
two	O
distinct	O
ways	O
by	O
a	O
shared	O
cis	O
acting	O
regulatory	O
region	O
upstream	O
of	O
H19	B-protein
.	O

Recombination	O
,	O
replication	O
,	O
repair	O
:	O
from	O
complexity	O
to	O
harmony	O
.	O

Elevated	O
expression	O
of	O
full	B-protein
-	I-protein
length	I-protein
UhpB	I-protein
or	O
of	O
a	O
soluble	O
hybrid	O
protein	O
,	O
GST	B-protein
-	I-protein
Bc	I-protein
,	O
which	O
is	O
glutathione	B-protein
S	I-protein
-	I-protein
transferase	I-protein
(	O
GST	B-protein
)	O
fused	O
to	O
the	O
cytoplasmic	O
C	O
-	O
terminal	O
portion	O
of	O
UhpB	B-protein
,	O
results	O
in	O
complete	O
blockage	O
of	O
uhpT	B-protein
expression	O
in	O
a	O
uhp	B-protein
(	I-protein
+	I-protein
)	I-protein
strain	O
.	O

Apoptosis	O
of	O
small	O
cells	O
is	O
still	O
observed	O
after	O
co	O
-	O
transfection	O
of	O
JBD	B-protein
and	O
LMP1	B-protein
but	O
in	O
addition	O
a	O
few	O
apoptotic	O
HD	O
-	O
MyZ	O
cells	O
with	O
large	O
fused	O
nuclear	O
masses	O
are	O
identified	O
suggesting	O
that	O
specific	O
inhibition	O
of	O
JNK	B-protein
leads	O
also	O
to	O
apoptosis	O
of	O
LMP1	B-protein
induced	O
RS	O
cells	O
.	O

Propranolol	O
(	O
Inderal	O
)	O
administered	O
in	O
a	O
dose	O
which	O
blocks	O
the	O
beta	O
-	O
adrenergic	O
apparatus	O
of	O
the	O
heart	O
prevents	O
the	O
development	O
of	O
the	O
positive	O
inotropic	O
effect	O
of	O
therapeutic	O
doses	O
of	O
strophanthin	O
K	O
on	O
a	O
hypodynamic	O
left	O
ventricular	O
myocardium	O
.	O

Multivariate	O
logistic	O
regression	O
analysis	O
indicated	O
that	O
seropositivity	O
was	O
strongly	O
associated	O
with	O
the	O
prevalence	O
of	O
hepatitis	O
B	O
in	O
an	O
employee	O
'	O
s	O
country	O
of	O
birth	O
and	O
with	O
age	O
.	O

In	O
the	O
rat	B-protein
rnu	I-protein
allele	I-protein
described	O
here	O
,	O
a	O
nonsense	O
mutation	O
in	O
exon	O
8	O
of	O
the	O
whn	B-protein
gene	I-protein
was	O
identified	O
.	O

The	O
present	O
study	O
investigated	O
dose	O
dependence	O
and	O
time	O
course	O
effects	O
of	O
the	O
benzodiazepine	O
(	O
BDZ	O
)	O
partial	O
inverse	O
agonist	O
,	O
RO19	O
-	O
4603	O
(	O
0	O
.	O
005	O
-	O
0	O
.	O
30	O
mg	O
/	O
kg	O
)	O
alone	O
,	O
and	O
in	O
combination	O
with	O
the	O
BDZ	B-protein
receptor	I-protein
antagonists	O
flumazenil	O
,	O
ZK	O
93426	O
,	O
and	O
CGS	O
8216	O
(	O
20	O
mg	O
/	O
kg	O
)	O
in	O
selectively	O
bred	O
alcohol	O
-	O
preferring	O
(	O
P	O
)	O
rats	O
provided	O
a	O
two	O
-	O
bottle	O
choice	O
test	O
between	O
ethanol	O
(	O
EtOH	O
)	O
(	O
10	O
%	O
v	O
/	O
v	O
)	O
,	O
and	O
a	O
palatable	O
saccharin	O
(	O
0	O
.	O
0125	O
%	O
g	O
/	O
v	O
)	O
solution	O
.	O

The	O
carcinogen	O
bioassay	O
therefore	O
is	O
a	O
very	O
important	O
component	O
of	O
the	O
battery	O
of	O
toxicological	O
tests	O
used	O
in	O
hazard	O
evaluation	O
.	O

Four	O
p53	B-protein
DNA	I-protein
-	I-protein
binding	I-protein
domain	I-protein
peptides	I-protein
bind	O
natural	O
p53	B-protein
-	I-protein
response	I-protein
elements	I-protein
and	O
bend	O
the	O
DNA	O
.	O

Bitter	O
cassava	O
contains	O
cyanogenic	O
glycosides	O
;	O
processing	O
breaks	O
them	O
down	O
to	O
acetone	O
cyanohydrin	O
and	O
hydrogen	O
cyanide	O
.	O

RESULTS	O
:	O
Average	O
age	O
at	O
symptom	O
onset	O
was	O
41	O
.	O
2	O
years	O
.	O

Two	O
out	O
of	O
five	O
patients	O
undergoing	O
selective	O
spinal	O
arteriography	O
developed	O
transient	O
neurological	O
complications	O
during	O
the	O
injection	O
of	O
Urografin	O
310	O
M	O
.	O

To	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
this	O
Tax	O
-	O
mediated	O
inhibition	O
,	O
we	O
analyzed	O
its	O
effect	O
on	O
the	O
transcriptional	O
activity	O
of	O
the	O
myogenic	O
MyoD	B-protein
protein	I-protein
,	O
which	O
was	O
used	O
as	O
a	O
paradigm	O
of	O
bHLH	B-protein
factors	I-protein
.	O

When	O
the	O
73	O
-	O
bp	O
fragment	O
was	O
fused	O
to	O
an	O
alpha1	B-protein
-	I-protein
globin	I-protein
promoter	I-protein
-	I-protein
CAT	I-protein
construct	I-protein
and	O
cotransfected	O
with	O
CCAAT	B-protein
transcription	I-protein
factor	I-protein
1	I-protein
(	O
CTF1	B-protein
)	O
/	B-protein
NF1	I-protein
into	O
Drosophila	O
Schneider	O
SL2	O
insect	O
cells	O
(	O
which	O
lack	O
NF1	B-protein
-	I-protein
like	I-protein
proteins	I-protein
)	O
trans	O
-	O
activation	O
of	O
CAT	B-protein
activity	O
was	O
observed	O
.	O

The	O
deubiquitinating	O
enzyme	O
DUB	B-protein
-	I-protein
2	I-protein
is	O
induced	O
in	O
response	O
to	O
IL	B-protein
-	I-protein
2	I-protein
but	O
as	O
yet	O
its	O
function	O
has	O
not	O
been	O
determined	O
.	O

The	O
relative	O
abundance	O
of	O
each	O
alternatively	O
spliced	O
mRNA	O
was	O
determined	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
in	O
various	O
human	O
tissues	O
and	O
cell	O
lines	O
.	O

Expression	O
of	O
this	O
cDNA	O
in	O
vitro	O
yields	O
a	O
peptide	O
which	O
comigrates	O
with	O
natural	B-protein
eIF	I-protein
-	I-protein
2B	I-protein
alpha	I-protein
in	O
SDS	O
/	O
polyacrylamide	O
gels	O
.	O

Drosophila	B-protein
Menin1	I-protein
gene	I-protein
transcripts	I-protein
use	O
alternative	O
polyadenylation	O
sites	O
resulting	O
in	O
4	O
.	O
3	O
and	O
5	O
-	O
kb	O
messages	O
.	O

Dopamine	O
SERS	O
spectra	O
from	O
these	O
electrodes	O
are	O
similar	O
to	O
those	O
obtained	O
at	O
uncoated	O
electrodes	O
.	O

The	O
importance	O
of	O
posttranslational	O
regulation	O
of	O
p15INK4B	B-protein
by	O
TGF	B-protein
-	I-protein
beta	I-protein
is	O
underlined	O
by	O
the	O
observation	O
that	O
in	O
TGF	O
-	O
beta	O
-	O
resistant	O
184A1L5R	O
,	O
although	O
the	O
p15	B-protein
transcript	I-protein
increased	O
,	O
p15INK4B	B-protein
protein	I-protein
was	O
not	O
stabilized	O
and	O
did	O
not	O
accumulate	O
,	O
and	O
cyclin	B-protein
D1	I-protein
-	I-protein
cdk	I-protein
association	O
and	O
kinase	B-protein
activation	O
were	O
not	O
inhibited	O
.	O

Further	O
,	O
the	O
osteo	O
-	O
retentive	O
ability	O
of	O
the	O
hydroxyapatite	O
in	O
the	O
sockets	O
was	O
seen	O
to	O
be	O
close	O
to	O
significance	O
(	O
after	O
six	O
months	O
width	O
differences	O
,	O
in	O
the	O
canine	O
region	O
:	O
P	O
=	O
0	O
.	O
059	O
,	O
LHS	O
,	O
and	O
P	O
=	O
0	O
.	O
065	O
,	O
RHS	O
)	O
.	O

After	O
7	O
days	O
,	O
a	O
spontaneous	O
regression	O
of	O
the	O
morphologic	O
alterations	O
caused	O
by	O
caerulein	O
-	O
induced	O
acute	O
pancreatitis	O
occurs	O
;	O
however	O
,	O
recovery	O
of	O
the	O
secretory	O
function	O
of	O
the	O
pancreas	O
was	O
only	O
reached	O
after	O
this	O
period	O
of	O
time	O
when	O
L	O
-	O
364	O
,	O
718	O
was	O
administered	O
therapeutically	O
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
/	O
day	O
)	O
.	O

CONCLUSION	O
:	O
The	O
probability	O
of	O
cardiopulmonary	O
complications	O
increases	O
significantly	O
when	O
patients	O
develop	O
class	O
1	O
HELLP	O
syndrome	O
.	O

Sustained	O
activation	O
of	O
p21	B-protein
expression	O
is	O
proposed	O
to	O
be	O
a	O
distinguishing	O
feature	O
of	O
the	O
activity	O
of	O
NGF	B-protein
that	O
contributes	O
to	O
PC12	O
growth	O
arrest	O
during	O
differentiation	O

The	O
tryptase	B-protein
locus	I-protein
also	O
contains	O
at	O
least	O
four	O
tryptase	B-protein
-	I-protein
like	I-protein
pseudogenes	I-protein
,	O
including	O
mastin	B-protein
,	O
a	O
gene	O
expressed	O
in	O
dogs	O
but	O
not	O
in	O
humans	O
.	O

Osteocalcin	B-protein
(	O
and	O
urinary	O
hydroxyproline	O
)	O
were	O
not	O
elevated	O
in	O
isolated	O
hyperphosphatasaemia	O
,	O
indicating	O
that	O
mechanisms	O
other	O
than	O
increased	O
bone	O
turnover	O
may	O
account	O
for	O
the	O
markedly	O
elevated	O
serum	B-protein
alkaline	I-protein
phosphatase	I-protein
activity	O
in	O
these	O
subjects	O
.	O

Possibilities	O
and	O
outlook	O
for	O
wrist	O
joint	O
endoprosthesis	O
.	O

Acute	O
idiopathic	O
thrombocytopenic	O
purpura	O
presenting	O
a	O
high	O
serum	O
level	O
of	O
immunoglobulin	B-protein
E	I-protein
and	O
eosinophilia	O
in	O
an	O
elderly	O
patient	O
.	O

PrpB	B-protein
showed	O
homology	O
to	O
carboxyphosphonoenolpyruvate	B-protein
phosphonomutase	I-protein
of	I-protein
Streptomyces	I-protein
hygroscopicus	I-protein
and	O
to	O
its	O
homolog	O
in	O
the	O
carnation	O
Dianthus	O
caryophyllus	O
;	O
PrpC	B-protein
was	O
homologous	O
to	O
both	O
archaeal	B-protein
and	I-protein
bacterial	I-protein
citrate	I-protein
synthases	I-protein
;	O
PrpD	B-protein
showed	O
homology	O
to	O
yeast	O
and	O
Bacillus	O
subtilis	O
proteins	O
of	O
unknown	O
function	O
;	O
PrpE	B-protein
showed	O
homology	O
to	O
acetyl	B-protein
coenzyme	I-protein
A	I-protein
synthetases	I-protein
.	O

The	O
introduction	O
of	O
hARF4	B-protein
to	O
the	O
cells	O
maintained	O
the	O
balance	O
between	O
cytosolic	O
and	O
membrane	O
-	O
associated	O
Sec7p	B-protein
pools	O
.	O

The	O
final	O
screening	O
yielded	O
a	O
clone	O
containing	O
a	O
2	O
kilobase	O
(	O
kb	O
)	O
insert	O
.	O

Antidromic	O
invasion	O
of	O
impulses	O
and	O
recurrent	O
collateral	O
inhibition	O
in	O
pyramidal	O
tract	O
neurones	O
.	O

Another	O
element	O
necessary	O
for	O
augmenting	O
the	O
amplitude	O
of	O
the	O
oscillation	O
lies	O
between	O
-	O
178	O
and	O
-	O
264	O
.	O

In	O
addition	O
to	O
restoring	O
checkpoint	O
control	O
,	O
overexpression	O
of	O
sum1	B-protein
+	I-protein
inhibits	O
the	O
normal	O
cell	O
cycle	O
response	O
to	O
osmotic	O
stress	O
.	O

For	O
higher	O
expression	O
of	O
lipA	B-protein
in	O
S	O
.	O
lividans	O
,	O
the	O
gene	O
was	O
cloned	O
next	O
to	O
the	O
strong	O
aphII	B-protein
promoter	I-protein
.	O

LMP	B-protein
-	I-protein
1	I-protein
is	O
targeted	O
to	O
the	O
plasma	O
membrane	O
,	O
where	O
it	O
binds	O
TRAF	B-protein
,	O
TRADD	B-protein
,	O
and	O
JAK	B-protein
molecules	I-protein
to	O
activate	O
NF	O
-	O
kappaB	O
-	O
,	O
AP	O
-	O
1	O
-	O
,	O
and	O
STAT	O
-	O
dependent	O
pathways	O
as	O
does	O
CD40	B-protein
.	O

2	O
.	O

Disruption	O
of	O
the	O
IRA2	B-protein
gene	I-protein
resulted	O
in	O
(	O
i	O
)	O
increased	O
sensitivity	O
to	O
heat	O
shock	O
and	O
nitrogen	O
starvation	O
,	O
(	O
ii	O
)	O
sporulation	O
defects	O
,	O
and	O
(	O
iii	O
)	O
suppression	O
of	O
the	O
lethality	O
of	O
the	O
cdc25	B-protein
mutant	I-protein
.	O

A	O
careful	O
,	O
radiolabelled	O
tissue	O
-	O
distribution	O
study	O
is	O
warranted	O
to	O
elucidate	O
the	O
complicated	O
metabolic	O
fate	O
of	O
perhexiline	O
.	O

MutY	B-protein
is	O
an	O
adenine	B-protein
-	I-protein
DNA	I-protein
glycosylase	I-protein
with	O
specificity	O
for	O
mismatches	O
involving	O
8	O
-	O
oxoguanine	O
(	O
oG	O
.	O
A	O
)	O
or	O
guanine	O
(	O
G	O
.	O
A	O
)	O
.	O

Susceptibilities	O
of	O
540	O
anaerobic	O
gram	O
-	O
negative	O
bacilli	O
to	O
amoxicillin	O
,	O
amoxicillin	O
-	O
BRL	O
42715	O
,	O
amoxicillin	O
-	O
clavulanate	O
,	O
temafloxacin	O
,	O
and	O
clindamycin	O
.	O

This	O
effect	O
was	O
observed	O
in	O
the	O
absence	O
of	O
de	O
novo	O
protein	O
synthesis	O
and	O
was	O
independent	O
of	O
histone	B-protein
deacetylase	I-protein
activity	O
.	O

NF	B-protein
-	I-protein
kappaB	I-protein
plays	O
a	O
critical	O
role	O
in	O
activation	O
of	O
HIV	O
-	O
1	O
gene	O
expression	O
by	O
cytokines	O
and	O
other	O
stimuli	O
,	O
but	O
the	O
signal	O
transduction	O
pathways	O
that	O
regulate	O
the	O
switch	O
from	O
latent	O
to	O
productive	O
infection	O
have	O
not	O
been	O
defined	O
.	O

Thus	O
,	O
in	O
T47D	O
breast	O
carcinoma	O
cells	O
,	O
IL	B-protein
-	I-protein
6	I-protein
acts	O
in	O
synergy	O
with	O
EGF	B-protein
receptor	I-protein
autocrine	O
activity	O
to	O
signal	O
through	O
the	O
MAPK	B-protein
/	I-protein
PI3K	I-protein
pathways	O
.	O

CONCLUSION	O
:	O
This	O
study	O
documents	O
that	O
regression	O
of	O
choroidal	O
neovascularization	O
that	O
occurred	O
with	O
alpha	B-protein
interferon	I-protein
treatment	O
was	O
minimal	O
.	O

The	O
Authors	O
have	O
proposed	O
to	O
develop	O
this	O
research	O
employing	O
a	O
preparation	O
containing	O
exclusively	O
a	O
cortisonic	O
,	O
the	O
desametazone	O
,	O
in	O
order	O
to	O
evaluate	O
the	O
alterations	O
of	O
the	O
dentinogenesis	O
to	O
be	O
attributed	O
to	O
such	O
component	O
.	O

A	O
5	O
.	O
3	O
-	O
kb	O
DNA	O
fragment	O
,	O
which	O
included	O
the	O
entire	O
structural	O
porin	B-protein
gene	I-protein
(	O
named	O
porCa	B-protein
)	O
and	O
its	O
flanking	O
regions	O
,	O
was	O
identified	O
.	O

The	O
transactivation	O
function	O
of	O
EBNA2	B-protein
was	O
also	O
observed	O
in	O
the	O
HeLa	O
epithelial	O
cell	O
line	O
,	O
which	O
suggests	O
that	O
EBV	O
and	O
HIV	O
-	O
1	O
infection	O
of	O
non	O
-	O
B	O
cells	O
may	O
result	O
in	O
HIV	O
-	O
1	O
promoter	O
activation	O
.	O

Immunofluorescence	O
microscopy	O
revealed	O
extensive	O
deposition	O
of	O
such	O
extracellular	O
matrices	O
as	O
type	B-protein
IV	I-protein
collagen	I-protein
and	O
laminin	B-protein
in	O
the	O
vascular	O
wall	O
.	O

Members	O
of	O
the	O
C	B-protein
/	I-protein
EBP	I-protein
family	I-protein
of	O
basic	B-protein
-	I-protein
leucine	I-protein
zipper	I-protein
(	O
bZip	B-protein
)	O
transcription	O
factors	O
form	O
heterodimers	O
and	O
bind	O
to	O
the	O
CAAT	O
box	O
and	O
other	O
sequence	O
-	O
related	O
enhancer	O
motifs	O
.	O

Vitrectomy	O
and	O
removal	O
of	O
retained	O
lens	O
fragments	O
restores	O
good	O
visual	O
acuity	O
and	O
reduces	O
secondary	O
glaucoma	O
in	O
the	O
majority	O
of	O
patients	O
.	O

Adverse	O
reaction	O
of	O
the	O
apparently	O
healthy	O
partner	O
in	O
response	O
to	O
improvement	O
in	O
the	O
overtly	O
dysfunctional	O
partner	O
.	O

Our	O
study	O
was	O
addressed	O
to	O
the	O
synthesis	O
of	O
some	O
derivatives	O
of	O
this	O
sequence	O
in	O
order	O
to	O
obtain	O
both	O
peptide	O
substrates	O
suitable	O
for	O
the	O
detection	O
of	O
the	O
Src	B-protein
-	I-protein
like	I-protein
tyrosine	I-protein
kinase	I-protein
activity	O
and	O
active	O
site	O
-	O
directed	O
inhibitors	O
specific	O
for	O
this	O
class	O
of	O
enzymes	O
.	O

The	O
defect	O
in	O
these	O
proteins	O
was	O
also	O
uniformly	O
suppressed	O
by	O
either	O
Mn2	O
+	O
,	O
or	O
the	O
Mu	B-protein
B	I-protein
protein	I-protein
in	O
the	O
presence	O
of	O
ATP	O
and	O
target	O
DNA	O
.	O

As	O
such	O
the	O
findings	O
support	O
existing	O
studies	O
that	O
have	O
identified	O
given	O
social	O
characteristics	O
of	O
drink	O
drivers	O
.	O

SM	B-protein
is	O
also	O
shown	O
to	O
be	O
associated	O
in	O
vivo	O
with	O
other	O
components	O
of	O
the	O
CRM	B-protein
1	I-protein
export	O
pathway	O
,	O
including	O
the	O
small	B-protein
GTPase	I-protein
Ran	I-protein
and	O
the	O
nucleoporin	B-protein
CAN	I-protein
/	I-protein
Nup214	I-protein
.	O

As	O
a	O
result	O
,	O
we	O
have	O
defined	O
two	O
arginine	O
-	O
rich	O
motifs	O
(	O
ARM1	O
and	O
ARM2	O
)	O
that	O
mediate	O
the	O
RNA	O
binding	O
activity	O
of	O
SU	B-protein
(	I-protein
S	I-protein
)	I-protein
.	O

Study	O
on	O
micromelias	O
in	O
the	O
mouse	O
fetus	O
caused	O
by	O
x	O
-	O
radiation	O
,	O
hypoxia	O
,	O
trypan	O
blue	O
injection	O
of	O
hypervitaminosis	O
-	O
A	O
upon	O
mother	O
animals	O
during	O
pregnancy	O
.	O

Raman	O
investigation	O
of	O
YBa2	O
-	O
xLaxCu3O7	O
ceramics	O
.	O

San	O
Martin	O
'	O
s	O
psychological	O
traits	O
coupled	O
to	O
his	O
work	O
with	O
masonic	O
lodges	O
that	O
allowed	O
him	O
to	O
display	O
his	O
abilities	O
as	O
strategist	O
and	O
political	O
ruler	O
.	O

A	O
novel	O
Drosophila	B-protein
A	I-protein
kinase	I-protein
anchor	I-protein
protein	I-protein
,	O
Drosophila	B-protein
A	I-protein
kinase	I-protein
anchor	I-protein
protein	I-protein
200	I-protein
(	O
DAKAP200	B-protein
)	O
,	O
is	O
predicted	O
to	O
be	O
involved	O
in	O
routing	O
,	O
mediating	O
,	O
and	O
integrating	O
signals	O
carried	O
by	O
cAMP	O
,	O
Ca	O
(	O
2	O
+	O
)	O
,	O
and	O
diacylglycerol	O
(	O
Li	O
,	O
Z	O
.	O
,	O
Rossi	O
,	O
E	O
.	O

These	O
risk	O
factors	O
can	O
be	O
divided	O
into	O
2	O
groups	O
:	O
local	O
vessel	O
wall	O
-	O
related	O
factors	O
,	O
and	O
local	O
(	O
focal	O
action	O
)	O
systemic	O
factors	O
.	O

Hand	O
-	O
held	O
,	O
continuous	O
-	O
wave	O
Doppler	O
probes	O
,	O
coupled	O
with	O
sound	O
spectral	O
analysis	O
,	O
can	O
successfully	O
predict	O
carotid	O
artery	O
stenosis	O
.	O

D	B-protein
-	I-protein
cyclin	I-protein
-	I-protein
cdk	I-protein
activity	O
is	O
required	O
for	O
Rb	B-protein
phosphorylation	O
in	O
v	O
-	O
Jun	O
-	O
transformed	O
cells	O
,	O
since	O
ectopic	O
expression	O
of	O
the	O
cdk4	O
-	O
and	O
cdk6	B-protein
-	I-protein
specific	I-protein
inhibitor	I-protein
p16	I-protein
(	I-protein
INK4A	I-protein
)	I-protein
inhibits	O
both	O
DNA	O
synthesis	O
and	O
cell	O
proliferation	O
.	O

The	O
yeast	B-protein
SSS1	I-protein
gene	I-protein
is	O
essential	O
for	O
secretory	O
protein	O
translocation	O
and	O
encodes	O
a	O
conserved	O
protein	O
of	O
the	O
endoplasmic	O
reticulum	O
.	O

Intraoperatively	O
the	O
complement	B-protein
factor	I-protein
C3c	I-protein
decreased	O
by	O
20	O
%	O
,	O
while	O
alpha	B-protein
1	I-protein
-	I-protein
antitrypsin	I-protein
showed	O
postoperatively	O
an	O
increase	O
by	O
30	O
%	O
.	O

Overexpression	O
of	O
CDP	B-protein
/	I-protein
cut	I-protein
in	O
ROS	O
17	O
/	O
2	O
.	O
8	O
osteosarcoma	O
cells	O
results	O
in	O
repression	O
of	O
OC	B-protein
promoter	I-protein
activity	O
;	O
this	O
repression	O
is	O
abrogated	O
by	O
mutating	O
OC	B-protein
box	I-protein
I	I-protein
.	O

Co	O
-	O
existence	O
of	O
these	O
regulatory	O
elements	O
with	O
other	O
elements	O
,	O
such	O
as	O
the	O
AP	B-protein
-	I-protein
2	I-protein
element	I-protein
or	O
CCAAT	O
box	O
,	O
was	O
also	O
found	O
.	O

Update	O
on	O
maternal	O
-	O
fetal	O
infections	O
by	O
hepatitis	O
C	O
,	O
HIV	O
and	O
cytomegalovirus	O
.	O

Many	O
children	O
with	O
BGC	O
are	O
delayed	O
in	O
their	O
development	O
,	O
but	O
calcifications	O
are	O
not	O
directly	O
related	O
to	O
specific	O
forms	O
of	O
neurologic	O
dysfunction	O
.	O

The	O
presence	O
of	O
cutaneous	O
xanthomas	O
with	O
normal	O
serum	O
lipid	O
levels	O
is	O
due	O
to	O
the	O
antibetalipoproteic	O
activity	O
of	O
the	O
monoclonal	B-protein
immunoglobulin	I-protein
.	O

CONCLUSIONS	O
:	O
There	O
is	O
a	O
relation	O
in	O
the	O
topography	O
of	O
some	O
visual	O
field	O
areas	O
assessed	O
by	O
SWAP	O
and	O
the	O
inferotemporal	O
neuroretinal	O
rim	O
area	O
,	O
which	O
may	O
play	O
a	O
role	O
in	O
the	O
diagnosis	O
and	O
follow	O
-	O
up	O
of	O
suspected	O
glaucoma	O
.	O

Mutational	O
analysis	O
shows	O
that	O
both	O
an	O
AP	B-protein
-	I-protein
1	I-protein
like	I-protein
sequence	I-protein
(	O
-	B-protein
294	I-protein
/	I-protein
-	I-protein
285	I-protein
,	I-protein
TGAATCATCA	I-protein
)	O
and	O
an	O
A	O
/	O
T	O
-	O
rich	O
myocyte	B-protein
enhancer	I-protein
factor	I-protein
(	I-protein
MEF	I-protein
)	I-protein
-	I-protein
2	I-protein
like	I-protein
sequence	I-protein
(	O
-	B-protein
310	I-protein
/	I-protein
-	I-protein
298	I-protein
,	I-protein
TTAAAAATAAAAA	I-protein
)	O
in	O
the	O
33	O
-	O
bp	O
region	O
are	O
necessary	O
for	O
the	O
OP	B-protein
-	I-protein
1	I-protein
effect	O
.	O

Sources	O
of	O
noise	O
in	O
these	O
signals	O
were	O
evaluated	O
in	O
preparations	O
stained	O
with	O
the	O
potentiometric	O
probe	O
RH	O
-	O
414	O
.	O

The	O
effects	O
of	O
several	O
opioid	O
agonists	O
and	O
the	O
opioid	O
antagonist	O
naloxone	O
were	O
examined	O
in	O
rats	O
responding	O
under	O
a	O
fixed	O
-	O
consecutive	O
-	O
number	O
(	O
FCN	O
)	O
schedule	O
.	O

An	O
essential	O
role	O
of	O
c	B-protein
-	I-protein
Jun	I-protein
and	O
c	B-protein
-	I-protein
Fos	I-protein
in	O
basal	O
and	O
PMA	O
-	O
stimulated	O
transcription	O
of	O
the	O
PAI	B-protein
-	I-protein
1	I-protein
gene	I-protein
is	O
demonstrated	O
by	O
our	O
finding	O
that	O
antisense	O
c	B-protein
-	I-protein
jun	I-protein
and	O
c	B-protein
-	I-protein
fos	I-protein
oligodeoxynucleotides	O
both	O
strongly	O
reduced	O
basal	O
and	O
PMA	O
-	O
stimulated	O
PAI	B-protein
-	I-protein
1	I-protein
synthesis	O
.	O

The	O
responses	O
of	O
the	O
`	O
`	O
stress	O
hormones	O
'	O
'	O
cortisol	O
,	O
11	O
-	O
deoxycortisol	O
,	O
ACTH	B-protein
,	O
vasopressin	B-protein
(	O
AVP	B-protein
)	O
,	O
and	O
corticotropin	B-protein
releasing	I-protein
factor	I-protein
(	O
CRF	B-protein
)	O
were	O
studied	O
in	O
6	O
normal	O
males	O
in	O
response	O
to	O
acute	O
cortisol	O
deficiency	O
induced	O
by	O
the	O
11	B-protein
-	I-protein
beta	I-protein
-	I-protein
hydroxylase	I-protein
inhibitor	O
,	O
metyrapone	O
.	O

Cestode	O
invasion	O
in	O
irradiated	O
host	O
organism	O
increases	O
the	O
negative	O
effect	O
of	O
ionizing	O
radiation	O
on	O
the	O
hamster	O
immune	O
system	O
.	O

Hoeben	O
,	O
F	O
.	O
J	O
.	O

CONCLUSION	O
:	O
MMF	O
(	O
2	O
-	O
3	O
g	O
/	O
day	O
)	O
is	O
unable	O
to	O
control	O
the	O
signs	O
of	O
mucocutaneous	O
Adamantiades	O
-	O
Behcet	O
'	O
s	O
disease	O
.	O

Five	O
experiments	O
examined	O
the	O
influence	O
of	O
opiate	O
antagonists	O
on	O
both	O
the	O
short	O
-	O
term	O
analgesic	O
reaction	O
resulting	O
30	O
min	O
after	O
exposure	O
to	O
inescapable	O
shock	O
and	O
the	O
long	O
-	O
term	O
analgesic	O
reaction	O
resulting	O
after	O
reexposure	O
to	O
shock	O
24	O
hr	O
after	O
inescapable	O
shock	O
exposure	O
.	O

It	O
is	O
concluded	O
that	O
fludarabine	O
is	O
a	O
highly	O
useful	O
agent	O
in	O
CLL	O
.	O

These	O
HPV16	O
E6	B-protein
/	I-protein
E7	I-protein
cDNAs	O
were	O
cloned	O
under	O
the	O
SV40	B-protein
enhancer	I-protein
/	I-protein
promoter	I-protein
and	O
the	O
MMTV	O
LTR	B-protein
to	O
examine	O
the	O
activities	O
of	O
ras	O
-	O
collaborative	O
transformation	O
and	O
induction	O
of	O
cellular	O
DNA	O
synthesis	O
,	O
both	O
of	O
which	O
depend	O
on	O
the	O
E7	B-protein
gene	I-protein
product	O
.	O

The	O
GafChromic	O
method	O
has	O
proven	O
to	O
be	O
an	O
accurate	O
and	O
rapid	O
method	O
of	O
analysis	O
and	O
could	O
be	O
easily	O
incorporated	O
into	O
a	O
quality	O
assurance	O
program	O
.	O

High	O
-	O
level	O
gains	O
(	O
HLGs	O
)	O
indicative	O
of	O
gene	O
amplifications	O
were	O
identified	O
at	O
11q13	O
in	O
two	O
cases	O
,	O
and	O
in	O
one	O
case	O
each	O
at	O
2q33	O
-	O
34	O
,	O
3q25	O
-	O
29	O
,	O
5p15	O
.	O
1	O
-	O
15	O
.	O
2	O
,	O
7q21	O
-	O
22	O
,	O
11p11	O
.	O
2	O
,	O
12p11	O
.	O
2	O
-	O
12	O
,	O
and	O
13q34	O
.	O

Sensitive	O
fluorometric	O
method	O
of	O
determining	O
SH	O
-	O
and	O
S	O
-	O
S	O
-	O
groups	O
when	O
jointly	O
present	O
.	O

The	O
DNase	B-protein
I	I-protein
footprint	O
extended	O
5	O
'	O
in	O
the	O
silencer	O
region	O
to	O
include	O
an	O
inverted	O
repeat	O
of	O
a	O
six	O
-	O
nucleotide	O
motif	O
(	O
epsilon	O
-	O
267	O
to	O
-	O
278	O
bp	O
)	O
which	O
shares	O
5	O
of	O
6	O
bases	O
with	O
the	O
GATA	B-protein
-	I-protein
1	I-protein
consensus	I-protein
sequence	I-protein
.	O

Thus	O
,	O
in	O
stress	O
-	O
induced	O
arrhythmic	O
disease	O
as	O
well	O
as	O
in	O
ischemic	O
heart	O
disease	O
,	O
the	O
main	O
pathogenetic	O
links	O
are	O
outside	O
the	O
heart	O
,	O
but	O
they	O
differ	O
from	O
those	O
observed	O
in	O
ischemia	O
.	O

Extracellular	B-protein
-	I-protein
regulated	I-protein
kinase	I-protein
(	O
ERK	B-protein
)	O
activation	O
and	O
molecular	O
coupling	O
of	O
the	O
adaptor	O
proteins	O
p130	B-protein
Crk	I-protein
-	I-protein
associated	I-protein
substrate	I-protein
(	O
CAS	B-protein
)	O
and	O
c	B-protein
-	I-protein
CrkII	I-protein
(	O
Crk	B-protein
)	O
represent	O
two	O
distinct	O
pathways	O
that	O
induce	O
cell	O
invasion	O
and	O
protect	O
cells	O
from	O
apoptosis	O
in	O
a	O
three	O
-	O
dimensional	O
collagen	B-protein
matrix	O
.	O

We	O
demonstrate	O
that	O
both	O
R	O
and	O
Z	O
activate	O
the	O
cellular	O
stress	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinases	I-protein
,	O
p38	B-protein
and	O
JNK	B-protein
,	O
resulting	O
in	O
phosphorylation	O
(	O
and	O
activation	O
)	O
of	O
the	O
cellular	B-protein
transcription	I-protein
factor	I-protein
ATF2	I-protein
.	O

Hepatitis	O
C	O
virus	O
infection	O
and	O
lymphoproliferative	O
diseases	O
in	O
France	O
:	O
a	O
national	O
study	O
.	O

Mutant	O
enzyme	O
forms	O
were	O
prepared	O
to	O
eliminate	O
the	O
initial	O
autoprocessing	O
site	O
and	O
thus	O
form	O
an	O
active	O
single	O
-	O
chain	O
protein	O
for	O
structure	O
-	O
function	O
studies	O
.	O

A	O
new	O
echocardiographic	O
technique	O
is	O
described	O
with	O
a	O
conventional	O
M	O
mode	O
,	O
digitalised	O
2D	O
and	O
tissular	O
Doppler	O
which	O
has	O
a	O
comparable	O
ability	O
to	O
identify	O
the	O
anomalous	O
pathways	O
of	O
electric	O
conduction	O
using	O
a	O
non	O
-	O
invasive	O
method	O
.	O

Hepatitis	O
C	O
virus	O
infection	O
is	O
a	O
risk	O
factor	O
for	O
liver	O
failure	O
from	O
veno	O
-	O
occlusive	O
disease	O
after	O
bone	O
marrow	O
transplantation	O
.	O

NB	O
-	O
506	O
completely	O
inhibits	O
the	O
capacity	O
of	O
topoisomerase	B-protein
I	I-protein
to	O
phosphorylate	O
,	O
in	O
vitro	O
,	O
the	O
human	B-protein
splicing	I-protein
factor	I-protein
2	I-protein
/	I-protein
alternative	I-protein
splicing	I-protein
factor	I-protein
(	O
SF2	B-protein
/	I-protein
ASF	I-protein
)	O
.	O

Clinical	O
and	O
biological	O
correlates	O
of	O
panic	O
states	O
.	O

Comments	O
are	O
given	O
on	O
the	O
present	O
status	O
of	O
regulations	O
concerning	O
water	O
in	O
swimming	O
pools	O
and	O
baths	O
-	O
-	O
1991	O
-	O
-	O
(	O
in	O
connection	O
with	O
the	O
KOK	O
regulations	O
-	O
-	O
1972	O
-	O
-	O
and	O
the	O
Federal	O
German	O
standard	O
[	O
DIN	O
]	O
No	O
.	O

The	O
high	O
degree	O
of	O
conservation	O
between	O
NQO2	B-protein
and	O
NQO1	B-protein
gene	I-protein
organization	O
and	O
sequence	O
confirmed	O
that	O
NQO2	B-protein
gene	I-protein
encodes	O
for	O
a	O
second	O
member	O
of	O
the	O
NQO	B-protein
gene	I-protein
family	I-protein
in	O
human	O
.	O

The	O
concentration	O
of	O
mite	O
allergen	O
was	O
very	O
low	O
(	O
mean	O
0	O
.	O
18	O
micrograms	O
Der	O
p	O
milligrams	O
sieved	O
house	O
dust	O
)	O
,	O
whereas	O
that	O
of	O
cat	O
allergen	O
was	O
high	O
in	O
homes	O
with	O
a	O
cat	O
(	O
80	O
.	O
8	O
micrograms	O
Fel	O
d	O
milligrams	O
)	O
but	O
also	O
in	O
homes	O
with	O
no	O
cat	O
(	O
3	O
.	O
2	O
micrograms	O
Fel	O
d	O
milligrams	O
)	O
.	O

These	O
results	O
suggest	O
an	O
increased	O
risk	O
of	O
developing	O
cancer	O
among	O
polyp	O
patients	O
and	O
the	O
possibility	O
of	O
prophylactic	O
effect	O
of	O
polypectomy	O
against	O
subsequent	O
cancer	O
.	O

Such	O
knowledge	O
could	O
advance	O
diagnosis	O
and	O
treatment	O
of	O
the	O
patient	O
and	O
counseling	O
of	O
the	O
affected	O
family	O
.	O

Our	O
results	O
are	O
reassuring	O
and	O
we	O
therefore	O
advise	O
that	O
in	O
patients	O
undergoing	O
free	O
jejunum	O
flap	O
reconstruction	O
of	O
the	O
hypopharyngo	O
-	O
esophageal	O
tract	O
voice	O
restoration	O
should	O
be	O
attempted	O
by	O
placing	O
a	O
voice	O
prosthesis	O
through	O
a	O
secondary	O
tracheo	O
-	O
esophageal	O
puncture	O
and	O
providing	O
intensive	O
speech	O
training	O
.	O

The	O
results	O
indicate	O
that	O
folate	O
compounds	O
decrease	O
formate	O
accumulation	O
after	O
methanol	O
by	O
stimulating	O
formate	O
oxidation	O
or	O
utilization	O
and	O
suggest	O
a	O
possible	O
use	O
for	O
folates	O
in	O
the	O
treatment	O
of	O
certain	O
cases	O
of	O
human	O
methanol	O
poisoning	O
.	O

Gene	O
expression	O
occurs	O
in	O
a	O
circadian	O
rhythm	O
and	O
induced	O
by	O
light	O
in	O
leaves	O
of	O
dark	O
-	O
adapted	O
plants	O
.	O

In	O
this	O
study	O
,	O
the	O
abilities	O
of	O
constitutive	O
and	O
conditional	O
forms	O
of	O
the	O
three	O
Raf	B-protein
kinases	I-protein
to	O
abrogate	O
the	O
cytokine	O
dependency	O
of	O
FDC	O
-	O
P1	O
cells	O
were	O
examined	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
correlation	O
between	O
simultaneous	O
weekly	O
average	O
pollen	O
levels	O
in	O
Philadelphia	O
and	O
in	O
Cherry	O
Hill	O
(	O
Acer	O
,	O
r	O
(	O
p	O
)	O
=	O
0	O
.	O
987	O
,	O
Quercus	O
,	O
r	O
(	O
p	O
)	O
=	O
0	O
.	O
645	O
,	O
Betula	O
,	O
r	O
(	O
p	O
)	O
=	O
0	O
.	O
896	O
,	O
Pinus	O
,	O
r	O
(	O
p	O
)	O
=	O
0	O
.	O
732	O
,	O
Cupressaceae	O
,	O
r	O
(	O
p	O
)	O
=	O
0	O
.	O
695	O
,	O
Poaceae	O
,	O
r	O
(	O
p	O
)	O
=	O
0	O
.	O
950	O
,	O
Ambrosia	O
,	O
r	O
(	O
p	O
)	O
=	O
0	O
.	O
903	O
,	O
and	O
Rumex	O
,	O
r	O
(	O
p	O
)	O
=	O
0	O
.	O
572	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Despite	O
an	O
overall	O
survival	O
rate	O
of	O
43	O
%	O
,	O
survival	O
to	O
discharge	O
varied	O
greatly	O
(	O
0	O
to	O
100	O
%	O
)	O
among	O
the	O
24	O
diagnostic	O
groups	O
:	O
tumor	O
lysis	O
syndrome	O
and	O
systemic	O
lupus	O
erythematosus	O
(	O
3	O
/	O
3	O
patients	O
each	O
,	O
100	O
%	O
)	O
,	O
hemolytic	O
uremic	O
syndrome	O
(	O
8	O
/	O
9	O
patients	O
,	O
89	O
%	O
)	O
.	O

Scientific	O
cooperation	O
of	O
CMEA	O
member	O
countries	O
has	O
been	O
carried	O
out	O
since	O
1974	O
under	O
the	O
sponsorship	O
of	O
the	O
Cancer	O
Research	O
Institute	O
,	O
Slovak	O
Academy	O
of	O
Sciences	O
(	O
Czechoslovakia	O
)	O
within	O
the	O
framework	O
of	O
CMEA	O
.	O

These	O
observations	O
provide	O
strong	O
support	O
for	O
the	O
idea	O
that	O
expression	O
of	O
mutant	O
tRNA	O
can	O
confer	O
a	O
mutator	O
phenotype	O
,	O
including	O
the	O
UVM	O
-	O
constitutive	O
phenotype	O
observed	O
in	O
mutA	B-protein
and	O
mutC	B-protein
cells	O
.	O

Prior	O
to	O
meals	O
2	O
to	O
3	O
times	O
daily	O
,	O
1	O
-	O
2	O
tablespoons	O
of	O
Alzoon	O
are	O
recommended	O
.	O

Molecular	O
cloning	O
of	O
a	O
cysteine	B-protein
synthase	I-protein
cDNA	I-protein
from	O
Citrullus	O
vulgaris	O
(	O
watermelon	O
)	O
by	O
genetic	O
complementation	O
in	O
an	O
Escherichia	O
coli	O
Cys	O
-	O
auxotroph	O
.	O

The	O
absorbable	O
perisplenic	O
mesh	O
is	O
an	O
important	O
improvement	O
,	O
and	O
in	O
some	O
cases	O
it	O
may	O
replace	O
other	O
techniques	O
for	O
arresting	O
splenic	O
bleeding	O
.	O

Administration	O
of	O
adrenaline	O
resulted	O
in	O
a	O
large	O
overestimation	O
of	O
the	O
SaO2	O
in	O
6	O
of	O
the	O
7	O
measurements	O
.	O

This	O
finding	O
represents	O
both	O
a	O
potentially	O
important	O
mechanism	O
by	O
which	O
HPV	O
gene	O
expression	O
can	O
be	O
regulated	O
and	O
an	O
interesting	O
model	O
for	O
the	O
study	O
of	O
transcriptional	O
cooperativity	O
.	O

Expression	O
of	O
h6	O
.	O
1	O
in	O
COS	O
-	O
1	O
cells	O
led	O
to	O
the	O
production	O
of	O
a	O
typical	O
type	B-protein
IV	I-protein
PDE	I-protein
activity	O
in	O
that	O
cAMP	O
,	O
but	O
not	O
cGMP	O
,	O
served	O
as	O
substrate	O
and	O
its	O
activity	O
was	O
insensitive	O
to	O
either	O
Ca2	O
+	O
/	O
CaM	O
or	O
cGMP	O
but	O
was	O
inhibited	O
by	O
low	O
concentrations	O
of	O
rolipram	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

In	O
the	O
group	O
of	O
asthmatics	O
statistically	O
significant	O
correlation	O
was	O
found	O
between	O
PC20	O
PGF2	O
alpha	O
and	O
histamine	O
values	O
(	O
r	O
=	O
0	O
.	O
538	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

PURPOSE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
first	O
embryo	O
cleavage	O
(	O
FEC	O
)	O
25	O
-	O
27	O
h	O
after	O
intracytoplasmic	O
sperm	O
injection	O
(	O
ICSI	O
)	O
as	O
a	O
parameter	O
for	O
the	O
embryo	O
selection	O
process	O
.	O

The	O
recommendation	O
is	O
made	O
that	O
specific	O
sub	O
-	O
groups	O
of	O
attempters	O
need	O
to	O
be	O
identified	O
and	O
may	O
warrant	O
specialized	O
intervention	O
strategies	O
.	O

The	O
deduced	O
bovine	O
EFIA	B-protein
#	I-protein
1	I-protein
amino	O
acid	O
(	O
aa	O
)	O
sequence	O
is	O
98	O
%	O
identical	O
to	O
rat	O
EFIA	B-protein
and	O
100	O
%	O
identical	O
to	O
human	B-protein
EFIA	I-protein
/	I-protein
DbpB	I-protein
/	I-protein
YB	I-protein
-	I-protein
1	I-protein
family	I-protein
member	O
DNA	B-protein
-	I-protein
binding	I-protein
protein	I-protein
B	I-protein
(	O
DbpB	B-protein
)	O
.	O

The	O
author	O
gives	O
an	O
account	O
of	O
antipsychotic	O
,	O
analgetic	O
,	O
myorelaxing	O
and	O
vasodilatating	O
effects	O
of	O
some	O
calcium	O
antagonists	O
,	O
and	O
their	O
clinical	O
application	O
is	O
discussed	O
.	O

Quantitative	O
computed	O
tomography	O
for	O
measuring	O
vertebral	O
bone	O
mineral	O
content	O
offers	O
high	O
sensitivity	O
and	O
reproducibility	O
.	O

Autoregulation	O
enables	O
different	O
pathways	O
to	O
control	O
CCAAT	B-protein
/	I-protein
enhancer	I-protein
binding	I-protein
protein	I-protein
beta	I-protein
(	O
C	B-protein
/	I-protein
EBP	I-protein
beta	I-protein
)	O
transcription	O
.	O

Little	O
or	O
no	O
protection	O
was	O
detected	O
using	O
adrenal	O
cortex	O
,	O
adrenal	O
medulla	O
,	O
liver	O
,	O
kidney	O
cortex	O
,	O
spleen	O
,	O
or	O
T	O
-	O
lymphocyte	O
total	O
RNA	O
.	O

A	O
5	O
'	O
RNA	O
stem	O
-	O
loop	O
participates	O
in	O
the	O
transcription	O
attenuation	O
mechanism	O
that	O
controls	O
expression	O
of	O
the	O
Bacillus	B-protein
subtilis	I-protein
trpEDCFBA	I-protein
operon	I-protein
.	O

A	O
second	O
even	O
more	O
significant	O
match	O
to	O
this	O
E	O
.	O
coli	O
region	O
was	O
found	O
in	O
the	O
retroviral	B-protein
ribonuclease	I-protein
H	I-protein
(	O
RNase	B-protein
H	I-protein
)	O
domain	O
,	O
and	O
corresponds	O
precisely	O
to	O
a	O
region	O
that	O
has	O
been	O
aligned	O
by	O
previous	O
investigators	O
with	O
the	O
E	B-protein
.	I-protein
coli	I-protein
RNase	I-protein
H	I-protein
,	O
suggesting	O
that	O
Pol	B-protein
I	I-protein
helices	O
O	O
and	O
P	O
are	O
homologous	O
to	O
helices	O
A	O
and	O
D	O
of	O
the	O
RNase	B-protein
H	I-protein
crystal	O
structure	O
,	O
respectively	O
.	O

Relationship	O
of	O
CDK	B-protein
-	I-protein
activating	I-protein
kinase	I-protein
and	O
RNA	B-protein
polymerase	I-protein
II	I-protein
CTD	I-protein
kinase	I-protein
TFIIH	I-protein
/	I-protein
TFIIK	I-protein
.	O

In	O
conclusion	O
:	O
(	O
i	O
)	O
TECRA	O
kit	O
is	O
suggested	O
to	O
be	O
used	O
for	O
screening	O
SE	O
producing	O
strains	O
;	O
(	O
ii	O
)	O
SET	O
-	O
RPLA	O
and	O
RIDASCREEN	O
kits	O
are	O
suitable	O
for	O
epidemiological	O
investigation	O
of	O
SE	O
types	O
,	O
but	O
the	O
lack	O
of	O
ability	O
for	O
detecting	O
SEE	O
,	O
long	O
time	O
required	O
for	O
testing	O
with	O
SET	O
-	O
RPLA	O
kit	O
and	O
high	O
background	O
when	O
using	O
RIDASCREEN	O
kit	O
must	O
be	O
overcome	O
;	O
and	O
(	O
iii	O
)	O
because	O
of	O
the	O
complicated	O
test	O
procedures	O
and	O
the	O
lack	O
of	O
ability	O
for	O
detecting	O
SEE	O
,	O
the	O
practicality	O
of	O
SET	O
-	O
EIA	O
kit	O
in	O
screening	O
and	O
epidemiological	O
research	O
purposes	O
is	O
low	O
.	O

Young	O
fish	O
(	O
Oreochromis	O
mossambicus	O
)	O
were	O
exposed	O
to	O
microgravity	O
(	O
mug	O
)	O
for	O
9	O
to	O
10	O
days	O
during	O
space	O
missions	O
STS	O
-	O
55	O
and	O
STS	O
-	O
84	O
,	O
or	O
to	O
hypergravity	O
(	O
hg	O
)	O
for	O
9	O
days	O
.	O

Both	O
the	O
MVBF	O
and	O
the	O
maximum	O
EMG	O
activity	O
in	O
the	O
right	O
masseter	O
and	O
the	O
left	O
anterior	O
temporalis	O
muscles	O
were	O
significantly	O
decreased	O
during	O
muscle	O
pain	O
when	O
the	O
subjects	O
bit	O
on	O
the	O
painful	O
side	O
.	O

Molecular	O
cloning	O
of	O
rat	B-protein
SH2	I-protein
-	I-protein
containing	I-protein
inositol	I-protein
phosphatase	I-protein
2	I-protein
(	O
SHIP2	B-protein
)	O
and	O
its	O
role	O
in	O
the	O
regulation	O
of	O
insulin	B-protein
signaling	O
.	O

The	O
C	O
-	O
terminal	O
region	O
contains	O
the	O
PTP	B-protein
-	I-protein
like	I-protein
domain	I-protein
,	O
whereas	O
the	O
N	O
-	O
terminal	O
region	O
shows	O
no	O
homology	O
to	O
any	O
known	O
mammalian	O
protein	O
.	O

Selective	O
activation	O
of	O
adrenaline	O
secretion	O
by	O
the	O
rat	O
adrenal	O
in	O
neuroglycopenia	O
detected	O
via	O
microdialysis	O
.	O

A	O
limited	O
sampling	O
strategy	O
was	O
used	O
based	O
on	O
a	O
bayesian	O
parameter	O
estimation	O
algorithm	O
that	O
is	O
part	O
of	O
the	O
ADAPT	O
II	O
software	O
package	O
.	O

A	O
single	O
base	O
change	O
(	O
A8G	O
)	O
in	O
either	O
sequence	O
reduces	O
hnRNP	B-protein
A2	I-protein
binding	O
and	O
,	O
in	O
the	O
case	O
of	O
A2RE	B-protein
-	I-protein
2	I-protein
,	O
inhibits	O
RNA	O
transport	O
.	O

Halothane	O
is	O
metabolized	O
by	O
an	O
oxidative	O
pathway	O
to	O
stable	O
,	O
nonvolatile	O
end	O
products	O
,	O
trifluoroacetic	O
acid	O
(	O
TFAA	O
)	O
and	O
bromide	O
(	O
Br	O
-	O
)	O
,	O
and	O
by	O
reductive	O
pathways	O
to	O
Br	O
-	O
and	O
inorganic	O
fluoride	O
(	O
F	O
-	O
)	O
.	O

We	O
have	O
cloned	O
a	O
kinase	O
,	O
Nlk	B-protein
,	O
that	O
is	O
a	O
murine	B-protein
homolog	I-protein
of	I-protein
the	I-protein
Drosophila	I-protein
nemo	I-protein
(	O
nmo	B-protein
)	O
gene	O
.	O

The	O
UV	O
induction	O
of	O
c	B-protein
-	I-protein
jun	I-protein
is	O
mediated	O
by	O
two	O
UV	B-protein
response	I-protein
elements	I-protein
consisting	O
of	O
AP	B-protein
-	I-protein
1	I-protein
-	I-protein
like	I-protein
sequences	I-protein
within	O
its	O
5	O
'	O
control	O
region	O
.	O

We	O
found	O
that	O
TCR	B-protein
signaling	O
induces	O
AP	B-protein
-	I-protein
1	I-protein
binding	O
to	O
this	O
site	O
and	O
regulates	O
the	O
fasl	B-protein
promoter	I-protein
function	O
in	O
a	O
fashion	O
dependent	O
on	O
NF	B-protein
-	I-protein
kappaB	I-protein
binding	O
.	O

Specifically	O
,	O
I	O
use	O
molecular	O
markers	O
that	O
identify	O
particular	O
neuroectodermal	O
domains	O
,	O
all	O
neuroblasts	O
or	O
individual	O
neuroblasts	O
,	O
to	O
show	O
that	O
in	O
DER	B-protein
mutant	I-protein
embryos	O
(	O
1	O
)	O
intermediate	O
column	O
neuroblasts	O
do	O
not	O
form	O
,	O
(	O
2	O
)	O
medial	O
column	O
neuroblasts	O
often	O
acquire	O
identities	O
inappropriate	O
for	O
their	O
position	O
,	O
while	O
(	O
3	O
)	O
lateral	O
neuroblasts	O
develop	O
normally	O
.	O

The	O
primary	O
structure	O
of	O
the	O
GAL7	B-protein
5	I-protein
'	I-protein
flanking	I-protein
region	I-protein
has	O
many	O
features	O
common	O
to	O
those	O
of	O
multicellular	O
eukaryotic	O
genes	O
.	O

Hisako	O
Minowa	O
who	O
has	O
worked	O
as	O
a	O
psychiatric	O
counsellor	O
in	O
industry	O
for	O
the	O
past	O
20	O
years	O
.	O

Finally	O
,	O
nonphotosynthetic	O
mutants	O
,	O
including	O
the	O
tscA	B-protein
-	I-protein
lacking	I-protein
photosystem	I-protein
I	I-protein
mutant	I-protein
,	O
H13	O
,	O
did	O
not	O
show	O
evidence	O
of	O
light	O
-	O
stimulated	O
RNA	O
processing	O
.	O

Under	O
the	O
same	O
hematocrit	O
and	O
flow	O
conditions	O
,	O
the	O
rate	O
of	O
oxygen	O
saturation	O
decrease	O
was	O
significantly	O
higher	O
for	O
the	O
sickle	O
cells	O
than	O
for	O
normal	O
cells	O
.	O

The	O
syncytial	O
microvillous	O
projections	O
seemed	O
to	O
be	O
more	O
numerous	O
and	O
longer	O
in	O
CNF	O
,	O
otherwise	O
the	O
structure	O
of	O
the	O
trophoblastic	O
layer	O
of	O
the	O
villi	O
and	O
the	O
lining	O
of	O
the	O
subtrophoblastic	O
vessels	O
were	O
identical	O
in	O
CNF	O
and	O
controls	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
define	O
the	O
mechanism	O
for	O
the	O
respiratory	O
inhibition	O
observed	O
during	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
.	O

These	O
cells	O
averaged	O
17	O
microns	O
in	O
diameter	O
and	O
reproduced	O
by	O
fission	O
,	O
forming	O
clusters	O
of	O
two	O
or	O
four	O
daughter	O
cells	O
.	O

Then	O
we	O
correlated	O
HRCT	O
findings	O
with	O
the	O
clinical	O
features	O
,	O
pulmonary	O
functions	O
and	O
methacholine	O
PC20	O
(	O
PC20M	O
)	O
and	O
studied	O
their	O
clinical	O
significance	O
.	O

The	O
regulatory	O
region	O
also	O
has	O
a	O
sequence	O
similar	O
to	O
the	O
binding	O
site	O
for	O
a	O
liver	O
-	O
specific	O
transcription	O
factor	O
,	O
hepatocyte	B-protein
nuclear	I-protein
factor	I-protein
1	I-protein
(	O
HNF	B-protein
-	I-protein
1	I-protein
)	O
,	O
at	O
positions	O
-	O
120	O
to	O
-	O
132	O
.	O

Deletion	O
mutagenesis	O
demonstrated	O
that	O
these	O
two	O
elements	O
are	O
involved	O
in	O
the	O
positive	O
regulation	O
of	O
MLC	B-protein
-	I-protein
2	I-protein
gene	I-protein
transcription	O
.	O

Horseradish	B-protein
peroxidase	I-protein
as	O
a	O
permeability	O
marker	O
in	O
injured	O
rat	O
caudal	O
and	O
iliac	O
arteries	O
.	O

Recent	O
investigations	O
have	O
detailed	O
a	O
selective	O
dye	O
release	O
technique	O
in	O
which	O
a	O
pulse	O
of	O
laser	O
light	O
induces	O
the	O
release	O
of	O
a	O
fluorescent	O
dye	O
from	O
temperature	O
-	O
sensitive	O
liposomes	O
circulating	O
in	O
the	O
retinal	O
vasculature	O
.	O

No	O
therapy	O
exists	O
for	O
halting	O
the	O
progression	O
of	O
the	O
disease	O
with	O
the	O
possible	O
exception	O
of	O
laser	O
photocoagulation	O
treatment	O
used	O
to	O
ablate	O
subretinal	O
neovascular	O
membranes	O
in	O
an	O
attempt	O
to	O
avoid	O
complications	O
of	O
subretinal	O
hemorrhages	O
.	O

Association	O
of	O
stress	O
during	O
delivery	O
with	O
increased	O
numbers	O
of	O
nucleated	O
cells	O
and	O
hematopoietic	O
progenitor	O
cells	O
in	O
umbilical	O
cord	O
blood	O
.	O

The	O
pharmacokinetic	O
parameters	O
which	O
helped	O
predict	O
these	O
toxicities	O
included	O
area	O
under	O
the	O
curve	O
and	O
peak	O
plasma	O
level	O
.	O

In	O
contrast	O
,	O
capsid	O
proteins	O
derived	O
from	O
the	O
P1	B-protein
precursor	I-protein
with	O
a	O
valine	O
substitution	O
at	O
the	O
amino	O
terminus	O
of	O
VP1	B-protein
(	O
VP1	B-protein
-	I-protein
G001V	I-protein
)	O
assembled	O
empty	O
capsid	O
particles	O
but	O
were	O
deficient	O
in	O
assembling	O
RNA	O
-	O
containing	O
virions	O
.	O

The	O
glial	O
cyst	O
wall	O
was	O
lined	O
in	O
part	O
by	O
flattened	O
or	O
cuboidal	O
epithelium	O
.	O

Analysis	O
of	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
gene	O
also	O
revealed	O
the	O
presence	O
of	O
multiple	O
TATA	O
and	O
CAAT	O
sequences	O
.	O

In	O
the	O
infected	O
neonates	O
serum	O
alpha	B-protein
-	I-protein
amylase	I-protein
value	O
,	O
as	O
determined	O
by	O
the	O
blue	O
starch	O
method	O
,	O
was	O
only	O
40	O
%	O
that	O
of	O
healthy	O
controls	O
;	O
the	O
mean	O
value	O
of	O
175	O
.	O
1	O
+	O
/	O
-	O
64	O
.	O
9	O
IU	O
/	O
l	O
for	O
healthy	O
neonates	O
was	O
significantly	O
higher	O
(	O
p	O
less	O
than	O
0	O
.	O
0010	O
)	O
than	O
the	O
value	O
of	O
82	O
.	O
8	O
+	O
/	O
-	O
44	O
.	O
4	O
IU	O
/	O
l	O
for	O
the	O
infected	O
neonates	O
.	O

Motivational	O
factors	O
focusing	O
on	O
attitudes	O
,	O
perceived	O
susceptibility	O
to	O
pregnancy	O
,	O
and	O
normative	O
factors	O
were	O
also	O
relevant	O
.	O

The	O
abscess	O
was	O
debrided	O
and	O
the	O
septum	O
was	O
patched	O
with	O
a	O
single	O
layer	O
of	O
autologous	O
pericardium	O
.	O

In	O
wild	O
-	O
type	O
cells	O
,	O
SSM1b	B-protein
transcripts	I-protein
accumulate	O
to	O
twice	O
the	O
level	O
of	O
SSM1a	B-protein
transcripts	I-protein
,	O
suggesting	O
that	O
SSM1b	B-protein
is	O
responsible	O
for	O
the	O
majority	O
of	O
the	O
Ssm1p	B-protein
pool	O
.	O

There	O
was	O
either	O
no	O
change	O
or	O
an	O
improvement	O
in	O
renographic	O
findings	O
(	O
t1	O
/	O
2	O
time	O
and	O
/	O
or	O
split	O
function	O
)	O
in	O
40	O
patients	O
(	O
93	O
%	O
)	O
.	O

Biochemical	O
analysis	O
reveals	O
that	O
KS1	B-protein
is	O
a	O
nuclear	O
protein	O
containing	O
two	O
transcriptional	O
repressor	O
domains	O
,	O
R1	B-protein
and	O
R2	B-protein
.	O

To	O
gain	O
insight	O
into	O
the	O
expression	O
of	O
the	O
AtCP1	B-protein
gene	I-protein
,	O
northern	O
blot	O
analysis	O
was	O
carried	O
out	O
.	O

These	O
TxRE	B-protein
contain	O
cyclic	B-protein
AMP	I-protein
-	I-protein
responsive	I-protein
elements	I-protein
(	O
CRE	B-protein
)	O
,	O
but	O
,	O
remarkably	O
,	O
the	O
`	B-protein
`	I-protein
TGACGTCA	I-protein
'	I-protein
'	I-protein
consensus	I-protein
is	O
never	O
strictly	O
conserved	O
in	O
any	O
viral	O
strain	O
(	O
e	O
.	O
g	O
.	O
,	O
AGACGTCA	O
,	O
TGACGGCA	B-protein
,	O
TGACCTCA	B-protein
)	O
.	O

Three	O
large	O
field	O
placement	O
errors	O
(	O
two	O
patients	O
with	O
11	O
.	O
5	O
and	O
16	O
.	O
0	O
mm	O
distances	O
of	O
the	O
planned	O
versus	O
simulated	O
isocenter	O
,	O
respectively	O
and	O
one	O
patient	O
with	O
a	O
7	O
degree	O
rotational	O
error	O
)	O
were	O
detected	O
and	O
,	O
as	O
with	O
the	O
smaller	O
errors	O
,	O
were	O
immediately	O
corrected	O
.	O

Natl	O
.	O

The	O
sequencing	O
of	O
the	O
conditional	O
lethal	O
mutation	O
ts	O
-	O
A13	O
,	O
localized	O
in	O
the	O
nrdE	B-protein
cistron	I-protein
,	O
and	O
the	O
lethality	O
of	O
insertional	O
mutations	O
targeted	O
in	O
the	O
internal	O
region	O
of	O
nrdE	B-protein
and	O
nrdF	B-protein
,	O
demonstrated	O
the	O
essential	O
role	O
of	O
this	O
locus	O
.	O

RESULTS	O
:	O
We	O
identified	O
a	O
full	O
-	O
length	O
cDNA	O
with	O
an	O
open	O
reading	O
frame	O
of	O
2883	O
bp	O
corresponding	O
to	O
a	O
predicted	O
protein	O
of	O
961	O
amino	O
acids	O
that	O
shares	O
greater	O
than	O
95	O
%	O
homology	O
with	O
the	O
rat	B-protein
gamma	I-protein
-	I-protein
aminobutyric	I-protein
acid	I-protein
B	I-protein
(	I-protein
GABAB	I-protein
)	I-protein
receptor	I-protein
.	O

The	O
FinO	B-protein
protein	I-protein
of	O
IncF	O
plasmids	O
binds	O
FinP	B-protein
antisense	I-protein
RNA	I-protein
and	O
its	O
target	O
,	O
traJ	B-protein
mRNA	I-protein
,	O
and	O
promotes	O
duplex	O
formation	O
.	O

Because	O
of	O
the	O
operon	O
structure	O
of	O
this	O
organism	O
,	O
traditional	O
methods	O
such	O
as	O
insertional	O
mutagenesis	O
run	O
the	O
risk	O
of	O
introducing	O
polar	O
effects	O
on	O
downstream	O
genes	O
or	O
creating	O
secondary	O
mutations	O
elsewhere	O
in	O
the	O
genome	O
.	O

The	O
analysis	O
of	O
the	O
prevalence	O
values	O
shows	O
clearly	O
that	O
the	O
global	O
MS	O
-	O
frequency	O
is	O
closer	O
related	O
to	O
the	O
geomagnetic	O
than	O
to	O
the	O
geographic	O
latitude	O
.	O

A	O
single	O
rectal	O
dose	O
of	O
25	O
mg	O
/	O
kg	O
will	O
obtain	O
this	O
lower	O
concentration	O
within	O
1	O
h	O
of	O
administration	O
and	O
maintain	O
it	O
for	O
up	O
to	O
6	O
h	O
.	O

During	O
a	O
single	O
LAD	O
occlusion	O
lasting	O
35	O
minutes	O
(	O
series	O
I	O
,	O
n	O
=	O
10	O
)	O
9	O
microns	O
TMs	O
were	O
infused	O
immediately	O
and	O
30	O
minutes	O
after	O
ligation	O
,	O
15	O
microns	O
TMs	O
being	O
infused	O
after	O
15	O
-	O
20	O
minutes	O
.	O

Selective	O
translation	O
initiation	O
by	O
ribosome	O
jumping	O
in	O
adenovirus	O
-	O
infected	O
and	O
heat	O
-	O
shocked	O
cells	O
.	O

The	O
median	O
durations	O
for	O
response	O
and	O
survival	O
time	O
in	O
the	O
late	O
phase	O
II	O
trial	O
were	O
2	O
.	O
3	O
months	O
and	O
5	O
.	O
8	O
months	O
,	O
respectively	O
.	O

None	O
of	O
the	O
five	O
proprotein	O
processing	O
proteases	B-protein
tested	O
were	O
capable	O
of	O
cleaving	O
human	B-protein
pro	I-protein
-	I-protein
LPH	I-protein
,	O
strongly	O
suggesting	O
that	O
they	O
are	O
not	O
involved	O
in	O
the	O
maturation	O
of	O
this	O
enzyme	O
.	O

Single	O
-	O
alanine	O
-	O
substitution	O
mutations	O
had	O
minimal	O
,	O
if	O
any	O
,	O
effects	O
on	O
S	O
-	O
induced	O
cell	O
-	O
to	O
-	O
cell	O
fusion	O
.	O

Examination	O
of	O
the	O
immediate	O
sequence	O
5	O
'	O
to	O
the	O
mRNA	O
start	O
site	O
reveals	O
no	O
TATA	O
box	O
and	O
multiple	O
known	O
enhancer	O
sequences	O
.	O

We	O
show	O
that	O
LexA	B-protein
-	I-protein
GAL4	I-protein
and	O
LexA	B-protein
-	I-protein
Bicoid	I-protein
fusion	I-protein
proteins	I-protein
are	O
both	O
dependent	O
on	O
SNF2	B-protein
,	O
SNF5	B-protein
,	O
and	O
SNF6	B-protein
for	O
activation	O
of	O
target	O
genes	O
containing	O
one	O
or	O
multiple	O
lexA	B-protein
operators	I-protein
.	O

Alternative	O
transcript	O
of	O
the	O
nonselective	O
-	O
type	O
endothelin	B-protein
receptor	I-protein
from	O
rat	O
brain	O
.	O

The	O
incidence	O
of	O
cryptosporidiosis	O
in	O
young	O
children	O
was	O
determined	O
by	O
staining	O
of	O
faecal	O
specimens	O
with	O
a	O
modified	O
Kinyoun	O
stain	O
.	O

To	O
begin	O
to	O
characterize	O
the	O
role	O
of	O
the	O
RNA	B-protein
subunits	I-protein
in	O
enzyme	O
function	O
and	O
substrate	O
specificity	O
,	O
we	O
swapped	O
two	O
hairpin	O
structures	O
(	O
MRP3	B-protein
and	O
P3	B-protein
)	O
between	O
RNase	B-protein
MRP	I-protein
RNA	I-protein
and	O
RNase	B-protein
P	I-protein
RNA	I-protein
of	I-protein
S	I-protein
.	I-protein
cerevisiae	I-protein
.	O

The	O
central	O
visual	O
fields	O
of	O
2165	O
normal	O
and	O
106	O
glaucoma	O
eyes	O
were	O
measured	O
using	O
a	O
threshold	O
related	O
suprathreshold	O
strategy	O
.	O

Thus	O
,	O
we	O
have	O
identified	O
an	O
activation	O
target	O
of	O
a	O
human	O
activator	O
,	O
Oct	B-protein
-	I-protein
1	I-protein
,	O
within	O
its	O
cognate	O
basal	O
transcription	O
complex	O
.	O

Comparisons	O
with	O
other	O
known	O
germins	B-protein
and	O
germin	B-protein
-	I-protein
like	I-protein
proteins	I-protein
indicate	O
that	O
these	O
Arabidopsis	O
GLP	B-protein
subfamilies	O
are	O
unique	O
from	O
wheat	O
germin	B-protein
.	O

Bone	O
marrow	O
abnormalities	O
in	O
Hodgkin	O
'	O
s	O
disease	O
are	O
reviewed	O
and	O
the	O
current	O
understanding	O
of	O
the	O
pathological	O
mechanisms	O
leading	O
to	O
aplastic	O
anemia	O
is	O
discussed	O
.	O

For	O
this	O
purpose	O
,	O
the	O
immediate	O
and	O
the	O
final	O
(	O
after	O
swelling	O
)	O
fixation	O
strengths	O
of	O
two	O
variations	O
of	O
the	O
swellable	O
bone	O
anchor	O
designs	O
(	O
a	O
smooth	O
anchor	O
and	O
a	O
screw	O
anchor	O
)	O
were	O
measured	O
in	O
two	O
different	O
foams	O
(	O
used	O
to	O
simulate	O
bone	O
)	O
with	O
different	O
densities	O
.	O

Similar	O
observations	O
were	O
made	O
with	O
unilateral	O
pneumothorax	O
of	O
15	O
cmH2O	O
for	O
30	O
min	O
.	O

The	O
unphosphorylated	O
form	O
of	O
RNA	B-protein
polymerase	I-protein
II	I-protein
is	O
designated	O
IIA	B-protein
,	O
whereas	O
the	O
phosphorylated	O
form	O
is	O
designated	O
IIO	B-protein
.	O

When	O
desipramine	O
was	O
injected	O
16	O
hrs	O
after	O
fluoxetine	O
injection	O
,	O
brain	O
levels	O
of	O
desipramine	O
were	O
no	O
longer	O
elevated	O
.	O

These	O
discoloration	O
'	O
s	O
can	O
be	O
treated	O
in	O
several	O
ways	O
but	O
up	O
to	O
lately	O
tooth	O
structure	O
had	O
to	O
be	O
removed	O
in	O
an	O
irreversible	O
manner	O
in	O
order	O
to	O
provide	O
sufficient	O
bulk	O
for	O
the	O
new	O
restorative	O
material	O
.	O

Outcome	O
of	O
severe	O
congenital	O
hypothyroidism	O
.	O

The	O
effect	O
of	O
L	O
-	O
methionine	O
supplementation	O
on	O
the	O
utilization	O
of	O
a	O
soy	O
protein	O
isolate	O
(	O
SPI	O
)	O
was	O
evaluated	O
by	O
short	O
-	O
term	O
nitrogen	O
balance	O
studies	O
in	O
young	O
women	O
.	O

It	O
was	O
demonstrated	O
that	O
the	O
processing	O
signals	O
in	O
the	O
transcript	O
,	O
i	O
.	O
e	O
.	O
both	O
donor	O
splice	O
sites	O
and	O
the	O
polyadenylation	O
site	O
located	O
in	O
the	O
muscle	O
-	O
specific	O
intron	O
,	O
have	O
to	O
be	O
weak	O
.	O

We	O
conclude	O
that	O
at	O
these	O
low	O
levels	O
studied	O
,	O
aluminum	O
accumulates	O
in	O
intestinal	O
tissue	O
,	O
and	O
that	O
this	O
accumulation	O
is	O
enhanced	O
by	O
citrate	O
ligand	O
.	O

The	O
Rlm1	B-protein
protein	I-protein
,	O
a	O
member	O
of	O
the	O
MADS	B-protein
box	I-protein
family	I-protein
of	O
transcription	O
factors	O
,	O
functions	O
downstream	O
of	O
Mpk1	B-protein
in	O
the	O
pathway	O
.	O

Incorporation	O
of	O
the	O
polyene	O
antibiotic	O
amphotericin	O
B	O
(	O
AMB	O
)	O
in	O
liposomes	O
results	O
in	O
a	O
marked	O
reduction	O
in	O
drug	O
toxicity	O
with	O
no	O
loss	O
of	O
antifungal	O
potency	O
.	O

Expression	O
of	O
constitutively	O
active	O
MEK1	B-protein
,	O
the	O
kinase	O
that	O
activates	O
ERKs	B-protein
,	O
or	O
overexpression	O
of	O
ERK2	B-protein
,	O
but	O
not	O
JNK1	B-protein
,	O
inhibited	O
Stat3	B-protein
activation	O
.	O

Serum	B-protein
amylase	I-protein
became	O
markedly	O
elevated	O
(	O
2	O
,	O
624	O
CU	O
/	O
100	O
ml	O
)	O
,	O
as	O
did	O
the	O
serum	O
FFA	O
(	O
29	O
.	O
19	O
mEq	O
/	O
liter	O
)	O
.	O

Multivariate	O
predictors	O
were	O
concentric	O
remodeling	O
(	O
P	O
<	O
0	O
.	O
0001	O
;	O
odds	O
ratio	O
,	O
13	O
.	O
5	O
)	O
,	O
left	O
ventricular	O
ejection	O
fraction	O
>	O
2	O
SD	O
above	O
normal	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
,	O
and	O
single	O
-	O
vessel	O
left	O
circumflex	O
disease	O
(	O
P	O
<	O
0	O
.	O
0007	O
;	O
odds	O
ratio	O
,	O
7	O
.	O
6	O
)	O
.	O

Restriction	B-protein
enzyme	I-protein
and	O
heteroduplex	O
analyses	O
confirmed	O
that	O
sequences	O
unique	O
to	O
FeSV	O
(	O
src	B-protein
sequences	I-protein
)	O
are	O
located	O
at	O
the	O
center	O
of	O
the	O
FeSV	O
genome	O
and	O
are	O
approximately	O
1	O
.	O
5	O
kilobase	O
pairs	O
in	O
length	O
.	O

Similar	O
results	O
were	O
also	O
obtained	O
with	O
a	O
HepG2	O
hepatoblastoma	O
cell	O
line	O
carrying	O
wt	B-protein
p53	I-protein
.	O

Allagille	O
'	O
s	O
syndrome	O
associated	O
with	O
antenatal	O
ascites	O
.	O

Studies	O
on	O
the	O
hereditary	O
nature	O
of	O
sole	O
prints	O
-	O
-	O
with	O
special	O
reference	O
to	O
interdigital	O
and	O
triradii	O
.	O

We	O
infer	O
that	O
the	O
dominant	O
negative	O
inhibition	O
results	O
from	O
both	O
direct	O
proteolysis	O
of	O
the	O
beta	B-protein
-	I-protein
galactosidase	I-protein
tetramer	I-protein
by	O
the	O
fusion	O
subunit	O
and	O
detour	O
of	O
the	O
tetramer	O
to	O
the	O
lysosome	O
.	O

Exposure	O
to	O
hepatitis	O
B	O
virus	O
in	O
the	O
general	O
population	O
of	O
Hisayama	O
,	O
Japan	O
:	O
significance	O
of	O
isolated	O
antibody	O
to	O
hepatitis	B-protein
B	I-protein
surface	I-protein
antigen	I-protein
in	O
general	O
population	O
.	O

The	O
correcting	O
action	O
of	O
tropatepine	O
hydrochloride	O
upon	O
the	O
extrapyramidal	O
effects	O
induced	O
by	O
neuroleptics	O
has	O
been	O
studied	O
in	O
32	O
acute	O
psychotic	O
states	O
.	O

From	O
August	O
1989	O
to	O
October	O
1990	O
,	O
83	O
pregnant	O
Chinese	O
women	O
were	O
the	O
subjects	O
for	O
measuring	O
the	O
levels	O
of	O
plasma	O
functional	O
antithrombin	B-protein
III	I-protein
(	O
AT	B-protein
III	I-protein
)	O
activity	O
.	O

Histochemistry	O
and	O
electron	O
microscopy	O
of	O
acute	O
liver	O
lesions	O
induced	O
by	O
Aflatoxin	B-protein
B1	I-protein
in	O
ducklings	O
.	O

Schedule	O
2	O
,	O
in	O
which	O
2	O
.	O
4	O
mg	O
/	O
kg	O
c	O
-	O
DDP	O
was	O
administered	O
immediately	O
before	O
X	O
-	O
ray	O
on	O
5	O
consecutive	O
days	O
produced	O
the	O
highest	O
degree	O
of	O
enhancement	O
of	O
radiation	O
effect	O
(	O
expressed	O
as	O
dose	O
-	O
effect	O
factor	O
)	O
;	O
and	O
the	O
next	O
greatest	O
enhancement	O
was	O
produced	O
by	O
12	O
mg	O
/	O
kg	O
c	O
-	O
DDP	O
administered	O
24	O
h	O
before	O
the	O
start	O
of	O
fractionated	O
daily	O
radiotherapy	O
.	O

ArgR	B-protein
was	O
shown	O
to	O
be	O
a	O
dimer	O
of	O
two	O
equal	O
subunits	O
,	O
each	O
with	O
a	O
molecular	O
mass	O
of	O
37	O
,	O
000	O
Da	O
.	O

The	O
transcription	B-protein
factor	I-protein
CHOP	I-protein
/	I-protein
GADD153	I-protein
gene	I-protein
is	O
induced	O
by	O
cellular	O
stress	O
and	O
is	O
involved	O
in	O
mediating	O
apoptosis	O
.	O

Ha	B-protein
-	I-protein
RasV12	I-protein
and	O
activated	O
proteins	O
in	O
both	O
the	O
extra	B-protein
-	I-protein
cellular	I-protein
regulated	I-protein
kinase	I-protein
(	O
ERK	B-protein
)	O
and	O
the	O
stress	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
(	O
SAPK	B-protein
)	O
or	O
Jun	B-protein
N	I-protein
-	I-protein
terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
cascades	O
independently	O
stimulated	O
PEA3	O
-	O
mediated	O
gene	O
expression	O
.	O

Salivary	O
sodium	O
,	O
calcium	O
,	O
and	O
magnesium	O
concentrations	O
were	O
significantly	O
higher	O
in	O
the	O
SLE	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
,	O
whereas	O
potassium	O
and	O
total	O
protein	O
concentrations	O
and	O
amylase	B-protein
activity	O
did	O
not	O
differ	O
significantly	O
from	O
the	O
controls	O
.	O

The	O
influenza	O
virus	O
NS1	B-protein
protein	O
is	O
a	O
unique	O
posttranscriptional	O
regulator	O
that	O
has	O
two	O
activities	O
:	O
inhibition	O
of	O
the	O
nuclear	O
export	O
of	O
poly	O
A	O
-	O
containing	O
mRNAs	O
and	O
inhibition	O
of	O
pre	O
-	O
mRNA	O
splicing	O
.	O

Homology	O
was	O
also	O
detected	O
between	O
the	O
putative	O
transit	O
peptide	O
sequence	O
of	O
cysteine	B-protein
synthase	I-protein
C	I-protein
and	O
other	O
mitochondrion	O
-	O
targeting	O
leader	O
sequences	O
.	O

Of	O
its	O
gene	O
products	O
,	O
E6	B-protein
binds	O
to	O
and	O
inactivates	O
p53	B-protein
tumor	I-protein
suppressor	I-protein
protein	I-protein
by	O
ubiquitin	O
/	O
proteasome	O
-	O
dependent	O
degradation	O
.	O

As	O
normal	O
B	O
cells	O
also	O
present	O
this	O
variant	O
,	O
the	O
mechanism	O
of	O
CD79b	B-protein
posttranscriptional	O
regulation	O
might	O
reflect	O
the	O
activation	O
stage	O
of	O
the	O
normal	O
B	O
cell	O
from	O
which	O
B	O
-	O
CLL	O
derives	O
.	O

On	O
the	O
other	O
hand	O
,	O
hepatic	O
arterial	O
infusion	O
therapy	O
prolongs	O
the	O
survival	O
of	O
H3	O
patients	O
only	O
.	O

C	O
.	O
,	O
Sun	O
,	O
J	O
.	O
,	O
Hsu	O
,	O
M	O
.	O
-	O
Y	O
.	O
,	O
Vallejo	O
-	O
Ramirez	O
,	O
J	O
.	O
,	O
Inouye	O
,	O
S	O
.	O
,	O
and	O
Inouye	O
,	O
M	O
.	O

Upstream	O
from	O
the	O
transcription	O
start	O
point	O
(	O
tsp	O
)	O
,	O
a	O
nucleotide	O
sequence	O
highly	O
homologous	O
to	O
the	O
consensus	O
sequence	O
motif	O
for	O
the	O
sigma	O
35	O
-	O
recognized	O
promoters	O
was	O
found	O
.	O

The	O
possible	O
origin	O
and	O
role	O
of	O
CSF	B-protein
prolactin	I-protein
are	O
discussed	O
.	O

We	O
also	O
found	O
an	O
eIF	B-protein
-	I-protein
4A	I-protein
intronless	O
retroposon	O
which	O
,	O
when	O
compared	O
to	O
the	O
cDNA	O
,	O
contains	O
a	O
single	O
nucleotide	O
difference	O
.	O

High	O
levels	O
of	O
C	O
subunits	O
are	O
observed	O
in	O
several	O
subsequent	O
larval	O
and	O
adult	O
stages	O
of	O
development	O
.	O

These	O
alternative	O
splice	O
variants	O
were	O
detected	O
in	O
RNA	O
isolated	O
from	O
several	O
sources	O
,	O
including	O
primary	O
leptomeningeal	O
tissue	O
and	O
an	O
established	O
line	O
of	O
leptomeningeal	O
cells	O
(	O
LMC	O
)	O
.	O

On	O
the	O
basis	O
of	O
S1	B-protein
nuclease	I-protein
protection	O
analysis	O
of	O
RNA	O
preparations	O
from	O
several	O
mouse	O
tissues	O
,	O
both	O
dhfr	B-protein
and	O
divergent	O
genes	O
showed	O
similar	O
levels	O
of	O
expression	O
but	O
did	O
show	O
some	O
specificity	O
in	O
start	O
site	O
utilization	O
.	O

Forty	O
-	O
eight	O
10	O
-	O
12	O
-	O
week	O
-	O
old	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
randomized	O
to	O
receive	O
,	O
daily	O
for	O
28	O
days	O
:	O
(	O
1	O
)	O
CsA	O
vehicle	O
p	O
.	O
o	O
.	O
plus	O
FB	O
vehicle	O
sc	O
;	O
(	O
2	O
)	O
CsA	O
(	O
15	O
mg	O
/	O
kg	O
)	O
p	O
.	O
o	O
.	O
plus	O
FB	O
vehicle	O
sc	O
,	O
(	O
3	O
)	O
CsA	O
vehicle	O
p	O
.	O
o	O
.	O
plus	O
FB	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
)	O
sc	O
;	O
and	O
(	O
4	O
)	O
CsA	O
(	O
15	O
mg	O
/	O
kg	O
)	O
p	O
.	O
o	O
.	O
plus	O
FB	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
)	O
sc	O
.	O

Immunofluorescence	O
microscopy	O
and	O
cell	O
fractionation	O
analyses	O
showed	O
that	O
the	O
110	O
-	O
kDa	O
protein	O
was	O
exclusively	O
nuclear	O
,	O
whereas	O
the	O
150	O
-	O
kDa	O
protein	O
was	O
present	O
in	O
both	O
the	O
cytoplasm	O
and	O
nucleus	O
of	O
human	O
cells	O
.	O

The	O
properties	O
of	O
the	O
phi	B-protein
29	I-protein
SSB	I-protein
-	I-protein
ssDNA	I-protein
complex	O
are	O
described	O
.	O

Thus	O
,	O
although	O
multiple	O
senescence	O
pathways	O
are	O
activated	O
in	O
response	O
to	O
a	O
ras	B-protein
oncogene	I-protein
,	O
inactivation	O
of	O
TGFbeta1	B-protein
secretion	O
or	O
response	O
is	O
sufficient	O
to	O
block	O
the	O
senescence	O
program	O
.	O

Possible	O
factors	O
for	O
the	O
development	O
of	O
psychotic	O
symptomatology	O
during	O
group	O
activities	O
and	O
the	O
role	O
of	O
group	O
dynamics	O
acting	O
as	O
stress	O
factors	O
precipitating	O
functional	O
psychoses	O
,	O
especially	O
bipolar	O
manifestations	O
,	O
are	O
discussed	O
.	O

Upon	O
differentiation	O
with	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
transcription	O
of	O
the	O
Rex	B-protein
-	I-protein
1	I-protein
gene	I-protein
decreases	O
rapidly	O
.	O

They	O
were	O
found	O
to	O
stimulate	O
at	O
nanomolar	O
concentrations	O
the	O
turnover	O
of	O
biosynthetically	O
labeled	O
ceramide	O
,	O
glucosylceramide	O
,	O
and	O
lactosylceramide	O
.	O

The	O
low	O
molecular	O
mass	O
polypeptide	O
complex	O
is	O
assumed	O
to	O
be	O
involved	O
in	O
antigen	O
presentation	O
,	O
generating	O
peptides	O
from	O
cytosolic	O
protein	O
antigens	O
,	O
which	O
are	O
subsequently	O
presented	O
to	O
cytotoxic	O
T	O
-	O
lymphocytes	O
on	O
the	O
cell	O
surface	O
.	O

The	O
expression	O
of	O
this	O
clone	O
in	O
a	O
wee1	B-protein
/	I-protein
mik1	I-protein
-	I-protein
deficient	I-protein
mutant	I-protein
causes	O
an	O
elongated	O
cell	O
phenotype	O
under	O
non	O
-	O
permissive	O
growth	O
conditions	O
.	O

This	O
suggests	O
that	O
mechanisms	O
other	O
than	O
an	O
excessive	O
increase	O
in	O
myocardial	O
oxygen	O
demand	O
may	O
be	O
responsible	O
for	O
the	O
many	O
episodes	O
occurring	O
outside	O
the	O
hospital	O
.	O

These	O
results	O
provide	O
evidence	O
of	O
a	O
bypass	O
of	O
p53	O
-	O
induced	O
Waf1	O
/	O
Cip1	O
-	O
mediated	O
cell	O
cycle	O
regulatory	O
pathways	O
by	O
a	O
member	O
of	O
the	O
myb	B-protein
oncogene	I-protein
family	I-protein
.	O

The	O
4	O
-	O
AP	O
(	O
4	O
-	O
20	O
mM	O
)	O
effect	O
resulted	O
in	O
a	O
decrease	O
of	O
the	O
sensory	O
activity	O
,	O
which	O
was	O
fully	O
restored	O
by	O
TEA	O
or	O
Ba2	O
+	O
.	O

Cerebral	O
vasculitis	O
secondary	O
to	O
Crohn	O
'	O
s	O
disease	O
seems	O
to	O
be	O
a	O
very	O
rare	O
phenomenon	O
.	O

The	O
overall	O
prevalence	O
of	O
HBV	O
markers	O
was	O
higher	O
among	O
staff	O
members	O
than	O
in	O
the	O
blood	O
donors	O
of	O
our	O
area	O
.	O

The	O
routine	O
administration	O
of	O
fat	O
-	O
soluble	O
vitamins	O
appears	O
unnecessary	O
but	O
it	O
is	O
prudent	O
to	O
measure	O
prothrombin	B-protein
time	O
and	O
serum	O
vitamins	O
A	O
and	O
E	O
at	O
intervals	O
.	O

Many	O
cytokine	B-protein
receptors	I-protein
employ	O
Janus	B-protein
protein	I-protein
tyrosine	I-protein
kinases	I-protein
(	O
Jaks	B-protein
)	O
and	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	O
Stats	B-protein
)	O
for	O
nuclear	O
signaling	O
.	O

The	O
term	O
osteomesopycnosis	O
is	O
proposed	O
for	O
a	O
sclerosing	O
bone	O
disease	O
with	O
dominant	O
inheritance	O
that	O
has	O
been	O
discovered	O
in	O
five	O
members	O
of	O
four	O
different	O
families	O
.	O

Kss1	B-protein
binds	O
specifically	O
to	O
a	O
GST	B-protein
-	I-protein
Dig1	I-protein
fusion	O
in	O
the	O
absence	O
of	O
any	O
other	O
yeast	O
protein	O
.	O

Men	O
were	O
more	O
positive	O
about	O
their	O
physical	O
fitness	O
than	O
women	O
.	O

In	O
early	O
Xenopus	O
embryos	O
,	O
the	O
transforming	B-protein
growth	I-protein
factor	I-protein
-	I-protein
beta	I-protein
member	O
activin	B-protein
induces	O
the	O
gene	B-protein
Mix	I-protein
.	I-protein
2	I-protein
by	O
stimulating	O
the	O
formation	O
of	O
a	O
multiprotein	O
complex	O
,	O
activin	B-protein
-	I-protein
responsive	I-protein
factor	I-protein
(	O
ARF	B-protein
)	O
.	O

W	O
.	O

Described	O
X	O
-	O
ray	O
projection	O
were	O
performed	O
in	O
70	O
patients	O
.	O

The	O
C	O
/	O
D	O
ratio	O
was	O
equal	O
to	O
or	O
over	O
0	O
.	O
6	O
in	O
9	O
cases	O
(	O
16	O
eyes	O
)	O
,	O
and	O
the	O
values	O
were	O
inconsistent	O
between	O
both	O
eyes	O
in	O
55	O
%	O
of	O
the	O
patients	O
.	O

In	O
addition	O
,	O
the	O
time	O
to	O
engraftment	O
was	O
significantly	O
shorter	O
in	O
the	O
amifostine	O
arm	O
in	O
both	O
cohorts	O
.	O

In	O
nucleus	O
ventralis	O
anterior	O
thalami	O
-	O
nucleus	O
ventralis	O
lateralis	O
thalami	O
neurons	O
with	O
an	O
inhibitory	O
input	O
from	O
nucleus	O
entopeduncularis	O
,	O
a	O
shortening	O
of	O
inhibition	O
from	O
17	O
.	O
5	O
+	O
/	O
-	O
3	O
.	O
6	O
to	O
9	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
8	O
ms	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
under	O
the	O
haloperidol	O
influence	O
was	O
evident	O
.	O

The	O
expression	O
of	O
the	O
yam8	B-protein
(	I-protein
+	I-protein
)	I-protein
cDNA	I-protein
in	O
the	O
mid1	B-protein
mutant	I-protein
cells	O
partially	O
remediated	O
the	O
mid	O
phenotype	O
and	O
resulted	O
in	O
a	O
slight	O
increase	O
in	O
Ca	O
(	O
2	O
+	O
)	O
uptake	O
activity	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
overall	O
performance	O
of	O
a	O
new	O
oscillometric	O
wrist	O
blood	O
pressure	O
monitor	O
(	O
Braun	O
PrecisionSensor	O
,	O
Braun	O
GmbH	O
,	O
Kronberg	O
,	O
Germany	O
)	O
as	O
defined	O
by	O
the	O
ANSI	O
/	O
AAMI	O
SP10	O
-	O
1992	O
guidelines	O
,	O
and	O
to	O
analyze	O
the	O
data	O
for	O
the	O
optimized	O
selection	O
of	O
the	O
algorithm	O
that	O
derives	O
the	O
blood	O
pressure	O
values	O
from	O
the	O
oscillometric	O
blood	O
pressure	O
curves	O
.	O

Plasma	O
vitamin	O
E	O
,	O
total	O
lipids	O
and	O
myeloperoxidase	B-protein
levels	O
during	O
spinal	O
surgery	O
.	O

Is	O
radical	O
trachelectomy	O
a	O
safe	O
alternative	O
to	O
radical	O
hysterectomy	O
for	O
patients	O
with	O
stage	O
IA	O
-	O
B	O
carcinoma	O
of	O
the	O
cervix	O
?	O
BACKGROUND	O
:	O
The	O
prognosis	O
associated	O
with	O
lymph	O
node	O
negative	O
,	O
early	O
stage	O
carcinoma	O
of	O
the	O
cervix	O
is	O
excellent	O
,	O
with	O
5	O
-	O
year	O
survival	O
rates	O
greater	O
than	O
90	O
%	O
.	O

Cosmid	O
clones	O
containing	O
both	O
VNTR	B-protein
sequences	I-protein
were	O
identified	O
,	O
and	O
restriction	O
mapping	O
showed	O
them	O
to	O
be	O
less	O
than	O
15	O
kb	O
apart	O
.	O

Sip1	B-protein
was	O
initially	O
identified	O
by	O
virtue	O
of	O
its	O
interaction	O
with	O
SC35	B-protein
,	O
a	O
splicing	O
factor	O
of	O
the	O
SR	B-protein
family	I-protein
.	O

The	O
administration	O
of	O
the	O
GnRH	B-protein
agonist	O
reduced	O
the	O
bone	O
mineral	O
density	O
in	O
the	O
whole	O
femur	O
to	O
91	O
.	O
0	O
%	O
of	O
that	O
in	O
the	O
control	O
group	O
.	O

The	O
gene	O
for	O
the	O
RNA	B-protein
-	I-protein
dependent	I-protein
eIF	I-protein
-	I-protein
2	I-protein
alpha	I-protein
protein	I-protein
kinase	I-protein
(	O
PKR	B-protein
)	O
was	O
isolated	O
from	O
mouse	O
genomic	O
DNA	O
and	O
characterized	O
.	O

Basic	B-protein
fibroblast	I-protein
growth	I-protein
factor	I-protein
(	O
bFGF	B-protein
)	O
has	O
been	O
shown	O
to	O
induce	O
angiogenesis	O
in	O
various	O
animal	O
models	O
,	O
but	O
the	O
methods	O
of	O
administration	O
used	O
experimentally	O
are	O
not	O
clinically	O
feasible	O
.	O

1993	O
.	O

The	O
immunosuppressant	O
FK506	O
inhibits	O
amino	O
acid	O
import	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

LDL	B-protein
cholesterol	O
decreased	O
from	O
4	O
.	O
74	O
+	O
/	O
-	O
0	O
.	O
87	O
to	O
3	O
.	O
78	O
+	O
/	O
-	O
0	O
.	O
78	O
mmol	O
/	O
l	O
after	O
8	O
weeks	O
on	O
simvastatin	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
apo	B-protein
B	I-protein
fell	O
from	O
142	O
+	O
/	O
-	O
31	O
to	O
112	O
+	O
/	O
-	O
22	O
mg	O
/	O
dl	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

It	O
is	O
largely	O
predicted	O
by	O
lupus	O
anticoagulant	O
(	O
estimated	O
by	O
activated	O
partial	O
thromboplastin	B-protein
time	O
)	O
and	O
/	O
or	O
antibody	O
to	O
cardiolipin	O
.	O

The	O
effect	O
of	O
Vpu	B-protein
on	O
class	O
I	O
biogenesis	O
was	O
analyzed	O
in	O
more	O
detail	O
using	O
a	O
Vpu	O
-	O
expressing	O
recombinant	O
vaccinia	O
virus	O
(	O
VV	O
)	O
.	O

Following	O
the	O
observation	O
that	O
non	O
-	O
organ	O
-	O
specific	O
antibodies	O
are	O
related	O
with	O
pregnancy	O
loss	O
and	O
preeclampsia	O
,	O
the	O
role	O
of	O
organ	O
-	O
specific	O
antibodies	O
is	O
currently	O
being	O
extensively	O
investigated	O
.	O

Both	O
quantitative	O
and	O
qualitative	O
analysis	O
of	O
individual	O
cytoarchitectonic	O
peculiarities	O
of	O
Meynart	O
'	O
s	O
nucleus	O
as	O
well	O
as	O
of	O
external	O
part	O
of	O
dorsomedial	O
nucleus	O
of	O
thalamus	O
was	O
performed	O
in	O
mentally	O
normal	O
individuals	O
.	O

The	O
increased	O
clearance	O
observed	O
in	O
young	O
infants	O
is	O
in	O
contrast	O
to	O
other	O
opioids	O
.	O

We	O
also	O
observed	O
that	O
the	O
predictive	O
ability	O
of	O
the	O
selected	O
attitudes	O
and	O
orientations	O
increased	O
considerably	O
from	O
1975	O
to	O
1982	O
.	O

An	O
open	O
-	O
label	O
,	O
placebo	O
-	O
controlled	O
,	O
randomized	O
,	O
two	O
-	O
way	O
crossover	O
study	O
was	O
performed	O
in	O
12	O
healthy	O
volunteers	O
(	O
between	O
20	O
and	O
44	O
years	O
of	O
age	O
)	O
to	O
assess	O
the	O
effect	O
of	O
orlistat	O
,	O
a	O
gastrointestinal	B-protein
lipase	I-protein
inhibitor	O
that	O
reduces	O
dietary	O
fat	O
absorption	O
and	O
is	O
being	O
developed	O
for	O
weight	O
control	O
in	O
obesity	O
,	O
on	O
the	O
absorption	O
of	O
vitamins	O
A	O
and	O
E	O
.	O

LA	O
-	O
3848	O
-	O
MS	O
.	O

Renal	O
response	O
to	O
captopril	O
in	O
severe	O
heart	O
failure	O
:	O
role	O
of	O
furosemide	O
in	O
natriuresis	O
and	O
reversal	O
of	O
hyponatremia	O
.	O

Protein	O
splicing	O
:	O
evidence	O
for	O
an	O
N	O
-	O
O	O
acyl	O
rearrangement	O
as	O
the	O
initial	O
step	O
in	O
the	O
splicing	O
process	O
.	O

Because	O
the	O
deletion	O
included	O
the	O
TK	B-protein
gene	I-protein
,	O
selection	O
with	O
gancyclovir	O
against	O
cells	O
not	O
having	O
undergone	O
recombination	O
was	O
possible	O
.	O

We	O
conclude	O
that	O
class	O
I	O
cytologic	O
smears	O
with	O
moderate	O
to	O
severe	O
inflammation	O
may	O
be	O
associated	O
with	O
findings	O
of	O
condylomata	O
and	O
cervical	O
dysplasia	O
.	O

Epigenetic	O
switching	O
of	O
transcriptional	O
states	O
:	O
cis	O
-	O
and	O
trans	O
-	O
acting	O
factors	O
affecting	O
establishment	O
of	O
silencing	O
at	O
the	O
HMR	B-protein
locus	I-protein
in	O
Saccharomyces	O
cerevisiae	O
.	O

Flurazepam	O
thus	O
appears	O
to	O
be	O
an	O
effective	O
hypnotic	O
drug	O
with	O
the	O
optimum	O
dose	O
for	O
use	O
in	O
general	O
practice	O
being	O
15	O
mg	O
at	O
night	O
.	O

The	O
(	O
two	O
-	O
motif	O
)	O
domain	O
fold	O
contains	O
a	O
pair	O
of	O
calcium	O
binding	O
sites	O
very	O
similar	O
to	O
those	O
found	O
in	O
a	O
two	B-protein
-	I-protein
domain	I-protein
prokaryotic	I-protein
betagamma	I-protein
-	I-protein
crystallin	I-protein
fold	I-protein
family	I-protein
member	I-protein
,	O
Protein	B-protein
S	O
.	O

Surprisingly	O
,	O
the	O
results	O
of	O
several	O
experiments	O
suggest	O
that	O
the	O
TSF	B-protein
genes	I-protein
encode	O
global	O
regulatory	O
factors	O
.	O
tsf1	B-protein
to	O
tsf6	B-protein
mutations	O
derepressed	O
expression	O
from	O
yeast	B-protein
CYC	I-protein
-	I-protein
GAL	I-protein
hybrid	I-protein
promoters	I-protein
(	O
fused	O
to	O
lacZ	B-protein
)	O
that	O
harbor	O
a	O
variety	O
of	O
operator	O
sequences	O
,	O
and	O
caused	O
pleiotropic	O
defects	O
in	O
cell	O
growth	O
,	O
mating	O
,	O
and	O
sporulation	O
.	O

Characterization	O
of	O
these	O
R	O
subunits	O
by	O
their	O
8	O
-	O
azido	O
-	O
cAMP	O
photoaffinity	O
labeling	O
and	O
immunoreactivity	O
,	O
as	O
well	O
as	O
by	O
a	O
phosphorylation	O
-	O
dependent	O
mobility	O
shift	O
on	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
,	O
indicated	O
subunit	O
sizes	O
of	O
RII	B-protein
beta	I-protein
(	O
53	O
kDa	O
)	O
greater	O
than	O
RII	B-protein
alpha	I-protein
dephosphoform	O
(	O
51	O
kDa	O
)	O
greater	O
than	O
RI	B-protein
alpha	I-protein
(	O
49	O
kDa	O
)	O
.	O

In	O
general	O
lookback	O
,	O
all	O
patients	O
who	O
received	O
blood	O
before	O
being	O
tested	O
for	O
hepatitis	O
C	O
are	O
advised	O
to	O
undergo	O
testing	O
.	O

Closure	O
of	O
the	O
patent	O
ductus	O
arteriosus	O
with	O
a	O
Ligaclip	O
through	O
a	O
minithoracotomy	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
the	O
RP	B-protein
,	O
like	O
the	O
20S	B-protein
proteasome	I-protein
,	O
is	O
functionally	O
and	O
structurally	O
conserved	O
among	O
eukaryotes	O
and	O
indicate	O
that	O
the	O
plant	B-protein
RPT	I-protein
subunits	I-protein
,	O
like	O
their	O
yeast	O
counterparts	O
,	O
have	O
non	O
-	O
redundant	O
functions	O
.	O

Sequence	O
analysis	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
CD69	B-protein
gene	I-protein
revealed	O
the	O
presence	O
of	O
a	O
potential	O
TATA	O
element	O
30	O
base	O
pairs	O
upstream	O
of	O
the	O
major	O
transcription	O
initiation	O
site	O
and	O
several	O
putative	O
binding	O
sequences	O
for	O
inducible	O
transcription	O
factors	O
(	O
NF	B-protein
-	I-protein
kappa	I-protein
B	I-protein
,	O
Egr	B-protein
-	I-protein
1	I-protein
,	O
AP	B-protein
-	I-protein
1	I-protein
)	O
,	O
which	O
might	O
mediate	O
the	O
inducible	O
expression	O
of	O
this	O
gene	O
.	O

Histogenetic	O
aspects	O
of	O
mesoblastic	O
nephroma	O
.	O

The	O
C	O
-	O
terminal	O
end	O
of	O
this	O
polypeptide	O
harbors	O
three	O
types	O
of	O
repeated	O
sequences	O
.	O

All	O
patients	O
had	O
abnormal	O
von	B-protein
Willebrand	I-protein
factor	I-protein
(	O
vWF	B-protein
)	O
fragmentation	O
as	O
reflected	O
by	O
decreased	O
high	O
molecular	O
weight	O
and	O
increased	O
low	O
molecular	O
weight	O
vWF	B-protein
multimers	I-protein
in	O
the	O
circulation	O
.	O

Seventy	O
-	O
five	O
percent	O
of	O
children	O
who	O
received	O
a	O
second	O
transplant	O
for	O
HCV	O
hepatitis	O
had	O
early	O
histologic	O
recurrence	O
that	O
led	O
to	O
liver	O
failure	O
and	O
death	O
.	O

In	O
addition	O
to	O
the	O
bZIP	B-protein
protein	I-protein
Opaque2	I-protein
(	O
O2	B-protein
)	O
,	O
there	O
are	O
other	O
maize	O
endosperm	O
nuclear	O
proteins	O
that	O
recognize	O
the	O
O2	B-protein
box	I-protein
in	O
22	O
kDa	O
zein	B-protein
gene	O
promoters	O
.	O

Year	O
one	O
of	O
the	O
first	O
general	O
practitioner	O
medical	O
unit	O
in	O
the	O
greater	O
Glasgow	O
area	O
.	O

Serum	B-protein
ACTH	I-protein
did	O
not	O
respond	O
to	O
insulin	B-protein
and	O
metyrapone	O
.	O

Interestingly	O
,	O
an	O
antibody	O
against	O
N	B-protein
-	I-protein
SMase	I-protein
can	O
abrogate	O
Ox	O
-	O
LDL	O
-	O
and	O
TNF	O
-	O
alpha	O
-	O
induced	O
apoptosis	O
and	O
therefore	O
may	O
be	O
useful	O
for	O
in	O
vivo	O
studies	O
of	O
apoptosis	O
in	O
experimental	O
animals	O
.	O

During	O
exercise	O
,	O
the	O
Pes	O
-	O
Ves	O
relation	O
was	O
shifted	O
toward	O
the	O
left	O
and	O
the	O
slope	O
[	O
end	O
-	O
systolic	O
elastance	O
(	O
Ees	O
)	O
]	O
increased	O
from	O
7	O
.	O
7	O
+	O
/	O
-	O
2	O
.	O
8	O
to	O
12	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
2	O
(	O
SD	O
)	O
mmHg	O
/	O
ml	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
to	O
protein	O
binding	O
at	O
sequences	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
transcription	O
,	O
genomic	O
footprinting	O
of	O
the	O
entire	O
promoter	O
region	O
also	O
showed	O
that	O
a	O
protein	O
factor	O
is	O
constitutively	O
bound	O
to	O
the	O
first	O
intron	O
of	O
the	O
rep3	B-protein
gene	I-protein
.	O

The	O
parameters	O
of	O
nonspecific	O
humoral	O
immunity	O
-	O
-	O
serum	O
immunoglobulins	O
and	O
immune	O
complexes	O
-	O
-	O
were	O
evaluated	O
in	O
irradiated	O
group	O
of	O
patients	O
with	O
uterine	O
cervix	O
carcinoma	O
(	O
Stages	O
IIB	O
and	O
IIIB	O
)	O
,	O
during	O
one	O
year	O
follow	O
up	O
.	O

Preliminary	O
use	O
of	O
the	O
Nottingham	O
Eczema	O
Severity	O
Score	O
would	O
support	O
further	O
development	O
as	O
a	O
research	O
tool	O
for	O
a	O
simple	O
assessment	O
of	O
disease	O
severity	O
that	O
could	O
be	O
used	O
in	O
epidemiological	O
studies	O
.	O

The	O
order	O
of	O
the	O
helicase	B-protein
motif	I-protein
and	O
the	O
nsP3	B-protein
homology	I-protein
region	I-protein
in	O
the	O
RUB	O
genome	O
is	O
reversed	O
with	O
respect	O
to	O
the	O
alphavirus	O
genome	O
indicating	O
that	O
a	O
genetic	O
rearrangement	O
has	O
occurred	O
during	O
the	O
evolution	O
of	O
these	O
viruses	O
.	O

The	O
ORF1	O
protein	O
was	O
found	O
to	O
be	O
highly	O
homologous	O
to	O
the	O
putative	O
potexvirus	B-protein
RNA	I-protein
replicases	I-protein
;	O
ORF2	O
,	O
-	O
3	O
,	O
-	O
5	O
and	O
-	O
6	O
proteins	O
also	O
have	O
analogues	O
among	O
the	O
potex	O
-	O
and	O
/	O
or	O
carlavirus	O
-	O
encoded	O
proteins	O
.	O

The	O
regulation	O
of	O
Myf	B-protein
-	I-protein
5	I-protein
and	O
MyoD	B-protein
function	O
by	O
a	O
cAMP	O
-	O
dependent	O
pathway	O
may	O
partly	O
explain	O
how	O
external	O
signals	O
generated	O
by	O
serum	O
and	O
certain	O
peptide	B-protein
growth	I-protein
factors	I-protein
can	O
be	O
transduced	O
to	O
the	O
nucleus	O
and	O
inhibit	O
dominant	O
-	O
acting	O
factors	O
that	O
are	O
responsible	O
for	O
myoblast	O
differentiation	O
.	O

Together	O
,	O
our	O
data	O
suggest	O
that	O
the	O
TR2	B-protein
orphan	I-protein
receptor	I-protein
may	O
be	O
a	O
master	O
regulator	O
in	O
modulating	O
the	O
activation	O
of	O
two	O
key	O
HREs	O
,	O
RARE	B-protein
beta	I-protein
and	O
CRBPIIp	B-protein
,	O
involved	O
in	O
the	O
retinoic	O
acid	O
signal	O
transduction	O
pathway	O
.	O

CONCLUSIONS	O
:	O
These	O
routinely	O
collected	O
data	O
provided	O
quantitative	O
estimates	O
of	O
changes	O
in	O
CBZ	O
Cl	O
/	O
F	O
due	O
to	O
comedication	O
and	O
an	O
age	O
-	O
related	O
decrease	O
in	O
Cl	O
/	O
F	O
The	O
derived	O
regression	O
equations	O
reasonably	O
predicted	O
concentrations	O
in	O
a	O
separate	O
validation	O
set	O
.	O

We	O
show	O
here	O
that	O
the	O
binding	O
of	O
C1F	B-protein
in	O
vitro	O
is	O
sensitive	O
to	O
the	O
concentration	O
of	O
calcium	O
ions	O
.	O

Interestingly	O
,	O
following	O
induction	O
of	O
stress	O
by	O
heat	O
shock	O
,	O
high	O
salt	O
,	O
or	O
ethanol	O
,	O
conditions	O
under	O
which	O
most	O
mRNA	O
export	O
is	O
blocked	O
,	O
Npl3p	B-protein
is	O
still	O
exported	O
from	O
the	O
nucleus	O
.	O

After	O
a	O
baseline	O
study	O
,	O
WPW	O
syndrome	O
was	O
simulated	O
by	O
stimulation	O
at	O
seven	O
different	O
sites	O
around	O
the	O
base	O
of	O
the	O
ventricles	O
,	O
and	O
RNV	O
'	O
s	O
were	O
obtained	O
.	O

There	O
was	O
a	O
2	O
.	O
4	O
-	O
fold	O
difference	O
in	O
CAT	B-protein
produced	O
from	O
these	O
transcripts	O
in	O
HeLa	O
cells	O
,	O
which	O
contain	O
a	O
greater	O
natural	O
abundance	O
of	O
PTB	B-protein
.	O

We	O
speculate	O
that	O
these	O
tumors	O
may	O
represent	O
congenital	O
hamartomatous	O
growths	O
.	O

The	O
12	B-protein
,	I-protein
000	I-protein
MW	I-protein
(	I-protein
12K	I-protein
)	I-protein
IE	I-protein
polypeptide	I-protein
encoded	O
by	O
IEmRNA	B-protein
-	I-protein
5	I-protein
is	O
translated	O
from	O
an	O
88	O
codon	O
open	O
reading	O
frame	O
,	O
leaving	O
a	O
1200	O
base	O
3	O
'	O
non	O
-	O
translated	O
region	O
.	O

Evolutionary	O
relationships	O
among	O
putative	O
RNA	B-protein
-	I-protein
dependent	I-protein
RNA	I-protein
polymerases	I-protein
encoded	O
by	O
a	O
mitochondrial	O
virus	O
-	O
like	O
RNA	O
in	O
the	O
Dutch	O
elm	O
disease	O
fungus	O
,	O
Ophiostoma	O
novo	O
-	O
ulmi	O
,	O
by	O
other	O
viruses	O
and	O
virus	O
-	O
like	O
RNAs	O
and	O
by	O
the	O
Arabidopsis	O
mitochondrial	O
genome	O
.	O

Two	O
independent	O
promoters	O
as	O
well	O
as	O
5	O
'	O
untranslated	O
regions	O
regulate	O
Dd	B-protein
ras	I-protein
expression	O
in	O
Dictyostelium	O
.	O

Ischemia	O
-	O
induced	O
biphasic	O
arrhythmias	O
were	O
suppressed	O
in	O
both	O
zatebradine	O
and	O
propranolol	O
groups	O
.	O

Also	O
,	O
except	O
in	O
one	O
patient	O
who	O
developed	O
gallstones	O
following	O
institution	O
of	O
colestipol	O
,	O
saturation	O
of	O
gallbladder	O
bile	O
with	O
cholesterol	O
was	O
not	O
markedly	O
increased	O
by	O
this	O
drug	O
alone	O
.	O

Amino	O
acid	O
residues	O
147	O
-	O
167	O
of	O
the	O
previously	O
reported	O
sequence	O
are	O
replaced	O
by	O
new	O
residues	O
147	O
to	O
150	O
.	O

Morphofunctional	O
status	O
of	O
the	O
formed	O
elements	O
of	O
the	O
blood	O
in	O
rats	O
subjected	O
to	O
different	O
variants	O
of	O
combined	O
and	O
isolated	O
exposure	O
to	O
BR	O
-	O
1	O
benzene	O
.	O

Thus	O
in	O
this	O
region	O
of	O
the	O
vessel	O
pyridinoline	O
represents	O
the	O
major	O
stabilising	O
crosslink	O
of	O
collagen	B-protein
.	O

PhoP	B-protein
-	I-protein
PhoQ	I-protein
homologues	I-protein
in	I-protein
Pseudomonas	I-protein
aeruginosa	I-protein
regulate	O
expression	O
of	O
the	O
outer	B-protein
-	I-protein
membrane	I-protein
protein	I-protein
OprH	I-protein
and	O
polymyxin	O
B	O
resistance	O
.	O

Thus	O
,	O
both	O
YY1	B-protein
and	O
CDP	B-protein
appear	O
to	O
be	O
negative	O
regulators	O
of	O
the	O
differentiation	O
-	O
induced	O
HPV	B-protein
-	I-protein
6	I-protein
E1	I-protein
promoter	I-protein
and	O
thereby	O
the	O
HPV	O
life	O
cycle	O
.	O

DNA	O
strand	O
exchange	O
catalyzed	O
by	O
Rad51	B-protein
protein	I-protein
is	O
also	O
greatly	O
stimulated	O
by	O
RPA	B-protein
.	O

Htra2	B-protein
-	I-protein
beta3	I-protein
is	O
developmentally	O
regulated	O
and	O
expressed	O
predominantly	O
in	O
brain	O
,	O
liver	O
testis	O
,	O
and	O
weakly	O
in	O
kidney	O
.	O

Effects	O
of	O
nitrogen	O
(	O
PN2	O
:	O
5	O
and	O
14	O
MPa	O
)	O
and	O
helium	O
(	O
PHe	O
:	O
13	O
and	O
14	O
MPa	O
)	O
were	O
also	O
tested	O
.	O

Epidemiological	O
data	O
are	O
quite	O
controversial	O
but	O
sudden	O
death	O
occurring	O
during	O
sporting	O
activity	O
is	O
probably	O
not	O
a	O
rare	O
occurrence	O
.	O

A	O
similar	O
phenomenon	O
has	O
been	O
reported	O
in	O
a	O
few	O
humans	O
.	O

If	O
the	O
haemoglobin	B-protein
concentration	O
(	O
Hb	B-protein
)	O
was	O
less	O
than	O
12	O
g	O
dL	O
-	O
1	O
they	O
were	O
given	O
a	O
four	O
week	O
course	O
of	O
ferrous	O
sulphate	O
.	O

Therefore	O
,	O
we	O
have	O
identified	O
a	O
cis	O
-	O
acting	O
element	O
,	O
the	O
E1	B-protein
E	I-protein
-	I-protein
box	I-protein
,	O
located	O
in	O
the	O
GAP	B-protein
-	I-protein
43	I-protein
promoter	O
region	O
that	O
modulates	O
either	O
positively	O
or	O
negatively	O
the	O
expression	O
of	O
the	O
GAP	B-protein
-	I-protein
43	I-protein
gene	I-protein
depending	O
on	O
which	O
E	B-protein
-	I-protein
box	I-protein
-	I-protein
binding	I-protein
proteins	I-protein
occupy	O
this	O
site	O
.	O

Scanning	O
mutations	O
throughout	O
the	O
AC	B-protein
element	I-protein
interfered	O
with	O
induction	O
but	O
allowed	O
us	O
to	O
define	O
five	O
overlapping	O
sites	O
for	O
regulatory	O
factors	O
in	O
AC	B-protein
and	O
to	O
design	O
probes	O
binding	O
just	O
one	O
or	O
two	O
factors	O
.	O

Forty	O
-	O
five	O
patients	O
with	O
pleural	O
lesions	O
identified	O
on	O
CT	O
scans	O
were	O
subsequently	O
examined	O
by	O
MR	O
imaging	O
at	O
0	O
.	O
5	O
T	O
.	O

The	O
monoclonal	O
immunoglobulin	B-protein
products	O
of	O
plasma	O
cell	O
neoplasm	O
can	O
give	O
rise	O
to	O
a	O
variety	O
of	O
manifestations	O
including	O
hyperviscosity	O
,	O
amyloidosis	O
,	O
cryoglobulinemia	O
,	O
neuropathy	O
,	O
and	O
renal	O
failure	O
.	O

When	O
the	O
coding	O
segments	O
,	O
including	O
both	O
framework	O
and	O
complementarity	O
-	O
determining	O
regions	O
,	O
of	O
these	O
genes	O
and	O
the	O
murine	O
probe	O
sequences	O
are	O
compared	O
by	O
metric	O
analysis	O
,	O
it	O
is	O
apparent	O
that	O
the	O
caiman	B-protein
genes	I-protein
are	O
only	O
slightly	O
more	O
related	O
to	O
each	O
other	O
than	O
to	O
the	O
mammalian	O
sequence	O
,	O
consistent	O
with	O
significant	O
preservation	O
of	O
nucleotide	O
sequence	O
over	O
an	O
extended	O
period	O
of	O
phylogenetic	O
time	O
.	O

Behavioral	O
and	O
electrographic	O
expression	O
of	O
natural	O
sleep	O
and	O
wakefulness	O
in	O
reptiles	O
.	O

In	O
summary	O
,	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
activity	O
stimulates	O
G1	O
/	O
S	O
transition	O
in	O
immature	O
thymoblasts	O
and	O
maintains	O
cell	O
viability	O
via	O
transduction	O
of	O
constitutive	O
activation	O
signals	O
downstream	O
to	O
components	O
of	O
the	O
Ras	B-protein
/	I-protein
Raf	I-protein
/	I-protein
MAPK	I-protein
pathway	I-protein
.	O

A	O
prostaglandin	O
analogue	O
given	O
in	O
early	O
pregnancy	O
and	O
human	B-protein
chorionic	I-protein
gonadotropin	I-protein
given	O
near	O
the	O
end	O
of	O
the	O
ensuing	O
follicular	O
phase	O
were	O
used	O
for	O
controlling	O
the	O
reproductive	O
cycle	O
,	O
timing	O
oocyte	O
collection	O
,	O
and	O
synchronizing	O
the	O
cycles	O
of	O
oocyte	O
donors	O
and	O
embryo	O
recipients	O
.	O

However	O
,	O
an	O
intrinsic	O
DNA	O
-	O
binding	O
subunit	O
for	O
HiNF	B-protein
-	I-protein
D	I-protein
was	O
not	O
identified	O
.	O

Laboratory	O
exam	O
:	O
IDR	O
of	O
the	O
tuberculin	O
was	O
high	O
positive	O
,	O
chest	O
radiography	O
shows	O
hilar	O
bilateral	O
calcifications	O
,	O
ORL	O
exam	O
shows	O
a	O
tumor	O
at	O
the	O
foot	O
of	O
the	O
epiglottis	O
and	O
anatomopathological	O
exam	O
shows	O
low	O
differentiated	O
epidermoid	O
carcinoma	O
.	O

The	O
ORF	B-protein
4	I-protein
gene	I-protein
was	O
minimally	O
active	O
,	O
whereas	O
the	O
ORF	B-protein
62	I-protein
gene	I-protein
gave	O
twofold	O
induction	O
;	O
both	O
genes	O
,	O
acting	O
together	O
,	O
gave	O
fivefold	O
induction	O
.	O

We	O
have	O
separated	O
a	O
dermatan	O
sulfate	O
proteoglycan	O
,	O
epiphycan	O
,	O
from	O
decorin	O
and	O
biglycan	O
by	O
using	O
dissociative	O
extraction	O
of	O
bovine	O
fetal	O
epiphyseal	O
cartilage	O
,	O
followed	O
by	O
sequential	O
ion	O
-	O
exchange	O
,	O
gel	O
permeation	O
,	O
hydrophobic	O
,	O
and	O
Zn2	O
+	O
chelate	O
chromatographic	O
steps	O
.	O

In	O
vitro	O
transcription	O
assays	O
demonstrate	O
that	O
the	O
TCA	O
-	O
cycle	O
intermediate	O
,	O
fumarate	O
,	O
directly	O
and	O
specifically	O
inhibits	O
the	O
formation	O
of	O
the	O
clcA	B-protein
transcript	I-protein
.	O

Green	O
fluorescent	O
protein	O
-	O
tagged	O
UNC	B-protein
-	I-protein
49B	I-protein
and	O
UNC	B-protein
-	I-protein
49C	I-protein
subunits	I-protein
are	O
coexpressed	O
in	O
muscle	O
cells	O
and	O
are	O
colocalized	O
to	O
synaptic	O
regions	O
.	O

Effect	O
of	O
thrombotic	O
and	O
antithrombotic	O
drugs	O
on	O
the	O
surface	O
charge	O
characteristics	O
of	O
canine	O
blood	O
vessels	O
:	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
.	O

It	O
has	O
also	O
been	O
shown	O
that	O
a	O
variety	O
of	O
extracellular	O
factors	O
stimulate	O
a	O
pair	O
of	O
MAPK	B-protein
p44	I-protein
and	O
MAPK	B-protein
p42	I-protein
of	O
MAPK	B-protein
family	I-protein
members	I-protein
.	O

Constitutive	O
protection	O
of	O
E2F	B-protein
recognition	I-protein
sequences	I-protein
in	O
the	O
human	B-protein
thymidine	I-protein
kinase	I-protein
promoter	I-protein
during	O
cell	O
cycle	O
progression	O
.	O

These	O
contain	O
a	O
single	O
1977	O
-	O
bp	O
exon	O
that	O
encodes	O
900	O
bp	O
of	O
the	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
sequences	O
in	O
addition	O
to	O
a	O
1077	O
-	O
bp	O
open	O
reading	O
frame	O
identical	O
to	O
that	O
found	O
in	O
vascular	B-protein
smooth	I-protein
muscle	I-protein
cell	I-protein
AT1a	I-protein
receptor	I-protein
cDNAs	I-protein
.	O

These	O
factors	O
belong	O
to	O
a	O
set	O
of	O
genetically	O
distinct	O
molecules	O
,	O
including	O
AP	B-protein
-	I-protein
4	I-protein
and	O
MLTF	B-protein
,	O
that	O
bind	O
to	O
the	O
CACCTGTC	B-protein
motif	I-protein
or	O
related	O
sequences	O
.	O

Both	O
mutations	O
completely	O
abolished	O
binding	O
of	O
the	O
Abl	B-protein
SH3	I-protein
domain	I-protein
to	O
proline	O
-	O
rich	O
target	O
proteins	O
in	O
a	O
filter	O
-	O
binding	O
assay	O
.	O

These	O
patients	O
appear	O
to	O
have	O
slightly	O
better	O
pulmonary	O
function	O
and	O
nutritional	O
status	O
;	O
yet	O
,	O
they	O
seem	O
to	O
have	O
a	O
higher	O
degree	O
of	O
health	O
care	O
utilization	O
.	O

The	O
p53	B-protein
tumor	I-protein
suppressor	I-protein
gene	I-protein
product	I-protein
,	O
a	O
sequence	O
-	O
specific	O
DNA	O
-	O
binding	O
protein	O
,	O
has	O
been	O
shown	O
to	O
act	O
as	O
a	O
transcriptional	O
activator	O
and	O
repressor	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
PCr	O
resynthesis	O
rate	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
the	O
effective	O
maximal	O
rate	O
of	O
mitochondrial	O
ATP	O
synthesis	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
also	O
improved	O
.	O

Semidominant	O
mutations	O
in	O
the	O
yeast	B-protein
Rad51	I-protein
protein	I-protein
and	O
their	O
relationships	O
with	O
the	O
Srs2	B-protein
helicase	I-protein
.	O

The	O
cis	O
-	O
acting	O
elements	O
that	O
control	O
promoter	O
activity	O
include	O
binding	O
sites	O
for	O
transcription	O
factors	O
Sp1	B-protein
and	O
alphaCbf	B-protein
,	O
a	O
60	B-protein
-	I-protein
kDa	I-protein
CCAAT	I-protein
box	I-protein
-	I-protein
binding	I-protein
protein	I-protein
.	O

A	O
single	O
-	O
case	O
experimental	O
ABAB	O
multiple	O
baseline	O
design	O
was	O
employed	O
to	O
test	O
for	O
treatment	O
effectiveness	O
.	O

Histological	O
examination	O
showed	O
lichenoid	O
changes	O
,	O
acantholytic	O
blister	O
formation	O
and	O
apoptotic	O
keratinocytes	O
.	O

Patients	O
with	O
type	O
III	O
SOD	O
may	O
have	O
visceral	O
hyperalgesia	O
;	O
a	O
trial	O
of	O
antidepressants	O
or	O
a	O
therapeutic	O
trial	O
with	O
botulinum	B-protein
toxin	I-protein
injection	O
into	O
the	O
ampulla	O
should	O
be	O
considered	O
prior	O
to	O
more	O
invasive	O
endoscopic	O
therapy	O
.	O

Considering	O
that	O
the	O
reactor	O
is	O
thoroughly	O
mixed	O
during	O
each	O
discharge	O
and	O
that	O
LD50	O
=	O
0	O
.	O
9	O
values	O
are	O
nearly	O
independent	O
of	O
E	O
.	O
coli	O
concentrations	O
in	O
the	O
range	O
of	O
2	O
x	O
10	O
(	O
3	O
)	O
<	O
or	O
=	O
E	O
coli	O
/	O
cfu	O
mL	O
(	O
-	O
1	O
)	O
<	O
or	O
=	O
3	O
x	O
10	O
(	O
6	O
)	O
,	O
we	O
ascribe	O
the	O
nonexponential	O
Pn	O
decay	O
of	O
single	O
-	O
strain	O
E	O
.	O
coli	O
colonies	O
to	O
a	O
shielding	O
phenomenon	O
where	O
inactive	O
cells	O
protect	O
the	O
successively	O
smaller	O
numbers	O
of	O
viable	O
cells	O
in	O
the	O
EHD	O
.	O

Perturbation	O
of	O
dNTP	O
pools	O
also	O
affected	O
the	O
frameshift	O
fidelity	O
of	O
the	O
replicative	O
yeast	B-protein
DNA	I-protein
polymerase	I-protein
alpha	I-protein
.	O

Although	O
%	O
BF	O
was	O
correlated	O
with	O
all	O
the	O
BMIs	O
(	O
r	O
=	O
0	O
.	O
60	O
-	O
0	O
.	O
82	O
)	O
,	O
applying	O
objective	O
definitions	O
of	O
obesity	O
based	O
on	O
BMIs	O
or	O
%	O
BF	O
by	O
densitometry	O
often	O
produced	O
conflicting	O
results	O
.	O

The	O
IPL1	B-protein
gene	I-protein
is	O
required	O
for	O
high	O
-	O
fidelity	O
chromosome	O
segregation	O
in	O
the	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
system	O
,	O
designed	O
to	O
exploit	O
the	O
relatively	O
constant	O
small	O
intestine	O
transit	O
time	O
,	O
consists	O
of	O
a	O
drug	O
-	O
containing	O
core	O
coated	O
with	O
a	O
polymeric	O
matrix	O
formed	O
by	O
a	O
channeling	O
agent	O
(	O
NaCl	O
,	O
mannitol	O
,	O
and	O
Emdex	O
)	O
and	O
an	O
inert	O
polymer	O
(	O
Eudragit	O
RS100	O
)	O
.	O

Strengthening	O
the	O
biological	O
weapons	O
convention	O
and	O
implications	O
on	O
the	O
pharmaceutical	O
and	O
biotechnology	O
industry	O
.	O

Drag	O
reduction	O
in	O
turbulent	O
flows	O
by	O
polymers	O
.	O

Neuron	B-protein
-	I-protein
specific	I-protein
Bcl	I-protein
-	I-protein
2	I-protein
homology	I-protein
3	I-protein
domain	I-protein
-	I-protein
only	I-protein
splice	I-protein
variant	I-protein
of	O
Bak	B-protein
is	O
anti	O
-	O
apoptotic	O
in	O
neurons	O
,	O
but	O
pro	O
-	O
apoptotic	O
in	O
non	O
-	O
neuronal	O
cells	O
.	O

Expression	O
of	O
lacZ	B-protein
from	O
the	O
promoter	O
of	O
the	O
Escherichia	B-protein
coli	I-protein
spc	I-protein
operon	I-protein
cloned	O
into	O
vectors	O
carrying	O
the	O
W205	B-protein
trp	I-protein
-	I-protein
lac	I-protein
fusion	I-protein
.	O

(	O
LH	B-protein
P	O
<	O
0	O
.	O
05	O
,	O
LH	B-protein
/	I-protein
FSH	I-protein
P	O
<	O
0	O
.	O
01	O
)	O
.	O

In	O
addition	O
,	O
mapping	O
of	O
the	O
promoter	O
region	O
and	O
the	O
identification	O
of	O
putative	O
promoter	O
regulatory	O
sequences	O
should	O
give	O
insight	O
into	O
the	O
transcriptional	O
regulation	O
of	O
UCP2	B-protein
expression	O
-	O
-	O
in	O
particular	O
by	O
anyone	O
of	O
the	O
above	O
mentioned	O
factors	O
-	O
-	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Here	O
we	O
show	O
that	O
epidermal	B-protein
growth	I-protein
factor	I-protein
or	O
platelet	B-protein
-	I-protein
derived	I-protein
growth	I-protein
factor	I-protein
stimulation	O
of	O
intact	O
human	O
or	O
murine	O
cells	O
leads	O
to	O
phosphorylation	O
of	O
Nck	B-protein
protein	I-protein
on	O
tyrosine	O
,	O
serine	O
,	O
and	O
threonine	O
residues	O
.	O

Here	O
we	O
report	O
the	O
full	O
-	O
length	O
coding	O
cDNA	O
sequence	O
of	O
the	O
mouse	B-protein
homologue	I-protein
of	I-protein
MPP3	I-protein
.	O

Bone	O
marrow	O
transplantation	O
-	O
1979	O
.	O

Expression	O
of	O
a	O
dominant	O
-	O
negative	O
mutant	O
of	O
JNK1	B-protein
also	O
suppressed	O
glucose	O
deprivation	O
-	O
induced	O
JNK1	B-protein
activation	O
as	O
well	O
as	O
HSP70	B-protein
gene	I-protein
expression	O
.	O

In	O
contrast	O
,	O
receptor	O
/	O
G	O
protein	O
coupling	O
appeared	O
unaffected	O
by	O
expression	O
of	O
loop	O
3i	O
domains	O
derived	O
from	O
two	O
receptors	O
coupled	O
to	O
G	B-protein
(	I-protein
i	I-protein
/	I-protein
o	I-protein
)	I-protein
proteins	I-protein
(	O
M2Ach	B-protein
-	I-protein
muscarinic	I-protein
and	I-protein
alpha2A	I-protein
-	I-protein
adrenergic	I-protein
receptors	I-protein
)	O
.	O

Cardiac	B-protein
myosin	I-protein
-	I-protein
binding	I-protein
protein	I-protein
C	I-protein
(	O
MyBP	B-protein
-	I-protein
C	I-protein
)	O
:	O
identification	O
of	O
protein	B-protein
kinase	I-protein
A	I-protein
and	O
protein	B-protein
kinase	I-protein
C	I-protein
phosphorylation	O
sites	O
.	O

The	O
limits	O
of	O
agreement	O
between	O
DBS	O
and	O
TOF	O
responses	O
were	O
so	O
wide	O
that	O
they	O
can	O
not	O
be	O
used	O
interchangeably	O
.	O

The	O
analysis	O
of	O
the	O
structure	O
of	O
the	O
sleep	O
period	O
as	O
a	O
whole	O
reveals	O
that	O
with	O
increasing	O
of	O
the	O
age	O
the	O
delta	O
-	O
wave	O
stage	O
(	O
DS	O
)	O
of	O
the	O
QS	O
(	O
determined	O
by	O
defined	O
polygraphic	O
parameters	O
)	O
increases	O
,	O
while	O
the	O
paradoxical	O
phase	O
of	O
sleep	O
(	O
PS	O
)	O
decreases	O
,	O
this	O
change	O
being	O
more	O
pronounced	O
during	O
the	O
first	O
six	O
months	O
than	O
during	O
the	O
second	O
ones	O
of	O
the	O
first	O
year	O
of	O
the	O
life	O
.	O

We	O
previously	O
showed	O
that	O
the	O
N	O
-	O
terminal	O
portion	O
common	O
to	O
various	O
chimeric	B-protein
MLL	I-protein
products	I-protein
,	O
as	O
well	O
as	O
to	O
MLL	B-protein
-	I-protein
LTG9	I-protein
and	O
MLL	B-protein
-	I-protein
LTG19	I-protein
,	O
localizes	O
in	O
the	O
nuclei	O
,	O
and	O
therefore	O
suggested	O
that	O
it	O
might	O
play	O
an	O
important	O
role	O
in	O
leukemogenesis	O
.	O

We	O
propose	O
that	O
CTS1	B-protein
and	I-protein
CTS2	I-protein
of	I-protein
Ci	I-protein
are	O
members	O
of	O
two	O
distinct	O
classes	O
of	O
fungal	B-protein
chitinases	I-protein
,	O
an	O
observation	O
not	O
previously	O
reported	O
for	O
a	O
single	O
fungus	O
.	O

We	O
recently	O
characterized	O
a	O
single	O
yeast	B-protein
hnRNP	I-protein
methyltransferase	I-protein
(	O
HMT1	B-protein
)	O
.	O

Electronic	O
structure	O
of	O
delta	O
-	O
plutonium	O
and	O
of	O
single	O
Al	O
,	O
Ga	O
,	O
and	O
Sc	O
impurities	O
in	O
delta	O
-	O
plutonium	O
.	O

Investigation	O
on	O
the	O
exchange	O
of	O
Ca45	O
in	O
intact	O
and	O
burned	O
rats	O
by	O
the	O
kinetic	O
analysis	O
method	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
administration	O
of	O
misoprostol	O
prevents	O
gastric	O
hemorrhage	O
in	O
healthy	O
dogs	O
treated	O
with	O
high	O
doses	O
of	O
methylprednisolone	O
sodium	O
succinate	O
(	O
MPSS	O
)	O
.	O

The	O
gp330	B-protein
/	I-protein
Megalin	I-protein
/	I-protein
LRP	I-protein
-	I-protein
2	I-protein
protein	I-protein
belongs	O
to	O
the	O
low	B-protein
-	I-protein
density	I-protein
lipoprotein	I-protein
receptor	I-protein
gene	I-protein
family	I-protein
and	O
is	O
believed	O
to	O
function	O
as	O
an	O
endocytic	O
receptor	O
for	O
the	O
uptake	O
of	O
lipoproteins	O
and	O
many	O
other	O
ligands	O
.	O

Moreover	O
,	O
expression	O
of	O
antisense	B-protein
Ha	I-protein
-	I-protein
Ras	I-protein
or	O
dominant	B-protein
negative	I-protein
Raf	I-protein
-	I-protein
1	I-protein
abrogated	O
the	O
mitogenic	O
effect	O
of	O
TGF	B-protein
-	I-protein
beta1	I-protein
in	O
TSU	O
-	O
Pr1	O
,	O
and	O
the	O
TGF	B-protein
-	I-protein
beta1	I-protein
inhibition	O
of	O
DU145	O
was	O
switched	O
to	O
stimulation	O
by	O
V12Ha	B-protein
-	I-protein
Ras	I-protein
transfection	O
.	O

We	O
conclude	O
that	O
RPMS	B-protein
acts	O
as	O
a	O
negative	O
regulator	O
of	O
EBNA2	B-protein
and	O
Notch	B-protein
activity	O
through	O
its	O
interactions	O
with	O
the	O
CBF1	B-protein
-	I-protein
associated	I-protein
corepressor	I-protein
complex	I-protein
.	O

Effect	O
of	O
a	O
high	O
-	O
intensity	O
SHF	O
field	O
on	O
the	O
blood	O
coagulation	O
system	O
.	O

Functional	O
analysis	O
of	O
various	O
PTP	O
-	O
deficient	O
DT40	O
B	O
cell	O
lines	O
stably	O
expressing	O
wild	B-protein
-	I-protein
type	I-protein
chimeric	I-protein
Fc	I-protein
gamma	I-protein
RIIB1	I-protein
-	I-protein
PECAM	I-protein
-	I-protein
1	I-protein
receptor	I-protein
indicated	O
that	O
cytoplasmic	B-protein
Src	I-protein
homology	I-protein
2	I-protein
-	I-protein
domain	I-protein
-	I-protein
containing	I-protein
phosphatases	I-protein
,	O
SHP	B-protein
-	I-protein
1	I-protein
and	O
SHP	B-protein
-	I-protein
2	I-protein
,	O
were	O
both	O
necessary	O
and	O
sufficient	O
to	O
deliver	O
inhibitory	O
negative	O
regulation	O
upon	O
coligation	O
of	O
BCR	B-protein
complex	I-protein
with	O
inhibitory	O
receptor	O
.	O

Epidemiology	O
and	O
prevention	O
of	O
hospital	O
infections	O
in	O
the	O
Local	O
Health	O
Unit	O
of	O
Sassari	O
:	O
profile	O
of	O
bacterial	O
resistance	O
and	O
antimicrobial	O
agents	O
of	O
large	O
usage	O
.	O

The	O
results	O
confirm	O
that	O
a	O
single	O
base	O
change	O
in	O
the	O
branchpoint	O
consensus	O
sequence	O
of	O
an	O
intron	O
can	O
cause	O
human	O
disease	O
although	O
this	O
sequence	O
is	O
poorly	O
conserved	O
in	O
mammals	O
.	O

Prognosis	O
of	O
asymptomatic	O
multiple	O
myeloma	O
.	O

Among	O
38	O
patients	O
with	O
inducible	O
reentrant	O
VTs	O
who	O
underwent	O
electrophysiologic	O
study	O
(	O
EPS	O
)	O
,	O
10	O
VTs	O
of	O
six	O
patients	O
were	O
selected	O
.	O

The	O
hormonal	O
response	O
to	O
a	O
standardized	O
bicycle	O
exercise	O
test	O
was	O
studied	O
in	O
11	O
male	O
cadets	O
exposed	O
to	O
a	O
course	O
of	O
107	O
h	O
of	O
continuous	O
activity	O
with	O
less	O
than	O
2	O
h	O
sleep	O
.	O

Only	O
one	O
DC	O
cardioversion	O
was	O
required	O
in	O
the	O
HBS	O
group	O
,	O
whereas	O
2	O
DC	O
in	O
the	O
CBC	O
group	O
and	O
total	O
7	O
DC	O
in	O
the	O
GIK	O
group	O
.	O

This	O
suggests	O
that	O
alaproclate	O
acutely	O
increases	O
the	O
responsiveness	O
of	O
postsynaptic	O
muscarinic	B-protein
and	I-protein
alpha	I-protein
1	I-protein
adrenoceptors	I-protein
.	O

In	O
summary	O
,	O
we	O
conclude	O
that	O
the	O
adenoviral	O
oncoprotein	O
E1A	B-protein
activates	O
transcription	O
from	O
the	O
endogenous	O
AP	B-protein
-	I-protein
2alpha	I-protein
gene	I-protein
,	O
an	O
effect	O
that	O
involves	O
transcriptional	O
derepression	O
of	O
the	O
AP	B-protein
-	I-protein
2alpha	I-protein
promoter	I-protein
by	O
interaction	O
of	O
E1A	B-protein
with	O
the	O
AP	B-protein
-	I-protein
2rep	I-protein
corepressor	O
CtBP1	B-protein
.	O

The	O
subjects	O
of	O
the	O
study	O
were	O
10	O
normal	O
subjects	O
and	O
64	O
patients	O
with	O
gastroduodenal	O
disease	O
.	O

Analysis	O
of	O
the	O
sequence	O
upstream	O
of	O
this	O
initiation	O
codon	O
reveals	O
the	O
presence	O
of	O
a	O
promotor	O
sequence	O
.	O

PROCEDURE	O
:	O
Cannulas	O
were	O
surgically	O
positioned	O
in	O
the	O
abomasal	O
body	O
and	O
pyloric	O
antrum	O
of	O
each	O
calf	O
.	O

Generally	O
ILC	O
and	O
ILVF	O
values	O
decreased	O
with	O
increasing	O
exposure	O
time	O
with	O
rate	O
constants	O
ranging	O
from	O
0	O
.	O
03	O
to	O
0	O
.	O
33	O
day	O
-	O
1	O
(	O
wet	O
and	O
lipid	O
weight	O
)	O
for	O
ILC	O
and	O
0	O
.	O
03	O
to	O
0	O
.	O
31	O
day	O
-	O
1	O
for	O
ILVF	O
.	O

RESULTS	O
:	O
Coronary	O
mortality	O
during	O
the	O
median	O
follow	O
-	O
up	O
time	O
of	O
17	O
months	O
was	O
6	O
-	O
fold	O
higher	O
in	O
the	O
highest	O
tertile	O
for	O
CRP	B-protein
and	O
IL	B-protein
-	I-protein
6	I-protein
and	O
3	O
.	O
5	O
-	O
fold	O
higher	O
in	O
the	O
highest	O
tertile	O
for	O
fibrinogen	B-protein
and	O
TNF	B-protein
-	I-protein
alpha	I-protein
than	O
in	O
the	O
respective	O
combined	O
lower	O
tertiles	O
.	O

Protein	O
phosphorylation	O
appears	O
to	O
play	O
a	O
critical	O
role	O
in	O
uPA	B-protein
gene	I-protein
expression	O
in	O
these	O
cells	O
;	O
protein	B-protein
kinase	I-protein
C	O
-	O
activating	O
phorbol	O
esters	O
cooperate	O
with	O
pp60v	B-protein
-	I-protein
src	I-protein
to	O
synergistically	O
increase	O
uPA	B-protein
mRNA	I-protein
,	O
whereas	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
-	O
dependent	O
protein	O
kinase	O
-	O
activating	O
agents	O
(	O
e	O
.	O
g	O
.	O
,	O
8	O
-	O
bromo	O
cAMP	O
)	O
repress	O
uPA	B-protein
mRNA	I-protein
levels	O
.	O

One	O
of	O
these	O
,	O
an	O
AACA	O
motif	O
,	O
has	O
been	O
shown	O
to	O
be	O
a	O
negative	O
regulator	O
in	O
non	O
-	O
seed	O
tissues	O
and	O
has	O
a	O
similarity	O
to	O
the	O
barley	B-protein
gibberellin	I-protein
responsive	I-protein
element	I-protein
recognized	O
by	O
MYB	B-protein
-	I-protein
like	I-protein
DNA	I-protein
binding	I-protein
proteins	I-protein
.	O

Tissue	B-protein
plasminogen	I-protein
activator	I-protein
,	O
its	O
inhibitor	O
and	O
other	O
parameters	O
of	O
fibrinolysis	O
in	O
blood	O
of	O
patients	O
operated	O
for	O
mild	O
hypertrophy	O
of	O
the	O
prostate	O
.	O

In	O
a	O
screen	O
for	O
genes	O
with	O
oncogenic	O
potential	O
expressed	O
by	O
the	O
murine	O
B6SUtA1	O
myeloid	O
progenitor	O
cell	O
line	O
,	O
we	O
isolated	O
a	O
2	O
.	O

When	O
given	O
the	O
choice	O
between	O
an	O
estrous	O
female	O
and	O
a	O
sexually	O
active	O
male	O
in	O
the	O
AOF	O
,	O
flutamide	O
females	O
,	O
as	O
well	O
as	O
controls	O
,	O
preferred	O
the	O
male	O
partner	O
.	O

The	O
pulmonary	O
toxic	O
events	O
induced	O
by	O
acute	O
nitrogen	O
dioxide	O
(	O
NO	O
)	O
2	O
exposure	O
were	O
studied	O
in	O
the	O
rat	O
to	O
develop	O
an	O
inhalation	O
model	O
to	O
investigate	O
therapeutic	O
measures	O
.	O

The	O
cryptococcal	B-protein
antigen	I-protein
test	O
was	O
positive	O
at	O
1	O
:	O
125	O
by	O
latex	O
agglutination	O
.	O

Overexpression	O
of	O
POG1	B-protein
inhibits	O
alpha	O
-	O
factor	O
-	O
induced	O
G1	O
arrest	O
and	O
transcriptional	O
repression	O
of	O
the	O
CLN1	B-protein
and	O
CLN2	B-protein
genes	I-protein
.	O

The	O
levels	O
of	O
NSE	B-protein
and	O
MBP	B-protein
in	O
the	O
IJVB	O
were	O
compared	O
to	O
those	O
in	O
the	O
PVB	O
.	O

When	O
considered	O
with	O
the	O
known	O
neurotoxic	O
effects	O
on	O
children	O
of	O
`	O
`	O
low	O
levels	O
'	O
'	O
of	O
exposure	O
to	O
lead	O
,	O
these	O
results	O
also	O
suggest	O
that	O
either	O
an	O
excessively	O
narrow	O
margin	O
of	O
safety	O
or	O
insufficient	O
safety	O
is	O
provided	O
by	O
present	O
U	O
.	O
S	O
.	O
guidelines	O
,	O
which	O
classify	O
an	O
elevated	O
blood	O
lead	O
concentration	O
as	O
25	O
micrograms	O
/	O
dl	O
or	O
greater	O
.	O

The	O
GT	O
-	O
foreign	O
-	O
pictures	O
showed	O
that	O
the	O
judgment	O
of	O
other	O
subjects	O
changed	O
toward	O
hedonic	O
and	O
permeability	O
directions	O
.	O

Quantitative	O
analysis	O
of	O
DNA	O
using	O
flow	O
cytometry	O
and	O
immunocytochemical	O
findings	O
in	O
16	O
cases	O
of	O
cardiac	O
myxomas	O
.	O

The	O
lacS	B-protein
gene	I-protein
was	O
cloned	O
in	O
an	O
E	O
.	O
coli	O
-	O
Streptococcus	O
shuttle	O
vector	O
and	O
was	O
expressed	O
both	O
in	O
a	O
lacS	B-protein
deletion	O
derivative	O
of	O
S	O
.	O
thermophilus	O
and	O
in	O
a	O
pNZ63	O
-	O
cured	O
strain	O
,	O
L	O
.	O
lactis	O
NZ6091	O
.	O

ATP	O
by	O
itself	O
also	O
reduced	O
polypeptide	O
binding	O
to	O
Ssb1	B-protein
/	I-protein
2p	I-protein
to	O
a	O
level	O
that	O
was	O
intermediate	O
between	O
that	O
observed	O
for	O
the	O
Ssa	B-protein
Hsp70	I-protein
proteins	I-protein
tested	O
and	O
BiP	B-protein
and	O
DnaK	B-protein
.	O

We	O
compared	O
the	O
volume	O
of	O
the	O
pulmonary	O
extravascular	O
,	O
extracellular	O
water	O
space	O
using	O
sodium	O
and	O
sucrose	O
indicators	O
in	O
8	O
normal	O
and	O
11	O
edematous	O
rabbit	O
lungs	O
by	O
steady	O
-	O
state	O
techniques	O
.	O

Analysis	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
suggests	O
that	O
CHIP28	B-protein
protein	I-protein
contains	O
six	O
bilayer	O
-	O
spanning	O
domains	O
,	O
two	O
exofacial	O
potential	O
N	O
-	O
glycosylation	O
sites	O
,	O
and	O
intracellular	O
N	O
and	O
C	O
termini	O
.	O

Recombinant	B-protein
soluble	I-protein
pMCP	I-protein
that	O
lacked	O
transmembrane	O
and	O
cytoplasmic	O
domains	O
had	O
factor	B-protein
I	I-protein
cofactor	I-protein
activity	O
in	O
C3b	B-protein
cleavage	O
,	O
indicating	O
that	O
it	O
is	O
functionally	O
,	O
as	O
well	O
as	O
structurally	O
homologous	O
to	O
MCP	B-protein
.	O

Histamine	O
metabolism	O
in	O
hemorrhagic	O
-	O
hypotensive	O
shock	O
.	O

A	O
method	O
for	O
establishing	O
stimulus	O
control	O
of	O
ethanol	O
responding	O
was	O
developed	O
.	O

In	O
PAV	O
-	O
3	O
,	O
the	O
E1A	B-protein
region	I-protein
is	O
located	O
between	O
1	O
.	O
5	O
and	O
3	O
.	O
8	O
map	O
units	O
.	O

The	O
article	O
deals	O
with	O
the	O
diagnosing	O
and	O
correction	O
of	O
reversible	O
ischemia	O
of	O
the	O
intestine	O
.	O

This	O
region	O
contains	O
a	O
motif	O
with	O
partial	O
identity	O
with	O
the	O
binding	O
site	O
for	O
the	O
ubiquitous	O
transcription	O
factor	O
upstream	B-protein
stimulatory	I-protein
factor	I-protein
(	O
USF	B-protein
)	O
,	O
which	O
binds	O
to	O
the	O
human	B-protein
insulin	I-protein
promoter	I-protein
.	O

The	O
cis	O
-	O
acting	O
element	O
mediating	O
glucocorticoid	O
inducibility	O
of	O
the	O
chicken	B-protein
glutamine	I-protein
synthetase	I-protein
gene	I-protein
has	O
been	O
identified	O
.	O

Some	O
of	O
the	O
PCR	O
products	O
contained	O
mutations	O
in	O
ATG1	B-protein
and	O
/	O
or	O
ATG2	B-protein
.	O

The	O
dominant	O
negative	O
mutant	O
of	O
SHP	B-protein
-	I-protein
2	I-protein
was	O
found	O
to	O
inhibit	O
the	O
induction	O
of	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
-	O
binding	O
activity	O
of	O
m	B-protein
-	I-protein
Stat5a	I-protein
,	O
m	B-protein
-	I-protein
Stat5b	I-protein
,	O
and	O
the	O
carboxyl	O
-	O
terminal	O
deletion	O
variant	O
m	B-protein
-	I-protein
Stat5adelta749	I-protein
,	O
as	O
well	O
as	O
the	O
transactivation	O
potential	O
of	O
m	B-protein
-	I-protein
Stat5a	I-protein
and	O
m	B-protein
-	I-protein
Stat5b	I-protein
.	O

Routine	O
isotope	O
cystography	O
using	O
99M	O
Tc	O
sulfur	O
colloid	O
for	O
detection	O
and	O
follow	O
-	O
up	O
of	O
vesico	O
-	O
ureteral	O
reflux	O
.	O

The	O
detector	O
has	O
the	O
advantage	O
of	O
finding	O
both	O
ST	O
segment	O
deviations	O
and	O
entire	O
ST	O
-	O
T	O
complex	O
changes	O
thereby	O
providing	O
a	O
wider	O
characterization	O
of	O
the	O
potential	O
ischemic	O
events	O
.	O

We	O
have	O
overexpressed	O
,	O
purified	O
,	O
characterized	O
,	O
and	O
crystallized	O
the	O
BTB	B-protein
/	I-protein
POZ	I-protein
domain	I-protein
from	O
PLZF	B-protein
(	O
PLZF	B-protein
-	I-protein
BTB	I-protein
/	I-protein
POZ	I-protein
)	O
.	O

An	O
interaction	O
screen	O
with	O
the	O
repression	O
domain	O
of	O
the	O
orphan	B-protein
receptor	I-protein
RevErb	I-protein
identified	O
N	B-protein
-	I-protein
CoR	I-protein
,	O
the	O
corepressor	O
for	O
thyroid	B-protein
hormone	I-protein
receptor	I-protein
(	O
TR	B-protein
)	O
and	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
(	O
RAR	B-protein
)	O
.	O

Furthermore	O
,	O
rhoA	O
-	O
mediated	O
SRE	B-protein
activation	O
was	O
blocked	O
by	O
dominant	O
negative	O
mutants	O
of	O
PKC	B-protein
-	I-protein
alpha	I-protein
or	O
PKC	B-protein
-	I-protein
epsilon	I-protein
.	O

The	O
5	O
'	O
flanking	O
region	O
of	O
the	O
mouse	B-protein
Met	I-protein
-	I-protein
ase	I-protein
-	I-protein
1	I-protein
gene	I-protein
also	O
shares	O
considerable	O
regions	O
of	O
identity	O
with	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
rat	B-protein
Met	I-protein
-	I-protein
ase	I-protein
-	I-protein
1	I-protein
gene	I-protein
.	O

Pol32Delta	B-protein
strains	O
are	O
weak	O
antimutators	O
and	O
are	O
defective	O
for	O
damage	O
-	O
induced	O
mutagenesis	O
.	O

Although	O
we	O
predicted	O
that	O
overexpression	O
of	O
the	O
COOH	O
-	O
terminal	O
domains	O
,	O
which	O
were	O
thought	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
SREBP	B-protein
processing	O
,	O
would	O
result	O
in	O
disruption	O
of	O
the	O
SREBP	O
-	O
dependent	O
transcriptional	O
regulation	O
of	O
several	O
genes	O
,	O
the	O
mRNA	O
levels	O
for	O
3	B-protein
-	I-protein
hydroxy	I-protein
-	I-protein
3	I-protein
-	I-protein
methylglutaryl	I-protein
coenzyme	I-protein
A	I-protein
(	I-protein
HMG	I-protein
CoA	I-protein
)	I-protein
synthase	I-protein
in	O
these	O
two	O
cell	O
lines	O
were	O
regulated	O
in	O
a	O
sterol	O
-	O
dependent	O
manner	O
.	O

Both	O
increasing	O
basal	O
FSH	B-protein
and	O
age	O
were	O
associated	O
significantly	O
with	O
increased	O
total	O
gonadotrophin	B-protein
dose	O
,	O
and	O
reduced	O
number	O
of	O
oocytes	O
collected	O
and	O
pregnancy	O
rate	O
.	O

We	O
have	O
inactivated	O
Krox	B-protein
-	I-protein
20	I-protein
by	O
homologous	O
recombination	O
in	O
ES	O
cells	O
and	O
demonstrated	O
that	O
the	O
mutation	O
leads	O
to	O
the	O
deletion	O
of	O
r3	B-protein
and	O
r5	B-protein
.	O

Kinase	O
-	O
deficient	O
erbB	B-protein
proteins	I-protein
reduced	O
epidermal	B-protein
growth	I-protein
factor	I-protein
(	O
EGF	B-protein
)	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
endogenous	O
Shc	B-protein
proteins	I-protein
and	O
also	O
reduced	O
immediate	O
and	O
sustained	O
EGF	B-protein
-	I-protein
induced	I-protein
ERK	I-protein
MAPK	I-protein
activities	O
in	O
human	O
glioblastoma	O
cells	O
,	O
although	O
basal	O
ERK	B-protein
MAPK	I-protein
activities	O
were	O
unaffected	O
.	O

L	O
.	O
,	O
Greer	O
,	O
J	O
.	O
@	O
Carter	O
,	O
G	O
.	O

The	O
dichloromethane	O
is	O
removed	O
,	O
mobile	O
phase	O
solvent	O
is	O
added	O
,	O
and	O
aliquots	O
are	O
injected	O
onto	O
a	O
PRP	O
-	O
1	O
liquid	O
chromatographic	O
column	O
;	O
fluazifop	O
acid	O
is	O
separated	O
from	O
coextracted	O
compounds	O
and	O
detected	O
at	O
an	O
applied	O
potential	O
of	O
+	O
1	O
.	O
25	O
V	O
,	O
using	O
an	O
amperometric	O
electrochemical	O
detector	O
in	O
the	O
oxidation	O
mode	O
.	O

OBJECTIVES	O
:	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
analyze	O
the	O
clinical	O
characteristics	O
,	O
treatment	O
and	O
outcome	O
of	O
310	O
patients	O
with	O
hydatidiform	O
mole	O
.	O

The	O
results	O
from	O
the	O
first	O
five	O
years	O
of	O
follow	O
up	O
in	O
1972	O
showed	O
a	O
4	O
.	O
7	O
-	O
fold	O
excess	O
mortality	O
for	O
ischaemic	O
and	O
other	O
heart	O
diseases	O
(	O
ICD	O
A83	O
-	O
A84	O
)	O
compared	O
with	O
a	O
comparable	O
reference	O
cohort	O
of	O
paper	O
mill	O
workers	O
.	O

Based	O
on	O
the	O
estimated	O
values	O
of	O
divergence	O
of	O
apobec1	B-protein
sequences	I-protein
in	O
terms	O
of	O
the	O
numbers	O
of	O
synonymous	O
and	O
non	O
-	O
synonymous	O
suhstitutions	O
per	O
site	O
,	O
we	O
found	O
that	O
apobec1	B-protein
is	O
a	O
fairly	O
rapidly	O
evolving	O
protein	O
.	O

PNRC	B-protein
:	O
a	O
proline	O
-	O
rich	O
nuclear	O
receptor	O
coregulatory	O
protein	O
that	O
modulates	O
transcriptional	O
activation	O
of	O
multiple	O
nuclear	O
receptors	O
including	O
orphan	B-protein
receptors	I-protein
SF1	I-protein
(	O
steroidogenic	B-protein
factor	I-protein
1	I-protein
)	O
and	O
ERRalpha1	B-protein
(	O
estrogen	B-protein
related	I-protein
receptor	I-protein
alpha	I-protein
-	I-protein
1	I-protein
)	O
.	O

A	O
direct	O
role	O
for	O
sterol	B-protein
regulatory	I-protein
element	I-protein
binding	I-protein
protein	I-protein
in	O
activation	O
of	O
3	B-protein
-	I-protein
hydroxy	I-protein
-	I-protein
3	I-protein
-	I-protein
methylglutaryl	I-protein
coenzyme	I-protein
A	I-protein
reductase	I-protein
gene	I-protein
.	O

We	O
show	O
that	O
c	B-protein
-	I-protein
Fos	I-protein
(	O
the	O
c	B-protein
-	I-protein
fos	I-protein
protooncogene	I-protein
product	I-protein
)	O
,	O
which	O
is	O
an	O
intrinsically	O
unstable	O
nuclear	O
protein	O
,	O
is	O
metabolically	O
highly	O
stabilized	O
,	O
and	O
greatly	O
enhances	O
the	O
transforming	O
efficiency	O
of	O
NIH	O
3T3	O
cells	O
,	O
by	O
Mos	B-protein
.	O

METHODS	O
-	O
-	O
16	O
volunteered	O
for	O
spirometry	O
with	O
methacholine	O
provocation	O
test	O
including	O
a	O
test	O
for	O
small	O
airways	O
function	O
by	O
volume	O
of	O
trapped	O
gas	O
(	O
VTG	O
)	O
.	O

MEKs	B-protein
and	O
ERKs	B-protein
inhibited	O
IL	B-protein
-	I-protein
6	I-protein
activation	O
of	O
Stat3	B-protein
harboring	O
a	O
mutation	O
at	O
serine	O
-	O
727	O
,	O
the	O
major	O
site	O
for	O
serine	O
phosphorylation	O
,	O
similar	O
to	O
inhibition	O
of	O
wild	B-protein
-	I-protein
type	I-protein
Stat3	I-protein
,	O
and	O
inhibited	O
Janus	B-protein
kinases	I-protein
Jak1	I-protein
and	O
Jak2	B-protein
upstream	O
of	O
Stat3	B-protein
in	O
the	O
Jak	O
-	O
STAT	O
-	O
signaling	O
pathway	O
.	O

A	O
reciprocal	O
binding	O
assay	O
using	O
IM	O
-	O
9	O
cells	O
as	O
a	O
source	O
of	O
SHP	B-protein
-	I-protein
1	I-protein
and	O
SHP	B-protein
-	I-protein
2	I-protein
revealed	O
specific	O
association	O
of	O
SHP	B-protein
-	I-protein
2	I-protein
(	O
but	O
not	O
SHP	B-protein
-	I-protein
1	I-protein
)	O
with	O
a	O
glutathione	B-protein
S	I-protein
-	I-protein
transferase	I-protein
fusion	I-protein
incorporating	O
GHR	B-protein
cytoplasmic	I-protein
domain	I-protein
residues	I-protein
485	I-protein
-	I-protein
620	I-protein
,	O
but	O
only	O
if	O
the	O
fusion	O
was	O
first	O
rendered	O
tyrosine	O
-	O
phosphorylated	O
.	O

The	O
mean	O
values	O
of	O
protease	B-protein
activity	O
were	O
significantly	O
higher	O
in	O
the	O
test	O
groups	O
than	O
in	O
the	O
control	O
group	O
at	O
baseline	O
.	O

Although	O
IL	B-protein
-	I-protein
2	I-protein
and	O
IFN	B-protein
-	I-protein
alpha	I-protein
activated	O
STAT1	B-protein
alpha	I-protein
and	O
STAT5	B-protein
,	O
IL	B-protein
-	I-protein
2	I-protein
predominantly	O
activated	O
STAT5	B-protein
,	O
while	O
IFN	B-protein
-	I-protein
alpha	I-protein
predominantly	O
activated	O
STAT1	B-protein
alpha	I-protein
.	O

The	O
CDC7	B-protein
gene	I-protein
has	O
two	O
in	O
-	O
frame	O
AUG	O
codons	O
as	O
possible	O
translation	O
start	O
sites	O
,	O
which	O
would	O
produce	O
58	O
-	O
and	O
56	O
-	O
kDa	O
proteins	O
,	O
respectively	O
.	O

Natural	O
Haemophilus	O
influenzae	O
type	O
b	O
capsular	O
polysaccharide	O
antibodies	O
in	O
412	O
infants	O
and	O
children	O
from	O
West	O
Africa	O
(	O
Burkina	O
-	O
Faso	O
)	O
and	O
France	O
:	O
a	O
cross	O
-	O
sectional	O
serosurvey	O
.	O

Intermediate	O
levels	O
of	O
gene	O
activity	O
were	O
observed	O
for	O
TnI	B-protein
enhancers	I-protein
containing	O
E	O
-	O
boxes	O
derived	O
from	O
the	O
MCK	B-protein
left	I-protein
E	I-protein
-	I-protein
box	I-protein
site	I-protein
or	O
from	O
the	O
Ig	B-protein
kappa	I-protein
E2	I-protein
E	I-protein
-	I-protein
box	I-protein
.	O

A	O
comparison	O
of	O
the	O
predicted	O
polypeptide	O
sequence	O
of	O
the	O
Drosophila	O
protein	O
with	O
the	O
equivalent	O
subunits	O
from	O
mouse	O
and	O
yeast	O
suggests	O
that	O
they	O
are	O
closely	O
related	O
and	O
defines	O
three	O
conserved	O
regions	O
which	O
are	O
likely	O
to	O
be	O
important	O
for	O
enzyme	O
activity	O
.	O

Oligonucleotide	O
probes	O
corresponding	O
to	O
wild	B-protein
-	I-protein
type	I-protein
and	I-protein
mutant	I-protein
EpRE	I-protein
sequences	I-protein
were	O
used	O
in	O
gel	O
-	O
shift	O
and	O
super	O
-	O
shift	O
analyses	O
to	O
identify	O
proteins	O
binding	O
.	O

CONCLUSIONS	O
:	O
Ketamine	O
-	O
induced	O
dissociative	O
anesthesia	O
produces	O
persistently	O
elevated	O
BIS	O
index	O
which	O
is	O
different	O
from	O
thiamylal	O
and	O
those	O
reported	O
with	O
other	O
conventional	O
anesthetic	O
agents	O
.	O

Osmotic	O
shock	O
stimulates	O
GLUT4	B-protein
translocation	O
in	O
3T3L1	O
adipocytes	O
by	O
a	O
novel	O
tyrosine	B-protein
kinase	I-protein
pathway	O
.	O

They	O
were	O
called	O
PACE4	B-protein
and	O
PC4	B-protein
.	O

The	O
difficulties	O
to	O
analyse	O
prostaglandins	O
(	O
PG	O
)	O
by	O
gas	O
-	O
liquid	O
chromatography	O
are	O
mainly	O
due	O
to	O
the	O
lack	O
of	O
sensitivity	O
of	O
the	O
gas	O
-	O
chromatograph	O
itself	O
(	O
higher	O
than	O
200	O
ng	O
)	O
and	O
to	O
the	O
poor	O
resolution	O
of	O
the	O
packed	O
columns	O
.	O

Sequences	O
needed	O
for	O
iron	O
-	O
regulated	O
expression	O
of	O
sid1	B-protein
were	O
localized	O
to	O
a	O
306	O
bp	O
region	O
mapping	O
2	O
.	O
3	O
and	O
2	O
.	O
6	O
kb	O
upstream	O
of	O
the	O
ATG	O
.	O

cDNA	O
clones	O
encoding	O
Arabidopsis	O
thaliana	O
and	O
Zea	B-protein
mays	I-protein
mitochondrial	I-protein
chaperonin	I-protein
HSP60	I-protein
and	O
gene	O
expression	O
during	O
seed	O
germination	O
and	O
heat	O
shock	O
.	O

Therefore	O
,	O
a	O
prospective	O
Phase	O
II	O
trial	O
was	O
conducted	O
to	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
cryosurgery	O
following	O
radiation	O
therapy	O
in	O
men	O
with	O
local	O
recurrence	O
.	O

Expression	O
and	O
characterization	O
of	O
recombinant	B-protein
single	I-protein
-	I-protein
chain	I-protein
Fv	I-protein
and	O
Fv	B-protein
fragments	I-protein
derived	O
from	O
a	O
set	O
of	O
catalytic	O
antibodies	O
.	O

Although	O
ANP	B-protein
induced	O
systemic	O
capillary	O
filtration	O
,	O
in	O
the	O
calf	O
,	O
filtration	O
was	O
reduced	O
with	O
ANP	B-protein
.	O

Factors	O
influencing	O
in	O
vitro	O
skin	O
permeability	O
factor	O
production	O
by	O
Vibrio	O
cholerae	O
.	O

The	O
decrease	O
in	O
HDL	O
-	O
cholesterol	O
with	O
increasing	O
VLDL	O
-	O
triglycerides	O
was	O
relatively	O
much	O
larger	O
than	O
the	O
concomitant	O
decrease	O
in	O
apo	B-protein
A	I-protein
-	I-protein
I	I-protein
.	O

The	O
clinical	O
and	O
laboratory	O
features	O
of	O
72	O
children	O
with	O
Henoch	O
-	O
Schonlein	O
purpura	O
(	O
HSP	O
)	O
were	O
examined	O
to	O
determine	O
if	O
there	O
were	O
associations	O
between	O
the	O
laboratory	O
indices	O
-	O
-	O
including	O
white	O
blood	O
cell	O
(	O
WBC	O
)	O
counts	O
,	O
serum	B-protein
C	I-protein
-	I-protein
reactive	I-protein
protein	I-protein
(	O
CRP	B-protein
)	O
levels	O
,	O
platelet	O
(	O
PLT	O
)	O
counts	O
-	O
-	O
and	O
the	O
clinical	O
manifestations	O
of	O
acute	O
HSP	O
.	O

The	O
vigilance	O
task	O
and	O
the	O
measurement	O
of	O
attentional	O
deficits	O
.	O
pp	O
.	O

CONCLUSIONS	O
:	O
LSCC	O
malformation	O
,	O
like	O
other	O
inner	O
ear	O
malformations	O
such	O
as	O
large	O
vestibular	O
aqueduct	O
and	O
X	O
-	O
linked	O
mixed	O
deafness	O
with	O
perilymph	O
gusher	O
,	O
can	O
be	O
associated	O
with	O
CHL	O
,	O
SNHL	O
,	O
or	O
normal	O
hearing	O
.	O

Nucleotide	O
sequence	O
of	O
DNA	O
controlling	O
expression	O
of	O
genes	O
for	O
maltosaccharide	O
utilization	O
in	O
Streptococcus	O
pneumoniae	O
.	O

Previously	O
,	O
we	O
reported	O
the	O
sequence	O
of	O
the	O
gene	B-protein
encoding	I-protein
human	I-protein
K14	I-protein
(	O
D	O
.	O

Basal	O
plasma	O
renin	B-protein
activity	O
(	O
PRA	O
)	O
was	O
slightly	O
raised	O
prior	O
to	O
training	O
(	O
P	O
<	O
0	O
.	O
07	O
)	O
compared	O
to	O
the	O
controls	O
and	O
post	O
-	O
training	O
.	O

Applications	O
of	O
three	O
-	O
dimensional	O
analysis	O
to	O
the	O
auditory	O
P300	O
.	O

Linear	O
eight	B-protein
-	I-protein
or	I-protein
nine	I-protein
-	I-protein
residue	I-protein
D	I-protein
-	I-protein
peptides	I-protein
derived	O
from	O
the	O
pocket	O
-	O
binding	O
domain	O
of	O
the	O
cyclic	O
molecules	O
also	O
bind	O
specifically	O
.	O

Effect	O
of	O
single	O
base	O
substitutions	O
at	O
glycine	O
-	O
870	O
codon	O
of	O
gramicidin	B-protein
S	I-protein
synthetase	I-protein
2	I-protein
gene	I-protein
on	O
proline	O
activation	O
.	O

Inactivation	O
of	O
MAP	B-protein
kinases	I-protein
occurs	O
via	O
a	O
specific	O
phosphatase	B-protein
,	O
MKP	B-protein
-	I-protein
1	I-protein
.	O

These	O
lesions	O
may	O
be	O
treated	O
by	O
propranolol	O
or	O
phentolamine	O
.	O

Susceptibility	O
to	O
ischemia	O
-	O
induced	O
arrhythmias	O
was	O
lower	O
in	O
1	O
-	O
week	O
diabetics	O
:	O
only	O
42	O
%	O
of	O
diabetic	O
hearts	O
exhibited	O
ventricular	O
tachycardia	O
(	O
VT	O
)	O
and	O
16	O
%	O
had	O
short	O
episodes	O
of	O
ventricular	O
fibrillation	O
(	O
VF	O
)	O
as	O
compared	O
to	O
VT	O
100	O
%	O
and	O
VF	O
70	O
%	O
(	O
including	O
sustained	O
VF	O
36	O
%	O
)	O
in	O
the	O
non	O
-	O
diabetics	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
bactericidal	O
activity	O
of	O
six	O
new	O
rifamycin	O
derivatives	O
-	O
-	O
rifabutin	O
(	O
RBU	O
)	O
,	O
FCE	O
22250	O
(	O
F22	O
)	O
,	O
rifapentine	O
(	O
RPE	O
)	O
,	O
CGP	O
29861	O
(	O
C29	O
)	O
,	O
CGP	O
7040	O
(	O
C70	O
)	O
and	O
CGP	O
27557	O
(	O
C27	O
)	O
and	O
rifampicin	O
(	O
RMP	O
)	O
-	O
-	O
have	O
been	O
measured	O
against	O
log	O
phase	O
and	O
,	O
as	O
a	O
better	O
test	O
of	O
sterilising	O
activity	O
,	O
against	O
stationary	O
phase	O
cultures	O
of	O
Mycobacterium	O
tuberculosis	O
,	O
H37Rv	O
.	O

The	O
intron	O
8	O
enhancer	O
region	O
was	O
not	O
activated	O
by	O
GATA	B-protein
-	I-protein
1	I-protein
together	O
with	O
Sp1	B-protein
in	O
transactivation	O
experiments	O
in	O
COS	O
-	O
1	O
cells	O
indicating	O
the	O
involvement	O
of	O
a	O
related	O
Sp1	B-protein
protein	I-protein
or	O
of	O
another	O
unidentified	O
erythroid	O
factor	O
.	O

Estrogen	B-protein
receptor	I-protein
-	I-protein
related	I-protein
receptor	I-protein
alpha	I-protein
1	I-protein
interacts	O
with	O
coactivator	O
and	O
constitutively	O
activates	O
the	O
estrogen	B-protein
response	I-protein
elements	I-protein
of	O
the	O
human	B-protein
lactoferrin	I-protein
gene	I-protein
.	O

However	O
,	O
changing	O
the	O
half	O
-	O
site	O
to	O
the	O
consensus	B-protein
sequence	I-protein
AGGTCA	I-protein
(	O
IRper	B-protein
-	I-protein
1	I-protein
)	O
increased	O
binding	O
of	O
AaEcR	B-protein
.	I-protein
AaUSP	I-protein
10	O
-	O
fold	O
over	O
IRhsp	B-protein
-	I-protein
1	I-protein
and	O
,	O
at	O
the	O
same	O
time	O
,	O
reduced	O
the	O
stringency	O
of	O
the	O
spacer	O
length	O
requirement	O
,	O
with	O
IRper	B-protein
-	I-protein
0	I-protein
to	O
IRper	B-protein
-	I-protein
5	I-protein
showing	O
detectable	O
binding	O
.	O

The	O
glucose	O
/	O
insulin	O
stimulation	O
was	O
inhibited	O
by	O
the	O
addition	O
of	O
polyunsaturated	O
fatty	O
acids	O
.	O

MSSP	B-protein
-	I-protein
1	I-protein
produced	O
in	O
E	O
.	O
coli	O
as	O
a	O
fusion	O
protein	O
with	O
GST	B-protein
specifically	O
interacted	O
with	O
single	O
-	O
stranded	O
TCTTAT	B-protein
(	I-protein
plus	I-protein
myc	I-protein
(	I-protein
H	I-protein
-	I-protein
P	I-protein
)	I-protein
21	I-protein
)	I-protein
and	O
ACT	B-protein
-	I-protein
ATT	I-protein
(	O
in	O
minus	B-protein
myc	I-protein
(	I-protein
H	I-protein
-	I-protein
P	I-protein
)	I-protein
21	I-protein
)	O
,	O
the	O
consensus	O
of	O
which	O
can	O
be	O
referred	O
to	O
as	O
A	B-protein
/	I-protein
TCTA	I-protein
/	I-protein
TA	I-protein
/	I-protein
TT	I-protein
.	O

Although	O
both	O
transcripts	O
share	O
the	O
first	O
nine	O
exons	O
,	O
exon	O
10	O
of	O
ZIS	B-protein
-	I-protein
2	I-protein
is	O
lacking	O
in	O
ZIS	B-protein
-	I-protein
1	I-protein
,	O
and	O
instead	O
,	O
exon	O
11	O
(	O
10th	O
exon	O
)	O
of	O
ZIS	B-protein
-	I-protein
1	I-protein
is	O
larger	O
in	O
size	O
,	O
leading	O
to	O
the	O
longer	O
3	O
'	O
-	O
UTR	O
.	O

Urological	O
complications	O
are	O
frequent	O
during	O
and	O
after	O
the	O
treatment	O
of	O
gynecological	O
malignancy	O
.	O

The	O
final	O
sigma54	B-protein
-	I-protein
dependent	I-protein
DmpR	I-protein
activator	I-protein
regulates	O
transcription	O
of	O
the	O
dmp	B-protein
operon	I-protein
that	O
encodes	O
the	O
enzymes	O
for	O
catabolism	O
of	O
(	O
methyl	O
)	O
phenols	O
.	O

Electromobility	O
shift	O
and	O
cotransfection	O
assays	O
demonstrated	O
that	O
HNF1alpha	B-protein
,	O
but	O
not	O
HNF4	B-protein
,	O
bound	O
to	O
its	O
cognate	O
site	O
and	O
transactivated	O
G6Pase	B-protein
gene	I-protein
expression	O
.	O

Although	O
the	O
N13	O
-	O
N20	O
interpeak	O
interval	O
remained	O
stable	O
because	O
of	O
the	O
parallel	O
shift	O
of	O
the	O
2	O
peaks	O
,	O
the	O
central	O
conduction	O
time	O
measured	O
from	O
onset	O
latencies	O
of	O
N11	O
and	O
N20	O
significantly	O
increased	O
.	O

In	O
nine	O
patients	O
with	O
renal	O
failure	O
routine	O
haemodialysis	O
was	O
accompanied	O
by	O
a	O
30	O
per	O
cent	O
reduction	O
in	O
plasma	O
ANP	B-protein
concentration	O
.	O

The	O
U17	B-protein
/	I-protein
U16	I-protein
and	O
the	O
U16	B-protein
+	I-protein
gene	I-protein
products	I-protein
transactivated	O
the	O
HIV	B-protein
LTR	I-protein
.	O

BACKGROUND	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
and	O
compare	O
interleukin	B-protein
-	I-protein
6	I-protein
(	O
IL	B-protein
-	I-protein
6	I-protein
)	O
levels	O
in	O
gingival	O
crevicular	O
fluid	O
(	O
GCF	O
)	O
and	O
clinical	O
periodontal	O
findings	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
and	O
adult	O
periodontitis	O
(	O
AP	O
)	O
.	O

NKX2	B-protein
.	I-protein
1	I-protein
is	O
a	O
member	O
of	O
the	O
NK2	B-protein
family	I-protein
of	O
homeodomain	O
-	O
containing	O
transcription	O
factors	O
whose	O
targeted	O
disruption	O
in	O
mouse	O
results	O
in	O
the	O
absence	O
of	O
thyroid	O
tissue	O
and	O
a	O
severely	O
abnormal	O
lung	O
phenotype	O
.	O

Investigated	O
the	O
reliability	O
,	O
validity	O
and	O
dimensionality	O
of	O
scores	O
obtained	O
by	O
acute	O
psychiatric	O
inpatients	O
(	O
N	O
=	O
120	O
)	O
on	O
the	O
Michigan	O
Alcoholism	O
Screening	O
Test	O
adapted	O
to	O
assess	O
lifetime	O
and	O
current	O
symptomatology	O
.	O

The	O
C	O
-	O
terminal	O
mature	O
region	O
is	O
highly	O
conserved	O
in	O
other	O
serine	B-protein
carboxypeptidases	I-protein
.	O

The	O
induction	O
by	O
pseudorabies	O
virus	O
of	O
an	O
IL	B-protein
-	I-protein
6	I-protein
construct	I-protein
containing	O
the	O
IL	B-protein
-	I-protein
6	I-protein
TATA	I-protein
box	I-protein
and	O
the	O
RNA	O
start	O
site	O
(	O
`	O
`	O
initiator	O
'	O
'	O
or	O
Inr	B-protein
element	I-protein
)	O
but	O
not	O
the	O
MRE	B-protein
region	I-protein
was	O
also	O
repressed	O
by	O
Dex	O
in	O
the	O
presence	O
of	O
wild	B-protein
-	I-protein
type	I-protein
GR	I-protein
.	O

The	O
mRNA	O
was	O
converted	O
to	O
cDNA	O
and	O
amplified	O
by	O
the	O
polymerase	B-protein
chain	O
reaction	O
technique	O
.	O

The	O
requirement	O
of	O
PilE	B-protein
in	O
pilus	O
biogenesis	O
was	O
confirmed	O
by	O
demonstrating	O
that	O
chromosomal	B-protein
pilE	I-protein
insertion	I-protein
mutants	I-protein
were	O
pilus	O
-	O
and	O
twitching	O
-	O
motility	O
deficient	O
.	O

Three	O
of	O
the	O
proteins	O
involved	O
in	O
checkpoint	O
signaling	O
,	O
Rad1	B-protein
,	O
Hus1	B-protein
,	O
and	O
Rad9	B-protein
,	O
have	O
been	O
shown	O
to	O
interact	O
by	O
immunoprecipitation	O
and	O
yeast	O
two	O
-	O
hybrid	O
studies	O
.	O

This	O
distribution	O
implies	O
that	O
the	O
polycistronic	O
precursor	O
is	O
imported	O
into	O
the	O
nucleolus	O
for	O
processing	O
to	O
the	O
mature	O
snoRNAs	O
,	O
and	O
that	O
the	O
import	O
or	O
processing	O
pathway	O
involves	O
coiled	O
bodies	O
.	O

There	O
was	O
also	O
a	O
highly	O
significant	O
correlation	O
between	O
total	O
selenium	O
intake	O
and	O
liver	O
selenium	O
concentration	O
(	O
r	O
=	O
0	O
.	O
99	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
after	O
1	O
mo	O
of	O
treatment	O
,	O
but	O
this	O
time	O
liver	O
selenium	O
did	O
not	O
change	O
with	O
time	O
,	O
and	O
the	O
correlation	O
remained	O
highly	O
significant	O
throughout	O
the	O
investigation	O
.	O

Instead	O
,	O
affective	O
flattening	O
was	O
associated	O
with	O
both	O
dopamine	B-protein
receptor	I-protein
sensitivity	O
and	O
psychomotor	O
slowing	O
.	O

Whereas	O
cDNA	O
hybridization	O
to	O
genomic	O
DNA	O
blots	O
indicated	O
a	O
small	O
subfamily	O
of	O
G0S19	B-protein
genes	I-protein
,	O
simple	O
patterns	O
of	O
bands	O
indicated	O
that	O
most	O
cDNAs	O
,	O
including	O
G0S30	B-protein
cDNA	I-protein
,	O
corresponded	O
to	O
single	O
-	O
copy	O
genes	O
.	O

Substitutions	O
introduced	O
at	O
bases	O
surrounding	O
the	O
ICR2	B-protein
motif	I-protein
yielded	O
levels	O
of	O
pRNA	O
replication	O
that	O
differed	O
,	O
depending	O
on	O
the	O
maintenance	O
of	O
a	O
putative	O
5	O
'	O
stem	O
-	O
loop	O
structure	O
in	O
the	O
positive	O
strand	O
of	O
the	O
viral	O
genome	O
.	O

Pneumoscrotum	O
is	O
a	O
rare	O
condition	O
that	O
receives	O
little	O
discussion	O
in	O
standard	O
texts	O
of	O
urology	O
.	O

The	O
subunit	O
protein	O
of	O
curli	B-protein
was	O
highly	O
homologous	O
at	O
its	O
amino	O
terminus	O
to	O
SEF	B-protein
-	I-protein
17	I-protein
,	O
the	O
subunit	O
protein	O
of	O
thin	B-protein
,	O
aggregative	O
fimbriae	O
of	O
Salmonella	O
enteritidis	O
27655	O
strain	O
3b	O
,	O
suggesting	O
that	O
these	O
fibres	O
form	O
a	O
novel	O
class	O
of	O
surface	O
organelles	O
on	O
enterobacteria	O
.	O

To	O
facilitate	O
manipulation	O
of	O
large	O
genomic	O
sequences	O
,	O
we	O
developed	O
a	O
method	O
of	O
converting	O
Escherichia	O
coli	O
P1	O
artificial	O
chromosomes	O
(	O
PACs	O
)	O
into	O
yeast	O
artificial	O
chromosomes	O
(	O
YACs	O
)	O
.	O

The	O
effect	O
of	O
anticonvulsants	O
on	O
sodium	B-protein
-	I-protein
potassium	I-protein
-	I-protein
activated	I-protein
ATPase	I-protein
,	O
sodium	O
,	O
and	O
potassim	O
in	O
cortex	O
.	O

We	O
have	O
previously	O
identified	O
,	O
by	O
screening	O
a	O
lambda	O
gt11	O
expression	O
library	O
,	O
murine	B-protein
protein	I-protein
mXBP	I-protein
,	O
which	O
binds	O
to	O
a	O
sequence	O
which	O
overlaps	O
the	O
3	O
'	O
end	O
of	O
the	O
murine	B-protein
class	I-protein
II	I-protein
major	I-protein
histocompatibility	I-protein
complex	I-protein
A	I-protein
alpha	I-protein
gene	I-protein
X	I-protein
box	I-protein
,	O
a	O
conserved	O
transcription	O
element	O
found	O
upstream	O
of	O
all	O
class	B-protein
II	I-protein
genes	I-protein
.	O

Purification	O
and	O
cloning	O
of	O
a	O
novel	O
serine	B-protein
protease	I-protein
,	O
RNK	B-protein
-	I-protein
Met	I-protein
-	I-protein
1	I-protein
,	O
from	O
the	O
granules	O
of	O
a	O
rat	O
natural	O
killer	O
cell	O
leukemia	O
.	O

Positive	O
and	O
significant	O
correlations	O
were	O
found	O
between	O
the	O
weeks	O
of	O
pregnancy	O
and	O
Se	O
levels	O
in	O
kidney	O
(	O
r	O
=	O
0	O
.	O
433	O
,	O
P	O
=	O
0	O
.	O
023	O
)	O
and	O
heart	O
(	O
r	O
=	O
0	O
.	O
313	O
,	O
P	O
=	O
0	O
.	O
030	O
)	O
.	O

The	O
measurement	O
of	O
NO	O
in	O
biological	O
systems	O
using	O
chemiluminescence	O
.	O

In	O
female	O
Sl	B-protein
(	I-protein
pan	I-protein
)	I-protein
/	I-protein
Sl	I-protein
(	I-protein
pan	I-protein
)	I-protein
mice	O
,	O
ovarian	O
follicle	O
development	O
is	O
arrested	O
at	O
the	O
one	O
layered	O
cuboidal	O
stage	O
as	O
a	O
result	O
of	O
reduced	O
KL	B-protein
expression	O
in	O
follicle	O
cells	O
,	O
indicating	O
a	O
role	O
for	O
c	B-protein
-	I-protein
kit	I-protein
in	O
oocyte	O
growth	O
.	O

The	O
protooncogene	O
c	B-protein
-	I-protein
myb	I-protein
encodes	O
a	O
nuclear	O
transcription	O
factor	O
that	O
binds	O
to	O
DNA	O
in	O
a	O
sequence	O
-	O
specific	O
manner	O
and	O
transactivates	O
transcription	O
of	O
several	O
viral	O
and	O
cellular	O
genes	O
.	O

The	O
present	O
study	O
was	O
initiated	O
to	O
explore	O
the	O
potential	O
of	O
a	O
hybrid	O
biological	O
reactor	O
,	O
combining	O
trickling	O
filter	O
(	O
TF	O
)	O
and	O
activated	O
sludge	O
process	O
(	O
ASP	O
)	O
,	O
to	O
treat	O
wastewater	O
containing	O
trichloroethylene	O
(	O
TCE	O
)	O
at	O
ambient	O
temperature	O
at	O
different	O
hydraulic	O
retention	O
time	O
(	O
HRT	O
)	O
.	O

In	O
the	O
absence	O
of	O
E1A243	B-protein
,	O
YY1	B-protein
represses	O
CRE	O
-	O
dependent	O
transcription	O
of	O
c	B-protein
-	I-protein
fos	I-protein
by	O
physically	O
interacting	O
with	O
ATF	B-protein
/	I-protein
CREB	I-protein
proteins	I-protein
bound	O
to	O
the	O
-	B-protein
67	I-protein
CRE	I-protein
.	O

Biochemical	O
analysis	O
shows	O
that	O
Ssm1p	B-protein
is	O
a	O
structural	O
protein	O
that	O
forms	O
part	O
of	O
the	O
largest	O
60S	B-protein
ribosomal	I-protein
subunit	I-protein
,	O
which	O
does	O
not	O
exist	O
in	O
a	O
pool	O
of	O
free	O
proteins	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
altitude	O
on	O
adolescent	O
growth	O
and	O
development	O
,	O
three	O
groups	O
of	O
healthy	O
,	O
well	O
-	O
nourished	O
youth	O
of	O
similar	O
socioeconomic	O
status	O
and	O
ethnic	O
grouping	O
who	O
resided	O
at	O
sea	O
level	O
(	O
n	O
=	O
1262	O
subjects	O
)	O
,	O
mid	O
-	O
altitude	O
(	O
n	O
=	O
1743	O
subjects	O
)	O
,	O
and	O
high	O
altitude	O
(	O
n	O
=	O
1137	O
subjects	O
)	O
were	O
studied	O
.	O

A	O
third	O
ORF	O
,	O
ORF5	O
,	O
shows	O
homology	O
with	O
gene	B-protein
agrB	I-protein
from	O
Staphylococcus	O
aureus	O
,	O
which	O
is	O
involved	O
in	O
the	O
mechanism	O
of	O
regulation	O
of	O
the	O
virulence	O
phenotype	O
in	O
this	O
species	O
.	O

Calcifications	O
in	O
the	O
thoracic	O
aorta	O
at	O
the	O
level	O
of	O
the	O
11th	O
and	O
the	O
12th	O
thoracic	O
vertebrae	O
in	O
592	O
men	O
and	O
333	O
women	O
were	O
studied	O
using	O
computed	O
tomography	O
.	O

Most	O
patients	O
harboring	O
metronidazole	O
-	O
and	O
clarithromycin	O
-	O
resistant	O
strains	O
were	O
eradicated	O
at	O
an	O
equal	O
rate	O
by	O
each	O
of	O
the	O
three	O
regimens	O
.	O

Here	O
we	O
show	O
that	O
the	O
type	O
of	O
tyrosine	B-protein
kinase	I-protein
receptor	I-protein
stimulated	O
also	O
participates	O
in	O
the	O
nature	O
of	O
the	O
cAMP	O
effect	O
.	O

The	O
structure	O
of	O
the	O
enhancer	O
was	O
also	O
probed	O
by	O
inserting	O
a	O
pair	O
of	O
complementary	O
synthetic	O
oligodeoxynucleotides	O
which	O
represented	O
the	O
region	O
between	O
nt	O
positions	O
-	O
235	O
and	O
-	O
215	O
into	O
a	O
truncated	O
template	O
which	O
lacked	O
the	O
enhancer	O
.	O

We	O
investigated	O
the	O
production	O
of	O
hyaluronan	O
(	O
HA	O
)	O
and	O
its	O
effect	O
on	O
cell	O
motility	O
in	O
cells	O
expressing	O
the	O
v	B-protein
-	I-protein
src	I-protein
mutants	I-protein
.	O

For	O
85Sr	O
,	O
larger	O
-	O
than	O
-	O
expected	O
distribution	O
coefficients	O
were	O
obtained	O
in	O
the	O
desorption	O
experiments	O
,	O
an	O
indication	O
of	O
the	O
irreversible	O
formation	O
of	O
metal	O
-	O
oxyhydroxides	O
during	O
a	O
slow	O
reaction	O
.	O

The	O
role	O
of	O
HIV	B-protein
tat	I-protein
,	O
which	O
is	O
the	O
main	O
enhancing	O
factor	O
for	O
viral	O
LTR	O
,	O
in	O
the	O
regulation	O
of	O
IL	B-protein
-	I-protein
2	I-protein
gene	I-protein
transcription	O
has	O
been	O
studied	O
following	O
transient	O
expression	O
of	O
the	O
tat	B-protein
gene	I-protein
in	O
phorbol	O
ester	O
and	O
calcium	O
ionophore	O
-	O
activated	O
Jurkat	O
cells	O
transfected	O
with	O
IL	B-protein
-	I-protein
2	I-protein
promoter	I-protein
-	I-protein
chloramphenicol	I-protein
acetyltransferase	I-protein
reporter	I-protein
constructs	I-protein
.	O

Activation	O
of	O
ERK1	B-protein
/	I-protein
2	I-protein
is	O
correlated	O
with	O
induction	O
of	O
the	O
immediate	O
-	O
early	O
response	O
genes	O
.	O

We	O
argue	O
that	O
the	O
primary	O
role	O
of	O
hh	B-protein
in	O
controlling	O
polarity	O
is	O
to	O
cause	O
anterior	O
compartment	O
cells	O
to	O
reverse	O
their	O
interpretation	O
of	O
an	O
underlying	O
symmetric	O
polarization	O
.	O

Four	O
ruminally	O
and	O
duodenally	O
cannulated	O
Hampshire	O
wethers	O
were	O
used	O
in	O
a	O
4	O
x	O
4	O
Latin	O
square	O
experiment	O
to	O
determine	O
whether	O
linoleoyl	O
methionine	O
and	O
calcium	O
linoleate	O
would	O
increase	O
duodenal	O
flow	O
of	O
unsaturated	O
fatty	O
acids	O
(	O
C18	O
:	O
2	O
+	O
cis	O
C18	O
:	O
1	O
)	O
.	O

Polypeptides	O
of	O
the	O
same	O
apparent	O
sizes	O
are	O
detected	O
in	O
spores	O
of	O
a	O
cotE	B-protein
null	O
mutant	O
,	O
on	O
which	O
basis	O
we	O
infer	O
that	O
the	O
products	O
of	O
the	O
cotJ	B-protein
operon	I-protein
are	O
required	O
for	O
the	O
normal	O
formation	O
of	O
the	O
inner	O
layers	O
of	O
the	O
coat	O
or	O
are	O
themselves	O
structural	O
components	O
of	O
the	O
coat	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Studies	O
on	O
the	O
intracutaneous	O
infection	O
of	O
rabbits	O
by	O
Staphylococcus	O
aureus	O
.	O

Differential	O
regulation	O
of	O
the	O
alpha	O
/	O
beta	O
interferon	O
-	O
stimulated	O
Jak	B-protein
/	I-protein
Stat	I-protein
pathway	I-protein
by	O
the	O
SH2	B-protein
domain	O
-	O
containing	O
tyrosine	B-protein
phosphatase	I-protein
SHPTP1	I-protein
.	O

The	O
retrovesical	O
hydatid	O
cyst	O
is	O
a	O
very	O
rare	O
site	O
.	O

Thus	O
,	O
hypoxia	O
-	O
inducible	O
nuclear	O
import	O
and	O
transactivation	O
by	O
recruitment	O
of	O
CBP	B-protein
can	O
be	O
functionally	O
separated	O
from	O
one	O
another	O
and	O
play	O
critical	O
roles	O
in	O
signal	O
transduction	O
by	O
HIF	B-protein
-	I-protein
1alpha	I-protein
.	O

The	O
recovery	O
index	O
(	O
T25	O
-	O
T75	O
)	O
after	O
the	O
infusion	O
stopped	O
was	O
similar	O
in	O
patients	O
who	O
received	O
mivacurium	O
and	O
those	O
who	O
received	O
suxamethonium	O
.	O

During	O
conventional	O
hemofiltration	O
using	O
substitution	O
fluid	O
with	O
a	O
Na	O
+	O
concentration	O
of	O
140	O
mEq	O
/	O
L	O
,	O
a	O
decrease	O
in	O
extracellular	O
fluid	O
volume	O
was	O
noted	O
whereas	O
the	O
intracellular	O
fluid	O
volume	O
was	O
unaltered	O
.	O

Cells	O
respond	O
to	O
the	O
accumulation	O
of	O
unfolded	O
proteins	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
by	O
increasing	O
the	O
transcription	O
of	O
the	O
genes	O
encoding	O
ER	O
-	O
resident	O
chaperone	B-protein
proteins	I-protein
.	O

The	O
intracoronary	O
administration	O
of	O
both	O
drugs	O
markedly	O
reduced	O
the	O
incidence	O
of	O
VF	O
induced	O
by	O
the	O
release	O
of	O
a	O
40	O
-	O
min	O
coronary	O
artery	O
occlusion	O
.	O

In	O
comparison	O
with	O
normal	O
pregnant	O
women	O
and	O
normal	O
non	O
-	O
pregnant	O
women	O
,	O
women	O
with	O
PIH	O
showed	O
an	O
increase	O
in	O
heart	O
rate	O
,	O
suggesting	O
an	O
increased	O
peripheral	O
sympathetic	O
tone	O
,	O
and	O
an	O
initial	O
derangement	O
in	O
renal	O
function	O
as	O
shown	O
by	O
the	O
increase	O
in	O
serum	O
uric	O
acid	O
and	O
reduction	O
in	O
sodium	O
excretion	O
and	O
total	O
and	O
fractional	O
calcium	O
excretion	O
at	O
any	O
given	O
level	O
of	O
sodium	O
excretion	O
.	O

However	O
,	O
it	O
was	O
synthesized	O
at	O
both	O
temperatures	O
after	O
addition	O
of	O
A23187	O
.	O

The	O
YccA	B-protein
protein	I-protein
was	O
found	O
to	O
be	O
degraded	O
in	O
an	O
FtsH	O
-	O
dependent	O
manner	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
whereas	O
the	O
YccA11	B-protein
mutant	I-protein
protein	I-protein
,	O
lacking	O
eight	O
amino	O
acid	O
residues	O
within	O
the	O
amino	O
-	O
terminal	O
cytoplasmic	O
domain	O
,	O
was	O
refractory	O
to	O
the	O
degradation	O
.	O

Interestingly	O
,	O
the	O
CYP71D20	B-protein
-	I-protein
encoded	I-protein
enzyme	I-protein
activity	O
was	O
capable	O
of	O
converting	O
both	O
5	O
-	O
epi	O
-	O
aristolochene	O
and	O
1	O
-	O
deoxycapsidiol	O
to	O
capsidiol	O
in	O
vitro	O
,	O
consistent	O
with	O
the	O
notion	O
that	O
this	O
P450	B-protein
enzyme	I-protein
catalyzes	O
both	O
hydroxylations	O
of	O
its	O
hydrocarbon	O
substrate	O
.	O

Parathyroid	B-protein
hormone	I-protein
regulation	O
of	O
bone	B-protein
sialoprotein	I-protein
(	O
BSP	B-protein
)	O
gene	O
transcription	O
is	O
mediated	O
through	O
a	O
pituitary	B-protein
-	I-protein
specific	I-protein
transcription	I-protein
factor	I-protein
-	I-protein
1	I-protein
(	O
Pit	B-protein
-	I-protein
1	I-protein
)	O
motif	O
in	O
the	O
rat	B-protein
BSP	I-protein
gene	I-protein
promoter	I-protein
.	O

Hypoglycemic	O
action	O
of	O
`	O
`	O
he	O
xiang	O
zhuang	O
qi	O
gong	O
'	O
'	O
and	O
its	O
mechanism	O
on	O
diabetes	O
mellitus	O
.	O

While	O
all	O
deletions	O
within	O
the	O
sequence	O
coding	O
for	O
the	O
mature	O
tRNA	O
led	O
to	O
inactivity	O
of	O
the	O
mutated	O
genes	O
,	O
substitution	O
of	O
the	O
central	O
portion	O
by	O
concatenated	B-protein
Hind	I-protein
III	I-protein
linkers	I-protein
produced	O
gene	O
units	O
active	O
in	O
transcription	O
.	O

Similarly	O
,	O
a	O
human	O
but	O
not	O
a	O
bovine	B-protein
alpha	I-protein
transgene	I-protein
was	O
expressed	O
in	O
placenta	O
in	O
transgenic	O
mice	O
.	O

However	O
,	O
Southern	O
blot	O
and	O
karyotype	O
analyses	O
did	O
not	O
reveal	O
any	O
significant	O
changes	O
in	O
copy	O
number	O
or	O
gross	O
rearrangements	O
of	O
the	O
p53	B-protein
gene	I-protein
in	O
any	O
of	O
the	O
p53	B-protein
-	I-protein
cell	O
lines	O
.	O

Recognition	O
mechanisms	O
of	O
the	O
minus	O
-	O
strand	O
origin	O
of	O
phage	O
f1	O
by	O
Escherichia	B-protein
coli	I-protein
RNA	I-protein
polymerase	I-protein
.	O

Phosphorylation	O
and	O
spindle	O
pole	O
body	O
localization	O
of	O
the	O
Cdc15p	B-protein
mitotic	I-protein
regulatory	I-protein
protein	I-protein
kinase	I-protein
in	I-protein
budding	I-protein
yeast	I-protein
.	O

Three	O
pyridoxine	O
derivatives	O
have	O
been	O
isolated	O
from	O
the	O
fresh	O
stem	O
bark	O
of	O
Albizzia	O
julibrissin	O
DURAZZ	O
.	O
.	O

The	O
active	O
state	O
is	O
terminated	O
by	O
hydrolysis	O
of	O
bound	O
GTP	O
,	O
producing	O
inactive	O
ARF	B-protein
-	I-protein
GDP	I-protein
.	O

All	O
patients	O
in	O
the	O
control	O
group	O
showed	O
a	O
significant	O
improvement	O
in	O
their	O
PEFR	O
while	O
only	O
3	O
patients	O
in	O
the	O
treated	O
group	O
showed	O
an	O
improvement	O
.	O

A	O
Golgi	O
study	O
of	O
the	O
sixth	O
layer	O
of	O
the	O
cerebral	O
cortex	O
.	O

The	O
availability	O
of	O
sequence	O
from	O
multiple	O
species	O
has	O
permitted	O
us	O
to	O
determine	O
that	O
the	O
UBE	O
site	O
has	O
close	O
similarity	O
to	O
motifs	O
that	O
bind	O
members	O
of	O
the	O
NF	B-protein
-	I-protein
1	I-protein
family	I-protein
of	I-protein
transcription	I-protein
factors	O
.	O

To	O
address	O
this	O
issue	O
,	O
the	O
gene	O
for	O
factor	B-protein
Y	I-protein
has	O
been	O
cloned	O
molecularly	O
and	O
its	O
DNA	O
sequence	O
has	O
been	O
determined	O
.	O

Retention	O
behavior	O
of	O
steroids	O
in	O
gas	O
chromatography	O
with	O
a	O
series	O
of	O
combination	O
columns	O
.	O

We	O
found	O
that	O
the	O
relative	O
strengths	O
of	O
the	O
promoters	O
were	O
similar	O
in	O
different	O
contexts	O
.	O

In	O
MCCP	O
functions	O
of	O
the	O
source	O
emission	O
,	O
surface	O
reflection	O
,	O
photoacceptor	O
sensitivity	O
are	O
approximated	O
by	O
the	O
normal	O
distribution	O
curves	O
.	O

A	O
comparative	O
study	O
of	O
the	O
total	O
protein	O
profiles	O
of	O
wild	O
-	O
type	O
S	O
.	O
entomophila	O
UC9	O
and	O
mutant	O
UC21	O
revealed	O
that	O
the	O
mutant	O
lacked	O
an	O
approximately	O
44	O
-	O
kDa	O
protein	O
and	O
overexpressed	O
an	O
approximately	O
20	O
-	O
kDa	O
protein	O
.	O

The	O
images	O
showed	O
rapid	O
,	O
predominantly	O
urinary	O
excretion	O
of	O
99mTc	O
ciprofloxacin	O
,	O
with	O
low	O
to	O
absent	O
brain	O
,	O
lung	O
and	O
bone	O
marrow	O
uptake	O
and	O
low	O
liver	O
uptake	O
and	O
excretion	O
.	O

To	O
measure	O
the	O
enhancer	O
activity	O
of	O
DR60	B-protein
,	O
a	O
reporter	O
plasmid	O
was	O
constructed	O
that	O
contained	O
DR60	B-protein
cloned	O
upstream	O
of	O
the	O
reporter	O
chloramphenicol	B-protein
acetyltransferase	I-protein
gene	I-protein
under	O
the	O
control	O
of	O
the	O
delayed	B-protein
-	I-protein
early	I-protein
39K	I-protein
promoter	I-protein
.	O

Identification	O
of	O
an	O
immediate	B-protein
-	I-protein
early	I-protein
gene	I-protein
in	O
the	O
Marek	O
'	O
s	O
disease	O
virus	O
long	O
internal	O
repeat	O
region	O
which	O
encodes	O
a	O
unique	O
14	O
-	O
kilodalton	O
polypeptide	O
.	O

An	O
alternative	O
method	O
of	O
UKM	O
is	O
proposed	O
based	O
on	O
collecting	O
a	O
small	O
fraction	O
of	O
spent	O
dialysate	O
flow	O
for	O
3	O
consecutive	O
dialyses	O
.	O

The	O
decline	O
in	O
the	O
activity	O
of	O
cytochrome	B-protein
oxidase	I-protein
,	O
peroxidase	B-protein
and	O
in	O
the	O
lipid	O
content	O
of	O
peripheral	O
neutrophils	O
was	O
followed	O
by	O
a	O
decrease	O
in	O
the	O
phagocytic	O
activity	O
.	O

MS	O
characteristics	O
of	O
coumarins	O
,	O
psoralens	O
and	O
polymethoxylated	O
flavones	O
with	O
different	O
substitution	O
patterns	O
were	O
determined	O
on	O
the	O
basis	O
of	O
the	O
response	O
obtained	O
with	O
the	O
APcI	O
interface	O
.	O

We	O
have	O
used	O
mutation	O
-	O
directed	O
chemical	O
cross	O
-	O
linking	O
with	O
bis	O
(	O
sulfosuccinimidyl	O
)	O
suberate	O
(	O
BS3	O
)	O
to	O
investigate	O
the	O
architecture	O
of	O
the	O
gp41	B-protein
oligomer	I-protein
.	O

The	O
clinico	O
-	O
pathological	O
data	O
from	O
a	O
patient	O
with	O
irreversible	O
post	O
-	O
partum	O
renal	O
failure	O
(	O
IPRF	O
)	O
are	O
presented	O
.	O

Study	O
of	O
the	O
energy	O
metabolism	O
of	O
the	O
sensomotor	O
cortex	O
and	O
hippocampus	O
by	O
the	O
(	O
14C	O
)	O
2	O
-	O
deoxyglucose	O
method	O
during	O
the	O
development	O
of	O
dissociated	O
states	O
.	O

In	O
76	O
%	O
of	O
59	O
lead	O
-	O
toxic	O
children	O
,	O
bone	O
lead	O
values	O
measured	O
by	O
LXRF	O
were	O
equal	O
to	O
or	O
greater	O
than	O
those	O
measured	O
in	O
normal	O
and	O
industrially	O
exposed	O
adults	O
.	O

Only	O
seven	O
patients	O
,	O
five	O
of	O
whom	O
have	O
metastatic	O
disease	O
,	O
survive	O
more	O
than	O
10	O
years	O
after	O
first	O
presentation	O
;	O
nine	O
patients	O
,	O
one	O
of	O
whom	O
has	O
secondaries	O
,	O
survive	O
for	O
5	O
years	O
or	O
less	O
.	O

The	O
1	O
.	O
9	O
-	O
kb	O
C	B-protein
mu	I-protein
RNA	O
contains	O
the	O
3	O
'	O
sequence	O
characteristic	O
of	O
secreted	O
mu	B-protein
chain	I-protein
,	O
whereas	O
the	O
longer	O
species	O
bear	O
that	O
of	O
membrane	O
-	O
bound	O
mu	B-protein
chin	O
.	O

From	O
May	O
1985	O
to	O
May	O
1989	O
,	O
126	O
necropsies	O
were	O
performed	O
at	O
the	O
Sao	O
Paulo	O
City	O
Morgue	O
on	O
cadavers	O
of	O
individuals	O
AIDS	O
victims	O
whose	O
unnatural	O
deaths	O
had	O
prompted	O
police	O
investigations	O
.	O

Rad6	B-protein
mutants	I-protein
display	O
a	O
remarkably	O
pleiotropic	O
phenotype	O
,	O
implicating	O
the	O
protein	O
in	O
DNA	O
damage	O
-	O
induced	O
mutagenesis	O
,	O
postreplication	O
repair	O
,	O
repression	O
of	O
retrotransposition	O
,	O
and	O
sporulation	O
.	O

The	O
mammalian	B-protein
homeodomain	I-protein
proteins	I-protein
encoded	O
by	O
Hox	B-protein
genes	I-protein
play	O
an	O
important	O
role	O
in	O
embryonic	O
development	O
by	O
providing	O
positional	O
queues	O
which	O
define	O
developmental	O
identities	O
along	O
the	O
anteroposterior	O
axis	O
of	O
developing	O
organisms	O
.	O

Negative	O
-	O
staining	O
,	O
refractile	O
mycobacteria	O
in	O
Romanowsky	O
-	O
stained	O
smears	O
.	O

The	O
effective	O
and	O
low	O
toxic	O
dose	O
schedules	O
of	O
KW	O
-	O
2083	O
should	O
be	O
investigated	O
further	O
.	O

We	O
have	O
isolated	O
a	O
new	O
human	B-protein
RING	I-protein
-	I-protein
finger	I-protein
gene	I-protein
(	O
RNF4	B-protein
)	O
that	O
encodes	O
a	O
190	O
-	O
amino	O
-	O
acid	O
protein	O
.	O

The	O
PSS	B-protein
gene	I-protein
was	O
subcloned	O
into	O
a	O
1	O
.	O
1	O
-	O
kb	O
fragment	O
of	O
the	O
yeast	O
DNA	O
on	O
the	O
YEp13	O
vector	O
.	O

Interestingly	O
,	O
an	O
increase	O
of	O
distance	O
per	O
se	O
did	O
not	O
have	O
a	O
deleterious	O
effect	O
on	O
translation	O
efficiency	O
.	O

Per	O
kg	O
FFM	O
SMR	O
was	O
almost	O
restored	O
to	O
baseline	O
values	O
for	O
the	O
EX	O
group	O
,	O
whereas	O
the	O
non	O
-	O
exercising	O
subjects	O
still	O
showed	O
depressed	O
values	O
(	O
EX	O
3	O
.	O
7	O
per	O
cent	O
and	O
D	O
+	O
DE	O
15	O
.	O
8	O
per	O
cent	O
lower	O
than	O
before	O
treatment	O
;	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

GLUT5	B-protein
mRNA	I-protein
is	O
expressed	O
at	O
highest	O
levels	O
in	O
small	O
intestine	O
and	O
at	O
much	O
lower	O
levels	O
in	O
kidney	O
,	O
skeletal	O
muscle	O
,	O
and	O
adipose	O
tissue	O
.	O

Characterization	O
of	O
CR1	B-protein
repeat	I-protein
random	O
PCR	O
markers	O
for	O
mapping	O
the	O
chicken	O
genome	O
.	O

Comparative	O
analysis	O
with	O
an	O
antiandrogen	O
niftolid	O
and	O
synthetic	B-protein
GnRH	I-protein
was	O
carried	O
out	O
in	O
22	O
normal	O
subjects	O
,	O
14	O
patients	O
with	O
primary	O
and	O
20	O
ones	O
with	O
secondary	O
hypogonadism	O
,	O
and	O
in	O
5	O
patients	O
with	O
clinical	O
signs	O
of	O
gonadal	O
insufficiency	O
and	O
obscure	O
diagnosis	O
in	O
order	O
to	O
elucidate	O
the	O
pituitary	B-protein
gonadotropin	I-protein
reserves	O
.	O

We	O
have	O
isolated	O
a	O
novel	O
protein	O
from	O
Drosophila	O
nuclear	O
extracts	O
which	O
binds	O
specifically	O
to	O
a	O
site	O
in	O
this	O
second	O
region	O
.	O

These	O
data	O
suggest	O
that	O
ADAM	B-protein
-	I-protein
TS12	I-protein
may	O
play	O
roles	O
in	O
pulmonary	O
cells	O
during	O
fetal	O
development	O
or	O
in	O
tumor	O
processes	O
through	O
its	O
proteolytic	O
activity	O
or	O
as	O
a	O
molecule	O
potentially	O
involved	O
in	O
regulation	O
of	O
cell	O
adhesion	O
.	O

Furthermore	O
,	O
overexpression	O
of	O
AML3	B-protein
/	I-protein
CBFalpha1	I-protein
could	O
rescue	O
the	O
AML1	B-protein
-	I-protein
ETO	I-protein
repression	O
.	O

The	O
5	O
'	O
ends	O
of	O
F3R	B-protein
late	O
transcripts	O
were	O
located	O
to	O
an	O
A	O
within	O
the	O
sequence	B-protein
5	I-protein
'	I-protein
-	I-protein
TAAAG	I-protein
,	O
41	O
nt	O
downstream	O
from	O
the	O
early	O
promoter	O
and	O
17	O
nt	O
upstream	O
from	O
the	O
initiation	O
codon	O
.	O

These	O
results	O
were	O
robust	O
to	O
changes	O
in	O
the	O
baseline	O
assumptions	O
of	O
the	O
model	O
.	O

Lack	O
of	O
association	O
between	O
Kawasaki	O
syndrome	O
and	O
infection	O
with	O
Rickettsia	O
conorii	O
,	O
Rickettsia	O
typhi	O
,	O
Coxiella	O
burnetii	O
or	O
Ehrlichia	O
phagocytophila	O
group	O
.	O

Determination	O
of	O
aortic	O
distensibility	O
and	O
its	O
variations	O
in	O
arterial	O
hypertension	O
.	O

Members	O
of	O
the	O
AP	B-protein
-	I-protein
1	I-protein
superfamily	I-protein
of	I-protein
basic	I-protein
-	I-protein
leucine	I-protein
zipper	I-protein
factors	I-protein
bind	O
to	O
the	O
StRE	B-protein
.	O

Finally	O
,	O
a	O
complementary	O
footprinting	O
analysis	O
of	O
the	O
upstream	O
region	O
of	O
the	O
constitutively	O
expressed	O
HSC82	B-protein
gene	I-protein
reveals	O
the	O
presence	O
of	O
three	O
discrete	O
protein	O
complexes	O
.	O

The	O
somatoform	O
conundrum	O
:	O
a	O
question	O
of	O
nosological	O
valves	O
.	O

Gonadotropin	B-protein
levels	O
in	O
mothers	O
who	O
have	O
had	O
two	O
sets	O
of	O
DZ	O
twins	O
.	O

When	O
the	O
LCx	O
was	O
partially	O
occluded	O
,	O
mild	O
PM	O
-	O
induced	O
tachycardia	O
resulted	O
in	O
decreased	O
AoP	O
(	O
P	O
=	O
0	O
.	O
045	O
)	O
as	O
well	O
as	O
in	O
decreased	O
SV	O
(	O
P	O
=	O
0	O
.	O
048	O
)	O
;	O
the	O
LVEDP	O
remained	O
high	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

Two	O
cases	O
with	O
marked	O
chronic	O
arm	O
lymphoedema	O
reported	O
major	O
and	O
persistent	O
improvements	O
in	O
arm	O
volume	O
for	O
at	O
least	O
12	O
months	O
after	O
treatment	O
with	O
HBO2	O
.	O

The	O
M	O
-	O
3	O
subtype	O
was	O
an	O
adverse	O
prognostic	O
factor	O
.	O

Histopathology	O
and	O
pathogenesis	O
of	O
exanthematous	O
viroses	O
.	O

Quantitative	O
assays	O
in	O
which	O
the	O
activity	O
of	O
the	O
synthetic	B-protein
alpha	I-protein
s	I-protein
-	I-protein
1	I-protein
was	O
compared	O
to	O
that	O
of	O
native	O
purified	O
human	B-protein
erythrocyte	I-protein
type	I-protein
-	I-protein
1	I-protein
Gs	I-protein
,	O
indicated	O
that	O
the	O
two	O
products	O
are	O
equipotent	O
within	O
a	O
2	O
-	O
fold	O
margin	O
of	O
error	O
.	O

The	O
effect	O
of	O
the	O
Ca	O
entry	O
blocker	O
nitrendipine	O
,	O
the	O
antioxidant	O
superoxide	B-protein
dismutase	I-protein
(	O
SOD	B-protein
)	O
,	O
and	O
a	O
combination	O
of	O
nitrendipine	O
and	O
superoxide	B-protein
dismutase	I-protein
on	O
postischemic	O
renal	O
function	O
was	O
studied	O
in	O
four	O
groups	O
(	O
n	O
=	O
24	O
)	O
of	O
rats	O
.	O

European	O
Community	O
Huntington	O
'	O
s	O
Disease	O
Collaborative	O
Study	O
Group	O
.	O

Interestingly	O
,	O
a	O
portion	O
of	O
the	O
tail	O
domain	O
(	O
aa	O
,	O
1	O
,	O
094	O
-	O
1	O
,	O
830	O
)	O
shares	O
58	O
%	O
amino	O
acid	O
sequence	O
identity	O
with	O
a	O
723	O
-	O
aa	O
protein	O
from	O
mouse	O
brain	O
reported	O
to	O
be	O
a	O
glutamic	B-protein
acid	I-protein
decarboxylase	I-protein
.	O

A	O
multivariate	O
analysis	O
of	O
risk	O
factors	O
for	O
relapse	O
examined	O
age	O
,	O
WBC	O
at	O
diagnosis	O
,	O
blast	O
count	O
at	O
diagnosis	O
,	O
percentage	O
of	O
marrow	O
blasts	O
,	O
FAB	B-protein
subtype	O
,	O
the	O
number	O
of	O
remission	O
induction	O
courses	O
to	O
achieve	O
a	O
remission	O
,	O
maintenance	O
therapy	O
,	O
consolidation	O
therapy	O
,	O
marrow	O
cell	O
dose	O
,	O
donor	O
-	O
recipient	O
sex	O
,	O
GVHD	O
prophylaxis	O
regimen	O
and	O
isolation	O
and	O
decontamination	O
in	O
laminar	O
airflow	O
rooms	O
.	O

We	O
have	O
explored	O
the	O
mechanism	O
of	O
action	O
of	O
the	O
fibronectin	B-protein
splicing	I-protein
enhancer	I-protein
and	O
found	O
that	O
the	O
SE	B-protein
element	I-protein
is	O
required	O
for	O
efficient	O
assembly	O
of	O
early	O
splicing	O
complexes	O
,	O
allowing	O
a	O
more	O
efficient	O
interaction	O
of	O
the	O
U2	B-protein
snRNP	I-protein
with	O
branch	O
site	O
sequences	O
.	O

Unexpectedly	O
,	O
all	O
ENK	B-protein
-	I-protein
specific	I-protein
motifs	I-protein
formed	O
specific	O
and	O
highly	O
abundant	O
protein	O
-	O
DNA	O
complexes	O
when	O
nuclear	O
extracts	O
from	O
the	O
human	O
tumor	O
cell	O
line	O
(	O
HeLa	O
)	O
,	O
which	O
does	O
not	O
express	O
ENK	B-protein
,	O
were	O
used	O
.	O

Subsequently	O
,	O
HD	O
inhibited	O
healing	O
because	O
it	O
significantly	O
delayed	O
epithelialization	O
and	O
caused	O
protracted	O
inflammation	O
.	O

Vascular	O
responses	O
to	O
reactive	O
hyperemia	O
(	O
with	O
flow	O
increase	O
leading	O
to	O
endothelium	O
-	O
dependent	O
dilation	O
)	O
and	O
to	O
sublingual	O
glyceryl	O
trinitrate	O
(	O
GTN	O
;	O
endothelium	O
-	O
independent	O
dilation	O
)	O
were	O
recorded	O
.	O

We	O
compared	O
the	O
inhibitory	O
effect	O
of	O
naturally	O
occurring	O
mutant	B-protein
hTR	I-protein
beta	I-protein
1	I-protein
,	O
artificially	O
created	O
hTR	B-protein
alpha	I-protein
1	I-protein
mutants	I-protein
,	O
c	B-protein
-	I-protein
erbA	I-protein
alpha	I-protein
2	I-protein
and	O
the	O
human	B-protein
peroxisome	I-protein
proliferator	I-protein
-	I-protein
activated	I-protein
receptor	I-protein
(	O
hPPAR	B-protein
)	O
on	O
three	O
prototypic	O
T3	B-protein
-	I-protein
response	I-protein
elements	I-protein
(	O
TREs	B-protein
)	O
,	O
TRE	B-protein
-	I-protein
PAL	I-protein
,	O
DR	B-protein
+	I-protein
4	I-protein
and	O
TRE	B-protein
-	I-protein
LAP	I-protein
.	O

The	O
mean	O
change	O
in	O
HbA1	B-protein
,	O
adjusted	O
for	O
the	O
initial	O
value	O
,	O
was	O
-	O
0	O
.	O
4	O
%	O
in	O
the	O
experimental	O
and	O
+	O
0	O
.	O
5	O
%	O
in	O
the	O
control	O
group	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Regions	O
of	O
the	O
translated	O
open	O
reading	O
frames	O
of	O
cobA	B-protein
and	O
the	O
third	O
intron	O
of	O
the	O
cob	B-protein
gene	I-protein
in	I-protein
yeast	I-protein
show	O
high	O
amino	O
acid	O
homology	O
.	O

RNA	B-protein
polymerase	I-protein
IIA	I-protein
was	O
recovered	O
in	O
transcriptionally	O
active	O
complexes	O
in	O
reactions	O
in	O
which	O
the	O
input	O
enzyme	O
was	O
RNA	B-protein
polymerase	I-protein
IIA	I-protein
.	O

Isolation	O
and	O
genomic	O
structure	O
of	O
a	O
human	O
homolog	O
of	O
the	O
yeast	B-protein
periodic	I-protein
tryptophan	I-protein
protein	I-protein
2	I-protein
(	O
PWP2	B-protein
)	O
gene	O
mapping	O
to	O
21q22	O
.	O
3	O
.	O

In	O
14	O
of	O
21	O
infant	O
hearts	O
(	O
66	O
%	O
)	O
with	O
aortic	O
arch	O
interruption	O
between	O
the	O
left	O
common	O
carotid	O
and	O
left	O
subclavian	O
arteries	O
(	O
type	O
B	O
of	O
Celoria	O
and	O
Patton	O
)	O
,	O
the	O
right	O
subclavian	O
artery	O
(	O
SA	O
)	O
arose	O
anomalously	O
.	O

They	O
also	O
reported	O
that	O
E	B-protein
mu	I-protein
pim	I-protein
-	I-protein
1	I-protein
transgenic	O
mice	O
show	O
greatly	O
accelerated	O
lymphoma	O
development	O
when	O
infected	O
with	O
wild	O
-	O
type	O
M	O
-	O
MuLV	O
at	O
birth	O
.	O

This	O
slope	O
was	O
further	O
significantly	O
decreased	O
at	O
5	O
min	O
ischemia	O
(	O
-	O
26	O
.	O
5	O
+	O
/	O
-	O
8	O
.	O
8	O
@	O
mgr	O
;	O
m	O
/	O
mmHg	O
)	O
but	O
returned	O
toward	O
control	O
values	O
in	O
short	O
-	O
term	O
hibernating	O
myocardium	O
at	O
90	O
min	O
ischemia	O
(	O
-	O
17	O
.	O
2	O
+	O
/	O
-	O
6	O
.	O
6	O
@	O
mgr	O
;	O
m	O
/	O
mmHg	O
)	O
.	O

Lipid	O
concentration	O
and	O
lipase	B-protein
activity	O
in	O
the	O
epiphysis	O
of	O
adrenalectomized	O
rats	O
consuming	O
food	O
with	O
different	O
sodium	O
content	O
.	O

Results	O
showed	O
that	O
the	O
mean	O
bond	O
strength	O
of	O
H	O
.	O
T	O
.	O
V	O
.	O
specimens	O
ranged	O
from	O
9	O
.	O
6	O
to	O
13	O
.	O
12	O
kg	O
/	O
cm2	O
,	O
while	O
the	O
mean	O
bond	O
strength	O
of	O
R	O
.	O
T	O
.	O
V	O
.	O
specimens	O
ranged	O
from	O
0	O
.	O
36	O
to	O
1	O
.	O
75	O
kg	O
/	O
cm2	O
.	O

Nickel	O
is	O
the	O
most	O
common	O
cause	O
of	O
allergic	O
contact	O
dermatitis	O
in	O
Singapore	O
,	O
resulting	O
in	O
positive	O
reactions	O
in	O
patch	O
tests	O
between	O
7	O
and	O
14	O
%	O
.	O

J	O
.	O

The	O
CT	O
characteristics	O
are	O
discussed	O
and	O
the	O
recent	O
literature	O
is	O
reviewed	O
.	O

The	O
rationale	O
for	O
continuous	O
dopaminergic	O
stimulation	O
in	O
patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
.	O

Idiopathic	O
bilateral	O
recurrent	O
branch	O
retinal	O
arterial	O
occlusion	O
(	O
IBRBRAO	O
)	O
is	O
a	O
rare	O
syndrome	O
characterized	O
by	O
migraine	O
headaches	O
,	O
tinnitus	O
,	O
vertigo	O
,	O
hearing	O
loss	O
,	O
and	O
recurrent	O
branch	O
retinal	O
artery	O
occlusion	O
of	O
unknown	O
etiology	O
.	O

Male	B-protein
-	I-protein
enhanced	I-protein
antigen	I-protein
gene	I-protein
is	O
phylogenetically	O
conserved	O
and	O
expressed	O
at	O
late	O
stages	O
of	O
spermatogenesis	O
.	O

In	O
this	O
report	O
we	O
describe	O
the	O
isolation	O
of	O
a	O
Fab	B-protein
fragment	I-protein
(	O
Fab	B-protein
A8	I-protein
)	O
showing	O
a	O
high	O
relative	O
affinity	O
for	O
the	O
receptor	O
(	O
0	O
.	O
5	O
nM	O
)	O
.	O

In	O
the	O
Center	O
for	O
Human	O
Genetics	O
in	O
Leuven	O
,	O
predictive	O
DNA	O
-	O
testing	O
for	O
Huntington	O
'	O
s	O
disease	O
is	O
available	O
as	O
a	O
clinical	O
service	O
since	O
November	O
1987	O
,	O
initially	O
by	O
DNA	O
-	O
linkage	O
and	O
since	O
mid	O
1993	O
by	O
direct	O
mutation	O
analysis	O
.	O

Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
performed	O
with	O
the	O
HNF	B-protein
-	I-protein
3	I-protein
X	I-protein
and	I-protein
Y	I-protein
sites	I-protein
demonstrated	O
that	O
both	O
sites	O
are	O
capable	O
of	O
binding	O
HNF	B-protein
-	I-protein
3alpha	I-protein
and	O
HNF	B-protein
-	I-protein
3beta	I-protein
.	O

The	O
v	B-protein
-	I-protein
ets	I-protein
oncogene	I-protein
of	O
the	O
avian	O
retrovirus	O
E26	O
differs	O
from	O
its	O
cellular	O
progenitor	O
p68c	B-protein
-	I-protein
ets	I-protein
-	I-protein
1	I-protein
by	O
two	O
amino	O
acid	O
substitutions	O
(	O
alanine	O
285	O
and	O
isoleucine	O
445	O
in	O
c	B-protein
-	I-protein
ets	I-protein
-	I-protein
1	I-protein
both	O
substituted	O
by	O
valine	O
in	O
v	B-protein
-	I-protein
ets	I-protein
,	O
mutations	O
A	O
and	O
B	O
respectively	O
)	O
and	O
its	O
carboxy	O
-	O
terminal	O
end	O
(	O
mutation	O
C	O
)	O
.	O

Since	O
the	O
morphology	O
of	O
the	O
lesions	O
can	O
mimic	O
that	O
of	O
other	O
cutaneous	O
disorders	O
,	O
Bowen	O
'	O
s	O
disease	O
is	O
often	O
not	O
recognized	O
initially	O
.	O

This	O
promoter	O
could	O
direct	O
the	O
constitutive	O
expression	O
of	O
the	O
reporter	O
beta	O
-	O
galactosidase	O
at	O
high	O
frequency	O
in	O
transfected	O
colonies	O
of	O
transformed	O
cells	O
that	O
express	O
L	B-protein
-	I-protein
plastin	I-protein
constitutively	O
;	O
by	O
contrast	O
,	O
this	O
promoter	O
was	O
virtually	O
inactive	O
in	O
transfected	O
colonies	O
of	O
normal	O
fibroblasts	O
and	O
it	O
exhibited	O
a	O
low	O
frequency	O
of	O
constitutive	O
activation	O
in	O
transfected	O
colonies	O
of	O
in	O
vitro	O
SV40	O
-	O
transformed	O
fibroblasts	O
which	O
did	O
not	O
exhibit	O
L	B-protein
-	I-protein
plastin	I-protein
expression	O
.	O

This	O
study	O
examines	O
the	O
effects	O
of	O
hypovolemia	O
on	O
the	O
extracellular	O
ptO2	O
and	O
ptH	O
distributions	O
at	O
multiple	O
tissue	O
sites	O
using	O
a	O
recently	O
developed	O
multipoint	O
microelectrode	O
,	O
that	O
provides	O
simultaneous	O
measurements	O
of	O
ptO2	O
and	O
ptH	O
.	O

This	O
regulation	O
could	O
not	O
be	O
appreciably	O
modified	O
by	O
enhanced	O
expression	O
of	O
STAT	B-protein
proteins	I-protein
.	O

These	O
data	O
showed	O
:	O
that	O
progesterone	O
secretion	O
is	O
pulsatile	O
throughout	O
the	O
human	O
luteal	O
phase	O
,	O
with	O
maximum	O
frequency	O
in	O
the	O
mid	O
-	O
luteal	O
phase	O
;	O
that	O
during	O
the	O
mid	O
-	O
luteal	O
phase	O
most	O
subjects	O
had	O
progesterone	O
levels	O
both	O
above	O
and	O
below	O
currently	O
accepted	O
ovulatory	O
thresholds	O
;	O
the	O
use	O
of	O
a	O
single	O
measurement	O
of	O
progesterone	O
in	O
the	O
mid	O
-	O
luteal	O
phase	O
is	O
not	O
always	O
a	O
reliable	O
indicator	O
of	O
ovulation	O
;	O
a	O
threshold	O
greater	O
than	O
20	O
nmol	O
/	O
l	O
may	O
yield	O
an	O
unacceptable	O
number	O
of	O
false	O
negative	O
results	O
.	O

The	O
selenium	O
level	O
and	O
glutathione	B-protein
peroxidase	I-protein
activity	O
in	O
the	O
blood	O
,	O
liver	O
,	O
and	O
stomach	O
mucosa	O
were	O
significantly	O
higher	O
in	O
the	O
high	O
-	O
selenium	O
diet	O
group	O
than	O
in	O
the	O
low	O
-	O
selenium	O
diet	O
group	O
.	O

Oestrogen	O
implant	O
overdose	O
.	O

Electrocardiographic	O
QRS	O
complexes	O
and	O
vectorcardiographic	O
QRS	O
loop	O
.	O

Mucoepidermoid	O
and	O
acinous	O
cell	O
carcinomas	O
of	O
salivary	O
tissues	O
.	O

Fifty	O
-	O
six	O
semen	O
samples	O
were	O
included	O
in	O
this	O
study	O
;	O
18	O
were	O
subnormal	O
(	O
G1	O
)	O
and	O
38	O
were	O
normal	O
(	O
G2	O
)	O
based	O
on	O
World	O
Health	O
Organization	O
criteria	O
,	O
except	O
for	O
morphology	O
,	O
which	O
was	O
evaluated	O
according	O
to	O
strict	O
criteria	O
.	O

Both	O
groups	O
then	O
underwent	O
hypnotic	O
induction	O
,	O
and	O
completed	O
the	O
test	O
again	O
(	O
R2	O
)	O
.	O

We	O
examine	O
current	O
models	O
of	O
the	O
effects	O
of	O
aging	O
on	O
mean	O
response	O
time	O
and	O
show	O
how	O
they	O
might	O
be	O
reinterpreted	O
.	O

The	O
full	O
-	O
length	O
N	B-protein
gene	I-protein
,	O
encoded	O
by	O
open	O
reading	O
frame	O
7	O
,	O
was	O
cloned	O
from	O
the	O
Canadian	O
PRRS	O
virus	O
,	O
PA	O
-	O
8	O
.	O

All	O
lambs	O
with	O
B	O
breeding	O
had	O
significantly	O
higher	O
Hb	B-protein
levels	O
at	O
the	O
end	O
of	O
the	O
experiment	O
than	O
did	O
NB	O
lambs	O
.	O
b	O
and	O
S	O
x	O
B	O
lambs	O
had	O
higher	O
(	O
P	O
<	O
.	O
05	O
)	O
Hb	B-protein
levels	O
than	O
the	O
D	O
x	O
B	O
lambs	O
,	O
and	O
B	O
lambs	O
had	O
the	O
highest	O
(	O
P	O
<	O
.	O
05	O
)	O
mean	O
corpuscular	O
hemoglobin	B-protein
concentrations	O
.	O

In	O
the	O
stable	O
transfectants	O
(	O
BM3	O
cells	O
)	O
expressing	O
a	O
mutant	B-protein
bacterial	I-protein
P450	I-protein
AA	I-protein
epoxygenase	I-protein
,	O
F87V	O
BM3	O
,	O
which	O
was	O
genetically	O
engineered	O
to	O
metabolize	O
arachidonic	O
acid	O
only	O
to	O
14	O
,	O
15	O
-	O
EET	O
,	O
AA	O
did	O
not	O
induce	O
apoptosis	O
and	O
protected	O
against	O
agonist	O
-	O
induced	O
apoptosis	O
.	O

In	O
sorted	O
bone	O
marrow	O
cells	O
expression	O
of	O
both	O
VpreB	B-protein
genes	I-protein
was	O
detected	O
in	O
pro	O
-	O
B	O
/	O
pre	O
-	O
BI	O
and	O
large	O
pre	O
-	O
BII	O
cells	O
,	O
while	O
the	O
RNA	O
steady	O
state	O
levels	O
were	O
at	O
least	O
100	O
-	O
fold	O
lower	O
in	O
small	O
pre	O
-	O
BII	O
and	O
immature	O
/	O
mature	O
B	O
cells	O
.	O

Clinical	O
evaluation	O
of	O
the	O
Allergan	O
Humphrey	O
500	O
autorefractor	O
and	O
the	O
Nidek	O
AR	O
-	O
1000	O
autorefractor	O
.	O

Fourteen	O
different	O
species	O
(	O
eight	O
Platyhelmintha	O
,	O
one	O
Nematoda	O
and	O
five	O
Crustacea	O
)	O
have	O
been	O
inventorized	O
.	O

In	O
the	O
same	O
period	O
we	O
pointed	O
out	O
an	O
increase	O
of	O
hematocrit	O
(	O
from	O
29	O
%	O
to	O
35	O
%	O
)	O
and	O
of	O
the	O
Hb	B-protein
(	O
from	O
9	O
.	O
3	O
to	O
11	O
.	O
2	O
g	O
/	O
dl	O
)	O
.	O

Midge	O
control	O
in	O
flood	O
channels	O
.	O

Nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
-	I-protein
kappaB	I-protein
)	O
is	O
an	O
important	O
transcription	O
factor	O
for	O
the	O
genes	O
of	O
many	O
pro	O
-	O
inflammatory	O
proteins	O
and	O
is	O
strongly	O
activated	O
by	O
the	O
cytokines	O
interleukin	B-protein
-	I-protein
1	I-protein
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
alpha	I-protein
under	O
various	O
pathological	O
conditions	O
.	O

Identification	O
of	O
pulmonary	O
vein	O
stenosis	O
after	O
radiofrequency	O
ablation	O
for	O
atrial	O
fibrillation	O
using	O
MRI	O
.	O

EMSA	O
with	O
crude	O
nuclear	O
extracts	O
demonstrated	O
that	O
stimulation	O
with	O
CD40L	B-protein
results	O
in	O
the	O
induction	O
of	O
NF	B-protein
-	I-protein
kappaB	I-protein
complexes	I-protein
that	O
bind	O
to	O
each	O
of	O
the	O
three	O
NF	B-protein
-	I-protein
kappaB	I-protein
sites	I-protein
and	O
are	O
composed	O
mainly	O
of	O
p50	B-protein
and	O
RelB	B-protein
,	O
but	O
also	O
include	O
c	B-protein
-	I-protein
Rel	I-protein
and	O
p65	B-protein
.	O

Absorption	O
was	O
rapid	O
,	O
with	O
a	O
mean	O
time	O
to	O
peak	O
of	O
39	O
min	O
.	O

Post	O
-	O
transcriptional	O
regulation	O
of	O
ribosomal	B-protein
protein	I-protein
gene	I-protein
expression	O
during	O
development	O
in	O
Dictyostelium	O
discoideum	O
.	O

Myosin	B-protein
light	I-protein
chain	I-protein
kinase	I-protein
functions	O
downstream	O
of	O
Ras	B-protein
/	I-protein
ERK	I-protein
to	O
promote	O
migration	O
of	O
urokinase	O
-	O
type	O
plasminogen	O
activator	O
-	O
stimulated	O
cells	O
in	O
an	O
integrin	O
-	O
selective	O
manner	O
.	O

Thus	O
,	O
we	O
have	O
separated	O
the	O
signal	O
function	O
from	O
the	O
anchor	O
function	O
of	O
the	O
6	O
.	O
7K	O
SA	O
domain	O
.	O

Prevalence	O
of	O
sleep	O
-	O
disordered	O
breathing	O
(	O
SDB	O
)	O
is	O
reported	O
to	O
increase	O
in	O
menopausal	O
women	O
.	O

In	O
the	O
studies	O
described	O
in	O
this	O
report	O
,	O
we	O
have	O
investigated	O
the	O
signaling	O
pathway	O
(	O
s	O
)	O
that	O
are	O
responsible	O
for	O
CREB	B-protein
activation	O
in	O
normal	O
T	O
cells	O
.	O

With	O
only	O
purified	O
T	B-protein
antigen	I-protein
in	O
the	O
presence	O
of	O
topoisomerase	B-protein
I	I-protein
to	O
unwind	O
purified	O
DNA	O
,	O
ori	O
-	O
auxiliary	O
sequences	O
strongly	O
facilitated	O
T	O
-	O
antigen	O
-	O
dependent	O
DNA	O
conformational	O
changes	O
consistent	O
with	O
melting	O
the	O
first	O
50	O
base	O
pairs	O
.	O

CPDs	O
at	O
these	O
three	O
sites	O
may	O
partially	O
displace	O
TFIIIA	B-protein
,	O
thereby	O
enabling	O
rapid	O
repair	O
.	O

Inefficacy	O
of	O
phosphine	O
fumigation	O
against	O
ticks	O
.	O

Of	O
the	O
53	O
units	O
tested	O
during	O
sinusoidal	O
motion	O
at	O
0	O
.	O
05	O
Hz	O
(	O
9	O
.	O
1	O
cm	O
/	O
s	O
)	O
,	O
1	O
(	O
1	O
.	O
9	O
%	O
)	O
was	O
responsive	O
to	O
the	O
otolith	O
input	O
only	O
,	O
13	O
(	O
24	O
.	O
5	O
%	O
)	O
were	O
influenced	O
by	O
the	O
visual	O
input	O
only	O
and	O
23	O
(	O
43	O
.	O
4	O
%	O
)	O
responded	O
to	O
both	O
modalities	O
.	O

In	O
Cd	O
-	O
spiked	O
OECD	O
soil	O
,	O
internal	O
Cd	O
levels	O
were	O
linearly	O
related	O
to	O
external	O
Cd	O
concentrations	O
,	O
whereas	O
the	O
springtails	O
maintained	O
fixed	O
internal	O
levels	O
of	O
Cu	O
and	O
Zn	O
regardless	O
of	O
spiked	O
concentrations	O
.	O

In	O
general	O
,	O
two	O
separate	O
high	O
-	O
performance	O
liquid	O
chromatographic	O
runs	O
were	O
performed	O
,	O
one	O
for	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
determination	O
and	O
one	O
for	O
the	O
determination	O
of	O
the	O
monoamines	O
.	O

Amikacin	O
was	O
the	O
most	O
stable	O
and	O
tobramycin	O
was	O
the	O
least	O
stable	O
aminoglycoside	O
under	O
the	O
conditions	O
tested	O
.	O

Sequence	O
analysis	O
indicates	O
that	O
RBP21	B-protein
shares	O
homology	O
with	O
other	O
retinoblastoma	B-protein
-	I-protein
binding	I-protein
proteins	I-protein
in	O
the	O
pRb	B-protein
-	I-protein
binding	I-protein
motif	I-protein
LxCxE	I-protein
at	O
the	O
C	O
-	O
terminal	O
region	O
.	O

Rinit	O
reflects	O
the	O
Newtonian	O
resistances	O
and	O
Rdiff	O
represents	O
the	O
viscoelastic	O
/	O
inhomogeneous	O
pressure	O
dissipations	O
in	O
the	O
system	O
.	O

The	O
role	O
of	O
intraoperative	O
echocardiography	O
in	O
surgery	O
of	O
the	O
heart	O
and	O
large	O
vessels	O
.	O

As	O
the	O
length	O
of	O
the	O
fatty	O
acid	O
decreased	O
,	O
the	O
binding	O
affinity	O
was	O
reduced	O
;	O
myristic	O
acid	O
(	O
14	O
:	O
0	O
)	O
bound	O
with	O
a	O
K	O
(	O
d	O
)	O
of	O
1409	O
+	O
/	O
-	O
423	O
nM	O
,	O
but	O
medium	O
-	O
chain	O
(	O
decanoic	O
acid	O
,	O
10	O
:	O
0	O
)	O
and	O
short	O
-	O
chain	O
(	O
octanoic	O
acid	O
,	O
8	O
:	O
0	O
)	O
lipids	O
were	O
not	O
bound	O
at	O
all	O
.	O

The	O
sacT	B-protein
gene	I-protein
regulating	O
the	O
sacPA	B-protein
operon	I-protein
in	I-protein
Bacillus	I-protein
subtilis	I-protein
shares	O
strong	O
homology	O
with	O
transcriptional	O
antiterminators	O
.	O

The	O
gene	O
encoding	O
the	O
receptor	O
for	O
macrophage	B-protein
colony	I-protein
-	I-protein
stimulating	I-protein
factor	I-protein
1	I-protein
(	O
CSF	B-protein
-	I-protein
1	I-protein
)	O
,	O
the	O
c	B-protein
-	I-protein
fms	I-protein
protooncogene	I-protein
,	O
is	O
selectively	O
expressed	O
in	O
immature	O
and	O
mature	O
mononuclear	O
phagocytes	O
and	O
trophoblasts	O
.	O

They	O
are	O
subdivided	O
into	O
two	O
types	O
that	O
activate	O
transduction	O
pathways	O
via	O
different	O
cell	O
surface	O
receptors	O
.	O

The	O
corticosterone	O
synthesis	O
inhibitor	O
metyrapone	O
(	O
75	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
was	O
given	O
to	O
attenuate	O
the	O
rise	O
of	O
corticosterone	O
to	O
a	O
level	O
typical	O
of	O
stressed	O
males	O
.	O

This	O
effect	O
and	O
the	O
fact	O
that	O
all	O
three	O
doses	O
were	O
toxic	O
to	O
the	O
dams	O
dictated	O
that	O
a	O
second	O
experiment	O
be	O
carried	O
out	O
at	O
lower	O
doses	O
.	O

Both	O
examinations	O
are	O
sensitive	O
indicators	O
of	O
CNS	O
abnormalities	O
associated	O
with	O
bacterial	O
meningeal	O
infections	O
and	O
are	O
important	O
determinants	O
of	O
the	O
therapy	O
and	O
ultimate	O
prognosis	O
of	O
such	O
complications	O
.	O

Some	O
of	O
them	O
produce	O
gigantic	O
sperm	O
several	O
times	O
the	O
total	O
male	O
body	O
length	O
.	O

Modulation	O
of	O
25	B-protein
-	I-protein
hydroxyvitamin	I-protein
D3	I-protein
-	I-protein
24	I-protein
-	I-protein
hydroxylase	I-protein
by	O
aminophylline	O
:	O
a	O
cytochrome	B-protein
P	I-protein
-	I-protein
450	I-protein
monooxygenase	I-protein
system	O
.	O

Plasma	O
ion	O
changes	O
in	O
venous	O
blood	O
incubated	O
with	O
beta	B-protein
receptor	I-protein
blockers	O
and	O
subjected	O
to	O
tonometry	O
in	O
vitro	O
.	O

Transcripts	O
characterized	O
include	O
(	O
i	O
)	O
abundant	O
monocistronic	O
L11e	B-protein
and	O
tricistronic	O
L1e	B-protein
-	I-protein
L10e	I-protein
-	I-protein
L12e	I-protein
transcripts	I-protein
;	O
(	O
ii	O
)	O
less	O
abundant	O
bicistronic	O
NAB	B-protein
-	I-protein
L11e	I-protein
and	O
monocistronic	O
NAB	B-protein
transcripts	I-protein
and	O
(	O
iii	O
)	O
a	O
very	O
rare	O
ORF	B-protein
monocistronic	I-protein
transcript	I-protein
.	O

These	O
results	O
indicate	O
that	O
inhibition	O
of	O
Jun	B-protein
kinase	I-protein
activation	O
was	O
sufficient	O
to	O
inhibit	O
Ras	B-protein
transformation	O
even	O
in	O
the	O
presence	O
of	O
activated	O
Erk	B-protein
-	I-protein
2	I-protein
.	O

Plasma	O
was	O
tested	O
before	O
and	O
after	O
(	O
14	O
+	O
/	O
-	O
7	O
.	O
5	O
[	O
SD	O
]	O
days	O
)	O
surgery	O
for	O
IgG	B-protein
antibodies	I-protein
to	O
the	O
complex	O
of	O
heparin	B-protein
/	I-protein
platelet	I-protein
factor	I-protein
4	I-protein
,	O
using	O
a	O
standardized	O
,	O
validated	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O

Necrosis	O
appears	O
6	O
h	O
after	O
TA	O
infusion	O
,	O
being	O
5	O
.	O
77	O
%	O
in	O
extent	O
after	O
12	O
h	O
,	O
14	O
.	O
9	O
%	O
after	O
24	O
h	O
and	O
animals	O
die	O
with	O
an	O
area	O
of	O
29	O
.	O
5	O
%	O
necrosis	O
.	O

In	O
a	O
third	O
experiment	O
,	O
a	O
Chessmaster	O
gradually	O
increases	O
the	O
number	O
of	O
boards	O
he	O
can	O
reproduce	O
with	O
higher	O
than	O
70	O
%	O
average	O
accuracy	O
to	O
nine	O
,	O
replacing	O
as	O
many	O
as	O
160	O
pieces	O
correctly	O
.	O

In	O
Group	O
IV	O
dogs	O
that	O
received	O
alpha	B-protein
-	I-protein
MSH	I-protein
only	O
during	O
reperfusion	O
,	O
BAEPs	O
were	O
increased	O
approximately	O
10	O
to	O
14	O
%	O
more	O
than	O
in	O
Group	O
II	O
during	O
the	O
late	O
reperfusion	O
period	O
.	O

Using	O
mutagenesis	O
,	O
we	O
have	O
identified	O
two	O
mutations	O
of	O
the	O
second	O
actin	O
-	O
binding	O
domain	O
that	O
can	O
also	O
suppress	O
the	O
act1	B-protein
mutations	O
of	O
interest	O
.	O

In	O
addition	O
,	O
narZ	B-protein
expression	O
was	O
induced	O
approximately	O
20	O
-	O
fold	O
intracellularly	O
in	O
Madin	O
-	O
Darby	O
canine	O
kidney	O
epithelial	O
cells	O
and	O
16	O
-	O
fold	O
in	O
intracellular	O
salts	O
medium	O
,	O
which	O
is	O
believed	O
to	O
mimic	O
the	O
intracellular	O
milieu	O
.	O

As	O
hGM	B-protein
-	I-protein
CSF	I-protein
receptor	I-protein
(	O
hGMR	B-protein
)	O
does	O
not	O
contain	O
a	O
consensus	O
sequence	O
for	O
binding	O
of	O
PI	B-protein
3	I-protein
-	I-protein
kinase	I-protein
,	O
hGMR	B-protein
must	O
use	O
a	O
distinct	O
mechanism	O
for	O
its	O
association	O
with	O
and	O
activation	O
of	O
PI	B-protein
3	I-protein
-	I-protein
kinase	I-protein
.	O

This	O
study	O
allows	O
us	O
to	O
draw	O
conclusions	O
about	O
the	O
identity	O
of	O
proteins	O
required	O
for	O
the	O
development	O
of	O
the	O
nervous	O
system	O
in	O
Drosophila	O
and	O
provides	O
an	O
example	O
of	O
a	O
molecular	O
approach	O
to	O
characterize	O
en	O
masse	O
transposon	O
-	O
tagged	O
mutations	O
identified	O
in	O
genetic	O
screens	O
.	O

Pituitary	O
adenylate	B-protein
cyclase	I-protein
-	I-protein
activating	I-protein
polypeptide	I-protein
regulates	O
prolactin	B-protein
promoter	I-protein
activity	O
via	O
a	O
protein	B-protein
kinase	I-protein
A	O
-	O
mediated	O
pathway	O
that	O
is	O
independent	O
of	O
the	O
transcriptional	O
pathway	O
employed	O
by	O
thyrotropin	B-protein
-	I-protein
releasing	I-protein
hormone	I-protein
.	O

A	O
full	O
-	O
length	O
cDNA	O
clone	O
isolated	O
from	O
a	O
rat	O
lung	O
library	O
was	O
predicted	O
to	O
encode	O
a	O
55	O
-	O
kDa	O
protein	O
containing	O
at	O
its	O
amino	O
terminus	O
a	O
targeting	O
domain	O
that	O
binds	O
to	O
the	O
ANP	B-protein
-	I-protein
receptor	I-protein
kinase	I-protein
-	I-protein
like	I-protein
domain	I-protein
and	O
containing	O
at	O
its	O
carboxyl	O
terminus	O
a	O
putative	O
protein	B-protein
-	I-protein
serine	I-protein
phosphatase	I-protein
domain	O
.	O

It	O
has	O
been	O
shown	O
in	O
an	O
animal	O
experiment	O
that	O
alterations	O
of	O
the	O
renal	O
vasculature	O
and	O
parenchyma	O
after	O
hemostasis	O
performed	O
by	O
Infrared	O
-	O
Contact	O
-	O
Coagulation	O
are	O
best	O
shown	O
by	O
intravital	O
magnification	O
angiography	O
(	O
magnification	O
factor	O
2	O
.	O
22	O
)	O
.	O

Sensitization	O
to	O
hyperlactatemia	O
induced	O
by	O
phenformin	O
after	O
subtotal	O
ablation	O
of	O
the	O
pancreas	O
.	O

Nonlocal	O
approach	O
to	O
scattering	O
in	O
a	O
one	O
-	O
dimensional	O
problem	O
.	O

DAF	B-protein
is	O
a	O
70	O
kD	O
glycoprotein	O
containing	O
complement	O
regulatory	O
short	O
consensus	O
repeats	O
(	O
SCRs	O
)	O
;	O
its	O
gene	O
is	O
located	O
in	O
the	O
regulation	B-protein
of	I-protein
complement	I-protein
activation	I-protein
(	O
RCA	B-protein
)	O
gene	O
cluster	O
on	O
chromosome	O
1	O
and	O
is	O
about	O
40	O
kb	O
in	O
size	O
.	O

In	O
addition	O
,	O
the	O
calbindin	B-protein
-	I-protein
D28K	I-protein
promoter	I-protein
is	O
composed	O
of	O
a	O
variety	O
of	O
simple	O
repeated	O
sequences	O
,	O
some	O
of	O
which	O
are	O
components	O
of	O
putative	O
regulatory	O
signals	O
.	O

Chicken	B-protein
sterol	I-protein
carrier	I-protein
protein	I-protein
2	I-protein
/	I-protein
sterol	I-protein
carrier	I-protein
protein	I-protein
x	I-protein
:	O
cDNA	O
cloning	O
reveals	O
evolutionary	O
conservation	O
of	O
structure	O
and	O
regulated	O
expression	O
.	O

An	O
anchored	O
AFLP	O
-	O
and	O
retrotransposon	O
-	O
based	O
map	O
of	O
diploid	O
Avena	O
.	O

Both	O
betaAPP	B-protein
mRNA	I-protein
and	O
Abeta	B-protein
levels	O
are	O
increased	O
in	O
trisomy	O
21	O
.	O

In	O
contrast	O
,	O
neither	O
I	O
.	O
argentina	O
nor	O
I	O
.	O
theezans	O
exerted	O
any	O
effect	O
on	O
BF	O
or	O
intestinal	O
propulsion	O
.	O

An	O
apparent	O
ufo	B-protein
mRNA	I-protein
overexpression	O
was	O
not	O
found	O
in	O
any	O
of	O
the	O
positive	O
leukemia	O
cell	O
lines	O
,	O
but	O
was	O
identified	O
in	O
the	O
drug	O
-	O
resistant	O
subclones	O
of	O
the	O
cervix	O
carcinoma	O
cell	O
line	O
HeLa	O
.	O

The	O
present	O
data	O
also	O
indicate	O
that	O
patients	O
with	O
TGBM	O
nephropathy	O
often	O
have	O
concomitant	O
IgA	B-protein
nephropathy	O
and	O
mesangial	O
proliferative	O
glomerulonephritis	O
.	O

In	O
a	O
prospective	O
,	O
multicentre	O
trial	O
the	O
efficacy	O
of	O
an	O
Vitex	O
agnus	O
castus	O
L	O
extract	O
Ze	O
440	O
was	O
investigated	O
in	O
50	O
patients	O
with	O
pre	O
-	O
menstrual	O
syndrome	O
(	O
PMS	O
)	O
.	O

Among	O
known	O
flea	O
larvae	O
,	O
the	O
genus	O
Anomiopsyllus	O
(	O
Anomiopsyllinae	O
,	O
Anomiopsyllini	O
)	O
is	O
as	O
distinctive	O
in	O
larval	O
form	O
as	O
are	O
the	O
adults	O
.	O

Among	O
the	O
remaining	O
22	O
sites	O
,	O
six	O
are	O
in	O
the	O
promoters	O
of	O
known	O
alpha	O
-	O
specific	O
genes	O
and	O
two	O
other	O
sites	O
have	O
an	O
alpha2	O
-	O
Mcm1	O
-	O
dependent	O
role	O
in	O
determining	O
the	O
direction	O
of	O
mating	O
type	O
switching	O
.	O

Efferent	O
projections	O
of	O
the	O
ventral	O
portion	O
of	O
the	O
putamen	O
to	O
the	O
frontal	O
,	O
parietal	O
and	O
temporal	O
regions	O
of	O
the	O
cat	O
cerebral	O
cortex	O
.	O

A	O
high	O
mean	O
intensity	O
of	O
CLTPA	O
(	O
standardized	O
multivariate	O
regression	O
coefficient	O
beta	O
-	O
0	O
.	O
059	O
,	O
p	O
=	O
0	O
.	O
020	O
)	O
and	O
a	O
high	O
maximal	O
oxygen	O
uptake	O
(	O
beta	O
-	O
0	O
.	O
163	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
were	O
associated	O
with	O
reduced	O
plasma	B-protein
fibrinogen	I-protein
when	O
adjusting	O
for	O
the	O
strongest	O
covariates	O
.	O

Demyelinating	O
diseases	O
involving	O
the	O
grey	O
matter	O
were	O
very	O
rare	O
,	O
but	O
we	O
must	O
consider	O
the	O
presence	O
of	O
symmetrical	O
thalamic	O
involvement	O
in	O
patients	O
with	O
ADEM	O
.	O

One	O
hundred	O
units	O
/	O
kg	O
of	O
recombinant	B-protein
human	I-protein
erythropoietin	I-protein
(	O
rhEPO	B-protein
)	O
was	O
given	O
subcutaneously	O
3	O
times	O
a	O
week	O
for	O
3	O
weeks	O
.	O

This	O
growth	O
arrest	O
is	O
partly	O
suppressed	O
on	O
minimal	O
medium	O
or	O
under	O
conditions	O
in	O
which	O
the	O
cells	O
are	O
less	O
dependent	O
on	O
mitochondrial	O
metabolism	O
.	O

Removal	O
of	O
each	O
of	O
three	O
contiguous	O
segments	O
from	O
the	O
N	O
-	O
terminal	O
half	O
specifically	O
inhibits	O
the	O
formation	O
of	O
5	B-protein
.	I-protein
8Ss	I-protein
rRNA	I-protein
,	O
whereas	O
deleting	O
part	O
of	O
the	O
C	O
-	O
terminal	O
region	O
of	O
the	O
protein	O
only	O
blocks	O
the	O
production	O
of	O
18S	B-protein
rRNA	I-protein
.	O

This	O
report	O
expands	O
on	O
previous	O
work	O
with	O
interferon	B-protein
alfa	I-protein
-	I-protein
2b	I-protein
(	I-protein
Intron	I-protein
A	I-protein
;	I-protein
Schering	I-protein
-	I-protein
Plough	I-protein
)	I-protein
in	O
the	O
treatment	O
of	O
hairy	O
cell	O
leukemia	O
(	O
HCL	O
)	O
.	O

In	O
addition	O
,	O
a	O
microsatellite	O
repeat	O
polymorphism	O
with	O
a	O
heterozygosity	O
of	O
71	O
%	O
at	O
the	O
RET	B-protein
locus	I-protein
and	O
a	O
restriction	O
fragment	O
length	O
polymorphism	O
with	O
a	O
heterozygosity	O
of	O
42	O
%	O
detected	O
by	O
a	O
lambda	O
clone	O
from	O
the	O
D10S94	B-protein
locus	I-protein
have	O
been	O
developed	O
for	O
high	O
-	O
resolution	O
genetic	O
linkage	O
mapping	O
and	O
predictive	O
diagnostic	O
testing	O
.	O

The	O
upTRE	B-protein
binds	O
more	O
T3R	B-protein
homodimers	I-protein
and	O
less	O
T3R	B-protein
-	I-protein
RXR	I-protein
heterodimers	I-protein
than	O
the	O
dnTRE	B-protein
,	O
and	O
T3	B-protein
more	O
readily	O
facilitates	O
heterodimer	O
binding	O
to	O
the	O
dn	O
-	O
than	O
to	O
the	O
upTRE	B-protein
.	O

Analysis	O
of	O
glucocorticoid	O
unresponsive	O
cell	O
variants	O
using	O
a	O
mouse	B-protein
glucocorticoid	I-protein
receptor	I-protein
complementary	O
DNA	O
clone	O
.	O

Moreover	O
,	O
PTax	B-protein
expressed	O
higher	O
background	O
activities	O
than	O
PTF	B-protein
,	O
indicating	O
that	O
the	O
sequence	O
of	O
the	O
synthetic	O
regulatory	O
region	O
can	O
influence	O
background	O
levels	O
.	O

When	O
the	O
high	O
affinity	O
hnRNP	B-protein
A1	I-protein
binding	I-protein
site	I-protein
was	O
inserted	O
into	O
the	O
beta	B-protein
-	I-protein
globin	I-protein
reporter	I-protein
,	O
Rev	B-protein
was	O
able	O
to	O
increase	O
the	O
cytoplasmic	O
levels	O
of	O
unspliced	O
mRNAs	O
to	O
14	O
%	O
.	O

Intact	O
Flag	O
-	O
tagged	O
protein	O
products	O
from	O
all	O
six	O
were	O
produced	O
from	O
genomic	O
expression	O
vectors	O
,	O
although	O
the	O
ORF40	B-protein
/	I-protein
41	I-protein
transcript	I-protein
encoding	O
a	O
primase	B-protein
-	I-protein
helicase	I-protein
component	I-protein
proved	O
to	O
be	O
spliced	O
with	O
a	O
127	O
-	O
bp	O
intron	O
.	O

With	O
both	O
wild	O
-	O
type	O
and	O
the	O
mutant	O
enzymes	O
,	O
ATP	O
activates	O
both	O
[	O
14C	O
]	O
Asp	O
in	O
equilibrium	O
N	O
-	O
carbamyl	O
-	O
L	O
-	O
aspartate	O
(	O
C	O
-	O
Asp	O
)	O
and	O
the	O
[	O
32P	O
]	O
carbamyl	O
phosphate	O
(	O
C	O
-	O
P	O
)	O
in	O
equilibrium	O
Pi	O
exchanges	O
.	O

The	O
effect	O
of	O
water	O
deprivation	O
for	O
19	O
h	O
on	O
renal	O
Na	O
excretion	O
of	O
conscious	O
adrenalectomized	O
(	O
ADX	O
)	O
sheep	O
maintained	O
on	O
a	O
constant	O
intravenous	O
infusion	O
of	O
aldosterone	O
and	O
cortisol	O
(	O
ADX	O
-	O
constant	O
steroid	O
sheep	O
)	O
was	O
investigated	O
.	O

As	O
in	O
the	O
other	O
three	O
members	O
whose	O
gene	O
expression	O
is	O
altered	O
during	O
tumorigenesis	O
,	O
PI12	B-protein
expression	O
was	O
found	O
to	O
be	O
down	O
-	O
regulated	O
in	O
tumor	O
brain	O
tissues	O
and	O
in	O
two	O
brain	O
cancer	O
cell	O
lines	O
:	O
U	O
-	O
87	O
MG	O
and	O
H4	O
.	O

Similarly	O
,	O
actuarial	O
interpretations	O
for	O
the	O
second	O
protocols	O
were	O
not	O
more	O
frequently	O
selected	O
by	O
therapists	O
as	O
more	O
valid	O
,	O
regardless	O
of	O
treatment	O
condition	O
and	O
elevation	O
of	O
the	O
F	O
and	O
F	O
-	O
K	O
indices	O
on	O
the	O
first	O
MMPI	O
profile	O
.	O

All	O
patients	O
received	O
VCR	O
1	O
.	O
0	O
mg	O
/	O
m2	O
weekly	O
for	O
6	O
weeks	O
with	O
dose	O
modification	O
for	O
neurotoxicity	O
.	O

In	O
patients	O
who	O
respond	O
to	O
quetiapine	O
,	O
therapy	O
should	O
be	O
continued	O
at	O
the	O
optimal	O
dose	O
that	O
maintains	O
remission	O
,	O
within	O
the	O
range	O
of	O
150	O
to	O
750	O
mg	O
/	O
d	O
.	O

The	O
construction	O
of	O
a	O
small	O
library	O
of	O
mouse	O
repetitive	O
DNA	O
has	O
been	O
previously	O
reported	O
(	O
Pietras	O
et	O
al	O
.	O
,	O
Nucleic	O
Acids	O
Res	O
.	O

The	O
weak	O
relationships	O
between	O
F	O
and	O
Zn	O
to	O
Mg	O
clearly	O
have	O
no	O
significant	O
effect	O
on	O
the	O
contents	O
of	O
these	O
elements	O
in	O
bone	O
.	O

Deletion	O
analysis	O
showed	O
that	O
the	O
NF	B-protein
-	I-protein
4FA	I-protein
,	O
NF	B-protein
-	I-protein
4FB	I-protein
,	O
and	O
AP	B-protein
-	I-protein
1	I-protein
sequences	O
are	O
each	O
necessary	O
for	O
full	O
enhancer	O
activity	O
.	O

Serial	O
US	O
images	O
were	O
obtained	O
before	O
and	O
20	O
,	O
30	O
,	O
40	O
,	O
50	O
,	O
60	O
,	O
90	O
,	O
120	O
,	O
150	O
,	O
180	O
,	O
240	O
,	O
and	O
300	O
s	O
after	O
intravenous	O
injection	O
of	O
2	O
g	O
of	O
contrast	O
agent	O
using	O
conventional	O
and	O
harmonic	O
PD	O
US	O
.	O

The	O
catalytic	O
site	O
has	O
an	O
S1	B-protein
pocket	I-protein
lined	O
with	O
conserved	O
hydrophobic	O
residues	O
to	O
accommodate	O
the	O
pyroglutamyl	O
residue	O
.	O

Thus	O
,	O
MKK7	B-protein
is	O
an	O
essential	O
and	O
specific	O
regulator	O
of	O
stress	O
-	O
induced	O
SAPK	B-protein
/	I-protein
JNK	I-protein
activation	O
in	O
mast	O
cells	O
and	O
MKK7	B-protein
negatively	O
regulates	O
growth	B-protein
factor	I-protein
and	O
antigen	O
receptor	O
-	O
driven	O
proliferation	O
in	O
hematopoietic	O
cells	O
.	O

Glucose	O
disappearance	O
rate	O
and	O
changes	O
in	O
plasma	O
nutrients	O
after	O
intravenouly	O
injected	O
glucose	O
in	O
normoglycaemic	O
and	O
hypoglycaemic	O
underweight	O
newborns	O
.	O

Albumin	B-protein
dialysis	O
:	O
effective	O
removal	O
of	O
copper	O
in	O
a	O
patient	O
with	O
fulminant	O
Wilson	O
disease	O
and	O
successful	O
bridging	O
to	O
liver	O
transplantation	O
:	O
a	O
new	O
possibility	O
for	O
the	O
elimination	O
of	O
protein	O
-	O
bound	O
toxins	O
.	O

We	O
have	O
shown	O
previously	O
that	O
GH3	O
cells	O
transfected	O
with	O
the	O
rat	B-protein
GnRH	I-protein
receptor	I-protein
cDNA	I-protein
(	O
GGH3	O
-	O
1	O
'	O
cells	O
)	O
support	O
the	O
expression	O
of	O
a	O
cotransfected	O
fusion	O
gene	O
composed	O
of	O
797	O
base	O
pairs	O
of	O
rat	B-protein
LHbeta	I-protein
gene	I-protein
5	I-protein
'	I-protein
-	I-protein
flanking	I-protein
sequence	I-protein
and	O
the	O
first	O
5	O
base	O
pairs	O
of	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
fused	O
to	O
a	O
luciferase	B-protein
reporter	I-protein
(	I-protein
-	I-protein
797	I-protein
/	I-protein
+	I-protein
5LHbetaLUC	I-protein
)	I-protein
and	O
respond	O
to	O
a	O
GnRH	B-protein
agonist	O
with	O
a	O
10	O
-	O
fold	O
stimulation	O
of	O
activity	O
.	O

Here	O
we	O
describe	O
the	O
optimization	O
and	O
characterization	O
of	O
a	O
140	O
-	O
residue	O
fragment	O
,	O
containing	O
the	O
Runt	B-protein
domain	I-protein
of	O
AML1	B-protein
,	O
which	O
is	O
suitable	O
for	O
structural	O
studies	O
.	O

We	O
present	O
evidence	O
that	O
DNA	B-protein
polymerase	I-protein
delta	I-protein
of	I-protein
Saccharomyces	I-protein
cerevisiae	I-protein
,	O
an	O
enzyme	O
that	O
is	O
essential	O
for	O
viability	O
and	O
chromosomal	O
replication	O
,	O
is	O
also	O
required	O
for	O
base	O
excision	O
repair	O
of	O
exogenous	O
DNA	O
methylation	O
damage	O
.	O

The	O
behavior	O
of	O
suf12	B-protein
-	I-protein
null	I-protein
/	I-protein
SUF12	I-protein
+	I-protein
heterozygotes	I-protein
indicates	O
that	O
suf12	B-protein
is	O
co	O
-	O
dominantly	O
expressed	O
and	O
suggests	O
that	O
suf12	B-protein
allele	O
-	O
specific	O
suppression	O
may	O
result	O
from	O
functionally	O
distinct	O
mutant	O
proteins	O
rather	O
than	O
variation	O
in	O
residual	O
wild	B-protein
-	I-protein
type	I-protein
SUF12	I-protein
+	I-protein
activity	O
.	O

The	O
4	O
patients	O
with	O
carboxyhemoglobin	O
levels	O
in	O
excess	O
of	O
10	O
%	O
may	O
represent	O
occult	O
carbon	O
monoxide	O
poisoning	O
in	O
this	O
population	O
.	O

Risks	O
of	O
chronicity	O
following	O
acute	O
hepatitis	O
B	O
virus	O
infection	O
:	O
a	O
review	O
.	O

Folate	O
metabolism	O
in	O
the	O
human	O
malaria	O
parasite	O
Plasmodium	O
falciparum	O
is	O
an	O
essential	O
activity	O
for	O
cell	O
growth	O
and	O
replication	O
,	O
and	O
the	O
target	O
of	O
an	O
important	O
class	O
of	O
therapeutic	O
agents	O
in	O
widespread	O
use	O
.	O

The	O
decay	O
curves	O
of	O
chlorophyll	O
fluorescence	O
showed	O
a	O
superposition	O
of	O
three	O
exponentially	O
decaying	O
components	O
with	O
time	O
constants	O
of	O
T1	O
=	O
100	O
-	O
200	O
ps	O
,	O
T2	O
=	O
300	O
-	O
500	O
ps	O
and	O
T3	O
=	O
2	O
.	O
0	O
-	O
3	O
.	O
5	O
ns	O
.	O

IV	O
.	O
combined	O
sclerosis	O
and	O
resorption	O
of	O
the	O
skull	O
base	O
(	O
6	O
cases	O
,	O
2	O
group	O
I	O
lesions	O
and	O
4	O
group	O
II	O
lesions	O
)	O
.	O

Generally	O
,	O
a	O
correlation	O
was	O
observed	O
between	O
highest	O
concentrations	O
of	O
CSF	O
immunoglobulins	O
and	O
degree	O
of	O
meningeal	O
inflammatory	O
response	O
,	O
even	O
if	O
this	O
was	O
a	O
component	O
of	O
other	O
neurological	O
diseases	O
.	O

High	O
-	O
affinity	O
binding	O
of	O
NF	B-protein
-	I-protein
1	I-protein
to	O
PSE	B-protein
-	I-protein
B	I-protein
,	O
but	O
not	O
to	O
PSE	B-protein
-	I-protein
A	I-protein
,	O
was	O
confirmed	O
by	O
competition	O
of	O
DNA	O
-	O
protein	O
interactions	O
by	O
using	O
NF	B-protein
-	I-protein
1	I-protein
DNA	O
elements	O
and	O
antibodies	O
.	O

METHODS	O
:	O
TBN	O
measurements	O
were	O
performed	O
in	O
31	O
female	O
outpatients	O
with	O
breast	O
carcinoma	O
who	O
were	O
undergoing	O
standard	O
cyclophosphamide	O
,	O
methotrexate	O
,	O
and	O
5	O
-	O
fluorouracil	O
(	O
CMF	O
)	O
-	O
based	O
chemotherapy	O
(	O
median	O
age	O
,	O
48	O
years	O
;	O
range	O
,	O
26	O
-	O
77	O
years	O
)	O
.	O

While	O
daily	O
food	O
intake	O
was	O
almost	O
constant	O
regardless	O
of	O
the	O
dietary	O
protein	O
level	O
,	O
water	O
intake	O
and	O
urine	O
volume	O
increased	O
with	O
increasing	O
the	O
dietary	O
protein	O
.	O

None	O
of	O
the	O
cystometrograms	O
showed	O
uninhibited	O
detrusor	O
contractions	O
.	O

CXC	B-protein
chemokines	I-protein
bind	O
to	O
unique	O
sets	O
of	O
selectivity	O
determinants	O
that	O
can	O
function	O
independently	O
and	O
are	O
broadly	O
distributed	O
on	O
multiple	O
domains	O
of	O
human	O
interleukin	B-protein
-	I-protein
8	I-protein
receptor	I-protein
B	I-protein
.	O

An	O
explanation	O
explored	O
for	O
this	O
lack	O
of	O
gene	O
expression	O
was	O
that	O
increased	O
levels	O
of	O
RAR	B-protein
alpha	I-protein
or	O
PML	B-protein
might	O
suppress	O
APL	O
cell	O
growth	O
.	O

Transcription	O
initiation	O
occurred	O
predominantly	O
at	O
the	O
putative	O
sigmaA	B-protein
-	I-protein
dependent	I-protein
promoter	I-protein
in	O
exponentially	O
growing	O
cells	O
and	O
was	O
induced	O
under	O
stress	O
conditions	O
.	O

The	O
RFX	B-protein
protein	I-protein
family	I-protein
includes	O
members	O
from	O
yeast	O
to	O
humans	O
,	O
which	O
function	O
in	O
various	O
biological	O
systems	O
,	O
and	O
share	O
a	O
DNA	O
-	O
binding	O
domain	O
and	O
a	O
conserved	O
C	O
-	O
terminal	O
region	O
.	O

In	O
this	O
article	O
we	O
propose	O
to	O
find	O
out	O
the	O
percentage	O
of	O
normal	O
occlusion	O
and	O
the	O
distribution	O
of	O
maloclusions	O
,	O
according	O
to	O
the	O
anteroposterior	O
relationship	O
between	O
the	O
dental	O
archs	O
(	O
following	O
the	O
ANGLE3	O
classification	O
)	O
.	O

Some	O
research	O
studies	O
have	O
related	O
this	O
kind	O
of	O
tumors	O
with	O
prolonged	O
ingestion	O
of	O
H2	O
inhibitors	O
and	O
others	O
antacid	O
.	O

Detailed	O
mutagenesis	O
of	O
the	O
element	O
'	O
s	O
rare	O
-	O
codon	O
/	O
AU	O
-	O
rich	O
sequence	O
boundary	O
revealed	O
that	O
the	O
destabilizing	O
activity	O
of	O
the	O
MATalpha1	B-protein
IE	I-protein
is	O
observed	O
when	O
the	O
terminal	O
codon	O
of	O
the	O
element	O
'	O
s	O
rare	O
-	O
codon	O
interval	O
is	O
translated	O
.	O

Electromagnetic	O
blood	O
flow	O
(	O
BF	O
)	O
probe	O
was	O
applied	O
on	O
the	O
left	O
anterior	O
descending	O
artery	O
(	O
LAD	O
)	O
.	O

We	O
now	O
show	O
that	O
gp200	B-protein
-	I-protein
MR6	I-protein
ligation	O
can	O
also	O
mimic	O
IL	B-protein
-	I-protein
4	I-protein
and	O
have	O
an	O
anti	O
-	O
proliferative	O
pro	O
-	O
maturational	O
influence	O
within	O
the	O
immune	O
system	O
,	O
causing	O
up	O
-	O
regulation	O
of	O
co	O
-	O
stimulatory	O
molecules	O
on	O
B	O
lymphocytes	O
.	O

Iodine	O
deficiency	O
disorders	O
in	O
Bangladesh	O
.	O

Suppression	O
of	O
food	O
intake	O
in	O
the	O
rat	O
by	O
tung	O
oil	O
.	O

A	O
genomic	O
clone	O
,	O
pTt21	O
,	O
containing	O
DNA	O
apparently	O
transcribed	O
specifically	O
in	O
Trypanosoma	O
cruzi	O
trypomastigotes	O
,	O
was	O
obtained	O
by	O
differentially	O
screening	O
a	O
genomic	O
library	O
with	O
trypomastigote	O
and	O
epimastigote	O
cDNA	O
.	O

CONCLUSIONS	O
:	O
Using	O
icodextrin	O
-	O
based	O
instead	O
of	O
glucose	O
-	O
based	O
PD	O
fluids	O
can	O
largely	O
reduce	O
the	O
formation	O
of	O
Amadori	O
albumin	B-protein
and	O
AGEs	O
.	O

Five	O
healthy	O
male	O
subjects	O
inspired	O
air	O
for	O
20	O
min	O
and	O
then	O
5	O
%	O
CO2	O
/	O
95	O
%	O
O2	O
for	O
30	O
min	O
,	O
of	O
which	O
the	O
first	O
10	O
min	O
was	O
used	O
to	O
achieve	O
a	O
steady	O
-	O
state	O
end	O
-	O
tidal	O
CO2	O
measurement	O
.	O

Here	O
,	O
we	O
present	O
genetic	O
evidence	O
in	O
Saccharomyces	O
cerevisiae	O
for	O
a	O
functional	O
interaction	O
between	O
the	O
DEAH	B-protein
protein	I-protein
Prp16	I-protein
,	O
and	O
the	O
U6	B-protein
and	O
U2	B-protein
spliceosomal	I-protein
snRNAs	I-protein
.	O

Although	O
within	O
normal	O
limits	O
,	O
latency	O
was	O
high	O
.	O

Since	O
the	O
early	O
1980s	O
there	O
has	O
been	O
increasing	O
awareness	O
of	O
the	O
importance	O
of	O
quantifying	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQL	O
)	O
in	O
patients	O
with	O
chronic	O
respiratory	O
disorders	O
included	O
in	O
clinical	O
trials	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
the	O
616	O
amino	O
acid	O
,	O
70	B-protein
-	I-protein
kDa	I-protein
subunit	I-protein
of	I-protein
RPA	I-protein
(	O
RPA	B-protein
70	I-protein
)	O
is	O
composed	O
of	O
multiple	O
structural	O
/	O
functional	O
domains	O
.	O

One	O
of	O
these	O
factors	O
,	O
HRF	B-protein
-	I-protein
1	I-protein
,	O
recognizes	O
a	O
cis	O
element	O
consisting	O
of	O
an	O
inverted	O
palindromic	O
motif	O
.	O

The	O
N	O
-	O
terminal	O
domain	O
of	O
approximately	O
70	O
kDa	O
exhibits	O
11	O
imperfect	O
amino	O
acid	O
repeats	O
that	O
show	O
some	O
homology	O
to	O
promastigote	O
surface	O
glycoproteins	O
of	O
the	O
psa2	B-protein
/	I-protein
gp46	I-protein
complex	I-protein
.	O

In	O
the	O
present	O
article	O
,	O
the	O
causes	O
of	O
death	O
or	O
ill	O
-	O
being	O
as	O
found	O
in	O
10	O
consecutive	O
carcinogenicity	O
studies	O
-	O
-	O
5	O
studies	O
with	O
2400	O
OFA	O
(	O
Sprague	O
-	O
Dawley	O
-	O
derived	O
)	O
and	O
Wistar	O
rats	O
and	O
5	O
studies	O
with	O
2400	O
OF1	O
and	O
NMRI	O
mice	O
-	O
-	O
were	O
re	O
-	O
examined	O
.	O

Whereas	O
both	O
MAP	O
and	O
MSNA	O
increase	O
during	O
SHG	O
,	O
the	O
transition	O
from	O
SHG	O
to	O
PHI	O
is	O
characterized	O
by	O
a	O
transient	O
reduction	O
in	O
MAP	O
but	O
sustained	O
elevation	O
in	O
MSNA	O
,	O
facilitating	O
separation	O
of	O
these	O
factors	O
in	O
vivo	O
.	O

The	O
SV40	O
enhancer	O
augmented	O
replication	O
1	O
.	O
5	O
-	O
10	O
fold	O
.	O

E3	B-protein
/	I-protein
19K	I-protein
resides	O
in	O
the	O
endoplasmic	O
reticulum	O
where	O
it	O
binds	O
to	O
MHC	B-protein
class	I-protein
I	I-protein
molecules	I-protein
,	O
thereby	O
preventing	O
their	O
transport	O
to	O
the	O
cell	O
surface	O
.	O

Differential	O
drawing	O
size	O
associated	O
with	O
unilateral	O
brain	O
damage	O
.	O

The	O
pia	O
mater	O
at	O
the	O
site	O
of	O
the	O
entry	O
of	O
blood	O
vessels	O
into	O
the	O
central	O
nervous	O
system	O
.	O

The	O
optimum	O
technique	O
for	O
the	O
pathological	O
examination	O
of	O
sentinel	O
lymph	O
nodes	O
(	O
SLNs	O
)	O
is	O
still	O
under	O
debate	O
.	O

The	O
protein	B-protein
-	I-protein
tyrosine	I-protein
kinase	I-protein
fer	I-protein
associates	O
with	O
signaling	O
complexes	O
containing	O
insulin	B-protein
receptor	I-protein
substrate	I-protein
-	I-protein
1	I-protein
and	O
phosphatidylinositol	B-protein
3	I-protein
-	I-protein
kinase	I-protein
.	O

The	O
degree	O
of	O
hypoperfusion	O
was	O
slightly	O
related	O
to	O
decrease	O
in	O
FEV1	O
.	O
0	O
%	O
,	O
V25	O
and	O
PaO2	O
and	O
increase	O
in	O
circulating	O
blood	O
volume	O
and	O
peripheral	O
red	O
blood	O
cell	O
counts	O
.	O

IMPLICATIONS	O
:	O
Given	O
the	O
small	O
size	O
of	O
this	O
study	O
and	O
the	O
inconsistency	O
of	O
results	O
among	O
the	O
few	O
prospective	O
studies	O
of	O
ovarian	O
cancer	O
conducted	O
to	O
test	O
these	O
associations	O
,	O
replications	O
of	O
these	O
findings	O
are	O
highly	O
desirable	O
.	O

Abnormal	O
urinary	B-protein
coproporphyrin	I-protein
levels	O
in	O
patients	O
infected	O
by	O
hepatitis	O
C	O
virus	O
with	O
or	O
without	O
human	O
immunodeficiency	O
virus	O
.	O

Previous	O
studies	O
demonstrated	O
that	O
the	O
flavin	B-protein
-	I-protein
containing	I-protein
monooxygenases	I-protein
(	O
FMO	B-protein
)	O
are	O
expressed	O
in	O
a	O
tissue	O
-	O
specific	O
manner	O
.	O

A	O
comparison	O
of	O
the	O
duplicated	O
Vkappa	B-protein
genes	I-protein
suggests	O
positive	O
selection	O
on	O
the	O
complementarity	O
-	O
determining	O
regions	O
of	O
the	O
duplicated	O
genes	O
by	O
point	O
mutations	O
.	O

Concerted	O
transcriptional	O
activation	O
of	O
the	O
low	B-protein
density	I-protein
lipoprotein	I-protein
receptor	I-protein
gene	I-protein
by	O
insulin	B-protein
and	O
luteinizing	B-protein
hormone	I-protein
in	O
cultured	O
porcine	O
granulosa	O
-	O
luteal	O
cells	O
:	O
possible	O
convergence	O
of	O
protein	B-protein
kinase	I-protein
a	I-protein
,	O
phosphatidylinositol	B-protein
3	I-protein
-	I-protein
kinase	I-protein
,	O
and	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
signaling	O
pathways	O
.	O

Synthesis	O
of	O
(	O
+	O
)	O
-	O
lysergic	O
acid	O
diethylamide	O
tartrate	O
.	O

RESULTS	O
:	O
Among	O
women	O
,	O
the	O
age	O
-	O
related	O
decline	O
in	O
BMD	O
at	O
all	O
non	O
-	O
spine	O
skeletal	O
sites	O
was	O
significantly	O
different	O
from	O
zero	O
,	O
with	O
the	O
largest	O
decline	O
seen	O
at	O
the	O
femoral	O
neck	O
(	O
-	O
.	O
0038	O
g	O
/	O
cm2	O
/	O
y	O
,	O
p	O
<	O
.	O
001	O
)	O
and	O
the	O
smallest	O
at	O
the	O
trochanter	O
of	O
the	O
hip	O
(	O
-	O
.	O
0023	O
g	O
/	O
cm2	O
/	O
y	O
,	O
p	O
=	O
.	O
03	O
)	O
.	O

A	O
raised	O
amplitude	O
of	O
the	O
aggregation	O
of	O
plates	O
and	O
a	O
decrease	O
in	O
the	O
threshold	O
of	O
their	O
sensitivity	O
to	O
ADP	O
were	O
established	O
in	O
the	O
persons	O
with	O
types	O
IIa	O
and	O
IIb	O
HLP	O
and	O
in	O
CHD	O
without	O
HLP	O
.	O

To	O
determine	O
the	O
genomic	O
complexity	O
of	O
the	O
deleted	O
region	O
shared	O
among	O
tumors	O
,	O
we	O
assembled	O
a	O
physical	O
map	O
of	O
the	O
I	O
Mbp	O
SRO	O
consisting	O
predominantly	O
of	O
bacteriophage	O
P1	O
-	O
derived	O
artificial	O
chromosome	O
(	O
PAC	O
)	O
clones	O
.	O

Chronotherapeutics	O
in	O
cardiovascular	O
disease	O
.	O

Cycles	O
were	O
repeated	O
every	O
3	O
weeks	O
.	O

Change	O
in	O
the	O
makeup	O
of	O
the	O
blood	O
following	O
a	O
short	O
-	O
term	O
local	O
action	O
of	O
a	O
permanent	O
magnetic	O
field	O
on	O
the	O
human	O
body	O
.	O

Tolerance	O
to	O
fenfluramine	O
anorexia	O
:	O
fact	O
or	O
fiction	O
?	O
Recent	O
findings	O
in	O
this	O
laboratory	O
with	O
regard	O
to	O
tolerance	O
to	O
fenfluramine	O
anorexia	O
are	O
reviewed	O
with	O
respect	O
to	O
generality	O
of	O
the	O
behavioural	O
phenomenon	O
.	O

Here	O
,	O
we	O
evidence	O
that	O
the	O
developmental	O
functions	O
of	O
the	O
family	O
of	O
transcription	O
factors	O
characterized	O
by	O
the	O
POU	B-protein
DNA	I-protein
binding	I-protein
motif	I-protein
exerts	O
roles	O
in	O
mammalian	O
development	O
.	O

He	O
was	O
administered	O
recombinant	B-protein
IFN	I-protein
alpha	I-protein
-	I-protein
2b	I-protein
under	O
the	O
diagnosis	O
of	O
chronic	O
hepatitis	O
C	O
.	O

74	O
,	O
193	O
-	O
197	O
)	O
.	O

Serum	O
ascorbic	O
acid	O
had	O
an	O
inverse	O
and	O
the	O
strongest	O
association	O
with	O
systolic	O
blood	O
pressure	O
among	O
the	O
risk	O
factors	O
including	O
blood	O
pressure	O
,	O
total	O
cholesterol	O
,	O
triglyceride	O
,	O
gamma	O
-	O
GTP	O
and	O
obesity	O
.	O

Discrepant	O
results	O
with	O
a	O
latex	O
agglutination	O
test	O
in	O
the	O
assessment	O
of	O
cytomegalovirus	B-protein
antibody	I-protein
status	O
of	O
cardiac	O
transplant	O
donors	O
.	O

MSSP	B-protein
proteins	I-protein
have	O
been	O
identified	O
by	O
their	O
binding	O
to	O
an	O
upstream	O
element	O
of	O
c	B-protein
-	I-protein
myc	I-protein
.	O

Changes	O
in	O
stimulation	O
levels	O
over	O
time	O
in	O
nucleus	O
22	O
cochlear	O
implant	O
users	O
.	O

A	O
given	O
standard	O
input	O
function	O
and	O
a	O
given	O
value	O
of	O
distribution	O
volume	O
(	O
Vd	O
)	O
used	O
for	O
the	O
rCBF	O
measurement	O
of	O
this	O
method	O
were	O
calculated	O
from	O
the	O
dynamic	O
study	O
by	O
six	O
normal	O
volunteers	O
.	O

The	O
solution	O
structure	O
of	O
the	O
adduct	O
derived	O
from	O
the	O
covalent	O
bonding	O
of	O
the	O
fjord	O
region	O
(	O
+	O
)	O
-	O
(	O
11S	O
,	O
12R	O
,	O
13R	O
,	O
14S	O
)	O
stereoisomer	O
of	O
anti	O
-	O
11	O
,	O
12	O
-	O
dihydroxy	O
-	O
13	O
,	O
14	O
-	O
epoxy	O
-	O
11	O
,	O
12	O
,	O
13	O
,	O
14	O
-	O
tetrahydrobenzo	O
[	O
g	O
]	O
chrysene	O
,	O
(	O
+	O
)	O
-	O
anti	O
-	O
B	O
[	O
g	O
]	O
CDE	O
,	O
to	O
the	O
exocyclic	O
N	O
(	O
6	O
)	O
amino	O
group	O
of	O
the	O
adenine	O
residue	O
dA6	O
,	O
(	O
designated	O
(	O
+	O
)	O
-	O
trans	O
-	O
anti	O
-	O
(	O
B	O
[	O
g	O
]	O
C	O
)	O
dA6	O
)	O
,	O
positioned	O
opposite	O
a	O
thymine	O
residue	O
dT17	O
in	O
the	O
DNA	O
sequence	O
context	O
d	O
(	O
C1	O
-	O
T2	O
-	O
C3	O
-	O
T4	O
-	O
C5	O
-	O
(	O
B	O
[	O
g	O
]	O
C	O
)	O
A6	O
-	O
C7	O
-	O
T8	O
-	O
T9	O
-	O
C10	O
-	O
C11	O
)	O
.	O
d	O
(	O
G12	O
-	O
G13	O
-	O
A14	O
-	O
A15	O
-	O
G16	O
-	O
T17	O
-	O
G18	O
-	O
A19	O
-	O
G20	O
+	O
+	O
+	O
-	O
A21	O
-	O
G22	O
)	O
(	O
designated	O
(	O
B	O
[	O
g	O
]	O
C	O
)	O
dA	O
.	O
dT	O
11	O
-	O
mer	O
duplex	O
)	O
,	O
has	O
been	O
studied	O
using	O
structural	O
information	O
derived	O
from	O
NMR	O
data	O
in	O
combination	O
with	O
molecular	O
dynamics	O
(	O
MD	O
)	O
calculations	O
.	O

Uses	O
of	O
orthoclone	O
OKT3	B-protein
for	O
prophylaxis	O
of	O
rejection	O
and	O
induction	O
in	O
initial	O
nonfunction	O
in	O
kidney	O
transplantation	O
.	O

Relationship	O
between	O
gross	O
lesions	O
and	O
Escherichia	O
coli	O
serotypes	O
in	O
chronic	O
respiratory	O
disease	O
(	O
CRD	O
)	O
of	O
poultry	O
.	O

Furthermore	O
,	O
synergistic	O
activation	O
of	O
ERK2	B-protein
occurred	O
in	O
the	O
absence	O
of	O
changes	O
in	O
intracellular	O
Ca2	O
+	O
,	O
and	O
was	O
not	O
blocked	O
by	O
inhibition	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
activity	O
and	O
represents	O
a	O
separate	O
pathway	O
by	O
which	O
CD19	B-protein
regulates	O
B	O
cell	O
function	O
.	O

Pancreatic	O
and	O
biliary	O
secretion	O
and	O
gastric	O
emptying	O
rates	O
of	O
a	O
liquid	O
test	O
meal	O
(	O
LTM	O
)	O
were	O
determined	O
in	O
normal	O
persons	O
,	O
in	O
patients	O
with	O
subtotal	O
gastrectomy	O
with	O
gastroduodenostomy	O
(	O
STG	O
-	O
BI	O
)	O
or	O
with	O
gastrojejunostomy	O
(	O
STG	O
-	O
BII	O
)	O
,	O
and	O
in	O
patients	O
with	O
truncal	O
vagotomy	O
and	O
pyloroplasty	O
(	O
V	O
@	O
P	O
)	O
.	O

RNA	O
transcripts	O
that	O
hybridize	O
to	O
the	O
introduced	O
foreign	O
gene	O
have	O
been	O
identified	O
.	O

Transient	O
tyrosine	O
phosphorylation	O
of	O
Crk	B-protein
in	O
fibroblast	O
growth	O
factor	O
-	O
2	O
-	O
stimulated	O
endothelial	O
cells	O
was	O
dependent	O
on	O
the	O
juxtamembrane	O
tyrosine	O
residue	O
463	O
in	O
FGFR	B-protein
-	I-protein
1	I-protein
,	O
and	O
a	O
Crk	B-protein
SH2	I-protein
domain	I-protein
precipitated	O
FGFR	B-protein
-	I-protein
1	I-protein
via	O
phosphorylated	O
Tyr	O
-	O
463	O
,	O
indicating	O
direct	O
complex	O
formation	O
between	O
Crk	B-protein
and	O
FGFR	B-protein
-	I-protein
1	I-protein
.	O

Blood	O
pressure	O
also	O
was	O
increased	O
by	O
lidocaine	O
(	O
6	O
mg	O
kg	O
-	O
1	O
)	O
.	O

Multiple	O
SW16	O
-	O
dependent	O
cis	O
-	O
acting	O
elements	O
control	O
SWI4	B-protein
transcription	O
through	O
the	O
cell	O
cycle	O
.	O

This	O
Mr	O
is	O
similar	O
to	O
those	O
of	O
the	O
purified	B-protein
smg	I-protein
p25A	I-protein
GDI	I-protein
estimated	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
sucrose	O
density	O
gradient	O
ultracentrifugation	O
,	O
which	O
are	O
about	O
54	O
,	O
000	O
and	O
65	O
,	O
000	O
,	O
respectively	O
.	O

Measurement	O
of	O
SaO2	O
at	O
moderate	O
altitude	O
can	O
be	O
helpful	O
in	O
the	O
care	O
of	O
both	O
healthy	O
and	O
ill	O
newborns	O
or	O
infants	O
.	O

In	O
co	O
-	O
transfection	O
studies	O
,	O
an	O
AP	B-protein
-	I-protein
2	I-protein
but	O
not	O
an	O
Egr	B-protein
-	I-protein
1	I-protein
expression	O
vector	O
activated	O
VPF	B-protein
/	I-protein
VEGF	I-protein
transcription	O
,	O
thus	O
indicating	O
that	O
AP	B-protein
-	I-protein
2	I-protein
protein	I-protein
is	O
functionally	O
important	O
in	O
TGF	B-protein
alpha	I-protein
-	I-protein
induced	I-protein
VPF	I-protein
/	I-protein
VEGF	I-protein
gene	I-protein
expression	O
.	O

Similarly	O
,	O
curcumin	O
(	O
diferuloylmethane	O
)	O
,	O
an	O
anti	O
-	O
inflammatory	O
agent	O
,	O
suppressed	O
OSM	O
-	O
stimulated	O
STAT1	B-protein
phosphorylation	O
,	O
DNA	O
-	O
binding	O
activity	O
of	O
STAT1	B-protein
,	O
and	O
c	B-protein
-	I-protein
Jun	I-protein
N	I-protein
-	I-protein
terminal	I-protein
kinase	I-protein
activation	O
without	O
affecting	O
JAK1	B-protein
,	O
JAK2	B-protein
,	O
JAK3	B-protein
,	O
ERK1	B-protein
/	I-protein
2	I-protein
,	O
and	O
p38	B-protein
phosphorylation	O
.	O

The	O
rat	B-protein
branched	I-protein
-	I-protein
chain	I-protein
-	I-protein
2	I-protein
-	I-protein
oxo	I-protein
-	I-protein
acid	I-protein
dehydrogenase	I-protein
(	I-protein
BCOD	I-protein
)	I-protein
kinase	I-protein
mRNA	I-protein
is	O
transcribed	O
from	O
a	O
TATA	O
-	O
less	O
promoter	O
that	O
has	O
GC	O
-	O
rich	O
sequences	O
and	O
two	O
putative	O
Sp1	B-protein
binding	I-protein
sites	I-protein
near	O
the	O
transcription	O
start	O
site	O
.	O

67	O
393	O
bp	O
of	O
contiguous	O
DNA	O
located	O
between	O
markers	O
cdc18	B-protein
and	O
cdc14	B-protein
on	O
the	O
right	O
arm	O
of	O
fission	O
yeast	O
chromosome	O
II	O
has	O
been	O
sequenced	O
as	O
part	O
of	O
the	O
European	O
Union	O
Schizosaccharomyces	O
pombe	O
genome	O
sequencing	O
project	O
.	O

The	O
ability	O
of	O
rats	O
with	O
control	O
or	O
hippocampal	O
lesions	O
to	O
learn	O
an	O
object	O
-	O
place	O
,	O
odor	O
-	O
place	O
,	O
or	O
object	O
-	O
odor	O
paired	O
-	O
associate	O
task	O
was	O
assessed	O
in	O
a	O
cheeseboard	O
maze	O
apparatus	O
.	O

Gel	O
electrophoresis	O
and	O
Western	O
immunoblot	O
analyses	O
of	O
intracellular	O
fractions	O
derived	O
from	O
infected	O
cells	O
revealed	O
that	O
large	O
amounts	O
of	O
NS53	B-protein
were	O
present	O
in	O
the	O
cytosol	O
and	O
in	O
association	O
with	O
the	O
cytoskeletal	O
matrix	O
.	O

Bacterial	O
meningitis	O
secondary	O
to	O
abscess	O
of	O
the	O
nasal	O
septum	O
.	O

On	O
the	O
basis	O
of	O
serological	O
studies	O
,	O
the	O
highly	O
conserved	O
A	O
domain	O
of	O
HspA	B-protein
was	O
found	O
to	O
be	O
the	O
immunodominant	O
domain	O
.	O

In	O
PC12	O
cells	O
,	O
nerve	B-protein
growth	I-protein
factor	I-protein
induces	O
neuronal	O
differentiation	O
and	O
repressed	O
expression	O
of	O
nrg	B-protein
-	I-protein
1	I-protein
.	O

The	O
murine	B-protein
facilitative	I-protein
glucose	I-protein
transporter	I-protein
isoform	I-protein
3	I-protein
(	O
Glut	B-protein
3	I-protein
)	O
is	O
developmentally	O
regulated	O
and	O
is	O
predominantly	O
expressed	O
in	O
neurons	O
and	O
trophoblasts	O
.	O

To	O
investigate	O
the	O
regulation	O
of	O
expression	O
of	O
the	O
human	B-protein
mdr1	I-protein
gene	I-protein
,	O
the	O
response	O
of	O
the	O
mdr1	B-protein
promoter	I-protein
to	O
signals	O
involved	O
in	O
cell	O
proliferation	O
was	O
examined	O
.	O

Increased	O
urinary	O
riboflavin	O
excretion	O
resulting	O
from	O
boric	O
acid	O
ingestion	O
.	O

The	O
adenovirus	B-protein
E1A	I-protein
gene	I-protein
encodes	O
a	O
protein	O
that	O
transcriptionally	O
activates	O
viral	O
early	O
genes	O
.	O

This	O
compares	O
favorably	O
to	O
results	O
of	O
similarly	O
sized	O
melanomas	O
treated	O
by	O
enucleation	O
.	O

The	O
isolated	O
POT1	B-protein
clones	O
hybridized	O
to	O
a	O
1	O
.	O
4	O
kb	O
RNA	O
species	O
,	O
which	O
was	O
induced	O
approximately	O
30	O
-	O
fold	O
when	O
oleate	O
was	O
the	O
carbon	O
source	O
.	O

X	O
-	O
linked	O
liver	O
glycogenosis	O
:	O
localization	O
and	O
isolation	O
of	O
a	O
candidate	O
gene	O
.	O

Cell	O
lines	O
derived	O
from	O
the	O
tumors	O
were	O
examined	O
by	O
fluorescent	O
in	O
situ	O
hybridization	O
for	O
the	O
status	O
of	O
the	O
transferred	O
human	O
chromosome	O
and	O
by	O
PCR	O
for	O
marker	O
loss	O
.	O

Other	O
properties	O
of	O
Hg	O
-	O
and	O
Cd	O
-	O
spores	O
were	O
similar	O
to	O
those	O
of	O
control	O
spores	O
.	O

Accumulation	O
of	O
the	O
U4	B-protein
/	I-protein
U6	I-protein
duplex	I-protein
was	O
relieved	O
by	O
overexpression	O
of	O
wild	B-protein
-	I-protein
type	I-protein
Prp44p	I-protein
.	O

Its	O
transcription	O
has	O
been	O
shown	O
to	O
be	O
induced	O
40	O
-	O
50	O
-	O
fold	O
in	O
response	O
to	O
oxygen	O
or	O
heme	O
deficiency	O
,	O
in	O
part	O
through	O
relief	O
of	O
repression	O
exerted	O
by	O
Rox1p	B-protein
and	O
in	O
part	O
by	O
activation	O
mediated	O
by	O
an	O
upstream	B-protein
activation	I-protein
sequence	I-protein
(	O
UAS	B-protein
)	O
.	O

Methods	O
used	O
include	O
Cobb	O
angle	O
and	O
a	O
segmental	O
evaluation	O
(	O
T7	O
-	O
T12	O
)	O
of	O
each	O
of	O
convex	O
and	O
concave	O
rib	O
-	O
vertebra	O
angles	O
(	O
RVAs	O
)	O
,	O
rib	O
-	O
vertebra	O
angle	O
differences	O
(	O
RVADs	O
)	O
,	O
vertebral	O
rotation	O
,	O
tilt	O
and	O
displacement	O
.	O

The	O
exonic	O
sequence	O
encodes	O
a	O
protein	O
of	O
495	O
amino	O
acids	O
that	O
is	O
nearly	O
identical	O
to	O
the	O
previously	O
reported	O
protein	O
sequence	O
of	O
human	B-protein
GPT	I-protein
-	I-protein
1	I-protein
.	O

EMBO	O
J	O
.	O

The	O
promoter	O
for	O
HMG	B-protein
-	I-protein
CoA	I-protein
synthase	I-protein
contains	O
two	O
binding	O
sites	O
for	O
the	O
sterol	B-protein
regulatory	I-protein
element	I-protein
-	I-protein
binding	I-protein
proteins	I-protein
(	O
SREBPs	B-protein
)	O
.	O

U24	B-protein
has	O
two	O
separate	O
12	O
nt	O
long	O
complementarities	O
to	O
a	O
highly	O
conserved	O
tract	O
of	O
28S	B-protein
rRNA	I-protein
.	O

Thus	O
,	O
IHHNV	O
is	O
closely	O
related	O
to	O
densoviruses	O
of	O
the	O
genus	O
Brevidensovirus	O
in	O
the	O
family	O
Parvoviridae	O
,	O
and	O
we	O
therefore	O
propose	O
to	O
rename	O
this	O
virus	O
Penaeus	O
stylirostris	O
densovirus	O
(	O
PstDNV	O
)	O
.	O

Collectively	O
,	O
the	O
results	O
suggest	O
that	O
ARF	B-protein
binding	O
to	O
Mdm2	B-protein
induces	O
a	O
conformational	O
change	O
that	O
facilitates	O
nucleolar	O
import	O
of	O
the	O
ARF	B-protein
-	I-protein
Mdm2	I-protein
complex	I-protein
and	O
p53	O
-	O
dependent	O
cell	O
cycle	O
arrest	O
.	O

Inhibitor	B-protein
-	I-protein
1	I-protein
(	O
I	B-protein
-	I-protein
1	I-protein
)	O
and	O
inhibitor	B-protein
-	I-protein
2	I-protein
(	O
I	B-protein
-	I-protein
2	I-protein
)	O
selectively	O
inhibit	O
type	B-protein
1	I-protein
protein	I-protein
serine	I-protein
/	I-protein
threonine	I-protein
phosphatases	I-protein
(	O
PP1	B-protein
)	O
.	O

Deregulation	O
of	O
their	O
expression	O
may	O
contribute	O
to	O
malignant	O
transformation	O
associated	O
with	O
HTLV	O
-	O
1	O
infection	O
.	O

Thus	O
our	O
observations	O
establish	O
a	O
functional	O
link	O
between	O
the	O
PKC	B-protein
and	O
retinoid	O
pathways	O
,	O
which	O
are	O
generally	O
considered	O
to	O
have	O
antagonistic	O
activities	O
on	O
differentiation	O
processes	O
.	O

In	O
several	O
studies	O
the	O
RDFS	O
has	O
shown	O
evidence	O
of	O
reliability	O
and	O
validity	O
.	O

We	O
mapped	O
the	O
DGCR6	B-protein
gene	I-protein
to	O
chromosome	O
22q11	O
within	O
a	O
low	O
copy	O
repeat	O
,	O
termed	O
sc11	O
.	O
1a	O
,	O
and	O
identified	O
a	O
second	O
copy	O
of	O
the	O
gene	O
,	O
DGCR6L	B-protein
,	O
within	O
the	O
duplicate	O
locus	O
,	O
termed	O
sc11	O
.	O
1b	O
.	O

Pharmacological	O
action	O
of	O
eptazocine	O
(	O
l	O
-	O
1	O
,	O
4	O
-	O
dimethyl	O
-	O
10	O
-	O
hydroxy	O
-	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
-	O
hexahydro	O
-	O
1	O
,	O
6	O
-	O
methano	O
-	O
1H	O
-	O
4	O
-	O
benz	O
azonine	O
)	O
.	O

We	O
have	O
elucidated	O
the	O
exon	O
-	O
intron	O
organization	O
of	O
the	O
entire	O
human	O
CD58	B-protein
gene	I-protein
,	O
including	O
approximately	O
2	O
.	O
5	O
kilobases	O
(	O
kb	O
)	O
of	O
5	O
'	O
-	O
flanking	O
DNA	O
.	O

In	O
addition	O
to	O
the	O
significant	O
reduction	O
in	O
blood	O
pressure	O
,	O
the	O
angiotensin	B-protein
converting	I-protein
enzyme	I-protein
(	O
ACE	B-protein
)	O
inhibitor	O
ramipril	O
caused	O
a	O
significant	O
regression	O
of	O
pathologic	O
left	O
ventricular	O
hypertrophy	O
demonstrated	O
by	O
magnetic	O
resonance	O
imaging	O
and	O
echocardiography	O
.	O

We	O
show	O
that	O
the	O
5	O
'	O
UTR	O
characteristic	O
of	O
testis	B-protein
-	I-protein
specific	I-protein
c	I-protein
-	I-protein
mos	I-protein
mRNA	I-protein
strongly	O
represses	O
translation	O
relative	O
to	O
the	O
translation	O
of	O
transcripts	O
that	O
contain	O
a	O
5	O
'	O
UTR	O
derived	O
from	O
beta	B-protein
-	I-protein
globin	I-protein
mRNA	I-protein
,	O
and	O
this	O
is	O
mainly	O
due	O
to	O
the	O
four	O
uORFs	O
.	O

In	O
regards	O
to	O
the	O
latter	O
activity	O
,	O
it	O
has	O
been	O
shown	O
that	O
S3	B-protein
contains	O
vigorous	O
N	B-protein
-	I-protein
glycosylase	I-protein
activity	O
for	O
the	O
removal	O
of	O
8	O
-	O
oxoguanine	O
residues	O
in	O
DNA	O
that	O
leaves	O
baseless	O
sites	O
in	O
their	O
places	O
.	O

Analysis	O
of	O
proteins	O
synthesized	O
by	O
plasmids	O
containing	O
deleted	O
forms	O
of	O
the	O
trfA	B-protein
region	I-protein
indicates	O
that	O
the	O
A2	B-protein
protein	I-protein
is	O
the	O
essential	O
trfA	B-protein
-	I-protein
encoded	I-protein
replication	I-protein
protein	I-protein
of	O
plasmid	O
RK2	O
.	O

16	O
,	O
99	O
-	O
104	O
)	O
.	O

In	O
conclusion	O
,	O
NF	B-protein
-	I-protein
Y	I-protein
and	O
Sp1	B-protein
binding	O
sites	O
play	O
a	O
decisive	O
role	O
in	O
the	O
basal	O
expression	O
of	O
the	O
rat	B-protein
mrp2	I-protein
gene	I-protein
,	O
while	O
the	O
human	B-protein
MRP2	I-protein
gene	I-protein
is	O
regulated	O
differently	O
.	O

Minor	O
initiation	O
sites	O
were	O
found	O
at	O
positions	O
-	O
128	O
,	O
-	O
111	O
,	O
-	O
91	O
,	O
and	O
-	O
74	O
.	O

The	O
DNA	O
sequence	O
conferring	O
AP	B-protein
-	I-protein
1	I-protein
activity	O
was	O
located	O
in	O
the	O
proximal	O
promoter	O
region	O
.	O

In	O
both	O
experiments	O
,	O
average	O
daily	O
gain	O
and	O
gain	O
-	O
to	O
-	O
feed	O
ratio	O
were	O
similar	O
for	O
TR	O
and	O
CR	O
.	O

Molecular	O
cloning	O
,	O
genomic	O
mapping	O
,	O
and	O
expression	O
of	O
two	O
secretor	B-protein
blood	I-protein
group	I-protein
alpha	I-protein
(	I-protein
1	I-protein
,	I-protein
2	I-protein
)	I-protein
fucosyltransferase	I-protein
genes	I-protein
differentially	O
regulated	O
in	O
mouse	O
uterine	O
epithelium	O
and	O
gastrointestinal	O
tract	O
.	O

The	O
afferents	O
'	O
phase	O
of	O
response	O
was	O
unmodified	O
by	O
electrical	O
EVS	O
stimulation	O
.	O

A	O
log	O
-	O
linear	O
dose	O
-	O
response	O
was	O
obtained	O
for	O
the	O
average	O
increase	O
in	O
FEV1	O
up	O
to	O
6	O
h	O
(	O
AUC0	O
-	O
6	O
h	O
)	O
and	O
peak	O
FEV1	O
across	O
the	O
dose	O
range	O
administered	O
by	O
Respimat	O
.	O

Adipocyte	O
differentiation	O
of	O
nontransformed	O
cells	O
also	O
markedly	O
represses	O
the	O
ability	O
of	O
SRF	B-protein
to	O
bind	O
to	O
the	O
junB	B-protein
SRE	I-protein
,	O
the	O
c	B-protein
-	I-protein
fos	I-protein
SRE	I-protein
,	O
and	O
other	O
SREs	B-protein
,	O
as	O
determined	O
by	O
mobility	O
shift	O
and	O
gel	O
supershift	O
assays	O
,	O
without	O
affecting	O
the	O
DNA	O
binding	O
characteristics	O
of	O
the	O
nuclear	B-protein
protein	I-protein
SP	I-protein
-	I-protein
1	I-protein
.	O

The	O
PEBP2	B-protein
alpha	I-protein
proteins	I-protein
contain	O
a	O
128	O
-	O
amino	O
-	O
acid	O
(	O
aa	O
)	O
region	O
highly	O
homologous	O
to	O
the	O
Drosophila	B-protein
melanogaster	I-protein
segmentation	I-protein
gene	I-protein
runt	I-protein
.	O

Consistent	O
with	O
our	O
model	O
,	O
CTCF	B-protein
binding	O
is	O
abolished	O
by	O
DNA	O
methylation	O
.	O

Analysis	O
of	O
regulatory	O
regions	O
in	O
the	O
promoter	O
of	O
the	O
ctr4	B-protein
(	I-protein
+	I-protein
)	I-protein
copper	I-protein
transporter	I-protein
gene	I-protein
in	O
fission	O
yeast	O
Schizosaccharomyces	O
pombe	O
reveals	O
the	O
identity	O
of	O
a	O
conserved	O
copper	B-protein
-	I-protein
signaling	I-protein
element	I-protein
(	O
CuSE	B-protein
)	O
,	O
which	O
is	O
recognized	O
by	O
the	O
transcription	B-protein
factor	I-protein
Cuf1	I-protein
.	O

The	O
relative	O
risk	O
of	O
graft	O
loss	O
after	O
conversion	O
to	O
azathioprine	O
compared	O
with	O
graft	O
loss	O
after	O
conversion	O
to	O
azathioprine	O
compared	O
with	O
cyclosporin	O
maintenance	O
was	O
0	O
.	O
71	O
(	O
0	O
.	O
37	O
-	O
1	O
.	O
38	O
)	O
and	O
the	O
relative	O
risk	O
of	O
patient	O
death	O
was	O
0	O
.	O
57	O
(	O
0	O
.	O
23	O
-	O
1	O
.	O
41	O
)	O
.	O

Therefore	O
,	O
we	O
have	O
named	O
this	O
gene	O
UBP43	B-protein
.	O

Nucleotide	O
sequence	O
,	O
transcription	O
map	O
,	O
and	O
mutation	O
analysis	O
of	O
the	O
13q14	O
chromosomal	O
region	O
deleted	O
in	O
B	O
-	O
cell	O
chronic	O
lymphocytic	O
leukemia	O
.	O

Practical	O
use	O
and	O
interpretation	O
of	O
viral	O
hepatitis	O
B	O
markers	O
and	O
hepatic	O
biopsy	O
in	O
HBs	B-protein
Ag	I-protein
carriers	O
and	O
at	O
the	O
chronic	O
hepatitis	O
stage	O
.	O

HuEpo	B-protein
-	I-protein
R	I-protein
Ab	I-protein
inhibited	O
Epo	O
-	O
induced	O
parental	O
UT	O
-	O
7	O
cell	O
growth	O
,	O
but	O
not	O
that	O
of	O
cells	O
of	O
clone	O
12	O
,	O
suggesting	O
that	O
the	O
muEpo	B-protein
-	I-protein
R	I-protein
is	O
able	O
to	O
induce	O
human	O
UT	O
-	O
7	O
cell	O
proliferation	O
.	O

In	O
order	O
to	O
determine	O
which	O
sequences	O
in	O
the	O
GATA	B-protein
-	I-protein
1	I-protein
promoter	I-protein
are	O
crucial	O
for	O
activation	O
by	O
the	O
ME26	B-protein
viral	I-protein
protein	I-protein
,	O
we	O
made	O
deletions	O
of	O
the	O
promoter	O
,	O
cloned	O
them	O
into	O
a	O
luciferase	B-protein
expression	O
vector	O
and	O
tested	O
their	O
activity	O
in	O
mouse	O
fibroblasts	O
,	O
which	O
do	O
not	O
express	O
GATA	B-protein
-	I-protein
1	I-protein
.	O

The	O
effects	O
of	O
chlordiazepoxide	O
(	O
2	O
.	O
5	O
-	O
15	O
.	O
0mg	O
/	O
kg	O
)	O
,	O
a	O
full	O
benzodiazepine	B-protein
receptor	I-protein
agonist	O
,	O
and	O
bretazenil	O
(	O
5	O
.	O
0	O
-	O
30	O
.	O
0mg	O
/	O
kg	O
)	O
,	O
a	O
partial	O
benzodiazepine	B-protein
receptor	I-protein
agonist	O
,	O
were	O
examined	O
in	O
the	O
murine	O
elevated	O
plus	O
-	O
maze	O
paradigm	O
.	O

PMEK1	B-protein
displays	O
96	O
and	O
80	O
%	O
identity	O
respectively	O
with	O
the	O
tobacco	B-protein
NTF3	I-protein
and	O
Arabidopsis	B-protein
ATMPK1	I-protein
kinases	I-protein
,	O
and	O
only	O
50	O
%	O
to	O
the	O
more	O
distantly	O
related	O
plant	O
MAP	B-protein
kinase	I-protein
MsERK1	I-protein
from	O
alfalfa	O
.	O

We	O
conclude	O
that	O
the	O
QLMI	O
questionnaire	O
has	O
good	O
potential	O
as	O
an	O
instrument	O
for	O
assessing	O
QL	O
in	O
post	O
-	O
AMI	O
patients	O
and	O
that	O
it	O
can	O
be	O
successfully	O
self	O
-	O
administered	O
.	O

Ca2	B-protein
+	I-protein
/	I-protein
calmodulin	I-protein
-	I-protein
dependent	I-protein
protein	I-protein
kinase	I-protein
II	I-protein
(	O
CaMK	B-protein
II	I-protein
)	O
is	O
a	O
multifunctional	O
serine	B-protein
/	I-protein
threonine	I-protein
protein	I-protein
kinase	I-protein
that	O
regulates	O
ion	O
channels	O
,	O
metabolic	O
enzymes	O
,	O
cytoskeletal	O
proteins	O
,	O
and	O
possibly	O
transcription	O
factors	O
.	O

We	O
studied	O
the	O
GR	B-protein
in	O
DMS	O
-	O
79	O
cells	O
derived	O
from	O
a	O
human	O
ACTH	O
-	O
secreting	O
small	O
cell	O
lung	O
cancer	O
.	O

However	O
,	O
we	O
were	O
unable	O
to	O
identify	O
a	O
p4	B-protein
molecule	O
.	O

To	O
define	O
the	O
minimal	O
VDRE	B-protein
binding	O
domain	O
for	O
human	B-protein
VDR	I-protein
(	O
hVDR	B-protein
)	O
,	O
a	O
series	O
of	O
C	O
-	O
terminally	O
truncated	O
hVDR	B-protein
mutants	I-protein
(	O
Delta134	B-protein
,	O
Delta113	B-protein
,	O
Delta102	B-protein
,	O
Delta90	B-protein
,	O
Delta84	B-protein
,	O
Delta80	B-protein
,	O
and	O
Delta60	B-protein
)	O
was	O
generated	O
and	O
expressed	O
in	O
bacteria	O
.	O

The	O
urinary	O
protein	O
,	O
serum	O
albumin	B-protein
,	O
BUN	O
and	O
SCr	O
all	O
had	O
very	O
significant	O
improvement	O
.	O

Most	O
,	O
however	O
,	O
would	O
tell	O
the	O
spouse	O
the	O
full	O
truth	O
about	O
both	O
diagnosis	O
and	O
prognosis	O
.	O

The	O
combination	O
PIP	O
64	O
micrograms	O
-	O
PEF	O
4	O
micrograms	O
prevents	O
the	O
frequent	O
secondary	O
regrowth	O
seen	O
after	O
6	O
hours	O
with	O
the	O
antibiotics	O
used	O
alone	O
.	O

These	O
and	O
other	O
comparisons	O
suggest	O
that	O
,	O
during	O
evolution	O
,	O
both	O
the	O
RNA	B-protein
-	I-protein
polymerase	I-protein
specificity	O
of	O
telomerase	B-protein
RNA	I-protein
-	I-protein
gene	I-protein
promoters	I-protein
and	O
,	O
more	O
recently	O
,	O
the	O
position	O
of	O
the	O
template	O
sequence	O
in	O
the	O
telomerase	B-protein
RNA	I-protein
changed	O
.	O

Importantly	O
,	O
in	O
HeLa	O
and	O
293	O
cells	O
,	O
endogenous	O
and	O
transfected	O
I	B-protein
kappaB	I-protein
alpha	I-protein
coimmunoprecipitated	O
with	O
Myc	O
-	O
tagged	O
or	O
endogenous	O
Dlc	B-protein
-	I-protein
1	I-protein
.	O

Estrus	O
and	O
copulative	O
abilities	O
of	O
androgen	O
-	O
sterilized	O
rats	O
.	O

Analysis	O
of	O
corticosteroids	O
.	O

That	O
sequence	O
strongly	O
promoted	O
the	O
transcription	O
of	O
the	O
promotorless	O
chloramphenicol	B-protein
acetyltranferase	I-protein
(	O
CAT	B-protein
)	O
gene	O
in	O
cells	O
of	O
pancreatic	O
origin	O
(	O
AR	O
-	O
42J	O
)	O
but	O
not	O
in	O
cells	O
of	O
non	O
-	O
pancreatic	O
origin	O
(	O
Rat	O
2	O
and	O
IEC	O
6	O
)	O
.	O

We	O
report	O
the	O
molecular	O
cloning	O
and	O
functional	O
characterization	O
of	O
USF2	B-protein
isoforms	I-protein
,	O
corresponding	O
to	O
a	O
44	O
-	O
kDa	O
subunit	O
,	O
USF2a	B-protein
,	O
and	O
a	O
new	O
38	O
-	O
kDa	O
subunit	O
,	O
USF2b	B-protein
,	O
generated	O
by	O
differential	O
splicing	O
.	O

These	O
issues	O
include	O
the	O
use	O
of	O
LMWHs	O
in	O
patients	O
with	O
arterial	O
thrombosis	O
or	O
myocardial	O
infarction	O
(	O
e	O
.	O
g	O
.	O
in	O
conjunction	O
with	O
thrombolytic	O
treatment	O
)	O
,	O
and	O
in	O
patients	O
with	O
pulmonary	O
embolism	O
.	O

The	O
protein	B-protein
kinase	I-protein
domains	I-protein
of	O
LIMK1	B-protein
and	O
LIMK2	B-protein
are	O
unique	O
in	O
that	O
they	O
contain	O
an	O
unusual	O
sequence	B-protein
motif	I-protein
Asp	I-protein
-	I-protein
Leu	I-protein
-	I-protein
Asn	I-protein
-	I-protein
Ser	I-protein
-	I-protein
His	I-protein
-	I-protein
Asn	I-protein
in	O
subdomain	B-protein
VIB	I-protein
and	O
a	O
highly	O
basic	O
insert	O
between	O
subdomains	B-protein
VII	I-protein
and	I-protein
VIII	I-protein
.	O

In	O
Salmo	O
gairdneri	O
,	O
no	O
specialized	O
system	O
of	O
portal	O
vessels	O
appears	O
to	O
exist	O
between	O
the	O
pineal	O
organ	O
and	O
other	O
portions	O
of	O
the	O
brain	O
.	O

Diagnosis	O
and	O
treatment	O
planning	O
in	O
Class	O
II	O
,	O
division	O
2	O
.	O

Peripheral	O
vitreochorioretinal	O
dystrophies	O
in	O
myopia	O
patients	O
.	O

ESS	O
type	O
1	O
,	O
with	O
FT3	O
low	O
and	O
FT4	O
and	O
TSH	B-protein
normal	O
,	O
is	O
the	O
most	O
frequent	O
form	O
.	O

Our	O
results	O
indicate	O
that	O
periseizure	O
lipid	O
accumulation	O
is	O
related	O
to	O
cortical	O
oxygenation	O
.	O

Serum	O
lactate	B-protein
dehydrogenase	I-protein
and	O
haptoglobin	B-protein
levels	O
were	O
normal	O
,	O
and	O
total	O
bilirubin	O
was	O
only	O
slightly	O
elevated	O
.	O

During	O
the	O
cloning	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
of	O
the	O
human	B-protein
HIF	I-protein
-	I-protein
1alpha	I-protein
subunit	I-protein
,	O
we	O
isolated	O
two	O
cDNA	O
clones	O
which	O
corresponded	O
to	O
alternative	O
splicing	O
of	O
the	O
HIF	B-protein
-	I-protein
1alpha	I-protein
gene	I-protein
.	O

With	O
a	O
GC	O
content	O
of	O
45	O
%	O
the	O
one	O
segment	O
would	O
correspond	O
to	O
`	B-protein
`	I-protein
isochore	I-protein
H1	I-protein
'	I-protein
'	I-protein
and	O
the	O
other	O
segment	O
(	O
39	O
%	O
GC	O
in	O
human	O
,	O
40	O
%	O
GC	O
in	O
mouse	O
)	O
to	O
`	B-protein
`	I-protein
isochore	I-protein
L1	I-protein
/	I-protein
L2	I-protein
'	I-protein
'	I-protein
.	O

This	O
could	O
lead	O
to	O
subsequent	O
outbreaks	O
if	O
Babesia	O
carrier	O
animals	O
were	O
to	O
be	O
introduced	O
into	O
the	O
herd	O
.	O

Shear	O
bond	O
strength	O
of	O
a	O
composite	O
resin	O
to	O
an	O
etched	O
glass	O
ionomer	O
.	O

There	O
were	O
no	O
interfering	O
peaks	O
in	O
the	O
quantitation	O
of	O
sulbactam	O
.	O

Ultrasonic	O
evaluation	O
of	O
renal	O
calculi	O
.	O

Molecular	O
cloning	O
of	O
an	O
amphibian	B-protein
insulin	I-protein
receptor	I-protein
substrate	I-protein
1	I-protein
-	I-protein
like	I-protein
cDNA	I-protein
and	O
involvement	O
of	O
phosphatidylinositol	B-protein
3	I-protein
-	I-protein
kinase	I-protein
in	O
insulin	O
-	O
induced	O
Xenopus	O
oocyte	O
maturation	O
.	O

Hydrallazine	O
also	O
caused	O
a	O
slight	O
increase	O
in	O
plasma	B-protein
renin	I-protein
activity	O
and	O
urinary	O
excretion	O
of	O
noradrenaline	O
.	O

The	O
Delta6CCI	O
virus	O
was	O
extremely	O
attenuated	O
in	O
replication	O
capacity	O
yet	O
retained	O
infectiousness	O
for	O
CEMx174	O
and	O
MT4	O
cells	O
.	O

Tissue	O
necrosis	O
was	O
evaluated	O
using	O
triphenyltetrazolium	O
staining	O
and	O
was	O
related	O
to	O
two	O
major	O
baseline	O
predictors	O
of	O
infarct	O
size	O
:	O
anatomic	O
risk	O
zone	O
size	O
and	O
coronary	O
collateral	O
flow	O
.	O

Phenobarbital	O
-	O
induced	O
alterations	O
in	O
the	O
metabolism	O
of	O
[	O
3H	O
]	O
vitamin	O
D3	O
by	O
the	O
perfused	O
rachitic	O
rat	O
liver	O
in	O
vitro	O
.	O

Therefore	O
,	O
with	O
a	O
biopsy	O
from	O
the	O
stoma	O
site	O
there	O
is	O
a	O
risk	O
of	O
missing	O
early	O
rejection	O
.	O

Canalith	O
repositioning	O
is	O
the	O
mainstay	O
of	O
treatment	O
.	O

Further	O
,	O
the	O
reduction	O
in	O
5	O
-	O
hydroxytryptophan	O
(	O
5	O
-	O
HTP	O
)	O
accumulation	O
by	O
LSD	O
showed	O
regional	O
differences	O
in	O
inhibition	O
by	O
methiothepin	O
(	O
hypothalamus	O
greater	O
than	O
cortex	O
greater	O
than	O
striatum	O
)	O
which	O
paralleled	O
the	O
autoreceptor	O
antagonist	O
activity	O
of	O
methiothepin	O
in	O
vitro	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Fragments	O
containing	O
the	O
21	O
-	O
base	O
-	O
pair	O
repeat	O
region	O
,	O
the	O
enhancer	O
of	O
simian	O
virus	O
40	O
or	O
both	O
strongly	O
stimulated	O
beta	B-protein
-	I-protein
galactosidase	I-protein
synthesis	O
,	O
and	O
three	O
fragments	O
from	O
the	O
polyomavirus	O
enhancer	O
region	O
stimulated	O
moderate	O
levels	O
.	O

It	O
is	O
concluded	O
that	O
contact	O
allergy	O
to	O
K	O
-	O
CG	O
is	O
common	O
.	O

Characterization	O
of	O
LRP	B-protein
,	O
a	O
leucine	B-protein
-	I-protein
rich	I-protein
repeat	I-protein
(	I-protein
LRR	I-protein
)	I-protein
protein	I-protein
from	I-protein
tomato	I-protein
plants	I-protein
that	O
is	O
processed	O
during	O
pathogenesis	O
.	O

We	O
did	O
not	O
detect	O
p50	B-protein
in	O
association	O
with	O
native	B-protein
glucocorticoid	I-protein
receptor	I-protein
in	O
L	O
cells	O
or	O
with	O
the	O
overexpressed	O
glucocorticoid	B-protein
receptor	I-protein
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

Therefore	O
,	O
homozygous	O
co	O
-	O
deletions	O
of	O
CDKN2A	B-protein
and	O
CDKN2B	B-protein
rather	O
than	O
mutations	O
targeting	O
individual	O
transcripts	O
are	O
frequently	O
selected	O
for	O
in	O
these	O
tumors	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
progestin	O
-	O
mediated	O
increases	O
in	O
resting	O
core	O
temperature	O
and	O
the	O
core	O
temperature	O
threshold	O
for	O
sweating	O
onset	O
are	O
counteracted	O
by	O
estrogen	O
,	O
we	O
studied	O
eight	O
women	O
(	O
24	O
+	O
/	O
-	O
2	O
yr	O
)	O
at	O
27	O
degrees	O
C	O
rest	O
,	O
during	O
20	O
min	O
of	O
passive	O
heating	O
(	O
35	O
degrees	O
C	O
)	O
,	O
and	O
during	O
40	O
min	O
of	O
exercise	O
at	O
35	O
degrees	O
C	O
.	O

CONCLUSION	O
:	O
Treatment	O
of	O
sepsis	O
with	O
the	O
platelet	B-protein
-	I-protein
activating	I-protein
factor	I-protein
antagonist	O
BB	O
-	O
882	O
offers	O
no	O
advantage	O
over	O
placebo	O
on	O
survival	O
,	O
hemodynamic	O
status	O
,	O
respiratory	O
function	O
,	O
or	O
organ	O
failure	O
scores	O
.	O

No	O
differences	O
in	O
total	O
cholesterol	O
levels	O
were	O
observed	O
between	O
mapuches	O
and	O
aymaras	O
.	O

The	O
recovery	O
rates	O
for	O
the	O
MB	O
/	O
BacT	O
,	O
MGIT	O
960	O
,	O
and	O
solid	O
media	O
were	O
91	O
.	O
6	O
,	O
87	O
.	O
4	O
,	O
and	O
54	O
.	O
7	O
%	O
,	O
respectively	O
,	O
for	O
all	O
mycobacteria	O
;	O
the	O
recovery	O
rates	O
were	O
93	O
.	O
6	O
,	O
88	O
.	O
9	O
,	O
and	O
63	O
.	O
4	O
%	O
,	O
respectively	O
,	O
for	O
M	O
.	O
tuberculosis	O
complex	O
alone	O
,	O
and	O
87	O
.	O
5	O
,	O
84	O
.	O
4	O
,	O
and	O
37	O
.	O
5	O
%	O
,	O
respectively	O
,	O
for	O
all	O
nontuberculous	O
mycobacteria	O
.	O

Ras	B-protein
is	O
not	O
associated	O
with	O
the	O
tegument	O
.	O

In	O
293	O
cells	O
,	O
expression	O
of	O
the	O
NF	B-protein
-	I-protein
kappa	I-protein
B	I-protein
inhibitor	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
-	I-protein
alpha	I-protein
,	O
reduced	O
the	O
stimulatory	O
activity	O
of	O
LMP	B-protein
.	O

Studies	O
using	O
HLA	B-protein
-	I-protein
DR	I-protein
-	I-protein
B7	I-protein
-	I-protein
1	I-protein
-	I-protein
LFA	I-protein
-	I-protein
3	I-protein
triple	O
transfectants	O
showed	O
that	O
the	O
LFA	O
-	O
3	O
-	O
induced	O
NF	B-protein
-	I-protein
AT	I-protein
DNA	O
binding	O
activity	O
was	O
negatively	O
regulated	O
by	O
B7	B-protein
-	I-protein
1	I-protein
costimulation	O
.	O

It	O
contains	O
binding	O
sites	O
for	O
several	O
transcription	O
factors	O
,	O
for	O
example	O
:	O
(	O
i	O
)	O
a	O
well	O
-	O
characterized	O
binding	O
site	O
for	O
rel	B-protein
/	I-protein
NF	I-protein
-	I-protein
kappaB	I-protein
transcription	I-protein
factors	I-protein
in	O
its	O
3	O
'	O
-	O
end	O
(	O
the	O
H2TF1	B-protein
or	O
kappaB1	B-protein
element	I-protein
)	O
,	O
(	O
ii	O
)	O
a	O
second	O
kappaB	B-protein
site	I-protein
(	O
the	O
kappaB2	B-protein
element	I-protein
)	O
,	O
which	O
is	O
located	O
immediately	O
adjacent	O
5	O
'	O
to	O
the	O
H2TF1	B-protein
element	I-protein
and	O
which	O
is	O
recognized	O
by	O
p65	B-protein
/	I-protein
relA	I-protein
in	O
the	O
human	B-protein
HLA	I-protein
system	O
,	O
and	O
(	O
iii	O
)	O
an	O
AP	B-protein
-	I-protein
1	I-protein
/	I-protein
ATF	I-protein
recognition	I-protein
sequence	I-protein
in	O
the	O
5	O
'	O
end	O
(	O
EnA	B-protein
-	I-protein
TRE	I-protein
)	O
.	O

PURPOSE	O
:	O
The	O
purposes	O
of	O
the	O
present	O
study	O
were	O
to	O
assess	O
the	O
effects	O
of	O
a	O
12	O
-	O
wk	O
laboratory	O
based	O
aerobic	O
exercise	O
program	O
on	O
cardiopulmonary	O
function	O
,	O
CD4	O
cell	O
count	O
,	O
and	O
physician	O
-	O
assessed	O
health	O
status	O
among	O
symptomatic	O
pre	O
-	O
AIDS	O
HIV	O
-	O
infected	O
individuals	O
(	O
N	O
=	O
28	O
)	O
and	O
to	O
assess	O
the	O
degree	O
to	O
which	O
ill	O
health	O
was	O
associated	O
with	O
exercise	O
relapse	O
.	O

Ulcer	O
appeared	O
on	O
the	O
angulus	O
of	O
the	O
stomach	O
at	O
the	O
28th	O
week	O
and	O
resulted	O
in	O
ulcer	O
scar	O
at	O
the	O
42nd	O
week	O
.	O

These	O
similarities	O
suggest	O
that	O
these	O
E2	B-protein
proteins	I-protein
are	O
structurally	O
and	O
evolutionarily	O
related	O
.	O

Taxonomically	O
significant	O
colour	O
changes	O
in	O
Brevibacterium	O
linens	O
probably	O
associated	O
with	O
a	O
carotenoid	O
-	O
like	O
pigment	O
.	O

The	O
effect	O
of	O
a	O
tissue	O
emulsion	O
,	O
vitamin	O
A	O
and	O
nonspecific	O
gamma	B-protein
-	I-protein
globulin	I-protein
on	O
the	O
blood	O
clearance	O
in	O
rabbits	O
.	O

The	O
enhanced	O
cysteine	O
formation	O
in	O
a	O
pCSK4F	O
plant	O
responding	O
to	O
sulfite	O
was	O
also	O
observed	O
in	O
leaf	O
discs	O
.	O

Examination	O
of	O
immediate	O
-	O
early	O
transcription	O
factor	O
expression	O
during	O
the	O
MDI	O
regimen	O
revealed	O
that	O
RA	O
mediated	O
an	O
elevated	O
,	O
prolonged	O
expression	O
of	O
c	B-protein
-	I-protein
Jun	I-protein
mRNA	I-protein
accompanied	O
by	O
diminished	O
expression	O
of	O
c	B-protein
-	I-protein
Fos	I-protein
and	O
Jun	B-protein
-	I-protein
B	I-protein
mRNAs	I-protein
.	O

Six	O
of	O
them	O
,	O
NUC1	B-protein
,	O
PRP21	B-protein
(	O
also	O
called	O
SPP91	B-protein
)	O
,	O
CDC6	B-protein
,	O
CRY2	B-protein
,	O
the	O
gene	O
encoding	O
the	O
ribosomal	B-protein
protein	I-protein
S24	I-protein
and	O
the	O
gene	O
coding	O
for	O
a	O
hypothetical	O
protein	O
of	O
599	O
amino	O
acids	O
,	O
have	O
been	O
sequenced	O
previously	O
.	O

The	O
spacing	O
of	O
the	O
essential	O
N	O
-	O
terminal	O
domain	O
(	O
END	O
)	O
relative	O
to	O
the	O
HFD	O
can	O
be	O
changed	O
significantly	O
without	O
an	O
apparent	O
effect	O
on	O
Cse4p	B-protein
function	O
.	O

Vam7p	B-protein
,	O
a	O
SNAP	B-protein
-	I-protein
25	I-protein
-	I-protein
like	I-protein
molecule	I-protein
,	O
and	O
Vam3p	B-protein
,	O
a	O
syntaxin	B-protein
homolog	I-protein
,	O
function	O
together	O
in	O
yeast	O
vacuolar	O
protein	O
trafficking	O
.	O

A	O
potential	O
binding	O
site	O
for	O
the	O
dShc	B-protein
PTB	I-protein
domain	I-protein
is	O
located	O
at	O
Tyr	O
-	O
1228	O
of	O
DER	B-protein
.	O

After	O
10	O
months	O
of	O
treatment	O
with	O
the	O
conjugated	O
estrogen	O
,	O
both	O
his	O
height	O
and	O
weight	O
showed	O
improvement	O
,	O
while	O
his	O
bone	O
mineral	O
density	O
and	O
bone	O
age	O
were	O
increased	O
.	O

Agranulocytosis	O
treatment	O
with	O
rhGM	B-protein
-	I-protein
CSF	I-protein
.	O

This	O
sequence	O
is	O
very	O
similar	O
to	O
the	O
insulin	B-protein
response	I-protein
sequence	I-protein
found	O
in	O
the	O
regulatory	O
region	O
of	O
other	O
genes	O
negatively	O
regulated	O
by	O
insulin	B-protein
such	O
as	O
those	O
encoding	O
phosphoenolpyruvate	B-protein
carboxykinase	I-protein
,	O
tyrosine	B-protein
aminotransferase	I-protein
,	O
and	O
insulin	B-protein
-	I-protein
like	I-protein
growth	I-protein
factor	I-protein
-	I-protein
binding	I-protein
protein	I-protein
1	I-protein
.	O

Beyond	O
the	O
Tower	O
of	O
Babel	O
:	O
a	O
nomenclature	O
for	O
suicidology	O
.	O

Naltrexone	O
has	O
been	O
recently	O
approved	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
for	O
the	O
treatment	O
of	O
alcohol	O
dependence	O
.	O

The	O
mean	O
weight	O
and	O
height	O
velocities	O
were	O
148	O
%	O
and	O
122	O
%	O
of	O
the	O
standard	O
,	O
respectively	O
.	O

Albumin	B-protein
and	O
cyclic	O
AMP	O
levels	O
in	O
peritoneal	O
fluids	O
in	O
the	O
child	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
transiently	O
expressed	O
in	O
primary	O
cultures	O
of	O
rat	O
hepatocytes	O
plasmids	O
consisting	O
of	O
CYP3A1	B-protein
5	I-protein
'	I-protein
-	I-protein
flanking	I-protein
sequences	I-protein
fused	O
to	O
a	O
chloramphenicol	B-protein
acetyltransferase	I-protein
reporter	I-protein
plasmid	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
Ras	O
-	O
activated	O
Raf	B-protein
-	I-protein
MEK	I-protein
-	I-protein
extracellular	I-protein
signal	I-protein
-	I-protein
regulated	I-protein
kinase	I-protein
(	O
ERK	B-protein
)	O
signaling	O
pathway	O
can	O
specifically	O
control	O
the	O
expression	O
of	O
individual	O
integrin	B-protein
subunits	I-protein
in	O
a	O
variety	O
of	O
human	O
and	O
mouse	O
cell	O
lines	O
.	O

RESULTS	O
:	O
We	O
isolated	O
a	O
C	O
.	O
elegans	O
cDNA	O
that	O
encoded	O
a	O
protein	O
which	O
was	O
similar	O
to	O
,	O
but	O
not	O
exactly	O
homologous	O
with	O
mammalian	O
p120	B-protein
Ras	I-protein
-	I-protein
GAP	I-protein
.	O

Petko	O
,	O
and	O
S	O
.	O

Among	O
82	O
superficial	O
lesions	O
34	O
were	O
classified	O
as	O
showing	O
CR	O
and	O
another	O
23	O
as	O
showing	O
PR	O
,	O
with	O
a	O
response	O
rate	O
of	O
69	O
.	O
5	O
%	O
.	O

Transformed	O
bacterial	O
colonies	O
were	O
screened	O
for	O
recombinant	O
plasmids	O
containing	O
cDNA	O
coding	O
for	O
BiP	B-protein
by	O
hybrid	O
-	O
selected	O
mRNA	O
translation	O
.	O

Although	O
no	O
differences	O
were	O
noted	O
in	O
the	O
decrease	O
in	O
platelet	O
counts	O
between	O
the	O
two	O
groups	O
,	O
fibrinogen	B-protein
levels	O
and	O
alpha	B-protein
2	I-protein
-	I-protein
antiplasmin	I-protein
levels	O
declined	O
less	O
drastically	O
in	O
the	O
antithrombin	O
-	O
treated	O
group	O
.	O

Using	O
an	O
RNase	O
H	O
-	O
mediated	O
mapping	O
technique	O
,	O
we	O
show	O
that	O
the	O
64	O
-	O
kDa	O
subunit	O
of	O
CstF	B-protein
can	O
be	O
photo	O
cross	O
-	O
linked	O
to	O
pre	O
-	O
mRNAs	O
at	O
U	O
-	O
rich	O
regions	O
located	O
downstream	O
of	O
the	O
cleavage	O
site	O
of	O
the	O
simian	O
virus	O
40	O
late	O
and	O
adenovirus	O
L3	O
pre	O
-	O
mRNAs	O
.	O

Either	O
20	O
mg	O
mitomycin	O
/	O
20	O
ml	O
distilled	O
water	O
or	O
40	O
mg	O
/	O
40	O
ml	O
distilled	O
water	O
was	O
locally	O
instilled	O
into	O
the	O
bladder	O
with	O
a	O
catheter	O
after	O
emptying	O
it	O
and	O
was	O
left	O
for	O
about	O
25	O
-	O
l20	O
min	O
.	O

Saccharomyces	O
cerevisiae	O
has	O
been	O
used	O
widely	O
both	O
as	O
a	O
model	O
system	O
for	O
unraveling	O
the	O
biochemical	O
,	O
genetic	O
,	O
and	O
molecular	O
details	O
of	O
gene	O
expression	O
and	O
the	O
secretion	O
process	O
,	O
and	O
as	O
a	O
host	O
for	O
the	O
production	O
of	O
heterologous	O
proteins	O
of	O
biotechnological	O
interest	O
.	O

Giant	O
pilomatrix	O
carcinoma	O
:	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

The	O
RI	B-protein
alpha	I-protein
gene	I-protein
is	O
composed	O
of	O
nine	O
coding	O
exons	O
of	O
varying	O
lengths	O
,	O
separated	O
by	O
introns	O
,	O
giving	O
the	O
gene	O
a	O
total	O
length	O
of	O
at	O
least	O
21	O
kb	O
.	O
our	O
recent	O
cloning	O
of	O
a	O
processed	O
RI	B-protein
alpha	I-protein
pseudogene	I-protein
with	O
a	O
5	O
'	O
-	O
noncoding	O
region	O
different	O
from	O
the	O
previously	O
reported	O
RI	B-protein
alpha	I-protein
complementary	I-protein
RNA	I-protein
indicated	O
that	O
the	O
RI	B-protein
alpha	I-protein
gene	I-protein
may	O
have	O
multiple	O
leader	O
exons	O
giving	O
rise	O
to	O
alternately	O
spliced	O
messenger	O
RNAs	O
(	O
mRNAs	O
)	O
.	O

1	O
in	O
Ho	O
Chi	O
Minh	O
City	O
was	O
studied	O
by	O
culture	O
and	O
latex	O
agglutination	O
of	O
blood	O
,	O
cerebrospinal	O
fluid	O
,	O
urine	O
and	O
pleural	O
fluid	O
.	O

Genomic	O
Southern	O
blot	O
analysis	O
and	O
chromosome	O
mapping	O
showed	O
that	O
GPRK6	B-protein
hybridizes	O
to	O
two	O
closely	O
related	O
genes	O
located	O
on	O
chromosomes	O
5	O
and	O
13	O
and	O
are	O
,	O
therefore	O
,	O
distinct	O
from	O
the	O
GPRK	B-protein
located	O
near	O
the	O
Huntington	B-protein
disease	I-protein
locus	I-protein
on	O
chromosome	O
4	O
.	O

Candidate	O
tumor	O
suppressor	O
genes	O
,	O
Mts1	B-protein
(	O
p16INK4a	B-protein
)	O
and	O
Mts2	B-protein
(	O
p15INK4b	B-protein
)	O
,	O
have	O
been	O
mapped	O
to	O
this	O
region	O
,	O
but	O
by	O
Southern	O
blot	O
analysis	O
,	O
no	O
homozygous	O
deletions	O
were	O
detected	O
in	O
either	O
gene	O
.	O

The	O
effects	O
of	O
pharmacological	O
treatment	O
and	O
professional	O
care	O
and	O
support	O
may	O
improve	O
when	O
dementia	O
is	O
detected	O
in	O
an	O
early	O
stage	O
.	O

Apo	B-protein
A	I-protein
-	I-protein
I	I-protein
level	O
was	O
unrelated	O
to	O
age	O
,	O
but	O
increased	O
with	O
ethanol	O
consumption	O
and	O
decreased	O
with	O
adiposity	O
.	O

Paradoxically	O
,	O
coexpression	O
of	O
the	O
transcriptionally	O
inactive	O
,	O
amino	O
-	O
terminally	O
deleted	O
IDX	B-protein
-	I-protein
1	I-protein
mutant	I-protein
proteins	I-protein
,	O
either	O
with	O
the	O
wild	B-protein
-	I-protein
type	I-protein
IDX	I-protein
-	I-protein
1	I-protein
or	O
with	O
themselves	O
,	O
results	O
in	O
a	O
marked	O
enhancement	O
of	O
transactivation	O
of	O
the	O
transcriptional	O
TAAT	B-protein
-	I-protein
1	I-protein
element	I-protein
reporter	I-protein
.	O

However	O
,	O
the	O
rtFc	B-protein
gamma	I-protein
R	I-protein
alpha	I-protein
cDNA	I-protein
clone	O
is	O
complementary	O
to	O
at	O
least	O
two	O
different	O
-	O
sized	O
mRNAs	O
expressed	O
by	O
CRNK	O
-	O
16	O
cells	O
,	O
contrasting	O
the	O
single	O
Fc	B-protein
gamma	I-protein
R	I-protein
-	I-protein
related	I-protein
mRNA	I-protein
species	O
expressed	O
by	O
human	O
and	O
mouse	O
natural	O
killer	O
cells	O
.	O

Flap	O
survival	O
depends	O
on	O
the	O
development	O
of	O
a	O
small	O
number	O
of	O
vascular	O
connections	O
between	O
vessels	O
arising	O
from	O
the	O
pedicle	O
and	O
preexisting	O
dermal	O
vessels	O
.	O

The	O
predicted	O
molecular	O
weight	O
of	O
the	O
polyprotein	O
encoded	O
by	O
ORF1	O
is	O
33	O
kilodaltons	O
(	O
kDa	O
)	O
.	O

These	O
regions	O
contain	O
inverted	O
E	O
-	O
box	O
palindromic	O
or	O
direct	O
repeat	O
motifs	O
and	O
bind	O
SREBP	B-protein
-	I-protein
1	I-protein
with	O
different	O
affinities	O
.	O

Electronic	O
data	O
processing	O
(	O
EDP	O
)	O
latex	O
immunoassay	O
using	O
anti	B-protein
-	I-protein
human	I-protein
seminal	I-protein
acid	I-protein
phosphatase	I-protein
(	O
anti	B-protein
-	I-protein
HSAP	I-protein
)	O
immune	O
serum	O
was	O
applied	O
for	O
the	O
species	O
and	O
organ	O
identification	O
of	O
human	O
seminal	O
stains	O
.	O

The	O
author	O
provides	O
a	O
rationale	O
for	O
an	O
interactional	O
view	O
and	O
presents	O
a	O
case	O
in	O
which	O
post	O
-	O
surgical	O
hiccups	O
were	O
successfully	O
treated	O
,	O
using	O
principles	O
developed	O
by	O
the	O
Mental	O
Research	O
Institute	O
.	O

Near	O
a	O
third	O
(	O
31	O
.	O
6	O
%	O
)	O
of	O
Insulin	B-protein
Dependent	O
and	O
a	O
third	O
(	O
33	O
.	O
41	O
%	O
)	O
for	O
Non	O
Insulin	B-protein
Dependent	O
were	O
of	O
D	O
,	O
F	O
,	O
H	O
White	O
'	O
s	O
Class	O
.	O

In	O
each	O
compartment	O
O2	O
is	O
removed	O
by	O
the	O
tissues	O
as	O
a	O
chemical	O
reaction	O
takes	O
place	O
between	O
O2	O
and	O
oxyhemoglobin	B-protein
(	O
HbO2	B-protein
)	O
.	O

Additionally	O
,	O
the	O
enzyme	O
shows	O
activity	O
towards	O
triglycerides	O
such	O
as	O
olive	O
oil	O
and	O
tributyrin	O
and	O
towards	O
egg	O
-	O
yolk	O
emulsions	O
.	O

In	O
the	O
past	O
,	O
immunology	O
in	O
Singapore	O
was	O
mainly	O
confined	O
to	O
serology	O
for	O
the	O
diagnosis	O
of	O
certain	O
infectious	O
diseases	O
.	O

General	O
formulae	O
for	O
estimating	O
heritability	O
in	O
a	O
population	O
with	O
related	O
parents	O
.	O

The	O
potency	O
of	O
the	O
effect	O
of	O
Nim	O
(	O
0	O
.	O
5	O
mg	O
.	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
was	O
similar	O
to	O
that	O
of	O
NBP	O
(	O
10	O
mg	O
.	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
.	O

The	O
histamine	B-protein
H1	I-protein
receptor	I-protein
antagonists	O
(	O
antihistamines	O
)	O
are	O
an	O
important	O
class	O
of	O
medications	O
used	O
for	O
the	O
relief	O
of	O
common	O
symptoms	O
associated	O
with	O
hyperhistaminic	O
conditions	O
occurring	O
in	O
children	O
and	O
adults	O
.	O

Thalamotomy	O
aiming	O
at	O
the	O
CM	O
-	O
Pf	O
complex	O
and	O
using	O
stereotactic	O
gamma	O
irradiation	O
has	O
been	O
performed	O
in	O
a	O
series	O
of	O
52	O
patients	O
with	O
severe	O
pain	O
due	O
to	O
malignancy	O
.	O

The	O
zona	O
pellucida	O
(	O
ZP	O
)	O
,	O
the	O
extracellular	O
glycocalyx	O
that	O
surrounds	O
the	O
oocyte	O
,	O
is	O
well	O
known	O
to	O
mediate	O
homologous	O
gamete	O
interaction	O
.	O

The	O
cell	O
cycle	O
and	O
transcriptional	O
defects	O
caused	O
by	O
taf17	B-protein
(	I-protein
slm7	I-protein
-	I-protein
1	I-protein
)	I-protein
are	O
consistent	O
with	O
the	O
role	O
of	O
TAF	B-protein
(	I-protein
II	I-protein
)	I-protein
s	I-protein
as	O
modulators	O
of	O
transcriptional	O
activation	O
and	O
may	O
reflect	O
a	O
role	O
for	O
TAF17	B-protein
in	O
regulating	O
activation	O
by	O
SBF	B-protein
and	O
MBF	B-protein
.	O

These	O
data	O
will	O
help	O
us	O
to	O
better	O
detail	O
the	O
CXCR4	B-protein
structural	O
requirements	O
exhibited	O
by	O
different	O
HIV	O
-	O
1	O
strains	O
and	O
will	O
direct	O
further	O
mutagenesis	O
efforts	O
aimed	O
at	O
better	O
defining	O
the	O
domains	O
in	O
CXCR4	B-protein
involved	O
in	O
the	O
HIV	O
-	O
1	O
Env	O
-	O
mediated	O
fusion	O
process	O
.	O

There	O
was	O
no	O
apparent	O
effect	O
of	O
growth	O
temperature	O
on	O
the	O
steady	O
-	O
state	O
levels	O
of	O
fad7	B-protein
mRNA	I-protein
in	O
wild	O
type	O
plants	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
phorbol	O
ester	O
PMA	O
decreases	O
both	O
basal	O
and	O
dexamethasone	O
/	O
cAMP	O
-	O
induced	O
expression	O
of	O
a	O
luciferase	B-protein
gene	I-protein
under	O
the	O
control	O
of	O
the	O
G6Pase	B-protein
promoter	I-protein
in	O
transiently	O
transfected	O
H4IIE	O
hepatoma	O
cells	O
.	O

A511	O
is	O
a	O
broad	O
-	O
host	O
-	O
range	O
,	O
virulent	O
myovirus	O
for	O
Listeria	O
monocytogenes	O
.	O

Regional	O
cerebral	O
blood	O
flow	O
was	O
measured	O
using	O
N	O
-	O
isopropyl	O
-	O
123I	O
-	O
iodoamphetamine	O
with	O
single	O
-	O
photon	O
emission	O
computed	O
tomography	O
(	O
CT	O
)	O
in	O
16	O
aged	O
patients	O
with	O
noninsulin	O
-	O
dependent	O
diabetes	O
mellitus	O
(	O
NIDDM	O
,	O
average	O
age	O
72	O
.	O
8	O
years	O
,	O
average	O
fasting	O
plasma	O
glucose	O
7	O
.	O
7	O
mmol	O
/	O
L	O
)	O
,	O
and	O
12	O
nondiabetic	O
subjects	O
(	O
71	O
.	O
6	O
years	O
,	O
5	O
.	O
3	O
mmol	O
/	O
L	O
)	O
.	O

The	O
role	O
of	O
transport	O
by	O
sea	O
ice	O
from	O
the	O
Kara	O
Sea	O
into	O
the	O
Arctic	O
Ocean	O
was	O
assessed	O
by	O
a	O
small	O
subgroup	O
at	O
GEOMAR	O
.	O

Inhibition	O
of	O
constitutive	O
NF	B-protein
-	I-protein
kappaB	I-protein
activity	O
results	O
in	O
cell	O
death	O
of	O
TT	O
cells	O
and	O
blocks	O
focus	O
formation	O
induced	O
by	O
oncogenic	O
forms	O
of	O
RET	B-protein
in	O
NIH	O
3T3	O
cells	O
.	O

CD4	B-protein
lymphocyte	O
and	O
viral	O
load	O
levels	O
suggested	O
an	O
optimal	O
response	O
to	O
ARV	O
therapy	O
at	O
the	O
time	O
LD	O
developed	O
.	O

Central	O
venous	O
catheter	O
used	O
for	O
recording	O
intracardiac	O
electrocardiogram	O
.	O

The	O
receptor	B-protein
for	I-protein
hyaluronan	I-protein
mediated	I-protein
motility	I-protein
(	I-protein
RHAMM	I-protein
)	I-protein
gene	I-protein
expression	O
is	O
markedly	O
elevated	O
in	O
fibrosarcomas	O
exposed	O
to	O
transforming	B-protein
growth	I-protein
factor	I-protein
-	I-protein
beta1	I-protein
(	O
TGF	B-protein
-	I-protein
beta1	I-protein
)	O
.	O

SECONDARY	O
OUTCOME	O
MEASURE	O
-	O
-	O
Double	O
-	O
blind	O
caffeine	O
-	O
withdrawal	O
evaluation	O
.	O

Plastic	O
solution	O
of	O
elbow	O
joint	O
ankylosis	O
with	O
a	O
decorticated	O
cylindrical	O
flap	O
.	O

This	O
study	O
underlines	O
the	O
importance	O
of	O
terminal	O
SC5b	B-protein
-	I-protein
9	I-protein
complement	I-protein
complex	I-protein
as	O
a	O
suitable	O
marker	O
in	O
the	O
evaluation	O
of	O
complement	O
activation	O
during	O
cardiopulmonary	O
bypass	O
.	O

Glucagon	O
also	O
induced	O
LUC	B-protein
activity	O
very	O
strongly	O
when	O
the	O
CRE1	B-protein
and	O
CRE2	B-protein
sites	I-protein
were	O
combined	O
;	O
induction	O
of	O
the	O
(	B-protein
CRE1	I-protein
)	I-protein
3	I-protein
(	I-protein
CRE2	I-protein
)	I-protein
2SV40	I-protein
-	I-protein
LUC	I-protein
constructs	I-protein
was	O
positively	O
modulated	O
by	O
the	O
pO2	O
.	O

Problems	O
in	O
the	O
determination	O
of	O
the	O
antigenic	O
content	O
of	O
influenza	O
vaccines	O
.	O

It	O
is	O
concluded	O
that	O
the	O
unique	O
suppository	O
formulation	O
of	O
CZX	O
-	O
S	O
is	O
useful	O
in	O
the	O
treatment	O
of	O
infections	O
in	O
children	O
with	O
heavy	O
psychophysiologic	O
disorders	O
and	O
in	O
children	O
who	O
can	O
not	O
take	O
oral	O
drugs	O
because	O
of	O
severe	O
vomiting	O
.	O

Training	O
for	O
audit	O
.	O

Tyrosine	O
1356	O
forms	O
a	O
multisubstrate	O
binding	O
site	O
for	O
the	O
Grb2	B-protein
and	O
Shc	B-protein
adaptor	I-protein
proteins	I-protein
,	O
the	O
p85	B-protein
subunit	I-protein
of	O
phosphatidylinositol	B-protein
3	I-protein
'	I-protein
-	I-protein
kinase	I-protein
,	O
phospholipase	B-protein
Cgamma	I-protein
,	O
and	O
a	O
phosphatase	B-protein
,	O
SHP2	B-protein
.	O

In	O
the	O
case	O
of	O
the	O
unspliceable	O
intron	O
,	O
repression	O
of	O
luciferase	B-protein
expression	O
likely	O
involved	O
two	O
AUF1	B-protein
-	I-protein
binding	I-protein
sequences	I-protein
,	O
since	O
luciferase	B-protein
expression	O
was	O
increased	O
by	O
deletion	O
of	O
these	O
sites	O
.	O

A	O
method	O
for	O
determining	O
optimal	O
development	O
conditions	O
by	O
summary	O
oxygen	O
consumption	O
.	O

The	O
lines	O
also	O
differed	O
in	O
postsynaptic	O
,	O
but	O
not	O
presynaptic	O
,	O
5	B-protein
-	I-protein
HT1A	I-protein
receptors	I-protein
.	O

This	O
apparently	O
anomalous	O
structure	O
/	O
activity	O
relationship	O
raises	O
important	O
issues	O
for	O
understanding	O
the	O
evolution	O
of	O
regulatory	O
peptides	O
and	O
the	O
mechanisms	O
that	O
control	O
their	O
expression	O
.	O

Ultrastructural	O
study	O
of	O
polyarteritis	O
.	O

Dopamine	O
neurons	O
in	O
subjects	O
that	O
received	O
6	O
-	O
OHDA	O
were	O
protected	O
by	O
pre	O
-	O
treatment	O
with	O
GBR	O
-	O
12909	O
.	O

E2	B-protein
point	O
mutants	O
unable	O
to	O
inhibit	O
cell	O
growth	O
did	O
not	O
repress	O
cdc25A	B-protein
and	O
cdc25B	B-protein
expression	O
,	O
nor	O
did	O
the	O
cell	O
cycle	O
inhibitors	O
hydroxyurea	O
and	O
mimosine	O
.	O

Lys	O
(	O
193	O
)	O
and	O
Arg	O
(	O
194	O
)	O
,	O
located	O
at	O
the	O
COOH	O
-	O
terminal	O
end	O
of	O
HD	B-protein
,	O
are	O
essential	O
for	O
dimerization	O
.	O

Regression	O
line	O
slopes	O
of	O
IBDQ	O
scores	O
were	O
significantly	O
different	O
in	O
patients	O
who	O
deteriorated	O
from	O
those	O
who	O
remained	O
stable	O
(	O
[	O
b	O
]	O
<	O
0	O
.	O
15	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Inducible	O
VT	O
was	O
suppressed	O
entirely	O
in	O
one	O
patient	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
specific	O
nuclear	O
protein	O
binding	O
to	O
-	O
85	O
/	O
-	O
64	O
,	O
and	O
single	O
point	O
mutations	O
suggested	O
important	O
binding	O
nucleotides	O
between	O
-	O
79	O
/	O
-	O
68	O
with	O
five	O
critical	O
bases	O
between	O
-	O
74	O
/	O
-	O
70	O
(	O
5	B-protein
'	I-protein
-	I-protein
CTCCT	I-protein
-	I-protein
3	I-protein
'	I-protein
)	O
.	O

The	O
27	O
-	O
base	O
element	O
interacts	O
with	O
a	O
PDGF	B-protein
-	I-protein
activated	I-protein
serine	I-protein
/	I-protein
threonine	I-protein
phosphoprotein	I-protein
that	O
is	O
detected	O
only	O
within	O
the	O
nucleus	O
of	O
PDGF	O
-	O
treated	O
3T3	O
cells	O
.	O

The	O
inflation	O
hub	O
of	O
the	O
probe	O
is	O
recreated	O
by	O
modifying	O
a	O
standard	O
USCI	O
Tuohy	O
-	O
Borst	O
Y	O
adaptor	O
and	O
attaching	O
this	O
to	O
the	O
transected	O
probe	O
hypotube	O
.	O

The	O
detection	O
success	O
rate	O
was	O
determined	O
for	O
different	O
markers	O
using	O
this	O
MEK	B-protein
.	O

Binding	O
of	O
NusA	B-protein
to	O
RNA	O
in	O
the	O
presence	O
of	O
alpha	O
or	O
N	O
involves	O
an	O
amino	B-protein
-	I-protein
terminal	I-protein
S1	I-protein
homology	I-protein
region	I-protein
that	O
is	O
otherwise	O
inactive	O
in	O
full	B-protein
-	I-protein
length	I-protein
NusA	I-protein
.	O

Diagnosis	O
of	O
phenylalanine	B-protein
hydroxylase	I-protein
deficiency	O
(	O
phenylketonuria	O
)	O
.	O

The	O
unique	O
nature	O
and	O
arrangement	O
of	O
the	O
ANT1	B-protein
transcriptional	I-protein
control	I-protein
elements	I-protein
may	O
account	O
for	O
this	O
differential	O
expression	O
.	O

METHODS	O
:	O
The	O
former	O
group	O
included	O
patients	O
who	O
had	O
been	O
treated	O
with	O
at	O
least	O
four	O
PGE1	O
alpha	O
-	O
ciclodestrina	O
,	O
short	O
-	O
term	O
treatment	O
cycles	O
per	O
year	O
while	O
the	O
latter	O
was	O
a	O
historical	O
reference	O
group	O
managed	O
without	O
prostaglandins	O
.	O

However	O
,	O
the	O
relative	O
binding	O
affinity	O
for	O
the	O
motifs	O
is	O
different	O
.	O

In	O
1993	O
and	O
1994	O
and	O
infection	O
with	O
body	O
lice	O
was	O
registered	O
41	O
times	O
in	O
31	O
patients	O
at	O
the	O
clinic	O
for	O
homeless	O
of	O
the	O
Community	O
Health	O
Service	O
of	O
Utrecht	O
.	O

In	O
this	O
paper	O
,	O
we	O
show	O
that	O
,	O
like	O
BAP2	B-protein
,	O
the	O
expression	O
of	O
the	O
BAP3	B-protein
gene	I-protein
in	O
S	O
.	O
cerevisiae	O
is	O
induced	O
by	O
the	O
addition	O
of	O
branched	O
-	O
chain	O
amino	O
acids	O
to	O
the	O
medium	O
.	O

The	O
number	O
of	O
lactotropes	O
,	O
somatotropes	O
,	O
thyrotropes	O
,	O
and	O
gonadotropes	O
was	O
not	O
altered	O
compared	O
with	O
controls	O
,	O
indicating	O
that	O
in	O
the	O
adult	O
pituitary	O
,	O
POMC	B-protein
products	I-protein
are	O
not	O
required	O
to	O
maintain	O
the	O
distribution	O
of	O
cell	O
types	O
.	O

A	O
Dictyostelium	O
transformant	O
overexpressing	O
DdPTPa	B-protein
does	O
not	O
develop	O
normally	O
.	O

Using	O
the	O
balloon	O
-	O
gas	O
procedure	O
with	O
a	O
single	O
gas	O
injection	O
,	O
a	O
bubble	O
was	O
obtained	O
that	O
was	O
large	O
enough	O
to	O
tamponade	O
a	O
giant	O
tear	O
without	O
prior	O
drainage	O
of	O
subretinal	O
fluid	O
or	O
vitrectomy	O
.	O

Identification	O
and	O
nucleotide	O
sequence	O
of	O
Rhizobium	B-protein
meliloti	I-protein
insertion	I-protein
sequence	I-protein
ISRm3	I-protein
:	O
similarity	O
between	O
the	O
putative	O
transposase	B-protein
encoded	O
by	O
ISRm3	B-protein
and	O
those	O
encoded	O
by	O
Staphylococcus	B-protein
aureus	I-protein
IS256	I-protein
and	O
Thiobacillus	B-protein
ferrooxidans	I-protein
IST2	I-protein
.	O

The	O
protein	O
encoded	O
by	O
ORF113	B-protein
contains	O
a	O
transmembrane	O
domain	O
.	O

When	O
the	O
l	O
-	O
methadone	O
-	O
sensitive	O
,	O
opioid	B-protein
receptor	I-protein
is	O
blocked	O
by	O
naloxone	O
or	O
tolerance	O
has	O
developed	O
,	O
than	O
l	O
-	O
methadone	O
can	O
produce	O
behavioral	O
effects	O
by	O
a	O
nonopioid	O
mechanism	O
.	O

Two	O
new	O
temperature	O
-	O
sensitive	O
alleles	O
of	O
SEC3	B-protein
,	O
1	O
of	O
10	O
late	O
-	O
acting	O
SEC	B-protein
genes	I-protein
required	O
for	O
targeting	O
or	O
fusion	O
of	O
post	O
-	O
Golgi	O
secretory	O
vesicles	O
to	O
the	O
plasma	O
membrane	O
in	O
Saccharomyces	O
cerevisiae	O
,	O
were	O
isolated	O
in	O
a	O
screen	O
for	O
temperature	O
-	O
sensitive	O
secretory	O
mutants	O
that	O
are	O
synthetically	O
lethal	O
with	O
sec4	B-protein
-	I-protein
8	I-protein
.	O

The	O
hyperacute	O
phase	O
of	O
posterolateral	O
myocardial	O
infarction	O
.	O

Endoscopic	O
transthoracic	O
sympathectomy	O
as	O
adjuvant	O
treatment	O
for	O
critical	O
upper	O
-	O
limb	O
ischaemia	O
.	O

Furthermore	O
,	O
this	O
kinase	O
-	O
deficient	O
mutant	O
inhibited	O
2	O
-	O
MeSADP	O
-	O
induced	O
caspase	B-protein
-	I-protein
3	I-protein
stimulation	O
and	O
the	O
associated	O
decrease	O
in	O
cell	O
number	O
.	O

Furthermore	O
,	O
freezing	O
in	O
the	O
presence	O
of	O
bovine	B-protein
lactalbumin	I-protein
resulted	O
in	O
a	O
good	O
maintenance	O
of	O
the	O
cellular	O
viability	O
and	O
of	O
the	O
CCCD	O
heterogeneity	O
in	O
respect	O
to	O
fresh	O
cells	O
.	O

Using	O
the	O
polymerase	B-protein
chain	O
reaction	O
,	O
we	O
analyzed	O
the	O
U6	B-protein
RNA	I-protein
genes	I-protein
of	O
52	O
organisms	O
.	O

Additionally	O
,	O
putative	O
CF1	B-protein
/	I-protein
USP	I-protein
and	O
Broad	B-protein
Complex	I-protein
Z2	I-protein
transcription	O
factor	O
elements	O
were	O
found	O
in	O
the	O
upstream	O
regions	O
of	O
MIH	B-protein
and	O
MO	B-protein
-	I-protein
IH	I-protein
genes	O
respectively	O
.	O

By	O
electrophoresis	O
mobility	O
shift	O
assays	O
using	O
probes	O
corresponding	O
to	O
different	O
segments	O
of	O
the	O
putative	O
human	B-protein
c	I-protein
-	I-protein
myb	I-protein
intron	I-protein
1	I-protein
transcription	I-protein
pause	I-protein
region	I-protein
and	O
nuclear	O
extracts	O
from	O
myeloid	O
leukemia	O
HL	O
60	O
and	O
fibroblast	O
WI	O
38	O
cells	O
,	O
we	O
detected	O
a	O
HL	B-protein
-	I-protein
60	I-protein
-	I-protein
specific	I-protein
DNA	I-protein
-	I-protein
protein	I-protein
complex	I-protein
with	O
a	O
123	O
-	O
bp	O
fragment	O
containing	O
binding	O
sites	O
for	O
the	O
interferon	B-protein
regulatory	I-protein
factors	I-protein
(	O
IRFs	B-protein
)	O
nuclear	O
proteins	O
.	O

This	O
model	O
is	O
further	O
supported	O
by	O
binding	O
of	O
the	O
Fos	B-protein
-	I-protein
Jun	I-protein
complex	I-protein
at	O
an	O
AP	B-protein
-	I-protein
1	I-protein
site	I-protein
in	O
the	O
type	B-protein
alpha	I-protein
I	I-protein
collagen	I-protein
promoter	I-protein
that	O
is	O
contiguous	O
with	O
,	O
but	O
not	O
overlapping	O
,	O
the	O
VDRE	B-protein
.	O

Alpha	B-protein
-	I-protein
1	I-protein
antitrypsin	I-protein
and	O
Indian	O
childhood	O
cirrhosis	O
.	O

The	O
AD	O
components	O
were	O
markedly	O
more	O
dependent	O
on	O
the	O
affective	O
state	O
of	O
the	O
rat	O
then	O
was	O
the	O
V1	O
component	O
.	O

When	O
the	O
cervical	O
Pap	O
smear	O
is	O
positive	O
.	O

Causes	O
of	O
death	O
found	O
in	O
an	O
epidemiological	O
study	O
of	O
native	O
chickens	O
in	O
Thai	O
villages	O
.	O

To	O
study	O
the	O
origin	O
of	O
different	O
fMLF	B-protein
-	I-protein
R	I-protein
transcripts	I-protein
,	O
the	O
genetic	O
linkage	O
of	O
chemotactic	B-protein
receptor	I-protein
genes	O
,	O
and	O
the	O
regulation	O
of	O
fMLF	B-protein
-	I-protein
R	I-protein
gene	I-protein
expression	O
,	O
we	O
determined	O
the	O
copy	O
number	O
,	O
chromosomal	O
location	O
,	O
structural	O
organization	O
,	O
and	O
5	O
'	O
-	O
flanking	O
sequence	O
of	O
the	O
human	B-protein
fMLF	I-protein
-	I-protein
R	I-protein
gene	I-protein
.	O

A	O
canonical	O
TATA	O
box	O
was	O
not	O
detected	O
.	O

This	O
multimodality	O
treatment	O
for	O
locally	O
advanced	O
gynecologic	O
tumors	O
appears	O
feasible	O
with	O
modification	O
,	O
and	O
continued	O
work	O
exploring	O
this	O
approach	O
is	O
encouraged	O
.	O

Inactivation	O
of	O
Ulp2	B-protein
also	O
suppresses	O
several	O
ulp1	B-protein
(	I-protein
ts	I-protein
)	I-protein
defects	O
,	O
and	O
the	O
double	O
mutant	O
accumulates	O
far	O
fewer	O
Smt3	B-protein
-	I-protein
protein	I-protein
conjugates	O
than	O
either	O
single	O
mutant	O
.	O

In	O
addition	O
,	O
our	O
results	O
show	O
that	O
ERKs	B-protein
and	O
PI3Ks	B-protein
can	O
synergise	O
to	O
convert	O
ectoderm	O
into	O
mesoderm	O
.	O

Potential	O
indicators	O
were	O
assessed	O
for	O
the	O
two	O
classifications	O
of	O
protein	O
-	O
energy	O
malnutrition	O
in	O
the	O
guidelines	O
for	O
integrated	O
management	O
of	O
childhood	O
illness	O
:	O
severe	O
malnutrition	O
,	O
which	O
requires	O
immediate	O
referral	O
to	O
hospital	O
,	O
and	O
very	O
low	O
weight	O
,	O
which	O
calls	O
for	O
feeding	O
assessment	O
,	O
nutritional	O
counselling	O
and	O
follow	O
-	O
up	O
.	O

The	O
experimental	O
design	O
represents	O
a	O
2	O
x	O
3	O
factorial	O
arrangement	O
of	O
treatments	O
with	O
three	O
dietary	O
levels	O
of	O
incorporation	O
of	O
RSB	O
(	O
0	O
,	O
50	O
,	O
and	O
100	O
%	O
)	O
,	O
and	O
chickens	O
either	O
infected	O
or	O
uninfected	O
.	O

Deletion	O
analyses	O
implicate	O
the	O
N	O
-	O
terminal	O
110	O
amino	O
acids	O
of	O
Grb14	B-protein
and	O
ankyrin	B-protein
repeats	O
10	O
-	O
19	O
of	O
tankyrase	B-protein
2	I-protein
in	O
mediating	O
this	O
interaction	O
.	O

Characterization	O
of	O
the	O
human	B-protein
gene	I-protein
encoding	I-protein
cytokeratin	I-protein
17	I-protein
and	O
its	O
expression	O
pattern	O
.	O

In	O
an	O
effort	O
to	O
isolate	O
genes	O
with	O
down	O
-	O
regulated	O
expression	O
at	O
the	O
mRNA	O
level	O
during	O
oncogenic	O
transformation	O
of	O
human	O
mammary	O
epithelial	O
cells	O
(	O
MECs	O
)	O
,	O
we	O
performed	O
subtractive	O
hybridization	O
between	O
normal	O
MEC	O
strain	O
76N	O
and	O
its	O
radiation	O
-	O
transformed	O
tumorigenic	O
derivative	O
76R	O
-	O
30	O
.	O

OKT3	B-protein
prophylaxis	O
improves	O
long	O
-	O
term	O
renal	O
graft	O
survival	O
in	O
high	O
-	O
risk	O
patients	O
as	O
compared	O
to	O
cyclosporine	O
:	O
combined	O
results	O
from	O
the	O
prospective	O
,	O
randomized	O
Belgian	O
and	O
US	O
studies	O
.	O

Intra	O
-	O
operative	O
ultrasound	O
(	O
IOUS	O
)	O
has	O
been	O
widely	O
used	O
in	O
an	O
attempt	O
to	O
overcome	O
these	O
difficulties	O
,	O
but	O
is	O
limited	O
by	O
its	O
two	O
-	O
dimensional	O
nature	O
,	O
inter	O
-	O
user	O
variability	O
,	O
and	O
image	O
obliteration	O
with	O
ablative	O
or	O
resectional	O
techniques	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Semen	O
analyses	O
were	O
performed	O
on	O
58	O
patients	O
with	O
stages	O
I	O
-	O
III	O
HD	O
before	O
,	O
during	O
,	O
and	O
after	O
chemotherapy	O
and	O
after	O
the	O
sperm	O
count	O
recovered	O
from	O
the	O
effects	O
of	O
abdominal	O
radiotherapy	O
that	O
was	O
given	O
after	O
chemotherapy	O
.	O

An	O
evolutionary	O
conserved	O
element	O
is	O
essential	O
for	O
somite	O
and	O
adjacent	O
mesenchymal	O
expression	O
of	O
the	O
Hoxa1	B-protein
gene	I-protein
.	O

The	O
minus	O
-	O
end	O
-	O
directed	O
microtubule	O
motors	O
,	O
the	O
dyneins	B-protein
,	O
may	O
also	O
constitute	O
a	O
superfamily	O
of	O
force	O
-	O
generating	O
proteins	O
with	O
distinct	O
attachment	O
domains	O
.	O

Chronic	O
dose	O
effects	O
of	O
methyl	O
parathion	O
on	O
nuthatches	O
:	O
cholinesterase	B-protein
and	O
ptilochronology	O
.	O

Several	O
PTPases	B-protein
were	O
expressed	O
abundantly	O
in	O
the	O
5	O
-	O
FU	O
-	O
treated	O
bone	O
marrow	O
stem	O
cells	O
.	O

Decreased	O
cardiac	O
glycogen	O
following	O
phenformin	O
injection	O
in	O
hyperglycemic	O
,	O
hyperinsulinemic	O
anaesthetized	O
rats	O
.	O

Accordingly	O
,	O
we	O
designated	O
this	O
gene	B-protein
CTL1	I-protein
(	O
capping	B-protein
enzyme	I-protein
RNAtriphosphatase	I-protein
-	I-protein
like	I-protein
1	I-protein
)	O
.	O

Cyclosporine	O
treatment	O
for	O
intractable	O
polymyositis	O
.	O

Erythrocyte	B-protein
delta	I-protein
-	I-protein
aminolevulinic	I-protein
acid	I-protein
dehydratase	I-protein
(	O
ALAD	B-protein
)	O
activity	O
,	O
erythrocyte	O
zinc	O
protoporphyrin	O
(	O
ZPP	O
)	O
/	O
heme	O
ratio	O
,	O
and	O
urinary	O
coproporphyrin	O
(	O
UC	O
)	O
concentration	O
have	O
been	O
employed	O
as	O
biological	O
indicators	O
of	O
moderate	O
-	O
to	O
high	O
-	O
level	O
lead	O
exposure	O
,	O
corresponding	O
to	O
blood	O
levels	O
in	O
excess	O
of	O
50	O
micrograms	O
/	O
dl	O
,	O
in	O
human	O
subjects	O
.	O

This	O
tendency	O
is	O
likely	O
due	O
to	O
the	O
biased	O
nucleotide	O
composition	O
of	O
the	O
asparagus	O
genome	O
,	O
rather	O
than	O
to	O
the	O
translational	O
selection	O
for	O
specific	O
codons	O
.	O

PATIENTS	O
AND	O
METHOD	O
:	O
Since	O
1986	O
,	O
62	O
patients	O
were	O
irradiated	O
stereotactically	O
.	O

Liver	O
transplantation	O
in	O
one	O
patient	O
resolved	O
metabolic	O
complications	O
but	O
did	O
not	O
improve	O
PMN	O
count	O
or	O
the	O
infectious	O
status	O
,	O
while	O
neutropenia	O
was	O
corrected	O
by	O
G	B-protein
-	I-protein
CSF	I-protein
.	O

The	O
RING	O
finger	O
,	O
B2	O
box	O
,	O
and	O
coiled	O
-	O
coil	O
region	O
are	O
required	O
for	O
oligomerization	O
of	O
KAP	B-protein
-	I-protein
1	I-protein
-	I-protein
RBCC	I-protein
and	O
KRAB	B-protein
binding	O
,	O
as	O
mutations	O
in	O
these	O
domains	O
concomitantly	O
abolished	O
these	O
functions	O
.	O

We	O
suggest	O
that	O
MotA	B-protein
and	O
AsiA	B-protein
may	O
function	O
like	O
certain	O
eukaryotic	B-protein
TAFs	I-protein
(	O
TATA	B-protein
binding	I-protein
protein	I-protein
(	I-protein
TBP	I-protein
)	I-protein
associated	I-protein
factors	I-protein
)	O
whose	O
binding	O
to	O
TBP	B-protein
results	O
in	O
transcription	O
from	O
new	O
core	O
promoter	O
sequences	O
.	O

The	O
usefulness	O
of	O
the	O
lambda	O
PG15	O
and	O
the	O
lambda	O
AD5	O
cloning	O
vectors	O
was	O
demonstrated	O
by	O
constructing	O
large	O
Neurospora	O
crassa	O
cDNA	O
libraries	O
.	O

Manifest	O
anxiety	O
of	O
Vietnam	O
returnees	O
and	O
undergraduates	O
.	O

This	O
action	O
is	O
dependent	O
on	O
helix	O
-	O
loop	O
-	O
helix	O
factors	O
bound	O
to	O
the	O
E1	B-protein
element	I-protein
.	O

The	O
pheromone	O
response	O
pathway	O
activates	O
transcription	O
of	O
Ty5	B-protein
retrotransposons	I-protein
located	O
within	O
silent	O
chromatin	O
of	O
Saccharomyces	O
cerevisiae	O
.	O

Isopenicillin	B-protein
N	I-protein
isomerase	I-protein
(	O
epimerase	B-protein
)	O
has	O
been	O
purified	O
from	O
Streptomyces	O
clavuligerus	O
,	O
and	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
N	O
-	O
terminus	O
has	O
been	O
determined	O
.	O

Our	O
analysis	O
suggests	O
that	O
Upf1p	B-protein
is	O
a	O
multifunctional	O
protein	O
with	O
separable	O
activities	O
that	O
can	O
affect	O
mRNA	O
turnover	O
and	O
nonsense	O
suppression	O
.	O

A	O
2	O
kb	O
transcript	O
was	O
isolated	O
from	O
brain	O
that	O
encodes	O
a	O
approximately	O
57	O
kDa	O
protein	O
;	O
the	O
predicted	O
protein	O
contains	O
the	O
known	O
N	B-protein
-	I-protein
terminal	I-protein
Ets	I-protein
domain	I-protein
of	O
PE1	B-protein
and	O
a	O
novel	O
C	O
-	O
terminal	O
domain	O
with	O
signficant	O
homology	O
to	O
murine	B-protein
ERF	I-protein
.	O

We	O
show	O
here	O
that	O
this	O
difference	O
is	O
due	O
to	O
the	O
presence	O
of	O
a	O
Mot3	B-protein
binding	I-protein
site	I-protein
in	O
OpA	B-protein
.	O

Computer	O
analysis	O
included	O
digital	O
averaging	O
,	O
followed	O
by	O
digital	O
filtering	O
in	O
different	O
frequency	O
bands	O
in	O
order	O
to	O
determine	O
the	O
frequency	O
range	O
corresponding	O
to	O
notches	O
and	O
slurs	O
.	O

In	O
the	O
present	O
study	O
,	O
lesions	O
of	O
the	O
OPT	O
complex	O
(	O
the	O
thalamic	O
source	O
of	O
afferents	O
to	O
IHA	O
and	O
HD	O
)	O
were	O
found	O
to	O
have	O
no	O
effect	O
on	O
color	O
-	O
reversal	O
learning	O
performance	O
.	O

The	O
deduced	O
amino	O
acid	O
sequences	O
of	O
each	O
of	O
the	O
W3A1	B-protein
ETF	I-protein
subunits	I-protein
exhibit	O
only	O
approximately	O
30	O
%	O
identity	O
with	O
the	O
corresponding	O
subunits	O
of	O
the	O
ETF	B-protein
from	O
human	O
,	O
rat	O
,	O
and	O
Paracoccus	O
denitrificans	O
,	O
which	O
as	O
a	O
group	O
are	O
greater	O
than	O
50	O
%	O
identical	O
.	O

The	O
scores	O
are	O
dependent	O
in	O
part	O
on	O
the	O
reliability	O
of	O
faculty	O
evaluations	O
.	O

Thus	O
E14	O
.	O
1TG3B1	O
is	O
a	O
useful	O
ES	O
cell	O
line	O
for	O
modifying	O
the	O
mouse	O
genome	O
using	O
the	O
HPRT	B-protein
gene	I-protein
as	O
a	O
selection	O
marker	O
and	O
for	O
transmission	O
at	O
a	O
high	O
frequency	O
into	O
the	O
mouse	O
germ	O
line	O
.	O

This	O
virus	O
is	O
not	O
merely	O
a	O
South	O
African	O
strain	O
of	O
passion	O
fruit	O
woodiness	O
virus	O
(	O
PWV	O
)	O
:	O
the	O
deduced	O
CP	B-protein
sequence	I-protein
is	O
only	O
distantly	O
related	O
to	O
CPs	B-protein
of	O
other	O
sequenced	O
strains	O
of	O
PWV	O
,	O
although	O
it	O
is	O
part	O
of	O
a	O
distinct	O
subgroup	O
of	O
potyviruses	O
related	O
to	O
PWV	O
.	O

In	O
serum	O
-	O
free	O
media	O
,	O
p50E4F	B-protein
accelerated	O
E1A	O
-	O
induced	O
apoptosis	O
.	O

Morphological	O
features	O
of	O
Jat	O
dentition	O
.	O

The	O
TTG	B-protein
-	I-protein
2	I-protein
gene	I-protein
has	O
been	O
identified	O
at	O
the	O
site	O
of	O
chromosomal	O
translocations	O
in	O
acute	O
T	O
-	O
cell	O
leukemia	O
'	O
s	O
(	O
T	O
-	O
ALL	O
)	O
.	O

The	O
validity	O
of	O
the	O
FPS	O
-	O
R	O
was	O
further	O
supported	O
by	O
strong	O
positive	O
correlations	O
with	O
the	O
VAS	O
(	O
r	O
=	O
0	O
.	O
92	O
,	O
N	O
=	O
45	O
)	O
and	O
the	O
CAS	O
(	O
r	O
=	O
0	O
.	O
84	O
,	O
N	O
=	O
45	O
)	O
in	O
this	O
clinical	O
sample	O
.	O

The	O
abundance	O
of	O
transcripts	O
from	O
several	O
unrelated	O
genes	O
is	O
decreased	O
in	O
cdc68	B-protein
-	I-protein
1	I-protein
mutant	I-protein
cells	O
after	O
transfer	O
to	O
the	O
restrictive	O
temperature	O
,	O
while	O
at	O
least	O
one	O
transcript	O
,	O
from	O
the	O
HSP82	B-protein
gene	I-protein
,	O
persists	O
in	O
an	O
aberrant	O
fashion	O
.	O

Strikingly	O
,	O
stoichiometric	O
association	O
of	O
p107	B-protein
or	O
p130	B-protein
with	O
either	O
cyclin	B-protein
E	I-protein
-	I-protein
cdk2	I-protein
or	O
cyclin	B-protein
A	I-protein
-	I-protein
cdk2	I-protein
negated	O
the	O
activities	O
of	O
these	O
kinases	B-protein
.	O

The	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV	I-protein
-	I-protein
1	I-protein
)	I-protein
Rev	I-protein
protein	I-protein
is	O
a	O
positive	O
posttranscriptional	O
regulator	O
of	O
viral	O
structural	O
gene	O
expression	O
and	O
essential	O
for	O
virus	O
replication	O
.	O

Wnt	B-protein
-	I-protein
1	I-protein
overexpression	O
in	O
mammary	O
epithelial	O
cells	O
induced	O
cyclin	B-protein
D1	I-protein
mRNA	I-protein
and	O
targeted	O
overexpression	O
of	O
Wnt	B-protein
-	I-protein
1	I-protein
in	O
the	O
mammary	O
gland	O
of	O
transgenic	O
mice	O
increased	O
both	O
ILK	B-protein
activity	O
and	O
cyclin	B-protein
D1	I-protein
levels	O
.	O

The	O
immune	O
system	O
is	O
closely	O
integrated	O
with	O
the	O
neuroendocrine	O
system	O
,	O
and	O
infection	O
-	O
induced	O
increases	O
in	O
cytokines	O
such	O
as	O
IL	B-protein
-	I-protein
1	I-protein
,	O
IL	B-protein
-	I-protein
6	I-protein
and	O
TNF	B-protein
have	O
numerous	O
effects	O
on	O
the	O
central	O
nervous	O
system	O
.	O

Mature	O
and	O
old	O
B6AF1	O
and	O
B6D2F1	O
mice	O
were	O
given	O
acidified	O
tap	O
water	O
or	O
promethazine	O
HCl	O
(	O
a	O
phenothiazine	O
with	O
H1	B-protein
receptor	I-protein
blocking	O
activity	O
)	O
,	O
chlorpheniramine	O
(	O
an	O
H1	B-protein
blocker	O
)	O
or	O
trifluoperazine	O
(	O
a	O
phenothiazine	O
with	O
no	O
H1	B-protein
blocking	O
activity	O
)	O
in	O
their	O
drinking	O
water	O
,	O
and	O
the	O
effects	O
of	O
these	O
agents	O
on	O
bone	O
mineral	O
content	O
were	O
assessed	O
by	O
intermittently	O
measuring	O
the	O
24	O
-	O
h	O
whole	O
body	O
retention	O
of	O
Tc	O
99m	O
methylene	O
diphosphonate	O
(	O
Tc	O
99m	O
MDP	O
,	O
an	O
indicator	O
of	O
bone	O
metabolism	O
)	O
and	O
at	O
the	O
end	O
of	O
the	O
studies	O
by	O
determining	O
ash	O
weights	O
of	O
femur	O
,	O
ilium	O
and	O
sacrum	O
.	O

The	O
mechanism	O
of	O
the	O
induction	O
of	O
3beta	B-protein
-	I-protein
HSD	I-protein
type	I-protein
1	I-protein
gene	I-protein
expression	O
was	O
further	O
characterized	O
in	O
ZR	O
-	O
75	O
-	O
1	O
human	O
breast	O
cancer	O
cells	O
.	O

Analysis	O
of	O
strains	O
harboring	O
an	O
mds1	B-protein
null	I-protein
mutation	I-protein
demonstrates	O
that	O
MDS1	B-protein
is	O
not	O
essential	O
during	O
normal	O
vegetative	O
growth	O
but	O
appears	O
to	O
be	O
required	O
for	O
meiosis	O
.	O

Insert2	O
contains	O
repetitive	O
non	O
-	O
Ig	O
-	O
related	O
sequences	O
and	O
a	O
small	O
Ig	O
-	O
related	O
sequence	O
.	O

A	O
bacteriological	O
relapse	O
requiring	O
treatment	O
occurred	O
by	O
5	O
years	O
in	O
16	O
.	O
8	O
%	O
of	O
113	O
R3	O
,	O
5	O
.	O
2	O
%	O
of	O
97	O
R5	O
,	O
and	O
20	O
.	O
0	O
%	O
of	O
115	O
Z5	O
patients	O
with	O
organisms	O
sensitive	O
to	O
streptomycin	O
and	O
isoniazid	O
initially	O
.	O

Deflunia	O
was	O
well	O
tolerated	O
by	O
25	O
patients	O
,	O
very	O
well	O
tolerated	O
by	O
2	O
.	O

In	O
a	O
model	O
of	O
the	O
ternary	O
complex	O
,	O
the	O
segment	O
of	O
NFAT	B-protein
nearest	O
AP	B-protein
-	I-protein
1	I-protein
is	O
the	O
Rel	B-protein
insert	I-protein
region	I-protein
(	O
RIR	B-protein
)	O
,	O
a	O
feature	O
that	O
is	O
notable	O
for	O
its	O
hypervariability	O
in	O
size	O
and	O
in	O
sequence	O
amongst	O
members	O
of	O
the	O
Rel	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O

The	O
nucleotide	O
sequence	O
directly	O
upstream	O
of	O
fimA	B-protein
contains	O
two	O
open	O
reading	O
frames	O
,	O
ORF5	O
and	O
ORF1	O
,	O
whose	O
deduced	O
protein	O
products	O
are	O
homologous	O
to	O
members	O
of	O
a	O
superfamily	O
of	O
ATP	B-protein
-	I-protein
binding	I-protein
cassette	I-protein
membrane	I-protein
transport	I-protein
proteins	I-protein
,	O
including	O
both	O
prokaryotic	O
and	O
eukaryotic	O
uptake	O
and	O
export	O
systems	O
.	O

The	O
tissue	O
-	O
specific	O
expression	O
of	O
DP	B-protein
family	I-protein
members	I-protein
suggests	O
that	O
the	O
combination	O
of	O
DP	B-protein
/	I-protein
E2F	I-protein
heterodimers	I-protein
that	O
constitute	O
DRTF1	B-protein
/	I-protein
E2F	I-protein
is	O
influenced	O
by	O
the	O
phenotype	O
of	O
the	O
cell	O
.	O

Recent	O
studies	O
have	O
suggested	O
that	O
SHP	B-protein
-	I-protein
1	I-protein
regulates	O
the	O
function	O
of	O
Jak	B-protein
family	O
tyrosine	B-protein
kinases	I-protein
,	O
as	O
shown	O
by	O
its	O
constitutive	O
association	O
with	O
the	O
Tyk2	B-protein
kinase	I-protein
and	O
the	O
hyperphosphorylation	O
of	O
Jak	B-protein
kinases	I-protein
in	O
the	O
motheaten	O
cells	O
that	O
lack	O
functional	O
SHP	B-protein
-	I-protein
1	I-protein
.	O

Clinico	O
-	O
physiological	O
experiment	O
.	O

These	O
results	O
suggested	O
a	O
critical	O
role	O
for	O
tyrosine	O
residue	O
1229	O
in	O
the	O
regulation	O
of	O
L1	B-protein
endocytosis	O
.	O

Cleidocranial	O
dysostosis	O
.	O

The	O
partial	O
ORF	O
was	O
found	O
to	O
be	O
identical	O
to	O
the	O
C	O
terminus	O
of	O
HrpJ2	B-protein
.	O

The	O
Ras	B-protein
guanine	I-protein
nucleotide	I-protein
-	I-protein
binding	I-protein
protein	I-protein
functions	O
as	O
a	O
molecular	O
switch	O
in	O
signalling	O
downstream	O
of	O
protein	B-protein
-	I-protein
tyrosine	I-protein
kinases	I-protein
.	O

Isolation	O
of	O
a	O
novel	O
TP53	B-protein
target	I-protein
gene	I-protein
from	O
a	O
colon	O
cancer	O
cell	O
line	O
carrying	O
a	O
highly	O
regulated	O
wild	B-protein
-	I-protein
type	I-protein
TP53	I-protein
expression	O
system	O
.	O

All	O
samples	O
exhibited	O
a	O
decline	O
in	O
ethanol	O
concentration	O
,	O
with	O
most	O
losses	O
falling	O
within	O
the	O
expected	O
20	O
to	O
40	O
mg	O
%	O
range	O
.	O

MotA	B-protein
also	O
binds	O
a	O
DNA	O
sequence	O
(	O
a	O
MotA	B-protein
box	I-protein
)	O
,	O
centered	O
at	O
position	O
-	O
30	O
.	O

However	O
,	O
C3	B-protein
toxin	I-protein
alone	O
or	O
in	O
combination	O
with	O
growth	B-protein
factors	I-protein
did	O
not	O
stimulate	O
AP	B-protein
-	I-protein
1	I-protein
:	O
Luc	B-protein
activity	O
and	O
actually	O
antagonized	O
the	O
synergistic	O
activation	O
of	O
AP	B-protein
-	I-protein
1	I-protein
:	O
Luc	B-protein
observed	O
in	O
response	O
to	O
co	O
-	O
stimulation	O
with	O
growth	B-protein
factors	I-protein
and	O
Ro	O
-	O
31	O
-	O
8220	O
.	O

Basal	O
midexpiratory	O
lower	O
esophageal	O
sphincter	O
pressure	O
was	O
similar	O
in	O
the	O
study	O
group	O
(	O
mean	O
[	O
SD	O
]	O
20	O
.	O
1	O
[	O
9	O
.	O
1	O
]	O
mmHg	O
)	O
and	O
controls	O
(	O
17	O
.	O
6	O
[	O
6	O
.	O
0	O
]	O
mmHg	O
)	O
;	O
the	O
pressure	O
did	O
not	O
change	O
following	O
EVS	O
or	O
EVL	O
.	O

Using	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
show	O
that	O
the	O
RAREoct	B-protein
contributes	O
to	O
the	O
transcriptional	O
activation	O
of	O
Oct	B-protein
-	I-protein
3	I-protein
/	I-protein
4	I-protein
promoter	I-protein
in	O
P19	O
cells	O
and	O
,	O
most	O
interestingly	O
,	O
mediates	O
the	O
RA	O
-	O
induced	O
repression	O
in	O
RA	O
-	O
differentiated	O
EC	O
cells	O
.	O

Binding	O
of	O
U2	B-protein
small	I-protein
nuclear	I-protein
ribonucleoprotein	I-protein
(	O
snRNP	B-protein
)	O
to	O
the	O
pre	O
-	O
mRNA	O
is	O
an	O
early	O
and	O
important	O
step	O
in	O
spliceosome	O
assembly	O
.	O

Monitoring	O
of	O
rheumatoid	O
arthritis	O
.	O

Furthermore	O
,	O
the	O
initial	O
plasma	O
retinol	O
level	O
in	O
conjunction	O
with	O
RBP	B-protein
was	O
found	O
to	O
be	O
even	O
lower	O
in	O
12	O
patients	O
(	O
35	O
.	O
1	O
micrograms	O
dl	O
-	O
1	O
,	O
3	O
.	O
7	O
mg	O
dl	O
-	O
1	O
)	O
who	O
subsequently	O
had	O
cancer	O
recurrence	O
than	O
in	O
those	O
who	O
remained	O
free	O
of	O
apparent	O
cancer	O
(	O
44	O
.	O
5	O
micrograms	O
dl	O
-	O
1	O
,	O
4	O
.	O
6	O
mg	O
dl	O
-	O
1	O
)	O
.	O

Study	O
on	O
re	O
-	O
establishment	O
of	O
ovulation	O
after	O
termination	O
of	O
sex	O
-	O
steroidal	O
treatment	O
-	O
-	O
compared	O
with	O
re	O
-	O
appearance	O
of	O
ovulation	O
after	O
abortion	O
and	O
premature	O
delivery	O
.	O

Most	O
pituitary	B-protein
hormone	I-protein
-	I-protein
coding	I-protein
gene	I-protein
promoters	O
are	O
activated	O
by	O
Ptx1	B-protein
.	O

The	O
p97	O
-	O
depleted	O
nuclei	O
remained	O
largely	O
competent	O
for	O
nuclear	O
protein	O
import	O
.	O

BCR	B-protein
cross	O
-	O
linking	O
also	O
led	O
to	O
increased	O
MAPK	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
-	I-protein
2	I-protein
activity	O
,	O
an	O
enzyme	O
that	O
lies	O
immediately	O
downstream	O
from	O
p38	B-protein
MAPK	I-protein
;	O
MAPK	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
-	I-protein
2	I-protein
immune	O
complexes	O
phosphorylated	O
a	O
peptide	O
substrate	O
containing	O
the	O
CREB	B-protein
serine	I-protein
133	I-protein
phosphoacceptor	I-protein
motif	I-protein
.	O

Immunogenicity	O
of	O
various	O
mycobacteria	O
and	O
the	O
corresponding	O
levels	O
of	O
cross	O
-	O
protection	O
developed	O
between	O
species	O
.	O

Isomers	O
were	O
differentiated	O
based	O
on	O
the	O
MS	O
-	O
MS	O
data	O
of	O
the	O
trofluoroacetyl	O
-	O
biphenylol	O
derivatives	O
.	O

Most	O
importantly	O
,	O
the	O
addition	O
of	O
purified	O
17S	B-protein
U2	I-protein
snRNPs	I-protein
,	O
but	O
not	O
of	O
12S	B-protein
U2	I-protein
snRNPs	I-protein
,	O
to	O
HeLa	O
splicing	O
extracts	O
in	O
which	O
the	O
endogeneous	B-protein
U2	I-protein
snRNPs	I-protein
have	O
been	O
functionally	O
neutralized	O
with	O
anti	B-protein
-	I-protein
PRP9	I-protein
antibodies	I-protein
fully	O
restores	O
the	O
mRNA	O
-	O
splicing	O
activity	O
of	O
the	O
extracts	O
.	O

Diuretics	O
:	O
basic	O
clinical	O
pharmacology	O
and	O
therapeutic	O
use	O
.	O

The	O
December	O
armed	O
revolt	O
in	O
Moscow	O
and	O
the	O
paramedical	O
personnel	O
.	O

In	O
situ	O
hybridization	O
with	O
the	O
antisense	O
RNA	O
probes	O
further	O
supported	O
the	O
expression	O
changes	O
of	O
these	O
six	O
clones	O
and	O
localized	O
the	O
changes	O
in	O
multiple	O
germ	O
cell	O
stages	O
as	O
well	O
as	O
other	O
cell	O
types	O
(	O
Sertoli	O
,	O
interstitial	O
and	O
peritubular	O
cells	O
)	O
.	O

On	O
physical	O
examination	O
a	O
mild	O
symmetrical	O
polyarthritis	O
of	O
small	O
and	O
large	O
joints	O
was	O
seen	O
.	O

The	O
described	O
results	O
show	O
that	O
DTD	O
is	O
fast	O
,	O
simple	O
,	O
and	O
easy	O
to	O
automate	O
;	O
requires	O
only	O
a	O
small	O
amount	O
of	O
sample	O
(	O
approximately	O
50	O
mg	O
)	O
;	O
and	O
affords	O
quantitative	O
information	O
about	O
the	O
main	O
groups	O
of	O
compounds	O
present	O
in	O
cheeses	O
.	O

The	O
elevation	O
of	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
levels	O
in	O
the	O
cell	O
downregulates	O
the	O
activity	O
of	O
the	O
Raf	B-protein
-	I-protein
1	I-protein
kinase	I-protein
.	O

It	O
is	O
,	O
however	O
,	O
extremely	O
homologous	O
to	O
a	O
third	O
'	O
non	O
-	O
classical	O
'	O
gene	O
,	O
HLA	B-protein
-	I-protein
5	I-protein
.	I-protein
4	I-protein
,	O
and	O
to	O
the	O
chimpanzee	O
gene	O
,	O
Ch28	B-protein
.	O

Twenty	O
-	O
five	O
patients	O
(	O
80	O
,	O
6	O
%	O
)	O
with	O
mixed	O
neoplasms	O
were	O
operated	O
on	O
by	O
total	O
conservative	O
parotidectomy	O
(	O
T	O
.	O
C	O
.	O
P	O
.	O
)	O
,	O
3	O
(	O
9	O
,	O
7	O
%	O
)	O
by	O
S	O
.	O
P	O
.	O
and	O
3	O
(	O
9	O
,	O
7	O
%	O
)	O
by	O
En	O
.	O

Karger	O
AG	O
,	O
Basel	O

Magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
has	O
enabled	O
us	O
to	O
see	O
the	O
spinal	O
intramedullary	O
pathology	O
as	O
differences	O
in	O
signal	O
intensity	O
.	O

As	O
high	O
-	O
speed	O
,	O
volumetric	O
imaging	O
,	O
computed	O
tomographic	O
scan	O
machines	O
such	O
as	O
the	O
Dynamic	O
Spatial	O
Reconstructor	O
become	O
available	O
with	O
higher	O
density	O
resolution	O
,	O
perhaps	O
a	O
single	O
injection	O
of	O
contrast	O
agent	O
into	O
the	O
right	O
atrium	O
or	O
even	O
a	O
peripheral	O
vein	O
may	O
be	O
adequate	O
to	O
obtain	O
all	O
these	O
measurements	O
.	O

We	O
demonstrate	O
that	O
the	O
protein	O
is	O
a	O
murine	B-protein
homologue	I-protein
of	I-protein
SAF	I-protein
-	I-protein
A	I-protein
which	O
has	O
been	O
shown	O
to	O
bind	O
selectively	O
to	O
MARs	O
and	O
is	O
responsible	O
for	O
the	O
satMa	O
-	O
binding	O
activity	O
in	O
the	O
chromatographic	O
fractions	O
.	O

The	O
extent	O
of	O
the	O
fbpA	B-protein
operator	I-protein
sequence	I-protein
(	I-protein
42	I-protein
bp	I-protein
)	I-protein
,	O
as	O
defined	O
by	O
our	O
footprinting	O
analysis	O
,	O
would	O
suggest	O
the	O
binding	O
of	O
two	O
Fur	B-protein
repressor	I-protein
dimers	I-protein
.	O

The	O
number	O
of	O
crystalline	O
deposits	O
is	O
less	O
in	O
the	O
advanced	O
atrophic	O
areas	O
of	O
the	O
RPE	O
-	O
choriocapillaris	O
complex	O
.	O

Peroxydase	B-protein
reaction	O
stains	O
were	O
negative	O
,	O
chloroacetate	B-protein
esterase	I-protein
were	O
strongly	O
positive	O
.	O

Genesis	O
of	O
foam	O
cells	O
:	O
study	O
in	O
rats	O
after	O
administration	O
of	O
Cloforex	O
.	O

Risk	O
factors	O
associated	O
with	O
a	O
high	O
seroprevalence	O
of	O
hepatitis	O
C	O
virus	O
infection	O
in	O
Egyptian	O
blood	O
donors	O
.	O

These	O
findings	O
were	O
reinforced	O
by	O
an	O
analysis	O
that	O
was	O
restricted	O
to	O
living	O
donor	O
transplants	O
without	O
acute	O
rejection	O
.	O

There	O
is	O
general	O
agreement	O
that	O
the	O
hepatitis	O
C	O
virus	O
is	O
efficiently	O
transmitted	O
parenterally	O
,	O
while	O
data	O
on	O
viral	O
transmission	O
from	O
mothers	O
to	O
babies	O
or	O
by	O
sexual	O
or	O
non	O
-	O
sexual	O
household	O
contact	O
are	O
conflicting	O
.	O

Molecular	O
characterization	O
of	O
a	O
large	O
Borrelia	O
burgdorferi	O
motility	O
operon	O
which	O
is	O
initiated	O
by	O
a	O
consensus	O
sigma70	B-protein
promoter	I-protein
.	O

Demographic	O
characteristics	O
and	O
risk	O
factor	O
data	O
for	O
76	O
,	O
672	O
clients	O
were	O
studied	O
to	O
characterize	O
the	O
distribution	O
of	O
infection	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
and	O
the	O
use	O
of	O
counseling	O
and	O
testing	O
facilities	O
in	O
Houston	O
,	O
Tex	O
.	O

Anti	B-protein
-	I-protein
NPROSP	I-protein
-	I-protein
C	I-protein
also	O
exclusively	O
detected	O
time	O
-	O
dependent	O
appearances	O
of	O
5	B-protein
-	I-protein
10	I-protein
-	I-protein
kDa	I-protein
proSP	I-protein
-	I-protein
C	I-protein
forms	O
in	O
lamellar	O
bodies	O
and	O
homogenates	O
.	O

The	O
ubiquitously	O
expressed	O
E12	B-protein
bHLH	I-protein
protein	I-protein
dimerizes	O
with	O
numerous	O
cell	O
-	O
specific	O
bHLH	B-protein
factors	I-protein
.	O

Epithelial	O
cytotoxicity	O
of	O
combined	O
antibiotics	O
was	O
additive	O
,	O
with	O
no	O
evidence	O
of	O
competition	O
or	O
synergism	O
.	O

In	O
vitro	O
antimalarial	O
activity	O
of	O
neem	O
(	O
Azadirachta	O
indica	O
A	O
.	O

Managing	O
dysphagia	O
in	O
a	O
chronic	O
care	O
setting	O
:	O
an	O
introduction	O
.	O

In	O
none	O
of	O
the	O
44	O
type	O
I	O
attacks	O
and	O
29	O
type	O
II	O
attacks	O
which	O
were	O
recorded	O
did	O
circulatory	O
changes	O
;	O
the	O
latter	O
were	O
different	O
in	O
the	O
two	O
groups	O
.	O

By	O
stepwise	O
linear	O
multiple	O
regression	O
analysis	O
,	O
ionized	O
magnesium	O
was	O
significantly	O
related	O
to	O
cyclosporin	O
trough	O
level	O
and	O
total	O
cholesterol	O
but	O
not	O
to	O
serum	O
creatinine	O
,	O
time	O
after	O
transplant	O
or	O
the	O
dose	O
of	O
cyclosporin	O
.	O

These	O
findings	O
indicate	O
the	O
involvement	O
of	O
Sp1	B-protein
and	O
an	O
Inr	O
in	O
non	O
-	O
cell	O
-	O
specific	O
regulation	O
and	O
a	O
Kruppel	B-protein
-	I-protein
like	I-protein
transcription	I-protein
factor	I-protein
and	O
Sp1	B-protein
in	O
the	O
cell	O
-	O
specific	O
regulation	O
of	O
the	O
LTC	B-protein
(	I-protein
4	I-protein
)	I-protein
S	I-protein
gene	I-protein
.	O

In	O
all	O
experimental	O
eyes	O
,	O
there	O
was	O
a	O
marked	O
reduction	O
,	O
but	O
never	O
a	O
complete	O
absence	O
of	O
adrenergic	O
nerves	O
in	O
the	O
iris	O
.	O

RNA	O
in	O
situ	O
hybridization	O
on	O
brain	O
sections	O
of	O
normal	O
human	O
embryos	O
revealed	O
a	O
strong	O
labeling	O
in	O
restricted	O
areas	O
of	O
the	O
cerebral	O
cortex	O
.	O

Individual	O
alcohol	O
reaction	O
profiles	O
.	O

Tobramycin	O
-	O
loaded	O
SLN	O
administered	O
i	O
.	O
v	O
.	O
showed	O
a	O
prolonged	O
circulation	O
time	O
compared	O
to	O
the	O
i	O
.	O
v	O
.	O
administered	O
tobramycin	O
solution	O
.	O

Lithium	O
delays	O
the	O
circadian	O
rhythm	O
of	O
wheel	O
-	O
running	O
in	O
Syrian	O
hamsters	O
at	O
plasma	O
concentrations	O
(	O
0	O
.	O
59	O
-	O
0	O
.	O
74	O
mM	O
)	O
that	O
also	O
cause	O
toxic	O
weight	O
loss	O
.	O

The	O
recombinant	O
contains	O
the	O
normal	O
beta	B-protein
A	I-protein
-	I-protein
globin	I-protein
gene	I-protein
,	O
the	O
mutant	O
gene	O
and	O
Ylp	O
vector	O
sequences	O
between	O
the	O
two	O
copies	O
.	O

The	O
following	O
data	O
were	O
recorded	O
at	O
arrival	O
in	O
the	O
intensive	O
care	O
unit	O
6	O
,	O
12	O
,	O
24	O
,	O
and	O
48	O
hours	O
after	O
termination	O
of	O
CPB	O
:	O
heart	O
rate	O
,	O
blood	O
pressure	O
,	O
left	O
atrial	O
pressure	O
,	O
central	O
-	O
peripheral	O
temperature	O
difference	O
,	O
arterial	O
-	O
central	O
venous	O
oxygen	O
saturation	O
difference	O
,	O
urine	O
output	O
,	O
serum	O
creatinine	O
,	O
lactate	O
and	O
neutrophil	B-protein
elastase	I-protein
levels	O
,	O
the	O
Doppler	O
echocardiographic	O
factors	O
shortening	O
fraction	O
and	O
preejection	O
period	O
/	O
left	O
-	O
ventricular	O
ejection	O
time	O
,	O
and	O
cumulative	O
doses	O
of	O
catecholamines	O
(	O
epinephrine	O
)	O
,	O
enoximone	O
,	O
and	O
furosemide	O
.	O

Deaths	O
stopped	O
11	O
hours	O
after	O
copper	O
concentrations	O
decreased	O
below	O
0	O
.	O
2	O
ppm	O
and	O
signs	O
of	O
distress	O
stopped	O
in	O
surviving	O
pinfish	O
by	O
approximately	O
6	O
hours	O
after	O
the	O
last	O
death	O
.	O

Body	O
weight	O
reduction	O
increases	O
insulin	B-protein
sensitivity	O
and	O
improves	O
both	O
blood	O
glucose	O
and	O
blood	O
pressure	O
control	O
.	O

Several	O
mutations	O
disrupted	O
the	O
endonuclease	B-protein
and	O
helicase	B-protein
activities	O
;	O
however	O
,	O
only	O
one	O
amino	B-protein
-	I-protein
terminal	I-protein
-	I-protein
charge	I-protein
cluster	I-protein
mutant	I-protein
protein	I-protein
(	O
D40A	B-protein
-	I-protein
D42A	I-protein
-	I-protein
D44A	I-protein
)	O
completely	O
lost	O
AAV	O
hairpin	O
DNA	O
binding	O
activity	O
.	O

Gene	O
silencing	O
associated	O
with	O
repeated	O
DNA	O
sequences	O
has	O
been	O
reported	O
for	O
many	O
eukaryotes	O
,	O
including	O
plants	O
.	O

In	O
mammalian	O
cells	O
,	O
phosphorylation	O
of	O
eIF	B-protein
-	I-protein
2	I-protein
alpha	I-protein
inhibits	O
the	O
activity	O
of	O
eIF	B-protein
-	I-protein
2B	I-protein
,	O
the	O
GDP	B-protein
-	I-protein
GTP	I-protein
exchange	I-protein
factor	I-protein
for	O
eIF	B-protein
-	I-protein
2	I-protein
.	O

Although	O
inactive	O
in	O
cells	O
under	O
normal	O
conditions	O
,	O
the	O
CHOP	B-protein
gene	I-protein
is	O
markedly	O
induced	O
by	O
a	O
variety	O
of	O
cellular	O
stresses	O
,	O
including	O
nutrient	O
deprivation	O
and	O
metabolic	O
perturbations	O
.	O

DNase	B-protein
I	I-protein
footprint	O
analysis	O
identified	O
a	O
protected	O
region	O
from	O
-	O
37	O
to	O
-	O
53	O
.	O

Fine	O
analysis	O
at	O
the	O
nucleotide	O
level	O
of	O
the	O
early	O
events	O
in	O
the	O
digestion	O
with	O
nuclease	B-protein
S1	I-protein
shows	O
that	O
the	O
enzyme	O
attacks	O
preferentially	O
the	O
sequence	O
(	O
G	O
-	O
A	O
)	O
12	O
on	O
the	O
message	O
complementary	O
strand	O
.	O

Parodoxical	O
rise	O
in	O
urinary	B-protein
albumin	I-protein
levels	O
after	O
treatment	O
of	O
essential	O
hypertension	O
.	O

Efficacy	O
of	O
cervical	O
spine	O
immobilization	O
methods	O
.	O

BACKGROUND	O
:	O
Dermoscopy	O
is	O
a	O
noninvasive	O
technique	O
that	O
increases	O
the	O
diagnostic	O
accuracy	O
of	O
pigmented	O
skin	O
lesions	O
,	O
particularly	O
improving	O
the	O
diagnosis	O
of	O
patients	O
with	O
cutaneous	O
melanoma	O
in	O
situ	O
(	O
CMIS	O
)	O
and	O
early	O
invasive	O
melanoma	O
.	O

3600	O
-	O
fold	O
to	O
apparent	O
homogeneity	O
with	O
a	O
41	O
%	O
yield	O
by	O
affinity	O
chromatography	O
utilizing	O
DNA	O
-	O
cellulose	O
;	O
the	O
purity	O
of	O
the	O
final	O
preparation	O
was	O
assessed	O
by	O
SDS	O
/	O
PAGE	O
,	O
lack	O
of	O
contamination	O
by	O
other	O
nucleases	B-protein
and	O
production	O
of	O
a	O
monospecific	O
antibody	O
against	O
the	O
enzyme	O
.	O

Several	O
Src	B-protein
SH3	I-protein
-	I-protein
binding	I-protein
proteins	I-protein
were	O
phosphorylated	O
in	O
Src	O
-	O
transformed	O
cells	O
.	O

The	O
circadian	O
rhythmicity	O
of	O
sleep	O
was	O
pronounced	O
.	O

Sequence	O
analysis	O
reveals	O
that	O
the	O
DNA	O
binding	O
domain	O
of	O
ILF	B-protein
has	O
strong	O
homology	O
to	O
the	O
recently	O
described	O
fork	B-protein
head	I-protein
DNA	I-protein
binding	I-protein
domain	I-protein
found	O
in	O
the	O
Drosophila	B-protein
homeotic	I-protein
protein	I-protein
fork	I-protein
head	I-protein
and	O
a	O
family	O
of	O
hepatocyte	B-protein
nuclear	I-protein
factors	I-protein
,	O
HNF	B-protein
-	I-protein
3	I-protein
.	O

Plasma	B-protein
lactoferrin	I-protein
and	O
the	O
blood	O
count	O
of	O
polynuclear	O
neutrophils	O
.	O

Although	O
a	O
wide	O
range	O
of	O
cognitive	O
functions	O
had	O
been	O
tested	O
,	O
all	O
but	O
one	O
seizure	O
occurred	O
during	O
assessment	O
of	O
memory	O
performance	O
.	O

Mean	O
weighted	O
skin	O
temperature	O
(	O
Tsk	O
)	O
was	O
lower	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
following	O
acclimation	O
than	O
before	O
,	O
and	O
acclimation	O
resulted	O
in	O
a	O
larger	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
Tre	O
-	O
to	O
-	O
Tsk	O
gradient	O
.	O

Biol	O
.	O

Here	O
we	O
show	O
that	O
short	O
synthetic	O
peptides	O
containing	O
the	O
pRB	B-protein
-	I-protein
binding	I-protein
sequences	I-protein
of	O
E1A	B-protein
are	O
sufficient	O
for	O
interaction	O
with	O
p107	B-protein
,	O
cyclin	B-protein
A	I-protein
,	O
and	O
p130	B-protein
.	O

Evidence	O
forthe	O
electroosmosis	O
theory	O
of	O
transport	O
in	O
the	O
phloem	O
.	O

Paradoxically	O
,	O
however	O
,	O
the	O
GH	B-protein
receptor	I-protein
cloned	O
from	O
liver	O
exhibits	O
no	O
sequence	O
similarity	O
to	O
receptors	O
with	O
known	O
signal	O
transduction	O
mechanisms	O
,	O
including	O
those	O
exhibiting	O
ligand	O
-	O
activated	O
tyrosine	B-protein
kinase	I-protein
activity	O
.	O

RESULTS	O
:	O
Closure	O
time	O
of	O
fistulas	O
in	O
patients	O
receiving	O
TPN	O
+	O
somatostatin	B-protein
was	O
significantly	O
shorter	O
(	O
13	O
.	O
86	O
+	O
/	O
-	O
1	O
.	O
84	O
versus	O
20	O
.	O
4	O
+	O
/	O
-	O
2	O
.	O
89	O
days	O
)	O
than	O
in	O
those	O
receiving	O
TPN	O
alone	O
.	O

In	O
the	O
premating	O
period	O
male	O
rate	O
of	O
aggression	O
was	O
not	O
significantly	O
correlated	O
with	O
testosterone	O
level	O
.	O

Far	O
-	O
infrared	O
hopping	O
conductivity	O
in	O
the	O
CuO	O
chains	O
of	O
a	O
single	O
-	O
domain	O
YBa2Cu3O7	O
-	O
delta	O
crystal	O
.	O

Extracellular	O
fibril	O
formation	O
by	O
neuroglial	O
cells	O
at	O
the	O
vitreoretinal	O
junction	O
of	O
the	O
human	O
eye	O
.	O

The	O
site	O
-	O
specific	O
DNA	O
inversion	O
system	O
Cin	B-protein
encoded	O
by	O
the	O
bacteriophage	O
P1	O
consists	O
of	O
a	O
recombinase	B-protein
,	O
two	O
inverted	O
crossing	O
-	O
over	O
sites	O
and	O
a	O
recombinational	O
enhancer	O
.	O

The	O
product	O
of	O
rat	B-protein
gene	I-protein
33	I-protein
was	O
identified	O
as	O
an	O
ErbB	B-protein
-	I-protein
2	I-protein
-	I-protein
interacting	I-protein
protein	I-protein
in	O
a	O
two	O
-	O
hybrid	O
screen	O
employing	O
the	O
ErbB	B-protein
-	I-protein
2	I-protein
juxtamembrane	I-protein
and	I-protein
kinase	I-protein
domains	I-protein
as	O
bait	O
.	O

Both	O
fusion	O
proteins	O
form	O
stable	O
specific	O
complexes	O
with	O
a	O
short	O
DNA	O
duplex	O
harboring	O
the	O
CTGT	B-protein
(	I-protein
at	I-protein
)	I-protein
4ACAG	I-protein
consensus	I-protein
sequence	I-protein
of	O
the	O
LexA	B-protein
repressor	I-protein
.	O

Thus	O
,	O
the	O
interaction	O
of	O
Tat	B-protein
with	O
the	O
components	O
of	O
this	O
rel	B-protein
/	I-protein
AP1	I-protein
cooperative	I-protein
complex	I-protein
seems	O
to	O
induce	O
quantitative	O
and	O
qualitative	O
alterations	O
of	O
this	O
complex	O
as	O
activation	O
progresses	O
,	O
resulting	O
in	O
a	O
decrease	O
of	O
IL	B-protein
-	I-protein
2	I-protein
gene	I-protein
transcription	O
.	O

The	O
general	O
recombination	O
at	O
a	O
polarizing	O
voltage	O
of	O
300	O
V	O
is	O
less	O
than	O
2	O
%	O
for	O
dose	O
-	O
rates	O
up	O
to	O
about	O
100	O
mGy	O
min	O
-	O
1	O
.	O

The	O
3	O
'	O
terminus	O
of	O
the	O
genome	O
can	O
be	O
folded	O
into	O
a	O
tRNA	B-protein
-	I-protein
like	I-protein
secondary	O
structure	O
that	O
has	O
a	O
valine	O
anticodon	O
;	O
the	O
tRNA	B-protein
-	I-protein
like	I-protein
structure	O
lacks	O
a	O
pseudoknot	O
in	O
the	O
aminoacyl	O
stem	O
,	O
a	O
feature	O
common	O
to	O
both	O
genera	O
of	O
tetraviruses	O
.	O

Comprising	O
a	O
126	O
-	O
nucleotide	O
5	O
'	O
untranscribed	O
genomic	O
sequence	O
and	O
a	O
466	O
-	O
nucleotide	O
5	O
'	O
noncoding	O
cDNA	O
sequence	O
,	O
the	O
592	O
-	O
nucleotide	O
5	O
'	O
CpG	O
island	O
lacked	O
TATA	O
and	O
CAAT	O
boxes	O
but	O
displayed	O
a	O
high	O
G	O
+	O
C	O
content	O
,	O
was	O
enriched	O
for	O
CpG	O
dinucleotides	O
,	O
and	O
contained	O
a	O
potential	O
Sp1	B-protein
-	I-protein
binding	I-protein
site	I-protein
,	O
i	O
.	O
e	O
.	O
,	O
features	O
compatible	O
with	O
a	O
housekeeping	O
gene	O
.	O

A	O
total	O
of	O
25	O
patients	O
with	O
malignant	O
brain	O
tumours	O
were	O
investigated	O
.	O

Other	O
uncertainties	O
in	O
the	O
dosimetry	O
at	O
Y	O
-	O
12	O
and	O
Vinca	O
are	O
unaltered	O
.	O

The	O
binding	O
site	O
for	O
OxyR	B-protein
overlapped	O
P1oxyR	B-protein
,	O
reminiscent	O
of	O
the	O
autoregulatory	O
loops	O
controlling	O
expression	O
of	O
oxyR	B-protein
in	O
enteric	O
bacteria	O
and	O
characteristic	O
of	O
the	O
LysR	B-protein
superfamily	I-protein
in	O
general	O
.	O

Furthermore	O
,	O
the	O
UvrA	B-protein
protein	I-protein
interacts	O
with	O
the	O
UvrB	B-protein
protein	I-protein
to	O
modulate	O
its	O
activities	O
,	O
both	O
in	O
solution	O
and	O
in	O
association	O
with	O
DNA	O
,	O
where	O
the	O
UvrAB	B-protein
complex	I-protein
possesses	O
a	O
helicase	B-protein
activity	O
.	O

Crisis	O
of	O
the	O
therapeutic	O
community	O
in	O
Great	O
Britain	O
.	O

Two	O
of	O
these	O
resulted	O
in	O
increased	O
levels	O
of	O
the	O
alpha	O
subunit	O
,	O
and	O
one	O
caused	O
a	O
substitution	O
of	O
glycine	O
for	O
the	O
aspartic	O
acid	O
residue	O
at	O
position	O
171	O
,	O
in	O
the	O
N	O
-	O
terminal	O
domain	O
.	O

Analysis	O
of	O
nucleotide	O
sequence	O
of	O
the	O
rightmost	O
43	O
kbp	O
of	O
herpesvirus	O
saimiri	O
(	O
HVS	O
)	O
L	O
-	O
DNA	O
:	O
general	O
conservation	O
of	O
genetic	O
organization	O
between	O
HVS	O
and	O
Epstein	O
-	O
Barr	O
virus	O
.	O

Oncogenic	O
activation	O
of	O
the	O
tyrosine	B-protein
kinase	I-protein
domain	I-protein
of	O
the	O
human	B-protein
trk	I-protein
proto	I-protein
-	I-protein
oncogene	I-protein
by	O
fusion	O
to	O
a	O
cell	O
adhesion	O
molecule	O
.	O

With	O
regard	O
to	O
the	O
optimal	O
threshold	O
values	O
,	O
sensitivity	O
and	O
specificity	O
were	O
100	O
%	O
/	O
97	O
%	O
and	O
95	O
%	O
/	O
95	O
%	O
with	O
FDG	O
PET	O
,	O
compared	O
to	O
86	O
%	O
/	O
92	O
%	O
and	O
77	O
%	O
/	O
82	O
%	O
with	O
IS	O
,	O
respectively	O
.	O

Among	O
blood	O
donors	O
in	O
the	O
Republic	O
of	O
Serbia	O
,	O
regardless	O
the	O
number	O
of	O
blood	O
donations	O
,	O
the	O
percentage	O
of	O
female	O
donors	O
is	O
significantly	O
lower	O
compared	O
to	O
the	O
percentage	O
of	O
male	O
blood	O
donors	O
.	O

The	O
fragments	O
are	O
separated	O
and	O
directly	O
sized	O
by	O
agarose	O
gel	O
electrophoresis	O
.	O

In	O
Trial	O
1	O
,	O
eight	O
sows	O
were	O
allowed	O
to	O
farrow	O
naturally	O
(	O
d	O
114	O
,	O
NF	O
sows	O
)	O
and	O
eight	O
sows	O
were	O
induced	O
to	O
farrow	O
(	O
IF	O
sows	O
)	O
prematurely	O
by	O
injection	O
of	O
prostaglandin	O
F2	O
alpha	O
on	O
d	O
112	O
of	O
gestation	O
.	O

Moreover	O
,	O
the	O
major	O
site	O
of	O
transcriptional	O
initiation	O
,	O
which	O
was	O
localized	O
by	O
primer	O
extension	O
250	O
bp	O
upstream	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
Ets	B-protein
-	I-protein
1	I-protein
cDNA	I-protein
clone	I-protein
,	O
was	O
shown	O
to	O
be	O
identical	O
in	O
normal	O
cells	O
and	O
tumors	O
carrying	O
a	O
provirus	O
in	O
the	O
Tpl	B-protein
-	I-protein
1	I-protein
locus	I-protein
.	O

In	O
addition	O
,	O
using	O
biochemical	O
activity	O
assays	O
for	O
Rho	B-protein
-	I-protein
like	I-protein
GTPases	I-protein
,	O
we	O
show	O
that	O
the	O
expression	O
of	O
beta1A	B-protein
,	O
beta1D	B-protein
,	O
or	O
IL2R	B-protein
-	I-protein
beta1A	I-protein
in	O
GE11	O
or	O
GD25	O
cells	O
triggers	O
activation	O
of	O
both	O
RhoA	B-protein
and	O
Rac1	B-protein
,	O
but	O
not	O
of	O
Cdc42	B-protein
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
region	O
upstream	O
from	O
M	B-protein
.	I-protein
voltae	I-protein
ORFtrpA	I-protein
was	O
determined	O
and	O
revealed	O
the	O
presence	O
of	O
an	O
ORF	O
of	O
1227	O
nucleotides	O
(	O
ORFtrpB	B-protein
)	O
encoding	O
a	O
409	O
amino	O
acid	O
polypeptide	O
of	O
mol	O
.	O
wt	O
.	O

The	O
present	O
study	O
describes	O
the	O
cell	O
volume	O
dynamics	O
in	O
intact	O
rat	O
hearts	O
,	O
during	O
ischemia	O
and	O
after	O
reperfusion	O
.	O

When	O
expressed	O
in	O
COS	O
-	O
7	O
cells	O
,	O
MKP	B-protein
-	I-protein
4	I-protein
blocks	O
activation	O
of	O
MAP	B-protein
kinases	I-protein
with	O
the	O
selectivity	O
ERK	B-protein
>	O
p38	B-protein
=	O
JNK	B-protein
/	I-protein
SAPK	I-protein
.	O

Here	O
we	O
demonstrate	O
that	O
THOV	B-protein
NP	I-protein
contains	O
a	O
motif	O
(	O
KRxxxxxxxxxKTKK	B-protein
)	O
at	O
amino	O
acid	O
positions	O
179	O
-	O
193	O
that	O
represents	O
a	O
classical	O
bipartite	O
nuclear	O
localization	O
signal	O
(	O
NLS	O
)	O
.	O

Autotransfusion	O
was	O
performed	O
as	O
follows	O
:	O
Heparin	O
-	O
ACD	O
-	O
B	O
-	O
Heparin	O
-	O
DPD	O
-	O
Heparin	O
-	O
ACD	O
-	O
B	O
etc	O
.	O

Sterols	O
in	O
pollen	O
.	O

We	O
report	O
here	O
that	O
,	O
for	O
a	O
constant	O
amount	O
of	O
transfected	O
DNA	O
,	O
the	O
level	O
of	O
chloramphenicol	B-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
mRNA	O
is	O
increased	O
in	O
Vpr	O
-	O
expressing	O
cells	O
using	O
either	O
HIV	O
-	O
1	O
or	O
a	O
murine	B-protein
leukemia	I-protein
virus	I-protein
(	I-protein
MLV	I-protein
)	I-protein
SL3	I-protein
-	I-protein
3	I-protein
LTR	I-protein
-	I-protein
CAT	I-protein
reporter	I-protein
construct	I-protein
.	O

Gap1	B-protein
(	I-protein
IP4BP	I-protein
)	I-protein
,	O
one	O
of	O
a	O
member	O
of	O
Ras	B-protein
GTPase	I-protein
-	I-protein
activating	I-protein
proteins	I-protein
,	O
has	O
been	O
identified	O
as	O
a	O
specific	O
inositol	B-protein
1	I-protein
,	I-protein
3	I-protein
,	I-protein
4	I-protein
,	I-protein
5	I-protein
-	I-protein
tetrakisphosphate	I-protein
(	I-protein
IP4	I-protein
)	I-protein
-	I-protein
binding	I-protein
protein	I-protein
(	O
Cullen	O
,	O
P	O
.	O

Activity	O
of	O
palgD	B-protein
in	O
the	O
cysB	B-protein
mutant	I-protein
,	O
in	O
CHA	O
and	O
in	O
the	O
non	O
-	O
mucoid	O
strain	O
PAO	O
was	O
assessed	O
by	O
the	O
use	O
of	O
a	O
transcriptional	O
algD	B-protein
-	I-protein
xylE	I-protein
fusion	I-protein
.	O

These	O
results	O
indicate	O
that	O
ATF	B-protein
-	I-protein
2	I-protein
plays	O
a	O
central	O
role	O
in	O
TGF	B-protein
-	I-protein
beta	I-protein
signaling	O
by	O
acting	O
as	O
a	O
common	O
nuclear	O
target	O
of	O
both	O
Smad	B-protein
and	O
TAK1	B-protein
pathways	I-protein
.	O

Morphogenesis	O
of	O
the	O
trochanter	O
produced	O
by	O
femoral	O
regeneration	O
in	O
the	O
phasmid	O
Carausius	O
morosus	O
Br	O
.	O

Diagnosis	O
of	O
primary	O
sclerosing	O
cholangitis	O
in	O
a	O
blood	O
donor	O
with	O
elevated	O
serum	B-protein
alanine	I-protein
aminotransferase	I-protein
.	O

Control	O
experiments	O
showed	O
that	O
each	O
fusion	O
protein	O
had	O
a	O
high	O
affinity	O
binding	O
site	O
for	O
estradiol	O
-	O
17	O
beta	O
and	O
could	O
transactivate	O
an	O
ERE	B-protein
-	I-protein
LacZ	I-protein
reporter	I-protein
gene	I-protein
in	O
yeast	O
similar	O
to	O
the	O
wild	O
type	O
ER	O
.	O

STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O
A	O
study	O
was	O
initiated	O
to	O
compare	O
the	O
collection	O
of	O
PBPCs	O
with	O
the	O
new	O
device	O
,	O
the	O
AutoPBSC	O
(	O
version	O
[	O
V	O
]	O
6	O
.	O
0	O
with	O
AutoPBSC	O
tubing	O
set	O
)	O
,	O
and	O
that	O
with	O
the	O
MNC	O
(	O
mononuclear	O
cell	O
)	O
procedure	O
(	O
V4	O
.	O
7	O
with	O
white	O
cell	O
tubing	O
set	O
)	O
,	O
for	O
patients	O
and	O
healthy	O
donors	O
.	O

Studying	O
intracellular	O
signaling	O
pathways	O
,	O
which	O
may	O
be	O
involved	O
in	O
malignant	O
transformation	O
of	O
Ret	B-protein
-	I-protein
9bp	I-protein
expressing	O
NIH3T3	O
cells	O
,	O
we	O
could	O
demonstrate	O
Ret	B-protein
-	I-protein
9bp	I-protein
dependent	O
phosphorylation	O
of	O
insulin	B-protein
receptor	I-protein
substrate	I-protein
-	I-protein
2	I-protein
(	O
IRS	B-protein
-	I-protein
2	I-protein
)	O
with	O
consecutive	O
activation	O
of	O
phosphatidylinositol	B-protein
3	I-protein
-	I-protein
kinase	I-protein
(	O
PI	B-protein
3	I-protein
-	I-protein
kinase	I-protein
)	O
and	O
protein	B-protein
kinase	I-protein
B	I-protein
(	O
PKB	B-protein
/	I-protein
AKT	I-protein
)	O
.	O

The	O
duration	O
of	O
reactive	O
hyperemia	O
decreased	O
with	O
aging	O
,	O
but	O
the	O
difference	O
between	O
males	O
and	O
females	O
was	O
not	O
significant	O
at	O
any	O
age	O
.	O

The	O
P	B-protein
mRNA	I-protein
also	O
contains	O
a	O
third	O
ORF	O
for	O
the	O
V	B-protein
protein	I-protein
,	O
although	O
it	O
is	O
unclear	O
how	O
or	O
whether	O
this	O
ORF	O
is	O
accessed	O
.	O

Identification	O
of	O
p40x	O
-	O
responsive	O
regulatory	O
sequences	O
within	O
the	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
long	O
terminal	O
repeat	O
.	O

Cutaneous	O
necrosis	O
associated	O
with	O
protein	B-protein
S	I-protein
deficiency	O
.	O

Effects	O
of	O
early	O
monocular	O
deprivation	O
on	O
development	O
of	O
cortico	O
-	O
geniculate	O
projections	O
in	O
the	O
cat	O
.	O

The	O
nerve	B-protein
growth	I-protein
factor	I-protein
beta	I-protein
gene	I-protein
(	O
NGFB	B-protein
)	O
belongs	O
to	O
a	O
conserved	O
syntenic	O
group	O
on	O
human	O
chromosome	O
1	O
and	O
mouse	O
Chromosome	O
3	O
.	O

Studies	O
on	O
immunoglobulin	B-protein
E	I-protein
:	O
the	O
impact	O
of	O
a	O
sojourn	O
with	O
Professor	O
Dan	O
H	O
.	O

Several	O
dozen	O
HIF	B-protein
-	I-protein
1	I-protein
targets	I-protein
are	O
known	O
,	O
including	O
the	O
gene	O
encoding	O
vascular	B-protein
endothelial	I-protein
growth	I-protein
factor	I-protein
(	O
VEGF	B-protein
)	O
.	O

The	O
pet56	B-protein
and	O
his3	B-protein
genes	I-protein
are	O
transcribed	O
divergently	O
from	O
initiation	O
sites	O
that	O
are	O
separated	O
by	O
only	O
192	O
bp	O
.	O

To	O
further	O
investigate	O
the	O
nature	O
of	O
the	O
site	O
specificity	O
a	O
set	O
of	O
deletion	O
mutants	O
of	O
the	O
160	O
bp	O
sequence	O
were	O
analysed	O
.	O

Cataract	O
extraction	O
in	O
primary	O
glaucoma	O
.	O

The	O
0	B-protein
.	I-protein
22	I-protein
-	I-protein
kb	I-protein
NheI	I-protein
/	I-protein
BglII	I-protein
promoter	I-protein
exhibited	O
PMA	O
inducibility	O
in	O
myeloid	O
cells	O
and	O
contained	O
a	O
PMA	B-protein
-	I-protein
responsive	I-protein
element	I-protein
recognized	O
by	O
Sp1	B-protein
and	O
EGR	B-protein
-	I-protein
1	I-protein
transcription	I-protein
factors	I-protein
.	O

Both	O
mutations	O
confer	O
amino	O
acid	O
substitutions	O
in	O
the	O
viral	B-protein
coat	I-protein
protein	I-protein
but	O
differ	O
in	O
their	O
relative	O
abilities	O
to	O
utilize	O
the	O
foreign	O
scaffolding	B-protein
protein	I-protein
.	O

Cell	O
adhesion	O
and	O
migration	O
assays	O
demonstrate	O
that	O
alpha	B-protein
6	I-protein
beta	I-protein
1	I-protein
is	O
the	O
major	O
laminin	B-protein
receptor	I-protein
in	O
undifferentiated	O
F9	O
cells	O
as	O
well	O
as	O
F9	O
-	O
derived	O
PE	O
cells	O
.	O

Effects	O
of	O
a	O
low	O
-	O
energy	O
laser	O
beam	O
on	O
the	O
cells	O
of	O
the	O
newt	O
embryo	O
.	O

CCAAT	B-protein
displacement	I-protein
protein	I-protein
binds	O
to	O
and	O
negatively	O
regulates	O
human	B-protein
papillomavirus	I-protein
type	I-protein
6	I-protein
E6	I-protein
,	O
E7	B-protein
,	O
and	O
E1	B-protein
promoters	I-protein
.	O

SUMMARY	O
OF	O
REVIEW	O
:	O
We	O
discuss	O
the	O
criteria	O
that	O
make	O
such	O
studies	O
comparable	O
,	O
drawing	O
on	O
the	O
experiences	O
of	O
recent	O
studies	O
performed	O
around	O
the	O
world	O
.	O

Multiple	O
copies	O
of	O
rsmB	B-protein
+	I-protein
DNA	I-protein
,	O
on	O
the	O
other	O
hand	O
,	O
stimulate	O
exoenzyme	O
production	O
by	O
relieving	O
the	O
negative	O
effects	O
of	O
a	O
chromosomal	O
copy	O
of	O
hexA	B-protein
+	I-protein
.	O

Clones	O
that	O
expressed	O
DBD	O
exhibited	O
a	O
dominant	O
negative	O
phenotype	O
and	O
did	O
not	O
elicit	O
antiviral	O
activity	O
against	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
infection	O
upon	O
IFN	B-protein
treatment	O
.	O

Leukemia	B-protein
-	I-protein
inhibitory	I-protein
factor	I-protein
(	O
LIF	B-protein
)	O
is	O
a	O
neuropoietin	B-protein
able	O
to	O
regulate	O
the	O
differentiation	O
and	O
the	O
survival	O
of	O
many	O
cell	O
types	O
,	O
which	O
include	O
some	O
neuronal	O
populations	O
.	O

Groups	O
of	O
male	O
and	O
female	O
Fischer	O
344	O
rats	O
,	O
B6C3F1	O
mice	O
,	O
and	O
Hartley	O
guinea	O
pigs	O
were	O
exposed	O
once	O
for	O
6	O
hr	O
to	O
mean	O
concentrations	O
of	O
10	O
.	O
5	O
,	O
5	O
.	O
4	O
,	O
2	O
.	O
4	O
,	O
1	O
.	O
0	O
,	O
or	O
0	O
(	O
control	O
)	O
ppm	O
of	O
methyl	O
isocyanate	O
(	O
MIC	O
)	O
vapor	O
.	O

Here	O
we	O
demonstrate	O
that	O
Hh	B-protein
and	O
Patched	B-protein
(	O
Ptc	B-protein
)	O
act	O
through	O
those	O
Ci	B-protein
binding	O
sites	B-protein
to	O
modulate	O
the	O
level	O
of	O
Ci	O
-	O
dependent	O
transcriptional	O
activation	O
in	O
S2	O
cells	O
.	O

The	O
main	O
advantages	O
of	O
Multi	O
-	O
MUP	O
analysis	O
are	O
:	O
(	O
1	O
)	O
quick	O
acquisition	O
of	O
many	O
MUPs	O
;	O
(	O
2	O
)	O
simultaneous	O
collection	O
of	O
several	O
MUPs	O
at	O
one	O
recording	O
site	O
;	O
(	O
3	O
)	O
possibility	O
to	O
analyze	O
not	O
only	O
low	O
threshold	O
MUPs	O
;	O
(	O
4	O
)	O
less	O
bias	O
in	O
the	O
selection	O
of	O
MUPs	O
and	O
(	O
5	O
)	O
the	O
reproducibility	O
of	O
the	O
results	O
that	O
allow	O
the	O
same	O
reference	O
values	O
to	O
be	O
used	O
in	O
different	O
laboratories	O
.	O

Intraperitoneal	O
administration	O
of	O
L	O
-	O
5	O
-	O
hydroxytryptophan	O
(	O
L	O
-	O
5	O
-	O
HTP	O
)	O
at	O
doses	O
of	O
25	O
to	O
100	O
mg	O
/	O
kg	O
dramatically	O
increase	O
defecation	O
in	O
mice	O
.	O

Copyright	O
1998	O
Elsevier	O
Science	O
B	O
.	O
V	O
.	O

It	O
is	O
now	O
well	O
accepted	O
that	O
the	O
p53	B-protein
C	I-protein
-	I-protein
terminus	I-protein
plays	O
a	O
central	O
role	O
in	O
controlling	O
the	O
activity	O
of	O
the	O
wild	O
-	O
type	O
molecule	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
adenoviral	B-protein
12S	I-protein
E1A	I-protein
protein	I-protein
modulates	O
the	O
phosphorylation	O
status	O
of	O
p130	B-protein
and	O
p107	B-protein
without	O
apparent	O
changes	O
in	O
the	O
cell	O
cycle	O
dependent	O
phosphorylation	O
of	O
the	O
retinoblastoma	B-protein
protein	I-protein
.	O

The	O
PSD2	B-protein
gene	I-protein
was	O
heterologously	O
expressed	O
by	O
infection	O
of	O
Sf	O
-	O
9	O
insect	O
cells	O
with	O
recombinant	O
baculovirus	O
,	O
resulting	O
in	O
a	O
10	O
-	O
fold	O
increase	O
in	O
PSD	B-protein
activity	O
.	O

In	O
acute	O
-	O
phase	O
livers	O
,	O
we	O
observed	O
a	O
dramatic	O
reduction	O
in	O
HNF	B-protein
-	I-protein
3	I-protein
alpha	I-protein
expression	O
which	O
correlates	O
with	O
a	O
decrease	O
in	O
the	O
expression	O
of	O
its	O
target	O
gene	O
,	O
the	O
TTR	B-protein
gene	I-protein
.	O

A	O
comparative	O
study	O
of	O
the	O
effects	O
of	O
carbamazepine	O
and	O
the	O
NMDA	B-protein
receptor	I-protein
antagonist	O
remacemide	O
on	O
road	O
tracking	O
and	O
car	O
-	O
following	O
performance	O
in	O
actual	O
traffic	O
.	O

All	O
mutant	B-protein
JCV	I-protein
T	I-protein
antigens	I-protein
bound	O
to	O
JCV	O
and	O
SV40	O
origins	O
of	O
DNA	O
replication	O
.	O

EMSA	O
showed	O
that	O
nuclear	O
proteins	O
from	O
PC12	O
but	O
not	O
C6	O
or	O
Rat2	O
cells	O
bind	O
the	O
CRE	B-protein
as	O
a	O
complex	O
containing	O
activating	B-protein
transcription	I-protein
factor	I-protein
(	I-protein
ATF	I-protein
)	I-protein
-	I-protein
4	I-protein
and	O
CCAAT	B-protein
enhancer	I-protein
-	I-protein
binding	I-protein
protein	I-protein
beta	I-protein
,	O
while	O
both	O
PC12	O
and	O
C6	O
cell	O
nuclear	O
extracts	O
were	O
recruited	O
by	O
the	O
CCAAT	O
-	O
box	O
as	O
a	O
complex	O
containing	O
nuclear	B-protein
factor	I-protein
Y	O
.	O

The	O
disease	O
ran	O
an	O
atypical	O
course	O
;	O
with	O
early	O
jaundice	O
syndrome	O
,	O
severe	O
enterorrhagia	O
and	O
late	O
appearance	O
of	O
roseola	O
.	O

The	O
core	O
enzyme	O
is	O
homologous	O
to	O
those	O
of	O
bacteriophages	O
T3	O
,	O
T7	O
and	O
SP6	O
whereas	O
the	O
specificity	O
factor	O
shows	O
similarities	O
with	O
bacterial	B-protein
sigma	I-protein
factors	I-protein
.	O

The	O
binding	O
of	O
NF	B-protein
-	I-protein
ATp	I-protein
,	O
although	O
not	O
NF	B-protein
-	I-protein
AT4	I-protein
,	O
to	O
this	O
enhancer	O
also	O
occurs	O
along	O
with	O
HTLV	O
-	O
I	O
-	O
mediated	O
infection	O
of	O
human	O
peripheral	O
blood	O
T	O
-	O
cells	O
.	O

Since	O
1968	O
,	O
a	O
steep	O
decrease	O
in	O
the	O
number	O
of	O
strains	O
resistant	O
to	O
three	O
or	O
more	O
antibiotics	O
(	O
multiple	O
-	O
resistant	O
)	O
and	O
in	O
strains	O
of	O
the	O
83A	O
complex	O
was	O
noticed	O
.	O

An	O
int6	B-protein
deletion	I-protein
(	O
int6Delta	B-protein
)	O
mutant	O
was	O
viable	O
but	O
grew	O
slowly	O
in	O
minimal	O
medium	O
.	O

The	O
role	O
of	O
supercritical	O
fluid	O
chromatography	O
(	O
SFC	O
)	O
as	O
a	O
viable	O
technique	O
for	O
analyzing	O
agricultural	O
products	O
has	O
been	O
investigated	O
using	O
packed	O
and	O
capillary	O
column	O
methodology	O
.	O

Chronic	O
thyroiditis	O
as	O
a	O
risk	O
factor	O
of	O
B	O
-	O
cell	O
lymphoma	O
in	O
the	O
thyroid	O
gland	O
.	O

Iodine	O
-	O
123	O
was	O
satisfactorily	O
imaged	O
only	O
with	O
the	O
MEC	O
and	O
pinhole	O
collimators	O
,	O
which	O
in	O
turn	O
yielded	O
MTF	O
values	O
comparable	O
to	O
those	O
measured	O
for	O
99mTc	O
.	O

JNK	B-protein
and	O
p38	B-protein
are	O
constitutively	O
present	O
in	O
the	O
nucleus	O
,	O
and	O
DNA	O
-	O
bound	O
c	B-protein
-	I-protein
JUN	I-protein
and	O
ATF	B-protein
-	I-protein
2	I-protein
are	O
stably	O
contacted	O
by	O
JNK	B-protein
and	O
p38	B-protein
,	O
respectively	O
.	O

The	O
mean	O
minimum	O
steady	O
-	O
state	O
concentration	O
after	O
the	O
oral	O
regimen	O
(	O
23	O
micrograms	O
.	O
l	O
-	O
1	O
)	O
was	O
78	O
%	O
of	O
that	O
after	O
the	O
intramuscular	O
regime	O
(	O
29	O
micrograms	O
.	O
l	O
-	O
1	O
)	O
.	O

BACKGROUND	O
:	O
Previous	O
studies	O
have	O
indicated	O
that	O
the	O
60	O
-	O
,	O
30	O
-	O
,	O
28	O
-	O
and	O
12	O
-	O
item	O
versions	O
of	O
the	O
General	O
Health	O
Questionnaire	O
(	O
GHQ	O
)	O
are	O
liable	O
to	O
retest	O
effects	O
,	O
especially	O
when	O
administered	O
multiple	O
times	O
with	O
short	O
intervals	O
.	O

Promoter	O
transcriptional	O
activity	O
was	O
determined	O
for	O
a	O
wide	O
5	O
'	O
portion	O
of	O
the	O
human	O
annexin	B-protein
A5	I-protein
gene	I-protein
,	O
from	O
bp	O
-	O
1275	O
to	O
+	O
79	O
relative	O
to	O
the	O
most	O
5	O
'	O
of	O
several	O
discrete	O
transcription	O
start	O
points	O
.	O

Depth	O
-	O
controlled	O
grazing	O
-	O
incidence	O
diffraction	O
of	O
synchrotron	O
x	O
radiation	O
.	O

Our	O
results	O
suggested	O
that	O
the	O
hexamer	O
and	O
the	O
octamer	O
motifs	O
may	O
play	O
important	O
role	O
(	O
s	O
)	O
in	O
regulation	O
of	O
replication	O
-	O
dependent	O
but	O
not	O
of	O
replication	O
-	O
independent	O
expression	O
of	O
the	O
wheat	B-protein
histone	I-protein
H3	I-protein
gene	I-protein
.	O

These	O
results	O
indicate	O
that	O
ATF4	B-protein
regulates	O
basal	O
and	O
CdCl	O
(	O
2	O
)	O
-	O
induced	O
expression	O
of	O
the	O
ho	B-protein
-	I-protein
1	I-protein
gene	I-protein
in	O
a	O
cell	O
-	O
specific	O
manner	O
and	O
possibly	O
in	O
a	O
complex	O
with	O
Nrf2	B-protein
.	O

A	O
list	O
of	O
12	O
names	O
for	O
the	O
disease	O
and	O
37	O
diagnostic	O
criteria	O
were	O
proposed	O
to	O
a	O
Consensus	O
Panel	O
of	O
12	O
Italian	O
experts	O
who	O
ranked	O
them	O
in	O
order	O
so	O
as	O
to	O
identify	O
a	O
core	O
set	O
of	O
criteria	O
.	O

As	O
well	O
,	O
mixtures	O
of	O
(	O
LA	O
)	O
(	O
12	O
)	O
with	O
the	O
longer	O
chain	O
PEs	O
exhibit	O
unusual	O
biomodal	O
enthalpy	O
variations	O
,	O
suggesting	O
peptide	O
immiscibility	O
in	O
thicker	O
gel	O
state	O
bilayers	O
.	O

The	O
effects	O
of	O
contrast	O
media	O
on	O
coagulation	B-protein
factor	I-protein
XII	I-protein
.	O

Evidence	O
from	O
a	O
Northern	O
hybridization	O
indicated	O
that	O
jadM	B-protein
expression	O
is	O
correlated	O
with	O
jadomycin	B-protein
B	I-protein
synthesis	O
.	O

Mutation	O
of	O
the	O
NF	B-protein
-	I-protein
kappaB	I-protein
site	I-protein
in	O
the	O
Mdr1b	B-protein
promoter	I-protein
prevents	O
its	O
induction	O
by	O
TNF	B-protein
-	I-protein
alpha	I-protein
.	O

A	O
5	O
.	O
0	O
-	O
kb	O
transcript	O
detected	O
by	O
the	O
differential	O
display	O
amplicon	O
3G1	O
was	O
found	O
to	O
correlate	O
strongly	O
with	O
RAG1	B-protein
mRNA	I-protein
expression	O
in	O
various	O
human	O
cell	O
lines	O
.	O

Post	O
-	O
translational	O
modifications	O
such	O
as	O
glycosylation	O
and	O
phosphorylation	O
could	O
be	O
excluded	O
as	O
potential	O
explanations	O
for	O
the	O
protein	O
heterogeneity	O
.	O

In	O
4	O
spinalized	O
cats	O
,	O
the	O
effects	O
of	O
afferent	O
inputs	O
from	O
hindlimb	O
cutaneous	O
nerves	O
(	O
sural	O
cutaneous	O
nerve	O
:	O
Sur	O
)	O
on	O
mono	O
-	O
and	O
poly	O
-	O
synaptic	O
reflex	O
recorded	O
from	O
tail	O
muscle	O
motoneurons	O
were	O
studied	O
before	O
and	O
after	O
spinal	O
lesioning	O
at	O
S2	O
-	O
3	O
level	O
.	O

In	O
PB	O
mice	O
,	O
there	O
was	O
only	O
a	O
small	O
deficit	O
in	O
the	O
number	O
of	O
the	O
hippocampal	O
pyramidal	O
neurons	O
compared	O
to	O
controls	O
(	O
15	O
%	O
,	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
and	O
no	O
deficit	O
in	O
the	O
granule	O
cells	O
.	O

In	O
the	O
Arithmetic	O
subtest	O
one	O
of	O
the	O
items	O
would	O
not	O
meet	O
the	O
difficulty	O
grading	O
shown	O
while	O
the	O
last	O
two	O
items	O
offer	O
very	O
little	O
possibility	O
of	O
success	O
for	O
all	O
subjects	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

In	O
the	O
ileum	O
,	O
enterotoxin	B-protein
increased	O
the	O
luminal	O
disappearance	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
peripheral	O
blood	O
appearance	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
of	O
chloroquine	O
.	O

Both	O
Z	B-protein
and	O
R	B-protein
expression	O
resulted	O
in	O
PML	O
dispersion	O
in	O
EBV	O
-	O
positive	O
cells	O
.	O

Measurements	O
included	O
bone	O
mineral	O
density	O
of	O
the	O
lumbar	O
spine	O
and	O
proximal	O
femur	O
(	O
by	O
dual	O
-	O
energy	O
X	O
-	O
ray	O
absorptiometry	O
)	O
and	O
biochemical	O
markers	O
of	O
bone	O
remodeling	O
(	O
serum	O
bone	O
-	O
specific	O
alkaline	B-protein
phosphatase	I-protein
by	O
immunoassay	O
and	O
urine	O
deoxypyridinoline	O
by	O
high	O
-	O
pressure	O
liquid	O
chromatography	O
)	O
.	O

The	O
obvious	O
functional	O
necessity	O
for	O
editing	O
in	O
kinetoplastid	O
mitochondria	O
is	O
the	O
formation	O
of	O
translatable	O
mRNAs	O
.	O

The	O
mechanism	O
involves	O
Gbetagamma	B-protein
subunit	O
-	O
mediated	O
increases	O
in	O
tyrosine	O
phosphorylation	O
of	O
the	O
Shc	B-protein
adapter	I-protein
protein	I-protein
,	O
Shc	B-protein
*	I-protein
Grb2	I-protein
complex	I-protein
formation	O
,	O
and	O
recruitment	O
of	O
Ras	B-protein
guanine	I-protein
nucleotide	I-protein
exchange	I-protein
factor	I-protein
activity	O
.	O

The	O
Hagen	O
-	O
Poiseuille	O
equation	O
is	O
used	O
to	O
assess	O
the	O
effects	O
of	O
attached	O
parasites	O
in	O
the	O
foregut	O
of	O
Leishmania	O
-	O
infected	O
sandflies	O
on	O
blood	O
flow	O
.	O

Recently	O
,	O
a	O
protein	O
designated	O
GF14	B-protein
has	O
been	O
isolated	O
that	O
is	O
associated	O
with	O
the	O
GBF	B-protein
protein	I-protein
complex	I-protein
.	O

Diltiazem	O
caused	O
significant	O
decrease	O
in	O
the	O
ventricular	O
response	O
without	O
conversion	O
to	O
sinus	O
rhythm	O
.	O

Although	O
not	O
common	O
,	O
the	O
disorder	O
is	O
the	O
most	O
frequently	O
diagnosed	O
disturbance	O
of	O
porphyrin	O
metabolism	O
in	O
many	O
countries	O
,	O
and	O
further	O
insight	O
into	O
its	O
unusual	O
pathogenesis	O
may	O
clarify	O
the	O
hepatotoxic	O
effects	O
of	O
the	O
4	O
etiologic	O
agents	O
.	O

Resistance	O
to	O
thyroid	O
hormone	O
:	O
implications	O
for	O
neurodevelopmental	O
research	O
on	O
the	O
effects	O
of	O
thyroid	O
hormone	O
disruptors	O
.	O

We	O
established	O
the	O
radiosensitive	O
cell	O
line	O
SX9	O
from	O
mammary	O
carcinoma	O
cell	O
line	O
FM3A	O
.	O

CRS	B-protein
function	O
in	O
a	O
5	B-protein
'	I-protein
LTR	I-protein
-	I-protein
linked	I-protein
gene	I-protein
expression	O
assay	O
correlates	O
with	O
the	O
ability	O
of	O
both	O
p60CRS	B-protein
and	O
p40CRS	B-protein
to	O
interact	O
with	O
5	B-protein
'	I-protein
LTR	I-protein
RNA	I-protein
in	O
vitro	O
.	O

Null	O
mutations	O
in	O
daf	B-protein
-	I-protein
3	I-protein
suppress	O
mutations	O
in	O
genes	O
encoding	O
this	O
TGF	B-protein
-	I-protein
beta	I-protein
signal	O
,	O
its	O
receptors	O
,	O
and	O
associated	O
Smad	B-protein
signal	I-protein
transduction	I-protein
proteins	I-protein
.	O
daf	B-protein
-	I-protein
3	I-protein
encodes	O
a	O
Smad	B-protein
protein	I-protein
that	O
is	O
most	O
closely	O
related	O
to	O
mammalian	B-protein
DPC4	I-protein
,	O
and	O
is	O
expressed	O
throughout	O
development	O
in	O
many	O
of	O
the	O
tissues	O
that	O
are	O
remodeled	O
during	O
dauer	O
development	O
.	O

In	O
addition	O
,	O
the	O
R206S	B-protein
HSF	I-protein
substitution	O
exhibits	O
constitutive	O
transcriptional	O
activation	O
from	O
a	O
consensus	O
HSE	B-protein
(	O
HSE2	B-protein
)	O
.	O

The	O
IDF	O
standard	O
method	O
for	O
the	O
detection	O
of	O
penicillin	O
in	O
milk	O
is	O
not	O
suitable	O
for	O
the	O
detection	O
of	O
sulphonamide	O
residues	O
in	O
milk	O
.	O

Comparative	O
study	O
of	O
the	O
differential	O
white	O
blood	O
cell	O
count	O
using	O
three	O
automated	O
analyzers	O
:	O
Coulter	O
STKS	O
,	O
Sysmex	O
NE	O
8000	O
and	O
Technicon	O
H	O
-	O
1	O
.	O

This	O
sequence	O
similarity	O
raises	O
the	O
possibility	O
that	O
GCN1	B-protein
interacts	O
with	O
ribosomes	O
or	O
tRNA	O
molecules	O
and	O
functions	O
in	O
conjunction	O
with	O
GCN2	B-protein
in	O
monitoring	O
uncharged	O
tRNA	O
levels	O
during	O
the	O
process	O
of	O
translation	O
elongation	O
.	O

Moreover	O
,	O
xTAK1KN	B-protein
could	O
block	O
the	O
expression	O
of	O
ventral	O
mesoderm	O
marker	O
genes	O
induced	O
by	O
Smad1	B-protein
or	I-protein
5	I-protein
.	O

In	O
2	O
subjects	O
the	O
phytomitogen	O
reactivity	O
of	O
the	O
lymphocytes	O
was	O
improved	O
after	O
treatment	O
.	O

The	O
osmotic	O
diuretic	O
mannitol	O
was	O
administered	O
to	O
21	O
patients	O
.	O

A	O
2	B-protein
.	I-protein
4	I-protein
-	I-protein
kb	I-protein
MAPKAPK	I-protein
-	I-protein
2	I-protein
message	I-protein
is	O
expressed	O
throughout	O
development	O
,	O
while	O
two	O
shorter	O
transcripts	O
of	O
2	O
.	O
3	O
and	O
1	O
.	O
8	O
kb	O
appear	O
to	O
be	O
specifically	O
expressed	O
in	O
the	O
germline	O
.	O

Here	O
we	O
characterize	O
an	O
S	B-protein
.	I-protein
cerevisiae	I-protein
Swi3	I-protein
homolog	I-protein
(	O
Swh3	B-protein
)	O
and	O
present	O
evidence	O
that	O
it	O
associates	O
in	O
a	O
complex	O
with	O
a	O
Snf2	B-protein
homolog	I-protein
,	O
Sthl	B-protein
.	O

Both	O
EWS	B-protein
-	I-protein
FLI	I-protein
-	I-protein
1	I-protein
and	O
FLI	B-protein
-	I-protein
1	I-protein
proteins	I-protein
function	O
as	O
transcription	O
factors	O
that	O
bind	O
specifically	O
to	O
ets	B-protein
sequences	I-protein
(	O
the	O
ets	B-protein
boxes	I-protein
)	O
present	O
in	O
promoter	O
elements	O
.	O

Changes	O
in	O
immunologic	O
reactivity	O
in	O
subjects	O
receiving	O
transfer	B-protein
factor	I-protein
could	O
not	O
be	O
distinguished	O
from	O
those	O
in	O
subjects	O
receiving	O
placebo	O
.	O

Transitory	O
subclinical	O
and	O
permanent	O
hypothyroidism	O
in	O
the	O
course	O
of	O
subacute	O
thyroiditis	O
(	O
de	O
Quervain	O
)	O
.	O

Transient	O
,	O
high	O
-	O
level	O
Ras	O
-	O
expression	O
induces	O
transcriptional	O
activation	O
of	O
p21	B-protein
mediated	O
by	O
a	O
GC	O
-	O
rich	O
region	O
in	O
p21	B-protein
promoter	I-protein
-	O
83	O
-	O
54	O
bp	O
relative	O
to	O
the	O
transcription	O
initiation	O
site	O
containing	O
binding	O
sites	O
for	O
Sp1	B-protein
-	I-protein
family	I-protein
transcription	I-protein
factors	I-protein
.	O

Five	O
patients	O
with	O
type	O
III	O
musculoskeletal	O
infection	O
from	O
nongonococcal	O
Neisseria	O
species	O
were	O
examined	O
during	O
a	O
13	O
-	O
month	O
period	O
.	O

A	O
large	O
increase	O
of	O
serum	O
ketones	O
occurred	O
under	O
all	O
conditions	O
,	O
and	O
the	O
exercise	O
respiratory	O
quotient	O
suggested	O
some	O
increase	O
of	O
fat	O
utilization	O
,	O
WW	O
(	O
0	O
.	O
85	O
)	O
through	O
CW	O
(	O
0	O
.	O
84	O
)	O
to	O
CC	O
(	O
0	O
.	O
83	O
)	O
.	O

The	O
current	O
study	O
demonstrates	O
that	O
T3	O
-	O
activated	O
transcription	O
of	O
the	O
NADPH	O
:	O
cytochrome	B-protein
P450	I-protein
oxidoreductase	I-protein
(	O
P450R	B-protein
)	O
gene	O
is	O
dependent	O
on	O
the	O
thyroid	O
hormonal	O
status	O
of	O
the	O
animal	O
,	O
with	O
both	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
pathways	O
being	O
important	O
in	O
regulating	O
the	O
cellular	O
P450R	B-protein
mRNA	I-protein
level	O
.	O

From	O
this	O
library	O
,	O
LEU2	B-protein
and	O
HIS3	B-protein
cDNAs	O
were	O
recovered	O
at	O
a	O
frequency	O
of	O
about	O
1	O
in	O
10	O
(	O
4	O
)	O
and	O
in	O
12	O
out	O
of	O
13	O
cases	O
these	O
were	O
expressed	O
in	O
a	O
galactose	O
-	O
dependent	O
manner	O
.	O

Functional	B-protein
rearranged	I-protein
antibody	I-protein
genes	I-protein
were	O
detected	O
with	O
JH	B-protein
and	O
VH	B-protein
heavy	I-protein
chain	I-protein
probes	O
and	O
with	O
Jk	B-protein
and	O
Vk	B-protein
light	I-protein
chain	I-protein
probes	O
.	O

A	O
.	O

Sweet	O
oranges	O
,	O
mandarin	O
,	O
grapefruit	O
,	O
lemon	O
,	O
and	O
lime	O
are	O
generally	O
used	O
for	O
processing	O
.	O

Drug	O
-	O
drug	O
interactions	O
are	O
most	O
likely	O
to	O
occur	O
in	O
patients	O
receiving	O
multiple	O
medications	O
and	O
with	O
drugs	O
that	O
have	O
a	O
narrow	O
therapeutic	O
window	O
.	O

Gag	B-protein
protein	O
sequence	O
motifs	O
of	O
the	O
NC	B-protein
domain	I-protein
of	O
primate	O
foamy	O
viruses	O
assumed	O
to	O
be	O
involved	O
in	O
genome	O
encapsidation	O
are	O
not	O
conserved	O
in	O
FeFV	O
.	O

The	O
requirement	O
of	O
Tyr	O
-	O
19	O
dephosphorylation	O
for	O
spindle	O
assembly	O
is	O
also	O
observed	O
under	O
conditions	O
in	O
which	O
spindle	O
formation	O
is	O
independent	O
of	O
mitosis	O
,	O
suggesting	O
that	O
the	O
involvement	O
of	O
Cdc28	B-protein
/	I-protein
Clb	I-protein
kinase	I-protein
in	O
SPB	O
separation	O
is	O
direct	O
.	O

The	O
neuroprotective	O
efficacy	O
of	O
the	O
selective	O
N	O
-	O
type	O
voltage	O
-	O
sensitive	O
calcium	O
channel	O
blocker	O
,	O
SNX	O
-	O
111	O
,	O
was	O
evaluated	O
in	O
spontaneously	O
hypertensive	O
rats	O
subjected	O
to	O
60	O
min	O
of	O
focal	O
cerebral	O
ischemia	O
by	O
permanent	O
ligation	O
of	O
the	O
right	O
common	O
carotid	O
artery	O
and	O
temporary	O
occlusion	O
of	O
the	O
right	O
middle	O
cerebral	O
artery	O
.	O

Further	O
,	O
Tax	O
-	O
mediated	O
apoptosis	O
was	O
effectively	O
prevented	O
by	O
ectopic	O
expression	O
of	O
the	O
p300	B-protein
coactivator	I-protein
.	O

Aspirin	O
causes	O
peptic	O
ulcers	O
predominately	O
by	O
reducing	O
gastric	B-protein
mucosal	I-protein
cyclooxygenase	I-protein
(	O
COX	B-protein
)	O
activity	O
and	O
prostaglandin	O
synthesis	O
.	O

The	O
mEmBP	B-protein
-	I-protein
1	I-protein
protein	I-protein
can	O
activate	O
transcription	O
from	O
a	O
truncated	O
promoter	O
containing	O
a	O
pentamer	O
of	O
the	O
O2	B-protein
site	I-protein
in	O
yeast	O
cells	O
;	O
however	O
,	O
it	O
inhibited	O
regulated	O
transcription	O
of	O
a	O
22	B-protein
kDa	I-protein
zein	I-protein
promoter	I-protein
in	O
a	O
transient	O
expression	O
assay	O
using	O
cultured	O
maize	O
endosperm	O
cells	O
.	O

Partial	O
sequencing	O
of	O
the	O
region	O
downstream	O
of	O
ORF	O
-	O
Pto	O
revealed	O
homology	O
to	O
the	O
ru	B-protein
/	I-protein
AB	I-protein
genes	I-protein
,	O
involved	O
in	O
UV	O
resistance	O
,	O
from	O
plasmid	O
pPSR1	O
.	O

The	O
manifestations	O
often	O
include	O
a	O
moderate	O
thrombocytopenia	O
and	O
,	O
less	O
commonly	O
,	O
hemolysis	O
.	O

Liquid	O
chromatographic	O
method	O
for	O
determination	O
of	O
citreoviridin	O
in	O
corn	O
and	O
rice	O
.	O

Effects	O
of	O
moderate	O
hypercapnia	O
on	O
hypothermia	O
induced	O
by	O
cold	O
He	O
-	O
O2	O
in	O
rats	O
.	O

Solitary	O
thyroid	O
nodule	O
.	O

The	O
antioxidant	O
agent	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
has	O
been	O
shown	O
to	O
protect	O
endothelial	O
cells	O
(	O
EC	O
)	O
from	O
pro	O
-	O
inflammatory	O
-	O
induced	O
and	O
pro	O
-	O
oxidant	O
-	O
induced	O
NF	B-protein
-	I-protein
kappaB	I-protein
activation	O
.	O

It	O
was	O
found	O
that	O
the	O
disappearance	O
of	O
BOD5	O
and	O
NH3	O
-	O
N	O
could	O
be	O
approximated	O
using	O
first	O
-	O
order	O
kinetics	O
,	O
but	O
the	O
kinetics	O
of	O
TP	O
removal	O
were	O
unclear	O
.	O

A	O
great	O
deal	O
of	O
information	O
is	O
available	O
on	O
the	O
morphology	O
of	O
the	O
claustrum	O
in	O
various	O
animal	O
species	O
,	O
as	O
well	O
as	O
on	O
its	O
neuronal	O
distribution	O
and	O
relationships	O
with	O
the	O
cerebral	O
cortex	O
and	O
other	O
nuclei	O
.	O

These	O
results	O
suggest	O
that	O
the	O
M	O
.	O
jannaschii	O
as	O
well	O
as	O
related	O
archaeal	O
20S	O
proteasomes	O
require	O
a	O
nucleotidase	B-protein
complex	I-protein
such	O
as	O
PAN	B-protein
to	O
mediate	O
the	O
energy	O
-	O
dependent	O
hydrolysis	O
of	O
folded	O
-	O
substrate	O
proteins	O
and	O
that	O
the	O
N	O
-	O
terminal	O
73	O
amino	O
acid	O
residues	O
of	O
PAN	B-protein
are	O
not	O
absolutely	O
required	O
for	O
this	O
reaction	O
.	O

This	O
stimulatory	O
effect	O
could	O
also	O
be	O
elicited	O
by	O
c	B-protein
-	I-protein
Jun	I-protein
,	O
which	O
interacts	O
with	O
topo	B-protein
II	I-protein
,	O
but	O
not	O
by	O
c	B-protein
-	I-protein
Fos	I-protein
,	O
which	O
does	O
not	O
bind	O
topo	B-protein
II	I-protein
in	O
our	O
in	O
vitro	O
assay	O
.	O

Abstracts	O
.	O

A	O
simple	O
analytical	O
method	O
for	O
l	O
-	O
menthol	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
with	O
a	O
polarized	O
photometric	O
detector	O
was	O
established	O
.	O

Multistage	O
models	O
and	O
the	O
A	O
-	O
bomb	O
survivor	O
data	O
:	O
implications	O
for	O
carcinogenic	O
mechanisms	O
?	O

The	O
best	O
endometrial	O
ablation	O
was	O
seen	O
when	O
SnET2	O
was	O
given	O
by	O
intrauterine	O
administration	O
with	O
light	O
treatment	O
at	O
150	O
J	O
/	O
cm	O
24	O
hours	O
later	O
.	O

We	O
also	O
discovered	O
a	O
V	B-protein
lambda	I-protein
pseudogene	I-protein
,	O
called	O
psi	B-protein
V	I-protein
lambda	I-protein
1	I-protein
,	O
3	O
kb	O
upstream	O
of	O
the	O
U266	B-protein
lambda	I-protein
gene	I-protein
.	O

These	O
results	O
indicate	O
that	O
cynomolgus	O
monkeys	O
are	O
either	O
less	O
sensitive	O
or	O
respond	O
differently	O
than	O
rhesus	O
monkeys	O
to	O
some	O
of	O
the	O
pharmacological	O
effects	O
of	O
norcocaine	O
.	O

Experimental	O
cardiotoxicity	O
of	O
adriamycin	O
.	O

The	O
present	O
study	O
examined	O
the	O
effect	O
of	O
intensity	O
,	O
rate	O
,	O
and	O
polarity	O
on	O
the	O
spectral	O
content	O
of	O
ABRs	O
of	O
15	O
normal	O
-	O
hearing	O
subjects	O
.	O

The	O
applicability	O
of	O
laparoscopic	O
donor	O
nephrectomy	O
(	O
LDN	O
)	O
has	O
not	O
been	O
assessed	O
in	O
the	O
obese	O
donor	O
.	O

ERK	B-protein
MAP	I-protein
kinase	I-protein
links	O
cytokine	O
signals	O
to	O
activation	O
of	O
latent	O
HIV	O
-	O
1	O
infection	O
by	O
stimulating	O
a	O
cooperative	O
interaction	O
of	O
AP	B-protein
-	I-protein
1	I-protein
and	O
NF	B-protein
-	I-protein
kappaB	I-protein
.	O

Neural	O
-	O
specific	O
expression	O
,	O
genomic	O
structure	O
,	O
and	O
chromosomal	O
localization	O
of	O
the	O
gene	O
encoding	O
the	O
zinc	B-protein
-	I-protein
finger	I-protein
transcription	I-protein
factor	I-protein
NGFI	I-protein
-	I-protein
C	I-protein
.	O

The	O
skin	O
site	O
,	O
6	O
-	O
cm	O
-	O
distal	O
and	O
-	O
proximal	O
subcutaneous	O
segments	O
of	O
the	O
catheter	O
,	O
exudates	O
,	O
and	O
blood	O
were	O
cultured	O
.	O

A	O
human	O
nuclear	O
-	O
localized	O
chaperone	O
that	O
regulates	O
dimerization	O
,	O
DNA	O
binding	O
,	O
and	O
transcriptional	O
activity	O
of	O
bZIP	B-protein
proteins	I-protein
.	O

The	O
inhibition	O
by	O
cytosolic	O
Ca2	O
+	O
was	O
caused	O
by	O
a	O
decrease	O
in	O
cooperativity	O
and	O
by	O
a	O
shift	O
in	O
EC50	O
toward	O
higher	O
InsP3	O
concentrations	O
.	O

Some	O
studies	O
of	O
exercise	O
have	O
associated	O
beta	B-protein
-	I-protein
endorphin	I-protein
release	O
with	O
increased	O
exertion	O
levels	O
,	O
but	O
other	O
evidence	O
suggests	O
that	O
acidosis	O
may	O
stimulate	O
the	O
release	O
of	O
beta	B-protein
-	I-protein
endorphin	I-protein
.	O

The	O
event	O
rate	O
in	O
patients	O
with	O
chronic	O
Irr	O
-	O
rMFP	O
or	O
Un	O
-	O
nrMFP	O
was	O
markedly	O
higher	O
than	O
it	O
was	O
in	O
those	O
with	O
Rev	O
-	O
rMFP	O
or	O
Sta	O
-	O
nrMFP	O
.	O

In	O
wandering	O
stage	O
larvae	O
,	O
the	O
OBP	B-protein
transcript	I-protein
appeared	O
to	O
be	O
at	O
least	O
250	O
-	O
fold	O
less	O
abundant	O
than	O
ribosomal	B-protein
RNA	I-protein
.	O

A	O
sheep	O
testicular	O
cDNA	O
library	O
constructed	O
in	O
pcDNA1	O
vector	O
was	O
screened	O
with	O
a	O
probe	O
generated	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
corresponding	O
to	O
a	O
1	O
.	O
6	O
kb	O
fragment	O
of	O
the	O
rat	B-protein
luteinizing	I-protein
hormone	I-protein
receptor	I-protein
cDNA	I-protein
.	O

Plethysmographic	O
technique	O
and	O
indirect	O
blood	O
pressure	O
recordings	O
were	O
used	O
.	O

Dissipation	O
of	O
claudication	O
pain	O
after	O
walking	O
:	O
implications	O
for	O
endurance	O
training	O
.	O

Furthermore	O
,	O
we	O
demonstrated	O
that	O
Galpha11	B-protein
Q209L	I-protein
stimulated	O
Src	B-protein
family	I-protein
kinase	I-protein
activity	O
and	O
induced	O
tyrosine	O
phosphorylation	O
of	O
several	O
proteins	O
in	O
HEK	O
-	O
293	O
cells	O
.	O

The	O
percentages	O
of	O
recovery	O
decreased	O
with	O
storage	O
time	O
,	O
although	O
the	O
addition	O
of	O
dispersant	O
(	O
Tris	O
-	O
Tween	O
80	O
)	O
before	O
storage	O
appeared	O
to	O
partially	O
prevent	O
adhesion	O
.	O

The	O
results	O
are	O
given	O
as	O
:	O
flux	O
,	O
number	O
of	O
stars	O
per	O
CM3	O
,	O
charge	O
of	O
the	O
ions	O
,	O
comparison	O
with	O
other	O
detectors	O
(	O
plastics	O
,	O
AgCl	O
crystals	O
,	O
LiF	O
)	O
,	O
energy	O
loss	O
,	O
hit	O
region	O
in	O
the	O
biological	O
objects	O
.	O

Ultrasonography	O
provides	O
excellent	O
intraoperative	O
evaluation	O
of	O
spinal	O
cord	O
injury	O
.	O

At	O
least	O
some	O
of	O
the	O
difference	O
in	O
stability	O
of	O
the	O
two	O
kinds	O
of	O
complexes	O
was	O
due	O
to	O
the	O
fact	O
that	O
the	O
dissociation	O
rate	O
of	O
the	O
A	O
stem	O
substrate	O
from	O
the	O
protein	O
-	O
DNA	O
complexes	O
was	O
approximately	O
fourfold	O
faster	O
than	O
that	O
of	O
the	O
complete	O
TR	O
.	O

Disruption	O
mutations	O
have	O
been	O
constructed	O
in	O
the	O
SLK1	B-protein
gene	I-protein
.	O
slk1	B-protein
null	I-protein
mutants	I-protein
can	O
not	O
grow	O
at	O
37	O
degrees	O
C	O
,	O
but	O
many	O
cells	O
can	O
grow	O
at	O
30	O
,	O
24	O
,	O
and	O
17	O
degrees	O
C	O
.	O

As	O
an	O
application	O
of	O
reverse	O
genetics	O
,	O
we	O
introduced	O
one	O
nucleotide	O
change	O
(	O
UCU	O
to	O
ACU	O
)	O
to	O
immediate	O
downstream	O
of	O
the	O
RNA	O
-	O
editing	O
site	O
of	O
the	O
V	B-protein
gene	I-protein
in	O
the	O
full	B-protein
-	I-protein
length	I-protein
hPIV2	I-protein
cDNA	I-protein
and	O
were	O
able	O
to	O
obtain	O
infectious	O
viruses	O
[	O
rPIV2V	O
(	O
-	O
)	O
]	O
from	O
the	O
cDNA	O
.	O

ARPIA	O
has	O
been	O
implemented	O
by	O
using	O
a	O
relational	O
DBMS	O
,	O
very	O
cheap	O
and	O
highly	O
diffused	O
on	O
personal	O
computers	O
.	O

Stimulation	O
with	O
MCh	O
produced	O
a	O
Ca	O
-	O
dependent	O
transient	O
elevation	O
of	O
cGMP	O
level	O
from	O
10	O
to	O
80	O
fmol	O
/	O
gland	O
,	O
peaking	O
at	O
1	O
-	O
2	O
min	O
but	O
returning	O
to	O
the	O
basal	O
level	O
by	O
5	O
min	O
.	O

Courses	O
were	O
repeated	O
monthly	O
upon	O
recovery	O
of	O
myelosuppression	O
.	O

To	O
study	O
the	O
regulation	O
of	O
mdr2	B-protein
expression	O
,	O
the	O
promoter	O
of	O
the	O
mdr2	B-protein
gene	I-protein
has	O
been	O
isolated	O
from	O
a	O
murine	O
vinblastine	O
-	O
resistant	O
cell	O
line	O
,	O
J7	O
.	O
V2	O
-	O
1	O
,	O
and	O
characterized	O
.	O

The	O
MABP	O
and	O
MCBFV	O
signals	O
were	O
bandpass	O
filtered	O
in	O
the	O
very	O
low	O
-	O
frequency	O
range	O
(	O
VLF	O
,	O
0	O
.	O
015	O
-	O
0	O
.	O
07	O
Hz	O
)	O
,	O
low	O
-	O
frequency	O
range	O
(	O
LF	O
,	O
0	O
.	O
07	O
-	O
0	O
.	O
15	O
Hz	O
)	O
and	O
high	O
-	O
frequency	O
range	O
(	O
HF	O
,	O
0	O
.	O
15	O
-	O
0	O
.	O
40	O
Hz	O
)	O
before	O
applying	O
CCF	O
for	O
the	O
purpose	O
of	O
studying	O
the	O
effect	O
of	O
different	O
bandwidths	O
on	O
the	O
resulting	O
mean	O
CCFs	O
.	O

The	O
elm1	B-protein
kinase	I-protein
functions	O
in	O
a	O
mitotic	O
signaling	O
network	O
in	O
budding	O
yeast	O
.	O

We	O
have	O
mutated	O
to	O
cysteine	O
,	O
one	O
at	O
a	O
time	O
,	O
21	O
consecutive	O
residues	O
in	O
the	O
fourth	O
TMS	O
(	O
TM4	O
)	O
.	O

D	O
.	O
melanogaster	O
HeT	B-protein
-	I-protein
A	I-protein
coding	O
sequences	O
have	O
a	O
polymorphic	O
region	O
with	O
insertions	O
/	O
deletions	O
of	O
1	O
-	O
31	O
codons	O
and	O
many	O
nucleotide	O
changes	O
.	O

Although	O
no	O
Rh	B-protein
-	I-protein
antibodies	I-protein
were	O
demonstrable	O
,	O
a	O
similar	O
mechanism	O
can	O
be	O
postulated	O
for	O
the	O
Rh	O
-	O
system	O
.	O

These	O
REPs	B-protein
,	O
or	O
clusters	O
of	O
paralogous	O
loci	O
,	O
are	O
15	O
-	O
100	O
kb	O
and	O
harbor	O
at	O
least	O
four	O
ESTs	O
and	O
an	O
expressed	O
SH3GL	B-protein
pseudogene	I-protein
.	O

The	O
N	B-protein
terminus	I-protein
of	I-protein
beta	I-protein
(	I-protein
95	I-protein
kDa	I-protein
)	I-protein
corresponds	O
to	O
alpha	B-protein
with	O
the	O
integrase	B-protein
domain	I-protein
attached	O
to	O
the	O
C	O
terminus	O
(	O
32	O
kDa	O
)	O
.	O

Eukaryotic	B-protein
translation	I-protein
initiation	I-protein
factor	I-protein
4GI	I-protein
is	O
a	O
cellular	O
target	O
for	O
NS1	B-protein
protein	I-protein
,	O
a	O
translational	O
activator	O
of	O
influenza	O
virus	O
.	O

Various	O
assays	O
demonstrate	O
promoter	O
activity	O
in	O
this	O
sequence	O
that	O
reproduces	O
the	O
normal	O
control	O
of	O
E2F2	B-protein
expression	O
during	O
a	O
growth	O
stimulation	O
.	O

A	O
complete	O
drug	O
history	O
was	O
compiled	O
,	O
specifying	O
the	O
amount	O
and	O
duration	O
of	O
VGB	O
medication	O
.	O

Thus	O
,	O
unlike	O
other	O
proteins	O
reported	O
to	O
inhibit	O
SRF	B-protein
activity	O
,	O
the	O
repressor	O
activity	O
associated	O
with	O
the	O
GC	O
-	O
rich	O
element	O
does	O
not	O
appear	O
to	O
function	O
through	O
direct	O
inhibition	O
of	O
SRF	B-protein
binding	O
.	O

The	O
concomitant	O
interaction	O
of	O
mSTI1	B-protein
with	O
hsp70	B-protein
and	O
hsp90	B-protein
at	O
its	O
N	O
-	O
and	O
C	O
-	O
termini	O
respectively	O
is	O
mediated	O
by	O
the	O
tetratricopeptide	O
repeat	O
(	O
TPR	O
)	O
motifs	O
in	O
these	O
regions	O
.	O

The	O
5	O
'	O
regions	O
of	O
these	O
two	O
soybean	B-protein
actin	I-protein
genes	I-protein
contain	O
many	O
unusual	O
features	O
including	O
(	O
CT	O
)	O
repeats	O
and	O
long	O
stretches	O
of	O
pyrimidine	O
-	O
rich	O
DNA	O
.	O

The	O
effectiveness	O
of	O
NRT	O
appears	O
to	O
be	O
largely	O
independent	O
of	O
the	O
intensity	O
of	O
additional	O
support	O
provided	O
to	O
the	O
smoker	O
.	O

ROCK	B-protein
-	I-protein
I	I-protein
,	O
Kinectin	B-protein
,	O
and	O
mDia2	B-protein
can	O
bind	O
the	O
wild	O
type	O
forms	O
of	O
both	O
RhoA	B-protein
and	O
Cdc42	B-protein
in	O
a	O
GTP	O
-	O
dependent	O
manner	O
in	O
vitro	O
.	O

A	O
.	O
,	O
Bowers	O
,	O
K	O
.	O
E	O
,	O
and	O
Matthews	O
,	O
C	O
.	O

The	O
customary	O
coupling	O
reagent	O
sulfanilic	O
acid	O
has	O
been	O
replaced	O
by	O
1	O
,	O
3	O
-	O
dimethylbarbituric	O
acid	O
;	O
CNCl	O
is	O
produced	O
in	O
the	O
flow	O
through	O
system	O
directly	O
from	O
KCN	O
and	O
chloramine	O
T	O
.	O

A	O
-	O
-	O
A	O
natural	O
hydrostatic	O
phenomenon	O
,	O
at	O
the	O
level	O
of	O
the	O
ends	O
of	O
the	O
plantar	O
arcs	O
,	O
diffuses	O
body	O
weight	O
,	O
as	O
PAIN	O
plays	O
the	O
role	O
of	O
outsentry	O
(	O
fig	O
.	O
-	O
-	O
1	O
)	O
(	O
5	O
)	O
;	O
B	O
-	O
-	O
Plantar	O
perforating	O
ulceration	O
(	O
PPU	O
)	O
is	O
caused	O
by	O
a	O
combination	O
of	O
INSENSITIVITY	O
and	O
TRAUMATIS	O
(	O
1	O
)	O
;	O
C	O
-	O
-	O
The	O
patient	O
reposing	O
,	O
as	O
body	O
weight	O
(	O
traumatism	O
)	O
effects	O
disappear	O
,	O
cicatrization	O
process	O
can	O
be	O
easily	O
observed	O
;	O
D	O
-	O
-	O
PNEUMATIC	O
INSOLE	O
,	O
being	O
elastic	O
,	O
diffuses	O
localized	O
compression	O
at	O
the	O
ends	O
of	O
the	O
plantar	O
arcs	O
,	O
reduces	O
attrition	O
,	O
makes	O
easier	O
blood	O
circulation	O
,	O
as	O
well	O
as	O
cure	O
and	O
prophylaxis	O
of	O
PPU	O
(	O
fig	O
.	O
-	O
-	O
6	O
)	O
(	O
3	O
)	O
.	O

Equine	O
amnion	O
and	O
live	O
yeast	O
cell	O
derivative	O
were	O
evaluated	O
as	O
a	O
biological	O
dressing	O
and	O
as	O
a	O
topical	O
wound	O
medicament	O
respectively	O
,	O
in	O
the	O
treatment	O
of	O
granulating	O
wounds	O
of	O
the	O
distal	O
portion	O
of	O
the	O
limbs	O
of	O
horses	O
.	O

Osteocalcin	B-protein
(	O
OC	B-protein
)	O
is	O
a	O
matrix	O
calcium	O
-	O
binding	O
protein	O
expressed	O
in	O
osteoblasts	O
and	O
odontoblasts	O
undergoing	O
mineralization	O
.	O

A	O
computerized	O
method	O
of	O
determining	O
the	O
focal	O
point	O
of	O
electrical	O
activity	O
in	O
the	O
pallidum	O
of	O
parkinsonian	O
patients	O
was	O
developed	O
using	O
on	O
-	O
line	O
quantitative	O
physiological	O
data	O
analysis	O
.	O

(	O
iv	O
)	O
The	O
accumulation	O
of	O
cyclin	B-protein
D3	I-protein
protein	I-protein
in	O
Vero	O
cells	O
infected	O
with	O
an	O
alpha0	B-protein
deletion	I-protein
mutant	I-protein
was	O
reduced	O
relative	O
to	O
that	O
of	O
cells	O
infected	O
with	O
wild	O
-	O
type	O
virus	O
or	O
a	O
recombinant	O
virus	O
in	O
which	O
the	O
deleted	O
alpha0	B-protein
sequences	I-protein
were	O
restored	O
.	O

The	O
DAP5	B-protein
/	I-protein
p86	I-protein
apoptotic	O
form	O
was	O
more	O
potent	O
than	O
DAP5	B-protein
/	I-protein
p97	I-protein
in	O
these	O
functional	O
assays	O
.	O

Factor	O
V	O
Leiden	O
is	O
a	O
genetic	O
disorder	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
venous	O
thrombosis	O
.	O

The	O
interferon	O
-	O
induced	O
RNA	B-protein
-	I-protein
dependent	I-protein
protein	I-protein
kinase	I-protein
(	O
PKR	B-protein
)	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
cellular	O
defense	O
against	O
viral	O
infection	O
and	O
,	O
in	O
addition	O
,	O
has	O
been	O
suggested	O
to	O
be	O
a	O
tumor	O
suppressor	O
gene	O
because	O
of	O
its	O
growth	O
-	O
suppressive	O
properties	O
.	O

Energy	O
expenditure	O
was	O
obtained	O
using	O
a	O
primed	O
,	O
3	O
-	O
hour	O
infusion	O
of	O
NaH	O
(	O
13	O
)	O
CO	O
(	O
3	O
'	O
)	O
,	O
breath	O
(	O
13	O
)	O
CO	O
(	O
2	O
)	O
enrichment	O
determination	O
by	O
isotope	O
ratio	O
mass	O
spectroscopy	O
,	O
and	O
the	O
application	O
of	O
a	O
standard	O
regression	O
equation	O
.	O

We	O
have	O
found	O
that	O
the	O
expression	O
of	O
GTPase	O
-	O
deficient	O
mutants	O
of	O
alpha	B-protein
12	I-protein
(	O
alpha	B-protein
12Q229L	I-protein
)	O
or	O
alpha	B-protein
13	I-protein
(	O
alpha	B-protein
13Q226L	I-protein
)	O
leads	O
to	O
robust	O
activation	O
of	O
the	O
Jun	B-protein
kinase	I-protein
/	I-protein
stress	I-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
(	O
JNK	B-protein
/	I-protein
SAPK	I-protein
)	O
pathway	O
.	O

Tissues	O
and	O
exudates	O
contain	O
sufficient	O
thymidine	O
for	O
growth	O
of	O
anaerobic	O
bacteria	O
in	O
the	O
presence	O
of	O
inhibitory	O
levels	O
of	O
trimethoprim	O
-	O
sulfamethoxazole	O
.	O

Two	O
of	O
these	O
motifs	O
are	O
part	O
of	O
a	O
highly	O
conserved	O
and	O
inducible	O
dyad	O
symmetry	O
element	O
shown	O
previously	O
to	O
control	O
a	O
remote	O
IL	B-protein
-	I-protein
2	I-protein
enhancer	I-protein
and	O
the	O
CD18	B-protein
promoter	I-protein
.	O

Spliced	O
exons	O
of	O
adenovirus	O
late	O
RNAs	O
colocalize	O
with	O
snRNP	B-protein
in	O
a	O
specific	O
nuclear	O
domain	O
.	O

Degradation	O
of	O
the	O
soybean	B-protein
ribulose	I-protein
-	I-protein
1	I-protein
,	I-protein
5	I-protein
-	I-protein
bisphosphate	I-protein
carboxylase	I-protein
small	I-protein
-	I-protein
subunit	I-protein
mRNA	I-protein
,	O
SRS4	B-protein
,	O
initiates	O
with	O
endonucleolytic	O
cleavage	O
.	O

Results	O
of	O
a	O
controlled	O
study	O
.	O

How	O
many	O
embryos	O
to	O
transfer	O
in	O
patients	O
undergoing	O
IVF	O
?	O

The	O
structure	O
of	O
these	O
genes	O
suggests	O
a	O
common	O
ancestor	O
for	O
all	O
viperid	B-protein
PLA2	I-protein
genes	I-protein
.	O

CSF	O
adenosine	B-protein
deaminase	I-protein
activity	O
(	O
ADA	O
)	O
was	O
measured	O
at	O
the	O
same	O
time	O
.	O

The	O
Dox	B-protein
-	I-protein
A2	I-protein
locus	I-protein
is	O
within	O
3	O
.	O
4	O
to	O
4	O
.	O
4	O
kb	O
of	O
the	O
Df	B-protein
(	I-protein
2L	I-protein
)	I-protein
OD15	I-protein
breakpoint	I-protein
,	O
placing	O
four	O
of	O
the	O
vital	O
loci	O
within	O
a	O
maximum	O
of	O
15	O
.	O
5	O
kb	O
.	O

99Tcm	O
-	O
DMP	O
-	O
HSA	O
showed	O
an	O
almost	O
identical	O
behaviour	O
to	O
in	O
vitro	O
labelled	O
red	O
blood	O
cells	O
(	O
RBCs	O
)	O
,	O
which	O
are	O
generally	O
considered	O
the	O
reference	O
standard	O
for	O
blood	O
pool	O
agents	O
.	O

The	O
previously	O
described	O
four	O
sets	O
of	O
13	O
-	O
to	O
18	O
-	O
base	O
-	O
pair	O
interspersed	O
repeat	O
elements	O
between	O
-	O
55	O
and	O
-	O
580	O
provide	O
most	O
of	O
the	O
high	O
basal	O
transcriptional	O
strength	O
,	O
whereas	O
the	O
arrangement	O
of	O
further	O
upstream	O
tandemly	O
repeated	O
NF1	B-protein
-	I-protein
binding	I-protein
sites	I-protein
may	O
contribute	O
significantly	O
to	O
the	O
expanded	O
biological	O
host	O
range	O
for	O
expression	O
of	O
SCMV	B-protein
IE94	I-protein
compared	O
with	O
HCMV	B-protein
IE68	I-protein
.	O

These	O
characteristics	O
of	O
N22	O
/	O
P22	O
indicate	O
that	O
it	O
is	O
a	O
localized	O
synaptically	O
dependent	O
event	O
conforming	O
to	O
a	O
transverse	O
dipole	O
with	O
dorsal	O
negativity	O
and	O
a	O
simultaneous	O
anterior	O
positivity	O
.	O

Heterozygous	O
mutation	O
in	O
the	O
G	O
+	O
5	O
position	O
of	O
intron	O
33	O
of	O
the	O
pro	B-protein
-	I-protein
alpha	I-protein
2	I-protein
(	I-protein
I	I-protein
)	I-protein
gene	I-protein
(	O
COL1A2	B-protein
)	O
that	O
causes	O
aberrant	O
RNA	O
splicing	O
and	O
lethal	O
osteogenesis	O
imperfecta	O
.	O

Evidence	O
that	O
opiate	O
addiction	O
is	O
in	O
part	O
an	O
immune	O
response	O
.	O

On	O
cessation	O
of	O
steroid	O
therapy	O
the	O
patient	O
was	O
noted	O
to	O
have	O
radiologic	O
manifestations	O
of	O
hypertrophic	O
osteoarthropathy	O
(	O
HOA	O
)	O
as	O
well	O
as	O
clinical	O
and	O
laboratory	O
features	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

Specifically	O
,	O
this	O
study	O
determined	O
the	O
influence	O
of	O
:	O
(	O
1	O
)	O
an	O
awareness	O
strategy	O
,	O
(	O
2	O
)	O
a	O
non	O
-	O
awareness	O
strategy	O
,	O
(	O
3	O
)	O
a	O
Five	O
-	O
Step	O
Approach	O
strategy	O
and	O
(	O
4	O
)	O
a	O
control	O
condition	O
.	O

ISIS	O
5	O
possibilities	O
.	O

These	O
effects	O
were	O
abrogated	O
by	O
co	O
-	O
expression	O
of	O
kinase	B-protein
-	I-protein
deficient	I-protein
PKC	I-protein
zeta	I-protein
and	O
inhibition	O
of	O
phosphatidylinositol	B-protein
3	I-protein
-	I-protein
kinase	I-protein
p85alpha	I-protein
-	I-protein
p110	I-protein
by	O
wortmannin	O
,	O
LY294002	O
and	O
a	O
dominant	O
-	O
negative	O
mutant	O
of	O
p85alpha	B-protein
.	O

A	O
cDNA	O
clone	O
was	O
identified	O
encoding	O
a	O
second	O
GHS	B-protein
-	I-protein
R	I-protein
-	I-protein
related	I-protein
gene	I-protein
(	O
GPR39	B-protein
)	O
.	O

A	O
mutation	O
linked	O
to	O
the	O
SOC1	B-protein
gene	I-protein
,	O
previously	O
defined	O
by	O
recessive	O
mutations	O
that	O
suppress	O
cbp1	B-protein
ts	I-protein
alleles	I-protein
and	O
stabilize	O
many	O
mitochondrial	O
mRNAs	O
,	O
was	O
also	O
isolated	O
.	O

Intravenous	O
amine	O
pressor	O
tests	O
in	O
healthy	O
volunteers	O
.	O

During	O
transcript	O
elongation	O
,	O
the	O
sizes	O
of	O
the	O
DNA	O
footprint	O
and	O
the	O
single	O
-	O
stranded	O
transcription	O
bubble	O
vary	O
markedly	O
among	O
transcription	O
complexes	O
halted	O
at	O
different	O
template	O
positions	O
.	O

Blood	O
glucose	O
and	O
plasma	O
insulin	B-protein
were	O
measured	O
at	O
zero	O
time	O
and	O
then	O
at	O
15	O
,	O
30	O
,	O
60	O
,	O
90	O
and	O
120	O
min	O
after	O
ingestion	O
of	O
25	O
g	O
glucose	O
,	O
fructose	O
or	O
lactose	O
,	O
or	O
30	O
g	O
honey	O
,	O
50	O
g	O
white	O
bread	O
,	O
125	O
g	O
white	O
rice	O
or	O
potatoes	O
,	O
150	O
g	O
apples	O
or	O
260	O
g	O
carrots	O
.	O

A	O
total	O
of	O
1060	O
clones	O
were	O
randomly	O
selected	O
for	O
sequencing	O
of	O
one	O
end	O
.	O

The	O
5	O
'	O
region	O
shows	O
strong	O
sequence	O
similarity	O
to	O
Escherichia	O
coli	O
consensus	O
promoters	O
and	O
ribosome	O
-	O
binding	O
sequences	O
and	O
allows	O
high	O
levels	O
of	O
expression	O
in	O
E	O
.	O
coli	O
.	O

This	O
DNA	O
containing	O
promoter	O
activity	O
has	O
been	O
sequenced	O
in	O
its	O
entirety	O
and	O
found	O
to	O
contain	O
multiple	O
putative	O
regulatory	O
sites	O
.	O

Alanine	O
substitution	O
mutations	O
in	O
the	O
Zta	B-protein
activation	I-protein
domain	I-protein
which	O
eliminate	O
the	O
ability	O
of	O
Zta	B-protein
to	O
stimulate	O
the	O
D	B-protein
-	I-protein
A	I-protein
complex	I-protein
were	O
examined	O
.	O

MpB	B-protein
GroEL	I-protein
has	O
extensive	O
sequence	O
similarity	O
(	O
92	O
%	O
)	O
with	O
Escherichia	B-protein
coli	I-protein
GroEL	I-protein
and	O
other	O
members	O
of	O
the	O
chaperonin	B-protein
-	I-protein
60	I-protein
family	I-protein
.	O

GRP78	B-protein
,	O
a	O
molecular	O
chaperone	O
expressed	O
in	O
the	O
endoplasmic	O
reticulum	O
,	O
is	O
a	O
`	O
`	O
glucose	O
-	O
regulated	O
protein	O
'	O
'	O
induced	O
by	O
stress	O
responses	O
that	O
deplete	O
glucose	O
or	O
intracisternal	O
calcium	O
or	O
otherwise	O
disrupt	O
glycoprotein	O
trafficking	O
.	O

A	O
highly	O
hydrophobic	O
sequence	O
located	O
near	O
the	O
carboxyl	O
-	O
terminal	O
extremity	O
of	O
the	O
molecule	O
most	O
likely	O
constitutes	O
the	O
anchor	O
to	O
the	O
plasma	O
membrane	O
.	O

The	O
results	O
showed	O
that	O
fog	O
,	O
up	O
to	O
a	O
level	O
of	O
base	O
plus	O
fog	O
of	O
0	O
.	O
6	O
optical	O
density	O
units	O
,	O
had	O
no	O
influence	O
on	O
the	O
diagnostic	O
accuracy	O
in	O
the	O
absence	O
of	O
any	O
compensation	O
.	O

Theories	O
proffered	O
to	O
account	O
for	O
the	O
modality	O
shift	O
effect	O
are	O
critically	O
evaluated	O
.	O

Conversely	O
,	O
activated	O
glucocorticoid	B-protein
receptors	I-protein
suppressed	O
the	O
transactivation	O
function	O
of	O
p53	B-protein
,	O
while	O
transrepression	O
by	O
p53	B-protein
was	O
largely	O
unaffected	O
.	O

Molecular	O
cloning	O
,	O
expression	O
pattern	O
,	O
and	O
chromosomal	O
localization	O
of	O
human	B-protein
CDKN2D	I-protein
/	I-protein
INK4d	I-protein
,	O
an	O
inhibitor	O
of	O
cyclin	B-protein
D	I-protein
-	I-protein
dependent	I-protein
kinases	I-protein
.	O

Mutants	O
lacking	O
the	O
3	O
'	O
stem	O
-	O
loop	O
exhibited	O
a	O
75	O
%	O
reduction	O
in	O
the	O
level	O
of	O
psaB	B-protein
mRNA	O
.	O

In	O
the	O
intact	O
animal	O
,	O
postextrasystolic	O
potentiation	O
depended	O
on	O
the	O
basic	O
pacing	O
interval	O
,	O
t0	O
,	O
and	O
the	O
timing	O
of	O
the	O
extrasystole	O
,	O
t1	O
:	O
when	O
t0	O
was	O
held	O
constant	O
and	O
t1	O
was	O
increased	O
,	O
potentiation	O
decreased	O
;	O
when	O
t1	O
was	O
held	O
constant	O
and	O
t0	O
was	O
increased	O
,	O
potentiation	O
increased	O
.	O

We	O
have	O
cloned	O
and	O
characterized	O
a	O
55	O
-	O
kb	O
region	O
of	O
DNA	O
surrounding	O
HRAS1	B-protein
.	O

The	O
most	O
striking	O
difference	O
in	O
the	O
birch	B-protein
NAD	I-protein
(	I-protein
P	I-protein
)	I-protein
H	I-protein
-	I-protein
NR	I-protein
sequence	I-protein
in	O
comparison	O
to	O
NADH	B-protein
-	I-protein
NR	I-protein
sequences	I-protein
was	O
found	O
at	O
the	O
putative	O
pyridine	O
nucleotide	O
binding	O
site	O
.	O

Two	O
rare	O
novel	O
mutations	O
,	O
D811N	O
in	O
exon	O
20	O
and	O
R835C	O
in	O
exon	O
21	O
,	O
were	O
identified	O
in	O
the	O
first	O
nucleotide	O
-	O
binding	O
fold	O
(	O
NBF	O
)	O
,	O
a	O
functionally	O
important	O
region	O
of	O
SUR1	B-protein
,	O
in	O
one	O
patient	O
each	O
,	O
both	O
heterozygotes	O
.	O

Overexpression	O
of	O
c	B-protein
-	I-protein
Myc	I-protein
in	O
serum	O
-	O
starved	O
human	O
or	O
mouse	O
embryonic	O
cells	O
leads	O
to	O
apoptosis	O
which	O
is	O
significantly	O
reduced	O
in	O
the	O
presence	O
of	O
growth	O
factor	O
-	O
containing	O
serum	O
.	O
c	O
-	O
Myc	O
-	O
induced	O
apoptosis	O
appears	O
to	O
be	O
deficient	O
in	O
bax	O
-	O
null	O
as	O
compared	O
with	O
bax	B-protein
-	I-protein
wild	I-protein
-	I-protein
type	I-protein
mouse	O
embryonic	O
fibroblasts	O
.	O

Accurate	O
evaluation	O
of	O
the	O
treatment	O
results	O
in	O
unresectable	O
lung	O
cancer	O
patients	O
must	O
take	O
the	O
strong	O
prognostic	O
factors	O
into	O
account	O
.	O

Specifically	O
,	O
they	O
were	O
performed	O
to	O
determine	O
whether	O
detection	O
of	O
envelope	O
phase	O
disparity	O
was	O
consistent	O
with	O
processing	O
within	O
a	O
single	O
channel	O
in	O
which	O
the	O
AM	O
tones	O
were	O
simply	O
added	O
.	O

Unilateral	O
naris	O
occlusion	O
and	O
the	O
rat	O
accessory	O
olfactory	O
bulb	O
.	O

Acoustic	O
transmission	O
spectra	O
in	O
the	O
Penrose	O
lattice	O
.	O

The	O
latter	O
domain	O
appears	O
to	O
be	O
involved	O
in	O
targeting	O
Num1p	B-protein
to	O
the	O
mother	O
cell	O
cortex	O
.	O

Carbohydrate	O
metabolism	O
and	O
the	O
semen	O
profile	O
:	O
glucose	O
,	O
insulin	B-protein
,	O
and	O
sperm	O
studies	O
.	O

Childhood	O
misbehavior	O
and	O
the	O
risk	O
of	O
injecting	O
drug	O
use	O
.	O

Visual	O
acuity	O
may	O
be	O
decreased	O
by	O
transient	O
changes	O
in	O
refractive	O
error	O
caused	O
by	O
sulfonamides	O
,	O
the	O
antifungal	O
agent	O
metronidazole	O
,	O
thiazide	O
diuretics	O
,	O
and	O
carbonic	B-protein
anhydrase	I-protein
inhibitors	O
.	O

Transcriptional	O
analysis	O
of	O
a	O
series	O
of	O
deletion	O
mutants	O
of	O
the	O
gene	O
in	O
the	O
nuclear	O
extracts	O
prepared	O
from	O
the	O
middle	O
silk	O
gland	O
of	O
2	O
-	O
day	O
-	O
old	O
fifth	O
instar	O
larvae	O
revealed	O
the	O
presence	O
of	O
multiple	O
cis	O
-	O
regulatory	O
elements	O
located	O
both	O
upstream	O
and	O
downstream	O
of	O
the	O
initiation	O
site	O
.	O

This	O
study	O
provides	O
direct	O
evidence	O
that	O
USF	B-protein
,	O
a	O
member	O
of	O
the	O
basic	B-protein
helix	I-protein
-	I-protein
loop	I-protein
-	I-protein
helix	I-protein
leucine	I-protein
zipper	I-protein
family	I-protein
,	O
binds	O
to	O
MLE1	B-protein
,	O
HF	B-protein
-	I-protein
1a	I-protein
,	O
and	O
PRE	B-protein
B	I-protein
sites	I-protein
and	O
suggests	O
that	O
it	O
is	O
a	O
component	O
of	O
protein	O
complexes	O
that	O
may	O
coordinately	O
control	O
the	O
expression	O
of	O
MLC	B-protein
-	I-protein
2v	I-protein
and	O
alpha	B-protein
-	I-protein
myosin	I-protein
heavy	I-protein
-	I-protein
chain	I-protein
genes	I-protein
.	O

The	O
pp90rsk	B-protein
-	I-protein
protein	I-protein
kinase	I-protein
activity	O
(	O
referred	O
to	O
as	O
rsk	B-protein
-	I-protein
kinase	I-protein
)	O
is	O
also	O
not	O
related	O
to	O
cofactor	O
-	O
dependent	O
signal	O
transducing	O
protein	B-protein
kinases	I-protein
such	O
as	O
the	O
cyclic	B-protein
AMP	I-protein
-	I-protein
dependent	I-protein
protein	I-protein
kinases	I-protein
,	O
members	O
of	O
the	O
protein	B-protein
kinase	I-protein
C	I-protein
family	I-protein
,	O
or	O
other	O
Ca2	B-protein
(	I-protein
+	I-protein
)	I-protein
-	I-protein
dependent	I-protein
protein	I-protein
kinases	I-protein
.	O

The	O
beta	O
subunit	O
of	O
the	O
Fc	B-protein
epsilon	I-protein
R1	I-protein
is	O
a	O
33	O
-	O
kDa	O
tyrosine	O
phosphoprotein	O
,	O
but	O
the	O
p33	B-protein
Grb2	I-protein
-	I-protein
binding	I-protein
protein	I-protein
described	O
in	O
the	O
present	O
report	O
is	O
not	O
the	O
Fc	B-protein
epsilon	I-protein
R1	I-protein
beta	I-protein
chain	I-protein
and	O
its	O
identity	O
is	O
unknown	O
.	O

We	O
also	O
identify	O
several	O
regulatory	O
domain	O
mutants	O
in	O
which	O
Cd	O
(	O
2	O
+	O
)	O
tolerance	O
of	O
the	O
mutant	O
strain	O
and	O
transport	O
activity	O
of	O
the	O
protein	O
are	O
dissociated	O
.	O

ATX	B-protein
,	O
like	O
PC	B-protein
-	I-protein
1	I-protein
,	O
was	O
found	O
to	O
hydrolyze	O
the	O
type	B-protein
I	I-protein
phosphodiesterase	I-protein
substrate	O
p	O
-	O
nitrophenyl	O
thymidine	O
-	O
5	O
'	O
-	O
monophosphate	O
.	O

A	O
36	O
-	O
kDa	O
protein	O
that	O
was	O
localized	O
to	O
the	O
membrane	O
fraction	O
was	O
detected	O
in	O
minicells	O
containing	O
plasmids	O
with	O
the	O
ftsN	B-protein
gene	I-protein
,	O
confirming	O
that	O
FtsN	B-protein
was	O
a	O
membrane	O
protein	O
.	O

Mutations	O
in	O
the	O
yeast	B-protein
RNA14	I-protein
and	O
RNA15	B-protein
genes	I-protein
result	O
in	O
an	O
abnormal	O
mRNA	O
decay	O
rate	O
;	O
sequence	O
analysis	O
reveals	O
an	O
RNA	O
-	O
binding	O
domain	O
in	O
the	O
RNA15	B-protein
protein	I-protein
.	O

Online	O
LATCH	O
demonstrates	O
a	O
shift	O
in	O
identification	O
of	O
the	O
library	O
as	O
an	O
isolated	O
unit	O
to	O
an	O
interactive	O
resource	O
center	O
.	O

The	O
initial	O
translation	O
protein	O
encoded	O
by	O
the	O
cDNA	O
is	O
53	O
,	O
932	O
kDa	O
and	O
possesses	O
a	O
hydrophilic	O
amino	O
acid	O
composition	O
with	O
glutamic	O
acid	O
comprising	O
22	O
%	O
of	O
the	O
total	O
amino	O
acid	O
residues	O
.	O

Kinetic	O
coupling	O
and	O
requirement	O
for	O
ATP	O
hydrolysis	O
.	O

Northern	O
blot	O
analysis	O
of	O
RNAs	O
from	O
a	O
number	O
of	O
mouse	O
tissues	O
reveals	O
that	O
Atp6i	B-protein
is	O
expressed	O
predominantly	O
in	O
osteoclasts	O
,	O
and	O
this	O
predominant	O
expression	O
was	O
confirmed	O
by	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
and	O
immunohistochemical	O
analysis	O
.	O

We	O
found	O
a	O
direct	O
correlation	O
between	O
the	O
levels	O
of	O
transcription	O
of	O
the	O
acc	B-protein
genes	I-protein
and	O
the	O
rate	O
of	O
cellular	O
growth	O
.	O

A	O
lambda	O
gt10	O
cDNA	O
library	O
was	O
constructed	O
from	O
poly	O
(	O
A	O
+	O
)	O
RNA	O
of	O
young	O
green	O
leaves	O
of	O
spinach	O
.	O

Foreign	O
profiles	O
in	O
air	O
pollution	O
control	O
activities	O
.	O

Release	O
of	O
this	O
selective	O
pressure	O
,	O
however	O
,	O
gave	O
way	O
to	O
homologous	O
resolution	O
of	O
the	O
cointegrate	O
structures	O
.	O

Therefore	O
the	O
prevalences	O
of	O
total	O
diabetes	O
and	O
GDM	O
were	O
1	O
.	O
19	O
%	O
and	O
0	O
.	O
56	O
%	O
,	O
respectively	O
.	O

These	O
introns	O
contain	O
only	O
single	O
snoRNA	B-protein
genes	I-protein
and	O
their	O
processing	O
involves	O
exonucleolytic	O
release	O
of	O
the	O
snoRNA	B-protein
from	O
debranched	O
intron	O
lariats	O
.	O

Activation	O
of	O
the	O
aboral	O
ectoderm	B-protein
-	I-protein
specific	I-protein
Spec2a	I-protein
gene	I-protein
in	O
blastula	O
-	O
stage	O
sea	O
urchin	O
embryos	O
requires	O
an	O
upstream	O
regulatory	O
region	O
that	O
is	O
part	O
of	O
a	O
repetitive	O
sequence	O
element	O
(	O
RSR	B-protein
)	O
associated	O
with	O
all	O
Spec1	B-protein
/	I-protein
Spec2	I-protein
genes	I-protein
.	O

These	O
findings	O
suggest	O
that	O
the	O
MAP	B-protein
kinase	I-protein
activator	I-protein
/	I-protein
MAP	I-protein
kinase	I-protein
system	I-protein
may	O
be	O
the	O
downstream	O
components	O
of	O
ras	B-protein
signal	I-protein
transduction	I-protein
pathways	I-protein
.	O

The	O
present	O
research	O
evaluated	O
the	O
possibility	O
that	O
polyethylene	O
glycol	O
400	O
(	O
PEG	O
400	O
)	O
might	O
be	O
efficacious	O
,	O
toxic	O
,	O
or	O
both	O
.	O

Keeping	O
in	O
mind	O
the	O
limited	O
range	O
of	O
age	O
and	O
dosages	O
,	O
advantages	O
and	O
disadvantages	O
of	O
the	O
drug	O
are	O
discussed	O
,	O
comparing	O
the	O
experimental	O
results	O
with	O
those	O
derived	O
from	O
the	O
literature	O
.	O

We	O
evaluated	O
the	O
likelihood	O
of	O
tissues	O
to	O
be	O
positive	O
for	O
carcinoembryonic	B-protein
antigen	I-protein
and	O
the	O
intensity	O
of	O
carcinoembryonic	B-protein
antigen	I-protein
staining	O
in	O
specimens	O
of	O
villous	O
adenomas	O
,	O
mixed	O
polypoid	O
villous	O
adenomas	O
,	O
polypoid	O
adenomas	O
,	O
and	O
diverticulitis	O
using	O
the	O
peroxidase	O
-	O
antiperoxidase	O
technique	O
.	O

Serine	O
528	O
is	O
phosphorylated	O
in	O
vivo	O
in	O
several	O
cell	O
lines	O
,	O
and	O
substitution	O
of	O
serine	O
528	O
to	O
alanine	O
(	O
S528A	O
)	O
resulted	O
in	O
an	O
increased	O
ability	O
of	O
Myb	B-protein
to	O
transactivate	O
a	O
synthetic	O
promoter	O
containing	O
five	O
copies	O
of	O
the	O
mim	B-protein
-	I-protein
1A	I-protein
Myb	I-protein
-	I-protein
responsive	I-protein
element	I-protein
and	O
a	O
minimal	O
herpes	B-protein
tk	I-protein
promoter	I-protein
.	O

Teratogenic	O
effects	O
of	O
actinomycin	O
D	O
in	O
rats	O
.	O

To	O
determine	O
whether	O
food	O
and	O
/	O
or	O
water	O
in	O
the	O
gastrointestinal	O
tract	O
affects	O
restitution	O
of	O
blood	O
volume	O
and	O
plasma	O
protein	O
after	O
hemorrhage	O
,	O
fed	O
and	O
24	O
-	O
h	O
-	O
fasted	O
awake	O
rats	O
received	O
a	O
20	O
ml	O
.	O
kg	O
-	O
1	O
x	O
3	O
min	O
-	O
1	O
hemorrhage	O
,	O
and	O
restitution	O
of	O
blood	O
volume	O
was	O
measured	O
by	O
Evans	O
blue	O
dye	O
and	O
dilution	O
of	O
hematocrit	O
.	O

This	O
study	O
confirms	O
,	O
although	O
individual	O
reaction	O
is	O
remarkably	O
different	O
,	O
transportation	O
as	O
a	O
potent	O
stressor	O
for	O
Beagle	O
dogs	O
.	O

Sequence	O
analysis	O
identified	O
some	O
of	O
these	O
cDNA	O
clones	O
as	O
Dlc	B-protein
-	I-protein
1	I-protein
,	O
a	O
sequence	O
encoding	O
a	O
small	O
,	O
9	B-protein
-	I-protein
kDa	I-protein
human	I-protein
homolog	I-protein
of	I-protein
the	I-protein
outer	I-protein
-	I-protein
arm	I-protein
dynein	I-protein
light	I-protein
-	I-protein
chain	I-protein
protein	O
.	O

The	O
ratio	O
of	O
radioactivity	O
in	O
tumour	O
compared	O
with	O
normal	O
tissue	O
(	O
T	O
:	O
N	O
ratio	O
)	O
was	O
determined	O
after	O
simultaneously	O
injecting	O
microspheres	O
into	O
the	O
portal	O
and	O
arterial	O
circulation	O
of	O
each	O
animal	O
.	O

Five	O
cell	O
strains	O
of	O
human	O
dermal	O
fibroblasts	O
were	O
each	O
treated	O
with	O
three	O
samples	O
of	O
burn	O
blister	O
fluid	O
and	O
the	O
effect	O
compared	O
with	O
the	O
rate	O
of	O
contraction	O
of	O
free	O
floating	O
fibroblast	O
populated	O
collagen	B-protein
lattices	O
(	O
FPCL	O
)	O
.	O

The	O
cDNA	O
segment	O
is	O
flanked	O
by	O
the	O
immunoglobulin	B-protein
gene	I-protein
recombination	I-protein
signal	I-protein
sequences	I-protein
so	O
that	O
the	O
cDNA	O
segment	O
can	O
invert	O
and	O
the	O
human	B-protein
IL	I-protein
-	I-protein
2R	I-protein
L	I-protein
chain	I-protein
is	O
subsequently	O
expressed	O
under	O
the	O
control	O
of	O
the	O
SV40	O
promoter	O
.	O

Evaluation	O
of	O
left	O
ventricular	O
function	O
using	O
gated	O
planar	O
myocardial	O
imaging	O
with	O
Tc	O
-	O
99m	O
-	O
MIBI	O
.	O

Panlobular	O
emphysema	O
.	O

Mutating	O
the	O
Fcp1p	B-protein
-	I-protein
binding	I-protein
motif	I-protein
KEFGK	I-protein
in	O
the	O
RAP74	B-protein
(	O
Tfg1p	B-protein
)	O
subunit	O
of	O
TFIIF	B-protein
to	O
EEFGE	O
led	O
to	O
both	O
synthetic	O
phenotypes	O
in	O
certain	O
fcp1	B-protein
tfg1	I-protein
double	O
mutants	O
and	O
a	O
reduced	O
ability	O
of	O
Fcp1p	B-protein
to	O
activate	O
transcription	O
when	O
it	O
is	O
artificially	O
tethered	O
to	O
a	O
promoter	O
.	O

The	O
v	B-protein
-	I-protein
Src	I-protein
SH3	I-protein
domain	I-protein
facilitates	O
a	O
cell	O
adhesion	O
-	O
independent	O
association	O
with	O
focal	B-protein
adhesion	I-protein
kinase	I-protein
.	O

In	O
both	O
cases	O
,	O
at	O
the	O
end	O
of	O
exposure	O
the	O
same	O
level	O
of	O
blood	B-protein
carboxyhemoglobin	I-protein
(	O
COHb	B-protein
)	O
(	O
about	O
50	O
%	O
)	O
was	O
reached	O
.	O

We	O
conclude	O
that	O
the	O
SIMV	O
is	O
useful	O
in	O
weaning	O
neonates	O
from	O
the	O
ventilator	O
.	O

Identification	O
of	O
the	O
region	O
in	O
actin	B-protein
-	I-protein
binding	I-protein
protein	I-protein
that	O
binds	O
to	O
the	O
cytoplasmic	O
domain	O
of	O
glycoprotein	B-protein
IBalpha	I-protein
.	O

Histopathological	O
examination	O
revealed	O
dose	O
-	O
related	O
proliferation	O
of	O
type	O
II	O
pneumocytes	O
in	O
dams	O
and	O
proliferation	O
of	O
interstitial	O
cells	O
and	O
delayed	O
septal	O
/	O
capillary	O
development	O
in	O
neonates	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Little	O
is	O
known	O
about	O
the	O
mechanism	O
,	O
but	O
the	O
availability	O
of	O
rapid	O
facile	O
assays	O
for	O
monitoring	O
immunoglobulin	B-protein
hypermutation	O
would	O
greatly	O
aid	O
the	O
development	O
of	O
culture	O
systems	O
for	O
hypermutating	O
B	O
cells	O
as	O
well	O
as	O
the	O
screening	O
for	O
individuals	O
deficient	O
in	O
the	O
process	O
.	O

Xenopus	B-protein
Ran	I-protein
-	I-protein
binding	I-protein
protein	I-protein
1	I-protein
:	O
molecular	O
interactions	O
and	O
effects	O
on	O
nuclear	O
assembly	O
in	O
Xenopus	O
egg	O
extracts	O
.	O

Thus	O
,	O
both	O
the	O
hyperplasia	O
and	O
thrombotic	O
complications	O
which	O
often	O
follow	O
stenting	O
might	O
be	O
minimized	O
by	O
employing	O
gold	O
stents	O
,	O
which	O
have	O
a	O
greater	O
capacity	O
than	O
steel	O
in	O
supporting	O
a	O
functional	O
neo	O
-	O
endothelium	O
.	O

Native	O
human	B-protein
fibrinogen	I-protein
was	O
brought	O
to	O
coagulation	O
by	O
adding	O
thrombin	B-protein
.	O

Fission	B-protein
yeast	I-protein
mal2	I-protein
+	I-protein
is	O
required	O
for	O
chromosome	O
segregation	O
.	O

Surprisingly	O
,	O
the	O
Xenopus	B-protein
U7	I-protein
gene	I-protein
contains	O
two	O
adjacent	O
octamer	O
-	O
binding	O
motifs	O
located	O
only	O
12	O
and	O
24	O
bp	O
upstream	O
from	O
the	O
PSE	B-protein
,	O
instead	O
of	O
the	O
usual	O
location	O
around	O
150	O
-	O
200	O
bp	O
upstream	O
.	O

Insulin	B-protein
regulation	O
of	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
kinase	I-protein
(	O
MEK	B-protein
)	O
,	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
and	O
casein	B-protein
kinase	I-protein
in	O
the	O
cell	O
nucleus	O
:	O
a	O
possible	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
.	O

Our	O
results	O
indicate	O
that	O
interaction	O
between	O
Jak2	B-protein
and	O
PRLR	B-protein
requires	O
a	O
proline	O
-	O
rich	O
sequence	O
in	O
the	O
membrane	O
proximal	O
region	O
of	O
the	O
receptor	O
,	O
which	O
is	O
conserved	O
among	O
the	O
different	O
members	O
of	O
the	O
cytokine	B-protein
receptor	I-protein
superfamily	I-protein
.	O

Mouse	B-protein
mast	I-protein
cell	I-protein
protease	I-protein
9	I-protein
,	O
a	O
novel	O
member	O
of	O
the	O
chromosome	O
14	O
family	O
of	O
serine	B-protein
proteases	I-protein
that	O
is	O
selectively	O
expressed	O
in	O
uterine	O
mast	O
cells	O
.	O

Inhibition	O
of	O
Fusarium	O
moniliforme	O
var	O
.	O
subglutinans	O
,	O
the	O
causal	O
agent	O
of	O
pine	O
pitch	O
canker	O
,	O
by	O
the	O
soil	O
bacterium	O
Arthrobacter	O
sp	O
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
CKII	B-protein
may	O
act	O
as	O
a	O
positive	O
regulator	O
of	O
myogenesis	O
by	O
preventing	O
E	B-protein
protein	I-protein
homodimers	I-protein
from	O
binding	O
to	O
muscle	O
gene	O
regulatory	O
elements	O
.	O

At	O
the	O
basal	O
unstimulated	O
condition	O
,	O
Ren1d	B-protein
5	I-protein
'	I-protein
flanking	I-protein
sequence	I-protein
in	O
the	O
sense	O
orientation	O
inhibited	O
basal	O
CAT	B-protein
expression	O
from	O
the	O
TK	B-protein
promoter	I-protein
of	O
pUTKAT1	O
,	O
whereas	O
the	O
same	O
sequence	O
in	O
the	O
antisense	O
orientation	O
did	O
not	O
.	O

The	O
adeno	B-protein
-	I-protein
associated	I-protein
virus	I-protein
(	I-protein
AAV	I-protein
)	I-protein
rep	I-protein
gene	I-protein
encodes	O
four	O
proteins	O
(	O
Rep78	B-protein
,	O
Rep68	B-protein
,	O
Rep52	B-protein
,	O
and	O
Rep40	B-protein
)	O
required	O
for	O
AAV	O
DNA	O
replication	O
and	O
AAV	O
gene	O
regulation	O
.	O

Patients	O
with	O
types	O
I	O
and	O
III	O
MPGN	O
did	O
not	O
differ	O
in	O
age	O
at	O
apparent	O
onset	O
,	O
age	O
at	O
diagnosis	O
,	O
or	O
interval	O
from	O
apparent	O
onset	O
of	O
symptoms	O
to	O
diagnosis	O
(	O
biopsy	O
)	O
.	O

The	O
dnaQ	B-protein
-	I-protein
lacZ	I-protein
and	O
the	O
rnh	B-protein
-	I-protein
lacZ	I-protein
fused	I-protein
genes	I-protein
were	O
constructed	O
and	O
hybrid	O
proteins	O
with	O
beta	B-protein
-	I-protein
galactosidase	I-protein
activity	O
were	O
produced	O
.	O

The	O
preferential	O
heterodimerization	O
of	O
USF	B-protein
subunits	I-protein
was	O
reproduced	O
ex	O
vivo	O
,	O
while	O
the	O
in	O
vitro	O
association	O
of	O
cotranslated	O
subunits	O
,	O
or	O
recombinant	B-protein
USF	I-protein
proteins	I-protein
,	O
appeared	O
to	O
be	O
random	O
.	O

In	O
all	O
trials	O
,	O
antigen	O
challenge	O
followed	O
1	O
h	O
after	O
the	O
last	O
treatment	O
.	O

Since	O
considerable	O
variations	O
in	O
length	O
and	O
primary	O
sequence	O
in	O
the	O
CDR3	B-protein
(	O
complementarity	B-protein
determining	I-protein
region	I-protein
)	O
peptides	O
of	O
all	O
the	O
H	B-protein
-	I-protein
chains	I-protein
are	O
evident	O
,	O
conservation	O
of	O
the	O
D	B-protein
-	I-protein
region	I-protein
structure	O
does	O
not	O
appear	O
to	O
be	O
necessary	O
for	O
effective	O
hapten	O
binding	O
.	O

The	O
sequence	O
of	O
four	O
clones	O
was	O
sufficient	O
to	O
construct	O
a	O
3018	B-protein
-	I-protein
bp	I-protein
BAL	I-protein
cDNA	I-protein
structure	O
.	O

This	O
agent	O
,	O
isolated	O
from	O
the	O
fungus	O
Streptomyces	O
tsukubaensis	O
,	O
has	O
a	O
mechanism	O
of	O
action	O
similar	O
to	O
that	O
of	O
cyclosporine	O
.	O

Arnt3	B-protein
mRNA	I-protein
was	O
expressed	O
in	O
brain	O
,	O
skeletal	O
muscle	O
,	O
13	O
.	O
5	O
-	O
day	O
embryos	O
,	O
and	O
P19	O
cells	O
treated	O
with	O
retinoic	O
acid	O
.	O

Neither	O
RD19	B-protein
nor	O
RD21	B-protein
mRNA	I-protein
synthesis	O
was	O
responsive	O
to	O
cold	O
or	O
to	O
heat	O
stress	O
.	O

Diagnostic	O
importance	O
of	O
determining	O
the	O
complement	O
constituents	O
in	O
children	O
with	O
autoimmune	O
thyroiditis	O
.	O

Supplementary	O
Phase	O
Contraste	O
RSE	O
(	O
`	O
`	O
Rapid	O
Sequential	O
Excitation	O
'	O
'	O
)	O
sequences	O
were	O
carried	O
out	O
in	O
29	O
patients	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Between	O
January	O
1992	O
and	O
June	O
1994	O
at	O
St	O
.	O

It	O
is	O
concluded	O
that	O
in	O
patients	O
with	O
first	O
-	O
attack	O
genital	O
herpes	O
,	O
the	O
type	O
of	O
HSV	O
is	O
the	O
most	O
important	O
determinant	O
of	O
subsequent	O
recurrences	O
and	O
that	O
intravenous	O
acyclovir	O
has	O
little	O
effect	O
on	O
subsequent	O
recurrences	O
.	O

The	O
amino	O
acid	O
sequences	O
of	O
the	O
known	O
largest	O
subunits	O
of	O
DdRPs	B-protein
from	O
different	O
species	O
contain	O
highly	O
conserved	O
regions	O
.	O

Facioscapulohumeral	O
muscular	O
dystrophy	O
(	O
FSHD	O
)	O
is	O
an	O
autosomal	O
dominant	O
,	O
neuromuscular	O
disorder	O
characterized	O
by	O
progressive	O
weakness	O
of	O
muscles	O
in	O
the	O
face	O
,	O
shoulder	O
and	O
upper	O
arm	O
.	O

Significantly	O
lower	O
heart	O
rate	O
reactivity	O
and	O
significantly	O
less	O
pronounced	O
left	O
temporal	O
artery	O
pulse	O
amplitude	O
responses	O
were	O
found	O
in	O
non	O
-	O
medicated	O
TH	O
subjects	O
than	O
in	O
controls	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Coronal	O
3D	O
GRE	O
imaging	O
was	O
used	O
to	O
study	O
the	O
volar	O
,	O
middle	O
,	O
and	O
dorsal	O
portions	O
of	O
the	O
SLL	O
in	O
14	O
patients	O
with	O
an	O
arthroscopically	O
normal	O
SLL	O
and	O
in	O
five	O
cadaveric	O
wrists	O
that	O
had	O
a	O
normal	O
SLL	O
proved	O
with	O
dissection	O
.	O

Rex	B-protein
-	I-protein
1	I-protein
,	O
a	O
gene	O
encoding	O
a	O
transcription	O
factor	O
expressed	O
in	O
the	O
early	O
embryo	O
,	O
is	O
regulated	O
via	O
Oct	B-protein
-	I-protein
3	I-protein
/	I-protein
4	I-protein
and	O
Oct	B-protein
-	I-protein
6	I-protein
binding	O
to	O
an	O
octamer	O
site	O
and	O
a	O
novel	O
protein	O
,	O
Rox	B-protein
-	I-protein
1	I-protein
,	O
binding	O
to	O
an	O
adjacent	O
site	O
.	O

The	O
imino	O
proton	O
of	O
T3	O
in	O
the	O
O6meG	O
.	O
T	O
12	O
-	O
mer	O
and	O
G3	O
in	O
the	O
O6meG	O
.	O
N	O
12	O
-	O
mer	O
helix	O
,	O
which	O
are	O
associated	O
with	O
the	O
modification	O
site	O
,	O
resonate	O
at	O
unusually	O
high	O
field	O
(	O
8	O
.	O
5	O
to	O
9	O
.	O
0	O
ppm	O
)	O
compared	O
to	O
imino	O
protons	O
in	O
Watson	O
-	O
Crick	O
base	O
pairs	O
(	O
12	O
.	O
5	O
to	O
14	O
.	O
5	O
ppm	O
)	O
.	O

Update	O
:	O
diphtheria	O
epidemic	O
in	O
the	O
newly	O
independent	O
states	O
of	O
the	O
former	O
USSR	O
,	O
January	O
1995	O
-	O
March	O
1996	O
.	O

The	O
glomerular	O
filtration	O
rate	O
and	O
effective	O
renal	O
plasma	O
flow	O
were	O
determined	O
by	O
a	O
standard	O
clearance	O
method	O
,	O
employing	O
continuous	O
infusion	O
of	O
inulin	O
and	O
para	O
-	O
aminohippuric	O
acid	O
.	O

A	O
TATA	O
-	O
less	O
promoter	O
containing	O
binding	O
sites	O
for	O
ubiquitous	O
transcription	O
factors	O
mediates	O
cell	O
type	O
-	O
specific	O
regulation	O
of	O
the	O
gene	O
for	O
transcription	B-protein
enhancer	I-protein
factor	I-protein
-	I-protein
1	I-protein
(	O
TEF	B-protein
-	I-protein
1	I-protein
)	O
.	O

Analysis	O
of	O
the	O
E2F1	B-protein
gene	I-protein
promoter	I-protein
showed	O
that	O
the	O
-	O
146	O
to	O
-	O
54	O
region	O
was	O
required	O
for	O
E2	O
-	O
responsiveness	O
in	O
transient	O
transfection	O
assays	O
,	O
and	O
subsequent	O
deletion	O
/	O
mutation	O
analysis	O
showed	O
that	O
a	O
single	O
upstream	O
GC	O
-	O
rich	O
and	O
two	O
downstream	O
CCAAT	O
-	O
binding	O
sites	O
were	O
required	O
for	O
transactivation	O
by	O
E2	B-protein
.	O

Most	O
smokers	O
would	O
prefer	O
to	O
quit	O
smoking	O
on	O
their	O
own	O
.	O

Effect	O
of	O
separate	O
and	O
combined	O
effects	O
of	O
plutonium	O
-	O
239	O
,	O
hexachlorobutadiene	O
and	O
tributyl	O
phosphate	O
on	O
the	O
thymus	O
gland	O
of	O
rats	O
.	O

However	O
,	O
the	O
range	O
of	O
values	O
observed	O
is	O
suggestive	O
of	O
the	O
need	O
to	O
investigate	O
districts	O
with	O
contrasting	O
values	O
of	O
SYPLR	O
with	O
respect	O
to	O
the	O
inter	O
-	O
relationships	O
between	O
sociodemographic	O
characteristics	O
,	O
duration	O
of	O
symptoms	O
,	O
clinical	O
presentation	O
and	O
treatment	O
efficacy	O
.	O

IST	B-protein
is	O
not	O
the	O
RNA	O
target	O
(	O
TAR	O
)	O
for	O
Tat	B-protein
trans	O
-	O
activation	O
;	O
however	O
,	O
because	O
it	O
relies	O
entirely	O
on	O
cellular	O
factors	O
for	O
activity	O
,	O
IST	B-protein
may	O
serve	O
to	O
provide	O
abundant	O
RNA	O
targets	O
for	O
Tat	B-protein
trans	O
-	O
activation	O
without	O
a	O
requirement	O
for	O
full	O
-	O
length	O
viral	O
mRNA	O
expression	O
.	O

Immunocytochemical	O
analysis	O
demonstrated	O
the	O
presence	O
of	O
DREF	B-protein
polypeptide	I-protein
in	O
nuclei	O
after	O
the	O
eighth	O
nuclear	O
division	O
cycle	O
,	O
suggesting	O
that	O
nuclear	O
accumulation	O
of	O
DREF	B-protein
is	O
important	O
for	O
the	O
coordinate	O
zygotic	O
expression	O
of	O
DNA	O
replication	O
-	O
related	O
genes	O
carrying	O
DRE	B-protein
sequences	I-protein
.	O

Mean	O
growth	O
changes	O
in	O
this	O
Class	O
II	O
sample	O
were	O
comparable	O
to	O
those	O
previously	O
reported	O
for	O
male	O
subjects	O
with	O
Class	O
I	O
malocclusions	O
over	O
the	O
same	O
age	O
period	O
,	O
suggesting	O
a	O
similarity	O
in	O
postpubertal	O
development	O
between	O
these	O
two	O
groups	O
.	O

Large	O
genomic	O
constructs	O
integrate	O
at	O
the	O
endogenous	O
locus	O
by	O
homologous	O
recombination	O
,	O
but	O
cDNA	O
-	O
derived	O
sequences	O
lacking	O
long	O
stretches	O
of	O
contiguous	O
genomic	O
DNA	O
(	O
due	O
to	O
intron	O
excision	O
)	O
typically	O
integrate	O
into	O
chromosomal	O
DNA	O
by	O
nonhomologous	O
recombination	O
.	O

Unlike	O
most	O
other	O
members	O
of	O
the	O
Bcl	B-protein
-	I-protein
2	I-protein
family	I-protein
,	O
BAD	B-protein
(	O
Bcl	B-protein
-	I-protein
xL	I-protein
/	I-protein
Bcl	I-protein
-	I-protein
2	I-protein
associated	I-protein
death	I-protein
promoter	I-protein
)	O
,	O
a	O
death	B-protein
enhancer	I-protein
,	O
has	O
no	O
C	O
-	O
terminal	O
transmembrane	O
domain	O
for	O
targeting	O
to	O
the	O
outer	O
mitochondrial	O
membrane	O
and	O
nuclear	O
envelope	O
.	O

Analysis	O
of	O
promoter	O
and	O
androgen	O
regulatory	O
sequences	O
required	O
for	O
optimal	O
transcription	O
of	O
the	O
rat	O
androgen	B-protein
-	I-protein
binding	I-protein
protein	I-protein
gene	O
.	O

These	O
results	O
suggest	O
that	O
the	O
negative	O
inotropic	O
action	O
of	O
nicorandil	O
is	O
caused	O
by	O
inhibition	O
of	O
Ca	O
influx	O
and	O
intracellular	O
mobilization	O
of	O
Ca	O
.	O

Plasma	O
membranes	O
of	O
cultured	O
cells	O
contain	O
high	O
affinity	O
receptors	O
for	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
that	O
appear	O
to	O
mediate	O
removal	O
of	O
excess	O
intracellular	O
cholesterol	O
.	O

Interventions	O
aimed	O
at	O
these	O
specific	O
mediators	O
and	O
processes	O
may	O
be	O
successful	O
in	O
reducing	O
the	O
very	O
significant	O
human	O
and	O
economic	O
costs	O
of	O
vascular	O
access	O
dysfunction	O
.	O

Despite	O
the	O
high	O
frequency	O
of	O
natural	O
infection	O
,	O
the	O
seropositive	O
rates	O
of	O
JEV	O
antibody	O
still	O
correlated	O
well	O
with	O
the	O
dose	O
of	O
vaccine	O
received	O
,	O
i	O
.	O
e	O
.	O
,	O
67	O
%	O
(	O
1122	O
/	O
1664	O
)	O
,	O
66	O
%	O
(	O
65	O
/	O
97	O
)	O
,	O
33	O
%	O
(	O
4	O
/	O
12	O
)	O
and	O
40	O
%	O
(	O
19	O
/	O
47	O
)	O
for	O
children	O
receiving	O
3	O
,	O
2	O
,	O
1	O
,	O
and	O
0	O
dose	O
of	O
JE	O
vaccines	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
0001	O
Chi	O
-	O
square	O
for	O
trend	O
test	O
)	O
.	O

Isolated	O
proteinuria	O
(	O
i	O
.	O
e	O
.	O
without	O
hematuria	O
and	O
/	O
or	O
pyuria	O
)	O
is	O
a	O
frequent	O
finding	O
.	O

Concomitantly	O
,	O
p34CDC2	B-protein
histone	I-protein
H1	I-protein
kinase	I-protein
activity	O
increases	O
in	O
the	O
former	O
,	O
but	O
not	O
in	O
the	O
latter	O
cell	O
lines	O
,	O
hence	O
suggesting	O
a	O
role	O
for	O
this	O
protein	O
in	O
radiation	O
-	O
induced	O
cell	O
death	O
.	O

Although	O
the	O
fertility	O
decline	O
in	O
the	O
black	O
population	O
in	O
the	O
Mississippi	O
Delta	O
between	O
the	O
late	O
1870	O
'	O
s	O
and	O
early	O
1930	O
'	O
s	O
closely	O
paralleled	O
that	O
of	O
the	O
national	O
black	O
population	O
,	O
it	O
rose	O
much	O
more	O
dramatically	O
in	O
the	O
1940	O
'	O
s	O
and	O
1950	O
'	O
s	O
to	O
almost	O
1880	O
levels	O
.	O

During	O
a	O
28	O
-	O
week	O
promotion	O
bioassay	O
,	O
groups	O
of	O
30	O
male	O
CD	B-protein
-	I-protein
1	I-protein
mice	O
were	O
treated	O
once	O
with	O
50	O
microliter	O
of	O
either	O
DMBA	O
(	O
1	O
.	O
0	O
mg	O
/	O
ml	O
)	O
or	O
acetone	O
,	O
rested	O
for	O
2	O
weeks	O
,	O
and	O
then	O
treated	O
twice	O
per	O
week	O
with	O
test	O
material	O
for	O
the	O
remaining	O
25	O
weeks	O
.	O

Retransformation	O
of	O
uvsH77	B-protein
mutants	I-protein
with	O
the	O
rescued	O
cosmids	O
from	O
the	O
MMS	O
-	O
resistant	O
transformants	O
resulted	O
in	O
restoration	O
of	O
both	O
UV	O
and	O
MMS	O
resistance	O
to	O
wild	O
-	O
type	O
levels	O
.	O

Similar	O
mechanisms	O
leading	O
to	O
deregulation	O
of	O
Tcf	B-protein
target	I-protein
gene	I-protein
activity	O
are	O
likely	O
to	O
be	O
involved	O
in	O
melanoma	O
and	O
other	O
forms	O
of	O
cancer	O
.	O

However	O
,	O
there	O
was	O
a	O
difference	O
in	O
the	O
quality	O
of	O
immunity	O
:	O
fever	O
and	O
body	O
weight	O
loss	O
were	O
seen	O
in	O
hamsters	O
vaccinated	O
with	O
the	O
killed	O
-	O
toxoplasma	O
vaccine	O
after	O
they	O
were	O
challenge	O
exposed	O
with	O
T	O
-	O
1	O
strain	O
,	O
whereas	O
these	O
changes	O
were	O
rarely	O
seen	O
in	O
hamsters	O
given	O
the	O
live	O
-	O
toxoplasma	O
vaccine	O
and	O
then	O
challenge	O
exposed	O
with	O
RH	O
strain	O
.	O

We	O
analyzed	O
serial	O
biopsy	O
specimens	O
from	O
eight	O
patients	O
with	O
FL	O
for	O
secondary	O
alterations	O
of	O
the	O
rearranged	B-protein
bcl	I-protein
-	I-protein
2	I-protein
gene	I-protein
in	O
the	O
breakpoint	O
and	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
regions	O
.	O

Eight	O
of	O
14	O
infectious	O
or	O
inflammatory	O
lesions	O
could	O
be	O
detected	O
in	O
the	O
early	O
scan	O
(	O
4	O
-	O
6	O
h	O
p	O
.	O
i	O
.	O
)	O
.	O

In	O
the	O
adult	O
mouse	O
,	O
ERR	B-protein
alpha	I-protein
is	O
most	O
highly	O
expressed	O
in	O
kidney	O
,	O
heart	O
,	O
and	O
brown	O
adipocytes	O
,	O
tissues	O
which	O
preferentially	O
metabolize	O
fatty	O
acids	O
.	O

The	O
pentafluorobenzyl	O
derivative	O
of	O
clonidine	O
yields	O
an	O
intense	O
ion	O
fragment	O
at	O
m	O
/	O
z	O
354	O
,	O
and	O
the	O
lower	O
limit	O
of	O
detection	O
is	O
0	O
.	O
025	O
ng	O
/	O
ml	O
for	O
a	O
1	O
-	O
ml	O
plasma	O
sample	O
.	O

We	O
recently	O
reported	O
the	O
molecular	O
cloning	O
of	O
a	O
PL	B-protein
scramblase	I-protein
of	O
human	O
(	O
HuPLSCR1	B-protein
)	O
and	O
mouse	O
origin	O
,	O
respectively	O
.	O

However	O
,	O
unlike	O
Bcl	B-protein
-	I-protein
2	I-protein
and	O
the	O
E1B	B-protein
19K	I-protein
proteins	I-protein
,	O
which	O
completely	O
block	O
apoptosis	O
but	O
not	O
p53	O
-	O
dependent	O
growth	O
arrest	O
,	O
H	B-protein
-	I-protein
ras	I-protein
expression	O
permitted	O
DNA	O
synthesis	O
and	O
cell	O
proliferation	O
in	O
the	O
presence	O
of	O
high	O
levels	O
of	O
wild	B-protein
-	I-protein
type	I-protein
p53	I-protein
.	O

Of	O
these	O
proteins	O
,	O
five	O
have	O
previously	O
been	O
shown	O
to	O
be	O
phosphorylated	O
during	O
mitosis	O
(	O
epithelial	B-protein
-	I-protein
microtubule	I-protein
associated	I-protein
protein	I-protein
-	I-protein
115	I-protein
,	O
Oct91	B-protein
,	O
Elongation	B-protein
factor	I-protein
1gamma	I-protein
,	O
BRG1	B-protein
and	O
Ribosomal	B-protein
protein	I-protein
L18A	I-protein
)	O
,	O
five	O
are	O
related	O
to	O
proteins	O
postulated	O
to	O
have	O
roles	O
in	O
mitosis	O
(	O
epithelial	B-protein
-	I-protein
microtubule	I-protein
associated	I-protein
protein	I-protein
-	I-protein
115	I-protein
,	O
Schizosaccharomyces	B-protein
pombe	I-protein
Cdc5	I-protein
,	O
innercentrosome	B-protein
protein	I-protein
,	O
BRG1	B-protein
and	O
the	O
RNA	B-protein
helicase	I-protein
WM6	I-protein
)	O
,	O
and	O
nine	O
are	O
related	O
to	O
transcription	O
factors	O
(	O
BRG1	B-protein
,	O
negative	B-protein
co	I-protein
-	I-protein
factor	I-protein
2alpha	I-protein
,	O
Oct91	B-protein
,	O
S	O
.	O
pombe	O
Cdc5	B-protein
,	O
HoxD1	B-protein
,	O
Sox3	B-protein
,	O
Vent2	B-protein
,	O
and	O
two	O
isoforms	O
of	O
Xbr1b	B-protein
)	O
.	O

Caution	O
should	O
be	O
exercised	O
in	O
the	O
use	O
of	O
these	O
dyes	O
for	O
lymphograms	O
.	O

In	O
addition	O
,	O
mutation	O
of	O
the	O
Sp1	B-protein
site	I-protein
also	O
significantly	O
reduced	O
promoter	O
activity	O
.	O

This	O
conclusion	O
is	O
based	O
on	O
the	O
observations	O
of	O
the	O
immunologic	O
changes	O
that	O
characterize	O
the	O
acute	O
stages	O
of	O
illness	O
as	O
well	O
as	O
on	O
the	O
demonstrated	O
association	O
with	O
toxin	O
-	O
producing	O
bacteria	O
in	O
the	O
pharynx	O
and	O
gastrointestinal	O
tract	O
.	O

RESULTS	O
:	O
Sixty	O
per	O
cent	O
of	O
African	O
Americans	O
exposed	O
in	O
26	O
community	O
outbreaks	O
were	O
TST	O
positive	O
compared	O
to	O
only	O
40	O
%	O
of	O
whites	O
following	O
comparable	O
exposures	O
.	O

Botulinum	B-protein
toxin	I-protein
:	O
preferred	O
treatment	O
for	O
hemifacial	O
spasm	O
.	O

Objective	O
:	O
To	O
evaluate	O
endometrial	O
thickness	O
and	O
the	O
incidence	O
of	O
uterine	O
bleeding	O
in	O
postmenopausal	O
women	O
using	O
either	O
tibolone	O
2	O
.	O
5	O
mg	O
or	O
continuous	O
combined	O
2	O
mg	O
estradiol	O
and	O
1	O
mg	O
norethisterone	O
acetate	O
(	O
E	O
+	O
NETA	O
)	O
daily	O
as	O
hormone	O
replacement	O
therapy	O
.	O

Nerve	O
stimulation	O
(	O
1	O
.	O
5	O
-	O
12	O
cycles	O
/	O
s	O
)	O
produced	O
frequency	O
-	O
dependent	O
reductions	O
in	O
CBF	O
,	O
a	O
decrease	O
of	O
50	O
percent	O
occurring	O
with	O
the	O
highest	O
frequency	O
.	O

Sibling	O
aggregation	O
of	O
low	O
-	O
and	O
high	O
-	O
density	O
lipoprotein	O
cholesterol	O
and	O
apolipoproteins	B-protein
B	I-protein
and	O
A	B-protein
-	I-protein
I	I-protein
levels	O
in	O
black	O
and	O
white	O
children	O
:	O
the	O
Bogalusa	O
Heart	O
Study	O
.	O

EMSA	O
showed	O
that	O
nuclear	O
proteins	O
from	O
PC12	O
but	O
not	O
C6	O
or	O
Rat2	O
cells	O
bind	O
the	O
CRE	B-protein
as	O
a	O
complex	O
containing	O
activating	B-protein
transcription	I-protein
factor	I-protein
(	I-protein
ATF	I-protein
)	I-protein
-	I-protein
4	I-protein
and	O
CCAAT	B-protein
enhancer	I-protein
-	I-protein
binding	I-protein
protein	I-protein
beta	I-protein
,	O
while	O
both	O
PC12	O
and	O
C6	O
cell	O
nuclear	O
extracts	O
were	O
recruited	O
by	O
the	O
CCAAT	O
-	O
box	O
as	O
a	O
complex	O
containing	O
nuclear	B-protein
factor	I-protein
Y	I-protein
.	O

Auditory	O
-	O
visual	O
interaction	O
in	O
the	O
generation	O
of	O
saccades	O
in	O
man	O
.	O

In	O
addition	O
,	O
a	O
noncanonical	O
C	B-protein
/	I-protein
EBP	I-protein
-	I-protein
binding	I-protein
site	I-protein
within	O
the	O
Gadd45gamma	B-protein
promoter	I-protein
where	O
C	B-protein
/	I-protein
EBPbeta	I-protein
and	O
C	B-protein
/	I-protein
EBPdelta	I-protein
could	O
bind	O
,	O
was	O
identified	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
reporter	O
gene	O
analysis	O
.	O

BCR	B-protein
-	I-protein
ABL	I-protein
and	O
v	B-protein
-	I-protein
abl	I-protein
oncogenes	I-protein
induce	O
distinct	O
patterns	O
of	O
thymic	O
lymphoma	O
involving	O
different	O
lymphocyte	O
subsets	O
.	O

Biometric	O
analysis	O
of	O
intraocular	O
lens	O
power	O
required	O
to	O
produce	O
emmetropia	O
:	O
results	O
of	O
450	O
implants	O
.	O

There	O
was	O
a	O
trend	O
toward	O
an	O
association	O
between	O
IENF	O
and	O
sural	O
nerve	O
unmyelinated	O
fiber	O
densities	O
(	O
r	O
=	O
0	O
.	O
32	O
,	O
p	O
=	O
0	O
.	O
054	O
)	O
.	O

CDNA	O
cloning	O
of	O
chick	B-protein
brain	I-protein
alpha	I-protein
-	I-protein
amino	I-protein
-	I-protein
3	I-protein
-	I-protein
hydroxy	I-protein
-	I-protein
5	I-protein
-	I-protein
methyl	I-protein
-	I-protein
4	I-protein
-	I-protein
isoxazolepropionic	I-protein
acid	I-protein
receptors	I-protein
reveals	O
conservation	O
of	O
structure	O
,	O
function	O
and	O
post	O
-	O
transcriptional	O
processes	O
with	O
mammalian	O
receptors	O
.	O

The	O
apparent	O
Kd	O
of	O
the	O
MetRS	B-protein
/	I-protein
CAU	I-protein
operator	I-protein
complex	I-protein
is	O
one	O
order	O
magnitude	O
higher	O
than	O
that	O
of	O
the	O
ThrRS	B-protein
/	I-protein
CGU	I-protein
operator	I-protein
complex	I-protein
.	O

Deletional	O
analyses	O
of	O
VDR	B-protein
indicated	O
that	O
GRIP1	B-protein
and	O
RAC3	B-protein
required	O
an	O
intact	O
VDR	B-protein
activation	I-protein
function	I-protein
(	I-protein
AF	I-protein
-	I-protein
2	I-protein
)	I-protein
domain	I-protein
for	O
efficient	O
interaction	O
as	O
well	O
as	O
additional	O
but	O
distinct	O
regions	O
of	O
the	O
VDR	B-protein
.	O

Sequence	O
comparisons	O
strongly	O
suggest	O
that	O
the	O
S27a	B-protein
and	O
the	O
ubiquitin	B-protein
coding	O
sequences	O
found	O
in	O
the	O
genome	O
of	O
CP	O
Rit	O
were	O
both	O
derived	O
from	O
a	O
bovine	O
mRNA	O
encoding	O
a	O
hybrid	O
protein	O
with	O
the	O
structure	O
NH2	B-protein
-	I-protein
ubiquitin	I-protein
-	I-protein
S27a	I-protein
-	I-protein
COOH	I-protein
.	O

Kinetics	O
of	O
the	O
inhibition	O
indicated	O
that	O
this	O
polymerase	B-protein
domain	I-protein
can	O
inhibit	O
viral	O
replication	O
only	O
during	O
the	O
preinitiation	O
stage	O
.	O

The	O
reduced	O
NO	O
production	O
in	O
these	O
cells	O
was	O
associated	O
with	O
low	O
levels	O
of	O
mRNA	O
of	O
inducible	B-protein
NO	I-protein
synthetase	I-protein
.	O

We	O
found	O
that	O
virulent	O
Ngo	O
strains	O
induce	O
phosphorylation	O
and	O
activation	O
of	O
JNK	B-protein
but	O
not	O
of	O
p38	B-protein
kinase	I-protein
.	O

In	O
terms	O
of	O
sequence	O
repetitions	O
,	O
seven	O
tandemly	O
repeated	O
copies	O
of	O
the	O
hexanucleotide	B-protein
ATTGTT	I-protein
and	O
three	O
flanking	O
regions	O
of	O
dyad	O
symmetry	O
were	O
detected	O
,	O
all	O
in	O
ORF	B-protein
T3C	I-protein
.	O

The	O
cDNA	O
encoded	O
a	O
mature	O
protein	O
of	O
240	O
amino	O
acids	O
,	O
including	O
a	O
29	O
-	O
amino	O
acid	O
signal	O
sequence	O
.	O

Cdk2	B-protein
formed	O
a	O
complex	O
with	O
cyclin	B-protein
D1	I-protein
in	O
this	O
system	O
.	O

Biological	O
properties	O
of	O
sumithion	O
.	O

These	O
results	O
suggest	O
that	O
different	O
models	O
of	O
intestinal	O
ischemia	O
have	O
different	O
cytokine	O
profiles	O
and	O
that	O
the	O
early	O
TNF	B-protein
response	O
associated	O
with	O
SMA	O
occlusion	O
model	O
is	O
primarily	O
due	O
to	O
the	O
laparotomy	O
.	O

An	O
in	O
vitro	O
binding	O
site	O
selection	O
procedure	O
was	O
used	O
to	O
determine	O
DNA	O
sequences	O
preferentially	O
bound	O
by	O
wild	B-protein
-	I-protein
type	I-protein
HLF	I-protein
and	O
chimeric	B-protein
E2A	I-protein
-	I-protein
HLF	I-protein
proteins	I-protein
isolated	O
from	O
various	O
t	O
(	O
17	O
;	O
19	O
)	O
-	O
bearing	O
leukemias	O
.	O

The	O
science	O
of	O
tissue	O
engineering	O
.	O

The	O
inferred	O
amino	O
acid	O
sequence	O
of	O
the	O
cyanobacterial	B-protein
HemB	I-protein
protein	I-protein
indicates	O
a	O
significant	O
difference	O
in	O
the	O
metal	O
cofactor	O
requirement	O
from	O
the	O
higher	O
-	O
plant	O
enzymes	O
,	O
which	O
was	O
confirmed	O
by	O
overexpression	O
and	O
biochemical	O
analysis	O
.	O

Besides	O
,	O
it	O
was	O
considered	O
that	O
the	O
NPF	O
was	O
a	O
useful	O
tool	O
for	O
activation	O
of	O
velopharyngeal	O
activity	O
by	O
way	O
of	O
visual	O
feed	O
-	O
back	O
control	O
.	O

Using	O
these	O
antibodies	O
,	O
we	O
were	O
able	O
to	O
define	O
the	O
conditions	O
to	O
completely	O
solubilize	O
the	O
Cdc25	B-protein
protein	I-protein
.	O

Here	O
,	O
we	O
report	O
the	O
characterization	O
of	O
an	O
alternatively	O
processed	O
form	O
of	O
AFAP	B-protein
-	I-protein
110	I-protein
that	O
encodes	O
an	O
additional	O
258	O
base	O
pair	O
(	O
bp	O
)	O
of	O
open	O
reading	O
frame	O
.	O

2	O
Silastic	O
capsules	O
,	O
each	O
containing	O
22	O
-	O
23	O
mg	O
of	O
ethinyl	O
estradiol	O
,	O
were	O
inserted	O
subcutaneously	O
in	O
5	O
men	O
with	O
benign	O
prostatic	O
hypertrophy	O
.	O

Sixty	O
-	O
one	O
cases	O
of	O
cholera	O
,	O
all	O
caused	O
by	O
V	O
.	O
cholerae	O
O1	O
,	O
were	O
reported	O
.	O

Multiple	O
chemical	O
sensitivity	O
(	O
MCS	O
)	O
is	O
a	O
syndrome	O
in	O
which	O
multiple	O
symptoms	O
reportedly	O
occur	O
with	O
low	O
-	O
level	O
chemical	O
exposure	O
.	O

The	O
minimum	O
and	O
essential	O
subunits	O
for	O
RNA	O
synthesis	O
have	O
not	O
yet	O
been	O
identified	O
.	O

Induced	O
gamma	O
-	O
ray	O
spectroscopy	O
.	O

We	O
compared	O
the	O
efficacy	O
and	O
costs	O
of	O
valacyclovir	O
in	O
preventing	O
HSV	O
reactivation	O
among	O
HSV	O
seropositive	O
autologous	O
progenitor	O
cell	O
transplantation	O
(	O
APCT	O
)	O
patients	O
with	O
historical	O
controls	O
in	O
whom	O
intravenous	O
acyclovir	O
or	O
no	O
HSV	O
prophylaxis	O
were	O
used	O
.	O

Frozen	O
/	O
thawed	O
extensor	O
digitorum	O
longus	O
muscle	O
tendon	O
units	O
had	O
significantly	O
lower	O
values	O
for	O
load	O
to	O
failure	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
energy	O
absorbed	O
to	O
failure	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
strain	O
at	O
failure	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
they	O
tended	O
to	O
fail	O
at	O
a	O
different	O
anatomic	O
location	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
(	O
broadly	O
at	O
the	O
fascia	O
-	O
muscle	O
interface	O
as	O
compared	O
with	O
horizontally	O
at	O
the	O
musculotendinous	O
junction	O
)	O
than	O
fresh	O
units	O
.	O

Latexin	B-protein
,	O
a	O
carboxypeptidase	B-protein
A	I-protein
inhibitor	O
,	O
is	O
expressed	O
in	O
a	O
cell	O
type	O
-	O
specific	O
manner	O
in	O
both	O
central	O
and	O
peripheral	O
nervous	O
systems	O
in	O
the	O
rat	O
.	O

We	O
show	O
here	O
that	O
the	O
protein	B-protein
kinase	I-protein
MEKK1	I-protein
can	O
induce	O
reporter	O
gene	O
expression	O
from	O
the	O
atrial	B-protein
natriuretic	I-protein
factor	I-protein
(	O
ANF	B-protein
)	O
promoter	O
,	O
a	O
genetic	O
marker	O
that	O
is	O
activated	O
during	O
in	O
vivo	O
hypertrophy	O
.	O

The	O
other	O
hypoglycaemic	O
patient	O
showed	O
an	O
exaggerated	O
insulin	B-protein
release	O
in	O
response	O
to	O
tolbutamide	O
.	O

In	O
addition	O
,	O
the	O
regulation	O
of	O
Glvr	B-protein
-	I-protein
1	I-protein
gene	I-protein
expression	O
also	O
has	O
potential	O
applications	O
to	O
gene	O
therapy	O
,	O
since	O
retroviral	O
vectors	O
carrying	O
gibbon	B-protein
ape	I-protein
leukemia	I-protein
virus	I-protein
envelope	I-protein
proteins	I-protein
are	O
used	O
for	O
gene	O
delivery	O
into	O
different	O
cell	O
types	O
.	O

The	O
motor	O
unit	O
viewed	O
from	O
above	O
.	O
pp	O
.	O

The	O
method	O
also	O
eliminates	O
tagging	O
of	O
venous	O
spins	O
and	O
concern	O
about	O
asymmetric	O
magnetization	O
transfer	O
effects	O
.	O

MDS1	B-protein
/	I-protein
EVI1	I-protein
,	O
located	O
on	O
chromosome	O
3	O
band	O
q26	O
,	O
encodes	O
a	O
zinc	O
-	O
finger	O
DNA	O
-	O
binding	O
transcription	O
activator	O
not	O
detected	O
in	O
normal	O
hematopoietic	O
cells	O
but	O
expressed	O
in	O
several	O
normal	O
tissues	O
.	O

We	O
have	O
now	O
shown	O
that	O
in	O
vivo	O
phosphorylation	O
of	O
14	B-protein
-	I-protein
3	I-protein
-	I-protein
3	I-protein
zeta	I-protein
at	O
the	O
CKIalpha	B-protein
site	I-protein
(	I-protein
Thr	I-protein
-	I-protein
233	I-protein
)	I-protein
negatively	O
regulates	O
its	O
binding	O
to	O
c	B-protein
-	I-protein
Raf	I-protein
,	O
and	O
may	O
be	O
important	O
in	O
Raf	O
-	O
mediated	O
signal	O
transduction	O
.	O

Fusion	O
of	O
ubiquitin	B-protein
to	O
pADPRP	B-protein
increased	O
the	O
yield	O
of	O
pADPRP	B-protein
approximately	O
10	O
-	O
fold	O
compared	O
to	O
that	O
of	O
the	O
unfused	O
enzyme	O
.	O

Reciprocally	O
,	O
HMGI	B-protein
-	I-protein
C	I-protein
expression	O
also	O
coordinately	O
enhances	O
PIAS3	O
-	O
mediated	O
repression	O
of	O
STAT3	O
-	O
dependent	O
transactivation	O
.	O

The	O
determination	O
of	O
immunoglobulin	B-protein
E	I-protein
(	O
IgE	B-protein
)	O
antibodies	O
by	O
one	O
of	O
several	O
laboratory	O
tests	O
,	O
by	O
skin	O
-	O
prick	O
tests	O
or	O
by	O
appropriate	O
challenge	O
procedures	O
is	O
useful	O
either	O
to	O
identify	O
atopic	O
individuals	O
or	O
as	O
outcome	O
predictors	O
in	O
wheezy	O
children	O
.	O

A	O
P22	B-protein
R17	I-protein
derivative	I-protein
with	O
an	O
OcRNA	B-protein
site	I-protein
(	O
P22	B-protein
R17	I-protein
[	I-protein
A	I-protein
(	I-protein
-	I-protein
10	I-protein
)	I-protein
U	I-protein
]	I-protein
)	I-protein
develops	O
lytically	O
following	O
infection	O
of	O
these	O
strains	O
.	O

Determinants	O
of	O
recurrent	O
ischaemia	O
and	O
revascularisation	O
procedures	O
after	O
thrombolysis	O
with	O
recombinant	O
tissue	B-protein
plasminogen	I-protein
activator	I-protein
in	O
primary	O
coronary	O
occlusion	O
.	O

Tumor	O
cell	O
lines	O
transduced	O
at	O
an	O
MOI	O
of	O
8	O
for	O
3	O
days	O
led	O
to	O
>	O
90	O
%	O
gene	O
transfer	O
efficiency	O
.	O

It	O
may	O
also	O
be	O
suggested	O
that	O
particular	O
care	O
should	O
be	O
taken	O
when	O
such	O
a	O
trans	O
-	O
dominant	O
Rev	B-protein
mutant	I-protein
is	O
considered	O
to	O
be	O
used	O
as	O
a	O
genetic	O
therapy	O
against	O
HIV	O
-	O
I	O
infection	O
,	O
in	O
individuals	O
infected	O
with	O
both	O
HIV	O
-	O
I	O
and	O
HTLV	O
-	O
1	O
.	O

These	O
results	O
provide	O
direct	O
evidence	O
for	O
differential	O
susceptibility	O
to	O
endonuclease	O
-	O
mediated	O
mRNA	O
decay	O
resulting	O
from	O
the	O
differential	O
affinity	O
of	O
a	O
RNA	O
-	O
binding	O
protein	O
for	O
cis	O
-	O
acting	O
stability	O
determinants	O
.	O

LH	B-protein
/	I-protein
CG	I-protein
receptor	I-protein
activation	O
of	O
ARNO	B-protein
is	O
not	O
mediated	O
by	O
activation	O
of	O
phosphatidylinositol	B-protein
3	I-protein
-	I-protein
kinase	I-protein
(	O
PI	B-protein
3	I-protein
-	I-protein
kinase	I-protein
)	O
or	O
by	O
G	B-protein
protein	I-protein
beta	I-protein
gamma	I-protein
subunits	I-protein
.	O

A	O
much	O
less	O
expensive	O
solution	O
than	O
UW	O
,	O
containing	O
only	O
K	O
(	O
+	O
)	O
-	O
lactobionate	O
,	O
KH2PO4	O
,	O
MgSO4	O
and	O
raffinose	O
,	O
can	O
be	O
used	O
successfully	O
for	O
preservation	O
of	O
rat	O
hepatocytes	O
for	O
24	O
hr	O
for	O
drug	O
transport	O
studies	O
.	O

Rss1p	B-protein
encodes	O
a	O
novel	O
essential	O
protein	O
of	O
538	O
amino	O
acids	O
,	O
which	O
contains	O
an	O
extended	O
predicted	O
coiled	O
-	O
coil	O
domain	O
and	O
is	O
located	O
both	O
at	O
nuclear	O
pore	O
complexes	O
(	O
NPCs	O
)	O
and	O
in	O
the	O
cytoplasm	O
.	O

In	O
the	O
absence	O
of	O
enhancer	O
sequences	O
,	O
the	O
adenovirus	B-protein
E1A	I-protein
gene	I-protein
can	O
not	O
stimulate	O
CATase	B-protein
synthesis	O
.	O

To	O
characterize	O
the	O
gene	O
products	O
,	O
the	O
cvaA	B-protein
gene	I-protein
was	O
subcloned	O
and	O
expressed	O
under	O
the	O
control	O
of	O
T7	B-protein
RNA	I-protein
polymerase	I-protein
promoter	I-protein
.	O

Three	O
FGF	B-protein
-	I-protein
AS	I-protein
cDNAs	I-protein
were	O
isolated	O
;	O
the	O
full	B-protein
-	I-protein
length	I-protein
FGF	I-protein
-	I-protein
AS	I-protein
mRNA	I-protein
and	O
two	O
alternative	O
splice	O
variants	O
lacking	O
exon	O
2	O
or	O
exons	O
2	O
and	O
3	O
of	O
the	O
FGF	B-protein
-	I-protein
AS	I-protein
sequence	I-protein
.	O

The	O
authors	O
did	O
not	O
detect	O
any	O
significant	O
correlations	O
between	O
parameters	O
of	O
the	O
lipids	O
of	O
bone	O
marrow	O
and	O
leptin	B-protein
levels	O
in	O
serum	O
and	O
bone	O
marrow	O
.	O

We	O
inserted	O
genes	O
or	O
gene	O
segments	O
,	O
that	O
code	O
for	O
the	O
bacterial	B-protein
chloramphenicol	I-protein
acetyltransferase	I-protein
,	O
the	O
bacterial	O
gene	O
conferring	O
resistance	O
against	O
hygromycin	O
,	O
and	O
the	O
ORF	O
E7	B-protein
of	O
the	O
human	O
papillomavirus	O
type	O
18	O
into	O
these	O
vectors	O
.	O

Troglitazone	O
also	O
induced	O
an	O
endogenous	B-protein
PPARgamma	I-protein
target	I-protein
gene	I-protein
in	O
T24	O
cells	O
,	O
adipocyte	B-protein
-	I-protein
type	I-protein
fatty	I-protein
acid	I-protein
binding	I-protein
protein	I-protein
(	O
A	B-protein
-	I-protein
FABP	I-protein
)	O
,	O
the	O
expression	O
of	O
which	O
correlates	O
with	O
bladder	O
cancer	O
differentiation	O
.	O

Bertioga	O
(	O
Guama	O
group	O
)	O
and	O
Anhembi	O
(	O
Bunyamwera	O
group	O
)	O
,	O
two	O
new	O
arboviruses	O
isolated	O
in	O
Sao	O
Paulo	O
,	O
Brazil	O
.	O

The	O
ADP	B-protein
-	I-protein
ribosylation	I-protein
factor	I-protein
(	O
ARF	B-protein
)	O
family	O
is	O
one	O
of	O
four	O
subfamilies	O
of	O
the	O
RAS	B-protein
superfamily	I-protein
of	O
low	B-protein
molecular	I-protein
weight	I-protein
GTP	I-protein
-	I-protein
binding	I-protein
proteins	I-protein
(	O
G	B-protein
proteins	I-protein
)	O
.	O

We	O
found	O
that	O
both	O
the	O
E26	O
virus	O
-	O
encoded	O
v	B-protein
-	I-protein
ets	I-protein
and	O
the	O
myeloid	B-protein
/	I-protein
B	I-protein
-	I-protein
cell	I-protein
-	I-protein
specific	I-protein
factor	I-protein
PU	I-protein
.	I-protein
1	I-protein
bind	O
efficiently	O
to	O
this	O
site	O
in	O
vitro	O
.	O

Cimetidine	O
800	O
mg	O
given	O
at	O
night	O
is	O
as	O
effective	O
as	O
400	O
mg	O
twice	O
daily	O
;	O
the	O
single	O
dose	O
regimen	O
may	O
improve	O
patient	O
compliance	O
,	O
thus	O
facilitating	O
treatment	O
.	O

Quantitative	O
evaluation	O
of	O
magneto	O
-	O
optical	O
parameters	O
is	O
necessary	O
in	O
order	O
to	O
apply	O
scanning	O
near	O
-	O
field	O
optical	O
microscope	O
(	O
SNOM	O
)	O
technology	O
to	O
the	O
study	O
of	O
magnetism	O
on	O
the	O
mesoscopic	O
scale	O
.	O

Identification	O
of	O
five	O
new	O
genes	O
,	O
closely	O
related	O
to	O
the	O
interleukin	B-protein
-	I-protein
1beta	I-protein
converting	I-protein
enzyme	I-protein
gene	I-protein
,	O
that	O
do	O
not	O
encode	O
functional	O
proteases	B-protein
.	O

Colorectal	O
polyps	O
should	O
be	O
removed	O
endoscopically	O
whenever	O
possible	O
.	O

The	O
architecture	O
of	O
microvasculature	O
in	O
these	O
two	O
regions	O
was	O
also	O
examined	O
by	O
scanning	O
electron	O
microscopy	O
,	O
using	O
the	O
resin	O
casting	O
method	O
.	O

Thus	O
,	O
the	O
screen	O
for	O
toxic	O
p53	B-protein
mutants	I-protein
in	O
yeast	O
can	O
identify	O
novel	O
p53	B-protein
variants	O
that	O
may	O
be	O
useful	O
in	O
dissecting	O
p53	B-protein
regulated	O
cellular	O
responses	O
and	O
in	O
developing	O
p53	O
-	O
based	O
cancer	O
therapies	O
.	O

Cases	O
of	O
lung	O
cancer	O
with	O
intramedullary	O
metastasis	O
are	O
rare	O
,	O
especially	O
those	O
diagnosed	O
before	O
death	O
.	O

The	O
new	O
algorithm	O
,	O
called	O
RBI	O
-	O
MAP	O
,	O
is	O
based	O
on	O
the	O
rescaled	O
block	O
iterative	O
EM	O
(	O
RBI	O
-	O
EM	O
)	O
algorithm	O
.	O

These	O
results	O
suggested	O
the	O
possibility	O
that	O
the	O
fetus	O
played	O
some	O
role	O
in	O
the	O
production	O
of	O
E3	O
-	O
16	O
-	O
G	O
in	O
early	O
pregnancy	O
.	O

Respiratory	O
interaction	O
after	O
spinal	O
anesthesia	O
and	O
sedation	O
with	O
midazolam	O
.	O

The	O
percentages	O
of	O
formed	O
cysts	O
and	O
growth	O
rates	O
were	O
monthly	O
estimated	O
and	O
analyzed	O
rhythmometrically	O
by	O
cosinor	O
for	O
5	O
clonal	O
cultures	O
of	O
Scripsiella	O
trochoidea	O
Stein	O
grown	O
for	O
2	O
years	O
under	O
laboratory	O
conditions	O
,	O
rended	O
as	O
constant	O
as	O
possible	O
from	O
the	O
view	O
point	O
of	O
environmental	O
temperature	O
(	O
24	O
+	O
/	O
-	O
1	O
degree	O
C	O
)	O
,	O
lighting	O
(	O
25	O
microEin	O
m	O
-	O
2	O
s	O
-	O
1	O
)	O
,	O
and	O
artificial	O
seawater	O
.	O

Antenatal	O
diagnosis	O
of	O
haematological	O
disorders	O
-	O
-	O
'	O
1978	O
'	O
.	O

The	O
results	O
point	O
to	O
the	O
effectiveness	O
of	O
the	O
educational	O
intervention	O
.	O

Descriptions	O
of	O
this	O
locus	O
would	O
allow	O
comparison	O
with	O
functionally	O
relevant	O
molecular	O
genetic	O
features	O
of	O
other	O
species	O
'	O
homologous	O
loci	O
including	O
the	O
single	O
-	O
copy	O
equid	B-protein
LH	I-protein
/	I-protein
CGbeta	I-protein
gene	I-protein
and	O
the	O
primate	B-protein
LHbeta	I-protein
-	I-protein
CGbeta	I-protein
gene	I-protein
cluster	I-protein
locus	I-protein
.	O

In	O
contrast	O
to	O
the	O
morphological	O
criteria	O
,	O
the	O
few	O
data	O
available	O
from	O
recent	O
studies	O
at	O
the	O
genetic	O
level	O
have	O
suggested	O
that	O
EPVs	O
infecting	O
different	O
insect	O
orders	O
are	O
phylogenetically	O
distant	O
.	O

To	O
assess	O
the	O
effects	O
of	O
alveolar	O
hypoxia	O
and	O
angiotensin	B-protein
II	I-protein
infusion	O
on	O
distribution	O
of	O
blood	O
flow	O
to	O
the	O
lung	O
we	O
performed	O
perfusion	O
lung	O
scans	O
on	O
anesthetized	O
mechanically	O
ventilated	O
lambs	O
.	O

Its	O
clinical	O
and	O
histopathologic	O
characteristics	O
.	O

A	O
1	B-protein
.	I-protein
5	I-protein
-	I-protein
kb	I-protein
HindIII	I-protein
genomic	I-protein
fragment	I-protein
carrying	I-protein
the	I-protein
vspA	I-protein
gene	I-protein
from	O
M	O
.	O
bovis	O
PG45	O
was	O
cloned	O
and	O
sequenced	O
.	O

Cerebrospinal	O
fluid	O
transferrin	B-protein
II	I-protein
studies	O
in	O
ischemic	O
disorders	O
of	O
the	O
central	O
nervous	O
system	O
.	O

These	O
results	O
suggest	O
that	O
Cdc42p	B-protein
is	O
in	O
fact	O
required	O
for	O
pheromone	O
response	O
and	O
that	O
interaction	O
with	O
the	O
PAK	B-protein
Ste20p	I-protein
is	O
critical	O
for	O
that	O
role	O
.	O

C	O
.	O
elegans	O
embryogenesis	O
begins	O
with	O
a	O
stereotyped	O
sequence	O
of	O
asymmetric	O
cell	O
divisions	O
that	O
are	O
largely	O
responsible	O
for	O
establishing	O
the	O
nematode	O
body	O
plan	O
.	O

The	O
HBP	B-protein
gene	I-protein
is	O
composed	O
of	O
eight	O
exons	O
covering	O
19	O
.	O
5	O
kb	O
on	O
the	O
short	O
arm	O
of	O
chromosome	O
4	O
.	O

Bilateral	O
Charnley	O
arthroplasty	O
as	O
a	O
single	O
procedure	O
.	O

It	O
is	O
likely	O
that	O
the	O
sequence	O
similarities	O
reflect	O
a	O
common	O
molecular	O
architecture	O
of	O
the	O
two	O
heme	O
binding	O
sites	O
and	O
of	O
a	O
copper	O
binding	O
site	O
in	O
these	O
enzymes	O
.	O

Five	O
of	O
the	O
PDP1	B-protein
isoforms	I-protein
differ	O
by	O
the	O
substitution	O
or	O
insertion	O
of	O
amino	O
acids	O
at	O
or	O
near	O
the	O
N	O
-	O
terminal	O
of	O
the	O
protein	O
.	O

In	O
the	O
long	O
term	O
,	O
questions	O
still	O
remain	O
about	O
whether	O
pre	O
-	O
dialysis	O
rHu	B-protein
EPO	I-protein
either	O
speeds	O
up	O
or	O
delays	O
the	O
onset	O
of	O
dialysis	O
.	O

T	O
.	O
,	O
Mahasneh	O
,	O
A	O
.	O
,	O
and	O
Cote	O
,	O
G	O
.	O

In	O
both	O
cities	O
,	O
HTLV	O
-	O
I	O
/	O
II	O
prevalence	O
increased	O
significantly	O
with	O
age	O
,	O
and	O
the	O
New	O
Orleans	O
age	O
-	O
and	O
sex	O
-	O
adjusted	O
HTLV	O
-	O
I	O
/	O
II	O
prevalence	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
Baltimore	O
(	O
P	O
less	O
than	O
.	O
001	O
)	O
.	O

As	O
well	O
,	O
further	O
deletion	O
of	O
the	O
promoter	O
region	O
to	O
nucleotide	O
-	O
110	O
,	O
which	O
contains	O
only	O
one	O
SF	B-protein
-	I-protein
1	I-protein
binding	I-protein
site	I-protein
,	O
still	O
retained	O
the	O
ability	O
to	O
respond	O
to	O
exogenous	O
SF	B-protein
-	I-protein
1	I-protein
.	O

Structural	O
characteristics	O
of	O
the	O
erythrocyte	O
membrane	O
,	O
peroxidation	O
processes	O
and	O
antioxidant	O
function	O
in	O
children	O
with	O
diffuse	O
glomerulonephritis	O
.	O

In	O
the	O
tissues	O
tested	O
,	O
except	O
brain	O
,	O
the	O
message	O
for	O
CLIP	B-protein
-	I-protein
170	I-protein
was	O
more	O
abundant	O
than	O
that	O
for	O
Restin	B-protein
.	O

Promoter	O
elements	O
include	O
an	O
atypical	O
TATA	O
box	O
(	O
GTTA	O
)	O
,	O
one	O
CCAAT	O
box	O
much	O
further	O
from	O
the	O
initiation	O
site	O
,	O
three	O
reverse	O
compliments	O
of	O
CCAAT	O
(	O
ATTGG	O
)	O
,	O
and	O
two	O
pyrimidine	O
-	O
rich	O
nucleotide	O
stretches	O
.	O

M	O
.	O
M	O
.	O
C	O
.	O
was	O
used	O
for	O
2	O
.	O
5	O
minutes	O
in	O
44	O
cases	O
(	O
20	O
HR	O
patients	O
,	O
24	O
LR	O
patients	O
)	O
,	O
and	O
for	O
5	O
minutes	O
in	O
66	O
cases	O
(	O
46	O
HR	O
patients	O
,	O
20	O
LR	O
patients	O
)	O
.	O

In	O
HCMV	O
(	O
Towne	O
)	O
-	O
infected	O
HF	O
cells	O
at	O
24	O
to	O
48	O
h	O
,	O
IE2	B-protein
also	O
accumulated	O
in	O
newly	O
formed	O
viral	O
DNA	O
replication	O
compartments	O
containing	O
the	O
polymerase	B-protein
processivity	I-protein
factor	I-protein
(	O
UL44	B-protein
)	O
,	O
the	O
single	B-protein
-	I-protein
stranded	I-protein
DNA	I-protein
binding	I-protein
protein	I-protein
(	O
SSB	B-protein
;	O
UL57	B-protein
)	O
,	O
the	O
UL112	B-protein
-	I-protein
113	I-protein
accessory	I-protein
protein	I-protein
,	O
and	O
newly	O
incorporated	O
bromodeoxyuridine	O
(	O
BrdU	O
)	O
.	O

A	O
preoperative	O
teaching	O
booklet	O
for	O
pediatric	O
patients	O
.	O

These	O
kinases	B-protein
belong	O
to	O
a	O
new	O
subfamily	O
related	O
to	O
the	O
Trk	B-protein
subfamily	I-protein
.	O

Substitutions	O
in	O
the	O
YFV	B-protein
Ag	I-protein
-	I-protein
binding	I-protein
region	I-protein
(	O
ABR	B-protein
)	O
occur	O
at	O
four	O
of	O
the	O
eight	O
highly	O
conserved	O
residues	O
that	O
are	O
essential	O
for	O
binding	O
of	O
peptide	O
-	O
Ag	O
in	O
the	O
class	B-protein
Ia	I-protein
molecules	I-protein
.	O

This	O
paper	O
reports	O
the	O
results	O
of	O
a	O
laboratory	O
study	O
on	O
aldicarb	O
and	O
its	O
main	O
metabolites	O
,	O
aldicarb	O
sulfone	O
and	O
aldicarb	O
sulfoxide	O
.	O

In	O
comparison	O
with	O
the	O
16	O
introns	O
reported	O
in	O
AHA3	B-protein
,	O
AHA2	B-protein
is	O
missing	O
one	O
intron	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
and	O
a	O
second	O
intron	O
in	O
the	O
C	O
-	O
terminal	O
coding	O
region	O
.	O

The	O
data	O
provide	O
evidence	O
both	O
for	O
a	O
signal	O
transduction	O
pathway	O
independent	O
of	O
JNK	B-protein
,	O
ERK	B-protein
,	O
and	O
p38	B-protein
MAP	I-protein
kinase	I-protein
to	O
be	O
involved	O
in	O
the	O
induction	O
of	O
rhoB	B-protein
by	O
genotoxic	O
stress	O
,	O
and	O
furthermore	O
,	O
indicate	O
autoregulation	O
of	O
rhoB	B-protein
.	O

Gel	O
-	O
mobility	O
-	O
shift	O
assays	O
confirmed	O
that	O
the	O
Raji	B-protein
nuclear	I-protein
proteins	I-protein
that	O
bound	O
to	O
W	B-protein
and	I-protein
V	I-protein
elements	I-protein
were	O
competed	O
with	O
by	O
an	O
HLA	B-protein
-	I-protein
DRA	I-protein
X	I-protein
-	I-protein
box	I-protein
oligonucleotide	I-protein
.	O

Slap	B-protein
negatively	O
regulates	O
Src	B-protein
mitogenic	O
function	O
but	O
does	O
not	O
revert	O
Src	O
-	O
induced	O
cell	O
morphology	O
changes	O
.	O

Twelve	O
patients	O
without	O
abnormalities	O
in	O
the	O
PTT	O
are	O
assumed	O
to	O
harbor	O
missense	O
mutations	O
,	O
probably	O
in	O
TSC2	B-protein
.	O

These	O
include	O
NPF	B-protein
repeats	I-protein
,	O
a	O
leucine	O
heptad	O
repeat	O
enriched	O
in	O
charged	O
residues	O
,	O
and	O
a	O
proline	O
-	O
rich	O
SH3	B-protein
-	I-protein
like	I-protein
and	O
/	O
or	O
WW	B-protein
domain	I-protein
-	I-protein
binding	I-protein
site	I-protein
in	O
the	O
N	O
-	O
terminal	O
domain	O
,	O
which	O
is	O
followed	O
by	O
a	O
membrane	O
core	O
containing	O
four	O
putative	O
transmembrane	O
spans	O
and	O
three	O
amphiphilic	O
segments	O
that	O
are	O
the	O
most	O
highly	O
conserved	O
structural	O
elements	O
.	O

At	O
maximum	O
photosensitivity	O
the	O
inhibitory	O
amino	O
acids	O
gamma	O
-	O
aminobutyric	O
acid	O
and	O
taurine	O
were	O
lower	O
,	O
and	O
those	O
of	O
asparagine	O
(	O
metabolite	O
of	O
the	O
excitatory	O
amino	O
acid	O
aspartate	O
)	O
were	O
higher	O
,	O
than	O
when	O
the	O
animals	O
were	O
not	O
photosensitive	O
.	O

RESULTS	O
:	O
The	O
introduction	O
of	O
the	O
PAIP	O
resulted	O
in	O
a	O
significant	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
reduction	O
in	O
contaminating	O
WBCs	O
(	O
median	O
,	O
30	O
,	O
000	O
)	O
from	O
the	O
numbers	O
seen	O
with	O
FIP	O
(	O
median	O
,	O
2	O
,	O
300	O
,	O
000	O
)	O
while	O
maintaining	O
the	O
separation	O
efficacy	O
(	O
47	O
%	O
)	O
and	O
separation	O
time	O
.	O

We	O
then	O
studied	O
four	O
unrelated	O
Japanese	O
families	O
with	O
GSD	O
-	O
Ib	O
,	O
and	O
found	O
three	O
novel	O
mutations	O
:	O
a	O
four	O
-	O
base	O
deletion	O
/	O
two	O
-	O
base	O
insertion	O
,	O
a	O
point	O
mutation	O
within	O
a	O
consensus	O
splicing	O
donor	O
site	O
,	O
and	O
a	O
missense	O
mutation	O
(	O
W118R	O
)	O
.	O

Human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV	I-protein
-	I-protein
1	I-protein
)	I-protein
IN	I-protein
,	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
was	O
purified	O
to	O
near	O
homogeneity	O
.	O

The	O
other	O
inhibitor	O
was	O
a	O
single	O
TAR	B-protein
decoy	O
,	O
driven	O
by	O
the	O
U6	B-protein
small	I-protein
nuclear	I-protein
RNA	I-protein
promoter	I-protein
(	O
U6	B-protein
-	I-protein
P	I-protein
)	O
.	O

Hailey	O
-	O
Hailey	O
disease	O
is	O
caused	O
by	O
mutations	O
in	O
ATP2C1	B-protein
encoding	O
a	O
novel	O
Ca	O
(	O
2	O
+	O
)	O
pump	O
.	O

Thus	O
,	O
the	O
absence	O
of	O
residual	O
infarct	O
-	O
zone	O
viability	O
discriminates	O
patients	O
who	O
develop	O
progressive	O
left	O
ventricular	O
dilation	O
after	O
reperfused	O
AMI	O
from	O
those	O
who	O
maintain	O
normal	O
left	O
ventricular	O
geometry	O
.	O

Furthermore	O
,	O
deletion	O
and	O
mutation	O
analyses	O
of	O
the	O
VCAM	B-protein
-	I-protein
1	I-protein
promoter	I-protein
performed	O
with	O
chloramphenicol	B-protein
acetyltransferase	I-protein
constructs	I-protein
revealed	O
that	O
Tax	B-protein
was	O
trans	O
activating	O
the	O
VCAM	B-protein
-	I-protein
1	I-protein
promoter	I-protein
via	O
two	O
NF	B-protein
-	I-protein
kappaB	I-protein
sites	I-protein
present	O
at	O
bp	O
-	O
72	O
and	O
-	O
57	O
in	O
the	O
VCAM	B-protein
-	I-protein
1	I-protein
gene	I-protein
promoter	I-protein
,	O
with	O
both	O
of	O
them	O
being	O
required	O
for	O
the	O
Tax	O
-	O
induced	O
expression	O
of	O
this	O
adhesion	O
molecule	O
.	O

These	O
data	O
suggest	O
that	O
RPF	B-protein
-	I-protein
1	I-protein
is	O
likely	O
to	O
be	O
involved	O
in	O
early	O
steps	O
in	O
the	O
differentiation	O
of	O
amacrine	O
and	O
ganglion	O
cells	O
.	O

Paper	O
alert	O
.	O

Recurrence	O
of	O
bladder	O
tumors	O
among	O
the	O
original	O
9	O
cases	O
has	O
occurred	O
only	O
among	O
the	O
5	O
whose	O
properdin	B-protein
levels	O
remained	O
below	O
the	O
median	O
.	O

CONCLUSIONS	O
:	O
The	O
methodology	O
of	O
LHR	O
measurement	O
significantly	O
influences	O
the	O
clinical	O
contribution	O
of	O
Tl	O
-	O
201	O
lung	O
uptake	O
evaluation	O
.	O

This	O
failure	O
to	O
execute	O
regulated	O
G1	O
/	O
S	O
arrest	O
is	O
correlated	O
with	O
enhanced	O
thermosensitivity	O
of	O
colony	O
-	O
forming	O
ability	O
.	O

Atomic	O
absorption	O
spectrophotometry	O
applied	O
to	O
bacterially	O
expressed	O
E1A	B-protein
proteins	I-protein
revealed	O
that	O
the	O
289	O
-	O
amino	O
acid	O
protein	O
binds	O
one	O
zinc	O
ion	O
,	O
whereas	O
the	O
243	O
-	O
amino	O
acid	O
protein	O
binds	O
no	O
zinc	O
.	O

Using	O
the	O
presented	O
categorical	O
structure	O
as	O
domain	O
model	O
a	O
prototype	O
DSS	O
for	O
dipslide	O
urine	O
cultures	O
has	O
been	O
developed	O
.	O

Nip7p	O
-	O
depleted	O
cells	O
exhibited	O
the	O
same	O
defects	O
as	O
Nop8p	O
-	O
depleted	O
cells	O
,	O
except	O
that	O
they	O
accumulated	O
27S	B-protein
precursors	I-protein
.	O

Discordance	O
on	O
the	O
cost	O
dimension	O
correlated	O
negatively	O
with	O
G	B-protein
Hb	I-protein
,	O
suggesting	O
better	O
glycemic	O
control	O
with	O
greater	O
disagreement	O
.	O

In	O
this	O
paper	O
the	O
tyrosine	O
dephosphorylating	O
enzymes	O
,	O
the	O
protein	B-protein
-	I-protein
tyrosine	I-protein
phosphatases	I-protein
(	O
PTPs	B-protein
)	O
,	O
are	O
studied	O
which	O
can	O
be	O
grouped	O
into	O
two	O
subfamilies	O
,	O
the	O
soluble	B-protein
PTPs	I-protein
and	O
the	O
receptor	B-protein
PTPs	I-protein
(	O
RPTPs	B-protein
)	O
.	O

We	O
report	O
here	O
that	O
microinjection	O
of	O
an	O
anti	B-protein
-	I-protein
CBP	I-protein
antiserum	I-protein
into	O
fibroblasts	O
can	O
inhibit	O
transcription	O
from	O
a	O
cAMP	B-protein
responsive	I-protein
promoter	I-protein
.	O

Relatively	O
little	O
is	O
known	O
regarding	O
the	O
role	O
of	O
5	B-protein
-	I-protein
HT2	I-protein
receptor	I-protein
activity	O
in	O
male	O
rat	O
sexual	O
behavior	O
.	O

S2F	B-protein
,	O
a	O
leaf	O
-	O
specific	O
trans	O
-	O
acting	O
factor	O
,	O
binds	O
to	O
a	O
novel	O
cis	O
-	O
acting	O
element	O
and	O
differentially	O
activates	O
the	O
RPL21	B-protein
gene	I-protein
.	O

The	O
overall	O
results	O
of	O
this	O
paper	O
are	O
consistent	O
with	O
the	O
conclusion	O
that	O
the	O
carboxyl	O
-	O
terminal	O
LBD	O
is	O
not	O
sufficient	O
for	O
mediating	O
PR	B-protein
dimerization	O
and	O
that	O
multiple	O
regions	O
,	O
including	O
the	O
hinge	O
and	O
amino	O
-	O
terminal	O
sequences	O
,	O
contribute	O
either	O
directly	O
or	O
indirectly	O
to	O
homodimerization	O
of	O
PR	B-protein
.	O

A	O
water	O
-	O
vapour	O
giga	O
-	O
maser	O
in	O
the	O
active	O
galaxy	O
TXFS2226	O
-	O
184	O
.	O

A	O
potential	O
outcome	O
of	O
these	O
biochemical	O
effects	O
may	O
include	O
the	O
limited	O
responsiveness	O
of	O
infected	O
T	O
cells	O
to	O
antigenic	O
stimulation	O
observed	O
during	O
HIV	O
-	O
1	O
infection	O
.	O

Analysis	O
by	O
cell	O
surface	O
immunofluorescence	O
showed	O
that	O
the	O
UL28	B-protein
gene	I-protein
is	O
not	O
required	O
for	O
expression	O
of	O
viral	O
glycoproteins	O
on	O
the	O
surface	O
of	O
infected	O
cells	O
.	O

Secretory	B-protein
IgA	I-protein
and	O
serum	B-protein
immunoglobulins	I-protein
as	O
indices	O
of	O
the	O
local	O
immunity	O
of	O
the	O
intestinal	O
mucosa	O
in	O
acute	O
leukemias	O
.	O

Digitalis	O
glycosides	O
or	O
beta	B-protein
-	I-protein
receptor	I-protein
antagonists	O
are	O
not	O
helpful	O
in	O
the	O
therapy	O
of	O
this	O
form	O
of	O
atrial	O
fibrillation	O
whereas	O
class	O
I	O
antiarrhythmic	O
drugs	O
have	O
been	O
shown	O
to	O
be	O
more	O
effective	O
.	O

Our	O
data	O
show	O
that	O
multiple	O
MLSN1	B-protein
transcripts	I-protein
,	O
both	O
constitutively	O
expressed	O
and	O
inducible	O
,	O
are	O
present	O
in	O
cultured	O
pigmented	O
melanoma	O
cells	O
,	O
and	O
suggest	O
that	O
MLSN1	B-protein
expression	O
can	O
be	O
regulated	O
at	O
the	O
level	O
of	O
both	O
transcription	O
and	O
mRNA	O
processing	O
.	O

Both	O
classes	O
of	O
MHBst	B-protein
proteins	I-protein
were	O
found	O
to	O
form	O
dimers	O
;	O
an	O
which	O
is	O
involved	O
in	O
mediating	O
the	O
dimerization	O
.	O

The	O
specificity	O
of	O
action	O
of	O
C	B-protein
/	I-protein
EBP	I-protein
family	I-protein
members	I-protein
may	O
be	O
derived	O
from	O
the	O
characteristics	O
of	O
each	O
factor	O
,	O
including	O
the	O
expression	O
profiles	O
,	O
the	O
DNA	O
binding	O
affinities	O
,	O
the	O
cofactors	O
,	O
and	O
so	O
on	O
,	O
in	O
addition	O
to	O
the	O
DNA	O
binding	O
specificities	O
.	O

We	O
have	O
performed	O
toeprinting	O
analyses	O
on	O
repA	B-protein
mRNA	I-protein
of	O
plasmid	O
R1	O
,	O
both	O
free	O
and	O
in	O
duplex	O
with	O
the	O
antisense	O
RNA	O
,	O
CopA	B-protein
.	O

The	O
yeast	B-protein
LPD1	I-protein
gene	I-protein
encoding	O
lipoamide	B-protein
dehydrogenase	I-protein
is	O
subject	O
to	O
the	O
general	O
control	O
of	O
amino	O
acid	O
biosynthesis	O
mediated	O
by	O
the	O
GCN4	B-protein
transcription	I-protein
factor	I-protein
.	O

Either	O
a	O
UV	O
detector	O
set	O
at	O
268	O
nm	O
or	O
an	O
electrochemical	O
(	O
EC	O
)	O
detector	O
set	O
at	O
a	O
potential	O
of	O
+	O
0	O
.	O
9	O
V	O
(	O
versus	O
Ag	O
/	O
AgCl	O
/	O
3	O
M	O
NaCl	O
)	O
was	O
used	O
to	O
monitor	O
the	O
drug	O
.	O

The	O
most	O
common	O
grade	O
3	O
toxicity	O
was	O
neutropenia	O
,	O
thrombocytopenia	O
,	O
and	O
parasthesias	O
(	O
observed	O
in	O
<	O
10	O
%	O
of	O
cycles	O
)	O
.	O

Mitogen	O
-	O
induced	O
lymphocyte	O
proliferation	O
was	O
diminished	O
.	O

A	O
striking	O
feature	O
of	O
the	O
recombinant	B-protein
H19	I-protein
allele	I-protein
is	O
the	O
occurrence	O
of	O
a	O
parental	O
imprint	O
set	O
on	O
the	O
neo	B-protein
replacement	I-protein
cassette	I-protein
.	O

The	O
yeast	B-protein
C	I-protein
-	I-protein
type	I-protein
cyclin	I-protein
Ume3p	I-protein
/	I-protein
Srb11p	I-protein
and	O
its	O
cyclin	B-protein
-	I-protein
dependent	I-protein
kinase	I-protein
(	O
Cdk	B-protein
)	O
Ume5p	B-protein
are	O
required	O
for	O
the	O
full	O
repression	O
of	O
genes	O
involved	O
in	O
the	O
stress	O
response	O
or	O
meiosis	O
.	O

Except	O
for	O
nonperfusion	O
of	O
neurosensory	O
retinal	O
vessels	O
at	O
a	O
light	O
dose	O
of	O
150	O
J	O
/	O
cm2	O
,	O
no	O
other	O
adverse	O
events	O
were	O
of	O
concern	O
.	O

Interlimb	O
coordination	O
during	O
fictive	O
locomotion	O
in	O
the	O
thalamic	O
cat	O
.	O

Restriction	O
enzyme	O
mapping	O
,	O
subcloning	O
,	O
and	O
DNA	O
sequencing	O
analysis	O
of	O
recombinant	O
phage	O
lambda	O
and	O
P1	O
clones	O
revealed	O
that	O
exons	O
encoding	O
the	O
1	O
.	O
9	O
-	O
kb	O
mouse	B-protein
TS	I-protein
mRNA	I-protein
are	O
dispersed	O
over	O
>	O
150	O
kb	O
genomic	O
DNA	O
.	O

However	O
,	O
butyrate	O
was	O
at	O
least	O
2	O
-	O
fold	O
more	O
effective	O
in	O
stimulating	O
CAT	B-protein
activity	O
of	O
fusion	O
genes	O
containing	O
upstream	O
sequences	O
(	O
-	O
834	O
to	O
-	O
576	O
)	O
than	O
those	O
containing	O
proximal	O
sequences	O
(	O
-	O
456	O
to	O
-	O
172	O
)	O
,	O
suggesting	O
two	O
regions	O
in	O
the	O
PSG1	B-protein
-	I-protein
I	I-protein
gene	I-protein
that	O
mediate	O
the	O
butyrate	O
response	O
.	O

The	O
murine	B-protein
int	I-protein
-	I-protein
6	I-protein
locus	I-protein
,	O
identified	O
as	O
a	O
frequent	O
integration	O
site	O
of	O
mouse	O
mammary	O
tumor	O
viruses	O
,	O
encodes	O
the	O
48	B-protein
-	I-protein
kDa	I-protein
eIF3e	I-protein
subunit	I-protein
of	I-protein
translation	I-protein
initiation	I-protein
factor	I-protein
eIF3	I-protein
.	O

In	O
30	O
dogs	O
the	O
left	O
limb	O
(	O
tail	O
)	O
of	O
the	O
pancreas	O
was	O
removed	O
but	O
left	O
in	O
the	O
abdominal	O
cavity	O
after	O
cessation	O
of	O
blood	O
flow	O
to	O
produce	O
warm	O
ischemia	O
for	O
30	O
,	O
60	O
,	O
and	O
120	O
min	O
(	O
10	O
dogs	O
at	O
each	O
time	O
point	O
)	O
,	O
and	O
then	O
was	O
flushed	O
with	O
cold	O
Ringers	O
'	O
lactate	O
and	O
transplanted	O
to	O
the	O
iliac	O
vessels	O
.	O

The	O
core	O
of	O
this	O
enhancer	O
contains	O
two	O
evolutionarily	O
conserved	O
binding	O
sites	O
for	O
the	O
homeodomain	B-protein
protein	I-protein
Tinman	I-protein
(	O
Tin	B-protein
)	O
,	O
expressed	O
in	O
developing	O
cardiac	O
,	O
somatic	O
,	O
and	O
visceral	O
muscle	O
lineages	O
.	O

The	O
por	B-protein
gene	I-protein
has	O
been	O
expressed	O
,	O
for	O
the	O
first	O
time	O
,	O
in	O
anaerobically	O
grown	O
Escherichia	O
coli	O
behind	O
the	O
isopropyl	O
-	O
beta	O
-	O
D	O
-	O
thiogalactopyranoside	O
-	O
inducible	O
tac	B-protein
promoter	I-protein
,	O
resulting	O
in	O
the	O
production	O
of	O
POR	B-protein
in	O
its	O
active	O
form	O
.	O

Proximal	O
CBD	O
was	O
inversely	O
correlated	O
with	O
bone	B-protein
alkaline	I-protein
phosphatase	I-protein
(	O
r	O
=	O
-	O
0	O
.	O
71	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
intact	O
PTH	O
(	O
r	O
=	O
-	O
0	O
.	O
59	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Recombinant	B-protein
BRI1	I-protein
-	I-protein
KD	I-protein
autophosphorylated	O
on	O
serine	O
(	O
Ser	O
)	O
and	O
threonine	O
(	O
Thr	O
)	O
residues	O
with	O
p	O
-	O
Ser	O
predominating	O
.	O

The	O
C	O
terminus	O
of	O
TRBP	B-protein
binds	O
to	O
CBP	B-protein
/	I-protein
p300	I-protein
and	O
DRIP130	B-protein
,	O
a	O
component	O
of	O
the	O
DRIP	B-protein
/	I-protein
TRAP	I-protein
/	I-protein
ARC	I-protein
complex	I-protein
,	O
which	O
suggests	O
that	O
TRBP	B-protein
may	O
activate	O
transcription	O
by	O
means	O
of	O
such	O
interactions	O
.	O

FISH	O
using	O
a	O
whole	O
chromosome	O
4	O
paint	O
demonstrated	O
multiple	O
rearrangements	O
involving	O
chromosome	O
4	O
in	O
MCF	O
-	O
7	O
AdVp3000	O
and	O
MCF	O
-	O
7	O
MX	O
,	O
while	O
S1	O
-	O
M1	O
-	O
80	O
contained	O
only	O
a	O
simple	O
reciprocal	O
translocation	O
.	O

Schistosoma	O
mansoni	O
schistosomiasis	O
Schistosomosis	O
are	O
parasitic	O
diseases	O
caused	O
by	O
blood	O
flukes	O
of	O
the	O
Schistosoma	O
genus	O
.	O

They	O
contrast	O
trends	O
in	O
fertility	O
,	O
life	O
expectancy	O
ratios	O
,	O
and	O
gender	O
differences	O
in	O
these	O
countries	O
with	O
the	O
Hispanic	O
population	O
of	O
the	O
United	O
States	O
.	O

These	O
results	O
imply	O
that	O
the	O
GCN3	B-protein
product	I-protein
can	O
promote	O
either	O
repression	O
or	O
activation	O
of	O
GCN4	B-protein
expression	O
depending	O
on	O
amino	O
acid	O
availability	O
.	O

Twenty	O
-	O
two	O
consecutive	O
patients	O
with	O
ischaemic	O
ulcers	O
had	O
tcPO2	O
measured	O
and	O
the	O
ankle	O
/	O
brachial	O
(	O
ABI	O
)	O
and	O
toe	O
/	O
brachial	O
(	O
TBI	O
)	O
indices	O
calculated	O
.	O

In	O
order	O
to	O
better	O
characterize	O
the	O
distribution	O
of	O
ML	O
and	O
MAP	O
estimates	O
under	O
these	O
conditions	O
,	O
we	O
derive	O
a	O
point	O
approximation	O
to	O
density	O
values	O
of	O
the	O
conditional	O
distribution	O
of	O
such	O
estimates	O
.	O

We	O
conclude	O
that	O
cAMP	O
,	O
acting	O
through	O
PKA	B-protein
,	O
is	O
an	O
essential	O
regulator	O
of	O
basal	O
CFTR	B-protein
gene	I-protein
expression	O
and	O
may	O
mediate	O
an	O
induction	O
of	O
CFTR	B-protein
in	O
responsive	O
cell	O
types	O
.	O

We	O
have	O
demonstrated	O
that	O
the	O
activity	O
of	O
ILK	B-protein
is	O
constitutively	O
elevated	O
in	O
PTEN	B-protein
mutant	I-protein
cells	O
.	O

A	O
normal	O
systemic	O
response	O
was	O
obtained	O
after	O
IF	O
,	O
indicating	O
that	O
rhG	B-protein
-	I-protein
CSF	I-protein
retains	O
activity	O
in	O
the	O
solid	O
state	O
.	O

METHODS	O
:	O
Thyroid	O
status	O
was	O
measured	O
at	O
baseline	O
(	O
1990	O
-	O
93	O
)	O
,	O
through	O
assessment	O
of	O
serum	O
antibodies	O
to	O
thyroid	B-protein
peroxidase	I-protein
(	O
TPO	B-protein
-	I-protein
Abs	I-protein
,	O
positive	O
:	O
>	O
10	O
IU	O
/	O
ml	O
)	O
,	O
serum	B-protein
TSH	I-protein
levels	O
,	O
and	O
when	O
TSH	B-protein
was	O
abnormal	O
(	O
<	O
0	O
.	O
4	O
or	O
>	O
4	O
.	O
0	O
mU	O
/	O
l	O
)	O
,	O
serum	B-protein
thyroxin	I-protein
levels	O
(	O
T4	O
)	O
.	O

Two	O
hundred	O
forty	O
-	O
three	O
patients	O
have	O
received	O
WR	O
-	O
2721	O
in	O
Phase	O
I	O
-	O
II	O
studies	O
.	O

All	O
three	O
NR	B-protein
isoforms	O
are	O
expressed	O
in	O
cv	O
.	O

These	O
results	O
demonstrate	O
that	O
a	O
diverse	O
set	O
of	O
carboxyl	O
-	O
terminal	O
sequence	O
motifs	O
and	O
posttranslational	O
modifications	O
lead	O
to	O
functional	O
Ras	B-protein
proteins	I-protein
in	O
yeast	O
.	O

Five	O
-	O
year	O
survivals	O
amounted	O
to	O
100	O
%	O
,	O
86	O
.	O
2	O
%	O
,	O
59	O
.	O
4	O
%	O
,	O
29	O
.	O
8	O
%	O
,	O
and	O
20	O
%	O
for	O
stages	O
I	O
,	O
II	O
,	O
III	O
,	O
IVA	O
and	O
IVB	O
respectively	O
.	O

In	O
biopsies	O
CK	B-protein
-	I-protein
MB	I-protein
fraction	O
of	O
total	O
myocardial	O
CPK	B-protein
was	O
37	O
%	O
,	O
the	O
total	B-protein
-	I-protein
CPK	I-protein
activity	O
of	O
human	O
skeletal	O
muscles	O
still	O
shows	O
a	O
5	O
%	O
fraction	O
of	O
CK	B-protein
-	I-protein
MB	I-protein
.	O

Measurements	O
were	O
obtained	O
:	O
(	O
i	O
)	O
just	O
after	O
the	O
traumatic	O
exposure	O
(	O
D0	O
)	O
;	O
(	O
ii	O
)	O
3	O
days	O
after	O
this	O
first	O
measurement	O
(	O
D3	O
)	O
;	O
and	O
(	O
iii	O
)	O
30	O
days	O
after	O
(	O
D30	O
)	O
.	O

The	O
results	O
of	O
our	O
ten	O
-	O
fold	O
cross	O
-	O
validation	O
experiments	O
show	O
that	O
,	O
on	O
the	O
average	O
,	O
the	O
system	O
increases	O
the	O
specificity	O
from	O
0	O
.	O
19	O
(	O
0	O
.	O
35	O
)	O
to	O
0	O
.	O
69	O
(	O
0	O
.	O
74	O
)	O
at	O
a	O
sensitivity	O
level	O
of	O
1	O
.	O
0	O
(	O
0	O
.	O
95	O
)	O
.	O

HTLV	O
-	O
1	O
gene	O
expression	O
by	O
defective	O
proviruses	O
in	O
an	O
infected	O
T	O
-	O
cell	O
line	O
.	O

The	O
structural	O
analysis	O
also	O
demonstrated	O
that	O
the	O
heterogeneity	O
of	O
the	O
HDC	B-protein
mRNA	I-protein
is	O
caused	O
by	O
an	O
insertion	O
of	O
the	O
seventh	O
intron	O
sequence	O
and	O
alternative	O
use	O
of	O
the	O
splicing	O
acceptor	O
site	O
at	O
the	O
12th	O
exon	O
.	O

Thus	O
,	O
ZNF74	B-protein
sublocalization	O
in	O
nuclear	O
domains	O
enriched	O
in	O
pre	O
-	O
mRNA	O
maturating	O
factors	O
,	O
its	O
RNA	O
binding	O
activity	O
,	O
and	O
its	O
direct	O
phosphodependent	O
interaction	O
with	O
the	O
pol	B-protein
IIo	I-protein
,	O
a	O
form	O
of	O
the	O
RNA	B-protein
polymerase	I-protein
functionally	O
associated	O
with	O
pre	O
-	O
mRNA	O
processing	O
,	O
suggest	O
a	O
role	O
for	O
this	O
member	O
of	O
the	O
KRAB	B-protein
multifinger	I-protein
protein	I-protein
family	I-protein
in	O
RNA	O
processing	O
.	O

The	O
blood	O
levels	O
of	O
lactate	O
,	O
pyruvate	O
and	O
amino	O
acids	O
were	O
not	O
elevated	O
.	O

This	O
element	O
was	O
used	O
to	O
screen	O
an	O
EMBL3	O
mouse	O
genomic	O
library	O
.	O

The	O
nucleotide	O
sequence	O
consists	O
of	O
48	O
bp	O
of	O
5	O
'	O
-	O
end	O
non	O
-	O
coding	O
region	O
,	O
1695	O
bp	O
of	O
coding	O
region	O
and	O
212	O
bp	O
of	O
3	O
'	O
-	O
end	O
non	O
-	O
coding	O
region	O
including	O
a	O
20	O
bp	O
poly	O
(	O
A	O
)	O
tail	O
.	O

Effects	O
of	O
a	O
new	O
antihypertensive	O
agent	O
,	O
SGB	O
-	O
1534	O
,	O
on	O
rat	O
platelet	O
aggregation	O
.	O

Plasma	O
levels	O
of	O
protein	B-protein
C	I-protein
,	O
protein	B-protein
S	I-protein
,	O
and	O
antithrombin	B-protein
III	I-protein
in	O
patients	O
with	O
subarachnoid	O
haemorrhage	O
.	O

Among	O
9	O
group	O
I	O
patients	O
with	O
a	O
positive	O
result	O
on	O
head	O
-	O
up	O
tilt	O
-	O
table	O
testing	O
and	O
no	O
evidence	O
of	O
structural	O
heart	O
disease	O
(	O
mean	O
follow	O
-	O
up	O
4	O
.	O
3	O
years	O
)	O
,	O
7	O
are	O
without	O
further	O
episodes	O
of	O
syncope	O
;	O
3	O
have	O
discontinued	O
medication	O
and	O
5	O
have	O
resumed	O
at	O
least	O
limited	O
exercise	O
.	O

In	O
contrast	O
,	O
COUP	B-protein
-	I-protein
TF	I-protein
alone	O
had	O
no	O
effect	O
on	O
repCRS2	O
-	O
dependent	O
reporter	O
gene	O
activity	O
.	O

Pups	O
placed	O
into	O
the	O
novel	O
environment	O
with	O
their	O
mothers	O
exhibited	O
an	O
intermediate	O
level	O
of	O
DA	O
turnover	O
.	O

With	O
this	O
bisected	O
diastolic	O
driving	O
,	O
the	O
abnormal	O
echo	O
disappeared	O
completely	O
.	O

Using	O
either	O
a	O
p50	B-protein
-	I-protein
or	O
p65	B-protein
-	I-protein
selected	I-protein
kappa	I-protein
B	I-protein
motif	I-protein
,	O
which	O
displayed	O
differential	O
binding	O
with	O
respect	O
to	O
the	O
other	O
protein	O
,	O
little	O
to	O
no	O
binding	O
was	O
observed	O
with	O
the	O
heterodimeric	B-protein
NF	I-protein
-	I-protein
kappa	I-protein
B	I-protein
complex	I-protein
.	O

We	O
have	O
isolated	O
a	O
novel	O
human	B-protein
cyclin	I-protein
,	O
cyclin	B-protein
E2	I-protein
,	O
that	O
contains	O
significant	O
homology	O
to	O
cyclin	B-protein
E	I-protein
.	O

He	O
is	O
well	O
,	O
five	O
years	O
after	O
relapse	O
.	O

The	O
concentration	O
of	O
alpha	B-protein
2	I-protein
-	I-protein
macroglobulin	I-protein
,	O
alpha	B-protein
1	I-protein
-	I-protein
antitrypsin	I-protein
,	O
plasminogen	B-protein
,	O
C3	B-protein
-	I-protein
complement	I-protein
,	O
fibrinogen	B-protein
degradation	O
products	O
(	O
FDP	O
)	O
and	O
fibrinolytic	O
activity	O
,	O
were	O
studied	O
in	O
the	O
aqueous	O
humour	O
and	O
serum	O
from	O
nine	O
patients	O
with	O
Fuchs	O
'	O
endothelial	O
dystrophy	O
,	O
17	O
patients	O
with	O
uncomplicated	O
senile	O
cataract	O
and	O
in	O
the	O
secondary	O
aqueous	O
from	O
six	O
cataract	O
patients	O
.	O

However	O
,	O
mandibular	O
position	O
(	O
S	O
-	O
N	O
-	O
B	O
and	O
S	O
-	O
N	O
-	O
Pog	O
)	O
was	O
found	O
to	O
be	O
significantly	O
more	O
retrusive	O
in	O
Class	O
II	O
when	O
compared	O
with	O
Class	O
I	O
subjects	O
.	O

State	O
-	O
approved	O
schools	O
of	O
nursing	O
R	O
.	O
N	O
.	O

B	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
(	O
BCR	B-protein
)	O
-	O
mediated	O
formation	O
of	O
a	O
SHP	B-protein
-	I-protein
2	I-protein
-	I-protein
pp120	I-protein
complex	I-protein
and	O
its	O
inhibition	O
by	O
Fc	B-protein
gamma	I-protein
RIIB1	I-protein
-	I-protein
BCR	I-protein
coligation	O
.	O

The	O
method	O
involves	O
preliminary	O
isolation	O
of	O
oxiracetam	O
and	O
internal	O
standard	O
from	O
plasma	O
by	O
solid	O
-	O
phase	O
extraction	O
prior	O
to	O
the	O
formation	O
of	O
their	O
n	O
-	O
propyl	O
carbamate	O
derivatives	O
.	O

The	O
patient	O
was	O
a	O
78	O
-	O
year	O
-	O
old	O
male	O
in	O
whom	O
skin	O
lesions	O
preceded	O
the	O
diagnosis	O
of	O
myelofibrosis	O
.	O

Isolation	O
of	O
Weeksella	O
virosa	O
(	O
formerly	O
CDC	O
group	O
IIf	O
)	O
from	O
a	O
vaginal	O
sample	O
.	O

Biochemical	O
analysis	O
demonstrates	O
that	O
the	O
BJ1	B-protein
protein	I-protein
is	O
associated	O
with	O
nucleosomes	O
and	O
is	O
released	O
from	O
chromatin	O
by	O
agents	O
which	O
intercalate	O
into	O
DNA	O
,	O
as	O
previously	O
shown	O
for	O
the	O
high	B-protein
mobility	I-protein
group	I-protein
proteins	I-protein
(	O
HMGs	B-protein
)	O
.	O

Overexpression	O
of	O
Trdpm1	B-protein
in	O
a	O
dpm1	B-protein
(	I-protein
+	I-protein
)	I-protein
:	O
:	O
his7	B-protein
/	I-protein
dpm1	I-protein
(	I-protein
+	I-protein
)	I-protein
S	O
.	O
pombe	O
diploid	O
resulted	O
in	O
a	O
4	O
-	O
fold	O
increase	O
in	O
specific	O
DPM	B-protein
synthase	I-protein
activity	O
.	O

The	O
proposed	O
mechanism	O
of	O
effect	O
states	O
that	O
mono	O
(	O
2	O
-	O
ethylhexyl	O
)	O
phthalate	O
(	O
MEHP	O
)	O
,	O
the	O
primary	O
hydrolysis	O
product	O
of	O
DEHP	O
,	O
mimics	O
the	O
inducing	O
prostaglandins	O
(	O
PG	O
)	O
PGD	O
(	O
2	O
)	O
,	O
9alpha	O
,	O
11betaPGF2	O
,	O
and	O
PGF2alpha	O
,	O
and	O
thromboxanes	O
in	O
the	O
lungs	O
,	O
thereby	O
increasing	O
the	O
risk	O
of	O
inducing	O
inflammation	O
in	O
the	O
airways	O
,	O
which	O
is	O
a	O
characteristic	O
of	O
asthma	O
.	O

Effect	O
of	O
the	O
methods	O
of	O
cutaneous	O
administration	O
of	O
methyl	O
isobutyl	O
ketone	O
on	O
its	O
toxicity	O
.	O

TIP30	B-protein
has	O
an	O
intrinsic	O
kinase	B-protein
activity	O
required	O
for	O
up	O
-	O
regulation	O
of	O
a	O
subset	O
of	O
apoptotic	O
genes	O
.	O

The	O
optimal	O
care	O
of	O
CHF	O
patient	O
includes	O
the	O
recognition	O
and	O
management	O
of	O
these	O
electrolyte	O
disturbances	O
.	O

Randomised	O
comparison	O
of	O
addition	O
of	O
autologous	O
bone	O
-	O
marrow	O
transplantation	O
to	O
intensive	O
chemotherapy	O
for	O
acute	O
myeloid	O
leukaemia	O
in	O
first	O
remission	O
:	O
results	O
of	O
MRC	O
AML	O
10	O
trial	O
.	O

The	O
organization	O
of	O
SPP1	B-protein
genes	I-protein
involved	O
in	O
the	O
replication	O
,	O
DNA	O
packaging	O
and	O
phage	O
assembly	O
proteins	O
resembles	O
the	O
organization	O
of	O
genes	O
of	O
equivalent	O
regions	O
of	O
different	O
E	O
.	O
coli	O
double	O
-	O
stranded	O
DNA	O
phages	O
.	O

The	O
retention	O
index	O
of	O
201Tl	O
SPECT	O
is	O
a	O
useful	O
indicator	O
of	O
metastatic	O
potential	O
,	O
thereby	O
facilitating	O
the	O
prediction	O
of	O
prognosis	O
,	O
and	O
provides	O
insight	O
into	O
the	O
relationship	O
between	O
201Tl	O
uptake	O
and	O
malignancy	O
.	O

The	O
gene	O
organization	O
of	O
CRSV	B-protein
RNA	I-protein
-	I-protein
1	I-protein
is	O
similar	O
to	O
those	O
of	O
red	O
clover	O
necrotic	O
mosaic	O
(	O
RCNMV	O
)	O
and	O
sweet	O
clover	O
necrotic	O
mosaic	O
(	O
SCNMV	O
)	O
dianthoviruses	O
with	O
the	O
exception	O
that	O
CRSV	B-protein
RNA	I-protein
-	I-protein
1	I-protein
contains	O
the	O
additional	O
3	O
'	O
-	O
terminal	O
ORF	O
.	O

The	O
data	O
indicate	O
a	O
three	O
-	O
phase	O
reaction	O
after	O
B1	O
injection	O
:	O
Phase	O
1	O
-	O
-	O
shortly	O
after	O
injection	O
there	O
is	O
a	O
drop	O
of	O
all	O
parameters	O
lasting	O
for	O
30	O
sec	O
.	O

A	O
secondary	O
phosphorylation	O
of	O
CREB341	B-protein
at	O
Ser129	O
is	O
required	O
for	O
the	O
cAMP	O
-	O
mediated	O
control	O
of	O
gene	O
expression	O
.	O

After	O
declamping	O
of	O
the	O
aorta	O
,	O
there	O
were	O
also	O
severe	O
edema	O
,	O
local	O
fibre	O
necrosis	O
,	O
and	O
adhesion	O
of	O
leucocytes	O
,	O
whereas	O
muscle	O
fibre	O
areas	O
became	O
3	O
,	O
935	O
.	O
18	O
@	O
mgr	O
;	O
531	O
@	O
mgr	O
;	O
m	O
(	O
2	O
)	O
for	O
type	O
I	O
and	O
5	O
,	O
804	O
+	O
/	O
-	O
1	O
,	O
075	O
@	O
mgr	O
;	O
m	O
(	O
2	O
)	O
for	O
type	O
II	O
.	O

RNase	B-protein
MRP	I-protein
is	O
a	O
ribonucleoprotein	O
endoribonuclease	O
that	O
has	O
been	O
shown	O
to	O
have	O
roles	O
in	O
both	O
mitochondrial	O
DNA	O
replication	O
and	O
nuclear	B-protein
5	I-protein
.	I-protein
8S	I-protein
rRNA	I-protein
processing	O
.	O

The	O
method	O
is	O
accurate	O
,	O
with	O
good	O
precision	O
and	O
adequate	O
sensitivity	O
.	O

Tyrosine	B-protein
kinase	I-protein
oncogenes	O
abrogate	O
interleukin	B-protein
-	I-protein
3	I-protein
dependence	O
of	O
murine	O
myeloid	O
cells	O
through	O
signaling	O
pathways	O
involving	O
c	B-protein
-	I-protein
myc	I-protein
:	O
conditional	O
regulation	O
of	O
c	B-protein
-	I-protein
myc	I-protein
transcription	O
by	O
temperature	O
-	O
sensitive	O
v	B-protein
-	I-protein
abl	I-protein
.	O

In	O
mice	O
,	O
three	O
major	O
families	O
of	O
L1	B-protein
elements	I-protein
,	O
termed	O
`	B-protein
`	I-protein
A	I-protein
,	I-protein
`	I-protein
`	I-protein
`	I-protein
`	I-protein
F	I-protein
,	I-protein
`	I-protein
`	I-protein
and	O
`	B-protein
`	I-protein
V	I-protein
,	I-protein
`	I-protein
`	I-protein
have	O
been	O
defined	O
on	O
the	O
basis	O
of	O
the	O
sequence	O
found	O
at	O
the	O
5	O
'	O
terminus	O
.	O

ST	O
elevation	O
occurs	O
in	O
5	O
patients	O
(	O
55	O
.	O
5	O
%	O
)	O
of	O
subgroup	O
A	O
and	O
in	O
no	O
patient	O
of	O
the	O
subgroup	O
B	O
.	O

Of	O
49	O
receptors	O
which	O
fired	O
in	O
phase	O
with	O
ventilation	O
,	O
13	O
behaved	O
like	O
mammalian	O
rapidly	O
adapting	O
pulmonary	O
stretch	O
receptors	O
,	O
19	O
like	O
mammalian	O
slowly	O
adapting	O
pulmonary	O
stretch	O
receptors	O
(	O
PSR	O
)	O
,	O
and	O
17	O
like	O
avian	O
intrapulmonary	O
CO2	O
-	O
sensitive	O
chemoreceptors	O
(	O
IPC	O
)	O
.	O

Our	O
results	O
,	O
when	O
combined	O
with	O
previously	O
published	O
in	O
vitro	O
results	O
,	O
support	O
a	O
direct	O
role	O
for	O
Prp44p	B-protein
in	O
unwinding	O
of	O
the	O
U4	B-protein
/	I-protein
U6	I-protein
helix	O
.	O

Tryptic	O
cleavage	O
and	O
peptide	O
sequence	O
analysis	O
demonstrated	O
that	O
the	O
98	O
-	O
kD	O
protein	O
is	O
identical	O
to	O
a	O
recently	O
cloned	O
protein	O
,	O
special	B-protein
A	I-protein
-	I-protein
T	I-protein
-	I-protein
rich	I-protein
binding	I-protein
protein	I-protein
1	I-protein
(	O
SATB1	B-protein
)	O
,	O
that	O
binds	O
selectively	O
to	O
nuclear	O
matrix	O
/	O
scaffold	O
-	O
associated	O
regions	O
of	O
DNA	O
(	O
MARs	O
/	O
SARs	O
)	O
.	O

Conversely	O
,	O
E1A	B-protein
binding	O
to	O
only	O
p300	B-protein
/	I-protein
CBP	I-protein
results	O
in	O
an	O
increase	O
in	O
PARP	B-protein
enzyme	I-protein
activity	O
and	O
consequently	O
in	O
cell	O
death	O
susceptibility	O
to	O
irradiation	O
,	O
which	O
is	O
effectively	O
counteracted	O
by	O
the	O
PARP	B-protein
chemical	O
inhibitor	O
3	O
-	O
aminobenzamide	O
.	O

We	O
reviewed	O
the	O
records	O
of	O
151	O
patients	O
with	O
optic	O
neuritis	O
examined	O
over	O
an	O
eight	O
-	O
year	O
period	O
.	O

Contributions	O
from	O
pairs	O
of	O
source	O
and	O
target	O
volume	O
elements	O
are	O
summed	O
for	O
the	O
S	O
values	O
between	O
the	O
tumor	O
and	O
itself	O
,	O
between	O
the	O
remaining	O
healthy	O
host	O
organ	O
and	O
itself	O
,	O
and	O
between	O
the	O
tumor	O
and	O
the	O
remaining	O
healthy	O
host	O
organ	O
,	O
with	O
the	O
reciprocity	O
theorem	O
assumed	O
for	O
the	O
last	O
.	O

Transfection	O
studies	O
also	O
showed	O
that	O
3	O
'	O
-	O
deletion	O
of	O
sequences	O
downstream	O
of	O
the	O
transcriptional	O
start	O
site	O
(	O
+	O
1	O
/	O
+	O
47	O
)	O
markedly	O
reduced	O
OSM	O
-	O
fold	O
induction	O
.	O

Indeed	O
,	O
mutation	O
of	O
two	O
of	O
these	O
motifs	O
,	O
known	O
to	O
be	O
important	O
to	O
regulation	O
of	O
sid1	B-protein
,	O
altered	O
the	O
differential	O
regulation	O
of	O
sid2	B-protein
by	O
iron	O
.	O

Pet	B-protein
-	I-protein
1	I-protein
can	O
bind	O
specifically	O
to	O
a	O
PEA3	B-protein
ETS	I-protein
DNA	I-protein
-	I-protein
binding	I-protein
motif	I-protein
and	O
can	O
modulate	O
transcription	O
of	O
synthetic	O
promoter	O
constructs	O
in	O
a	O
sequence	O
-	O
specific	O
manner	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
do	O
not	O
support	O
a	O
role	O
for	O
IVIg	O
in	O
the	O
remyelination	O
of	O
stable	O
multiple	O
sclerosis	O
lesions	O
as	O
measured	O
by	O
central	O
conduction	O
time	O
.	O

Isolation	O
of	O
tha	O
avian	O
reticuloendothelial	O
virus	O
(	O
strain	O
T	O
)	O
.	O

To	O
explore	O
the	O
mechanism	O
of	O
RSK	B-protein
activation	O
,	O
a	O
cloned	O
human	O
RSK	B-protein
cDNA	O
(	O
RSK3	B-protein
)	O
was	O
used	O
to	O
generate	O
and	O
characterize	O
several	O
site	O
-	O
directed	O
RSK	B-protein
mutants	I-protein
;	O
K91A	O
(	O
N	O
-	O
Lys	O
,	O
NH2	O
-	O
terminal	O
ATP	O
-	O
binding	O
mutant	O
)	O
,	O
K444A	O
(	O
C	O
-	O
Lys	O
,	O
COOH	O
-	O
terminal	O
ATP	O
-	O
binding	O
mutant	O
)	O
,	O
N	O
/	O
C	O
-	O
Lys	O
(	O
double	O
ATP	O
-	O
binding	O
mutant	O
)	O
T570A	O
(	O
C	O
-	O
Thr	O
,	O
mutant	O
of	O
the	O
putative	O
MAPK	B-protein
phosphorylation	O
site	O
in	O
subdomain	O
VIII	O
of	O
the	O
C	O
-	O
domain	O
)	O
,	O
S218A	O
(	O
N	O
-	O
Ser	O
,	O
mutant	O
of	O
the	O
corresponding	O
NH2	O
-	O
terminal	O
residue	O
)	O
.	O

When	O
two	O
determinations	O
were	O
performed	O
on	O
12	O
samples	O
of	O
plasma	O
taken	O
from	O
normal	O
adults	O
in	O
October	O
,	O
the	O
values	O
were	O
22	O
.	O
6	O
+	O
/	O
-	O
4	O
.	O
8	O
and	O
21	O
.	O
0	O
+	O
/	O
-	O
3	O
.	O
6	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
ng	O
/	O
ml	O
,	O
respectively	O
.	O

Based	O
on	O
peptide	O
map	O
similarities	O
,	O
partial	O
amino	O
-	O
terminal	O
sequence	O
data	O
,	O
and	O
common	O
genetic	O
origin	O
,	O
it	O
is	O
suggested	O
that	O
p60	B-protein
and	O
p62	B-protein
have	O
identical	O
amino	O
acid	O
sequences	O
carboxy	O
-	O
terminal	O
to	O
the	O
p60	B-protein
initiator	O
methionine	O
(	O
residue	O
21	O
of	O
p62	B-protein
)	O
.	O

Overexpression	O
of	O
ICBP90	B-protein
in	O
COS	O
-	O
1	O
-	O
transfected	O
cells	O
induced	O
an	O
enhanced	O
expression	O
of	O
endogenous	B-protein
topoisomerase	I-protein
IIalpha	I-protein
.	O

The	O
latter	O
method	O
adds	O
clamping	O
of	O
the	O
inferior	O
vena	O
cava	O
,	O
which	O
results	O
in	O
hypotension	O
,	O
requiring	O
invasive	O
anesthetic	O
management	O
.	O

313	O
,	O
98	O
-	O
102	O
)	O
.	O

These	O
primers	O
yielded	O
a	O
PCR	O
product	O
of	O
a	O
characteristic	O
length	O
within	O
most	O
Xanthomonas	O
species	O
and	O
pathovars	O
tested	O
.	O

We	O
have	O
thus	O
identified	O
the	O
first	O
mammalian	B-protein
homolog	I-protein
of	I-protein
yeast	I-protein
UPF1	I-protein
,	O
a	O
protein	O
that	O
regulates	O
levels	O
of	O
nonsense	O
mRNA	O
,	O
and	O
we	O
tentatively	O
name	O
this	O
protein	O
human	B-protein
HUPF1	I-protein
(	O
for	O
human	B-protein
homolog	I-protein
of	I-protein
UPF1	I-protein
)	O
.	O

Of	O
the	O
three	O
known	O
C	B-protein
/	I-protein
EBP	I-protein
family	I-protein
inhibitors	O
,	O
Ig	B-protein
/	I-protein
EBP	I-protein
,	O
LIP	B-protein
and	O
CHOP	B-protein
-	I-protein
10	I-protein
,	O
only	O
Ig	B-protein
/	I-protein
EBP	I-protein
is	O
ubiquitously	O
expressed	O
.	O

Failures	O
of	O
colorimetric	O
additivity	O
under	O
these	O
experimental	O
conditions	O
are	O
discussed	O
.	O

0	O
%	O
)	O
and	O
IL	B-protein
-	I-protein
12	I-protein
(	O
42	O
.	O
6	O
%	O
vs	O
.	O

[	O
Diabetologia	O
(	O
2001	O
)	O
44	O
[	O
Suppl	O
3	O
]	O
:	O
B	O
37	O
-	O
B	O
44	O
]	O

The	O
Cox	O
proportional	O
hazards	O
model	O
was	O
applied	O
to	O
the	O
data	O
in	O
order	O
to	O
determine	O
the	O
prognostic	O
factors	O
for	O
long	O
-	O
term	O
survival	O
.	O

This	O
protein	O
can	O
bind	O
to	O
a	O
region	O
of	O
the	O
promoter	O
of	O
an	O
Arabidopsis	B-protein
light	I-protein
-	I-protein
harvesting	I-protein
chlorophyll	I-protein
a	I-protein
/	I-protein
b	I-protein
protein	I-protein
gene	I-protein
,	O
Lhcb1	B-protein
*	I-protein
3	I-protein
,	O
which	O
is	O
necessary	O
for	O
its	O
regulation	O
by	O
phytochrome	O
.	O

The	O
metabolic	O
events	O
occurring	O
at	O
or	O
near	O
that	O
structure	O
and	O
involving	O
cyclin	B-protein
D3	I-protein
cause	O
the	O
translocation	O
of	O
ICP0	B-protein
to	O
the	O
cytoplasm	O
.	O

The	O
PDGFR	B-protein
mutants	I-protein
that	O
failed	O
to	O
associate	O
with	O
PLC	B-protein
gamma	I-protein
were	O
not	O
able	O
to	O
mediate	O
the	O
PDGF	O
-	O
dependent	O
production	O
of	O
inositol	O
phosphates	O
.	O

There	O
were	O
3	O
/	O
32	O
(	O
9	O
.	O
4	O
per	O
cent	O
)	O
adverse	O
reactions	O
(	O
ADRs	O
)	O
,	O
and	O
one	O
case	O
each	O
of	O
nausea	O
,	O
dizziness	O
and	O
increased	O
menstrual	O
flow	O
.	O

II	O
.	O

Sex	O
selection	O
via	O
albumin	B-protein
columns	O
:	O
20	O
years	O
of	O
results	O
.	O

Tl	O
-	O
201	O
uptake	O
ratio	O
of	O
the	O
right	O
ventricle	O
,	O
which	O
represents	O
the	O
ratio	O
of	O
total	O
counts	O
of	O
the	O
right	O
ventricle	O
to	O
counts	O
of	O
the	O
administered	O
dose	O
of	O
Tl	O
-	O
201	O
,	O
was	O
higher	O
in	O
COPD	O
,	O
especially	O
in	O
pulmonary	O
emphysema	O
and	O
B	O
type	O
COPD	O
by	O
Burrows	O
classification	O
than	O
in	O
controls	O
.	O

Substantial	O
amounts	O
of	O
liposomal	O
ampicillin	O
were	O
recovered	O
from	O
isolated	O
Kupffer	O
cells	O
,	O
the	O
target	O
cells	O
of	O
L	O
.	O
monocytogenes	O
after	O
intravenous	O
inoculation	O
.	O

The	O
preferential	O
serum	B-protein
IgA	I-protein
response	O
observed	O
in	O
the	O
patient	O
population	O
suggests	O
that	O
bronchial	O
associated	O
lymphoid	O
tissue	O
in	O
the	O
diseased	O
lung	O
is	O
an	O
important	O
source	O
of	O
circulating	O
IgA	B-protein
.	O

Indium	O
-	O
111	O
OncoScint	O
CR	O
/	O
OV	O
and	O
F	O
-	O
18	O
FDG	O
in	O
colorectal	O
and	O
ovarian	O
carcinoma	O
recurrences	O
.	O

Possible	O
pathogenetic	O
mechanisms	O
of	O
hemopoietic	O
changes	O
in	O
response	O
to	O
space	O
flight	O
effects	O
are	O
described	O
.	O

One	O
such	O
mutant	O
also	O
affects	O
the	O
overlapping	O
-	O
10	O
hexamer	O
of	O
PR	O
and	O
results	O
in	O
reduced	O
occupancy	O
by	O
both	O
MerR	B-protein
and	O
RNA	B-protein
polymerase	I-protein
,	O
likely	O
as	O
a	O
result	O
of	O
inefficient	O
transcriptional	O
initiation	O
of	O
merR	B-protein
mRNA	I-protein
.	O

Complete	O
sequences	O
were	O
obtained	O
for	O
the	O
three	O
large	O
thrombic	O
peptides	O
,	O
and	O
these	O
were	O
aligned	O
by	O
using	O
peptides	O
from	O
the	O
V8	B-protein
protease	I-protein
digest	O
.	O

Mutation	O
of	O
the	O
presumptive	O
phosphorylated	O
tyrosine	O
and	O
threonine	O
residues	O
of	O
Mpk1p	B-protein
individually	O
to	O
phenylalanine	O
and	O
alanine	O
,	O
respectively	O
,	O
severely	O
impaired	O
Mpk1p	B-protein
function	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Using	O
Southern	O
blot	O
analysis	O
and	O
restriction	O
mapping	O
of	O
genomic	O
YAC	O
(	O
yeast	O
artificial	O
chromosome	O
)	O
and	O
cosmid	O
clones	O
,	O
we	O
located	O
the	O
human	B-protein
RIL	I-protein
gene	I-protein
240	O
-	O
260	O
kb	O
telomeric	O
to	O
the	O
IRF1	B-protein
gene	I-protein
and	O
characterized	O
its	O
genomic	O
structure	O
.	O

In	O
49	O
patients	O
in	O
whom	O
gated	O
equilibrium	O
ventriculography	O
and	O
cardiac	O
catheterization	O
were	O
performed	O
within	O
a	O
6	O
day	O
interval	O
,	O
total	O
and	O
fractional	O
portions	O
of	O
global	O
and	O
regional	O
right	O
ventricular	O
ejection	O
fraction	O
(	O
RVEF	O
)	O
were	O
correlated	O
with	O
pulmonary	O
arterial	O
systolic	O
pressure	O
.	O

METHODS	O
:	O
302	O
consecutive	O
patients	O
with	O
BS	O
and	O
438	O
patients	O
with	O
other	O
rheumatological	O
conditions	O
were	O
surveyed	O
for	O
the	O
presence	O
or	O
absence	O
of	O
the	O
features	O
of	O
BS	O
by	O
means	O
of	O
a	O
standard	O
form	O
which	O
had	O
been	O
prepared	O
according	O
to	O
ISG	O
criteria	O
.	O

In	O
general	O
,	O
however	O
,	O
this	O
study	O
provided	O
little	O
evidence	O
of	O
any	O
effect	O
of	O
supplementation	O
to	O
athletic	O
performance	O
for	O
athletes	O
consuming	O
the	O
dietary	O
RDIs	O
.	O

In	O
contrast	O
,	O
AP	B-protein
-	I-protein
2	I-protein
binding	O
activity	O
was	O
significantly	O
greater	O
in	O
T47D	O
cells	O
,	O
and	O
Western	O
blots	O
confirmed	O
increased	O
AP	B-protein
-	I-protein
2	I-protein
protein	I-protein
levels	O
in	O
these	O
cells	O
.	O

Deletion	O
of	O
the	O
last	O
two	O
Ser	O
residues	O
,	O
including	O
one	O
PKC	B-protein
consensus	O
site	O
in	O
the	O
receptor	O
tail	O
,	O
prevented	O
only	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
-	O
induced	O
desensitization	O
by	O
30	O
%	O
.	O

This	O
was	O
performed	O
in	O
a	O
double	O
blinded	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O

E2F	B-protein
-	I-protein
6	I-protein
shares	O
significant	O
homology	O
with	O
E2Fs	B-protein
1	I-protein
-	I-protein
5	I-protein
,	O
especially	O
within	O
the	O
DNA	O
binding	O
,	O
heterodimerization	O
and	O
marked	O
box	O
domains	O
.	O

Pharmacoeconomic	O
assessment	O
of	O
HMG	B-protein
-	I-protein
CoA	I-protein
reductase	I-protein
inhibitor	O
therapy	O
:	O
an	O
analysis	O
based	O
on	O
the	O
CURVES	O
study	O
.	O

A	O
quantitative	O
analysis	O
of	O
the	O
diffraction	O
intensity	O
as	O
function	O
of	O
the	O
accumulated	O
electron	O
dose	O
suggests	O
the	O
possibility	O
of	O
recording	O
up	O
to	O
250	O
diffraction	O
patterns	O
with	O
3	O
.	O
5	O
A	O
resolution	O
from	O
a	O
single	O
crotoxin	O
complex	O
crystal	O
128	O
A	O
thick	O
.	O

Essential	O
features	O
of	O
this	O
model	O
are	O
bending	O
of	O
the	O
DNA	O
double	O
helix	O
and	O
contact	O
of	O
operator	O
sites	O
with	O
repressor	O
domains	O
bearing	O
sequence	O
homologies	O
with	O
the	O
helix	O
-	O
turn	O
-	O
helix	O
(	O
HTH	O
)	O
motifs	O
of	O
other	O
DNA	O
-	O
binding	O
proteins	O
.	O

Organisms	O
were	O
recovered	O
from	O
the	O
conjunctiva	O
for	O
several	O
weeks	O
,	O
and	O
persistent	O
genital	O
and	O
gastrointestinal	O
infection	O
also	O
resulted	O
from	O
the	O
ocular	O
infection	O
in	O
some	O
cats	O
.	O

Mean	O
rCBF	O
increased	O
in	O
some	O
patients	O
4	O
-	O
8	O
weeks	O
after	O
surgery	O
on	O
the	O
ipsilateral	O
side	O
.	O

The	O
first	O
exon	O
encodes	O
66	O
bp	O
of	O
the	O
5	O
'	O
-	O
untranslated	O
sequence	O
,	O
while	O
exon	O
2	O
encodes	O
the	O
coding	O
and	O
3	O
'	O
-	O
untranslated	O
sequences	O
.	O

A	O
key	O
event	O
in	O
this	O
process	O
is	O
the	O
selective	O
recognition	O
of	O
the	O
target	O
membrane	O
by	O
the	O
vesicle	O
and	O
the	O
current	O
view	O
is	O
that	O
SNARE	B-protein
protein	I-protein
interactions	O
likely	O
play	O
a	O
central	O
role	O
in	O
vesicle	O
-	O
target	O
recognition	O
and	O
or	O
membrane	O
fusion	O
.	O

This	O
site	O
acts	O
as	O
a	O
negative	O
element	O
when	O
transferred	O
to	O
the	O
thymidine	B-protein
kinase	I-protein
promoter	I-protein
,	O
but	O
does	O
not	O
confer	O
inducibility	O
.	O

CONCLUSION	O
:	O
Vitrectomy	O
for	O
vitreous	O
hemorrhage	O
in	O
Terson	O
syndrome	O
is	O
a	O
safe	O
and	O
effective	O
procedure	O
,	O
offering	O
a	O
rapid	O
and	O
prolonged	O
improvement	O
in	O
vision	O
.	O

Mouse	B-protein
growth	I-protein
hormone	I-protein
transcription	I-protein
factor	I-protein
Zn	I-protein
-	I-protein
16	I-protein
:	O
unique	O
bipartite	O
structure	O
containing	O
tandemly	O
repeated	O
zinc	O
finger	O
domains	O
not	O
reported	O
in	O
rat	B-protein
Zn	I-protein
-	I-protein
15	I-protein
.	O

By	O
screening	O
a	O
Y1	O
cell	O
cDNA	O
library	O
with	O
the	O
DNA	O
-	O
binding	O
region	O
of	O
the	O
H	B-protein
-	I-protein
2RIIBP	I-protein
nuclear	I-protein
hormone	I-protein
receptor	I-protein
cDNA	I-protein
,	O
we	O
isolated	O
a	O
cDNA	O
that	O
is	O
selectively	O
expressed	O
in	O
steroidogenic	O
cells	O
.	O

Pentachlorophenol	O
accelerates	O
the	O
onset	O
of	O
HCB	O
porphyria	O
,	O
in	O
other	O
words	O
it	O
increases	O
the	O
total	O
urinary	B-protein
porphyrin	I-protein
excretion	O
and	O
causes	O
an	O
earlier	O
disturbance	O
of	O
the	O
porphyrin	B-protein
pattern	O
.	O

A	O
cDNA	O
clone	O
encoding	O
C2H2	B-protein
-	I-protein
type	I-protein
zinc	I-protein
finger	I-protein
protein	I-protein
,	O
SCOF	B-protein
-	I-protein
1	I-protein
,	O
was	O
isolated	O
from	O
soybean	O
.	O

EGV	O
had	O
no	O
detectable	O
effect	O
on	O
PP	B-protein
secretion	O
under	O
basal	O
or	O
stimulated	O
conditions	O
.	O

Linearized	O
overall	O
infection	O
rates	O
(	O
events	O
/	O
100	O
patient	O
-	O
days	O
)	O
were	O
2	O
.	O
05	O
+	O
/	O
-	O
0	O
.	O
33	O
(	O
heart	O
-	O
lung	O
)	O
and	O
2	O
.	O
34	O
+	O
/	O
-	O
0	O
.	O
34	O
(	O
double	O
-	O
lung	O
;	O
P	O
=	O
NS	O
)	O
at	O
3	O
months	O
.	O

Hepatitis	O
B	O
and	O
C	O
seroprevalence	O
rates	O
among	O
high	O
-	O
risk	O
adolescents	O
are	O
lower	O
in	O
El	O
Paso	O
than	O
in	O
other	O
similar	O
US	O
populations	O
,	O
presenting	O
an	O
ideal	O
climate	O
for	O
prevention	O
programs	O
.	O

The	O
results	O
suggest	O
that	O
the	O
presence	O
or	O
absence	O
per	O
se	O
of	O
keratan	O
sulfate	O
on	O
native	O
G1	O
-	O
G2	O
does	O
not	O
affect	O
the	O
activity	O
of	O
atrolysin	O
C	O
toward	O
the	O
two	O
sites	O
.	O

Charcoal	O
-	O
facilitated	O
dialysis	O
.	O

This	O
means	O
that	O
the	O
loss	O
of	O
recessives	O
must	O
be	O
calculated	O
by	O
using	O
a	O
hypergeometric	O
and	O
not	O
a	O
binomial	O
model	O
as	O
Fisher	O
did	O
.	O

We	O
have	O
cloned	O
a	O
novel	O
100	O
-	O
kDa	O
mammalian	O
protein	O
,	O
which	O
was	O
recognized	O
by	O
an	O
anti	O
-	O
peptide	O
antibody	O
against	O
an	O
epitope	O
-	O
containing	O
nuclear	O
localization	O
signal	O
of	O
NF	B-protein
-	I-protein
kappaB	I-protein
p65	I-protein
subunit	I-protein
.	O

The	O
U14	B-protein
genes	I-protein
of	O
mouse	O
as	O
well	O
as	O
rat	O
,	O
hamster	O
,	O
human	O
,	O
Xenopus	O
and	O
trout	O
are	O
encoded	O
within	O
introns	O
of	O
the	O
constitutively	O
expressed	O
70	B-protein
-	I-protein
kDa	I-protein
-	I-protein
cognate	I-protein
-	I-protein
heat	I-protein
-	I-protein
shock	I-protein
protein	I-protein
gene	I-protein
(	O
hsc70	B-protein
)	O
.	O

Presidential	O
address	O
1990	O
-	O
-	O
coming	O
in	O
from	O
the	O
cold	O
.	O

The	O
control	O
group	O
included	O
8	O
afterbirth	O
samples	O
from	O
physiological	O
full	O
-	O
term	O
pregnancies	O
.	O

Scalp	O
flaps	O
can	O
be	O
expanded	O
just	O
to	O
the	O
point	O
of	O
becoming	O
noticeable	O
over	O
4	O
to	O
6	O
weeks	O
followed	O
by	O
scalp	O
flap	O
transposition	O
and	O
easy	O
closure	O
of	O
the	O
donor	O
site	O
.	O

The	O
negative	O
calcium	O
balance	O
with	O
hyperparathyroidemia	O
occurred	O
after	O
continuous	O
oral	O
administration	O
of	O
Cd	O
and	O
developed	O
via	O
increased	O
urinary	O
excretion	O
of	O
calcium	O
.	O

Wild	B-protein
type	I-protein
and	I-protein
mutant	I-protein
Epo	I-protein
cDNAs	I-protein
were	O
transiently	O
expressed	O
at	O
high	O
levels	O
in	O
COS1	O
and	O
COS7	O
cells	O
.	O

This	O
technique	O
was	O
employed	O
in	O
12	O
patients	O
with	O
a	O
unicameral	O
bone	O
cyst	O
.	O

Studies	O
of	O
MPO	B-protein
gene	I-protein
regulation	O
can	O
help	O
to	O
elucidate	O
the	O
mechanism	O
of	O
normal	O
and	O
abnormal	O
myeloid	O
differentiation	O
.	O

The	O
sympathetic	O
neuroeffector	O
influence	O
on	O
the	O
myocardium	O
with	O
ATCI	O
depends	O
to	O
a	O
large	O
measure	O
on	O
the	O
intensity	O
of	O
the	O
neurotransmitter	O
biosynthesis	O
and	O
function	O
of	O
cardiomyocyte	O
adrenoreceptors	B-protein
.	O

Oncological	O
,	O
clinical	O
and	O
psychological	O
aspects	O
are	O
evaluated	O
according	O
to	O
experience	O
accumulated	O
in	O
recent	O
years	O
,	O
with	O
immediate	O
and	O
delayed	O
reconstruction	O
,	O
carried	O
out	O
in	O
the	O
most	O
diverse	O
specialized	O
centers	O
.	O

All	O
of	O
the	O
elements	O
exhibited	O
a	O
uniform	O
structure	O
.	O

Vivid	O
visual	O
hallucinations	O
without	O
other	O
psychopathology	O
have	O
been	O
reported	O
for	O
several	O
hundred	O
years	O
.	O

Sequencing	O
of	O
the	O
facB	B-protein
gene	I-protein
revealed	O
that	O
it	O
encodes	O
a	O
protein	O
that	O
contains	O
an	O
N	B-protein
-	I-protein
terminal	I-protein
GAL4	I-protein
-	I-protein
like	I-protein
Zn	I-protein
(	I-protein
II	I-protein
)	I-protein
2Cys6	I-protein
(	I-protein
or	I-protein
C6	I-protein
zinc	I-protein
)	I-protein
binuclear	I-protein
cluster	I-protein
for	O
DNA	O
binding	O
,	O
leucine	O
zipper	O
-	O
like	O
heptad	O
repeat	O
motifs	O
and	O
central	O
and	O
C	O
-	O
terminal	O
acidic	O
alpha	O
-	O
helical	O
regions	O
,	O
consistent	O
with	O
a	O
function	O
as	O
a	O
DNA	O
-	O
binding	O
transcriptional	O
activator	O
.	O

The	O
previously	O
described	O
enhanced	O
translation	O
of	O
spinach	O
L12	B-protein
mRNA	I-protein
from	O
its	O
two	O
tandem	O
AUG	O
codons	O
and	O
the	O
two	O
functional	O
rpl12	B-protein
genes	I-protein
in	O
Arabidopsis	O
probably	O
provide	O
two	O
mechanisms	O
for	O
generating	O
the	O
four	O
copies	O
of	O
L12	B-protein
/	I-protein
chloroplast	I-protein
ribosome	I-protein
,	O
qualitatively	O
different	O
from	O
those	O
attempted	O
in	O
eubacteria	O
.	O

We	O
report	O
a	O
patient	O
developing	O
factor	B-protein
VII	I-protein
inhibitor	I-protein
possibly	O
as	O
a	O
reaction	O
to	O
penicillin	O
administration	O
;	O
it	O
gave	O
rise	O
to	O
fatal	O
haemorrhage	O
.	O

Both	O
inserts	O
are	O
larger	O
than	O
their	O
homologues	O
in	O
eIF	B-protein
-	I-protein
2alpha	I-protein
kinases	I-protein
.	O

Wnt	B-protein
-	I-protein
1	I-protein
(	O
int	B-protein
-	I-protein
1	I-protein
)	O
is	O
a	O
cellular	O
oncogene	O
often	O
activated	O
by	O
insertion	O
of	O
proviral	O
DNA	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
.	O

Effects	O
of	O
ketamine	O
on	O
the	O
circulatory	O
functions	O
and	O
body	O
tissue	O
oxygenation	O
in	O
dogs	O
under	O
normal	O
and	O
hypovolemic	O
conditions	O
.	O

Polymerization	O
of	O
neurofilament	B-protein
L	I-protein
protein	I-protein
in	O
vitro	O
was	O
inhibited	O
by	O
phosphorylation	O
of	O
neurofilament	B-protein
L	I-protein
protein	I-protein
by	O
PKN	B-protein
.	O

Repair	O
of	O
this	O
insertion	O
by	O
homologous	O
recombination	O
restores	O
the	O
activity	O
of	O
the	O
hprt	B-protein
locus	I-protein
,	O
thus	O
confirming	O
the	O
site	O
of	O
mutation	O
.	O

Ten	O
selenocysteine	O
residues	O
(	O
deduced	O
)	O
are	O
present	O
.	O

Recent	O
studies	O
have	O
revealed	O
unconventional	O
myosin	B-protein
V	I-protein
to	O
be	O
an	O
important	O
actin	O
-	O
based	O
molecular	O
motor	O
involved	O
in	O
vesicular	O
movement	O
.	O

Hepatitis	O
-	O
B	O
vaccination	O
in	O
the	O
elderly	O
.	O

No	O
evidence	O
of	O
either	O
positive	O
or	O
negative	O
chemography	O
was	O
found	O
.	O

A	O
third	O
series	O
of	O
mice	O
were	O
given	O
a	O
single	O
injection	O
of	O
5	O
-	O
OH	O
-	O
DA	O
,	O
sacrificed	O
,	O
and	O
prepared	O
for	O
ultrastructural	O
study	O
.	O

We	O
also	O
present	O
evidence	O
for	O
a	O
negative	O
regulatory	O
element	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
Mlu	B-protein
I	I-protein
upstream	I-protein
activation	I-protein
sequence	I-protein
.	O

No	O
causal	O
relations	O
may	O
be	O
inferred	O
from	O
the	O
correlation	O
between	O
the	O
level	O
of	O
trapezius	O
activity	O
and	O
complaints	O
,	O
though	O
it	O
indicates	O
that	O
individual	O
,	O
inexpedient	O
muscle	O
activity	O
patterns	O
may	O
constitute	O
an	O
important	O
risk	O
factor	O
for	O
development	O
of	O
musculo	O
-	O
skeletal	O
complaints	O
.	O

Finally	O
,	O
the	O
C	O
-	O
terminal	O
region	O
of	O
ENBP1	B-protein
shows	O
strong	O
homology	O
to	O
a	O
protein	O
from	O
rat	O
that	O
is	O
specifically	O
expressed	O
in	O
testis	O
tissue	O
.	O

Modality	O
-	O
specific	O
areas	O
(	O
e	O
.	O
g	O
.	O
,	O
right	O
Wernicke	O
,	O
left	O
fusiform	O
gyrus	O
,	O
Broca	O
BA44	O
,	O
supramarginal	O
gyrus	O
)	O
,	O
appear	O
to	O
cope	O
with	O
the	O
computations	O
relevant	O
to	O
making	O
contact	O
with	O
these	O
more	O
abstract	O
dimensions	O
.	O

The	O
promoter	O
mutation	O
is	O
complemented	O
in	O
trans	O
by	O
E1A	B-protein
products	O
of	O
the	O
heterologous	O
helper	O
adenovirus	O
type	O
5	O
(	O
Ad5	O
)	O
.	O

The	O
predictive	O
value	O
of	O
a	O
positive	O
flag	O
was	O
77	O
.	O
7	O
%	O
.	O

Significance	O
of	O
cytokine	O
production	O
and	O
adhesion	O
molecules	O
in	O
malarial	O
immunopathology	O
.	O

Myocardial	O
interstitial	O
edema	O
is	O
more	O
likely	O
a	O
potential	O
mechanism	O
of	O
diastolic	O
dysfunction	O
after	O
DC	O
shocks	O
.	O

All	O
loci	O
have	O
a	O
similar	O
organization	O
,	O
except	O
for	O
H1	B-protein
.	I-protein
8	I-protein
that	O
harbors	O
two	O
TcP2beta	B-protein
genes	I-protein
arranged	O
in	O
tandem	O
and	O
separated	O
by	O
a	O
short	O
repetitive	O
sequence	O
,	O
named	O
SIRE	B-protein
(	O
short	B-protein
interspersed	I-protein
repetitive	I-protein
element	I-protein
)	O
,	O
which	O
is	O
also	O
found	O
upstream	O
of	O
the	O
first	O
gene	O
of	O
the	O
tandem	O
and	O
downstream	O
of	O
the	O
second	O
.	O

Statins	B-protein
:	O
lower	O
lipids	O
and	O
better	O
bones	O
?	O
Although	O
statins	O
are	O
widely	O
used	O
as	O
cholesterol	O
-	O
lowering	O
drugs	O
,	O
a	O
recent	O
study	O
suggests	O
that	O
these	O
compounds	O
have	O
anabolic	O
effects	O
on	O
bone	O
and	O
could	O
be	O
developed	O
into	O
new	O
treatments	O
for	O
common	O
metabolic	O
bone	O
diseases	O
such	O
as	O
osteoporosis	O

Campomelic	O
dysplasia	O
translocation	O
breakpoints	O
are	O
scattered	O
over	O
1	O
Mb	O
proximal	O
to	O
SOX9	B-protein
:	O
evidence	O
for	O
an	O
extended	O
control	O
region	O
.	O

It	O
was	O
found	O
that	O
intrathecal	O
administration	O
(	O
i	O
.	O
t	O
.	O
)	O
of	O
D2	B-protein
receptor	I-protein
agonist	O
LY171555	O
or	O
D1	B-protein
/	I-protein
D2	I-protein
receptor	I-protein
agonist	O
apomorphine	O
increased	O
pain	O
threshold	O
and	O
had	O
a	O
potentiating	O
effect	O
on	O
AA	O
.	O

The	O
Babcock	O
Surgical	O
Clinic	O
.	O

Internal	O
biliary	O
drainage	O
,	O
unlike	O
external	O
drainage	O
,	O
does	O
not	O
suppress	O
the	O
regeneration	O
of	O
cholestatic	O
rat	O
liver	O
after	O
partial	O
hepatectomy	O
.	O

Induced	O
expression	O
of	O
c	B-protein
-	I-protein
myc	I-protein
is	O
likely	O
to	O
contribute	O
to	O
the	O
proliferation	O
of	O
Stat1	O
-	O
null	O
cells	O
in	O
response	O
to	O
IFNs	B-protein
.	O

Further	O
experiments	O
will	O
be	O
required	O
to	O
highlight	O
the	O
in	O
vivo	O
role	O
of	O
ELE1	B-protein
in	O
nuclear	O
receptor	O
functioning	O
.	O

The	O
incidence	O
of	O
early	O
neonatal	O
convulsions	O
for	O
inborn	O
babies	O
was	O
3	O
.	O
0	O
/	O
1000	O
live	O
births	O
.	O

A	O
comprehensive	O
neuropsychological	O
battery	O
was	O
administered	O
to	O
48	O
veterans	O
with	O
Gulf	O
War	O
Illness	O
(	O
GWI	O
)	O
characterized	O
by	O
severe	O
fatigue	O
(	O
GV	O
-	O
F	O
)	O
and	O
39	O
healthy	O
veterans	O
(	O
GV	O
-	O
H	O
)	O
.	O

Comparison	O
of	O
propofol	O
and	O
thiopentone	O
as	O
anaesthetic	O
agents	O
for	O
electroconvulsive	O
therapy	O
.	O

It	O
is	O
suggested	O
that	O
the	O
use	O
of	O
endogenous	O
creatinine	O
clearance	O
to	O
estimate	O
the	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
requires	O
caution	O
and	O
the	O
recognition	O
of	O
the	O
limitations	O
of	O
the	O
method	O
,	O
and	O
that	O
simpler	O
techniques	O
(	O
serum	O
creatinine	O
or	O
estimated	O
endogenous	O
creatinine	O
clearance	O
)	O
are	O
preferable	O
in	O
routine	O
practice	O
.	O

PURPOSE	O
/	O
OBJECTIVES	O
:	O
To	O
examine	O
the	O
question	O
of	O
whether	O
an	O
early	O
first	O
full	O
-	O
term	O
pregnancy	O
(	O
FFTP	O
)	O
protects	O
against	O
breast	O
cancer	O
and	O
whether	O
interruption	O
of	O
the	O
pregnancy	O
with	O
an	O
induced	O
abortion	O
increases	O
breast	O
cancer	O
risk	O
.	O

The	O
hypBFCDE	B-protein
operon	I-protein
from	O
Rhizobium	O
leguminosarum	O
biovar	O
viciae	O
is	O
expressed	O
from	O
an	O
Fnr	B-protein
-	I-protein
type	I-protein
promoter	I-protein
that	O
escapes	O
mutagenesis	O
of	O
the	O
fnrN	B-protein
gene	I-protein
.	O

This	O
interaction	O
inhibits	O
the	O
histone	B-protein
acetyltransferase	I-protein
activity	O
of	O
p300	B-protein
,	O
resulting	O
in	O
drastic	O
reduction	O
of	O
nucleosomal	O
histone	B-protein
acetylation	O
and	O
alteration	O
of	O
chromatin	O
structure	O
.	O

Unlike	O
the	O
MAR	O
-	O
binding	O
domain	O
,	O
the	O
homeodomain	O
when	O
isolated	O
binds	O
poorly	O
and	O
with	O
low	O
specificity	O
to	O
DNA	O
.	O

In	O
addition	O
,	O
severe	O
vision	O
loss	O
can	O
be	O
seen	O
with	O
interferon	B-protein
alfa	O
-	O
2b	O
-	O
associated	O
retinopathy	O
.	O

Previous	O
investigators	O
have	O
suggested	O
that	O
subretinal	O
blood	O
damages	O
the	O
retina	O
in	O
part	O
because	O
of	O
its	O
solid	O
fibrin	B-protein
meshwork	O
.	O

High	O
expression	O
of	O
the	O
peroxisome	B-protein
proliferator	I-protein
-	I-protein
activated	I-protein
receptor	I-protein
alpha	I-protein
(	O
PPARalpha	B-protein
)	O
differentiates	O
brown	O
fat	O
from	O
white	O
,	O
and	O
is	O
related	O
to	O
its	O
high	O
capacity	O
of	O
lipid	O
oxidation	O
.	O

In	O
vitro	O
translation	O
and	O
in	O
vivo	O
polysome	O
profile	O
analysis	O
indicated	O
that	O
transcripts	B-protein
C	I-protein
and	I-protein
E	I-protein
were	O
translated	O
with	O
similar	O
translational	O
efficiencies	O
that	O
are	O
substantially	O
greater	O
than	O
that	O
of	O
transcript	B-protein
D	I-protein
,	O
suggesting	O
that	O
5	O
'	O
-	O
untranslated	O
regions	O
play	O
a	O
role	O
in	O
translational	O
control	O
.	O

RNase	B-protein
protection	O
analyses	O
indicate	O
that	O
either	O
61	B-protein
-	I-protein
kDa	I-protein
CaM	I-protein
PDE	I-protein
mRNA	I-protein
or	O
structurally	O
related	O
transcripts	O
encoding	O
different	O
CaM	B-protein
PDE	I-protein
isoforms	I-protein
are	O
expressed	O
in	O
a	O
tissue	O
-	O
specific	O
manner	O
.	O

The	O
5	O
'	O
end	O
of	O
the	O
coding	O
region	O
was	O
located	O
precisely	O
by	O
comparing	O
the	O
deduced	O
amino	O
acid	O
sequence	O
to	O
the	O
actual	O
N	O
-	O
terminal	O
amino	O
acid	O
sequence	O
of	O
IHF	B-protein
.	O

The	O
missing	O
5	O
'	O
sequences	O
were	O
obtained	O
by	O
5	O
'	O
-	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
and	O
by	O
analysis	O
of	O
an	O
NHE5	B-protein
genomic	I-protein
clone	I-protein
,	O
and	O
the	O
missing	O
3	O
'	O
sequences	O
were	O
obtained	O
by	O
3	O
'	O
-	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
.	O

We	O
showed	O
that	O
Stat3	B-protein
and	O
Stat3beta	B-protein
were	O
affinity	O
purified	O
using	O
phosphopeptides	O
containing	O
Y704	O
and	O
Y744	O
but	O
not	O
by	O
nonphosphorylated	O
peptide	O
analogues	O
or	O
by	O
phosphopeptides	O
containing	O
Y729	O
and	O
Y764	O
.	O

Brain	B-protein
cholinesterase	I-protein
activity	O
of	O
nestling	O
great	O
egrets	O
,	O
snowy	O
egrets	O
and	O
black	O
-	O
crowned	O
night	O
-	O
herons	O
.	O
inhibition	O
of	O
brain	B-protein
cholinesterase	I-protein
(	O
ChE	B-protein
)	O
activity	O
in	O
birds	O
is	O
often	O
used	O
to	O
diagnose	O
exposure	O
or	O
death	O
from	O
organophosphorus	O
or	O
carbamate	O
pesticides	O
.	O

Furthermore	O
,	O
competitor	O
containing	O
the	O
YY1	B-protein
consensus	I-protein
sequence	I-protein
competed	O
for	O
protein	B-protein
B	I-protein
binding	O
,	O
whereas	O
competitor	O
containing	O
a	O
perfect	O
yeast	B-protein
ABF	I-protein
-	I-protein
1	I-protein
consensus	I-protein
sequence	I-protein
did	O
not	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

VaI	B-protein
and	O
VaII	B-protein
co	O
-	O
immunoprecipitated	O
with	O
ErbB2	B-protein
,	O
but	O
not	O
with	O
ErbB1	B-protein
,	O
ErbB3	B-protein
,	O
or	O
ErbB4	B-protein
.	O

ELISA	O
was	O
found	O
to	O
make	O
a	O
contribution	O
to	O
the	O
diagnosis	O
of	O
tuberculosis	O
similar	O
to	O
that	O
of	O
sputum	O
smear	O
.	O

The	O
levels	O
of	O
both	O
MAP1	B-protein
-	I-protein
specific	I-protein
and	I-protein
MAP2	I-protein
-	I-protein
specific	I-protein
mRNAs	I-protein
decline	O
in	O
the	O
postnatal	O
developing	O
brain	O
;	O
the	O
level	O
of	O
MAP1	B-protein
-	I-protein
specific	I-protein
mRNA	I-protein
also	O
increases	O
slightly	O
in	O
rat	O
PC12	O
cells	O
upon	O
exposure	O
to	O
nerve	B-protein
growth	I-protein
factor	I-protein
.	O

Human	O
SRF	B-protein
-	I-protein
related	I-protein
proteins	I-protein
:	O
DNA	O
-	O
binding	O
properties	O
and	O
potential	O
regulatory	O
targets	O
.	O

Comparison	O
of	O
transmembrane	O
and	O
cytoplasmic	O
domains	O
to	O
a	O
third	O
cell	O
-	O
surface	O
proteoglycan	O
,	O
48K5	B-protein
from	O
human	O
lung	O
fibroblasts	O
(	O
Marynen	O
,	O
P	O
.	O
,	O
Zhang	O
,	O
J	O
.	O
,	O
Cassiman	O
,	O
J	O
.	O
,	O
Vanden	O
Berghe	O
,	O
H	O
.	O
,	O
and	O
David	O
,	O
C	O
.	O

Heterodimers	O
of	O
myogenin	B-protein
and	O
E12	B-protein
(	O
or	O
MyoD	B-protein
and	O
E12	B-protein
)	O
specifically	O
bound	O
a	O
restriction	O
fragment	O
extending	O
from	O
-	O
200	O
to	O
-	O
103	O
relative	O
to	O
the	O
start	O
of	O
cardiac	B-protein
alpha	I-protein
-	I-protein
actin	I-protein
transcription	O
.	O

Regulation	O
of	O
irgA	B-protein
by	O
iron	O
in	O
V	O
.	O
cholerae	O
occurs	O
at	O
the	O
transcriptional	O
level	O
,	O
and	O
there	O
is	O
an	O
interrupted	O
dyad	O
symmetric	O
sequence	O
in	O
the	O
vicinity	O
of	O
the	O
promoter	O
that	O
is	O
homologous	O
to	O
Fur	B-protein
binding	I-protein
sites	I-protein
of	O
E	O
.	O
coli	O
.	O

Intravenous	O
L	O
-	O
carnitine	O
treatment	O
increased	O
plasma	O
carnitine	O
concentrations	O
,	O
improved	O
patient	O
-	O
assessed	O
fatigue	O
,	O
and	O
may	O
prevent	O
the	O
decline	O
in	O
peak	O
exercise	O
capacity	O
in	O
hemodialysis	O
patients	O
.	O

Dose	O
of	O
20	O
ig	O
were	O
administered	O
within	O
a	O
scheme	O
from	O
0	O
.	O
1	O
to	O
6	O
months	O
in	O
order	O
to	O
study	O
its	O
immunogenicity	O
,	O
which	O
was	O
evaluated	O
at	O
2	O
,	O
7	O
,	O
and	O
12	O
months	O
after	O
the	O
first	O
dose	O
.	O

Initiation	O
of	O
translation	O
of	O
the	O
human	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
RNA	O
genome	O
occurs	O
by	O
internal	O
ribosome	O
entry	O
into	O
the	O
5	O
'	O
noncoding	O
region	O
(	O
5	O
'	O
NCR	O
)	O
in	O
a	O
cap	O
-	O
independent	O
manner	O
.	O

Appl	O
.	O

The	O
effect	O
of	O
nitric	B-protein
oxide	I-protein
synthase	I-protein
inhibitor	O
on	O
reperfusion	O
injury	O
of	O
the	O
brain	O
under	O
hypothermic	O
circulatory	O
arrest	O
.	O

The	O
c	B-protein
-	I-protein
myc	I-protein
and	O
skeletal	B-protein
alpha	I-protein
-	I-protein
actin	I-protein
gene	I-protein
promoters	I-protein
contain	O
YY1	B-protein
binding	I-protein
sites	I-protein
thought	O
to	O
act	O
either	O
as	O
positive	O
or	O
negative	O
cis	O
-	O
acting	O
elements	O
.	O

Sixteen	O
other	O
normal	O
subjects	O
with	O
2	O
g	O
of	O
Metyrapone	O
are	O
best	O
responses	O
.	O

cDNA	O
cloning	O
,	O
expression	O
analysis	O
,	O
and	O
chromosomal	O
localization	O
of	O
a	O
gene	O
with	O
high	O
homology	O
to	O
wheat	B-protein
eIF	I-protein
-	I-protein
(	I-protein
iso	I-protein
)	I-protein
4F	I-protein
and	O
mammalian	B-protein
eIF	I-protein
-	I-protein
4G	I-protein
.	O

We	O
used	O
oligonucleotide	O
-	O
directed	O
mutagenesis	O
to	O
alter	O
a	O
site	O
in	O
MucA	B-protein
homologous	O
to	O
the	O
Ala	O
-	O
Gly	O
cleavage	O
site	O
of	O
LexA	B-protein
.	O

The	O
C	O
-	O
terminal	O
peptide	O
sequences	O
of	O
the	O
human	B-protein
lymphocyte	I-protein
-	I-protein
specific	I-protein
high	I-protein
mobility	I-protein
group	I-protein
(	I-protein
HMG	I-protein
)	I-protein
-	I-protein
box	I-protein
transcription	I-protein
factor	I-protein
TCF	I-protein
-	I-protein
1	I-protein
are	O
determined	O
by	O
alternative	O
splice	O
mechanisms	O
affecting	O
the	O
exons	O
VIII	O
to	O
X	O
.	O

Five	O
concensus	O
poly	O
A	O
addition	O
sites	O
are	O
located	O
in	O
the	O
350	O
base	O
pairs	O
immediately	O
following	O
the	O
protein	B-protein
IX	I-protein
coding	O
region	O
.	O

Colorimetric	O
method	O
of	O
determining	O
glycerin	O
in	O
the	O
blood	O
.	O

Comparison	O
of	O
Tc	O
-	O
99m	O
sestamibi	O
perfusion	O
imaging	O
and	O
echocardiography	O
using	O
an	O
arbutamine	O
infusion	O
for	O
the	O
detection	O
of	O
coronary	O
artery	O
disease	O
.	O

These	O
sequences	O
were	O
then	O
used	O
to	O
clone	O
the	O
full	O
-	O
length	O
genes	O
from	O
a	O
yeast	O
genomic	O
library	O
.	O

This	O
gave	O
rise	O
to	O
RNA	O
molecules	O
with	O
3	O
'	O
-	O
untranslated	O
regions	O
of	O
roughly	O
375	O
,	O
655	O
,	O
and	O
945	O
base	O
pairs	O
.	O

Organ	O
transplantation	O
in	O
Denmark	O
.	O

We	O
conclude	O
that	O
at	O
steady	O
state	O
the	O
timing	O
of	O
a	O
light	O
meal	O
is	O
unlikely	O
to	O
alter	O
in	O
any	O
clinically	O
important	O
manner	O
the	O
pharmacokinetics	O
of	O
nifedipine	O
released	O
from	O
'	O
biphasic	O
'	O
tablets	O
.	O

Family	O
planning	O
continues	O
to	O
play	O
a	O
minor	O
role	O
,	O
and	O
only	O
25	O
.	O
3	O
per	O
cent	O
of	O
all	O
patients	O
reviewed	O
took	O
to	O
oral	O
contraceptives	O
for	O
shorter	O
or	O
longer	O
periods	O
of	O
time	O
.	O
-	O
The	O
percentages	O
of	O
primiparae	O
and	O
secundiparae	O
in	O
all	O
births	O
as	O
well	O
as	O
the	O
high	O
percentage	O
of	O
multigravidity	O
are	O
parameters	O
by	O
which	O
the	O
approach	O
to	O
reproduction	O
differs	O
substantively	O
from	O
behaviour	O
patterns	O
in	O
Europe	O
.	O

The	O
double	O
-	O
stranded	O
RNA	O
binding	O
domain	O
(	O
dsRBD	O
)	O
is	O
an	O
approximately	O
65	O
amino	O
acid	O
motif	O
that	O
is	O
found	O
in	O
a	O
variety	O
of	O
proteins	O
that	O
interact	O
with	O
double	O
-	O
stranded	O
(	O
ds	O
)	O
RNA	O
,	O
such	O
as	O
Escherichia	O
coli	O
RNase	B-protein
III	I-protein
and	O
the	O
dsRNA	B-protein
-	I-protein
dependent	I-protein
kinase	I-protein
,	O
PKR	B-protein
.	O

Sexually	O
conditioned	O
incentives	O
:	O
Attenuation	O
of	O
motivational	O
impact	O
during	O
dopamine	B-protein
receptor	I-protein
antagonism	O
.	O

Of	O
the	O
serum	B-protein
neutralizing	I-protein
(	I-protein
SN	I-protein
)	I-protein
antibody	I-protein
negative	O
calves	O
89	O
.	O
7	O
%	O
(	O
26	O
/	O
29	O
)	O
and	O
92	O
.	O
8	O
%	O
(	O
90	O
/	O
97	O
)	O
developed	O
SN	B-protein
antibody	I-protein
1	O
month	O
after	O
intranasal	O
and	O
intramuscular	O
vaccination	O
,	O
respectively	O
.	O

Direct	O
binding	O
and	O
competition	O
assays	O
using	O
30	O
-	O
mer	O
oligonucleotide	O
probes	O
representing	O
the	O
individual	O
CBF1	B-protein
binding	I-protein
sites	I-protein
indicated	O
that	O
CBF1	B-protein
bound	O
less	O
efficiently	O
to	O
the	O
CD23	B-protein
promoter	I-protein
and	O
the	O
EBV	B-protein
LMP	I-protein
-	I-protein
1	I-protein
promoter	I-protein
sites	I-protein
than	O
to	O
the	O
Cp	B-protein
site	I-protein
.	O

The	O
present	O
study	O
investigates	O
whether	O
prostaglandins	O
`	O
`	O
cytoprotect	O
'	O
'	O
the	O
gastric	O
mucosa	O
against	O
hemorrhage	O
-	O
induced	O
stress	O
ulceration	O
by	O
assessing	O
the	O
influence	O
of	O
16	O
,	O
16	O
-	O
dimethyl	O
prostaglandin	O
E2	O
(	O
16	O
,	O
16	O
-	O
dm	O
PGE2	O
)	O
on	O
gross	O
and	O
microscopic	O
lesion	O
formation	O
,	O
intramucosal	O
tissue	O
pH	O
,	O
H	O
+	O
back	O
-	O
diffusion	O
,	O
and	O
mucosal	O
blood	O
flow	O
in	O
rat	O
gastric	O
mucosa	O
exposed	O
to	O
luminal	O
acid	O
(	O
100	O
mM	O
HCl	O
)	O
during	O
hemorrhagic	O
shock	O
(	O
13	O
ml	O
/	O
kg	O
for	O
20	O
min	O
)	O
.	O

In	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
copper	O
levels	O
exert	O
some	O
control	O
over	O
the	O
level	O
of	O
SOD1	B-protein
expression	O
.	O

Human	B-protein
homologue	I-protein
of	I-protein
yeast	I-protein
Rad23	I-protein
protein	I-protein
A	I-protein
interacts	O
with	O
p300	B-protein
/	I-protein
cyclic	I-protein
AMP	I-protein
-	I-protein
responsive	I-protein
element	I-protein
binding	I-protein
(	I-protein
CREB	I-protein
)	I-protein
-	I-protein
binding	I-protein
protein	I-protein
to	O
down	O
-	O
regulate	O
transcriptional	O
activity	O
of	O
p53	B-protein
.	O

They	O
consisted	O
of	O
behavioural	O
disorders	O
,	O
tetraparesis	O
,	O
incontinence	O
and	O
oculomotor	O
paralysis	O
.	O

Structural	O
features	O
of	O
the	O
minimal	O
DNA	O
binding	O
domain	O
(	O
M98	B-protein
-	I-protein
F219	I-protein
)	O
of	O
human	B-protein
nucleotide	I-protein
excision	I-protein
repair	I-protein
protein	I-protein
XPA	I-protein
.	O

Mining	O
the	O
diagnostic	O
iron	O
ore	O
.	O

We	O
report	O
the	O
successful	O
use	O
of	O
electroconvulsive	O
therapy	O
for	O
treatment	O
of	O
severe	O
depression	O
in	O
a	O
young	O
man	O
with	O
adult	O
GM2	O
gangliosidosis	O
.	O

The	O
transmembrane	O
topology	O
of	O
Na	O
(	O
+	O
)	O
/	O
H	O
(	O
+	O
)	O
exchanger	O
NHE3	B-protein
has	O
been	O
studied	O
using	O
in	O
vitro	O
transcription	O
/	O
translation	O
of	O
two	O
types	O
of	O
fusion	O
vectors	O
designed	O
to	O
test	O
membrane	O
insertion	O
properties	O
of	O
cDNA	O
sequences	O
encoding	O
putative	O
NHE3	B-protein
membrane	O
spanning	O
domains	O
(	O
msds	O
)	O
.	O

Stress	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
1	I-protein
(	O
SAPK1	B-protein
)	O
,	O
also	O
called	O
c	B-protein
-	I-protein
Jun	I-protein
N	I-protein
-	I-protein
terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
,	O
becomes	O
activated	O
in	O
vivo	O
in	O
response	O
to	O
pro	O
-	O
inflammatory	O
cytokines	O
or	O
cellular	O
stresses	O
.	O

The	O
therapeutic	O
use	O
of	O
botulinum	B-protein
toxin	I-protein
(	O
Botox	B-protein
)	O
is	O
increasing	O
in	O
popularity	O
.	O

Skin	O
pH	O
changes	O
associated	O
with	O
iontophoresis	O
.	O

METHODS	O
:	O
We	O
retrospectively	O
selected	O
13	O
TFCD	O
patients	O
who	O
underwent	O
surgery	O
for	O
intractable	O
epilepsy	O
with	O
the	O
aim	O
of	O
removing	O
the	O
magnetic	O
resonance	O
(	O
MR	O
)	O
-	O
detectable	O
lesion	O
and	O
/	O
or	O
the	O
epileptogenic	O
zone	O
defined	O
by	O
stereoelectroencephalographic	O
recordings	O
.	O

Isoform	B-protein
C	I-protein
beta	I-protein
2	I-protein
,	O
an	O
unusual	O
form	O
of	O
the	O
bovine	O
catalytic	O
subunit	O
of	O
cAMP	B-protein
-	I-protein
dependent	I-protein
protein	I-protein
kinase	I-protein
.	O

The	O
C	O
-	O
LIP	O
also	O
was	O
compared	O
with	O
transcather	O
arterial	O
embolization	O
(	O
TAE	O
;	O
C	O
-	O
LIP	O
followed	O
by	O
gelatin	O
sponge	O
)	O
and	O
percutaneous	O
ethanol	O
injection	O
therapy	O
(	O
PEIT	O
)	O
.	O

In	O
metastasis	O
-	O
free	O
patients	O
,	O
the	O
best	O
results	O
were	O
obtained	O
with	O
tumor	O
diameters	O
under	O
2	O
cm	O
regardless	O
of	O
their	O
localization	O
in	O
lung	O
tissue	O
and	O
with	O
2	O
-	O
-	O
4	O
.	O
9	O
cm	O
tumors	O
embedded	O
in	O
lung	O
parenchyma	O
.	O

In	O
vitro	O
assessment	O
of	O
the	O
biocompatibility	O
of	O
dental	O
materials	O
-	O
-	O
the	O
millipore	O
filter	O
method	O
.	O

The	O
N3	O
wave	O
of	O
the	O
SSEP	O
'	O
s	O
,	O
which	O
has	O
been	O
found	O
to	O
correlate	O
best	O
with	O
neurological	O
recovery	O
,	O
returned	O
to	O
65	O
%	O
+	O
/	O
-	O
48	O
%	O
of	O
the	O
preischemia	O
amplitude	O
in	O
the	O
insulin	O
-	O
treated	O
animals	O
,	O
compared	O
to	O
40	O
%	O
+	O
/	O
-	O
34	O
%	O
in	O
the	O
fasted	O
group	O
and	O
26	O
%	O
+	O
/	O
-	O
24	O
%	O
in	O
the	O
control	O
animals	O
.	O

Out	O
of	O
40	O
patients	O
,	O
who	O
initially	O
did	O
not	O
show	O
eye	O
complications	O
due	O
to	O
leprosy	O
,	O
37	O
patients	O
were	O
essentially	O
the	O
same	O
10	O
years	O
later	O
.	O

Data	O
were	O
obtained	O
from	O
2	O
undergraduate	O
student	O
samples	O
,	O
a	O
self	O
-	O
report	O
group	O
(	O
n	O
=	O
132	O
)	O
who	O
provided	O
NEO	O
-	O
PI	O
-	O
R	O
self	O
-	O
ratings	O
on	O
2	O
occasions	O
separated	O
by	O
a	O
7	O
-	O
to	O
14	O
-	O
day	O
interval	O
and	O
an	O
informant	O
group	O
(	O
n	O
=	O
109	O
)	O
who	O
provided	O
ratings	O
of	O
well	O
-	O
known	O
friends	O
or	O
relatives	O
on	O
2	O
occasions	O
separated	O
by	O
a	O
6	O
month	O
interval	O
.	O

These	O
are	O
two	O
regions	O
of	O
known	O
conserved	O
synteny	O
,	O
providing	O
further	O
evidence	O
that	O
the	O
human	B-protein
STEP	I-protein
is	O
a	O
true	O
homolog	O
of	O
the	O
murine	B-protein
STEP	I-protein
gene	I-protein
.	O

However	O
,	O
the	O
presence	O
of	O
Tax	B-protein
I	I-protein
increased	O
the	O
extent	O
and	O
altered	O
the	O
profile	O
of	O
proteins	O
binding	O
TRE	B-protein
-	I-protein
2	I-protein
in	O
vivo	O
.	O

The	O
FCMS	O
conditions	O
were	O
as	O
follows	O
:	O
2	O
kW	O
maximum	O
electrical	O
power	O
consumption	O
,	O
800	O
V	O
maximum	O
capacitor	O
voltage	O
,	O
720	O
microseconds	O
pulsewidth	O
(	O
180	O
microseconds	O
rise	O
time	O
)	O
,	O
and	O
5	O
-	O
30	O
Hz	O
frequency	O
.	O

The	O
study	O
goals	O
were	O
to	O
isolate	O
a	O
full	O
-	O
length	O
clone	O
encoding	O
CO	B-protein
-	I-protein
Ag	I-protein
from	O
a	O
bovine	O
corneal	O
cDNA	O
library	O
and	O
to	O
express	O
this	O
clone	O
in	O
Escherichia	O
coli	O
(	O
E	O
.	O
coli	O
)	O
.	O

The	O
promoter	O
activity	O
was	O
measured	O
by	O
a	O
transient	O
expression	O
of	O
a	O
chloramphenicol	B-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
gene	O
connected	O
with	O
various	O
5	O
'	O
-	O
deletion	O
mutants	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
.	O

To	O
further	O
our	O
knowledge	O
about	O
the	O
systemic	O
humoral	O
immune	O
system	O
response	O
to	O
weak	O
hapten	O
-	O
syngeneic	O
or	O
allogeneic	O
protein	O
conjugates	O
(	O
corrosion	O
and	O
wear	O
products	O
of	O
metallic	O
orthopedic	O
devices	O
)	O
,	O
a	O
sensitive	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
method	O
for	O
testing	O
for	O
antibody	O
(	O
humoral	O
immunity	O
)	O
to	O
metals	O
was	O
developed	O
.	O

Single	O
-	O
photon	O
emission	O
computed	O
tomography	O
(	O
SPECT	O
)	O
with	O
99mTc	O
-	O
hexamethylpropyleneamine	O
oxime	O
(	O
HMPAO	O
)	O
was	O
used	O
to	O
investigate	O
changes	O
in	O
cerebral	O
blood	O
flow	O
in	O
seven	O
patients	O
with	O
cortical	O
visual	O
impairment	O
.	O

Post	O
and	O
core	O
fabrication	O
for	O
divergent	O
canals	O
with	O
a	O
cast	O
post	O
and	O
core	O
and	O
a	O
prefabricated	O
dowel	O
.	O

Alison	O
Bell	O
Memorial	O
Award	O
.	O

Menetrier	O
disease	O
in	O
a	O
child	O
.	O

The	O
population	O
of	O
between	O
75	O
,	O
000	O
and	O
100	O
,	O
000	O
was	O
largely	O
unstable	O
,	O
and	O
cost	O
per	O
capita	O
was	O
$	O
0	O
.	O
95	O
to	O
$	O
1	O
.	O
21	O
.	O

Mutations	O
at	O
the	O
suf12	B-protein
locus	I-protein
were	O
isolated	O
in	O
Saccharomyces	O
cerevisiae	O
as	O
extragenic	O
suppressors	O
of	O
+	O
1	O
frameshift	O
mutations	O
in	O
glycine	O
(	O
GGX	O
)	O
and	O
proline	O
(	O
CCX	O
)	O
codons	O
,	O
as	O
well	O
as	O
UGA	O
and	O
UAG	O
nonsense	O
mutations	O
.	O

Absence	O
of	O
action	O
potentials	O
in	O
frog	O
slow	O
muscle	O
fibres	O
paralysed	O
by	O
botulinum	B-protein
toxin	I-protein
.	O

Pronounced	O
microangiopathy	O
characterized	O
by	O
avascular	O
fields	O
,	O
enlarged	O
and	O
tortuous	O
capillaries	O
and	O
increased	O
transcapillary	O
diffusion	O
of	O
sodium	O
fluorescein	O
,	O
was	O
clearly	O
demonstrable	O
in	O
the	O
area	O
of	O
the	O
nodules	O
.	O

Logistic	O
regression	O
analysis	O
revealed	O
that	O
physicians	O
were	O
3	O
.	O
6	O
times	O
more	O
likely	O
to	O
detect	O
thin	O
lesions	O
(	O
<	O
/	O
=	O
0	O
.	O
75	O
mm	O
)	O
compared	O
with	O
nonphysician	O
detectors	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
95	O
%	O
CI	O
]	O
,	O
2	O
.	O
1	O
,	O
6	O
.	O
5	O
;	O
P	O
=	O
0	O
.	O
0001	O
)	O
.	O

Relationships	O
with	O
the	O
acquired	O
immune	O
deficiency	O
syndrome	O
.	O

The	O
results	O
of	O
the	O
ISIS	O
-	O
2	O
trial	O
and	O
the	O
data	O
from	O
the	O
Antiplatelet	O
Trialists	O
'	O
Collaboration	O
indicated	O
that	O
aspirin	O
is	O
mandatory	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
and	O
for	O
secondary	O
prevention	O
.	O

This	O
paper	O
reviews	O
the	O
middleware	O
-	O
based	O
approach	O
adopted	O
by	O
CEN	O
ENV	O
12967	O
-	O
1	O
and	O
the	O
specialisation	O
necessary	O
for	O
the	O
healthcare	O
record	O
based	O
on	O
CEN	O
ENV	O
12265	O
'	O
Electronic	O
Healthcare	O
Record	O
Architecture	O
'	O
.	O

Double	O
mutant	O
analysis	O
suggests	O
that	O
Rad54p	B-protein
and	O
Mus81p	B-protein
act	O
in	O
one	O
pathway	O
for	O
the	O
repair	O
of	O
,	O
or	O
tolerance	O
to	O
,	O
UV	O
-	O
induced	O
DNA	O
damage	O
.	O

Furthermore	O
,	O
early	O
-	O
and	O
late	O
-	O
firing	O
origins	O
differ	O
not	O
in	O
the	O
timing	O
of	O
their	O
recruitment	O
of	O
an	O
Mcm	B-protein
protein	I-protein
,	O
but	O
in	O
the	O
timing	O
of	O
RPA	B-protein
'	I-protein
s	I-protein
recruitment	O
.	O

All	O
Cu	O
values	O
obtained	O
from	O
the	O
organs	O
investigated	O
had	O
reached	O
a	O
saturation	O
level	O
at	O
8	O
mug	O
Cu	O
/	O
g	O
diet	O
with	O
the	O
exception	O
of	O
the	O
values	O
for	O
body	O
Cu	O
found	O
in	O
the	O
dams	O
that	O
were	O
killed	O
on	O
the	O
day	O
of	O
delivery	O
.	O

The	O
CEM	O
receives	O
registration	O
updates	O
via	O
an	O
HL7	O
message	O
and	O
evaluates	O
data	O
dependencies	O
in	O
rules	O
via	O
an	O
interface	O
to	O
the	O
relational	O
database	O
.	O

Since	O
only	O
58	O
%	O
of	O
our	O
sample	O
could	O
be	O
adequately	O
classified	O
with	O
one	O
diagnosis	O
,	O
we	O
expect	O
that	O
the	O
ASDC	O
nosology	O
will	O
need	O
to	O
evolve	O
further	O
.	O

The	O
treatments	O
were	O
60	O
mg	O
t	O
.	O
i	O
.	O
d	O
.	O
and	O
120	O
mg	O
t	O
.	O
i	O
.	O
d	O
.	O
during	O
14	O
days	O
'	O
treatment	O
,	O
with	O
the	O
last	O
dose	O
pulsed	O
with	O
1	O
.	O
85	O
MBq	O
[	O
14C	O
]	O
diltiazem	O
.	O

We	O
have	O
identified	O
amino	O
acid	O
sequences	O
in	O
mammalian	B-protein
and	I-protein
Xenopus	I-protein
NeuroD1	I-protein
/	I-protein
BETA2	I-protein
that	O
are	O
necessary	O
for	O
insulin	B-protein
gene	I-protein
expression	O
and	O
ectopic	O
neurogenesis	O
.	O

For	O
the	O
2	O
.	O
5	O
to	O
4	O
ng	O
/	O
mL	O
model	O
,	O
the	O
AUC	O
of	O
the	O
ANN	O
ROC	O
curve	O
was	O
significantly	O
higher	O
than	O
the	O
AUCs	O
for	O
percentage	O
of	O
free	O
PSA	B-protein
(	O
P	O
=	O
.	O
0239	O
)	O
,	O
PSA	O
-	O
TZ	O
(	O
P	O
=	O
.	O
0204	O
)	O
,	O
and	O
PSA	B-protein
density	O
and	O
total	O
prostate	O
volume	O
(	O
P	O
<	O
.	O
01	O
for	O
both	O
)	O
.	O

Mechanisms	O
of	O
visible	O
-	O
light	O
emission	O
from	O
electro	O
-	O
oxidized	O
porous	O
silicon	O
.	O

A	O
17	O
-	O
mer	O
oligodeoxynucleotide	O
,	O
corresponding	O
to	O
a	O
region	O
of	O
the	O
VtHb	B-protein
amino	I-protein
acid	I-protein
sequence	I-protein
was	O
used	O
as	O
a	O
hybridization	O
probe	O
to	O
screen	O
a	O
Vitreoscilla	O
genomic	O
library	O
constructed	O
in	O
broad	O
-	O
host	O
-	O
range	O
cosmid	O
vector	O
pVK102	O
.	O

The	O
results	O
suggest	O
that	O
,	O
although	O
both	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
regions	O
of	O
talin	B-protein
bind	O
actin	B-protein
,	O
the	O
properties	O
of	O
these	O
two	O
regions	O
of	O
the	O
protein	O
are	O
distinct	O
.	O

Cam	B-protein
kinase	I-protein
II	I-protein
induces	O
in	O
vivo	O
phosphorylation	O
of	O
Smad2	B-protein
and	O
Smad4	B-protein
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
Smad3	B-protein
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
SAP	B-protein
-	I-protein
1	I-protein
cDNA	I-protein
showed	O
that	O
mature	B-protein
SAP	I-protein
-	I-protein
1	I-protein
consisted	O
of	O
1093	O
amino	O
acids	O
and	O
a	O
transmembrane	B-protein
-	I-protein
type	I-protein
PTP	I-protein
,	O
which	O
possessed	O
a	O
single	O
PTP	B-protein
-	I-protein
conserved	I-protein
domain	I-protein
in	O
the	O
cytoplasmic	O
region	O
.	O

However	O
,	O
the	O
promoter	O
region	O
contains	O
several	O
potential	O
cis	O
-	O
regulatory	O
elements	O
such	O
as	O
Sp1	B-protein
,	O
early	B-protein
growth	I-protein
response	I-protein
-	I-protein
1	I-protein
,	O
activator	B-protein
protein	I-protein
-	I-protein
2	I-protein
,	O
MyoD	B-protein
,	O
p300	B-protein
,	O
nuclear	B-protein
factor	I-protein
-	I-protein
kappaB	I-protein
,	O
myeloid	B-protein
zinc	I-protein
finger	I-protein
protein	I-protein
-	I-protein
1	I-protein
,	O
caudal	B-protein
-	I-protein
related	I-protein
homeobox	I-protein
(	I-protein
Cdx	I-protein
)	I-protein
gene	I-protein
A	I-protein
,	O
and	O
Cdx	B-protein
protein	I-protein
-	I-protein
2	I-protein
binding	I-protein
sites	I-protein
.	O

Functional	O
analysis	O
of	O
the	O
mutant	B-protein
desmin	I-protein
in	O
SW13	O
(	O
vim	O
-	O
)	O
cells	O
showed	O
aggregation	O
of	O
abnormal	O
coarse	O
clumps	O
of	O
desmin	B-protein
positive	O
material	O
dispersed	O
throughout	O
the	O
cytoplasm	O
.	O

Cleavage	O
by	O
the	O
intron	O
-	O
encoded	O
enzyme	O
(	O
I	B-protein
-	I-protein
CreI	I-protein
)	O
occurs	O
5	O
bp	O
and	O
1	O
bp	O
3	O
'	O
to	O
the	O
intron	O
insertion	O
site	O
(	O
in	O
the	O
3	O
'	O
-	O
exon	O
)	O
in	O
the	O
top	O
(	O
/	O
)	O
and	O
bottom	O
(	O
,	O
)	O
strands	O
,	O
respectively	O
,	O
resulting	O
in	O
4	O
-	O
nt	O
single	O
-	O
stranded	O
overhangs	O
with	O
3	O
'	O
-	O
OH	O
termini	O
.	O

Based	O
on	O
the	O
sequence	O
of	O
the	O
conRTRE	B-protein
,	O
we	O
located	O
a	O
putative	O
RTRE	B-protein
,	O
referred	O
to	O
as	O
P2	B-protein
-	I-protein
RE	I-protein
,	O
in	O
the	O
5	O
'	O
promoter	O
-	O
flanking	O
region	O
of	O
the	O
mouse	B-protein
protamine	I-protein
2	I-protein
gene	I-protein
,	O
which	O
is	O
induced	O
during	O
the	O
same	O
stage	O
of	O
spermatogenesis	O
as	O
RTR	B-protein
.	O

Possibly	O
,	O
the	O
scr1	B-protein
-	I-protein
1	I-protein
mutation	I-protein
does	O
not	O
affect	O
signal	O
recognition	O
or	O
translational	O
arrest	O
but	O
instead	O
results	O
in	O
maintenance	O
of	O
translational	O
arrest	O
of	O
AEP	B-protein
synthesis	O
.	O

A	O
recombinant	O
vector	O
,	O
p410	O
+	O
,	O
was	O
constructed	O
which	O
carried	O
the	O
BamHI	B-protein
-	I-protein
K	I-protein
fragment	I-protein
(	O
nucleotides	O
107565	O
to	O
112625	O
of	O
the	O
B95	O
-	O
8	O
strain	O
,	O
encoding	O
the	O
EBV	B-protein
-	I-protein
associated	I-protein
nuclear	I-protein
antigen	I-protein
EBNA	I-protein
-	I-protein
1	I-protein
)	O
,	O
the	O
cis	O
-	O
acting	O
sequence	O
from	O
the	O
BamHI	B-protein
-	I-protein
C	I-protein
fragment	I-protein
,	O
and	O
a	O
dominant	O
selectable	O
marker	O
gene	O
encoding	O
G	O
-	O
418	O
resistance	O
in	O
animal	O
cells	O
.	O

When	O
this	O
CCAAT	O
box	O
was	O
inserted	O
into	O
a	O
heterologous	O
promoter	O
construct	O
,	O
OA	O
induction	O
was	O
dependent	O
on	O
an	O
intact	O
CCAAT	O
box	O
.	O

Radioimmunoassays	O
of	O
pregnenolone	O
,	O
progesterone	O
,	O
dehydroepiandrosterone	O
(	O
DHA	O
)	O
16	O
alpha	O
-	O
hydroxy	O
-	O
DHA	O
,	O
estriol	O
,	O
and	O
cortisol	O
were	O
performed	O
on	O
a	O
total	O
of	O
0	O
;	O
1	O
ml	O
;	O
of	O
fetal	O
plasma	O
,	O
collected	O
during	O
the	O
course	O
of	O
normal	O
vaginal	O
delivery	O
.	O

The	O
transcription	O
initiation	O
site	O
was	O
determined	O
by	O
S1	B-protein
nuclease	I-protein
mapping	O
.	O

Ivermectin	O
uptake	O
and	O
distribution	O
in	O
the	O
plasma	O
and	O
tissue	O
of	O
Sudanese	O
and	O
Mexican	O
patients	O
infected	O
with	O
Onchocerca	O
volvulus	O
.	O

Total	O
cumulative	O
doses	O
of	O
doxorubicin	O
ranged	O
from	O
145	O
to	O
625	O
mg	O
.	O
/	O
m	O
.	O
2	O
.	O

Using	O
PRL	B-protein
-	I-protein
R	I-protein
tagged	O
both	O
in	O
the	O
N	O
-	O
terminal	O
or	O
C	O
-	O
terminal	O
regions	O
of	O
the	O
mature	O
receptor	O
excludes	O
the	O
possibility	O
of	O
a	O
cleaved	O
fragment	O
which	O
could	O
have	O
been	O
subsequently	O
imported	O
into	O
the	O
nucleus	O
.	O

Analysis	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
mouse	B-protein
Elavl1	I-protein
(	O
mHuA	B-protein
)	O
gene	O
reveals	O
a	O
transcriptional	O
regulatory	O
element	O
and	O
evidence	O
for	O
conserved	O
genomic	O
organization	O
.	O
mHuA	B-protein
(	O
Elavl1	B-protein
)	O
belongs	O
to	O
a	O
highly	O
conserved	O
family	O
of	O
genes	O
encoding	O
RNA	O
-	O
binding	O
proteins	O
and	O
has	O
been	O
linked	O
to	O
cell	O
growth	O
and	O
proliferation	O
through	O
its	O
regulation	O
of	O
mRNA	O
stability	O
.	O

The	O
results	O
indicate	O
that	O
a	O
more	O
differentiated	O
diagnosis	O
of	O
the	O
molar	O
relationship	O
will	O
allow	O
for	O
a	O
more	O
causally	O
directed	O
correction	O
of	O
Class	O
II	O
molar	O
relationship	O
.	O

After	O
i	O
.	O
v	O
.	O

Splice	O
-	O
junction	O
elements	O
and	O
intronic	O
sequences	O
regulate	O
alternative	O
splicing	O
of	O
the	O
Drosophila	O
myosin	B-protein
heavy	I-protein
chain	I-protein
gene	I-protein
transcript	O
.	O

Some	O
of	O
these	O
targets	O
were	O
reported	O
to	O
code	O
for	O
molecules	O
involved	O
in	O
cell	O
-	O
cell	O
interactions	O
,	O
whereas	O
no	O
relationship	O
has	O
yet	O
been	O
demonstrated	O
between	O
Hox	B-protein
genes	I-protein
and	O
other	O
transcription	O
factors	O
involved	O
in	O
determining	O
and	O
/	O
or	O
maintaining	O
tissue	O
specificity	O
.	O

Upstream	O
activation	O
sites	O
of	O
the	O
CYC1	B-protein
gene	I-protein
of	O
Saccharomyces	O
cerevisiae	O
are	O
active	O
when	O
inverted	O
but	O
not	O
when	O
placed	O
downstream	O
of	O
the	O
`	O
`	O
TATA	O
box	O
'	O
'	O
.	O

The	O
relative	O
R	O
-	O
and	O
L	O
-	O
brain	O
weights	O
were	O
found	O
to	O
be	O
inversely	O
related	O
to	O
the	O
relative	O
R	O
-	O
L	O
brain	O
weight	O
only	O
in	O
the	O
RH	O
female	O
cats	O
with	O
R	O
-	O
L	O
brain	O
weight	O
smaller	O
than	O
zero	O
(	O
testosterone	O
in	O
males	O
,	O
estrogen	O
in	O
females	O
)	O
.	O

Chemotherapy	O
was	O
administered	O
without	O
altering	O
the	O
course	O
of	O
the	O
disorder	O
.	O

Our	O
studies	O
also	O
excluded	O
the	O
possibility	O
that	O
the	O
phosphorylation	O
of	O
Ser	B-protein
-	I-protein
2	I-protein
,	O
Ser	B-protein
-	I-protein
123	I-protein
,	O
or	O
Ser	B-protein
-	I-protein
210	I-protein
,	O
had	O
roles	O
in	O
the	O
trans	O
-	O
suppression	O
activity	O
of	O
the	O
large	B-protein
HDAg	I-protein
,	O
in	O
the	O
assembly	O
of	O
empty	O
virus	B-protein
-	I-protein
like	I-protein
HDAg	I-protein
particle	I-protein
,	O
and	O
in	O
the	O
nuclear	O
transport	O
of	O
HDAgs	B-protein
.	O

Workplace	O
violence	O
-	O
-	O
nurses	O
at	O
risk	O
.	O

Effect	O
of	O
noise	O
on	O
CO	O
-	O
induced	O
increases	O
of	O
LAP	B-protein
and	O
GPT	B-protein
activity	O
in	O
the	O
plasma	O
of	O
rats	O
.	O

It	O
contains	O
three	O
putative	O
TATA	O
boxes	O
far	O
upstream	O
of	O
the	O
main	O
start	O
sites	O
region	O
,	O
one	O
AP	B-protein
-	I-protein
1	I-protein
box	I-protein
,	O
one	O
AP	B-protein
-	I-protein
2	I-protein
box	I-protein
,	O
one	O
Malt	B-protein
box	I-protein
,	O
one	O
GAGA	O
box	O
,	O
one	O
half	O
serum	B-protein
-	I-protein
responsive	I-protein
element	I-protein
,	O
and	O
putative	O
binding	O
sites	O
for	O
Sp1	B-protein
(	O
five	O
)	O
,	O
GC	B-protein
-	I-protein
rich	I-protein
binding	I-protein
factor	I-protein
(	O
five	O
)	O
,	O
CTF	B-protein
-	I-protein
NF1	I-protein
(	O
one	O
)	O
,	O
Myb	B-protein
(	O
one	O
)	O
,	O
p53	B-protein
(	O
two	O
)	O
,	O
Ets	B-protein
-	I-protein
1	I-protein
(	O
one	O
)	O
,	O
NF	B-protein
-	I-protein
IL6	I-protein
(	O
two	O
)	O
,	O
MyoD	B-protein
(	O
two	O
)	O
,	O
Zeste	B-protein
(	O
one	O
)	O
,	O
and	O
hepatocyte	B-protein
nuclear	I-protein
factor	I-protein
-	I-protein
5	I-protein
(	O
one	O
)	O
.	O

MBI	O
and	O
MMBI	O
showed	O
similar	O
Cmax	O
values	O
,	O
but	O
the	O
former	O
disappeared	O
slower	O
in	O
the	O
serum	O
than	O
the	O
latter	O
and	O
resulted	O
in	O
its	O
larger	O
AUC	O
values	O
.	O

Both	O
4	O
,	O
8	O
-	O
DiMeIQx	O
and	O
A	O
alpha	O
C	O
were	O
found	O
at	O
<	O
1	O
p	O
.	O
p	O
.	O
b	O
.	O

Epitope	O
mapping	O
revealed	O
that	O
these	O
three	O
clones	O
appear	O
to	O
recognize	O
an	O
identical	O
epitope	O
domain	O
present	O
on	O
the	O
C	O
-	O
terminal	O
RNP	B-protein
motif	I-protein
of	O
the	O
U1A	B-protein
protein	I-protein
.	O

Emphysematous	O
cholecystitis	O
:	O
sonographic	O
findings	O
.	O

Nevertheless	O
,	O
they	O
are	O
functionally	O
distinct	O
in	O
that	O
FcalphaRI	B-protein
binds	O
human	B-protein
IgA	I-protein
(	O
hIgA	B-protein
)	O
but	O
not	O
bovine	B-protein
IgG2	I-protein
(	O
bIgG2	B-protein
)	O
,	O
whereas	O
bFcgamma2R	B-protein
binds	O
bIgG2	B-protein
but	O
not	O
hIgA	B-protein
.	O

CD3	B-protein
cross	O
-	O
linking	O
induced	O
tyrosine	O
phosphorylation	O
of	O
Sam68	B-protein
in	O
uninfected	O
T	O
cells	O
.	O

Another	O
long	O
insertion	O
in	O
the	O
cathepsin	B-protein
X	I-protein
amino	I-protein
acid	I-protein
sequence	O
forms	O
a	O
beta	O
-	O
hairpin	O
pointing	O
away	O
from	O
the	O
active	O
site	O
.	O

One	O
chimpanzee	O
reliably	O
selected	O
the	O
larger	O
numeral	O
4	O
during	O
testing	O
with	O
a	O
nonadjacent	O
pair	O
(	O
2	O
-	O
4	O
)	O
,	O
and	O
2	O
chimps	O
showed	O
no	O
preference	O
.	O

Analysis	O
of	O
cell	O
cycle	O
proteins	O
showed	O
that	O
24	O
h	O
of	O
lovastatin	O
treatment	O
in	O
the	O
control	O
cells	O
caused	O
an	O
elevation	O
in	O
the	O
levels	O
of	O
the	O
cyclin	B-protein
-	I-protein
dependent	I-protein
kinase	I-protein
inhibitor	I-protein
p27	I-protein
(	I-protein
kip1	I-protein
)	I-protein
,	O
inhibition	O
of	O
both	O
cyclin	B-protein
E	I-protein
-	I-protein
and	O
cyclin	B-protein
A	I-protein
-	I-protein
dependent	I-protein
kinase	I-protein
activity	O
,	O
and	O
decreased	O
levels	O
of	O
hyperphosphorylated	O
retinoblastoma	B-protein
protein	I-protein
(	O
pRb	B-protein
)	O
.	O

Urease	B-protein
activity	O
of	O
97	O
%	O
of	O
these	O
organisms	O
became	O
evident	O
within	O
30	O
min	O
.	O

Structure	O
and	O
regulation	O
of	O
a	O
nuclear	O
gene	O
in	O
Saccharomyces	O
cerevisiae	O
that	O
specifies	O
MRP13	B-protein
,	O
a	O
protein	O
of	O
the	O
small	O
subunit	O
of	O
the	O
mitochondrial	O
ribosome	O
.	O

Nuclear	B-protein
-	I-protein
encoded	I-protein
chloroplast	I-protein
ribosomal	I-protein
protein	I-protein
L12	I-protein
of	O
Nicotiana	O
tabacum	O
:	O
characterization	O
of	O
mature	O
protein	O
and	O
isolation	O
and	O
sequence	O
analysis	O
of	O
cDNA	O
clones	O
encoding	O
its	O
cytoplasmic	O
precursor	O
.	O

Resting	O
plasma	O
norepinephrine	O
(	O
NE	O
)	O
and	O
epinephrine	O
(	O
E	O
)	O
levels	O
were	O
lower	O
during	O
active	O
therapy	O
than	O
2	O
wk	O
after	O
withdrawal	O
(	O
guanfacine	O
and	O
control	O
:	O
plasma	O
NE	O
,	O
0	O
.	O
27	O
+	O
/	O
-	O
0	O
.	O
03	O
/	O
0	O
.	O
64	O
+	O
/	O
-	O
0	O
.	O
13	O
ng	O
/	O
ml	O
;	O
plasma	O
E	O
,	O
0	O
.	O
09	O
+	O
/	O
-	O
0	O
.	O
02	O
/	O
0	O
.	O
17	O
+	O
/	O
-	O
0	O
.	O
05	O
ng	O
/	O
ml	O
)	O
.	O

A	O
diagnosis	O
of	O
IgA	B-protein
lambda	I-protein
multiple	O
myeloma	O
with	O
peritoneal	O
involvement	O
was	O
made	O
.	O

After	O
90	O
d	O
a	O
subsurface	O
,	O
radiolucent	O
caries	O
-	O
like	O
lesion	O
was	O
observed	O
in	O
two	O
specimens	O
only	O
.	O

In	O
all	O
tissues	O
examined	O
only	O
transcripts	O
positive	O
for	O
insert	O
3	O
,	O
an	O
18	O
bp	O
insertion	O
in	O
repeat	O
21	O
,	O
were	O
amplified	O
,	O
even	O
under	O
conditions	O
in	O
which	O
a	O
30	O
%	O
level	O
of	O
insert	O
3	O
negative	O
transcript	O
could	O
be	O
easily	O
detected	O
in	O
artificially	O
prepared	O
control	O
samples	O
.	O

Purple	O
photosynthetic	O
bacteria	O
are	O
capable	O
of	O
generating	O
cellular	O
energy	O
from	O
several	O
sources	O
,	O
including	O
photosynthesis	O
,	O
respiration	O
,	O
and	O
H	O
(	O
2	O
)	O
oxidation	O
.	O

Effect	O
of	O
Azadirachta	O
indica	O
hydroalcoholic	O
leaf	O
extract	O
on	O
the	O
cardiovascular	O
system	O
.	O

Hepatitis	O
B	O
virus	O
and	O
hepatoma	O
.	O

All	O
groups	O
were	O
challenged	O
subsequently	O
with	O
naloxone	O
(	O
0	O
.	O
4	O
mg	O
/	O
kg	O
)	O
in	O
the	O
distinctive	O
environment	O
and	O
then	O
observed	O
for	O
signs	O
of	O
opiate	O
withdrawal	O
.	O

The	O
heterogeneity	O
of	O
bovine	B-protein
IgG2	I-protein
-	I-protein
-	I-protein
VIII	I-protein
.	O

Erythromycin	O
and	O
clindamycin	O
resistance	O
in	O
Corynebacterium	O
diphtheriae	O
from	O
skin	O
lesions	O
.	O

MRI	O
disclosed	O
one	O
or	O
more	O
of	O
the	O
following	O
abnormalities	O
in	O
24	O
(	O
63	O
%	O
)	O
of	O
38	O
treated	O
kidneys	O
:	O
(	O
1	O
)	O
loss	O
of	O
corticomedullary	O
differentiation	O
,	O
(	O
2	O
)	O
perirenal	O
fluid	O
,	O
(	O
3	O
)	O
subcapsular	O
hematoma	O
,	O
(	O
4	O
)	O
hemorrhage	O
into	O
a	O
renal	O
cyst	O
,	O
and	O
(	O
5	O
)	O
unexplained	O
abnormalities	O
.	O

As	O
was	O
observed	O
previously	O
for	O
MATa	B-protein
cna1	I-protein
cna2	I-protein
double	O
mutants	O
,	O
MATa	B-protein
cnb1	I-protein
mutants	I-protein
were	O
defective	O
in	O
their	O
ability	O
to	O
recover	O
from	O
alpha	O
-	O
factor	O
-	O
induced	O
growth	O
arrest	O
.	O

In	O
transient	O
assays	O
,	O
using	O
rice	O
suspension	O
-	O
cultured	O
cells	O
transformed	O
by	O
particle	O
bombardment	O
,	O
we	O
showed	O
previously	O
that	O
Oshox1	B-protein
can	O
transcriptionally	O
repress	O
the	O
activity	O
of	O
reporter	O
gene	O
constructs	O
with	O
upstream	O
HD	B-protein
-	I-protein
Zip	I-protein
binding	I-protein
sites	I-protein
.	O

A	O
mutation	O
in	O
the	O
5	B-protein
'	I-protein
C2U4	I-protein
repeat	I-protein
causes	O
underaccumulation	O
of	O
snR13F	B-protein
,	O
whereas	O
mutations	O
in	O
the	O
3	B-protein
'	I-protein
C2U4	I-protein
repeat	I-protein
cause	O
the	O
accumulation	O
of	O
two	O
novel	O
RNAs	O
that	O
migrate	O
in	O
the	O
500	O
-	O
nt	O
range	O
.	O

Atorvastatin	O
was	O
the	O
most	O
cost	O
-	O
effective	O
HMG	B-protein
-	I-protein
CoA	I-protein
reductase	I-protein
inhibitor	O
.	O

Slp1	B-protein
represses	O
transcription	O
via	O
this	O
binding	O
site	O
in	O
yeast	O
cells	O
,	O
consistent	O
with	O
its	O
role	O
as	O
a	O
direct	O
repressor	O
of	O
ftz	B-protein
stripes	O
in	O
interstripe	O
regions	O
during	O
late	O
stages	O
of	O
embryogenesis	O
.	O

In	O
addition	O
to	O
targeting	O
partially	O
assembled	O
Ti	B-protein
alpha	I-protein
-	I-protein
beta	I-protein
CD3	I-protein
gamma	I-protein
delta	I-protein
epsilon	I-protein
TCR	I-protein
complexes	I-protein
to	O
the	O
cell	O
surface	O
,	O
CD3	B-protein
zeta	I-protein
appears	O
to	O
be	O
essential	O
for	O
interleukin	B-protein
-	I-protein
2	I-protein
production	O
after	O
TCR	B-protein
stimulation	O
with	O
antigen	B-protein
/	I-protein
major	I-protein
histocompatibility	I-protein
complex	I-protein
.	O

Quantitative	O
predictions	O
are	O
confirmed	O
for	O
the	O
positive	O
responses	O
,	O
but	O
not	O
for	O
the	O
negatives	O
,	O
suggesting	O
that	O
the	O
SSTS	O
model	O
is	O
incorrect	O
.	O

Bimodal	O
cochlear	O
response	O
curves	O
in	O
rodents	O
.	O

Structure	O
of	O
the	O
gene	O
encoding	O
the	O
human	B-protein
cyclin	I-protein
-	I-protein
dependent	I-protein
kinase	I-protein
inhibitor	I-protein
p18	I-protein
and	O
mutational	O
analysis	O
in	O
breast	O
cancer	O
.	O

However	O
,	O
when	O
,	O
where	O
and	O
how	O
the	O
DSPP	B-protein
is	O
cleaved	O
into	O
DSP	B-protein
and	O
DPP	B-protein
is	O
not	O
clear	O
.	O

Low	O
-	O
dose	O
D	O
(	O
0	O
.	O
4	O
-	O
0	O
.	O
8	O
mg	O
)	O
and	O
DB	O
(	O
1	O
.	O
0	O
-	O
5	O
.	O
0	O
mg	O
)	O
did	O
not	O
significantly	O
alter	O
any	O
parameter	O
from	O
control	O
.	O

We	O
have	O
investigated	O
the	O
influence	O
of	O
NaFe3	O
+	O
EDTA	O
,	O
and	O
of	O
increasing	O
dietary	O
levels	O
of	O
Na2EDTA	O
,	O
on	O
Zn	O
,	O
Cu	O
and	O
Ca	O
metabolism	O
in	O
rats	O
fed	O
on	O
Zn	O
-	O
sufficient	O
and	O
Zn	O
-	O
deficient	O
soya	O
-	O
bean	O
-	O
isolate	O
-	O
based	O
diets	O
.	O

Further	O
evidence	O
for	O
a	O
clustered	O
organization	O
of	O
FAX	B-protein
-	I-protein
ZFP	I-protein
transcription	I-protein
units	I-protein
is	O
provided	O
by	O
Southern	O
blot	O
analysis	O
of	O
large	O
genomic	O
restriction	O
fragments	O
separated	O
by	O
transverse	O
field	O
gel	O
electrophoresis	O
,	O
and	O
by	O
in	O
situ	O
hybridization	O
on	O
intact	O
chromosomes	O
.	O

Metastasis	O
of	O
colon	O
carcinoma	O
to	O
the	O
lip	O
.	O

During	O
heat	O
exposure	O
,	O
chicks	O
that	O
had	O
been	O
subjected	O
to	O
early	O
60	O
%	O
restriction	O
with	O
non	O
-	O
metyrapone	O
-	O
treated	O
food	O
had	O
lower	O
H	O
/	O
L	O
ratios	O
and	O
improved	O
resistance	O
to	O
marble	O
spleen	O
disease	O
infection	O
.	O

No	O
recombination	O
signal	O
sequences	O
have	O
been	O
found	O
contiguous	O
to	O
the	O
recombination	O
point	O
.	O

Abnormal	O
intrapulmonary	O
shunting	O
(	O
IPS	O
)	O
,	O
which	O
was	O
proved	O
in	O
4	O
cases	O
by	O
whole	O
-	O
body	O
radionuclide	O
scanning	O
with	O
99mTc	O
-	O
MAA	O
,	O
is	O
suggested	O
as	O
the	O
major	O
cause	O
of	O
cyanosis	O
in	O
liver	O
cirrhosis	O
.	O

The	O
5	O
'	O
-	O
nontranslated	O
sequences	O
and	O
parts	O
of	O
the	O
coding	O
sequences	O
of	O
various	O
yeast	O
genes	O
have	O
been	O
cloned	O
into	O
representative	O
lacZ	B-protein
fusion	O
vectors	O
.	O

In	O
this	O
study	O
we	O
provide	O
evidence	O
that	O
B	B-protein
-	I-protein
Myb	I-protein
is	O
a	O
direct	O
physiological	O
target	O
for	O
cyclin	B-protein
A	I-protein
/	I-protein
Cdk2	I-protein
.	O

Thus	O
,	O
while	O
the	O
genomic	O
organization	O
of	O
mHuA	B-protein
is	O
similar	O
to	O
the	O
neural	O
-	O
restricted	O
members	O
of	O
the	O
Elav	B-protein
family	I-protein
,	O
the	O
promoter	O
element	O
differs	O
substantially	O
both	O
by	O
sequence	O
analysis	O
and	O
transcriptional	O
activity	O
in	O
non	O
-	O
neural	O
cell	O
types	O
.	O

A	O
total	O
of	O
90	O
patients	O
were	O
randomly	O
allocated	O
either	O
to	O
an	O
MY	O
-	O
1	O
treated	O
or	O
an	O
untreated	O
group	O
.	O

A	O
chicken	B-protein
paxillin	I-protein
cDNA	I-protein
was	O
also	O
cloned	O
and	O
is	O
predicted	O
to	O
encode	O
a	O
protein	O
approximately	O
90	O
%	O
identical	O
to	O
human	B-protein
paxil	I-protein
-	I-protein
lin	I-protein
.	O

In	O
the	O
normal	O
,	O
basal	O
(	O
unstimulated	O
)	O
condition	O
there	O
were	O
no	O
significant	O
correlations	O
(	O
p	O
greater	O
than	O
0	O
.	O
05	O
)	O
between	O
the	O
systolic	O
blood	O
pressure	O
and	O
dopamine	O
(	O
r	O
=	O
0	O
.	O
09	O
)	O
,	O
norepinephrine	O
(	O
r	O
=	O
0	O
.	O
26	O
)	O
,	O
or	O
epinephrine	O
(	O
r	O
=	O
0	O
.	O
27	O
)	O
,	O
nor	O
were	O
there	O
significant	O
correlations	O
between	O
melatonin	O
and	O
dopamine	O
(	O
r	O
=	O
-	O
0	O
.	O
01	O
)	O
,	O
norepinephrine	O
(	O
r	O
=	O
-	O
0	O
.	O
26	O
)	O
,	O
or	O
growth	B-protein
hormone	I-protein
(	O
r	O
=	O
0	O
.	O
17	O
)	O
.	O

Transition	O
between	O
P	O
-	O
and	O
H	O
-	O
BPPV	O
was	O
found	O
in	O
6	O
cases	O
.	O

The	O
study	O
suggests	O
the	O
presence	O
of	O
an	O
anatomical	O
sphincter	O
at	O
the	O
RSJ	O
which	O
seems	O
to	O
regulate	O
the	O
passage	O
of	O
stools	O
from	O
the	O
sigmoid	O
colon	O
to	O
the	O
rectum	O
.	O

In	O
the	O
ISO	O
group	O
,	O
at	O
pre	O
-	O
DEX	O
,	O
CBF	O
increased	O
from	O
86	O
+	O
/	O
-	O
8	O
to	O
166	O
+	O
/	O
-	O
19	O
mL	O
.	O
min	O
-	O
1	O
.	O
100	O
g	O
-	O
1	O
in	O
response	O
to	O
hypercapnia	O
(	O
PCO2	O
approximately	O
90	O
mmHg	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Maximum	O
induction	O
of	O
AP	B-protein
-	I-protein
1	I-protein
was	O
reached	O
at	O
a	O
concentration	O
of	O
250	O
nmol	O
/	O
L	O
of	O
CalC	O
.	O

Pregnancy	O
screening	O
by	O
uterine	O
artery	O
Doppler	O
velocimetry	O
-	O
-	O
which	O
criterion	O
performs	O
best	O
?	O
OBJECTIVE	O
:	O
To	O
test	O
whether	O
repeating	O
Doppler	O
studies	O
of	O
the	O
uteroplacental	O
circulation	O
late	O
in	O
gestation	O
will	O
improve	O
the	O
test	O
'	O
s	O
power	O
for	O
predicting	O
pregnancy	O
-	O
induced	O
hypertension	O
and	O
fetal	O
growth	O
restriction	O
(	O
FGR	O
)	O
,	O
and	O
whether	O
analysis	O
based	O
on	O
a	O
combination	O
of	O
quantitative	O
and	O
qualitative	O
assessments	O
of	O
the	O
uterine	O
arterial	O
waveforms	O
will	O
yield	O
better	O
results	O
than	O
analysis	O
based	O
on	O
either	O
alone	O
.	O

The	O
relationships	O
among	O
blood	O
concentrations	O
of	O
thyroid	O
hormones	O
and	O
selenium	O
,	O
zinc	O
,	O
retinol	O
,	O
and	O
alpha	O
-	O
tocopherol	O
were	O
studied	O
in	O
44	O
healthy	O
Northern	O
Italian	O
oldest	O
-	O
old	O
subjects	O
(	O
age	O
range	O
,	O
90	O
-	O
107	O
yr	O
)	O
,	O
selected	O
by	O
the	O
criteria	O
of	O
the	O
SENIEUR	O
protocol	O
.	O

The	O
intrapancreatic	O
spread	O
of	O
the	O
carcinoma	O
correlated	O
with	O
portal	O
invasion	O
of	O
carcinoma	O
,	O
hardness	O
of	O
the	O
body	O
and	O
tail	O
,	O
obstruction	O
of	O
main	O
pancreatic	O
duct	O
and	O
irregular	O
pancreaticogram	O
.	O

The	O
content	O
of	O
glucosamine	O
and	O
galactosamine	O
in	O
tartar	O
.	O

The	O
two	O
bases	O
immediately	O
flanking	O
the	O
5	O
'	O
end	O
of	O
the	O
element	O
proved	O
to	O
be	O
very	O
important	O
to	O
its	O
function	O
as	O
a	O
UAS	B-protein
element	I-protein
as	O
did	O
the	O
two	O
bases	O
immediately	O
3	O
'	O
of	O
the	O
bHLH	O
core	O
motif	O
.	O

2	O
.	O

Issues	O
of	O
distribution	O
of	O
kinetic	O
energy	O
of	O
traumatizing	O
object	O
in	O
direct	O
contact	O
interaction	O
with	O
head	O
during	O
impact	O
are	O
discussed	O
from	O
position	O
of	O
biomechanics	O
.	O

Urine	O
antibodies	O
could	O
not	O
be	O
demonstrated	O
in	O
any	O
other	O
cases	O
.	O

Glutamyl	B-protein
-	I-protein
tRNA	I-protein
synthetase	I-protein
and	O
prolyl	B-protein
-	I-protein
tRNA	I-protein
synthetase	I-protein
belong	O
to	O
different	O
classes	O
of	O
aminoacyl	B-protein
-	I-protein
tRNA	I-protein
synthetases	I-protein
that	O
are	O
thought	O
to	O
have	O
evolved	O
along	O
independent	O
evolutionary	O
pathways	O
.	O

This	O
soluble	O
form	O
of	O
the	O
HGFr	B-protein
(	O
sHGFr	B-protein
)	O
bound	O
HGF	B-protein
with	O
an	O
affinity	O
similar	O
to	O
that	O
of	O
the	O
authentic	O
,	O
membrane	O
-	O
associated	O
receptor	O
.	O

Functional	O
analysis	O
of	O
promoter	O
activity	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
cyclin	B-protein
D2	I-protein
suggested	O
that	O
the	O
region	O
-	O
1	O
,	O
100	O
to	O
-	O
805	O
including	O
C	B-protein
/	I-protein
EBP	I-protein
,	O
PEA3	B-protein
,	O
AP2	B-protein
,	O
NF	B-protein
-	I-protein
Y	I-protein
,	O
c	B-protein
-	I-protein
Myc	I-protein
,	O
and	O
Sp1	B-protein
may	O
have	O
a	O
major	O
positive	O
regulatory	O
activity	O
for	O
expression	O
of	O
cyclin	B-protein
D2	I-protein
.	O

Technetium	O
-	O
99m	O
stannous	O
pyrophosphate	O
myocardial	O
scintigrams	O
were	O
obtained	O
in	O
138	O
clinically	O
stable	O
patients	O
32	O
.	O
7	O
+	O
/	O
-	O
47	O
.	O
3	O
weeks	O
(	O
range	O
6	O
to	O
260	O
)	O
after	O
acute	O
myocardial	O
infarction	O
.	O

By	O
Caveman	O
.	O

Identification	O
of	O
this	O
region	O
as	O
the	O
E	B-protein
.	I-protein
coli	I-protein
tmk	I-protein
gene	I-protein
was	O
confirmed	O
by	O
functional	O
complementation	O
of	O
a	O
yeast	B-protein
dTMP	I-protein
kinase	I-protein
temperature	O
-	O
sensitive	O
mutant	O
and	O
by	O
in	O
vitro	O
enzyme	O
assay	O
of	O
the	O
thymidylate	B-protein
kinase	I-protein
activity	O
in	O
cell	O
extracts	O
of	O
E	O
.	O
coli	O
by	O
use	O
of	O
tmk	O
-	O
overproducing	O
plasmids	O
.	O

62	O
:	O
2491	O
-	O
2499	O
,	O
1987	O
)	O
.	O

These	O
results	O
further	O
support	O
an	O
important	O
role	O
for	O
CBF2	B-protein
in	O
mediating	O
EBNA2	B-protein
transactivation	O
;	O
they	O
identify	O
the	O
hnRNP	B-protein
protein	I-protein
AUF1	I-protein
as	O
a	O
major	O
component	O
of	O
CBF2	B-protein
and	O
are	O
also	O
the	O
first	O
evidence	O
of	O
a	O
cis	O
-	O
acting	O
sequence	O
other	O
than	O
a	O
CBF1	B-protein
binding	I-protein
element	I-protein
that	O
is	O
able	O
to	O
confer	O
responsiveness	O
to	O
EBNA2	B-protein
.	O

The	O
Twentieth	O
Anniversary	O
of	O
the	O
Pomeranian	O
Medical	O
Academy	O
.	O

We	O
have	O
developed	O
a	O
new	O
method	O
for	O
estimation	O
of	O
regional	O
CBF	O
(	O
rCBF	O
)	O
and	O
cerebrovascular	O
reserve	O
capacity	O
on	O
a	O
pixel	O
-	O
by	O
-	O
pixel	O
basis	O
by	O
means	O
of	O
dynamic	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
.	O

The	O
epidermal	B-protein
growth	I-protein
factor	I-protein
(	I-protein
EGF	I-protein
)	I-protein
receptor	I-protein
,	O
which	O
exhibits	O
intrinsic	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activity	O
,	O
undergoes	O
a	O
rapid	O
,	O
intramolecular	O
self	O
-	O
phosphorylation	O
reaction	O
following	O
EGF	B-protein
activation	O
.	O

These	O
results	O
suggest	O
that	O
N	O
-	O
nitroso	O
compounds	O
can	O
be	O
formed	O
in	O
vivo	O
in	O
the	O
infected	O
bladder	O
,	O
which	O
could	O
explain	O
the	O
association	O
between	O
urinary	O
-	O
tract	O
infections	O
and	O
increased	O
risk	O
for	O
bladder	O
cancer	O
.	O

The	O
effects	O
of	O
high	O
intensity	O
light	O
emissions	O
,	O
produced	O
by	O
a	O
novel	O
pulsed	O
power	O
energization	O
technique	O
(	O
PPET	O
)	O
,	O
on	O
the	O
survival	O
of	O
bacterial	O
populations	O
of	O
verocytotoxigenic	O
Escherichia	O
coli	O
(	O
serotype	O
0157	O
:	O
H7	O
)	O
and	O
Listeria	O
monocytogenes	O
(	O
serotype	O
4b	O
)	O
were	O
investigated	O
.	O

Bilateral	O
basal	O
arteries	O
were	O
measured	O
by	O
the	O
transtemporal	O
approach	O
with	O
a	O
2	O
MHz	O
pulsed	O
Doppler	O
instrument	O
(	O
TC	O
-	O
2	O
64B	O
EME	O
)	O
.	O

Southern	O
blot	O
analysis	O
of	O
genomic	O
DNA	O
from	O
somatic	O
cell	O
hybrids	O
showed	O
that	O
endothelial	B-protein
-	I-protein
TACC	I-protein
-	I-protein
related	I-protein
cDNA	I-protein
maps	O
to	O
chromosome	O
10	O
.	O

We	O
have	O
tested	O
this	O
proposal	O
by	O
carrying	O
out	O
circular	O
dichroism	O
(	O
CD	O
)	O
and	O
NMR	O
experiments	O
on	O
the	O
Skn	B-protein
domain	I-protein
and	O
five	O
truncated	O
proteins	O
.	O

We	O
show	O
here	O
that	O
these	O
Jun	B-protein
/	I-protein
eb1	I-protein
chimeras	I-protein
are	O
potent	O
transactivators	O
of	O
AP1	B-protein
sites	I-protein
and	O
that	O
they	O
can	O
cooperate	O
with	O
c	B-protein
-	I-protein
Ha	I-protein
-	I-protein
Ras	I-protein
to	O
induce	O
foci	O
.	O

Visual	O
response	O
properties	O
of	O
neurons	O
in	O
four	O
extrastriate	O
visual	O
areas	O
of	O
the	O
owl	O
monkey	O
(	O
Aotus	O
trivirgatus	O
)	O
:	O
a	O
quantitative	O
comparison	O
of	O
medial	O
,	O
dorsomedial	O
,	O
dorsolateral	O
,	O
and	O
middle	O
temporal	O
areas	O
.	O

The	O
former	O
group	O
did	O
excrete	O
less	O
dry	O
fecal	O
material	O
compared	O
to	O
both	O
other	O
groups	O
.	O

Domains	O
I	O
and	O
II	O
of	O
B	B-protein
'	I-protein
'	I-protein
are	O
buried	O
upon	O
assembly	O
of	O
the	O
TFIIIB	B-protein
-	I-protein
DNA	I-protein
complex	I-protein
,	O
as	O
determined	O
by	O
protein	O
footprinting	O
.	O

We	O
have	O
found	O
a	O
satisfactory	O
reproducibility	O
in	O
vitro	O
(	O
T1	O
:	O
1	O
.	O
9	O
%	O
;	O
T2	O
:	O
6	O
.	O
2	O
%	O
)	O
,	O
while	O
the	O
reproducibility	O
was	O
less	O
satisfactory	O
in	O
vivo	O
(	O
T1	O
:	O
16	O
.	O
4	O
%	O
;	O
T2	O
:	O
13	O
.	O
4	O
%	O
)	O
.	O

This	O
test	O
should	O
provide	O
another	O
practical	O
means	O
to	O
study	O
leprosy	O
.	O

The	O
non	O
-	O
role	O
of	O
fluoride	O
in	O
the	O
control	O
of	O
plasma	O
calcium	O
in	O
the	O
parathyroidectomized	O
rat	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
chloroplast	O
(	O
cp	O
)	O
DNA	O
from	O
maize	O
(	O
Zea	O
mays	O
)	O
has	O
been	O
completed	O
.	O

Although	O
basal	O
vessels	O
may	O
constrict	O
distal	O
parenchymal	O
vessels	O
tend	O
to	O
dilate	O
after	O
SAH	O
.	O

Exchange	O
of	O
the	O
LPL	B-protein
and	O
HL	B-protein
lids	O
resulted	O
in	O
a	O
reversal	O
of	O
the	O
phospholipase	O
/	O
neutral	O
lipase	B-protein
ratio	O
,	O
establishing	O
the	O
important	O
role	O
of	O
this	O
region	O
in	O
mediating	O
substrate	O
specificity	O
.	O

A	O
new	O
hemagglutination	O
test	O
for	O
the	O
on	O
-	O
slide	O
assay	O
of	O
rheumatoid	B-protein
factor	I-protein
.	O

Through	O
transient	O
transfection	O
of	O
NIH3T3	O
fibroblast	O
cells	O
and	O
gel	O
mobility	O
shift	O
assays	O
,	O
the	O
functional	O
binding	O
site	O
was	O
localized	O
to	O
a	O
short	O
region	O
(	O
-	O
318	O
to	O
-	O
303	O
bp	O
from	O
the	O
transcription	O
start	O
site	O
)	O
which	O
has	O
a	O
CTCCC	B-protein
sequence	I-protein
.	O

The	O
DHEAS	O
levels	O
in	O
all	O
stages	O
of	O
decreased	O
BMD	O
were	O
significantly	O
lower	O
than	O
those	O
in	O
the	O
group	O
with	O
normal	O
BMD	O
.	O

Most	O
apneic	O
events	O
occurred	O
during	O
Stages	O
I	O
and	O
II	O
,	O
and	O
REM	O
,	O
but	O
this	O
proportion	O
was	O
less	O
during	O
the	O
gamma	O
OH	O
study	O
(	O
77	O
.	O
9	O
+	O
/	O
-	O
8	O
.	O
9	O
%	O
)	O
than	O
during	O
the	O
control	O
studies	O
(	O
92	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
and	O
95	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
2	O
%	O
)	O
,	O
apneas	O
occurring	O
even	O
during	O
SWS	O
with	O
gamma	O
OH	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Is	O
leishmaniasis	O
endemic	O
on	O
the	O
island	O
of	O
Minorca	O
(	O
Spain	O
)	O
?	O
A	O
human	O
visceral	O
case	O
after	O
living	O
13	O
years	O
in	O
Minorca	O
.	O

Interferon	B-protein
Regulatory	I-protein
Factor	I-protein
(	I-protein
IRF	I-protein
)	I-protein
-	I-protein
1	I-protein
has	O
been	O
characterized	O
as	O
an	O
important	O
growth	O
regulatory	O
and	O
immunomodulatory	O
transcription	O
factor	O
.	O

A	O
genomic	O
clone	O
for	O
the	O
cyc07	B-protein
gene	I-protein
,	O
which	O
is	O
expressed	O
specifically	O
at	O
the	O
S	O
phase	O
during	O
the	O
cell	O
cycle	O
in	O
synchronous	O
cultures	O
of	O
periwinkle	O
(	O
Catharanthus	O
roseus	O
)	O
cells	O
,	O
was	O
isolated	O
.	O

BACKGROUND	O
:	O
To	O
determine	O
the	O
predictors	O
of	O
desipramine	O
-	O
refractory	O
depression	O
,	O
the	O
authors	O
examined	O
the	O
outcome	O
in	O
patients	O
with	O
major	O
depression	O
who	O
were	O
admitted	O
to	O
a	O
general	O
hospital	O
and	O
treated	O
with	O
desipramine	O
adjusted	O
to	O
an	O
adequate	O
blood	O
level	O
.	O

Herceptin	O
,	O
which	O
recognizes	O
the	O
HER	B-protein
-	I-protein
2	I-protein
/	I-protein
neu	I-protein
antigen	I-protein
and	O
has	O
similar	O
size	O
(	O
10	O
nm	O
)	O
to	O
G6	O
-	O
(	O
1B4M	O
-	O
Gd	O
)	O
(	O
256	O
)	O
,	O
accumulated	O
and	O
internalized	O
in	O
the	O
WIBC	O
-	O
9	O
tumors	O
more	O
quickly	O
than	O
in	O
the	O
control	O
MC	O
-	O
5	O
tumors	O
that	O
progress	O
with	O
normal	O
angiogenesis	O
.	O

This	O
intron	O
occupies	O
a	O
conserved	O
position	O
corresponding	O
to	O
that	O
of	O
intron	O
1	O
in	O
the	O
transit	O
peptide	O
region	O
of	O
chloroplast	B-protein
GAPDH	I-protein
genes	I-protein
(	O
GapA	B-protein
and	O
GapB	B-protein
)	O
of	O
higher	O
plants	O
.	O

We	O
conclude	O
that	O
TA	O
caused	O
a	O
specific	O
decrease	O
in	O
AGD	O
on	O
GD	O
20	O
that	O
was	O
largely	O
reversed	O
by	O
PCD	O
23	O
.	O

Peripheral	O
visual	O
stimuli	O
and	O
monoaural	O
auditory	O
stimuli	O
were	O
used	O
as	O
targets	O
.	O

Electrochemical	O
detection	O
of	O
depressed	O
circulating	O
levels	O
of	O
vitamin	O
K1	O
in	O
osteoporosis	O
.	O

Conversely	O
,	O
the	O
inactive	O
dAK	B-protein
subunit	I-protein
is	O
progressively	O
activated	O
by	O
1	O
)	O
association	O
with	O
a	O
dGK	B-protein
or	O
dCK	B-protein
subunit	I-protein
and	O
2	O
)	O
the	O
conformationally	O
driven	O
heterotropic	O
affect	O
of	O
dGuo	B-protein
or	O
dCyd	B-protein
bound	O
to	O
the	O
opposing	O
subunit	O
.	O

Mutation	O
of	O
TTF	B-protein
-	I-protein
1	I-protein
-	I-protein
binding	I-protein
sites	I-protein
(	I-protein
TBE	I-protein
)	I-protein
1	I-protein
,	I-protein
3	I-protein
,	I-protein
and	I-protein
4	I-protein
in	O
combination	O
markedly	O
decreased	O
transcriptional	O
activity	O
of	O
SP	B-protein
-	I-protein
A	I-protein
promoter	I-protein
-	I-protein
chloramphenicol	I-protein
acetyltransferase	I-protein
constructs	O
containing	O
SP	B-protein
-	I-protein
A	I-protein
gene	I-protein
sequences	O
from	O
-	O
256	O
to	O
+	O
45	O
.	O

Unrecognized	O
amnionitis	O
and	O
prematurity	O
:	O
a	O
preliminary	O
report	O
.	O

Although	O
the	O
RAD23	B-protein
equivalents	O
are	O
well	O
conserved	O
during	O
evolution	O
,	O
the	O
mammalian	O
genes	O
did	O
not	O
express	O
the	O
UV	O
-	O
inducible	O
phenotype	O
of	O
their	O
yeast	O
counterpart	O
.	O

Measurement	O
of	O
gastric	O
acid	O
secretion	O
by	O
conductivity	O
.	O

Routine	O
clinical	O
analysis	O
revealed	O
lower	O
hematocrit	O
and	O
hemoglobin	B-protein
,	O
and	O
elevated	O
BUN	O
and	O
alkaline	B-protein
phosphatase	I-protein
in	O
the	O
treated	O
group	O
.	O

The	O
C	O
-	O
terminal	O
region	O
of	O
the	O
150	O
-	O
kDa	O
protein	O
contains	O
an	O
NTP	O
-	O
binding	O
helicase	B-protein
motif	I-protein
and	O
the	O
readthrough	O
region	O
,	O
an	O
RNA	B-protein
polymerase	I-protein
motif	I-protein
,	O
indicating	O
that	O
these	O
two	O
overlapping	O
proteins	O
may	O
form	O
an	O
RNA	O
replication	O
complex	O
similar	O
to	O
those	O
of	O
tobamo	O
-	O
and	O
tobraviruses	O
.	O

In	O
the	O
course	O
of	O
Hepatitis	B-protein
A	I-protein
HBs	I-protein
-	I-protein
and	I-protein
HBe	I-protein
-	I-protein
antigen	I-protein
as	O
well	O
as	O
HBc	B-protein
(	I-protein
IgM	I-protein
and	I-protein
IgG	I-protein
)	I-protein
-	I-protein
,	O
HBs	B-protein
-	I-protein
and	I-protein
HBe	I-protein
-	I-protein
antibodies	I-protein
can	O
be	O
detected	O
.	O

The	O
high	O
density	O
of	O
tegumental	O
spines	O
on	O
posterior	O
half	O
of	O
the	O
body	O
and	O
the	O
distribution	O
of	O
type	O
II	O
papillae	O
on	O
dorsal	O
surface	O
are	O
considered	O
to	O
be	O
characteristic	O
of	O
C	O
.	O
armatus	O
.	O

It	O
could	O
be	O
detected	O
exclusively	O
in	O
the	O
culture	O
medium	O
of	O
cDNA	O
-	O
transfected	O
COS	O
cells	O
.	O

Two	O
classes	O
of	O
Xanthomonas	O
pathogens	O
evading	O
Bs2	O
host	O
resistance	O
and	O
displaying	O
reduced	O
fitness	O
were	O
found	O
to	O
be	O
specifically	O
mutated	O
in	O
avrBs2	B-protein
.	O

At	O
the	O
same	O
time	O
we	O
obtained	O
easily	O
understandable	O
EEG	O
-	O
information	O
which	O
has	O
never	O
previously	O
been	O
available	O
to	O
us	O
.	O

Air	O
ion	O
action	O
on	O
bacteria	O
.	O

Induction	O
of	O
the	O
urokinase	B-protein
promoter	I-protein
by	O
HGF	B-protein
/	I-protein
SF	I-protein
via	O
the	O
Met	B-protein
receptor	I-protein
was	O
blocked	O
by	O
co	O
-	O
expression	O
of	O
a	O
dominant	O
-	O
negative	O
Grb2	B-protein
and	O
Sos1	B-protein
expression	O
construct	O
.	O

The	O
Harleco	O
apparatus	O
is	O
a	O
simple	O
,	O
useful	O
,	O
cost	O
-	O
effective	O
adjunct	O
to	O
the	O
diagnosis	O
and	O
treatment	O
of	O
this	O
life	O
-	O
threatening	O
condition	O
.	O

A	O
patient	O
suffering	O
from	O
heparin	O
-	O
associated	O
thrombocytopenia	O
(	O
HAT	O
)	O
,	O
recurrent	O
arteriothromboses	O
,	O
and	O
acute	O
renal	O
failure	O
after	O
treatment	O
with	O
standard	O
heparin	O
is	O
described	O
.	O

However	O
,	O
conversions	O
of	O
12	O
mm	O
or	O
more	O
from	O
a	O
documented	O
negative	O
result	O
indicated	O
spread	O
of	O
infection	O
.	O

In	O
a	O
series	O
of	O
patients	O
with	O
neuroinfection	O
,	O
Lyme	O
disease	O
,	O
Guillain	O
Barre	O
syndrome	O
,	O
demyelinization	O
,	O
partial	O
or	O
generalized	O
,	O
epilepsy	O
,	O
we	O
have	O
investigated	O
antiphospholipid	O
antibodies	O
of	O
IgG	B-protein
and	O
IgM	B-protein
subtypes	O
,	O
together	O
with	O
anticoagulant	O
factors	O
,	O
member	O
of	O
thrombocytes	O
,	O
sedimentation	O
rate	O
of	O
erythrocytes	O
.	O

Inclusion	O
in	O
this	O
family	O
of	O
proteins	O
suggests	O
that	O
FliQ	B-protein
and	O
FliR	B-protein
may	O
participate	O
in	O
an	O
export	O
pathway	O
required	O
for	O
flagellum	O
assembly	O
.	O

The	O
duration	O
and	O
the	O
amplitude	O
of	O
the	O
negative	O
potential	O
were	O
greatest	O
for	O
completely	O
regenerating	O
ears	O
with	O
overgrowth	O
,	O
smaller	O
for	O
partially	O
regenerating	O
ears	O
,	O
and	O
smallest	O
for	O
the	O
nonregenerating	O
ears	O
.	O

Ozagrel	O
,	O
ifenprodil	O
,	O
cinnarizine	O
and	O
dilazep	O
were	O
more	O
effective	O
than	O
pentoxifylline	O
in	O
increasing	O
rCBF	O
at	O
the	O
HPC	O
.	O

Scapulae	O
with	O
a	O
Type	O
I	O
configuration	O
were	O
found	O
to	O
have	O
low	O
values	O
for	O
the	O
coraco	O
-	O
glenoid	O
angle	O
and	O
coracoid	O
overlap	O
,	O
which	O
are	O
known	O
to	O
be	O
associated	O
with	O
a	O
short	O
coraco	O
-	O
humeral	O
distance	O
.	O

Addition	O
of	O
sucralfate	O
or	O
De	O
-	O
Nol	O
resulted	O
in	O
increments	O
of	O
gastric	O
HCO3	O
secretion	O
,	O
reaching	O
about	O
45	O
%	O
and	O
59	O
%	O
,	O
respectively	O
,	O
of	O
the	O
maximal	O
HCO3	O
response	O
to	O
16	O
,	O
16	O
-	O
dimethyl	O
PGE2	O
(	O
dmPGE2	O
)	O
.	O

Factors	O
involved	O
in	O
specific	O
transcription	O
by	O
mammalian	O
RNA	B-protein
polymerase	I-protein
II	I-protein
:	O
purification	O
,	O
genetic	O
specificity	O
,	O
and	O
TATA	O
box	O
-	O
promoter	O
interactions	O
of	O
TFIID	B-protein
.	O

Aplastic	O
crisis	O
in	O
sickle	O
cell	O
disorders	O
:	O
bone	O
marrow	O
necrosis	O
and	O
human	O
parvovirus	O
infection	O
.	O

K	O
.	O

This	O
sensitivity	O
analysis	O
showed	O
that	O
the	O
practical	O
limits	O
of	O
the	O
accuracy	O
of	O
the	O
used	O
screening	O
test	O
jeopardize	O
the	O
estimation	O
of	O
the	O
true	O
herd	O
prevalence	O
within	O
reasonable	O
confidence	O
limits	O
,	O
because	O
the	O
within	O
-	O
herd	O
PTB	O
true	O
prevalence	O
was	O
low	O
.	O
For	O
this	O
reason	O
we	O
augmented	O
the	O
herd	O
specificity	O
for	O
herds	O
with	O
larger	O
adult	O
herd	O
size	O
(	O
>	O
5	O
)	O
.	O

HNF	B-protein
-	I-protein
3	I-protein
beta	I-protein
amino	I-protein
-	I-protein
terminal	I-protein
sequences	I-protein
defined	O
by	O
conserved	B-protein
region	I-protein
IV	I-protein
also	O
contributed	O
to	O
transactivation	O
,	O
but	O
region	B-protein
IV	I-protein
activity	O
required	O
the	O
participation	O
of	O
the	O
region	B-protein
II	I-protein
-	I-protein
III	I-protein
domain	I-protein
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
,	O
prognostic	O
factors	O
,	O
and	O
treatment	O
-	O
related	O
mortality	O
of	O
women	O
with	O
stage	O
IIIB	O
inflammatory	O
breast	O
cancer	O
(	O
IBC	O
)	O
treated	O
with	O
combined	O
modality	O
therapy	O
(	O
CMT	O
)	O
and	O
high	O
-	O
dose	O
chemotherapy	O
(	O
HDCT	O
)	O
with	O
autologous	O
stem	O
-	O
cell	O
transplantation	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
indicate	O
a	O
physical	O
barrier	O
of	O
oesophageal	O
surfactant	O
which	O
could	O
offer	O
some	O
degree	O
of	O
protection	O
against	O
gastro	O
-	O
oesophageal	O
reflux	O
but	O
one	O
which	O
is	O
particularly	O
prone	O
to	O
attack	O
by	O
bile	O
.	O

In	O
this	O
study	O
,	O
the	O
effect	O
of	O
acute	O
administration	O
of	O
various	O
doses	O
of	O
malathion	O
via	O
oral	O
and	O
dermal	O
routes	O
to	O
mice	O
and	O
rats	O
on	O
serum	O
levels	O
of	O
histamine	O
was	O
evaluated	O
.	O

At	O
the	O
MTD	O
(	O
8	O
mg	O
/	O
m2	O
/	O
day	O
)	O
,	O
the	O
dose	O
-	O
limiting	O
toxicity	O
of	O
this	O
agent	O
is	O
myelosuppression	O
.	O

All	O
control	O
persons	O
had	O
a	O
normal	O
reaction	O
to	O
DNFB	O
.	O

Therapeutic	O
action	O
of	O
a	O
new	O
antibiotic	O
-	O
corticoid	O
association	O
used	O
for	O
instillations	O
in	O
otology	O
.	O

Small	B-protein
GTPases	I-protein
of	O
the	O
Ypt	B-protein
/	I-protein
Rab	I-protein
family	I-protein
are	O
involved	O
in	O
the	O
regulation	O
of	O
vesicular	O
transport	O
.	O

Renin	B-protein
secretion	O
in	O
essential	O
and	O
accelerated	O
hypertension	O
.	O

These	O
findings	O
suggest	O
that	O
there	O
may	O
be	O
a	O
relationship	O
between	O
the	O
pathogenesis	O
of	O
MAL	O
,	O
narcolepsy	O
,	O
and	O
OSA	O
.	O

An	O
N	O
-	O
terminal	O
arm	O
from	O
each	O
subunit	O
wraps	O
around	O
the	O
dinucleotide	O
-	O
binding	O
domain	O
of	O
an	O
adjacent	O
subunit	O
,	O
covering	O
the	O
adenine	O
ring	O
of	O
NADP	O
.	O

At	O
rest	O
AFF	O
was	O
significantly	O
higher	O
in	O
UT	O
(	O
29	O
%	O
)	O
as	O
compared	O
to	O
AT	O
(	O
25	O
%	O
)	O
and	O
UEA	O
(	O
25	O
%	O
)	O
.	O

In	O
concept	O
II	O
62	O
patients	O
were	O
treated	O
with	O
selective	O
vagotomy	O
and	O
pyloroplasty	O
.	O

Abnormal	O
characteristics	O
and	O
verticillation	O
in	O
Platynothrus	O
peltifer	O
.	O

Next	O
,	O
with	O
carcinoma	O
presenting	O
a	O
leather	O
bottle	O
(	O
linitis	O
plastica	O
type	O
)	O
of	O
the	O
stomach	O
itself	O
,	O
the	O
II	O
c	O
portion	O
of	O
the	O
stomach	O
consisted	O
of	O
fundic	O
glands	O
(	O
undifferentiated	O
carcinoma	O
)	O
shall	O
become	O
the	O
primary	O
focus	O
supporting	O
Nakamura	O
'	O
s	O
theory	O
.	O

The	O
abluminal	O
surface	O
is	O
often	O
almost	O
entirely	O
encircled	O
by	O
a	O
thick	O
layer	O
of	O
fibrillary	O
connective	O
tissue	O
.	O

By	O
150	O
minutes	O
after	O
Cr2O3	O
inhalation	O
,	O
FEV1	O
.	O
0	O
had	O
decreased	O
by	O
32	O
%	O
.	O

A	O
deletion	O
mutation	O
analysis	O
of	O
the	O
recombinant	O
protein	O
has	O
shown	O
that	O
the	O
N	O
-	O
terminal	O
region	O
and	O
the	O
two	O
leucine	O
zippers	O
are	O
necessary	O
for	O
the	O
binding	O
.	O

The	O
influence	O
of	O
a	O
mobile	O
pupil	O
on	O
the	O
response	O
in	O
the	O
DC	O
-	O
ERG	O
is	O
demonstrated	O
.	O

On	O
the	O
basis	O
of	O
a	O
global	O
assessment	O
patients	O
showed	O
a	O
highly	O
significant	O
preference	O
for	O
imipramine	O
compared	O
with	O
placebo	O
as	O
adjunctive	O
therapy	O
.	O

Many	O
human	O
viruses	O
are	O
able	O
to	O
develop	O
suitable	O
strategies	O
for	O
modifying	O
apoptosis	O
in	O
virus	O
-	O
infected	O
cells	O
and	O
in	O
virus	O
-	O
primed	O
T	O
cells	O
.	O

This	O
motif	O
is	O
similar	O
to	O
but	O
distinct	O
from	O
the	O
LIM	B-protein
domain	I-protein
and	O
the	O
RING	B-protein
finger	I-protein
family	I-protein
,	O
and	O
is	O
reminiscent	O
of	O
known	O
metal	O
-	O
binding	O
regions	O
.	O

The	O
femoroarterial	O
coronary	O
sinus	O
difference	O
in	O
lactate	O
turned	O
negative	O
,	O
and	O
pH	O
,	O
PCO2	O
and	O
potassium	O
differences	O
increased	O
in	O
group	O
2	O
during	O
pacing	O
.	O

T	B-protein
antigen	I-protein
contains	O
four	O
H	B-protein
-	I-protein
2Db	I-protein
-	I-protein
restricted	I-protein
cytotoxic	I-protein
T	I-protein
lymphocyte	I-protein
(	I-protein
CTL	I-protein
)	I-protein
recognition	I-protein
epitopes	I-protein
that	O
are	O
targets	O
for	O
CTL	O
clones	O
Y	O
-	O
1	O
,	O
Y	O
-	O
2	O
,	O
Y	O
-	O
3	O
,	O
and	O
Y	O
-	O
5	O
.	O

Histopathological	O
features	O
of	O
relapsed	O
leprosy	O
.	O

Intracellular	O
activity	O
studies	O
indicated	O
that	O
,	O
at	O
ten	O
times	O
MBC	O
,	O
only	O
penicillin	O
had	O
any	O
significant	O
activity	O
against	O
intracellular	O
staphylococci	O
,	O
reducing	O
survival	O
by	O
28	O
%	O
.	O

Regulators	O
of	O
G	B-protein
protein	I-protein
signaling	I-protein
(	I-protein
RGS	I-protein
)	I-protein
proteins	I-protein
that	O
contain	O
DEP	B-protein
(	O
disheveled	B-protein
,	O
EGL	B-protein
-	I-protein
10	I-protein
,	O
pleckstrin	B-protein
)	O
and	O
GGL	B-protein
(	O
G	B-protein
protein	I-protein
gamma	I-protein
subunit	I-protein
-	I-protein
like	I-protein
)	O
domains	O
form	O
a	O
subfamily	O
that	O
includes	O
the	O
mammalian	B-protein
RGS	I-protein
proteins	I-protein
RGS6	I-protein
,	O
RGS7	B-protein
,	O
RGS9	B-protein
,	O
and	O
RGS11	B-protein
.	O

The	O
results	O
demonstrate	O
(	O
i	O
)	O
that	O
the	O
selenocysteine	O
-	O
specific	O
UGA	O
codon	O
is	O
readily	O
suppressed	O
under	O
conditions	O
where	O
the	O
homologous	B-protein
SelB	I-protein
protein	I-protein
is	O
absent	O
and	O
(	O
ii	O
)	O
that	O
apart	O
from	O
the	O
specificity	O
of	O
the	O
SelB	B-protein
-	I-protein
mRNA	I-protein
interaction	O
,	O
a	O
structural	O
compatibility	O
of	O
the	O
quaternary	O
complex	O
with	O
the	O
ribosome	O
is	O
required	O
.	O

Chem	O
.	O

Later	O
in	O
development	O
,	O
Tbx6	B-protein
expression	O
is	O
restricted	O
to	O
presomitic	O
,	O
paraxial	O
mesoderm	O
and	O
to	O
the	O
tail	O
bud	O
,	O
which	O
replaces	O
the	O
streak	O
as	O
the	O
source	O
of	O
mesoderm	O
.	O

RAS2val19	B-protein
,	O
a	O
dominant	O
activated	O
form	O
of	O
Saccharomyces	B-protein
cerevisiae	I-protein
Ras2	I-protein
,	O
stimulates	O
both	O
filamentous	O
growth	O
and	O
expression	O
of	O
a	O
transcriptional	B-protein
reporter	I-protein
FG	I-protein
(	I-protein
TyA	I-protein
)	I-protein
:	O
:	O
lacZ	B-protein
but	O
does	O
not	O
induce	O
the	O
mating	B-protein
pathway	I-protein
reporter	I-protein
FUS1	I-protein
:	O
:	O
lacZ	B-protein
.	O

The	O
eluent	O
from	O
the	O
column	O
was	O
mixed	O
with	O
the	O
chemiluminescent	O
solution	O
containing	O
lucigenin	O
and	O
Triton	O
X	O
-	O
100	O
and	O
a	O
0	O
.	O
28	O
M	O
KOH	O
solution	O
by	O
pumps	O
and	O
monitored	O
by	O
a	O
chemiluminescence	O
detector	O
.	O

The	O
Ng	B-protein
/	I-protein
RC3	I-protein
and	O
PKC	B-protein
-	I-protein
gamma	I-protein
genes	I-protein
have	O
a	O
similar	O
expression	O
pattern	O
in	O
the	O
brain	O
during	O
development	O
.	O

RESULTS	O
:	O
In	O
vivo	O
,	O
there	O
was	O
a	O
wide	O
distribution	O
with	O
the	O
coefficient	O
of	O
variation	O
(	O
SD	O
/	O
mean	O
x	O
100	O
%	O
)	O
for	O
different	O
valve	O
sizes	O
ranging	O
from	O
21	O
%	O
to	O
39	O
%	O
in	O
the	O
St	O
Jude	O
Medical	O
valve	O
and	O
from	O
25	O
%	O
to	O
33	O
%	O
in	O
the	O
Omnicarbon	O
valve	O
.	O

CONCLUSIONS	O
:	O
This	O
retrospective	O
uncontrolled	O
study	O
shows	O
that	O
in	O
patients	O
with	O
type	O
1	O
HRS	O
,	O
terlipressin	O
-	O
induced	O
improved	O
renal	O
function	O
is	O
associated	O
with	O
an	O
increase	O
in	O
survival	O
.	O

HRES	O
has	O
been	O
found	O
to	O
be	O
clinically	O
useful	O
in	O
assessing	O
histologic	O
damage	O
following	O
pneumatic	O
dilatation	O
and	O
in	O
localizing	O
the	O
LES	O
during	O
the	O
administration	O
of	O
intrasphincter	O
botulinum	B-protein
toxin	I-protein
injection	O
in	O
the	O
treatment	O
of	O
achalasia	O
.	O

On	O
parents	O
.	O

Relationship	O
of	O
mast	O
cells	O
to	O
sarcoidosis	O
granuloma	O
of	O
the	O
skin	O
.	O

In	O
6	O
of	O
24	O
infants	O
studied	O
(	O
27th	O
-	O
40th	O
weeks	O
of	O
gestation	O
)	O
,	O
acquired	O
and	O
congenital	O
structural	O
anomalies	O
of	O
the	O
airways	O
were	O
detected	O
with	O
an	O
ultrathin	O
flexible	O
fiberscope	O
(	O
Olympus	O
PF18	O
S	O
,	O
1	O
.	O
8	O
mm	O
)	O
.	O

The	O
cellular	O
rate	O
of	O
anticoagulant	O
heparan	O
sulfate	O
proteoglycan	O
(	O
HSPGact	O
)	O
generation	O
is	O
determined	O
by	O
the	O
level	O
of	O
a	O
kinetically	O
limiting	O
microsomal	O
activity	O
,	O
HSact	O
conversion	O
activity	O
,	O
which	O
is	O
predominantly	O
composed	O
of	O
the	O
long	O
sought	O
heparan	B-protein
sulfate	I-protein
D	I-protein
-	I-protein
glucosaminyl	I-protein
3	I-protein
-	I-protein
O	I-protein
-	I-protein
sulfotransferase	I-protein
(	O
3	B-protein
-	I-protein
OST	I-protein
)	O
(	O
Shworak	O
,	O
N	O
.	O

Molecular	O
cloning	O
of	O
a	O
novel	O
human	B-protein
I	I-protein
-	I-protein
mfa	I-protein
domain	I-protein
-	I-protein
containing	I-protein
protein	I-protein
that	O
differently	O
regulates	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
and	O
HIV	O
-	O
1	O
expression	O
.	O

Aluminium	O
resin	O
for	O
the	O
treatment	O
of	O
the	O
hyperkalamia	O
of	O
renal	O
failure	O
.	O

Strategic	O
change	O
in	O
the	O
NHS	O
.	O

Interestingly	O
,	O
PKA	B-protein
activity	O
is	O
dispensable	O
in	O
a	O
strain	O
lacking	O
Msn2p	B-protein
and	O
Msn4p	B-protein
activity	O
.	O

In	O
addition	O
to	O
its	O
elongation	O
activity	O
,	O
ELL	B-protein
contains	O
a	O
novel	O
type	O
of	O
RNA	B-protein
polymerase	I-protein
II	I-protein
interaction	I-protein
domain	I-protein
that	O
is	O
capable	O
of	O
repressing	O
polymerase	B-protein
activity	O
in	O
promoter	O
-	O
specific	O
transcription	O
.	O

In	O
contrast	O
,	O
we	O
observed	O
high	O
concentrations	O
in	O
29	O
of	O
75	O
patients	O
with	O
tumors	O
of	O
the	O
central	O
nervous	O
system	O
,	O
especially	O
in	O
meningioma	O
(	O
6	O
/	O
9	O
)	O
,	O
glioblastoma	O
(	O
9	O
/	O
23	O
)	O
,	O
and	O
neurinoma	O
(	O
5	O
/	O
5	O
)	O
.	O

We	O
present	O
evidence	O
that	O
YY1	B-protein
,	O
a	O
ubiquitously	O
expressed	O
DNA	O
-	O
binding	O
protein	O
,	O
regulates	O
the	O
activity	O
of	O
the	O
c	B-protein
-	I-protein
fos	I-protein
promoter	I-protein
primarily	O
through	O
an	O
effect	O
on	O
DNA	O
structure	O
.	O

DNase	B-protein
I	I-protein
genomic	O
footprinting	O
revealed	O
that	O
the	O
c	B-protein
-	I-protein
Myb	I-protein
site	I-protein
is	O
occupied	O
in	O
a	O
tissue	O
-	O
specific	O
fashion	O
in	O
vivo	O
.	O

Cystatin	B-protein
A	I-protein
,	O
a	O
cysteine	B-protein
proteinase	I-protein
inhibitor	O
,	O
is	O
one	O
of	O
the	O
precursor	O
proteins	O
of	O
cornified	O
cell	O
envelope	O
of	O
keratinocytes	O
and	O
is	O
expressed	O
during	O
the	O
late	O
stage	O
of	O
keratinocyte	O
differentiation	O
.	O

Emergency	O
treatment	O
of	O
facial	O
and	O
maxillary	O
/	O
mandibular	O
injuries	O
.	O

A	O
rare	O
chronic	O
course	O
of	O
Budd	O
-	O
Chiari	O
syndrome	O
associated	O
with	O
thrombosis	O
of	O
the	O
portal	O
vein	O
was	O
observed	O
in	O
a	O
30	O
-	O
year	O
-	O
old	O
male	O
patient	O
suffering	O
from	O
postmyocarditic	O
cardiosclerosis	O
.	O

The	O
contribution	O
that	O
alternative	O
splicing	O
events	O
in	O
c	B-protein
-	I-protein
myb	I-protein
expression	O
may	O
make	O
on	O
c	B-protein
-	I-protein
myb	I-protein
function	O
remains	O
to	O
be	O
elucidated	O
.	O

We	O
report	O
the	O
results	O
of	O
a	O
detailed	O
policy	O
analysis	O
comparing	O
2	O
CJD	O
-	O
related	O
decisions	O
:	O
a	O
1995	O
recall	O
of	O
blood	O
from	O
a	O
donor	O
with	O
classic	O
CJD	O
and	O
the	O
1999	O
decision	O
to	O
defer	O
donations	O
from	O
individuals	O
with	O
a	O
6	O
-	O
month	O
travel	O
history	O
to	O
the	O
UK	O
between	O
1980	O
and	O
1996	O
due	O
to	O
concerns	O
related	O
to	O
variant	O
CJD	O
.	O

Identification	O
of	O
a	O
cis	O
-	O
acting	O
element	O
in	O
the	O
class	B-protein
I	I-protein
major	I-protein
histocompatibility	I-protein
complex	I-protein
gene	I-protein
promoter	I-protein
responsive	O
to	O
activation	O
by	O
retroviral	O
sequences	O
.	O

DESIGN	O
:	O
Comparison	O
of	O
number	O
of	O
women	O
with	O
PKU	O
aged	O
15	O
-	O
44	O
years	O
on	O
the	O
NSW	O
PKU	O
database	O
(	O
observed	O
number	O
)	O
with	O
expected	O
number	O
derived	O
from	O
population	O
data	O
.	O

Most	O
strains	O
(	O
95	O
%	O
)	O
of	O
S	O
.	O
lugdunensis	O
produced	O
a	O
delta	B-protein
hemolysin	I-protein
like	O
that	O
seen	O
with	O
nine	O
other	O
species	O
of	O
CNS	O
.	O

Aggregation	O
of	O
vHnf1	O
-	O
deficient	O
embryonic	O
stem	O
cells	O
with	O
wild	O
-	O
type	O
tetraploid	O
embryos	O
,	O
which	O
contribute	O
exclusively	O
to	O
extraembryonic	O
tissues	O
,	O
rescues	O
periimplantation	O
lethality	O
and	O
allows	O
development	O
to	O
progress	O
to	O
early	O
organogenesis	O
.	O

Endogenous	O
release	O
of	O
neuronal	O
serotonin	O
and	O
5	O
-	O
hydroxyindoleacetic	O
acid	O
in	O
the	O
caudate	O
-	O
putamen	O
of	O
the	O
rat	O
as	O
revealed	O
by	O
intracerebral	O
dialysis	O
coupled	O
to	O
high	O
-	O
performance	O
liquid	O
chromatography	O
with	O
fluorimetric	O
detection	O
.	O

The	O
use	O
of	O
primary	O
GE	O
cells	O
thus	O
provides	O
a	O
convenient	O
in	O
vitro	O
system	O
for	O
further	O
study	O
of	O
the	O
endocrine	O
,	O
paracrine	O
,	O
and	O
autocrine	O
factors	O
regulating	O
endometrial	O
gene	O
expression	O
during	O
pregnancy	O
.	O

We	O
found	O
14	O
protein	O
binding	O
sites	O
that	O
were	O
occupied	O
in	O
vivo	O
.	O

CPAP	O
reduced	O
isotime	O
(	O
defined	O
as	O
the	O
last	O
common	O
minute	O
of	O
exercise	O
)	O
VO2	O
and	O
dyspnea	O
in	O
those	O
patients	O
with	O
more	O
severe	O
lung	O
disease	O
,	O
but	O
these	O
values	O
tended	O
to	O
increase	O
slightly	O
in	O
the	O
patients	O
with	O
only	O
mild	O
lung	O
disease	O
.	O

High	O
-	O
frequency	O
electrical	O
stimulation	O
in	O
the	O
hippocampus	O
leads	O
to	O
an	O
increase	O
in	O
synaptic	O
efficacy	O
that	O
lasts	O
for	O
many	O
hours	O
.	O

The	O
histologic	O
grade	O
for	O
the	O
same	O
anatomic	O
site	O
varied	O
among	O
hearts	O
and	O
among	O
different	O
anatomic	O
sites	O
in	O
the	O
same	O
heart	O
.	O

The	O
RanQ69L	B-protein
preincubation	O
leads	O
to	O
accumulation	O
of	O
CRM1	B-protein
at	O
the	O
cytoplasmic	O
periphery	O
of	O
the	O
nuclear	B-protein
pore	I-protein
complex	I-protein
(	O
NPC	B-protein
)	O
in	O
association	O
with	O
the	O
p62	B-protein
complex	I-protein
and	O
Can	B-protein
/	I-protein
Nup214	I-protein
.	O

This	O
domain	O
without	O
the	O
canonical	O
anticodon	O
loop	O
or	O
the	O
tyrosine	O
anticodon	O
acts	O
as	O
an	O
anchor	O
for	O
TyrRS	B-protein
interaction	O
leading	O
to	O
a	O
better	O
efficiency	O
of	O
tyrosylation	O
.	O

Static	O
orthoses	O
for	O
the	O
management	O
of	O
microstomia	O
.	O

Value	O
of	O
urine	O
glucose	O
tests	O
in	O
the	O
management	O
of	O
type	O
II	O
diabetes	O
mellitus	O
.	O

Two	O
US	O
commercial	O
cultivars	O
(	O
Tehama	O
and	O
Vina	O
)	O
,	O
three	O
European	O
commercial	O
cultivars	O
(	O
Esterhazy	O
,	O
139	O
,	O
G120	O
)	O
and	O
five	O
New	O
Zealand	O
selections	O
(	O
Rex	O
,	O
Dublin	O
'	O
s	O
Glory	O
,	O
Meyric	O
,	O
McKinster	O
,	O
Stanley	O
)	O
were	O
evaluated	O
.	O

Twenty	O
-	O
eight	O
(	O
7	O
.	O
0	O
%	O
)	O
infants	O
without	O
periventricular	O
hemorrhage	O
were	O
revealed	O
as	O
having	O
spastic	O
cerebral	O
palsy	O
by	O
neurodevelopmental	O
evaluation	O
in	O
later	O
infancy	O
.	O

The	O
statistical	O
analysis	O
of	O
data	O
of	O
TRH	B-protein
test	O
on	O
a	O
sample	O
of	O
57	O
healthy	O
volunteers	O
has	O
permitted	O
an	O
evaluation	O
of	O
the	O
upper	O
limits	O
of	O
the	O
normal	O
thyrotropin	B-protein
response	O
;	O
the	O
secretory	O
area	O
(	O
As	O
)	O
was	O
shown	O
to	O
be	O
more	O
discriminating	O
.	O

The	O
alpha	B-protein
2A	I-protein
-	I-protein
adrenergic	I-protein
receptor	I-protein
(	O
alpha	B-protein
2AAR	I-protein
)	O
is	O
coupled	O
to	O
a	O
variety	O
of	O
effectors	O
via	O
pertussis	O
toxin	O
-	O
sensitive	O
GTP	B-protein
-	I-protein
binding	I-protein
proteins	I-protein
.	O

Cardiac	B-protein
endothelin	I-protein
release	O
and	O
infarct	O
size	O
,	O
myocardial	O
blood	O
flow	O
,	O
and	O
ventricular	O
function	O
in	O
canine	O
infarction	O
and	O
reperfusion	O
.	O

The	O
effects	O
of	O
L655	O
,	O
240	O
,	O
a	O
selective	O
thromboxane	O
and	O
prostaglandin	O
endoperoxide	O
antagonist	O
,	O
on	O
ischemia	O
-	O
and	O
reperfusion	O
-	O
induced	O
cardiac	O
arrhythmias	O
.	O

However	O
,	O
in	O
TF	O
-	O
1	O
cells	O
grown	O
on	O
GM	B-protein
-	I-protein
CSF	I-protein
before	O
starvation	O
,	O
CREB	B-protein
phosphorylation	O
was	O
observed	O
10	O
minutes	O
after	O
PIXY321	B-protein
stimulation	O
.	O

The	O
Cr	B-protein
.	I-protein
psbA	I-protein
-	I-protein
4	I-protein
ORF	I-protein
contains	O
an	O
H	B-protein
-	I-protein
N	I-protein
-	I-protein
H	I-protein
motif	I-protein
,	O
and	O
possibly	O
a	O
GIY	B-protein
-	I-protein
YIG	I-protein
motif	I-protein
.	O

The	O
promoter	O
and	O
upstream	O
region	O
of	O
the	O
Brassica	B-protein
napus	I-protein
2S	I-protein
storage	I-protein
protein	I-protein
napA	I-protein
gene	I-protein
were	O
studied	O
to	O
identify	O
cis	O
-	O
acting	O
sequences	O
involved	O
in	O
developmental	O
seed	O
-	O
specific	O
expression	O
.	O

The	O
diagnosis	O
of	O
metachromatic	O
leukodystrophy	O
(	O
MLD	O
)	O
was	O
confirmed	O
by	O
the	O
finding	O
of	O
low	O
arylsulfatase	B-protein
A	I-protein
(	O
ASA	B-protein
)	O
levels	O
in	O
cultured	O
fibroblasts	O
in	O
both	O
sisters	O
.	O

Once	O
more	O
Hong	O
Kong	O
influenza	O
in	O
the	O
Netherlands	O
.	O

In	O
addition	O
,	O
this	O
kinase	O
is	O
well	O
conserved	O
evolutionarily	O
,	O
ubiquitously	O
expressed	O
,	O
and	O
its	O
genes	O
map	O
to	O
a	O
position	O
on	O
human	O
chromosome	O
1	O
frequently	O
deleted	O
in	O
the	O
late	O
stages	O
of	O
tumorigenesis	O
.	O

Deletions	O
in	O
each	O
of	O
these	O
regions	O
abolish	O
membrane	O
localization	O
of	O
Tiam1	B-protein
and	O
membrane	O
ruffling	O
,	O
suggesting	O
that	O
they	O
function	O
cooperatively	O
.	O

During	O
IC	O
breaths	O
and	O
following	O
EC	O
and	O
VC	O
breaths	O
at	O
rest	O
,	O
end	O
-	O
tidal	O
CO2	O
pressure	O
(	O
PET	O
,	O
CO2	O
)	O
fell	O
by	O
7	O
.	O
5	O
,	O
8	O
.	O
5	O
and	O
9	O
.	O
5	O
mmHg	O
,	O
respectively	O
.	O

It	O
is	O
postulated	O
that	O
altered	O
blood	O
flow	O
,	O
mediated	O
through	O
the	O
well	O
-	O
known	O
prostaglandin	B-protein
synthetase	I-protein
inhibitory	O
effects	O
of	O
ibuprofen	O
,	O
resulted	O
in	O
tubular	O
necrosis	O
.	O

Mitochondrial	B-protein
Mas70p	I-protein
signal	I-protein
anchor	I-protein
sequence	I-protein
.	O

Genetic	O
and	O
phenotypic	O
analysis	O
indicates	O
that	O
NHP6A	B-protein
and	O
NHP6B	B-protein
function	O
downstream	O
of	O
SLT2	B-protein
.	O

BACKGROUND	O
:	O
Studies	O
in	O
lean	O
men	O
show	O
poor	O
regulation	O
of	O
energy	O
(	O
EB	O
)	O
and	O
fat	O
balance	O
(	O
FB	O
)	O
during	O
manipulation	O
of	O
dietary	O
ratios	O
of	O
fat	O
to	O
carbohydrate	O
.	O

TCR	B-protein
alpha	I-protein
(	O
TCRA	B-protein
)	O
expression	O
was	O
examined	O
in	O
RNA	O
samples	O
from	O
PBMC	O
and	O
isolated	O
populations	O
of	O
CD4	B-protein
+	I-protein
,	O
CD8	B-protein
+	I-protein
,	O
and	O
DN	B-protein
T	O
cells	O
from	O
15	O
healthy	O
individuals	O
.	O

The	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
contains	O
three	O
binding	O
sites	O
for	O
the	O
transcriptional	O
factor	O
Sp1	B-protein
.	O

The	O
used	O
expression	O
system	O
could	O
allow	O
to	O
produce	O
mutated	O
forms	O
of	O
SsEF	B-protein
-	I-protein
2	I-protein
obtained	O
by	O
mutagenesis	O
of	O
the	O
corresponding	O
gene	O
.	O

This	O
model	O
is	O
supported	O
by	O
experiments	O
showing	O
that	O
Cdr2	B-protein
associates	O
with	O
the	O
N	B-protein
-	I-protein
terminal	I-protein
regulatory	I-protein
domain	I-protein
of	I-protein
Wee1	I-protein
in	O
cell	O
lysates	O
and	O
phosphorylates	O
Wee1	B-protein
in	O
vitro	O
.	O

Greek	O
classicism	O
in	O
living	O
structure	O
?	O
Some	O
deductive	O
pathways	O
in	O
animal	O
morphology	O
.	O

We	O
linked	O
a	O
4	O
.	O
1	O
-	O
kilobase	O
pair	O
HindIII	B-protein
DNA	I-protein
fragment	I-protein
from	O
the	O
region	O
upstream	O
of	O
the	O
human	B-protein
AP	I-protein
endonuclease	I-protein
gene	I-protein
(	O
APE	B-protein
)	O
to	O
the	O
chloramphenicol	B-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
gene	O
.	O

It	O
was	O
concluded	O
that	O
patients	O
with	O
acute	O
respiratory	O
failure	O
requiring	O
artificial	O
ventilation	O
have	O
two	O
componenents	O
of	O
the	O
pulmonary	O
shunt	O
,	O
one	O
parallel	O
with	O
and	O
the	O
other	O
inversely	O
related	O
with	O
the	O
PAO2	O
.	O

The	O
control	O
group	O
revealed	O
significantly	O
higher	O
levels	O
of	O
coagulation	B-protein
factors	I-protein
II	I-protein
,	O
V	B-protein
and	O
VIII	B-protein
,	O
compared	O
to	O
the	O
index	O
group	O
.	O

Whereas	O
,	O
in	O
the	O
single	O
-	O
chambered	O
body	O
box	O
,	O
PenH	O
units	O
(	O
Enhanced	O
Pause	O
)	O
reflect	O
`	O
`	O
effort	O
of	O
breathing	O
.	O
`	O
`	O
This	O
is	O
measured	O
as	O
the	O
pause	O
between	O
inspiration	O
and	O
expiration	O
.	O

These	O
thyroid	O
hormone	O
changes	O
may	O
be	O
mediated	O
in	O
part	O
by	O
cytokines	O
or	O
other	O
inflammatory	O
mediators	O
,	O
acting	O
at	O
the	O
level	O
of	O
the	O
hypothalamus	O
and	O
pituitary	O
gland	O
,	O
the	O
thyroid	O
gland	O
,	O
and	O
the	O
hepatic	B-protein
deiodinase	I-protein
system	I-protein
.	O

Compared	O
with	O
normal	O
control	O
subjects	O
,	O
all	O
74	O
TOF	O
patients	O
had	O
decreased	O
systolic	O
and	O
diastolic	O
myocardial	O
velocities	O
and	O
a	O
longer	O
isovolumic	O
relaxation	O
time	O
.	O

The	O
cyclins	B-protein
bind	O
to	O
and	O
activate	O
the	O
CDK	B-protein
,	O
which	O
leads	O
to	O
phosphorylation	O
(	O
and	O
then	O
inhibition	O
)	O
of	O
the	O
tumor	O
suppressor	O
protein	O
,	O
pRb	B-protein
.	O
pRb	B-protein
controls	O
commitment	O
to	O
progress	O
from	O
the	O
G1	O
to	O
S	O
phase	O
,	O
at	O
least	O
in	O
part	O
by	O
repressing	O
the	O
activity	O
of	O
the	O
E2F	B-protein
transcription	I-protein
factors	I-protein
known	O
to	O
promote	O
cell	O
proliferation	O
.	O

Snail	B-protein
family	I-protein
proteins	I-protein
are	O
zinc	O
finger	O
transcriptional	O
regulators	O
first	O
identified	O
in	O
Drosophila	O
which	O
play	O
critical	O
roles	O
in	O
cell	O
fate	O
determination	O
.	O

When	O
tethered	O
to	O
a	O
heterologous	O
DNA	O
-	O
binding	O
domain	O
,	O
PSU1	B-protein
can	O
activate	O
transcription	O
on	O
its	O
own	O
.	O

The	O
promoter	O
of	O
the	O
first	O
gene	O
,	O
epiF	B-protein
,	O
responded	O
to	O
the	O
activator	B-protein
protein	I-protein
EpiQ	I-protein
and	O
contained	O
a	O
palindromic	O
sequence	O
similar	O
to	O
the	O
EpiQ	B-protein
binding	I-protein
site	I-protein
of	O
the	O
epiA	B-protein
promoter	I-protein
,	O
which	O
is	O
also	O
activated	O
by	O
EpiQ	B-protein
.	O

Lastly	O
,	O
there	O
are	O
multiple	O
instances	O
in	O
which	O
short	O
oligonucleotide	O
direct	O
repeats	O
flank	O
a	O
region	O
absent	O
from	O
either	O
variola	O
or	O
vaccinia	O
virus	O
.	O

The	O
attainment	O
of	O
sexual	O
maturity	O
in	O
terms	O
of	O
secondary	O
sexual	O
characteristics	O
,	O
the	O
production	O
of	O
spermatozoa	O
in	O
the	O
male	O
,	O
and	O
the	O
cyclical	O
female	O
pattern	O
with	O
release	O
of	O
ova	O
are	O
end	O
-	O
points	O
of	O
the	O
developmental	O
process	O
.	O

CONCLUSIONS	O
:	O
Free	O
protein	B-protein
S	I-protein
deficiency	O
is	O
common	O
among	O
hospitalized	O
patients	O
,	O
even	O
in	O
the	O
absence	O
of	O
a	O
recognized	O
predisposing	O
condition	O
.	O

She	O
had	O
been	O
receiving	O
MTX	O
7	O
.	O
5	O
mg	O
/	O
week	O
for	O
2	O
.	O
5	O
months	O
because	O
of	O
her	O
vasculitis	O
symptoms	O
.	O

Type	O
IV	O
splice	O
pattern	O
,	O
containing	O
exon	B-protein
U3	I-protein
and	I-protein
S	I-protein
was	O
found	O
both	O
in	O
kidney	O
and	O
ovary	O
.	O

Sestamibi	O
scintigraphy	O
,	O
performed	O
in	O
70	O
patients	O
,	O
was	O
less	O
sensitive	O
than	O
ultrasonography	O
(	O
80	O
%	O
)	O
.	O

Neither	O
clone	O
encoded	O
the	O
cognate	O
endonuclease	B-protein
.	O

Clinical	O
nutrition	O
of	O
adult	O
horses	O
.	O

Dll3	B-protein
is	O
mutated	O
in	O
the	O
X	O
-	O
ray	O
-	O
induced	O
mouse	B-protein
mutant	I-protein
pudgy	I-protein
(	O
pu	B-protein
)	O
,	O
causing	O
a	O
variety	O
of	O
vertebrocostal	O
defects	O
similar	O
to	O
SD	O
phenotypes	O
.	O

The	O
junctions	O
between	O
viral	O
and	O
cellular	O
sequences	O
were	O
determined	O
by	O
DNA	O
sequence	O
analysis	O
to	O
be	O
517	O
nucleotides	O
into	O
the	O
p30	B-protein
sequence	I-protein
and	O
1	O
,	O
920	O
nucleotides	O
into	O
the	O
polymerase	B-protein
sequence	I-protein
.	O

In	O
this	O
study	O
we	O
describe	O
that	O
platelet	B-protein
-	I-protein
derived	I-protein
growth	I-protein
factor	I-protein
(	O
PDGF	B-protein
)	O
,	O
12	O
-	O
O	O
-	O
tetradecanoyl	O
-	O
phorbol	O
-	O
acetate	O
(	O
TPA	O
)	O
,	O
and	O
forskolin	O
induced	O
CREB	B-protein
(	O
cAMP	B-protein
-	I-protein
responsive	I-protein
element	I-protein
-	I-protein
binding	I-protein
protein	I-protein
)	O
Ser	O
-	O
133	O
phosphorylation	O
with	O
comparable	O
magnitude	O
and	O
kinetics	O
in	O
NIH	O
3T3	O
cells	O
.	O

On	O
the	O
other	O
hand	O
factor	B-protein
IX	I-protein
activity	O
is	O
decreased	O
in	O
coumarin	O
treatment	O
with	O
factor	B-protein
IX	I-protein
antigen	O
remaining	O
normal	O
.	O

The	O
coding	O
sequence	O
for	O
a	O
260	O
-	O
amino	O
-	O
acid	O
residue	O
polypeptide	O
was	O
interrupted	O
by	O
a	O
single	O
short	O
intron	O
of	O
60	O
base	O
pairs	O
(	O
bp	O
)	O
,	O
and	O
about	O
70	O
%	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
Drosophila	B-protein
PCNA	I-protein
was	O
identical	O
to	O
the	O
rat	O
and	O
human	B-protein
PCNA	I-protein
polypeptides	I-protein
,	O
with	O
conserved	O
unique	O
repeats	O
of	O
leucine	O
in	O
the	O
C	O
-	O
terminal	O
region	O
.	O

No	O
homology	O
was	O
found	O
between	O
the	O
36K	O
protein	O
and	O
known	O
structures	O
of	O
proteins	O
.	O

Nursing	O
education	O
-	O
-	O
the	O
computer	O
obligation	O
.	O

Plasma	O
fibrinogen	B-protein
was	O
measured	O
by	O
the	O
turbidimetric	O
method	O
in	O
timol	O
turbidimetric	O
units	O
.	O

The	O
results	O
indicate	O
that	O
:	O
1	O
)	O
the	O
initial	O
response	O
to	O
tethering	O
varies	O
according	O
to	O
previous	O
penning	O
and	O
handling	O
experience	O
,	O
2	O
)	O
although	O
the	O
circadian	O
rhythm	O
of	O
cortisol	O
was	O
either	O
altered	O
or	O
disrupted	O
during	O
estrus	O
,	O
such	O
disruptions	O
were	O
not	O
influenced	O
by	O
type	O
of	O
penning	O
and	O
3	O
)	O
tether	O
stalls	O
may	O
chronically	O
increase	O
cortisol	O
concentrations	O
in	O
gilts	O
.	O

This	O
unique	O
work	O
needs	O
to	O
be	O
edited	O
critically	O
and	O
afterwards	O
translated	O
into	O
Urdu	O
and	O
other	O
languages	O
for	O
the	O
benefit	O
of	O
the	O
present	O
day	O
students	O
and	O
scholars	O
.	O

Macroscopic	O
researches	O
on	O
heart	O
vascularization	O
have	O
indicated	O
that	O
the	O
angioarchitecture	O
of	O
the	O
conducting	O
system	O
differs	O
from	O
that	O
of	O
the	O
normal	O
myocardium	O
.	O

Key	O
areas	O
of	O
the	O
selection	O
process	O
including	O
medical	O
and	O
surgical	O
alternatives	O
to	O
transplantation	O
,	O
the	O
composition	O
of	O
the	O
transplant	O
work	O
-	O
up	O
,	O
specific	O
inclusion	O
criteria	O
as	O
well	O
as	O
specific	O
psychosocial	O
factors	O
and	O
specific	O
disease	O
etiologies	O
and	O
co	O
-	O
morbidities	O
that	O
might	O
represent	O
contraindications	O
were	O
extensively	O
reviewed	O
.	O

Adapromine	O
was	O
established	O
to	O
evoke	O
a	O
decrease	O
of	O
the	O
amplitude	O
of	O
the	O
dominant	O
peak	O
and	O
dominant	O
theta	O
-	O
activity	O
in	O
power	O
spectra	O
of	O
the	O
EEG	O
in	O
the	O
cortex	O
and	O
hippocamp	O
,	O
with	O
an	O
increase	O
of	O
rapid	O
wave	O
activity	O
in	O
the	O
beta	O
2	O
range	O
in	O
the	O
right	O
cortex	O
and	O
hippocamp	O
.	O

Although	O
no	O
statistical	O
significance	O
was	O
achieved	O
,	O
it	O
is	O
remarkable	O
that	O
there	O
was	O
a	O
clear	O
trend	O
for	O
the	O
superiority	O
of	O
Galphimia	O
D6	O
while	O
the	O
Galphimia	O
dilution	O
10	O
(	O
-	O
6	O
)	O
was	O
about	O
equally	O
effective	O
compared	O
with	O
placebo	O
.	O

Definite	O
JPsA	O
(	O
24	O
patients	O
)	O
was	O
defined	O
as	O
arthritis	O
associated	O
,	O
but	O
not	O
necessarily	O
coincident	O
,	O
with	O
a	O
typical	O
psoriatic	O
rash	O
,	O
or	O
arthritis	O
plus	O
at	O
least	O
3	O
of	O
4	O
minor	O
criteria	O
:	O
dactylitis	O
,	O
nail	O
pitting	O
,	O
psoriasis	O
-	O
like	O
rash	O
,	O
or	O
family	O
history	O
of	O
psoriasis	O
.	O

Hprp3p	B-protein
is	O
a	O
77	O
kDa	O
protein	O
,	O
which	O
is	O
homologous	O
to	O
the	O
Saccharomyces	B-protein
cerevisiae	I-protein
splicing	I-protein
factor	I-protein
Prp3p	I-protein
.	O

For	O
monocytes	O
,	O
as	O
measured	O
on	O
the	O
Hematrak	O
,	O
it	O
was	O
13	O
.	O
4	O
%	O
.	O

Absorption	O
varied	O
between	O
65	O
and	O
95	O
per	O
cent	O
,	O
with	O
a	O
mean	O
absorption	O
of	O
80	O
per	O
cent	O
,	O
in	O
both	O
pregnant	O
and	O
non	O
-	O
pregnant	O
subjects	O
.	O

In	O
contrast	O
,	O
extracts	O
of	O
the	O
mutant	O
virions	O
catalyze	O
the	O
wild	O
-	O
type	O
level	O
of	O
transcription	O
from	O
an	O
exogenous	O
template	O
containing	O
an	O
early	O
promoter	O
.	O

Influence	O
of	O
diet	O
on	O
urinary	O
VMA	O
excretion	O
.	O

BACKGROUND	O
:	O
Hepatic	O
encephalopathy	O
is	O
a	O
neuropsychiatric	O
syndrome	O
associated	O
with	O
acute	O
liver	O
failure	O
,	O
chronic	O
parenchymal	O
liver	O
disease	O
or	O
portal	O
systemic	O
anastomosis	O
.	O

METHODS	O
:	O
Between	O
August	O
1991	O
and	O
June	O
1994	O
,	O
198	O
men	O
with	O
clinical	O
T2	O
or	O
T3	O
classified	O
(	O
TNM	O
)	O
prostate	O
carcinoma	O
(	O
bone	O
scan	O
negative	O
)	O
who	O
were	O
at	O
high	O
risk	O
of	O
lymph	O
node	O
involvement	O
underwent	O
a	O
111In	O
-	O
capromab	O
pendetide	O
scan	O
prior	O
to	O
staging	O
lymphadenectomy	O
.	O

Organisms	O
were	O
not	O
observed	O
in	O
the	O
5	O
bobcats	O
trapped	O
in	O
2	O
other	O
counties	O
.	O

However	O
,	O
expression	O
of	O
sigma	B-protein
3	I-protein
from	O
S4	B-protein
(	O
3	B-protein
'	I-protein
UTR	I-protein
/	I-protein
S1	I-protein
)	O
,	O
which	O
included	O
the	O
PKR	B-protein
activator	I-protein
sequence	I-protein
from	O
S1	B-protein
within	O
the	O
3	B-protein
'	I-protein
-	I-protein
UTR	I-protein
of	I-protein
S4	I-protein
,	O
was	O
comparable	O
to	O
that	O
from	O
wild	B-protein
-	I-protein
type	I-protein
S4	I-protein
.	O

These	O
data	O
support	O
a	O
possible	O
biological	O
significance	O
of	O
the	O
frameshift	O
to	O
occur	O
at	O
this	O
position	O
of	O
the	O
large	O
overlap	O
by	O
including	O
the	O
putative	O
RNA	O
template	O
-	O
binding	O
site	O
of	O
the	O
PLRV	B-protein
replicase	I-protein
in	O
the	O
ORF2a	B-protein
/	I-protein
ORF2b	I-protein
transframe	I-protein
protein	I-protein
.	O

Hepatitis	O
B	O
vaccine	O
.	O

A	O
new	O
method	O
for	O
the	O
quantitative	O
analysis	O
of	O
sleep	O
spindles	O
during	O
continuous	O
overnight	O
EEG	O
recordings	O
.	O

The	O
cDNA	O
of	O
cpm7	B-protein
encodes	O
a	O
closely	O
related	O
protein	O
of	O
36	O
.	O
8	O
kDa	O
.	O

Utilizing	O
transient	O
transfection	O
studies	O
in	O
HepG2	O
cells	O
,	O
we	O
have	O
shown	O
that	O
deletion	O
of	O
the	O
factor	B-protein
VIII	I-protein
promoter	I-protein
sequences	I-protein
distal	O
to	O
nucleotide	O
-	O
44	O
results	O
in	O
a	O
significant	O
but	O
small	O
increase	O
in	O
promoter	O
activity	O
.	O

Clinical	O
findings	O
were	O
:	O
height	O
183	O
cm	O
,	O
weight	O
62	O
kg	O
,	O
increased	O
length	O
of	O
lower	O
limbs	O
,	O
P2	O
-	O
A2	O
pilosity	O
and	O
micropenis	O
.	O

Moreover	O
,	O
a	O
recombinant	O
Ad	O
expressing	O
Ad5	B-protein
E4orf6	I-protein
/	I-protein
7	I-protein
induced	O
apoptosis	O
in	O
rat	O
cells	O
when	O
coinfected	O
with	O
wild	O
-	O
type	O
p53	O
-	O
expressing	O
Ad	O
.	O

Hyperthyroidism	O
is	O
one	O
of	O
the	O
numerous	O
causes	O
of	O
infertility	O
and	O
recurrent	O
abortion	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
the	O
Src	B-protein
homology	I-protein
-	I-protein
2	I-protein
(	O
SH2	B-protein
)	O
domain	O
-	O
containing	O
protein	B-protein
-	I-protein
tyrosine	I-protein
phosphatase	I-protein
,	O
SHP	B-protein
-	I-protein
2	I-protein
,	O
associates	O
with	O
the	O
cytoplasmic	O
domain	O
of	O
PECAM	B-protein
-	I-protein
1	I-protein
as	O
it	O
becomes	O
tyrosine	O
-	O
phosphorylated	O
during	O
platelet	O
aggregation	O
:	O
a	O
process	O
that	O
can	O
be	O
mimicked	O
in	O
part	O
by	O
small	O
synthetic	O
phosphopeptides	O
corresponding	O
to	O
the	O
cytoplasmic	O
domain	O
of	O
PECAM	B-protein
-	I-protein
1	I-protein
encompassing	O
tyrosine	O
residues	O
Tyr	O
-	O
663	O
or	O
Tyr	O
-	O
686	O
.	O

All	O
8	O
(	O
100	O
%	O
)	O
patients	O
with	O
fulminant	O
hepatic	O
failure	O
who	O
received	O
grafts	O
survived	O
,	O
including	O
3	O
who	O
received	O
ABO	O
-	O
incompatible	O
grafts	O
,	O
though	O
2	O
of	O
these	O
subsequently	O
required	O
retransplantation	O
.	O

High	O
dosages	O
of	O
D	O
-	O
penicillamine	O
in	O
pulmonary	O
fibroses	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Percentage	O
change	O
in	O
the	O
apnea	O
-	O
hypopnea	O
index	O
(	O
AHI	O
;	O
apnea	O
events	O
+	O
hypopnea	O
events	O
per	O
hour	O
of	O
sleep	O
)	O
and	O
odds	O
of	O
developing	O
moderate	O
-	O
to	O
-	O
severe	O
SDB	O
(	O
defined	O
by	O
an	O
AHI	O
>	O
or	O
=	O
15	O
events	O
per	O
hour	O
of	O
sleep	O
)	O
,	O
with	O
respect	O
to	O
change	O
in	O
weight	O
.	O

Expression	O
in	O
early	O
postnatal	O
pituitary	O
and	O
in	O
pre	O
-	O
somatotrophic	O
cells	O
suggests	O
that	O
Zn	B-protein
-	I-protein
16	I-protein
could	O
play	O
a	O
role	O
in	O
pituitary	O
development	O
prior	O
to	O
somatotroph	O
differentiation	O
.	O

The	O
repetitive	O
ETn	B-protein
(	O
early	B-protein
transposon	I-protein
)	O
family	O
of	O
sequences	O
represents	O
an	O
active	O
`	O
`	O
mobile	O
mutagen	O
'	O
'	O
in	O
the	O
mouse	O
genome	O
.	O

Ume6p	B-protein
,	O
which	O
also	O
controls	O
the	O
expression	O
of	O
early	O
meiotic	O
genes	O
,	O
represses	O
CAR1	B-protein
expression	O
through	O
a	O
sequence	O
called	O
URS	B-protein
,	O
as	O
a	O
function	O
of	O
nitrogen	O
availability	O
.	O

Slowed	O
lysosomal	B-protein
enzyme	I-protein
release	O
and	O
its	O
normalization	O
by	O
drugs	O
in	O
adjuvant	O
-	O
induced	O
polyarthritis	O
.	O

I	O
.	O

Nitrogen	O
-	O
hydrogen	O
tautomerism	O
in	O
porphyrins	O
and	O
chlorins	O
.	O

Interspecific	O
mouse	O
back	O
-	O
cross	O
analysis	O
identified	O
the	O
loci	O
for	O
mouse	B-protein
3Ost	I-protein
genes	I-protein
and	O
syntenic	O
assignments	O
of	O
corresponding	O
human	O
isologs	O
were	O
confirmed	O
by	O
the	O
identification	O
of	O
mapped	O
sequence	O
-	O
tagged	O
site	O
markers	O
.	O

Two	O
closely	O
related	O
IgH	B-protein
constant	I-protein
region	I-protein
genes	I-protein
,	O
CHA	B-protein
and	O
CHB	B-protein
,	O
have	O
been	O
sequenced	O
completely	O
.	O

Fraction	O
2	O
contains	O
1	O
,	O
25	O
(	O
OH	O
)	O
2	O
-	O
vitamin	O
D3	O
,	O
vitamin	O
D3	O
,	O
25	O
(	O
OH	O
)	O
-	O
vitamin	O
D3	O
and	O
1	O
,	O
24	O
,	O
25	O
(	O
OH	O
)	O
3	O
-	O
vitamin	O
D3	O
.	O

The	O
healing	O
rate	O
in	O
HIV	O
-	O
positive	O
patients	O
was	O
66	O
percent	O
after	O
14	O
weeks	O
and	O
100	O
percent	O
after	O
32	O
weeks	O
;	O
the	O
corresponding	O
figures	O
for	O
patients	O
with	O
acquired	O
immunodeficiency	O
syndrome	O
were	O
0	O
and	O
50	O
percent	O
.	O

Regional	O
CBF	O
was	O
determined	O
by	O
clearance	O
of	O
xenon	O
133	O
in	O
67	O
patients	O
undergoing	O
coronary	O
bypass	O
grafting	O
procedures	O
.	O

RVEF	O
and	O
LVEF	O
both	O
increased	O
by	O
about	O
14	O
%	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
and	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Among	O
the	O
few	O
proteins	O
of	O
the	O
eukaryotic	O
nucleolus	O
that	O
have	O
been	O
characterized	O
,	O
four	O
proteins	O
,	O
nucleolin	B-protein
,	O
fibrillarin	B-protein
,	O
SSB1	B-protein
and	O
NSR1	B-protein
,	O
possess	O
a	O
common	O
structural	O
motif	O
,	O
the	O
GAR	B-protein
domain	I-protein
,	O
which	O
is	O
rich	O
in	O
glycine	O
and	O
arginine	O
residues	O
.	O

Cross	O
reactivity	O
in	O
theophylline	O
RIA	O
kit	O
decreased	O
.	O

In	O
particular	O
,	O
changes	O
in	O
intracellular	O
Ca2	O
+	O
have	O
the	O
potential	O
to	O
either	O
inhibit	O
or	O
augment	O
the	O
ability	O
of	O
cAMP	O
to	O
stimulate	O
transcription	O
,	O
depending	O
on	O
the	O
presence	O
of	O
specific	O
forms	O
of	O
Ca2	B-protein
+	I-protein
/	I-protein
calmodulin	I-protein
-	I-protein
dependent	I-protein
protein	I-protein
kinases	I-protein
.	O

In	O
contrast	O
,	O
injection	O
of	O
a	O
plasmid	O
encoding	O
simian	B-protein
virus	I-protein
40	I-protein
small	I-protein
t	I-protein
antigen	I-protein
,	O
which	O
interacts	O
with	O
PP2A	B-protein
to	O
inhibit	O
its	O
activity	O
towards	O
several	O
phosphoprotein	O
substrates	O
,	O
had	O
no	O
effect	O
on	O
the	O
phosphorylation	O
state	O
of	O
CREB	B-protein
in	O
stimulated	O
or	O
unstimulated	O
NIH	O
3T3	O
cells	O
.	O

Primary	O
amenorrhoea	O
in	O
a	O
phenotypically	O
female	O
individual	O
with	O
a	O
karyotype	O
46	O
,	O
xy	O
and	O
bilateral	O
gonadoblastoma	O
.	O

Vimentin	B-protein
positivity	O
was	O
noted	O
in	O
the	O
undifferentiated	O
and	O
fibroblastic	O
components	O
.	O

This	O
fraction	O
is	O
resistant	O
to	O
digestions	O
by	O
DNase	B-protein
I	I-protein
and	O
RNase	B-protein
T1	I-protein
and	O
disappears	O
completely	O
upon	O
alkali	O
hydrolysis	O
.	O

SCID	O
V	B-protein
(	I-protein
D	I-protein
)	I-protein
J	I-protein
recombination	O
can	O
be	O
partly	O
rescued	O
in	O
T	O
-	O
lymphocytes	O
by	O
either	O
DNA	O
-	O
damaging	O
agents	O
(	O
gamma	O
-	O
irradiation	O
and	O
bieomycin	O
)	O
or	O
a	O
null	O
mutation	O
of	O
the	O
p53	B-protein
gene	I-protein
,	O
possibly	O
because	O
of	O
transiently	O
elevated	O
DNA	O
repair	O
activity	O
in	O
response	O
to	O
DNA	O
damage	O
or	O
to	O
delayed	O
apoptosis	O
in	O
the	O
absence	O
of	O
p53	B-protein
.	O

A	O
larval	B-protein
albumin	I-protein
-	I-protein
like	I-protein
protein	I-protein
was	O
not	O
detectable	O
by	O
silver	O
staining	O
in	O
serum	O
of	O
tadpoles	O
before	O
the	O
beginning	O
of	O
metamorphosis	O
at	O
stage	O
48	O
.	O

All	O
these	O
processes	O
were	O
fully	O
developed	O
during	O
the	O
last	O
month	O
of	O
pregnancy	O
,	O
offering	O
the	O
same	O
picture	O
as	O
the	O
controls	O
.	O

It	O
has	O
been	O
previously	O
shown	O
that	O
genes	O
transcribed	O
by	O
RNA	B-protein
polymerase	I-protein
II	I-protein
(	O
RNAP	B-protein
II	I-protein
)	O
are	O
subject	O
to	O
position	O
effect	O
variegation	O
when	O
located	O
near	O
yeast	O
telomeres	O
.	O

Alignment	O
of	O
different	O
cDNAs	O
of	O
the	O
NR5A2	B-protein
(	O
hB1F	B-protein
)	O
gene	O
with	O
the	O
genomic	O
sequence	O
facilitated	O
the	O
delineation	O
of	O
its	O
structural	O
organization	O
,	O
which	O
spans	O
over	O
150	O
kb	O
and	O
consists	O
of	O
eight	O
exons	O
interrupted	O
by	O
seven	O
introns	O
.	O

Genetic	O
interactions	O
between	O
BCK2	B-protein
and	O
other	O
pathway	O
components	O
suggested	O
that	O
BCK2	B-protein
functions	O
on	O
a	O
common	O
pathway	O
branch	O
with	O
PPZ1	B-protein
and	O
PPZ2	B-protein
.	O

Trial	O
3	O
broiler	O
chickens	O
were	O
maintained	O
on	O
control	O
feed	O
until	O
they	O
reached	O
3	O
weeks	O
of	O
age	O
at	O
which	O
time	O
they	O
were	O
taken	O
off	O
of	O
feed	O
for	O
2	O
.	O
5	O
hr	O
and	O
then	O
placed	O
on	O
either	O
control	O
feed	O
or	O
feed	O
containing	O
4	O
.	O
0	O
ppm	O
ochratoxin	O
A	O
,	O
and	O
heart	O
rate	O
and	O
blood	O
pressure	O
were	O
measured	O
every	O
half	O
hour	O
through	O
7	O
hr	O
.	O

We	O
also	O
provide	O
evidence	O
that	O
neither	O
the	O
lambda	B-protein
O	I-protein
and	O
P	B-protein
initiators	I-protein
nor	O
the	O
E	B-protein
.	I-protein
coli	I-protein
DnaJ	I-protein
and	O
DnaK	B-protein
heat	I-protein
shock	I-protein
proteins	I-protein
play	O
a	O
direct	O
role	O
in	O
the	O
propagation	O
of	O
lambda	O
replication	O
forks	O
in	O
vitro	O
.	O

Limited	O
role	O
for	O
PCR	O
-	O
based	O
diagnosis	O
of	O
Whipple	O
'	O
s	O
disease	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Study	O
of	O
the	O
physico	O
-	O
chemical	O
state	O
of	O
plutonium	O
-	O
239	O
in	O
a	O
citrate	O
solution	O
-	O
blood	O
system	O
.	O

Insertion	O
of	O
short	O
oligonucleotides	O
encoding	O
the	O
basic	O
amino	O
acid	O
motifs	O
726	B-protein
-	I-protein
GRKRKSP	I-protein
-	I-protein
732	I-protein
from	O
IE175	B-protein
and	O
500	B-protein
-	I-protein
VRPRKRR	I-protein
-	I-protein
506	I-protein
from	O
IE110	B-protein
into	O
deleted	O
cytoplasmic	O
forms	O
of	O
the	O
two	O
proteins	O
restored	O
the	O
karyophilic	O
phenotype	O
and	O
confirmed	O
that	O
these	O
motifs	O
are	O
both	O
necessary	O
and	O
sufficient	O
for	O
proper	O
nuclear	O
localization	O
.	O

This	O
negative	O
element	O
may	O
,	O
at	O
least	O
in	O
part	O
,	O
be	O
responsible	O
for	O
the	O
cell	O
type	O
-	O
specific	O
expression	O
of	O
the	O
DGK	B-protein
gene	I-protein
.	O

A	O
case	O
of	O
anterior	O
cleavage	O
syndrome	O
in	O
a	O
27	O
-	O
year	O
-	O
old	O
female	O
patient	O
is	O
described	O
.	O

Mutations	O
that	O
alter	O
photoreceptor	O
cell	O
structure	O
and	O
development	O
were	O
isolated	O
that	O
fail	O
to	O
complement	O
these	O
deletions	O
.	O

In	O
that	O
case	O
,	O
the	O
ratio	O
of	O
brush	O
abrasion	O
was	O
0	O
.	O
268	O
,	O
compressive	O
and	O
transverse	O
strength	O
,	O
124	O
.	O
3	O
and	O
86	O
.	O
3	O
MPa	O
respectively	O
,	O
hardness	O
,	O
43	O
.	O
2	O
Hk	O
,	O
water	O
absorption	O
14	O
.	O
2	O
micrograms	O
/	O
mm3	O
and	O
thermal	O
expansion	O
coefficient	O
,	O
47	O
.	O
4	O
x	O
10	O
(	O
-	O
6	O
)	O
/	O
degrees	O
C	O
.	O

A	O
proportion	O
of	O
APC	B-protein
wild	O
-	O
type	O
colon	O
carcinomas	O
and	O
melanomas	O
also	O
contains	O
constitutive	O
nuclear	B-protein
Tcf	I-protein
-	I-protein
4	I-protein
/	I-protein
beta	I-protein
-	I-protein
catenin	I-protein
complexes	I-protein
as	O
a	O
result	O
of	O
dominant	O
mutations	O
in	O
the	O
N	O
terminus	O
of	O
beta	B-protein
-	I-protein
catenin	I-protein
that	O
render	O
it	O
insensitive	O
to	O
downregulation	O
by	O
APC	B-protein
,	O
GSK3	B-protein
beta	I-protein
,	O
and	O
Axin	B-protein
/	I-protein
Conductin	I-protein
.	O

Hydrogels	O
for	O
tissue	O
engineering	O
.	O

In	O
a	O
country	O
where	O
general	O
HIV	O
prevalence	O
is	O
low	O
,	O
the	O
strategy	O
is	O
cost	O
-	O
effective	O
for	O
location	O
and	O
counselling	O
of	O
unknowingly	O
seropositive	O
individuals	O
.	O

CONCLUSIONS	O
:	O
Serum	O
levels	O
of	O
S	B-protein
-	I-protein
100beta	I-protein
are	O
reliable	O
markers	O
for	O
adverse	O
neurologic	O
outcomes	O
after	O
cardiac	O
surgery	O
.	O

If	O
,	O
however	O
,	O
the	O
mean	O
temperature	O
rise	O
was	O
higher	O
(	O
0	O
.	O
57	O
degrees	O
C	O
or	O
0	O
.	O
69	O
degrees	O
C	O
)	O
,	O
such	O
a	O
selection	O
practically	O
resulted	O
in	O
the	O
disappearance	O
of	O
'	O
passable	O
'	O
qualifications	O
in	O
the	O
triplet	O
groups	O
and	O
a	O
great	O
predominance	O
of	O
'	O
to	O
be	O
rejected	O
'	O
qualifications	O
in	O
the	O
large	O
groups	O
.	O

These	O
regions	O
overlap	O
with	O
the	O
HIT	B-protein
protein	I-protein
similarity	I-protein
regions	I-protein
.	O

Critical	O
evaluation	O
of	O
various	O
methods	O
of	O
determining	O
markers	O
of	O
fetal	O
maturity	O
in	O
amniotic	O
fluid	O
.	O

This	O
review	O
summarizes	O
the	O
clinical	O
evidence	O
to	O
support	O
current	O
therapies	O
in	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
.	O

The	O
technical	O
construction	O
of	O
the	O
mouth	O
protectors	O
is	O
illustrated	O
,	O
as	O
is	O
the	O
need	O
for	O
instrumentation	O
and	O
its	O
costs	O
and	O
the	O
materials	O
required	O
to	O
manufacture	O
these	O
mouth	O
protectors	O
.	O

The	O
same	O
ligands	O
also	O
exhibit	O
a	O
similar	O
inhibitory	O
effect	O
on	O
PDGF	O
-	O
BB	O
-	O
dependent	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
in	O
PAE	O
cells	O
expressing	O
the	O
PDGF	B-protein
beta	I-protein
-	I-protein
receptors	I-protein
.	O

The	O
plant	O
hormone	O
auxin	O
transcriptionally	O
activates	O
early	O
genes	O
.	O

Oxygen	O
delivery	O
and	O
base	O
excess	O
decreased	O
significantly	O
and	O
four	O
pigs	O
died	O
.	O

The	O
P69	O
cell	O
line	O
was	O
derived	O
by	O
immortalization	O
of	O
human	O
primary	O
prostate	O
epithelial	O
cells	O
with	O
simian	B-protein
virus	I-protein
-	I-protein
40	I-protein
T	I-protein
antigen	I-protein
and	O
is	O
rarely	O
tumorigenic	O
.	O

It	O
was	O
also	O
found	O
that	O
there	O
is	O
no	O
significant	O
difference	O
between	O
the	O
prevalence	O
of	O
nasal	O
carriage	O
of	O
S	O
.	O
aureus	O
amongst	O
the	O
hospital	O
staff	O
and	O
the	O
patients	O
.	O

The	O
application	O
of	O
ISH	O
and	O
IHC	O
did	O
not	O
change	O
significantly	O
the	O
routine	O
histologic	O
classification	O
of	O
pneumonias	O
into	O
CMV	O
-	O
IP	O
and	O
IIP	O
.	O

The	O
most	O
common	O
types	O
of	O
malformations	O
were	O
eye	O
defects	O
and	O
open	O
coeloms	O
.	O

Our	O
findings	O
further	O
our	O
understanding	O
of	O
how	O
ZBP	B-protein
-	I-protein
89	I-protein
modulates	O
cell	O
proliferation	O
and	O
reveals	O
a	O
novel	O
mechanism	O
by	O
which	O
the	O
p53	B-protein
protein	I-protein
is	O
stabilized	O
.	O

This	O
study	O
investigated	O
whether	O
boron	O
would	O
enhance	O
the	O
ability	O
of	O
17beta	O
-	O
estradiol	O
(	O
E2	O
)	O
or	O
parathyroid	B-protein
hormone	I-protein
(	O
PTH	B-protein
)	O
to	O
improve	O
bone	O
quality	O
in	O
ovariectomized	O
OVX	O
rats	O
.	O

Weight	O
and	O
height	O
z	O
-	O
scores	O
were	O
significantly	O
associated	O
with	O
BMD	O
z	O
-	O
scores	O
.	O

DDP1	B-protein
also	O
localizes	O
to	O
heterochromatin	O
in	O
interphase	O
nuclei	O
of	O
larval	O
neuroblasts	O
.	O

Moreover	O
,	O
in	O
transient	O
transfection	O
assays	O
,	O
PU	B-protein
.	I-protein
1	I-protein
alone	O
activated	O
reporter	O
constructs	O
containing	O
the	O
JB	B-protein
cis	I-protein
-	I-protein
element	I-protein
,	O
and	O
the	O
activation	O
was	O
shown	O
to	O
be	O
dependent	O
on	O
a	O
glutamine	O
-	O
rich	O
sequence	O
in	O
the	O
amino	O
-	O
terminal	O
portion	O
of	O
PU	B-protein
.	I-protein
1	I-protein
.	O

It	O
is	O
reported	O
that	O
,	O
at	O
present	O
,	O
most	O
of	O
the	O
MRSAs	O
spreading	O
in	O
Japan	O
are	O
acceleratedly	O
acquiring	O
resistance	O
to	O
many	O
drugs	O
,	O
and	O
especially	O
,	O
they	O
are	O
developing	O
high	O
resistance	O
against	O
beta	O
-	O
lactams	O
.	O

The	O
integrity	O
of	O
the	O
cDNA	O
sequence	O
was	O
confirmed	O
by	O
analysis	O
of	O
several	O
overlapping	O
genomic	O
clones	O
that	O
span	O
the	O
GAR1	B-protein
gene	I-protein
.	O

In	O
one	O
patient	O
with	O
severe	O
diarrhea	O
the	O
estriol	O
concentration	O
in	O
serum	O
was	O
low	O
until	O
the	O
intestinal	O
function	O
normalised	O
and	O
the	O
estriol	O
concentration	O
went	O
up	O
exactly	O
when	O
the	O
diarrhea	O
stopped	O
.	O

We	O
conclude	O
that	O
c	B-protein
-	I-protein
Myb	I-protein
regulates	O
the	O
RAG	B-protein
-	I-protein
2	I-protein
promoter	I-protein
in	O
T	O
cells	O
by	O
binding	O
to	O
this	O
consensus	B-protein
c	I-protein
-	I-protein
Myb	I-protein
binding	I-protein
site	I-protein
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
CBP90	B-protein
had	O
no	O
significant	O
similarity	O
to	O
any	O
other	O
protein	O
,	O
but	O
it	O
had	O
a	O
proline	O
-	O
rich	O
domain	O
at	O
the	O
C	O
-	O
terminal	O
region	O
.	O

Children	O
born	O
from	O
chronic	O
alcoholic	O
mothers	O
have	O
shown	O
behavioral	O
teratogenic	O
effects	O
more	O
frequently	O
than	O
morphological	O
malformations	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
show	O
that	O
once	O
daily	O
oral	O
valganciclovir	O
can	O
produce	O
exposures	O
of	O
ganciclovir	O
(	O
AUC24	O
)	O
exceeding	O
those	O
attained	O
using	O
intravenous	O
ganciclovir	O
10	O
mg	O
/	O
kg	O
.	O

Copyright	O
2000	O
The	O
Royal	O
College	O
of	O
Radiologists	O
.	O

A	O
rise	O
of	O
hemoglobin	B-protein
concentration	O
accompanied	O
by	O
an	O
increase	O
of	O
the	O
total	O
iron	O
in	O
the	O
blood	O
serum	O
of	O
white	O
mice	O
was	O
found	O
under	O
oxygen	O
pressure	O
of	O
4	O
atm	O
for	O
an	O
hour	O
(	O
preconvulsive	O
state	O
)	O
and	O
6	O
atm	O
(	O
convulsive	O
state	O
)	O
.	O

This	O
regulation	O
requires	O
two	O
HMG	B-protein
-	I-protein
box	I-protein
proteins	I-protein
:	O
the	O
ubiquitous	O
Ste11	B-protein
transcription	I-protein
factor	I-protein
and	O
the	O
M	O
cell	O
-	O
controlling	O
protein	O
Mat1	B-protein
-	I-protein
Mc	I-protein
.	O

Two	O
related	O
studies	O
conducted	O
over	O
a	O
five	O
week	O
period	O
measured	O
and	O
typed	O
HLA	B-protein
-	I-protein
DQA1	I-protein
from	O
accumulated	O
DNA	O
on	O
autopsy	O
room	O
and	O
Forensic	O
DNA	O
Laboratory	O
structures	O
.	O

In	O
the	O
p51	B-protein
subunit	I-protein
,	O
the	O
Cys181	O
side	O
-	O
chain	O
is	O
oriented	O
in	O
a	O
similar	O
direction	O
to	O
the	O
Tyr181	O
side	O
-	O
chain	O
in	O
the	O
wild	O
-	O
type	O
complex	O
.	O

The	O
pyrR	B-protein
and	O
pyrP	B-protein
genes	I-protein
encoded	O
polypeptides	O
with	O
calculated	O
molecular	O
masses	O
of	O
19	O
.	O
9	O
and	O
45	O
.	O
2	O
kDa	O
,	O
respectively	O
.	O

Therapy	O
with	O
dietary	O
modification	O
and	O
triglyceride	O
lowering	O
drugs	O
resulted	O
in	O
resolution	O
of	O
symptoms	O
and	O
parotid	O
swelling	O
in	O
one	O
patient	O
.	O

Further	O
outbreaks	O
of	O
ocular	O
disease	O
in	O
farmed	O
red	O
deer	O
calves	O
caused	O
by	O
HVC	O
-	O
1	O
were	O
investigated	O
.	O

Expression	O
of	O
a	O
novel	O
murine	B-protein
phospholipase	I-protein
D	I-protein
homolog	I-protein
coincides	O
with	O
late	O
neuronal	O
development	O
in	O
the	O
forebrain	O
.	O

These	O
results	O
suggest	O
that	O
VP1	B-protein
was	O
efficiently	O
transported	O
to	O
the	O
nucleus	O
and	O
localized	O
in	O
the	O
discrete	O
subnuclear	O
regions	O
,	O
possibly	O
with	O
VP2	B-protein
and	O
VP3	B-protein
.	O

To	O
avoid	O
misinterpretations	O
,	O
special	O
reference	O
values	O
should	O
be	O
applied	O
for	O
preadolescents	O
,	O
at	O
least	O
with	O
regard	O
to	O
FVC	O
and	O
FEV1	O
.	O

Utilization	O
of	O
alternative	O
polyadenylation	O
signals	O
was	O
previously	O
shown	O
to	O
generate	O
two	O
sialophorin	B-protein
mRNAs	I-protein
of	I-protein
1	I-protein
.	I-protein
9	I-protein
and	I-protein
4	I-protein
.	I-protein
3	I-protein
kb	I-protein
,	O
which	O
differ	O
in	O
the	O
length	O
of	O
their	O
3	O
'	O
untranslated	O
regions	O
.	O

Moreover	O
,	O
we	O
observed	O
that	O
the	O
function	O
of	O
T3R	B-protein
-	I-protein
RXR	I-protein
heterodimers	I-protein
on	O
response	O
elements	O
composed	O
of	O
two	O
half	O
-	O
sites	O
in	O
a	O
directly	O
repeated	O
orientation	O
spaced	O
by	O
4	O
nucleotides	O
is	O
determined	O
in	O
major	O
parts	O
by	O
the	O
5	O
'	O
-	O
flanking	O
sequence	O
of	O
the	O
upstream	O
half	O
-	O
site	O
.	O

Magnetotherapy	O
of	O
hepatitis	O
A	O
and	O
B	O
in	O
children	O
.	O

Volume	O
of	O
distribution	O
of	O
total	O
DMDZ	O
(	O
range	O
,	O
1	O
.	O
33	O
to	O
6	O
.	O
30	O
l	O
/	O
kg	O
)	O
and	O
of	O
unbound	O
DMDZ	O
after	O
correction	O
for	O
protein	O
binding	O
(	O
range	O
,	O
43	O
to	O
243	O
l	O
/	O
kg	O
)	O
was	O
larger	O
in	O
women	O
than	O
in	O
men	O
of	O
all	O
ages	O
,	O
and	O
in	O
the	O
elderly	O
as	O
opposed	O
to	O
the	O
young	O
.	O

Finally	O
,	O
a	O
chromogenic	O
method	O
was	O
used	O
,	O
based	O
on	O
thrombin	B-protein
inhibition	O
and	O
the	O
substrate	O
S	O
-	O
2238	O
.	O

It	O
is	O
now	O
well	O
established	O
that	O
progression	O
through	O
the	O
eukaryotic	O
cell	O
cycle	O
is	O
controlled	O
by	O
oscillations	O
in	O
the	O
activity	O
of	O
cyclin	B-protein
-	I-protein
dependent	I-protein
kinases	I-protein
(	O
CDKs	B-protein
)	O
.	O

No	O
drop	O
in	O
oxygen	O
saturation	O
(	O
SaO2	O
)	O
or	O
visual	O
evidence	O
of	O
transient	O
electroencephalographic	O
(	O
EEG	O
)	O
arousals	O
can	O
be	O
found	O
at	O
repeat	O
polysomnography	O
.	O

Sequencing	O
analysis	O
revealed	O
that	O
the	O
0	O
.	O
54	O
-	O
and	O
0	O
.	O
4	O
-	O
kb	O
fragments	O
are	O
identical	O
except	O
for	O
150	O
nucleotides	O
missing	O
at	O
the	O
5	O
'	O
region	O
of	O
the	O
0	O
.	O
4	O
-	O
kb	O
fragment	O
.	O

Instead	O
,	O
they	O
contained	O
dendritic	O
cells	O
that	O
express	O
melanogenic	O
marker	O
proteins	O
such	O
as	O
tyrosinase	B-protein
and	O
tyrosinase	B-protein
-	I-protein
related	I-protein
protein	I-protein
1	O
.	O

A	O
double	O
-	O
blind	O
trial	O
of	O
half	O
-	O
strength	O
Polybactrin	O
Soluble	O
GU	O
bladder	O
irrigation	O
in	O
cystoscopy	O
.	O

In	O
the	O
next	O
week	O
,	O
the	O
beta	O
-	O
adrenergic	O
antagonist	O
atenolol	O
was	O
added	O
at	O
an	O
initial	O
dose	O
of	O
25	O
mg	O
/	O
day	O
and	O
titrated	O
to	O
50	O
mg	O
/	O
day	O
within	O
1	O
week	O
.	O

A	O
second	O
hydrophobic	O
domain	O
,	O
bordered	O
by	O
two	O
hydrophilic	O
regions	O
strongly	O
suggests	O
a	O
transmembrane	O
region	O
.	O

The	O
insulin	B-protein
-	I-protein
induced	I-protein
DNA	I-protein
-	I-protein
binding	I-protein
complex	I-protein
was	O
identified	O
as	O
the	O
p50	B-protein
/	I-protein
p65	I-protein
heterodimer	I-protein
.	O

It	O
is	O
concluded	O
that	O
attention	O
to	O
these	O
issues	O
can	O
substantially	O
improve	O
the	O
quality	O
of	O
research	O
on	O
AIDS	O
related	O
behaviors	O
on	O
Black	O
communities	O
.	O

2	O
patients	O
(	O
11	O
%	O
)	O
had	O
significant	O
morbidity	O
502	O
and	O
529	O
days	O
respectively	O
after	O
transplantation	O
.	O

The	O
SCH9	B-protein
protein	I-protein
kinase	I-protein
mRNA	I-protein
contains	O
a	O
long	O
5	O
'	O
leader	O
with	O
a	O
small	O
open	O
reading	O
frame	O
.	O

In	O
addition	O
,	O
the	O
affinities	O
of	O
CBF2	B-protein
for	O
binding	O
to	O
the	O
LMP	B-protein
-	I-protein
1	I-protein
,	O
LMP	B-protein
-	I-protein
2	I-protein
,	O
and	O
CD23	B-protein
promoters	I-protein
were	O
also	O
measured	O
.	O

Multilayer	O
-	O
relaxation	O
geometry	O
and	O
electronic	O
structure	O
of	O
a	O
W	O
(	O
111	O
)	O
surface	O
.	O

Conditions	O
influencing	O
inhibitors	O
of	O
the	O
colony	B-protein
-	I-protein
stimulating	I-protein
factor	I-protein
(	O
CSF	B-protein
)	O
.	O

In	O
one	O
glioblastoma	O
cell	O
line	O
,	O
a	O
Shc	O
-	O
associated	O
p190	B-protein
was	O
identified	O
as	O
the	O
activated	O
PDGFR	B-protein
.	O

The	O
expression	O
of	O
the	O
gene	O
encoding	O
the	O
enzyme	O
(	O
CYP19	B-protein
)	O
is	O
regulated	O
,	O
in	O
part	O
,	O
by	O
tissue	O
-	O
specific	O
promoters	O
through	O
the	O
use	O
of	O
alternative	O
-	O
splicing	O
mechanisms	O
.	O

The	O
role	O
of	O
negative	O
regulators	O
such	O
as	O
NCE3	B-protein
,	O
as	O
well	O
as	O
the	O
previously	O
described	O
SIN5	B-protein
gene	I-protein
,	O
in	O
determining	O
the	O
promoter	O
specificity	O
of	O
homologous	O
activators	O
is	O
discussed	O
.	O

By	O
contrast	O
,	O
mTRAP100	B-protein
coprecipitates	O
in	O
vivo	O
with	O
another	O
component	O
of	O
the	O
TRAP	B-protein
complex	I-protein
(	O
TRAP220	B-protein
)	O
,	O
which	O
directly	O
contacts	O
TR	B-protein
and	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
.	O

Study	O
on	O
distribution	O
of	O
metal	O
in	O
the	O
teeth	O
treated	O
by	O
iontophoresis	O
with	O
transparent	O
specimens	O
.	O

Regulation	O
of	O
Gax	B-protein
homeobox	I-protein
gene	I-protein
transcription	O
by	O
a	O
combination	O
of	O
positive	O
factors	O
including	O
myocyte	B-protein
-	I-protein
specific	I-protein
enhancer	I-protein
factor	I-protein
2	I-protein
.	O

The	O
genomic	O
structure	O
of	O
the	O
human	B-protein
SPEC1	I-protein
gene	I-protein
reveals	O
complex	O
splicing	O
and	O
close	O
promoter	O
proximity	O
to	O
the	O
AF1q	B-protein
translocation	I-protein
gene	I-protein
.	O

Quantitative	O
PCR	O
studies	O
indicated	O
that	O
synthesis	O
and	O
transport	O
of	O
vector	O
DNA	O
into	O
the	O
nucleus	O
were	O
similar	O
for	O
macrophages	O
infected	O
with	O
the	O
clone	O
239	O
and	O
316	O
pseudotypes	O
,	O
suggesting	O
that	O
the	O
restriction	O
for	O
SIVmac239	O
infection	O
is	O
after	O
reverse	O
transcription	O
and	O
nuclear	O
import	O
of	O
viral	O
DNA	O
.	O

ECG	O
-	O
gated	O
myocardial	O
Technetium	O
-	O
99m	O
sestamibi	O
SPECT	O
is	O
a	O
useful	O
technique	O
to	O
measure	O
myocardial	O
perfusion	O
and	O
function	O
simultaneously	O
.	O

This	O
suggests	O
that	O
cardiovascular	O
magnetic	O
resonance	O
is	O
the	O
preferred	O
technique	O
for	O
volume	O
and	O
ejection	O
fraction	O
estimation	O
in	O
heart	O
failure	O
patients	O
,	O
because	O
of	O
its	O
3D	O
approach	O
for	O
non	O
-	O
symmetric	O
ventricles	O
and	O
superior	O
image	O
quality	O
.	O

No	O
symptoms	O
other	O
than	O
hot	O
flush	O
showed	O
such	O
significant	O
correlation	O
with	O
plasma	O
epinephrine	O
or	O
norepinephrine	O
levels	O
.	O

Ti	O
exhibited	O
a	O
feather	O
-	O
like	O
morphology	O
.	O

The	O
gene	O
encoding	O
the	O
105	B-protein
-	I-protein
kDa	I-protein
protein	I-protein
(	I-protein
p105	I-protein
)	I-protein
precursor	I-protein
of	O
the	O
p50	B-protein
subunit	I-protein
of	O
transcription	O
factor	O
NF	B-protein
-	I-protein
kappa	I-protein
B	I-protein
also	O
encodes	O
a	O
p70	B-protein
I	I-protein
kappa	I-protein
B	I-protein
protein	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
,	O
which	O
is	O
identical	O
to	O
the	O
C	O
-	O
terminal	O
607	O
amino	O
acids	O
of	O
p105	B-protein
.	O

Though	O
hepatomegaly	O
and	O
mild	O
elevation	O
of	O
enzymes	O
can	O
be	O
observed	O
in	O
a	O
significant	O
proportion	O
of	O
patients	O
,	O
involvement	O
of	O
liver	O
leading	O
to	O
acute	O
hepatitis	O
or	O
liver	O
cell	O
necrosis	O
is	O
a	O
relatively	O
uncommon	O
complication	O
in	O
P	O
.	O
falciparum	O
malaria	O
.	O

Serotonin	B-protein
receptors	I-protein
in	O
suicide	O
victims	O
with	O
major	O
depression	O
.	O

The	O
volume	O
fraction	O
(	O
Vv	O
)	O
and	O
number	O
/	O
mm2	O
(	O
Na	O
)	O
of	O
all	O
capillaries	O
(	O
perfused	O
and	O
nonperfused	O
)	O
in	O
a	O
given	O
area	O
of	O
brain	O
were	O
determined	O
after	O
staining	O
for	O
alkaline	B-protein
phosphatase	I-protein
.	O

Local	O
control	O
rates	O
were	O
91	O
%	O
for	O
metastatic	O
lung	O
cancer	O
,	O
89	O
%	O
for	O
primary	O
lung	O
cancer	O
and	O
85	O
%	O
for	O
T1	O
,	O
2N0M0	O
cases	O
.	O

Here	O
the	O
conventional	O
tests	O
clearly	O
pointed	O
to	O
the	O
presence	O
of	O
retrocochlear	O
disease	O
.	O

A	B-protein
further	O
mechanism	O
increasing	O
specific	O
activation	O
was	O
cooperation	O
of	O
receptors	O
at	O
multiple	O
and	O
weak	O
HREs	B-protein
,	O
which	O
was	O
accentuated	O
in	O
the	O
presence	O
of	O
both	O
the	O
AR	B-protein
N	O
terminus	O
and	O
ligand	O
binding	O
domain	O
.	O

Estimation	O
of	O
renin	B-protein
secretion	O
rate	O
and	O
renal	O
plasma	O
flow	O
from	O
peripheral	O
and	O
renal	B-protein
vein	I-protein
renin	I-protein
levels	O
.	O

PAS1	B-protein
,	O
a	O
yeast	O
gene	O
required	O
for	O
peroxisome	O
biogenesis	O
,	O
encodes	O
a	O
member	O
of	O
a	O
novel	O
family	O
of	O
putative	O
ATPases	B-protein
.	O

However	O
,	O
ICK1	B-protein
was	O
induced	O
by	O
ABA	O
,	O
and	O
along	O
with	O
ICK1	B-protein
induction	O
there	O
was	O
a	O
decrease	O
in	O
Cdc2	B-protein
-	I-protein
like	I-protein
histone	I-protein
H1	I-protein
kinase	I-protein
activity	O
.	O

The	O
models	O
were	O
tested	O
by	O
studying	O
their	O
response	O
to	O
disturbances	O
of	O
the	O
afferent	O
signal	O
from	O
the	O
bladder	O
.	O

Functional	O
analysis	O
of	O
the	O
sGTH	B-protein
alpha	I-protein
subunit	I-protein
promoter	I-protein
by	O
the	O
transient	O
transfection	O
of	O
several	O
sGTH	B-protein
alpha	I-protein
/	I-protein
CAT	I-protein
chimeric	O
plasmids	O
into	O
rainbow	O
trout	O
pituitary	O
cells	O
suggests	O
that	O
its	O
pituitary	O
-	O
specific	O
expression	O
is	O
GSE	O
-	O
dependent	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
the	O
production	O
of	O
active	B-protein
recombinant	I-protein
telomerase	I-protein
requires	O
a	O
factor	O
in	O
rabbit	O
reticulocyte	O
lysate	O
that	O
promotes	O
ribonucleoprotein	O
assembly	O
.	O

A	O
simple	O
method	O
for	O
measuring	O
urinary	O
iron	O
following	O
the	O
administration	O
of	O
desferrioxamine	O
(	O
DF	O
)	O
is	O
described	O
.	O

Recent	O
studies	O
using	O
isolated	O
rat	O
adipocytes	O
and	O
chemically	O
synthesized	O
PIG	O
compounds	O
point	O
to	O
IRS1	B-protein
/	I-protein
3	I-protein
tyrosine	O
phosphorylation	O
by	O
p59Lyn	B-protein
kinase	I-protein
as	O
the	O
site	O
of	O
cross	O
-	O
talk	O
,	O
the	O
negative	O
regulation	O
of	O
which	O
by	O
interaction	O
with	O
caveolin	B-protein
is	O
apparently	O
abrogated	O
by	O
PIG	O
.	O

Thus	O
,	O
the	O
P	O
.	O
aeruginosa	O
orfX	B-protein
and	O
vfr	B-protein
promoters	I-protein
are	O
arranged	O
in	O
a	O
back	O
-	O
to	O
-	O
back	O
orientation	O
rather	O
than	O
the	O
face	O
-	O
to	O
-	O
face	O
orientation	O
of	O
the	O
dorf	B-protein
and	O
crp	B-protein
promoters	I-protein
.	O

Fourteen	O
patients	O
were	O
in	O
the	O
multifocal	O
disease	O
group	O
;	O
13	O
were	O
detected	O
by	O
SPECT	O
and	O
10	O
by	O
TCT	O
.	O

High	O
ADR1	B-protein
gene	I-protein
dosage	O
increased	O
the	O
transcription	O
of	O
genes	O
encoding	O
peroxisomal	O
proteins	O
as	O
compared	O
to	O
one	O
copy	O
of	O
the	O
ADR1	B-protein
gene	I-protein
.	O

The	O
65	O
-	O
bp	O
sequence	O
contains	O
the	O
octameric	O
cAMP	B-protein
-	I-protein
responsive	I-protein
enhancer	I-protein
(	O
CRE	B-protein
)	O
TGACGTCA	B-protein
(	O
nucleotides	O
-	O
48	O
to	O
-	O
41	O
)	O
.	O

The	O
bioavailability	O
of	O
etodolac	O
from	O
capsules	O
exposed	O
to	O
stressed	O
conditions	O
was	O
compared	O
in	O
both	O
dogs	O
and	O
humans	O
to	O
capsules	O
stored	O
at	O
RT	O
conditions	O
.	O

In	O
this	O
paper	O
,	O
an	O
analysis	O
of	O
the	O
dynamics	O
in	O
the	O
closing	O
phase	O
of	O
the	O
occluder	O
of	O
a	O
mechanical	O
monoleaflet	O
heart	O
valve	O
prosthesis	O
is	O
presented	O
.	O

Investigation	O
of	O
the	O
structural	O
basis	O
of	O
the	O
interaction	O
between	O
human	B-protein
Igs	I-protein
and	O
gp120	B-protein
shows	O
that	O
the	O
viral	B-protein
gp120	I-protein
SAg	I-protein
can	O
interact	O
only	O
with	O
a	O
subset	O
of	O
human	B-protein
V	I-protein
(	I-protein
H	I-protein
)	I-protein
3	I-protein
+	I-protein
Igs	I-protein
.	O

JPEG	O
53	O
,	O
resulting	O
in	O
a	O
compression	O
ratio	O
of	O
1	O
:	O
21	O
,	O
does	O
not	O
compromise	O
the	O
diagnostic	O
performance	O
in	O
general	O
.	O

The	O
presence	O
of	O
the	O
corresponding	O
mature	O
mRNA	O
transcripts	O
(	O
3	O
.	O
2	O
-	O
3	O
.	O
5	O
kilobase	O
pairs	O
(	O
kb	O
]	O
in	O
human	O
fibroblasts	O
was	O
shown	O
by	O
Northern	O
blot	O
hybridization	O
,	O
S1	B-protein
nuclease	I-protein
protection	O
assay	O
,	O
and	O
the	O
polymerase	B-protein
chain	O
reaction	O
.	O

However	O
,	O
mean	O
food	O
intake	O
in	O
the	O
40	O
%	O
group	O
was	O
half	O
that	O
of	O
the	O
ACT	O
group	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
significantly	O
less	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
than	O
the	O
SEP	O
group	O
,	O
which	O
consumed	O
amounts	O
equivalent	O
to	O
65	O
%	O
of	O
daily	O
requirement	O
.	O

Wrist	O
measurement	O
of	O
blood	O
pressure	O
:	O
some	O
critical	O
remarks	O
to	O
oscillometry	O
.	O

The	O
effects	O
of	O
the	O
transfected	O
receptors	O
were	O
associated	O
with	O
antagonism	O
of	O
activator	B-protein
protein	I-protein
1	I-protein
(	O
AP	B-protein
-	I-protein
1	I-protein
)	O
activity	O
.	O

In	O
the	O
COPD	O
patients	O
,	O
the	O
variability	O
of	O
Delta	O
-	O
inst	O
Rrs	O
(	O
30	O
%	O
)	O
was	O
greater	O
than	O
that	O
of	O
FOT	O
Rrs	O
(	O
21	O
%	O
)	O
.	O

Regression	O
analyses	O
identified	O
7	O
risk	O
and	O
7	O
protective	O
factors	O
with	O
minimal	O
overlap	O
.	O

However	O
,	O
multiple	O
alanine	O
substitutions	O
or	O
proline	O
(	O
helix	O
-	O
destabilizing	O
)	O
substitutions	O
disrupted	O
both	O
oligomerization	O
and	O
transport	O
of	O
GP64	B-protein
EFP	I-protein
.	O

The	O
hepatocyte	B-protein
nuclear	I-protein
factor	I-protein
-	I-protein
3	I-protein
(	O
HNF	B-protein
-	I-protein
3	I-protein
)	O
/	B-protein
orkhead	I-protein
(	O
fkh	B-protein
)	O
proteins	O
consist	O
of	O
an	O
extensive	O
family	O
of	O
tissue	O
-	O
specific	O
and	O
developmental	O
gene	O
regulators	O
which	O
share	O
homology	O
within	O
the	O
winged	B-protein
helix	I-protein
DNA	I-protein
binding	I-protein
motif	I-protein
.	O

Nucleotide	O
sequences	O
of	O
the	O
clones	O
revealed	O
that	O
one	O
clone	O
,	O
cap3	B-protein
,	O
contained	O
an	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
that	O
would	O
code	O
for	O
a	O
26	O
-	O
amino	O
acid	O
,	O
cysteine	O
-	O
rich	O
peptide	O
with	O
significant	O
homology	O
to	O
Neurospora	B-protein
crassa	I-protein
copper	I-protein
metallothionein	I-protein
.	O

Immunohistochemical	O
analysis	O
of	O
several	O
rat	O
organs	O
also	O
showed	O
staining	O
in	O
epithelial	O
cells	O
.	O

CONCLUSION	O
:	O
Twice	O
daily	O
treatment	O
with	O
inhaled	O
fluticasone	O
propionate	O
50	O
micrograms	O
or	O
100	O
micrograms	O
was	O
significantly	O
more	O
effective	O
than	O
theophylline	O
in	O
the	O
treatment	O
of	O
mild	O
-	O
to	O
-	O
moderate	O
asthma	O
.	O

The	O
elevated	O
Viso	O
V	O
in	O
the	O
RDS	O
group	O
suggests	O
an	O
increase	O
in	O
small	O
airway	O
resistance	O
secondary	O
to	O
the	O
disease	O
or	O
to	O
its	O
therapy	O
.	O

The	O
GEF	B-protein
and	O
GAP	B-protein
activities	O
for	O
Ypt1p	B-protein
localize	O
to	O
particulate	O
cellular	O
fractions	O
.	O

Our	O
results	O
demonstrate	O
that	O
cis	O
elements	O
positioned	O
between	O
the	O
alpha	B-protein
3	I-protein
and	O
beta	B-protein
4	I-protein
coding	O
regions	O
are	O
important	O
for	O
establishing	O
part	O
of	O
the	O
restricted	O
CNS	O
patterns	O
of	O
beta	B-protein
4	I-protein
,	O
alpha	B-protein
3	I-protein
,	O
and	O
alpha	B-protein
5	I-protein
gene	I-protein
transcription	O
.	O

However	O
,	O
no	O
genetic	O
alteration	O
was	O
detected	O
in	O
any	O
of	O
the	O
cancers	O
examined	O
.	O

Although	O
RAD17	B-protein
,	O
RAD24	B-protein
and	O
MEC3	B-protein
are	O
not	O
required	O
for	O
cell	O
cycle	O
arrest	O
when	O
S	O
phase	O
is	O
inhibited	O
by	O
hydroxyurea	O
(	O
HU	O
)	O
,	O
they	O
do	O
contribute	O
to	O
the	O
viability	O
of	O
yeast	O
cells	O
grown	O
in	O
the	O
presence	O
of	O
HU	O
,	O
possibly	O
because	O
they	O
are	O
required	O
for	O
the	O
repair	O
of	O
HU	O
-	O
induced	O
DNA	O
damage	O
.	O

D5	B-protein
/	I-protein
D1	I-protein
(	I-protein
CT	I-protein
)	I-protein
or	O
D5	B-protein
/	I-protein
D1D	I-protein
(	I-protein
CT	I-protein
)	I-protein
tail	O
substitution	O
mutants	O
displayed	O
a	O
rank	O
order	O
of	O
potency	O
and	O
agonist	O
affinities	O
virtually	O
mimicking	O
wild	B-protein
-	I-protein
type	I-protein
(	I-protein
wt	I-protein
)	I-protein
D1	I-protein
receptors	I-protein
,	O
as	O
indexed	O
by	O
both	O
ligand	O
binding	O
and	O
dopamine	O
-	O
stimulated	O
cAMP	O
accumulation	O
assays	O
,	O
and	O
,	O
similar	O
to	O
wt	O
D1	B-protein
receptors	I-protein
,	O
did	O
not	O
exhibit	O
receptor	O
constitutive	O
activity	O
or	O
responsiveness	O
to	O
inverse	O
agonists	O
.	O

Doppler	O
echo	O
in	O
evaluating	O
arteriovenous	O
fistulae	O
for	O
dialysis	O
.	O

GTPase	B-protein
activating	O
specificity	O
of	O
RGS12	B-protein
and	O
binding	O
specificity	O
of	O
an	O
alternatively	O
spliced	O
PDZ	B-protein
(	O
PSD	B-protein
-	I-protein
95	I-protein
/	I-protein
Dlg	I-protein
/	I-protein
ZO	I-protein
-	I-protein
1	I-protein
)	O
domain	O
.	O

The	O
non	O
-	O
homologous	O
sequences	O
in	O
the	O
5	O
'	O
untranslated	O
regions	O
might	O
be	O
acquired	O
at	O
or	O
after	O
transcription	O
during	O
retrotransposition	O
of	O
the	O
ATLN	B-protein
elements	I-protein
.	O

Chem	O
.	O

Pitfalls	O
in	O
the	O
use	O
of	O
chromosome	O
aberration	O
analysis	O
for	O
biological	O
radiation	O
dosimetry	O
.	O

Both	O
GH	B-protein
deficiency	O
and	O
impaired	O
spinal	O
growth	O
may	O
result	O
in	O
short	O
stature	O
,	O
whereas	O
the	O
occurrence	O
of	O
early	O
puberty	O
in	O
association	O
with	O
GH	B-protein
deficiency	O
reduces	O
the	O
time	O
available	O
for	O
GH	B-protein
therapy	O
.	O

The	O
DNA	O
sequences	O
upstream	O
of	O
these	O
termini	O
exhibit	O
homology	O
to	O
plant	O
mitochondrial	O
-	O
processing	O
sites	O
,	O
therefore	O
the	O
proximal	O
5	O
'	O
ends	O
are	O
most	O
probably	O
generated	O
by	O
RNA	O
processing	O
.	O

Brief	O
report	O
.	O

But	O
,	O
as	O
Theriault	O
explains	O
,	O
improvements	O
in	O
assessing	O
exposure	O
have	O
not	O
yet	O
translated	O
into	O
clear	O
and	O
consistent	O
findings	O
.	O

Concomitantly	O
,	O
the	O
total	O
cellular	O
level	O
of	O
p21	B-protein
increased	O
severalfold	O
via	O
a	O
posttranscriptional	O
mechanism	O
.	O

BACKGROUND	O
:	O
The	O
Bazett	O
-	O
corrected	O
QT	O
(	O
QTc	O
)	O
interval	O
during	O
exercise	O
has	O
been	O
used	O
as	O
a	O
marker	O
for	O
ischemic	O
disease	O
,	O
arrhythmogenic	O
substrate	O
and	O
the	O
long	O
QT	O
syndrome	O
.	O

The	O
data	O
suggest	O
that	O
ICP10	B-protein
constitutively	O
increases	O
ras	B-protein
activity	O
,	O
and	O
its	O
TM	O
segment	O
plays	O
a	O
critical	O
role	O
in	O
transformation	O
-	O
related	O
signaling	O
pathways	O
.	O

In	O
a	O
retrospective	O
analysis	O
of	O
first	O
-	O
time	O
total	O
colonoscopies	O
in	O
685	O
patients	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
hyperplastic	O
and	O
adenomatous	O
polyps	O
.	O

The	O
TIMP	B-protein
(	I-protein
-	I-protein
59	I-protein
/	I-protein
-	I-protein
53	I-protein
)	I-protein
AP1	I-protein
site	I-protein
is	O
a	O
promiscuous	O
motif	O
that	O
binds	O
c	B-protein
-	I-protein
Fos	I-protein
/	I-protein
c	I-protein
-	I-protein
Jun	I-protein
AP1	I-protein
translated	O
in	O
vitro	O
and	O
is	O
an	O
effective	O
competitor	O
for	O
binding	O
of	O
nuclear	B-protein
AP1	I-protein
factors	I-protein
to	O
the	O
consensus	B-protein
TRE	I-protein
,	O
but	O
in	O
addition	O
it	O
binds	O
factors	O
that	O
do	O
not	O
associate	O
with	O
the	O
consensus	B-protein
TRE	I-protein
.	O

These	O
data	O
indicate	O
that	O
the	O
SmSmad2	B-protein
responds	O
to	O
the	O
TGF	B-protein
-	I-protein
beta	I-protein
signals	O
by	O
interaction	O
with	O
receptor	B-protein
I	I-protein
,	O
which	O
phosphorylates	O
it	O
,	O
whereupon	O
it	O
translocates	O
into	O
the	O
nucleus	O
presumably	O
to	O
regulate	O
target	O
gene	O
transcription	O
and	O
consequently	O
elicit	O
a	O
specific	O
TGF	B-protein
-	I-protein
beta	I-protein
effect	O
.	O

Hence	O
,	O
scs32	B-protein
only	O
partially	O
suppressed	O
the	O
ts	O
phenotype	O
and	O
was	O
unable	O
to	O
suppress	O
the	O
Ino	O
-	O
phenotype	O
of	O
rpo26	B-protein
-	I-protein
31	I-protein
.	O

An	O
expression	O
library	O
was	O
constructed	O
by	O
inserting	O
5	O
'	O
portion	O
-	O
enriched	O
cDNAs	O
from	O
phytohemagglutinin	O
-	O
stimulated	O
peripheral	O
blood	O
mononuclear	O
cells	O
into	O
upstream	O
of	O
signal	B-protein
sequence	I-protein
-	I-protein
deleted	I-protein
CD4	I-protein
cDNA	I-protein
in	O
an	O
Epstein	O
-	O
Barr	O
virus	O
shuttle	O
vector	O
.	O

The	O
finding	O
that	O
the	O
chimeric	B-protein
TdT	I-protein
:	O
:	O
Pol	B-protein
beta	I-protein
protein	I-protein
possessed	O
significant	O
template	O
-	O
dependent	O
polymerase	B-protein
activity	O
suggests	O
that	O
aa	O
1	O
-	O
60	O
of	O
Pol	B-protein
beta	I-protein
are	O
involved	O
in	O
template	O
utilization	O
during	O
the	O
polymerization	O
reaction	O
,	O
as	O
suggested	O
by	O
the	O
previous	O
finding	O
that	O
the	O
8	O
-	O
kDa	O
N	O
-	O
terminal	O
domain	O
of	O
Pol	B-protein
beta	I-protein
possesses	O
ssDNA	O
-	O
binding	O
activity	O
[	O
Kumar	O
et	O
al	O
.	O
,	O
J	O
.	O

When	O
extracorporeal	O
CO2	O
removal	O
approximated	O
CO2	O
production	O
(	O
VCO2	O
)	O
,	O
alveolar	O
ventilation	O
almost	O
ceased	O
.	O

This	O
result	O
supports	O
the	O
argument	O
that	O
the	O
beta	B-protein
'	I-protein
subunit	I-protein
plays	O
an	O
essential	O
role	O
in	O
determining	O
the	O
progress	O
of	O
transcription	O
elongation	O
.	O

The	O
calculated	O
values	O
of	O
lambda	O
tb	O
at	O
37	O
degrees	O
C	O
and	O
50	O
per	O
cent	O
haematocrit	O
were	O
0	O
.	O
650	O
for	O
the	O
pulp	O
,	O
0	O
.	O
674	O
for	O
the	O
tongue	O
,	O
0	O
.	O
828	O
for	O
the	O
submandibular	O
gland	O
and	O
0	O
.	O
881	O
for	O
the	O
gingiva	O
of	O
the	O
dog	O
.	O
lambda	O
cp	O
increased	O
and	O
lambda	O
tp	O
decreased	O
as	O
the	O
temperature	O
was	O
reduced	O
from	O
37	O
to	O
4	O
degrees	O
C	O
.	O

The	O
sequence	O
has	O
a	O
1092	O
-	O
bp	O
open	O
reading	O
frame	O
encoding	O
a	O
protein	O
of	O
364	O
amino	O
acids	O
.	O

Bacterial	O
recovery	O
of	O
SA	O
from	O
the	O
liver	O
/	O
spleen	O
and	O
the	O
cecal	O
tonsil	O
in	O
contact	O
poults	O
and	O
SG	O
from	O
contact	O
chicks	O
treated	O
with	O
ILK	B-protein
was	O
dramatically	O
reduced	O
when	O
compared	O
to	O
non	O
-	O
treated	O
contact	O
poults	O
and	O
chicks	O
.	O

Absorption	O
of	O
electrolytes	O
from	O
the	O
colon	O
in	O
cases	O
of	O
ulcerative	O
colitis	O
and	O
in	O
control	O
subjects	O
.	O

This	O
article	O
reports	O
the	O
design	O
and	O
development	O
of	O
an	O
ECG	O
simulator	O
intended	O
for	O
use	O
in	O
the	O
testing	O
,	O
calibration	O
and	O
maintenance	O
of	O
electrocardiographic	O
equipment	O
.	O

Allergy	O
and	O
Tourette	O
'	O
s	O
syndrome	O
.	O

Gel	O
mobility	O
shift	O
assays	O
indicated	O
that	O
at	O
least	O
four	O
nuclear	O
proteins	O
with	O
distinct	O
biochemical	O
and	O
binding	O
properties	O
possess	O
the	O
ability	O
to	O
bind	O
the	O
3	B-protein
beta	I-protein
I	I-protein
-	I-protein
A	I-protein
element	I-protein
to	O
produce	O
four	O
DNA	O
-	O
protein	O
complexes	O
(	O
R1	O
to	O
R4	O
)	O
.	O

Workers	O
with	O
`	O
`	O
sensitivity	O
'	O
'	O
to	O
toluene	O
diisocyanate	O
(	O
TDI	O
)	O
studied	O
in	O
depth	O
in	O
an	O
attempt	O
to	O
determine	O
mechanisms	O
of	O
bronchial	O
hyperreactivity	O
.	O

Calcinosis	O
cutis	O
following	O
intravenous	O
infusion	O
of	O
calcium	O
gluconate	O
.	O

Inhibition	O
of	O
JNK1	B-protein
and	O
ERK	B-protein
kinase	O
activities	O
either	O
by	O
expression	O
of	O
the	O
dominant	O
negative	O
mutant	O
JNK1	B-protein
or	O
by	O
treatment	O
with	O
a	O
selective	O
chemical	O
inhibitor	O
of	O
ERK	B-protein
(	O
PD098059	O
)	O
substantially	O
abrogates	O
the	O
UV	O
induction	O
of	O
the	O
GADD45	B-protein
promoter	I-protein
.	O

Transforming	B-protein
growth	I-protein
factor	I-protein
-	I-protein
beta1	I-protein
(	O
TGF	B-protein
-	I-protein
beta1	I-protein
)	O
can	O
act	O
as	O
a	O
tumor	O
suppressor	O
or	O
a	O
tumor	O
promoter	O
depending	O
on	O
the	O
characteristics	O
of	O
the	O
malignant	O
cell	O
.	O

Nor	O
is	O
such	O
adjustment	O
possible	O
unless	O
one	O
posits	O
a	O
model	O
that	O
relates	O
the	O
missing	O
observations	O
to	O
other	O
observed	O
information	O
for	O
each	O
subject	O
-	O
models	O
that	O
are	O
inherently	O
untestable	O
.	O

A	O
mail	O
survey	O
of	O
Georgia	O
members	O
of	O
the	O
American	O
College	O
of	O
Obstetricians	O
and	O
Gynecologists	O
was	O
conducted	O
.	O

Subacute	O
diencephalic	O
angioencephalopathy	O
(	O
SDAE	O
)	O
is	O
a	O
rare	O
and	O
fatal	O
disease	O
of	O
unknown	O
etiology	O
that	O
involves	O
the	O
thalami	O
bilaterally	O
.	O

We	O
estimate	O
that	O
the	O
protease	B-protein
activity	O
is	O
at	O
least	O
35	O
-	O
fold	O
greater	O
in	O
mature	O
B	O
cells	O
than	O
in	O
pre	O
-	O
B	O
cells	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Plectin	B-protein
and	O
desmoplakin	B-protein
have	O
GSR	O
-	O
containing	O
domains	O
at	O
their	O
C	O
-	O
termini	O
and	O
we	O
further	O
demonstrate	O
that	O
the	O
GSR	O
-	O
containing	O
domain	O
of	O
plectin	B-protein
,	O
but	O
not	O
desmoplakin	B-protein
,	O
can	O
bind	O
to	O
MTs	O
in	O
vivo	O
.	O

During	O
the	O
years	O
1980	O
-	O
87	O
a	O
total	O
of	O
287	O
persons	O
received	O
disability	O
pensions	O
in	O
the	O
municipality	O
of	O
Nordreisa	O
in	O
northern	O
Norway	O
.	O

This	O
article	O
will	O
briefly	O
review	O
the	O
published	O
data	O
on	O
the	O
morphology	O
,	O
function	O
,	O
and	O
biochemistry	O
of	O
the	O
normal	O
renal	O
medulla	O
and	O
the	O
pathology	O
associated	O
with	O
RPN	O
,	O
together	O
with	O
the	O
secondary	O
changes	O
which	O
give	O
rise	O
to	O
cortical	O
degeneration	O
or	O
epithelial	O
carcinoma	O
.	O

Novel	O
multigene	O
families	O
encoding	O
highly	O
repetitive	O
peptide	O
sequences	O
.	O

The	O
STAT	B-protein
-	I-protein
1	I-protein
signaling	O
pathway	O
provides	O
at	O
least	O
one	O
mechanism	O
for	O
activation	O
of	O
the	O
CAEV	B-protein
LTR	I-protein
by	O
IFN	B-protein
-	I-protein
gamma	I-protein
in	O
monocytes	O
.	O

Patient	O
characteristics	O
associated	O
with	O
deep	O
wounds	O
as	O
well	O
as	O
patient	O
and	O
wound	O
characteristics	O
predictive	O
of	O
the	O
extent	O
of	O
healing	O
and	O
time	O
required	O
for	O
healing	O
were	O
identified	O
.	O

The	O
retention	O
of	O
75SeHCAT	O
was	O
low	O
.	O

When	O
the	O
PHT	O
and	O
CSA	O
groups	O
were	O
compared	O
,	O
Hyp	O
levels	O
were	O
significantly	O
higher	O
in	O
the	O
PHT	O
-	O
GO	O
+	O
group	O
than	O
in	O
the	O
CSA	O
-	O
GO	O
+	O
group	O
.	O

Sequence	O
of	O
10q24	B-protein
locus	I-protein
surrounding	O
the	O
HOX11	B-protein
oncogene	I-protein
reveals	O
a	O
new	O
gene	O
HUG1	B-protein
expressed	O
in	O
a	O
T	O
-	O
ALL	O
cell	O
line	O
.	O

In	O
addition	O
,	O
TRP1	O
RI	O
Circle	O
DNA	O
is	O
organized	O
into	O
nucleosomes	O
whose	O
size	O
and	O
spacing	O
are	O
indistinguishable	O
from	O
that	O
of	O
bulk	O
yeast	O
chromatin	O
.	O

Surprisingly	O
,	O
the	O
CSF1R	B-protein
/	I-protein
IRDelta960	I-protein
was	O
as	O
effective	O
as	O
the	O
CSF1R	B-protein
/	I-protein
IR	I-protein
in	O
mediating	O
CSF	B-protein
-	I-protein
1	I-protein
protection	O
of	O
cells	O
from	O
staurosporine	O
-	O
induced	O
apoptosis	O
.	O

Therefore	O
,	O
we	O
suggested	O
that	O
both	O
proteins	O
might	O
belong	O
to	O
the	O
PLTP	B-protein
family	I-protein
.	O

These	O
tumors	O
were	O
classified	O
into	O
three	O
broad	O
groups	O
:	O
I	O
,	O
cystadenoma	O
;	O
II	O
,	O
cystadenocarcinoma	O
;	O
and	O
III	O
,	O
adenocarcinoma	O
with	O
mucin	O
production	O
or	O
an	O
associated	O
cyst	O
.	O

26	O
micrograms	O
PAF	B-protein
or	O
placebo	O
was	O
sprayed	O
into	O
each	O
nasal	O
cavity	O
8	O
h	O
and	O
1	O
h	O
before	O
a	O
nasal	O
allergen	O
challenge	O
.	O

In	O
contrast	O
,	O
Y239	B-protein
/	I-protein
240F	I-protein
Shc	I-protein
,	O
but	O
not	O
Y317F	B-protein
Shc	I-protein
,	O
reduced	O
the	O
EGF	O
-	O
induced	O
c	B-protein
-	I-protein
myc	I-protein
message	O
.	O

The	O
wavenumbers	O
corresponding	O
to	O
the	O
normal	O
modes	O
of	O
vibration	O
were	O
calculated	O
using	O
the	O
DFT	O
(	O
B3LYP	O
/	O
6	O
-	O
31G	O
*	O
*	O
)	O
approximation	O
and	O
their	O
agreement	O
with	O
the	O
measured	O
values	O
improved	O
after	O
scaling	O
of	O
the	O
associated	O
force	O
field	O
.	O

A	O
total	O
number	O
of	O
1628	O
cases	O
were	O
collected	O
from	O
135	O
medical	O
institutions	O
.	O

By	O
adapting	O
a	O
method	O
for	O
DNA	O
-	O
footprinting	O
using	O
impure	O
extracts	O
of	O
ner	B-protein
overproducing	O
cells	O
,	O
we	O
were	O
able	O
to	O
determine	O
that	O
the	O
ner	B-protein
-	I-protein
binding	I-protein
sites	I-protein
are	O
located	O
between	O
nucleotides	O
1026	O
and	O
1058	O
from	O
the	O
Mu	O
left	O
end	O
.	O

After	O
dopamine	O
infusion	O
in	O
women	O
with	O
polycystic	O
ovary	O
syndrome	O
and	O
in	O
matched	O
controls	O
,	O
steady	O
state	O
levels	O
of	O
plasma	O
dopamine	O
,	O
norepinephrine	O
,	O
and	O
the	O
ratio	O
of	O
dopamine	O
/	O
norepinephrine	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O

Delta	O
-	O
aminolevulinic	O
acid	O
in	O
physiological	O
conditions	O
and	O
some	O
diseases	O
in	O
children	O
.	O

Cloning	O
and	O
sequencing	O
revealed	O
that	O
dMax	B-protein
contains	O
a	O
deletion	O
spanning	O
the	O
basic	O
region	O
and	O
helix	O
1	O
and	O
the	O
loop	O
of	O
the	O
helix	O
-	O
loop	O
-	O
helix	O
region	O
,	O
presumably	O
as	O
a	O
result	O
of	O
alternative	O
splicing	O
of	O
max	B-protein
RNA	I-protein
.	O

To	O
quantify	O
any	O
mechanical	O
inhibitory	O
effect	O
of	O
nasal	O
intermittent	O
positive	O
pressure	O
ventilation	O
(	O
IPPV	O
)	O
on	O
inspiratory	O
activity	O
of	O
the	O
diaphragm	O
we	O
ventilated	O
five	O
conscious	O
relaxed	O
subjects	O
on	O
two	O
occasions	O
at	O
respiratory	O
rates	O
similar	O
to	O
quiet	O
breathing	O
(	O
QB	O
)	O
and	O
at	O
three	O
levels	O
of	O
applied	O
pressure	O
(	O
Pappl	O
)	O
-	O
-	O
6	O
,	O
9	O
and	O
12	O
cmH2O	O
,	O
each	O
during	O
hypocapnia	O
(	O
P	O
(	O
CO2	O
)	O
allowed	O
to	O
decrease	O
)	O
and	O
eucapnia	O
(	O
CO2	O
added	O
to	O
inspired	O
gas	O
)	O
.	O

In	O
the	O
multivariate	O
analysis	O
,	O
six	O
variables	O
were	O
independently	O
correlated	O
with	O
survival	O
:	O
blood	O
urea	O
nitrogen	O
level	O
,	O
serum	B-protein
aspartate	I-protein
aminotransferase	I-protein
level	O
,	O
community	O
-	O
acquired	O
vs	O
.	O
hospital	O
-	O
acquired	O
peritonitis	O
,	O
age	O
,	O
Child	O
-	O
Pugh	O
score	O
and	O
ileus	O
.	O

X2	O
test	O
,	O
with	O
Yates	O
correction	O
if	O
need	O
,	O
was	O
used	O
as	O
statistical	O
.	O
method	O
.	O

Carboxy	O
-	O
terminal	O
Spc110p	B-protein
truncations	O
lacking	O
the	O
calmodulin	B-protein
binding	O
site	O
can	O
support	O
growth	O
and	O
are	O
also	O
phosphorylated	O
in	O
a	O
cell	O
cycle	O
-	O
specific	O
manner	O
.	O

Biol	O
.	O

The	O
Penn	O
State	O
Worry	O
Questionnaire	O
for	O
Children	O
(	O
PSWQ	O
-	O
C	O
)	O
is	O
a	O
14	O
-	O
item	O
self	O
-	O
report	O
questionnaire	O
that	O
intends	O
to	O
measure	O
the	O
tendency	O
of	O
children	O
to	O
engage	O
in	O
excessive	O
,	O
generalized	O
,	O
and	O
uncontrollable	O
worry	O
(	O
Chorpita	O
et	O
al	O
.	O
,	O
Behav	O
.	O

In	O
contrast	O
to	O
previously	O
characterized	O
proteophosphoglycans	O
,	O
the	O
ppg1	B-protein
gene	O
product	O
is	O
predominantly	O
membrane	O
-	O
associated	O
and	O
it	O
is	O
expressed	O
on	O
the	O
promastigote	O
cell	O
surface	O
.	O

The	O
greatest	O
difference	O
between	O
the	O
Ad7	B-protein
and	I-protein
Ad5	I-protein
DBPs	I-protein
is	O
the	O
absence	O
,	O
in	O
the	O
Ad7	O
protein	O
,	O
of	O
12	O
amino	O
acids	O
located	O
between	O
the	O
two	O
functional	O
domains	O
in	O
the	O
Ad5	O
protein	O
(	O
amino	O
acids	O
151	O
-	O
162	O
)	O
.	O

Characteristics	O
of	O
anesthesia	O
and	O
resuscitation	O
in	O
emergency	O
lung	O
surgery	O
.	O

Northern	O
and	O
RT	O
-	O
PCR	O
analysis	O
of	O
Ube3a	B-protein
expression	O
in	O
mouse	O
tissues	O
from	O
animals	O
with	O
segmental	O
,	O
paternal	O
uniparental	O
disomy	O
failed	O
to	O
detect	O
substantially	O
reduced	O
or	O
absent	O
expression	O
compared	O
to	O
control	O
animals	O
,	O
failing	O
to	O
provide	O
any	O
evidence	O
for	O
maternal	O
-	O
specific	O
expression	O
from	O
this	O
locus	O
.	O

Age	O
and	O
sex	O
structure	O
of	O
the	O
natural	O
population	O
of	O
Ornithodoros	O
tatarovski	O
Ol	O
.	O

Over	O
a	O
period	O
of	O
15	O
days	O
16	O
%	O
of	O
the	O
dose	O
administered	O
was	O
excreted	O
with	O
faeces	O
and	O
0	O
.	O
9	O
%	O
in	O
the	O
urine	O
.	O

The	O
fourth	O
dose	O
produced	O
favorable	O
results	O
(	O
66	O
.	O
7	O
%	O
)	O
in	O
individuals	O
with	O
HB	B-protein
antibodies	I-protein
between	O
10	O
and	O
100	O
IU	O
/	O
ml	O
and	O
unfavorable	O
ones	O
(	O
3	O
.	O
8	O
%	O
)	O
where	O
the	O
HB	B-protein
antibodies	I-protein
were	O
below	O
10	O
IU	O
/	O
ml	O
.	O

Employing	O
this	O
sequence	O
information	O
from	O
c11	O
/	O
1	O
,	O
the	O
c11	O
/	O
1	O
-	O
specific	O
cDNA	O
was	O
generated	O
from	O
poly	O
(	O
A	O
)	O
+	O
RNA	O
of	O
bovine	O
PMNLs	O
by	O
reverse	O
transcription	O
and	O
a	O
combination	O
of	O
polymerase	B-protein
chain	O
reaction	O
(	O
PCR	O
)	O
methods	O
.	O

Cyclophilins	B-protein
are	O
cis	B-protein
-	I-protein
trans	I-protein
-	I-protein
peptidyl	I-protein
-	I-protein
prolyl	I-protein
isomerases	I-protein
that	O
bind	O
to	O
and	O
are	O
inhibited	O
by	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

The	O
17	O
-	O
kDa	O
protein	O
is	O
required	O
for	O
the	O
systemic	O
infection	O
of	O
plants	O
.	O

Consumption	O
of	O
4	O
%	O
sucrose	O
was	O
not	O
affected	O
by	O
excitotoxic	O
lesions	O
of	O
the	O
PPTg	O
,	O
but	O
PPTg	O
lesioned	O
rats	O
consumed	O
significantly	O
more	O
12	O
%	O
and	O
20	O
%	O
sucrose	O
than	O
sham	O
controls	O
.	O

The	O
presence	O
in	O
such	O
patients	O
of	O
antibodies	O
to	O
adrenaline	O
and	O
noradrenaline	O
is	O
indicative	O
of	O
considerable	O
disruption	O
of	O
catecholamine	O
biotransformation	O
.	O

Low	O
molecular	O
weight	O
heparins	O
have	O
stimulated	O
much	O
interest	O
because	O
of	O
their	O
supposedly	O
more	O
selective	O
action	O
on	O
Xa	B-protein
factor	I-protein
.	O

In	O
all	O
of	O
these	O
cases	O
,	O
expression	O
of	O
the	O
implicated	O
genes	O
was	O
absent	O
.	O

Anastrozole	O
is	O
the	O
first	O
aromatase	B-protein
inhibitor	O
to	O
show	O
a	O
significant	O
survival	O
advantage	O
over	O
megestrol	O
acetate	O
in	O
post	O
-	O
menopausal	O
women	O
with	O
advanced	O
breast	O
cancer	O
.	O

These	O
genes	O
are	O
expressed	O
within	O
a	O
few	O
hours	O
of	O
the	O
initiation	O
of	O
development	O
;	O
their	O
mRNAs	O
accumulate	O
to	O
a	O
peak	O
at	O
12	O
hr	O
and	O
persist	O
until	O
culmination	O
.	O

Fourteen	O
patients	O
with	O
New	O
York	O
Heart	O
Association	O
class	O
II	O
congestive	O
heart	O
failure	O
were	O
enrolled	O
in	O
a	O
double	O
-	O
blind	O
,	O
cross	O
-	O
over	O
study	O
.	O

Doxorubicin	O
(	O
DOX	O
)	O
is	O
commonly	O
used	O
for	O
the	O
treatment	O
of	O
hematological	O
and	O
solid	O
tumors	O
.	O

It	O
was	O
found	O
that	O
the	O
primary	O
visual	O
cortex	O
of	O
the	O
rat	O
is	O
asymmetrical	O
in	O
volume	O
,	O
and	O
that	O
the	O
asymmetry	O
reflects	O
side	O
differences	O
in	O
the	O
number	O
of	O
neurons	O
.	O

Using	O
Spurr	O
'	O
s	O
resin	O
as	O
a	O
mounting	O
medium	O
,	O
we	O
could	O
observe	O
thick	O
specimens	O
with	O
oil	O
immersion	O
objective	O
lens	O
without	O
the	O
use	O
of	O
coverslips	O
,	O
then	O
avoid	O
air	O
bubbles	O
near	O
the	O
specimen	O
.	O

Mutations	O
within	O
conserved	B-protein
region	I-protein
2	I-protein
(	O
CR2	B-protein
)	O
of	O
E1A	B-protein
that	O
inhibit	O
the	O
binding	O
of	O
E1A	B-protein
to	O
the	O
retinoblastoma	B-protein
gene	I-protein
product	I-protein
(	O
pRb	B-protein
)	O
further	O
enhanced	O
the	O
stimulation	O
of	O
transcription	O
from	O
the	O
PEPCK	B-protein
promoter	I-protein
by	O
2	O
3	O
-	O
fold	O
compared	O
with	O
wild	B-protein
type	I-protein
E1A	I-protein
.	O

Factor	B-protein
VIII	I-protein
procoagulant	O
activity	O
,	O
antigen	O
concentration	O
and	O
von	O
Willebrand	O
activity	O
as	O
ristocetin	B-protein
cofactor	I-protein
were	O
determined	O
several	O
times	O
in	O
10	O
patients	O
with	O
DIC	O
.	O

In	O
vitro	O
,	O
Arix	B-protein
and	O
NBPhox	B-protein
form	O
DNA	O
-	O
independent	O
multimers	O
and	O
exhibit	O
cooperative	O
binding	O
to	O
the	O
DB1	B-protein
regulatory	I-protein
element	I-protein
,	O
which	O
contains	O
two	O
homeodomain	B-protein
recognition	O
sites	O
.	O

These	O
findings	O
suggest	O
that	O
fodrin	B-protein
proteolysis	O
in	O
vivo	O
may	O
reflect	O
the	O
activity	O
of	O
multiple	O
ICE	B-protein
/	I-protein
Ced	I-protein
-	I-protein
3	I-protein
proteases	I-protein
whose	O
partial	O
sensitivity	O
to	O
DEVD	O
-	O
CHO	O
reflects	O
a	O
limited	O
contribution	O
from	O
CPP32	B-protein
,	O
or	O
an	O
ICE	B-protein
/	I-protein
Ced	I-protein
-	I-protein
3	I-protein
protease	I-protein
less	O
sensitive	O
than	O
CPP32	B-protein
to	O
DEVD	O
-	O
CHO	O
inhibition	O
.	O

Molecular	O
cloning	O
of	O
the	O
human	O
homolog	O
of	O
a	O
striatum	B-protein
-	I-protein
enriched	I-protein
phosphatase	I-protein
(	I-protein
STEP	I-protein
)	I-protein
gene	I-protein
and	O
chromosomal	O
mapping	O
of	O
the	O
human	O
and	O
murine	O
loci	O
.	O

According	O
to	O
the	O
investigation	O
,	O
the	O
recent	O
burst	O
of	O
pseudoterranovosis	O
in	O
this	O
area	O
can	O
be	O
attributed	O
to	O
the	O
increased	O
presence	O
of	O
sea	O
lions	O
,	O
which	O
proliferate	O
in	O
the	O
Arctic	O
region	O
,	O
then	O
migrate	O
to	O
the	O
northern	O
Japan	O
Sea	O
and	O
eat	O
the	O
intermediate	O
host	O
fish	O
.	O

Mutations	O
in	O
seven	O
other	O
lts	B-protein
genes	I-protein
do	O
not	O
result	O
in	O
the	O
mak	B-protein
-	I-protein
phenotype	I-protein
.	O

The	O
tramtrack	B-protein
(	O
ttk	B-protein
)	O
gene	O
of	O
Drosophila	O
encodes	O
69	O
-	O
kDa	O
and	O
88	O
-	O
kDa	O
proteins	O
through	O
alternative	O
splicing	O
of	O
the	O
primary	O
ttk	B-protein
transcript	I-protein
.	O

The	O
lowest	O
detectable	O
concentration	O
was	O
1	O
.	O
0	O
ng	O
/	O
ml	O
in	O
the	O
serum	O
.	O

The	O
examination	O
was	O
focused	O
on	O
assessment	O
of	O
different	O
types	O
of	O
drusen	O
,	O
on	O
evaluation	O
of	O
the	O
development	O
and	O
incidence	O
of	O
risk	O
factors	O
leading	O
to	O
complications	O
and	O
loss	O
of	O
central	O
vision	O
.	O

Clinical	O
value	O
of	O
the	O
estimation	O
of	O
growth	O
kinetics	O
of	O
primary	O
ovarian	O
cancer	O
recurrences	O
by	O
CA125	B-protein
doubling	O
time	O
.	O

Dystonic	O
movement	O
of	O
the	O
left	O
upper	O
limb	O
in	O
a	O
case	O
of	O
the	O
right	O
pontine	O
hemorrhage	O
.	O

TNF	B-protein
-	I-protein
alpha	I-protein
induced	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
increase	O
in	O
cyclooxygenase	B-protein
-	I-protein
2	I-protein
(	O
COX	B-protein
-	I-protein
2	I-protein
)	O
expression	O
and	O
PGE2	O
formation	O
in	O
human	O
NCI	O
-	O
H292	O
epithelial	O
cells	O
.	O

After	O
a	O
survey	O
of	O
the	O
anatomical	O
and	O
physiological	O
basis	O
of	O
operative	O
treatment	O
of	O
behaviour	O
disorders	O
by	O
stereotactic	O
lesions	O
in	O
the	O
amygdala	O
and	O
the	O
posterior	O
medial	O
hypothalamus	O
the	O
author	O
describes	O
his	O
own	O
experiences	O
with	O
603	O
operations	O
for	O
control	O
of	O
conservatively	O
untreatable	O
aggressiveness	O
.	O

Interleukin	B-protein
-	I-protein
6	I-protein
may	O
possibly	O
potentiate	O
metastasis	O
of	O
cardiac	O
myxoma	O
.	O

We	O
have	O
determined	O
that	O
several	O
E1	B-protein
mutants	I-protein
mapping	O
in	O
both	O
the	O
M	O
and	O
R	O
regions	O
and	O
a	O
single	O
mutant	O
of	O
the	O
upstream	O
regulatory	O
region	O
have	O
a	O
higher	O
transforming	O
activity	O
on	O
mouse	O
C127	O
cells	O
than	O
the	O
wild	O
-	O
type	O
genome	O
does	O
.	O

Antimicrobial	O
substance	O
isolated	O
from	O
an	O
acorn	O
extract	O
.	O

Army	O
veterans	O
given	O
yellow	O
fever	O
vaccine	O
contaminated	O
with	O
hepatitis	O
B	O
virus	O
in	O
1942	O
and	O
controls	O
and	O
(	O
b	O
)	O
a	O
case	O
-	O
control	O
study	O
comparing	O
veterans	O
with	O
hepatocellular	O
carcinoma	O
in	O
Veterans	O
Affairs	O
hospitals	O
with	O
matched	O
controls	O
with	O
respect	O
to	O
receipt	O
of	O
contaminated	O
vaccine	O
in	O
1942	O
.	O

This	O
is	O
the	O
first	O
description	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
regulatory	O
elements	O
that	O
control	O
expression	O
of	O
a	O
gene	O
encoding	O
a	O
B7	B-protein
costimulatory	I-protein
molecule	I-protein
.	O

Particularly	O
striking	O
was	O
the	O
conservation	O
of	O
an	O
AP	B-protein
-	I-protein
4	I-protein
binding	I-protein
site	I-protein
within	O
100	O
nucleotides	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
in	O
both	O
Aal	B-protein
-	I-protein
rpL34	I-protein
and	O
Aal	B-protein
-	I-protein
rpL8	I-protein
genes	I-protein
.	O

We	O
find	O
that	O
beta	B-protein
II	I-protein
PKC	I-protein
phosphorylates	O
nuclear	B-protein
envelope	I-protein
lamin	I-protein
B	I-protein
at	O
10	O
-	O
20	O
times	O
the	O
rate	O
of	O
alpha	B-protein
PKC	I-protein
,	O
whereas	O
both	O
kinases	B-protein
phosphorylate	O
soluble	B-protein
lamin	I-protein
B	I-protein
at	O
similar	O
rates	O
.	O

Gel	O
route	O
preparation	O
of	O
low	O
fusing	O
dental	O
porcelain	O
frit	O
.	O

Even	O
when	O
the	O
inoculum	O
size	O
was	O
reduced	O
sixfold	O
(	O
i	O
.	O
e	O
.	O
,	O
6	O
x	O
10	O
(	O
6	O
)	O
CFU	O
/	O
mouse	O
)	O
,	O
50	O
%	O
of	O
the	O
RB6	O
-	O
8C5	O
-	O
treated	O
animals	O
died	O
within	O
6	O
days	O
.	O

YAC	O
and	O
cosmid	O
contigs	O
spanning	O
the	O
BRCA1	B-protein
region	I-protein
were	O
used	O
to	O
select	O
cDNA	O
clones	O
from	O
pools	O
of	O
cDNAs	O
derived	O
from	O
human	O
placenta	O
,	O
HeLa	O
cells	O
,	O
activated	O
T	O
cells	O
,	O
and	O
fetal	O
head	O
.	O

These	O
results	O
illuminate	O
a	O
hitherto	O
unanticipated	O
function	O
of	O
U6	B-protein
RNA	I-protein
:	O
the	O
modulation	O
of	O
a	O
phosphorylation	O
-	O
dephosphorylation	O
cycle	O
of	O
C1	B-protein
hnRNP	I-protein
protein	I-protein
that	O
influences	O
the	O
binding	O
affinity	O
of	O
this	O
protein	O
for	O
pre	O
-	O
mRNA	O
.	O

The	O
interaction	O
between	O
DDB	B-protein
and	O
E2F1	B-protein
can	O
also	O
be	O
detected	O
by	O
coimmunoprecipitation	O
experiments	O
.	O

In	O
most	O
cases	O
of	O
acute	O
transmural	O
infarction	O
,	O
the	O
reciprocal	O
ST	O
segment	O
depressions	O
observed	O
in	O
contralateral	O
leads	O
are	O
less	O
marked	O
than	O
the	O
primary	O
ST	O
segment	O
elevations	O
.	O

This	O
expression	O
assumes	O
:	O
(	O
1	O
)	O
a	O
laminar	O
flow	O
regimen	O
during	O
expiration	O
,	O
and	O
(	O
2	O
)	O
a	O
constant	O
CT	O
value	O
over	O
the	O
range	O
of	O
VT	O
.	O

Mutation	O
of	O
the	O
central	O
Tyr497	O
to	O
Phe	O
blocks	O
the	O
tyrosine	O
phosphorylation	O
of	O
the	O
insulin	B-protein
receptor	I-protein
substrate	I-protein
1	I-protein
(	O
IRS1	B-protein
)	O
and	O
diminishes	O
proliferation	O
in	O
response	O
to	O
IL	B-protein
-	I-protein
4	I-protein
.	O

ULKs	B-protein
and	O
UNC	B-protein
-	I-protein
51	I-protein
share	O
a	O
typical	O
domain	O
structure	O
of	O
an	O
amino	B-protein
-	I-protein
terminal	I-protein
kinase	I-protein
domain	I-protein
,	O
a	O
central	O
proline	O
/	O
serine	O
rich	O
(	O
PS	O
)	O
domain	O
,	O
and	O
a	O
carboxy	O
-	O
terminal	O
(	O
C	O
)	O
domain	O
.	O

Comparison	O
of	O
German	O
language	O
versions	O
of	O
the	O
QWB	O
-	O
SA	O
and	O
SF	O
-	O
36	O
evaluating	O
outcomes	O
for	O
patients	O
with	O
prostate	O
disease	O
.	O

RBP56	B-protein
protein	I-protein
turned	O
out	O
to	O
be	O
hTAFII68	B-protein
which	O
was	O
isolated	O
as	O
a	O
TATA	B-protein
-	I-protein
binding	I-protein
protein	I-protein
associated	I-protein
factor	I-protein
(	O
TAF	B-protein
)	O
from	O
a	O
sub	O
-	O
population	O
of	O
TFIID	B-protein
complexes	I-protein
(	O
Bertolotti	O
A	O
.	O
,	O
Lutz	O
,	O
Y	O
.	O
,	O
Heard	O
,	O
D	O
.	O
J	O
.	O
,	O
Chambon	O
,	O
P	O
.	O
,	O
Tora	O
,	O
L	O
.	O
,	O
1996	O
.	O
hTAFII68	B-protein
,	O
a	O
novel	O
RNA	B-protein
/	I-protein
ssDNA	I-protein
-	I-protein
binding	I-protein
protein	I-protein
with	O
homology	O
to	O
the	O
proto	B-protein
-	I-protein
oncoproteins	I-protein
TLS	I-protein
/	I-protein
FUS	I-protein
and	O
EWS	B-protein
is	O
associated	O
with	O
both	O
TFIID	B-protein
and	O
RNA	B-protein
polymerase	I-protein
II	I-protein
.	O

Effect	O
of	O
acute	O
and	O
chronic	O
psychogenic	O
stress	O
on	O
corticoadrenal	O
and	O
pituitary	O
-	O
thyroid	O
hormones	O
in	O
male	O
rats	O
.	O

Capnography	O
curves	O
of	O
40	O
HVS	O
patients	O
,	O
40	O
non	O
-	O
HVS	O
patients	O
with	O
psycho	O
-	O
somatic	O
complaints	O
and	O
26	O
healthy	O
controls	O
were	O
analyzed	O
.	O

Human	B-protein
LTBP	I-protein
-	I-protein
1	I-protein
is	O
known	O
to	O
exist	O
in	O
different	O
forms	O
.	O

In	O
contrast	O
,	O
the	O
lumenal	O
domains	O
of	O
Sec12p	B-protein
,	O
Stl1p	B-protein
and	O
Stl2p	B-protein
are	O
very	O
different	O
in	O
size	O
and	O
do	O
not	O
show	O
any	O
appreciable	O
homology	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
central	O
role	O
of	O
the	O
Notch	B-protein
-	I-protein
CBF1	I-protein
/	I-protein
RBP	I-protein
-	I-protein
Jkappa	I-protein
signaling	I-protein
pathway	I-protein
in	O
cell	O
fate	O
decisions	O
renders	O
it	O
susceptible	O
to	O
pathways	O
of	O
viral	O
replication	O
and	O
oncogenic	O
conversion	O
.	O

The	O
possibility	O
of	O
selective	O
chemotherapy	O
of	O
progressive	O
recurring	O
ovarian	O
carcinoma	O
with	O
the	O
aid	O
of	O
cytodiagnosis	O
and	O
incorporation	O
of	O
tagged	O
idoxuridine	O
.	O

To	O
determine	O
the	O
genetic	O
basis	O
for	O
the	O
differences	O
between	O
the	O
cardiac	O
and	O
brain	B-protein
AE3	I-protein
variants	I-protein
,	O
we	O
isolated	O
and	O
characterized	O
the	O
rat	O
gene	O
.	O

All	O
ABFI	B-protein
-	I-protein
binding	I-protein
sites	I-protein
,	O
regardless	O
of	O
origin	O
,	O
provided	O
weak	O
UAS	O
function	O
in	O
vivo	O
when	O
examined	O
in	O
test	O
plasmids	O
.	O

Patterns	O
of	O
connections	O
underlying	O
cross	O
-	O
modality	O
integration	O
were	O
studied	O
by	O
injecting	O
distinguishable	O
,	O
retrograde	O
tracers	O
(	O
Fluoro	O
-	O
Gold	O
and	O
diamidino	O
yellow	O
)	O
in	O
pairwise	O
manner	O
into	O
different	O
sensory	O
representations	O
(	O
visual	O
,	O
somatosensory	O
,	O
and	O
auditory	O
)	O
in	O
the	O
cerebral	O
cortex	O
of	O
the	O
rat	O
.	O

In	O
this	O
study	O
we	O
have	O
investigated	O
the	O
role	O
of	O
C	B-protein
/	I-protein
EBP	I-protein
beta	I-protein
in	O
initiating	O
the	O
adipogenic	O
program	O
by	O
overexpressing	O
C	B-protein
/	I-protein
EBP	I-protein
beta	I-protein
in	O
multipotential	O
NIH	O
-	O
3T3	O
fibroblasts	O
.	O

As	O
hypothesized	O
,	O
believers	O
showed	O
relatively	O
higher	O
right	O
hemispheric	O
activation	O
and	O
reduced	O
hemispheric	O
asymmetry	O
of	O
functional	O
complexity	O
.	O

In	O
the	O
whole	O
group	O
,	O
basal	O
GH	B-protein
and	O
somatomedin	B-protein
-	I-protein
C	I-protein
levels	O
decreased	O
from	O
a	O
mean	O
(	O
+	O
/	O
-	O
standard	O
error	O
of	O
the	O
mean	O
)	O
of	O
52	O
.	O
3	O
+	O
/	O
-	O
12	O
.	O
7	O
to	O
11	O
.	O
1	O
+	O
/	O
-	O
6	O
.	O
3	O
ng	O
/	O
ml	O
and	O
from	O
7	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
7	O
to	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
5	O
U	O
/	O
ml	O
,	O
respectively	O
.	O

We	O
describe	O
49	O
cases	O
with	O
papillary	O
tumor	O
<	O
1	O
cm	O
.	O

Structure	O
and	O
regulation	O
of	O
the	O
gene	O
encoding	O
the	O
neuron	O
-	O
specific	O
protein	B-protein
kinase	I-protein
C	I-protein
substrate	O
neurogranin	B-protein
(	O
RC3	B-protein
protein	I-protein
)	O
.	O

Transient	O
hyperammonaemia	O
in	O
an	O
adult	O
German	O
shepherd	O
dog	O
.	O

Because	O
of	O
concerns	O
regarding	O
blood	O
transfusion	O
-	O
related	O
communicable	O
disease	O
(	O
eg	O
,	O
acquired	O
immune	O
deficiency	O
syndrome	O
and	O
non	O
-	O
A	O
,	O
non	O
-	O
B	O
hepatitis	O
)	O
,	O
there	O
has	O
been	O
increasing	O
research	O
effort	O
into	O
postoperative	O
hemorrhage	O
related	O
to	O
cardiopulmonary	O
bypass	O
with	O
extracorporeal	O
circulation	O
.	O

Inhibition	O
of	O
the	O
Raf	B-protein
-	I-protein
1	I-protein
kinase	I-protein
by	O
cyclic	O
AMP	O
agonists	O
causes	O
apoptosis	O
of	O
v	O
-	O
abl	O
-	O
transformed	O
cells	O
.	O

CREB	B-protein
was	O
identified	O
as	O
one	O
of	O
the	O
protein	O
components	O
in	O
several	O
of	O
the	O
gel	O
shift	O
complexes	O
formed	O
with	O
the	O
variant	O
CRE	B-protein
.	O

Biol	O
.	O

Mammalian	O
sperm	O
motility	O
is	O
regulated	O
by	O
a	O
cascade	O
of	O
cAMP	O
-	O
dependent	O
protein	O
phosphorylation	O
events	O
mediated	O
by	O
protein	B-protein
kinase	I-protein
A	O
.	O

The	O
`	O
`	O
tobacco	O
issue	O
'	O
'	O
.	O

Diltiazem	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
epicardial	O
diameter	O
(	O
+	O
10	O
%	O
;	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
in	O
coronary	O
blood	O
flow	O
(	O
CBF	O
)	O
(	O
+	O
30	O
%	O
;	O
p	O
=	O
0	O
.	O
0001	O
)	O
.	O

These	O
results	O
establish	O
that	O
hydroquinones	O
lead	O
to	O
mutagenicity	O
and	O
carcinogenicity	O
.	O

Glutamic	O
acid	O
in	O
a	O
dose	O
of	O
1	O
/	O
100	O
of	O
the	O
LD50	O
was	O
injected	O
in	O
the	O
form	O
of	O
sodium	O
salt	O
into	O
male	O
and	O
female	O
Wistar	O
rats	O
for	O
7	O
days	O
after	O
8	O
-	O
and	O
12	O
-	O
day	O
injections	O
of	O
dexazone	O
.	O

Members	O
of	O
the	O
JAK	B-protein
/	I-protein
Tyk	I-protein
family	I-protein
of	O
tyrosine	B-protein
kinases	I-protein
mediate	O
phosphorylation	O
of	O
STAT3	B-protein
at	O
Tyr705	O
during	O
CNTF	B-protein
signaling	O
;	O
however	O
,	O
the	O
kinase	B-protein
responsible	O
for	O
phosphorylation	O
at	O
STAT3	B-protein
Tyr727	O
appears	O
to	O
depend	O
on	O
both	O
the	O
extracellular	O
stimulus	O
and	O
the	O
cellular	O
context	O
.	O

Also	O
,	O
HR21ap	B-protein
as	O
well	O
as	O
HR21Xap	B-protein
are	O
specific	O
in	O
their	O
inhibition	O
of	O
Sp1	B-protein
binding	O
.	O

Isolation	O
and	O
identification	O
of	O
genes	O
activating	O
UAS2	B-protein
-	I-protein
dependent	I-protein
ADH2	I-protein
expression	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Methisergide	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
a	O
blocker	O
of	O
serotonin	B-protein
receptors	I-protein
,	O
prevented	O
the	O
development	O
of	O
the	O
antinociceptive	O
effect	O
of	O
serotonin	O
.	O

Although	O
the	O
binding	O
of	O
IE2	B-protein
86	I-protein
to	O
nonphosphorylated	O
full	B-protein
-	I-protein
length	I-protein
CREB	I-protein
or	O
deltaCREB	B-protein
is	O
minimal	O
,	O
IE2	B-protein
86	I-protein
does	O
form	O
complexes	O
with	O
p300	B-protein
and	O
the	O
CREB	B-protein
-	I-protein
binding	I-protein
protein	I-protein
(	O
CBP	B-protein
)	O
,	O
which	O
in	O
turn	O
bind	O
to	O
CREB	B-protein
and	O
can	O
serve	O
as	O
adaptor	O
proteins	O
for	O
CREB	B-protein
function	O
.	O

These	O
results	O
demonstrate	O
that	O
endogenous	O
N	O
-	O
methylation	O
of	O
salsolinol	O
into	O
N	O
-	O
methylsalsolinol	O
occurs	O
in	O
the	O
brain	O
in	O
vivo	O
.	O

Survival	O
was	O
calculated	O
both	O
from	O
the	O
date	O
of	O
onset	O
and	O
from	O
the	O
date	O
of	O
diagnosis	O
.	O

Reverse	O
transcription	O
-	O
PCR	O
analysis	O
of	O
mRNA	O
from	O
patients	O
shows	O
that	O
each	O
of	O
these	O
five	O
mutations	O
results	O
in	O
aberrant	O
splicing	O
.	O

Acute	O
inhalation	O
toxicity	O
of	O
T	O
-	O
2	O
mycotoxin	O
in	O
mice	O
.	O

Envelope	O
-	O
function	O
matching	O
conditions	O
for	O
GaAs	B-protein
/	I-protein
(	I-protein
Al	I-protein
,	I-protein
Ga	I-protein
)	I-protein
As	I-protein
heterojunctions	I-protein
.	O

The	O
ubiquitously	O
expressed	O
hypoxia	B-protein
-	I-protein
inducible	I-protein
factor	I-protein
-	I-protein
1	I-protein
(	O
HIF	B-protein
-	I-protein
1	I-protein
)	O
is	O
involved	O
in	O
expression	O
of	O
a	O
large	O
number	O
of	O
oxygen	O
-	O
regulated	O
genes	O
.	O

Because	O
ATF	B-protein
-	I-protein
1	I-protein
and	O
CREM	B-protein
are	O
known	O
to	O
bind	O
to	O
cAMP	B-protein
response	I-protein
elements	I-protein
(	O
CRE	B-protein
)	O
,	O
this	O
functional	O
sequence	O
was	O
named	O
the	O
kappa	B-protein
E3	I-protein
'	I-protein
-	I-protein
CRE	I-protein
.	O

INTERVENTIONS	O
:	O
Patients	O
received	O
rt	B-protein
-	I-protein
PA	I-protein
,	O
heparin	O
,	O
and	O
aspirin	O
.	O

The	O
incidence	O
of	O
tumours	O
in	O
young	O
chickens	O
.	O

In	O
the	O
matched	O
control	O
group	O
the	O
acquisition	O
-	O
rate	O
of	O
both	O
symptomatic	O
and	O
asymptomatic	O
0acteriuria	O
was	O
over	O
12	O
%	O
,	O
a	O
figure	O
similar	O
to	O
the	O
percentage	O
of	O
women	O
present	O
in	O
the	O
practice	O
population	O
during	O
one	O
year	O
with	O
transient	O
,	O
symptomatic	O
,	O
and	O
persistent	O
A	O
.	O
B	O
.	O

We	O
identified	O
telSMN	B-protein
mutations	O
in	O
11	O
of	O
these	O
unrelated	O
SMA	O
-	O
like	O
individuals	O
who	O
carry	O
a	O
single	O
copy	O
of	O
telSMN	B-protein
:	O
these	O
include	O
two	O
frameshift	O
mutations	O
(	O
800ins11	O
and	O
542delGT	O
)	O
and	O
three	O
missense	O
mutations	O
(	O
A2G	O
,	O
S262I	O
,	O
and	O
T274I	O
)	O
.	O

The	O
presence	O
of	O
an	O
additional	O
sequence	O
of	O
nucleotides	O
145	O
-	O
165	O
from	O
the	O
3	O
'	O
end	O
of	O
RNA3	B-protein
enhanced	O
template	O
recognition	O
by	O
RdRp	B-protein
in	O
vitro	O
and	O
accumulation	O
of	O
RNA3	B-protein
in	O
vivo	O
to	O
wild	O
-	O
type	O
levels	O
.	O

At	O
visit	O
5	O
,	O
the	O
isokinetic	O
test	O
showed	O
impaired	O
muscle	O
function	O
recovery	O
from	O
23	O
%	O
to	O
32	O
%	O
,	O
while	O
the	O
manual	O
test	O
showed	O
almost	O
full	O
recovery	O
.	O

Folded	O
tissue	O
and	O
crimped	O
collagen	B-protein
fibers	O
in	O
the	O
tunica	O
albuginea	O
permit	O
its	O
expansion	O
during	O
erection	O
.	O

12	O
-	O
O	O
-	O
Tetradecanoylphorbol	O
13	O
-	O
acetate	O
was	O
found	O
to	O
inhibit	O
rapidly	O
and	O
potently	O
the	O
expression	O
of	O
mRNAs	O
coding	O
for	O
the	O
myogenic	O
regulators	O
CMD1	B-protein
and	O
myogenin	B-protein
.	O

The	O
XS2	B-protein
gene	I-protein
down	O
-	O
regulates	O
but	O
does	O
not	O
abolish	O
expression	O
of	O
LU	B-protein
genes	I-protein
and	O
does	O
not	O
affect	O
expression	O
of	O
CD44	B-protein
.	O

Additionally	O
,	O
a	O
variety	O
of	O
regulatory	O
schemes	O
contribute	O
temporal	O
and	O
/	O
or	O
spatial	O
restriction	O
to	O
TGF	B-protein
-	I-protein
beta	I-protein
responses	O
.	O

This	O
information	O
,	O
together	O
with	O
estimation	O
of	O
the	O
size	O
of	O
the	O
deglycosylated	O
A	O
subunit	O
relative	O
to	O
a	O
series	O
of	O
C	B-protein
-	I-protein
terminal	I-protein
truncated	I-protein
TSHR	I-protein
ectodomain	I-protein
variants	I-protein
,	O
places	O
cleavage	O
Site	O
1	O
in	O
the	O
vicinity	O
of	O
,	O
or	O
closely	O
upstream	O
to	O
,	O
residue	O
317	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
:	O
Serum	O
levels	O
of	O
FSH	B-protein
,	O
LH	B-protein
,	O
and	O
inhibin	B-protein
A	I-protein
and	I-protein
B	I-protein
.	O

We	O
generated	O
transformed	O
B	O
lymphoblast	O
cell	O
lines	O
from	O
controls	O
,	O
from	O
four	O
patients	O
with	O
p47	O
-	O
phox	O
-	O
deficient	O
chronic	O
granulomatous	O
disease	O
,	O
and	O
from	O
three	O
parents	O
.	O

In	O
a	O
blind	O
controlled	O
trial	O
,	O
15	O
patients	O
with	O
COCM	O
(	O
NYHA	O
II	O
-	O
III	O
)	O
with	O
sinus	O
rhythm	O
and	O
a	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LV	O
-	O
EF	O
)	O
of	O
34	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
6	O
%	O
received	O
consecutively	O
D	O
(	O
0	O
.	O
25	O
-	O
0	O
.	O
5	O
mg	O
/	O
d	O
)	O
,	O
placebo	O
(	O
PLAC	O
)	O
,	O
P	O
(	O
slow	O
releases	O
=	O
SR	O
)	O
(	O
80	O
mg	O
/	O
d	O
SR	O
)	O
and	O
both	O
drugs	O
combined	O
in	O
respective	O
doses	O
.	O

Vitrectomy	O
in	O
ocular	O
traumatology	O
.	O

We	O
further	O
demonstrate	O
that	O
RU486	O
-	O
PR	O
-	O
B	O
interacts	O
physically	O
with	O
NCoR	B-protein
in	O
vitro	O
.	O

We	O
have	O
isolated	O
and	O
sequenced	O
two	O
overlapping	O
cDNA	O
fragments	O
which	O
could	O
encode	O
the	O
complete	O
amino	O
acid	O
sequence	O
of	O
rat	B-protein
testis	I-protein
fructose	I-protein
-	I-protein
6	I-protein
-	I-protein
phosphate	I-protein
,	I-protein
2	I-protein
-	I-protein
kinase	I-protein
:	I-protein
fructose	I-protein
-	I-protein
2	I-protein
,	I-protein
6	I-protein
-	I-protein
bisphosphatase	I-protein
.	O

One	O
site	O
,	O
PAL	B-protein
,	O
occurs	O
within	O
the	O
10	B-protein
bp	I-protein
sequence	I-protein
GGGGAGGAGG	I-protein
.	O

Replacement	O
of	O
the	O
spacer	O
sequence	O
between	O
the	O
two	O
ARMs	O
with	O
a	O
shorter	O
stretch	O
of	O
sequence	O
also	O
reduced	O
RNA	O
binding	O
in	O
vitro	O
.	O

It	O
is	O
possible	O
that	O
the	O
patch	O
determines	O
the	O
proper	O
conformation	O
of	O
the	O
site	O
and	O
thereby	O
contributes	O
to	O
recognition	O
indirectly	O
.	O

In	O
addition	O
,	O
another	O
derivative	O
of	O
pCMVJS21	O
(	O
pCMVJS21DeltaGP	O
)	O
in	O
which	O
the	O
gag	B-protein
,	O
pol	B-protein
(	O
and	O
orf	B-protein
-	I-protein
x	I-protein
)	O
coding	O
sequences	O
were	O
deleted	O
also	O
gave	O
transformed	O
foci	O
.	O

In	O
ferrets	O
naturally	O
infected	O
with	O
H	O
.	O
mustelae	O
,	O
a	O
single	O
dose	O
(	O
50	O
mg	O
/	O
kg	O
,	O
per	O
os	O
)	O
of	O
fluorofamide	O
completely	O
inhibited	O
bacterial	B-protein
urease	I-protein
.	O

We	O
show	O
that	O
the	O
surfaces	O
of	O
tracheal	O
cartilage	O
matrix	O
are	O
collagen	O
-	O
rich	O
and	O
surround	O
a	O
proteoglycan	O
-	O
rich	O
core	O
.	O

Haemodilution	O
in	O
cardiopulmonary	O
bypass	O
using	O
a	O
gelatine	O
derivative	O
for	O
priming	O
.	O

The	O
Jenkins	O
Activity	O
Survey	O
and	O
the	O
CPI	O
-	O
revised	O
:	O
further	O
evidence	O
of	O
adaptive	O
and	O
maladaptive	O
type	O
A	O
traits	O
.	O

Irmiere	O
,	O
and	O
W	O
.	O

Two	O
copies	O
of	O
the	O
72	O
-	O
bp	O
repeat	O
provided	O
efficient	O
activation	O
of	O
gene	O
expression	O
.	O

Consistent	O
with	O
this	O
prediction	O
,	O
transfections	O
into	O
the	O
hematopoietic	O
cell	O
line	O
Jurkat	O
showed	O
a	O
9	O
.	O
0	O
-	O
and	O
2	O
.	O
5	O
-	O
fold	O
activation	O
of	O
the	O
mim	B-protein
-	I-protein
1	I-protein
promoter	I-protein
by	O
the	O
p32	B-protein
and	O
p30	B-protein
isoforms	I-protein
,	O
respectively	O
.	O

In	O
our	O
previous	O
studies	O
,	O
transcriptional	O
activation	O
was	O
shown	O
to	O
correlate	O
with	O
IEP86	B-protein
binding	O
to	O
both	O
the	O
TATA	B-protein
-	I-protein
box	I-protein
binding	I-protein
protein	I-protein
(	O
TBP	B-protein
)	O
and	O
the	O
transcription	O
factor	O
bound	O
upstream	O
.	O

Two	O
siblings	O
with	O
hemolytic	O
anemia	O
caused	O
by	O
triosephosphate	B-protein
isomerase	I-protein
deficiency	O
developed	O
a	O
progressive	O
neurological	O
syndrome	O
featuring	O
dystonic	O
movements	O
,	O
tremor	O
,	O
pyramidal	O
tract	O
signs	O
,	O
and	O
evidence	O
of	O
spinal	O
motor	O
neuron	O
involvement	O
.	O

Female	O
subjects	O
,	O
including	O
both	O
normal	O
subjects	O
and	O
idiopathic	O
calcium	O
stone	O
-	O
formers	O
,	O
have	O
higher	O
urinary	O
cyclic	O
AMP	O
levels	O
than	O
their	O
male	O
counterparts	O
,	O
and	O
this	O
difference	O
is	O
significant	O
when	O
urinary	O
cyclic	O
AMP	O
is	O
expressed	O
in	O
the	O
units	O
mumol	O
/	O
g	O
of	O
creatinine	O
.	O

He	O
visited	O
our	O
hospital	O
and	O
left	O
solitary	O
renal	O
cyst	O
was	O
suspected	O
.	O

The	O
effect	O
of	O
maternal	O
ingestion	O
of	O
the	O
reduced	O
energy	O
sweetener	O
erythritol	O
was	O
investigated	O
in	O
KBL	O
:	O
JW	O
strain	O
pregnant	O
rabbits	O
.	O

Our	O
results	O
concluded	O
that	O
1	O
)	O
the	O
two	O
inhibin	B-protein
/	I-protein
activin	I-protein
beta	I-protein
B	I-protein
-	I-protein
subunit	I-protein
mRNAs	I-protein
were	O
transcribed	O
from	O
different	O
initiation	O
sites	O
;	O
2	O
)	O
both	O
promoters	O
may	O
be	O
controlled	O
by	O
up	O
-	O
stream	O
negative	O
regulatory	O
elements	O
;	O
and	O
3	O
)	O
neither	O
of	O
these	O
promoters	O
is	O
responsive	O
to	O
cAMP	O
and	O
/	O
or	O
phorbol	O
esters	O
under	O
the	O
conditions	O
employed	O
.	O

The	O
HSD3B1	B-protein
and	O
HSD3B2	B-protein
genes	I-protein
encoding	O
the	O
types	B-protein
I	I-protein
and	I-protein
II	I-protein
3	I-protein
beta	I-protein
-	I-protein
HSD	I-protein
isoenzymes	I-protein
,	O
respectively	O
,	O
have	O
been	O
previously	O
assigned	O
by	O
in	O
situ	O
hybridization	O
to	O
the	O
chromosome	O
1p13	O
.	O
1	O
region	O
.	O

Effect	O
of	O
enteral	O
nutritional	O
products	O
differing	O
in	O
carbohydrate	O
and	O
fat	O
on	O
indices	O
of	O
carbohydrate	O
and	O
lipid	O
metabolism	O
in	O
patients	O
with	O
NIDDM	O
.	O

A	O
study	O
was	O
performed	O
to	O
compare	O
the	O
ONLINE	O
and	O
EMIT	O
II	O
immunoassays	O
with	O
gas	O
chromatographic	O
/	O
mass	O
spectrometric	O
(	O
GC	O
/	O
MS	O
)	O
analysis	O
of	O
methaqualone	O
metabolites	O
on	O
urine	O
using	O
samples	O
obtained	O
from	O
a	O
clinical	O
study	O
.	O

Functional	O
analysis	O
of	O
aryl	B-protein
hydrocarbon	I-protein
receptor	I-protein
nuclear	I-protein
translocator	I-protein
interactions	O
with	O
aryl	B-protein
hydrocarbon	I-protein
receptor	I-protein
in	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
.	O

Alternatively	O
,	O
loss	O
-	O
of	O
-	O
function	O
alleles	O
of	O
genes	O
that	O
inhibit	O
cAPK	B-protein
lead	O
to	O
the	O
inability	O
to	O
undergo	O
sexual	O
differentiation	O
.	O

These	O
different	O
observations	O
exclude	O
a	O
heterozygosity	O
of	O
the	O
A	O
-	O
-	O
>	O
G	O
mutation	O
at	O
codon	O
beta	O
77	O
,	O
as	O
well	O
as	O
a	O
deletion	O
comparable	O
to	O
that	O
of	O
Hbs	B-protein
Lepore	I-protein
or	I-protein
Kenya	I-protein
,	O
or	O
a	O
beta	B-protein
-	I-protein
globin	I-protein
gene	I-protein
duplication	O
,	O
and	O
point	O
to	O
a	O
nontraditional	O
inheritance	O
of	O
Hb	B-protein
Costa	I-protein
Rica	I-protein
.	O

Remarkably	O
,	O
a	O
construct	O
corresponding	O
to	O
residues	O
631	O
to	O
970	O
,	O
which	O
contains	O
only	O
the	O
LXXLL	B-protein
motifs	I-protein
and	O
the	O
AD1	B-protein
region	I-protein
of	O
SRC1	B-protein
,	O
retained	O
strong	O
coactivator	O
activity	O
in	O
our	O
assays	O
.	O

The	O
alternative	O
sigma	B-protein
factor	I-protein
sigmaB	I-protein
in	I-protein
Staphylococcus	I-protein
aureus	I-protein
:	O
regulation	O
of	O
the	O
sigB	B-protein
operon	I-protein
in	O
response	O
to	O
growth	O
phase	O
and	O
heat	O
shock	O
.	O

Endorphins	B-protein
at	O
the	O
approach	O
of	O
death	O
.	O

UDP	B-protein
-	I-protein
Gal	I-protein
:	I-protein
Gal	I-protein
beta	I-protein
1	I-protein
-	I-protein
-	I-protein
-	I-protein
-	I-protein
4GlcNAc	I-protein
alpha	I-protein
1	I-protein
-	I-protein
-	I-protein
-	I-protein
-	I-protein
3	I-protein
-	I-protein
galactosyltransferase	I-protein
is	O
a	O
terminal	B-protein
glycosyltransferase	I-protein
that	O
is	O
widely	O
expressed	O
in	O
a	O
variety	O
of	O
mammalian	O
species	O
,	O
with	O
the	O
notable	O
exception	O
of	O
man	O
,	O
apes	O
,	O
and	O
Old	O
World	O
monkeys	O
.	O

The	O
underlying	O
cirrhosis	O
was	O
alcoholic	O
in	O
11	O
(	O
53	O
.	O
3	O
%	O
)	O
,	O
cryptogenic	O
in	O
5	O
(	O
23	O
.	O
8	O
%	O
)	O
,	O
and	O
hepatitis	O
B	O
chronic	O
infection	O
related	O
in	O
5	O
(	O
23	O
.	O
8	O
%	O
)	O
.	O

The	O
model	O
captures	O
the	O
essence	O
of	O
predator	O
-	O
prey	O
dynamics	O
to	O
provide	O
reasonable	O
predictions	O
of	O
population	O
patterns	O
.	O

The	O
bases	O
of	O
this	O
comparison	O
are	O
reviewed	O
and	O
discussed	O
.	O

In	O
the	O
TVD	O
-	O
patients	O
decreases	O
in	O
skin	O
blood	O
flow	O
were	O
similar	O
compared	O
with	O
the	O
healthy	O
controls	O
.	O

The	O
cpc	O
-	O
1	O
-	O
encoded	O
transcript	O
contains	O
three	O
open	O
reading	O
frames	O
,	O
two	O
of	O
which	O
are	O
located	O
in	O
the	O
720	O
-	O
nucleotide	O
leader	O
segment	O
preceding	O
the	O
cpc	B-protein
-	I-protein
1	I-protein
coding	I-protein
region	I-protein
.	O

The	O
complete	O
exon	O
-	O
intron	O
organization	O
of	O
the	O
murine	O
gene	O
encoding	O
M	B-protein
-	I-protein
protein	I-protein
,	O
a	O
structural	O
protein	O
of	O
sarcomeric	O
myofibrils	O
,	O
was	O
determined	O
.	O

Pigmentary	O
rhythms	O
as	O
indicators	O
of	O
neurosecretion	O
.	O

Deadenylation	O
and	O
decay	O
of	O
beta	B-protein
-	I-protein
globin	I-protein
mRNA	I-protein
in	O
K562	O
cells	O
is	O
extraordinarily	O
slow	O
compared	O
with	O
NIH	O
3T3	O
cells	O
,	O
suggesting	O
that	O
the	O
increased	O
stability	O
gained	O
by	O
beta	B-protein
-	I-protein
globin	I-protein
mRNA	I-protein
in	O
K562	O
cells	O
is	O
mainly	O
controlled	O
at	O
the	O
deadenylation	O
step	O
.	O

Role	O
of	O
NH	O
(	O
2	O
)	O
-	O
and	O
COOH	O
-	O
terminal	O
domains	O
of	O
the	O
P	B-protein
protein	I-protein
of	O
human	O
parainfluenza	O
virus	O
type	O
3	O
in	O
transcription	O
and	O
replication	O
.	O

Otte	O
,	O
Mol	O
.	O

Ste18p	B-protein
was	O
targeted	O
to	O
the	O
plasma	O
membrane	O
even	O
in	O
the	O
absence	O
of	O
prenylation	O
or	O
thioacylation	O
.	O

81	O
milk	O
samples	O
collected	O
from	O
35	O
donors	O
3	O
days	O
to	O
7	O
months	O
after	O
delivery	O
were	O
examined	O
for	O
the	O
occurrence	O
of	O
cytomegalovirus	O
(	O
CMV	O
)	O
.	O

A	O
novel	O
gene	O
designated	O
cmr	B-protein
,	O
which	O
mapped	O
to	O
18	O
.	O
8	O
min	O
of	O
the	O
Escherichia	O
coli	O
K	O
-	O
12	O
genome	O
,	O
was	O
shown	O
to	O
mediate	O
resistance	O
to	O
chloramphenicol	O
when	O
it	O
was	O
expressed	O
from	O
a	O
multicopy	O
vector	O
.	O

Neither	O
the	O
reaction	O
of	O
monosaccharides	O
nor	O
the	O
disaccharides	O
with	O
beta	O
-	O
alanine	O
resulted	O
in	O
the	O
formation	O
of	O
maltol	O
.	O

Transplantation	O
of	O
kidneys	O
of	O
juvenile	O
donors	O
in	O
adult	O
recipients	O
.	O

The	O
role	O
of	O
saliva	O
in	O
sour	O
taste	O
perception	O
was	O
investigated	O
in	O
a	O
series	O
of	O
4	O
experiments	O
.	O

Ventral	O
rhinotomy	O
is	O
no	O
more	O
difficult	O
than	O
dorsal	O
rhinotomy	O
,	O
has	O
less	O
patient	O
morbidity	O
and	O
fewer	O
postoperative	O
complications	O
,	O
and	O
is	O
more	O
cosmetically	O
acceptable	O
.	O

The	O
financial	O
impact	O
of	O
childhood	O
asthma	O
has	O
not	O
been	O
assessed	O
since	O
Vance	O
and	O
Taylor	O
reported	O
their	O
data	O
in	O
Annals	O
of	O
Allergy	O
13	O
years	O
ago	O
.	O

Primary	O
infection	O
is	O
usually	O
managed	O
conservatively	O
.	O

In	O
addition	O
to	O
DNA	O
-	O
protein	O
interactions	O
,	O
protein	O
-	O
protein	O
interactions	O
with	O
partner	O
proteins	O
often	O
play	O
major	O
roles	O
in	O
targeting	O
ETS	B-protein
-	I-protein
domain	I-protein
proteins	I-protein
to	O
specific	O
promoters	O
.	O

Alignment	O
of	O
the	O
selected	O
sequences	O
allowed	O
us	O
to	O
predict	O
a	O
consensus	O
sequence	O
for	O
binding	O
of	O
the	O
individual	O
homodimeric	O
Rel	B-protein
-	I-protein
related	I-protein
proteins	I-protein
,	O
and	O
DNA	O
-	O
protein	O
binding	O
analysis	O
of	O
the	O
selected	O
DNA	O
sequences	O
revealed	O
sequence	O
specificity	O
of	O
the	O
proteins	O
.	O

In	O
diethyl	O
ether	O
solution	O
the	O
main	O
peak	O
is	O
that	O
of	O
2	O
-	O
benzylidenamio	O
-	O
1	O
-	O
phenylpropane	O
,	O
which	O
has	O
a	O
retention	O
time	O
of	O
23	O
,	O
2	O
minutes	O
under	O
the	O
condition	O
delineated	O
.	O

Area	O
under	O
the	O
drug	O
concentration	O
-	O
time	O
curves	O
(	O
AUC0	O
-	O
24	O
hr	O
)	O
for	O
MTX	O
were	O
2379	O
and	O
3534	O
ng	O
*	O
hr	O
/	O
ml	O
from	O
PG	O
-	O
2	O
.	O
5	O
%	O
Azone	O
and	O
PG	O
-	O
7	O
.	O
5	O
%	O
Azone	O
systems	O
respectively	O
.	O

From	O
S3	O
(	O
CBF	O
:	O
79	O
-	O
60	O
%	O
)	O
to	O
S5	O
(	O
CBF	O
:	O
39	O
-	O
0	O
%	O
)	O
,	O
%	O
WTh	O
,	O
1	O
/	O
TPC	O
and	O
1	O
/	O
T	O
were	O
significantly	O
decreased	O
from	O
those	O
of	O
the	O
control	O
levels	O
(	O
all	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

One	O
complex	O
appears	O
to	O
be	O
ubiquitous	O
but	O
enriched	O
in	O
lymphoid	O
cells	O
and	O
represents	O
the	O
binding	O
of	O
a	O
potentially	O
novel	O
factor	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
approximately	O
50	O
kDa	O
.	O

With	O
a	O
view	O
to	O
identifying	O
other	O
important	O
U14	B-protein
interactions	O
,	O
a	O
stem	O
-	O
loop	O
domain	O
required	O
for	O
activity	O
of	O
Saccharomyces	B-protein
cerevisiae	I-protein
U14	I-protein
RNAs	I-protein
(	O
the	O
Y	B-protein
domain	I-protein
)	O
was	O
first	O
subjected	O
to	O
detailed	O
mutational	O
analysis	O
.	O

Pre	B-protein
-	I-protein
beta	I-protein
-	I-protein
1	I-protein
lipoprotein	I-protein
and	O
early	O
detection	O
of	O
risk	O
factors	O
for	O
coronary	O
heart	O
disease	O
.	O

We	O
conclude	O
that	O
androgenic	O
hormones	O
reduce	O
HDL	O
-	O
cholesterol	O
concentrations	O
and	O
the	O
HDL2	O
-	O
cholesterol	O
subfraction	O
,	O
possibly	O
by	O
enhancing	O
hepatic	B-protein
triglyceride	I-protein
lipase	I-protein
activity	O
.	O

Thus	O
,	O
prostacyclin	O
enhanced	O
the	O
autoregulative	O
property	O
of	O
the	O
inner	O
ear	O
vessels	O
.	O

In	O
addition	O
to	O
the	O
nine	O
and	O
51	O
terminal	O
amino	O
acid	O
forms	O
already	O
known	O
,	O
we	O
identified	O
a	O
third	O
with	O
43	O
terminal	O
amino	O
acids	O
predicted	O
to	O
encode	O
a	O
novel	O
RET	B-protein
protein	I-protein
isoform	I-protein
.	O

Embryo	O
coculture	O
system	O
may	O
contribute	O
to	O
understand	O
the	O
mechanisms	O
underlying	O
the	O
decrease	O
of	O
fertility	O
with	O
aging	O
.	O

METHODS	O
:	O
The	O
responses	O
of	O
a	O
31	O
-	O
year	O
-	O
old	O
woman	O
with	O
complex	O
regional	O
pain	O
syndrome	O
type	O
I	O
(	O
reflex	O
sympathetic	O
dystrophy	O
)	O
to	O
a	O
thermal	O
grill	O
were	O
evaluated	O
before	O
and	O
after	O
stellate	O
ganglion	O
block	O
.	O

Ultrastructure	O
of	O
the	O
tumor	O
in	O
1	O
patient	O
in	O
whom	O
transurethral	O
resection	O
was	O
performed	O
2	O
weeks	O
after	O
alum	O
irrigation	O
revealed	O
well	O
preserved	O
nuclear	O
chromatin	O
,	O
thus	O
,	O
suggesting	O
that	O
whatever	O
changes	O
occur	O
after	O
alum	O
irrigation	O
are	O
short	O
-	O
lived	O
.	O

In	O
addition	O
,	O
we	O
sought	O
to	O
test	O
the	O
hypothesis	O
that	O
,	O
when	O
equal	O
volumes	O
are	O
administered	O
intrathecally	O
,	O
significant	O
differences	O
exist	O
in	O
the	O
potential	O
to	O
three	O
commonly	O
used	O
anesthetic	O
solutions	O
to	O
induce	O
sensory	O
impairment	O
.	O

It	O
is	O
concluded	O
that	O
CT	O
should	O
be	O
routinely	O
employed	O
in	O
patients	O
with	O
N1	O
-	O
N3	O
neck	O
disease	O
to	O
determine	O
the	O
proper	O
electron	O
-	O
energy	O
prescription	O
.	O

The	O
management	O
of	O
the	O
`	O
`	O
chronic	O
'	O
'	O
patient	O
.	O

In	O
agreement	O
with	O
this	O
southern	O
blotting	O
of	O
mouse	O
DNA	O
with	O
SmN	B-protein
probes	O
reveals	O
bands	O
,	O
additional	O
to	O
those	O
derived	O
from	O
the	O
pseudogene	O
,	O
which	O
are	O
characteristic	O
of	O
an	O
intron	O
-	O
containing	O
SmN	B-protein
gene	I-protein
.	O

Interestingly	O
,	O
disruption	O
of	O
the	O
VPS34	B-protein
locus	I-protein
resulted	O
in	O
a	O
temperature	O
-	O
sensitive	O
growth	O
defect	O
,	O
indicating	O
that	O
the	O
VPS34	B-protein
gene	I-protein
is	O
essential	O
for	O
vegetative	O
growth	O
only	O
at	O
elevated	O
growth	O
temperatures	O
.	O

Regulation	O
of	O
the	O
alpha	B-protein
inhibin	I-protein
gene	I-protein
by	O
cyclic	O
adenosine	O
3	O
'	O
,	O
5	O
'	O
-	O
monophosphate	O
after	O
transfection	O
into	O
rat	O
granulosa	O
cells	O
.	O

Multiparity	O
had	O
a	O
protective	O
effect	O
with	O
0	O
.	O
66	O
less	O
risk	O
(	O
95	O
%	O
CI	O
0	O
.	O
44	O
-	O
0	O
.	O
99	O
)	O
.	O

Renal	O
pathology	O
and	O
long	O
-	O
term	O
outcome	O
in	O
childhood	O
SLE	O
.	O

Amino	O
acid	O
sequence	O
comparisons	O
of	O
the	O
E74A	B-protein
protein	I-protein
reveal	O
a	O
highly	O
conserved	O
C	O
-	O
terminal	O
region	O
that	O
is	O
rich	O
in	O
basic	O
amino	O
acid	O
residues	O
and	O
which	O
has	O
been	O
proposed	O
to	O
possess	O
sequence	O
-	O
specific	O
DNA	O
binding	O
activity	O
.	O

Alkoxymetgyl	O
-	O
3	O
,	O
4	O
-	O
dimethylpyridinium	O
chlorides	O
were	O
synthetized	O
by	O
reacting	O
3	O
,	O
4	O
-	O
dimethylpyridine	O
with	O
chloromethyl	O
alkyl	O
ethers	O
,	O
while	O
1	O
-	O
ethyloxymethyl	O
-	O
3	O
-	O
alkylthiomethylimidazolium	O
chlorides	O
were	O
obtained	O
in	O
reactions	O
of	O
1	O
-	O
ethyloxymethylimidazol	O
with	O
chloromethyl	O
alkyl	O
sulfides	O
.	O

Thirty	O
-	O
five	O
patients	O
were	O
included	O
.	O

Polyglactin	O
910	O
suture	O
absorption	O
and	O
the	O
role	O
of	O
cellular	O
enzymes	O
.	O

A	O
human	O
cytoplasmic	O
signaling	O
protein	O
has	O
been	O
cloned	O
that	O
possesses	O
the	O
same	O
structural	O
arrangement	O
of	O
SH3	B-protein
-	I-protein
SH2	I-protein
-	I-protein
SH3	I-protein
domains	I-protein
as	O
Grb2	B-protein
.	O

The	O
transcription	O
initiation	O
site	O
was	O
determined	O
to	O
occur	O
66	O
bp	O
upstream	O
of	O
the	O
initiating	O
Met	O
.	O

The	O
importance	O
of	O
these	O
sites	O
for	O
transcriptional	O
activation	O
was	O
studied	O
by	O
site	O
-	O
directed	O
mutagenesis	O
followed	O
by	O
promoter	O
function	O
analysis	O
of	O
the	O
mutants	O
with	O
a	O
chloramphenicol	B-protein
acetyltransferase	I-protein
reporter	I-protein
system	O
.	O

After	O
selection	O
and	O
conversion	O
to	O
adipocytes	O
,	O
the	O
level	O
of	O
EGFR	B-protein
expression	O
was	O
retained	O
in	O
infectant	O
adipocytes	O
(	O
150	O
,	O
000	O
and	O
250	O
,	O
000	O
/	O
cell	O
,	O
respectively	O
)	O
,	O
but	O
not	O
in	O
the	O
parental	O
3T3	O
-	O
L1	O
adipocytes	O
(	O
<	O
5000	O
/	O
cell	O
)	O
.	O

CONCLUSIONS	O
:	O
Serum	B-protein
prolactin	I-protein
concentrations	O
show	O
age	O
related	O
variations	O
in	O
presumably	O
fertile	O
men	O
.	O

There	O
is	O
a	O
national	O
effort	O
to	O
begin	O
to	O
ask	O
all	O
female	O
patients	O
about	O
family	O
violence	O
.	O

In	O
addition	O
,	O
we	O
found	O
differences	O
in	O
the	O
binding	O
of	O
nuclear	O
factors	O
from	O
shoots	O
versus	O
from	O
roots	O
,	O
in	O
agreement	O
with	O
the	O
different	O
activities	O
of	O
the	O
promoter	O
in	O
these	O
two	O
organs	O
.	O

(	O
3	O
)	O
.	O

Interestingly	O
,	O
this	O
activation	O
occurred	O
only	O
when	O
the	O
regions	O
were	O
cloned	O
in	O
the	O
same	O
relative	O
orientation	O
in	O
which	O
they	O
exist	O
on	O
wild	O
-	O
type	O
pCF10	O
.	O

Exon	O
-	O
intron	O
junctions	O
in	O
the	O
human	O
and	O
rat	B-protein
AdoMet	I-protein
decarboxylase	I-protein
genes	I-protein
were	O
in	O
identical	O
positions	O
except	O
that	O
exons	O
6	O
and	O
7	O
of	O
the	O
human	O
gene	O
formed	O
a	O
single	O
exon	O
in	O
the	O
rat	O
gene	O
.	O

Multiresistant	O
strains	O
isolated	O
from	O
humans	O
in	O
enteral	O
toxico	O
-	O
infections	O
kill	O
orally	O
infected	O
mice	O
more	O
frequently	O
than	O
strains	O
isolated	O
in	O
hospital	O
infections	O
.	O

Pharmacodynamic	O
studies	O
on	O
the	O
cardiovascular	O
system	O
of	O
spontaneously	O
hypertensive	O
rats	O
.	O

Is	O
clopidogrel	O
superior	O
to	O
aspirin	O
in	O
secondary	O
prevention	O
of	O
vascular	O
disease	O
?	O
The	O
cornerstone	O
in	O
clinical	O
evidence	O
of	O
the	O
relative	O
efficacy	O
of	O
thienopyridines	O
(	O
clopidogrel	O
,	O
ticlopidine	O
)	O
versus	O
aspirin	O
in	O
the	O
secondary	O
prevention	O
of	O
vascular	O
disease	O
is	O
the	O
Clopidogrel	O
versus	O
Aspirin	O
in	O
Patients	O
at	O
Risk	O
of	O
Ischaemic	O
Events	O
trial	O
.	O

The	O
N	O
-	O
terminal	O
sequence	O
of	O
one	O
hydrophilic	O
peptide	O
of	O
the	O
FeS	B-protein
protein	I-protein
has	O
been	O
also	O
obtained	O
confirming	O
the	O
fbcF	B-protein
reading	O
frame	O
.	O

The	O
mutant	O
protein	O
is	O
present	O
at	O
levels	O
slightly	O
greater	O
than	O
wild	O
-	O
type	O
,	O
but	O
exhibits	O
the	O
same	O
tissue	O
distribution	O
as	O
wild	O
-	O
type	O
protein	O
,	O
and	O
has	O
approximately	O
normal	O
affinity	O
for	O
known	O
target	O
sequences	O
(	O
though	O
no	O
DNA	O
targets	O
identified	O
to	O
date	O
require	O
the	O
first	O
cut	O
repeat	O
for	O
binding	O
)	O
.	O

13	O
men	O
with	O
a	O
history	O
of	O
recurrent	O
genital	O
herpes	O
simplex	O
virus	O
type	O
2	O
(	O
HSV	O
-	O
2	O
)	O
infection	O
were	O
followed	O
daily	O
for	O
4	O
weeks	O
with	O
samples	O
taken	O
from	O
the	O
urethra	O
for	O
virus	O
isolation	O
.	O

Furthermore	O
,	O
DNA	O
-	O
bound	O
LAZ3	B-protein
/	I-protein
BCL6	I-protein
recruits	O
SMRT	B-protein
in	O
vivo	O
,	O
and	O
both	O
overexpressed	O
proteins	O
completely	O
colocalize	O
in	O
nuclear	O
dots	O
.	O

Such	O
an	O
hemoglobin	B-protein
solution	O
was	O
shown	O
to	O
exhibit	O
a	O
high	O
affinity	O
for	O
oxygen	O
and	O
a	O
low	O
Bohr	O
effect	O
(	O
assessed	O
from	O
the	O
delta	O
log	O
Po2	O
/	O
delta	O
pH	O
ratio	O
)	O
.	O

The	O
latent	O
periods	O
from	O
the	O
antral	O
exclusion	O
to	O
the	O
occurrence	O
of	O
anastomotic	O
ulcers	O
after	O
a	O
subtotal	O
gastrectomy	O
with	O
Billroth	O
'	O
s	O
type	O
II	O
reconstruction	O
varied	O
from	O
a	O
few	O
days	O
to	O
19	O
years	O
,	O
with	O
an	O
average	O
of	O
2	O
.	O
8	O
years	O
.	O

Consistent	O
with	O
this	O
interpretation	O
,	O
recombinant	B-protein
CREB	I-protein
and	O
activating	O
transcription	O
factor	O
proteins	O
bound	O
the	O
junB	B-protein
CRE	I-protein
-	I-protein
like	I-protein
site	I-protein
,	O
but	O
did	O
not	O
interact	O
with	O
a	O
mutant	B-protein
CRE	I-protein
-	I-protein
like	I-protein
site	I-protein
.	O

However	O
,	O
a	O
clear	O
difference	O
exists	O
between	O
myoblasts	O
and	O
10T1	O
/	O
2	O
cells	O
(	O
and	O
other	O
non	O
-	O
muscle	O
cell	O
types	O
)	O
in	O
the	O
chromatin	O
structure	O
of	O
the	O
chromosomal	O
myoD	B-protein
core	I-protein
enhancer	I-protein
,	O
suggesting	O
that	O
the	O
myoD	B-protein
enhancer	I-protein
is	O
repressed	O
by	O
epigenetic	O
mechanisms	O
in	O
10T1	O
/	O
2	O
cells	O
.	O

Mammalian	B-protein
Ras	I-protein
GTPase	I-protein
-	I-protein
activating	I-protein
protein	I-protein
(	O
GAP	B-protein
)	O
,	O
p120	B-protein
Ras	I-protein
-	I-protein
GAP	I-protein
,	O
has	O
been	O
implicated	O
as	O
both	O
a	O
downregulator	O
and	O
effector	O
of	O
Ras	B-protein
proteins	I-protein
,	O
but	O
its	O
precise	O
role	O
in	O
Ras	O
-	O
mediated	O
signal	O
transduction	O
pathways	O
is	O
unclear	O
.	O

A	O
further	O
analysis	O
has	O
been	O
performed	O
using	O
the	O
series	O
of	O
maximum	O
intensity	O
for	O
fixed	O
duration	O
(	O
1	O
,	O
3	O
,	O
6	O
,	O
12	O
,	O
24	O
hrs	O
)	O
and	O
annual	O
daily	O
maxima	O
.	O

ACE	B-protein
-	I-protein
2	I-protein
has	O
a	O
hydrophobic	O
C	O
terminus	O
of	O
H	O
type	O
.	O

The	O
coexpression	O
of	O
full	O
-	O
length	O
expression	O
constructs	O
for	O
both	O
DBP	B-protein
and	O
hepatic	B-protein
leukemia	I-protein
factor	I-protein
resulted	O
in	O
a	O
dramatic	O
increase	O
in	O
activation	O
mediated	O
by	O
the	O
GAL4	B-protein
-	I-protein
DBP	I-protein
fusion	I-protein
proteins	I-protein
,	O
suggesting	O
the	O
involvement	O
of	O
a	O
regulated	O
coactivator	O
in	O
this	O
process	O
.	O

Rheumatoid	B-protein
factor	I-protein
and	O
antinuclear	O
antibody	O
tests	O
were	O
frequently	O
positive	O
,	O
and	O
reactions	O
to	O
gold	O
therapy	O
were	O
more	O
frequent	O
than	O
in	O
other	O
rheumatoid	O
populations	O
.	O

Moreover	O
,	O
moderate	O
overexpression	O
of	O
Chk1	B-protein
suppresses	O
the	O
phenotypes	O
of	O
cut5	B-protein
and	O
crb2	B-protein
mutants	I-protein
.	O

Solution	O
structure	O
of	O
the	O
IRF	B-protein
-	I-protein
2	I-protein
DNA	I-protein
-	I-protein
binding	I-protein
domain	O
:	O
a	O
novel	O
subgroup	O
of	O
the	O
winged	B-protein
helix	I-protein
-	I-protein
turn	I-protein
-	I-protein
helix	I-protein
family	I-protein
.	O

Vancomycin	O
data	O
were	O
analyzed	O
according	O
to	O
a	O
one	O
-	O
compartment	O
open	O
model	O
with	O
use	O
of	O
NONMEM	O
population	O
pharmacokinetic	O
software	O
.	O

Addition	O
of	O
synthetic	O
tyrosine	O
-	O
phosphorylated	O
peptides	O
derived	O
from	O
betac	O
cytoplasmic	O
tyrosines	O
prior	O
to	O
GM	B-protein
-	I-protein
CSF	I-protein
stimulation	O
inhibited	O
the	O
in	O
vitro	O
activation	O
of	O
STAT5	B-protein
.	O

Thus	O
,	O
while	O
the	O
folds	O
of	O
all	O
Myb	B-protein
domains	I-protein
resemble	O
each	O
other	O
closely	O
,	O
the	O
function	O
of	O
each	O
Myb	B-protein
domain	I-protein
depends	O
on	O
the	O
amino	O
acid	O
residues	O
that	O
are	O
located	O
on	O
the	O
surface	O
of	O
each	O
protein	O
.	O

The	O
Ets	B-protein
-	I-protein
1	I-protein
binding	I-protein
site	I-protein
was	O
localized	O
to	O
a	O
17	O
-	O
base	O
pair	O
(	O
bp	O
)	O
region	O
from	O
the	O
3	O
'	O
end	O
of	O
T	B-protein
alpha	I-protein
2	I-protein
.	O

Northern	O
blot	O
analyses	O
show	O
that	O
the	O
hBub1	B-protein
mRNA	I-protein
level	O
is	O
abundantly	O
expressed	O
in	O
tissues	O
or	O
cells	O
with	O
a	O
high	O
mitotic	O
index	O
.	O

Sak	B-protein
kinase	I-protein
gene	O
structure	O
and	O
transcriptional	O
regulation	O
.	O

Two	O
mutants	O
,	O
each	O
representative	O
of	O
a	O
separate	O
pet	O
complementation	O
group	O
,	O
have	O
been	O
analyzed	O
.	O

The	O
cloned	O
genes	O
were	O
identified	O
in	O
genetic	O
libraries	O
by	O
hybridization	O
screening	O
using	O
four	O
deoxyoligonucleotide	O
probes	O
which	O
corresponded	O
to	O
the	O
partial	O
amino	O
acid	O
sequence	O
of	O
the	O
purified	O
enzyme	O
.	O

The	O
objectives	O
of	O
the	O
present	O
study	O
were	O
to	O
evaluate	O
the	O
effects	O
of	O
adding	O
Equex	O
to	O
a	O
TRIS	O
-	O
extender	O
,	O
diluting	O
the	O
semen	O
in	O
1	O
or	O
2	O
steps	O
,	O
freezing	O
according	O
to	O
2	O
methods	O
,	O
thawing	O
at	O
2	O
rates	O
,	O
and	O
the	O
interactions	O
between	O
these	O
treatments	O
,	O
on	O
the	O
post	O
-	O
thaw	O
survival	O
of	O
dog	O
spermatozoa	O
at	O
38	O
degrees	O
C	O
.	O

The	O
region	O
that	O
imparts	O
inducibility	O
by	O
IL	B-protein
-	I-protein
1	I-protein
or	O
TNF	B-protein
(	O
positions	O
-	O
165	O
to	O
-	O
58	O
)	O
contains	O
potential	O
binding	O
sites	O
for	O
IRF	B-protein
-	I-protein
1	I-protein
and	I-protein
-	I-protein
2	I-protein
,	O
AP	B-protein
-	I-protein
1	I-protein
,	O
and	O
NF	B-protein
-	I-protein
IL	I-protein
-	I-protein
6	I-protein
.	O

To	O
avoid	O
complications	O
,	O
accurate	O
quantitative	O
analysis	O
of	O
NO	O
and	O
NO2	O
is	O
necessary	O
during	O
this	O
therapy	O
.	O

RNA	O
of	O
GBV	O
-	O
C	O
was	O
detected	O
in	O
14	O
(	O
18	O
%	O
)	O
patients	O
before	O
BMT	O
.	O

In	O
addition	O
,	O
we	O
also	O
constructed	O
and	O
expressed	O
chimeric	O
fusion	O
protein	O
that	O
contains	O
HIV	B-protein
-	I-protein
2	I-protein
gag	I-protein
with	O
V3	B-protein
domains	I-protein
of	O
HIV	O
-	O
1IIIB	O
,	O
HIV	O
-	O
1MN	O
,	O
HIV	O
-	O
1SF2	O
and	O
HIV	O
-	O
1RF	O
.	O

These	O
observations	O
link	O
actin	B-protein
plaque	O
assembly	O
to	O
increased	O
cell	O
substrate	O
adhesion	O
.	O

These	O
mutations	O
are	O
localized	O
in	O
the	O
same	O
region	O
where	O
the	O
HSV	B-protein
transactivator	I-protein
VP16	I-protein
binds	O
,	O
but	O
did	O
not	O
coincide	O
with	O
the	O
VP16	B-protein
contacts	O
.	O

Statokinesimetric	O
recording	O
in	O
Huntington	O
choreas	O
.	O

An	O
experiment	O
was	O
carried	O
on	O
133	O
grown	O
up	O
fowls	O
and	O
broilers	O
from	O
4	O
industrial	O
farms	O
,	O
vaccinated	O
with	O
spray	O
lento	O
and	O
mesogenic	O
vaccines	O
for	O
straining	O
the	O
immunity	O
against	O
pseodopest	O
through	O
RIHA	O
and	O
provoking	O
pseudoplague	O
with	O
a	O
pathogenic	O
virus	O
.	O

The	O
results	O
showed	O
that	O
the	O
sensitivity	O
of	O
the	O
3	O
given	O
guinea	O
pig	O
strains	O
was	O
comparable	O
.	O

Plasma	B-protein
thromboxane	I-protein
B2	I-protein
levels	O
in	O
the	O
older	O
group	O
were	O
about	O
double	O
those	O
in	O
younger	O
piglets	O
.	O

However	O
,	O
one	O
3	O
'	O
splice	O
site	O
,	O
located	O
at	O
nucleotide	O
(	O
nt	O
)	O
3225	O
,	O
is	O
used	O
for	O
the	O
processing	O
of	O
most	O
BPV	O
-	O
1	O
pre	O
-	O
mRNAs	O
in	O
BPV	O
-	O
1	O
-	O
transformed	O
C127	O
cells	O
and	O
at	O
early	O
to	O
intermediate	O
times	O
in	O
productively	O
infected	O
warts	O
.	O

Particles	O
resembling	O
microbodies	O
in	O
normal	O
and	O
neoplastic	O
perianal	O
glands	O
of	O
dogs	O
.	O

The	O
differential	O
diagnosis	O
of	O
both	O
affections	O
is	O
based	O
on	O
the	O
clinical	O
course	O
,	O
sialography	O
and	O
CT	O
examination	O
which	O
along	O
with	O
modern	O
ATB	O
treatment	O
significantly	O
modify	O
hitherto	O
used	O
surgical	O
therapy	O
.	O

The	O
pre	O
-	O
and	O
postoperative	O
haemoglobin	B-protein
concentrations	O
in	O
the	O
autologous	O
group	O
were	O
lower	O
by	O
15	O
and	O
10	O
g	O
/	O
L	O
,	O
respectively	O
,	O
after	O
primary	O
THR	O
and	O
by	O
10	O
g	O
/	O
L	O
in	O
both	O
instances	O
after	O
revision	O
THR	O
.	O

The	O
same	O
IL	O
-	O
4	O
-	O
inducible	O
reporter	O
gene	O
is	O
also	O
synergistically	O
activated	O
by	O
the	O
endogenous	B-protein
Stat6	I-protein
and	O
NF	B-protein
-	I-protein
kappaB	I-protein
proteins	I-protein
in	O
IL	O
-	O
4	O
-	O
stimulated	O
I	O
.	O
29mu	O
B	O
lymphoma	O
cells	O
.	O

The	O
odds	O
ratio	O
for	O
CHD	O
was	O
1	O
.	O
21	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
.	O
84	O
-	O
1	O
.	O
75	O
)	O
given	O
a	O
positive	O
serostatus	O
of	O
specific	O
IgG	B-protein
antibodies	O
after	O
adjustment	O
for	O
covariates	O
.	O

This	O
report	O
presents	O
state	O
-	O
specific	O
MMRs	O
for	O
1987	O
-	O
1996	O
,	O
focusing	O
on	O
persistent	O
disparities	O
in	O
maternal	O
mortality	O
between	O
black	O
and	O
white	O
women	O
.	O

The	O
results	O
indicate	O
considerable	O
flexibility	O
in	O
the	O
spacing	O
between	O
DH	O
regulatory	O
sites	O
.	O

The	O
utility	O
of	O
such	O
analyses	O
in	O
the	O
design	O
of	O
ceramic	O
/	O
substrate	O
bilayer	O
systems	O
for	O
optimal	O
resistance	O
to	O
lifetime	O
-	O
threatening	O
damage	O
is	O
discussed	O
.	O

Each	O
parent	O
interacted	O
with	O
their	O
4	O
-	O
or	O
5	O
-	O
year	O
-	O
old	O
son	O
or	O
daughter	O
in	O
each	O
of	O
two	O
conversations	O
-	O
-	O
unstructured	O
(	O
social	O
conversation	O
)	O
and	O
structured	O
(	O
task	O
activity	O
)	O
.	O

The	O
Saccharomyces	B-protein
cerevisiae	I-protein
14DM	I-protein
gene	I-protein
,	O
encoding	O
cytochrome	B-protein
P450	I-protein
lanosterol	I-protein
14	I-protein
alpha	I-protein
-	I-protein
demethylase	I-protein
(	O
14DM	B-protein
)	O
,	O
was	O
overexpressed	O
in	O
various	O
S	O
.	O
cerevisiae	O
strains	O
under	O
the	O
control	O
of	O
three	O
strong	O
heterologous	O
yeast	O
transcription	O
promoters	O
(	O
pADC1	B-protein
,	O
pGPD	B-protein
,	O
pPHO5	B-protein
)	O
and	O
under	O
the	O
control	O
of	O
its	O
own	O
promoter	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
the	O
APRE	B-protein
is	O
a	O
cytokine	O
[	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
-	I-protein
alpha	I-protein
(	O
TNFalpha	B-protein
)	O
]	O
-	O
inducible	O
enhancer	O
by	O
binding	O
the	O
heterodimeric	B-protein
nuclear	I-protein
factor	I-protein
-	I-protein
kappaB	I-protein
(	O
NF	B-protein
-	I-protein
kappaB	I-protein
)	O
complex	O
Rel	B-protein
A	I-protein
x	O
NF	B-protein
-	I-protein
kappaB1	I-protein
.	O

Marked	O
thrombocytopenia	O
,	O
depletion	O
of	O
serum	B-protein
fibrinogen	I-protein
and	O
prolonged	O
prothrombin	B-protein
and	O
activated	O
partial	O
thromboplastin	B-protein
time	O
,	O
were	O
recorded	O
at	O
5	O
to	O
10	O
and	O
30	O
to	O
40	O
minutes	O
after	O
intravenous	O
envenomation	O
.	O

Stroop	O
interference	O
:	O
aging	O
effects	O
assessed	O
with	O
the	O
Stroop	O
Color	O
-	O
Word	O
Test	O
.	O

The	O
partial	O
categories	O
of	O
the	O
SIP	O
that	O
were	O
more	O
affected	O
were	O
work	O
,	O
recreation	O
and	O
pastimes	O
,	O
home	O
management	O
,	O
and	O
sleep	O
and	O
rest	O
.	O

Patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
showed	O
a	O
relatively	O
high	O
incidence	O
to	O
psychoses	O
during	O
drug	O
treatment	O
(	O
51	O
.	O
47	O
%	O
)	O
.	O

Thus	O
,	O
patients	O
with	O
metastatic	O
melanoma	O
are	O
not	O
tolerant	O
to	O
gp100	B-protein
Ag	I-protein
based	O
on	O
the	O
detection	O
of	O
CD8	B-protein
+	I-protein
T	O
cells	O
specific	O
for	O
multiple	O
HLA	O
-	O
A	O
*	O
0201	O
-	O
restricted	O
,	O
gp100	O
-	O
derived	O
epitopes	O
.	O

Despite	O
the	O
small	O
number	O
of	O
patients	O
,	O
on	O
the	O
basis	O
of	O
this	O
report	O
,	O
we	O
can	O
confirm	O
that	O
1	O
.	O
5	O
MU	O
/	O
day	O
of	O
alpha	B-protein
-	I-protein
IFN	I-protein
is	O
an	O
adequate	O
treatment	O
for	O
patients	O
with	O
hairy	O
cell	O
leukemia	O
.	O

All	O
subjects	O
were	O
submitted	O
to	O
ECG	O
and	O
arterial	O
blood	O
pressure	O
determination	O
and	O
were	O
assayed	O
for	O
TSH	B-protein
,	O
thyroid	O
hormone	O
,	O
PRL	B-protein
,	O
glucose	O
,	O
creatinine	O
,	O
nitrogen	O
,	O
glutamine	B-protein
transaminase	I-protein
,	O
cholesterol	O
and	O
triglycerides	O
plasma	O
levels	O
before	O
therapy	O
(	O
T0	O
)	O
,	O
after	O
30	O
treatment	O
days	O
(	O
T30	O
)	O
and	O
after	O
a	O
15	O
days	O
washout	O
(	O
T45	O
)	O
.	O

This	O
may	O
explain	O
in	O
part	O
a	O
secular	O
trend	O
towards	O
reduced	O
birthweight	O
for	O
gestation	O
in	O
preterm	O
infants	O
.	O

The	O
utilities	O
measured	O
in	O
our	O
study	O
can	O
be	O
applied	O
directly	O
to	O
quality	O
-	O
of	O
-	O
life	O
determinations	O
in	O
clinical	O
trials	O
of	O
adjuvant	O
IFN	B-protein
alpha	I-protein
-	I-protein
2b	I-protein
to	O
measure	O
the	O
net	O
benefit	O
of	O
therapy	O
.	O

Effect	O
of	O
castration	O
on	O
pituitary	B-protein
and	I-protein
serum	I-protein
LH	I-protein
and	O
FSH	B-protein
in	O
testosterone	O
-	O
sterilized	O
rats	O
.	O

PURPOSE	O
:	O
The	O
role	O
interleukin	B-protein
-	I-protein
6	I-protein
(	O
IL	B-protein
-	I-protein
6	I-protein
)	O
in	O
the	O
treatment	O
of	O
congenital	O
thrombocytopenias	O
is	O
unknown	O
.	O

Truncated	B-protein
ICSBP	I-protein
lacking	O
the	O
first	O
33	O
amino	O
-	O
terminal	O
amino	O
acids	O
fails	O
to	O
bind	O
to	O
the	O
ICS	O
,	O
indicating	O
that	O
at	O
least	O
part	O
of	O
the	O
DNA	O
binding	O
domain	O
is	O
located	O
within	O
the	O
well	O
conserved	O
amino	O
terminus	O
.	O

DNA	O
sequence	O
and	O
functions	O
of	O
the	O
actVI	B-protein
region	I-protein
of	O
the	O
actinorhodin	B-protein
biosynthetic	I-protein
gene	I-protein
cluster	I-protein
of	I-protein
Streptomyces	I-protein
coelicolor	I-protein
A3	I-protein
(	I-protein
2	I-protein
)	I-protein
.	O

Leads	O
from	O
the	O
MMWR	O
.	O

Using	O
a	O
natural	O
dominant	O
negative	O
for	O
AP	B-protein
-	I-protein
1	I-protein
transcriptional	O
activity	O
in	O
ROS	O
17	O
/	O
2	O
.	O
8	O
cells	O
,	O
we	O
then	O
showed	O
that	O
AP	B-protein
-	I-protein
1	I-protein
transcription	I-protein
factors	I-protein
mediated	O
TGF	O
-	O
beta1	O
-	O
and	O
BMP	O
-	O
2	O
-	O
regulated	O
expression	O
of	O
the	O
(	B-protein
alpha1	I-protein
)	I-protein
collagen	I-protein
I	I-protein
gene	I-protein
as	O
well	O
as	O
TGF	O
-	O
beta1	O
-	O
regulated	O
expression	O
of	O
the	O
parathyroid	B-protein
hormone	I-protein
(	I-protein
PTH	I-protein
)	I-protein
/	I-protein
PTH	I-protein
-	I-protein
related	I-protein
peptide	I-protein
(	I-protein
PTHrP	I-protein
)	I-protein
receptor	I-protein
.	O

The	O
physicians	O
in	O
charge	O
of	O
all	O
patients	O
with	O
evidence	O
of	O
acute	O
Q	O
fever	O
(	O
seroconversion	O
and	O
/	O
or	O
presence	O
of	O
IgM	B-protein
)	O
or	O
chronic	O
Q	O
fever	O
(	O
prolonged	O
disease	O
and	O
/	O
or	O
IgG	B-protein
antibody	I-protein
titer	O
to	O
phase	O
I	O
of	O
Coxiella	O
burnetii	O
>	O
or	O
=	O
800	O
)	O
were	O
asked	O
to	O
complete	O
a	O
questionnaire	O
,	O
which	O
was	O
computerized	O
.	O

Furthermore	O
,	O
the	O
wide	O
distribution	O
of	O
the	O
GFP	B-protein
-	I-protein
POLO	I-protein
protein	I-protein
to	O
all	O
compartments	O
of	O
the	O
mitotic	O
apparatus	O
provides	O
a	O
valuable	O
tool	O
for	O
future	O
studies	O
on	O
cell	O
cycle	O
during	O
development	O
.	O

Liquid	O
chromatography	O
with	O
amperometric	O
detection	O
(	O
LC	O
/	O
AD	O
)	O
is	O
used	O
to	O
determine	O
fluazifop	O
acid	O
produced	O
from	O
the	O
metabolism	O
or	O
base	O
hydrolysis	O
of	O
fluazifop	O
-	O
butyl	O
in	O
soybeans	O
and	O
soybean	O
oil	O
.	O

Sequence	O
analysis	O
reveals	O
that	O
the	O
newly	O
discovered	O
oasA2	B-protein
gene	I-protein
represents	O
a	O
pseudogene	O
that	O
is	O
still	O
transcribed	O
,	O
but	O
is	O
not	O
functionally	O
translated	O
.	O

Our	O
findings	O
provide	O
the	O
first	O
evidence	O
that	O
the	O
function	O
of	O
WT1	B-protein
can	O
be	O
modulated	O
by	O
its	O
phosphorylation	O
in	O
vivo	O
.	O

Genomic	O
Southern	O
blot	O
analysis	O
of	O
rat	B-protein
EFIA	I-protein
(	O
gene	O
encoding	O
enhancer	B-protein
factor	I-protein
I	I-protein
subunit	I-protein
A	I-protein
)	O
reveals	O
a	O
complex	O
band	O
pattern	O
when	O
cDNA	O
subfragment	O
probes	O
are	O
used	O
.	O

To	O
study	O
the	O
sensitivity	O
of	O
some	O
central	O
brain	O
structures	O
to	O
the	O
action	O
of	O
an	O
electromagnetic	O
field	O
of	O
decimeter	O
waves	O
(	O
EMF	O
of	O
DW	O
)	O
a	O
dynamic	O
investigation	O
of	O
single	O
unit	O
activity	O
was	O
undertaken	O
.	O

In	O
all	O
other	O
cases	O
,	O
vestibular	O
neurectomy	O
or	O
chemical	O
vestibular	O
labyrinthectomy	O
,	O
by	O
means	O
of	O
intratympanic	O
low	O
concentration	O
gentamicin	O
(	O
20	O
mg	O
/	O
mL	O
)	O
,	O
are	O
indicated	O
.	O

This	O
region	O
constitutes	O
the	O
DNA	O
-	O
binding	O
domain	O
with	O
basic	O
-	O
helix	O
-	O
loop	O
-	O
helix	O
and	O
leucine	O
-	O
zipper	O
motifs	O
,	O
features	O
common	O
to	O
the	O
myc	B-protein
-	I-protein
related	I-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O

Consistent	O
with	O
this	O
model	O
,	O
a	O
synthetic	O
construct	O
containing	O
three	O
tandem	O
copies	O
of	O
the	O
native	O
LDL	B-protein
receptor	I-protein
SREBP	I-protein
site	O
linked	O
to	O
a	O
single	O
Sp1	B-protein
site	I-protein
was	O
also	O
significantly	O
activated	O
in	O
a	O
buttonhead	O
-	O
independent	O
fashion	O
.	O

Heat	O
-	O
labile	O
-	O
like	O
enterotoxin	B-protein
(	O
LT	B-protein
)	O
was	O
produced	O
by	O
26	O
of	O
42	O
stool	O
isolates	O
(	O
62	O
%	O
)	O
,	O
while	O
only	O
1	O
of	O
the	O
42	O
isolates	O
(	O
2	O
%	O
)	O
produced	O
enterotoxinlike	O
activity	O
in	O
suckling	O
mice	O
;	O
65	O
%	O
of	O
the	O
cytotoxin	O
-	O
producing	O
strains	O
also	O
produced	O
an	O
LT	O
-	O
like	O
material	O
.	O

Oncogenic	B-protein
Raf	I-protein
-	I-protein
1	I-protein
activates	O
p70	B-protein
S6	I-protein
kinase	I-protein
via	O
a	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
-	O
independent	O
pathway	O
.	O

Long	O
-	O
latency	O
:	O
locked	O
units	O
responded	O
to	O
shocks	O
with	O
little	O
jitter	O
and	O
long	O
latency	O
(	O
4	O
-	O
11	O
ms	O
)	O
.	O

CCAAT	B-protein
/	I-protein
enhancer	I-protein
-	I-protein
binding	I-protein
protein	I-protein
isoforms	I-protein
beta	I-protein
and	I-protein
delta	I-protein
are	O
expressed	O
in	O
mammary	O
epithelial	O
cells	O
and	O
bind	O
to	O
multiple	O
sites	O
in	O
the	O
beta	B-protein
-	I-protein
casein	I-protein
gene	I-protein
promoter	I-protein
.	O

The	O
pel	B-protein
gene	I-protein
from	O
an	O
Amycolata	O
sp	O
.	O
encoding	O
a	O
pectate	B-protein
lyase	I-protein
(	O
EC	B-protein
4	I-protein
.	I-protein
2	I-protein
.	I-protein
2	I-protein
.	I-protein
2	I-protein
)	O
was	O
isolated	O
by	O
activity	O
screening	O
a	O
genomic	O
DNA	O
library	O
in	O
Streptomyces	O
lividans	O
TK24	O
.	O

The	O
high	O
sequence	O
homology	O
,	O
similar	O
genomic	O
structure	O
,	O
and	O
identical	O
chromosomal	O
loci	O
of	O
hKID	B-protein
,	O
MIP	B-protein
,	O
and	O
AQP	B-protein
-	I-protein
2	I-protein
suggest	O
a	O
MIP	B-protein
family	I-protein
gene	I-protein
cluster	I-protein
at	O
chromosome	O
locus	O
12q13	O
.	O

As	O
is	O
deduced	O
from	O
the	O
nucleotide	O
sequence	O
of	O
the	O
cDNA	O
,	O
CBS	B-protein
-	I-protein
1	I-protein
contains	O
an	O
open	O
reading	O
frame	O
consisting	O
of	O
182	O
amino	O
acids	O
,	O
with	O
a	O
molecular	O
weight	O
of	O
19	O
.	O
5kDa	O
.	O

The	O
mean	O
duration	O
of	O
pain	O
relief	O
was	O
4	O
-	O
6	O
weeks	O
.	O

The	O
serine	B-protein
-	I-protein
threonine	I-protein
kinase	I-protein
gene	I-protein
is	O
likely	O
functional	O
,	O
whereas	O
the	O
zinc	O
finger	O
motif	O
is	O
likely	O
nonfunctional	O
.	O

Genetic	O
abnormalities	O
that	O
could	O
lead	O
to	O
mutagenesis	O
include	O
chromosomal	O
abnormalities	O
and	O
single	O
-	O
gene	O
mutations	O
.	O

Based	O
on	O
these	O
results	O
,	O
a	O
new	O
model	O
for	O
the	O
regulation	O
of	O
nif	B-protein
/	I-protein
fix	I-protein
gene	I-protein
expression	O
in	O
A	O
.	O
caulinodans	O
is	O
proposed	O
.	O

However	O
,	O
a	O
>	O
10	O
-	O
fold	O
increase	O
in	O
ERK3	B-protein
activity	O
in	O
each	O
PKC	B-protein
beta	I-protein
transfectant	O
was	O
shown	O
by	O
immunoprecipitation	O
with	O
anti	B-protein
-	I-protein
ERK3	I-protein
monoclonal	I-protein
antibody	I-protein
followed	O
by	O
either	O
immune	O
complex	O
kinase	O
assay	O
or	O
by	O
in	O
gel	O
kinase	B-protein
assay	O
.	O

The	O
residue	O
functions	O
,	O
R	O
(	O
t	O
)	O
,	O
for	O
C	O
-	O
11	O
CPZ	O
and	O
In	O
-	O
113m	O
transferrin	O
were	O
plotted	O
against	O
time	O
for	O
selected	O
areas	O
of	O
interest	O
,	O
and	O
the	O
CPZ	O
area	O
-	O
weighted	O
extraction	O
,	O
E	O
(	O
t	O
)	O
,	O
was	O
computed	O
for	O
the	O
same	O
areas	O
every	O
250	O
msec	O
using	O
the	O
formula	O
:	O
E	O
(	O
t	O
)	O
=	O
[	O
RT	O
(	O
t	O
)	O
-	O
RR	O
(	O
t	O
)	O
]	O
/	O
[	O
1	O
-	O
RR	O
(	O
t	O
)	O
]	O
,	O
where	O
RT	O
and	O
RR	O
are	O
the	O
normalized	O
residue	O
functions	O
for	O
CPZ	O
and	O
transferrin	B-protein
,	O
respectively	O
.	O

In	O
contrast	O
,	O
deletion	O
of	O
the	O
upstream	O
portion	O
of	O
the	O
delta	B-protein
promoter	I-protein
led	O
to	O
a	O
10	O
fold	O
decrease	O
in	O
expression	O
.	O

The	O
clinical	O
stage	O
was	O
I	O
(	O
T1N0M0	O
)	O
,	O
and	O
S2	O
sleeve	O
segmentectomy	O
with	O
lymph	O
node	O
dissection	O
(	O
R	O
2	O
b	O
)	O
was	O
performed	O
.	O

Expression	O
of	O
ME31B	B-protein
cDNA	I-protein
in	O
S	O
.	O
pombe	O
suppresses	O
the	O
ste13	B-protein
mutation	O
.	O

Transduction	O
of	O
the	O
human	O
leukemic	O
cell	O
line	O
K562	O
showed	O
that	O
viral	O
MRP1	O
-	O
PG13	O
supernatants	O
routinely	O
transfer	O
the	O
MRP1	B-protein
gene	I-protein
to	O
approximately	O
35	O
%	O
of	O
target	O
K562	O
cells	O
,	O
of	O
which	O
at	O
least	O
one	O
third	O
are	O
capable	O
of	O
proliferating	O
in	O
the	O
presence	O
of	O
otherwise	O
toxic	O
concentrations	O
of	O
etoposide	O
.	O

33	O
out	O
of	O
90	O
neurons	O
of	O
the	O
cat	O
medial	O
geniculate	O
body	O
revealed	O
the	O
selectivity	O
of	O
their	O
afterdischarges	O
to	O
movement	O
of	O
sound	O
when	O
velocity	O
of	O
the	O
movement	O
changed	O
from	O
30	O
to	O
180	O
deg	O
/	O
s	O
.	O

Ampicillin	O
(	O
AMP	O
)	O
alone	O
or	O
with	O
an	O
aminoglycoside	O
(	O
AMI	O
)	O
was	O
the	O
treatment	O
in	O
9	O
and	O
16	O
cases	O
,	O
respectively	O
.	O

These	O
results	O
were	O
compared	O
with	O
those	O
obtained	O
in	O
-	O
D	O
mothers	O
and	O
pups	O
,	O
after	O
giving	O
the	O
mothers	O
an	O
oral	O
supplement	O
(	O
10	O
i	O
.	O
u	O
.	O
vitamin	O
D3	O
/	O
day	O
)	O
during	O
the	O
period	O
of	O
lactation	O
(	O
20	O
days	O
)	O
.	O

The	O
most	O
common	O
risk	O
factor	O
reported	O
for	O
both	O
recent	O
and	O
all	O
other	O
hepatitis	O
C	O
cases	O
was	O
a	O
history	O
of	O
injecting	O
drug	O
use	O
,	O
although	O
the	O
proportion	O
of	O
cases	O
with	O
that	O
history	O
was	O
different	O
in	O
NT	O
from	O
ACT	O
and	O
Queensland	O
.	O

ATF1	B-protein
transcription	O
is	O
negatively	O
regulated	O
by	O
unsaturated	O
fatty	O
acids	O
and	O
oxygen	O
.	O

Rats	O
treated	O
with	O
8	O
-	O
OH	O
-	O
DPAT	O
were	O
not	O
impaired	O
in	O
their	O
ability	O
to	O
learn	O
a	O
visual	O
discrimination	O
in	O
a	O
water	O
maze	O
.	O

An	O
immunologic	O
test	O
using	O
stomach	B-protein
and	I-protein
tumor	I-protein
antigens	I-protein
for	O
screening	O
of	O
those	O
at	O
high	O
risk	O
for	O
stomach	O
cancer	O
is	O
suggested	O
.	O

Independent	O
protrudor	O
muscle	O
stimulation	O
increased	O
VI	O
,	O
max	O
(	O
peak	O
increase	O
61	O
%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
did	O
not	O
change	O
Pcrit	O
,	O
and	O
decreased	O
Rn	O
(	O
peak	O
decrease	O
of	O
41	O
%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
individual	O
subunits	O
of	O
Ku	B-protein
have	O
been	O
difficult	O
to	O
isolate	O
from	O
human	O
cells	O
without	O
denaturation	O
and	O
attempts	O
to	O
produce	O
functional	B-protein
recombinant	I-protein
Ku	I-protein
have	O
been	O
largely	O
unsuccessful	O
.	O

Role	O
of	O
the	O
infectious	O
-	O
disease	O
specialist	O
of	O
a	O
polyclinic	O
in	O
reducing	O
the	O
incidence	O
of	O
communicable	O
diseases	O
.	O

CONCLUSIONS	O
:	O
Valproate	O
appears	O
to	O
inhibit	O
the	O
glucuronidation	O
of	O
carbamazepine	O
-	O
10	O
,	O
11	O
-	O
trans	O
-	O
diol	O
,	O
and	O
probably	O
also	O
inhibits	O
the	O
conversion	O
of	O
carbamazepine	O
-	O
10	O
,	O
11	O
-	O
epoxide	O
to	O
this	O
trans	O
-	O
diol	O
derivative	O
,	O
rather	O
than	O
simply	O
inhibiting	O
the	O
latter	O
reaction	O
only	O
.	O

IgE	B-protein
levels	O
showed	O
higher	O
values	O
compared	O
to	O
normal	O
individuals	O
and	O
IgE	B-protein
levels	O
were	O
higher	O
in	O
children	O
groups	O
than	O
in	O
adults	O
regardless	O
of	O
the	O
intensity	O
of	O
infection	O
.	O

Removal	O
of	O
the	O
GST	B-protein
domain	I-protein
from	O
GST	B-protein
-	I-protein
Tax	I-protein
by	O
thrombin	B-protein
restores	O
Tax	B-protein
'	I-protein
s	I-protein
ability	O
to	O
assemble	O
a	O
ternary	O
Tax	B-protein
-	I-protein
CREB	I-protein
-	I-protein
21	I-protein
-	I-protein
bp	I-protein
-	I-protein
repeat	I-protein
complex	I-protein
.	I-protein
(	I-protein
ABSTRACT	I-protein
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Saccharomyces	O
cerevisiae	O
contains	O
a	O
genetically	O
and	O
biochemically	O
proven	O
CAK	B-protein
gene	I-protein
,	O
CAK1	B-protein
,	O
that	O
encodes	O
a	O
monomeric	O
44	B-protein
-	I-protein
kDa	I-protein
Cak1p	I-protein
protein	I-protein
unrelated	O
to	O
Cdk7	B-protein
.	O

R	O
.	O

The	O
majority	O
of	O
the	O
cases	O
with	O
0	O
-	O
I	O
or	O
0	O
-	O
III	O
components	O
were	O
sm	O
.	O
cancer	O
.	O

TAR	B-protein
and	O
Sp1	O
-	O
independent	O
transactivation	O
of	O
HIV	B-protein
long	I-protein
terminal	I-protein
repeat	I-protein
by	O
the	O
Tat	B-protein
protein	I-protein
in	O
the	O
presence	O
of	O
human	B-protein
cytomegalovirus	I-protein
IE1	I-protein
/	I-protein
IE2	I-protein
.	O

Ectopic	O
expression	O
of	O
d	B-protein
-	I-protein
axin	I-protein
inhibited	O
Wingless	B-protein
signaling	O
.	O

In	O
11	O
eyes	O
that	O
had	O
been	O
selected	O
at	O
random	O
10	O
micrograms	O
of	O
recombinant	B-protein
tissue	I-protein
plasminogen	I-protein
activator	I-protein
were	O
injected	O
midvitreally	O
24	O
hrs	O
later	O
.	O

Our	O
study	O
cohorts	O
consisted	O
of	O
15	O
patients	O
who	O
received	O
SC	O
rIL	B-protein
-	I-protein
2	I-protein
at	O
doses	O
of	O
4	O
.	O
8	O
-	O
14	O
.	O
4	O
million	O
IU	O
/	O
m2	O
/	O
day	O
on	O
5	O
days	O
per	O
week	O
for	O
a	O
total	O
of	O
8	O
weeks	O
,	O
20	O
patients	O
who	O
received	O
rIFN	B-protein
-	I-protein
alpha	I-protein
2b	I-protein
at	O
3	O
.	O
0	O
-	O
6	O
.	O
0	O
million	O
U	O
/	O
m2	O
/	O
day	O
thrice	O
weekly	O
for	O
a	O
total	O
of	O
6	O
weeks	O
,	O
and	O
72	O
patients	O
who	O
were	O
given	O
SC	O
rIFN	B-protein
-	I-protein
alpha	I-protein
2b	I-protein
at	O
6	O
.	O
0	O
million	O
U	O
/	O
m2	O
/	O
day	O
thrice	O
weekly	O
plus	O
SC	O
rIL	B-protein
-	I-protein
2	I-protein
at	O
14	O
.	O
4	O
-	O
18	O
.	O
0	O
million	O
IU	O
/	O
m2	O
/	O
day	O
on	O
days	O
1	O
and	O
2	O
,	O
followed	O
by	O
4	O
.	O
8	O
million	O
IU	O
/	O
m2	O
/	O
day	O
,	O
5	O
days	O
per	O
week	O
for	O
6	O
consecutive	O
weeks	O
.	O

Personal	O
satisfaction	O
in	O
nursing	O
:	O
an	O
encounter	O
with	O
extremely	O
hostile	O
patients	O
.	O

Determination	O
of	O
three	O
-	O
dimensional	O
imaging	O
properties	O
of	O
a	O
light	O
microscope	O
system	O
.	O

Mutation	O
of	O
the	O
P450BM	B-protein
-	I-protein
3	I-protein
Barbie	I-protein
box	I-protein
significantly	O
increased	O
the	O
expression	O
of	O
both	O
P450BM	B-protein
-	I-protein
3	I-protein
and	O
Bm3P1	B-protein
(	O
another	O
small	O
gene	O
located	O
upstream	O
of	O
the	O
P450BM	B-protein
-	I-protein
3	I-protein
gene	I-protein
that	O
encodes	O
a	O
second	O
putative	O
regulatory	O
protein	O
)	O
in	O
response	O
to	O
pentobarbital	O
induction	O
but	O
left	O
the	O
basal	O
levels	O
unaffected	O
.	O

This	O
function	O
requires	O
not	O
only	O
the	O
kinase	O
domain	O
of	O
Csk	B-protein
,	O
but	O
also	O
its	O
Src	B-protein
homology	I-protein
3	I-protein
(	O
SH3	B-protein
)	O
and	O
SH2	B-protein
regions	O
.	O

Association	O
of	O
human	B-protein
Pur	I-protein
alpha	I-protein
with	O
the	O
retinoblastoma	B-protein
protein	I-protein
,	O
Rb	B-protein
,	O
regulates	O
binding	O
to	O
the	O
single	O
-	O
stranded	O
DNA	O
Pur	B-protein
alpha	I-protein
recognition	I-protein
element	I-protein
.	O

A	O
cDNA	O
encoding	O
a	O
putative	O
RNA	B-protein
and	I-protein
/	I-protein
or	I-protein
DNA	I-protein
helicase	I-protein
has	O
been	O
isolated	O
from	O
Arabidopsis	O
thaliana	O
cDNA	O
libraries	O
.	O

By	O
analyzing	O
5	O
'	O
-	O
deletion	O
insulin	B-protein
promoter	I-protein
-	I-protein
reporter	I-protein
constructs	I-protein
in	O
transient	O
transfections	O
of	O
clonal	O
INS	B-protein
-	I-protein
1	I-protein
beta	O
-	O
cells	O
,	O
we	O
located	O
activating	O
Hh	B-protein
-	I-protein
responsive	I-protein
regions	I-protein
within	O
the	O
rat	B-protein
insulin	I-protein
I	I-protein
promoter	I-protein
that	O
include	O
the	O
glucose	B-protein
-	I-protein
response	I-protein
elements	I-protein
Far	I-protein
(	O
E2	B-protein
)	O
and	O
Flat	B-protein
(	O
A2	B-protein
/	I-protein
A3	I-protein
)	O
.	O

Human	O
and	O
Chinese	B-protein
hamster	I-protein
S14	I-protein
protein	I-protein
sequences	I-protein
deduced	O
from	O
the	O
cDNAs	O
are	O
identical	O
.	O

These	O
transcripts	O
contain	O
the	O
5	O
'	O
ends	O
of	O
mature	O
UbCRBP	B-protein
mRNAs	I-protein
;	O
extend	O
through	O
UbCRBP	B-protein
,	O
across	O
the	O
intergenic	O
region	O
,	O
and	O
a	O
significant	O
distance	O
3	O
'	O
into	O
the	O
enolase	B-protein
gene	I-protein
.	O

Courses	O
were	O
repeated	O
every	O
four	O
weeks	O
.	O

Medicare	O
SNF	O
benefits	O
revised	O
-	O
-	O
again	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
graft	O
survival	O
between	O
groups	O
with	O
early	O
graft	O
function	O
(	O
EGF	O
)	O
and	O
DGF	O
,	O
either	O
in	O
first	O
transplantations	O
or	O
retransplantations	O
.	O

One	O
of	O
the	O
conserved	O
RNA	O
subdomains	O
,	O
designated	O
P3	B-protein
,	O
has	O
previously	O
been	O
shown	O
to	O
be	O
required	O
for	O
nucleolar	O
localization	O
.	O

Consistent	O
with	O
effects	O
on	O
STAT	B-protein
activation	O
,	O
altered	O
SHP	B-protein
-	I-protein
1	I-protein
expression	O
also	O
affected	O
EGF	O
-	O
induced	O
activation	O
of	O
the	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
pathway	I-protein
;	O
expression	O
of	O
SHP	B-protein
-	I-protein
1	I-protein
-	I-protein
(	I-protein
Cys	I-protein
-	I-protein
-	I-protein
>	I-protein
Ser	I-protein
)	I-protein
inhibited	O
activity	O
of	O
MEK	B-protein
by	O
approximately	O
25	O
%	O
,	O
whereas	O
expression	O
of	O
SHP	B-protein
-	I-protein
1	I-protein
resulted	O
in	O
a	O
approximately	O
25	O
%	O
increase	O
.	O

Myasthenia	O
gravis	O
is	O
an	O
autoimmune	O
disease	O
resulting	O
from	O
the	O
production	O
of	O
antibodies	O
against	O
the	O
ACh	B-protein
receptors	I-protein
of	O
the	O
neuromuscular	O
synapse	O
.	O

Raf	B-protein
is	O
a	O
key	O
serine	B-protein
-	I-protein
threonine	I-protein
protein	I-protein
kinase	I-protein
which	O
participates	O
in	O
the	O
transmission	O
of	O
growth	O
,	O
anti	O
-	O
apoptotic	O
and	O
differentiation	O
messages	O
.	O

Terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
nick	O
end	O
labeling	O
assays	O
revealed	O
that	O
hormonal	O
activation	O
of	O
the	O
PAX3	B-protein
repressors	I-protein
induced	O
extensive	O
apoptosis	O
that	O
correlated	O
with	O
down	O
-	O
regulation	O
of	O
BCL	B-protein
-	I-protein
X	I-protein
(	I-protein
L	I-protein
)	I-protein
expression	O
.	O

It	O
was	O
found	O
that	O
the	O
disappearance	O
of	O
BOD5	O
and	O
NH3	O
-	O
N	O
could	O
be	O
approximated	O
using	O
first	O
-	O
order	O
kinetics	O
,	O
but	O
the	O
kinetics	O
of	O
TP	O
removal	O
were	O
unclear	O
.	O

Differential	O
sensitivity	O
of	O
the	O
MMPI	O
-	O
2	O
depression	O
scales	O
and	O
subscales	O
.	O

The	O
two	O
most	O
recent	O
patients	O
(	O
35	O
and	O
132	O
days	O
)	O
received	O
only	O
oral	O
dipyridamole	O
(	O
75	O
mg	O
X	O
3	O
/	O
day	O
)	O
and	O
aspirin	O
(	O
80	O
mg	O
/	O
day	O
)	O
after	O
the	O
early	O
recovery	O
period	O
(	O
four	O
-	O
six	O
days	O
)	O
,	O
resulting	O
in	O
normal	O
prothrombin	B-protein
and	O
partial	O
thromboplastin	B-protein
times	O
.	O

Neuromyelitis	O
optica	O
(	O
Devic	O
'	O
s	O
syndrome	O
)	O
:	O
not	O
always	O
multiple	O
sclerosis	O
.	O

Cytological	O
data	O
suggest	O
that	O
the	O
transgenes	O
associate	O
with	O
a	O
nucleolus	O
.	O

Aeromonas	O
salmonicida	O
possesses	O
two	O
genes	O
encoding	O
homologs	O
of	O
the	O
major	B-protein
outer	I-protein
membrane	I-protein
protein	I-protein
,	O
OmpA	B-protein
.	O

PO2	O
measurements	O
using	O
a	O
double	O
barrelled	O
recess	O
type	O
microelectrodes	O
were	O
measured	O
in	O
the	O
optic	O
nerve	O
head	O
of	O
miniature	O
pigs	O
in	O
normoxia	O
and	O
hyperoxia	O
.	O

Since	O
AP	B-protein
-	I-protein
1	I-protein
is	O
an	O
important	O
mediator	O
of	O
tumor	O
promoter	O
action	O
,	O
these	O
findings	O
may	O
explain	O
the	O
anti	O
-	O
tumor	O
-	O
promoting	O
activity	O
of	O
phenolic	O
antioxidants	O
.	O

Interestingly	O
,	O
virions	O
also	O
contained	O
smaller	O
proteins	O
that	O
reacted	O
with	O
antibodies	O
specific	O
for	O
the	O
accessory	O
proteins	O
as	O
well	O
as	O
SN	B-protein
and	O
CAT	B-protein
fusion	I-protein
partners	O
.	O

Propagation	O
and	O
hormone	O
production	O
by	O
human	O
normal	O
and	O
malignant	O
trophoblast	O
in	O
rats	O
.	O

These	O
results	O
demonstrate	O
that	O
tip	B-protein
acts	O
at	O
an	O
early	O
stage	O
of	O
the	O
T	O
-	O
cell	O
signal	O
transduction	O
cascade	O
by	O
associating	O
with	O
Lck	B-protein
and	O
downregulating	O
Lck	O
-	O
mediated	O
activation	O
.	O

For	O
comparison	O
conventional	O
heparin	O
was	O
used	O
during	O
18	O
dialyses	O
in	O
the	O
same	O
patients	O
.	O

F	B-protein
-	I-protein
box	I-protein
proteins	I-protein
are	O
receptors	O
that	O
recruit	O
phosphorylated	O
substrates	O
to	O
the	O
SCF	B-protein
ubiquitin	I-protein
-	I-protein
ligase	I-protein
complex	I-protein
.	O

ERV1	B-protein
is	O
involved	O
in	O
the	O
cell	O
-	O
division	O
cycle	O
and	O
the	O
maintenance	O
of	O
mitochondrial	O
genomes	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

This	O
protein	O
,	O
designated	O
p532	B-protein
based	O
on	O
its	O
predicted	O
molecular	O
weight	O
(	O
EMBO	O
J	O
15	O
:	O
5738	O
,	O
1996	O
)	O
,	O
contains	O
multiple	O
structural	O
domains	O
including	O
two	O
regions	O
of	O
seven	O
internal	O
repeats	O
highly	O
related	O
to	O
the	O
cell	O
cycle	O
regulator	O
RCC1	B-protein
,	O
a	O
guanine	B-protein
nucleotide	I-protein
exchange	I-protein
factor	I-protein
for	O
the	O
small	B-protein
GTP	I-protein
-	I-protein
binding	I-protein
protein	I-protein
Ran	I-protein
,	O
seven	O
beta	O
-	O
repeat	O
domains	O
characteristic	O
of	O
the	O
beta	O
subunit	O
of	O
heterotrimeric	B-protein
G	I-protein
proteins	I-protein
,	O
three	O
putative	O
SH3	B-protein
binding	I-protein
sites	I-protein
,	O
a	O
putative	O
leucine	O
-	O
zipper	O
and	O
a	O
carboxy	B-protein
-	I-protein
terminal	I-protein
HECT	I-protein
domain	I-protein
characteristic	O
of	O
E3	B-protein
ubiquitin	I-protein
-	I-protein
protein	I-protein
ligases	I-protein
.	O

For	O
wild	O
type	O
MutT	B-protein
and	O
its	O
E53D	B-protein
and	O
E44D	B-protein
mutants	I-protein
,	O
plots	O
of	O
log	O
(	O
k	O
(	O
cat	O
)	O
)	O
versus	O
pH	O
exhibited	O
a	O
limiting	O
slope	O
of	O
1	O
on	O
the	O
ascending	O
limb	O
and	O
then	O
a	O
hump	O
,	O
i	O
.	O
e	O
.	O
,	O
a	O
sharply	O
defined	O
maximum	O
near	O
pH	O
8	O
followed	O
by	O
a	O
plateau	O
,	O
yielding	O
apparent	O
pK	O
(	O
a	O
)	O
values	O
of	O
7	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
3	O
and	O
8	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
4	O
for	O
an	O
essential	O
base	O
and	O
a	O
nonessential	O
acid	O
catalyst	O
,	O
respectively	O
,	O
in	O
the	O
active	O
quaternary	O
MutT	B-protein
-	I-protein
Mg	I-protein
(	I-protein
2	I-protein
+	I-protein
)	I-protein
-	I-protein
dGTP	I-protein
-	I-protein
Mg	I-protein
(	I-protein
2	I-protein
+	I-protein
)	I-protein
complex	I-protein
.	O

Arm	O
function	O
tests	O
.	O

Groups	O
dicker	O
for	O
price	O
breaks	O
as	O
anesthetic	O
gas	O
goes	O
multi	O
-	O
source	O
.	O

Research	O
on	O
ethylene	O
glycol	O
and	O
diethylene	O
glycol	O
for	O
carcinogenic	O
effects	O
.	O

Cytogenetic	O
studies	O
were	O
performed	O
in	O
lymphocytes	O
from	O
hospital	O
workers	O
exposed	O
to	O
low	O
doses	O
of	O
radiation	O
(	O
1	O
.	O
6	O
-	O
42	O
.	O
71	O
mSv	O
)	O
.	O

According	O
to	O
the	O
laboratory	O
results	O
,	O
the	O
application	O
of	O
neural	O
network	O
can	O
solve	O
the	O
problem	O
successfully	O
.	O

Upon	O
induction	O
of	O
SOS	O
,	O
viability	O
increased	O
2	O
-	O
6	O
-	O
fold	O
.	O

Processing	O
,	O
secretion	O
,	O
and	O
immunoreactivity	O
of	O
carboxy	B-protein
terminally	I-protein
truncated	I-protein
dengue	I-protein
-	I-protein
2	I-protein
virus	I-protein
envelope	I-protein
proteins	I-protein
expressed	O
in	O
insect	O
cells	O
by	O
recombinant	O
baculoviruses	O
.	O

Similarly	O
,	O
supraventricular	O
tachycaydia	O
following	O
resuscitative	O
efforts	O
appeared	O
to	O
be	O
associated	O
with	O
a	O
negative	O
outcome	O
.	O

Abnormalities	O
of	O
plasma	B-protein
cholecystokinin	I-protein
were	O
observed	O
only	O
in	O
patients	O
with	O
delayed	O
gastric	O
emptying	O
.	O

Reaction	O
of	O
human	O
organism	O
to	O
exercise	O
.	O

In	O
sixteen	O
patients	O
with	O
moderate	O
essential	O
hypertension	O
the	O
effects	O
of	O
10	O
-	O
day	O
nifedipine	O
treatment	O
on	O
serum	O
uric	O
acid	O
and	O
renal	O
excretion	O
of	O
uric	O
acid	O
were	O
evaluated	O
.	O

To	O
characterize	O
the	O
O7	B-protein
-	I-protein
LPS	I-protein
region	I-protein
,	O
the	O
recombinant	O
cosmids	O
pJHCV31	O
and	O
pJHCV32	O
were	O
mutagenized	O
by	O
transposon	O
mutagenesis	O
with	O
Tn3HoHo1	B-protein
,	O
which	O
carries	O
a	O
promoterless	O
lac	B-protein
operon	I-protein
and	O
can	O
therefore	O
generate	O
lacZ	B-protein
transcriptional	O
fusions	O
with	O
target	O
DNA	O
sequences	O
.	O

The	O
only	O
abundant	O
viral	O
transcript	O
expressed	O
during	O
latency	O
is	O
the	O
latency	B-protein
-	I-protein
related	I-protein
(	I-protein
LR	I-protein
)	I-protein
RNA	I-protein
.	O

The	O
influence	O
of	O
adrenergic	O
nerves	O
of	O
the	O
response	O
of	O
blood	O
vessels	O
in	O
the	O
rabbit	O
ear	O
to	O
2	B-protein
-	I-protein
-	I-protein
phenylalanine	I-protein
-	I-protein
8	I-protein
-	I-protein
lysine	I-protein
vasopressin	I-protein
(	O
Octapressin	B-protein
)	O
.	O

Following	O
conditioning	O
,	O
a	O
single	O
coat	O
of	O
adhesive	O
was	O
applied	O
and	O
light	O
-	O
cured	O
.	O

The	O
gene	O
pairs	O
psbB	B-protein
-	I-protein
psbT	I-protein
and	O
psbH	B-protein
-	I-protein
psbN	I-protein
are	O
cotranscribed	O
from	O
opposite	O
strands	O
.	O

About	O
20	O
kb	O
upstream	O
of	O
LAMB2	B-protein
we	O
found	O
a	O
gene	O
encoding	O
a	O
transcribed	O
,	O
non	O
-	O
processed	O
LAMB2	B-protein
-	I-protein
like	I-protein
pseudogene	I-protein
(	O
LAMB2L	B-protein
)	O
.	O

Site	B-protein
S	I-protein
-	I-protein
II	I-protein
also	O
spans	O
a	O
23	O
bp	O
sequence	O
containing	O
two	O
tandem	O
consensus	O
binding	O
sites	O
with	O
three	O
base	O
pair	O
mismatches	O
in	O
each	O
and	O
a	O
one	O
base	O
pair	O
deletion	O
.	O

FZD4	B-protein
is	O
homologous	O
to	O
FZD9	B-protein
and	O
FZD10	B-protein
,	O
and	O
overall	O
amino	O
acid	O
identity	O
is	O
as	O
follows	O
:	O
FZD4	B-protein
vs	O
FZD9	B-protein
,	O
51	O
.	O
6	O
%	O
;	O
FZD4	B-protein
vs	O
FZD10	B-protein
,	O
51	O
.	O
2	O
%	O
;	O
FZD9	B-protein
vs	O
FZD10	B-protein
,	O
65	O
.	O
7	O
%	O
.	O

The	O
mustard	B-protein
chloroplast	I-protein
gene	I-protein
rps16	I-protein
is	O
split	O
by	O
an	O
887	O
bp	O
group	O
II	O
(	O
or	O
III	O
)	O
intron	O
.	O

Armed	O
with	O
a	O
clear	O
understanding	O
of	O
the	O
pathophysiologic	O
pathways	O
that	O
may	O
cause	O
and	O
/	O
or	O
contribute	O
to	O
the	O
development	O
of	O
unconjugated	O
hyperbilirubinemia	O
and	O
the	O
associated	O
jaundice	O
,	O
the	O
practitioner	O
will	O
be	O
successful	O
in	O
helping	O
the	O
family	O
understand	O
their	O
child	O
'	O
s	O
illness	O
.	O

Twenty	O
-	O
five	O
patients	O
also	O
received	O
PET	O
examinations	O
during	O
the	O
staging	O
procedures	O
.	O

Reward	O
value	O
of	O
prosodic	O
features	O
of	O
language	O
for	O
autistic	O
,	O
mentally	O
retarded	O
,	O
and	O
normal	O
children	O
.	O

An	O
infectious	O
origin	O
should	O
always	O
be	O
excluded	O
since	O
specific	O
etiologic	O
therapy	O
may	O
be	O
implemented	O
.	O

We	O
have	O
mapped	O
the	O
human	B-protein
STAG3	I-protein
gene	I-protein
to	O
the	O
7q22	O
region	O
of	O
chromosome	O
7	O
;	O
six	O
human	B-protein
STAG3	I-protein
-	I-protein
related	I-protein
genes	I-protein
have	O
also	O
been	O
mapped	O
:	O
two	O
at	O
7q22	O
near	O
the	O
functional	O
gene	O
,	O
one	O
at	O
7q11	O
.	O
22	O
,	O
and	O
three	O
at	O
7q11	O
.	O
23	O
,	O
two	O
of	O
them	O
flanking	O
the	O
breakpoints	O
commonly	O
associated	O
with	O
the	O
Williams	B-protein
-	I-protein
Beuren	I-protein
syndrome	I-protein
(	I-protein
WBS	I-protein
)	I-protein
deletion	I-protein
.	O

Surprisingly	O
,	O
3	O
full	B-protein
-	I-protein
length	I-protein
murine	I-protein
survivin	I-protein
cDNA	I-protein
clones	O
were	O
isolated	O
,	O
predicting	O
the	O
existence	O
of	O
3	O
distinct	O
survivin	B-protein
proteins	I-protein
.	O

A	O
data	O
base	O
homology	O
search	O
revealed	O
that	O
the	O
predicted	O
ER1	B-protein
amino	O
acid	O
sequence	O
contains	O
three	O
regions	O
of	O
similarity	O
to	O
the	O
rat	O
and	O
human	O
proteins	O
encoded	O
by	O
the	O
metastasis	B-protein
-	I-protein
associated	I-protein
gene	I-protein
,	O
mta1	B-protein
,	O
and	O
two	O
regions	O
of	O
similarity	O
to	O
the	O
Caenorhabditis	O
elegans	O
sequence	O
that	O
is	O
similar	O
to	O
mta1	B-protein
.	O

Cross	O
-	O
linking	O
the	O
B	B-protein
cell	I-protein
Ag	I-protein
receptor	I-protein
(	O
BCR	B-protein
)	O
to	O
surface	B-protein
Fc	I-protein
receptors	I-protein
for	O
IgG	B-protein
(	O
Fc	B-protein
gamma	I-protein
R	I-protein
)	O
inhibits	O
G1	O
-	O
to	O
-	O
S	O
progression	O
;	O
the	O
mechanism	O
by	O
which	O
this	O
occurs	O
is	O
not	O
completely	O
known	O
.	O

The	O
DSF	O
regimen	O
appears	O
to	O
have	O
significant	O
activity	O
in	O
patients	O
who	O
have	O
metastatic	O
pancreatic	O
islet	O
-	O
cell	O
carcinoma	O
,	O
and	O
patient	O
tolerance	O
of	O
the	O
regimen	O
is	O
excellent	O
,	O
thus	O
warranting	O
further	O
investigation	O
.	O

A	O
comparative	O
study	O
by	O
holographic	O
interferometry	O
of	O
ten	O
porcine	O
bioprosthetic	O
valves	O
(	O
seven	O
Carpentier	O
-	O
Edwards	O
SAV	O
,	O
two	O
BioImplant	O
and	O
one	O
Valcor	O
)	O
with	O
five	O
human	O
aortic	O
valves	O
before	O
and	O
after	O
glutaraldehyde	O
treatment	O
is	O
presented	O
.	O

In	O
contrast	O
,	O
the	O
failure	O
of	O
the	O
QKTT	B-protein
motif	I-protein
and	O
TGN46	B-protein
cytoplasmic	O
tail	O
to	O
induce	O
steady	O
-	O
state	O
ER	O
localization	O
of	O
vesicular	B-protein
stomatitis	I-protein
virus	I-protein
glycoprotein	I-protein
(	O
VSVG	B-protein
)	O
chimeras	O
in	O
HeLa	O
and	O
NRK	O
cells	O
indicates	O
that	O
significant	O
differences	O
in	O
early	O
secretory	O
trafficking	O
also	O
exist	O
.	O

Two	O
episodes	O
of	O
peritonitis	O
occurred	O
while	O
the	O
patient	O
received	O
CAPD	O
(	O
1	O
episode	O
/	O
3	O
.	O
5	O
patient	O
-	O
months	O
)	O
.	O

Potential	O
translational	O
start	O
signals	O
are	O
upstream	O
of	O
ORF1	O
and	O
ORF2	O
.	O

The	O
recombinant	O
protein	O
was	O
purified	O
to	O
homogeneity	O
by	O
(	O
NH4	O
)	O
2SO4	O
-	O
precipitation	O
and	O
affinity	O
chromatography	O
on	O
5	O
'	O
AMP	O
-	O
Sepharose	O
.	O

Here	O
we	O
show	O
that	O
IIIa	O
pre	O
-	O
mRNA	O
splicing	O
is	O
activated	O
more	O
than	O
200	O
-	O
fold	O
in	O
nuclear	O
extracts	O
prepared	O
from	O
late	O
adenovirus	O
-	O
infected	O
cells	O
(	O
Ad	O
-	O
NE	O
)	O
compared	O
to	O
uninfected	O
HeLa	O
cell	O
nuclear	O
extracts	O
(	O
HeLa	O
-	O
NE	O
)	O
.	O

In	O
these	O
cells	O
,	O
ras	O
-	O
induced	O
transition	O
is	O
accompanied	O
by	O
a	O
strong	O
induction	O
of	O
AP	O
-	O
1	O
-	O
binding	O
activity	O
along	O
with	O
increased	O
expression	O
of	O
CD44	B-protein
mRNA	I-protein
and	O
protein	O
.	O

Structural	O
analysis	O
of	O
the	O
5	O
'	O
-	O
regulatory	O
region	O
reveals	O
that	O
the	O
c	B-protein
-	I-protein
met	I-protein
promoter	I-protein
lacks	O
TATA	O
or	O
CAAT	O
elements	O
but	O
has	O
an	O
extremely	O
high	O
G	O
-	O
C	O
content	O
and	O
multiple	O
Sp1	B-protein
binding	I-protein
sites	I-protein
.	O

In	O
the	O
last	O
case	O
,	O
both	O
hydroxychloroquine	O
,	O
carbamazepine	O
and	O
fluvoxamine	O
had	O
a	O
common	O
imputability	O
which	O
was	O
plausible	O
.	O

Perceptions	O
of	O
illness	O
intrusiveness	O
were	O
significantly	O
higher	O
when	O
both	O
muscle	O
cramp	O
and	O
headache	O
symptoms	O
occurred	O
during	O
one	O
or	O
more	O
assessment	O
intervals	O
as	O
compared	O
to	O
when	O
muscle	O
cramps	O
or	O
headaches	O
,	O
only	O
,	O
occurred	O
.	O

Neither	O
of	O
these	O
proteins	O
,	O
individually	O
or	O
as	O
a	O
pair	O
,	O
can	O
bind	O
the	O
alpha	B-protein
-	I-protein
globin	I-protein
3	I-protein
'	I-protein
UTR	I-protein
unless	O
they	O
are	O
complexed	O
with	O
the	O
remaining	O
non	O
-	O
poly	O
(	O
C	O
)	O
binding	O
proteins	O
of	O
the	O
alpha	B-protein
-	I-protein
complex	I-protein
.	O

This	O
is	O
the	O
first	O
report	O
that	O
an	O
in	O
vitro	O
-	O
synthesized	O
alphavirus	O
RNA	O
lacking	O
a	O
poly	O
(	O
A	O
)	O
tail	O
can	O
initiate	O
infection	O
and	O
produce	O
3	O
'	O
polyadenylated	O
viral	O
genome	O
in	O
vivo	O
.	O

Groups	O
of	O
ten	O
dependent	O
and	O
ten	O
saline	O
mice	O
were	O
singly	O
tested	O
in	O
both	O
light	O
and	O
dark	O
conditions	O
in	O
each	O
of	O
five	O
covered	O
cylinders	O
(	O
2	O
-	O
23	O
in	O
high	O
)	O
.	O

Mapping	O
of	O
the	O
DNA	O
binding	O
domain	O
of	O
the	O
copper	O
-	O
responsive	O
transcription	O
factor	O
Mac1	B-protein
from	I-protein
Saccharomyces	I-protein
cerevisiae	I-protein
.	O

Nitrogen	O
balance	O
was	O
compared	O
,	O
and	O
metabolic	O
complications	O
were	O
monitored	O
by	O
evaluating	O
BUN	O
,	O
serum	O
creatinine	O
,	O
creatinine	O
clearance	O
,	O
serum	O
CO2	O
,	O
SGOT	O
,	O
SGPT	O
,	O
serum	B-protein
LDH	I-protein
,	O
and	O
serum	B-protein
alkaline	I-protein
phosphatase	I-protein
.	O

The	O
drug	O
was	O
given	O
in	O
a	O
daily	O
oral	O
dose	O
of	O
0	O
.	O
5	O
g	O
/	O
m2	O
,	O
3	O
.	O
5	O
h	O
prior	O
to	O
each	O
radiation	O
treatment	O
.	O

Because	O
the	O
biosynthetic	O
pathway	O
to	O
the	O
vacuole	O
intersects	O
with	O
the	O
endocytic	O
pathway	O
,	O
internalization	O
of	O
a	O
bulk	O
membrane	O
endocytic	O
marker	O
FM	O
4	O
-	O
64	O
was	O
assayed	O
in	O
the	O
sop	B-protein
mutants	I-protein
.	O

RESULTS	O
:	O
256	O
Periods	O
of	O
TTP	O
or	O
PUNP	O
were	O
reported	O
by	O
men	O
and	O
174	O
by	O
women	O
.	O

The	O
remaining	O
80	O
patients	O
underwent	O
recordings	O
of	O
ECG	O
,	O
beat	O
-	O
to	O
-	O
beat	O
arterial	O
oxygen	O
saturation	O
(	O
SaO2	O
)	O
,	O
and	O
respiration	O
during	O
both	O
spontaneous	O
and	O
controlled	O
breathing	O
.	O

The	O
SH2	O
-	O
containing	O
adapter	O
protein	O
GRB10	B-protein
interacts	O
with	O
BCR	B-protein
-	I-protein
ABL	I-protein
.	O

Controlled	O
versus	O
uncontrolled	O
reperfusion	O
of	O
ischemic	O
myocardium	O
after	O
experimental	O
coronary	O
artery	O
occlusion	O
was	O
studied	O
to	O
determine	O
the	O
effect	O
on	O
regional	O
ventricular	O
wall	O
motion	O
and	O
associated	O
biochemical	O
alterations	O
.	O

No	O
somatic	O
mutations	O
were	O
found	O
in	O
any	O
of	O
the	O
samples	O
,	O
suggesting	O
that	O
ING1	B-protein
is	O
not	O
a	O
tumor	O
suppressor	O
gene	O
target	O
in	O
head	O
and	O
neck	O
cancer	O
.	O

The	O
report	O
highlights	O
the	O
possible	O
contribution	O
of	O
stress	O
factors	O
in	O
the	O
context	O
of	O
therapy	O
resistant	O
periodontal	O
disease	O
,	O
and	O
the	O
results	O
seem	O
to	O
be	O
understandable	O
within	O
the	O
context	O
of	O
a	O
stress	O
system	O
disorder	O
perspective	O
.	O

Four	O
putative	O
positive	O
cDNA	O
clones	O
were	O
isolated	O
,	O
and	O
the	O
largest	O
insert	O
(	O
pASB	B-protein
-	I-protein
1	I-protein
)	O
was	O
sequenced	O
in	O
both	O
orientations	O
.	O

DNA	O
-	O
protein	O
UV	O
cross	O
-	O
linking	O
studies	O
indicated	O
that	O
UHF	B-protein
-	I-protein
1	I-protein
has	O
an	O
electrophoretic	O
mobility	O
on	O
sodium	O
dodecyl	O
sulfate	O
-	O
acrylamide	O
gels	O
of	O
approximately	O
85	O
kDa	O
and	O
suggested	O
that	O
additional	O
proteins	O
,	O
specific	O
to	O
each	O
promoter	O
,	O
bind	O
to	O
each	O
site	O
.	O

In	O
myometrial	O
SMC	O
,	O
both	O
isoforms	O
of	O
the	O
progesterone	B-protein
receptor	I-protein
,	O
PR	B-protein
-	I-protein
B	I-protein
and	O
PR	B-protein
-	I-protein
A	I-protein
,	O
caused	O
a	O
ligand	O
-	O
dependent	O
activation	O
of	O
PGDH	B-protein
-	I-protein
2368	I-protein
/	I-protein
luc3	I-protein
.	O

Methods	O
of	O
clinical	O
and	O
experimental	O
algesimetry	O
are	O
described	O
that	O
have	O
been	O
used	O
to	O
evaluate	O
effects	O
of	O
peripherally	O
and	O
centrally	O
acting	O
analgesics	O
.	O

Facts	O
on	O
the	O
Economic	O
Recovery	O
Tax	O
Act	O
of	O
1981	O
for	O
speech	O
-	O
language	O
pathologists	O
and	O
audiologists	O
.	O

However	O
,	O
Cbf5p	B-protein
was	O
found	O
to	O
be	O
nucleolar	O
and	O
is	O
highly	O
homologous	O
to	O
the	O
rat	B-protein
nucleolar	I-protein
protein	I-protein
NAP57	I-protein
,	O
which	O
coimmunoprecipitates	O
with	O
Nopp140	B-protein
and	O
which	O
is	O
postulated	O
to	O
be	O
involved	O
in	O
nucleolar	O
-	O
cytoplasmic	O
shuttling	O
(	O
U	O
.	O

RESULTS	O
:	O
Horses	O
with	O
colic	O
had	O
significantly	O
higher	O
fibrinogen	B-protein
concentration	O
,	O
greater	O
alpha	B-protein
2AP	I-protein
and	O
protein	B-protein
C	I-protein
activities	O
,	O
and	O
longer	O
PT	O
and	O
APTT	O
than	O
did	O
healthy	O
horses	O
.	O

The	O
Myc	B-protein
LZ	I-protein
was	O
found	O
to	O
prevent	O
homodimeric	O
interactions	O
,	O
thus	O
explaining	O
Myc	B-protein
inability	O
to	O
homodimerize	O
efficiently	O
.	O

A	O
major	O
pool	O
of	O
Dsg	B-protein
-	I-protein
plakoglobin	I-protein
complexes	I-protein
sedimented	O
at	O
8S	O
and	O
exhibited	O
a	O
1	O
:	O
1	O
stoichiometry	O
.	O

Conclusion	O
:	O
The	O
Lp	B-protein
(	I-protein
a	I-protein
)	I-protein
levels	O
in	O
these	O
children	O
were	O
the	O
lower	O
ever	O
reported	O
.	O

In	O
vitro	O
translation	O
experiments	O
show	O
that	O
human	O
cDNA	O
derived	O
RNA	O
translates	O
into	O
a	O
protein	O
with	O
a	O
mobility	O
of	O
44	O
-	O
46	O
kD	O
on	O
SDS	O
polyacrylamide	O
gels	O
.	O

There	O
is	O
a	O
cysteine	O
clustering	O
region	O
in	O
an	O
N	O
-	O
terminal	O
region	O
of	O
the	O
c	B-protein
-	I-protein
raf	I-protein
(	I-protein
-	I-protein
1	I-protein
)	I-protein
product	I-protein
deduced	O
from	O
the	O
nucleotide	O
sequence	O
,	O
and	O
this	O
cysteine	O
clustering	O
region	O
was	O
found	O
to	O
be	O
highly	O
homologous	O
to	O
that	O
present	O
in	O
an	O
N	O
-	O
terminal	O
region	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
although	O
,	O
in	O
the	O
latter	O
cysteine	O
clusters	O
are	O
present	O
in	O
duplicate	O
.	O

In	O
transient	O
cotransfections	O
E1A	B-protein
could	O
induce	O
the	O
activity	O
of	O
the	O
p53	B-protein
promoter	I-protein
to	O
a	O
high	O
level	O
;	O
12S	B-protein
E1A	I-protein
was	O
threefold	O
as	O
efficient	O
as	O
13S	B-protein
E1A	I-protein
in	O
this	O
activity	O
,	O
and	O
YY1	B-protein
bound	O
to	O
the	O
composite	O
element	O
was	O
shown	O
to	O
mediate	O
55	O
%	O
of	O
this	O
induction	O
.	O

Two	O
variant	O
PRP	B-protein
-	I-protein
precursor	I-protein
alleles	I-protein
occur	O
which	O
slightly	O
differ	O
in	O
the	O
number	O
of	O
repeats	O
in	O
domain	B-protein
C	I-protein
.	O

The	O
first	O
open	O
reading	O
frame	O
of	O
the	O
blueberry	O
scorch	O
carlavirus	O
(	O
BBScV	O
)	O
genome	O
encodes	O
a	O
putative	O
replication	O
-	O
associated	O
protein	O
of	O
223	O
kDa	O
(	O
p223	B-protein
)	O
.	O

An	O
evolutionary	O
comparison	O
of	O
amino	O
acid	O
sequences	O
of	O
34	O
HSP70	B-protein
proteins	I-protein
from	O
17	O
species	O
suggests	O
that	O
BiP	B-protein
genes	I-protein
share	O
a	O
common	O
ancestor	O
,	O
which	O
diverged	O
from	O
other	O
HSP70	B-protein
genes	I-protein
near	O
the	O
time	O
when	O
eukaryotes	O
first	O
appeared	O
.	O

To	O
understand	O
whether	O
Shc	B-protein
localization	O
in	O
membrane	O
rafts	O
is	O
sufficient	O
to	O
regulate	O
Shc	B-protein
function	O
,	O
we	O
constructed	O
a	O
Shc	B-protein
chimera	I-protein
containing	O
the	O
Ras	B-protein
membrane	I-protein
localization	I-protein
motif	I-protein
at	O
the	O
C	O
-	O
terminus	O
.	O

On	O
the	O
other	O
hand	O
,	O
cells	O
containing	O
a	O
PTP1C	B-protein
in	O
which	O
the	O
catalytic	O
site	O
had	O
been	O
inactivated	O
through	O
mutagenesis	O
,	O
stably	O
phosphorylated	O
the	O
phosphatase	B-protein
.	O

Haemodynamic	O
responses	O
to	O
antagonism	O
of	O
bocurarine	O
block	O
with	O
atropine	O
-	O
neostigmine	O
mixture	O
in	O
children	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
prospectively	O
compared	O
the	O
automated	O
measurements	O
of	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
and	O
volumes	O
from	O
rest	O
-	O
injected	O
gated	O
Technetium	O
99m	O
(	O
Tc99m	O
)	O
perfusion	O
SPECT	O
with	O
equilibrium	O
radionuclide	O
angiocardiography	O
(	O
ERNA	O
)	O
in	O
62	O
patients	O
and	O
the	O
assessment	O
of	O
regional	O
function	O
with	O
echocardiography	O
in	O
22	O
patients	O
.	O

The	O
DNA	O
helix	O
at	O
the	O
tandemly	O
repeated	O
,	O
13mer	O
sequence	O
is	O
thermodynamically	O
unstable	O
,	O
as	O
evidenced	O
by	O
hypersensitivity	O
to	O
single	B-protein
-	I-protein
strand	I-protein
-	I-protein
specific	I-protein
nuclease	I-protein
in	O
a	O
negatively	O
supercoiled	O
plasmid	O
,	O
and	O
demonstrated	O
by	O
stable	O
DNA	O
unwinding	O
seen	O
after	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
of	O
topoisomers	O
.	O

Here	O
,	O
we	O
present	O
evidence	O
for	O
a	O
model	O
in	O
which	O
mRNA	O
sequences	O
up	O
to	O
around	O
100	O
nucleotides	O
downstream	O
from	O
the	O
start	O
codon	O
of	O
21K	O
fold	O
back	O
and	O
base	O
-	O
pair	O
to	O
the	O
21K	O
translation	O
initiation	O
region	O
,	O
thereby	O
decreasing	O
the	O
translation	O
initiation	O
frequency	O
.	O

Consistent	O
effects	O
on	O
pVHL	B-protein
function	O
were	O
observed	O
for	O
all	O
mutations	O
within	O
each	O
subclass	O
.	O

Furthermore	O
,	O
our	O
data	O
also	O
show	O
that	O
,	O
in	O
addition	O
to	O
TEF	B-protein
-	I-protein
1	I-protein
,	O
another	O
HF	B-protein
-	I-protein
1a	I-protein
-	I-protein
related	I-protein
factor	I-protein
may	O
be	O
recognized	O
by	O
the	O
alpha	B-protein
-	I-protein
MHC	I-protein
gene	I-protein
EM	I-protein
element	I-protein
.	O

In	O
this	O
way	O
it	O
is	O
possible	O
to	O
simulate	O
the	O
growth	O
function	O
of	O
the	O
embryofetal	O
curve	O
of	O
the	O
length	O
'	O
increase	O
of	O
man	O
and	O
the	O
curve	O
of	O
the	O
mass	O
'	O
increase	O
of	O
rat	O
.	O

The	O
use	O
of	O
this	O
model	O
for	O
investigating	O
pathophysiologically	O
significant	O
issues	O
in	O
denervating	O
diseases	O
is	O
illustrated	O
with	O
five	O
different	O
sets	O
of	O
parameters	O
.	O

The	O
14	B-protein
.	I-protein
1	I-protein
(	I-protein
IGLL1	I-protein
)	I-protein
gene	I-protein
is	O
expressed	O
in	O
a	O
lineage	O
-	O
and	O
stage	O
-	O
restricted	O
manner	O
.	O

IA	O
-	O
CT	O
with	O
cisplatin	O
50	O
mg	O
and	O
doxorubicin	O
30	O
mg	O
was	O
administered	O
by	O
one	O
shot	O
method	O
in	O
bilateral	O
internal	O
iliac	O
arteries	O
.	O

Greater	O
attenuation	O
of	O
the	O
N1	O
-	O
P2	O
and	O
baseline	O
-	O
P2	O
amplitude	O
of	O
the	O
probe	O
EPs	O
was	O
observed	O
when	O
the	O
probe	O
stimulus	O
was	O
presented	O
to	O
the	O
right	O
ear	O
and	O
the	O
verbal	O
material	O
presented	O
to	O
the	O
left	O
ear	O
than	O
when	O
the	O
opposite	O
stimulation	O
arrangement	O
was	O
used	O
.	O

The	O
upstream	O
promoter	O
is	O
located	O
within	O
the	O
coding	O
sequence	O
of	O
a	O
divergent	O
gene	O
expressing	O
a	O
protein	O
of	O
Mr	O
39	O
kDa	O
of	O
unknown	O
function	O
.	O

METHODS	O
:	O
All	O
these	O
30	O
non	O
-	O
responders	O
received	O
an	O
extra	O
dose	O
of	O
the	O
same	O
vaccine	O
2	O
months	O
after	O
primary	O
immunization	O
and	O
a	O
booster	O
dose	O
with	O
a	O
yeast	O
-	O
derived	O
vaccine	O
6	O
years	O
later	O
.	O

The	O
interrelation	O
of	O
the	O
levels	O
of	O
glucocorticoids	O
and	O
insulin	B-protein
in	O
the	O
blood	O
of	O
irradiated	O
animals	O
.	O

CYP2C19	B-protein
genotype	I-protein
was	O
determined	O
by	O
the	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
method	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
Glc7	B-protein
phosphatase	I-protein
and	O
its	O
Gac1	B-protein
regulatory	O
subunit	O
play	O
positive	O
roles	O
in	O
HSF	B-protein
activation	O
of	O
CUP1	B-protein
transcription	O
.	O

Most	O
of	O
them	O
were	O
situated	O
at	O
Sylvius	O
fissure	O
(	O
13	O
cases	O
)	O
.	O

A	O
database	O
search	O
has	O
revealed	O
as	O
the	O
most	O
significative	O
homology	O
a	O
match	O
with	O
the	O
human	B-protein
mitochondrial	I-protein
transcription	I-protein
termination	I-protein
factor	I-protein
(	O
mTERF	B-protein
)	O
,	O
a	O
protein	O
that	O
also	O
binds	O
DNA	O
as	O
a	O
monomer	O
and	O
contains	O
three	O
leucine	O
zippers	O
forming	O
intramolecular	O
interactions	O
.	O

PRH75	B-protein
,	O
a	O
new	O
nucleus	O
-	O
localized	O
member	O
of	O
the	O
DEAD	B-protein
-	I-protein
box	I-protein
protein	I-protein
family	I-protein
from	O
higher	O
plants	O
.	O

Furthermore	O
,	O
the	O
negative	O
transcriptional	O
effect	O
of	O
COUP	B-protein
-	I-protein
TFs	I-protein
is	O
dominant	O
over	O
the	O
activating	O
effect	O
of	O
the	O
Oct4	B-protein
embryonic	I-protein
stem	I-protein
cell	I-protein
-	I-protein
specific	I-protein
enhancer	I-protein
.	O

Point	O
mutations	O
in	O
the	O
third	O
SH3	B-protein
domain	I-protein
abolished	O
the	O
vinexin	B-protein
-	I-protein
Sos	I-protein
interaction	O
.	O

Cholesterol	B-protein
side	I-protein
-	I-protein
chain	I-protein
cleavage	I-protein
cytochrome	I-protein
P450	I-protein
(	O
CYP11A	B-protein
;	O
P450scc	B-protein
)	O
gene	O
expression	O
is	O
regulated	O
by	O
gonadotropins	B-protein
via	O
cAMP	O
in	O
the	O
ovary	O
and	O
by	O
ACTH	B-protein
via	O
cAMP	O
in	O
adrenal	O
cortical	O
cells	O
.	O

Stable	O
patients	O
have	O
mucous	O
hypersecretion	O
and	O
little	O
evidence	O
of	O
acute	O
inflammation	O
.	O

Selenium	O
status	O
of	O
thoroughbreds	O
in	O
the	O
United	O
Kingdom	O
.	O

The	O
carcinoma	O
was	O
restricted	O
within	O
the	O
epithelium	O
in	O
one	O
,	O
the	O
mucosal	O
layer	O
in	O
five	O
,	O
and	O
the	O
submucosal	O
layer	O
in	O
two	O
.	O

In	O
two	O
-	O
field	O
nodal	O
dissection	O
,	O
two	O
components	O
are	O
included	O
with	O
(	O
modern	O
two	O
-	O
field	O
)	O
or	O
without	O
(	O
traditional	O
two	O
-	O
field	O
)	O
nodal	O
dissection	O
around	O
both	O
recurrent	O
laryngeal	O
nerve	O
chains	O
in	O
the	O
upper	O
mediastinum	O
.	O

Comparison	O
of	O
the	O
p50	B-protein
sequence	I-protein
to	O
other	O
cloned	O
proteins	O
revealed	O
89	O
%	O
homology	O
with	O
a	O
glycosaminoglycan	O
-	O
binding	O
protein	O
and	O
54	O
%	O
homology	O
with	O
Drosophila	B-protein
cell	I-protein
cycle	I-protein
control	I-protein
protein	I-protein
(	I-protein
cdc	I-protein
)	I-protein
37	O
.	O

The	O
metabolism	O
and	O
pharmacology	O
of	O
5	O
-	O
fluorouracil	O
.	O

Structure	O
-	O
function	O
analysis	O
of	O
the	O
Z	O
-	O
DNA	O
-	O
binding	O
domain	O
Zalpha	O
of	O
dsRNA	B-protein
adenosine	I-protein
deaminase	I-protein
type	I-protein
I	I-protein
reveals	O
similarity	O
to	O
the	O
(	O
alpha	O
+	O
beta	O
)	O
family	O
of	O
helix	O
-	O
turn	O
-	O
helix	O
proteins	O
.	O

The	O
GRE	B-protein
at	O
nucleotide	O
7640	O
is	O
a	O
composite	B-protein
GRE	I-protein
(	O
cGRE	B-protein
)	O
containing	O
an	O
overlapping	O
activator	B-protein
protein	I-protein
-	I-protein
1	I-protein
(	O
AP	B-protein
-	I-protein
1	I-protein
)	O
motif	O
for	O
the	O
c	B-protein
-	I-protein
jun	I-protein
homodimer	I-protein
and	O
c	B-protein
-	I-protein
jun	I-protein
/	I-protein
c	I-protein
-	I-protein
fos	I-protein
heterodimer	I-protein
.	O

Feline	O
leukemia	O
viruses	O
(	O
FeLVs	O
)	O
,	O
which	O
are	O
replication	O
-	O
competent	O
oncoretroviruses	O
of	O
the	O
domestic	O
cat	O
species	O
,	O
are	O
contagiously	O
transmitted	O
in	O
natural	O
environments	O
.	O

Altogether	O
our	O
data	O
indicate	O
that	O
PEDF	B-protein
belongs	O
to	O
the	O
subgroup	O
of	O
noninhibitory	O
serpins	B-protein
and	O
that	O
its	O
N	O
-	O
terminal	O
region	O
confers	O
a	O
neurite	O
-	O
promoting	O
activity	O
to	O
the	O
protein	O
.	O

Our	O
data	O
suggest	O
that	O
,	O
at	O
least	O
at	O
high	O
temperature	O
,	O
a	O
critical	O
minimal	O
level	O
of	O
Ypt	B-protein
protein	I-protein
prenylation	O
is	O
required	O
for	O
maintaining	O
vesicle	O
polarization	O
.	O

On	O
T2	O
weighted	O
images	O
,	O
low	O
intensity	O
areas	O
in	O
the	O
thalamus	O
,	O
the	O
striatum	O
,	O
the	O
anterior	O
limb	O
of	O
the	O
internal	O
capsule	O
,	O
the	O
tegmentum	O
of	O
midbrain	O
,	O
high	O
intensity	O
areas	O
in	O
middle	O
cerebellar	O
peduncle	O
,	O
the	O
posterior	O
limb	O
of	O
the	O
internal	O
capsule	O
,	O
the	O
lateral	O
part	O
of	O
the	O
cerebral	O
peduncle	O
,	O
and	O
the	O
cerebral	O
white	O
matter	O
were	O
noted	O
.	O

Northern	O
blot	O
hybridization	O
demonstrated	O
that	O
HEP	B-protein
-	I-protein
COP	I-protein
was	O
expressed	O
in	O
a	O
wide	O
range	O
of	O
human	O
adult	O
and	O
fetal	O
tissues	O
.	O

We	O
have	O
isolated	O
a	O
cosmid	O
containing	O
DNA	O
that	O
corresponds	O
to	O
the	O
site	O
of	O
transposon	O
insertion	O
in	O
257DH4	O
and	O
have	O
localized	O
Tn5	B-protein
on	O
an	O
8	B-protein
.	I-protein
0	I-protein
kb	I-protein
EcoRI	I-protein
fragment	I-protein
.	O

A	O
complementary	O
DNA	O
was	O
isolated	O
from	O
Caenorhabditis	O
elegans	O
that	O
encoded	O
a	O
polypeptide	O
of	O
1438	O
amino	O
acid	O
residues	O
,	O
CeGAP	B-protein
,	O
which	O
contains	O
a	O
domain	O
with	O
sequence	O
similarity	O
to	O
the	O
COOH	B-protein
-	I-protein
terminal	I-protein
segment	I-protein
(	I-protein
GTPase	I-protein
-	I-protein
activating	I-protein
protein	I-protein
region	I-protein
)	I-protein
of	O
Bcr	B-protein
and	O
other	O
known	O
GTPase	B-protein
-	I-protein
activating	I-protein
proteins	I-protein
of	O
the	O
Rho	B-protein
subfamily	I-protein
.	O

The	O
results	O
of	O
a	O
quantitative	O
study	O
of	O
vasculosyncytial	O
membranes	O
in	O
123	O
placentas	O
are	O
presented	O
.	O

The	O
Stryker	O
frame	O
modification	O
to	O
the	O
standard	O
Dornier	O
HM3	O
lithotriptor	O
allows	O
for	O
improved	O
visualization	O
and	O
easier	O
localization	O
of	O
distal	O
ureteral	O
calculi	O
compared	O
to	O
the	O
standard	O
gantry	O
.	O

The	O
Ishasha	O
samples	O
show	O
a	O
range	O
encompassing	O
three	O
trophic	O
levels	O
.	O

Transfection	O
experiments	O
demonstrated	O
that	O
the	O
5	O
'	O
-	O
flanking	O
region	O
(	O
-	O
1894	O
to	O
+	O
37	O
)	O
of	O
the	O
mStaf	B-protein
gene	I-protein
drives	O
transcription	O
in	O
mouse	O
NMuMG	O
cells	O
and	O
that	O
a	O
construct	O
containing	O
a	O
fragment	O
from	O
-	O
387	O
to	O
+	O
37	O
showed	O
the	O
highest	O
transcriptional	O
activity	O
.	O

Human	B-protein
PDK1	I-protein
is	O
homologous	O
to	O
the	O
Drosophila	B-protein
protein	I-protein
kinase	I-protein
DSTPK61	I-protein
,	O
which	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
sex	O
differentiation	O
,	O
oogenesis	O
and	O
spermatogenesis	O
.	O

Phylogenetic	O
position	O
of	O
the	O
Phacotaceae	O
within	O
the	O
Chlamydophyceaeas	O
revealed	O
by	O
analysis	O
of	O
18S	B-protein
rDNA	I-protein
and	O
rbcL	B-protein
sequences	I-protein
.	O

Additional	O
studies	O
with	O
new	O
and	O
reprocessed	O
regenerated	O
cellulose	O
dialyzers	O
comparing	O
450	O
and	O
220	O
mL	O
/	O
min	O
blood	O
flow	O
rates	O
at	O
10	O
minutes	O
showed	O
no	O
change	O
in	O
BTG	O
.	O

S	O
.	O
,	O
and	O
Walter	O
,	O
P	O
.	O

A	O
significant	O
correlation	O
between	O
a	O
number	O
of	O
functional	O
parameters	O
of	O
gastric	O
secretion	O
,	O
incretion	O
and	O
histological	O
changes	O
of	O
gastric	O
mucosa	O
was	O
found	O
in	O
patients	O
with	O
chronic	O
gastritis	O
.	O

These	O
mutations	O
,	O
when	O
placed	O
in	O
a	O
wild	B-protein
-	I-protein
type	I-protein
fliF	I-protein
background	O
,	O
had	O
no	O
mutant	O
phenotype	O
.	O

65	O
,	O
3829	O
-	O
3838	O
,	O
1991	O
)	O
,	O
a	O
truncated	O
form	O
of	O
the	O
IE	B-protein
polypeptide	I-protein
lacking	O
IE	B-protein
amino	I-protein
acid	I-protein
residues	I-protein
1	I-protein
-	I-protein
322	I-protein
(	O
and	O
,	O
therefore	O
lacks	O
the	O
deduced	O
transcriptional	O
activation	O
domain	O
)	O
,	O
fails	O
to	O
transactivate	O
the	O
EHV	B-protein
-	I-protein
1	I-protein
tk	I-protein
promoter	I-protein
,	O
but	O
retains	O
the	O
ability	O
to	O
down	O
-	O
regulate	O
the	O
EHV	B-protein
-	I-protein
1	I-protein
IE	I-protein
promoter	I-protein
.	O

Seven	O
out	O
of	O
34	O
patients	O
died	O
,	O
giving	O
a	O
mortality	O
rate	O
of	O
21	O
%	O
.	O

Large	O
interpatient	O
variation	O
in	O
peak	O
PCZ	O
plasma	O
levels	O
(	O
91	O
-	O
3215	O
ng	O
/	O
ml	O
)	O
was	O
seen	O
,	O
with	O
the	O
plasma	O
half	O
-	O
life	O
(	O
t1	O
/	O
2	O
alpha	O
)	O
being	O
approximately	O
57	O
min	O
in	O
patients	O
given	O
135	O
-	O
180	O
mg	O
/	O
m2	O
PCZ	O
.	O

Intravenous	O
gamma	B-protein
globulins	I-protein
.	O

G	B-protein
-	I-protein
CSF	I-protein
was	O
started	O
on	O
day	O
3	O
of	O
each	O
cycle	O
(	O
5	O
microg	O
/	O
kg	O
/	O
day	O
)	O
and	O
was	O
stopped	O
the	O
day	O
before	O
the	O
last	O
apheresis	O
or	O
when	O
absolute	O
neutrophil	O
count	O
was	O
above	O
0	O
.	O
5	O
x	O
10	O
(	O
9	O
)	O
/	O
l	O
.	O

Experiment	O
3	O
showed	O
that	O
the	O
long	O
-	O
term	O
analgesic	O
reaction	O
could	O
also	O
be	O
reduced	O
by	O
administration	O
of	O
naltrexone	O
prior	O
to	O
reexposure	O
to	O
shock	O
.	O

Acetoin	O
-	O
dependent	O
expression	O
of	O
the	O
acoABCD	B-protein
operon	I-protein
could	O
be	O
restored	O
in	O
the	O
E	B-protein
.	I-protein
coli	I-protein
acoK	I-protein
mutants	I-protein
by	O
supplying	O
a	O
plasmid	O
carrying	O
an	O
intact	O
acoK	B-protein
,	O
suggesting	O
a	O
transactivating	O
function	O
of	O
the	O
gene	O
product	O
.	O

Activation	O
of	O
transcription	O
through	O
the	O
AP	B-protein
-	I-protein
1	I-protein
site	I-protein
in	O
Jurkat	O
cells	O
by	O
JunD	B-protein
and	O
/	O
or	O
Fra	B-protein
-	I-protein
2	I-protein
was	O
weak	O
.	O
c	B-protein
-	I-protein
Jun	I-protein
,	O
JunB	B-protein
,	O
and	O
c	B-protein
-	I-protein
Fos	I-protein
activation	O
was	O
greater	O
,	O
although	O
the	O
level	O
was	O
still	O
less	O
than	O
that	O
with	O
Tax	B-protein
.	O

Frequency	O
of	O
seeing	O
curves	O
were	O
examined	O
for	O
the	O
method	O
most	O
similar	O
to	O
FDT	O
.	O

Estradiol	O
is	O
known	O
to	O
induce	O
expression	O
of	O
certain	O
proto	O
-	O
oncogenes	O
,	O
and	O
this	O
led	O
us	O
to	O
examine	O
potential	O
regulatory	O
regions	O
of	O
the	O
cellular	B-protein
c	I-protein
-	I-protein
fos	I-protein
oncogene	I-protein
.	O

The	O
MMA	B-protein
,	I-protein
DMA	I-protein
,	I-protein
and	I-protein
TMA	I-protein
methyltransferases	I-protein
are	O
not	O
homologs	O
;	O
however	O
,	O
like	O
the	O
MMA	B-protein
methyltransferase	I-protein
gene	I-protein
,	O
the	O
genes	O
encoding	O
the	O
DMA	B-protein
and	I-protein
TMA	I-protein
methyltransferases	I-protein
each	O
contain	O
a	O
single	O
in	O
-	O
frame	O
amber	O
codon	O
.	O

Mutational	O
analysis	O
of	O
mammalian	B-protein
translation	I-protein
initiation	I-protein
factor	I-protein
5	I-protein
(	O
eIF5	B-protein
)	O
:	O
role	O
of	O
interaction	O
between	O
the	O
beta	O
subunit	O
of	O
eIF2	B-protein
and	O
eIF5	B-protein
in	O
eIF5	B-protein
function	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

DNA	O
methylation	O
,	O
especially	O
of	O
either	O
one	O
or	O
both	O
of	O
the	O
deoxyadenosines	O
at	O
the	O
two	O
GATC	B-protein
motifs	I-protein
(	O
one	O
in	O
the	O
first	O
exon	O
and	O
the	O
other	O
in	O
the	O
first	O
intron	O
of	O
the	O
rice	O
CatA	B-protein
gene	I-protein
)	O
,	O
appeared	O
to	O
be	O
responsible	O
for	O
the	O
CatA	B-protein
promoter	I-protein
activity	O
identified	O
in	O
the	O
transient	O
assay	O
.	O

Genetic	O
studies	O
in	O
Drosophila	O
have	O
led	O
to	O
the	O
identification	O
of	O
several	O
components	O
of	O
the	O
Notch	B-protein
pathway	I-protein
.	O

No	O
significant	O
differences	O
between	O
the	O
substituted	O
and	O
wild	O
type	O
peptides	O
were	O
observed	O
,	O
suggesting	O
that	O
this	O
substitution	O
in	O
the	O
intact	O
protein	O
may	O
cause	O
disruption	O
of	O
global	O
rather	O
than	O
local	O
structures	O
.	O

Competition	O
experiments	O
demonstrate	O
a	O
negative	O
allosteric	O
relationship	O
between	O
these	O
RGD	B-protein
recognition	I-protein
sites	I-protein
.	O

The	O
favourable	O
effect	O
of	O
thymic	O
shielding	O
was	O
also	O
reflected	O
in	O
a	O
significant	O
increase	O
of	O
LD50	O
/	O
30	O
,	O
and	O
the	O
dose	O
reduction	O
factor	O
was	O
equal	O
to	O
2	O
.	O

As	O
shown	O
previously	O
,	O
EBNA2	B-protein
transactivates	O
the	O
promoters	O
of	O
the	O
viral	B-protein
latent	I-protein
membrane	I-protein
proteins	I-protein
.	O

The	O
B	B-protein
.	I-protein
germanica	I-protein
cyclophilin	I-protein
amino	I-protein
acid	I-protein
sequence	I-protein
shares	O
83	O
%	O
identity	O
with	O
the	O
cytosolic	B-protein
cyclophilin	I-protein
isoform	I-protein
from	I-protein
Drosophila	I-protein
melanogaster	I-protein
(	O
Cyp	B-protein
-	I-protein
1	I-protein
)	O
.	O

First	O
,	O
two	O
MCTs	O
using	O
a	O
long	O
electrode	O
,	O
3	O
cm	O
in	O
size	O
,	O
were	O
performed	O
in	O
the	O
central	O
area	O
of	O
the	O
tumor	O
,	O
and	O
eight	O
MCTs	O
by	O
a	O
short	O
electrode	O
,	O
2	O
cm	O
in	O
size	O
,	O
were	O
done	O
in	O
the	O
peripheral	O
and	O
surrounding	O
area	O
of	O
the	O
tumor	O
.	O

Factors	O
influencing	O
direct	O
-	O
immersion	O
(	O
DI	O
)	O
-	O
SPME	O
process	O
were	O
also	O
checked	O
and	O
chosen	O
experimentally	O
.	O

Argatroban	O
may	O
be	O
more	O
effective	O
under	O
low	O
HC	B-protein
II	I-protein
conditions	O
because	O
of	O
its	O
potent	O
inhibition	O
of	O
thrombin	B-protein
activity	O
at	O
sites	O
of	O
vascular	O
wall	O
damage	O
.	O

Salivary	O
estradiol	O
17	O
beta	O
(	O
E2	O
-	O
17	O
beta	O
)	O
and	O
progesterone	O
(	O
P	O
)	O
were	O
determined	O
by	O
using	O
radioimmunoassay	O
techniques	O
in	O
30	O
pregnant	O
females	O
in	O
the	O
first	O
,	O
second	O
and	O
third	O
trimesters	O
as	O
well	O
as	O
in	O
10	O
non	O
-	O
pregnant	O
controls	O
during	O
the	O
luteal	O
phase	O
of	O
the	O
menstrual	O
cycle	O
.	O

Triton	O
-	O
disrupted	O
cells	O
retained	O
capacity	O
for	O
activation	O
of	O
the	O
pathway	O
by	O
both	O
peptide	B-protein
growth	I-protein
factors	I-protein
and	O
by	O
addition	O
of	O
GTP	O
-	O
loaded	O
p21	B-protein
rasVal12	I-protein
.	O

In	O
vitro	O
transcription	O
extracts	O
from	O
ret1	B-protein
-	I-protein
1	I-protein
cells	O
terminate	O
less	O
efficiently	O
at	O
weak	O
transcription	O
termination	O
signals	O
than	O
those	O
from	O
RET1	B-protein
cells	O
,	O
using	O
a	O
variety	O
of	O
tRNA	O
templates	O
.	O

Liu	O
,	O
B	O
.	O

The	O
gene	O
is	O
1	O
,	O
139	O
base	O
pairs	O
(	O
bp	O
)	O
long	O
,	O
and	O
,	O
like	O
other	O
members	O
of	O
the	O
SIG	B-protein
family	I-protein
,	O
the	O
beta	B-protein
TG	I-protein
gene	I-protein
is	O
divided	O
into	O
3	O
exons	O
.	O

The	O
rCBF	O
and	O
vasomotion	O
were	O
recorded	O
by	O
laser	O
-	O
doppler	O
fluxmetry	O
.	O

None	O
of	O
these	O
organic	O
manifestations	O
was	O
discovered	O
by	O
scintigraphic	O
means	O
.	O

TCZ	O
provides	O
quick	O
,	O
inexpensive	O
,	O
noninvasive	O
indication	O
of	O
tissue	O
necrosis	O
,	O
moderate	O
-	O
to	O
-	O
severe	O
intracranial	O
hemorrhage	O
,	O
and	O
delayed	O
brain	O
maturation	O
.	O

The	O
alpha	O
T3	O
-	O
1	O
cell	O
line	O
,	O
a	O
GnRH	O
-	O
responsive	O
gonadotroph	O
cell	O
line	O
developed	O
by	O
targeted	O
oncogenesis	O
in	O
transgenic	O
mice	O
,	O
was	O
used	O
to	O
study	O
regulation	O
of	O
the	O
glycoprotein	B-protein
hormone	I-protein
alpha	I-protein
-	I-protein
subunit	I-protein
by	O
activin	B-protein
.	O

The	O
therapy	O
with	O
a	O
H2	B-protein
-	I-protein
receptor	I-protein
antagonist	O
is	O
less	O
effective	O
than	O
the	O
triple	O
therapies	O
with	O
omeprazole	O
or	O
lansoprazole	O
.	O

Finally	O
,	O
we	O
show	O
that	O
PhLP	B-protein
complexes	O
,	O
at	O
least	O
partially	O
,	O
with	O
Gbetagamma	B-protein
in	O
vivo	O
.	O

The	O
rhabdomyosarcoma	O
R1H	O
growing	O
on	O
the	O
right	O
flank	O
of	O
male	O
WAG	O
/	O
Rij	O
rats	O
was	O
clamped	O
for	O
2	O
or	O
4	O
h	O
at	O
20	O
degrees	O
C	O
or	O
37	O
degrees	O
C	O
.	O

The	O
electrocardiogram	O
.	O

PAI	B-protein
-	I-protein
1	I-protein
levels	O
increased	O
significantly	O
in	O
patients	O
who	O
received	O
iohexol	O
but	O
not	O
in	O
those	O
who	O
received	O
ioxaglate	O
.	O

Development	O
of	O
basophilic	O
leukemia	O
with	O
trisomy	O
8	O
and	O
atypical	O
erythroblastosis	O
in	O
a	O
patient	O
with	O
a	O
history	O
of	O
aplastic	O
anemia	O
22	O
years	O
earlier	O
.	O

A	O
polypeptide	O
encoded	O
by	O
the	O
NTS	O
16	O
open	O
reading	O
frame	O
has	O
sequence	O
similarity	O
to	O
the	O
catalytic	O
domain	O
of	O
several	O
receptor	B-protein
protein	I-protein
kinases	I-protein
from	I-protein
plants	I-protein
including	O
the	O
S	B-protein
-	I-protein
receptor	I-protein
kinases	I-protein
implicated	O
in	O
the	O
rejection	O
of	O
self	O
-	O
pollen	O
in	O
Brassica	O
species	O
and	O
the	O
Pto	B-protein
gene	I-protein
product	I-protein
of	I-protein
tomato	I-protein
which	O
confers	O
resistance	O
to	O
a	O
bacterial	O
pathogen	O
.	O

Improving	O
fissure	O
sealant	O
quality	O
:	O
mechanical	O
preparation	O
and	O
filling	O
level	O
.	O

Do	O
overall	O
treatment	O
time	O
,	O
field	O
size	O
,	O
and	O
treatment	O
energy	O
influence	O
local	O
control	O
of	O
T1	O
-	O
T2	O
squamous	O
cell	O
carcinomas	O
of	O
the	O
glottic	O
larynx	O
?	O
PURPOSE	O
:	O
To	O
evaluate	O
treatment	O
and	O
patient	O
related	O
prognostic	O
factors	O
that	O
may	O
influence	O
local	O
control	O
in	O
the	O
treatment	O
of	O
T1	O
-	O
T2	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
glottic	O
larynx	O
.	O

These	O
results	O
demonstrate	O
the	O
existence	O
of	O
different	O
PI	B-protein
3	I-protein
-	I-protein
kinase	I-protein
isoforms	I-protein
and	O
define	O
a	O
family	O
of	O
genes	O
encoding	O
distinct	O
PI	B-protein
3	I-protein
-	I-protein
kinase	I-protein
catalytic	I-protein
subunits	I-protein
that	O
can	O
associate	O
with	O
p85	B-protein
.	O

Cognate	O
promoter	O
elements	O
implicated	O
in	O
glucocorticoid	O
-	O
and	O
cAMP	O
-	O
mediated	O
regulation	O
as	O
well	O
as	O
in	O
liver	O
-	O
,	O
myeloid	O
-	O
,	O
and	O
lymphocyte	O
-	O
specific	O
expression	O
are	O
located	O
within	O
the	O
5	O
'	O
flanking	O
sequence	O
.	O

An	O
outbreak	O
of	O
hepatitis	O
A	O
among	O
homosexual	O
men	O
in	O
Amsterdam	O
,	O
1991	O
-	O
1993	O
.	O

The	O
differential	O
investigation	O
of	O
lipoproteins	O
,	O
however	O
,	O
showed	O
that	O
the	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
fractions	O
are	O
absolutely	O
or	O
relatively	O
decreased	O
with	O
respect	O
to	O
low	B-protein
-	I-protein
density	I-protein
lipoproteins	I-protein
(	O
LDL	B-protein
)	O
in	O
cerebral	O
infarcts	O
and	O
in	O
transient	O
ischaemic	O
attacks	O
.	O

Auto	O
-	O
and	O
isotopy	O
of	O
the	O
conjunctiva	O
.	O

Prazosin	O
alone	O
was	O
effective	O
in	O
volume	O
responsive	O
patients	O
at	O
a	O
dose	O
of	O
5	O
+	O
/	O
-	O
1	O
.	O
0	O
mg	O
daily	O
.	O

Coexisting	O
vertical	O
and	O
horizontal	O
one	O
and	O
a	O
half	O
syndromes	O
.	O

Recently	O
,	O
studies	O
of	O
agents	O
that	O
disrupt	O
collagen	B-protein
synthesis	O
and	O
deposition	O
have	O
yielded	O
several	O
new	O
angiogenesis	O
inhibitors	O
.	O

A	O
single	O
exon	O
encodes	O
the	O
carboxyl	O
-	O
terminal	O
26	O
amino	O
acids	O
of	O
the	O
ssd	B-protein
chain	I-protein
and	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
its	O
mRNA	O
,	O
ending	O
with	O
a	O
poly	O
(	O
A	O
)	O
-	O
addition	O
site	O
.	O

Mutational	O
analysis	O
of	O
the	O
-	O
84	O
/	O
-	O
55	O
DNA	O
showed	O
that	O
JEG	B-protein
-	I-protein
3	I-protein
nuclear	I-protein
proteins	I-protein
bound	O
to	O
a	O
site	O
containing	O
,	O
but	O
not	O
identical	O
to	O
,	O
the	O
SF	B-protein
-	I-protein
1	I-protein
sequence	I-protein
.	O

RESULT	O
(	O
S	O
)	O
:	O
In	O
patients	O
with	O
elevated	O
FSH	B-protein
levels	O
on	O
cycle	O
day	O
3	O
,	O
a	O
low	O
oocyte	O
yield	O
was	O
achieved	O
(	O
7	O
versus	O
11	O
)	O
and	O
a	O
high	O
number	O
of	O
ampules	O
of	O
hMG	O
was	O
necessary	O
(	O
56	O
versus	O
33	O
)	O
.	O

Nrf2	B-protein
regulates	O
expression	O
of	O
genes	O
encoding	O
enzymes	O
with	O
antioxidant	O
(	O
e	O
.	O
g	O
.	O
heme	B-protein
oxygenase	I-protein
-	I-protein
1	I-protein
(	O
HO	B-protein
-	I-protein
1	I-protein
)	O
)	O
or	O
xenobiotic	O
detoxification	O
(	O
e	O
.	O
g	O
.	O

Cardiovascular	O
and	O
adrenal	O
medullo	O
-	O
sympathetic	O
reactions	O
to	O
acute	O
tobacco	O
poisoning	O
.	O

This	O
in	O
turn	O
will	O
further	O
enhance	O
the	O
role	O
of	O
meta	O
-	O
analysis	O
in	O
helping	O
clinicians	O
and	O
policy	O
makers	O
answer	O
clinical	O
questions	O
.	O

Proctoscopy	O
and	O
roentgenographic	O
studies	O
may	O
be	O
an	O
important	O
part	O
of	O
evaluation	O
,	O
especially	O
in	O
patients	O
who	O
present	O
with	O
perianal	O
suppuration	O
,	O
masses	O
,	O
or	O
anal	O
fissures	O
.	O

Human	B-protein
MGP	I-protein
is	O
a	O
10	B-protein
-	I-protein
kD	I-protein
skeletal	I-protein
extracellular	I-protein
matrix	I-protein
(	I-protein
ECM	I-protein
)	I-protein
protein	I-protein
that	O
consists	O
of	O
an	O
84	O
-	O
aa	O
mature	O
protein	O
and	O
a	O
19	O
-	O
aa	O
transmembrane	O
signal	O
peptide	O
.	O

By	O
directly	O
interacting	O
with	O
both	O
Arfs	B-protein
and	O
tyrosine	B-protein
kinases	I-protein
involved	O
in	O
regulating	O
cell	O
growth	O
and	O
cytoskeletal	O
organization	O
,	O
ASAP1	B-protein
could	O
coordinate	O
membrane	O
remodeling	O
events	O
with	O
these	O
processes	O
.	O

In	O
cells	O
limited	O
for	O
His	O
,	O
increased	O
expression	O
of	O
arg	B-protein
-	I-protein
2	I-protein
and	O
cpc	B-protein
-	I-protein
1	I-protein
,	O
and	O
decreased	O
expression	O
of	O
cox	B-protein
-	I-protein
5	I-protein
,	O
also	O
had	O
translational	O
and	O
transcriptional	O
components	O
.	O

Resistance	O
pattern	O
of	O
Mycobacterium	O
tuberculosis	O
(	O
H	O
37	O
Rv	O
)	O
to	O
a	O
new	O
antibiotic	O
,	O
lividomycin	O
.	O

Subsequent	O
experiments	O
showed	O
that	O
motoric	O
tasks	O
rather	O
than	O
cognitive	O
aspects	O
of	O
the	O
COWA	O
task	O
were	O
critical	O
in	O
potentiating	O
finger	O
-	O
tapping	O
performance	O
.	O

Mutational	O
studies	O
provide	O
evidence	O
to	O
this	O
end	O
and	O
indicate	O
that	O
the	O
side	O
chains	O
of	O
subdomain	O
4	O
.	O
2	O
make	O
specific	O
contacts	O
with	O
the	O
nucleotides	O
at	O
-	O
35	O
.	O

These	O
data	O
reveal	O
a	O
complex	O
network	O
of	O
interactions	O
between	O
GTPases	B-protein
in	O
the	O
ARF	B-protein
family	I-protein
and	O
their	O
effectors	O
and	O
reveal	O
a	O
potential	O
for	O
cross	O
-	O
talk	O
not	O
demonstrated	O
previously	O
.	O

I	O
.	O

Using	O
mutated	B-protein
IL2R	I-protein
alpha	I-protein
promoter	I-protein
constructs	I-protein
in	O
transient	O
transfection	O
and	O
DNA	O
binding	O
assays	O
,	O
we	O
now	O
demonstrate	O
that	O
sequences	O
located	O
immediately	O
upstream	O
and	O
downstream	O
of	O
the	O
kappa	B-protein
B	I-protein
enhancer	I-protein
also	O
contribute	O
to	O
the	O
regulation	O
of	O
IL2R	B-protein
alpha	I-protein
gene	I-protein
expression	O
.	O

A	O
single	O
case	O
of	O
an	O
adenocarcinoma	O
,	O
arising	O
in	O
a	O
retroperitoneal	O
enterogenous	O
cyst	O
and	O
which	O
presented	O
as	O
a	O
left	O
renal	O
cyst	O
,	O
is	O
reported	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
structures	O
of	O
the	O
b	O
-	O
Zip	O
domain	O
are	O
well	O
conserved	O
among	O
these	O
Maf	B-protein
-	I-protein
related	I-protein
proteins	I-protein
.	O

At	O
each	O
level	O
of	O
PaO2	O
we	O
obtained	O
simultaneous	O
measures	O
of	O
arterial	O
and	O
venous	O
blood	O
gases	O
,	O
venous	O
lactate	O
concentration	O
,	O
and	O
changes	O
in	O
the	O
relative	O
concentrations	O
of	O
inorganic	O
phosphate	O
,	O
phosphocreatine	O
,	O
and	O
ATP	O
measured	O
with	O
31P	O
magnetic	O
resonance	O
spectroscopy	O
.	O

Truncated	O
mammalian	B-protein
Notch1	I-protein
activates	O
CBF1	O
/	O
RBPJk	O
-	O
repressed	O
genes	O
by	O
a	O
mechanism	O
resembling	O
that	O
of	O
Epstein	B-protein
-	I-protein
Barr	I-protein
virus	I-protein
EBNA2	I-protein
.	O

Immunohistochemically	O
,	O
anticytokeratin	B-protein
19	I-protein
antibody	I-protein
revealed	O
strong	O
staining	O
in	O
both	O
epithelial	O
and	O
sarcomatous	O
MPM	O
tissues	O
.	O

Lack	O
of	O
controlled	O
prospective	O
studies	O
of	O
sleep	O
electroencephalograms	O
(	O
EEG	O
)	O
,	O
and	O
the	O
use	O
of	O
medication	O
,	O
in	O
children	O
with	O
developmental	O
dysphasia	O
,	O
may	O
deny	O
appropriate	O
treatment	O
strategies	O
to	O
children	O
with	O
severe	O
developmental	O
speech	O
and	O
language	O
disorders	O
.	O

Nuclease	O
footprinting	O
revealed	O
that	O
purified	B-protein
glucocorticoid	I-protein
receptor	I-protein
bound	O
at	O
multiple	O
discrete	O
sites	O
within	O
and	O
at	O
the	O
borders	O
of	O
the	O
tandemly	O
repeated	O
sequence	O
motif	O
that	O
defines	O
Sa	B-protein
.	O

A	O
medical	O
-	O
geographical	O
review	O
.	O

Topical	O
L	O
-	O
NNA	O
attenuated	O
the	O
hypercapnic	O
increase	O
of	O
CoBF	O
by	O
52	O
+	O
/	O
-	O
6	O
%	O
and	O
CeBF	O
by	O
29	O
+	O
/	O
-	O
5	O
%	O
after	O
45	O
-	O
min	O
exposure	O
.	O

In	O
contrast	O
with	O
the	O
previously	O
reported	O
HMGR1	B-protein
mRNA	I-protein
(	O
HMGR1S	B-protein
mRNA	I-protein
)	O
,	O
which	O
is	O
detected	O
at	O
high	O
levels	O
in	O
all	O
tissues	O
of	O
the	O
plant	O
,	O
HMGR1L	B-protein
mRNA	I-protein
is	O
present	O
at	O
relatively	O
low	O
levels	O
and	O
its	O
expression	O
is	O
restricted	O
mostly	O
to	O
seedlings	O
,	O
roots	O
and	O
inflorescences	O
.	O

The	O
sequences	O
following	O
the	O
X	O
.	O
borealis	O
oocyte	O
and	O
somatic	O
5S	B-protein
genes	I-protein
are	O
identical	O
in	O
12	O
of	O
the	O
first	O
14	O
residues	O
and	O
contain	O
two	O
or	O
more	O
T	O
clusters	O
,	O
as	O
does	O
the	O
corresponding	O
region	O
of	O
X	B-protein
.	I-protein
laevis	I-protein
oocyte	I-protein
5S	I-protein
DNA	I-protein
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
find	O
out	O
whether	O
it	O
was	O
possible	O
to	O
detect	O
normal	O
lymph	O
nodes	O
by	O
high	O
-	O
resolution	O
mediastinal	O
US	O
.	O

While	O
mutations	O
in	O
K	B-protein
-	I-protein
Rev	I-protein
that	O
inactivate	O
any	O
one	O
of	O
these	O
properties	O
also	O
blocked	O
K	O
-	O
Rev	O
-	O
dependent	O
nuclear	O
RNA	O
export	O
,	O
several	O
K	B-protein
-	I-protein
Rev	I-protein
mutants	I-protein
were	O
comparable	O
to	O
wild	O
type	O
when	O
assayed	O
for	O
any	O
of	O
these	O
individual	O
activities	O
yet	O
nevertheless	O
defective	O
for	O
RNA	O
export	O
.	O

A	O
randomized	O
,	O
prospective	O
study	O
was	O
conducted	O
to	O
compare	O
ovarian	O
stimulation	O
with	O
human	B-protein
menopausal	I-protein
gonadotropin	I-protein
(	O
hMG	B-protein
)	O
and	O
human	B-protein
follicle	I-protein
-	I-protein
stimulating	I-protein
hormone	I-protein
(	O
hFSH	B-protein
)	O
in	O
an	O
in	O
vitro	O
fertilization	O
and	O
embryo	O
transfer	O
(	O
IVF	O
-	O
ET	O
)	O
program	O
.	O

We	O
conducted	O
a	O
clinical	O
and	O
pathologic	O
review	O
of	O
nine	O
patients	O
with	O
immature	O
ovarian	O
teratoma	O
.	O

Approximately	O
60	O
%	O
of	O
cell	O
bodies	O
of	O
primary	O
neurons	O
innervating	O
the	O
intra	O
and	O
perioral	O
structures	O
through	O
the	O
inferior	O
alveolar	O
,	O
lingual	O
,	O
mental	O
,	O
and	O
buccal	O
nerves	O
were	O
in	O
the	O
range	O
between	O
300	O
and	O
600	O
micron	O
2	O
in	O
cross	O
-	O
sectional	O
area	O
:	O
mean	O
+	O
/	O
-	O
SD	O
509	O
+	O
/	O
-	O
243	O
micron	O
2	O
,	O
420	O
+	O
/	O
-	O
181	O
micron	O
2	O
,	O
469	O
+	O
/	O
-	O
200	O
micron	O
2	O
,	O
and	O
444	O
+	O
/	O
-	O
186	O
micron	O
2	O
,	O
respectively	O
.	O

ASL	O
-	O
8123	O
demonstrated	O
weak	O
competitive	O
beta	B-protein
-	I-protein
adrenoreceptor	I-protein
blocking	O
activity	O
in	O
isolated	O
guinea	O
pig	O
right	O
atria	O
with	O
a	O
pA2	O
of	O
3	O
.	O
73	O
+	O
/	O
-	O
0	O
.	O
07	O
;	O
no	O
agonist	O
-	O
like	O
activity	O
was	O
observed	O
in	O
this	O
tissue	O
at	O
concentrations	O
of	O
ASL	O
-	O
8123	O
from	O
3	O
X	O
10	O
(	O
-	O
5	O
)	O
to	O
1	O
X	O
10	O
(	O
-	O
2	O
)	O
M	O
.	O

As	O
with	O
the	O
heterologous	O
DNA	O
binding	O
domain	O
,	O
MZF	B-protein
-	I-protein
1	I-protein
represses	O
reporter	O
gene	O
expression	O
in	O
nonhematopoietic	O
cell	O
lines	O
and	O
activates	O
expression	O
in	O
hematopoietic	O
cell	O
lines	O
.	O

Clin	O
.	O

Recovery	O
was	O
characterized	O
by	O
rapid	O
improvement	O
such	O
that	O
all	O
measured	O
parameters	O
normalized	O
by	O
1	O
week	O
,	O
except	O
for	O
cross	O
-	O
sectional	O
cardiac	O
area	O
which	O
remained	O
dilated	O
up	O
to	O
4	O
weeks	O
(	O
14	O
+	O
/	O
-	O
3	O
cm2	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
versus	O
control	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Harmful	O
effects	O
in	O
animals	O
and	O
man	O
may	O
result	O
from	O
both	O
deficient	O
or	O
excessive	O
amounts	O
of	O
intake	O
.	O

In	O
the	O
course	O
of	O
a	O
study	O
of	O
low	O
dose	O
X	O
-	O
rays	O
effects	O
,	O
we	O
found	O
that	O
male	O
ICR	O
white	O
Swiss	O
mice	O
showed	O
remarkable	O
suppression	O
of	O
mounting	O
behavior	O
after	O
whole	O
body	O
irradiation	O
by	O
5	O
to	O
15	O
cGy	O
X	O
-	O
rays	O
.	O

Simultaneous	O
determination	O
of	O
theophylline	O
and	O
its	O
metabolites	O
by	O
HPLC	O
A	O
high	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
method	O
has	O
been	O
developed	O
for	O
the	O
simultaneous	O
determination	O
of	O
theophylline	O
and	O
its	O
metabolites	O
,	O
with	O
caffeine	O
and	O
its	O
metabolites	O
.	O

RESULTS	O
:	O
Glaucoma	O
suspects	O
were	O
divided	O
into	O
two	O
groups	O
according	O
to	O
their	O
SWAP	O
results	O
:	O
high	O
risk	O
(	O
with	O
SWAP	O
abnormalities	O
)	O
and	O
low	O
risk	O
(	O
with	O
normal	O
SWAP	O
result	O
)	O
.	O

Encompassing	O
tamponade	O
and	O
pericardiocentesis	O
data	O
,	O
left	O
ventricular	O
stroke	O
work	O
index	O
showed	O
positive	O
correlation	O
with	O
TMFP1	O
(	O
r	O
=	O
.	O
59	O
)	O
and	O
TMFP2	O
(	O
r	O
=	O
.	O
52	O
)	O
but	O
not	O
with	O
TMFP3	O
.	O

Serum	B-protein
alkaline	I-protein
phosphatase	I-protein
activity	O
,	O
bone	O
mass	O
measurements	O
,	O
dual	O
energy	O
x	O
-	O
ray	O
absortiometric	O
analysis	O
of	O
mineral	O
density	O
,	O
and	O
mechanical	O
testing	O
values	O
in	O
vertebrae	O
and	O
femora	O
of	O
the	O
-	O
D	O
Sal	O
animals	O
did	O
not	O
significantly	O
differ	O
from	O
those	O
in	O
+	O
D	O
Sal	O
animals	O
.	O

We	O
used	O
expression	O
cloning	O
to	O
identify	O
interleukin	B-protein
-	I-protein
6	I-protein
(	O
IL	B-protein
-	I-protein
6	I-protein
)	O
as	O
one	O
factor	O
that	O
suppressed	O
growth	O
of	O
a	O
pre	O
-	O
B	O
-	O
cell	O
variant	O
line	O
,	O
1A9	O
-	O
M	O
.	O

(	O
anti	O
-	O
IIa	O
)	O
and	O
Holmer	O
et	O
al	O
.	O

Using	O
5	O
ng	O
/	O
mL	O
as	O
the	O
cutoff	O
,	O
the	O
sensitivity	O
of	O
CEA	O
was	O
68	O
%	O
.	O

APETALA3	B-protein
transcripts	I-protein
are	O
first	O
detected	O
in	O
a	O
meristematic	O
region	O
that	O
will	O
give	O
rise	O
to	O
the	O
petal	O
and	O
stamen	O
primordia	O
,	O
and	O
expression	O
is	O
maintained	O
in	O
this	O
region	O
during	O
subsequent	O
development	O
of	O
these	O
organs	O
.	O

In	O
a	O
randomized	O
single	O
-	O
blind	O
3	O
x	O
3	O
Latin	O
-	O
square	O
study	O
with	O
corrections	O
for	O
any	O
carryover	O
effects	O
,	O
27	O
males	O
and	O
30	O
females	O
consumed	O
supplements	O
containing	O
glucose	O
or	O
resistant	O
starch	O
(	O
RS	O
)	O
from	O
raw	O
high	O
-	O
amylose	O
cornstarch	O
(	O
RS2	O
)	O
or	O
from	O
retrograded	O
high	O
-	O
amylose	O
cornstarch	O
(	O
RS3	O
)	O
.	O

Biliary	O
-	O
enteric	O
fistulas	O
.	O

Both	O
domains	O
were	O
required	O
for	O
specific	O
DNA	O
binding	O
to	O
the	O
beta	B-protein
-	I-protein
retinoic	I-protein
acid	I-protein
receptor	I-protein
element	I-protein
,	O
producing	O
a	O
DNase	B-protein
I	I-protein
footprint	O
covering	O
predominantly	O
one	O
strand	O
.	O

The	O
results	O
indicate	O
that	O
the	O
bradycardic	O
agents	O
alinidine	O
and	O
zatebradine	O
do	O
not	O
exert	O
antiarrhythmic	O
efficacy	O
against	O
SVT	O
induced	O
during	O
subacute	O
myocardial	O
infarction	O
in	O
conscious	O
dogs	O
.	O

Further	O
,	O
mutational	O
analysis	O
of	O
NS5A	B-protein
assigned	O
the	O
SH3	B-protein
-	I-protein
binding	I-protein
region	I-protein
to	O
a	O
proline	O
-	O
rich	O
motif	O
that	O
is	O
highly	O
conserved	O
among	O
HCV	O
genotypes	O
.	O

Dotarizine	O
produced	O
arterial	O
dilation	O
in	O
both	O
systemic	O
and	O
pulmonary	O
circulation	O
:	O
the	O
total	O
peripheral	O
resistance	O
dropped	O
,	O
and	O
femoral	O
artery	O
flow	O
rose	O
;	O
aortic	O
and	O
pulmonary	O
artery	O
mean	O
and	O
diastolic	O
pressures	O
declined	O
,	O
and	O
systolic	O
pressures	O
remained	O
almost	O
stable	O
.	O

We	O
analyzed	O
the	O
P	O
-	O
SAECG	O
in	O
the	O
time	O
and	O
frequency	O
domain	O
in	O
23	O
patients	O
with	O
Paf	O
and	O
19	O
controls	O
.	O

Rolandic	O
spikes	O
and	O
cognitive	O
function	O
.	O

Adduction	O
of	O
the	O
human	B-protein
N	I-protein
-	I-protein
ras	I-protein
codon	I-protein
61	I-protein
sequence	I-protein
with	O
(	O
-	O
)	O
-	O
(	O
7S	O
,	O
8R	O
,	O
9R	O
,	O
10S	O
)	O
-	O
7	O
,	O
8	O
-	O
dihydroxy	O
-	O
9	O
,	O
10	O
-	O
epoxy	O
-	O
7	O
,	O
8	O
,	O
9	O
,	O
10	O
-	O
tetrahydrobenzo	O
[	O
a	O
]	O
pyrene	O
:	O
structural	O
refinement	O
of	O
the	O
intercalated	O
SRSR	O
(	O
61	O
,	O
2	O
)	O
(	O
-	O
)	O
-	O
(	O
7S	O
,	O
8R	O
,	O
9S	O
,	O
10R	O
)	O
-	O
N6	O
-	O
[	O
10	O
-	O
(	O
7	O
,	O
8	O
,	O
9	O
,	O
10	O
-	O
tetrahydrobenzo	O
[	O
a	O
]	O
pyrenyl	O
)	O
]	O
-	O
2	O
'	O
-	O
deoxyadenosyl	O
adduct	O
from	O
1H	O
NMR	O
.	O

Histological	O
observations	O
on	O
the	O
decidua	O
in	O
the	O
second	O
half	O
of	O
pregnancy	O
.	O

The	O
effect	O
of	O
desipramine	O
probably	O
represents	O
inhibition	O
of	O
neuronal	O
uptake	O
and	O
that	O
of	O
amitriptyline	O
and	O
mianserin	O
blockade	O
of	O
neuronal	O
uptake	O
and	O
prejunctional	O
alpha	B-protein
2	I-protein
-	I-protein
adrenoreceptors	I-protein
.	O

Scaling	O
of	O
fluctuations	O
in	O
one	O
-	O
dimensional	O
interface	O
and	O
hopping	O
models	O
.	O

RESULTS	O
:	O
No	O
significant	O
deformation	O
in	O
vertebral	O
artery	O
flow	O
was	O
noted	O
in	O
the	O
flexion	O
-	O
distraction	O
Stage	O
I	O
injuries	O
within	O
the	O
physiologic	O
range	O
of	O
cervical	O
flexion	O
.	O

The	O
poly	O
(	O
A	O
)	O
segment	O
of	O
the	O
RNA	O
was	O
selectively	O
cross	O
-	O
linked	O
to	O
the	O
72	O
,	O
000	O
-	O
molecular	O
-	O
weight	O
protein	O
(	O
72K	O
protein	O
)	O
.	O

Interspecific	O
backcross	O
analysis	O
using	O
progeny	O
derived	O
from	O
matings	O
of	O
(	O
C57BL	O
/	O
6J	O
x	O
Mus	O
spretus	O
)	O
F1	O
x	O
C57BL	O
/	O
6J	O
mice	O
indicates	O
that	O
the	O
thrombospondin	B-protein
gene	I-protein
is	O
tightly	O
linked	O
to	O
the	O
Fshb	B-protein
,	O
Actcl	B-protein
,	O
Ltk	B-protein
,	O
and	O
B2M	B-protein
loci	I-protein
on	O
murine	O
chromosome	O
2	O
.	O

However	O
,	O
primary	O
transcripts	O
of	O
a	O
variant	B-protein
tRNA	I-protein
(	I-protein
Val	I-protein
)	I-protein
(	I-protein
UAC	I-protein
)	I-protein
gene	I-protein
are	O
processing	O
deficient	O
under	O
standard	O
growth	O
conditions	O
(	O
30	O
degrees	O
C	O
)	O
,	O
due	O
to	O
a	O
slightly	O
altered	O
5	O
'	O
flanking	O
region	O
.	O

Furthermore	O
,	O
addition	O
of	O
B	B-protein
-	I-protein
Myb	I-protein
-	I-protein
glutathionine	I-protein
S	I-protein
-	I-protein
transferase	I-protein
fusion	I-protein
protein	I-protein
inhibited	O
complex	O
formation	O
.	O

Neomycin	O
is	O
fairly	O
effective	O
against	O
staphylococci	O
,	O
less	O
effective	O
against	O
streptococci	O
,	O
and	O
fairly	O
effective	O
against	O
gram	O
-	O
negative	O
intestinal	O
organisms	O
.	O

In	O
addition	O
,	O
REP21	O
plants	O
were	O
resistant	O
to	O
an	O
unusually	O
broad	O
range	O
of	O
tobamoviruses	O
including	O
tomato	O
mosaic	O
virus	O
,	O
tobacco	O
mild	O
green	O
mosaic	O
virus	O
,	O
TMV	O
-	O
U5	O
,	O
green	O
tomato	O
atypical	O
mosaic	O
virus	O
,	O
and	O
ribgrass	O
mosaic	O
virus	O
.	O

Three	O
cDNAs	O
encoding	O
basic	B-protein
leucine	I-protein
zipper	I-protein
(	I-protein
bZIP	I-protein
)	I-protein
-	I-protein
type	I-protein
ABRE	I-protein
-	I-protein
binding	I-protein
proteins	I-protein
were	O
isolated	O
by	O
using	O
the	O
yeast	O
one	O
-	O
hybrid	O
system	O
and	O
were	O
designated	O
AREB1	B-protein
,	O
AREB2	B-protein
,	O
and	O
AREB3	B-protein
(	O
ABA	B-protein
-	I-protein
responsive	I-protein
element	I-protein
binding	I-protein
protein	I-protein
)	O
.	O

Twenty	O
-	O
four	O
hours	O
later	O
,	O
the	O
animals	O
were	O
randomized	O
to	O
subretinal	O
treatment	O
with	O
2	O
.	O
5	O
micrograms	O
of	O
tissue	B-protein
plasminogen	I-protein
activator	I-protein
or	O
a	O
similar	O
volume	O
of	O
physiologic	O
saline	O
.	O

Junctions	O
between	O
cells	O
of	O
the	O
human	B-protein
enamel	I-protein
organ	O
.	O

These	O
studies	O
demonstrate	O
that	O
both	O
G	B-protein
alpha	I-protein
i	I-protein
genes	I-protein
are	O
dynamically	O
regulated	O
in	O
LLC	O
-	O
PK1	O
cells	O
by	O
both	O
growth	O
,	O
differentiation	O
,	O
and	O
hormone	O
signals	O
.	O

The	O
Nostoc	O
petBD	B-protein
genes	I-protein
are	O
not	O
closely	O
linked	O
to	O
the	O
psbB	B-protein
gene	I-protein
(	O
encoding	O
the	O
51	O
-	O
kDa	O
photosystem	B-protein
II	I-protein
polypeptide	I-protein
)	O
and	O
do	O
not	O
contain	O
introns	O
as	O
do	O
the	O
closely	O
related	O
chloroplast	B-protein
genes	I-protein
.	O

Mutations	O
of	O
the	O
AP	B-protein
-	I-protein
1	I-protein
site	I-protein
of	O
the	O
TIMP	B-protein
-	I-protein
1	I-protein
promoter	I-protein
that	O
prevented	O
formation	O
of	O
HMAP	B-protein
-	I-protein
1	I-protein
caused	O
a	O
70	O
%	O
loss	O
of	O
activity	O
in	O
transfected	O
activated	O
HSCs	O
.	O

Sera	O
from	O
euthyroid	O
post	O
-	O
menopausal	O
or	O
pregnant	O
women	O
yielded	O
TSH	B-protein
levels	O
within	O
the	O
normal	O
range	O
.	O

Expense	O
limits	O
the	O
use	O
of	O
hepatitis	O
B	O
vaccines	O
,	O
but	O
low	O
-	O
dose	O
intradermal	O
immunization	O
has	O
been	O
evaluated	O
as	O
a	O
cost	O
-	O
saving	O
strategy	O
in	O
numerous	O
studies	O
.	O

It	O
is	O
now	O
estimated	O
that	O
inactivation	O
mutants	O
of	O
PTEN	B-protein
exist	O
in	O
60	O
%	O
of	O
all	O
forms	O
of	O
solid	O
tumors	O
.	O

In	O
the	O
TLE	O
patients	O
the	O
NAA	O
:	O
Cr	O
ratios	O
were	O
reduced	O
in	O
the	O
seizure	O
focus	O
,	O
while	O
in	O
the	O
FLE	O
patients	O
they	O
were	O
not	O
always	O
reduced	O
in	O
the	O
seizure	O
focus	O
.	O

Element	B-protein
B	I-protein
(	O
-	O
249	O
/	O
-	O
229	O
)	O
shows	O
more	O
than	O
80	O
%	O
homology	O
to	O
a	O
consensus	B-protein
c	I-protein
-	I-protein
myb	I-protein
element	I-protein
,	O
but	O
formed	O
two	O
specific	O
complexes	O
that	O
differed	O
from	O
that	O
of	O
c	B-protein
-	I-protein
myb	I-protein
in	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

These	O
results	O
demonstrate	O
that	O
N	O
-	O
glycans	O
flanking	O
the	O
receptor	O
-	O
binding	O
site	O
of	O
the	O
HA	B-protein
molecule	I-protein
are	O
potent	O
regulators	O
of	O
influenza	O
virus	O
growth	O
,	O
with	O
the	O
glycan	O
at	O
Asn149	O
being	O
dominant	O
and	O
that	O
at	O
Asn123	O
being	O
less	O
effective	O
.	O

These	O
data	O
show	O
that	O
the	O
alpha	O
-	O
helix	O
domain	O
of	O
p57	B-protein
(	I-protein
Kip2	I-protein
)	I-protein
,	O
which	O
is	O
conserved	O
in	O
the	O
Cip	B-protein
/	I-protein
Kip	I-protein
proteins	I-protein
,	O
is	O
implicated	O
in	O
protein	O
-	O
protein	O
interaction	O
and	O
confers	O
a	O
specific	O
regulatory	O
mechanism	O
,	O
outside	O
of	O
their	O
Cdk	O
-	O
inhibitory	O
activity	O
,	O
by	O
which	O
the	O
p57	B-protein
(	I-protein
Kip2	I-protein
)	I-protein
family	O
members	O
positively	O
act	O
on	O
myogenic	O
differentiation	O
.	O

Replacement	O
of	O
residues	O
in	O
positions	O
+	O
3	O
(	O
His128Asn	O
)	O
and	O
+	O
2	O
(	O
Gln155Lys	O
)	O
of	O
the	O
reading	O
helices	O
of	O
fingers	O
2	O
and	O
3	O
,	O
respectively	O
,	O
prevented	O
binding	O
.	O

Diagnostic	O
value	O
of	O
adenosine	B-protein
deaminase	I-protein
activity	O
in	O
tuberculous	O
effusions	O
.	O

Modern	O
studies	O
,	O
conducted	O
with	O
Delta	O
-	O
9	O
-	O
THC	O
,	O
in	O
healthy	O
voluntaries	O
,	O
again	O
suggest	O
the	O
comparison	O
or	O
even	O
the	O
identity	O
of	O
the	O
modifications	O
caused	O
by	O
cannabis	O
with	O
sleep	O
and	O
dream	O
.	O

To	O
determine	O
the	O
effects	O
on	O
the	O
pulmonary	O
barrier	O
of	O
several	O
surface	O
active	O
agents	O
,	O
a	O
series	O
of	O
metered	O
dose	O
inhalers	O
(	O
MDIs	O
)	O
was	O
prepared	O
and	O
used	O
to	O
dose	O
aerosolized	O
surfactant	O
to	O
the	O
airways	O
of	O
isolated	O
perfused	O
rat	O
lungs	O
.	O

With	O
NEU	B-protein
overexpression	O
,	O
nodal	O
control	O
decreased	O
from	O
72	O
%	O
to	O
34	O
%	O
(	O
p	O
=	O
.	O
008	O
)	O
.	O

The	O
solitary	O
kidney	O
:	O
a	O
model	O
of	O
chronic	O
hyperfiltration	O
in	O
humans	O
.	O

Mutagenesis	O
of	O
the	O
pecT	B-protein
regulatory	O
region	O
revealed	O
the	O
presence	O
of	O
two	O
sites	O
in	O
which	O
insertions	O
reproduced	O
the	O
pec	B-protein
-	I-protein
1	I-protein
phenotype	O
.	O

Overexpression	O
of	O
MDR1	B-protein
has	O
been	O
demonstrated	O
in	O
many	O
cancers	O
,	O
both	O
in	O
patient	O
tumors	O
and	O
in	O
cell	O
lines	O
selected	O
with	O
a	O
variety	O
of	O
chemotherapeutic	O
agents	O
.	O

These	O
studies	O
support	O
the	O
view	O
that	O
HMG	B-protein
I	I-protein
(	I-protein
Y	I-protein
)	I-protein
is	O
an	O
important	O
cofactor	O
for	O
HLA	B-protein
-	I-protein
DRA	I-protein
gene	I-protein
activation	O
by	O
Oct	B-protein
-	I-protein
2A	I-protein
and	O
provide	O
insights	O
into	O
its	O
mechanism	O
of	O
action	O
.	O

Down	O
-	O
regulation	O
of	O
IRS	B-protein
-	I-protein
1	I-protein
is	O
linked	O
to	O
its	O
serine	O
phosphorylation	O
dependent	O
on	O
PI	B-protein
3	I-protein
-	I-protein
kinase	I-protein
activity	O
and	O
appears	O
required	O
for	O
differentiation	O
to	O
occur	O
,	O
as	O
IRS	B-protein
-	I-protein
1	I-protein
is	O
not	O
modified	O
and	O
continues	O
to	O
accumulate	O
in	O
a	O
nondifferentiating	O
myoblast	O
cell	O
line	O
.	O

As	O
pleural	O
thickening	O
is	O
seen	O
commonly	O
in	O
asbestosis	O
and	O
may	O
influence	O
lung	O
volumes	O
and	O
the	O
ratio	O
of	O
transfer	O
factor	O
to	O
effective	O
alveolar	O
volume	O
,	O
the	O
results	O
of	O
these	O
measurements	O
were	O
compared	O
only	O
in	O
the	O
cases	O
showing	O
absent	O
or	O
minimal	O
pleural	O
thickening	O
.	O

The	O
protein	B-protein
ELT	I-protein
-	I-protein
1	I-protein
,	O
encoded	O
by	O
a	O
single	O
-	O
copy	O
gene	O
homologous	O
to	O
the	O
GATA	B-protein
family	I-protein
of	I-protein
vertebrate	I-protein
transcription	I-protein
factors	I-protein
,	O
is	O
potentially	O
capable	O
of	O
interacting	O
with	O
this	O
element	O
.	O

The	O
increase	O
in	O
number	O
of	O
terminal	O
hairs	O
,	O
which	O
are	O
defined	O
as	O
hairs	O
more	O
than	O
60	O
microm	O
in	O
diameter	O
,	O
in	O
the	O
designated	O
area	O
(	O
0	O
.	O
5	O
cm	O
square	O
=	O
0	O
.	O
25	O
cm2	O
area	O
)	O
of	O
the	O
procyanidin	O
B	O
-	O
2	O
group	O
subjects	O
after	O
the	O
6	O
-	O
month	O
trial	O
was	O
significantly	O
greater	O
than	O
that	O
of	O
the	O
placebo	O
control	O
group	O
subjects	O
(	O
procyanidin	O
B	O
-	O
2	O
,	O
1	O
.	O
99	O
+	O
/	O
-	O
2	O
.	O
58	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
/	O
0	O
.	O
25	O
cm2	O
;	O
placebo	O
,	O
-	O
0	O
.	O
82	O
+	O
/	O
-	O
3	O
.	O
40	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
/	O
0	O
.	O
25	O
cm2	O
;	O
P	O
<	O
0	O
.	O
02	O
,	O
two	O
-	O
sample	O
t	O
test	O
)	O
.	O

CONCLUSION	O
:	O
The	O
training	O
of	O
novices	O
using	O
MIST	O
-	O
VR	O
yields	O
quantifiable	O
changes	O
in	O
skill	O
that	O
are	O
transferable	O
to	O
a	O
simple	O
real	O
task	O
and	O
are	O
similar	O
to	O
the	O
results	O
achieved	O
with	O
conventional	O
training	O
.	O

Within	O
a	O
135	O
-	O
bp	O
core	O
homology	O
region	O
,	O
the	O
human	B-protein
HS12	I-protein
enhancers	I-protein
are	O
approximately	O
90	O
%	O
identical	O
to	O
the	O
murine	O
homolog	O
and	O
include	O
several	O
motifs	O
previously	O
demonstrated	O
to	O
be	O
important	O
for	O
function	O
of	O
the	O
murine	O
enhancer	O
;	O
additional	O
segments	O
of	O
high	O
sequence	O
conservation	O
suggest	O
the	O
possibility	O
of	O
previously	O
unrecognized	O
functional	O
motifs	O
.	O

The	O
detection	O
of	O
ORF	O
-	O
1	O
sequences	O
in	O
human	O
tumors	O
,	O
while	O
not	O
proof	O
per	O
se	O
,	O
is	O
a	O
prerequisite	O
for	O
establishing	O
its	O
role	O
in	O
tumor	O
development	O
.	O

Roentgenographically	O
,	O
the	O
lesion	O
was	O
usually	O
a	O
well	O
-	O
defined	O
and	O
benign	O
appearing	O
one	O
,	O
either	O
purely	O
lytic	O
(	O
3	O
cases	O
)	O
or	O
with	O
central	O
radiodensity	O
(	O
2	O
cases	O
)	O
.	O

The	O
use	O
of	O
CRF	O
-	O
41	O
in	O
the	O
differential	O
diagnosis	O
of	O
Cushing	O
'	O
s	O
syndrome	O
and	O
obesity	O
.	O

A	O
novel	O
phosphotyrosine	O
-	O
binding	O
domain	O
in	O
the	O
N	O
-	O
terminal	O
transforming	O
region	O
of	O
Cbl	B-protein
interacts	O
directly	O
and	O
selectively	O
with	O
ZAP	B-protein
-	I-protein
70	I-protein
in	O
T	O
cells	O
.	O

Ischemic	O
heart	O
disease	O
evaluated	O
by	O
exercise	O
stress	O
thallium	O
-	O
201	O
myocardial	O
scintigraphy	O
:	O
a	O
comparison	O
of	O
SPECT	O
and	O
bull	O
'	O
s	O
eye	O
display	O
.	O

Both	O
mu	B-protein
and	O
gamma	B-protein
2b	I-protein
heavy	I-protein
chain	I-protein
genes	I-protein
cause	O
this	O
feedback	O
inhibition	O
of	O
heavy	B-protein
chain	I-protein
gene	I-protein
rearrangement	O
.	O

KRN2391	O
and	O
cromakalim	O
produced	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
aortic	O
and	O
coronary	O
blood	O
flow	O
.	O

The	O
prevalence	O
of	O
opportunistic	O
infection	O
among	O
surviving	O
AIDS	O
patients	O
and	O
the	O
probability	O
of	O
being	O
in	O
tumour	O
response	O
following	O
cancer	O
therapy	O
conditional	O
on	O
being	O
alive	O
are	O
two	O
examples	O
of	O
such	O
functions	O
.	O

The	O
interpretation	O
of	O
antibiotic	O
disc	O
sensitivities	O
.	O

The	O
ultrastructure	O
of	O
retinal	O
vessels	O
was	O
examined	O
in	O
three	O
eyes	O
from	O
diabetic	O
patients	O
and	O
two	O
eyes	O
from	O
control	O
subjects	O
.	O

Enzyme	B-protein
I	I-protein
of	I-protein
the	I-protein
phosphoenolpyruvate	I-protein
:	I-protein
sugar	I-protein
phosphotransferase	I-protein
system	I-protein
.	O

Rainbow	O
trout	O
were	O
obtained	O
from	O
a	O
commercial	O
trout	O
farm	O
,	O
kept	O
in	O
running	O
water	O
and	O
feeding	O
in	O
experimental	O
pellets	O
for	O
4	O
to	O
8	O
weeks	O
.	O

The	O
effect	O
of	O
hydrostatic	O
pressure	O
on	O
the	O
swimming	O
activity	O
of	O
three	O
hyponeustonic	O
crustacea	O
,	O
Anomalocera	O
patersoni	O
,	O
Pontella	O
mediterranea	O
,	O
Labidocera	O
wollastoni	O
.	O

Taken	O
together	O
,	O
they	O
uphold	O
the	O
emerging	O
concern	O
that	O
women	O
with	O
ER	B-protein
(	I-protein
+	I-protein
)	I-protein
cancers	O
may	O
not	O
benefit	O
significantly	O
from	O
endocrine	O
treatment	O
if	O
the	O
tumors	O
also	O
overexpress	O
HER	B-protein
-	I-protein
2	I-protein
.	O

Because	O
of	O
a	O
rapid	O
development	O
of	O
the	O
connective	O
tissue	O
scars	O
,	O
however	O
,	O
at	O
the	O
place	O
of	O
the	O
destroyed	O
glandular	O
parenchyma	O
areas	O
,	O
there	O
is	O
no	O
normalization	O
of	O
the	O
organ	O
'	O
s	O
structure	O
and	O
function	O
by	O
the	O
42d	O
day	O
.	O

In	O
silicosis	O
,	O
significant	O
relationships	O
between	O
patients	O
and	O
sons	O
were	O
not	O
seen	O
with	O
respect	O
to	O
arterial	O
blood	O
gas	O
determinations	O
and	O
ventilatory	O
responses	O
except	O
for	O
Paco2	O
of	O
patients	O
and	O
hypercapnic	O
ventilatory	O
responses	O
of	O
sons	O
.	O

The	O
above	O
results	O
mean	O
that	O
the	O
increase	O
in	O
alpha	B-protein
-	I-protein
adrenergic	I-protein
receptors	I-protein
makes	O
the	O
prostate	O
,	O
which	O
has	O
been	O
already	O
hypertrophied	O
,	O
less	O
elastic	O
,	O
inhibiting	O
external	O
urinary	O
sphincter	O
function	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Systemic	O
and	O
pulmonary	O
hemodynamics	O
,	O
arterial	O
blood	O
gas	O
determination	O
,	O
bronchoalveolar	O
lavage	O
protein	O
and	O
neutrophil	O
content	O
,	O
neutrophil	O
oxidant	O
burst	O
,	O
lung	B-protein
myeloperoxidase	I-protein
content	O
,	O
and	O
scanning	O
electron	O
micrographic	O
studies	O
.	O

Benign	O
intramural	O
tumors	O
of	O
the	O
esophagus	O
.	O

Gal4	B-protein
-	I-protein
Eed	I-protein
fusion	I-protein
protein	I-protein
represses	O
transcription	O
of	O
a	O
reporter	O
gene	O
driven	O
by	O
a	O
promoter	O
that	O
contains	O
Gal4	B-protein
-	I-protein
binding	I-protein
DNA	I-protein
elements	I-protein
.	O

A	O
method	O
is	O
described	O
for	O
detecting	O
targeted	O
events	O
at	O
the	O
mu	B-protein
heavy	I-protein
chain	I-protein
gene	I-protein
which	O
relies	O
on	O
co	O
-	O
conversion	O
(	O
or	O
co	O
-	O
exchange	O
)	O
of	O
a	O
point	O
mutation	O
with	O
a	O
selectable	O
marker	O
contained	O
on	O
a	O
replacement	O
vector	O
.	O

As	O
a	O
last	O
resort	O
,	O
it	O
may	O
be	O
possible	O
to	O
maintain	O
a	O
patient	O
on	O
dialysis	O
in	O
reasonable	O
health	O
with	O
a	O
DiaTAP	O
button	O
graft	O
complex	O
infected	O
with	O
Staphylococcus	O
epidermidis	O
and	O
intermittent	O
positive	O
blood	O
cultures	O
using	O
long	O
term	O
vancomycin	O
therapy	O
.	O

Using	O
an	O
RNase	B-protein
H	I-protein
protection	O
assay	O
and	O
specific	O
blocking	O
oligonucleotides	O
,	O
we	O
find	O
that	O
recognition	O
of	O
the	O
5	O
'	O
splice	O
-	O
site	O
(	O
5	O
'	O
ss	O
)	O
and	O
branchpoint	B-protein
sequence	I-protein
(	I-protein
BPS	I-protein
)	I-protein
elements	I-protein
by	O
U11	B-protein
and	O
U12	B-protein
snRNPs	I-protein
,	O
respectively	O
,	O
displays	O
strong	O
cooperativity	O
,	O
requiring	O
both	O
sites	O
in	O
the	O
pre	O
-	O
mRNA	O
substrate	O
for	O
efficient	O
complex	O
formation	O
.	O

Point	O
mutations	O
of	O
the	O
site	O
that	O
suppressed	O
Pit	B-protein
-	I-protein
1	I-protein
binding	O
in	O
vitro	O
restored	O
full	O
tiGH	B-protein
promoter	I-protein
activity	O
.	O

A	O
review	O
of	O
the	O
literature	O
identified	O
8	O
comprehensive	O
clinical	O
studies	O
,	O
all	O
of	O
which	O
failed	O
to	O
document	O
any	O
relationship	O
between	O
NF1	B-protein
and	O
intracranial	O
aneurysms	O
.	O

LD50	O
values	O
of	O
terms	O
of	O
KP	O
were	O
84	O
mg	O
/	O
kg	O
in	O
male	O
rats	O
and	O
122	O
mg	O
/	O
kg	O
in	O
female	O
rats	O
when	O
KP	O
-	O
CMC	O
was	O
administered	O
intrarectally	O
,	O
and	O
117	O
mg	O
/	O
kg	O
in	O
male	O
and	O
92	O
mg	O
/	O
kg	O
in	O
female	O
when	O
KP	O
-	O
T10	O
was	O
administered	O
intrarectally	O
.	O
,	O
while	O
peroral	O
administration	O
of	O
KP	O
-	O
CMC	O
showed	O
LD50	O
values	O
of	O
68	O
mg	O
/	O
kg	O
in	O
males	O
and	O
78	O
mg	O
/	O
kg	O
in	O
females	O
in	O
terms	O
of	O
KP	O
.	O

Blood	O
platelets	O
,	O
coagulation	O
factors	O
and	O
morphologic	O
organ	O
changes	O
following	O
scadling	O
shock	O
in	O
rhesus	O
monkeys	O
.	O

Sequencing	O
revealed	O
one	O
large	O
open	O
reading	O
frame	O
encoding	O
a	O
39	O
-	O
kDa	O
protein	O
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
-	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
is	O
one	O
of	O
several	O
autocrine	O
/	O
paracrine	O
factors	O
known	O
to	O
exert	O
potent	O
inhibitory	O
effects	O
on	O
bone	O
.	O

For	O
functional	O
studies	O
,	O
two	O
promoter	O
regions	O
were	O
cloned	O
upstream	O
of	O
the	O
reporter	O
gene	O
,	O
chloramphenicol	B-protein
acetyl	I-protein
transferase	I-protein
(	O
CAT	B-protein
)	O
:	O
(	O
i	O
)	O
phbetaE	O
-	O
B	O
-	O
the	O
plasmid	O
that	O
contains	O
the	O
human	O
(	O
h	O
)	O
promoter	O
region	O
(	O
-	O
2832	O
to	O
+	O
101	O
)	O
including	O
URE	B-protein
,	O
and	O
(	O
ii	O
)	O
prhbetaE	O
-	O
B	O
-	O
the	O
plasmid	O
that	O
contains	O
the	O
rhesus	O
(	O
rh	O
)	O
promoter	O
region	O
excluding	O
URE	B-protein
as	O
it	O
lacks	O
a	O
270	O
bp	O
region	O
of	O
the	O
hbetaAPP	B-protein
promoter	I-protein
(	O
-	O
2435	O
to	O
-	O
2165	O
)	O
.	O

SIM1	B-protein
and	O
SIM2	B-protein
do	O
not	O
form	O
homodimers	O
,	O
and	O
they	O
do	O
not	O
interact	O
with	O
AHR	B-protein
.	O

Our	O
results	O
indicate	O
that	O
serum	B-protein
BGP	I-protein
is	O
a	O
valuable	O
measurement	O
of	O
bone	O
metabolism	O
.	O

National	O
Institutes	O
of	O
Health	O
Consensus	O
Development	O
Conference	O
Statement	O
.	O

The	O
Oct	B-protein
and	O
HMG2	B-protein
proteins	I-protein
also	O
interact	O
in	O
vivo	O
.	O

Voluntary	O
wheel	O
running	O
did	O
not	O
significantly	O
increase	O
estimated	O
alanine	O
or	O
pyruvate	O
Gneo	O
or	O
absolute	O
glycerol	O
Ra	O
.	O

End	O
points	O
measured	O
were	O
perioperative	O
(	O
30	O
-	O
day	O
)	O
myocardial	O
infarction	O
(	O
MI	O
)	O
rate	O
and	O
death	O
.	O

Surprisingly	O
,	O
nuclear	O
forms	O
of	O
IE110	B-protein
were	O
found	O
to	O
move	O
a	O
cytoplasmic	O
form	O
of	O
IE175	B-protein
into	O
nuclear	O
punctate	O
structures	O
,	O
and	O
a	O
cytoplasmic	O
form	O
of	O
IE110	B-protein
was	O
able	O
to	O
retain	O
nuclear	O
forms	O
of	O
IE175	B-protein
in	O
cytoplasmic	O
punctate	O
structures	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
in	O
addition	O
to	O
the	O
non	O
-	O
spliced	O
variant	O
,	O
multiple	O
mRNA	O
species	O
were	O
generated	O
by	O
alternative	O
splicing	O
resulting	O
in	O
the	O
exclusion	O
of	O
92	O
,	O
166	O
,	O
170	O
,	O
174	O
and	O
263	O
nucleotides	O
(	O
nt	O
)	O
,	O
respectively	O
,	O
from	O
exon	O
1	O
.	O

Cp	O
is	O
normally	O
the	O
main	O
promoter	O
for	O
EBNA	B-protein
mRNA	I-protein
initiation	O
,	O
so	O
it	O
appears	O
that	O
EBNA3C	B-protein
contributes	O
to	O
a	O
negative	O
autoregulatory	O
control	O
loop	O
.	O

Using	O
a	O
v	B-protein
-	I-protein
erbA	I-protein
probe	O
,	O
we	O
obtained	O
a	O
cDNA	O
which	O
encodes	O
a	O
novel	O
445	O
-	O
amino	O
-	O
acid	O
protein	O
,	O
RLD	B-protein
-	I-protein
1	I-protein
,	O
that	O
contains	O
the	O
characteristic	O
domains	O
of	O
nuclear	O
receptors	O
.	O

The	O
solubility	O
of	O
all	O
the	O
mutated	O
proteins	O
was	O
remarkably	O
reduced	O
.	O

Synthesis	O
of	O
antisense	O
RNA	O
and	O
S	O
phase	O
-	O
dependent	O
binding	O
of	O
E2F	B-protein
complexes	I-protein
in	O
intron	O
1	O
.	O

ORFA	O
and	O
ccdA	B-protein
were	O
constitutively	O
cotranscribed	O
as	O
determined	O
by	O
primer	O
extension	O
analysis	O
.	O

Commercially	O
available	O
formulations	O
of	O
2	O
.	O
5	O
%	O
and	O
5	O
%	O
lambdacyhalothrin	O
can	O
be	O
diluted	O
either	O
with	O
water	O
for	O
ULV	O
cold	O
aerosol	O
space	O
-	O
spraying	O
or	O
with	O
diesel	O
/	O
kerosene	O
for	O
thermal	O
fogging	O
at	O
recommended	O
application	O
rates	O
of	O
0	O
.	O
5	O
-	O
1	O
g	O
ai	O
/	O
ha	O
for	O
mosquito	O
control	O
and	O
2	O
g	O
ai	O
/	O
ha	O
for	O
housefly	O
control	O
.	O

Confocal	O
fluorescence	O
microscopy	O
in	O
modern	O
cell	O
biology	O
.	O

All	O
other	O
ejaculate	O
parameters	O
(	O
density	O
,	O
motility	O
,	O
swelling	O
test	O
,	O
penetration	O
test	O
)	O
remained	O
unchanged	O
,	O
and	O
there	O
was	O
only	O
one	O
post	O
-	O
therapeutic	O
pregnancy	O
.	O

Other	O
than	O
d	O
7	O
,	O
there	O
was	O
no	O
significant	O
effect	O
on	O
the	O
number	O
of	O
implants	O
.	O

However	O
,	O
further	O
analyses	O
of	O
the	O
data	O
indicate	O
that	O
increasing	O
VO2	O
AT	O
(	O
r	O
=	O
-	O
0	O
.	O
63	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
rather	O
than	O
VO2max	O
(	O
r	O
=	O
-	O
0	O
.	O
15	O
)	O
could	O
result	O
in	O
improving	O
the	O
10	O
,	O
000	O
m	O
race	O
performance	O
to	O
a	O
larger	O
extent	O
,	O
and	O
that	O
the	O
absolute	O
amount	O
of	O
change	O
(	O
delta	O
)	O
in	O
the	O
10	O
,	O
000	O
m	O
run	O
time	O
is	O
best	O
accounted	O
for	O
by	O
a	O
combination	O
of	O
delta	O
VO2	O
AT	O
and	O
delta	O
5	O
,	O
000	O
m	O
run	O
time	O
.	O

For	O
instance	O
,	O
a	O
total	O
SIP	O
score	O
of	O
an	O
individual	O
patient	O
of	O
28	O
.	O
3	O
%	O
(	O
which	O
is	O
taken	O
as	O
an	O
example	O
,	O
being	O
the	O
mean	O
score	O
in	O
the	O
study	O
population	O
)	O
should	O
decrease	O
by	O
at	O
least	O
9	O
.	O
26	O
%	O
or	O
approximately	O
13	O
items	O
,	O
before	O
any	O
improvement	O
beyond	O
reproducibility	O
noise	O
can	O
be	O
detected	O
.	O

Double	O
-	O
staining	O
confirmed	O
that	O
there	O
were	O
separate	O
populations	O
of	O
CD68	O
-	O
positive	O
macrophages	O
and	O
XIIIa	O
-	O
positive	O
dendrocytes	O
.	O

Managing	O
HIV	O
.	O

Deleting	O
SNF1	B-protein
repressed	O
meiosis	O
at	O
the	O
same	O
three	O
steps	O
that	O
were	O
inhibited	O
by	O
glucose	O
,	O
suggesting	O
that	O
glucose	O
blocks	O
meiosis	O
by	O
inhibiting	O
Snf1	B-protein
.	O

Gel	O
shift	O
analysis	O
indicates	O
that	O
the	O
full	B-protein
-	I-protein
length	I-protein
ERM	I-protein
protein	I-protein
is	O
able	O
to	O
bind	O
specifically	O
to	O
an	O
oligonucleotide	O
containing	O
the	O
consensus	O
nucleotide	O
core	O
sequence	O
GGAA	O
recognized	O
by	O
the	O
Ets	O
proteins	O
.	O

This	O
paper	O
describes	O
the	O
advantages	O
and	O
limitations	O
of	O
the	O
main	O
study	O
approaches	O
used	O
.	O

Directives	O
concerning	O
medical	O
care	O
.	O

Whole	O
blood	O
serotonin	O
levels	O
were	O
investigated	O
in	O
a	O
control	O
group	O
(	O
n	O
=	O
35	O
)	O
and	O
in	O
a	O
group	O
of	O
chronic	O
renal	O
failure	O
patients	O
(	O
n	O
=	O
127	O
)	O
on	O
various	O
treatment	O
regimen	O
i	O
.	O
e	O
.	O
conservative	O
treatment	O
(	O
n	O
=	O
39	O
)	O
,	O
maintenance	O
haemodialysis	O
(	O
n	O
=	O
35	O
)	O
and	O
after	O
renal	O
transplantation	O
(	O
n	O
=	O
53	O
)	O
.	O

These	O
responses	O
were	O
compared	O
with	O
others	O
in	O
the	O
same	O
subjects	O
under	O
the	O
same	O
conditions	O
and	O
it	O
was	O
concluded	O
that	O
the	O
antihypertensive	O
effect	O
of	O
labetalol	O
is	O
explained	O
by	O
concurrent	O
blockade	O
of	O
alpha	B-protein
-	I-protein
and	I-protein
beta	I-protein
-	I-protein
adrenoceptors	I-protein
.	O

In	O
the	O
artificial	O
lung	O
,	O
like	O
in	O
the	O
natural	O
lung	O
and	O
peripheral	O
tissues	O
,	O
gas	O
exchanges	O
depend	O
on	O
several	O
parameters	O
:	O
blood	O
inlet	O
conditions	O
,	O
blood	O
flow	O
rate	O
,	O
temperature	O
,	O
composition	O
of	O
the	O
gas	O
mixture	O
used	O
for	O
ventilation	O
,	O
blood	O
tissue	O
perfusion	O
,	O
O2	O
consumption	O
,	O
etc	O
.	O

Confirmatory	O
statistics	O
included	O
item	O
2	O
of	O
the	O
Clinical	O
Global	O
Impression	O
(	O
CGI	O
)	O
,	O
the	O
total	O
score	O
of	O
the	O
Sandoz	O
Clinical	O
Assessment	O
Geriatric	O
(	O
SCAG	O
)	O
scale	O
,	O
the	O
subscale	O
'	O
need	O
for	O
help	O
'	O
of	O
the	O
nurse	O
'	O
s	O
rating	O
of	O
geriatric	O
patients	O
(	O
Beurteilungsskala	O
fur	O
geriatrische	O
Patienten	O
;	O
BGP	O
)	O
and	O
the	O
total	O
score	O
of	O
the	O
Short	O
Cognitive	O
Performance	O
Test	O
(	O
Syndrom	O
-	O
Kurztest	O
;	O
SKT	O
)	O
.	O

Cotransfection	O
with	O
the	O
ie1	B-protein
gene	I-protein
resulted	O
in	O
a	O
dramatic	O
increase	O
in	O
the	O
amount	O
of	O
the	O
two	O
enzymes	O
expressed	O
in	O
the	O
transfected	O
cells	O
.	O

Our	O
previous	O
study	O
suggested	O
that	O
pertussis	B-protein
toxin	I-protein
(	O
IAP	B-protein
)	O
-	O
sensitive	O
GTP	B-protein
-	I-protein
binding	I-protein
protein	I-protein
(	I-protein
s	I-protein
)	I-protein
(	O
G	B-protein
-	I-protein
protein	I-protein
)	O
is	O
involved	O
in	O
the	O
process	O
of	O
differentiation	O
by	O
hormones	O
/	O
IBMX	O
,	O
accompanied	O
by	O
c	B-protein
-	I-protein
fos	I-protein
induction	O
.	O

Insulin	B-protein
receptor	I-protein
substrate	O
-	O
1	O
-	O
mediated	O
enhancement	O
of	O
growth	O
hormone	O
-	O
induced	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
activation	O
.	O

The	O
pea	B-protein
rps10	I-protein
intron	I-protein
is	O
homologous	O
to	O
introns	O
in	O
rrn26	B-protein
and	O
cox3	B-protein
in	O
the	O
Marchantia	O
mitochondrial	O
genome	O
,	O
while	O
the	O
Marchantia	B-protein
rps10	I-protein
gene	I-protein
lacks	O
an	O
intron	O
.	O

Rip1p	B-protein
is	O
inessential	O
,	O
associated	O
with	O
nuclear	B-protein
pore	I-protein
complexes	I-protein
,	O
and	O
structurally	O
related	O
to	O
the	O
FG	B-protein
-	I-protein
nucleoporin	I-protein
family	I-protein
of	O
pore	B-protein
proteins	I-protein
.	O

Homodimers	O
of	O
the	O
three	O
proteins	O
specifically	O
recognize	O
the	O
G	O
-	O
box	O
motif	O
,	O
with	O
GBF1	B-protein
and	O
GBF3	B-protein
binding	O
symmetrically	O
to	O
this	O
palindromic	O
sequence	O
.	O

Stable	O
transfection	O
of	O
the	O
BL	O
cell	O
line	O
Raji	O
with	O
constructs	O
containing	O
core	O
promoter	O
mutations	O
confirmed	O
that	O
the	O
proximal	O
Sp1	B-protein
site	I-protein
and	O
the	O
TATA	O
box	O
are	O
essential	O
for	O
the	O
activation	O
of	O
promoter	B-protein
P1	I-protein
by	O
the	O
Ig	B-protein
kappa	I-protein
enhancers	I-protein
.	O

Patients	O
were	O
subclassified	O
into	O
age	O
-	O
matched	O
groups	O
of	O
primary	O
untreated	O
cancer	O
(	O
21	O
)	O
,	O
recurrent	O
cancer	O
(	O
18	O
)	O
,	O
and	O
`	O
`	O
cured	O
'	O
'	O
patients	O
who	O
had	O
been	O
free	O
of	O
disease	O
for	O
at	O
least	O
9	O
months	O
(	O
16	O
)	O
.	O

Histiocytic	O
panniculitis	O
was	O
observed	O
in	O
biopsy	O
specimens	O
with	O
cytophagocytosis	O
.	O

With	O
each	O
of	O
the	O
three	O
pairs	O
of	O
isolates	O
(	O
case	O
and	O
suspicious	O
case	O
)	O
,	O
identical	O
IS6110	O
banding	O
patterns	O
were	O
found	O
suggesting	O
identical	O
MTB	O
strains	O
.	O

(	O
1995	O
)	O
J	O
.	O

In	O
the	O
chicken	O
liver	O
,	O
levels	O
of	O
chicken	B-protein
MT	I-protein
mRNA	I-protein
were	O
rapidly	O
induced	O
by	O
metals	O
(	O
Cd2	O
+	O
,	O
Zn2	O
+	O
,	O
Cu2	O
+	O
)	O
,	O
glucocorticoids	O
and	O
lipopolysaccharide	O
.	O

Tendon	O
also	O
shows	O
a	O
degree	O
of	O
extensibility	O
.	O

Molecular	O
cloning	O
of	O
Elk	B-protein
-	I-protein
3	I-protein
,	O
a	O
new	O
member	O
of	O
the	O
Ets	B-protein
family	I-protein
expressed	O
during	O
mouse	O
embryogenesis	O
and	O
analysis	O
of	O
its	O
transcriptional	O
repression	O
activity	O
.	O

These	O
modifications	O
may	O
improve	O
the	O
interlaboratory	O
reproducibility	O
of	O
CD34	B-protein
determinations	O
due	O
to	O
the	O
reduction	O
in	O
sample	O
handling	O
and	O
calculation	O
of	O
results	O
.	O

Evaluation	O
of	O
automatic	O
blood	O
cell	O
counters	O
.	O

The	O
region	O
of	O
plasmid	O
pCM2	O
encoding	O
the	O
pathogenicity	B-protein
locus	I-protein
pat	I-protein
-	I-protein
1	I-protein
was	O
mapped	O
by	O
deletion	O
analysis	O
and	O
complementation	O
studies	O
to	O
a	O
1	B-protein
.	I-protein
5	I-protein
-	I-protein
kb	I-protein
Bg	I-protein
/	I-protein
II	I-protein
/	I-protein
SmaI	I-protein
DNA	I-protein
fragment	I-protein
.	O

The	O
pathogenicity	O
of	O
Achromobacter	O
puntatum	O
for	O
cold	O
blooded	O
and	O
warm	O
blooded	O
animals	O
.	O

The	O
Trx	B-protein
-	I-protein
CT	I-protein
fusion	I-protein
protein	I-protein
was	O
produced	O
less	O
efficiently	O
(	O
20	O
%	O
of	O
total	O
soluble	O
cellular	O
protein	O
)	O
.	O

The	O
elements	O
responsible	O
for	O
glucocorticoid	O
stimulation	O
of	O
ADH	B-protein
gene	I-protein
transcription	O
appear	O
to	O
reside	O
outside	O
of	O
this	O
region	O
.	O

Early	O
treatment	O
mechanics	O
of	O
the	O
Class	O
II	O
division	O
2	O
malocclusion	O
.	O

With	O
the	O
human	B-protein
Rhotekin	I-protein
cDNA	I-protein
as	O
a	O
probe	O
,	O
Northern	O
hybridization	O
revealed	O
that	O
a	O
4	O
.	O
0	O
-	O
kb	O
transcript	O
was	O
expressed	O
at	O
a	O
high	O
level	O
in	O
prostate	O
and	O
at	O
a	O
middle	O
level	O
in	O
13	O
of	O
16	O
tissues	O
examined	O
,	O
but	O
it	O
can	O
not	O
be	O
detected	O
in	O
liver	O
and	O
lung	O
tissues	O
.	O

A	O
recent	O
index	O
(	O
Fluorosis	O
Risk	O
Index	O
)	O
developed	O
by	O
Pendrys	O
(	O
1990	O
)	O
is	O
also	O
included	O
in	O
this	O
review	O
.	O

However	O
,	O
study	O
of	O
the	O
productive	O
gamma	B-protein
gene	I-protein
showed	O
that	O
the	O
skipped	O
variable	O
exon	O
was	O
bounded	O
by	O
normal	O
splicing	O
signals	O
and	O
that	O
the	O
adjacent	O
intron	O
organization	O
was	O
not	O
altered	O
.	O

Because	O
a	O
close	O
correlation	O
between	O
regional	O
decreases	O
in	O
FMZ	O
binding	O
and	O
spiking	O
activity	O
was	O
recently	O
demonstrated	O
in	O
neocortical	O
epilepsies	O
,	O
abnormal	O
peri	O
-	O
lesional	O
FMZ	O
binding	O
may	O
bear	O
some	O
relation	O
to	O
the	O
mechanisms	O
of	O
epileptogenesis	O
in	O
symptomatic	O
epilepsies	O
.	O

Choice	O
of	O
vessel	O
.	O

Wave	O
cybernetics	O
:	O
A	O
simple	O
model	O
of	O
wave	O
-	O
controlled	O
nonlinear	O
and	O
nonlocal	O
cooperative	O
phenomena	O
.	O

The	O
microphthalmia	B-protein
-	I-protein
TFE	I-protein
(	O
MiT	B-protein
)	O
subfamily	O
of	O
basic	B-protein
helix	I-protein
-	I-protein
loop	I-protein
-	I-protein
helix	I-protein
leucine	I-protein
zipper	I-protein
(	I-protein
bHLH	I-protein
-	I-protein
ZIP	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
,	O
including	O
TFE3	B-protein
,	O
TFEB	B-protein
,	O
TFEC	B-protein
,	O
and	O
Mitf	B-protein
,	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
tissue	O
-	O
specific	O
gene	O
expression	O
in	O
several	O
cell	O
lineages	O
.	O

Asthma	O
was	O
significantly	O
more	O
often	O
associated	O
with	O
ASA	O
group	O
(	O
91	O
%	O
)	O
vs	O
46	O
%	O
at	O
AT	O
and	O
in	O
only	O
16	O
%	O
at	O
INTR	O
group	O
.	O

Moreover	O
,	O
a	O
severe	O
decrease	O
of	O
antithrombin	B-protein
activity	O
became	O
evident	O
during	O
both	O
experiments	O
(	O
eg	O
,	O
in	O
experiment	O
2	O
from	O
95	O
.	O
6	O
+	O
/	O
-	O
4	O
.	O
8	O
to	O
59	O
.	O
2	O
+	O
/	O
-	O
6	O
.	O
6	O
%	O
)	O
.	O

Sprague	O
-	O
Dawley	O
newborn	O
rats	O
(	O
n	O
=	O
85	O
)	O
breathed	O
100	O
%	O
oxygen	O
(	O
O2	O
)	O
or	O
room	O
air	O
(	O
RA	O
)	O
during	O
the	O
first	O
8	O
days	O
of	O
life	O
,	O
and	O
then	O
RA	O
.	O

Following	O
20	O
min	O
of	O
steady	O
state	O
anaesthesia	O
during	O
which	O
measurements	O
of	O
IOP	O
,	O
arterial	O
pressure	O
,	O
heart	O
rate	O
,	O
FIO2	O
,	O
FE	O
'	O
CO2	O
and	O
CVP	O
were	O
recorded	O
,	O
one	O
group	O
of	O
patients	O
received	O
atracurium	O
0	O
.	O
45	O
mg	O
kg	O
-	O
1	O
and	O
the	O
other	O
pancuronium	O
0	O
.	O
1	O
mg	O
kg	O
-	O
1	O
.	O

P	O
.	O
,	O
Peyron	O
,	O
J	O
.	O

Newcastle	B-protein
disease	I-protein
antibody	I-protein
titre	O
is	O
dependent	O
on	O
serum	O
calcium	O
concentration	O
.	O

A	O
possible	O
mechanism	O
is	O
that	O
elevated	O
alveolar	O
pressure	O
and	O
decreased	O
cardiac	O
output	O
eliminate	O
blood	O
flow	O
from	O
corner	O
vessels	O
in	O
nondependent	O
high	O
VA	O
/	O
Q	O
regions	O
.	O

RESULTS	O
:	O
Soluble	O
CD23	B-protein
levels	O
were	O
significantly	O
higher	O
in	O
women	O
with	O
endometriosis	O
before	O
treatment	O
than	O
in	O
ten	O
normal	O
controls	O
.	O

CONCLUSIONS	O
:	O
We	O
obtained	O
normal	O
EPO	B-protein
levels	O
for	O
mothers	O
and	O
newborns	O
for	O
our	O
area	O
,	O
similarly	O
to	O
the	O
previously	O
described	O
ones	O
.	O

Naturally	O
acquired	O
antibodies	O
were	O
demonstrated	O
in	O
some	O
rabbits	O
kept	O
on	O
commercial	O
farms	O
.	O

The	O
following	O
aspects	O
were	O
assessed	O
:	O
(	O
1	O
)	O
The	O
effect	O
on	O
the	O
cardiovascular	O
system	O
in	O
terms	O
of	O
brachial	O
arterial	O
pressure	O
,	O
pulse	O
rate	O
,	O
and	O
oxygen	O
consumption	O
(	O
VO2	O
)	O
during	O
exercise	O
in	O
5	O
health	O
volunteers	O
;	O
(	O
2	O
)	O
emg	O
activity	O
of	O
the	O
tibialis	O
anterior	O
and	O
gastrocnemius	O
muscles	O
during	O
exercise	O
in	O
the	O
same	O
5	O
volunteers	O
;	O
and	O
(	O
3	O
)	O
postexercise	O
ankle	O
pressure	O
changes	O
in	O
10	O
subjects	O
with	O
angiographically	O
proven	O
occlusive	O
arterial	O
diseases	O
of	O
the	O
lower	O
extremities	O
.	O

On	O
the	O
amount	O
and	O
significance	O
of	O
the	O
effective	O
glucose	O
level	O
in	O
tumors	O
.	O

The	O
protein	O
encoded	O
by	O
the	O
fruA	B-protein
transcript	I-protein
is	O
well	O
conserved	O
with	O
the	O
D	B-protein
.	I-protein
melanogaster	I-protein
type	I-protein
A	I-protein
protein	I-protein
,	O
particularly	O
the	O
BTB	B-protein
protein	I-protein
-	I-protein
protein	I-protein
-	I-protein
binding	I-protein
domain	I-protein
,	O
which	O
is	O
encoded	O
by	O
exons	O
I	O
and	O
II	O
and	O
is	O
100	O
%	O
conserved	O
.	O

The	O
activity	O
of	O
the	O
minimal	O
promoter	O
was	O
found	O
to	O
be	O
controlled	O
by	O
a	O
combination	O
of	O
the	O
activities	O
of	O
the	O
transcription	O
factors	O
Sp1	B-protein
,	O
Sp3	B-protein
,	O
and	O
NF	B-protein
-	I-protein
Y	I-protein
.	O

In	O
this	O
study	O
we	O
wanted	O
to	O
assess	O
the	O
DR	O
using	O
the	O
'	O
combined	O
test	O
'	O
in	O
an	O
unselected	O
population	O
of	O
self	O
-	O
referred	O
pregnant	O
women	O
at	O
a	O
false	O
-	O
positive	O
rate	O
(	O
FPR	O
)	O
of	O
about	O
5	O
%	O
.	O

The	O
bile	O
acid	O
sequestrants	O
(	O
cholestyramine	O
and	O
colestipol	O
)	O
,	O
nicotinic	O
acid	O
,	O
fenofibrate	O
and	O
inhibitors	O
of	O
hydroxymethylglutaryl	B-protein
coenzyme	I-protein
A	I-protein
(	I-protein
HMG	I-protein
CoA	I-protein
)	I-protein
reductase	I-protein
(	O
e	O
.	O
g	O
.	O
lovastatin	O
or	O
simvastatin	O
)	O
are	O
the	O
most	O
effective	O
drugs	O
for	O
use	O
in	O
patients	O
with	O
primary	O
hypercholesterolaemia	O
;	O
these	O
agents	O
reduce	O
plasma	O
concentrations	O
of	O
total	O
and	O
LDL	O
-	O
cholesterol	O
by	O
15	O
to	O
45	O
%	O
.	O

Cloning	O
and	O
primary	O
structure	O
of	O
neurocan	O
,	O
a	O
developmentally	O
regulated	O
,	O
aggregating	O
chondroitin	O
sulfate	O
proteoglycan	O
of	O
brain	O
.	O

During	O
the	O
aftermath	O
of	O
excitation	O
of	O
the	O
skin	O
sympathetic	O
nerve	O
by	O
mental	O
arithmetics	O
,	O
3	O
/	O
12	O
A	O
delta	O
units	O
were	O
turned	O
to	O
the	O
active	O
state	O
with	O
decreased	O
mechanical	O
threshold	O
.	O

Phosphate	B-protein
glucose	I-protein
dehydrogenase	I-protein
deficiency	O
causing	O
hyperbilirubinemia	O
in	O
the	O
newborn	O
.	O

A	O
total	O
of	O
1459	O
men	O
aged	O
48	O
to	O
84	O
years	O
,	O
who	O
were	O
diagnosed	O
for	O
the	O
first	O
time	O
by	O
physicians	O
as	O
having	O
BPH	O
in	O
1994	O
and	O
who	O
had	O
not	O
received	O
treatment	O
,	O
participated	O
in	O
the	O
study	O
.	O

Selective	O
effect	O
of	O
pulmonary	O
oedema	O
on	O
prostaglandin	O
E2	O
pharmacokinetics	O
in	O
rat	O
lung	O
.	O

As	O
measured	O
by	O
the	O
PDQ	O
-	O
39	O
,	O
STN	O
-	O
DBS	O
significantly	O
improves	O
important	O
aspects	O
of	O
QoL	O
in	O
patients	O
with	O
advanced	O
PD	O
.	O

Two	O
patients	O
withdrew	O
from	O
therapy	O
,	O
one	O
for	O
personal	O
reasons	O
and	O
one	O
because	O
a	O
paraspinal	O
mass	O
developed	O
.	O

CONCLUSION	O
:	O
A	O
valve	O
-	O
like	O
mechanism	O
formed	O
by	O
the	O
capsulorhexis	O
rim	O
partially	O
adhered	O
to	O
the	O
IOL	O
optic	O
can	O
occur	O
postoperatively	O
.	O

SUP46	B-protein
is	O
implicated	O
in	O
translation	O
fidelity	O
and	O
encodes	O
the	O
ribosomal	B-protein
protein	I-protein
S13	I-protein
.	O

The	O
present	O
study	O
shows	O
that	O
phosphatidylinositol	O
3	O
-	O
kinase	O
-	O
dependent	O
p38	B-protein
kinase	I-protein
activation	O
regulates	O
Akt	B-protein
phosphorylation	O
and	O
activity	O
in	O
human	O
neutrophils	O
.	O

To	O
lower	O
the	O
current	O
high	O
incidence	O
of	O
NANB	O
-	O
induced	O
PTH	O
,	O
in	O
1986	O
,	O
the	O
American	O
Association	O
of	O
Blood	O
Banks	O
(	O
AABB	O
)	O
recommended	O
testing	O
for	O
these	O
PTH	O
-	O
associated	O
`	O
`	O
surrogate	O
'	O
'	O
markers	O
on	O
all	O
donated	O
units	O
of	O
blood	O
.	O

As	O
assessed	O
by	O
a	O
genetic	O
assay	O
that	O
measures	O
AAI	O
-	O
dependent	O
DNA	O
binding	O
,	O
TraM	B-protein
inhibited	O
TraR	B-protein
function	O
before	O
and	O
after	O
the	O
transcription	O
factor	O
had	O
bound	O
to	O
its	O
DNA	O
recognition	O
site	O
.	O

The	O
gray	O
matter	O
NAA	O
/	O
mI	O
ratio	O
clearly	O
separated	O
the	O
two	O
groups	O
.	O

The	O
feed	O
consumed	O
which	O
was	O
lowered	O
by	O
25	O
%	O
initially	O
,	O
did	O
not	O
alter	O
later	O
.	O

Using	O
a	O
series	O
of	O
mutant	O
T	O
antigens	O
expressed	O
by	O
recombinant	O
baculoviruses	O
in	O
Sf9	O
cells	O
,	O
we	O
find	O
that	O
the	O
origin	O
unwinding	O
activities	O
of	O
both	O
TS677	O
-	O
-	O
>	O
A	O
and	O
TS677	O
,	O
679	O
-	O
-	O
>	O
A	O
are	O
inhibited	O
by	O
the	O
T	B-protein
-	I-protein
antigen	I-protein
kinase	I-protein
,	O
as	O
is	O
wild	B-protein
-	I-protein
type	I-protein
T	I-protein
antigen	I-protein
.	O

Information	O
on	O
conserved	O
noncoding	O
sequences	O
will	O
help	O
in	O
studies	O
on	O
the	O
regulation	O
of	O
the	O
pro	B-protein
alpha	I-protein
1	I-protein
(	I-protein
II	I-protein
)	I-protein
collagen	I-protein
gene	I-protein
.	O

HA	O
resulted	O
in	O
decreased	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
Tre	O
(	O
0	O
.	O
4	O
degrees	O
C	O
)	O
and	O
HR	O
(	O
17	O
b	O
X	O
min	O
-	O
1	O
)	O
,	O
and	O
increased	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
Msw	O
(	O
16	O
g	O
X	O
m	O
-	O
2	O
X	O
h	O
-	O
1	O
)	O
during	O
the	O
saline	O
experiments	O
.	O

Our	O
findings	O
demonstrate	O
a	O
dose	O
-	O
dependent	O
blockade	O
of	O
the	O
mechanical	O
sensitivity	O
caused	O
by	O
a	O
mild	O
thermal	O
injury	O
by	O
both	O
GBP	O
and	O
IBG	O
.	O

The	O
method	O
described	O
may	O
prove	O
useful	O
in	O
studying	O
the	O
physiology	O
of	O
the	O
nasal	O
cycle	O
.	O

Plasma	B-protein
renin	I-protein
concentration	O
is	O
significantly	O
higher	O
in	O
the	O
subcapsular	O
venous	O
outflow	O
,	O
which	O
drains	O
the	O
superficial	O
cortex	O
,	O
than	O
in	O
the	O
deep	O
venous	O
outflow	O
,	O
which	O
drains	O
the	O
inner	O
half	O
of	O
the	O
cortex	O
and	O
medulla	O
of	O
the	O
cat	O
kidney	O
.	O

The	O
factor	O
designated	O
B	O
formed	O
a	O
complex	O
centered	O
on	O
the	O
sequence	O
TGTGGT	B-protein
,	O
a	O
core	O
motif	O
recognized	O
by	O
members	O
of	O
the	O
AML	B-protein
/	I-protein
CBFalpha	I-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O

A	O
new	O
vector	O
,	O
pHBK280	O
,	O
was	O
designed	O
to	O
facilitate	O
this	O
analysis	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
two	O
(	O
26	O
%	O
)	O
patients	O
had	O
PHG	O
before	O
(	O
group	O
A	O
)	O
and	O
64	O
(	O
74	O
%	O
)	O
developed	O
PHG	O
after	O
variceal	O
eradication	O
(	O
group	O
B	O
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Immediately	O
before	O
radical	O
prostatectomy	O
,	O
bone	O
marrow	O
aspirates	O
from	O
both	O
sides	O
of	O
the	O
iliac	O
crest	O
were	O
taken	O
from	O
287	O
patients	O
.	O

Transcription	O
of	O
these	O
genes	O
was	O
also	O
elevated	O
in	O
gut	O
and	O
lung	O
during	O
freezing	O
,	O
but	O
mRNA	O
levels	O
in	O
these	O
tissues	O
were	O
lower	O
than	O
in	O
liver	O
.	O

Findings	O
of	O
positive	O
potentials	O
showed	O
that	O
N1	O
originated	O
in	O
the	O
area	O
of	O
ventral	O
gray	O
matter	O
through	O
the	O
ventro	O
-	O
lateral	O
column	O
and	O
N2	O
through	O
the	O
dorsal	O
column	O
.	O

Vector	O
stocks	O
containing	O
envelope	O
proteins	O
from	O
three	O
different	O
SIVmac	O
clones	O
,	O
namely	O
,	O
SIVmac239	O
(	O
T	O
-	O
lymphocyte	O
tropic	O
[	O
T	O
-	O
tropic	O
]	O
)	O
,	O
SIVmac316	O
(	O
macrophage	O
tropic	O
[	O
M	O
-	O
tropic	O
]	O
)	O
,	O
and	O
SIVmac1A11	O
(	O
dualtropic	O
)	O
,	O
were	O
tested	O
.	O

A	O
twelfth	O
insertion	O
disrupts	O
two	O
genes	O
,	O
Nrk	B-protein
,	O
a	O
`	B-protein
`	I-protein
neurospecific	I-protein
'	I-protein
'	I-protein
receptor	I-protein
tyrosine	I-protein
kinase	I-protein
,	O
and	O
Tpp	B-protein
,	O
which	O
encodes	O
a	O
neuropeptidase	B-protein
.	O

The	O
Southern	O
technique	O
allowed	O
a	O
further	O
localization	O
of	O
the	O
region	O
of	O
most	O
extensive	O
transcription	O
to	O
a	O
1	B-protein
.	I-protein
8	I-protein
kb	I-protein
HindIII	I-protein
-	I-protein
EcoRI	I-protein
fragment	I-protein
.	O

In	O
literature	O
,	O
the	O
HBE	O
has	O
been	O
displayed	O
by	O
application	O
of	O
the	O
averaging	O
method	O
.	O

Patulin	O
is	O
extracted	O
from	O
apple	O
butter	O
samples	O
with	O
ethyl	O
acetate	O
and	O
the	O
extract	O
is	O
cleaned	O
up	O
on	O
a	O
silica	O
gel	O
column	O
,	O
using	O
benzene	O
-	O
ethyl	O
acetate	O
(	O
75	O
+	O
25	O
)	O
as	O
the	O
eluant	O
.	O

The	O
lowest	O
culture	O
failure	O
rate	O
of	O
0	O
.	O
2	O
per	O
cent	O
was	O
found	O
after	O
EAF	O
compared	O
with	O
0	O
.	O
9	O
per	O
cent	O
among	O
CVS	O
.	O

Homograft	O
response	O
and	O
hemagglutinin	B-protein
production	O
by	O
sensitized	O
thymectomized	O
irradiated	O
adult	O
mice	O
.	O

Pregnant	O
rats	O
were	O
exposed	O
to	O
one	O
of	O
the	O
following	O
:	O
(	O
1	O
)	O
10	O
%	O
O2	O
in	O
N2	O
or	O
100	O
%	O
O2	O
for	O
2	O
days	O
beginning	O
at	O
day	O
7	O
,	O
11	O
,	O
14	O
,	O
or	O
18	O
of	O
pregnancy	O
;	O
(	O
2	O
)	O
10	O
%	O
O2	O
in	O
N2	O
or	O
100	O
%	O
O2	O
for	O
10	O
h	O
/	O
day	O
beginning	O
at	O
day	O
7	O
;	O
or	O
(	O
3	O
)	O
14	O
-	O
11	O
%	O
O2	O
in	O
N2	O
continuously	O
beginning	O
at	O
day	O
14	O
till	O
day	O
21	O
when	O
they	O
were	O
sacrificed	O
.	O

Serum	O
HBV	O
-	O
DNA	O
,	O
viral	O
serology	O
,	O
and	O
liver	O
enzymes	O
were	O
measured	O
sequentially	O
;	O
liver	O
histology	O
was	O
taken	O
before	O
and	O
during	O
treatment	O
in	O
12	O
patients	O
.	O

The	O
high	B-protein
density	I-protein
lipoprotein	I-protein
(	I-protein
HDL	I-protein
)	I-protein
receptor	I-protein
mediates	O
the	O
uptake	O
of	O
cholesterol	O
and	O
cholesteryl	O
esters	O
,	O
substrates	O
for	O
steroidogenesis	O
,	O
from	O
an	O
HDL	O
particle	O
in	O
the	O
adrenal	O
gland	O
and	O
gonads	O
.	O

Retrograde	O
filling	O
consists	O
in	O
sealing	O
endodontics	O
system	O
directly	O
at	O
the	O
apical	O
zone	O
after	O
surgical	O
approach	O
.	O

The	O
hematopoietic	B-protein
colony	I-protein
-	I-protein
stimulating	I-protein
factors	I-protein
(	O
CSF	B-protein
)	O
have	O
been	O
introduced	O
into	O
clinical	O
practice	O
as	O
additional	O
supportive	O
measures	O
that	O
can	O
reduce	O
the	O
incidence	O
of	O
infectious	O
complications	O
in	O
patients	O
with	O
cancer	O
and	O
neutropenia	O
.	O

A	O
critical	O
heart	O
rate	O
and	O
/	O
or	O
appropriate	O
sympathetic	O
state	O
was	O
found	O
to	O
provoke	O
all	O
instances	O
of	O
reentrant	O
or	O
automatic	O
atrial	O
tachycardia	O
and	O
atypical	O
junctional	O
tachycardia	O
.	O

Chlorambucil	O
and	O
interferon	B-protein
for	O
low	O
grade	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
.	O

The	O
DNA	O
binding	O
activities	O
of	O
the	O
three	O
repressor	O
preparations	O
were	O
studied	O
using	O
fragments	O
containing	O
CIRs	O
(	O
CIR3	O
-	O
CIR6	O
)	O
from	O
the	O
essential	O
early	O
region	O
as	O
templates	O
for	O
DNase	B-protein
I	I-protein
footprinting	O
.	O

XII	O
.	O

Synaptic	O
targeting	O
of	O
the	O
postsynaptic	B-protein
density	I-protein
protein	I-protein
PSD	I-protein
-	I-protein
95	I-protein
mediated	O
by	O
a	O
tyrosine	O
-	O
based	O
trafficking	O
signal	O
.	O

Regulation	O
of	O
HIV	O
-	O
1	O
transcription	O
.	O

We	O
isolated	O
the	O
human	B-protein
FGF	I-protein
-	I-protein
BP	I-protein
promoter	I-protein
and	O
determined	O
by	O
deletion	O
analysis	O
that	O
TPA	B-protein
regulatory	I-protein
elements	I-protein
were	O
all	O
contained	O
in	O
the	O
first	O
118	O
base	O
pairs	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O

Derivatives	O
of	O
boswellic	O
acids	O
.	O

Serum	O
prostatic	B-protein
acid	I-protein
phosphatase	I-protein
levels	O
showed	O
a	O
significantly	O
weaker	O
correlation	O
with	O
cancer	O
volume	O
(	O
r	O
equals	O
0	O
.	O
51	O
)	O
and	O
every	O
other	O
pathological	O
parameter	O
.	O

With	O
exon	O
trapping	O
,	O
we	O
could	O
isolate	O
five	O
potential	O
exons	O
from	O
the	O
YAC	O
946E12	O
that	O
spans	O
the	O
region	O
,	O
four	O
of	O
which	O
could	O
be	O
placed	O
in	O
the	O
contig	O
in	O
the	O
vicinity	O
of	O
the	O
breakpoints	O
.	O

No	O
preferential	O
VH	B-protein
/	I-protein
VL	I-protein
-	I-protein
chains	I-protein
correlated	O
with	O
any	O
of	O
the	O
12	O
different	O
antigen	O
reactivities	O
,	O
even	O
for	O
mAbs	O
with	O
nearly	O
identical	O
cross	O
-	O
reactivities	O
.	O

In	O
Xenopus	O
laevis	O
,	O
the	O
gene	O
encoding	O
the	O
elongation	B-protein
factor	I-protein
1	I-protein
-	I-protein
alpha	I-protein
variant	I-protein
EF	I-protein
-	I-protein
1	I-protein
alpha	I-protein
O	I-protein
,	O
where	O
O	O
stands	O
for	O
oocyte	O
,	O
is	O
expressed	O
in	O
oocytes	O
and	O
early	O
embryos	O
.	O

We	O
also	O
show	O
that	O
p65	B-protein
binds	O
to	O
these	O
targets	O
with	O
almost	O
equal	O
affinity	O
and	O
that	O
different	O
residues	O
have	O
variable	O
roles	O
in	O
binding	O
different	O
kappaB	B-protein
targets	I-protein
.	O

Although	O
the	O
Src	B-protein
tyrosine	I-protein
kinase	I-protein
induces	O
constitutive	O
Stat3	B-protein
phosphorylation	O
on	O
tyrosine	O
,	O
activation	O
of	O
Stat3	O
-	O
mediated	O
gene	O
regulation	O
requires	O
both	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	B-protein
.	O

IgM	B-protein
and	O
IgG	B-protein
anti	I-protein
A	I-protein
and	O
anti	B-protein
B	I-protein
antibody	I-protein
status	O
of	O
100	O
antenatal	O
O	O
group	O
mothers	O
(	O
who	O
had	O
non	O
O	O
group	O
husbands	O
)	O
were	O
studied	O
.	O

A	O
triple	B-protein
-	I-protein
mutant	I-protein
TBP	I-protein
(	O
R231E	O
+	O
R235E	O
+	O
R239S	O
)	O
had	O
greatly	O
reduced	O
activity	O
for	O
yeast	B-protein
U6	I-protein
snRNA	I-protein
gene	I-protein
transcription	O
while	O
remaining	O
active	O
for	O
Pol	B-protein
II	I-protein
basal	O
transcription	O
.	O

Samples	O
obtained	O
from	O
normal	O
volunteers	O
and	O
from	O
the	O
great	O
majority	O
of	O
the	O
patients	O
,	O
excluding	O
those	O
with	O
asthma	O
,	O
had	O
no	O
effect	O
on	O
ciliary	O
beating	O
.	O

Gng3lg	B-protein
transcripts	I-protein
are	O
expressed	O
in	O
a	O
variety	O
of	O
tissues	O
including	O
both	O
brain	O
and	O
testes	O
.	O

Interdigitated	O
residues	O
within	O
a	O
small	O
region	O
of	O
VP16	B-protein
interact	O
with	O
Oct	B-protein
-	I-protein
1	I-protein
,	O
HCF	B-protein
,	O
and	O
DNA	O
.	O

In	O
an	O
earlier	O
study	O
(	O
Kimura	O
,	O
Y	O
.	O
,	O
Kurzydlowski	O
,	O
K	O
.	O
,	O
Tada	O
,	O
M	O
.	O
,	O
and	O
MacLennan	O
,	O
D	O
.	O

Laser	O
therapy	O
of	O
penile	O
carcinoma	O
.	O

Vocal	O
cord	O
abduction	O
rehabilitation	O
by	O
nervous	O
selective	O
anastomosis	O
.	O

Dissociative	O
anesthetics	O
2	O
-	O
(	O
o	O
-	O
chlorophenyl	O
)	O
-	O
2	O
-	O
methyl	O
-	O
amino	O
cyclohexane	O
HCL	O
(	O
CI	O
-	O
581	O
)	O
.	O

If	O
this	O
is	O
the	O
case	O
,	O
identification	O
and	O
characterization	O
of	O
transcripts	O
from	O
the	O
Ig	B-protein
loci	I-protein
should	O
permit	O
a	O
better	O
understanding	O
of	O
the	O
gene	O
rearrangement	O
process	O
.	O

Deletion	O
of	O
the	O
RVH	B-protein
domain	I-protein
resulted	O
in	O
loss	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
activation	O
.	O

The	O
presence	O
of	O
the	O
RV	O
5	O
'	O
(	O
+	O
)	O
SL	O
sequence	O
had	O
the	O
primary	O
enhancing	O
effect	O
on	O
translation	O
.	O

Three	O
high	O
mobility	O
group	O
-	O
like	O
sequences	O
within	O
a	O
48	O
-	O
base	O
pair	O
enhancer	O
of	O
the	O
Col2a1	B-protein
gene	I-protein
are	O
required	O
for	O
cartilage	O
-	O
specific	O
expression	O
in	O
vivo	O
.	O

The	O
findings	O
suggest	O
that	O
ERP	O
effects	O
of	O
distinct	O
memory	O
processes	O
are	O
differentially	O
influenced	O
by	O
the	O
encoding	O
instructions	O
.	O

Risk	O
factors	O
influencing	O
lymph	O
nodes	O
metastasis	O
in	O
lung	O
cancer	O
with	O
stage	O
I	O
,	O
II	O
or	O
IIIA	O
.	O

Our	O
results	O
establish	O
GKLF	B-protein
as	O
a	O
sequence	O
-	O
specific	O
transcription	O
factor	O
likely	O
involved	O
in	O
regulation	O
of	O
expression	O
of	O
endogenous	O
genes	O
.	O

Sequence	O
comparison	O
and	O
binding	O
studies	O
of	O
the	O
18	B-protein
-	I-protein
bp	I-protein
MOK2	I-protein
-	I-protein
binding	I-protein
sites	I-protein
present	O
in	O
intron	O
2	O
of	O
human	O
,	O
bovine	O
,	O
and	O
mouse	B-protein
IRBP	I-protein
genes	I-protein
show	O
that	O
the	O
3	O
'	O
-	O
half	O
sequence	O
is	O
the	O
essential	O
core	O
element	O
for	O
MOK2	B-protein
binding	O
.	O

Carnitine	B-protein
palmitoyltransferase	I-protein
(	I-protein
CPT	I-protein
)	I-protein
II	I-protein
deficiency	O
is	O
the	O
most	O
common	O
inherited	O
disorder	O
of	O
lipid	O
metabolism	O
affecting	O
skeletal	O
muscle	O
.	O

Each	O
trial	O
consisted	O
of	O
light	O
and	O
buzzer	O
for	O
five	O
seconds	O
as	O
conditioned	O
stimuli	O
and	O
electric	O
shock	O
for	O
five	O
seconds	O
as	O
an	O
unconditioned	O
stimulus	O
.	O

Conversely	O
,	O
when	O
VDR	B-protein
is	O
overexpressed	O
,	O
vitamin	O
D3	O
attenuates	O
9	O
-	O
cis	O
RA	O
induction	O
from	O
an	O
RXR	B-protein
-	I-protein
responsive	I-protein
element	I-protein
.	O

Rigorous	O
treatment	O
protocols	O
for	O
diet	O
delivery	O
and	O
EEN	O
-	O
related	O
GI	O
adverse	O
effects	O
were	O
applied	O
.	O

Furthermore	O
,	O
the	O
potency	O
of	O
Dacarbacine	O
in	O
the	O
treatment	O
of	O
carcinoid	O
tumors	O
seems	O
to	O
be	O
underestimated	O
up	O
to	O
now	O
.	O

Thus	O
,	O
the	O
induction	O
of	O
E2F	B-protein
binding	O
to	O
the	O
E2F	B-protein
-	I-protein
1	I-protein
promoter	I-protein
by	O
the	O
E4	B-protein
-	I-protein
6	I-protein
/	I-protein
7	I-protein
protein	I-protein
observed	O
in	O
vitro	O
correlates	O
with	O
transactivation	O
of	O
E2F	B-protein
-	I-protein
1	I-protein
promoter	I-protein
activity	O
in	O
vivo	O
.	O

With	O
steady	O
illumination	O
,	O
outer	O
retinal	O
(	O
photoreceptor	O
)	O
QO2	O
decreased	O
to	O
1	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
9	O
ml	O
O2	O
/	O
(	O
100	O
g	O
.	O
min	O
)	O
,	O
but	O
inner	O
retinal	O
QO2	O
remained	O
unchanged	O
at	O
3	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
5	O
ml	O
O2	O
/	O
(	O
100	O
g	O
.	O
min	O
)	O
(	O
5	O
cats	O
)	O
.	O

Cumulated	O
maximum	O
lod	O
scores	O
between	O
FRDA	B-protein
and	O
D9S5	B-protein
and	O
between	O
FRDA	B-protein
and	O
D9S15	B-protein
are	O
above	O
36	O
and	O
61	O
,	O
respectively	O
,	O
at	O
a	O
recombination	O
fraction	O
of	O
0	O
,	O
indicating	O
that	O
recombination	O
events	O
needed	O
to	O
orient	O
the	O
search	O
of	O
the	O
gene	O
are	O
very	O
difficult	O
to	O
identify	O
and	O
ascertain	O
.	O

BACKGROUND	O
:	O
Fluoroquinolones	O
(	O
FQ	O
)	O
are	O
contraindicated	O
in	O
children	O
because	O
of	O
the	O
risk	O
of	O
cartilage	O
damage	O
.	O

On	O
the	O
other	O
hand	O
,	O
total	O
pinealectomy	O
in	O
these	O
already	O
sympathectomized	O
blinded	O
rabbits	O
always	O
resulted	O
in	O
a	O
substantial	O
deceleration	O
of	O
the	O
rhythms	O
(	O
mean	O
delta	O
tau	O
=	O
+	O
0	O
.	O
23	O
h	O
)	O
.	O

NiCl	O
(	O
2	O
)	O
-	O
induced	O
MCP	B-protein
-	I-protein
1	I-protein
synthesis	O
required	O
activation	O
of	O
NF	B-protein
-	I-protein
kappaB	I-protein
since	O
mutation	O
of	O
NF	B-protein
-	I-protein
kappaB	I-protein
-	I-protein
binding	I-protein
sites	I-protein
in	O
the	O
promoter	O
resulted	O
in	O
complete	O
loss	O
of	O
inducible	O
promoter	O
activity	O
.	O

A	O
more	O
complete	O
analysis	O
of	O
dose	O
response	O
,	O
time	O
and	O
mode	O
of	O
Ga	O
administration	O
(	O
preinjury	O
or	O
postinjury	O
)	O
,	O
and	O
availability	O
of	O
Ga	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
is	O
needed	O
to	O
further	O
evaluate	O
the	O
efficacy	O
of	O
this	O
compound	O
.	O

Spc42p	B-protein
also	O
was	O
identified	O
as	O
a	O
component	O
of	O
a	O
cytoplasmic	B-protein
SPB	I-protein
subcomplex	I-protein
containing	O
Spc94p	B-protein
/	I-protein
Nud1p	I-protein
,	O
Cnm67p	B-protein
,	O
and	O
Spc42p	B-protein
.	O

However	O
,	O
such	O
a	O
mechanism	O
was	O
not	O
detected	O
in	O
preliminary	O
observations	O
on	O
M	O
.	O
synoviae	O
.	O

Ea	O
value	O
was	O
calculated	O
as	O
the	O
ratio	O
of	O
the	O
steady	O
-	O
state	O
end	O
-	O
systolic	O
aortic	O
pressure	O
(	O
ESAP	O
)	O
to	O
stroke	O
volume	O
(	O
thermodilution	O
)	O
.	O

The	O
mobility	O
shift	O
of	O
both	O
of	O
these	O
proteins	O
is	O
abolished	O
by	O
treatment	O
with	O
inhibitors	O
of	O
PKC	B-protein
or	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
/	I-protein
extracellular	I-protein
signal	I-protein
-	I-protein
related	I-protein
kinase	I-protein
kinase	I-protein
.	O

Amiodarone	O
,	O
seldom	O
used	O
as	O
first	O
-	O
line	O
treatment	O
,	O
appears	O
to	O
be	O
the	O
most	O
effective	O
drug	O
.	O

These	O
results	O
indicate	O
that	O
BACM	O
has	O
antiplaque	O
and	O
stronger	O
antidegradation	O
effects	O
than	O
GLCM	O
.	O

Expression	O
is	O
exclusively	O
limited	O
to	O
the	O
CNS	O
at	O
this	O
and	O
later	O
stages	O
.	O

However	O
,	O
in	O
a	O
multivariate	O
analysis	O
considering	O
age	O
,	O
gender	O
,	O
and	O
a	O
previous	O
history	O
of	O
cardiovascular	O
diseases	O
,	O
female	O
gender	O
was	O
not	O
independently	O
associated	O
with	O
death	O
.	O

Antihistamines	O
in	O
asthma	O
.	O

During	O
pentobarbital	O
anesthesia	O
,	O
the	O
basal	O
VO2	O
was	O
5	O
.	O
26	O
ml	O
/	O
kg	O
/	O
min	O
and	O
was	O
increased	O
by	O
epinephrine	O
in	O
a	O
dose	O
dependent	O
manner	O
at	O
plasma	O
concentrations	O
between	O
3	O
.	O
9	O
ng	O
/	O
ml	O
(	O
VO2	O
=	O
5	O
.	O
68	O
ml	O
/	O
kg	O
/	O
min	O
)	O
and	O
36	O
.	O
5	O
ng	O
/	O
ml	O
(	O
VO2	O
=	O
6	O
.	O
47	O
ml	O
/	O
kg	O
/	O
min	O
)	O
.	O

Previous	O
studies	O
have	O
shown	O
[	O
Hisanaga	O
,	O
S	O
.	O
,	O
Kusubata	O
,	O
M	O
.	O
,	O
Okumura	O
,	O
E	O
.	O
@	O
Kishimoto	O
,	O
T	O
.	O

These	O
findings	O
suggest	O
that	O
both	O
in	O
the	O
early	O
stages	O
(	O
0T	O
,	O
0N	O
)	O
and	O
in	O
more	O
severe	O
stages	O
of	O
VWF	O
(	O
stages	O
1	O
-	O
2	O
)	O
cold	O
induced	O
hyperreactivity	O
in	O
the	O
digital	O
vessels	O
and	O
Raynaud	O
'	O
s	O
syndrome	O
are	O
vascular	O
disorders	O
of	O
functional	O
origin	O
occurring	O
without	O
any	O
prethrombotic	O
alterations	O
.	O

Response	O
to	O
treatment	O
was	O
better	O
in	O
patients	O
with	O
less	O
pretreatment	O
(	O
one	O
-	O
two	O
prior	O
treatments	O
)	O
than	O
in	O
heavily	O
pretreated	O
ones	O
(	O
more	O
than	O
three	O
)	O
and	O
this	O
relation	O
was	O
found	O
to	O
be	O
statistically	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Can	O
survival	O
be	O
prolonged	O
for	O
patients	O
with	O
hormone	O
-	O
resistant	O
prostate	O
cancer	O
?	O

Treatment	O
of	O
ischemic	O
heart	O
disease	O
in	O
the	O
elderly	O

Thus	O
,	O
cibenzoline	O
is	O
an	O
effective	O
antiarrhythmic	O
agent	O
with	O
a	O
favourable	O
pharmacokinetic	O
profile	O
that	O
may	O
be	O
considered	O
with	O
other	O
class	O
I	O
drugs	O
in	O
patients	O
requiring	O
therapy	O
for	O
high	O
risk	O
arrhythmias	O
.	O

Using	O
a	O
series	O
of	O
mutant	O
proteins	O
,	O
we	O
have	O
characterized	O
domains	O
responsible	O
for	O
activation	O
or	O
repression	O
.	O

Liposomal	O
Amphotericin	O
-	O
B	O
failed	O
in	O
6	O
/	O
7	O
patients	O
with	O
culture	O
-	O
proven	O
mycosis	O
who	O
died	O
from	O
infection	O
with	O
Aspergillus	O
(	O
n	O
=	O
2	O
)	O
and	O
Candida	O
(	O
n	O
=	O
4	O
)	O
,	O
respectively	O
.	O

In	O
all	O
instances	O
the	O
apparent	O
alcohol	O
responses	O
were	O
very	O
small	O
and	O
never	O
exceeded	O
a	O
reading	O
of	O
1	O
microgram	O
/	O
100ml	O
for	O
breath	O
samples	O
more	O
than	O
10min	O
post	O
-	O
exposure	O
.	O

Viruses	O
were	O
isolated	O
from	O
9	O
lungs	O
:	O
7	O
with	O
PI	O
-	O
3V	O
,	O
1	O
with	O
NCP	O
BVDV	O
type	O
1	O
,	O
and	O
1	O
with	O
both	O
BVHV	O
-	O
1	O
and	O
BVDV	O
.	O

In	O
consequence	O
,	O
the	O
gpI	B-protein
derived	O
from	O
cells	O
infected	O
with	O
mO74	O
showed	O
antigenic	O
characteristics	O
similar	O
to	O
those	O
of	O
gpI	B-protein
from	O
VZV	O
-	O
infected	O
cells	O
as	O
determined	O
from	O
the	O
immunoprecipitation	O
pattern	O
,	O
although	O
the	O
molecular	O
weight	O
of	O
each	O
polypeptide	O
was	O
different	O
,	O
and	O
antibody	O
produced	O
in	O
rabbits	O
infected	O
with	O
recombinant	O
virus	O
had	O
a	O
high	O
neutralizing	O
activity	O
,	O
when	O
the	O
reaction	O
was	O
performed	O
with	O
complement	O
.	O

As	O
an	O
alternative	O
approach	O
to	O
this	O
question	O
,	O
we	O
have	O
studied	O
the	O
effects	O
of	O
ectopically	O
expressed	O
SHIP	B-protein
,	O
SHP	B-protein
-	I-protein
1	I-protein
,	O
or	O
SHP	B-protein
-	I-protein
2	I-protein
SH2	O
-	O
containing	O
decoy	O
proteins	O
on	O
Fc	B-protein
gamma	I-protein
RIIB1	I-protein
signaling	O
.	O

This	O
machinery	O
involves	O
a	O
secondary	O
structure	O
,	O
SECIS	B-protein
element	I-protein
,	O
in	O
the	O
selenoprotein	B-protein
-	I-protein
encoding	I-protein
mRNA	I-protein
,	O
directing	O
selenocysteine	O
insertion	O
at	O
the	O
position	O
of	O
an	O
opal	O
(	O
UGA	O
)	O
codon	O
,	O
normally	O
conferring	O
termination	O
of	O
translation	O
.	O

Infection	O
with	O
Neisseria	O
meningitidis	O
group	O
B	O
has	O
been	O
difficult	O
to	O
detect	O
,	O
partly	O
because	O
this	O
bacterial	O
group	O
'	O
s	O
polysaccharide	O
is	O
a	O
weak	O
immunogen	O
.	O

The	O
relatively	O
high	O
level	O
transcription	O
from	O
this	O
gene	O
shows	O
that	O
the	O
polymorphic	O
chromosome	O
ends	O
of	O
P	O
.	O
falciparum	O
,	O
which	O
have	O
been	O
proposed	O
to	O
be	O
transcriptionally	O
silent	O
,	O
can	O
be	O
active	O
expression	O
sites	O
for	O
var	B-protein
genes	I-protein
.	O

Even	O
if	O
the	O
electrocardiographic	O
signs	O
are	O
subdued	O
,	O
the	O
underlying	O
blockade	O
of	O
I	O
(	O
Kr	O
)	O
current	O
may	O
precipitate	O
the	O
occurrence	O
of	O
arrhythmia	O
.	O

To	O
identify	O
structural	O
features	O
of	O
residues	O
flanking	O
the	O
c	O
-	O
region	O
that	O
influence	O
the	O
fidelity	O
and	O
efficiency	O
of	O
signal	O
peptidase	B-protein
cleavage	O
as	O
well	O
as	O
co	O
-	O
translational	O
translocation	O
,	O
we	O
introduced	O
six	O
amino	O
acid	O
substitutions	O
into	O
the	O
COOH	O
terminus	O
of	O
the	O
hydrophobic	O
core	O
and	O
seven	O
substitutions	O
at	O
the	O
NH2	O
terminus	O
of	O
the	O
mature	O
region	O
(	O
the	O
+	O
1	O
position	O
)	O
of	O
a	O
model	O
eukaryotic	B-protein
preprotein	I-protein
-	I-protein
human	I-protein
pre	I-protein
(	I-protein
delta	I-protein
pro	I-protein
)	I-protein
apoA	I-protein
-	I-protein
II	I-protein
.	O

We	O
also	O
studied	O
a	O
new	O
parameter	O
:	O
the	O
angle	O
to	O
maximal	O
peak	O
torque	O
(	O
APT	O
)	O
.	O

Photopic	O
spectral	O
sensitivity	O
determined	O
electroretinographically	O
for	O
the	O
pigeon	O
eye	O
.	O

The	O
hydrophobicity	O
plot	O
of	O
NHE	B-protein
-	I-protein
3	I-protein
is	O
very	O
similar	O
to	O
that	O
of	O
NHE	B-protein
-	I-protein
1	I-protein
and	O
NHE	B-protein
-	I-protein
2	I-protein
.	O

Subhuman	O
primates	O
appear	O
to	O
be	O
more	O
sensitive	O
to	O
reproductive	O
and	O
other	O
adverse	O
effects	O
of	O
PCBs	O
than	O
humans	O
.	O

CT	O
abnormalities	O
noted	O
in	O
term	O
babies	O
included	O
hemorrhage	O
(	O
subarachnoid	O
5	O
.	O
8	O
%	O
,	O
intracerebral	O
11	O
.	O
6	O
%	O
)	O
,	O
hypodensity	O
(	O
mild	O
23	O
.	O
2	O
%	O
,	O
moderate	O
11	O
.	O
6	O
%	O
severe	O
5	O
.	O
8	O
%	O
)	O
;	O
hypodensity	O
with	O
hemorrhage	O
5	O
.	O
8	O
%	O
and	O
cerebral	O
atrophy	O
5	O
.	O
8	O
%	O
.	O

Repeated	O
administration	O
of	O
GRg2	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
significantly	O
improved	O
the	O
CYP	O
-	O
induced	O
recognitional	O
deficits	O
by	O
increasing	O
the	O
CYP	O
-	O
decreased	O
rate	O
from	O
55	O
.	O
8	O
+	O
/	O
-	O
9	O
.	O
6	O
to	O
80	O
.	O
8	O
+	O
/	O
-	O
4	O
.	O
2	O
in	O
d	O
3	O
learning	O
acquisition	O
(	O
F	O
(	O
1	O
,	O
14	O
)	O
=	O
5	O
.	O
6	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
from	O
53	O
.	O
4	O
+	O
/	O
-	O
8	O
.	O
4	O
to	O
60	O
.	O
0	O
+	O
/	O
-	O
8	O
.	O
2	O
in	O
48	O
h	O
memory	O
acquisition	O
(	O
F	O
(	O
1	O
,	O
14	O
)	O
=	O
7	O
.	O
5	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
from	O
55	O
.	O
0	O
+	O
/	O
-	O
5	O
.	O
5	O
to	O
88	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
5	O
in	O
24	O
h	O
memory	O
retention	O
(	O
F	O
(	O
1	O
,	O
12	O
)	O
27	O
.	O
5	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
as	O
well	O
as	O
from	O
60	O
.	O
0	O
+	O
/	O
-	O
6	O
.	O
8	O
to	O
85	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
9	O
in	O
48	O
h	O
memory	O
retrieval	O
(	O
F	O
(	O
1	O
,	O
12	O
)	O
=	O
5	O
.	O
2	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
respectively	O
.	O

This	O
study	O
reports	O
the	O
effects	O
of	O
a	O
preparation	O
with	O
50	O
micrograms	O
ethinyl	O
estradiol	O
and	O
2	O
mg	O
cyproterone	O
acetate	O
on	O
gonadotropins	B-protein
,	O
prolactin	B-protein
,	O
testosterone	O
,	O
sex	B-protein
hormone	I-protein
binding	I-protein
globulin	I-protein
(	O
SHBG	B-protein
)	O
,	O
androstenedione	O
,	O
and	O
calculated	O
free	O
testosterone	O
index	O
before	O
and	O
after	O
six	O
months	O
of	O
treatment	O
.	O

Lithium	O
-	O
carbonate	O
action	O
during	O
radiation	O
therapy	O
has	O
been	O
studied	O
,	O
valuing	O
the	O
positive	O
effect	O
on	O
leukopoiesis	O
and	O
the	O
consequent	O
better	O
clinical	O
conditions	O
of	O
the	O
patients	O
in	O
course	O
of	O
treatment	O
.	O

Yang	O
and	O
H	O
.	O

Type	O
I	O
position	O
-	O
vestibular	O
-	O
pause	O
(	O
PVP	O
I	O
)	O
and	O
vestibular	O
-	O
only	O
(	O
V	O
I	O
)	O
neurons	O
,	O
as	O
well	O
as	O
a	O
smaller	O
number	O
of	O
other	O
type	O
I	O
and	O
type	O
II	O
eye	O
-	O
plus	O
-	O
vestibular	O
neurons	O
were	O
studied	O
.	O

A	O
rat	O
cDNA	O
that	O
encodes	O
eIF	B-protein
-	I-protein
5	I-protein
has	O
been	O
isolated	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
to	O
yield	O
a	O
catalytically	O
active	O
eIF	B-protein
-	I-protein
5	I-protein
protein	I-protein
.	O

Thus	O
,	O
Hex	B-protein
expression	O
marks	O
the	O
earliest	O
unequivocal	O
molecular	O
anteroposterior	O
asymmetry	O
in	O
the	O
mouse	O
embryo	O
and	O
indicates	O
that	O
the	O
anteroposterior	O
axis	O
of	O
the	O
embryo	O
develops	O
from	O
conversion	O
of	O
a	O
proximodistal	O
asymmetry	O
established	O
in	O
the	O
primitive	O
endoderm	O
lineage	O
.	O

The	O
96	O
-	O
bp	O
insert	O
contained	O
a	O
termination	O
signal	O
which	O
caused	O
the	O
premature	O
termination	O
of	O
the	O
protein	O
,	O
leading	O
to	O
the	O
generation	O
of	O
a	O
p53	B-protein
product	I-protein
9	O
amino	O
acids	O
shorter	O
than	O
usual	O
.	O

The	O
data	O
are	O
compatible	O
with	O
the	O
idea	O
that	O
YLL031c	B-protein
transfers	O
the	O
ethanolaminephosphate	O
to	O
the	O
inner	O
alpha1	O
-	O
2	O
-	O
linked	O
mannose	O
,	O
i	O
.	O
e	O
.	O
the	O
group	O
that	O
links	O
the	O
GPI	O
lipid	O
anchor	O
to	O
proteins	O
,	O
whereas	O
Mcd4p	B-protein
and	O
Gpi7p	B-protein
transfer	O
ethanolaminephosphate	O
onto	O
the	O
alpha1	O
-	O
4	O
-	O
and	O
alpha1	O
-	O
6	O
-	O
linked	O
mannoses	O
of	O
the	O
GPI	O
anchor	O
,	O
respectively	O
.	O

The	O
relative	O
tumor	O
FDG	O
-	O
uptake	O
(	O
Q	O
-	O
MRGlu	O
)	O
(	O
tumor	O
/	O
contralateral	O
cortex	O
)	O
of	O
all	O
meningiomas	O
was	O
calculated	O
with	O
0	O
.	O
73	O
+	O
/	O
-	O
0	O
.	O
37	O
(	O
0	O
.	O
24	O
-	O
1	O
.	O
79	O
)	O
.	O

The	O
minimal	O
region	O
of	O
overlap	O
of	O
Langer	B-protein
-	I-protein
Giedion	I-protein
syndrome	I-protein
deletions	I-protein
,	O
previously	O
identified	O
by	O
analysis	O
of	O
15	O
patients	O
,	O
was	O
placed	O
on	O
the	O
map	O
by	O
analysis	O
of	O
2	O
patients	O
whose	O
deletions	O
define	O
the	O
endpoints	O
.	O

For	O
symptomatic	O
relief	O
and	O
inhibition	O
of	O
the	O
growth	O
of	O
the	O
metastases	O
interferon	B-protein
-	I-protein
a	I-protein
and	O
somatostatin	B-protein
analogues	O
can	O
be	O
employed	O
.	O

We	O
have	O
therefore	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
doxazosin	O
,	O
a	O
new	O
orally	O
active	O
selective	O
alpha	B-protein
1	I-protein
blocker	O
,	O
in	O
patients	O
with	O
systemic	O
hypertension	O
with	O
concomitant	O
airflow	O
limitation	O
.	O

Of	O
419	O
persons	O
surveyed	O
,	O
207	O
(	O
49	O
.	O
4	O
%	O
)	O
were	O
antigen	O
-	O
positive	O
with	O
the	O
Og4C3	B-protein
assay	O
.	O

The	O
PEPCK	B-protein
promoter	O
fragment	O
was	O
introduced	O
either	O
in	O
the	O
proper	O
orientation	O
for	O
transcription	O
of	O
the	O
TK	B-protein
gene	I-protein
or	O
in	O
the	O
opposite	O
orientation	O
.	O

Very	O
good	O
accuracy	O
(	O
r	O
greater	O
than	O
0	O
.	O
9	O
)	O
was	O
found	O
when	O
except	O
comparing	O
H	O
*	O
2	O
with	O
the	O
other	O
machine	O
and	O
the	O
reference	O
methods	O
,	O
except	O
for	O
MCHCH	O
and	O
basophil	O
count	O
.	O

Primer	O
extension	O
experiments	O
revealed	O
a	O
strong	O
transcription	O
initiation	O
site	O
102	O
bp	O
upstream	O
of	O
the	O
translational	O
start	O
site	O
.	O

Studies	O
suggest	O
that	O
the	O
DGOR	O
without	O
acid	O
reflux	O
may	O
result	O
in	O
symptoms	O
but	O
unless	O
acid	O
reflux	O
is	O
present	O
simultaneously	O
,	O
it	O
does	O
not	O
cause	O
oesophagitis	O
.	O

In	O
viral	O
infections	O
,	O
G	B-protein
-	I-protein
CSF	I-protein
was	O
correlated	O
with	O
mononuclear	O
cells	O
(	O
rs	O
=	O
0	O
.	O
41	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
white	O
blood	O
cell	O
counts	O
(	O
rs	O
=	O
0	O
.	O
56	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
neutrophils	O
(	O
rs	O
=	O
0	O
.	O
41	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
CRP	B-protein
(	O
rs	O
=	O
0	O
.	O
47	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
effect	O
of	O
emotional	O
-	O
painful	O
stress	O
(	O
EPS	O
)	O
on	O
myocardial	O
extensibility	O
and	O
contractility	O
was	O
studied	O
on	O
an	O
isolated	O
rat	O
atrium	O
.	O

We	O
also	O
recovered	O
mutations	O
in	O
the	O
60A	B-protein
gene	I-protein
which	O
encodes	O
another	O
TGF	B-protein
-	I-protein
beta	I-protein
-	I-protein
related	I-protein
factor	I-protein
in	O
Drosophila	O
.	O

Factors	O
affecting	O
the	O
inhibition	O
of	O
phagocytosis	O
by	O
chlorpromazine	O
.	O

BACKGROUND	O
:	O
Checkpoint	O
pathways	O
prevent	O
cell	O
-	O
cycle	O
progression	O
in	O
the	O
event	O
of	O
DNA	O
lesions	O
.	O

There	O
were	O
18	O
patients	O
with	O
Group	O
II	O
(	O
a	O
)	O
tumors	O
;	O
although	O
tumor	O
biopsy	O
was	O
attempted	O
on	O
eight	O
of	O
these	O
,	O
pathological	O
diagnosis	O
at	O
the	O
time	O
of	O
surgery	O
was	O
made	O
in	O
only	O
one	O
case	O
.	O

Interleukin	B-protein
-	I-protein
12	I-protein
(	O
IL	B-protein
-	I-protein
12	I-protein
)	O
is	O
a	O
cytokine	O
produced	O
by	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
that	O
causes	O
interferon	B-protein
-	I-protein
gamma	I-protein
(	O
IFN	B-protein
-	I-protein
gamma	I-protein
)	O
production	O
and	O
enhancement	O
of	O
cell	O
-	O
mediated	O
cytotoxicity	O
.	O

Comparison	O
of	O
promoters	O
repressed	O
by	O
c	B-protein
-	I-protein
myc	I-protein
reveals	O
a	O
weak	O
consensus	O
sequence	O
of	O
the	O
initiator	B-protein
(	I-protein
Inr	I-protein
)	I-protein
element	I-protein
:	I-protein
TCA	I-protein
(	I-protein
+	I-protein
1	I-protein
)	I-protein
YYYNY	I-protein
.	O

Ecthyma	O
,	O
a	O
known	O
disease	O
,	O
of	O
which	O
little	O
is	O
known	O
.	O

Future	O
analysis	O
of	O
long	O
-	O
term	O
outcome	O
measures	O
of	O
performance	O
with	O
the	O
implant	O
will	O
confirm	O
or	O
dispute	O
the	O
benefit	O
of	O
ear	O
selection	O
using	O
the	O
Prom	O
-	O
EABR	O
.	O

Furthermore	O
,	O
a	O
minor	O
start	O
site	O
was	O
localized	O
179	O
bp	O
upstream	O
of	O
the	O
major	O
site	O
using	O
reverse	B-protein
transcriptase	I-protein
-	I-protein
polymerase	I-protein
chain	O
reaction	O
with	O
various	O
P1	B-protein
primers	O
(	O
primer	O
walking	O
)	O
,	O
primer	O
extension	O
,	O
and	O
cDNA	O
cloning	O
.	O

CONCLUSIONS	O
:	O
Translocation	O
of	O
bacteria	O
or	O
endotoxin	B-protein
from	O
the	O
gastrointestinal	O
tract	O
into	O
the	O
bloodstream	O
has	O
been	O
noted	O
in	O
animal	O
experiments	O
;	O
however	O
,	O
translocation	O
was	O
not	O
detected	O
in	O
our	O
patients	O
with	O
hemorrhagic	O
shock	O
.	O

Nocodazole	O
arrest	O
of	O
DU249	O
cells	O
was	O
exploited	O
for	O
the	O
detection	O
of	O
an	O
M	O
-	O
phase	O
-	O
activated	O
MBP	B-protein
kinase	I-protein
that	O
was	O
resolved	O
from	O
p41	B-protein
MAP	I-protein
kinase	I-protein
by	O
phenyl	O
-	O
Superose	O
chromatography	O
.	O

This	O
compound	O
is	O
the	O
main	O
bioactive	O
metabolite	O
of	O
trimebutine	O
II	O
(	O
Debridat	O
,	O
CAS	O
39133	O
-	O
31	O
-	O
8	O
)	O
,	O
an	O
antispasmodic	O
widely	O
used	O
for	O
intestinal	O
diseases	O
since	O
1969	O
.	O

There	O
was	O
a	O
slight	O
increase	O
in	O
total	O
transferrin	B-protein
2	O
hr	O
after	O
1	O
tablet	O
and	O
values	O
remained	O
high	O
throughout	O
the	O
experiment	O
.	O

Rep63A	B-protein
(	I-protein
513	I-protein
amino	I-protein
acids	I-protein
[	I-protein
aa	I-protein
]	I-protein
)	I-protein
,	O
encoded	O
by	O
the	O
largest	O
ORF	O
,	O
displayed	O
strong	O
similarity	O
(	O
40	O
%	O
identity	O
)	O
to	O
the	O
replication	O
proteins	O
from	O
plasmids	O
pAMbeta1	O
,	O
pIP501	O
,	O
and	O
pSM19035	O
,	O
indicating	O
that	O
the	O
pAW63	O
replicon	O
belongs	O
to	O
the	O
pAMbeta1	O
family	O
of	O
gram	O
-	O
positive	O
theta	O
-	O
replicating	O
plasmids	O
.	O

Finally	O
,	O
we	O
show	O
that	O
complexes	O
similar	O
to	O
the	O
C25	B-protein
,	O
C30	B-protein
and	O
C35	B-protein
complexes	I-protein
are	O
formed	O
by	O
rat	O
cortex	O
nuclear	O
extracts	O
and	O
the	O
SAA	B-protein
element	I-protein
in	O
EMSA	O
experiments	O
,	O
suggesting	O
the	O
relevance	O
of	O
our	O
in	O
vitro	O
observations	O
to	O
the	O
in	O
vivo	O
functioning	O
of	O
the	O
rat	B-protein
APP	I-protein
promoter	I-protein
.	O

The	O
nmr	B-protein
gene	I-protein
is	O
the	O
major	O
negative	O
regulatory	O
gene	O
in	O
the	O
nitrogen	O
control	O
circuit	O
of	O
Neurospora	O
crassa	O
,	O
which	O
,	O
together	O
with	O
positive	O
regulatory	O
genes	O
,	O
governs	O
the	O
expression	O
of	O
multiple	O
unlinked	O
structural	O
genes	O
of	O
the	O
circuit	O
.	O

At	O
least	O
one	O
clone	O
,	O
lambda	O
HHG	O
41	O
,	O
contains	O
,	O
in	O
addition	O
to	O
the	O
histone	B-protein
genes	I-protein
,	O
a	O
region	O
that	O
hybridizes	O
with	O
a	O
cytoplasmic	O
RNA	O
approximately	O
330	O
nucleotides	O
in	O
length	O
.	O

Adult	O
H	O
,	O
but	O
not	O
R	O
,	O
manifested	O
the	O
burrowing	O
preference	O
whenever	O
offered	O
the	O
opportunity	O
.	O

Thromboplastin	B-protein
time	O
,	O
partial	O
thromboplastin	B-protein
time	O
,	O
thrombin	B-protein
time	O
,	O
heat	O
-	O
dependent	O
fibrin	B-protein
,	O
clot	O
retraction	O
,	O
and	O
clotting	B-protein
factors	I-protein
II	I-protein
,	I-protein
V	I-protein
,	I-protein
VIII	I-protein
,	I-protein
IX	I-protein
,	I-protein
X	I-protein
,	O
and	O
the	O
platelet	O
count	O
were	O
determined	O
.	O

The	O
elevations	O
achieved	O
by	O
LDEE	O
given	O
s	O
.	O
c	O
.	O
were	O
higher	O
than	O
those	O
achieved	O
after	O
i	O
.	O
p	O
.	O
administration	O
and	O
lasted	O
for	O
longer	O
periods	O
.	O

We	O
show	O
that	O
Rlm1	B-protein
and	O
Smp1	B-protein
have	O
MEF2	O
-	O
related	O
DNA	O
-	O
binding	O
specificities	O
:	O
Rlm1	B-protein
binds	O
with	O
the	O
same	O
specificity	O
as	O
MEF2	B-protein
,	O
CTA	B-protein
(	I-protein
T	I-protein
/	I-protein
A	I-protein
)	I-protein
4TAG	I-protein
,	O
while	O
SMP1	B-protein
binds	O
a	O
more	O
extended	O
consensus	O
sequence	O
,	O
ACTACTA	B-protein
(	I-protein
T	I-protein
/	I-protein
A	I-protein
)	I-protein
4TAG	I-protein
.	O

Multizone	O
PRK	O
has	O
been	O
suggested	O
to	O
increase	O
the	O
predictability	O
of	O
higher	O
myopic	O
corrections	O
.	O

A	O
convenient	O
measure	O
of	O
this	O
impairment	O
may	O
be	O
obtained	O
using	O
the	O
ratio	O
of	O
urine	O
volume	O
(	O
V	O
)	O
divided	O
by	O
lithium	O
clearance	O
(	O
CLi	O
)	O
.	O

Depleted	O
and	O
enriched	O
U3O8	O
standard	O
reference	O
materials	O
were	O
used	O
to	O
calibrate	O
the	O
system	O
.	O

Our	O
study	O
reveals	O
that	O
the	O
modular	O
structure	O
of	O
the	O
FSH	B-protein
receptor	I-protein
gene	O
generates	O
motifs	O
that	O
allows	O
coupling	O
to	O
different	O
effectors	O
.	O

The	O
in	O
vitro	O
relaxivity	O
of	O
the	O
complex	O
is	O
16	O
.	O
24	O
s	O
(	O
-	O
1	O
)	O
mM	O
(	O
-	O
1	O
)	O
.	O

The	O
possible	O
roles	O
of	O
HRMT1L1	B-protein
and	O
HRMT1L2	B-protein
in	O
human	O
disease	O
are	O
currently	O
unknown	O
.	O

Mutations	O
in	O
UPF1	B-protein
lead	O
to	O
the	O
selective	O
stabilization	O
of	O
mRNAs	O
containing	O
early	O
nonsense	O
mutations	O
without	O
affecting	O
the	O
decay	O
rates	O
of	O
most	O
other	O
mRNAs	O
.	O

Acad	O
.	O

The	O
roll	O
-	O
over	O
test	O
to	O
predict	O
toxemia	O
in	O
pregnancy	O
.	O

A	O
reduced	O
matrix	O
distribution	O
and	O
enhanced	O
cell	O
density	O
were	O
observed	O
as	O
the	O
biofilm	O
aged	O
.	O

The	O
activation	O
and	O
injury	O
of	O
endothelial	O
cells	O
induced	O
by	O
TNF	B-protein
and	O
other	O
proinflammatory	O
cytokines	O
may	O
underlie	O
the	O
local	O
effects	O
of	O
these	O
mediators	O
in	O
vivo	O
.	O

Compensative	O
justice	O
and	O
moral	O
investment	O
among	O
Japanese	O
,	O
Chinese	O
,	O
and	O
Koreans	O
.	O

One	O
possible	O
solution	O
is	O
a	O
thin	O
radial	O
forearm	O
free	O
flap	O
.	O

Assuming	O
O2	O
consumption	O
of	O
the	O
isolated	O
skin	O
to	O
be	O
same	O
as	O
in	O
situ	O
,	O
calculations	O
showed	O
that	O
when	O
water	O
PO2	O
was	O
high	O
(	O
150	O
mm	O
Hg	O
)	O
,	O
about	O
40	O
%	O
of	O
total	O
cutaneous	O
O2	O
uptake	O
was	O
consumed	O
by	O
the	O
skin	O
.	O

Then	O
,	O
pure	O
pancreatic	O
juice	O
was	O
infused	O
into	O
the	O
duodenum	O
.	O

These	O
clones	O
were	O
found	O
to	O
share	O
a	O
common	O
domain	O
encoded	O
by	O
p	O
(	O
CA	O
)	O
n	O
repeats	O
;	O
a	O
simple	O
sequence	O
length	O
polymorphism	O
(	O
SSLP	O
)	O
.	O

The	O
other	O
two	O
clones	O
,	O
Ash	B-protein
-	I-protein
m	I-protein
and	I-protein
-	I-protein
s	I-protein
,	O
had	O
nucleotide	O
sequences	O
identical	O
with	O
Ash	B-protein
-	I-protein
l	I-protein
cDNA	O
in	O
the	O
amino	O
-	O
terminal	O
region	O
.	O

Temporal	O
control	O
of	O
GUS	B-protein
expression	O
was	O
found	O
to	O
involve	O
two	O
negative	O
regulatory	O
sequences	O
,	O
NRS1	B-protein
(	I-protein
-	I-protein
391	I-protein
to	I-protein
-	I-protein
295	I-protein
)	I-protein
and	O
NRS2	B-protein
(	I-protein
-	I-protein
518	I-protein
to	I-protein
-	I-protein
418	I-protein
)	I-protein
,	O
as	O
well	O
as	O
the	O
positive	O
domain	O
UAS1	B-protein
.	O

In	O
untransformed	O
cells	O
,	O
three	O
major	O
proteins	O
coprecipitated	O
with	O
CRKL	B-protein
,	O
identified	O
as	O
C3G	B-protein
,	O
SOS	B-protein
and	O
c	B-protein
-	I-protein
ABL	I-protein
.	O

I	O
.	O

These	O
results	O
indicate	O
that	O
both	O
PKC	B-protein
alpha	I-protein
(	O
calcium	O
dependent	O
)	O
and	O
PKC	B-protein
delta	I-protein
(	O
calcium	O
independent	O
)	O
may	O
mediate	O
the	O
transcription	O
of	O
TPA	B-protein
-	I-protein
inducible	I-protein
genes	I-protein
through	O
both	O
AP	B-protein
-	I-protein
1	I-protein
and	O
non	B-protein
-	I-protein
AP	I-protein
-	I-protein
1	I-protein
sequences	I-protein
.	O

One	O
hundred	O
and	O
four	O
(	O
14	O
per	O
cent	O
)	O
second	O
primary	O
tumours	O
were	O
reported	O
.	O

RegA	B-protein
is	O
a	O
positive	O
yet	O
nonessential	O
regulator	O
of	O
tol	B-protein
-	I-protein
oprL	I-protein
expression	O
.	O

The	O
patient	O
was	O
treated	O
with	O
benzathine	O
penicillin	O
,	O
2	O
,	O
400	O
,	O
000	O
U	O
weekly	O
for	O
three	O
weeks	O
.	O

We	O
have	O
screened	O
the	O
mouse	O
cDNA	O
library	O
of	O
an	O
MIN6	O
cell	O
line	O
,	O
derived	O
from	O
pancreatic	O
beta	O
cells	O
,	O
for	O
its	O
novel	O
isoform	O
and	O
have	O
identified	O
a	O
cDNA	O
encoding	O
a	O
593	O
-	O
amino	O
acid	O
protein	O
having	O
63	O
,	O
53	O
,	O
and	O
30	O
%	O
identity	O
with	O
munc	B-protein
-	I-protein
18	I-protein
/	I-protein
n	I-protein
-	I-protein
Sec1	I-protein
/	I-protein
rbSec1	I-protein
,	O
Caenorhabditis	B-protein
elegans	I-protein
unc18	I-protein
,	O
and	O
Saccharomyces	B-protein
cerevisiae	I-protein
Sec1p	I-protein
,	O
respectively	O
.	O

Comparison	O
of	O
immunoassay	O
kits	O
for	O
detection	O
of	O
staphylococcal	B-protein
enterotoxins	I-protein
produced	O
by	O
Staphylococcus	O
aureus	O
.	O

The	O
C	O
-	O
terminal	O
approximately	O
50	O
amino	O
acids	O
of	O
Bel	B-protein
-	I-protein
1	I-protein
are	O
shown	O
to	O
be	O
essential	O
for	O
Bel	B-protein
-	I-protein
1	I-protein
activity	O
but	O
can	O
be	O
effectively	O
substituted	O
by	O
the	O
C	O
-	O
terminal	O
activation	O
domain	O
of	O
VP16	B-protein
.	O

Our	O
study	O
also	O
demonstrated	O
significant	O
increases	O
in	O
the	O
number	O
of	O
larger	O
myelinated	O
fibers	O
crossing	O
the	O
repair	O
site	O
in	O
comparison	O
with	O
the	O
neonatal	O
and	O
adult	O
groups	O
(	O
p	O
<	O
0	O
.	O
04	O
)	O
.	O

Hematopoietic	B-protein
growth	I-protein
factors	I-protein
are	O
being	O
used	O
to	O
accelerate	O
the	O
recovery	O
of	O
myelopoiesis	O
following	O
high	O
-	O
dose	O
chemotherapy	O
in	O
cancer	O
patients	O
.	O

Man	O
and	O
insect	O
,	O
past	O
,	O
present	O
,	O
future	O
.	O

In	O
a	O
retrospective	O
analysis	O
of	O
data	O
from	O
35	O
cases	O
with	O
malignant	O
lymphoma	O
from	O
a	O
cohort	O
of	O
2017	O
HIV	O
-	O
infected	O
patients	O
,	O
the	O
stage	O
of	O
HIV	O
-	O
disease	O
,	O
the	O
CD4	B-protein
counts	O
at	O
the	O
time	O
of	O
diagnosis	O
,	O
and	O
the	O
use	O
of	O
antineoplastic	O
agents	O
or	O
radiotherapy	O
were	O
correlated	O
with	O
outcome	O
.	O

Further	O
studies	O
on	O
a	O
`	O
`	O
new	O
'	O
'	O
human	O
isoprecipitin	O
system	O
(	O
Australia	O
antigen	O
)	O
.	O

A	O
clinical	O
,	O
serological	O
and	O
prognostic	O
study	O
.	O

Dermatology	O
is	O
no	O
exception	O
.	O

Oral	O
supplementation	O
of	O
L	O
-	O
arginine	O
significantly	O
increased	O
plasma	O
L	O
-	O
citrulline	O
,	O
which	O
indicated	O
enhancement	O
of	O
NO	O
production	O
.	O

The	O
relative	O
importance	O
of	O
these	O
two	O
mechanisms	O
differed	O
in	O
a	O
response	O
element	O
-	O
specific	O
manner	O
.	O

Invertases	B-protein
are	O
responsible	O
for	O
the	O
breakdown	O
of	O
sucrose	O
to	O
fructose	O
and	O
glucose	O
.	O

Like	O
the	O
Tob	B-protein
protein	I-protein
,	O
Tob2	B-protein
inhibited	O
cell	O
cycle	O
progression	O
from	O
the	O
G0	O
/	O
G1	O
to	O
S	O
phases	O
.	O

In	O
overdoses	O
up	O
to	O
2	O
g	O
fluvoxamine	O
no	O
lasting	O
toxic	O
effects	O
were	O
observed	O
.	O

The	O
hemodynamics	O
of	O
isoproterenol	O
-	O
induced	O
cardiac	O
failure	O
in	O
the	O
rat	O
.	O

Like	O
many	O
eukaryotic	O
transcription	O
factors	O
,	O
these	O
proteins	O
bind	O
to	O
DNA	O
as	O
dimers	O
.	O

SSeCKS	B-protein
(	O
pronounced	O
essex	B-protein
)	O
encodes	O
a	O
major	O
protein	B-protein
kinase	I-protein
C	I-protein
substrate	O
,	O
the	O
expression	O
of	O
which	O
is	O
down	O
-	O
regulated	O
in	O
src	O
-	O
and	O
ras	O
-	O
transformed	O
rodent	O
fibroblasts	O
but	O
not	O
in	O
raf	O
-	O
transformed	O
rodent	O
fibroblasts	O
(	O
X	O
.	O

A	O
new	O
hypothesis	O
on	O
mechanisms	O
for	O
inhibiting	O
catalytic	O
subunits	O
by	O
gamma	O
-	O
subunits	O
and	O
activation	O
of	O
a	O
holoenzyme	O
by	O
transducin	B-protein
.	O

Yeast	O
mutants	O
lacking	O
a	O
functional	O
NOP1	B-protein
gene	I-protein
can	O
be	O
complemented	O
by	O
human	B-protein
fibrillarin	I-protein
but	O
are	O
temperature	O
sensitive	O
for	O
growth	O
and	O
impaired	O
in	O
pre	O
-	O
rRNA	O
processing	O
.	O

2	O
:	O
121	O
-	O
133	O
,	O
1988	O
)	O
.	O

We	O
propose	O
that	O
epigenetic	O
features	O
of	O
tissue	O
-	O
specific	O
control	O
and	O
of	O
the	O
control	O
of	O
allelic	O
expression	O
are	O
intricately	O
linked	O
.	O

According	O
to	O
the	O
results	O
of	O
assays	O
obtained	O
with	O
the	O
use	O
of	O
assay	O
systems	O
ORTHO	O
ELISA	O
and	O
ABBOTT	O
HCV	O
EIA	O
(	O
USA	O
)	O
,	O
the	O
detection	O
rate	O
of	O
anti	B-protein
-	I-protein
HCV	I-protein
-	I-protein
C100	I-protein
-	I-protein
3	I-protein
among	O
primary	O
blood	O
donors	O
in	O
Moscow	O
was	O
1	O
.	O
37	O
%	O
and	O
was	O
not	O
different	O
from	O
that	O
among	O
HBsAg	B-protein
carriers	O
(	O
1	O
.	O
8	O
%	O
)	O
and	O
among	O
donors	O
with	O
anti	B-protein
-	I-protein
HCV	I-protein
-	I-protein
C100	I-protein
-	I-protein
3	I-protein
in	O
the	O
blood	O
(	O
1	O
.	O
6	O
%	O
)	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Control	O
examination	O
was	O
performed	O
at	O
the	O
end	O
of	O
each	O
period	O
.	O

By	O
contrast	O
,	O
their	O
basal	O
adrenal	O
androgen	O
levels	O
were	O
significantly	O
decreased	O
compared	O
to	O
those	O
in	O
normal	O
subjects	O
on	O
both	O
the	O
day	O
on	O
and	O
the	O
day	O
off	O
prednisone	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
spontaneous	O
reports	O
of	O
suspected	O
adverse	O
drug	O
reactions	O
,	O
observed	O
in	O
elderly	O
patients	O
(	O
over	O
65	O
years	O
of	O
age	O
)	O
in	O
Sicily	O
(	O
Italy	O
)	O
during	O
the	O
period	O
from	O
1	O
January	O
1995	O
to	O
31	O
December	O
1997	O
.	O

Second	O
report	O
of	O
the	O
Norwegian	O
Cancer	O
Society	O
.	O

These	O
adverse	O
effects	O
usually	O
abate	O
with	O
time	O
.	O

Restriction	O
maps	O
of	O
the	O
cloned	O
plasmids	O
revealed	O
that	O
their	O
chromosomal	O
inserts	O
consisted	O
of	O
overlapping	O
fragments	O
.	O

Opposite	O
effects	O
of	O
CYP1	B-protein
are	O
observed	O
in	O
aerobic	O
,	O
heme	O
-	O
sufficient	O
cells	O
.	O

The	O
Fis	B-protein
protein	I-protein
regulates	O
site	O
-	O
specific	O
DNA	O
inversion	O
catalyzed	O
by	O
a	O
family	O
of	O
DNA	B-protein
invertases	I-protein
when	O
bound	O
to	O
a	O
cis	O
-	O
acting	O
recombinational	O
enhancer	O
.	O

How	O
plants	O
respond	O
to	O
attack	O
by	O
the	O
range	O
of	O
herbivores	O
and	O
pathogens	O
that	O
confront	O
them	O
in	O
the	O
field	O
is	O
the	O
subject	O
of	O
considerable	O
research	O
by	O
both	O
molecular	O
biologists	O
and	O
ecologists	O
.	O

DNA	O
hybridization	O
analysis	O
revealed	O
that	O
both	O
pigmented	O
and	O
nonpigmented	O
cells	O
of	O
Y	O
.	O
pestis	O
possess	O
a	O
DNA	O
locus	O
homologous	O
to	O
the	O
Escherichia	B-protein
coli	I-protein
fur	I-protein
gene	I-protein
.	O

A	O
large	O
deletion	O
in	O
the	O
CTD	B-protein
-	I-protein
binding	I-protein
motif	I-protein
blocks	O
down	O
-	O
regulation	O
but	O
does	O
not	O
affect	O
the	O
essential	O
function	O
of	O
Nrd1	B-protein
.	O

Application	O
of	O
different	O
criteria	O
of	O
cure	O
revealed	O
that	O
19	O
patients	O
(	O
66	O
%	O
)	O
had	O
basal	O
GH	B-protein
levels	O
below	O
5	O
ng	O
/	O
ml	O
,	O
17	O
patients	O
(	O
59	O
%	O
)	O
had	O
normal	O
somatomedin	B-protein
-	I-protein
C	I-protein
values	O
,	O
16	O
patients	O
(	O
55	O
%	O
)	O
had	O
complete	O
GH	B-protein
suppression	O
(	O
less	O
than	O
1	O
ng	O
/	O
ml	O
)	O
during	O
OGTT	O
,	O
and	O
13	O
patients	O
(	O
45	O
%	O
)	O
met	O
the	O
above	O
-	O
mentioned	O
criteria	O
with	O
disappearance	O
of	O
the	O
paradoxical	O
GH	B-protein
response	O
to	O
TRH	B-protein
/	I-protein
GnRH	I-protein
test	O
.	O

NF	B-protein
-	I-protein
kappaB	I-protein
is	O
involved	O
in	O
the	O
regulation	O
of	O
CD154	B-protein
(	O
CD40	B-protein
ligand	I-protein
)	O
expression	O
in	O
primary	O
human	O
T	O
cells	O
.	O

Radiation	O
-	O
induced	O
changes	O
in	O
the	O
area	O
of	O
alveoli	O
and	O
septa	O
as	O
well	O
as	O
collagen	B-protein
content	O
were	O
seen	O
11	O
weeks	O
after	O
irradiation	O
.	O

A	O
favourable	O
response	O
was	O
achieved	O
with	O
a	O
combination	O
of	O
amphotericin	O
B	O
and	O
cotrimoxazole	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
cooperation	O
of	O
transcription	B-protein
factors	I-protein
NF	I-protein
-	I-protein
kappaB	I-protein
and	O
AP	B-protein
-	I-protein
1	I-protein
is	O
essential	O
for	O
transactivation	O
of	O
IL	B-protein
-	I-protein
8	I-protein
gene	I-protein
by	O
HTLV	B-protein
-	I-protein
I	I-protein
Tax	I-protein
.	O

Five	O
women	O
(	O
15	O
.	O
6	O
%	O
)	O
met	O
criteria	O
for	O
PMS	O
.	O

DNA	O
sequence	O
analysis	O
of	O
a	O
3213	B-protein
bp	I-protein
BamHI	I-protein
-	I-protein
ClaI	I-protein
fragment	I-protein
revealed	O
that	O
three	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
were	O
encoded	O
in	O
the	O
same	O
orientation	O
.	O

CONCLUSIONS	O
:	O
The	O
myocardial	O
uptake	O
of	O
99mTc	O
sestamibi	O
in	O
normal	O
subjects	O
and	O
patients	O
with	O
coronary	O
artery	O
disease	O
is	O
comparable	O
after	O
exercise	O
,	O
dipyridamole	O
,	O
and	O
adenosine	O
stress	O
.	O

The	O
results	O
suggest	O
that	O
the	O
organization	O
of	O
functional	O
units	O
of	O
the	O
72	O
-	O
bp	O
repeat	O
required	O
for	O
transcriptional	O
enhancement	O
of	O
the	O
early	O
promoter	O
is	O
different	O
from	O
that	O
required	O
for	O
late	O
promoter	O
function	O
.	O

Consistent	O
with	O
previous	O
reports	O
,	O
addition	O
of	O
a	O
myristoylation	O
signal	O
to	O
mSos1	B-protein
(	O
MyrSos1	B-protein
)	O
rendered	O
it	O
transforming	O
for	O
NIH	O
3T3	O
cells	O
and	O
deletion	O
of	O
the	O
mSos	B-protein
C	I-protein
terminus	I-protein
(	O
MyrSos1	B-protein
-	I-protein
deltaC	I-protein
)	O
did	O
not	O
interfere	O
with	O
this	O
activity	O
.	O

Comparison	O
of	O
the	O
deduced	O
amino	B-protein
acid	I-protein
sequence	I-protein
of	I-protein
gamma	I-protein
-	I-protein
kafirin	I-protein
with	O
the	O
published	O
sequences	B-protein
of	I-protein
gamma	I-protein
-	I-protein
prolamins	I-protein
of	I-protein
maize	I-protein
,	I-protein
and	I-protein
Coix	I-protein
revealed	O
highly	O
conserved	O
domains	O
.	O

Setting	O
takes	O
place	O
through	O
complex	O
formation	O
of	O
(	O
NH4Mg	O
PO4	O
.	O
6H2O	O
)	O
n	O
,	O
excess	O
reactants	O
,	O
and	O
water	O
.	O

Airflow	O
through	O
the	O
dust	O
trap	O
was	O
controlled	O
with	O
a	O
vacuum	O
pump	O
.	O

Climatic	O
treatment	O
of	O
children	O
with	O
respiratory	O
allergy	O
.	O

In	O
controls	O
,	O
most	O
of	O
the	O
output	O
from	O
the	O
conduit	O
occurred	O
during	O
type	O
I	O
activity	O
(	O
73	O
+	O
/	O
-	O
14	O
%	O
)	O
.	O

Thus	O
,	O
the	O
class	B-protein
C	I-protein
-	I-protein
Vps	I-protein
complex	I-protein
directs	O
multiple	O
reactions	O
during	O
the	O
docking	O
and	O
fusion	O
of	O
vesicles	O
with	O
the	O
vacuole	O
,	O
each	O
of	O
which	O
contributes	O
to	O
the	O
overall	O
specificity	O
and	O
efficiency	O
of	O
this	O
transport	O
process	O
.	O

The	O
predicted	O
protein	O
products	O
of	O
ORFs	B-protein
N2417	I-protein
and	O
N2403	B-protein
present	O
similarities	O
with	O
domains	O
from	O
proteins	O
of	O
other	O
organisms	O
:	O
the	O
Candida	O
maltosa	O
cycloheximide	B-protein
-	I-protein
resistance	I-protein
protein	I-protein
,	O
the	O
human	O
interleukin	B-protein
enhancer	I-protein
-	I-protein
binding	I-protein
factor	I-protein
(	O
ILF	B-protein
-	I-protein
2	I-protein
)	O
.	O

Manganese	O
ions	O
were	O
found	O
to	O
be	O
essential	O
for	O
autophosphorylation	O
of	O
BGLF4	B-protein
,	O
and	O
magnesium	O
can	O
stimulate	O
the	O
activity	O
.	O

The	O
human	B-protein
MSH	I-protein
-	I-protein
2	I-protein
gene	I-protein
product	I-protein
is	O
a	O
member	O
of	O
a	O
highly	O
conserved	O
family	O
of	O
proteins	O
which	O
are	O
involved	O
in	O
post	O
-	O
replication	O
mismatch	O
repair	O
.	O
hMSH	B-protein
-	I-protein
2	I-protein
is	O
homologous	O
to	O
Escherichia	O
coli	O
(	O
E	O
.	O
coli	O
)	O
MutS	B-protein
and	O
Sacchromyces	B-protein
cerevisiae	I-protein
MSH	I-protein
-	I-protein
1	I-protein
and	O
MSH	B-protein
-	I-protein
2	I-protein
proteins	I-protein
,	O
which	O
recognise	O
heteroduplex	O
DNA	O
at	O
the	O
sites	O
of	O
all	O
single	O
base	O
mismatches	O
and	O
deletions	O
or	O
insertions	O
up	O
to	O
4	O
base	O
pairs	O
.	O
hMSH	B-protein
-	I-protein
2	I-protein
is	O
one	O
of	O
the	O
hereditary	B-protein
non	I-protein
-	I-protein
polyposis	I-protein
colorectal	I-protein
cancer	I-protein
(	I-protein
HNPCC	I-protein
)	I-protein
tumor	I-protein
suppressor	I-protein
genes	I-protein
,	O
and	O
maps	O
to	O
human	O
chromosome	O
2p16	O
.	O

In	O
addition	O
,	O
the	O
-	O
119	O
to	O
-	O
81	O
fragment	O
of	O
the	O
CCK	B-protein
promoter	I-protein
contains	O
a	O
transcriptional	O
enhancer	O
that	O
potentiates	O
the	O
transcription	O
from	O
the	O
herpes	O
simplex	O
virus	O
thymidine	B-protein
kinase	I-protein
promoter	I-protein
in	O
a	O
position	O
-	O
and	O
orientation	O
-	O
independent	O
manner	O
.	O

This	O
vector	O
transfected	O
into	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
directs	O
expression	O
of	O
a	O
secreted	O
mature	O
protein	O
at	O
levels	O
up	O
to	O
200	O
mg	O
of	O
LAPP	O
/	O
liter	O
of	O
culture	O
medium	O
.	O

Such	O
multisensory	O
interactions	O
can	O
be	O
significant	O
for	O
behavior	O
.	O

Neither	O
CES1	B-protein
nor	O
CES4	B-protein
is	O
essential	O
for	O
cell	O
growth	O
,	O
and	O
a	O
double	O
deletion	O
mutant	O
is	O
viable	O
.	O

Alternative	O
splicing	O
of	O
fibroblast	B-protein
growth	I-protein
factor	I-protein
receptor	I-protein
2	I-protein
(	O
FGF	B-protein
-	I-protein
R2	I-protein
)	O
is	O
an	O
example	O
of	O
highly	O
regulated	O
alternative	O
splicing	O
in	O
which	O
exons	O
IIIb	O
and	O
IIIc	O
are	O
utilized	O
in	O
a	O
mutually	O
exclusive	O
manner	O
in	O
different	O
cell	O
types	O
.	O

This	O
newly	O
described	O
organism	O
was	O
difficult	O
to	O
identify	O
due	O
to	O
discrepancies	O
between	O
the	O
Vitek	O
and	O
API	O
20E	O
identification	O
systems	O
.	O

This	O
relatively	O
simple	O
and	O
easily	O
performed	O
technique	O
of	O
measuring	O
deep	O
muscle	O
temperature	O
appears	O
to	O
be	O
a	O
useful	O
adjunct	O
in	O
choosing	O
the	O
amputation	O
level	O
.	O

An	O
anatomical	O
and	O
histochemical	O
study	O
has	O
been	O
undertaken	O
and	O
as	O
a	O
result	O
emphasis	O
is	O
given	O
to	O
recent	O
hypotheses	O
that	O
suggest	O
there	O
are	O
similarities	O
with	O
Type	O
IV	O
glycogen	O
storage	O
disease	O
(	O
Andersen	O
'	O
s	O
disease	O
)	O
which	O
,	O
although	O
clinically	O
distinct	O
,	O
has	O
the	O
same	O
enzyme	O
defect	O
.	O

Ten	O
volunteers	O
were	O
tested	O
at	O
18	O
,	O
000	O
ft	O
(	O
5	O
,	O
486	O
m	O
)	O
,	O
and	O
through	O
12	O
,	O
000	O
,	O
8	O
,	O
000	O
,	O
and	O
5	O
,	O
000	O
ft	O
(	O
3	O
,	O
657	O
,	O
2	O
,	O
438	O
,	O
and	O
1	O
,	O
524	O
m	O
)	O
with	O
directional	O
sounds	O
recorded	O
via	O
a	O
dummy	O
head	O
microphone	O
and	O
presented	O
binaurally	O
.	O

Because	O
the	O
high	B-protein
-	I-protein
density	I-protein
lipoprotein	I-protein
receptor	I-protein
(	O
HDL	B-protein
-	I-protein
R	I-protein
)	O
is	O
a	O
key	O
element	O
in	O
cholesterol	O
homeostasis	O
and	O
a	O
potential	O
therapeutic	O
target	O
for	O
hypercholesterolemic	O
drugs	O
,	O
an	O
understanding	O
of	O
HDL	B-protein
-	I-protein
R	I-protein
regulation	O
is	O
essential	O
.	O

Patients	O
with	O
CF	O
and	O
meconium	O
ileus	O
presented	O
a	O
poor	O
nutritional	O
status	O
at	O
diagnosis	O
and	O
a	O
lower	O
survival	O
rate	O
compared	O
to	O
the	O
general	O
CF	O
population	O
.	O

Finally	O
,	O
profiling	O
of	O
a	O
gcn4Delta	B-protein
mutant	I-protein
uncovered	O
an	O
alternative	O
induction	O
pathway	O
operating	O
at	O
many	O
Gcn4p	B-protein
target	I-protein
genes	I-protein
in	O
histidine	O
-	O
starved	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
pattern	O
of	O
blood	O
supply	O
is	O
relevant	O
to	O
the	O
structural	O
organisation	O
of	O
mature	O
lamellar	O
bone	O
around	O
the	O
implant	O
.	O

Thus	O
,	O
a	O
negative	O
test	O
is	O
compatible	O
with	O
low	O
disease	O
activity	O
and	O
/	O
or	O
efficacy	O
of	O
calcium	O
antagonist	O
treatment	O
.	O

The	O
loss	O
of	O
avirulence	O
activity	O
because	O
of	O
mutations	O
in	O
the	O
acidic	O
transcriptional	O
activation	O
domain	O
was	O
restored	O
by	O
addition	O
of	O
the	O
activation	O
domain	O
from	O
the	O
herpes	B-protein
simplex	I-protein
viral	I-protein
protein	I-protein
VP16	I-protein
.	O

By	O
an	O
induced	O
-	O
fit	O
mechanism	O
,	O
contacts	O
with	O
the	O
anticodon	O
can	O
activate	O
formation	O
of	O
a	O
robust	O
transition	O
state	O
at	O
a	O
site	O
over	O
70	O
A	O
away	O
.	O

The	O
effect	O
of	O
zinc	O
deficiency	O
on	O
trace	O
metals	O
in	O
the	O
liver	O
,	O
spleen	O
,	O
kidney	O
,	O
pancreas	O
and	O
duodenum	O
was	O
investigated	O
in	O
the	O
control	O
and	O
zinc	O
-	O
deficient	O
rats	O
at	O
17	O
days	O
and	O
20	O
days	O
of	O
pregnancy	O
.	O

Several	O
studies	O
have	O
characterized	O
the	O
upstream	O
regulatory	O
region	O
of	O
c	B-protein
-	I-protein
fos	I-protein
,	O
and	O
identified	O
cis	O
-	O
acting	O
elements	O
termed	O
the	O
cyclic	B-protein
AMP	I-protein
(	I-protein
cAMP	I-protein
)	I-protein
response	I-protein
elements	I-protein
(	O
CREs	B-protein
)	O
that	O
are	O
critical	O
for	O
c	B-protein
-	I-protein
fos	I-protein
transcription	O
in	O
response	O
to	O
a	O
variety	O
of	O
extracellular	O
stimuli	O
.	O

Using	O
a	O
high	O
-	O
copy	O
suppression	O
strategy	O
,	O
we	O
have	O
identified	O
a	O
yeast	O
gene	O
(	O
UBS1	B-protein
)	O
whose	O
elevated	O
expression	O
suppresses	O
the	O
conditional	O
cell	O
cycle	O
defects	O
associated	O
with	O
cdc34	B-protein
mutations	O
.	O

Dynamic	O
and	O
static	O
scintigrams	O
,	O
using	O
99mtechnetium	O
methylene	O
diphosphonate	O
,	O
were	O
obtained	O
at	O
zero	O
,	O
six	O
,	O
and	O
12	O
weeks	O
after	O
fracture	O
.	O

The	O
persistent	O
fetal	O
dispersion	O
of	O
nodal	O
and	O
Hiss	O
bundle	O
fragments	O
within	O
the	O
ventricular	O
septum	O
is	O
proposed	O
as	O
a	O
possible	O
explanation	O
.	O

Residual	O
urinary	O
abnormalities	O
were	O
significantly	O
more	O
frequent	O
in	O
patients	O
with	O
type	O
III	O
than	O
type	O
I	O
MPGN	O
.	O

A	O
range	O
of	O
normal	O
ventricular	O
measurements	O
for	O
the	O
EMI	O
scan	O
is	O
suggested	O
.	O

Most	O
likely	O
they	O
might	O
represent	O
regulatory	O
RNAs	O
or	O
transcribed	O
transposable	O
elements	O
.	O

A	O
new	O
UASH	B-protein
consensus	I-protein
sequence	I-protein
derived	O
from	O
this	O
mutational	O
analysis	O
closely	O
matches	O
a	O
consensus	O
Abf1	B-protein
binding	I-protein
site	I-protein
.	O

A	O
hybridoma	O
clone	O
(	O
7H1	O
)	O
resulting	O
from	O
the	O
fusion	O
between	O
CEMLAI	O
/	O
NP	O
and	O
human	O
embryonic	O
fibroblasts	O
MRC5	O
cells	O
produced	O
very	O
large	O
amounts	O
of	O
P47	B-protein
that	O
was	O
purified	O
using	O
Jacalin	O
lectin	O
(	O
specific	O
for	O
O	O
-	O
glycans	O
)	O
and	O
microsequenced	O
.	O

The	O
use	O
of	O
antibodies	O
to	O
the	O
polypyrimidine	B-protein
tract	I-protein
binding	I-protein
protein	I-protein
(	O
PTB	B-protein
)	O
to	O
analyze	O
the	O
protein	O
components	O
that	O
assemble	O
on	O
alternatively	O
spliced	O
pre	O
-	O
mRNAs	O
that	O
use	O
distant	O
branch	O
points	O
.	O

2	O
-	O
AP	O
induced	O
marked	O
,	O
steady	O
rises	O
in	O
mRNA	O
accumulation	O
from	O
both	O
transfected	O
and	O
chromosomally	O
integrated	O
HIV	O
-	O
1	O
constructs	O
but	O
no	O
increases	O
from	O
an	O
endogenous	O
gene	O
encoding	O
gamma	B-protein
-	I-protein
actin	I-protein
or	O
glucose	B-protein
6	I-protein
-	I-protein
phosphate	I-protein
dehydrogenase	I-protein
.	O

The	O
gene	O
is	O
essential	O
for	O
yeast	O
vegetative	O
growth	O
.	O

Group	O
A	O
(	O
68	O
.	O
7	O
+	O
/	O
-	O
2	O
.	O
7	O
years	O
)	O
consisted	O
of	O
patients	O
with	O
0	O
or	O
1	O
risk	O
factors	O
;	O
B	O
(	O
68	O
.	O
3	O
+	O
/	O
-	O
4	O
.	O
2	O
years	O
)	O
those	O
with	O
2	O
risk	O
factors	O
;	O
and	O
C	O
(	O
69	O
.	O
2	O
+	O
/	O
-	O
3	O
.	O
6	O
years	O
)	O
those	O
with	O
3	O
or	O
more	O
risk	O
factors	O
.	O

50	O
kDa	O
and	O
130	O
-	O
170	O
kDa	O
were	O
detected	O
.	O

Several	O
different	O
oncogenes	O
and	O
growth	B-protein
factors	I-protein
promote	O
G1	O
phase	O
progression	O
.	O

The	O
opioid	O
antagonist	O
naltrexone	O
(	O
0	O
.	O
01	O
-	O
1	O
.	O
0	O
mg	O
/	O
kg	O
)	O
antagonized	O
the	O
discriminative	O
stimulus	O
effects	O
of	O
heroin	O
,	O
but	O
naltrexone	O
at	O
doses	O
up	O
to	O
10	O
mg	O
/	O
kg	O
had	O
no	O
effect	O
on	O
the	O
discriminative	O
stimulus	O
effects	O
of	O
cocaine	O
.	O

The	O
objective	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
the	O
age	O
,	O
sex	O
,	O
clinical	O
conditions	O
,	O
family	O
history	O
,	O
site	O
,	O
catheter	O
association	O
,	O
means	O
of	O
radiologic	O
evaluation	O
,	O
development	O
of	O
pulmonary	O
involvement	O
,	O
prevalence	O
of	O
antithrombin	B-protein
III	I-protein
,	O
protein	B-protein
C	I-protein
and	O
protein	B-protein
S	I-protein
deficiencies	O
,	O
and	O
lupus	O
anticoagulants	O
in	O
children	O
who	O
suffered	O
a	O
thrombotic	O
event	O
.	O

Vascular	O
endothelial	O
cells	O
undergo	O
profound	O
changes	O
upon	O
cellular	O
activation	O
including	O
expression	O
of	O
a	O
spectrum	O
of	O
cell	O
activation	O
-	O
associated	O
genes	O
.	O

Furthermore	O
,	O
LB1	B-protein
gene	I-protein
mapped	O
to	O
chromosome	O
13q14	O
,	O
a	O
region	O
that	O
has	O
been	O
involved	O
as	O
a	O
chromosomal	O
breakpoint	O
in	O
DLBL	O
.	O

These	O
results	O
show	O
that	O
targeting	O
of	O
Ras	B-protein
-	I-protein
GAP	I-protein
could	O
represent	O
a	O
novel	O
anticancer	O
approach	O
.	O

The	O
gene	B-protein
ccpA	I-protein
encoding	O
the	O
catabolite	B-protein
control	I-protein
protein	I-protein
CcpA	I-protein
of	O
Staphylococcus	O
xylosus	O
has	O
been	O
cloned	O
and	O
characterized	O
.	O

A	O
total	O
of	O
194	O
STSs	O
map	O
to	O
this	O
interval	O
of	O
3	O
Mb	O
,	O
giving	O
an	O
average	O
marker	O
resolution	O
of	O
approximately	O
one	O
per	O
15	O
kb	O
.	O

The	O
influence	O
of	O
a	O
high	O
ionic	O
strength	O
on	O
the	O
resolution	O
was	O
clearly	O
shown	O
.	O

The	O
American	O
Burkitt	O
Lymphoma	O
Registry	O
:	O
a	O
progress	O
report	O
.	O

Immunoglobulin	B-protein
light	I-protein
chain	I-protein
(	O
IgL	B-protein
)	O
diversity	O
is	O
generated	O
in	O
the	O
chicken	O
by	O
recombination	O
between	O
the	O
single	O
functional	O
variable	B-protein
(	O
VL	B-protein
)	O
and	O
joining	B-protein
(	O
JL	B-protein
)	O
gene	O
segments	O
and	O
subsequent	O
somatic	O
diversification	O
of	O
the	O
rearranged	B-protein
VL	I-protein
region	I-protein
.	O

Interactions	O
between	O
the	O
checkpoint	O
abrogator	O
UCN	B-protein
-	I-protein
01	I-protein
and	O
several	O
pharmacological	O
inhibitors	O
of	O
the	O
mitogen	B-protein
-	I-protein
activated	I-protein
protein	I-protein
kinase	I-protein
(	I-protein
MAPK	I-protein
)	I-protein
kinase	I-protein
(	O
MEK	B-protein
)	O
/	B-protein
MAPK	I-protein
pathway	O
have	O
been	O
examined	O
in	O
a	O
variety	O
of	O
human	O
leukemia	O
cell	O
lines	O
.	O

Using	O
bovine	B-protein
and	I-protein
murine	I-protein
c	I-protein
-	I-protein
myb	I-protein
clones	O
,	O
no	O
change	O
in	O
the	O
rate	O
of	O
c	B-protein
-	I-protein
myb	I-protein
gene	I-protein
transcription	O
or	O
mRNA	O
stability	O
was	O
detected	O
during	O
the	O
cell	O
cycle	O
.	O

The	O
orbitofrontal	O
,	O
cingulate	O
,	O
and	O
anteromedial	O
part	O
of	O
the	O
dorsal	O
premotor	O
areas	O
were	O
preferentially	O
activated	O
by	O
the	O
self	O
-	O
initiated	O
hand	O
movement	O
task	O
(	O
SELF	O
)	O
.	O

An	O
unusual	O
complication	O
in	O
an	O
unsuitable	O
patient	O
.	O

C	B-protein
/	I-protein
EBP	I-protein
alpha	I-protein
also	O
activates	O
the	O
promoter	O
of	O
the	O
rat	B-protein
class	I-protein
-	I-protein
I	I-protein
ADH	I-protein
gene	I-protein
in	O
a	O
sequence	O
-	O
specific	O
manner	O
[	O
Potter	O
et	O
al	O
.	O
,	O
Arch	O
.	O

The	O
30	O
-	O
day	O
mortality	O
in	O
the	O
CPB	O
group	O
and	O
the	O
non	O
-	O
CPB	O
group	O
were	O
20	O
%	O
and	O
4	O
.	O
6	O
%	O
,	O
respectively	O
which	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
06	O
)	O
.	O

We	O
show	O
that	O
the	O
en	B-protein
stripes	O
expand	O
anteriorly	O
in	O
slp	B-protein
mutant	O
embryos	O
and	O
that	O
slp	B-protein
activity	O
is	O
an	O
absolute	O
requirement	O
for	O
maintenance	O
of	O
wg	B-protein
expression	O
at	O
the	O
same	O
time	O
that	O
wg	B-protein
transcription	O
is	O
dependent	O
on	O
hh	B-protein
.	O

Bailey	O
Instruments	O
and	O
Owen	O
Mumford	O
filaments	O
were	O
the	O
most	O
accurate	O
with	O
100	O
%	O
buckling	O
within	O
+	O
/	O
-	O
1	O
.	O
0	O
g	O
of	O
10	O
g	O
.	O

In	O
the	O
budding	O
yeast	O
,	O
Saccharomyces	O
cerevisiae	O
,	O
replicators	O
can	O
function	O
outside	O
the	O
chromosome	O
as	O
autonomously	O
replicating	O
sequence	O
(	O
ARS	O
)	O
elements	O
;	O
however	O
,	O
within	O
chromosome	O
III	O
,	O
certain	O
ARSs	O
near	O
the	O
transcriptionally	O
silent	O
HML	B-protein
locus	I-protein
show	O
no	O
replication	O
origin	O
activity	O
.	O

Molecular	O
cloning	O
of	O
the	O
cDNA	O
for	O
the	O
human	B-protein
U2	I-protein
snRNA	I-protein
-	I-protein
specific	I-protein
A	I-protein
'	I-protein
protein	I-protein
.	O

Analysis	O
of	O
the	O
genome	O
sequence	O
revealed	O
26	O
,	O
588	O
protein	O
-	O
encoding	O
transcripts	O
for	O
which	O
there	O
was	O
strong	O
corroborating	O
evidence	O
and	O
an	O
additional	O
approximately	O
12	O
,	O
000	O
computationally	O
derived	O
genes	O
with	O
mouse	O
matches	O
or	O
other	O
weak	O
supporting	O
evidence	O
.	O

Thus	O
,	O
CHOP	B-protein
not	O
only	O
is	O
a	O
negative	O
or	O
a	O
positive	O
regulator	O
of	O
C	B-protein
/	I-protein
EBP	I-protein
target	O
genes	O
but	O
also	O
,	O
when	O
tethered	O
to	O
AP	B-protein
-	I-protein
1	I-protein
factors	I-protein
,	O
can	O
activate	O
AP	B-protein
-	I-protein
1	I-protein
target	O
genes	O
.	O

The	O
lymph	O
nodes	O
from	O
two	O
of	O
the	O
patients	O
with	O
rheumatoid	O
arthritis	O
contained	O
numerous	O
sarcoid	O
like	O
granulomata	O
,	O
further	O
indicating	O
a	O
possible	O
association	O
between	O
sarcoidosis	O
and	O
rheumatoid	O
arthritis	O
.	O

Effects	O
of	O
prostaglandin	O
inhibitors	O
on	O
the	O
onset	O
of	O
proteinuria	O
and	O
stroke	O
in	O
stroke	O
-	O
prone	O
spontaneously	O
hypertensive	O
rats	O
.	O

Female	O
patients	O
with	O
breast	O
cancer	O
diagnosed	O
between	O
1982	O
and	O
1991	O
at	O
Roswell	O
Park	O
Cancer	O
Institute	O
(	O
RPCI	O
)	O
in	O
Buffalo	O
,	O
New	O
York	O
,	O
who	O
provided	O
information	O
on	O
their	O
cigarette	O
smoking	O
history	O
at	O
the	O
time	O
of	O
their	O
diagnosis	O
were	O
included	O
.	O

One	O
antibody	O
,	O
mAb1C2	B-protein
,	O
and	O
a	O
synthetic	O
peptide	O
comprising	O
its	O
epitope	O
selectively	O
inhibited	O
in	O
vitro	O
transcription	O
from	O
TATA	O
-	O
containing	O
,	O
but	O
not	O
from	O
TATA	O
-	O
less	O
promoters	O
,	O
irrespective	O
of	O
whether	O
they	O
were	O
transcribed	O
by	O
Pol	B-protein
II	I-protein
or	O
Pol	B-protein
III	I-protein
.	O

Supershift	O
EMSAs	O
identified	O
that	O
upstream	B-protein
stimulatory	I-protein
factor	I-protein
-	I-protein
1	I-protein
and	I-protein
-	I-protein
2	I-protein
(	O
USF	B-protein
-	I-protein
1	I-protein
and	I-protein
-	I-protein
2	I-protein
)	O
were	O
part	O
of	O
these	O
complexes	O
.	O

Abdominal	O
tumors	O
in	O
childhood	O
.	O

Deletion	O
or	O
inactivation	O
of	O
CRY1	B-protein
leads	O
to	O
5	O
-	O
to	O
10	O
-	O
fold	O
-	O
increased	O
levels	O
of	O
CRY2	B-protein
mRNA	I-protein
.	O

Effect	O
of	O
indomethacin	O
on	O
coronary	O
circulation	O
:	O
effect	O
on	O
ECG	O
tracing	O
.	O

Review	O
of	O
the	O
literature	O
and	O
report	O
of	O
a	O
case	O
of	O
a	O
dermoid	O
cyst	O
.	O

Identification	O
,	O
purification	O
,	O
and	O
molecular	O
cloning	O
of	O
autonomously	B-protein
replicating	I-protein
sequence	I-protein
-	I-protein
binding	I-protein
protein	I-protein
1	I-protein
from	I-protein
fission	I-protein
yeast	I-protein
Schizosaccharomyces	I-protein
pombe	I-protein
.	O

A	O
comparison	O
among	O
the	O
5	O
'	O
flanking	O
regions	O
encompassing	O
the	O
presumptive	O
HS	B-protein
promoter	I-protein
of	O
the	O
soybean	B-protein
HS	I-protein
-	I-protein
protein	I-protein
genes	I-protein
demonstrated	O
this	O
region	O
to	O
be	O
extremely	O
homologous	O
.	O

M	B-protein
.	I-protein
leprae	I-protein
OxyR	I-protein
was	O
overproduced	O
and	O
purified	O
,	O
and	O
its	O
binding	O
to	O
the	O
oxyR	B-protein
-	I-protein
ahpC	I-protein
intergenic	I-protein
region	I-protein
of	I-protein
M	I-protein
.	I-protein
leprae	I-protein
was	O
demonstrated	O
.	O

Regulatory	O
regions	O
in	O
the	O
promoter	O
and	O
third	O
intron	O
of	O
the	O
growth	B-protein
hormone	I-protein
gene	I-protein
in	I-protein
rainbow	I-protein
trout	I-protein
,	O
Oncorhynchus	O
mykiss	O
walbaum	O
.	O

Proceedings	O
:	O
Barrels	O
and	O
somatotopy	O
in	O
S	O
I	O
neocortex	O
of	O
the	O
brush	O
-	O
tailed	O
possum	O
.	O

The	O
T	O
-	O
box	O
motif	O
is	O
present	O
in	O
a	O
family	O
of	O
genes	O
whose	O
structural	O
features	O
and	O
expression	O
patterns	O
support	O
their	O
involvement	O
in	O
developmental	O
gene	O
regulation	O
.	O

KAR1	B-protein
encodes	O
an	O
essential	O
component	O
of	O
the	O
yeast	O
spindle	O
pole	O
body	O
(	O
SPB	O
)	O
that	O
is	O
required	O
for	O
karyogamy	O
and	O
SPB	O
duplication	O
.	O

To	O
study	O
the	O
significance	O
of	O
these	O
domains	O
and	O
the	O
overall	O
evolutionary	O
conservation	O
of	O
the	O
gene	O
,	O
the	O
homolog	O
from	O
Drosophila	O
melanogaster	O
was	O
isolated	O
by	O
low	O
stringency	O
hybridizations	O
using	O
two	O
flanking	O
probes	O
of	O
the	O
human	B-protein
ERCC3	I-protein
cDNA	I-protein
.	O

PAO	O
blocks	O
turnover	O
of	O
the	O
phosphoryl	O
group	O
of	O
pp15	B-protein
,	O
causing	O
its	O
accumulation	O
,	O
and	O
thereby	O
appears	O
to	O
interrupt	O
signal	O
transmission	O
from	O
the	O
receptor	O
to	O
the	O
glucose	O
-	O
transport	O
system	O
.	O

Because	O
L	B-protein
-	I-protein
plastin	I-protein
expression	O
in	O
tissue	O
-	O
specifically	O
regulated	O
in	O
both	O
humans	O
and	O
rodents	O
,	O
it	O
is	O
likely	O
that	O
similar	O
mechanisms	O
regulate	O
L	B-protein
-	I-protein
plastin	I-protein
gene	I-protein
expression	O
in	O
human	O
and	O
rodent	O
cells	O
and	O
that	O
they	O
could	O
be	O
identified	O
by	O
comparing	O
the	O
function	O
and	O
nucleotide	O
sequences	O
of	O
the	O
human	O
and	O
murine	O
L	B-protein
-	I-protein
plastin	I-protein
gene	O
promoters	O
.	O

We	O
studied	O
120	O
male	O
and	O
42	O
female	O
patients	O
with	O
early	O
CAD	O
who	O
were	O
unrelated	O
to	O
each	O
other	O
but	O
were	O
from	O
families	O
in	O
which	O
at	O
least	O
one	O
other	O
sibling	O
had	O
early	O
CAD	O
.	O

On	O
the	O
trail	O
of	O
Dr	O
.	O

Second	O
,	O
when	O
the	O
NBF1	B-protein
+	I-protein
R	I-protein
protein	I-protein
,	O
the	O
NBF2	B-protein
protein	I-protein
,	O
and	O
a	O
mixture	O
of	O
the	O
two	O
proteins	O
were	O
folded	O
separately	O
and	O
analyzed	O
by	O
molecular	O
sieve	O
chomatography	O
,	O
the	O
mixture	O
was	O
found	O
to	O
elute	O
prior	O
to	O
either	O
NBF1	B-protein
+	I-protein
R	I-protein
or	O
NBF2	B-protein
.	O

The	O
addition	O
of	O
a	O
Paf	O
-	O
containing	O
extract	O
does	O
not	O
lead	O
to	O
significant	O
protein	O
binding	O
to	O
these	O
two	O
hly	B-protein
target	I-protein
sequences	I-protein
in	O
the	O
absence	O
of	O
PrfA	B-protein
but	O
converts	O
the	O
complex	O
(	O
CIII	B-protein
)	O
consisting	O
of	O
PrfA	B-protein
and	O
the	O
109	B-protein
bp	I-protein
hly	I-protein
DNA	I-protein
fragment	I-protein
to	O
a	O
slower	O
migrating	O
PrfA	B-protein
-	I-protein
Paf	I-protein
-	I-protein
DNA	I-protein
complex	I-protein
(	O
CI	B-protein
)	O
.	O

We	O
demonstrate	O
that	O
Ddc1p	B-protein
interacts	O
physically	O
in	O
vivo	O
with	O
Mec3p	B-protein
,	O
and	O
this	O
interaction	O
requires	O
Rad17p	B-protein
.	O

Our	O
data	O
,	O
however	O
,	O
did	O
not	O
suggest	O
the	O
existence	O
of	O
a	O
conversion	O
factor	O
for	O
LDF	O
signal	O
to	O
absolute	O
flow	O
values	O
from	O
experiment	O
to	O
experiment	O
.	O

Bullous	O
keratopathy	O
was	O
usually	O
aphakic	O
in	O
origin	O
in	O
1982	O
,	O
but	O
after	O
1983	O
pseudophakic	O
bullous	O
keratopathy	O
(	O
PBK	O
)	O
was	O
the	O
most	O
common	O
cause	O
of	O
bullous	O
keratopathy	O
.	O

Assay	O
of	O
urea	O
by	O
immobilized	O
urease	B-protein
coupled	O
to	O
a	O
differential	O
pH	O
-	O
meter	O
.	O

Because	O
single	O
-	O
chamber	O
rate	O
-	O
adaptive	O
atrial	O
pacing	O
leaves	O
the	O
patient	O
exposed	O
to	O
the	O
risk	O
of	O
future	O
development	O
of	O
AV	O
block	O
and	O
DDD	O
pacing	O
does	O
not	O
provide	O
chronotropic	O
support	O
,	O
it	O
is	O
likely	O
that	O
the	O
new	O
rate	O
-	O
adaptive	O
dual	O
-	O
chamber	O
(	O
DDDR	O
)	O
devices	O
will	O
be	O
used	O
in	O
a	O
significant	O
number	O
of	O
these	O
patients	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Among	O
100	O
cases	O
of	O
post	O
-	O
transfusion	O
hepatitis	O
,	O
10	O
are	O
due	O
to	O
the	O
hepatitis	O
B	O
virus	O
(	O
despite	O
systematic	O
search	O
for	O
HBs	B-protein
Ag	I-protein
)	O
,	O
89	O
are	O
due	O
to	O
one	O
of	O
the	O
non	O
-	O
A	O
non	O
-	O
B	O
viruses	O
(	O
not	O
detectable	O
by	O
specific	O
serological	O
tests	O
)	O
and	O
1	O
to	O
several	O
viruses	O
,	O
specially	O
CMV	O
.	O

Sex	O
of	O
calf	O
(	O
variate	O
2	O
)	O
was	O
associated	O
most	O
closely	O
with	O
width	O
of	O
muzzle	O
and	O
head	O
.	O

Postglucose	O
serum	B-protein
insulin	I-protein
levels	O
showed	O
no	O
significant	O
correlations	O
with	O
systolic	O
or	O
diastolic	O
blood	O
pressure	O
levels	O
in	O
men	O
,	O
but	O
in	O
female	O
diabetic	O
and	O
non	O
-	O
diabetic	O
subjects	O
significant	O
correlations	O
were	O
found	O
in	O
particular	O
with	O
systolic	O
blood	O
pressure	O
level	O
.	O

Endometrial	O
biopsies	O
and	O
plasma	O
oestradiol	O
(	O
E2	O
)	O
and	O
progesterone	O
(	O
P4	O
)	O
levels	O
in	O
23	O
patients	O
were	O
evaluated	O
during	O
26	O
replacement	O
therapy	O
cycles	O
for	O
premature	O
ovarian	O
failure	O
.	O

We	O
propose	O
that	O
the	O
technique	O
of	O
low	O
-	O
frequency	O
kindling	O
is	O
a	O
useful	O
experimental	O
model	O
in	O
assessing	O
the	O
effects	O
of	O
antipsychotic	O
or	O
antiepileptic	O
drugs	O
on	O
the	O
excitability	O
of	O
the	O
limbic	O
regions	O
.	O

RNA	B-protein
polymerase	I-protein
II	I-protein
inhibition	O
increased	O
the	O
binding	O
of	O
ARE	O
(	O
AUBP	O
activity	O
)	O
and	O
poly	O
(	O
U	O
)	O
-	O
Sepharose	O
by	O
cytoplasmic	B-protein
hnRNP	I-protein
A1	I-protein
,	O
while	O
nuclear	B-protein
hnRNP	I-protein
A1	I-protein
binding	O
was	O
unaffected	O
.	O

The	O
present	O
investigation	O
has	O
revealed	O
that	O
the	O
distribution	O
of	O
the	O
main	O
fatty	O
acids	O
in	O
Leptospira	O
phospholipids	O
is	O
similar	O
to	O
their	O
distribution	O
in	O
Leptospira	O
neutral	O
lipids	O
with	O
the	O
exception	O
of	O
unsaturated	O
fatty	O
acid	O
with	O
14	O
carbon	O
atoms	O
,	O
occurring	O
mainly	O
in	O
phospholipids	O
.	O

The	O
endodontal	O
treatment	O
need	O
has	O
been	O
forming	O
a	O
clinical	O
order	O
of	O
magnitude	O
.	O

These	O
data	O
do	O
not	O
support	O
the	O
use	O
of	O
LDD	O
to	O
reduce	O
risk	O
of	O
progression	O
to	O
MSOF	O
in	O
sepsis	O
.	O

The	O
distribution	O
of	O
body	O
fluids	O
following	O
hemorrhage	O
and	O
resuscitation	O
in	O
combat	O
casualties	O
.	O

Receptor	B-protein
protein	I-protein
tyrosine	I-protein
phosphatases	I-protein
(	O
RPTPs	B-protein
)	O
comprise	O
a	O
family	O
of	O
proteins	O
that	O
feature	O
intracellular	O
phosphatase	B-protein
domains	O
and	O
an	O
ectodomain	O
with	O
putative	O
ligand	O
-	O
binding	O
motifs	O
.	O

Analysis	O
of	O
the	O
protein	O
sequences	O
of	O
these	O
two	O
replicases	B-protein
,	O
together	O
with	O
previously	O
characterized	O
H	O
.	O
pylori	O
plasmid	O
replication	O
proteins	O
,	O
supports	O
the	O
formation	O
of	O
a	O
distinct	O
class	O
of	O
H	O
.	O
pylori	O
plasmid	O
proteins	O
.	O

Hence	O
,	O
the	O
replacement	O
of	O
Phe	O
-	O
62	O
with	O
Ser	O
specifically	O
affects	O
a	O
determinant	O
on	O
the	O
lambda	B-protein
I	I-protein
light	I-protein
chain	I-protein
that	O
is	O
necessary	O
for	O
the	O
intracellular	O
transport	O
of	O
this	O
molecule	O
.	O

The	O
rational	O
for	O
the	O
prophylactic	O
treatment	O
,	O
the	O
therapy	O
of	O
the	O
meningopathy	O
and	O
AIL	O
-	O
AIEOP	O
protocols	O
are	O
exposed	O
.	O

Immunolocalization	O
of	O
Sop1p	B-protein
revealed	O
a	O
cytoplasmic	O
distribution	O
and	O
cell	O
fractionation	O
studies	O
showed	O
that	O
a	O
significant	O
fraction	O
of	O
Sop1p	B-protein
was	O
recovered	O
in	O
a	O
sedimentable	O
fraction	O
of	O
the	O
cytosolic	O
material	O
.	O

These	O
results	O
indicate	O
that	O
in	O
addition	O
to	O
Grb2	O
-	O
mediated	O
activation	O
of	O
Ras	B-protein
,	O
PLC	O
-	O
gamma1	O
-	O
mediated	O
DAG	O
production	O
is	O
required	O
for	O
EGF	O
-	O
and	O
PDGF	O
-	O
induced	O
S	O
-	O
phase	O
entry	O
and	O
gene	O
expression	O
,	O
possibly	O
through	O
activation	O
of	O
PKC	B-protein
.	O

For	O
this	O
,	O
cDNAs	O
containing	O
the	O
60K	O
,	O
87K	O
,	O
110K	O
and	O
170K	O
protein	O
coding	O
sequences	O
were	O
each	O
provided	O
with	O
an	O
ATG	O
start	O
codon	O
and	O
the	O
cDNA	O
containing	O
the	O
60K	O
coding	O
sequence	O
with	O
a	O
TAA	O
stop	O
codon	O
immediately	O
downstream	O
of	O
the	O
coding	O
sequence	O
.	O

Differential	O
signaling	O
and	O
immediate	O
-	O
early	O
gene	O
activation	O
by	O
four	O
splice	O
variants	O
of	O
the	O
human	B-protein
pituitary	I-protein
adenylate	I-protein
cyclase	I-protein
-	I-protein
activating	I-protein
polypeptide	I-protein
receptor	I-protein
(	O
hPACAP	B-protein
-	I-protein
R	I-protein
)	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
mouse	B-protein
cytosolic	I-protein
chaperonin	I-protein
subunit	I-protein
gene	I-protein
Ccta	I-protein
/	I-protein
t	I-protein
-	I-protein
complex	I-protein
polypeptide	I-protein
1	I-protein
by	O
selenocysteine	B-protein
tRNA	I-protein
gene	I-protein
transcription	I-protein
activating	I-protein
factor	I-protein
family	I-protein
zinc	I-protein
finger	I-protein
proteins	I-protein
.	O

Online	O
teaching	O
:	O
design	O
and	O
techniques	O
.	O

It	O
was	O
subsequently	O
shown	O
that	O
Tip60	B-protein
had	O
histone	B-protein
acetyltransferase	I-protein
(	O
HAT	B-protein
)	O
activity	O
.	O

The	O
Community	O
Adjustment	O
Scale	O
provided	O
outcome	O
data	O
related	O
to	O
the	O
subjects	O
'	O
degree	O
of	O
productivity	O
,	O
ability	O
to	O
maintain	O
close	O
relationships	O
,	O
and	O
presence	O
/	O
absence	O
of	O
symptomatology	O
an	O
average	O
of	O
32	O
years	O
after	O
initial	O
admission	O
.	O

Volunteers	O
were	O
irradiated	O
on	O
their	O
backs	O
with	O
suberythemal	O
UV	O
daily	O
for	O
5	O
d	O
after	O
application	O
of	O
the	O
sunscreens	O
and	O
their	O
base	O
lotion	O
to	O
different	O
sites	O
.	O

Range	O
,	O
variations	O
and	O
neoplastic	O
potential	O
.	O

Lipid	O
hydroperoxide	O
levels	O
in	O
plasma	O
and	O
LDL	B-protein
remained	O
unchanged	O
throughout	O
the	O
study	O
.	O

Patients	O
subsequently	O
returned	O
to	O
the	O
clinic	O
every	O
3	O
days	O
to	O
have	O
the	O
wounds	O
checked	O
and	O
dressings	O
changed	O
.	O

In	O
an	O
effort	O
to	O
separate	O
domains	O
of	O
FadR	B-protein
required	O
for	O
DNA	O
binding	O
,	O
dimerization	O
,	O
and	O
ligand	O
binding	O
,	O
chimeric	O
protein	O
fusions	O
between	O
the	O
DNA	O
binding	O
domain	O
of	O
LexA	B-protein
and	O
different	O
regions	O
of	O
FadR	B-protein
were	O
constructed	O
.	O

These	O
natural	O
antisense	O
S	B-protein
transcripts	I-protein
co	O
-	O
exist	O
with	O
several	O
less	O
abundant	O
sense	O
S	B-protein
transcripts	I-protein
.	O

Genoa	O
,	O
Italy	O
,	O
24	O
-	O
28	O
August	O
1997	O
.	O

They	O
have	O
not	O
been	O
previously	O
reported	O
as	O
a	O
reaction	O
to	O
i	O
.	O
v	O
.	O
contrast	O
material	O
.	O

Our	O
evidence	O
derives	O
from	O
three	O
principal	O
observations	O
:	O
1	O
)	O
a	O
transfection	O
construct	O
containing	O
only	O
122	O
nucleotides	O
(	O
nt	O
)	O
of	O
promoter	O
1	O
and	O
328	O
nt	O
of	O
the	O
5	O
'	O
-	O
UTR	O
retained	O
full	O
PGE2	O
-	O
stimulated	O
reporter	O
expression	O
;	O
2	O
)	O
maximal	O
PGE2	O
-	O
driven	O
reporter	O
expression	O
required	O
the	O
presence	O
of	O
nt	O
196	O
to	O
328	O
of	O
exon	O
1	O
when	O
tested	O
within	O
the	O
context	O
of	O
IGF	B-protein
-	I-protein
I	I-protein
promoter	I-protein
1	I-protein
;	O
3	O
)	O
cotransfection	O
of	O
IGF	B-protein
-	I-protein
I	I-protein
promoter	I-protein
-	I-protein
luciferase	I-protein
-	I-protein
reporter	I-protein
constructs	O
with	O
a	O
plasmid	O
encoding	O
the	O
alpha	O
-	O
isoform	O
of	O
the	O
catalytic	O
subunit	O
of	O
murine	B-protein
cAMP	I-protein
-	I-protein
dependent	I-protein
protein	I-protein
kinase	I-protein
(	O
PKA	B-protein
)	O
produced	O
results	O
comparable	O
to	O
those	O
seen	O
with	O
PGE2	O
treatment	O
,	O
whereas	O
cotransfection	O
with	O
a	O
plasmid	O
encoding	O
a	O
mutant	O
regulatory	O
subunit	O
of	O
PKA	B-protein
that	O
can	O
not	O
bind	O
cAMP	O
blocked	O
PGE2	O
-	O
induced	O
reporter	O
expression	O
.	O

Bound	O
-	O
exciton	O
transfer	O
and	O
photoluminescence	O
undulation	O
spectra	O
for	O
acceptors	O
in	O
ZnTe	O
.	O

The	O
available	O
data	O
suggest	O
that	O
the	O
NF	B-protein
kappa	I-protein
B2	I-protein
nucleoprotein	I-protein
complex	I-protein
may	O
cooperate	O
with	O
DNA	O
-	O
bound	O
STAT6	B-protein
to	O
achieve	O
IL	O
-	O
4	O
-	O
dependent	O
activation	O
of	O
the	O
human	B-protein
IgE	I-protein
germline	I-protein
gene	I-protein
.	O

Our	O
results	O
show	O
that	O
the	O
ORF	O
of	O
hAMPK	B-protein
encodes	O
552	O
amino	O
acids	O
(	O
aa	O
)	O
(	O
62	O
.	O
250	O
kDa	O
)	O
and	O
is	O
highly	O
conserved	O
with	O
rAMPK	B-protein
with	O
identities	O
of	O
97	O
.	O
3	O
and	O
90	O
%	O
at	O
the	O
aa	O
and	O
nt	O
levels	O
,	O
respectively	O
.	O

One	O
air	O
embolism	O
occurred	O
;	O
this	O
was	O
the	O
only	O
filter	O
-	O
or	O
retrieval	O
-	O
related	O
complication	O
.	O

Here	O
,	O
the	O
cloning	O
and	O
characterization	O
of	O
S	B-protein
-	I-protein
RNase	I-protein
genes	I-protein
from	O
two	O
species	O
of	O
Rosaceae	O
,	O
apple	O
(	O
Malus	O
x	O
domestica	O
)	O
and	O
Japanese	O
pear	O
(	O
Pyrus	O
serotina	O
)	O
is	O
described	O
and	O
these	O
sequences	O
are	O
compared	O
with	O
those	O
of	O
other	O
T2	B-protein
-	I-protein
type	I-protein
RNases	I-protein
.	O

Angionephroscintigraphy	O
in	O
the	O
diagnosis	O
of	O
diseases	O
of	O
the	O
kidney	O
.	O

Supershift	O
assays	O
,	O
using	O
Jun	B-protein
and	O
Fos	B-protein
family	I-protein
member	I-protein
-	I-protein
specific	I-protein
antibodies	I-protein
,	O
showed	O
that	O
protein	O
complexes	O
formed	O
by	O
AtT	O
-	O
20	O
cell	O
nuclear	O
extracts	O
bound	O
to	O
the	O
c	B-protein
-	I-protein
jun	I-protein
AP	I-protein
-	I-protein
1	I-protein
site	I-protein
were	O
comprised	O
of	O
Jun	B-protein
family	O
members	O
,	O
JunD	B-protein
,	O
JunB	B-protein
,	O
and	O
cJun	B-protein
.	O

Curing	O
shrinkage	O
and	O
volumetric	O
changes	O
of	O
resin	O
-	O
modified	O
glass	O
ionomer	O
restorative	O
materials	O
.	O

Consistent	O
with	O
this	O
finding	O
,	O
wild	B-protein
-	I-protein
type	I-protein
SAGA	I-protein
inhibits	O
TBP	B-protein
binding	O
to	O
the	O
HIS3	B-protein
promoter	I-protein
in	O
vitro	O
,	O
while	O
SAGA	B-protein
lacking	O
Spt3	B-protein
or	O
Spt8	B-protein
is	O
not	O
inhibitory	O
.	O

Variable	O
FHR	O
decelerations	O
or	O
bradycardias	O
were	O
encountered	O
on	O
95	O
nonstress	O
tests	O
(	O
18	O
.	O
8	O
%	O
)	O
in	O
80	O
(	O
33	O
.	O
5	O
%	O
)	O
postdate	O
patients	O
.	O

Information	O
about	O
immunologic	O
drug	O
interactions	O
is	O
needed	O
by	O
pharmacists	O
to	O
make	O
rational	O
drug	O
-	O
use	O
decisions	O
.	O

The	O
authors	O
evaluated	O
the	O
potential	O
for	O
thrombotic	O
complications	O
arising	O
from	O
implantation	O
of	O
a	O
ventricular	O
assist	O
device	O
(	O
Sarns	O
/	O
3M	O
-	O
VAD	O
)	O
in	O
four	O
calves	O
.	O

A	O
late	O
diagnosis	O
of	O
retinoblastoma	O
is	O
an	O
unquestionable	O
fact	O
that	O
allows	O
its	O
growth	O
and	O
leads	O
to	O
a	O
deterioration	O
in	O
the	O
outlook	O
.	O

Through	O
deletion	O
mutagenesis	O
,	O
we	O
identify	O
amino	O
acids	O
2003	O
to	O
2212	O
of	O
CBP	B-protein
,	O
which	O
we	O
call	O
carboxy	O
-	O
terminal	O
region	O
2	O
(	O
CR2	O
)	O
,	O
as	O
the	O
minimal	O
region	O
for	O
Tax	B-protein
interaction	O
.	O

Our	O
results	O
demonstrate	O
the	O
importance	O
of	O
phosphate	O
and	O
calcium	O
in	O
influencing	O
the	O
secretion	O
of	O
PTH	B-protein
and	O
CT	B-protein
in	O
uremia	O
.	O

A	O
degenerate	O
DNA	O
transposon	O
,	O
Pat	B-protein
,	O
was	O
identified	O
in	O
the	O
genomes	O
of	O
various	O
wild	O
-	O
type	O
strains	O
of	O
the	O
filamentous	O
fungus	O
Podospora	O
anserina	O
.	O

The	O
importance	O
of	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
as	O
a	O
cause	O
of	O
chronic	O
liver	O
disease	O
has	O
become	O
clear	O
with	O
the	O
introduction	O
of	O
serologic	O
detection	O
methods	O
.	O

XXI	O
.	O

1111	O
)	O
;	O
L	O
/	O
H	O
>	O
0	O
.	O
61	O
(	O
chi	O
(	O
2	O
)	O
=	O
10	O
.	O
8	O
;	O
P	O
:	O
<	O
0	O
.	O
1111	O
)	O
and	O
a	O
restrictive	O
filling	O
pattern	O
(	O
chi	O
(	O
2	O
)	O
=	O
3	O
.	O
6	O
;	O
P	O
:	O
<	O
0	O
.	O
09	O
)	O
were	O
independent	O
predictors	O
of	O
events	O
.	O

In	O
addition	O
,	O
we	O
identified	O
two	O
mutations	O
,	O
Delta	O
M1281	O
and	O
IVS51	O
+	O
5G	O
-	O
-	O
>	O
A	O
,	O
in	O
a	O
German	O
USH1	B-protein
patient	O
.	O

We	O
propose	O
that	O
two	O
pathways	O
regulate	O
Stat5	B-protein
serine	O
phosphorylation	O
,	O
one	O
that	O
is	O
prolactin	O
-	O
activated	O
and	O
PD98059	O
-	O
resistant	O
and	O
one	O
that	O
is	O
constitutively	O
active	O
and	O
PD98059	O
-	O
sensitive	O
and	O
preferentially	O
targets	O
Stat5a	B-protein
.	O

The	O
authors	O
conclude	O
that	O
nonspecificity	O
of	O
low	O
platelet	B-protein
MAO	I-protein
as	O
a	O
possible	O
correlate	O
of	O
bipolar	O
affective	O
disorder	O
,	O
as	O
well	O
as	O
schizophrenia	O
,	O
increases	O
the	O
burden	O
of	O
proof	O
necessary	O
before	O
findings	O
of	O
low	O
platelet	B-protein
MAO	I-protein
can	O
be	O
accepted	O
as	O
primary	O
.	O

The	O
effect	O
of	O
lithium	O
on	O
the	O
osmoregulation	O
of	O
arginine	B-protein
vasopressin	I-protein
secretion	O
.	O

Effect	O
of	O
ingestion	O
of	O
Norbiogest	O
during	O
the	O
quiescent	O
period	O
of	O
the	O
genital	O
organs	O
.	O

The	O
Thr161Val	O
mutation	O
causes	O
a	O
lethal	O
phenotype	O
in	O
the	O
fission	O
yeast	O
Schizosaccharomyces	O
pombe	O
,	O
while	O
replacement	O
of	O
Thr161	O
with	O
glutamic	O
acid	O
,	O
potentially	O
mimicking	O
phosphorylation	O
,	O
causes	O
uncoordination	O
of	O
mitosis	O
and	O
multiple	O
cytokinesis	O
.	O

No	O
effect	O
was	O
found	O
on	O
grooming	O
behavior	O
.	O

Fourth	O
,	O
sometime	O
between	O
4	O
and	O
24	O
hours	O
of	O
recovery	O
is	O
necessary	O
to	O
reverse	O
the	O
effect	O
of	O
chronic	O
hypoxia	O
on	O
cerebral	O
blood	O
flow	O
.	O

OBJECTIVE	O
:	O
To	O
perform	O
a	O
cost	O
-	O
effectiveness	O
analysis	O
(	O
CEA	O
)	O
between	O
a	O
standard	O
antiemetic	O
regimen	O
-	O
chlorpromazine	O
+	O
dexamethasone	O
(	O
CPM	O
-	O
DEX	O
)	O
-	O
and	O
a	O
5	B-protein
-	I-protein
HT3	I-protein
receptor	I-protein
antagonist	O
-	O
tropisetron	O
(	O
TROP	O
)	O
-	O
-	O
in	O
the	O
control	O
of	O
acute	O
emesis	O
induced	O
by	O
highly	O
emetogenic	O
chemotherapy	O
in	O
children	O
,	O
considering	O
two	O
analytic	O
perspectives	O
:	O
hospital	O
and	O
patients	O
.	O

The	O
patients	O
were	O
divided	O
into	O
4	O
groups	O
receiving	O
NLA	O
II	O
with	O
or	O
without	O
nalorphine	O
,	O
morphine	O
or	O
Micoren	O
.	O

The	O
promoter	O
segment	O
was	O
inactive	O
when	O
introduced	O
into	O
the	O
rat	O
glioma	O
cell	O
line	O
C6B4	O
,	O
the	O
rat	O
submandibular	O
cell	O
line	O
RSMT	O
-	O
A5	O
,	O
and	O
the	O
rat	O
pancreatic	O
beta	O
cell	O
line	O
RIN	O
-	O
5AH	O
,	O
all	O
of	O
which	O
do	O
not	O
express	O
the	O
endogenous	O
alpha2c	B-protein
-	I-protein
AR	I-protein
gene	I-protein
.	O

Following	O
treatment	O
,	O
serum	O
estradiol	O
levels	O
were	O
higher	O
in	O
groups	O
E	O
+	O
T	O
and	O
E	O
than	O
in	O
group	O
C	O
.	O

These	O
data	O
suggest	O
that	O
combined	O
lesions	O
of	O
cholinergic	O
and	O
serotonergic	O
neurons	O
in	O
the	O
rat	O
brain	O
do	O
not	O
alter	O
olfactory	O
perception	O
or	O
olfactory	O
short	O
-	O
term	O
memory	O
.	O

Both	O
antidepressants	O
elevated	O
the	O
pain	O
threshold	O
acutely	O
,	O
while	O
pretreatment	O
with	O
pCPA	O
largely	O
blocked	O
the	O
analgesia	O
.	O

Sequence	O
analysis	O
of	O
cloned	O
PCR	O
products	O
confirmed	O
the	O
presence	O
of	O
two	O
different	O
nifV	B-protein
-	I-protein
like	I-protein
DNA	I-protein
fragments	I-protein
,	O
which	O
were	O
subsequently	O
used	O
as	O
nifV	O
-	O
and	O
leuA	B-protein
-	I-protein
specific	I-protein
probes	I-protein
,	O
respectively	O
,	O
to	O
clone	O
XbaI	B-protein
fragments	I-protein
of	O
2	O
.	O
1	O
kbp	O
(	O
pOST4	O
)	O
and	O
2	O
.	O
6	O
kbp	O
(	O
pOST2	O
)	O
.	O

A	O
technique	O
for	O
thermal	O
imaging	O
of	O
the	O
animal	O
and	O
human	O
brain	O
cortex	O
using	O
an	O
infrared	O
optical	O
system	O
is	O
described	O
.	O

Identification	O
and	O
characterization	O
of	O
IS2404	B-protein
and	O
IS2606	B-protein
:	O
two	O
distinct	O
repeated	O
sequences	O
for	O
detection	O
of	O
Mycobacterium	O
ulcerans	O
by	O
PCR	O
.	O

Cloning	O
of	O
individual	O
ZI	B-protein
domains	I-protein
upstream	O
of	O
a	O
minimal	O
promoter	O
demonstrated	O
that	O
the	O
ZIA	B-protein
,	O
ZIC	B-protein
,	O
and	O
ZID	B-protein
domains	O
,	O
but	O
not	O
the	O
ZIB	B-protein
domain	O
,	O
are	O
TPA	B-protein
responsive	O
.	O

These	O
data	O
suggest	O
that	O
the	O
levels	O
of	O
oxygen	O
free	O
radicals	O
were	O
increased	O
in	O
hepatocytes	O
and	O
mitochondria	O
.	O

Breast	O
cancer	O
risk	O
assessment	O
:	O
who	O
holds	O
the	O
magic	O
crystal	O
ball	O
?	O

Significantly	O
higher	O
lung	O
function	O
parameters	O
were	O
obtained	O
in	O
extubated	O
recipients	O
of	O
LPD	O
preserved	O
grafts	O
2	O
weeks	O
after	O
TX	O
.	O

These	O
mutants	O
all	O
failed	O
to	O
interact	O
with	O
the	O
TraR	B-protein
fusion	I-protein
in	O
the	O
two	O
-	O
hybrid	O
system	O
.	O

Tih1	B-protein
maps	O
to	O
distal	O
mouse	O
Chr	O
1	O
and	O
human	O
Chr	O
1q31	O
,	O
chromosomal	O
regions	O
that	O
have	O
not	O
shown	O
evidence	O
for	O
imprinting	O
and	O
,	O
in	O
contrast	O
to	O
Ipl	B-protein
,	O
Tih1	B-protein
is	O
expressed	O
equally	O
from	O
both	O
parental	O
alleles	O
.	O

To	O
establish	O
a	O
possible	O
association	O
between	O
familial	O
dysfibrinogenemia	O
and	O
thrombophilia	O
,	O
data	O
on	O
cases	O
with	O
both	O
affections	O
were	O
collected	O
in	O
a	O
study	O
within	O
the	O
framework	O
of	O
the	O
SSC	O
Subcommittee	O
on	O
Fibrinogen	B-protein
of	O
the	O
International	O
Society	O
on	O
Thrombosis	O
and	O
Haemostasis	O
.	O

Rabbit	B-protein
skeletal	I-protein
muscle	I-protein
glycogenin	I-protein
.	O

Furthermore	O
,	O
direct	O
association	O
with	O
D3	O
phosphatidylinositides	O
seems	O
to	O
be	O
essential	O
for	O
activation	O
of	O
PKB	B-protein
/	I-protein
Akt	I-protein
.	O

PIP2	B-protein
,	O
when	O
incorporated	O
into	O
phosphatidylcholine	O
carrier	O
vesicles	O
,	O
binds	O
tightly	O
to	O
the	O
guanine	O
nucleotide	O
-	O
depleted	O
form	O
of	O
Cdc42Hs	B-protein
and	O
weakly	O
to	O
the	O
GDP	O
-	O
bound	O
form	O
of	O
the	O
GTP	B-protein
-	I-protein
binding	I-protein
protein	I-protein
but	O
does	O
not	O
bind	O
to	O
GTP	O
-	O
bound	O
Cdc42Hs	B-protein
,	O
similar	O
to	O
what	O
was	O
observed	O
for	O
the	O
Dbl	B-protein
oncoprotein	I-protein
.	O

We	O
have	O
cloned	O
a	O
novel	O
protein	B-protein
kinase	I-protein
,	O
termed	O
hematopoietic	B-protein
progenitor	I-protein
kinase	I-protein
1	I-protein
(	O
HPK1	B-protein
)	O
,	O
that	O
is	O
expressed	O
predominantly	O
in	O
hematopoietic	O
cells	O
,	O
including	O
early	O
progenitor	O
cells	O
.	O

By	O
progressive	O
5	O
'	O
-	O
deletion	O
studies	O
,	O
we	O
have	O
identified	O
a	O
248	O
-	O
bp	O
DNA	O
fragment	O
(	O
-	O
1018	O
to	O
-	O
771	O
,	O
relative	O
to	O
the	O
translation	O
start	O
site	O
)	O
at	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
human	B-protein
GnRHR	I-protein
gene	I-protein
that	O
is	O
responsible	O
for	O
the	O
GnRHa	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
human	B-protein
GnRHR	I-protein
promoter	I-protein
activity	O
.	O

Working	O
session	O
report	O
:	O
in	O
vivo	O
-	O
in	O
vitro	O
screening	O
.	O

Nearly	O
all	O
isolates	O
of	O
S	O
.	O
intermedius	O
and	O
most	O
isolates	O
of	O
S	O
.	O
constellatus	O
,	O
but	O
only	O
19	O
%	O
of	O
those	O
of	O
S	O
.	O
anginosus	O
,	O
were	O
associated	O
with	O
abscess	O
.	O

Genetics	O
Institute	O
has	O
developed	O
and	O
launched	O
oprelvekin	B-protein
(	O
rhIL	B-protein
-	I-protein
11	I-protein
;	O
Neumega	O
)	O
,	O
a	O
recombinant	O
form	O
of	O
human	B-protein
IL	I-protein
-	I-protein
11	I-protein
.	O

In	O
order	O
to	O
provide	O
adequate	O
local	O
control	O
without	O
compromising	O
cosmetic	O
outcome	O
,	O
the	O
amount	O
of	O
breast	O
tissue	O
that	O
must	O
be	O
excised	O
in	O
BCT	O
needs	O
to	O
be	O
individualized	O
.	O

Fractionation	O
of	O
crude	O
nuclear	O
extracts	O
by	O
heparin	O
-	O
agarose	O
chromatography	O
indicates	O
that	O
PCAT	B-protein
-	I-protein
1	I-protein
is	O
more	O
prevalent	O
in	O
extracts	O
prepared	O
from	O
salt	O
-	O
stressed	O
leaf	O
tissue	O
.	O

Possibility	O
of	O
a	O
TSH	O
-	O
Screening	O
method	O
for	O
detection	O
of	O
hypothyroidism	O
in	O
the	O
newborn	O
.	O

The	O
5	O
'	O
flanking	O
sequence	O
of	O
the	O
3B	B-protein
gene	I-protein
is	O
extremely	O
A	O
+	O
T	O
rich	O
but	O
contains	O
five	O
G	O
/	O
C	O
rich	O
stretches	O
,	O
each	O
approximately	O
7bp	O
long	O
,	O
which	O
have	O
strong	O
sequence	O
similarity	O
to	O
the	O
G	O
boxes	O
found	O
upstream	O
of	O
other	O
developmentally	O
regulated	O
Dictyostelium	O
genes	O
.	O

A	O
-	O
tracts	O
functioned	O
best	O
when	O
positioned	O
close	O
to	O
the	O
-	O
35	O
hexamer	O
rather	O
than	O
one	O
helical	O
turn	O
farther	O
upstream	O
,	O
similar	O
to	O
the	O
positioning	O
optimal	O
for	O
UP	B-protein
element	I-protein
function	O
.	O

The	O
total	O
alkaloids	O
contained	O
in	O
the	O
peel	O
of	O
Atzimba	O
,	O
Lopez	O
,	O
Marciana	O
,	O
Montsama	O
,	O
Murca	O
,	O
and	O
Puebla	O
was	O
lower	O
than	O
the	O
limits	O
recommended	O
for	O
food	O
safety	O
.	O

Scratching	O
during	O
sleep	O
in	O
children	O
with	O
atopic	O
dermatitis	O
is	O
associated	O
with	O
increased	O
VO2	O
.	O

This	O
enhancer	O
activates	O
both	O
the	O
K19	B-protein
and	O
TK	B-protein
basal	I-protein
promoters	I-protein
in	O
HeLa	O
cells	O
.	O

The	O
treatment	O
of	O
hydronephrosis	O
in	O
children	O
.	O

Platelet	O
number	O
and	O
life	O
span	O
were	O
determined	O
in	O
the	O
last	O
trimester	O
of	O
pregnancy	O
in	O
22	O
women	O
who	O
were	O
delivered	O
of	O
small	O
-	O
for	O
-	O
gestational	O
age	O
(	O
SGA	O
)	O
infants	O
and	O
in	O
21	O
women	O
with	O
infants	O
having	O
normal	O
birth	O
weights	O
.	O

Significant	O
treatment	O
-	O
related	O
problems	O
appeared	O
during	O
the	O
second	O
decade	O
in	O
5	O
patients	O
,	O
including	O
one	O
chest	O
wall	O
sarcoma	O
;	O
all	O
of	O
these	O
patients	O
had	O
received	O
at	O
least	O
60	O
Gy	O
to	O
breast	O
and	O
regional	O
nodal	O
areas	O
.	O

Subjects	O
with	O
a	O
short	O
postexposure	O
time	O
and	O
a	O
dioxin	O
burden	O
>	O
0	O
.	O
6	O
pg	O
/	O
m3	O
had	O
a	O
significantly	O
higher	O
risk	O
of	O
hypoergy	O
than	O
unexposed	O
subjects	O
(	O
hypoergy	O
I	O
:	O
OR	O
=	O
9	O
.	O
51	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
96	O
-	O
42	O
.	O
02	O
;	O
hypoergy	O
II	O
:	O
OR	O
=	O
2	O
.	O
92	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
14	O
-	O
7	O
.	O
5	O
)	O
.	O

The	O
gene	O
(	O
ApxII	B-protein
)	O
encoding	O
both	O
chloroplastic	B-protein
ascorbate	I-protein
peroxidase	I-protein
isoenzymes	I-protein
was	O
isolated	O
and	O
the	O
organization	O
of	O
the	O
gene	O
was	O
determined	O
.	O

The	O
mechanism	O
of	O
peroxisome	O
proliferation	O
is	O
poorly	O
understood	O
.	O

The	O
method	O
involved	O
deproteinizing	O
samples	O
with	O
two	O
volumes	O
of	O
acetonitrile	O
followed	O
by	O
injection	O
of	O
5	O
microliters	O
of	O
deproteinized	O
supernatant	O
onto	O
a	O
C18	O
reversed	O
-	O
phase	O
column	O
.	O

However	O
,	O
C4B	B-protein
proteins	I-protein
encoded	O
by	O
monomodular	O
short	O
genes	O
may	O
have	O
relatively	O
higher	O
concentrations	O
than	O
those	O
from	O
long	B-protein
C4A	I-protein
genes	I-protein
.	O

Independent	O
splicing	O
events	O
involve	O
three	O
previously	O
described	O
cassette	O
exons	O
,	O
which	O
are	O
predicted	O
to	O
encode	O
most	O
of	O
the	O
second	O
transmembrane	O
domain	O
.	O

As	O
it	O
had	O
been	O
previously	O
reported	O
that	O
the	O
18	O
-	O
bp	O
palindrome	O
contains	O
sufficient	O
nucleotide	O
sequence	O
information	O
for	O
E1	B-protein
binding	O
,	O
we	O
speculate	O
that	O
a	O
minimal	O
E1	B-protein
recognition	O
motif	O
is	O
presented	O
in	O
each	O
half	O
site	O
.	O

Clinically	O
meaningful	O
decreases	O
due	O
to	O
alkalinization	O
alone	O
within	O
30	O
minutes	O
are	O
unlikely	O
.	O

To	O
explore	O
the	O
function	O
of	O
human	O
SINA	B-protein
-	I-protein
homologous	I-protein
(	I-protein
Siah	I-protein
)	I-protein
proteins	I-protein
,	O
expression	O
plasmids	O
encoding	O
Siah	B-protein
-	I-protein
1A	I-protein
were	O
transiently	O
transfected	O
into	O
293	O
epithelial	O
cells	O
and	O
GM701	O
fibroblast	O
cells	O
,	O
resulting	O
in	O
growth	O
arrest	O
without	O
induction	O
of	O
apoptosis	O
.	O

Airway	O
pressure	O
and	O
air	O
flow	O
were	O
measured	O
at	O
the	O
endotracheal	O
tube	O
in	O
13	O
children	O
on	O
a	O
variety	O
of	O
ventilators	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
:	O
A	O
positive	O
test	O
result	O
for	O
gonococcal	O
or	O
chlamydial	O
infection	O
by	O
the	O
ligase	B-protein
chain	O
reaction	O
assay	O
;	O
secondary	O
outcome	O
measure	O
was	O
a	O
positive	O
test	O
result	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O

The	O
GPI	B-protein
anchor	I-protein
moiety	I-protein
is	O
either	O
absent	O
or	O
present	O
at	O
a	O
very	O
low	O
level	O
in	O
the	O
polypeptide	O
expressed	O
from	O
the	O
cDNA	O
that	O
contained	O
both	O
the	O
signal	O
peptide	O
and	O
GPI	B-protein
signal	I-protein
sequences	I-protein
.	O

We	O
also	O
identified	O
an	O
alternative	O
spliced	O
form	O
of	O
Lyp	B-protein
RNA	I-protein
,	O
Lyp2	B-protein
.	O

With	O
regard	O
to	O
the	O
characteristic	O
expression	O
pattern	O
of	O
DJ	B-protein
protein	I-protein
and	O
its	O
conspicuous	O
repeat	O
units	O
possible	O
functional	O
roles	O
are	O
discussed	O
.	O

Fibrin	B-protein
cloaking	O
along	O
the	O
catheter	O
was	O
found	O
in	O
20	O
patients	O
studied	O
by	O
pull	O
-	O
out	O
arteriography	O
and	O
was	O
unassociated	O
with	O
clinical	O
symptoms	O
.	O

Sequence	O
requirements	O
for	O
premature	O
transcription	O
arrest	O
within	O
the	O
first	O
intron	O
of	O
the	O
mouse	B-protein
c	I-protein
-	I-protein
fos	I-protein
gene	I-protein
.	O

This	O
brief	O
hypercapnic	O
challenge	O
induced	O
a	O
rapid	O
increase	O
in	O
CBF	O
in	O
the	O
absence	O
of	O
any	O
change	O
in	O
MABP	O
.	O

The	O
sequence	O
was	O
determined	O
for	O
a	O
4024	O
-	O
base	O
pair	O
(	O
bp	O
)	O
segment	O
that	O
extends	O
from	O
149	O
bp	O
5	O
'	O
to	O
the	O
cap	O
site	O
of	O
alpha	B-protein
1	I-protein
to	O
207	O
bp	O
3	O
'	O
to	O
psi	B-protein
alpha	I-protein
.	O

Collectively	O
,	O
our	O
findings	O
demonstrate	O
that	O
SF	B-protein
-	I-protein
1	I-protein
plays	O
a	O
key	O
role	O
in	O
controlling	O
the	O
basal	O
and	O
cAMP	O
-	O
stimulated	O
expression	O
of	O
the	O
StAR	B-protein
gene	I-protein
.	O

In	O
contrast	O
the	O
human	O
and	O
mouse	B-protein
BCNT	I-protein
proteins	I-protein
contain	O
one	O
repeat	O
unit	O
and	O
lack	O
the	O
RTE	O
-	O
1	O
-	O
derived	O
portion	O
.	O

This	O
article	O
comparatively	O
evaluates	O
five	O
Generic	O
Systems	O
that	O
describe	O
the	O
basic	O
alternatives	O
to	O
composting	O
facility	O
design	O
and	O
control	O
.	O

ORFK10	B-protein
.	I-protein
5	I-protein
encodes	O
a	O
protein	O
,	O
latency	B-protein
-	I-protein
associated	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
(	O
LANA2	B-protein
)	O
,	O
which	O
is	O
expressed	O
in	O
KSHV	O
-	O
infected	O
hematopoietic	O
tissues	O
,	O
including	O
PEL	O
and	O
CD	O
but	O
not	O
KS	O
lesions	O
.	O

In	O
view	O
of	O
the	O
presence	O
of	O
SECIS	B-protein
elements	I-protein
in	O
the	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
of	O
bacterial	O
selenoproteins	O
,	O
we	O
examine	O
the	O
effects	O
in	O
the	O
type	B-protein
1	I-protein
deiodinase	I-protein
of	O
extending	O
the	O
ORF	O
into	O
the	O
SECIS	B-protein
element	I-protein
,	O
and	O
find	O
that	O
this	O
dramatically	O
inhibits	O
SECIS	B-protein
function	O
.	O

The	O
dorsal	O
nerves	O
of	O
the	O
penis	O
were	O
anesthetized	O
bilaterally	O
with	O
lidocaine	O
.	O

Dosimetric	O
estimates	O
for	O
these	O
organs	O
were	O
2	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
1	O
and	O
2	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
4	O
rad	O
(	O
.	O
02	O
+	O
/	O
-	O
.	O
01	O
Gy	O
)	O
,	O
respectively	O
,	O
with	O
a	O
whole	O
-	O
body	O
estimate	O
of	O
0	O
.	O
28	O
rad	O
(	O
.	O
003	O
Gy	O
)	O
.	O

Its	O
early	O
lesions	O
were	O
characterized	O
by	O
angiomatosis	O
,	O
vasculopathy	O
,	O
and	O
proliferation	O
of	O
synoviocytes	O
and	O
fibroblasts	O
.	O

Ig	B-protein
heavy	I-protein
chain	I-protein
class	O
switching	O
is	O
directed	O
by	O
cytokines	O
inducing	O
transcription	O
from	O
unrearranged	O
CH	B-protein
genes	I-protein
.	O

Conserved	O
and	O
distinct	O
roles	O
of	O
kreisler	B-protein
in	O
regulation	O
of	O
the	O
paralogous	O
Hoxa3	B-protein
and	O
Hoxb3	B-protein
genes	I-protein
.	O

The	O
mean	O
blood	O
flow	O
in	O
the	O
penile	O
foreskin	O
was	O
estimated	O
to	O
be	O
15	O
ml	O
/	O
min	O
/	O
100	O
g	O
and	O
it	O
increased	O
to	O
150	O
-	O
200	O
%	O
after	O
the	O
induction	O
of	O
anesthesia	O
,	O
and	O
then	O
decreased	O
to	O
72	O
%	O
at	O
the	O
tip	O
of	O
the	O
created	O
parameatal	O
foreskin	O
flap	O
.	O

A	O
32P	O
-	O
labeled	O
LAP	O
DNA	O
-	O
binding	O
and	O
dimerization	O
domain	O
`	O
`	O
zipper	O
probe	O
'	O
'	O
was	O
used	O
to	O
isolate	O
a	O
clone	O
that	O
encodes	O
a	O
new	O
C	B-protein
/	I-protein
EBP	I-protein
-	I-protein
homologous	I-protein
protein	I-protein
:	O
CHOP	B-protein
-	I-protein
10	I-protein
.	O

Thrombocyte	O
function	O
was	O
impaired	O
in	O
all	O
patients	O
,	O
characterized	O
by	O
a	O
diminished	O
platelet	O
shape	O
change	O
.	O

The	O
genome	O
of	O
the	O
human	O
herpesvirus	O
8	O
(	O
HHV	O
-	O
8	O
)	O
contains	O
a	O
cluster	O
of	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
encoding	O
proteins	O
with	O
homology	O
to	O
the	O
cellular	O
transcription	O
factors	O
of	O
the	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
(	O
IRF	B-protein
)	O
family	O
.	O

Resting	O
VE	O
in	O
the	O
luteal	O
phase	O
was	O
7	O
.	O
8	O
%	O
greater	O
than	O
that	O
in	O
the	O
follicular	O
phase	O
.	O

However	O
,	O
its	O
participation	O
in	O
gagging	O
induced	O
by	O
oropharyngeal	O
irritation	O
is	O
unclear	O
.	O

Experience	O
with	O
xylene	O
-	O
free	O
sections	O
since	O
1995	O
at	O
the	O
Vrinnevi	O
Hospital	O
is	O
favorable	O
.	O

Among	O
the	O
total	O
CDSs	O
,	O
8	O
.	O
8	O
%	O
match	O
sequences	O
of	O
proteins	O
found	O
only	O
in	O
Bacillus	O
subtilis	O
and	O
66	O
.	O
7	O
%	O
are	O
widely	O
conserved	O
in	O
comparison	O
with	O
the	O
proteins	O
of	O
various	O
organisms	O
,	O
including	O
B	O
.	O
subtilis	O
.	O

USA	O
80	O
,	O
802	O
-	O
806	O
]	O
was	O
used	O
to	O
isolate	O
a	O
genomic	O
clone	O
lambda	O
PGK	B-protein
-	I-protein
1	I-protein
containing	O
a	O
portion	O
of	O
an	O
autosomal	O
locus	O
for	O
phosphoglycerate	B-protein
kinase	I-protein
(	O
PGK	B-protein
)	O
.	O

Changes	O
in	O
xanthine	B-protein
oxidase	I-protein
activity	O
in	O
patients	O
with	O
circulatory	O
failure	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
relatively	O
weak	O
transcriptional	O
silencing	O
by	O
the	O
native	O
VDR	B-protein
was	O
observed	O
using	O
the	O
osteopontin	B-protein
VDRE	I-protein
.	O

HER2	B-protein
overexpressing	O
cells	O
showed	O
a	O
single	O
prominent	O
DNase	B-protein
I	I-protein
hypersensitive	O
site	O
near	O
a	O
conserved	O
and	O
hitherto	O
unrecognized	O
ets	B-protein
response	I-protein
element	I-protein
(	O
GAGGAA	B-protein
)	O
,	O
located	O
38	O
bases	O
down	O
-	O
stream	O
from	O
the	O
CAAT	O
box	O
and	O
directly	O
5	O
'	O
of	O
the	O
TATA	O
box	O
in	O
the	O
human	B-protein
HER2	I-protein
promoter	I-protein
.	O

A	O
neonatal	O
alloimmune	O
thrombocytopenia	O
with	O
an	O
HPA	O
-	O
3a	O
(	O
Baka	O
)	O
incompatibility	O
was	O
confirmed	O
.	O

Of	O
the	O
153	O
patients	O
studied	O
,	O
CK	B-protein
-	I-protein
MB	I-protein
results	O
were	O
positive	O
in	O
91	O
(	O
59	O
%	O
)	O
patients	O
;	O
ECG	O
revealed	O
AMI	O
in	O
72	O
(	O
47	O
%	O
)	O
patients	O
.	O

Cardiovascular	O
risk	O
factors	O
were	O
measured	O
by	O
standardized	O
techniques	O
.	O

Such	O
studied	O
acquired	O
with	O
low	O
energy	O
or	O
medium	O
energy	O
collimation	O
and	O
a	O
window	O
centered	O
on	O
the	O
159	O
keV	O
123I	O
photopeak	O
contain	O
appreciable	O
septal	O
breakthrough	O
signals	O
originating	O
from	O
Compton	O
scatter	O
of	O
high	O
energy	O
photons	O
primarily	O
from	O
124I	O
.	O

Bites	O
by	O
two	O
species	O
of	O
adders	O
(	O
Vipera	O
aspis	O
and	O
Vipera	O
berus	O
)	O
can	O
lead	O
to	O
extensive	O
swelling	O
with	O
multiorgan	O
failure	O
.	O

In	O
addition	O
,	O
the	O
overall	O
chance	O
that	O
a	O
patient	O
would	O
undergo	O
ET	O
was	O
greater	O
in	O
a	O
cycle	O
in	O
which	O
more	O
than	O
one	O
follicle	O
20	O
mm	O
or	O
larger	O
was	O
developing	O
than	O
in	O
a	O
cycle	O
in	O
which	O
a	O
single	O
large	O
follicle	O
was	O
developing	O
.	O

The	O
87K	O
protein	O
,	O
together	O
with	O
proteins	O
of	O
105	O
,	O
000	O
and	O
75	O
,	O
000	O
daltons	O
,	O
are	O
translated	O
from	O
leftward	O
transcribed	O
(	O
1	O
-	O
strand	O
)	O
messenger	O
RNAs	O
that	O
are	O
complementary	O
to	O
the	O
viral	O
genome	O
between	O
positions	O
11	O
.	O
2	O
and	O
31	O
.	O
5	O
.	O

However	O
,	O
the	O
abi1	B-protein
-	I-protein
1	I-protein
gene	I-protein
product	I-protein
has	O
no	O
effect	O
on	O
the	O
ABA	O
suppression	O
of	O
a	O
GA	O
-	O
responsive	O
alpha	B-protein
-	I-protein
amylase	I-protein
gene	I-protein
.	O

Since	O
the	O
regulation	O
of	O
SWI4	B-protein
is	O
required	O
for	O
normal	O
cell	O
cycle	O
progression	O
,	O
we	O
have	O
characterized	O
cis	O
-	O
and	O
trans	O
-	O
acting	O
regulators	O
of	O
SWI4	B-protein
transcription	O
.	O

Which	O
cineangiographically	O
assessed	O
anatomic	O
variable	O
correlates	O
best	O
with	O
functional	O
measurements	O
of	O
stenosis	O
severity	O
?	O
A	O
comparison	O
of	O
quantitative	O
analysis	O
of	O
the	O
coronary	O
cineangiogram	O
with	O
measured	O
coronary	O
flow	O
reserve	O
and	O
exercise	O
/	O
redistribution	O
thallium	O
-	O
201	O
scintigraphy	O
.	O

The	O
third	O
ORF	O
generates	O
a	O
transcript	O
of	O
1	O
.	O
6	O
kb	O
and	O
encodes	O
a	O
protein	O
of	O
382	O
residues	O
including	O
a	O
perfect	O
match	O
to	O
the	O
consensus	O
sequence	O
of	O
a	O
C2H2	B-protein
zinc	I-protein
finger	I-protein
domain	I-protein
;	O
it	O
shares	O
a	O
strong	O
homology	O
with	O
yeast	B-protein
Mig1p	I-protein
and	O
Cre	B-protein
-	I-protein
A	I-protein
from	I-protein
Aspergillus	I-protein
,	I-protein
Emericella	I-protein
and	I-protein
E	I-protein
.	I-protein
coli	I-protein
.	O

Parasitological	O
and	O
pathological	O
findings	O
in	O
capuchin	O
monkeys	O
infected	O
with	O
Schistosoma	O
japonicum	O
or	O
Schistosoma	O
mansoni	O
.	O

The	O
multiple	O
functions	O
of	O
Pmt3p	B-protein
described	O
here	O
suggest	O
that	O
several	O
nuclear	O
proteins	O
are	O
regulated	O
by	O
Pmt3p	B-protein
conjugation	O
.	O

The	O
relationships	O
among	O
four	O
descriptors	O
of	O
lactate	O
increase	O
:	O
lactate	O
threshold	O
(	O
LT	O
)	O
(	O
the	O
VO2	O
at	O
which	O
blood	O
lactate	O
concentration	O
begins	O
to	O
increase	O
above	O
the	O
resting	O
level	O
during	O
an	O
incremental	O
exercise	O
test	O
)	O
,	O
LT1	O
(	O
the	O
VO2	O
at	O
which	O
blood	O
lactate	O
increases	O
1	O
mM	O
above	O
the	O
resting	O
level	O
)	O
,	O
LT2	O
(	O
the	O
VO2	O
at	O
which	O
blood	O
lactate	O
concentration	O
reaches	O
a	O
fixed	O
value	O
of	O
2	O
mM	O
)	O
,	O
onset	O
of	O
blood	O
lactate	O
accumulation	O
(	O
OBLA	O
;	O
the	O
VO2	O
at	O
which	O
blood	O
lactate	O
reaches	O
a	O
concentration	O
of	O
4	O
mM	O
)	O
,	O
were	O
compared	O
with	O
aerobic	O
capacity	O
(	O
VO2max	O
)	O
and	O
12	O
min	O
running	O
performance	O
in	O
19	O
untrained	O
female	O
students	O
.	O

The	O
protein	O
encoded	O
is	O
114	O
kDa	O
and	O
contains	O
eight	O
zinc	O
finger	O
motifs	O
,	O
seven	O
of	O
which	O
are	O
present	O
in	O
two	O
clusters	O
at	O
opposite	O
ends	O
of	O
the	O
molecule	O
.	O

INTERPRETATION	O
:	O
It	O
is	O
probable	O
that	O
the	O
cognitive	O
dissonance	O
created	O
by	O
more	O
health	O
information	O
on	O
smoking	O
after	O
1964	O
,	O
i	O
.	O
e	O
.	O
the	O
necessary	O
motivation	O
to	O
quit	O
,	O
was	O
reduced	O
as	O
a	O
result	O
of	O
strategic	O
changes	O
in	O
the	O
amount	O
and	O
content	O
of	O
advertising	O
.	O

In	O
addition	O
,	O
in	O
vitro	O
mutagenesis	O
of	O
both	O
Engrailed	B-protein
and	O
Pbx1	B-protein
sites	I-protein
indicated	O
that	O
other	O
unidentified	O
sites	O
are	O
responsible	O
for	O
the	O
transcriptional	O
enhancement	O
observed	O
with	O
the	O
intronic	O
fragment	O
.	O

On	O
admission	O
to	O
the	O
ICU	O
,	O
117	O
patients	O
(	O
61	O
percent	O
)	O
had	O
hypomagnesemia	O
(	O
serum	O
Mg	O
less	O
than	O
1	O
.	O
5	O
mEq	O
/	O
dl	O
)	O
,	O
66	O
patients	O
(	O
34	O
percent	O
)	O
had	O
normomagnesemia	O
(	O
1	O
.	O
5	O
to	O
2	O
.	O
0	O
mEq	O
/	O
dl	O
)	O
,	O
and	O
ten	O
patients	O
(	O
5	O
percent	O
)	O
had	O
hypermagnesemia	O
(	O
greater	O
than	O
2	O
.	O
0	O
mEq	O
/	O
dl	O
)	O
.	O

With	O
aging	O
,	O
many	O
aspects	O
of	O
immune	O
function	O
change	O
.	O

In	O
the	O
base	O
-	O
case	O
analysis	O
,	O
total	O
direct	O
costs	O
per	O
patient	O
were	O
$	O
728	O
for	O
zoledronic	O
acid	O
and	O
$	O
776	O
for	O
pamidronate	O
.	O

In	O
the	O
first	O
series	O
of	O
experiments	O
,	O
Sprague	O
-	O
Dawley	O
male	O
rats	O
were	O
implanted	O
unilaterally	O
with	O
guide	O
cannulas	O
aimed	O
at	O
the	O
lateral	O
ventricle	O
.	O

Double	O
-	O
blind	O
randomised	O
trial	O
of	O
intravenous	O
tissue	B-protein
-	I-protein
type	I-protein
plasminogen	I-protein
activator	I-protein
versus	O
placebo	O
in	O
acute	O
myocardial	O
infarction	O
.	O

Up	O
to	O
now	O
the	O
number	O
of	O
patients	O
examined	O
is	O
about	O
300	O
,	O
additionally	O
6	O
persons	O
who	O
underwent	O
binephrectomy	O
.	O

An	O
aromatic	O
stacking	O
interaction	O
between	O
subunits	O
helps	O
mediate	O
DNA	O
sequence	O
specificity	O
:	O
operator	O
site	O
discrimination	O
by	O
phage	B-protein
lambda	I-protein
cI	I-protein
repressor	I-protein
.	O

According	O
to	O
pilot	O
experiments	O
which	O
considered	O
various	O
durations	O
of	O
global	O
no	O
-	O
flow	O
ischemia	O
ranging	O
from	O
10	O
to	O
20	O
minutes	O
,	O
two	O
durations	O
were	O
chosen	O
for	O
the	O
present	O
study	O
:	O
20	O
minutes	O
(	O
group	O
20	O
)	O
in	O
which	O
ventricular	O
fibrillation	O
(	O
VF	O
)	O
was	O
the	O
predominant	O
form	O
of	O
arrhythmias	O
,	O
and	O
18	O
minutes	O
(	O
group	O
18	O
)	O
in	O
which	O
the	O
prevalence	O
of	O
VF	O
was	O
markedly	O
lower	O
despite	O
the	O
small	O
difference	O
in	O
the	O
duration	O
of	O
ischemia	O
.	O

The	O
nonconsensus	O
TATA	O
box	O
in	O
promoter	B-protein
B	I-protein
plays	O
a	O
more	O
important	O
role	O
in	O
promoter	O
activity	O
than	O
the	O
TATA	O
box	O
in	O
promoter	B-protein
A	I-protein
.	O

High	O
-	O
resolution	O
computed	O
tomography	O
in	O
the	O
diagnosis	O
of	O
miliary	O
tuberculosis	O
.	O

State	O
-	O
approved	O
schools	O
of	O
nursing	O
-	O
-	O
R	O
.	O
Z	O
.	O
,	O
1972	O
.	O

Based	O
on	O
our	O
observations	O
,	O
we	O
propose	O
a	O
model	O
whereby	O
inactive	O
precursor	O
molecules	O
produced	O
from	O
the	O
PEP4	B-protein
gene	I-protein
self	O
-	O
activate	O
within	O
the	O
yeast	O
vacuole	O
and	O
subsequently	O
activate	O
other	O
vacuolar	O
hydrolases	O
.	O

In	O
this	O
respect	O
C	B-protein
reactive	I-protein
protein	I-protein
concentrations	O
are	O
superior	O
to	O
white	O
cell	O
count	O
,	O
erythrocyte	O
sedimentation	O
rate	O
,	O
and	O
temperature	O
and	O
the	O
concentrations	O
of	O
antiproteases	O
.	O

During	O
both	O
encephalopathy	O
episodes	O
,	O
CSF	O
protein	O
and	O
immunoglobulin	B-protein
G	I-protein
(	O
IgG	B-protein
)	O
levels	O
were	O
elevated	O
without	O
an	O
increased	O
IgG	B-protein
index	O
or	O
IgG	B-protein
synthesis	O
rate	O
.	O

Bulbar	O
pouches	O
were	O
perfused	O
with	O
solutions	O
of	O
0	O
.	O
9	O
%	O
Na	O
C1	O
,	O
0	O
.	O
1	O
N	O
HC1	O
,	O
40	O
%	O
glucose	O
,	O
40	O
%	O
NaC1	O
,	O
and	O
40	O
%	O
peptone	O
or	O
with	O
0	O
.	O
1	O
%	O
solutions	O
of	O
acetylcholine	O
chloride	O
.	O

Insulin	O
-	O
stimulated	O
glucose	O
transport	O
in	O
adipocytes	O
is	O
mediated	O
by	O
the	O
insulin	B-protein
receptor	I-protein
.	O

Veterinary	O
certification	O
for	O
livestock	O
export	O
.	O

A	O
0	O
.	O
5	O
rating	O
was	O
intended	O
to	O
characterize	O
subjects	O
in	O
whom	O
mild	O
cognitive	O
impairment	O
due	O
to	O
senile	O
dementia	O
of	O
the	O
Alzheimer	O
type	O
was	O
suspected	O
but	O
was	O
insufficient	O
in	O
degree	O
to	O
warrant	O
a	O
diagnosis	O
of	O
definite	O
dementia	O
.	O

Selenium	O
(	O
.	O
1	O
ppm	O
)	O
and	O
E	O
(	O
50	O
IU	O
/	O
kg	O
)	O
supplementation	O
of	O
the	O
diet	O
of	O
the	O
sow	O
increased	O
plasma	O
tocopherol	O
and	O
Se	O
concentrations	O
,	O
but	O
did	O
not	O
increase	O
plasma	B-protein
glutathione	I-protein
peroxidase	I-protein
(	O
GSH	B-protein
-	I-protein
Px	I-protein
)	O
activity	O
.	O

The	O
interaction	O
of	O
radiation	O
and	O
hyperthermia	O
was	O
systematically	O
studied	O
in	O
the	O
Dunning	O
R3327G	O
prostatic	O
adenocarcinoma	O
,	O
the	O
preeminent	O
animal	O
model	O
for	O
human	O
prostatic	O
cancer	O
.	O

Failure	O
of	O
stapedius	O
reflexometry	O
in	O
the	O
diagnosis	O
of	O
myasthenia	O
gravis	O
.	O

As	O
an	O
initial	O
step	O
towards	O
the	O
characterization	O
of	O
replicative	O
DNA	B-protein
polymerases	I-protein
of	I-protein
trypanosomes	I-protein
,	O
we	O
have	O
cloned	O
,	O
sequenced	O
and	O
examined	O
the	O
expression	O
of	O
the	O
Trypanosoma	O
(	O
Trypanozoon	O
)	O
brucei	O
brucei	O
gene	O
that	O
encodes	O
the	O
DNA	B-protein
polymerase	I-protein
alpha	I-protein
catalytic	I-protein
core	I-protein
(	O
pol	B-protein
alpha	I-protein
)	O
.	O

Encapsidation	O
of	O
poliovirus	O
replicons	O
encoding	O
the	O
complete	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
gag	I-protein
gene	I-protein
by	O
using	O
a	O
complementation	O
system	O
which	O
provides	O
the	O
P1	B-protein
capsid	I-protein
protein	I-protein
in	O
trans	O
.	O

Beg2	B-protein
and	O
Beg1	B-protein
are	O
regulated	O
differently	O
which	O
may	O
indicate	O
variation	O
in	O
storage	O
or	O
utilization	O
properties	O
among	O
the	O
barley	B-protein
globulins	I-protein
.	O

An	O
abnormally	O
high	O
percentage	O
of	O
hypertensive	O
patients	O
(	O
approximately	O
30	O
%	O
)	O
undergoing	O
cardiac	O
catheterization	O
because	O
of	O
anginal	O
pain	O
and	O
/	O
or	O
exercise	O
-	O
induced	O
ST	O
-	O
segment	O
depressions	O
has	O
angiographically	O
normal	O
coronary	O
arteries	O
.	O

The	O
mature	O
protein	O
also	O
contains	O
a	O
cysteine	O
-	O
rich	O
,	O
highly	O
hydrophilic	O
region	O
homologous	O
to	O
the	O
ovomucoid	B-protein
serine	I-protein
protease	I-protein
inhibitors	I-protein
(	O
residues	O
76	O
-	O
132	O
)	O
.	O

Severe	O
hemolysis	O
resulted	O
in	O
statistically	O
significant	O
changes	O
in	O
the	O
mean	O
values	O
of	O
the	O
above	O
analytes	O
in	O
addition	O
to	O
the	O
following	O
increases	O
:	O
alanine	B-protein
aminotransferase	I-protein
,	O
calcium	O
,	O
and	O
serum	B-protein
globulins	I-protein
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
albumin	B-protein
and	O
total	O
protein	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Diclofenac	O
sodium	O
-	O
chlormezanone	O
poisoning	O
.	O

If	O
you	O
think	O
education	O
is	O
expensive	O
-	O
-	O
try	O
ignorance	O
-	O
-	O
Bok	O
'	O
s	O
Law	O
.	O

Alternatively	O
,	O
PC12	O
-	O
E2	O
cells	O
were	O
submitted	O
to	O
treatment	O
with	O
antibodies	O
to	O
the	O
fibroblast	B-protein
growth	I-protein
factor	I-protein
(	I-protein
FGF	I-protein
)	I-protein
receptor	I-protein
,	O
inhibitors	O
of	O
the	O
nonreceptor	B-protein
tyrosine	I-protein
kinase	I-protein
p59	I-protein
(	I-protein
fyn	I-protein
)	O
,	O
PLC	B-protein
,	O
PKC	B-protein
and	O
MEK	B-protein
and	O
an	O
activator	O
of	O
PKC	B-protein
,	O
phorbol	O
-	O
12	O
-	O
myristate	O
-	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
.	O

However	O
,	O
experiments	O
with	O
S1	B-protein
mapping	O
of	O
in	O
vivo	O
transcripts	O
,	O
gene	O
disruptions	O
in	O
the	O
alpha	O
region	O
,	O
and	O
a	O
single	O
-	O
copy	O
transcriptional	O
fusion	O
vector	O
all	O
suggested	O
that	O
these	O
possible	O
promoters	O
were	O
largely	O
inactive	O
during	O
logarithmic	O
growth	O
,	O
that	O
the	O
major	O
promoter	O
for	O
the	O
alpha	B-protein
operon	I-protein
lay	O
upstream	O
from	O
the	O
region	O
cloned	O
,	O
and	O
that	O
the	O
genes	O
in	O
the	O
IF1	B-protein
to	O
L17	B-protein
interval	O
were	O
cotranscribed	O
.	O

Mapping	O
of	O
intracellular	O
localization	O
domains	O
and	O
evidence	O
for	O
colocalization	O
interactions	O
between	O
the	O
IE110	B-protein
and	O
IE175	B-protein
nuclear	O
transactivator	O
proteins	O
of	O
herpes	O
simplex	O
virus	O
.	O

However	O
,	O
the	O
same	O
U1A	B-protein
peptide	I-protein
,	O
when	O
conjugated	O
to	O
BSA	B-protein
,	O
inhibits	O
vertebrate	B-protein
PAP	I-protein
.	O

Lymphocyte	O
subpopulations	O
,	O
serum	B-protein
IgE	I-protein
and	O
total	O
eosinophil	O
counts	O
in	O
patients	O
with	O
bronchial	O
asthma	O
.	O

Respiratory	O
chain	O
enzyme	O
activity	O
was	O
normal	O
.	O

An	O
undilated	O
type	O
of	O
APBD	O
is	O
frequently	O
associated	O
with	O
AMT	O
and	O
we	O
believe	O
,	O
therefore	O
,	O
that	O
clinicians	O
should	O
be	O
aware	O
of	O
a	O
possible	O
coexistence	O
of	O
APBD	O
and	O
AMT	O
.	O

Cotransfection	O
of	O
the	O
helicase	B-protein
-	I-protein
primase	I-protein
proteins	I-protein
,	O
one	O
of	O
which	O
was	O
fused	O
to	O
a	O
heterologous	O
activation	O
domain	O
,	O
led	O
to	O
Zta	O
-	O
dependent	O
superactivation	O
of	O
CAT	B-protein
expression	O
.	O

In	O
addition	O
,	O
the	O
hGCSFR	B-protein
gene	I-protein
was	O
chromosomally	O
localized	O
by	O
Southern	O
blot	O
analysis	O
of	O
its	O
segregation	O
pattern	O
in	O
a	O
panel	O
of	O
rodent	O
-	O
human	O
hybrid	O
DNAs	O
using	O
the	O
radiolabeled	O
cDNA	O
probe	O
.	O

Concurrently	O
,	O
we	O
monitored	O
weather	O
conditions	O
and	O
used	O
time	O
-	O
activity	O
budget	O
data	O
of	O
free	O
-	O
living	O
birds	O
and	O
laboratory	O
data	O
on	O
resting	O
metabolic	O
rate	O
to	O
construct	O
time	O
-	O
activity	O
laboratory	O
(	O
TAL	O
)	O
estimates	O
of	O
daily	O
energy	O
expenditure	O
(	O
DEE	O
)	O
and	O
to	O
partition	O
the	O
verdins	O
'	O
energy	O
budget	O
into	O
thermoregulatory	O
,	O
activity	O
and	O
basal	O
components	O
.	O

The	O
proliferation	B-protein
potential	I-protein
protein	I-protein
-	I-protein
related	I-protein
(	O
P2P	B-protein
-	I-protein
R	I-protein
)	O
gene	O
with	O
domains	O
encoding	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
association	O
and	O
Rb1	B-protein
binding	O
shows	O
repressed	O
expression	O
during	O
terminal	O
differentiation	O
.	O

The	O
intracellular	O
basic	B-protein
region	I-protein
/	I-protein
helix	I-protein
-	I-protein
loop	I-protein
-	I-protein
helix	I-protein
(	I-protein
bHLH	I-protein
)	I-protein
dioxin	I-protein
receptor	I-protein
mediates	O
signal	O
transduction	O
by	O
dioxin	O
(	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
)	O
and	O
functions	O
as	O
a	O
ligand	O
-	O
activated	O
DNA	O
binding	O
protein	O
directly	O
interacting	O
with	O
target	O
genes	O
by	O
binding	O
to	O
dioxin	B-protein
response	I-protein
elements	I-protein
.	O

We	O
conclude	O
that	O
solidification	O
could	O
occur	O
in	O
all	O
feeds	O
containing	O
casein	B-protein
and	O
that	O
alternative	O
feeds	O
should	O
be	O
considered	O
in	O
patients	O
with	O
increased	O
gastric	O
acidity	O
.	O

These	O
results	O
may	O
suggest	O
involvement	O
of	O
peripheral	O
enkephalins	B-protein
in	O
pain	O
modulation	O
in	O
patients	O
with	O
episodic	O
cluster	O
headache	O
.	O

Overexpression	O
of	O
mcl	B-protein
-	I-protein
1	I-protein
is	O
sufficient	O
to	O
protect	O
against	O
apoptosis	O
,	O
while	O
transfection	O
of	O
a	O
mcl	B-protein
-	I-protein
1	I-protein
antisense	O
plasmid	O
causes	O
cell	O
death	O
.	O

Preliminary	O
experiments	O
demonstrated	O
that	O
it	O
was	O
possible	O
to	O
produce	O
fasD	B-protein
mutants	I-protein
,	O
whose	O
products	O
remain	O
functional	O
for	O
fimbrial	O
export	O
and	O
assembly	O
.	O

Porcelain	O
to	O
dentin	B-protein
bond	O
strength	O
with	O
a	O
dentin	B-protein
adhesive	O
.	O

The	O
role	O
of	O
the	O
Vp1	B-protein
DBD	I-protein
during	O
infection	O
was	O
investigated	O
by	O
taking	O
advantage	O
of	O
NLS	B-protein
phenotypic	O
complementation	O
(	O
N	O
.	O

Indeed	O
,	O
ERM	B-protein
and	O
c	B-protein
-	I-protein
Jun	I-protein
synergistically	O
activated	O
the	O
EBS	B-protein
-	I-protein
CRE	I-protein
without	O
making	O
an	O
apparent	O
ternary	O
complex	O
.	O

Pentazocine	O
analgesia	O
:	O
is	O
there	O
a	O
niche	O
for	O
Talwin	O
Nx	O
?	O
Pentazocine	O
can	O
be	O
a	O
useful	O
analgesic	O
agent	O
for	O
the	O
management	O
of	O
acute	O
dental	O
pain	O
.	O

Myocardial	O
SPET	O
imaging	O
with	O
99Tcm	O
-	O
tetrofosmin	O
in	O
clinical	O
practice	O
:	O
comparison	O
of	O
a	O
1	O
day	O
and	O
a	O
2	O
day	O
imaging	O
protocol	O
.	O

Animals	O
received	O
a	O
dose	O
of	O
dexamethasone	O
(	O
10	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
prior	O
to	O
the	O
protein	O
-	O
free	O
surfactant	O
preparation	O
Exosurf	O
(	O
pure	O
phospholipids	O
containing	O
surfactant	O
,	O
Wellcome	O
GmbH	O
,	O
Burgwedel	O
,	O
Germany	O
)	O
and	O
a	O
rSP	O
-	O
C	O
based	O
surfactant	O
,	O
respectively	O
.	O

No	O
other	O
changes	O
in	O
hematopoietic	O
differentiation	O
status	O
were	O
observed	O
in	O
association	O
with	O
Id	B-protein
-	I-protein
SCL	I-protein
expression	O
.	O

Thus	O
,	O
our	O
studies	O
define	O
Rac	B-protein
/	I-protein
Cdc42	I-protein
/	I-protein
Pak	I-protein
as	O
a	O
module	O
upstream	O
of	O
Raf	B-protein
-	I-protein
1	I-protein
during	O
its	O
activation	O
by	O
microtubule	O
disruption	O
.	O

RT	O
-	O
PCR	O
using	O
1	O
.	O
D	O
-	O
specific	O
primers	O
showed	O
that	O
kidney	O
,	O
brain	O
and	O
prostate	O
do	O
not	O
express	O
1	O
.	O
D	O
mRNA	O
even	O
though	O
kidney	O
and	O
brain	O
are	O
the	O
most	O
abundant	O
source	O
for	O
aFGF	B-protein
protein	I-protein
.	O

Conversely	O
,	O
activation	O
of	O
this	O
signaling	O
pathway	O
by	O
expression	O
of	O
a	O
constitutively	O
active	O
MKK1	B-protein
mutant	I-protein
dramatically	O
increased	O
cyclin	B-protein
D1	I-protein
promoter	O
activity	O
and	O
cyclin	B-protein
D1	I-protein
protein	I-protein
expression	O
,	O
in	O
a	O
growth	O
factor	O
-	O
independent	O
manner	O
.	O

Co	O
-	O
transfection	O
of	O
a	O
tat	B-protein
expressing	O
plasmid	O
with	O
these	O
viruses	O
containing	O
the	O
tat	B-protein
ORF	I-protein
mutations	O
resulted	O
in	O
higher	O
levels	O
of	O
virus	O
production	O
demonstrating	O
that	O
the	O
effects	O
of	O
both	O
mutants	O
are	O
tat	B-protein
specific	O
.	O

Epileptiform	O
activity	O
recorded	O
from	O
superficial	O
laminae	O
bordering	O
layer	O
4	O
,	O
and	O
into	O
which	O
layer	O
4	O
'	O
s	O
primary	O
projections	O
terminate	O
,	O
is	O
suppressed	O
preferentially	O
by	O
phenytoin	O
.	O

After	O
allowing	O
time	O
for	O
absorption	O
,	O
participants	O
completed	O
a	O
bridge	O
simulator	O
task	O
.	O

Static	O
lung	O
function	O
in	O
puppies	O
after	O
pneumonectomy	O
.	O

This	O
analysis	O
,	O
together	O
with	O
a	O
consideration	O
of	O
the	O
SCBs	O
found	O
upstream	O
of	O
known	O
SWI4	B-protein
,	I-protein
6	I-protein
-	I-protein
dependent	I-protein
genes	I-protein
,	O
leads	O
to	O
the	O
proposal	O
of	O
a	O
revised	O
consensus	O
sequence	O
for	O
this	O
important	O
regulatory	O
element	O
.	O

Of	O
the	O
cases	O
with	O
PLD	O
,	O
50	O
%	O
had	O
associated	O
renal	O
cysts	O
and	O
10	O
%	O
of	O
the	O
cases	O
with	O
APCD	O
had	O
associated	O
liver	O
cysts	O
.	O

It	O
was	O
postulated	O
that	O
persistent	O
challenge	O
by	O
M	O
.	O
leprae	O
or	O
its	O
antigens	O
to	O
the	O
IgA	B-protein
immunocytes	O
of	O
the	O
intestinal	O
epithelium	O
might	O
have	O
induced	O
tolerance	O
leading	O
to	O
IgA	B-protein
deficiency	O
and	O
subsequent	O
subtotal	O
atrophy	O
of	O
the	O
intestinal	O
villi	O
in	O
the	O
patients	O
with	O
lepromatous	O
leprosy	O
.	O

Lysozyme	B-protein
activity	O
was	O
evidently	O
increased	O
as	O
well	O
in	O
undiluted	O
as	O
in	O
diluted	O
sera	O
in	O
all	O
our	O
tested	O
patients	O
.	O

As	O
well	O
,	O
IFN	O
-	O
gamma	O
-	O
induced	O
expression	O
of	O
IRF	B-protein
-	I-protein
1	I-protein
and	O
its	O
binding	O
to	O
the	O
IRF	B-protein
element	I-protein
is	O
inhibited	O
.	O

We	O
exploit	O
the	O
properties	O
of	O
LexA	B-protein
fusion	I-protein
proteins	I-protein
to	O
study	O
the	O
dimerization	O
and	O
DNA	O
-	O
contacting	O
domains	O
of	O
cRel	B-protein
.	O

Endocardial	O
fibro	O
-	O
elastosis	O
,	O
mitral	O
incompetence	O
,	O
and	O
coarctation	O
of	O
abdominal	O
aorta	O
.	O

Endothelium	O
of	O
the	O
central	O
ear	O
artery	O
of	O
an	O
anesthetized	O
rabbit	O
is	O
damaged	O
by	O
placing	O
artery	O
forceps	O
on	O
the	O
ear	O
directly	O
over	O
the	O
vessel	O
.	O

These	O
results	O
demonstrate	O
a	O
specific	O
association	O
of	O
SIV	O
and	O
HIV	B-protein
-	I-protein
2	I-protein
nef	I-protein
,	O
but	O
not	O
HIV	B-protein
-	I-protein
1	I-protein
nef	I-protein
,	O
with	O
TCRzeta	B-protein
.	O

This	O
study	O
was	O
performed	O
to	O
clarify	O
the	O
location	O
of	O
a	O
transesophageal	O
echocardiographic	O
(	O
TEE	O
)	O
transducer	O
when	O
obtaining	O
the	O
short	O
-	O
axis	O
view	O
of	O
the	O
left	O
ventricle	O
(	O
S	O
-	O
LV	O
)	O
.	O

Low	O
PbrO2	O
readings	O
,	O
however	O
,	O
could	O
be	O
caused	O
by	O
local	O
microhemorrhages	O
,	O
undetectable	O
on	O
CT	O
or	O
MRI	O
.	O

One	O
of	O
the	O
sequelae	O
of	O
the	O
antiphospholipid	B-protein
-	I-protein
antibodies	I-protein
is	O
an	O
impaired	O
uteroplacental	O
circulation	O
.	O

During	O
the	O
first	O
3	O
min	O
of	O
recovery	O
,	O
plasma	O
potassium	O
fell	O
rapidly	O
in	O
spite	O
of	O
nearly	O
unchanged	O
blood	O
acidosis	O
and	O
significantly	O
decreasing	O
bicarbonate	O
concentration	O
.	O

All	O
three	O
genes	O
have	O
been	O
mapped	O
precisely	O
to	O
a	O
small	O
region	O
on	O
human	O
chromosome	O
16p12	O
.	O
1	O
-	O
p11	O
.	O
2	O
(	O
homologous	O
to	O
mouse	O
chromosome	O
7	O
)	O
,	O
using	O
somatic	O
cell	O
hybrids	O
and	O
cosmid	O
clones	O
.	O

The	O
role	O
of	O
neuroplasticity	O
in	O
the	O
response	O
to	O
drugs	O
.	O

Effect	O
of	O
corticosteroid	O
-	O
containing	O
antirheumatic	O
combination	O
drugs	O
on	O
endogenous	O
ACTH	B-protein
and	O
cortisol	O
production	O
.	O

Finally	O
,	O
the	O
recovery	O
indexes	O
represented	O
by	O
the	O
times	O
required	O
for	O
T1	O
/	O
T0	O
and	O
T4	O
/	O
T1	O
to	O
rise	O
from	O
25	O
%	O
to	O
75	O
%	O
respectively	O
were	O
studied	O
.	O

This	O
Tbx6	B-protein
-	I-protein
subfamily	I-protein
gene	I-protein
is	O
likely	O
to	O
participate	O
in	O
paraxial	O
mesoderm	O
formation	O
and	O
somitogenesis	O
in	O
human	O
embryo	O
.	O

Enantiomer	O
separation	O
of	O
venlafaxine	O
and	O
O	O
-	O
desmethylvenlafaxine	O
in	O
human	O
plasma	O
.	O

Acid	O
instilled	O
on	O
the	O
larynx	O
of	O
maturing	O
rabbits	O
resulted	O
in	O
significant	O
obstructive	O
,	O
central	O
,	O
and	O
mixed	O
apnea	O
.	O

METHODS	O
:	O
Total	O
muscle	O
paralysis	O
was	O
induced	O
under	O
general	O
anesthesia	O
in	O
a	O
group	O
of	O
obese	O
persons	O
(	O
n	O
=	O
9	O
;	O
body	O
mass	O
index	O
,	O
32	O
+	O
/	O
-	O
3	O
kg	O
[	O
-	O
2	O
]	O
)	O
and	O
in	O
a	O
group	O
of	O
nonobese	O
persons	O
(	O
n	O
=	O
9	O
;	O
body	O
mas	O
index	O
,	O
21	O
+	O
/	O
-	O
2	O
kg	O
[	O
-	O
2	O
]	O
)	O
.	O

In	O
addition	O
,	O
these	O
patients	O
show	O
both	O
quantitative	O
and	O
qualitative	O
differences	O
in	O
their	O
infectious	O
microbiological	O
spectrum	O
,	O
mainly	O
in	O
clean	O
-	O
contaminated	O
,	O
contaminated	O
and	O
dirty	O
surgical	O
procedures	O
.	O

Testing	O
gravity	O
to	O
second	O
post	O
-	O
Newtonian	O
order	O
:	O
A	O
field	O
-	O
theory	O
approach	O
.	O

Several	O
lines	O
of	O
evidence	O
presented	O
here	O
suggest	O
that	O
PKC	B-protein
-	I-protein
zeta	I-protein
plays	O
a	O
role	O
in	O
alpha	B-protein
2	I-protein
integrin	I-protein
gene	I-protein
expression	O
.	O

Each	O
mRNA	O
contained	O
five	O
or	O
six	O
internal	O
uridine	O
residues	O
,	O
which	O
were	O
transcribed	O
using	O
a	O
mixture	O
of	O
UTP	O
and	O
thio	O
-	O
UTP	O
.	O

The	O
total	O
number	O
of	O
specimens	O
was	O
131	O
with	O
78	O
nonsmokers	O
and	O
53	O
smokers	O
.	O

Evidence	O
for	O
such	O
peak	O
shifts	O
has	O
been	O
found	O
in	O
the	O
responses	O
of	O
auditory	O
nerve	O
fibers	O
,	O
cochlear	O
microphonics	O
,	O
and	O
the	O
responses	O
of	O
outer	O
hair	O
cells	O
and	O
supporting	O
cells	O
in	O
the	O
cochlea	O
,	O
as	O
well	O
as	O
in	O
basilar	O
membrane	O
vibration	O
measurements	O
,	O
and	O
indirectly	O
,	O
in	O
psychophysical	O
data	O
.	O

The	O
data	O
normally	O
available	O
are	O
insufficient	O
and	O
take	O
no	O
account	O
of	O
the	O
direction	O
of	O
recirculation	O
,	O
which	O
may	O
be	O
a	O
determining	O
factor	O
.	O

We	O
present	O
a	O
case	O
of	O
carcinoma	O
of	O
the	O
breast	O
presenting	O
concurrently	O
with	O
SSc	O
that	O
subsequently	O
progressed	O
to	O
dialysis	O
-	O
dependent	O
renal	O
failure	O
in	O
just	O
1	O
month	O
.	O

Accepting	O
arbitrarily	O
chosen	O
limits	O
of	O
maximized	O
errors	O
of	O
+	O
/	O
-	O
10	O
%	O
,	O
it	O
could	O
be	O
shown	O
that	O
the	O
system	O
did	O
not	O
work	O
acceptably	O
when	O
the	O
mean	O
carbon	O
dioxide	O
concentration	O
was	O
below	O
1	O
.	O
5	O
vol	O
.	O
%	O
within	O
the	O
fresh	O
gas	O
flow	O
rates	O
(	O
2	O
.	O
2	O
-	O
-	O
7	O
.	O
7	O
1	O
min	O
-	O
1	O
)	O
and	O
the	O
range	O
of	O
minute	O
ventilation	O
(	O
4	O
-	O
-	O
10	O
1	O
min	O
-	O
1	O
)	O
employed	O
.	O

Overall	O
agreement	O
between	O
rest	O
/	O
postnitroglycerin	O
technetium	O
-	O
99m	O
tetrofosmin	O
SPET	O
studies	O
and	O
rest	O
/	O
redistribution	O
or	O
rest	O
/	O
reinjection	O
thallium	O
-	O
201	O
SPET	O
studies	O
,	O
regarding	O
the	O
presence	O
of	O
myocardial	O
viability	O
,	O
was	O
87	O
%	O
and	O
90	O
%	O
,	O
respectively	O
.	O

Southern	O
blot	O
analysis	O
using	O
probes	O
from	O
the	O
3	O
'	O
portions	O
of	O
the	O
genomic	O
and	O
B	B-protein
.	I-protein
napus	I-protein
MA	I-protein
and	O
MB	B-protein
cDNA	I-protein
clones	O
showed	O
that	O
MA	B-protein
type	I-protein
myrosinases	I-protein
are	O
encoded	O
by	O
approximately	O
4	O
genes	O
,	O
while	O
MB	B-protein
type	I-protein
myrosinases	I-protein
are	O
encoded	O
by	O
more	O
than	O
10	O
genes	O
in	O
B	O
.	O
napus	O
.	O

Congruent	O
with	O
empirical	O
predictions	O
,	O
the	O
most	O
homesick	O
children	O
perceived	O
low	O
control	O
over	O
homesickness	O
and	O
separation	O
,	O
and	O
coped	O
by	O
relinquishing	O
control	O
.	O

Downregulation	O
of	O
FUS	B-protein
expression	O
in	O
BCR	O
/	O
ABL	O
-	O
expressing	O
32Dcl3	O
cells	O
was	O
associated	O
with	O
suppression	O
of	O
growth	O
factor	O
-	O
independent	O
colony	O
formation	O
,	O
restoration	O
of	O
G	O
-	O
CSF	O
-	O
induced	O
granulocytic	O
differentiation	O
and	O
reduced	O
tumorigenic	O
potential	O
in	O
vivo	O
.	O

Differential	O
expression	O
was	O
confirmed	O
by	O
Northern	O
blot	O
analysis	O
employing	O
multiple	O
normal	O
and	O
tumor	O
cell	O
lines	O
.	O

To	O
examine	O
the	O
biochemical	O
basis	O
of	O
the	O
end	O
joining	O
,	O
nuclear	O
extracts	O
were	O
prepared	O
from	O
a	O
wide	O
variety	O
of	O
mammalian	O
cell	O
lines	O
and	O
tested	O
for	O
their	O
ability	O
to	O
join	O
test	O
plasmid	O
substrates	O
.	O

Genomic	O
DNA	O
sequencing	O
in	O
the	O
vicinity	O
of	O
methylmalonyl	B-protein
-	I-protein
CoA	I-protein
mutase	I-protein
gene	I-protein
(	O
mutAB	B-protein
)	O
from	O
a	O
rifamycin	O
SV	O
-	O
producing	O
Amycolatopsis	O
mediterranei	O
U32	O
allowed	O
us	O
to	O
clone	O
,	O
sequence	O
,	O
and	O
identify	O
a	O
gene	O
encoding	O
a	O
novel	O
serine	B-protein
/	I-protein
threonine	I-protein
protein	I-protein
kinase	I-protein
(	O
amk	B-protein
)	O
.	O

The	O
genes	O
at	O
each	O
locus	O
are	O
divergently	O
transcribed	O
and	O
the	O
coding	O
sequences	O
are	O
separated	O
by	O
646	O
base	O
-	O
pairs	O
at	O
one	O
locus	O
and	O
676	O
base	O
-	O
pairs	O
at	O
the	O
other	O
.	O

Surprisingly	O
,	O
the	O
full	O
-	O
deletion	O
mutant	O
showed	O
a	O
strong	O
block	O
in	O
virus	O
release	O
,	O
suggesting	O
that	O
NC	B-protein
is	O
involved	O
in	O
virus	O
assembly	O
.	O

It	O
has	O
come	O
out	O
that	O
CAEC	O
is	O
between	O
CC	O
and	O
CIEC	O
and	O
that	O
attacks	O
of	O
biliary	O
fever	O
and	O
high	O
levels	O
of	O
alkaline	B-protein
phosphatase	I-protein
and	O
transaminases	B-protein
in	O
the	O
serum	O
are	O
the	O
helpful	O
findings	O
for	O
preoperative	O
diagnosis	O
.	O

The	O
Mig1	B-protein
repressor	I-protein
is	O
a	O
zinc	B-protein
finger	I-protein
protein	I-protein
that	O
mediates	O
glucose	O
repression	O
in	O
yeast	O
.	O

Combined	O
immunochemotherapy	O
with	O
cyclophosphamide	O
plus	O
BCG	O
gave	O
a	O
better	O
enhancement	O
of	O
the	O
antitumor	O
effect	O
of	O
the	O
cytostatic	O
than	O
that	O
of	O
the	O
combination	O
of	O
methotrexate	O
plus	O
BCG	O
and	O
cyclophosphamide	O
plus	O
levamisole	O
.	O

In	O
addition	O
,	O
SLK	B-protein
displays	O
high	O
homology	O
to	O
microtubule	B-protein
and	I-protein
nuclear	I-protein
associated	I-protein
protein	I-protein
(	O
M	B-protein
-	I-protein
NAP	I-protein
)	O
and	O
AT1	B-protein
-	I-protein
46	I-protein
,	O
both	O
of	O
unknown	O
function	O
.	O

In	O
the	O
DNA	O
recognition	O
helix	O
of	O
finger	O
II	O
,	O
the	O
conserved	O
Arg	O
at	O
position	O
62	O
(	O
N	O
-	O
terminal	O
side	O
of	O
the	O
first	O
zinc	O
-	O
coordinating	O
histidine	O
)	O
was	O
changed	O
to	O
a	O
Leu	O
or	O
Gln	O
.	O

The	O
IL	B-protein
-	I-protein
8	I-protein
receptor	I-protein
is	O
a	O
seven	O
-	O
transmembrane	O
spanning	O
receptor	O
coupled	O
to	O
specific	O
heterotrimeric	B-protein
G	I-protein
proteins	I-protein
including	O
Gi	B-protein
and	O
G16	B-protein
.	O

The	O
gene	O
contains	O
six	O
exons	O
separated	O
by	O
1	O
.	O
1	O
-	O
5	O
.	O
8	O
kb	O
introns	O
and	O
has	O
been	O
localized	O
to	O
the	O
murine	O
chromosome	O
2	O
by	O
linkage	O
analysis	O
.	O

RNA	O
blot	O
hybridizations	O
identified	O
an	O
1	O
.	O
8	O
-	O
kb	O
mRNA	O
common	O
to	O
cytochrome	B-protein
b6	I-protein
and	O
subunit	B-protein
IV	I-protein
,	O
and	O
an	O
intensely	O
hybridizing	O
0	O
.	O
8	O
-	O
kb	O
mRNA	O
specific	O
to	O
the	O
subunit	B-protein
IV	I-protein
gene	O
probe	O
.	O

To	O
address	O
the	O
biological	O
effect	O
of	O
specific	O
isoform	O
expression	O
,	O
NIH3T3	O
cells	O
were	O
transfected	O
with	O
a	O
eukaryotic	O
expression	O
vector	O
containing	O
cDNA	O
for	O
FGF8a	B-protein
,	O
FGF8b	B-protein
,	O
or	O
FGF8e	B-protein
.	O

Mutational	O
analysis	O
of	O
essential	O
IncP	B-protein
alpha	I-protein
plasmid	I-protein
transfer	I-protein
genes	I-protein
traF	I-protein
and	O
traG	B-protein
and	O
involvement	O
of	O
traF	B-protein
in	O
phage	O
sensitivity	O
.	O

Substitution	O
of	O
either	O
Val33	O
(	O
by	O
Gly	O
)	O
or	O
Gly28	O
(	O
by	O
Ser	O
)	O
,	O
two	O
of	O
the	O
most	O
conserved	O
residues	O
in	O
all	O
protein	B-protein
kinases	I-protein
,	O
resulted	O
in	O
enzyme	O
with	O
marginally	O
detectable	O
activity	O
.	O

Sites	O
1	O
and	O
4	O
in	O
lumican	B-protein
and	O
keratocan	B-protein
are	O
in	O
a	O
homologous	O
location	O
.	O

Genomic	O
organization	O
of	O
the	O
human	B-protein
beta	I-protein
-	I-protein
catenin	I-protein
gene	I-protein
(	O
CTNNB1	B-protein
)	O
.	O

Analysis	O
of	O
the	O
mouse	B-protein
STAP	I-protein
gene	I-protein
isolated	O
from	O
the	O
genomic	O
library	O
revealed	O
that	O
the	O
STAP	B-protein
gene	I-protein
spans	O
a	O
region	O
of	O
over	O
11	O
kb	O
and	O
comprises	O
eight	O
exons	O
.	O

Glomerular	O
hemodynamics	O
during	O
abortion	O
induced	O
by	O
RU	O
486	O
and	O
sepsis	O
in	O
rats	O
.	O

Southern	O
blot	O
analyses	O
demonstrated	O
a	O
low	O
,	O
if	O
not	O
single	O
,	O
copy	O
number	O
for	O
this	O
gene	O
and	O
conservation	O
of	O
this	O
domain	O
in	O
other	O
vertebrates	O
.	O

Handling	O
on	O
PND	O
9	O
did	O
not	O
result	O
in	O
elevated	O
CORT	O
levels	O
in	O
any	O
of	O
the	O
groups	O
.	O

Familial	O
glutathione	B-protein
reductase	I-protein
deficiency	O
and	O
disorder	O
of	O
glutathione	O
synthesis	O
in	O
the	O
erythrocyte	O
.	O

Stable	O
expression	O
of	O
truncated	B-protein
inositol	I-protein
1	I-protein
,	I-protein
4	I-protein
,	I-protein
5	I-protein
-	I-protein
trisphosphate	I-protein
receptor	I-protein
subunits	I-protein
in	O
3T3	O
fibroblasts	O
.	O

Naval	O
personnel	O
who	O
exceed	O
standards	O
for	O
%	O
BF	O
can	O
be	O
separated	O
from	O
active	O
duty	O
.	O

Transcription	O
of	O
the	O
six	O
EBNA	B-protein
genes	I-protein
,	O
which	O
are	O
expressed	O
in	O
EBV	O
-	O
immortalized	O
primary	O
B	O
cells	O
,	O
arises	O
from	O
one	O
of	O
two	O
promoters	O
,	O
Cp	B-protein
and	O
Wp	B-protein
,	O
located	O
near	O
the	O
left	O
end	O
of	O
the	O
viral	O
genome	O
.	O

BACKGROUND	O
:	O
Gamma	O
knife	O
radiosurgery	O
(	O
GKR	O
)	O
is	O
a	O
safe	O
and	O
effective	O
alternative	O
to	O
surgery	O
for	O
intracranial	O
lesions	O
.	O

Furthermore	O
,	O
the	O
3	O
'	O
-	O
untranslated	O
regions	O
of	O
pmGT10	B-protein
display	O
a	O
marked	O
degree	O
of	O
homology	O
to	O
the	O
3	O
'	O
region	O
of	O
the	O
rat	B-protein
Yb1	I-protein
gene	I-protein
,	O
while	O
this	O
region	O
of	O
pmGT2	B-protein
displays	O
marked	O
homology	O
to	O
the	O
corresponding	O
region	O
of	O
the	O
rat	B-protein
Yb2	I-protein
gene	I-protein
.	O

Based	O
on	O
AUC	O
infinity	O
analyses	O
,	O
the	O
pharmacokinetics	O
of	O
buflomedil	O
were	O
found	O
to	O
be	O
linear	O
within	O
the	O
dose	O
ranges	O
studied	O
(	O
50	O
to	O
200	O
mg	O
for	O
i	O
.	O
v	O
.	O
injection	O
and	O
150	O
to	O
450	O
mg	O
for	O
oral	O
administration	O
)	O
.	O

Translational	O
fusions	O
of	O
the	O
aroF	B-protein
regulatory	I-protein
regions	I-protein
to	O
lacZ	B-protein
were	O
constructed	O
and	O
then	O
introduced	O
in	O
single	O
copy	O
into	O
the	O
E	O
.	O
coli	O
chromosome	O
.	O
beta	B-protein
-	I-protein
Galactosidase	I-protein
assays	O
for	O
tyrR	O
-	O
mediated	O
regulation	O
of	O
aroF	B-protein
-	I-protein
lacZ	I-protein
expression	O
revealed	O
that	O
the	O
E	B-protein
.	I-protein
coli	I-protein
TyrR	I-protein
repressor	I-protein
apparently	O
recognizes	O
the	O
operators	O
of	O
both	O
organisms	O
with	O
about	O
equal	O
efficiency	O
.	O

The	O
integration	O
at	O
the	O
VIP	B-protein
CyRE	I-protein
of	O
the	O
Jak	B-protein
-	I-protein
Stat	I-protein
and	O
AP	B-protein
-	I-protein
1	I-protein
signaling	I-protein
pathways	I-protein
with	O
other	O
pre	O
-	O
existing	O
proteins	O
provides	O
a	O
cellular	O
mechanism	O
for	O
cell	O
-	O
and	O
cytokine	O
-	O
specific	O
signaling	O
.	O

ORF1	O
(	O
1029	O
bp	O
;	O
EMBL	O
databank	O
,	O
Accession	O
No	O
.	O

Members	O
of	O
the	O
MAPK	B-protein
family	I-protein
include	O
the	O
extracellular	B-protein
response	I-protein
kinases	I-protein
(	O
ERKs	B-protein
or	O
p42	B-protein
/	I-protein
44	I-protein
(	I-protein
MAPK	I-protein
)	I-protein
)	O
,	O
the	O
c	B-protein
-	I-protein
Jun	I-protein
amino	I-protein
-	I-protein
terminal	I-protein
kinases	I-protein
(	O
JNKs	B-protein
)	O
,	O
and	O
the	O
p38	B-protein
/	I-protein
Hog	I-protein
1	I-protein
protein	I-protein
kinases	I-protein
.	O

Technique	O
for	O
obtaining	O
refined	O
ceramics	O
with	O
dense	O
mass	O
.	O

We	O
report	O
the	O
isolation	O
of	O
human	O
cDNAs	O
homologous	O
to	O
the	O
Drosophila	B-protein
dishevelled	I-protein
(	O
dsh	B-protein
)	O
segment	O
-	O
polarity	O
gene	O
.	O

Closeup	O
:	O
a	O
resource	O
for	O
nurses	O
who	O
smoke	O
.	O

No	O
ISREs	B-protein
could	O
be	O
identified	O
in	O
the	O
mouse	O
promoter	O
.	O

The	O
hydrophobicity	O
profile	O
of	O
the	O
methyltransferase	B-protein
reveals	O
the	O
presence	O
of	O
at	O
least	O
five	O
potential	O
transmembrane	O
domains	O
.	O

The	O
data	O
support	O
the	O
notion	O
that	O
suppression	O
of	O
images	O
during	O
binocular	O
rivalry	O
is	O
independent	O
in	O
both	O
eyes	O
.	O

RESULTS	O
:	O
Prevalence	O
of	O
obesity	O
(	O
BMI	O
SDS	O
>	O
2	O
.	O
0	O
)	O
was	O
<	O
2	O
%	O
at	O
diagnosis	O
,	O
but	O
increased	O
to	O
16	O
%	O
at	O
3y	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
describe	O
a	O
new	O
formulation	O
of	O
silver	O
sulfadiazine	O
in	O
a	O
water	O
soluble	O
gel	O
,	O
poloxamer	O
188	O
.	O

These	O
mutations	O
create	O
stop	O
codons	O
in	O
exon	O
7	O
and	O
8	O
,	O
respectively	O
,	O
and	O
probably	O
result	O
in	O
truncated	O
proteins	O
lacking	O
HLH	B-protein
-	I-protein
Zip	I-protein
or	O
Zip	B-protein
structure	O
.	O

Two	O
sterol	B-protein
regulatory	I-protein
element	I-protein
-	I-protein
like	I-protein
sequences	I-protein
mediate	O
up	O
-	O
regulation	O
of	O
caveolin	B-protein
gene	I-protein
transcription	O
in	O
response	O
to	O
low	B-protein
density	I-protein
lipoprotein	I-protein
free	O
cholesterol	O
.	O

2	O
were	O
nonviable	O
,	O
and	O
the	O
mutant	B-protein
Vp1s	I-protein
unexpectedly	O
failed	O
to	O
localize	O
to	O
the	O
nucleus	O
though	O
Vp2	B-protein
and	O
Vp3	B-protein
did	O
,	O
suggesting	O
that	O
the	O
mutated	B-protein
NLS1	I-protein
acted	O
as	O
a	O
dominant	O
signal	O
for	O
the	O
cytoplasmic	O
localization	O
of	O
Vp1	B-protein
.	O

Underestimations	O
by	O
as	O
much	O
as	O
35	O
%	O
may	O
occur	O
due	O
to	O
the	O
problems	O
in	O
the	O
existing	O
methodologies	O
.	O

This	O
laser	O
provided	O
sufficient	O
power	O
in	O
an	O
amniotic	O
fluid	O
medium	O
to	O
occlude	O
placental	O
vessels	O
as	O
large	O
as	O
7	O
mm	O
in	O
diameter	O
within	O
6	O
seconds	O
at	O
a	O
power	O
density	O
of	O
2000	O
W	O
/	O
cm2	O
.	O

We	O
have	O
found	O
that	O
mcs4	B-protein
-	I-protein
cells	O
are	O
defective	O
at	O
activation	O
of	O
Spc1	B-protein
in	O
response	O
to	O
various	O
forms	O
of	O
stress	O
.	O

Cloning	O
of	O
a	O
human	O
cDNA	O
encoding	O
a	O
CDC2	B-protein
-	I-protein
related	I-protein
kinase	I-protein
by	O
complementation	O
of	O
a	O
budding	B-protein
yeast	I-protein
cdc28	I-protein
mutation	O
.	O

A	O
7	O
-	O
day	O
treatment	O
of	O
amphotericin	O
B	O
(	O
5	O
mg	O
/	O
kg	O
/	O
day	O
i	O
.	O
p	O
.	O
)	O
significantly	O
reduced	O
the	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
measured	O
as	O
inuline	O
clearance	O
and	O
creatinine	O
clearance	O
(	O
0	O
.	O
74	O
+	O
/	O
-	O
0	O
.	O
29	O
and	O
0	O
.	O
16	O
+	O
/	O
-	O
0	O
.	O
04	O
ml	O
/	O
min	O
,	O
respectively	O
)	O
in	O
comparison	O
to	O
vehicle	O
-	O
treated	O
rats	O
(	O
2	O
.	O
04	O
+	O
/	O
-	O
0	O
.	O
23	O
and	O
1	O
.	O
29	O
+	O
/	O
-	O
0	O
.	O
19	O
ml	O
/	O
min	O
,	O
respectively	O
)	O
.	O

The	O
mutant	O
receptors	O
,	O
as	O
well	O
as	O
sBMPR	B-protein
-	I-protein
IA	I-protein
,	O
were	O
expressed	O
as	O
fusion	O
proteins	O
with	O
thioredoxin	B-protein
in	O
Escherichia	O
coli	O
,	O
and	O
purified	O
using	O
reverse	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
(	O
RP	O
-	O
HPLC	O
)	O
after	O
digestion	O
with	O
enterokinase	B-protein
.	O

The	O
Ig	O
-	O
related	O
,	O
typical	O
metazoan	O
,	O
module	O
is	O
classified	O
to	O
the	O
disulphide	O
lacking	O
Ig	B-protein
members	I-protein
and	O
represents	O
the	O
phylogenetic	O
earliest	O
member	O
of	O
this	O
group	O
.	O

Comparison	O
of	O
the	O
sequences	O
of	O
the	O
xFxFG	B-protein
repeat	I-protein
regions	I-protein
of	O
p62	B-protein
and	O
Nsplp	B-protein
indicated	O
that	O
NTF2	B-protein
was	O
probably	O
interacting	O
with	O
the	O
phenylalanine	O
-	O
containing	O
core	O
of	O
these	O
repeats	O
and	O
not	O
the	O
intervening	O
hydrophilic	O
linkers	O
.	O

These	O
fusion	O
proteins	O
also	O
allowed	O
the	O
localization	O
of	O
the	O
transcriptional	O
activation	O
and	O
DNA	O
binding	O
domains	O
of	O
the	O
ToxR	B-protein
protein	I-protein
to	O
its	O
cytoplasmically	O
located	O
N	O
-	O
terminal	O
portion	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
residues	O
in	O
this	O
domain	O
(	O
R82A	O
,	O
K85A	O
,	O
K88A	O
,	O
and	O
V89A	O
)	O
resulted	O
in	O
proteins	O
which	O
failed	O
to	O
transactivate	O
from	O
the	O
HTLV	B-protein
-	I-protein
1	I-protein
LTR	I-protein
in	O
vivo	O
.	O

Naltrexone	O
hydrochloride	O
is	O
a	O
synthetic	O
opioid	O
receptor	O
antagonist	O
recently	O
used	O
in	O
efforts	O
to	O
provide	O
rapid	O
opioid	O
detoxification	O
.	O

The	O
survival	O
in	O
the	O
case	O
of	O
these	O
patients	O
was	O
studied	O
five	O
years	O
later	O
.	O

Receptors	O
for	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-	I-protein
10	I-protein
and	O
IL	B-protein
-	I-protein
6	I-protein
-	I-protein
type	I-protein
cytokines	I-protein
use	O
similar	O
signaling	O
mechanisms	O
for	O
inducing	O
transcription	O
through	O
IL	B-protein
-	I-protein
6	I-protein
response	I-protein
elements	I-protein
.	O

This	O
new	O
knowledge	O
has	O
contributed	O
to	O
the	O
development	O
of	O
a	O
successful	O
immunoprophylactic	O
strategy	O
for	O
eliminating	O
Hib	O
disease	O
.	O

The	O
yeast	O
retrotransposon	B-protein
Ty5	I-protein
preferentially	O
integrates	O
into	O
regions	O
of	O
silent	O
chromatin	O
.	O

Finding	O
of	O
Rhodnius	O
prolixus	O
Stal	O
,	O
1859	O
,	O
in	O
babassu	O
palm	O
trees	O
.	O

In	O
the	O
first	O
,	O
homologous	O
sequences	O
were	O
deleted	O
from	O
a	O
mouse	O
enhancer	O
,	O
resulting	O
in	O
a	O
tissue	O
-	O
specific	O
loss	O
of	O
activity	O
when	O
assayed	O
in	O
transgenic	O
mice	O
.	O

Parasitological	O
post	O
-	O
mortem	O
examination	O
of	O
all	O
seropositive	O
animals	O
showed	O
five	O
and	O
seven	O
false	O
-	O
positive	O
animals	O
when	O
E	B-protein
/	I-protein
S	I-protein
and	I-protein
CWE	I-protein
antigens	I-protein
were	O
used	O
,	O
respectively	O
.	O

Children	O
'	O
s	O
temperament	O
and	O
maternal	O
socialization	O
at	O
Time	O
1	O
(	O
n	O
=	O
103	O
,	O
aged	O
2	O
-	O
3	O
years	O
)	O
were	O
considered	O
predictors	O
of	O
future	O
conscience	O
,	O
assessed	O
using	O
new	O
observational	O
and	O
narrative	O
measures	O
.	O

The	O
assay	O
herein	O
described	O
allows	O
the	O
comparison	O
of	O
relative	O
FGFR	B-protein
expression	O
levels	O
,	O
both	O
within	O
a	O
single	O
RNA	O
pool	O
and	O
among	O
multiple	O
RNA	O
pool	O
samples	O
.	O

The	O
%	O
SVend	O
of	O
HCM	O
-	O
I	O
was	O
significantly	O
lower	O
than	O
the	O
respective	O
values	O
of	O
the	O
HCM	O
-	O
II	O
and	O
Control	O
groups	O
.	O

All	O
patients	O
then	O
received	O
suxamethonium	O
1	O
.	O
5	O
mg	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O

Magnetic	O
resonance	O
spectroscopy	O
(	O
MRS	O
)	O
and	O
imaging	O
(	O
MRI	O
)	O
are	O
now	O
well	O
established	O
techniques	O
for	O
the	O
study	O
of	O
cellular	O
metabolism	O
and	O
gross	O
structure	O
of	O
muscle	O
.	O

The	O
peroxisome	B-protein
proliferator	I-protein
-	I-protein
activated	I-protein
receptors	I-protein
(	O
PPARs	B-protein
)	O
are	O
members	O
of	O
the	O
nuclear	B-protein
hormone	I-protein
receptor	I-protein
superfamily	I-protein
.	O

The	O
unexpected	O
presence	O
of	O
the	O
tRNA	B-protein
(	I-protein
trp	I-protein
)	I-protein
(	I-protein
CCA	I-protein
)	I-protein
-	I-protein
gene	I-protein
transcript	I-protein
in	I-protein
mitochondria	I-protein
is	O
also	O
reported	O
.	O

Cyclin	B-protein
A	I-protein
expression	O
is	O
repressed	O
in	O
quiescent	O
cells	O
by	O
E2F	B-protein
acting	O
in	O
conjunction	O
with	O
its	O
pocket	O
protein	O
partners	O
Rb	B-protein
,	O
p107	B-protein
,	O
and	O
p130	B-protein
;	O
however	O
,	O
v	B-protein
-	I-protein
Jun	I-protein
overrides	O
this	O
control	O
,	O
causing	O
phosphorylated	O
Rb	B-protein
and	O
proliferation	O
-	O
specific	O
E2F	B-protein
-	I-protein
p107	I-protein
complexes	I-protein
to	O
persist	O
after	O
mitogen	O
withdrawal	O
.	O

The	O
present	O
findings	O
revealed	O
that	O
the	O
rib	B-protein
-	I-protein
2	I-protein
protein	I-protein
was	O
a	O
unique	O
alpha1	B-protein
,	I-protein
4	I-protein
-	I-protein
N	I-protein
-	I-protein
acetylglucosaminyltransferase	I-protein
involved	O
in	O
the	O
biosynthetic	O
initiation	O
and	O
elongation	O
of	O
heparan	O
sulfate	O
.	O

The	O
ipiO	B-protein
genes	I-protein
code	O
for	O
two	O
almost	O
identical	O
152	O
-	O
aa	O
proteins	O
which	O
do	O
not	O
have	O
any	O
homology	O
with	O
sequences	O
present	O
in	O
data	O
libraries	O
.	O

RESULTS	O
:	O
The	O
analyzed	O
fragment	O
has	O
significant	O
activity	O
in	O
EpCAM	B-protein
positive	O
cells	O
,	O
and	O
it	O
is	O
regulated	O
negatively	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNFalpha	B-protein
)	O
.	O

Because	O
PET	O
is	O
also	O
useful	O
for	O
the	O
pretreatment	O
and	O
follow	O
-	O
up	O
evaluation	O
,	O
the	O
use	O
of	O
stereotactic	O
PET	O
in	O
these	O
patients	O
can	O
enable	O
an	O
accurate	O
comparison	O
of	O
PET	O
-	O
based	O
metabolic	O
data	O
with	O
MR	O
-	O
based	O
anatomical	O
data	O
.	O

In	O
eight	O
groups	O
of	O
subjects	O
operating	O
various	O
hand	O
-	O
held	O
vibrating	O
tools	O
and	O
aged	O
from	O
30	O
to	O
59	O
years	O
,	O
the	O
prevalence	O
rates	O
of	O
vibration	O
-	O
induced	O
white	O
finger	O
(	O
VWF	O
)	O
and	O
numbness	O
,	O
pain	O
,	O
or	O
stiffness	O
in	O
the	O
upper	O
and	O
lower	O
extremities	O
were	O
investigated	O
.	O

Among	O
non	O
-	O
cirrhotics	O
,	O
lack	O
of	O
portal	O
vein	O
visualisation	O
had	O
a	O
90	O
%	O
sensitivity	O
,	O
88	O
%	O
specificity	O
,	O
94	O
%	O
negative	O
predictive	O
value	O
,	O
and	O
83	O
%	O
positive	O
predictive	O
value	O
in	O
the	O
diagnosis	O
of	O
pre	O
-	O
sinusoidal	O
portal	O
hypertension	O
.	O

The	O
activation	O
of	O
the	O
HIV	O
promoter	O
required	O
the	O
nuclear	O
localization	O
of	O
c	B-protein
-	I-protein
Abl	I-protein
and	O
could	O
be	O
correlated	O
with	O
increased	O
tyrosine	O
phosphorylation	O
of	O
RNA	B-protein
polymerase	I-protein
II	I-protein
.	O

The	O
SEB1	B-protein
homologue	O
thus	O
isolated	O
,	O
SEB2	B-protein
,	O
encodes	O
a	O
protein	O
53	O
%	O
identical	O
to	O
Seb1p	B-protein
.	O

Carbohydrates	O
and	O
glycoconjugates	O
biophysical	O
methods	O
.	O

Molecular	O
cloning	O
and	O
characterisation	O
of	O
the	O
two	O
homologous	O
genes	O
coding	O
for	O
nitrate	B-protein
reductase	I-protein
in	I-protein
tobacco	I-protein
.	O

IL	B-protein
-	I-protein
2	I-protein
is	O
accepted	O
as	O
a	O
standard	O
treatment	O
used	O
alone	O
,	O
or	O
in	O
combination	O
with	O
chemotherapy	O
or	O
biotherapy	O
in	O
the	O
management	O
of	O
metastatic	O
melanoma	O
and	O
metastatic	O
renal	O
cell	O
carcinoma	O
.	O

Cloning	O
and	O
sequencing	O
of	O
the	O
upstream	O
region	O
of	O
pepX	B-protein
revealed	O
the	O
presence	O
of	O
two	O
ORFs	O
of	O
360	O
and	O
1	O
,	O
338	O
bp	O
that	O
were	O
shown	O
to	O
be	O
able	O
to	O
encode	O
proteins	O
with	O
high	O
homology	O
to	O
GlnR	B-protein
and	O
GlnA	B-protein
proteins	I-protein
,	O
respectively	O
.	O

DESIGN	O
:	O
Serum	O
aldosterone	O
and	O
plasma	B-protein
renin	I-protein
activity	O
were	O
measured	O
supine	O
prior	O
to	O
and	O
60	O
,	O
90	O
,	O
120	O
minutes	O
after	O
oral	O
captopril	O
,	O
25	O
mg	O
.	O

At	O
43	O
%	O
blood	O
pressure	O
reduction	O
,	O
PCO2	O
fell	O
by	O
0	O
.	O
53	O
kPa	O
,	O
a	O
decrease	O
which	O
could	O
not	O
explain	O
the	O
observed	O
CBF	O
fall	O
of	O
27	O
%	O
.	O

Chronic	O
hepatitis	O
B	O
in	O
adopted	O
Romanian	O
children	O
.	O

This	O
coat	B-protein
protein	I-protein
consists	O
of	O
Sar1p	B-protein
,	O
the	O
Sec23p	B-protein
protein	I-protein
complex	I-protein
containing	O
Sec23p	B-protein
and	O
Sec24p	B-protein
,	O
and	O
the	O
Sec13p	B-protein
protein	I-protein
complex	I-protein
containing	O
Sec13p	B-protein
and	O
a	O
novel	O
150	B-protein
-	I-protein
kDa	I-protein
protein	I-protein
,	I-protein
p150	I-protein
.	O

Thus	O
,	O
Esigma54	B-protein
promoters	I-protein
are	O
responsive	O
to	O
CRP	B-protein
,	O
a	O
protein	O
unrelated	O
to	O
sigma54	B-protein
activators	I-protein
,	O
and	O
the	O
repression	O
exerted	O
is	O
the	O
direct	O
result	O
of	O
an	O
interaction	O
between	O
Esigma54	B-protein
and	O
the	O
CRP	B-protein
-	I-protein
cAMP	I-protein
complex	I-protein
.	O

Three	O
different	O
techniques	O
of	O
EA	O
analysis	O
were	O
used	O
in	O
the	O
study	O
:	O
1	O
)	O
fast	O
Fourier	O
transformation	O
(	O
FFT	O
)	O
of	O
EA	O
in	O
a	O
broad	O
band	O
,	O
2	O
)	O
developed	O
by	O
us	O
alternative	O
method	O
of	O
non	O
-	O
harmonic	O
expansion	O
of	O
the	O
EEG	O
curves	O
taking	O
into	O
account	O
their	O
shape	O
,	O
3	O
)	O
factor	O
analysis	O
of	O
the	O
EA	O
spectral	O
densities	O
.	O

We	O
show	O
that	O
these	O
three	O
gain	O
-	O
of	O
-	O
function	O
mutants	O
differ	O
considerably	O
in	O
their	O
ability	O
to	O
bypass	O
the	O
sex	O
determination	O
signal	O
,	O
with	O
SxlM4	B-protein
being	O
the	O
strongest	O
and	O
SxlM1	B-protein
the	O
weakest	O
.	O

These	O
studies	O
identify	O
several	O
of	O
the	O
signal	O
-	O
transduction	O
events	O
involved	O
in	O
the	O
apoptosis	O
of	O
malignant	O
B	O
cells	O
that	O
transpire	O
following	O
ligation	O
of	O
CD20	B-protein
by	O
anti	B-protein
-	I-protein
CD20	I-protein
antibodies	I-protein
in	O
the	O
presence	O
of	O
Fc	O
-	O
receptor	O
-	O
expressing	O
cells	O
or	O
secondary	O
goat	O
anti	B-protein
-	I-protein
(	I-protein
mouse	I-protein
Ig	I-protein
)	I-protein
antibodies	I-protein
and	O
which	O
may	O
contribute	O
to	O
the	O
tumor	O
regressions	O
observed	O
in	O
mouse	O
models	O
and	O
clinical	O
trials	O
.	O

The	O
findings	O
demonstrate	O
that	O
AMPH	O
administration	O
induces	O
a	O
significant	O
increase	O
in	O
the	O
height	O
of	O
a	O
major	O
electroactive	O
peak	O
in	O
the	O
caudate	O
nucleus	O
of	O
pigtail	O
monkeys	O
,	O
and	O
further	O
that	O
such	O
amphetamine	O
-	O
induced	O
increases	O
can	O
be	O
manipulated	O
by	O
altering	O
the	O
affective	O
and	O
/	O
or	O
emotional	O
state	O
of	O
the	O
animal	O
.	O

Cloning	O
and	O
sequencing	O
of	O
the	O
corresponding	O
cDNAs	O
indicates	O
that	O
,	O
via	O
alternative	O
splicing	O
,	O
the	O
rearranged	O
gene	O
codes	O
for	O
two	O
proteins	O
of	O
84	O
and	O
85	O
kD	O
(	O
p84	B-protein
/	I-protein
85	I-protein
)	O
which	O
retain	O
the	O
DNA	O
-	O
binding	O
rel	B-protein
domain	I-protein
and	O
the	O
first	O
five	O
ankyrin	B-protein
repeats	O
,	O
but	O
have	O
lost	O
their	O
carboxy	O
-	O
terminus	O
including	O
the	O
seventh	O
ankyrin	B-protein
repeat	O
.	O

Light	B-protein
regulatory	I-protein
unit	I-protein
1	I-protein
(	O
LRU1	B-protein
)	O
is	O
necessary	O
for	O
and	O
sufficient	O
to	O
mediate	O
light	O
-	O
dependent	O
activation	O
of	O
the	O
chalcone	B-protein
synthase	I-protein
(	I-protein
CHS	I-protein
)	I-protein
minimal	I-protein
promoter	I-protein
in	O
Petroselinum	O
crispum	O
.	O

One	O
patient	O
only	O
had	O
any	O
test	O
abnormalities	O
.	O

JNK	B-protein
is	O
additionally	O
regulated	O
by	O
the	O
Ras	O
-	O
related	O
G	B-protein
proteins	I-protein
Rac	I-protein
and	O
Cdc42	B-protein
.	O

Expression	O
of	O
the	O
second	O
gene	O
(	O
XT3	B-protein
)	O
was	O
found	O
to	O
be	O
conserved	O
in	O
human	O
kidney	O
,	O
and	O
partial	O
sequence	O
was	O
obtained	O
from	O
a	O
human	O
cDNA	O
library	O
.	O

Genetic	O
experiments	O
using	O
mutants	O
defective	O
in	O
apontic	B-protein
and	O
bruno	B-protein
reveal	O
a	O
functional	O
interaction	O
between	O
these	O
genes	O
.	O

Deletion	O
of	O
the	O
POR2	B-protein
gene	I-protein
alone	O
had	O
no	O
detectable	O
phenotype	O
,	O
while	O
yeasts	O
with	O
deletions	O
of	O
both	O
the	O
POR1	B-protein
and	O
POR2	B-protein
genes	I-protein
were	O
viable	O
and	O
able	O
to	O
grow	O
on	O
glycerol	O
at	O
30	O
degrees	O
C	O
,	O
albeit	O
more	O
slowly	O
than	O
delta	B-protein
por1	I-protein
single	I-protein
mutants	I-protein
.	O

The	O
salient	O
clinical	O
features	O
,	O
the	O
problems	O
of	O
management	O
and	O
the	O
modern	O
approaches	O
to	O
the	O
reconstruction	O
of	O
facial	O
deformities	O
seen	O
in	O
this	O
disease	O
are	O
described	O
.	O

CsA	O
alone	O
resulted	O
in	O
elevated	O
bone	O
turnover	O
.	O

Mutational	O
analysis	O
of	O
potential	O
activating	O
phosphorylation	O
sites	O
found	O
in	O
NIMA	B-protein
,	O
NIM	B-protein
-	I-protein
1	I-protein
,	O
and	O
related	O
protein	B-protein
kinases	I-protein
was	O
performed	O
on	O
NIMA	B-protein
.	O

In	O
the	O
8	O
patients	O
the	O
difference	O
betweent	O
he	O
mean	O
diastolic	O
values	O
of	O
delta	O
PU	O
and	O
delta	O
PM	O
was	O
-	O
0	O
.	O
54	O
+	O
/	O
-	O
1	O
.	O
0	O
(	O
SD	O
)	O
mmHg	O
.	O

The	O
structure	O
has	O
been	O
established	O
by	O
a	O
study	O
of	O
its	O
mono	O
-	O
and	O
bidimensional	O
NMR	O
spectra	O
and	O
mass	O
spectrometry	O
.	O

Interaction	O
of	O
Ets	B-protein
-	I-protein
1	I-protein
and	O
the	O
POU	B-protein
-	I-protein
homeodomain	I-protein
protein	I-protein
GHF	I-protein
-	I-protein
1	I-protein
/	I-protein
Pit	I-protein
-	I-protein
1	I-protein
reconstitutes	O
pituitary	O
-	O
specific	O
gene	O
expression	O
.	O

These	O
bacteria	O
produce	O
and	O
export	O
proteins	O
capable	O
of	O
specific	O
interactions	O
with	O
key	O
mammalian	O
cell	O
regulatory	O
molecules	O
in	O
order	O
to	O
derail	O
the	O
normal	O
functions	O
of	O
the	O
cells	O
.	O

Seventeen	O
of	O
the	O
35	O
patients	O
were	O
randomly	O
chosen	O
to	O
receive	O
a	O
training	O
program	O
(	O
lasting	O
approximately	O
1	O
month	O
)	O
designed	O
to	O
establish	O
a	O
systematic	O
strategy	O
of	O
organizing	O
complex	O
visual	O
material	O
.	O

A	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
,	O
performed	O
separately	O
for	O
men	O
and	O
women	O
for	O
differences	O
among	O
the	O
three	O
phobic	O
groups	O
on	O
field	O
dependence	O
,	O
showed	O
significance	O
(	O
rho	O
less	O
than	O
.	O
05	O
)	O
for	O
the	O
females	O
,	O
with	O
the	O
famale	O
agoraphobic	O
being	O
more	O
field	O
dependent	O
than	O
the	O
female	O
simple	O
phobic	O
groups	O
,	O
but	O
not	O
for	O
the	O
males	O
.	O

Inactivation	O
of	O
the	O
Neurospora	B-protein
crassa	I-protein
mitochondrial	I-protein
outer	I-protein
membrane	I-protein
protein	I-protein
TOM70	I-protein
by	O
repeat	O
-	O
induced	O
point	O
mutation	O
(	O
RIP	O
)	O
causes	O
defects	O
in	O
mitochondrial	O
protein	O
import	O
and	O
morphology	O
.	O

A	O
minimal	O
ER3	B-protein
sequence	I-protein
of	O
DNA	O
was	O
further	O
demonstrated	O
to	O
function	O
as	O
a	O
FXR	B-protein
HRE	I-protein
and	O
was	O
bound	O
in	O
vitro	O
by	O
FXR	O
-	O
expressing	O
yeast	O
extracts	O
.	O

Radiosensitive	O
nature	O
of	O
paravascular	O
infiltrate	O
-	O
producing	O
potential	O
of	O
parental	O
spleen	O
cells	O
.	O

Thus	O
,	O
Pet111p	B-protein
could	O
play	O
dual	O
roles	O
in	O
both	O
membrane	O
localization	O
and	O
regulation	O
of	O
Cox2p	B-protein
synthesis	O
within	O
mitochondria	O
.	O

Small	O
Maf	B-protein
proteins	I-protein
interact	O
with	O
the	O
human	O
transcription	O
factor	O
TCF11	B-protein
/	I-protein
Nrf1	I-protein
/	I-protein
LCR	I-protein
-	I-protein
F1	I-protein
.	O

A	O
study	O
of	O
chromosomes	O
of	O
lymphocytes	O
from	O
patients	O
treated	O
with	O
hycanthone	O
.	O

These	O
results	O
suggest	O
that	O
HAPE	O
-	O
S	O
-	O
S	O
are	O
prone	O
to	O
irregular	O
nocturnal	O
breathing	O
patterns	O
at	O
high	O
altitude	O
,	O
which	O
is	O
associated	O
with	O
the	O
development	O
of	O
AMS	O
,	O
but	O
it	O
was	O
not	O
possible	O
to	O
determine	O
whether	O
these	O
abnormal	O
breathing	O
patterns	O
are	O
a	O
cause	O
or	O
an	O
effect	O
of	O
AMS	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
exhibited	O
98	O
%	O
identity	O
to	O
the	O
human	O
cellular	O
transglutaminase	B-protein
sequence	O
.	O

However	O
,	O
the	O
inability	O
to	O
export	O
RNA	O
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
was	O
not	O
limited	O
to	O
a	O
particular	O
phase	O
of	O
the	O
cell	O
division	O
cycle	O
.	O

Alanine	B-protein
aminotransferase	I-protein
(	O
ALT	B-protein
)	O
levels	O
had	O
been	O
elevated	O
for	O
six	O
months	O
in	O
all	O
patients	O
and	O
hepatitis	O
B	O
viral	O
infection	O
was	O
replicative	O
.	O

Marked	O
elevation	O
of	O
creatine	B-protein
kinase	I-protein
was	O
observed	O
while	O
serum	O
albumin	B-protein
,	O
immunoglobulin	B-protein
,	O
and	O
complement	O
were	O
decreased	O
.	O

Endothelial	O
cells	O
stored	O
with	O
University	O
of	O
Wisconsin	O
solution	O
excluded	O
trypan	O
blue	O
better	O
(	O
1	O
.	O
0	O
%	O
+	O
/	O
-	O
0	O
.	O
5	O
%	O
cells	O
stained	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
.	O

A	O
comparison	O
of	O
the	O
predicted	O
amino	O
acid	O
sequences	O
of	O
the	O
two	O
human	B-protein
PKC	I-protein
-	I-protein
delta	I-protein
clones	O
with	O
the	O
rat	O
and	O
mouse	O
homologues	O
indicated	O
a	O
greater	O
degree	O
of	O
sequence	O
divergence	O
(	O
89	O
-	O
90	O
%	O
homology	O
)	O
compared	O
to	O
the	O
high	O
degree	O
of	O
sequence	O
conservation	O
observed	O
with	O
other	O
human	B-protein
PKC	I-protein
family	I-protein
members	I-protein
and	O
their	O
mammalian	O
counterparts	O
.	O

Students	O
,	O
parents	O
,	O
teachers	O
and	O
hearing	O
disorders	O
.	O

Therefore	O
,	O
Mxi1	B-protein
and	O
Mad	B-protein
might	O
antagonize	O
Myc	B-protein
function	O
and	O
are	O
candidate	O
tumor	O
suppressor	O
genes	O
.	O

When	O
excluding	O
children	O
with	O
ocular	O
and	O
cerebral	O
pathology	O
,	O
32	O
matched	O
pairs	O
of	O
premature	O
and	O
control	O
children	O
remained	O
.	O

Optically	O
detected	O
librons	O
and	O
phonons	O
in	O
crystalline	O
C60	O
.	O

The	O
effects	O
of	O
loading	O
the	O
respiratory	O
pumps	O
on	O
the	O
oxygen	O
consumption	O
of	O
Callionymus	O
lyra	O
.	O

Expression	O
of	O
the	O
phenylalanine	B-protein
hydroxylase	I-protein
gene	I-protein
in	O
livers	O
and	O
kidneys	O
of	O
rodents	O
is	O
activated	O
at	O
birth	O
and	O
is	O
induced	O
by	O
glucocorticoids	O
and	O
cyclic	O
AMP	O
in	O
the	O
liver	O
.	O

EB	B-protein
-	I-protein
1	I-protein
,	O
a	O
tyrosine	B-protein
kinase	I-protein
signal	I-protein
transduction	I-protein
gene	I-protein
,	O
is	O
transcriptionally	O
activated	O
in	O
the	O
t	O
(	O
1	O
;	O
19	O
)	O
subset	O
of	O
pre	O
-	O
B	O
ALL	O
,	O
which	O
express	O
oncoprotein	B-protein
E2a	I-protein
-	I-protein
Pbx1	I-protein
.	O

C3	B-protein
toxin	I-protein
completely	O
inhibited	O
RhoA	B-protein
function	O
,	O
partially	O
inhibited	O
SRE	B-protein
:	O
Luc	B-protein
activity	O
,	O
but	O
had	O
no	O
effect	O
on	O
LPA	O
-	O
stimulated	O
c	B-protein
-	I-protein
Fos	I-protein
expression	O
.	O

It	O
is	O
impossible	O
to	O
define	O
only	O
one	O
clinical	O
outline	O
because	O
both	O
symptomatic	O
and	O
asymptomatic	O
infected	O
NB	O
may	O
be	O
found	O
with	O
gestational	O
age	O
at	O
term	O
and	O
pre	O
-	O
term	O
and	O
when	O
born	O
with	O
a	O
weight	O
above	O
or	O
below	O
2000	O
g	O
.	O

Mutation	O
of	O
either	O
the	O
AP	B-protein
-	I-protein
1	I-protein
or	O
the	O
ets	B-protein
component	O
of	O
this	O
site	O
also	O
prevented	O
promoter	O
activity	O
in	O
SMCs	O
.	O

Novel	O
8	O
-	O
base	O
pair	O
sequence	O
(	O
Drosophila	B-protein
DNA	I-protein
replication	I-protein
-	I-protein
related	I-protein
element	I-protein
)	O
and	O
specific	O
binding	O
factor	O
involved	O
in	O
the	O
expression	O
of	O
Drosophila	O
genes	O
for	O
DNA	B-protein
polymerase	I-protein
alpha	I-protein
and	O
proliferating	B-protein
cell	I-protein
nuclear	I-protein
antigen	I-protein
.	O

Mutational	O
analysis	O
supports	O
a	O
role	O
for	O
multiple	O
structural	O
features	O
in	O
the	O
C	O
-	O
terminal	O
secretion	O
signal	O
of	O
Escherichia	B-protein
coli	I-protein
haemolysin	I-protein
.	O

Five	O
out	O
of	O
eight	O
consecutive	O
cases	O
with	O
initial	O
symptoms	O
of	O
a	O
'	O
midline	O
granuloma	O
'	O
were	O
identified	O
as	O
malignant	O
histiocytosis	O
(	O
histiocytic	O
sarcoma	O
)	O
which	O
within	O
5	O
months	O
to	O
4	O
years	O
led	O
to	O
generalization	O
and	O
death	O
.	O

Thus	O
,	O
these	O
studies	O
indicate	O
that	O
the	O
104	O
-	O
kDa	O
isoform	O
is	O
required	O
for	O
normal	O
proliferation	O
of	O
female	O
germline	O
cells	O
and	O
perhaps	O
for	O
oocyte	O
differentiation	O
.	O

A	O
region	O
of	O
the	O
deduced	O
protein	O
shares	O
extensive	O
homology	O
with	O
a	O
catalytic	O
region	O
of	O
Raf	B-protein
kinases	I-protein
,	O
a	O
feature	O
shared	O
only	O
with	O
TFIIE	B-protein
among	O
transcription	O
factors	O
.	O

Conjugated	O
and	O
unconjugated	O
phenylacetic	O
acid	O
and	O
m	O
-	O
and	O
p	O
-	O
hydroxyphenylacetic	O
acid	O
have	O
been	O
determined	O
in	O
the	O
plasma	O
of	O
normal	O
,	O
healthy	O
subjects	O
after	O
fasting	O
,	O
consumption	O
of	O
a	O
meal	O
and	O
ingestion	O
of	O
deuterium	O
labelled	O
amine	O
precursors	O
,	O
by	O
high	O
-	O
resolution	O
gas	O
chromatography	O
-	O
-	O
high	O
resolution	O
mass	O
spectrometry	O
with	O
selected	O
ion	O
monitoring	O
of	O
their	O
trifluoroethyl	O
-	O
pentafluoropropionyl	O
derivatives	O
.	O

We	O
calculated	O
differences	O
in	O
late	O
occlusion	O
rates	O
by	O
the	O
chi2	O
(	O
chi	O
-	O
square	O
)	O
test	O
,	O
and	O
found	O
these	O
differences	O
were	O
significant	O
(	O
P	O
=	O
.	O
04	O
)	O
.	O

Plasma	B-protein
renin	I-protein
activity	O
does	O
not	O
predict	O
the	O
antihypertensive	O
efficacy	O
of	O
chlorthalidone	O
.	O

Nitric	O
oxide	O
inhalation	O
selectively	O
reduces	O
pulmonary	O
hypertension	O
in	O
porcine	O
endotoxin	B-protein
shock	O
and	O
improves	O
arterial	O
oxygenation	O
and	O
pH	O
with	O
a	O
marked	O
attenuation	O
of	O
sympathetic	O
activation	O
.	O

SNAC	O
or	O
PBS	O
was	O
infused	O
for	O
6	O
.	O
5	O
h	O
,	O
beginning	O
30	O
min	O
before	O
ischemia	O
and	O
continuing	O
throughout	O
the	O
duration	O
of	O
reperfusion	O
.	O

Wild	O
-	O
type	O
and	O
mutant	O
MyoD	B-protein
were	O
introduced	O
into	O
cells	O
using	O
an	O
E1	B-protein
,	O
E3	O
-	O
deleted	O
adenoviral	O
vector	O
.	O

Results	O
of	O
the	O
recognition	O
task	O
revealed	O
significant	O
effects	O
of	O
consonant	O
voicing	O
,	O
position	O
and	O
vowel	O
context	O
on	O
syllable	O
recognition	O
.	O

Pharmacokinetic	O
profile	O
of	O
clonazepam	O
in	O
rhesus	O
monkeys	O
.	O

NH2	O
-	O
terminal	O
trimming	O
of	O
Xenopus	O
and	O
mammalian	B-protein
FGF3s	I-protein
may	O
therefore	O
be	O
a	O
prerequisite	O
of	O
optimal	O
biological	O
activity	O
.	O

In	O
vitro	O
precipitation	O
with	O
a	O
glutathione	B-protein
-	I-protein
S	I-protein
-	I-protein
transferase	I-protein
-	I-protein
fusion	I-protein
protein	I-protein
containing	O
the	O
C	O
-	O
terminal	O
transactivation	O
domain	O
of	O
STAT5a	B-protein
showed	O
GH	O
-	O
regulated	O
association	O
of	O
ERK1	B-protein
/	I-protein
2	I-protein
with	O
the	O
fusion	O
protein	O
,	O
while	O
this	O
was	O
not	O
seen	O
when	O
serine	O
780	O
in	O
STAT5a	B-protein
was	O
changed	O
to	O
alanine	O
.	O

The	O
biochemical	O
and	O
molecular	O
spectrum	O
of	O
ornithine	B-protein
transcarbamylase	I-protein
deficiency	O
.	O

Temperature	O
measurement	O
in	O
microfluidic	O
systems	O
using	O
a	O
temperature	O
-	O
dependent	O
fluorescent	O
dye	O
.	O

Holliday	B-protein
junction	I-protein
resolvase	I-protein
in	O
Schizosaccharomyces	O
pombe	O
has	O
identical	O
endonuclease	B-protein
activity	O
to	O
the	O
CCE1	B-protein
homologue	O
YDC2	B-protein
.	O

The	O
negative	O
regulatory	O
activity	O
of	O
the	O
N	O
-	O
terminal	O
domain	O
was	O
antagonized	O
by	O
a	O
C	O
-	O
terminal	O
segment	O
of	O
Pho81p	B-protein
supplied	O
in	O
trans	O
.	O

IE2	B-protein
-	I-protein
IE2	I-protein
interactions	O
were	O
mapped	O
to	O
a	O
domain	O
containing	O
a	O
putative	O
helix	B-protein
-	I-protein
turn	I-protein
-	I-protein
helix	I-protein
motif	I-protein
located	O
near	O
the	O
C	O
terminus	O
of	O
IE2	B-protein
,	O
between	O
amino	O
acids	O
456	O
and	O
539	O
.	O

Middle	O
-	O
latency	O
auditory	O
evoked	O
potentials	O
(	O
MAEPs	O
)	O
were	O
recorded	O
in	O
controls	O
and	O
patients	O
with	O
focal	O
lesions	O
in	O
dorsolateral	O
prefrontal	O
cortex	O
.	O

From	O
the	O
15	O
-	O
kb	O
clone	O
a	O
4	B-protein
-	I-protein
kb	I-protein
EcoRI	I-protein
fragment	I-protein
containing	O
the	O
first	O
two	O
exons	O
and	O
2	O
.	O
6	O
kb	O
of	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
opn	B-protein
gene	I-protein
was	O
sequenced	O
,	O
and	O
the	O
transcriptional	O
start	O
site	O
determined	O
by	O
primer	O
extension	O
analysis	O
and	O
S1	B-protein
nuclease	I-protein
mapping	O
.	O

With	O
a	O
BMI	O
cutoff	O
of	O
27	O
,	O
mean	O
cardiac	O
NE	O
spillover	O
was	O
46	O
%	O
lower	O
in	O
the	O
obese	O
subjects	O
when	O
compared	O
with	O
the	O
lean	O
subjects	O
(	O
P	O
=	O
.	O
017	O
)	O
.	O

However	O
,	O
the	O
favored	O
,	O
parallel	O
beta	O
helix	O
model	O
is	O
a	O
compact	O
coil	O
of	O
ten	O
helically	O
arranged	O
beta	O
strands	O
forming	O
two	O
parallel	O
beta	O
sheet	O
faces	O
.	O

Small	O
-	O
molecule	O
control	O
of	O
insulin	B-protein
and	O
PDGF	B-protein
receptor	I-protein
signaling	O
and	O
the	O
role	O
of	O
membrane	O
attachment	O
.	O

The	O
Trk	B-protein
/	I-protein
Nerve	I-protein
Growth	I-protein
Factor	I-protein
receptor	I-protein
mediates	O
the	O
rapid	O
activation	O
of	O
a	O
number	O
of	O
intracellular	O
signaling	O
proteins	O
,	O
including	O
phosphatidylinositol	B-protein
3	I-protein
-	I-protein
kinase	I-protein
(	O
PI	B-protein
3	I-protein
-	I-protein
kinase	I-protein
)	O
.	O

Roux	O
-	O
en	O
-	O
Y	O
gastroenterostomy	O
severely	O
disturbs	O
emptying	O
of	O
the	O
gallbladder	O
.	O

Levels	O
of	O
both	O
PGF	O
and	O
PGFM	O
were	O
significantly	O
higher	O
during	O
early	O
spontaneous	O
labour	O
,	O
at	O
a	O
cervical	O
dilatation	O
of	O
less	O
than	O
4	O
cm	O
,	O
than	O
before	O
the	O
onset	O
of	O
labour	O
.	O

After	O
nadolol	O
,	O
heart	O
rate	O
decreased	O
(	O
-	O
22	O
+	O
/	O
-	O
8	O
%	O
)	O
,	O
and	O
so	O
did	O
PBV	O
and	O
PBF	O
(	O
8	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
4	O
vs	O
.	O

The	O
mRNAs	O
of	O
the	O
GRF	B-protein
genes	I-protein
are	O
encoded	O
by	O
six	O
exons	O
interrupted	O
by	O
five	O
introns	O
.	O

Changes	O
in	O
muscarinic	B-protein
acetylcholine	I-protein
receptors	I-protein
in	O
guinea	O
-	O
pig	O
lung	O
:	O
effects	O
of	O
aging	O
,	O
inhalation	O
of	O
an	O
allergen	O
,	O
administration	O
of	O
drugs	O
,	O
and	O
vagotomy	O
.	O

No	O
reflow	O
occurred	O
in	O
approximately	O
30	O
percent	O
of	O
the	O
muscle	O
microvasculature	O
upon	O
reperfusion	O
.	O

Type	O
II	O
could	O
be	O
divided	O
further	O
into	O
two	O
forms	O
(	O
IIA	O
and	O
IIB	O
)	O
that	O
may	O
represent	O
two	O
underscribed	O
species	O
or	O
developmental	O
stages	O
of	O
the	O
same	O
species	O
.	O

Net	O
lift	O
and	O
combined	O
drag	O
from	O
all	O
8	O
bearings	O
of	O
the	O
4	O
-	O
bladed	O
impeller	O
are	O
compared	O
with	O
predictions	O
based	O
on	O
2	O
-	O
D	O
theory	O
.	O

Transvenous	O
serial	O
xeroradiography	O
.	O

Of	O
the	O
single	O
-	O
stranded	O
DNA	O
transformants	O
,	O
65	O
%	O
resulted	O
from	O
replacement	O
of	O
the	O
resident	O
met2	B-protein
mutation	I-protein
by	O
the	O
exogenous	O
wild	O
-	O
type	O
allele	O
.	O

Laboratory	O
evaluation	O
was	O
normal	O
,	O
and	O
neuroimaging	O
failed	O
to	O
confirm	O
obstruction	O
of	O
venous	O
or	O
lymphatic	O
drainage	O
.	O

The	O
Fyn	B-protein
NH2	I-protein
terminus	I-protein
was	O
necessary	O
but	O
not	O
sufficient	O
for	O
interaction	O
with	O
zeta	B-protein
and	O
both	O
Fyn	B-protein
kinase	I-protein
and	O
SH2	B-protein
domains	I-protein
were	O
required	O
,	O
directing	O
phosphorylation	O
of	O
zeta	B-protein
ITAM	I-protein
tyrosines	O
and	O
binding	O
to	O
zeta	B-protein
ITAM	I-protein
phosphotyrosines	O
.	O

These	O
offspring	O
of	O
the	O
alpha	B-protein
-	I-protein
MSH	I-protein
treated	O
mothers	O
were	O
less	O
sensitive	O
to	O
pain	O
and	O
as	O
adults	O
showed	O
a	O
reduced	O
analgesic	O
response	O
to	O
morphine	O
.	O

Although	O
eight	O
contiguous	O
genes	O
necessary	O
for	O
urease	B-protein
activity	O
have	O
been	O
cloned	O
and	O
sequenced	O
,	O
the	O
transcriptional	O
organization	O
and	O
regulation	O
of	O
specific	O
genes	O
within	O
the	O
Proteus	B-protein
gene	I-protein
cluster	I-protein
has	O
not	O
been	O
investigated	O
in	O
detail	O
.	O

The	O
cases	O
included	O
35	O
de	O
novo	O
diffuse	O
aggressive	O
lymphomas	O
(	O
DAL	O
;	O
19	O
large	O
-	O
cell	O
,	O
4	O
mixed	O
-	O
cell	O
,	O
and	O
12	O
large	O
-	O
cell	O
immunoblastic	O
)	O
,	O
52	O
transformed	O
aggressive	O
lymphomas	O
derived	O
from	O
follicular	O
lymphomas	O
(	O
TFL	O
)	O
,	O
42	O
indolent	O
follicular	O
lymphomas	O
(	O
FL	O
)	O
,	O
14	O
mantle	O
cell	O
lymphomas	O
(	O
MCL	O
)	O
,	O
and	O
27	O
small	O
noncleaved	O
cell	O
lymphomas	O
(	O
SNCL	O
)	O
.	O

Furthermore	O
,	O
this	O
study	O
demonstrates	O
that	O
reduced	O
inotropy	O
with	O
timolol	O
helped	O
uniform	O
local	O
contraction	O
as	O
estimated	O
by	O
the	O
increased	O
LONG	O
/	O
CIRC	O
ratio	O
,	O
a	O
transition	O
that	O
could	O
improve	O
contraction	O
efficacy	O
.	O

Splenectomized	O
patients	O
are	O
predisposed	O
toward	O
developing	O
overwhelming	O
bacterial	O
infections	O
.	O

In	O
humans	O
,	O
three	O
tissue	B-protein
-	I-protein
specific	I-protein
plastin	I-protein
isoforms	I-protein
have	O
been	O
identified	O
.	O

In	O
the	O
mouse	O
,	O
both	O
genes	O
reside	O
in	O
the	O
syntenic	B-protein
region	I-protein
8E1	I-protein
on	O
chromosome	O
8	O
.	O

Although	O
upstream	O
regulators	O
of	O
Tec	B-protein
family	I-protein
kinases	I-protein
are	O
relatively	O
well	O
characterized	O
,	O
little	O
is	O
known	O
of	O
the	O
downstream	O
effectors	O
of	O
these	O
enzymes	O
.	O

The	O
drug	O
packets	O
contained	O
acetyl	O
aspirin	O
,	O
acetaminophen	O
and	O
chloramphenicol	O
.	O

Anterior	O
body	O
pattern	O
in	O
Drosophila	O
is	O
specified	O
by	O
the	O
graded	O
distribution	O
of	O
the	O
bicoid	B-protein
protein	I-protein
(	O
bcd	B-protein
)	O
,	O
which	O
activates	O
subordinate	O
genes	O
in	O
distinct	O
anterior	O
domains	O
.	O

Serotonin	O
concentration	O
in	O
the	O
blood	O
of	O
patients	O
with	O
hemorrhagic	O
fever	O
with	O
renal	O
syndrome	O
.	O

Primer	O
extension	O
experiments	O
indicated	O
that	O
the	O
transcription	O
initiation	O
site	O
mapped	O
to	O
a	O
position	O
on	O
gene	B-protein
IV	I-protein
that	O
was	O
analogous	O
to	O
that	O
reported	O
for	O
the	O
structurally	O
similar	O
P	B-protein
-	I-protein
450e	I-protein
gene	I-protein
.	O

Actuarial	O
freedom	O
from	O
ventricular	O
arrhythmias	O
at	O
4	O
-	O
year	O
follow	O
-	O
up	O
was	O
74	O
.	O
1	O
+	O
/	O
-	O
6	O
.	O
0	O
%	O
in	O
group	O
A	O
vs	O
.	O

Similarly	O
,	O
maternal	B-protein
serum	I-protein
somatomedin	I-protein
A	I-protein
was	O
significantly	O
reduced	O
in	O
rats	O
nursing	O
large	O
litters	O
.	O

They	O
self	O
-	O
completed	O
the	O
SF	O
-	O
36	O
questionnaire	O
and	O
their	O
QoL	O
was	O
described	O
and	O
retrospectively	O
compared	O
to	O
that	O
of	O
historical	O
controls	O
.	O

Ligand	O
binding	O
to	O
the	O
receptor	O
complex	O
leads	O
to	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
Janus	B-protein
kinases	I-protein
(	O
Jak	B-protein
)	O
,	O
phosphorylation	O
of	O
the	O
signal	B-protein
transducing	I-protein
subunit	I-protein
gp130	I-protein
,	O
followed	O
by	O
recruitment	O
and	O
phosphorylation	O
of	O
the	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
factors	I-protein
STAT3	I-protein
and	O
STAT1	B-protein
and	O
the	O
src	B-protein
homology	I-protein
domain	I-protein
(	O
SH2	B-protein
)	O
-	O
containing	O
protein	B-protein
tyrosine	I-protein
phosphatase	I-protein
(	O
SHP2	B-protein
)	O
.	O

Alanine	B-protein
aminotransferase	I-protein
in	O
clinical	O
practice	O
.	O

An	O
open	O
reading	O
frame	O
of	O
2862	O
bp	O
encoding	O
a	O
954	O
amino	O
acid	O
protein	O
was	O
identified	O
.	O

The	O
Sp1	B-protein
region	I-protein
,	O
however	O
,	O
is	O
converted	O
to	O
a	O
functionally	O
strong	O
TRE	O
by	O
the	O
viral	B-protein
tat	I-protein
factor	I-protein
.	O

Disruption	O
of	O
the	O
chromosomal	B-protein
AAR1	I-protein
gene	I-protein
in	O
alpha	O
and	O
a	O
/	O
alpha	O
cells	O
conferred	O
the	O
nonmating	O
phenotype	O
,	O
and	O
the	O
a	O
/	O
alpha	O
diploids	O
could	O
not	O
sporulate	O
.	O

All	O
clinical	O
isolates	O
were	O
concomitantly	O
tested	O
by	O
disk	O
diffusion	O
and	O
agar	O
dilution	O
procedures	O
as	O
outlined	O
by	O
the	O
National	O
Committee	O
for	O
Clinical	O
Laboratory	O
Standards	O
.	O

Movement	O
time	O
and	O
kinematic	O
characteristics	O
were	O
analyzed	O
together	O
with	O
the	O
magnitude	O
of	O
cerebral	O
blood	O
flow	O
to	O
identify	O
areas	O
of	O
brain	O
activity	O
proportionate	O
to	O
task	O
and	O
movement	O
variables	O
.	O

We	O
have	O
determined	O
the	O
nucleotide	O
(	O
nt	O
)	O
sequence	O
of	O
the	O
7	B-protein
.	I-protein
5	I-protein
-	I-protein
kb	I-protein
COR	I-protein
segment	I-protein
that	O
encompasses	O
a	O
cluster	O
of	O
six	O
genes	O
(	O
CYC1	B-protein
,	O
UTR1	B-protein
,	O
UTR3	B-protein
,	O
OSM1	B-protein
,	O
tRNA	B-protein
(	I-protein
Gly	I-protein
)	I-protein
and	O
RAD7	B-protein
)	O
located	O
on	O
chromosome	O
X	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
effect	O
of	O
sodium	O
18	O
beta	O
-	O
glycyrrhetate	O
(	O
SGA	O
)	O
on	O
experimental	O
arrhythmia	O
was	O
investigated	O
.	O

Extraction	O
procedure	O
for	O
the	O
measurement	O
of	O
butyltin	O
compounds	O
in	O
biological	O
tissues	O
using	O
toluene	O
,	O
HBr	O
,	O
and	O
tropolone	O
.	O

In	O
untreated	O
mice	O
,	O
bactericidal	O
activity	O
of	O
peritoneal	O
macrophages	O
decreased	O
from	O
one	O
day	O
to	O
3	O
days	O
after	O
ip	O
injection	O
of	O
killed	O
L	O
.	O
monocytogenes	O
.	O

The	O
structural	O
gene	O
for	O
copper	B-protein
-	I-protein
and	I-protein
topa	I-protein
quinone	I-protein
-	I-protein
containing	I-protein
monoamine	I-protein
oxidase	I-protein
(	O
maoA	B-protein
)	O
and	O
an	O
unknown	O
amine	B-protein
oxidase	I-protein
gene	I-protein
have	O
been	O
located	O
at	O
30	O
.	O
9	O
min	O
on	O
the	O
Escherichia	O
coli	O
chromosome	O
.	O

METHODS	O
:	O
Humphrey	O
Field	O
Analyzer	O
model	O
630	O
(	O
HFA	O
I	O
,	O
program	O
30	O
-	O
2	O
with	O
a	O
rectangular	O
6	O
degrees	O
x	O
6	O
degrees	O
grid	O
)	O
was	O
used	O
as	O
the	O
conventional	O
perimetric	O
method	O
.	O

Methyl	O
mercury	O
intoxication	O
in	O
rat	O
kidneys	O
.	O

Cyclic	O
loading	O
of	O
bone	O
during	O
normal	O
daily	O
activity	O
leads	O
to	O
the	O
formation	O
of	O
microcracks	O
within	O
the	O
tissue	O
matrix	O
of	O
compact	O
bone	O
.	O

The	O
clinical	O
application	O
of	O
the	O
antibody	O
-	O
targeted	O
Phthalocyanine	O
was	O
performed	O
in	O
3	O
patients	O
suffering	O
from	O
an	O
advanced	O
ovarian	O
carcinoma	O
(	O
FIGO	O
III	O
)	O
.	O

The	O
DNA	O
sequence	O
immediately	O
upstream	O
from	O
the	O
-	O
10	O
hexamer	O
contained	O
the	O
TGn	B-protein
motif	I-protein
described	O
as	O
an	O
extended	O
-	O
10	O
region	O
in	O
prokaryotic	O
promoters	O
.	O

Because	O
of	O
the	O
small	O
number	O
of	O
visceral	O
angiography	O
procedures	O
performed	O
(	O
38	O
)	O
,	O
no	O
definitive	O
conclusions	O
could	O
be	O
drawn	O
as	O
to	O
the	O
differences	O
between	O
ionic	O
and	O
nonionic	O
agents	O
regarding	O
grade	O
-	O
2	O
and	O
grade	O
-	O
3	O
adverse	O
events	O
.	O

Growth	O
curves	O
indicated	O
that	O
proliferation	O
of	O
clone	O
CA9	O
in	O
the	O
presence	O
of	O
10	O
%	O
serum	O
was	O
reduced	O
by	O
60	O
%	O
compared	O
with	O
clone	O
ME10	O
.	O

These	O
data	O
suggest	O
that	O
spontaneous	O
recovery	O
of	O
central	O
respiratory	O
function	O
after	O
intoxication	O
with	O
Soman	O
or	O
Sarin	O
may	O
not	O
be	O
related	O
to	O
the	O
return	O
of	O
AChE	B-protein
activity	O
.	O

Additionally	O
,	O
although	O
c	B-protein
-	I-protein
fos	I-protein
and	O
egr	B-protein
-	I-protein
1	I-protein
mRNAs	I-protein
are	O
expressed	O
at	O
elevated	O
levels	O
in	O
stimulated	O
liver	O
cells	O
,	O
fos	B-protein
-	I-protein
B	I-protein
,	O
fra	B-protein
-	I-protein
1	I-protein
,	O
and	O
egr	B-protein
-	I-protein
2	I-protein
are	O
not	O
,	O
which	O
suggests	O
that	O
factors	O
in	O
addition	O
to	O
the	O
serum	B-protein
response	I-protein
factor	I-protein
participate	O
in	O
the	O
regulation	O
of	O
immediate	B-protein
-	I-protein
early	I-protein
gene	I-protein
induction	O
.	O

We	O
describe	O
here	O
17	O
dominant	B-protein
GCN2	I-protein
mutations	I-protein
that	O
lead	O
to	O
derepression	O
of	O
GCN4	B-protein
expression	O
in	O
the	O
absence	O
of	O
amino	O
acid	O
starvation	O
.	O

Baseline	O
variables	O
associated	O
with	O
CD	O
included	O
a	O
less	O
frequent	O
use	O
of	O
prestroke	O
aspirin	O
and	O
a	O
higher	O
incidence	O
of	O
early	O
CT	O
changes	O
of	O
edema	O
or	O
mass	O
effect	O
or	O
dense	O
middle	O
cerebral	O
artery	O
sign	O
.	O

These	O
findings	O
indicate	O
that	O
autophosphorylation	O
of	O
Thr286	O
(	O
alpha	O
subunit	O
)	O
and	O
Thr287	O
(	O
beta	O
subunit	O
)	O
is	O
responsible	O
for	O
transition	O
of	O
CaM	B-protein
-	I-protein
kinase	I-protein
II	I-protein
to	O
the	O
Ca2	O
+	O
-	O
independent	O
form	O
.	O

For	O
replication	O
reporter	O
constructs	O
where	O
E1	B-protein
and	O
E2	B-protein
are	O
supplied	O
in	O
trans	O
by	O
the	O
respective	O
expression	O
vectors	O
,	O
distance	O
between	O
the	O
half	O
sites	O
seems	O
to	O
play	O
a	O
major	O
role	O
,	O
yet	O
the	O
phasing	O
relationships	O
are	O
measurable	O
.	O

Transcripts	O
of	O
the	O
immunoglobulin	B-protein
C	I-protein
mu	I-protein
gene	I-protein
vary	O
in	O
structure	O
and	O
splicing	O
during	O
lymphoid	O
development	O
.	O

Within	O
the	O
span	O
of	O
attenuator	O
region	O
encoding	O
the	O
three	O
stem	O
-	O
loop	O
structures	O
of	O
mRNA	O
secondary	O
configuration	O
,	O
hot	O
spots	O
of	O
base	O
-	O
residue	O
divergence	O
were	O
localized	O
to	O
looped	O
-	O
out	O
regions	O
.	O

In	O
a	O
112	O
-	O
d	O
feedlot	O
trial	O
,	O
105	O
heifers	O
were	O
assigned	O
to	O
light	O
,	O
medium	O
and	O
heavy	O
weight	O
blocks	O
on	O
five	O
treatments	O
:	O
dietary	O
MGA	O
(	O
.	O
5	O
mg	O
.	O
hd	O
-	O
1	O
.	O
d	O
-	O
1	O
)	O
,	O
control	O
(	O
no	O
MGA	O
)	O
or	O
DEPO	O
-	O
MGA	O
on	O
d	O
1	O
at	O
.	O
5	O
,	O
1	O
.	O
0	O
or	O
1	O
.	O
5	O
ml	O
/	O
hd	O
(	O
30	O
,	O
60	O
or	O
90	O
mg	O
MGA	O
/	O
hd	O
,	O
respectively	O
)	O
.	O

Escherichia	O
of	O
a	O
single	O
sero	O
-	O
anzymatic	O
type	O
(	O
06a6b	O
:	O
K13	O
:	O
H1	O
)	O
were	O
isolated	O
in	O
a	O
group	O
affection	O
.	O

Lung	O
function	O
tests	O
(	O
EFR	O
)	O
were	O
performed	O
on	O
these	O
patients	O
for	O
a	O
period	O
of	O
19	O
.	O
2	O
+	O
/	O
-	O
3	O
.	O
4	O
months	O
.	O

Respiratory	O
parameters	O
suggested	O
that	O
M6G	O
produced	O
less	O
respiratory	O
depression	O
than	O
morphine	O
.	O

Eight	O
patients	O
received	O
1	O
.	O
5	O
mg	O
of	O
adefovir	O
dipivoxil	O
per	O
kg	O
of	O
body	O
weight	O
,	O
and	O
six	O
patients	O
received	O
3	O
.	O
0	O
mg	O
of	O
adefovir	O
dipivoxil	O
per	O
kg	O
.	O

A	O
fine	O
-	O
structure	O
deletion	O
map	O
of	O
human	O
chromosome	O
11p	O
:	O
analysis	O
of	O
J1	O
series	O
hybrids	O
.	O

Rifabutin	O
has	O
substantial	O
efficacy	O
when	O
combined	O
with	O
other	O
agents	O
.	O

However	O
,	O
only	O
complete	B-protein
DnaJ	I-protein
can	O
cooperate	O
with	O
DnaK	B-protein
and	O
a	O
third	O
protein	O
,	O
GrpE	B-protein
,	O
in	O
refolding	O
denatured	B-protein
firefly	I-protein
luciferase	I-protein
.	O

We	O
have	O
recently	O
discovered	O
that	O
CCAAAT	B-protein
/	I-protein
Enhancer	I-protein
binding	I-protein
protein	I-protein
-	I-protein
beta	I-protein
(	O
C	B-protein
/	I-protein
EBP	I-protein
-	I-protein
b	I-protein
)	O
induces	O
gene	O
transcription	O
through	O
a	O
novel	O
IFN	B-protein
-	I-protein
response	I-protein
element	I-protein
called	O
,	O
gamma	B-protein
-	I-protein
IFN	I-protein
activated	I-protein
transcriptional	I-protein
element	I-protein
(	O
GATE	B-protein
)	O
.	O

Spore	O
inocula	O
(	O
approximately	O
10	O
(	O
6	O
)	O
/	O
coupon	O
)	O
were	O
dried	O
onto	O
0	O
.	O
5	O
-	O
in	O
.	O

Basal	O
components	O
of	O
the	O
transcription	O
apparatus	O
(	O
RNA	B-protein
polymerase	I-protein
II	I-protein
,	O
TATA	B-protein
-	I-protein
binding	I-protein
protein	I-protein
)	O
contain	O
activation	O
domains	O
:	O
is	O
the	O
repetitive	O
C	O
-	O
terminal	O
domain	O
(	O
CTD	O
)	O
of	O
RNA	B-protein
polymerase	I-protein
II	I-protein
a	O
`	O
`	O
portable	O
enhancer	O
domain	O
'	O
'	O
?	O
Regions	O
rich	O
in	O
serine	O
,	O
threonine	O
,	O
and	O
proline	O
residues	O
can	O
be	O
found	O
in	O
transcriptional	O
activation	O
domains	O
,	O
as	O
well	O
as	O
in	O
the	O
N	O
-	O
terminal	O
parts	O
of	O
mammalian	B-protein
TATA	I-protein
-	I-protein
binding	I-protein
proteins	I-protein
,	O
where	O
they	O
are	O
interrupted	O
by	O
polyglutamine	O
stretches	O
.	O

The	O
pretransplant	O
regimen	O
consisted	O
of	O
cyclophosphamide	O
(	O
120	O
mg	O
/	O
kg	O
)	O
and	O
total	O
body	O
irradiation	O
.	O
